Model	Tumor Type	Treatment	Volume (mm3)	body weight (g)	Days Post T0	% TVol Difference	% BW Difference
X-1004	BRCA	BGJ398	199.7	28.2	0	0	0
X-1004	BRCA	BGJ398	181.9	28	2	-8.9	-0.7
X-1004	BRCA	BGJ398	172.7	28.4	5	-13.5	0.7
X-1004	BRCA	BGJ398	129.6	27.2	9	-35.1	-3.5
X-1004	BRCA	BGJ398	91.3	26.7	12	-54.3	-5.3
X-1004	BRCA	BGJ398	117.1	26.2	16	-41.4	-7.1
X-1004	BRCA	BGJ398	122.7	27	19	-38.6	-4.3
X-1004	BRCA	BGJ398	134.4	24.9	23	-32.7	-11.7
X-1004	BRCA	BGJ398	143.3	23.2	26	-28.2	-17.7
X-1004	BRCA	BKM120	271.1	30.5	0	0	0
X-1004	BRCA	BKM120	402.7	30.9	4	48.5	1.3
X-1004	BRCA	BKM120	332.3	30.7	11	22.6	0.7
X-1004	BRCA	BKM120	549.7	31.2	15	102.8	2.3
X-1004	BRCA	BKM120	444.2	30.3	18	63.9	-0.7
X-1004	BRCA	BKM120	446.1	32.1	22	64.6	5.2
X-1004	BRCA	BKM120	613.6	31.1	25	126.3	2
X-1004	BRCA	BKM120	813.4	31.8	27	200	4.3
X-1004	BRCA	BYL719 + LEE011	298.5	26.6	0	0	0
X-1004	BRCA	BYL719 + LEE011	417.2	27.1	3	39.8	1.9
X-1004	BRCA	BYL719 + LEE011	516.6	26.4	7	73.1	-0.8
X-1004	BRCA	BYL719 + LEE011	588.8	25.8	11	97.3	-3
X-1004	BRCA	BYL719 + LEE011	586	26.4	15	96.3	-0.8
X-1004	BRCA	BYL719 + LEE011	613.3	25.3	18	105.5	-4.9
X-1004	BRCA	BYL719 + LEE011	653.8	24.8	22	119	-6.8
X-1004	BRCA	BYL719 + LEE011	744.7	27.3	26	149.5	2.6
X-1004	BRCA	BYL719 + LEE011	777.4	25	30	160.4	-6
X-1004	BRCA	BYL719 + LEE011	795.4	25.4	32	166.5	-4.5
X-1004	BRCA	BYL719 + LEE011	870.7	23.7	35	191.7	-10.9
X-1004	BRCA	BYL719 + LJM716	200.6	26.1	0	0	0
X-1004	BRCA	BYL719 + LJM716	171.3	24.9	4	-14.6	-4.6
X-1004	BRCA	BYL719 + LJM716	246.2	25	11	22.7	-4.2
X-1004	BRCA	BYL719 + LJM716	246.7	21.9	15	23	-16.1
X-1004	BRCA	BYL719 + LJM716	271.6	22.4	18	35.4	-14.2
X-1004	BRCA	BYL719 + LJM716	260.4	23.7	22	29.8	-9.2
X-1004	BRCA	BYL719 + LJM716	256.1	24.4	25	27.7	-6.5
X-1004	BRCA	BYL719 + LJM716	424	24.1	29	111.4	-7.7
X-1004	BRCA	BYL719 + LJM716	620.8	24.4	32	209.5	-6.5
X-1004	BRCA	BYL719 + LJM716	747.2	25.2	34	272.5	-3.4
X-1004	BRCA	BYL719	203.4	31.7	0	0	0
X-1004	BRCA	BYL719	214.7	30.2	7	5.6	-4.7
X-1004	BRCA	BYL719	248.8	30.7	11	22.3	-3.2
X-1004	BRCA	BYL719	260.4	29.4	14	28	-7.3
X-1004	BRCA	BYL719	244.1	30.6	18	20	-3.5
X-1004	BRCA	BYL719	264.4	29.4	21	30	-7.3
X-1004	BRCA	BYL719	288.6	28.8	25	41.9	-9.1
X-1004	BRCA	BYL719	350.9	28.5	28	72.5	-10.1
X-1004	BRCA	BYL719	396.2	29.8	32	94.8	-6
X-1004	BRCA	BYL719	492.7	31.2	35	142.2	-1.6
X-1004	BRCA	BYL719	716.1	31.8	39	252.1	0.3
X-1004	BRCA	BYL719	882	29.9	42	333.6	-5.7
X-1004	BRCA	CGM097	294.9	28.2	0	0	0
X-1004	BRCA	CGM097	395.6	30.4	4	34.1	7.8
X-1004	BRCA	CGM097	604.3	30.7	11	104.9	8.9
X-1004	BRCA	CGM097	780.5	31.5	15	164.7	11.7
X-1004	BRCA	CGM097	1342	31.4	18	355.1	11.3
X-1004	BRCA	CLR457	204.1	27	0	0	0
X-1004	BRCA	CLR457	207.8	27.6	2	1.8	2.2
X-1004	BRCA	CLR457	212.4	26.9	5	4.1	-0.4
X-1004	BRCA	CLR457	229.6	26.4	9	12.5	-2.2
X-1004	BRCA	CLR457	223.6	26.6	12	9.6	-1.5
X-1004	BRCA	CLR457	279.5	26.2	16	36.9	-3
X-1004	BRCA	CLR457	260.4	25.8	19	27.6	-4.4
X-1004	BRCA	CLR457	304.5	27.5	23	49.2	1.9
X-1004	BRCA	CLR457	398.5	28.1	26	95.2	4.1
X-1004	BRCA	CLR457	464.9	27.7	30	127.8	2.6
X-1004	BRCA	CLR457	492.2	27.2	33	141.2	0.7
X-1004	BRCA	CLR457	474.4	28.4	37	132.4	5.2
X-1004	BRCA	CLR457	480.4	28.6	40	135.4	5.9
X-1004	BRCA	CLR457	560.2	28.8	44	174.5	6.7
X-1004	BRCA	CLR457	652.1	28.1	47	219.5	4.1
X-1004	BRCA	HDM201	196.6	25	0	0	0
X-1004	BRCA	HDM201	232.1	26.5	4	18.1	6
X-1004	BRCA	HDM201	258.5	26.4	11	31.5	5.6
X-1004	BRCA	HDM201	285.1	NA	15	45	5.6
X-1004	BRCA	HDM201	297.6	25.7	18	51.4	2.8
X-1004	BRCA	HDM201	308.6	25.3	22	57	1.2
X-1004	BRCA	HDM201	358.7	23.8	25	82.5	-4.8
X-1004	BRCA	HDM201	450.4	20.7	29	129.1	-17.2
X-1004	BRCA	HDM201	484.9	17.8	32	146.6	-28.8
X-1004	BRCA	INC424	197	29.5	0	0	0
X-1004	BRCA	INC424	167.4	28.1	4	-15	-4.7
X-1004	BRCA	INC424	169.9	27.6	7	-13.8	-6.4
X-1004	BRCA	INC424	237.5	27.9	11	20.6	-5.4
X-1004	BRCA	INC424	258.4	27.5	14	31.2	-6.8
X-1004	BRCA	INC424	267.2	28.2	18	35.6	-4.4
X-1004	BRCA	INC424	317.4	28.3	21	61.1	-4.1
X-1004	BRCA	INC424	440.9	28.6	25	123.8	-3.1
X-1004	BRCA	INC424	581.9	28.4	28	195.4	-3.7
X-1004	BRCA	INC424	635.7	26.5	32	222.7	-10.2
X-1004	BRCA	INC424	716.2	24.8	35	263.6	-15.9
X-1004	BRCA	LEE011 + everolimus	209.6	26.8	0	0	0
X-1004	BRCA	LEE011 + everolimus	196.2	26.6	4	-6.4	-0.7
X-1004	BRCA	LEE011 + everolimus	178.3	26.3	7	-14.9	-1.9
X-1004	BRCA	LEE011 + everolimus	162.4	27	11	-22.5	0.7
X-1004	BRCA	LEE011 + everolimus	94.3	26.6	18	-55	-0.7
X-1004	BRCA	LEE011 + everolimus	84.6	26.6	21	-59.6	-0.7
X-1004	BRCA	LEE011 + everolimus	94.2	26.9	24	-55.1	0.4
X-1004	BRCA	LEE011 + everolimus	102	27.6	28	-51.3	3
X-1004	BRCA	LEE011 + everolimus	103.2	27.4	31	-50.8	2.2
X-1004	BRCA	LEE011 + everolimus	103.4	27	35	-50.7	0.7
X-1004	BRCA	LEE011 + everolimus	104.2	27.2	38	-50.3	1.5
X-1004	BRCA	LEE011 + everolimus	107.8	27.5	42	-48.6	2.6
X-1004	BRCA	LEE011 + everolimus	81.2	26.8	46	-61.3	0
X-1004	BRCA	LEE011 + everolimus	79.1	26.9	49	-62.3	0.4
X-1004	BRCA	LEE011 + everolimus	74.9	28.2	52	-64.3	5.2
X-1004	BRCA	LEE011 + everolimus	84.8	27.1	56	-59.5	1.1
X-1004	BRCA	LEE011 + everolimus	113.9	27.2	60	-45.7	1.5
X-1004	BRCA	LEE011 + everolimus	114.6	26.6	64	-45.3	-0.7
X-1004	BRCA	LEE011 + everolimus	127.5	27.2	67	-39.2	1.5
X-1004	BRCA	LEE011 + everolimus	113.3	27.3	71	-45.9	1.9
X-1004	BRCA	LEE011 + everolimus	125.3	27.9	75	-40.2	4.1
X-1004	BRCA	LEE011 + everolimus	137.9	26.9	79	-34.2	0.4
X-1004	BRCA	LEE011 + everolimus	136.2	27.1	81	-35	1.1
X-1004	BRCA	LEE011 + everolimus	117.2	26.6	84	-44.1	-0.7
X-1004	BRCA	LEE011 + everolimus	137.6	27.2	88	-34.4	1.5
X-1004	BRCA	LEE011 + everolimus	137.9	27.1	91	-34.2	1.1
X-1004	BRCA	LEE011 + everolimus	143.6	26.7	98	-31.5	-0.4
X-1004	BRCA	LEE011 + everolimus	147.6	27.2	101	-29.6	1.5
X-1004	BRCA	LEE011 + everolimus	156.1	27	105	-25.5	0.7
X-1004	BRCA	LEE011 + everolimus	133.8	27.6	109	-36.2	3
X-1004	BRCA	LEE011 + everolimus	146.5	28.1	116	-30.1	4.9
X-1004	BRCA	LEE011 + everolimus	177.7	28.1	121	-15.2	4.9
X-1004	BRCA	LEE011 + everolimus	189.2	28.6	128	-9.7	6.7
X-1004	BRCA	LEE011 + everolimus	219.7	27.1	134	4.8	1.1
X-1004	BRCA	LEE011 + everolimus	225.7	26.9	144	7.7	0.4
X-1004	BRCA	LEE011 + everolimus	219.2	27	149	4.6	0.7
X-1004	BRCA	LEE011 + everolimus	278.9	27.3	158	33.1	1.9
X-1004	BRCA	LEE011 + everolimus	277.8	27.3	163	32.5	1.9
X-1004	BRCA	LEE011	196.3	27.8	0	0	0
X-1004	BRCA	LEE011	159.2	28.9	3	-18.9	4
X-1004	BRCA	LEE011	158.9	29.2	6	-19.1	5
X-1004	BRCA	LEE011	183	29	10	-6.8	4.3
X-1004	BRCA	LEE011	165.7	29.3	13	-15.6	5.4
X-1004	BRCA	LEE011	199	29.5	17	1.4	6.1
X-1004	BRCA	LEE011	247.3	29.2	20	26	5
X-1004	BRCA	LEE011	255.2	30.6	24	30	10.1
X-1004	BRCA	LEE011	266.8	29.8	27	35.9	7.2
X-1004	BRCA	LEE011	245.9	29.8	31	25.3	7.2
X-1004	BRCA	LEE011	257	30.7	34	30.9	10.4
X-1004	BRCA	LEE011	291.5	30.5	37	48.5	9.7
X-1004	BRCA	LEE011	329.4	31.2	41	67.8	12.2
X-1004	BRCA	LEE011	350.1	31.2	44	78.3	12.2
X-1004	BRCA	LEE011	385.6	30.7	48	96.4	10.4
X-1004	BRCA	LEE011	412	32	51	109.9	15.1
X-1004	BRCA	LEE011	453.8	31.3	55	131.2	12.6
X-1004	BRCA	LEE011	501.7	31.7	59	155.6	14
X-1004	BRCA	LEE011	583.5	32.4	62	197.2	16.5
X-1004	BRCA	LEE011	749.2	31.9	65	281.7	14.7
X-1004	BRCA	LEE011	952.1	30.8	69	385	10.8
X-1004	BRCA	LEE011	990.4	31	73	404.5	11.5
X-1004	BRCA	LEE011	1091.3	32.9	77	455.9	18.3
X-1004	BRCA	LFA102	253.4	25.1	0	0	0
X-1004	BRCA	LFA102	223	24.7	3	-12	-1.6
X-1004	BRCA	LFA102	305.4	26.3	6	20.5	4.8
X-1004	BRCA	LFA102	417.1	26.6	13	64.6	6
X-1004	BRCA	LFA102	841.7	27.5	17	232.2	9.6
X-1004	BRCA	LFA102	1212.5	27.9	20	378.5	11.2
X-1004	BRCA	LJM716	199.2	27.9	0	0	0
X-1004	BRCA	LJM716	180.4	27.9	4	-9.4	0
X-1004	BRCA	LJM716	242	26.6	11	21.5	-4.7
X-1004	BRCA	LJM716	259.7	26.9	15	30.4	-3.6
X-1004	BRCA	LJM716	256.2	27.4	18	28.6	-1.8
X-1004	BRCA	LJM716	333.5	27.4	22	67.4	-1.8
X-1004	BRCA	LJM716	403	26.9	25	102.3	-3.6
X-1004	BRCA	LJM716	584.3	26.6	29	193.3	-4.7
X-1004	BRCA	LJM716	745.2	26.8	32	274.1	-3.9
X-1004	BRCA	LJM716	839.9	27.9	34	321.6	0
X-1004	BRCA	LJM716 + trastuzumab	213.1	31.4	0	0	0
X-1004	BRCA	LJM716 + trastuzumab	242.7	30.7	3	13.9	-2.2
X-1004	BRCA	LJM716 + trastuzumab	232.3	30.4	6	9	-3.2
X-1004	BRCA	LJM716 + trastuzumab	224.8	30.5	13	5.5	-2.9
X-1004	BRCA	LJM716 + trastuzumab	248.6	30.9	17	16.7	-1.6
X-1004	BRCA	LJM716 + trastuzumab	278	30.5	20	30.5	-2.9
X-1004	BRCA	LJM716 + trastuzumab	379.4	30.3	24	78	-3.5
X-1004	BRCA	LJM716 + trastuzumab	431.4	28.9	27	102.4	-8
X-1004	BRCA	LJM716 + trastuzumab	553.2	28.1	31	159.6	-10.5
X-1004	BRCA	LJM716 + trastuzumab	694.2	28.5	34	225.8	-9.2
X-1004	BRCA	LKA136	213.1	27.9	0	0	0
X-1004	BRCA	LKA136	173	27.5	2	-18.8	-1.4
X-1004	BRCA	LKA136	190.2	27.5	5	-10.7	-1.4
X-1004	BRCA	LKA136	200.1	26.8	9	-6.1	-3.9
X-1004	BRCA	LKA136	273.8	27.5	12	28.5	-1.4
X-1004	BRCA	LKA136	304.1	28	16	42.7	0.4
X-1004	BRCA	LKA136	309.3	27.8	19	45.1	-0.4
X-1004	BRCA	LKA136	336.9	29.3	23	58.1	5
X-1004	BRCA	LKA136	416.1	29.4	26	95.3	5.4
X-1004	BRCA	LKA136	578.6	27.5	30	171.5	-1.4
X-1004	BRCA	LKA136	703.5	21.5	33	230.1	-22.9
X-1004	BRCA	LLM871	207.4	29.3	0	0	0
X-1004	BRCA	LLM871	195.1	28.8	6	-5.9	-1.7
X-1004	BRCA	LLM871	229.9	29.1	10	10.8	-0.7
X-1004	BRCA	LLM871	292.8	28.9	13	41.2	-1.4
X-1004	BRCA	LLM871	352.9	29.1	17	70.2	-0.7
X-1004	BRCA	LLM871	412.1	30.2	20	98.7	3.1
X-1004	BRCA	LLM871	619.2	30.6	24	198.6	4.4
X-1004	BRCA	LLM871	1212.8	30.5	27	484.8	4.1
X-1004	BRCA	binimetinib	250.8	27.7	0	0	0
X-1004	BRCA	binimetinib	320.4	26.6	3	27.8	-4
X-1004	BRCA	binimetinib	402.3	26.4	7	60.4	-4.7
X-1004	BRCA	binimetinib	382.6	27.6	11	52.6	-0.4
X-1004	BRCA	binimetinib	384	28.2	18	53.1	1.8
X-1004	BRCA	binimetinib	445.9	28.1	22	77.8	1.4
X-1004	BRCA	binimetinib	460.2	27.5	26	83.5	-0.7
X-1004	BRCA	binimetinib	546.8	27.9	30	118	0.7
X-1004	BRCA	binimetinib	554.3	27	32	121	-2.5
X-1004	BRCA	binimetinib	617.9	26.7	35	146.4	-3.6
X-1004	BRCA	paclitaxel	209.1	29.4	0	0	0
X-1004	BRCA	paclitaxel	192.6	29.6	3	-7.9	0.7
X-1004	BRCA	paclitaxel	134.5	29.5	6	-35.7	0.3
X-1004	BRCA	paclitaxel	153.8	29.3	13	-26.4	-0.3
X-1004	BRCA	paclitaxel	189	28.8	17	-9.6	-2
X-1004	BRCA	paclitaxel	201.4	29.4	20	-3.7	0
X-1004	BRCA	paclitaxel	226.6	29.8	24	8.4	1.4
X-1004	BRCA	paclitaxel	277.8	30.4	27	32.9	3.4
X-1004	BRCA	paclitaxel	294.3	30.4	31	40.7	3.4
X-1004	BRCA	paclitaxel	305.1	30.4	34	45.9	3.4
X-1004	BRCA	paclitaxel	336.4	31.6	38	60.9	7.5
X-1004	BRCA	paclitaxel	354.8	32.1	41	69.7	9.2
X-1004	BRCA	paclitaxel	403.8	31.7	45	93.1	7.8
X-1004	BRCA	paclitaxel	464.9	31.7	48	122.3	7.8
X-1004	BRCA	paclitaxel	496.8	32.4	52	137.6	10.2
X-1004	BRCA	paclitaxel	523.3	32.1	55	150.3	9.2
X-1004	BRCA	paclitaxel	555.7	32	59	165.8	8.8
X-1004	BRCA	paclitaxel	611.8	32.4	62	192.6	10.2
X-1004	BRCA	tamoxifen	205	25.3	0	0	0
X-1004	BRCA	tamoxifen	303.8	25.2	4	48.2	-0.4
X-1004	BRCA	tamoxifen	402.4	26.6	11	96.3	5.1
X-1004	BRCA	tamoxifen	634.6	27.6	15	209.6	9.1
X-1004	BRCA	tamoxifen	786.6	28.1	18	283.7	11.1
X-1004	BRCA	tamoxifen	1055.8	28.8	22	415	13.8
X-1004	BRCA	tamoxifen	1452.3	27.9	25	608.4	10.3
X-1004	BRCA	tamoxifen	1863.6	29.2	27	809.1	15.4
X-1004	BRCA	trastuzumab	228.6	28.9	0	0	0
X-1004	BRCA	trastuzumab	211.9	29.4	3	-7.3	1.7
X-1004	BRCA	trastuzumab	184.5	27.7	6	-19.3	-4.2
X-1004	BRCA	trastuzumab	185.9	26.4	13	-18.7	-8.7
X-1004	BRCA	trastuzumab	199.6	26.9	17	-12.7	-6.9
X-1004	BRCA	trastuzumab	239.4	25.7	20	4.7	-11.1
X-1004	BRCA	trastuzumab	218.1	26	24	-4.6	-10
X-1004	BRCA	trastuzumab	261.6	26.8	27	14.4	-7.3
X-1004	BRCA	trastuzumab	381.7	27.3	31	67	-5.5
X-1004	BRCA	trastuzumab	679.1	27.2	34	197.1	-5.9
X-1004	BRCA	trastuzumab	757.3	27.9	36	231.3	-3.5
X-1004	BRCA	untreated	214.1	28	0	0	0
X-1004	BRCA	untreated	301.4	27.8	3	40.8	-0.7
X-1004	BRCA	untreated	324	27.3	6	51.3	-2.5
X-1004	BRCA	untreated	391.4	27	13	82.8	-3.6
X-1004	BRCA	untreated	630.9	26.4	17	194.7	-5.7
X-1004	BRCA	untreated	730.3	27.5	20	241.1	-1.8
X-1004	BRCA	untreated	859.1	27.5	24	301.3	-1.8
X-1004	BRCA	untreated	1030.4	27.7	27	381.3	-1.1
X-1004	BRCA	untreated	1438.2	28.9	29	571.7	3.2
X-1004	BRCA	LFW527 + everolimus	208.64	26.9	0	0	0
X-1004	BRCA	LFW527 + everolimus	170.91	27	3	-18.1	0.4
X-1004	BRCA	LFW527 + everolimus	193.69	26.4	7	-7.2	-1.9
X-1004	BRCA	LFW527 + everolimus	174.64	27.1	9	-16.3	0.7
X-1004	BRCA	LFW527 + everolimus	180.79	26.6	13	-13.3	-1.1
X-1004	BRCA	LFW527 + everolimus	179.16	28.3	17	-14.1	5.2
X-1004	BRCA	LFW527 + everolimus	209.1	28.2	21	0.2	4.8
X-1004	BRCA	LFW527 + everolimus	205.75	27.2	24	-1.4	1.1
X-1004	BRCA	LFW527 + everolimus	185.8	28.6	28	-10.9	6.3
X-1004	BRCA	LFW527 + everolimus	148.07	27.2	31	-29	1.1
X-1004	BRCA	LFW527 + everolimus	185.66	27	35	-11	0.4
X-1004	BRCA	LFW527 + everolimus	174.48	25.8	37	-16.4	-4.1
X-1004	BRCA	LFW527 + everolimus	151.9	25.5	41	-27.2	-5.2
X-1004	BRCA	LFW527 + everolimus	189.25	27.8	44	-9.3	3.3
X-1004	BRCA	LFW527 + everolimus	166.14	26.6	49	-20.4	-1.1
X-1004	BRCA	LFW527 + everolimus	198.14	27.3	52	-5	1.5
X-1004	BRCA	LFW527 + everolimus	171.01	27.1	62	-18	0.7
X-1004	BRCA	LFW527 + everolimus	162.3	28.8	66	-22.2	7.1
X-1004	BRCA	LFW527 + everolimus	124.47	27.8	70	-40.3	3.3
X-1004	BRCA	LFW527 + everolimus	116.65	26.7	73	-44.1	-0.7
X-1004	BRCA	LFW527 + everolimus	134.56	27.7	77	-35.5	3
X-1004	BRCA	LFW527 + everolimus	172.06	28.3	80	-17.5	5.2
X-1004	BRCA	LFW527 + everolimus	204.57	27.5	84	-2	2.2
X-1004	BRCA	LFW527 + everolimus	195.89	27.5	87	-6.1	2.2
X-1004	BRCA	LFW527 + everolimus	205.1	29.4	90	-1.7	9.3
X-1004	BRCA	LFW527 + everolimus	173.31	26.8	94	-16.9	-0.4
X-1004	BRCA	LFW527 + everolimus	118.65	27.9	97	-43.1	3.7
X-1004	BRCA	LFW527 + everolimus	131.76	28	100	-36.8	4.1
X-1004	BRCA	LFW527 + everolimus	153.95	27.6	105	-26.2	2.6
X-1004	BRCA	LFW527 + everolimus	148.12	27.1	108	-29	0.7
X-1004	BRCA	LFW527 + everolimus	112.82	28.2	111	-45.9	4.8
X-1004	BRCA	LFW527 + everolimus	135.67	27.4	114	-35	1.9
X-1004	BRCA	LFW527 + everolimus	207.01	27.9	118	-0.8	3.7
X-1004	BRCA	LFW527 + everolimus	211.42	27.2	121	1.3	1.1
X-1004	BRCA	LFW527 + everolimus	222.38	26.4	125	6.6	-1.9
X-1004	BRCA	LFW527 + everolimus	215.37	26.1	128	3.2	-3
X-1004	BRCA	LFW527 + everolimus	195.96	25.1	132	-6.1	-6.7
X-1004	BRCA	LFW527 + everolimus	255.92	25.3	136	22.7	-5.9
X-1004	BRCA	LFW527 + everolimus	233.54	25.4	139	11.9	-5.6
X-1004	BRCA	LFW527 + everolimus	241.04	25.6	142	15.5	-4.8
X-1004	BRCA	LFW527 + everolimus	308.65	26	146	47.9	-3.3
X-1004	BRCA	LFW527 + everolimus	276.7	25.4	149	32.6	-5.6
X-1004	BRCA	LFW527 + everolimus	282.72	26.3	153	35.5	-2.2
X-1008	BRCA	BGJ398	224.7	26.2	0	0	0
X-1008	BRCA	BGJ398	240.1	27.5	3	6.9	5
X-1008	BRCA	BGJ398	280	27.8	7	24.6	6.1
X-1008	BRCA	BGJ398	284.9	27.7	10	26.8	5.7
X-1008	BRCA	BGJ398	321.9	28.9	17	43.3	10.3
X-1008	BRCA	BGJ398	353.3	NA	20	57.2	10.3
X-1008	BRCA	BGJ398	394.2	28.3	25	75.4	8
X-1008	BRCA	BGJ398	376	27.4	28	67.3	4.6
X-1008	BRCA	BGJ398	431.9	28.3	31	92.2	8
X-1008	BRCA	BGJ398	451.4	29.5	35	100.9	12.6
X-1008	BRCA	BGJ398	500.3	29.6	38	122.7	13
X-1008	BRCA	BGJ398	548.5	29.5	42	144.1	12.6
X-1008	BRCA	BGJ398	613.1	29.5	45	172.9	12.6
X-1008	BRCA	BGJ398	578.4	29.8	49	157.4	13.7
X-1008	BRCA	BGJ398	706.5	28.9	52	214.4	10.3
X-1008	BRCA	BGJ398	760.5	28.9	56	238.5	10.3
X-1008	BRCA	BGJ398	776.7	28.7	59	245.7	9.5
X-1008	BRCA	BGJ398	792.2	29.1	63	252.6	11.1
X-1008	BRCA	BGJ398	840	29.4	66	273.8	12.2
X-1008	BRCA	BGJ398	899.8	29.4	70	300.4	12.2
X-1008	BRCA	BGJ398	882.3	29.1	73	292.7	11.1
X-1008	BRCA	BGJ398	956.2	28.9	76	325.5	10.3
X-1008	BRCA	BGJ398	998.1	29.6	80	344.2	13
X-1008	BRCA	BKM120	278.8	26.8	0	0	0
X-1008	BRCA	BKM120	266	28.6	3	-4.6	6.7
X-1008	BRCA	BKM120	298.4	27.7	7	7	3.4
X-1008	BRCA	BKM120	317.5	28.2	10	13.9	5.2
X-1008	BRCA	BKM120	380.4	28.9	17	36.4	7.8
X-1008	BRCA	BKM120	400.8	29	20	43.8	8.2
X-1008	BRCA	BKM120	392.8	28.3	25	40.9	5.6
X-1008	BRCA	BKM120	379.9	28.5	28	36.3	6.3
X-1008	BRCA	BKM120	363.5	29.2	31	30.4	9
X-1008	BRCA	BKM120	363.2	31.6	35	30.3	17.9
X-1008	BRCA	BKM120	362.5	30.9	38	30	15.3
X-1008	BRCA	BKM120	356.6	31	42	27.9	15.7
X-1008	BRCA	BKM120	371.3	30.2	45	33.2	12.7
X-1008	BRCA	BKM120	351.8	30.7	49	26.2	14.6
X-1008	BRCA	BKM120	349.3	30.5	52	25.3	13.8
X-1008	BRCA	BKM120	379.3	30	56	36	11.9
X-1008	BRCA	BKM120	356.4	30	59	27.8	11.9
X-1008	BRCA	BKM120	421.9	31.2	63	51.3	16.4
X-1008	BRCA	BKM120	407.8	31.5	66	46.3	17.5
X-1008	BRCA	BKM120	418.4	31.2	70	50.1	16.4
X-1008	BRCA	BKM120	429.1	30.7	73	53.9	14.6
X-1008	BRCA	BKM120	418.8	30.5	76	50.2	13.8
X-1008	BRCA	BKM120	403.2	31.2	80	44.6	16.4
X-1008	BRCA	BKM120	461.5	31.5	84	65.5	17.5
X-1008	BRCA	BKM120	566.2	30.9	87	103.1	15.3
X-1008	BRCA	BYL719	257.7	25.2	0	0	0
X-1008	BRCA	BYL719	191.2	26	4	-25.8	3.2
X-1008	BRCA	BYL719	224.7	25.6	7	-12.8	1.6
X-1008	BRCA	BYL719	241.9	25.8	12	-6.1	2.4
X-1008	BRCA	BYL719	234.7	25.4	15	-8.9	0.8
X-1008	BRCA	BYL719	233.5	25.4	18	-9.4	0.8
X-1008	BRCA	BYL719	204.7	26.4	22	-20.6	4.8
X-1008	BRCA	BYL719	224.6	26.8	25	-12.8	6.3
X-1008	BRCA	BYL719	182.5	26.3	29	-29.2	4.4
X-1008	BRCA	BYL719	178.7	25.9	32	-30.7	2.8
X-1008	BRCA	BYL719	193.8	25.9	36	-24.8	2.8
X-1008	BRCA	BYL719	206.6	27.4	39	-19.8	8.7
X-1008	BRCA	BYL719	190.3	25.5	43	-26.2	1.2
X-1008	BRCA	BYL719	192.3	26.2	46	-25.4	4
X-1008	BRCA	BYL719	189.7	26.6	50	-26.4	5.6
X-1008	BRCA	BYL719	179	26.8	53	-30.5	6.3
X-1008	BRCA	BYL719	132.6	27.5	57	-48.5	9.1
X-1008	BRCA	BYL719	127.8	27.4	60	-50.4	8.7
X-1008	BRCA	BYL719	122.8	27	63	-52.3	7.1
X-1008	BRCA	BYL719	119.2	27.7	67	-53.7	9.9
X-1008	BRCA	BYL719	122.3	28	71	-52.5	11.1
X-1008	BRCA	BYL719	114.3	27.6	74	-55.6	9.5
X-1008	BRCA	BYL719	126.9	27.4	78	-50.8	8.7
X-1008	BRCA	BYL719	95	26.3	88	-63.1	4.4
X-1008	BRCA	BYL719 + LJM716	241.5	28.3	0	0	0
X-1008	BRCA	BYL719 + LJM716	186	26.1	3	-23	-7.8
X-1008	BRCA	BYL719 + LJM716	182.3	26.5	6	-24.5	-6.4
X-1008	BRCA	BYL719 + LJM716	177.8	25.5	10	-26.4	-9.9
X-1008	BRCA	BYL719 + LJM716	217.7	25.1	13	-9.9	-11.3
X-1008	BRCA	BYL719 + LJM716	230.6	26.8	17	-4.5	-5.3
X-1008	BRCA	BYL719 + LJM716	324.8	28.5	20	34.5	0.7
X-1008	BRCA	BYL719 + LJM716	339.6	28.1	24	40.6	-0.7
X-1008	BRCA	BYL719 + LJM716	321.4	25.4	27	33.1	-10.2
X-1008	BRCA	BYL719 + LJM716	336.3	25.5	31	39.3	-9.9
X-1008	BRCA	BYL719 + LJM716	345	26.9	34	42.9	-4.9
X-1008	BRCA	BYL719 + LJM716	360.9	27.7	38	49.4	-2.1
X-1008	BRCA	BYL719 + LJM716	416.1	28	41	72.3	-1.1
X-1008	BRCA	BYL719 + LJM716	429.7	27.7	44	77.9	-2.1
X-1008	BRCA	BYL719 + LJM716	431.2	28.3	48	78.6	0
X-1008	BRCA	BYL719 + LJM716	439.5	26.5	52	82	-6.4
X-1008	BRCA	BYL719 + LJM716	471	27.5	55	95	-2.8
X-1008	BRCA	BYL719 + LJM716	458.5	26.1	59	89.9	-7.8
X-1008	BRCA	BYL719 + LJM716	473.7	26.9	69	96.1	-4.9
X-1008	BRCA	BYL719 + LJM716	466.7	27.7	73	93.3	-2.1
X-1008	BRCA	BYL719 + LJM716	483	26.1	76	100	-7.8
X-1008	BRCA	BYL719 + LJM716	493.6	27.7	80	104.4	-2.1
X-1008	BRCA	BYL719 + LJM716	497.7	29	83	106.1	2.5
X-1008	BRCA	BYL719 + LJM716	533.5	27.9	87	120.9	-1.4
X-1008	BRCA	BYL719 + LJM716	540.7	29.4	90	123.9	3.9
X-1008	BRCA	BYL719 + LJM716	544.7	28.4	93	125.5	0.4
X-1008	BRCA	BYL719 + LJM716	572.5	27	97	137.1	-4.6
X-1008	BRCA	BYL719 + LEE011	213	29	0	0	0
X-1008	BRCA	BYL719 + LEE011	175	29.1	4	-17.8	0.3
X-1008	BRCA	BYL719 + LEE011	181.5	28.6	8	-14.8	-1.4
X-1008	BRCA	BYL719 + LEE011	138.8	29.5	11	-34.8	1.7
X-1008	BRCA	BYL719 + LEE011	140.5	29.2	15	-34	0.7
X-1008	BRCA	BYL719 + LEE011	155.1	29.1	25	-27.2	0.3
X-1008	BRCA	BYL719 + LEE011	147.6	29	29	-30.7	0
X-1008	BRCA	BYL719 + LEE011	142.8	29.2	32	-33	0.7
X-1008	BRCA	BYL719 + LEE011	164.9	29.3	36	-22.6	1
X-1008	BRCA	BYL719 + LEE011	163.6	29.8	39	-23.2	2.8
X-1008	BRCA	BYL719 + LEE011	136.6	29.8	43	-35.9	2.8
X-1008	BRCA	BYL719 + LEE011	139	29.2	46	-34.7	0.7
X-1008	BRCA	BYL719 + LEE011	143.8	30.1	49	-32.5	3.8
X-1008	BRCA	BYL719 + LEE011	145.7	29.5	53	-31.6	1.7
X-1008	BRCA	BYL719 + LEE011	153.9	29.4	56	-27.7	1.4
X-1008	BRCA	BYL719 + LEE011	158.8	28.6	60	-25.4	-1.4
X-1008	BRCA	BYL719 + LEE011	167.8	29.7	63	-21.2	2.4
X-1008	BRCA	BYL719 + LEE011	196.4	28.1	67	-7.8	-3.1
X-1008	BRCA	BYL719 + LEE011	193	30	71	-9.4	3.4
X-1008	BRCA	BYL719 + LEE011	174.3	26.5	74	-18.2	-8.6
X-1008	BRCA	BYL719 + LEE011	192.9	28.2	78	-9.4	-2.8
X-1008	BRCA	BYL719 + LEE011	203.8	27.8	81	-4.3	-4.1
X-1008	BRCA	BYL719 + LEE011	192.1	25.3	85	-9.8	-12.8
X-1008	BRCA	BYL719 + LEE011	220.4	31	88	3.5	6.9
X-1008	BRCA	BYL719 + LEE011	192.3	28	92	-9.7	-3.4
X-1008	BRCA	BYL719 + LEE011	181.1	28.1	95	-15	-3.1
X-1008	BRCA	CGM097	205.2	26.4	0	0	0
X-1008	BRCA	CGM097	232.7	28.2	3	13.4	6.8
X-1008	BRCA	CGM097	292	28.5	6	42.3	8
X-1008	BRCA	CGM097	440.5	29.4	11	114.7	11.4
X-1008	BRCA	CGM097	479.8	29.6	14	133.8	12.1
X-1008	BRCA	CGM097	558.1	30.7	17	172	16.3
X-1008	BRCA	CGM097	626	30.1	21	205.1	14
X-1008	BRCA	CGM097	711.2	29.3	24	246.6	11
X-1008	BRCA	CGM097	806.9	29.9	28	293.2	13.3
X-1008	BRCA	CGM097	763.5	31.9	31	272.1	20.8
X-1008	BRCA	CGM097	1030.9	30.7	35	402.4	16.3
X-1008	BRCA	CGM097	1008.8	30.9	38	391.6	17
X-1008	BRCA	CLR457	204.2	26.9	0	0	0
X-1008	BRCA	CLR457	185.6	27.2	3	-9.1	1.1
X-1008	BRCA	CLR457	180.9	27	7	-11.4	0.4
X-1008	BRCA	CLR457	200.5	27.2	10	-1.8	1.1
X-1008	BRCA	CLR457	173.5	27.6	14	-15	2.6
X-1008	BRCA	CLR457	228.8	27.3	17	12	1.5
X-1008	BRCA	CLR457	236.7	27.6	21	15.9	2.6
X-1008	BRCA	CLR457	260.1	28.5	24	27.4	5.9
X-1008	BRCA	CLR457	277.9	28	28	36.1	4.1
X-1008	BRCA	CLR457	290.9	28.4	31	42.5	5.6
X-1008	BRCA	CLR457	279.5	27.3	34	36.9	1.5
X-1008	BRCA	CLR457	309.4	27.7	38	51.5	3
X-1008	BRCA	CLR457	317.1	27.1	42	55.3	0.7
X-1008	BRCA	CLR457	338.8	29.2	45	65.9	8.6
X-1008	BRCA	CLR457	372.8	27.8	49	82.6	3.3
X-1008	BRCA	CLR457	382.1	27.8	59	87.1	3.3
X-1008	BRCA	CLR457	419.7	28.1	63	105.5	4.5
X-1008	BRCA	CLR457	424	27.9	66	107.6	3.7
X-1008	BRCA	CLR457	513.8	27.7	70	151.6	3
X-1008	BRCA	CLR457	480.9	28.9	73	135.5	7.4
X-1008	BRCA	CLR457	558.5	28.4	77	173.5	5.6
X-1008	BRCA	CLR457	571.4	27.7	80	179.8	3
X-1008	BRCA	CLR457	585.3	28.6	83	186.6	6.3
X-1008	BRCA	CLR457	605.2	28.8	87	196.4	7.1
X-1008	BRCA	CLR457	641.5	28.4	90	214.2	5.6
X-1008	BRCA	CLR457	649	29.7	94	217.8	10.4
X-1008	BRCA	HDM201	289.6	29.6	0	0	0
X-1008	BRCA	HDM201	399.9	29.3	3	38.1	-1
X-1008	BRCA	HDM201	548.1	28.4	7	89.3	-4.1
X-1008	BRCA	HDM201	585	29.1	10	102	-1.7
X-1008	BRCA	HDM201	769.4	30.3	17	165.7	2.4
X-1008	BRCA	HDM201	870.2	30	20	200.5	1.4
X-1008	BRCA	HDM201	1369.5	29.9	25	372.9	1
X-1008	BRCA	INC424	245.6	27.4	0	0	0
X-1008	BRCA	INC424	235.9	27.2	4	-3.9	-0.7
X-1008	BRCA	INC424	281	28.1	7	14.4	2.6
X-1008	BRCA	INC424	279.9	27.4	11	14	0
X-1008	BRCA	INC424	326.4	27.3	14	32.9	-0.4
X-1008	BRCA	INC424	367.1	27.2	18	49.5	-0.7
X-1008	BRCA	INC424	384.4	27.9	21	56.5	1.8
X-1008	BRCA	INC424	381.9	27.5	25	55.5	0.4
X-1008	BRCA	INC424	430.7	28.7	28	75.4	4.7
X-1008	BRCA	INC424	465	28.1	31	89.3	2.6
X-1008	BRCA	INC424	542.1	28.2	35	120.7	2.9
X-1008	BRCA	INC424	575.6	28.2	39	134.4	2.9
X-1008	BRCA	INC424	561	28.9	42	128.4	5.5
X-1008	BRCA	INC424	660.2	28.6	46	168.8	4.4
X-1008	BRCA	INC424	908.5	28.8	56	269.9	5.1
X-1008	BRCA	INC424	971.9	28.5	60	295.7	4
X-1008	BRCA	INC424	1048	28.7	63	326.7	4.7
X-1008	BRCA	LEE011 + everolimus	221.6	23.5	0	0	0
X-1008	BRCA	LEE011 + everolimus	193.8	22.4	4	-12.5	-4.7
X-1008	BRCA	LEE011 + everolimus	187.8	23.7	7	-15.3	0.9
X-1008	BRCA	LEE011 + everolimus	185.3	23.3	11	-16.4	-0.9
X-1008	BRCA	LEE011 + everolimus	176.3	22.5	14	-20.4	-4.3
X-1008	BRCA	LEE011 + everolimus	178.4	22.5	18	-19.5	-4.3
X-1008	BRCA	LEE011 + everolimus	178.8	23.9	21	-19.3	1.7
X-1008	BRCA	LEE011 + everolimus	187.5	22.7	24	-15.4	-3.4
X-1008	BRCA	LEE011 + everolimus	186	24.1	28	-16.1	2.6
X-1008	BRCA	LEE011 + everolimus	191.9	23.8	32	-13.4	1.3
X-1008	BRCA	LEE011 + everolimus	201.9	23.6	35	-8.9	0.4
X-1008	BRCA	LEE011 + everolimus	203.4	23.8	39	-8.2	1.3
X-1008	BRCA	LEE011 + everolimus	161.6	22.9	49	-27.1	-2.6
X-1008	BRCA	LEE011 + everolimus	156	22.8	53	-29.6	-3
X-1008	BRCA	LEE011 + everolimus	167.1	24	56	-24.6	2.1
X-1008	BRCA	LEE011 + everolimus	200.6	23.1	60	-9.5	-1.7
X-1008	BRCA	LEE011 + everolimus	187.6	23.4	63	-15.3	-0.4
X-1008	BRCA	LEE011 + everolimus	235.8	23.4	67	6.4	-0.4
X-1008	BRCA	LEE011 + everolimus	236.1	23.8	70	6.5	1.3
X-1008	BRCA	LEE011 + everolimus	235.7	23.8	73	6.4	1.3
X-1008	BRCA	LEE011 + everolimus	239.4	24	77	8	2.1
X-1008	BRCA	LEE011 + everolimus	238.4	24.2	80	7.6	3
X-1008	BRCA	LEE011 + everolimus	245.8	23.4	84	10.9	-0.4
X-1008	BRCA	LEE011 + everolimus	247	23.6	87	11.5	0.4
X-1008	BRCA	LEE011 + everolimus	264.4	23.1	91	19.3	-1.7
X-1008	BRCA	LEE011 + everolimus	254.2	23	95	14.7	-2.1
X-1008	BRCA	LEE011 + everolimus	209.2	23.6	98	-5.6	0.4
X-1008	BRCA	LEE011	231.4	26.4	0	0	0
X-1008	BRCA	LEE011	230.6	27.6	4	-0.3	4.5
X-1008	BRCA	LEE011	183.6	26.7	7	-20.7	1.1
X-1008	BRCA	LEE011	223.8	27.7	11	-3.3	4.9
X-1008	BRCA	LEE011	221.8	28.1	14	-4.1	6.4
X-1008	BRCA	LEE011	282.5	29.6	18	22.1	12.1
X-1008	BRCA	LEE011	259.2	28.3	21	12	7.2
X-1008	BRCA	LEE011	315.8	27.7	25	36.5	4.9
X-1008	BRCA	LEE011	344.3	27.7	28	48.8	4.9
X-1008	BRCA	LEE011	344	28.6	32	48.7	8.3
X-1008	BRCA	LEE011	368.4	29.3	35	59.2	11
X-1008	BRCA	LEE011	361.5	28.2	39	56.2	6.8
X-1008	BRCA	LEE011	375.6	29.3	42	62.3	11
X-1008	BRCA	LEE011	500.5	29.1	45	116.3	10.2
X-1008	BRCA	LEE011	522.5	30.2	49	125.8	14.4
X-1008	BRCA	LEE011	526	30.1	53	127.3	14
X-1008	BRCA	LEE011	513.7	29.5	56	122	11.7
X-1008	BRCA	LEE011	505.9	29.9	60	118.6	13.3
X-1008	BRCA	LEE011	818.4	30.3	70	253.7	14.8
X-1008	BRCA	LEE011	858.2	30.3	74	270.9	14.8
X-1008	BRCA	LEE011	905.7	31.5	77	291.4	19.3
X-1008	BRCA	LFA102	227.5	27.4	0	0	0
X-1008	BRCA	LFA102	324.7	27.6	6	42.7	0.7
X-1008	BRCA	LFA102	379.8	27.1	9	66.9	-1.1
X-1008	BRCA	LFA102	473.3	27.8	14	108	1.5
X-1008	BRCA	LFA102	541.8	27.6	17	138.2	0.7
X-1008	BRCA	LFA102	673	27.7	20	195.8	1.1
X-1008	BRCA	LFA102	744	28.2	24	227	2.9
X-1008	BRCA	LFA102	790	29	27	247.3	5.8
X-1008	BRCA	LFA102	797.6	29.3	31	250.6	6.9
X-1008	BRCA	LFA102	959.7	29.1	34	321.8	6.2
X-1008	BRCA	LFA102	1051.4	29	38	362.2	5.8
X-1008	BRCA	LFA102	1019.5	29.8	41	348.1	8.8
X-1008	BRCA	LFA102	1191.3	29.2	45	423.6	6.6
X-1008	BRCA	LFA102	1204.1	29.7	48	429.3	8.4
X-1008	BRCA	LJM716	251.8	29.9	0	0	0
X-1008	BRCA	LJM716	189.9	29.2	4	-24.6	-2.3
X-1008	BRCA	LJM716	179	30.4	7	-28.9	1.7
X-1008	BRCA	LJM716	205.8	30.4	11	-18.3	1.7
X-1008	BRCA	LJM716	230.4	30.7	14	-8.5	2.7
X-1008	BRCA	LJM716	234.9	31.1	18	-6.7	4
X-1008	BRCA	LJM716	238.3	30.9	21	-5.4	3.3
X-1008	BRCA	LJM716	235.8	31.3	24	-6.4	4.7
X-1008	BRCA	LJM716	255.7	30.7	28	1.5	2.7
X-1008	BRCA	LJM716	325.6	31.4	32	29.3	5
X-1008	BRCA	LJM716	313.2	31.6	35	24.4	5.7
X-1008	BRCA	LJM716	384.5	31.6	39	52.7	5.7
X-1008	BRCA	LJM716	381.3	32.5	49	51.4	8.7
X-1008	BRCA	LJM716	424.5	32.2	53	68.6	7.7
X-1008	BRCA	LJM716	441.5	31.8	56	75.3	6.4
X-1008	BRCA	LJM716	505.5	30.7	60	100.8	2.7
X-1008	BRCA	LJM716	488.2	31.7	63	93.9	6
X-1008	BRCA	LJM716	491.7	30.5	67	95.3	2
X-1008	BRCA	LJM716	501	30.7	70	99	2.7
X-1008	BRCA	LJM716	499.8	30.9	73	98.5	3.3
X-1008	BRCA	LJM716	511.3	30.7	77	103.1	2.7
X-1008	BRCA	LJM716	526.2	31.1	80	109	4
X-1008	BRCA	LJM716	556.8	32.8	84	121.1	9.7
X-1008	BRCA	LJM716 + trastuzumab	238	31.4	0	0	0
X-1008	BRCA	LJM716 + trastuzumab	234.2	29.1	2	-1.6	-7.3
X-1008	BRCA	LJM716 + trastuzumab	246.1	28.5	7	3.4	-9.2
X-1008	BRCA	LJM716 + trastuzumab	210.2	27.7	10	-11.7	-11.8
X-1008	BRCA	LJM716 + trastuzumab	221.8	30.2	13	-6.8	-3.8
X-1008	BRCA	LJM716 + trastuzumab	151.7	29.6	17	-36.3	-5.7
X-1008	BRCA	LJM716 + trastuzumab	140.6	29.2	20	-40.9	-7
X-1008	BRCA	LJM716 + trastuzumab	106.1	30.2	24	-55.4	-3.8
X-1008	BRCA	LJM716 + trastuzumab	81.9	30.1	27	-65.6	-4.1
X-1008	BRCA	LJM716 + trastuzumab	87.1	29.4	31	-63.4	-6.4
X-1008	BRCA	LJM716 + trastuzumab	58	30.2	34	-75.6	-3.8
X-1008	BRCA	LJM716 + trastuzumab	64.7	30.4	38	-72.8	-3.2
X-1008	BRCA	LJM716 + trastuzumab	52.2	29.5	41	-78.1	-6.1
X-1008	BRCA	LJM716 + trastuzumab	50.1	31.5	45	-78.9	0.3
X-1008	BRCA	LJM716 + trastuzumab	59.6	30.8	48	-75	-1.9
X-1008	BRCA	LJM716 + trastuzumab	71.5	30.6	52	-70	-2.5
X-1008	BRCA	LJM716 + trastuzumab	88.3	30.5	55	-62.9	-2.9
X-1008	BRCA	LJM716 + trastuzumab	93.7	29	58	-60.6	-7.6
X-1008	BRCA	LJM716 + trastuzumab	122.1	30.1	62	-48.7	-4.1
X-1008	BRCA	LJM716 + trastuzumab	199.2	30.3	66	-16.3	-3.5
X-1008	BRCA	LJM716 + trastuzumab	174.7	30.4	69	-26.6	-3.2
X-1008	BRCA	LJM716 + trastuzumab	220.9	30.4	73	-7.2	-3.2
X-1008	BRCA	LJM716 + trastuzumab	345.9	31.1	83	45.3	-1
X-1008	BRCA	LJM716 + trastuzumab	389	30.3	87	63.4	-3.5
X-1008	BRCA	LJM716 + trastuzumab	380.1	30.7	90	59.7	-2.2
X-1008	BRCA	LJM716 + trastuzumab	408.2	30.3	94	71.5	-3.5
X-1008	BRCA	LJM716 + trastuzumab	518.3	31.1	97	117.8	-1
X-1008	BRCA	LJM716 + trastuzumab	568.2	30.9	101	138.7	-1.6
X-1008	BRCA	LJM716 + trastuzumab	580.6	30.9	104	143.9	-1.6
X-1008	BRCA	LJM716 + trastuzumab	583.1	30.8	107	145	-1.9
X-1008	BRCA	LJM716 + trastuzumab	594.6	30.8	111	149.8	-1.9
X-1008	BRCA	LJM716 + trastuzumab	619	31.3	114	160.1	-0.3
X-1008	BRCA	LJM716 + trastuzumab	733.7	32.3	118	208.3	2.9
X-1008	BRCA	LJM716 + trastuzumab	794.7	31.4	121	233.9	0
X-1008	BRCA	LJM716 + trastuzumab	968.9	31.7	125	307.1	1
X-1008	BRCA	LKA136	211.8	26.5	0	0	0
X-1008	BRCA	LKA136	278	26.2	4	31.3	-1.1
X-1008	BRCA	LKA136	310	26.5	7	46.4	0
X-1008	BRCA	LKA136	402.5	27	11	90	1.9
X-1008	BRCA	LKA136	390.6	27.2	14	84.4	2.6
X-1008	BRCA	LKA136	449.9	27.1	18	112.4	2.3
X-1008	BRCA	LKA136	499.2	27.7	21	135.7	4.5
X-1008	BRCA	LKA136	622.5	27.3	25	193.9	3
X-1008	BRCA	LKA136	608.2	27.3	28	187.2	3
X-1008	BRCA	LKA136	812.4	28.2	31	283.6	6.4
X-1008	BRCA	LKA136	856.1	28	35	304.2	5.7
X-1008	BRCA	LKA136	878.4	28.1	39	314.7	6
X-1008	BRCA	LKA136	900.9	29.1	42	325.4	9.8
X-1008	BRCA	LLM871	335.5	25.3	0	0	0
X-1008	BRCA	LLM871	551.6	24.9	6	64.4	-1.6
X-1008	BRCA	LLM871	644	25.5	9	92	0.8
X-1008	BRCA	LLM871	799.2	25.9	14	138.2	2.4
X-1008	BRCA	LLM871	785.7	25.8	17	134.2	2
X-1008	BRCA	LLM871	979.8	27.7	20	192	9.5
X-1008	BRCA	LLM871	1101.7	27.5	24	228.4	8.7
X-1008	BRCA	LLM871	1159.5	27.3	27	245.6	7.9
X-1008	BRCA	binimetinib	216.6	24.8	0	0	0
X-1008	BRCA	binimetinib	242.9	25.8	4	12.1	4
X-1008	BRCA	binimetinib	260.3	25.8	7	20.2	4
X-1008	BRCA	binimetinib	307.2	25	11	41.8	0.8
X-1008	BRCA	binimetinib	245.5	23.6	14	13.3	-4.8
X-1008	BRCA	binimetinib	300.2	23	18	38.6	-7.3
X-1008	BRCA	binimetinib	310	23.8	21	43.1	-4
X-1008	BRCA	binimetinib	364.3	26.1	25	68.2	5.2
X-1008	BRCA	binimetinib	402.3	26	28	85.7	4.8
X-1008	BRCA	binimetinib	492.7	25.3	31	127.5	2
X-1008	BRCA	binimetinib	498.7	25.1	35	130.2	1.2
X-1008	BRCA	binimetinib	513.6	24.6	39	137.1	-0.8
X-1008	BRCA	binimetinib	495.8	24.4	42	128.9	-1.6
X-1008	BRCA	binimetinib	443.6	23.4	46	104.8	-5.6
X-1008	BRCA	binimetinib	390.5	20.2	56	80.3	-18.5
X-1008	BRCA	binimetinib	526.8	25.4	60	143.2	2.4
X-1008	BRCA	binimetinib	489.5	25.4	63	126	2.4
X-1008	BRCA	binimetinib	543.6	25.2	67	151	1.6
X-1008	BRCA	binimetinib	629.6	23.6	70	190.7	-4.8
X-1008	BRCA	binimetinib	683	22.2	74	215.3	-10.5
X-1008	BRCA	binimetinib	688.2	21.3	77	217.7	-14.1
X-1008	BRCA	binimetinib	707.9	21.6	80	226.8	-12.9
X-1008	BRCA	binimetinib	725.3	26.6	84	234.9	7.3
X-1008	BRCA	binimetinib	740.8	26.2	87	242	5.6
X-1008	BRCA	binimetinib	755.8	24.2	91	248.9	-2.4
X-1008	BRCA	binimetinib	792.5	24.1	94	265.9	-2.8
X-1008	BRCA	binimetinib	1023.4	22.4	98	372.5	-9.7
X-1008	BRCA	paclitaxel	202.5	26.9	0	0	0
X-1008	BRCA	paclitaxel	251.2	26.6	6	24	-1.1
X-1008	BRCA	paclitaxel	268.4	26.5	9	32.5	-1.5
X-1008	BRCA	paclitaxel	196.5	26.8	14	-3	-0.4
X-1008	BRCA	paclitaxel	154	26.5	17	-24	-1.5
X-1008	BRCA	paclitaxel	145.8	26.8	20	-28	-0.4
X-1008	BRCA	paclitaxel	106.3	27.3	24	-47.5	1.5
X-1008	BRCA	paclitaxel	83.5	27	27	-58.8	0.4
X-1008	BRCA	paclitaxel	90.6	27.6	31	-55.3	2.6
X-1008	BRCA	paclitaxel	89.2	28	34	-56	4.1
X-1008	BRCA	paclitaxel	95.3	26.8	38	-52.9	-0.4
X-1008	BRCA	paclitaxel	81.1	27.9	41	-60	3.7
X-1008	BRCA	paclitaxel	81.5	27	45	-59.8	0.4
X-1008	BRCA	paclitaxel	82.9	27.4	48	-59.1	1.9
X-1008	BRCA	paclitaxel	55.4	27.6	52	-72.6	2.6
X-1008	BRCA	paclitaxel	75.5	27.5	55	-62.7	2.2
X-1008	BRCA	paclitaxel	77.9	29	59	-61.5	7.8
X-1008	BRCA	paclitaxel	101.3	27.9	62	-50	3.7
X-1008	BRCA	paclitaxel	113.8	28.8	65	-43.8	7.1
X-1008	BRCA	paclitaxel	78.9	28.8	69	-61	7.1
X-1008	BRCA	paclitaxel	96.2	28.4	73	-52.5	5.6
X-1008	BRCA	paclitaxel	50.6	28.9	76	-75	7.4
X-1008	BRCA	paclitaxel	61.4	28.8	80	-69.7	7.1
X-1008	BRCA	paclitaxel	45.3	29.9	90	-77.6	11.2
X-1008	BRCA	tamoxifen	245.2	22.8	0	0	0
X-1008	BRCA	tamoxifen	314.4	23.6	3	28.2	3.5
X-1008	BRCA	tamoxifen	304.5	23.4	7	24.2	2.6
X-1008	BRCA	tamoxifen	342.8	23.3	10	39.8	2.2
X-1008	BRCA	tamoxifen	459.9	25.1	17	87.6	10.1
X-1008	BRCA	tamoxifen	598.4	24.4	20	144	7
X-1008	BRCA	tamoxifen	646.4	24.4	25	163.6	7
X-1008	BRCA	tamoxifen	775.5	25.1	28	216.3	10.1
X-1008	BRCA	tamoxifen	789.5	25.2	31	222	10.5
X-1008	BRCA	tamoxifen	902.8	25.8	35	268.2	13.2
X-1008	BRCA	tamoxifen	944.4	25.4	38	285.2	11.4
X-1008	BRCA	tamoxifen	958	25.5	42	290.7	11.8
X-1008	BRCA	tamoxifen	1241.2	26.3	45	406.2	15.4
X-1008	BRCA	trastuzumab	267.5	24.6	0	0	0
X-1008	BRCA	trastuzumab	350	25.5	6	30.8	3.7
X-1008	BRCA	trastuzumab	440.7	25.1	9	64.7	2
X-1008	BRCA	trastuzumab	484.6	25	14	81.2	1.6
X-1008	BRCA	trastuzumab	540	25.3	17	101.9	2.8
X-1008	BRCA	trastuzumab	625.5	25.8	20	133.8	4.9
X-1008	BRCA	trastuzumab	764.9	26.2	24	185.9	6.5
X-1008	BRCA	trastuzumab	779.3	25.7	27	191.3	4.5
X-1008	BRCA	trastuzumab	912.9	26.4	31	241.3	7.3
X-1008	BRCA	trastuzumab	971.1	26.6	34	263	8.1
X-1008	BRCA	trastuzumab	1078.6	26.9	38	303.2	9.3
X-1008	BRCA	trastuzumab	1194.4	27.7	41	346.5	12.6
X-1008	BRCA	untreated	255.6	27.2	0	0	0
X-1008	BRCA	untreated	289.4	27.6	4	13.2	1.5
X-1008	BRCA	untreated	331.5	27.5	7	29.7	1.1
X-1008	BRCA	untreated	350.3	28.6	11	37.1	5.1
X-1008	BRCA	untreated	449.3	28.8	14	75.8	5.9
X-1008	BRCA	untreated	463.9	28.4	18	81.5	4.4
X-1008	BRCA	untreated	516.5	28.2	21	102.1	3.7
X-1008	BRCA	untreated	568.9	28.4	25	122.6	4.4
X-1008	BRCA	untreated	581.9	28.7	28	127.7	5.5
X-1008	BRCA	untreated	664	28.7	32	159.8	5.5
X-1008	BRCA	untreated	721.6	28.4	35	182.3	4.4
X-1008	BRCA	untreated	877.1	29.4	39	243.2	8.1
X-1008	BRCA	untreated	1028.5	29.8	42	302.4	9.6
X-1008	BRCA	LFW527 + everolimus	233.38	26.2	0	0	0
X-1008	BRCA	LFW527 + everolimus	165.09	25.2	4	-29.3	-3.8
X-1008	BRCA	LFW527 + everolimus	178.59	25.9	7	-23.5	-1.1
X-1008	BRCA	LFW527 + everolimus	146.31	23.6	11	-37.3	-9.9
X-1008	BRCA	LFW527 + everolimus	145.06	24.4	14	-37.8	-6.9
X-1008	BRCA	LFW527 + everolimus	176.76	24.8	17	-24.3	-5.3
X-1008	BRCA	LFW527 + everolimus	148.74	25.1	21	-36.3	-4.2
X-1008	BRCA	LFW527 + everolimus	195.18	25.7	25	-16.4	-1.9
X-1008	BRCA	LFW527 + everolimus	180.13	25.2	28	-22.8	-3.8
X-1008	BRCA	LFW527 + everolimus	160.96	24.4	32	-31	-6.9
X-1008	BRCA	LFW527 + everolimus	164.45	21.2	35	-29.5	-19.1
X-1027	CRC	5FU	245	26	0	0	0
X-1027	CRC	5FU	318.8	23.9	2	30.1	-8.1
X-1027	CRC	5FU	553.5	24.1	6	125.9	-7.3
X-1027	CRC	5FU	1145.1	24.3	9	367.4	-6.5
X-1027	CRC	5FU	1219.4	22.4	13	397.7	-13.8
X-1027	CRC	5FU	1664.6	26.1	17	579.4	0.4
X-1027	CRC	5FU	1813.8	26.2	20	640.3	0.8
X-1027	CRC	BKM120	200.1	20.8	0	0	0
X-1027	CRC	BKM120	331.5	20.1	3	65.7	-3.4
X-1027	CRC	BKM120	316.4	19.5	7	58.1	-6.2
X-1027	CRC	BKM120	370.5	18.8	10	85.2	-9.6
X-1027	CRC	BKM120	442.4	18.2	14	121.1	-12.5
X-1027	CRC	BKM120	516.9	18.6	18	158.3	-10.6
X-1027	CRC	BKM120	514.7	20	21	157.2	-3.8
X-1027	CRC	BKM120	576.1	19.7	24	187.9	-5.3
X-1027	CRC	BKM120 + LJC049	300.2	23.5	0	0	0
X-1027	CRC	BKM120 + LJC049	796.6	22.7	7	165.4	-3.4
X-1027	CRC	BKM120 + LJC049	965.9	21.9	10	221.8	-6.8
X-1027	CRC	BKM120 + LJC049	1253	22.4	13	317.4	-4.7
X-1027	CRC	BKM120 + LJC049	1593.1	21.9	17	430.7	-6.8
X-1027	CRC	BYL719 + cetuximab + encorafenib	248.4	20.6	0	0	0
X-1027	CRC	BYL719 + cetuximab + encorafenib	324.9	20.1	3	30.8	-2.4
X-1027	CRC	BYL719 + cetuximab + encorafenib	371.4	18.9	6	49.5	-8.3
X-1027	CRC	BYL719 + cetuximab + encorafenib	406.6	19.6	9	63.7	-4.9
X-1027	CRC	BYL719 + cetuximab + encorafenib	745.7	21.4	13	200.2	3.9
X-1027	CRC	BYL719 + cetuximab + encorafenib	952.5	20.1	16	283.5	-2.4
X-1027	CRC	BYL719 + cetuximab + encorafenib	1100.1	20.4	20	342.9	-1
X-1027	CRC	BYL719 + cetuximab + encorafenib	1356.6	19.2	22	446.1	-6.8
X-1027	CRC	BYL719 + cetuximab	223.6	20.1	0	0	0
X-1027	CRC	BYL719 + cetuximab	250.3	18.7	3	11.9	-7
X-1027	CRC	BYL719 + cetuximab	255.4	20.1	6	14.2	0
X-1027	CRC	BYL719 + cetuximab	288	22.9	10	28.8	13.9
X-1027	CRC	BYL719 + cetuximab	321.6	21.8	13	43.8	8.5
X-1027	CRC	BYL719 + cetuximab	357.4	21	17	59.8	4.5
X-1027	CRC	BYL719 + cetuximab	415.2	22.4	19	85.7	11.4
X-1027	CRC	BYL719 + cetuximab	492.4	20.8	23	120.2	3.5
X-1027	CRC	BYL719 + cetuximab	498.3	20.7	27	122.9	3
X-1027	CRC	BYL719 + cetuximab	659.9	22.2	30	195.1	10.4
X-1027	CRC	BYL719 + cetuximab	669.7	21.4	31	199.5	6.5
X-1027	CRC	BYL719	257.8	22.7	0	0	0
X-1027	CRC	BYL719	263.8	21.6	4	2.3	-4.8
X-1027	CRC	BYL719	279.6	21.1	7	8.5	-7
X-1027	CRC	BYL719	384.8	19.3	11	49.3	-15
X-1027	CRC	BYL719	503.8	18.6	14	95.4	-18.1
X-1027	CRC	BYL719	480.1	21.3	15	86.2	-6.2
X-1027	CRC	BYL719	703.6	20.7	18	172.9	-8.8
X-1027	CRC	BYL719	704.4	20	21	173.2	-11.9
X-1027	CRC	BYL719 + LJM716	204.2	20.6	0	0	0
X-1027	CRC	BYL719 + LJM716	191.7	18.8	4	-6.1	-8.7
X-1027	CRC	BYL719 + LJM716	193.9	19	7	-5	-7.8
X-1027	CRC	BYL719 + LJM716	201.9	18.1	11	-1.1	-12.1
X-1027	CRC	BYL719 + LJM716	288.9	18.4	15	41.5	-10.7
X-1027	CRC	BYL719 + LJM716	330.7	17.9	18	61.9	-13.1
X-1027	CRC	BYL719 + LJM716	338.2	17.4	21	65.6	-15.5
X-1027	CRC	BYL719 + binimetinib	301.4	21.7	0	0	0
X-1027	CRC	BYL719 + binimetinib	648.6	18	7	115.2	-17.1
X-1027	CRC	BYL719 + binimetinib	701.4	18.9	10	132.7	-12.9
X-1027	CRC	BYL719 + binimetinib	809.6	19.6	13	168.6	-9.7
X-1027	CRC	BYL719 + encorafenib	300.7	24.3	0	0	0
X-1027	CRC	BYL719 + encorafenib	738	22.4	7	145.4	-7.8
X-1027	CRC	BYL719 + encorafenib	1029.3	22.5	10	242.3	-7.4
X-1027	CRC	BYL719 + encorafenib	1232.6	22.4	13	309.9	-7.8
X-1027	CRC	BYL719 + encorafenib	1426.7	22	17	374.5	-9.5
X-1027	CRC	CGM097	302.8	23.6	0	0	0
X-1027	CRC	CGM097	576.3	22	3	90.3	-6.8
X-1027	CRC	CGM097	753.5	21.3	7	148.8	-9.7
X-1027	CRC	CGM097	1090.6	20.3	10	260.2	-14
X-1027	CRC	CGM097	1357.1	19	14	348.2	-19.5
X-1027	CRC	CKX620	194.4	19.2	0	0	0
X-1027	CRC	CKX620	241.1	19.1	3	24	-0.5
X-1027	CRC	CKX620	273.4	18.7	7	40.6	-2.6
X-1027	CRC	CKX620	284.4	18.9	10	46.3	-1.6
X-1027	CRC	CKX620	299.2	18.5	14	53.9	-3.6
X-1027	CRC	CKX620	326	18.6	17	67.7	-3.1
X-1027	CRC	CKX620	380.7	18.2	21	95.8	-5.2
X-1027	CRC	CKX620	388.5	19	24	99.8	-1
X-1027	CRC	CLR457	220.1	21.7	0	0	0
X-1027	CRC	CLR457	249.7	19.7	3	13.4	-9.2
X-1027	CRC	CLR457	262.1	20.3	7	19.1	-6.5
X-1027	CRC	CLR457	313	19.9	10	42.2	-8.3
X-1027	CRC	CLR457	322.5	20.2	14	46.5	-6.9
X-1027	CRC	CLR457	453.7	19.6	18	106.1	-9.7
X-1027	CRC	CLR457	546.9	19.3	21	148.5	-11.1
X-1027	CRC	CLR457	615.4	20	24	179.6	-7.8
X-1027	CRC	HDM201	236.8	23.1	0	0	0
X-1027	CRC	HDM201	417.6	22.2	3	76.4	-3.9
X-1027	CRC	HDM201	587.1	20.7	7	147.9	-10.4
X-1027	CRC	HDM201	743.9	20.1	10	214.1	-13
X-1027	CRC	HDM201	1048.6	20.2	14	342.8	-12.6
X-1027	CRC	HDM201	1191.5	21.8	18	403.2	-5.6
X-1027	CRC	HDM201	1433.1	20.3	21	505.2	-12.1
X-1027	CRC	HDM201	1800.3	22.3	24	660.3	-3.5
X-1027	CRC	cetuximab	200.5	24.7	0	0	0
X-1027	CRC	cetuximab	314.5	23.7	5	56.9	-4
X-1027	CRC	cetuximab	423.1	23.9	8	111	-3.2
X-1027	CRC	cetuximab	530.5	22.7	11	164.6	-8.1
X-1027	CRC	cetuximab	634	22.5	14	216.2	-8.9
X-1027	CRC	cetuximab	1074.1	23.3	18	435.7	-5.7
X-1027	CRC	cetuximab	1201.1	23.5	21	499.1	-4.9
X-1027	CRC	cetuximab	1621.6	23	24	708.8	-6.9
X-1027	CRC	cetuximab + encorafenib	215.6	19	0	0	0
X-1027	CRC	cetuximab + encorafenib	300.3	19.4	3	39.3	2.1
X-1027	CRC	cetuximab + encorafenib	368.3	18.6	6	70.8	-2.1
X-1027	CRC	cetuximab + encorafenib	436.2	19.8	9	102.3	4.2
X-1027	CRC	cetuximab + encorafenib	617.5	23.2	13	186.4	22.1
X-1027	CRC	cetuximab + encorafenib	978.1	23	16	353.7	21.1
X-1027	CRC	cetuximab + encorafenib	1275.5	21.1	20	491.6	11.1
X-1027	CRC	cetuximab + encorafenib	1340.8	21.4	22	521.9	12.6
X-1027	CRC	LEE011	226.9	21.5	0	0	0
X-1027	CRC	LEE011	243.9	18.9	3	7.5	-12.1
X-1027	CRC	LEE011	289.8	19.2	7	27.7	-10.7
X-1027	CRC	LEE011	324.5	18.4	10	43	-14.4
X-1027	CRC	encorafenib	219.9	21.5	0	0	0
X-1027	CRC	encorafenib	346.6	22.2	3	57.6	3.3
X-1027	CRC	encorafenib	514.1	20.6	7	133.8	-4.2
X-1027	CRC	encorafenib	829.8	20.9	10	277.4	-2.8
X-1027	CRC	encorafenib	925.9	20.7	14	321.1	-3.7
X-1027	CRC	encorafenib	1306.2	21	18	494	-2.3
X-1027	CRC	encorafenib	1963.7	21.3	21	793	-0.9
X-1027	CRC	LJC049	283.2	20.9	0	0	0
X-1027	CRC	LJC049	450	19	3	58.9	-9.1
X-1027	CRC	LJC049	746.6	19.5	7	163.6	-6.7
X-1027	CRC	LJC049	1088.9	18.7	10	284.5	-10.5
X-1027	CRC	LKA136	308.1	20.3	0	0	0
X-1027	CRC	LKA136	627.8	19.7	3	103.8	-3
X-1027	CRC	LKA136	882.9	18.5	7	186.6	-8.9
X-1027	CRC	LKA136	1076.4	17.1	10	249.4	-15.8
X-1027	CRC	LKA136	1557.6	20.4	14	405.6	0.5
X-1027	CRC	binimetinib	225.5	20.9	0	0	0
X-1027	CRC	binimetinib	260.7	18.3	3	15.6	-12.4
X-1027	CRC	binimetinib	370.4	21.2	7	64.3	1.4
X-1027	CRC	binimetinib	368.2	17.6	10	63.3	-15.8
X-1027	CRC	untreated	299.2	24.7	0	0	0
X-1027	CRC	untreated	590.9	23.4	3	97.5	-5.3
X-1027	CRC	untreated	770.5	24.6	7	157.5	-0.4
X-1027	CRC	untreated	1161.9	23	10	288.3	-6.9
X-1027	CRC	untreated	1485.3	22.4	14	396.4	-9.3
X-1027	CRC	untreated	1707.1	21.9	17	470.6	-11.3
X-1119	CRC	5FU	214.9	22.1	0	0	0
X-1119	CRC	5FU	226.5	20.6	2	5.4	-6.8
X-1119	CRC	5FU	177.8	20.5	6	-17.3	-7.2
X-1119	CRC	5FU	175.6	19.8	10	-18.3	-10.4
X-1119	CRC	5FU	157.6	20.6	15	-26.7	-6.8
X-1119	CRC	5FU	150.4	22.9	20	-30	3.6
X-1119	CRC	5FU	199.2	22.5	23	-7.3	1.8
X-1119	CRC	5FU	154.8	22.3	27	-28	0.9
X-1119	CRC	5FU	172.4	22.5	30	-19.8	1.8
X-1119	CRC	5FU	174	23.1	35	-19	4.5
X-1119	CRC	5FU	169	23	38	-21.4	4.1
X-1119	CRC	5FU	157.5	23.1	41	-26.7	4.5
X-1119	CRC	5FU	154	23.7	44	-28.3	7.2
X-1119	CRC	5FU	146.8	23.1	48	-31.7	4.5
X-1119	CRC	5FU	178.8	21.9	51	-16.8	-0.9
X-1119	CRC	5FU	159.9	22.7	56	-25.6	2.7
X-1119	CRC	5FU	180.5	22.1	58	-16	0
X-1119	CRC	5FU	142	23.3	62	-33.9	5.4
X-1119	CRC	5FU	159.3	24.5	65	-25.9	10.9
X-1119	CRC	5FU	101.5	25.4	70	-52.8	14.9
X-1119	CRC	5FU	92.9	25.3	71	-56.8	14.5
X-1119	CRC	5FU	103.9	22.3	73	-51.7	0.9
X-1119	CRC	5FU	109.2	22.5	77	-49.2	1.8
X-1119	CRC	5FU	100.6	23.6	80	-53.2	6.8
X-1119	CRC	5FU	114.8	23.3	86	-46.6	5.4
X-1119	CRC	5FU	104.2	23.1	90	-51.5	4.5
X-1119	CRC	BKM120	200.1	22.3	0	0	0
X-1119	CRC	BKM120	201.8	23.3	2	0.8	4.5
X-1119	CRC	BKM120	164.2	23.5	6	-17.9	5.4
X-1119	CRC	BKM120	243.7	23.1	10	21.8	3.6
X-1119	CRC	BKM120	296.8	22.3	15	48.3	0
X-1119	CRC	BKM120	421.9	21.3	20	110.8	-4.5
X-1119	CRC	BKM120	505.9	20.8	23	152.8	-6.7
X-1119	CRC	BKM120 + LJC049	208.4	22.2	0	0	0
X-1119	CRC	BKM120 + LJC049	259.1	21.4	3	24.3	-3.6
X-1119	CRC	BKM120 + LJC049	390.2	20.7	8	87.2	-6.8
X-1119	CRC	BKM120 + LJC049	461.8	18.5	13	121.6	-16.7
X-1119	CRC	BKM120 + LJC049	503.9	17.1	15	141.8	-23
X-1119	CRC	BYL719 + cetuximab + encorafenib	268.1	26	0	0	0
X-1119	CRC	BYL719 + cetuximab + encorafenib	406.8	25.5	3	51.7	-1.9
X-1119	CRC	BYL719 + cetuximab + encorafenib	407.3	24.1	6	51.9	-7.3
X-1119	CRC	BYL719 + cetuximab + encorafenib	570.4	25.1	13	112.8	-3.5
X-1119	CRC	BYL719 + cetuximab + encorafenib	878.9	24.3	17	227.8	-6.5
X-1119	CRC	BYL719 + cetuximab + encorafenib	999.3	24	20	272.7	-7.7
X-1119	CRC	BYL719 + cetuximab + encorafenib	1249.7	23.6	27	366.1	-9.2
X-1119	CRC	BYL719 + cetuximab + encorafenib	1388.1	23.2	28	417.8	-10.8
X-1119	CRC	BYL719 + cetuximab	247.3	24.4	0	0	0
X-1119	CRC	BYL719 + cetuximab	245.1	25.5	2	-0.9	4.5
X-1119	CRC	BYL719 + cetuximab	282.7	25.2	7	14.3	3.3
X-1119	CRC	BYL719 + cetuximab	399.2	24.3	11	61.4	-0.4
X-1119	CRC	BYL719 + cetuximab	447.6	24.8	14	81	1.6
X-1119	CRC	BYL719 + cetuximab	657.1	24.2	21	165.7	-0.8
X-1119	CRC	BYL719 + cetuximab	756.4	22.5	24	205.9	-7.8
X-1119	CRC	BYL719 + cetuximab	963.6	23.3	28	289.6	-4.5
X-1119	CRC	BYL719	225.6	23.2	0	0	0
X-1119	CRC	BYL719	286.1	22.5	3	26.8	-3
X-1119	CRC	BYL719	374	22.2	8	65.8	-4.3
X-1119	CRC	BYL719	450.4	21.2	13	99.6	-8.6
X-1119	CRC	BYL719	552	22.8	16	144.7	-1.7
X-1119	CRC	BYL719	633.8	19.9	20	180.9	-14.2
X-1119	CRC	BYL719 + LJM716	203.9	25.8	0	0	0
X-1119	CRC	BYL719 + LJM716	178.2	24.4	3	-12.6	-5.4
X-1119	CRC	BYL719 + LJM716	239.2	24.2	8	17.3	-6.2
X-1119	CRC	BYL719 + LJM716	334.4	25.3	13	64	-1.9
X-1119	CRC	BYL719 + LJM716	473.1	24.2	16	132	-6.2
X-1119	CRC	BYL719 + LJM716	652.1	25.4	20	219.8	-1.6
X-1119	CRC	BYL719 + binimetinib	278.4	24.1	0	0	0
X-1119	CRC	BYL719 + binimetinib	270.4	22.2	3	-2.9	-7.9
X-1119	CRC	BYL719 + binimetinib	334.2	22	8	20	-8.7
X-1119	CRC	BYL719 + binimetinib	409.7	24	13	47.2	-0.4
X-1119	CRC	BYL719 + binimetinib	385.1	23.3	16	38.3	-3.3
X-1119	CRC	BYL719 + binimetinib	365.5	22.9	20	31.3	-5
X-1119	CRC	BYL719 + binimetinib	350.4	23.1	23	25.9	-4.1
X-1119	CRC	BYL719 + binimetinib	394.7	22.4	28	41.8	-7.1
X-1119	CRC	BYL719 + binimetinib	374.8	21.2	31	34.6	-12
X-1119	CRC	BYL719 + binimetinib	365.3	20.3	34	31.2	-15.8
X-1119	CRC	BYL719 + binimetinib	361.8	20.9	37	30	-13.3
X-1119	CRC	BYL719 + binimetinib	402.2	21.1	41	44.5	-12.4
X-1119	CRC	BYL719 + binimetinib	397.1	21.1	44	42.6	-12.4
X-1119	CRC	BYL719 + binimetinib	388.5	20.4	49	39.5	-15.4
X-1119	CRC	BYL719 + binimetinib	369.3	18.4	51	32.7	-23.7
X-1119	CRC	BYL719 + encorafenib	198	25.4	0	0	0
X-1119	CRC	BYL719 + encorafenib	236.1	26.1	3	19.2	2.8
X-1119	CRC	BYL719 + encorafenib	384.2	24.4	8	94	-3.9
X-1119	CRC	BYL719 + encorafenib	467.4	24.3	13	136.1	-4.3
X-1119	CRC	BYL719 + encorafenib	627.1	25.7	16	216.7	1.2
X-1119	CRC	BYL719 + encorafenib	683.8	24.4	20	245.4	-3.9
X-1119	CRC	CGM097	212.1	23.8	0	0	0
X-1119	CRC	CGM097	238.3	23.3	2	12.4	-2.1
X-1119	CRC	CGM097	284	21.9	6	33.9	-8
X-1119	CRC	CGM097	256.4	22.6	10	20.9	-5
X-1119	CRC	CGM097	421.3	23	15	98.6	-3.4
X-1119	CRC	CGM097	388.6	23.2	20	83.2	-2.5
X-1119	CRC	CGM097	454.8	23.3	23	114.4	-2.1
X-1119	CRC	CGM097	467.4	25.5	27	120.4	7.1
X-1119	CRC	CKX620	197.1	22.4	0	0	0
X-1119	CRC	CKX620	192.9	21.8	2	-2.1	-2.7
X-1119	CRC	CKX620	215.8	22.1	6	9.5	-1.3
X-1119	CRC	CKX620	272.7	25.6	10	38.4	14.3
X-1119	CRC	CKX620	330.6	22.2	15	67.7	-0.9
X-1119	CRC	CKX620	323.5	25.2	20	64.1	12.5
X-1119	CRC	CKX620	287.3	23.5	23	45.8	4.9
X-1119	CRC	CKX620	286.8	26.3	27	45.5	17.4
X-1119	CRC	CKX620	283.4	25.6	30	43.8	14.3
X-1119	CRC	CKX620	368.1	23.9	35	86.8	6.7
X-1119	CRC	CKX620	332.9	25	38	68.9	11.6
X-1119	CRC	CKX620	354.6	25.4	41	79.9	13.4
X-1119	CRC	CKX620	266.1	25	44	35	11.6
X-1119	CRC	CKX620	338.2	25.5	48	71.6	13.8
X-1119	CRC	CKX620	338.3	26	51	71.6	16.1
X-1119	CRC	CKX620	386.5	25.9	56	96.1	15.6
X-1119	CRC	CLR457	233.8	23.5	0	0	0
X-1119	CRC	CLR457	223.4	24.4	3	-4.4	3.8
X-1119	CRC	CLR457	239.4	24.1	8	2.4	2.6
X-1119	CRC	CLR457	329.7	24.6	13	41	4.7
X-1119	CRC	CLR457	366.4	24.5	16	56.7	4.3
X-1119	CRC	CLR457	421.7	24.4	20	80.4	3.8
X-1119	CRC	CLR457	494	25.2	23	111.3	7.2
X-1119	CRC	CLR457	614.6	24.2	28	162.9	3
X-1119	CRC	CLR457	737.8	25.2	34	215.6	7.2
X-1119	CRC	HDM201	205.5	22.1	0	0	0
X-1119	CRC	HDM201	260.1	21.8	2	26.6	-1.4
X-1119	CRC	HDM201	282.5	20.5	6	37.5	-7.2
X-1119	CRC	HDM201	315.3	21.1	10	53.4	-4.5
X-1119	CRC	HDM201	350	20.9	15	70.3	-5.4
X-1119	CRC	HDM201	358	20.7	20	74.2	-6.3
X-1119	CRC	HDM201	545.8	20.5	23	165.6	-7.2
X-1119	CRC	cetuximab	214.1	24.7	0	0	0
X-1119	CRC	cetuximab	289.4	23.3	3	35.2	-5.7
X-1119	CRC	cetuximab	312.7	24	6	46.1	-2.8
X-1119	CRC	cetuximab	420.2	24.7	10	96.3	0
X-1119	CRC	cetuximab	485.9	24.5	13	127	-0.8
X-1119	CRC	cetuximab	542.2	24.5	17	153.2	-0.8
X-1119	CRC	cetuximab	731.9	24	20	241.8	-2.8
X-1119	CRC	cetuximab	899.3	24.8	25	320	0.4
X-1119	CRC	cetuximab	1120.7	24.1	28	423.4	-2.4
X-1119	CRC	cetuximab	1399.9	24.8	31	553.9	0.4
X-1119	CRC	cetuximab + encorafenib	245	24.7	0	0	0
X-1119	CRC	cetuximab + encorafenib	362	24.7	3	47.8	0
X-1119	CRC	cetuximab + encorafenib	365.6	26.1	7	49.2	5.7
X-1119	CRC	cetuximab + encorafenib	401.2	26.6	10	63.8	7.7
X-1119	CRC	cetuximab + encorafenib	567	26.4	15	131.4	6.9
X-1119	CRC	cetuximab + encorafenib	679.3	25.5	18	177.3	3.2
X-1119	CRC	cetuximab + encorafenib	733.6	25.1	21	199.4	1.6
X-1119	CRC	cetuximab + encorafenib	1108.8	27.8	28	352.6	12.6
X-1119	CRC	LEE011	208.4	22.8	0	0	0
X-1119	CRC	LEE011	195.7	21.5	4	-6.1	-5.7
X-1119	CRC	LEE011	221.3	21.3	6	6.2	-6.6
X-1119	CRC	LEE011	265.3	21.1	10	27.3	-7.5
X-1119	CRC	LEE011	431.5	21.4	14	107.1	-6.1
X-1119	CRC	LEE011	559.3	22.5	19	168.4	-1.3
X-1119	CRC	LEE011	741.1	23.3	24	255.6	2.2
X-1119	CRC	LEE011	817.6	22.4	27	292.3	-1.8
X-1119	CRC	encorafenib	214	24.6	0	0	0
X-1119	CRC	encorafenib	223.6	24	2	4.5	-2.4
X-1119	CRC	encorafenib	352.3	23.4	6	64.6	-4.9
X-1119	CRC	encorafenib	510.3	24.9	10	138.5	1.2
X-1119	CRC	encorafenib	803.2	23.7	15	275.3	-3.7
X-1119	CRC	encorafenib	1106.1	23.5	20	416.9	-4.5
X-1119	CRC	encorafenib	1458.7	23.7	23	581.6	-3.7
X-1119	CRC	LJC049	224.8	21.8	0	0	0
X-1119	CRC	LJC049	292.5	21.9	2	30.1	0.5
X-1119	CRC	LJC049	397.4	21.4	6	76.8	-1.8
X-1119	CRC	LJC049	588.2	20.9	10	161.7	-4.1
X-1119	CRC	LJC049	1124.9	20.7	15	400.4	-5
X-1119	CRC	LJC049	1344.4	20.5	20	498	-6
X-1119	CRC	LJC049	1963.9	20.8	22	773.6	-4.6
X-1119	CRC	LKA136	209.6	22.2	0	0	0
X-1119	CRC	LKA136	277.3	22.3	3	32.3	0.5
X-1119	CRC	LKA136	330.8	21.8	8	57.8	-1.8
X-1119	CRC	LKA136	492.3	22.2	13	134.9	0
X-1119	CRC	LKA136	631.4	22.7	16	201.2	2.3
X-1119	CRC	LKA136	705.5	22.7	20	236.6	2.3
X-1119	CRC	binimetinib	208	20.9	0	0	0
X-1119	CRC	binimetinib	303	20.4	4	45.7	-2.4
X-1119	CRC	binimetinib	289.5	21.1	6	39.2	1
X-1119	CRC	binimetinib	333	20.3	10	60.1	-2.9
X-1119	CRC	binimetinib	339.9	20.6	14	63.4	-1.4
X-1119	CRC	binimetinib	452.3	20.6	19	117.5	-1.4
X-1119	CRC	binimetinib	539.1	21.7	24	159.2	3.8
X-1119	CRC	binimetinib	529.3	22.4	27	154.5	7.2
X-1119	CRC	untreated	219.7	24	0	0	0
X-1119	CRC	untreated	201.1	24.1	1	-8.5	0.4
X-1119	CRC	untreated	337.6	24.2	6	53.7	0.8
X-1119	CRC	untreated	455.8	24	11	107.5	0
X-1119	CRC	untreated	590.9	25.7	14	169	7.1
X-1119	CRC	untreated	611.2	24.8	18	178.2	3.3
X-1119	CRC	untreated	859.9	24.9	21	291.4	3.7
X-1119	CRC	untreated	1065.9	23.3	26	385.2	-2.9
X-1119	CRC	untreated	1420	24.5	29	546.3	2.1
X-1119	CRC	LFW527 + binimetinib	217.13	27.36	0	0	0
X-1119	CRC	LFW527 + binimetinib	304.15	27.77	1	40.1	1.5
X-1119	CRC	LFW527 + binimetinib	439.48	NA	4	102.4	1.5
X-1119	CRC	LFW527 + binimetinib	289.9	26.7	8	33.5	-2.4
X-1119	CRC	LFW527 + binimetinib	288.28	26.17	11	32.8	-4.3
X-1119	CRC	LFW527 + binimetinib	285.01	27.03	17	31.3	-1.2
X-1119	CRC	LFW527 + binimetinib	319.42	27.07	21	47.1	-1.1
X-1119	CRC	LFW527 + binimetinib	430.75	27.09	25	98.4	-1
X-1119	CRC	LFW527 + binimetinib	380.21	27.57	28	75.1	0.8
X-1119	CRC	LFW527 + binimetinib	418.56	26.08	31	92.8	-4.7
X-1119	CRC	LFW527 + binimetinib	511.89	27.09	38	135.8	-1
X-1119	CRC	LFW527 + binimetinib	486.48	28.05	43	124.1	2.5
X-1119	CRC	LFW527 + binimetinib	535.01	27.07	46	146.4	-1.1
X-1119	CRC	LFW527 + binimetinib	461.81	27.23	49	112.7	-0.5
X-1119	CRC	LFW527 + binimetinib	681.61	26.7	52	213.9	-2.4
X-1119	CRC	LFW527 + binimetinib	842.63	27.69	58	288.1	1.2
X-1119	CRC	LFW527 + binimetinib	1012	27.65	63	366.1	1.1
X-1119	CRC	LFW527 + binimetinib	1062.34	27.51	66	389.3	0.5
X-1119	CRC	LFW527 + binimetinib	1369.88	27.85	70	530.9	1.8
X-1156	NSCLC	BGJ398	174.3	23.9	0	0	0
X-1156	NSCLC	BGJ398	222.3	23.4	2	27.5	-2.1
X-1156	NSCLC	BGJ398	371.1	22.9	7	112.9	-4.2
X-1156	NSCLC	BGJ398	348.1	25	10	99.7	4.6
X-1156	NSCLC	BGJ398	463.8	23.6	13	166.1	-1.3
X-1156	NSCLC	BGJ398	604	19.8	17	246.5	-17.2
X-1156	NSCLC	BGJ398	918.9	20	21	427.2	-16.3
X-1156	NSCLC	BKM120	195.4	23	0	0	0
X-1156	NSCLC	BKM120	230.8	23	1	18.1	0
X-1156	NSCLC	BKM120	256.5	22.6	2	31.3	-1.7
X-1156	NSCLC	BKM120	534.5	22.9	7	173.5	-0.4
X-1156	NSCLC	BKM120	534.9	21.5	10	173.7	-6.5
X-1156	NSCLC	BKM120	574.7	21.8	13	194.1	-5.2
X-1156	NSCLC	BKM120	874.5	22.3	17	347.5	-3
X-1156	NSCLC	BKM120	1168.5	22.3	20	498	-3
X-1156	NSCLC	BKM120 + binimetinib	153.5	21.4	0	0	0
X-1156	NSCLC	BKM120 + binimetinib	233.4	21.3	2	52.1	-0.5
X-1156	NSCLC	BKM120 + binimetinib	265.6	21.8	7	73	1.9
X-1156	NSCLC	BKM120 + binimetinib	227.5	21.4	10	48.2	0
X-1156	NSCLC	BKM120 + binimetinib	324.9	21.6	13	111.7	0.9
X-1156	NSCLC	BKM120 + binimetinib	353	22.4	17	130	4.7
X-1156	NSCLC	BKM120 + binimetinib	428.4	22.4	21	179.1	4.7
X-1156	NSCLC	BKM120 + binimetinib	526.5	21.3	24	243	-0.5
X-1156	NSCLC	BKM120 + binimetinib	573.7	21.7	27	273.7	1.4
X-1156	NSCLC	BKM120 + binimetinib	799.8	21.1	31	421	-1.4
X-1156	NSCLC	BKM120 + binimetinib	1252.4	21.5	34	715.9	0.5
X-1156	NSCLC	BYL719 + LGH447	377.9	21.6	0	0	0
X-1156	NSCLC	BYL719 + LGH447	361.1	19.9	2	-4.4	-7.9
X-1156	NSCLC	BYL719 + LGH447	476.3	18.6	7	26	-13.9
X-1156	NSCLC	BYL719 + LGH447	611.9	19.5	10	61.9	-9.7
X-1156	NSCLC	BYL719 + LGH447	624.2	21	13	65.2	-2.8
X-1156	NSCLC	BYL719 + LGH447	843.4	21	17	123.2	-2.8
X-1156	NSCLC	BYL719 + LGH447	874.8	21	20	131.5	-2.8
X-1156	NSCLC	BYL719 + LGH447	896.8	20.8	21	137.3	-3.7
X-1156	NSCLC	BYL719 + LGH447	1101.1	20.1	24	191.4	-6.9
X-1156	NSCLC	BYL719 + LGH447	1034	20.9	27	173.6	-3.2
X-1156	NSCLC	BYL719 + LGH447	929.9	19.4	31	146.1	-10.2
X-1156	NSCLC	BYL719 + LGH447	1145.3	20.3	34	203.1	-6
X-1156	NSCLC	BYL719 + LJM716	241.1	21.6	0	0	0
X-1156	NSCLC	BYL719 + LJM716	256.3	21.7	2	6.3	0.5
X-1156	NSCLC	BYL719 + LJM716	572	21.9	7	137.2	1.4
X-1156	NSCLC	BYL719 + LJM716	622.7	19.3	10	158.3	-10.6
X-1156	NSCLC	BYL719 + LJM716	1060.3	NA	13	339.8	-10.6
X-1156	NSCLC	BYL719 + LJM716	1215.9	22.2	17	404.3	2.8
X-1156	NSCLC	BYL719 + LJM716	1688.6	21.8	20	600.4	0.9
X-1156	NSCLC	BYL719	161.9	20.2	0	0	0
X-1156	NSCLC	BYL719	212.2	19.6	2	31.1	-3
X-1156	NSCLC	BYL719	277.3	19.8	7	71.3	-2
X-1156	NSCLC	BYL719	283	20.3	10	74.8	0.5
X-1156	NSCLC	BYL719	385.6	19.3	13	138.2	-4.5
X-1156	NSCLC	BYL719	401.6	20.4	17	148.1	1
X-1156	NSCLC	BYL719	382.8	19.4	21	136.4	-4
X-1156	NSCLC	BYL719	415.4	19.6	24	156.6	-3
X-1156	NSCLC	BYL719	540.8	19	27	234	-5.9
X-1156	NSCLC	BYL719	600.3	17.8	31	270.8	-11.9
X-1156	NSCLC	CGM097	175	23.2	0	0	0
X-1156	NSCLC	CGM097	232.5	22.8	2	32.9	-1.7
X-1156	NSCLC	CGM097	366.3	24.7	7	109.3	6.5
X-1156	NSCLC	CGM097	489.5	24.5	10	179.7	5.6
X-1156	NSCLC	CGM097	820.2	24.6	13	368.7	6
X-1156	NSCLC	CGM097	1400.8	26	17	700.5	12.1
X-1156	NSCLC	CGM097	1949.9	25.9	20	1014.2	11.6
X-1156	NSCLC	CKX620	212.7	23.1	0	0	0
X-1156	NSCLC	CKX620	305.2	23.6	2	43.5	2.2
X-1156	NSCLC	CKX620	447.2	25.1	7	110.2	8.7
X-1156	NSCLC	CKX620	514.5	24.8	10	141.9	7.4
X-1156	NSCLC	CKX620	973.4	25.3	13	357.6	9.5
X-1156	NSCLC	CKX620	1475.4	25.4	17	593.7	10
X-1156	NSCLC	CKX620	1840.3	26.1	20	765.2	13
X-1156	NSCLC	CLR457	243.9	21.6	0	0	0
X-1156	NSCLC	CLR457	375.2	20.3	4	53.8	-6
X-1156	NSCLC	CLR457	398.6	20.3	7	63.4	-6
X-1156	NSCLC	CLR457	454.2	20.8	10	86.2	-3.7
X-1156	NSCLC	CLR457	653.5	20.9	14	167.9	-3.2
X-1156	NSCLC	CLR457	631.1	20.2	18	158.8	-6.5
X-1156	NSCLC	CLR457	666.8	19.8	21	173.4	-8.3
X-1156	NSCLC	CLR457	683.7	19.3	24	180.3	-10.6
X-1156	NSCLC	CLR457	734.9	18.7	28	201.3	-13.4
X-1156	NSCLC	CLR457	850.3	17.9	32	248.6	-17.1
X-1156	NSCLC	HDM201	232.8	21.3	0	0	0
X-1156	NSCLC	HDM201	296.2	20	2	27.2	-6.1
X-1156	NSCLC	HDM201	532.2	20.8	7	128.6	-2.3
X-1156	NSCLC	HDM201	651.6	20.3	10	179.9	-4.7
X-1156	NSCLC	HDM201	764.7	20.1	13	228.5	-5.6
X-1156	NSCLC	HDM201	1165.8	20	17	400.8	-6.1
X-1156	NSCLC	HDM201	1747.1	18.9	20	650.5	-11.3
X-1156	NSCLC	cetuximab	139.9	21.9	0	0	0
X-1156	NSCLC	cetuximab	156.8	23.1	4	12.1	5.5
X-1156	NSCLC	cetuximab	280.5	23.4	7	100.5	6.8
X-1156	NSCLC	cetuximab	388.5	24.4	10	177.7	11.4
X-1156	NSCLC	cetuximab	613.7	24.6	14	338.7	12.3
X-1156	NSCLC	cetuximab	1039.3	24.9	18	642.9	13.7
X-1156	NSCLC	cetuximab	1083.5	25.5	21	674.5	16.4
X-1156	NSCLC	cetuximab	1537.7	25.2	24	999.1	15.1
X-1156	NSCLC	erlotinib	241.4	26.1	0	0	0
X-1156	NSCLC	erlotinib	389.5	26.5	3	61.4	1.5
X-1156	NSCLC	erlotinib	729.3	25.3	7	202.1	-3.1
X-1156	NSCLC	erlotinib	733.3	23.6	10	203.8	-9.6
X-1156	NSCLC	erlotinib	687.5	26.8	13	184.8	2.7
X-1156	NSCLC	erlotinib	958	27	17	296.9	3.4
X-1156	NSCLC	erlotinib	1415.8	27.4	20	486.5	5
X-1156	NSCLC	HSP990	207.7	21.2	0	0	0
X-1156	NSCLC	HSP990	243.2	20.7	4	17.1	-2.4
X-1156	NSCLC	HSP990	306.7	21	7	47.7	-0.9
X-1156	NSCLC	HSP990	399	22.7	10	92.1	7.1
X-1156	NSCLC	HSP990	474.7	22.3	14	128.6	5.2
X-1156	NSCLC	HSP990	862.4	22.6	18	315.2	6.6
X-1156	NSCLC	HSP990	1043.1	23.3	21	402.2	9.9
X-1156	NSCLC	HSP990	1410.1	22.2	24	578.9	4.7
X-1156	NSCLC	INC280	224.7	20.9	0	0	0
X-1156	NSCLC	INC280	305.7	21.3	4	36	1.9
X-1156	NSCLC	INC280	448.8	21.9	7	99.7	4.8
X-1156	NSCLC	INC280	459.9	21.6	10	104.7	3.3
X-1156	NSCLC	INC280	658.6	22.1	14	193.1	5.7
X-1156	NSCLC	INC280	856.9	21.5	18	281.4	2.9
X-1156	NSCLC	INC280	1116.3	21.6	21	396.8	3.3
X-1156	NSCLC	INC280	1385.7	21.4	24	516.7	2.4
X-1156	NSCLC	LCL161 + paclitaxel	233.1	25.1	0	0	0
X-1156	NSCLC	LCL161 + paclitaxel	308.5	23.8	4	32.3	-5.2
X-1156	NSCLC	LCL161 + paclitaxel	480.3	24.5	7	106	-2.4
X-1156	NSCLC	LCL161 + paclitaxel	487.8	24.8	10	109.3	-1.2
X-1156	NSCLC	LCL161 + paclitaxel	811.7	24.3	14	248.2	-3.2
X-1156	NSCLC	LCL161 + paclitaxel	742.9	22.4	17	218.7	-10.8
X-1156	NSCLC	LCL161 + paclitaxel	852.2	22.3	18	265.6	-11.2
X-1156	NSCLC	LCL161 + paclitaxel	915	23.5	21	292.5	-6.4
X-1156	NSCLC	LCL161 + paclitaxel	1030.5	22.7	24	342.1	-9.6
X-1156	NSCLC	LCL161 + paclitaxel	1089.6	23	28	367.4	-8.4
X-1156	NSCLC	LCL161 + paclitaxel	1098.7	19.1	31	371.3	-23.9
X-1156	NSCLC	LEE011	224.2	21.5	0	0	0
X-1156	NSCLC	LEE011	290.4	20.2	2	29.5	-6
X-1156	NSCLC	LEE011	445.9	20.6	7	98.9	-4.2
X-1156	NSCLC	LEE011	505.4	19.4	10	125.4	-9.8
X-1156	NSCLC	LEE011	515.6	19.6	13	130	-8.8
X-1156	NSCLC	LEE011	530.8	20.5	17	136.8	-4.7
X-1156	NSCLC	LEE011	633.2	19.3	21	182.4	-10.2
X-1156	NSCLC	LEE011	568.5	20.2	24	153.6	-6
X-1156	NSCLC	LEE011	540.5	20.7	27	141.1	-3.7
X-1156	NSCLC	LEE011	660.4	19.8	31	194.6	-7.9
X-1156	NSCLC	LEE011	806.6	19.4	34	259.8	-9.8
X-1156	NSCLC	LEE011	959.4	20.8	38	327.9	-3.3
X-1156	NSCLC	LEE011	997.2	20.1	41	344.8	-6.5
X-1156	NSCLC	LGH447	161.6	20.5	0	0	0
X-1156	NSCLC	LGH447	254.4	20	2	57.4	-2.4
X-1156	NSCLC	LGH447	365.3	20.3	7	126.1	-1
X-1156	NSCLC	LGH447	493.9	20.1	10	205.6	-2
X-1156	NSCLC	LGH447	571.7	20	13	253.8	-2.4
X-1156	NSCLC	LGH447	842.6	20	17	421.4	-2.4
X-1156	NSCLC	LGH447	1294.4	20.7	20	701	1
X-1156	NSCLC	LLM871	167	21.9	0	0	0
X-1156	NSCLC	LLM871	302.1	NA	4	80.9	0
X-1156	NSCLC	LLM871	316.6	21.2	7	89.6	-3.2
X-1156	NSCLC	LLM871	435.9	22.2	10	161	1.4
X-1156	NSCLC	LLM871	572.9	22.7	14	243.1	3.7
X-1156	NSCLC	LLM871	822.3	21.5	17	392.4	-1.8
X-1156	NSCLC	LLM871	1024.3	21.8	21	513.4	-0.5
X-1156	NSCLC	LLM871	1374.4	22.2	24	723	1.4
X-1156	NSCLC	binimetinib	145.9	22	0	0	0
X-1156	NSCLC	binimetinib	258.2	22.7	4	77	3.2
X-1156	NSCLC	binimetinib	259.3	23.4	7	77.7	6.4
X-1156	NSCLC	binimetinib	238.6	24	10	63.5	9.1
X-1156	NSCLC	binimetinib	244.1	24.4	14	67.3	10.9
X-1156	NSCLC	binimetinib	342.7	24.1	18	134.9	9.5
X-1156	NSCLC	binimetinib	393.9	24.3	21	170	10.5
X-1156	NSCLC	binimetinib	468.9	22.9	24	221.4	4.1
X-1156	NSCLC	binimetinib	502.3	22.6	28	244.3	2.7
X-1156	NSCLC	binimetinib	593.3	21	35	306.6	-4.5
X-1156	NSCLC	binimetinib	702.6	19.5	40	381.6	-11.4
X-1156	NSCLC	binimetinib	748.7	19.5	42	413.2	-11.4
X-1156	NSCLC	binimetinib	816.5	18.4	46	459.6	-16.4
X-1156	NSCLC	paclitaxel	156.6	19	0	0	0
X-1156	NSCLC	paclitaxel	251.7	19.4	4	60.7	2.1
X-1156	NSCLC	paclitaxel	300.4	20.6	7	91.8	8.4
X-1156	NSCLC	paclitaxel	367.6	20.8	10	134.7	9.5
X-1156	NSCLC	paclitaxel	363.8	21.6	14	132.3	13.7
X-1156	NSCLC	paclitaxel	679.1	20.3	18	333.7	6.8
X-1156	NSCLC	paclitaxel	775.8	20.2	21	395.4	6.3
X-1156	NSCLC	paclitaxel	877.2	20.5	24	460.2	7.9
X-1156	NSCLC	paclitaxel	999.3	20.2	28	538.1	6.3
X-1156	NSCLC	paclitaxel	1247.6	21.1	31	696.7	11.1
X-1156	NSCLC	untreated	187.1	22.8	0	0	0
X-1156	NSCLC	untreated	268.8	21.7	2	43.7	-4.8
X-1156	NSCLC	untreated	475.9	21.9	7	154.4	-3.9
X-1156	NSCLC	untreated	832.9	22	13	345.2	-3.5
X-1156	NSCLC	untreated	1283.5	21.8	17	586	-4.4
X-1156	NSCLC	untreated	1744.9	21	20	832.6	-7.9
X-1156	NSCLC	LFW527 + binimetinib	271.14	23.2	0	0	0
X-1156	NSCLC	LFW527 + binimetinib	255.08	23	3	-5.9	-0.9
X-1156	NSCLC	LFW527 + binimetinib	371.11	23.5	8	36.9	1.3
X-1156	NSCLC	LFW527 + binimetinib	362.19	23.4	11	33.6	0.9
X-1156	NSCLC	LFW527 + binimetinib	542.11	23.5	14	99.9	1.3
X-1156	NSCLC	LFW527 + binimetinib	663.71	23.2	18	144.8	0
X-1156	NSCLC	LFW527 + binimetinib	539.07	22.6	21	98.8	-2.6
X-1156	NSCLC	LFW527 + binimetinib	746.58	22.4	24	175.3	-3.4
X-1156	NSCLC	LFW527 + binimetinib	1519.25	22.7	29	460.3	-2.2
X-1156	NSCLC	LFW527 + binimetinib	1215.27	22.1	30	348.2	-4.7
X-1167	CRC	5FU	267.5	26.5	0	0	0
X-1167	CRC	5FU	330.9	24.3	3	23.7	-8.3
X-1167	CRC	5FU	343.4	24.4	6	28.4	-7.9
X-1167	CRC	5FU	358.7	23	9	34.1	-13.2
X-1167	CRC	5FU	357.9	25.6	14	33.8	-3.4
X-1167	CRC	5FU	329.7	25.5	17	23.3	-3.8
X-1167	CRC	5FU	324.8	26.7	20	21.4	0.8
X-1167	CRC	5FU	339.6	28.3	22	27	6.8
X-1167	CRC	5FU	332.2	27.2	27	24.2	2.6
X-1167	CRC	5FU	394.4	24.6	31	47.4	-7.2
X-1167	CRC	5FU	365.3	28.8	35	36.6	8.7
X-1167	CRC	5FU	333.3	28.7	38	24.6	8.3
X-1167	CRC	5FU	322.7	28.1	43	20.6	6
X-1167	CRC	5FU	331.5	28.5	45	23.9	7.5
X-1167	CRC	5FU	318.9	28.2	49	19.2	6.4
X-1167	CRC	5FU	322.5	28.2	51	20.6	6.4
X-1167	CRC	5FU	323.7	29.6	56	21	11.7
X-1167	CRC	5FU	305.6	28.2	62	14.2	6.4
X-1167	CRC	5FU	301.7	27.2	66	12.8	2.6
X-1167	CRC	5FU	339.4	28	69	26.9	5.7
X-1167	CRC	5FU	358.9	27.9	73	34.2	5.3
X-1167	CRC	5FU	317.5	30	78	18.7	13.2
X-1167	CRC	5FU	350	29.1	83	30.8	9.8
X-1167	CRC	5FU	307.6	29.2	90	15	10.2
X-1167	CRC	5FU	302.6	28.5	93	13.1	7.5
X-1167	CRC	5FU	344.7	27	98	28.9	1.9
X-1167	CRC	5FU	335.3	28.1	101	25.3	6
X-1167	CRC	5FU	405.5	27.3	105	51.6	3
X-1167	CRC	BKM120	217.8	25.8	0	0	0
X-1167	CRC	BKM120	156.4	24.8	3	-28.2	-3.9
X-1167	CRC	BKM120	177.5	24.9	6	-18.5	-3.5
X-1167	CRC	BKM120	236.3	23.9	9	8.5	-7.4
X-1167	CRC	BKM120	216.1	24.6	14	-0.8	-4.7
X-1167	CRC	BKM120	187.7	26.1	17	-13.8	1.2
X-1167	CRC	BKM120	216.3	26.8	20	-0.7	3.9
X-1167	CRC	BKM120	257.3	27.9	22	18.1	8.1
X-1167	CRC	BKM120	314.7	28	27	44.5	8.5
X-1167	CRC	BKM120	326.1	27.7	31	49.7	7.4
X-1167	CRC	BKM120	490	27.7	35	125	7.4
X-1167	CRC	BKM120	579	29.6	38	165.8	14.7
X-1167	CRC	BKM120	619	28.7	43	184.2	11.2
X-1167	CRC	BKM120 + LJC049	218.4	26.9	0	0	0
X-1167	CRC	BKM120 + LJC049	288.7	27	5	32.2	0.4
X-1167	CRC	BKM120 + LJC049	523.1	29.4	10	139.5	9.3
X-1167	CRC	BKM120 + LJC049	860.4	29.2	14	294	8.6
X-1167	CRC	BKM120 + LJC049	936.1	28.6	18	328.6	6.3
X-1167	CRC	BKM120 + LJC049	1132.9	29.1	21	418.7	8.2
X-1167	CRC	BKM120 + LJC049	1359.1	28	26	522.3	4.1
X-1167	CRC	BKM120 + LJC049	1408.2	27.2	28	544.8	1.1
X-1167	CRC	BKM120 + LJC049	1571.6	27.3	32	619.6	1.5
X-1167	CRC	BYL719	289.4	24.8	0	0	0
X-1167	CRC	BYL719	265.3	26.2	3	-8.3	5.6
X-1167	CRC	BYL719	444.4	24.9	8	53.6	0.4
X-1167	CRC	BYL719	478.6	25.2	11	65.4	1.6
X-1167	CRC	BYL719	792.6	25.2	14	173.9	1.6
X-1167	CRC	BYL719	786.4	24.3	16	171.7	-2
X-1167	CRC	BYL719	1346.6	25.7	21	365.3	3.6
X-1167	CRC	BYL719	1373.8	24.1	25	374.7	-2.8
X-1167	CRC	BYL719	1981.6	24	29	584.7	-3.2
X-1167	CRC	BYL719 + LJM716	244.8	24.7	0	0	0
X-1167	CRC	BYL719 + LJM716	237.5	23.8	3	-3	-3.6
X-1167	CRC	BYL719 + LJM716	246.2	22.7	8	0.6	-8.1
X-1167	CRC	BYL719 + LJM716	353.8	22.9	11	44.5	-7.3
X-1167	CRC	BYL719 + LJM716	371	23.1	14	51.6	-6.5
X-1167	CRC	BYL719 + LJM716	412.1	22.5	16	68.3	-8.9
X-1167	CRC	BYL719 + LJM716	563.6	22.8	21	130.2	-7.7
X-1167	CRC	BYL719 + LJM716	617.9	23.9	25	152.4	-3.2
X-1167	CRC	BYL719 + LJM716	651.3	23.7	29	166.1	-4
X-1167	CRC	BYL719 + binimetinib	248.4	25.6	0	0	0
X-1167	CRC	BYL719 + binimetinib	244.7	27.7	3	-1.5	8.2
X-1167	CRC	BYL719 + binimetinib	181.5	26.5	8	-26.9	3.5
X-1167	CRC	BYL719 + binimetinib	141.7	27.3	11	-43	6.6
X-1167	CRC	BYL719 + binimetinib	128.6	26.3	14	-48.2	2.7
X-1167	CRC	BYL719 + binimetinib	139.9	26.6	16	-43.7	3.9
X-1167	CRC	BYL719 + binimetinib	152.6	26.8	25	-38.6	4.7
X-1167	CRC	BYL719 + binimetinib	203.2	26	29	-18.2	1.6
X-1167	CRC	BYL719 + binimetinib	176.9	28.1	32	-28.8	9.8
X-1167	CRC	BYL719 + binimetinib	219.8	26.5	37	-11.5	3.5
X-1167	CRC	BYL719 + binimetinib	225.5	26.7	43	-9.2	4.3
X-1167	CRC	BYL719 + binimetinib	262.5	26.9	45	5.7	5.1
X-1167	CRC	BYL719 + binimetinib	309.6	27.6	50	24.6	7.8
X-1167	CRC	BYL719 + binimetinib	414.9	27.2	56	67	6.2
X-1167	CRC	BYL719 + cetuximab + encorafenib	253.9	25.4	0	0	0
X-1167	CRC	BYL719 + cetuximab + encorafenib	249.1	25.8	3	-1.9	1.6
X-1167	CRC	BYL719 + cetuximab + encorafenib	256.9	25.3	8	1.2	-0.4
X-1167	CRC	BYL719 + cetuximab + encorafenib	250.6	26	11	-1.3	2.4
X-1167	CRC	BYL719 + cetuximab + encorafenib	266.8	25.8	14	5.1	1.6
X-1167	CRC	BYL719 + cetuximab + encorafenib	270.5	26.7	16	6.5	5.1
X-1167	CRC	BYL719 + cetuximab + encorafenib	335.4	29.6	21	32.1	16.5
X-1167	CRC	BYL719 + cetuximab + encorafenib	354.2	27.8	25	39.5	9.4
X-1167	CRC	BYL719 + cetuximab + encorafenib	443.7	27.4	29	74.8	7.9
X-1167	CRC	BYL719 + cetuximab + encorafenib	435.9	27.9	32	71.7	9.8
X-1167	CRC	BYL719 + cetuximab + encorafenib	473.7	27.6	37	86.6	8.7
X-1167	CRC	BYL719 + cetuximab	289.1	26	0	0	0
X-1167	CRC	BYL719 + cetuximab	331.7	26.4	4	14.7	1.5
X-1167	CRC	BYL719 + cetuximab	393.9	26	7	36.3	0
X-1167	CRC	BYL719 + cetuximab	516.1	26.3	10	78.5	1.2
X-1167	CRC	BYL719 + cetuximab	568.2	25.8	12	96.5	-0.8
X-1167	CRC	BYL719 + cetuximab	1018.5	27.1	17	252.3	4.2
X-1167	CRC	BYL719 + cetuximab	1258.3	26.2	21	335.2	0.8
X-1167	CRC	BYL719 + cetuximab	1447.8	26.6	25	400.8	2.3
X-1167	CRC	BYL719 + cetuximab	1712.9	27.6	28	492.5	6.2
X-1167	CRC	BYL719 + encorafenib	228.8	28.3	0	0	0
X-1167	CRC	BYL719 + encorafenib	376.6	26.7	4	64.6	-5.7
X-1167	CRC	BYL719 + encorafenib	476.2	27.5	7	108.1	-2.8
X-1167	CRC	BYL719 + encorafenib	478.9	27.5	10	109.3	-2.8
X-1167	CRC	BYL719 + encorafenib	517.9	28.6	12	126.4	1.1
X-1167	CRC	BYL719 + encorafenib	580.2	30.2	17	153.6	6.7
X-1167	CRC	BYL719 + encorafenib	652.1	27.9	21	185	-1.4
X-1167	CRC	BYL719 + encorafenib	1042.7	28.9	25	355.7	2.1
X-1167	CRC	BYL719 + encorafenib	1121.8	28.8	28	390.3	1.8
X-1167	CRC	BYL719 + encorafenib	1351.7	28.3	33	490.8	0
X-1167	CRC	CGM097	228.5	27.5	0	0	0
X-1167	CRC	CGM097	215.3	24.9	3	-5.8	-9.5
X-1167	CRC	CGM097	242.9	26.3	8	6.3	-4.4
X-1167	CRC	CGM097	327.7	26.8	11	43.4	-2.5
X-1167	CRC	CGM097	314.9	27.5	14	37.8	0
X-1167	CRC	CGM097	340.5	28.3	16	49	2.9
X-1167	CRC	CGM097	488.6	29.2	21	113.8	6.2
X-1167	CRC	CGM097	493.6	27.9	25	116	1.5
X-1167	CRC	CGM097	592.2	27.1	29	159.2	-1.5
X-1167	CRC	CKX620	249.9	26.1	0	0	0
X-1167	CRC	CKX620	200.7	24.5	3	-19.7	-6.1
X-1167	CRC	CKX620	213.7	26.2	6	-14.5	0.4
X-1167	CRC	CKX620	234.8	26.9	9	-6	3.1
X-1167	CRC	CKX620	284.9	26.1	14	14	0
X-1167	CRC	CKX620	287.3	27.1	17	15	3.8
X-1167	CRC	CKX620	288.4	26.9	20	15.4	3.1
X-1167	CRC	CKX620	301	26.5	22	20.4	1.5
X-1167	CRC	CKX620	337.7	28.2	27	35.1	8
X-1167	CRC	CKX620	337.4	27.5	31	35	5.4
X-1167	CRC	CKX620	367	26.6	35	46.9	1.9
X-1167	CRC	CKX620	374.2	27.7	38	49.7	6.1
X-1167	CRC	CKX620	495.2	26.9	43	98.2	3.1
X-1167	CRC	CLR457	199.8	25.7	0	0	0
X-1167	CRC	CLR457	212.3	24.9	3	6.3	-3.1
X-1167	CRC	CLR457	228	24.6	6	14.1	-4.3
X-1167	CRC	CLR457	345.1	24.6	11	72.7	-4.3
X-1167	CRC	CLR457	340	24.5	14	70.2	-4.7
X-1167	CRC	CLR457	340.8	24.3	17	70.6	-5.4
X-1167	CRC	CLR457	393.4	25.7	19	96.9	0
X-1167	CRC	CLR457	616.9	25.7	24	208.8	0
X-1167	CRC	CLR457	731.1	25.4	28	265.9	-1.2
X-1167	CRC	CLR457	1051.8	25.7	32	426.4	0
X-1167	CRC	HDM201	184.2	27.1	0	0	0
X-1167	CRC	HDM201	139.8	27.1	3	-24.1	0
X-1167	CRC	HDM201	116.9	28.1	6	-36.5	3.7
X-1167	CRC	HDM201	128.4	27.4	9	-30.3	1.1
X-1167	CRC	HDM201	193.1	27.6	14	4.8	1.8
X-1167	CRC	HDM201	253.9	29.5	17	37.8	8.9
X-1167	CRC	HDM201	356.7	29.9	20	93.6	10.3
X-1167	CRC	HDM201	367	30	22	99.2	10.7
X-1167	CRC	HDM201	390.5	28.7	27	112	5.9
X-1167	CRC	HDM201	532.6	29.4	31	189.1	8.5
X-1167	CRC	HDM201	802.5	30.7	35	335.7	13.3
X-1167	CRC	cetuximab	228	25.5	0	0	0
X-1167	CRC	cetuximab	299.3	25.5	3	31.3	0
X-1167	CRC	cetuximab	421.2	25.6	6	84.7	0.4
X-1167	CRC	cetuximab	571	26.3	9	150.4	3.1
X-1167	CRC	cetuximab	725	25.8	14	218	1.2
X-1167	CRC	cetuximab	865.4	25.8	17	279.6	1.2
X-1167	CRC	cetuximab	1125.5	27.2	20	393.6	6.7
X-1167	CRC	cetuximab	1270.5	27.9	22	457.2	9.4
X-1167	CRC	cetuximab	1505.3	27	27	560.2	5.9
X-1167	CRC	cetuximab + encorafenib	243.8	26.5	0	0	0
X-1167	CRC	cetuximab + encorafenib	360.8	28	5	48	5.7
X-1167	CRC	cetuximab + encorafenib	446	27.2	9	82.9	2.6
X-1167	CRC	cetuximab + encorafenib	502.5	27	13	106.1	1.9
X-1167	CRC	cetuximab + encorafenib	457.8	26.5	16	87.8	0
X-1167	CRC	cetuximab + encorafenib	445.4	24.9	21	82.7	-6
X-1167	CRC	cetuximab + encorafenib	482.9	26.2	23	98.1	-1.1
X-1167	CRC	cetuximab + encorafenib	519.4	26.5	27	113	0
X-1167	CRC	LEE011	191.6	25.6	0	0	0
X-1167	CRC	LEE011	200.2	25.8	3	4.5	0.8
X-1167	CRC	LEE011	185.7	25.6	6	-3.1	0
X-1167	CRC	LEE011	291.1	25.8	9	51.9	0.8
X-1167	CRC	LEE011	376.9	26	14	96.7	1.6
X-1167	CRC	LEE011	405.9	27.3	17	111.8	6.6
X-1167	CRC	LEE011	457.9	27.8	20	139	8.6
X-1167	CRC	LEE011	465.8	27.6	22	143.1	7.8
X-1167	CRC	LEE011	463.7	28.4	27	142	10.9
X-1167	CRC	LEE011	524	28	31	173.5	9.4
X-1167	CRC	LEE011	710.4	28.5	35	270.8	11.3
X-1167	CRC	encorafenib	265.1	24.3	0	0	0
X-1167	CRC	encorafenib	236.4	24.4	3	-10.8	0.4
X-1167	CRC	encorafenib	264.4	25.7	6	-0.3	5.8
X-1167	CRC	encorafenib	430.5	25.1	14	62.4	3.3
X-1167	CRC	encorafenib	534	25.4	17	101.4	4.5
X-1167	CRC	encorafenib	733	26.3	19	176.5	8.2
X-1167	CRC	encorafenib	1075.3	25.8	24	305.6	6.2
X-1167	CRC	encorafenib	1155.3	24.4	28	335.8	0.4
X-1167	CRC	encorafenib	1215.3	25.6	32	358.4	5.3
X-1167	CRC	LJC049	247.3	23.6	0	0	0
X-1167	CRC	LJC049	382.9	23.5	3	54.8	-0.4
X-1167	CRC	LJC049	684	23.2	6	176.6	-1.7
X-1167	CRC	LJC049	984.8	22.3	11	298.2	-5.5
X-1167	CRC	LJC049	1128.7	21.9	14	356.4	-7.2
X-1167	CRC	LJC049	1311.2	21.9	17	430.2	-7.2
X-1167	CRC	LKA136	197.3	20	0	0	0
X-1167	CRC	LKA136	213.4	19	3	8.2	-5
X-1167	CRC	LKA136	241.2	19.3	6	22.3	-3.5
X-1167	CRC	LKA136	551.2	18.9	11	179.4	-5.5
X-1167	CRC	LKA136	764.2	20.2	14	287.3	1
X-1167	CRC	LKA136	1017.1	19.6	17	415.5	-2
X-1167	CRC	LKA136	1168.2	21	19	492.1	5
X-1167	CRC	LKA136	1321	16.8	24	569.5	-16
X-1167	CRC	binimetinib	191	26.2	0	0	0
X-1167	CRC	binimetinib	190.3	24.9	3	-0.4	-5
X-1167	CRC	binimetinib	239.4	25.3	6	25.3	-3.4
X-1167	CRC	binimetinib	345.4	25.8	9	80.8	-1.5
X-1167	CRC	binimetinib	362.5	25	14	89.8	-4.6
X-1167	CRC	binimetinib	417.3	24.8	17	118.5	-5.3
X-1167	CRC	binimetinib	452.2	24.6	20	136.8	-6.1
X-1167	CRC	binimetinib	456.9	25.2	22	139.2	-3.8
X-1167	CRC	binimetinib	466.5	26.2	27	144.2	0
X-1167	CRC	binimetinib	519.7	25.2	31	172.1	-3.8
X-1167	CRC	binimetinib	599	26.5	35	213.6	1.1
X-1167	CRC	untreated	200.9	26.1	0	0	0
X-1167	CRC	untreated	244.1	27.8	6	21.5	6.5
X-1167	CRC	untreated	239.4	27.3	9	19.2	4.6
X-1167	CRC	untreated	281.2	26.9	12	40	3.1
X-1167	CRC	untreated	353	27.6	15	75.7	5.7
X-1167	CRC	untreated	407.6	27.6	20	102.9	5.7
X-1167	CRC	untreated	472.7	30.4	23	135.3	16.5
X-1167	CRC	untreated	696.2	28.6	26	246.5	9.6
X-1167	CRC	untreated	753.1	28.4	28	274.9	8.8
X-1167	CRC	untreated	1182.2	28.8	33	488.5	10.3
X-1167	CRC	untreated	1438.3	31.1	36	615.9	19.2
X-1167	CRC	LFW527 + binimetinib	268.31	27.35	0	0	0
X-1167	CRC	LFW527 + binimetinib	294.11	26.76	3	9.6	-2.2
X-1167	CRC	LFW527 + binimetinib	481.07	26.51	7	79.3	-3.1
X-1167	CRC	LFW527 + binimetinib	396.46	25.36	9	47.8	-7.3
X-1167	CRC	LFW527 + binimetinib	425.36	26.33	12	58.5	-3.7
X-1167	CRC	LFW527 + binimetinib	578.58	26.8	16	115.6	-2
X-1167	CRC	LFW527 + binimetinib	325.93	27.29	18	21.5	-0.2
X-1167	CRC	LFW527 + binimetinib	696.76	27.88	22	159.7	1.9
X-1167	CRC	LFW527 + binimetinib	787.25	26.94	25	193.4	-1.5
X-1167	CRC	LFW527 + binimetinib	913.24	28.23	29	240.4	3.2
X-1172	NSCLC	BGJ398	269.6	24.6	0	0	0
X-1172	NSCLC	BGJ398	316.5	24.6	4	17.4	0
X-1172	NSCLC	BGJ398	369.8	24.4	6	37.2	-0.8
X-1172	NSCLC	BGJ398	645.4	25.2	11	139.4	2.4
X-1172	NSCLC	BGJ398	608.8	25.2	13	125.8	2.4
X-1172	NSCLC	BGJ398	522.3	25.2	14	93.7	2.4
X-1172	NSCLC	BGJ398	558.8	24.6	18	107.3	0
X-1172	NSCLC	BGJ398	545.6	24.7	21	102.4	0.4
X-1172	NSCLC	BGJ398	668.7	24.2	25	148	-1.6
X-1172	NSCLC	BGJ398	819.5	24.7	27	204	0.4
X-1172	NSCLC	BKM120 + binimetinib	194	26.5	0	0	0
X-1172	NSCLC	BKM120 + binimetinib	102.1	25.4	2	-47.4	-4.2
X-1172	NSCLC	BKM120 + binimetinib	104.8	25.7	5	-46	-3
X-1172	NSCLC	BKM120 + binimetinib	115.8	26.2	7	-40.3	-1.1
X-1172	NSCLC	BKM120 + binimetinib	101.4	26.1	12	-47.7	-1.5
X-1172	NSCLC	BKM120 + binimetinib	100.6	26.4	15	-48.1	-0.4
X-1172	NSCLC	BKM120 + binimetinib	133.4	27.5	19	-31.2	3.8
X-1172	NSCLC	BKM120 + binimetinib	179.5	26.7	22	-7.5	0.8
X-1172	NSCLC	BKM120 + binimetinib	155.6	27.8	26	-19.8	4.9
X-1172	NSCLC	BKM120 + binimetinib	184.1	28.1	29	-5.1	6
X-1172	NSCLC	BKM120 + binimetinib	151	28.5	33	-22.2	7.5
X-1172	NSCLC	BKM120 + binimetinib	150	27.8	36	-22.7	4.9
X-1172	NSCLC	BKM120 + binimetinib	149.4	28	40	-23	5.7
X-1172	NSCLC	BKM120 + binimetinib	226.9	28.1	43	17	6
X-1172	NSCLC	BKM120 + binimetinib	267.7	27.9	50	38	5.3
X-1172	NSCLC	BKM120 + binimetinib	243.9	27.6	54	25.7	4.2
X-1172	NSCLC	BKM120 + binimetinib	326.4	28	57	68.2	5.7
X-1172	NSCLC	BKM120 + binimetinib	388	27.4	61	100	3.4
X-1172	NSCLC	BKM120 + binimetinib	362.2	27.5	64	86.7	3.8
X-1172	NSCLC	BKM120 + binimetinib	425.2	27.5	68	119.2	3.8
X-1172	NSCLC	BKM120 + binimetinib	606.8	27.1	71	212.8	2.3
X-1172	NSCLC	BKM120 + binimetinib	590	27	75	204.1	1.9
X-1172	NSCLC	BKM120 + binimetinib	419	27.7	77	116	4.5
X-1172	NSCLC	BKM120 + binimetinib	524.6	27.8	82	170.4	4.9
X-1172	NSCLC	BKM120 + binimetinib	585.4	27.5	85	201.8	3.8
X-1172	NSCLC	BKM120 + binimetinib	723.2	27.8	89	272.8	4.9
X-1172	NSCLC	BKM120 + binimetinib	889.7	27.2	90	358.6	2.6
X-1172	NSCLC	BKM120	321.3	22.6	0	0	0
X-1172	NSCLC	BKM120	131.8	22.1	2	-59	-2.2
X-1172	NSCLC	BKM120	85.3	23	5	-73.5	1.8
X-1172	NSCLC	BKM120	124.5	23.4	7	-61.3	3.5
X-1172	NSCLC	BKM120	133.7	24.2	12	-58.4	7.1
X-1172	NSCLC	BKM120	154.2	25	15	-52	10.6
X-1172	NSCLC	BKM120	97.8	24.5	19	-69.6	8.4
X-1172	NSCLC	BKM120	90.3	25	22	-71.9	10.6
X-1172	NSCLC	BKM120	101.1	24.6	26	-68.5	8.8
X-1172	NSCLC	BKM120	102.2	24.7	29	-68.2	9.3
X-1172	NSCLC	BKM120	107.6	25	33	-66.5	10.6
X-1172	NSCLC	BKM120	109.4	24.9	36	-66	10.2
X-1172	NSCLC	BKM120	105.8	25.5	40	-67.1	12.8
X-1172	NSCLC	BKM120	106.7	25.4	43	-66.8	12.4
X-1172	NSCLC	BKM120	134.5	25.7	47	-58.1	13.7
X-1172	NSCLC	BKM120	140.8	25.7	50	-56.2	13.7
X-1172	NSCLC	BKM120	212.9	26.1	54	-33.7	15.5
X-1172	NSCLC	BKM120	225.7	25.7	57	-29.8	13.7
X-1172	NSCLC	BKM120	236.4	25.8	61	-26.4	14.2
X-1172	NSCLC	BKM120	318	25.7	64	-1	13.7
X-1172	NSCLC	BKM120	311	25.9	68	-3.2	14.6
X-1172	NSCLC	BKM120	338.4	26.1	71	5.3	15.5
X-1172	NSCLC	BKM120	440.1	26.4	75	37	16.8
X-1172	NSCLC	BKM120	457.3	26.1	77	42.3	15.5
X-1172	NSCLC	BKM120	466.1	26.2	82	45.1	15.9
X-1172	NSCLC	BKM120	664.8	26.6	85	106.9	17.7
X-1172	NSCLC	BKM120	607	26.4	89	88.9	16.8
X-1172	NSCLC	BKM120	774.8	26.2	90	141.1	15.9
X-1172	NSCLC	BYL719 + LGH447	249.3	28.1	0	0	0
X-1172	NSCLC	BYL719 + LGH447	186.8	26.2	2	-25.1	-6.8
X-1172	NSCLC	BYL719 + LGH447	194.3	26.4	5	-22.1	-6
X-1172	NSCLC	BYL719 + LGH447	175.8	26.9	7	-29.5	-4.3
X-1172	NSCLC	BYL719 + LGH447	289.6	28	12	16.2	-0.4
X-1172	NSCLC	BYL719 + LGH447	267.4	27.5	15	7.3	-2.1
X-1172	NSCLC	BYL719 + LGH447	332.8	28.1	19	33.5	0
X-1172	NSCLC	BYL719 + LGH447	320.6	28.8	22	28.6	2.5
X-1172	NSCLC	BYL719 + LGH447	436.7	28.6	26	75.2	1.8
X-1172	NSCLC	BYL719 + LGH447	478.2	29.6	29	91.8	5.3
X-1172	NSCLC	BYL719 + LGH447	646.4	30	33	159.3	6.8
X-1172	NSCLC	BYL719 + LGH447	593.2	29.5	36	137.9	5
X-1172	NSCLC	BYL719 + LGH447	778.9	28.7	40	212.4	2.1
X-1172	NSCLC	BYL719 + LGH447	862.9	29.2	42	246.1	3.9
X-1172	NSCLC	BYL719 + LJM716	297	24.4	0	0	0
X-1172	NSCLC	BYL719 + LJM716	284.6	23.1	2	-4.2	-5.3
X-1172	NSCLC	BYL719 + LJM716	278.3	22.4	5	-6.3	-8.2
X-1172	NSCLC	BYL719 + LJM716	392.6	22.8	7	32.2	-6.6
X-1172	NSCLC	BYL719 + LJM716	509.6	23.2	12	71.6	-4.9
X-1172	NSCLC	BYL719 + LJM716	615.9	23.2	15	107.4	-4.9
X-1172	NSCLC	BYL719 + LJM716	642.8	23.4	19	116.4	-4.1
X-1172	NSCLC	BYL719 + LJM716	740.6	23.6	22	149.4	-3.3
X-1172	NSCLC	BYL719 + LJM716	888	23	26	199	-5.7
X-1172	NSCLC	BYL719 + LJM716	993.9	23.2	28	234.6	-4.9
X-1172	NSCLC	BYL719	222.1	26.1	0	0	0
X-1172	NSCLC	BYL719	142	24.9	2	-36.1	-4.6
X-1172	NSCLC	BYL719	159	24	5	-28.4	-8
X-1172	NSCLC	BYL719	191.5	24.1	7	-13.8	-7.7
X-1172	NSCLC	BYL719	208	23.8	12	-6.3	-8.8
X-1172	NSCLC	BYL719	243.5	23.7	15	9.6	-9.2
X-1172	NSCLC	BYL719	356	23.4	19	60.3	-10.3
X-1172	NSCLC	BYL719	434.2	22.7	22	95.5	-13
X-1172	NSCLC	BYL719	429.5	22.6	26	93.4	-13.4
X-1172	NSCLC	BYL719	556	22.2	29	150.3	-14.9
X-1172	NSCLC	CGM097	272.8	26.4	0	0	0
X-1172	NSCLC	CGM097	282.2	26.2	2	3.4	-0.8
X-1172	NSCLC	CGM097	325	27.2	5	19.1	3
X-1172	NSCLC	CGM097	532.8	27.5	7	95.3	4.2
X-1172	NSCLC	CGM097	715.7	27.2	12	162.4	3
X-1172	NSCLC	CGM097	980.1	NA	14	259.3	3
X-1172	NSCLC	CKX620	181.1	26.4	0	0	0
X-1172	NSCLC	CKX620	206	26.4	4	13.7	0
X-1172	NSCLC	CKX620	193.8	26.6	6	7	0.8
X-1172	NSCLC	CKX620	234.5	25.5	11	29.5	-3.4
X-1172	NSCLC	CKX620	293.1	25.6	14	61.8	-3
X-1172	NSCLC	CKX620	281.1	26	18	55.2	-1.5
X-1172	NSCLC	CKX620	193.5	27.1	21	6.8	2.7
X-1172	NSCLC	CKX620	164.6	27.2	25	-9.1	3
X-1172	NSCLC	CKX620	138.5	27.3	28	-23.5	3.4
X-1172	NSCLC	CKX620	126.4	27	32	-30.2	2.3
X-1172	NSCLC	CKX620	230	27.6	35	27	4.5
X-1172	NSCLC	CKX620	271.4	27.3	39	49.9	3.4
X-1172	NSCLC	CKX620	433.5	26.9	42	139.4	1.9
X-1172	NSCLC	CKX620	266.8	26.7	46	47.3	1.1
X-1172	NSCLC	CKX620	232.9	27.2	49	28.6	3
X-1172	NSCLC	CKX620	417.5	27.5	53	130.5	4.2
X-1172	NSCLC	CKX620	316.1	26.3	56	74.5	-0.4
X-1172	NSCLC	CKX620	330.6	26.6	60	82.6	0.8
X-1172	NSCLC	CKX620	491.1	27	63	171.2	2.3
X-1172	NSCLC	CKX620	443.8	27.3	67	145.1	3.4
X-1172	NSCLC	CKX620	384.6	27.1	70	112.4	2.7
X-1172	NSCLC	CKX620	583.4	26.9	74	222.1	1.9
X-1172	NSCLC	CKX620	688.5	25.7	75	280.2	-2.7
X-1172	NSCLC	CLR457	321.9	32.4	0	0	0
X-1172	NSCLC	CLR457	256.7	29.4	2	-20.3	-9.3
X-1172	NSCLC	CLR457	289.4	29.9	5	-10.1	-7.7
X-1172	NSCLC	CLR457	410.7	NA	7	27.6	-7.7
X-1172	NSCLC	CLR457	564.9	30.4	12	75.5	-6.2
X-1172	NSCLC	CLR457	479	30.9	15	48.8	-4.6
X-1172	NSCLC	CLR457	1343.6	31.4	19	317.4	-3.1
X-1172	NSCLC	CLR457	1228.1	32.1	21	281.5	-0.9
X-1172	NSCLC	HDM201	212.3	NA	0	0	0
X-1172	NSCLC	HDM201	100.4	21.7	3	-52.7	0
X-1172	NSCLC	HDM201	136.2	22	5	-35.8	1.4
X-1172	NSCLC	HDM201	194.9	23.1	10	-8.2	6.5
X-1172	NSCLC	HDM201	218.4	23.2	13	2.9	6.9
X-1172	NSCLC	HDM201	226.2	23.5	17	6.5	8.3
X-1172	NSCLC	HDM201	307.5	24.2	20	44.8	11.5
X-1172	NSCLC	HDM201	304.6	24.1	24	43.5	11.1
X-1172	NSCLC	HDM201	472.2	24.7	27	122.4	13.8
X-1172	NSCLC	HDM201	985.7	24.3	31	364.3	12
X-1172	NSCLC	HDM201	1120.6	23.8	33	427.8	9.7
X-1172	NSCLC	cetuximab	193.7	23.4	0	0	0
X-1172	NSCLC	cetuximab	327.4	23	4	69	-1.7
X-1172	NSCLC	cetuximab	402.7	23.2	6	107.9	-0.9
X-1172	NSCLC	cetuximab	466.1	24.6	11	140.6	5.1
X-1172	NSCLC	cetuximab	566.1	24.1	14	192.3	3
X-1172	NSCLC	cetuximab	786.3	24.7	18	305.9	5.6
X-1172	NSCLC	cetuximab	761.8	25	20	293.3	6.8
X-1172	NSCLC	erlotinib	270.8	25.7	0	0	0
X-1172	NSCLC	erlotinib	233.5	23.1	2	-13.8	-10.1
X-1172	NSCLC	erlotinib	304.8	23.5	5	12.6	-8.6
X-1172	NSCLC	erlotinib	471.2	23.6	7	74	-8.2
X-1172	NSCLC	erlotinib	697.9	24.1	12	157.7	-6.2
X-1172	NSCLC	erlotinib	775.6	22.6	14	186.4	-12.1
X-1172	NSCLC	HSP990	388.7	27.6	0	0	0
X-1172	NSCLC	HSP990	371.8	24.7	4	-4.3	-10.5
X-1172	NSCLC	HSP990	364.6	25.8	6	-6.2	-6.5
X-1172	NSCLC	HSP990	367.2	25.2	11	-5.5	-8.7
X-1172	NSCLC	HSP990	425.5	25.4	14	9.5	-8
X-1172	NSCLC	HSP990	484.5	27.4	18	24.6	-0.7
X-1172	NSCLC	HSP990	416.1	25.7	21	7	-6.9
X-1172	NSCLC	HSP990	587.8	26.4	25	51.2	-4.3
X-1172	NSCLC	HSP990	573.8	25	28	47.6	-9.4
X-1172	NSCLC	INC280	278.9	25.9	0	0	0
X-1172	NSCLC	INC280	290.7	25.1	2	4.2	-3.1
X-1172	NSCLC	INC280	258.1	25.4	5	-7.5	-1.9
X-1172	NSCLC	INC280	432.5	26.2	7	55.1	1.2
X-1172	NSCLC	INC280	843.6	26.1	12	202.5	0.8
X-1172	NSCLC	INC280	932.6	26	14	234.4	0.4
X-1172	NSCLC	LCL161 + paclitaxel	369.1	27	0	0	0
X-1172	NSCLC	LCL161 + paclitaxel	242.6	21.8	4	-34.3	-19.3
X-1172	NSCLC	LCL161 + paclitaxel	163.5	23.1	6	-55.7	-14.4
X-1172	NSCLC	LCL161 + paclitaxel	144.6	23.7	11	-60.8	-12.2
X-1172	NSCLC	LCL161 + paclitaxel	222.1	23.9	14	-39.8	-11.5
X-1172	NSCLC	LCL161 + paclitaxel	170.3	NA	18	-53.9	-11.5
X-1172	NSCLC	LCL161 + paclitaxel	164.9	24.2	21	-55.3	-10.4
X-1172	NSCLC	LCL161 + paclitaxel	167.6	21.8	25	-54.6	-19.3
X-1172	NSCLC	LCL161 + paclitaxel	218.4	24.1	28	-40.8	-10.7
X-1172	NSCLC	LCL161 + paclitaxel	197.2	22.1	32	-46.6	-18.1
X-1172	NSCLC	LCL161 + paclitaxel	223.4	23.9	35	-39.5	-11.5
X-1172	NSCLC	LCL161 + paclitaxel	213.8	25	39	-42.1	-7.4
X-1172	NSCLC	LCL161 + paclitaxel	218.1	25.5	42	-40.9	-5.6
X-1172	NSCLC	LCL161 + paclitaxel	267.7	23.5	46	-27.5	-13
X-1172	NSCLC	LCL161 + paclitaxel	246.8	24.9	49	-33.1	-7.8
X-1172	NSCLC	LCL161 + paclitaxel	219.1	24.3	53	-40.6	-10
X-1172	NSCLC	LCL161 + paclitaxel	158.9	25.6	56	-56.9	-5.2
X-1172	NSCLC	LCL161 + paclitaxel	140.3	25.2	60	-62	-6.7
X-1172	NSCLC	LCL161 + paclitaxel	136.4	26.5	63	-63	-1.9
X-1172	NSCLC	LCL161 + paclitaxel	189	21.2	67	-48.8	-21.5
X-1172	NSCLC	LCL161 + paclitaxel	121.7	24.7	70	-67	-8.5
X-1172	NSCLC	LCL161 + paclitaxel	120.7	22.6	74	-67.3	-16.3
X-1172	NSCLC	LCL161 + paclitaxel	122.6	24.6	76	-66.8	-8.9
X-1172	NSCLC	LCL161 + paclitaxel	112	22.8	81	-69.7	-15.6
X-1172	NSCLC	LCL161 + paclitaxel	83.4	26.4	84	-77.4	-2.2
X-1172	NSCLC	LCL161 + paclitaxel	100.9	22.9	88	-72.7	-15.2
X-1172	NSCLC	LCL161 + paclitaxel	69.2	25.1	91	-81.3	-7
X-1172	NSCLC	LCL161 + paclitaxel	8.5	21	95	-97.7	-22.2
X-1172	NSCLC	LEE011	219.3	25.7	0	0	0
X-1172	NSCLC	LEE011	157	25	2	-28.4	-2.7
X-1172	NSCLC	LEE011	162	24.9	5	-26.1	-3.1
X-1172	NSCLC	LEE011	162	25	7	-26.1	-2.7
X-1172	NSCLC	LEE011	155	25.7	12	-29.3	0
X-1172	NSCLC	LEE011	172.6	26	15	-21.3	1.2
X-1172	NSCLC	LEE011	316.3	26.5	19	44.2	3.1
X-1172	NSCLC	LEE011	257.3	27.2	22	17.3	5.8
X-1172	NSCLC	LEE011	265	26.5	26	20.8	3.1
X-1172	NSCLC	LEE011	266.3	26.7	29	21.4	3.9
X-1172	NSCLC	LEE011	193.7	27.4	33	-11.7	6.6
X-1172	NSCLC	LEE011	266	27.3	36	21.3	6.2
X-1172	NSCLC	LEE011	236.2	26.8	40	7.7	4.3
X-1172	NSCLC	LEE011	234.2	27.6	43	6.8	7.4
X-1172	NSCLC	LEE011	289.9	27.4	47	32.2	6.6
X-1172	NSCLC	LEE011	244.5	27.8	50	11.5	8.2
X-1172	NSCLC	LEE011	267.1	26.6	54	21.8	3.5
X-1172	NSCLC	LEE011	309.4	28	57	41.1	8.9
X-1172	NSCLC	LEE011	295.7	27.2	61	34.8	5.8
X-1172	NSCLC	LEE011	313.4	28.1	64	42.9	9.3
X-1172	NSCLC	LEE011	412.9	27.6	68	88.3	7.4
X-1172	NSCLC	LEE011	439	28	71	100.2	8.9
X-1172	NSCLC	LEE011	346.3	27.4	75	57.9	6.6
X-1172	NSCLC	LEE011	450.4	28.3	77	105.4	10.1
X-1172	NSCLC	LEE011	387.8	27.5	82	76.8	7
X-1172	NSCLC	LEE011	476.6	27.7	85	117.3	7.8
X-1172	NSCLC	LEE011	407.2	28	89	85.7	8.9
X-1172	NSCLC	LEE011	430.9	28.1	92	96.5	9.3
X-1172	NSCLC	LEE011	399	26.7	96	81.9	3.9
X-1172	NSCLC	LEE011	450	27.6	99	105.2	7.4
X-1172	NSCLC	LEE011	456.6	27.6	103	108.2	7.4
X-1172	NSCLC	LEE011	532.6	27.9	106	142.9	8.6
X-1172	NSCLC	LEE011	418.4	28	110	90.8	8.9
X-1172	NSCLC	LEE011	591.9	27.8	113	169.9	8.2
X-1172	NSCLC	LEE011	547.3	28.2	117	149.6	9.7
X-1172	NSCLC	LGH447	213.3	22.2	0	0	0
X-1172	NSCLC	LGH447	197.5	21.8	1	-7.4	-1.8
X-1172	NSCLC	LGH447	295.5	21.3	4	38.5	-4.1
X-1172	NSCLC	LGH447	289.9	21.4	6	35.9	-3.6
X-1172	NSCLC	LGH447	441.8	22.4	11	107.1	0.9
X-1172	NSCLC	LGH447	559.4	22.6	14	162.3	1.8
X-1172	NSCLC	LGH447	690	22.9	18	223.5	3.2
X-1172	NSCLC	LGH447	806.4	22.5	20	278.1	1.4
X-1172	NSCLC	LLM871	241.7	23.3	0	0	0
X-1172	NSCLC	LLM871	242.6	21.9	4	0.4	-6
X-1172	NSCLC	LLM871	368.7	21.7	6	52.5	-6.9
X-1172	NSCLC	LLM871	626.6	21.8	11	159.2	-6.4
X-1172	NSCLC	LLM871	749	21.7	13	209.9	-6.9
X-1172	NSCLC	binimetinib	278.5	28.1	0	0	0
X-1172	NSCLC	binimetinib	274.4	26.7	2	-1.5	-5
X-1172	NSCLC	binimetinib	179.5	26.8	5	-35.5	-4.6
X-1172	NSCLC	binimetinib	206.9	26.4	7	-25.7	-6
X-1172	NSCLC	binimetinib	230.6	27.5	12	-17.2	-2.1
X-1172	NSCLC	binimetinib	129.7	27.4	15	-53.4	-2.5
X-1172	NSCLC	binimetinib	145.5	25.8	19	-47.8	-8.2
X-1172	NSCLC	binimetinib	186.7	26.1	22	-33	-7.1
X-1172	NSCLC	binimetinib	178.3	24.8	26	-36	-11.7
X-1172	NSCLC	binimetinib	154.6	25.1	29	-44.5	-10.7
X-1172	NSCLC	binimetinib	241.5	25.2	33	-13.3	-10.3
X-1172	NSCLC	binimetinib	223.9	26.1	36	-19.6	-7.1
X-1172	NSCLC	binimetinib	181.8	26	40	-34.7	-7.5
X-1172	NSCLC	binimetinib	194.6	26.3	43	-30.1	-6.4
X-1172	NSCLC	binimetinib	226.6	NA	47	-18.6	-6.4
X-1172	NSCLC	binimetinib	276.6	25.5	50	-0.7	-9.3
X-1172	NSCLC	binimetinib	245.6	25.2	54	-11.8	-10.3
X-1172	NSCLC	binimetinib	280.1	24	57	0.6	-14.6
X-1172	NSCLC	binimetinib	245.6	23.9	61	-11.8	-14.9
X-1172	NSCLC	binimetinib	254.4	22.3	64	-8.7	-20.6
X-1172	NSCLC	binimetinib	241.9	25.4	71	-13.1	-9.6
X-1172	NSCLC	binimetinib	316.9	22.6	75	13.8	-19.6
X-1172	NSCLC	binimetinib	258.8	22.6	76	-7.1	-19.6
X-1172	NSCLC	paclitaxel	296.4	30.8	0	0	0
X-1172	NSCLC	paclitaxel	228.8	29.9	4	-22.8	-2.9
X-1172	NSCLC	paclitaxel	277.9	30.5	6	-6.2	-1
X-1172	NSCLC	paclitaxel	210.2	30.5	11	-29.1	-1
X-1172	NSCLC	paclitaxel	451.5	29.6	14	52.3	-3.9
X-1172	NSCLC	paclitaxel	1120	29.6	18	277.9	-3.9
X-1172	NSCLC	paclitaxel	1250.1	29.5	20	321.8	-4.2
X-1172	NSCLC	untreated	334.5	25.3	0	0	0
X-1172	NSCLC	untreated	671.3	25	2	100.7	-1.2
X-1172	NSCLC	untreated	605.5	26.2	5	81	3.6
X-1172	NSCLC	untreated	690.7	26.3	7	106.5	4
X-1172	NSCLC	untreated	1754.4	26.7	12	424.5	5.5
X-1172	NSCLC	untreated	1530.9	26.7	14	357.7	5.5
X-1172	NSCLC	LFW527 + binimetinib	138.95	25.8	0	0	0
X-1172	NSCLC	LFW527 + binimetinib	100.62	24.3	3	-27.6	-5.8
X-1172	NSCLC	LFW527 + binimetinib	75.51	24.9	6	-45.7	-3.5
X-1172	NSCLC	LFW527 + binimetinib	76.71	25.5	10	-44.8	-1.2
X-1172	NSCLC	LFW527 + binimetinib	79.11	25.2	13	-43.1	-2.3
X-1172	NSCLC	LFW527 + binimetinib	104.89	26.4	18	-24.5	2.3
X-1172	NSCLC	LFW527 + binimetinib	120.18	25.8	20	-13.5	0
X-1172	NSCLC	LFW527 + binimetinib	133.44	26.6	24	-4	3.1
X-1172	NSCLC	LFW527 + binimetinib	120.42	26.4	27	-13.3	2.3
X-1172	NSCLC	LFW527 + binimetinib	155.67	25.5	31	12	-1.2
X-1172	NSCLC	LFW527 + binimetinib	155.81	26.5	34	12.1	2.7
X-1172	NSCLC	LFW527 + binimetinib	170.06	27.5	38	22.4	6.6
X-1172	NSCLC	LFW527 + binimetinib	245.41	28	41	76.6	8.5
X-1172	NSCLC	LFW527 + binimetinib	159.85	27.4	46	15	6.2
X-1172	NSCLC	LFW527 + binimetinib	212.73	27.8	49	53.1	7.8
X-1172	NSCLC	LFW527 + binimetinib	120.62	28.4	52	-13.2	10.1
X-1172	NSCLC	LFW527 + binimetinib	134.68	27.8	56	-3.1	7.8
X-1172	NSCLC	LFW527 + binimetinib	202.47	28	59	45.7	8.5
X-1172	NSCLC	LFW527 + binimetinib	216.31	27.5	62	55.7	6.6
X-1172	NSCLC	LFW527 + binimetinib	260.21	26.7	67	87.3	3.5
X-1172	NSCLC	LFW527 + binimetinib	130.59	27.1	69	-6	5
X-1172	NSCLC	LFW527 + binimetinib	235.37	26.5	73	69.4	2.7
X-1172	NSCLC	LFW527 + binimetinib	237.34	27.4	76	70.8	6.2
X-1172	NSCLC	LFW527 + binimetinib	161	26.3	80	15.9	1.9
X-1172	NSCLC	LFW527 + binimetinib	171.32	26.6	83	23.3	3.1
X-1172	NSCLC	LFW527 + binimetinib	202.03	26.7	87	45.4	3.5
X-1172	NSCLC	LFW527 + binimetinib	150.29	22.6	90	8.2	-12.4
X-1172	NSCLC	LFW527 + binimetinib	169.27	26.1	94	21.8	1.2
X-1172	NSCLC	LFW527 + binimetinib	207.38	26.3	97	49.2	1.9
X-1172	NSCLC	LFW527 + binimetinib	233.72	27.8	101	68.2	7.8
X-1172	NSCLC	LFW527 + binimetinib	199.8	27.8	104	43.8	7.8
X-1172	NSCLC	LFW527 + binimetinib	217.69	28	108	56.7	8.5
X-1172	NSCLC	LFW527 + binimetinib	256.03	26.6	111	84.3	3.1
X-1172	NSCLC	LFW527 + binimetinib	224.96	26	115	61.9	0.8
X-1172	NSCLC	LFW527 + binimetinib	246.22	26.6	118	77.2	3.1
X-1172	NSCLC	LFW527 + binimetinib	277.78	27.2	122	99.9	5.4
X-1172	NSCLC	LFW527 + binimetinib	344.27	26.3	125	147.8	1.9
X-1172	NSCLC	LFW527 + binimetinib	321.79	25.4	129	131.6	-1.6
X-1172	NSCLC	LFW527 + binimetinib	306.88	25.1	132	120.9	-2.7
X-1172	NSCLC	LFW527 + binimetinib	309.64	25.1	136	122.8	-2.7
X-1172	NSCLC	LFW527 + binimetinib	273.28	24	139	96.7	-7
X-1172	NSCLC	LFW527 + binimetinib	270.39	26.8	143	94.6	3.9
X-1172	NSCLC	LFW527 + binimetinib	385.39	25.5	146	177.4	-1.2
X-1172	NSCLC	LFW527 + binimetinib	314.64	24.8	150	126.4	-3.9
X-1172	NSCLC	LFW527 + binimetinib	314.58	25.1	153	126.4	-2.7
X-1172	NSCLC	LFW527 + binimetinib	317.92	24.4	157	128.8	-5.4
X-1172	NSCLC	LFW527 + binimetinib	287.4	25.7	160	106.8	-0.4
X-1172	NSCLC	LFW527 + binimetinib	334.55	NA	165	140.8	-0.4
X-1172	NSCLC	LFW527 + binimetinib	364.6	26.7	168	162.4	3.5
X-1172	NSCLC	LFW527 + binimetinib	427.38	25.7	171	207.6	-0.4
X-1172	NSCLC	LFW527 + binimetinib	496.88	25.2	173	257.6	-2.3
X-1173	CRC	5FU	245	24	0	0	0
X-1173	CRC	5FU	261.5	23.9	1	6.7	-0.4
X-1173	CRC	5FU	284.1	23.5	6	16	-2.1
X-1173	CRC	5FU	353	23.4	9	44.1	-2.5
X-1173	CRC	5FU	314.2	24	13	28.2	0
X-1173	CRC	5FU	247.5	24.2	15	1	0.8
X-1173	CRC	5FU	266.3	24.4	19	8.7	1.7
X-1173	CRC	5FU	267	23.6	22	9	-1.7
X-1173	CRC	5FU	297.2	23.9	27	21.3	-0.4
X-1173	CRC	5FU	308.3	23.9	30	25.8	-0.4
X-1173	CRC	5FU	316.7	25.7	35	29.3	7.1
X-1173	CRC	5FU	198.2	24.1	37	-19.1	0.4
X-1173	CRC	5FU	215.2	24.9	40	-12.2	3.7
X-1173	CRC	5FU	222.2	23.5	44	-9.3	-2.1
X-1173	CRC	5FU	182.6	25.6	48	-25.5	6.7
X-1173	CRC	5FU	221	23	51	-9.8	-4.2
X-1173	CRC	5FU	200.7	24.4	54	-18.1	1.7
X-1173	CRC	5FU	190.1	25.5	57	-22.4	6.2
X-1173	CRC	5FU	189.9	26.3	62	-22.5	9.6
X-1173	CRC	5FU	211.8	25.7	69	-13.6	7.1
X-1173	CRC	5FU	154.6	24.2	71	-36.9	0.8
X-1173	CRC	5FU	180.8	25.2	75	-26.2	5
X-1173	CRC	5FU	212.9	27	78	-13.1	12.5
X-1173	CRC	5FU	196.6	27	83	-19.8	12.5
X-1173	CRC	5FU	155.2	25	86	-36.7	4.2
X-1173	CRC	5FU	163.5	24.4	90	-33.3	1.7
X-1173	CRC	BKM120	209.8	24	0	0	0
X-1173	CRC	BKM120	174.4	24.9	1	-16.9	3.7
X-1173	CRC	BKM120	146.2	24.4	6	-30.3	1.7
X-1173	CRC	BKM120	184.5	24.4	9	-12.1	1.7
X-1173	CRC	BKM120	101.6	25.1	13	-51.6	4.6
X-1173	CRC	BKM120	119.6	24	15	-43	0
X-1173	CRC	BKM120	209	25.1	19	-0.4	4.6
X-1173	CRC	BKM120	190.6	24.9	22	-9.2	3.7
X-1173	CRC	BKM120	277.5	24.9	27	32.3	3.7
X-1173	CRC	BKM120	344.6	24.7	30	64.3	2.9
X-1173	CRC	BKM120	287.3	25.4	35	36.9	5.8
X-1173	CRC	BKM120	244.9	25.2	37	16.7	5
X-1173	CRC	BKM120	265.7	25.5	40	26.6	6.2
X-1173	CRC	BKM120	266	25.1	44	26.8	4.6
X-1173	CRC	BKM120	243.9	25.2	48	16.3	5
X-1173	CRC	BKM120	281.7	24.7	51	34.3	2.9
X-1173	CRC	BKM120	343.1	25.2	54	63.5	5
X-1173	CRC	BKM120	373.5	25.1	57	78	4.6
X-1173	CRC	BKM120	348.3	26.1	62	66	8.8
X-1173	CRC	BKM120 + LJC049	201.8	24	0	0	0
X-1173	CRC	BKM120 + LJC049	175.6	22.7	4	-13	-5.4
X-1173	CRC	BKM120 + LJC049	191.1	22.2	8	-5.3	-7.5
X-1173	CRC	BKM120 + LJC049	328.4	22.2	10	62.7	-7.5
X-1173	CRC	BKM120 + LJC049	278.2	22.6	14	37.9	-5.8
X-1173	CRC	BKM120 + LJC049	250.2	22.5	17	24	-6.2
X-1173	CRC	BKM120 + LJC049	461.4	20.8	22	128.6	-13.3
X-1173	CRC	BYL719 + cetuximab + encorafenib	247.5	26.3	0	0	0
X-1173	CRC	BYL719 + cetuximab + encorafenib	253.1	24.9	3	2.3	-5.3
X-1173	CRC	BYL719 + cetuximab + encorafenib	269.7	25.1	7	9	-4.6
X-1173	CRC	BYL719 + cetuximab + encorafenib	323.3	25.2	10	30.6	-4.2
X-1173	CRC	BYL719 + cetuximab + encorafenib	383.8	25.8	15	55.1	-1.9
X-1173	CRC	BYL719 + cetuximab + encorafenib	422.8	28.1	18	70.8	6.8
X-1173	CRC	BYL719 + cetuximab + encorafenib	425.7	28.1	21	72	6.8
X-1173	CRC	BYL719 + cetuximab + encorafenib	469.9	26	23	89.9	-1.1
X-1173	CRC	BYL719 + cetuximab + encorafenib	541.8	24.1	28	118.9	-8.4
X-1173	CRC	BYL719 + cetuximab + encorafenib	533.5	22.3	32	115.6	-15.2
X-1173	CRC	BYL719 + cetuximab + encorafenib	615.1	24.6	35	148.5	-6.5
X-1173	CRC	BYL719 + cetuximab + encorafenib	633.4	25.1	42	155.9	-4.6
X-1173	CRC	BYL719 + cetuximab + encorafenib	743.5	25.9	45	200.4	-1.5
X-1173	CRC	BYL719 + cetuximab + encorafenib	758.5	26	49	206.5	-1.1
X-1173	CRC	BYL719 + cetuximab	196.3	25.6	0	0	0
X-1173	CRC	BYL719 + cetuximab	215.5	25	7	9.8	-2.3
X-1173	CRC	BYL719 + cetuximab	305.6	25.3	10	55.7	-1.2
X-1173	CRC	BYL719 + cetuximab	317.8	25.4	15	61.9	-0.8
X-1173	CRC	BYL719 + cetuximab	471.2	26.5	18	140	3.5
X-1173	CRC	BYL719 + cetuximab	504.8	26.2	21	157.2	2.3
X-1173	CRC	BYL719 + cetuximab	566.8	26	23	188.7	1.6
X-1173	CRC	BYL719 + cetuximab	809.5	26.9	28	312.4	5.1
X-1173	CRC	BYL719	226.2	29.2	0	0	0
X-1173	CRC	BYL719	235.6	29.2	1	4.2	0
X-1173	CRC	BYL719	279.8	28.3	6	23.7	-3.1
X-1173	CRC	BYL719	372.3	27.4	9	64.6	-6.2
X-1173	CRC	BYL719	442.2	27.9	13	95.5	-4.5
X-1173	CRC	BYL719	460.6	27.3	15	103.6	-6.5
X-1173	CRC	BYL719	661.7	26.8	19	192.5	-8.2
X-1173	CRC	BYL719	585.6	25.9	22	158.9	-11.3
X-1173	CRC	BYL719 + encorafenib	200.7	28	0	0	0
X-1173	CRC	BYL719 + encorafenib	171	27.9	4	-14.8	-0.4
X-1173	CRC	BYL719 + encorafenib	201.5	28.1	8	0.4	0.4
X-1173	CRC	BYL719 + encorafenib	188.2	27.2	10	-6.2	-2.9
X-1173	CRC	BYL719 + encorafenib	145.7	27.9	14	-27.4	-0.4
X-1173	CRC	BYL719 + encorafenib	228.9	27.6	17	14.1	-1.4
X-1173	CRC	BYL719 + encorafenib	225.2	27.8	22	12.2	-0.7
X-1173	CRC	BYL719 + encorafenib	216.2	27.7	25	7.7	-1.1
X-1173	CRC	BYL719 + encorafenib	356.7	28.1	30	77.7	0.4
X-1173	CRC	BYL719 + encorafenib	266.7	27.7	32	32.9	-1.1
X-1173	CRC	BYL719 + encorafenib	254.3	27.7	35	26.7	-1.1
X-1173	CRC	BYL719 + encorafenib	260.5	28.2	39	29.8	0.7
X-1173	CRC	BYL719 + encorafenib	419.9	28.6	43	109.2	2.1
X-1173	CRC	BYL719 + binimetinib	193.3	24	0	0	0
X-1173	CRC	BYL719 + binimetinib	148	23.7	4	-23.4	-1.3
X-1173	CRC	BYL719 + binimetinib	115.9	24	8	-40	0
X-1173	CRC	BYL719 + binimetinib	129.7	23.4	10	-32.9	-2.5
X-1173	CRC	BYL719 + binimetinib	73.9	24.7	14	-61.8	2.9
X-1173	CRC	BYL719 + binimetinib	82.7	23.5	17	-57.2	-2.1
X-1173	CRC	BYL719 + binimetinib	79.6	24.6	22	-58.8	2.5
X-1173	CRC	BYL719 + binimetinib	99.2	22.4	25	-48.7	-6.7
X-1173	CRC	BYL719 + binimetinib	89	23.5	30	-54	-2.1
X-1173	CRC	BYL719 + binimetinib	83.8	25.1	35	-56.6	4.6
X-1173	CRC	BYL719 + binimetinib	91.1	23.1	39	-52.9	-3.7
X-1173	CRC	BYL719 + binimetinib	94.2	23.2	43	-51.3	-3.3
X-1173	CRC	BYL719 + binimetinib	115.9	23.8	46	-40	-0.8
X-1173	CRC	BYL719 + binimetinib	116	23.7	49	-40	-1.3
X-1173	CRC	BYL719 + binimetinib	98.5	23.7	52	-49	-1.3
X-1173	CRC	BYL719 + binimetinib	124.9	23.7	57	-35.4	-1.3
X-1173	CRC	BYL719 + binimetinib	114.3	23.1	64	-40.9	-3.7
X-1173	CRC	BYL719 + binimetinib	104.1	23.3	66	-46.1	-2.9
X-1173	CRC	BYL719 + binimetinib	164.2	23	70	-15.1	-4.2
X-1173	CRC	BYL719 + binimetinib	175.3	23.8	73	-9.3	-0.8
X-1173	CRC	BYL719 + binimetinib	192.7	23.4	79	-0.3	-2.5
X-1173	CRC	BYL719 + binimetinib	162.7	22.8	81	-15.8	-5
X-1173	CRC	BYL719 + binimetinib	181.9	23.9	85	-5.9	-0.4
X-1173	CRC	BYL719 + binimetinib	140.5	23.1	88	-27.3	-3.7
X-1173	CRC	BYL719 + binimetinib	162.4	23.3	91	-16	-2.9
X-1173	CRC	BYL719 + binimetinib	150.3	24.7	98	-22.2	2.9
X-1173	CRC	BYL719 + LJM716	239	29.9	0	0	0
X-1173	CRC	BYL719 + LJM716	200.6	27.2	4	-16.1	-9
X-1173	CRC	BYL719 + LJM716	168.2	26.3	6	-29.6	-12
X-1173	CRC	BYL719 + LJM716	181.2	28	10	-24.2	-6.4
X-1173	CRC	BYL719 + LJM716	170.8	28.6	13	-28.5	-4.3
X-1173	CRC	BYL719 + LJM716	157.6	27.1	18	-34.1	-9.4
X-1173	CRC	BYL719 + LJM716	168.6	27.6	21	-29.5	-7.7
X-1173	CRC	BYL719 + LJM716	161.1	26.4	26	-32.6	-11.7
X-1173	CRC	BYL719 + LJM716	194.8	25.9	28	-18.5	-13.4
X-1173	CRC	BYL719 + LJM716	158.4	26.7	31	-33.7	-10.7
X-1173	CRC	BYL719 + LJM716	171.9	26.2	35	-28.1	-12.4
X-1173	CRC	BYL719 + LJM716	198	25.5	39	-17.2	-14.7
X-1173	CRC	BYL719 + LJM716	271.2	26.5	42	13.5	-11.4
X-1173	CRC	BYL719 + LJM716	269.5	26.4	45	12.8	-11.7
X-1173	CRC	BYL719 + LJM716	310.5	26.9	48	29.9	-10
X-1173	CRC	BYL719 + LJM716	462.5	27.7	53	93.5	-7.4
X-1173	CRC	CGM097	194.9	24.5	0	0	0
X-1173	CRC	CGM097	253.4	24.5	3	30	0
X-1173	CRC	CGM097	256.8	23.8	8	31.8	-2.9
X-1173	CRC	CGM097	386.4	25.7	11	98.3	4.9
X-1173	CRC	CGM097	483.2	26.1	15	147.9	6.5
X-1173	CRC	CGM097	501.4	24.5	17	157.3	0
X-1173	CRC	CGM097	809.3	25.4	24	315.2	3.7
X-1173	CRC	CKX620	281.4	23.3	0	0	0
X-1173	CRC	CKX620	386.5	24	1	37.3	3
X-1173	CRC	CKX620	320.5	23.9	4	13.9	2.6
X-1173	CRC	CKX620	390	22.6	8	38.6	-3
X-1173	CRC	CKX620	362.6	21.9	10	28.9	-6
X-1173	CRC	CKX620	812.8	21.6	14	188.8	-7.3
X-1173	CRC	CKX620	470.8	22.4	17	67.3	-3.9
X-1173	CRC	CKX620	464.4	22.9	22	65	-1.7
X-1173	CRC	CLR457	226.6	26.5	0	0	0
X-1173	CRC	CLR457	183.9	24.8	2	-18.8	-6.4
X-1173	CRC	CLR457	126.2	24.8	6	-44.3	-6.4
X-1173	CRC	CLR457	139.5	24.8	9	-38.4	-6.4
X-1173	CRC	CLR457	156.5	25.2	14	-30.9	-4.9
X-1173	CRC	CLR457	137.3	25.6	17	-39.4	-3.4
X-1173	CRC	CLR457	146.7	26.3	22	-35.3	-0.8
X-1173	CRC	CLR457	187.3	25.9	24	-17.3	-2.3
X-1173	CRC	CLR457	182.1	26.3	27	-19.6	-0.8
X-1173	CRC	CLR457	154	25.3	31	-32	-4.5
X-1173	CRC	CLR457	175.9	26.1	35	-22.4	-1.5
X-1173	CRC	CLR457	200.3	25.5	38	-11.6	-3.8
X-1173	CRC	CLR457	213.9	25.8	41	-5.6	-2.6
X-1173	CRC	CLR457	211	25.4	44	-6.9	-4.2
X-1173	CRC	CLR457	229.2	25.8	49	1.1	-2.6
X-1173	CRC	CLR457	215.4	26.2	56	-4.9	-1.1
X-1173	CRC	CLR457	226.3	25.4	58	-0.1	-4.2
X-1173	CRC	CLR457	235.3	25.5	62	3.8	-3.8
X-1173	CRC	CLR457	253.9	25.1	65	12	-5.3
X-1173	CRC	CLR457	297.2	25.5	70	31.2	-3.8
X-1173	CRC	CLR457	299	26.2	73	32	-1.1
X-1173	CRC	CLR457	286.2	26.9	77	26.3	1.5
X-1173	CRC	CLR457	262.4	27.3	80	15.8	3
X-1173	CRC	CLR457	276.4	28.8	83	22	8.7
X-1173	CRC	CLR457	313.1	25.5	90	38.2	-3.8
X-1173	CRC	HDM201	235	28.1	0	0	0
X-1173	CRC	HDM201	204.5	28	3	-13	-0.4
X-1173	CRC	HDM201	324.2	25.6	8	38	-8.9
X-1173	CRC	HDM201	254.7	26.4	11	8.4	-6
X-1173	CRC	HDM201	340.6	24.8	15	44.9	-11.7
X-1173	CRC	HDM201	342.7	24.1	17	45.8	-14.2
X-1173	CRC	HDM201	476.1	22.9	21	102.6	-18.5
X-1173	CRC	HDM201	425	25.2	24	80.9	-10.3
X-1173	CRC	cetuximab	196.5	24.9	0	0	0
X-1173	CRC	cetuximab	331.5	24.3	4	68.7	-2.4
X-1173	CRC	cetuximab	417.1	24.3	7	112.3	-2.4
X-1173	CRC	cetuximab	581.8	23	11	196.1	-7.6
X-1173	CRC	cetuximab	1092.2	22.3	14	455.8	-10.4
X-1173	CRC	cetuximab	1484.9	22.7	19	655.7	-8.8
X-1173	CRC	cetuximab + encorafenib	273.2	21.5	0	0	0
X-1173	CRC	cetuximab + encorafenib	320.9	20.4	3	17.5	-5.1
X-1173	CRC	cetuximab + encorafenib	433.6	23.3	7	58.7	8.4
X-1173	CRC	cetuximab + encorafenib	592.7	24.1	10	116.9	12.1
X-1173	CRC	cetuximab + encorafenib	736.2	23.4	15	169.5	8.8
X-1173	CRC	cetuximab + encorafenib	843.8	22.6	18	208.9	5.1
X-1173	CRC	cetuximab + encorafenib	928.3	22.6	21	239.8	5.1
X-1173	CRC	cetuximab + encorafenib	949.5	22.6	23	247.5	5.1
X-1173	CRC	cetuximab + encorafenib	1601.8	25.3	28	486.3	17.7
X-1173	CRC	LEE011	198.7	29.9	0	0	0
X-1173	CRC	LEE011	304	29.7	3	53	-0.7
X-1173	CRC	LEE011	396.3	27.6	8	99.4	-7.7
X-1173	CRC	LEE011	430.6	28	11	116.7	-6.4
X-1173	CRC	LEE011	499.6	29.7	15	151.4	-0.7
X-1173	CRC	LEE011	489.4	28.9	17	146.3	-3.3
X-1173	CRC	LEE011	574.9	27.8	21	189.3	-7
X-1173	CRC	LEE011	553.2	27.2	24	178.4	-9
X-1173	CRC	encorafenib	235.9	27.9	0	0	0
X-1173	CRC	encorafenib	229.8	27.4	3	-2.6	-1.8
X-1173	CRC	encorafenib	605.1	26	8	156.5	-6.8
X-1173	CRC	encorafenib	648.4	26.5	11	174.9	-5
X-1173	CRC	encorafenib	1024.6	26.4	15	334.3	-5.4
X-1173	CRC	encorafenib	1176.7	24.9	17	398.8	-10.8
X-1173	CRC	encorafenib	1959.2	24.7	24	730.5	-11.5
X-1173	CRC	LJC049	193.9	26.8	0	0	0
X-1173	CRC	LJC049	228.3	27.3	3	17.7	1.9
X-1173	CRC	LJC049	156.6	26.3	8	-19.2	-1.9
X-1173	CRC	LJC049	473.6	27.5	11	144.2	2.6
X-1173	CRC	LJC049	1032.1	26.4	15	432.3	-1.5
X-1173	CRC	LJC049	1851.1	25.9	17	854.7	-3.4
X-1173	CRC	LKA136	198.8	24.1	0	0	0
X-1173	CRC	LKA136	403.7	24.1	3	103.1	0
X-1173	CRC	LKA136	762.7	24.4	8	283.7	1.2
X-1173	CRC	LKA136	1268.7	23.7	11	538.2	-1.7
X-1173	CRC	LKA136	2101.6	23.4	15	957.1	-2.9
X-1173	CRC	binimetinib	257.7	23.4	0	0	0
X-1173	CRC	binimetinib	309.9	22.1	3	20.3	-5.6
X-1173	CRC	binimetinib	296	20.5	8	14.9	-12.4
X-1173	CRC	binimetinib	293	22.7	11	13.7	-3
X-1173	CRC	binimetinib	400.5	22.9	15	55.4	-2.1
X-1173	CRC	binimetinib	386.6	23.1	17	50	-1.3
X-1173	CRC	binimetinib	525.1	23	21	103.8	-1.7
X-1173	CRC	binimetinib	467.4	22.8	24	81.4	-2.6
X-1173	CRC	binimetinib	466.4	23	29	81	-1.7
X-1173	CRC	untreated	246.4	26.8	0	0	0
X-1173	CRC	untreated	307	26.8	3	24.6	0
X-1173	CRC	untreated	485	27.4	7	96.8	2.2
X-1173	CRC	untreated	456.3	27.2	10	85.2	1.5
X-1173	CRC	untreated	552.2	26.4	13	124.1	-1.5
X-1173	CRC	untreated	884	27	16	258.8	0.7
X-1173	CRC	untreated	985.7	27.5	21	300	2.6
X-1173	CRC	untreated	1199.4	28	28	386.8	4.5
X-1173	CRC	untreated	1448.6	27.4	30	487.9	2.2
X-1199	PDAC	abraxane	231.5	28.8	0	0	0
X-1199	PDAC	abraxane	261.8	27.5	2	13.1	-4.5
X-1199	PDAC	abraxane	287.7	27.7	5	24.3	-3.8
X-1199	PDAC	abraxane	531.3	27.3	8	129.5	-5.2
X-1199	PDAC	abraxane	526.9	29.4	12	127.6	2.1
X-1199	PDAC	abraxane	532.6	28.8	15	130.1	0
X-1199	PDAC	abraxane	721.8	28	19	211.8	-2.8
X-1199	PDAC	abraxane	781.8	28.1	22	237.7	-2.4
X-1199	PDAC	abraxane	750.3	29.9	26	224.1	3.8
X-1199	PDAC	abraxane	693.4	28.4	29	199.5	-1.4
X-1199	PDAC	BKM120 + binimetinib	224.8	27.1	0	0	0
X-1199	PDAC	BKM120 + binimetinib	237.8	25.4	4	5.8	-6.3
X-1199	PDAC	BKM120 + binimetinib	220.5	26.3	11	-1.9	-3
X-1199	PDAC	BKM120 + binimetinib	194.4	27.5	14	-13.5	1.5
X-1199	PDAC	BKM120 + binimetinib	177.7	27.9	18	-21	3
X-1199	PDAC	BKM120 + binimetinib	167.9	28.1	21	-25.3	3.7
X-1199	PDAC	BKM120 + binimetinib	174.7	27	25	-22.3	-0.4
X-1199	PDAC	BKM120 + binimetinib	135.9	27.7	27	-39.5	2.2
X-1199	PDAC	BKM120 + binimetinib	158.7	27	32	-29.4	-0.4
X-1199	PDAC	BKM120 + binimetinib	130.6	29	34	-41.9	7
X-1199	PDAC	BKM120 + binimetinib	75.6	28.4	39	-66.4	4.8
X-1199	PDAC	BKM120 + binimetinib	107.2	27.2	42	-52.3	0.4
X-1199	PDAC	BKM120 + binimetinib	159.8	27.3	46	-28.9	0.7
X-1199	PDAC	BKM120 + binimetinib	108.7	26.9	49	-51.6	-0.7
X-1199	PDAC	BKM120 + binimetinib	101.4	27.3	53	-54.9	0.7
X-1199	PDAC	BKM120 + binimetinib	87	28.2	56	-61.3	4.1
X-1199	PDAC	BKM120 + binimetinib	99.3	26.5	60	-55.8	-2.2
X-1199	PDAC	BKM120 + binimetinib	76.7	27	63	-65.9	-0.4
X-1199	PDAC	BKM120 + LDE225	269.1	26.2	0	0	0
X-1199	PDAC	BKM120 + LDE225	380.6	27.1	4	41.4	3.4
X-1199	PDAC	BKM120 + LDE225	270.3	25.4	7	0.4	-3.1
X-1199	PDAC	BKM120 + LDE225	347.5	26.9	11	29.1	2.7
X-1199	PDAC	BKM120 + LDE225	368	25.1	14	36.8	-4.2
X-1199	PDAC	BKM120 + LDE225	415.2	25.7	18	54.3	-1.9
X-1199	PDAC	BKM120 + LDE225	303.6	23.6	21	12.8	-9.9
X-1199	PDAC	BKM120 + LDE225	299.3	25.7	24	11.2	-1.9
X-1199	PDAC	BKM120 + LDE225	216.5	24.1	27	-19.5	-8
X-1199	PDAC	BKM120 + LDE225	177.5	23	32	-34	-12.2
X-1199	PDAC	BKM120 + LDE225	218.5	21	35	-18.8	-19.8
X-1199	PDAC	BKM120	213.2	26.9	0	0	0
X-1199	PDAC	BKM120	215.4	27	4	1	0.4
X-1199	PDAC	BKM120	218	28.8	7	2.3	7.1
X-1199	PDAC	BKM120	212.3	28.6	11	-0.4	6.3
X-1199	PDAC	BKM120	235.4	29.2	14	10.4	8.6
X-1199	PDAC	BKM120	250.6	28.8	18	17.5	7.1
X-1199	PDAC	BKM120	224	28.6	21	5.1	6.3
X-1199	PDAC	BKM120	254.3	29.4	25	19.3	9.3
X-1199	PDAC	BKM120	275.5	29.6	28	29.2	10
X-1199	PDAC	BKM120	261.5	29	34	22.7	7.8
X-1199	PDAC	BYL719 + LJM716	213.7	26.5	0	0	0
X-1199	PDAC	BYL719 + LJM716	193.3	26.5	5	-9.5	0
X-1199	PDAC	BYL719 + LJM716	232.5	26.1	8	8.8	-1.5
X-1199	PDAC	BYL719 + LJM716	233.9	26.6	12	9.5	0.4
X-1199	PDAC	BYL719 + LJM716	245.1	25	15	14.7	-5.7
X-1199	PDAC	BYL719 + LJM716	223.4	26	19	4.5	-1.9
X-1199	PDAC	BYL719 + LJM716	242.8	26.1	22	13.6	-1.5
X-1199	PDAC	BYL719 + LJM716	244.4	26.7	26	14.4	0.8
X-1199	PDAC	BYL719 + LJM716	240.2	25.4	28	12.4	-4.2
X-1199	PDAC	BYL719 + LJM716	204.3	26.7	33	-4.4	0.8
X-1199	PDAC	BYL719 + LJM716	208.8	26.2	36	-2.3	-1.1
X-1199	PDAC	BYL719 + LJM716	220.5	25.9	40	3.2	-2.3
X-1199	PDAC	BYL719 + LJM716	210.9	25.9	43	-1.3	-2.3
X-1199	PDAC	BYL719 + LJM716	212.9	26.6	46	-0.4	0.4
X-1199	PDAC	BYL719	308.5	28.1	0	0	0
X-1199	PDAC	BYL719	359.1	26	5	16.4	-7.5
X-1199	PDAC	BYL719	373.8	25.9	8	21.2	-7.8
X-1199	PDAC	BYL719	390.6	26.5	12	26.6	-5.7
X-1199	PDAC	BYL719	412.9	26.9	15	33.8	-4.3
X-1199	PDAC	BYL719	421.1	26.9	19	36.5	-4.3
X-1199	PDAC	BYL719	449.2	26.8	22	45.6	-4.6
X-1199	PDAC	BYL719	472.4	27.7	26	53.1	-1.4
X-1199	PDAC	BYL719	461.4	26.6	28	49.6	-5.3
X-1199	PDAC	BYL719	514.1	27.6	33	66.6	-1.8
X-1199	PDAC	BYL719	522.5	27.1	36	69.4	-3.6
X-1199	PDAC	BYL719	487.6	27	40	58.1	-3.9
X-1199	PDAC	BYL719	503.2	27.5	43	63.1	-2.1
X-1199	PDAC	BYL719	507.9	29.1	46	64.6	3.6
X-1199	PDAC	CLR457	326.6	26.8	0	0	0
X-1199	PDAC	CLR457	389.3	28	3	19.2	4.5
X-1199	PDAC	CLR457	429.8	27.6	7	31.6	3
X-1199	PDAC	CLR457	489.6	28.2	10	49.9	5.2
X-1199	PDAC	CLR457	548.3	29	13	67.9	8.2
X-1199	PDAC	CLR457	569.1	27.2	16	74.2	1.5
X-1199	PDAC	CLR457	594.2	29.2	21	81.9	9
X-1199	PDAC	CLR457	571.3	28.7	24	74.9	7.1
X-1199	PDAC	CLR457	616.4	28.6	28	88.7	6.7
X-1199	PDAC	CLR457	593.5	28.3	31	81.7	5.6
X-1199	PDAC	CLR457	575	28.4	34	76.1	6
X-1199	PDAC	figitumumab"	260.6	27.7	0	0	0
X-1199	PDAC	figitumumab"	292	27.8	2	12	0.4
X-1199	PDAC	figitumumab"	1028.6	27.5	6	294.7	-0.7
X-1199	PDAC	figitumumab"	972.8	26.5	9	273.3	-4.3
X-1199	PDAC	figitumumab"	1184.3	27.6	12	354.5	-0.4
X-1199	PDAC	figitumumab"	1138.2	27.9	16	336.8	0.7
X-1199	PDAC	figitumumab"	934.6	27.6	23	258.6	-0.4
X-1199	PDAC	figitumumab"	1445.6	27.3	27	454.7	-1.4
X-1199	PDAC	figitumumab" + binimetinib	194.3	27.7	0	0	0
X-1199	PDAC	figitumumab" + binimetinib	192.4	27.5	4	-1	-0.7
X-1199	PDAC	figitumumab" + binimetinib	197.9	27.4	7	1.9	-1.1
X-1199	PDAC	figitumumab" + binimetinib	377.9	28.5	11	94.5	2.9
X-1199	PDAC	figitumumab" + binimetinib	233.5	27.6	13	20.2	-0.4
X-1199	PDAC	figitumumab" + binimetinib	134.7	28.4	18	-30.7	2.5
X-1199	PDAC	figitumumab" + binimetinib	240.5	29	21	23.8	4.7
X-1199	PDAC	figitumumab" + binimetinib	207	28	25	6.5	1.1
X-1199	PDAC	figitumumab" + binimetinib	235.5	27.5	28	21.2	-0.7
X-1199	PDAC	figitumumab" + binimetinib	212.9	27.7	31	9.6	0
X-1199	PDAC	figitumumab" + binimetinib	252.4	28.4	34	29.9	2.5
X-1199	PDAC	figitumumab" + binimetinib	263	28	39	35.4	1.1
X-1199	PDAC	gemcitabine-50mpk	264.3	27	0	0	0
X-1199	PDAC	gemcitabine-50mpk	347.5	25.9	5	31.5	-4.1
X-1199	PDAC	gemcitabine-50mpk	322.2	26.1	7	21.9	-3.3
X-1199	PDAC	gemcitabine-50mpk	340.4	25.6	11	28.8	-5.2
X-1199	PDAC	gemcitabine-50mpk	372.3	24.1	14	40.9	-10.7
X-1199	PDAC	gemcitabine-50mpk	360.9	27.5	17	36.5	1.9
X-1199	PDAC	gemcitabine-50mpk	382.5	26.9	20	44.7	-0.4
X-1199	PDAC	gemcitabine-50mpk	343.2	27.3	25	29.9	1.1
X-1199	PDAC	gemcitabine-50mpk	329.2	25.9	28	24.6	-4.1
X-1199	PDAC	gemcitabine-50mpk	429.4	27.1	32	62.5	0.4
X-1199	PDAC	gemcitabine-50mpk	415.7	26.7	35	57.3	-1.1
X-1199	PDAC	gemcitabine-50mpk	383.3	27	38	45	0
X-1199	PDAC	gemcitabine-50mpk	374.4	26.6	41	41.7	-1.5
X-1199	PDAC	gemcitabine-50mpk	377	26.5	46	42.6	-1.9
X-1199	PDAC	gemcitabine-50mpk	355.3	26.5	49	34.4	-1.9
X-1199	PDAC	gemcitabine-50mpk	329.9	26	53	24.8	-3.7
X-1199	PDAC	gemcitabine-50mpk	342.9	26.7	55	29.7	-1.1
X-1199	PDAC	gemcitabine-50mpk	357.7	27.7	60	35.3	2.6
X-1199	PDAC	gemcitabine-50mpk	372.7	26.4	62	41	-2.2
X-1199	PDAC	gemcitabine-50mpk	317.9	26.9	67	20.3	-0.4
X-1199	PDAC	gemcitabine-50mpk	366.4	27.2	70	38.6	0.7
X-1199	PDAC	gemcitabine-50mpk	304.2	27.7	74	15.1	2.6
X-1199	PDAC	gemcitabine-50mpk	420.6	28.9	77	59.1	7
X-1199	PDAC	gemcitabine-50mpk	443.8	29.2	80	67.9	8.1
X-1199	PDAC	gemcitabine-50mpk	521.9	28.3	84	97.5	4.8
X-1199	PDAC	gemcitabine-50mpk	373.3	28.6	87	41.2	5.9
X-1199	PDAC	gemcitabine-50mpk	562.1	27.4	91	112.7	1.5
X-1199	PDAC	gemcitabine-50mpk	427.7	27.2	94	61.8	0.7
X-1199	PDAC	gemcitabine-50mpk	455.2	29	98	72.2	7.4
X-1199	PDAC	gemcitabine-50mpk	489.2	28.6	101	85.1	5.9
X-1199	PDAC	INC424 + binimetinib	236.9	27.4	0	0	0
X-1199	PDAC	INC424 + binimetinib	252.3	27.3	4	6.5	-0.4
X-1199	PDAC	INC424 + binimetinib	220	26.4	11	-7.1	-3.6
X-1199	PDAC	INC424 + binimetinib	257.3	26.9	14	8.6	-1.8
X-1199	PDAC	INC424 + binimetinib	281.7	26.7	18	18.9	-2.6
X-1199	PDAC	INC424 + binimetinib	229	25.1	21	-3.3	-8.4
X-1199	PDAC	INC424 + binimetinib	213.2	26.2	25	-10	-4.4
X-1199	PDAC	INC424 + binimetinib	190.4	26.2	27	-19.6	-4.4
X-1199	PDAC	INC424 + binimetinib	186.5	22.6	32	-21.3	-17.5
X-1199	PDAC	INC424 + binimetinib	166.6	21.6	34	-29.7	-21.2
X-1199	PDAC	INC424	207.5	27	0	0	0
X-1199	PDAC	INC424	163.2	26.9	4	-21.3	-0.4
X-1199	PDAC	INC424	164.4	26	7	-20.8	-3.7
X-1199	PDAC	INC424	168	26.5	11	-19	-1.9
X-1199	PDAC	INC424	167.7	26	14	-19.2	-3.7
X-1199	PDAC	INC424	171	27.1	19	-17.6	0.4
X-1199	PDAC	INC424	347.8	27.3	22	67.6	1.1
X-1199	PDAC	INC424	369.2	25.8	26	77.9	-4.4
X-1199	PDAC	INC424	413.9	26.9	29	99.5	-0.4
X-1199	PDAC	INC424	527.4	27.8	32	154.2	3
X-1199	PDAC	INC424	542	27.8	35	161.2	3
X-1199	PDAC	INC424	610.7	27.3	39	194.3	1.1
X-1199	PDAC	INC424	644.5	27.9	43	210.6	3.3
X-1199	PDAC	INC424	750.7	27.4	47	261.8	1.5
X-1199	PDAC	INC424	808.9	27.1	51	289.8	0.4
X-1199	PDAC	INC424	932.1	27.4	54	349.2	1.5
X-1199	PDAC	INC424	1092.4	27.6	56	426.5	2.2
X-1199	PDAC	INC424	1135.5	26.9	60	447.2	-0.4
X-1199	PDAC	LEE011	219.2	27.8	0	0	0
X-1199	PDAC	LEE011	247.2	27.3	4	12.8	-1.8
X-1199	PDAC	LEE011	308.5	26	7	40.7	-6.5
X-1199	PDAC	LEE011	299.8	27.1	11	36.8	-2.5
X-1199	PDAC	LEE011	339.8	28.4	18	55	2.2
X-1199	PDAC	LEE011	269.1	27.9	21	22.8	0.4
X-1199	PDAC	LEE011	368	29.2	25	67.9	5
X-1199	PDAC	LEE011	272.7	28.7	28	24.4	3.2
X-1199	PDAC	LEE011	216.6	29.2	32	-1.2	5
X-1199	PDAC	LEE011	225.7	28.5	35	3	2.5
X-1199	PDAC	LEE011	272	28.5	39	24.1	2.5
X-1199	PDAC	LEE011	209.5	29.2	42	-4.4	5
X-1199	PDAC	LEE011	210.9	28.9	46	-3.8	4
X-1199	PDAC	LEE011	171.8	28.5	49	-21.6	2.5
X-1199	PDAC	LEE011	186.7	28.3	53	-14.8	1.8
X-1199	PDAC	LEE011	145	27.5	56	-33.9	-1.1
X-1199	PDAC	LEE011	151.5	28.3	60	-30.9	1.8
X-1199	PDAC	LEE011	192.6	26.9	63	-12.1	-3.2
X-1199	PDAC	LEE011	170.9	27.5	67	-22	-1.1
X-1199	PDAC	LEE011	164.5	27.7	70	-25	-0.4
X-1199	PDAC	LEE011	140.8	28.8	74	-35.8	3.6
X-1199	PDAC	LEE011	143.6	29.2	77	-34.5	5
X-1199	PDAC	LEE011	167.2	28.1	81	-23.7	1.1
X-1199	PDAC	WNT974	249.3	28.2	0	0	0
X-1199	PDAC	WNT974	241.7	27.6	1	-3	-2.1
X-1199	PDAC	WNT974	220.6	26.9	6	-11.5	-4.6
X-1199	PDAC	WNT974	231.5	27.8	9	-7.1	-1.4
X-1199	PDAC	WNT974	267.3	27.5	12	7.2	-2.5
X-1199	PDAC	WNT974	354.5	29.5	15	42.2	4.6
X-1199	PDAC	WNT974	417.4	27.4	19	67.4	-2.8
X-1199	PDAC	WNT974	415.9	27.5	23	66.8	-2.5
X-1199	PDAC	WNT974	410.5	26.6	27	64.7	-5.7
X-1199	PDAC	WNT974	343.7	27.5	30	37.9	-2.5
X-1199	PDAC	WNT974	379.1	27.9	33	52.1	-1.1
X-1199	PDAC	WNT974	353.5	28.2	36	41.8	0
X-1199	PDAC	WNT974	396.5	27.5	41	59	-2.5
X-1199	PDAC	WNT974	383.2	27.8	44	53.7	-1.4
X-1199	PDAC	WNT974	385.8	27	48	54.8	-4.3
X-1199	PDAC	WNT974	324.3	26.5	51	30.1	-6
X-1199	PDAC	WNT974	370.6	27.7	56	48.7	-1.8
X-1199	PDAC	WNT974	452.9	NA	58	81.7	-1.8
X-1199	PDAC	WNT974	446.4	27.4	62	79.1	-2.8
X-1199	PDAC	WNT974	483.5	27.8	65	93.9	-1.4
X-1199	PDAC	WNT974	435.3	26.9	68	74.6	-4.6
X-1199	PDAC	WNT974	450.7	27.3	71	80.8	-3.2
X-1199	PDAC	WNT974	404.1	23.8	76	62.1	-15.6
X-1199	PDAC	WNT974	324.1	27.1	79	30	-3.9
X-1199	PDAC	WNT974	304.5	27.2	83	22.1	-3.5
X-1199	PDAC	WNT974	388.9	27.3	86	56	-3.2
X-1199	PDAC	WNT974	272.6	26.8	89	9.3	-5
X-1199	PDAC	WNT974	379.9	26.1	91	52.4	-7.4
X-1199	PDAC	WNT974	393.3	27.5	97	57.8	-2.5
X-1199	PDAC	WNT974	353.4	28.4	99	41.8	0.7
X-1199	PDAC	WNT974	379.9	27.3	104	52.4	-3.2
X-1199	PDAC	WNT974	392.9	27	106	57.6	-4.3
X-1199	PDAC	LKA136	257.9	25.3	0	0	0
X-1199	PDAC	LKA136	215.6	25.1	4	-16.4	-0.8
X-1199	PDAC	LKA136	365.5	25.7	7	41.7	1.6
X-1199	PDAC	LKA136	358.6	25.6	10	39	1.2
X-1199	PDAC	LKA136	395	26.1	14	53.2	3.2
X-1199	PDAC	LKA136	384.3	25.3	17	49	0
X-1199	PDAC	LKA136	418.5	26.4	22	62.3	4.3
X-1199	PDAC	LKA136	433.3	25.9	25	68	2.4
X-1199	PDAC	LKA136	427.5	25.8	28	65.8	2
X-1199	PDAC	LKA136	290.7	24.8	32	12.7	-2
X-1199	PDAC	LKA136	384.3	26.3	35	49	4
X-1199	PDAC	LKA136	481.5	26.5	38	86.7	4.7
X-1199	PDAC	LKA136	488.3	25.7	42	89.3	1.6
X-1199	PDAC	LKA136	591.6	25.4	45	129.4	0.4
X-1199	PDAC	LKA136	530	24.5	50	105.5	-3.2
X-1199	PDAC	LKA136	694.3	25	53	169.2	-1.2
X-1199	PDAC	LKA136	705.8	26.2	57	173.7	3.6
X-1199	PDAC	LKA136	745.7	25.7	60	189.1	1.6
X-1199	PDAC	binimetinib	230.8	25.3	0	0	0
X-1199	PDAC	binimetinib	244.2	24.9	2	5.8	-1.6
X-1199	PDAC	binimetinib	113.3	24.8	6	-50.9	-2
X-1199	PDAC	binimetinib	207.6	24.7	9	-10.1	-2.4
X-1199	PDAC	binimetinib	99	24	13	-57.1	-5.1
X-1199	PDAC	binimetinib	57.9	23.8	20	-74.9	-5.9
X-1199	PDAC	binimetinib	86.8	24.4	23	-62.4	-3.6
X-1199	PDAC	binimetinib	60.1	24.2	27	-74	-4.3
X-1199	PDAC	binimetinib	38.7	24.1	30	-83.2	-4.7
X-1199	PDAC	binimetinib	39.3	23.3	34	-83	-7.9
X-1199	PDAC	binimetinib	56.3	23.6	36	-75.6	-6.7
X-1199	PDAC	binimetinib	40.4	22.8	41	-82.5	-9.9
X-1199	PDAC	binimetinib	42.1	23.1	43	-81.8	-8.7
X-1199	PDAC	binimetinib	26.8	21.8	48	-88.4	-13.8
X-1199	PDAC	binimetinib	27	20.7	51	-88.3	-18.2
X-1199	PDAC	binimetinib-3.5mpk	279.5	31.5	0	0	0
X-1199	PDAC	binimetinib-3.5mpk	257.9	31.2	2	-7.7	-1
X-1199	PDAC	binimetinib-3.5mpk	290.9	32.5	7	4.1	3.2
X-1199	PDAC	binimetinib-3.5mpk	294	32.7	12	5.2	3.8
X-1199	PDAC	binimetinib-3.5mpk	292.8	33.1	15	4.8	5.1
X-1199	PDAC	binimetinib-3.5mpk	346.4	32.7	19	23.9	3.8
X-1199	PDAC	binimetinib-3.5mpk	239.5	32.6	22	-14.3	3.5
X-1199	PDAC	binimetinib-3.5mpk	223.7	32.2	26	-20	2.2
X-1199	PDAC	binimetinib-3.5mpk	352.3	32.7	29	26	3.8
X-1199	PDAC	binimetinib-3.5mpk	210.1	32.2	34	-24.8	2.2
X-1199	PDAC	binimetinib-3.5mpk	268.9	34	37	-3.8	7.9
X-1199	PDAC	binimetinib-3.5mpk	252.8	32.3	42	-9.6	2.5
X-1199	PDAC	binimetinib-3.5mpk	157.3	31.8	44	-43.7	1
X-1199	PDAC	binimetinib-3.5mpk	209.4	31.8	48	-25.1	1
X-1199	PDAC	binimetinib-3.5mpk	273.1	31.7	51	-2.3	0.6
X-1199	PDAC	binimetinib-3.5mpk	298.5	31.2	55	6.8	-1
X-1199	PDAC	binimetinib-3.5mpk	226.1	31.3	57	-19.1	-0.6
X-1199	PDAC	binimetinib-3.5mpk	304.4	32.1	62	8.9	1.9
X-1199	PDAC	binimetinib-3.5mpk	239.9	32.1	65	-14.2	1.9
X-1199	PDAC	binimetinib-3.5mpk	243.6	32	69	-12.8	1.6
X-1199	PDAC	binimetinib-3.5mpk	256.1	32	72	-8.4	1.6
X-1199	PDAC	binimetinib-3.5mpk	285	32.2	76	2	2.2
X-1199	PDAC	binimetinib-3.5mpk	214.7	29.6	79	-23.2	-6
X-1199	PDAC	binimetinib-3.5mpk	195.8	29.3	83	-29.9	-7
X-1199	PDAC	binimetinib-3.5mpk	217.7	31.6	86	-22.1	0.3
X-1199	PDAC	binimetinib-3.5mpk	162.9	32.1	90	-41.7	1.9
X-1199	PDAC	binimetinib-3.5mpk	182.2	31.8	93	-34.8	1
X-1199	PDAC	binimetinib-3.5mpk	183.4	32	96	-34.4	1.6
X-1199	PDAC	trametinib	203.8	26.7	0	0	0
X-1199	PDAC	trametinib	195	25.7	4	-4.3	-3.7
X-1199	PDAC	trametinib	177.1	25.3	7	-13.1	-5.2
X-1199	PDAC	trametinib	187.3	25.2	11	-8.1	-5.6
X-1199	PDAC	trametinib	163.6	25.3	14	-19.7	-5.2
X-1199	PDAC	trametinib	185.2	25.3	19	-9.1	-5.2
X-1199	PDAC	trametinib	125.4	24.8	22	-38.5	-7.1
X-1199	PDAC	trametinib	129	25.6	26	-36.7	-4.1
X-1199	PDAC	trametinib	104.4	25.7	29	-48.8	-3.7
X-1199	PDAC	trametinib	124	24.6	33	-39.2	-7.9
X-1199	PDAC	trametinib	92.9	24.1	36	-54.4	-9.7
X-1199	PDAC	trametinib	89.3	26.1	41	-56.2	-2.2
X-1199	PDAC	trametinib	78.6	24.4	43	-61.4	-8.6
X-1199	PDAC	trametinib	95.1	25.7	47	-53.3	-3.7
X-1199	PDAC	trametinib	90.8	25.1	50	-55.4	-6
X-1199	PDAC	trametinib	121	25.4	54	-40.6	-4.9
X-1199	PDAC	trametinib	87.6	24.9	57	-57	-6.7
X-1199	PDAC	trametinib	93.5	25.1	61	-54.1	-6
X-1199	PDAC	trametinib	95.1	24.2	64	-53.3	-9.4
X-1199	PDAC	trametinib	69.6	24.8	69	-65.8	-7.1
X-1199	PDAC	trametinib	129.5	25	74	-36.5	-6.4
X-1199	PDAC	trametinib	88.5	24.4	77	-56.6	-8.6
X-1199	PDAC	trametinib	76.3	25.2	81	-62.6	-5.6
X-1199	PDAC	trametinib	54.5	24.5	84	-73.3	-8.2
X-1199	PDAC	trametinib	87.1	24.9	88	-57.3	-6.7
X-1199	PDAC	trametinib	81.5	25.1	91	-60	-6
X-1199	PDAC	trametinib	70.8	26.2	95	-65.3	-1.9
X-1199	PDAC	trametinib	70.4	25.6	98	-65.5	-4.1
X-1199	PDAC	untreated	274	20.9	0	0	0
X-1199	PDAC	untreated	317.4	22.3	3	15.8	6.7
X-1199	PDAC	untreated	303.2	22.4	6	10.7	7.2
X-1199	PDAC	untreated	349.3	22.9	10	27.5	9.6
X-1199	PDAC	untreated	342.6	22.6	14	25	8.1
X-1199	PDAC	untreated	374.4	22	18	36.6	5.3
X-1199	PDAC	untreated	374.9	22	20	36.8	5.3
X-1199	PDAC	untreated	381.4	23.9	24	39.2	14.4
X-1199	PDAC	untreated	338.4	24	27	23.5	14.8
X-1199	PDAC	untreated	402.7	22.9	32	47	9.6
X-1199	PDAC	untreated	386.6	22.8	38	41.1	9.1
X-1199	PDAC	untreated	400.2	22.7	42	46.1	8.6
X-1199	PDAC	untreated	404.9	24.2	45	47.8	15.8
X-1199	PDAC	untreated	555.2	23.7	48	102.6	13.4
X-1199	PDAC	untreated	515.9	23.5	52	88.3	12.4
X-1199	PDAC	untreated	514.9	22.7	55	87.9	8.6
X-1199	PDAC	untreated	505.6	22.5	60	84.5	7.7
X-1199	PDAC	untreated	459.7	22.9	63	67.8	9.6
X-1199	PDAC	untreated	573.6	23.4	67	109.3	12
X-1199	PDAC	untreated	640.7	22.6	70	133.8	8.1
X-1210	CRC	LFW527 + binimetinib	243.49	24.13	0	0	0
X-1210	CRC	LFW527 + binimetinib	378.57	23.24	4	55.5	-3.7
X-1210	CRC	LFW527 + binimetinib	626.74	20.98	7	157.4	-13.1
X-1210	CRC	LFW527 + binimetinib	805.09	22.19	10	230.6	-8
X-1210	CRC	LFW527 + binimetinib	952.08	22.11	13	291	-8.4
X-1210	CRC	LFW527 + binimetinib	1166.27	22.27	17	379	-7.7
X-1234	CRC	LFW527 + binimetinib	220.99	26.16	0	0	0
X-1234	CRC	LFW527 + binimetinib	200.92	24.54	1	-9.1	-6.2
X-1234	CRC	LFW527 + binimetinib	242.77	24.7	5	9.9	-5.6
X-1234	CRC	LFW527 + binimetinib	293.95	24.92	9	33	-4.7
X-1234	CRC	LFW527 + binimetinib	344.35	24.36	12	55.8	-6.9
X-1234	CRC	LFW527 + binimetinib	348.47	24.67	16	57.7	-5.7
X-1234	CRC	LFW527 + binimetinib	438.28	24.45	19	98.3	-6.5
X-1234	CRC	LFW527 + binimetinib	598.75	24.77	23	170.9	-5.3
X-1234	CRC	LFW527 + binimetinib	638.31	24.32	26	188.8	-7
X-1234	CRC	LFW527 + binimetinib	652.07	23.91	30	195.1	-8.6
X-1234	CRC	LFW527 + binimetinib	671.31	23.58	34	203.8	-9.9
X-1234	CRC	LFW527 + binimetinib	721.86	25.25	37	226.6	-3.5
X-1234	CRC	LFW527 + binimetinib	851.85	24.5	41	285.5	-6.3
X-1256	CRC	LFW527 + binimetinib	260.59	28.11	0	0	0
X-1256	CRC	LFW527 + binimetinib	264.84	27.27	1	1.6	-3
X-1256	CRC	LFW527 + binimetinib	340.8	26.19	5	30.8	-6.8
X-1256	CRC	LFW527 + binimetinib	445.96	25.23	8	71.1	-10.2
X-1256	CRC	LFW527 + binimetinib	485.03	26.47	12	86.1	-5.8
X-1256	CRC	LFW527 + binimetinib	596.14	25.84	17	128.8	-8.1
X-1256	CRC	LFW527 + binimetinib	642	26.38	20	146.4	-6.2
X-1256	CRC	LFW527 + binimetinib	722.25	25.8	23	177.2	-8.2
X-1256	CRC	LFW527 + binimetinib	991.34	26.1	26	280.4	-7.2
X-1270	CRC	5FU	255.6	27.9	0	0	0
X-1270	CRC	5FU	431.2	26.7	6	68.7	-4.3
X-1270	CRC	5FU	463.3	24.9	9	81.3	-10.8
X-1270	CRC	5FU	535.6	25.2	12	109.5	-9.7
X-1270	CRC	5FU	601.9	23.9	16	135.5	-14.3
X-1270	CRC	5FU	719.3	24.8	20	181.4	-11.1
X-1270	CRC	5FU	641.1	25.4	23	150.8	-9
X-1270	CRC	BKM120	212.4	27.3	0	0	0
X-1270	CRC	BKM120	350.9	27.3	4	65.2	0
X-1270	CRC	BKM120	440.9	26.2	7	107.6	-4
X-1270	CRC	BKM120	607.4	26.9	10	186	-1.5
X-1270	CRC	BKM120	709	27.2	14	233.8	-0.4
X-1270	CRC	BKM120	974.9	26.8	18	359	-1.8
X-1270	CRC	BKM120	1022.2	25.9	21	381.3	-5.1
X-1270	CRC	BKM120 + LJC049	204	25.5	0	0	0
X-1270	CRC	BKM120 + LJC049	175.2	26.4	4	-14.1	3.5
X-1270	CRC	BKM120 + LJC049	223.8	25.5	6	9.7	0
X-1270	CRC	BKM120 + LJC049	184.3	25.9	10	-9.7	1.6
X-1270	CRC	BKM120 + LJC049	251.4	26	13	23.2	2
X-1270	CRC	BKM120 + LJC049	249.6	26	17	22.4	2
X-1270	CRC	BKM120 + LJC049	249.7	26.5	21	22.4	3.9
X-1270	CRC	BKM120 + LJC049	297.5	24.8	24	45.8	-2.7
X-1270	CRC	BKM120 + LJC049	301.8	24.9	27	47.9	-2.4
X-1270	CRC	BKM120 + LJC049	299.4	25	31	46.8	-2
X-1270	CRC	BKM120 + LJC049	284.1	22.4	37	39.3	-12.2
X-1270	CRC	BKM120 + LJC049	333.1	22.6	43	63.3	-11.4
X-1270	CRC	BYL719 + cetuximab + encorafenib	202.9	25.5	0	0	0
X-1270	CRC	BYL719 + cetuximab + encorafenib	225.1	27.8	4	10.9	9
X-1270	CRC	BYL719 + cetuximab + encorafenib	270.6	27.3	7	33.4	7.1
X-1270	CRC	BYL719 + cetuximab + encorafenib	327.9	27.8	11	61.6	9
X-1270	CRC	BYL719 + cetuximab + encorafenib	383	27.8	13	88.8	9
X-1270	CRC	BYL719 + cetuximab + encorafenib	405.9	27.7	17	100	8.6
X-1270	CRC	BYL719 + cetuximab + encorafenib	409.5	27.9	21	101.8	9.4
X-1270	CRC	BYL719 + cetuximab + encorafenib	500.7	28.1	24	146.8	10.2
X-1270	CRC	BYL719 + cetuximab + encorafenib	566	27.6	27	179	8.2
X-1270	CRC	BYL719 + cetuximab + encorafenib	616.5	26.1	32	203.8	2.4
X-1270	CRC	BYL719 + cetuximab + encorafenib	556.2	25.9	35	174.1	1.6
X-1270	CRC	BYL719 + cetuximab + encorafenib	635.3	26.7	38	213.1	4.7
X-1270	CRC	BYL719 + cetuximab + encorafenib	797.4	26.5	41	293	3.9
X-1270	CRC	BYL719 + cetuximab	249	26.4	0	0	0
X-1270	CRC	BYL719 + cetuximab	290.5	27.6	3	16.7	4.5
X-1270	CRC	BYL719 + cetuximab	289.2	27.2	9	16.1	3
X-1270	CRC	BYL719 + cetuximab	364.4	27.2	13	46.3	3
X-1270	CRC	BYL719 + cetuximab	344	27.4	17	38.2	3.8
X-1270	CRC	BYL719 + cetuximab	422.5	29.4	20	69.7	11.4
X-1270	CRC	BYL719 + cetuximab	402.6	29.5	23	61.7	11.7
X-1270	CRC	BYL719 + cetuximab	414.2	27.8	28	66.3	5.3
X-1270	CRC	BYL719 + cetuximab	442.8	28	31	77.8	6.1
X-1270	CRC	BYL719 + cetuximab	455.8	28.1	34	83.1	6.4
X-1270	CRC	BYL719 + cetuximab	470.8	28.9	37	89.1	9.5
X-1270	CRC	BYL719	212.3	25.1	0	0	0
X-1270	CRC	BYL719	214.5	25.8	1	1	2.8
X-1270	CRC	BYL719	191.3	25.7	5	-9.9	2.4
X-1270	CRC	BYL719	201.5	25.9	8	-5.1	3.2
X-1270	CRC	BYL719	232.2	27	12	9.4	7.6
X-1270	CRC	BYL719	193.7	25.6	18	-8.8	2
X-1270	CRC	BYL719	192.9	26.8	22	-9.1	6.8
X-1270	CRC	BYL719	242	26.5	27	14	5.6
X-1270	CRC	BYL719	271.5	26.4	29	27.9	5.2
X-1270	CRC	BYL719	250	26.5	33	17.8	5.6
X-1270	CRC	BYL719	283.9	26.5	36	33.7	5.6
X-1270	CRC	BYL719	334.9	26.2	40	57.7	4.4
X-1270	CRC	BYL719	373.7	25.4	43	76	1.2
X-1270	CRC	BYL719	331.5	26.9	44	56.1	7.2
X-1270	CRC	BYL719	319.6	25.9	47	50.5	3.2
X-1270	CRC	BYL719	298.9	26.2	50	40.8	4.4
X-1270	CRC	BYL719	325.1	25.8	54	53.1	2.8
X-1270	CRC	BYL719	350.1	25.6	60	64.9	2
X-1270	CRC	BYL719	413.3	25.4	66	94.7	1.2
X-1270	CRC	BYL719 + LJM716	207.9	24.7	0	0	0
X-1270	CRC	BYL719 + LJM716	199.7	22.6	5	-3.9	-8.5
X-1270	CRC	BYL719 + LJM716	189.3	22.8	8	-8.9	-7.7
X-1270	CRC	BYL719 + LJM716	319.4	23.5	12	53.6	-4.9
X-1270	CRC	BYL719 + LJM716	318.9	23.9	18	53.4	-3.2
X-1270	CRC	BYL719 + LJM716	356.9	21.6	22	71.7	-12.6
X-1270	CRC	BYL719 + LJM716	344.3	23.9	27	65.6	-3.2
X-1270	CRC	BYL719 + LJM716	456.7	24.4	29	119.7	-1.2
X-1270	CRC	BYL719 + LJM716	443.2	24.2	33	113.2	-2
X-1270	CRC	BYL719 + LJM716	507.8	23.6	36	144.3	-4.5
X-1270	CRC	BYL719 + LJM716	470.1	23.3	40	126.1	-5.7
X-1270	CRC	BYL719 + LJM716	496.9	23.1	43	139	-6.5
X-1270	CRC	BYL719 + binimetinib	212.7	26.1	0	0	0
X-1270	CRC	BYL719 + binimetinib	219.8	25.2	4	3.3	-3.4
X-1270	CRC	BYL719 + binimetinib	198	25.2	6	-6.9	-3.4
X-1270	CRC	BYL719 + binimetinib	183.9	24.6	10	-13.5	-5.7
X-1270	CRC	BYL719 + binimetinib	195.5	24.6	13	-8.1	-5.7
X-1270	CRC	BYL719 + binimetinib	211.9	25.4	17	-0.4	-2.7
X-1270	CRC	BYL719 + binimetinib	162.8	25.5	21	-23.5	-2.3
X-1270	CRC	BYL719 + binimetinib	175.4	26.2	24	-17.5	0.4
X-1270	CRC	BYL719 + binimetinib	191.3	24.7	27	-10.1	-5.4
X-1270	CRC	BYL719 + binimetinib	186	24.6	31	-12.6	-5.7
X-1270	CRC	BYL719 + binimetinib	198.8	24.7	37	-6.5	-5.4
X-1270	CRC	BYL719 + binimetinib	218.9	25.8	43	2.9	-1.1
X-1270	CRC	BYL719 + binimetinib	217.2	25.6	52	2.1	-1.9
X-1270	CRC	BYL719 + binimetinib	208	25	55	-2.2	-4.2
X-1270	CRC	BYL719 + binimetinib	262.6	25.9	59	23.5	-0.8
X-1270	CRC	BYL719 + binimetinib	266.2	25.1	62	25.2	-3.8
X-1270	CRC	BYL719 + binimetinib	253.4	25.2	66	19.1	-3.4
X-1270	CRC	BYL719 + binimetinib	269.9	25.3	70	26.9	-3.1
X-1270	CRC	BYL719 + binimetinib	246.8	25.8	73	16	-1.1
X-1270	CRC	BYL719 + binimetinib	267.4	25.7	76	25.7	-1.5
X-1270	CRC	BYL719 + binimetinib	269.8	26.1	80	26.8	0
X-1270	CRC	BYL719 + binimetinib	297.4	26.1	83	39.8	0
X-1270	CRC	BYL719 + binimetinib	280.5	25	87	31.9	-4.2
X-1270	CRC	BYL719 + encorafenib	278.3	28.7	0	0	0
X-1270	CRC	BYL719 + encorafenib	428.5	27.9	4	54	-2.8
X-1270	CRC	BYL719 + encorafenib	458	26.7	6	64.6	-7
X-1270	CRC	BYL719 + encorafenib	525.3	27.5	10	88.8	-4.2
X-1270	CRC	BYL719 + encorafenib	707.5	25.9	13	154.2	-9.8
X-1270	CRC	BYL719 + encorafenib	741.1	25	17	166.3	-12.9
X-1270	CRC	BYL719 + encorafenib	829.4	25.4	21	198	-11.5
X-1270	CRC	BYL719 + encorafenib	790.9	25.3	24	184.2	-11.8
X-1270	CRC	BYL719 + encorafenib	829.6	25.9	27	198.1	-9.8
X-1270	CRC	CGM097	230.7	26.2	0	0	0
X-1270	CRC	CGM097	315.3	25.1	3	36.7	-4.2
X-1270	CRC	CGM097	415.9	26.4	6	80.3	0.8
X-1270	CRC	CGM097	659	27.6	10	185.7	5.3
X-1270	CRC	CGM097	916.1	26.7	14	297.1	1.9
X-1270	CRC	CGM097	1186.4	26.8	17	414.3	2.3
X-1270	CRC	CGM097	1552.5	27.1	21	573	3.4
X-1270	CRC	CKX620	211.5	24.4	0	0	0
X-1270	CRC	CKX620	167.5	23.7	4	-20.8	-2.9
X-1270	CRC	CKX620	150.9	23.5	7	-28.7	-3.7
X-1270	CRC	CKX620	208.4	24.6	10	-1.5	0.8
X-1270	CRC	CKX620	248	24.3	14	17.3	-0.4
X-1270	CRC	CKX620	323.6	24.1	18	53	-1.2
X-1270	CRC	CKX620	399	24	21	88.7	-1.6
X-1270	CRC	CKX620	301.1	24	25	42.4	-1.6
X-1270	CRC	CKX620	280.5	24.4	31	32.6	0
X-1270	CRC	CKX620	271.2	23.3	35	28.2	-4.5
X-1270	CRC	CKX620	291.4	23.6	39	37.8	-3.3
X-1270	CRC	CLR457	249.1	24	0	0	0
X-1270	CRC	CLR457	286.1	24.1	1	14.9	0.4
X-1270	CRC	CLR457	283.5	24.2	5	13.8	0.8
X-1270	CRC	CLR457	276.7	24	8	11.1	0
X-1270	CRC	CLR457	334.3	25.3	12	34.2	5.4
X-1270	CRC	CLR457	296.8	25	18	19.1	4.2
X-1270	CRC	CLR457	314.3	23.6	22	26.2	-1.7
X-1270	CRC	CLR457	331.9	25.1	27	33.2	4.6
X-1270	CRC	CLR457	308.6	24.4	29	23.9	1.7
X-1270	CRC	CLR457	325.4	25.2	33	30.6	5
X-1270	CRC	CLR457	349	25.1	36	40.1	4.6
X-1270	CRC	CLR457	469.7	25.2	40	88.6	5
X-1270	CRC	CLR457	423.6	25	43	70.1	4.2
X-1270	CRC	CLR457	349.5	25.2	44	40.3	5
X-1270	CRC	CLR457	444.4	24.6	47	78.4	2.5
X-1270	CRC	CLR457	459.5	24.9	54	84.5	3.7
X-1270	CRC	CLR457	516.4	25.9	66	107.3	7.9
X-1270	CRC	HDM201	237.5	25.3	0	0	0
X-1270	CRC	HDM201	399.7	22.6	4	68.3	-10.7
X-1270	CRC	HDM201	550.1	21.5	7	131.6	-15
X-1270	CRC	HDM201	777.1	23.8	10	227.2	-5.9
X-1270	CRC	HDM201	844.4	22.7	14	255.5	-10.3
X-1270	CRC	HDM201	1282.6	24.4	18	440	-3.6
X-1270	CRC	HDM201	1399.4	21.9	21	489.2	-13.4
X-1270	CRC	cetuximab	263.1	19	0	0	0
X-1270	CRC	cetuximab	307.3	19	3	16.8	0
X-1270	CRC	cetuximab	351.9	19.7	7	33.8	3.7
X-1270	CRC	cetuximab	417.5	19.7	10	58.7	3.7
X-1270	CRC	cetuximab	458.5	20.3	14	74.3	6.8
X-1270	CRC	cetuximab	474.3	22.1	16	80.3	16.3
X-1270	CRC	cetuximab	564.2	20	20	114.4	5.3
X-1270	CRC	cetuximab	658.2	19.6	24	150.2	3.2
X-1270	CRC	cetuximab	705	20.5	27	168	7.9
X-1270	CRC	cetuximab	734.6	20.3	30	179.2	6.8
X-1270	CRC	cetuximab	785.5	20	35	198.6	5.3
X-1270	CRC	cetuximab	810.7	20.1	38	208.1	5.8
X-1270	CRC	cetuximab + encorafenib	265.3	23	0	0	0
X-1270	CRC	cetuximab + encorafenib	448.6	23.6	4	69.1	2.6
X-1270	CRC	cetuximab + encorafenib	522.8	24.1	7	97.1	4.8
X-1270	CRC	cetuximab + encorafenib	530.7	23.6	11	100	2.6
X-1270	CRC	cetuximab + encorafenib	596.6	23.4	13	124.9	1.7
X-1270	CRC	cetuximab + encorafenib	671.8	23.7	17	153.2	3
X-1270	CRC	cetuximab + encorafenib	727.7	23.1	21	174.3	0.4
X-1270	CRC	cetuximab + encorafenib	798.5	23.4	24	201	1.7
X-1270	CRC	cetuximab + encorafenib	828.1	22.7	27	212.1	-1.3
X-1270	CRC	cetuximab + encorafenib	949.4	22.3	32	257.9	-3
X-1270	CRC	cetuximab + encorafenib	1003.4	22.1	35	278.2	-3.9
X-1270	CRC	LEE011	250.2	25.4	0	0	0
X-1270	CRC	LEE011	274.3	25.7	6	9.6	1.2
X-1270	CRC	LEE011	288.8	25	9	15.4	-1.6
X-1270	CRC	LEE011	305.2	26	12	22	2.4
X-1270	CRC	LEE011	346	25.9	16	38.3	2
X-1270	CRC	LEE011	363.5	25.6	20	45.3	0.8
X-1270	CRC	LEE011	393.2	24.7	23	57.2	-2.8
X-1270	CRC	LEE011	381.6	26.7	27	52.5	5.1
X-1270	CRC	LEE011	573.4	27.2	33	129.2	7.1
X-1270	CRC	encorafenib	213.9	28.1	0	0	0
X-1270	CRC	encorafenib	273.1	28.2	3	27.7	0.4
X-1270	CRC	encorafenib	261.6	27.8	6	22.3	-1.1
X-1270	CRC	encorafenib	307.2	27.8	10	43.6	-1.1
X-1270	CRC	encorafenib	367.2	28.9	14	71.7	2.8
X-1270	CRC	encorafenib	433.7	27.9	17	102.8	-0.7
X-1270	CRC	encorafenib	492.7	27.5	21	130.3	-2.1
X-1270	CRC	encorafenib	848.4	28.9	27	296.6	2.8
X-1270	CRC	LJC049	200.9	26.8	0	0	0
X-1270	CRC	LJC049	233.1	28.2	3	16	5.2
X-1270	CRC	LJC049	263.2	26.2	7	31	-2.2
X-1270	CRC	LJC049	296.6	26.9	11	47.6	0.4
X-1270	CRC	LJC049	334.4	26.8	14	66.5	0
X-1270	CRC	LJC049	359.5	27.5	18	78.9	2.6
X-1270	CRC	LJC049	307.5	27.2	24	53.1	1.5
X-1270	CRC	LJC049	247	26.8	28	22.9	0
X-1270	CRC	LJC049	216.9	28.2	33	8	5.2
X-1270	CRC	LJC049	215.5	27.2	35	7.3	1.5
X-1270	CRC	LJC049	155.9	26.9	39	-22.4	0.4
X-1270	CRC	LJC049	171.9	28.7	42	-14.4	7.1
X-1270	CRC	LJC049	160.1	24.1	46	-20.3	-10.1
X-1270	CRC	LJC049	195	25.5	50	-2.9	-4.9
X-1270	CRC	LJC049	202.3	22.7	53	0.7	-15.3
X-1270	CRC	LKA136	203	25.2	0	0	0
X-1270	CRC	LKA136	252.4	25.5	3	24.3	1.2
X-1270	CRC	LKA136	293.7	25.3	7	44.7	0.4
X-1270	CRC	LKA136	476.4	24.7	11	134.7	-2
X-1270	CRC	LKA136	566.9	24.4	14	179.3	-3.2
X-1270	CRC	LKA136	703.4	24.1	18	246.5	-4.4
X-1270	CRC	LKA136	972.3	27.9	24	379	10.7
X-1270	CRC	binimetinib	230	24.7	0	0	0
X-1270	CRC	binimetinib	438.4	21.5	6	90.6	-13
X-1270	CRC	binimetinib	446.7	19.5	9	94.2	-21.1
X-1270	CRC	untreated	258.2	27	0	0	0
X-1270	CRC	untreated	276.4	26.8	1	7	-0.7
X-1270	CRC	untreated	267.5	26.2	3	3.6	-3
X-1270	CRC	untreated	300.3	27.1	7	16.3	0.4
X-1270	CRC	untreated	328.1	26.3	10	27.1	-2.6
X-1270	CRC	untreated	373.9	26.6	14	44.8	-1.5
X-1270	CRC	untreated	324.2	27	18	25.6	0
X-1270	CRC	untreated	460.4	25.8	21	78.3	-4.4
X-1270	CRC	untreated	466.4	26.4	24	80.6	-2.2
X-1270	CRC	untreated	567.8	25.6	28	119.9	-5.2
X-1270	CRC	untreated	575.9	25.9	34	123	-4.1
X-1270	CRC	untreated	638.5	26.7	40	147.3	-1.1
X-1270	CRC	untreated	843.8	26	49	226.8	-3.7
X-1270	CRC	untreated	912.3	25.7	52	253.3	-4.8
X-1270	CRC	untreated	918.7	26.4	56	255.8	-2.2
X-1289	PDAC	abraxane	217.9	28.5	0	0	0
X-1289	PDAC	abraxane	357.4	29.6	2	64	3.9
X-1289	PDAC	abraxane	440.9	29.7	6	102.3	4.2
X-1289	PDAC	abraxane	520.8	30.4	9	139	6.7
X-1289	PDAC	abraxane	549.2	30.5	13	152	7
X-1289	PDAC	abraxane	637.5	30.4	16	192.6	6.7
X-1289	PDAC	abraxane	940.5	29.6	21	331.6	3.9
X-1289	PDAC	BKM120	266.1	28.3	0	0	0
X-1289	PDAC	BKM120	377.5	30	4	41.9	6
X-1289	PDAC	BKM120	607.8	25.9	7	128.4	-8.5
X-1289	PDAC	BKM120	691.1	26.9	12	159.7	-4.9
X-1289	PDAC	BKM120	704.2	26.4	14	164.6	-6.7
X-1289	PDAC	BKM120	696.3	27.7	18	161.7	-2.1
X-1289	PDAC	BKM120	757.9	27.5	21	184.8	-2.8
X-1289	PDAC	BKM120	845.7	28.3	25	217.8	0
X-1289	PDAC	BKM120	853.7	26	28	220.8	-8.1
X-1289	PDAC	BKM120	1069.9	26.8	32	302.1	-5.3
X-1289	PDAC	BYL719	202.8	27.9	0	0	0
X-1289	PDAC	BYL719	262.4	27.8	4	29.4	-0.4
X-1289	PDAC	BYL719	267.1	28.1	6	31.7	0.7
X-1289	PDAC	BYL719	291.4	26.7	10	43.7	-4.3
X-1289	PDAC	BYL719	358.8	27.7	13	76.9	-0.7
X-1289	PDAC	BYL719	362.4	27.7	17	78.7	-0.7
X-1289	PDAC	BYL719	386.5	27.9	20	90.6	0
X-1289	PDAC	BYL719	441.5	27.7	24	117.7	-0.7
X-1289	PDAC	BYL719	525.1	27.7	27	158.9	-0.7
X-1289	PDAC	BYL719	609.2	27.5	31	200.4	-1.4
X-1289	PDAC	BYL719	729.3	27	34	259.6	-3.2
X-1289	PDAC	BYL719	799.4	27.7	38	294.2	-0.7
X-1289	PDAC	BYL719	831.8	27.9	41	310.2	0
X-1289	PDAC	BYL719	980.6	27.3	45	383.5	-2.2
X-1289	PDAC	BYL719	1108.7	27.1	48	446.7	-2.9
X-1289	PDAC	BYL719 + LJM716	203.8	24.3	0	0	0
X-1289	PDAC	BYL719 + LJM716	206.3	23.8	4	1.2	-2.1
X-1289	PDAC	BYL719 + LJM716	199.2	22.9	7	-2.3	-5.8
X-1289	PDAC	BYL719 + LJM716	140.8	24.8	11	-30.9	2.1
X-1289	PDAC	BYL719 + LJM716	97.6	24.7	14	-52.1	1.6
X-1289	PDAC	BYL719 + LJM716	67.2	24.7	18	-67	1.6
X-1289	PDAC	BYL719 + LJM716	29.8	25	21	-85.4	2.9
X-1289	PDAC	BYL719 + LJM716	25.5	25.1	25	-87.5	3.3
X-1289	PDAC	BYL719 + LJM716	5.8	24.7	29	-97.2	1.6
X-1289	PDAC	BYL719 + LJM716	3.6	24.8	32	-98.2	2.1
X-1289	PDAC	BYL719 + LJM716	0	24.4	35	-100	0.4
X-1289	PDAC	BYL719 + LJM716	0	24.5	39	-100	0.8
X-1289	PDAC	BYL719 + LJM716	0	25.1	42	-100	3.3
X-1289	PDAC	BYL719 + LJM716	0	24.9	46	-100	2.5
X-1289	PDAC	BYL719 + LJM716	0	24.2	49	-100	-0.4
X-1289	PDAC	BYL719 + LJM716	21	24.7	53	-89.7	1.6
X-1289	PDAC	BYL719 + LJM716	13.8	24.6	56	-93.2	1.2
X-1289	PDAC	BYL719 + LJM716	11.9	24.8	60	-94.2	2.1
X-1289	PDAC	BYL719 + LJM716	9.8	24.8	63	-95.2	2.1
X-1289	PDAC	BYL719 + LJM716	22	25.3	67	-89.2	4.1
X-1289	PDAC	BYL719 + LJM716	22.8	24.5	70	-88.8	0.8
X-1289	PDAC	BYL719 + LJM716	21.8	23.5	75	-89.3	-3.3
X-1289	PDAC	BYL719 + LJM716	22.2	22.2	78	-89.1	-8.6
X-1289	PDAC	BYL719 + LJM716	0	21.9	81	-100	-9.9
X-1289	PDAC	BYL719 + LJM716	0	22.5	84	-100	-7.4
X-1289	PDAC	BYL719 + LJM716	0	21.4	88	-100	-11.9
X-1289	PDAC	BYL719 + LJM716	0	21.2	91	-100	-12.8
X-1289	PDAC	BYL719 + LJM716	0	21.4	95	-100	-11.9
X-1289	PDAC	CLR457	219	24.4	0	0	0
X-1289	PDAC	CLR457	246.1	24.9	4	12.4	2
X-1289	PDAC	CLR457	273.4	24.9	6	24.8	2
X-1289	PDAC	CLR457	312	24.3	10	42.5	-0.4
X-1289	PDAC	CLR457	317.5	24.2	13	45	-0.8
X-1289	PDAC	CLR457	345.4	23.8	17	57.7	-2.5
X-1289	PDAC	CLR457	413.6	24.1	20	88.9	-1.2
X-1289	PDAC	CLR457	421.8	25.3	24	92.6	3.7
X-1289	PDAC	CLR457	437.9	25.1	27	100	2.9
X-1289	PDAC	CLR457	488.8	25.3	31	123.2	3.7
X-1289	PDAC	CLR457	576.3	24.8	34	163.2	1.6
X-1289	PDAC	CLR457	737.2	24.8	38	236.6	1.6
X-1289	PDAC	CLR457	875.7	24.8	41	299.9	1.6
X-1289	PDAC	CLR457	1013.8	25.3	45	362.9	3.7
X-1289	PDAC	HDM201	201.2	26	0	0	0
X-1289	PDAC	HDM201	258.1	27	4	28.3	3.8
X-1289	PDAC	HDM201	269.5	28.2	7	33.9	8.5
X-1289	PDAC	HDM201	258.8	25.9	11	28.6	-0.4
X-1289	PDAC	HDM201	285.1	27.2	14	41.7	4.6
X-1289	PDAC	HDM201	291.1	27.9	18	44.7	7.3
X-1289	PDAC	HDM201	284.7	27.1	21	41.5	4.2
X-1289	PDAC	HDM201	195.6	26.4	25	-2.8	1.5
X-1289	PDAC	HDM201	208.7	25.7	28	3.7	-1.2
X-1289	PDAC	HDM201	199.9	25.3	32	-0.6	-2.7
X-1289	PDAC	HDM201	195.1	24	35	-3	-7.7
X-1289	PDAC	HDM201	169.6	21.3	39	-15.7	-18.1
X-1289	PDAC	figitumumab"	249.8	31.5	0	0	0
X-1289	PDAC	figitumumab"	366.6	30.6	2	46.8	-2.9
X-1289	PDAC	figitumumab"	492.8	29.4	8	97.3	-6.7
X-1289	PDAC	figitumumab"	628.5	30.5	12	151.6	-3.2
X-1289	PDAC	figitumumab"	780.6	30.2	15	212.5	-4.1
X-1289	PDAC	figitumumab"	919.8	29.7	19	268.2	-5.7
X-1289	PDAC	figitumumab"	1093.6	30.1	22	337.8	-4.4
X-1289	PDAC	figitumumab" + binimetinib	280.7	26.6	0	0	0
X-1289	PDAC	figitumumab" + binimetinib	471	26.9	4	67.8	1.1
X-1289	PDAC	figitumumab" + binimetinib	423.5	26.9	8	50.9	1.1
X-1289	PDAC	figitumumab" + binimetinib	370.7	28	12	32.1	5.3
X-1289	PDAC	figitumumab" + binimetinib	473.7	27.7	15	68.8	4.1
X-1289	PDAC	figitumumab" + binimetinib	568.6	27.1	19	102.6	1.9
X-1289	PDAC	figitumumab" + binimetinib	541.6	27.4	22	92.9	3
X-1289	PDAC	figitumumab" + binimetinib	649.9	26.9	26	131.5	1.1
X-1289	PDAC	figitumumab" + binimetinib	538.4	26.7	29	91.8	0.4
X-1289	PDAC	figitumumab" + binimetinib	597.4	27.5	34	112.8	3.4
X-1289	PDAC	figitumumab" + binimetinib	690.9	28.1	39	146.1	5.6
X-1289	PDAC	gemcitabine-50mpk	246.2	31.6	0	0	0
X-1289	PDAC	gemcitabine-50mpk	227.6	30.1	3	-7.6	-4.7
X-1289	PDAC	gemcitabine-50mpk	197.1	29.2	7	-19.9	-7.6
X-1289	PDAC	gemcitabine-50mpk	243.7	29.9	10	-1	-5.4
X-1289	PDAC	gemcitabine-50mpk	147.7	29.8	15	-40	-5.7
X-1289	PDAC	gemcitabine-50mpk	154.6	30.2	17	-37.2	-4.4
X-1289	PDAC	gemcitabine-50mpk	109.1	29.3	21	-55.7	-7.3
X-1289	PDAC	gemcitabine-50mpk	79.4	28.7	24	-67.7	-9.2
X-1289	PDAC	gemcitabine-50mpk	82.1	31.3	27	-66.7	-0.9
X-1289	PDAC	gemcitabine-50mpk	75.2	31.5	30	-69.5	-0.3
X-1289	PDAC	gemcitabine-50mpk	66.8	29.7	35	-72.9	-6
X-1289	PDAC	gemcitabine-50mpk	64.7	29.3	38	-73.7	-7.3
X-1289	PDAC	gemcitabine-50mpk	59	30.1	42	-76	-4.7
X-1289	PDAC	gemcitabine-50mpk	29.5	31.4	45	-88	-0.6
X-1289	PDAC	gemcitabine-50mpk	0	31.9	48	-100	0.9
X-1289	PDAC	gemcitabine-50mpk	0	30.7	51	-100	-2.8
X-1289	PDAC	gemcitabine-50mpk	0	30	56	-100	-5.1
X-1289	PDAC	gemcitabine-50mpk	0	30.6	59	-100	-3.2
X-1289	PDAC	gemcitabine-50mpk	0	30.6	63	-100	-3.2
X-1289	PDAC	gemcitabine-50mpk	0	30.9	65	-100	-2.2
X-1289	PDAC	gemcitabine-50mpk	0	33.1	70	-100	4.7
X-1289	PDAC	gemcitabine-50mpk	0	31.2	72	-100	-1.3
X-1289	PDAC	gemcitabine-50mpk	0	30.3	77	-100	-4.1
X-1289	PDAC	gemcitabine-50mpk	0	30.3	80	-100	-4.1
X-1289	PDAC	gemcitabine-50mpk	0	30	84	-100	-5.1
X-1289	PDAC	gemcitabine-50mpk	0	31.4	87	-100	-0.6
X-1289	PDAC	gemcitabine-50mpk	0	32.3	90	-100	2.2
X-1289	PDAC	gemcitabine-50mpk	0	32.9	94	-100	4.1
X-1289	PDAC	gemcitabine-50mpk	0	30.3	97	-100	-4.1
X-1289	PDAC	gemcitabine-50mpk	0	30.1	104	-100	-4.7
X-1289	PDAC	gemcitabine-50mpk	11.8	32.5	108	-95.2	2.8
X-1289	PDAC	gemcitabine-50mpk	11.3	31.3	111	-95.4	-0.9
X-1289	PDAC	INC424	204.7	27.3	0	0	0
X-1289	PDAC	INC424	208.1	25.1	3	1.7	-8.1
X-1289	PDAC	INC424	270.6	26.5	6	32.2	-2.9
X-1289	PDAC	INC424	413.3	26	10	101.9	-4.8
X-1289	PDAC	INC424	475.5	26.9	13	132.3	-1.5
X-1289	PDAC	INC424	549	27.7	17	168.2	1.5
X-1289	PDAC	INC424	603.4	26.1	20	194.8	-4.4
X-1289	PDAC	INC424	751.9	27.3	24	267.3	0
X-1289	PDAC	INC424	868.8	27	27	324.4	-1.1
X-1289	PDAC	LEE011	201	26.8	0	0	0
X-1289	PDAC	LEE011	216.5	25.8	2	7.7	-3.7
X-1289	PDAC	LEE011	336.1	26.7	6	67.2	-0.4
X-1289	PDAC	LEE011	555.5	27	9	176.4	0.7
X-1289	PDAC	LEE011	647.3	27.9	13	222	4.1
X-1289	PDAC	LEE011	775.5	27.9	16	285.8	4.1
X-1289	PDAC	WNT974	223.5	26.4	0	0	0
X-1289	PDAC	WNT974	226.4	NA	2	1.3	0
X-1289	PDAC	WNT974	269.1	25.7	5	20.4	-2.7
X-1289	PDAC	WNT974	363.9	25.3	8	62.8	-4.2
X-1289	PDAC	WNT974	508.4	24.4	12	127.5	-7.6
X-1289	PDAC	WNT974	728.9	24.3	15	226.1	-8
X-1289	PDAC	WNT974	817	25.2	20	265.5	-4.5
X-1289	PDAC	WNT974	758.4	25	23	239.3	-5.3
X-1289	PDAC	WNT974	789.8	26.1	27	253.4	-1.1
X-1289	PDAC	WNT974	848.5	25.4	30	279.6	-3.8
X-1289	PDAC	LKA136	215.7	24.7	0	0	0
X-1289	PDAC	LKA136	232.6	24.4	2	7.8	-1.2
X-1289	PDAC	LKA136	453.4	21.9	7	110.2	-11.3
X-1289	PDAC	LKA136	321.7	25.6	10	49.1	3.6
X-1289	PDAC	LKA136	239.2	24.6	13	10.9	-0.4
X-1289	PDAC	LKA136	162.9	24.2	17	-24.5	-2
X-1289	PDAC	LKA136	166.7	25.8	20	-22.7	4.5
X-1289	PDAC	LKA136	142.4	24.8	23	-34	0.4
X-1289	PDAC	LKA136	58.3	24.6	27	-73	-0.4
X-1289	PDAC	LKA136	30	25.1	30	-86.1	1.6
X-1289	PDAC	LKA136	45.8	24.3	35	-78.8	-1.6
X-1289	PDAC	LKA136	15.6	24.4	38	-92.8	-1.2
X-1289	PDAC	LKA136	29.3	25.2	42	-86.4	2
X-1289	PDAC	LKA136	10.1	24.7	45	-95.3	0
X-1289	PDAC	LKA136	10.3	24.7	48	-95.2	0
X-1289	PDAC	LKA136	0	25.1	51	-100	1.6
X-1289	PDAC	LKA136	0	25.9	56	-100	4.9
X-1289	PDAC	LKA136	0	25.3	62	-100	2.4
X-1289	PDAC	LKA136	11.4	25.6	70	-94.7	3.6
X-1289	PDAC	LKA136	13.6	25.2	73	-93.7	2
X-1289	PDAC	LKA136	7.7	25.5	76	-96.4	3.2
X-1289	PDAC	LKA136	0	23.9	79	-100	-3.2
X-1289	PDAC	LKA136	0	26	83	-100	5.3
X-1289	PDAC	binimetinib-3.5mpk	224	26.6	0	0	0
X-1289	PDAC	binimetinib-3.5mpk	264.9	27.2	4	18.3	2.3
X-1289	PDAC	binimetinib-3.5mpk	381.4	27.4	8	70.3	3
X-1289	PDAC	binimetinib-3.5mpk	172.2	28.5	12	-23.1	7.1
X-1289	PDAC	binimetinib-3.5mpk	258.5	28.6	15	15.4	7.5
X-1289	PDAC	binimetinib-3.5mpk	259.7	28.6	19	15.9	7.5
X-1289	PDAC	binimetinib-3.5mpk	362.5	28.8	22	61.8	8.3
X-1289	PDAC	binimetinib-3.5mpk	411.3	29.6	26	83.6	11.3
X-1289	PDAC	binimetinib-3.5mpk	346.6	NA	29	54.7	11.3
X-1289	PDAC	binimetinib-3.5mpk	456.8	29	34	103.9	9
X-1289	PDAC	binimetinib-3.5mpk	601.3	29.7	39	168.4	11.7
X-1289	PDAC	trametinib	206.1	24.7	0	0	0
X-1289	PDAC	trametinib	214.1	23.6	3	3.9	-4.5
X-1289	PDAC	trametinib	117	23.8	7	-43.2	-3.6
X-1289	PDAC	trametinib	179.7	23.6	10	-12.8	-4.5
X-1289	PDAC	trametinib	148.9	23.8	14	-27.8	-3.6
X-1289	PDAC	trametinib	132.4	23.5	17	-35.8	-4.9
X-1289	PDAC	trametinib	120.1	23.6	22	-41.7	-4.5
X-1289	PDAC	trametinib	239.7	23.2	27	16.3	-6.1
X-1289	PDAC	trametinib	142.9	23.1	30	-30.7	-6.5
X-1289	PDAC	trametinib	141.4	23.8	34	-31.4	-3.6
X-1289	PDAC	trametinib	93.6	23.2	37	-54.6	-6.1
X-1289	PDAC	trametinib	120.8	23.7	41	-41.4	-4
X-1289	PDAC	trametinib	118.1	24.5	44	-42.7	-0.8
X-1289	PDAC	trametinib	142.7	22.7	48	-30.8	-8.1
X-1289	PDAC	trametinib	146.8	24.3	51	-28.8	-1.6
X-1289	PDAC	trametinib	71.5	24.6	55	-65.3	-0.4
X-1289	PDAC	trametinib	62.6	24.8	58	-69.6	0.4
X-1289	PDAC	trametinib	81.1	25.2	62	-60.7	2
X-1289	PDAC	trametinib	66.8	24.6	66	-67.6	-0.4
X-1289	PDAC	trametinib	44.8	24.7	72	-78.3	0
X-1289	PDAC	trametinib	30.6	24.5	76	-85.2	-0.8
X-1289	PDAC	trametinib	15.2	25.1	79	-92.6	1.6
X-1289	PDAC	trametinib	9	21.8	87	-95.6	-11.7
X-1289	PDAC	untreated	275.2	25.5	0	0	0
X-1289	PDAC	untreated	296.5	23.5	2	7.7	-7.8
X-1289	PDAC	untreated	316.9	25	5	15.2	-2
X-1289	PDAC	untreated	475.3	25.1	8	72.7	-1.6
X-1289	PDAC	untreated	576.1	25.8	12	109.3	1.2
X-1289	PDAC	untreated	733.4	25.5	15	166.5	0
X-1289	PDAC	untreated	929.3	25.2	20	237.7	-1.2
X-1289	PDAC	untreated	884.8	25	23	221.5	-2
X-1289	PDAC	untreated	1004.5	26.3	27	265	3.1
X-1289	PDAC	untreated	1029.9	24.6	30	274.2	-3.5
X-1289	PDAC	untreated	1276.2	25.4	33	363.7	-0.4
X-1290	CRC	5FU	196.7	22.6	0	0	0
X-1290	CRC	5FU	141.2	23	1	-28.2	1.8
X-1290	CRC	5FU	73.8	23.2	6	-62.5	2.7
X-1290	CRC	5FU	132	22.2	9	-32.9	-1.8
X-1290	CRC	5FU	127.4	23.8	13	-35.2	5.3
X-1290	CRC	5FU	177.6	23.9	15	-9.7	5.8
X-1290	CRC	5FU	183.2	24	19	-6.9	6.2
X-1290	CRC	5FU	163.4	23.4	22	-16.9	3.5
X-1290	CRC	5FU	175.2	23.8	27	-10.9	5.3
X-1290	CRC	5FU	213.6	22.5	30	8.6	-0.4
X-1290	CRC	5FU	207.4	23.2	35	5.4	2.7
X-1290	CRC	5FU	249.6	22.9	37	26.9	1.3
X-1290	CRC	5FU	244.1	22.3	40	24.1	-1.3
X-1290	CRC	5FU	290.4	22.3	44	47.6	-1.3
X-1290	CRC	5FU	324	23.2	48	64.7	2.7
X-1290	CRC	5FU	348	23	51	76.9	1.8
X-1290	CRC	5FU	275.3	23.9	54	40	5.8
X-1290	CRC	5FU	394.9	24.6	57	100.8	8.8
X-1290	CRC	5FU	395.2	24.8	62	100.9	9.7
X-1290	CRC	BKM120	203.5	23.1	0	0	0
X-1290	CRC	BKM120	350.4	22.6	4	72.2	-2.2
X-1290	CRC	BKM120	387.9	21.9	7	90.6	-5.2
X-1290	CRC	BKM120	758.4	20.8	12	272.7	-10
X-1290	CRC	BKM120 + LJC049	182.3	31.6	0	0	0
X-1290	CRC	BKM120 + LJC049	172.6	29.4	2	-5.3	-7
X-1290	CRC	BKM120 + LJC049	151.4	28.9	6	-17	-8.5
X-1290	CRC	BKM120 + LJC049	223.8	28.2	9	22.8	-10.8
X-1290	CRC	BKM120 + LJC049	248.7	27.1	14	36.4	-14.2
X-1290	CRC	BKM120 + LJC049	232.4	22.9	16	27.5	-27.5
X-1290	CRC	BYL719 + cetuximab + encorafenib	227.3	23.6	0	0	0
X-1290	CRC	BYL719 + cetuximab + encorafenib	307.4	23.9	4	35.2	1.3
X-1290	CRC	BYL719 + cetuximab + encorafenib	342.2	23.4	8	50.5	-0.8
X-1290	CRC	BYL719 + cetuximab + encorafenib	512.9	23.1	11	125.6	-2.1
X-1290	CRC	BYL719 + cetuximab + encorafenib	503.4	24.7	14	121.5	4.7
X-1290	CRC	BYL719 + cetuximab + encorafenib	715	24.9	17	214.6	5.5
X-1290	CRC	BYL719 + cetuximab + encorafenib	841.8	24.4	22	270.3	3.4
X-1290	CRC	BYL719 + cetuximab + encorafenib	864.2	24	25	280.2	1.7
X-1290	CRC	BYL719 + cetuximab + encorafenib	1138.8	23	29	401	-2.5
X-1290	CRC	BYL719 + cetuximab	300.2	25.2	0	0	0
X-1290	CRC	BYL719 + cetuximab	349.8	25.3	3	16.5	0.4
X-1290	CRC	BYL719 + cetuximab	442.3	25.8	6	47.3	2.4
X-1290	CRC	BYL719 + cetuximab	546.1	24.8	9	81.9	-1.6
X-1290	CRC	BYL719 + cetuximab	530.6	25.2	14	76.7	0
X-1290	CRC	BYL719 + cetuximab	620.8	24	17	106.8	-4.8
X-1290	CRC	BYL719 + cetuximab	737.6	24.2	21	145.7	-4
X-1290	CRC	BYL719 + LJM716	192.3	27.5	0	0	0
X-1290	CRC	BYL719 + LJM716	151.1	27.3	3	-21.4	-0.7
X-1290	CRC	BYL719 + LJM716	156.7	26.4	8	-18.5	-4
X-1290	CRC	BYL719 + LJM716	106.3	28	11	-44.7	1.8
X-1290	CRC	BYL719 + LJM716	136.6	28.6	15	-29	4
X-1290	CRC	BYL719 + LJM716	138.4	27.5	17	-28	0
X-1290	CRC	BYL719 + LJM716	130.4	28.5	21	-32.2	3.6
X-1290	CRC	BYL719 + LJM716	116.3	28	24	-39.5	1.8
X-1290	CRC	BYL719 + LJM716	143.1	27.4	29	-25.6	-0.4
X-1290	CRC	BYL719 + LJM716	159.9	28.1	32	-16.8	2.2
X-1290	CRC	BYL719 + LJM716	166.5	27.5	37	-13.4	0
X-1290	CRC	BYL719 + LJM716	131.3	27.3	39	-31.7	-0.7
X-1290	CRC	BYL719 + LJM716	145.3	28.7	42	-24.4	4.4
X-1290	CRC	BYL719 + LJM716	141.5	29.2	46	-26.4	6.2
X-1290	CRC	BYL719 + LJM716	159.1	27.9	50	-17.3	1.5
X-1290	CRC	BYL719 + LJM716	153.4	28.2	53	-20.2	2.5
X-1290	CRC	BYL719 + LJM716	156.3	28.9	56	-18.7	5.1
X-1290	CRC	BYL719 + LJM716	153.5	29.2	59	-20.2	6.2
X-1290	CRC	BYL719 + LJM716	140.8	30.2	64	-26.8	9.8
X-1290	CRC	BYL719 + LJM716	164.5	29.8	71	-14.5	8.4
X-1290	CRC	BYL719 + LJM716	156.1	31.2	80	-18.8	13.5
X-1290	CRC	BYL719 + LJM716	131.7	30.3	85	-31.5	10.2
X-1290	CRC	BYL719 + LJM716	155.8	30.8	88	-19	12
X-1290	CRC	BYL719 + LJM716	175.5	30.4	92	-8.7	10.5
X-1290	CRC	BYL719	232.5	25.1	0	0	0
X-1290	CRC	BYL719	275.8	23.6	8	18.6	-6
X-1290	CRC	BYL719	410.4	23.3	11	76.5	-7.2
X-1290	CRC	BYL719	598.4	23.4	15	157.4	-6.8
X-1290	CRC	BYL719	933.5	23.2	17	301.5	-7.6
X-1290	CRC	BYL719	1050.8	23.5	21	352	-6.4
X-1290	CRC	BYL719	1138	21.5	24	389.5	-14.3
X-1290	CRC	BYL719 + binimetinib	261.6	30.7	0	0	0
X-1290	CRC	BYL719 + binimetinib	332.3	30.1	2	27	-2
X-1290	CRC	BYL719 + binimetinib	581.2	29.4	6	122.2	-4.2
X-1290	CRC	BYL719 + binimetinib	599.8	28.4	9	129.3	-7.5
X-1290	CRC	BYL719 + binimetinib	592.7	27.5	14	126.6	-10.4
X-1290	CRC	BYL719 + binimetinib	366.4	27.6	17	40.1	-10.1
X-1290	CRC	BYL719 + binimetinib	467.4	26.4	22	78.7	-14
X-1290	CRC	BYL719 + binimetinib	658.4	24.3	24	151.7	-20.8
X-1290	CRC	BYL719 + encorafenib	186.6	26.6	0	0	0
X-1290	CRC	BYL719 + encorafenib	187.9	25.1	2	0.7	-5.6
X-1290	CRC	BYL719 + encorafenib	180.8	25.4	6	-3.1	-4.5
X-1290	CRC	BYL719 + encorafenib	250.8	25.4	9	34.4	-4.5
X-1290	CRC	BYL719 + encorafenib	372.3	26.7	14	99.5	0.4
X-1290	CRC	BYL719 + encorafenib	344.2	26.1	22	84.5	-1.9
X-1290	CRC	BYL719 + encorafenib	386.4	25.4	24	107.1	-4.5
X-1290	CRC	BYL719 + encorafenib	414.5	25.9	27	122.1	-2.6
X-1290	CRC	CGM097	219.8	25.1	0	0	0
X-1290	CRC	CGM097	617.6	23.2	4	181	-7.6
X-1290	CRC	CGM097	1086.2	23.1	7	394.2	-8
X-1290	CRC	CGM097	1163.9	21	12	429.5	-16.3
X-1290	CRC	CGM097	2018	24	15	818.1	-4.4
X-1290	CRC	CKX620	202.7	23.2	0	0	0
X-1290	CRC	CKX620	207	22.5	4	2.1	-3
X-1290	CRC	CKX620	604.7	21.2	12	198.3	-8.6
X-1290	CRC	CKX620	904.3	22.2	15	346.1	-4.3
X-1290	CRC	CKX620	1209	22.2	19	496.4	-4.3
X-1290	CRC	CKX620	1255.7	22.6	21	519.5	-2.6
X-1290	CRC	CKX620	1765.2	22.4	25	770.8	-3.4
X-1290	CRC	CLR457	195.3	26	0	0	0
X-1290	CRC	CLR457	230.2	24.9	8	17.9	-4.2
X-1290	CRC	CLR457	377.1	24.9	11	93.1	-4.2
X-1290	CRC	CLR457	486	24.6	15	148.8	-5.4
X-1290	CRC	CLR457	548.5	23.6	17	180.8	-9.2
X-1290	CRC	CLR457	892.4	24.4	21	356.9	-6.2
X-1290	CRC	CLR457	1104	25	24	465.3	-3.8
X-1290	CRC	HDM201	212.5	32.1	0	0	0
X-1290	CRC	HDM201	312.3	28.1	4	47	-12.5
X-1290	CRC	HDM201	346.7	30.2	7	63.2	-5.9
X-1290	CRC	HDM201	648.6	28.3	12	205.2	-11.8
X-1290	CRC	HDM201	690.8	28.5	15	225.1	-11.2
X-1290	CRC	HDM201	818.6	27.7	19	285.2	-13.7
X-1290	CRC	HDM201	1017.1	27.7	21	378.6	-13.7
X-1290	CRC	HDM201	838	26.5	25	294.4	-17.4
X-1290	CRC	HDM201	927.2	28.2	28	336.3	-12.1
X-1290	CRC	cetuximab	225.3	26.8	0	0	0
X-1290	CRC	cetuximab	184.2	25.8	3	-18.2	-3.7
X-1290	CRC	cetuximab	187.5	25.5	6	-16.8	-4.9
X-1290	CRC	cetuximab	161.4	26.1	13	-28.4	-2.6
X-1290	CRC	cetuximab	152.5	26.4	17	-32.3	-1.5
X-1290	CRC	cetuximab	264.2	28	21	17.3	4.5
X-1290	CRC	cetuximab	212.1	27.6	24	-5.9	3
X-1290	CRC	cetuximab	228.5	27.8	27	1.4	3.7
X-1290	CRC	cetuximab	196	27.4	30	-13	2.2
X-1290	CRC	cetuximab	206.6	27.9	35	-8.3	4.1
X-1290	CRC	cetuximab	248.9	28	38	10.5	4.5
X-1290	CRC	cetuximab	229.6	27.7	42	1.9	3.4
X-1290	CRC	cetuximab	208.7	27.1	45	-7.4	1.1
X-1290	CRC	cetuximab	191.6	28.3	50	-15	5.6
X-1290	CRC	cetuximab	224.1	27.2	52	-0.5	1.5
X-1290	CRC	cetuximab	189.2	26.5	57	-16	-1.1
X-1290	CRC	cetuximab	227.9	27.3	59	1.2	1.9
X-1290	CRC	cetuximab	204.7	28.5	62	-9.1	6.3
X-1290	CRC	cetuximab	219.1	29	66	-2.8	8.2
X-1290	CRC	cetuximab	209.3	29	69	-7.1	8.2
X-1290	CRC	cetuximab	227.1	NA	73	0.8	8.2
X-1290	CRC	cetuximab	187.7	28	76	-16.7	4.5
X-1290	CRC	cetuximab + encorafenib	206.5	19.9	0	0	0
X-1290	CRC	cetuximab + encorafenib	346.9	20.2	7	68	1.5
X-1290	CRC	cetuximab + encorafenib	519.2	21.5	11	151.4	8
X-1290	CRC	cetuximab + encorafenib	633.2	20.1	15	206.6	1
X-1290	CRC	cetuximab + encorafenib	842.8	19.2	18	308.1	-3.5
X-1290	CRC	cetuximab + encorafenib	1091.6	19.6	21	428.6	-1.5
X-1290	CRC	cetuximab + encorafenib	1183.7	19.6	24	473.2	-1.5
X-1290	CRC	cetuximab + encorafenib	1778.2	21.6	29	761.1	8.5
X-1290	CRC	LEE011	200.6	29.4	0	0	0
X-1290	CRC	LEE011	204.6	26.7	4	2	-9.2
X-1290	CRC	LEE011	281.8	28.9	7	40.5	-1.7
X-1290	CRC	LEE011	355.8	28.3	12	77.4	-3.7
X-1290	CRC	LEE011	314.9	28	15	57	-4.8
X-1290	CRC	LEE011	507.7	27.4	19	153.1	-6.8
X-1290	CRC	LEE011	612	26.7	21	205.1	-9.2
X-1290	CRC	LEE011	840.4	26.7	25	318.9	-9.2
X-1290	CRC	LEE011	982.8	26.7	28	389.9	-9.2
X-1290	CRC	encorafenib	201.8	24.6	0	0	0
X-1290	CRC	encorafenib	287	25.5	3	42.2	3.7
X-1290	CRC	encorafenib	359.7	23.9	8	78.2	-2.8
X-1290	CRC	encorafenib	672.7	23.4	11	233.3	-4.9
X-1290	CRC	encorafenib	1110.7	23.5	15	450.4	-4.5
X-1290	CRC	encorafenib	1691	22.4	17	738	-8.9
X-1290	CRC	LJC049	223.8	26.2	0	0	0
X-1290	CRC	LJC049	301.6	25.5	3	34.8	-2.7
X-1290	CRC	LJC049	778.3	24.1	8	247.8	-8
X-1290	CRC	LJC049	982.4	27.1	11	339	3.4
X-1290	CRC	LJC049	1089.9	26.2	15	387	0
X-1290	CRC	LJC049	1127.3	24.9	17	403.7	-5
X-1290	CRC	LJC049	1236.6	21.9	21	452.5	-16.4
X-1290	CRC	LKA136	195.4	22.5	0	0	0
X-1290	CRC	LKA136	316.2	21.9	3	61.8	-2.7
X-1290	CRC	LKA136	445.9	21.2	8	128.2	-5.8
X-1290	CRC	LKA136	487.2	21.7	11	149.3	-3.6
X-1290	CRC	LKA136	627.1	23.2	15	220.9	3.1
X-1290	CRC	LKA136	516.6	22.4	17	164.4	-0.4
X-1290	CRC	LKA136	446.8	23	21	128.7	2.2
X-1290	CRC	LKA136	413.4	23.6	24	111.6	4.9
X-1290	CRC	binimetinib	205	24.4	0	0	0
X-1290	CRC	binimetinib	262.7	22.2	4	28.1	-9
X-1290	CRC	binimetinib	431.5	21.7	7	110.5	-11.1
X-1290	CRC	binimetinib	584.1	20	12	184.9	-18
X-1290	CRC	untreated	195.8	29.2	0	0	0
X-1290	CRC	untreated	282.4	28.7	8	44.2	-1.7
X-1290	CRC	untreated	452	28	10	130.8	-4.1
X-1290	CRC	untreated	462.1	27.7	13	136	-5.1
X-1290	CRC	untreated	691.7	28	17	253.3	-4.1
X-1290	CRC	untreated	1029.8	29.5	21	425.9	1
X-1290	CRC	untreated	1091.1	27.6	24	457.3	-5.5
X-1290	CRC	untreated	1354.6	28.9	27	591.8	-1
X-1290	CRC	untreated	1705.5	29.3	30	771	0.3
X-1290	CRC	LFW527 + binimetinib	205.61	26.77	0	0	0
X-1290	CRC	LFW527 + binimetinib	212.12	25.83	3	3.2	-3.5
X-1290	CRC	LFW527 + binimetinib	260.68	24.25	6	26.8	-9.4
X-1290	CRC	LFW527 + binimetinib	329.92	24.41	10	60.5	-8.8
X-1290	CRC	LFW527 + binimetinib	379.96	23.58	13	84.8	-11.9
X-1290	CRC	LFW527 + binimetinib	434.81	23.73	17	111.5	-11.4
X-1298	BRCA	BGJ398	204.9	24.8	0	0	0
X-1298	BRCA	BGJ398	199.5	25.5	6	-2.6	2.8
X-1298	BRCA	BGJ398	253.8	25.5	9	23.9	2.8
X-1298	BRCA	BGJ398	274.5	25.8	12	34	4
X-1298	BRCA	BGJ398	458.7	26.4	16	123.9	6.5
X-1298	BRCA	BGJ398	424.1	25.2	19	107	1.6
X-1298	BRCA	BGJ398	548	26.1	27	167.4	5.2
X-1298	BRCA	BGJ398	657.7	26.7	34	221	7.7
X-1298	BRCA	BGJ398	650.2	26.8	37	217.3	8.1
X-1298	BRCA	BKM120	214.9	23.9	0	0	0
X-1298	BRCA	BKM120	153.3	25.5	6	-28.7	6.7
X-1298	BRCA	BKM120	120.9	25.5	9	-43.7	6.7
X-1298	BRCA	BKM120	109.8	25.7	12	-48.9	7.5
X-1298	BRCA	BKM120	107.6	25.6	16	-49.9	7.1
X-1298	BRCA	BKM120	159.2	24.9	19	-25.9	4.2
X-1298	BRCA	BKM120	135	25.6	27	-37.2	7.1
X-1298	BRCA	BKM120	138.1	26.8	34	-35.7	12.1
X-1298	BRCA	BKM120	134.7	26.1	37	-37.3	9.2
X-1298	BRCA	BKM120	161.1	26	41	-25	8.8
X-1298	BRCA	BKM120	133.7	25.1	44	-37.8	5
X-1298	BRCA	BKM120	117.1	25	48	-45.5	4.6
X-1298	BRCA	BKM120	105.7	24.5	50	-50.8	2.5
X-1298	BRCA	BKM120	113.4	25	54	-47.2	4.6
X-1298	BRCA	BKM120	78.8	25.7	57	-63.3	7.5
X-1298	BRCA	BKM120	83.2	27.2	62	-61.3	13.8
X-1298	BRCA	BKM120	72.2	27.5	65	-66.4	15.1
X-1298	BRCA	BKM120	139.6	26.4	69	-35	10.5
X-1298	BRCA	BKM120	153.3	25.3	72	-28.7	5.9
X-1298	BRCA	BKM120	109.1	25.2	75	-49.2	5.4
X-1298	BRCA	BKM120	91.3	24.5	80	-57.5	2.5
X-1298	BRCA	BKM120	85.5	24.9	83	-60.2	4.2
X-1298	BRCA	BKM120	100.1	25	86	-53.4	4.6
X-1298	BRCA	BKM120	94.7	25.4	89	-55.9	6.3
X-1298	BRCA	BKM120	75.7	26.3	93	-64.8	10
X-1298	BRCA	BKM120	127.4	25.4	96	-40.7	6.3
X-1298	BRCA	BKM120	115.5	25.3	103	-46.3	5.9
X-1298	BRCA	BKM120	84.1	25.9	107	-60.9	8.4
X-1298	BRCA	BKM120	74.5	26.8	110	-65.3	12.1
X-1298	BRCA	BKM120	78.6	26.9	114	-63.4	12.6
X-1298	BRCA	BYL719	224.2	28.4	0	0	0
X-1298	BRCA	BYL719	356.1	28.4	6	58.8	0
X-1298	BRCA	BYL719	482.7	27.5	9	115.3	-3.2
X-1298	BRCA	BYL719	483.8	28.4	12	115.8	0
X-1298	BRCA	BYL719	627.6	28.6	16	179.9	0.7
X-1298	BRCA	BYL719	828.9	27.9	19	269.7	-1.8
X-1298	BRCA	BYL719	838.4	29.1	21	274	2.5
X-1298	BRCA	BYL719 + LEE011	231.6	26.5	0	0	0
X-1298	BRCA	BYL719 + LEE011	268.8	26.9	1	16.1	1.5
X-1298	BRCA	BYL719 + LEE011	313.8	28.4	4	35.5	7.2
X-1298	BRCA	BYL719 + LEE011	442.8	27.7	7	91.2	4.5
X-1298	BRCA	BYL719 + LEE011	470.1	27	11	103	1.9
X-1298	BRCA	BYL719 + LEE011	573.8	25.4	14	147.8	-4.2
X-1298	BRCA	BYL719 + LEE011	685.8	26.7	22	196.1	0.8
X-1298	BRCA	BYL719 + LEE011	818.1	26.2	29	253.2	-1.1
X-1298	BRCA	BYL719 + LEE011	888.6	24.8	32	283.7	-6.4
X-1298	BRCA	BYL719 + LJM716	241.7	26.3	0	0	0
X-1298	BRCA	BYL719 + LJM716	290.5	25.7	3	20.2	-2.3
X-1298	BRCA	BYL719 + LJM716	277.7	26.6	6	14.9	1.1
X-1298	BRCA	BYL719 + LJM716	456.6	26.6	10	88.9	1.1
X-1298	BRCA	BYL719 + LJM716	602.8	25.6	13	149.4	-2.7
X-1298	BRCA	BYL719 + LJM716	1010.2	26.8	21	318	1.9
X-1298	BRCA	BYL719 + LJM716	1443.2	27.1	28	497.1	3
X-1298	BRCA	BYL719 + LJM716	1531.3	26.3	31	533.6	0
X-1298	BRCA	CGM097	215.8	23.6	0	0	0
X-1298	BRCA	CGM097	255.5	25.6	6	18.4	8.5
X-1298	BRCA	CGM097	415.7	26.1	9	92.6	10.6
X-1298	BRCA	CGM097	536.9	26.5	12	148.8	12.3
X-1298	BRCA	CGM097	724.1	26.9	16	235.5	14
X-1298	BRCA	CGM097	1027.2	25.5	19	376	8.1
X-1298	BRCA	CGM097	1036.4	27.5	21	380.3	16.5
X-1298	BRCA	CLR457	219.5	22.5	0	0	0
X-1298	BRCA	CLR457	222.6	22.1	6	1.4	-1.8
X-1298	BRCA	CLR457	318.4	22	9	45.1	-2.2
X-1298	BRCA	CLR457	346.3	22.5	12	57.8	0
X-1298	BRCA	CLR457	346.8	21.9	16	58	-2.7
X-1298	BRCA	CLR457	480.5	21.2	19	118.9	-5.8
X-1298	BRCA	CLR457	540.4	20.2	27	146.2	-10.2
X-1298	BRCA	HDM201	221.5	25.8	0	0	0
X-1298	BRCA	HDM201	333.8	26	6	50.7	0.8
X-1298	BRCA	HDM201	465.3	27.5	9	110.1	6.6
X-1298	BRCA	HDM201	539.9	26.6	12	143.7	3.1
X-1298	BRCA	HDM201	793.5	27.2	16	258.2	5.4
X-1298	BRCA	HDM201	954.6	25.4	19	331	-1.6
X-1298	BRCA	HDM201	1010.4	26.5	21	356.2	2.7
X-1298	BRCA	INC424	216.1	22.2	0	0	0
X-1298	BRCA	INC424	191.7	23	6	-11.3	3.6
X-1298	BRCA	INC424	191.9	23.1	9	-11.2	4.1
X-1298	BRCA	INC424	171.9	22.8	12	-20.5	2.7
X-1298	BRCA	INC424	229.6	23	16	6.2	3.6
X-1298	BRCA	INC424	225.5	22.1	19	4.3	-0.5
X-1298	BRCA	INC424	504.3	22.4	27	133.4	0.9
X-1298	BRCA	INC424	409.7	23	34	89.6	3.6
X-1298	BRCA	INC424	457	23.9	37	111.5	7.7
X-1298	BRCA	LEE011	201.4	25.8	0	0	0
X-1298	BRCA	LEE011	209.5	26.3	6	4	1.9
X-1298	BRCA	LEE011	261.7	27.4	9	29.9	6.2
X-1298	BRCA	LEE011	253.5	26.3	12	25.9	1.9
X-1298	BRCA	LEE011	268.2	26.1	16	33.2	1.2
X-1298	BRCA	LEE011	385.6	25.6	19	91.5	-0.8
X-1298	BRCA	LEE011	358	27.2	27	77.8	5.4
X-1298	BRCA	LEE011	427.2	24.9	34	112.1	-3.5
X-1298	BRCA	LEE011	516.8	23.7	37	156.6	-8.1
X-1298	BRCA	LEE011 + everolimus	204.4	24.4	0	0	0
X-1298	BRCA	LEE011 + everolimus	149.3	24.4	6	-27	0
X-1298	BRCA	LEE011 + everolimus	136.6	25.8	9	-33.2	5.7
X-1298	BRCA	LEE011 + everolimus	90.9	24.3	12	-55.5	-0.4
X-1298	BRCA	LEE011 + everolimus	69.7	24.5	16	-65.9	0.4
X-1298	BRCA	LEE011 + everolimus	125.5	23.9	19	-38.6	-2
X-1298	BRCA	LEE011 + everolimus	139.6	24.8	27	-31.7	1.6
X-1298	BRCA	LEE011 + everolimus	65.7	23.8	34	-67.9	-2.5
X-1298	BRCA	LEE011 + everolimus	71.3	23.2	37	-65.1	-4.9
X-1298	BRCA	LEE011 + everolimus	65.3	24.4	41	-68.1	0
X-1298	BRCA	LEE011 + everolimus	95.5	24.4	44	-53.3	0
X-1298	BRCA	LEE011 + everolimus	62.9	24.4	48	-69.2	0
X-1298	BRCA	LEE011 + everolimus	41.4	24.8	50	-79.7	1.6
X-1298	BRCA	LEE011 + everolimus	26.9	26.2	54	-86.8	7.4
X-1298	BRCA	LEE011 + everolimus	46.6	25.5	57	-77.2	4.5
X-1298	BRCA	LEE011 + everolimus	43	24.2	62	-79	-0.8
X-1298	BRCA	LEE011 + everolimus	50.4	24.8	65	-75.3	1.6
X-1298	BRCA	LEE011 + everolimus	60.2	24	69	-70.5	-1.6
X-1298	BRCA	LEE011 + everolimus	54.7	24.5	72	-73.2	0.4
X-1298	BRCA	LEE011 + everolimus	95.7	23.7	75	-53.2	-2.9
X-1298	BRCA	LEE011 + everolimus	48.5	24.3	80	-76.3	-0.4
X-1298	BRCA	LEE011 + everolimus	48.1	23.7	83	-76.5	-2.9
X-1298	BRCA	LEE011 + everolimus	46.3	23.9	86	-77.3	-2
X-1298	BRCA	LEE011 + everolimus	45	23	89	-78	-5.7
X-1298	BRCA	LEE011 + everolimus	49.1	23.3	93	-76	-4.5
X-1298	BRCA	LEE011 + everolimus	44.7	23.5	96	-78.1	-3.7
X-1298	BRCA	LEE011 + everolimus	28.6	24	103	-86	-1.6
X-1298	BRCA	LEE011 + everolimus	57.5	23.5	107	-71.9	-3.7
X-1298	BRCA	LEE011 + everolimus	47.9	23.8	110	-76.6	-2.5
X-1298	BRCA	LEE011 + everolimus	35.7	25	114	-82.5	2.5
X-1298	BRCA	LFA102	219.9	24.9	0	0	0
X-1298	BRCA	LFA102	183.7	25	1	-16.5	0.4
X-1298	BRCA	LFA102	177.3	25.5	4	-19.4	2.4
X-1298	BRCA	LFA102	253.7	25.6	7	15.4	2.8
X-1298	BRCA	LFA102	342	25.8	11	55.5	3.6
X-1298	BRCA	LFA102	365	24.7	14	66	-0.8
X-1298	BRCA	LJM716	220.5	23.4	0	0	0
X-1298	BRCA	LJM716	202.3	24.2	1	-8.3	3.4
X-1298	BRCA	LJM716	230.7	23.6	4	4.6	0.9
X-1298	BRCA	LJM716	269.3	23.6	7	22.1	0.9
X-1298	BRCA	LJM716	323.6	23.5	11	46.8	0.4
X-1298	BRCA	LJM716	431.2	22.8	14	95.6	-2.6
X-1298	BRCA	LJM716	495.8	23.7	22	124.9	1.3
X-1298	BRCA	LJM716	598.1	22.6	29	171.2	-3.4
X-1298	BRCA	LJM716	641.6	22.8	32	191	-2.6
X-1298	BRCA	LJM716 + trastuzumab	221.3	23.5	0	0	0
X-1298	BRCA	LJM716 + trastuzumab	172.1	24.8	1	-22.2	5.5
X-1298	BRCA	LJM716 + trastuzumab	196	24.9	4	-11.4	6
X-1298	BRCA	LJM716 + trastuzumab	234.8	23.9	7	6.1	1.7
X-1298	BRCA	LJM716 + trastuzumab	287.9	24.4	11	30.1	3.8
X-1298	BRCA	LJM716 + trastuzumab	376	23.8	14	69.9	1.3
X-1298	BRCA	LJM716 + trastuzumab	505.5	24.1	22	128.4	2.6
X-1298	BRCA	LJM716 + trastuzumab	590.4	18.1	29	166.8	-23
X-1298	BRCA	LKA136	256.2	27.4	0	0	0
X-1298	BRCA	LKA136	403.4	27.8	6	57.5	1.5
X-1298	BRCA	LKA136	669	28.4	9	161.1	3.6
X-1298	BRCA	LKA136	686.8	28.3	12	168.1	3.3
X-1298	BRCA	LKA136	838.3	28.2	16	227.2	2.9
X-1298	BRCA	LKA136	953.2	26.5	19	272.1	-3.3
X-1298	BRCA	LKA136	1020.2	27.4	21	298.2	0
X-1298	BRCA	LLM871	203.9	25.7	0	0	0
X-1298	BRCA	LLM871	232	25	2	13.8	-2.7
X-1298	BRCA	LLM871	198.8	24.6	5	-2.5	-4.3
X-1298	BRCA	LLM871	263.4	25.2	9	29.2	-1.9
X-1298	BRCA	LLM871	305.7	24.4	12	49.9	-5.1
X-1298	BRCA	LLM871	260.1	24.8	20	27.6	-3.5
X-1298	BRCA	LLM871	271.6	23.5	27	33.2	-8.6
X-1298	BRCA	LLM871	299.7	25.2	30	47	-1.9
X-1298	BRCA	LLM871	332.7	24.9	33	63.2	-3.1
X-1298	BRCA	binimetinib	224.8	25.6	0	0	0
X-1298	BRCA	binimetinib	342.5	26.3	6	52.4	2.7
X-1298	BRCA	binimetinib	456.5	27	9	103.1	5.5
X-1298	BRCA	binimetinib	490.9	26.8	12	118.4	4.7
X-1298	BRCA	binimetinib	428.8	27.6	16	90.7	7.8
X-1298	BRCA	binimetinib	408.8	23.1	19	81.9	-9.8
X-1298	BRCA	binimetinib	432	21.4	22	92.2	-16.4
X-1298	BRCA	paclitaxel	215.7	28.1	0	0	0
X-1298	BRCA	paclitaxel	205.5	28.2	4	-4.7	0.4
X-1298	BRCA	paclitaxel	278.1	27.2	7	28.9	-3.2
X-1298	BRCA	paclitaxel	312.6	26.5	15	44.9	-5.7
X-1298	BRCA	paclitaxel	365.8	25.1	22	69.6	-10.7
X-1298	BRCA	paclitaxel	373.2	23.9	25	73	-14.9
X-1298	BRCA	paclitaxel	468.4	23.7	28	117.2	-15.7
X-1298	BRCA	tamoxifen	218	23.8	0	0	0
X-1298	BRCA	tamoxifen	168.9	24.6	1	-22.5	3.4
X-1298	BRCA	tamoxifen	188.6	23.8	4	-13.5	0
X-1298	BRCA	tamoxifen	232.8	23.4	7	6.8	-1.7
X-1298	BRCA	tamoxifen	275.9	24.2	11	26.6	1.7
X-1298	BRCA	tamoxifen	270.8	23	14	24.2	-3.4
X-1298	BRCA	tamoxifen	391	25.6	22	79.4	7.6
X-1298	BRCA	tamoxifen	499.8	24.9	29	129.3	4.6
X-1298	BRCA	tamoxifen	559.1	26.1	32	156.5	9.7
X-1298	BRCA	trastuzumab	219.5	24.6	0	0	0
X-1298	BRCA	trastuzumab	233.2	25.3	1	6.2	2.8
X-1298	BRCA	trastuzumab	277.8	25.7	4	26.6	4.5
X-1298	BRCA	trastuzumab	345.7	26.8	7	57.5	8.9
X-1298	BRCA	trastuzumab	381.6	26.7	11	73.8	8.5
X-1298	BRCA	trastuzumab	550.8	25.8	14	150.9	4.9
X-1298	BRCA	trastuzumab	649.2	25.9	22	195.8	5.3
X-1298	BRCA	trastuzumab	937.7	26.7	29	327.2	8.5
X-1298	BRCA	trastuzumab	1012.7	27.1	32	361.4	10.2
X-1298	BRCA	untreated	197.9	23.6	0	0	0
X-1298	BRCA	untreated	313.8	23.3	6	58.6	-1.3
X-1298	BRCA	untreated	349.3	23.9	9	76.5	1.3
X-1298	BRCA	untreated	402.3	24.6	12	103.3	4.2
X-1298	BRCA	untreated	478.5	24.2	16	141.8	2.5
X-1298	BRCA	untreated	610.2	23.2	19	208.3	-1.7
X-1298	BRCA	untreated	836.1	24.8	27	322.5	5.1
X-1298	BRCA	untreated	1172.8	24.4	34	492.6	3.4
X-1298	BRCA	untreated	1283	20.5	37	548.3	-13.1
X-1298	BRCA	LFW527 + everolimus	292.22	27.3	0	0	0
X-1298	BRCA	LFW527 + everolimus	247.73	26.4	2	-15.2	-3.3
X-1298	BRCA	LFW527 + everolimus	178.4	25.6	6	-39	-6.2
X-1298	BRCA	LFW527 + everolimus	122.11	26.2	9	-58.2	-4
X-1298	BRCA	LFW527 + everolimus	147.78	25.1	13	-49.4	-8.1
X-1303	CRC	5FU	238	24.7	0	0	0
X-1303	CRC	5FU	203.6	25.4	2	-14.5	2.8
X-1303	CRC	5FU	141.6	23	4	-40.5	-6.9
X-1303	CRC	5FU	208.1	24	7	-12.6	-2.8
X-1303	CRC	5FU	191.9	25.9	11	-19.4	4.9
X-1303	CRC	5FU	194.7	26.3	16	-18.2	6.5
X-1303	CRC	5FU	259.9	24.1	21	9.2	-2.4
X-1303	CRC	5FU	264.2	24.1	25	11	-2.4
X-1303	CRC	5FU	249.7	23.6	29	4.9	-4.5
X-1303	CRC	5FU	209.9	25	32	-11.8	1.2
X-1303	CRC	5FU	264	25	36	10.9	1.2
X-1303	CRC	5FU	278	23.5	39	16.8	-4.9
X-1303	CRC	5FU	277.7	22.8	42	16.7	-7.7
X-1303	CRC	5FU	277.3	22.6	46	16.5	-8.5
X-1303	CRC	5FU	319.6	24.7	52	34.3	0
X-1303	CRC	5FU	385.3	24	56	61.9	-2.8
X-1303	CRC	5FU	446.8	24.1	60	87.7	-2.4
X-1303	CRC	5FU	492.5	24.3	63	106.9	-1.6
X-1303	CRC	5FU	568	24.6	67	138.7	-0.4
X-1303	CRC	5FU	478.4	25.1	71	101	1.6
X-1303	CRC	5FU	520.7	24.2	74	118.8	-2
X-1303	CRC	5FU	497.1	24	77	108.9	-2.8
X-1303	CRC	5FU	465.5	23.2	80	95.6	-6.1
X-1303	CRC	5FU	424.9	23.5	85	78.5	-4.9
X-1303	CRC	5FU	368.3	22.7	88	54.7	-8.1
X-1303	CRC	5FU	370.1	22.4	92	55.5	-9.3
X-1303	CRC	BKM120	241.6	23.7	0	0	0
X-1303	CRC	BKM120	324.2	22.2	3	34.2	-6.3
X-1303	CRC	BKM120	370.6	21.1	9	53.4	-11
X-1303	CRC	BKM120	363.3	23.8	11	50.4	0.4
X-1303	CRC	BKM120	356.4	22.8	14	47.5	-3.8
X-1303	CRC	BKM120	548	21.8	18	126.8	-8
X-1303	CRC	BKM120	685.1	20.4	23	183.6	-13.9
X-1303	CRC	BYL719	266.7	25.9	0	0	0
X-1303	CRC	BYL719	212.9	22.9	4	-20.2	-11.6
X-1303	CRC	BYL719	189.2	23.7	9	-29.1	-8.5
X-1303	CRC	BYL719	231.5	22.2	14	-13.2	-14.3
X-1303	CRC	BYL719	194.3	23	18	-27.1	-11.2
X-1303	CRC	BYL719	293.1	22.7	22	9.9	-12.4
X-1303	CRC	BYL719	309.5	21.2	25	16	-18.1
X-1303	CRC	BYL719	373.3	23.9	28	40	-7.7
X-1303	CRC	BYL719 + LJM716	198.6	26.2	0	0	0
X-1303	CRC	BYL719 + LJM716	125.3	25	4	-36.9	-4.6
X-1303	CRC	BYL719 + LJM716	114.7	25.1	9	-42.2	-4.2
X-1303	CRC	BYL719 + LJM716	205.6	24.7	14	3.5	-5.7
X-1303	CRC	BYL719 + LJM716	221.9	25.2	18	11.7	-3.8
X-1303	CRC	BYL719 + LJM716	241.1	25	22	21.4	-4.6
X-1303	CRC	BYL719 + LJM716	199.1	24.3	25	0.3	-7.3
X-1303	CRC	BYL719 + LJM716	158.7	23.4	29	-20.1	-10.7
X-1303	CRC	BYL719 + LJM716	133	21.1	32	-33	-19.5
X-1303	CRC	BYL719 + cetuximab + encorafenib	159.1	30.7	0	0	0
X-1303	CRC	BYL719 + cetuximab + encorafenib	147.5	28.9	3	-7.3	-5.9
X-1303	CRC	BYL719 + cetuximab + encorafenib	178.4	28.4	6	12.1	-7.5
X-1303	CRC	BYL719 + cetuximab + encorafenib	187.3	28.8	10	17.7	-6.2
X-1303	CRC	BYL719 + cetuximab + encorafenib	235.9	28.8	16	48.3	-6.2
X-1303	CRC	BYL719 + cetuximab + encorafenib	230.8	29.2	20	45.1	-4.9
X-1303	CRC	BYL719 + cetuximab + encorafenib	230.1	29.3	24	44.6	-4.6
X-1303	CRC	BYL719 + cetuximab + encorafenib	252.9	28.8	27	59	-6.2
X-1303	CRC	BYL719 + cetuximab + encorafenib	226.5	30.1	31	42.4	-2
X-1303	CRC	BYL719 + cetuximab + encorafenib	259.3	28.9	35	63	-5.9
X-1303	CRC	BYL719 + cetuximab + encorafenib	256.8	29.6	38	61.4	-3.6
X-1303	CRC	BYL719 + cetuximab + encorafenib	252.5	29.3	41	58.7	-4.6
X-1303	CRC	BYL719 + cetuximab + encorafenib	293.3	29	44	84.3	-5.5
X-1303	CRC	BYL719 + cetuximab + encorafenib	286.3	29.4	49	79.9	-4.2
X-1303	CRC	BYL719 + cetuximab + encorafenib	294.5	28.9	52	85.1	-5.9
X-1303	CRC	BYL719 + cetuximab + encorafenib	239	30.5	56	50.2	-0.7
X-1303	CRC	BYL719 + cetuximab + encorafenib	233.4	29.7	59	46.7	-3.3
X-1303	CRC	BYL719 + binimetinib	213.8	29	0	0	0
X-1303	CRC	BYL719 + binimetinib	218.1	27.5	3	2	-5.2
X-1303	CRC	BYL719 + binimetinib	229	27.7	6	7.1	-4.5
X-1303	CRC	BYL719 + binimetinib	227.2	28.3	10	6.3	-2.4
X-1303	CRC	BYL719 + binimetinib	216.3	28.3	16	1.2	-2.4
X-1303	CRC	BYL719 + binimetinib	225.9	29.9	20	5.7	3.1
X-1303	CRC	BYL719 + binimetinib	174.5	29.1	24	-18.4	0.3
X-1303	CRC	BYL719 + binimetinib	207.1	28.6	27	-3.1	-1.4
X-1303	CRC	BYL719 + binimetinib	245.6	29.3	31	14.9	1
X-1303	CRC	BYL719 + binimetinib	241.4	27.4	35	12.9	-5.5
X-1303	CRC	BYL719 + binimetinib	224.1	28.2	38	4.8	-2.8
X-1303	CRC	BYL719 + binimetinib	198.1	27.5	41	-7.3	-5.2
X-1303	CRC	BYL719 + binimetinib	200.3	27.5	44	-6.3	-5.2
X-1303	CRC	BYL719 + binimetinib	208.3	28.3	49	-2.6	-2.4
X-1303	CRC	BYL719 + binimetinib	232.7	27.4	52	8.8	-5.5
X-1303	CRC	BYL719 + binimetinib	237.8	27.7	56	11.2	-4.5
X-1303	CRC	BYL719 + binimetinib	258.6	27.5	59	21	-5.2
X-1303	CRC	BYL719 + binimetinib	264.9	30.4	62	23.9	4.8
X-1303	CRC	BYL719 + binimetinib	242.9	27.3	67	13.6	-5.9
X-1303	CRC	BYL719 + binimetinib	234.6	27.2	70	9.7	-6.2
X-1303	CRC	BYL719 + binimetinib	244.8	28.4	73	14.5	-2.1
X-1303	CRC	BYL719 + binimetinib	259.3	27.2	76	21.3	-6.2
X-1303	CRC	BYL719 + binimetinib	296.4	26.8	80	38.6	-7.6
X-1303	CRC	BYL719 + binimetinib	262	26.8	83	22.5	-7.6
X-1303	CRC	BYL719 + binimetinib	270.8	27.6	87	26.7	-4.8
X-1303	CRC	BYL719 + binimetinib	298	27.8	90	39.4	-4.1
X-1303	CRC	BYL719 + binimetinib	317.8	27.6	92	48.6	-4.8
X-1303	CRC	BYL719 + cetuximab	293.6	27.5	0	0	0
X-1303	CRC	BYL719 + cetuximab	399	27.1	4	35.9	-1.5
X-1303	CRC	BYL719 + cetuximab	428.2	26.1	8	45.8	-5.1
X-1303	CRC	BYL719 + cetuximab	393.6	25.8	11	34.1	-6.2
X-1303	CRC	BYL719 + cetuximab	476.5	27.5	15	62.3	0
X-1303	CRC	BYL719 + cetuximab	515	27.2	19	75.4	-1.1
X-1303	CRC	BYL719 + cetuximab	510	27	22	73.7	-1.8
X-1303	CRC	BYL719 + cetuximab	544.8	26.8	25	85.6	-2.5
X-1303	CRC	BYL719 + cetuximab	590.3	26.7	28	101.1	-2.9
X-1303	CRC	BYL719 + cetuximab	561.8	29.9	33	91.3	8.7
X-1303	CRC	BYL719 + cetuximab	511.5	26.4	36	74.2	-4
X-1303	CRC	BYL719 + cetuximab	481.6	25.9	40	64	-5.8
X-1303	CRC	BYL719 + cetuximab	565.2	26.7	43	92.5	-2.9
X-1303	CRC	BYL719 + cetuximab	614.9	28.8	46	109.4	4.7
X-1303	CRC	BYL719 + cetuximab	613.7	26.9	51	109	-2.2
X-1303	CRC	BYL719 + cetuximab	668.2	26.3	54	127.6	-4.4
X-1303	CRC	BYL719 + cetuximab	674.2	27.8	57	129.6	1.1
X-1303	CRC	BYL719 + cetuximab	626.7	27.2	60	113.5	-1.1
X-1303	CRC	BYL719 + cetuximab	608.1	27.4	64	107.1	-0.4
X-1303	CRC	BYL719 + cetuximab	591.8	28.7	67	101.6	4.4
X-1303	CRC	BYL719 + cetuximab	621.6	28.2	71	111.7	2.5
X-1303	CRC	BYL719 + cetuximab	699.9	28	74	138.4	1.8
X-1303	CRC	BYL719 + cetuximab	718.8	28.6	76	144.8	4
X-1303	CRC	CGM097	239.5	27.8	0	0	0
X-1303	CRC	CGM097	337	30.8	2	40.7	10.8
X-1303	CRC	CGM097	300.6	27.2	4	25.5	-2.2
X-1303	CRC	CGM097	390.8	29.5	7	63.2	6.1
X-1303	CRC	CGM097	410.7	28.9	11	71.5	4
X-1303	CRC	CGM097	455.5	29.3	16	90.2	5.4
X-1303	CRC	CGM097	485.7	28.6	21	102.8	2.9
X-1303	CRC	CGM097	499.2	28.9	24	108.4	4
X-1303	CRC	CKX620	286	26.9	0	0	0
X-1303	CRC	CKX620	479.3	25.3	3	67.6	-5.9
X-1303	CRC	CKX620	506.4	25.4	9	77.1	-5.6
X-1303	CRC	CKX620	418.6	25	11	46.4	-7.1
X-1303	CRC	CKX620	328.7	27.1	14	14.9	0.7
X-1303	CRC	CKX620	348.7	27.9	18	21.9	3.7
X-1303	CRC	CKX620	364.5	28.3	23	27.4	5.2
X-1303	CRC	CKX620	223	25.3	28	-22	-5.9
X-1303	CRC	CKX620	190.9	25.9	32	-33.3	-3.7
X-1303	CRC	CKX620	121.7	26.4	36	-57.4	-1.9
X-1303	CRC	CKX620	91.9	25.7	39	-67.9	-4.5
X-1303	CRC	CKX620	77.3	25	43	-73	-7.1
X-1303	CRC	CKX620	90.2	28	46	-68.5	4.1
X-1303	CRC	CKX620	94	28.5	49	-67.1	5.9
X-1303	CRC	CKX620	98.5	25.2	53	-65.6	-6.3
X-1303	CRC	CKX620	97.3	22.8	55	-66	-15.2
X-1303	CRC	CLR457	240.8	28.6	0	0	0
X-1303	CRC	CLR457	289.9	27.2	4	20.4	-4.9
X-1303	CRC	CLR457	366.2	26.5	9	52.1	-7.3
X-1303	CRC	CLR457	405.7	26.8	14	68.5	-6.3
X-1303	CRC	CLR457	482.3	26.9	18	100.3	-5.9
X-1303	CRC	CLR457	548.9	28.1	22	127.9	-1.7
X-1303	CRC	HDM201	226.2	26.8	0	0	0
X-1303	CRC	HDM201	382.7	26.3	2	69.2	-1.9
X-1303	CRC	HDM201	373.5	25.6	4	65.1	-4.5
X-1303	CRC	HDM201	379.2	24.8	7	67.6	-7.5
X-1303	CRC	HDM201	533.9	24.9	11	136	-7.1
X-1303	CRC	HDM201	492.2	25	16	117.6	-6.7
X-1303	CRC	HDM201	567.6	27.1	21	150.9	1.1
X-1303	CRC	HDM201	570.5	27.4	24	152.2	2.2
X-1303	CRC	cetuximab	295.8	28.7	0	0	0
X-1303	CRC	cetuximab	259.4	28.3	3	-12.3	-1.4
X-1303	CRC	cetuximab	323.9	27.6	9	9.5	-3.8
X-1303	CRC	cetuximab	294.5	27.4	11	-0.4	-4.5
X-1303	CRC	cetuximab	349	27.4	14	18	-4.5
X-1303	CRC	cetuximab	327.3	27.5	18	10.6	-4.2
X-1303	CRC	cetuximab	282.6	27.6	23	-4.5	-3.8
X-1303	CRC	cetuximab	225.2	28.6	28	-23.9	-0.3
X-1303	CRC	cetuximab	181.4	30.1	32	-38.7	4.9
X-1303	CRC	cetuximab	134	30.3	36	-54.7	5.6
X-1303	CRC	cetuximab	117.3	30.1	39	-60.3	4.9
X-1303	CRC	cetuximab	105.4	30.3	43	-64.4	5.6
X-1303	CRC	cetuximab	125	29.9	46	-57.7	4.2
X-1303	CRC	cetuximab	106	30	49	-64.2	4.5
X-1303	CRC	cetuximab	86.1	30.4	53	-70.9	5.9
X-1303	CRC	cetuximab	66.4	29.7	59	-77.6	3.5
X-1303	CRC	cetuximab	49.8	30.9	63	-83.2	7.7
X-1303	CRC	cetuximab	43.3	31	67	-85.4	8
X-1303	CRC	cetuximab	34.3	30.1	70	-88.4	4.9
X-1303	CRC	cetuximab	38.2	30.6	74	-87.1	6.6
X-1303	CRC	cetuximab	38.4	29.8	78	-87	3.8
X-1303	CRC	cetuximab	39.6	29.8	81	-86.6	3.8
X-1303	CRC	cetuximab	28.9	31	84	-90.2	8
X-1303	CRC	cetuximab	33.1	30.5	87	-88.8	6.3
X-1303	CRC	cetuximab	48.6	30.7	92	-83.6	7
X-1303	CRC	cetuximab + encorafenib	193.7	25.8	0	0	0
X-1303	CRC	cetuximab + encorafenib	179.7	25.8	2	-7.2	0
X-1303	CRC	cetuximab + encorafenib	209.8	23.2	6	8.3	-10.1
X-1303	CRC	cetuximab + encorafenib	204.8	25.7	9	5.7	-0.4
X-1303	CRC	cetuximab + encorafenib	216.3	26.7	13	11.7	3.5
X-1303	CRC	cetuximab + encorafenib	258	26	16	33.2	0.8
X-1303	CRC	cetuximab + encorafenib	249.6	25.2	19	28.9	-2.3
X-1303	CRC	cetuximab + encorafenib	263.6	25.2	23	36.1	-2.3
X-1303	CRC	cetuximab + encorafenib	302.9	25	29	56.4	-3.1
X-1303	CRC	cetuximab + encorafenib	300.2	NA	33	55	-3.1
X-1303	CRC	cetuximab + encorafenib	308.4	25.7	37	59.2	-0.4
X-1303	CRC	cetuximab + encorafenib	383.3	24.7	40	97.9	-4.3
X-1303	CRC	cetuximab + encorafenib	330.2	25.6	44	70.5	-0.8
X-1303	CRC	cetuximab + encorafenib	384.8	25.2	48	98.7	-2.3
X-1303	CRC	cetuximab + encorafenib	379.9	25.1	51	96.1	-2.7
X-1303	CRC	cetuximab + encorafenib	412.9	26	54	113.2	0.8
X-1303	CRC	cetuximab + encorafenib	445.1	26.4	57	129.8	2.3
X-1303	CRC	cetuximab + encorafenib	403.9	25.2	62	108.5	-2.3
X-1303	CRC	cetuximab + encorafenib	445.1	23.3	65	129.8	-9.7
X-1303	CRC	cetuximab + encorafenib	449	25.1	69	131.8	-2.7
X-1303	CRC	cetuximab + encorafenib	515	25.1	72	165.9	-2.7
X-1303	CRC	cetuximab + encorafenib	613.8	26.9	75	216.9	4.3
X-1303	CRC	LEE011	224	28.7	0	0	0
X-1303	CRC	LEE011	231.2	29	4	3.2	1
X-1303	CRC	LEE011	187	28.2	9	-16.5	-1.7
X-1303	CRC	LEE011	268.2	27.2	14	19.7	-5.2
X-1303	CRC	LEE011	213.1	27.7	18	-4.9	-3.5
X-1303	CRC	LEE011	252.5	27.2	22	12.7	-5.2
X-1303	CRC	LEE011	223	26.3	25	-0.4	-8.4
X-1303	CRC	LEE011	223	25.3	29	-0.4	-11.8
X-1303	CRC	LEE011	253.9	25.6	32	13.3	-10.8
X-1303	CRC	LEE011	261.9	25.6	35	16.9	-10.8
X-1303	CRC	LEE011	246.6	26.3	39	10.1	-8.4
X-1303	CRC	LEE011	261	27.1	45	16.5	-5.6
X-1303	CRC	LEE011	323.5	28	49	44.4	-2.4
X-1303	CRC	LEE011	408.3	28.3	53	82.3	-1.4
X-1303	CRC	LEE011	551.8	26.6	56	146.3	-7.3
X-1303	CRC	LEE011	541.1	26	60	141.6	-9.4
X-1303	CRC	LEE011	507.9	26.2	64	126.7	-8.7
X-1303	CRC	LEE011	465.6	26	67	107.9	-9.4
X-1303	CRC	LEE011	471.1	24.4	70	110.3	-15
X-1303	CRC	LEE011	479.3	24.4	73	114	-15
X-1303	CRC	LEE011	441.6	24.7	78	97.1	-13.9
X-1303	CRC	encorafenib	256.9	25.4	0	0	0
X-1303	CRC	encorafenib	330.8	24.3	3	28.8	-4.3
X-1303	CRC	encorafenib	558.8	24.7	9	117.5	-2.8
X-1303	CRC	encorafenib	489.4	24.5	11	90.5	-3.5
X-1303	CRC	encorafenib	596.4	25.7	14	132.2	1.2
X-1303	CRC	encorafenib	658.8	25	18	156.4	-1.6
X-1303	CRC	encorafenib	744.3	24.5	23	189.7	-3.5
X-1303	CRC	LJC049	186.4	29.2	0	0	0
X-1303	CRC	LJC049	231.3	29.4	2	24.1	0.7
X-1303	CRC	LJC049	199.7	28.7	4	7.1	-1.7
X-1303	CRC	LJC049	305	29.7	7	63.6	1.7
X-1303	CRC	LJC049	410.7	28.9	11	120.3	-1
X-1303	CRC	LJC049	442.1	31.5	16	137.2	7.9
X-1303	CRC	LJC049	675.2	30.8	21	262.2	5.5
X-1303	CRC	LJC049	654.3	29.6	24	251	1.4
X-1303	CRC	LKA136	235.4	22.8	0	0	0
X-1303	CRC	LKA136	419.6	23.7	2	78.2	3.9
X-1303	CRC	LKA136	455.6	25.5	4	93.5	11.8
X-1303	CRC	LKA136	556	25.7	7	136.2	12.7
X-1303	CRC	LKA136	814.3	25.9	11	245.9	13.6
X-1303	CRC	LKA136	1278.5	26	16	443.1	14
X-1303	CRC	LKA136	1466.7	24.8	21	523.1	8.8
X-1303	CRC	binimetinib	240.1	27.3	0	0	0
X-1303	CRC	binimetinib	204.2	27.6	3	-15	1.1
X-1303	CRC	binimetinib	320.4	26.6	9	33.4	-2.6
X-1303	CRC	binimetinib	285.1	27.1	11	18.7	-0.7
X-1303	CRC	binimetinib	259.4	27.5	14	8	0.7
X-1303	CRC	binimetinib	239.3	27	18	-0.3	-1.1
X-1303	CRC	binimetinib	294.1	26	23	22.5	-4.8
X-1303	CRC	binimetinib	269.2	26.2	28	12.1	-4
X-1303	CRC	binimetinib	247.2	25.7	32	3	-5.9
X-1303	CRC	binimetinib	237.2	25	36	-1.2	-8.4
X-1303	CRC	binimetinib	197.9	28.2	39	-17.6	3.3
X-1303	CRC	binimetinib	284.3	26.2	43	18.4	-4
X-1303	CRC	binimetinib	263.4	25.7	46	9.7	-5.9
X-1303	CRC	binimetinib	282.3	25.2	49	17.6	-7.7
X-1303	CRC	binimetinib	280.6	24.5	53	16.9	-10.3
X-1303	CRC	binimetinib	304.2	24.7	59	26.7	-9.5
X-1303	CRC	binimetinib	303.3	26.8	63	26.3	-1.8
X-1303	CRC	binimetinib	346.2	25.7	67	44.2	-5.9
X-1303	CRC	binimetinib	402.2	25.1	70	67.5	-8.1
X-1303	CRC	binimetinib	412.8	26	74	71.9	-4.8
X-1303	CRC	binimetinib	291.7	26.1	78	21.5	-4.4
X-1303	CRC	binimetinib	310.8	25.9	81	29.4	-5.1
X-1303	CRC	binimetinib	299.9	26.8	84	24.9	-1.8
X-1303	CRC	binimetinib	303.9	25.8	87	26.6	-5.5
X-1303	CRC	binimetinib	294	24.7	92	22.4	-9.5
X-1303	CRC	untreated	227.1	26.3	0	0	0
X-1303	CRC	untreated	242.8	25.2	3	6.9	-4.2
X-1303	CRC	untreated	813.7	24.1	9	258.3	-8.4
X-1303	CRC	untreated	929.4	24.4	11	309.2	-7.2
X-1303	CRC	untreated	1051.3	24	14	362.9	-8.7
X-1303	CRC	untreated	1051.3	26.9	18	362.9	2.3
X-1303	CRC	untreated	1228.7	27.4	23	441	4.2
X-1303	CRC	LFW527 + binimetinib	230.84	25.34	0	0	0
X-1303	CRC	LFW527 + binimetinib	238.23	23.81	4	3.2	-6
X-1303	CRC	LFW527 + binimetinib	261.51	23.85	10	13.3	-5.9
X-1303	CRC	LFW527 + binimetinib	243.79	23.72	13	5.6	-6.4
X-1303	CRC	LFW527 + binimetinib	216.83	24.28	17	-6.1	-4.2
X-1303	CRC	LFW527 + binimetinib	204.65	24.62	20	-11.3	-2.8
X-1303	CRC	LFW527 + binimetinib	155.91	24.12	24	-32.5	-4.8
X-1303	CRC	LFW527 + binimetinib	233.08	24.77	27	1	-2.2
X-1303	CRC	LFW527 + binimetinib	144.04	23.75	32	-37.6	-6.3
X-1303	CRC	LFW527 + binimetinib	279.18	24.49	35	20.9	-3.4
X-1303	CRC	LFW527 + binimetinib	255.19	24.28	39	10.5	-4.2
X-1303	CRC	LFW527 + binimetinib	275.26	23.97	42	19.2	-5.4
X-1303	CRC	LFW527 + binimetinib	288.17	25.74	45	24.8	1.6
X-1303	CRC	LFW527 + binimetinib	287.83	24.87	48	24.7	-1.9
X-1303	CRC	LFW527 + binimetinib	288.67	25.21	53	25.1	-0.5
X-1303	CRC	LFW527 + binimetinib	338.52	25.13	56	46.6	-0.8
X-1303	CRC	LFW527 + binimetinib	330.4	26.97	60	43.1	6.4
X-1303	CRC	LFW527 + binimetinib	318.34	24.31	63	37.9	-4.1
X-1303	CRC	LFW527 + binimetinib	396.11	24.88	67	71.6	-1.8
X-1303	CRC	LFW527 + binimetinib	488.71	25.28	70	111.7	-0.2
X-1303	CRC	LFW527 + binimetinib	469.6	25.06	75	103.4	-1.1
X-1303	CRC	LFW527 + binimetinib	508.38	24.74	81	120.2	-2.4
X-1303	CRC	LFW527 + binimetinib	644.58	25.61	84	179.2	1.1
X-1303	CRC	LFW527 + binimetinib	707.84	24.86	88	206.6	-1.9
X-1303	CRC	LFW527 + binimetinib	723.85	23.96	91	213.6	-5.4
X-1303	CRC	LFW527 + binimetinib	864.42	25.17	94	274.5	-0.7
X-1317	PDAC	BKM120 + binimetinib	310.3	28.5	0	0	0
X-1317	PDAC	BKM120 + binimetinib	361.6	27.4	4	16.5	-3.9
X-1317	PDAC	BKM120 + binimetinib	255.9	26.7	7	-17.5	-6.3
X-1317	PDAC	BKM120 + binimetinib	206.5	27.7	11	-33.5	-2.8
X-1317	PDAC	BKM120 + binimetinib	121.5	27.1	14	-60.8	-4.9
X-1317	PDAC	BKM120 + binimetinib	170.2	27.2	18	-45.1	-4.6
X-1317	PDAC	BKM120 + binimetinib	215.5	26	21	-30.6	-8.8
X-1317	PDAC	BKM120 + binimetinib	210.7	27.1	24	-32.1	-4.9
X-1317	PDAC	BKM120 + binimetinib	127.7	26.1	27	-58.8	-8.4
X-1317	PDAC	BKM120 + binimetinib	132.7	26.7	32	-57.2	-6.3
X-1317	PDAC	BKM120 + binimetinib	137.9	26	35	-55.6	-8.8
X-1317	PDAC	BKM120 + binimetinib	83.3	26.5	39	-73.2	-7
X-1317	PDAC	BKM120 + binimetinib	125.3	26.5	42	-59.6	-7
X-1317	PDAC	BKM120 + binimetinib	124.9	26.3	45	-59.7	-7.7
X-1317	PDAC	BKM120 + binimetinib	91.8	25.7	49	-70.4	-9.8
X-1317	PDAC	BKM120 + binimetinib	91.9	26	52	-70.4	-8.8
X-1317	PDAC	BKM120 + binimetinib	58.7	26.2	55	-81.1	-8.1
X-1317	PDAC	BKM120 + binimetinib	76.4	25.5	59	-75.4	-10.5
X-1317	PDAC	BKM120 + binimetinib	77.6	26.6	63	-75	-6.7
X-1317	PDAC	BKM120 + binimetinib	84.2	27.3	67	-72.9	-4.2
X-1317	PDAC	BKM120 + binimetinib	71.4	26.6	70	-77	-6.7
X-1317	PDAC	BKM120 + binimetinib	97.5	26.8	73	-68.6	-6
X-1317	PDAC	BKM120 + binimetinib	101.8	27	77	-67.2	-5.3
X-1317	PDAC	BKM120 + binimetinib	99	25.8	81	-68.1	-9.5
X-1317	PDAC	BKM120 + LDE225	297.6	26.7	0	0	0
X-1317	PDAC	BKM120 + LDE225	286	27.6	2	-3.9	3.4
X-1317	PDAC	BKM120 + LDE225	413.8	27.2	6	39	1.9
X-1317	PDAC	BKM120 + LDE225	360.4	26.7	9	21.1	0
X-1317	PDAC	BKM120 + LDE225	230.3	25.3	13	-22.6	-5.2
X-1317	PDAC	BKM120 + LDE225	283.7	25.9	16	-4.7	-3
X-1317	PDAC	BKM120 + LDE225	246.2	24.9	20	-17.3	-6.7
X-1317	PDAC	BKM120 + LDE225	161.8	25.9	23	-45.6	-3
X-1317	PDAC	BKM120 + LDE225	243.3	25.8	27	-18.2	-3.4
X-1317	PDAC	BKM120 + LDE225	272.6	25.9	30	-8.4	-3
X-1317	PDAC	BKM120 + LDE225	308.6	26	34	3.7	-2.6
X-1317	PDAC	BKM120 + LDE225	300.3	25.6	37	0.9	-4.1
X-1317	PDAC	BKM120 + LDE225	228.6	24.9	40	-23.2	-6.7
X-1317	PDAC	BKM120 + LDE225	211.6	24.2	43	-28.9	-9.4
X-1317	PDAC	BKM120 + LDE225	142.3	21.9	48	-52.2	-18
X-1317	PDAC	BKM120 + LDE225	136.1	23	51	-54.3	-13.9
X-1317	PDAC	BKM120 + LDE225	155.7	24.1	55	-47.7	-9.7
X-1317	PDAC	BKM120 + LDE225	252.9	24.7	58	-15	-7.5
X-1317	PDAC	BKM120 + LDE225	217.3	24.7	61	-27	-7.5
X-1317	PDAC	BKM120 + LDE225	157.2	24.9	65	-47.2	-6.7
X-1317	PDAC	BKM120 + LDE225	233.8	23.6	68	-21.4	-11.6
X-1317	PDAC	BKM120 + LDE225	185.2	23.5	71	-37.8	-12
X-1317	PDAC	BKM120 + LDE225	164.3	22.9	75	-44.8	-14.2
X-1317	PDAC	BKM120 + LDE225	189.8	19.7	79	-36.2	-26.2
X-1317	PDAC	figitumumab"	277.4	25.1	0	0	0
X-1317	PDAC	figitumumab"	388	25.9	2	39.9	3.2
X-1317	PDAC	figitumumab"	414.4	26	6	49.4	3.6
X-1317	PDAC	figitumumab"	419.2	25.5	9	51.1	1.6
X-1317	PDAC	figitumumab"	445	25.4	13	60.4	1.2
X-1317	PDAC	figitumumab"	564.4	25.7	16	103.5	2.4
X-1317	PDAC	figitumumab"	588.3	26.6	20	112.1	6
X-1317	PDAC	figitumumab"	661.2	25.8	22	138.4	2.8
X-1317	PDAC	figitumumab"	786.7	26.2	26	183.6	4.4
X-1317	PDAC	figitumumab"	858.1	26	29	209.3	3.6
X-1317	PDAC	figitumumab"	996.1	26.8	33	259.1	6.8
X-1317	PDAC	gemcitabine-50mpk	274.2	28.2	0	0	0
X-1317	PDAC	gemcitabine-50mpk	255.4	27.8	3	-6.9	-1.4
X-1317	PDAC	gemcitabine-50mpk	286.4	28.8	7	4.4	2.1
X-1317	PDAC	gemcitabine-50mpk	273.3	29.7	10	-0.3	5.3
X-1317	PDAC	gemcitabine-50mpk	405.3	30.8	14	47.8	9.2
X-1317	PDAC	gemcitabine-50mpk	502.4	29.9	17	83.2	6
X-1317	PDAC	gemcitabine-50mpk	622.3	28.8	20	127	2.1
X-1317	PDAC	INC424 + binimetinib	247.2	30.4	0	0	0
X-1317	PDAC	INC424 + binimetinib	303.9	30.8	1	22.9	1.3
X-1317	PDAC	INC424 + binimetinib	250.1	30.6	4	1.2	0.7
X-1317	PDAC	INC424 + binimetinib	238.1	30.5	8	-3.7	0.3
X-1317	PDAC	INC424 + binimetinib	340.4	31	11	37.7	2
X-1317	PDAC	INC424 + binimetinib	261.7	28.8	14	5.9	-5.3
X-1317	PDAC	INC424 + binimetinib	197.4	29.5	18	-20.1	-3
X-1317	PDAC	INC424 + binimetinib	207.6	30.1	22	-16	-1
X-1317	PDAC	INC424 + binimetinib	225.9	30.2	26	-8.6	-0.7
X-1317	PDAC	INC424 + binimetinib	229.2	30.5	29	-7.3	0.3
X-1317	PDAC	INC424 + binimetinib	265.7	30.7	32	7.5	1
X-1317	PDAC	INC424 + binimetinib	214.3	31.1	36	-13.3	2.3
X-1317	PDAC	INC424 + binimetinib	219.6	29.9	40	-11.2	-1.6
X-1317	PDAC	INC424 + binimetinib	197.1	30.3	43	-20.3	-0.3
X-1317	PDAC	INC424 + binimetinib	227.9	30.1	47	-7.8	-1
X-1317	PDAC	INC424 + binimetinib	262.4	30.2	53	6.1	-0.7
X-1317	PDAC	LEE011	318.5	26.2	0	0	0
X-1317	PDAC	LEE011	383.8	28.1	2	20.5	7.3
X-1317	PDAC	LEE011	562.6	28.1	6	76.6	7.3
X-1317	PDAC	LEE011	501.2	28.8	9	57.4	9.9
X-1317	PDAC	LEE011	530.7	27.6	13	66.6	5.3
X-1317	PDAC	LEE011	602.8	28.6	16	89.3	9.2
X-1317	PDAC	LEE011	662.3	28.3	20	107.9	8
X-1317	PDAC	LEE011	765.2	28.8	22	140.3	9.9
X-1317	PDAC	LEE011	839.3	28.8	26	163.5	9.9
X-1317	PDAC	LEE011	913.3	28.7	29	186.8	9.5
X-1317	PDAC	binimetinib	215.5	27.6	0	0	0
X-1317	PDAC	binimetinib	153.7	27.6	2	-28.7	0
X-1317	PDAC	binimetinib	227.9	27	6	5.8	-2.2
X-1317	PDAC	binimetinib	149.6	26.9	9	-30.6	-2.5
X-1317	PDAC	binimetinib	156.3	26.6	13	-27.5	-3.6
X-1317	PDAC	binimetinib	169	27	16	-21.6	-2.2
X-1317	PDAC	binimetinib	215.2	28.2	20	-0.1	2.2
X-1317	PDAC	binimetinib	117.7	26.6	23	-45.4	-3.6
X-1317	PDAC	binimetinib	116.5	27.3	27	-45.9	-1.1
X-1317	PDAC	binimetinib	159.6	26.4	30	-25.9	-4.3
X-1317	PDAC	binimetinib	167.9	26.4	34	-22.1	-4.3
X-1317	PDAC	binimetinib	173	24.6	37	-19.7	-10.9
X-1317	PDAC	binimetinib	205.5	26.1	40	-4.6	-5.4
X-1317	PDAC	binimetinib	195.6	25.5	43	-9.2	-7.6
X-1317	PDAC	binimetinib	151.8	25.7	48	-29.6	-6.9
X-1317	PDAC	binimetinib	158.5	25.4	51	-26.5	-8
X-1317	PDAC	binimetinib	115.2	24.7	55	-46.5	-10.5
X-1317	PDAC	binimetinib-3.5mpk	277.8	24.9	0	0	0
X-1317	PDAC	binimetinib-3.5mpk	231.6	24.3	6	-16.6	-2.4
X-1317	PDAC	binimetinib-3.5mpk	284.7	23.6	8	2.5	-5.2
X-1317	PDAC	binimetinib-3.5mpk	262.4	23.5	12	-5.5	-5.6
X-1317	PDAC	binimetinib-3.5mpk	182.4	24.2	19	-34.3	-2.8
X-1317	PDAC	binimetinib-3.5mpk	119.9	25.1	27	-56.8	0.8
X-1317	PDAC	binimetinib-3.5mpk	115	25.1	30	-58.6	0.8
X-1317	PDAC	binimetinib-3.5mpk	80.6	24.3	36	-71	-2.4
X-1317	PDAC	binimetinib-3.5mpk	60.1	24.9	42	-78.4	0
X-1317	PDAC	binimetinib-3.5mpk	37.4	25.5	44	-86.5	2.4
X-1317	PDAC	untreated	329.7	32.7	0	0	0
X-1317	PDAC	untreated	409.4	31.8	4	24.2	-2.8
X-1317	PDAC	untreated	543	31.3	8	64.7	-4.3
X-1317	PDAC	untreated	653.7	31.9	11	98.3	-2.4
X-1317	PDAC	untreated	1068.8	32.8	15	224.2	0.3
X-1317	PDAC	untreated	1175.9	32.3	18	256.7	-1.2
X-1323	NSCLC	BGJ398	243.7	23.9	0	0	0
X-1323	NSCLC	BGJ398	170.9	23	4	-29.9	-3.8
X-1323	NSCLC	BGJ398	215.3	24	7	-11.7	0.4
X-1323	NSCLC	BGJ398	214.5	24	11	-12	0.4
X-1323	NSCLC	BGJ398	354.8	24.5	14	45.6	2.5
X-1323	NSCLC	BGJ398	513.8	24.3	18	110.8	1.7
X-1323	NSCLC	BGJ398	721.5	24.1	21	196.1	0.8
X-1323	NSCLC	BGJ398	1012.2	24.9	25	315.3	4.2
X-1323	NSCLC	BGJ398	1302.1	25	26	434.3	4.6
X-1323	NSCLC	BKM120 + binimetinib	193.5	23.6	0	0	0
X-1323	NSCLC	BKM120 + binimetinib	154.8	24.4	3	-20	3.4
X-1323	NSCLC	BKM120 + binimetinib	127.1	24.3	7	-34.3	3
X-1323	NSCLC	BKM120 + binimetinib	160.2	24.7	10	-17.2	4.7
X-1323	NSCLC	BKM120 + binimetinib	140.6	24.4	14	-27.3	3.4
X-1323	NSCLC	BKM120 + binimetinib	140.9	24.8	17	-27.2	5.1
X-1323	NSCLC	BKM120 + binimetinib	143.6	24.8	21	-25.8	5.1
X-1323	NSCLC	BKM120 + binimetinib	146.5	25.4	24	-24.3	7.6
X-1323	NSCLC	BKM120 + binimetinib	127.7	24.8	29	-34	5.1
X-1323	NSCLC	BKM120 + binimetinib	124.9	24.9	31	-35.5	5.5
X-1323	NSCLC	BKM120 + binimetinib	238.5	24.8	35	23.3	5.1
X-1323	NSCLC	BKM120 + binimetinib	149.6	24.8	38	-22.7	5.1
X-1323	NSCLC	BKM120 + binimetinib	227.5	24.9	42	17.6	5.5
X-1323	NSCLC	BKM120 + binimetinib	221.6	25.3	46	14.5	7.2
X-1323	NSCLC	BKM120 + binimetinib	210.7	24.9	49	8.9	5.5
X-1323	NSCLC	BKM120 + binimetinib	217.9	25	53	12.6	5.9
X-1323	NSCLC	BKM120 + binimetinib	195.6	25.4	56	1.1	7.6
X-1323	NSCLC	BKM120 + binimetinib	212	25.4	59	9.6	7.6
X-1323	NSCLC	BKM120 + binimetinib	284.7	24.7	63	47.1	4.7
X-1323	NSCLC	BKM120 + binimetinib	202	25	66	4.4	5.9
X-1323	NSCLC	BKM120 + binimetinib	220.5	25	71	14	5.9
X-1323	NSCLC	BKM120 + binimetinib	236.9	24.5	74	22.4	3.8
X-1323	NSCLC	BKM120 + binimetinib	376.6	25.6	78	94.6	8.5
X-1323	NSCLC	BKM120 + binimetinib	349.8	25.3	81	80.8	7.2
X-1323	NSCLC	BKM120 + binimetinib	300.4	24.6	84	55.2	4.2
X-1323	NSCLC	BKM120 + binimetinib	349.5	25.8	87	80.6	9.3
X-1323	NSCLC	BKM120 + binimetinib	397	25.4	91	105.2	7.6
X-1323	NSCLC	BKM120 + binimetinib	426.2	25.3	94	120.3	7.2
X-1323	NSCLC	BKM120 + binimetinib	267.1	25.3	98	38	7.2
X-1323	NSCLC	BKM120 + binimetinib	516.6	25.8	101	167	9.3
X-1323	NSCLC	BKM120 + binimetinib	325.4	25	105	68.2	5.9
X-1323	NSCLC	BKM120 + binimetinib	389.5	24.8	112	101.3	5.1
X-1323	NSCLC	BKM120 + binimetinib	398.6	25	115	106	5.9
X-1323	NSCLC	BKM120 + binimetinib	359	24.8	119	85.5	5.1
X-1323	NSCLC	BKM120 + binimetinib	506.7	24.6	120	161.9	4.2
X-1323	NSCLC	BKM120	222.9	24.6	0	0	0
X-1323	NSCLC	BKM120	177.1	25.5	4	-20.5	3.7
X-1323	NSCLC	BKM120	135.8	26.4	7	-39.1	7.3
X-1323	NSCLC	BKM120	156.8	26.5	11	-29.7	7.7
X-1323	NSCLC	BKM120	173.9	27.1	14	-22	10.2
X-1323	NSCLC	BKM120	206.7	27.8	18	-7.3	13
X-1323	NSCLC	BKM120	226.2	27.5	21	1.5	11.8
X-1323	NSCLC	BKM120	242.3	26.8	25	8.7	8.9
X-1323	NSCLC	BKM120	255.5	26.7	28	14.6	8.5
X-1323	NSCLC	BKM120	273.9	27.7	33	22.9	12.6
X-1323	NSCLC	BKM120	355.4	27.7	35	59.4	12.6
X-1323	NSCLC	BKM120	279.5	27.5	39	25.4	11.8
X-1323	NSCLC	BKM120	301.5	28.5	42	35.3	15.9
X-1323	NSCLC	BKM120	317.9	28.1	46	42.6	14.2
X-1323	NSCLC	BKM120	241.9	28.8	50	8.5	17.1
X-1323	NSCLC	BKM120	319.8	28	53	43.5	13.8
X-1323	NSCLC	BKM120	283	28.7	57	27	16.7
X-1323	NSCLC	BKM120	363.2	29.1	60	62.9	18.3
X-1323	NSCLC	BKM120	316.6	28.7	63	42	16.7
X-1323	NSCLC	BKM120	282.8	28.9	67	26.9	17.5
X-1323	NSCLC	BKM120	292.9	28.8	70	31.4	17.1
X-1323	NSCLC	BKM120	410.1	29	75	84	17.9
X-1323	NSCLC	BYL719	218.2	27	0	0	0
X-1323	NSCLC	BYL719	135.8	26.3	4	-37.8	-2.6
X-1323	NSCLC	BYL719	188.7	27.2	7	-13.5	0.7
X-1323	NSCLC	BYL719	147.5	27.4	11	-32.4	1.5
X-1323	NSCLC	BYL719	203.9	27	14	-6.6	0
X-1323	NSCLC	BYL719	198.3	27.7	18	-9.1	2.6
X-1323	NSCLC	BYL719	225.7	26.9	21	3.4	-0.4
X-1323	NSCLC	BYL719	234.6	27.3	25	7.5	1.1
X-1323	NSCLC	BYL719	228.8	28	28	4.9	3.7
X-1323	NSCLC	BYL719	252.9	28.7	33	15.9	6.3
X-1323	NSCLC	BYL719	271.9	29	35	24.6	7.4
X-1323	NSCLC	BYL719	273.4	28.3	39	25.3	4.8
X-1323	NSCLC	BYL719	395.9	29.5	42	81.4	9.3
X-1323	NSCLC	BYL719	323.6	29.5	46	48.3	9.3
X-1323	NSCLC	BYL719	402.6	29.2	50	84.5	8.1
X-1323	NSCLC	BYL719	620.4	29.6	53	184.3	9.6
X-1323	NSCLC	BYL719	678.1	29.8	55	210.8	10.4
X-1323	NSCLC	BYL719 + LJM716	213.9	23.4	0	0	0
X-1323	NSCLC	BYL719 + LJM716	190.6	23	3	-10.9	-1.7
X-1323	NSCLC	BYL719 + LJM716	232.8	22.6	7	8.8	-3.4
X-1323	NSCLC	BYL719 + LJM716	282.9	23.4	10	32.3	0
X-1323	NSCLC	BYL719 + LJM716	351.5	23.8	14	64.3	1.7
X-1323	NSCLC	BYL719 + LJM716	418.8	23	17	95.8	-1.7
X-1323	NSCLC	BYL719 + LJM716	540.8	23.6	21	152.8	0.9
X-1323	NSCLC	BYL719 + LJM716	622.5	24	24	191	2.6
X-1323	NSCLC	BYL719 + LJM716	589.8	23.9	29	175.7	2.1
X-1323	NSCLC	BYL719 + LJM716	684.8	24.2	31	220.1	3.4
X-1323	NSCLC	BYL719 + LJM716	814.7	23.1	35	280.9	-1.3
X-1323	NSCLC	BYL719 + LJM716	1037.8	24	37	385.2	2.6
X-1323	NSCLC	BYL719 + LGH447	217.6	24.8	0	0	0
X-1323	NSCLC	BYL719 + LGH447	128.4	23.8	3	-41	-4
X-1323	NSCLC	BYL719 + LGH447	128	23.3	7	-41.2	-6
X-1323	NSCLC	BYL719 + LGH447	118.4	22.8	10	-45.6	-8.1
X-1323	NSCLC	BYL719 + LGH447	98.6	23.6	14	-54.7	-4.8
X-1323	NSCLC	BYL719 + LGH447	102.9	22.9	17	-52.7	-7.7
X-1323	NSCLC	BYL719 + LGH447	124.7	23.8	21	-42.7	-4
X-1323	NSCLC	BYL719 + LGH447	126.1	24	24	-42	-3.2
X-1323	NSCLC	BYL719 + LGH447	194.8	24	29	-10.5	-3.2
X-1323	NSCLC	BYL719 + LGH447	178.9	24.2	31	-17.8	-2.4
X-1323	NSCLC	BYL719 + LGH447	178.1	24.3	35	-18.2	-2
X-1323	NSCLC	BYL719 + LGH447	161.5	24.5	38	-25.8	-1.2
X-1323	NSCLC	BYL719 + LGH447	158.2	23.3	42	-27.3	-6
X-1323	NSCLC	BYL719 + LGH447	157	21.1	46	-27.8	-14.9
X-1323	NSCLC	BYL719 + LGH447	237.7	21.4	49	9.2	-13.7
X-1323	NSCLC	BYL719 + LGH447	248	23.8	53	14	-4
X-1323	NSCLC	BYL719 + LGH447	194.8	24.7	56	-10.5	-0.4
X-1323	NSCLC	BYL719 + LGH447	362.2	24.6	59	66.5	-0.8
X-1323	NSCLC	BYL719 + LGH447	322.1	26.8	63	48	8.1
X-1323	NSCLC	BYL719 + LGH447	443.6	27.3	66	103.9	10.1
X-1323	NSCLC	BYL719 + LGH447	547.8	26.8	71	151.7	8.1
X-1323	NSCLC	BYL719 + LGH447	629.4	27.7	74	189.2	11.7
X-1323	NSCLC	BYL719 + LGH447	599.8	27.7	78	175.6	11.7
X-1323	NSCLC	BYL719 + LGH447	694.6	27.6	81	219.2	11.3
X-1323	NSCLC	BYL719 + LGH447	896.9	27.4	84	312.2	10.5
X-1323	NSCLC	BYL719 + LGH447	850.6	27.5	85	290.9	10.9
X-1323	NSCLC	CGM097	191.1	27.8	0	0	0
X-1323	NSCLC	CGM097	166.1	29.6	4	-13.1	6.5
X-1323	NSCLC	CGM097	239.6	30.2	7	25.4	8.6
X-1323	NSCLC	CGM097	327.4	30.9	11	71.3	11.2
X-1323	NSCLC	CGM097	453.7	29.7	14	137.4	6.8
X-1323	NSCLC	CGM097	629.9	30.9	18	229.6	11.2
X-1323	NSCLC	CGM097	642.5	31.3	21	236.2	12.6
X-1323	NSCLC	CGM097	1127.6	31.8	25	490.1	14.4
X-1323	NSCLC	CGM097	1245	32.2	26	551.5	15.8
X-1323	NSCLC	CKX620	192.8	22.7	0	0	0
X-1323	NSCLC	CKX620	135.7	22.8	4	-29.6	0.4
X-1323	NSCLC	CKX620	166.1	23.2	7	-13.8	2.2
X-1323	NSCLC	CKX620	186.3	23.4	11	-3.4	3.1
X-1323	NSCLC	CKX620	230.3	23.5	14	19.5	3.5
X-1323	NSCLC	CKX620	248.7	23.7	18	29	4.4
X-1323	NSCLC	CKX620	338.8	23.4	21	75.7	3.1
X-1323	NSCLC	CKX620	249.1	23.8	25	29.2	4.8
X-1323	NSCLC	CKX620	144.6	24.4	28	-25	7.5
X-1323	NSCLC	CKX620	257.1	24.5	33	33.4	7.9
X-1323	NSCLC	CKX620	425.1	24.7	35	120.5	8.8
X-1323	NSCLC	CKX620	415.3	25.7	39	115.4	13.2
X-1323	NSCLC	CKX620	359.8	25	42	86.6	10.1
X-1323	NSCLC	CKX620	335	25.6	46	73.8	12.8
X-1323	NSCLC	CKX620	404.4	25.5	50	109.8	12.3
X-1323	NSCLC	CKX620	384.8	25.1	53	99.6	10.6
X-1323	NSCLC	CKX620	479.4	25.6	57	148.7	12.8
X-1323	NSCLC	CKX620	399.7	25.9	60	107.3	14.1
X-1323	NSCLC	CKX620	471.4	25.4	63	144.5	11.9
X-1323	NSCLC	CKX620	391.6	25.3	67	103.1	11.5
X-1323	NSCLC	CKX620	400.1	26.1	70	107.5	15
X-1323	NSCLC	CKX620	379.1	26	75	96.6	14.5
X-1323	NSCLC	CKX620	560.5	26.3	78	190.7	15.9
X-1323	NSCLC	CKX620	648.7	26.5	82	236.5	16.7
X-1323	NSCLC	CKX620	1186.3	27.2	85	515.3	19.8
X-1323	NSCLC	CKX620	1179.3	25.8	88	511.7	13.7
X-1323	NSCLC	CKX620	1368.6	NA	89	609.9	13.7
X-1323	NSCLC	CLR457	200.5	21.7	0	0	0
X-1323	NSCLC	CLR457	187.4	NA	2	-6.5	0
X-1323	NSCLC	CLR457	157.4	22.9	6	-21.5	5.5
X-1323	NSCLC	CLR457	163.9	23.4	9	-18.3	7.8
X-1323	NSCLC	CLR457	197.3	23.2	13	-1.6	6.9
X-1323	NSCLC	CLR457	237.8	22.9	16	18.6	5.5
X-1323	NSCLC	CLR457	194.1	23.3	20	-3.2	7.4
X-1323	NSCLC	CLR457	204.5	23	23	2	6
X-1323	NSCLC	CLR457	243.9	23.5	27	21.6	8.3
X-1323	NSCLC	CLR457	270.2	23.8	30	34.8	9.7
X-1323	NSCLC	CLR457	393.5	23.7	35	96.3	9.2
X-1323	NSCLC	CLR457	431.4	24	37	115.2	10.6
X-1323	NSCLC	CLR457	364.2	23.8	41	81.6	9.7
X-1323	NSCLC	CLR457	338.1	23	44	68.6	6
X-1323	NSCLC	CLR457	325	23.1	48	62.1	6.5
X-1323	NSCLC	CLR457	513.8	20.7	52	156.3	-4.6
X-1323	NSCLC	CLR457	614.3	21.2	55	206.4	-2.3
X-1323	NSCLC	CLR457	560.1	20.3	57	179.4	-6.5
X-1323	NSCLC	HDM201	239.5	25.7	0	0	0
X-1323	NSCLC	HDM201	281	24.4	2	17.3	-5.1
X-1323	NSCLC	HDM201	347.6	24.1	6	45.1	-6.2
X-1323	NSCLC	HDM201	458.6	25.2	9	91.5	-1.9
X-1323	NSCLC	HDM201	593.9	25.4	13	148	-1.2
X-1323	NSCLC	HDM201	633.8	25.9	16	164.6	0.8
X-1323	NSCLC	HDM201	770.9	25.5	20	221.9	-0.8
X-1323	NSCLC	HDM201	812.7	26	22	239.3	1.2
X-1323	NSCLC	cetuximab	267.1	24.1	0	0	0
X-1323	NSCLC	cetuximab	245.8	24.2	3	-8	0.4
X-1323	NSCLC	cetuximab	259.4	24.3	7	-2.9	0.8
X-1323	NSCLC	cetuximab	319.3	24.3	10	19.5	0.8
X-1323	NSCLC	cetuximab	394.8	24.4	14	47.8	1.2
X-1323	NSCLC	cetuximab	649.5	25.5	17	143.2	5.8
X-1323	NSCLC	cetuximab	970.2	26.5	21	263.2	10
X-1323	NSCLC	cetuximab	894.2	26.3	22	234.8	9.1
X-1323	NSCLC	erlotinib	191.1	24.1	0	0	0
X-1323	NSCLC	erlotinib	155.6	23.8	4	-18.6	-1.2
X-1323	NSCLC	erlotinib	155	23.5	7	-18.9	-2.5
X-1323	NSCLC	erlotinib	229.9	23.4	11	20.3	-2.9
X-1323	NSCLC	erlotinib	257.7	22.8	14	34.9	-5.4
X-1323	NSCLC	erlotinib	300.5	25.9	18	57.2	7.5
X-1323	NSCLC	erlotinib	435.1	23.6	21	127.7	-2.1
X-1323	NSCLC	erlotinib	448.4	24.6	25	134.6	2.1
X-1323	NSCLC	erlotinib	673.9	24.4	28	252.6	1.2
X-1323	NSCLC	erlotinib	670	24.4	33	250.6	1.2
X-1323	NSCLC	erlotinib	887.6	23.3	35	364.5	-3.3
X-1323	NSCLC	erlotinib	1040.4	25	39	444.4	3.7
X-1323	NSCLC	erlotinib	1275.3	24	41	567.3	-0.4
X-1323	NSCLC	HSP990	295.1	25.8	0	0	0
X-1323	NSCLC	HSP990	266.8	21.1	2	-9.6	-18.2
X-1323	NSCLC	HSP990	250.8	20.2	3	-15	-21.7
X-1323	NSCLC	INC280	185	21.4	0	0	0
X-1323	NSCLC	INC280	158.2	21.1	2	-14.5	-1.4
X-1323	NSCLC	INC280	258.3	21.9	6	39.6	2.3
X-1323	NSCLC	INC280	306.2	22.4	9	65.5	4.7
X-1323	NSCLC	INC280	590.5	22.6	13	219.2	5.6
X-1323	NSCLC	INC280	902	22.9	16	387.6	7
X-1323	NSCLC	INC280	1008.2	23.5	20	445	9.8
X-1323	NSCLC	INC280	1190.2	23.7	22	543.4	10.7
X-1323	NSCLC	LCL161 + paclitaxel	213.9	22.3	0	0	0
X-1323	NSCLC	LCL161 + paclitaxel	145.8	22.3	2	-31.8	0
X-1323	NSCLC	LCL161 + paclitaxel	130.7	23.8	6	-38.9	6.7
X-1323	NSCLC	LCL161 + paclitaxel	159	22.7	9	-25.7	1.8
X-1323	NSCLC	LCL161 + paclitaxel	151.7	25	13	-29.1	12.1
X-1323	NSCLC	LCL161 + paclitaxel	221.7	24.2	16	3.6	8.5
X-1323	NSCLC	LCL161 + paclitaxel	192.9	25.7	20	-9.8	15.2
X-1323	NSCLC	LCL161 + paclitaxel	253.8	24.4	23	18.7	9.4
X-1323	NSCLC	LCL161 + paclitaxel	314.3	25.8	28	46.9	15.7
X-1323	NSCLC	LCL161 + paclitaxel	359.4	25.4	34	68	13.9
X-1323	NSCLC	LCL161 + paclitaxel	272.4	25.2	41	27.3	13
X-1323	NSCLC	LCL161 + paclitaxel	433.2	26.6	45	102.5	19.3
X-1323	NSCLC	LCL161 + paclitaxel	426.1	25	48	99.2	12.1
X-1323	NSCLC	LCL161 + paclitaxel	622	27	52	190.8	21.1
X-1323	NSCLC	LCL161 + paclitaxel	952.8	26.2	55	345.4	17.5
X-1323	NSCLC	LCL161 + paclitaxel	945.9	26.8	56	342.2	20.2
X-1323	NSCLC	LEE011	210.5	26.4	0	0	0
X-1323	NSCLC	LEE011	186.8	26.8	4	-11.3	1.5
X-1323	NSCLC	LEE011	217.6	27.1	7	3.4	2.7
X-1323	NSCLC	LEE011	299.1	27.5	11	42.1	4.2
X-1323	NSCLC	LEE011	315.4	28	14	49.8	6.1
X-1323	NSCLC	LEE011	289	28.7	18	37.3	8.7
X-1323	NSCLC	LEE011	335.3	29.6	21	59.3	12.1
X-1323	NSCLC	LEE011	339.4	29.9	25	61.2	13.3
X-1323	NSCLC	LEE011	358	29.6	28	70.1	12.1
X-1323	NSCLC	LEE011	329	29.4	33	56.3	11.4
X-1323	NSCLC	LEE011	338.6	29.3	35	60.9	11
X-1323	NSCLC	LEE011	399.1	29.9	39	89.6	13.3
X-1323	NSCLC	LEE011	371.8	30.6	42	76.6	15.9
X-1323	NSCLC	LEE011	405.1	29.4	46	92.4	11.4
X-1323	NSCLC	LEE011	745.2	30.1	50	254	14
X-1323	NSCLC	LEE011	730.8	30.1	53	247.2	14
X-1323	NSCLC	LEE011	763.4	30.1	55	262.7	14
X-1323	NSCLC	LGH447	161.1	26.9	0	0	0
X-1323	NSCLC	LGH447	207.9	25.3	4	29.1	-5.9
X-1323	NSCLC	LGH447	281.4	26.2	7	74.7	-2.6
X-1323	NSCLC	LGH447	337.3	26.1	11	109.4	-3
X-1323	NSCLC	LGH447	374.6	26	14	132.5	-3.3
X-1323	NSCLC	LGH447	311.2	26.4	18	93.2	-1.9
X-1323	NSCLC	LGH447	539.1	26.7	21	234.6	-0.7
X-1323	NSCLC	LGH447	385.2	27.2	25	139.1	1.1
X-1323	NSCLC	LGH447	384.4	27.7	28	138.6	3
X-1323	NSCLC	LGH447	401.4	28.2	33	149.2	4.8
X-1323	NSCLC	LGH447	592.4	28.3	35	267.7	5.2
X-1323	NSCLC	LGH447	702.6	29.1	39	336.1	8.2
X-1323	NSCLC	LGH447	1463.1	28.3	41	808.2	5.2
X-1323	NSCLC	LLM871	186.6	22.5	0	0	0
X-1323	NSCLC	LLM871	175.1	22.6	3	-6.2	0.4
X-1323	NSCLC	LLM871	146.5	23.4	7	-21.5	4
X-1323	NSCLC	LLM871	294.1	23.3	10	57.6	3.6
X-1323	NSCLC	LLM871	254	23.2	14	36.1	3.1
X-1323	NSCLC	LLM871	438.6	22.9	17	135	1.8
X-1323	NSCLC	LLM871	740.7	23.7	21	296.9	5.3
X-1323	NSCLC	LLM871	890.6	23.7	22	377.3	5.3
X-1323	NSCLC	binimetinib	197.3	25.7	0	0	0
X-1323	NSCLC	binimetinib	150.9	25.3	2	-23.5	-1.6
X-1323	NSCLC	binimetinib	119.8	25.4	6	-39.3	-1.2
X-1323	NSCLC	binimetinib	122.8	25.5	9	-37.8	-0.8
X-1323	NSCLC	binimetinib	97.3	25.9	13	-50.7	0.8
X-1323	NSCLC	binimetinib	177.9	25.4	16	-9.8	-1.2
X-1323	NSCLC	binimetinib	160.5	26.3	20	-18.7	2.3
X-1323	NSCLC	binimetinib	232.6	26.5	23	17.9	3.1
X-1323	NSCLC	binimetinib	291.4	27.3	27	47.7	6.2
X-1323	NSCLC	binimetinib	240.1	28.2	30	21.7	9.7
X-1323	NSCLC	binimetinib	301.3	27.8	35	52.7	8.2
X-1323	NSCLC	binimetinib	277.7	27.7	37	40.8	7.8
X-1323	NSCLC	binimetinib	340.8	27.2	41	72.7	5.8
X-1323	NSCLC	binimetinib	441.6	26.7	44	123.8	3.9
X-1323	NSCLC	binimetinib	363.7	26.8	48	84.3	4.3
X-1323	NSCLC	binimetinib	601.7	27.9	52	205	8.6
X-1323	NSCLC	binimetinib	575	27.8	55	191.4	8.2
X-1323	NSCLC	binimetinib	534.1	28.3	59	170.7	10.1
X-1323	NSCLC	binimetinib	537.8	28.4	62	172.6	10.5
X-1323	NSCLC	binimetinib	614.1	28.7	65	211.3	11.7
X-1323	NSCLC	binimetinib	744.5	28.4	69	277.3	10.5
X-1323	NSCLC	binimetinib	832.5	27.7	70	321.9	7.8
X-1323	NSCLC	paclitaxel	262.5	24.1	0	0	0
X-1323	NSCLC	paclitaxel	258.7	23.7	2	-1.4	-1.7
X-1323	NSCLC	paclitaxel	275.3	23.6	6	4.9	-2.1
X-1323	NSCLC	paclitaxel	604.1	24	9	130.1	-0.4
X-1323	NSCLC	paclitaxel	905.1	25	13	244.8	3.7
X-1323	NSCLC	paclitaxel	969.2	24.6	15	269.2	2.1
X-1323	NSCLC	untreated	221.8	22.7	0	0	0
X-1323	NSCLC	untreated	210.6	23.3	2	-5	2.6
X-1323	NSCLC	untreated	458.9	24.1	6	106.9	6.2
X-1323	NSCLC	untreated	512.4	24.5	9	131	7.9
X-1323	NSCLC	untreated	758	24.6	13	241.7	8.4
X-1323	NSCLC	untreated	852.7	24.7	16	284.4	8.8
X-1323	NSCLC	untreated	1081.9	25.6	20	387.8	12.8
X-1323	NSCLC	untreated	1195	25	22	438.8	10.1
X-1323	NSCLC	LFW527 + binimetinib	255.75	28.1	0	0	0
X-1323	NSCLC	LFW527 + binimetinib	216.21	27.5	8	-15.5	-2.1
X-1323	NSCLC	LFW527 + binimetinib	198.71	27	11	-22.3	-3.9
X-1323	NSCLC	LFW527 + binimetinib	318.61	27.2	15	24.6	-3.2
X-1323	NSCLC	LFW527 + binimetinib	339.04	28.8	22	32.6	2.5
X-1323	NSCLC	LFW527 + binimetinib	435.33	27.6	29	70.2	-1.8
X-1323	NSCLC	LFW527 + binimetinib	544.49	28.3	36	112.9	0.7
X-1323	NSCLC	LFW527 + binimetinib	582.69	28	43	127.8	-0.4
X-1323	NSCLC	LFW527 + binimetinib	737.26	28.6	51	188.3	1.8
X-1323	NSCLC	LFW527 + binimetinib	696.91	28.1	57	172.5	0
X-1323	NSCLC	LFW527 + binimetinib	831.27	29.6	60	225	5.3
X-1323	NSCLC	LFW527 + binimetinib	806.7	29.7	64	215.4	5.7
X-1323	NSCLC	LFW527 + binimetinib	1115.14	28.9	65	336	2.8
X-1329	CRC	5FU	219.4	21.2	0	0	0
X-1329	CRC	5FU	253.2	21.7	5	15.4	2.4
X-1329	CRC	5FU	238.7	20.8	8	8.8	-1.9
X-1329	CRC	5FU	303.2	20.8	15	38.2	-1.9
X-1329	CRC	5FU	372.7	19.4	19	69.9	-8.5
X-1329	CRC	5FU	429.3	20.3	23	95.7	-4.2
X-1329	CRC	5FU	464.5	21.8	26	111.7	2.8
X-1329	CRC	5FU	520.6	21.9	29	137.3	3.3
X-1329	CRC	5FU	682.2	21.3	33	210.9	0.5
X-1329	CRC	5FU	708	20.3	36	222.7	-4.2
X-1329	CRC	5FU	1005.4	21.6	41	358.2	1.9
X-1329	CRC	5FU	1252.4	21.3	47	470.8	0.5
X-1329	CRC	5FU	1280.5	21.3	50	483.6	0.5
X-1329	CRC	5FU	1570.7	22.4	54	615.9	5.7
X-1329	CRC	BKM120	212.8	21.2	0	0	0
X-1329	CRC	BKM120	280	19.9	5	31.6	-6.1
X-1329	CRC	BKM120	314	19.2	8	47.6	-9.4
X-1329	CRC	BKM120	422.5	17.3	15	98.5	-18.4
X-1329	CRC	BKM120	445.4	17.3	19	109.3	-18.4
X-1329	CRC	BKM120	689	20	23	223.8	-5.7
X-1329	CRC	BKM120	820.7	19.7	26	285.7	-7.1
X-1329	CRC	BKM120	835.6	17.9	29	292.7	-15.6
X-1329	CRC	BKM120 + LJC049	222.7	25.8	0	0	0
X-1329	CRC	BKM120 + LJC049	323.8	26.2	3	45.4	1.6
X-1329	CRC	BKM120 + LJC049	566.6	25.3	10	154.4	-1.9
X-1329	CRC	BKM120 + LJC049	868.3	24	14	289.9	-7
X-1329	CRC	BKM120 + LJC049	1051.8	22.8	18	372.3	-11.6
X-1329	CRC	BKM120 + LJC049	1383	22.2	21	521	-14
X-1329	CRC	BYL719 + cetuximab + encorafenib	222.6	23.1	0	0	0
X-1329	CRC	BYL719 + cetuximab + encorafenib	285.6	24	3	28.3	3.9
X-1329	CRC	BYL719 + cetuximab + encorafenib	337.7	23.2	6	51.7	0.4
X-1329	CRC	BYL719 + cetuximab + encorafenib	376.1	22.9	9	69	-0.9
X-1329	CRC	BYL719 + cetuximab + encorafenib	463.1	24.2	13	108	4.8
X-1329	CRC	BYL719 + cetuximab + encorafenib	468.1	23.1	16	110.3	0
X-1329	CRC	BYL719 + cetuximab + encorafenib	443.9	23.8	20	99.4	3
X-1329	CRC	BYL719 + cetuximab + encorafenib	380.1	22	22	70.8	-4.8
X-1329	CRC	BYL719 + cetuximab + encorafenib	433	22.9	26	94.5	-0.9
X-1329	CRC	BYL719 + cetuximab + encorafenib	473	23.2	30	112.5	0.4
X-1329	CRC	BYL719 + cetuximab + encorafenib	592.4	24.5	33	166.1	6.1
X-1329	CRC	BYL719 + cetuximab + encorafenib	537.9	24.2	36	141.6	4.8
X-1329	CRC	BYL719 + cetuximab + encorafenib	450.9	23.6	41	102.6	2.2
X-1329	CRC	BYL719 + cetuximab + encorafenib	407.4	24.2	44	83	4.8
X-1329	CRC	BYL719 + cetuximab + encorafenib	455.2	23.7	47	104.5	2.6
X-1329	CRC	BYL719 + cetuximab + encorafenib	541.1	23.2	50	143.1	0.4
X-1329	CRC	BYL719 + cetuximab + encorafenib	673.9	23.5	54	202.7	1.7
X-1329	CRC	BYL719 + cetuximab	251	22.5	0	0	0
X-1329	CRC	BYL719 + cetuximab	288.5	22.5	3	14.9	0
X-1329	CRC	BYL719 + cetuximab	413.9	24.4	7	64.9	8.4
X-1329	CRC	BYL719 + cetuximab	533.6	23.1	10	112.6	2.7
X-1329	CRC	BYL719 + cetuximab	560.7	22.3	14	123.4	-0.9
X-1329	CRC	BYL719 + cetuximab	579.1	22.7	16	130.7	0.9
X-1329	CRC	BYL719 + cetuximab	716	23.3	20	185.3	3.6
X-1329	CRC	BYL719 + cetuximab	933.8	22.6	24	272	0.4
X-1329	CRC	BYL719 + cetuximab	1114.3	24.2	27	343.9	7.6
X-1329	CRC	BYL719 + cetuximab	1146.7	23.3	28	356.9	3.6
X-1329	CRC	BYL719	204.2	23.7	0	0	0
X-1329	CRC	BYL719	265.8	22.8	3	30.2	-3.8
X-1329	CRC	BYL719	302.9	21.4	6	48.3	-9.7
X-1329	CRC	BYL719	419.3	19.5	13	105.3	-17.7
X-1329	CRC	BYL719 + LJM716	206.8	23.4	0	0	0
X-1329	CRC	BYL719 + LJM716	228.2	21.6	3	10.3	-7.7
X-1329	CRC	BYL719 + LJM716	209	21.6	6	1.1	-7.7
X-1329	CRC	BYL719 + LJM716	326.2	21.6	13	57.7	-7.7
X-1329	CRC	BYL719 + LJM716	406.2	21.8	17	96.4	-6.8
X-1329	CRC	BYL719 + LJM716	382.8	21.9	21	85.1	-6.4
X-1329	CRC	BYL719 + LJM716	578.6	22.5	24	179.8	-3.8
X-1329	CRC	BYL719 + LJM716	597.9	22.3	27	189.1	-4.7
X-1329	CRC	BYL719 + LJM716	614.3	21.1	31	197.1	-9.8
X-1329	CRC	BYL719 + LJM716	645.5	20.9	34	212.1	-10.7
X-1329	CRC	BYL719 + LJM716	1016.4	21.1	39	391.5	-9.8
X-1329	CRC	BYL719 + LJM716	1328.4	21.7	45	542.4	-7.3
X-1329	CRC	BYL719 + binimetinib	226.8	24.8	0	0	0
X-1329	CRC	BYL719 + binimetinib	231.8	23.4	3	2.2	-5.6
X-1329	CRC	BYL719 + binimetinib	170.2	23.3	10	-25	-6
X-1329	CRC	BYL719 + binimetinib	144.2	23.6	14	-36.4	-4.8
X-1329	CRC	BYL719 + binimetinib	130.7	23.9	18	-42.4	-3.6
X-1329	CRC	BYL719 + binimetinib	138.8	23.8	21	-38.8	-4
X-1329	CRC	BYL719 + binimetinib	162.7	24.6	24	-28.3	-0.8
X-1329	CRC	BYL719 + binimetinib	167.7	24.4	28	-26.1	-1.6
X-1329	CRC	BYL719 + binimetinib	122.9	24.8	31	-45.8	0
X-1329	CRC	BYL719 + binimetinib	114.8	24.4	36	-49.4	-1.6
X-1329	CRC	BYL719 + binimetinib	95.4	24.9	42	-57.9	0.4
X-1329	CRC	BYL719 + binimetinib	101.1	23.9	45	-55.4	-3.6
X-1329	CRC	BYL719 + binimetinib	110.6	24.9	49	-51.2	0.4
X-1329	CRC	BYL719 + binimetinib	132.8	24.7	52	-41.4	-0.4
X-1329	CRC	BYL719 + binimetinib	132.8	24.7	56	-41.4	-0.4
X-1329	CRC	BYL719 + binimetinib	103	25	59	-54.6	0.8
X-1329	CRC	BYL719 + binimetinib	125	25.5	63	-44.9	2.8
X-1329	CRC	BYL719 + binimetinib	118.5	25.1	67	-47.8	1.2
X-1329	CRC	BYL719 + binimetinib	145.4	25.6	70	-35.9	3.2
X-1329	CRC	BYL719 + binimetinib	146.3	24.3	73	-35.5	-2
X-1329	CRC	BYL719 + binimetinib	144.9	25.6	78	-36.1	3.2
X-1329	CRC	BYL719 + binimetinib	198.2	25	81	-12.6	0.8
X-1329	CRC	BYL719 + binimetinib	176.3	25.4	84	-22.3	2.4
X-1329	CRC	BYL719 + binimetinib	242.4	25.5	87	6.9	2.8
X-1329	CRC	BYL719 + binimetinib	236.4	26.1	92	4.2	5.2
X-1329	CRC	BYL719 + encorafenib	249.7	24.6	0	0	0
X-1329	CRC	BYL719 + encorafenib	233.7	22.5	3	-6.4	-8.5
X-1329	CRC	BYL719 + encorafenib	231.4	21.1	10	-7.3	-14.2
X-1329	CRC	BYL719 + encorafenib	280.5	20.8	14	12.3	-15.4
X-1329	CRC	BYL719 + encorafenib	323	21.5	18	29.4	-12.6
X-1329	CRC	BYL719 + encorafenib	321.3	22	21	28.7	-10.6
X-1329	CRC	BYL719 + encorafenib	286.2	22.6	24	14.6	-8.1
X-1329	CRC	BYL719 + encorafenib	262.1	22.6	28	5	-8.1
X-1329	CRC	BYL719 + encorafenib	220.3	24.8	31	-11.8	0.8
X-1329	CRC	BYL719 + encorafenib	215.9	24.2	36	-13.5	-1.6
X-1329	CRC	BYL719 + encorafenib	234.5	23.4	42	-6.1	-4.9
X-1329	CRC	BYL719 + encorafenib	267.7	22.6	45	7.2	-8.1
X-1329	CRC	BYL719 + encorafenib	343.6	23.8	49	37.6	-3.3
X-1329	CRC	BYL719 + encorafenib	362.5	22.6	52	45.2	-8.1
X-1329	CRC	BYL719 + encorafenib	450	21.9	56	80.2	-11
X-1329	CRC	BYL719 + encorafenib	563.9	22	59	125.8	-10.6
X-1329	CRC	BYL719 + encorafenib	628.8	22.1	63	151.8	-10.2
X-1329	CRC	BYL719 + encorafenib	740.3	22.6	67	196.5	-8.1
X-1329	CRC	BYL719 + encorafenib	832.3	22	70	233.3	-10.6
X-1329	CRC	BYL719 + encorafenib	1011.6	24.8	73	305.1	0.8
X-1329	CRC	BYL719 + encorafenib	1359.8	23.9	78	444.6	-2.8
X-1329	CRC	BYL719 + encorafenib	1534.6	22.6	81	514.6	-8.1
X-1329	CRC	CGM097	285.6	21.5	0	0	0
X-1329	CRC	CGM097	372.9	20.1	5	30.6	-6.5
X-1329	CRC	CGM097	487	20.2	8	70.5	-6
X-1329	CRC	CGM097	763.4	20.8	15	167.3	-3.3
X-1329	CRC	CGM097	890.2	20.1	19	211.7	-6.5
X-1329	CRC	CGM097	1055.3	20.7	23	269.5	-3.7
X-1329	CRC	CGM097	1243.3	21	26	335.3	-2.3
X-1329	CRC	CGM097	1417.7	21.5	29	396.4	0
X-1329	CRC	CKX620	252.1	19.8	0	0	0
X-1329	CRC	CKX620	227.5	22.2	5	-9.8	12.1
X-1329	CRC	CKX620	232.3	21.9	8	-7.9	10.6
X-1329	CRC	CKX620	249.8	23.3	15	-0.9	17.7
X-1329	CRC	CKX620	244.9	23.2	19	-2.9	17.2
X-1329	CRC	CKX620	253.4	23.8	23	0.5	20.2
X-1329	CRC	CKX620	272.1	22.9	26	7.9	15.7
X-1329	CRC	CKX620	273.9	24.1	29	8.6	21.7
X-1329	CRC	CKX620	305.7	23.9	33	21.3	20.7
X-1329	CRC	CKX620	313.6	24.3	36	24.4	22.7
X-1329	CRC	CKX620	321.9	24.2	41	27.7	22.2
X-1329	CRC	CKX620	408.9	25.2	47	62.2	27.3
X-1329	CRC	CKX620	441.2	24.5	50	75	23.7
X-1329	CRC	CKX620	462.8	24.8	54	83.6	25.3
X-1329	CRC	CKX620	514.5	25.3	57	104.1	27.8
X-1329	CRC	CKX620	525.9	25.1	61	108.6	26.8
X-1329	CRC	CKX620	567.2	24.6	64	125	24.2
X-1329	CRC	CKX620	662.7	25.6	68	162.9	29.3
X-1329	CRC	CKX620	664.2	25.3	72	163.5	27.8
X-1329	CRC	CKX620	746.4	26	75	196.1	31.3
X-1329	CRC	CKX620	759.7	24.7	78	201.3	24.7
X-1329	CRC	CKX620	791.3	24.1	83	213.9	21.7
X-1329	CRC	CKX620	788.1	24.3	86	212.6	22.7
X-1329	CRC	CKX620	910.7	25.6	92	261.2	29.3
X-1329	CRC	CLR457	265	20	0	0	0
X-1329	CRC	CLR457	407.9	19.9	3	53.9	-0.5
X-1329	CRC	CLR457	457.5	19.7	6	72.6	-1.5
X-1329	CRC	CLR457	639.6	18.9	13	141.4	-5.5
X-1329	CRC	CLR457	876.3	19.3	17	230.7	-3.5
X-1329	CRC	CLR457	1161	20.2	21	338.1	1
X-1329	CRC	CLR457	1355.8	19.8	24	411.6	-1
X-1329	CRC	HDM201	220	23.1	0	0	0
X-1329	CRC	HDM201	362.4	23.2	5	64.7	0.4
X-1329	CRC	HDM201	393	22	8	78.6	-4.8
X-1329	CRC	HDM201	560	23.4	15	154.5	1.3
X-1329	CRC	HDM201	617.3	20.7	19	180.6	-10.4
X-1329	CRC	HDM201	912.9	22.4	23	315	-3
X-1329	CRC	HDM201	849.5	22.1	26	286.1	-4.3
X-1329	CRC	HDM201	964.2	21.7	29	338.3	-6.1
X-1329	CRC	cetuximab	237.4	22.9	0	0	0
X-1329	CRC	cetuximab	404.1	24	5	70.2	4.8
X-1329	CRC	cetuximab	533.5	24.8	8	124.7	8.3
X-1329	CRC	cetuximab	619.6	24.8	11	161	8.3
X-1329	CRC	cetuximab	807.6	24.9	14	240.2	8.7
X-1329	CRC	cetuximab	987.6	25.6	18	316	11.8
X-1329	CRC	cetuximab	1250.9	26.4	21	426.9	15.3
X-1329	CRC	cetuximab	1495.3	27	25	529.9	17.9
X-1329	CRC	cetuximab + encorafenib	257	23.9	0	0	0
X-1329	CRC	cetuximab + encorafenib	347.9	23.2	5	35.4	-2.9
X-1329	CRC	cetuximab + encorafenib	501	22.2	8	94.9	-7.1
X-1329	CRC	cetuximab + encorafenib	593.4	22.6	11	130.9	-5.4
X-1329	CRC	cetuximab + encorafenib	567.1	22.7	14	120.7	-5
X-1329	CRC	cetuximab + encorafenib	644.6	25.6	18	150.8	7.1
X-1329	CRC	cetuximab + encorafenib	861.7	24.9	21	235.3	4.2
X-1329	CRC	cetuximab + encorafenib	822	24.1	25	219.8	0.8
X-1329	CRC	cetuximab + encorafenib	881.4	23.9	27	243	0
X-1329	CRC	cetuximab + encorafenib	793.1	23.6	31	208.6	-1.3
X-1329	CRC	cetuximab + encorafenib	773	23.3	35	200.8	-2.5
X-1329	CRC	cetuximab + encorafenib	780.2	24.2	38	203.6	1.3
X-1329	CRC	cetuximab + encorafenib	827.4	24.8	41	221.9	3.8
X-1329	CRC	cetuximab + encorafenib	918.4	23.8	46	257.4	-0.4
X-1329	CRC	cetuximab + encorafenib	972	23.3	49	278.2	-2.5
X-1329	CRC	LEE011	271.7	25.3	0	0	0
X-1329	CRC	LEE011	389.7	24.2	5	43.4	-4.3
X-1329	CRC	LEE011	381.2	23.6	8	40.3	-6.7
X-1329	CRC	LEE011	506.1	23.3	15	86.3	-7.9
X-1329	CRC	LEE011	550.8	23.5	19	102.7	-7.1
X-1329	CRC	LEE011	832.2	22.6	23	206.3	-10.7
X-1329	CRC	LEE011	1047.9	24.3	26	285.7	-4
X-1329	CRC	LEE011	1434.7	24.1	29	428	-4.7
X-1329	CRC	encorafenib	315.2	21.9	0	0	0
X-1329	CRC	encorafenib	315	21.7	5	-0.1	-0.9
X-1329	CRC	encorafenib	303.9	21.5	8	-3.6	-1.8
X-1329	CRC	encorafenib	443.8	21.3	15	40.8	-2.7
X-1329	CRC	encorafenib	470.9	22.1	19	49.4	0.9
X-1329	CRC	encorafenib	512.5	23.1	23	62.6	5.5
X-1329	CRC	encorafenib	376.9	23.7	26	19.6	8.2
X-1329	CRC	encorafenib	356.9	23.4	29	13.2	6.8
X-1329	CRC	encorafenib	327.7	22.9	33	4	4.6
X-1329	CRC	encorafenib	449.4	23.5	41	42.6	7.3
X-1329	CRC	encorafenib	721.7	23.2	47	129	5.9
X-1329	CRC	encorafenib	779.8	22.4	50	147.4	2.3
X-1329	CRC	encorafenib	802.5	22.8	54	154.6	4.1
X-1329	CRC	encorafenib	1064.5	22.5	57	237.7	2.7
X-1329	CRC	encorafenib	1633.9	21.8	61	418.4	-0.5
X-1329	CRC	LJC049	247.7	24.9	0	0	0
X-1329	CRC	LJC049	343.6	24.6	5	38.7	-1.2
X-1329	CRC	LJC049	592.3	24.8	8	139.1	-0.4
X-1329	CRC	LJC049	1336.2	23.3	15	439.4	-6.4
X-1329	CRC	LJC049	1854.9	22.9	19	648.8	-8
X-1329	CRC	LKA136	217.7	21.6	0	0	0
X-1329	CRC	LKA136	279.9	21.4	5	28.6	-0.9
X-1329	CRC	LKA136	352.8	20.9	8	62.1	-3.2
X-1329	CRC	LKA136	742.2	22.3	15	240.9	3.2
X-1329	CRC	LKA136	1034	22.6	19	375	4.6
X-1329	CRC	LKA136	1276	21.8	23	486.1	0.9
X-1329	CRC	LKA136	1612.8	21.9	26	640.8	1.4
X-1329	CRC	binimetinib	219.7	23	0	0	0
X-1329	CRC	binimetinib	265.3	23.1	5	20.8	0.4
X-1329	CRC	binimetinib	278.6	23.8	8	26.8	3.5
X-1329	CRC	binimetinib	318.8	22.6	15	45.1	-1.7
X-1329	CRC	binimetinib	379.9	22.6	19	72.9	-1.7
X-1329	CRC	binimetinib	456.6	23.7	23	107.8	3
X-1329	CRC	binimetinib	587.7	23	26	167.5	0
X-1329	CRC	binimetinib	541.1	23.9	29	146.3	3.9
X-1329	CRC	binimetinib	495.6	24.4	33	125.6	6.1
X-1329	CRC	binimetinib	639.4	24	36	191	4.3
X-1329	CRC	binimetinib	727	23.9	41	230.9	3.9
X-1329	CRC	binimetinib	798.2	25.1	47	263.3	9.1
X-1329	CRC	binimetinib	789.2	23.8	50	259.2	3.5
X-1329	CRC	binimetinib	855.7	25.6	54	289.5	11.3
X-1329	CRC	binimetinib	830	25	57	277.8	8.7
X-1329	CRC	binimetinib	887.8	24.7	61	304.1	7.4
X-1329	CRC	binimetinib	948.4	24.9	64	331.7	8.3
X-1329	CRC	binimetinib	910.7	25.5	68	314.5	10.9
X-1329	CRC	binimetinib	1137	26.7	72	417.5	16.1
X-1329	CRC	binimetinib	1505.5	26.3	75	585.3	14.3
X-1329	CRC	untreated	221.8	30.2	0	0	0
X-1329	CRC	untreated	315.5	30.5	5	42.2	1
X-1329	CRC	untreated	441.4	30.3	8	99	0.3
X-1329	CRC	untreated	578.8	30.2	15	161	0
X-1329	CRC	untreated	887.1	31	19	300	2.6
X-1329	CRC	untreated	1006.4	31.2	23	353.7	3.3
X-1329	CRC	untreated	1230.8	32	26	454.9	6
X-1329	CRC	untreated	1541.1	31.3	29	594.8	3.6
X-1329	CRC	LFW527 + binimetinib	200.6	22.73	0	0	0
X-1329	CRC	LFW527 + binimetinib	201.35	21.31	3	0.4	-6.2
X-1329	CRC	LFW527 + binimetinib	223.03	21.96	6	11.2	-3.4
X-1329	CRC	LFW527 + binimetinib	236.03	22.1	10	17.7	-2.8
X-1329	CRC	LFW527 + binimetinib	242.1	20.88	13	20.7	-8.1
X-1329	CRC	LFW527 + binimetinib	230.02	21.68	17	14.7	-4.6
X-1329	CRC	LFW527 + binimetinib	237.39	22.26	20	18.3	-2.1
X-1329	CRC	LFW527 + binimetinib	265.84	23.1	24	32.5	1.6
X-1329	CRC	LFW527 + binimetinib	284.28	24.61	27	41.7	8.3
X-1329	CRC	LFW527 + binimetinib	338.7	24	31	68.8	5.6
X-1329	CRC	LFW527 + binimetinib	368.28	22.29	34	83.6	-1.9
X-1329	CRC	LFW527 + binimetinib	409.68	22.24	38	104.2	-2.2
X-1329	CRC	LFW527 + binimetinib	425.38	22.8	41	112.1	0.3
X-1329	CRC	LFW527 + binimetinib	472.84	23.42	45	135.7	3
X-1349	BRCA	LFW527 + everolimus	388.58	27.9	0	0	0
X-1349	BRCA	LFW527 + everolimus	1563.52	26.2	5	302.4	-6.1
X-1362	PDAC	abraxane	215	23.9	0	0	0
X-1362	PDAC	abraxane	267.7	24.8	4	24.5	3.8
X-1362	PDAC	abraxane	306.2	24.6	7	42.4	2.9
X-1362	PDAC	abraxane	319.3	25.3	11	48.5	5.9
X-1362	PDAC	abraxane	344.9	24.8	14	60.4	3.8
X-1362	PDAC	abraxane	379.3	25.4	18	76.4	6.3
X-1362	PDAC	abraxane	467	24.8	21	117.2	3.8
X-1362	PDAC	abraxane	422.5	26.4	25	96.5	10.5
X-1362	PDAC	abraxane	473.4	24.8	28	120.2	3.8
X-1362	PDAC	abraxane	602.8	25.7	32	180.4	7.5
X-1362	PDAC	abraxane	607.5	25.8	35	182.6	7.9
X-1362	PDAC	abraxane	693	26.1	39	222.3	9.2
X-1362	PDAC	abraxane	797	26.3	43	270.7	10
X-1362	PDAC	abraxane	882.2	26.4	46	310.3	10.5
X-1362	PDAC	abraxane	903.7	26.6	49	320.3	11.3
X-1362	PDAC	BKM120 + binimetinib	209	27	0	0	0
X-1362	PDAC	BKM120 + binimetinib	197.8	26.7	4	-5.4	-1.1
X-1362	PDAC	BKM120 + binimetinib	141.7	27.5	6	-32.2	1.9
X-1362	PDAC	BKM120 + binimetinib	233.6	27.4	11	11.8	1.5
X-1362	PDAC	BKM120 + binimetinib	260	26.8	14	24.4	-0.7
X-1362	PDAC	BKM120 + binimetinib	165.9	26.3	19	-20.6	-2.6
X-1362	PDAC	BKM120 + binimetinib	201.9	26.3	21	-3.4	-2.6
X-1362	PDAC	BKM120 + binimetinib	149.2	27.1	26	-28.6	0.4
X-1362	PDAC	BKM120 + binimetinib	284.7	26.4	29	36.2	-2.2
X-1362	PDAC	BKM120 + binimetinib	172.3	26.9	32	-17.6	-0.4
X-1362	PDAC	BKM120 + binimetinib	299.9	26.6	36	43.5	-1.5
X-1362	PDAC	BKM120 + binimetinib	326.8	25.8	41	56.4	-4.4
X-1362	PDAC	BKM120 + binimetinib	353.7	25.6	43	69.2	-5.2
X-1362	PDAC	BKM120 + binimetinib	363.7	25.6	46	74	-5.2
X-1362	PDAC	BKM120 + binimetinib	235.9	26.4	48	12.9	-2.2
X-1362	PDAC	BKM120 + binimetinib	237.3	26.9	50	13.5	-0.4
X-1362	PDAC	BKM120 + binimetinib	266.7	27.1	54	27.6	0.4
X-1362	PDAC	BKM120 + binimetinib	343.3	26	56	64.3	-3.7
X-1362	PDAC	BKM120 + binimetinib	430	24.7	61	105.7	-8.5
X-1362	PDAC	BKM120 + binimetinib	417.9	25.4	64	100	-5.9
X-1362	PDAC	BKM120 + binimetinib	385.2	25.1	68	84.3	-7
X-1362	PDAC	BKM120 + binimetinib	432.8	24.9	71	107.1	-7.8
X-1362	PDAC	BKM120 + binimetinib	389.7	25.2	75	86.5	-6.7
X-1362	PDAC	BKM120 + binimetinib	483.2	25.1	78	131.2	-7
X-1362	PDAC	BKM120 + binimetinib	373.7	25.2	82	78.8	-6.7
X-1362	PDAC	BKM120 + binimetinib	461.9	24.7	85	121	-8.5
X-1362	PDAC	BKM120 + binimetinib	464.3	25.3	89	122.2	-6.3
X-1362	PDAC	BKM120 + binimetinib	495.6	25.5	92	137.1	-5.6
X-1362	PDAC	BKM120 + binimetinib	382.4	25.1	96	83	-7
X-1362	PDAC	BKM120 + binimetinib	584.5	24.8	103	179.7	-8.1
X-1362	PDAC	BKM120 + binimetinib	339.1	25	106	62.2	-7.4
X-1362	PDAC	BKM120 + binimetinib	519.8	24.4	110	148.7	-9.6
X-1362	PDAC	BKM120 + binimetinib	405	23	116	93.8	-14.8
X-1362	PDAC	BKM120 + LDE225	313.5	26.9	0	0	0
X-1362	PDAC	BKM120 + LDE225	298.4	25.9	1	-4.8	-3.7
X-1362	PDAC	BKM120 + LDE225	222	26.3	4	-29.2	-2.2
X-1362	PDAC	BKM120 + LDE225	216.4	26	8	-31	-3.3
X-1362	PDAC	BKM120 + LDE225	243.3	27	11	-22.4	0.4
X-1362	PDAC	BKM120 + LDE225	219.3	25.8	14	-30	-4.1
X-1362	PDAC	BKM120 + LDE225	237.8	25.7	18	-24.1	-4.5
X-1362	PDAC	BKM120 + LDE225	243.1	26.1	22	-22.5	-3
X-1362	PDAC	BKM120 + LDE225	236.8	26.2	26	-24.5	-2.6
X-1362	PDAC	BKM120 + LDE225	230	24.8	29	-26.6	-7.8
X-1362	PDAC	BKM120 + LDE225	228.4	25.9	32	-27.1	-3.7
X-1362	PDAC	BKM120 + LDE225	190.8	26.1	36	-39.1	-3
X-1362	PDAC	BKM120 + LDE225	227.5	23.9	40	-27.4	-11.2
X-1362	PDAC	BKM120	214.5	24.7	0	0	0
X-1362	PDAC	BKM120	307.4	23.8	4	43.3	-3.6
X-1362	PDAC	BKM120	259.8	23.4	7	21.1	-5.3
X-1362	PDAC	BKM120	310.3	23.8	11	44.7	-3.6
X-1362	PDAC	BKM120	379.5	23.1	14	76.9	-6.5
X-1362	PDAC	BKM120	438.8	23.4	18	104.6	-5.3
X-1362	PDAC	BKM120	441.9	22.7	20	106	-8.1
X-1362	PDAC	BKM120	408.7	23.1	25	90.5	-6.5
X-1362	PDAC	BKM120	565.2	22.9	28	163.5	-7.3
X-1362	PDAC	BYL719 + LJM716	212.4	31.8	0	0	0
X-1362	PDAC	BYL719 + LJM716	340.6	NA	3	60.4	0
X-1362	PDAC	BYL719 + LJM716	391.9	31.4	6	84.5	-1.3
X-1362	PDAC	BYL719 + LJM716	427.3	30.7	9	101.2	-3.5
X-1362	PDAC	BYL719 + LJM716	467.9	30.7	13	120.3	-3.5
X-1362	PDAC	BYL719 + LJM716	536.1	30.9	16	152.4	-2.8
X-1362	PDAC	BYL719 + LJM716	670.1	30.4	20	215.5	-4.4
X-1362	PDAC	BYL719 + LJM716	711.8	30.8	23	235.1	-3.1
X-1362	PDAC	BYL719 + LJM716	795.1	30.1	27	274.3	-5.3
X-1362	PDAC	BYL719 + LJM716	929	31.2	30	337.4	-1.9
X-1362	PDAC	BYL719 + LJM716	1112.9	28.6	34	424	-10.1
X-1362	PDAC	BYL719	207	26.8	0	0	0
X-1362	PDAC	BYL719	208.7	26.4	3	0.8	-1.5
X-1362	PDAC	BYL719	232.9	26.2	6	12.5	-2.2
X-1362	PDAC	BYL719	247.3	26.1	9	19.5	-2.6
X-1362	PDAC	BYL719	303.2	25.4	13	46.5	-5.2
X-1362	PDAC	BYL719	326.8	24.6	16	57.9	-8.2
X-1362	PDAC	BYL719	398	24.1	20	92.3	-10.1
X-1362	PDAC	BYL719	422.7	23.7	23	104.2	-11.6
X-1362	PDAC	BYL719	440.7	22.8	27	112.9	-14.9
X-1362	PDAC	BYL719	424.9	22.6	28	105.3	-15.7
X-1362	PDAC	BYL719	411.1	21.7	29	98.6	-19
X-1362	PDAC	CLR457	216.7	28.1	0	0	0
X-1362	PDAC	CLR457	232.7	NA	3	7.4	0
X-1362	PDAC	CLR457	295	27.8	6	36.1	-1.1
X-1362	PDAC	CLR457	345.6	29.4	10	59.5	4.6
X-1362	PDAC	CLR457	369.1	29.1	13	70.3	3.6
X-1362	PDAC	CLR457	438.9	28.8	16	102.5	2.5
X-1362	PDAC	CLR457	496.9	27.9	20	129.3	-0.7
X-1362	PDAC	CLR457	528.7	27.8	23	144	-1.1
X-1362	PDAC	CLR457	585.3	27.9	27	170.1	-0.7
X-1362	PDAC	CLR457	605.3	28	30	179.3	-0.4
X-1362	PDAC	CLR457	627.7	27.5	34	189.7	-2.1
X-1362	PDAC	HDM201	209.1	25.7	0	0	0
X-1362	PDAC	HDM201	236.5	23.8	4	13.1	-7.4
X-1362	PDAC	HDM201	276.2	24.6	7	32.1	-4.3
X-1362	PDAC	HDM201	338.2	24.5	11	61.7	-4.7
X-1362	PDAC	HDM201	379.7	23.6	14	81.6	-8.2
X-1362	PDAC	HDM201	481.1	22.9	18	130.1	-10.9
X-1362	PDAC	HDM201	599.6	21.6	21	186.8	-16
X-1362	PDAC	HDM201	616.3	20.3	22	194.7	-21
X-1362	PDAC	figitumumab" + binimetinib	221.8	27.9	0	0	0
X-1362	PDAC	figitumumab" + binimetinib	163.6	28.5	3	-26.2	2.2
X-1362	PDAC	figitumumab" + binimetinib	218.6	28	6	-1.4	0.4
X-1362	PDAC	figitumumab" + binimetinib	288.2	27.8	10	29.9	-0.4
X-1362	PDAC	figitumumab" + binimetinib	291.2	28.9	12	31.3	3.6
X-1362	PDAC	figitumumab" + binimetinib	245.4	28.6	17	10.6	2.5
X-1362	PDAC	figitumumab" + binimetinib	182.7	28.7	20	-17.6	2.9
X-1362	PDAC	figitumumab" + binimetinib	285.2	28.8	24	28.6	3.2
X-1362	PDAC	figitumumab" + binimetinib	243.1	28.1	27	9.6	0.7
X-1362	PDAC	figitumumab" + binimetinib	338.7	28.9	31	52.7	3.6
X-1362	PDAC	figitumumab" + binimetinib	256.1	27.4	34	15.5	-1.8
X-1362	PDAC	figitumumab" + binimetinib	417	27.7	39	88	-0.7
X-1362	PDAC	figitumumab" + binimetinib	408.7	28.5	42	84.3	2.2
X-1362	PDAC	figitumumab" + binimetinib	428.2	28.6	47	93.1	2.5
X-1362	PDAC	figitumumab" + binimetinib	429.2	28.3	49	93.5	1.4
X-1362	PDAC	figitumumab" + binimetinib	471.6	29.4	52	112.6	5.4
X-1362	PDAC	figitumumab" + binimetinib	488.2	27.4	55	120.1	-1.8
X-1362	PDAC	figitumumab" + binimetinib	442.9	27.7	60	99.7	-0.7
X-1362	PDAC	figitumumab" + binimetinib	663.3	27.7	63	199.1	-0.7
X-1362	PDAC	figitumumab"	222.8	26.6	0	0	0
X-1362	PDAC	figitumumab"	210.5	24.9	5	-5.5	-6.4
X-1362	PDAC	figitumumab"	303.6	25.1	11	36.3	-5.6
X-1362	PDAC	figitumumab"	329.7	25	14	48	-6
X-1362	PDAC	figitumumab"	335	26.6	18	50.4	0
X-1362	PDAC	figitumumab"	392.1	26.7	21	76	0.4
X-1362	PDAC	figitumumab"	416.7	25.3	25	87	-4.9
X-1362	PDAC	figitumumab"	366.3	24.9	28	64.4	-6.4
X-1362	PDAC	figitumumab"	357.2	27.2	32	60.3	2.3
X-1362	PDAC	figitumumab"	356.5	25.9	35	60	-2.6
X-1362	PDAC	figitumumab"	408.2	26.6	39	83.2	0
X-1362	PDAC	figitumumab"	405.1	25.7	42	81.8	-3.4
X-1362	PDAC	figitumumab"	459.8	26.6	46	106.4	0
X-1362	PDAC	figitumumab"	525.3	26.1	50	135.8	-1.9
X-1362	PDAC	figitumumab"	639.1	26	53	186.8	-2.3
X-1362	PDAC	figitumumab"	678.2	26.2	56	204.4	-1.5
X-1362	PDAC	figitumumab"	764.1	25.5	61	243	-4.1
X-1362	PDAC	figitumumab"	778	26.5	64	249.2	-0.4
X-1362	PDAC	figitumumab"	796.9	26.3	67	257.7	-1.1
X-1362	PDAC	figitumumab"	743	26	70	233.5	-2.3
X-1362	PDAC	figitumumab"	787.9	26.8	74	253.6	0.8
X-1362	PDAC	figitumumab"	810.8	26.3	77	263.9	-1.1
X-1362	PDAC	figitumumab"	819.1	26.5	81	267.6	-0.4
X-1362	PDAC	figitumumab"	853.2	26.3	84	282.9	-1.1
X-1362	PDAC	figitumumab"	1133.6	26.6	88	408.8	0
X-1362	PDAC	gemcitabine-50mpk	218.5	25.3	0	0	0
X-1362	PDAC	gemcitabine-50mpk	249.1	25.3	3	14	0
X-1362	PDAC	gemcitabine-50mpk	294.3	24.8	7	34.7	-2
X-1362	PDAC	gemcitabine-50mpk	346.3	24.6	10	58.5	-2.8
X-1362	PDAC	gemcitabine-50mpk	405	24.5	14	85.4	-3.2
X-1362	PDAC	gemcitabine-50mpk	394.8	23.8	17	80.7	-5.9
X-1362	PDAC	gemcitabine-50mpk	323.2	23.7	20	47.9	-6.3
X-1362	PDAC	gemcitabine-50mpk	402.1	NA	24	84	-6.3
X-1362	PDAC	gemcitabine-50mpk	388.7	23.5	28	77.9	-7.1
X-1362	PDAC	gemcitabine-50mpk	460	23.5	31	110.5	-7.1
X-1362	PDAC	gemcitabine-50mpk	573.1	23.6	35	162.3	-6.7
X-1362	PDAC	gemcitabine-50mpk	495.4	22.7	37	126.7	-10.3
X-1362	PDAC	INC424 + binimetinib	219.4	28.9	0	0	0
X-1362	PDAC	INC424 + binimetinib	192.3	28.6	1	-12.4	-1
X-1362	PDAC	INC424 + binimetinib	240.9	28.5	6	9.8	-1.4
X-1362	PDAC	INC424 + binimetinib	272.7	28.4	8	24.3	-1.7
X-1362	PDAC	INC424 + binimetinib	178.7	28.8	13	-18.6	-0.3
X-1362	PDAC	INC424 + binimetinib	265.5	28.6	16	21	-1
X-1362	PDAC	INC424 + binimetinib	263.1	29	19	19.9	0.3
X-1362	PDAC	INC424 + binimetinib	225.8	28	23	2.9	-3.1
X-1362	PDAC	INC424 + binimetinib	257.3	27.7	28	17.3	-4.2
X-1362	PDAC	INC424 + binimetinib	249.1	27.5	30	13.5	-4.8
X-1362	PDAC	INC424 + binimetinib	219.9	27.8	33	0.2	-3.8
X-1362	PDAC	INC424 + binimetinib	263.4	28.4	35	20.1	-1.7
X-1362	PDAC	INC424 + binimetinib	218.4	27.7	37	-0.5	-4.2
X-1362	PDAC	INC424 + binimetinib	255.8	27.2	41	16.6	-5.9
X-1362	PDAC	INC424 + binimetinib	281	27.7	43	28.1	-4.2
X-1362	PDAC	INC424 + binimetinib	308.8	27.4	51	40.7	-5.2
X-1362	PDAC	INC424 + binimetinib	336.2	27.5	55	53.2	-4.8
X-1362	PDAC	INC424 + binimetinib	419.9	26.7	58	91.4	-7.6
X-1362	PDAC	INC424 + binimetinib	490.2	27.7	62	123.4	-4.2
X-1362	PDAC	INC424 + binimetinib	505.3	27.4	65	130.3	-5.2
X-1362	PDAC	INC424 + binimetinib	435.9	27.6	69	98.7	-4.5
X-1362	PDAC	INC424 + binimetinib	571.7	27.9	72	160.6	-3.5
X-1362	PDAC	INC424 + binimetinib	630.1	28.3	76	187.2	-2.1
X-1362	PDAC	INC424 + binimetinib	707.4	27.8	79	222.4	-3.8
X-1362	PDAC	INC424 + binimetinib	550.2	27.9	83	150.8	-3.5
X-1362	PDAC	INC424 + binimetinib	563.7	27.5	86	156.9	-4.8
X-1362	PDAC	INC424 + binimetinib	677.3	28	90	208.7	-3.1
X-1362	PDAC	INC424 + binimetinib	640.5	28	93	191.9	-3.1
X-1362	PDAC	INC424 + binimetinib	716	28.2	97	226.3	-2.4
X-1362	PDAC	INC424 + binimetinib	1134.7	27.5	104	417.2	-4.8
X-1362	PDAC	INC424 + binimetinib	891.4	27.8	107	306.3	-3.8
X-1362	PDAC	INC424 + binimetinib	780.1	28.2	111	255.6	-2.4
X-1362	PDAC	INC424 + binimetinib	855.8	28.4	114	290.1	-1.7
X-1362	PDAC	INC424	214.2	23.7	0	0	0
X-1362	PDAC	INC424	221	24.9	4	3.2	5.1
X-1362	PDAC	INC424	233.1	24.7	7	8.8	4.2
X-1362	PDAC	INC424	293.8	23.7	11	37.2	0
X-1362	PDAC	INC424	319.7	25	14	49.3	5.5
X-1362	PDAC	INC424	358.4	25	18	67.3	5.5
X-1362	PDAC	INC424	423.8	25.3	21	97.9	6.8
X-1362	PDAC	INC424	433.7	25.2	24	102.5	6.3
X-1362	PDAC	INC424	464.6	24.6	27	116.9	3.8
X-1362	PDAC	INC424	568.7	25.7	32	165.5	8.4
X-1362	PDAC	INC424	587.3	25.8	35	174.2	8.9
X-1362	PDAC	INC424	668.4	25.3	39	212	6.8
X-1362	PDAC	INC424	745.9	25	42	248.2	5.5
X-1362	PDAC	INC424	873.9	26.9	45	308	13.5
X-1362	PDAC	LEE011	205.1	23.1	0	0	0
X-1362	PDAC	LEE011	209.1	25.3	3	2	9.5
X-1362	PDAC	LEE011	232.9	25	7	13.6	8.2
X-1362	PDAC	LEE011	206.1	24.9	10	0.5	7.8
X-1362	PDAC	LEE011	213.4	25.1	14	4	8.7
X-1362	PDAC	LEE011	265.8	25.4	17	29.6	10
X-1362	PDAC	LEE011	300.7	26.2	21	46.6	13.4
X-1362	PDAC	LEE011	312.2	24.9	24	52.2	7.8
X-1362	PDAC	LEE011	327.3	26.9	28	59.6	16.5
X-1362	PDAC	LEE011	418.8	25.8	31	104.2	11.7
X-1362	PDAC	LEE011	340.8	26.2	35	66.2	13.4
X-1362	PDAC	LEE011	336.2	25.5	38	63.9	10.4
X-1362	PDAC	LEE011	440.4	26.9	42	114.7	16.5
X-1362	PDAC	LEE011	373.4	25.9	45	82.1	12.1
X-1362	PDAC	LEE011	440	26.9	52	114.5	16.5
X-1362	PDAC	LEE011	536.6	27.9	56	161.6	20.8
X-1362	PDAC	LEE011	610.5	26	60	197.7	12.6
X-1362	PDAC	LEE011	638.6	26.3	63	211.4	13.9
X-1362	PDAC	LEE011	644	26.2	66	214	13.4
X-1362	PDAC	LEE011	526.8	25.5	71	156.9	10.4
X-1362	PDAC	LEE011	542	26.1	74	164.3	13
X-1362	PDAC	LEE011	618.8	26.3	77	201.7	13.9
X-1362	PDAC	LEE011	685.8	25.9	80	234.4	12.1
X-1362	PDAC	LEE011	704.3	26.3	84	243.4	13.9
X-1362	PDAC	LEE011	689.9	24.7	87	236.4	6.9
X-1362	PDAC	LEE011	687.5	26.3	91	235.2	13.9
X-1362	PDAC	LEE011	735.8	25.1	94	258.8	8.7
X-1362	PDAC	LEE011	726.4	26.6	98	254.2	15.2
X-1362	PDAC	WNT974	295.5	24.5	0	0	0
X-1362	PDAC	WNT974	280.8	23.9	2	-5	-2.4
X-1362	PDAC	WNT974	381.2	23.7	6	29	-3.3
X-1362	PDAC	WNT974	448.4	22.8	9	51.7	-6.9
X-1362	PDAC	WNT974	547.2	23.8	13	85.2	-2.9
X-1362	PDAC	WNT974	733.4	22.9	16	148.2	-6.5
X-1362	PDAC	WNT974	907.4	22.9	20	207.1	-6.5
X-1362	PDAC	WNT974	907.1	24.5	23	207	0
X-1362	PDAC	WNT974	1105.7	22.7	26	274.2	-7.3
X-1362	PDAC	LKA136	218.9	26.3	0	0	0
X-1362	PDAC	LKA136	248	26.7	3	13.3	1.5
X-1362	PDAC	LKA136	309.1	27	5	41.2	2.7
X-1362	PDAC	LKA136	375.6	27.6	10	71.6	4.9
X-1362	PDAC	LKA136	519.1	27.2	14	137.1	3.4
X-1362	PDAC	LKA136	540.4	26.9	17	146.9	2.3
X-1362	PDAC	LKA136	547.1	NA	19	149.9	2.3
X-1362	PDAC	LKA136	590.2	27.6	21	169.6	4.9
X-1362	PDAC	LKA136	716.8	27.5	25	227.5	4.6
X-1362	PDAC	LKA136	735	26.7	26	235.8	1.5
X-1362	PDAC	binimetinib	242	25.3	0	0	0
X-1362	PDAC	binimetinib	269.2	25.6	1	11.2	1.2
X-1362	PDAC	binimetinib	309	25.2	6	27.7	-0.4
X-1362	PDAC	binimetinib	310.2	25.4	9	28.2	0.4
X-1362	PDAC	binimetinib	256.6	24.6	14	6	-2.8
X-1362	PDAC	binimetinib	256	24.1	16	5.8	-4.7
X-1362	PDAC	binimetinib	310.6	23	21	28.3	-9.1
X-1362	PDAC	binimetinib	268.9	22.5	24	11.1	-11.1
X-1362	PDAC	binimetinib	346	22.7	27	43	-10.3
X-1362	PDAC	binimetinib	337.3	22	31	39.4	-13
X-1362	PDAC	binimetinib-3.5mpk	239.8	25.9	0	0	0
X-1362	PDAC	binimetinib-3.5mpk	285.4	25.9	4	19	0
X-1362	PDAC	binimetinib-3.5mpk	203.8	26.3	6	-15	1.5
X-1362	PDAC	binimetinib-3.5mpk	217.4	27.6	11	-9.3	6.6
X-1362	PDAC	binimetinib-3.5mpk	241.5	26.9	14	0.7	3.9
X-1362	PDAC	binimetinib-3.5mpk	270.5	27.1	18	12.8	4.6
X-1362	PDAC	binimetinib-3.5mpk	231.6	26.5	21	-3.4	2.3
X-1362	PDAC	binimetinib-3.5mpk	335.3	26.8	25	39.8	3.5
X-1362	PDAC	binimetinib-3.5mpk	297.3	23.8	28	24	-8.1
X-1362	PDAC	binimetinib-3.5mpk	325.9	25.8	33	35.9	-0.4
X-1362	PDAC	binimetinib-3.5mpk	461.9	26.3	36	92.6	1.5
X-1362	PDAC	binimetinib-3.5mpk	358.4	26.1	41	49.5	0.8
X-1362	PDAC	binimetinib-3.5mpk	389	25.7	43	62.2	-0.8
X-1362	PDAC	binimetinib-3.5mpk	480	26.6	46	100.2	2.7
X-1362	PDAC	binimetinib-3.5mpk	434.3	26	49	81.1	0.4
X-1362	PDAC	binimetinib-3.5mpk	796.5	25.9	54	232.2	0
X-1362	PDAC	trametinib	191.2	29.1	0	0	0
X-1362	PDAC	trametinib	138.4	30.2	3	-27.6	3.8
X-1362	PDAC	trametinib	123.9	28.8	7	-35.2	-1
X-1362	PDAC	trametinib	65.8	28.4	10	-65.6	-2.4
X-1362	PDAC	trametinib	79.7	27.2	14	-58.3	-6.5
X-1362	PDAC	trametinib	85.6	25.6	17	-55.2	-12
X-1362	PDAC	trametinib	80.5	27.8	23	-57.9	-4.5
X-1362	PDAC	untreated	274.9	26.6	0	0	0
X-1362	PDAC	untreated	263.4	26.1	1	-4.2	-1.9
X-1362	PDAC	untreated	356.4	26.3	5	29.6	-1.1
X-1362	PDAC	untreated	431.3	26.8	7	56.9	0.8
X-1362	PDAC	untreated	493.5	28	15	79.5	5.3
X-1362	PDAC	untreated	533.2	29.5	18	94	10.9
X-1362	PDAC	untreated	596	27.7	22	116.8	4.1
X-1371	BRCA	BGJ398	222.6	26.9	0	0	0
X-1371	BRCA	BGJ398	281.4	27	4	26.4	0.4
X-1371	BRCA	BGJ398	395	27.9	7	77.4	3.7
X-1371	BRCA	BGJ398	432.2	27.2	11	94.2	1.1
X-1371	BRCA	BGJ398	438.9	26.7	14	97.2	-0.7
X-1371	BRCA	BGJ398	570.6	25.7	18	156.3	-4.5
X-1371	BRCA	BGJ398	765.4	26.8	21	243.8	-0.4
X-1371	BRCA	BGJ398	1122.5	26.3	23	404.3	-2.2
X-1371	BRCA	BKM120	208.8	28.9	0	0	0
X-1371	BRCA	BKM120	207.9	29.7	2	-0.4	2.8
X-1371	BRCA	BKM120	227	30.2	5	8.7	4.5
X-1371	BRCA	BKM120	265.5	30.3	9	27.2	4.8
X-1371	BRCA	BKM120	227.5	29.5	12	9	2.1
X-1371	BRCA	BKM120	337.9	29.9	19	61.8	3.5
X-1371	BRCA	BKM120	342.2	30.3	23	63.9	4.8
X-1371	BRCA	BKM120	413.4	29.8	26	98	3.1
X-1371	BRCA	BKM120	468	31.3	30	124.1	8.3
X-1371	BRCA	BKM120	720.2	29.9	33	244.9	3.5
X-1371	BRCA	BKM120	962.4	31	35	360.9	7.3
X-1371	BRCA	BYL719 + LEE011	273.7	32.3	0	0	0
X-1371	BRCA	BYL719 + LEE011	261.4	32.9	3	-4.5	1.9
X-1371	BRCA	BYL719 + LEE011	219.4	29.9	7	-19.8	-7.4
X-1371	BRCA	BYL719 + LEE011	198.4	27.7	11	-27.5	-14.2
X-1371	BRCA	BYL719 + LEE011	243.3	30.5	15	-11.1	-5.6
X-1371	BRCA	BYL719 + LEE011	301.9	31.1	18	10.3	-3.7
X-1371	BRCA	BYL719 + LEE011	380.2	31.6	22	38.9	-2.2
X-1371	BRCA	BYL719 + LEE011	532.4	33.4	26	94.5	3.4
X-1371	BRCA	BYL719 + LEE011	558.1	29.7	30	103.9	-8
X-1371	BRCA	BYL719 + LEE011	517.8	24.5	32	89.2	-24.1
X-1371	BRCA	BYL719 + LJM716	219	25.7	0	0	0
X-1371	BRCA	BYL719 + LJM716	236.8	26.6	2	8.1	3.5
X-1371	BRCA	BYL719 + LJM716	258.3	26.3	5	17.9	2.3
X-1371	BRCA	BYL719 + LJM716	242.6	25	9	10.8	-2.7
X-1371	BRCA	BYL719 + LJM716	168.6	24.3	12	-23	-5.4
X-1371	BRCA	BYL719 + LJM716	221	25.5	19	0.9	-0.8
X-1371	BRCA	BYL719 + LJM716	265.6	25.1	23	21.3	-2.3
X-1371	BRCA	BYL719 + LJM716	268.1	24.6	26	22.4	-4.3
X-1371	BRCA	BYL719 + LJM716	240.2	23.5	30	9.7	-8.6
X-1371	BRCA	BYL719 + LJM716	269	21.7	33	22.8	-15.6
X-1371	BRCA	BYL719 + LJM716	326.9	22.9	37	49.3	-10.9
X-1371	BRCA	BYL719 + LJM716	333	24.6	40	52.1	-4.3
X-1371	BRCA	BYL719 + LJM716	433.7	25.9	44	98	0.8
X-1371	BRCA	BYL719 + LJM716	551	26.3	47	151.6	2.3
X-1371	BRCA	BYL719 + LJM716	684.4	25.7	48	212.5	0
X-1371	BRCA	BYL719	224.2	25.3	0	0	0
X-1371	BRCA	BYL719	281.5	25.6	3	25.6	1.2
X-1371	BRCA	BYL719	363.6	27	6	62.2	6.7
X-1371	BRCA	BYL719	467.8	25.8	10	108.7	2
X-1371	BRCA	BYL719	636.8	25.8	13	184	2
X-1371	BRCA	BYL719	720	26.7	20	221.1	5.5
X-1371	BRCA	BYL719	1112	27.6	22	396	9.1
X-1371	BRCA	CGM097	205.1	27.1	0	0	0
X-1371	BRCA	CGM097	181.1	27.4	2	-11.7	1.1
X-1371	BRCA	CGM097	188.4	27.1	5	-8.1	0
X-1371	BRCA	CGM097	238.3	28	9	16.2	3.3
X-1371	BRCA	CGM097	244.6	26	12	19.3	-4.1
X-1371	BRCA	CGM097	369.2	27.7	16	80	2.2
X-1371	BRCA	CGM097	554.3	28.7	19	170.3	5.9
X-1371	BRCA	CGM097	671.3	28.1	23	227.3	3.7
X-1371	BRCA	CGM097	840.9	28.5	26	310	5.2
X-1371	BRCA	CGM097	970.8	29.3	27	373.3	8.1
X-1371	BRCA	CLR457	299.6	27.4	0	0	0
X-1371	BRCA	CLR457	357.8	26.9	3	19.4	-1.8
X-1371	BRCA	CLR457	410.1	26.8	6	36.9	-2.2
X-1371	BRCA	CLR457	700.2	26.3	10	133.7	-4
X-1371	BRCA	CLR457	762.1	26	13	154.4	-5.1
X-1371	BRCA	CLR457	960.3	27.3	20	220.5	-0.4
X-1371	BRCA	CLR457	1157.9	28.1	22	286.5	2.6
X-1371	BRCA	HDM201	220.9	27.4	0	0	0
X-1371	BRCA	HDM201	271.8	26.7	3	23	-2.6
X-1371	BRCA	HDM201	327.7	25.2	6	48.3	-8
X-1371	BRCA	HDM201	470	26.2	10	112.8	-4.4
X-1371	BRCA	HDM201	474	25.6	13	114.6	-6.6
X-1371	BRCA	HDM201	710.6	25.4	17	221.7	-7.3
X-1371	BRCA	HDM201	807.4	24.6	20	265.5	-10.2
X-1371	BRCA	HDM201	911.2	24.7	24	312.5	-9.9
X-1371	BRCA	HDM201	1142.1	23.9	27	417	-12.8
X-1371	BRCA	HDM201	1205.5	24.3	28	445.7	-11.3
X-1371	BRCA	INC424	214.3	28	0	0	0
X-1371	BRCA	INC424	283.7	29.1	3	32.4	3.9
X-1371	BRCA	INC424	301.8	29.1	6	40.8	3.9
X-1371	BRCA	INC424	531.8	28.8	10	148.2	2.9
X-1371	BRCA	INC424	513.7	28.7	13	139.7	2.5
X-1371	BRCA	INC424	636.7	28.3	20	197.1	1.1
X-1371	BRCA	INC424	721.1	29.1	24	236.5	3.9
X-1371	BRCA	INC424	954.5	29.8	27	345.4	6.4
X-1371	BRCA	INC424	1235.7	29.8	29	476.6	6.4
X-1371	BRCA	LEE011	218.9	23	0	0	0
X-1371	BRCA	LEE011	259.9	28.8	3	18.7	25.2
X-1371	BRCA	LEE011	349.7	27.6	6	59.8	20
X-1371	BRCA	LEE011	550.3	27.6	10	151.4	20
X-1371	BRCA	LEE011	585.7	28.8	13	167.6	25.2
X-1371	BRCA	LEE011	649.7	29.6	17	196.8	28.7
X-1371	BRCA	LEE011	865.5	29.2	20	295.4	27
X-1371	BRCA	LEE011	981.4	29.9	24	348.3	30
X-1371	BRCA	LEE011	1444.7	29.8	27	560	29.6
X-1371	BRCA	LFA102	227.4	29.4	0	0	0
X-1371	BRCA	LFA102	244.6	30.6	3	7.6	4.1
X-1371	BRCA	LFA102	250	30.2	6	9.9	2.7
X-1371	BRCA	LFA102	315	30.2	10	38.5	2.7
X-1371	BRCA	LFA102	473.8	31.6	13	108.4	7.5
X-1371	BRCA	LFA102	637.7	31.2	17	180.4	6.1
X-1371	BRCA	LFA102	907.8	30.8	20	299.2	4.8
X-1371	BRCA	LFA102	1119.7	32.3	21	392.4	9.9
X-1371	BRCA	LJM716 + trastuzumab	197.8	26.5	0	0	0
X-1371	BRCA	LJM716 + trastuzumab	172.8	25.5	3	-12.6	-3.8
X-1371	BRCA	LJM716 + trastuzumab	237.5	26.6	6	20.1	0.4
X-1371	BRCA	LJM716 + trastuzumab	285.6	26.1	10	44.4	-1.5
X-1371	BRCA	LJM716 + trastuzumab	350.6	27.2	13	77.2	2.6
X-1371	BRCA	LJM716 + trastuzumab	502.4	27.1	17	154	2.3
X-1371	BRCA	LJM716 + trastuzumab	589	27.4	20	197.8	3.4
X-1371	BRCA	LJM716 + trastuzumab	675.4	28.2	27	241.5	6.4
X-1371	BRCA	LJM716 + trastuzumab	893	28	31	351.5	5.7
X-1371	BRCA	LJM716 + trastuzumab	1029.4	28.5	34	420.4	7.5
X-1371	BRCA	LJM716	205.2	30.9	0	0	0
X-1371	BRCA	LJM716	196.1	31.5	1	-4.4	1.9
X-1371	BRCA	LJM716	185.8	31.2	4	-9.5	1
X-1371	BRCA	LJM716	269	30.7	8	31.1	-0.6
X-1371	BRCA	LJM716	311.7	31.1	11	51.9	0.6
X-1371	BRCA	LJM716	375	31.1	15	82.7	0.6
X-1371	BRCA	LJM716	380.8	31.1	18	85.6	0.6
X-1371	BRCA	LJM716	413.9	30.6	25	101.7	-1
X-1371	BRCA	LJM716	420.6	30.5	29	105	-1.3
X-1371	BRCA	LJM716	443.7	30.8	32	116.2	-0.3
X-1371	BRCA	LJM716	694.5	32	34	238.5	3.6
X-1371	BRCA	LKA136	268	25.5	0	0	0
X-1371	BRCA	LKA136	389.3	26.3	3	45.3	3.1
X-1371	BRCA	LKA136	529.5	27.9	6	97.6	9.4
X-1371	BRCA	LKA136	636	27.8	10	137.3	9
X-1371	BRCA	LKA136	853.1	27.4	13	218.3	7.5
X-1371	BRCA	LKA136	1880.9	30.4	20	601.8	19.2
X-1371	BRCA	LKA136	2053.9	32.7	22	666.4	28.2
X-1371	BRCA	LLM871	212.7	23.5	0	0	0
X-1371	BRCA	LLM871	238.2	22.8	3	12	-3
X-1371	BRCA	LLM871	278.5	23.8	6	30.9	1.3
X-1371	BRCA	LLM871	488.6	24.1	10	129.7	2.6
X-1371	BRCA	LLM871	623.6	23.8	13	193.2	1.3
X-1371	BRCA	LLM871	1261.2	23.6	20	492.9	0.4
X-1371	BRCA	LLM871	1541.6	24.8	21	624.8	5.5
X-1371	BRCA	binimetinib	208.7	29.3	0	0	0
X-1371	BRCA	binimetinib	230.1	29.9	3	10.3	2
X-1371	BRCA	binimetinib	224.5	28.7	6	7.6	-2
X-1371	BRCA	binimetinib	219.1	29.8	10	5	1.7
X-1371	BRCA	binimetinib	216.6	28.6	13	3.8	-2.4
X-1371	BRCA	binimetinib	267.4	28.5	20	28.1	-2.7
X-1371	BRCA	binimetinib	282.6	28.5	24	35.4	-2.7
X-1371	BRCA	binimetinib	352.2	27.6	27	68.8	-5.8
X-1371	BRCA	binimetinib	491.3	28.2	31	135.4	-3.8
X-1371	BRCA	binimetinib	605.5	27.5	34	190.1	-6.1
X-1371	BRCA	binimetinib	1002.9	28.5	36	380.5	-2.7
X-1371	BRCA	paclitaxel	220.7	26.5	0	0	0
X-1371	BRCA	paclitaxel	213.5	27.4	3	-3.3	3.4
X-1371	BRCA	paclitaxel	188.6	26.2	6	-14.5	-1.1
X-1371	BRCA	paclitaxel	265.7	26.7	10	20.4	0.8
X-1371	BRCA	paclitaxel	341.2	28.1	13	54.6	6
X-1371	BRCA	paclitaxel	352	27.3	17	59.5	3
X-1371	BRCA	paclitaxel	390.1	27.4	20	76.8	3.4
X-1371	BRCA	paclitaxel	449.6	28.1	27	103.7	6
X-1371	BRCA	paclitaxel	626.3	27.9	31	183.8	5.3
X-1371	BRCA	paclitaxel	850.8	23.9	34	285.5	-9.8
X-1371	BRCA	tamoxifen	192.9	26.2	0	0	0
X-1371	BRCA	tamoxifen	249.8	25.9	3	29.5	-1.1
X-1371	BRCA	tamoxifen	251.2	25.9	6	30.2	-1.1
X-1371	BRCA	tamoxifen	285.2	25.5	10	47.8	-2.7
X-1371	BRCA	tamoxifen	377.6	26.4	13	95.7	0.8
X-1371	BRCA	tamoxifen	502.4	27	20	160.4	3.1
X-1371	BRCA	tamoxifen	692.9	28.5	24	259.2	8.8
X-1371	BRCA	tamoxifen	868.8	29.2	27	350.4	11.5
X-1371	BRCA	tamoxifen	1136.2	30.7	29	489	17.2
X-1371	BRCA	trastuzumab	235.9	30.7	0	0	0
X-1371	BRCA	trastuzumab	294	31.2	3	24.6	1.6
X-1371	BRCA	trastuzumab	346.5	31.1	6	46.9	1.3
X-1371	BRCA	trastuzumab	395.4	32.1	10	67.6	4.6
X-1371	BRCA	trastuzumab	593.1	31.8	13	151.4	3.6
X-1371	BRCA	trastuzumab	879.8	32.2	20	273	4.9
X-1371	BRCA	trastuzumab	1193.1	32.4	21	405.8	5.5
X-1371	BRCA	untreated	214.6	27.9	0	0	0
X-1371	BRCA	untreated	307.7	28.2	3	43.4	1.1
X-1371	BRCA	untreated	340.5	28.2	6	58.7	1.1
X-1371	BRCA	untreated	433.1	29.2	10	101.8	4.7
X-1371	BRCA	untreated	613.3	28.9	13	185.8	3.6
X-1371	BRCA	untreated	1040	29.8	20	384.6	6.8
X-1371	BRCA	untreated	1282.8	30.1	21	497.8	7.9
X-1371	BRCA	LFW527 + everolimus	215.09	25.8	0	0	0
X-1371	BRCA	LFW527 + everolimus	175.62	25	3	-18.4	-3.1
X-1371	BRCA	LFW527 + everolimus	195.89	25.7	7	-8.9	-0.4
X-1371	BRCA	LFW527 + everolimus	202.03	26.2	10	-6.1	1.6
X-1371	BRCA	LFW527 + everolimus	216.93	26	14	0.9	0.8
X-1371	BRCA	LFW527 + everolimus	244.54	27.6	17	13.7	7
X-1371	BRCA	LFW527 + everolimus	286.28	26.8	21	33.1	3.9
X-1371	BRCA	LFW527 + everolimus	309.02	27.7	24	43.7	7.4
X-1371	BRCA	LFW527 + everolimus	333.6	28.1	27	55.1	8.9
X-1371	BRCA	LFW527 + everolimus	436.31	28.1	31	102.8	8.9
X-1371	BRCA	LFW527 + everolimus	453.77	28.2	35	111	9.3
X-1371	BRCA	LFW527 + everolimus	460.34	27.9	38	114	8.1
X-1371	BRCA	LFW527 + everolimus	404.58	28.9	41	88.1	12
X-1371	BRCA	LFW527 + everolimus	457.68	29.3	46	112.8	13.6
X-1371	BRCA	LFW527 + everolimus	494.51	29	49	129.9	12.4
X-1371	BRCA	LFW527 + everolimus	513.15	30.4	52	138.6	17.8
X-1371	BRCA	LFW527 + everolimus	508.91	29.8	55	136.6	15.5
X-1371	BRCA	LFW527 + everolimus	540.35	30.2	59	151.2	17.1
X-1371	BRCA	LFW527 + everolimus	516.49	29.8	62	140.1	15.5
X-1371	BRCA	LFW527 + everolimus	499.84	28.9	66	132.4	12
X-1371	BRCA	LFW527 + everolimus	592.38	28.9	69	175.4	12
X-1371	BRCA	LFW527 + everolimus	587.66	29.1	73	173.2	12.8
X-1371	BRCA	LFW527 + everolimus	670.75	27.4	76	211.8	6.2
X-1371	BRCA	LFW527 + everolimus	706.87	28.3	80	228.6	9.7
X-1371	BRCA	LFW527 + everolimus	753.08	28.9	83	250.1	12
X-1371	BRCA	LFW527 + everolimus	682.45	28.4	87	217.3	10.1
X-1371	BRCA	LFW527 + everolimus	710.04	28.6	91	230.1	10.9
X-1371	BRCA	LFW527 + everolimus	642.77	28.4	94	198.8	10.1
X-1371	BRCA	LFW527 + everolimus	914.13	29.4	98	325	14
X-1371	BRCA	LFW527 + everolimus	982.6	28.8	101	356.8	11.6
X-1383	BRCA	BGJ398	265.3	26.1	0	0	0
X-1383	BRCA	BGJ398	258.5	27.7	4	-2.6	6.1
X-1383	BRCA	BGJ398	319.2	27	7	20.3	3.4
X-1383	BRCA	BGJ398	327.1	27.9	11	23.3	6.9
X-1383	BRCA	BGJ398	443.1	28.5	14	67	9.2
X-1383	BRCA	BGJ398	632	28.1	18	138.2	7.7
X-1383	BRCA	BGJ398	641.3	27.5	21	141.7	5.4
X-1383	BRCA	BGJ398	911.7	27.6	25	243.6	5.7
X-1383	BRCA	BGJ398	1085.6	27.3	28	309.2	4.6
X-1383	BRCA	BKM120	204.3	29.3	0	0	0
X-1383	BRCA	BKM120	230.1	28	4	12.6	-4.4
X-1383	BRCA	BKM120	190.8	29.3	8	-6.6	0
X-1383	BRCA	BKM120	158	29.5	11	-22.7	0.7
X-1383	BRCA	BKM120	141.3	30.2	15	-30.8	3.1
X-1383	BRCA	BKM120	146.1	30.1	18	-28.5	2.7
X-1383	BRCA	BKM120	125.5	31.2	22	-38.6	6.5
X-1383	BRCA	BKM120	135.9	30.4	25	-33.5	3.8
X-1383	BRCA	BKM120	159	30.6	29	-22.2	4.4
X-1383	BRCA	BKM120	123.1	30.8	32	-39.7	5.1
X-1383	BRCA	BKM120	137.5	31.4	36	-32.7	7.2
X-1383	BRCA	BKM120	176.1	32.1	39	-13.8	9.6
X-1383	BRCA	BKM120	137.1	31.8	43	-32.9	8.5
X-1383	BRCA	BKM120	166.3	31.5	46	-18.6	7.5
X-1383	BRCA	BKM120	141.9	29.8	49	-30.5	1.7
X-1383	BRCA	BKM120	155.9	31.2	53	-23.7	6.5
X-1383	BRCA	BKM120	161.3	31.3	57	-21	6.8
X-1383	BRCA	BKM120	137.6	31.4	60	-32.6	7.2
X-1383	BRCA	BKM120	203.3	31.7	64	-0.5	8.2
X-1383	BRCA	BKM120	238.9	31.2	74	16.9	6.5
X-1383	BRCA	BKM120	252.9	31.2	78	23.8	6.5
X-1383	BRCA	BKM120	251.1	31.2	81	22.9	6.5
X-1383	BRCA	BKM120	284	30.9	85	39	5.5
X-1383	BRCA	BKM120	301.1	30.5	88	47.4	4.1
X-1383	BRCA	BKM120	306.9	30.7	92	50.2	4.8
X-1383	BRCA	BKM120	293	30.5	95	43.4	4.1
X-1383	BRCA	BKM120	295.9	31.3	98	44.8	6.8
X-1383	BRCA	BKM120	292.7	29.6	102	43.3	1
X-1383	BRCA	BKM120	299.1	30.8	105	46.4	5.1
X-1383	BRCA	BKM120	300.8	31.1	109	47.2	6.1
X-1383	BRCA	BKM120	304.7	31.1	112	49.1	6.1
X-1383	BRCA	BKM120	364.3	30.8	116	78.3	5.1
X-1383	BRCA	BKM120	412.2	30.8	120	101.8	5.1
X-1383	BRCA	BKM120	425.1	31.9	123	108.1	8.9
X-1383	BRCA	BKM120	418.9	31.5	127	105	7.5
X-1383	BRCA	BKM120	512.6	31.2	130	150.9	6.5
X-1383	BRCA	BKM120	490.7	32.5	134	140.2	10.9
X-1383	BRCA	BKM120	479.7	33	137	134.8	12.6
X-1383	BRCA	BKM120	495.2	33.1	141	142.4	13
X-1383	BRCA	BKM120	560.6	32.5	144	174.4	10.9
X-1383	BRCA	BKM120	544.7	32.4	148	166.6	10.6
X-1383	BRCA	BKM120	535.6	32.5	151	162.2	10.9
X-1383	BRCA	BYL719 + LEE011	247.6	24.6	0	0	0
X-1383	BRCA	BYL719 + LEE011	303	23.5	4	22.4	-4.5
X-1383	BRCA	BYL719 + LEE011	275.9	19.8	7	11.4	-19.5
X-1383	BRCA	BYL719 + LEE011	316.2	24.8	11	27.7	0.8
X-1383	BRCA	BYL719 + LEE011	299.6	25.1	14	21	2
X-1383	BRCA	BYL719 + LEE011	307	23.2	18	24	-5.7
X-1383	BRCA	BYL719 + LEE011	325.9	21.3	21	31.6	-13.4
X-1383	BRCA	BYL719 + LEE011	429.3	23.8	24	73.4	-3.3
X-1383	BRCA	BYL719 + LEE011	521.5	26.8	28	110.6	8.9
X-1383	BRCA	BYL719 + LEE011	561.8	25.5	32	126.9	3.7
X-1383	BRCA	BYL719 + LEE011	489.5	23.8	35	97.7	-3.3
X-1383	BRCA	BYL719 + LJM716	222.5	29.6	0	0	0
X-1383	BRCA	BYL719 + LJM716	256.6	27.9	4	15.3	-5.7
X-1383	BRCA	BYL719 + LJM716	179.6	27.9	7	-19.3	-5.7
X-1383	BRCA	BYL719 + LJM716	197.9	28.3	11	-11.1	-4.4
X-1383	BRCA	BYL719 + LJM716	181.6	29.6	14	-18.4	0
X-1383	BRCA	BYL719 + LJM716	166.7	28.1	17	-25.1	-5.1
X-1383	BRCA	BYL719 + LJM716	166.2	29.2	21	-25.3	-1.4
X-1383	BRCA	BYL719 + LJM716	171.8	29.7	24	-22.8	0.3
X-1383	BRCA	BYL719 + LJM716	176.2	30.8	28	-20.8	4.1
X-1383	BRCA	BYL719 + LJM716	176.9	31.5	31	-20.5	6.4
X-1383	BRCA	BYL719 + LJM716	163.2	30.1	35	-26.7	1.7
X-1383	BRCA	BYL719 + LJM716	149.7	29.8	39	-32.7	0.7
X-1383	BRCA	BYL719 + LJM716	145.3	30.6	42	-34.7	3.4
X-1383	BRCA	BYL719 + LJM716	164.8	31.8	46	-25.9	7.4
X-1383	BRCA	BYL719 + LJM716	192.8	30.8	49	-13.3	4.1
X-1383	BRCA	BYL719 + LJM716	216.9	30.8	53	-2.5	4.1
X-1383	BRCA	BYL719 + LJM716	235.2	31.9	56	5.7	7.8
X-1383	BRCA	BYL719 + LJM716	222.7	31.3	60	0.1	5.7
X-1383	BRCA	BYL719 + LJM716	220.9	30.4	63	-0.7	2.7
X-1383	BRCA	BYL719 + LJM716	255.4	30.8	67	14.8	4.1
X-1383	BRCA	BYL719 + LJM716	269.5	31.3	70	21.1	5.7
X-1383	BRCA	BYL719 + LJM716	255.7	31.1	74	14.9	5.1
X-1383	BRCA	BYL719 + LJM716	252	29.8	77	13.3	0.7
X-1383	BRCA	BYL719 + LJM716	280.4	31.5	81	26	6.4
X-1383	BRCA	BYL719 + LJM716	297.1	31	84	33.5	4.7
X-1383	BRCA	BYL719 + LJM716	328.1	33.8	88	47.5	14.2
X-1383	BRCA	BYL719 + LJM716	327.4	32.8	91	47.1	10.8
X-1383	BRCA	BYL719	283.5	25.3	0	0	0
X-1383	BRCA	BYL719	258.7	24.7	4	-8.7	-2.4
X-1383	BRCA	BYL719	244.9	26.2	8	-13.6	3.6
X-1383	BRCA	BYL719	241.5	25.8	11	-14.8	2
X-1383	BRCA	BYL719	251.6	26	15	-11.3	2.8
X-1383	BRCA	BYL719	255.4	25	18	-9.9	-1.2
X-1383	BRCA	BYL719	280.4	25.4	22	-1.1	0.4
X-1383	BRCA	BYL719	283.5	26.1	25	0	3.2
X-1383	BRCA	BYL719	316.2	25.9	29	11.5	2.4
X-1383	BRCA	BYL719	309.2	26.7	32	9.1	5.5
X-1383	BRCA	BYL719	322.6	27.6	36	13.8	9.1
X-1383	BRCA	BYL719	304.9	27.9	39	7.5	10.3
X-1383	BRCA	BYL719	324.8	28.5	43	14.6	12.6
X-1383	BRCA	BYL719	329.9	27	46	16.4	6.7
X-1383	BRCA	BYL719	331.9	27.3	49	17.1	7.9
X-1383	BRCA	BYL719	366.6	27.6	53	29.3	9.1
X-1383	BRCA	BYL719	452.7	28.6	57	59.7	13
X-1383	BRCA	BYL719	477.4	28.2	60	68.4	11.5
X-1383	BRCA	BYL719	524	28.8	64	84.8	13.8
X-1383	BRCA	BYL719	649	28.6	74	128.9	13
X-1383	BRCA	BYL719	667.1	25.7	78	135.3	1.6
X-1383	BRCA	BYL719	653	26.7	81	130.3	5.5
X-1383	BRCA	BYL719	750.1	27.6	85	164.6	9.1
X-1383	BRCA	BYL719	786.2	28.4	88	177.3	12.3
X-1383	BRCA	CGM097	233.1	28.4	0	0	0
X-1383	BRCA	CGM097	248.5	29.9	4	6.6	5.3
X-1383	BRCA	CGM097	306.7	30.2	8	31.6	6.3
X-1383	BRCA	CGM097	320.8	29.8	11	37.6	4.9
X-1383	BRCA	CGM097	316.3	30.2	15	35.7	6.3
X-1383	BRCA	CGM097	420.1	30.5	18	80.2	7.4
X-1383	BRCA	CGM097	424.4	30.8	22	82.1	8.5
X-1383	BRCA	CGM097	370.8	30.1	25	59.1	6
X-1383	BRCA	CGM097	514.5	30.5	29	120.7	7.4
X-1383	BRCA	CGM097	589.8	31.2	32	153	9.9
X-1383	BRCA	CGM097	590.2	31.3	36	153.2	10.2
X-1383	BRCA	CGM097	560.6	30.9	39	140.5	8.8
X-1383	BRCA	CGM097	695.8	31.2	43	198.5	9.9
X-1383	BRCA	CGM097	742.4	32.5	46	218.5	14.4
X-1383	BRCA	CGM097	852.7	30.7	49	265.8	8.1
X-1383	BRCA	CGM097	815.6	31.5	53	249.9	10.9
X-1383	BRCA	CGM097	1079.3	32.4	57	363	14.1
X-1383	BRCA	CGM097	985.4	32.3	60	322.7	13.7
X-1383	BRCA	CLR457	211.1	29.5	0	0	0
X-1383	BRCA	CLR457	217.1	29.9	3	2.8	1.4
X-1383	BRCA	CLR457	274	29.5	7	29.8	0
X-1383	BRCA	CLR457	262.8	29.8	10	24.5	1
X-1383	BRCA	CLR457	281.9	30.1	14	33.5	2
X-1383	BRCA	CLR457	300.8	30.2	17	42.5	2.4
X-1383	BRCA	CLR457	281.7	29.6	21	33.4	0.3
X-1383	BRCA	CLR457	317.3	30.9	24	50.3	4.7
X-1383	BRCA	CLR457	284.1	30.9	28	34.6	4.7
X-1383	BRCA	CLR457	307.1	31.5	31	45.5	6.8
X-1383	BRCA	CLR457	374.9	31.2	34	77.6	5.8
X-1383	BRCA	CLR457	396.7	31.4	38	87.9	6.4
X-1383	BRCA	CLR457	424.3	31	42	101	5.1
X-1383	BRCA	CLR457	494.3	32.4	45	134.2	9.8
X-1383	BRCA	CLR457	498.5	31.9	49	136.1	8.1
X-1383	BRCA	CLR457	671.1	32.4	59	217.9	9.8
X-1383	BRCA	CLR457	722.8	32.8	63	242.4	11.2
X-1383	BRCA	CLR457	735.3	33	66	248.3	11.9
X-1383	BRCA	CLR457	906.9	33.2	70	329.6	12.5
X-1383	BRCA	CLR457	917.9	34	73	334.8	15.3
X-1383	BRCA	HDM201	239.6	24.1	0	0	0
X-1383	BRCA	HDM201	263.2	24.9	4	9.8	3.3
X-1383	BRCA	HDM201	231.2	24.7	7	-3.5	2.5
X-1383	BRCA	HDM201	233.6	24.8	11	-2.5	2.9
X-1383	BRCA	HDM201	229.9	26.5	14	-4	10
X-1383	BRCA	HDM201	204.9	24.7	18	-14.5	2.5
X-1383	BRCA	HDM201	214.5	26.2	21	-10.5	8.7
X-1383	BRCA	HDM201	215.1	24.3	24	-10.2	0.8
X-1383	BRCA	HDM201	206.4	26.7	28	-13.9	10.8
X-1383	BRCA	HDM201	221.3	26.6	32	-7.6	10.4
X-1383	BRCA	HDM201	194.1	27.3	35	-19	13.3
X-1383	BRCA	HDM201	193.7	27.4	39	-19.2	13.7
X-1383	BRCA	HDM201	183.8	26.6	49	-23.3	10.4
X-1383	BRCA	HDM201	133.7	25.4	53	-44.2	5.4
X-1383	BRCA	HDM201	157.1	25.4	56	-34.4	5.4
X-1383	BRCA	HDM201	178	25.3	60	-25.7	5
X-1383	BRCA	HDM201	162.3	25.6	63	-32.3	6.2
X-1383	BRCA	HDM201	149.7	24.8	67	-37.5	2.9
X-1383	BRCA	HDM201	148.6	25.9	70	-38	7.5
X-1383	BRCA	HDM201	148.4	25.5	73	-38.1	5.8
X-1383	BRCA	HDM201	144.5	27.2	77	-39.7	12.9
X-1383	BRCA	HDM201	142.3	26.6	80	-40.6	10.4
X-1383	BRCA	HDM201	136.3	25.7	84	-43.1	6.6
X-1383	BRCA	HDM201	127	25.3	87	-47	5
X-1383	BRCA	HDM201	147.5	25.3	91	-38.4	5
X-1383	BRCA	INC424	204.4	27.2	0	0	0
X-1383	BRCA	INC424	261.7	28.6	4	28	5.1
X-1383	BRCA	INC424	261	28.5	7	27.7	4.8
X-1383	BRCA	INC424	382.3	NA	11	87	4.8
X-1383	BRCA	INC424	365.1	29.7	14	78.6	9.2
X-1383	BRCA	INC424	452.8	29.6	18	121.5	8.8
X-1383	BRCA	INC424	463.1	30.4	21	126.6	11.8
X-1383	BRCA	INC424	584.1	31.2	25	185.8	14.7
X-1383	BRCA	INC424	568.3	31.6	28	178	16.2
X-1383	BRCA	INC424	718.2	31.2	31	251.4	14.7
X-1383	BRCA	INC424	802.3	31.1	35	292.5	14.3
X-1383	BRCA	INC424	947.1	30.7	39	363.4	12.9
X-1383	BRCA	INC424	1113.4	31.6	42	444.7	16.2
X-1383	BRCA	LEE011 + everolimus	217.8	29	0	0	0
X-1383	BRCA	LEE011 + everolimus	234.7	28.8	3	7.8	-0.7
X-1383	BRCA	LEE011 + everolimus	246.7	28.7	7	13.3	-1
X-1383	BRCA	LEE011 + everolimus	222.9	29.8	10	2.3	2.8
X-1383	BRCA	LEE011 + everolimus	267.7	30.8	14	22.9	6.2
X-1383	BRCA	LEE011 + everolimus	265.1	29.7	17	21.7	2.4
X-1383	BRCA	LEE011 + everolimus	261.4	30.6	21	20	5.5
X-1383	BRCA	LEE011 + everolimus	264.8	30.6	24	21.6	5.5
X-1383	BRCA	LEE011 + everolimus	308.9	30.2	27	41.8	4.1
X-1383	BRCA	LEE011 + everolimus	284.8	29.9	31	30.8	3.1
X-1383	BRCA	LEE011 + everolimus	275.8	30.3	35	26.6	4.5
X-1383	BRCA	LEE011 + everolimus	302.6	30.9	38	38.9	6.6
X-1383	BRCA	LEE011 + everolimus	298.1	29.8	42	36.9	2.8
X-1383	BRCA	LEE011 + everolimus	272.9	30.6	52	25.3	5.5
X-1383	BRCA	LEE011 + everolimus	308.5	29.9	56	41.6	3.1
X-1383	BRCA	LEE011 + everolimus	299.3	31.5	59	37.4	8.6
X-1383	BRCA	LEE011 + everolimus	447	30.7	63	105.2	5.9
X-1383	BRCA	LEE011 + everolimus	564	31.3	66	159	7.9
X-1383	BRCA	LEE011 + everolimus	519	30.4	70	138.3	4.8
X-1383	BRCA	LEE011 + everolimus	526.2	31	73	141.6	6.9
X-1383	BRCA	LEE011 + everolimus	540.7	31.1	76	148.3	7.2
X-1383	BRCA	LEE011 + everolimus	548.7	30.9	80	151.9	6.6
X-1383	BRCA	LEE011 + everolimus	560.2	30.2	83	157.2	4.1
X-1383	BRCA	LEE011 + everolimus	609.1	31	87	179.7	6.9
X-1383	BRCA	LEE011 + everolimus	629.2	30.1	90	188.9	3.8
X-1383	BRCA	LEE011 + everolimus	635.9	29.7	94	192	2.4
X-1383	BRCA	LEE011 + everolimus	629.3	28.9	98	188.9	-0.3
X-1383	BRCA	LEE011 + everolimus	651.2	29.4	101	199	1.4
X-1383	BRCA	LEE011	251.7	26.9	0	0	0
X-1383	BRCA	LEE011	289	29.7	4	14.8	10.4
X-1383	BRCA	LEE011	340.8	29.9	7	35.4	11.2
X-1383	BRCA	LEE011	335.4	29.1	11	33.3	8.2
X-1383	BRCA	LEE011	380.5	29.8	14	51.2	10.8
X-1383	BRCA	LEE011	392.1	29.4	18	55.8	9.3
X-1383	BRCA	LEE011	388.7	30.1	21	54.4	11.9
X-1383	BRCA	LEE011	471.8	29	25	87.4	7.8
X-1383	BRCA	LEE011	474.4	29.3	28	88.5	8.9
X-1383	BRCA	LEE011	575	29.3	32	128.4	8.9
X-1383	BRCA	LEE011	607.6	29.9	35	141.4	11.2
X-1383	BRCA	LEE011	733.4	29.2	39	191.4	8.6
X-1383	BRCA	LEE011	804.8	30.1	42	219.7	11.9
X-1383	BRCA	LEE011	859.5	29.4	45	241.5	9.3
X-1383	BRCA	LEE011	934.7	29.6	49	271.4	10
X-1383	BRCA	LEE011	1107.6	30.3	53	340	12.6
X-1383	BRCA	LEE011	1194.5	30.4	56	374.6	13
X-1383	BRCA	LFA102	230.8	26.4	0	0	0
X-1383	BRCA	LFA102	286.9	25.9	6	24.3	-1.9
X-1383	BRCA	LFA102	342	25.6	9	48.2	-3
X-1383	BRCA	LFA102	305.8	26.4	14	32.5	0
X-1383	BRCA	LFA102	395.4	26.2	17	71.3	-0.8
X-1383	BRCA	LFA102	444.4	26.4	20	92.5	0
X-1383	BRCA	LFA102	605.4	26.6	24	162.3	0.8
X-1383	BRCA	LFA102	634.3	26.7	27	174.8	1.1
X-1383	BRCA	LFA102	810.4	27.7	31	251.1	4.9
X-1383	BRCA	LFA102	872.1	27.4	34	277.9	3.8
X-1383	BRCA	LFA102	857.4	27.9	38	271.5	5.7
X-1383	BRCA	LFA102	882.8	28.3	41	282.5	7.2
X-1383	BRCA	LFA102	1011.3	28	45	338.2	6.1
X-1383	BRCA	LFA102	924.4	28	48	300.5	6.1
X-1383	BRCA	LFA102	988.6	27.9	52	328.3	5.7
X-1383	BRCA	LFA102	1038.4	27.7	55	349.9	4.9
X-1383	BRCA	LJM716	213	24.6	0	0	0
X-1383	BRCA	LJM716	262.8	23.5	5	23.4	-4.5
X-1383	BRCA	LJM716	267.1	22.9	8	25.4	-6.9
X-1383	BRCA	LJM716	280.7	23.3	11	31.8	-5.3
X-1383	BRCA	LJM716	358.2	23.7	15	68.2	-3.7
X-1383	BRCA	LJM716	266.4	23.9	18	25.1	-2.8
X-1383	BRCA	LJM716	270.3	24.6	22	26.9	0
X-1383	BRCA	LJM716	335.2	23.8	25	57.4	-3.3
X-1383	BRCA	LJM716	442.4	24.3	29	107.7	-1.2
X-1383	BRCA	LJM716	470.7	25.8	32	121	4.9
X-1383	BRCA	LJM716	641.9	24.1	36	201.4	-2
X-1383	BRCA	LJM716	698.9	25.1	39	228.1	2
X-1383	BRCA	LJM716	897.5	25.7	43	321.4	4.5
X-1383	BRCA	LJM716	988.8	26.4	46	364.2	7.3
X-1383	BRCA	LJM716	1038	25.3	50	387.3	2.8
X-1383	BRCA	LJM716	1208.7	26	53	467.5	5.7
X-1383	BRCA	LJM716 + trastuzumab	193	25.1	0	0	0
X-1383	BRCA	LJM716 + trastuzumab	229.7	25	2	19	-0.4
X-1383	BRCA	LJM716 + trastuzumab	285	26.4	7	47.7	5.2
X-1383	BRCA	LJM716 + trastuzumab	307.8	26.3	10	59.5	4.8
X-1383	BRCA	LJM716 + trastuzumab	386.7	27.6	13	100.4	10
X-1383	BRCA	LJM716 + trastuzumab	445.2	26.7	17	130.7	6.4
X-1383	BRCA	LJM716 + trastuzumab	412.7	26.8	20	113.8	6.8
X-1383	BRCA	LJM716 + trastuzumab	546.9	26.9	24	183.4	7.2
X-1383	BRCA	LJM716 + trastuzumab	653.4	26.9	27	238.5	7.2
X-1383	BRCA	LJM716 + trastuzumab	856.5	27.2	31	343.8	8.4
X-1383	BRCA	LJM716 + trastuzumab	932.3	28.3	34	383.1	12.7
X-1383	BRCA	LJM716 + trastuzumab	1157.3	27.2	38	499.6	8.4
X-1383	BRCA	LJM716 + trastuzumab	1139.6	26.8	41	490.5	6.8
X-1383	BRCA	LKA136	244.8	27.5	0	0	0
X-1383	BRCA	LKA136	285.2	28.1	3	16.5	2.2
X-1383	BRCA	LKA136	306.4	28	7	25.2	1.8
X-1383	BRCA	LKA136	278.3	28.4	10	13.7	3.3
X-1383	BRCA	LKA136	330.8	29.5	14	35.1	7.3
X-1383	BRCA	LKA136	394.7	29.6	17	61.2	7.6
X-1383	BRCA	LKA136	468.6	29.3	21	91.4	6.5
X-1383	BRCA	LKA136	498.2	29.6	24	103.5	7.6
X-1383	BRCA	LKA136	584.3	29.3	28	138.7	6.5
X-1383	BRCA	LKA136	585.5	29.3	31	139.2	6.5
X-1383	BRCA	LKA136	659.2	30	35	169.3	9.1
X-1383	BRCA	LKA136	639.6	29.9	38	161.3	8.7
X-1383	BRCA	LKA136	647.1	29.8	42	164.3	8.4
X-1383	BRCA	LKA136	872.1	30.2	45	256.2	9.8
X-1383	BRCA	LKA136	960.7	30.5	48	292.4	10.9
X-1383	BRCA	LKA136	1078.8	30	52	340.7	9.1
X-1383	BRCA	LLM871	204.9	26.9	0	0	0
X-1383	BRCA	LLM871	272.8	26.4	6	33.1	-1.9
X-1383	BRCA	LLM871	308	26	9	50.3	-3.3
X-1383	BRCA	LLM871	364.3	25.4	14	77.8	-5.6
X-1383	BRCA	LLM871	428.5	25.2	17	109.1	-6.3
X-1383	BRCA	LLM871	455.2	27.3	20	122.2	1.5
X-1383	BRCA	LLM871	559.7	27	24	173.2	0.4
X-1383	BRCA	LLM871	578.1	26.5	27	182.1	-1.5
X-1383	BRCA	LLM871	655	27.4	31	219.7	1.9
X-1383	BRCA	LLM871	704.1	27.3	34	243.6	1.5
X-1383	BRCA	LLM871	861.9	26.6	38	320.6	-1.1
X-1383	BRCA	LLM871	935.1	28.1	41	356.4	4.5
X-1383	BRCA	binimetinib	227.9	25.5	0	0	0
X-1383	BRCA	binimetinib	277.1	25.6	4	21.6	0.4
X-1383	BRCA	binimetinib	310.3	25.9	7	36.2	1.6
X-1383	BRCA	binimetinib	385	25.8	11	68.9	1.2
X-1383	BRCA	binimetinib	370.3	25.4	14	62.5	-0.4
X-1383	BRCA	binimetinib	407	25.8	18	78.6	1.2
X-1383	BRCA	binimetinib	480.7	26.3	21	110.9	3.1
X-1383	BRCA	binimetinib	503.5	25.6	25	120.9	0.4
X-1383	BRCA	binimetinib	558.3	25.7	28	145	0.8
X-1383	BRCA	binimetinib	626.3	24.8	31	174.8	-2.7
X-1383	BRCA	binimetinib	709.5	25.5	35	211.3	0
X-1383	BRCA	binimetinib	767.4	24.8	39	236.7	-2.7
X-1383	BRCA	binimetinib	866.8	25.4	42	280.3	-0.4
X-1383	BRCA	binimetinib	982	25.4	46	330.9	-0.4
X-1383	BRCA	binimetinib	1093.3	25.6	56	379.7	0.4
X-1383	BRCA	paclitaxel	255.2	29	0	0	0
X-1383	BRCA	paclitaxel	285.9	29.7	3	12	2.4
X-1383	BRCA	paclitaxel	317.8	29.5	6	24.5	1.7
X-1383	BRCA	paclitaxel	303.7	30.7	10	19	5.9
X-1383	BRCA	paclitaxel	345.1	30.6	13	35.2	5.5
X-1383	BRCA	paclitaxel	315.8	31.2	17	23.7	7.6
X-1383	BRCA	paclitaxel	346.1	30.8	20	35.6	6.2
X-1383	BRCA	paclitaxel	370.5	30.7	24	45.2	5.9
X-1383	BRCA	paclitaxel	348.7	32.2	27	36.6	11
X-1383	BRCA	paclitaxel	357.9	31.1	31	40.2	7.2
X-1383	BRCA	paclitaxel	420.4	31.1	34	64.7	7.2
X-1383	BRCA	paclitaxel	358	30.8	38	40.3	6.2
X-1383	BRCA	paclitaxel	407.1	30.7	41	59.5	5.9
X-1383	BRCA	paclitaxel	420.2	31.2	44	64.7	7.6
X-1383	BRCA	paclitaxel	458.9	30.9	48	79.8	6.6
X-1383	BRCA	paclitaxel	504.5	31.5	52	97.7	8.6
X-1383	BRCA	paclitaxel	538.6	31.4	55	111.1	8.3
X-1383	BRCA	paclitaxel	569	31.3	59	123	7.9
X-1383	BRCA	paclitaxel	629.2	32.1	69	146.6	10.7
X-1383	BRCA	paclitaxel	615.6	32.1	73	141.2	10.7
X-1383	BRCA	paclitaxel	726.1	32.2	76	184.5	11
X-1383	BRCA	paclitaxel	885.8	31.8	80	247.1	9.7
X-1383	BRCA	paclitaxel	936.6	31.7	83	267	9.3
X-1383	BRCA	tamoxifen	251.6	26.7	0	0	0
X-1383	BRCA	tamoxifen	301	27.8	3	19.6	4.1
X-1383	BRCA	tamoxifen	363.2	28.5	7	44.4	6.7
X-1383	BRCA	tamoxifen	389.4	28.5	10	54.8	6.7
X-1383	BRCA	tamoxifen	505.5	29.3	14	100.9	9.7
X-1383	BRCA	tamoxifen	549	29.2	17	118.2	9.4
X-1383	BRCA	tamoxifen	603.4	28.4	21	139.8	6.4
X-1383	BRCA	tamoxifen	662.8	28.7	24	163.4	7.5
X-1383	BRCA	tamoxifen	838.9	28.3	28	233.4	6
X-1383	BRCA	tamoxifen	941.1	27.9	31	274	4.5
X-1383	BRCA	tamoxifen	1059.3	28.5	35	321	6.7
X-1383	BRCA	tamoxifen	1183	28.8	38	370.2	7.9
X-1383	BRCA	trastuzumab	236.5	26.8	0	0	0
X-1383	BRCA	trastuzumab	319.1	27.5	6	34.9	2.6
X-1383	BRCA	trastuzumab	416.6	26.9	9	76.2	0.4
X-1383	BRCA	trastuzumab	400	27.6	14	69.1	3
X-1383	BRCA	trastuzumab	442.9	27.3	17	87.3	1.9
X-1383	BRCA	trastuzumab	461.2	28.4	20	95	6
X-1383	BRCA	trastuzumab	515.6	27.9	24	118	4.1
X-1383	BRCA	trastuzumab	594.9	28.3	27	151.5	5.6
X-1383	BRCA	trastuzumab	732	28.8	31	209.5	7.5
X-1383	BRCA	trastuzumab	734.8	27.9	34	210.7	4.1
X-1383	BRCA	trastuzumab	950	28.2	38	301.7	5.2
X-1383	BRCA	trastuzumab	1010.3	28.2	41	327.2	5.2
X-1383	BRCA	trastuzumab	1109.4	29.2	45	369.1	9
X-1383	BRCA	trastuzumab	1252.4	28.9	48	429.6	7.8
X-1383	BRCA	untreated	204.2	27.1	0	0	0
X-1383	BRCA	untreated	275.8	27.2	6	35.1	0.4
X-1383	BRCA	untreated	283.2	27.3	9	38.7	0.7
X-1383	BRCA	untreated	286.7	27.3	14	40.4	0.7
X-1383	BRCA	untreated	323.7	27.6	17	58.5	1.8
X-1383	BRCA	untreated	389.5	28.1	20	90.7	3.7
X-1383	BRCA	untreated	400.1	28	24	95.9	3.3
X-1383	BRCA	untreated	429.2	28.4	27	110.2	4.8
X-1383	BRCA	untreated	462.8	28.6	31	126.6	5.5
X-1383	BRCA	untreated	486.3	28.2	34	138.1	4.1
X-1383	BRCA	untreated	519.1	28.5	38	154.2	5.2
X-1383	BRCA	untreated	511.8	27.9	41	150.6	3
X-1383	BRCA	untreated	665.4	28.3	45	225.9	4.4
X-1383	BRCA	untreated	683	27.9	48	234.5	3
X-1383	BRCA	untreated	764.8	27.9	52	274.5	3
X-1383	BRCA	untreated	835.1	27.8	55	309	2.6
X-1383	BRCA	untreated	900.1	28	59	340.8	3.3
X-1383	BRCA	untreated	895.1	27.7	62	338.3	2.2
X-1383	BRCA	untreated	1002.9	27.6	65	391.1	1.8
X-1383	BRCA	untreated	1059.7	28.5	69	419	5.2
X-1383	BRCA	untreated	1290.9	28.8	73	532.2	6.3
X-1383	BRCA	untreated	1407	27.9	76	589	3
X-1383	BRCA	LFW527 + everolimus	219.72	30.2	0	0	0
X-1383	BRCA	LFW527 + everolimus	288.24	29.4	2	31.2	-2.6
X-1383	BRCA	LFW527 + everolimus	331.98	29.7	6	51.1	-1.7
X-1383	BRCA	LFW527 + everolimus	389.87	28.6	9	77.4	-5.3
X-1383	BRCA	LFW527 + everolimus	447.96	30.1	13	103.9	-0.3
X-1383	BRCA	LFW527 + everolimus	421.51	27.6	16	91.8	-8.6
X-1383	BRCA	LFW527 + everolimus	433.91	28.5	20	97.5	-5.6
X-1383	BRCA	LFW527 + everolimus	495.43	29.3	24	125.5	-3
X-1383	BRCA	LFW527 + everolimus	627.68	27.6	28	185.7	-8.6
X-1383	BRCA	LFW527 + everolimus	694.11	27.6	31	215.9	-8.6
X-1383	BRCA	LFW527 + everolimus	677.41	28.1	34	208.3	-7
X-1383	BRCA	LFW527 + everolimus	745.26	27.8	37	239.2	-7.9
X-1383	BRCA	LFW527 + everolimus	850.84	26.9	41	287.2	-10.9
X-1407	BRCA	BGJ398	214.1	30.4	0	0	0
X-1407	BRCA	BGJ398	221.4	29.4	3	3.4	-3.3
X-1407	BRCA	BGJ398	296.7	30.1	7	38.6	-1
X-1407	BRCA	BGJ398	303.4	29.4	10	41.7	-3.3
X-1407	BRCA	BGJ398	365.5	30.7	14	70.7	1
X-1407	BRCA	BGJ398	376.6	29	17	75.9	-4.6
X-1407	BRCA	BGJ398	439.4	30.1	20	105.2	-1
X-1407	BRCA	BGJ398	424.1	28.2	24	98.1	-7.2
X-1407	BRCA	BGJ398	478.8	29.1	28	123.6	-4.3
X-1407	BRCA	BGJ398	494	29.5	31	130.7	-3
X-1407	BRCA	BGJ398	615.2	28.3	35	187.3	-6.9
X-1407	BRCA	BGJ398	968.8	29.1	45	352.5	-4.3
X-1407	BRCA	BGJ398	1172.6	29.8	49	447.7	-2
X-1407	BRCA	BGJ398	1339.1	28.7	52	525.5	-5.6
X-1407	BRCA	BKM120	207	26.4	0	0	0
X-1407	BRCA	BKM120	212.5	25.9	1	2.7	-1.9
X-1407	BRCA	BKM120	220.3	25.4	4	6.4	-3.8
X-1407	BRCA	BKM120	260.2	26.9	8	25.7	1.9
X-1407	BRCA	BKM120	261.8	26.9	11	26.5	1.9
X-1407	BRCA	BKM120	236.8	27.6	15	14.4	4.5
X-1407	BRCA	BKM120	266.6	27.4	18	28.8	3.8
X-1407	BRCA	BKM120	277	27.7	22	33.8	4.9
X-1407	BRCA	BKM120	305.9	27.3	25	47.8	3.4
X-1407	BRCA	BKM120	304.7	26.9	29	47.2	1.9
X-1407	BRCA	BKM120	335.8	27.7	32	62.2	4.9
X-1407	BRCA	BKM120	345.8	28	36	67.1	6.1
X-1407	BRCA	BKM120	384.7	27.3	39	85.8	3.4
X-1407	BRCA	BKM120	485.9	28	46	134.7	6.1
X-1407	BRCA	BKM120	559.9	26.9	49	170.5	1.9
X-1407	BRCA	BKM120	561	27.7	53	171	4.9
X-1407	BRCA	BKM120	654.5	28.7	57	216.2	8.7
X-1407	BRCA	BKM120	692.7	29.2	60	234.6	10.6
X-1407	BRCA	BKM120	727.6	29.2	64	251.5	10.6
X-1407	BRCA	BKM120	882.9	29.4	74	326.5	11.4
X-1407	BRCA	BKM120	963.3	29.5	78	365.4	11.7
X-1407	BRCA	BKM120	1141.2	28.8	81	451.3	9.1
X-1407	BRCA	BYL719 + LEE011	251	25.4	0	0	0
X-1407	BRCA	BYL719 + LEE011	257.3	25.1	4	2.5	-1.2
X-1407	BRCA	BYL719 + LEE011	273.7	24.4	7	9	-3.9
X-1407	BRCA	BYL719 + LEE011	240.6	22.2	11	-4.1	-12.6
X-1407	BRCA	BYL719 + LEE011	348.8	23.7	14	39	-6.7
X-1407	BRCA	BYL719 + LEE011	312	27.1	18	24.3	6.7
X-1407	BRCA	BYL719 + LEE011	359.3	27.2	21	43.1	7.1
X-1407	BRCA	BYL719 + LEE011	391.1	24.7	25	55.8	-2.8
X-1407	BRCA	BYL719 + LEE011	285.1	22.4	28	13.6	-11.8
X-1407	BRCA	BYL719 + LEE011	347.8	26.7	32	38.6	5.1
X-1407	BRCA	BYL719 + LEE011	266.5	24.6	35	6.2	-3.1
X-1407	BRCA	BYL719 + LEE011	230.4	23.4	39	-8.2	-7.9
X-1407	BRCA	BYL719 + LEE011	183.2	25.9	42	-27	2
X-1407	BRCA	BYL719 + LEE011	199.2	25.8	45	-20.6	1.6
X-1407	BRCA	BYL719 + LEE011	134.6	25	49	-46.4	-1.6
X-1407	BRCA	BYL719 + LEE011	160.1	24.9	53	-36.2	-2
X-1407	BRCA	BYL719 + LEE011	86.5	22.7	56	-65.5	-10.6
X-1407	BRCA	BYL719 + LJM716	193.2	26.5	0	0	0
X-1407	BRCA	BYL719 + LJM716	185.8	25.4	5	-3.8	-4.2
X-1407	BRCA	BYL719 + LJM716	179.8	24.7	8	-6.9	-6.8
X-1407	BRCA	BYL719 + LJM716	204.6	26.4	11	5.9	-0.4
X-1407	BRCA	BYL719 + LJM716	208.2	26.1	15	7.8	-1.5
X-1407	BRCA	BYL719 + LJM716	215.6	26.6	18	11.6	0.4
X-1407	BRCA	BYL719 + LJM716	230.9	26.9	22	19.5	1.5
X-1407	BRCA	BYL719 + LJM716	256.2	26.4	25	32.6	-0.4
X-1407	BRCA	BYL719 + LJM716	251.2	27.8	29	30	4.9
X-1407	BRCA	BYL719 + LJM716	236.4	28.2	32	22.4	6.4
X-1407	BRCA	BYL719 + LJM716	231	27.3	36	19.6	3
X-1407	BRCA	BYL719 + LJM716	249.5	26.6	39	29.1	0.4
X-1407	BRCA	BYL719 + LJM716	241.1	27.3	43	24.8	3
X-1407	BRCA	BYL719 + LJM716	302	28.9	46	56.3	9.1
X-1407	BRCA	BYL719 + LJM716	374.5	28.6	50	93.8	7.9
X-1407	BRCA	BYL719 + LJM716	275.6	29.2	53	42.7	10.2
X-1407	BRCA	BYL719 + LJM716	250.8	27.5	56	29.8	3.8
X-1407	BRCA	BYL719 + LJM716	295.6	28.1	60	53	6
X-1407	BRCA	BYL719 + LJM716	274.1	28.2	64	41.9	6.4
X-1407	BRCA	BYL719 + LJM716	209	28.7	67	8.2	8.3
X-1407	BRCA	BYL719 + LJM716	190.8	27.7	71	-1.2	4.5
X-1407	BRCA	BYL719 + LJM716	125.3	29.6	81	-35.1	11.7
X-1407	BRCA	BYL719 + LJM716	142.7	28.6	85	-26.1	7.9
X-1407	BRCA	BYL719 + LJM716	116.8	28.3	88	-39.5	6.8
X-1407	BRCA	BYL719 + LJM716	124.2	28.8	92	-35.7	8.7
X-1407	BRCA	BYL719 + LJM716	105.4	28.8	95	-45.4	8.7
X-1407	BRCA	BYL719	221.3	25.5	0	0	0
X-1407	BRCA	BYL719	264.1	25.3	4	19.3	-0.8
X-1407	BRCA	BYL719	300.4	25.1	7	35.7	-1.6
X-1407	BRCA	BYL719	389.6	25.5	12	76.1	0
X-1407	BRCA	BYL719	374.5	25	15	69.2	-2
X-1407	BRCA	BYL719	409.8	25.6	18	85.2	0.4
X-1407	BRCA	BYL719	484.6	26.4	22	119	3.5
X-1407	BRCA	BYL719	530.6	27.1	25	139.8	6.3
X-1407	BRCA	BYL719	568.2	26.9	29	156.8	5.5
X-1407	BRCA	BYL719	676.9	26.5	32	205.9	3.9
X-1407	BRCA	BYL719	727.8	27.1	36	228.9	6.3
X-1407	BRCA	BYL719	798.1	26.7	39	260.6	4.7
X-1407	BRCA	BYL719	870.5	26.6	43	293.4	4.3
X-1407	BRCA	BYL719	890.3	27.4	46	302.3	7.5
X-1407	BRCA	BYL719	921.3	27	50	316.3	5.9
X-1407	BRCA	BYL719	1141.1	27.9	53	415.6	9.4
X-1407	BRCA	CGM097	322.1	26.4	0	0	0
X-1407	BRCA	CGM097	499.8	27.5	3	55.2	4.2
X-1407	BRCA	CGM097	639.8	28.3	7	98.6	7.2
X-1407	BRCA	CGM097	815.1	29.5	10	153.1	11.7
X-1407	BRCA	CGM097	1035.1	29.8	14	221.4	12.9
X-1407	BRCA	CGM097	1226.2	30.7	17	280.7	16.3
X-1407	BRCA	CLR457	259.1	28.2	0	0	0
X-1407	BRCA	CLR457	256	26.9	3	-1.2	-4.6
X-1407	BRCA	CLR457	247.9	27.8	6	-4.3	-1.4
X-1407	BRCA	CLR457	243.2	27.6	10	-6.1	-2.1
X-1407	BRCA	CLR457	241.4	27.6	13	-6.8	-2.1
X-1407	BRCA	CLR457	229.9	28.4	17	-11.3	0.7
X-1407	BRCA	CLR457	232.2	28.7	20	-10.4	1.8
X-1407	BRCA	CLR457	236.1	28.1	24	-8.9	-0.4
X-1407	BRCA	CLR457	202.4	29.7	28	-21.9	5.3
X-1407	BRCA	CLR457	183	28	31	-29.4	-0.7
X-1407	BRCA	CLR457	177.4	28.4	35	-31.5	0.7
X-1407	BRCA	CLR457	192.8	28.6	38	-25.6	1.4
X-1407	BRCA	CLR457	178.1	28.4	42	-31.3	0.7
X-1407	BRCA	CLR457	228.2	28.4	45	-11.9	0.7
X-1407	BRCA	CLR457	229.6	28.5	49	-11.4	1.1
X-1407	BRCA	CLR457	257.2	28	52	-0.7	-0.7
X-1407	BRCA	CLR457	315	29.7	56	21.6	5.3
X-1407	BRCA	CLR457	332.7	28.9	59	28.4	2.5
X-1407	BRCA	CLR457	367.1	28.9	63	41.7	2.5
X-1407	BRCA	CLR457	419	29.1	66	61.7	3.2
X-1407	BRCA	CLR457	457.7	29.9	70	76.6	6
X-1407	BRCA	CLR457	573.8	29.5	73	121.5	4.6
X-1407	BRCA	CLR457	712.4	29.7	77	175	5.3
X-1407	BRCA	CLR457	763.2	29.6	80	194.6	5
X-1407	BRCA	HDM201	217.7	25.8	0	0	0
X-1407	BRCA	HDM201	320.7	27.3	4	47.3	5.8
X-1407	BRCA	HDM201	425.4	27.1	7	95.4	5
X-1407	BRCA	HDM201	497.7	26.4	12	128.6	2.3
X-1407	BRCA	HDM201	544.5	27.7	15	150.1	7.4
X-1407	BRCA	HDM201	643.1	27.3	18	195.4	5.8
X-1407	BRCA	HDM201	804.4	27.7	22	269.5	7.4
X-1407	BRCA	HDM201	839.5	28.3	25	285.6	9.7
X-1407	BRCA	HDM201	792.8	29.9	29	264.2	15.9
X-1407	BRCA	HDM201	1011.5	28.6	32	364.6	10.9
X-1407	BRCA	INC424	299.5	29.5	0	0	0
X-1407	BRCA	INC424	320.2	29	4	6.9	-1.7
X-1407	BRCA	INC424	323.8	29	7	8.1	-1.7
X-1407	BRCA	INC424	431.1	29.5	11	43.9	0
X-1407	BRCA	INC424	442.3	29.9	14	47.7	1.4
X-1407	BRCA	INC424	522.9	28.8	18	74.6	-2.4
X-1407	BRCA	INC424	665.1	29.8	21	122.1	1
X-1407	BRCA	INC424	661.4	29.6	25	120.8	0.3
X-1407	BRCA	INC424	678.8	30.4	28	126.6	3.1
X-1407	BRCA	INC424	824.4	29.4	31	175.3	-0.3
X-1407	BRCA	INC424	845.1	29.3	35	182.2	-0.7
X-1407	BRCA	INC424	930.9	29.1	39	210.8	-1.4
X-1407	BRCA	INC424	1004	29.9	42	235.2	1.4
X-1407	BRCA	LEE011 + everolimus	271.3	28.2	0	0	0
X-1407	BRCA	LEE011 + everolimus	291.3	29.1	4	7.4	3.2
X-1407	BRCA	LEE011 + everolimus	326.5	28.7	7	20.3	1.8
X-1407	BRCA	LEE011 + everolimus	355.1	28.9	11	30.9	2.5
X-1407	BRCA	LEE011 + everolimus	331.8	30.4	14	22.3	7.8
X-1407	BRCA	LEE011 + everolimus	319.4	30.4	18	17.7	7.8
X-1407	BRCA	LEE011 + everolimus	323	29.9	21	19.1	6
X-1407	BRCA	LEE011 + everolimus	343.9	29.8	24	26.8	5.7
X-1407	BRCA	LEE011 + everolimus	341.4	29.9	28	25.8	6
X-1407	BRCA	LEE011 + everolimus	351	28.7	32	29.4	1.8
X-1407	BRCA	LEE011 + everolimus	380.8	30.3	35	40.4	7.4
X-1407	BRCA	LEE011 + everolimus	368.9	29.1	39	36	3.2
X-1407	BRCA	LEE011 + everolimus	426.4	29.2	49	57.2	3.5
X-1407	BRCA	LEE011 + everolimus	514.6	30.2	53	89.7	7.1
X-1407	BRCA	LEE011 + everolimus	545	31.6	56	100.9	12.1
X-1407	BRCA	LEE011 + everolimus	539.8	30.7	60	99	8.9
X-1407	BRCA	LEE011 + everolimus	579.4	30.7	63	113.6	8.9
X-1407	BRCA	LEE011 + everolimus	633	29.7	67	133.3	5.3
X-1407	BRCA	LEE011 + everolimus	670.5	30	70	147.1	6.4
X-1407	BRCA	LEE011 + everolimus	698	29.8	73	157.3	5.7
X-1407	BRCA	LEE011 + everolimus	749	30.2	77	176.1	7.1
X-1407	BRCA	LEE011 + everolimus	815.7	30	80	200.7	6.4
X-1407	BRCA	LEE011 + everolimus	853.4	30.2	84	214.6	7.1
X-1407	BRCA	LEE011 + everolimus	879.1	30	87	224	6.4
X-1407	BRCA	LEE011 + everolimus	989.5	29.9	91	264.7	6
X-1407	BRCA	LEE011	225.5	26.2	0	0	0
X-1407	BRCA	LEE011	285	28.6	4	26.4	9.2
X-1407	BRCA	LEE011	270.1	28.7	7	19.8	9.5
X-1407	BRCA	LEE011	311.7	27.9	11	38.2	6.5
X-1407	BRCA	LEE011	349.2	29.4	14	54.9	12.2
X-1407	BRCA	LEE011	422	29.1	18	87.1	11.1
X-1407	BRCA	LEE011	423.8	29.3	21	87.9	11.8
X-1407	BRCA	LEE011	473.4	29.4	25	109.9	12.2
X-1407	BRCA	LEE011	507	29.5	28	124.8	12.6
X-1407	BRCA	LEE011	620	30.1	32	174.9	14.9
X-1407	BRCA	LEE011	574.2	30.8	35	154.6	17.6
X-1407	BRCA	LEE011	713.1	30.3	39	216.2	15.6
X-1407	BRCA	LEE011	852.2	31.2	42	277.9	19.1
X-1407	BRCA	LEE011	865.1	30.6	45	283.6	16.8
X-1407	BRCA	LEE011	968.5	31.6	49	329.5	20.6
X-1407	BRCA	LFA102	301.8	26.3	0	0	0
X-1407	BRCA	LFA102	449.5	27	6	48.9	2.7
X-1407	BRCA	LFA102	559.8	26.7	9	85.5	1.5
X-1407	BRCA	LFA102	719	27.2	14	138.2	3.4
X-1407	BRCA	LFA102	845.3	27.4	17	180.1	4.2
X-1407	BRCA	LFA102	1100.3	28	20	264.6	6.5
X-1407	BRCA	LJM716	197.8	21.9	0	0	0
X-1407	BRCA	LJM716	318	21.8	5	60.8	-0.5
X-1407	BRCA	LJM716	352.6	22.4	8	78.3	2.3
X-1407	BRCA	LJM716	426.4	23	11	115.6	5
X-1407	BRCA	LJM716	509.4	23.5	15	157.5	7.3
X-1407	BRCA	LJM716	535.3	23.6	18	170.6	7.8
X-1407	BRCA	LJM716	588	24.1	22	197.3	10
X-1407	BRCA	LJM716	776.4	23.2	25	292.5	5.9
X-1407	BRCA	LJM716	963.5	23.8	29	387.1	8.7
X-1407	BRCA	LJM716	1010.9	24.6	32	411.1	12.3
X-1407	BRCA	LJM716 + trastuzumab	229.1	29	0	0	0
X-1407	BRCA	LJM716 + trastuzumab	177.8	27.7	2	-22.4	-4.5
X-1407	BRCA	LJM716 + trastuzumab	168.7	27	7	-26.4	-6.9
X-1407	BRCA	LJM716 + trastuzumab	192.5	27.1	10	-16	-6.6
X-1407	BRCA	LJM716 + trastuzumab	380.5	27.6	13	66.1	-4.8
X-1407	BRCA	LJM716 + trastuzumab	288.4	28.1	17	25.9	-3.1
X-1407	BRCA	LJM716 + trastuzumab	318	28.7	20	38.8	-1
X-1407	BRCA	LJM716 + trastuzumab	356.6	28.5	24	55.7	-1.7
X-1407	BRCA	LJM716 + trastuzumab	380.3	27.4	27	66	-5.5
X-1407	BRCA	LJM716 + trastuzumab	420.1	28.6	31	83.4	-1.4
X-1407	BRCA	LJM716 + trastuzumab	474.4	29.3	34	107.1	1
X-1407	BRCA	LJM716 + trastuzumab	610.6	29.3	38	166.5	1
X-1407	BRCA	LJM716 + trastuzumab	627.9	28.8	41	174.1	-0.7
X-1407	BRCA	LJM716 + trastuzumab	697	28.8	45	204.2	-0.7
X-1407	BRCA	LJM716 + trastuzumab	809.9	28.5	48	253.5	-1.7
X-1407	BRCA	LJM716 + trastuzumab	901	29.2	52	293.3	0.7
X-1407	BRCA	LJM716 + trastuzumab	1025	29	55	347.4	0
X-1407	BRCA	LKA136	240.3	26.5	0	0	0
X-1407	BRCA	LKA136	350.6	26.6	3	45.9	0.4
X-1407	BRCA	LKA136	355.2	27.1	7	47.8	2.3
X-1407	BRCA	LKA136	442.3	27.8	10	84.1	4.9
X-1407	BRCA	LKA136	542.3	28.2	14	125.7	6.4
X-1407	BRCA	LKA136	526	28.2	17	118.9	6.4
X-1407	BRCA	LKA136	829.9	28.4	21	245.4	7.2
X-1407	BRCA	LKA136	755	28.1	24	214.2	6
X-1407	BRCA	LKA136	991.8	28.4	28	312.7	7.2
X-1407	BRCA	LKA136	1104.1	27.9	31	359.5	5.3
X-1407	BRCA	LLM871	269.9	29.5	0	0	0
X-1407	BRCA	LLM871	409.1	28.7	6	51.6	-2.7
X-1407	BRCA	LLM871	517.8	28.2	9	91.8	-4.4
X-1407	BRCA	LLM871	515.9	28.6	14	91.1	-3.1
X-1407	BRCA	LLM871	580.6	28.4	17	115.1	-3.7
X-1407	BRCA	LLM871	562.7	29.3	20	108.5	-0.7
X-1407	BRCA	LLM871	593.3	30.4	24	119.8	3.1
X-1407	BRCA	LLM871	543.9	30.9	27	101.5	4.7
X-1407	BRCA	LLM871	540.2	30.9	31	100.1	4.7
X-1407	BRCA	LLM871	547.3	31.2	34	102.8	5.8
X-1407	BRCA	LLM871	565.5	30.7	38	109.5	4.1
X-1407	BRCA	LLM871	588.6	31.3	41	118.1	6.1
X-1407	BRCA	LLM871	608.7	31	45	125.5	5.1
X-1407	BRCA	LLM871	546	30	48	102.3	1.7
X-1407	BRCA	LLM871	541.5	30.6	52	100.6	3.7
X-1407	BRCA	LLM871	550.7	31.4	55	104	6.4
X-1407	BRCA	LLM871	513.4	30.1	59	90.2	2
X-1407	BRCA	LLM871	539.8	30.8	62	100	4.4
X-1407	BRCA	LLM871	503.2	30.3	65	86.4	2.7
X-1407	BRCA	LLM871	521	30	69	93	1.7
X-1407	BRCA	LLM871	582.6	31	73	115.9	5.1
X-1407	BRCA	LLM871	525.6	31	76	94.7	5.1
X-1407	BRCA	LLM871	545.5	30.6	80	102.1	3.7
X-1407	BRCA	LLM871	666.8	30.2	90	147.1	2.4
X-1407	BRCA	LLM871	608.4	30.7	94	125.4	4.1
X-1407	BRCA	LLM871	600.9	29.3	97	122.6	-0.7
X-1407	BRCA	LLM871	627.3	29.5	101	132.4	0
X-1407	BRCA	LLM871	649	33	104	140.5	11.9
X-1407	BRCA	LLM871	763.4	29.7	108	182.8	0.7
X-1407	BRCA	LLM871	766.5	30.6	111	184	3.7
X-1407	BRCA	binimetinib	222.6	27.1	0	0	0
X-1407	BRCA	binimetinib	283.8	27.2	4	27.5	0.4
X-1407	BRCA	binimetinib	316.8	27.3	8	42.3	0.7
X-1407	BRCA	binimetinib	313.3	27.1	11	40.7	0
X-1407	BRCA	binimetinib	285.8	26.7	15	28.4	-1.5
X-1407	BRCA	binimetinib	254.7	26.2	18	14.4	-3.3
X-1407	BRCA	binimetinib	237.3	23.6	22	6.6	-12.9
X-1407	BRCA	binimetinib	239.4	24.5	25	7.5	-9.6
X-1407	BRCA	binimetinib	240.2	26.5	29	7.9	-2.2
X-1407	BRCA	binimetinib	265.3	27.6	32	19.2	1.8
X-1407	BRCA	binimetinib	264	27.1	36	18.6	0
X-1407	BRCA	binimetinib	263.4	27.4	39	18.3	1.1
X-1407	BRCA	binimetinib	241.5	25.9	42	8.5	-4.4
X-1407	BRCA	binimetinib	234.5	24.1	46	5.3	-11.1
X-1407	BRCA	binimetinib	236.4	25.4	50	6.2	-6.3
X-1407	BRCA	binimetinib	198.2	26.5	53	-11	-2.2
X-1407	BRCA	binimetinib	173.7	26.4	57	-22	-2.6
X-1407	BRCA	binimetinib	119.5	26.7	67	-46.3	-1.5
X-1407	BRCA	binimetinib	69.3	26	71	-68.9	-4.1
X-1407	BRCA	binimetinib	56.6	24.7	74	-74.6	-8.9
X-1407	BRCA	binimetinib	79.3	25.2	78	-64.4	-7
X-1407	BRCA	binimetinib	73.3	26.9	81	-67.1	-0.7
X-1407	BRCA	binimetinib	82.9	25.7	85	-62.8	-5.2
X-1407	BRCA	binimetinib	81.6	25.6	88	-63.3	-5.5
X-1407	BRCA	binimetinib	89	25.5	91	-60	-5.9
X-1407	BRCA	binimetinib	91	25.6	95	-59.1	-5.5
X-1407	BRCA	binimetinib	90.4	25.1	98	-59.4	-7.4
X-1407	BRCA	binimetinib	112.9	22.1	102	-49.3	-18.5
X-1407	BRCA	paclitaxel	301.3	26.3	0	0	0
X-1407	BRCA	paclitaxel	473.1	26.5	6	57	0.8
X-1407	BRCA	paclitaxel	574.1	26.8	9	90.5	1.9
X-1407	BRCA	paclitaxel	679.7	26.8	14	125.6	1.9
X-1407	BRCA	paclitaxel	750.1	27.2	17	149	3.4
X-1407	BRCA	paclitaxel	758.8	27.6	20	151.8	4.9
X-1407	BRCA	paclitaxel	960.7	27.8	24	218.9	5.7
X-1407	BRCA	paclitaxel	955.8	27.6	27	217.2	4.9
X-1407	BRCA	paclitaxel	998	28.8	31	231.2	9.5
X-1407	BRCA	paclitaxel	984.6	28.7	34	226.8	9.1
X-1407	BRCA	paclitaxel	986.5	28.4	38	227.4	8
X-1407	BRCA	paclitaxel	953.4	29.5	41	216.4	12.2
X-1407	BRCA	paclitaxel	986.4	28.4	45	227.4	8
X-1407	BRCA	paclitaxel	940.7	28.5	48	212.2	8.4
X-1407	BRCA	tamoxifen	244.7	30	0	0	0
X-1407	BRCA	tamoxifen	350.4	29.6	3	43.2	-1.3
X-1407	BRCA	tamoxifen	410	29	8	67.6	-3.3
X-1407	BRCA	tamoxifen	503.1	30.6	11	105.6	2
X-1407	BRCA	tamoxifen	676.4	30.7	14	176.4	2.3
X-1407	BRCA	tamoxifen	728.5	31.6	18	197.7	5.3
X-1407	BRCA	tamoxifen	834.1	31.6	21	240.9	5.3
X-1407	BRCA	tamoxifen	942.3	33	25	285.1	10
X-1407	BRCA	tamoxifen	1240.8	33.6	28	407.1	12
X-1407	BRCA	trastuzumab	265.6	26.2	0	0	0
X-1407	BRCA	trastuzumab	379.2	26.8	6	42.8	2.3
X-1407	BRCA	trastuzumab	536.5	26.4	9	102	0.8
X-1407	BRCA	trastuzumab	583.8	26.8	14	119.8	2.3
X-1407	BRCA	trastuzumab	683	27	17	157.2	3.1
X-1407	BRCA	trastuzumab	874.1	27.1	20	229.1	3.4
X-1407	BRCA	trastuzumab	1028.9	27.3	24	287.4	4.2
X-1407	BRCA	trastuzumab	1177.1	27.5	27	343.2	5
X-1407	BRCA	untreated	216.2	27.1	0	0	0
X-1407	BRCA	untreated	284.7	25.7	6	31.7	-5.2
X-1407	BRCA	untreated	334.4	26	9	54.7	-4.1
X-1407	BRCA	untreated	402.5	26.5	14	86.2	-2.2
X-1407	BRCA	untreated	501	26.8	17	131.7	-1.1
X-1407	BRCA	untreated	625	27.5	20	189.1	1.5
X-1407	BRCA	untreated	760.3	27.9	24	251.7	3
X-1407	BRCA	untreated	800.9	27.7	27	270.4	2.2
X-1407	BRCA	untreated	882.9	27.7	31	308.4	2.2
X-1407	BRCA	untreated	1039.8	28.4	34	380.9	4.8
X-1407	BRCA	LFW527 + everolimus	244.66	27.8	0	0	0
X-1407	BRCA	LFW527 + everolimus	248.87	28.6	3	1.7	2.9
X-1407	BRCA	LFW527 + everolimus	276.14	28.7	6	12.9	3.2
X-1407	BRCA	LFW527 + everolimus	212.38	28.5	10	-13.2	2.5
X-1407	BRCA	LFW527 + everolimus	197.52	27.7	13	-19.3	-0.4
X-1407	BRCA	LFW527 + everolimus	133.35	22.2	18	-45.5	-20.1
X-1407	BRCA	LFW527 + everolimus	138.18	22	20	-43.5	-20.9
X-1441	CRC	5FU	203.6	24.7	0	0	0
X-1441	CRC	5FU	201.2	24.5	2	-1.2	-0.8
X-1441	CRC	5FU	233	24.2	6	14.4	-2
X-1441	CRC	5FU	249.7	22.4	9	22.6	-9.3
X-1441	CRC	5FU	220.3	23.4	13	8.2	-5.3
X-1441	CRC	5FU	261.7	22.3	16	28.5	-9.7
X-1441	CRC	5FU	295.4	26.1	23	45.1	5.7
X-1441	CRC	5FU	363.2	26.8	27	78.4	8.5
X-1441	CRC	5FU	307	23.8	31	50.8	-3.6
X-1441	CRC	5FU	326.1	23.5	34	60.2	-4.9
X-1441	CRC	5FU	321	22.9	37	57.7	-7.3
X-1441	CRC	5FU	341.7	25.6	41	67.8	3.6
X-1441	CRC	5FU	328	23.3	44	61.1	-5.7
X-1441	CRC	5FU	338.5	23.1	49	66.3	-6.5
X-1441	CRC	5FU	389	22.8	55	91.1	-7.7
X-1441	CRC	5FU	454.2	21.9	58	123.1	-11.3
X-1441	CRC	5FU	500.4	21.6	62	145.8	-12.6
X-1441	CRC	5FU	453.6	21.2	65	122.8	-14.2
X-1441	CRC	5FU	508.4	20.8	69	149.7	-15.8
X-1441	CRC	5FU	421.2	21.9	72	106.9	-11.3
X-1441	CRC	5FU	422.5	22	76	107.5	-10.9
X-1441	CRC	5FU	429.2	21.4	80	110.8	-13.4
X-1441	CRC	5FU	567.6	20.5	83	178.8	-17
X-1441	CRC	5FU	582.6	25.2	86	186.1	2
X-1441	CRC	BKM120	217.6	25.9	0	0	0
X-1441	CRC	BKM120	145.4	25.4	3	-33.2	-1.9
X-1441	CRC	BKM120	109.7	25.3	6	-49.6	-2.3
X-1441	CRC	BKM120	118.4	25.7	13	-45.6	-0.8
X-1441	CRC	BKM120	105.2	24.8	17	-51.7	-4.2
X-1441	CRC	BKM120	131.8	25.9	21	-39.4	0
X-1441	CRC	BKM120	108	27.1	24	-50.4	4.6
X-1441	CRC	BKM120	125.8	25.6	27	-42.2	-1.2
X-1441	CRC	BKM120	117.1	25	31	-46.2	-3.5
X-1441	CRC	BKM120	131.9	25.7	34	-39.4	-0.8
X-1441	CRC	BKM120	136.1	25.7	39	-37.5	-0.8
X-1441	CRC	BKM120	132.7	26.2	45	-39	1.2
X-1441	CRC	BKM120	144.3	26.2	48	-33.7	1.2
X-1441	CRC	BKM120	138.1	26.1	52	-36.5	0.8
X-1441	CRC	BKM120	142.5	26.7	55	-34.5	3.1
X-1441	CRC	BKM120	149.7	26	59	-31.2	0.4
X-1441	CRC	BKM120	152.6	26.5	62	-29.9	2.3
X-1441	CRC	BKM120	155.9	25	66	-28.4	-3.5
X-1441	CRC	BKM120	143.4	24.4	70	-34.1	-5.8
X-1441	CRC	BKM120	134.5	24.7	73	-38.2	-4.6
X-1441	CRC	BKM120	139	23.6	76	-36.1	-8.9
X-1441	CRC	BKM120	141.6	23.4	81	-34.9	-9.7
X-1441	CRC	BKM120 + LJC049	220.4	29.3	0	0	0
X-1441	CRC	BKM120 + LJC049	220.9	29.5	3	0.2	0.7
X-1441	CRC	BKM120 + LJC049	172.8	27.6	8	-21.6	-5.8
X-1441	CRC	BKM120 + LJC049	195.7	23.9	14	-11.2	-18.4
X-1441	CRC	BYL719	199.1	28.7	0	0	0
X-1441	CRC	BYL719	221.1	27.4	1	11	-4.5
X-1441	CRC	BYL719	186.6	26.3	8	-6.3	-8.4
X-1441	CRC	BYL719	221.4	26.5	12	11.2	-7.7
X-1441	CRC	BYL719	205.3	26.4	16	3.1	-8
X-1441	CRC	BYL719	220.5	28	19	10.7	-2.4
X-1441	CRC	BYL719	222	28.2	22	11.5	-1.7
X-1441	CRC	BYL719	223.5	27.7	26	12.3	-3.5
X-1441	CRC	BYL719	198.9	27.2	29	-0.1	-5.2
X-1441	CRC	BYL719	215.5	26.8	34	8.2	-6.6
X-1441	CRC	BYL719	208.2	27	40	4.6	-5.9
X-1441	CRC	BYL719	222.2	29	43	11.6	1
X-1441	CRC	BYL719	222.7	27.8	47	11.9	-3.1
X-1441	CRC	BYL719	264	27.6	50	32.6	-3.8
X-1441	CRC	BYL719	249.8	28.6	54	25.5	-0.3
X-1441	CRC	BYL719	246.6	27.7	57	23.9	-3.5
X-1441	CRC	BYL719	257.9	27.1	61	29.5	-5.6
X-1441	CRC	BYL719	258.4	26.6	65	29.8	-7.3
X-1441	CRC	BYL719	289.6	27.2	68	45.5	-5.2
X-1441	CRC	BYL719	250.8	26.8	71	26	-6.6
X-1441	CRC	BYL719	252.4	26.1	76	26.8	-9.1
X-1441	CRC	BYL719	246.7	28.6	79	23.9	-0.3
X-1441	CRC	BYL719	246.6	26.4	82	23.9	-8
X-1441	CRC	BYL719	247.4	26.5	85	24.3	-7.7
X-1441	CRC	BYL719	248.6	26.9	90	24.9	-6.3
X-1441	CRC	BYL719 + LJM716	210.5	25.2	0	0	0
X-1441	CRC	BYL719 + LJM716	210.3	24.6	4	-0.1	-2.4
X-1441	CRC	BYL719 + LJM716	211.1	24.3	7	0.3	-3.6
X-1441	CRC	BYL719 + LJM716	205.5	23.7	10	-2.4	-6
X-1441	CRC	BYL719 + LJM716	191.8	23	14	-8.9	-8.7
X-1441	CRC	BYL719 + LJM716	174	22.7	17	-17.3	-9.9
X-1441	CRC	BYL719 + LJM716	194.2	22.4	22	-7.7	-11.1
X-1441	CRC	BYL719 + LJM716	202.3	23.9	28	-3.9	-5.2
X-1441	CRC	BYL719 + LJM716	174	22.7	31	-17.3	-9.9
X-1441	CRC	BYL719 + LJM716	193.3	22.8	35	-8.2	-9.5
X-1441	CRC	BYL719 + LJM716	212.6	24.1	38	1	-4.4
X-1441	CRC	BYL719 + LJM716	209.8	24.5	42	-0.3	-2.8
X-1441	CRC	BYL719 + LJM716	203.1	24.2	45	-3.5	-4
X-1441	CRC	BYL719 + LJM716	206.6	23.6	49	-1.9	-6.3
X-1441	CRC	BYL719 + LJM716	229.1	23.2	53	8.8	-7.9
X-1441	CRC	BYL719 + LJM716	239.3	23.7	56	13.7	-6
X-1441	CRC	BYL719 + LJM716	250.6	24.7	59	19	-2
X-1441	CRC	BYL719 + LJM716	261.8	24.2	64	24.4	-4
X-1441	CRC	BYL719 + LJM716	284.1	23.8	67	35	-5.6
X-1441	CRC	BYL719 + LJM716	300.5	23.9	70	42.8	-5.2
X-1441	CRC	BYL719 + LJM716	308.3	23.9	73	46.5	-5.2
X-1441	CRC	BYL719 + LJM716	303.3	23.1	78	44.1	-8.3
X-1441	CRC	BYL719 + LJM716	315.5	22.5	81	49.9	-10.7
X-1441	CRC	BYL719 + LJM716	344.8	24.4	85	63.8	-3.2
X-1441	CRC	BYL719 + LJM716	347.4	23.4	88	65	-7.1
X-1441	CRC	BYL719 + binimetinib	207.9	24.8	0	0	0
X-1441	CRC	BYL719 + binimetinib	193.5	23.6	4	-6.9	-4.8
X-1441	CRC	BYL719 + binimetinib	172.6	21.7	7	-17	-12.5
X-1441	CRC	BYL719 + binimetinib	165.3	22.2	10	-20.5	-10.5
X-1441	CRC	BYL719 + binimetinib	146.1	23	14	-29.7	-7.3
X-1441	CRC	BYL719 + binimetinib	96.5	23.8	17	-53.6	-4
X-1441	CRC	BYL719 + binimetinib	90.6	23.2	22	-56.4	-6.5
X-1441	CRC	BYL719 + binimetinib	135.8	22.9	28	-34.7	-7.7
X-1441	CRC	BYL719 + binimetinib	100.1	21.9	31	-51.9	-11.7
X-1441	CRC	BYL719 + binimetinib	120.6	22.5	35	-42	-9.3
X-1441	CRC	BYL719 + binimetinib	129.8	21.1	38	-37.6	-14.9
X-1441	CRC	BYL719 + binimetinib	122.2	22.9	42	-41.2	-7.7
X-1441	CRC	BYL719 + binimetinib	134.9	21.7	45	-35.1	-12.5
X-1441	CRC	BYL719 + binimetinib	113.3	21.7	49	-45.5	-12.5
X-1441	CRC	BYL719 + binimetinib	124.7	22.7	53	-40	-8.5
X-1441	CRC	BYL719 + binimetinib	131.7	21.7	56	-36.7	-12.5
X-1441	CRC	BYL719 + binimetinib	143.2	22.7	59	-31.1	-8.5
X-1441	CRC	BYL719 + binimetinib	138.1	22.4	64	-33.6	-9.7
X-1441	CRC	BYL719 + binimetinib	156.5	21	67	-24.7	-15.3
X-1441	CRC	BYL719 + binimetinib	141.6	20.9	70	-31.9	-15.7
X-1441	CRC	BYL719 + binimetinib	142.2	21.1	73	-31.6	-14.9
X-1441	CRC	BYL719 + binimetinib	141.5	21.3	78	-31.9	-14.1
X-1441	CRC	BYL719 + binimetinib	141.6	22.3	81	-31.9	-10.1
X-1441	CRC	BYL719 + binimetinib	145.1	22.6	85	-30.2	-8.9
X-1441	CRC	BYL719 + binimetinib	146.9	22.7	88	-29.3	-8.5
X-1441	CRC	BYL719 + cetuximab	217.6	23.5	0	0	0
X-1441	CRC	BYL719 + cetuximab	215	23.5	1	-1.2	0
X-1441	CRC	BYL719 + cetuximab	205.3	23.7	4	-5.7	0.9
X-1441	CRC	BYL719 + cetuximab	197.5	24.6	7	-9.2	4.7
X-1441	CRC	BYL719 + cetuximab	201.6	24	11	-7.4	2.1
X-1441	CRC	BYL719 + cetuximab	222.3	23.6	14	2.2	0.4
X-1441	CRC	BYL719 + cetuximab	229.6	23.5	19	5.5	0
X-1441	CRC	BYL719 + cetuximab	245.6	23.3	25	12.9	-0.9
X-1441	CRC	BYL719 + cetuximab	254.2	23.7	28	16.8	0.9
X-1441	CRC	BYL719 + cetuximab	286.7	22.8	32	31.8	-3
X-1441	CRC	BYL719 + cetuximab	296.4	22.7	35	36.2	-3.4
X-1441	CRC	BYL719 + cetuximab	347.6	22	39	59.7	-6.4
X-1441	CRC	BYL719 + cetuximab	365.1	22.6	42	67.8	-3.8
X-1441	CRC	BYL719 + cetuximab	363.5	22	46	67	-6.4
X-1441	CRC	BYL719 + cetuximab	368	22	50	69.1	-6.4
X-1441	CRC	BYL719 + cetuximab	377.3	22.2	53	73.4	-5.5
X-1441	CRC	BYL719 + cetuximab	377.4	21.9	56	73.4	-6.8
X-1441	CRC	BYL719 + cetuximab	412.5	22	61	89.6	-6.4
X-1441	CRC	BYL719 + cetuximab	474.2	21.1	64	117.9	-10.2
X-1441	CRC	BYL719 + cetuximab	476	21	67	118.8	-10.6
X-1441	CRC	BYL719 + cetuximab	459.3	21	70	111.1	-10.6
X-1441	CRC	BYL719 + cetuximab	561.1	20.9	75	157.9	-11.1
X-1441	CRC	BYL719 + cetuximab	546.6	19.8	78	151.2	-15.7
X-1441	CRC	BYL719 + encorafenib	202.1	25.8	0	0	0
X-1441	CRC	BYL719 + encorafenib	202.1	24.4	1	0	-5.4
X-1441	CRC	BYL719 + encorafenib	194.2	24.3	4	-3.9	-5.8
X-1441	CRC	BYL719 + encorafenib	194.3	24.1	7	-3.9	-6.6
X-1441	CRC	BYL719 + encorafenib	214.9	22.9	11	6.3	-11.2
X-1441	CRC	BYL719 + encorafenib	190.5	23.5	14	-5.7	-8.9
X-1441	CRC	BYL719 + encorafenib	190.8	25.4	19	-5.6	-1.6
X-1441	CRC	BYL719 + encorafenib	211.7	22.5	25	4.8	-12.8
X-1441	CRC	BYL719 + encorafenib	220.1	22.1	28	8.9	-14.3
X-1441	CRC	BYL719 + encorafenib	213	24.6	32	5.4	-4.7
X-1441	CRC	BYL719 + encorafenib	235	22.6	35	16.3	-12.4
X-1441	CRC	BYL719 + encorafenib	251.3	20.9	39	24.3	-19
X-1441	CRC	BYL719 + encorafenib	220.6	20.8	42	9.2	-19.4
X-1441	CRC	BYL719 + cetuximab + encorafenib	206.2	28.2	0	0	0
X-1441	CRC	BYL719 + cetuximab + encorafenib	220.6	26.8	5	7	-5
X-1441	CRC	BYL719 + cetuximab + encorafenib	227.3	26	8	10.2	-7.8
X-1441	CRC	BYL719 + cetuximab + encorafenib	238.2	26.4	11	15.5	-6.4
X-1441	CRC	BYL719 + cetuximab + encorafenib	238.3	27.2	14	15.6	-3.5
X-1441	CRC	BYL719 + cetuximab + encorafenib	258.7	27.6	19	25.5	-2.1
X-1441	CRC	BYL719 + cetuximab + encorafenib	245.2	26.3	22	18.9	-6.7
X-1441	CRC	BYL719 + cetuximab + encorafenib	247.4	26.7	26	20	-5.3
X-1441	CRC	BYL719 + cetuximab + encorafenib	244.6	26.9	29	18.6	-4.6
X-1441	CRC	BYL719 + cetuximab + encorafenib	253.7	27.2	32	23	-3.5
X-1441	CRC	BYL719 + cetuximab + encorafenib	263.2	26.8	35	27.6	-5
X-1441	CRC	BYL719 + cetuximab + encorafenib	302	26.9	39	46.5	-4.6
X-1441	CRC	BYL719 + cetuximab + encorafenib	298.1	30.1	46	44.6	6.7
X-1441	CRC	BYL719 + cetuximab + encorafenib	326.3	28.6	50	58.2	1.4
X-1441	CRC	BYL719 + cetuximab + encorafenib	317.5	26.9	53	54	-4.6
X-1441	CRC	BYL719 + cetuximab + encorafenib	332	26.2	56	61	-7.1
X-1441	CRC	BYL719 + cetuximab + encorafenib	365.4	26.2	60	77.2	-7.1
X-1441	CRC	BYL719 + cetuximab + encorafenib	355.6	26	63	72.5	-7.8
X-1441	CRC	BYL719 + cetuximab + encorafenib	355.6	26.5	67	72.5	-6
X-1441	CRC	BYL719 + cetuximab + encorafenib	341.1	26.1	70	65.4	-7.4
X-1441	CRC	BYL719 + cetuximab + encorafenib	355.7	26.2	74	72.5	-7.1
X-1441	CRC	BYL719 + cetuximab + encorafenib	357.8	26	79	73.5	-7.8
X-1441	CRC	BYL719 + cetuximab + encorafenib	381.7	26.4	82	85.1	-6.4
X-1441	CRC	BYL719 + cetuximab + encorafenib	400.9	25.9	85	94.4	-8.2
X-1441	CRC	BYL719 + cetuximab + encorafenib	400	25.1	88	94	-11
X-1441	CRC	CGM097	211.2	22.9	0	0	0
X-1441	CRC	CGM097	241.1	21.6	3	14.2	-5.7
X-1441	CRC	CGM097	231.9	23.3	7	9.8	1.7
X-1441	CRC	CGM097	317.2	23.5	10	50.2	2.6
X-1441	CRC	CGM097	306.6	25.2	14	45.2	10
X-1441	CRC	CGM097	317.8	24.8	17	50.5	8.3
X-1441	CRC	CGM097	364.1	24.3	21	72.4	6.1
X-1441	CRC	CGM097	372	24.2	24	76.1	5.7
X-1441	CRC	CGM097	438.2	24	31	107.5	4.8
X-1441	CRC	CGM097	502.2	21.9	35	137.8	-4.4
X-1441	CRC	CGM097	538.8	22.5	39	155.1	-1.7
X-1441	CRC	CGM097	500.6	21.3	42	137	-7
X-1441	CRC	CGM097	527.2	23.1	45	149.6	0.9
X-1441	CRC	CGM097	633.6	23.6	49	200	3.1
X-1441	CRC	CGM097	636.3	25.6	52	201.3	11.8
X-1441	CRC	CGM097	694.9	24.3	57	229	6.1
X-1441	CRC	CGM097	763	23.4	63	261.3	2.2
X-1441	CRC	CGM097	847.7	23.3	66	301.4	1.7
X-1441	CRC	CGM097	768.8	23	70	264	0.4
X-1441	CRC	CGM097	1002.7	22.9	73	374.8	0
X-1441	CRC	CGM097	1051.3	22.9	77	397.8	0
X-1441	CRC	CGM097	1089.5	22.6	80	415.9	-1.3
X-1441	CRC	CGM097	1087.8	23	84	415.1	0.4
X-1441	CRC	CKX620	206.5	22.8	0	0	0
X-1441	CRC	CKX620	201.9	21.2	3	-2.2	-7
X-1441	CRC	CKX620	163.2	22.3	7	-21	-2.2
X-1441	CRC	CKX620	200.9	21.8	10	-2.7	-4.4
X-1441	CRC	CKX620	187.4	22.5	14	-9.2	-1.3
X-1441	CRC	CKX620	149.4	22.7	17	-27.7	-0.4
X-1441	CRC	CKX620	131.3	22.6	21	-36.4	-0.9
X-1441	CRC	CKX620	90.5	22.7	24	-56.2	-0.4
X-1441	CRC	CKX620	150.3	23	31	-27.2	0.9
X-1441	CRC	CKX620	149.6	22.6	35	-27.6	-0.9
X-1441	CRC	CKX620	158.4	22.6	39	-23.3	-0.9
X-1441	CRC	CKX620	215.9	22	42	4.6	-3.5
X-1441	CRC	CKX620	231.8	22.4	45	12.3	-1.8
X-1441	CRC	CKX620	235.2	24.5	49	13.9	7.5
X-1441	CRC	CKX620	191.6	23.5	52	-7.2	3.1
X-1441	CRC	CKX620	208.6	24	57	1	5.3
X-1441	CRC	CKX620	208.3	23.6	63	0.9	3.5
X-1441	CRC	CKX620	211.8	23.6	66	2.6	3.5
X-1441	CRC	CKX620	208.5	23.2	70	1	1.8
X-1441	CRC	CKX620	202	22.3	73	-2.2	-2.2
X-1441	CRC	CKX620	223.8	23.1	77	8.4	1.3
X-1441	CRC	CKX620	225.5	22.4	80	9.2	-1.8
X-1441	CRC	CKX620	217.3	23	84	5.2	0.9
X-1441	CRC	CKX620	187.8	22.3	88	-9.1	-2.2
X-1441	CRC	CLR457	225.8	27.7	0	0	0
X-1441	CRC	CLR457	215.5	27.3	3	-4.6	-1.4
X-1441	CRC	CLR457	197.6	27.7	6	-12.5	0
X-1441	CRC	CLR457	179.9	26.4	13	-20.3	-4.7
X-1441	CRC	CLR457	185.5	27.7	17	-17.8	0
X-1441	CRC	CLR457	188.3	27.3	21	-16.6	-1.4
X-1441	CRC	CLR457	196.8	27.8	24	-12.8	0.4
X-1441	CRC	CLR457	183.8	27.7	27	-18.6	0
X-1441	CRC	CLR457	159.1	27.1	31	-29.5	-2.2
X-1441	CRC	CLR457	155.8	27.3	34	-31	-1.4
X-1441	CRC	CLR457	176.5	25.8	39	-21.8	-6.9
X-1441	CRC	CLR457	184.2	27.4	45	-18.4	-1.1
X-1441	CRC	CLR457	200.4	26.6	48	-11.2	-4
X-1441	CRC	CLR457	210.2	26.4	52	-6.9	-4.7
X-1441	CRC	CLR457	213.3	26.6	55	-5.5	-4
X-1441	CRC	CLR457	260.6	26.4	59	15.4	-4.7
X-1441	CRC	CLR457	192.7	26.5	62	-14.7	-4.3
X-1441	CRC	CLR457	206.1	27.1	66	-8.7	-2.2
X-1441	CRC	CLR457	217.2	27	70	-3.8	-2.5
X-1441	CRC	CLR457	276.2	26.8	73	22.3	-3.2
X-1441	CRC	CLR457	247	26.4	76	9.4	-4.7
X-1441	CRC	CLR457	275.5	25.9	81	22	-6.5
X-1441	CRC	CLR457	279.9	26.3	84	24	-5.1
X-1441	CRC	CLR457	292.9	25.6	87	29.7	-7.6
X-1441	CRC	CLR457	295.8	25.7	90	31	-7.2
X-1441	CRC	HDM201	215.6	24.7	0	0	0
X-1441	CRC	HDM201	220.1	24.9	3	2.1	0.8
X-1441	CRC	HDM201	217.4	24.4	7	0.8	-1.2
X-1441	CRC	HDM201	243.3	24.5	10	12.8	-0.8
X-1441	CRC	HDM201	256.8	23.6	14	19.1	-4.5
X-1441	CRC	HDM201	337.6	23.8	17	56.6	-3.6
X-1441	CRC	HDM201	309.3	24.1	21	43.5	-2.4
X-1441	CRC	HDM201	337.2	24.7	24	56.4	0
X-1441	CRC	HDM201	290	24.5	28	34.5	-0.8
X-1441	CRC	HDM201	349.5	24.5	31	62.1	-0.8
X-1441	CRC	HDM201	397.4	24.1	38	84.3	-2.4
X-1441	CRC	HDM201	387.3	22.6	42	79.6	-8.5
X-1441	CRC	HDM201	333.6	22.1	46	54.7	-10.5
X-1441	CRC	HDM201	407	25	49	88.8	1.2
X-1441	CRC	HDM201	407.1	24.4	52	88.8	-1.2
X-1441	CRC	cetuximab	200.6	23.4	0	0	0
X-1441	CRC	cetuximab	197.8	23.3	2	-1.4	-0.4
X-1441	CRC	cetuximab	157.9	24	6	-21.3	2.6
X-1441	CRC	cetuximab	182.7	23.8	9	-8.9	1.7
X-1441	CRC	cetuximab	135	24.3	13	-32.7	3.8
X-1441	CRC	cetuximab	160.2	23.4	16	-20.1	0
X-1441	CRC	cetuximab	213.1	23.5	23	6.2	0.4
X-1441	CRC	cetuximab	235.8	23.4	27	17.5	0
X-1441	CRC	cetuximab	259.6	24.3	31	29.4	3.8
X-1441	CRC	cetuximab	278.8	26.5	34	39	13.2
X-1441	CRC	cetuximab	302.4	24.5	37	50.7	4.7
X-1441	CRC	cetuximab	328.7	25.4	41	63.9	8.5
X-1441	CRC	cetuximab	334.8	24.5	44	66.9	4.7
X-1441	CRC	cetuximab	405.5	25.3	49	102.1	8.1
X-1441	CRC	cetuximab	448	24.9	55	123.3	6.4
X-1441	CRC	cetuximab	459.6	23.9	58	129.1	2.1
X-1441	CRC	cetuximab	519.6	24	62	159	2.6
X-1441	CRC	cetuximab	574.6	24.4	65	186.4	4.3
X-1441	CRC	cetuximab	627.9	24.5	69	213	4.7
X-1441	CRC	cetuximab	653.2	23.7	72	225.6	1.3
X-1441	CRC	cetuximab	718.4	25.5	76	258.1	9
X-1441	CRC	cetuximab	814.3	24	80	305.9	2.6
X-1441	CRC	cetuximab	958.4	24	83	377.8	2.6
X-1441	CRC	cetuximab	1048.3	23.6	86	422.6	0.9
X-1441	CRC	cetuximab + encorafenib	226.6	26.7	0	0	0
X-1441	CRC	cetuximab + encorafenib	260.9	25.8	4	15.1	-3.4
X-1441	CRC	cetuximab + encorafenib	285.6	26.2	7	26	-1.9
X-1441	CRC	cetuximab + encorafenib	259	27.1	10	14.3	1.5
X-1441	CRC	cetuximab + encorafenib	265.1	27.1	14	17	1.5
X-1441	CRC	cetuximab + encorafenib	244.4	27.6	17	7.9	3.4
X-1441	CRC	cetuximab + encorafenib	238.7	26.5	22	5.3	-0.7
X-1441	CRC	cetuximab + encorafenib	206.5	28.4	28	-8.9	6.4
X-1441	CRC	cetuximab + encorafenib	206	26.5	31	-9.1	-0.7
X-1441	CRC	cetuximab + encorafenib	212.2	26.1	35	-6.4	-2.2
X-1441	CRC	cetuximab + encorafenib	218.4	25.3	38	-3.6	-5.2
X-1441	CRC	cetuximab + encorafenib	233.6	25.4	42	3.1	-4.9
X-1441	CRC	cetuximab + encorafenib	260.3	25.5	45	14.9	-4.5
X-1441	CRC	cetuximab + encorafenib	268.9	25.5	49	18.7	-4.5
X-1441	CRC	cetuximab + encorafenib	264.7	25.4	53	16.8	-4.9
X-1441	CRC	cetuximab + encorafenib	276.8	25.1	56	22.2	-6
X-1441	CRC	cetuximab + encorafenib	240.7	24.1	59	6.2	-9.7
X-1441	CRC	cetuximab + encorafenib	250.8	25.1	64	10.7	-6
X-1441	CRC	cetuximab + encorafenib	280.7	23.9	67	23.9	-10.5
X-1441	CRC	cetuximab + encorafenib	287.8	23.7	70	27	-11.2
X-1441	CRC	cetuximab + encorafenib	273.4	22.8	73	20.7	-14.6
X-1441	CRC	cetuximab + encorafenib	309.4	22.9	78	36.5	-14.2
X-1441	CRC	cetuximab + encorafenib	309.9	22	81	36.8	-17.6
X-1441	CRC	LEE011	215.2	24.1	0	0	0
X-1441	CRC	LEE011	214.7	23.6	3	-0.2	-2.1
X-1441	CRC	LEE011	212	23.8	7	-1.5	-1.2
X-1441	CRC	LEE011	254.1	24.3	10	18.1	0.8
X-1441	CRC	LEE011	233.2	25.6	14	8.4	6.2
X-1441	CRC	LEE011	229.8	25.5	17	6.8	5.8
X-1441	CRC	LEE011	236.7	26.4	21	10	9.5
X-1441	CRC	LEE011	256.9	25.9	24	19.4	7.5
X-1441	CRC	LEE011	310.4	24.6	28	44.2	2.1
X-1441	CRC	LEE011	298.2	25.9	31	38.6	7.5
X-1441	CRC	LEE011	330.4	25.3	38	53.5	5
X-1441	CRC	LEE011	305.3	25.1	42	41.9	4.1
X-1441	CRC	LEE011	329.8	23.6	46	53.3	-2.1
X-1441	CRC	LEE011	367.6	25.2	49	70.8	4.6
X-1441	CRC	LEE011	325.6	25	52	51.3	3.7
X-1441	CRC	LEE011	346.5	23.5	56	61	-2.5
X-1441	CRC	LEE011	364	25.3	59	69.1	5
X-1441	CRC	LEE011	375.3	24.8	64	74.4	2.9
X-1441	CRC	LEE011	418.9	24.5	70	94.7	1.7
X-1441	CRC	LEE011	488.8	23.6	73	127.1	-2.1
X-1441	CRC	LEE011	596.1	24.3	77	177	0.8
X-1441	CRC	LEE011	530.8	23.6	80	146.7	-2.1
X-1441	CRC	LEE011	546	22.7	84	153.7	-5.8
X-1441	CRC	LEE011	561.3	23.8	87	160.8	-1.2
X-1441	CRC	LEE011	558.6	24.5	91	159.6	1.7
X-1441	CRC	encorafenib	215.2	25.1	0	0	0
X-1441	CRC	encorafenib	266.1	25.4	3	23.7	1.2
X-1441	CRC	encorafenib	270.4	24.9	7	25.7	-0.8
X-1441	CRC	encorafenib	385.9	23.8	10	79.3	-5.2
X-1441	CRC	encorafenib	394	24.8	14	83.1	-1.2
X-1441	CRC	encorafenib	430.2	23.5	17	99.9	-6.4
X-1441	CRC	encorafenib	402.2	22.3	21	86.9	-11.2
X-1441	CRC	encorafenib	390.5	21.5	24	81.5	-14.3
X-1441	CRC	encorafenib	488.7	21.5	31	127.1	-14.3
X-1441	CRC	encorafenib	532.1	20.5	35	147.3	-18.3
X-1441	CRC	encorafenib	583.4	21.5	39	171.1	-14.3
X-1441	CRC	encorafenib	752.5	21.6	42	249.7	-13.9
X-1441	CRC	encorafenib	703.9	19.8	45	227.1	-21.1
X-1441	CRC	LJC049	205.6	25.5	0	0	0
X-1441	CRC	LJC049	218.4	26.2	3	6.2	2.7
X-1441	CRC	LJC049	245.3	25	7	19.3	-2
X-1441	CRC	LJC049	374.8	24.6	10	82.3	-3.5
X-1441	CRC	LJC049	413.8	25.3	14	101.3	-0.8
X-1441	CRC	LJC049	485.2	25.3	17	136	-0.8
X-1441	CRC	LJC049	420.6	25.7	21	104.6	0.8
X-1441	CRC	LJC049	493.3	25.7	24	139.9	0.8
X-1441	CRC	LJC049	738.6	25	31	259.2	-2
X-1441	CRC	LJC049	798.4	24.2	35	288.3	-5.1
X-1441	CRC	LJC049	758.6	22.6	39	269	-11.4
X-1441	CRC	LJC049	739.5	19	42	259.7	-25.5
X-1441	CRC	LKA136	221.5	25.4	0	0	0
X-1441	CRC	LKA136	214.5	26.6	3	-3.2	4.7
X-1441	CRC	LKA136	252	26.1	6	13.8	2.8
X-1441	CRC	LKA136	235.1	26.5	13	6.1	4.3
X-1441	CRC	LKA136	343.8	26.2	17	55.2	3.1
X-1441	CRC	LKA136	313.3	25.3	21	41.4	-0.4
X-1441	CRC	LKA136	309.6	25.7	24	39.8	1.2
X-1441	CRC	LKA136	370.8	26.2	27	67.4	3.1
X-1441	CRC	LKA136	407.3	26.4	31	83.9	3.9
X-1441	CRC	LKA136	373.8	25.4	34	68.8	0
X-1441	CRC	LKA136	386.2	25.3	39	74.4	-0.4
X-1441	CRC	LKA136	468.6	25.8	45	111.6	1.6
X-1441	CRC	LKA136	478.4	25.4	48	116	0
X-1441	CRC	LKA136	498.1	25.5	52	124.9	0.4
X-1441	CRC	LKA136	515.3	25.6	55	132.6	0.8
X-1441	CRC	LKA136	510.7	25.2	59	130.6	-0.8
X-1441	CRC	LKA136	483.4	24.9	62	118.2	-2
X-1441	CRC	LKA136	489.1	25.9	66	120.8	2
X-1441	CRC	LKA136	523.9	25	70	136.5	-1.6
X-1441	CRC	LKA136	558.4	24.8	73	152.1	-2.4
X-1441	CRC	LKA136	577.9	25	76	160.9	-1.6
X-1441	CRC	LKA136	602.6	24.9	81	172.1	-2
X-1441	CRC	LKA136	739.6	24.7	84	233.9	-2.8
X-1441	CRC	LKA136	814	26.8	87	267.5	5.5
X-1441	CRC	LKA136	712.9	25.7	90	221.9	1.2
X-1441	CRC	binimetinib	205.3	23.8	0	0	0
X-1441	CRC	binimetinib	203.4	23.5	3	-0.9	-1.3
X-1441	CRC	binimetinib	182.1	22.5	7	-11.3	-5.5
X-1441	CRC	binimetinib	162.9	22.6	10	-20.7	-5
X-1441	CRC	binimetinib	142.2	22.9	14	-30.7	-3.8
X-1441	CRC	binimetinib	128.1	22.9	17	-37.6	-3.8
X-1441	CRC	binimetinib	138	23.7	21	-32.8	-0.4
X-1441	CRC	binimetinib	133.4	23.2	24	-35	-2.5
X-1441	CRC	binimetinib	87.1	23.7	28	-57.6	-0.4
X-1441	CRC	binimetinib	99.2	25.7	31	-51.7	8
X-1441	CRC	binimetinib	101.7	24.5	38	-50.5	2.9
X-1441	CRC	binimetinib	108.2	23.9	42	-47.3	0.4
X-1441	CRC	binimetinib	127.2	24	46	-38	0.8
X-1441	CRC	binimetinib	118.8	24.2	49	-42.1	1.7
X-1441	CRC	binimetinib	155	24.1	52	-24.5	1.3
X-1441	CRC	binimetinib	135.9	24.4	56	-33.8	2.5
X-1441	CRC	binimetinib	148.7	23.2	59	-27.6	-2.5
X-1441	CRC	binimetinib	159.3	23.1	64	-22.4	-2.9
X-1441	CRC	binimetinib	169.3	23.6	70	-17.5	-0.8
X-1441	CRC	binimetinib	163	22.5	73	-20.6	-5.5
X-1441	CRC	binimetinib	161.9	22.3	77	-21.1	-6.3
X-1441	CRC	binimetinib	166.8	22.2	80	-18.8	-6.7
X-1441	CRC	binimetinib	166.1	22.3	84	-19.1	-6.3
X-1441	CRC	binimetinib	154	22.9	87	-25	-3.8
X-1441	CRC	binimetinib	159.9	23	91	-22.1	-3.4
X-1441	CRC	untreated	240.3	29	0	0	0
X-1441	CRC	untreated	303	28.9	3	26.1	-0.3
X-1441	CRC	untreated	404.5	27.8	7	68.3	-4.1
X-1441	CRC	untreated	404.5	28.2	10	68.3	-2.8
X-1441	CRC	untreated	438.5	29.3	14	82.5	1
X-1441	CRC	untreated	554.5	27.4	17	130.8	-5.5
X-1441	CRC	untreated	597.1	27.5	21	148.5	-5.2
X-1441	CRC	untreated	676.5	26.2	24	181.5	-9.7
X-1441	CRC	untreated	763.6	27.1	28	217.8	-6.6
X-1441	CRC	untreated	677.8	28.7	31	182.1	-1
X-1441	CRC	untreated	959.1	26.1	38	299.1	-10
X-1441	CRC	untreated	1091.8	25.2	42	354.3	-13.1
X-1441	CRC	untreated	1270	28.7	46	428.5	-1
X-1441	CRC	untreated	1555.8	30	49	547.4	3.4
X-1442	NSCLC	BGJ398	157.9	25.9	0	0	0
X-1442	NSCLC	BGJ398	310.4	26.6	7	96.6	2.7
X-1442	NSCLC	BGJ398	344.3	26.5	10	118	2.3
X-1442	NSCLC	BGJ398	463.6	25.9	13	193.6	0
X-1442	NSCLC	BGJ398	418.5	24.4	17	165	-5.8
X-1442	NSCLC	BGJ398	578	24.9	21	266.1	-3.9
X-1442	NSCLC	BKM120 + binimetinib	194.8	24.2	0	0	0
X-1442	NSCLC	BKM120 + binimetinib	255.4	24.5	7	31.1	1.2
X-1442	NSCLC	BKM120 + binimetinib	280.6	24.8	10	44	2.5
X-1442	NSCLC	BKM120 + binimetinib	320	25	13	64.3	3.3
X-1442	NSCLC	BKM120 + binimetinib	302.7	25.1	17	55.4	3.7
X-1442	NSCLC	BKM120 + binimetinib	287.9	25.8	21	47.8	6.6
X-1442	NSCLC	BKM120 + binimetinib	396.7	24.9	24	103.6	2.9
X-1442	NSCLC	BKM120 + binimetinib	284.8	25.2	27	46.2	4.1
X-1442	NSCLC	BKM120 + binimetinib	253.6	25	30	30.2	3.3
X-1442	NSCLC	BKM120 + binimetinib	171.5	25.8	34	-12	6.6
X-1442	NSCLC	BKM120 + binimetinib	186.9	25.1	44	-4.1	3.7
X-1442	NSCLC	BKM120 + binimetinib	34	26.7	49	-82.5	10.3
X-1442	NSCLC	BKM120 + binimetinib	20.3	26.1	52	-89.6	7.9
X-1442	NSCLC	BKM120 + binimetinib	15.3	26	55	-92.1	7.4
X-1442	NSCLC	BKM120 + binimetinib	16	27.5	62	-91.8	13.6
X-1442	NSCLC	BKM120 + binimetinib	13.7	26.9	66	-93	11.2
X-1442	NSCLC	BKM120 + binimetinib	28.5	27.5	70	-85.4	13.6
X-1442	NSCLC	BKM120 + binimetinib	26.5	27.2	73	-86.4	12.4
X-1442	NSCLC	BKM120 + binimetinib	12	27.3	77	-93.8	12.8
X-1442	NSCLC	BKM120 + binimetinib	0	27.3	80	-100	12.8
X-1442	NSCLC	BKM120 + binimetinib	0	27.9	83	-100	15.3
X-1442	NSCLC	BKM120 + binimetinib	0	26.9	87	-100	11.2
X-1442	NSCLC	BKM120 + binimetinib	0	27.7	91	-100	14.5
X-1442	NSCLC	BKM120 + binimetinib	0	27.1	97	-100	12
X-1442	NSCLC	BKM120 + binimetinib	0	28	101	-100	15.7
X-1442	NSCLC	BKM120 + binimetinib	0	28.3	104	-100	16.9
X-1442	NSCLC	BKM120 + binimetinib	0	28.3	108	-100	16.9
X-1442	NSCLC	BKM120 + binimetinib	0	27.8	111	-100	14.9
X-1442	NSCLC	BKM120 + binimetinib	0	27.8	115	-100	14.9
X-1442	NSCLC	BKM120 + binimetinib	0	27.4	118	-100	13.2
X-1442	NSCLC	BKM120 + binimetinib	0	26.7	125	-100	10.3
X-1442	NSCLC	BKM120	179	21.9	0	0	0
X-1442	NSCLC	BKM120	212	23.3	7	18.4	6.4
X-1442	NSCLC	BKM120	258.7	22.5	10	44.5	2.7
X-1442	NSCLC	BKM120	239.4	22.8	13	33.7	4.1
X-1442	NSCLC	BKM120	278.8	23.3	17	55.8	6.4
X-1442	NSCLC	BKM120	259.2	23.8	21	44.8	8.7
X-1442	NSCLC	BKM120	270.5	23.2	24	51.1	5.9
X-1442	NSCLC	BKM120	274.2	23.3	27	53.2	6.4
X-1442	NSCLC	BKM120	375	22.9	30	109.5	4.6
X-1442	NSCLC	BKM120	346.3	22.6	34	93.5	3.2
X-1442	NSCLC	BKM120	457.5	22.2	41	155.6	1.4
X-1442	NSCLC	BKM120	491.8	21.2	44	174.7	-3.2
X-1442	NSCLC	BKM120	435.1	22.4	49	143.1	2.3
X-1442	NSCLC	BKM120	504.3	22.1	52	181.7	0.9
X-1442	NSCLC	BKM120	548	21.1	55	206.1	-3.7
X-1442	NSCLC	BYL719 + LJM716	152	25.2	0	0	0
X-1442	NSCLC	BYL719 + LJM716	155.5	23.1	7	2.3	-8.3
X-1442	NSCLC	BYL719 + LJM716	217.9	23	10	43.4	-8.7
X-1442	NSCLC	BYL719 + LJM716	235.7	23	13	55.1	-8.7
X-1442	NSCLC	BYL719 + LJM716	271.2	24.3	17	78.4	-3.6
X-1442	NSCLC	BYL719 + LJM716	282.6	23.6	21	85.9	-6.3
X-1442	NSCLC	BYL719 + LJM716	391.4	23.7	24	157.5	-6
X-1442	NSCLC	BYL719 + LJM716	548.4	24	27	260.8	-4.8
X-1442	NSCLC	BYL719 + LJM716	496.6	23.4	30	226.7	-7.1
X-1442	NSCLC	BYL719 + LJM716	645	24.7	34	324.3	-2
X-1442	NSCLC	BYL719	227.7	21.5	0	0	0
X-1442	NSCLC	BYL719	304	22.1	7	33.5	2.8
X-1442	NSCLC	BYL719	298.5	22.6	10	31.1	5.1
X-1442	NSCLC	BYL719	411.1	22.6	13	80.5	5.1
X-1442	NSCLC	BYL719	361.3	22.2	17	58.7	3.3
X-1442	NSCLC	BYL719	519	21.9	21	127.9	1.9
X-1442	NSCLC	BYL719 + LGH447	211.5	23.7	0	0	0
X-1442	NSCLC	BYL719 + LGH447	395.3	23.6	7	86.9	-0.4
X-1442	NSCLC	BYL719 + LGH447	553.4	24	10	161.7	1.3
X-1442	NSCLC	BYL719 + LGH447	510.4	25.1	13	141.3	5.9
X-1442	NSCLC	BYL719 + LGH447	722.5	25	17	241.6	5.5
X-1442	NSCLC	BYL719 + LGH447	773.6	24.5	21	265.8	3.4
X-1442	NSCLC	CGM097	275.4	22.8	0	0	0
X-1442	NSCLC	CGM097	687.4	25	7	149.6	9.6
X-1442	NSCLC	CGM097	664	25.8	10	141.1	13.2
X-1442	NSCLC	CGM097	996.8	26.9	13	261.9	18
X-1442	NSCLC	CKX620	222.1	21.1	0	0	0
X-1442	NSCLC	CKX620	223.8	22.7	7	0.8	7.6
X-1442	NSCLC	CKX620	256.1	22.9	10	15.3	8.5
X-1442	NSCLC	CKX620	191.4	23.5	13	-13.8	11.4
X-1442	NSCLC	CKX620	262.1	23.5	17	18	11.4
X-1442	NSCLC	CKX620	344.2	23.4	21	55	10.9
X-1442	NSCLC	CKX620	306.4	23.6	24	38	11.8
X-1442	NSCLC	CKX620	301.5	24.3	27	35.7	15.2
X-1442	NSCLC	CKX620	387.5	23.9	30	74.5	13.3
X-1442	NSCLC	CKX620	376.8	24.2	34	69.7	14.7
X-1442	NSCLC	CKX620	467.2	24.8	41	110.4	17.5
X-1442	NSCLC	CKX620	494.5	24.5	44	122.6	16.1
X-1442	NSCLC	CKX620	561.6	24.6	49	152.9	16.6
X-1442	NSCLC	CKX620	519.9	25.2	52	134.1	19.4
X-1442	NSCLC	CKX620	512.1	25	55	130.6	18.5
X-1442	NSCLC	CKX620	576.1	27	62	159.4	28
X-1442	NSCLC	CKX620	1107.8	27.2	70	398.8	28.9
X-1442	NSCLC	CKX620	997.8	26.8	71	349.3	27
X-1442	NSCLC	CLR457	236.9	25.9	0	0	0
X-1442	NSCLC	CLR457	292.9	26.4	3	23.6	1.9
X-1442	NSCLC	CLR457	385.5	26.6	6	62.7	2.7
X-1442	NSCLC	CLR457	552.4	26.8	10	133.2	3.5
X-1442	NSCLC	CLR457	499.6	28	14	110.9	8.1
X-1442	NSCLC	CLR457	501.1	28.1	17	111.5	8.5
X-1442	NSCLC	CLR457	542.5	28.1	20	129	8.5
X-1442	NSCLC	CLR457	756.9	28.8	23	219.5	11.2
X-1442	NSCLC	CLR457	831.3	28.3	27	250.9	9.3
X-1442	NSCLC	HDM201	249.8	25.7	0	0	0
X-1442	NSCLC	HDM201	406	25.3	7	62.5	-1.6
X-1442	NSCLC	HDM201	559.5	24	10	124	-6.6
X-1442	NSCLC	HDM201	644.9	25.8	13	158.2	0.4
X-1442	NSCLC	cetuximab	111	23.4	0	0	0
X-1442	NSCLC	cetuximab	260.7	23.9	7	134.9	2.1
X-1442	NSCLC	cetuximab	287.6	24	10	159.1	2.6
X-1442	NSCLC	cetuximab	428.9	24.2	13	286.4	3.4
X-1442	NSCLC	cetuximab	726.6	25.3	17	554.6	8.1
X-1442	NSCLC	cetuximab	894.6	25.7	21	705.9	9.8
X-1442	NSCLC	erlotinib	199.8	27.2	0	0	0
X-1442	NSCLC	erlotinib	179.1	25.4	3	-10.4	-6.6
X-1442	NSCLC	erlotinib	193.9	24.6	7	-3	-9.6
X-1442	NSCLC	erlotinib	227	22.7	11	13.6	-16.5
X-1442	NSCLC	HSP990	167.1	22.7	0	0	0
X-1442	NSCLC	HSP990	307.3	24.1	4	83.9	6.2
X-1442	NSCLC	HSP990	478	24.1	7	186.1	6.2
X-1442	NSCLC	HSP990	362.3	23.9	10	116.8	5.3
X-1442	NSCLC	HSP990	566.8	24.9	14	239.2	9.7
X-1442	NSCLC	HSP990	623.3	21.9	18	273	-3.5
X-1442	NSCLC	INC280	143.7	26.6	0	0	0
X-1442	NSCLC	INC280	166.2	26.4	3	15.7	-0.8
X-1442	NSCLC	INC280	140.7	27.3	6	-2.1	2.6
X-1442	NSCLC	INC280	298.2	27.6	10	107.5	3.8
X-1442	NSCLC	INC280	222.7	27.7	14	55	4.1
X-1442	NSCLC	INC280	241.7	27.1	17	68.2	1.9
X-1442	NSCLC	INC280	252.2	27.7	20	75.5	4.1
X-1442	NSCLC	INC280	247.3	27.3	23	72.1	2.6
X-1442	NSCLC	INC280	317.4	27.9	27	120.9	4.9
X-1442	NSCLC	INC280	379.8	28.5	34	164.3	7.1
X-1442	NSCLC	INC280	489.8	28.2	37	240.8	6
X-1442	NSCLC	INC280	439.4	28.4	42	205.8	6.8
X-1442	NSCLC	INC280	481.4	28.8	45	235	8.3
X-1442	NSCLC	INC280	598.1	30.1	48	316.2	13.2
X-1442	NSCLC	INC280	568.1	29.2	55	295.3	9.8
X-1442	NSCLC	INC280	574.9	28.8	59	300.1	8.3
X-1442	NSCLC	INC280	628	29.6	63	337	11.3
X-1442	NSCLC	INC280	609.2	29.6	66	323.9	11.3
X-1442	NSCLC	INC280	671.1	30.2	70	367	13.5
X-1442	NSCLC	INC280	784.4	29.9	73	445.9	12.4
X-1442	NSCLC	INC280	798.7	29.9	76	455.8	12.4
X-1442	NSCLC	INC280	746.1	29.9	80	419.2	12.4
X-1442	NSCLC	INC280	717.7	29.2	84	399.4	9.8
X-1442	NSCLC	INC280	763.6	29.2	90	431.4	9.8
X-1442	NSCLC	INC280	720	31.8	94	401	19.5
X-1442	NSCLC	INC280	799.8	29.8	97	456.6	12
X-1442	NSCLC	LCL161 + paclitaxel	198.4	25.5	0	0	0
X-1442	NSCLC	LCL161 + paclitaxel	266	24.9	3	34.1	-2.4
X-1442	NSCLC	LCL161 + paclitaxel	328.8	27.4	7	65.7	7.5
X-1442	NSCLC	LCL161 + paclitaxel	375.3	27.2	11	89.2	6.7
X-1442	NSCLC	LCL161 + paclitaxel	409	27.6	14	106.1	8.2
X-1442	NSCLC	LCL161 + paclitaxel	402.9	25.9	17	103.1	1.6
X-1442	NSCLC	LCL161 + paclitaxel	703.4	26.8	20	254.5	5.1
X-1442	NSCLC	LCL161 + paclitaxel	652.4	23.1	24	228.8	-9.4
X-1442	NSCLC	LEE011	242.6	24.1	0	0	0
X-1442	NSCLC	LEE011	629.1	25.8	7	159.3	7.1
X-1442	NSCLC	LEE011	709.1	26.1	10	192.3	8.3
X-1442	NSCLC	LEE011	892.1	26.6	13	267.7	10.4
X-1442	NSCLC	LGH447	206.7	22.4	0	0	0
X-1442	NSCLC	LGH447	239.6	23.6	7	15.9	5.4
X-1442	NSCLC	LGH447	349.1	24.1	10	68.9	7.6
X-1442	NSCLC	LGH447	401.7	24.8	13	94.3	10.7
X-1442	NSCLC	LGH447	485.9	25.1	17	135.1	12.1
X-1442	NSCLC	LGH447	615.8	25.2	21	197.9	12.5
X-1442	NSCLC	LLM871	167.5	22	0	0	0
X-1442	NSCLC	LLM871	160.3	22.2	4	-4.3	0.9
X-1442	NSCLC	LLM871	258.8	22.9	7	54.5	4.1
X-1442	NSCLC	LLM871	322.6	22.9	10	92.6	4.1
X-1442	NSCLC	LLM871	572.1	22.4	14	241.6	1.8
X-1442	NSCLC	LLM871	831.7	22.4	18	396.5	1.8
X-1442	NSCLC	binimetinib	214.5	25.9	0	0	0
X-1442	NSCLC	binimetinib	144.5	26.7	3	-32.6	3.1
X-1442	NSCLC	binimetinib	158.6	27.3	6	-26.1	5.4
X-1442	NSCLC	binimetinib	189.9	28.2	10	-11.5	8.9
X-1442	NSCLC	binimetinib	151.1	27.2	14	-29.6	5
X-1442	NSCLC	binimetinib	214.8	27.6	17	0.1	6.6
X-1442	NSCLC	binimetinib	285	28.1	20	32.9	8.5
X-1442	NSCLC	binimetinib	227.2	28.5	23	5.9	10
X-1442	NSCLC	binimetinib	156.2	28.8	27	-27.2	11.2
X-1442	NSCLC	binimetinib	260.6	29.4	34	21.5	13.5
X-1442	NSCLC	binimetinib	332.8	27.5	37	55.2	6.2
X-1442	NSCLC	binimetinib	272.8	29.3	42	27.2	13.1
X-1442	NSCLC	binimetinib	347.2	28.7	45	61.9	10.8
X-1442	NSCLC	binimetinib	330.7	29.7	48	54.2	14.7
X-1442	NSCLC	binimetinib	376.6	29.3	55	75.6	13.1
X-1442	NSCLC	binimetinib	380.3	29.3	59	77.3	13.1
X-1442	NSCLC	binimetinib	406.6	29.3	63	89.6	13.1
X-1442	NSCLC	binimetinib	363.6	29.8	66	69.5	15.1
X-1442	NSCLC	binimetinib	323.8	29.8	70	51	15.1
X-1442	NSCLC	binimetinib	283.9	30.2	73	32.4	16.6
X-1442	NSCLC	binimetinib	306.3	31.1	76	42.8	20.1
X-1442	NSCLC	binimetinib	421.2	29.5	80	96.4	13.9
X-1442	NSCLC	binimetinib	426.7	29.5	84	98.9	13.9
X-1442	NSCLC	binimetinib	427.8	29.5	90	99.4	13.9
X-1442	NSCLC	binimetinib	405.4	29.1	94	89	12.4
X-1442	NSCLC	binimetinib	361.6	29.6	97	68.6	14.3
X-1442	NSCLC	paclitaxel	207.3	24.2	0	0	0
X-1442	NSCLC	paclitaxel	447.1	25.3	4	115.7	4.5
X-1442	NSCLC	paclitaxel	585.3	25.5	7	182.3	5.4
X-1442	NSCLC	paclitaxel	717.9	25.9	10	246.3	7
X-1442	NSCLC	untreated	363.9	23.8	0	0	0
X-1442	NSCLC	untreated	622.4	25.4	7	71	6.7
X-1442	NSCLC	untreated	605.5	25.1	10	66.4	5.5
X-1442	NSCLC	untreated	770.7	25.8	13	111.8	8.4
X-1443	CRC	5FU	251.1	25.2	0	0	0
X-1443	CRC	5FU	308.7	21.8	15	22.9	-13.5
X-1443	CRC	5FU	267.3	25.8	20	6.5	2.4
X-1443	CRC	5FU	348.1	24.9	24	38.6	-1.2
X-1443	CRC	5FU	404.1	22.2	29	60.9	-11.9
X-1443	CRC	BKM120	210.8	22.1	0	0	0
X-1443	CRC	BKM120	582.2	21.8	7	176.2	-1.4
X-1443	CRC	BKM120	723.7	21.4	15	243.3	-3.2
X-1443	CRC	BKM120	655	21	20	210.7	-5
X-1443	CRC	BKM120	971.9	20.7	24	361.1	-6.3
X-1443	CRC	BKM120	750.1	20.4	29	255.8	-7.7
X-1443	CRC	BKM120 + LJC049	218.8	26	0	0	0
X-1443	CRC	BKM120 + LJC049	187.6	26.2	6	-14.3	0.8
X-1443	CRC	BKM120 + LJC049	206.7	24.6	9	-5.5	-5.4
X-1443	CRC	BKM120 + LJC049	342	23.5	14	56.3	-9.6
X-1443	CRC	BKM120 + LJC049	657.4	24.7	18	200.5	-5
X-1443	CRC	BKM120 + LJC049	810.5	25.5	23	270.4	-1.9
X-1443	CRC	BKM120 + LJC049	683.9	23.8	33	212.6	-8.5
X-1443	CRC	BKM120 + LJC049	876.8	24.5	38	300.7	-5.8
X-1443	CRC	BKM120 + LJC049	832	23.5	46	280.3	-9.6
X-1443	CRC	BYL719	253.6	26.1	0	0	0
X-1443	CRC	BYL719	431.6	23.8	7	70.2	-8.8
X-1443	CRC	BYL719	786.7	24.5	15	210.2	-6.1
X-1443	CRC	BYL719	733.2	21.8	20	189.1	-16.5
X-1443	CRC	BYL719	709.9	21.6	24	179.9	-17.2
X-1443	CRC	BYL719	1109.8	22.6	29	337.6	-13.4
X-1443	CRC	BYL719	998.6	24.1	33	293.8	-7.7
X-1443	CRC	BYL719	1021.9	23.2	38	303	-11.1
X-1443	CRC	BYL719	1162.2	21.4	48	358.3	-18
X-1443	CRC	BYL719 + LJM716	185.8	23.2	0	0	0
X-1443	CRC	BYL719 + LJM716	125.2	20.1	9	-32.6	-13.4
X-1443	CRC	BYL719 + LJM716	150.9	24.1	14	-18.8	3.9
X-1443	CRC	BYL719 + LJM716	143.7	21.2	18	-22.7	-8.6
X-1443	CRC	BYL719 + LJM716	147.7	21.2	23	-20.5	-8.6
X-1443	CRC	BYL719 + LJM716	168.7	20.2	27	-9.2	-12.9
X-1443	CRC	BYL719 + LJM716	123.1	19.9	32	-33.7	-14.2
X-1443	CRC	BYL719 + cetuximab + encorafenib	220.3	24.9	0	0	0
X-1443	CRC	BYL719 + cetuximab + encorafenib	115.1	25.8	6	-47.8	3.6
X-1443	CRC	BYL719 + cetuximab + encorafenib	73	25.5	9	-66.9	2.4
X-1443	CRC	BYL719 + cetuximab + encorafenib	79.9	24.4	14	-63.7	-2
X-1443	CRC	BYL719 + cetuximab + encorafenib	66	24.6	18	-70	-1.2
X-1443	CRC	BYL719 + cetuximab + encorafenib	49.6	25.4	23	-77.5	2
X-1443	CRC	BYL719 + cetuximab + encorafenib	34.4	25.7	33	-84.4	3.2
X-1443	CRC	BYL719 + cetuximab + encorafenib	16.5	26.5	38	-92.5	6.4
X-1443	CRC	BYL719 + cetuximab + encorafenib	27.7	26.8	46	-87.4	7.6
X-1443	CRC	BYL719 + cetuximab + encorafenib	0	26.5	52	-100	6.4
X-1443	CRC	BYL719 + cetuximab + encorafenib	0	25.9	57	-100	4
X-1443	CRC	BYL719 + cetuximab + encorafenib	0	26.1	62	-100	4.8
X-1443	CRC	BYL719 + cetuximab + encorafenib	0	26.4	66	-100	6
X-1443	CRC	BYL719 + cetuximab + encorafenib	0	27.1	71	-100	8.8
X-1443	CRC	BYL719 + cetuximab + encorafenib	0	26.3	74	-100	5.6
X-1443	CRC	BYL719 + cetuximab + encorafenib	0	26.5	78	-100	6.4
X-1443	CRC	BYL719 + cetuximab + encorafenib	0	27	82	-100	8.4
X-1443	CRC	BYL719 + cetuximab + encorafenib	0	25.6	85	-100	2.8
X-1443	CRC	BYL719 + cetuximab + encorafenib	0	26.4	89	-100	6
X-1443	CRC	BYL719 + cetuximab + encorafenib	0	25.9	96	-100	4
X-1443	CRC	BYL719 + encorafenib	192.9	24	0	0	0
X-1443	CRC	BYL719 + encorafenib	204.7	21.7	4	6.1	-9.6
X-1443	CRC	BYL719 + encorafenib	190.5	21.8	9	-1.2	-9.2
X-1443	CRC	BYL719 + encorafenib	223.7	22.6	13	16	-5.8
X-1443	CRC	BYL719 + encorafenib	229.1	23.8	18	18.8	-0.8
X-1443	CRC	BYL719 + encorafenib	257.7	23.2	28	33.6	-3.3
X-1443	CRC	BYL719 + encorafenib	309.8	21.7	33	60.6	-9.6
X-1443	CRC	BYL719 + encorafenib	438.4	23.5	41	127.3	-2.1
X-1443	CRC	BYL719 + encorafenib	428.1	23.8	47	121.9	-0.8
X-1443	CRC	BYL719 + encorafenib	331.9	23.5	52	72.1	-2.1
X-1443	CRC	BYL719 + encorafenib	535.5	22.2	57	177.6	-7.5
X-1443	CRC	BYL719 + encorafenib	883.6	23.8	61	358.1	-0.8
X-1443	CRC	BYL719 + encorafenib	896.9	23.4	66	365	-2.5
X-1443	CRC	BYL719 + encorafenib	684.3	22.6	69	254.7	-5.8
X-1443	CRC	BYL719 + cetuximab	214.1	26.3	0	0	0
X-1443	CRC	BYL719 + cetuximab	155	24.5	6	-27.6	-6.8
X-1443	CRC	BYL719 + cetuximab	152	25	9	-29	-4.9
X-1443	CRC	BYL719 + cetuximab	136.5	25	13	-36.2	-4.9
X-1443	CRC	BYL719 + cetuximab	127.4	26	18	-40.5	-1.1
X-1443	CRC	BYL719 + cetuximab	132.2	25.4	28	-38.3	-3.4
X-1443	CRC	BYL719 + cetuximab	147.1	24.8	33	-31.3	-5.7
X-1443	CRC	BYL719 + cetuximab	116.9	25.7	41	-45.4	-2.3
X-1443	CRC	BYL719 + cetuximab	94.8	27	47	-55.7	2.7
X-1443	CRC	BYL719 + cetuximab	85.7	26	57	-60	-1.1
X-1443	CRC	BYL719 + cetuximab	95.9	26.6	61	-55.2	1.1
X-1443	CRC	BYL719 + cetuximab	64.1	22.9	66	-70.1	-12.9
X-1443	CRC	BYL719 + cetuximab	56.2	26.2	69	-73.8	-0.4
X-1443	CRC	BYL719 + cetuximab	56.2	27.1	73	-73.8	3
X-1443	CRC	BYL719 + cetuximab	54.1	26.8	77	-74.7	1.9
X-1443	CRC	BYL719 + cetuximab	54.3	26.4	80	-74.6	0.4
X-1443	CRC	BYL719 + cetuximab	57.1	27.9	84	-73.3	6.1
X-1443	CRC	BYL719 + cetuximab	59.9	27.4	91	-72	4.2
X-1443	CRC	BYL719 + binimetinib	197.9	26.4	0	0	0
X-1443	CRC	BYL719 + binimetinib	118.3	26.3	1	-40.2	-0.4
X-1443	CRC	BYL719 + binimetinib	81.3	25.9	5	-58.9	-1.9
X-1443	CRC	BYL719 + binimetinib	83.4	26.3	10	-57.9	-0.4
X-1443	CRC	BYL719 + binimetinib	96.2	26.9	25	-51.4	1.9
X-1443	CRC	BYL719 + binimetinib	139.6	27.8	33	-29.5	5.3
X-1443	CRC	BYL719 + binimetinib	130.5	27.2	40	-34.1	3
X-1443	CRC	BYL719 + binimetinib	80	25.6	49	-59.6	-3
X-1443	CRC	BYL719 + binimetinib	114.4	26.8	53	-42.2	1.5
X-1443	CRC	BYL719 + binimetinib	86.7	28	58	-56.2	6.1
X-1443	CRC	BYL719 + binimetinib	85.6	26.5	61	-56.7	0.4
X-1443	CRC	BYL719 + binimetinib	101.9	27	65	-48.5	2.3
X-1443	CRC	BYL719 + binimetinib	130.3	26.7	69	-34.2	1.1
X-1443	CRC	BYL719 + binimetinib	113.4	26.9	72	-42.7	1.9
X-1443	CRC	BYL719 + binimetinib	110.5	27.2	76	-44.2	3
X-1443	CRC	BYL719 + binimetinib	128.3	26.7	83	-35.2	1.1
X-1443	CRC	CGM097	191.2	25.6	0	0	0
X-1443	CRC	CGM097	256	24.4	7	33.9	-4.7
X-1443	CRC	CGM097	288.5	26.2	15	50.9	2.3
X-1443	CRC	CGM097	418.3	26.5	20	118.8	3.5
X-1443	CRC	CGM097	621	24.7	24	224.8	-3.5
X-1443	CRC	CGM097	706.2	24.9	29	269.4	-2.7
X-1443	CRC	CKX620	238.8	24.6	0	0	0
X-1443	CRC	CKX620	237.2	24	7	-0.7	-2.4
X-1443	CRC	CKX620	202.8	25.7	15	-15.1	4.5
X-1443	CRC	CKX620	218.7	25.8	20	-8.4	4.9
X-1443	CRC	CKX620	237.4	24.9	24	-0.6	1.2
X-1443	CRC	CKX620	347.3	25.5	29	45.4	3.7
X-1443	CRC	CLR457	204.7	21.5	0	0	0
X-1443	CRC	CLR457	184.1	24.4	9	-10.1	13.5
X-1443	CRC	CLR457	167.5	24.3	14	-18.2	13
X-1443	CRC	CLR457	221.4	23.1	18	8.2	7.4
X-1443	CRC	CLR457	254.1	23.1	23	24.1	7.4
X-1443	CRC	CLR457	236.3	24.5	27	15.4	14
X-1443	CRC	CLR457	299.6	25.2	32	46.4	17.2
X-1443	CRC	CLR457	200.4	24.2	42	-2.1	12.6
X-1443	CRC	CLR457	330.4	22.3	47	61.4	3.7
X-1443	CRC	CLR457	380.2	23.7	55	85.7	10.2
X-1443	CRC	HDM201	260.8	24.6	0	0	0
X-1443	CRC	HDM201	531	22	7	103.6	-10.6
X-1443	CRC	HDM201	597.2	24	15	129	-2.4
X-1443	CRC	HDM201	714.4	24.8	20	173.9	0.8
X-1443	CRC	HDM201	1003.9	20.8	26	284.9	-15.4
X-1443	CRC	HDM201	759.9	21.6	29	191.4	-12.2
X-1443	CRC	cetuximab + encorafenib	245.7	23.9	0	0	0
X-1443	CRC	cetuximab + encorafenib	200.1	25.8	9	-18.6	7.9
X-1443	CRC	cetuximab + encorafenib	169.3	28.8	14	-31.1	20.5
X-1443	CRC	cetuximab + encorafenib	118.8	26.2	18	-51.6	9.6
X-1443	CRC	cetuximab + encorafenib	226.4	26.8	23	-7.9	12.1
X-1443	CRC	cetuximab + encorafenib	143.3	26.2	27	-41.7	9.6
X-1443	CRC	cetuximab + encorafenib	128.4	22.6	32	-47.7	-5.4
X-1443	CRC	cetuximab + encorafenib	95.1	26.6	42	-61.3	11.3
X-1443	CRC	cetuximab + encorafenib	51.3	27.4	61	-79.1	14.6
X-1443	CRC	cetuximab + encorafenib	11.6	26.5	66	-95.3	10.9
X-1443	CRC	cetuximab + encorafenib	13.4	27.1	71	-94.5	13.4
X-1443	CRC	cetuximab + encorafenib	32.7	27.8	83	-86.7	16.3
X-1443	CRC	cetuximab + encorafenib	35.1	28.3	87	-85.7	18.4
X-1443	CRC	cetuximab + encorafenib	42.1	27.9	91	-82.9	16.7
X-1443	CRC	cetuximab + encorafenib	45.8	27.8	94	-81.4	16.3
X-1443	CRC	cetuximab + encorafenib	43.3	28.7	98	-82.4	20.1
X-1443	CRC	cetuximab + encorafenib	42.6	28.4	105	-82.7	18.8
X-1443	CRC	cetuximab	200.5	27.8	0	0	0
X-1443	CRC	cetuximab	118.4	27.5	1	-40.9	-1.1
X-1443	CRC	cetuximab	71.2	27.3	5	-64.5	-1.8
X-1443	CRC	cetuximab	80.2	28.3	10	-60	1.8
X-1443	CRC	cetuximab	34.1	28.6	20	-83	2.9
X-1443	CRC	cetuximab	44.6	28.9	25	-77.8	4
X-1443	CRC	cetuximab	40	30.1	33	-80	8.3
X-1443	CRC	cetuximab	0	31	39	-100	11.5
X-1443	CRC	cetuximab	0	30.5	44	-100	9.7
X-1443	CRC	cetuximab	24.2	32.5	49	-87.9	16.9
X-1443	CRC	cetuximab	19	32.1	53	-90.5	15.5
X-1443	CRC	cetuximab	14.1	31.5	58	-93	13.3
X-1443	CRC	cetuximab	0	30.5	61	-100	9.7
X-1443	CRC	cetuximab	0	30.9	65	-100	11.2
X-1443	CRC	cetuximab	0	32	69	-100	15.1
X-1443	CRC	cetuximab	0	31.6	72	-100	13.7
X-1443	CRC	cetuximab	12.7	30.9	76	-93.7	11.2
X-1443	CRC	cetuximab	12.5	31.4	83	-93.8	12.9
X-1443	CRC	LEE011	202.3	24.7	0	0	0
X-1443	CRC	LEE011	191.9	24.5	7	-5.1	-0.8
X-1443	CRC	LEE011	195.9	26.1	15	-3.2	5.7
X-1443	CRC	LEE011	195.5	27.1	20	-3.4	9.7
X-1443	CRC	LEE011	291.3	25.1	24	44	1.6
X-1443	CRC	LEE011	373.2	25.6	29	84.5	3.6
X-1443	CRC	encorafenib	206.1	21.8	0	0	0
X-1443	CRC	encorafenib	265.1	21.8	7	28.6	0
X-1443	CRC	encorafenib	460.1	23.3	15	123.2	6.9
X-1443	CRC	encorafenib	463.9	24.3	20	125.1	11.5
X-1443	CRC	encorafenib	639.5	23.4	24	210.3	7.3
X-1443	CRC	encorafenib	795	23.5	29	285.7	7.8
X-1443	CRC	LJC049	200.3	23.6	0	0	0
X-1443	CRC	LJC049	238.6	22.6	7	19.1	-4.2
X-1443	CRC	LJC049	417.5	19.6	15	108.4	-16.9
X-1443	CRC	LJC049	445.4	19.2	16	122.4	-18.6
X-1443	CRC	LKA136	223.1	23.1	0	0	0
X-1443	CRC	LKA136	191	24.6	9	-14.4	6.5
X-1443	CRC	LKA136	199.1	23.6	14	-10.8	2.2
X-1443	CRC	LKA136	233.4	24.4	18	4.6	5.6
X-1443	CRC	LKA136	329.3	25	23	47.6	8.2
X-1443	CRC	LKA136	292.8	25.5	27	31.2	10.4
X-1443	CRC	LKA136	383	25.5	32	71.7	10.4
X-1443	CRC	LKA136	391	25.1	42	75.3	8.7
X-1443	CRC	LKA136	427.2	24.7	47	91.5	6.9
X-1443	CRC	LKA136	478	25.5	55	114.3	10.4
X-1443	CRC	binimetinib	195.5	25.6	0	0	0
X-1443	CRC	binimetinib	88.1	27.1	7	-54.9	5.9
X-1443	CRC	binimetinib	117.6	27.8	15	-39.8	8.6
X-1443	CRC	binimetinib	151.1	28.2	20	-22.7	10.2
X-1443	CRC	binimetinib	146.2	25	24	-25.2	-2.3
X-1443	CRC	binimetinib	168.9	26.7	29	-13.6	4.3
X-1443	CRC	untreated	189.8	26.7	0	0	0
X-1443	CRC	untreated	198	26.6	1	4.3	-0.4
X-1443	CRC	untreated	176.1	26.8	5	-7.2	0.4
X-1443	CRC	untreated	190.7	26.8	10	0.5	0.4
X-1443	CRC	untreated	174.9	26.4	20	-7.9	-1.1
X-1443	CRC	untreated	193.1	25.5	25	1.7	-4.5
X-1443	CRC	untreated	244.7	27.8	33	28.9	4.1
X-1443	CRC	untreated	331.7	28	39	74.8	4.9
X-1443	CRC	untreated	464.6	27.6	44	144.8	3.4
X-1443	CRC	untreated	576.1	27.7	49	203.5	3.7
X-1443	CRC	untreated	624.9	27.4	53	229.2	2.6
X-1443	CRC	untreated	905.6	28.4	58	377.1	6.4
X-1443	CRC	untreated	778.1	26.6	61	310	-0.4
X-1443	CRC	LFW527 + binimetinib	208.98	21.95	0	0	0
X-1443	CRC	LFW527 + binimetinib	223.03	22.4	4	6.7	2.1
X-1443	CRC	LFW527 + binimetinib	221.52	22.33	7	6	1.7
X-1443	CRC	LFW527 + binimetinib	212.39	20.71	11	1.6	-5.6
X-1443	CRC	LFW527 + binimetinib	288.87	21.75	14	38.2	-0.9
X-1443	CRC	LFW527 + binimetinib	397.91	21.56	20	90.4	-1.8
X-1443	CRC	LFW527 + binimetinib	235.41	21.99	25	12.6	0.2
X-1443	CRC	LFW527 + binimetinib	219.13	21.93	28	4.9	-0.1
X-1443	CRC	LFW527 + binimetinib	252.34	22.5	32	20.7	2.5
X-1468		BGJ398	222.1	27.2	0	0	0
X-1468		BGJ398	268.3	27.2	3	20.8	0
X-1468	BRCA	BGJ398	282.9	27.5	7	27.4	1.1
X-1468	BRCA	BGJ398	302.8	27.6	10	36.3	1.5
X-1468	BRCA	BGJ398	318.2	28.7	14	43.3	5.5
X-1468	BRCA	BGJ398	351.8	28.9	17	58.4	6.2
X-1468	BRCA	BGJ398	444.2	28.7	21	100	5.5
X-1468	BRCA	BGJ398	522.9	28.6	24	135.4	5.1
X-1468	BRCA	BGJ398	587.4	28.3	28	164.5	4
X-1468	BRCA	BGJ398	652.8	28.3	31	193.9	4
X-1468	BRCA	BGJ398	831	30	35	274.2	10.3
X-1468	BRCA	BGJ398	843.8	29.7	38	279.9	9.2
X-1468	BRCA	BGJ398	885.7	30.3	42	298.8	11.4
X-1468	BRCA	BGJ398	936.5	29	45	321.7	6.6
X-1468	BRCA	BGJ398	1036.5	28.5	49	366.7	4.8
X-1468	BRCA	BGJ398	1141.9	27.5	52	414.1	1.1
X-1468	BRCA	BGJ398	1200	27.9	56	440.3	2.6
X-1468	BRCA	BKM120	210.4	25.3	0	0	0
X-1468	BRCA	BKM120	211.2	25.5	3	0.4	0.8
X-1468	BRCA	BKM120	211.4	25.3	7	0.5	0
X-1468	BRCA	BKM120	211.5	25.2	10	0.5	-0.4
X-1468	BRCA	BKM120	196.3	25.2	14	-6.7	-0.4
X-1468	BRCA	BKM120	153.2	25.6	17	-27.2	1.2
X-1468	BRCA	BKM120	161.3	25	21	-23.3	-1.2
X-1468	BRCA	BKM120	161.7	25.5	24	-23.1	0.8
X-1468	BRCA	BKM120	158.6	25.4	28	-24.6	0.4
X-1468	BRCA	BKM120	164	25.5	31	-22.1	0.8
X-1468	BRCA	BKM120	161.1	25.8	35	-23.4	2
X-1468	BRCA	BKM120	172	25.8	38	-18.3	2
X-1468	BRCA	BKM120	183	25.4	42	-13	0.4
X-1468	BRCA	BKM120	194	25.8	45	-7.8	2
X-1468	BRCA	BKM120	196.1	26	49	-6.8	2.8
X-1468	BRCA	BKM120	214.2	26.5	52	1.8	4.7
X-1468	BRCA	BKM120	215.9	26.6	56	2.6	5.1
X-1468	BRCA	BKM120	214.5	25.9	59	1.9	2.4
X-1468	BRCA	BKM120	220.8	26.3	63	4.9	4
X-1468	BRCA	BKM120	225.5	26.2	66	7.2	3.6
X-1468	BRCA	BKM120	236.3	26.3	70	12.3	4
X-1468	BRCA	BKM120	240.8	25.2	77	14.4	-0.4
X-1468	BRCA	BKM120	253.6	25.3	80	20.5	0
X-1468	BRCA	BKM120	315.3	26.2	84	49.9	3.6
X-1468	BRCA	BKM120	341.2	26.2	87	62.2	3.6
X-1468	BRCA	BKM120	352.2	26.2	91	67.4	3.6
X-1468	BRCA	BYL719	203.3	26.8	0	0	0
X-1468	BRCA	BYL719	208.4	25.6	3	2.5	-4.5
X-1468	BRCA	BYL719	218.5	26	7	7.5	-3
X-1468	BRCA	BYL719	208.3	26.5	10	2.5	-1.1
X-1468	BRCA	BYL719	205.4	27	14	1	0.7
X-1468	BRCA	BYL719	198.3	26.5	17	-2.5	-1.1
X-1468	BRCA	BYL719	201.6	27	21	-0.8	0.7
X-1468	BRCA	BYL719	211.9	26.5	24	4.2	-1.1
X-1468	BRCA	BYL719	213.8	26.4	28	5.2	-1.5
X-1468	BRCA	BYL719	222.1	25.9	31	9.2	-3.4
X-1468	BRCA	BYL719	214.8	26.9	35	5.7	0.4
X-1468	BRCA	BYL719	217	27.6	38	6.7	3
X-1468	BRCA	BYL719	212.4	27.1	42	4.5	1.1
X-1468	BRCA	BYL719	210.5	27	45	3.5	0.7
X-1468	BRCA	BYL719	219.3	27.7	49	7.9	3.4
X-1468	BRCA	BYL719	224.4	28.4	52	10.4	6
X-1468	BRCA	BYL719	229.4	27.7	56	12.8	3.4
X-1468	BRCA	BYL719	239	27.8	59	17.6	3.7
X-1468	BRCA	BYL719	250.7	27.6	63	23.3	3
X-1468	BRCA	BYL719	257	27.3	66	26.4	1.9
X-1468	BRCA	BYL719	263.5	27.3	70	29.6	1.9
X-1468	BRCA	BYL719	277.6	28	77	36.5	4.5
X-1468	BRCA	BYL719	310.8	28.3	80	52.9	5.6
X-1468	BRCA	BYL719	332.7	27.8	84	63.6	3.7
X-1468	BRCA	BYL719	362.8	28.7	87	78.5	7.1
X-1468	BRCA	BYL719	437.6	27.5	91	115.2	2.6
X-1468	BRCA	BYL719 + LEE011	209	26.4	0	0	0
X-1468	BRCA	BYL719 + LEE011	211.5	25.6	3	1.2	-3
X-1468	BRCA	BYL719 + LEE011	187.5	24.2	7	-10.3	-8.3
X-1468	BRCA	BYL719 + LEE011	172.8	24	10	-17.3	-9.1
X-1468	BRCA	BYL719 + LEE011	175.7	23.7	14	-15.9	-10.2
X-1468	BRCA	BYL719 + LEE011	171.2	24.3	17	-18.1	-8
X-1468	BRCA	BYL719 + LEE011	173.7	23.9	21	-16.9	-9.5
X-1468	BRCA	BYL719 + LEE011	162.8	25.2	24	-22.1	-4.5
X-1468	BRCA	BYL719 + LEE011	164.6	23.4	28	-21.2	-11.4
X-1468	BRCA	BYL719 + LEE011	155.4	24.5	31	-25.6	-7.2
X-1468	BRCA	BYL719 + LEE011	148.5	24.7	35	-28.9	-6.4
X-1468	BRCA	BYL719 + LEE011	142.2	25	38	-32	-5.3
X-1468	BRCA	BYL719 + LEE011	143.1	24.5	42	-31.5	-7.2
X-1468	BRCA	BYL719 + LEE011	139.3	25.1	45	-33.3	-4.9
X-1468	BRCA	BYL719 + LEE011	132.4	25.3	49	-36.7	-4.2
X-1468	BRCA	BYL719 + LEE011	119.9	24.4	52	-42.6	-7.6
X-1468	BRCA	BYL719 + LEE011	111.7	25	56	-46.6	-5.3
X-1468	BRCA	BYL719 + LEE011	111.2	25.7	63	-46.8	-2.7
X-1468	BRCA	BYL719 + LEE011	121.3	26	66	-42	-1.5
X-1468	BRCA	BYL719 + LEE011	119.4	25.4	70	-42.9	-3.8
X-1468	BRCA	BYL719 + LEE011	124.8	25.7	73	-40.3	-2.7
X-1468	BRCA	BYL719 + LEE011	121.4	25	77	-41.9	-5.3
X-1468	BRCA	BYL719 + LEE011	122.1	25.1	80	-41.6	-4.9
X-1468	BRCA	BYL719 + LEE011	126.4	24.4	84	-39.5	-7.6
X-1468	BRCA	BYL719 + LEE011	121.9	25.4	87	-41.7	-3.8
X-1468	BRCA	BYL719 + LEE011	123.3	25.9	91	-41	-1.9
X-1468	BRCA	BYL719 + LEE011	126.1	26	94	-39.7	-1.5
X-1468	BRCA	BYL719 + LEE011	114.9	24.4	97	-45	-7.6
X-1468	BRCA	BYL719 + LJM716	236.1	28	0	0	0
X-1468	BRCA	BYL719 + LJM716	186.2	27.1	3	-21.1	-3.2
X-1468	BRCA	BYL719 + LJM716	198.6	26.4	7	-15.9	-5.7
X-1468	BRCA	BYL719 + LJM716	208	25.2	10	-11.9	-10
X-1468	BRCA	BYL719 + LJM716	211.6	23	14	-10.4	-17.9
X-1468	BRCA	BYL719 + LJM716	224.9	25.3	17	-4.7	-9.6
X-1468	BRCA	BYL719 + LJM716	244.2	26.3	21	3.4	-6.1
X-1468	BRCA	BYL719 + LJM716	251.6	27.3	24	6.6	-2.5
X-1468	BRCA	BYL719 + LJM716	332.3	27.4	28	40.7	-2.1
X-1468	BRCA	BYL719 + LJM716	359.8	27.7	31	52.4	-1.1
X-1468	BRCA	BYL719 + LJM716	393.9	27.9	35	66.8	-0.4
X-1468	BRCA	BYL719 + LJM716	407.2	29.5	38	72.5	5.4
X-1468	BRCA	BYL719 + LJM716	571.5	29.4	42	142.1	5
X-1468	BRCA	BYL719 + LJM716	595.7	29.3	45	152.3	4.6
X-1468	BRCA	BYL719 + LJM716	597.5	28.4	49	153.1	1.4
X-1468	BRCA	BYL719 + LJM716	606.7	27	52	157	-3.6
X-1468	BRCA	BYL719 + LJM716	615.9	26.9	56	160.9	-3.9
X-1468	BRCA	BYL719 + LJM716	606.3	26.9	63	156.8	-3.9
X-1468	BRCA	BYL719 + LJM716	617.6	27.3	66	161.6	-2.5
X-1468	BRCA	BYL719 + LJM716	637.8	27.8	70	170.1	-0.7
X-1468	BRCA	BYL719 + LJM716	657.6	26.7	73	178.5	-4.6
X-1468	BRCA	BYL719 + LJM716	658.9	27.7	77	179.1	-1.1
X-1468	BRCA	BYL719 + LJM716	660.7	25.9	80	179.8	-7.5
X-1468	BRCA	BYL719 + LJM716	678.4	26.7	84	187.3	-4.6
X-1468	BRCA	BYL719 + LJM716	702.7	27	87	197.6	-3.6
X-1468	BRCA	BYL719 + LJM716	722.6	27.4	91	206.1	-2.1
X-1468	BRCA	CGM097	223.8	25.2	0	0	0
X-1468	BRCA	CGM097	227.6	26	3	1.7	3.2
X-1468	BRCA	CGM097	235.6	25.9	7	5.3	2.8
X-1468	BRCA	CGM097	287.3	26.2	10	28.4	4
X-1468	BRCA	CGM097	322	27.1	14	43.9	7.5
X-1468	BRCA	CGM097	460.1	28.2	17	105.6	11.9
X-1468	BRCA	CGM097	639.9	28.3	21	185.9	12.3
X-1468	BRCA	CGM097	748.4	27.6	24	234.4	9.5
X-1468	BRCA	CGM097	983.6	28.1	28	339.5	11.5
X-1468	BRCA	CGM097	1164.8	28.6	31	420.5	13.5
X-1468	BRCA	CGM097	1486.3	27.7	35	564.1	9.9
X-1468	BRCA	CLR457	212.6	26.9	0	0	0
X-1468	BRCA	CLR457	221	25.7	3	4	-4.5
X-1468	BRCA	CLR457	230.8	26.1	7	8.6	-3
X-1468	BRCA	CLR457	228.9	26.2	10	7.7	-2.6
X-1468	BRCA	CLR457	233.7	27	14	9.9	0.4
X-1468	BRCA	CLR457	243.6	26.9	17	14.6	0
X-1468	BRCA	CLR457	241	27.8	21	13.4	3.3
X-1468	BRCA	CLR457	248.4	27.6	24	16.8	2.6
X-1468	BRCA	CLR457	244.1	28.6	28	14.8	6.3
X-1468	BRCA	CLR457	242.4	28.8	31	14	7.1
X-1468	BRCA	CLR457	254.5	27.7	35	19.7	3
X-1468	BRCA	CLR457	262	29.1	38	23.2	8.2
X-1468	BRCA	CLR457	296.8	28.9	42	39.6	7.4
X-1468	BRCA	CLR457	305.2	28.7	45	43.6	6.7
X-1468	BRCA	CLR457	313.6	29.2	49	47.5	8.6
X-1468	BRCA	CLR457	309.2	28.7	52	45.4	6.7
X-1468	BRCA	CLR457	320	28	56	50.5	4.1
X-1468	BRCA	CLR457	327.8	27.6	59	54.2	2.6
X-1468	BRCA	CLR457	326.2	28	63	53.4	4.1
X-1468	BRCA	CLR457	347.1	28.5	70	63.3	5.9
X-1468	BRCA	CLR457	349	29.4	73	64.2	9.3
X-1468	BRCA	CLR457	352.8	29.2	77	65.9	8.6
X-1468	BRCA	CLR457	357.5	28.5	80	68.2	5.9
X-1468	BRCA	CLR457	361.7	29.2	84	70.1	8.6
X-1468	BRCA	CLR457	364.8	28.7	87	71.6	6.7
X-1468	BRCA	CLR457	377.8	28	91	77.7	4.1
X-1468	BRCA	HDM201	208.7	22.9	0	0	0
X-1468	BRCA	HDM201	212.6	23.5	3	1.9	2.6
X-1468	BRCA	HDM201	213.3	22.4	7	2.2	-2.2
X-1468	BRCA	HDM201	229.5	22.5	10	10	-1.7
X-1468	BRCA	HDM201	241.1	23.4	14	15.5	2.2
X-1468	BRCA	HDM201	243	23.5	17	16.4	2.6
X-1468	BRCA	HDM201	254.3	22.8	21	21.8	-0.4
X-1468	BRCA	HDM201	259.9	23.4	24	24.5	2.2
X-1468	BRCA	HDM201	266.8	24	28	27.8	4.8
X-1468	BRCA	HDM201	280.2	23.6	31	34.3	3.1
X-1468	BRCA	HDM201	288.8	24.4	35	38.4	6.6
X-1468	BRCA	HDM201	318.5	25.2	38	52.6	10
X-1468	BRCA	HDM201	376	24.3	42	80.2	6.1
X-1468	BRCA	HDM201	453.4	24.1	45	117.2	5.2
X-1468	BRCA	HDM201	480.7	23.6	49	130.3	3.1
X-1468	BRCA	HDM201	523.6	23.7	52	150.9	3.5
X-1468	BRCA	HDM201	621	23.7	56	197.6	3.5
X-1468	BRCA	HDM201	729.1	24.5	59	249.4	7
X-1468	BRCA	HDM201	825	24.4	63	295.3	6.6
X-1468	BRCA	HDM201	1036.7	24	70	396.7	4.8
X-1468	BRCA	HDM201	1110.9	23.8	73	432.3	3.9
X-1468	BRCA	HDM201	1224.9	24	77	486.9	4.8
X-1468	BRCA	INC424	207.4	29	0	0	0
X-1468	BRCA	INC424	230.4	28.8	3	11.1	-0.7
X-1468	BRCA	INC424	268.6	29.3	7	29.5	1
X-1468	BRCA	INC424	381.1	30.8	10	83.8	6.2
X-1468	BRCA	INC424	509.5	31.2	14	145.7	7.6
X-1468	BRCA	INC424	599.9	31.1	17	189.2	7.2
X-1468	BRCA	INC424	736.2	32.1	21	255	10.7
X-1468	BRCA	INC424	823.8	32.1	24	297.2	10.7
X-1468	BRCA	INC424	903.2	32.7	28	335.5	12.8
X-1468	BRCA	INC424	1160.4	33.1	31	459.5	14.1
X-1468	BRCA	INC424	1205.2	35.1	35	481.1	21
X-1468	BRCA	INC424	1234.5	33.9	38	495.2	16.9
X-1468	BRCA	INC424	1316	33.3	42	534.5	14.8
X-1468	BRCA	INC424	1364.5	33.1	45	557.9	14.1
X-1468	BRCA	INC424	1424.5	34.1	49	586.8	17.6
X-1468	BRCA	LEE011 + everolimus	204.8	31.9	0	0	0
X-1468	BRCA	LEE011 + everolimus	218.1	30.3	3	6.5	-5
X-1468	BRCA	LEE011 + everolimus	227.2	27.6	7	10.9	-13.5
X-1468	BRCA	LEE011 + everolimus	234.9	28.3	10	14.7	-11.3
X-1468	BRCA	LEE011 + everolimus	244.3	28.1	14	19.3	-11.9
X-1468	BRCA	LEE011 + everolimus	248	28.2	17	21.1	-11.6
X-1468	BRCA	LEE011 + everolimus	260.2	28.8	21	27.1	-9.7
X-1468	BRCA	LEE011 + everolimus	245	28	24	19.6	-12.2
X-1468	BRCA	LEE011 + everolimus	260.3	27.1	28	27.1	-15
X-1468	BRCA	LEE011 + everolimus	273.2	27.3	31	33.4	-14.4
X-1468	BRCA	LEE011 + everolimus	311.2	27.1	35	52	-15
X-1468	BRCA	LEE011 + everolimus	322.9	27.9	38	57.7	-12.5
X-1468	BRCA	LEE011 + everolimus	332.7	27.8	42	62.5	-12.9
X-1468	BRCA	LEE011 + everolimus	402.5	28.5	45	96.5	-10.7
X-1468	BRCA	LEE011 + everolimus	490.6	28.4	49	139.6	-11
X-1468	BRCA	LEE011 + everolimus	512	27.8	56	150	-12.9
X-1468	BRCA	LEE011 + everolimus	630.7	27.6	59	208	-13.5
X-1468	BRCA	LEE011 + everolimus	669.9	28	63	227.1	-12.2
X-1468	BRCA	LEE011 + everolimus	734.3	28.1	66	258.5	-11.9
X-1468	BRCA	LEE011 + everolimus	785.9	27.1	70	283.7	-15
X-1468	BRCA	LEE011 + everolimus	827	26.1	73	303.8	-18.2
X-1468	BRCA	LEE011 + everolimus	910.7	27.8	77	344.7	-12.9
X-1468	BRCA	LEE011 + everolimus	1086.6	28.7	80	430.6	-10
X-1468	BRCA	LEE011 + everolimus	1164.1	28.4	84	468.4	-11
X-1468	BRCA	LEE011	205.9	31	0	0	0
X-1468	BRCA	LEE011	214.5	32	3	4.2	3.2
X-1468	BRCA	LEE011	213.2	30.7	7	3.5	-1
X-1468	BRCA	LEE011	200.3	29.8	10	-2.7	-3.9
X-1468	BRCA	LEE011	175.6	29.8	14	-14.7	-3.9
X-1468	BRCA	LEE011	194.1	28.7	17	-5.7	-7.4
X-1468	BRCA	LEE011	193.6	30.1	21	-6	-2.9
X-1468	BRCA	LEE011	204.6	29.6	24	-0.6	-4.5
X-1468	BRCA	LEE011	225.1	29.1	28	9.3	-6.1
X-1468	BRCA	LEE011	244.5	29.8	31	18.7	-3.9
X-1468	BRCA	LEE011	263.2	29.5	35	27.8	-4.8
X-1468	BRCA	LEE011	271.4	30	38	31.8	-3.2
X-1468	BRCA	LEE011	277.5	30.6	42	34.8	-1.3
X-1468	BRCA	LEE011	289.6	30.6	45	40.7	-1.3
X-1468	BRCA	LEE011	293.2	31.6	49	42.4	1.9
X-1468	BRCA	LEE011	324.4	30.2	52	57.6	-2.6
X-1468	BRCA	LEE011	349.4	30.9	56	69.7	-0.3
X-1468	BRCA	LEE011	368.1	31.2	63	78.8	0.6
X-1468	BRCA	LEE011	392.9	30.2	66	90.8	-2.6
X-1468	BRCA	LEE011	433.7	31.2	70	110.6	0.6
X-1468	BRCA	LEE011	460.1	30.1	73	123.5	-2.9
X-1468	BRCA	LEE011	484.1	32.9	77	135.1	6.1
X-1468	BRCA	LEE011	507.3	30.2	80	146.4	-2.6
X-1468	BRCA	LEE011	519.5	31.9	84	152.3	2.9
X-1468	BRCA	LEE011	581.4	30.5	87	182.4	-1.6
X-1468	BRCA	LEE011	615.1	31.5	91	198.7	1.6
X-1468	BRCA	LFA102	230.4	25.9	0	0	0
X-1468	BRCA	LFA102	281	25.2	3	22	-2.7
X-1468	BRCA	LFA102	303.5	25.8	7	31.7	-0.4
X-1468	BRCA	LFA102	371.9	26.6	10	61.4	2.7
X-1468	BRCA	LFA102	463.1	27.2	14	101	5
X-1468	BRCA	LFA102	507.6	26.6	17	120.3	2.7
X-1468	BRCA	LFA102	584.2	26.7	21	153.6	3.1
X-1468	BRCA	LFA102	724.4	26.8	24	214.4	3.5
X-1468	BRCA	LFA102	799.6	27	28	247	4.2
X-1468	BRCA	LFA102	916.9	27.7	31	298	6.9
X-1468	BRCA	LFA102	1050.4	27.5	35	355.9	6.2
X-1468	BRCA	LFA102	1150.3	27.6	38	399.3	6.6
X-1468	BRCA	LFA102	1348	28.7	42	485.1	10.8
X-1468	BRCA	LJM716	228.7	26.1	0	0	0
X-1468	BRCA	LJM716	242.5	25.2	5	6	-3.4
X-1468	BRCA	LJM716	256.5	24.7	8	12.2	-5.4
X-1468	BRCA	LJM716	297.7	24.8	12	30.2	-5
X-1468	BRCA	LJM716	235.4	25.4	15	2.9	-2.7
X-1468	BRCA	LJM716	278.4	25.7	19	21.7	-1.5
X-1468	BRCA	LJM716	319.4	26.4	22	39.7	1.1
X-1468	BRCA	LJM716	333.9	26.3	26	46	0.8
X-1468	BRCA	LJM716	342.8	26	33	49.9	-0.4
X-1468	BRCA	LJM716	359.4	26	36	57.1	-0.4
X-1468	BRCA	LJM716	387.4	26.1	40	69.4	0
X-1468	BRCA	LJM716	432.9	27	47	89.3	3.4
X-1468	BRCA	LJM716	485.4	27.1	50	112.2	3.8
X-1468	BRCA	LJM716	543.5	28.1	54	137.6	7.7
X-1468	BRCA	LJM716	596.7	26.6	57	160.9	1.9
X-1468	BRCA	LJM716	656	27.4	61	186.8	5
X-1468	BRCA	LJM716	676.9	27.7	64	196	6.1
X-1468	BRCA	LJM716	700.1	27.5	68	206.1	5.4
X-1468	BRCA	LJM716	779.9	27.6	71	241	5.7
X-1468	BRCA	LJM716	729.9	27.6	75	219.2	5.7
X-1468	BRCA	LJM716	801.8	26.7	78	250.6	2.3
X-1468	BRCA	LJM716	927.2	26.5	81	305.4	1.5
X-1468	BRCA	LJM716 + trastuzumab	217.9	26.6	0	0	0
X-1468	BRCA	LJM716 + trastuzumab	227.2	26.3	3	4.3	-1.1
X-1468	BRCA	LJM716 + trastuzumab	240.9	26.7	7	10.6	0.4
X-1468	BRCA	LJM716 + trastuzumab	251.9	26.7	10	15.6	0.4
X-1468	BRCA	LJM716 + trastuzumab	229.2	26	14	5.2	-2.3
X-1468	BRCA	LJM716 + trastuzumab	260.8	26.5	17	19.7	-0.4
X-1468	BRCA	LJM716 + trastuzumab	312.9	25.6	21	43.6	-3.8
X-1468	BRCA	LJM716 + trastuzumab	380.9	25.8	24	74.8	-3
X-1468	BRCA	LJM716 + trastuzumab	419.6	26.4	28	92.6	-0.8
X-1468	BRCA	LJM716 + trastuzumab	447.2	27.1	31	105.2	1.9
X-1468	BRCA	LJM716 + trastuzumab	550	29.4	35	152.4	10.5
X-1468	BRCA	LJM716 + trastuzumab	576.9	29.2	38	164.8	9.8
X-1468	BRCA	LJM716 + trastuzumab	747.8	28.7	42	243.2	7.9
X-1468	BRCA	LJM716 + trastuzumab	838.8	28.4	45	284.9	6.8
X-1468	BRCA	LJM716 + trastuzumab	902.9	27.8	49	314.4	4.5
X-1468	BRCA	LJM716 + trastuzumab	1242.6	28.5	52	470.3	7.1
X-1468	BRCA	LJM716 + trastuzumab	1336.1	28.6	56	513.2	7.5
X-1468	BRCA	LKA136	216.6	26.3	0	0	0
X-1468	BRCA	LKA136	239.7	26.5	3	10.7	0.8
X-1468	BRCA	LKA136	273	26.6	7	26	1.1
X-1468	BRCA	LKA136	298.4	27	10	37.8	2.7
X-1468	BRCA	LKA136	332	27.2	14	53.3	3.4
X-1468	BRCA	LKA136	387.5	27.2	17	78.9	3.4
X-1468	BRCA	LKA136	482.3	27.3	21	122.7	3.8
X-1468	BRCA	LKA136	539.8	27.4	24	149.2	4.2
X-1468	BRCA	LKA136	638.8	27.8	28	194.9	5.7
X-1468	BRCA	LKA136	751.6	27.6	31	247	4.9
X-1468	BRCA	LKA136	809.2	28.3	35	273.6	7.6
X-1468	BRCA	LKA136	849.7	28.6	38	292.3	8.7
X-1468	BRCA	LKA136	893	29.2	42	312.3	11
X-1468	BRCA	LKA136	977.2	29.8	45	351.2	13.3
X-1468	BRCA	LKA136	1032.6	29.6	49	376.7	12.5
X-1468	BRCA	LKA136	1067.7	29.3	52	392.9	11.4
X-1468	BRCA	LKA136	1199.4	28.9	56	453.7	9.9
X-1468	BRCA	LLM871	256.1	26	0	0	0
X-1468	BRCA	LLM871	262.7	25.3	3	2.6	-2.7
X-1468	BRCA	LLM871	272.3	25.3	7	6.3	-2.7
X-1468	BRCA	LLM871	268.6	25	10	4.9	-3.8
X-1468	BRCA	LLM871	281	25	14	9.7	-3.8
X-1468	BRCA	LLM871	291.5	24.9	17	13.8	-4.2
X-1468	BRCA	LLM871	308.8	25.8	21	20.6	-0.8
X-1468	BRCA	LLM871	290.5	25	24	13.4	-3.8
X-1468	BRCA	LLM871	294.5	26	28	15	0
X-1468	BRCA	LLM871	301.9	25.1	31	17.9	-3.5
X-1468	BRCA	LLM871	325	25.9	35	26.9	-0.4
X-1468	BRCA	LLM871	371.7	26.1	42	45.1	0.4
X-1468	BRCA	LLM871	374.1	25.8	45	46.1	-0.8
X-1468	BRCA	LLM871	382.3	26.2	49	49.3	0.8
X-1468	BRCA	LLM871	444.9	25.3	56	73.7	-2.7
X-1468	BRCA	LLM871	465.8	25.4	59	81.9	-2.3
X-1468	BRCA	LLM871	470.7	26	63	83.8	0
X-1468	BRCA	LLM871	500.4	25.5	66	95.4	-1.9
X-1468	BRCA	LLM871	535.5	26.5	70	109.1	1.9
X-1468	BRCA	LLM871	551.9	26	73	115.5	0
X-1468	BRCA	LLM871	626	26.7	77	144.4	2.7
X-1468	BRCA	LLM871	676.1	26.4	80	164	1.5
X-1468	BRCA	LLM871	747.4	27.4	84	191.8	5.4
X-1468	BRCA	LLM871	796.7	27.5	87	211.1	5.8
X-1468	BRCA	LLM871	846.9	25.5	90	230.7	-1.9
X-1468	BRCA	LLM871	817.6	26	94	219.3	0
X-1468	BRCA	LLM871	970.7	27.4	97	279	5.4
X-1468	BRCA	binimetinib	200.7	23.9	0	0	0
X-1468	BRCA	binimetinib	205.2	23.3	3	2.2	-2.5
X-1468	BRCA	binimetinib	202.3	23.4	7	0.8	-2.1
X-1468	BRCA	binimetinib	203.2	24.3	10	1.2	1.7
X-1468	BRCA	binimetinib	204.8	24	14	2	0.4
X-1468	BRCA	binimetinib	212.4	24	17	5.8	0.4
X-1468	BRCA	binimetinib	215.9	24.3	21	7.6	1.7
X-1468	BRCA	binimetinib	232	24	24	15.6	0.4
X-1468	BRCA	binimetinib	230.2	24.1	28	14.7	0.8
X-1468	BRCA	binimetinib	244.2	23.1	31	21.7	-3.3
X-1468	BRCA	binimetinib	263.7	23.1	35	31.4	-3.3
X-1468	BRCA	binimetinib	277.4	22.9	38	38.2	-4.2
X-1468	BRCA	binimetinib	294.6	22.1	42	46.8	-7.5
X-1468	BRCA	binimetinib	308	22.1	45	53.5	-7.5
X-1468	BRCA	binimetinib	315.1	22.1	49	57	-7.5
X-1468	BRCA	binimetinib	337.2	22.8	52	68	-4.6
X-1468	BRCA	binimetinib	348.5	21.2	56	73.6	-11.3
X-1468	BRCA	binimetinib	360.2	22.1	59	79.5	-7.5
X-1468	BRCA	binimetinib	364.6	21.5	63	81.7	-10
X-1468	BRCA	binimetinib	384.8	23.8	70	91.7	-0.4
X-1468	BRCA	binimetinib	434	24.6	73	116.2	2.9
X-1468	BRCA	binimetinib	444.6	23.1	77	121.5	-3.3
X-1468	BRCA	binimetinib	478.6	23.9	80	138.5	0
X-1468	BRCA	binimetinib	496.8	23.1	84	147.5	-3.3
X-1468	BRCA	binimetinib	528.2	22.7	87	163.2	-5
X-1468	BRCA	binimetinib	586	22.7	91	192	-5
X-1468	BRCA	paclitaxel	215.4	25.5	0	0	0
X-1468	BRCA	paclitaxel	224.8	25.7	3	4.4	0.8
X-1468	BRCA	paclitaxel	249.4	27.6	7	15.8	8.2
X-1468	BRCA	paclitaxel	283.7	28	10	31.7	9.8
X-1468	BRCA	paclitaxel	296.1	28.7	14	37.5	12.5
X-1468	BRCA	paclitaxel	311	27.5	17	44.4	7.8
X-1468	BRCA	paclitaxel	326.2	27.9	21	51.4	9.4
X-1468	BRCA	paclitaxel	346.6	27	24	60.9	5.9
X-1468	BRCA	paclitaxel	347.2	29.5	28	61.2	15.7
X-1468	BRCA	paclitaxel	355.4	29.2	31	65	14.5
X-1468	BRCA	paclitaxel	363.2	29.9	35	68.6	17.3
X-1468	BRCA	paclitaxel	364	28.6	38	69	12.2
X-1468	BRCA	paclitaxel	321.2	29.8	42	49.1	16.9
X-1468	BRCA	paclitaxel	319.4	29.8	45	48.3	16.9
X-1468	BRCA	paclitaxel	334.5	30.9	49	55.3	21.2
X-1468	BRCA	paclitaxel	343.2	30.5	52	59.3	19.6
X-1468	BRCA	paclitaxel	341.6	30.6	56	58.6	20
X-1468	BRCA	paclitaxel	365.4	30.9	59	69.6	21.2
X-1468	BRCA	paclitaxel	377.2	30.3	63	75.1	18.8
X-1468	BRCA	paclitaxel	380.1	30.9	70	76.5	21.2
X-1468	BRCA	paclitaxel	379.1	30.7	73	76	20.4
X-1468	BRCA	paclitaxel	406.8	30.6	77	88.9	20
X-1468	BRCA	paclitaxel	446.4	30.4	80	107.2	19.2
X-1468	BRCA	paclitaxel	453.8	31.3	84	110.7	22.7
X-1468	BRCA	paclitaxel	460.7	30	87	113.9	17.6
X-1468	BRCA	paclitaxel	519.4	30	91	141.1	17.6
X-1468	BRCA	tamoxifen	222.2	24.2	0	0	0
X-1468	BRCA	tamoxifen	262.4	25.8	3	18.1	6.6
X-1468	BRCA	tamoxifen	327.1	26.2	7	47.2	8.3
X-1468	BRCA	tamoxifen	463.2	27.1	10	108.5	12
X-1468	BRCA	tamoxifen	660.4	28	14	197.2	15.7
X-1468	BRCA	tamoxifen	775.5	27.7	17	249	14.5
X-1468	BRCA	tamoxifen	974.3	27	21	338.5	11.6
X-1468	BRCA	tamoxifen	1020.3	27.9	24	359.2	15.3
X-1468	BRCA	tamoxifen	1229.1	28.5	28	453.2	17.8
X-1468	BRCA	trastuzumab	219.2	23.1	0	0	0
X-1468	BRCA	trastuzumab	233.9	22.6	3	6.7	-2.2
X-1468	BRCA	trastuzumab	260.1	23.1	7	18.7	0
X-1468	BRCA	trastuzumab	262.8	22.7	10	19.9	-1.7
X-1468	BRCA	trastuzumab	283.5	22.7	14	29.3	-1.7
X-1468	BRCA	trastuzumab	324.8	22.9	17	48.2	-0.9
X-1468	BRCA	trastuzumab	369.6	23.3	21	68.6	0.9
X-1468	BRCA	trastuzumab	449.7	24	24	105.2	3.9
X-1468	BRCA	trastuzumab	593.8	23.8	28	170.9	3
X-1468	BRCA	trastuzumab	639.2	23.4	31	191.6	1.3
X-1468	BRCA	trastuzumab	753.8	23.7	35	243.9	2.6
X-1468	BRCA	trastuzumab	887	23.8	38	304.7	3
X-1468	BRCA	trastuzumab	1000.2	25.1	42	356.3	8.7
X-1468	BRCA	untreated	245.6	32	0	0	0
X-1468	BRCA	untreated	274.2	32.8	3	11.6	2.5
X-1468	BRCA	untreated	280.9	30.6	7	14.4	-4.4
X-1468	BRCA	untreated	330.3	32.6	10	34.5	1.9
X-1468	BRCA	untreated	352.8	32.4	14	43.6	1.2
X-1468	BRCA	untreated	407.4	32	17	65.9	0
X-1468	BRCA	untreated	542.7	32.9	21	121	2.8
X-1468	BRCA	untreated	904.1	32.8	24	268.1	2.5
X-1468	BRCA	untreated	961.5	31.3	28	291.5	-2.2
X-1468	BRCA	untreated	1066.7	32.9	31	334.3	2.8
X-1468	BRCA	untreated	1397.4	32.8	35	469	2.5
X-1468	BRCA	LFW527 + everolimus	185.88	27.1	0	0	0
X-1468	BRCA	LFW527 + everolimus	231.16	24.8	3	24.4	-8.5
X-1468	BRCA	LFW527 + everolimus	203.26	24.3	6	9.4	-10.3
X-1468	BRCA	LFW527 + everolimus	176.95	23.1	10	-4.8	-14.8
X-1468	BRCA	LFW527 + everolimus	194.34	24.9	13	4.6	-8.1
X-1468	BRCA	LFW527 + everolimus	195.66	24.8	17	5.3	-8.5
X-1468	BRCA	LFW527 + everolimus	207.22	25.6	20	11.5	-5.5
X-1468	BRCA	LFW527 + everolimus	228.52	25.3	24	22.9	-6.6
X-1468	BRCA	LFW527 + everolimus	242.03	25.4	27	30.2	-6.3
X-1468	BRCA	LFW527 + everolimus	241.7	25.3	31	30	-6.6
X-1468	BRCA	LFW527 + everolimus	244.26	23.4	35	31.4	-13.7
X-1468	BRCA	LFW527 + everolimus	226.15	21.7	38	21.7	-19.9
X-1468	BRCA	LFW527 + everolimus	246.23	24.7	41	32.5	-8.9
X-1468	BRCA	LFW527 + everolimus	214.23	24.6	45	15.3	-9.2
X-1468	BRCA	LFW527 + everolimus	188.62	22.4	48	1.5	-17.3
X-1479	CRC	5FU	213.3	26.2	0	0	0
X-1479	CRC	5FU	213.6	24.6	1	0.1	-6.1
X-1479	CRC	5FU	176.4	24.3	5	-17.3	-7.3
X-1479	CRC	5FU	205	24.6	8	-3.9	-6.1
X-1479	CRC	5FU	224.9	26.7	12	5.4	1.9
X-1479	CRC	5FU	260.8	26.3	15	22.3	0.4
X-1479	CRC	5FU	254.6	26.7	19	19.4	1.9
X-1479	CRC	5FU	259.2	25.3	22	21.5	-3.4
X-1479	CRC	5FU	290.8	25.9	26	36.3	-1.1
X-1479	CRC	5FU	250.3	25.1	29	17.3	-4.2
X-1479	CRC	5FU	256.6	24.9	33	20.3	-5
X-1479	CRC	5FU	249.8	24.4	36	17.1	-6.9
X-1479	CRC	5FU	213.1	24.1	40	-0.1	-8
X-1479	CRC	5FU	262	24.9	43	22.8	-5
X-1479	CRC	5FU	279.9	26.4	47	31.2	0.8
X-1479	CRC	5FU	336.1	25	50	57.6	-4.6
X-1479	CRC	5FU	273.2	27.2	54	28.1	3.8
X-1479	CRC	5FU	250	26.1	57	17.2	-0.4
X-1479	CRC	5FU	415.7	26.9	61	94.9	2.7
X-1479	CRC	5FU	352.3	26.5	64	65.2	1.1
X-1479	CRC	5FU	496.3	25.2	71	132.7	-3.8
X-1479	CRC	5FU	474	26.1	75	122.2	-0.4
X-1479	CRC	5FU	677.2	25.8	79	217.5	-1.5
X-1479	CRC	5FU	561.8	26.7	82	163.4	1.9
X-1479	CRC	BKM120	196.5	26.4	0	0	0
X-1479	CRC	BKM120	194.6	25.5	3	-1	-3.4
X-1479	CRC	BKM120	222	24.5	7	13	-7.2
X-1479	CRC	BKM120	201.3	24.3	10	2.4	-8
X-1479	CRC	BKM120	218.8	24.9	14	11.3	-5.7
X-1479	CRC	BKM120	235.1	25.7	17	19.6	-2.7
X-1479	CRC	BKM120	254.5	25.8	21	29.5	-2.3
X-1479	CRC	BKM120	267.7	26	24	36.2	-1.5
X-1479	CRC	BKM120	278.4	25.9	28	41.7	-1.9
X-1479	CRC	BKM120	281.8	26.3	31	43.4	-0.4
X-1479	CRC	BKM120	296.8	26.3	35	51	-0.4
X-1479	CRC	BKM120	325.9	26.9	38	65.9	1.9
X-1479	CRC	BKM120	366.2	27.2	42	86.4	3
X-1479	CRC	BKM120	387.1	27.5	45	97	4.2
X-1479	CRC	BKM120	414.4	27.6	49	110.9	4.5
X-1479	CRC	BKM120	408.8	27.1	52	108	2.7
X-1479	CRC	BKM120	339.3	28.2	56	72.7	6.8
X-1479	CRC	BKM120	360.9	28.2	59	83.7	6.8
X-1479	CRC	BKM120	328.3	27.8	63	67.1	5.3
X-1479	CRC	BKM120	347.6	27.2	66	76.9	3
X-1479	CRC	BKM120	372.3	27.9	73	89.5	5.7
X-1479	CRC	BKM120	364.3	27.2	77	85.4	3
X-1479	CRC	BKM120	336.5	30.3	81	71.2	14.8
X-1479	CRC	BKM120	428.4	31.1	84	118	17.8
X-1479	CRC	BKM120 + LJC049	196.8	25.5	0	0	0
X-1479	CRC	BKM120 + LJC049	190.3	27	5	-3.3	5.9
X-1479	CRC	BKM120 + LJC049	193.5	26	8	-1.7	2
X-1479	CRC	BKM120 + LJC049	190.8	24.9	12	-3	-2.4
X-1479	CRC	BKM120 + LJC049	202.7	24.4	15	3	-4.3
X-1479	CRC	BKM120 + LJC049	211.8	24.6	19	7.6	-3.5
X-1479	CRC	BKM120 + LJC049	317	25.3	22	61.1	-0.8
X-1479	CRC	BKM120 + LJC049	309.3	25.3	26	57.2	-0.8
X-1479	CRC	BKM120 + LJC049	357.2	23.8	29	81.5	-6.7
X-1479	CRC	BKM120 + LJC049	329.9	20.3	33	67.6	-20.4
X-1479	CRC	BYL719 + cetuximab + encorafenib	200.1	24.4	0	0	0
X-1479	CRC	BYL719 + cetuximab + encorafenib	259.5	22.8	5	29.7	-6.6
X-1479	CRC	BYL719 + cetuximab + encorafenib	240.6	22.8	8	20.2	-6.6
X-1479	CRC	BYL719 + cetuximab + encorafenib	317.5	22.7	11	58.7	-7
X-1479	CRC	BYL719 + cetuximab + encorafenib	291.8	22.3	14	45.8	-8.6
X-1479	CRC	BYL719 + cetuximab + encorafenib	337.9	23.3	18	68.9	-4.5
X-1479	CRC	BYL719 + cetuximab + encorafenib	355.6	22.1	21	77.7	-9.4
X-1479	CRC	BYL719 + cetuximab + encorafenib	407.6	23.8	25	103.7	-2.5
X-1479	CRC	BYL719 + cetuximab + encorafenib	386.9	23.9	28	93.4	-2
X-1479	CRC	BYL719 + cetuximab + encorafenib	375.7	22.4	33	87.8	-8.2
X-1479	CRC	BYL719 + cetuximab + encorafenib	499.2	25.9	36	149.5	6.1
X-1479	CRC	BYL719 + cetuximab + encorafenib	453.1	26	39	126.4	6.6
X-1479	CRC	BYL719 + cetuximab + encorafenib	444.3	24.3	41	122	-0.4
X-1479	CRC	BYL719 + cetuximab + encorafenib	437.3	26.1	46	118.5	7
X-1479	CRC	BYL719 + cetuximab + encorafenib	415.9	22.9	50	107.8	-6.1
X-1479	CRC	BYL719 + cetuximab + encorafenib	444.6	24.4	53	122.2	0
X-1479	CRC	BYL719 + cetuximab + encorafenib	611.3	23.9	60	205.5	-2
X-1479	CRC	BYL719 + cetuximab + encorafenib	549.6	23.5	63	174.7	-3.7
X-1479	CRC	BYL719 + cetuximab + encorafenib	521.2	21.5	67	160.5	-11.9
X-1479	CRC	BYL719 + cetuximab	197.6	23.1	0	0	0
X-1479	CRC	BYL719 + cetuximab	203.5	23.9	2	3	3.5
X-1479	CRC	BYL719 + cetuximab	218.6	25.2	7	10.6	9.1
X-1479	CRC	BYL719 + cetuximab	258.4	22.9	11	30.8	-0.9
X-1479	CRC	BYL719 + cetuximab	270.3	23.1	14	36.8	0
X-1479	CRC	BYL719 + cetuximab	264.6	23	21	33.9	-0.4
X-1479	CRC	BYL719 + cetuximab	251.1	24.2	24	27.1	4.8
X-1479	CRC	BYL719 + cetuximab	273.5	25.1	28	38.4	8.7
X-1479	CRC	BYL719 + LJM716	199.9	23	0	0	0
X-1479	CRC	BYL719 + LJM716	181.9	22	3	-9	-4.3
X-1479	CRC	BYL719 + LJM716	150.7	22.5	6	-24.6	-2.2
X-1479	CRC	BYL719 + LJM716	170.1	22.1	10	-14.9	-3.9
X-1479	CRC	BYL719 + LJM716	182.1	23.1	13	-8.9	0.4
X-1479	CRC	BYL719 + LJM716	169.9	23.3	17	-15	1.3
X-1479	CRC	BYL719 + LJM716	217.4	23.6	20	8.8	2.6
X-1479	CRC	BYL719 + LJM716	196.4	24.6	24	-1.8	7
X-1479	CRC	BYL719 + LJM716	231.3	25.1	27	15.7	9.1
X-1479	CRC	BYL719 + LJM716	216.2	25.4	31	8.2	10.4
X-1479	CRC	BYL719 + LJM716	228.1	26.1	34	14.1	13.5
X-1479	CRC	BYL719 + LJM716	274.7	25.5	38	37.4	10.9
X-1479	CRC	BYL719 + LJM716	263	24.7	41	31.6	7.4
X-1479	CRC	BYL719 + LJM716	268.4	25.6	45	34.3	11.3
X-1479	CRC	BYL719 + LJM716	334.8	25.6	48	67.5	11.3
X-1479	CRC	BYL719 + LJM716	323.8	26.6	52	62	15.7
X-1479	CRC	BYL719 + LJM716	359.7	25.6	55	79.9	11.3
X-1479	CRC	BYL719 + LJM716	380.8	26.2	59	90.5	13.9
X-1479	CRC	BYL719 + LJM716	369	26.1	62	84.6	13.5
X-1479	CRC	BYL719 + LJM716	468.7	25.5	69	134.5	10.9
X-1479	CRC	BYL719 + LJM716	429.9	26.3	73	115.1	14.3
X-1479	CRC	BYL719 + LJM716	471.8	25.6	77	136	11.3
X-1479	CRC	BYL719 + LJM716	488.3	26.2	80	144.3	13.9
X-1479	CRC	BYL719 + LJM716	486.8	26.4	83	143.5	14.8
X-1479	CRC	BYL719	213	32.6	0	0	0
X-1479	CRC	BYL719	202.2	30.4	5	-5.1	-6.7
X-1479	CRC	BYL719	203.8	31.7	8	-4.3	-2.8
X-1479	CRC	BYL719	215.6	31.7	12	1.2	-2.8
X-1479	CRC	BYL719	227.8	31.4	15	6.9	-3.7
X-1479	CRC	BYL719	268.2	32.1	19	25.9	-1.5
X-1479	CRC	BYL719	286.3	31.9	22	34.4	-2.1
X-1479	CRC	BYL719	249.9	32	26	17.3	-1.8
X-1479	CRC	BYL719	305.2	32.5	29	43.3	-0.3
X-1479	CRC	BYL719	318.7	31.9	33	49.6	-2.1
X-1479	CRC	BYL719	358.3	32.1	36	68.2	-1.5
X-1479	CRC	BYL719	327.3	30.7	43	53.7	-5.8
X-1479	CRC	BYL719	447.1	33.1	47	109.9	1.5
X-1479	CRC	BYL719	517	33.1	50	142.7	1.5
X-1479	CRC	BYL719	529.7	31.7	54	148.7	-2.8
X-1479	CRC	BYL719	543.8	32.4	57	155.3	-0.6
X-1479	CRC	BYL719	565.1	32.4	64	165.3	-0.6
X-1479	CRC	BYL719	601.1	33.1	68	182.2	1.5
X-1479	CRC	BYL719	649.6	32.4	72	205	-0.6
X-1479	CRC	BYL719	691	32.9	75	224.4	0.9
X-1479	CRC	BYL719	860.7	32.5	78	304.1	-0.3
X-1479	CRC	BYL719 + binimetinib	201.9	26	0	0	0
X-1479	CRC	BYL719 + binimetinib	215.8	24.8	5	6.9	-4.6
X-1479	CRC	BYL719 + binimetinib	214.8	25.7	8	6.4	-1.2
X-1479	CRC	BYL719 + binimetinib	163.2	25.9	12	-19.2	-0.4
X-1479	CRC	BYL719 + binimetinib	163.3	25.2	15	-19.1	-3.1
X-1479	CRC	BYL719 + binimetinib	136.8	26.6	19	-32.2	2.3
X-1479	CRC	BYL719 + binimetinib	118.1	27.2	22	-41.5	4.6
X-1479	CRC	BYL719 + binimetinib	113.8	28.4	26	-43.6	9.2
X-1479	CRC	BYL719 + binimetinib	160.6	28.2	29	-20.5	8.5
X-1479	CRC	BYL719 + binimetinib	105.2	28.1	33	-47.9	8.1
X-1479	CRC	BYL719 + binimetinib	116.1	27.7	36	-42.5	6.5
X-1479	CRC	BYL719 + binimetinib	92.5	27.5	40	-54.2	5.8
X-1479	CRC	BYL719 + binimetinib	118	27.3	43	-41.6	5
X-1479	CRC	BYL719 + binimetinib	78.6	26.1	47	-61.1	0.4
X-1479	CRC	BYL719 + binimetinib	100.3	25.3	50	-50.3	-2.7
X-1479	CRC	BYL719 + binimetinib	92	24.5	54	-54.4	-5.8
X-1479	CRC	BYL719 + binimetinib	126.6	24.9	57	-37.3	-4.2
X-1479	CRC	BYL719 + binimetinib	106.1	26.5	64	-47.4	1.9
X-1479	CRC	BYL719 + binimetinib	108.9	26.4	68	-46.1	1.5
X-1479	CRC	BYL719 + binimetinib	123.8	26.4	72	-38.7	1.5
X-1479	CRC	BYL719 + binimetinib	169.8	25.4	75	-15.9	-2.3
X-1479	CRC	BYL719 + binimetinib	144	26.4	78	-28.7	1.5
X-1479	CRC	BYL719 + binimetinib	131.3	26.1	82	-35	0.4
X-1479	CRC	BYL719 + binimetinib	133.9	26	85	-33.7	0
X-1479	CRC	BYL719 + binimetinib	121.5	26.2	90	-39.8	0.8
X-1479	CRC	BYL719 + encorafenib	198.7	23.5	0	0	0
X-1479	CRC	BYL719 + encorafenib	182.7	24.4	5	-8.1	3.8
X-1479	CRC	BYL719 + encorafenib	205.8	24.6	8	3.6	4.7
X-1479	CRC	BYL719 + encorafenib	183.6	24.9	12	-7.6	6
X-1479	CRC	BYL719 + encorafenib	210.1	24.6	15	5.7	4.7
X-1479	CRC	BYL719 + encorafenib	212.3	25.7	19	6.8	9.4
X-1479	CRC	BYL719 + encorafenib	204.9	26.3	22	3.1	11.9
X-1479	CRC	BYL719 + encorafenib	222.4	26	26	11.9	10.6
X-1479	CRC	BYL719 + encorafenib	243.7	25.8	29	22.6	9.8
X-1479	CRC	BYL719 + encorafenib	226.4	25.7	33	13.9	9.4
X-1479	CRC	BYL719 + encorafenib	281.5	27.4	36	41.7	16.6
X-1479	CRC	BYL719 + encorafenib	291	26.4	40	46.5	12.3
X-1479	CRC	BYL719 + encorafenib	353.1	27.5	43	77.7	17
X-1479	CRC	BYL719 + encorafenib	410.1	26.7	47	106.4	13.6
X-1479	CRC	BYL719 + encorafenib	377	25.6	50	89.7	8.9
X-1479	CRC	BYL719 + encorafenib	509.4	25.1	54	156.4	6.8
X-1479	CRC	BYL719 + encorafenib	429	24.5	57	115.9	4.3
X-1479	CRC	BYL719 + encorafenib	508.9	23.4	64	156.1	-0.4
X-1479	CRC	BYL719 + encorafenib	538.6	23	68	171.1	-2.1
X-1479	CRC	BYL719 + encorafenib	512.8	22.2	72	158.1	-5.5
X-1479	CRC	BYL719 + encorafenib	600.5	22.8	75	202.2	-3
X-1479	CRC	BYL719 + encorafenib	554.4	24.3	78	179	3.4
X-1479	CRC	BYL719 + encorafenib	549.8	21.8	82	176.7	-7.2
X-1479	CRC	BYL719 + encorafenib	513.2	25.9	85	158.3	10.2
X-1479	CRC	BYL719 + encorafenib	562.6	25.5	90	183.1	8.5
X-1479	CRC	CGM097	212.8	26.7	0	0	0
X-1479	CRC	CGM097	230.1	26.7	5	8.1	0
X-1479	CRC	CGM097	271.9	27	8	27.8	1.1
X-1479	CRC	CGM097	367.1	27.8	12	72.5	4.1
X-1479	CRC	CGM097	411.8	29.9	15	93.5	12
X-1479	CRC	CGM097	564.6	29	19	165.3	8.6
X-1479	CRC	CGM097	684.9	28.9	22	221.9	8.2
X-1479	CRC	CKX620	212.6	26.7	0	0	0
X-1479	CRC	CKX620	219.6	27.2	3	3.3	1.9
X-1479	CRC	CKX620	204.7	27.6	7	-3.7	3.4
X-1479	CRC	CKX620	211.3	27.9	10	-0.6	4.5
X-1479	CRC	CKX620	223.6	28.1	14	5.2	5.2
X-1479	CRC	CKX620	202.9	28.9	17	-4.6	8.2
X-1479	CRC	CKX620	195.9	27.7	21	-7.9	3.7
X-1479	CRC	CKX620	173.2	27.6	24	-18.5	3.4
X-1479	CRC	CKX620	229.3	28.9	28	7.9	8.2
X-1479	CRC	CKX620	181.8	28.8	31	-14.5	7.9
X-1479	CRC	CKX620	154.8	28.5	35	-27.2	6.7
X-1479	CRC	CKX620	194.7	29.3	38	-8.4	9.7
X-1479	CRC	CKX620	193.7	28.8	42	-8.9	7.9
X-1479	CRC	CKX620	180.5	29	45	-15.1	8.6
X-1479	CRC	CKX620	151.6	29.7	49	-28.7	11.2
X-1479	CRC	CKX620	202.4	21.9	52	-4.8	-18
X-1479	CRC	CKX620	184	26.1	56	-13.5	-2.2
X-1479	CRC	CLR457	214.5	28.9	0	0	0
X-1479	CRC	CLR457	219.9	28.6	3	2.5	-1
X-1479	CRC	CLR457	230.4	29.2	7	7.4	1
X-1479	CRC	CLR457	238.3	29.1	10	11.1	0.7
X-1479	CRC	CLR457	271.4	28.6	14	26.5	-1
X-1479	CRC	CLR457	268.1	29	17	25	0.3
X-1479	CRC	CLR457	243.5	29.9	21	13.5	3.5
X-1479	CRC	CLR457	252.1	29.9	24	17.5	3.5
X-1479	CRC	CLR457	269.6	29.5	28	25.7	2.1
X-1479	CRC	CLR457	295.9	29	31	37.9	0.3
X-1479	CRC	CLR457	324.6	28.7	35	51.3	-0.7
X-1479	CRC	CLR457	354.5	28.7	38	65.3	-0.7
X-1479	CRC	CLR457	390.8	28.9	42	82.2	0
X-1479	CRC	CLR457	390.8	28.1	45	82.2	-2.8
X-1479	CRC	CLR457	505.2	29.2	49	135.5	1
X-1479	CRC	CLR457	433.8	27.9	52	102.2	-3.5
X-1479	CRC	CLR457	459.4	28.6	56	114.2	-1
X-1479	CRC	CLR457	469.4	28.8	59	118.8	-0.3
X-1479	CRC	CLR457	486.2	28.5	66	126.7	-1.4
X-1479	CRC	CLR457	544.8	28.6	70	154	-1
X-1479	CRC	CLR457	670.6	28.9	74	212.6	0
X-1479	CRC	CLR457	867.2	29	77	304.3	0.3
X-1479	CRC	CLR457	834.7	29.7	80	289.1	2.8
X-1479	CRC	HDM201	208.7	28.5	0	0	0
X-1479	CRC	HDM201	214.2	29.2	3	2.6	2.5
X-1479	CRC	HDM201	263.5	28.4	7	26.3	-0.4
X-1479	CRC	HDM201	264.3	28.7	10	26.6	0.7
X-1479	CRC	HDM201	346.1	29.6	14	65.8	3.9
X-1479	CRC	HDM201	403.4	30.4	17	93.3	6.7
X-1479	CRC	HDM201	460.5	29.3	21	120.7	2.8
X-1479	CRC	HDM201	568.4	26.5	24	172.4	-7
X-1479	CRC	cetuximab	224.2	24.9	0	0	0
X-1479	CRC	cetuximab	246.5	25.2	5	9.9	1.2
X-1479	CRC	cetuximab	296.1	24.9	8	32.1	0
X-1479	CRC	cetuximab	292.8	24.8	11	30.6	-0.4
X-1479	CRC	cetuximab	298	24.4	14	32.9	-2
X-1479	CRC	cetuximab	316.4	25.8	18	41.1	3.6
X-1479	CRC	cetuximab	296.7	25.8	21	32.3	3.6
X-1479	CRC	cetuximab	326.3	24.8	25	45.5	-0.4
X-1479	CRC	cetuximab	405.3	23.9	28	80.8	-4
X-1479	CRC	cetuximab	388.2	25	33	73.1	0.4
X-1479	CRC	cetuximab	391.6	25.5	36	74.7	2.4
X-1479	CRC	cetuximab	395.7	24.6	39	76.5	-1.2
X-1479	CRC	cetuximab	423.8	24.7	41	89	-0.8
X-1479	CRC	cetuximab	479.8	24.8	46	114	-0.4
X-1479	CRC	cetuximab + encorafenib	229.1	24.4	0	0	0
X-1479	CRC	cetuximab + encorafenib	330.3	23.5	5	44.2	-3.7
X-1479	CRC	cetuximab + encorafenib	358.6	23.6	8	56.5	-3.3
X-1479	CRC	cetuximab + encorafenib	416.1	24.3	11	81.6	-0.4
X-1479	CRC	cetuximab + encorafenib	388.3	24.1	14	69.5	-1.2
X-1479	CRC	cetuximab + encorafenib	447	25.1	18	95.1	2.9
X-1479	CRC	cetuximab + encorafenib	527.3	24.2	21	130.2	-0.8
X-1479	CRC	cetuximab + encorafenib	633.3	26	25	176.4	6.6
X-1479	CRC	cetuximab + encorafenib	741.7	26.3	28	223.7	7.8
X-1479	CRC	cetuximab + encorafenib	822.7	25.7	33	259.1	5.3
X-1479	CRC	cetuximab + encorafenib	853.2	24.3	36	272.4	-0.4
X-1479	CRC	cetuximab + encorafenib	857.9	24.2	39	274.5	-0.8
X-1479	CRC	LEE011	290.7	25.6	0	0	0
X-1479	CRC	LEE011	306.8	24.2	3	5.5	-5.5
X-1479	CRC	LEE011	277.9	25	6	-4.4	-2.3
X-1479	CRC	LEE011	291.2	24.7	10	0.2	-3.5
X-1479	CRC	LEE011	297.3	24.9	13	2.3	-2.7
X-1479	CRC	LEE011	306	26.2	17	5.3	2.3
X-1479	CRC	LEE011	327.7	26.8	20	12.7	4.7
X-1479	CRC	LEE011	337.6	26.8	24	16.1	4.7
X-1479	CRC	LEE011	500.1	26.5	27	72	3.5
X-1479	CRC	encorafenib	219	24.4	0	0	0
X-1479	CRC	encorafenib	217.2	23.9	3	-0.8	-2
X-1479	CRC	encorafenib	229.2	24.5	6	4.7	0.4
X-1479	CRC	encorafenib	253.7	25.4	10	15.8	4.1
X-1479	CRC	encorafenib	257.2	25.2	13	17.4	3.3
X-1479	CRC	encorafenib	366.7	24.9	17	67.4	2
X-1479	CRC	encorafenib	438.3	24.9	20	100.1	2
X-1479	CRC	encorafenib	440.6	25.4	24	101.2	4.1
X-1479	CRC	encorafenib	510.1	25.2	27	132.9	3.3
X-1479	CRC	encorafenib	590.2	25.2	31	169.5	3.3
X-1479	CRC	LJC049	226.7	25.4	0	0	0
X-1479	CRC	LJC049	245.3	25.5	3	8.2	0.4
X-1479	CRC	LJC049	294.3	26.2	6	29.8	3.1
X-1479	CRC	LJC049	306.9	26.8	10	35.4	5.5
X-1479	CRC	LJC049	458.7	25.7	13	102.3	1.2
X-1479	CRC	LJC049	496	25.1	17	118.8	-1.2
X-1479	CRC	LJC049	616	23.7	20	171.7	-6.7
X-1479	CRC	LKA136	193.8	23.6	0	0	0
X-1479	CRC	LKA136	217	24.3	3	12	3
X-1479	CRC	LKA136	218.6	24.8	6	12.8	5.1
X-1479	CRC	LKA136	251.8	24.6	10	29.9	4.2
X-1479	CRC	LKA136	272.1	24.7	13	40.4	4.7
X-1479	CRC	LKA136	324.5	25.4	17	67.4	7.6
X-1479	CRC	LKA136	425.6	24.8	20	119.6	5.1
X-1479	CRC	binimetinib	236.3	26.5	0	0	0
X-1479	CRC	binimetinib	233.6	23.9	3	-1.1	-9.8
X-1479	CRC	binimetinib	218.8	25.1	6	-7.4	-5.3
X-1479	CRC	binimetinib	233.6	25.2	10	-1.1	-4.9
X-1479	CRC	binimetinib	271.7	25	13	15	-5.7
X-1479	CRC	binimetinib	274	26.3	17	16	-0.8
X-1479	CRC	binimetinib	251.5	24.8	20	6.4	-6.4
X-1479	CRC	binimetinib	290.2	25.1	24	22.8	-5.3
X-1479	CRC	binimetinib	277.7	23.8	27	17.5	-10.2
X-1479	CRC	binimetinib	327.8	24.5	31	38.7	-7.5
X-1479	CRC	binimetinib	377.2	25.8	34	59.6	-2.6
X-1479	CRC	binimetinib	419.7	26	38	77.6	-1.9
X-1479	CRC	binimetinib	390.8	26.6	41	65.4	0.4
X-1479	CRC	binimetinib	376.3	26	45	59.2	-1.9
X-1479	CRC	binimetinib	354	25.9	48	49.8	-2.3
X-1479	CRC	binimetinib	295.6	25.7	52	25.1	-3
X-1479	CRC	binimetinib	372.7	24.6	55	57.7	-7.2
X-1479	CRC	binimetinib	412.7	26.5	59	74.7	0
X-1479	CRC	binimetinib	439.5	28.7	62	86	8.3
X-1479	CRC	binimetinib	422.1	25.5	66	78.6	-3.8
X-1479	CRC	binimetinib	450	26.1	69	90.4	-1.5
X-1479	CRC	binimetinib	558.6	25.2	76	136.4	-4.9
X-1479	CRC	binimetinib	560.8	25.1	80	137.3	-5.3
X-1479	CRC	binimetinib	588.3	25.2	84	149	-4.9
X-1479	CRC	binimetinib	785.6	24.7	87	232.5	-6.8
X-1479	CRC	untreated	218.2	26.7	0	0	0
X-1479	CRC	untreated	205.6	26.7	4	-5.8	0
X-1479	CRC	untreated	201.1	27.5	7	-7.8	3
X-1479	CRC	untreated	209.3	26.5	11	-4.1	-0.7
X-1479	CRC	untreated	273.1	27.2	14	25.2	1.9
X-1479	CRC	untreated	247.2	27.2	18	13.3	1.9
X-1479	CRC	untreated	324.2	26.5	21	48.6	-0.7
X-1479	CRC	untreated	294	28.3	25	34.7	6
X-1479	CRC	untreated	244.6	27.4	28	12.1	2.6
X-1479	CRC	untreated	282	28.3	32	29.2	6
X-1479	CRC	untreated	284.7	28.1	35	30.5	5.2
X-1479	CRC	untreated	298.8	27.6	42	36.9	3.4
X-1479	CRC	untreated	301.2	27.7	46	38	3.7
X-1479	CRC	untreated	317.4	28.1	50	45.5	5.2
X-1479	CRC	untreated	325.3	29.2	53	49.1	9.4
X-1479	CRC	untreated	284.2	28.3	56	30.2	6
X-1479	CRC	untreated	345.6	28	60	58.4	4.9
X-1479	CRC	untreated	344.8	27.9	63	58	4.5
X-1479	CRC	untreated	304.1	27.8	68	39.4	4.1
X-1479	CRC	untreated	271.2	29.7	74	24.3	11.2
X-1479	CRC	untreated	271.6	28.1	77	24.5	5.2
X-1479	CRC	untreated	308.5	28	81	41.4	4.9
X-1479	CRC	untreated	311.7	28.4	84	42.9	6.4
X-1479	CRC	untreated	332	27.6	88	52.2	3.4
X-1499	NSCLC	BGJ398	260.2	24.7	0	0	0
X-1499	NSCLC	BGJ398	278.5	25.2	4	7	2
X-1499	NSCLC	BGJ398	434.5	25.6	8	67	3.6
X-1499	NSCLC	BGJ398	653.4	25.9	11	151.1	4.9
X-1499	NSCLC	BGJ398	672	25.9	15	158.3	4.9
X-1499	NSCLC	BKM120	224	25.6	0	0	0
X-1499	NSCLC	BKM120	177.6	27.1	1	-20.7	5.9
X-1499	NSCLC	BKM120	308	27.8	4	37.5	8.6
X-1499	NSCLC	BKM120	470.9	28.8	8	110.2	12.5
X-1499	NSCLC	BKM120	529.8	28.4	11	136.5	10.9
X-1499	NSCLC	BKM120	709.4	28.7	15	216.7	12.1
X-1499	NSCLC	BKM120 + binimetinib	187.7	23.8	0	0	0
X-1499	NSCLC	BKM120 + binimetinib	173.2	24.3	4	-7.7	2.1
X-1499	NSCLC	BKM120 + binimetinib	199.5	24.3	6	6.3	2.1
X-1499	NSCLC	BKM120 + binimetinib	304.5	24.8	10	62.2	4.2
X-1499	NSCLC	BKM120 + binimetinib	364	25.2	13	93.9	5.9
X-1499	NSCLC	BKM120 + binimetinib	538.8	25.4	14	187.1	6.7
X-1499	NSCLC	BKM120 + binimetinib	465.5	25.4	17	148	6.7
X-1499	NSCLC	BKM120 + binimetinib	472.9	25.9	20	151.9	8.8
X-1499	NSCLC	BKM120 + binimetinib	711.4	26.3	25	279	10.5
X-1499	NSCLC	BYL719 + LGH447	174.8	24.4	0	0	0
X-1499	NSCLC	BYL719 + LGH447	210.5	23.5	4	20.4	-3.7
X-1499	NSCLC	BYL719 + LGH447	533.8	23	8	205.4	-5.7
X-1499	NSCLC	BYL719 + LGH447	648.1	24.1	11	270.8	-1.2
X-1499	NSCLC	BYL719 + LGH447	1078.7	23.5	15	517.1	-3.7
X-1499	NSCLC	BYL719	190	23.3	0	0	0
X-1499	NSCLC	BYL719	437.4	25.2	4	130.2	8.2
X-1499	NSCLC	BYL719	600.9	24.6	8	216.3	5.6
X-1499	NSCLC	BYL719	700.4	24.4	9	268.6	4.7
X-1499	NSCLC	BYL719 + LJM716	184.9	24.8	0	0	0
X-1499	NSCLC	BYL719 + LJM716	206.5	23.7	4	11.7	-4.4
X-1499	NSCLC	BYL719 + LJM716	338.9	24.2	8	83.3	-2.4
X-1499	NSCLC	BYL719 + LJM716	411.6	24.1	11	122.6	-2.8
X-1499	NSCLC	BYL719 + LJM716	437.9	25.2	15	136.8	1.6
X-1499	NSCLC	CGM097	242.9	24.3	0	0	0
X-1499	NSCLC	CGM097	359.4	23.2	4	48	-4.5
X-1499	NSCLC	CGM097	270	25.4	8	11.2	4.5
X-1499	NSCLC	CGM097	169.9	25.6	11	-30.1	5.3
X-1499	NSCLC	CGM097	93.7	25	15	-61.4	2.9
X-1499	NSCLC	CGM097	54.3	25.3	17	-77.6	4.1
X-1499	NSCLC	CGM097	0	25.8	21	-100	6.2
X-1499	NSCLC	CGM097	0	26.1	24	-100	7.4
X-1499	NSCLC	CGM097	0	26.2	25	-100	7.8
X-1499	NSCLC	CGM097	0	26.5	28	-100	9.1
X-1499	NSCLC	CGM097	0	26.4	31	-100	8.6
X-1499	NSCLC	CGM097	0	26.5	36	-100	9.1
X-1499	NSCLC	CGM097	0	27.1	39	-100	11.5
X-1499	NSCLC	CGM097	0	28	43	-100	15.2
X-1499	NSCLC	CGM097	0	26.9	45	-100	10.7
X-1499	NSCLC	CGM097	0	27.4	50	-100	12.8
X-1499	NSCLC	CGM097	0	23.6	52	-100	-2.9
X-1499	NSCLC	CGM097	0	26.3	57	-100	8.2
X-1499	NSCLC	CGM097	0	27.1	60	-100	11.5
X-1499	NSCLC	CGM097	0	26.8	64	-100	10.3
X-1499	NSCLC	CGM097	0	27.3	67	-100	12.3
X-1499	NSCLC	CGM097	0	28	74	-100	15.2
X-1499	NSCLC	CGM097	0	27.4	78	-100	12.8
X-1499	NSCLC	CGM097	0	27.8	81	-100	14.4
X-1499	NSCLC	CGM097	0	27.5	88	-100	13.2
X-1499	NSCLC	CGM097	0	27	93	-100	11.1
X-1499	NSCLC	CGM097	0	28.3	98	-100	16.5
X-1499	NSCLC	CGM097	0	28.2	100	-100	16
X-1499	NSCLC	CKX620	281.9	NA	0	0	0
X-1499	NSCLC	CKX620	437.9	26.2	4	55.3	0
X-1499	NSCLC	CKX620	436.6	25.9	7	54.9	-1.1
X-1499	NSCLC	CKX620	541.6	26.9	11	92.1	2.7
X-1499	NSCLC	CKX620	573.1	26.9	14	103.3	2.7
X-1499	NSCLC	CKX620	672.6	25.1	19	138.6	-4.2
X-1499	NSCLC	CKX620	795.4	26.3	22	182.2	0.4
X-1499	NSCLC	CKX620	830	23.1	26	194.4	-11.8
X-1499	NSCLC	CLR457	179.5	23.5	0	0	0
X-1499	NSCLC	CLR457	161.5	23.2	3	-10	-1.3
X-1499	NSCLC	CLR457	218.2	23.5	7	21.6	0
X-1499	NSCLC	CLR457	387.1	23.5	10	115.7	0
X-1499	NSCLC	CLR457	712.4	23.9	14	296.9	1.7
X-1499	NSCLC	CLR457	709.3	23.8	15	295.2	1.3
X-1499	NSCLC	HDM201	170.6	21.4	0	0	0
X-1499	NSCLC	HDM201	232.5	21.8	3	36.3	1.9
X-1499	NSCLC	HDM201	402.7	21.9	7	136	2.3
X-1499	NSCLC	HDM201	666.9	21.4	10	290.9	0
X-1499	NSCLC	HDM201	918.3	22.2	14	438.3	3.7
X-1499	NSCLC	HDM201	1024.4	21	15	500.5	-1.9
X-1499	NSCLC	cetuximab	190.9	25.3	0	0	0
X-1499	NSCLC	cetuximab	277.8	25.7	3	45.5	1.6
X-1499	NSCLC	cetuximab	489.5	26.5	7	156.4	4.7
X-1499	NSCLC	cetuximab	778.9	26.8	10	308	5.9
X-1499	NSCLC	cetuximab	1219.3	27.2	14	538.7	7.5
X-1499	NSCLC	cetuximab	1437.6	27.5	15	653.1	8.7
X-1499	NSCLC	erlotinib	188.6	24.1	0	0	0
X-1499	NSCLC	erlotinib	208.5	23.8	3	10.6	-1.2
X-1499	NSCLC	erlotinib	343.9	21.6	7	82.3	-10.4
X-1499	NSCLC	erlotinib	384.9	22.4	10	104.1	-7.1
X-1499	NSCLC	erlotinib	749.1	23.9	14	297.2	-0.8
X-1499	NSCLC	erlotinib	769	22.8	15	307.7	-5.4
X-1499	NSCLC	HSP990	203.1	26.4	0	0	0
X-1499	NSCLC	HSP990	315.8	26.7	4	55.5	1.1
X-1499	NSCLC	HSP990	408.4	26	7	101.1	-1.5
X-1499	NSCLC	HSP990	472.5	26	11	132.6	-1.5
X-1499	NSCLC	INC280	334.2	23.9	0	0	0
X-1499	NSCLC	INC280	654.8	25	4	95.9	4.6
X-1499	NSCLC	INC280	1101.5	25.8	8	229.6	7.9
X-1499	NSCLC	LCL161 + paclitaxel	220.5	29.2	0	0	0
X-1499	NSCLC	LCL161 + paclitaxel	226.3	28.9	4	2.6	-1
X-1499	NSCLC	LCL161 + paclitaxel	285.3	27.8	6	29.4	-4.8
X-1499	NSCLC	LCL161 + paclitaxel	445.7	28.9	10	102.1	-1
X-1499	NSCLC	LCL161 + paclitaxel	688.6	30.3	13	212.3	3.8
X-1499	NSCLC	LEE011	154.2	24.2	0	0	0
X-1499	NSCLC	LEE011	151.4	25	3	-1.8	3.3
X-1499	NSCLC	LEE011	222.4	25.9	7	44.2	7
X-1499	NSCLC	LEE011	215.7	25.6	10	39.9	5.8
X-1499	NSCLC	LEE011	192	27.1	14	24.5	12
X-1499	NSCLC	LEE011	187.7	26.5	17	21.7	9.5
X-1499	NSCLC	LEE011	157.4	26.9	21	2.1	11.2
X-1499	NSCLC	LEE011	168.4	26.7	23	9.2	10.3
X-1499	NSCLC	LEE011	109.9	27	27	-28.7	11.6
X-1499	NSCLC	LEE011	110.8	27.6	30	-28.1	14
X-1499	NSCLC	LEE011	141.9	27.6	31	-8	14
X-1499	NSCLC	LEE011	96.6	27.8	34	-37.4	14.9
X-1499	NSCLC	LEE011	109.3	27.7	37	-29.1	14.5
X-1499	NSCLC	LEE011	73.2	26.8	42	-52.5	10.7
X-1499	NSCLC	LEE011	46.9	28.3	45	-69.6	16.9
X-1499	NSCLC	LEE011	58.2	28	49	-62.3	15.7
X-1499	NSCLC	LEE011	62.9	28.5	51	-59.2	17.8
X-1499	NSCLC	LEE011	36.9	29.4	56	-76.1	21.5
X-1499	NSCLC	LEE011	82.6	27.8	58	-46.4	14.9
X-1499	NSCLC	LEE011	61.3	29.6	63	-60.2	22.3
X-1499	NSCLC	LEE011	61.8	29.6	66	-59.9	22.3
X-1499	NSCLC	LEE011	44.1	29.2	70	-71.4	20.7
X-1499	NSCLC	LEE011	61	29.7	73	-60.4	22.7
X-1499	NSCLC	LEE011	59.2	29.3	84	-61.6	21.1
X-1499	NSCLC	LEE011	43.5	29.3	87	-71.8	21.1
X-1499	NSCLC	LEE011	99.9	29	94	-35.2	19.8
X-1499	NSCLC	LEE011	188.2	29.1	104	22	20.2
X-1499	NSCLC	LEE011	180.4	29.5	108	17	21.9
X-1499	NSCLC	LEE011	301	29.7	112	95.2	22.7
X-1499	NSCLC	LEE011	327.3	29.1	115	112.3	20.2
X-1499	NSCLC	LEE011	339.1	30.1	119	119.9	24.4
X-1499	NSCLC	LEE011	413.8	28.7	126	168.4	18.6
X-1499	NSCLC	LEE011	488.7	29.6	133	216.9	22.3
X-1499	NSCLC	LEE011	514	29.9	136	233.3	23.6
X-1499	NSCLC	LEE011	590.9	30.2	139	283.2	24.8
X-1499	NSCLC	LGH447	197.6	26.8	0	0	0
X-1499	NSCLC	LGH447	265.9	26.6	4	34.6	-0.7
X-1499	NSCLC	LGH447	610.6	27.3	8	209	1.9
X-1499	NSCLC	LGH447	685.7	26.5	9	247	-1.1
X-1499	NSCLC	LLM871	259.1	25.4	0	0	0
X-1499	NSCLC	LLM871	655.1	26.2	4	152.8	3.1
X-1499	NSCLC	LLM871	852	26.3	5	228.8	3.5
X-1499	NSCLC	binimetinib	192.5	23.6	0	0	0
X-1499	NSCLC	binimetinib	261.4	23.8	1	35.8	0.8
X-1499	NSCLC	binimetinib	391.8	23.6	4	103.5	0
X-1499	NSCLC	binimetinib	476.3	24	8	147.4	1.7
X-1499	NSCLC	binimetinib	628.5	23.1	11	226.5	-2.1
X-1499	NSCLC	binimetinib	663.1	23.2	15	244.5	-1.7
X-1499	NSCLC	binimetinib	647.3	22.3	16	236.3	-5.5
X-1499	NSCLC	paclitaxel	236.1	23.9	0	0	0
X-1499	NSCLC	paclitaxel	454	22.9	4	92.3	-4.2
X-1499	NSCLC	paclitaxel	525.1	23	7	122.4	-3.8
X-1499	NSCLC	paclitaxel	867.3	23.4	11	267.3	-2.1
X-1499	NSCLC	untreated	296	23.4	0	0	0
X-1499	NSCLC	untreated	655.4	24.8	5	121.4	6
X-1499	NSCLC	untreated	910	25.4	8	207.4	8.5
X-1499	NSCLC	untreated	1518.1	26.9	12	412.9	15
X-1499	NSCLC	LFW527 + binimetinib	237.18	26.1	0	0	0
X-1499	NSCLC	LFW527 + binimetinib	211.73	25.4	7	-10.7	-2.7
X-1499	NSCLC	LFW527 + binimetinib	190.45	25.8	10	-19.7	-1.1
X-1499	NSCLC	LFW527 + binimetinib	266.06	27	14	12.2	3.4
X-1499	NSCLC	LFW527 + binimetinib	302.9	27	17	27.7	3.4
X-1499	NSCLC	LFW527 + binimetinib	492.81	26.3	21	107.8	0.8
X-1499	NSCLC	LFW527 + binimetinib	716.34	26.1	24	202	0
X-1500	CRC	5FU	278.7	24.1	0	0	0
X-1500	CRC	5FU	290	22.4	7	4.1	-7.1
X-1500	CRC	5FU	290	22.4	10	4.1	-7.1
X-1500	CRC	5FU	275.8	22.7	13	-1	-5.8
X-1500	CRC	5FU	240.9	22.4	18	-13.6	-7.1
X-1500	CRC	5FU	246	21.7	23	-11.7	-10
X-1500	CRC	5FU	221.6	21.7	28	-20.5	-10
X-1500	CRC	5FU	250.3	20.6	31	-10.2	-14.5
X-1500	CRC	5FU	238.1	19.7	35	-14.6	-18.3
X-1500	CRC	5FU	247.4	21.6	43	-11.2	-10.4
X-1500	CRC	5FU	263.1	26.4	50	-5.6	9.5
X-1500	CRC	5FU	226.4	23	57	-18.8	-4.6
X-1500	CRC	5FU	298.6	25.5	63	7.1	5.8
X-1500	CRC	5FU	347.4	26	67	24.7	7.9
X-1500	CRC	5FU	416	24.5	72	49.3	1.7
X-1500	CRC	5FU	413.4	23.9	76	48.3	-0.8
X-1500	CRC	BKM120	206.1	26.1	0	0	0
X-1500	CRC	BKM120	267	26	4	29.5	-0.4
X-1500	CRC	BKM120	331.5	24.9	10	60.8	-4.6
X-1500	CRC	BKM120	179.3	25.6	22	-13	-1.9
X-1500	CRC	BKM120	172	27	25	-16.5	3.4
X-1500	CRC	BKM120	185.3	27.1	29	-10.1	3.8
X-1500	CRC	BKM120	173.5	26.1	32	-15.8	0
X-1500	CRC	BKM120	174.5	28.2	35	-15.3	8
X-1500	CRC	BKM120	157.1	27	40	-23.8	3.4
X-1500	CRC	BKM120	137.6	26.4	45	-33.2	1.1
X-1500	CRC	BKM120	95.8	27	50	-53.5	3.4
X-1500	CRC	BKM120	102.5	26.3	53	-50.3	0.8
X-1500	CRC	BKM120	112.9	26.4	57	-45.2	1.1
X-1500	CRC	BKM120	64.4	26.7	65	-68.8	2.3
X-1500	CRC	BKM120	40.2	24.3	72	-80.5	-6.9
X-1500	CRC	BKM120	32.3	29.7	79	-84.3	13.8
X-1500	CRC	BKM120	32.9	28.3	85	-84	8.4
X-1500	CRC	BKM120	58.5	28.9	89	-71.6	10.7
X-1500	CRC	BKM120	41.6	28.2	94	-79.8	8
X-1500	CRC	BKM120	36.6	27.4	98	-82.2	5
X-1500	CRC	BKM120	13.3	29.6	103	-93.5	13.4
X-1500	CRC	BKM120	18.5	28.5	113	-91	9.2
X-1500	CRC	BKM120	22.8	28.1	118	-88.9	7.7
X-1500	CRC	BKM120	12.2	26.2	126	-94.1	0.4
X-1500	CRC	BKM120	13.8	30.5	132	-93.3	16.9
X-1500	CRC	BKM120	15.7	28.6	137	-92.4	9.6
X-1500	CRC	BKM120	13	28.5	142	-93.7	9.2
X-1500	CRC	BKM120	28.9	27.9	146	-86	6.9
X-1500	CRC	BKM120	33.7	27.9	151	-83.6	6.9
X-1500	CRC	BKM120	11.6	28.1	154	-94.4	7.7
X-1500	CRC	BKM120 + LJC049	201.5	20.8	0	0	0
X-1500	CRC	BKM120 + LJC049	212.8	21.6	4	5.6	3.8
X-1500	CRC	BKM120 + LJC049	200.4	21.9	6	-0.5	5.3
X-1500	CRC	BKM120 + LJC049	158.6	20.7	18	-21.3	-0.5
X-1500	CRC	BKM120 + LJC049	93.2	20.4	25	-53.7	-1.9
X-1500	CRC	BKM120 + LJC049	141	20.1	28	-30	-3.4
X-1500	CRC	BKM120 + LJC049	90.7	20.5	31	-55	-1.4
X-1500	CRC	BYL719 + LJM716	199	23.9	0	0	0
X-1500	CRC	BYL719 + LJM716	153.4	21.2	4	-22.9	-11.3
X-1500	CRC	BYL719 + LJM716	141	22.2	6	-29.1	-7.1
X-1500	CRC	BYL719 + LJM716	131.1	22.1	18	-34.1	-7.5
X-1500	CRC	BYL719 + LJM716	156.9	23.3	21	-21.2	-2.5
X-1500	CRC	BYL719 + LJM716	199.2	22.5	25	0.1	-5.9
X-1500	CRC	BYL719 + LJM716	142.1	22.7	28	-28.6	-5
X-1500	CRC	BYL719 + LJM716	153.8	21.9	31	-22.7	-8.4
X-1500	CRC	BYL719 + LJM716	212.4	22.7	36	6.7	-5
X-1500	CRC	BYL719 + LJM716	240.3	21.2	41	20.8	-11.3
X-1500	CRC	BYL719 + LJM716	282.7	22.3	46	42.1	-6.7
X-1500	CRC	BYL719 + LJM716	340.6	21.6	49	71.2	-9.6
X-1500	CRC	BYL719	245.8	22.4	0	0	0
X-1500	CRC	BYL719	244.1	21.4	4	-0.7	-4.5
X-1500	CRC	BYL719	153.9	21.9	6	-37.4	-2.2
X-1500	CRC	BYL719	127.1	21.3	18	-48.3	-4.9
X-1500	CRC	BYL719	115.9	21.5	21	-52.8	-4
X-1500	CRC	BYL719	105.3	20.2	25	-57.2	-9.8
X-1500	CRC	BYL719	151.6	19.8	28	-38.3	-11.6
X-1500	CRC	BYL719	154.8	21	31	-37	-6.2
X-1500	CRC	BYL719	223	19.6	36	-9.3	-12.5
X-1500	CRC	BYL719	128.9	20.5	41	-47.6	-8.5
X-1500	CRC	BYL719	137.7	19.4	46	-44	-13.4
X-1500	CRC	BYL719	132.1	18.6	49	-46.3	-17
X-1500	CRC	BYL719 + binimetinib	199.8	24.1	0	0	0
X-1500	CRC	BYL719 + binimetinib	121.4	23	4	-39.2	-4.6
X-1500	CRC	BYL719 + binimetinib	128.8	21.7	6	-35.5	-10
X-1500	CRC	BYL719 + binimetinib	37.6	21.4	18	-81.2	-11.2
X-1500	CRC	BYL719 + binimetinib	34.6	22.7	21	-82.7	-5.8
X-1500	CRC	BYL719 + binimetinib	28.1	22.7	25	-85.9	-5.8
X-1500	CRC	BYL719 + binimetinib	41.1	23.5	28	-79.4	-2.5
X-1500	CRC	BYL719 + binimetinib	28.9	23.3	31	-85.5	-3.3
X-1500	CRC	BYL719 + binimetinib	35.4	23.2	36	-82.3	-3.7
X-1500	CRC	BYL719 + binimetinib	49.6	23	41	-75.2	-4.6
X-1500	CRC	BYL719 + binimetinib	49.1	22.5	46	-75.4	-6.6
X-1500	CRC	BYL719 + binimetinib	67.5	22.4	49	-66.2	-7.1
X-1500	CRC	BYL719 + binimetinib	66.6	23.1	53	-66.7	-4.1
X-1500	CRC	BYL719 + binimetinib	55.7	23.5	61	-72.1	-2.5
X-1500	CRC	BYL719 + binimetinib	54.3	24.8	68	-72.8	2.9
X-1500	CRC	BYL719 + binimetinib	79.9	23.7	75	-60	-1.7
X-1500	CRC	BYL719 + binimetinib	64.6	25	81	-67.7	3.7
X-1500	CRC	BYL719 + binimetinib	102.6	24.4	85	-48.6	1.2
X-1500	CRC	BYL719 + binimetinib	80.9	24.1	90	-59.5	0
X-1500	CRC	BYL719 + binimetinib	74.9	23.6	94	-62.5	-2.1
X-1500	CRC	BYL719 + binimetinib	72.1	23.6	99	-63.9	-2.1
X-1500	CRC	BYL719 + binimetinib	80.9	22.1	109	-59.5	-8.3
X-1500	CRC	BYL719 + binimetinib	113.1	22.9	114	-43.4	-5
X-1500	CRC	BYL719 + binimetinib	82	20.6	122	-59	-14.5
X-1500	CRC	BYL719 + encorafenib	253.3	24.7	0	0	0
X-1500	CRC	BYL719 + encorafenib	438	23.4	4	72.9	-5.3
X-1500	CRC	BYL719 + encorafenib	477.7	23.6	6	88.6	-4.5
X-1500	CRC	BYL719 + encorafenib	476.9	25.8	18	88.3	4.5
X-1500	CRC	BYL719 + encorafenib	478.7	23.2	25	89	-6.1
X-1500	CRC	BYL719 + encorafenib	344.5	25	28	36	1.2
X-1500	CRC	BYL719 + encorafenib	469.4	25.4	31	85.3	2.8
X-1500	CRC	BYL719 + encorafenib	613.1	25	36	142	1.2
X-1500	CRC	BYL719 + cetuximab	203	26.9	0	0	0
X-1500	CRC	BYL719 + cetuximab	149.8	27.5	4	-26.2	2.2
X-1500	CRC	BYL719 + cetuximab	101.5	27.3	9	-50	1.5
X-1500	CRC	BYL719 + cetuximab	67.8	28.7	14	-66.6	6.7
X-1500	CRC	BYL719 + cetuximab	56	28.8	17	-72.4	7.1
X-1500	CRC	BYL719 + cetuximab	46.6	27.7	21	-77	3
X-1500	CRC	BYL719 + cetuximab	38.3	27.1	29	-81.1	0.7
X-1500	CRC	BYL719 + cetuximab	32.4	27.6	36	-84	2.6
X-1500	CRC	BYL719 + cetuximab	34	28	43	-83.3	4.1
X-1500	CRC	BYL719 + cetuximab	20.1	28.1	49	-90.1	4.5
X-1500	CRC	BYL719 + cetuximab	40.9	28	53	-79.9	4.1
X-1500	CRC	BYL719 + cetuximab	22.9	27.9	58	-88.7	3.7
X-1500	CRC	BYL719 + cetuximab	23.8	28.8	62	-88.3	7.1
X-1500	CRC	BYL719 + cetuximab	16.8	28.9	67	-91.7	7.4
X-1500	CRC	BYL719 + cetuximab	13.5	28.2	77	-93.3	4.8
X-1500	CRC	BYL719 + cetuximab	17.8	32.3	82	-91.2	20.1
X-1500	CRC	BYL719 + cetuximab	14.8	28.5	90	-92.7	5.9
X-1500	CRC	BYL719 + cetuximab	11.2	25.7	96	-94.5	-4.5
X-1500	CRC	BYL719 + cetuximab	0	29.4	101	-100	9.3
X-1500	CRC	BYL719 + cetuximab	0	29.3	106	-100	8.9
X-1500	CRC	BYL719 + cetuximab	0	30	110	-100	11.5
X-1500	CRC	BYL719 + cetuximab	0	29.1	115	-100	8.2
X-1500	CRC	BYL719 + cetuximab	0	28	118	-100	4.1
X-1500	CRC	BYL719 + cetuximab + encorafenib	208.9	25.9	0	0	0
X-1500	CRC	BYL719 + cetuximab + encorafenib	133.2	25.7	4	-36.2	-0.8
X-1500	CRC	BYL719 + cetuximab + encorafenib	140.9	24.4	9	-32.6	-5.8
X-1500	CRC	BYL719 + cetuximab + encorafenib	94.6	25.2	13	-54.7	-2.7
X-1500	CRC	BYL719 + cetuximab + encorafenib	38.3	24.9	18	-81.7	-3.9
X-1500	CRC	BYL719 + cetuximab + encorafenib	30.5	24.5	28	-85.4	-5.4
X-1500	CRC	BYL719 + cetuximab + encorafenib	35.4	24.1	33	-83.1	-6.9
X-1500	CRC	BYL719 + cetuximab + encorafenib	22	23	41	-89.5	-11.2
X-1500	CRC	BYL719 + cetuximab + encorafenib	15.9	25.2	47	-92.4	-2.7
X-1500	CRC	BYL719 + cetuximab + encorafenib	13.8	25.3	52	-93.4	-2.3
X-1500	CRC	BYL719 + cetuximab + encorafenib	0	25.6	57	-100	-1.2
X-1500	CRC	BYL719 + cetuximab + encorafenib	30.3	25.7	61	-85.5	-0.8
X-1500	CRC	BYL719 + cetuximab + encorafenib	27.7	25.9	66	-86.7	0
X-1500	CRC	BYL719 + cetuximab + encorafenib	20.4	24.8	69	-90.2	-4.2
X-1500	CRC	CGM097	187.9	22.6	0	0	0
X-1500	CRC	CGM097	263.8	22.6	4	40.4	0
X-1500	CRC	CGM097	435.3	22.1	8	131.7	-2.2
X-1500	CRC	CGM097	380.9	22	10	102.7	-2.7
X-1500	CRC	CGM097	594.5	24.8	22	216.4	9.7
X-1500	CRC	CGM097	810.8	22.5	25	331.5	-0.4
X-1500	CRC	CGM097	1044.6	24.7	29	455.9	9.3
X-1500	CRC	CKX620	233.2	25	0	0	0
X-1500	CRC	CKX620	214.3	24.7	4	-8.1	-1.2
X-1500	CRC	CKX620	253	24.4	8	8.5	-2.4
X-1500	CRC	CKX620	262.3	24.1	10	12.5	-3.6
X-1500	CRC	CKX620	249.6	24.3	22	7	-2.8
X-1500	CRC	CKX620	241.1	25.5	25	3.4	2
X-1500	CRC	CKX620	245.4	25	29	5.2	0
X-1500	CRC	CKX620	219.1	25.4	32	-6	1.6
X-1500	CRC	CKX620	241.7	24.7	35	3.6	-1.2
X-1500	CRC	CKX620	302.4	25.9	40	29.7	3.6
X-1500	CRC	CKX620	327.7	24.9	45	40.5	-0.4
X-1500	CRC	CKX620	312.4	25.4	50	34	1.6
X-1500	CRC	CKX620	388.1	25.1	53	66.4	0.4
X-1500	CRC	CLR457	206.9	21.8	0	0	0
X-1500	CRC	CLR457	167.9	20.5	4	-18.8	-6
X-1500	CRC	CLR457	209.3	20.9	6	1.2	-4.1
X-1500	CRC	CLR457	81.1	22.3	18	-60.8	2.3
X-1500	CRC	CLR457	85.1	20.9	25	-58.9	-4.1
X-1500	CRC	CLR457	75.3	21.2	28	-63.6	-2.8
X-1500	CRC	CLR457	79	21.3	31	-61.8	-2.3
X-1500	CRC	CLR457	69.6	21.7	36	-66.4	-0.5
X-1500	CRC	CLR457	57.2	20.7	41	-72.4	-5
X-1500	CRC	CLR457	72	20.4	46	-65.2	-6.4
X-1500	CRC	CLR457	87.7	20.7	49	-57.6	-5
X-1500	CRC	CLR457	74.2	20.2	53	-64.1	-7.3
X-1500	CRC	CLR457	87.4	21	61	-57.8	-3.7
X-1500	CRC	CLR457	60.7	20.1	68	-70.7	-7.8
X-1500	CRC	CLR457	83	18.9	75	-59.9	-13.3
X-1500	CRC	HDM201	180.5	24.2	0	0	0
X-1500	CRC	HDM201	313.8	22.5	4	73.9	-7
X-1500	CRC	HDM201	392	21.4	8	117.2	-11.6
X-1500	CRC	HDM201	514.2	21.4	10	184.9	-11.6
X-1500	CRC	HDM201	1067.3	22.4	22	491.3	-7.4
X-1500	CRC	HDM201	1073.9	20.5	25	495	-15.3
X-1500	CRC	HDM201	1228.6	20.7	29	580.7	-14.5
X-1500	CRC	HDM201	1469.6	21.6	32	714.2	-10.7
X-1500	CRC	cetuximab	210.9	28.4	0	0	0
X-1500	CRC	cetuximab	266.2	28.7	1	26.2	1.1
X-1500	CRC	cetuximab	265.4	29.2	4	25.8	2.8
X-1500	CRC	cetuximab	221	29.8	9	4.8	4.9
X-1500	CRC	cetuximab	182.9	29	14	-13.3	2.1
X-1500	CRC	cetuximab	88.1	28.6	19	-58.2	0.7
X-1500	CRC	cetuximab	56.3	28.6	22	-73.3	0.7
X-1500	CRC	cetuximab	80.2	29	26	-62	2.1
X-1500	CRC	cetuximab	130.3	28.4	34	-38.2	0
X-1500	CRC	cetuximab	73.5	28.4	41	-65.1	0
X-1500	CRC	cetuximab	84.6	28.9	48	-59.9	1.8
X-1500	CRC	cetuximab	75.2	30.3	54	-64.3	6.7
X-1500	CRC	cetuximab	136.2	31	58	-35.4	9.2
X-1500	CRC	cetuximab	35.4	29.5	63	-83.2	3.9
X-1500	CRC	cetuximab	48.8	29.2	67	-76.9	2.8
X-1500	CRC	cetuximab	40.3	30.2	72	-80.9	6.3
X-1500	CRC	cetuximab	51.6	30.8	82	-75.5	8.5
X-1500	CRC	cetuximab	33	30.2	95	-84.4	6.3
X-1500	CRC	cetuximab	26.8	29.8	101	-87.3	4.9
X-1500	CRC	cetuximab	14.7	29.6	106	-93	4.2
X-1500	CRC	cetuximab	53.7	29.4	111	-74.5	3.5
X-1500	CRC	cetuximab	47.7	30	115	-77.4	5.6
X-1500	CRC	cetuximab	47.8	29.5	120	-77.3	3.9
X-1500	CRC	cetuximab	46.6	NA	123	-77.9	3.9
X-1500	CRC	cetuximab + encorafenib	223	26.5	0	0	0
X-1500	CRC	cetuximab + encorafenib	194.9	26.1	1	-12.6	-1.5
X-1500	CRC	cetuximab + encorafenib	161.5	24.5	4	-27.6	-7.5
X-1500	CRC	cetuximab + encorafenib	88.6	24.7	9	-60.3	-6.8
X-1500	CRC	cetuximab + encorafenib	48.9	25	14	-78.1	-5.7
X-1500	CRC	cetuximab + encorafenib	31.9	24	19	-85.7	-9.4
X-1500	CRC	cetuximab + encorafenib	38.7	24.5	22	-82.6	-7.5
X-1500	CRC	cetuximab + encorafenib	37.9	24.1	26	-83	-9.1
X-1500	CRC	cetuximab + encorafenib	14.3	24.4	34	-93.6	-7.9
X-1500	CRC	cetuximab + encorafenib	20.7	25.2	41	-90.7	-4.9
X-1500	CRC	cetuximab + encorafenib	52	24.4	48	-76.7	-7.9
X-1500	CRC	cetuximab + encorafenib	19	24.9	54	-91.5	-6
X-1500	CRC	cetuximab + encorafenib	40.6	25.1	58	-81.8	-5.3
X-1500	CRC	cetuximab + encorafenib	25.4	24	63	-88.6	-9.4
X-1500	CRC	cetuximab + encorafenib	24	24.6	67	-89.2	-7.2
X-1500	CRC	cetuximab + encorafenib	13.4	25.4	82	-94	-4.2
X-1500	CRC	cetuximab + encorafenib	0	24.8	87	-100	-6.4
X-1500	CRC	cetuximab + encorafenib	0	24.4	95	-100	-7.9
X-1500	CRC	cetuximab + encorafenib	0	24.2	101	-100	-8.7
X-1500	CRC	cetuximab + encorafenib	0	24.5	106	-100	-7.5
X-1500	CRC	cetuximab + encorafenib	0	24.6	111	-100	-7.2
X-1500	CRC	cetuximab + encorafenib	11	25.6	115	-95.1	-3.4
X-1500	CRC	cetuximab + encorafenib	0	24.2	123	-100	-8.7
X-1500	CRC	LEE011	242.5	24.1	0	0	0
X-1500	CRC	LEE011	232.2	23.7	7	-4.2	-1.7
X-1500	CRC	LEE011	303.1	24.5	13	25	1.7
X-1500	CRC	LEE011	231.2	26.4	25	-4.7	9.5
X-1500	CRC	LEE011	290.7	27.7	28	19.9	14.9
X-1500	CRC	LEE011	307.6	26.5	32	26.8	10
X-1500	CRC	LEE011	256.8	27.5	35	5.9	14.1
X-1500	CRC	LEE011	227	27.9	38	-6.4	15.8
X-1500	CRC	LEE011	253	27.5	43	4.3	14.1
X-1500	CRC	LEE011	305.8	25.2	48	26.1	4.6
X-1500	CRC	LEE011	354.7	24.8	53	46.3	2.9
X-1500	CRC	LEE011	452.4	24.4	56	86.6	1.2
X-1500	CRC	encorafenib	247.8	24.6	0	0	0
X-1500	CRC	encorafenib	467.5	24.4	4	88.7	-0.8
X-1500	CRC	encorafenib	581	25	8	134.5	1.6
X-1500	CRC	encorafenib	516.4	24.2	10	108.4	-1.6
X-1500	CRC	encorafenib	904.1	24.3	22	264.9	-1.2
X-1500	CRC	encorafenib	1147.5	24.7	25	363.1	0.4
X-1500	CRC	encorafenib	1374.5	23.6	29	454.7	-4.1
X-1500	CRC	LJC049	267.6	25.7	0	0	0
X-1500	CRC	LJC049	223	25.4	4	-16.7	-1.2
X-1500	CRC	LJC049	304.8	23.6	6	13.9	-8.2
X-1500	CRC	LJC049	434.3	23.2	18	62.3	-9.7
X-1500	CRC	LJC049	623.3	23.4	21	132.9	-8.9
X-1500	CRC	LJC049	601.1	21.9	25	124.6	-14.8
X-1500	CRC	LKA136	197.6	23.7	0	0	0
X-1500	CRC	LKA136	196.2	23.6	2	-0.7	-0.4
X-1500	CRC	LKA136	310.7	26.3	17	57.2	11
X-1500	CRC	LKA136	314.7	25.2	21	59.3	6.3
X-1500	CRC	binimetinib	201.6	24.4	0	0	0
X-1500	CRC	binimetinib	234.8	25	3	16.5	2.5
X-1500	CRC	binimetinib	188.1	25.8	7	-6.7	5.7
X-1500	CRC	binimetinib	218.7	25.3	11	8.5	3.7
X-1500	CRC	binimetinib	218.2	24.7	13	8.2	1.2
X-1500	CRC	binimetinib	181.8	24.9	25	-9.8	2
X-1500	CRC	binimetinib	143	26.4	28	-29.1	8.2
X-1500	CRC	binimetinib	188	26.4	32	-6.7	8.2
X-1500	CRC	binimetinib	183.7	26.5	35	-8.9	8.6
X-1500	CRC	binimetinib	183.3	26.2	38	-9.1	7.4
X-1500	CRC	binimetinib	165.5	27.9	43	-17.9	14.3
X-1500	CRC	binimetinib	167.5	25.5	48	-16.9	4.5
X-1500	CRC	binimetinib	171.7	26.7	53	-14.8	9.4
X-1500	CRC	binimetinib	203.1	27.1	56	0.7	11.1
X-1500	CRC	binimetinib	240.7	26.6	60	19.4	9
X-1500	CRC	binimetinib	224	28.6	68	11.1	17.2
X-1500	CRC	binimetinib	364.6	29.9	82	80.9	22.5
X-1500	CRC	binimetinib	415.5	28	88	106.1	14.8
X-1500	CRC	binimetinib	402.3	28.7	92	99.6	17.6
X-1500	CRC	binimetinib	440.6	28.6	97	118.6	17.2
X-1500	CRC	binimetinib	460.3	27.6	101	128.3	13.1
X-1500	CRC	binimetinib	576.4	28.3	106	185.9	16
X-1500	CRC	binimetinib	440.6	27.5	116	118.6	12.7
X-1500	CRC	binimetinib	438.9	27	121	117.7	10.7
X-1500	CRC	binimetinib	351.4	28.6	129	74.3	17.2
X-1500	CRC	untreated	261.1	23.5	0	0	0
X-1500	CRC	untreated	344	25.1	3	31.8	6.8
X-1500	CRC	untreated	440.8	23.7	7	68.8	0.9
X-1500	CRC	untreated	620	23.4	11	137.5	-0.4
X-1500	CRC	untreated	688.7	23.3	13	163.8	-0.9
X-1500	CRC	untreated	1015.8	24.1	25	289	2.6
X-1500	CRC	untreated	1235	23.6	28	373	0.4
X-1500	CRC	untreated	1210.4	22.6	32	363.6	-3.8
X-1500	CRC	LFW527 + binimetinib	255.56	26.35	0	0	0
X-1500	CRC	LFW527 + binimetinib	246.21	26.15	2	-3.7	-0.8
X-1500	CRC	LFW527 + binimetinib	251.87	25.21	4	-1.4	-4.3
X-1500	CRC	LFW527 + binimetinib	300.82	25.68	7	17.7	-2.5
X-1500	CRC	LFW527 + binimetinib	306.99	25.02	10	20.1	-5
X-1500	CRC	LFW527 + binimetinib	370.01	25.08	15	44.8	-4.8
X-1500	CRC	LFW527 + binimetinib	359.39	26.2	24	40.6	-0.6
X-1500	CRC	LFW527 + binimetinib	404.85	26.05	28	58.4	-1.1
X-1500	CRC	LFW527 + binimetinib	403.91	25.83	31	58	-2
X-1500	CRC	LFW527 + binimetinib	483.07	26.71	35	89	1.4
X-1500	CRC	LFW527 + binimetinib	570.87	25.73	38	123.4	-2.4
X-1500	CRC	LFW527 + binimetinib	567.11	26	42	121.9	-1.3
X-1500	CRC	LFW527 + binimetinib	519.08	25.55	46	103.1	-3
X-1500	CRC	LFW527 + binimetinib	550.64	25.04	52	115.5	-5
X-1500	CRC	LFW527 + binimetinib	521.13	24.68	57	103.9	-6.3
X-1500	CRC	LFW527 + binimetinib	569.37	25.28	59	122.8	-4.1
X-1500	CRC	LFW527 + binimetinib	557.82	24.44	65	118.3	-7.2
X-1500	CRC	LFW527 + binimetinib	572.72	24.74	67	124.1	-6.1
X-1500	CRC	LFW527 + binimetinib	561.1	25.05	71	119.6	-4.9
X-1500	CRC	LFW527 + binimetinib	545.08	24.55	73	113.3	-6.8
X-1500	CRC	LFW527 + binimetinib	540.93	25.14	78	111.7	-4.6
X-1500	CRC	LFW527 + binimetinib	627.08	24.86	80	145.4	-5.7
X-1500	CRC	LFW527 + binimetinib	526.4	24.16	85	106	-8.3
X-1500	CRC	LFW527 + binimetinib	564.6	24.11	87	120.9	-8.5
X-1500	CRC	LFW527 + binimetinib	644.14	23.72	92	152.1	-10
X-1500	CRC	LFW527 + binimetinib	596.14	24.55	94	133.3	-6.8
X-1500	CRC	LFW527 + binimetinib	538.13	24.4	99	110.6	-7.4
X-1500	CRC	LFW527 + binimetinib	558.61	24.2	101	118.6	-8.2
X-1500	CRC	LFW527 + binimetinib	593.49	24.57	106	132.2	-6.8
X-1500	CRC	LFW527 + binimetinib	597.48	24.28	108	133.8	-7.9
X-1500	CRC	LFW527 + binimetinib	640.62	23.56	113	150.7	-10.6
X-1500	CRC	LFW527 + binimetinib	584.76	23.99	115	128.8	-9
X-1500	CRC	LFW527 + binimetinib	682.61	24.68	120	167.1	-6.3
X-1500	CRC	LFW527 + binimetinib	645.46	24.4	122	152.6	-7.4
X-1500	CRC	LFW527 + binimetinib	632.7	24.33	128	147.6	-7.7
X-1500	CRC	LFW527 + binimetinib	666.09	22.92	130	160.6	-13
X-1500	CRC	LFW527 + binimetinib	680.83	23.1	136	166.4	-12.3
X-1500	CRC	LFW527 + binimetinib	817.86	24.08	143	220	-8.6
X-1536	CRC	5FU	213.4	26.3	0	0	0
X-1536	CRC	5FU	242.1	26.1	4	13.4	-0.8
X-1536	CRC	5FU	247.1	24.9	7	15.8	-5.3
X-1536	CRC	5FU	289.7	25.9	10	35.8	-1.5
X-1536	CRC	5FU	301.8	25.7	14	41.4	-2.3
X-1536	CRC	5FU	304	27.2	17	42.5	3.4
X-1536	CRC	5FU	293.6	24.1	20	37.6	-8.4
X-1536	CRC	5FU	287.9	25.7	24	34.9	-2.3
X-1536	CRC	5FU	310.2	23.8	29	45.4	-9.5
X-1536	CRC	5FU	306.3	28.6	32	43.5	8.7
X-1536	CRC	5FU	303.1	26.7	35	42	1.5
X-1536	CRC	5FU	367	26.2	39	72	-0.4
X-1536	CRC	5FU	371.8	24.5	43	74.2	-6.8
X-1536	CRC	5FU	376	25.3	46	76.2	-3.8
X-1536	CRC	BKM120	209.4	25.9	0	0	0
X-1536	CRC	BKM120	223.7	26.1	3	6.8	0.8
X-1536	CRC	BKM120	245.6	26.3	6	17.3	1.5
X-1536	CRC	BKM120	256.5	25.8	10	22.5	-0.4
X-1536	CRC	BKM120	281.3	26.6	13	34.3	2.7
X-1536	CRC	BKM120	285.9	24.5	16	36.5	-5.4
X-1536	CRC	BKM120	297.9	24.4	20	42.3	-5.8
X-1536	CRC	BKM120	315.1	22.4	25	50.5	-13.5
X-1536	CRC	BKM120	316.6	27	28	51.2	4.2
X-1536	CRC	BKM120	323.8	28	31	54.6	8.1
X-1536	CRC	BKM120	340	26.9	35	62.4	3.9
X-1536	CRC	BKM120	375.9	26.9	39	79.5	3.9
X-1536	CRC	BKM120	454.5	25.2	42	117	-2.7
X-1536	CRC	BKM120	461.9	25.1	44	120.6	-3.1
X-1536	CRC	BKM120 + LJC049	198.8	25.3	0	0	0
X-1536	CRC	BKM120 + LJC049	200.7	25	2	1	-1.2
X-1536	CRC	BKM120 + LJC049	202.5	24.3	5	1.9	-4
X-1536	CRC	BKM120 + LJC049	213.8	24.8	7	7.5	-2
X-1536	CRC	BKM120 + LJC049	215.9	24.5	11	8.6	-3.2
X-1536	CRC	BKM120 + LJC049	193.4	23.9	14	-2.7	-5.5
X-1536	CRC	BKM120 + LJC049	189.9	23.9	18	-4.5	-5.5
X-1536	CRC	BKM120 + LJC049	183.1	24.7	21	-7.9	-2.4
X-1536	CRC	BKM120 + LJC049	181.8	24.8	24	-8.6	-2
X-1536	CRC	BKM120 + LJC049	190.2	22	27	-4.3	-13
X-1536	CRC	BKM120 + LJC049	211.3	23.3	30	6.3	-7.9
X-1536	CRC	BKM120 + LJC049	220.4	23.8	34	10.9	-5.9
X-1536	CRC	BKM120 + LJC049	217.3	23.9	38	9.3	-5.5
X-1536	CRC	BKM120 + LJC049	218.6	23.2	42	10	-8.3
X-1536	CRC	BKM120 + LJC049	257.9	23.2	45	29.7	-8.3
X-1536	CRC	BKM120 + LJC049	303.1	24.5	48	52.5	-3.2
X-1536	CRC	BKM120 + LJC049	310.8	25.7	51	56.3	1.6
X-1536	CRC	BKM120 + LJC049	321.4	22.7	54	61.7	-10.3
X-1536	CRC	BKM120 + LJC049	332.9	24	59	67.5	-5.1
X-1536	CRC	BKM120 + LJC049	333.2	23.2	62	67.6	-8.3
X-1536	CRC	BKM120 + LJC049	347.2	22.2	65	74.6	-12.3
X-1536	CRC	BKM120 + LJC049	331	22	69	66.5	-13
X-1536	CRC	BYL719	206.7	26.5	0	0	0
X-1536	CRC	BYL719	227.7	27.8	2	10.2	4.9
X-1536	CRC	BYL719	240.2	25.1	7	16.2	-5.3
X-1536	CRC	BYL719	259.8	25.2	10	25.7	-4.9
X-1536	CRC	BYL719	301.5	25.3	13	45.9	-4.5
X-1536	CRC	BYL719	329.9	25.7	17	59.6	-3
X-1536	CRC	BYL719	443.3	25.5	21	114.5	-3.8
X-1536	CRC	BYL719	529.6	25.3	24	156.2	-4.5
X-1536	CRC	BYL719	555.9	24.5	28	168.9	-7.5
X-1536	CRC	BYL719	600.2	24.7	31	190.4	-6.8
X-1536	CRC	BYL719	644.2	25.6	33	211.7	-3.4
X-1536	CRC	BYL719	792.5	24.9	37	283.4	-6
X-1536	CRC	BYL719	825.8	24.6	40	299.5	-7.2
X-1536	CRC	BYL719	909.5	24.9	44	340	-6
X-1536	CRC	BYL719 + LJM716	221.2	24.8	0	0	0
X-1536	CRC	BYL719 + LJM716	254.6	24.6	3	15.1	-0.8
X-1536	CRC	BYL719 + LJM716	251.9	23.9	6	13.9	-3.6
X-1536	CRC	BYL719 + LJM716	242.2	21.9	10	9.5	-11.7
X-1536	CRC	BYL719 + LJM716	237.5	22.3	14	7.4	-10.1
X-1536	CRC	BYL719 + LJM716	260.8	23	17	17.9	-7.3
X-1536	CRC	BYL719 + LJM716	279.3	23.1	21	26.3	-6.9
X-1536	CRC	BYL719 + LJM716	288.1	24.3	24	30.2	-2
X-1536	CRC	BYL719 + LJM716	296.2	24.6	26	33.9	-0.8
X-1536	CRC	BYL719 + LJM716	361.4	25.3	30	63.4	2
X-1536	CRC	BYL719 + LJM716	384.9	26.3	33	74	6
X-1536	CRC	BYL719 + LJM716	403.5	24.7	37	82.4	-0.4
X-1536	CRC	BYL719 + LJM716	450.5	24.8	40	103.7	0
X-1536	CRC	BYL719 + LJM716	478.5	25.3	43	116.3	2
X-1536	CRC	BYL719 + cetuximab + encorafenib	208.9	26.6	0	0	0
X-1536	CRC	BYL719 + cetuximab + encorafenib	211.3	26.2	2	1.1	-1.5
X-1536	CRC	BYL719 + cetuximab + encorafenib	209.6	24.3	6	0.3	-8.6
X-1536	CRC	BYL719 + cetuximab + encorafenib	228.2	28	10	9.2	5.3
X-1536	CRC	BYL719 + cetuximab + encorafenib	223.8	27.7	13	7.1	4.1
X-1536	CRC	BYL719 + cetuximab + encorafenib	231.7	26.3	17	10.9	-1.1
X-1536	CRC	BYL719 + cetuximab + encorafenib	239.6	26.1	20	14.7	-1.9
X-1536	CRC	BYL719 + cetuximab + encorafenib	245.9	25.6	22	17.7	-3.8
X-1536	CRC	BYL719 + cetuximab + encorafenib	294.9	26.1	26	41.2	-1.9
X-1536	CRC	BYL719 + cetuximab + encorafenib	306.7	25.5	29	46.8	-4.1
X-1536	CRC	BYL719 + cetuximab + encorafenib	333.8	25	33	59.8	-6
X-1536	CRC	BYL719 + cetuximab + encorafenib	350.6	25.3	36	67.8	-4.9
X-1536	CRC	BYL719 + cetuximab + encorafenib	369.9	24.7	39	77.1	-7.1
X-1536	CRC	BYL719 + cetuximab + encorafenib	378.6	24.2	42	81.2	-9
X-1536	CRC	BYL719 + cetuximab + encorafenib	414	24.6	45	98.2	-7.5
X-1536	CRC	BYL719 + cetuximab + encorafenib	506.3	23.7	49	142.4	-10.9
X-1536	CRC	BYL719 + binimetinib	213.8	24.2	0	0	0
X-1536	CRC	BYL719 + binimetinib	211.8	24.6	2	-0.9	1.7
X-1536	CRC	BYL719 + binimetinib	174.5	21.8	6	-18.4	-9.9
X-1536	CRC	BYL719 + binimetinib	162	22.9	10	-24.2	-5.4
X-1536	CRC	BYL719 + binimetinib	166.1	22.7	13	-22.3	-6.2
X-1536	CRC	BYL719 + binimetinib	171.4	22	17	-19.8	-9.1
X-1536	CRC	BYL719 + binimetinib	173.3	19.3	20	-18.9	-20.2
X-1536	CRC	BYL719 + cetuximab	208.6	26.9	0	0	0
X-1536	CRC	BYL719 + cetuximab	229.3	27.1	4	9.9	0.7
X-1536	CRC	BYL719 + cetuximab	230.1	26.9	7	10.3	0
X-1536	CRC	BYL719 + cetuximab	226.9	26.6	11	8.8	-1.1
X-1536	CRC	BYL719 + cetuximab	247.5	26.6	14	18.6	-1.1
X-1536	CRC	BYL719 + cetuximab	239.3	26.5	16	14.7	-1.5
X-1536	CRC	BYL719 + cetuximab	245.3	26.2	20	17.6	-2.6
X-1536	CRC	BYL719 + cetuximab	241.9	26.4	27	16	-1.9
X-1536	CRC	BYL719 + cetuximab	237	26.7	30	13.6	-0.7
X-1536	CRC	BYL719 + cetuximab	253.5	26.6	33	21.5	-1.1
X-1536	CRC	BYL719 + cetuximab	244.9	26.7	36	17.4	-0.7
X-1536	CRC	BYL719 + cetuximab	258.9	27.3	39	24.1	1.5
X-1536	CRC	BYL719 + cetuximab	269	26.4	43	29	-1.9
X-1536	CRC	BYL719 + cetuximab	272.6	25.7	47	30.7	-4.5
X-1536	CRC	BYL719 + cetuximab	266.7	26.6	51	27.9	-1.1
X-1536	CRC	BYL719 + cetuximab	267.5	26.2	54	28.2	-2.6
X-1536	CRC	BYL719 + cetuximab	273.3	26.3	57	31	-2.2
X-1536	CRC	BYL719 + cetuximab	281.8	25.7	60	35.1	-4.5
X-1536	CRC	BYL719 + cetuximab	277.8	26.6	63	33.2	-1.1
X-1536	CRC	BYL719 + cetuximab	278.2	26.2	68	33.4	-2.6
X-1536	CRC	BYL719 + cetuximab	278.2	26.3	71	33.4	-2.2
X-1536	CRC	BYL719 + cetuximab	281	27.1	74	34.7	0.7
X-1536	CRC	BYL719 + cetuximab	271.4	26.7	78	30.1	-0.7
X-1536	CRC	BYL719 + cetuximab	254.1	27.2	84	21.8	1.1
X-1536	CRC	BYL719 + cetuximab	251.7	26.6	87	20.7	-1.1
X-1536	CRC	BYL719 + cetuximab	247.1	26.8	91	18.5	-0.4
X-1536	CRC	BYL719 + encorafenib	209.2	26.5	0	0	0
X-1536	CRC	BYL719 + encorafenib	214.5	26.4	3	2.5	-0.4
X-1536	CRC	BYL719 + encorafenib	227.5	24.4	7	8.7	-7.9
X-1536	CRC	BYL719 + encorafenib	247.6	25.1	10	18.4	-5.3
X-1536	CRC	BYL719 + encorafenib	240.3	24.8	13	14.9	-6.4
X-1536	CRC	BYL719 + encorafenib	280.3	24.3	16	34	-8.3
X-1536	CRC	BYL719 + encorafenib	329.4	25.4	19	57.5	-4.2
X-1536	CRC	BYL719 + encorafenib	425.2	25.6	23	103.3	-3.4
X-1536	CRC	BYL719 + encorafenib	450.2	24.9	27	115.2	-6
X-1536	CRC	BYL719 + encorafenib	497.6	25.2	31	137.9	-4.9
X-1536	CRC	BYL719 + encorafenib	546.6	25	34	161.3	-5.7
X-1536	CRC	BYL719 + encorafenib	618.8	24.9	37	195.8	-6
X-1536	CRC	BYL719 + encorafenib	643	24.6	40	207.4	-7.2
X-1536	CRC	BYL719 + encorafenib	782.6	26.3	43	274.1	-0.8
X-1536	CRC	CKX620	220.5	27.3	0	0	0
X-1536	CRC	CKX620	241.2	26.2	3	9.4	-4
X-1536	CRC	CKX620	238.8	26.5	7	8.3	-2.9
X-1536	CRC	CKX620	238.4	27.3	10	8.1	0
X-1536	CRC	CKX620	243.8	27.2	13	10.6	-0.4
X-1536	CRC	CKX620	251.2	27.4	17	13.9	0.4
X-1536	CRC	CKX620	252	27.9	22	14.3	2.2
X-1536	CRC	CKX620	248.8	26.7	25	12.8	-2.2
X-1536	CRC	CKX620	243	27.4	28	10.2	0.4
X-1536	CRC	CKX620	243.6	27	32	10.5	-1.1
X-1536	CRC	CKX620	252.2	27.3	36	14.4	0
X-1536	CRC	CKX620	250	27.3	39	13.4	0
X-1536	CRC	CKX620	254.2	27.7	43	15.3	1.5
X-1536	CRC	CKX620	261.2	27	46	18.5	-1.1
X-1536	CRC	CKX620	259.5	26.9	48	17.7	-1.5
X-1536	CRC	CKX620	277.2	27.5	52	25.7	0.7
X-1536	CRC	CKX620	282.4	28.3	55	28.1	3.7
X-1536	CRC	CKX620	318.8	28.3	59	44.6	3.7
X-1536	CRC	CKX620	317.9	28.3	62	44.2	3.7
X-1536	CRC	CKX620	315.7	28.4	65	43.2	4
X-1536	CRC	CKX620	314.6	28.4	68	42.7	4
X-1536	CRC	CKX620	337.3	29.2	71	53	7
X-1536	CRC	CKX620	350.2	27.8	75	58.8	1.8
X-1536	CRC	CKX620	335.4	28	79	52.1	2.6
X-1536	CRC	CKX620	339.9	26.6	83	54.1	-2.6
X-1536	CRC	CKX620	364	27.9	86	65.1	2.2
X-1536	CRC	CKX620	399.5	28.4	89	81.2	4
X-1536	CRC	CKX620	407.5	28.8	92	84.8	5.5
X-1536	CRC	CKX620	429.5	29.5	95	94.8	8.1
X-1536	CRC	CLR457	205.2	24.1	0	0	0
X-1536	CRC	CLR457	214.3	26.5	2	4.4	10
X-1536	CRC	CLR457	218.9	24.2	7	6.7	0.4
X-1536	CRC	CLR457	212.8	25.5	10	3.7	5.8
X-1536	CRC	CLR457	205	24.8	13	-0.1	2.9
X-1536	CRC	CLR457	196.5	23.6	17	-4.2	-2.1
X-1536	CRC	CLR457	189.4	23.8	21	-7.7	-1.2
X-1536	CRC	CLR457	182.3	24.4	24	-11.2	1.2
X-1536	CRC	CLR457	192.6	23.9	28	-6.1	-0.8
X-1536	CRC	CLR457	192.6	25.5	31	-6.1	5.8
X-1536	CRC	CLR457	198.8	25.4	33	-3.1	5.4
X-1536	CRC	CLR457	199.2	25	37	-2.9	3.7
X-1536	CRC	CLR457	232.4	24.9	40	13.3	3.3
X-1536	CRC	CLR457	264.4	25.4	44	28.8	5.4
X-1536	CRC	CLR457	275.6	25.1	47	34.3	4.1
X-1536	CRC	CLR457	298.5	24.5	50	45.5	1.7
X-1536	CRC	CLR457	294.1	23.9	53	43.3	-0.8
X-1536	CRC	CLR457	312.9	24.2	56	52.5	0.4
X-1536	CRC	CLR457	331.9	24.3	60	61.7	0.8
X-1536	CRC	CLR457	349.3	24.1	64	70.2	0
X-1536	CRC	CLR457	359.5	24.5	68	75.2	1.7
X-1536	CRC	CLR457	378.7	24.4	71	84.6	1.2
X-1536	CRC	CLR457	398.2	24.4	74	94.1	1.2
X-1536	CRC	CLR457	411.1	23.9	77	100.3	-0.8
X-1536	CRC	CLR457	413.8	24.9	80	101.7	3.3
X-1536	CRC	CLR457	448.4	23.4	85	118.5	-2.9
X-1536	CRC	CLR457	448	23.6	88	118.3	-2.1
X-1536	CRC	CLR457	447.3	23.7	91	118	-1.7
X-1536	CRC	HDM201	200.6	25.7	0	0	0
X-1536	CRC	HDM201	206.9	25.4	3	3.1	-1.2
X-1536	CRC	HDM201	207.9	24.4	7	3.6	-5.1
X-1536	CRC	HDM201	216.8	25.9	10	8.1	0.8
X-1536	CRC	HDM201	209.8	24.2	13	4.6	-5.8
X-1536	CRC	HDM201	222.4	25.6	17	10.9	-0.4
X-1536	CRC	HDM201	250.7	23.7	22	25	-7.8
X-1536	CRC	HDM201	264.1	23.9	25	31.7	-7
X-1536	CRC	HDM201	267.2	23.7	28	33.2	-7.8
X-1536	CRC	HDM201	276.8	22.6	32	38	-12.1
X-1536	CRC	HDM201	296.3	23.8	36	47.7	-7.4
X-1536	CRC	HDM201	315.6	24.5	39	57.3	-4.7
X-1536	CRC	HDM201	366.5	26.7	43	82.7	3.9
X-1536	CRC	HDM201	395.3	26.6	46	97.1	3.5
X-1536	CRC	cetuximab	216	24.4	0	0	0
X-1536	CRC	cetuximab	252.4	23.9	4	16.9	-2
X-1536	CRC	cetuximab	281	23.1	9	30.1	-5.3
X-1536	CRC	cetuximab	325	22.7	12	50.5	-7
X-1536	CRC	cetuximab	342.4	23.3	15	58.5	-4.5
X-1536	CRC	cetuximab	418.2	22.9	19	93.6	-6.1
X-1536	CRC	cetuximab	472.9	23.4	22	118.9	-4.1
X-1536	CRC	cetuximab	526.9	23	25	143.9	-5.7
X-1536	CRC	cetuximab	736.7	23.3	29	241.1	-4.5
X-1536	CRC	cetuximab	797	22.6	34	269	-7.4
X-1536	CRC	cetuximab	985.7	22.5	37	356.3	-7.8
X-1536	CRC	cetuximab	1100.7	22.2	40	409.6	-9
X-1536	CRC	cetuximab	1175.8	26.4	42	444.4	8.2
X-1536	CRC	cetuximab + encorafenib	207.5	27.3	0	0	0
X-1536	CRC	cetuximab + encorafenib	231	26.9	3	11.3	-1.5
X-1536	CRC	cetuximab + encorafenib	265.8	26.6	6	28.1	-2.6
X-1536	CRC	cetuximab + encorafenib	267	25.8	10	28.7	-5.5
X-1536	CRC	cetuximab + encorafenib	275.7	26.9	14	32.9	-1.5
X-1536	CRC	cetuximab + encorafenib	282.6	27	17	36.2	-1.1
X-1536	CRC	cetuximab + encorafenib	315.5	26.1	21	52	-4.4
X-1536	CRC	cetuximab + encorafenib	355.4	26.3	24	71.3	-3.7
X-1536	CRC	cetuximab + encorafenib	386.1	26.3	26	86.1	-3.7
X-1536	CRC	cetuximab + encorafenib	433.9	26.7	30	109.1	-2.2
X-1536	CRC	cetuximab + encorafenib	460.8	26.4	33	122.1	-3.3
X-1536	CRC	cetuximab + encorafenib	501.6	26.3	37	141.7	-3.7
X-1536	CRC	cetuximab + encorafenib	518.6	25.9	40	149.9	-5.1
X-1536	CRC	cetuximab + encorafenib	570.7	25.7	43	175	-5.9
X-1536	CRC	LEE011	212.7	27.7	0	0	0
X-1536	CRC	LEE011	223.9	26.7	3	5.3	-3.6
X-1536	CRC	LEE011	222.7	27.4	6	4.7	-1.1
X-1536	CRC	LEE011	218.9	27.9	10	2.9	0.7
X-1536	CRC	LEE011	215.5	28.5	13	1.3	2.9
X-1536	CRC	LEE011	209.4	28.4	16	-1.6	2.5
X-1536	CRC	LEE011	202.8	28.6	20	-4.7	3.2
X-1536	CRC	LEE011	201.3	28.3	25	-5.4	2.2
X-1536	CRC	LEE011	199.1	28.5	28	-6.4	2.9
X-1536	CRC	LEE011	171	30.4	31	-19.6	9.7
X-1536	CRC	LEE011	148.9	29.3	35	-30	5.8
X-1536	CRC	LEE011	145.2	30.3	39	-31.7	9.4
X-1536	CRC	LEE011	144.2	30.2	42	-32.2	9
X-1536	CRC	LEE011	121.3	29.7	46	-43	7.2
X-1536	CRC	LEE011	130.8	29.6	49	-38.5	6.9
X-1536	CRC	LEE011	123.9	29.7	51	-41.7	7.2
X-1536	CRC	LEE011	116.2	30.6	55	-45.4	10.5
X-1536	CRC	LEE011	141.9	30.1	58	-33.3	8.7
X-1536	CRC	LEE011	121.9	30.4	62	-42.7	9.7
X-1536	CRC	LEE011	124.3	29.7	65	-41.6	7.2
X-1536	CRC	LEE011	127.9	29.3	68	-39.9	5.8
X-1536	CRC	LEE011	95.9	29.9	71	-54.9	7.9
X-1536	CRC	LEE011	98.7	28.9	74	-53.6	4.3
X-1536	CRC	LEE011	97.7	30	78	-54.1	8.3
X-1536	CRC	LEE011	96	29.9	82	-54.9	7.9
X-1536	CRC	LEE011	97.2	29.4	86	-54.3	6.1
X-1536	CRC	LEE011	98.1	29.5	89	-53.9	6.5
X-1536	CRC	encorafenib	196.3	22	0	0	0
X-1536	CRC	encorafenib	218.2	23.7	1	11.2	7.7
X-1536	CRC	encorafenib	254.6	22.5	5	29.7	2.3
X-1536	CRC	encorafenib	306.1	21.4	8	55.9	-2.7
X-1536	CRC	encorafenib	357.1	21.1	11	81.9	-4.1
X-1536	CRC	encorafenib	416.9	23.6	15	112.4	7.3
X-1536	CRC	encorafenib	484.6	22.1	20	146.9	0.5
X-1536	CRC	encorafenib	573.8	22.7	23	192.3	3.2
X-1536	CRC	encorafenib	634.4	22.7	26	223.2	3.2
X-1536	CRC	encorafenib	659.8	21.3	30	236.1	-3.2
X-1536	CRC	encorafenib	711.7	20.5	34	262.6	-6.8
X-1536	CRC	encorafenib	746.7	20	37	280.4	-9.1
X-1536	CRC	encorafenib	862.1	20.7	41	339.2	-5.9
X-1536	CRC	LJC049	216.4	23	0	0	0
X-1536	CRC	LJC049	237.9	24.5	3	9.9	6.5
X-1536	CRC	LJC049	284.9	25.1	6	31.7	9.1
X-1536	CRC	LJC049	377.1	26.5	10	74.3	15.2
X-1536	CRC	LJC049	456	23.1	15	110.7	0.4
X-1536	CRC	LJC049	503	22.4	18	132.4	-2.6
X-1536	CRC	LJC049	561.1	22.6	21	159.3	-1.7
X-1536	CRC	LJC049	677.6	23.3	25	213.1	1.3
X-1536	CRC	LJC049	749.9	22.7	29	246.5	-1.3
X-1536	CRC	LJC049	790.4	21.9	30	265.2	-4.8
X-1536	CRC	LKA136	212.7	25.7	0	0	0
X-1536	CRC	LKA136	251.3	27.5	3	18.1	7
X-1536	CRC	LKA136	266.4	26.3	6	25.2	2.3
X-1536	CRC	LKA136	280.4	26.2	10	31.8	1.9
X-1536	CRC	LKA136	300.4	25.7	15	41.2	0
X-1536	CRC	LKA136	331.5	25.5	18	55.9	-0.8
X-1536	CRC	LKA136	340.2	25.5	21	59.9	-0.8
X-1536	CRC	LKA136	436.6	25.5	25	105.3	-0.8
X-1536	CRC	LKA136	464	24.9	29	118.1	-3.1
X-1536	CRC	LKA136	458.7	25.2	32	115.7	-1.9
X-1536	CRC	LKA136	484.3	25.1	36	127.7	-2.3
X-1536	CRC	LKA136	498.6	24.7	39	134.4	-3.9
X-1536	CRC	LKA136	522.4	24.8	41	145.6	-3.5
X-1536	CRC	LKA136	569.8	25	45	167.9	-2.7
X-1536	CRC	binimetinib	211.9	24.6	0	0	0
X-1536	CRC	binimetinib	218.2	24	3	3	-2.4
X-1536	CRC	binimetinib	222.2	23.5	6	4.9	-4.5
X-1536	CRC	binimetinib	230.9	23.6	10	9	-4.1
X-1536	CRC	binimetinib	232.1	25	13	9.5	1.6
X-1536	CRC	binimetinib	241.6	24.3	16	14	-1.2
X-1536	CRC	binimetinib	228	24.6	20	7.6	0
X-1536	CRC	binimetinib	226.5	24.3	25	6.9	-1.2
X-1536	CRC	binimetinib	225.7	24.9	28	6.5	1.2
X-1536	CRC	binimetinib	206.2	24.9	31	-2.7	1.2
X-1536	CRC	binimetinib	195	24.5	35	-8	-0.4
X-1536	CRC	binimetinib	181.8	25.1	39	-14.2	2
X-1536	CRC	binimetinib	178.1	25.5	42	-16	3.7
X-1536	CRC	binimetinib	166.7	25.6	46	-21.3	4.1
X-1536	CRC	binimetinib	138.7	26	49	-34.5	5.7
X-1536	CRC	binimetinib	138.6	26	51	-34.6	5.7
X-1536	CRC	binimetinib	141	25.7	55	-33.5	4.5
X-1536	CRC	binimetinib	161.8	24.8	58	-23.6	0.8
X-1536	CRC	binimetinib	156	25.5	62	-26.4	3.7
X-1536	CRC	binimetinib	157.6	25	65	-25.6	1.6
X-1536	CRC	binimetinib	140	25.2	68	-33.9	2.4
X-1536	CRC	binimetinib	131.6	24.5	71	-37.9	-0.4
X-1536	CRC	binimetinib	136.2	25.6	74	-35.7	4.1
X-1536	CRC	binimetinib	133.3	25.1	78	-37.1	2
X-1536	CRC	binimetinib	101.3	27.2	82	-52.2	10.6
X-1536	CRC	binimetinib	108	26.9	86	-49	9.3
X-1536	CRC	binimetinib	107.8	23.7	89	-49.1	-3.7
X-1536	CRC	untreated	204.3	25.1	0	0	0
X-1536	CRC	untreated	210.7	25.2	3	3.1	0.4
X-1536	CRC	untreated	238.8	25.2	7	16.9	0.4
X-1536	CRC	untreated	252.5	25.3	10	23.6	0.8
X-1536	CRC	untreated	270.1	25.9	13	32.2	3.2
X-1536	CRC	untreated	314.7	25.3	16	54	0.8
X-1536	CRC	untreated	353.1	26.3	19	72.8	4.8
X-1536	CRC	untreated	424.2	25.1	23	107.6	0
X-1536	CRC	untreated	445.6	25.2	27	118.1	0.4
X-1536	CRC	untreated	492.1	25.1	31	140.9	0
X-1536	CRC	untreated	540	24.2	34	164.3	-3.6
X-1536	CRC	untreated	596	25.1	37	191.7	0
X-1536	CRC	untreated	654.6	26.3	40	220.4	4.8
X-1536	CRC	untreated	827.5	25.3	43	305	0.8
X-1538	CRC	BYL719	187.9	26.1	0	0	0
X-1538	CRC	BYL719	183.6	26.4	3	-2.3	1.1
X-1538	CRC	BYL719	179.6	26	7	-4.4	-0.4
X-1538	CRC	BYL719	187.9	26.3	11	0	0.8
X-1538	CRC	BYL719	190	26.6	14	1.1	1.9
X-1538	CRC	BYL719	184.8	26.2	17	-1.6	0.4
X-1538	CRC	BYL719	191.3	26.3	21	1.8	0.8
X-1538	CRC	BYL719	186	26.2	25	-1	0.4
X-1538	CRC	BYL719	174.9	25.8	28	-6.9	-1.1
X-1538	CRC	BYL719	185.8	27.3	32	-1.1	4.6
X-1538	CRC	BYL719	184	26	35	-2.1	-0.4
X-1538	CRC	BYL719	188.6	26.2	39	0.4	0.4
X-1538	CRC	BYL719	188.7	26.3	42	0.4	0.8
X-1538	CRC	BYL719	191.2	26.4	46	1.8	1.1
X-1538	CRC	BYL719	189.9	27.2	49	1.1	4.2
X-1538	CRC	BYL719	198.6	27.2	53	5.7	4.2
X-1538	CRC	BYL719	196.9	26.6	56	4.8	1.9
X-1538	CRC	BYL719 + binimetinib	203.1	25.3	0	0	0
X-1538	CRC	BYL719 + binimetinib	203.6	24.4	4	0.2	-3.6
X-1538	CRC	BYL719 + binimetinib	200	24.2	8	-1.5	-4.3
X-1538	CRC	BYL719 + binimetinib	197.9	24.9	11	-2.6	-1.6
X-1538	CRC	BYL719 + binimetinib	195.1	25	14	-3.9	-1.2
X-1538	CRC	BYL719 + binimetinib	197.1	27	18	-3	6.7
X-1538	CRC	BYL719 + binimetinib	203	25.1	22	0	-0.8
X-1538	CRC	BYL719 + binimetinib	203.3	25.5	25	0.1	0.8
X-1538	CRC	BYL719 + binimetinib	222.9	25.5	29	9.7	0.8
X-1538	CRC	BYL719 + binimetinib	213.5	24.3	32	5.1	-4
X-1538	CRC	BYL719 + binimetinib	206.5	24.8	36	1.7	-2
X-1538	CRC	BYL719 + binimetinib	210.1	25.8	39	3.4	2
X-1538	CRC	BYL719 + binimetinib	210.7	25.5	43	3.7	0.8
X-1538	CRC	BYL719 + binimetinib	211.6	25.6	46	4.2	1.2
X-1538	CRC	BYL719 + binimetinib	221.4	24.6	50	9	-2.8
X-1538	CRC	BYL719 + binimetinib	221.8	24.1	53	9.2	-4.7
X-1538	CRC	CLR457	206.5	28.3	0	0	0
X-1538	CRC	CLR457	212.1	28.9	3	2.7	2.1
X-1538	CRC	CLR457	235.9	28.5	7	14.2	0.7
X-1538	CRC	CLR457	245	29.3	11	18.6	3.5
X-1538	CRC	CLR457	248.4	29.3	14	20.3	3.5
X-1538	CRC	CLR457	239.4	28.9	17	15.9	2.1
X-1538	CRC	CLR457	217.8	27.7	21	5.5	-2.1
X-1538	CRC	CLR457	237.2	28.8	25	14.9	1.8
X-1538	CRC	CLR457	240.9	27.7	28	16.7	-2.1
X-1538	CRC	CLR457	251.7	29.3	32	21.9	3.5
X-1538	CRC	CLR457	237.6	28.7	35	15.1	1.4
X-1538	CRC	CLR457	252.6	28.3	39	22.3	0
X-1538	CRC	CLR457	259.9	27.3	42	25.9	-3.5
X-1538	CRC	CLR457	257	24.5	46	24.5	-13.4
X-1538	CRC	CLR457	254.3	23.3	49	23.1	-17.7
X-1538	CRC	cetuximab	229.5	25.6	0	0	0
X-1538	CRC	cetuximab	238.4	25.5	5	3.9	-0.4
X-1538	CRC	cetuximab	239	25.9	7	4.1	1.2
X-1538	CRC	cetuximab	307	25.1	10	33.8	-2
X-1538	CRC	cetuximab	369.8	25.5	13	61.1	-0.4
X-1538	CRC	cetuximab	392.6	21.7	17	71.1	-15.2
X-1538	CRC	LEE011	214.8	26.3	0	0	0
X-1538	CRC	LEE011	192.7	25.2	5	-10.3	-4.2
X-1538	CRC	LEE011	196.2	26.3	7	-8.7	0
X-1538	CRC	LEE011	172.7	27.2	10	-19.6	3.4
X-1538	CRC	LEE011	173	26.4	13	-19.5	0.4
X-1538	CRC	LEE011	175.8	26.8	17	-18.2	1.9
X-1538	CRC	LEE011	179.8	27.5	21	-16.3	4.6
X-1538	CRC	LEE011	184.7	27.1	24	-14	3
X-1538	CRC	LEE011	177.5	26.7	27	-17.4	1.5
X-1538	CRC	LEE011	171.5	27.6	31	-20.2	4.9
X-1538	CRC	LEE011	169.2	27.5	35	-21.2	4.6
X-1538	CRC	LEE011	182.9	28	38	-14.9	6.5
X-1538	CRC	LEE011	183.2	28.7	42	-14.7	9.1
X-1538	CRC	LEE011	179.8	28.4	45	-16.3	8
X-1538	CRC	LEE011	181.9	29.8	49	-15.3	13.3
X-1538	CRC	LEE011	184.2	28.6	52	-14.2	8.7
X-1538	CRC	LEE011	184.8	29.3	56	-14	11.4
X-1538	CRC	LEE011	185.8	29.3	59	-13.5	11.4
X-1538	CRC	LEE011	180.7	29.6	63	-15.9	12.5
X-1538	CRC	LEE011	192.7	28.1	66	-10.3	6.8
X-1538	CRC	encorafenib	188.5	26.1	0	0	0
X-1538	CRC	encorafenib	189.9	26	4	0.7	-0.4
X-1538	CRC	encorafenib	190.4	26.6	8	1	1.9
X-1538	CRC	encorafenib	190	26.4	11	0.8	1.1
X-1538	CRC	encorafenib	191.4	26.3	15	1.5	0.8
X-1538	CRC	encorafenib	197.9	25.9	18	5	-0.8
X-1538	CRC	encorafenib	200.9	25.7	22	6.6	-1.5
X-1538	CRC	encorafenib	209.6	25.9	25	11.2	-0.8
X-1538	CRC	encorafenib	233.6	26.3	29	23.9	0.8
X-1538	CRC	encorafenib	246.2	25.2	32	30.6	-3.4
X-1538	CRC	untreated	184	29.3	0	0	0
X-1538	CRC	untreated	182.2	28.4	3	-1	-3.1
X-1538	CRC	untreated	187.9	29.1	6	2.1	-0.7
X-1538	CRC	untreated	190.3	30.1	10	3.4	2.7
X-1538	CRC	untreated	197.3	30.3	15	7.2	3.4
X-1538	CRC	untreated	198.2	30.1	17	7.7	2.7
X-1538	CRC	untreated	201.6	29.4	20	9.6	0.3
X-1538	CRC	untreated	202.8	29.8	23	10.2	1.7
X-1538	CRC	untreated	217.4	30.1	27	18.2	2.7
X-1538	CRC	untreated	225.8	29.7	31	22.7	1.4
X-1538	CRC	untreated	254	30.2	34	38	3.1
X-1538	CRC	untreated	263.1	30.1	37	43	2.7
X-1538	CRC	untreated	250.2	30.2	41	36	3.1
X-1538	CRC	untreated	249.2	30.3	45	35.4	3.4
X-1538	CRC	untreated	262.6	30.2	48	42.7	3.1
X-1538	CRC	untreated	279.4	29.4	52	51.8	0.3
X-1538	CRC	untreated	266.9	30	55	45.1	2.4
X-1538	CRC	untreated	270	30.8	59	46.7	5.1
X-1538	CRC	untreated	271.4	29.9	62	47.5	2
X-1538	CRC	untreated	325.4	30.9	66	76.8	5.5
X-1538	CRC	untreated	280.5	31.5	69	52.4	7.5
X-1538	CRC	untreated	282.6	30.2	73	53.6	3.1
X-1538	CRC	untreated	284.8	28.2	76	54.8	-3.8
X-1586	NSCLC	BGJ398	190.7	25.3	0	0	0
X-1586	NSCLC	BGJ398	142.2	25.4	4	-25.4	0.4
X-1586	NSCLC	BGJ398	159.9	25.8	7	-16.2	2
X-1586	NSCLC	BGJ398	202.8	25.5	11	6.3	0.8
X-1586	NSCLC	BGJ398	205.6	25.7	14	7.8	1.6
X-1586	NSCLC	BGJ398	243.2	25.6	18	27.5	1.2
X-1586	NSCLC	BGJ398	244.5	24.8	21	28.2	-2
X-1586	NSCLC	BGJ398	278	24.6	25	45.8	-2.8
X-1586	NSCLC	BGJ398	221.9	24.7	28	16.4	-2.4
X-1586	NSCLC	BGJ398	298.6	24.3	32	56.6	-4
X-1586	NSCLC	BGJ398	290.8	24.9	35	52.5	-1.6
X-1586	NSCLC	BKM120 + binimetinib	279.3	28.2	0	0	0
X-1586	NSCLC	BKM120 + binimetinib	161.4	27.4	3	-42.2	-2.8
X-1586	NSCLC	BKM120 + binimetinib	105.4	26	7	-62.3	-7.8
X-1586	NSCLC	BKM120 + binimetinib	122.6	27	10	-56.1	-4.3
X-1586	NSCLC	BKM120 + binimetinib	151	27.3	14	-45.9	-3.2
X-1586	NSCLC	BKM120 + binimetinib	153.9	27.8	17	-44.9	-1.4
X-1586	NSCLC	BKM120 + binimetinib	187.6	27	21	-32.8	-4.3
X-1586	NSCLC	BKM120 + binimetinib	212.4	27.4	24	-24	-2.8
X-1586	NSCLC	BKM120 + binimetinib	148.7	27.9	28	-46.8	-1.1
X-1586	NSCLC	BKM120 + binimetinib	119.4	28.2	31	-57.3	0
X-1586	NSCLC	BKM120 + binimetinib	79.9	28.3	35	-71.4	0.4
X-1586	NSCLC	BKM120 + binimetinib	92.4	28.2	38	-66.9	0
X-1586	NSCLC	BKM120 + binimetinib	83.8	28.4	42	-70	0.7
X-1586	NSCLC	BKM120 + binimetinib	81.4	28.5	45	-70.9	1.1
X-1586	NSCLC	BKM120 + binimetinib	109.3	24.5	49	-60.9	-13.1
X-1586	NSCLC	BKM120 + binimetinib	72.4	29.8	52	-74.1	5.7
X-1586	NSCLC	BKM120 + binimetinib	105.9	29.9	56	-62.1	6
X-1586	NSCLC	BKM120 + binimetinib	118.3	30.4	60	-57.6	7.8
X-1586	NSCLC	BKM120 + binimetinib	116.2	30.8	63	-58.4	9.2
X-1586	NSCLC	BKM120 + binimetinib	117.9	31.2	67	-57.8	10.6
X-1586	NSCLC	BKM120 + binimetinib	140.5	31.8	70	-49.7	12.8
X-1586	NSCLC	BKM120 + binimetinib	134.3	31.9	73	-51.9	13.1
X-1586	NSCLC	BKM120 + binimetinib	158.5	31.7	78	-43.3	12.4
X-1586	NSCLC	BKM120 + binimetinib	187.3	32	80	-32.9	13.5
X-1586	NSCLC	BKM120 + binimetinib	168.9	31.3	84	-39.5	11
X-1586	NSCLC	BKM120 + binimetinib	169.8	32.6	87	-39.2	15.6
X-1586	NSCLC	BKM120 + binimetinib	135.7	32.3	91	-51.4	14.5
X-1586	NSCLC	BKM120 + binimetinib	133.7	32.3	94	-52.1	14.5
X-1586	NSCLC	BKM120 + binimetinib	114.4	31.7	98	-59	12.4
X-1586	NSCLC	BKM120 + binimetinib	139.2	32.1	101	-50.2	13.8
X-1586	NSCLC	BKM120 + binimetinib	176.5	32.5	105	-36.8	15.2
X-1586	NSCLC	BKM120 + binimetinib	200.1	31.7	106	-28.4	12.4
X-1586	NSCLC	BKM120	201.4	28.3	0	0	0
X-1586	NSCLC	BKM120	153.6	28.5	4	-23.7	0.7
X-1586	NSCLC	BKM120	133.5	29.3	7	-33.7	3.5
X-1586	NSCLC	BKM120	149.6	29.5	11	-25.7	4.2
X-1586	NSCLC	BKM120	123.4	29.3	14	-38.7	3.5
X-1586	NSCLC	BKM120	124	29.1	18	-38.4	2.8
X-1586	NSCLC	BKM120	162.5	30	21	-19.3	6
X-1586	NSCLC	BKM120	179.8	30	25	-10.7	6
X-1586	NSCLC	BKM120	109.9	30	28	-45.4	6
X-1586	NSCLC	BKM120	172.3	30.2	32	-14.4	6.7
X-1586	NSCLC	BKM120	218	30.8	35	8.2	8.8
X-1586	NSCLC	BKM120	207.1	30.2	39	2.8	6.7
X-1586	NSCLC	BKM120	152.6	31.1	42	-24.2	9.9
X-1586	NSCLC	BKM120	194.2	31	46	-3.6	9.5
X-1586	NSCLC	BKM120	212.3	31.6	49	5.4	11.7
X-1586	NSCLC	BKM120	247.8	31.2	53	23	10.2
X-1586	NSCLC	BKM120	219.1	30.3	56	8.8	7.1
X-1586	NSCLC	BKM120	253.3	31.1	60	25.8	9.9
X-1586	NSCLC	BKM120	267.2	31	63	32.7	9.5
X-1586	NSCLC	BKM120	376.2	32	67	86.8	13.1
X-1586	NSCLC	BKM120	483.1	32.1	71	139.9	13.4
X-1586	NSCLC	BKM120	455.3	32.7	74	126.1	15.5
X-1586	NSCLC	BKM120	464.2	31	78	130.5	9.5
X-1586	NSCLC	BKM120	364.2	32.3	81	80.8	14.1
X-1586	NSCLC	BKM120	338.6	32.8	84	68.1	15.9
X-1586	NSCLC	BKM120	273.6	32.4	89	35.8	14.5
X-1586	NSCLC	BKM120	366.9	32.7	91	82.2	15.5
X-1586	NSCLC	BKM120	383	32.6	95	90.2	15.2
X-1586	NSCLC	BKM120	463.2	33.1	98	130	17
X-1586	NSCLC	BKM120	428	33.4	102	112.5	18
X-1586	NSCLC	BKM120	414.4	34.4	105	105.8	21.6
X-1586	NSCLC	BKM120	416.2	33.7	109	106.7	19.1
X-1586	NSCLC	BKM120	464	33.7	112	130.4	19.1
X-1586	NSCLC	BKM120	419.8	34.2	116	108.4	20.8
X-1586	NSCLC	BKM120	562.8	34	117	179.4	20.1
X-1586	NSCLC	BYL719	225.3	25.8	0	0	0
X-1586	NSCLC	BYL719	149.4	25.6	4	-33.7	-0.8
X-1586	NSCLC	BYL719	194.7	25.3	7	-13.6	-1.9
X-1586	NSCLC	BYL719	162.8	25.5	11	-27.7	-1.2
X-1586	NSCLC	BYL719	124.6	25.8	14	-44.7	0
X-1586	NSCLC	BYL719	117.9	26.1	18	-47.7	1.2
X-1586	NSCLC	BYL719	150.6	26.8	21	-33.2	3.9
X-1586	NSCLC	BYL719	161	26.9	25	-28.5	4.3
X-1586	NSCLC	BYL719	201.9	26.1	28	-10.4	1.2
X-1586	NSCLC	BYL719	189.9	26.1	32	-15.7	1.2
X-1586	NSCLC	BYL719	186.1	26.5	35	-17.4	2.7
X-1586	NSCLC	BYL719	201.7	26.9	39	-10.5	4.3
X-1586	NSCLC	BYL719	172.8	26.3	42	-23.3	1.9
X-1586	NSCLC	BYL719	228	27	46	1.2	4.7
X-1586	NSCLC	BYL719	215.4	26.8	49	-4.4	3.9
X-1586	NSCLC	BYL719	152.5	27.4	53	-32.3	6.2
X-1586	NSCLC	BYL719	187.5	27.6	56	-16.8	7
X-1586	NSCLC	BYL719	278.9	26.9	60	23.8	4.3
X-1586	NSCLC	BYL719	287.3	26.1	64	27.5	1.2
X-1586	NSCLC	BYL719	313.7	27.2	67	39.2	5.4
X-1586	NSCLC	BYL719	326.7	26.1	71	45	1.2
X-1586	NSCLC	BYL719	307.9	27.3	74	36.7	5.8
X-1586	NSCLC	BYL719	380.7	27.6	77	69	7
X-1586	NSCLC	BYL719	297.8	27.5	82	32.2	6.6
X-1586	NSCLC	BYL719	457.4	27.5	84	103	6.6
X-1586	NSCLC	BYL719	307	26.7	88	36.3	3.5
X-1586	NSCLC	BYL719	423.2	27.2	91	87.8	5.4
X-1586	NSCLC	BYL719	468	27.9	95	107.7	8.1
X-1586	NSCLC	BYL719	407.8	28	98	81	8.5
X-1586	NSCLC	BYL719	409.9	28.2	102	81.9	9.3
X-1586	NSCLC	BYL719	456.3	28.3	105	102.5	9.7
X-1586	NSCLC	BYL719	570.7	28.1	109	153.3	8.9
X-1586	NSCLC	BYL719	674.1	28.2	110	199.2	9.3
X-1586	NSCLC	BYL719 + LJM716	163.3	26.3	0	0	0
X-1586	NSCLC	BYL719 + LJM716	88.2	25.3	3	-46	-3.8
X-1586	NSCLC	BYL719 + LJM716	114.6	25.6	7	-29.8	-2.7
X-1586	NSCLC	BYL719 + LJM716	110.5	25.5	10	-32.3	-3
X-1586	NSCLC	BYL719 + LJM716	81.8	24.9	14	-49.9	-5.3
X-1586	NSCLC	BYL719 + LJM716	79.9	25.8	17	-51.1	-1.9
X-1586	NSCLC	BYL719 + LJM716	81.5	26	21	-50.1	-1.1
X-1586	NSCLC	BYL719 + LJM716	98.9	26	24	-39.4	-1.1
X-1586	NSCLC	BYL719 + LJM716	122.8	26.4	28	-24.8	0.4
X-1586	NSCLC	BYL719 + LJM716	146.1	25.3	31	-10.5	-3.8
X-1586	NSCLC	BYL719 + LJM716	147.2	26.5	35	-9.9	0.8
X-1586	NSCLC	BYL719 + LJM716	114.4	26.2	38	-29.9	-0.4
X-1586	NSCLC	BYL719 + LJM716	158.3	26.7	42	-3.1	1.5
X-1586	NSCLC	BYL719 + LJM716	119.6	26.7	45	-26.8	1.5
X-1586	NSCLC	BYL719 + LJM716	189.2	27.1	49	15.9	3
X-1586	NSCLC	BYL719 + LJM716	176.7	27.2	52	8.2	3.4
X-1586	NSCLC	BYL719 + LJM716	263.4	26.9	56	61.3	2.3
X-1586	NSCLC	BYL719 + LJM716	327.3	26.9	60	100.4	2.3
X-1586	NSCLC	BYL719 + LJM716	321.8	26.8	63	97.1	1.9
X-1586	NSCLC	BYL719 + LJM716	421.2	27.5	67	157.9	4.6
X-1586	NSCLC	BYL719 + LJM716	284.5	26.8	70	74.2	1.9
X-1586	NSCLC	BYL719 + LJM716	227.6	26.4	73	39.4	0.4
X-1586	NSCLC	BYL719 + LJM716	241.1	27.3	78	47.6	3.8
X-1586	NSCLC	BYL719 + LJM716	223.2	27.6	80	36.7	4.9
X-1586	NSCLC	BYL719 + LJM716	296	28.1	84	81.3	6.8
X-1586	NSCLC	BYL719 + LJM716	313.5	27.7	87	92	5.3
X-1586	NSCLC	BYL719 + LJM716	310.9	28.3	91	90.4	7.6
X-1586	NSCLC	BYL719 + LJM716	276.4	28.1	94	69.3	6.8
X-1586	NSCLC	BYL719 + LJM716	347.2	28.7	98	112.6	9.1
X-1586	NSCLC	BYL719 + LJM716	411.7	29	101	152.1	10.3
X-1586	NSCLC	BYL719 + LJM716	327.4	28.3	105	100.5	7.6
X-1586	NSCLC	BYL719 + LJM716	416.6	28.2	106	155.1	7.2
X-1586	NSCLC	BYL719 + LGH447	240.9	28.3	0	0	0
X-1586	NSCLC	BYL719 + LGH447	152.6	26	7	-36.7	-8.1
X-1586	NSCLC	BYL719 + LGH447	148.9	25.8	10	-38.2	-8.8
X-1586	NSCLC	BYL719 + LGH447	97.5	26.5	14	-59.5	-6.4
X-1586	NSCLC	BYL719 + LGH447	134.4	25.3	17	-44.2	-10.6
X-1586	NSCLC	BYL719 + LGH447	144.5	26.7	21	-40	-5.7
X-1586	NSCLC	BYL719 + LGH447	187.4	26.3	24	-22.2	-7.1
X-1586	NSCLC	BYL719 + LGH447	160.3	26.1	28	-33.5	-7.8
X-1586	NSCLC	BYL719 + LGH447	222.7	26	31	-7.6	-8.1
X-1586	NSCLC	BYL719 + LGH447	193.9	24.5	35	-19.5	-13.4
X-1586	NSCLC	BYL719 + LGH447	256.2	25.3	38	6.4	-10.6
X-1586	NSCLC	BYL719 + LGH447	299.2	25.5	42	24.2	-9.9
X-1586	NSCLC	BYL719 + LGH447	369.1	25.8	45	53.2	-8.8
X-1586	NSCLC	BYL719 + LGH447	313.8	23.7	49	30.3	-16.3
X-1586	NSCLC	BYL719 + LGH447	308.3	26.6	52	28	-6
X-1586	NSCLC	BYL719 + LGH447	586.5	27.2	56	143.5	-3.9
X-1586	NSCLC	BYL719 + LGH447	642.9	26.9	60	166.9	-4.9
X-1586	NSCLC	BYL719 + LGH447	762.4	24.2	63	216.5	-14.5
X-1586	NSCLC	CGM097	205.3	28.2	0	0	0
X-1586	NSCLC	CGM097	161.4	28.6	4	-21.4	1.4
X-1586	NSCLC	CGM097	200	29	7	-2.6	2.8
X-1586	NSCLC	CGM097	181.7	29.5	11	-11.5	4.6
X-1586	NSCLC	CGM097	259.7	29.2	14	26.5	3.5
X-1586	NSCLC	CGM097	214.9	30.8	18	4.7	9.2
X-1586	NSCLC	CGM097	206	30.5	21	0.3	8.2
X-1586	NSCLC	CGM097	302.8	30.2	25	47.5	7.1
X-1586	NSCLC	CGM097	300.8	29.7	28	46.5	5.3
X-1586	NSCLC	CGM097	300.5	30.2	32	46.4	7.1
X-1586	NSCLC	CGM097	291.8	29.7	35	42.1	5.3
X-1586	NSCLC	CGM097	345.9	30.4	39	68.5	7.8
X-1586	NSCLC	CGM097	347.1	31	42	69.1	9.9
X-1586	NSCLC	CGM097	379.7	30.6	46	84.9	8.5
X-1586	NSCLC	CGM097	334.3	30.6	49	62.8	8.5
X-1586	NSCLC	CGM097	396.9	30.8	53	93.3	9.2
X-1586	NSCLC	CGM097	418.5	31.3	56	103.8	11
X-1586	NSCLC	CGM097	760.6	31.3	60	270.5	11
X-1586	NSCLC	CKX620	223.7	26.7	0	0	0
X-1586	NSCLC	CKX620	137.4	26.8	4	-38.6	0.4
X-1586	NSCLC	CKX620	146.2	28	7	-34.6	4.9
X-1586	NSCLC	CKX620	148.8	28.1	11	-33.5	5.2
X-1586	NSCLC	CKX620	129.3	28.5	14	-42.2	6.7
X-1586	NSCLC	CKX620	134.5	28.5	18	-39.9	6.7
X-1586	NSCLC	CKX620	117.1	27.9	21	-47.7	4.5
X-1586	NSCLC	CKX620	125	28.3	25	-44.1	6
X-1586	NSCLC	CKX620	161.3	28.3	28	-27.9	6
X-1586	NSCLC	CKX620	110.3	28	32	-50.7	4.9
X-1586	NSCLC	CKX620	138.5	28.1	35	-38.1	5.2
X-1586	NSCLC	CKX620	137.9	29.5	39	-38.4	10.5
X-1586	NSCLC	CKX620	106.5	29.2	42	-52.4	9.4
X-1586	NSCLC	CKX620	116.3	28.8	46	-48	7.9
X-1586	NSCLC	CKX620	146.4	29	49	-34.6	8.6
X-1586	NSCLC	CKX620	152.9	29.3	53	-31.6	9.7
X-1586	NSCLC	CKX620	118.3	28.4	56	-47.1	6.4
X-1586	NSCLC	CKX620	141.6	28.6	60	-36.7	7.1
X-1586	NSCLC	CKX620	91.5	28.7	63	-59.1	7.5
X-1586	NSCLC	CKX620	175.5	28.6	67	-21.5	7.1
X-1586	NSCLC	CKX620	185.2	29	71	-17.2	8.6
X-1586	NSCLC	CKX620	213.6	28.3	74	-4.5	6
X-1586	NSCLC	CKX620	280.2	28.5	78	25.3	6.7
X-1586	NSCLC	CKX620	174.2	28.4	81	-22.1	6.4
X-1586	NSCLC	CKX620	133.6	28.6	84	-40.3	7.1
X-1586	NSCLC	CKX620	158.7	27.8	89	-29.1	4.1
X-1586	NSCLC	CKX620	188.5	27.9	91	-15.7	4.5
X-1586	NSCLC	CKX620	179.2	27.2	95	-19.9	1.9
X-1586	NSCLC	CKX620	161.8	27.7	98	-27.7	3.7
X-1586	NSCLC	CKX620	177.9	28.5	102	-20.5	6.7
X-1586	NSCLC	CKX620	186.2	28.2	105	-16.8	5.6
X-1586	NSCLC	CKX620	167	28.3	109	-25.3	6
X-1586	NSCLC	CKX620	207.9	27.2	112	-7.1	1.9
X-1586	NSCLC	CKX620	265	27.4	116	18.5	2.6
X-1586	NSCLC	CKX620	300.9	26.8	117	34.5	0.4
X-1586	NSCLC	CLR457	147.1	26.9	0	0	0
X-1586	NSCLC	CLR457	119.1	26.2	4	-19	-2.6
X-1586	NSCLC	CLR457	122.2	26.8	7	-16.9	-0.4
X-1586	NSCLC	CLR457	178.7	27.1	11	21.5	0.7
X-1586	NSCLC	CLR457	197.8	26.6	14	34.5	-1.1
X-1586	NSCLC	CLR457	166.7	27.2	18	13.3	1.1
X-1586	NSCLC	CLR457	215.7	27	21	46.6	0.4
X-1586	NSCLC	CLR457	219	27.6	25	48.9	2.6
X-1586	NSCLC	CLR457	243.7	27.8	28	65.7	3.3
X-1586	NSCLC	CLR457	247.9	28.5	32	68.5	5.9
X-1586	NSCLC	CLR457	212.7	28.3	35	44.6	5.2
X-1586	NSCLC	CLR457	286.4	28.8	39	94.7	7.1
X-1586	NSCLC	CLR457	295.5	28.2	42	100.9	4.8
X-1586	NSCLC	CLR457	296.6	27.1	46	101.6	0.7
X-1586	NSCLC	CLR457	370.9	27.7	49	152.1	3
X-1586	NSCLC	CLR457	280.8	26.5	53	90.9	-1.5
X-1586	NSCLC	CLR457	400.8	27.5	56	172.5	2.2
X-1586	NSCLC	CLR457	430.8	27.5	60	192.9	2.2
X-1586	NSCLC	CLR457	450.4	26.8	63	206.2	-0.4
X-1586	NSCLC	CLR457	524	26.8	67	256.2	-0.4
X-1586	NSCLC	CLR457	432	28.2	70	193.7	4.8
X-1586	NSCLC	CLR457	862.1	27.5	74	486.1	2.2
X-1586	NSCLC	HDM201	205.9	23	0	0	0
X-1586	NSCLC	HDM201	126.8	23.5	4	-38.4	2.2
X-1586	NSCLC	HDM201	147.1	24.1	7	-28.6	4.8
X-1586	NSCLC	HDM201	158.7	24.2	11	-22.9	5.2
X-1586	NSCLC	HDM201	156	24.5	14	-24.2	6.5
X-1586	NSCLC	HDM201	210.5	23.4	18	2.2	1.7
X-1586	NSCLC	HDM201	182.8	24.3	21	-11.2	5.7
X-1586	NSCLC	HDM201	145.1	23.7	25	-29.5	3
X-1586	NSCLC	HDM201	166.3	23.4	28	-19.2	1.7
X-1586	NSCLC	HDM201	170.1	22.6	32	-17.4	-1.7
X-1586	NSCLC	HDM201	174.2	21.6	35	-15.4	-6.1
X-1586	NSCLC	HDM201	121.3	20.2	39	-41.1	-12.2
X-1586	NSCLC	HDM201	178.4	18.6	42	-13.4	-19.1
X-1586	NSCLC	cetuximab	241.2	27.6	0	0	0
X-1586	NSCLC	cetuximab	257.2	28.5	3	6.6	3.3
X-1586	NSCLC	cetuximab	316.6	27.5	7	31.3	-0.4
X-1586	NSCLC	cetuximab	281.6	27.8	10	16.7	0.7
X-1586	NSCLC	cetuximab	342.1	28.7	14	41.8	4
X-1586	NSCLC	cetuximab	538.9	29.9	17	123.4	8.3
X-1586	NSCLC	cetuximab	358.9	29.9	21	48.8	8.3
X-1586	NSCLC	cetuximab	428.7	29.5	24	77.7	6.9
X-1586	NSCLC	cetuximab	496.7	29.2	28	105.9	5.8
X-1586	NSCLC	cetuximab	1320.5	29.5	31	447.5	6.9
X-1586	NSCLC	erlotinib	346.7	27.4	0	0	0
X-1586	NSCLC	erlotinib	214.4	21	5	-38.2	-23.4
X-1586	NSCLC	erlotinib	316.6	23	8	-8.7	-16.1
X-1586	NSCLC	erlotinib	185.4	22	12	-46.5	-19.7
X-1586	NSCLC	erlotinib	286.5	26.9	15	-17.4	-1.8
X-1586	NSCLC	erlotinib	383.5	23.7	19	10.6	-13.5
X-1586	NSCLC	HSP990	204.5	32.8	0	0	0
X-1586	NSCLC	HSP990	123.3	30.3	5	-39.7	-7.6
X-1586	NSCLC	HSP990	113.6	29	8	-44.4	-11.6
X-1586	NSCLC	HSP990	114.9	31.9	12	-43.8	-2.7
X-1586	NSCLC	HSP990	140.2	30.2	15	-31.4	-7.9
X-1586	NSCLC	HSP990	146.3	31.7	19	-28.5	-3.4
X-1586	NSCLC	HSP990	169.2	27.1	22	-17.3	-17.4
X-1586	NSCLC	HSP990	122.5	31.1	26	-40.1	-5.2
X-1586	NSCLC	HSP990	116.9	28.4	29	-42.8	-13.4
X-1586	NSCLC	HSP990	134.5	32	33	-34.2	-2.4
X-1586	NSCLC	HSP990	132.9	29	36	-35	-11.6
X-1586	NSCLC	HSP990	113.4	32.4	40	-44.5	-1.2
X-1586	NSCLC	HSP990	128.9	32.1	43	-37	-2.1
X-1586	NSCLC	HSP990	169.2	29.8	47	-17.3	-9.1
X-1586	NSCLC	HSP990	144.4	31.4	50	-29.4	-4.3
X-1586	NSCLC	HSP990	136.7	25.6	54	-33.2	-22
X-1586	NSCLC	HSP990	153.7	25.4	56	-24.8	-22.6
X-1586	NSCLC	INC280	207.9	24.4	0	0	0
X-1586	NSCLC	INC280	160.8	24.8	3	-22.7	1.6
X-1586	NSCLC	INC280	130.8	26.1	7	-37.1	7
X-1586	NSCLC	INC280	152.4	25.5	10	-26.7	4.5
X-1586	NSCLC	INC280	131.3	25.5	14	-36.8	4.5
X-1586	NSCLC	INC280	349	25.9	17	67.9	6.1
X-1586	NSCLC	INC280	296.9	25.5	21	42.8	4.5
X-1586	NSCLC	INC280	350	26.1	24	68.4	7
X-1586	NSCLC	INC280	372.6	27.9	28	79.2	14.3
X-1586	NSCLC	INC280	420.6	26.2	31	102.3	7.4
X-1586	NSCLC	INC280	415.9	26.4	35	100	8.2
X-1586	NSCLC	INC280	471.5	26.4	38	126.8	8.2
X-1586	NSCLC	INC280	301.5	27	42	45	10.7
X-1586	NSCLC	INC280	419.2	27.2	45	101.6	11.5
X-1586	NSCLC	INC280	549.1	27.9	49	164.1	14.3
X-1586	NSCLC	INC280	780.3	28.1	51	275.3	15.2
X-1586	NSCLC	LCL161 + paclitaxel	157.6	25.1	0	0	0
X-1586	NSCLC	LCL161 + paclitaxel	158.2	23.9	4	0.4	-4.8
X-1586	NSCLC	LCL161 + paclitaxel	99.3	24.3	7	-37	-3.2
X-1586	NSCLC	LCL161 + paclitaxel	124.9	24.3	11	-20.7	-3.2
X-1586	NSCLC	LCL161 + paclitaxel	132.1	24.8	14	-16.2	-1.2
X-1586	NSCLC	LCL161 + paclitaxel	120.8	23.6	18	-23.4	-6
X-1586	NSCLC	LCL161 + paclitaxel	163.9	24.1	21	4	-4
X-1586	NSCLC	LCL161 + paclitaxel	121.1	24.1	25	-23.2	-4
X-1586	NSCLC	LCL161 + paclitaxel	174.9	24.2	28	11	-3.6
X-1586	NSCLC	LCL161 + paclitaxel	147.9	26	32	-6.2	3.6
X-1586	NSCLC	LCL161 + paclitaxel	144.3	26	35	-8.4	3.6
X-1586	NSCLC	LCL161 + paclitaxel	173.7	23.2	39	10.2	-7.6
X-1586	NSCLC	LCL161 + paclitaxel	224.7	24.6	42	42.6	-2
X-1586	NSCLC	LCL161 + paclitaxel	175.3	17.3	46	11.2	-31.1
X-1586	NSCLC	LCL161 + paclitaxel	215.6	18.7	49	36.8	-25.5
X-1586	NSCLC	LCL161 + paclitaxel	98	17.8	53	-37.8	-29.1
X-1586	NSCLC	LCL161 + paclitaxel	71.1	19.5	55	-54.9	-22.3
X-1586	NSCLC	LEE011	239.4	24.1	0	0	0
X-1586	NSCLC	LEE011	124.4	24.7	4	-48	2.5
X-1586	NSCLC	LEE011	136.3	24.6	7	-43.1	2.1
X-1586	NSCLC	LEE011	239	24.7	11	-0.2	2.5
X-1586	NSCLC	LEE011	178.7	25.4	14	-25.4	5.4
X-1586	NSCLC	LEE011	178.7	25.6	18	-25.4	6.2
X-1586	NSCLC	LEE011	176.8	25.2	21	-26.1	4.6
X-1586	NSCLC	LEE011	235	26.1	25	-1.8	8.3
X-1586	NSCLC	LEE011	176.3	26.4	28	-26.4	9.5
X-1586	NSCLC	LEE011	344.5	25.7	32	43.9	6.6
X-1586	NSCLC	LEE011	181.7	26.1	35	-24.1	8.3
X-1586	NSCLC	LEE011	221	26.1	39	-7.7	8.3
X-1586	NSCLC	LEE011	338.5	26.3	42	41.4	9.1
X-1586	NSCLC	LEE011	312.1	26.6	46	30.4	10.4
X-1586	NSCLC	LEE011	337.6	26.7	49	41	10.8
X-1586	NSCLC	LEE011	322.7	26.9	53	34.8	11.6
X-1586	NSCLC	LEE011	358.9	27.5	56	49.9	14.1
X-1586	NSCLC	LEE011	829.4	27.7	60	246.4	14.9
X-1586	NSCLC	LGH447	291	27.2	0	0	0
X-1586	NSCLC	LGH447	307.2	23.9	5	5.6	-12.1
X-1586	NSCLC	LGH447	235.5	23.6	8	-19.1	-13.2
X-1586	NSCLC	LGH447	261.1	24.1	12	-10.3	-11.4
X-1586	NSCLC	LGH447	469.6	26.2	15	61.4	-3.7
X-1586	NSCLC	LGH447	696.7	26.1	19	139.4	-4
X-1586	NSCLC	LGH447	853.5	25.8	23	193.3	-5.1
X-1586	NSCLC	LGH447	945.3	25.4	26	224.8	-6.6
X-1586	NSCLC	LLM871	181.9	28.8	0	0	0
X-1586	NSCLC	LLM871	146.6	28.9	4	-19.4	0.3
X-1586	NSCLC	LLM871	156.4	29.2	7	-14	1.4
X-1586	NSCLC	LLM871	195.4	28.2	11	7.4	-2.1
X-1586	NSCLC	LLM871	252.6	28.7	14	38.9	-0.3
X-1586	NSCLC	LLM871	231.1	28.8	18	27	0
X-1586	NSCLC	LLM871	259.6	29.5	21	42.7	2.4
X-1586	NSCLC	LLM871	282.8	29.7	25	55.5	3.1
X-1586	NSCLC	LLM871	269.2	30.4	28	48	5.6
X-1586	NSCLC	LLM871	316.2	31	32	73.8	7.6
X-1586	NSCLC	LLM871	401.2	30.9	35	120.6	7.3
X-1586	NSCLC	LLM871	480.8	30.9	39	164.3	7.3
X-1586	NSCLC	LLM871	436	31.2	42	139.7	8.3
X-1586	NSCLC	LLM871	440.5	30.9	46	142.2	7.3
X-1586	NSCLC	LLM871	609	30.9	48	234.8	7.3
X-1586	NSCLC	binimetinib	198.9	26.5	0	0	0
X-1586	NSCLC	binimetinib	108.6	26	3	-45.4	-1.9
X-1586	NSCLC	binimetinib	125.6	27.8	7	-36.9	4.9
X-1586	NSCLC	binimetinib	131.5	27.8	10	-33.9	4.9
X-1586	NSCLC	binimetinib	142.7	27.9	14	-28.3	5.3
X-1586	NSCLC	binimetinib	209.5	27.6	17	5.3	4.2
X-1586	NSCLC	binimetinib	148.7	27.9	21	-25.2	5.3
X-1586	NSCLC	binimetinib	169	28.7	24	-15	8.3
X-1586	NSCLC	binimetinib	150.6	28.7	28	-24.3	8.3
X-1586	NSCLC	binimetinib	163.9	28.5	31	-17.6	7.5
X-1586	NSCLC	binimetinib	193.3	28.8	35	-2.8	8.7
X-1586	NSCLC	binimetinib	222.7	28.8	38	12	8.7
X-1586	NSCLC	binimetinib	241.9	28.3	42	21.6	6.8
X-1586	NSCLC	binimetinib	215.4	28.5	45	8.3	7.5
X-1586	NSCLC	binimetinib	224.7	28.5	49	13	7.5
X-1586	NSCLC	binimetinib	297.7	28.1	52	49.7	6
X-1586	NSCLC	binimetinib	256.4	28.3	56	28.9	6.8
X-1586	NSCLC	binimetinib	320.8	29.2	59	61.3	10.2
X-1586	NSCLC	binimetinib	287.5	27.7	63	44.5	4.5
X-1586	NSCLC	binimetinib	299.4	26.4	66	50.5	-0.4
X-1586	NSCLC	binimetinib	495.6	24.8	70	149.2	-6.4
X-1586	NSCLC	binimetinib	427.7	27.7	74	115	4.5
X-1586	NSCLC	binimetinib	536.6	28.6	77	169.8	7.9
X-1586	NSCLC	binimetinib	618.3	28.5	81	210.9	7.5
X-1586	NSCLC	binimetinib	532.5	28.8	84	167.7	8.7
X-1586	NSCLC	binimetinib	551	25.9	87	177	-2.3
X-1586	NSCLC	binimetinib	437.3	27.3	92	119.9	3
X-1586	NSCLC	binimetinib	536.1	26.8	94	169.5	1.1
X-1586	NSCLC	binimetinib	517.7	25	98	160.3	-5.7
X-1586	NSCLC	binimetinib	730.3	25.8	100	267.2	-2.6
X-1586	NSCLC	paclitaxel	148.8	29.3	0	0	0
X-1586	NSCLC	paclitaxel	167.1	28.4	4	12.3	-3.1
X-1586	NSCLC	paclitaxel	210	29	7	41.1	-1
X-1586	NSCLC	paclitaxel	201.4	29.8	11	35.3	1.7
X-1586	NSCLC	paclitaxel	206.8	30.1	14	39	2.7
X-1586	NSCLC	paclitaxel	298.4	29.8	18	100.5	1.7
X-1586	NSCLC	paclitaxel	296.3	30.5	21	99.1	4.1
X-1586	NSCLC	paclitaxel	361.6	29.9	25	143	2
X-1586	NSCLC	paclitaxel	326	30.4	28	119.1	3.8
X-1586	NSCLC	paclitaxel	545.8	30.7	32	266.8	4.8
X-1586	NSCLC	paclitaxel	673.5	31.1	34	352.6	6.1
X-1586	NSCLC	untreated	280.4	27	0	0	0
X-1586	NSCLC	untreated	224.3	26.4	5	-20	-2.2
X-1586	NSCLC	untreated	319.4	26	8	13.9	-3.7
X-1586	NSCLC	untreated	319.5	26.2	12	13.9	-3
X-1586	NSCLC	untreated	248.1	27.3	15	-11.5	1.1
X-1586	NSCLC	untreated	375.4	26.4	19	33.9	-2.2
X-1586	NSCLC	untreated	406.1	26.4	23	44.8	-2.2
X-1586	NSCLC	untreated	392	25.8	26	39.8	-4.4
X-1586	NSCLC	untreated	417.8	25.7	30	49	-4.8
X-1586	NSCLC	untreated	337.2	25.7	33	20.3	-4.8
X-1586	NSCLC	untreated	289.9	25.9	36	3.4	-4.1
X-1586	NSCLC	untreated	447.5	25.6	41	59.6	-5.2
X-1586	NSCLC	untreated	315	25.4	43	12.3	-5.9
X-1586	NSCLC	untreated	421.2	25.4	47	50.2	-5.9
X-1586	NSCLC	untreated	443.1	24.9	50	58	-7.8
X-1586	NSCLC	untreated	537.3	26.3	54	91.6	-2.6
X-1586	NSCLC	untreated	507	25.8	57	80.8	-4.4
X-1586	NSCLC	untreated	670.8	26.1	61	139.2	-3.3
X-1586	NSCLC	untreated	743.6	24.8	64	165.2	-8.1
X-1586	NSCLC	untreated	654.7	25.2	68	133.5	-6.7
X-1586	NSCLC	untreated	907.1	24.7	70	223.5	-8.5
X-1586	NSCLC	LFW527 + binimetinib	192.75	30.7	0	0	0
X-1586	NSCLC	LFW527 + binimetinib	124.3	29.8	3	-35.5	-2.9
X-1586	NSCLC	LFW527 + binimetinib	166.43	28.5	10	-13.7	-7.2
X-1586	NSCLC	LFW527 + binimetinib	214.14	29.2	13	11.1	-4.9
X-1586	NSCLC	LFW527 + binimetinib	166.47	29.5	14	-13.6	-3.9
X-1586	NSCLC	LFW527 + binimetinib	194.3	28.9	21	0.8	-5.9
X-1586	NSCLC	LFW527 + binimetinib	202.64	29.1	24	5.1	-5.2
X-1586	NSCLC	LFW527 + binimetinib	213.26	28.8	28	10.6	-6.2
X-1586	NSCLC	LFW527 + binimetinib	203.21	27.8	31	5.4	-9.4
X-1586	NSCLC	LFW527 + binimetinib	216.23	28.6	35	12.2	-6.8
X-1586	NSCLC	LFW527 + binimetinib	193.01	28.4	38	0.1	-7.5
X-1586	NSCLC	LFW527 + binimetinib	215.26	28.8	42	11.7	-6.2
X-1586	NSCLC	LFW527 + binimetinib	226.99	29.1	45	17.8	-5.2
X-1586	NSCLC	LFW527 + binimetinib	206.85	28.5	49	7.3	-7.2
X-1586	NSCLC	LFW527 + binimetinib	218.27	29	52	13.2	-5.5
X-1586	NSCLC	LFW527 + binimetinib	260.44	29.9	56	35.1	-2.6
X-1586	NSCLC	LFW527 + binimetinib	261.55	29.3	59	35.7	-4.6
X-1586	NSCLC	LFW527 + binimetinib	246.89	NA	63	28.1	-4.6
X-1586	NSCLC	LFW527 + binimetinib	278.94	28.9	66	44.7	-5.9
X-1586	NSCLC	LFW527 + binimetinib	278.41	28	70	44.4	-8.8
X-1586	NSCLC	LFW527 + binimetinib	328.74	29.6	73	70.6	-3.6
X-1586	NSCLC	LFW527 + binimetinib	380.97	29.8	77	97.6	-2.9
X-1586	NSCLC	LFW527 + binimetinib	330.44	28.8	80	71.4	-6.2
X-1586	NSCLC	LFW527 + binimetinib	323.45	30.3	84	67.8	-1.3
X-1586	NSCLC	LFW527 + binimetinib	289.68	26.8	87	50.3	-12.7
X-1600	BRCA	BGJ398	226.1	21.5	0	0	0
X-1600	BRCA	BGJ398	431.9	23.8	4	91	10.7
X-1600	BRCA	BGJ398	510.2	27	8	125.7	25.6
X-1600	BRCA	BGJ398	961.1	23.1	11	325.1	7.4
X-1600	BRCA	BGJ398	1717.9	24.2	14	659.8	12.6
X-1600	BRCA	BKM120	305.5	25	0	0	0
X-1600	BRCA	BKM120	297.5	26.6	4	-2.6	6.4
X-1600	BRCA	BKM120	178.6	24.3	7	-41.5	-2.8
X-1600	BRCA	BKM120	207.2	26	11	-32.2	4
X-1600	BRCA	BKM120	234.9	26	14	-23.1	4
X-1600	BRCA	BKM120	264.9	26.7	18	-13.3	6.8
X-1600	BRCA	BKM120	286.8	26.6	21	-6.1	6.4
X-1600	BRCA	BKM120	288.7	26.2	25	-5.5	4.8
X-1600	BRCA	BKM120	293.6	26.2	28	-3.9	4.8
X-1600	BRCA	BKM120	453	27.7	35	48.3	10.8
X-1600	BRCA	BKM120	585	27.7	39	91.5	10.8
X-1600	BRCA	BKM120	605	26.9	42	98	7.6
X-1600	BRCA	BKM120	728.6	28.3	46	138.5	13.2
X-1600	BRCA	BKM120	1128.6	27.2	49	269.4	8.8
X-1600	BRCA	BKM120	1203.6	28.1	51	294	12.4
X-1600	BRCA	BYL719 + LEE011	225.1	25.7	0	0	0
X-1600	BRCA	BYL719 + LEE011	211.2	25.6	3	-6.2	-0.4
X-1600	BRCA	BYL719 + LEE011	180.3	24.7	6	-19.9	-3.9
X-1600	BRCA	BYL719 + LEE011	190.4	25.4	9	-15.4	-1.2
X-1600	BRCA	BYL719 + LEE011	222.1	25	13	-1.3	-2.7
X-1600	BRCA	BYL719 + LEE011	229.8	24.6	16	2.1	-4.3
X-1600	BRCA	BYL719 + LEE011	229.2	24.9	20	1.8	-3.1
X-1600	BRCA	BYL719 + LEE011	232.8	27	23	3.4	5.1
X-1600	BRCA	BYL719 + LEE011	257	25.6	27	14.2	-0.4
X-1600	BRCA	BYL719 + LEE011	291.3	26.6	31	29.4	3.5
X-1600	BRCA	BYL719 + LEE011	310.9	27.2	34	38.1	5.8
X-1600	BRCA	BYL719 + LEE011	320.7	28.6	37	42.5	11.3
X-1600	BRCA	BYL719 + LEE011	429.3	26	41	90.7	1.2
X-1600	BRCA	BYL719 + LEE011	467.2	25.9	45	107.6	0.8
X-1600	BRCA	BYL719 + LEE011	483.5	23.6	49	114.8	-8.2
X-1600	BRCA	BYL719 + LJM716	251.3	31.4	0	0	0
X-1600	BRCA	BYL719 + LJM716	318.1	31.2	4	26.6	-0.6
X-1600	BRCA	BYL719 + LJM716	561.3	31.7	8	123.4	1
X-1600	BRCA	BYL719 + LJM716	740.6	29.5	11	194.7	-6.1
X-1600	BRCA	BYL719 + LJM716	829.1	30.1	15	229.9	-4.1
X-1600	BRCA	BYL719 + LJM716	1034	29.2	18	311.5	-7
X-1600	BRCA	BYL719 + LJM716	1560.4	29.9	20	520.9	-4.8
X-1600	BRCA	BYL719	194.1	26.3	0	0	0
X-1600	BRCA	BYL719	207.4	27.4	3	6.9	4.2
X-1600	BRCA	BYL719	267.2	25.8	7	37.7	-1.9
X-1600	BRCA	BYL719	319.4	27.2	10	64.6	3.4
X-1600	BRCA	BYL719	461.8	27.2	14	137.9	3.4
X-1600	BRCA	BYL719	495.5	27.5	17	155.3	4.6
X-1600	BRCA	BYL719	729.5	26.3	24	275.8	0
X-1600	BRCA	BYL719	1124.9	26.8	26	479.5	1.9
X-1600	BRCA	CGM097	408.8	23.7	0	0	0
X-1600	BRCA	CGM097	505.8	25.7	4	23.7	8.4
X-1600	BRCA	CGM097	746.3	25.9	8	82.6	9.3
X-1600	BRCA	CGM097	1231.8	24.9	11	201.3	5.1
X-1600	BRCA	CGM097	1552.8	25.8	14	279.8	8.9
X-1600	BRCA	CLR457	186.4	25.2	0	0	0
X-1600	BRCA	CLR457	150.9	24.6	4	-19	-2.4
X-1600	BRCA	CLR457	174.6	26.2	8	-6.3	4
X-1600	BRCA	CLR457	157.1	25.9	11	-15.7	2.8
X-1600	BRCA	CLR457	195.4	25.3	15	4.8	0.4
X-1600	BRCA	CLR457	206.7	25.6	18	10.9	1.6
X-1600	BRCA	CLR457	256.8	26	22	37.8	3.2
X-1600	BRCA	CLR457	303.4	25.3	25	62.8	0.4
X-1600	BRCA	CLR457	320.5	27.2	32	71.9	7.9
X-1600	BRCA	CLR457	313.3	25.8	36	68.1	2.4
X-1600	BRCA	CLR457	351.2	26	39	88.4	3.2
X-1600	BRCA	CLR457	477.3	23.5	43	156.1	-6.7
X-1600	BRCA	CLR457	413.6	24	46	121.9	-4.8
X-1600	BRCA	CLR457	663.6	25.6	48	256	1.6
X-1600	BRCA	HDM201	221.2	25.2	0	0	0
X-1600	BRCA	HDM201	260.8	25.7	3	17.9	2
X-1600	BRCA	HDM201	482.4	25.4	7	118.1	0.8
X-1600	BRCA	HDM201	631.8	25.4	10	185.6	0.8
X-1600	BRCA	HDM201	811.4	25.2	14	266.8	0
X-1600	BRCA	HDM201	1025.5	24	17	363.6	-4.8
X-1600	BRCA	HDM201	1245.4	24.6	24	463	-2.4
X-1600	BRCA	HDM201	1579.5	23.5	26	614.1	-6.7
X-1600	BRCA	INC424	212	23.5	0	0	0
X-1600	BRCA	INC424	280.2	22.8	4	32.2	-3
X-1600	BRCA	INC424	444.4	24.7	8	109.6	5.1
X-1600	BRCA	INC424	642.2	24.2	11	202.9	3
X-1600	BRCA	INC424	1292.6	24.8	15	509.7	5.5
X-1600	BRCA	INC424	2379.2	25	18	1022.3	6.4
X-1600	BRCA	LEE011	245.3	25	0	0	0
X-1600	BRCA	LEE011	255.8	25.5	3	4.3	2
X-1600	BRCA	LEE011	263.1	25.7	6	7.3	2.8
X-1600	BRCA	LEE011	287.6	25.1	9	17.2	0.4
X-1600	BRCA	LEE011	373.4	25.4	13	52.2	1.6
X-1600	BRCA	LEE011	413.5	25.7	16	68.6	2.8
X-1600	BRCA	LEE011	437.4	25.8	20	78.3	3.2
X-1600	BRCA	LEE011	545.1	26.2	23	122.2	4.8
X-1600	BRCA	LEE011	693	26.7	27	182.5	6.8
X-1600	BRCA	LEE011	1110.2	27.3	31	352.6	9.2
X-1600	BRCA	LEE011	1645.9	27	34	571	8
X-1600	BRCA	LEE011 + everolimus	389.8	23.6	0	0	0
X-1600	BRCA	LEE011 + everolimus	276.2	23.3	3	-29.1	-1.3
X-1600	BRCA	LEE011 + everolimus	225.2	23.6	6	-42.2	0
X-1600	BRCA	LEE011 + everolimus	248.4	23.1	9	-36.3	-2.1
X-1600	BRCA	LEE011 + everolimus	294.4	23.3	13	-24.5	-1.3
X-1600	BRCA	LEE011 + everolimus	297.8	24.1	16	-23.6	2.1
X-1600	BRCA	LEE011 + everolimus	304.5	24.1	20	-21.9	2.1
X-1600	BRCA	LEE011 + everolimus	317	23.9	23	-18.7	1.3
X-1600	BRCA	LEE011 + everolimus	327.9	24.5	27	-15.9	3.8
X-1600	BRCA	LEE011 + everolimus	371.8	24.3	31	-4.6	3
X-1600	BRCA	LEE011 + everolimus	337.4	24.5	34	-13.4	3.8
X-1600	BRCA	LEE011 + everolimus	338.5	24.9	37	-13.2	5.5
X-1600	BRCA	LEE011 + everolimus	329.4	23.9	41	-15.5	1.3
X-1600	BRCA	LEE011 + everolimus	331.5	24.3	45	-15	3
X-1600	BRCA	LEE011 + everolimus	357.1	24.7	49	-8.4	4.7
X-1600	BRCA	LEE011 + everolimus	377.8	23.8	52	-3.1	0.8
X-1600	BRCA	LEE011 + everolimus	408.5	23.7	56	4.8	0.4
X-1600	BRCA	LEE011 + everolimus	389.8	23.6	60	0	0
X-1600	BRCA	LEE011 + everolimus	359.4	23.5	64	-7.8	-0.4
X-1600	BRCA	LEE011 + everolimus	416.8	22.8	66	6.9	-3.4
X-1600	BRCA	LEE011 + everolimus	488	23.4	69	25.2	-0.8
X-1600	BRCA	LEE011 + everolimus	479.5	23	73	23	-2.5
X-1600	BRCA	LEE011 + everolimus	466.5	24.1	76	19.7	2.1
X-1600	BRCA	LEE011 + everolimus	527.8	23.1	83	35.4	-2.1
X-1600	BRCA	LEE011 + everolimus	515.7	24.1	86	32.3	2.1
X-1600	BRCA	LEE011 + everolimus	509.8	24.4	90	30.8	3.4
X-1600	BRCA	LEE011 + everolimus	430.8	23.3	94	10.5	-1.3
X-1600	BRCA	LEE011 + everolimus	451.1	23.4	101	15.7	-0.8
X-1600	BRCA	LEE011 + everolimus	508.3	23	106	30.4	-2.5
X-1600	BRCA	LEE011 + everolimus	538.7	24.3	113	38.2	3
X-1600	BRCA	LEE011 + everolimus	558.4	24	119	43.3	1.7
X-1600	BRCA	LEE011 + everolimus	782.9	23.2	129	100.8	-1.7
X-1600	BRCA	LEE011 + everolimus	780.4	23.3	134	100.2	-1.3
X-1600	BRCA	LEE011 + everolimus	863.5	23.1	143	121.5	-2.1
X-1600	BRCA	LEE011 + everolimus	1010.2	22.9	148	159.2	-3
X-1600	BRCA	LFA102	193.2	24.8	0	0	0
X-1600	BRCA	LFA102	252	25.9	3	30.4	4.4
X-1600	BRCA	LFA102	398.3	25.6	6	106.2	3.2
X-1600	BRCA	LFA102	578.4	26.8	10	199.4	8.1
X-1600	BRCA	LFA102	1066.2	27.2	13	451.9	9.7
X-1600	BRCA	LFA102	1635.6	26.7	14	746.6	7.7
X-1600	BRCA	LJM716 + trastuzumab	197.2	25.3	0	0	0
X-1600	BRCA	LJM716 + trastuzumab	211.9	24.4	3	7.5	-3.6
X-1600	BRCA	LJM716 + trastuzumab	276.9	25.3	6	40.4	0
X-1600	BRCA	LJM716 + trastuzumab	319.2	25	10	61.9	-1.2
X-1600	BRCA	LJM716 + trastuzumab	507.2	26.3	13	157.2	4
X-1600	BRCA	LJM716 + trastuzumab	556.2	26	17	182	2.8
X-1600	BRCA	LJM716 + trastuzumab	824.6	25.5	20	318.2	0.8
X-1600	BRCA	LJM716 + trastuzumab	1061.3	25.8	21	438.2	2
X-1600	BRCA	LJM716	260	25.6	0	0	0
X-1600	BRCA	LJM716	416.5	24.6	4	60.2	-3.9
X-1600	BRCA	LJM716	724	26.5	8	178.5	3.5
X-1600	BRCA	LJM716	1264.8	25.9	11	386.5	1.2
X-1600	BRCA	LJM716	2326.7	27.1	14	794.9	5.9
X-1600	BRCA	LKA136	176.6	26	0	0	0
X-1600	BRCA	LKA136	275.9	26.7	4	56.2	2.7
X-1600	BRCA	LKA136	540.4	28.6	8	206	10
X-1600	BRCA	LKA136	939.1	28.6	11	431.8	10
X-1600	BRCA	LKA136	1558.3	29.3	13	782.4	12.7
X-1600	BRCA	LLM871	260.1	24.3	0	0	0
X-1600	BRCA	LLM871	248.1	23.1	3	-4.6	-4.9
X-1600	BRCA	LLM871	350	23.8	6	34.6	-2.1
X-1600	BRCA	LLM871	384	25.1	10	47.6	3.3
X-1600	BRCA	LLM871	628.4	24.2	13	141.6	-0.4
X-1600	BRCA	LLM871	1078.8	24	17	314.8	-1.2
X-1600	BRCA	LLM871	1567.2	24.7	20	502.5	1.6
X-1600	BRCA	binimetinib	210.1	23.7	0	0	0
X-1600	BRCA	binimetinib	322.7	23.7	4	53.6	0
X-1600	BRCA	binimetinib	481.3	26.3	8	129.1	11
X-1600	BRCA	binimetinib	808.1	25.1	11	284.6	5.9
X-1600	BRCA	binimetinib	1373.9	25.1	15	553.9	5.9
X-1600	BRCA	binimetinib	2203.2	26.2	18	948.6	10.5
X-1600	BRCA	paclitaxel	248.1	23.6	0	0	0
X-1600	BRCA	paclitaxel	246	24.1	3	-0.8	2.1
X-1600	BRCA	paclitaxel	281.8	23.9	6	13.6	1.3
X-1600	BRCA	paclitaxel	405.8	24.8	10	63.6	5.1
X-1600	BRCA	paclitaxel	718.6	25.1	13	189.6	6.4
X-1600	BRCA	paclitaxel	859.2	25.4	17	246.3	7.6
X-1600	BRCA	paclitaxel	916.6	24.9	20	269.4	5.5
X-1600	BRCA	paclitaxel	952.7	25.6	21	284	8.5
X-1600	BRCA	tamoxifen	189	27.4	0	0	0
X-1600	BRCA	tamoxifen	218.2	26	4	15.4	-5.1
X-1600	BRCA	tamoxifen	227.9	26.2	8	20.6	-4.4
X-1600	BRCA	tamoxifen	286.2	25.3	11	51.4	-7.7
X-1600	BRCA	tamoxifen	475.8	24.9	15	151.7	-9.1
X-1600	BRCA	tamoxifen	556	24.4	18	194.2	-10.9
X-1600	BRCA	tamoxifen	625.8	24.8	22	231.1	-9.5
X-1600	BRCA	tamoxifen	805.5	24.9	25	326.2	-9.1
X-1600	BRCA	tamoxifen	970.7	24.8	26	413.6	-9.5
X-1600	BRCA	trastuzumab	190.3	24.1	0	0	0
X-1600	BRCA	trastuzumab	270.7	25.4	3	42.2	5.4
X-1600	BRCA	trastuzumab	546	25.5	6	186.9	5.8
X-1600	BRCA	trastuzumab	1267.3	25.7	10	565.9	6.6
X-1600	BRCA	trastuzumab	2728.4	27.3	13	1333.7	13.3
X-1600	BRCA	untreated	215.3	25.4	0	0	0
X-1600	BRCA	untreated	432.4	25.7	3	100.8	1.2
X-1600	BRCA	untreated	951.5	26.3	7	341.9	3.5
X-1600	BRCA	untreated	1588.7	26.6	10	637.9	4.7
X-1600	BRCA	LFW527 + everolimus	204.43	28.2	0	0	0
X-1600	BRCA	LFW527 + everolimus	182.87	25.7	3	-10.5	-8.9
X-1600	BRCA	LFW527 + everolimus	174.55	25.9	7	-14.6	-8.2
X-1600	BRCA	LFW527 + everolimus	213.53	26.8	13	4.5	-5
X-1600	BRCA	LFW527 + everolimus	274.26	26.2	17	34.2	-7.1
X-1600	BRCA	LFW527 + everolimus	290.84	24.5	20	42.3	-13.1
X-1600	BRCA	LFW527 + everolimus	294.98	25.9	25	44.3	-8.2
X-1600	BRCA	LFW527 + everolimus	273.15	26.5	27	33.6	-6
X-1600	BRCA	LFW527 + everolimus	296	26.9	31	44.8	-4.6
X-1600	BRCA	LFW527 + everolimus	304.85	26.2	34	49.1	-7.1
X-1600	BRCA	LFW527 + everolimus	439.15	26.5	38	114.8	-6
X-1600	BRCA	LFW527 + everolimus	457.71	26.5	41	123.9	-6
X-1600	BRCA	LFW527 + everolimus	554	26	45	171	-7.8
X-1600	BRCA	LFW527 + everolimus	597.61	26.4	48	192.3	-6.4
X-1600	BRCA	LFW527 + everolimus	718.02	24.8	53	251.2	-12.1
X-1600	BRCA	LFW527 + everolimus	706.06	26.1	56	245.4	-7.4
X-1600	BRCA	LFW527 + everolimus	976.68	25.4	59	377.8	-9.9
X-1600	BRCA	LFW527 + everolimus	986.16	24.7	63	382.4	-12.4
X-1631	BRCA	BGJ398	322.6	27.6	0	0	0
X-1631	BRCA	BGJ398	675.2	25.8	4	109.3	-6.5
X-1631	BRCA	BGJ398	1025.4	23.7	8	217.9	-14.1
X-1631	BRCA	BGJ398	1493.6	24.5	11	363	-11.2
X-1631	BRCA	BKM120	255.3	29.2	0	0	0
X-1631	BRCA	BKM120	277.2	30.8	4	8.6	5.5
X-1631	BRCA	BKM120	317.6	32.1	12	24.4	9.9
X-1631	BRCA	BKM120	343.8	32.5	15	34.7	11.3
X-1631	BRCA	BKM120	304.3	32.3	18	19.2	10.6
X-1631	BRCA	BKM120	404.5	32	22	58.4	9.6
X-1631	BRCA	BKM120	382.6	31.8	25	49.9	8.9
X-1631	BRCA	BKM120	489.6	31.2	29	91.8	6.8
X-1631	BRCA	BKM120	436.2	31.2	32	70.9	6.8
X-1631	BRCA	BKM120	452.2	31.3	36	77.1	7.2
X-1631	BRCA	BKM120	477.4	31.4	39	87	7.5
X-1631	BRCA	BKM120	459.8	31.2	43	80.1	6.8
X-1631	BRCA	BKM120	582.6	30.5	46	128.2	4.5
X-1631	BRCA	BKM120	616.2	29.7	53	141.4	1.7
X-1631	BRCA	BKM120	681.9	28.4	56	167.1	-2.7
X-1631	BRCA	BKM120	815.4	26.8	61	219.4	-8.2
X-1631	BRCA	BKM120	974.5	26.4	64	281.7	-9.6
X-1631	BRCA	BKM120	1031.7	25.1	67	304.1	-14
X-1631	BRCA	BYL719 + LEE011	214.6	28	0	0	0
X-1631	BRCA	BYL719 + LEE011	217.1	27.1	3	1.2	-3.2
X-1631	BRCA	BYL719 + LEE011	184.6	24.6	10	-14	-12.1
X-1631	BRCA	BYL719 + LEE011	215.5	25.3	13	0.4	-9.6
X-1631	BRCA	BYL719 + LEE011	168.1	26.3	18	-21.7	-6.1
X-1631	BRCA	BYL719 + LEE011	172.1	25.2	21	-19.8	-10
X-1631	BRCA	BYL719 + LEE011	211.3	27.2	24	-1.5	-2.9
X-1631	BRCA	BYL719 + LEE011	175.5	28.7	28	-18.2	2.5
X-1631	BRCA	BYL719 + LEE011	197.3	26.8	31	-8.1	-4.3
X-1631	BRCA	BYL719 + LEE011	177.7	26.2	35	-17.2	-6.4
X-1631	BRCA	BYL719 + LEE011	166.1	23.1	38	-22.6	-17.5
X-1631	BRCA	BYL719 + LEE011	235.5	27.1	42	9.7	-3.2
X-1631	BRCA	BYL719 + LEE011	236.2	27.6	45	10.1	-1.4
X-1631	BRCA	BYL719 + LEE011	250.1	26.1	49	16.5	-6.8
X-1631	BRCA	BYL719 + LEE011	247.4	24.7	52	15.3	-11.8
X-1631	BRCA	BYL719 + LEE011	378	27.2	56	76.1	-2.9
X-1631	BRCA	BYL719 + LEE011	393.9	26.3	59	83.6	-6.1
X-1631	BRCA	BYL719 + LEE011	386.5	25.1	63	80.1	-10.4
X-1631	BRCA	BYL719 + LEE011	522.2	25.4	66	143.3	-9.3
X-1631	BRCA	BYL719 + LEE011	510	25.5	69	137.7	-8.9
X-1631	BRCA	BYL719 + LEE011	606.8	24.4	73	182.8	-12.9
X-1631	BRCA	BYL719 + LEE011	689.9	22.9	77	221.5	-18.2
X-1631	BRCA	BYL719 + LEE011	819	26	80	281.6	-7.1
X-1631	BRCA	BYL719 + LEE011	991.9	27.5	84	362.2	-1.8
X-1631	BRCA	BYL719 + LEE011	1043.3	23.9	94	386.2	-14.6
X-1631	BRCA	BYL719	377.9	22.4	0	0	0
X-1631	BRCA	BYL719	453.2	22.3	3	19.9	-0.4
X-1631	BRCA	BYL719	449.4	21	6	18.9	-6.2
X-1631	BRCA	BYL719	470.2	20.5	10	24.4	-8.5
X-1631	BRCA	BYL719	569.4	20.9	13	50.7	-6.7
X-1631	BRCA	BYL719	525.8	20	17	39.1	-10.7
X-1631	BRCA	BYL719	557.2	20.5	20	47.4	-8.5
X-1631	BRCA	BYL719	631.6	20.6	24	67.1	-8
X-1631	BRCA	BYL719	684.8	21.5	27	81.2	-4
X-1631	BRCA	BYL719	807.1	20.9	31	113.6	-6.7
X-1631	BRCA	BYL719	978.3	20.9	34	158.9	-6.7
X-1631	BRCA	BYL719 + LJM716	226.9	24.6	0	0	0
X-1631	BRCA	BYL719 + LJM716	207.1	22.9	4	-8.7	-6.9
X-1631	BRCA	BYL719 + LJM716	358	21.7	12	57.8	-11.8
X-1631	BRCA	BYL719 + LJM716	327.3	21.5	15	44.2	-12.6
X-1631	BRCA	BYL719 + LJM716	442.1	22.8	18	94.8	-7.3
X-1631	BRCA	BYL719 + LJM716	496.8	21.5	22	119	-12.6
X-1631	BRCA	BYL719 + LJM716	653.1	21.1	25	187.8	-14.2
X-1631	BRCA	CGM097	204.9	28.7	0	0	0
X-1631	BRCA	CGM097	251.2	29.2	3	22.6	1.7
X-1631	BRCA	CGM097	294	29.4	6	43.5	2.4
X-1631	BRCA	CGM097	351.8	29.2	10	71.7	1.7
X-1631	BRCA	CGM097	468.6	29.5	13	128.7	2.8
X-1631	BRCA	CGM097	580.6	29.3	17	183.4	2.1
X-1631	BRCA	CGM097	747.8	30.4	20	265	5.9
X-1631	BRCA	CGM097	778.6	29	24	280	1
X-1631	BRCA	CGM097	907.7	29.6	27	343	3.1
X-1631	BRCA	CLR457	218.3	29.8	0	0	0
X-1631	BRCA	CLR457	179.8	28.7	4	-17.6	-3.7
X-1631	BRCA	CLR457	205.1	29.4	7	-6	-1.3
X-1631	BRCA	CLR457	208.4	27.9	11	-4.5	-6.4
X-1631	BRCA	CLR457	207	27.4	14	-5.2	-8.1
X-1631	BRCA	CLR457	228.9	27.8	18	4.9	-6.7
X-1631	BRCA	CLR457	238.4	29.2	21	9.2	-2
X-1631	BRCA	CLR457	235.6	28.6	25	7.9	-4
X-1631	BRCA	CLR457	219.6	29.1	28	0.6	-2.3
X-1631	BRCA	CLR457	184.5	27.8	31	-15.5	-6.7
X-1631	BRCA	CLR457	235.3	28.5	35	7.8	-4.4
X-1631	BRCA	CLR457	245.9	28	39	12.6	-6
X-1631	BRCA	CLR457	236.3	28.5	42	8.2	-4.4
X-1631	BRCA	CLR457	241.9	26.5	46	10.8	-11.1
X-1631	BRCA	CLR457	230.4	29.1	56	5.5	-2.3
X-1631	BRCA	CLR457	195.6	29.4	60	-10.4	-1.3
X-1631	BRCA	CLR457	184.1	27.1	63	-15.7	-9.1
X-1631	BRCA	CLR457	231.4	27	67	6	-9.4
X-1631	BRCA	CLR457	223.6	28.2	70	2.4	-5.4
X-1631	BRCA	CLR457	258.1	28.8	74	18.2	-3.4
X-1631	BRCA	CLR457	201.1	26.4	77	-7.9	-11.4
X-1631	BRCA	CLR457	200.3	27.5	80	-8.2	-7.7
X-1631	BRCA	CLR457	200.8	25.7	84	-8	-13.8
X-1631	BRCA	CLR457	208.1	25.3	87	-4.7	-15.1
X-1631	BRCA	CLR457	213	24.2	91	-2.4	-18.8
X-1631	BRCA	CLR457	233.6	24.9	94	7	-16.4
X-1631	BRCA	CLR457	363.2	25.5	98	66.4	-14.4
X-1631	BRCA	HDM201	262.2	23	0	0	0
X-1631	BRCA	HDM201	319.7	25.4	4	21.9	10.4
X-1631	BRCA	HDM201	349.5	19.9	8	33.3	-13.5
X-1631	BRCA	HDM201	371.5	20.1	11	41.7	-12.6
X-1631	BRCA	HDM201	384.6	19.7	15	46.7	-14.3
X-1631	BRCA	HDM201	392.5	20.9	18	49.7	-9.1
X-1631	BRCA	HDM201	559.4	22.2	25	113.3	-3.5
X-1631	BRCA	HDM201	769.9	21.1	28	193.6	-8.3
X-1631	BRCA	HDM201	812.9	18.5	33	210	-19.6
X-1631	BRCA	LEE011 + everolimus	211.7	26.8	0	0	0
X-1631	BRCA	LEE011 + everolimus	260.2	25.3	6	22.9	-5.6
X-1631	BRCA	LEE011 + everolimus	254.4	24.4	9	20.2	-9
X-1631	BRCA	LEE011 + everolimus	267.3	24	14	26.3	-10.4
X-1631	BRCA	LEE011 + everolimus	242.4	25.1	17	14.5	-6.3
X-1631	BRCA	LEE011	200.3	28.9	0	0	0
X-1631	BRCA	LEE011	315	29.5	3	57.3	2.1
X-1631	BRCA	LEE011	541	29.7	10	170.1	2.8
X-1631	BRCA	LEE011	537.8	28.8	13	168.5	-0.3
X-1631	BRCA	LEE011	572.4	28.1	18	185.8	-2.8
X-1631	BRCA	LEE011	638.6	29.1	21	218.8	0.7
X-1631	BRCA	LEE011	685	28.7	24	242	-0.7
X-1631	BRCA	LFA102	271	24.9	0	0	0
X-1631	BRCA	LFA102	359.4	23.7	3	32.6	-4.8
X-1631	BRCA	LFA102	398.6	23.2	6	47.1	-6.8
X-1631	BRCA	LFA102	790.6	22.2	14	191.7	-10.8
X-1631	BRCA	LFA102	1041.5	22.2	17	284.3	-10.8
X-1631	BRCA	LFA102	1116.9	21.2	20	312.1	-14.9
X-1631	BRCA	LJM716 + trastuzumab	308.9	24.2	0	0	0
X-1631	BRCA	LJM716 + trastuzumab	398.4	22.2	3	29	-8.3
X-1631	BRCA	LJM716 + trastuzumab	532.9	21.3	6	72.5	-12
X-1631	BRCA	LJM716 + trastuzumab	953.9	21.2	14	208.8	-12.4
X-1631	BRCA	LJM716 + trastuzumab	1233.6	18.9	17	299.4	-21.9
X-1631	BRCA	LJM716 + trastuzumab	1535.8	18.4	20	397.2	-24
X-1631	BRCA	LJM716	303.4	24.7	0	0	0
X-1631	BRCA	LJM716	460.5	23.7	4	51.8	-4
X-1631	BRCA	LJM716	843.1	22.3	12	177.9	-9.7
X-1631	BRCA	LJM716	1055.5	23	15	247.9	-6.9
X-1631	BRCA	LJM716	1378.1	22.1	18	354.2	-10.5
X-1631	BRCA	LKA136	252	28.2	0	0	0
X-1631	BRCA	LKA136	288.6	26	3	14.5	-7.8
X-1631	BRCA	LKA136	396.4	27.4	6	57.3	-2.8
X-1631	BRCA	LKA136	677.8	26.5	13	169	-6
X-1631	BRCA	LKA136	939.7	25.7	16	272.9	-8.9
X-1631	BRCA	LKA136	1070.9	24.5	21	325	-13.1
X-1631	BRCA	LLM871	298.2	21	0	0	0
X-1631	BRCA	LLM871	337.8	20.5	3	13.3	-2.4
X-1631	BRCA	LLM871	290.7	21.6	6	-2.5	2.9
X-1631	BRCA	LLM871	170.3	21.9	10	-42.9	4.3
X-1631	BRCA	LLM871	124.4	22.4	13	-58.3	6.7
X-1631	BRCA	LLM871	21.8	23.4	20	-92.7	11.4
X-1631	BRCA	LLM871	13.1	23	23	-95.6	9.5
X-1631	BRCA	LLM871	13.4	23.1	28	-95.5	10
X-1631	BRCA	LLM871	9.8	22.9	31	-96.7	9
X-1631	BRCA	LLM871	9.9	23.9	34	-96.7	13.8
X-1631	BRCA	LLM871	6.6	24	38	-97.8	14.3
X-1631	BRCA	LLM871	3.8	23.9	41	-98.7	13.8
X-1631	BRCA	LLM871	7.6	24.1	45	-97.5	14.8
X-1631	BRCA	LLM871	3.9	24.3	48	-98.7	15.7
X-1631	BRCA	LLM871	5.8	23.9	52	-98.1	13.8
X-1631	BRCA	LLM871	5.8	24.9	55	-98.1	18.6
X-1631	BRCA	LLM871	9.1	23.9	59	-96.9	13.8
X-1631	BRCA	LLM871	5.6	23.5	62	-98.1	11.9
X-1631	BRCA	LLM871	7.3	24.2	66	-97.6	15.2
X-1631	BRCA	LLM871	13.2	24.1	69	-95.6	14.8
X-1631	BRCA	LLM871	14.8	23.7	73	-95	12.9
X-1631	BRCA	LLM871	18.9	24.6	76	-93.7	17.1
X-1631	BRCA	LLM871	18.7	24	79	-93.7	14.3
X-1631	BRCA	LLM871	26.8	24.2	83	-91	15.2
X-1631	BRCA	LLM871	55	24.5	87	-81.6	16.7
X-1631	BRCA	LLM871	67	24.3	90	-77.5	15.7
X-1631	BRCA	LLM871	107.9	24.4	94	-63.8	16.2
X-1631	BRCA	LLM871	161.3	24.7	104	-45.9	17.6
X-1631	BRCA	LLM871	169.9	24.6	108	-43	17.1
X-1631	BRCA	LLM871	189.9	24.2	111	-36.3	15.2
X-1631	BRCA	LLM871	312.7	24	115	4.9	14.3
X-1631	BRCA	LLM871	367.4	24.8	118	23.2	18.1
X-1631	BRCA	LLM871	406.3	24.2	122	36.3	15.2
X-1631	BRCA	LLM871	404.3	21.7	125	35.6	3.3
X-1631	BRCA	LLM871	448.6	26	128	50.4	23.8
X-1631	BRCA	LLM871	458.5	25.7	132	53.8	22.4
X-1631	BRCA	LLM871	547.2	24.9	135	83.5	18.6
X-1631	BRCA	LLM871	623	24.9	139	108.9	18.6
X-1631	BRCA	LLM871	666.6	24.6	142	123.5	17.1
X-1631	BRCA	LLM871	534.7	24.4	146	79.3	16.2
X-1631	BRCA	LLM871	569.4	24.5	150	90.9	16.7
X-1631	BRCA	LLM871	594.1	26	153	99.2	23.8
X-1631	BRCA	LLM871	618.5	25.5	157	107.4	21.4
X-1631	BRCA	LLM871	627.2	24.4	160	110.3	16.2
X-1631	BRCA	LLM871	631.4	24.8	164	111.7	18.1
X-1631	BRCA	LLM871	649.5	25.4	167	117.8	21
X-1631	BRCA	LLM871	627.9	25.7	171	110.6	22.4
X-1631	BRCA	LLM871	650.6	25	174	118.2	19
X-1631	BRCA	LLM871	740.5	25.5	178	148.3	21.4
X-1631	BRCA	LLM871	794.6	26.2	181	166.5	24.8
X-1631	BRCA	binimetinib	215	26.3	0	0	0
X-1631	BRCA	binimetinib	266.1	25.7	3	23.8	-2.3
X-1631	BRCA	binimetinib	286.9	24.1	7	33.4	-8.4
X-1631	BRCA	binimetinib	305.3	24.1	10	42	-8.4
X-1631	BRCA	binimetinib	402.6	23.3	17	87.3	-11.4
X-1631	BRCA	binimetinib	428.9	21.6	20	99.5	-17.9
X-1631	BRCA	binimetinib	524.5	24	25	144	-8.7
X-1631	BRCA	binimetinib	549	27.9	28	155.3	6.1
X-1631	BRCA	binimetinib	616.8	27.3	31	186.9	3.8
X-1631	BRCA	binimetinib	697.3	25	35	224.3	-4.9
X-1631	BRCA	binimetinib	757.6	24.6	38	252.4	-6.5
X-1631	BRCA	binimetinib	751.9	23	42	249.7	-12.5
X-1631	BRCA	binimetinib	950.3	23.7	45	342	-9.9
X-1631	BRCA	paclitaxel	324.6	24.9	0	0	0
X-1631	BRCA	paclitaxel	384	23.7	3	18.3	-4.8
X-1631	BRCA	paclitaxel	378.6	24.1	6	16.6	-3.2
X-1631	BRCA	paclitaxel	248.1	24.8	14	-23.6	-0.4
X-1631	BRCA	paclitaxel	196.6	24.6	17	-39.4	-1.2
X-1631	BRCA	paclitaxel	157.3	26.2	20	-51.5	5.2
X-1631	BRCA	paclitaxel	124.6	25.5	24	-61.6	2.4
X-1631	BRCA	paclitaxel	130.5	26.9	27	-59.8	8
X-1631	BRCA	paclitaxel	122.4	23.2	31	-62.3	-6.8
X-1631	BRCA	paclitaxel	161.8	25.5	34	-50.2	2.4
X-1631	BRCA	paclitaxel	194	25.4	38	-40.2	2
X-1631	BRCA	paclitaxel	246	26.2	41	-24.2	5.2
X-1631	BRCA	paclitaxel	346.1	25.7	45	6.6	3.2
X-1631	BRCA	paclitaxel	446.1	26.2	48	37.4	5.2
X-1631	BRCA	paclitaxel	930.4	24.9	55	186.6	0
X-1631	BRCA	tamoxifen	316	22.7	0	0	0
X-1631	BRCA	tamoxifen	404	23.2	3	27.8	2.2
X-1631	BRCA	tamoxifen	505.5	21.1	6	60	-7
X-1631	BRCA	tamoxifen	682.4	19.2	10	115.9	-15.4
X-1631	BRCA	tamoxifen	798.4	18.9	13	152.7	-16.7
X-1631	BRCA	trastuzumab	217.1	26.8	0	0	0
X-1631	BRCA	trastuzumab	319.7	26.2	3	47.3	-2.2
X-1631	BRCA	trastuzumab	430.4	24.8	6	98.2	-7.5
X-1631	BRCA	trastuzumab	665.9	24.8	14	206.7	-7.5
X-1631	BRCA	trastuzumab	761.3	24.5	17	250.7	-8.6
X-1631	BRCA	trastuzumab	1011	27.4	20	365.7	2.2
X-1631	BRCA	untreated	236.5	27.6	0	0	0
X-1631	BRCA	untreated	419.1	27	8	77.2	-2.2
X-1631	BRCA	untreated	478	25.5	11	102.1	-7.6
X-1631	BRCA	untreated	655.9	25.1	14	177.3	-9.1
X-1631	BRCA	untreated	943.7	24.1	18	299	-12.7
X-1631	BRCA	untreated	1188.7	24.2	21	402.6	-12.3
X-1655	CM	BKM120	203.7	26.6	0	0	0
X-1655	CM	BKM120	286.7	26.5	3	40.7	-0.4
X-1655	CM	BKM120	416.8	27.2	8	104.6	2.3
X-1655	CM	BKM120	289.9	28.1	11	42.3	5.6
X-1655	CM	BKM120	320	28.8	16	57.1	8.3
X-1655	CM	BKM120	311.7	29.7	19	53	11.7
X-1655	CM	BKM120	391.1	28.9	23	92	8.6
X-1655	CM	BKM120	489.3	29.5	26	140.2	10.9
X-1655	CM	BKM120	461.7	30.1	30	126.6	13.2
X-1655	CM	BKM120	558.4	29	32	174.1	9
X-1655	CM	BKM120 + encorafenib	204.8	23.6	0	0	0
X-1655	CM	BKM120 + encorafenib	217.6	23.5	3	6.2	-0.4
X-1655	CM	BKM120 + encorafenib	374.1	23.2	8	82.6	-1.7
X-1655	CM	BKM120 + encorafenib	405	23.6	11	97.8	0
X-1655	CM	BKM120 + encorafenib	525.1	24	15	156.4	1.7
X-1655	CM	BKM120 + encorafenib	554.5	24.5	18	170.7	3.8
X-1655	CM	BKM120 + encorafenib	1040.4	24.9	22	408	5.5
X-1655	CM	BKM120 + encorafenib	992.1	25.3	28	384.4	7.2
X-1655	CM	BKM120 + encorafenib	1259.1	25.3	30	514.8	7.2
X-1655	CM	CGM097	192.1	19.8	0	0	0
X-1655	CM	CGM097	341.3	19.9	2	77.7	0.5
X-1655	CM	CGM097	554.1	21.6	6	188.5	9.1
X-1655	CM	CGM097	640	21.1	9	233.2	6.6
X-1655	CM	CGM097	813.6	22.1	14	323.6	11.6
X-1655	CM	CGM097	775	22.4	17	303.5	13.1
X-1655	CM	CGM097	878.9	22.1	22	357.6	11.6
X-1655	CM	CGM097	1229.2	23.4	25	539.9	18.2
X-1655	CM	CGM097	1720.6	23.3	29	795.8	17.7
X-1655	CM	CGM097	1720.6	23.3	30	795.8	17.7
X-1655	CM	CLR457	222.2	26	0	0	0
X-1655	CM	CLR457	215.5	26.5	3	-3	1.9
X-1655	CM	CLR457	178.6	26.8	7	-19.6	3.1
X-1655	CM	CLR457	226.7	26.7	10	2	2.7
X-1655	CM	CLR457	257.3	26.2	14	15.8	0.8
X-1655	CM	CLR457	369.8	25.9	20	66.4	-0.4
X-1655	CM	CLR457	381	26.5	23	71.5	1.9
X-1655	CM	CLR457	384	26.1	27	72.8	0.4
X-1655	CM	CLR457	468.5	26.6	31	110.8	2.3
X-1655	CM	CLR457	495.5	26.6	34	123	2.3
X-1655	CM	dacarbazine	191.1	23.2	0	0	0
X-1655	CM	dacarbazine	353	21.4	3	84.7	-7.8
X-1655	CM	dacarbazine	240.9	23.7	7	26.1	2.2
X-1655	CM	dacarbazine	242.5	23	10	26.9	-0.9
X-1655	CM	dacarbazine	284.8	23.5	14	49	1.3
X-1655	CM	dacarbazine	702.3	23.9	20	267.5	3
X-1655	CM	dacarbazine	601.1	23	23	214.6	-0.9
X-1655	CM	dacarbazine	787.2	23.1	27	311.9	-0.4
X-1655	CM	LDE225	204.2	22.4	0	0	0
X-1655	CM	LDE225	299.2	22.2	5	46.6	-0.9
X-1655	CM	LDE225	321.4	22.3	8	57.4	-0.4
X-1655	CM	LDE225	585.2	22.1	13	186.6	-1.3
X-1655	CM	LDE225	577.6	22.3	16	182.9	-0.4
X-1655	CM	LDE225	775.3	23.3	20	279.7	4
X-1655	CM	LDE225	819.8	23	23	301.5	2.7
X-1655	CM	LDE225	1065.7	23.1	27	422	3.1
X-1655	CM	LDE225	1148.7	23.5	29	462.6	4.9
X-1655	CM	LDK378	239.6	23.4	0	0	0
X-1655	CM	LDK378	387.2	23	3	61.6	-1.7
X-1655	CM	LDK378	464	23	8	93.7	-1.7
X-1655	CM	LDK378	521.4	23.7	11	117.6	1.3
X-1655	CM	LDK378	662.7	23	15	176.6	-1.7
X-1655	CM	LDK378	691.2	23.5	18	188.5	0.4
X-1655	CM	LDK378	863.5	23.6	22	260.4	0.9
X-1655	CM	LDK378	1116.4	24	24	366	2.6
X-1655	CM	LDK378	1190.2	24.3	28	396.8	3.8
X-1655	CM	LDK378	1057.4	24.3	30	341.4	3.8
X-1655	CM	LEE011	200.9	25.2	0	0	0
X-1655	CM	LEE011	226.8	24.4	3	12.9	-3.2
X-1655	CM	LEE011	228.2	23.6	8	13.6	-6.3
X-1655	CM	LEE011	213	24.4	11	6	-3.2
X-1655	CM	LEE011	264.1	24.6	16	31.4	-2.4
X-1655	CM	LEE011	276.1	24.8	19	37.4	-1.6
X-1655	CM	LEE011	277.4	25.1	23	38.1	-0.4
X-1655	CM	LEE011	381.2	25.6	26	89.7	1.6
X-1655	CM	LEE011	376.9	25	30	87.6	-0.8
X-1655	CM	LEE011	397.2	25.1	32	97.7	-0.4
X-1655	CM	LEE011 + encorafenib	204.1	26	0	0	0
X-1655	CM	LEE011 + encorafenib	299.5	25.7	3	46.7	-1.2
X-1655	CM	LEE011 + encorafenib	456.3	24.8	8	123.6	-4.6
X-1655	CM	LEE011 + encorafenib	503.1	25	11	146.5	-3.8
X-1655	CM	LEE011 + encorafenib	483.5	24.6	15	136.9	-5.4
X-1655	CM	LEE011 + encorafenib	507.1	25.1	18	148.4	-3.5
X-1655	CM	LEE011 + encorafenib	662.6	25.9	22	224.7	-0.4
X-1655	CM	LEE011 + encorafenib	687.5	26	28	236.9	0
X-1655	CM	LEE011 + encorafenib	632.5	26	30	209.9	0
X-1655	CM	LEE011 + binimetinib	200.9	24.1	0	0	0
X-1655	CM	LEE011 + binimetinib	203.6	24.8	3	1.3	2.9
X-1655	CM	LEE011 + binimetinib	220.3	24.5	7	9.6	1.7
X-1655	CM	LEE011 + binimetinib	212.3	25.6	10	5.7	6.2
X-1655	CM	LEE011 + binimetinib	207	25.3	14	3	5
X-1655	CM	LEE011 + binimetinib	158.4	25.5	20	-21.2	5.8
X-1655	CM	LEE011 + binimetinib	164.8	26.1	23	-18	8.3
X-1655	CM	LEE011 + binimetinib	189.8	25.2	27	-5.6	4.6
X-1655	CM	LEE011 + binimetinib	180	26.5	31	-10.4	10
X-1655	CM	LEE011 + binimetinib	190.5	26.6	36	-5.2	10.4
X-1655	CM	LEE011 + binimetinib	159.8	27	41	-20.5	12
X-1655	CM	LEE011 + binimetinib	162	25.8	44	-19.4	7.1
X-1655	CM	LEE011 + binimetinib	123.6	26.6	48	-38.5	10.4
X-1655	CM	LEE011 + binimetinib	106.6	26.4	51	-46.9	9.5
X-1655	CM	LEE011 + binimetinib	134.6	27.3	57	-33	13.3
X-1655	CM	LEE011 + binimetinib	118	27.2	62	-41.3	12.9
X-1655	CM	LEE011 + binimetinib	105.5	25.9	65	-47.5	7.5
X-1655	CM	LEE011 + binimetinib	119.4	27.5	77	-40.6	14.1
X-1655	CM	LEE011 + binimetinib	137.6	26.9	84	-31.5	11.6
X-1655	CM	LEE011 + binimetinib	186.5	26.6	91	-7.2	10.4
X-1655	CM	LEE011 + binimetinib	231.2	27.6	101	15.1	14.5
X-1655	CM	LEE011 + binimetinib	297.4	28.5	109	48	18.3
X-1655	CM	LEE011 + binimetinib	178.6	26.6	115	-11.1	10.4
X-1655	CM	WNT974	207.9	24.2	0	0	0
X-1655	CM	WNT974	335.4	23.8	3	61.3	-1.7
X-1655	CM	WNT974	673.7	23.8	8	224	-1.7
X-1655	CM	WNT974	685	24.4	11	229.4	0.8
X-1655	CM	WNT974	1092.7	24.6	15	425.5	1.7
X-1655	CM	WNT974	1610.5	25.9	18	674.5	7
X-1655	CM	LGW813	198.5	23.1	0	0	0
X-1655	CM	LGW813	228.7	23.4	5	15.3	1.3
X-1655	CM	LGW813	257	23.3	8	29.5	0.9
X-1655	CM	LGW813	367.7	23.8	13	85.3	3
X-1655	CM	LGW813	437.1	23.9	16	120.2	3.5
X-1655	CM	LGW813	777.3	24.6	20	291.7	6.5
X-1655	CM	LGW813	1127.4	24.6	23	468.1	6.5
X-1655	CM	LGW813	1328.1	25.6	27	569.2	10.8
X-1655	CM	LGW813	1576.9	25.4	29	694.6	10
X-1655	CM	encorafenib	191.1	23	0	0	0
X-1655	CM	encorafenib	221.8	22.6	2	16.1	-1.7
X-1655	CM	encorafenib	284.6	24.3	6	48.9	5.7
X-1655	CM	encorafenib	366.9	23.6	9	92	2.6
X-1655	CM	encorafenib	557.9	23.6	14	191.9	2.6
X-1655	CM	encorafenib	639	23.9	17	234.4	3.9
X-1655	CM	encorafenib	884.3	23.6	22	362.8	2.6
X-1655	CM	encorafenib	1032.3	24.3	25	440.2	5.7
X-1655	CM	encorafenib	1211.5	24.5	29	534	6.5
X-1655	CM	encorafenib	1643.2	26	32	759.9	13
X-1655	CM	encorafenib + binimetinib	202.3	24.2	0	0	0
X-1655	CM	encorafenib + binimetinib	336	21	5	66.1	-13.2
X-1655	CM	encorafenib + binimetinib	353	21.4	8	74.5	-11.6
X-1655	CM	encorafenib + binimetinib	530	22	12	161.9	-9.1
X-1655	CM	encorafenib + binimetinib	487.1	22.1	15	140.8	-8.7
X-1655	CM	encorafenib + binimetinib	682.2	22.1	19	237.1	-8.7
X-1655	CM	encorafenib + binimetinib	760	22.5	25	275.6	-7
X-1655	CM	encorafenib + binimetinib	841.6	22.3	28	315.9	-7.9
X-1655	CM	encorafenib + binimetinib	795.9	22.3	32	293.4	-7.9
X-1655	CM	binimetinib	190.6	22.2	0	0	0
X-1655	CM	binimetinib	136.9	22.8	3	-28.2	2.7
X-1655	CM	binimetinib	215.3	23	8	12.9	3.6
X-1655	CM	binimetinib	177.7	23.2	11	-6.8	4.5
X-1655	CM	binimetinib	313.3	23	16	64.4	3.6
X-1655	CM	binimetinib	433.3	23.1	19	127.3	4.1
X-1655	CM	binimetinib	705.6	23.8	23	270.2	7.2
X-1655	CM	binimetinib	764.7	23.8	26	301.2	7.2
X-1655	CM	binimetinib	843.9	24	30	342.8	8.1
X-1655	CM	binimetinib	811.4	23.5	32	325.8	5.9
X-1655	CM	TAS266	189.7	22.8	0	0	0
X-1655	CM	TAS266	210.6	22.9	2	11	0.4
X-1655	CM	TAS266	289.4	23.9	6	52.6	4.8
X-1655	CM	TAS266	355.4	24.4	9	87.3	7
X-1655	CM	TAS266	575.2	24.4	14	203.2	7
X-1655	CM	TAS266	706.7	25	17	272.5	9.6
X-1655	CM	TAS266	1073.1	24.9	22	465.7	9.2
X-1655	CM	TAS266	1172.9	25.5	25	518.3	11.8
X-1655	CM	TAS266	1818.6	26.3	29	858.6	15.4
X-1655	CM	TAS266	1818.6	26.3	30	858.6	15.4
X-1655	CM	untreated	198.2	21.6	0	0	0
X-1655	CM	untreated	248.3	22.3	3	25.3	3.2
X-1655	CM	untreated	314.4	23	5	58.6	6.5
X-1655	CM	untreated	386.1	24.2	9	94.8	12
X-1655	CM	untreated	400.2	23.5	12	101.9	8.8
X-1655	CM	untreated	474.3	23.4	17	139.3	8.3
X-1655	CM	untreated	483.7	23.5	20	144	8.8
X-1655	CM	untreated	524.5	23.2	25	164.6	7.4
X-1655	CM	untreated	704.9	24.7	28	255.6	14.4
X-1655	CM	untreated	815	24.5	32	311.2	13.4
X-1655	CM	untreated	815	24.5	33	311.2	13.4
X-1658	NSCLC	BGJ398	306.5	21.5	0	0	0
X-1658	NSCLC	BGJ398	398	22.6	3	29.9	5.1
X-1658	NSCLC	BGJ398	603.6	22.9	7	96.9	6.5
X-1658	NSCLC	BGJ398	845.2	23.6	10	175.8	9.8
X-1658	NSCLC	BGJ398	1055.5	22.8	13	244.4	6
X-1658	NSCLC	BKM120	139.2	20.2	0	0	0
X-1658	NSCLC	BKM120	132.2	21.7	3	-5	7.4
X-1658	NSCLC	BKM120	126.3	22	7	-9.3	8.9
X-1658	NSCLC	BKM120	118.7	22.5	10	-14.7	11.4
X-1658	NSCLC	BKM120	91.1	22.8	13	-34.6	12.9
X-1658	NSCLC	BKM120	129.1	22.9	17	-7.3	13.4
X-1658	NSCLC	BKM120	245.6	23.9	21	76.4	18.3
X-1658	NSCLC	BKM120	437.9	23.5	24	214.6	16.3
X-1658	NSCLC	BKM120	522	23.5	28	275	16.3
X-1658	NSCLC	BKM120	537.7	23.8	31	286.3	17.8
X-1658	NSCLC	BKM120	698.8	23.9	35	402	18.3
X-1658	NSCLC	BKM120	715.9	24.5	38	414.3	21.3
X-1658	NSCLC	BKM120	918.9	24.7	42	560.1	22.3
X-1658	NSCLC	BKM120 + binimetinib	305.7	22	0	0	0
X-1658	NSCLC	BKM120 + binimetinib	239.6	21.6	3	-21.6	-1.8
X-1658	NSCLC	BKM120 + binimetinib	237.9	22.1	7	-22.2	0.5
X-1658	NSCLC	BKM120 + binimetinib	237.4	21.7	10	-22.3	-1.4
X-1658	NSCLC	BKM120 + binimetinib	261.3	21.9	13	-14.5	-0.5
X-1658	NSCLC	BKM120 + binimetinib	319.3	22.3	17	4.4	1.4
X-1658	NSCLC	BKM120 + binimetinib	310.3	20.3	21	1.5	-7.7
X-1658	NSCLC	BKM120 + binimetinib	345.6	22	24	13.1	0
X-1658	NSCLC	BKM120 + binimetinib	414.3	22.9	28	35.5	4.1
X-1658	NSCLC	BKM120 + binimetinib	537.7	22.9	31	75.9	4.1
X-1658	NSCLC	BKM120 + binimetinib	542	22.7	35	77.3	3.2
X-1658	NSCLC	BKM120 + binimetinib	563	23.8	38	84.2	8.2
X-1658	NSCLC	BKM120 + binimetinib	530.4	24.1	42	73.5	9.5
X-1658	NSCLC	BKM120 + binimetinib	538.8	24.3	45	76.3	10.5
X-1658	NSCLC	BKM120 + binimetinib	626.9	23.7	49	105.1	7.7
X-1658	NSCLC	BKM120 + binimetinib	641	23.8	52	109.7	8.2
X-1658	NSCLC	BKM120 + binimetinib	770.3	24	55	152	9.1
X-1658	NSCLC	BYL719 + LJM716	106	20.7	0	0	0
X-1658	NSCLC	BYL719 + LJM716	92.9	21.6	3	-12.4	4.3
X-1658	NSCLC	BYL719 + LJM716	114.3	22.2	7	7.8	7.2
X-1658	NSCLC	BYL719 + LJM716	120.1	22.8	10	13.3	10.1
X-1658	NSCLC	BYL719 + LJM716	92.4	21.6	13	-12.8	4.3
X-1658	NSCLC	BYL719 + LJM716	81.8	21.3	17	-22.8	2.9
X-1658	NSCLC	BYL719 + LJM716	68	22.4	21	-35.8	8.2
X-1658	NSCLC	BYL719 + LJM716	58.5	22.5	24	-44.8	8.7
X-1658	NSCLC	BYL719 + LJM716	23.7	21.5	28	-77.6	3.9
X-1658	NSCLC	BYL719 + LJM716	18.1	19.5	31	-82.9	-5.8
X-1658	NSCLC	BYL719 + LJM716	21.9	17.4	35	-79.3	-15.9
X-1658	NSCLC	BYL719 + LJM716	6.5	18.4	38	-93.9	-11.1
X-1658	NSCLC	BYL719 + LJM716	6	18	42	-94.3	-13
X-1658	NSCLC	BYL719	162.7	21.8	0	0	0
X-1658	NSCLC	BYL719	167.8	21.2	3	3.1	-2.8
X-1658	NSCLC	BYL719	212.1	21.7	7	30.4	-0.5
X-1658	NSCLC	BYL719	240	22.2	10	47.5	1.8
X-1658	NSCLC	BYL719	213.7	22	13	31.3	0.9
X-1658	NSCLC	BYL719	220.6	22.1	17	35.6	1.4
X-1658	NSCLC	BYL719	221.7	22.7	21	36.3	4.1
X-1658	NSCLC	BYL719	245.1	22.6	24	50.6	3.7
X-1658	NSCLC	BYL719	235	23.1	28	44.4	6
X-1658	NSCLC	BYL719	193.1	22.6	31	18.7	3.7
X-1658	NSCLC	BYL719	226.4	22.7	35	39.2	4.1
X-1658	NSCLC	BYL719	232.6	23.5	38	43	7.8
X-1658	NSCLC	BYL719	270.4	23	42	66.2	5.5
X-1658	NSCLC	BYL719	290	22.7	45	78.2	4.1
X-1658	NSCLC	BYL719	334.8	22.6	49	105.8	3.7
X-1658	NSCLC	BYL719	349.4	22.6	50	114.8	3.7
X-1658	NSCLC	BYL719 + LGH447	199.5	21.5	0	0	0
X-1658	NSCLC	BYL719 + LGH447	137.9	20.9	3	-30.9	-2.8
X-1658	NSCLC	BYL719 + LGH447	176.3	21.1	7	-11.6	-1.9
X-1658	NSCLC	BYL719 + LGH447	184.8	21.5	11	-7.4	0
X-1658	NSCLC	BYL719 + LGH447	218.1	21.2	14	9.3	-1.4
X-1658	NSCLC	BYL719 + LGH447	207.5	21.6	18	4	0.5
X-1658	NSCLC	BYL719 + LGH447	196.3	21.3	21	-1.6	-0.9
X-1658	NSCLC	BYL719 + LGH447	234	20.6	25	17.3	-4.2
X-1658	NSCLC	BYL719 + LGH447	260.3	22	28	30.5	2.3
X-1658	NSCLC	BYL719 + LGH447	297.7	21.1	32	49.2	-1.9
X-1658	NSCLC	BYL719 + LGH447	292.8	21.8	35	46.8	1.4
X-1658	NSCLC	BYL719 + LGH447	276.2	21.2	39	38.4	-1.4
X-1658	NSCLC	BYL719 + LGH447	283.6	21.2	42	42.2	-1.4
X-1658	NSCLC	BYL719 + LGH447	332	21.9	45	66.4	1.9
X-1658	NSCLC	BYL719 + LGH447	273.4	20.6	48	37	-4.2
X-1658	NSCLC	BYL719 + LGH447	305.6	21.5	53	53.2	0
X-1658	NSCLC	BYL719 + LGH447	303.8	20.7	56	52.3	-3.7
X-1658	NSCLC	BYL719 + LGH447	345.4	20.5	60	73.1	-4.7
X-1658	NSCLC	BYL719 + LGH447	327.4	20.4	63	64.1	-5.1
X-1658	NSCLC	BYL719 + LGH447	390.1	20.7	67	95.5	-3.7
X-1658	NSCLC	BYL719 + LGH447	481.1	21.1	70	141.2	-1.9
X-1658	NSCLC	BYL719 + LGH447	423.6	20.5	74	112.3	-4.7
X-1658	NSCLC	BYL719 + LGH447	371.6	20.9	76	86.3	-2.8
X-1658	NSCLC	BYL719 + LGH447	416.2	21.4	80	108.6	-0.5
X-1658	NSCLC	BYL719 + LGH447	369	21.8	83	85	1.4
X-1658	NSCLC	BYL719 + LGH447	487.9	21.5	84	144.6	0
X-1658	NSCLC	BYL719 + LGH447	353	21.2	87	76.9	-1.4
X-1658	NSCLC	BYL719 + LGH447	401.6	20.8	90	101.3	-3.3
X-1658	NSCLC	BYL719 + LGH447	464.5	21.5	95	132.8	0
X-1658	NSCLC	BYL719 + LGH447	599.4	20.7	98	200.5	-3.7
X-1658	NSCLC	BYL719 + LGH447	620.9	20.7	102	211.2	-3.7
X-1658	NSCLC	CGM097	252.3	22.8	0	0	0
X-1658	NSCLC	CGM097	204.6	22.8	2	-18.9	0
X-1658	NSCLC	CGM097	316	22.6	6	25.2	-0.9
X-1658	NSCLC	CGM097	499	23.3	9	97.8	2.2
X-1658	NSCLC	CGM097	562.3	24.1	13	122.9	5.7
X-1658	NSCLC	CGM097	690.3	24.2	16	173.6	6.1
X-1658	NSCLC	CGM097	1140.1	22.7	20	351.9	-0.4
X-1658	NSCLC	CKX620	245.5	22.8	0	0	0
X-1658	NSCLC	CKX620	624.3	21.8	3	154.3	-4.4
X-1658	NSCLC	CKX620	1012.7	22.6	7	312.5	-0.9
X-1658	NSCLC	CKX620	1145.8	24.5	10	366.7	7.5
X-1658	NSCLC	CKX620	1288.9	24.8	13	425	8.8
X-1658	NSCLC	CLR457	309.3	21.4	0	0	0
X-1658	NSCLC	CLR457	354.4	22.6	4	14.6	5.6
X-1658	NSCLC	CLR457	212.6	22.1	7	-31.3	3.3
X-1658	NSCLC	CLR457	241.9	22.6	10	-21.8	5.6
X-1658	NSCLC	CLR457	273.8	22.4	14	-11.5	4.7
X-1658	NSCLC	CLR457	326.7	23.9	18	5.6	11.7
X-1658	NSCLC	CLR457	396.2	24	21	28.1	12.1
X-1658	NSCLC	CLR457	335.6	24.1	25	8.5	12.6
X-1658	NSCLC	CLR457	335.8	24.2	28	8.6	13.1
X-1658	NSCLC	CLR457	284.5	23.8	32	-8	11.2
X-1658	NSCLC	CLR457	333	24.3	35	7.7	13.6
X-1658	NSCLC	CLR457	342.1	24.5	39	10.6	14.5
X-1658	NSCLC	CLR457	421.9	25	42	36.4	16.8
X-1658	NSCLC	CLR457	425.4	25.2	46	37.5	17.8
X-1658	NSCLC	CLR457	532.3	24.4	49	72.1	14
X-1658	NSCLC	CLR457	523.6	24.2	52	69.3	13.1
X-1658	NSCLC	CLR457	555.3	23.7	55	79.5	10.7
X-1658	NSCLC	CLR457	816.3	24.3	60	163.9	13.6
X-1658	NSCLC	HDM201	170.3	18.9	0	0	0
X-1658	NSCLC	HDM201	180.8	20.7	4	6.2	9.5
X-1658	NSCLC	HDM201	180.9	19.6	7	6.2	3.7
X-1658	NSCLC	HDM201	201.7	21.1	11	18.4	11.6
X-1658	NSCLC	HDM201	209.8	22.5	14	23.2	19
X-1658	NSCLC	HDM201	188.3	22.6	17	10.6	19.6
X-1658	NSCLC	HDM201	180.1	22.4	21	5.8	18.5
X-1658	NSCLC	HDM201	163.5	21.1	25	-4	11.6
X-1658	NSCLC	HDM201	163.4	21	28	-4.1	11.1
X-1658	NSCLC	HDM201	167	21.6	32	-1.9	14.3
X-1658	NSCLC	HDM201	132.2	21.3	35	-22.4	12.7
X-1658	NSCLC	HDM201	129.6	21	39	-23.9	11.1
X-1658	NSCLC	HDM201	148.5	21.4	42	-12.8	13.2
X-1658	NSCLC	HDM201	201.9	21.1	46	18.6	11.6
X-1658	NSCLC	HDM201	238.4	19.6	49	40	3.7
X-1658	NSCLC	HDM201	247.7	19.3	53	45.4	2.1
X-1658	NSCLC	HDM201	240.8	18.4	56	41.4	-2.6
X-1658	NSCLC	HDM201	193.4	18.6	59	13.6	-1.6
X-1658	NSCLC	HDM201	184.1	18.4	62	8.1	-2.6
X-1658	NSCLC	HDM201	210.5	18.8	67	23.6	-0.5
X-1658	NSCLC	HDM201	231.7	20.8	70	36.1	10.1
X-1658	NSCLC	HDM201	321	22.6	74	88.5	19.6
X-1658	NSCLC	HDM201	356.8	23.9	77	109.5	26.5
X-1658	NSCLC	HDM201	617.1	24.7	81	262.4	30.7
X-1658	NSCLC	HDM201	603.6	24	82	254.4	27
X-1658	NSCLC	cetuximab	188.5	23.8	0	0	0
X-1658	NSCLC	cetuximab	194.7	25.1	3	3.3	5.5
X-1658	NSCLC	cetuximab	232	24.2	7	23.1	1.7
X-1658	NSCLC	cetuximab	333.8	24.3	10	77.1	2.1
X-1658	NSCLC	cetuximab	441	24.8	13	134	4.2
X-1658	NSCLC	cetuximab	578.5	25.8	17	206.9	8.4
X-1658	NSCLC	cetuximab	808	26.8	21	328.6	12.6
X-1658	NSCLC	erlotinib	247.1	22.4	0	0	0
X-1658	NSCLC	erlotinib	110.1	21	4	-55.4	-6.2
X-1658	NSCLC	erlotinib	69.3	19	7	-72	-15.2
X-1658	NSCLC	erlotinib	65.9	18.6	11	-73.3	-17
X-1658	NSCLC	erlotinib	48.7	21.9	14	-80.3	-2.2
X-1658	NSCLC	erlotinib	58.3	23.6	17	-76.4	5.4
X-1658	NSCLC	erlotinib	75.8	24.4	21	-69.3	8.9
X-1658	NSCLC	erlotinib	59.9	24.2	25	-75.8	8
X-1658	NSCLC	erlotinib	72	24.2	28	-70.9	8
X-1658	NSCLC	erlotinib	71.5	23.9	32	-71.1	6.7
X-1658	NSCLC	erlotinib	78.9	24.1	35	-68.1	7.6
X-1658	NSCLC	erlotinib	81.2	23.6	39	-67.1	5.4
X-1658	NSCLC	erlotinib	83	25	42	-66.4	11.6
X-1658	NSCLC	erlotinib	110.1	25.9	46	-55.4	15.6
X-1658	NSCLC	erlotinib	93.7	26	49	-62.1	16.1
X-1658	NSCLC	erlotinib	101.5	22.8	53	-58.9	1.8
X-1658	NSCLC	erlotinib	88	24.1	56	-64.4	7.6
X-1658	NSCLC	erlotinib	90.2	23.2	59	-63.5	3.6
X-1658	NSCLC	erlotinib	115.7	25.1	62	-53.2	12.1
X-1658	NSCLC	erlotinib	107.4	23.8	67	-56.5	6.2
X-1658	NSCLC	erlotinib	117	22.8	70	-52.7	1.8
X-1658	NSCLC	erlotinib	121.4	23.2	74	-50.9	3.6
X-1658	NSCLC	erlotinib	122.6	23.5	77	-50.4	4.9
X-1658	NSCLC	erlotinib	96.3	25.1	81	-61	12.1
X-1658	NSCLC	erlotinib	85.3	24.1	84	-65.5	7.6
X-1658	NSCLC	erlotinib	86.6	25.1	88	-65	12.1
X-1658	NSCLC	HSP990	213.6	22.2	0	0	0
X-1658	NSCLC	HSP990	199.5	22.3	4	-6.6	0.5
X-1658	NSCLC	HSP990	231	22.7	7	8.1	2.3
X-1658	NSCLC	HSP990	141.6	23.4	10	-33.7	5.4
X-1658	NSCLC	HSP990	263.7	23.2	14	23.5	4.5
X-1658	NSCLC	HSP990	272.2	24.5	18	27.4	10.4
X-1658	NSCLC	HSP990	454.9	24.3	21	113	9.5
X-1658	NSCLC	HSP990	356	23.9	25	66.7	7.7
X-1658	NSCLC	HSP990	343.3	24.4	28	60.7	9.9
X-1658	NSCLC	HSP990	490.8	23.5	32	129.8	5.9
X-1658	NSCLC	HSP990	470.3	25.3	35	120.2	14
X-1658	NSCLC	HSP990	364	22.7	39	70.4	2.3
X-1658	NSCLC	HSP990	377.7	25.2	42	76.8	13.5
X-1658	NSCLC	HSP990	413.6	23.9	46	93.6	7.7
X-1658	NSCLC	HSP990	452.2	24.5	47	111.7	10.4
X-1658	NSCLC	INC280	243.5	21.1	0	0	0
X-1658	NSCLC	INC280	261.2	21.7	3	7.3	2.8
X-1658	NSCLC	INC280	314.2	22.1	7	29	4.7
X-1658	NSCLC	INC280	415	20.8	10	70.4	-1.4
X-1658	NSCLC	INC280	448.6	22.2	13	84.2	5.2
X-1658	NSCLC	INC280	672.9	21.6	17	176.3	2.4
X-1658	NSCLC	INC280	771.3	23.2	21	216.8	10
X-1658	NSCLC	INC280	864.9	23.2	24	255.2	10
X-1658	NSCLC	INC280	1212.1	22.9	28	397.8	8.5
X-1658	NSCLC	LCL161 + paclitaxel	130.7	23.8	0	0	0
X-1658	NSCLC	LCL161 + paclitaxel	120.8	24.2	3	-7.6	1.7
X-1658	NSCLC	LCL161 + paclitaxel	119.4	24.4	7	-8.6	2.5
X-1658	NSCLC	LCL161 + paclitaxel	0	26.4	39	-100	10.9
X-1658	NSCLC	LCL161 + paclitaxel	0	26.8	42	-100	12.6
X-1658	NSCLC	LCL161 + paclitaxel	0	26.2	45	-100	10.1
X-1658	NSCLC	LCL161 + paclitaxel	0	26.4	48	-100	10.9
X-1658	NSCLC	LCL161 + paclitaxel	0	27.5	53	-100	15.5
X-1658	NSCLC	LCL161 + paclitaxel	0	28	56	-100	17.6
X-1658	NSCLC	LCL161 + paclitaxel	0	25	60	-100	5
X-1658	NSCLC	LCL161 + paclitaxel	0	27.2	63	-100	14.3
X-1658	NSCLC	LCL161 + paclitaxel	0	27.9	67	-100	17.2
X-1658	NSCLC	LCL161 + paclitaxel	0	27.9	70	-100	17.2
X-1658	NSCLC	LCL161 + paclitaxel	0	27.8	74	-100	16.8
X-1658	NSCLC	LCL161 + paclitaxel	0	27.1	76	-100	13.9
X-1658	NSCLC	LCL161 + paclitaxel	0	28.3	80	-100	18.9
X-1658	NSCLC	LCL161 + paclitaxel	6.9	28.8	83	-94.7	21
X-1658	NSCLC	LCL161 + paclitaxel	6.9	28.7	87	-94.7	20.6
X-1658	NSCLC	LCL161 + paclitaxel	0	28.8	90	-100	21
X-1658	NSCLC	LCL161 + paclitaxel	0	27.3	95	-100	14.7
X-1658	NSCLC	LCL161 + paclitaxel	0	26.1	98	-100	9.7
X-1658	NSCLC	LEE011	208	24	0	0	0
X-1658	NSCLC	LEE011	355.8	25.5	4	71.1	6.2
X-1658	NSCLC	LEE011	490.4	26	7	135.8	8.3
X-1658	NSCLC	LEE011	964.3	25.9	11	363.6	7.9
X-1658	NSCLC	LEE011	951.3	25.6	14	357.4	6.7
X-1658	NSCLC	LEE011	1224.6	26.3	17	488.7	9.6
X-1658	NSCLC	LGH447	202	21.1	0	0	0
X-1658	NSCLC	LGH447	195.9	19.3	3	-3	-8.5
X-1658	NSCLC	LGH447	443.3	20.5	7	119.5	-2.8
X-1658	NSCLC	LGH447	507.4	21.4	10	151.2	1.4
X-1658	NSCLC	LGH447	548.7	21.7	13	171.6	2.8
X-1658	NSCLC	LGH447	1238.1	21.8	17	512.9	3.3
X-1658	NSCLC	LGH447	1414.9	21.4	20	600.4	1.4
X-1658	NSCLC	LLM871	156.6	21.6	0	0	0
X-1658	NSCLC	LLM871	183.2	20.8	4	17	-3.7
X-1658	NSCLC	LLM871	227	21.5	10	45	-0.5
X-1658	NSCLC	LLM871	502.3	22.3	14	220.8	3.2
X-1658	NSCLC	LLM871	849.2	23.1	18	442.3	6.9
X-1658	NSCLC	binimetinib	263.1	21.9	0	0	0
X-1658	NSCLC	binimetinib	388.9	21.3	3	47.8	-2.7
X-1658	NSCLC	binimetinib	554.3	21.9	7	110.7	0
X-1658	NSCLC	binimetinib	418.7	21.8	10	59.1	-0.5
X-1658	NSCLC	binimetinib	469.4	22.8	13	78.4	4.1
X-1658	NSCLC	binimetinib	500.2	22.5	17	90.1	2.7
X-1658	NSCLC	binimetinib	513.7	23.4	21	95.2	6.8
X-1658	NSCLC	binimetinib	507.5	22.5	24	92.9	2.7
X-1658	NSCLC	binimetinib	608	22.1	28	131.1	0.9
X-1658	NSCLC	binimetinib	751.1	21.7	30	185.5	-0.9
X-1658	NSCLC	binimetinib	617.1	21.6	31	134.5	-1.4
X-1658	NSCLC	binimetinib	793.9	20.8	35	201.7	-5
X-1658	NSCLC	binimetinib	891.8	20.5	38	239	-6.4
X-1658	NSCLC	binimetinib	1211.6	20.2	42	360.5	-7.8
X-1658	NSCLC	paclitaxel	244.2	23.7	0	0	0
X-1658	NSCLC	paclitaxel	396.2	23.6	3	62.2	-0.4
X-1658	NSCLC	paclitaxel	389.6	22.9	6	59.5	-3.4
X-1658	NSCLC	paclitaxel	399.5	23.1	10	63.6	-2.5
X-1658	NSCLC	paclitaxel	391.6	25.4	14	60.4	7.2
X-1658	NSCLC	paclitaxel	241.2	25.6	17	-1.2	8
X-1658	NSCLC	paclitaxel	204.5	25.9	21	-16.3	9.3
X-1658	NSCLC	paclitaxel	191.7	25.3	24	-21.5	6.8
X-1658	NSCLC	paclitaxel	174.4	24.2	28	-28.6	2.1
X-1658	NSCLC	paclitaxel	150	25.1	31	-38.6	5.9
X-1658	NSCLC	paclitaxel	213.1	26	35	-12.7	9.7
X-1658	NSCLC	paclitaxel	235.9	24.3	38	-3.4	2.5
X-1658	NSCLC	paclitaxel	239.7	26.4	42	-1.8	11.4
X-1658	NSCLC	paclitaxel	244.4	26.4	45	0.1	11.4
X-1658	NSCLC	paclitaxel	213	26.5	48	-12.8	11.8
X-1658	NSCLC	paclitaxel	179.8	26.5	56	-26.4	11.8
X-1658	NSCLC	paclitaxel	203.1	26.3	59	-16.8	11
X-1658	NSCLC	paclitaxel	220.2	26.8	63	-9.8	13.1
X-1658	NSCLC	paclitaxel	245.8	27.2	66	0.7	14.8
X-1658	NSCLC	paclitaxel	169.5	26.7	70	-30.6	12.7
X-1658	NSCLC	paclitaxel	185	27.8	73	-24.2	17.3
X-1658	NSCLC	paclitaxel	266.5	27.8	77	9.1	17.3
X-1658	NSCLC	paclitaxel	313.1	27	79	28.2	13.9
X-1658	NSCLC	paclitaxel	368.3	27.5	83	50.8	16
X-1658	NSCLC	paclitaxel	325.4	27.5	86	33.3	16
X-1658	NSCLC	paclitaxel	421.1	27.2	87	72.4	14.8
X-1658	NSCLC	paclitaxel	419.2	27.6	90	71.7	16.5
X-1658	NSCLC	paclitaxel	516.9	27.6	93	111.7	16.5
X-1658	NSCLC	paclitaxel	650.2	28.1	98	166.3	18.6
X-1658	NSCLC	paclitaxel	644.8	27.2	101	164	14.8
X-1658	NSCLC	paclitaxel	742.7	28.3	105	204.1	19.4
X-1658	NSCLC	untreated	241	21	0	0	0
X-1658	NSCLC	untreated	232	23.2	4	-3.7	10.5
X-1658	NSCLC	untreated	236.3	23.5	7	-2	11.9
X-1658	NSCLC	untreated	373.1	24.2	11	54.8	15.2
X-1658	NSCLC	untreated	474.1	25.7	14	96.7	22.4
X-1658	NSCLC	untreated	540.8	25.7	17	124.4	22.4
X-1658	NSCLC	untreated	618.3	24.8	21	156.6	18.1
X-1658	NSCLC	untreated	906	26.3	25	275.9	25.2
X-1658	NSCLC	LFW527 + binimetinib	220.57	24.4	0	0	0
X-1658	NSCLC	LFW527 + binimetinib	486.24	25.1	4	120.4	2.9
X-1658	NSCLC	LFW527 + binimetinib	472.47	24.9	7	114.2	2
X-1658	NSCLC	LFW527 + binimetinib	788.34	25	11	257.4	2.5
X-1658	NSCLC	LFW527 + binimetinib	1211.45	25.1	14	449.2	2.9
X-1683	NSCLC	BGJ398	180	27.7	0	0	0
X-1683	NSCLC	BGJ398	23	27.7	3	-87.2	0
X-1683	NSCLC	BGJ398	41.1	26.8	6	-77.2	-3.2
X-1683	NSCLC	BGJ398	0	27.4	10	-100	-1.1
X-1683	NSCLC	BGJ398	0	28.2	14	-100	1.8
X-1683	NSCLC	BGJ398	0	28	17	-100	1.1
X-1683	NSCLC	BGJ398	0	27.9	21	-100	0.7
X-1683	NSCLC	BGJ398	0	28.9	24	-100	4.3
X-1683	NSCLC	BGJ398	0	28.8	27	-100	4
X-1683	NSCLC	BGJ398	0	29.3	31	-100	5.8
X-1683	NSCLC	BGJ398	0	29.2	34	-100	5.4
X-1683	NSCLC	BGJ398	0	29.5	39	-100	6.5
X-1683	NSCLC	BGJ398	0	28.7	42	-100	3.6
X-1683	NSCLC	BGJ398	0	28.6	46	-100	3.2
X-1683	NSCLC	BGJ398	0	28.9	49	-100	4.3
X-1683	NSCLC	BGJ398	0	28.7	52	-100	3.6
X-1683	NSCLC	BGJ398	0	28	55	-100	1.1
X-1683	NSCLC	BKM120 + binimetinib	205.4	30.5	0	0	0
X-1683	NSCLC	BKM120 + binimetinib	75.8	30.6	3	-63.1	0.3
X-1683	NSCLC	BKM120 + binimetinib	63.1	30.7	6	-69.3	0.7
X-1683	NSCLC	BKM120 + binimetinib	55.3	31.6	10	-73.1	3.6
X-1683	NSCLC	BKM120 + binimetinib	72.8	30.7	14	-64.6	0.7
X-1683	NSCLC	BKM120 + binimetinib	62	30.9	17	-69.8	1.3
X-1683	NSCLC	BKM120 + binimetinib	51.6	31	21	-74.9	1.6
X-1683	NSCLC	BKM120 + binimetinib	74	31.3	24	-64	2.6
X-1683	NSCLC	BKM120 + binimetinib	85.7	31.4	27	-58.3	3
X-1683	NSCLC	BKM120 + binimetinib	58.4	31.2	31	-71.6	2.3
X-1683	NSCLC	BKM120 + binimetinib	67.3	31.5	34	-67.2	3.3
X-1683	NSCLC	BKM120 + binimetinib	37.6	32.1	39	-81.7	5.2
X-1683	NSCLC	BKM120 + binimetinib	68	32.2	42	-66.9	5.6
X-1683	NSCLC	BKM120 + binimetinib	43.6	32.7	46	-78.8	7.2
X-1683	NSCLC	BKM120 + binimetinib	60.6	32.4	49	-70.5	6.2
X-1683	NSCLC	BKM120 + binimetinib	69.9	31.8	52	-66	4.3
X-1683	NSCLC	BKM120 + binimetinib	58.5	32.3	55	-71.5	5.9
X-1683	NSCLC	BKM120 + binimetinib	64.3	31.8	59	-68.7	4.3
X-1683	NSCLC	BKM120 + binimetinib	61.2	32.1	62	-70.2	5.2
X-1683	NSCLC	BKM120 + binimetinib	31.3	32.7	66	-84.8	7.2
X-1683	NSCLC	BKM120 + binimetinib	68.8	32.5	69	-66.5	6.6
X-1683	NSCLC	BKM120 + binimetinib	65.6	32.1	73	-68.1	5.2
X-1683	NSCLC	BKM120 + binimetinib	48.3	32.3	76	-76.5	5.9
X-1683	NSCLC	BKM120 + binimetinib	56.8	32.9	80	-72.3	7.9
X-1683	NSCLC	BKM120 + binimetinib	62.7	33.3	83	-69.5	9.2
X-1683	NSCLC	BKM120 + binimetinib	65.4	33.3	87	-68.2	9.2
X-1683	NSCLC	BKM120 + binimetinib	59.9	33.3	90	-70.8	9.2
X-1683	NSCLC	BKM120 + binimetinib	36.4	33.6	97	-82.3	10.2
X-1683	NSCLC	BKM120 + binimetinib	53.8	35.6	104	-73.8	16.7
X-1683	NSCLC	BKM120 + binimetinib	88.7	35.5	109	-56.8	16.4
X-1683	NSCLC	BKM120 + binimetinib	65.8	35.1	112	-68	15.1
X-1683	NSCLC	BKM120 + binimetinib	49.4	34.3	115	-75.9	12.5
X-1683	NSCLC	BKM120 + binimetinib	56.8	34.8	117	-72.3	14.1
X-1683	NSCLC	BKM120 + binimetinib	39.7	33.7	122	-80.7	10.5
X-1683	NSCLC	BKM120 + binimetinib	53.3	27.2	129	-74.1	-10.8
X-1683	NSCLC	BKM120 + binimetinib	34.3	24.3	131	-83.3	-20.3
X-1683	NSCLC	BKM120	206.2	26.4	0	0	0
X-1683	NSCLC	BKM120	101	26.2	3	-51	-0.8
X-1683	NSCLC	BKM120	66.1	26.9	6	-67.9	1.9
X-1683	NSCLC	BKM120	65.1	27.6	10	-68.4	4.5
X-1683	NSCLC	BKM120	95.7	27.4	14	-53.6	3.8
X-1683	NSCLC	BKM120	114	27.4	17	-44.7	3.8
X-1683	NSCLC	BKM120	115.9	28.1	21	-43.8	6.4
X-1683	NSCLC	BKM120	117.7	28.4	24	-42.9	7.6
X-1683	NSCLC	BKM120	105.2	28.5	27	-49	8
X-1683	NSCLC	BKM120	168.9	28.5	31	-18.1	8
X-1683	NSCLC	BKM120	145.5	28.6	34	-29.4	8.3
X-1683	NSCLC	BKM120	221.2	28.8	39	7.3	9.1
X-1683	NSCLC	BKM120	291.2	28.7	42	41.2	8.7
X-1683	NSCLC	BKM120	177.8	29.4	46	-13.8	11.4
X-1683	NSCLC	BKM120	277.4	29.4	49	34.5	11.4
X-1683	NSCLC	BKM120	196.9	29.2	52	-4.5	10.6
X-1683	NSCLC	BKM120	208.2	29.5	55	1	11.7
X-1683	NSCLC	BKM120	216.6	29.4	59	5	11.4
X-1683	NSCLC	BKM120	200	29.2	62	-3	10.6
X-1683	NSCLC	BKM120	242.5	29.6	66	17.6	12.1
X-1683	NSCLC	BKM120	262.8	29.2	69	27.4	10.6
X-1683	NSCLC	BKM120	289	29.7	73	40.2	12.5
X-1683	NSCLC	BKM120	284.6	30	76	38	13.6
X-1683	NSCLC	BKM120	300.6	28.9	80	45.8	9.5
X-1683	NSCLC	BKM120	270.8	29.3	83	31.3	11
X-1683	NSCLC	BKM120	337.6	29.3	87	63.7	11
X-1683	NSCLC	BKM120	309.2	29.3	90	50	11
X-1683	NSCLC	BKM120	542.4	28.3	97	163	7.2
X-1683	NSCLC	BKM120	728.8	28.9	104	253.4	9.5
X-1683	NSCLC	BKM120	483.1	29.5	109	134.3	11.7
X-1683	NSCLC	BKM120	553.9	28.7	110	168.6	8.7
X-1683	NSCLC	BYL719	217.4	25.2	0	0	0
X-1683	NSCLC	BYL719	85.2	24.4	2	-60.8	-3.2
X-1683	NSCLC	BYL719	50.3	23.2	6	-76.9	-7.9
X-1683	NSCLC	BYL719	56.4	23	10	-74.1	-8.7
X-1683	NSCLC	BYL719	48.9	23.6	13	-77.5	-6.3
X-1683	NSCLC	BYL719	46.1	24	17	-78.8	-4.8
X-1683	NSCLC	BYL719	52.3	24	20	-75.9	-4.8
X-1683	NSCLC	BYL719	70.3	24.1	23	-67.7	-4.4
X-1683	NSCLC	BYL719	54.8	24.9	27	-74.8	-1.2
X-1683	NSCLC	BYL719	69.9	24.5	30	-67.8	-2.8
X-1683	NSCLC	BYL719	70.9	24.3	35	-67.4	-3.6
X-1683	NSCLC	BYL719	42.1	24.5	38	-80.6	-2.8
X-1683	NSCLC	BYL719	62.4	25.4	42	-71.3	0.8
X-1683	NSCLC	BYL719	54	25	45	-75.2	-0.8
X-1683	NSCLC	BYL719	56.2	25.2	48	-74.1	0
X-1683	NSCLC	BYL719	64.3	24.9	51	-70.4	-1.2
X-1683	NSCLC	BYL719	59	24.5	55	-72.9	-2.8
X-1683	NSCLC	BYL719	63.5	24.1	58	-70.8	-4.4
X-1683	NSCLC	BYL719	51.1	24.1	62	-76.5	-4.4
X-1683	NSCLC	BYL719	50.7	24.7	65	-76.7	-2
X-1683	NSCLC	BYL719	29.4	24.5	69	-86.5	-2.8
X-1683	NSCLC	BYL719	43.2	24.5	72	-80.1	-2.8
X-1683	NSCLC	BYL719	41.1	24.7	76	-81.1	-2
X-1683	NSCLC	BYL719	43.7	24.7	79	-79.9	-2
X-1683	NSCLC	BYL719	21.6	24.7	83	-90.1	-2
X-1683	NSCLC	BYL719	29.3	25.4	86	-86.5	0.8
X-1683	NSCLC	BYL719	46.9	24.1	93	-78.4	-4.4
X-1683	NSCLC	BYL719	49	24.4	100	-77.5	-3.2
X-1683	NSCLC	BYL719	55.2	23.8	105	-74.6	-5.6
X-1683	NSCLC	BYL719	47.5	23.8	108	-78.2	-5.6
X-1683	NSCLC	BYL719	41.8	23.9	111	-80.8	-5.2
X-1683	NSCLC	BYL719	36.4	23.7	113	-83.3	-6
X-1683	NSCLC	BYL719	60.1	24.1	118	-72.4	-4.4
X-1683	NSCLC	BYL719	46.8	23.5	121	-78.5	-6.7
X-1683	NSCLC	BYL719	36.7	23.8	125	-83.1	-5.6
X-1683	NSCLC	BYL719	51.1	23.2	128	-76.5	-7.9
X-1683	NSCLC	BYL719	36.6	23	132	-83.2	-8.7
X-1683	NSCLC	BYL719	43.1	22.7	134	-80.2	-9.9
X-1683	NSCLC	BYL719 + LJM716	212.2	24.5	0	0	0
X-1683	NSCLC	BYL719 + LJM716	83.8	23.7	2	-60.5	-3.3
X-1683	NSCLC	BYL719 + LJM716	62	23.7	6	-70.8	-3.3
X-1683	NSCLC	BYL719 + LJM716	49.6	23.9	10	-76.6	-2.4
X-1683	NSCLC	BYL719 + LJM716	37.3	25.1	13	-82.4	2.4
X-1683	NSCLC	BYL719 + LJM716	52.6	25.6	17	-75.2	4.5
X-1683	NSCLC	BYL719 + LJM716	39.9	24.5	20	-81.2	0
X-1683	NSCLC	BYL719 + LJM716	33.9	23.5	23	-84	-4.1
X-1683	NSCLC	BYL719 + LJM716	51.6	20.2	27	-75.7	-17.6
X-1683	NSCLC	BYL719 + LJM716	32	21.6	30	-84.9	-11.8
X-1683	NSCLC	BYL719 + LJM716	18.6	19.7	35	-91.2	-19.6
X-1683	NSCLC	BYL719 + LJM716	27.4	20.1	36	-87.1	-18
X-1683	NSCLC	BYL719 + LGH447	282.1	24.1	0	0	0
X-1683	NSCLC	BYL719 + LGH447	94.1	22.6	2	-66.6	-6.2
X-1683	NSCLC	BYL719 + LGH447	66.7	22.1	6	-76.4	-8.3
X-1683	NSCLC	BYL719 + LGH447	102.7	NA	10	-63.6	-8.3
X-1683	NSCLC	BYL719 + LGH447	92.8	23.1	13	-67.1	-4.1
X-1683	NSCLC	BYL719 + LGH447	71.7	23.7	17	-74.6	-1.7
X-1683	NSCLC	BYL719 + LGH447	77.7	23.5	20	-72.5	-2.5
X-1683	NSCLC	BYL719 + LGH447	85.8	23.5	23	-69.6	-2.5
X-1683	NSCLC	BYL719 + LGH447	84.8	24.5	27	-69.9	1.7
X-1683	NSCLC	BYL719 + LGH447	68.3	24.1	30	-75.8	0
X-1683	NSCLC	BYL719 + LGH447	57.4	24.3	35	-79.7	0.8
X-1683	NSCLC	BYL719 + LGH447	105.9	24.4	38	-62.5	1.2
X-1683	NSCLC	BYL719 + LGH447	85.1	24.7	42	-69.8	2.5
X-1683	NSCLC	BYL719 + LGH447	80.7	24.4	45	-71.4	1.2
X-1683	NSCLC	BYL719 + LGH447	87.4	24.4	48	-69	1.2
X-1683	NSCLC	BYL719 + LGH447	83.4	24.6	51	-70.4	2.1
X-1683	NSCLC	BYL719 + LGH447	92.6	24.4	55	-67.2	1.2
X-1683	NSCLC	BYL719 + LGH447	88.2	24.4	58	-68.7	1.2
X-1683	NSCLC	BYL719 + LGH447	83.5	24.5	62	-70.4	1.7
X-1683	NSCLC	BYL719 + LGH447	71.6	24.5	65	-74.6	1.7
X-1683	NSCLC	BYL719 + LGH447	69.4	23.7	69	-75.4	-1.7
X-1683	NSCLC	BYL719 + LGH447	70.1	24.1	72	-75.2	0
X-1683	NSCLC	BYL719 + LGH447	98.6	24.1	76	-65	0
X-1683	NSCLC	BYL719 + LGH447	94.4	23.9	79	-66.5	-0.8
X-1683	NSCLC	BYL719 + LGH447	70.8	24.2	83	-74.9	0.4
X-1683	NSCLC	BYL719 + LGH447	71.3	23.4	86	-74.7	-2.9
X-1683	NSCLC	BYL719 + LGH447	95.7	24	93	-66.1	-0.4
X-1683	NSCLC	BYL719 + LGH447	97.4	24.4	100	-65.5	1.2
X-1683	NSCLC	BYL719 + LGH447	118.4	25.4	105	-58	5.4
X-1683	NSCLC	BYL719 + LGH447	83.1	24.3	108	-70.5	0.8
X-1683	NSCLC	BYL719 + LGH447	68.5	24.6	111	-75.7	2.1
X-1683	NSCLC	BYL719 + LGH447	79.8	24.6	113	-71.7	2.1
X-1683	NSCLC	BYL719 + LGH447	92.4	24.5	118	-67.2	1.7
X-1683	NSCLC	BYL719 + LGH447	84.2	24.4	121	-70.2	1.2
X-1683	NSCLC	BYL719 + LGH447	93.5	24.4	125	-66.9	1.2
X-1683	NSCLC	BYL719 + LGH447	62.9	23.8	128	-77.7	-1.2
X-1683	NSCLC	BYL719 + LGH447	85.4	NA	132	-69.7	-1.2
X-1683	NSCLC	BYL719 + LGH447	90	24.3	135	-68.1	0.8
X-1683	NSCLC	BYL719 + LGH447	76.9	24.4	139	-72.7	1.2
X-1683	NSCLC	BYL719 + LGH447	80.7	24.6	141	-71.4	2.1
X-1683	NSCLC	CGM097	217.4	24.2	0	0	0
X-1683	NSCLC	CGM097	107.9	25.4	2	-50.4	5
X-1683	NSCLC	CGM097	64.5	25.9	6	-70.3	7
X-1683	NSCLC	CGM097	138.2	25.3	10	-36.4	4.5
X-1683	NSCLC	CGM097	112.8	25.8	13	-48.1	6.6
X-1683	NSCLC	CGM097	81.6	26.1	17	-62.5	7.9
X-1683	NSCLC	CGM097	65.4	25.9	20	-69.9	7
X-1683	NSCLC	CGM097	51.7	26.2	23	-76.2	8.3
X-1683	NSCLC	CGM097	70.2	27.1	27	-67.7	12
X-1683	NSCLC	CGM097	118.7	26.7	30	-45.4	10.3
X-1683	NSCLC	CGM097	127.5	27	35	-41.4	11.6
X-1683	NSCLC	CGM097	120.3	27.2	38	-44.7	12.4
X-1683	NSCLC	CGM097	107.2	27.3	42	-50.7	12.8
X-1683	NSCLC	CGM097	78	28	45	-64.1	15.7
X-1683	NSCLC	CGM097	114.1	27.4	48	-47.5	13.2
X-1683	NSCLC	CGM097	111.1	27.2	51	-48.9	12.4
X-1683	NSCLC	CGM097	108.1	28	55	-50.3	15.7
X-1683	NSCLC	CGM097	181.1	27.2	58	-16.7	12.4
X-1683	NSCLC	CGM097	98.6	25.9	62	-54.6	7
X-1683	NSCLC	CGM097	186.6	25.9	65	-14.2	7
X-1683	NSCLC	CGM097	208	26.6	69	-4.3	9.9
X-1683	NSCLC	CGM097	128.7	27.2	72	-40.8	12.4
X-1683	NSCLC	CGM097	178.3	26.8	76	-18	10.7
X-1683	NSCLC	CGM097	119.8	25.7	79	-44.9	6.2
X-1683	NSCLC	CGM097	143.9	26.3	83	-33.8	8.7
X-1683	NSCLC	CGM097	165.1	26.2	86	-24.1	8.3
X-1683	NSCLC	CGM097	301.3	25.7	93	38.6	6.2
X-1683	NSCLC	CGM097	296.9	27	100	36.6	11.6
X-1683	NSCLC	CGM097	223.2	27.4	105	2.7	13.2
X-1683	NSCLC	CGM097	269.7	27.8	108	24.1	14.9
X-1683	NSCLC	CGM097	249.3	27.6	111	14.7	14
X-1683	NSCLC	CGM097	281.2	28	113	29.3	15.7
X-1683	NSCLC	CGM097	193.1	27.8	118	-11.2	14.9
X-1683	NSCLC	CGM097	301.9	27.4	121	38.9	13.2
X-1683	NSCLC	CGM097	352.7	27.4	125	62.2	13.2
X-1683	NSCLC	CGM097	366.9	27.6	128	68.8	14
X-1683	NSCLC	CGM097	294.3	26.9	132	35.4	11.2
X-1683	NSCLC	CGM097	350.1	26.9	134	61	11.2
X-1683	NSCLC	CKX620	211	24.6	0	0	0
X-1683	NSCLC	CKX620	34	24.4	3	-83.9	-0.8
X-1683	NSCLC	CKX620	23.2	25.1	6	-89	2
X-1683	NSCLC	CKX620	19.9	25.4	10	-90.6	3.3
X-1683	NSCLC	CKX620	14.6	25.3	14	-93.1	2.8
X-1683	NSCLC	CKX620	20.4	25.1	17	-90.3	2
X-1683	NSCLC	CKX620	44.3	25.1	21	-79	2
X-1683	NSCLC	CKX620	27	24.6	24	-87.2	0
X-1683	NSCLC	CKX620	11	24	27	-94.8	-2.4
X-1683	NSCLC	CKX620	20	23	31	-90.5	-6.5
X-1683	NSCLC	CKX620	44.6	23.6	34	-78.9	-4.1
X-1683	NSCLC	CLR457	127.8	22.6	0	0	0
X-1683	NSCLC	CLR457	86.1	23.2	5	-32.6	2.7
X-1683	NSCLC	CLR457	99.9	23.2	8	-21.8	2.7
X-1683	NSCLC	CLR457	102.6	23.9	12	-19.7	5.8
X-1683	NSCLC	CLR457	114.3	23.6	15	-10.6	4.4
X-1683	NSCLC	CLR457	113.6	23.8	20	-11.1	5.3
X-1683	NSCLC	CLR457	131.1	23.4	22	2.6	3.5
X-1683	NSCLC	CLR457	115	21.6	26	-10	-4.4
X-1683	NSCLC	CLR457	147.7	22.7	29	15.6	0.4
X-1683	NSCLC	CLR457	169.6	23.3	33	32.7	3.1
X-1683	NSCLC	CLR457	179.6	23.1	37	40.5	2.2
X-1683	NSCLC	CLR457	173.3	24.2	40	35.6	7.1
X-1683	NSCLC	CLR457	234.4	24	44	83.4	6.2
X-1683	NSCLC	CLR457	210.6	24.7	47	64.8	9.3
X-1683	NSCLC	CLR457	208.9	24.4	50	63.5	8
X-1683	NSCLC	CLR457	266.3	24.1	54	108.4	6.6
X-1683	NSCLC	CLR457	278	24.4	57	117.5	8
X-1683	NSCLC	CLR457	420.4	24.3	62	229	7.5
X-1683	NSCLC	CLR457	484.1	24.4	65	278.8	8
X-1683	NSCLC	CLR457	265.2	24.6	69	107.5	8.8
X-1683	NSCLC	CLR457	387.9	25	72	203.5	10.6
X-1683	NSCLC	CLR457	351.4	24.8	75	175	9.7
X-1683	NSCLC	CLR457	415.2	24.5	78	224.9	8.4
X-1683	NSCLC	CLR457	485.5	25.1	82	279.9	11.1
X-1683	NSCLC	CLR457	532.1	25.2	85	316.4	11.5
X-1683	NSCLC	CLR457	474.7	24.9	89	271.4	10.2
X-1683	NSCLC	CLR457	523.1	24.8	92	309.3	9.7
X-1683	NSCLC	CLR457	550.3	25.3	96	330.6	11.9
X-1683	NSCLC	CLR457	469.6	25.1	99	267.4	11.1
X-1683	NSCLC	CLR457	455.8	24.7	103	256.7	9.3
X-1683	NSCLC	CLR457	739	25	106	478.2	10.6
X-1683	NSCLC	CLR457	723.9	24.6	110	466.4	8.8
X-1683	NSCLC	CLR457	706	24.4	111	452.4	8
X-1683	NSCLC	HDM201	184.3	24.1	0	0	0
X-1683	NSCLC	HDM201	79.7	24.6	3	-56.8	2.1
X-1683	NSCLC	HDM201	72.4	24	6	-60.7	-0.4
X-1683	NSCLC	HDM201	93.4	24.5	11	-49.3	1.7
X-1683	NSCLC	HDM201	122.4	24.6	13	-33.6	2.1
X-1683	NSCLC	HDM201	103	23.4	17	-44.1	-2.9
X-1683	NSCLC	HDM201	110.7	23.2	20	-39.9	-3.7
X-1683	NSCLC	HDM201	102.4	23.2	24	-44.4	-3.7
X-1683	NSCLC	HDM201	113	23.2	28	-38.7	-3.7
X-1683	NSCLC	HDM201	123.9	23.1	31	-32.8	-4.1
X-1683	NSCLC	HDM201	151.6	24.3	35	-17.7	0.8
X-1683	NSCLC	HDM201	95.1	24.4	38	-48.4	1.2
X-1683	NSCLC	HDM201	124.2	24	41	-32.6	-0.4
X-1683	NSCLC	HDM201	164.9	24.1	45	-10.5	0
X-1683	NSCLC	HDM201	132.2	22.5	48	-28.3	-6.6
X-1683	NSCLC	HDM201	156.5	20.4	53	-15.1	-15.4
X-1683	NSCLC	cetuximab	271.4	26	0	0	0
X-1683	NSCLC	cetuximab	169.2	25.5	3	-37.7	-1.9
X-1683	NSCLC	cetuximab	119.4	25.8	7	-56	-0.8
X-1683	NSCLC	cetuximab	167.7	25.1	10	-38.2	-3.5
X-1683	NSCLC	cetuximab	194.4	26.2	15	-28.4	0.8
X-1683	NSCLC	cetuximab	186.6	25.7	17	-31.2	-1.2
X-1683	NSCLC	cetuximab	192.9	26.2	21	-28.9	0.8
X-1683	NSCLC	cetuximab	283.6	26.3	24	4.5	1.2
X-1683	NSCLC	cetuximab	197	26.5	28	-27.4	1.9
X-1683	NSCLC	cetuximab	234.9	26.8	32	-13.4	3.1
X-1683	NSCLC	cetuximab	237.4	26.7	35	-12.5	2.7
X-1683	NSCLC	cetuximab	219.2	27.8	39	-19.2	6.9
X-1683	NSCLC	cetuximab	206.3	26.8	42	-24	3.1
X-1683	NSCLC	cetuximab	255.4	26.9	45	-5.9	3.5
X-1683	NSCLC	cetuximab	280.6	27.7	49	3.4	6.5
X-1683	NSCLC	cetuximab	207.2	28	52	-23.7	7.7
X-1683	NSCLC	cetuximab	378	27	57	39.3	3.8
X-1683	NSCLC	cetuximab	387.7	26.4	60	42.9	1.5
X-1683	NSCLC	cetuximab	197.2	26	64	-27.3	0
X-1683	NSCLC	cetuximab	277.6	25.8	67	2.3	-0.8
X-1683	NSCLC	cetuximab	270.4	25.5	70	-0.4	-1.9
X-1683	NSCLC	cetuximab	246.5	24.8	73	-9.2	-4.6
X-1683	NSCLC	cetuximab	266	25.2	77	-2	-3.1
X-1683	NSCLC	cetuximab	310.2	26	80	14.3	0
X-1683	NSCLC	cetuximab	289.8	27.7	84	6.8	6.5
X-1683	NSCLC	cetuximab	272.8	26.6	87	0.5	2.3
X-1683	NSCLC	cetuximab	471.9	26.5	91	73.9	1.9
X-1683	NSCLC	cetuximab	492.1	26.5	94	81.3	1.9
X-1683	NSCLC	cetuximab	429.5	26.4	98	58.3	1.5
X-1683	NSCLC	cetuximab	486.1	27.3	101	79.1	5
X-1683	NSCLC	cetuximab	434.6	26.3	105	60.1	1.2
X-1683	NSCLC	cetuximab	486.3	26.8	108	79.2	3.1
X-1683	NSCLC	cetuximab	649	26.1	115	139.1	0.4
X-1683	NSCLC	cetuximab	835.2	26	122	207.7	0
X-1683	NSCLC	cetuximab	862.8	27	127	217.9	3.8
X-1683	NSCLC	cetuximab	791.1	27.3	128	191.5	5
X-1683	NSCLC	erlotinib	212.5	26	0	0	0
X-1683	NSCLC	erlotinib	89.7	24.2	3	-57.8	-6.9
X-1683	NSCLC	erlotinib	54.5	19.4	6	-74.4	-25.4
X-1683	NSCLC	erlotinib	87.7	25.1	10	-58.7	-3.5
X-1683	NSCLC	erlotinib	92	21.1	14	-56.7	-18.8
X-1683	NSCLC	erlotinib	81.2	22.5	17	-61.8	-13.5
X-1683	NSCLC	erlotinib	81.1	20.4	21	-61.8	-21.5
X-1683	NSCLC	erlotinib	64.6	19.6	24	-69.6	-24.6
X-1683	NSCLC	erlotinib	73.5	20.2	25	-65.4	-22.3
X-1683	NSCLC	HSP990	246.2	28.1	0	0	0
X-1683	NSCLC	HSP990	128.4	26	5	-47.8	-7.5
X-1683	NSCLC	HSP990	131.4	26	8	-46.6	-7.5
X-1683	NSCLC	HSP990	166.9	26.1	12	-32.2	-7.1
X-1683	NSCLC	HSP990	117.5	25.6	15	-52.3	-8.9
X-1683	NSCLC	HSP990	206.6	27.4	19	-16.1	-2.5
X-1683	NSCLC	HSP990	195.1	26.5	22	-20.8	-5.7
X-1683	NSCLC	HSP990	220.7	22.6	26	-10.4	-19.6
X-1683	NSCLC	HSP990	187.3	20.9	28	-23.9	-25.6
X-1683	NSCLC	INC280	159.6	25.2	0	0	0
X-1683	NSCLC	INC280	46.2	25.1	5	-71.1	-0.4
X-1683	NSCLC	INC280	81.7	24.4	8	-48.8	-3.2
X-1683	NSCLC	INC280	77.7	24.7	12	-51.3	-2
X-1683	NSCLC	INC280	85.7	25.2	15	-46.3	0
X-1683	NSCLC	INC280	92.8	25.7	20	-41.9	2
X-1683	NSCLC	INC280	88.9	25.5	22	-44.3	1.2
X-1683	NSCLC	INC280	113.7	25.4	26	-28.8	0.8
X-1683	NSCLC	INC280	130.1	25.8	29	-18.5	2.4
X-1683	NSCLC	INC280	115.1	26	33	-27.9	3.2
X-1683	NSCLC	INC280	164.6	25.3	37	3.1	0.4
X-1683	NSCLC	INC280	130.7	26	40	-18.1	3.2
X-1683	NSCLC	INC280	156.9	25.9	44	-1.7	2.8
X-1683	NSCLC	INC280	179.6	26.8	47	12.5	6.3
X-1683	NSCLC	INC280	238.8	26.3	50	49.6	4.4
X-1683	NSCLC	INC280	232.4	26	54	45.6	3.2
X-1683	NSCLC	INC280	180.5	26.4	57	13.1	4.8
X-1683	NSCLC	INC280	304.1	26.8	62	90.5	6.3
X-1683	NSCLC	INC280	339.3	26.9	65	112.6	6.7
X-1683	NSCLC	INC280	235.1	26.7	69	47.3	6
X-1683	NSCLC	INC280	290.9	27.1	72	82.3	7.5
X-1683	NSCLC	INC280	260.1	26.8	75	63	6.3
X-1683	NSCLC	INC280	327.3	27.1	78	105.1	7.5
X-1683	NSCLC	INC280	239.9	27.4	82	50.3	8.7
X-1683	NSCLC	INC280	356.9	26.9	85	123.6	6.7
X-1683	NSCLC	INC280	354.7	27.1	89	122.2	7.5
X-1683	NSCLC	INC280	587.4	27.1	92	268	7.5
X-1683	NSCLC	INC280	436.1	27.3	96	173.2	8.3
X-1683	NSCLC	INC280	575.7	27.2	99	260.7	7.9
X-1683	NSCLC	INC280	461.3	27.4	103	189	8.7
X-1683	NSCLC	INC280	815.1	27.5	106	410.7	9.1
X-1683	NSCLC	INC280	758.3	27.6	110	375.1	9.5
X-1683	NSCLC	INC280	774.3	26.9	111	385.2	6.7
X-1683	NSCLC	LCL161 + paclitaxel	200.4	26	0	0	0
X-1683	NSCLC	LCL161 + paclitaxel	64.2	24.8	6	-68	-4.6
X-1683	NSCLC	LCL161 + paclitaxel	40.8	22.3	8	-79.6	-14.2
X-1683	NSCLC	LCL161 + paclitaxel	25	24.1	12	-87.5	-7.3
X-1683	NSCLC	LCL161 + paclitaxel	0	22.9	15	-100	-11.9
X-1683	NSCLC	LCL161 + paclitaxel	0	25.9	19	-100	-0.4
X-1683	NSCLC	LCL161 + paclitaxel	0	25.9	23	-100	-0.4
X-1683	NSCLC	LCL161 + paclitaxel	0	21.5	26	-100	-17.3
X-1683	NSCLC	LCL161 + paclitaxel	0	24.1	30	-100	-7.3
X-1683	NSCLC	LCL161 + paclitaxel	0	19.2	33	-100	-26.2
X-1683	NSCLC	LCL161 + paclitaxel	0	21.3	36	-100	-18.1
X-1683	NSCLC	LCL161 + paclitaxel	0	23.7	40	-100	-8.8
X-1683	NSCLC	LCL161 + paclitaxel	0	23.3	43	-100	-10.4
X-1683	NSCLC	LCL161 + paclitaxel	0	16.6	48	-100	-36.2
X-1683	NSCLC	LEE011	203.3	24.6	0	0	0
X-1683	NSCLC	LEE011	76.1	24.4	3	-62.6	-0.8
X-1683	NSCLC	LEE011	112.1	24.8	6	-44.9	0.8
X-1683	NSCLC	LEE011	117.6	26.2	11	-42.2	6.5
X-1683	NSCLC	LEE011	87.1	26.3	13	-57.2	6.9
X-1683	NSCLC	LEE011	133.1	26.5	17	-34.5	7.7
X-1683	NSCLC	LEE011	150.7	26.9	20	-25.9	9.3
X-1683	NSCLC	LEE011	243.7	27.1	24	19.9	10.2
X-1683	NSCLC	LEE011	215	28.5	28	5.8	15.9
X-1683	NSCLC	LEE011	346	27.8	31	70.2	13
X-1683	NSCLC	LEE011	348.8	28.1	35	71.6	14.2
X-1683	NSCLC	LEE011	266.3	27.8	38	31	13
X-1683	NSCLC	LEE011	329.3	28.4	41	62	15.4
X-1683	NSCLC	LEE011	425.3	28	45	109.2	13.8
X-1683	NSCLC	LEE011	297.9	28.2	48	46.5	14.6
X-1683	NSCLC	LEE011	632.4	28.3	53	211.1	15
X-1683	NSCLC	LEE011	661.2	28	56	225.2	13.8
X-1683	NSCLC	LEE011	382.3	29.1	60	88	18.3
X-1683	NSCLC	LEE011	567.3	29.1	63	179	18.3
X-1683	NSCLC	LEE011	525.1	29	66	158.3	17.9
X-1683	NSCLC	LEE011	487.6	29.2	69	139.8	18.7
X-1683	NSCLC	LEE011	574.2	28.6	73	182.4	16.3
X-1683	NSCLC	LEE011	655.1	28.7	76	222.2	16.7
X-1683	NSCLC	LEE011	744.9	28.7	80	266.4	16.7
X-1683	NSCLC	LEE011	789.3	28.2	81	288.2	14.6
X-1683	NSCLC	LGH447	213.8	30.6	0	0	0
X-1683	NSCLC	LGH447	49.7	25	3	-76.8	-18.3
X-1683	NSCLC	LGH447	72.8	26.6	6	-65.9	-13.1
X-1683	NSCLC	LGH447	82.4	28.2	11	-61.5	-7.8
X-1683	NSCLC	LGH447	112.3	27.3	13	-47.5	-10.8
X-1683	NSCLC	LGH447	142	28.3	17	-33.6	-7.5
X-1683	NSCLC	LGH447	169.7	27	20	-20.6	-11.8
X-1683	NSCLC	LGH447	172.5	27.3	24	-19.3	-10.8
X-1683	NSCLC	LGH447	184	27.2	28	-13.9	-11.1
X-1683	NSCLC	LGH447	245.6	28.9	31	14.9	-5.6
X-1683	NSCLC	LGH447	235	28.6	35	9.9	-6.5
X-1683	NSCLC	LGH447	241.1	28.1	38	12.8	-8.2
X-1683	NSCLC	LLM871	220.9	29.4	0	0	0
X-1683	NSCLC	LLM871	106.2	27.8	3	-51.9	-5.4
X-1683	NSCLC	LLM871	102.9	27.5	7	-53.4	-6.5
X-1683	NSCLC	LLM871	86	27.2	10	-61.1	-7.5
X-1683	NSCLC	LLM871	167.8	26.3	15	-24	-10.5
X-1683	NSCLC	LLM871	119.7	25.8	17	-45.8	-12.2
X-1683	NSCLC	LLM871	104	26.5	21	-52.9	-9.9
X-1683	NSCLC	LLM871	172.7	26.4	24	-21.8	-10.2
X-1683	NSCLC	LLM871	186.8	26.9	28	-15.4	-8.5
X-1683	NSCLC	LLM871	191.1	25.4	32	-13.5	-13.6
X-1683	NSCLC	LLM871	263.4	25.6	35	19.2	-12.9
X-1683	NSCLC	LLM871	292.4	25.4	39	32.4	-13.6
X-1683	NSCLC	LLM871	297.7	25.4	42	34.8	-13.6
X-1683	NSCLC	LLM871	408.5	24.6	45	84.9	-16.3
X-1683	NSCLC	LLM871	552	24.9	49	149.9	-15.3
X-1683	NSCLC	LLM871	576.2	24.6	50	160.8	-16.3
X-1683	NSCLC	binimetinib	200.4	24.3	0	0	0
X-1683	NSCLC	binimetinib	71.1	24.8	5	-64.5	2.1
X-1683	NSCLC	binimetinib	115.4	24.9	8	-42.4	2.5
X-1683	NSCLC	binimetinib	130.9	25.8	12	-34.7	6.2
X-1683	NSCLC	binimetinib	80.5	25.2	15	-59.8	3.7
X-1683	NSCLC	binimetinib	86.6	25.8	20	-56.8	6.2
X-1683	NSCLC	binimetinib	85.2	26.6	22	-57.5	9.5
X-1683	NSCLC	binimetinib	99	26.8	26	-50.6	10.3
X-1683	NSCLC	binimetinib	126.5	26.3	29	-36.9	8.2
X-1683	NSCLC	binimetinib	177.9	27	33	-11.2	11.1
X-1683	NSCLC	binimetinib	183.7	26.6	37	-8.3	9.5
X-1683	NSCLC	binimetinib	195.1	27.2	40	-2.6	11.9
X-1683	NSCLC	binimetinib	189.1	27.9	44	-5.6	14.8
X-1683	NSCLC	binimetinib	177.6	27	47	-11.4	11.1
X-1683	NSCLC	binimetinib	218.5	27.6	50	9	13.6
X-1683	NSCLC	binimetinib	258.5	27.9	54	29	14.8
X-1683	NSCLC	binimetinib	305.3	26.6	57	52.3	9.5
X-1683	NSCLC	binimetinib	374.8	26.5	62	87	9.1
X-1683	NSCLC	binimetinib	345.9	27	65	72.6	11.1
X-1683	NSCLC	binimetinib	309.6	27.3	69	54.5	12.3
X-1683	NSCLC	binimetinib	383.4	27.1	72	91.3	11.5
X-1683	NSCLC	binimetinib	376.5	26.6	75	87.9	9.5
X-1683	NSCLC	binimetinib	413.3	26.4	78	106.2	8.6
X-1683	NSCLC	binimetinib	472.6	26.2	82	135.8	7.8
X-1683	NSCLC	binimetinib	503.2	26.1	85	151.1	7.4
X-1683	NSCLC	binimetinib	597.1	26.3	89	198	8.2
X-1683	NSCLC	binimetinib	786.8	26.1	92	292.6	7.4
X-1683	NSCLC	binimetinib	755.4	25.6	96	276.9	5.3
X-1683	NSCLC	binimetinib	1086.4	25.4	97	442.1	4.5
X-1683	NSCLC	paclitaxel	200.4	25	0	0	0
X-1683	NSCLC	paclitaxel	108.6	25.8	6	-45.8	3.2
X-1683	NSCLC	paclitaxel	92.2	24.8	8	-54	-0.8
X-1683	NSCLC	paclitaxel	135.7	25.5	12	-32.3	2
X-1683	NSCLC	paclitaxel	111.1	25.7	15	-44.6	2.8
X-1683	NSCLC	paclitaxel	92.4	25.8	19	-53.9	3.2
X-1683	NSCLC	paclitaxel	90.2	25.5	23	-55	2
X-1683	NSCLC	paclitaxel	104.3	25.6	26	-48	2.4
X-1683	NSCLC	paclitaxel	136.3	25.5	30	-32	2
X-1683	NSCLC	paclitaxel	127.3	26	33	-36.5	4
X-1683	NSCLC	paclitaxel	149.8	26.5	36	-25.2	6
X-1683	NSCLC	paclitaxel	115.2	26.9	40	-42.5	7.6
X-1683	NSCLC	paclitaxel	133.8	27	43	-33.2	8
X-1683	NSCLC	paclitaxel	126.1	26.5	48	-37.1	6
X-1683	NSCLC	paclitaxel	122.8	26.3	51	-38.7	5.2
X-1683	NSCLC	paclitaxel	131.7	27.3	55	-34.3	9.2
X-1683	NSCLC	paclitaxel	208.1	27.2	58	3.8	8.8
X-1683	NSCLC	paclitaxel	157.4	26.8	61	-21.5	7.2
X-1683	NSCLC	paclitaxel	207.6	26.7	64	3.6	6.8
X-1683	NSCLC	paclitaxel	169.8	27.4	68	-15.3	9.6
X-1683	NSCLC	paclitaxel	236.5	28	71	18	12
X-1683	NSCLC	paclitaxel	276	27	75	37.7	8
X-1683	NSCLC	paclitaxel	226.4	27.3	78	13	9.2
X-1683	NSCLC	paclitaxel	324.3	27.7	82	61.8	10.8
X-1683	NSCLC	paclitaxel	315.8	28.2	85	57.6	12.8
X-1683	NSCLC	paclitaxel	346.8	27.9	89	73.1	11.6
X-1683	NSCLC	paclitaxel	331.2	27.7	92	65.3	10.8
X-1683	NSCLC	paclitaxel	346.3	28.4	96	72.8	13.6
X-1683	NSCLC	paclitaxel	384.8	28.4	99	92	13.6
X-1683	NSCLC	paclitaxel	494.7	26.7	106	146.9	6.8
X-1683	NSCLC	paclitaxel	464.1	27.9	113	131.6	11.6
X-1683	NSCLC	paclitaxel	468.9	27.8	118	134	11.2
X-1683	NSCLC	paclitaxel	540.8	27.7	119	169.9	10.8
X-1683	NSCLC	untreated	204.5	23.4	0	0	0
X-1683	NSCLC	untreated	201.9	23.9	3	-1.3	2.1
X-1683	NSCLC	untreated	136.1	24.3	6	-33.4	3.8
X-1683	NSCLC	untreated	167.2	24.9	11	-18.2	6.4
X-1683	NSCLC	untreated	184.5	25.4	13	-9.8	8.5
X-1683	NSCLC	untreated	398.6	25.8	17	94.9	10.3
X-1683	NSCLC	untreated	455.9	25.6	20	122.9	9.4
X-1683	NSCLC	untreated	501.2	26.3	24	145.1	12.4
X-1683	NSCLC	untreated	625.2	26.4	28	205.7	12.8
X-1683	NSCLC	untreated	615.9	26.5	31	201.2	13.2
X-1683	NSCLC	untreated	840	26.5	35	310.8	13.2
X-1683	NSCLC	untreated	1032.2	27.2	38	404.7	16.2
X-1683	NSCLC	untreated	958.1	26.7	39	368.5	14.1
X-1725	NSCLC	BGJ398	210.3	25.9	0	0	0
X-1725	NSCLC	BGJ398	152	25.1	5	-27.7	-3.1
X-1725	NSCLC	BGJ398	122.6	25.8	8	-41.7	-0.4
X-1725	NSCLC	BGJ398	248	26	12	17.9	0.4
X-1725	NSCLC	BGJ398	345.8	26.2	15	64.4	1.2
X-1725	NSCLC	BGJ398	339.7	26.6	19	61.5	2.7
X-1725	NSCLC	BGJ398	328	26.9	22	56	3.9
X-1725	NSCLC	BGJ398	361.8	26	26	72	0.4
X-1725	NSCLC	BGJ398	383.2	26.1	29	82.2	0.8
X-1725	NSCLC	BGJ398	462.2	25.6	33	119.8	-1.2
X-1725	NSCLC	BGJ398	650.6	25.7	34	209.4	-0.8
X-1725	NSCLC	BKM120 + binimetinib	233.8	27.5	0	0	0
X-1725	NSCLC	BKM120 + binimetinib	167.1	27.1	3	-28.5	-1.5
X-1725	NSCLC	BKM120 + binimetinib	146.9	27	6	-37.2	-1.8
X-1725	NSCLC	BKM120 + binimetinib	168.3	27.9	10	-28	1.5
X-1725	NSCLC	BKM120 + binimetinib	205.4	28.4	13	-12.1	3.3
X-1725	NSCLC	BKM120 + binimetinib	234.3	28.4	17	0.2	3.3
X-1725	NSCLC	BKM120 + binimetinib	246	29.3	20	5.2	6.5
X-1725	NSCLC	BKM120 + binimetinib	233.3	28.6	24	-0.2	4
X-1725	NSCLC	BKM120 + binimetinib	243.3	28.5	27	4.1	3.6
X-1725	NSCLC	BKM120 + binimetinib	209.8	28.3	31	-10.3	2.9
X-1725	NSCLC	BKM120 + binimetinib	244.2	28.7	34	4.4	4.4
X-1725	NSCLC	BKM120 + binimetinib	247.2	28.8	38	5.7	4.7
X-1725	NSCLC	BKM120 + binimetinib	329.5	28.8	41	40.9	4.7
X-1725	NSCLC	BKM120 + binimetinib	304.7	28.2	45	30.3	2.5
X-1725	NSCLC	BKM120 + binimetinib	301.3	28.1	48	28.9	2.2
X-1725	NSCLC	BKM120 + binimetinib	310.4	27.8	52	32.8	1.1
X-1725	NSCLC	BKM120 + binimetinib	340.9	28.3	55	45.8	2.9
X-1725	NSCLC	BKM120 + binimetinib	301	24	59	28.7	-12.7
X-1725	NSCLC	BKM120 + binimetinib	288.4	28.9	62	23.4	5.1
X-1725	NSCLC	BKM120 + binimetinib	265	28.9	66	13.3	5.1
X-1725	NSCLC	BKM120 + binimetinib	518.6	29.3	70	121.8	6.5
X-1725	NSCLC	BKM120 + binimetinib	513.4	29.8	73	119.6	8.4
X-1725	NSCLC	BKM120 + binimetinib	522.5	30.1	77	123.5	9.5
X-1725	NSCLC	BKM120 + binimetinib	337.7	29.9	80	44.4	8.7
X-1725	NSCLC	BKM120 + binimetinib	394.6	30.1	83	68.8	9.5
X-1725	NSCLC	BKM120 + binimetinib	351.6	29.7	88	50.4	8
X-1725	NSCLC	BKM120 + binimetinib	405.8	30.2	90	73.6	9.8
X-1725	NSCLC	BKM120 + binimetinib	415.3	28.5	94	77.6	3.6
X-1725	NSCLC	BKM120 + binimetinib	469.5	29.3	97	100.8	6.5
X-1725	NSCLC	BKM120 + binimetinib	399.5	29.5	101	70.9	7.3
X-1725	NSCLC	BKM120 + binimetinib	358.3	29.8	104	53.3	8.4
X-1725	NSCLC	BKM120 + binimetinib	372.3	30.4	108	59.2	10.5
X-1725	NSCLC	BKM120 + binimetinib	489.2	30.9	111	109.2	12.4
X-1725	NSCLC	BKM120 + binimetinib	406.5	30.4	115	73.9	10.5
X-1725	NSCLC	BKM120 + binimetinib	530.8	30.1	116	127	9.5
X-1725	NSCLC	BKM120	229.3	27	0	0	0
X-1725	NSCLC	BKM120	253.8	26.7	3	10.7	-1.1
X-1725	NSCLC	BKM120	272.8	26.8	7	19	-0.7
X-1725	NSCLC	BKM120	230.9	27.6	10	0.7	2.2
X-1725	NSCLC	BKM120	283.8	27.5	14	23.8	1.9
X-1725	NSCLC	BKM120	299	27.6	17	30.4	2.2
X-1725	NSCLC	BKM120	272.7	28.3	21	18.9	4.8
X-1725	NSCLC	BKM120	318	28.6	24	38.7	5.9
X-1725	NSCLC	BKM120	325.8	28.5	28	42.1	5.6
X-1725	NSCLC	BKM120	350	29.4	31	52.6	8.9
X-1725	NSCLC	BKM120	321.6	29.3	35	40.3	8.5
X-1725	NSCLC	BKM120	336.4	30.3	38	46.7	12.2
X-1725	NSCLC	BKM120	329.7	29.7	42	43.8	10
X-1725	NSCLC	BKM120	332.4	30.1	45	45	11.5
X-1725	NSCLC	BKM120	282.5	29.8	49	23.2	10.4
X-1725	NSCLC	BKM120	344.3	30	52	50.2	11.1
X-1725	NSCLC	BKM120	377.7	29.7	56	64.7	10
X-1725	NSCLC	BKM120	287.2	29.7	59	25.3	10
X-1725	NSCLC	BKM120	290	29.6	63	26.5	9.6
X-1725	NSCLC	BKM120	254.2	30.1	66	10.9	11.5
X-1725	NSCLC	BKM120	355.1	30	70	54.9	11.1
X-1725	NSCLC	BKM120	251.4	30.1	73	9.6	11.5
X-1725	NSCLC	BKM120	298.7	30.4	77	30.3	12.6
X-1725	NSCLC	BKM120	224.2	30.2	80	-2.2	11.9
X-1725	NSCLC	BKM120	336.6	30.1	84	46.8	11.5
X-1725	NSCLC	BKM120	430.4	31.1	88	87.7	15.2
X-1725	NSCLC	BKM120	355.6	31.8	91	55.1	17.8
X-1725	NSCLC	BKM120	344.7	29.2	95	50.3	8.1
X-1725	NSCLC	BKM120	325.4	31.3	98	41.9	15.9
X-1725	NSCLC	BKM120	223.5	31.4	101	-2.5	16.3
X-1725	NSCLC	BKM120	206.9	30.9	106	-9.8	14.4
X-1725	NSCLC	BKM120	210.5	31.4	108	-8.2	16.3
X-1725	NSCLC	BKM120	109.1	31.8	112	-52.4	17.8
X-1725	NSCLC	BKM120	167.6	32.6	115	-26.9	20.7
X-1725	NSCLC	BKM120	120.6	32.1	119	-47.4	18.9
X-1725	NSCLC	BKM120	97	33.5	122	-57.7	24.1
X-1725	NSCLC	BKM120	77.5	32.6	126	-66.2	20.7
X-1725	NSCLC	BKM120	81.5	31.7	129	-64.5	17.4
X-1725	NSCLC	BKM120	42.5	32.2	133	-81.5	19.3
X-1725	NSCLC	BKM120	81.1	32.3	134	-64.6	19.6
X-1725	NSCLC	BYL719 + LJM716	209.6	28	0	0	0
X-1725	NSCLC	BYL719 + LJM716	162.4	28.2	3	-22.5	0.7
X-1725	NSCLC	BYL719 + LJM716	190.2	27.5	7	-9.3	-1.8
X-1725	NSCLC	BYL719 + LJM716	193.9	27.9	10	-7.5	-0.4
X-1725	NSCLC	BYL719 + LJM716	215.7	26.6	14	2.9	-5
X-1725	NSCLC	BYL719 + LJM716	202.7	27.2	17	-3.3	-2.9
X-1725	NSCLC	BYL719 + LJM716	247.1	27.4	21	17.9	-2.1
X-1725	NSCLC	BYL719 + LJM716	285.2	26.7	24	36.1	-4.6
X-1725	NSCLC	BYL719 + LJM716	154.5	26.3	28	-26.3	-6.1
X-1725	NSCLC	BYL719 + LJM716	199.3	26.2	31	-4.9	-6.4
X-1725	NSCLC	BYL719 + LJM716	246.1	25.6	35	17.4	-8.6
X-1725	NSCLC	BYL719 + LJM716	255.3	25.5	38	21.8	-8.9
X-1725	NSCLC	BYL719 + LJM716	423.9	24.8	42	102.2	-11.4
X-1725	NSCLC	BYL719 + LJM716	374.9	23.8	45	78.9	-15
X-1725	NSCLC	BYL719 + LJM716	359.7	22.7	49	71.6	-18.9
X-1725	NSCLC	BYL719 + LJM716	426.3	22.7	52	103.4	-18.9
X-1725	NSCLC	BYL719 + LJM716	463.8	20.7	56	121.3	-26.1
X-1725	NSCLC	BYL719 + LJM716	478.9	20.4	57	128.5	-27.1
X-1725	NSCLC	BYL719	141.6	28.8	0	0	0
X-1725	NSCLC	BYL719	194.7	28	3	37.5	-2.8
X-1725	NSCLC	BYL719	214.5	28.7	7	51.5	-0.3
X-1725	NSCLC	BYL719	157.8	28	10	11.4	-2.8
X-1725	NSCLC	BYL719	237.9	29.1	14	68	1
X-1725	NSCLC	BYL719	208.4	29.1	17	47.2	1
X-1725	NSCLC	BYL719	174.7	28.5	21	23.4	-1
X-1725	NSCLC	BYL719	239	29.3	24	68.8	1.7
X-1725	NSCLC	BYL719	218.4	29	28	54.2	0.7
X-1725	NSCLC	BYL719	175.1	28.9	31	23.7	0.3
X-1725	NSCLC	BYL719	264.2	29.1	35	86.6	1
X-1725	NSCLC	BYL719	292.5	28.8	38	106.6	0
X-1725	NSCLC	BYL719	235.2	29.5	42	66.1	2.4
X-1725	NSCLC	BYL719	243.6	29	45	72	0.7
X-1725	NSCLC	BYL719	239.2	29.5	49	68.9	2.4
X-1725	NSCLC	BYL719	156.3	28.7	52	10.4	-0.3
X-1725	NSCLC	BYL719	238.9	29.4	56	68.7	2.1
X-1725	NSCLC	BYL719	237.1	29.4	59	67.4	2.1
X-1725	NSCLC	BYL719	336.3	29.6	63	137.5	2.8
X-1725	NSCLC	BYL719	261.5	29.7	66	84.7	3.1
X-1725	NSCLC	BYL719	227.4	29.4	70	60.6	2.1
X-1725	NSCLC	BYL719	220.5	29.9	73	55.7	3.8
X-1725	NSCLC	BYL719	277.7	28.7	77	96.1	-0.3
X-1725	NSCLC	BYL719	343.8	28.5	81	142.8	-1
X-1725	NSCLC	BYL719	346.6	30.3	84	144.8	5.2
X-1725	NSCLC	BYL719	365.3	29.3	88	158	1.7
X-1725	NSCLC	BYL719	283.2	30.1	91	100	4.5
X-1725	NSCLC	BYL719	206.5	30.4	94	45.8	5.6
X-1725	NSCLC	BYL719	217.6	29.4	99	53.7	2.1
X-1725	NSCLC	BYL719	338.2	29.6	101	138.8	2.8
X-1725	NSCLC	BYL719	325.9	28.7	105	130.2	-0.3
X-1725	NSCLC	BYL719	374.2	29	108	164.3	0.7
X-1725	NSCLC	BYL719	220.2	29.3	112	55.5	1.7
X-1725	NSCLC	BYL719	225.2	29.7	115	59	3.1
X-1725	NSCLC	BYL719	155.8	28.4	119	10	-1.4
X-1725	NSCLC	BYL719	186.2	29.3	122	31.5	1.7
X-1725	NSCLC	BYL719	180.4	29.5	126	27.4	2.4
X-1725	NSCLC	BYL719	327.9	29.6	127	131.6	2.8
X-1725	NSCLC	BYL719 + LGH447	219.5	30.8	0	0	0
X-1725	NSCLC	BYL719 + LGH447	283.1	28.8	3	29	-6.5
X-1725	NSCLC	BYL719 + LGH447	333.6	29	7	52	-5.8
X-1725	NSCLC	BYL719 + LGH447	385.3	29.2	10	75.5	-5.2
X-1725	NSCLC	BYL719 + LGH447	371.1	29.4	14	69.1	-4.5
X-1725	NSCLC	BYL719 + LGH447	419.1	29	17	90.9	-5.8
X-1725	NSCLC	BYL719 + LGH447	498.7	29	21	127.2	-5.8
X-1725	NSCLC	BYL719 + LGH447	524.6	29.3	24	139	-4.9
X-1725	NSCLC	BYL719 + LGH447	552	30.1	28	151.5	-2.3
X-1725	NSCLC	BYL719 + LGH447	652.5	29.6	29	197.3	-3.9
X-1725	NSCLC	CGM097	232.6	23.8	0	0	0
X-1725	NSCLC	CGM097	221	24.6	5	-5	3.4
X-1725	NSCLC	CGM097	279.9	25.7	8	20.3	8
X-1725	NSCLC	CGM097	400.9	27.1	12	72.4	13.9
X-1725	NSCLC	CGM097	346.5	27.3	15	49	14.7
X-1725	NSCLC	CGM097	364.5	27.4	19	56.7	15.1
X-1725	NSCLC	CGM097	314.4	27.4	22	35.2	15.1
X-1725	NSCLC	CGM097	259.2	27.4	26	11.4	15.1
X-1725	NSCLC	CGM097	501.9	27.8	29	115.8	16.8
X-1725	NSCLC	CGM097	524.1	28.1	33	125.3	18.1
X-1725	NSCLC	CGM097	427.2	28.1	36	83.7	18.1
X-1725	NSCLC	CGM097	397.1	28.8	40	70.7	21
X-1725	NSCLC	CGM097	360.1	27.8	43	54.8	16.8
X-1725	NSCLC	CGM097	344.7	29.3	47	48.2	23.1
X-1725	NSCLC	CGM097	456.9	29.6	50	96.4	24.4
X-1725	NSCLC	CGM097	510.5	29.4	54	119.5	23.5
X-1725	NSCLC	CGM097	423.4	29.3	57	82	23.1
X-1725	NSCLC	CGM097	427.2	29.1	61	83.7	22.3
X-1725	NSCLC	CGM097	575.7	29.5	63	147.5	23.9
X-1725	NSCLC	CKX620	223.6	25.2	0	0	0
X-1725	NSCLC	CKX620	153.5	25.2	5	-31.4	0
X-1725	NSCLC	CKX620	202.3	25.6	8	-9.5	1.6
X-1725	NSCLC	CKX620	180.7	26	12	-19.2	3.2
X-1725	NSCLC	CKX620	170.5	26.1	15	-23.7	3.6
X-1725	NSCLC	CKX620	220.7	26.2	19	-1.3	4
X-1725	NSCLC	CKX620	183.4	26.4	22	-18	4.8
X-1725	NSCLC	CKX620	179.4	26.2	26	-19.8	4
X-1725	NSCLC	CKX620	301.1	26.6	29	34.7	5.6
X-1725	NSCLC	CKX620	166.8	27.4	33	-25.4	8.7
X-1725	NSCLC	CKX620	291	27.4	36	30.1	8.7
X-1725	NSCLC	CKX620	276.9	26.1	40	23.8	3.6
X-1725	NSCLC	CKX620	268.8	27.3	43	20.2	8.3
X-1725	NSCLC	CKX620	328.4	27	47	46.9	7.1
X-1725	NSCLC	CKX620	356.1	26.7	50	59.3	6
X-1725	NSCLC	CKX620	171.7	25.1	54	-23.2	-0.4
X-1725	NSCLC	CKX620	282.3	26.3	57	26.3	4.4
X-1725	NSCLC	CKX620	313.9	26.1	61	40.4	3.6
X-1725	NSCLC	CKX620	295.8	27	64	32.3	7.1
X-1725	NSCLC	CKX620	250.3	27	68	11.9	7.1
X-1725	NSCLC	CKX620	249.2	27.2	71	11.4	7.9
X-1725	NSCLC	CKX620	285	26.5	75	27.5	5.2
X-1725	NSCLC	CKX620	206.7	28	78	-7.6	11.1
X-1725	NSCLC	CKX620	366.3	28.1	82	63.8	11.5
X-1725	NSCLC	CKX620	471.9	28.5	86	111	13.1
X-1725	NSCLC	CKX620	444.4	28.1	89	98.7	11.5
X-1725	NSCLC	CKX620	509.5	28.4	93	127.9	12.7
X-1725	NSCLC	CKX620	322.9	27.7	96	44.4	9.9
X-1725	NSCLC	CKX620	267.7	28	99	19.7	11.1
X-1725	NSCLC	CKX620	244.7	26.2	104	9.4	4
X-1725	NSCLC	CKX620	316.3	26.1	106	41.5	3.6
X-1725	NSCLC	CKX620	238	25.2	110	6.4	0
X-1725	NSCLC	CKX620	298.9	25.3	113	33.7	0.4
X-1725	NSCLC	CLR457	204	25.1	0	0	0
X-1725	NSCLC	CLR457	225.4	25.6	3	10.5	2
X-1725	NSCLC	CLR457	267.6	25.9	7	31.2	3.2
X-1725	NSCLC	CLR457	304	26	10	49	3.6
X-1725	NSCLC	CLR457	310.8	26.4	14	52.4	5.2
X-1725	NSCLC	CLR457	360.9	26.7	17	76.9	6.4
X-1725	NSCLC	CLR457	424.8	27.6	21	108.2	10
X-1725	NSCLC	CLR457	492.6	27.6	24	141.5	10
X-1725	NSCLC	CLR457	434.2	27.7	28	112.8	10.4
X-1725	NSCLC	CLR457	506.3	27.7	31	148.2	10.4
X-1725	NSCLC	CLR457	444	27.8	35	117.6	10.8
X-1725	NSCLC	CLR457	602.3	27.2	38	195.2	8.4
X-1725	NSCLC	CLR457	727.3	27.6	42	256.5	10
X-1725	NSCLC	CLR457	920.7	27.6	43	351.3	10
X-1725	NSCLC	HDM201	219.2	24.2	0	0	0
X-1725	NSCLC	HDM201	137.5	24	3	-37.3	-0.8
X-1725	NSCLC	HDM201	167.1	23.6	7	-23.8	-2.5
X-1725	NSCLC	HDM201	191	23.5	10	-12.9	-2.9
X-1725	NSCLC	HDM201	176.3	22.7	14	-19.6	-6.2
X-1725	NSCLC	HDM201	212.2	23.1	17	-3.2	-4.5
X-1725	NSCLC	HDM201	148.8	22.8	21	-32.1	-5.8
X-1725	NSCLC	HDM201	136.2	22.7	24	-37.9	-6.2
X-1725	NSCLC	HDM201	155.5	24	28	-29.1	-0.8
X-1725	NSCLC	HDM201	146	24.2	31	-33.4	0
X-1725	NSCLC	HDM201	145.1	24.1	35	-33.8	-0.4
X-1725	NSCLC	HDM201	108.7	24.1	38	-50.4	-0.4
X-1725	NSCLC	HDM201	98.6	23.9	42	-55	-1.2
X-1725	NSCLC	HDM201	69	23.8	45	-68.5	-1.7
X-1725	NSCLC	HDM201	67	23.7	49	-69.4	-2.1
X-1725	NSCLC	HDM201	70.8	22.6	52	-67.7	-6.6
X-1725	NSCLC	HDM201	70.6	21.6	56	-67.8	-10.7
X-1725	NSCLC	HDM201	44.2	20.7	59	-79.8	-14.5
X-1725	NSCLC	HDM201	76.2	19.4	63	-65.2	-19.8
X-1725	NSCLC	HDM201	42.6	16.9	66	-80.6	-30.2
X-1725	NSCLC	cetuximab	202.9	24.8	0	0	0
X-1725	NSCLC	cetuximab	227.9	25.5	3	12.3	2.8
X-1725	NSCLC	cetuximab	215.4	26.1	7	6.2	5.2
X-1725	NSCLC	cetuximab	270.4	25.8	10	33.3	4
X-1725	NSCLC	cetuximab	310.3	26.8	14	52.9	8.1
X-1725	NSCLC	cetuximab	331.9	27.5	17	63.6	10.9
X-1725	NSCLC	cetuximab	428.8	27.3	21	111.3	10.1
X-1725	NSCLC	cetuximab	482.5	27.4	24	137.8	10.5
X-1725	NSCLC	cetuximab	567	28.2	28	179.4	13.7
X-1725	NSCLC	cetuximab	861.4	28	31	324.5	12.9
X-1725	NSCLC	cetuximab	1027.2	26.8	35	406.3	8.1
X-1725	NSCLC	cetuximab	1062.7	28.1	36	423.8	13.3
X-1725	NSCLC	erlotinib	239.3	22.4	0	0	0
X-1725	NSCLC	erlotinib	242	22.6	3	1.1	0.9
X-1725	NSCLC	erlotinib	185.8	20.6	7	-22.4	-8
X-1725	NSCLC	erlotinib	220	19.4	9	-8.1	-13.4
X-1725	NSCLC	erlotinib	175.4	21.8	11	-26.7	-2.7
X-1725	NSCLC	erlotinib	160	17.6	14	-33.1	-21.4
X-1725	NSCLC	erlotinib	191.7	20.3	16	-19.9	-9.4
X-1725	NSCLC	erlotinib	190.6	18.2	17	-20.4	-18.8
X-1725	NSCLC	HSP990	241.5	28	0	0	0
X-1725	NSCLC	HSP990	114.6	25.2	1	-52.5	-10
X-1725	NSCLC	HSP990	163.1	27.3	5	-32.5	-2.5
X-1725	NSCLC	HSP990	147.1	26	8	-39.1	-7.1
X-1725	NSCLC	HSP990	182.3	27.8	12	-24.5	-0.7
X-1725	NSCLC	HSP990	176.7	28.7	19	-26.8	2.5
X-1725	NSCLC	HSP990	191.4	26.9	22	-20.7	-3.9
X-1725	NSCLC	HSP990	172.1	28.5	26	-28.7	1.8
X-1725	NSCLC	HSP990	204.1	25.8	29	-15.5	-7.9
X-1725	NSCLC	HSP990	198.5	28.5	33	-17.8	1.8
X-1725	NSCLC	HSP990	160.2	25	36	-33.7	-10.7
X-1725	NSCLC	HSP990	194.9	28.9	40	-19.3	3.2
X-1725	NSCLC	HSP990	236.2	28.6	43	-2.2	2.1
X-1725	NSCLC	HSP990	152.6	26.4	47	-36.8	-5.7
X-1725	NSCLC	HSP990	105.7	28.2	50	-56.2	0.7
X-1725	NSCLC	INC280	174.6	21.8	0	0	0
X-1725	NSCLC	INC280	200.5	21.3	3	14.8	-2.3
X-1725	NSCLC	INC280	215.8	22.2	7	23.6	1.8
X-1725	NSCLC	INC280	326.1	22.1	10	86.8	1.4
X-1725	NSCLC	INC280	341.4	22.8	14	95.5	4.6
X-1725	NSCLC	INC280	322.7	22.5	17	84.8	3.2
X-1725	NSCLC	INC280	341.8	23.6	21	95.8	8.3
X-1725	NSCLC	INC280	401	23.2	24	129.7	6.4
X-1725	NSCLC	INC280	519.1	24.3	28	197.3	11.5
X-1725	NSCLC	INC280	669	24.8	31	283.2	13.8
X-1725	NSCLC	INC280	773.9	24.7	35	343.2	13.3
X-1725	NSCLC	INC280	1026.3	24.7	36	487.8	13.3
X-1725	NSCLC	LCL161 + paclitaxel	193.6	24.6	0	0	0
X-1725	NSCLC	LCL161 + paclitaxel	186.8	24.2	4	-3.5	-1.6
X-1725	NSCLC	LCL161 + paclitaxel	197.8	24.4	7	2.2	-0.8
X-1725	NSCLC	LCL161 + paclitaxel	225.1	24.5	11	16.3	-0.4
X-1725	NSCLC	LCL161 + paclitaxel	203.9	24.9	14	5.3	1.2
X-1725	NSCLC	LCL161 + paclitaxel	239.5	24.4	18	23.7	-0.8
X-1725	NSCLC	LCL161 + paclitaxel	270.1	25	21	39.5	1.6
X-1725	NSCLC	LCL161 + paclitaxel	200.1	25.8	25	3.4	4.9
X-1725	NSCLC	LCL161 + paclitaxel	238.1	20.9	28	23	-15
X-1725	NSCLC	LCL161 + paclitaxel	293.8	25.3	32	51.8	2.8
X-1725	NSCLC	LCL161 + paclitaxel	276.1	25.5	35	42.6	3.7
X-1725	NSCLC	LCL161 + paclitaxel	365.2	25.5	39	88.6	3.7
X-1725	NSCLC	LCL161 + paclitaxel	342.7	25.9	42	77	5.3
X-1725	NSCLC	LCL161 + paclitaxel	316.1	23.9	46	63.3	-2.8
X-1725	NSCLC	LCL161 + paclitaxel	461.1	25.2	49	138.2	2.4
X-1725	NSCLC	LCL161 + paclitaxel	384.8	23.8	53	98.8	-3.3
X-1725	NSCLC	LCL161 + paclitaxel	365.4	25.4	56	88.7	3.3
X-1725	NSCLC	LCL161 + paclitaxel	382.2	24.4	60	97.4	-0.8
X-1725	NSCLC	LCL161 + paclitaxel	436.8	25.6	63	125.6	4.1
X-1725	NSCLC	LCL161 + paclitaxel	612.3	25.9	67	216.3	5.3
X-1725	NSCLC	LCL161 + paclitaxel	663.5	26.3	71	242.7	6.9
X-1725	NSCLC	LCL161 + paclitaxel	742.8	25.3	74	283.7	2.8
X-1725	NSCLC	LEE011	273.7	25.5	0	0	0
X-1725	NSCLC	LEE011	187.7	25.1	4	-31.4	-1.6
X-1725	NSCLC	LEE011	316	26.4	7	15.5	3.5
X-1725	NSCLC	LEE011	366.1	25.9	11	33.8	1.6
X-1725	NSCLC	LEE011	256.4	26.1	14	-6.3	2.4
X-1725	NSCLC	LEE011	238.7	26.3	18	-12.8	3.1
X-1725	NSCLC	LEE011	351.3	26.8	21	28.4	5.1
X-1725	NSCLC	LEE011	374.1	26.9	25	36.7	5.5
X-1725	NSCLC	LEE011	443.3	27.2	28	62	6.7
X-1725	NSCLC	LEE011	360.9	26.9	32	31.9	5.5
X-1725	NSCLC	LEE011	598.5	26.9	35	118.7	5.5
X-1725	NSCLC	LEE011	338.2	26.7	39	23.6	4.7
X-1725	NSCLC	LEE011	493.1	27.2	42	80.2	6.7
X-1725	NSCLC	LEE011	602	27.9	46	119.9	9.4
X-1725	NSCLC	LEE011	663.2	28	48	142.3	9.8
X-1725	NSCLC	LGH447	272.5	25.4	0	0	0
X-1725	NSCLC	LGH447	220.9	25.4	4	-18.9	0
X-1725	NSCLC	LGH447	317	25.2	7	16.3	-0.8
X-1725	NSCLC	LGH447	254.3	25.5	11	-6.7	0.4
X-1725	NSCLC	LGH447	295.6	25.8	14	8.5	1.6
X-1725	NSCLC	LGH447	263.9	26.3	18	-3.2	3.5
X-1725	NSCLC	LGH447	453.1	26.2	21	66.3	3.1
X-1725	NSCLC	LGH447	641.9	24.9	25	135.6	-2
X-1725	NSCLC	LGH447	616.7	26.8	28	126.3	5.5
X-1725	NSCLC	LGH447	647.3	26.1	32	137.5	2.8
X-1725	NSCLC	LGH447	695.6	26.3	35	155.3	3.5
X-1725	NSCLC	LGH447	825.2	26.1	39	202.8	2.8
X-1725	NSCLC	LGH447	918.9	26.1	40	237.2	2.8
X-1725	NSCLC	LLM871	226.5	28.7	0	0	0
X-1725	NSCLC	LLM871	138.5	28.2	4	-38.9	-1.7
X-1725	NSCLC	LLM871	116.8	28.2	7	-48.4	-1.7
X-1725	NSCLC	LLM871	208.4	27.5	11	-8	-4.2
X-1725	NSCLC	LLM871	257.8	27.8	14	13.8	-3.1
X-1725	NSCLC	LLM871	216.3	29.6	18	-4.5	3.1
X-1725	NSCLC	LLM871	180.1	29.8	21	-20.5	3.8
X-1725	NSCLC	LLM871	295.4	30	25	30.4	4.5
X-1725	NSCLC	LLM871	188.9	29.1	28	-16.6	1.4
X-1725	NSCLC	LLM871	399.3	30	32	76.3	4.5
X-1725	NSCLC	LLM871	324.1	30.1	35	43.1	4.9
X-1725	NSCLC	LLM871	451.4	30.1	39	99.3	4.9
X-1725	NSCLC	LLM871	407.5	29.3	42	79.9	2.1
X-1725	NSCLC	LLM871	342.5	29.2	46	51.2	1.7
X-1725	NSCLC	LLM871	528.6	29.1	49	133.4	1.4
X-1725	NSCLC	LLM871	446.3	29	53	97	1
X-1725	NSCLC	LLM871	477.9	29.1	54	111	1.4
X-1725	NSCLC	binimetinib	224	23.9	0	0	0
X-1725	NSCLC	binimetinib	190.3	24	3	-15	0.4
X-1725	NSCLC	binimetinib	227.2	24.3	7	1.4	1.7
X-1725	NSCLC	binimetinib	144	24.5	10	-35.7	2.5
X-1725	NSCLC	binimetinib	221	25	14	-1.3	4.6
X-1725	NSCLC	binimetinib	190.7	24.6	17	-14.9	2.9
X-1725	NSCLC	binimetinib	179.4	24.3	21	-19.9	1.7
X-1725	NSCLC	binimetinib	314.1	25.3	24	40.2	5.9
X-1725	NSCLC	binimetinib	237.5	25.8	28	6	7.9
X-1725	NSCLC	binimetinib	186.9	25.9	31	-16.6	8.4
X-1725	NSCLC	binimetinib	242.6	25.9	35	8.3	8.4
X-1725	NSCLC	binimetinib	207.7	25.3	38	-7.3	5.9
X-1725	NSCLC	binimetinib	139.1	26	42	-37.9	8.8
X-1725	NSCLC	binimetinib	253	26	45	12.9	8.8
X-1725	NSCLC	binimetinib	337.4	26.4	49	50.6	10.5
X-1725	NSCLC	binimetinib	362.9	25.9	52	62	8.4
X-1725	NSCLC	binimetinib	247.4	26.6	56	10.4	11.3
X-1725	NSCLC	binimetinib	375.9	26.1	59	67.8	9.2
X-1725	NSCLC	binimetinib	317.8	26	63	41.9	8.8
X-1725	NSCLC	binimetinib	300.2	26.3	66	34	10
X-1725	NSCLC	binimetinib	281.2	25.9	70	25.5	8.4
X-1725	NSCLC	binimetinib	463.5	26.1	73	106.9	9.2
X-1725	NSCLC	binimetinib	547.4	25.7	77	144.4	7.5
X-1725	NSCLC	binimetinib	472.8	25.4	80	111.1	6.3
X-1725	NSCLC	binimetinib	284.3	25.7	84	26.9	7.5
X-1725	NSCLC	binimetinib	412.3	25.3	87	84.1	5.9
X-1725	NSCLC	binimetinib	548.6	25.6	91	144.9	7.1
X-1725	NSCLC	binimetinib	623.8	26.3	95	178.5	10
X-1725	NSCLC	binimetinib	720	25.8	98	221.4	7.9
X-1725	NSCLC	paclitaxel	183	26.6	0	0	0
X-1725	NSCLC	paclitaxel	203.7	26	4	11.3	-2.3
X-1725	NSCLC	paclitaxel	188.2	26.3	7	2.8	-1.1
X-1725	NSCLC	paclitaxel	157	25.8	11	-14.2	-3
X-1725	NSCLC	paclitaxel	210.7	25.3	14	15.1	-4.9
X-1725	NSCLC	paclitaxel	249.6	25.5	18	36.4	-4.1
X-1725	NSCLC	paclitaxel	177.3	26.4	21	-3.1	-0.8
X-1725	NSCLC	paclitaxel	249.9	26.1	25	36.6	-1.9
X-1725	NSCLC	paclitaxel	270.3	26.7	28	47.7	0.4
X-1725	NSCLC	paclitaxel	247.7	25.5	32	35.4	-4.1
X-1725	NSCLC	paclitaxel	255.1	25.8	35	39.4	-3
X-1725	NSCLC	paclitaxel	311.6	26.2	39	70.3	-1.5
X-1725	NSCLC	paclitaxel	348.2	26.7	42	90.3	0.4
X-1725	NSCLC	paclitaxel	324.4	26.9	46	77.3	1.1
X-1725	NSCLC	paclitaxel	389.1	27.3	49	112.6	2.6
X-1725	NSCLC	paclitaxel	338.6	27.8	53	85	4.5
X-1725	NSCLC	paclitaxel	385	27	56	110.4	1.5
X-1725	NSCLC	paclitaxel	342	27.7	60	86.9	4.1
X-1725	NSCLC	paclitaxel	515.4	27.8	63	181.6	4.5
X-1725	NSCLC	paclitaxel	653.4	28.1	67	257	5.6
X-1725	NSCLC	paclitaxel	759.7	28.6	71	315.1	7.5
X-1725	NSCLC	paclitaxel	773.8	28.6	74	322.8	7.5
X-1725	NSCLC	untreated	151.1	25.2	0	0	0
X-1725	NSCLC	untreated	301.6	25.8	3	99.6	2.4
X-1725	NSCLC	untreated	273	26.1	7	80.7	3.6
X-1725	NSCLC	untreated	413.7	26.5	10	173.8	5.2
X-1725	NSCLC	untreated	415.1	26.3	14	174.7	4.4
X-1725	NSCLC	untreated	468.2	26.7	17	209.9	6
X-1725	NSCLC	untreated	593.2	26.9	21	292.6	6.7
X-1725	NSCLC	untreated	685.2	27.5	24	353.5	9.1
X-1725	NSCLC	untreated	836.4	27.9	28	453.5	10.7
X-1725	NSCLC	untreated	955.7	27.3	29	532.5	8.3
X-1725	NSCLC	LFW527 + binimetinib	196.26	27.3	0	0	0
X-1725	NSCLC	LFW527 + binimetinib	143.35	27.8	1	-27	1.8
X-1725	NSCLC	LFW527 + binimetinib	149.35	27.9	4	-23.9	2.2
X-1725	NSCLC	LFW527 + binimetinib	398.91	27	8	103.3	-1.1
X-1725	NSCLC	LFW527 + binimetinib	312.03	27.2	22	59	-0.4
X-1725	NSCLC	LFW527 + binimetinib	177.02	27.8	30	-9.8	1.8
X-1725	NSCLC	LFW527 + binimetinib	168.36	29.6	32	-14.2	8.4
X-1725	NSCLC	LFW527 + binimetinib	246.78	28.8	36	25.7	5.5
X-1725	NSCLC	LFW527 + binimetinib	260.77	28.3	39	32.9	3.7
X-1725	NSCLC	LFW527 + binimetinib	360.15	29.1	43	83.5	6.6
X-1725	NSCLC	LFW527 + binimetinib	416.83	28.8	46	112.4	5.5
X-1725	NSCLC	LFW527 + binimetinib	311.07	29.7	49	58.5	8.8
X-1725	NSCLC	LFW527 + binimetinib	356.85	29.3	53	81.8	7.3
X-1725	NSCLC	LFW527 + binimetinib	407.11	29.5	57	107.4	8.1
X-1725	NSCLC	LFW527 + binimetinib	317.14	28.8	60	61.6	5.5
X-1725	NSCLC	LFW527 + binimetinib	397.87	29	64	102.7	6.2
X-1725	NSCLC	LFW527 + binimetinib	391.28	28.2	67	99.4	3.3
X-1725	NSCLC	LFW527 + binimetinib	439.6	28.3	71	124	3.7
X-1725	NSCLC	LFW527 + binimetinib	437.14	29.1	74	122.7	6.6
X-1725	NSCLC	LFW527 + binimetinib	367.19	28.8	78	87.1	5.5
X-1725	NSCLC	LFW527 + binimetinib	454.97	27.8	81	131.8	1.8
X-1725	NSCLC	LFW527 + binimetinib	368.77	27.9	85	87.9	2.2
X-1725	NSCLC	LFW527 + binimetinib	361.18	28.6	88	84	4.8
X-1725	NSCLC	LFW527 + binimetinib	363.9	28	92	85.4	2.6
X-1725	NSCLC	LFW527 + binimetinib	281.08	28.2	95	43.2	3.3
X-1725	NSCLC	LFW527 + binimetinib	388.48	27	99	97.9	-1.1
X-1725	NSCLC	LFW527 + binimetinib	339.96	27.7	102	73.2	1.5
X-1725	NSCLC	LFW527 + binimetinib	391.13	28.6	109	99.3	4.8
X-1725	NSCLC	LFW527 + binimetinib	370.26	28.4	112	88.7	4
X-1725	NSCLC	LFW527 + binimetinib	301.05	29.3	113	53.4	7.3
X-1725	NSCLC	LFW527 + binimetinib	329.47	28.2	120	67.9	3.3
X-1725	NSCLC	LFW527 + binimetinib	298.06	28.3	123	51.9	3.7
X-1725	NSCLC	LFW527 + binimetinib	348.02	27.7	127	77.3	1.5
X-1725	NSCLC	LFW527 + binimetinib	386.02	27.7	130	96.7	1.5
X-1725	NSCLC	LFW527 + binimetinib	400.03	27.3	137	103.8	0
X-1725	NSCLC	LFW527 + binimetinib	367.36	27.2	141	87.2	-0.4
X-1725	NSCLC	LFW527 + binimetinib	332.79	27.3	144	69.6	0
X-1725	NSCLC	LFW527 + binimetinib	357.49	27.6	148	82.2	1.1
X-1725	NSCLC	LFW527 + binimetinib	379.88	27.1	151	93.6	-0.7
X-1725	NSCLC	LFW527 + binimetinib	379.44	27.6	155	93.3	1.1
X-1725	NSCLC	LFW527 + binimetinib	398.21	28	158	102.9	2.6
X-1725	NSCLC	LFW527 + binimetinib	343.54	27.7	162	75	1.5
X-1725	NSCLC	LFW527 + binimetinib	364.52	26.1	165	85.7	-4.4
X-1725	NSCLC	LFW527 + binimetinib	385.71	26.1	169	96.5	-4.4
X-1725	NSCLC	LFW527 + binimetinib	423.63	27.4	172	115.9	0.4
X-1725	NSCLC	LFW527 + binimetinib	397.62	28.5	176	102.6	4.4
X-1725	NSCLC	LFW527 + binimetinib	402.44	28.5	179	105.1	4.4
X-1725	NSCLC	LFW527 + binimetinib	389.05	28.5	183	98.2	4.4
X-1725	NSCLC	LFW527 + binimetinib	368.35	27.3	184	87.7	0
X-1787	NSCLC	BGJ398	276.2	23.8	0	0	0
X-1787	NSCLC	BGJ398	340.5	23.9	3	23.3	0.4
X-1787	NSCLC	BGJ398	463.2	24.7	7	67.7	3.8
X-1787	NSCLC	BGJ398	526.8	24.4	10	90.7	2.5
X-1787	NSCLC	BGJ398	598.2	22.4	14	116.6	-5.9
X-1787	NSCLC	BGJ398	494.8	24.4	17	79.1	2.5
X-1787	NSCLC	BGJ398	528.7	24.3	21	91.4	2.1
X-1787	NSCLC	BGJ398	768.9	25	24	178.4	5
X-1787	NSCLC	BGJ398	805.4	24.4	28	191.6	2.5
X-1787	NSCLC	BGJ398	886.7	24.3	31	221	2.1
X-1787	NSCLC	BKM120 + binimetinib	207.1	21.9	0	0	0
X-1787	NSCLC	BKM120 + binimetinib	248.8	22.2	5	20.1	1.4
X-1787	NSCLC	BKM120 + binimetinib	267.3	23.2	8	29.1	5.9
X-1787	NSCLC	BKM120 + binimetinib	272.5	23.4	12	31.6	6.8
X-1787	NSCLC	BKM120 + binimetinib	252.6	22.2	15	22	1.4
X-1787	NSCLC	BKM120 + binimetinib	233.4	22.6	19	12.7	3.2
X-1787	NSCLC	BKM120 + binimetinib	298.3	23.4	22	44	6.8
X-1787	NSCLC	BKM120 + binimetinib	356.6	24	26	72.2	9.6
X-1787	NSCLC	BKM120 + binimetinib	295	24.1	29	42.4	10
X-1787	NSCLC	BKM120 + binimetinib	354.4	24	33	71.1	9.6
X-1787	NSCLC	BKM120 + binimetinib	335.5	24.4	36	62	11.4
X-1787	NSCLC	BKM120 + binimetinib	366.7	24.8	40	77.1	13.2
X-1787	NSCLC	BKM120 + binimetinib	370.5	25.4	43	78.9	16
X-1787	NSCLC	BKM120 + binimetinib	361	24.9	47	74.3	13.7
X-1787	NSCLC	BKM120 + binimetinib	439.7	24.9	50	112.3	13.7
X-1787	NSCLC	BKM120 + binimetinib	306.8	24.8	54	48.1	13.2
X-1787	NSCLC	BKM120 + binimetinib	343.4	25.2	57	65.8	15.1
X-1787	NSCLC	BKM120 + binimetinib	265.9	24.8	61	28.4	13.2
X-1787	NSCLC	BKM120 + binimetinib	415.6	24.6	64	100.7	12.3
X-1787	NSCLC	BKM120 + binimetinib	510.8	23.6	68	146.6	7.8
X-1787	NSCLC	BKM120 + binimetinib	471.1	24	71	127.5	9.6
X-1787	NSCLC	BKM120 + binimetinib	505.9	24	75	144.3	9.6
X-1787	NSCLC	BKM120 + binimetinib	572.3	24	78	176.3	9.6
X-1787	NSCLC	BKM120 + binimetinib	477.5	24.2	82	130.6	10.5
X-1787	NSCLC	BKM120 + binimetinib	542.9	24.7	85	162.1	12.8
X-1787	NSCLC	BKM120 + binimetinib	598.7	24.9	89	189.1	13.7
X-1787	NSCLC	BKM120 + binimetinib	728	24.9	90	251.5	13.7
X-1787	NSCLC	BKM120	191.3	24.6	0	0	0
X-1787	NSCLC	BKM120	158.2	24.9	3	-17.3	1.2
X-1787	NSCLC	BKM120	317.4	25	7	65.9	1.6
X-1787	NSCLC	BKM120	163.2	25.7	10	-14.7	4.5
X-1787	NSCLC	BKM120	138.6	26.1	14	-27.5	6.1
X-1787	NSCLC	BKM120	250.4	25.7	17	30.9	4.5
X-1787	NSCLC	BKM120	214.4	25	21	12.1	1.6
X-1787	NSCLC	BKM120	139.3	24.9	24	-27.2	1.2
X-1787	NSCLC	BKM120	186	25.9	28	-2.8	5.3
X-1787	NSCLC	BKM120	194.6	23	31	1.7	-6.5
X-1787	NSCLC	BKM120	295.2	25.2	35	54.3	2.4
X-1787	NSCLC	BKM120	279.1	25.4	38	45.9	3.3
X-1787	NSCLC	BKM120	197.3	26	42	3.1	5.7
X-1787	NSCLC	BKM120	397.9	26.4	45	108	7.3
X-1787	NSCLC	BKM120	519.3	27.3	49	171.5	11
X-1787	NSCLC	BKM120	703.6	27.6	52	267.8	12.2
X-1787	NSCLC	BKM120	936.2	27.5	56	389.4	11.8
X-1787	NSCLC	BKM120	2139.2	27.9	58	1018.2	13.4
X-1787	NSCLC	BYL719	238.1	24.3	0	0	0
X-1787	NSCLC	BYL719	407.4	23.7	3	71.1	-2.5
X-1787	NSCLC	BYL719	399.7	23.1	7	67.9	-4.9
X-1787	NSCLC	BYL719	572.1	24.3	10	140.3	0
X-1787	NSCLC	BYL719	362.1	22.6	14	52.1	-7
X-1787	NSCLC	BYL719	322.5	24.4	17	35.4	0.4
X-1787	NSCLC	BYL719	651.4	25.1	21	173.6	3.3
X-1787	NSCLC	BYL719	1092.2	24.6	23	358.7	1.2
X-1787	NSCLC	BYL719 + LJM716	255.5	24.3	0	0	0
X-1787	NSCLC	BYL719 + LJM716	226	23.4	5	-11.5	-3.7
X-1787	NSCLC	BYL719 + LJM716	302.9	23.3	8	18.6	-4.1
X-1787	NSCLC	BYL719 + LJM716	229.2	23.7	12	-10.3	-2.5
X-1787	NSCLC	BYL719 + LJM716	264.4	23.2	15	3.5	-4.5
X-1787	NSCLC	BYL719 + LJM716	386.4	23.8	19	51.2	-2.1
X-1787	NSCLC	BYL719 + LJM716	291.1	24.5	22	13.9	0.8
X-1787	NSCLC	BYL719 + LJM716	563.3	25.2	26	120.5	3.7
X-1787	NSCLC	BYL719 + LJM716	568.5	25.5	29	122.5	4.9
X-1787	NSCLC	BYL719 + LJM716	893.7	25.6	33	249.8	5.3
X-1787	NSCLC	BYL719 + LJM716	959.3	26	36	275.5	7
X-1787	NSCLC	BYL719 + LJM716	1467.5	26.5	40	474.4	9.1
X-1787	NSCLC	BYL719 + LJM716	1351.3	26.3	41	428.9	8.2
X-1787	NSCLC	BYL719 + LGH447	173	22.7	0	0	0
X-1787	NSCLC	BYL719 + LGH447	254.5	21.8	5	47.1	-4
X-1787	NSCLC	BYL719 + LGH447	281.5	23	8	62.7	1.3
X-1787	NSCLC	BYL719 + LGH447	392.5	23.4	12	126.9	3.1
X-1787	NSCLC	BYL719 + LGH447	304.4	23.2	15	76	2.2
X-1787	NSCLC	BYL719 + LGH447	380.2	24.4	19	119.8	7.5
X-1787	NSCLC	BYL719 + LGH447	262.9	24	22	52	5.7
X-1787	NSCLC	BYL719 + LGH447	329.7	23.7	26	90.6	4.4
X-1787	NSCLC	BYL719 + LGH447	304.1	24.6	29	75.8	8.4
X-1787	NSCLC	BYL719 + LGH447	497.9	24	33	187.8	5.7
X-1787	NSCLC	BYL719 + LGH447	622.9	24.3	36	260.1	7
X-1787	NSCLC	BYL719 + LGH447	773.6	24.8	40	347.2	9.3
X-1787	NSCLC	BYL719 + LGH447	1070.5	25.5	43	518.8	12.3
X-1787	NSCLC	BYL719 + LGH447	2040.3	26.1	47	1079.4	15
X-1787	NSCLC	CGM097	286.2	24.6	0	0	0
X-1787	NSCLC	CGM097	377.2	26.5	3	31.8	7.7
X-1787	NSCLC	CGM097	614.1	28.2	7	114.6	14.6
X-1787	NSCLC	CGM097	991.2	29.6	10	246.3	20.3
X-1787	NSCLC	CGM097	997.6	28.6	14	248.6	16.3
X-1787	NSCLC	CGM097	1636.9	30.5	17	471.9	24
X-1787	NSCLC	CKX620	230	25.2	0	0	0
X-1787	NSCLC	CKX620	308.9	24.7	3	34.3	-2
X-1787	NSCLC	CKX620	289.8	26.3	6	26	4.4
X-1787	NSCLC	CKX620	247.6	26.5	10	7.7	5.2
X-1787	NSCLC	CKX620	417	27.2	13	81.3	7.9
X-1787	NSCLC	CKX620	281	27.4	17	22.2	8.7
X-1787	NSCLC	CKX620	291.7	27.2	20	26.8	7.9
X-1787	NSCLC	CKX620	324.9	26.9	24	41.3	6.7
X-1787	NSCLC	CKX620	322	27.9	27	40	10.7
X-1787	NSCLC	CKX620	372.7	27.9	31	62	10.7
X-1787	NSCLC	CKX620	322.7	27.9	34	40.3	10.7
X-1787	NSCLC	CKX620	456	27.8	38	98.3	10.3
X-1787	NSCLC	CKX620	657	28.2	41	185.7	11.9
X-1787	NSCLC	CKX620	903.7	28.5	45	292.9	13.1
X-1787	NSCLC	CKX620	929	28.6	48	303.9	13.5
X-1787	NSCLC	CKX620	1181	28.7	52	413.5	13.9
X-1787	NSCLC	CKX620	1152.5	29.4	53	401.1	16.7
X-1787	NSCLC	CLR457	256.4	22.7	0	0	0
X-1787	NSCLC	CLR457	401.6	22.4	3	56.6	-1.3
X-1787	NSCLC	CLR457	510.6	23.7	6	99.1	4.4
X-1787	NSCLC	CLR457	676.5	23.3	10	163.8	2.6
X-1787	NSCLC	CLR457	814.9	23.6	13	217.8	4
X-1787	NSCLC	CLR457	994.8	25	17	288	10.1
X-1787	NSCLC	CLR457	1085.9	24.7	20	323.5	8.8
X-1787	NSCLC	HDM201	216.7	21.5	0	0	0
X-1787	NSCLC	HDM201	437.9	23.2	3	102.1	7.9
X-1787	NSCLC	HDM201	706.5	23.1	7	226	7.4
X-1787	NSCLC	HDM201	691.7	22.9	10	219.2	6.5
X-1787	NSCLC	HDM201	643	21.5	14	196.7	0
X-1787	NSCLC	HDM201	829.7	21.6	17	282.9	0.5
X-1787	NSCLC	HDM201	724.4	18.5	21	234.3	-14
X-1787	NSCLC	cetuximab	261.1	25.2	0	0	0
X-1787	NSCLC	cetuximab	506.9	26.3	5	94.1	4.4
X-1787	NSCLC	cetuximab	726.2	26.6	8	178.1	5.6
X-1787	NSCLC	cetuximab	1642.2	27	12	529	7.1
X-1787	NSCLC	erlotinib	323.8	23.5	0	0	0
X-1787	NSCLC	erlotinib	581.4	23.5	3	79.6	0
X-1787	NSCLC	erlotinib	805.3	20.2	7	148.7	-14
X-1787	NSCLC	erlotinib	614.7	22.1	10	89.8	-6
X-1787	NSCLC	erlotinib	831.9	NA	14	156.9	-6
X-1787	NSCLC	erlotinib	975.8	26.7	17	201.4	13.6
X-1787	NSCLC	erlotinib	1266.4	28	21	291.1	19.1
X-1787	NSCLC	erlotinib	1053.2	28.6	24	225.3	21.7
X-1787	NSCLC	erlotinib	2600.7	28	28	703.2	19.1
X-1787	NSCLC	erlotinib	2992.1	29.8	30	824.1	26.8
X-1787	NSCLC	HSP990	224.5	22.9	0	0	0
X-1787	NSCLC	HSP990	309.2	23.6	3	37.7	3.1
X-1787	NSCLC	HSP990	529.8	23.7	7	136	3.5
X-1787	NSCLC	HSP990	500	23.4	10	122.7	2.2
X-1787	NSCLC	HSP990	547.3	24.3	14	143.8	6.1
X-1787	NSCLC	HSP990	471.1	23.6	17	109.8	3.1
X-1787	NSCLC	HSP990	701	25.1	21	212.2	9.6
X-1787	NSCLC	HSP990	770.5	23.8	23	243.2	3.9
X-1787	NSCLC	INC280	200.8	26.6	0	0	0
X-1787	NSCLC	INC280	146.4	27.4	3	-27.1	3
X-1787	NSCLC	INC280	176.3	27.6	6	-12.2	3.8
X-1787	NSCLC	INC280	166.6	27.7	10	-17	4.1
X-1787	NSCLC	INC280	154.2	28.7	13	-23.2	7.9
X-1787	NSCLC	INC280	279.7	29.3	17	39.3	10.2
X-1787	NSCLC	INC280	230.6	28.6	20	14.8	7.5
X-1787	NSCLC	INC280	314	28.4	24	56.4	6.8
X-1787	NSCLC	INC280	441.5	28.9	27	119.9	8.6
X-1787	NSCLC	INC280	730.2	30.1	34	263.6	13.2
X-1787	NSCLC	INC280	1212.4	30.9	38	503.8	16.2
X-1787	NSCLC	INC280	1809.7	30.8	39	801.2	15.8
X-1787	NSCLC	LCL161 + paclitaxel	191.9	23.2	0	0	0
X-1787	NSCLC	LCL161 + paclitaxel	297	23.3	2	54.8	0.4
X-1787	NSCLC	LCL161 + paclitaxel	322.5	23.5	6	68.1	1.3
X-1787	NSCLC	LCL161 + paclitaxel	415.7	23.5	9	116.6	1.3
X-1787	NSCLC	LCL161 + paclitaxel	647.7	24.2	13	237.5	4.3
X-1787	NSCLC	LCL161 + paclitaxel	748.6	24.5	16	290.1	5.6
X-1787	NSCLC	LCL161 + paclitaxel	1287	25.2	20	570.7	8.6
X-1787	NSCLC	LCL161 + paclitaxel	1425.6	25.2	22	642.9	8.6
X-1787	NSCLC	LEE011	256.7	22.7	0	0	0
X-1787	NSCLC	LEE011	239.2	23.2	3	-6.8	2.2
X-1787	NSCLC	LEE011	368.7	23.3	7	43.6	2.6
X-1787	NSCLC	LEE011	269.8	24.7	10	5.1	8.8
X-1787	NSCLC	LEE011	295.2	25.1	14	15	10.6
X-1787	NSCLC	LEE011	669.6	25	17	160.8	10.1
X-1787	NSCLC	LEE011	604.5	26.2	21	135.5	15.4
X-1787	NSCLC	LEE011	874	26.2	23	240.5	15.4
X-1787	NSCLC	LGH447	257.2	24.1	0	0	0
X-1787	NSCLC	LGH447	277.3	24.2	3	7.8	0.4
X-1787	NSCLC	LGH447	446.6	22.5	7	73.6	-6.6
X-1787	NSCLC	LGH447	607.7	23	10	136.3	-4.6
X-1787	NSCLC	LGH447	758.5	23.4	14	194.9	-2.9
X-1787	NSCLC	LGH447	871.8	25.2	17	239	4.6
X-1787	NSCLC	LGH447	1263.7	23.7	21	391.3	-1.7
X-1787	NSCLC	LGH447	1936.8	24.5	23	653	1.7
X-1787	NSCLC	LLM871	268.5	23	0	0	0
X-1787	NSCLC	LLM871	219.4	23.7	5	-18.3	3
X-1787	NSCLC	LLM871	275.7	23.3	8	2.7	1.3
X-1787	NSCLC	LLM871	242.3	23.7	12	-9.8	3
X-1787	NSCLC	LLM871	396.6	26.5	28	47.7	15.2
X-1787	NSCLC	LLM871	507.1	25.2	29	88.9	9.6
X-1787	NSCLC	LLM871	518.1	24.8	33	93	7.8
X-1787	NSCLC	LLM871	645.2	26	36	140.3	13
X-1787	NSCLC	LLM871	720.3	26.2	40	168.3	13.9
X-1787	NSCLC	LLM871	947.7	26.1	43	253	13.5
X-1787	NSCLC	LLM871	1340.2	26.5	47	399.1	15.2
X-1787	NSCLC	LLM871	1252.5	26.7	48	366.5	16.1
X-1787	NSCLC	binimetinib	211.1	25	0	0	0
X-1787	NSCLC	binimetinib	165.2	24.3	3	-21.7	-2.8
X-1787	NSCLC	binimetinib	175	24.7	6	-17.1	-1.2
X-1787	NSCLC	binimetinib	182.2	24.8	10	-13.7	-0.8
X-1787	NSCLC	binimetinib	273.9	25.8	13	29.7	3.2
X-1787	NSCLC	binimetinib	357.2	26.8	17	69.2	7.2
X-1787	NSCLC	binimetinib	346.2	26.3	20	64	5.2
X-1787	NSCLC	binimetinib	222.2	25.9	24	5.3	3.6
X-1787	NSCLC	binimetinib	471	25.4	27	123.1	1.6
X-1787	NSCLC	binimetinib	444.3	26.3	31	110.5	5.2
X-1787	NSCLC	binimetinib	473.5	26.5	34	124.3	6
X-1787	NSCLC	binimetinib	536	26.6	38	153.9	6.4
X-1787	NSCLC	binimetinib	632.5	26.8	41	199.6	7.2
X-1787	NSCLC	binimetinib	901.7	27	45	327.1	8
X-1787	NSCLC	binimetinib	843.6	27.5	48	299.6	10
X-1787	NSCLC	binimetinib	980.6	26.9	52	364.5	7.6
X-1787	NSCLC	paclitaxel	257.8	20.3	0	0	0
X-1787	NSCLC	paclitaxel	308.9	21	3	19.8	3.4
X-1787	NSCLC	paclitaxel	524.3	20.8	7	103.4	2.5
X-1787	NSCLC	paclitaxel	480.4	21.1	10	86.3	3.9
X-1787	NSCLC	paclitaxel	378.3	21.2	14	46.7	4.4
X-1787	NSCLC	paclitaxel	459.5	21.4	17	78.2	5.4
X-1787	NSCLC	paclitaxel	383.6	25.5	29	48.8	25.6
X-1787	NSCLC	paclitaxel	345.7	25	31	34.1	23.2
X-1787	NSCLC	paclitaxel	403.4	25.5	35	56.5	25.6
X-1787	NSCLC	paclitaxel	401.7	25.6	38	55.8	26.1
X-1787	NSCLC	paclitaxel	562.6	25.3	42	118.2	24.6
X-1787	NSCLC	paclitaxel	705.5	25.1	45	173.7	23.6
X-1787	NSCLC	paclitaxel	472.2	26	49	83.2	28.1
X-1787	NSCLC	paclitaxel	544.3	25.7	52	111.1	26.6
X-1787	NSCLC	paclitaxel	368.9	26.1	56	43.1	28.6
X-1787	NSCLC	paclitaxel	426.4	25.8	59	65.4	27.1
X-1787	NSCLC	paclitaxel	427.1	26.2	63	65.7	29.1
X-1787	NSCLC	paclitaxel	422.4	25.5	66	63.8	25.6
X-1787	NSCLC	paclitaxel	542.7	25.7	70	110.5	26.6
X-1787	NSCLC	paclitaxel	492.9	25.9	73	91.2	27.6
X-1787	NSCLC	paclitaxel	534.4	25.5	77	107.3	25.6
X-1787	NSCLC	paclitaxel	860.5	25.7	80	233.8	26.6
X-1787	NSCLC	paclitaxel	558.3	26	84	116.6	28.1
X-1787	NSCLC	paclitaxel	1153.4	26.4	91	347.4	30
X-1787	NSCLC	paclitaxel	1517.6	26.2	92	488.7	29.1
X-1787	NSCLC	untreated	259.5	24.5	0	0	0
X-1787	NSCLC	untreated	483.7	23.4	3	86.4	-4.5
X-1787	NSCLC	untreated	487.6	24.2	6	87.9	-1.2
X-1787	NSCLC	untreated	765.2	24.6	10	194.9	0.4
X-1787	NSCLC	untreated	957.4	25.3	13	268.9	3.3
X-1787	NSCLC	untreated	1095.7	26.1	17	322.2	6.5
X-1787	NSCLC	untreated	1874.6	26.8	20	622.4	9.4
X-1787	NSCLC	LFW527 + binimetinib	265.93	24.3	0	0	0
X-1787	NSCLC	LFW527 + binimetinib	398.83	24.1	3	50	-0.8
X-1787	NSCLC	LFW527 + binimetinib	335.99	24.9	6	26.3	2.5
X-1787	NSCLC	LFW527 + binimetinib	426.77	25.1	10	60.5	3.3
X-1787	NSCLC	LFW527 + binimetinib	355.56	26.2	13	33.7	7.8
X-1787	NSCLC	LFW527 + binimetinib	485.01	25.6	17	82.4	5.3
X-1787	NSCLC	LFW527 + binimetinib	336.54	25.2	20	26.6	3.7
X-1787	NSCLC	LFW527 + binimetinib	464.08	26.2	24	74.5	7.8
X-1787	NSCLC	LFW527 + binimetinib	351.96	25.8	27	32.4	6.2
X-1787	NSCLC	LFW527 + binimetinib	412.69	25.5	31	55.2	4.9
X-1787	NSCLC	LFW527 + binimetinib	420.88	25.3	34	58.3	4.1
X-1787	NSCLC	LFW527 + binimetinib	1000.68	25.4	39	276.3	4.5
X-1795	NSCLC	LFW527 + binimetinib	191.13	22.8	0	0	0
X-1795	NSCLC	LFW527 + binimetinib	235.95	23.7	4	23.5	3.9
X-1795	NSCLC	LFW527 + binimetinib	263.02	24	7	37.6	5.3
X-1795	NSCLC	LFW527 + binimetinib	324.32	24.6	11	69.7	7.9
X-1795	NSCLC	LFW527 + binimetinib	405.13	24.9	14	112	9.2
X-1795	NSCLC	LFW527 + binimetinib	553.26	25.7	18	189.5	12.7
X-1795	NSCLC	LFW527 + binimetinib	453.54	25.6	21	137.3	12.3
X-1795	NSCLC	LFW527 + binimetinib	799.7	25.6	25	318.4	12.3
X-1795	NSCLC	LFW527 + binimetinib	916.79	25	26	379.7	9.6
X-1823	NSCLC	BGJ398	155.9	22.9	0	0	0
X-1823	NSCLC	BGJ398	190	22.5	1	21.9	-1.7
X-1823	NSCLC	BGJ398	275	22.1	5	76.4	-3.5
X-1823	NSCLC	BGJ398	356.7	22.6	12	128.8	-1.3
X-1823	NSCLC	BGJ398	409.3	21.2	15	162.5	-7.4
X-1823	NSCLC	BGJ398	493.3	21.4	21	216.4	-6.6
X-1823	NSCLC	BGJ398	570.3	21.9	26	265.8	-4.4
X-1823	NSCLC	BKM120 + binimetinib	141.2	24.8	0	0	0
X-1823	NSCLC	BKM120 + binimetinib	157.8	24.3	1	11.8	-2
X-1823	NSCLC	BKM120 + binimetinib	172.2	25.4	5	22	2.4
X-1823	NSCLC	BKM120 + binimetinib	215.3	26.4	12	52.5	6.5
X-1823	NSCLC	BKM120 + binimetinib	232.9	25.1	15	64.9	1.2
X-1823	NSCLC	BKM120 + binimetinib	309.8	26.5	21	119.4	6.9
X-1823	NSCLC	BKM120 + binimetinib	288.5	26.6	26	104.3	7.3
X-1823	NSCLC	BKM120 + binimetinib	291.5	26.3	34	106.4	6
X-1823	NSCLC	BKM120 + binimetinib	359.8	27.6	40	154.8	11.3
X-1823	NSCLC	BKM120 + binimetinib	613	26.9	47	334.1	8.5
X-1823	NSCLC	BKM120 + binimetinib	634.8	26.3	50	349.6	6
X-1823	NSCLC	BKM120 + binimetinib	598	28.1	53	323.5	13.3
X-1823	NSCLC	BKM120	157.9	27	0	0	0
X-1823	NSCLC	BKM120	195.5	26.3	1	23.8	-2.6
X-1823	NSCLC	BKM120	269.6	27.7	5	70.7	2.6
X-1823	NSCLC	BKM120	767.7	28	12	386.2	3.7
X-1823	NSCLC	BYL719 + LJM716	113.3	21	0	0	0
X-1823	NSCLC	BYL719 + LJM716	142	21.8	1	25.3	3.8
X-1823	NSCLC	BYL719 + LJM716	129.1	21.2	5	13.9	1
X-1823	NSCLC	BYL719 + LJM716	210.7	22.6	12	86	7.6
X-1823	NSCLC	BYL719 + LJM716	235.5	21.6	15	107.9	2.9
X-1823	NSCLC	BYL719 + LJM716	369.4	23.4	21	226	11.4
X-1823	NSCLC	BYL719 + LJM716	422.4	23.2	26	272.8	10.5
X-1823	NSCLC	BYL719 + LJM716	504.6	23.1	34	345.4	10
X-1823	NSCLC	BYL719 + LJM716	961.2	23.4	40	748.4	11.4
X-1823	NSCLC	BYL719	137.4	23.3	0	0	0
X-1823	NSCLC	BYL719	247.2	22.1	1	79.9	-5.2
X-1823	NSCLC	BYL719	242.3	22.3	5	76.3	-4.3
X-1823	NSCLC	BYL719	386.6	22.5	12	181.4	-3.4
X-1823	NSCLC	BYL719	356.3	21.1	15	159.3	-9.4
X-1823	NSCLC	BYL719	246.3	21.6	21	79.3	-7.3
X-1823	NSCLC	BYL719	125.5	20.8	26	-8.7	-10.7
X-1823	NSCLC	BYL719	86.5	19.7	34	-37	-15.5
X-1823	NSCLC	BYL719	41.1	19.3	40	-70.1	-17.2
X-1823	NSCLC	BYL719 + LGH447	124.1	24.4	0	0	0
X-1823	NSCLC	BYL719 + LGH447	136	23.6	1	9.6	-3.3
X-1823	NSCLC	BYL719 + LGH447	174.3	20.7	5	40.5	-15.2
X-1823	NSCLC	BYL719 + LGH447	219.1	19	12	76.6	-22.1
X-1823	NSCLC	CGM097	142.5	24.2	0	0	0
X-1823	NSCLC	CGM097	175.3	24.1	2	23	-0.4
X-1823	NSCLC	CGM097	218.9	23.8	4	53.6	-1.7
X-1823	NSCLC	CGM097	441.8	24.4	8	210	0.8
X-1823	NSCLC	CGM097	628.8	23.8	15	341.3	-1.7
X-1823	NSCLC	CKX620	156.2	25.8	0	0	0
X-1823	NSCLC	CKX620	225.3	26.8	5	44.2	3.9
X-1823	NSCLC	CKX620	311.2	26.8	7	99.2	3.9
X-1823	NSCLC	CKX620	325	27.3	11	108.1	5.8
X-1823	NSCLC	CKX620	370.7	25.9	18	137.3	0.4
X-1823	NSCLC	CKX620	395.3	25.6	21	153.1	-0.8
X-1823	NSCLC	CKX620	301.1	23.4	27	92.8	-9.3
X-1823	NSCLC	CKX620	352.7	24.2	32	125.8	-6.2
X-1823	NSCLC	CKX620	573.4	24.1	40	267.1	-6.6
X-1823	NSCLC	CKX620	568.4	21	46	263.9	-18.6
X-1823	NSCLC	CLR457	162.9	26.1	0	0	0
X-1823	NSCLC	CLR457	187	25.3	2	14.8	-3.1
X-1823	NSCLC	CLR457	168.5	25.5	4	3.4	-2.3
X-1823	NSCLC	CLR457	219.7	26.3	8	34.9	0.8
X-1823	NSCLC	CLR457	360.9	26.5	15	121.5	1.5
X-1823	NSCLC	CLR457	370.6	26.4	18	127.5	1.1
X-1823	NSCLC	CLR457	570.8	27	24	250.4	3.4
X-1823	NSCLC	CLR457	600.1	27.1	29	268.4	3.8
X-1823	NSCLC	CLR457	819.6	27.3	37	403.1	4.6
X-1823	NSCLC	HDM201	150.8	24.1	0	0	0
X-1823	NSCLC	HDM201	454.1	23.4	6	201.1	-2.9
X-1823	NSCLC	HDM201	364.5	22.5	7	141.7	-6.6
X-1823	NSCLC	HDM201	445.3	22.6	9	195.3	-6.2
X-1823	NSCLC	HDM201	466.3	23.1	13	209.2	-4.1
X-1823	NSCLC	HDM201	640	23.1	20	324.4	-4.1
X-1823	NSCLC	cetuximab	183	25.4	0	0	0
X-1823	NSCLC	cetuximab	192.9	25.5	2	5.4	0.4
X-1823	NSCLC	cetuximab	224.8	25.3	4	22.8	-0.4
X-1823	NSCLC	cetuximab	263.1	26.6	8	43.8	4.7
X-1823	NSCLC	cetuximab	414.2	27.1	15	126.3	6.7
X-1823	NSCLC	cetuximab	421	27.2	18	130.1	7.1
X-1823	NSCLC	cetuximab	670.3	27.4	24	266.3	7.9
X-1823	NSCLC	cetuximab	1080.5	27.3	29	490.4	7.5
X-1823	NSCLC	erlotinib	178.4	24.4	0	0	0
X-1823	NSCLC	erlotinib	209.5	24	4	17.4	-1.6
X-1823	NSCLC	erlotinib	340.9	21.4	11	91.1	-12.3
X-1823	NSCLC	erlotinib	531.5	21.2	14	197.9	-13.1
X-1823	NSCLC	erlotinib	1109.6	20.5	20	522	-16
X-1823	NSCLC	erlotinib	2317.5	24.2	25	1199	-0.8
X-1823	NSCLC	HSP990	215.6	26	0	0	0
X-1823	NSCLC	HSP990	271.5	26.7	5	25.9	2.7
X-1823	NSCLC	HSP990	389.4	27.4	7	80.6	5.4
X-1823	NSCLC	HSP990	546.3	27.3	11	153.4	5
X-1823	NSCLC	HSP990	636.7	21.2	18	195.3	-18.5
X-1823	NSCLC	INC280	147.4	24.4	0	0	0
X-1823	NSCLC	INC280	180.5	23.2	2	22.5	-4.9
X-1823	NSCLC	INC280	263.8	23.3	4	79	-4.5
X-1823	NSCLC	INC280	374.6	23.5	8	154.1	-3.7
X-1823	NSCLC	INC280	762.2	24.6	15	417.1	0.8
X-1823	NSCLC	LCL161 + paclitaxel	243.6	26	0	0	0
X-1823	NSCLC	LCL161 + paclitaxel	440.4	24.7	5	80.8	-5
X-1823	NSCLC	LCL161 + paclitaxel	567.6	24.6	7	133	-5.4
X-1823	NSCLC	LCL161 + paclitaxel	983.2	25.3	11	303.6	-2.7
X-1823	NSCLC	LEE011	156.5	24.1	0	0	0
X-1823	NSCLC	LEE011	154	24.6	2	-1.6	2.1
X-1823	NSCLC	LEE011	259.2	26.8	7	65.6	11.2
X-1823	NSCLC	LEE011	265.5	26.8	9	69.6	11.2
X-1823	NSCLC	LEE011	321.4	27	13	105.4	12
X-1823	NSCLC	LEE011	294.7	26.7	20	88.3	10.8
X-1823	NSCLC	LEE011	338.3	26.7	23	116.2	10.8
X-1823	NSCLC	LEE011	334.5	27.7	29	113.7	14.9
X-1823	NSCLC	LEE011	453.2	27.9	34	189.6	15.8
X-1823	NSCLC	LEE011	434.5	28.2	42	177.6	17
X-1823	NSCLC	LEE011	560.6	28.4	48	258.2	17.8
X-1823	NSCLC	LEE011	834.2	28.6	55	433	18.7
X-1823	NSCLC	LGH447	201.3	24.3	0	0	0
X-1823	NSCLC	LGH447	322.1	25.2	5	60	3.7
X-1823	NSCLC	LGH447	412.2	24.5	7	104.8	0.8
X-1823	NSCLC	LGH447	640.5	25.2	11	218.2	3.7
X-1823	NSCLC	LGH447	1232.1	24.4	18	512.1	0.4
X-1823	NSCLC	LLM871	188.2	25.7	0	0	0
X-1823	NSCLC	LLM871	387.2	26.4	7	105.7	2.7
X-1823	NSCLC	LLM871	476.9	26.4	11	153.4	2.7
X-1823	NSCLC	LLM871	956.7	25.6	18	408.3	-0.4
X-1823	NSCLC	binimetinib	288.2	24.2	0	0	0
X-1823	NSCLC	binimetinib	295.4	24.3	2	2.5	0.4
X-1823	NSCLC	binimetinib	495.8	24.9	7	72	2.9
X-1823	NSCLC	binimetinib	595.6	24.7	9	106.7	2.1
X-1823	NSCLC	binimetinib	900.3	25.5	13	212.4	5.4
X-1823	NSCLC	paclitaxel	180.7	26.4	0	0	0
X-1823	NSCLC	paclitaxel	288	26.3	5	59.4	-0.4
X-1823	NSCLC	paclitaxel	324.4	26.8	7	79.5	1.5
X-1823	NSCLC	paclitaxel	354.7	27	11	96.3	2.3
X-1823	NSCLC	paclitaxel	650.9	28.5	18	260.2	8
X-1823	NSCLC	untreated	142	22.8	0	0	0
X-1823	NSCLC	untreated	218.7	23.3	2	54	2.2
X-1823	NSCLC	untreated	265.9	24.2	7	87.3	6.1
X-1823	NSCLC	untreated	371.2	23.7	9	161.4	3.9
X-1823	NSCLC	untreated	552.7	25.2	13	289.2	10.5
X-1823	NSCLC	untreated	331.1	25.8	20	133.2	13.2
X-1823	NSCLC	untreated	0	26.9	42	-100	18
X-1823	NSCLC	untreated	0	28.1	48	-100	23.2
X-1823	NSCLC	untreated	0	27.1	55	-100	18.9
X-1823	NSCLC	untreated	0	26.6	58	-100	16.7
X-1823	NSCLC	untreated	0	27.1	61	-100	18.9
X-1823	NSCLC	untreated	0	28.3	69	-100	24.1
X-1823	NSCLC	untreated	0	28.4	72	-100	24.6
X-1823	NSCLC	untreated	0	29.7	76	-100	30.3
X-1823	NSCLC	untreated	0	29.2	79	-100	28.1
X-1823	NSCLC	untreated	0	35	84	-100	53.5
X-1823	NSCLC	untreated	0	28.5	91	-100	25
X-1823	NSCLC	untreated	0	28.5	97	-100	25
X-1823	NSCLC	untreated	0	28.6	100	-100	25.4
X-1823	NSCLC	LFW527 + binimetinib	241.5	25.7	0	0	0
X-1823	NSCLC	LFW527 + binimetinib	305.28	25	2	26.4	-2.7
X-1823	NSCLC	LFW527 + binimetinib	266.42	25	6	10.3	-2.7
X-1823	NSCLC	LFW527 + binimetinib	312.04	25.1	9	29.2	-2.3
X-1823	NSCLC	LFW527 + binimetinib	399.56	25.1	13	65.4	-2.3
X-1823	NSCLC	LFW527 + binimetinib	345.91	25.1	16	43.2	-2.3
X-1823	NSCLC	LFW527 + binimetinib	518.69	23.8	20	114.8	-7.4
X-1823	NSCLC	LFW527 + binimetinib	563.78	23.5	23	133.4	-8.6
X-1823	NSCLC	LFW527 + binimetinib	504.52	24.1	28	108.9	-6.2
X-1823	NSCLC	LFW527 + binimetinib	495.36	23.9	31	105.1	-7
X-1823	NSCLC	LFW527 + binimetinib	788.67	23	34	226.6	-10.5
X-1823	NSCLC	LFW527 + binimetinib	552.41	22.5	37	128.7	-12.5
X-1823	NSCLC	LFW527 + binimetinib	809.96	22.2	41	235.4	-13.6
X-1823	NSCLC	LFW527 + binimetinib	1034.62	NA	45	328.4	-13.6
X-1828	BRCA	BGJ398	214.2	29.7	0	0	0
X-1828	BRCA	BGJ398	244.5	29.8	2	14.1	0.3
X-1828	BRCA	BGJ398	251.3	28.6	6	17.3	-3.7
X-1828	BRCA	BGJ398	246.7	29.3	9	15.2	-1.3
X-1828	BRCA	BGJ398	251.1	29.6	12	17.2	-0.3
X-1828	BRCA	BGJ398	231.4	29.8	16	8	0.3
X-1828	BRCA	BGJ398	230	29.1	19	7.4	-2
X-1828	BRCA	BGJ398	222.2	28.6	22	3.7	-3.7
X-1828	BRCA	BGJ398	226.9	29.9	26	5.9	0.7
X-1828	BRCA	BGJ398	232.2	27.7	31	8.4	-6.7
X-1828	BRCA	BGJ398	238.8	26.8	33	11.5	-9.8
X-1828	BRCA	BGJ398	262.7	27.3	37	22.6	-8.1
X-1828	BRCA	BGJ398	320.6	26.7	40	49.7	-10.1
X-1828	BRCA	BGJ398	419.4	27	44	95.8	-9.1
X-1828	BRCA	BGJ398	466.7	27.7	47	117.9	-6.7
X-1828	BRCA	BGJ398	484.8	27.4	51	126.3	-7.7
X-1828	BRCA	BGJ398	556	26.9	54	159.6	-9.4
X-1828	BRCA	BGJ398	664	26.5	58	210	-10.8
X-1828	BRCA	BGJ398	736.4	23.6	61	243.8	-20.5
X-1828	BRCA	BGJ398	909	25.8	65	324.4	-13.1
X-1828	BRCA	BKM120	288.7	27	0	0	0
X-1828	BRCA	BKM120	292.7	28.5	3	1.4	5.6
X-1828	BRCA	BKM120	285.3	27.5	7	-1.2	1.9
X-1828	BRCA	BKM120	281.6	28.3	10	-2.5	4.8
X-1828	BRCA	BKM120	286	28	14	-0.9	3.7
X-1828	BRCA	BKM120	288.9	27.6	17	0.1	2.2
X-1828	BRCA	BKM120	298.7	28.6	21	3.5	5.9
X-1828	BRCA	BKM120	322.6	27.5	24	11.7	1.9
X-1828	BRCA	BKM120	341	28	28	18.1	3.7
X-1828	BRCA	BKM120	363.5	27.7	31	25.9	2.6
X-1828	BRCA	BKM120	427.6	27.9	35	48.1	3.3
X-1828	BRCA	BKM120	433.8	28.9	38	50.3	7
X-1828	BRCA	BKM120	438.9	27.4	41	52	1.5
X-1828	BRCA	BKM120	450.9	27.8	45	56.2	3
X-1828	BRCA	BKM120	458.6	25.9	49	58.9	-4.1
X-1828	BRCA	BKM120	366.9	20.3	52	27.1	-24.8
X-1828	BRCA	BYL719 + LJM716	204.6	29.3	0	0	0
X-1828	BRCA	BYL719 + LJM716	199.6	27.5	3	-2.4	-6.1
X-1828	BRCA	BYL719 + LJM716	182	26.2	7	-11	-10.6
X-1828	BRCA	BYL719 + LJM716	171.3	26.6	10	-16.3	-9.2
X-1828	BRCA	BYL719 + LJM716	183.9	26.5	14	-10.1	-9.6
X-1828	BRCA	BYL719 + LJM716	189.2	26.4	17	-7.5	-9.9
X-1828	BRCA	BYL719 + LJM716	189.7	26.2	21	-7.3	-10.6
X-1828	BRCA	BYL719 + LJM716	192.9	25.8	24	-5.7	-11.9
X-1828	BRCA	BYL719 + LJM716	200.6	24.6	28	-2	-16
X-1828	BRCA	BYL719 + LJM716	221.4	25.7	31	8.2	-12.3
X-1828	BRCA	BYL719 + LJM716	333.7	26.6	35	63.1	-9.2
X-1828	BRCA	BYL719 + LJM716	374	27.6	38	82.8	-5.8
X-1828	BRCA	BYL719 + LJM716	420.9	28.4	41	105.7	-3.1
X-1828	BRCA	BYL719 + LJM716	441.8	26.8	45	115.9	-8.5
X-1828	BRCA	BYL719 + LJM716	445	25.1	49	117.5	-14.3
X-1828	BRCA	BYL719 + LJM716	467	25.5	52	128.3	-13
X-1828	BRCA	BYL719 + LJM716	468	24	56	128.7	-18.1
X-1828	BRCA	BYL719 + LJM716	464.9	26.2	59	127.2	-10.6
X-1828	BRCA	BYL719 + LJM716	448.1	26.2	63	119	-10.6
X-1828	BRCA	BYL719 + LJM716	402.8	28	66	96.9	-4.4
X-1828	BRCA	BYL719 + LJM716	270.4	27.7	70	32.2	-5.5
X-1828	BRCA	BYL719 + LJM716	291.9	28.2	73	42.7	-3.8
X-1828	BRCA	BYL719 + LJM716	305.4	28.3	81	49.3	-3.4
X-1828	BRCA	BYL719 + LJM716	333.4	27.3	84	63	-6.8
X-1828	BRCA	BYL719 + LJM716	348.5	28.8	88	70.3	-1.7
X-1828	BRCA	BYL719 + LJM716	364.7	29.3	91	78.3	0
X-1828	BRCA	BYL719 + LJM716	375	28	94	83.3	-4.4
X-1828	BRCA	BYL719 + LJM716	391.8	26.7	98	91.5	-8.9
X-1828	BRCA	BYL719 + LJM716	373	24.9	101	82.3	-15
X-1828	BRCA	BYL719 + LEE011	210.2	32.7	0	0	0
X-1828	BRCA	BYL719 + LEE011	231.4	29.2	8	10.1	-10.7
X-1828	BRCA	BYL719 + LEE011	245.9	25.3	11	17	-22.6
X-1828	BRCA	BYL719 + LEE011	250.7	26.1	15	19.3	-20.2
X-1828	BRCA	BYL719 + LEE011	247.4	26.3	18	17.7	-19.6
X-1828	BRCA	BYL719 + LEE011	258.4	27.8	21	22.9	-15
X-1828	BRCA	BYL719 + LEE011	264.6	31	25	25.9	-5.2
X-1828	BRCA	BYL719 + LEE011	272.2	33.2	28	29.5	1.5
X-1828	BRCA	BYL719 + LEE011	275.1	33.4	31	30.9	2.1
X-1828	BRCA	BYL719 + LEE011	244.8	31.6	35	16.5	-3.4
X-1828	BRCA	BYL719 + LEE011	223.1	24.6	40	6.1	-24.8
X-1828	BRCA	BYL719 + LEE011	165.5	26.1	42	-21.3	-20.2
X-1828	BRCA	BYL719 + LEE011	173.3	24.2	46	-17.6	-26
X-1828	BRCA	BYL719	247	28.6	0	0	0
X-1828	BRCA	BYL719	452.1	27.9	3	83	-2.4
X-1828	BRCA	BYL719	571.5	27.9	7	131.4	-2.4
X-1828	BRCA	BYL719	603.7	27.6	10	144.4	-3.5
X-1828	BRCA	BYL719	543.2	25.3	13	119.9	-11.5
X-1828	BRCA	BYL719	374.1	22.2	17	51.5	-22.4
X-1828	BRCA	BYL719	448.8	22.6	20	81.7	-21
X-1828	BRCA	BYL719	513.1	24.6	25	107.7	-14
X-1828	BRCA	BYL719	590.5	23	28	139.1	-19.6
X-1828	BRCA	BYL719	790.4	23.2	32	220	-18.9
X-1828	BRCA	CGM097	211.8	32.4	0	0	0
X-1828	BRCA	CGM097	236.8	33.2	3	11.8	2.5
X-1828	BRCA	CGM097	260.8	32.3	7	23.1	-0.3
X-1828	BRCA	CGM097	328	33.5	10	54.9	3.4
X-1828	BRCA	CGM097	363.3	34.4	14	71.5	6.2
X-1828	BRCA	CGM097	426.3	34.4	17	101.3	6.2
X-1828	BRCA	CGM097	440.2	35	20	107.8	8
X-1828	BRCA	CGM097	543.6	35.2	24	156.7	8.6
X-1828	BRCA	CGM097	545.3	34.8	28	157.5	7.4
X-1828	BRCA	CGM097	602	33.9	31	184.2	4.6
X-1828	BRCA	CGM097	671	33.3	35	216.8	2.8
X-1828	BRCA	CGM097	676.6	33.1	38	219.5	2.2
X-1828	BRCA	CGM097	710.2	33.9	42	235.3	4.6
X-1828	BRCA	CGM097	721.6	35.5	45	240.7	9.6
X-1828	BRCA	CGM097	751.3	33.1	49	254.7	2.2
X-1828	BRCA	CLR457	221.3	25.4	0	0	0
X-1828	BRCA	CLR457	173.6	26.7	3	-21.6	5.1
X-1828	BRCA	CLR457	177	27.1	6	-20	6.7
X-1828	BRCA	CLR457	135.6	26.5	10	-38.7	4.3
X-1828	BRCA	CLR457	104	27	13	-53	6.3
X-1828	BRCA	CLR457	109.3	27.4	18	-50.6	7.9
X-1828	BRCA	CLR457	106.2	27.2	21	-52	7.1
X-1828	BRCA	CLR457	103.4	27.8	25	-53.3	9.4
X-1828	BRCA	CLR457	103.8	27.4	28	-53.1	7.9
X-1828	BRCA	CLR457	103.4	27.2	32	-53.3	7.1
X-1828	BRCA	CLR457	104.1	26.8	35	-53	5.5
X-1828	BRCA	CLR457	104.8	27	39	-52.6	6.3
X-1828	BRCA	CLR457	104.5	26.2	42	-52.8	3.1
X-1828	BRCA	CLR457	108	26.7	46	-51.2	5.1
X-1828	BRCA	CLR457	109.9	27.6	49	-50.3	8.7
X-1828	BRCA	CLR457	108.6	27.4	53	-50.9	7.9
X-1828	BRCA	CLR457	116.7	27.4	56	-47.3	7.9
X-1828	BRCA	CLR457	126.2	27	59	-43	6.3
X-1828	BRCA	CLR457	133.7	27.5	63	-39.6	8.3
X-1828	BRCA	CLR457	151.1	26.7	67	-31.7	5.1
X-1828	BRCA	CLR457	166.4	24.7	70	-24.8	-2.8
X-1828	BRCA	CLR457	261.2	22.1	74	18	-13
X-1828	BRCA	CLR457	120.1	23.1	77	-45.7	-9.1
X-1828	BRCA	CLR457	0	23	81	-100	-9.4
X-1828	BRCA	HDM201	254.4	26.2	0	0	0
X-1828	BRCA	HDM201	300.3	26.1	3	18	-0.4
X-1828	BRCA	HDM201	304.5	25.6	8	19.7	-2.3
X-1828	BRCA	HDM201	356.8	26.3	11	40.3	0.4
X-1828	BRCA	HDM201	371.9	27.2	15	46.2	3.8
X-1828	BRCA	HDM201	410.9	26.9	18	61.5	2.7
X-1828	BRCA	HDM201	440.8	27	22	73.3	3.1
X-1828	BRCA	HDM201	498.5	26.9	25	96	2.7
X-1828	BRCA	HDM201	615.8	27.4	29	142.1	4.6
X-1828	BRCA	HDM201	689.8	26.6	32	171.1	1.5
X-1828	BRCA	HDM201	889.2	26.7	36	249.5	1.9
X-1828	BRCA	HDM201	991.2	26.5	39	289.6	1.1
X-1828	BRCA	HDM201	1340	25.5	43	426.7	-2.7
X-1828	BRCA	INC424	239.5	27.1	0	0	0
X-1828	BRCA	INC424	293	25.8	3	22.3	-4.8
X-1828	BRCA	INC424	357.2	26.5	7	49.1	-2.2
X-1828	BRCA	INC424	527.7	26.5	10	120.3	-2.2
X-1828	BRCA	INC424	548.1	27.4	13	128.9	1.1
X-1828	BRCA	INC424	726.9	26.6	17	203.5	-1.8
X-1828	BRCA	INC424	845.6	26.6	20	253.1	-1.8
X-1828	BRCA	INC424	835.1	26.8	25	248.7	-1.1
X-1828	BRCA	INC424	867.3	27	28	262.1	-0.4
X-1828	BRCA	INC424	895.3	26.2	32	273.8	-3.3
X-1828	BRCA	LEE011 + everolimus	226.3	30.3	0	0	0
X-1828	BRCA	LEE011 + everolimus	239.2	30.3	4	5.7	0
X-1828	BRCA	LEE011 + everolimus	256.7	28.8	7	13.4	-5
X-1828	BRCA	LEE011 + everolimus	296.5	28.1	11	31	-7.3
X-1828	BRCA	LEE011 + everolimus	315.7	28	14	39.5	-7.6
X-1828	BRCA	LEE011 + everolimus	327.6	26.8	18	44.8	-11.6
X-1828	BRCA	LEE011 + everolimus	351.2	26.9	21	55.2	-11.2
X-1828	BRCA	LEE011 + everolimus	371.2	27.3	29	64	-9.9
X-1828	BRCA	LEE011 + everolimus	384	26.4	32	69.7	-12.9
X-1828	BRCA	LEE011 + everolimus	326.8	25.9	36	44.4	-14.5
X-1828	BRCA	LEE011 + everolimus	336.2	25.9	39	48.6	-14.5
X-1828	BRCA	LEE011 + everolimus	309.8	22.8	42	36.9	-24.8
X-1828	BRCA	LEE011	237.2	32.2	0	0	0
X-1828	BRCA	LEE011	244.5	32.2	3	3.1	0
X-1828	BRCA	LEE011	262.5	31.5	7	10.7	-2.2
X-1828	BRCA	LEE011	274.6	31.4	11	15.8	-2.5
X-1828	BRCA	LEE011	306.9	31.1	14	29.4	-3.4
X-1828	BRCA	LEE011	329.8	32.7	18	39	1.6
X-1828	BRCA	LEE011	338.9	33.3	21	42.9	3.4
X-1828	BRCA	LEE011	345.8	33.1	25	45.8	2.8
X-1828	BRCA	LEE011	371.5	34.4	28	56.6	6.8
X-1828	BRCA	LEE011	416.1	33.7	32	75.4	4.7
X-1828	BRCA	LEE011	446.9	33.5	35	88.4	4
X-1828	BRCA	LEE011	512.9	33.5	43	116.2	4
X-1828	BRCA	LEE011	546.4	33.7	46	130.4	4.7
X-1828	BRCA	LEE011	585.5	33.7	50	146.8	4.7
X-1828	BRCA	LEE011	682	34.8	53	187.5	8.1
X-1828	BRCA	LEE011	687.5	33.8	56	189.8	5
X-1828	BRCA	LEE011	712.6	33.5	60	200.4	4
X-1828	BRCA	LFA102	205.4	27.7	0	0	0
X-1828	BRCA	LFA102	224.9	27	3	9.5	-2.5
X-1828	BRCA	LFA102	272.3	27.1	7	32.6	-2.2
X-1828	BRCA	LFA102	289.1	27.2	10	40.7	-1.8
X-1828	BRCA	LFA102	295.8	28.3	14	44	2.2
X-1828	BRCA	LFA102	358.7	27.5	17	74.6	-0.7
X-1828	BRCA	LFA102	404.6	27.9	21	97	0.7
X-1828	BRCA	LFA102	447.4	27.4	24	117.8	-1.1
X-1828	BRCA	LFA102	487.3	27.5	28	137.2	-0.7
X-1828	BRCA	LJM716	202.9	28.4	0	0	0
X-1828	BRCA	LJM716	205.2	26.8	3	1.1	-5.6
X-1828	BRCA	LJM716	207.5	25.5	7	2.3	-10.2
X-1828	BRCA	LJM716	214.9	25.3	10	5.9	-10.9
X-1828	BRCA	LJM716 + trastuzumab	247.9	32.1	0	0	0
X-1828	BRCA	LJM716 + trastuzumab	251.8	30.3	3	1.6	-5.6
X-1828	BRCA	LJM716 + trastuzumab	273.8	28.6	6	10.4	-10.9
X-1828	BRCA	LJM716 + trastuzumab	282.2	31	15	13.8	-3.4
X-1828	BRCA	LJM716 + trastuzumab	319.4	30.9	17	28.8	-3.7
X-1828	BRCA	LJM716 + trastuzumab	350.2	31.8	21	41.3	-0.9
X-1828	BRCA	LJM716 + trastuzumab	390.9	31.6	24	57.7	-1.6
X-1828	BRCA	LJM716 + trastuzumab	422.8	30.9	28	70.6	-3.7
X-1828	BRCA	LJM716 + trastuzumab	449.4	31.1	31	81.3	-3.1
X-1828	BRCA	LJM716 + trastuzumab	462.3	32.2	35	86.5	0.3
X-1828	BRCA	LJM716 + trastuzumab	480.3	31.8	38	93.7	-0.9
X-1828	BRCA	LJM716 + trastuzumab	474.7	32.3	42	91.5	0.6
X-1828	BRCA	LJM716 + trastuzumab	481.4	31.4	45	94.2	-2.2
X-1828	BRCA	LJM716 + trastuzumab	487.8	31.8	49	96.8	-0.9
X-1828	BRCA	LJM716 + trastuzumab	496	31.1	52	100.1	-3.1
X-1828	BRCA	LJM716 + trastuzumab	494.3	27.4	56	99.4	-14.6
X-1828	BRCA	LJM716 + trastuzumab	500.8	28	59	102	-12.8
X-1828	BRCA	LJM716 + trastuzumab	628.9	31.2	64	153.7	-2.8
X-1828	BRCA	LJM716 + trastuzumab	940	31	66	279.2	-3.4
X-1828	BRCA	LJM716 + trastuzumab	1066.4	31.6	70	330.2	-1.6
X-1828	BRCA	LKA136	192.6	26.4	0	0	0
X-1828	BRCA	LKA136	215.9	28.4	3	12.1	7.6
X-1828	BRCA	LKA136	275.7	28.1	6	43.1	6.4
X-1828	BRCA	LKA136	331.9	27.6	10	72.3	4.5
X-1828	BRCA	LKA136	344.8	28.5	13	79	8
X-1828	BRCA	LKA136	365.9	28.1	18	90	6.4
X-1828	BRCA	LKA136	388.2	28.8	21	101.6	9.1
X-1828	BRCA	LKA136	451.3	28.9	25	134.3	9.5
X-1828	BRCA	LKA136	519.6	28.9	28	169.8	9.5
X-1828	BRCA	LKA136	588.4	27.9	32	205.5	5.7
X-1828	BRCA	LKA136	607.4	28.4	35	215.4	7.6
X-1828	BRCA	LKA136	650.2	27.6	39	237.6	4.5
X-1828	BRCA	LKA136	662.2	26.4	42	243.8	0
X-1828	BRCA	LKA136	639.8	25.4	46	232.2	-3.8
X-1828	BRCA	LKA136	625	26.1	49	224.5	-1.1
X-1828	BRCA	LKA136	641.5	23.5	53	233.1	-11
X-1828	BRCA	LLM871	246.1	28.4	0	0	0
X-1828	BRCA	LLM871	277.2	27.8	2	12.6	-2.1
X-1828	BRCA	LLM871	288.6	27.5	6	17.3	-3.2
X-1828	BRCA	LLM871	304.2	28.2	9	23.6	-0.7
X-1828	BRCA	LLM871	317.4	27.3	12	29	-3.9
X-1828	BRCA	LLM871	339.5	27.5	16	38	-3.2
X-1828	BRCA	LLM871	341.9	27.4	20	38.9	-3.5
X-1828	BRCA	LLM871	359	27	23	45.9	-4.9
X-1828	BRCA	LLM871	359.6	26.8	27	46.1	-5.6
X-1828	BRCA	LLM871	366.4	26.8	29	48.9	-5.6
X-1828	BRCA	LLM871	362.7	26.3	33	47.4	-7.4
X-1828	BRCA	LLM871	357.4	26.8	37	45.2	-5.6
X-1828	BRCA	LLM871	330.5	27.7	41	34.3	-2.5
X-1828	BRCA	LLM871	356.2	26.7	44	44.7	-6
X-1828	BRCA	LLM871	372.6	26.5	48	51.4	-6.7
X-1828	BRCA	LLM871	379.2	26.4	51	54.1	-7
X-1828	BRCA	LLM871	408.1	27.1	55	65.8	-4.6
X-1828	BRCA	binimetinib	229	31.4	0	0	0
X-1828	BRCA	binimetinib	256.8	29.3	3	12.1	-6.7
X-1828	BRCA	binimetinib	259.6	29.7	7	13.4	-5.4
X-1828	BRCA	binimetinib	158.2	30.2	10	-30.9	-3.8
X-1828	BRCA	binimetinib	114.5	30.2	13	-50	-3.8
X-1828	BRCA	binimetinib	109.3	29.8	17	-52.3	-5.1
X-1828	BRCA	binimetinib	112.8	30	20	-50.7	-4.5
X-1828	BRCA	binimetinib	112.5	29	25	-50.9	-7.6
X-1828	BRCA	binimetinib	89.4	28.3	28	-61	-9.9
X-1828	BRCA	binimetinib	95	28.2	32	-58.5	-10.2
X-1828	BRCA	binimetinib	113.9	25.5	35	-50.3	-18.8
X-1828	BRCA	binimetinib	121.4	28.9	39	-47	-8
X-1828	BRCA	binimetinib	123.2	29.7	42	-46.2	-5.4
X-1828	BRCA	binimetinib	180.4	31.4	46	-21.2	0
X-1828	BRCA	binimetinib	218.4	29.6	49	-4.6	-5.7
X-1828	BRCA	binimetinib	237.2	27.9	53	3.6	-11.1
X-1828	BRCA	binimetinib	243.4	28.7	56	6.3	-8.6
X-1828	BRCA	binimetinib	239.1	28.8	60	4.4	-8.3
X-1828	BRCA	binimetinib	289	30.9	63	26.2	-1.6
X-1828	BRCA	binimetinib	260.1	30.7	66	13.6	-2.2
X-1828	BRCA	binimetinib	280.1	28.7	70	22.3	-8.6
X-1828	BRCA	binimetinib	284.7	29.2	74	24.3	-7
X-1828	BRCA	binimetinib	285.2	27.6	77	24.5	-12.1
X-1828	BRCA	binimetinib	287.8	26.8	81	25.7	-14.6
X-1828	BRCA	binimetinib	261.5	25.1	84	14.2	-20.1
X-1828	BRCA	binimetinib	258.8	27.9	88	13	-11.1
X-1828	BRCA	paclitaxel	243	28.3	0	0	0
X-1828	BRCA	paclitaxel	239.2	28.6	3	-1.6	1.1
X-1828	BRCA	paclitaxel	233	29.3	6	-4.1	3.5
X-1828	BRCA	paclitaxel	313.6	28.8	9	29.1	1.8
X-1828	BRCA	paclitaxel	297.3	29	13	22.3	2.5
X-1828	BRCA	paclitaxel	270.9	30.5	16	11.5	7.8
X-1828	BRCA	paclitaxel	227.5	31.2	21	-6.4	10.2
X-1828	BRCA	paclitaxel	228.5	28.6	24	-6	1.1
X-1828	BRCA	paclitaxel	206.2	29.1	28	-15.1	2.8
X-1828	BRCA	paclitaxel	222.4	27.6	31	-8.5	-2.5
X-1828	BRCA	paclitaxel	240.7	26.8	35	-0.9	-5.3
X-1828	BRCA	paclitaxel	238.9	27.1	38	-1.7	-4.2
X-1828	BRCA	paclitaxel	272.7	26	42	12.2	-8.1
X-1828	BRCA	paclitaxel	305.1	24.1	45	25.6	-14.8
X-1828	BRCA	paclitaxel	216.3	20.5	49	-11	-27.6
X-1828	BRCA	tamoxifen	205.5	30.8	0	0	0
X-1828	BRCA	tamoxifen	255.2	31.3	8	24.2	1.6
X-1828	BRCA	tamoxifen	261.6	30.8	11	27.3	0
X-1828	BRCA	tamoxifen	282.3	31.4	15	37.4	1.9
X-1828	BRCA	tamoxifen	292.9	32.7	18	42.5	6.2
X-1828	BRCA	tamoxifen	324.9	33	21	58.1	7.1
X-1828	BRCA	tamoxifen	332.5	33.1	25	61.8	7.5
X-1828	BRCA	tamoxifen	354.2	32	28	72.4	3.9
X-1828	BRCA	tamoxifen	357.4	32	31	73.9	3.9
X-1828	BRCA	tamoxifen	348.6	31.8	35	69.6	3.2
X-1828	BRCA	tamoxifen	362.8	32.3	40	76.5	4.9
X-1828	BRCA	tamoxifen	424.3	32.7	46	106.5	6.2
X-1828	BRCA	tamoxifen	517.3	32.2	49	151.7	4.5
X-1828	BRCA	tamoxifen	581.7	32.6	53	183.1	5.8
X-1828	BRCA	tamoxifen	635.7	32.3	56	209.3	4.9
X-1828	BRCA	tamoxifen	704.3	31.6	60	242.7	2.6
X-1828	BRCA	tamoxifen	742.8	32.9	63	261.5	6.8
X-1828	BRCA	tamoxifen	772	32.4	67	275.7	5.2
X-1828	BRCA	tamoxifen	924.2	31.8	70	349.7	3.2
X-1828	BRCA	tamoxifen	1001.2	31.1	74	387.2	1
X-1828	BRCA	trastuzumab	215.7	29.8	0	0	0
X-1828	BRCA	trastuzumab	226.1	30	3	4.8	0.7
X-1828	BRCA	trastuzumab	220.1	31.6	6	2	6
X-1828	BRCA	trastuzumab	243.1	31	15	12.7	4
X-1828	BRCA	trastuzumab	246.9	31.6	21	14.5	6
X-1828	BRCA	trastuzumab	248.5	31.2	24	15.2	4.7
X-1828	BRCA	trastuzumab	244.7	31.7	28	13.4	6.4
X-1828	BRCA	trastuzumab	211.6	32.2	31	-1.9	8.1
X-1828	BRCA	trastuzumab	222.6	32.3	35	3.2	8.4
X-1828	BRCA	trastuzumab	228.8	32.2	38	6.1	8.1
X-1828	BRCA	trastuzumab	227.5	32.6	42	5.5	9.4
X-1828	BRCA	trastuzumab	240.6	32.9	45	11.5	10.4
X-1828	BRCA	trastuzumab	259.2	31.4	49	20.2	5.4
X-1828	BRCA	trastuzumab	270.8	30.1	52	25.5	1
X-1828	BRCA	trastuzumab	270.6	28.9	56	25.5	-3
X-1828	BRCA	trastuzumab	316.4	29.7	59	46.7	-0.3
X-1828	BRCA	trastuzumab	336.2	29.1	64	55.9	-2.3
X-1828	BRCA	trastuzumab	396.6	29.7	66	83.9	-0.3
X-1828	BRCA	trastuzumab	494.5	31.7	70	129.3	6.4
X-1828	BRCA	trastuzumab	587.1	32	73	172.2	7.4
X-1828	BRCA	trastuzumab	640.7	32.2	76	197	8.1
X-1828	BRCA	untreated	235.9	27.4	0	0	0
X-1828	BRCA	untreated	306.3	27.7	3	29.8	1.1
X-1828	BRCA	untreated	335.4	27.8	7	42.2	1.5
X-1828	BRCA	untreated	446.1	28.4	10	89.1	3.6
X-1828	BRCA	untreated	453.6	28.8	13	92.3	5.1
X-1828	BRCA	untreated	555	28.6	17	135.3	4.4
X-1828	BRCA	untreated	632.5	29.6	20	168.1	8
X-1828	BRCA	untreated	652.1	29.8	25	176.4	8.8
X-1828	BRCA	untreated	703.3	29	28	198.1	5.8
X-1828	BRCA	untreated	700.4	29.2	32	196.9	6.6
X-1828	BRCA	untreated	833.8	29.5	35	253.5	7.7
X-1828	BRCA	untreated	997.8	30	39	323	9.5
X-1828	BRCA	untreated	1152.6	30.5	42	388.6	11.3
X-1828	BRCA	untreated	1191.3	31.1	46	405	13.5
X-1828	BRCA	untreated	1398	30.4	49	492.6	10.9
X-1828	BRCA	untreated	1595.8	30.7	53	576.5	12
X-1832	BRCA	BGJ398	289.3	27.2	0	0	0
X-1832	BRCA	BGJ398	392.1	28.2	3	35.5	3.7
X-1832	BRCA	BGJ398	487.4	28.6	7	68.5	5.1
X-1832	BRCA	BGJ398	648.1	29	10	124	6.6
X-1832	BRCA	BGJ398	900.5	29	14	211.3	6.6
X-1832	BRCA	BGJ398	1337.7	29.4	17	362.4	8.1
X-1832	BRCA	BGJ398	1794.3	29.8	21	520.2	9.6
X-1832	BRCA	BKM120	210.2	29.2	0	0	0
X-1832	BRCA	BKM120	215	29.7	3	2.3	1.7
X-1832	BRCA	BKM120	250.6	28.8	7	19.2	-1.4
X-1832	BRCA	BKM120	337.5	28.8	10	60.6	-1.4
X-1832	BRCA	BKM120	418	29.8	14	98.9	2.1
X-1832	BRCA	BKM120	509.6	29.6	17	142.4	1.4
X-1832	BRCA	BKM120	662.3	29.5	21	215.1	1
X-1832	BRCA	BKM120	780.7	29.7	24	271.4	1.7
X-1832	BRCA	BKM120	837.7	30.6	28	298.5	4.8
X-1832	BRCA	BKM120	1010.6	30.1	31	380.8	3.1
X-1832	BRCA	BKM120	1330.2	30.9	35	532.8	5.8
X-1832	BRCA	BYL719 + LJM716	200.9	26.9	0	0	0
X-1832	BRCA	BYL719 + LJM716	204.4	26.4	3	1.7	-1.9
X-1832	BRCA	BYL719 + LJM716	224.7	26.2	7	11.8	-2.6
X-1832	BRCA	BYL719 + LJM716	252.6	25.9	10	25.7	-3.7
X-1832	BRCA	BYL719 + LJM716	301.7	24.8	14	50.2	-7.8
X-1832	BRCA	BYL719 + LJM716	395.7	26.8	17	97	-0.4
X-1832	BRCA	BYL719 + LJM716	466.1	27.5	21	132	2.2
X-1832	BRCA	BYL719 + LJM716	485.6	27.8	24	141.7	3.3
X-1832	BRCA	BYL719 + LJM716	639.4	27.2	28	218.3	1.1
X-1832	BRCA	BYL719 + LJM716	643.2	26.3	31	220.2	-2.2
X-1832	BRCA	BYL719 + LJM716	667.4	25.2	35	232.2	-6.3
X-1832	BRCA	BYL719 + LJM716	723.3	26.3	38	260	-2.2
X-1832	BRCA	BYL719 + LJM716	781.8	25.6	42	289.1	-4.8
X-1832	BRCA	BYL719 + LJM716	794.1	26.1	45	295.3	-3
X-1832	BRCA	BYL719 + LJM716	735	25.8	49	265.9	-4.1
X-1832	BRCA	BYL719 + LJM716	709.3	24.3	52	253.1	-9.7
X-1832	BRCA	BYL719 + LJM716	722.1	25.3	56	259.4	-5.9
X-1832	BRCA	BYL719 + LJM716	899.5	25.9	63	347.7	-3.7
X-1832	BRCA	BYL719 + LJM716	1006.3	25.8	66	400.9	-4.1
X-1832	BRCA	BYL719 + LJM716	1554.2	27	70	673.6	0.4
X-1832	BRCA	BYL719	330.5	25.2	0	0	0
X-1832	BRCA	BYL719	365.1	26.1	3	10.5	3.6
X-1832	BRCA	BYL719	661.7	25.4	7	100.2	0.8
X-1832	BRCA	BYL719	750.4	27.7	10	127	9.9
X-1832	BRCA	BYL719	1020.5	26.5	14	208.8	5.2
X-1832	BRCA	BYL719	1583.6	27.1	17	379.2	7.5
X-1832	BRCA	BYL719 + LEE011	290.7	25.3	0	0	0
X-1832	BRCA	BYL719 + LEE011	336.4	25	4	15.7	-1.2
X-1832	BRCA	BYL719 + LEE011	372.4	20.9	7	28.1	-17.4
X-1832	BRCA	BYL719 + LEE011	407.2	21.5	10	40.1	-15
X-1832	BRCA	BYL719 + LEE011	1260.8	26.3	19	333.7	4
X-1832	BRCA	BYL719 + LEE011	1416.2	26.8	21	387.2	5.9
X-1832	BRCA	BYL719 + LEE011	1835.5	26.4	25	531.4	4.3
X-1832	BRCA	CGM097	237.8	NA	0	0	0
X-1832	BRCA	CGM097	341.2	30	4	43.5	0
X-1832	BRCA	CGM097	462.2	29.8	7	94.4	-0.7
X-1832	BRCA	CGM097	716.4	31.2	11	201.3	4
X-1832	BRCA	CGM097	1174.9	31.6	14	394.1	5.3
X-1832	BRCA	CGM097	1678.3	31.2	17	605.8	4
X-1832	BRCA	CLR457	213.9	26	0	0	0
X-1832	BRCA	CLR457	297.9	27.8	4	39.3	6.9
X-1832	BRCA	CLR457	406.9	27.6	7	90.2	6.2
X-1832	BRCA	CLR457	499.9	28	11	133.7	7.7
X-1832	BRCA	CLR457	771.2	28.2	14	260.5	8.5
X-1832	BRCA	CLR457	995	28.4	17	365.2	9.2
X-1832	BRCA	CLR457	1324.6	27.5	26	519.3	5.8
X-1832	BRCA	CLR457	1758.2	28.9	28	722	11.2
X-1832	BRCA	CLR457	2133	29.8	32	897.2	14.6
X-1832	BRCA	HDM201	275.1	28	0	0	0
X-1832	BRCA	HDM201	542.3	28.1	3	97.1	0.4
X-1832	BRCA	HDM201	774.1	28	7	181.4	0
X-1832	BRCA	HDM201	1097.8	27	10	299.1	-3.6
X-1832	BRCA	HDM201	1301.3	27.7	14	373	-1.1
X-1832	BRCA	HDM201	1534.3	27.4	17	457.7	-2.1
X-1832	BRCA	INC424	251.5	29.2	0	0	0
X-1832	BRCA	INC424	344.7	31.5	4	37.1	7.9
X-1832	BRCA	INC424	521.6	30.7	7	107.4	5.1
X-1832	BRCA	INC424	852.8	31.8	11	239.1	8.9
X-1832	BRCA	INC424	1172.8	32.2	14	366.3	10.3
X-1832	BRCA	INC424	1779.6	32.7	17	607.6	12
X-1832	BRCA	LEE011 + everolimus	225.8	26.5	0	0	0
X-1832	BRCA	LEE011 + everolimus	275.9	28.3	4	22.2	6.8
X-1832	BRCA	LEE011 + everolimus	310.2	27.7	7	37.4	4.5
X-1832	BRCA	LEE011 + everolimus	340.1	26.7	10	50.6	0.8
X-1832	BRCA	LEE011 + everolimus	529.6	28.1	19	134.5	6
X-1832	BRCA	LEE011 + everolimus	608.1	28.2	21	169.3	6.4
X-1832	BRCA	LEE011 + everolimus	649.8	28.6	25	187.8	7.9
X-1832	BRCA	LEE011 + everolimus	733.4	28.2	28	224.8	6.4
X-1832	BRCA	LEE011 + everolimus	879	28.4	32	289.3	7.2
X-1832	BRCA	LEE011 + everolimus	924.7	28.3	35	309.5	6.8
X-1832	BRCA	LEE011 + everolimus	973.2	27.7	39	331	4.5
X-1832	BRCA	LEE011 + everolimus	1051.4	28.6	42	365.6	7.9
X-1832	BRCA	LEE011 + everolimus	1225.8	28.8	46	442.9	8.7
X-1832	BRCA	LEE011	244	27.1	0	0	0
X-1832	BRCA	LEE011	303.9	28.4	4	24.5	4.8
X-1832	BRCA	LEE011	338.3	28.1	7	38.6	3.7
X-1832	BRCA	LEE011	419.7	28.8	11	72	6.3
X-1832	BRCA	LEE011	488.5	28.7	14	100.2	5.9
X-1832	BRCA	LEE011	540.6	28.8	17	121.6	6.3
X-1832	BRCA	LEE011	1109.5	30.2	26	354.7	11.4
X-1832	BRCA	LEE011	1165	29.7	28	377.5	9.6
X-1832	BRCA	LEE011	1758.7	31.3	32	620.8	15.5
X-1832	BRCA	LFA102	239.5	25.2	0	0	0
X-1832	BRCA	LFA102	279.5	24.7	3	16.7	-2
X-1832	BRCA	LFA102	454.3	25.5	10	89.7	1.2
X-1832	BRCA	LFA102	567	25.2	13	136.7	0
X-1832	BRCA	LFA102	875.6	26.1	22	265.6	3.6
X-1832	BRCA	LFA102	944.5	26.5	24	294.4	5.2
X-1832	BRCA	LFA102	1391	26.5	28	480.8	5.2
X-1832	BRCA	LJM716	213	27.8	0	0	0
X-1832	BRCA	LJM716	162.4	25.9	4	-23.8	-6.8
X-1832	BRCA	LJM716	285.8	27.7	8	34.2	-0.4
X-1832	BRCA	LJM716	378.7	27.4	11	77.8	-1.4
X-1832	BRCA	LJM716	411.7	27.9	14	93.3	0.4
X-1832	BRCA	LJM716	691.8	27.5	23	224.8	-1.1
X-1832	BRCA	LJM716	931	28.8	25	337.1	3.6
X-1832	BRCA	LJM716	1525.8	29.2	29	616.3	5
X-1832	BRCA	LJM716 + trastuzumab	234.1	22.7	0	0	0
X-1832	BRCA	LJM716 + trastuzumab	327.5	21.4	3	39.9	-5.7
X-1832	BRCA	LJM716 + trastuzumab	633.9	22.6	7	170.8	-0.4
X-1832	BRCA	LJM716 + trastuzumab	803.8	23.4	10	243.4	3.1
X-1832	BRCA	LJM716 + trastuzumab	1195.3	23.7	13	410.6	4.4
X-1832	BRCA	LJM716 + trastuzumab	2325.2	24.4	22	893.3	7.5
X-1832	BRCA	LKA136	213.1	27.2	0	0	0
X-1832	BRCA	LKA136	216.9	27.3	4	1.8	0.4
X-1832	BRCA	LKA136	229.2	26.4	7	7.6	-2.9
X-1832	BRCA	LKA136	320.7	27.6	11	50.5	1.5
X-1832	BRCA	LKA136	434.9	27.1	14	104.1	-0.4
X-1832	BRCA	LKA136	475.4	28.3	17	123.1	4
X-1832	BRCA	LKA136	1116.1	29.2	26	423.7	7.4
X-1832	BRCA	LKA136	1249	29.3	28	486.1	7.7
X-1832	BRCA	LKA136	1798.7	30.2	32	744.1	11
X-1832	BRCA	LLM871	215	25.8	0	0	0
X-1832	BRCA	LLM871	325.5	26	8	51.4	0.8
X-1832	BRCA	LLM871	455.5	26.1	10	111.9	1.2
X-1832	BRCA	LLM871	564.9	23.6	14	162.7	-8.5
X-1832	BRCA	binimetinib	322.2	24.9	0	0	0
X-1832	BRCA	binimetinib	408.2	25.3	4	26.7	1.6
X-1832	BRCA	binimetinib	556.8	24.9	7	72.8	0
X-1832	BRCA	binimetinib	932.1	26.1	11	189.3	4.8
X-1832	BRCA	binimetinib	1135.3	25.5	14	252.4	2.4
X-1832	BRCA	binimetinib	1376	28	17	327.1	12.4
X-1832	BRCA	paclitaxel	199	25.1	0	0	0
X-1832	BRCA	paclitaxel	191.6	25.5	3	-3.7	1.6
X-1832	BRCA	paclitaxel	193.7	25.6	6	-2.7	2
X-1832	BRCA	paclitaxel	207.4	25.7	15	4.2	2.4
X-1832	BRCA	paclitaxel	205.7	26.1	17	3.4	4
X-1832	BRCA	paclitaxel	216	25.3	21	8.5	0.8
X-1832	BRCA	paclitaxel	212.2	26.1	24	6.6	4
X-1832	BRCA	paclitaxel	260.2	26.2	28	30.8	4.4
X-1832	BRCA	paclitaxel	327.2	26.3	31	64.4	4.8
X-1832	BRCA	paclitaxel	439.4	25.7	35	120.8	2.4
X-1832	BRCA	paclitaxel	496.1	26.7	38	149.3	6.4
X-1832	BRCA	paclitaxel	734.1	27.2	42	268.9	8.4
X-1832	BRCA	paclitaxel	774.4	28.2	45	289.1	12.4
X-1832	BRCA	paclitaxel	1168.1	27.9	49	487	11.2
X-1832	BRCA	tamoxifen	219.3	24.9	0	0	0
X-1832	BRCA	tamoxifen	331.7	26.8	4	51.3	7.6
X-1832	BRCA	tamoxifen	547.3	27.1	7	149.6	8.8
X-1832	BRCA	tamoxifen	721.3	26.9	10	228.9	8
X-1832	BRCA	tamoxifen	1913.5	28.4	19	772.5	14.1
X-1832	BRCA	trastuzumab	262.4	28.4	0	0	0
X-1832	BRCA	trastuzumab	412	27.9	3	57	-1.8
X-1832	BRCA	trastuzumab	1012.1	30.3	10	285.7	6.7
X-1832	BRCA	trastuzumab	1540.4	31	13	487	9.2
X-1832	BRCA	untreated	356.1	27.9	0	0	0
X-1832	BRCA	untreated	607.7	28	5	70.7	0.4
X-1832	BRCA	untreated	700.2	28.9	8	96.6	3.6
X-1832	BRCA	untreated	927.7	29	12	160.5	3.9
X-1832	BRCA	untreated	1045.5	29.4	15	193.6	5.4
X-1832	BRCA	untreated	1082.1	28.7	19	203.9	2.9
X-1832	BRCA	untreated	1122.2	29.7	22	215.1	6.5
X-1832	BRCA	untreated	1200.6	29.3	26	237.2	5
X-1832	BRCA	untreated	1220.3	29.3	29	242.7	5
X-1832	BRCA	untreated	1232	28.9	33	246	3.6
X-1832	BRCA	LFW527 + everolimus	279.39	22.1	0	0	0
X-1832	BRCA	LFW527 + everolimus	416.26	21.2	6	49	-4.1
X-1832	BRCA	LFW527 + everolimus	399.29	19	10	42.9	-14
X-1832	BRCA	LFW527 + everolimus	481.9	20.6	14	72.5	-6.8
X-1832	BRCA	LFW527 + everolimus	496.11	19	17	77.6	-14
X-1834	NSCLC	BGJ398	187.4	26.3	0	0	0
X-1834	NSCLC	BGJ398	171.5	25.7	2	-8.5	-2.3
X-1834	NSCLC	BGJ398	249.4	25.2	6	33.1	-4.2
X-1834	NSCLC	BGJ398	340.8	25.8	13	81.9	-1.9
X-1834	NSCLC	BGJ398	332.9	25.7	20	77.6	-2.3
X-1834	NSCLC	BKM120	169	23.9	0	0	0
X-1834	NSCLC	BKM120	218.8	24.7	2	29.5	3.3
X-1834	NSCLC	BKM120	136.2	24.5	6	-19.4	2.5
X-1834	NSCLC	BKM120	138.6	25.7	13	-18	7.5
X-1834	NSCLC	BKM120	183.7	26.7	20	8.7	11.7
X-1834	NSCLC	BKM120	266.6	26.9	23	57.8	12.6
X-1834	NSCLC	BKM120	299.6	26.9	26	77.3	12.6
X-1834	NSCLC	BKM120	379.3	26.9	30	124.4	12.6
X-1834	NSCLC	BKM120	382.1	27.4	34	126.1	14.6
X-1834	NSCLC	BKM120	546.1	27	37	223.1	13
X-1834	NSCLC	BKM120	577.6	26.9	40	241.8	12.6
X-1834	NSCLC	BKM120	803.5	26.1	43	375.4	9.2
X-1834	NSCLC	BKM120	925.1	26.9	47	447.4	12.6
X-1834	NSCLC	BKM120 + binimetinib	223.9	22.6	0	0	0
X-1834	NSCLC	BKM120 + binimetinib	290.4	22.8	2	29.7	0.9
X-1834	NSCLC	BKM120 + binimetinib	219.7	23.2	6	-1.9	2.7
X-1834	NSCLC	BKM120 + binimetinib	245.7	25.2	13	9.7	11.5
X-1834	NSCLC	BKM120 + binimetinib	426.3	26	20	90.4	15
X-1834	NSCLC	BKM120 + binimetinib	450.1	26.4	23	101	16.8
X-1834	NSCLC	BKM120 + binimetinib	479.2	27	26	114	19.5
X-1834	NSCLC	BKM120 + binimetinib	532.9	27	30	138	19.5
X-1834	NSCLC	BKM120 + binimetinib	545.3	27.5	34	143.5	21.7
X-1834	NSCLC	BKM120 + binimetinib	630.7	26.9	37	181.7	19
X-1834	NSCLC	BKM120 + binimetinib	628.3	27.1	40	180.6	19.9
X-1834	NSCLC	BKM120 + binimetinib	736.3	27.4	43	228.9	21.2
X-1834	NSCLC	BKM120 + binimetinib	863.3	28.4	47	285.6	25.7
X-1834	NSCLC	BYL719	138.5	23	0	0	0
X-1834	NSCLC	BYL719	117.7	23.8	2	-15	3.5
X-1834	NSCLC	BYL719	101.9	23.1	6	-26.4	0.4
X-1834	NSCLC	BYL719	132.1	23.8	13	-4.6	3.5
X-1834	NSCLC	BYL719	184.6	23.9	20	33.3	3.9
X-1834	NSCLC	BYL719	197.4	23.2	23	42.5	0.9
X-1834	NSCLC	BYL719	186.6	23.2	26	34.7	0.9
X-1834	NSCLC	BYL719	181.9	23.6	30	31.3	2.6
X-1834	NSCLC	BYL719	281.4	24.1	34	103.2	4.8
X-1834	NSCLC	BYL719	382.1	24.2	37	175.9	5.2
X-1834	NSCLC	BYL719	408.8	24.7	40	195.2	7.4
X-1834	NSCLC	BYL719	275.5	24.4	43	98.9	6.1
X-1834	NSCLC	BYL719	290.1	24.9	47	109.5	8.3
X-1834	NSCLC	BYL719	344.1	25.2	54	148.4	9.6
X-1834	NSCLC	BYL719	434.9	23.9	57	214	3.9
X-1834	NSCLC	BYL719	453	25.2	62	227.1	9.6
X-1834	NSCLC	BYL719	550.9	25.8	65	297.8	12.2
X-1834	NSCLC	BYL719	619.5	25.9	68	347.3	12.6
X-1834	NSCLC	BYL719 + LGH447	160.9	25	0	0	0
X-1834	NSCLC	BYL719 + LGH447	188.3	25.6	2	17	2.4
X-1834	NSCLC	BYL719 + LGH447	226.6	24.6	6	40.8	-1.6
X-1834	NSCLC	BYL719 + LGH447	331.4	26.7	13	106	6.8
X-1834	NSCLC	BYL719 + LJM716	241.2	24.3	0	0	0
X-1834	NSCLC	BYL719 + LJM716	292	25.4	2	21.1	4.5
X-1834	NSCLC	BYL719 + LJM716	416.2	24.2	6	72.6	-0.4
X-1834	NSCLC	BYL719 + LJM716	517.9	25.2	13	114.7	3.7
X-1834	NSCLC	BYL719 + LJM716	601	25.7	20	149.2	5.8
X-1834	NSCLC	BYL719 + LJM716	689.8	25.2	21	186	3.7
X-1834	NSCLC	CGM097	183.7	24.9	0	0	0
X-1834	NSCLC	CGM097	346	26.3	2	88.4	5.6
X-1834	NSCLC	CGM097	428.1	26.9	6	133	8
X-1834	NSCLC	CGM097	423.3	28.2	13	130.4	13.3
X-1834	NSCLC	CGM097	600.9	28.7	20	227.1	15.3
X-1834	NSCLC	CGM097	715.8	28.2	21	289.7	13.3
X-1834	NSCLC	CKX620	267.5	29.1	0	0	0
X-1834	NSCLC	CKX620	503.5	28.4	2	88.2	-2.4
X-1834	NSCLC	CKX620	421.5	29.1	6	57.6	0
X-1834	NSCLC	CKX620	285.8	30.9	13	6.8	6.2
X-1834	NSCLC	CKX620	288.5	30.5	20	7.9	4.8
X-1834	NSCLC	CKX620	309.9	30.9	23	15.9	6.2
X-1834	NSCLC	CKX620	311.9	30.4	26	16.6	4.5
X-1834	NSCLC	CKX620	372.1	30.8	30	39.1	5.8
X-1834	NSCLC	CKX620	242.6	31.4	34	-9.3	7.9
X-1834	NSCLC	CKX620	228.9	32.4	37	-14.4	11.3
X-1834	NSCLC	CKX620	206.1	32.5	40	-23	11.7
X-1834	NSCLC	CKX620	245.7	30.1	43	-8.1	3.4
X-1834	NSCLC	CKX620	291.9	30.9	47	9.1	6.2
X-1834	NSCLC	CKX620	203.7	31	54	-23.9	6.5
X-1834	NSCLC	CKX620	240.2	32	57	-10.2	10
X-1834	NSCLC	CKX620	293.6	31.5	62	9.8	8.2
X-1834	NSCLC	CKX620	237.6	29.3	65	-11.2	0.7
X-1834	NSCLC	CKX620	245.3	26.6	68	-8.3	-8.6
X-1834	NSCLC	CKX620	248.8	27.1	75	-7	-6.9
X-1834	NSCLC	CKX620	243.6	26.7	79	-8.9	-8.2
X-1834	NSCLC	CKX620	317.6	29	83	18.7	-0.3
X-1834	NSCLC	CKX620	249.5	27	86	-6.7	-7.2
X-1834	NSCLC	CLR457	207.9	30.6	0	0	0
X-1834	NSCLC	CLR457	149.6	29.4	4	-28	-3.9
X-1834	NSCLC	CLR457	175.3	29.2	8	-15.7	-4.6
X-1834	NSCLC	CLR457	156.2	29.8	11	-24.9	-2.6
X-1834	NSCLC	CLR457	129.7	29.5	15	-37.6	-3.6
X-1834	NSCLC	CLR457	234.1	30	18	12.6	-2
X-1834	NSCLC	CLR457	215.9	29.8	21	3.8	-2.6
X-1834	NSCLC	CLR457	240.7	29.9	25	15.8	-2.3
X-1834	NSCLC	CLR457	214.2	30.1	29	3	-1.6
X-1834	NSCLC	CLR457	156.8	30	35	-24.6	-2
X-1834	NSCLC	CLR457	151.8	30.5	39	-27	-0.3
X-1834	NSCLC	CLR457	150.8	30.1	42	-27.5	-1.6
X-1834	NSCLC	CLR457	144.3	30	46	-30.6	-2
X-1834	NSCLC	CLR457	126.6	29.7	49	-39.1	-2.9
X-1834	NSCLC	CLR457	187.9	28.7	53	-9.6	-6.2
X-1834	NSCLC	CLR457	156.7	26.3	56	-24.6	-14.1
X-1834	NSCLC	HDM201	127.6	23.3	0	0	0
X-1834	NSCLC	HDM201	257.6	24.1	2	101.9	3.4
X-1834	NSCLC	HDM201	300.5	23.9	6	135.5	2.6
X-1834	NSCLC	HDM201	361.1	24.4	13	183	4.7
X-1834	NSCLC	HDM201	528.3	25.7	20	314	10.3
X-1834	NSCLC	HDM201	642	25.8	21	403.1	10.7
X-1834	NSCLC	cetuximab	172.2	21.9	0	0	0
X-1834	NSCLC	cetuximab	179.2	22.2	3	4.1	1.4
X-1834	NSCLC	cetuximab	325.6	22.8	7	89.1	4.1
X-1834	NSCLC	cetuximab	335.6	24	14	94.9	9.6
X-1834	NSCLC	cetuximab	271.8	23.9	21	57.8	9.1
X-1834	NSCLC	cetuximab	328.3	24	24	90.7	9.6
X-1834	NSCLC	cetuximab	396.5	24.4	27	130.3	11.4
X-1834	NSCLC	cetuximab	437.7	25.2	31	154.2	15.1
X-1834	NSCLC	cetuximab	492	24.8	35	185.7	13.2
X-1834	NSCLC	cetuximab	537.9	24.3	38	212.4	11
X-1834	NSCLC	cetuximab	536.7	23.7	44	211.7	8.2
X-1834	NSCLC	cetuximab	536.2	24.4	48	211.4	11.4
X-1834	NSCLC	cetuximab	557.7	25.3	55	223.9	15.5
X-1834	NSCLC	cetuximab	602.8	24.1	58	250.1	10
X-1834	NSCLC	cetuximab	589.5	25.4	63	242.3	16
X-1834	NSCLC	cetuximab	718	25.5	66	317	16.4
X-1834	NSCLC	cetuximab	702.1	25.7	69	307.7	17.4
X-1834	NSCLC	erlotinib	136.4	26	0	0	0
X-1834	NSCLC	erlotinib	188.2	27.1	2	38	4.2
X-1834	NSCLC	erlotinib	143.6	25.9	6	5.3	-0.4
X-1834	NSCLC	erlotinib	132.4	22.9	13	-2.9	-11.9
X-1834	NSCLC	erlotinib	159.1	23.8	20	16.6	-8.5
X-1834	NSCLC	erlotinib	221.7	22.7	23	62.5	-12.7
X-1834	NSCLC	erlotinib	305.3	26.4	26	123.8	1.5
X-1834	NSCLC	erlotinib	319.2	24.6	30	134	-5.4
X-1834	NSCLC	erlotinib	231.2	25	34	69.5	-3.8
X-1834	NSCLC	erlotinib	289.9	23.1	37	112.5	-11.2
X-1834	NSCLC	erlotinib	280.1	26.5	40	105.4	1.9
X-1834	NSCLC	erlotinib	274.3	26.3	43	101.1	1.2
X-1834	NSCLC	erlotinib	261.4	24.1	47	91.6	-7.3
X-1834	NSCLC	erlotinib	429.8	24.1	54	215.1	-7.3
X-1834	NSCLC	erlotinib	470.4	26.4	58	244.9	1.5
X-1834	NSCLC	erlotinib	462.3	24.4	62	238.9	-6.2
X-1834	NSCLC	erlotinib	520.5	24.5	65	281.6	-5.8
X-1834	NSCLC	erlotinib	595.6	25.5	68	336.7	-1.9
X-1834	NSCLC	HSP990	150.8	25.4	0	0	0
X-1834	NSCLC	HSP990	147.7	24.4	3	-2.1	-3.9
X-1834	NSCLC	HSP990	227.7	26	10	51	2.4
X-1834	NSCLC	HSP990	294.6	25.3	14	95.4	-0.4
X-1834	NSCLC	HSP990	246.5	25.1	18	63.5	-1.2
X-1834	NSCLC	HSP990	198.3	24.6	21	31.5	-3.1
X-1834	NSCLC	HSP990	183.5	26	25	21.7	2.4
X-1834	NSCLC	HSP990	115.7	25.1	28	-23.3	-1.2
X-1834	NSCLC	HSP990	90.7	18.2	31	-39.9	-28.3
X-1834	NSCLC	INC280	140.9	25.4	0	0	0
X-1834	NSCLC	INC280	202.1	26.1	2	43.4	2.8
X-1834	NSCLC	INC280	162	26.1	6	15	2.8
X-1834	NSCLC	INC280	174.5	26.7	13	23.8	5.1
X-1834	NSCLC	INC280	259.7	26.8	20	84.3	5.5
X-1834	NSCLC	INC280	262.8	27.2	23	86.5	7.1
X-1834	NSCLC	INC280	229.4	27.4	26	62.8	7.9
X-1834	NSCLC	INC280	386.2	26.9	30	174.1	5.9
X-1834	NSCLC	INC280	307.1	27.4	34	118	7.9
X-1834	NSCLC	INC280	379.9	26.7	37	169.6	5.1
X-1834	NSCLC	INC280	462	27.1	40	227.9	6.7
X-1834	NSCLC	INC280	405.8	27.5	43	188	8.3
X-1834	NSCLC	INC280	434.2	27.6	47	208.2	8.7
X-1834	NSCLC	INC280	410.9	27.1	54	191.6	6.7
X-1834	NSCLC	INC280	574.9	26.3	57	308	3.5
X-1834	NSCLC	INC280	641.6	27	62	355.4	6.3
X-1834	NSCLC	INC280	679.5	27.3	65	382.3	7.5
X-1834	NSCLC	INC280	1014.6	27.5	68	620.1	8.3
X-1834	NSCLC	LCL161 + paclitaxel	269.9	27.6	0	0	0
X-1834	NSCLC	LCL161 + paclitaxel	123	22.4	6	-54.4	-18.8
X-1834	NSCLC	LCL161 + paclitaxel	105	23	9	-61.1	-16.7
X-1834	NSCLC	LCL161 + paclitaxel	88.8	27.1	14	-67.1	-1.8
X-1834	NSCLC	LCL161 + paclitaxel	28.3	28.7	17	-89.5	4
X-1834	NSCLC	LEE011	210.5	24.5	0	0	0
X-1834	NSCLC	LEE011	303.4	24.6	2	44.1	0.4
X-1834	NSCLC	LEE011	429.9	25	6	104.2	2
X-1834	NSCLC	LEE011	400.8	25.9	13	90.4	5.7
X-1834	NSCLC	LEE011	305.4	26.3	20	45.1	7.3
X-1834	NSCLC	LEE011	352	26.9	23	67.2	9.8
X-1834	NSCLC	LEE011	334.5	27.1	26	58.9	10.6
X-1834	NSCLC	LEE011	335.4	28.6	30	59.3	16.7
X-1834	NSCLC	LEE011	292.7	28.4	34	39	15.9
X-1834	NSCLC	LEE011	289.4	28.7	37	37.5	17.1
X-1834	NSCLC	LEE011	271.7	28.2	40	29.1	15.1
X-1834	NSCLC	LEE011	274.6	27.4	43	30.5	11.8
X-1834	NSCLC	LEE011	324.2	28.2	47	54	15.1
X-1834	NSCLC	LEE011	281.7	28.9	54	33.8	18
X-1834	NSCLC	LEE011	350.7	28.7	57	66.6	17.1
X-1834	NSCLC	LEE011	388.8	30.8	62	84.7	25.7
X-1834	NSCLC	LEE011	313.3	30.7	65	48.8	25.3
X-1834	NSCLC	LEE011	292	30.1	68	38.7	22.9
X-1834	NSCLC	LEE011	417.1	30.5	75	98.1	24.5
X-1834	NSCLC	LEE011	458	30.2	79	117.6	23.3
X-1834	NSCLC	LEE011	350.3	30.6	83	66.4	24.9
X-1834	NSCLC	LEE011	444.5	31.7	86	111.2	29.4
X-1834	NSCLC	LEE011	399.1	32.2	90	89.6	31.4
X-1834	NSCLC	LEE011	468.6	32.5	93	122.6	32.7
X-1834	NSCLC	LEE011	463.9	31.4	96	120.4	28.2
X-1834	NSCLC	LEE011	428.7	33.4	100	103.7	36.3
X-1834	NSCLC	LEE011	467.9	32.8	104	122.3	33.9
X-1834	NSCLC	LEE011	492.3	33.2	110	133.9	35.5
X-1834	NSCLC	LEE011	431.1	34	114	104.8	38.8
X-1834	NSCLC	LEE011	431.9	33.3	117	105.2	35.9
X-1834	NSCLC	LGH447	188.5	24.9	0	0	0
X-1834	NSCLC	LGH447	206.7	24.8	2	9.7	-0.4
X-1834	NSCLC	LGH447	380.9	25.5	6	102.1	2.4
X-1834	NSCLC	LGH447	776.2	25.7	13	311.8	3.2
X-1834	NSCLC	LLM871	280.9	28.5	0	0	0
X-1834	NSCLC	LLM871	483.8	27.2	4	72.2	-4.6
X-1834	NSCLC	LLM871	857.1	29.5	11	205.1	3.5
X-1834	NSCLC	binimetinib	243.7	26.9	0	0	0
X-1834	NSCLC	binimetinib	193.9	26.1	3	-20.4	-3
X-1834	NSCLC	binimetinib	198.1	26.6	7	-18.7	-1.1
X-1834	NSCLC	binimetinib	230.1	27.7	14	-5.6	3
X-1834	NSCLC	binimetinib	193.9	26.4	21	-20.4	-1.9
X-1834	NSCLC	binimetinib	180.1	26.9	24	-26.1	0
X-1834	NSCLC	binimetinib	214.4	27.5	27	-12	2.2
X-1834	NSCLC	binimetinib	209.6	27.9	31	-14	3.7
X-1834	NSCLC	binimetinib	167.7	28	35	-31.2	4.1
X-1834	NSCLC	binimetinib	161.3	27.9	38	-33.8	3.7
X-1834	NSCLC	binimetinib	150.5	27.7	41	-38.2	3
X-1834	NSCLC	binimetinib	178.3	27.8	44	-26.8	3.3
X-1834	NSCLC	binimetinib	253.1	28	48	3.9	4.1
X-1834	NSCLC	binimetinib	264	27.6	55	8.3	2.6
X-1834	NSCLC	binimetinib	286.9	27.8	58	17.7	3.3
X-1834	NSCLC	binimetinib	253.9	28.1	63	4.2	4.5
X-1834	NSCLC	binimetinib	310.3	28.5	66	27.3	5.9
X-1834	NSCLC	binimetinib	326.8	27.5	69	34.1	2.2
X-1834	NSCLC	binimetinib	325.6	27.8	76	33.6	3.3
X-1834	NSCLC	binimetinib	362.5	28.6	80	48.7	6.3
X-1834	NSCLC	binimetinib	462.8	27.8	84	89.9	3.3
X-1834	NSCLC	binimetinib	388.2	27.4	87	59.3	1.9
X-1834	NSCLC	binimetinib	357.8	27	91	46.8	0.4
X-1834	NSCLC	binimetinib	340.8	26.3	94	39.8	-2.2
X-1834	NSCLC	binimetinib	338.5	26.8	97	38.9	-0.4
X-1834	NSCLC	binimetinib	394.8	26.6	101	62	-1.1
X-1834	NSCLC	binimetinib	345.2	25.8	105	41.6	-4.1
X-1834	NSCLC	binimetinib	326.1	26.3	111	33.8	-2.2
X-1834	NSCLC	binimetinib	284.2	26.5	115	16.6	-1.5
X-1834	NSCLC	binimetinib	312.5	25.9	118	28.2	-3.7
X-1834	NSCLC	paclitaxel	197.1	24.5	0	0	0
X-1834	NSCLC	paclitaxel	186.8	23.8	4	-5.2	-2.9
X-1834	NSCLC	paclitaxel	316.9	24.7	11	60.8	0.8
X-1834	NSCLC	paclitaxel	279.3	25.3	18	41.7	3.3
X-1834	NSCLC	paclitaxel	337.2	25.6	21	71.1	4.5
X-1834	NSCLC	paclitaxel	376.8	25.7	24	91.2	4.9
X-1834	NSCLC	paclitaxel	352.3	25.8	28	78.7	5.3
X-1834	NSCLC	paclitaxel	340.9	25.8	32	73	5.3
X-1834	NSCLC	paclitaxel	470.6	25.4	35	138.8	3.7
X-1834	NSCLC	paclitaxel	633.3	26.4	38	221.3	7.8
X-1834	NSCLC	paclitaxel	946	26	41	380	6.1
X-1834	NSCLC	paclitaxel	1172.6	26.3	45	494.9	7.3
X-1834	NSCLC	untreated	207.7	22.7	0	0	0
X-1834	NSCLC	untreated	237.7	23.6	3	14.4	4
X-1834	NSCLC	untreated	300.8	24.8	14	44.8	9.3
X-1834	NSCLC	untreated	321	25.1	21	54.5	10.6
X-1834	NSCLC	untreated	383.9	24.9	24	84.8	9.7
X-1834	NSCLC	untreated	393	25.3	27	89.2	11.5
X-1834	NSCLC	untreated	410.3	25.4	31	97.5	11.9
X-1834	NSCLC	untreated	480.3	25.6	35	131.2	12.8
X-1834	NSCLC	untreated	508.5	25.4	38	144.8	11.9
X-1834	NSCLC	untreated	572.3	25.4	41	175.5	11.9
X-1834	NSCLC	untreated	535.9	25.3	44	158	11.5
X-1834	NSCLC	untreated	590.5	25.6	48	184.3	12.8
X-1834	NSCLC	untreated	663.4	26	55	219.4	14.5
X-1834	NSCLC	LFW527 + binimetinib	267.32	22.2	0	0	0
X-1834	NSCLC	LFW527 + binimetinib	197.89	22.4	2	-26	0.9
X-1834	NSCLC	LFW527 + binimetinib	268	21.2	6	0.3	-4.5
X-1834	NSCLC	LFW527 + binimetinib	373.83	20.9	9	39.8	-5.9
X-1834	NSCLC	LFW527 + binimetinib	424.45	21.4	13	58.8	-3.6
X-1834	NSCLC	LFW527 + binimetinib	460.55	22.4	16	72.3	0.9
X-1834	NSCLC	LFW527 + binimetinib	579.36	22.5	20	116.7	1.4
X-1834	NSCLC	LFW527 + binimetinib	575.68	21.9	23	115.4	-1.4
X-1834	NSCLC	LFW527 + binimetinib	501.3	22.5	27	87.5	1.4
X-1834	NSCLC	LFW527 + binimetinib	644.75	22.2	30	141.2	0
X-1834	NSCLC	LFW527 + binimetinib	818.95	22.8	34	206.4	2.7
X-1834	NSCLC	LFW527 + binimetinib	1065.03	22.4	35	298.4	0.9
X-1835	NSCLC	BGJ398	310.8	23.2	0	0	0
X-1835	NSCLC	BGJ398	491.4	23.9	4	58.1	3
X-1835	NSCLC	BGJ398	833.1	24	11	168.1	3.4
X-1835	NSCLC	BGJ398	855.8	24.1	15	175.4	3.9
X-1835	NSCLC	BKM120	223.7	NA	0	0	0
X-1835	NSCLC	BKM120	259.2	20.6	2	15.9	0
X-1835	NSCLC	BKM120	242.4	22.2	7	8.4	7.8
X-1835	NSCLC	BKM120	264.7	22.4	9	18.3	8.7
X-1835	NSCLC	BKM120	403.4	23.8	14	80.3	15.5
X-1835	NSCLC	BKM120	391.3	23.3	17	74.9	13.1
X-1835	NSCLC	BKM120	557.6	24.4	21	149.3	18.4
X-1835	NSCLC	BKM120	671.9	24.3	24	200.4	18
X-1835	NSCLC	BKM120	805.9	25.5	31	260.3	23.8
X-1835	NSCLC	BKM120	959.6	25.4	35	329	23.3
X-1835	NSCLC	BKM120 + binimetinib	193.7	27.9	0	0	0
X-1835	NSCLC	BKM120 + binimetinib	225.8	27.4	2	16.6	-1.8
X-1835	NSCLC	BKM120 + binimetinib	327.7	27.9	7	69.2	0
X-1835	NSCLC	BKM120 + binimetinib	284.1	27.2	9	46.7	-2.5
X-1835	NSCLC	BKM120 + binimetinib	279	28.4	14	44	1.8
X-1835	NSCLC	BKM120 + binimetinib	259.5	28.1	17	34	0.7
X-1835	NSCLC	BKM120 + binimetinib	351.4	29.1	21	81.4	4.3
X-1835	NSCLC	BKM120 + binimetinib	362.4	28.8	24	87.1	3.2
X-1835	NSCLC	BKM120 + binimetinib	185.2	29.2	31	-4.4	4.7
X-1835	NSCLC	BKM120 + binimetinib	241.8	29.1	35	24.8	4.3
X-1835	NSCLC	BKM120 + binimetinib	330.9	28.5	38	70.8	2.2
X-1835	NSCLC	BKM120 + binimetinib	585.5	29.7	45	202.3	6.5
X-1835	NSCLC	BKM120 + binimetinib	661.9	28.9	50	241.7	3.6
X-1835	NSCLC	BYL719 + LGH447	225.3	26	0	0	0
X-1835	NSCLC	BYL719 + LGH447	273.8	25.2	7	21.5	-3.1
X-1835	NSCLC	BYL719 + LGH447	436.7	24.7	11	93.8	-5
X-1835	NSCLC	BYL719 + LGH447	517.4	22.5	14	129.6	-13.5
X-1835	NSCLC	BYL719 + LGH447	557.4	23.4	17	147.4	-10
X-1835	NSCLC	BYL719 + LGH447	532.3	23.7	24	136.3	-8.8
X-1835	NSCLC	BYL719 + LGH447	616	23.7	28	173.4	-8.8
X-1835	NSCLC	BYL719 + LGH447	871.2	25	31	286.7	-3.8
X-1835	NSCLC	BYL719 + LGH447	579.6	24	35	157.3	-7.7
X-1835	NSCLC	BYL719 + LGH447	963.2	25.5	38	327.5	-1.9
X-1835	NSCLC	BYL719 + LGH447	1067.2	24.8	43	373.7	-4.6
X-1835	NSCLC	BYL719	183.8	29.5	0	0	0
X-1835	NSCLC	BYL719	323.8	28.9	4	76.2	-2
X-1835	NSCLC	BYL719	373.1	29	11	103	-1.7
X-1835	NSCLC	BYL719	370.8	27.6	15	101.7	-6.4
X-1835	NSCLC	BYL719	364.5	27.2	18	98.3	-7.8
X-1835	NSCLC	BYL719	332.7	28.9	25	81	-2
X-1835	NSCLC	BYL719	327.3	29.1	35	78.1	-1.4
X-1835	NSCLC	BYL719	468.1	28.9	39	154.7	-2
X-1835	NSCLC	BYL719	599.8	29.5	43	226.3	0
X-1835	NSCLC	BYL719 + LJM716	201.4	23.7	0	0	0
X-1835	NSCLC	BYL719 + LJM716	146	22.9	2	-27.5	-3.4
X-1835	NSCLC	BYL719 + LJM716	183.6	24.2	7	-8.8	2.1
X-1835	NSCLC	BYL719 + LJM716	237.5	23.6	10	17.9	-0.4
X-1835	NSCLC	BYL719 + LJM716	261.1	23.8	14	29.6	0.4
X-1835	NSCLC	BYL719 + LJM716	249	23.4	17	23.6	-1.3
X-1835	NSCLC	BYL719 + LJM716	307.9	24.2	24	52.9	2.1
X-1835	NSCLC	BYL719 + LJM716	353.2	24.1	28	75.4	1.7
X-1835	NSCLC	BYL719 + LJM716	479.1	23.5	31	137.9	-0.8
X-1835	NSCLC	BYL719 + LJM716	508.1	24.4	38	152.3	3
X-1835	NSCLC	BYL719 + LJM716	786.1	24.1	43	290.3	1.7
X-1835	NSCLC	BYL719 + LJM716	700	20.2	48	247.6	-14.8
X-1835	NSCLC	BYL719 + LJM716	740	19.6	50	267.4	-17.3
X-1835	NSCLC	CGM097	190.3	21.1	0	0	0
X-1835	NSCLC	CGM097	151.7	21.4	2	-20.3	1.4
X-1835	NSCLC	CGM097	125.5	23.3	8	-34.1	10.4
X-1835	NSCLC	CGM097	275.4	23.6	14	44.7	11.8
X-1835	NSCLC	CGM097	355.6	23.5	17	86.9	11.4
X-1835	NSCLC	CGM097	562.6	23.7	24	195.6	12.3
X-1835	NSCLC	CGM097	503.3	23.3	28	164.5	10.4
X-1835	NSCLC	CGM097	726.3	23.7	31	281.7	12.3
X-1835	NSCLC	CGM097	940.8	23.7	38	394.4	12.3
X-1835	NSCLC	CGM097	1265.4	23.8	43	565	12.8
X-1835	NSCLC	CKX620	176.7	23	0	0	0
X-1835	NSCLC	CKX620	73.1	22.8	2	-58.6	-0.9
X-1835	NSCLC	CKX620	78.1	23.2	7	-55.8	0.9
X-1835	NSCLC	CKX620	50.5	23.7	9	-71.4	3
X-1835	NSCLC	CKX620	31.5	24.5	14	-82.2	6.5
X-1835	NSCLC	CKX620	56.7	24.8	17	-67.9	7.8
X-1835	NSCLC	CKX620	74.5	24.9	21	-57.8	8.3
X-1835	NSCLC	CKX620	69.6	24.8	24	-60.6	7.8
X-1835	NSCLC	CKX620	53.7	25.2	31	-69.6	9.6
X-1835	NSCLC	CKX620	34.5	25.9	35	-80.5	12.6
X-1835	NSCLC	CKX620	41.4	26.3	38	-76.6	14.3
X-1835	NSCLC	CKX620	48.7	25.5	45	-72.4	10.9
X-1835	NSCLC	CKX620	63.2	25.8	55	-64.2	12.2
X-1835	NSCLC	CKX620	60.7	26.7	59	-65.6	16.1
X-1835	NSCLC	CKX620	56.1	26.2	63	-68.3	13.9
X-1835	NSCLC	CKX620	53.8	26.8	66	-69.6	16.5
X-1835	NSCLC	CKX620	54	25.5	70	-69.4	10.9
X-1835	NSCLC	CKX620	59.2	25.5	77	-66.5	10.9
X-1835	NSCLC	CKX620	59.9	25.4	84	-66.1	10.4
X-1835	NSCLC	CKX620	44.2	24.9	85	-75	8.3
X-1835	NSCLC	CLR457	175.8	24.8	0	0	0
X-1835	NSCLC	CLR457	127	24.6	2	-27.8	-0.8
X-1835	NSCLC	CLR457	151.9	24.2	7	-13.6	-2.4
X-1835	NSCLC	CLR457	145	23.8	9	-17.5	-4
X-1835	NSCLC	CLR457	181.8	25.4	14	3.4	2.4
X-1835	NSCLC	CLR457	189.8	24.8	17	8	0
X-1835	NSCLC	CLR457	304	25.9	21	72.9	4.4
X-1835	NSCLC	CLR457	406.8	25.6	24	131.4	3.2
X-1835	NSCLC	CLR457	303.2	26	31	72.5	4.8
X-1835	NSCLC	CLR457	329	25.9	35	87.1	4.4
X-1835	NSCLC	CLR457	362.7	26.5	38	106.3	6.9
X-1835	NSCLC	CLR457	542.9	26.2	45	208.8	5.6
X-1835	NSCLC	CLR457	931.1	26.2	50	429.6	5.6
X-1835	NSCLC	HDM201	204.8	24.6	0	0	0
X-1835	NSCLC	HDM201	207.6	24.7	3	1.4	0.4
X-1835	NSCLC	HDM201	274.4	24	7	34	-2.4
X-1835	NSCLC	HDM201	270.2	23.2	10	31.9	-5.7
X-1835	NSCLC	HDM201	300.9	23.8	17	46.9	-3.3
X-1835	NSCLC	HDM201	332.9	24.1	21	62.5	-2
X-1835	NSCLC	HDM201	337.9	24	24	65	-2.4
X-1835	NSCLC	HDM201	497.2	25	31	142.8	1.6
X-1835	NSCLC	HDM201	518	24.2	36	152.9	-1.6
X-1835	NSCLC	cetuximab	242.3	28.4	0	0	0
X-1835	NSCLC	cetuximab	247.3	28.1	3	2.1	-1.1
X-1835	NSCLC	cetuximab	283.1	28.6	10	16.8	0.7
X-1835	NSCLC	cetuximab	390.5	29.3	14	61.2	3.2
X-1835	NSCLC	cetuximab	475.9	28.7	17	96.4	1.1
X-1835	NSCLC	cetuximab	417.2	30.3	24	72.2	6.7
X-1835	NSCLC	cetuximab	581.4	29.1	29	140	2.5
X-1835	NSCLC	cetuximab	567.1	29.7	34	134	4.6
X-1835	NSCLC	cetuximab	557.8	30.7	38	130.2	8.1
X-1835	NSCLC	cetuximab	693.6	30.8	42	186.3	8.5
X-1835	NSCLC	erlotinib	199.6	27.2	0	0	0
X-1835	NSCLC	erlotinib	189.7	27.3	3	-5	0.4
X-1835	NSCLC	erlotinib	213.6	25.9	7	7	-4.8
X-1835	NSCLC	erlotinib	176.2	23.3	10	-11.7	-14.3
X-1835	NSCLC	erlotinib	177.1	23.8	17	-11.3	-12.5
X-1835	NSCLC	erlotinib	175.7	25	21	-12	-8.1
X-1835	NSCLC	erlotinib	221.3	27.2	24	10.9	0
X-1835	NSCLC	erlotinib	296.4	27.9	31	48.5	2.6
X-1835	NSCLC	erlotinib	272	27.4	36	36.3	0.7
X-1835	NSCLC	erlotinib	298.8	24.7	41	49.7	-9.2
X-1835	NSCLC	erlotinib	701.5	24.1	45	251.5	-11.4
X-1835	NSCLC	erlotinib	666.7	23.1	49	234	-15.1
X-1835	NSCLC	erlotinib	743.1	29.1	52	272.3	7
X-1835	NSCLC	erlotinib	529.6	27.9	56	165.3	2.6
X-1835	NSCLC	erlotinib	613.8	24.7	63	207.5	-9.2
X-1835	NSCLC	erlotinib	608.8	25.5	70	205	-6.2
X-1835	NSCLC	erlotinib	636.6	27.6	73	218.9	1.5
X-1835	NSCLC	erlotinib	869.6	30.1	76	335.7	10.7
X-1835	NSCLC	HSP990	197.5	27	0	0	0
X-1835	NSCLC	HSP990	170.7	27.1	7	-13.6	0.4
X-1835	NSCLC	HSP990	182	24.9	11	-7.8	-7.8
X-1835	NSCLC	HSP990	133.6	26	14	-32.4	-3.7
X-1835	NSCLC	HSP990	195.2	28.7	21	-1.2	6.3
X-1835	NSCLC	HSP990	101.1	27.9	31	-48.8	3.3
X-1835	NSCLC	HSP990	186.7	28.6	35	-5.5	5.9
X-1835	NSCLC	HSP990	182	27.3	39	-7.8	1.1
X-1835	NSCLC	HSP990	224.2	28.7	42	13.5	6.3
X-1835	NSCLC	INC280	206.1	27.7	0	0	0
X-1835	NSCLC	INC280	265.4	27.1	3	28.8	-2.2
X-1835	NSCLC	INC280	296.6	26.6	7	43.9	-4
X-1835	NSCLC	INC280	462.2	26.8	10	124.3	-3.2
X-1835	NSCLC	INC280	417.2	26.7	17	102.4	-3.6
X-1835	NSCLC	INC280	540.9	26.5	21	162.4	-4.3
X-1835	NSCLC	INC280	523.3	27.2	24	153.9	-1.8
X-1835	NSCLC	INC280	562.9	26.5	31	173.1	-4.3
X-1835	NSCLC	INC280	828.7	27.3	36	302.1	-1.4
X-1835	NSCLC	LCL161 + paclitaxel	255.9	28	0	0	0
X-1835	NSCLC	LCL161 + paclitaxel	210.9	27.9	10	-17.6	-0.4
X-1835	NSCLC	LCL161 + paclitaxel	125.3	28.6	14	-51	2.1
X-1835	NSCLC	LEE011	185.3	26.4	0	0	0
X-1835	NSCLC	LEE011	200.3	26.8	2	8.1	1.5
X-1835	NSCLC	LEE011	245.7	27.6	7	32.6	4.5
X-1835	NSCLC	LEE011	242.6	26.9	9	30.9	1.9
X-1835	NSCLC	LEE011	212.7	28.4	14	14.8	7.6
X-1835	NSCLC	LEE011	219.7	28.9	17	18.6	9.5
X-1835	NSCLC	LEE011	240.8	28.4	21	30	7.6
X-1835	NSCLC	LEE011	234.7	28.4	24	26.7	7.6
X-1835	NSCLC	LEE011	214.6	29.1	31	15.8	10.2
X-1835	NSCLC	LEE011	183.5	29.1	35	-1	10.2
X-1835	NSCLC	LEE011	129	28	38	-30.4	6.1
X-1835	NSCLC	LEE011	126.6	29	45	-31.7	9.8
X-1835	NSCLC	LEE011	80.6	28.4	55	-56.5	7.6
X-1835	NSCLC	LEE011	66.1	30.1	59	-64.3	14
X-1835	NSCLC	LEE011	59.8	29.9	63	-67.7	13.3
X-1835	NSCLC	LEE011	61.2	30.1	66	-67	14
X-1835	NSCLC	LEE011	49.1	29	70	-73.5	9.8
X-1835	NSCLC	LEE011	47.4	30.4	77	-74.4	15.2
X-1835	NSCLC	LEE011	33.4	30	84	-82	13.6
X-1835	NSCLC	LEE011	44.3	30	87	-76.1	13.6
X-1835	NSCLC	LEE011	26.6	30.4	90	-85.6	15.2
X-1835	NSCLC	LEE011	26.1	29.4	94	-85.9	11.4
X-1835	NSCLC	LEE011	21.4	29.2	98	-88.5	10.6
X-1835	NSCLC	LEE011	36	29.2	101	-80.6	10.6
X-1835	NSCLC	LEE011	24.2	29.4	104	-86.9	11.4
X-1835	NSCLC	LEE011	36.5	29.8	107	-80.3	12.9
X-1835	NSCLC	LEE011	31.4	28.8	111	-83.1	9.1
X-1835	NSCLC	LEE011	19.5	30.5	118	-89.5	15.5
X-1835	NSCLC	LEE011	27.4	29.6	121	-85.2	12.1
X-1835	NSCLC	LEE011	15.3	31.1	126	-91.7	17.8
X-1835	NSCLC	LEE011	20.2	31.6	129	-89.1	19.7
X-1835	NSCLC	LEE011	20.8	31	132	-88.8	17.4
X-1835	NSCLC	LEE011	16.8	30.6	139	-90.9	15.9
X-1835	NSCLC	LEE011	15.1	29.8	143	-91.9	12.9
X-1835	NSCLC	LEE011	14.5	31.3	147	-92.2	18.6
X-1835	NSCLC	LEE011	15.5	30.9	150	-91.6	17
X-1835	NSCLC	LEE011	8	30.6	154	-95.7	15.9
X-1835	NSCLC	LEE011	23.9	30.6	157	-87.1	15.9
X-1835	NSCLC	LEE011	19	31.2	160	-89.7	18.2
X-1835	NSCLC	LEE011	22.5	29.9	164	-87.9	13.3
X-1835	NSCLC	LEE011	17.8	30.3	168	-90.4	14.8
X-1835	NSCLC	LEE011	12.1	29.7	174	-93.5	12.5
X-1835	NSCLC	LEE011	13.3	29.7	178	-92.8	12.5
X-1835	NSCLC	LEE011	18.5	30	181	-90	13.6
X-1835	NSCLC	LGH447	188.2	26.8	0	0	0
X-1835	NSCLC	LGH447	206.3	27.4	10	9.6	2.2
X-1835	NSCLC	LGH447	202.4	27.6	14	7.5	3
X-1835	NSCLC	LGH447	199.2	27.4	18	5.8	2.2
X-1835	NSCLC	LGH447	242.8	26.5	21	29	-1.1
X-1835	NSCLC	LGH447	247.1	27.5	25	31.3	2.6
X-1835	NSCLC	LGH447	270.1	27.2	32	43.5	1.5
X-1835	NSCLC	LGH447	294.6	27.7	39	56.5	3.4
X-1835	NSCLC	LGH447	299.8	28.3	42	59.3	5.6
X-1835	NSCLC	LGH447	332.1	27.9	45	76.5	4.1
X-1835	NSCLC	LGH447	286.8	28.2	49	52.4	5.2
X-1835	NSCLC	LGH447	377	28.1	53	100.3	4.9
X-1835	NSCLC	LGH447	384.7	27.4	56	104.4	2.2
X-1835	NSCLC	LGH447	410.2	27.7	59	118	3.4
X-1835	NSCLC	LGH447	435.4	27	62	131.3	0.7
X-1835	NSCLC	LGH447	422.2	26.8	66	124.3	0
X-1835	NSCLC	LGH447	452.5	27.7	73	140.4	3.4
X-1835	NSCLC	LLM871	171.5	24.3	0	0	0
X-1835	NSCLC	LLM871	146.5	24.3	7	-14.6	0
X-1835	NSCLC	LLM871	175.3	23.5	17	2.2	-3.3
X-1835	NSCLC	LLM871	195.7	24.1	21	14.1	-0.8
X-1835	NSCLC	LLM871	283.3	24	25	65.2	-1.2
X-1835	NSCLC	LLM871	307.2	24.3	28	79.1	0
X-1835	NSCLC	LLM871	317	24.4	32	84.8	0.4
X-1835	NSCLC	LLM871	506.9	26	39	195.6	7
X-1835	NSCLC	binimetinib	203.2	25.5	0	0	0
X-1835	NSCLC	binimetinib	136.1	26.3	1	-33	3.1
X-1835	NSCLC	binimetinib	46.6	26	4	-77.1	2
X-1835	NSCLC	binimetinib	85.9	26	8	-57.7	2
X-1835	NSCLC	binimetinib	0	26.9	10	-100	5.5
X-1835	NSCLC	binimetinib	0	26.7	15	-100	4.7
X-1835	NSCLC	binimetinib	0	27.3	17	-100	7.1
X-1835	NSCLC	binimetinib	0	27.3	22	-100	7.1
X-1835	NSCLC	binimetinib	0	27	25	-100	5.9
X-1835	NSCLC	binimetinib	0	25.6	29	-100	0.4
X-1835	NSCLC	binimetinib	0	25.8	32	-100	1.2
X-1835	NSCLC	binimetinib	0	25.5	39	-100	0
X-1835	NSCLC	binimetinib	0	24.6	43	-100	-3.5
X-1835	NSCLC	binimetinib	0	24.6	46	-100	-3.5
X-1835	NSCLC	binimetinib	0	23.4	53	-100	-8.2
X-1835	NSCLC	binimetinib	0	22.9	63	-100	-10.2
X-1835	NSCLC	binimetinib	0	25	65	-100	-2
X-1835	NSCLC	paclitaxel	159.6	23.4	0	0	0
X-1835	NSCLC	paclitaxel	236.8	24.8	7	48.4	6
X-1835	NSCLC	paclitaxel	259.5	25.4	11	62.6	8.5
X-1835	NSCLC	paclitaxel	288.8	24.9	14	81	6.4
X-1835	NSCLC	paclitaxel	235.9	25.9	21	47.8	10.7
X-1835	NSCLC	paclitaxel	145.3	26.4	31	-9	12.8
X-1835	NSCLC	paclitaxel	206.6	27	35	29.4	15.4
X-1835	NSCLC	paclitaxel	328.1	26.5	39	105.6	13.2
X-1835	NSCLC	paclitaxel	369.9	26.5	42	131.8	13.2
X-1835	NSCLC	paclitaxel	497.6	25.8	46	211.8	10.3
X-1835	NSCLC	paclitaxel	666.8	26.1	53	317.8	11.5
X-1835	NSCLC	untreated	145.6	24.5	0	0	0
X-1835	NSCLC	untreated	163.3	25.1	1	12.2	2.4
X-1835	NSCLC	untreated	186.3	25.6	4	28	4.5
X-1835	NSCLC	untreated	188.9	26.1	8	29.7	6.5
X-1835	NSCLC	untreated	180.8	25.6	10	24.2	4.5
X-1835	NSCLC	untreated	398.5	25.8	15	173.7	5.3
X-1835	NSCLC	untreated	722.4	27.7	25	396.2	13.1
X-1835	NSCLC	untreated	875.1	27.8	29	501	13.5
X-1835	NSCLC	LFW527 + binimetinib	266.17	26.3	0	0	0
X-1835	NSCLC	LFW527 + binimetinib	213.67	26	3	-19.7	-1.1
X-1835	NSCLC	LFW527 + binimetinib	167.18	25.2	7	-37.2	-4.2
X-1835	NSCLC	LFW527 + binimetinib	136.97	26.2	10	-48.5	-0.4
X-1835	NSCLC	LFW527 + binimetinib	330.05	25.2	14	24	-4.2
X-1835	NSCLC	LFW527 + binimetinib	307.67	25.2	17	15.6	-4.2
X-1835	NSCLC	LFW527 + binimetinib	222.09	26.3	21	-16.6	0
X-1835	NSCLC	LFW527 + binimetinib	140.17	26.2	24	-47.3	-0.4
X-1835	NSCLC	LFW527 + binimetinib	89.19	26	28	-66.5	-1.1
X-1835	NSCLC	LFW527 + binimetinib	194.89	23.8	31	-26.8	-9.5
X-1835	NSCLC	LFW527 + binimetinib	277.97	23.7	36	4.4	-9.9
X-1835	NSCLC	LFW527 + binimetinib	264.97	25.2	45	-0.5	-4.2
X-1835	NSCLC	LFW527 + binimetinib	182.75	25.6	49	-31.3	-2.7
X-1835	NSCLC	LFW527 + binimetinib	128.45	24.2	56	-51.7	-8
X-1835	NSCLC	LFW527 + binimetinib	188.58	25.8	66	-29.2	-1.9
X-1835	NSCLC	LFW527 + binimetinib	324.73	25.4	70	22	-3.4
X-1835	NSCLC	LFW527 + binimetinib	169.33	23.7	73	-36.4	-9.9
X-1835	NSCLC	LFW527 + binimetinib	347.81	24.1	77	30.7	-8.4
X-1835	NSCLC	LFW527 + binimetinib	226.91	23.5	80	-14.7	-10.6
X-1835	NSCLC	LFW527 + binimetinib	381.06	22.3	84	43.2	-15.2
X-1835	NSCLC	LFW527 + binimetinib	324.91	23.8	87	22.1	-9.5
X-1835	NSCLC	LFW527 + binimetinib	299.4	23.6	94	12.5	-10.3
X-1835	NSCLC	LFW527 + binimetinib	176.57	22.9	98	-33.7	-12.9
X-1835	NSCLC	LFW527 + binimetinib	193.23	22.8	101	-27.4	-13.3
X-1835	NSCLC	LFW527 + binimetinib	288.11	22.5	108	8.2	-14.4
X-1835	NSCLC	LFW527 + binimetinib	419.7	21.5	113	57.7	-18.3
X-1835	NSCLC	LFW527 + binimetinib	402.66	21.8	120	51.3	-17.1
X-1855	CRC	5FU	199.5	24.7	0	0	0
X-1855	CRC	5FU	202.2	26.6	3	1.4	7.7
X-1855	CRC	5FU	206.9	24	6	3.7	-2.8
X-1855	CRC	5FU	217.6	24.4	10	9.1	-1.2
X-1855	CRC	5FU	221.1	22.9	17	10.8	-7.3
X-1855	CRC	5FU	222.6	23.1	21	11.6	-6.5
X-1855	CRC	5FU	246.9	23.5	24	23.8	-4.9
X-1855	CRC	5FU	275.4	23.1	27	38	-6.5
X-1855	CRC	5FU	266.7	24.2	31	33.7	-2
X-1855	CRC	5FU	308.3	24.2	34	54.5	-2
X-1855	CRC	5FU	343.6	23.8	38	72.2	-3.6
X-1855	CRC	5FU	346.6	22.8	41	73.7	-7.7
X-1855	CRC	5FU	338.5	24.7	45	69.7	0
X-1855	CRC	5FU	322.5	25.6	50	61.7	3.6
X-1855	CRC	5FU	289.8	25.7	53	45.3	4
X-1855	CRC	5FU	275	25.4	56	37.8	2.8
X-1855	CRC	5FU	274.6	26.3	59	37.6	6.5
X-1855	CRC	5FU	255.2	23.8	63	27.9	-3.6
X-1855	CRC	5FU	249.1	25.3	66	24.9	2.4
X-1855	CRC	5FU	263.1	25	69	31.9	1.2
X-1855	CRC	5FU	258.7	26	74	29.7	5.3
X-1855	CRC	5FU	260.8	24.8	77	30.7	0.4
X-1855	CRC	5FU	252.8	24.9	80	26.7	0.8
X-1855	CRC	5FU	256	25.9	83	28.3	4.9
X-1855	CRC	5FU	243.3	25.6	87	22	3.6
X-1855	CRC	BKM120	201.7	24.7	0	0	0
X-1855	CRC	BKM120	200.2	26.1	3	-0.7	5.7
X-1855	CRC	BKM120	202.2	25.2	14	0.2	2
X-1855	CRC	BKM120	228.2	25.6	18	13.1	3.6
X-1855	CRC	BKM120	233.4	21.4	21	15.7	-13.4
X-1855	CRC	BKM120	255.2	24.4	24	26.5	-1.2
X-1855	CRC	BKM120	287	26.5	28	42.3	7.3
X-1855	CRC	BKM120	279.3	26.4	31	38.5	6.9
X-1855	CRC	BKM120	297.4	26	35	47.4	5.3
X-1855	CRC	BKM120	279.7	26	38	38.7	5.3
X-1855	CRC	BKM120	279.1	27.5	42	38.4	11.3
X-1855	CRC	BKM120	282.7	26.4	47	40.2	6.9
X-1855	CRC	BKM120	290.9	26	50	44.2	5.3
X-1855	CRC	BKM120	291.6	26.3	53	44.6	6.5
X-1855	CRC	BKM120	294.2	25.9	56	45.9	4.9
X-1855	CRC	BKM120	307.7	27.9	60	52.6	13
X-1855	CRC	BKM120	309.6	26.9	63	53.5	8.9
X-1855	CRC	BKM120	313.2	28.2	66	55.3	14.2
X-1855	CRC	BKM120	319.3	26.9	71	58.3	8.9
X-1855	CRC	BKM120	327.4	26.7	74	62.3	8.1
X-1855	CRC	BKM120	330.9	27	77	64.1	9.3
X-1855	CRC	BKM120	314.2	25.7	80	55.8	4
X-1855	CRC	BKM120	316.1	26.7	84	56.7	8.1
X-1855	CRC	BKM120 + LJC049	202.5	24.1	0	0	0
X-1855	CRC	BKM120 + LJC049	206.7	24.2	3	2.1	0.4
X-1855	CRC	BKM120 + LJC049	210.9	22.8	7	4.1	-5.4
X-1855	CRC	BKM120 + LJC049	221.9	25.6	12	9.6	6.2
X-1855	CRC	BKM120 + LJC049	281.4	23.8	15	39	-1.2
X-1855	CRC	BKM120 + LJC049	324.9	23	18	60.4	-4.6
X-1855	CRC	BKM120 + LJC049	332.2	22.1	21	64	-8.3
X-1855	CRC	BKM120 + LJC049	409.9	22.9	25	102.4	-5
X-1855	CRC	BKM120 + LJC049	419.8	22.9	28	107.3	-5
X-1855	CRC	BKM120 + LJC049	446.7	22.7	31	120.6	-5.8
X-1855	CRC	BKM120 + LJC049	544.8	24.6	36	169	2.1
X-1855	CRC	BKM120 + LJC049	610.8	25.4	39	201.6	5.4
X-1855	CRC	BKM120 + LJC049	780.1	25.4	42	285.2	5.4
X-1855	CRC	BKM120 + LJC049	967	23.1	45	377.5	-4.1
X-1855	CRC	BYL719	207.7	27.5	0	0	0
X-1855	CRC	BYL719	215.2	27.9	4	3.6	1.5
X-1855	CRC	BYL719	217	26.7	7	4.5	-2.9
X-1855	CRC	BYL719	217.5	27.7	11	4.7	0.7
X-1855	CRC	BYL719	238.7	28	14	14.9	1.8
X-1855	CRC	BYL719	237.7	28.5	18	14.4	3.6
X-1855	CRC	BYL719	263.8	28.4	23	27	3.3
X-1855	CRC	BYL719	263.4	28.6	26	26.8	4
X-1855	CRC	BYL719	269.9	28.9	29	29.9	5.1
X-1855	CRC	BYL719	273.2	27.2	32	31.5	-1.1
X-1855	CRC	BYL719	285.5	27.1	36	37.5	-1.5
X-1855	CRC	BYL719	332.4	29.8	39	60	8.4
X-1855	CRC	BYL719	356.6	28.4	42	71.7	3.3
X-1855	CRC	BYL719	351.5	29.7	47	69.2	8
X-1855	CRC	BYL719	352	29.9	50	69.5	8.7
X-1855	CRC	BYL719	353.4	29.1	53	70.1	5.8
X-1855	CRC	BYL719	358.9	28.1	56	72.8	2.2
X-1855	CRC	BYL719	401.6	30.6	60	93.4	11.3
X-1855	CRC	BYL719	409.3	29.2	63	97.1	6.2
X-1855	CRC	BYL719	431.8	30.2	67	107.9	9.8
X-1855	CRC	BYL719	499.3	28.3	70	140.4	2.9
X-1855	CRC	BYL719	519	28.9	74	149.9	5.1
X-1855	CRC	BYL719	664	27.8	77	219.7	1.1
X-1855	CRC	BYL719	716.2	28.4	81	244.8	3.3
X-1855	CRC	BYL719	708.9	27.5	84	241.3	0
X-1855	CRC	BYL719	857.4	29.7	88	312.8	8
X-1855	CRC	BYL719	845.6	29.8	91	307.1	8.4
X-1855	CRC	BYL719 + LJM716	199.5	26.4	0	0	0
X-1855	CRC	BYL719 + LJM716	203.4	24.6	4	2	-6.8
X-1855	CRC	BYL719 + LJM716	203.7	24.8	7	2.1	-6.1
X-1855	CRC	BYL719 + LJM716	211.3	24.9	11	5.9	-5.7
X-1855	CRC	BYL719 + LJM716	214.2	24.1	14	7.4	-8.7
X-1855	CRC	BYL719 + LJM716	220.3	26.7	18	10.4	1.1
X-1855	CRC	BYL719 + LJM716	220.9	24.2	23	10.7	-8.3
X-1855	CRC	BYL719 + LJM716	228.1	23	26	14.3	-12.9
X-1855	CRC	BYL719 + LJM716	239.5	23.9	29	20.1	-9.5
X-1855	CRC	BYL719 + LJM716	254.9	25.2	32	27.8	-4.5
X-1855	CRC	BYL719 + LJM716	302	24	36	51.4	-9.1
X-1855	CRC	BYL719 + LJM716	341.7	23.2	39	71.3	-12.1
X-1855	CRC	BYL719 + LJM716	408.2	26	42	104.6	-1.5
X-1855	CRC	BYL719 + LJM716	440.3	22.8	47	120.7	-13.6
X-1855	CRC	BYL719 + LJM716	509.5	23.5	50	155.4	-11
X-1855	CRC	BYL719 + LJM716	533	25.2	53	167.2	-4.5
X-1855	CRC	BYL719 + LJM716	551.7	24.1	56	176.5	-8.7
X-1855	CRC	BYL719 + LJM716	584	25.4	60	192.7	-3.8
X-1855	CRC	BYL719 + LJM716	828.4	23.3	63	315.2	-11.7
X-1855	CRC	BYL719 + cetuximab + encorafenib	202.8	23.8	0	0	0
X-1855	CRC	BYL719 + cetuximab + encorafenib	207.7	24	3	2.4	0.8
X-1855	CRC	BYL719 + cetuximab + encorafenib	208.3	24.1	7	2.7	1.3
X-1855	CRC	BYL719 + cetuximab + encorafenib	201.3	23.7	10	-0.7	-0.4
X-1855	CRC	BYL719 + cetuximab + encorafenib	202.1	23.8	14	-0.3	0
X-1855	CRC	BYL719 + cetuximab + encorafenib	221.4	24.3	19	9.2	2.1
X-1855	CRC	BYL719 + cetuximab + encorafenib	246.5	23.8	22	21.5	0
X-1855	CRC	BYL719 + cetuximab + encorafenib	252.6	23.7	25	24.6	-0.4
X-1855	CRC	BYL719 + cetuximab + encorafenib	245.1	23.1	28	20.9	-2.9
X-1855	CRC	BYL719 + cetuximab + encorafenib	261.6	24.1	32	29	1.3
X-1855	CRC	BYL719 + cetuximab + encorafenib	281.2	24.5	35	38.7	2.9
X-1855	CRC	BYL719 + cetuximab + encorafenib	278.5	24.7	38	37.3	3.8
X-1855	CRC	BYL719 + cetuximab + encorafenib	285.8	25.1	43	40.9	5.5
X-1855	CRC	BYL719 + cetuximab + encorafenib	301.6	25.3	46	48.7	6.3
X-1855	CRC	BYL719 + cetuximab + encorafenib	302.9	24.1	49	49.4	1.3
X-1855	CRC	BYL719 + cetuximab + encorafenib	300.8	24.5	52	48.3	2.9
X-1855	CRC	BYL719 + cetuximab + encorafenib	331.5	25.8	56	63.5	8.4
X-1855	CRC	BYL719 + cetuximab + encorafenib	352.7	24.4	59	73.9	2.5
X-1855	CRC	BYL719 + cetuximab + encorafenib	382.9	24.5	63	88.8	2.9
X-1855	CRC	BYL719 + cetuximab + encorafenib	445	24.9	66	119.4	4.6
X-1855	CRC	BYL719 + cetuximab + encorafenib	479.2	24.1	70	136.3	1.3
X-1855	CRC	BYL719 + cetuximab + encorafenib	470.9	23.7	73	132.2	-0.4
X-1855	CRC	BYL719 + cetuximab + encorafenib	630.8	23.1	77	211	-2.9
X-1855	CRC	BYL719 + cetuximab + encorafenib	622.1	21	80	206.8	-11.8
X-1855	CRC	BYL719 + cetuximab + encorafenib	699	23.7	84	244.7	-0.4
X-1855	CRC	BYL719 + cetuximab + encorafenib	687.5	23.9	87	239	0.4
X-1855	CRC	BYL719 + binimetinib	197.4	27.9	0	0	0
X-1855	CRC	BYL719 + binimetinib	195.4	26.8	3	-1	-3.9
X-1855	CRC	BYL719 + binimetinib	193	26.3	7	-2.2	-5.7
X-1855	CRC	BYL719 + binimetinib	187.9	27.2	12	-4.8	-2.5
X-1855	CRC	BYL719 + binimetinib	142.5	26.6	15	-27.8	-4.7
X-1855	CRC	BYL719 + binimetinib	138.6	26.5	18	-29.8	-5
X-1855	CRC	BYL719 + binimetinib	132.3	26.5	21	-33	-5
X-1855	CRC	BYL719 + binimetinib	134.2	26.7	25	-32	-4.3
X-1855	CRC	BYL719 + binimetinib	125.7	27.4	28	-36.3	-1.8
X-1855	CRC	BYL719 + binimetinib	113.4	27.1	31	-42.6	-2.9
X-1855	CRC	BYL719 + binimetinib	118.2	27.9	36	-40.1	0
X-1855	CRC	BYL719 + binimetinib	113.4	27.6	39	-42.6	-1.1
X-1855	CRC	BYL719 + binimetinib	139	27.3	42	-29.6	-2.2
X-1855	CRC	BYL719 + binimetinib	110.6	28.3	45	-44	1.4
X-1855	CRC	BYL719 + binimetinib	113.6	27.4	49	-42.5	-1.8
X-1855	CRC	BYL719 + binimetinib	118.6	27	52	-39.9	-3.2
X-1855	CRC	BYL719 + binimetinib	121.6	27.4	56	-38.4	-1.8
X-1855	CRC	BYL719 + binimetinib	123.6	27.1	59	-37.4	-2.9
X-1855	CRC	BYL719 + binimetinib	150.5	26.2	63	-23.8	-6.1
X-1855	CRC	BYL719 + binimetinib	138.9	27.1	66	-29.6	-2.9
X-1855	CRC	BYL719 + binimetinib	187.9	27.5	70	-4.8	-1.4
X-1855	CRC	BYL719 + binimetinib	202.8	26.1	73	2.7	-6.5
X-1855	CRC	BYL719 + binimetinib	194.3	27.3	77	-1.6	-2.2
X-1855	CRC	BYL719 + binimetinib	199.6	27.4	80	1.1	-1.8
X-1855	CRC	BYL719 + binimetinib	189.7	26	84	-3.9	-6.8
X-1855	CRC	BYL719 + cetuximab	222.1	26.8	0	0	0
X-1855	CRC	BYL719 + cetuximab	229.5	27.2	3	3.3	1.5
X-1855	CRC	BYL719 + cetuximab	240.3	27.1	7	8.2	1.1
X-1855	CRC	BYL719 + cetuximab	311.7	27.9	12	40.3	4.1
X-1855	CRC	BYL719 + cetuximab	356.4	27.4	15	60.5	2.2
X-1855	CRC	BYL719 + cetuximab	363.2	27.9	18	63.5	4.1
X-1855	CRC	BYL719 + cetuximab	374.6	26.7	21	68.7	-0.4
X-1855	CRC	BYL719 + cetuximab	390.2	27.9	25	75.7	4.1
X-1855	CRC	BYL719 + cetuximab	421.4	28	28	89.7	4.5
X-1855	CRC	BYL719 + cetuximab	444.6	28.1	31	100.2	4.9
X-1855	CRC	BYL719 + cetuximab	503	28.7	36	126.5	7.1
X-1855	CRC	BYL719 + cetuximab	541	28.4	39	143.6	6
X-1855	CRC	BYL719 + cetuximab	760	28.5	42	242.2	6.3
X-1855	CRC	BYL719 + cetuximab	911.1	28.7	45	310.2	7.1
X-1855	CRC	BYL719 + encorafenib	201.9	24.5	0	0	0
X-1855	CRC	BYL719 + encorafenib	200.5	24.3	5	-0.7	-0.8
X-1855	CRC	BYL719 + encorafenib	201.1	24.1	8	-0.4	-1.6
X-1855	CRC	BYL719 + encorafenib	200.5	24.1	11	-0.7	-1.6
X-1855	CRC	BYL719 + encorafenib	201.7	23.9	14	-0.1	-2.4
X-1855	CRC	BYL719 + encorafenib	205	24	18	1.5	-2
X-1855	CRC	BYL719 + encorafenib	199.8	24.1	21	-1	-1.6
X-1855	CRC	BYL719 + encorafenib	206.9	23.9	24	2.5	-2.4
X-1855	CRC	BYL719 + encorafenib	207.3	23.9	29	2.7	-2.4
X-1855	CRC	BYL719 + encorafenib	204.2	24.9	32	1.1	1.6
X-1855	CRC	BYL719 + encorafenib	197.7	24.1	35	-2.1	-1.6
X-1855	CRC	BYL719 + encorafenib	187.5	23.3	38	-7.1	-4.9
X-1855	CRC	BYL719 + encorafenib	128.8	24	42	-36.2	-2
X-1855	CRC	BYL719 + encorafenib	140.5	23.7	45	-30.4	-3.3
X-1855	CRC	BYL719 + encorafenib	116.4	24.1	49	-42.3	-1.6
X-1855	CRC	BYL719 + encorafenib	117.6	24.5	52	-41.8	0
X-1855	CRC	BYL719 + encorafenib	120.3	23.6	56	-40.4	-3.7
X-1855	CRC	BYL719 + encorafenib	124.6	23.5	59	-38.3	-4.1
X-1855	CRC	BYL719 + encorafenib	168.5	23.8	63	-16.5	-2.9
X-1855	CRC	BYL719 + encorafenib	150.4	23.7	66	-25.5	-3.3
X-1855	CRC	BYL719 + encorafenib	149.4	23	70	-26	-6.1
X-1855	CRC	BYL719 + encorafenib	118.9	23.6	73	-41.1	-3.7
X-1855	CRC	BYL719 + encorafenib	106.5	23.4	77	-47.3	-4.5
X-1855	CRC	BYL719 + encorafenib	104.3	23.8	80	-48.3	-2.9
X-1855	CRC	BYL719 + encorafenib	97.9	23.5	84	-51.5	-4.1
X-1855	CRC	BYL719 + encorafenib	76.1	23.8	88	-62.3	-2.9
X-1855	CRC	BYL719 + encorafenib	74.8	23.5	91	-63	-4.1
X-1855	CRC	CGM097	200.7	25.6	0	0	0
X-1855	CRC	CGM097	200.3	26.1	4	-0.2	2
X-1855	CRC	CGM097	214.9	27.3	11	7.1	6.6
X-1855	CRC	CGM097	234.9	26.9	15	17	5.1
X-1855	CRC	CGM097	294.7	29.4	18	46.8	14.8
X-1855	CRC	CGM097	292.5	30	21	45.7	17.2
X-1855	CRC	CGM097	305.5	30.4	25	52.2	18.7
X-1855	CRC	CGM097	326.1	30.8	28	62.5	20.3
X-1855	CRC	CGM097	435.2	31	32	116.8	21.1
X-1855	CRC	CGM097	453.7	29.3	35	126.1	14.5
X-1855	CRC	CGM097	463.1	29	39	130.7	13.3
X-1855	CRC	CGM097	490.8	28.7	44	144.5	12.1
X-1855	CRC	CGM097	495.4	28.1	47	146.8	9.8
X-1855	CRC	CGM097	547.8	25.7	50	172.9	0.4
X-1855	CRC	CGM097	588	27.4	53	193	7
X-1855	CRC	CGM097	603.7	25.5	57	200.8	-0.4
X-1855	CRC	CGM097	637.5	27.2	60	217.6	6.2
X-1855	CRC	CGM097	648.7	29.9	63	223.2	16.8
X-1855	CRC	CGM097	727.9	27.7	68	262.7	8.2
X-1855	CRC	CGM097	830.5	27.4	71	313.8	7
X-1855	CRC	CGM097	900.1	27.3	74	348.5	6.6
X-1855	CRC	CGM097	905.1	27.2	77	351	6.2
X-1855	CRC	CKX620	197.4	24.5	0	0	0
X-1855	CRC	CKX620	197.2	24.3	3	-0.1	-0.8
X-1855	CRC	CKX620	202.2	24.9	7	2.4	1.6
X-1855	CRC	CKX620	194.9	26	14	-1.3	6.1
X-1855	CRC	CKX620	201.3	25.6	18	2	4.5
X-1855	CRC	CKX620	218.2	24.8	21	10.5	1.2
X-1855	CRC	CKX620	218.4	25.3	24	10.6	3.3
X-1855	CRC	CKX620	217.2	26	28	10	6.1
X-1855	CRC	CKX620	213.4	25.6	31	8.1	4.5
X-1855	CRC	CKX620	215.1	26.4	35	9	7.8
X-1855	CRC	CKX620	233.4	26	38	18.2	6.1
X-1855	CRC	CKX620	241.8	26.1	42	22.5	6.5
X-1855	CRC	CKX620	243	25.8	47	23.1	5.3
X-1855	CRC	CKX620	261.1	25.3	50	32.3	3.3
X-1855	CRC	CKX620	270.7	26.4	53	37.1	7.8
X-1855	CRC	CKX620	284.7	27.7	56	44.2	13.1
X-1855	CRC	CKX620	305	25.9	60	54.5	5.7
X-1855	CRC	CKX620	304.6	27.3	63	54.3	11.4
X-1855	CRC	CKX620	311.3	26.9	66	57.7	9.8
X-1855	CRC	CKX620	350.6	27.3	71	77.6	11.4
X-1855	CRC	CKX620	366.1	26.4	74	85.5	7.8
X-1855	CRC	CKX620	391.2	26.4	77	98.2	7.8
X-1855	CRC	CKX620	411.6	26.9	80	108.5	9.8
X-1855	CRC	CKX620	409.5	26.8	84	107.4	9.4
X-1855	CRC	HDM201	205.2	27.5	0	0	0
X-1855	CRC	HDM201	205.5	27.5	3	0.1	0
X-1855	CRC	HDM201	258.6	28.3	8	26	2.9
X-1855	CRC	HDM201	294	27.3	11	43.3	-0.7
X-1855	CRC	HDM201	298.8	26.4	14	45.6	-4
X-1855	CRC	HDM201	337.8	26.6	17	64.6	-3.3
X-1855	CRC	HDM201	392.7	26.8	21	91.4	-2.5
X-1855	CRC	HDM201	396.9	28.7	24	93.4	4.4
X-1855	CRC	HDM201	442.4	28.5	28	115.6	3.6
X-1855	CRC	HDM201	490.3	26.6	31	138.9	-3.3
X-1855	CRC	HDM201	632	26.6	35	208	-3.3
X-1855	CRC	HDM201	842.2	26.3	38	310.4	-4.4
X-1855	CRC	HDM201	868.8	25.4	42	323.4	-7.6
X-1855	CRC	HDM201	887.7	25.1	45	332.6	-8.7
X-1855	CRC	HDM201	1012.5	26.5	49	393.4	-3.6
X-1855	CRC	HDM201	1048.7	24.8	52	411.1	-9.8
X-1855	CRC	HDM201	1101.8	27	56	436.9	-1.8
X-1855	CRC	cetuximab	202.8	23.3	0	0	0
X-1855	CRC	cetuximab	203.9	22.9	4	0.5	-1.7
X-1855	CRC	cetuximab	205.4	22.6	7	1.3	-3
X-1855	CRC	cetuximab	202.8	21.1	10	0	-9.4
X-1855	CRC	cetuximab	217	23.6	14	7	1.3
X-1855	CRC	cetuximab	227.6	21.3	21	12.2	-8.6
X-1855	CRC	cetuximab	301.1	21.6	25	48.5	-7.3
X-1855	CRC	cetuximab	326.9	24.9	28	61.2	6.9
X-1855	CRC	cetuximab	371.3	23.5	31	83.1	0.9
X-1855	CRC	cetuximab	434.4	24.4	35	114.2	4.7
X-1855	CRC	cetuximab	417.5	22.3	38	105.9	-4.3
X-1855	CRC	cetuximab	512.6	20	42	152.8	-14.2
X-1855	CRC	cetuximab	640.1	22.4	45	215.6	-3.9
X-1855	CRC	cetuximab	689.2	23.7	49	239.8	1.7
X-1855	CRC	cetuximab	770.4	20.6	54	279.9	-11.6
X-1855	CRC	cetuximab	959.6	20.7	57	373.2	-11.2
X-1855	CRC	cetuximab + encorafenib	222.7	28.5	0	0	0
X-1855	CRC	cetuximab + encorafenib	218.8	27.7	3	-1.8	-2.8
X-1855	CRC	cetuximab + encorafenib	217.9	28.4	7	-2.2	-0.4
X-1855	CRC	cetuximab + encorafenib	223.4	27.7	10	0.3	-2.8
X-1855	CRC	cetuximab + encorafenib	280.6	28.9	14	26	1.4
X-1855	CRC	cetuximab + encorafenib	309.5	28.8	19	39	1.1
X-1855	CRC	cetuximab + encorafenib	309.3	28.9	22	38.9	1.4
X-1855	CRC	cetuximab + encorafenib	346.9	29.1	25	55.8	2.1
X-1855	CRC	cetuximab + encorafenib	345.9	28.1	28	55.3	-1.4
X-1855	CRC	cetuximab + encorafenib	368.2	29.5	32	65.3	3.5
X-1855	CRC	cetuximab + encorafenib	365.5	30	35	64.1	5.3
X-1855	CRC	cetuximab + encorafenib	388	30.3	38	74.2	6.3
X-1855	CRC	cetuximab + encorafenib	385.3	30	43	73	5.3
X-1855	CRC	cetuximab + encorafenib	369.7	30.4	46	66	6.7
X-1855	CRC	cetuximab + encorafenib	368.2	29.5	49	65.3	3.5
X-1855	CRC	cetuximab + encorafenib	361.3	30.3	52	62.2	6.3
X-1855	CRC	cetuximab + encorafenib	356.9	30	56	60.3	5.3
X-1855	CRC	cetuximab + encorafenib	359.5	30.2	59	61.4	6
X-1855	CRC	cetuximab + encorafenib	333.6	30.2	63	49.8	6
X-1855	CRC	cetuximab + encorafenib	329.8	30	66	48.1	5.3
X-1855	CRC	cetuximab + encorafenib	363	28.3	70	63	-0.7
X-1855	CRC	cetuximab + encorafenib	424.7	29	73	90.7	1.8
X-1855	CRC	cetuximab + encorafenib	444.6	28.5	77	99.6	0
X-1855	CRC	cetuximab + encorafenib	457.7	28.4	80	105.5	-0.4
X-1855	CRC	cetuximab + encorafenib	488.7	28.7	84	119.4	0.7
X-1855	CRC	cetuximab + encorafenib	472.7	28.1	87	112.3	-1.4
X-1855	CRC	LEE011	199.8	22.9	0	0	0
X-1855	CRC	LEE011	199.8	22.8	3	0	-0.4
X-1855	CRC	LEE011	200.4	22.1	6	0.3	-3.5
X-1855	CRC	LEE011	199.8	23.6	17	0	3.1
X-1855	CRC	LEE011	201.2	25.3	21	0.7	10.5
X-1855	CRC	LEE011	205.8	24.5	24	3	7
X-1855	CRC	LEE011	206.4	24.7	27	3.3	7.9
X-1855	CRC	LEE011	216.4	25.1	31	8.3	9.6
X-1855	CRC	LEE011	225.6	24.3	34	12.9	6.1
X-1855	CRC	LEE011	232.8	24.9	38	16.5	8.7
X-1855	CRC	LEE011	248.2	23.3	41	24.2	1.7
X-1855	CRC	LEE011	246.9	24.5	45	23.6	7
X-1855	CRC	LEE011	245.3	23.4	50	22.8	2.2
X-1855	CRC	LEE011	245.4	21.5	53	22.8	-6.1
X-1855	CRC	LEE011	253.8	23.9	56	27	4.4
X-1855	CRC	LEE011	260.4	23.9	59	30.3	4.4
X-1855	CRC	LEE011	272.4	24.4	63	36.3	6.6
X-1855	CRC	LEE011	315.1	24.4	66	57.7	6.6
X-1855	CRC	LEE011	320	22	69	60.2	-3.9
X-1855	CRC	LEE011	340.1	23.7	74	70.2	3.5
X-1855	CRC	LEE011	360.6	24	77	80.5	4.8
X-1855	CRC	LEE011	364.9	23.5	80	82.6	2.6
X-1855	CRC	LEE011	413.7	24.1	83	107.1	5.2
X-1855	CRC	LEE011	436.6	23.5	87	118.5	2.6
X-1855	CRC	encorafenib	199.5	27.4	0	0	0
X-1855	CRC	encorafenib	211.3	29.4	7	5.9	7.3
X-1855	CRC	encorafenib	248.6	28.7	11	24.6	4.7
X-1855	CRC	encorafenib	312.1	28.3	14	56.4	3.3
X-1855	CRC	encorafenib	343.9	28.5	17	72.4	4
X-1855	CRC	encorafenib	396.7	28.8	21	98.8	5.1
X-1855	CRC	encorafenib	407.5	28.6	24	104.3	4.4
X-1855	CRC	encorafenib	400.1	31.2	28	100.6	13.9
X-1855	CRC	encorafenib	428.8	30.6	31	114.9	11.7
X-1855	CRC	encorafenib	401.4	29.7	35	101.2	8.4
X-1855	CRC	encorafenib	397.3	29.2	40	99.1	6.6
X-1855	CRC	encorafenib	388	29.8	43	94.5	8.8
X-1855	CRC	encorafenib	392.2	29.9	46	96.6	9.1
X-1855	CRC	encorafenib	383.9	29.6	49	92.4	8
X-1855	CRC	encorafenib	394.6	30.1	53	97.8	9.9
X-1855	CRC	encorafenib	392.8	30.2	56	96.9	10.2
X-1855	CRC	encorafenib	408.6	31.8	59	104.8	16.1
X-1855	CRC	encorafenib	401.8	30.7	64	101.4	12
X-1855	CRC	encorafenib	397.1	30.2	67	99	10.2
X-1855	CRC	encorafenib	381.3	30.1	70	91.1	9.9
X-1855	CRC	encorafenib	388	30	73	94.5	9.5
X-1855	CRC	encorafenib	410.3	30.7	77	105.7	12
X-1855	CRC	encorafenib	423.2	30.5	80	112.1	11.3
X-1855	CRC	encorafenib	518.9	30.4	84	160.1	10.9
X-1855	CRC	LJC049	199.3	25.5	0	0	0
X-1855	CRC	LJC049	208.8	25.6	7	4.8	0.4
X-1855	CRC	LJC049	232.8	24	11	16.8	-5.9
X-1855	CRC	LJC049	293.4	24.4	14	47.2	-4.3
X-1855	CRC	LJC049	336.4	23.8	17	68.8	-6.7
X-1855	CRC	LJC049	394	24.7	21	97.7	-3.1
X-1855	CRC	LJC049	421.9	24.3	24	111.7	-4.7
X-1855	CRC	LJC049	502.4	25.4	28	152.1	-0.4
X-1855	CRC	LJC049	642	25.2	31	222.1	-1.2
X-1855	CRC	LJC049	735.6	23.9	35	269.1	-6.3
X-1855	CRC	LJC049	827.6	24.3	40	315.3	-4.7
X-1855	CRC	LJC049	1124.9	24.2	43	464.4	-5.1
X-1855	CRC	LKA136	199.5	25.4	0	0	0
X-1855	CRC	LKA136	217.5	27.8	7	9	9.4
X-1855	CRC	LKA136	234.1	26.9	11	17.3	5.9
X-1855	CRC	LKA136	289	25.6	14	44.9	0.8
X-1855	CRC	LKA136	336.4	25.5	17	68.6	0.4
X-1855	CRC	LKA136	356.8	25.6	21	78.8	0.8
X-1855	CRC	LKA136	397.3	25.1	24	99.1	-1.2
X-1855	CRC	LKA136	527.3	25.7	28	164.3	1.2
X-1855	CRC	LKA136	844	26.1	31	323.1	2.8
X-1855	CRC	LKA136	836.6	26.4	35	319.3	3.9
X-1855	CRC	binimetinib	208.4	24	0	0	0
X-1855	CRC	binimetinib	207.9	22.9	3	-0.2	-4.6
X-1855	CRC	binimetinib	207.7	22.9	6	-0.3	-4.6
X-1855	CRC	binimetinib	206	25.2	17	-1.2	5
X-1855	CRC	binimetinib	199.6	24	21	-4.2	0
X-1855	CRC	binimetinib	203.4	24.8	24	-2.4	3.3
X-1855	CRC	binimetinib	202.9	25	27	-2.6	4.2
X-1855	CRC	binimetinib	211.7	24.6	31	1.6	2.5
X-1855	CRC	binimetinib	203.3	24.1	34	-2.4	0.4
X-1855	CRC	binimetinib	202.5	24.3	38	-2.8	1.2
X-1855	CRC	binimetinib	211.2	24.4	41	1.3	1.7
X-1855	CRC	binimetinib	208.9	24	45	0.2	0
X-1855	CRC	binimetinib	203.7	23.5	50	-2.3	-2.1
X-1855	CRC	binimetinib	204	23.2	53	-2.1	-3.3
X-1855	CRC	binimetinib	209.4	23.5	56	0.5	-2.1
X-1855	CRC	binimetinib	210.3	23	59	0.9	-4.2
X-1855	CRC	binimetinib	212.9	23.3	63	2.2	-2.9
X-1855	CRC	binimetinib	211	23.5	66	1.2	-2.1
X-1855	CRC	binimetinib	205.6	23.5	69	-1.3	-2.1
X-1855	CRC	binimetinib	201.4	23.2	74	-3.4	-3.3
X-1855	CRC	binimetinib	199.9	23	77	-4.1	-4.2
X-1855	CRC	binimetinib	191.8	22.6	80	-8	-5.8
X-1855	CRC	binimetinib	193	21.7	83	-7.4	-9.6
X-1855	CRC	binimetinib	195.5	22.7	87	-6.2	-5.4
X-1855	CRC	untreated	255.8	23.7	0	0	0
X-1855	CRC	untreated	258.1	23.8	4	0.9	0.4
X-1855	CRC	untreated	297.8	26.9	7	16.4	13.5
X-1855	CRC	untreated	393.9	26.4	10	54	11.4
X-1855	CRC	untreated	481.2	24.8	14	88.1	4.6
X-1855	CRC	untreated	574.1	22.6	21	124.4	-4.6
X-1855	CRC	untreated	645.2	23.7	25	152.2	0
X-1855	CRC	untreated	805.4	22.6	28	214.9	-4.6
X-1855	CRC	untreated	843.7	26.4	31	229.8	11.4
X-1855	CRC	untreated	1188.2	27	35	364.5	13.9
X-1855	CRC	untreated	1526.9	25	38	496.9	5.5
X-1855	CRC	LFW527 + binimetinib	207.3	25.88	0	0	0
X-1855	CRC	LFW527 + binimetinib	215.45	24.71	3	3.9	-4.5
X-1855	CRC	LFW527 + binimetinib	224.22	25.22	6	8.2	-2.6
X-1855	CRC	LFW527 + binimetinib	223.55	24.91	9	7.8	-3.7
X-1855	CRC	LFW527 + binimetinib	223.33	24.76	13	7.7	-4.3
X-1855	CRC	LFW527 + binimetinib	221.44	24.69	16	6.8	-4.6
X-1855	CRC	LFW527 + binimetinib	219.56	25.32	20	5.9	-2.2
X-1855	CRC	LFW527 + binimetinib	216.28	26.02	23	4.3	0.5
X-1855	CRC	LFW527 + binimetinib	210.57	24.97	27	1.6	-3.5
X-1855	CRC	LFW527 + binimetinib	200.34	25.02	30	-3.4	-3.3
X-1855	CRC	LFW527 + binimetinib	209.88	25.02	34	1.2	-3.3
X-1855	CRC	LFW527 + binimetinib	207.41	25.21	37	0.1	-2.6
X-1855	CRC	LFW527 + binimetinib	213.22	25.38	41	2.9	-1.9
X-1855	CRC	LFW527 + binimetinib	202.47	25.38	44	-2.3	-1.9
X-1855	CRC	LFW527 + binimetinib	200.08	25.96	48	-3.5	0.3
X-1855	CRC	LFW527 + binimetinib	208.37	25.8	51	0.5	-0.3
X-1855	CRC	LFW527 + binimetinib	209.55	25.67	56	1.1	-0.8
X-1855	CRC	LFW527 + binimetinib	209.55	25.96	59	1.1	0.3
X-1855	CRC	LFW527 + binimetinib	207.86	26.2	62	0.3	1.2
X-1855	CRC	LFW527 + binimetinib	206.41	25.76	65	-0.4	-0.5
X-1855	CRC	LFW527 + binimetinib	226.24	26.27	69	9.1	1.5
X-1855	CRC	LFW527 + binimetinib	227.14	26.01	73	9.6	0.5
X-1855	CRC	LFW527 + binimetinib	217.92	25.26	76	5.1	-2.4
X-1855	CRC	LFW527 + binimetinib	220.7	25.1	79	6.5	-3
X-1855	CRC	LFW527 + binimetinib	205.58	25.26	83	-0.8	-2.4
X-1855	CRC	LFW527 + binimetinib	202.66	25.24	90	-2.2	-2.5
X-1855	CRC	LFW527 + binimetinib	232.88	25.5	93	12.3	-1.5
X-1855	CRC	LFW527 + binimetinib	209.53	25.69	97	1.1	-0.7
X-1855	CRC	LFW527 + binimetinib	219.35	25.6	100	5.8	-1.1
X-1855	CRC	LFW527 + binimetinib	211.07	25.58	104	1.8	-1.2
X-1855	CRC	LFW527 + binimetinib	231.36	25.48	107	11.6	-1.5
X-1855	CRC	LFW527 + binimetinib	233.55	25.75	115	12.7	-0.5
X-1855	CRC	LFW527 + binimetinib	235.94	25.9	122	13.8	0.1
X-1855	CRC	LFW527 + binimetinib	258.25	25.89	125	24.6	0
X-1855	CRC	LFW527 + binimetinib	256.94	25.5	128	23.9	-1.5
X-1855	CRC	LFW527 + binimetinib	251.57	25.6	132	21.4	-1.1
X-1855	CRC	LFW527 + binimetinib	252.2	25.49	136	21.7	-1.5
X-1855	CRC	LFW527 + binimetinib	286.58	25.89	139	38.2	0
X-1855	CRC	LFW527 + binimetinib	273.35	25.16	142	31.9	-2.8
X-1855	CRC	LFW527 + binimetinib	255.52	25.72	146	23.3	-0.6
X-1855	CRC	LFW527 + binimetinib	348.26	24.67	149	68	-4.7
X-1855	CRC	LFW527 + binimetinib	317.61	25.09	153	53.2	-3.1
X-1855	CRC	LFW527 + binimetinib	349.95	25.78	156	68.8	-0.4
X-1855	CRC	LFW527 + binimetinib	309.96	25.27	163	49.5	-2.4
X-1855	CRC	LFW527 + binimetinib	390.17	24.76	170	88.2	-4.3
X-1855	CRC	LFW527 + binimetinib	338.39	23.95	174	63.2	-7.5
X-1855	CRC	LFW527 + binimetinib	290.42	23	178	40.1	-11.1
X-1855	CRC	LFW527 + binimetinib	350.8	23.56	181	69.2	-9
X-1855	CRC	LFW527 + binimetinib	456.89	22.8	184	120.4	-11.9
X-1855	CRC	LFW527 + binimetinib	352.78	23.21	188	70.2	-10.3
X-1855	CRC	LFW527 + binimetinib	401.4	22.87	191	93.6	-11.6
X-1855	CRC	LFW527 + binimetinib	458.92	21.83	195	121.4	-15.6
X-1906	CM	BKM120	200.6	21.7	0	0	0
X-1906	CM	BKM120	183.3	22.7	3	-8.6	4.6
X-1906	CM	BKM120	203.4	23.5	7	1.4	8.3
X-1906	CM	BKM120	267.7	23.6	11	33.5	8.8
X-1906	CM	BKM120	237.1	23.6	16	18.2	8.8
X-1906	CM	BKM120	262.8	23.5	21	31	8.3
X-1906	CM	BKM120	245.5	24.1	24	22.4	11.1
X-1906	CM	BKM120	326.1	23.8	28	62.6	9.7
X-1906	CM	BKM120	312.7	24.6	32	55.9	13.4
X-1906	CM	BKM120	359.9	24.2	38	79.4	11.5
X-1906	CM	BKM120	374	24.9	43	86.5	14.7
X-1906	CM	BKM120	444.4	24.5	47	121.6	12.9
X-1906	CM	BKM120 + encorafenib	215.1	23.9	0	0	0
X-1906	CM	BKM120 + encorafenib	81.7	23.4	6	-62	-2.1
X-1906	CM	BKM120 + encorafenib	50.8	23.3	11	-76.4	-2.5
X-1906	CM	BKM120 + encorafenib	44.6	23.7	14	-79.3	-0.8
X-1906	CM	BKM120 + encorafenib	53.7	23.8	18	-75.1	-0.4
X-1906	CM	BKM120 + encorafenib	42.4	24.1	22	-80.3	0.8
X-1906	CM	BKM120 + encorafenib	0	24	28	-100	0.4
X-1906	CM	BKM120 + encorafenib	0	23.8	33	-100	-0.4
X-1906	CM	BKM120 + encorafenib	0	24.3	37	-100	1.7
X-1906	CM	BKM120 + encorafenib	0	24.2	41	-100	1.3
X-1906	CM	BKM120 + encorafenib	0	24.8	44	-100	3.8
X-1906	CM	BKM120 + encorafenib	0	24.1	48	-100	0.8
X-1906	CM	BKM120 + encorafenib	0	24.8	51	-100	3.8
X-1906	CM	BKM120 + encorafenib	0	25.2	55	-100	5.4
X-1906	CM	BKM120 + encorafenib	0	25.7	62	-100	7.5
X-1906	CM	BKM120 + encorafenib	0	25.6	67	-100	7.1
X-1906	CM	BKM120 + encorafenib	0	25.5	70	-100	6.7
X-1906	CM	BKM120 + encorafenib	0	25.4	75	-100	6.3
X-1906	CM	BKM120 + encorafenib	0	25.9	78	-100	8.4
X-1906	CM	BKM120 + encorafenib	0	26.2	82	-100	9.6
X-1906	CM	BKM120 + encorafenib	0	26.3	85	-100	10
X-1906	CM	BKM120 + encorafenib	0	26	89	-100	8.8
X-1906	CM	BKM120 + encorafenib	0	25.8	95	-100	7.9
X-1906	CM	BKM120 + encorafenib	0	25.5	98	-100	6.7
X-1906	CM	BKM120 + encorafenib	0	26	102	-100	8.8
X-1906	CM	BKM120 + encorafenib	0	26.3	106	-100	10
X-1906	CM	BKM120 + encorafenib	0	26.5	111	-100	10.9
X-1906	CM	BKM120 + encorafenib	0	26.2	116	-100	9.6
X-1906	CM	BKM120 + encorafenib	0	26.1	119	-100	9.2
X-1906	CM	BKM120 + encorafenib	0	26.8	123	-100	12.1
X-1906	CM	BKM120 + encorafenib	0	26.1	132	-100	9.2
X-1906	CM	BKM120 + encorafenib	0	25.5	137	-100	6.7
X-1906	CM	BKM120 + encorafenib	0	26.2	146	-100	9.6
X-1906	CM	BKM120 + encorafenib	0	26	152	-100	8.8
X-1906	CM	BKM120 + encorafenib	0	25.8	160	-100	7.9
X-1906	CM	BKM120 + encorafenib	0	24.9	172	-100	4.2
X-1906	CM	BKM120 + encorafenib	0	26.6	179	-100	11.3
X-1906	CM	BKM120 + encorafenib	0	25.9	186	-100	8.4
X-1906	CM	BKM120 + encorafenib	0	25.6	196	-100	7.1
X-1906	CM	BKM120 + encorafenib	0	25.3	204	-100	5.9
X-1906	CM	BKM120 + encorafenib	0	25.2	210	-100	5.4
X-1906	CM	BKM120 + encorafenib	0	25.6	218	-100	7.1
X-1906	CM	BKM120 + encorafenib	0	25.8	224	-100	7.9
X-1906	CM	BKM120 + encorafenib	0	26.9	232	-100	12.6
X-1906	CM	BKM120 + encorafenib	0	26.4	241	-100	10.5
X-1906	CM	BKM120 + encorafenib	0	26.5	245	-100	10.9
X-1906	CM	BKM120 + encorafenib	0	26.1	249	-100	9.2
X-1906	CM	BKM120 + encorafenib	0	27.1	261	-100	13.4
X-1906	CM	BKM120 + encorafenib	0	26.5	264	-100	10.9
X-1906	CM	BKM120 + encorafenib	41.2	26.6	267	-80.9	11.3
X-1906	CM	BKM120 + encorafenib	108.8	26.5	280	-49.4	10.9
X-1906	CM	BKM120 + encorafenib	165.5	26.4	284	-23.1	10.5
X-1906	CM	BKM120 + encorafenib	229.2	27	291	6.5	13
X-1906	CM	BKM120 + encorafenib	236.9	25.9	299	10.1	8.4
X-1906	CM	BKM120 + encorafenib	293.9	26.5	305	36.6	10.9
X-1906	CM	BKM120 + encorafenib	196.9	26.4	312	-8.5	10.5
X-1906	CM	BKM120 + encorafenib	101.3	26.6	319	-52.9	11.3
X-1906	CM	BKM120 + encorafenib	98.6	28.5	322	-54.2	19.2
X-1906	CM	BKM120 + encorafenib	71.6	26.6	329	-66.7	11.3
X-1906	CM	BKM120 + encorafenib	65.4	25.7	336	-69.6	7.5
X-1906	CM	BKM120 + encorafenib	38.9	26.4	343	-81.9	10.5
X-1906	CM	BKM120 + encorafenib	42.2	26.4	349	-80.4	10.5
X-1906	CM	BKM120 + encorafenib	13.5	25.5	358	-93.7	6.7
X-1906	CM	BKM120 + encorafenib	0	25.6	364	-100	7.1
X-1906	CM	BKM120 + encorafenib	0	26.3	371	-100	10
X-1906	CM	BKM120 + encorafenib	107.1	27.3	378	-50.2	14.2
X-1906	CM	BKM120 + encorafenib	103.5	27.7	385	-51.9	15.9
X-1906	CM	BKM120 + encorafenib	109.6	28.2	392	-49.1	18
X-1906	CM	BKM120 + encorafenib	108.1	27.3	399	-49.8	14.2
X-1906	CM	BKM120 + encorafenib	119.3	27.5	401	-44.5	15.1
X-1906	CM	CGM097	201.2	22.8	0	0	0
X-1906	CM	CGM097	245.7	22.4	3	22.1	-1.8
X-1906	CM	CGM097	321.7	21.4	6	59.9	-6.1
X-1906	CM	CGM097	396.9	24.1	10	97.3	5.7
X-1906	CM	CGM097	612.4	24.5	14	204.4	7.5
X-1906	CM	CGM097	828.5	24.1	19	311.8	5.7
X-1906	CM	CGM097	930.9	24	21	362.7	5.3
X-1906	CM	CLR457	190.5	24.2	0	0	0
X-1906	CM	CLR457	219.6	24.8	4	15.3	2.5
X-1906	CM	CLR457	266.5	25.8	8	39.9	6.6
X-1906	CM	CLR457	240.1	25.6	14	26.1	5.8
X-1906	CM	CLR457	259.2	24.2	19	36.1	0
X-1906	CM	CLR457	233.3	24.8	23	22.5	2.5
X-1906	CM	CLR457	198.2	24.7	27	4.1	2.1
X-1906	CM	CLR457	178.6	24.9	30	-6.2	2.9
X-1906	CM	CLR457	240.1	24.8	34	26.1	2.5
X-1906	CM	CLR457	324.5	25.1	37	70.4	3.7
X-1906	CM	CLR457	316.4	25.5	41	66.1	5.4
X-1906	CM	CLR457	211.9	25.4	48	11.2	5
X-1906	CM	CLR457	261.8	25.2	53	37.5	4.1
X-1906	CM	CLR457	337	25.3	56	76.9	4.5
X-1906	CM	CLR457	454.9	25	61	138.8	3.3
X-1906	CM	CLR457	542.6	25.2	63	184.9	4.1
X-1906	CM	dacarbazine	196	24	0	0	0
X-1906	CM	dacarbazine	191.1	22.8	3	-2.5	-5
X-1906	CM	dacarbazine	267.7	23.6	7	36.6	-1.7
X-1906	CM	dacarbazine	282.1	22.7	11	43.9	-5.4
X-1906	CM	dacarbazine	305.1	22	17	55.7	-8.3
X-1906	CM	dacarbazine	348.2	21.5	22	77.6	-10.4
X-1906	CM	dacarbazine	299.2	20.6	26	52.7	-14.2
X-1906	CM	dacarbazine	325.1	21	30	65.9	-12.5
X-1906	CM	dacarbazine	306.6	21.4	33	56.4	-10.8
X-1906	CM	dacarbazine	389.2	20.9	37	98.6	-12.9
X-1906	CM	dacarbazine	371.7	21	40	89.6	-12.5
X-1906	CM	dacarbazine	489.8	20.8	44	149.9	-13.3
X-1906	CM	dacarbazine	489.3	20.8	45	149.6	-13.3
X-1906	CM	LDE225	205.8	25.2	0	0	0
X-1906	CM	LDE225	252.1	25	4	22.5	-0.8
X-1906	CM	LDE225	393.7	23.7	8	91.3	-6
X-1906	CM	LDE225	810.3	22.1	13	293.8	-12.3
X-1906	CM	LDE225	1178.6	20.7	18	472.7	-17.9
X-1906	CM	LDE225	1229.8	19.4	21	497.6	-23
X-1906	CM	LDK378	197.2	22.1	0	0	0
X-1906	CM	LDK378	207.4	21.6	4	5.2	-2.3
X-1906	CM	LDK378	262.4	22.5	9	33.1	1.8
X-1906	CM	LDK378	413.1	22.4	14	109.5	1.4
X-1906	CM	LDK378	422.3	22.5	17	114.2	1.8
X-1906	CM	LDK378	561.8	22.9	21	184.9	3.6
X-1906	CM	LEE011	195.3	20.1	0	0	0
X-1906	CM	LEE011	232.7	19.9	3	19.2	-1
X-1906	CM	LEE011	239.8	20	7	22.8	-0.5
X-1906	CM	LEE011	236.3	20	11	21	-0.5
X-1906	CM	LEE011	181.3	19.7	16	-7.2	-2
X-1906	CM	LEE011	150	20	21	-23.2	-0.5
X-1906	CM	LEE011	156.8	20.7	24	-19.7	3
X-1906	CM	LEE011	156.8	20.8	28	-19.7	3.5
X-1906	CM	LEE011	112.7	20.5	32	-42.3	2
X-1906	CM	LEE011	79.3	21	38	-59.4	4.5
X-1906	CM	LEE011	107.9	21	43	-44.7	4.5
X-1906	CM	LEE011	115.4	21.1	47	-40.9	5
X-1906	CM	LEE011	61.2	20.8	51	-68.6	3.5
X-1906	CM	LEE011	75.7	21.6	54	-61.2	7.5
X-1906	CM	LEE011	59.1	22	58	-69.8	9.5
X-1906	CM	LEE011	58.8	21.9	61	-69.9	9
X-1906	CM	LEE011	46.6	22.3	65	-76.1	10.9
X-1906	CM	LEE011	57.6	22.6	72	-70.5	12.4
X-1906	CM	LEE011	59.6	22.3	77	-69.5	10.9
X-1906	CM	LEE011	32.7	22.9	80	-83.3	13.9
X-1906	CM	LEE011	35.3	21.9	85	-81.9	9
X-1906	CM	LEE011	32.8	23.2	88	-83.2	15.4
X-1906	CM	LEE011	31.2	23.4	92	-84	16.4
X-1906	CM	LEE011	27.4	23.3	95	-86	15.9
X-1906	CM	LEE011	32.8	22.2	99	-83.2	10.4
X-1906	CM	LEE011	50.8	23.2	105	-74	15.4
X-1906	CM	LEE011	37	22.3	108	-81.1	10.9
X-1906	CM	LEE011	41.5	22.2	112	-78.8	10.4
X-1906	CM	LEE011	58.8	22.6	116	-69.9	12.4
X-1906	CM	LEE011	46.6	22.9	121	-76.1	13.9
X-1906	CM	LEE011	75.7	23.4	126	-61.2	16.4
X-1906	CM	LEE011	56.5	23.2	129	-71.1	15.4
X-1906	CM	LEE011	53	23.6	133	-72.8	17.4
X-1906	CM	LEE011	23.1	24.6	142	-88.2	22.4
X-1906	CM	LEE011	89.2	24.1	147	-54.3	19.9
X-1906	CM	LEE011	84.7	24.9	156	-56.6	23.9
X-1906	CM	LEE011	102.3	23.9	162	-47.6	18.9
X-1906	CM	LEE011	70	23.5	170	-64.2	16.9
X-1906	CM	LEE011	73	25.5	182	-62.6	26.9
X-1906	CM	LEE011	32	24.2	189	-83.6	20.4
X-1906	CM	LEE011	128.8	24.3	196	-34.1	20.9
X-1906	CM	LEE011	122.8	25	206	-37.1	24.4
X-1906	CM	LEE011	128.4	24.4	214	-34.3	21.4
X-1906	CM	LEE011	154.6	25	220	-20.8	24.4
X-1906	CM	LEE011	180.9	24.4	228	-7.3	21.4
X-1906	CM	LEE011	188.1	24.7	234	-3.7	22.9
X-1906	CM	LEE011	154.6	24.3	242	-20.8	20.9
X-1906	CM	LEE011	193.8	23.7	251	-0.7	17.9
X-1906	CM	LEE011	219.3	23.5	255	12.3	16.9
X-1906	CM	LEE011	220.5	23.4	259	12.9	16.4
X-1906	CM	LEE011	214.2	24	266	9.7	19.4
X-1906	CM	LEE011	215.6	21.7	271	10.4	8
X-1906	CM	LEE011	233.3	22.8	274	19.5	13.4
X-1906	CM	LEE011	208.3	23.3	277	6.6	15.9
X-1906	CM	LEE011	215.8	22.1	290	10.5	10
X-1906	CM	LEE011	197.2	22.5	294	1	11.9
X-1906	CM	LEE011	303.7	22.5	301	55.5	11.9
X-1906	CM	LEE011	316.9	22.2	309	62.3	10.4
X-1906	CM	LEE011	406.8	22.4	315	108.3	11.4
X-1906	CM	LEE011 + encorafenib	224.5	24.2	0	0	0
X-1906	CM	LEE011 + encorafenib	211.3	24.2	5	-5.9	0
X-1906	CM	LEE011 + encorafenib	169.2	24.9	8	-24.6	2.9
X-1906	CM	LEE011 + encorafenib	106.8	24.1	12	-52.4	-0.4
X-1906	CM	LEE011 + encorafenib	72	24.6	16	-67.9	1.7
X-1906	CM	LEE011 + encorafenib	27.9	24.8	22	-87.6	2.5
X-1906	CM	LEE011 + encorafenib	20.7	25	27	-90.8	3.3
X-1906	CM	LEE011 + encorafenib	0	24.8	31	-100	2.5
X-1906	CM	LEE011 + encorafenib	0	25.2	35	-100	4.1
X-1906	CM	LEE011 + encorafenib	0	26	38	-100	7.4
X-1906	CM	LEE011 + encorafenib	0	25.4	42	-100	5
X-1906	CM	LEE011 + encorafenib	0	25.9	45	-100	7
X-1906	CM	LEE011 + encorafenib	0	27.4	49	-100	13.2
X-1906	CM	LEE011 + encorafenib	0	26.5	56	-100	9.5
X-1906	CM	LEE011 + encorafenib	0	26	61	-100	7.4
X-1906	CM	LEE011 + encorafenib	0	26.3	64	-100	8.7
X-1906	CM	LEE011 + encorafenib	0	27	69	-100	11.6
X-1906	CM	LEE011 + encorafenib	0	27.1	72	-100	12
X-1906	CM	LEE011 + encorafenib	0	26.3	76	-100	8.7
X-1906	CM	LEE011 + encorafenib	0	27.3	79	-100	12.8
X-1906	CM	LEE011 + encorafenib	0	27.6	83	-100	14
X-1906	CM	LEE011 + encorafenib	0	26.6	89	-100	9.9
X-1906	CM	LEE011 + encorafenib	0	27.1	92	-100	12
X-1906	CM	LEE011 + encorafenib	0	26.8	96	-100	10.7
X-1906	CM	LEE011 + encorafenib	0	26.6	100	-100	9.9
X-1906	CM	LEE011 + encorafenib	0	26.8	105	-100	10.7
X-1906	CM	LEE011 + encorafenib	0	27.1	110	-100	12
X-1906	CM	LEE011 + encorafenib	0	26.3	113	-100	8.7
X-1906	CM	LEE011 + encorafenib	0	27.2	117	-100	12.4
X-1906	CM	LEE011 + encorafenib	0	27.7	126	-100	14.5
X-1906	CM	LEE011 + encorafenib	0	27.6	131	-100	14
X-1906	CM	LEE011 + encorafenib	0	28.2	140	-100	16.5
X-1906	CM	LEE011 + encorafenib	0	28	146	-100	15.7
X-1906	CM	LEE011 + encorafenib	0	27.2	154	-100	12.4
X-1906	CM	LEE011 + encorafenib	0	28.2	166	-100	16.5
X-1906	CM	LEE011 + encorafenib	0	28.6	173	-100	18.2
X-1906	CM	LEE011 + encorafenib	0	27.5	180	-100	13.6
X-1906	CM	LEE011 + encorafenib	0	27.2	190	-100	12.4
X-1906	CM	LEE011 + encorafenib	0	26.9	198	-100	11.2
X-1906	CM	LEE011 + encorafenib	0	27.3	204	-100	12.8
X-1906	CM	LEE011 + encorafenib	0	28.2	212	-100	16.5
X-1906	CM	LEE011 + encorafenib	0	29.4	218	-100	21.5
X-1906	CM	LEE011 + encorafenib	78.3	28.7	226	-65.1	18.6
X-1906	CM	LEE011 + encorafenib	183	27.6	235	-18.5	14
X-1906	CM	LEE011 + encorafenib	221.2	27.9	239	-1.5	15.3
X-1906	CM	LEE011 + encorafenib	133.3	27.8	243	-40.6	14.9
X-1906	CM	LEE011 + encorafenib	32.4	28.2	250	-85.6	16.5
X-1906	CM	LEE011 + encorafenib	0	28.4	255	-100	17.4
X-1906	CM	LEE011 + encorafenib	0	28.6	258	-100	18.2
X-1906	CM	LEE011 + encorafenib	0	27.8	261	-100	14.9
X-1906	CM	LEE011 + encorafenib	0	28.7	274	-100	18.6
X-1906	CM	LEE011 + encorafenib	0	28.9	278	-100	19.4
X-1906	CM	LEE011 + encorafenib	0	30.1	285	-100	24.4
X-1906	CM	LEE011 + encorafenib	0	29.2	293	-100	20.7
X-1906	CM	LEE011 + encorafenib	0	27.5	299	-100	13.6
X-1906	CM	LEE011 + encorafenib	0	28.2	306	-100	16.5
X-1906	CM	LEE011 + encorafenib	0	28.8	313	-100	19
X-1906	CM	LEE011 + encorafenib	0	29.3	316	-100	21.1
X-1906	CM	LEE011 + encorafenib	0	27.9	323	-100	15.3
X-1906	CM	LEE011 + encorafenib	0	28.4	330	-100	17.4
X-1906	CM	LEE011 + encorafenib	0	28.8	337	-100	19
X-1906	CM	LEE011 + encorafenib	0	27.8	343	-100	14.9
X-1906	CM	LEE011 + encorafenib	0	27.7	352	-100	14.5
X-1906	CM	LEE011 + encorafenib	0	26.3	358	-100	8.7
X-1906	CM	LEE011 + encorafenib	0	28.3	365	-100	16.9
X-1906	CM	LEE011 + encorafenib	104.4	28.9	372	-53.5	19.4
X-1906	CM	LEE011 + encorafenib	125.3	27.8	379	-44.2	14.9
X-1906	CM	LEE011 + encorafenib	211.2	28.7	386	-5.9	18.6
X-1906	CM	LEE011 + encorafenib	229.7	27.9	393	2.3	15.3
X-1906	CM	LEE011 + encorafenib	309.1	28.4	395	37.7	17.4
X-1906	CM	LEE011 + binimetinib	201.6	26.5	0	0	0
X-1906	CM	LEE011 + binimetinib	56.3	25.3	7	-72.1	-4.5
X-1906	CM	LEE011 + binimetinib	30.3	25.7	11	-85	-3
X-1906	CM	LEE011 + binimetinib	17.6	25.9	14	-91.3	-2.3
X-1906	CM	LEE011 + binimetinib	0	26.1	19	-100	-1.5
X-1906	CM	LEE011 + binimetinib	0	27	22	-100	1.9
X-1906	CM	LEE011 + binimetinib	0	27.4	26	-100	3.4
X-1906	CM	LEE011 + binimetinib	0	27.5	29	-100	3.8
X-1906	CM	LEE011 + binimetinib	0	27.5	34	-100	3.8
X-1906	CM	LEE011 + binimetinib	0	26.4	40	-100	-0.4
X-1906	CM	LEE011 + binimetinib	0	25.6	43	-100	-3.4
X-1906	CM	LEE011 + binimetinib	0	26.8	47	-100	1.1
X-1906	CM	LEE011 + binimetinib	0	28	51	-100	5.7
X-1906	CM	LEE011 + binimetinib	0	27.5	56	-100	3.8
X-1906	CM	LEE011 + binimetinib	0	27.5	61	-100	3.8
X-1906	CM	LEE011 + binimetinib	0	27.5	64	-100	3.8
X-1906	CM	LEE011 + binimetinib	0	27.4	68	-100	3.4
X-1906	CM	LEE011 + binimetinib	0	28.4	77	-100	7.2
X-1906	CM	LEE011 + binimetinib	0	28.6	82	-100	7.9
X-1906	CM	LEE011 + binimetinib	0	27.5	91	-100	3.8
X-1906	CM	LEE011 + binimetinib	0	27.4	106	-100	3.4
X-1906	CM	LEE011 + binimetinib	0	27.8	118	-100	4.9
X-1906	CM	LEE011 + binimetinib	0	27.5	125	-100	3.8
X-1906	CM	LEE011 + binimetinib	0	27.3	132	-100	3
X-1906	CM	LEE011 + binimetinib	0	27.5	142	-100	3.8
X-1906	CM	LEE011 + binimetinib	0	27.8	150	-100	4.9
X-1906	CM	LEE011 + binimetinib	0	29.2	156	-100	10.2
X-1906	CM	LEE011 + binimetinib	0	28.1	164	-100	6
X-1906	CM	LEE011 + binimetinib	0	28.3	170	-100	6.8
X-1906	CM	LEE011 + binimetinib	0	28.9	178	-100	9.1
X-1906	CM	LEE011 + binimetinib	0	27.5	187	-100	3.8
X-1906	CM	LEE011 + binimetinib	0	28.1	191	-100	6
X-1906	CM	LEE011 + binimetinib	0	27.9	195	-100	5.3
X-1906	CM	LEE011 + binimetinib	0	29	202	-100	9.4
X-1906	CM	LEE011 + binimetinib	0	28.4	207	-100	7.2
X-1906	CM	LEE011 + binimetinib	0	28.9	210	-100	9.1
X-1906	CM	LEE011 + binimetinib	0	29	213	-100	9.4
X-1906	CM	LEE011 + binimetinib	0	29.9	227	-100	12.8
X-1906	CM	LEE011 + binimetinib	0	29	231	-100	9.4
X-1906	CM	LEE011 + binimetinib	0	28.7	238	-100	8.3
X-1906	CM	LEE011 + binimetinib	0	29.1	246	-100	9.8
X-1906	CM	LEE011 + binimetinib	0	28.8	252	-100	8.7
X-1906	CM	LEE011 + binimetinib	0	28.7	259	-100	8.3
X-1906	CM	LEE011 + binimetinib	0	28.6	266	-100	7.9
X-1906	CM	LEE011 + binimetinib	0	28.4	273	-100	7.2
X-1906	CM	LEE011 + binimetinib	0	28.7	280	-100	8.3
X-1906	CM	LEE011 + binimetinib	0	29.1	287	-100	9.8
X-1906	CM	LEE011 + binimetinib	0	28.9	294	-100	9.1
X-1906	CM	LEE011 + binimetinib	0	28.5	300	-100	7.5
X-1906	CM	LEE011 + binimetinib	0	28.4	309	-100	7.2
X-1906	CM	LEE011 + binimetinib	0	27.9	315	-100	5.3
X-1906	CM	LEE011 + binimetinib	0	28.2	322	-100	6.4
X-1906	CM	LEE011 + binimetinib	9.6	28.1	329	-95.3	6
X-1906	CM	LEE011 + binimetinib	10	28.7	336	-95.1	8.3
X-1906	CM	LEE011 + binimetinib	10.4	28.3	343	-94.8	6.8
X-1906	CM	LEE011 + binimetinib	7.9	28.4	350	-96.1	7.2
X-1906	CM	LEE011 + binimetinib	0	28.4	371	-100	7.2
X-1906	CM	LEE011 + binimetinib	0	27.7	378	-100	4.5
X-1906	CM	LEE011 + binimetinib	0	27.8	385	-100	4.9
X-1906	CM	LEE011 + binimetinib	0	28.2	392	-100	6.4
X-1906	CM	LEE011 + binimetinib	0	27.8	399	-100	4.9
X-1906	CM	WNT974	224.5	24.8	0	0	0
X-1906	CM	WNT974	355	23.4	4	58.1	-5.6
X-1906	CM	WNT974	738.1	21.6	9	228.7	-12.9
X-1906	CM	WNT974	1145.2	21.6	14	410.1	-12.9
X-1906	CM	WNT974	1459.3	21.7	17	550	-12.5
X-1906	CM	LGW813	216.5	24.9	0	0	0
X-1906	CM	LGW813	201.6	22.4	3	-6.9	-10
X-1906	CM	LGW813	359.5	27.3	7	66	9.6
X-1906	CM	LGW813	377.2	27.1	11	74.2	8.8
X-1906	CM	LGW813	690	27.1	16	218.6	8.8
X-1906	CM	LGW813	664	25.9	21	206.7	4
X-1906	CM	encorafenib	196	21.9	0	0	0
X-1906	CM	encorafenib	201.6	22.4	3	2.9	2.3
X-1906	CM	encorafenib	80.2	22.1	7	-59.1	0.9
X-1906	CM	encorafenib	42.5	22	11	-78.3	0.5
X-1906	CM	encorafenib	18	21.8	16	-90.8	-0.5
X-1906	CM	encorafenib	25.9	22.2	21	-86.8	1.4
X-1906	CM	encorafenib	15.3	22.4	24	-92.2	2.3
X-1906	CM	encorafenib	38	22.6	28	-80.6	3.2
X-1906	CM	encorafenib	43.5	23.2	32	-77.8	5.9
X-1906	CM	encorafenib	0	23	38	-100	5
X-1906	CM	encorafenib	0	23.3	43	-100	6.4
X-1906	CM	encorafenib	0	23.7	47	-100	8.2
X-1906	CM	encorafenib	0	23.7	51	-100	8.2
X-1906	CM	encorafenib	0	23.8	54	-100	8.7
X-1906	CM	encorafenib	0	23.3	58	-100	6.4
X-1906	CM	encorafenib	0	24.1	61	-100	10
X-1906	CM	encorafenib	0	24.4	65	-100	11.4
X-1906	CM	encorafenib	0	24.6	72	-100	12.3
X-1906	CM	encorafenib	0	24.7	77	-100	12.8
X-1906	CM	encorafenib	0	24.7	80	-100	12.8
X-1906	CM	encorafenib	0	24.3	85	-100	11
X-1906	CM	encorafenib	0	24.8	88	-100	13.2
X-1906	CM	encorafenib	0	24.4	92	-100	11.4
X-1906	CM	encorafenib	0	24.3	95	-100	11
X-1906	CM	encorafenib	0	24.9	99	-100	13.7
X-1906	CM	encorafenib	0	24.6	105	-100	12.3
X-1906	CM	encorafenib	0	24.6	108	-100	12.3
X-1906	CM	encorafenib	0	24.8	112	-100	13.2
X-1906	CM	encorafenib	0	24.8	116	-100	13.2
X-1906	CM	encorafenib	0	25.1	121	-100	14.6
X-1906	CM	encorafenib	0	24.8	126	-100	13.2
X-1906	CM	encorafenib	0	24.8	129	-100	13.2
X-1906	CM	encorafenib	30.4	25	133	-84.5	14.2
X-1906	CM	encorafenib	64.5	25.3	142	-67.1	15.5
X-1906	CM	encorafenib	89.2	25.6	147	-54.5	16.9
X-1906	CM	encorafenib	66.3	25.5	156	-66.2	16.4
X-1906	CM	encorafenib	128.4	26.1	162	-34.5	19.2
X-1906	CM	encorafenib	118.4	25.9	170	-39.6	18.3
X-1906	CM	encorafenib	75.7	25.4	182	-61.4	16
X-1906	CM	encorafenib	63.6	25.4	189	-67.5	16
X-1906	CM	encorafenib	197	25.3	196	0.5	15.5
X-1906	CM	encorafenib	336.8	25.7	206	71.8	17.4
X-1906	CM	encorafenib	336	25.8	214	71.4	17.8
X-1906	CM	encorafenib	432.5	26	220	120.6	18.7
X-1906	CM	encorafenib	572.2	25.8	228	191.9	17.8
X-1906	CM	encorafenib	733.8	26.5	234	274.4	21
X-1906	CM	encorafenib	804.7	26.4	242	310.5	20.5
X-1906	CM	encorafenib	896.6	25.8	251	357.4	17.8
X-1906	CM	encorafenib	1461.2	26.5	255	645.5	21
X-1906	CM	encorafenib	1479.7	27.3	259	654.9	24.7
X-1906	CM	encorafenib	874.6	27.3	262	346.2	24.7
X-1906	CM	encorafenib	556.6	26.5	266	184	21
X-1906	CM	encorafenib	277.3	27.1	271	41.4	23.7
X-1906	CM	encorafenib	192.8	26.8	274	-1.6	22.4
X-1906	CM	encorafenib	157.1	27.8	277	-19.8	26.9
X-1906	CM	encorafenib	62.4	27.8	290	-68.1	26.9
X-1906	CM	encorafenib	0	27.7	294	-100	26.5
X-1906	CM	encorafenib	0	28	301	-100	27.9
X-1906	CM	encorafenib	0	27.9	309	-100	27.4
X-1906	CM	encorafenib	0	28.3	315	-100	29.2
X-1906	CM	encorafenib + binimetinib	207.8	24.5	0	0	0
X-1906	CM	encorafenib + binimetinib	109.8	24.2	3	-47.2	-1.2
X-1906	CM	encorafenib + binimetinib	83.1	23.6	7	-60	-3.7
X-1906	CM	encorafenib + binimetinib	0	24.1	11	-100	-1.6
X-1906	CM	encorafenib + binimetinib	0	24.4	17	-100	-0.4
X-1906	CM	encorafenib + binimetinib	0	24.6	22	-100	0.4
X-1906	CM	encorafenib + binimetinib	0	24.3	26	-100	-0.8
X-1906	CM	encorafenib + binimetinib	0	26.8	30	-100	9.4
X-1906	CM	encorafenib + binimetinib	0	24.6	33	-100	0.4
X-1906	CM	encorafenib + binimetinib	0	25.1	37	-100	2.4
X-1906	CM	encorafenib + binimetinib	0	25.4	40	-100	3.7
X-1906	CM	encorafenib + binimetinib	0	25.2	44	-100	2.9
X-1906	CM	encorafenib + binimetinib	0	25.2	51	-100	2.9
X-1906	CM	encorafenib + binimetinib	0	25.5	56	-100	4.1
X-1906	CM	encorafenib + binimetinib	0	25.6	59	-100	4.5
X-1906	CM	encorafenib + binimetinib	0	25.2	64	-100	2.9
X-1906	CM	encorafenib + binimetinib	0	25.9	67	-100	5.7
X-1906	CM	encorafenib + binimetinib	0	26.3	71	-100	7.3
X-1906	CM	encorafenib + binimetinib	0	26.2	74	-100	6.9
X-1906	CM	encorafenib + binimetinib	0	25.6	78	-100	4.5
X-1906	CM	encorafenib + binimetinib	0	25.8	84	-100	5.3
X-1906	CM	encorafenib + binimetinib	0	25.6	87	-100	4.5
X-1906	CM	encorafenib + binimetinib	0	25.5	91	-100	4.1
X-1906	CM	encorafenib + binimetinib	0	25.7	95	-100	4.9
X-1906	CM	encorafenib + binimetinib	0	25.8	100	-100	5.3
X-1906	CM	encorafenib + binimetinib	0	26	105	-100	6.1
X-1906	CM	encorafenib + binimetinib	0	25.5	108	-100	4.1
X-1906	CM	encorafenib + binimetinib	0	26	112	-100	6.1
X-1906	CM	encorafenib + binimetinib	0	26.4	121	-100	7.8
X-1906	CM	encorafenib + binimetinib	0	26.8	126	-100	9.4
X-1906	CM	encorafenib + binimetinib	0	26.7	135	-100	9
X-1906	CM	encorafenib + binimetinib	0	26.4	141	-100	7.8
X-1906	CM	encorafenib + binimetinib	0	26.7	149	-100	9
X-1906	CM	encorafenib + binimetinib	0	27	151	-100	10.2
X-1906	CM	encorafenib + binimetinib	0	27	158	-100	10.2
X-1906	CM	encorafenib + binimetinib	0	25.7	166	-100	4.9
X-1906	CM	encorafenib + binimetinib	0	26.8	176	-100	9.4
X-1906	CM	encorafenib + binimetinib	0	26.2	190	-100	6.9
X-1906	CM	encorafenib + binimetinib	0	26.4	196	-100	7.8
X-1906	CM	encorafenib + binimetinib	0	26.9	204	-100	9.8
X-1906	CM	encorafenib + binimetinib	0	27	210	-100	10.2
X-1906	CM	encorafenib + binimetinib	0	26.9	218	-100	9.8
X-1906	CM	encorafenib + binimetinib	0	27.1	227	-100	10.6
X-1906	CM	encorafenib + binimetinib	0	27.2	231	-100	11
X-1906	CM	encorafenib + binimetinib	0	26.9	235	-100	9.8
X-1906	CM	encorafenib + binimetinib	0	27	242	-100	10.2
X-1906	CM	encorafenib + binimetinib	0	27.7	247	-100	13.1
X-1906	CM	encorafenib + binimetinib	0	27.2	250	-100	11
X-1906	CM	encorafenib + binimetinib	0	26.9	253	-100	9.8
X-1906	CM	encorafenib + binimetinib	0	27.3	266	-100	11.4
X-1906	CM	encorafenib + binimetinib	0	27.5	300	-100	12.2
X-1906	CM	encorafenib + binimetinib	0	27.6	307	-100	12.7
X-1906	CM	encorafenib + binimetinib	0	26.8	315	-100	9.4
X-1906	CM	encorafenib + binimetinib	0	26.8	321	-100	9.4
X-1906	CM	encorafenib + binimetinib	100.6	25.8	328	-51.6	5.3
X-1906	CM	encorafenib + binimetinib	100.3	25.3	335	-51.7	3.3
X-1906	CM	encorafenib + binimetinib	140.2	25.4	339	-32.5	3.7
X-1906	CM	binimetinib	192.2	21.8	0	0	0
X-1906	CM	binimetinib	169	21.1	3	-12.1	-3.2
X-1906	CM	binimetinib	87.9	21.9	7	-54.3	0.5
X-1906	CM	binimetinib	0	22	11	-100	0.9
X-1906	CM	binimetinib	0	21.6	16	-100	-0.9
X-1906	CM	binimetinib	46.6	21.9	21	-75.8	0.5
X-1906	CM	binimetinib	38.8	22	24	-79.8	0.9
X-1906	CM	binimetinib	53	22.1	28	-72.4	1.4
X-1906	CM	binimetinib	53	22.4	32	-72.4	2.8
X-1906	CM	binimetinib	102.6	22.4	43	-46.6	2.8
X-1906	CM	binimetinib	66.8	22.7	47	-65.2	4.1
X-1906	CM	binimetinib	44.1	22.7	51	-77.1	4.1
X-1906	CM	binimetinib	51.6	22.8	54	-73.1	4.6
X-1906	CM	binimetinib	53.7	22.4	61	-72.1	2.8
X-1906	CM	binimetinib	43.6	23.2	65	-77.3	6.4
X-1906	CM	binimetinib	58.8	23.2	72	-69.4	6.4
X-1906	CM	binimetinib	65	23.5	77	-66.2	7.8
X-1906	CM	binimetinib	0	23	80	-100	5.5
X-1906	CM	binimetinib	0	23	85	-100	5.5
X-1906	CM	binimetinib	86	23.9	88	-55.2	9.6
X-1906	CM	binimetinib	71.7	23.8	92	-62.7	9.2
X-1906	CM	binimetinib	45.4	23.1	95	-76.4	6
X-1906	CM	binimetinib	87.7	22.8	99	-54.4	4.6
X-1906	CM	binimetinib	99.1	23.2	105	-48.4	6.4
X-1906	CM	binimetinib	100.7	23.3	108	-47.6	6.9
X-1906	CM	binimetinib	81.1	23.1	112	-57.8	6
X-1906	CM	binimetinib	107.9	22.7	116	-43.9	4.1
X-1906	CM	binimetinib	102.3	23.1	121	-46.8	6
X-1906	CM	binimetinib	159.4	23.1	126	-17.1	6
X-1906	CM	binimetinib	137.2	23	129	-28.6	5.5
X-1906	CM	binimetinib	133.1	23	133	-30.7	5.5
X-1906	CM	binimetinib	188.7	23.3	142	-1.9	6.9
X-1906	CM	binimetinib	228.2	23.9	147	18.7	9.6
X-1906	CM	binimetinib	214.2	23	156	11.5	5.5
X-1906	CM	binimetinib	332.4	23.3	162	72.9	6.9
X-1906	CM	TAS266	214	21	0	0	0
X-1906	CM	TAS266	118.9	20.6	3	-44.5	-1.9
X-1906	CM	TAS266	90.8	21.4	6	-57.6	1.9
X-1906	CM	TAS266	111.6	21.9	10	-47.9	4.3
X-1906	CM	TAS266	131	21.9	14	-38.8	4.3
X-1906	CM	TAS266	259.2	22.3	19	21.1	6.2
X-1906	CM	TAS266	410.8	22	24	91.9	4.8
X-1906	CM	TAS266	421.2	22.1	27	96.8	5.2
X-1906	CM	untreated	200.2	21	0	0	0
X-1906	CM	untreated	280.7	21.4	3	40.2	1.9
X-1906	CM	untreated	346.3	22	6	72.9	4.8
X-1906	CM	untreated	441.4	21.9	10	120.4	4.3
X-1906	CM	untreated	620	22.3	14	209.6	6.2
X-1906	CM	untreated	807.2	22.6	19	303.1	7.6
X-1906	CM	untreated	835.8	22.7	21	317.4	8.1
X-1916	BRCA	BGJ398	230.1	23.7	0	0	0
X-1916	BRCA	BGJ398	293.9	24.5	3	27.7	3.4
X-1916	BRCA	BGJ398	374.9	25.8	6	62.9	8.9
X-1916	BRCA	BGJ398	523.2	26.2	10	127.4	10.5
X-1916	BRCA	BGJ398	720.2	27.1	13	213	14.3
X-1916	BRCA	BGJ398	803.4	26.5	17	249.2	11.8
X-1916	BRCA	BGJ398	938.6	25.4	21	307.9	7.2
X-1916	BRCA	BGJ398	1007.6	27.9	23	337.9	17.7
X-1916	BRCA	BGJ398	1204.1	28	27	423.3	18.1
X-1916	BRCA	BKM120	208.1	23.1	0	0	0
X-1916	BRCA	BKM120	238.6	23.2	3	14.7	0.4
X-1916	BRCA	BKM120	302	23.2	7	45.1	0.4
X-1916	BRCA	BKM120	298.1	23.1	10	43.2	0
X-1916	BRCA	BKM120	282.2	23.2	14	35.6	0.4
X-1916	BRCA	BKM120	288.8	23.1	17	38.8	0
X-1916	BRCA	BKM120	294.4	24	21	41.5	3.9
X-1916	BRCA	BKM120	373.7	24.2	25	79.6	4.8
X-1916	BRCA	BKM120	419.2	23.4	27	101.4	1.3
X-1916	BRCA	BKM120	446.5	24.7	31	114.6	6.9
X-1916	BRCA	BKM120	590.1	24.7	35	183.6	6.9
X-1916	BRCA	BKM120	690.4	25.5	38	231.8	10.4
X-1916	BRCA	BKM120	959.1	26.5	42	360.9	14.7
X-1916	BRCA	BYL719	221.2	22.2	0	0	0
X-1916	BRCA	BYL719	271.1	22.6	3	22.6	1.8
X-1916	BRCA	BYL719	404.9	22.5	7	83	1.4
X-1916	BRCA	BYL719	551.2	22.7	10	149.2	2.3
X-1916	BRCA	BYL719	936.1	23.2	14	323.2	4.5
X-1916	BRCA	BYL719	1244.5	23.8	17	462.6	7.2
X-1916	BRCA	BYL719 + LEE011	217.4	23.2	0	0	0
X-1916	BRCA	BYL719 + LEE011	259.5	22.2	3	19.4	-4.3
X-1916	BRCA	BYL719 + LEE011	364.6	23.3	7	67.7	0.4
X-1916	BRCA	BYL719 + LEE011	440.9	21.8	10	102.8	-6
X-1916	BRCA	BYL719 + LEE011	506.8	23.4	14	133.1	0.9
X-1916	BRCA	BYL719 + LEE011	651	22.6	18	199.4	-2.6
X-1916	BRCA	BYL719 + LEE011	813.5	24.1	20	274.2	3.9
X-1916	BRCA	BYL719 + LEE011	1003.7	24.5	24	361.7	5.6
X-1916	BRCA	BYL719 + LEE011	1304	25.3	28	499.8	9.1
X-1916	BRCA	BYL719 + LJM716	220	26.8	0	0	0
X-1916	BRCA	BYL719 + LJM716	236.6	25	3	7.5	-6.7
X-1916	BRCA	BYL719 + LJM716	194.9	24.6	7	-11.4	-8.2
X-1916	BRCA	BYL719 + LJM716	155.4	24.1	10	-29.4	-10.1
X-1916	BRCA	BYL719 + LJM716	88.5	21.4	14	-59.8	-20.1
X-1916	BRCA	CGM097	202.5	22.6	0	0	0
X-1916	BRCA	CGM097	213.8	22.8	3	5.6	0.9
X-1916	BRCA	CGM097	265	22	7	30.9	-2.7
X-1916	BRCA	CGM097	319.8	21.8	10	57.9	-3.5
X-1916	BRCA	CGM097	444	23	14	119.3	1.8
X-1916	BRCA	CGM097	581.2	23.1	17	187	2.2
X-1916	BRCA	CGM097	768.7	24.4	21	279.6	8
X-1916	BRCA	CLR457	203.5	22.3	0	0	0
X-1916	BRCA	CLR457	244.9	22.9	3	20.3	2.7
X-1916	BRCA	CLR457	238	22.4	7	17	0.4
X-1916	BRCA	CLR457	249.9	21.5	10	22.8	-3.6
X-1916	BRCA	CLR457	247.4	21.5	14	21.6	-3.6
X-1916	BRCA	CLR457	247.5	21.8	17	21.6	-2.2
X-1916	BRCA	CLR457	259.6	22.5	21	27.6	0.9
X-1916	BRCA	CLR457	295.4	22.6	25	45.2	1.3
X-1916	BRCA	CLR457	299.6	22	27	47.2	-1.3
X-1916	BRCA	CLR457	354.4	22.9	31	74.2	2.7
X-1916	BRCA	CLR457	382.9	23.4	35	88.2	4.9
X-1916	BRCA	CLR457	493.5	23.6	38	142.5	5.8
X-1916	BRCA	CLR457	549.8	24.3	42	170.2	9
X-1916	BRCA	CLR457	583.8	24.1	44	186.9	8.1
X-1916	BRCA	CLR457	976.7	23.9	50	380	7.2
X-1916	BRCA	HDM201	222.8	25.1	0	0	0
X-1916	BRCA	HDM201	254.9	26	3	14.4	3.6
X-1916	BRCA	HDM201	430	25.9	7	93	3.2
X-1916	BRCA	HDM201	588.1	27.3	10	164	8.8
X-1916	BRCA	HDM201	1205.9	27.8	14	441.2	10.8
X-1916	BRCA	INC424	244.4	18.6	0	0	0
X-1916	BRCA	INC424	564	20.4	5	130.8	9.7
X-1916	BRCA	INC424	840.7	20.8	8	244	11.8
X-1916	BRCA	INC424	1464.7	20.2	12	499.3	8.6
X-1916	BRCA	LEE011	214.6	23.9	0	0	0
X-1916	BRCA	LEE011	248.5	24	3	15.8	0.4
X-1916	BRCA	LEE011	318.2	24.4	7	48.3	2.1
X-1916	BRCA	LEE011	383.9	24.6	10	78.9	2.9
X-1916	BRCA	LEE011	416.3	26.3	14	94	10
X-1916	BRCA	LEE011	576	25.5	17	168.4	6.7
X-1916	BRCA	LEE011	737.6	27.5	21	243.7	15.1
X-1916	BRCA	LEE011 + everolimus	210.2	24.7	0	0	0
X-1916	BRCA	LEE011 + everolimus	229.1	24.7	3	9	0
X-1916	BRCA	LEE011 + everolimus	240.6	25.5	7	14.5	3.2
X-1916	BRCA	LEE011 + everolimus	291.5	25	10	38.7	1.2
X-1916	BRCA	LEE011 + everolimus	360.1	26.6	14	71.3	7.7
X-1916	BRCA	LEE011 + everolimus	403.5	24.6	18	92	-0.4
X-1916	BRCA	LEE011 + everolimus	511.6	26.5	20	143.4	7.3
X-1916	BRCA	LEE011 + everolimus	566.1	27.2	24	169.3	10.1
X-1916	BRCA	LEE011 + everolimus	742.9	26.8	28	253.4	8.5
X-1916	BRCA	LFA102	215.6	25.2	0	0	0
X-1916	BRCA	LFA102	230.3	25.7	3	6.8	2
X-1916	BRCA	LFA102	243.4	27.3	7	12.9	8.3
X-1916	BRCA	LFA102	299.1	25.9	10	38.7	2.8
X-1916	BRCA	LFA102	370.3	25.9	14	71.8	2.8
X-1916	BRCA	LFA102	379.4	25.8	18	76	2.4
X-1916	BRCA	LFA102	432.6	25.9	20	100.6	2.8
X-1916	BRCA	LFA102	496.2	26.6	24	130.1	5.6
X-1916	BRCA	LFA102	656.4	27.9	28	204.5	10.7
X-1916	BRCA	LJM716	233.3	24.9	0	0	0
X-1916	BRCA	LJM716	241.5	25	3	3.5	0.4
X-1916	BRCA	LJM716	235.8	24	7	1.1	-3.6
X-1916	BRCA	LJM716	234.7	24.7	10	0.6	-0.8
X-1916	BRCA	LJM716	232.7	25.5	14	-0.3	2.4
X-1916	BRCA	LJM716	268.4	25.6	17	15	2.8
X-1916	BRCA	LJM716	365.2	25.7	21	56.5	3.2
X-1916	BRCA	LJM716	414.7	25.7	25	77.8	3.2
X-1916	BRCA	LJM716	487.4	25.7	27	108.9	3.2
X-1916	BRCA	LJM716	506.9	26.4	31	117.3	6
X-1916	BRCA	LJM716	557.8	27.7	35	139.1	11.2
X-1916	BRCA	LJM716	651.6	23.4	38	179.3	-6
X-1916	BRCA	LJM716	726.8	26.5	42	211.5	6.4
X-1916	BRCA	LJM716	755.5	26.2	44	223.8	5.2
X-1916	BRCA	LJM716	1002.9	26.6	50	329.9	6.8
X-1916	BRCA	LJM716 + trastuzumab	212.3	24.2	0	0	0
X-1916	BRCA	LJM716 + trastuzumab	176.6	22.9	2	-16.8	-5.4
X-1916	BRCA	LJM716 + trastuzumab	129.9	23.9	6	-38.8	-1.2
X-1916	BRCA	LJM716 + trastuzumab	116.6	24.2	9	-45.1	0
X-1916	BRCA	LJM716 + trastuzumab	116.9	25	13	-44.9	3.3
X-1916	BRCA	LJM716 + trastuzumab	107.9	25.5	17	-49.2	5.4
X-1916	BRCA	LJM716 + trastuzumab	104.6	25.7	19	-50.7	6.2
X-1916	BRCA	LJM716 + trastuzumab	113.3	27.1	23	-46.6	12
X-1916	BRCA	LJM716 + trastuzumab	109.2	26.7	27	-48.6	10.3
X-1916	BRCA	LJM716 + trastuzumab	107.4	25.7	30	-49.4	6.2
X-1916	BRCA	LJM716 + trastuzumab	138.4	25.5	34	-34.8	5.4
X-1916	BRCA	LJM716 + trastuzumab	188.4	25.8	36	-11.3	6.6
X-1916	BRCA	LJM716 + trastuzumab	217.8	26.3	42	2.6	8.7
X-1916	BRCA	LJM716 + trastuzumab	228	26.8	45	7.4	10.7
X-1916	BRCA	LJM716 + trastuzumab	267.7	27	49	26.1	11.6
X-1916	BRCA	LJM716 + trastuzumab	381.3	28	55	79.6	15.7
X-1916	BRCA	LJM716 + trastuzumab	462	28.9	58	117.6	19.4
X-1916	BRCA	LJM716 + trastuzumab	550.6	27.8	62	159.3	14.9
X-1916	BRCA	LJM716 + trastuzumab	607.9	27.4	65	186.3	13.2
X-1916	BRCA	LJM716 + trastuzumab	748.5	27.4	70	252.6	13.2
X-1916	BRCA	LJM716 + trastuzumab	849.6	28.2	76	300.2	16.5
X-1916	BRCA	LJM716 + trastuzumab	1065.3	28.8	80	401.8	19
X-1916	BRCA	LJM716 + trastuzumab	1229.3	28	83	479	15.7
X-1916	BRCA	LKA136	224.9	23.2	0	0	0
X-1916	BRCA	LKA136	229.1	23.8	3	1.9	2.6
X-1916	BRCA	LKA136	266.9	24.4	7	18.7	5.2
X-1916	BRCA	LKA136	280	24.9	10	24.5	7.3
X-1916	BRCA	LKA136	370.6	26	14	64.8	12.1
X-1916	BRCA	LKA136	407.7	25.9	17	81.3	11.6
X-1916	BRCA	LKA136	505.3	26.5	21	124.7	14.2
X-1916	BRCA	LLM871	203.9	24.5	0	0	0
X-1916	BRCA	LLM871	216.5	24.3	3	6.2	-0.8
X-1916	BRCA	LLM871	260.8	25.6	7	27.9	4.5
X-1916	BRCA	LLM871	422	24.1	10	107	-1.6
X-1916	BRCA	LLM871	700.6	25.1	14	243.6	2.4
X-1916	BRCA	LLM871	786.8	25.1	18	285.9	2.4
X-1916	BRCA	LLM871	914.8	25.5	20	348.7	4.1
X-1916	BRCA	LLM871	1329.6	26.3	24	552.1	7.3
X-1916	BRCA	binimetinib	208.5	23.3	0	0	0
X-1916	BRCA	binimetinib	234.3	21.8	5	12.4	-6.4
X-1916	BRCA	binimetinib	305.1	23.8	8	46.3	2.1
X-1916	BRCA	binimetinib	493.8	25	12	136.8	7.3
X-1916	BRCA	binimetinib	682.4	25.5	15	227.3	9.4
X-1916	BRCA	binimetinib	894.6	23.5	19	329.1	0.9
X-1916	BRCA	paclitaxel	208.9	25.2	0	0	0
X-1916	BRCA	paclitaxel	260.1	25	3	24.5	-0.8
X-1916	BRCA	paclitaxel	342.5	25.4	7	64	0.8
X-1916	BRCA	paclitaxel	360.3	25.1	11	72.5	-0.4
X-1916	BRCA	paclitaxel	389.4	26.1	13	86.4	3.6
X-1916	BRCA	paclitaxel	418	26.5	17	100.1	5.2
X-1916	BRCA	paclitaxel	551.4	27.1	21	164	7.5
X-1916	BRCA	paclitaxel	696.3	26.5	24	233.3	5.2
X-1916	BRCA	paclitaxel	735.2	27.3	28	251.9	8.3
X-1916	BRCA	tamoxifen	205.8	20.8	0	0	0
X-1916	BRCA	tamoxifen	231.1	22.7	5	12.3	9.1
X-1916	BRCA	tamoxifen	307.7	23	8	49.5	10.6
X-1916	BRCA	tamoxifen	438.5	24.9	12	113.1	19.7
X-1916	BRCA	tamoxifen	589.5	24.6	15	186.4	18.3
X-1916	BRCA	tamoxifen	807.3	24	19	292.3	15.4
X-1916	BRCA	trastuzumab	230.3	25.4	0	0	0
X-1916	BRCA	trastuzumab	262.1	25.8	3	13.8	1.6
X-1916	BRCA	trastuzumab	292.6	26.7	7	27.1	5.1
X-1916	BRCA	trastuzumab	416.7	25.5	10	80.9	0.4
X-1916	BRCA	trastuzumab	504.8	26.4	14	119.2	3.9
X-1916	BRCA	trastuzumab	524.2	26.2	18	127.6	3.1
X-1916	BRCA	trastuzumab	583.8	26.5	20	153.5	4.3
X-1916	BRCA	trastuzumab	770.9	26.4	24	234.7	3.9
X-1916	BRCA	trastuzumab	1091.5	27.3	28	373.9	7.5
X-1916	BRCA	untreated	218.3	25.1	0	0	0
X-1916	BRCA	untreated	273	24.5	3	25.1	-2.4
X-1916	BRCA	untreated	341.6	25.7	7	56.5	2.4
X-1916	BRCA	untreated	431.7	26	11	97.8	3.6
X-1916	BRCA	untreated	485.9	25.6	13	122.6	2
X-1916	BRCA	untreated	662.1	25.6	17	203.3	2
X-1916	BRCA	untreated	859.5	26.6	21	293.7	6
X-1916	BRCA	untreated	1146.8	26.8	24	425.3	6.8
X-1916	BRCA	untreated	1352	27.8	28	519.3	10.8
X-1916	BRCA	LFW527 + everolimus	197.39	25.9	0	0	0
X-1916	BRCA	LFW527 + everolimus	231.33	24.1	6	17.2	-6.9
X-1916	BRCA	LFW527 + everolimus	258.07	26	10	30.7	0.4
X-1916	BRCA	LFW527 + everolimus	243.16	25	14	23.2	-3.5
X-1916	BRCA	LFW527 + everolimus	216.44	25.6	17	9.7	-1.2
X-1916	BRCA	LFW527 + everolimus	236.51	25.2	20	19.8	-2.7
X-1916	BRCA	LFW527 + everolimus	277.71	25.7	24	40.7	-0.8
X-1916	BRCA	LFW527 + everolimus	293.55	24.3	28	48.7	-6.2
X-1916	BRCA	LFW527 + everolimus	317.77	25.4	31	61	-1.9
X-1916	BRCA	LFW527 + everolimus	332.33	25.3	34	68.4	-2.3
X-1916	BRCA	LFW527 + everolimus	424.85	26.4	38	115.2	1.9
X-1916	BRCA	LFW527 + everolimus	475.86	24.1	46	141.1	-6.9
X-1916	BRCA	LFW527 + everolimus	598.92	25.9	49	203.4	0
X-1916	BRCA	LFW527 + everolimus	748.13	25.8	52	279	-0.4
X-1916	BRCA	LFW527 + everolimus	885.63	26	56	348.7	0.4
X-1916	BRCA	LFW527 + everolimus	1001.84	26.2	59	407.5	1.2
X-1921	BRCA	BGJ398	252.8	23	0	0	0
X-1921	BRCA	BGJ398	355.6	23.3	4	40.7	1.3
X-1921	BRCA	BGJ398	377.3	25.6	8	49.2	11.3
X-1921	BRCA	BGJ398	398.7	25.1	11	57.7	9.1
X-1921	BRCA	BGJ398	375.9	26	15	48.7	13
X-1921	BRCA	BGJ398	442.3	26.1	18	75	13.5
X-1921	BRCA	BGJ398	457.4	25.4	22	80.9	10.4
X-1921	BRCA	BGJ398	516.8	24.7	25	104.4	7.4
X-1921	BRCA	BGJ398	536.7	24.6	29	112.3	7
X-1921	BRCA	BGJ398	547.9	24.5	32	116.7	6.5
X-1921	BRCA	BGJ398	610.8	24.7	36	141.6	7.4
X-1921	BRCA	BGJ398	589.5	24.8	39	133.2	7.8
X-1921	BRCA	BGJ398	596.4	24.4	43	135.9	6.1
X-1921	BRCA	BGJ398	576	24.4	46	127.8	6.1
X-1921	BRCA	BGJ398	658.7	24.7	49	160.6	7.4
X-1921	BRCA	BGJ398	662.8	25.1	53	162.2	9.1
X-1921	BRCA	BGJ398	662.1	24.5	57	161.9	6.5
X-1921	BRCA	BGJ398	638	25.1	60	152.4	9.1
X-1921	BRCA	BGJ398	761.8	25.4	64	201.3	10.4
X-1921	BRCA	BGJ398	799.9	25.1	74	216.4	9.1
X-1921	BRCA	BGJ398	789.2	25	78	212.2	8.7
X-1921	BRCA	BGJ398	865.7	24.6	81	242.4	7
X-1921	BRCA	BKM120	200	20.5	0	0	0
X-1921	BRCA	BKM120	176.3	21.4	4	-11.8	4.4
X-1921	BRCA	BKM120	180.4	21.3	7	-9.8	3.9
X-1921	BRCA	BKM120	215.2	21.2	12	7.6	3.4
X-1921	BRCA	BKM120	225	21.4	15	12.5	4.4
X-1921	BRCA	BKM120	260.9	20.9	18	30.4	2
X-1921	BRCA	BKM120	266.3	22.6	22	33.2	10.2
X-1921	BRCA	BKM120	280.9	22.5	25	40.4	9.8
X-1921	BRCA	BKM120	284.3	23	29	42.1	12.2
X-1921	BRCA	BKM120	289.3	22.8	32	44.7	11.2
X-1921	BRCA	BKM120	335.4	22.7	36	67.7	10.7
X-1921	BRCA	BKM120	328.3	22	39	64.1	7.3
X-1921	BRCA	BKM120	418	22	43	109	7.3
X-1921	BRCA	BKM120	474.1	22.3	46	137.1	8.8
X-1921	BRCA	BKM120	473.9	22.8	50	136.9	11.2
X-1921	BRCA	BKM120	493.4	24	53	146.7	17.1
X-1921	BRCA	BKM120	483.9	23.4	57	141.9	14.1
X-1921	BRCA	BKM120	503.7	22.8	60	151.8	11.2
X-1921	BRCA	BKM120	574.4	22.6	63	187.2	10.2
X-1921	BRCA	BKM120	653.5	23.8	67	226.8	16.1
X-1921	BRCA	BKM120	758	24.2	71	279	18
X-1921	BRCA	BKM120	719.8	24	74	259.9	17.1
X-1921	BRCA	BKM120	806.2	23.8	78	303.1	16.1
X-1921	BRCA	BKM120	1055	24.1	88	427.5	17.6
X-1921	BRCA	BYL719	190.1	25.2	0	0	0
X-1921	BRCA	BYL719	202.1	25.8	3	6.3	2.4
X-1921	BRCA	BYL719	209.2	25.1	6	10	-0.4
X-1921	BRCA	BYL719	218	25.2	11	14.7	0
X-1921	BRCA	BYL719	227.1	24.5	14	19.5	-2.8
X-1921	BRCA	BYL719	220.6	24.5	17	16	-2.8
X-1921	BRCA	BYL719	289.7	25.6	21	52.4	1.6
X-1921	BRCA	BYL719	301.9	26.5	24	58.8	5.2
X-1921	BRCA	BYL719	292	26	28	53.6	3.2
X-1921	BRCA	BYL719	288.9	26.1	31	52	3.6
X-1921	BRCA	BYL719	249.6	25.6	35	31.3	1.6
X-1921	BRCA	BYL719	278.7	25.6	38	46.6	1.6
X-1921	BRCA	BYL719	322.7	25.5	42	69.8	1.2
X-1921	BRCA	BYL719	281.1	26.6	45	47.9	5.6
X-1921	BRCA	BYL719	312	26.6	49	64.1	5.6
X-1921	BRCA	BYL719	357.7	26.9	52	88.2	6.7
X-1921	BRCA	BYL719	343.7	27.6	56	80.8	9.5
X-1921	BRCA	BYL719	333.5	26.6	59	75.4	5.6
X-1921	BRCA	BYL719	376.7	26.8	62	98.2	6.3
X-1921	BRCA	BYL719	405.5	27	66	113.3	7.1
X-1921	BRCA	BYL719	464.4	28.1	70	144.3	11.5
X-1921	BRCA	BYL719	432.9	27.4	73	127.7	8.7
X-1921	BRCA	BYL719	445.7	27.2	77	134.5	7.9
X-1921	BRCA	BYL719	526.7	28	87	177.1	11.1
X-1921	BRCA	BYL719	599.3	27.5	91	215.3	9.1
X-1921	BRCA	BYL719	679.3	27	94	257.3	7.1
X-1921	BRCA	BYL719 + LJM716	213.1	23.7	0	0	0
X-1921	BRCA	BYL719 + LJM716	199.9	21.9	5	-6.2	-7.6
X-1921	BRCA	BYL719 + LJM716	238.3	22.1	8	11.8	-6.8
X-1921	BRCA	BYL719 + LJM716	233.4	22	11	9.5	-7.2
X-1921	BRCA	BYL719 + LJM716	260.8	23.1	15	22.4	-2.5
X-1921	BRCA	BYL719 + LJM716	286.9	22.8	18	34.6	-3.8
X-1921	BRCA	BYL719 + LJM716	344.4	23.6	22	61.6	-0.4
X-1921	BRCA	BYL719 + LJM716	318.9	23.4	25	49.6	-1.3
X-1921	BRCA	BYL719 + LJM716	381.5	23.4	29	79	-1.3
X-1921	BRCA	BYL719 + LJM716	402.4	24.5	32	88.8	3.4
X-1921	BRCA	BYL719 + LJM716	423.1	24.5	36	98.5	3.4
X-1921	BRCA	BYL719 + LJM716	447.4	22.5	39	109.9	-5.1
X-1921	BRCA	BYL719 + LJM716	485.9	23.7	43	128	0
X-1921	BRCA	BYL719 + LJM716	508	24.3	46	138.4	2.5
X-1921	BRCA	BYL719 + LJM716	614.9	24.9	50	188.5	5.1
X-1921	BRCA	BYL719 + LJM716	650.8	23.6	53	205.4	-0.4
X-1921	BRCA	BYL719 + LJM716	755.2	23.5	56	254.4	-0.8
X-1921	BRCA	BYL719 + LJM716	757.1	24.4	60	255.3	3
X-1921	BRCA	BYL719 + LJM716	864.8	23.7	64	305.8	0
X-1921	BRCA	BYL719 + LJM716	966.5	24.1	67	353.5	1.7
X-1921	BRCA	BYL719 + LEE011	237.4	24.3	0	0	0
X-1921	BRCA	BYL719 + LEE011	191.1	23.6	4	-19.5	-2.9
X-1921	BRCA	BYL719 + LEE011	145.8	23.5	7	-38.6	-3.3
X-1921	BRCA	BYL719 + LEE011	174.1	23.7	11	-26.7	-2.5
X-1921	BRCA	BYL719 + LEE011	181.7	24.4	14	-23.5	0.4
X-1921	BRCA	BYL719 + LEE011	152.7	24.7	18	-35.7	1.6
X-1921	BRCA	BYL719 + LEE011	158.2	24.7	21	-33.4	1.6
X-1921	BRCA	BYL719 + LEE011	188.1	25	25	-20.8	2.9
X-1921	BRCA	BYL719 + LEE011	194.7	23.6	28	-18	-2.9
X-1921	BRCA	BYL719 + LEE011	186.1	25.4	32	-21.6	4.5
X-1921	BRCA	BYL719 + LEE011	186.3	25.1	35	-21.5	3.3
X-1921	BRCA	BYL719 + LEE011	182.1	25.4	39	-23.3	4.5
X-1921	BRCA	BYL719 + LEE011	174.2	25.6	42	-26.6	5.3
X-1921	BRCA	BYL719 + LEE011	202	24.8	45	-14.9	2.1
X-1921	BRCA	BYL719 + LEE011	183.2	25.1	49	-22.8	3.3
X-1921	BRCA	BYL719 + LEE011	198.4	25.3	53	-16.4	4.1
X-1921	BRCA	BYL719 + LEE011	188.9	24.1	56	-20.4	-0.8
X-1921	BRCA	BYL719 + LEE011	220.7	25.5	60	-7	4.9
X-1921	BRCA	BYL719 + LEE011	196.4	25.8	70	-17.3	6.2
X-1921	BRCA	BYL719 + LEE011	218.6	26.2	74	-7.9	7.8
X-1921	BRCA	BYL719 + LEE011	226.2	25	77	-4.7	2.9
X-1921	BRCA	BYL719 + LEE011	290.7	25.4	81	22.5	4.5
X-1921	BRCA	BYL719 + LEE011	272.5	25.9	84	14.8	6.6
X-1921	BRCA	BYL719 + LEE011	317.4	26.3	88	33.7	8.2
X-1921	BRCA	BYL719 + LEE011	317.5	25.6	91	33.7	5.3
X-1921	BRCA	BYL719 + LEE011	315	26.3	94	32.7	8.2
X-1921	BRCA	BYL719 + LEE011	318.2	26.5	98	34	9.1
X-1921	BRCA	BYL719 + LEE011	322.1	26.7	101	35.7	9.9
X-1921	BRCA	BYL719 + LEE011	334.8	25.8	105	41	6.2
X-1921	BRCA	BYL719 + LEE011	403	26.7	108	69.8	9.9
X-1921	BRCA	BYL719 + LEE011	384.4	25.4	112	61.9	4.5
X-1921	BRCA	BYL719 + LEE011	333.7	25.6	116	40.6	5.3
X-1921	BRCA	BYL719 + LEE011	343.9	26.3	119	44.9	8.2
X-1921	BRCA	BYL719 + LEE011	358.2	26.6	123	50.9	9.5
X-1921	BRCA	BYL719 + LEE011	386.2	25.7	126	62.7	5.8
X-1921	BRCA	BYL719 + LEE011	453.7	25.1	130	91.1	3.3
X-1921	BRCA	BYL719 + LEE011	412.5	25.7	133	73.8	5.8
X-1921	BRCA	BYL719 + LEE011	403.3	24.1	137	69.9	-0.8
X-1921	BRCA	BYL719 + LEE011	394.6	16.1	140	66.2	-33.7
X-1921	BRCA	CGM097	210.8	26.2	0	0	0
X-1921	BRCA	CGM097	282.5	28.7	3	34	9.5
X-1921	BRCA	CGM097	339	29	6	60.8	10.7
X-1921	BRCA	CGM097	399.2	29.7	11	89.4	13.4
X-1921	BRCA	CGM097	500.9	29.7	14	137.6	13.4
X-1921	BRCA	CGM097	615.2	29.8	17	191.8	13.7
X-1921	BRCA	CGM097	707.4	30.2	21	235.6	15.3
X-1921	BRCA	CGM097	799	29.5	24	279	12.6
X-1921	BRCA	CGM097	921	31.1	28	336.9	18.7
X-1921	BRCA	CGM097	937.8	31.5	31	344.9	20.2
X-1921	BRCA	CGM097	1157.4	31.2	35	449.1	19.1
X-1921	BRCA	CGM097	1246.3	31.1	38	491.2	18.7
X-1921	BRCA	CLR457	247.2	26.7	0	0	0
X-1921	BRCA	CLR457	188.6	25.7	3	-23.7	-3.7
X-1921	BRCA	CLR457	162.6	26.4	8	-34.2	-1.1
X-1921	BRCA	CLR457	157.2	25.6	11	-36.4	-4.1
X-1921	BRCA	CLR457	165	26	14	-33.3	-2.6
X-1921	BRCA	CLR457	199.5	26.5	18	-19.3	-0.7
X-1921	BRCA	CLR457	212.6	26.7	21	-14	0
X-1921	BRCA	CLR457	198.6	27.5	25	-19.7	3
X-1921	BRCA	CLR457	192.6	27.3	28	-22.1	2.2
X-1921	BRCA	CLR457	188.7	27	32	-23.7	1.1
X-1921	BRCA	CLR457	208.2	26.8	35	-15.8	0.4
X-1921	BRCA	CLR457	213.2	26.4	39	-13.8	-1.1
X-1921	BRCA	CLR457	221.7	26.8	42	-10.3	0.4
X-1921	BRCA	CLR457	240.7	26.2	46	-2.6	-1.9
X-1921	BRCA	CLR457	238.5	27	49	-3.5	1.1
X-1921	BRCA	CLR457	249.5	26.8	53	0.9	0.4
X-1921	BRCA	CLR457	281.2	27.4	56	13.8	2.6
X-1921	BRCA	CLR457	205.1	26.8	59	-17	0.4
X-1921	BRCA	CLR457	226.7	26.3	63	-8.3	-1.5
X-1921	BRCA	CLR457	280.7	25.3	67	13.6	-5.2
X-1921	BRCA	CLR457	235.7	27.2	70	-4.7	1.9
X-1921	BRCA	CLR457	332.8	27	74	34.6	1.1
X-1921	BRCA	CLR457	327.1	27.2	84	32.3	1.9
X-1921	BRCA	CLR457	304.4	27.8	88	23.1	4.1
X-1921	BRCA	CLR457	274	28.3	91	10.8	6
X-1921	BRCA	CLR457	319.2	27.4	95	29.1	2.6
X-1921	BRCA	CLR457	357.6	28.6	98	44.7	7.1
X-1921	BRCA	CLR457	346.1	28.3	102	40	6
X-1921	BRCA	CLR457	367.8	28.1	105	48.8	5.2
X-1921	BRCA	CLR457	366.4	27.7	108	48.2	3.7
X-1921	BRCA	CLR457	377.8	26.6	112	52.8	-0.4
X-1921	BRCA	CLR457	381.7	26.8	115	54.4	0.4
X-1921	BRCA	CLR457	392.8	27.4	119	58.9	2.6
X-1921	BRCA	CLR457	407	27.8	122	64.6	4.1
X-1921	BRCA	CLR457	408.5	27	126	65.3	1.1
X-1921	BRCA	CLR457	470.3	27.4	130	90.3	2.6
X-1921	BRCA	CLR457	414.4	27.2	133	67.6	1.9
X-1921	BRCA	CLR457	469	27.1	137	89.7	1.5
X-1921	BRCA	CLR457	466.1	27.8	140	88.6	4.1
X-1921	BRCA	CLR457	532.1	27.4	144	115.3	2.6
X-1921	BRCA	CLR457	546.7	26.9	147	121.2	0.7
X-1921	BRCA	CLR457	624	27.3	151	152.4	2.2
X-1921	BRCA	CLR457	571.1	26.4	154	131	-1.1
X-1921	BRCA	CLR457	605	27.3	158	144.7	2.2
X-1921	BRCA	CLR457	585.8	26.6	161	137	-0.4
X-1921	BRCA	CLR457	595.2	26.8	165	140.8	0.4
X-1921	BRCA	CLR457	587.8	26.1	168	137.8	-2.2
X-1921	BRCA	CLR457	619	27.3	172	150.4	2.2
X-1921	BRCA	CLR457	637.6	26.9	175	157.9	0.7
X-1921	BRCA	HDM201	185	22.8	0	0	0
X-1921	BRCA	HDM201	221.5	23.4	4	19.7	2.6
X-1921	BRCA	HDM201	277.7	23.5	7	50.1	3.1
X-1921	BRCA	HDM201	313.2	23.5	12	69.3	3.1
X-1921	BRCA	HDM201	384.2	23.8	15	107.7	4.4
X-1921	BRCA	HDM201	398.7	23.4	18	115.5	2.6
X-1921	BRCA	HDM201	375.1	23.1	22	102.8	1.3
X-1921	BRCA	HDM201	430.6	23.4	25	132.8	2.6
X-1921	BRCA	HDM201	466.9	24.4	29	152.4	7
X-1921	BRCA	HDM201	526.3	23.6	32	184.5	3.5
X-1921	BRCA	HDM201	491.3	21.6	36	165.6	-5.3
X-1921	BRCA	HDM201	482.2	20.4	39	160.6	-10.5
X-1921	BRCA	HDM201	511.6	19.2	43	176.5	-15.8
X-1921	BRCA	HDM201	539.1	19	46	191.4	-16.7
X-1921	BRCA	INC424	214.4	24.9	0	0	0
X-1921	BRCA	INC424	291.6	25.2	5	36	1.2
X-1921	BRCA	INC424	379.7	25.5	8	77.1	2.4
X-1921	BRCA	INC424	497.7	25.4	11	132.1	2
X-1921	BRCA	INC424	482.4	25	15	125	0.4
X-1921	BRCA	INC424	442	25.5	18	106.2	2.4
X-1921	BRCA	INC424	467.7	26.2	22	118.1	5.2
X-1921	BRCA	INC424	612.6	26.2	25	185.7	5.2
X-1921	BRCA	INC424	666.4	26.8	29	210.8	7.6
X-1921	BRCA	INC424	755.4	26.9	32	252.3	8
X-1921	BRCA	INC424	783.3	26.3	36	265.3	5.6
X-1921	BRCA	INC424	835.4	27.3	39	289.6	9.6
X-1921	BRCA	INC424	875.1	27.1	43	308.2	8.8
X-1921	BRCA	INC424	892.2	26.5	46	316.1	6.4
X-1921	BRCA	INC424	1091.5	26.4	50	409.1	6
X-1921	BRCA	INC424	1192.5	27.1	53	456.2	8.8
X-1921	BRCA	LEE011	236.3	24	0	0	0
X-1921	BRCA	LEE011	250	24.1	5	5.8	0.4
X-1921	BRCA	LEE011	217.3	24.7	8	-8	2.9
X-1921	BRCA	LEE011	227.4	25.1	11	-3.8	4.6
X-1921	BRCA	LEE011	159.5	25.3	15	-32.5	5.4
X-1921	BRCA	LEE011	162.4	25.3	18	-31.3	5.4
X-1921	BRCA	LEE011	153.2	25.5	22	-35.2	6.2
X-1921	BRCA	LEE011	227.4	26.9	25	-3.8	12.1
X-1921	BRCA	LEE011	193.5	27	29	-18.1	12.5
X-1921	BRCA	LEE011	177	26.7	32	-25.1	11.3
X-1921	BRCA	LEE011	193.2	26.6	36	-18.2	10.8
X-1921	BRCA	LEE011	168	26.8	39	-28.9	11.7
X-1921	BRCA	LEE011	172	27.2	43	-27.2	13.3
X-1921	BRCA	LEE011	167.1	27.3	46	-29.3	13.7
X-1921	BRCA	LEE011	195.1	26.8	50	-17.4	11.7
X-1921	BRCA	LEE011	184.8	24.7	53	-21.8	2.9
X-1921	BRCA	LEE011	172.7	23.7	56	-26.9	-1.3
X-1921	BRCA	LEE011	157.9	25.2	60	-33.2	5
X-1921	BRCA	LEE011	189.7	26.2	64	-19.7	9.2
X-1921	BRCA	LEE011	182.8	27.3	67	-22.6	13.7
X-1921	BRCA	LEE011	211.3	27.3	71	-10.6	13.7
X-1921	BRCA	LEE011	165.7	26.9	81	-29.9	12.1
X-1921	BRCA	LEE011	208.6	27.1	85	-11.7	12.9
X-1921	BRCA	LEE011	204.4	28	88	-13.5	16.7
X-1921	BRCA	LEE011	280.3	27.4	92	18.6	14.2
X-1921	BRCA	LEE011	306.7	27.5	95	29.8	14.6
X-1921	BRCA	LEE011	367.3	27.3	99	55.4	13.7
X-1921	BRCA	LEE011	343	27.4	102	45.2	14.2
X-1921	BRCA	LEE011	341	27.7	105	44.3	15.4
X-1921	BRCA	LEE011	351.6	28.7	109	48.8	19.6
X-1921	BRCA	LEE011	359.3	28.6	112	52.1	19.2
X-1921	BRCA	LEE011	373.1	28.8	116	57.9	20
X-1921	BRCA	LEE011	425.7	29	119	80.2	20.8
X-1921	BRCA	LEE011	557.4	29.9	123	135.9	24.6
X-1921	BRCA	LEE011	619.9	29.2	127	162.3	21.7
X-1921	BRCA	LEE011	603.1	29	130	155.2	20.8
X-1921	BRCA	LEE011	634.7	29.9	134	168.6	24.6
X-1921	BRCA	LEE011	714.4	30.2	137	202.3	25.8
X-1921	BRCA	LEE011	832.7	29.9	141	252.4	24.6
X-1921	BRCA	LEE011	931.3	31.1	144	294.1	29.6
X-1921	BRCA	LEE011	1098.4	30	148	364.8	25
X-1921	BRCA	LEE011	1092.8	31.6	151	362.5	31.7
X-1921	BRCA	LEE011 + everolimus	290.9	25.4	0	0	0
X-1921	BRCA	LEE011 + everolimus	340.8	24.4	4	17.2	-3.9
X-1921	BRCA	LEE011 + everolimus	349.6	25.7	7	20.2	1.2
X-1921	BRCA	LEE011 + everolimus	310.7	25.7	11	6.8	1.2
X-1921	BRCA	LEE011 + everolimus	294.5	25.5	14	1.2	0.4
X-1921	BRCA	LEE011 + everolimus	299.1	25.6	17	2.8	0.8
X-1921	BRCA	LEE011 + everolimus	300.1	26.2	21	3.2	3.1
X-1921	BRCA	LEE011 + everolimus	300.4	26.2	24	3.3	3.1
X-1921	BRCA	LEE011 + everolimus	296.7	26.5	28	2	4.3
X-1921	BRCA	LEE011 + everolimus	293.2	26.4	31	0.8	3.9
X-1921	BRCA	LEE011 + everolimus	272.7	26.3	35	-6.3	3.5
X-1921	BRCA	LEE011 + everolimus	238.8	25.9	39	-17.9	2
X-1921	BRCA	LEE011 + everolimus	221.2	25.5	42	-24	0.4
X-1921	BRCA	LEE011 + everolimus	219.9	25.8	46	-24.4	1.6
X-1921	BRCA	LEE011 + everolimus	232.6	25.3	49	-20	-0.4
X-1921	BRCA	LEE011 + everolimus	225.4	26	53	-22.5	2.4
X-1921	BRCA	LEE011 + everolimus	197.5	25.7	56	-32.1	1.2
X-1921	BRCA	LEE011 + everolimus	203.1	26.4	60	-30.2	3.9
X-1921	BRCA	LEE011 + everolimus	185.1	25.2	63	-36.4	-0.8
X-1921	BRCA	LEE011 + everolimus	195.3	24.8	67	-32.9	-2.4
X-1921	BRCA	LEE011 + everolimus	193	23.8	70	-33.7	-6.3
X-1921	BRCA	LEE011 + everolimus	180.1	24.6	74	-38.1	-3.1
X-1921	BRCA	LEE011 + everolimus	179	24.6	77	-38.5	-3.1
X-1921	BRCA	LEE011 + everolimus	171.6	24.8	81	-41	-2.4
X-1921	BRCA	LEE011 + everolimus	186.1	24.3	84	-36	-4.3
X-1921	BRCA	LFA102	247.5	24.6	0	0	0
X-1921	BRCA	LFA102	304.1	25.8	3	22.9	4.9
X-1921	BRCA	LFA102	368.1	26	6	48.7	5.7
X-1921	BRCA	LFA102	386.3	26.1	10	56.1	6.1
X-1921	BRCA	LFA102	495.8	26.4	13	100.3	7.3
X-1921	BRCA	LFA102	546.9	27.3	17	121	11
X-1921	BRCA	LFA102	575.1	27.7	20	132.4	12.6
X-1921	BRCA	LFA102	702.6	26.7	24	183.9	8.5
X-1921	BRCA	LFA102	714.7	26.7	27	188.8	8.5
X-1921	BRCA	LFA102	836	27.1	31	237.8	10.2
X-1921	BRCA	LFA102	893.9	26.8	34	261.2	8.9
X-1921	BRCA	LFA102	951.2	27.1	38	284.3	10.2
X-1921	BRCA	LFA102	1006.1	27.3	41	306.5	11
X-1921	BRCA	LJM716 + trastuzumab	209.8	23.8	0	0	0
X-1921	BRCA	LJM716 + trastuzumab	271.5	23.5	2	29.4	-1.3
X-1921	BRCA	LJM716 + trastuzumab	307.5	23.7	7	46.6	-0.4
X-1921	BRCA	LJM716 + trastuzumab	411	24.3	10	95.9	2.1
X-1921	BRCA	LJM716 + trastuzumab	388.7	25.7	13	85.3	8
X-1921	BRCA	LJM716 + trastuzumab	485.4	25.3	17	131.4	6.3
X-1921	BRCA	LJM716 + trastuzumab	501.2	25.1	20	138.9	5.5
X-1921	BRCA	LJM716 + trastuzumab	532.3	25.3	24	153.7	6.3
X-1921	BRCA	LJM716 + trastuzumab	719.8	25.8	27	243.1	8.4
X-1921	BRCA	LJM716 + trastuzumab	761.9	25.5	31	263.2	7.1
X-1921	BRCA	LJM716 + trastuzumab	730.1	25.9	34	248	8.8
X-1921	BRCA	LJM716 + trastuzumab	857.1	26.4	38	308.5	10.9
X-1921	BRCA	LJM716 + trastuzumab	940.8	25.8	41	348.4	8.4
X-1921	BRCA	LJM716 + trastuzumab	1017	26.5	45	384.7	11.3
X-1921	BRCA	LJM716 + trastuzumab	1119.2	26.6	48	433.5	11.8
X-1921	BRCA	LJM716	192.3	22.8	0	0	0
X-1921	BRCA	LJM716	202.2	23.1	2	5.1	1.3
X-1921	BRCA	LJM716	247.9	22.1	7	28.9	-3.1
X-1921	BRCA	LJM716	311.7	22.2	10	62.1	-2.6
X-1921	BRCA	LJM716	340.3	22.5	13	77	-1.3
X-1921	BRCA	LJM716	457.2	23.2	17	137.8	1.8
X-1921	BRCA	LJM716	481.7	23.6	20	150.5	3.5
X-1921	BRCA	LJM716	544.1	23.9	24	182.9	4.8
X-1921	BRCA	LJM716	669.5	23.6	27	248.2	3.5
X-1921	BRCA	LJM716	786.6	22.9	31	309	0.4
X-1921	BRCA	LJM716	867.3	25.3	34	351	11
X-1921	BRCA	LKA136	210.9	23.5	0	0	0
X-1921	BRCA	LKA136	279.6	24	5	32.6	2.1
X-1921	BRCA	LKA136	347.8	25.1	8	64.9	6.8
X-1921	BRCA	LKA136	432.2	25.1	11	104.9	6.8
X-1921	BRCA	LKA136	562.2	25.2	15	166.6	7.2
X-1921	BRCA	LKA136	622.9	24.8	18	195.4	5.5
X-1921	BRCA	LKA136	757.8	26.8	22	259.3	14
X-1921	BRCA	LKA136	1030.8	27.3	25	388.8	16.2
X-1921	BRCA	LLM871	222.9	22.9	0	0	0
X-1921	BRCA	LLM871	300.2	22.3	3	34.7	-2.6
X-1921	BRCA	LLM871	287.6	22.7	6	29	-0.9
X-1921	BRCA	LLM871	345.6	22.6	10	55	-1.3
X-1921	BRCA	LLM871	383.1	22.7	13	71.9	-0.9
X-1921	BRCA	LLM871	365.3	22.3	17	63.9	-2.6
X-1921	BRCA	LLM871	404.3	23.1	20	81.4	0.9
X-1921	BRCA	LLM871	457.3	22.4	23	105.2	-2.2
X-1921	BRCA	LLM871	519.9	23.1	27	133.2	0.9
X-1921	BRCA	LLM871	608.3	23.5	31	172.9	2.6
X-1921	BRCA	LLM871	645.6	24.1	34	189.6	5.2
X-1921	BRCA	LLM871	768	23.9	38	244.5	4.4
X-1921	BRCA	LLM871	925.8	23.8	48	315.3	3.9
X-1921	BRCA	LLM871	1288	24.1	55	477.8	5.2
X-1921	BRCA	binimetinib	220	25	0	0	0
X-1921	BRCA	binimetinib	235.5	24.9	3	7	-0.4
X-1921	BRCA	binimetinib	226.7	24.9	8	3	-0.4
X-1921	BRCA	binimetinib	230	26	11	4.5	4
X-1921	BRCA	binimetinib	258	26.5	14	17.3	6
X-1921	BRCA	binimetinib	270.8	26	18	23.1	4
X-1921	BRCA	binimetinib	219	26.1	21	-0.5	4.4
X-1921	BRCA	binimetinib	214.5	26.6	25	-2.5	6.4
X-1921	BRCA	binimetinib	257.6	27	28	17.1	8
X-1921	BRCA	binimetinib	325.2	26.1	32	47.8	4.4
X-1921	BRCA	binimetinib	309.4	26.3	35	40.6	5.2
X-1921	BRCA	binimetinib	325.9	24.5	39	48.1	-2
X-1921	BRCA	binimetinib	293.6	23	42	33.5	-8
X-1921	BRCA	binimetinib	318.9	22	46	45	-12
X-1921	BRCA	binimetinib	357.8	21.4	49	62.6	-14.4
X-1921	BRCA	binimetinib	445.8	20.5	53	102.6	-18
X-1921	BRCA	binimetinib	520.8	20.4	56	136.7	-18.4
X-1921	BRCA	binimetinib	570.9	20	59	159.5	-20
X-1921	BRCA	paclitaxel	237.7	24.1	0	0	0
X-1921	BRCA	paclitaxel	267.7	23.9	2	12.6	-0.8
X-1921	BRCA	paclitaxel	344.6	24.6	7	45	2.1
X-1921	BRCA	paclitaxel	350	24.7	10	47.2	2.5
X-1921	BRCA	paclitaxel	359.4	25.7	13	51.2	6.6
X-1921	BRCA	paclitaxel	428.5	25.2	17	80.3	4.6
X-1921	BRCA	paclitaxel	519	25.5	20	118.3	5.8
X-1921	BRCA	paclitaxel	609	25.9	24	156.2	7.5
X-1921	BRCA	paclitaxel	845.8	26.2	27	255.8	8.7
X-1921	BRCA	paclitaxel	987.8	26.2	31	315.6	8.7
X-1921	BRCA	paclitaxel	959.1	27.1	34	303.5	12.4
X-1921	BRCA	tamoxifen	208.5	24.5	0	0	0
X-1921	BRCA	tamoxifen	233	25.7	3	11.8	4.9
X-1921	BRCA	tamoxifen	246.4	25.5	6	18.2	4.1
X-1921	BRCA	tamoxifen	234.1	24.6	11	12.3	0.4
X-1921	BRCA	tamoxifen	296.3	25.9	14	42.1	5.7
X-1921	BRCA	tamoxifen	395.8	25.9	17	89.8	5.7
X-1921	BRCA	tamoxifen	367.5	27.2	21	76.3	11
X-1921	BRCA	tamoxifen	428.1	27.4	24	105.3	11.8
X-1921	BRCA	tamoxifen	459.3	28.8	28	120.3	17.6
X-1921	BRCA	tamoxifen	553.7	29.5	31	165.6	20.4
X-1921	BRCA	tamoxifen	561.6	28.2	35	169.4	15.1
X-1921	BRCA	tamoxifen	538.7	27.7	38	158.4	13.1
X-1921	BRCA	tamoxifen	613.9	28	42	194.4	14.3
X-1921	BRCA	tamoxifen	690.7	28.5	45	231.3	16.3
X-1921	BRCA	tamoxifen	777.7	28.7	49	273	17.1
X-1921	BRCA	tamoxifen	796	29.8	52	281.8	21.6
X-1921	BRCA	tamoxifen	846.7	28.6	56	306.1	16.7
X-1921	BRCA	tamoxifen	879.2	29.7	59	321.7	21.2
X-1921	BRCA	tamoxifen	1020.2	28.1	62	389.3	14.7
X-1921	BRCA	tamoxifen	986.9	29.1	66	373.3	18.8
X-1921	BRCA	trastuzumab	195.9	23.9	0	0	0
X-1921	BRCA	trastuzumab	258.5	24.8	6	32	3.8
X-1921	BRCA	trastuzumab	278.4	24.6	9	42.1	2.9
X-1921	BRCA	trastuzumab	337.7	24.3	14	72.4	1.7
X-1921	BRCA	trastuzumab	421.9	24.8	17	115.4	3.8
X-1921	BRCA	trastuzumab	533.5	25.5	20	172.3	6.7
X-1921	BRCA	trastuzumab	698.2	25.5	24	256.4	6.7
X-1921	BRCA	trastuzumab	749.7	26	27	282.7	8.8
X-1921	BRCA	trastuzumab	738.6	26.9	31	277	12.6
X-1921	BRCA	trastuzumab	793.9	26	34	305.3	8.8
X-1921	BRCA	trastuzumab	905.9	26.3	38	362.4	10
X-1921	BRCA	trastuzumab	773.5	27	41	294.8	13
X-1921	BRCA	trastuzumab	1020.2	27.6	45	420.8	15.5
X-1921	BRCA	trastuzumab	988.8	27.4	48	404.7	14.6
X-1921	BRCA	trastuzumab	982.3	27.6	52	401.4	15.5
X-1921	BRCA	trastuzumab	1083.7	27.2	55	453.2	13.8
X-1921	BRCA	untreated	241	22.1	0	0	0
X-1921	BRCA	untreated	320	23	3	32.8	4.1
X-1921	BRCA	untreated	363.8	23.8	6	51	7.7
X-1921	BRCA	untreated	410.3	24.3	11	70.2	10
X-1921	BRCA	untreated	572.1	24	14	137.4	8.6
X-1921	BRCA	untreated	594.7	24.6	17	146.8	11.3
X-1921	BRCA	untreated	708.4	24.7	21	193.9	11.8
X-1921	BRCA	untreated	767.9	25.4	24	218.6	14.9
X-1921	BRCA	untreated	801.7	26	28	232.7	17.6
X-1921	BRCA	untreated	812.2	25.8	31	237	16.7
X-1921	BRCA	untreated	1039.3	26.5	35	331.2	19.9
X-1921	BRCA	untreated	951.5	26.4	38	294.8	19.5
X-1921	BRCA	untreated	1251.6	26.5	42	419.3	19.9
X-1921	BRCA	untreated	1166.7	27	45	384.1	22.2
X-1921	BRCA	untreated	1410.5	27.7	49	485.3	25.3
X-1921	BRCA	untreated	1445.1	27.4	52	499.6	24
X-1921	BRCA	LFW527 + everolimus	250.61	24.6	0	0	0
X-1921	BRCA	LFW527 + everolimus	232.88	23.9	4	-7.1	-2.8
X-1921	BRCA	LFW527 + everolimus	227.62	24.3	7	-9.2	-1.2
X-1921	BRCA	LFW527 + everolimus	279.63	23.4	11	11.6	-4.9
X-1921	BRCA	LFW527 + everolimus	245.88	23.4	14	-1.9	-4.9
X-1921	BRCA	LFW527 + everolimus	265.11	22.7	19	5.8	-7.7
X-1921	BRCA	LFW527 + everolimus	191.79	24.7	22	-23.5	0.4
X-1921	BRCA	LFW527 + everolimus	251.24	23.4	25	0.3	-4.9
X-1921	BRCA	LFW527 + everolimus	247.14	22	29	-1.4	-10.6
X-1921	BRCA	LFW527 + everolimus	284.79	23.7	32	13.6	-3.7
X-1921	BRCA	LFW527 + everolimus	394.92	23	35	57.6	-6.5
X-1921	BRCA	LFW527 + everolimus	300.02	22.6	39	19.7	-8.1
X-1921	BRCA	LFW527 + everolimus	328.89	22	42	31.2	-10.6
X-1921	BRCA	LFW527 + everolimus	473.24	26.3	46	88.8	6.9
X-1921	BRCA	LFW527 + everolimus	296.47	23.2	49	18.3	-5.7
X-1921	BRCA	LFW527 + everolimus	349.96	21.3	52	39.6	-13.4
X-1921	BRCA	LFW527 + everolimus	0	22.7	56	-100	-7.7
X-1921	BRCA	LFW527 + everolimus	0	20.6	60	-100	-16.3
X-1921	BRCA	LFW527 + everolimus	0	22.1	63	-100	-10.2
X-1921	BRCA	LFW527 + everolimus	0	22.9	67	-100	-6.9
X-1921	BRCA	LFW527 + everolimus	0	21.9	70	-100	-11
X-1921	BRCA	LFW527 + everolimus	0	23.3	74	-100	-5.3
X-1921	BRCA	LFW527 + everolimus	0	21.5	77	-100	-12.6
X-1921	BRCA	LFW527 + everolimus	63.85	26	81	-74.5	5.7
X-1921	BRCA	LFW527 + everolimus	32.2	22.5	85	-87.2	-8.5
X-1921	BRCA	LFW527 + everolimus	55.17	21.4	88	-78	-13
X-1921	BRCA	LFW527 + everolimus	70.42	24.7	91	-71.9	0.4
X-1921	BRCA	LFW527 + everolimus	65.94	23.1	95	-73.7	-6.1
X-1921	BRCA	LFW527 + everolimus	57.45	22.3	98	-77.1	-9.3
X-1921	BRCA	LFW527 + everolimus	118.93	20.1	102	-52.5	-18.3
X-1921	BRCA	LFW527 + everolimus	110.28	23.7	105	-56	-3.7
X-1921	BRCA	LFW527 + everolimus	117.82	20.5	109	-53	-16.7
X-1934	NSCLC	BGJ398	166.1	26.1	0	0	0
X-1934	NSCLC	BGJ398	190.3	26.1	1	14.6	0
X-1934	NSCLC	BGJ398	144.8	26.5	4	-12.8	1.5
X-1934	NSCLC	BGJ398	99.7	27.3	7	-40	4.6
X-1934	NSCLC	BGJ398	93.3	28.1	12	-43.8	7.7
X-1934	NSCLC	BGJ398	244.9	28.3	15	47.4	8.4
X-1934	NSCLC	BGJ398	542.7	28.8	19	226.7	10.3
X-1934	NSCLC	BGJ398	701.2	28.3	21	322.2	8.4
X-1934	NSCLC	BGJ398	1577.4	29.9	26	849.7	14.6
X-1934	NSCLC	BKM120	266.6	23.1	0	0	0
X-1934	NSCLC	BKM120	294.1	24.2	1	10.3	4.8
X-1934	NSCLC	BKM120	347.6	23.1	4	30.4	0
X-1934	NSCLC	BKM120	651	23.5	7	144.2	1.7
X-1934	NSCLC	BKM120	1085.3	23.7	12	307.1	2.6
X-1934	NSCLC	BKM120 + binimetinib	161.3	23.4	0	0	0
X-1934	NSCLC	BKM120 + binimetinib	237	23.4	1	46.9	0
X-1934	NSCLC	BKM120 + binimetinib	247	23.3	4	53.1	-0.4
X-1934	NSCLC	BKM120 + binimetinib	258	22.9	7	60	-2.1
X-1934	NSCLC	BKM120 + binimetinib	432.3	23.5	12	168	0.4
X-1934	NSCLC	BKM120 + binimetinib	360.4	22.9	15	123.4	-2.1
X-1934	NSCLC	BKM120 + binimetinib	403.2	22.9	19	150	-2.1
X-1934	NSCLC	BKM120 + binimetinib	428.4	24.2	21	165.6	3.4
X-1934	NSCLC	BKM120 + binimetinib	504.2	24.2	26	212.6	3.4
X-1934	NSCLC	BKM120 + binimetinib	554.1	24.6	28	243.5	5.1
X-1934	NSCLC	BKM120 + binimetinib	587.8	24.9	33	264.4	6.4
X-1934	NSCLC	BKM120 + binimetinib	618.2	24	36	283.3	2.6
X-1934	NSCLC	BKM120 + binimetinib	604.5	24.7	40	274.8	5.6
X-1934	NSCLC	BYL719 + LGH447	333.5	23.4	0	0	0
X-1934	NSCLC	BYL719 + LGH447	284.2	23.8	1	-14.8	1.7
X-1934	NSCLC	BYL719 + LGH447	537.7	23.7	4	61.2	1.3
X-1934	NSCLC	BYL719 + LGH447	800	24.6	7	139.9	5.1
X-1934	NSCLC	BYL719	224.1	26.4	0	0	0
X-1934	NSCLC	BYL719	287.8	NA	3	28.4	0
X-1934	NSCLC	BYL719	439.4	26.7	6	96.1	1.1
X-1934	NSCLC	BYL719	680.4	27	11	203.6	2.3
X-1934	NSCLC	BYL719 + LJM716	169.5	24.6	0	0	0
X-1934	NSCLC	BYL719 + LJM716	207.9	24.4	1	22.7	-0.8
X-1934	NSCLC	BYL719 + LJM716	102.4	22.7	4	-39.6	-7.7
X-1934	NSCLC	BYL719 + LJM716	100.5	23.5	7	-40.7	-4.5
X-1934	NSCLC	BYL719 + LJM716	196.7	23.4	12	16	-4.9
X-1934	NSCLC	BYL719 + LJM716	428.6	23.7	15	152.9	-3.7
X-1934	NSCLC	BYL719 + LJM716	522.4	23.8	19	208.2	-3.3
X-1934	NSCLC	CGM097	177.6	24	0	0	0
X-1934	NSCLC	CGM097	220.2	25.1	1	24	4.6
X-1934	NSCLC	CGM097	225	25.7	4	26.7	7.1
X-1934	NSCLC	CGM097	440.1	26.3	7	147.8	9.6
X-1934	NSCLC	CGM097	816.3	26.6	12	359.6	10.8
X-1934	NSCLC	CKX620	257.7	24.8	0	0	0
X-1934	NSCLC	CKX620	221.2	25.4	1	-14.2	2.4
X-1934	NSCLC	CKX620	383.6	25.1	4	48.9	1.2
X-1934	NSCLC	CKX620	618.8	25.8	7	140.1	4
X-1934	NSCLC	CLR457	175.4	23.5	0	0	0
X-1934	NSCLC	CLR457	248	23.7	3	41.4	0.9
X-1934	NSCLC	CLR457	266.5	23.2	4	51.9	-1.3
X-1934	NSCLC	CLR457	445.9	23	7	154.2	-2.1
X-1934	NSCLC	CLR457	703.5	23.4	10	301.1	-0.4
X-1934	NSCLC	HDM201	253.3	24.9	0	0	0
X-1934	NSCLC	HDM201	533.6	24.6	1	110.7	-1.2
X-1934	NSCLC	HDM201	967.4	23.5	4	281.9	-5.6
X-1934	NSCLC	HDM201	1242	23.8	7	390.3	-4.4
X-1934	NSCLC	cetuximab	231.7	26	0	0	0
X-1934	NSCLC	cetuximab	428.1	26.2	3	84.8	0.8
X-1934	NSCLC	cetuximab	592.3	26.5	6	155.6	1.9
X-1934	NSCLC	cetuximab	1343.6	27	11	479.9	3.8
X-1934	NSCLC	erlotinib	199.8	23.2	0	0	0
X-1934	NSCLC	erlotinib	307	23.2	1	53.7	0
X-1934	NSCLC	erlotinib	426.2	23.1	4	113.3	-0.4
X-1934	NSCLC	erlotinib	636.2	21.3	7	218.4	-8.2
X-1934	NSCLC	HSP990	284	23.2	0	0	0
X-1934	NSCLC	HSP990	836.2	23.5	3	194.4	1.3
X-1934	NSCLC	HSP990	2040.4	24.4	6	618.5	5.2
X-1934	NSCLC	INC280	156.8	24.5	0	0	0
X-1934	NSCLC	INC280	176.4	24.7	1	12.5	0.8
X-1934	NSCLC	INC280	274.2	25.1	4	74.9	2.4
X-1934	NSCLC	INC280	638.3	25.6	7	307.1	4.5
X-1934	NSCLC	LCL161 + paclitaxel	191.6	20.2	0	0	0
X-1934	NSCLC	LCL161 + paclitaxel	200.5	19.1	1	4.6	-5.4
X-1934	NSCLC	LCL161 + paclitaxel	1041.1	21.2	40	443.4	5
X-1934	NSCLC	LEE011	167.9	23.1	0	0	0
X-1934	NSCLC	LEE011	337.9	23.8	3	101.3	3
X-1934	NSCLC	LEE011	560.7	24.4	6	233.9	5.6
X-1934	NSCLC	LEE011	1123.9	25.3	11	569.4	9.5
X-1934	NSCLC	LGH447	220.3	26.8	0	0	0
X-1934	NSCLC	LGH447	232.6	26.8	1	5.6	0
X-1934	NSCLC	LGH447	320.9	27.8	4	45.7	3.7
X-1934	NSCLC	LGH447	503.9	27.9	7	128.7	4.1
X-1934	NSCLC	LGH447	1096.3	28.6	12	397.6	6.7
X-1934	NSCLC	LLM871	244.3	26.8	0	0	0
X-1934	NSCLC	LLM871	536	27.4	5	119.4	2.2
X-1934	NSCLC	LLM871	740.1	26.5	8	202.9	-1.1
X-1934	NSCLC	LLM871	934.5	26.5	12	282.5	-1.1
X-1934	NSCLC	binimetinib	202.4	24.4	0	0	0
X-1934	NSCLC	binimetinib	304.1	22.6	4	50.2	-7.4
X-1934	NSCLC	binimetinib	432.3	23.7	7	113.6	-2.9
X-1934	NSCLC	binimetinib	689.5	23.9	10	240.7	-2
X-1934	NSCLC	binimetinib	1026.5	23.5	15	407.2	-3.7
X-1934	NSCLC	paclitaxel	195	22.4	0	0	0
X-1934	NSCLC	paclitaxel	206.3	22.6	1	5.8	0.9
X-1934	NSCLC	paclitaxel	323.6	23.8	4	65.9	6.2
X-1934	NSCLC	paclitaxel	512.3	23.8	7	162.7	6.2
X-1934	NSCLC	paclitaxel	609.6	24	12	212.6	7.1
X-1934	NSCLC	paclitaxel	707.7	24.2	15	262.9	8
X-1934	NSCLC	paclitaxel	897.7	24.5	19	360.4	9.4
X-1934	NSCLC	untreated	148	23.1	0	0	0
X-1934	NSCLC	untreated	179.8	24.1	1	21.5	4.3
X-1934	NSCLC	untreated	228.9	24.3	4	54.7	5.2
X-1934	NSCLC	untreated	321.8	25.3	7	117.4	9.5
X-1934	NSCLC	untreated	728	25.8	12	391.9	11.7
X-1934	NSCLC	LFW527 + binimetinib	266.2	25.5	0	0	0
X-1934	NSCLC	LFW527 + binimetinib	368.3	25.7	2	38.4	0.8
X-1934	NSCLC	LFW527 + binimetinib	499.7	26.5	6	87.7	3.9
X-1934	NSCLC	LFW527 + binimetinib	610.5	26.6	9	129.3	4.3
X-1934	NSCLC	LFW527 + binimetinib	1030.66	26.3	13	287.2	3.1
X-1934	NSCLC	LFW527 + binimetinib	1018.07	26	14	282.4	2
X-1948	PDAC	abraxane	250.5	26.4	0	0	0
X-1948	PDAC	abraxane	198.6	27.6	4	-20.7	4.5
X-1948	PDAC	abraxane	216.5	27.8	7	-13.6	5.3
X-1948	PDAC	abraxane	260.4	27.7	11	4	4.9
X-1948	PDAC	abraxane	257.9	27.3	13	3	3.4
X-1948	PDAC	abraxane	272.4	27.2	17	8.7	3
X-1948	PDAC	abraxane	352.4	27.5	20	40.7	4.2
X-1948	PDAC	abraxane	396.8	27.3	24	58.4	3.4
X-1948	PDAC	abraxane	449.6	27.2	27	79.5	3
X-1948	PDAC	abraxane	486.5	27.4	32	94.2	3.8
X-1948	PDAC	abraxane	506.3	27.1	34	102.1	2.7
X-1948	PDAC	abraxane	529.7	26.8	38	111.5	1.5
X-1948	PDAC	abraxane	566.5	27.7	41	126.1	4.9
X-1948	PDAC	abraxane	599.8	27.3	45	139.4	3.4
X-1948	PDAC	abraxane	639.8	27.8	48	155.4	5.3
X-1948	PDAC	BKM120 + binimetinib	273.1	28	0	0	0
X-1948	PDAC	BKM120 + binimetinib	390.7	27.4	4	43.1	-2.1
X-1948	PDAC	BKM120 + binimetinib	345.2	27.8	6	26.4	-0.7
X-1948	PDAC	BKM120 + binimetinib	395.7	28.5	11	44.9	1.8
X-1948	PDAC	BKM120 + binimetinib	387.6	28.2	18	41.9	0.7
X-1948	PDAC	BKM120 + binimetinib	544.7	28.6	25	99.5	2.1
X-1948	PDAC	BKM120 + binimetinib	472.4	27.8	28	73	-0.7
X-1948	PDAC	BKM120 + binimetinib	436.9	28.3	33	60	1.1
X-1948	PDAC	BKM120 + binimetinib	439.5	28.4	35	60.9	1.4
X-1948	PDAC	BKM120 + binimetinib	357	27.7	39	30.7	-1.1
X-1948	PDAC	BKM120 + binimetinib	513.2	29.3	42	87.9	4.6
X-1948	PDAC	BKM120 + binimetinib	456.9	26.4	46	67.3	-5.7
X-1948	PDAC	BKM120 + binimetinib	459.2	28.1	49	68.1	0.4
X-1948	PDAC	BKM120 + binimetinib	431.2	30.1	52	57.9	7.5
X-1948	PDAC	BKM120 + binimetinib	394.7	29.6	55	44.5	5.7
X-1948	PDAC	BKM120 + binimetinib	551.8	28.3	60	102.1	1.1
X-1948	PDAC	BKM120 + binimetinib	553	28.8	66	102.5	2.9
X-1948	PDAC	BKM120 + binimetinib	661.9	28.9	69	142.4	3.2
X-1948	PDAC	BKM120 + binimetinib	545.3	29.9	74	99.7	6.8
X-1948	PDAC	BKM120 + binimetinib	514.2	30	77	88.3	7.1
X-1948	PDAC	BKM120 + binimetinib	576.9	30.7	81	111.2	9.6
X-1948	PDAC	BKM120 + binimetinib	492.1	30.4	84	80.2	8.6
X-1948	PDAC	BKM120 + LDE225	292.5	28.8	0	0	0
X-1948	PDAC	BKM120 + LDE225	344.4	29.3	4	17.7	1.7
X-1948	PDAC	BKM120 + LDE225	343.3	29.6	7	17.4	2.8
X-1948	PDAC	BKM120 + LDE225	309.2	30.6	11	5.7	6.2
X-1948	PDAC	BKM120 + LDE225	327.4	29.1	14	11.9	1
X-1948	PDAC	BKM120 + LDE225	309.9	29.4	18	5.9	2.1
X-1948	PDAC	BKM120 + LDE225	363.9	28.8	21	24.4	0
X-1948	PDAC	BKM120 + LDE225	308.9	29.4	25	5.6	2.1
X-1948	PDAC	BKM120 + LDE225	305.5	27.2	28	4.4	-5.6
X-1948	PDAC	BKM120 + LDE225	288.4	28.9	31	-1.4	0.3
X-1948	PDAC	BKM120 + LDE225	332.6	29.5	34	13.7	2.4
X-1948	PDAC	BKM120 + LDE225	326.7	29.4	39	11.7	2.1
X-1948	PDAC	BKM120 + LDE225	370.3	27.9	42	26.6	-3.1
X-1948	PDAC	BKM120 + LDE225	400.9	28.5	46	37.1	-1
X-1948	PDAC	BKM120 + LDE225	406.1	28.9	49	38.8	0.3
X-1948	PDAC	BKM120 + LDE225	407.4	28.6	52	39.3	-0.7
X-1948	PDAC	BKM120 + LDE225	386.9	28.6	56	32.3	-0.7
X-1948	PDAC	BKM120 + LDE225	619.3	28.9	59	111.7	0.3
X-1948	PDAC	BKM120 + LDE225	398.7	27.5	62	36.3	-4.5
X-1948	PDAC	BKM120 + LDE225	447.6	28.1	66	53	-2.4
X-1948	PDAC	BKM120 + LDE225	449.6	27.8	70	53.7	-3.5
X-1948	PDAC	BKM120 + LDE225	512.1	27.8	74	75.1	-3.5
X-1948	PDAC	BKM120 + LDE225	455.7	27.4	77	55.8	-4.9
X-1948	PDAC	BKM120 + LDE225	487.7	26.2	80	66.7	-9
X-1948	PDAC	BKM120 + LDE225	492.4	26	84	68.3	-9.7
X-1948	PDAC	BKM120	254.5	25.2	0	0	0
X-1948	PDAC	BKM120	197.1	24.7	4	-22.6	-2
X-1948	PDAC	BKM120	206.5	24.5	7	-18.9	-2.8
X-1948	PDAC	BKM120	194.4	25.3	10	-23.6	0.4
X-1948	PDAC	BKM120	298.7	25.2	13	17.4	0
X-1948	PDAC	BKM120	250.8	25.7	17	-1.5	2
X-1948	PDAC	BKM120	202	25	20	-20.6	-0.8
X-1948	PDAC	BKM120	220.6	26.4	24	-13.3	4.8
X-1948	PDAC	BKM120	355.2	26.7	27	39.6	6
X-1948	PDAC	BKM120	228.6	27.3	31	-10.2	8.3
X-1948	PDAC	BKM120	297.4	26.9	34	16.9	6.7
X-1948	PDAC	BKM120	292.1	24.9	39	14.8	-1.2
X-1948	PDAC	BYL719	206.3	28.3	0	0	0
X-1948	PDAC	BYL719	194.9	27	4	-5.5	-4.6
X-1948	PDAC	BYL719	200.7	28	7	-2.7	-1.1
X-1948	PDAC	BYL719	210.2	27.6	11	1.9	-2.5
X-1948	PDAC	BYL719	200.1	27.9	15	-3	-1.4
X-1948	PDAC	BYL719	194.7	27.5	18	-5.6	-2.8
X-1948	PDAC	BYL719	186.8	28.6	21	-9.5	1.1
X-1948	PDAC	BYL719	195.1	29.2	25	-5.4	3.2
X-1948	PDAC	BYL719	208.9	29.9	28	1.3	5.7
X-1948	PDAC	BYL719	213.9	27	32	3.7	-4.6
X-1948	PDAC	BYL719	225	27.7	35	9.1	-2.1
X-1948	PDAC	BYL719	231.6	27.2	39	12.3	-3.9
X-1948	PDAC	BYL719	237	29.2	42	14.9	3.2
X-1948	PDAC	BYL719	250.6	27.3	47	21.5	-3.5
X-1948	PDAC	BYL719	238	25.1	50	15.4	-11.3
X-1948	PDAC	BYL719	236.1	24	53	14.4	-15.2
X-1948	PDAC	BYL719 + LJM716	269.4	29.1	0	0	0
X-1948	PDAC	BYL719 + LJM716	342.6	26.8	5	27.2	-7.9
X-1948	PDAC	BYL719 + LJM716	374.9	26.9	7	39.2	-7.6
X-1948	PDAC	BYL719 + LJM716	445.8	26.2	11	65.5	-10
X-1948	PDAC	BYL719 + LJM716	488.3	27.3	18	81.3	-6.2
X-1948	PDAC	BYL719 + LJM716	489.3	26.6	21	81.6	-8.6
X-1948	PDAC	BYL719 + LJM716	494.9	26.5	26	83.7	-8.9
X-1948	PDAC	BYL719 + LJM716	511.6	26.7	29	89.9	-8.2
X-1948	PDAC	BYL719 + LJM716	550.4	27.7	32	104.3	-4.8
X-1948	PDAC	BYL719 + LJM716	624.9	27	36	132	-7.2
X-1948	PDAC	BYL719 + LJM716	340.3	25.1	42	26.3	-13.7
X-1948	PDAC	BYL719 + LJM716	587.7	26.8	47	118.2	-7.9
X-1948	PDAC	BYL719 + LJM716	415.2	26.3	50	54.1	-9.6
X-1948	PDAC	BYL719 + LJM716	526.1	28.1	54	95.3	-3.4
X-1948	PDAC	BYL719 + LJM716	559.4	28.3	57	107.6	-2.7
X-1948	PDAC	BYL719 + LJM716	554.9	26.6	61	106	-8.6
X-1948	PDAC	BYL719 + LJM716	556.5	27.4	64	106.6	-5.8
X-1948	PDAC	CLR457	249.3	26	0	0	0
X-1948	PDAC	CLR457	263.2	25.4	4	5.6	-2.3
X-1948	PDAC	CLR457	295.5	25.1	8	18.5	-3.5
X-1948	PDAC	CLR457	373.2	25.3	12	49.7	-2.7
X-1948	PDAC	CLR457	517.5	24.9	15	107.6	-4.2
X-1948	PDAC	CLR457	553.5	25.5	17	122	-1.9
X-1948	PDAC	CLR457	559.6	26.4	21	124.5	1.5
X-1948	PDAC	CLR457	653	25.4	28	161.9	-2.3
X-1948	PDAC	CLR457	815.6	26.2	31	227.2	0.8
X-1948	PDAC	CLR457	849.9	26.2	35	240.9	0.8
X-1948	PDAC	CLR457	962.3	26.9	38	286	3.5
X-1948	PDAC	CLR457	1004.8	26.5	42	303	1.9
X-1948	PDAC	CLR457	1161.5	26.4	49	365.9	1.5
X-1948	PDAC	CLR457	1354.7	26.6	53	443.4	2.3
X-1948	PDAC	HDM201	208.8	28.7	0	0	0
X-1948	PDAC	HDM201	241.2	26.6	4	15.5	-7.3
X-1948	PDAC	HDM201	284.5	28.3	7	36.3	-1.4
X-1948	PDAC	HDM201	305.1	28.4	11	46.1	-1
X-1948	PDAC	HDM201	334.7	28.1	15	60.3	-2.1
X-1948	PDAC	HDM201	373.6	28.2	18	78.9	-1.7
X-1948	PDAC	HDM201	382.2	27.8	21	83	-3.1
X-1948	PDAC	HDM201	393.3	27.6	25	88.4	-3.8
X-1948	PDAC	HDM201	427.6	27.4	28	104.8	-4.5
X-1948	PDAC	HDM201	438.4	26.8	32	110	-6.6
X-1948	PDAC	HDM201	454.7	27	35	117.8	-5.9
X-1948	PDAC	HDM201	462.9	26.3	39	121.7	-8.4
X-1948	PDAC	HDM201	415.3	27.7	42	98.9	-3.5
X-1948	PDAC	HDM201	393.5	26.6	47	88.5	-7.3
X-1948	PDAC	HDM201	424.3	26.2	50	103.2	-8.7
X-1948	PDAC	HDM201	442.6	26.6	53	112	-7.3
X-1948	PDAC	HDM201	428.3	25.4	56	105.1	-11.5
X-1948	PDAC	HDM201	430.1	25.3	60	106	-11.8
X-1948	PDAC	HDM201	443.3	24.5	63	112.3	-14.6
X-1948	PDAC	figitumumab" + binimetinib	214.6	26	0	0	0
X-1948	PDAC	figitumumab" + binimetinib	348.7	25.1	4	62.5	-3.5
X-1948	PDAC	figitumumab" + binimetinib	407	25	7	89.7	-3.8
X-1948	PDAC	figitumumab" + binimetinib	423.8	25.9	11	97.5	-0.4
X-1948	PDAC	figitumumab" + binimetinib	566.5	25.7	14	164	-1.2
X-1948	PDAC	figitumumab" + binimetinib	483.7	25.7	18	125.4	-1.2
X-1948	PDAC	figitumumab" + binimetinib	629	25.5	21	193.1	-1.9
X-1948	PDAC	figitumumab" + binimetinib	679.9	25.9	25	216.8	-0.4
X-1948	PDAC	figitumumab" + binimetinib	673	25.5	28	213.6	-1.9
X-1948	PDAC	figitumumab"	207.2	34.2	0	0	0
X-1948	PDAC	figitumumab"	201	33.9	5	-3	-0.9
X-1948	PDAC	figitumumab"	236.9	32.6	7	14.3	-4.7
X-1948	PDAC	figitumumab"	234.7	28.6	11	13.3	-16.4
X-1948	PDAC	figitumumab"	211.3	26.4	14	2	-22.8
X-1948	PDAC	gemcitabine-50mpk	273.3	26.2	0	0	0
X-1948	PDAC	gemcitabine-50mpk	286.9	27	2	5	3.1
X-1948	PDAC	gemcitabine-50mpk	287.1	26.8	8	5	2.3
X-1948	PDAC	gemcitabine-50mpk	362.1	NA	13	32.5	2.3
X-1948	PDAC	gemcitabine-50mpk	366.5	26.3	15	34.1	0.4
X-1948	PDAC	gemcitabine-50mpk	435.2	25.6	19	59.2	-2.3
X-1948	PDAC	gemcitabine-50mpk	361.3	27.4	21	32.2	4.6
X-1948	PDAC	gemcitabine-50mpk	370.3	27	27	35.5	3.1
X-1948	PDAC	gemcitabine-50mpk	348.4	27.7	31	27.5	5.7
X-1948	PDAC	gemcitabine-50mpk	322.9	27.2	33	18.1	3.8
X-1948	PDAC	gemcitabine-50mpk	380	27.2	37	39	3.8
X-1948	PDAC	gemcitabine-50mpk	418.2	26.8	41	53	2.3
X-1948	PDAC	gemcitabine-50mpk	457.4	27.5	44	67.4	5
X-1948	PDAC	gemcitabine-50mpk	472.3	27.9	47	72.8	6.5
X-1948	PDAC	gemcitabine-50mpk	519.6	28.7	51	90.1	9.5
X-1948	PDAC	gemcitabine-50mpk	525.2	28.6	54	92.2	9.2
X-1948	PDAC	gemcitabine-50mpk	520.5	27.3	59	90.5	4.2
X-1948	PDAC	gemcitabine-50mpk	486.7	28.2	63	78.1	7.6
X-1948	PDAC	gemcitabine-50mpk	629.3	27.8	65	130.3	6.1
X-1948	PDAC	gemcitabine-50mpk	660.9	27.3	69	141.8	4.2
X-1948	PDAC	gemcitabine-50mpk	725.1	27.4	72	165.3	4.6
X-1948	PDAC	gemcitabine-50mpk	757.3	24.9	76	177.1	-5
X-1948	PDAC	gemcitabine-50mpk	743.7	28	79	172.1	6.9
X-1948	PDAC	gemcitabine-50mpk	807.6	28	82	195.5	6.9
X-1948	PDAC	gemcitabine-50mpk	881.2	28.5	86	222.4	8.8
X-1948	PDAC	gemcitabine-50mpk	848.3	28	90	210.4	6.9
X-1948	PDAC	gemcitabine-50mpk	830.4	28.7	93	203.8	9.5
X-1948	PDAC	gemcitabine-50mpk	924.9	27.9	97	238.4	6.5
X-1948	PDAC	gemcitabine-50mpk	993.5	27.8	100	263.5	6.1
X-1948	PDAC	gemcitabine-50mpk	1033.5	29	104	278.2	10.7
X-1948	PDAC	INC424 + binimetinib	221.3	34.4	0	0	0
X-1948	PDAC	INC424 + binimetinib	332.2	32	2	50.1	-7
X-1948	PDAC	INC424 + binimetinib	221.9	31.9	6	0.3	-7.3
X-1948	PDAC	INC424 + binimetinib	350.5	31.2	9	58.4	-9.3
X-1948	PDAC	INC424 + binimetinib	286.2	32.8	12	29.3	-4.7
X-1948	PDAC	INC424 + binimetinib	248.2	31.8	16	12.2	-7.6
X-1948	PDAC	INC424 + binimetinib	344.7	31.4	20	55.8	-8.7
X-1948	PDAC	INC424 + binimetinib	374.6	31.5	22	69.3	-8.4
X-1948	PDAC	INC424 + binimetinib	462.6	31.7	27	109	-7.8
X-1948	PDAC	INC424 + binimetinib	379.1	32.4	34	71.3	-5.8
X-1948	PDAC	INC424 + binimetinib	420.8	32.8	41	90.1	-4.7
X-1948	PDAC	INC424 + binimetinib	465.2	33.2	44	110.2	-3.5
X-1948	PDAC	INC424 + binimetinib	463.3	32.4	49	109.4	-5.8
X-1948	PDAC	INC424 + binimetinib	470.8	32.7	51	112.7	-4.9
X-1948	PDAC	INC424 + binimetinib	450.5	32.9	55	103.6	-4.4
X-1948	PDAC	INC424 + binimetinib	424.3	33.1	58	91.7	-3.8
X-1948	PDAC	INC424 + binimetinib	484.8	35.1	62	119.1	2
X-1948	PDAC	INC424 + binimetinib	387.8	32.2	65	75.2	-6.4
X-1948	PDAC	INC424 + binimetinib	351.2	33.3	68	58.7	-3.2
X-1948	PDAC	INC424 + binimetinib	581.5	34.8	71	162.8	1.2
X-1948	PDAC	INC424 + binimetinib	592.9	31.1	76	167.9	-9.6
X-1948	PDAC	INC424 + binimetinib	679.6	31.3	82	207.1	-9
X-1948	PDAC	INC424 + binimetinib	776.3	31.6	85	250.8	-8.1
X-1948	PDAC	INC424 + binimetinib	712.2	31.8	90	221.8	-7.6
X-1948	PDAC	INC424 + binimetinib	869.3	32.1	93	292.8	-6.7
X-1948	PDAC	INC424 + binimetinib	834.4	32.8	97	277	-4.7
X-1948	PDAC	INC424 + binimetinib	746.5	31.8	100	237.3	-7.6
X-1948	PDAC	INC424	224.6	29.8	0	0	0
X-1948	PDAC	INC424	239	26.8	3	6.4	-10.1
X-1948	PDAC	INC424	265.1	28.7	5	18	-3.7
X-1948	PDAC	INC424	238.4	30.9	9	6.1	3.7
X-1948	PDAC	INC424	245.2	29.9	13	9.2	0.3
X-1948	PDAC	INC424	245.3	28.9	16	9.2	-3
X-1948	PDAC	INC424	267.1	29.8	19	18.9	0
X-1948	PDAC	INC424	250.9	30.5	23	11.7	2.3
X-1948	PDAC	INC424	285.8	29.8	26	27.2	0
X-1948	PDAC	INC424	297.2	29.4	30	32.3	-1.3
X-1948	PDAC	INC424	379.6	28.7	37	69	-3.7
X-1948	PDAC	INC424	408.4	29.6	41	81.8	-0.7
X-1948	PDAC	INC424	455	29.2	44	102.6	-2
X-1948	PDAC	INC424	524.5	30.5	47	133.5	2.3
X-1948	PDAC	INC424	482.8	26.4	52	115	-11.4
X-1948	PDAC	INC424	534	28.4	54	137.8	-4.7
X-1948	PDAC	INC424	579.3	29.9	58	157.9	0.3
X-1948	PDAC	INC424	603.2	29.6	65	168.6	-0.7
X-1948	PDAC	INC424	636.6	30.2	68	183.4	1.3
X-1948	PDAC	INC424	648.9	30.2	73	188.9	1.3
X-1948	PDAC	INC424	706.1	30.8	76	214.4	3.4
X-1948	PDAC	INC424	722.7	31.5	79	221.8	5.7
X-1948	PDAC	INC424	720.6	29.7	83	220.8	-0.3
X-1948	PDAC	INC424	958.8	27.8	89	326.9	-6.7
X-1948	PDAC	INC424	872.7	29.8	94	288.6	0
X-1948	PDAC	INC424	630	29.1	97	180.5	-2.3
X-1948	PDAC	INC424	852.2	26.6	101	279.4	-10.7
X-1948	PDAC	INC424	867.1	30.2	104	286.1	1.3
X-1948	PDAC	INC424	880.3	30	108	291.9	0.7
X-1948	PDAC	INC424	1108.6	30.3	111	393.6	1.7
X-1948	PDAC	LEE011	208.4	24.9	0	0	0
X-1948	PDAC	LEE011	269.1	26.1	5	29.1	4.8
X-1948	PDAC	LEE011	331.1	25.5	8	58.9	2.4
X-1948	PDAC	LEE011	392.6	26.4	12	88.4	6
X-1948	PDAC	LEE011	423.1	25.5	15	103	2.4
X-1948	PDAC	LEE011	338.7	26.3	20	62.5	5.6
X-1948	PDAC	LEE011	403.8	27	22	93.8	8.4
X-1948	PDAC	LEE011	441.1	26.7	26	111.7	7.2
X-1948	PDAC	LEE011	516.6	27.4	30	147.9	10
X-1948	PDAC	LEE011	1010.5	27	34	384.9	8.4
X-1948	PDAC	LEE011	854.9	28.7	37	310.2	15.3
X-1948	PDAC	LEE011	516.7	28.5	40	147.9	14.5
X-1948	PDAC	LEE011	494.8	29.4	44	137.4	18.1
X-1948	PDAC	LEE011	337	29.5	48	61.7	18.5
X-1948	PDAC	LEE011	487.6	29.3	51	134	17.7
X-1948	PDAC	LEE011	629.9	28.6	55	202.3	14.9
X-1948	PDAC	WNT974	278.7	23	0	0	0
X-1948	PDAC	WNT974	337.4	22.4	1	21.1	-2.6
X-1948	PDAC	WNT974	429.9	22.6	5	54.3	-1.7
X-1948	PDAC	WNT974	417.7	22.6	9	49.9	-1.7
X-1948	PDAC	WNT974	516.9	22.7	12	85.5	-1.3
X-1948	PDAC	WNT974	544	22.1	15	95.2	-3.9
X-1948	PDAC	WNT974	611.9	23.4	19	119.6	1.7
X-1948	PDAC	WNT974	637	23.1	22	128.6	0.4
X-1948	PDAC	WNT974	835.6	23.7	27	199.8	3
X-1948	PDAC	WNT974	858.7	23.3	30	208.1	1.3
X-1948	PDAC	LKA136	252.5	29	0	0	0
X-1948	PDAC	LKA136	279.2	29.2	3	10.6	0.7
X-1948	PDAC	LKA136	282.5	28.8	7	11.9	-0.7
X-1948	PDAC	LKA136	359.4	28.4	10	42.3	-2.1
X-1948	PDAC	LKA136	363	27.9	15	43.8	-3.8
X-1948	PDAC	LKA136	330.4	28.3	18	30.9	-2.4
X-1948	PDAC	LKA136	322.9	28.8	22	27.9	-0.7
X-1948	PDAC	LKA136	449.5	28.8	25	78	-0.7
X-1948	PDAC	LKA136	528	29.8	28	109.1	2.8
X-1948	PDAC	binimetinib	245.5	26.9	0	0	0
X-1948	PDAC	binimetinib	246	27.1	4	0.2	0.7
X-1948	PDAC	binimetinib	242	26.2	6	-1.4	-2.6
X-1948	PDAC	binimetinib	225.1	23.9	11	-8.3	-11.2
X-1948	PDAC	binimetinib	271.6	23.3	18	10.6	-13.4
X-1948	PDAC	binimetinib-3.5mpk	247.8	21.2	0	0	0
X-1948	PDAC	binimetinib-3.5mpk	238.8	20.7	3	-3.6	-2.4
X-1948	PDAC	binimetinib-3.5mpk	189.2	21.4	6	-23.6	0.9
X-1948	PDAC	binimetinib-3.5mpk	272.3	21.5	11	9.9	1.4
X-1948	PDAC	binimetinib-3.5mpk	345.6	21.8	14	39.5	2.8
X-1948	PDAC	binimetinib-3.5mpk	345.6	21.6	18	39.5	1.9
X-1948	PDAC	binimetinib-3.5mpk	265	21.9	21	6.9	3.3
X-1948	PDAC	binimetinib-3.5mpk	403.8	21.7	24	63	2.4
X-1948	PDAC	binimetinib-3.5mpk	376.5	21.5	27	51.9	1.4
X-1948	PDAC	binimetinib-3.5mpk	495.2	21.2	31	99.8	0
X-1948	PDAC	binimetinib-3.5mpk	543.6	21.6	34	119.4	1.9
X-1948	PDAC	binimetinib-3.5mpk	599.7	21.7	38	142	2.4
X-1948	PDAC	binimetinib-3.5mpk	728.3	22.2	41	193.9	4.7
X-1948	PDAC	trametinib	205.4	24.5	0	0	0
X-1948	PDAC	trametinib	158.7	24.8	4	-22.7	1.2
X-1948	PDAC	trametinib	118	24.7	7	-42.6	0.8
X-1948	PDAC	trametinib	207.6	25.1	11	1.1	2.4
X-1948	PDAC	trametinib	206.6	24.4	14	0.6	-0.4
X-1948	PDAC	trametinib	204	24.9	19	-0.7	1.6
X-1948	PDAC	trametinib	203.3	25.8	26	-1	5.3
X-1948	PDAC	trametinib	162.1	25	29	-21.1	2
X-1948	PDAC	trametinib	124.9	24.3	33	-39.2	-0.8
X-1948	PDAC	trametinib	170.8	24.5	36	-16.8	0
X-1948	PDAC	trametinib	226.5	25.6	41	10.3	4.5
X-1948	PDAC	trametinib	180.2	23.8	43	-12.3	-2.9
X-1948	PDAC	trametinib	175.8	25.6	48	-14.4	4.5
X-1948	PDAC	trametinib	163.2	25	50	-20.5	2
X-1948	PDAC	trametinib	143.3	25.5	54	-30.2	4.1
X-1948	PDAC	trametinib	143.4	24.8	57	-30.2	1.2
X-1948	PDAC	trametinib	152.8	25.4	61	-25.6	3.7
X-1948	PDAC	trametinib	144	24.6	64	-29.9	0.4
X-1948	PDAC	trametinib	149.2	25.5	69	-27.4	4.1
X-1948	PDAC	trametinib	228.6	25.6	74	11.3	4.5
X-1948	PDAC	trametinib	151.9	25.4	77	-26	3.7
X-1948	PDAC	trametinib	162	26.1	81	-21.1	6.5
X-1948	PDAC	trametinib	162	25.2	84	-21.1	2.9
X-1948	PDAC	trametinib	164.4	25.3	88	-20	3.3
X-1948	PDAC	trametinib	151.3	25.3	91	-26.3	3.3
X-1948	PDAC	trametinib	144.2	25.9	95	-29.8	5.7
X-1948	PDAC	trametinib	114.8	26.1	98	-44.1	6.5
X-1948	PDAC	untreated	200.2	26.6	0	0	0
X-1948	PDAC	untreated	205.8	29	6	2.8	9
X-1948	PDAC	untreated	222.8	29.3	8	11.3	10.2
X-1948	PDAC	untreated	219.6	28.3	13	9.7	6.4
X-1948	PDAC	untreated	272	27.6	16	35.9	3.8
X-1948	PDAC	untreated	255.5	26.8	19	27.6	0.8
X-1948	PDAC	untreated	317.2	26.5	23	58.4	-0.4
X-1948	PDAC	untreated	317.8	28.6	27	58.7	7.5
X-1948	PDAC	untreated	409.4	31	30	104.5	16.5
X-1948	PDAC	untreated	447.3	29.3	35	123.4	10.2
X-1948	PDAC	untreated	450.3	28.1	41	124.9	5.6
X-1948	PDAC	untreated	452.9	27.8	44	126.2	4.5
X-1948	PDAC	untreated	516.5	29.6	47	158	11.3
X-1948	PDAC	untreated	515.1	29.2	50	157.3	9.8
X-1948	PDAC	untreated	675.1	31	55	237.2	16.5
X-1948	PDAC	untreated	697.4	28	58	248.4	5.3
X-1948	PDAC	untreated	775.6	27.5	62	287.4	3.4
X-1948	PDAC	untreated	764.2	29.4	65	281.7	10.5
X-1948	PDAC	untreated	914.8	28	69	356.9	5.3
X-1948	PDAC	untreated	929.2	28	71	364.1	5.3
X-1959	PDAC	BKM120 + binimetinib	258.6	24.9	0	0	0
X-1959	PDAC	BKM120 + binimetinib	238.5	24.5	2	-7.8	-1.6
X-1959	PDAC	BKM120 + binimetinib	271.9	25.4	5	5.1	2
X-1959	PDAC	BKM120 + binimetinib	223.5	24.8	8	-13.6	-0.4
X-1959	PDAC	BKM120 + binimetinib	180.3	24.5	12	-30.3	-1.6
X-1959	PDAC	BKM120 + binimetinib	197	25.3	16	-23.8	1.6
X-1959	PDAC	BKM120 + binimetinib	193	24.8	20	-25.4	-0.4
X-1959	PDAC	BKM120 + binimetinib	145.2	23.4	23	-43.9	-6
X-1959	PDAC	BKM120 + binimetinib	177.3	25.2	26	-31.4	1.2
X-1959	PDAC	BKM120 + binimetinib	167.3	24.2	30	-35.3	-2.8
X-1959	PDAC	BKM120 + binimetinib	205.7	23.9	34	-20.5	-4
X-1959	PDAC	BKM120 + binimetinib	109.7	24	37	-57.6	-3.6
X-1959	PDAC	BKM120 + binimetinib	149.1	22.9	41	-42.3	-8
X-1959	PDAC	BKM120 + binimetinib	114.4	18.9	47	-55.8	-24.1
X-1959	PDAC	gemcitabine-50mpk	313	27.8	0	0	0
X-1959	PDAC	gemcitabine-50mpk	326.4	25.7	4	4.3	-7.6
X-1959	PDAC	gemcitabine-50mpk	327	25.3	6	4.5	-9
X-1959	PDAC	gemcitabine-50mpk	405.8	25.5	11	29.6	-8.3
X-1959	PDAC	gemcitabine-50mpk	425.2	25.2	13	35.8	-9.4
X-1959	PDAC	gemcitabine-50mpk	669	24.5	18	113.7	-11.9
X-1959	PDAC	gemcitabine-50mpk	481.8	25.3	21	53.9	-9
X-1959	PDAC	gemcitabine-50mpk	543.1	26.7	25	73.5	-4
X-1959	PDAC	gemcitabine-50mpk	411.7	26.1	28	31.5	-6.1
X-1959	PDAC	gemcitabine-50mpk	471.8	25.8	32	50.7	-7.2
X-1959	PDAC	gemcitabine-50mpk	462.5	28.2	35	47.8	1.4
X-1959	PDAC	INC424 + binimetinib	255	28.4	0	0	0
X-1959	PDAC	INC424 + binimetinib	241.2	27.6	2	-5.4	-2.8
X-1959	PDAC	INC424 + binimetinib	229.8	28.3	5	-9.9	-0.4
X-1959	PDAC	INC424 + binimetinib	233.7	28.2	8	-8.4	-0.7
X-1959	PDAC	INC424 + binimetinib	257.4	28.1	12	0.9	-1.1
X-1959	PDAC	INC424 + binimetinib	271	28.3	16	6.3	-0.4
X-1959	PDAC	INC424 + binimetinib	288.1	27.8	20	13	-2.1
X-1959	PDAC	INC424 + binimetinib	288.9	28.4	23	13.3	0
X-1959	PDAC	INC424 + binimetinib	287.2	28.4	26	12.6	0
X-1959	PDAC	INC424 + binimetinib	291.8	28.9	30	14.4	1.8
X-1959	PDAC	INC424 + binimetinib	239.3	28.6	34	-6.2	0.7
X-1959	PDAC	INC424 + binimetinib	242.1	28.5	37	-5.1	0.4
X-1959	PDAC	INC424 + binimetinib	250	29	41	-2	2.1
X-1959	PDAC	INC424 + binimetinib	351.3	29.3	47	37.8	3.2
X-1959	PDAC	INC424 + binimetinib	1323.7	30.8	58	419.1	8.5
X-1959	PDAC	INC424 + binimetinib	1723.6	30.5	61	575.9	7.4
X-1959	PDAC	LEE011	318.7	28.3	0	0	0
X-1959	PDAC	LEE011	357.4	27.2	4	12.1	-3.9
X-1959	PDAC	LEE011	486.1	27.3	7	52.5	-3.5
X-1959	PDAC	LEE011	497	28.3	11	55.9	0
X-1959	PDAC	LEE011	515.4	28.6	14	61.7	1.1
X-1959	PDAC	LEE011	594.6	29.3	19	86.6	3.5
X-1959	PDAC	LEE011	498.6	27.5	21	56.4	-2.8
X-1959	PDAC	LEE011	586.5	29.2	25	84	3.2
X-1959	PDAC	LEE011	609.9	29.2	28	91.4	3.2
X-1959	PDAC	LEE011	678.1	29	32	112.8	2.5
X-1959	PDAC	LEE011	597.5	29.7	35	87.5	4.9
X-1959	PDAC	binimetinib	310	27.1	0	0	0
X-1959	PDAC	binimetinib	296	27.2	4	-4.5	0.4
X-1959	PDAC	binimetinib	381.5	26.6	7	23.1	-1.8
X-1959	PDAC	binimetinib	218.5	26.3	11	-29.5	-3
X-1959	PDAC	binimetinib	171	26.4	14	-44.8	-2.6
X-1959	PDAC	binimetinib	204.9	27.3	17	-33.9	0.7
X-1959	PDAC	binimetinib	179.4	27.5	20	-42.1	1.5
X-1959	PDAC	binimetinib	200.8	27.2	25	-35.2	0.4
X-1959	PDAC	binimetinib	164.8	26	28	-46.8	-4.1
X-1959	PDAC	binimetinib	188.1	26.7	32	-39.3	-1.5
X-1959	PDAC	binimetinib	162.7	26.8	35	-47.5	-1.1
X-1979	NSCLC	LFW527 + binimetinib	317.31	26.6	0	0	0
X-1979	NSCLC	LFW527 + binimetinib	266.79	27	3	-15.9	1.5
X-1979	NSCLC	LFW527 + binimetinib	254.41	26.9	7	-19.8	1.1
X-1979	NSCLC	LFW527 + binimetinib	350.3	29.7	10	10.4	11.7
X-1979	NSCLC	LFW527 + binimetinib	340.21	29.1	14	7.2	9.4
X-1979	NSCLC	LFW527 + binimetinib	365.77	29	17	15.3	9
X-1979	NSCLC	LFW527 + binimetinib	265.2	28.2	21	-16.4	6
X-1979	NSCLC	LFW527 + binimetinib	236.13	28.7	24	-25.6	7.9
X-1979	NSCLC	LFW527 + binimetinib	369.65	28.2	28	16.5	6
X-1979	NSCLC	LFW527 + binimetinib	331.32	31	31	4.4	16.5
X-1979	NSCLC	LFW527 + binimetinib	501.21	30.6	36	58	15
X-1979	NSCLC	LFW527 + binimetinib	552.45	30.5	38	74.1	14.7
X-1979	NSCLC	LFW527 + binimetinib	606.31	31.4	43	91.1	18
X-1979	NSCLC	LFW527 + binimetinib	502.12	30.3	45	58.2	13.9
X-1979	NSCLC	LFW527 + binimetinib	594.63	29.3	49	87.4	10.2
X-1979	NSCLC	LFW527 + binimetinib	374.28	28.5	52	18	7.1
X-1979	NSCLC	LFW527 + binimetinib	456.26	27.4	56	43.8	3
X-1979	NSCLC	LFW527 + binimetinib	388.13	26.8	59	22.3	0.8
X-1979	NSCLC	LFW527 + binimetinib	554.75	25.2	63	74.8	-5.3
X-1979	NSCLC	LFW527 + binimetinib	667.7	26.3	66	110.4	-1.1
X-1979	NSCLC	LFW527 + binimetinib	456.01	24.6	70	43.7	-7.5
X-1979	NSCLC	LFW527 + binimetinib	438.92	24.5	73	38.3	-7.9
X-1979	NSCLC	LFW527 + binimetinib	517.25	23.2	77	63	-12.8
X-1979	NSCLC	LFW527 + binimetinib	525.02	22.7	79	65.5	-14.7
X-1979	NSCLC	LFW527 + binimetinib	722.69	23	85	127.8	-13.5
X-1980	NSCLC	BGJ398	249.9	25.9	0	0	0
X-1980	NSCLC	BGJ398	281.7	25.2	3	12.7	-2.7
X-1980	NSCLC	BGJ398	641.3	24.8	6	156.6	-4.2
X-1980	NSCLC	BGJ398	513.1	25.8	10	105.3	-0.4
X-1980	NSCLC	BGJ398	1292.6	24	13	417.2	-7.3
X-1980	NSCLC	BGJ398	1366.1	23	17	446.7	-11.2
X-1980	NSCLC	BGJ398	1703	22.9	18	581.5	-11.6
X-1980	NSCLC	BKM120	316.8	25.2	0	0	0
X-1980	NSCLC	BKM120	205	25.9	5	-35.3	2.8
X-1980	NSCLC	BKM120	260.5	26.2	8	-17.8	4
X-1980	NSCLC	BKM120	308.2	24.5	12	-2.7	-2.8
X-1980	NSCLC	BKM120	305.8	25	15	-3.5	-0.8
X-1980	NSCLC	BKM120	288.6	25.3	19	-8.9	0.4
X-1980	NSCLC	BKM120	257.3	25.3	22	-18.8	0.4
X-1980	NSCLC	BKM120	295.6	25.3	26	-6.7	0.4
X-1980	NSCLC	BKM120	273.7	25.5	29	-13.6	1.2
X-1980	NSCLC	BKM120	322.7	25.9	33	1.9	2.8
X-1980	NSCLC	BKM120	300.8	25.4	36	-5.1	0.8
X-1980	NSCLC	BKM120	265.2	25.6	40	-16.3	1.6
X-1980	NSCLC	BKM120	386.2	25.1	43	21.9	-0.4
X-1980	NSCLC	BKM120	319.9	24.9	47	1	-1.2
X-1980	NSCLC	BKM120	273.7	24.5	50	-13.6	-2.8
X-1980	NSCLC	BKM120	357.9	25.2	54	13	0
X-1980	NSCLC	BKM120	377.1	24.4	57	19	-3.2
X-1980	NSCLC	BKM120	346.5	23.6	61	9.4	-6.3
X-1980	NSCLC	BKM120	447.9	23.2	64	41.4	-7.9
X-1980	NSCLC	BKM120	389	23.8	68	22.8	-5.6
X-1980	NSCLC	BKM120	489.9	23.8	71	54.6	-5.6
X-1980	NSCLC	BKM120	448.6	24.2	75	41.6	-4
X-1980	NSCLC	BKM120	488.8	24.2	78	54.3	-4
X-1980	NSCLC	BKM120	446.4	24.6	82	40.9	-2.4
X-1980	NSCLC	BKM120	372.6	24.6	85	17.6	-2.4
X-1980	NSCLC	BKM120	534.6	24.1	89	68.8	-4.4
X-1980	NSCLC	BKM120	410.7	24.5	92	29.6	-2.8
X-1980	NSCLC	BKM120	551.6	23.5	96	74.1	-6.7
X-1980	NSCLC	BKM120	1053.3	24.2	98	232.5	-4
X-1980	NSCLC	BKM120 + binimetinib	275.1	25.5	0	0	0
X-1980	NSCLC	BKM120 + binimetinib	235.1	24.2	2	-14.5	-5.1
X-1980	NSCLC	BKM120 + binimetinib	306.8	29.1	6	11.5	14.1
X-1980	NSCLC	BKM120 + binimetinib	277.6	25.7	9	0.9	0.8
X-1980	NSCLC	BKM120 + binimetinib	214.8	25.4	13	-21.9	-0.4
X-1980	NSCLC	BKM120 + binimetinib	252.6	26.1	16	-8.2	2.4
X-1980	NSCLC	BKM120 + binimetinib	215.3	25.9	20	-21.7	1.6
X-1980	NSCLC	BKM120 + binimetinib	257.4	26.3	23	-6.4	3.1
X-1980	NSCLC	BKM120 + binimetinib	208.9	26	27	-24.1	2
X-1980	NSCLC	BKM120 + binimetinib	235.3	26	30	-14.5	2
X-1980	NSCLC	BKM120 + binimetinib	431.6	25.6	34	56.9	0.4
X-1980	NSCLC	BKM120 + binimetinib	280.3	25.8	37	1.9	1.2
X-1980	NSCLC	BKM120 + binimetinib	311.2	26.5	41	13.1	3.9
X-1980	NSCLC	BKM120 + binimetinib	280	26.1	44	1.8	2.4
X-1980	NSCLC	BKM120 + binimetinib	354.9	26.2	48	29	2.7
X-1980	NSCLC	BKM120 + binimetinib	278.7	26.4	51	1.3	3.5
X-1980	NSCLC	BKM120 + binimetinib	307.6	26	55	11.8	2
X-1980	NSCLC	BKM120 + binimetinib	333	25.8	58	21	1.2
X-1980	NSCLC	BKM120 + binimetinib	348.1	26.4	62	26.5	3.5
X-1980	NSCLC	BKM120 + binimetinib	389.3	26.2	65	41.5	2.7
X-1980	NSCLC	BKM120 + binimetinib	502.3	26.3	69	82.6	3.1
X-1980	NSCLC	BKM120 + binimetinib	336	26	72	22.1	2
X-1980	NSCLC	BKM120 + binimetinib	377.9	26.2	76	37.4	2.7
X-1980	NSCLC	BKM120 + binimetinib	362.9	25.9	79	31.9	1.6
X-1980	NSCLC	BKM120 + binimetinib	380.8	25.7	83	38.4	0.8
X-1980	NSCLC	BKM120 + binimetinib	490.4	25.7	86	78.3	0.8
X-1980	NSCLC	BKM120 + binimetinib	463.2	25.6	90	68.4	0.4
X-1980	NSCLC	BKM120 + binimetinib	705.7	25.6	92	156.5	0.4
X-1980	NSCLC	BYL719	360.3	25.4	0	0	0
X-1980	NSCLC	BYL719	321.1	24.4	3	-10.9	-3.9
X-1980	NSCLC	BYL719	433.9	24.4	6	20.4	-3.9
X-1980	NSCLC	BYL719	668.4	29	10	85.5	14.2
X-1980	NSCLC	BYL719	552.9	24.2	13	53.5	-4.7
X-1980	NSCLC	BYL719	649.9	25	17	80.4	-1.6
X-1980	NSCLC	BYL719	701.3	25.8	20	94.6	1.6
X-1980	NSCLC	BYL719	720.7	26.1	24	100	2.8
X-1980	NSCLC	BYL719	832.4	26.4	27	131	3.9
X-1980	NSCLC	BYL719	926.1	26.9	31	157	5.9
X-1980	NSCLC	BYL719	1119.2	26.4	33	210.6	3.9
X-1980	NSCLC	BYL719 + LJM716	230.9	27.2	0	0	0
X-1980	NSCLC	BYL719 + LJM716	430.3	26.5	3	86.4	-2.6
X-1980	NSCLC	BYL719 + LJM716	468.1	26.5	6	102.7	-2.6
X-1980	NSCLC	BYL719 + LJM716	485.9	25.6	10	110.4	-5.9
X-1980	NSCLC	BYL719 + LJM716	688.3	25.1	13	198.1	-7.7
X-1980	NSCLC	BYL719 + LJM716	661.4	25.1	17	186.4	-7.7
X-1980	NSCLC	BYL719 + LJM716	734.7	26	20	218.2	-4.4
X-1980	NSCLC	BYL719 + LJM716	1042.4	26.4	24	351.5	-2.9
X-1980	NSCLC	BYL719 + LJM716	1382.6	26.3	25	498.8	-3.3
X-1980	NSCLC	BYL719 + LGH447	301.5	23.7	0	0	0
X-1980	NSCLC	BYL719 + LGH447	238.6	23.2	6	-20.9	-2.1
X-1980	NSCLC	BYL719 + LGH447	370.1	23.2	9	22.8	-2.1
X-1980	NSCLC	BYL719 + LGH447	313.4	23.3	13	3.9	-1.7
X-1980	NSCLC	BYL719 + LGH447	570.8	23.1	16	89.3	-2.5
X-1980	NSCLC	BYL719 + LGH447	658.8	23.4	20	118.5	-1.3
X-1980	NSCLC	BYL719 + LGH447	663.5	23.7	23	120.1	0
X-1980	NSCLC	BYL719 + LGH447	686.8	23.6	27	127.8	-0.4
X-1980	NSCLC	BYL719 + LGH447	1048.7	23.6	29	247.8	-0.4
X-1980	NSCLC	CGM097	265.6	22.3	0	0	0
X-1980	NSCLC	CGM097	220.1	22.3	5	-17.1	0
X-1980	NSCLC	CGM097	357.3	22.1	8	34.5	-0.9
X-1980	NSCLC	CGM097	903	25.9	12	240	16.1
X-1980	NSCLC	CGM097	533.7	22.1	15	100.9	-0.9
X-1980	NSCLC	CGM097	525.4	22.4	19	97.8	0.4
X-1980	NSCLC	CGM097	402.3	22.7	22	51.5	1.8
X-1980	NSCLC	CGM097	1159.8	22.8	26	336.7	2.2
X-1980	NSCLC	CGM097	1382.3	22.9	27	420.4	2.7
X-1980	NSCLC	CKX620	282	22.6	0	0	0
X-1980	NSCLC	CKX620	329.7	21.3	4	16.9	-5.8
X-1980	NSCLC	CKX620	336.1	21.4	7	19.2	-5.3
X-1980	NSCLC	CKX620	281.4	23	11	-0.2	1.8
X-1980	NSCLC	CKX620	368.2	24	14	30.6	6.2
X-1980	NSCLC	CKX620	520.2	24.2	18	84.5	7.1
X-1980	NSCLC	CKX620	426.3	24.3	21	51.2	7.5
X-1980	NSCLC	CKX620	498.8	24	25	76.9	6.2
X-1980	NSCLC	CKX620	433.7	24.8	28	53.8	9.7
X-1980	NSCLC	CKX620	604.3	24.8	32	114.3	9.7
X-1980	NSCLC	CKX620	660.7	24.3	34	134.3	7.5
X-1980	NSCLC	CLR457	165.2	21.5	0	0	0
X-1980	NSCLC	CLR457	120.9	21.1	2	-26.8	-1.9
X-1980	NSCLC	CLR457	134.9	21.7	6	-18.3	0.9
X-1980	NSCLC	CLR457	125.2	22.2	9	-24.2	3.3
X-1980	NSCLC	CLR457	134.3	22.4	13	-18.7	4.2
X-1980	NSCLC	CLR457	211.8	22.2	16	28.2	3.3
X-1980	NSCLC	CLR457	146.4	22.8	20	-11.4	6
X-1980	NSCLC	CLR457	181.7	22.4	23	10	4.2
X-1980	NSCLC	CLR457	147.2	22.5	27	-10.9	4.7
X-1980	NSCLC	CLR457	142.3	22.6	30	-13.9	5.1
X-1980	NSCLC	CLR457	229.9	22.6	34	39.2	5.1
X-1980	NSCLC	CLR457	166	22.5	37	0.5	4.7
X-1980	NSCLC	CLR457	198.9	22.4	41	20.4	4.2
X-1980	NSCLC	CLR457	256.2	22.3	44	55.1	3.7
X-1980	NSCLC	CLR457	250.1	22.3	48	51.4	3.7
X-1980	NSCLC	CLR457	287.4	22.8	51	74	6
X-1980	NSCLC	CLR457	294.2	22.9	55	78.1	6.5
X-1980	NSCLC	CLR457	299.6	22.5	58	81.4	4.7
X-1980	NSCLC	CLR457	359.5	22.4	62	117.6	4.2
X-1980	NSCLC	CLR457	350.5	22.5	65	112.2	4.7
X-1980	NSCLC	CLR457	392.4	22.9	69	137.5	6.5
X-1980	NSCLC	CLR457	468.7	23.3	72	183.7	8.4
X-1980	NSCLC	CLR457	409.1	23.4	76	147.6	8.8
X-1980	NSCLC	CLR457	561.5	23.1	79	239.9	7.4
X-1980	NSCLC	CLR457	532.3	23.2	83	222.2	7.9
X-1980	NSCLC	CLR457	835.8	22.7	85	405.9	5.6
X-1980	NSCLC	HDM201	213.9	22.9	0	0	0
X-1980	NSCLC	HDM201	149.2	22.1	2	-30.2	-3.5
X-1980	NSCLC	HDM201	174.6	21.7	6	-18.4	-5.2
X-1980	NSCLC	HDM201	218.4	22	9	2.1	-3.9
X-1980	NSCLC	HDM201	275	21.7	13	28.6	-5.2
X-1980	NSCLC	HDM201	323.4	21.4	16	51.2	-6.6
X-1980	NSCLC	HDM201	474	20.1	20	121.6	-12.2
X-1980	NSCLC	HDM201	452.3	19.9	23	111.5	-13.1
X-1980	NSCLC	HDM201	756.3	19.4	27	253.6	-15.3
X-1980	NSCLC	HDM201	497.9	19.7	29	132.8	-14
X-1980	NSCLC	HDM201	613	19.3	30	186.6	-15.7
X-1980	NSCLC	cetuximab	197	25.6	0	0	0
X-1980	NSCLC	cetuximab	211.9	25.3	2	7.6	-1.2
X-1980	NSCLC	cetuximab	304.2	30.5	6	54.4	19.1
X-1980	NSCLC	cetuximab	278.7	26.7	9	41.5	4.3
X-1980	NSCLC	cetuximab	312.7	27.2	13	58.7	6.2
X-1980	NSCLC	cetuximab	189	26.8	16	-4.1	4.7
X-1980	NSCLC	cetuximab	172	27.6	20	-12.7	7.8
X-1980	NSCLC	cetuximab	275.6	27.5	23	39.9	7.4
X-1980	NSCLC	cetuximab	293.4	28	27	48.9	9.4
X-1980	NSCLC	cetuximab	368.6	28.6	30	87.1	11.7
X-1980	NSCLC	cetuximab	295.2	29.4	34	49.8	14.8
X-1980	NSCLC	cetuximab	326.7	30.4	37	65.8	18.7
X-1980	NSCLC	cetuximab	334.6	29.4	41	69.8	14.8
X-1980	NSCLC	cetuximab	463.9	28.9	44	135.5	12.9
X-1980	NSCLC	cetuximab	701.4	29.1	48	256	13.7
X-1980	NSCLC	cetuximab	789.3	29.9	50	300.7	16.8
X-1980	NSCLC	erlotinib	279.1	21.1	0	0	0
X-1980	NSCLC	erlotinib	282.5	19.3	2	1.2	-8.5
X-1980	NSCLC	erlotinib	237	21.5	6	-15.1	1.9
X-1980	NSCLC	erlotinib	240	21.5	9	-14	1.9
X-1980	NSCLC	erlotinib	417.8	21.5	13	49.7	1.9
X-1980	NSCLC	erlotinib	334.8	21.7	16	20	2.8
X-1980	NSCLC	erlotinib	282	19.3	20	1	-8.5
X-1980	NSCLC	erlotinib	779.1	18	23	179.1	-14.7
X-1980	NSCLC	erlotinib	800.2	20.4	27	186.7	-3.3
X-1980	NSCLC	erlotinib	833.9	19.2	30	198.8	-9
X-1980	NSCLC	erlotinib	890.9	20.1	34	219.2	-4.7
X-1980	NSCLC	erlotinib	1119.7	19.7	35	301.2	-6.6
X-1980	NSCLC	HSP990	384.8	27.5	0	0	0
X-1980	NSCLC	HSP990	274.9	26.5	5	-28.6	-3.6
X-1980	NSCLC	HSP990	253.5	24.4	8	-34.1	-11.3
X-1980	NSCLC	HSP990	255.5	26.9	12	-33.6	-2.2
X-1980	NSCLC	HSP990	369	24.6	15	-4.1	-10.5
X-1980	NSCLC	HSP990	451	26.7	19	17.2	-2.9
X-1980	NSCLC	HSP990	297	23.8	22	-22.8	-13.5
X-1980	NSCLC	HSP990	294.8	27	26	-23.4	-1.8
X-1980	NSCLC	HSP990	315.9	24.2	29	-17.9	-12
X-1980	NSCLC	HSP990	368.1	28.2	33	-4.3	2.5
X-1980	NSCLC	HSP990	399.6	25.8	36	3.8	-6.2
X-1980	NSCLC	HSP990	476.2	27.3	40	23.8	-0.7
X-1980	NSCLC	HSP990	463.5	25	43	20.5	-9.1
X-1980	NSCLC	HSP990	506.3	23.5	47	31.6	-14.5
X-1980	NSCLC	HSP990	576.7	22.9	50	49.9	-16.7
X-1980	NSCLC	HSP990	479.9	26.3	54	24.7	-4.4
X-1980	NSCLC	HSP990	728	24.5	57	89.2	-10.9
X-1980	NSCLC	HSP990	699.8	25.2	61	81.9	-8.4
X-1980	NSCLC	HSP990	932	26.2	63	142.2	-4.7
X-1980	NSCLC	INC280	220.1	23.5	0	0	0
X-1980	NSCLC	INC280	400.8	22	2	82.1	-6.4
X-1980	NSCLC	INC280	403.4	22.2	6	83.3	-5.5
X-1980	NSCLC	INC280	515.7	21.9	9	134.3	-6.8
X-1980	NSCLC	INC280	585.3	22.7	13	165.9	-3.4
X-1980	NSCLC	INC280	542.2	22.4	16	146.3	-4.7
X-1980	NSCLC	INC280	902.8	22.3	20	310.2	-5.1
X-1980	NSCLC	INC280	844	22.1	23	283.5	-6
X-1980	NSCLC	INC280	1229	21.6	27	458.4	-8.1
X-1980	NSCLC	INC280	1549.5	21.7	28	604	-7.7
X-1980	NSCLC	LCL161 + paclitaxel	268.5	29.2	0	0	0
X-1980	NSCLC	LCL161 + paclitaxel	280.2	28.5	5	4.4	-2.4
X-1980	NSCLC	LCL161 + paclitaxel	370.3	28.3	8	37.9	-3.1
X-1980	NSCLC	LCL161 + paclitaxel	463.8	28.1	12	72.7	-3.8
X-1980	NSCLC	LCL161 + paclitaxel	413.8	28.7	15	54.1	-1.7
X-1980	NSCLC	LCL161 + paclitaxel	475.2	28.4	19	77	-2.7
X-1980	NSCLC	LCL161 + paclitaxel	550.7	28.5	22	105.1	-2.4
X-1980	NSCLC	LCL161 + paclitaxel	493.9	27.4	26	83.9	-6.2
X-1980	NSCLC	LCL161 + paclitaxel	529.4	27.7	29	97.2	-5.1
X-1980	NSCLC	LCL161 + paclitaxel	455.2	26.7	33	69.5	-8.6
X-1980	NSCLC	LCL161 + paclitaxel	531.8	27.8	36	98.1	-4.8
X-1980	NSCLC	LCL161 + paclitaxel	726.6	27.4	40	170.6	-6.2
X-1980	NSCLC	LCL161 + paclitaxel	844.2	28.5	42	214.4	-2.4
X-1980	NSCLC	LEE011	188.9	21.9	0	0	0
X-1980	NSCLC	LEE011	174	22.3	4	-7.9	1.8
X-1980	NSCLC	LEE011	181.4	22.7	7	-4	3.7
X-1980	NSCLC	LEE011	343.4	23.8	11	81.8	8.7
X-1980	NSCLC	LEE011	329	23.2	14	74.2	5.9
X-1980	NSCLC	LEE011	343.7	24.2	18	81.9	10.5
X-1980	NSCLC	LEE011	423.9	24.2	21	124.4	10.5
X-1980	NSCLC	LEE011	287.5	25.5	25	52.2	16.4
X-1980	NSCLC	LEE011	338.6	25.3	28	79.2	15.5
X-1980	NSCLC	LEE011	383.2	24.8	32	102.9	13.2
X-1980	NSCLC	LEE011	480.2	25	35	154.2	14.2
X-1980	NSCLC	LEE011	764.7	25.4	39	304.8	16
X-1980	NSCLC	LEE011	431.2	26.1	41	128.3	19.2
X-1980	NSCLC	LEE011	298.1	26	46	57.8	18.7
X-1980	NSCLC	LEE011	333.6	25.9	49	76.6	18.3
X-1980	NSCLC	LEE011	323.2	26.1	53	71.1	19.2
X-1980	NSCLC	LEE011	286.8	26	56	51.8	18.7
X-1980	NSCLC	LEE011	359.8	26.6	60	90.5	21.5
X-1980	NSCLC	LEE011	503.2	26.8	63	166.4	22.4
X-1980	NSCLC	LEE011	367	25.3	67	94.3	15.5
X-1980	NSCLC	LEE011	340.1	26.7	70	80	21.9
X-1980	NSCLC	LEE011	276.3	26.2	74	46.3	19.6
X-1980	NSCLC	LEE011	385.5	25.9	77	104.1	18.3
X-1980	NSCLC	LEE011	461.8	26.6	81	144.5	21.5
X-1980	NSCLC	LEE011	778	27	83	311.9	23.3
X-1980	NSCLC	LGH447	282.3	25	0	0	0
X-1980	NSCLC	LGH447	200.3	22.4	5	-29	-10.4
X-1980	NSCLC	LGH447	207.5	24.3	8	-26.5	-2.8
X-1980	NSCLC	LGH447	306.1	24.7	12	8.4	-1.2
X-1980	NSCLC	LGH447	321.6	25.8	15	13.9	3.2
X-1980	NSCLC	LGH447	315.1	25.7	19	11.6	2.8
X-1980	NSCLC	LGH447	338.5	25.2	22	19.9	0.8
X-1980	NSCLC	LGH447	308.4	24.9	26	9.2	-0.4
X-1980	NSCLC	LGH447	380.9	25.4	29	34.9	1.6
X-1980	NSCLC	LGH447	329.9	24.7	33	16.9	-1.2
X-1980	NSCLC	LGH447	286.7	25.4	36	1.6	1.6
X-1980	NSCLC	LGH447	402.4	23.4	40	42.5	-6.4
X-1980	NSCLC	LGH447	359.5	24.9	43	27.3	-0.4
X-1980	NSCLC	LGH447	637.3	24.7	47	125.8	-1.2
X-1980	NSCLC	LGH447	776.4	24.1	50	175	-3.6
X-1980	NSCLC	LGH447	911.6	24.4	54	222.9	-2.4
X-1980	NSCLC	LGH447	1306.6	24.8	56	362.8	-0.8
X-1980	NSCLC	LLM871	226.8	22.2	0	0	0
X-1980	NSCLC	LLM871	342.8	20.9	2	51.1	-5.9
X-1980	NSCLC	LLM871	451.9	24.9	6	99.3	12.2
X-1980	NSCLC	LLM871	454	20.7	9	100.2	-6.8
X-1980	NSCLC	LLM871	540.5	21.3	13	138.3	-4.1
X-1980	NSCLC	LLM871	936.6	21.2	16	313	-4.5
X-1980	NSCLC	LLM871	1285.6	20.9	20	466.8	-5.9
X-1980	NSCLC	LLM871	938.7	20.9	21	313.9	-5.9
X-1980	NSCLC	binimetinib	264.6	20.7	0	0	0
X-1980	NSCLC	binimetinib	194.9	19.5	2	-26.3	-5.8
X-1980	NSCLC	binimetinib	250.5	18.7	6	-5.3	-9.7
X-1980	NSCLC	binimetinib	262.7	18.3	9	-0.7	-11.6
X-1980	NSCLC	binimetinib	205.9	19.2	13	-22.2	-7.2
X-1980	NSCLC	binimetinib	221.5	19.5	16	-16.3	-5.8
X-1980	NSCLC	binimetinib	216.2	19.5	20	-18.3	-5.8
X-1980	NSCLC	binimetinib	307.2	18.5	23	16.1	-10.6
X-1980	NSCLC	binimetinib	252	18.4	27	-4.8	-11.1
X-1980	NSCLC	binimetinib	260.2	18.2	30	-1.7	-12.1
X-1980	NSCLC	binimetinib	349.8	18.4	34	32.2	-11.1
X-1980	NSCLC	binimetinib	288.4	17.1	37	9	-17.4
X-1980	NSCLC	binimetinib	403.5	16.9	41	52.5	-18.4
X-1980	NSCLC	binimetinib	372.3	16.8	44	40.7	-18.8
X-1980	NSCLC	paclitaxel	277.8	24	0	0	0
X-1980	NSCLC	paclitaxel	393.4	22.8	2	41.6	-5
X-1980	NSCLC	paclitaxel	251.7	23.7	6	-9.4	-1.3
X-1980	NSCLC	paclitaxel	495.3	24	9	78.3	0
X-1980	NSCLC	paclitaxel	625.3	22.8	13	125.1	-5
X-1980	NSCLC	paclitaxel	509.4	22.3	16	83.4	-7.1
X-1980	NSCLC	paclitaxel	618.3	22.3	20	122.6	-7.1
X-1980	NSCLC	paclitaxel	745.9	22.3	23	168.5	-7.1
X-1980	NSCLC	paclitaxel	733.5	22.3	27	164	-7.1
X-1980	NSCLC	paclitaxel	981.1	22.6	29	253.2	-5.8
X-1980	NSCLC	untreated	312	NA	0	0	0
X-1980	NSCLC	untreated	412.2	23	2	32.1	0
X-1980	NSCLC	untreated	365.3	23.1	6	17.1	0.4
X-1980	NSCLC	untreated	395	23.4	9	26.6	1.7
X-1980	NSCLC	untreated	614.1	23.3	13	96.8	1.3
X-1980	NSCLC	untreated	987.1	24.1	16	216.4	4.8
X-1980	NSCLC	untreated	727.9	23.8	20	133.3	3.5
X-1980	NSCLC	untreated	967.2	24.1	23	210	4.8
X-1980	NSCLC	untreated	1092.3	24.4	27	250.1	6.1
X-1980	NSCLC	untreated	1653.3	24	30	429.9	4.3
X-1980	NSCLC	untreated	2123	24.2	34	580.4	5.2
X-1980	NSCLC	LFW527 + binimetinib	263.22	24.7	0	0	0
X-1980	NSCLC	LFW527 + binimetinib	194.5	24.8	8	-26.1	0.4
X-1980	NSCLC	LFW527 + binimetinib	208.44	25.2	10	-20.8	2
X-1980	NSCLC	LFW527 + binimetinib	190.68	24.2	14	-27.6	-2
X-1980	NSCLC	LFW527 + binimetinib	147.81	25.4	17	-43.8	2.8
X-1980	NSCLC	LFW527 + binimetinib	218.62	25.6	21	-16.9	3.6
X-1980	NSCLC	LFW527 + binimetinib	258.07	25.4	24	-2	2.8
X-1980	NSCLC	LFW527 + binimetinib	359.74	26.9	27	36.7	8.9
X-1980	NSCLC	LFW527 + binimetinib	229.42	26.1	31	-12.8	5.7
X-1980	NSCLC	LFW527 + binimetinib	481.1	27.1	35	82.8	9.7
X-1980	NSCLC	LFW527 + binimetinib	502.49	26.2	38	90.9	6.1
X-1980	NSCLC	LFW527 + binimetinib	577.98	26.2	42	119.6	6.1
X-1980	NSCLC	LFW527 + binimetinib	618.96	25.9	45	135.1	4.9
X-1980	NSCLC	LFW527 + binimetinib	771.24	24.9	49	193	0.8
X-1980	NSCLC	LFW527 + binimetinib	843.77	25.5	52	220.6	3.2
X-1980	NSCLC	LFW527 + binimetinib	810.87	26.8	56	208.1	8.5
X-1980	NSCLC	LFW527 + binimetinib	1265.69	26.1	58	380.8	5.7
X-1993	NSCLC	BGJ398	226	25.1	0	0	0
X-1993	NSCLC	BGJ398	206.8	26.2	2	-8.5	4.4
X-1993	NSCLC	BGJ398	345.6	26.3	6	52.9	4.8
X-1993	NSCLC	BGJ398	418.6	27	9	85.2	7.6
X-1993	NSCLC	BGJ398	611.7	27.1	13	170.7	8
X-1993	NSCLC	BGJ398	671	27.3	16	196.9	8.8
X-1993	NSCLC	BGJ398	708.5	26.7	19	213.5	6.4
X-1993	NSCLC	BKM120 + binimetinib	178.5	26.3	0	0	0
X-1993	NSCLC	BKM120 + binimetinib	144.9	26.4	4	-18.8	0.4
X-1993	NSCLC	BKM120 + binimetinib	138.9	26.1	7	-22.2	-0.8
X-1993	NSCLC	BKM120 + binimetinib	260.8	25.8	11	46.1	-1.9
X-1993	NSCLC	BKM120 + binimetinib	269	24.8	14	50.7	-5.7
X-1993	NSCLC	BKM120 + binimetinib	312.7	25.8	18	75.2	-1.9
X-1993	NSCLC	BKM120 + binimetinib	332.1	26.2	21	86.1	-0.4
X-1993	NSCLC	BKM120 + binimetinib	423.5	26	25	137.3	-1.1
X-1993	NSCLC	BKM120 + binimetinib	467	26.1	28	161.6	-0.8
X-1993	NSCLC	BKM120 + binimetinib	462.5	25.8	31	159.1	-1.9
X-1993	NSCLC	BKM120 + binimetinib	500.4	25.4	34	180.3	-3.4
X-1993	NSCLC	BKM120 + binimetinib	577	26.7	39	223.2	1.5
X-1993	NSCLC	BKM120 + binimetinib	633.8	26.5	42	255.1	0.8
X-1993	NSCLC	BKM120 + binimetinib	650.6	27.1	46	264.5	3
X-1993	NSCLC	BKM120	283.5	26.8	0	0	0
X-1993	NSCLC	BKM120	284.7	27.3	1	0.4	1.9
X-1993	NSCLC	BKM120	285.2	26.9	4	0.6	0.4
X-1993	NSCLC	BKM120	419.9	27.6	8	48.1	3
X-1993	NSCLC	BKM120	468.4	28.4	11	65.2	6
X-1993	NSCLC	BKM120	678.3	29.5	15	139.3	10.1
X-1993	NSCLC	BKM120	715.2	29.5	18	152.3	10.1
X-1993	NSCLC	BKM120	704	29.9	22	148.3	11.6
X-1993	NSCLC	BKM120	609.8	29.4	23	115.1	9.7
X-1993	NSCLC	BYL719	202.1	21.1	0	0	0
X-1993	NSCLC	BYL719	194.4	22.1	2	-3.8	4.7
X-1993	NSCLC	BYL719	180.5	21.6	6	-10.7	2.4
X-1993	NSCLC	BYL719	144.6	22.2	9	-28.5	5.2
X-1993	NSCLC	BYL719	113.8	22.6	13	-43.7	7.1
X-1993	NSCLC	BYL719	116.1	22	16	-42.6	4.3
X-1993	NSCLC	BYL719	177.2	21.7	19	-12.3	2.8
X-1993	NSCLC	BYL719	193.2	20.5	22	-4.4	-2.8
X-1993	NSCLC	BYL719	265.4	20.7	27	31.3	-1.9
X-1993	NSCLC	BYL719	336.8	20.9	30	66.7	-0.9
X-1993	NSCLC	BYL719	394.2	20.6	34	95.1	-2.4
X-1993	NSCLC	BYL719	408.9	20.6	37	102.3	-2.4
X-1993	NSCLC	BYL719	507.2	20.6	41	151	-2.4
X-1993	NSCLC	BYL719	489	20.6	44	142	-2.4
X-1993	NSCLC	BYL719	456.3	20.3	48	125.8	-3.8
X-1993	NSCLC	BYL719 + LJM716	165.7	23.7	0	0	0
X-1993	NSCLC	BYL719 + LJM716	142.3	22.5	2	-14.1	-5.1
X-1993	NSCLC	BYL719 + LJM716	139.4	23.8	6	-15.9	0.4
X-1993	NSCLC	BYL719 + LJM716	180.3	24.2	9	8.8	2.1
X-1993	NSCLC	BYL719 + LJM716	214.5	24.3	13	29.5	2.5
X-1993	NSCLC	BYL719 + LJM716	215.9	24.6	16	30.3	3.8
X-1993	NSCLC	BYL719 + LJM716	233.1	24	19	40.7	1.3
X-1993	NSCLC	BYL719 + LJM716	239.5	23.5	22	44.5	-0.8
X-1993	NSCLC	BYL719 + LJM716	245.5	24	27	48.2	1.3
X-1993	NSCLC	BYL719 + LJM716	238.4	24.3	30	43.9	2.5
X-1993	NSCLC	BYL719 + LJM716	260.6	24.1	34	57.3	1.7
X-1993	NSCLC	BYL719 + LJM716	261.6	24	37	57.9	1.3
X-1993	NSCLC	BYL719 + LJM716	285.1	24.1	41	72.1	1.7
X-1993	NSCLC	BYL719 + LJM716	334.8	23.9	44	102.1	0.8
X-1993	NSCLC	BYL719 + LJM716	345.8	24.6	48	108.7	3.8
X-1993	NSCLC	BYL719 + LJM716	317	24.2	50	91.3	2.1
X-1993	NSCLC	BYL719 + LJM716	272.5	24.1	54	64.5	1.7
X-1993	NSCLC	BYL719 + LJM716	227.3	24.5	57	37.2	3.4
X-1993	NSCLC	BYL719 + LJM716	282.6	24.2	58	70.5	2.1
X-1993	NSCLC	BYL719 + LJM716	249.2	24.3	61	50.4	2.5
X-1993	NSCLC	BYL719 + LJM716	241.8	23.9	64	45.9	0.8
X-1993	NSCLC	BYL719 + LJM716	278.3	23.4	69	68	-1.3
X-1993	NSCLC	BYL719 + LJM716	352.1	24	72	112.5	1.3
X-1993	NSCLC	BYL719 + LJM716	330.8	24	76	99.6	1.3
X-1993	NSCLC	BYL719 + LJM716	295.8	23.6	78	78.5	-0.4
X-1993	NSCLC	BYL719 + LJM716	344.6	24.2	83	108	2.1
X-1993	NSCLC	BYL719 + LJM716	355.2	24.6	85	114.4	3.8
X-1993	NSCLC	BYL719 + LJM716	390.8	25.8	90	135.8	8.9
X-1993	NSCLC	BYL719 + LJM716	409.2	25.8	93	147	8.9
X-1993	NSCLC	BYL719 + LJM716	447.2	25.7	97	169.9	8.4
X-1993	NSCLC	BYL719 + LGH447	311.8	26.1	0	0	0
X-1993	NSCLC	BYL719 + LGH447	232.3	25.6	2	-25.5	-1.9
X-1993	NSCLC	BYL719 + LGH447	327.9	25.6	6	5.2	-1.9
X-1993	NSCLC	BYL719 + LGH447	312.1	25.8	9	0.1	-1.1
X-1993	NSCLC	BYL719 + LGH447	360.2	25	13	15.5	-4.2
X-1993	NSCLC	BYL719 + LGH447	374.8	26.2	16	20.2	0.4
X-1993	NSCLC	BYL719 + LGH447	395	26.5	19	26.7	1.5
X-1993	NSCLC	BYL719 + LGH447	390.1	26	22	25.1	-0.4
X-1993	NSCLC	BYL719 + LGH447	411.2	26.2	27	31.9	0.4
X-1993	NSCLC	BYL719 + LGH447	412.7	22.4	30	32.4	-14.2
X-1993	NSCLC	CGM097	196.2	24.7	0	0	0
X-1993	NSCLC	CGM097	229.5	25.4	1	17	2.8
X-1993	NSCLC	CGM097	276.6	25.5	4	41	3.2
X-1993	NSCLC	CGM097	664.5	26.9	8	238.7	8.9
X-1993	NSCLC	CGM097	703.2	27.6	11	258.4	11.7
X-1993	NSCLC	CGM097	954.6	28.4	15	386.5	15
X-1993	NSCLC	CKX620	221.5	23.7	0	0	0
X-1993	NSCLC	CKX620	232.5	23.6	1	5	-0.4
X-1993	NSCLC	CKX620	170.1	23.2	4	-23.2	-2.1
X-1993	NSCLC	CKX620	172.6	23.6	8	-22.1	-0.4
X-1993	NSCLC	CKX620	129.4	24.1	11	-41.6	1.7
X-1993	NSCLC	CKX620	112.9	25.6	15	-49	8
X-1993	NSCLC	CKX620	72.5	25.7	18	-67.3	8.4
X-1993	NSCLC	CKX620	72.5	25.4	22	-67.3	7.2
X-1993	NSCLC	CKX620	69.3	25.8	25	-68.7	8.9
X-1993	NSCLC	CKX620	63.7	26.3	28	-71.2	11
X-1993	NSCLC	CKX620	69.8	25.1	31	-68.5	5.9
X-1993	NSCLC	CKX620	61.2	26.3	36	-72.4	11
X-1993	NSCLC	CKX620	55.4	26.1	39	-75	10.1
X-1993	NSCLC	CKX620	60.6	26.7	43	-72.6	12.7
X-1993	NSCLC	CKX620	67.1	27.2	46	-69.7	14.8
X-1993	NSCLC	CKX620	52.9	27.2	50	-76.1	14.8
X-1993	NSCLC	CKX620	36.1	26.9	53	-83.7	13.5
X-1993	NSCLC	CKX620	50.4	27.5	57	-77.2	16
X-1993	NSCLC	CKX620	35.5	27.8	59	-84	17.3
X-1993	NSCLC	CKX620	15	27.8	63	-93.2	17.3
X-1993	NSCLC	CKX620	21.1	27.4	66	-90.5	15.6
X-1993	NSCLC	CKX620	9.3	27.6	67	-95.8	16.5
X-1993	NSCLC	CKX620	15.6	28.7	70	-93	21.1
X-1993	NSCLC	CKX620	18.3	28	73	-91.7	18.1
X-1993	NSCLC	CKX620	16	26.9	78	-92.8	13.5
X-1993	NSCLC	CKX620	13.8	26.4	81	-93.8	11.4
X-1993	NSCLC	CKX620	14.1	24.8	85	-93.6	4.6
X-1993	NSCLC	CLR457	156.3	25.1	0	0	0
X-1993	NSCLC	CLR457	115.4	23.6	4	-26.2	-6
X-1993	NSCLC	CLR457	106.5	23.8	7	-31.9	-5.2
X-1993	NSCLC	CLR457	109	23.3	11	-30.3	-7.2
X-1993	NSCLC	CLR457	106.5	24.2	14	-31.9	-3.6
X-1993	NSCLC	CLR457	78.7	24.3	18	-49.6	-3.2
X-1993	NSCLC	CLR457	74.2	25	21	-52.5	-0.4
X-1993	NSCLC	CLR457	84.6	24.9	25	-45.9	-0.8
X-1993	NSCLC	CLR457	78.2	25.3	28	-50	0.8
X-1993	NSCLC	CLR457	76.7	25	31	-50.9	-0.4
X-1993	NSCLC	CLR457	88.4	24.4	34	-43.4	-2.8
X-1993	NSCLC	CLR457	82.1	24.7	39	-47.5	-1.6
X-1993	NSCLC	CLR457	79.7	23.4	42	-49	-6.8
X-1993	NSCLC	CLR457	82	24.4	46	-47.5	-2.8
X-1993	NSCLC	CLR457	100	24.6	49	-36	-2
X-1993	NSCLC	CLR457	87.5	25.3	53	-44	0.8
X-1993	NSCLC	CLR457	71.5	26	56	-54.3	3.6
X-1993	NSCLC	CLR457	94.4	26.9	60	-39.6	7.2
X-1993	NSCLC	CLR457	64.6	25.4	62	-58.7	1.2
X-1993	NSCLC	CLR457	106.4	25.9	66	-31.9	3.2
X-1993	NSCLC	CLR457	112.1	27.1	69	-28.3	8
X-1993	NSCLC	CLR457	146.1	26.7	70	-6.5	6.4
X-1993	NSCLC	CLR457	121.6	25.8	73	-22.2	2.8
X-1993	NSCLC	CLR457	247.2	26.9	76	58.2	7.2
X-1993	NSCLC	CLR457	326.2	27.4	81	108.7	9.2
X-1993	NSCLC	CLR457	455.6	26.6	84	191.5	6
X-1993	NSCLC	CLR457	641.4	26.8	88	310.4	6.8
X-1993	NSCLC	CLR457	621.2	26.3	90	297.4	4.8
X-1993	NSCLC	CLR457	1018.9	27	95	551.9	7.6
X-1993	NSCLC	HDM201	242.1	22.7	0	0	0
X-1993	NSCLC	HDM201	268.8	22.4	1	11	-1.3
X-1993	NSCLC	HDM201	383.9	21.6	4	58.6	-4.8
X-1993	NSCLC	HDM201	655.8	21.3	8	170.9	-6.2
X-1993	NSCLC	HDM201	560.4	22.6	11	131.5	-0.4
X-1993	NSCLC	HDM201	713.2	23.9	15	194.6	5.3
X-1993	NSCLC	cetuximab	198.8	22.2	0	0	0
X-1993	NSCLC	cetuximab	216.3	22.8	4	8.8	2.7
X-1993	NSCLC	cetuximab	250.1	23.1	7	25.8	4.1
X-1993	NSCLC	cetuximab	253.9	23.8	11	27.7	7.2
X-1993	NSCLC	cetuximab	256.5	22.9	14	29	3.2
X-1993	NSCLC	cetuximab	277.9	23.6	18	39.8	6.3
X-1993	NSCLC	cetuximab	310.6	23.5	21	56.2	5.9
X-1993	NSCLC	cetuximab	327.5	24.1	24	64.7	8.6
X-1993	NSCLC	cetuximab	292.7	23.3	27	47.2	5
X-1993	NSCLC	cetuximab	301.4	24	32	51.6	8.1
X-1993	NSCLC	cetuximab	328.2	24.2	35	65.1	9
X-1993	NSCLC	cetuximab	404.2	24.1	39	103.3	8.6
X-1993	NSCLC	cetuximab	465.5	23.5	42	134.2	5.9
X-1993	NSCLC	cetuximab	491.2	25.2	46	147.1	13.5
X-1993	NSCLC	cetuximab	552.2	24.2	49	177.8	9
X-1993	NSCLC	cetuximab	530.7	24.3	53	167	9.5
X-1993	NSCLC	erlotinib	236	23.8	0	0	0
X-1993	NSCLC	erlotinib	193.8	24.2	1	-17.9	1.7
X-1993	NSCLC	erlotinib	211.8	23.8	4	-10.3	0
X-1993	NSCLC	erlotinib	268.8	23.2	8	13.9	-2.5
X-1993	NSCLC	erlotinib	242.7	24.2	11	2.8	1.7
X-1993	NSCLC	erlotinib	363.9	25.8	15	54.2	8.4
X-1993	NSCLC	erlotinib	483.8	26	18	105	9.2
X-1993	NSCLC	erlotinib	678.1	25.3	22	187.3	6.3
X-1993	NSCLC	erlotinib	672.5	25.8	25	185	8.4
X-1993	NSCLC	erlotinib	777.2	25.2	28	229.3	5.9
X-1993	NSCLC	HSP990	239.8	23.5	0	0	0
X-1993	NSCLC	HSP990	335.6	24	4	39.9	2.1
X-1993	NSCLC	HSP990	364.4	24.1	7	52	2.6
X-1993	NSCLC	HSP990	389.3	23.7	11	62.3	0.9
X-1993	NSCLC	HSP990	450.6	25.3	14	87.9	7.7
X-1993	NSCLC	HSP990	414.6	24.3	18	72.9	3.4
X-1993	NSCLC	HSP990	477.6	25	21	99.2	6.4
X-1993	NSCLC	HSP990	420.8	23.2	24	75.5	-1.3
X-1993	NSCLC	HSP990	444.8	25	27	85.5	6.4
X-1993	NSCLC	HSP990	453	21.9	32	88.9	-6.8
X-1993	NSCLC	HSP990	400.3	22.7	35	66.9	-3.4
X-1993	NSCLC	HSP990	449.3	22.7	39	87.4	-3.4
X-1993	NSCLC	HSP990	617.2	25	42	157.4	6.4
X-1993	NSCLC	HSP990	797.5	25.4	46	232.6	8.1
X-1993	NSCLC	HSP990	825.4	24.9	47	244.2	6
X-1993	NSCLC	INC280	320.2	24.5	0	0	0
X-1993	NSCLC	INC280	590.5	26.1	4	84.4	6.5
X-1993	NSCLC	INC280	581.7	26.3	7	81.7	7.3
X-1993	NSCLC	INC280	677.9	21.9	11	111.7	-10.6
X-1993	NSCLC	INC280	676.2	20.1	12	111.2	-18
X-1993	NSCLC	LCL161 + paclitaxel	254.8	25.5	0	0	0
X-1993	NSCLC	LCL161 + paclitaxel	299.2	24.8	4	17.4	-2.7
X-1993	NSCLC	LCL161 + paclitaxel	370.5	25.7	7	45.4	0.8
X-1993	NSCLC	LCL161 + paclitaxel	79.7	25.6	35	-68.7	0.4
X-1993	NSCLC	LCL161 + paclitaxel	86.9	27.2	39	-65.9	6.7
X-1993	NSCLC	LCL161 + paclitaxel	54.5	27.9	42	-78.6	9.4
X-1993	NSCLC	LCL161 + paclitaxel	67.8	27	46	-73.4	5.9
X-1993	NSCLC	LCL161 + paclitaxel	98.3	26.5	48	-61.4	3.9
X-1993	NSCLC	LCL161 + paclitaxel	147.7	28.4	55	-42	11.4
X-1993	NSCLC	LCL161 + paclitaxel	191.1	27.9	59	-25	9.4
X-1993	NSCLC	LCL161 + paclitaxel	345.8	28.4	62	35.7	11.4
X-1993	NSCLC	LCL161 + paclitaxel	551.4	28.1	67	116.4	10.2
X-1993	NSCLC	LCL161 + paclitaxel	582.4	28.4	70	128.6	11.4
X-1993	NSCLC	LCL161 + paclitaxel	427	28.4	76	67.6	11.4
X-1993	NSCLC	LCL161 + paclitaxel	336.8	27.4	81	32.2	7.5
X-1993	NSCLC	LCL161 + paclitaxel	350.5	26.8	83	37.6	5.1
X-1993	NSCLC	LCL161 + paclitaxel	540.1	28.9	89	112	13.3
X-1993	NSCLC	LCL161 + paclitaxel	671.8	28.7	92	163.7	12.5
X-1993	NSCLC	LCL161 + paclitaxel	922.4	28.5	95	262	11.8
X-1993	NSCLC	LEE011	243.9	26.8	0	0	0
X-1993	NSCLC	LEE011	191.9	26.5	1	-21.3	-1.1
X-1993	NSCLC	LEE011	219.3	27.3	4	-10.1	1.9
X-1993	NSCLC	LEE011	616.7	26.7	8	152.8	-0.4
X-1993	NSCLC	LEE011	566.6	27.2	11	132.3	1.5
X-1993	NSCLC	LEE011	557.8	27.4	15	128.7	2.2
X-1993	NSCLC	LEE011	573	27.5	18	134.9	2.6
X-1993	NSCLC	LEE011	682.9	28	22	180	4.5
X-1993	NSCLC	LEE011	687	28.3	25	181.7	5.6
X-1993	NSCLC	LEE011	706.2	28.2	28	189.5	5.2
X-1993	NSCLC	LGH447	333	24.5	0	0	0
X-1993	NSCLC	LGH447	425.5	24.5	2	27.8	0
X-1993	NSCLC	LGH447	512.3	25.4	6	53.8	3.7
X-1993	NSCLC	LGH447	758	25.9	9	127.6	5.7
X-1993	NSCLC	LGH447	1110.8	27.1	13	233.6	10.6
X-1993	NSCLC	LGH447	1122.2	26.9	14	237	9.8
X-1993	NSCLC	LLM871	246.3	25.1	0	0	0
X-1993	NSCLC	LLM871	448.5	24.5	4	82.1	-2.4
X-1993	NSCLC	LLM871	439.1	25.6	7	78.3	2
X-1993	NSCLC	LLM871	642.4	26.3	11	160.8	4.8
X-1993	NSCLC	LLM871	767.9	26	14	211.8	3.6
X-1993	NSCLC	LLM871	1070.2	26	18	334.5	3.6
X-1993	NSCLC	LLM871	1259.9	26.6	19	411.5	6
X-1993	NSCLC	binimetinib	246	23.4	0	0	0
X-1993	NSCLC	binimetinib	244	23.5	4	-0.8	0.4
X-1993	NSCLC	binimetinib	320.2	24.4	7	30.2	4.3
X-1993	NSCLC	binimetinib	324.4	24.6	11	31.9	5.1
X-1993	NSCLC	binimetinib	397.5	24.9	14	61.6	6.4
X-1993	NSCLC	binimetinib	294	24.3	18	19.5	3.8
X-1993	NSCLC	binimetinib	303.9	24	21	23.5	2.6
X-1993	NSCLC	binimetinib	307.7	23.4	25	25.1	0
X-1993	NSCLC	binimetinib	308	23.2	28	25.2	-0.9
X-1993	NSCLC	binimetinib	328	22.4	31	33.3	-4.3
X-1993	NSCLC	binimetinib	283.4	20.7	34	15.2	-11.5
X-1993	NSCLC	binimetinib	268.8	22.4	39	9.3	-4.3
X-1993	NSCLC	binimetinib	274.2	23.1	42	11.5	-1.3
X-1993	NSCLC	binimetinib	311.3	23.3	46	26.5	-0.4
X-1993	NSCLC	binimetinib	263.1	22.3	49	7	-4.7
X-1993	NSCLC	binimetinib	218.1	21.8	53	-11.3	-6.8
X-1993	NSCLC	binimetinib	199.4	24.2	56	-18.9	3.4
X-1993	NSCLC	binimetinib	192.3	23.7	60	-21.8	1.3
X-1993	NSCLC	binimetinib	194.5	24.5	62	-20.9	4.7
X-1993	NSCLC	binimetinib	206.8	25.5	66	-15.9	9
X-1993	NSCLC	binimetinib	219.1	26.3	69	-10.9	12.4
X-1993	NSCLC	binimetinib	214.8	25.8	70	-12.7	10.3
X-1993	NSCLC	binimetinib	142.5	25.2	73	-42.1	7.7
X-1993	NSCLC	binimetinib	145	25	76	-41.1	6.8
X-1993	NSCLC	binimetinib	128.4	23.4	81	-47.8	0
X-1993	NSCLC	binimetinib	125	23.6	84	-49.2	0.9
X-1993	NSCLC	binimetinib	140.2	23	88	-43	-1.7
X-1993	NSCLC	paclitaxel	239.8	26.5	0	0	0
X-1993	NSCLC	paclitaxel	402.4	25.8	4	67.8	-2.6
X-1993	NSCLC	paclitaxel	537.1	27.3	7	124	3
X-1993	NSCLC	paclitaxel	704.4	27.6	11	193.7	4.2
X-1993	NSCLC	paclitaxel	950.5	27.9	12	296.4	5.3
X-1993	NSCLC	untreated	149	23.6	0	0	0
X-1993	NSCLC	untreated	136.4	24.4	4	-8.5	3.4
X-1993	NSCLC	untreated	160.6	24.1	7	7.8	2.1
X-1993	NSCLC	untreated	298.2	24	11	100.1	1.7
X-1993	NSCLC	untreated	410	24.7	14	175.2	4.7
X-1993	NSCLC	untreated	477.5	25.3	18	220.5	7.2
X-1993	NSCLC	untreated	504.1	25.6	21	238.3	8.5
X-1993	NSCLC	untreated	666.8	26.8	25	347.5	13.6
X-1993	NSCLC	untreated	913.7	26.3	28	513.2	11.4
X-1993	NSCLC	untreated	1032.7	26.6	31	593.1	12.7
X-1993	NSCLC	LFW527 + binimetinib	184.96	24.6	0	0	0
X-1993	NSCLC	LFW527 + binimetinib	95.92	25.4	3	-48.1	3.3
X-1993	NSCLC	LFW527 + binimetinib	105.36	22.5	9	-43	-8.5
X-1993	NSCLC	LFW527 + binimetinib	109.18	24	13	-41	-2.4
X-1993	NSCLC	LFW527 + binimetinib	124.99	23.3	17	-32.4	-5.3
X-1993	NSCLC	LFW527 + binimetinib	124.79	23.4	20	-32.5	-4.9
X-1993	NSCLC	LFW527 + binimetinib	83.64	24.7	24	-54.8	0.4
X-1993	NSCLC	LFW527 + binimetinib	90.31	24.5	27	-51.2	-0.4
X-1993	NSCLC	LFW527 + binimetinib	156.07	23.9	31	-15.6	-2.8
X-1993	NSCLC	LFW527 + binimetinib	134.82	26.3	34	-27.1	6.9
X-1993	NSCLC	LFW527 + binimetinib	81.8	26.6	38	-55.8	8.1
X-1993	NSCLC	LFW527 + binimetinib	122.39	26.3	41	-33.8	6.9
X-1993	NSCLC	LFW527 + binimetinib	109.18	25.7	45	-41	4.5
X-1993	NSCLC	LFW527 + binimetinib	116.68	27.3	48	-36.9	11
X-1993	NSCLC	LFW527 + binimetinib	153.29	26.5	52	-17.1	7.7
X-1993	NSCLC	LFW527 + binimetinib	105.05	28.5	55	-43.2	15.9
X-1993	NSCLC	LFW527 + binimetinib	97.65	27.3	60	-47.2	11
X-1993	NSCLC	LFW527 + binimetinib	107.72	25.9	67	-41.8	5.3
X-1993	NSCLC	LFW527 + binimetinib	63.89	25.3	69	-65.5	2.8
X-1993	NSCLC	LFW527 + binimetinib	52.99	25	73	-71.4	1.6
X-1993	NSCLC	LFW527 + binimetinib	89.03	24.4	76	-51.9	-0.8
X-1993	NSCLC	LFW527 + binimetinib	123.28	24.2	80	-33.3	-1.6
X-1993	NSCLC	LFW527 + binimetinib	67.88	22.9	83	-63.3	-6.9
X-1993	NSCLC	LFW527 + binimetinib	98.82	21.8	87	-46.6	-11.4
X-1993	NSCLC	LFW527 + binimetinib	108.08	23.6	90	-41.6	-4.1
X-1993	NSCLC	LFW527 + binimetinib	78.25	21.7	94	-57.7	-11.8
X-1993	NSCLC	LFW527 + binimetinib	144.46	22.1	97	-21.9	-10.2
X-1993	NSCLC	LFW527 + binimetinib	90.97	21.7	101	-50.8	-11.8
X-1993	NSCLC	LFW527 + binimetinib	111.04	21.4	103	-40	-13
X-1993	NSCLC	LFW527 + binimetinib	111.97	21.2	109	-39.5	-13.8
X-1993	NSCLC	LFW527 + binimetinib	129.06	20.5	111	-30.2	-16.7
X-1993	NSCLC	LFW527 + binimetinib	106.81	21.9	119	-42.3	-11
X-1993	NSCLC	LFW527 + binimetinib	66.64	22.4	122	-64	-8.9
X-1993	NSCLC	LFW527 + binimetinib	148.49	22.4	124	-19.7	-8.9
X-2017	NSCLC	BGJ398	219.4	24.4	0	0	0
X-2017	NSCLC	BGJ398	304	24.5	3	38.6	0.4
X-2017	NSCLC	BGJ398	344.9	25.9	8	57.2	6.1
X-2017	NSCLC	BGJ398	410.7	25.6	10	87.2	4.9
X-2017	NSCLC	BGJ398	440.1	25.4	14	100.6	4.1
X-2017	NSCLC	BGJ398	622.7	25.2	17	183.8	3.3
X-2017	NSCLC	BGJ398	578.5	25.2	21	163.7	3.3
X-2017	NSCLC	BGJ398	627.5	26.1	24	186	7
X-2017	NSCLC	BGJ398	784.6	26	29	257.6	6.6
X-2017	NSCLC	BKM120 + binimetinib	197.3	24	0	0	0
X-2017	NSCLC	BKM120 + binimetinib	152.6	22.7	3	-22.7	-5.4
X-2017	NSCLC	BKM120 + binimetinib	186.6	24.1	8	-5.4	0.4
X-2017	NSCLC	BKM120 + binimetinib	162	24.3	10	-17.9	1.2
X-2017	NSCLC	BKM120 + binimetinib	189.3	23.8	14	-4.1	-0.8
X-2017	NSCLC	BKM120 + binimetinib	149.9	25	17	-24	4.2
X-2017	NSCLC	BKM120 + binimetinib	144	24	21	-27	0
X-2017	NSCLC	BKM120 + binimetinib	106.4	25.9	24	-46.1	7.9
X-2017	NSCLC	BKM120 + binimetinib	117.9	25.4	29	-40.2	5.8
X-2017	NSCLC	BKM120 + binimetinib	118	24.6	31	-40.2	2.5
X-2017	NSCLC	BKM120 + binimetinib	108.7	25.2	36	-44.9	5
X-2017	NSCLC	BKM120 + binimetinib	128.1	26	38	-35.1	8.3
X-2017	NSCLC	BKM120 + binimetinib	176.5	25.9	41	-10.5	7.9
X-2017	NSCLC	BKM120 + binimetinib	126.8	27.2	48	-35.7	13.3
X-2017	NSCLC	BKM120 + binimetinib	191.3	27.3	52	-3	13.7
X-2017	NSCLC	BKM120 + binimetinib	169.3	26.8	55	-14.2	11.7
X-2017	NSCLC	BKM120 + binimetinib	190.3	26.7	59	-3.5	11.3
X-2017	NSCLC	BKM120 + binimetinib	174.7	26.1	64	-11.5	8.8
X-2017	NSCLC	BKM120 + binimetinib	175.6	27.4	70	-11	14.2
X-2017	NSCLC	BKM120 + binimetinib	155.4	27.3	73	-21.2	13.7
X-2017	NSCLC	BKM120 + binimetinib	130	27.4	78	-34.1	14.2
X-2017	NSCLC	BKM120 + binimetinib	207.5	27.1	84	5.2	12.9
X-2017	NSCLC	BKM120 + binimetinib	221.4	27.9	87	12.2	16.2
X-2017	NSCLC	BKM120 + binimetinib	241.6	27.1	92	22.5	12.9
X-2017	NSCLC	BKM120 + binimetinib	202.1	27.1	94	2.4	12.9
X-2017	NSCLC	BKM120 + binimetinib	198.7	28.4	98	0.7	18.3
X-2017	NSCLC	BKM120 + binimetinib	201.8	28.2	105	2.3	17.5
X-2017	NSCLC	BKM120	182.3	24.4	0	0	0
X-2017	NSCLC	BKM120	201.7	23.3	3	10.6	-4.5
X-2017	NSCLC	BKM120	293.2	25.1	8	60.8	2.9
X-2017	NSCLC	BKM120	261.7	23.6	10	43.6	-3.3
X-2017	NSCLC	BKM120	328.5	24.6	14	80.2	0.8
X-2017	NSCLC	BKM120	352.1	24.5	17	93.1	0.4
X-2017	NSCLC	BKM120	367.1	24.6	21	101.4	0.8
X-2017	NSCLC	BKM120	451.7	25.4	24	147.8	4.1
X-2017	NSCLC	BKM120	397.4	24.9	29	118	2
X-2017	NSCLC	BKM120	476	24.1	31	161.1	-1.2
X-2017	NSCLC	BKM120	613.9	25.2	36	236.8	3.3
X-2017	NSCLC	BKM120	653.2	25	38	258.3	2.5
X-2017	NSCLC	BKM120	667.7	25.8	41	266.3	5.7
X-2017	NSCLC	BKM120	714.3	26.4	48	291.8	8.2
X-2017	NSCLC	BKM120	771.2	26.1	50	323	7
X-2017	NSCLC	BYL719 + LGH447	276.8	22.8	0	0	0
X-2017	NSCLC	BYL719 + LGH447	265.9	23.8	5	-3.9	4.4
X-2017	NSCLC	BYL719 + LGH447	280.3	22	18	1.3	-3.5
X-2017	NSCLC	BYL719 + LGH447	366.3	22.8	26	32.3	0
X-2017	NSCLC	BYL719 + LGH447	271.8	22	28	-1.8	-3.5
X-2017	NSCLC	BYL719 + LGH447	284	22	33	2.6	-3.5
X-2017	NSCLC	BYL719 + LGH447	294.8	22.1	35	6.5	-3.1
X-2017	NSCLC	BYL719 + LGH447	365.3	22.8	38	32	0
X-2017	NSCLC	BYL719 + LGH447	435	23	45	57.2	0.9
X-2017	NSCLC	BYL719 + LGH447	1347.7	23.2	48	386.9	1.8
X-2017	NSCLC	BYL719 + LGH447	1270.1	23.3	49	358.9	2.2
X-2017	NSCLC	BYL719 + LJM716	181.3	25.3	0	0	0
X-2017	NSCLC	BYL719 + LJM716	206.5	24	3	13.9	-5.1
X-2017	NSCLC	BYL719 + LJM716	314.3	26.2	8	73.4	3.6
X-2017	NSCLC	BYL719 + LJM716	388.2	24.9	10	114.1	-1.6
X-2017	NSCLC	BYL719 + LJM716	436.9	25.5	14	141	0.8
X-2017	NSCLC	BYL719 + LJM716	442.3	25.4	17	144	0.4
X-2017	NSCLC	BYL719 + LJM716	436.9	25.3	21	141	0
X-2017	NSCLC	BYL719 + LJM716	478	25.3	24	163.7	0
X-2017	NSCLC	BYL719 + LJM716	621.9	25.4	29	243	0.4
X-2017	NSCLC	BYL719 + LJM716	564.9	23.1	31	211.6	-8.7
X-2017	NSCLC	BYL719 + LJM716	614.3	24.1	36	238.8	-4.7
X-2017	NSCLC	BYL719 + LJM716	555.5	23	38	206.4	-9.1
X-2017	NSCLC	BYL719 + LJM716	700	23.8	41	286.1	-5.9
X-2017	NSCLC	BYL719 + LJM716	830	23.9	48	357.8	-5.5
X-2017	NSCLC	BYL719 + LJM716	811.2	24.1	50	347.4	-4.7
X-2017	NSCLC	BYL719	182.5	24.2	0	0	0
X-2017	NSCLC	BYL719	197.5	23.2	3	8.2	-4.1
X-2017	NSCLC	BYL719	237.2	24	8	30	-0.8
X-2017	NSCLC	BYL719	223.8	22.9	10	22.6	-5.4
X-2017	NSCLC	BYL719	234.7	23.2	14	28.6	-4.1
X-2017	NSCLC	BYL719	224.1	23.1	17	22.8	-4.5
X-2017	NSCLC	BYL719	261.2	23.9	21	43.1	-1.2
X-2017	NSCLC	BYL719	310	24.9	24	69.9	2.9
X-2017	NSCLC	BYL719	282	25.4	29	54.5	5
X-2017	NSCLC	BYL719	305.4	23.9	31	67.3	-1.2
X-2017	NSCLC	BYL719	344.2	23.7	36	88.6	-2.1
X-2017	NSCLC	BYL719	339	23.9	38	85.8	-1.2
X-2017	NSCLC	BYL719	376.3	24.2	41	106.2	0
X-2017	NSCLC	BYL719	510.5	25	48	179.7	3.3
X-2017	NSCLC	BYL719	434.3	25	50	138	3.3
X-2017	NSCLC	CGM097	167.3	22.9	0	0	0
X-2017	NSCLC	CGM097	228.9	22.8	3	36.8	-0.4
X-2017	NSCLC	CGM097	222.7	24.9	8	33.1	8.7
X-2017	NSCLC	CGM097	273.1	24.6	10	63.2	7.4
X-2017	NSCLC	CGM097	365.3	25.3	14	118.4	10.5
X-2017	NSCLC	CGM097	441.3	25.1	17	163.8	9.6
X-2017	NSCLC	CGM097	398.7	25.1	21	138.3	9.6
X-2017	NSCLC	CGM097	385	26.3	24	130.1	14.8
X-2017	NSCLC	CGM097	637.5	26.8	29	281.1	17
X-2017	NSCLC	CGM097	926.9	26	31	454	13.5
X-2017	NSCLC	CGM097	960	27.1	35	473.8	18.3
X-2017	NSCLC	CKX620	176.9	22.9	0	0	0
X-2017	NSCLC	CKX620	194.3	23	3	9.8	0.4
X-2017	NSCLC	CKX620	188.7	24.4	8	6.7	6.6
X-2017	NSCLC	CKX620	197.8	24	10	11.8	4.8
X-2017	NSCLC	CKX620	178.6	24.9	14	1	8.7
X-2017	NSCLC	CKX620	121.7	23.8	17	-31.2	3.9
X-2017	NSCLC	CKX620	101.8	24.3	21	-42.5	6.1
X-2017	NSCLC	CKX620	87.9	24.7	24	-50.3	7.9
X-2017	NSCLC	CKX620	124.9	24.6	29	-29.4	7.4
X-2017	NSCLC	CKX620	94.4	24.1	31	-46.6	5.2
X-2017	NSCLC	CKX620	104	25.1	36	-41.2	9.6
X-2017	NSCLC	CKX620	116.8	25.5	38	-34	11.4
X-2017	NSCLC	CKX620	132	24.8	41	-25.4	8.3
X-2017	NSCLC	CKX620	106	24.8	48	-40.1	8.3
X-2017	NSCLC	CKX620	116.4	25.3	52	-34.2	10.5
X-2017	NSCLC	CKX620	104.1	25.3	55	-41.2	10.5
X-2017	NSCLC	CKX620	137.8	25.9	59	-22.1	13.1
X-2017	NSCLC	CKX620	109	26.1	64	-38.4	14
X-2017	NSCLC	CKX620	152.5	26.1	70	-13.8	14
X-2017	NSCLC	CKX620	168.3	25.7	73	-4.9	12.2
X-2017	NSCLC	CKX620	130.5	25.2	78	-26.2	10
X-2017	NSCLC	CKX620	109.6	25.6	84	-38	11.8
X-2017	NSCLC	CKX620	90	26.3	87	-49.1	14.8
X-2017	NSCLC	CKX620	105.3	26.5	92	-40.5	15.7
X-2017	NSCLC	CLR457	198.4	24.1	0	0	0
X-2017	NSCLC	CLR457	225.2	23.5	3	13.5	-2.5
X-2017	NSCLC	CLR457	247.5	24.1	8	24.7	0
X-2017	NSCLC	CLR457	328.8	24	14	65.7	-0.4
X-2017	NSCLC	CLR457	472.3	23.5	17	138.1	-2.5
X-2017	NSCLC	CLR457	460	24.2	21	131.9	0.4
X-2017	NSCLC	CLR457	648.7	25.6	24	227	6.2
X-2017	NSCLC	CLR457	761.7	25	29	283.9	3.7
X-2017	NSCLC	HDM201	169.5	24.3	0	0	0
X-2017	NSCLC	HDM201	215.1	23.6	3	26.9	-2.9
X-2017	NSCLC	HDM201	428.8	24.1	8	153	-0.8
X-2017	NSCLC	HDM201	390.6	23.8	10	130.4	-2.1
X-2017	NSCLC	HDM201	495	24.5	14	192	0.8
X-2017	NSCLC	HDM201	472	24.8	17	178.5	2.1
X-2017	NSCLC	HDM201	436.1	25	21	157.3	2.9
X-2017	NSCLC	HDM201	550	24.9	24	224.5	2.5
X-2017	NSCLC	HDM201	836.1	23.7	29	393.3	-2.5
X-2017	NSCLC	HDM201	853.5	23.3	31	403.5	-4.1
X-2017	NSCLC	HDM201	1012.4	25	35	497.3	2.9
X-2017	NSCLC	cetuximab	277.7	25.1	0	0	0
X-2017	NSCLC	cetuximab	459.7	25.2	5	65.5	0.4
X-2017	NSCLC	cetuximab	548.3	25.4	7	97.4	1.2
X-2017	NSCLC	cetuximab	650.9	26.3	11	134.4	4.8
X-2017	NSCLC	cetuximab	688.6	26.3	14	148	4.8
X-2017	NSCLC	cetuximab	828.8	NA	18	198.5	4.8
X-2017	NSCLC	cetuximab	971.2	26.4	21	249.7	5.2
X-2017	NSCLC	cetuximab	1647.8	25.7	26	493.4	2.4
X-2017	NSCLC	erlotinib	191.4	23.4	0	0	0
X-2017	NSCLC	erlotinib	349.8	21.5	8	82.8	-8.1
X-2017	NSCLC	erlotinib	308.5	22.5	10	61.2	-3.8
X-2017	NSCLC	erlotinib	262.8	20.9	14	37.3	-10.7
X-2017	NSCLC	erlotinib	330.8	22.3	17	72.8	-4.7
X-2017	NSCLC	erlotinib	410.9	24.6	21	114.7	5.1
X-2017	NSCLC	erlotinib	389.6	24.8	24	103.6	6
X-2017	NSCLC	erlotinib	619.5	25.8	29	223.7	10.3
X-2017	NSCLC	erlotinib	630.2	25.6	31	229.3	9.4
X-2017	NSCLC	erlotinib	612.7	25.4	36	220.1	8.5
X-2017	NSCLC	erlotinib	666.6	25.6	38	248.3	9.4
X-2017	NSCLC	erlotinib	708.8	25.2	41	270.3	7.7
X-2017	NSCLC	erlotinib	974.2	25.6	48	409	9.4
X-2017	NSCLC	erlotinib	1126.7	26.3	50	488.7	12.4
X-2017	NSCLC	HSP990	159.5	24.4	0	0	0
X-2017	NSCLC	HSP990	217.3	25	5	36.2	2.5
X-2017	NSCLC	HSP990	222.9	25	7	39.7	2.5
X-2017	NSCLC	HSP990	223.5	26	11	40.1	6.6
X-2017	NSCLC	HSP990	274	24.8	14	71.8	1.6
X-2017	NSCLC	HSP990	378.9	25.9	18	137.6	6.1
X-2017	NSCLC	HSP990	413.5	26.7	21	159.2	9.4
X-2017	NSCLC	HSP990	554.9	27.3	26	247.9	11.9
X-2017	NSCLC	HSP990	684.8	25.4	28	329.3	4.1
X-2017	NSCLC	HSP990	964.7	26.2	32	504.8	7.4
X-2017	NSCLC	INC280	185.2	22.6	0	0	0
X-2017	NSCLC	INC280	224	21.9	3	21	-3.1
X-2017	NSCLC	INC280	293.1	22.8	8	58.3	0.9
X-2017	NSCLC	INC280	267.9	23.2	10	44.7	2.7
X-2017	NSCLC	INC280	354.1	23.7	14	91.2	4.9
X-2017	NSCLC	INC280	409.9	24.4	17	121.3	8
X-2017	NSCLC	INC280	621.6	24.6	21	235.6	8.8
X-2017	NSCLC	INC280	757.4	25.1	24	309	11.1
X-2017	NSCLC	INC280	949.7	24.7	29	412.8	9.3
X-2017	NSCLC	LCL161 + paclitaxel	210.4	24.8	0	0	0
X-2017	NSCLC	LCL161 + paclitaxel	219	23.9	5	4.1	-3.6
X-2017	NSCLC	LCL161 + paclitaxel	235.3	23.8	7	11.8	-4
X-2017	NSCLC	LCL161 + paclitaxel	248.8	25.2	11	18.3	1.6
X-2017	NSCLC	LCL161 + paclitaxel	323.1	24.9	14	53.6	0.4
X-2017	NSCLC	LCL161 + paclitaxel	326	24.9	18	54.9	0.4
X-2017	NSCLC	LCL161 + paclitaxel	275.2	25.9	21	30.8	4.4
X-2017	NSCLC	LCL161 + paclitaxel	350	26.1	26	66.3	5.2
X-2017	NSCLC	LCL161 + paclitaxel	306.3	25	28	45.6	0.8
X-2017	NSCLC	LCL161 + paclitaxel	231.1	22.7	33	9.8	-8.5
X-2017	NSCLC	LCL161 + paclitaxel	288.3	23.2	35	37	-6.5
X-2017	NSCLC	LCL161 + paclitaxel	330.5	25.5	38	57.1	2.8
X-2017	NSCLC	LCL161 + paclitaxel	388.5	23.7	45	84.6	-4.4
X-2017	NSCLC	LCL161 + paclitaxel	454.1	26.4	49	115.8	6.5
X-2017	NSCLC	LCL161 + paclitaxel	426.2	19.7	52	102.6	-20.6
X-2017	NSCLC	LEE011	171.4	23.9	0	0	0
X-2017	NSCLC	LEE011	180.2	25.5	3	5.1	6.7
X-2017	NSCLC	LEE011	208.2	26.5	8	21.5	10.9
X-2017	NSCLC	LEE011	270.5	26.9	10	57.8	12.6
X-2017	NSCLC	LEE011	289.2	26.9	14	68.7	12.6
X-2017	NSCLC	LEE011	295.9	27.4	17	72.6	14.6
X-2017	NSCLC	LEE011	288.5	27.3	21	68.3	14.2
X-2017	NSCLC	LEE011	298.1	27.9	24	73.9	16.7
X-2017	NSCLC	LEE011	448.5	27.7	29	161.7	15.9
X-2017	NSCLC	LEE011	582.7	27.3	31	240	14.2
X-2017	NSCLC	LEE011	515.4	28.1	36	200.7	17.6
X-2017	NSCLC	LEE011	637.8	28.3	38	272.1	18.4
X-2017	NSCLC	LEE011	870.4	28.7	41	407.8	20.1
X-2017	NSCLC	LEE011	847.7	29.4	48	394.6	23
X-2017	NSCLC	LEE011	1015.1	29.3	50	492.2	22.6
X-2017	NSCLC	LGH447	167.2	25.3	0	0	0
X-2017	NSCLC	LGH447	214.7	25.2	3	28.4	-0.4
X-2017	NSCLC	LGH447	216.7	25.4	8	29.6	0.4
X-2017	NSCLC	LGH447	292.5	25.3	10	74.9	0
X-2017	NSCLC	LGH447	311.7	26.3	14	86.4	4
X-2017	NSCLC	LGH447	268.5	25.4	17	60.6	0.4
X-2017	NSCLC	LGH447	356	26.4	21	112.9	4.3
X-2017	NSCLC	LGH447	393.3	26.5	24	135.2	4.7
X-2017	NSCLC	LGH447	553.6	27.4	29	231.1	8.3
X-2017	NSCLC	LGH447	599.5	26.7	31	258.6	5.5
X-2017	NSCLC	LGH447	665	27.4	35	297.7	8.3
X-2017	NSCLC	LGH447	788.7	27.1	36	371.7	7.1
X-2017	NSCLC	LGH447	803	27.5	38	380.3	8.7
X-2017	NSCLC	LGH447	949.4	28.4	41	467.8	12.3
X-2017	NSCLC	LGH447	1144.5	28.7	48	584.5	13.4
X-2017	NSCLC	LGH447	1647.3	29	50	885.2	14.6
X-2017	NSCLC	LLM871	203.5	23.3	0	0	0
X-2017	NSCLC	LLM871	181.7	23.6	4	-10.7	1.3
X-2017	NSCLC	LLM871	243.3	23.3	7	19.6	0
X-2017	NSCLC	LLM871	219.2	22.9	11	7.7	-1.7
X-2017	NSCLC	LLM871	219.4	24.5	14	7.8	5.2
X-2017	NSCLC	LLM871	345.9	24.7	19	70	6
X-2017	NSCLC	LLM871	368.5	23.8	21	81.1	2.1
X-2017	NSCLC	LLM871	482.5	25.6	25	137.1	9.9
X-2017	NSCLC	LLM871	618.5	26.3	28	203.9	12.9
X-2017	NSCLC	LLM871	683.9	26.9	31	236.1	15.5
X-2017	NSCLC	LLM871	711.8	25.9	38	249.8	11.2
X-2017	NSCLC	LLM871	866.5	26	40	325.8	11.6
X-2017	NSCLC	binimetinib	141.1	21.9	0	0	0
X-2017	NSCLC	binimetinib	81.2	21.7	5	-42.5	-0.9
X-2017	NSCLC	binimetinib	51	21.5	7	-63.9	-1.8
X-2017	NSCLC	binimetinib	58.3	22.7	11	-58.7	3.7
X-2017	NSCLC	binimetinib	70	22.3	14	-50.4	1.8
X-2017	NSCLC	binimetinib	49	22.8	18	-65.3	4.1
X-2017	NSCLC	binimetinib	18	22.3	21	-87.2	1.8
X-2017	NSCLC	binimetinib	16.6	22.2	26	-88.2	1.4
X-2017	NSCLC	binimetinib	11.5	22.3	28	-91.8	1.8
X-2017	NSCLC	binimetinib	22.5	21.3	33	-84.1	-2.7
X-2017	NSCLC	binimetinib	17.8	23	35	-87.4	5
X-2017	NSCLC	binimetinib	20.8	22	38	-85.3	0.5
X-2017	NSCLC	binimetinib	15.3	23.1	45	-89.2	5.5
X-2017	NSCLC	binimetinib	12.3	24	49	-91.3	9.6
X-2017	NSCLC	binimetinib	19.4	22.8	52	-86.3	4.1
X-2017	NSCLC	binimetinib	20.2	22.9	56	-85.7	4.6
X-2017	NSCLC	binimetinib	9.3	23.4	61	-93.4	6.8
X-2017	NSCLC	binimetinib	6.2	23.7	67	-95.6	8.2
X-2017	NSCLC	binimetinib	8.5	24	70	-94	9.6
X-2017	NSCLC	binimetinib	0	23.5	81	-100	7.3
X-2017	NSCLC	binimetinib	0	22.8	84	-100	4.1
X-2017	NSCLC	binimetinib	0	22.3	89	-100	1.8
X-2017	NSCLC	paclitaxel	210.4	22.9	0	0	0
X-2017	NSCLC	paclitaxel	262.8	23.9	5	24.9	4.4
X-2017	NSCLC	paclitaxel	263.7	22.8	7	25.3	-0.4
X-2017	NSCLC	paclitaxel	252.1	23.1	11	19.8	0.9
X-2017	NSCLC	paclitaxel	244.1	24.1	14	16	5.2
X-2017	NSCLC	paclitaxel	275.3	23.2	18	30.8	1.3
X-2017	NSCLC	paclitaxel	285.5	23.7	21	35.7	3.5
X-2017	NSCLC	paclitaxel	286.4	23.9	26	36.1	4.4
X-2017	NSCLC	paclitaxel	334.6	23.1	28	59	0.9
X-2017	NSCLC	paclitaxel	411.7	23.8	33	95.7	3.9
X-2017	NSCLC	paclitaxel	405.7	23.7	35	92.8	3.5
X-2017	NSCLC	paclitaxel	492.6	24.3	38	134.1	6.1
X-2017	NSCLC	paclitaxel	508.5	24.9	45	141.7	8.7
X-2017	NSCLC	paclitaxel	632.1	25.1	47	200.4	9.6
X-2017	NSCLC	untreated	207.9	24.6	0	0	0
X-2017	NSCLC	untreated	259.4	25.3	3	24.8	2.8
X-2017	NSCLC	untreated	391.5	26.5	8	88.3	7.7
X-2017	NSCLC	untreated	516.5	25.4	10	148.4	3.3
X-2017	NSCLC	untreated	746.1	26.1	14	258.9	6.1
X-2017	NSCLC	untreated	806	25.9	17	287.7	5.3
X-2017	NSCLC	untreated	958.5	26.5	21	361	7.7
X-2017	NSCLC	untreated	1096.3	28	24	427.3	13.8
X-2017	NSCLC	untreated	1445.5	27.3	29	595.3	11
X-2017	NSCLC	LFW527 + binimetinib	281.38	26.5	0	0	0
X-2017	NSCLC	LFW527 + binimetinib	208.15	26.4	2	-26	-0.4
X-2017	NSCLC	LFW527 + binimetinib	217.79	26.5	7	-22.6	0
X-2017	NSCLC	LFW527 + binimetinib	185.36	26.7	10	-34.1	0.8
X-2017	NSCLC	LFW527 + binimetinib	148.95	26.4	13	-47.1	-0.4
X-2017	NSCLC	LFW527 + binimetinib	137.73	25.8	17	-51.1	-2.6
X-2017	NSCLC	LFW527 + binimetinib	103.65	26.5	20	-63.2	0
X-2017	NSCLC	LFW527 + binimetinib	104.01	25.8	23	-63	-2.6
X-2017	NSCLC	LFW527 + binimetinib	67.43	26.7	28	-76	0.8
X-2017	NSCLC	LFW527 + binimetinib	117.1	27.6	30	-58.4	4.2
X-2017	NSCLC	LFW527 + binimetinib	86.03	27.7	37	-69.4	4.5
X-2017	NSCLC	LFW527 + binimetinib	47.85	28.1	41	-83	6
X-2017	NSCLC	LFW527 + binimetinib	77.07	28.2	44	-72.6	6.4
X-2017	NSCLC	LFW527 + binimetinib	66.1	28.9	48	-76.5	9.1
X-2017	NSCLC	LFW527 + binimetinib	64	28.8	51	-77.3	8.7
X-2017	NSCLC	LFW527 + binimetinib	0	31	55	-100	17
X-2017	NSCLC	LFW527 + binimetinib	0	30.9	58	-100	16.6
X-2017	NSCLC	LFW527 + binimetinib	0	32.4	62	-100	22.3
X-2017	NSCLC	LFW527 + binimetinib	0	31.6	65	-100	19.2
X-2017	NSCLC	LFW527 + binimetinib	0	32.1	69	-100	21.1
X-2017	NSCLC	LFW527 + binimetinib	0	31.1	72	-100	17.4
X-2017	NSCLC	LFW527 + binimetinib	0	29.6	76	-100	11.7
X-2017	NSCLC	LFW527 + binimetinib	0	29.8	79	-100	12.5
X-2017	NSCLC	LFW527 + binimetinib	0	31	83	-100	17
X-2017	NSCLC	LFW527 + binimetinib	0	30.6	86	-100	15.5
X-2017	NSCLC	LFW527 + binimetinib	0	30.1	90	-100	13.6
X-2017	NSCLC	LFW527 + binimetinib	0	29.7	93	-100	12.1
X-2017	NSCLC	LFW527 + binimetinib	0	29.8	97	-100	12.5
X-2017	NSCLC	LFW527 + binimetinib	0	31.3	100	-100	18.1
X-2017	NSCLC	LFW527 + binimetinib	0	30.9	107	-100	16.6
X-2017	NSCLC	LFW527 + binimetinib	81.45	30.6	111	-71.1	15.5
X-2017	NSCLC	LFW527 + binimetinib	120.45	30.3	114	-57.2	14.3
X-2017	NSCLC	LFW527 + binimetinib	86.38	31	118	-69.3	17
X-2017	NSCLC	LFW527 + binimetinib	59.15	32	121	-79	20.8
X-2017	NSCLC	LFW527 + binimetinib	0	33.1	126	-100	24.9
X-2017	NSCLC	LFW527 + binimetinib	0	32.1	129	-100	21.1
X-2017	NSCLC	LFW527 + binimetinib	0	30.2	132	-100	14
X-2017	NSCLC	LFW527 + binimetinib	0	30.2	135	-100	14
X-2017	NSCLC	LFW527 + binimetinib	0	34	139	-100	28.3
X-2017	NSCLC	LFW527 + binimetinib	0	34.3	143	-100	29.4
X-2017	NSCLC	LFW527 + binimetinib	69.05	33.7	146	-75.5	27.2
X-2017	NSCLC	LFW527 + binimetinib	63.5	32.7	149	-77.4	23.4
X-2017	NSCLC	LFW527 + binimetinib	61.35	32.4	153	-78.2	22.3
X-2017	NSCLC	LFW527 + binimetinib	56.12	31.2	156	-80.1	17.7
X-2017	NSCLC	LFW527 + binimetinib	79.73	31.3	160	-71.7	18.1
X-2017	NSCLC	LFW527 + binimetinib	143.26	31.1	162	-49.1	17.4
X-2026	PDAC	BKM120 + binimetinib	267.4	26.8	0	0	0
X-2026	PDAC	BKM120 + binimetinib	341.5	26.5	4	27.7	-1.1
X-2026	PDAC	BKM120 + binimetinib	278.9	28	7	4.3	4.5
X-2026	PDAC	BKM120 + binimetinib	313.7	27.8	11	17.3	3.7
X-2026	PDAC	BKM120 + binimetinib	248.1	27.4	14	-7.2	2.2
X-2026	PDAC	BKM120 + binimetinib	296.9	27.9	18	11	4.1
X-2026	PDAC	BKM120 + binimetinib	285.8	27.5	21	6.9	2.6
X-2026	PDAC	BKM120 + binimetinib	169.4	28.5	25	-36.6	6.3
X-2026	PDAC	BKM120 + binimetinib	241.8	27.2	28	-9.6	1.5
X-2026	PDAC	BKM120 + binimetinib	257.8	29	31	-3.6	8.2
X-2026	PDAC	BKM120 + binimetinib	216	28.3	34	-19.2	5.6
X-2026	PDAC	BKM120 + binimetinib	316.7	29.1	39	18.4	8.6
X-2026	PDAC	BKM120 + binimetinib	320.4	28.2	42	19.8	5.2
X-2026	PDAC	BKM120 + binimetinib	305	27.6	46	14.1	3
X-2026	PDAC	BKM120 + binimetinib	329.7	27.4	49	23.3	2.2
X-2026	PDAC	BKM120 + binimetinib	285.1	27.7	52	6.6	3.4
X-2026	PDAC	BKM120 + binimetinib	329.5	27.8	56	23.2	3.7
X-2026	PDAC	BKM120 + binimetinib	421.5	28	59	57.6	4.5
X-2026	PDAC	BKM120 + binimetinib	454.6	26.9	62	70	0.4
X-2026	PDAC	BKM120 + binimetinib	494.9	26.9	66	85.1	0.4
X-2026	PDAC	BKM120 + binimetinib	501	28.8	70	87.4	7.5
X-2026	PDAC	BKM120 + binimetinib	500.3	29	74	87.1	8.2
X-2026	PDAC	BKM120 + binimetinib	530.1	28.2	77	98.2	5.2
X-2026	PDAC	BKM120 + binimetinib	561.1	28.5	80	109.8	6.3
X-2026	PDAC	BKM120 + binimetinib	488	28.6	84	82.5	6.7
X-2026	PDAC	BKM120	254.4	25.7	0	0	0
X-2026	PDAC	BKM120	306.8	25.5	4	20.6	-0.8
X-2026	PDAC	BKM120	316	24.6	7	24.2	-4.3
X-2026	PDAC	BKM120	404.1	25.9	12	58.8	0.8
X-2026	PDAC	BKM120	433.3	25.9	14	70.3	0.8
X-2026	PDAC	BKM120	450.3	25.7	18	77	0
X-2026	PDAC	BKM120	466.1	26.7	21	83.2	3.9
X-2026	PDAC	BKM120	500.3	25.9	25	96.7	0.8
X-2026	PDAC	BKM120	553.9	25.8	28	117.7	0.4
X-2026	PDAC	BKM120	565.9	25.5	32	122.4	-0.8
X-2026	PDAC	BYL719 + LJM716	246.7	23.7	0	0	0
X-2026	PDAC	BYL719 + LJM716	267.1	24.1	3	8.3	1.7
X-2026	PDAC	BYL719 + LJM716	327.9	23.6	6	32.9	-0.4
X-2026	PDAC	BYL719 + LJM716	388.6	23.7	10	57.5	0
X-2026	PDAC	BYL719 + LJM716	476.1	23.9	13	93	0.8
X-2026	PDAC	BYL719 + LJM716	525.3	22.6	18	112.9	-4.6
X-2026	PDAC	BYL719 + LJM716	547.3	22.3	21	121.8	-5.9
X-2026	PDAC	BYL719 + LJM716	574.2	22.6	24	132.8	-4.6
X-2026	PDAC	BYL719 + LJM716	604.9	23.9	27	145.2	0.8
X-2026	PDAC	BYL719 + LJM716	643	22.3	31	160.6	-5.9
X-2026	PDAC	BYL719 + LJM716	643	22.9	34	160.6	-3.4
X-2026	PDAC	BYL719 + LJM716	691.5	24.3	38	180.3	2.5
X-2026	PDAC	BYL719 + LJM716	759.8	23.4	42	208	-1.3
X-2026	PDAC	BYL719 + LJM716	923.1	22.8	45	274.2	-3.8
X-2026	PDAC	BYL719 + LJM716	1080.6	22.6	48	338	-4.6
X-2026	PDAC	BYL719	218.6	26.5	0	0	0
X-2026	PDAC	BYL719	207.9	26.9	3	-4.9	1.5
X-2026	PDAC	BYL719	217.3	26.8	6	-0.6	1.1
X-2026	PDAC	BYL719	207.9	27.4	10	-4.9	3.4
X-2026	PDAC	BYL719	229	27.3	13	4.8	3
X-2026	PDAC	BYL719	241.3	25.9	18	10.4	-2.3
X-2026	PDAC	BYL719	264.3	25.6	21	20.9	-3.4
X-2026	PDAC	BYL719	277.1	25.7	24	26.8	-3
X-2026	PDAC	BYL719	284.3	27.4	27	30.1	3.4
X-2026	PDAC	BYL719	302.1	26	31	38.2	-1.9
X-2026	PDAC	BYL719	329.1	26.8	34	50.5	1.1
X-2026	PDAC	BYL719	334.3	27.1	38	52.9	2.3
X-2026	PDAC	BYL719	439.1	26.9	42	100.9	1.5
X-2026	PDAC	BYL719	490.2	26.7	45	124.2	0.8
X-2026	PDAC	BYL719	618.6	27.2	48	183	2.6
X-2026	PDAC	BYL719	726.6	27.8	52	232.4	4.9
X-2026	PDAC	CLR457	206.9	25.3	0	0	0
X-2026	PDAC	CLR457	211.1	25.7	3	2	1.6
X-2026	PDAC	CLR457	224.6	24.7	6	8.6	-2.4
X-2026	PDAC	CLR457	243.4	25.7	10	17.6	1.6
X-2026	PDAC	CLR457	296.2	26	13	43.2	2.8
X-2026	PDAC	CLR457	298.7	25.9	18	44.4	2.4
X-2026	PDAC	CLR457	342.2	25.6	21	65.4	1.2
X-2026	PDAC	CLR457	347.7	24.7	24	68.1	-2.4
X-2026	PDAC	CLR457	353.4	25.6	27	70.8	1.2
X-2026	PDAC	CLR457	414.5	24.9	31	100.3	-1.6
X-2026	PDAC	CLR457	447.6	25.2	34	116.3	-0.4
X-2026	PDAC	CLR457	534.7	25.9	38	158.4	2.4
X-2026	PDAC	CLR457	634.5	25.6	42	206.7	1.2
X-2026	PDAC	CLR457	763.4	23.8	45	269	-5.9
X-2026	PDAC	CLR457	858.5	26	48	314.9	2.8
X-2026	PDAC	CLR457	1004.1	25.9	52	385.3	2.4
X-2026	PDAC	HDM201	245.7	31.5	0	0	0
X-2026	PDAC	HDM201	318.5	32	3	29.6	1.6
X-2026	PDAC	HDM201	366.3	32.2	6	49.1	2.2
X-2026	PDAC	HDM201	503.2	31.4	10	104.8	-0.3
X-2026	PDAC	HDM201	585.6	31.6	13	138.3	0.3
X-2026	PDAC	HDM201	618	32.7	18	151.5	3.8
X-2026	PDAC	HDM201	765.2	31.2	21	211.4	-1
X-2026	PDAC	HDM201	1080.8	31.8	24	339.9	1
X-2026	PDAC	HDM201	1286.9	33.4	27	423.8	6
X-2026	PDAC	HDM201	1390.2	32.4	31	465.8	2.9
X-2026	PDAC	figitumumab" + binimetinib	236.3	30.5	0	0	0
X-2026	PDAC	figitumumab" + binimetinib	373	29.4	2	57.9	-3.6
X-2026	PDAC	figitumumab" + binimetinib	379.8	28.9	6	60.7	-5.2
X-2026	PDAC	figitumumab" + binimetinib	293.9	28.2	9	24.4	-7.5
X-2026	PDAC	figitumumab" + binimetinib	299.7	28.8	12	26.8	-5.6
X-2026	PDAC	figitumumab" + binimetinib	391.2	29	15	65.6	-4.9
X-2026	PDAC	figitumumab" + binimetinib	346.2	28.9	20	46.5	-5.2
X-2026	PDAC	figitumumab" + binimetinib	412.1	29.4	26	74.4	-3.6
X-2026	PDAC	figitumumab" + binimetinib	426	29.4	30	80.3	-3.6
X-2026	PDAC	figitumumab" + binimetinib	534.5	28.4	33	126.2	-6.9
X-2026	PDAC	gemcitabine-50mpk	249.8	27	0	0	0
X-2026	PDAC	gemcitabine-50mpk	292.7	26.1	4	17.2	-3.3
X-2026	PDAC	gemcitabine-50mpk	233.6	26.4	7	-6.5	-2.2
X-2026	PDAC	gemcitabine-50mpk	148.7	26.8	12	-40.5	-0.7
X-2026	PDAC	gemcitabine-50mpk	158.5	26.7	15	-36.5	-1.1
X-2026	PDAC	gemcitabine-50mpk	133.9	25.2	18	-46.4	-6.7
X-2026	PDAC	gemcitabine-50mpk	84.9	25.9	21	-66	-4.1
X-2026	PDAC	gemcitabine-50mpk	110.4	26.8	26	-55.8	-0.7
X-2026	PDAC	gemcitabine-50mpk	56.2	28	29	-77.5	3.7
X-2026	PDAC	gemcitabine-50mpk	38.9	27.7	32	-84.4	2.6
X-2026	PDAC	gemcitabine-50mpk	31.8	27	35	-87.3	0
X-2026	PDAC	gemcitabine-50mpk	36.6	27	39	-85.3	0
X-2026	PDAC	gemcitabine-50mpk	31	25.7	43	-87.6	-4.8
X-2026	PDAC	gemcitabine-50mpk	46.2	26.3	47	-81.5	-2.6
X-2026	PDAC	gemcitabine-50mpk	39.2	28.9	53	-84.3	7
X-2026	PDAC	gemcitabine-50mpk	29.4	28.2	56	-88.2	4.4
X-2026	PDAC	gemcitabine-50mpk	11.7	26.9	61	-95.3	-0.4
X-2026	PDAC	gemcitabine-50mpk	19.8	28.8	64	-92.1	6.7
X-2026	PDAC	gemcitabine-50mpk	25.4	26.9	68	-89.8	-0.4
X-2026	PDAC	gemcitabine-50mpk	0	27.4	71	-100	1.5
X-2026	PDAC	gemcitabine-50mpk	0	28.1	75	-100	4.1
X-2026	PDAC	gemcitabine-50mpk	0	28.9	78	-100	7
X-2026	PDAC	gemcitabine-50mpk	0	29	82	-100	7.4
X-2026	PDAC	gemcitabine-50mpk	0	28.8	85	-100	6.7
X-2026	PDAC	gemcitabine-50mpk	0	27	88	-100	0
X-2026	PDAC	INC424 + binimetinib	244.5	23.6	0	0	0
X-2026	PDAC	INC424 + binimetinib	244.8	24.3	4	0.1	3
X-2026	PDAC	INC424 + binimetinib	344.2	25	7	40.8	5.9
X-2026	PDAC	INC424 + binimetinib	341.7	25.5	11	39.8	8.1
X-2026	PDAC	INC424 + binimetinib	355.9	24.6	14	45.6	4.2
X-2026	PDAC	INC424 + binimetinib	419	25.2	18	71.4	6.8
X-2026	PDAC	INC424 + binimetinib	495	25.6	21	102.5	8.5
X-2026	PDAC	INC424 + binimetinib	394	25.8	25	61.1	9.3
X-2026	PDAC	INC424 + binimetinib	382.6	27	28	56.5	14.4
X-2026	PDAC	INC424 + binimetinib	331.2	26	31	35.5	10.2
X-2026	PDAC	INC424 + binimetinib	401.9	26.5	34	64.4	12.3
X-2026	PDAC	INC424 + binimetinib	517.9	25	39	111.8	5.9
X-2026	PDAC	INC424 + binimetinib	386.9	24.1	42	58.2	2.1
X-2026	PDAC	INC424 + binimetinib	353	25	46	44.4	5.9
X-2026	PDAC	INC424 + binimetinib	390.5	25.2	49	59.7	6.8
X-2026	PDAC	INC424 + binimetinib	312.7	25.5	52	27.9	8.1
X-2026	PDAC	INC424 + binimetinib	373.7	25.9	56	52.8	9.7
X-2026	PDAC	INC424 + binimetinib	494.8	25.4	59	102.4	7.6
X-2026	PDAC	INC424 + binimetinib	524.2	25.3	62	114.4	7.2
X-2026	PDAC	INC424 + binimetinib	471.1	25.1	66	92.7	6.4
X-2026	PDAC	INC424 + binimetinib	536.5	25.5	70	119.4	8.1
X-2026	PDAC	INC424 + binimetinib	523.8	26.1	74	114.2	10.6
X-2026	PDAC	INC424 + binimetinib	521.8	25.6	77	113.4	8.5
X-2026	PDAC	INC424 + binimetinib	537.6	25.7	80	119.9	8.9
X-2026	PDAC	INC424 + binimetinib	526	26	84	115.1	10.2
X-2026	PDAC	INC424	248.2	27.1	0	0	0
X-2026	PDAC	INC424	268.2	26.3	4	8.1	-3
X-2026	PDAC	INC424	312.9	27	7	26.1	-0.4
X-2026	PDAC	INC424	334.1	26.7	11	34.6	-1.5
X-2026	PDAC	INC424	408.3	27.1	15	64.5	0
X-2026	PDAC	INC424	467	28.3	18	88.2	4.4
X-2026	PDAC	INC424	547.4	28.1	21	120.5	3.7
X-2026	PDAC	INC424	593.9	27.9	25	139.3	3
X-2026	PDAC	INC424	603.8	28.2	28	143.3	4.1
X-2026	PDAC	INC424	688.7	27.3	32	177.5	0.7
X-2026	PDAC	INC424	716.8	27	35	188.8	-0.4
X-2026	PDAC	INC424	745.7	27.2	39	200.4	0.4
X-2026	PDAC	INC424	771.5	27.9	42	210.8	3
X-2026	PDAC	INC424	839.5	27.9	47	238.2	3
X-2026	PDAC	INC424	862.5	27.6	50	247.5	1.8
X-2026	PDAC	INC424	1018.3	28.1	53	310.3	3.7
X-2026	PDAC	WNT974	209.4	24.2	0	0	0
X-2026	PDAC	WNT974	212.4	24	1	1.4	-0.8
X-2026	PDAC	WNT974	245.8	23.3	5	17.4	-3.7
X-2026	PDAC	WNT974	331.4	23	9	58.3	-5
X-2026	PDAC	WNT974	284.3	22.9	12	35.8	-5.4
X-2026	PDAC	WNT974	395.7	22.5	15	89	-7
X-2026	PDAC	WNT974	456.5	24.2	19	118	0
X-2026	PDAC	WNT974	576	23.4	22	175.1	-3.3
X-2026	PDAC	WNT974	637.6	24	27	204.5	-0.8
X-2026	PDAC	WNT974	737.6	24	30	252.2	-0.8
X-2026	PDAC	LKA136	250	24.1	0	0	0
X-2026	PDAC	LKA136	287.8	23.5	2	15.1	-2.5
X-2026	PDAC	LKA136	417	24.2	5	66.8	0.4
X-2026	PDAC	LKA136	599.4	25	8	139.8	3.7
X-2026	PDAC	LKA136	927.6	25.7	13	271	6.6
X-2026	PDAC	LKA136	1099	25.1	16	339.6	4.1
X-2026	PDAC	LKA136	1290.9	24.9	19	416.4	3.3
X-2026	PDAC	LKA136	1411	25.3	22	464.4	5
X-2026	PDAC	binimetinib	268.2	26.2	0	0	0
X-2026	PDAC	binimetinib	296.7	25.7	4	10.6	-1.9
X-2026	PDAC	binimetinib	332.3	26.3	7	23.9	0.4
X-2026	PDAC	binimetinib	290	26.8	11	8.1	2.3
X-2026	PDAC	binimetinib	502.7	26.6	14	87.4	1.5
X-2026	PDAC	binimetinib	320	25.8	18	19.3	-1.5
X-2026	PDAC	binimetinib	279.8	26.1	20	4.3	-0.4
X-2026	PDAC	binimetinib	472.7	25.5	25	76.2	-2.7
X-2026	PDAC	binimetinib	273	25.7	27	1.8	-1.9
X-2026	PDAC	binimetinib	271.3	26.2	32	1.2	0
X-2026	PDAC	binimetinib	255.1	26.1	35	-4.9	-0.4
X-2026	PDAC	binimetinib	354.4	26	39	32.1	-0.8
X-2026	PDAC	binimetinib	408.2	25.7	42	52.2	-1.9
X-2026	PDAC	binimetinib	355.5	26.4	46	32.6	0.8
X-2026	PDAC	binimetinib	398.9	27.1	49	48.7	3.4
X-2026	PDAC	binimetinib	299.2	28.4	53	11.6	8.4
X-2026	PDAC	binimetinib	262.5	27.8	56	-2.1	6.1
X-2026	PDAC	binimetinib	367.3	27.6	60	37	5.3
X-2026	PDAC	binimetinib	286.9	28.3	63	7	8
X-2026	PDAC	binimetinib	455.9	27.9	67	70	6.5
X-2026	PDAC	binimetinib	431.5	28.3	74	60.9	8
X-2026	PDAC	binimetinib	423.5	28.1	77	57.9	7.3
X-2026	PDAC	binimetinib	386.6	28.5	81	44.1	8.8
X-2026	PDAC	binimetinib	334.9	28.1	91	24.9	7.3
X-2026	PDAC	binimetinib	323.2	28.1	95	20.5	7.3
X-2026	PDAC	binimetinib	301.8	28.1	98	12.5	7.3
X-2026	PDAC	binimetinib	395.5	26.8	102	47.5	2.3
X-2026	PDAC	trametinib	271	24.4	0	0	0
X-2026	PDAC	trametinib	316	24.4	4	16.6	0
X-2026	PDAC	trametinib	341.2	24.2	7	25.9	-0.8
X-2026	PDAC	trametinib	262.2	23.6	12	-3.2	-3.3
X-2026	PDAC	trametinib	303.2	22.7	14	11.9	-7
X-2026	PDAC	trametinib	281	25.1	18	3.7	2.9
X-2026	PDAC	trametinib	436.8	25.5	21	61.2	4.5
X-2026	PDAC	trametinib	508.8	24.6	25	87.7	0.8
X-2026	PDAC	trametinib	418	24.1	28	54.2	-1.2
X-2026	PDAC	trametinib	472.3	24.9	32	74.3	2
X-2026	PDAC	trametinib	450.9	24.3	35	66.4	-0.4
X-2026	PDAC	trametinib	364.5	24.5	40	34.5	0.4
X-2026	PDAC	trametinib	500.3	24.9	45	84.6	2
X-2026	PDAC	trametinib	484	24.4	48	78.6	0
X-2026	PDAC	trametinib	558.2	25.2	52	106	3.3
X-2026	PDAC	untreated	269.3	24.5	0	0	0
X-2026	PDAC	untreated	367.8	23.6	4	36.6	-3.7
X-2026	PDAC	untreated	491.2	24.1	7	82.4	-1.6
X-2026	PDAC	untreated	490.8	24	13	82.3	-2
X-2026	PDAC	untreated	546.2	24.4	16	102.8	-0.4
X-2026	PDAC	untreated	830.1	25.1	18	208.2	2.4
X-2026	PDAC	untreated	1166.4	NA	21	333.1	2.4
X-2026	PDAC	untreated	1577.8	25.6	25	485.9	4.5
X-2026	PDAC	untreated	1661.4	25.4	28	516.9	3.7
X-2042	NSCLC	BGJ398	232.9	26.9	0	0	0
X-2042	NSCLC	BGJ398	259.9	27.6	6	11.6	2.6
X-2042	NSCLC	BGJ398	285.5	27.2	8	22.6	1.1
X-2042	NSCLC	BGJ398	429.6	27.6	12	84.5	2.6
X-2042	NSCLC	BGJ398	305.4	27.8	15	31.1	3.3
X-2042	NSCLC	BGJ398	500.2	28.1	19	114.8	4.5
X-2042	NSCLC	BGJ398	732.9	26.9	26	214.7	0
X-2042	NSCLC	BKM120 + binimetinib	167.5	23.7	0	0	0
X-2042	NSCLC	BKM120 + binimetinib	113.6	23	3	-32.2	-3
X-2042	NSCLC	BKM120 + binimetinib	97.9	23.2	7	-41.6	-2.1
X-2042	NSCLC	BKM120 + binimetinib	94.4	22.9	10	-43.6	-3.4
X-2042	NSCLC	BKM120 + binimetinib	106.9	24.3	15	-36.2	2.5
X-2042	NSCLC	BKM120 + binimetinib	88.4	24.4	22	-47.2	3
X-2042	NSCLC	BKM120 + binimetinib	116.1	23.9	24	-30.7	0.8
X-2042	NSCLC	BKM120 + binimetinib	102.7	24.7	28	-38.7	4.2
X-2042	NSCLC	BKM120 + binimetinib	114.3	23.8	31	-31.8	0.4
X-2042	NSCLC	BKM120 + binimetinib	76.4	24.3	35	-54.4	2.5
X-2042	NSCLC	BKM120 + binimetinib	124	23.3	42	-26	-1.7
X-2042	NSCLC	BKM120 + binimetinib	103.2	23.4	45	-38.4	-1.3
X-2042	NSCLC	BKM120 + binimetinib	97.4	23.4	49	-41.9	-1.3
X-2042	NSCLC	BKM120	166.6	24.2	0	0	0
X-2042	NSCLC	BKM120	163	25.2	7	-2.2	4.1
X-2042	NSCLC	BKM120	108.7	24.6	10	-34.8	1.7
X-2042	NSCLC	BKM120	154.3	25.8	16	-7.4	6.6
X-2042	NSCLC	BKM120	171	26.7	21	2.6	10.3
X-2042	NSCLC	BKM120	227.6	26.8	29	36.6	10.7
X-2042	NSCLC	BKM120	261.9	27	35	57.2	11.6
X-2042	NSCLC	BKM120	223.3	26.1	42	34	7.9
X-2042	NSCLC	BKM120	233.1	26.1	45	39.9	7.9
X-2042	NSCLC	BKM120	227.2	27.3	48	36.4	12.8
X-2042	NSCLC	BKM120	250.8	27.6	56	50.5	14
X-2042	NSCLC	BKM120	173.1	28.3	59	3.9	16.9
X-2042	NSCLC	BKM120	218.4	28.4	63	31.1	17.4
X-2042	NSCLC	BKM120	190.2	27.6	66	14.2	14
X-2042	NSCLC	BKM120	189	28.8	71	13.4	19
X-2042	NSCLC	BKM120	198.9	28.7	78	19.4	18.6
X-2042	NSCLC	BKM120	209.1	28.2	80	25.5	16.5
X-2042	NSCLC	BKM120	197.9	28.6	84	18.8	18.2
X-2042	NSCLC	BKM120	195.1	27.6	87	17.1	14
X-2042	NSCLC	BKM120	190.5	28.9	91	14.3	19.4
X-2042	NSCLC	BKM120	211.6	28.3	98	27	16.9
X-2042	NSCLC	BKM120	189.8	28.5	101	13.9	17.8
X-2042	NSCLC	BKM120	165.4	28.7	105	-0.7	18.6
X-2042	NSCLC	BYL719 + LJM716	160.8	23.6	0	0	0
X-2042	NSCLC	BYL719 + LJM716	165	23.9	3	2.6	1.3
X-2042	NSCLC	BYL719 + LJM716	130.1	23.2	7	-19.1	-1.7
X-2042	NSCLC	BYL719 + LJM716	166.2	22.4	10	3.4	-5.1
X-2042	NSCLC	BYL719 + LJM716	167.4	25.4	15	4.1	7.6
X-2042	NSCLC	BYL719 + LJM716	207.1	25.5	22	28.8	8.1
X-2042	NSCLC	BYL719 + LJM716	234.9	24.7	28	46.1	4.7
X-2042	NSCLC	BYL719 + LJM716	180.9	24.3	31	12.5	3
X-2042	NSCLC	BYL719 + LJM716	247.6	24.9	35	54	5.5
X-2042	NSCLC	BYL719 + LJM716	302.1	22.5	45	87.9	-4.7
X-2042	NSCLC	BYL719 + LJM716	365	23.2	49	127	-1.7
X-2042	NSCLC	BYL719 + LJM716	380	22.8	52	136.3	-3.4
X-2042	NSCLC	BYL719 + LJM716	410.9	23	59	155.5	-2.5
X-2042	NSCLC	BYL719 + LJM716	325.8	23.5	64	102.6	-0.4
X-2042	NSCLC	BYL719 + LJM716	388.3	23.9	71	141.5	1.3
X-2042	NSCLC	BYL719 + LJM716	518.8	23	78	222.6	-2.5
X-2042	NSCLC	BYL719 + LGH447	133.8	19.7	0	0	0
X-2042	NSCLC	BYL719 + LGH447	109.7	18.9	3	-18	-4.1
X-2042	NSCLC	BYL719 + LGH447	111.7	19.3	7	-16.5	-2
X-2042	NSCLC	BYL719 + LGH447	117.2	19.7	10	-12.4	0
X-2042	NSCLC	BYL719 + LGH447	99.7	20.3	15	-25.5	3
X-2042	NSCLC	BYL719 + LGH447	136.6	20.5	22	2.1	4.1
X-2042	NSCLC	BYL719 + LGH447	144.8	21.1	24	8.2	7.1
X-2042	NSCLC	BYL719 + LGH447	169.6	21.4	28	26.8	8.6
X-2042	NSCLC	BYL719 + LGH447	209.7	20.7	31	56.7	5.1
X-2042	NSCLC	BYL719 + LGH447	233.7	21.3	35	74.7	8.1
X-2042	NSCLC	BYL719 + LGH447	291.5	20.2	45	117.9	2.5
X-2042	NSCLC	BYL719 + LGH447	311	21	49	132.4	6.6
X-2042	NSCLC	BYL719 + LGH447	392.7	21.1	52	193.5	7.1
X-2042	NSCLC	BYL719 + LGH447	543.6	21.3	59	306.3	8.1
X-2042	NSCLC	BYL719 + LGH447	546.1	21.8	64	308.1	10.7
X-2042	NSCLC	BYL719 + LGH447	617.7	22.1	71	361.7	12.2
X-2042	NSCLC	BYL719	119.4	24.9	0	0	0
X-2042	NSCLC	BYL719	103.7	24	1	-13.1	-3.6
X-2042	NSCLC	BYL719	84	24.4	5	-29.6	-2
X-2042	NSCLC	BYL719	91.2	26	12	-23.6	4.4
X-2042	NSCLC	BYL719	92.3	24.7	15	-22.7	-0.8
X-2042	NSCLC	BYL719	122.9	25.9	21	2.9	4
X-2042	NSCLC	BYL719	126	26	26	5.5	4.4
X-2042	NSCLC	BYL719	122.8	25.7	34	2.8	3.2
X-2042	NSCLC	BYL719	147.7	26.6	40	23.7	6.8
X-2042	NSCLC	BYL719	125.3	25.6	47	4.9	2.8
X-2042	NSCLC	BYL719	118.9	26.2	50	-0.4	5.2
X-2042	NSCLC	BYL719	135.7	25.9	53	13.7	4
X-2042	NSCLC	BYL719	135.4	26.1	61	13.4	4.8
X-2042	NSCLC	BYL719	143.3	26.9	64	20	8
X-2042	NSCLC	BYL719	191.4	26.8	68	60.3	7.6
X-2042	NSCLC	BYL719	164.1	25.8	71	37.4	3.6
X-2042	NSCLC	BYL719	233.9	28	76	95.9	12.4
X-2042	NSCLC	BYL719	223	27.3	83	86.8	9.6
X-2042	NSCLC	BYL719	212	26.5	85	77.6	6.4
X-2042	NSCLC	BYL719	177.1	27.3	89	48.3	9.6
X-2042	NSCLC	BYL719	260.1	26.8	92	117.8	7.6
X-2042	NSCLC	BYL719	241.5	27.5	96	102.3	10.4
X-2042	NSCLC	BYL719	222.9	25.4	103	86.7	2
X-2042	NSCLC	BYL719	268	25.4	106	124.5	2
X-2042	NSCLC	BYL719	258.2	25.5	110	116.2	2.4
X-2042	NSCLC	CGM097	140.6	23.8	0	0	0
X-2042	NSCLC	CGM097	155.6	23.9	4	10.7	0.4
X-2042	NSCLC	CGM097	150.1	24.8	7	6.8	4.2
X-2042	NSCLC	CGM097	227.2	25.8	13	61.6	8.4
X-2042	NSCLC	CGM097	248	25.9	18	76.4	8.8
X-2042	NSCLC	CGM097	318.5	25.8	26	126.5	8.4
X-2042	NSCLC	CGM097	319.9	25.5	32	127.5	7.1
X-2042	NSCLC	CGM097	369.1	26.2	39	162.5	10.1
X-2042	NSCLC	CGM097	406	27.1	42	188.8	13.9
X-2042	NSCLC	CGM097	336.9	27.2	45	139.6	14.3
X-2042	NSCLC	CGM097	477.9	27.8	53	239.9	16.8
X-2042	NSCLC	CGM097	429.1	28.3	56	205.2	18.9
X-2042	NSCLC	CGM097	552.4	28.2	60	292.9	18.5
X-2042	NSCLC	CGM097	499.7	27.7	63	255.4	16.4
X-2042	NSCLC	CGM097	556	28.8	68	295.4	21
X-2042	NSCLC	CGM097	496	28.8	75	252.8	21
X-2042	NSCLC	CGM097	594.9	28.1	77	323.1	18.1
X-2042	NSCLC	CGM097	510.6	28.9	81	263.2	21.4
X-2042	NSCLC	CGM097	641.5	27.5	84	356.3	15.5
X-2042	NSCLC	CGM097	642.9	29.1	88	357.3	22.3
X-2042	NSCLC	CKX620	171.8	25.2	0	0	0
X-2042	NSCLC	CKX620	137.9	24.9	4	-19.7	-1.2
X-2042	NSCLC	CKX620	109.3	25.1	7	-36.4	-0.4
X-2042	NSCLC	CKX620	129.6	25.2	13	-24.6	0
X-2042	NSCLC	CKX620	84.6	26.2	18	-50.8	4
X-2042	NSCLC	CKX620	94.8	25.7	26	-44.8	2
X-2042	NSCLC	CKX620	106.9	26	32	-37.8	3.2
X-2042	NSCLC	CKX620	104	25.7	39	-39.5	2
X-2042	NSCLC	CKX620	84.2	25.5	42	-51	1.2
X-2042	NSCLC	CKX620	68.9	24.5	45	-59.9	-2.8
X-2042	NSCLC	CKX620	107.2	24.7	53	-37.6	-2
X-2042	NSCLC	CKX620	73.8	23.8	56	-57	-5.6
X-2042	NSCLC	CKX620	91.1	22.7	60	-47	-9.9
X-2042	NSCLC	CLR457	195.4	21.2	0	0	0
X-2042	NSCLC	CLR457	123.2	22.7	5	-36.9	7.1
X-2042	NSCLC	CLR457	175.8	23.8	13	-10	12.3
X-2042	NSCLC	CLR457	140.1	23.7	19	-28.3	11.8
X-2042	NSCLC	CLR457	174.6	23.1	26	-10.6	9
X-2042	NSCLC	CLR457	171.4	22.7	29	-12.3	7.1
X-2042	NSCLC	CLR457	161.3	23.6	32	-17.5	11.3
X-2042	NSCLC	CLR457	229.2	24.7	40	17.3	16.5
X-2042	NSCLC	CLR457	202.3	25.7	43	3.5	21.2
X-2042	NSCLC	CLR457	186.4	24.9	47	-4.6	17.5
X-2042	NSCLC	CLR457	228.8	24.3	50	17.1	14.6
X-2042	NSCLC	CLR457	246.6	24.7	55	26.2	16.5
X-2042	NSCLC	CLR457	245.4	24	62	25.6	13.2
X-2042	NSCLC	CLR457	268	24	64	37.2	13.2
X-2042	NSCLC	CLR457	263.5	24.3	68	34.9	14.6
X-2042	NSCLC	CLR457	304.7	23.7	71	55.9	11.8
X-2042	NSCLC	CLR457	311.3	24.5	75	59.3	15.6
X-2042	NSCLC	CLR457	314.9	24.7	82	61.2	16.5
X-2042	NSCLC	CLR457	361	24.5	85	84.7	15.6
X-2042	NSCLC	CLR457	350.2	24.1	92	79.2	13.7
X-2042	NSCLC	CLR457	397.8	24.5	99	103.6	15.6
X-2042	NSCLC	CLR457	441.4	25.1	104	125.9	18.4
X-2042	NSCLC	CLR457	505.4	25.6	111	158.6	20.8
X-2042	NSCLC	CLR457	413.2	25.4	118	111.5	19.8
X-2042	NSCLC	CLR457	529.4	25.3	120	170.9	19.3
X-2042	NSCLC	CLR457	549.2	24.9	124	181.1	17.5
X-2042	NSCLC	HDM201	123.5	25.2	0	0	0
X-2042	NSCLC	HDM201	190.7	24.1	7	54.4	-4.4
X-2042	NSCLC	HDM201	235.3	23.8	10	90.5	-5.6
X-2042	NSCLC	HDM201	280.6	24.9	16	127.2	-1.2
X-2042	NSCLC	HDM201	343.9	24.3	21	178.5	-3.6
X-2042	NSCLC	HDM201	431.2	24.5	29	249.1	-2.8
X-2042	NSCLC	HDM201	384	23.3	35	210.9	-7.5
X-2042	NSCLC	HDM201	431.6	20	42	249.5	-20.6
X-2042	NSCLC	cetuximab	161.9	23.2	0	0	0
X-2042	NSCLC	cetuximab	250.1	23.6	7	54.5	1.7
X-2042	NSCLC	cetuximab	301.5	23.9	10	86.2	3
X-2042	NSCLC	cetuximab	360.5	24.3	16	122.7	4.7
X-2042	NSCLC	cetuximab	473.9	25	21	192.7	7.8
X-2042	NSCLC	cetuximab	500	25.5	29	208.8	9.9
X-2042	NSCLC	cetuximab	513.6	25.7	35	217.2	10.8
X-2042	NSCLC	cetuximab	792.5	25.8	42	389.5	11.2
X-2042	NSCLC	erlotinib	152.1	25.6	0	0	0
X-2042	NSCLC	erlotinib	101.3	21.3	7	-33.4	-16.8
X-2042	NSCLC	erlotinib	95.2	18.9	15	-37.4	-26.2
X-2042	NSCLC	HSP990	229.8	27.6	0	0	0
X-2042	NSCLC	HSP990	196.1	27.6	4	-14.7	0
X-2042	NSCLC	HSP990	198.3	25.9	7	-13.7	-6.2
X-2042	NSCLC	HSP990	150.6	27.4	12	-34.5	-0.7
X-2042	NSCLC	HSP990	183.5	27.7	19	-20.1	0.4
X-2042	NSCLC	HSP990	181	27.2	21	-21.2	-1.4
X-2042	NSCLC	HSP990	186.8	28	25	-18.7	1.4
X-2042	NSCLC	HSP990	159.1	26.6	28	-30.8	-3.6
X-2042	NSCLC	HSP990	173.2	27.7	32	-24.6	0.4
X-2042	NSCLC	HSP990	177.9	27.6	39	-22.6	0
X-2042	NSCLC	HSP990	146.9	28.2	42	-36.1	2.2
X-2042	NSCLC	HSP990	150.2	28.8	46	-34.6	4.3
X-2042	NSCLC	HSP990	177.2	28.5	49	-22.9	3.3
X-2042	NSCLC	HSP990	149.2	28.7	56	-35.1	4
X-2042	NSCLC	HSP990	157	29.7	61	-31.7	7.6
X-2042	NSCLC	HSP990	138.3	29.5	68	-39.8	6.9
X-2042	NSCLC	HSP990	106.7	31	75	-53.6	12.3
X-2042	NSCLC	HSP990	109.4	30.2	77	-52.4	9.4
X-2042	NSCLC	HSP990	99.5	29	81	-56.7	5.1
X-2042	NSCLC	HSP990	95.3	28.6	84	-58.5	3.6
X-2042	NSCLC	HSP990	89.5	28.9	88	-61.1	4.7
X-2042	NSCLC	HSP990	82.4	30.6	94	-64.1	10.9
X-2042	NSCLC	HSP990	46.2	27.3	98	-79.9	-1.1
X-2042	NSCLC	HSP990	43	31.2	101	-81.3	13
X-2042	NSCLC	HSP990	61.4	27.2	105	-73.3	-1.4
X-2042	NSCLC	HSP990	40.2	23.1	108	-82.5	-16.3
X-2042	NSCLC	HSP990	43.8	21.1	110	-80.9	-23.6
X-2042	NSCLC	INC280	149.6	32.6	0	0	0
X-2042	NSCLC	INC280	193.3	32.1	5	29.2	-1.5
X-2042	NSCLC	INC280	172.5	33.1	13	15.3	1.5
X-2042	NSCLC	INC280	270.3	32.9	19	80.7	0.9
X-2042	NSCLC	INC280	195.6	33.4	29	30.7	2.5
X-2042	NSCLC	INC280	213.1	34.9	32	42.4	7.1
X-2042	NSCLC	INC280	232.1	33.8	40	55.1	3.7
X-2042	NSCLC	INC280	202.2	34.5	43	35.2	5.8
X-2042	NSCLC	INC280	293.5	34.9	47	96.2	7.1
X-2042	NSCLC	INC280	267.9	34.4	50	79.1	5.5
X-2042	NSCLC	INC280	219.4	33.9	55	46.7	4
X-2042	NSCLC	INC280	239.4	34.5	62	60	5.8
X-2042	NSCLC	INC280	270.6	34	64	80.9	4.3
X-2042	NSCLC	INC280	268.2	35	68	79.3	7.4
X-2042	NSCLC	INC280	321.5	34.4	71	114.9	5.5
X-2042	NSCLC	INC280	311.9	34.6	75	108.5	6.1
X-2042	NSCLC	INC280	270.1	32.9	82	80.5	0.9
X-2042	NSCLC	INC280	306.6	32.7	85	104.9	0.3
X-2042	NSCLC	INC280	266.5	32.5	89	78.1	-0.3
X-2042	NSCLC	INC280	303.7	32.1	92	103	-1.5
X-2042	NSCLC	INC280	303.8	32.6	99	103.1	0
X-2042	NSCLC	INC280	291.1	32.4	104	94.6	-0.6
X-2042	NSCLC	INC280	258.6	32.4	111	72.9	-0.6
X-2042	NSCLC	LCL161 + paclitaxel	276.5	29	0	0	0
X-2042	NSCLC	LCL161 + paclitaxel	218.1	27.2	7	-21.1	-6.2
X-2042	NSCLC	LCL161 + paclitaxel	192.8	27.6	10	-30.3	-4.8
X-2042	NSCLC	LCL161 + paclitaxel	163.1	27.5	14	-41	-5.2
X-2042	NSCLC	LCL161 + paclitaxel	142.8	28.3	17	-48.4	-2.4
X-2042	NSCLC	LCL161 + paclitaxel	172.2	28.4	24	-37.7	-2.1
X-2042	NSCLC	LCL161 + paclitaxel	173.1	29.4	29	-37.4	1.4
X-2042	NSCLC	LCL161 + paclitaxel	175.6	29.7	31	-36.5	2.4
X-2042	NSCLC	LCL161 + paclitaxel	121.2	28.1	36	-56.2	-3.1
X-2042	NSCLC	LCL161 + paclitaxel	69.5	27.8	43	-74.9	-4.1
X-2042	NSCLC	LCL161 + paclitaxel	106.3	28.3	45	-61.6	-2.4
X-2042	NSCLC	LCL161 + paclitaxel	64.4	26.9	49	-76.7	-7.2
X-2042	NSCLC	LCL161 + paclitaxel	82.8	27.1	52	-70.1	-6.6
X-2042	NSCLC	LCL161 + paclitaxel	85.3	26.3	56	-69.2	-9.3
X-2042	NSCLC	LCL161 + paclitaxel	58.1	27.9	62	-79	-3.8
X-2042	NSCLC	LCL161 + paclitaxel	45.1	25.9	66	-83.7	-10.7
X-2042	NSCLC	LCL161 + paclitaxel	58.6	27.2	69	-78.8	-6.2
X-2042	NSCLC	LCL161 + paclitaxel	63.7	25.7	73	-77	-11.4
X-2042	NSCLC	LCL161 + paclitaxel	48.6	28.8	76	-82.4	-0.7
X-2042	NSCLC	LCL161 + paclitaxel	38.6	28.4	85	-86	-2.1
X-2042	NSCLC	LCL161 + paclitaxel	49.3	29.2	91	-82.2	0.7
X-2042	NSCLC	LCL161 + paclitaxel	39.3	27.5	101	-85.8	-5.2
X-2042	NSCLC	LEE011	132.9	23.8	0	0	0
X-2042	NSCLC	LEE011	216.6	23.6	7	63	-0.8
X-2042	NSCLC	LEE011	258.5	23.6	10	94.5	-0.8
X-2042	NSCLC	LEE011	275.1	24.5	16	107	2.9
X-2042	NSCLC	LEE011	409.3	24.9	21	208	4.6
X-2042	NSCLC	LEE011	474	26.5	29	256.7	11.3
X-2042	NSCLC	LEE011	470.7	25.6	35	254.2	7.6
X-2042	NSCLC	LEE011	571.8	26.5	42	330.2	11.3
X-2042	NSCLC	LEE011	604.1	26.8	45	354.6	12.6
X-2042	NSCLC	LEE011	589.5	26.8	48	343.6	12.6
X-2042	NSCLC	LEE011	653.6	27	56	391.8	13.4
X-2042	NSCLC	LGH447	218.8	27.6	0	0	0
X-2042	NSCLC	LGH447	256.4	29.4	5	17.2	6.5
X-2042	NSCLC	LGH447	283	29.6	13	29.3	7.2
X-2042	NSCLC	LGH447	255.4	29.7	19	16.7	7.6
X-2042	NSCLC	LGH447	412.3	29.6	26	88.4	7.2
X-2042	NSCLC	LGH447	344.5	29.4	29	57.4	6.5
X-2042	NSCLC	LGH447	381.5	30.4	32	74.4	10.1
X-2042	NSCLC	LGH447	429.5	31	40	96.3	12.3
X-2042	NSCLC	LGH447	448	31.3	43	104.8	13.4
X-2042	NSCLC	LGH447	473.3	32.2	47	116.3	16.7
X-2042	NSCLC	LGH447	618.6	31.6	50	182.7	14.5
X-2042	NSCLC	LGH447	660.9	32	55	202.1	15.9
X-2042	NSCLC	LGH447	862.8	31.9	62	294.3	15.6
X-2042	NSCLC	LGH447	791.9	32.3	64	261.9	17
X-2042	NSCLC	LGH447	1052.9	33	68	381.2	19.6
X-2042	NSCLC	LLM871	126.5	23.6	0	0	0
X-2042	NSCLC	LLM871	118.4	24	7	-6.4	1.7
X-2042	NSCLC	LLM871	139.1	24	11	10	1.7
X-2042	NSCLC	LLM871	223.6	24.5	18	76.8	3.8
X-2042	NSCLC	LLM871	313.1	24.2	21	147.5	2.5
X-2042	NSCLC	LLM871	408.2	25.7	27	222.7	8.9
X-2042	NSCLC	LLM871	393.6	27.3	32	211.1	15.7
X-2042	NSCLC	LLM871	479.7	26.2	40	279.2	11
X-2042	NSCLC	LLM871	769.5	25.4	46	508.3	7.6
X-2042	NSCLC	binimetinib	169.7	20.5	29	0	0
X-2042	NSCLC	binimetinib	215.1	22.4	35	26.8	9.3
X-2042	NSCLC	paclitaxel	478.5	24.5	21	0	0
X-2042	NSCLC	paclitaxel	622.4	24.7	25	30.1	0.8
X-2042	NSCLC	untreated	180.8	25.6	0	0	0
X-2042	NSCLC	untreated	191.6	25.9	3	6	1.2
X-2042	NSCLC	untreated	231	26.7	7	27.8	4.3
X-2042	NSCLC	untreated	251.2	25.4	10	38.9	-0.8
X-2042	NSCLC	untreated	272.6	26.2	15	50.8	2.3
X-2042	NSCLC	untreated	277.8	27	22	53.7	5.5
X-2042	NSCLC	untreated	357.6	26.8	24	97.8	4.7
X-2042	NSCLC	untreated	387.4	27.4	28	114.3	7
X-2042	NSCLC	untreated	423.9	27.5	31	134.5	7.4
X-2042	NSCLC	untreated	437.7	27.6	35	142.1	7.8
X-2042	NSCLC	untreated	540.6	28.5	42	199	11.3
X-2042	NSCLC	untreated	572.4	28.1	45	216.6	9.8
X-2042	NSCLC	untreated	701.6	27.7	49	288.1	8.2
X-2042	NSCLC	LFW527 + binimetinib	143.73	29.6	0	0	0
X-2042	NSCLC	LFW527 + binimetinib	161.34	28.3	3	12.3	-4.4
X-2042	NSCLC	LFW527 + binimetinib	155.4	26.8	7	8.1	-9.5
X-2042	NSCLC	LFW527 + binimetinib	183.17	27.3	14	27.4	-7.8
X-2042	NSCLC	LFW527 + binimetinib	170.3	26.4	21	18.5	-10.8
X-2042	NSCLC	LFW527 + binimetinib	102.11	26.9	29	-29	-9.1
X-2042	NSCLC	LFW527 + binimetinib	97.9	28.1	31	-31.9	-5.1
X-2042	NSCLC	LFW527 + binimetinib	82.43	27	35	-42.6	-8.8
X-2042	NSCLC	LFW527 + binimetinib	60.63	27.3	38	-57.8	-7.8
X-2042	NSCLC	LFW527 + binimetinib	66.83	27.6	42	-53.5	-6.8
X-2042	NSCLC	LFW527 + binimetinib	54.56	26.8	45	-62	-9.5
X-2042	NSCLC	LFW527 + binimetinib	37.93	27.6	48	-73.6	-6.8
X-2042	NSCLC	LFW527 + binimetinib	34.68	26.9	52	-75.9	-9.1
X-2042	NSCLC	LFW527 + binimetinib	49.18	27.8	56	-65.8	-6.1
X-2042	NSCLC	LFW527 + binimetinib	26.39	26.8	59	-81.6	-9.5
X-2042	NSCLC	LFW527 + binimetinib	30.19	27.5	63	-79	-7.1
X-2042	NSCLC	LFW527 + binimetinib	19.97	26.8	66	-86.1	-9.5
X-2042	NSCLC	LFW527 + binimetinib	24.62	26.2	70	-82.9	-11.5
X-2042	NSCLC	LFW527 + binimetinib	0	27.4	73	-100	-7.4
X-2042	NSCLC	LFW527 + binimetinib	0	26.6	77	-100	-10.1
X-2042	NSCLC	LFW527 + binimetinib	0	25.7	80	-100	-13.2
X-2042	NSCLC	LFW527 + binimetinib	0	25	84	-100	-15.5
X-2042	NSCLC	LFW527 + binimetinib	7.13	27.5	87	-95	-7.1
X-2042	NSCLC	LFW527 + binimetinib	0	26.1	94	-100	-11.8
X-2042	NSCLC	LFW527 + binimetinib	0	25.9	98	-100	-12.5
X-2042	NSCLC	LFW527 + binimetinib	0	26.3	101	-100	-11.1
X-2042	NSCLC	LFW527 + binimetinib	0	26	108	-100	-12.2
X-2042	NSCLC	LFW527 + binimetinib	0	27.6	112	-100	-6.8
X-2042	NSCLC	LFW527 + binimetinib	0	25.8	119	-100	-12.8
X-2042	NSCLC	LFW527 + binimetinib	0	25.8	122	-100	-12.8
X-2042	NSCLC	LFW527 + binimetinib	0	26.1	126	-100	-11.8
X-2042	NSCLC	LFW527 + binimetinib	0	26.8	129	-100	-9.5
X-2042	NSCLC	LFW527 + binimetinib	0	26.1	136	-100	-11.8
X-2042	NSCLC	LFW527 + binimetinib	0	26.2	140	-100	-11.5
X-2042	NSCLC	LFW527 + binimetinib	0	26.2	143	-100	-11.5
X-2042	NSCLC	LFW527 + binimetinib	0	25.6	147	-100	-13.5
X-2042	NSCLC	LFW527 + binimetinib	0	26.2	150	-100	-11.5
X-2042	NSCLC	LFW527 + binimetinib	0	26.3	154	-100	-11.1
X-2042	NSCLC	LFW527 + binimetinib	0	26	157	-100	-12.2
X-2042	NSCLC	LFW527 + binimetinib	0	25.7	161	-100	-13.2
X-2042	NSCLC	LFW527 + binimetinib	0	25.6	164	-100	-13.5
X-2042	NSCLC	LFW527 + binimetinib	0	25.4	168	-100	-14.2
X-2042	NSCLC	LFW527 + binimetinib	0	27	171	-100	-8.8
X-2042	NSCLC	LFW527 + binimetinib	0	26.4	175	-100	-10.8
X-2042	NSCLC	LFW527 + binimetinib	0	25.5	178	-100	-13.9
X-2042	NSCLC	LFW527 + binimetinib	0	26.5	182	-100	-10.5
X-2043	PDAC	abraxane	230.7	26.6	0	0	0
X-2043	PDAC	abraxane	411.2	26.6	5	78.2	0
X-2043	PDAC	abraxane	634.8	26.6	8	175.2	0
X-2043	PDAC	abraxane	617.5	27.8	12	167.7	4.5
X-2043	PDAC	abraxane	728.5	27.2	15	215.8	2.3
X-2043	PDAC	abraxane	893.5	28.3	19	287.3	6.4
X-2043	PDAC	abraxane	977.7	26.6	22	323.8	0
X-2043	PDAC	BKM120 + binimetinib	202.9	25.7	0	0	0
X-2043	PDAC	BKM120 + binimetinib	194.5	24	3	-4.1	-6.6
X-2043	PDAC	BKM120 + binimetinib	168.6	22.9	6	-16.9	-10.9
X-2043	PDAC	BKM120 + binimetinib	233.6	23.8	8	15.1	-7.4
X-2043	PDAC	BKM120 + binimetinib	264.6	25	9	30.4	-2.7
X-2043	PDAC	BKM120 + binimetinib	214.4	23.9	13	5.7	-7
X-2043	PDAC	BKM120 + binimetinib	280.9	23.4	16	38.4	-8.9
X-2043	PDAC	BKM120 + binimetinib	282.6	23.4	20	39.3	-8.9
X-2043	PDAC	BKM120 + binimetinib	167	24.4	22	-17.7	-5.1
X-2043	PDAC	BKM120 + binimetinib	299.7	25.1	27	47.7	-2.3
X-2043	PDAC	BKM120 + binimetinib	300.8	25.3	30	48.3	-1.6
X-2043	PDAC	BKM120 + binimetinib	253.4	24.7	35	24.9	-3.9
X-2043	PDAC	BKM120 + binimetinib	293.4	25.4	37	44.6	-1.2
X-2043	PDAC	BKM120 + binimetinib	238.2	25.1	42	17.4	-2.3
X-2043	PDAC	BKM120 + binimetinib	350	25	45	72.5	-2.7
X-2043	PDAC	BKM120 + binimetinib	353.3	25.2	48	74.1	-1.9
X-2043	PDAC	BKM120 + binimetinib	444.9	25	52	119.3	-2.7
X-2043	PDAC	BKM120 + binimetinib	467.2	24.7	57	130.3	-3.9
X-2043	PDAC	BKM120 + binimetinib	365.2	24.6	59	80	-4.3
X-2043	PDAC	BKM120 + binimetinib	412.6	23.8	62	103.4	-7.4
X-2043	PDAC	BKM120 + binimetinib	361.1	25.5	64	78	-0.8
X-2043	PDAC	BKM120 + binimetinib	340.4	24.9	66	67.8	-3.1
X-2043	PDAC	BKM120 + binimetinib	315.4	23.5	70	55.4	-8.6
X-2043	PDAC	BKM120 + binimetinib	428.8	24.4	72	111.3	-5.1
X-2043	PDAC	BKM120 + binimetinib	457.6	24.1	77	125.5	-6.2
X-2043	PDAC	BKM120 + binimetinib	458.9	24.6	80	126.2	-4.3
X-2043	PDAC	BKM120 + binimetinib	453.1	24.3	84	123.3	-5.4
X-2043	PDAC	BKM120 + binimetinib	483.9	23.8	87	138.5	-7.4
X-2043	PDAC	BKM120 + binimetinib	446.8	24.1	91	120.2	-6.2
X-2043	PDAC	BKM120 + binimetinib	498.2	23.7	94	145.5	-7.8
X-2043	PDAC	BKM120 + binimetinib	461.3	23.6	98	127.4	-8.2
X-2043	PDAC	BKM120 + binimetinib	385.2	24	101	89.8	-6.6
X-2043	PDAC	BKM120 + binimetinib	524.1	23.6	105	158.3	-8.2
X-2043	PDAC	BKM120 + binimetinib	466	24.1	108	129.7	-6.2
X-2043	PDAC	BKM120 + binimetinib	674.2	23.7	112	232.3	-7.8
X-2043	PDAC	BKM120 + binimetinib	480.1	23.1	115	136.6	-10.1
X-2043	PDAC	BKM120 + binimetinib	595.2	24	119	193.3	-6.6
X-2043	PDAC	BKM120 + binimetinib	726.8	24.1	122	258.2	-6.2
X-2043	PDAC	BKM120 + binimetinib	438.3	23	126	116	-10.5
X-2043	PDAC	BKM120 + binimetinib	541.3	20.6	132	166.8	-19.8
X-2043	PDAC	BKM120 + LDE225	205.2	25.1	0	0	0
X-2043	PDAC	BKM120 + LDE225	222.3	26.3	1	8.3	4.8
X-2043	PDAC	BKM120 + LDE225	247.1	22.9	5	20.4	-8.8
X-2043	PDAC	BKM120 + LDE225	318	23.8	7	55	-5.2
X-2043	PDAC	BKM120 + LDE225	447.1	23.6	12	117.9	-6
X-2043	PDAC	BKM120 + LDE225	421.6	24.4	14	105.5	-2.8
X-2043	PDAC	BKM120 + LDE225	471.2	23.6	19	129.6	-6
X-2043	PDAC	BKM120 + LDE225	568.2	22.3	22	176.9	-11.2
X-2043	PDAC	BKM120 + LDE225	640.3	22	26	212	-12.4
X-2043	PDAC	BKM120 + LDE225	681.9	23	29	232.3	-8.4
X-2043	PDAC	BKM120	256	25.3	0	0	0
X-2043	PDAC	BKM120	298.8	24.8	2	16.7	-2
X-2043	PDAC	BKM120	429.6	22.2	6	67.8	-12.3
X-2043	PDAC	BKM120	443.8	22.5	9	73.4	-11.1
X-2043	PDAC	BKM120	607	23.3	13	137.1	-7.9
X-2043	PDAC	BKM120	750.2	22.5	16	193	-11.1
X-2043	PDAC	BKM120	787.8	22.2	20	207.7	-12.3
X-2043	PDAC	BKM120	907.7	21.7	23	254.6	-14.2
X-2043	PDAC	BKM120	1099.5	21.7	27	329.5	-14.2
X-2043	PDAC	BYL719	242.4	27.7	0	0	0
X-2043	PDAC	BYL719	298	27.2	2	22.9	-1.8
X-2043	PDAC	BYL719	318.8	26.3	6	31.5	-5.1
X-2043	PDAC	BYL719	353.1	25.6	9	45.7	-7.6
X-2043	PDAC	BYL719	375.9	25.7	13	55.1	-7.2
X-2043	PDAC	BYL719	381.4	25.3	16	57.3	-8.7
X-2043	PDAC	BYL719	427	26.3	20	76.2	-5.1
X-2043	PDAC	BYL719	471.9	25.8	27	94.7	-6.9
X-2043	PDAC	BYL719	560.8	26.7	30	131.4	-3.6
X-2043	PDAC	BYL719	636	26.6	34	162.4	-4
X-2043	PDAC	BYL719 + LJM716	223.8	27.4	0	0	0
X-2043	PDAC	BYL719 + LJM716	235.4	27.6	4	5.2	0.7
X-2043	PDAC	BYL719 + LJM716	264.3	26.7	7	18.1	-2.6
X-2043	PDAC	BYL719 + LJM716	272.5	27.2	11	21.8	-0.7
X-2043	PDAC	BYL719 + LJM716	292.9	27.7	14	30.9	1.1
X-2043	PDAC	BYL719 + LJM716	307.8	27.7	18	37.5	1.1
X-2043	PDAC	BYL719 + LJM716	323.1	27.5	21	44.4	0.4
X-2043	PDAC	BYL719 + LJM716	321.7	28.9	27	43.7	5.5
X-2043	PDAC	BYL719 + LJM716	321.4	28	32	43.6	2.2
X-2043	PDAC	BYL719 + LJM716	341.1	27.4	35	52.4	0
X-2043	PDAC	BYL719 + LJM716	360.1	27.4	39	60.9	0
X-2043	PDAC	BYL719 + LJM716	389.2	27.3	42	73.9	-0.4
X-2043	PDAC	BYL719 + LJM716	414.3	26.5	47	85.1	-3.3
X-2043	PDAC	BYL719 + LJM716	401.7	26.6	49	79.5	-2.9
X-2043	PDAC	BYL719 + LJM716	445.3	25.5	53	99	-6.9
X-2043	PDAC	BYL719 + LJM716	452.2	25.2	56	102.1	-8
X-2043	PDAC	BYL719 + LJM716	459	26.3	60	105.1	-4
X-2043	PDAC	BYL719 + LJM716	468.8	25.7	63	109.5	-6.2
X-2043	PDAC	BYL719 + LJM716	490.2	24.3	67	119	-11.3
X-2043	PDAC	BYL719 + LJM716	490.6	22.6	70	119.2	-17.5
X-2043	PDAC	CLR457	247.7	28.8	0	0	0
X-2043	PDAC	CLR457	297.8	27.9	6	20.2	-3.1
X-2043	PDAC	CLR457	311.3	28.9	9	25.7	0.3
X-2043	PDAC	CLR457	337.3	28.5	13	36.2	-1
X-2043	PDAC	CLR457	341.3	28.6	16	37.8	-0.7
X-2043	PDAC	CLR457	356.9	28.9	20	44.1	0.3
X-2043	PDAC	CLR457	365.9	28.4	23	47.7	-1.4
X-2043	PDAC	CLR457	375.6	28.4	27	51.6	-1.4
X-2043	PDAC	CLR457	401.3	27.2	30	62	-5.6
X-2043	PDAC	CLR457	445.6	29.4	36	79.9	2.1
X-2043	PDAC	CLR457	451.2	28.2	41	82.2	-2.1
X-2043	PDAC	CLR457	454.5	29	44	83.5	0.7
X-2043	PDAC	CLR457	465.2	28.8	48	87.8	0
X-2043	PDAC	CLR457	477.3	27.7	51	92.7	-3.8
X-2043	PDAC	CLR457	487.9	28.2	56	97	-2.1
X-2043	PDAC	CLR457	486.2	28	58	96.3	-2.8
X-2043	PDAC	CLR457	492.9	27.3	62	99	-5.2
X-2043	PDAC	CLR457	515.6	27.2	65	108.2	-5.6
X-2043	PDAC	CLR457	526.8	27.5	69	112.7	-4.5
X-2043	PDAC	CLR457	546.4	27.7	72	120.6	-3.8
X-2043	PDAC	CLR457	587.8	27.6	76	137.3	-4.2
X-2043	PDAC	CLR457	651.1	28	79	162.9	-2.8
X-2043	PDAC	HDM201	209.9	30.2	0	0	0
X-2043	PDAC	HDM201	233.8	27.2	3	11.4	-9.9
X-2043	PDAC	HDM201	291.9	28.3	7	39.1	-6.3
X-2043	PDAC	HDM201	306.4	27.9	10	46	-7.6
X-2043	PDAC	HDM201	331.7	27.1	14	58	-10.3
X-2043	PDAC	HDM201	332.5	27.5	16	58.4	-8.9
X-2043	PDAC	HDM201	348.2	28.6	21	65.9	-5.3
X-2043	PDAC	HDM201	391.8	27	24	86.7	-10.6
X-2043	PDAC	HDM201	393.4	26.8	28	87.4	-11.3
X-2043	PDAC	HDM201	416.8	27	31	98.6	-10.6
X-2043	PDAC	HDM201	432.2	27.8	35	105.9	-7.9
X-2043	PDAC	HDM201	435.5	28.3	38	107.5	-6.3
X-2043	PDAC	HDM201	460.4	27.8	42	119.3	-7.9
X-2043	PDAC	HDM201	518.5	27.5	45	147	-8.9
X-2043	PDAC	figitumumab" + binimetinib	269.9	25.7	0	0	0
X-2043	PDAC	figitumumab" + binimetinib	594.8	24.2	2	120.4	-5.8
X-2043	PDAC	figitumumab" + binimetinib	791.6	22.1	6	193.3	-14
X-2043	PDAC	figitumumab" + binimetinib	873.7	24.5	9	223.7	-4.7
X-2043	PDAC	figitumumab" + binimetinib	1144.7	23.1	13	324.1	-10.1
X-2043	PDAC	figitumumab" + binimetinib	1242.6	24.6	16	360.4	-4.3
X-2043	PDAC	figitumumab" + binimetinib	1291	23.2	20	378.3	-9.7
X-2043	PDAC	figitumumab" + binimetinib	1321.4	23.5	23	389.6	-8.6
X-2043	PDAC	figitumumab" + binimetinib	1587.4	24.2	27	488.1	-5.8
X-2043	PDAC	figitumumab"	213	26.8	0	0	0
X-2043	PDAC	figitumumab"	224	27.5	5	5.2	2.6
X-2043	PDAC	figitumumab"	432.7	28.8	12	103.1	7.5
X-2043	PDAC	figitumumab"	510	28.8	15	139.4	7.5
X-2043	PDAC	figitumumab"	610.8	28.4	19	186.8	6
X-2043	PDAC	figitumumab"	727.1	26.9	22	241.4	0.4
X-2043	PDAC	figitumumab"	891	28.3	26	318.3	5.6
X-2043	PDAC	figitumumab"	1013.3	28.2	29	375.7	5.2
X-2043	PDAC	gemcitabine-50mpk	214.3	24.7	0	0	0
X-2043	PDAC	gemcitabine-50mpk	247.4	23.2	4	15.4	-6.1
X-2043	PDAC	gemcitabine-50mpk	362.6	22.8	7	69.2	-7.7
X-2043	PDAC	gemcitabine-50mpk	235.6	21.6	10	9.9	-12.6
X-2043	PDAC	gemcitabine-50mpk	287.8	20.3	14	34.3	-17.8
X-2043	PDAC	INC424 + binimetinib	252.4	23	0	0	0
X-2043	PDAC	INC424 + binimetinib	215	22.8	5	-14.8	-0.9
X-2043	PDAC	INC424 + binimetinib	261.5	22.9	8	3.6	-0.4
X-2043	PDAC	INC424 + binimetinib	200.1	24.7	12	-20.7	7.4
X-2043	PDAC	INC424 + binimetinib	258.5	24	15	2.4	4.3
X-2043	PDAC	INC424 + binimetinib	331	23.7	19	31.1	3
X-2043	PDAC	INC424 + binimetinib	281.6	24.2	22	11.6	5.2
X-2043	PDAC	INC424 + binimetinib	296.7	23.1	26	17.6	0.4
X-2043	PDAC	INC424 + binimetinib	266.7	23.8	29	5.7	3.5
X-2043	PDAC	INC424 + binimetinib	327.8	24.2	33	29.9	5.2
X-2043	PDAC	INC424 + binimetinib	288.6	24.5	36	14.3	6.5
X-2043	PDAC	INC424 + binimetinib	368.5	24.1	40	46	4.8
X-2043	PDAC	INC424 + binimetinib	371.6	24	43	47.2	4.3
X-2043	PDAC	INC424 + binimetinib	356.6	24	47	41.3	4.3
X-2043	PDAC	INC424 + binimetinib	362.1	23.6	50	43.5	2.6
X-2043	PDAC	INC424 + binimetinib	388.5	23.9	54	53.9	3.9
X-2043	PDAC	INC424 + binimetinib	413	23.4	61	63.6	1.7
X-2043	PDAC	INC424 + binimetinib	410.9	23.4	64	62.8	1.7
X-2043	PDAC	INC424 + binimetinib	447.7	23.3	68	77.4	1.3
X-2043	PDAC	INC424 + binimetinib	444.1	22.5	71	76	-2.2
X-2043	PDAC	INC424 + binimetinib	349.8	22.6	75	38.6	-1.7
X-2043	PDAC	INC424 + binimetinib	634.6	22.7	77	151.4	-1.3
X-2043	PDAC	INC424 + binimetinib	558.9	23.3	82	121.4	1.3
X-2043	PDAC	INC424 + binimetinib	499.1	23.8	84	97.7	3.5
X-2043	PDAC	INC424 + binimetinib	440.7	22.2	89	74.6	-3.5
X-2043	PDAC	INC424 + binimetinib	521.4	21.6	92	106.6	-6.1
X-2043	PDAC	INC424 + binimetinib	490.3	22.3	96	94.3	-3
X-2043	PDAC	INC424 + binimetinib	560.4	21.7	99	122	-5.7
X-2043	PDAC	INC424	253.1	26.2	0	0	0
X-2043	PDAC	INC424	321	26.8	6	26.8	2.3
X-2043	PDAC	INC424	398.6	26.1	9	57.5	-0.4
X-2043	PDAC	INC424	392.7	26	13	55.2	-0.8
X-2043	PDAC	INC424	443.5	24.5	16	75.2	-6.5
X-2043	PDAC	INC424	443.6	25.3	20	75.3	-3.4
X-2043	PDAC	INC424	437.3	25.3	23	72.8	-3.4
X-2043	PDAC	INC424	468.2	25.7	27	85	-1.9
X-2043	PDAC	INC424	506.1	24.8	30	100	-5.3
X-2043	PDAC	INC424	525.4	26.2	36	107.6	0
X-2043	PDAC	INC424	543.9	25.9	41	114.9	-1.1
X-2043	PDAC	INC424	555.5	25.3	44	119.5	-3.4
X-2043	PDAC	INC424	584.8	26.2	48	131.1	0
X-2043	PDAC	INC424	613.7	26.5	51	142.5	1.1
X-2043	PDAC	INC424	690.1	23.9	56	172.7	-8.8
X-2043	PDAC	INC424	696.3	25.5	58	175.1	-2.7
X-2043	PDAC	INC424	716.8	24.7	62	183.2	-5.7
X-2043	PDAC	INC424	804.2	23	65	217.7	-12.2
X-2043	PDAC	LEE011	212.1	23.8	0	0	0
X-2043	PDAC	LEE011	245.4	23.1	4	15.7	-2.9
X-2043	PDAC	LEE011	406.6	21.7	7	91.7	-8.8
X-2043	PDAC	LEE011	362.4	21.3	8	70.9	-10.5
X-2043	PDAC	LEE011	443.7	21.5	11	109.2	-9.7
X-2043	PDAC	LEE011	467.1	21.3	14	120.2	-10.5
X-2043	PDAC	LEE011	501.2	21.5	18	136.3	-9.7
X-2043	PDAC	LEE011	524.7	21.4	21	147.4	-10.1
X-2043	PDAC	LEE011	526	19	23	148	-20.2
X-2043	PDAC	LKA136	284.8	25.8	0	0	0
X-2043	PDAC	LKA136	344.4	24.5	3	20.9	-5
X-2043	PDAC	LKA136	434.7	24.4	6	52.6	-5.4
X-2043	PDAC	LKA136	523.8	24.3	10	83.9	-5.8
X-2043	PDAC	LKA136	558.8	22.6	13	96.2	-12.4
X-2043	PDAC	LKA136	669.8	22.6	17	135.2	-12.4
X-2043	PDAC	LKA136	715.5	23.7	19	151.2	-8.1
X-2043	PDAC	LKA136	728.3	23.3	24	155.7	-9.7
X-2043	PDAC	binimetinib	262.7	26.3	0	0	0
X-2043	PDAC	binimetinib	227.9	25.7	3	-13.2	-2.3
X-2043	PDAC	binimetinib	246.8	24.9	6	-6.1	-5.3
X-2043	PDAC	binimetinib	170.7	25.5	10	-35	-3
X-2043	PDAC	binimetinib	255.1	25.1	13	-2.9	-4.6
X-2043	PDAC	binimetinib	206.9	27.2	17	-21.2	3.4
X-2043	PDAC	binimetinib	178.7	26.1	19	-32	-0.8
X-2043	PDAC	binimetinib	250.3	23.9	24	-4.7	-9.1
X-2043	PDAC	binimetinib	279.4	24.1	27	6.4	-8.4
X-2043	PDAC	binimetinib-3.5mpk	236.4	25.8	0	0	0
X-2043	PDAC	binimetinib-3.5mpk	304.1	24.7	2	28.6	-4.3
X-2043	PDAC	binimetinib-3.5mpk	272.1	23.3	6	15.1	-9.7
X-2043	PDAC	binimetinib-3.5mpk	372.9	22.4	9	57.7	-13.2
X-2043	PDAC	binimetinib-3.5mpk	381.1	23.1	13	61.2	-10.5
X-2043	PDAC	binimetinib-3.5mpk	404.4	23.7	16	71.1	-8.1
X-2043	PDAC	binimetinib-3.5mpk	542.9	23	20	129.7	-10.9
X-2043	PDAC	binimetinib-3.5mpk	550	23.8	23	132.7	-7.8
X-2043	PDAC	binimetinib-3.5mpk	729.7	24.4	27	208.7	-5.4
X-2043	PDAC	untreated	273.6	28.4	0	0	0
X-2043	PDAC	untreated	433.2	28.5	2	58.3	0.4
X-2043	PDAC	untreated	564.3	28	7	106.2	-1.4
X-2043	PDAC	untreated	669.9	27.8	11	144.8	-2.1
X-2043	PDAC	untreated	675.5	27.7	14	146.9	-2.5
X-2043	PDAC	untreated	759.1	NA	16	177.4	-2.5
X-2043	PDAC	untreated	828.3	27	18	202.7	-4.9
X-2043	PDAC	untreated	1123.1	28.5	22	310.5	0.4
X-2043	PDAC	untreated	1131.6	27.2	24	313.6	-4.2
X-2081	PDAC	BKM120 + binimetinib	355.4	27.9	0	0	0
X-2081	PDAC	BKM120 + binimetinib	242.6	27.1	1	-31.7	-2.9
X-2081	PDAC	BKM120 + binimetinib	240.5	26.8	4	-32.3	-3.9
X-2081	PDAC	BKM120 + binimetinib	244.5	26.8	8	-31.2	-3.9
X-2081	PDAC	BKM120 + binimetinib	137.9	27.6	11	-61.2	-1.1
X-2081	PDAC	BKM120 + binimetinib	200.8	NA	14	-43.5	-1.1
X-2081	PDAC	BKM120 + binimetinib	204.3	26.3	18	-42.5	-5.7
X-2081	PDAC	BKM120 + binimetinib	238.4	27.3	22	-32.9	-2.2
X-2081	PDAC	BKM120 + binimetinib	251.3	27.6	26	-29.3	-1.1
X-2081	PDAC	BKM120 + binimetinib	193	26.9	29	-45.7	-3.6
X-2081	PDAC	BKM120 + binimetinib	243.3	27.2	32	-31.5	-2.5
X-2081	PDAC	BKM120 + binimetinib	229.2	27.6	36	-35.5	-1.1
X-2081	PDAC	BKM120 + binimetinib	373.7	26.9	40	5.1	-3.6
X-2081	PDAC	BKM120 + binimetinib	367.1	26.9	43	3.3	-3.6
X-2081	PDAC	BKM120 + binimetinib	393.8	26.5	47	10.8	-5
X-2081	PDAC	BKM120 + binimetinib	770.1	26	53	116.7	-6.8
X-2081	PDAC	BKM120 + LDE225	317.7	26.4	0	0	0
X-2081	PDAC	BKM120 + LDE225	258.9	26.3	1	-18.5	-0.4
X-2081	PDAC	BKM120 + LDE225	240.9	26.8	4	-24.2	1.5
X-2081	PDAC	BKM120 + LDE225	212.7	26.9	8	-33.1	1.9
X-2081	PDAC	BKM120 + LDE225	416	27.4	11	30.9	3.8
X-2081	PDAC	BKM120 + LDE225	301.1	25.6	14	-5.2	-3
X-2081	PDAC	BKM120 + LDE225	317.5	26.4	18	-0.1	0
X-2081	PDAC	BKM120 + LDE225	312.1	26.9	22	-1.8	1.9
X-2081	PDAC	BKM120 + LDE225	290.1	27.2	26	-8.7	3
X-2081	PDAC	BKM120 + LDE225	331.5	26.2	29	4.3	-0.8
X-2081	PDAC	BKM120 + LDE225	246.2	26.7	32	-22.5	1.1
X-2081	PDAC	BKM120 + LDE225	204.5	25.9	36	-35.6	-1.9
X-2081	PDAC	BKM120 + LDE225	277.6	26	40	-12.6	-1.5
X-2081	PDAC	BKM120 + LDE225	288.1	25.7	43	-9.3	-2.7
X-2081	PDAC	BKM120 + LDE225	332.3	26	47	4.6	-1.5
X-2081	PDAC	BKM120 + LDE225	413.3	25.8	53	30.1	-2.3
X-2081	PDAC	BKM120 + LDE225	668	27.4	64	110.3	3.8
X-2081	PDAC	BKM120 + LDE225	752.2	24.9	67	136.8	-5.7
X-2081	PDAC	BKM120 + LDE225	773.6	24.3	70	143.5	-8
X-2081	PDAC	BKM120 + LDE225	833.3	24.3	74	162.3	-8
X-2081	PDAC	BKM120 + LDE225	835.3	22.6	77	162.9	-14.4
X-2081	PDAC	BKM120 + LDE225	906.4	20.4	82	185.3	-22.7
X-2081	PDAC	BKM120	208.7	23.8	0	0	0
X-2081	PDAC	BKM120	203.5	24.2	3	-2.5	1.7
X-2081	PDAC	BKM120	292.7	25.2	7	40.2	5.9
X-2081	PDAC	BKM120	306.2	25	10	46.7	5
X-2081	PDAC	BKM120	315.1	25.6	14	51	7.6
X-2081	PDAC	BKM120	281.4	25.7	17	34.8	8
X-2081	PDAC	BKM120	535.3	25.3	21	156.5	6.3
X-2081	PDAC	BKM120	776.1	24.7	24	271.9	3.8
X-2081	PDAC	BKM120	808.7	24.7	28	287.5	3.8
X-2081	PDAC	BYL719	204.8	23.8	0	0	0
X-2081	PDAC	BYL719	219	24.5	4	6.9	2.9
X-2081	PDAC	BYL719	208.1	22.1	7	1.6	-7.1
X-2081	PDAC	BYL719	212.2	24	11	3.6	0.8
X-2081	PDAC	BYL719	204.7	24.3	15	0	2.1
X-2081	PDAC	BYL719	235.4	23.3	18	14.9	-2.1
X-2081	PDAC	BYL719	275.2	25.6	22	34.4	7.6
X-2081	PDAC	BYL719	359	24.6	25	75.3	3.4
X-2081	PDAC	BYL719	433.4	25.7	28	111.6	8
X-2081	PDAC	BYL719	669	25.5	32	226.7	7.1
X-2081	PDAC	BYL719	870	25.9	36	324.8	8.8
X-2081	PDAC	BYL719	1185.3	25.8	39	478.8	8.4
X-2081	PDAC	BYL719	1585	25.9	42	673.9	8.8
X-2081	PDAC	BYL719 + LJM716	228.1	24.8	0	0	0
X-2081	PDAC	BYL719 + LJM716	296	24.1	3	29.8	-2.8
X-2081	PDAC	BYL719 + LJM716	362.6	24.6	6	59	-0.8
X-2081	PDAC	BYL719 + LJM716	452.6	25	10	98.4	0.8
X-2081	PDAC	BYL719 + LJM716	484.4	24.5	13	112.4	-1.2
X-2081	PDAC	BYL719 + LJM716	541.5	26	17	137.4	4.8
X-2081	PDAC	BYL719 + LJM716	609.8	25.9	20	167.3	4.4
X-2081	PDAC	BYL719 + LJM716	690.6	26.1	23	202.8	5.2
X-2081	PDAC	BYL719 + LJM716	933.3	26	27	309.2	4.8
X-2081	PDAC	BYL719 + LJM716	1034.6	23	31	353.6	-7.3
X-2081	PDAC	BYL719 + LJM716	1135.2	20	34	397.7	-19.4
X-2081	PDAC	CLR457	238.6	24.6	0	0	0
X-2081	PDAC	CLR457	357.4	26.3	4	49.8	6.9
X-2081	PDAC	CLR457	379.6	25.6	7	59.1	4.1
X-2081	PDAC	CLR457	474.6	26.9	11	98.9	9.3
X-2081	PDAC	CLR457	589.2	27.1	15	146.9	10.2
X-2081	PDAC	CLR457	719.6	27.1	18	201.6	10.2
X-2081	PDAC	CLR457	1096.8	27.4	22	359.7	11.4
X-2081	PDAC	CLR457	1187.1	27.7	25	397.5	12.6
X-2081	PDAC	CLR457	1270.9	27.5	28	432.6	11.8
X-2081	PDAC	CLR457	1635	27.8	32	585.2	13
X-2081	PDAC	HDM201	205.9	22.6	0	0	0
X-2081	PDAC	HDM201	269.1	22.9	4	30.7	1.3
X-2081	PDAC	HDM201	460.8	23.2	7	123.8	2.7
X-2081	PDAC	HDM201	585.8	23	11	184.5	1.8
X-2081	PDAC	HDM201	779.5	24.1	15	278.6	6.6
X-2081	PDAC	HDM201	1036.6	23.8	18	403.4	5.3
X-2081	PDAC	HDM201	1289	24.2	22	526	7.1
X-2081	PDAC	HDM201	1440.7	24	25	599.7	6.2
X-2081	PDAC	HDM201	1527.9	24.7	28	642.1	9.3
X-2081	PDAC	figitumumab" + binimetinib	245.6	27.4	0	0	0
X-2081	PDAC	figitumumab" + binimetinib	281.4	25.5	3	14.6	-6.9
X-2081	PDAC	figitumumab" + binimetinib	441.5	26.3	6	79.8	-4
X-2081	PDAC	figitumumab" + binimetinib	523.5	26.9	10	113.2	-1.8
X-2081	PDAC	figitumumab" + binimetinib	699.5	27	13	184.8	-1.5
X-2081	PDAC	figitumumab" + binimetinib	876.2	24.2	17	256.8	-11.7
X-2081	PDAC	figitumumab" + binimetinib	959.4	22.9	20	290.6	-16.4
X-2081	PDAC	figitumumab" + binimetinib	1093	25.5	24	345	-6.9
X-2081	PDAC	figitumumab" + binimetinib	1299	25.7	27	428.9	-6.2
X-2081	PDAC	figitumumab"	220.2	25.1	0	0	0
X-2081	PDAC	figitumumab"	319.5	24.4	3	45.1	-2.8
X-2081	PDAC	figitumumab"	878.4	26.2	10	298.9	4.4
X-2081	PDAC	figitumumab"	1440	26.9	13	554	7.2
X-2081	PDAC	gemcitabine-50mpk	296.2	25.3	0	0	0
X-2081	PDAC	gemcitabine-50mpk	308.5	26.3	3	4.2	4
X-2081	PDAC	gemcitabine-50mpk	447.4	26.2	7	51	3.6
X-2081	PDAC	gemcitabine-50mpk	488.5	26.3	10	64.9	4
X-2081	PDAC	gemcitabine-50mpk	545.3	27.6	14	84.1	9.1
X-2081	PDAC	gemcitabine-50mpk	568.6	26	17	92	2.8
X-2081	PDAC	gemcitabine-50mpk	587	27.5	20	98.2	8.7
X-2081	PDAC	gemcitabine-50mpk	578.7	28.6	24	95.4	13
X-2081	PDAC	gemcitabine-50mpk	653.8	25.5	28	120.7	0.8
X-2081	PDAC	gemcitabine-50mpk	630.4	26	31	112.8	2.8
X-2081	PDAC	gemcitabine-50mpk	585.8	28.4	35	97.8	12.3
X-2081	PDAC	gemcitabine-50mpk	677.1	27.9	37	128.6	10.3
X-2081	PDAC	INC424 + binimetinib	248.5	23.7	0	0	0
X-2081	PDAC	INC424 + binimetinib	310.3	23.8	4	24.9	0.4
X-2081	PDAC	INC424 + binimetinib	265.8	24.1	7	7	1.7
X-2081	PDAC	INC424 + binimetinib	349	25.4	11	40.4	7.2
X-2081	PDAC	INC424 + binimetinib	347.7	24.1	14	39.9	1.7
X-2081	PDAC	INC424 + binimetinib	283.2	24.8	18	14	4.6
X-2081	PDAC	INC424 + binimetinib	266.6	22.3	21	7.3	-5.9
X-2081	PDAC	INC424 + binimetinib	240.1	23.9	25	-3.4	0.8
X-2081	PDAC	INC424 + binimetinib	297.3	25.3	28	19.6	6.8
X-2081	PDAC	INC424 + binimetinib	258.8	24.8	31	4.1	4.6
X-2081	PDAC	INC424 + binimetinib	351	24.8	34	41.2	4.6
X-2081	PDAC	INC424 + binimetinib	331.7	24.7	39	33.5	4.2
X-2081	PDAC	INC424 + binimetinib	363.1	24.4	42	46.1	3
X-2081	PDAC	INC424 + binimetinib	300.2	24.5	46	20.8	3.4
X-2081	PDAC	INC424 + binimetinib	287.5	24.2	49	15.7	2.1
X-2081	PDAC	INC424 + binimetinib	321.2	24.9	52	29.3	5.1
X-2081	PDAC	INC424 + binimetinib	321.4	24.9	56	29.3	5.1
X-2081	PDAC	INC424 + binimetinib	390.2	25.1	59	57	5.9
X-2081	PDAC	INC424 + binimetinib	398	24.7	62	60.2	4.2
X-2081	PDAC	INC424 + binimetinib	454.2	24.4	66	82.8	3
X-2081	PDAC	INC424 + binimetinib	449	24.9	70	80.7	5.1
X-2081	PDAC	INC424 + binimetinib	429.7	25	74	72.9	5.5
X-2081	PDAC	INC424 + binimetinib	402.5	24.8	77	62	4.6
X-2081	PDAC	INC424 + binimetinib	361.6	24.7	80	45.5	4.2
X-2081	PDAC	INC424 + binimetinib	472.8	25.2	84	90.3	6.3
X-2081	PDAC	LEE011	230.5	26.3	0	0	0
X-2081	PDAC	LEE011	309.2	25.6	2	34.1	-2.7
X-2081	PDAC	LEE011	385.1	26.2	6	67.1	-0.4
X-2081	PDAC	LEE011	477.4	26.8	9	107.1	1.9
X-2081	PDAC	LEE011	542.4	27.5	14	135.3	4.6
X-2081	PDAC	LEE011	630.3	26.8	17	173.4	1.9
X-2081	PDAC	LEE011	796.7	28.7	20	245.6	9.1
X-2081	PDAC	LEE011	841.8	28.5	23	265.2	8.4
X-2081	PDAC	LEE011	1205.5	25.8	27	423	-1.9
X-2081	PDAC	WNT974	249.7	23.3	0	0	0
X-2081	PDAC	WNT974	301.4	22.8	1	20.7	-2.1
X-2081	PDAC	WNT974	420.5	NA	4	68.4	-2.1
X-2081	PDAC	WNT974	561	21.3	8	124.7	-8.6
X-2081	PDAC	WNT974	793.3	21.6	11	217.7	-7.3
X-2081	PDAC	WNT974	915.2	21.1	14	266.5	-9.4
X-2081	PDAC	WNT974	1128.2	19.3	18	351.8	-17.2
X-2081	PDAC	WNT974	1141.8	18.9	20	357.3	-18.9
X-2081	PDAC	LKA136	253.4	26.8	0	0	0
X-2081	PDAC	LKA136	465.9	27.7	4	83.9	3.4
X-2081	PDAC	LKA136	587.1	26.6	7	131.7	-0.7
X-2081	PDAC	LKA136	1070	26.8	11	322.3	0
X-2081	PDAC	LKA136	1429.9	28.9	15	464.3	7.8
X-2081	PDAC	LKA136	1889.5	28.3	18	645.7	5.6
X-2081	PDAC	binimetinib	271	23.9	0	0	0
X-2081	PDAC	binimetinib	296.3	24.7	1	9.3	3.3
X-2081	PDAC	binimetinib	189.3	24.2	7	-30.1	1.3
X-2081	PDAC	binimetinib	150.7	24.7	10	-44.4	3.3
X-2081	PDAC	binimetinib	192.1	25.3	14	-29.1	5.9
X-2081	PDAC	binimetinib	133.3	25.8	17	-50.8	7.9
X-2081	PDAC	binimetinib	203.9	26.1	21	-24.8	9.2
X-2081	PDAC	binimetinib	231.6	24.9	24	-14.5	4.2
X-2081	PDAC	binimetinib	271.8	25.1	27	0.3	5
X-2081	PDAC	binimetinib	325.8	25	30	20.2	4.6
X-2081	PDAC	binimetinib	259.8	24	34	-4.1	0.4
X-2081	PDAC	binimetinib	311.6	23.8	37	15	-0.4
X-2081	PDAC	binimetinib	195.9	24.7	41	-27.7	3.3
X-2081	PDAC	binimetinib	368	23	43	35.8	-3.8
X-2081	PDAC	binimetinib	480.1	22.1	48	77.2	-7.5
X-2081	PDAC	binimetinib	410.5	20	51	51.5	-16.3
X-2081	PDAC	binimetinib-3.5mpk	230.2	28.7	0	0	0
X-2081	PDAC	binimetinib-3.5mpk	359.4	27.6	3	56.1	-3.8
X-2081	PDAC	binimetinib-3.5mpk	481.1	28.1	6	109	-2.1
X-2081	PDAC	binimetinib-3.5mpk	470.1	28	11	104.2	-2.4
X-2081	PDAC	binimetinib-3.5mpk	503.8	28.6	13	118.9	-0.3
X-2081	PDAC	binimetinib-3.5mpk	703.6	28	17	205.6	-2.4
X-2081	PDAC	binimetinib-3.5mpk	581.1	28.5	24	152.4	-0.7
X-2081	PDAC	trametinib	195	24.1	0	0	0
X-2081	PDAC	trametinib	215.1	24.6	2	10.3	2.1
X-2081	PDAC	trametinib	475.3	24.4	6	143.7	1.2
X-2081	PDAC	trametinib	464.7	25.7	9	138.3	6.6
X-2081	PDAC	trametinib	529.8	25.8	13	171.7	7.1
X-2081	PDAC	trametinib	465.7	25.3	16	138.8	5
X-2081	PDAC	trametinib	663.7	28.3	21	240.4	17.4
X-2081	PDAC	trametinib	572.8	25.5	23	193.7	5.8
X-2081	PDAC	trametinib	570.1	25.9	27	192.4	7.5
X-2081	PDAC	trametinib	575.3	26.6	30	195	10.4
X-2081	PDAC	untreated	254.2	25.8	0	0	0
X-2081	PDAC	untreated	452.9	26.2	4	78.2	1.6
X-2081	PDAC	untreated	557.6	25.3	7	119.4	-1.9
X-2081	PDAC	untreated	934.5	26.3	11	267.6	1.9
X-2081	PDAC	untreated	1100.5	27.4	15	332.9	6.2
X-2081	PDAC	untreated	1531.1	27.4	18	502.3	6.2
X-2081	PDAC	untreated	2027.6	28	22	697.6	8.5
X-2082	NSCLC	BGJ398	176.5	24	0	0	0
X-2082	NSCLC	BGJ398	168.2	25	4	-4.7	4.2
X-2082	NSCLC	BGJ398	187.6	24.1	7	6.3	0.4
X-2082	NSCLC	BGJ398	250.7	24.4	11	42	1.7
X-2082	NSCLC	BGJ398	303.2	25	14	71.8	4.2
X-2082	NSCLC	BGJ398	377.4	25.4	19	113.8	5.8
X-2082	NSCLC	BKM120	153.7	23.5	0	0	0
X-2082	NSCLC	BKM120	173.5	22.9	4	12.9	-2.6
X-2082	NSCLC	BKM120	210	23.5	7	36.6	0
X-2082	NSCLC	BKM120	242.3	23.4	11	57.6	-0.4
X-2082	NSCLC	BKM120	340.7	25	16	121.7	6.4
X-2082	NSCLC	BKM120	462.6	24.2	18	201	3
X-2082	NSCLC	BKM120	415.5	24.4	22	170.3	3.8
X-2082	NSCLC	BKM120	538	24.3	25	250	3.4
X-2082	NSCLC	BKM120	731	24	29	375.6	2.1
X-2082	NSCLC	BKM120	865.5	24.8	32	463.1	5.5
X-2082	NSCLC	BKM120	826.6	24.8	37	437.8	5.5
X-2082	NSCLC	BKM120 + binimetinib	192.2	26.1	0	0	0
X-2082	NSCLC	BKM120 + binimetinib	188.6	25.2	4	-1.9	-3.4
X-2082	NSCLC	BKM120 + binimetinib	177.1	25.8	7	-7.9	-1.1
X-2082	NSCLC	BKM120 + binimetinib	169.7	25.7	8	-11.7	-1.5
X-2082	NSCLC	BKM120 + binimetinib	168.9	26.6	11	-12.1	1.9
X-2082	NSCLC	BKM120 + binimetinib	260.9	27.5	16	35.7	5.4
X-2082	NSCLC	BKM120 + binimetinib	162.6	26.9	18	-15.4	3.1
X-2082	NSCLC	BKM120 + binimetinib	149.5	26.3	22	-22.2	0.8
X-2082	NSCLC	BKM120 + binimetinib	171.3	26.6	25	-10.9	1.9
X-2082	NSCLC	BKM120 + binimetinib	165.8	26.3	29	-13.7	0.8
X-2082	NSCLC	BKM120 + binimetinib	135.4	27.8	32	-29.6	6.5
X-2082	NSCLC	BKM120 + binimetinib	150.1	27.2	37	-21.9	4.2
X-2082	NSCLC	BKM120 + binimetinib	188.2	26.2	39	-2.1	0.4
X-2082	NSCLC	BKM120 + binimetinib	256.8	26.6	44	33.6	1.9
X-2082	NSCLC	BKM120 + binimetinib	298.3	27.8	46	55.2	6.5
X-2082	NSCLC	BKM120 + binimetinib	259.1	27.3	49	34.8	4.6
X-2082	NSCLC	BKM120 + binimetinib	308.7	28.1	56	60.6	7.7
X-2082	NSCLC	BKM120 + binimetinib	335.6	27.9	60	74.6	6.9
X-2082	NSCLC	BKM120 + binimetinib	386	27.8	63	100.8	6.5
X-2082	NSCLC	BKM120 + binimetinib	332.7	27.6	67	73.1	5.7
X-2082	NSCLC	BKM120 + binimetinib	179.8	26.5	72	-6.5	1.5
X-2082	NSCLC	BKM120 + binimetinib	219.6	27.4	78	14.3	5
X-2082	NSCLC	BKM120 + binimetinib	229	28	81	19.1	7.3
X-2082	NSCLC	BKM120 + binimetinib	307.4	26.5	86	59.9	1.5
X-2082	NSCLC	BKM120 + binimetinib	212.2	26.7	92	10.4	2.3
X-2082	NSCLC	BKM120 + binimetinib	301	27.2	95	56.6	4.2
X-2082	NSCLC	BKM120 + binimetinib	265.7	26.4	100	38.2	1.1
X-2082	NSCLC	BYL719	161	21.6	0	0	0
X-2082	NSCLC	BYL719	184.5	21.6	2	14.6	0
X-2082	NSCLC	BYL719	143.3	21.1	6	-11	-2.3
X-2082	NSCLC	BYL719	168.1	21.2	9	4.4	-1.9
X-2082	NSCLC	BYL719	183.2	21	13	13.8	-2.8
X-2082	NSCLC	BYL719	174.9	23.4	16	8.6	8.3
X-2082	NSCLC	BYL719	156	23.5	21	-3.1	8.8
X-2082	NSCLC	BYL719	206.9	22.1	23	28.5	2.3
X-2082	NSCLC	BYL719	249.6	22.4	28	55	3.7
X-2082	NSCLC	BYL719	236.2	22.7	30	46.7	5.1
X-2082	NSCLC	BYL719	250.4	23.9	33	55.5	10.6
X-2082	NSCLC	BYL719	487.5	23.6	40	202.8	9.3
X-2082	NSCLC	BYL719	448	23.9	42	178.3	10.6
X-2082	NSCLC	BYL719 + LGH447	289	26.8	0	0	0
X-2082	NSCLC	BYL719 + LGH447	367	26.5	5	27	-1.1
X-2082	NSCLC	BYL719 + LGH447	367.3	25.2	7	27.1	-6
X-2082	NSCLC	BYL719 + LGH447	364.1	24.7	12	26	-7.8
X-2082	NSCLC	BYL719 + LGH447	492.4	24	14	70.4	-10.4
X-2082	NSCLC	BYL719 + LGH447	533	24.9	17	84.4	-7.1
X-2082	NSCLC	BYL719 + LGH447	967.8	25.2	24	234.9	-6
X-2082	NSCLC	BYL719 + LGH447	903.1	24.7	26	212.5	-7.8
X-2082	NSCLC	BYL719 + LJM716	127.8	26.9	0	0	0
X-2082	NSCLC	BYL719 + LJM716	130.3	26.1	4	2	-3
X-2082	NSCLC	BYL719 + LJM716	137.2	24.9	7	7.4	-7.4
X-2082	NSCLC	BYL719 + LJM716	145.5	25.7	11	13.8	-4.5
X-2082	NSCLC	BYL719 + LJM716	113.3	27.2	14	-11.3	1.1
X-2082	NSCLC	BYL719 + LJM716	194.9	27.8	19	52.5	3.3
X-2082	NSCLC	BYL719 + LJM716	156.1	27.8	21	22.1	3.3
X-2082	NSCLC	BYL719 + LJM716	162.7	26.7	26	27.3	-0.7
X-2082	NSCLC	BYL719 + LJM716	195.8	27.2	28	53.2	1.1
X-2082	NSCLC	BYL719 + LJM716	217.3	27.6	31	70	2.6
X-2082	NSCLC	BYL719 + LJM716	276	27.3	38	116	1.5
X-2082	NSCLC	BYL719 + LJM716	398.8	28.2	42	212.1	4.8
X-2082	NSCLC	BYL719 + LJM716	386.4	27.2	45	202.3	1.1
X-2082	NSCLC	BYL719 + LJM716	408.6	27.8	49	219.7	3.3
X-2082	NSCLC	BYL719 + LJM716	455.9	27.6	54	256.7	2.6
X-2082	NSCLC	BYL719 + LJM716	709.8	29.2	60	455.4	8.6
X-2082	NSCLC	BYL719 + LJM716	732.4	29.7	61	473.1	10.4
X-2082	NSCLC	CGM097	264.7	24.9	0	0	0
X-2082	NSCLC	CGM097	269.9	26.5	5	2	6.4
X-2082	NSCLC	CGM097	276.4	25.3	7	4.4	1.6
X-2082	NSCLC	CGM097	346.6	26.2	11	30.9	5.2
X-2082	NSCLC	CGM097	421.8	25.8	14	59.4	3.6
X-2082	NSCLC	CGM097	423.9	26.2	18	60.1	5.2
X-2082	NSCLC	CGM097	550.4	27.4	21	107.9	10
X-2082	NSCLC	CGM097	528.2	25.4	26	99.5	2
X-2082	NSCLC	CGM097	591.7	24.7	28	123.5	-0.8
X-2082	NSCLC	CGM097	758.3	26.5	32	186.5	6.4
X-2082	NSCLC	CGM097	808.8	25.8	35	205.6	3.6
X-2082	NSCLC	CGM097	844.7	26.2	38	219.1	5.2
X-2082	NSCLC	CGM097	1185.9	26	45	348	4.4
X-2082	NSCLC	CGM097	1231.9	25.9	47	365.4	4
X-2082	NSCLC	CKX620	185	24.9	0	0	0
X-2082	NSCLC	CKX620	93.8	25.3	5	-49.3	1.6
X-2082	NSCLC	CKX620	88.5	25.5	7	-52.2	2.4
X-2082	NSCLC	CKX620	83	26.7	11	-55.1	7.2
X-2082	NSCLC	CKX620	79.2	26	14	-57.2	4.4
X-2082	NSCLC	CKX620	61.6	26.8	18	-66.7	7.6
X-2082	NSCLC	CKX620	60.1	26.7	21	-67.5	7.2
X-2082	NSCLC	CKX620	76.6	26.3	28	-58.6	5.6
X-2082	NSCLC	CKX620	81.3	28.5	33	-56.1	14.5
X-2082	NSCLC	CKX620	79	28.8	35	-57.3	15.7
X-2082	NSCLC	CKX620	91.8	27.5	38	-50.4	10.4
X-2082	NSCLC	CKX620	108	28.4	45	-41.6	14.1
X-2082	NSCLC	CKX620	127.1	28.4	49	-31.3	14.1
X-2082	NSCLC	CKX620	172.6	28	52	-6.7	12.4
X-2082	NSCLC	CKX620	158.2	27.4	56	-14.5	10
X-2082	NSCLC	CKX620	114.6	28.3	61	-38.1	13.7
X-2082	NSCLC	CKX620	194	27.7	67	4.9	11.2
X-2082	NSCLC	CKX620	232.9	28.1	70	25.9	12.9
X-2082	NSCLC	CKX620	245.6	27.7	75	32.8	11.2
X-2082	NSCLC	CKX620	179.7	28.7	81	-2.9	15.3
X-2082	NSCLC	CKX620	183	28.5	84	-1.1	14.5
X-2082	NSCLC	CKX620	178.4	29.3	89	-3.6	17.7
X-2082	NSCLC	CKX620	140.9	27.6	91	-23.8	10.8
X-2082	NSCLC	CKX620	193.5	27.3	95	4.6	9.6
X-2082	NSCLC	CKX620	235.4	28.9	102	27.2	16.1
X-2082	NSCLC	CLR457	185.5	25.8	0	0	0
X-2082	NSCLC	CLR457	208.3	25.3	4	12.3	-1.9
X-2082	NSCLC	CLR457	270.6	25.2	8	45.9	-2.3
X-2082	NSCLC	CLR457	299.5	25.5	11	61.5	-1.2
X-2082	NSCLC	CLR457	259.5	26.2	16	39.9	1.6
X-2082	NSCLC	CLR457	307.9	25.6	18	66	-0.8
X-2082	NSCLC	CLR457	450	25.8	22	142.6	0
X-2082	NSCLC	CLR457	677.9	25.3	25	265.4	-1.9
X-2082	NSCLC	CLR457	851.4	27.4	29	359	6.2
X-2082	NSCLC	CLR457	1154.5	27.7	32	522.4	7.4
X-2082	NSCLC	CLR457	1125.1	27.3	37	506.5	5.8
X-2082	NSCLC	HDM201	161.5	25.8	0	0	0
X-2082	NSCLC	HDM201	247.4	24.8	4	53.2	-3.9
X-2082	NSCLC	HDM201	355.9	24.9	7	120.4	-3.5
X-2082	NSCLC	HDM201	317.8	24.4	11	96.8	-5.4
X-2082	NSCLC	HDM201	432.5	25	16	167.8	-3.1
X-2082	NSCLC	HDM201	423.7	24.2	18	162.4	-6.2
X-2082	NSCLC	HDM201	478.5	25	22	196.3	-3.1
X-2082	NSCLC	HDM201	530.4	25	25	228.4	-3.1
X-2082	NSCLC	HDM201	545.8	25.1	29	238	-2.7
X-2082	NSCLC	HDM201	655.8	25.5	32	306.1	-1.2
X-2082	NSCLC	HDM201	800.2	25.4	37	395.5	-1.6
X-2082	NSCLC	HDM201	839	24.8	39	419.5	-3.9
X-2082	NSCLC	HDM201	1075.1	25.3	43	565.7	-1.9
X-2082	NSCLC	cetuximab	245.6	24	0	0	0
X-2082	NSCLC	cetuximab	325.6	24.3	5	32.6	1.2
X-2082	NSCLC	cetuximab	322.2	24.1	7	31.2	0.4
X-2082	NSCLC	cetuximab	365.7	23.7	11	48.9	-1.3
X-2082	NSCLC	cetuximab	337.9	24.3	14	37.6	1.2
X-2082	NSCLC	cetuximab	433.1	24.3	18	76.3	1.2
X-2082	NSCLC	cetuximab	415.2	24.6	21	69.1	2.5
X-2082	NSCLC	cetuximab	499.3	24.5	26	103.3	2.1
X-2082	NSCLC	cetuximab	588.8	24.5	28	139.7	2.1
X-2082	NSCLC	cetuximab	670.6	25.1	33	173	4.6
X-2082	NSCLC	cetuximab	681.2	24.7	35	177.4	2.9
X-2082	NSCLC	cetuximab	731.3	25.6	38	197.8	6.7
X-2082	NSCLC	cetuximab	807.7	25.4	45	228.9	5.8
X-2082	NSCLC	cetuximab	904.5	25.7	47	268.3	7.1
X-2082	NSCLC	erlotinib	160.4	22.7	0	0	0
X-2082	NSCLC	erlotinib	248.6	22.9	5	55	0.9
X-2082	NSCLC	erlotinib	175.4	21.4	7	9.4	-5.7
X-2082	NSCLC	erlotinib	140.6	17.3	11	-12.3	-23.8
X-2082	NSCLC	erlotinib	116.2	19.4	12	-27.6	-14.5
X-2082	NSCLC	erlotinib	132.4	21.7	14	-17.5	-4.4
X-2082	NSCLC	erlotinib	173.4	21.8	18	8.1	-4
X-2082	NSCLC	erlotinib	196.8	21.7	21	22.7	-4.4
X-2082	NSCLC	erlotinib	189.6	20.6	26	18.2	-9.3
X-2082	NSCLC	erlotinib	239.3	20.7	28	49.2	-8.8
X-2082	NSCLC	erlotinib	232	21.5	33	44.6	-5.3
X-2082	NSCLC	erlotinib	265.7	21.9	35	65.6	-3.5
X-2082	NSCLC	erlotinib	268.8	21.7	38	67.6	-4.4
X-2082	NSCLC	erlotinib	369.7	20.7	45	130.5	-8.8
X-2082	NSCLC	erlotinib	446.2	19.4	47	178.2	-14.5
X-2082	NSCLC	HSP990	272.7	27.5	0	0	0
X-2082	NSCLC	HSP990	263.5	26.4	5	-3.4	-4
X-2082	NSCLC	HSP990	269.6	25.6	7	-1.1	-6.9
X-2082	NSCLC	HSP990	330.6	27	11	21.2	-1.8
X-2082	NSCLC	HSP990	420.2	25.5	14	54.1	-7.3
X-2082	NSCLC	HSP990	332.8	26.2	18	22	-4.7
X-2082	NSCLC	HSP990	431.6	27.3	21	58.3	-0.7
X-2082	NSCLC	HSP990	368.5	26	26	35.1	-5.5
X-2082	NSCLC	HSP990	411.3	25.3	28	50.8	-8
X-2082	NSCLC	HSP990	318.3	21.5	32	16.7	-21.8
X-2082	NSCLC	INC280	194.3	21.8	0	0	0
X-2082	NSCLC	INC280	278.6	22.2	4	43.4	1.8
X-2082	NSCLC	INC280	305	22.1	8	57	1.4
X-2082	NSCLC	INC280	371.8	22.7	11	91.4	4.1
X-2082	NSCLC	INC280	406.1	22.9	16	109	5
X-2082	NSCLC	INC280	459.8	22.9	18	136.6	5
X-2082	NSCLC	INC280	414.5	22.8	22	113.3	4.6
X-2082	NSCLC	INC280	547	22.7	25	181.5	4.1
X-2082	NSCLC	INC280	657.9	23.7	29	238.6	8.7
X-2082	NSCLC	INC280	850.6	24.3	32	337.8	11.5
X-2082	NSCLC	INC280	1020.2	23.7	37	425.1	8.7
X-2082	NSCLC	LCL161 + paclitaxel	197.3	23.4	0	0	0
X-2082	NSCLC	LCL161 + paclitaxel	180.9	22.8	5	-8.3	-2.6
X-2082	NSCLC	LCL161 + paclitaxel	174.5	22.6	7	-11.6	-3.4
X-2082	NSCLC	LCL161 + paclitaxel	134.1	23.5	11	-32	0.4
X-2082	NSCLC	LCL161 + paclitaxel	106.8	24.1	14	-45.9	3
X-2082	NSCLC	LCL161 + paclitaxel	99.3	22	18	-49.7	-6
X-2082	NSCLC	LCL161 + paclitaxel	76.9	24.4	21	-61	4.3
X-2082	NSCLC	LCL161 + paclitaxel	128.5	25	26	-34.9	6.8
X-2082	NSCLC	LCL161 + paclitaxel	147.1	24.5	28	-25.4	4.7
X-2082	NSCLC	LCL161 + paclitaxel	156.6	23.8	33	-20.6	1.7
X-2082	NSCLC	LCL161 + paclitaxel	157.5	23.4	35	-20.2	0
X-2082	NSCLC	LCL161 + paclitaxel	176.8	24	38	-10.4	2.6
X-2082	NSCLC	LCL161 + paclitaxel	277.8	25.4	45	40.8	8.5
X-2082	NSCLC	LCL161 + paclitaxel	390.5	26.4	49	97.9	12.8
X-2082	NSCLC	LCL161 + paclitaxel	402.4	24.3	52	104	3.8
X-2082	NSCLC	LCL161 + paclitaxel	401.7	23.1	56	103.6	-1.3
X-2082	NSCLC	LCL161 + paclitaxel	399.2	24.1	61	102.3	3
X-2082	NSCLC	LCL161 + paclitaxel	417.7	24.6	67	111.7	5.1
X-2082	NSCLC	LCL161 + paclitaxel	439.5	21.3	70	122.8	-9
X-2082	NSCLC	LCL161 + paclitaxel	660.1	23.8	75	234.6	1.7
X-2082	NSCLC	LCL161 + paclitaxel	781.1	25.8	81	295.9	10.3
X-2082	NSCLC	LCL161 + paclitaxel	840.3	25.8	84	325.9	10.3
X-2082	NSCLC	LCL161 + paclitaxel	897.6	25.3	89	354.9	8.1
X-2082	NSCLC	LEE011	267.4	28.6	0	0	0
X-2082	NSCLC	LEE011	401.4	26.7	4	50.1	-6.6
X-2082	NSCLC	LEE011	418	25.9	7	56.3	-9.4
X-2082	NSCLC	LEE011	290	27.1	11	8.5	-5.2
X-2082	NSCLC	LEE011	212.7	27.8	16	-20.5	-2.8
X-2082	NSCLC	LEE011	210.1	27.6	18	-21.4	-3.5
X-2082	NSCLC	LEE011	139.5	29.2	22	-47.8	2.1
X-2082	NSCLC	LEE011	112.7	28.7	25	-57.9	0.3
X-2082	NSCLC	LEE011	84.7	28.5	29	-68.3	-0.3
X-2082	NSCLC	LEE011	82.9	29.4	32	-69	2.8
X-2082	NSCLC	LEE011	45.8	28.7	37	-82.9	0.3
X-2082	NSCLC	LEE011	44.4	28.2	39	-83.4	-1.4
X-2082	NSCLC	LEE011	29.5	28.7	44	-89	0.3
X-2082	NSCLC	LEE011	66.7	28.7	46	-75.1	0.3
X-2082	NSCLC	LEE011	23.7	28	49	-91.1	-2.1
X-2082	NSCLC	LEE011	18.6	28.8	56	-93	0.7
X-2082	NSCLC	LEE011	24.9	29.6	60	-90.7	3.5
X-2082	NSCLC	LEE011	24	28.7	63	-91	0.3
X-2082	NSCLC	LEE011	13.7	27.9	67	-94.9	-2.4
X-2082	NSCLC	LEE011	0	29.9	72	-100	4.5
X-2082	NSCLC	LEE011	0	29.9	78	-100	4.5
X-2082	NSCLC	LEE011	0	31.7	81	-100	10.8
X-2082	NSCLC	LEE011	0	29.6	86	-100	3.5
X-2082	NSCLC	LEE011	0	31.8	92	-100	11.2
X-2082	NSCLC	LEE011	0	30.7	95	-100	7.3
X-2082	NSCLC	LEE011	0	31	100	-100	8.4
X-2082	NSCLC	LGH447	225.8	24.7	0	0	0
X-2082	NSCLC	LGH447	262.9	26.8	5	16.4	8.5
X-2082	NSCLC	LGH447	235.9	25.9	7	4.5	4.9
X-2082	NSCLC	LGH447	270.3	26.8	11	19.7	8.5
X-2082	NSCLC	LGH447	277.5	26.9	14	22.9	8.9
X-2082	NSCLC	LGH447	423.4	26.3	18	87.5	6.5
X-2082	NSCLC	LGH447	447.8	27.7	21	98.3	12.1
X-2082	NSCLC	LGH447	926.6	28.4	26	310.4	15
X-2082	NSCLC	LGH447	948.9	26.5	28	320.2	7.3
X-2082	NSCLC	LGH447	1110.6	28.3	32	391.9	14.6
X-2082	NSCLC	LLM871	236.2	22.5	0	0	0
X-2082	NSCLC	LLM871	360.8	21.1	4	52.8	-6.2
X-2082	NSCLC	LLM871	600.3	22.4	7	154.1	-0.4
X-2082	NSCLC	LLM871	738.1	21.9	11	212.5	-2.7
X-2082	NSCLC	LLM871	777.8	23.1	14	229.3	2.7
X-2082	NSCLC	LLM871	910	23.3	19	285.3	3.6
X-2082	NSCLC	LLM871	1239.4	21.8	21	424.7	-3.1
X-2082	NSCLC	LLM871	1248.5	22.6	25	428.6	0.4
X-2082	NSCLC	binimetinib	171.9	20.5	0	0	0
X-2082	NSCLC	binimetinib	117.9	20	4	-31.4	-2.4
X-2082	NSCLC	binimetinib	76.4	20.8	8	-55.6	1.5
X-2082	NSCLC	binimetinib	70.2	21	11	-59.2	2.4
X-2082	NSCLC	binimetinib	72	21	16	-58.1	2.4
X-2082	NSCLC	binimetinib	67.2	20.4	18	-60.9	-0.5
X-2082	NSCLC	binimetinib	59.4	20.1	22	-65.4	-2
X-2082	NSCLC	binimetinib	60.3	20.5	25	-64.9	0
X-2082	NSCLC	binimetinib	51.4	19.6	29	-70.1	-4.4
X-2082	NSCLC	binimetinib	44.9	18.8	32	-73.9	-8.3
X-2082	NSCLC	binimetinib	56.9	20.4	37	-66.9	-0.5
X-2082	NSCLC	binimetinib	39.4	20.8	39	-77.1	1.5
X-2082	NSCLC	binimetinib	40.9	18.5	44	-76.2	-9.8
X-2082	NSCLC	binimetinib	44.9	20.5	46	-73.9	0
X-2082	NSCLC	binimetinib	52.2	19.9	49	-69.6	-2.9
X-2082	NSCLC	binimetinib	56.7	21.1	56	-67	2.9
X-2082	NSCLC	binimetinib	49.4	21.3	60	-71.3	3.9
X-2082	NSCLC	binimetinib	84.8	20.4	63	-50.7	-0.5
X-2082	NSCLC	binimetinib	66.9	20.8	67	-61.1	1.5
X-2082	NSCLC	binimetinib	54.9	20.1	72	-68.1	-2
X-2082	NSCLC	binimetinib	92.4	20.9	78	-46.2	2
X-2082	NSCLC	binimetinib	98.2	20.3	81	-42.9	-1
X-2082	NSCLC	binimetinib	88.5	20.1	92	-48.5	-2
X-2082	NSCLC	binimetinib	77.6	20.2	95	-54.9	-1.5
X-2082	NSCLC	binimetinib	67.4	18.3	100	-60.8	-10.7
X-2082	NSCLC	paclitaxel	205.3	24.5	0	0	0
X-2082	NSCLC	paclitaxel	342.7	24.6	5	66.9	0.4
X-2082	NSCLC	paclitaxel	399.5	24.9	7	94.6	1.6
X-2082	NSCLC	paclitaxel	461.3	24.3	11	124.7	-0.8
X-2082	NSCLC	paclitaxel	654.2	24.3	14	218.7	-0.8
X-2082	NSCLC	paclitaxel	759.2	24.9	18	269.8	1.6
X-2082	NSCLC	paclitaxel	824.3	25.4	21	301.5	3.7
X-2082	NSCLC	paclitaxel	927.9	26.8	26	352	9.4
X-2082	NSCLC	untreated	188.8	21.3	0	0	0
X-2082	NSCLC	untreated	231.2	21.5	5	22.5	0.9
X-2082	NSCLC	untreated	273.3	21.3	7	44.8	0
X-2082	NSCLC	untreated	282.5	22.1	11	49.6	3.8
X-2082	NSCLC	untreated	300.9	21.5	14	59.4	0.9
X-2082	NSCLC	untreated	330	22.2	18	74.8	4.2
X-2082	NSCLC	untreated	313.7	23	21	66.2	8
X-2082	NSCLC	untreated	418.2	23	26	121.5	8
X-2082	NSCLC	untreated	589.2	22.3	28	212.1	4.7
X-2082	NSCLC	untreated	526.1	21.9	33	178.7	2.8
X-2082	NSCLC	untreated	560.9	21.6	35	197.1	1.4
X-2082	NSCLC	untreated	667.1	21	38	253.3	-1.4
X-2082	NSCLC	untreated	661.8	20.4	45	250.5	-4.2
X-2082	NSCLC	LFW527 + binimetinib	183.61	26.6	0	0	0
X-2082	NSCLC	LFW527 + binimetinib	138.08	26.1	3	-24.8	-1.9
X-2082	NSCLC	LFW527 + binimetinib	100.95	26.8	6	-45	0.8
X-2082	NSCLC	LFW527 + binimetinib	160.71	29.1	11	-12.5	9.4
X-2082	NSCLC	LFW527 + binimetinib	103.04	29.3	14	-43.9	10.2
X-2082	NSCLC	LFW527 + binimetinib	122.11	27.9	17	-33.5	4.9
X-2082	NSCLC	LFW527 + binimetinib	86.19	27.1	20	-53.1	1.9
X-2082	NSCLC	LFW527 + binimetinib	95.37	29.4	24	-48.1	10.5
X-2082	NSCLC	LFW527 + binimetinib	86.48	29.6	28	-52.9	11.3
X-2082	NSCLC	LFW527 + binimetinib	69.05	29.4	31	-62.4	10.5
X-2082	NSCLC	LFW527 + binimetinib	67.74	28.7	38	-63.1	7.9
X-2082	NSCLC	LFW527 + binimetinib	83.57	28.1	41	-54.5	5.6
X-2082	NSCLC	LFW527 + binimetinib	85.83	28.3	45	-53.3	6.4
X-2082	NSCLC	LFW527 + binimetinib	95.22	28.1	48	-48.1	5.6
X-2082	NSCLC	LFW527 + binimetinib	74.47	28.1	52	-59.4	5.6
X-2082	NSCLC	LFW527 + binimetinib	72.56	28.5	55	-60.5	7.1
X-2082	NSCLC	LFW527 + binimetinib	119.6	27.9	59	-34.9	4.9
X-2082	NSCLC	LFW527 + binimetinib	87.11	29	62	-52.6	9
X-2082	NSCLC	LFW527 + binimetinib	116.52	27.5	66	-36.5	3.4
X-2082	NSCLC	LFW527 + binimetinib	81.03	27.7	69	-55.9	4.1
X-2082	NSCLC	LFW527 + binimetinib	122.5	29.5	73	-33.3	10.9
X-2082	NSCLC	LFW527 + binimetinib	89.51	29	76	-51.2	9
X-2082	NSCLC	LFW527 + binimetinib	97.65	28.1	80	-46.8	5.6
X-2082	NSCLC	LFW527 + binimetinib	133.43	27.4	83	-27.3	3
X-2082	NSCLC	LFW527 + binimetinib	82.86	26.5	88	-54.9	-0.4
X-2082	NSCLC	LFW527 + binimetinib	87.59	27	95	-52.3	1.5
X-2082	NSCLC	LFW527 + binimetinib	85.7	25.4	97	-53.3	-4.5
X-2082	NSCLC	LFW527 + binimetinib	108.83	24.6	101	-40.7	-7.5
X-2082	NSCLC	LFW527 + binimetinib	135.34	25.6	104	-26.3	-3.8
X-2082	NSCLC	LFW527 + binimetinib	90.1	27.2	108	-50.9	2.3
X-2082	NSCLC	LFW527 + binimetinib	105.36	26.3	114	-42.6	-1.1
X-2082	NSCLC	LFW527 + binimetinib	195.43	25.6	118	6.4	-3.8
X-2082	NSCLC	LFW527 + binimetinib	133.36	25.3	122	-27.4	-4.9
X-2082	NSCLC	LFW527 + binimetinib	121.79	25.7	125	-33.7	-3.4
X-2082	NSCLC	LFW527 + binimetinib	141.84	26.8	129	-22.7	0.8
X-2082	NSCLC	LFW527 + binimetinib	153.22	26.5	136	-16.6	-0.4
X-2082	NSCLC	LFW527 + binimetinib	216.5	28.5	143	17.9	7.1
X-2082	NSCLC	LFW527 + binimetinib	117.37	28.4	145	-36.1	6.8
X-2088	NSCLC	BGJ398	220.5	30	0	0	0
X-2088	NSCLC	BGJ398	250.2	31.9	10	13.5	6.3
X-2088	NSCLC	BGJ398	912.2	33.1	14	313.7	10.3
X-2088	NSCLC	BGJ398	1171.4	29.4	18	431.2	-2
X-2088	NSCLC	BKM120 + binimetinib	224.1	26.6	0	0	0
X-2088	NSCLC	BKM120 + binimetinib	451.9	26.2	7	101.7	-1.5
X-2088	NSCLC	BKM120 + binimetinib	934.1	27.5	11	316.8	3.4
X-2088	NSCLC	BKM120	225.6	26.4	0	0	0
X-2088	NSCLC	BKM120	372.7	27	4	65.2	2.3
X-2088	NSCLC	BKM120	525.2	27.4	8	132.8	3.8
X-2088	NSCLC	BKM120	577.2	27.4	11	155.9	3.8
X-2088	NSCLC	BKM120	751.4	27.2	15	233.1	3
X-2088	NSCLC	BKM120	844.3	28.2	18	274.2	6.8
X-2088	NSCLC	BKM120	1161.2	28.2	23	414.7	6.8
X-2088	NSCLC	BYL719 + LJM716	286.1	24.5	0	0	0
X-2088	NSCLC	BYL719 + LJM716	335.8	24.3	2	17.4	-0.8
X-2088	NSCLC	BYL719 + LJM716	457.7	24.5	5	60	0
X-2088	NSCLC	BYL719 + LJM716	472.5	23.8	8	65.2	-2.9
X-2088	NSCLC	BYL719 + LJM716	794.8	24	12	177.8	-2
X-2088	NSCLC	BYL719 + LGH447	223.1	29.6	0	0	0
X-2088	NSCLC	BYL719 + LGH447	156.9	28.9	3	-29.7	-2.4
X-2088	NSCLC	BYL719 + LGH447	210.3	27	7	-5.7	-8.8
X-2088	NSCLC	BYL719 + LGH447	149.3	28.7	14	-33.1	-3
X-2088	NSCLC	BYL719 + LGH447	176.3	27	21	-21	-8.8
X-2088	NSCLC	BYL719 + LGH447	191	26.8	24	-14.4	-9.5
X-2088	NSCLC	BYL719 + LGH447	201.7	26.9	27	-9.6	-9.1
X-2088	NSCLC	BYL719 + LGH447	222.7	26.2	31	-0.2	-11.5
X-2088	NSCLC	BYL719 + LGH447	230.7	27.2	35	3.4	-8.1
X-2088	NSCLC	BYL719 + LGH447	247.1	26.9	38	10.8	-9.1
X-2088	NSCLC	BYL719 + LGH447	243.7	27.1	41	9.2	-8.4
X-2088	NSCLC	BYL719 + LGH447	228.3	27.2	48	2.3	-8.1
X-2088	NSCLC	BYL719 + LGH447	244.3	26.2	55	9.5	-11.5
X-2088	NSCLC	BYL719 + LGH447	219.2	26.2	58	-1.7	-11.5
X-2088	NSCLC	BYL719 + LGH447	258.9	27.4	63	16	-7.4
X-2088	NSCLC	BYL719 + LGH447	171.4	27.7	66	-23.2	-6.4
X-2088	NSCLC	BYL719 + LGH447	198	26.5	69	-11.3	-10.5
X-2088	NSCLC	BYL719 + LGH447	205.2	27	76	-8	-8.8
X-2088	NSCLC	BYL719 + LGH447	203	27.3	80	-9	-7.8
X-2088	NSCLC	BYL719 + LGH447	130.2	27.1	84	-41.6	-8.4
X-2088	NSCLC	BYL719 + LGH447	155	26.6	87	-30.5	-10.1
X-2088	NSCLC	BYL719 + LGH447	115.9	28	91	-48.1	-5.4
X-2088	NSCLC	BYL719 + LGH447	153.7	27.4	94	-31.1	-7.4
X-2088	NSCLC	BYL719 + LGH447	176	28.2	97	-21.1	-4.7
X-2088	NSCLC	BYL719 + LGH447	167.8	27.4	101	-24.8	-7.4
X-2088	NSCLC	BYL719 + LGH447	170.7	28.2	105	-23.5	-4.7
X-2088	NSCLC	BYL719 + LGH447	187.7	28.7	111	-15.9	-3
X-2088	NSCLC	BYL719 + LGH447	227.8	28.6	115	2.1	-3.4
X-2088	NSCLC	BYL719 + LGH447	274.3	28.8	118	22.9	-2.7
X-2088	NSCLC	BYL719 + LGH447	260.1	27.4	122	16.6	-7.4
X-2088	NSCLC	BYL719 + LGH447	288.8	28.4	125	29.4	-4.1
X-2088	NSCLC	BYL719 + LGH447	307.7	28.7	127	37.9	-3
X-2088	NSCLC	BYL719	261	30.9	0	0	0
X-2088	NSCLC	BYL719	434.8	30.6	3	66.6	-1
X-2088	NSCLC	BYL719	878.7	30.5	10	236.7	-1.3
X-2088	NSCLC	BYL719	1000.2	30.5	15	283.2	-1.3
X-2088	NSCLC	BYL719	1151.9	33.3	20	341.3	7.8
X-2088	NSCLC	BYL719	1537.7	33.5	22	489.2	8.4
X-2088	NSCLC	CGM097	1236.2	27.6	15	0	0
X-2088	NSCLC	CKX620	207.2	25.6	0	0	0
X-2088	NSCLC	CKX620	169.8	25.4	3	-18.1	-0.8
X-2088	NSCLC	CKX620	176.1	25.4	7	-15	-0.8
X-2088	NSCLC	CKX620	158.7	25.8	10	-23.4	0.8
X-2088	NSCLC	CKX620	230.9	25.6	17	11.4	0
X-2088	NSCLC	CKX620	254.1	25.3	27	22.6	-1.2
X-2088	NSCLC	CKX620	194.2	25.1	31	-6.3	-2
X-2088	NSCLC	CKX620	198.5	24.5	35	-4.2	-4.3
X-2088	NSCLC	CKX620	109.1	24.9	38	-47.3	-2.7
X-2088	NSCLC	CKX620	144.3	23.7	42	-30.4	-7.4
X-2088	NSCLC	CKX620	64.3	22.7	49	-69	-11.3
X-2088	NSCLC	CKX620	109	20.7	55	-47.4	-19.1
X-2088	NSCLC	CLR457	197.8	24	0	0	0
X-2088	NSCLC	CLR457	457.8	23.5	7	131.4	-2.1
X-2088	NSCLC	CLR457	855.3	24.2	11	332.4	0.8
X-2088	NSCLC	HDM201	155.4	28	0	0	0
X-2088	NSCLC	HDM201	261.6	28.6	3	68.3	2.1
X-2088	NSCLC	HDM201	383.3	29	10	146.7	3.6
X-2088	NSCLC	HDM201	254	28.7	15	63.4	2.5
X-2088	NSCLC	HDM201	592.4	29.4	20	281.2	5
X-2088	NSCLC	HDM201	556.1	29.4	24	257.9	5
X-2088	NSCLC	HDM201	657	28.7	28	322.8	2.5
X-2088	NSCLC	cetuximab	190.5	27.5	0	0	0
X-2088	NSCLC	cetuximab	847.8	29.4	7	345	6.9
X-2088	NSCLC	cetuximab	2239.6	30.3	11	1075.6	10.2
X-2088	NSCLC	erlotinib	294.4	28.4	0	0	0
X-2088	NSCLC	erlotinib	648.4	26.5	4	120.2	-6.7
X-2088	NSCLC	erlotinib	766.8	20.9	8	160.5	-26.4
X-2088	NSCLC	HSP990	217.4	25.7	0	0	0
X-2088	NSCLC	HSP990	261.4	25.2	7	20.2	-1.9
X-2088	NSCLC	HSP990	229.5	20.3	11	5.6	-21
X-2088	NSCLC	HSP990	253.7	21.6	14	16.7	-16
X-2088	NSCLC	HSP990	485.8	27.6	21	123.5	7.4
X-2088	NSCLC	HSP990	845.5	26.9	26	288.9	4.7
X-2088	NSCLC	INC280	308.1	27.3	0	0	0
X-2088	NSCLC	INC280	718.7	26.8	7	133.3	-1.8
X-2088	NSCLC	INC280	910.7	27.6	11	195.6	1.1
X-2088	NSCLC	LCL161 + paclitaxel	188.7	24.4	0	0	0
X-2088	NSCLC	LCL161 + paclitaxel	14.7	24.6	10	-92.2	0.8
X-2088	NSCLC	LCL161 + paclitaxel	9.4	25	14	-95	2.5
X-2088	NSCLC	LCL161 + paclitaxel	149	28.6	49	-21	17.2
X-2088	NSCLC	LCL161 + paclitaxel	276.4	28.6	53	46.5	17.2
X-2088	NSCLC	LCL161 + paclitaxel	453.6	29	56	140.4	18.9
X-2088	NSCLC	LCL161 + paclitaxel	820.4	29.6	59	334.8	21.3
X-2088	NSCLC	LCL161 + paclitaxel	975.1	28.7	60	416.7	17.6
X-2088	NSCLC	LEE011	248.9	24	0	0	0
X-2088	NSCLC	LEE011	450.6	24.9	4	81	3.7
X-2088	NSCLC	LEE011	810.3	25.1	8	225.6	4.6
X-2088	NSCLC	LGH447	131.6	24.8	0	0	0
X-2088	NSCLC	LGH447	153.6	25.1	4	16.7	1.2
X-2088	NSCLC	LGH447	296.6	24.8	8	125.4	0
X-2088	NSCLC	LGH447	348.4	25.4	11	164.7	2.4
X-2088	NSCLC	LGH447	346.2	26.1	18	163.1	5.2
X-2088	NSCLC	LGH447	207.8	27	28	57.9	8.9
X-2088	NSCLC	LGH447	110.1	27.1	32	-16.3	9.3
X-2088	NSCLC	LGH447	57.6	26.9	36	-56.2	8.5
X-2088	NSCLC	LGH447	38.1	26.8	39	-71	8.1
X-2088	NSCLC	LGH447	49.9	27.2	43	-62.1	9.7
X-2088	NSCLC	LGH447	20.5	28	50	-84.4	12.9
X-2088	NSCLC	LGH447	14.4	28	57	-89.1	12.9
X-2088	NSCLC	LGH447	9	28.9	60	-93.2	16.5
X-2088	NSCLC	LGH447	12.3	28.8	63	-90.7	16.1
X-2088	NSCLC	LGH447	10.3	28.9	67	-92.2	16.5
X-2088	NSCLC	LGH447	0	28.4	71	-100	14.5
X-2088	NSCLC	LGH447	0	28.4	74	-100	14.5
X-2088	NSCLC	LGH447	0	29.1	77	-100	17.3
X-2088	NSCLC	LGH447	0	27.4	80	-100	10.5
X-2088	NSCLC	LGH447	0	28.5	84	-100	14.9
X-2088	NSCLC	LGH447	0	29.1	91	-100	17.3
X-2088	NSCLC	LGH447	0	26.7	94	-100	7.7
X-2088	NSCLC	LGH447	0	27.5	99	-100	10.9
X-2088	NSCLC	LGH447	0	27.8	102	-100	12.1
X-2088	NSCLC	LGH447	0	28.5	105	-100	14.9
X-2088	NSCLC	LGH447	0	27.2	112	-100	9.7
X-2088	NSCLC	LGH447	0	27.1	116	-100	9.3
X-2088	NSCLC	LGH447	0	27	120	-100	8.9
X-2088	NSCLC	LGH447	0	26.8	123	-100	8.1
X-2088	NSCLC	LGH447	0	27	127	-100	8.9
X-2088	NSCLC	LGH447	0	27.3	128	-100	10.1
X-2088	NSCLC	LLM871	194.3	NA	0	0	0
X-2088	NSCLC	LLM871	114.8	31.5	7	-40.9	0
X-2088	NSCLC	LLM871	152.3	27.8	12	-21.6	-11.7
X-2088	NSCLC	LLM871	83	28.1	17	-57.3	-10.8
X-2088	NSCLC	LLM871	0	29.1	21	-100	-7.6
X-2088	NSCLC	LLM871	0	28.8	25	-100	-8.6
X-2088	NSCLC	LLM871	0	29.9	28	-100	-5.1
X-2088	NSCLC	LLM871	0	29.4	32	-100	-6.7
X-2088	NSCLC	LLM871	0	33	39	-100	4.8
X-2088	NSCLC	LLM871	0	32.3	46	-100	2.5
X-2088	NSCLC	LLM871	0	31.8	49	-100	1
X-2088	NSCLC	LLM871	0	31.8	52	-100	1
X-2088	NSCLC	LLM871	0	31.3	56	-100	-0.6
X-2088	NSCLC	LLM871	0	30.7	60	-100	-2.5
X-2088	NSCLC	LLM871	0	30	63	-100	-4.8
X-2088	NSCLC	LLM871	0	29.7	66	-100	-5.7
X-2088	NSCLC	LLM871	0	28.9	69	-100	-8.3
X-2088	NSCLC	LLM871	0	29.4	73	-100	-6.7
X-2088	NSCLC	LLM871	0	30.1	80	-100	-4.4
X-2088	NSCLC	LLM871	0	28.4	83	-100	-9.8
X-2088	NSCLC	LLM871	0	30.2	88	-100	-4.1
X-2088	NSCLC	LLM871	0	29.9	91	-100	-5.1
X-2088	NSCLC	LLM871	0	29.3	94	-100	-7
X-2088	NSCLC	LLM871	0	28.9	101	-100	-8.3
X-2088	NSCLC	LLM871	0	27.4	105	-100	-13
X-2088	NSCLC	LLM871	0	30.6	109	-100	-2.9
X-2088	NSCLC	LLM871	0	31.1	112	-100	-1.3
X-2088	NSCLC	LLM871	0	31.6	116	-100	0.3
X-2088	NSCLC	LLM871	0	30.2	117	-100	-4.1
X-2088	NSCLC	binimetinib	224	28.8	0	0	0
X-2088	NSCLC	binimetinib	708	30.3	7	216.1	5.2
X-2088	NSCLC	binimetinib	821.4	31.7	11	266.7	10.1
X-2088	NSCLC	untreated	254.1	25.9	0	0	0
X-2088	NSCLC	untreated	899.1	26.9	7	253.8	3.9
X-2088	NSCLC	untreated	1467.8	28.2	11	477.6	8.9
X-2088	NSCLC	LFW527 + binimetinib	263.21	22.3	0	0	0
X-2088	NSCLC	LFW527 + binimetinib	1343.42	22.5	4	410.4	0.9
X-2088	NSCLC	LFW527 + binimetinib	2278.99	23.1	5	765.8	3.6
X-2094	NSCLC	BGJ398	224.8	23.4	0	0	0
X-2094	NSCLC	BGJ398	462.3	24	4	105.6	2.6
X-2094	NSCLC	BGJ398	500.1	23.9	7	122.5	2.1
X-2094	NSCLC	BGJ398	515.5	23.3	10	129.3	-0.4
X-2094	NSCLC	BGJ398	606	23.6	14	169.6	0.9
X-2094	NSCLC	BGJ398	732.7	23.1	18	225.9	-1.3
X-2094	NSCLC	BGJ398	1043.2	22.8	21	364.1	-2.6
X-2094	NSCLC	BGJ398	1293	23.5	24	475.2	0.4
X-2094	NSCLC	BKM120	261.7	22.2	0	0	0
X-2094	NSCLC	BKM120	319.8	22.2	4	22.2	0
X-2094	NSCLC	BKM120	416.5	21.2	7	59.2	-4.5
X-2094	NSCLC	BKM120	500.4	21.9	10	91.2	-1.4
X-2094	NSCLC	BKM120	623.7	23.3	14	138.3	5
X-2094	NSCLC	BKM120	676.7	22.9	18	158.6	3.2
X-2094	NSCLC	BKM120	1086.3	23.1	21	315.1	4.1
X-2094	NSCLC	BKM120	1260.9	23.6	24	381.8	6.3
X-2094	NSCLC	BKM120 + binimetinib	219.6	24.7	0	0	0
X-2094	NSCLC	BKM120 + binimetinib	211.3	24.4	4	-3.8	-1.2
X-2094	NSCLC	BKM120 + binimetinib	258.9	25.6	7	17.9	3.6
X-2094	NSCLC	BKM120 + binimetinib	270.1	25.8	10	23	4.5
X-2094	NSCLC	BKM120 + binimetinib	375.9	26	14	71.2	5.3
X-2094	NSCLC	BKM120 + binimetinib	423.1	25.7	18	92.7	4
X-2094	NSCLC	BKM120 + binimetinib	303.4	25.6	21	38.2	3.6
X-2094	NSCLC	BKM120 + binimetinib	298	26.1	24	35.7	5.7
X-2094	NSCLC	BKM120 + binimetinib	328.2	25.7	28	49.5	4
X-2094	NSCLC	BKM120 + binimetinib	361.6	26	31	64.7	5.3
X-2094	NSCLC	BKM120 + binimetinib	414.9	26.1	32	88.9	5.7
X-2094	NSCLC	BKM120 + binimetinib	462.9	26.4	35	110.8	6.9
X-2094	NSCLC	BKM120 + binimetinib	534.7	28	40	143.5	13.4
X-2094	NSCLC	BKM120 + binimetinib	395.8	27.2	42	80.2	10.1
X-2094	NSCLC	BKM120 + binimetinib	434.3	26.9	46	97.8	8.9
X-2094	NSCLC	BKM120 + binimetinib	417.9	27	49	90.3	9.3
X-2094	NSCLC	BKM120 + binimetinib	444.9	27.1	53	102.6	9.7
X-2094	NSCLC	BKM120 + binimetinib	512.5	27.9	56	133.4	13
X-2094	NSCLC	BKM120 + binimetinib	517.3	28.4	61	135.6	15
X-2094	NSCLC	BKM120 + binimetinib	456.9	27.7	68	108.1	12.1
X-2094	NSCLC	BKM120 + binimetinib	549.4	28.1	70	150.2	13.8
X-2094	NSCLC	BKM120 + binimetinib	518.7	28.3	73	136.2	14.6
X-2094	NSCLC	BKM120 + binimetinib	670	29.3	80	205.1	18.6
X-2094	NSCLC	BKM120 + binimetinib	621.5	28.6	82	183	15.8
X-2094	NSCLC	BYL719	269.7	24.1	0	0	0
X-2094	NSCLC	BYL719	340.8	23.8	4	26.4	-1.2
X-2094	NSCLC	BYL719	411.4	22.6	7	52.5	-6.2
X-2094	NSCLC	BYL719	478.7	23.1	10	77.5	-4.1
X-2094	NSCLC	BYL719	659.1	24.1	14	144.4	0
X-2094	NSCLC	BYL719	629	23.3	18	133.2	-3.3
X-2094	NSCLC	BYL719	667.3	23.6	21	147.4	-2.1
X-2094	NSCLC	BYL719	722.6	24.4	24	167.9	1.2
X-2094	NSCLC	BYL719	1252.8	25.1	31	364.5	4.1
X-2094	NSCLC	BYL719 + LGH447	329.8	25.6	0	0	0
X-2094	NSCLC	BYL719 + LGH447	468.4	24.8	4	42	-3.1
X-2094	NSCLC	BYL719 + LGH447	254.9	24.8	7	-22.7	-3.1
X-2094	NSCLC	BYL719 + LGH447	319.2	25	10	-3.2	-2.3
X-2094	NSCLC	BYL719 + LGH447	484.3	26.1	14	46.8	2
X-2094	NSCLC	BYL719 + LGH447	673.9	25.6	18	104.3	0
X-2094	NSCLC	BYL719 + LGH447	740.8	25.5	21	124.6	-0.4
X-2094	NSCLC	BYL719 + LGH447	831.9	25	24	152.2	-2.3
X-2094	NSCLC	BYL719 + LGH447	853.3	25.7	28	158.7	0.4
X-2094	NSCLC	BYL719 + LGH447	945.1	25.5	31	186.6	-0.4
X-2094	NSCLC	BYL719 + LJM716	252.9	25.1	0	0	0
X-2094	NSCLC	BYL719 + LJM716	457.9	25.2	4	81.1	0.4
X-2094	NSCLC	BYL719 + LJM716	427	24.5	7	68.8	-2.4
X-2094	NSCLC	BYL719 + LJM716	519.9	24.1	10	105.6	-4
X-2094	NSCLC	BYL719 + LJM716	567.1	25.3	14	124.2	0.8
X-2094	NSCLC	BYL719 + LJM716	530.3	24.2	18	109.7	-3.6
X-2094	NSCLC	BYL719 + LJM716	571.5	23.9	21	126	-4.8
X-2094	NSCLC	BYL719 + LJM716	593.9	25.1	24	134.8	0
X-2094	NSCLC	BYL719 + LJM716	543.9	24.3	28	115.1	-3.2
X-2094	NSCLC	BYL719 + LJM716	618	24.5	31	144.4	-2.4
X-2094	NSCLC	BYL719 + LJM716	765	24.3	35	202.5	-3.2
X-2094	NSCLC	BYL719 + LJM716	967	25.3	40	282.4	0.8
X-2094	NSCLC	BYL719 + LJM716	1125.4	24.4	42	345	-2.8
X-2094	NSCLC	BYL719 + LJM716	1214.5	24.9	46	380.2	-0.8
X-2094	NSCLC	CGM097	183.7	22.9	0	0	0
X-2094	NSCLC	CGM097	341.7	24.2	4	86	5.7
X-2094	NSCLC	CGM097	450.8	25.1	7	145.4	9.6
X-2094	NSCLC	CGM097	424.1	25.1	10	130.9	9.6
X-2094	NSCLC	CGM097	699.4	26.4	14	280.7	15.3
X-2094	NSCLC	CGM097	793	25.2	18	331.7	10
X-2094	NSCLC	CGM097	858	24.4	21	367.1	6.6
X-2094	NSCLC	CGM097	1088.3	25.2	24	492.4	10
X-2094	NSCLC	CKX620	258.6	23.5	0	0	0
X-2094	NSCLC	CKX620	318.7	24.8	4	23.2	5.5
X-2094	NSCLC	CKX620	508.3	25.2	7	96.6	7.2
X-2094	NSCLC	CKX620	560.3	25.4	10	116.7	8.1
X-2094	NSCLC	CKX620	461.1	25.5	14	78.3	8.5
X-2094	NSCLC	CKX620	321.1	25	18	24.2	6.4
X-2094	NSCLC	CKX620	266.3	26	21	3	10.6
X-2094	NSCLC	CKX620	264.3	26	24	2.2	10.6
X-2094	NSCLC	CKX620	198	25.5	28	-23.4	8.5
X-2094	NSCLC	CKX620	241.1	25.9	31	-6.8	10.2
X-2094	NSCLC	CKX620	182	26.4	35	-29.6	12.3
X-2094	NSCLC	CKX620	269	26.6	40	4	13.2
X-2094	NSCLC	CKX620	368.8	25.7	42	42.6	9.4
X-2094	NSCLC	CKX620	414.9	26.8	46	60.4	14
X-2094	NSCLC	CKX620	389.8	26.3	49	50.7	11.9
X-2094	NSCLC	CKX620	343.2	26.7	53	32.7	13.6
X-2094	NSCLC	CKX620	395.5	27.1	56	52.9	15.3
X-2094	NSCLC	CKX620	430.2	26.6	61	66.4	13.2
X-2094	NSCLC	CKX620	452.5	26.4	63	75	12.3
X-2094	NSCLC	CKX620	563.7	26.9	68	118	14.5
X-2094	NSCLC	CKX620	456.7	27	70	76.6	14.9
X-2094	NSCLC	CKX620	603.1	26.7	73	133.2	13.6
X-2094	NSCLC	CKX620	848.5	28	80	228.1	19.1
X-2094	NSCLC	CKX620	823.4	26.8	82	218.4	14
X-2094	NSCLC	CLR457	293.6	24.1	0	0	0
X-2094	NSCLC	CLR457	336.2	24.7	4	14.5	2.5
X-2094	NSCLC	CLR457	302.5	24.7	7	3	2.5
X-2094	NSCLC	CLR457	432.7	25.5	10	47.4	5.8
X-2094	NSCLC	CLR457	511.6	26.5	14	74.3	10
X-2094	NSCLC	CLR457	475.6	26	18	62	7.9
X-2094	NSCLC	CLR457	602.6	24.8	21	105.2	2.9
X-2094	NSCLC	CLR457	637.1	25.9	24	117	7.5
X-2094	NSCLC	CLR457	510.6	25.9	28	73.9	7.5
X-2094	NSCLC	CLR457	655.4	25.5	32	123.2	5.8
X-2094	NSCLC	CLR457	586.2	25.3	35	99.7	5
X-2094	NSCLC	CLR457	571.1	26.3	40	94.5	9.1
X-2094	NSCLC	CLR457	560.4	25.4	42	90.9	5.4
X-2094	NSCLC	CLR457	547.9	26	46	86.6	7.9
X-2094	NSCLC	CLR457	702.5	25.3	49	139.3	5
X-2094	NSCLC	CLR457	738.8	25.9	53	151.6	7.5
X-2094	NSCLC	CLR457	773.8	26.5	56	163.6	10
X-2094	NSCLC	CLR457	742.7	25.5	61	153	5.8
X-2094	NSCLC	HDM201	179.3	22.9	0	0	0
X-2094	NSCLC	HDM201	337.7	23.8	4	88.3	3.9
X-2094	NSCLC	HDM201	396.8	24	7	121.3	4.8
X-2094	NSCLC	HDM201	482.7	24.1	10	169.2	5.2
X-2094	NSCLC	HDM201	710.3	24.2	14	296.2	5.7
X-2094	NSCLC	HDM201	720.1	24.4	17	301.6	6.6
X-2094	NSCLC	HDM201	826.4	24.9	21	360.9	8.7
X-2094	NSCLC	HDM201	916.2	24.5	24	411	7
X-2094	NSCLC	cetuximab	232.5	23.3	0	0	0
X-2094	NSCLC	cetuximab	330.8	24.9	4	42.3	6.9
X-2094	NSCLC	cetuximab	463.8	24.6	7	99.5	5.6
X-2094	NSCLC	cetuximab	564.2	25.8	10	142.7	10.7
X-2094	NSCLC	cetuximab	595.5	26.3	14	156.1	12.9
X-2094	NSCLC	cetuximab	665.1	26	18	186.1	11.6
X-2094	NSCLC	cetuximab	822	26.2	21	253.5	12.4
X-2094	NSCLC	cetuximab	770.9	26.1	24	231.6	12
X-2094	NSCLC	cetuximab	1083.2	25.7	28	365.9	10.3
X-2094	NSCLC	cetuximab	1080.9	26.5	31	364.9	13.7
X-2094	NSCLC	erlotinib	366.6	24.1	0	0	0
X-2094	NSCLC	erlotinib	598.9	23.7	3	63.4	-1.7
X-2094	NSCLC	erlotinib	763.6	22.6	7	108.3	-6.2
X-2094	NSCLC	erlotinib	891.2	20.5	10	143.1	-14.9
X-2094	NSCLC	erlotinib	1098.5	22.2	13	199.6	-7.9
X-2094	NSCLC	erlotinib	1627.2	23.5	17	343.9	-2.5
X-2094	NSCLC	erlotinib	2178.8	23.4	20	494.3	-2.9
X-2094	NSCLC	HSP990	233.1	23.9	0	0	0
X-2094	NSCLC	HSP990	457	25.1	4	96.1	5
X-2094	NSCLC	HSP990	616.3	24.9	7	164.4	4.2
X-2094	NSCLC	HSP990	612	25.8	10	162.5	7.9
X-2094	NSCLC	HSP990	520.6	26.4	14	123.3	10.5
X-2094	NSCLC	HSP990	661.4	26.2	18	183.7	9.6
X-2094	NSCLC	HSP990	879.9	25.6	21	277.5	7.1
X-2094	NSCLC	HSP990	840.7	23.9	24	260.7	0
X-2094	NSCLC	HSP990	563.2	21.9	28	141.6	-8.4
X-2094	NSCLC	HSP990	1078	26.8	35	362.5	12.1
X-2094	NSCLC	HSP990	739.6	25.5	40	217.3	6.7
X-2094	NSCLC	HSP990	611.7	24.3	42	162.4	1.7
X-2094	NSCLC	HSP990	584.4	27.3	46	150.7	14.2
X-2094	NSCLC	HSP990	858	26.1	49	268.1	9.2
X-2094	NSCLC	HSP990	672.1	25.1	53	188.3	5
X-2094	NSCLC	HSP990	683.8	27.2	56	193.4	13.8
X-2094	NSCLC	HSP990	629.8	25.2	61	170.2	5.4
X-2094	NSCLC	INC280	210	22.5	0	0	0
X-2094	NSCLC	INC280	420.4	23.5	4	100.2	4.4
X-2094	NSCLC	INC280	456.5	22.7	7	117.4	0.9
X-2094	NSCLC	INC280	723.7	23.6	10	244.6	4.9
X-2094	NSCLC	INC280	1203.8	24.6	14	473.2	9.3
X-2094	NSCLC	INC280	1704.9	24.3	17	711.9	8
X-2094	NSCLC	LCL161 + paclitaxel	132.6	26.6	0	0	0
X-2094	NSCLC	LCL161 + paclitaxel	202.3	26.9	4	52.6	1.1
X-2094	NSCLC	LCL161 + paclitaxel	269.7	27.5	7	103.4	3.4
X-2094	NSCLC	LCL161 + paclitaxel	221.6	27.6	10	67.1	3.8
X-2094	NSCLC	LCL161 + paclitaxel	372.8	29.1	14	181.1	9.4
X-2094	NSCLC	LCL161 + paclitaxel	393.7	28.3	18	196.9	6.4
X-2094	NSCLC	LCL161 + paclitaxel	519.9	28.7	21	292.1	7.9
X-2094	NSCLC	LCL161 + paclitaxel	524.7	29.2	24	295.7	9.8
X-2094	NSCLC	LCL161 + paclitaxel	641	28.9	28	383.4	8.6
X-2094	NSCLC	LCL161 + paclitaxel	679.4	28.3	31	412.4	6.4
X-2094	NSCLC	LCL161 + paclitaxel	882.9	28.8	35	565.8	8.3
X-2094	NSCLC	LCL161 + paclitaxel	990.1	29.6	40	646.7	11.3
X-2094	NSCLC	LCL161 + paclitaxel	1148.4	28.7	42	766.1	7.9
X-2094	NSCLC	LCL161 + paclitaxel	1306	30	46	884.9	12.8
X-2094	NSCLC	LEE011	218.7	25.2	0	0	0
X-2094	NSCLC	LEE011	344.7	26.8	4	57.6	6.3
X-2094	NSCLC	LEE011	294	26.8	7	34.4	6.3
X-2094	NSCLC	LEE011	341.1	27.9	10	56	10.7
X-2094	NSCLC	LEE011	604.2	28.3	14	176.3	12.3
X-2094	NSCLC	LEE011	645.5	27.9	18	195.2	10.7
X-2094	NSCLC	LEE011	690.5	28.2	21	215.7	11.9
X-2094	NSCLC	LEE011	716	28.6	24	227.4	13.5
X-2094	NSCLC	LEE011	886.7	28.9	28	305.4	14.7
X-2094	NSCLC	LEE011	991.6	28.3	31	353.4	12.3
X-2094	NSCLC	LEE011	1146.8	29.5	35	424.4	17.1
X-2094	NSCLC	LEE011	1227.3	29.8	38	461.2	18.3
X-2094	NSCLC	LGH447	260.4	24.2	0	0	0
X-2094	NSCLC	LGH447	563.5	23.7	4	116.4	-2.1
X-2094	NSCLC	LGH447	497.3	23.6	7	91	-2.5
X-2094	NSCLC	LGH447	509.3	24.6	10	95.6	1.7
X-2094	NSCLC	LGH447	661.4	23.4	14	154	-3.3
X-2094	NSCLC	LGH447	645.8	23	18	148	-5
X-2094	NSCLC	LGH447	586.6	24.1	21	125.3	-0.4
X-2094	NSCLC	LGH447	868.3	24.9	24	233.4	2.9
X-2094	NSCLC	LGH447	819	25	28	214.5	3.3
X-2094	NSCLC	LGH447	1199.7	25	31	360.7	3.3
X-2094	NSCLC	LLM871	214.4	24	0	0	0
X-2094	NSCLC	LLM871	540.1	23.6	4	151.9	-1.7
X-2094	NSCLC	LLM871	508.2	23.5	7	137	-2.1
X-2094	NSCLC	LLM871	517.1	24.6	10	141.2	2.5
X-2094	NSCLC	LLM871	824.8	24.9	14	284.7	3.7
X-2094	NSCLC	LLM871	1014.5	24.8	17	373.2	3.3
X-2094	NSCLC	binimetinib	306.7	25.2	0	0	0
X-2094	NSCLC	binimetinib	370.8	25.8	4	20.9	2.4
X-2094	NSCLC	binimetinib	356.4	25.2	7	16.2	0
X-2094	NSCLC	binimetinib	112.3	25.3	10	-63.4	0.4
X-2094	NSCLC	binimetinib	63.8	25.4	14	-79.2	0.8
X-2094	NSCLC	binimetinib	41.3	24.8	18	-86.5	-1.6
X-2094	NSCLC	binimetinib	35.3	25.8	21	-88.5	2.4
X-2094	NSCLC	binimetinib	25.3	25.2	24	-91.8	0
X-2094	NSCLC	binimetinib	9.5	25.6	28	-96.9	1.6
X-2094	NSCLC	binimetinib	6	25.5	32	-98	1.2
X-2094	NSCLC	binimetinib	0	25.4	35	-100	0.8
X-2094	NSCLC	binimetinib	0	24.3	40	-100	-3.6
X-2094	NSCLC	binimetinib	0	23.6	42	-100	-6.3
X-2094	NSCLC	binimetinib	0	22.8	46	-100	-9.5
X-2094	NSCLC	binimetinib	0	22.9	49	-100	-9.1
X-2094	NSCLC	paclitaxel	198.7	24.9	0	0	0
X-2094	NSCLC	paclitaxel	149.2	24.9	4	-24.9	0
X-2094	NSCLC	paclitaxel	192.1	24.8	7	-3.3	-0.4
X-2094	NSCLC	paclitaxel	168.6	25.5	10	-15.1	2.4
X-2094	NSCLC	paclitaxel	215.4	25.9	14	8.4	4
X-2094	NSCLC	paclitaxel	222.3	25.6	18	11.9	2.8
X-2094	NSCLC	paclitaxel	226.3	25.2	21	13.9	1.2
X-2094	NSCLC	paclitaxel	212.4	25.5	24	6.9	2.4
X-2094	NSCLC	paclitaxel	247.9	25	28	24.8	0.4
X-2094	NSCLC	paclitaxel	287.1	25.3	31	44.5	1.6
X-2094	NSCLC	paclitaxel	310.5	25.8	35	56.3	3.6
X-2094	NSCLC	paclitaxel	325.6	26	40	63.9	4.4
X-2094	NSCLC	paclitaxel	488.2	25.9	42	145.7	4
X-2094	NSCLC	paclitaxel	514.9	25.9	46	159.1	4
X-2094	NSCLC	paclitaxel	540.9	25.8	49	172.2	3.6
X-2094	NSCLC	paclitaxel	510.7	25.9	53	157	4
X-2094	NSCLC	paclitaxel	507	26.7	56	155.2	7.2
X-2094	NSCLC	paclitaxel	606.7	26.6	61	205.3	6.8
X-2094	NSCLC	untreated	174.5	23.9	0	0	0
X-2094	NSCLC	untreated	306.3	25.3	4	75.5	5.9
X-2094	NSCLC	untreated	399.8	25.9	7	129.1	8.4
X-2094	NSCLC	untreated	472	25.4	10	170.5	6.3
X-2094	NSCLC	untreated	840.5	25.8	14	381.7	7.9
X-2094	NSCLC	untreated	1209	26.4	17	592.8	10.5
X-2094	NSCLC	LFW527 + binimetinib	221.32	28.2	0	0	0
X-2094	NSCLC	LFW527 + binimetinib	218.75	28.7	1	-1.2	1.8
X-2094	NSCLC	LFW527 + binimetinib	257.37	28.1	4	16.3	-0.4
X-2094	NSCLC	LFW527 + binimetinib	295.3	29.4	8	33.4	4.3
X-2094	NSCLC	LFW527 + binimetinib	178.47	29.2	11	-19.4	3.5
X-2094	NSCLC	LFW527 + binimetinib	225.49	31.1	15	1.9	10.3
X-2094	NSCLC	LFW527 + binimetinib	156.95	31.1	18	-29.1	10.3
X-2094	NSCLC	LFW527 + binimetinib	124.9	32.3	22	-43.6	14.5
X-2094	NSCLC	LFW527 + binimetinib	106.73	32.1	25	-51.8	13.8
X-2094	NSCLC	LFW527 + binimetinib	113.82	33.6	29	-48.6	19.1
X-2094	NSCLC	LFW527 + binimetinib	118.33	33.5	32	-46.5	18.8
X-2094	NSCLC	LFW527 + binimetinib	213.78	33.5	36	-3.4	18.8
X-2094	NSCLC	LFW527 + binimetinib	246.71	33.4	39	11.5	18.4
X-2094	NSCLC	LFW527 + binimetinib	337.76	32.6	43	52.6	15.6
X-2094	NSCLC	LFW527 + binimetinib	692.62	31	50	212.9	9.9
X-2094	NSCLC	LFW527 + binimetinib	861.01	31.1	57	289	10.3
X-2127	BRCA	LFW527 + everolimus	356.37	21.9	0	0	0
X-2127	BRCA	LFW527 + everolimus	393.53	21.8	2	10.4	-0.5
X-2127	BRCA	LFW527 + everolimus	442.91	21.9	6	24.3	0
X-2127	BRCA	LFW527 + everolimus	525.13	22.8	9	47.4	4.1
X-2127	BRCA	LFW527 + everolimus	499.03	22.6	14	40	3.2
X-2127	BRCA	LFW527 + everolimus	723.84	22	17	103.1	0.5
X-2127	BRCA	LFW527 + everolimus	549.02	21.8	20	54.1	-0.5
X-2127	BRCA	LFW527 + everolimus	454.66	21.7	23	27.6	-0.9
X-2127	BRCA	LFW527 + everolimus	505.51	20.2	27	41.8	-7.8
X-2145	CRC	5FU	223.7	26.4	0	0	0
X-2145	CRC	5FU	294.9	25.4	5	31.8	-3.8
X-2145	CRC	5FU	374	24.3	9	67.2	-8
X-2145	CRC	5FU	373.9	25.9	13	67.1	-1.9
X-2145	CRC	5FU	403.8	25.2	16	80.5	-4.5
X-2145	CRC	5FU	511.1	25.6	21	128.5	-3
X-2145	CRC	5FU	556	24.7	27	148.5	-6.4
X-2145	CRC	5FU	548	22.8	30	145	-13.6
X-2145	CRC	5FU	572	23.1	33	155.7	-12.5
X-2145	CRC	5FU	474.4	23	37	112.1	-12.9
X-2145	CRC	5FU	423.7	23.9	41	89.4	-9.5
X-2145	CRC	BKM120	204	24.4	0	0	0
X-2145	CRC	BKM120	192.3	23.4	4	-5.7	-4.1
X-2145	CRC	BKM120	178.6	22.3	10	-12.5	-8.6
X-2145	CRC	BKM120	207.5	23.1	15	1.7	-5.3
X-2145	CRC	BKM120	185.6	23.2	19	-9	-4.9
X-2145	CRC	BKM120	219.1	22.4	23	7.4	-8.2
X-2145	CRC	BKM120	188.7	22.1	26	-7.5	-9.4
X-2145	CRC	BKM120	196.9	25.3	31	-3.5	3.7
X-2145	CRC	BKM120	219.7	23.4	37	7.7	-4.1
X-2145	CRC	BKM120	251.1	23.5	40	23.1	-3.7
X-2145	CRC	BKM120	257.3	24.6	43	26.1	0.8
X-2145	CRC	BKM120	274.9	23.2	47	34.8	-4.9
X-2145	CRC	BKM120	285.7	26	51	40	6.6
X-2145	CRC	BKM120	304.9	23.7	54	49.5	-2.9
X-2145	CRC	BKM120	320.3	22.5	58	57	-7.8
X-2145	CRC	BKM120	498.9	23.5	64	144.6	-3.7
X-2145	CRC	BKM120	456.9	22.5	68	124	-7.8
X-2145	CRC	BKM120	548.7	22.2	73	169	-9
X-2145	CRC	BKM120	511.4	22.1	75	150.7	-9.4
X-2145	CRC	BKM120 + LJC049	206.7	22.1	0	0	0
X-2145	CRC	BKM120 + LJC049	214.9	21.9	4	4	-0.9
X-2145	CRC	BKM120 + LJC049	248.7	23.7	10	20.3	7.2
X-2145	CRC	BKM120 + LJC049	207.7	21.9	15	0.5	-0.9
X-2145	CRC	BKM120 + LJC049	249.1	22.3	19	20.5	0.9
X-2145	CRC	BKM120 + LJC049	275.1	20.3	23	33.1	-8.1
X-2145	CRC	BKM120 + LJC049	275.5	20.7	26	33.3	-6.3
X-2145	CRC	BKM120 + LJC049	325.5	20.5	31	57.5	-7.2
X-2145	CRC	BKM120 + LJC049	321.7	20.1	37	55.6	-9
X-2145	CRC	BKM120 + LJC049	368.9	20.4	40	78.5	-7.7
X-2145	CRC	BKM120 + LJC049	368.6	21.1	43	78.3	-4.5
X-2145	CRC	BKM120 + LJC049	430.6	21	47	108.3	-5
X-2145	CRC	BKM120 + LJC049	408.1	20.9	51	97.4	-5.4
X-2145	CRC	BKM120 + LJC049	421.9	21.4	54	104.1	-3.2
X-2145	CRC	BYL719	204	23.3	0	0	0
X-2145	CRC	BYL719	274.7	22.6	4	34.7	-3
X-2145	CRC	BYL719	321.1	20.4	7	57.4	-12.4
X-2145	CRC	BYL719	375.2	20.3	13	83.9	-12.9
X-2145	CRC	BYL719	408.9	20	19	100.4	-14.2
X-2145	CRC	BYL719	439.3	20.5	24	115.3	-12
X-2145	CRC	BYL719	531.7	21.1	28	160.6	-9.4
X-2145	CRC	BYL719	556	22.6	32	172.5	-3
X-2145	CRC	BYL719	639	21.4	35	213.2	-8.2
X-2145	CRC	BYL719	623.5	20.3	40	205.6	-12.9
X-2145	CRC	BYL719 + LJM716	214.3	22.6	0	0	0
X-2145	CRC	BYL719 + LJM716	194.8	20.3	4	-9.1	-10.2
X-2145	CRC	BYL719 + LJM716	216.5	19.3	7	1	-14.6
X-2145	CRC	BYL719 + LJM716	240.7	19.6	13	12.3	-13.3
X-2145	CRC	BYL719 + LJM716	403.3	20	19	88.2	-11.5
X-2145	CRC	BYL719 + LJM716	550.9	21.3	24	157.1	-5.8
X-2145	CRC	BYL719 + LJM716	625.3	19.8	28	191.8	-12.4
X-2145	CRC	BYL719 + LJM716	615.8	19.1	32	187.4	-15.5
X-2145	CRC	BYL719 + LJM716	770.4	21.9	35	259.5	-3.1
X-2145	CRC	BYL719 + LJM716	879.7	20.3	40	310.5	-10.2
X-2145	CRC	BYL719 + binimetinib	214.3	21.8	0	0	0
X-2145	CRC	BYL719 + binimetinib	163.9	19.4	4	-23.5	-11
X-2145	CRC	BYL719 + binimetinib	138.5	18.6	7	-35.4	-14.7
X-2145	CRC	BYL719 + binimetinib	104.2	18.6	13	-51.4	-14.7
X-2145	CRC	BYL719 + binimetinib	106.7	19.8	19	-50.2	-9.2
X-2145	CRC	BYL719 + binimetinib	114.3	19.9	24	-46.7	-8.7
X-2145	CRC	BYL719 + binimetinib	95.4	19.4	28	-55.5	-11
X-2145	CRC	BYL719 + binimetinib	81.2	19.7	35	-62.1	-9.6
X-2145	CRC	BYL719 + binimetinib	100.2	20.9	40	-53.2	-4.1
X-2145	CRC	BYL719 + binimetinib	68	19.9	46	-68.3	-8.7
X-2145	CRC	BYL719 + binimetinib	81.1	19.5	49	-62.2	-10.6
X-2145	CRC	BYL719 + binimetinib	86.7	20	52	-59.5	-8.3
X-2145	CRC	BYL719 + binimetinib	106.5	19.7	56	-50.3	-9.6
X-2145	CRC	BYL719 + binimetinib	105.6	20.2	60	-50.7	-7.3
X-2145	CRC	BYL719 + binimetinib	78.2	19.9	63	-63.5	-8.7
X-2145	CRC	BYL719 + binimetinib	99	19.8	67	-53.8	-9.2
X-2145	CRC	BYL719 + binimetinib	88.4	20	73	-58.7	-8.3
X-2145	CRC	BYL719 + binimetinib	105.4	19.7	77	-50.8	-9.6
X-2145	CRC	BYL719 + binimetinib	129.4	22.2	82	-39.6	1.8
X-2145	CRC	BYL719 + binimetinib	123.2	19	84	-42.5	-12.8
X-2145	CRC	BYL719 + binimetinib	111.5	19.8	88	-48	-9.2
X-2145	CRC	BYL719 + binimetinib	139	19.6	91	-35.1	-10.1
X-2145	CRC	BYL719 + binimetinib	129.9	19.9	95	-39.4	-8.7
X-2145	CRC	BYL719 + cetuximab	197.6	22.7	0	0	0
X-2145	CRC	BYL719 + cetuximab	184.2	22	4	-6.8	-3.1
X-2145	CRC	BYL719 + cetuximab	193	22.1	7	-2.3	-2.6
X-2145	CRC	BYL719 + cetuximab	269.4	20.6	13	36.3	-9.3
X-2145	CRC	BYL719 + cetuximab	440.4	21.3	19	122.9	-6.2
X-2145	CRC	BYL719 + cetuximab	511.2	20.5	24	158.7	-9.7
X-2145	CRC	BYL719 + cetuximab	596.2	22	28	201.7	-3.1
X-2145	CRC	BYL719 + cetuximab	664.9	20.6	32	236.5	-9.3
X-2145	CRC	BYL719 + cetuximab	682.5	19.8	35	245.4	-12.8
X-2145	CRC	BYL719 + cetuximab	682.2	20.4	40	245.2	-10.1
X-2145	CRC	BYL719 + encorafenib	223.3	26.8	0	0	0
X-2145	CRC	BYL719 + encorafenib	183.6	25.1	5	-17.8	-6.3
X-2145	CRC	BYL719 + encorafenib	100.5	25.6	9	-55	-4.5
X-2145	CRC	BYL719 + encorafenib	107.4	25.6	13	-51.9	-4.5
X-2145	CRC	BYL719 + encorafenib	102.1	26.1	16	-54.3	-2.6
X-2145	CRC	BYL719 + encorafenib	73.6	25.1	21	-67	-6.3
X-2145	CRC	BYL719 + encorafenib	52.8	25.7	27	-76.4	-4.1
X-2145	CRC	BYL719 + encorafenib	41.3	25.1	30	-81.5	-6.3
X-2145	CRC	BYL719 + encorafenib	61.6	25.6	33	-72.4	-4.5
X-2145	CRC	BYL719 + encorafenib	39.7	26.3	37	-82.2	-1.9
X-2145	CRC	BYL719 + encorafenib	48	26.5	41	-78.5	-1.1
X-2145	CRC	BYL719 + encorafenib	41.7	26	44	-81.3	-3
X-2145	CRC	BYL719 + encorafenib	45.3	25.7	48	-79.7	-4.1
X-2145	CRC	BYL719 + cetuximab + encorafenib	201.9	24	0	0	0
X-2145	CRC	BYL719 + cetuximab + encorafenib	202.3	23	3	0.2	-4.2
X-2145	CRC	BYL719 + cetuximab + encorafenib	145.2	23.2	7	-28.1	-3.3
X-2145	CRC	BYL719 + cetuximab + encorafenib	149	23.7	11	-26.2	-1.3
X-2145	CRC	BYL719 + cetuximab + encorafenib	141.2	24.2	14	-30.1	0.8
X-2145	CRC	BYL719 + cetuximab + encorafenib	128.7	24.7	19	-36.3	2.9
X-2145	CRC	BYL719 + cetuximab + encorafenib	132	24.4	25	-34.6	1.7
X-2145	CRC	BYL719 + cetuximab + encorafenib	123.5	23.9	28	-38.8	-0.4
X-2145	CRC	BYL719 + cetuximab + encorafenib	147.7	24.9	31	-26.8	3.7
X-2145	CRC	BYL719 + cetuximab + encorafenib	122.6	24.2	35	-39.3	0.8
X-2145	CRC	BYL719 + cetuximab + encorafenib	109.7	25.2	39	-45.7	5
X-2145	CRC	BYL719 + cetuximab + encorafenib	104.8	25	42	-48.1	4.2
X-2145	CRC	BYL719 + cetuximab + encorafenib	86.9	25	46	-57	4.2
X-2145	CRC	BYL719 + cetuximab + encorafenib	118	25	52	-41.6	4.2
X-2145	CRC	BYL719 + cetuximab + encorafenib	139.1	25.1	56	-31.1	4.6
X-2145	CRC	BYL719 + cetuximab + encorafenib	131.4	25.5	61	-34.9	6.2
X-2145	CRC	BYL719 + cetuximab + encorafenib	155.1	24.7	63	-23.2	2.9
X-2145	CRC	BYL719 + cetuximab + encorafenib	149.7	24.1	67	-25.9	0.4
X-2145	CRC	BYL719 + cetuximab + encorafenib	153.1	24.4	70	-24.2	1.7
X-2145	CRC	BYL719 + cetuximab + encorafenib	186.1	24.6	74	-7.8	2.5
X-2145	CRC	BYL719 + cetuximab + encorafenib	179.3	24.7	78	-11.2	2.9
X-2145	CRC	BYL719 + cetuximab + encorafenib	192	25.2	81	-4.9	5
X-2145	CRC	BYL719 + cetuximab + encorafenib	187.7	25.7	84	-7	7.1
X-2145	CRC	BYL719 + cetuximab + encorafenib	207.7	25.9	88	2.9	7.9
X-2145	CRC	BYL719 + cetuximab + encorafenib	178.4	24.9	94	-11.6	3.7
X-2145	CRC	BYL719 + cetuximab + encorafenib	171.7	27.3	100	-15	13.7
X-2145	CRC	CGM097	201.9	23.7	0	0	0
X-2145	CRC	CGM097	213	25.3	3	5.5	6.8
X-2145	CRC	CGM097	164.1	21.9	7	-18.7	-7.6
X-2145	CRC	CGM097	174.8	24.6	11	-13.4	3.8
X-2145	CRC	CGM097	142.2	21.8	14	-29.6	-8
X-2145	CRC	CGM097	116.4	21.8	19	-42.3	-8
X-2145	CRC	CGM097	183.3	21.7	25	-9.2	-8.4
X-2145	CRC	CGM097	152.3	19.8	28	-24.6	-16.5
X-2145	CRC	CGM097	173.6	21.2	31	-14	-10.5
X-2145	CRC	CGM097	193.7	21.6	35	-4.1	-8.9
X-2145	CRC	CGM097	181.4	23.2	39	-10.2	-2.1
X-2145	CRC	CGM097	311.1	23.1	42	54.1	-2.5
X-2145	CRC	CGM097	273.4	21.7	46	35.4	-8.4
X-2145	CRC	CGM097	225.3	22.4	52	11.6	-5.5
X-2145	CRC	CGM097	217	21.4	56	7.5	-9.7
X-2145	CRC	CGM097	313.2	21.4	61	55.1	-9.7
X-2145	CRC	CGM097	241.4	20.5	63	19.6	-13.5
X-2145	CRC	CKX620	200.3	22.8	0	0	0
X-2145	CRC	CKX620	227.9	21.2	4	13.8	-7
X-2145	CRC	CKX620	240.6	23.6	7	20.1	3.5
X-2145	CRC	CKX620	163.2	20.7	13	-18.5	-9.2
X-2145	CRC	CKX620	149.4	21.6	19	-25.4	-5.3
X-2145	CRC	CKX620	150.5	23.1	24	-24.9	1.3
X-2145	CRC	CKX620	147	23.3	28	-26.6	2.2
X-2145	CRC	CKX620	129	24.4	32	-35.6	7
X-2145	CRC	CKX620	164.6	26	35	-17.8	14
X-2145	CRC	CKX620	219.8	26.7	40	9.7	17.1
X-2145	CRC	CKX620	191.5	25.3	46	-4.4	11
X-2145	CRC	CKX620	189.2	25.9	49	-5.5	13.6
X-2145	CRC	CKX620	125.8	27	52	-37.2	18.4
X-2145	CRC	CKX620	160.4	27.5	56	-19.9	20.6
X-2145	CRC	CKX620	156.4	27.9	60	-21.9	22.4
X-2145	CRC	CKX620	162.5	27.7	63	-18.9	21.5
X-2145	CRC	CKX620	150.2	28.6	67	-25	25.4
X-2145	CRC	CKX620	160.1	27.1	73	-20.1	18.9
X-2145	CRC	CKX620	112.7	27.2	77	-43.7	19.3
X-2145	CRC	CKX620	124.4	27.5	82	-37.9	20.6
X-2145	CRC	CKX620	118.6	27	84	-40.8	18.4
X-2145	CRC	CKX620	122.8	28.2	88	-38.7	23.7
X-2145	CRC	CKX620	131.8	27.2	91	-34.2	19.3
X-2145	CRC	CKX620	135.8	28.7	95	-32.2	25.9
X-2145	CRC	CKX620	152.2	28.3	98	-24	24.1
X-2145	CRC	CLR457	215.9	20.9	0	0	0
X-2145	CRC	CLR457	270.7	20.2	4	25.4	-3.3
X-2145	CRC	CLR457	291.5	19.5	7	35	-6.7
X-2145	CRC	CLR457	308.7	19.2	13	43	-8.1
X-2145	CRC	CLR457	283.4	19.6	19	31.3	-6.2
X-2145	CRC	CLR457	244.1	20	24	13.1	-4.3
X-2145	CRC	CLR457	267.2	21.3	28	23.8	1.9
X-2145	CRC	CLR457	333	22.5	32	54.2	7.7
X-2145	CRC	CLR457	323.3	21.9	35	49.7	4.8
X-2145	CRC	CLR457	382.3	22	40	77.1	5.3
X-2145	CRC	CLR457	431.9	20.4	46	100	-2.4
X-2145	CRC	CLR457	450	18	49	108.4	-13.9
X-2145	CRC	CLR457	447.8	19.4	52	107.4	-7.2
X-2145	CRC	HDM201	230.1	26.9	0	0	0
X-2145	CRC	HDM201	188.3	23.2	5	-18.2	-13.8
X-2145	CRC	HDM201	176.3	24.3	9	-23.4	-9.7
X-2145	CRC	HDM201	180.9	23.4	13	-21.4	-13
X-2145	CRC	HDM201	177.1	23.2	16	-23	-13.8
X-2145	CRC	HDM201	193.9	26.5	21	-15.7	-1.5
X-2145	CRC	HDM201	176.7	24.7	27	-23.2	-8.2
X-2145	CRC	HDM201	186.9	24.6	30	-18.8	-8.6
X-2145	CRC	HDM201	225.5	22.3	33	-2	-17.1
X-2145	CRC	HDM201	221.6	23	37	-3.7	-14.5
X-2145	CRC	HDM201	263.8	24.6	41	14.6	-8.6
X-2145	CRC	HDM201	259.5	22.7	44	12.8	-15.6
X-2145	CRC	HDM201	252.7	23.7	48	9.8	-11.9
X-2145	CRC	HDM201	264.6	22.5	54	15	-16.4
X-2145	CRC	HDM201	275.7	25.4	58	19.8	-5.6
X-2145	CRC	HDM201	309.8	23.1	63	34.6	-14.1
X-2145	CRC	HDM201	360	26.6	65	56.5	-1.1
X-2145	CRC	HDM201	343.3	24.7	69	49.2	-8.2
X-2145	CRC	HDM201	421	24.1	72	83	-10.4
X-2145	CRC	HDM201	470.3	23.3	76	104.4	-13.4
X-2145	CRC	HDM201	554.2	23	79	140.9	-14.5
X-2145	CRC	cetuximab + encorafenib	200.9	22.9	0	0	0
X-2145	CRC	cetuximab + encorafenib	210.4	22.4	4	4.7	-2.2
X-2145	CRC	cetuximab + encorafenib	210.6	22	7	4.8	-3.9
X-2145	CRC	cetuximab + encorafenib	179.3	21.9	13	-10.8	-4.4
X-2145	CRC	cetuximab + encorafenib	170.6	22.4	19	-15.1	-2.2
X-2145	CRC	cetuximab + encorafenib	192	22.4	24	-4.4	-2.2
X-2145	CRC	cetuximab + encorafenib	188.2	23	28	-6.3	0.4
X-2145	CRC	cetuximab + encorafenib	190.2	23.4	32	-5.3	2.2
X-2145	CRC	cetuximab + encorafenib	185.9	23.2	35	-7.5	1.3
X-2145	CRC	cetuximab + encorafenib	235.9	24	40	17.4	4.8
X-2145	CRC	cetuximab + encorafenib	284.8	24.7	46	41.8	7.9
X-2145	CRC	cetuximab + encorafenib	350.2	24.1	49	74.3	5.2
X-2145	CRC	cetuximab + encorafenib	316.8	23.4	52	57.7	2.2
X-2145	CRC	cetuximab + encorafenib	409.3	23.5	56	103.7	2.6
X-2145	CRC	cetuximab + encorafenib	463.6	23	60	130.8	0.4
X-2145	CRC	cetuximab	236.4	22.4	0	0	0
X-2145	CRC	cetuximab	307.5	21.3	3	30.1	-4.9
X-2145	CRC	cetuximab	509.3	21.1	9	115.4	-5.8
X-2145	CRC	cetuximab	642.9	20.5	15	172	-8.5
X-2145	CRC	cetuximab	928.9	19.4	20	292.9	-13.4
X-2145	CRC	cetuximab	1063.5	20.4	24	349.9	-8.9
X-2145	CRC	cetuximab	1196.4	19.9	28	406.1	-11.2
X-2145	CRC	cetuximab	1269.6	18.9	31	437.1	-15.6
X-2145	CRC	cetuximab	1600.8	19.3	36	577.2	-13.8
X-2145	CRC	LEE011	245.8	24.1	0	0	0
X-2145	CRC	LEE011	416.6	21.8	6	69.5	-9.5
X-2145	CRC	LEE011	451.4	23.7	12	83.6	-1.7
X-2145	CRC	LEE011	443.1	20.3	17	80.3	-15.8
X-2145	CRC	LEE011	412.1	19.5	21	67.7	-19.1
X-2145	CRC	LEE011	393.6	20.9	25	60.1	-13.3
X-2145	CRC	LEE011	385	21.7	28	56.6	-10
X-2145	CRC	LEE011	478.7	20.3	33	94.8	-15.8
X-2145	CRC	LEE011	480.7	21.7	39	95.6	-10
X-2145	CRC	LEE011	460.6	20.3	42	87.4	-15.8
X-2145	CRC	LEE011	485.9	20.9	45	97.7	-13.3
X-2145	CRC	encorafenib	227.3	24.2	0	0	0
X-2145	CRC	encorafenib	211.5	22.9	3	-7	-5.4
X-2145	CRC	encorafenib	237.1	22.9	7	4.3	-5.4
X-2145	CRC	encorafenib	275.8	23.2	11	21.3	-4.1
X-2145	CRC	encorafenib	204	22.7	14	-10.3	-6.2
X-2145	CRC	encorafenib	212.1	25.8	19	-6.7	6.6
X-2145	CRC	encorafenib	240.6	25	25	5.9	3.3
X-2145	CRC	encorafenib	236.1	23.7	28	3.9	-2.1
X-2145	CRC	encorafenib	256.3	23.4	31	12.8	-3.3
X-2145	CRC	encorafenib	261.9	22.5	35	15.2	-7
X-2145	CRC	encorafenib	306.3	24.1	39	34.8	-0.4
X-2145	CRC	encorafenib	386.1	22.5	42	69.9	-7
X-2145	CRC	encorafenib	367.8	21.2	46	61.8	-12.4
X-2145	CRC	encorafenib	449.3	24.9	52	97.7	2.9
X-2145	CRC	encorafenib	436.7	23.7	56	92.1	-2.1
X-2145	CRC	encorafenib	550.5	25.6	61	142.2	5.8
X-2145	CRC	encorafenib	616	26.1	63	171	7.9
X-2145	CRC	LJC049	228.7	21.2	0	0	0
X-2145	CRC	LJC049	281.7	21.9	3	23.2	3.3
X-2145	CRC	LJC049	326.1	20.2	7	42.6	-4.7
X-2145	CRC	LJC049	470.5	21.8	11	105.7	2.8
X-2145	CRC	LJC049	470.5	18.6	14	105.7	-12.3
X-2145	CRC	LKA136	237.8	21.2	0	0	0
X-2145	CRC	LKA136	456.6	21.1	4	92	-0.5
X-2145	CRC	LKA136	514.2	20.6	7	116.2	-2.8
X-2145	CRC	LKA136	682.8	20.8	13	187.1	-1.9
X-2145	CRC	LKA136	971.4	20.5	19	308.5	-3.3
X-2145	CRC	LKA136	1092.5	20.5	24	359.4	-3.3
X-2145	CRC	LKA136	1367.9	20.9	28	475.2	-1.4
X-2145	CRC	LKA136	1267.3	21.8	32	432.9	2.8
X-2145	CRC	LKA136	1396.1	21.2	35	487.1	0
X-2145	CRC	LKA136	1826.4	22.7	40	668	7.1
X-2145	CRC	binimetinib	199.2	23.4	0	0	0
X-2145	CRC	binimetinib	191.3	23	6	-4	-1.7
X-2145	CRC	binimetinib	166.6	23.8	12	-16.4	1.7
X-2145	CRC	binimetinib	140.3	23.8	17	-29.6	1.7
X-2145	CRC	binimetinib	128	25	21	-35.7	6.8
X-2145	CRC	binimetinib	133.8	24.7	25	-32.8	5.6
X-2145	CRC	binimetinib	128.8	25.6	28	-35.3	9.4
X-2145	CRC	binimetinib	130.7	23.9	33	-34.4	2.1
X-2145	CRC	binimetinib	110.3	24	39	-44.6	2.6
X-2145	CRC	binimetinib	127.8	23.6	42	-35.8	0.9
X-2145	CRC	binimetinib	134.7	24.2	45	-32.4	3.4
X-2145	CRC	binimetinib	160.1	24.3	49	-19.6	3.8
X-2145	CRC	binimetinib	212.2	24.9	53	6.5	6.4
X-2145	CRC	binimetinib	226.6	23.7	56	13.8	1.3
X-2145	CRC	binimetinib	173.3	23.8	60	-13	1.7
X-2145	CRC	binimetinib	244.1	24.7	66	22.5	5.6
X-2145	CRC	binimetinib	230.8	23.8	70	15.9	1.7
X-2145	CRC	binimetinib	287.2	25.1	75	44.2	7.3
X-2145	CRC	binimetinib	264.9	24.3	77	33	3.8
X-2145	CRC	binimetinib	255.4	27.5	81	28.2	17.5
X-2145	CRC	binimetinib	266.3	25.3	84	33.7	8.1
X-2145	CRC	binimetinib	287.1	25	88	44.1	6.8
X-2145	CRC	binimetinib	320.5	24.7	91	60.9	5.6
X-2145	CRC	untreated	200	23.2	0	0	0
X-2145	CRC	untreated	334.9	23.1	4	67.4	-0.4
X-2145	CRC	untreated	413.4	22.1	7	106.7	-4.7
X-2145	CRC	untreated	516	22.2	13	158	-4.3
X-2145	CRC	untreated	572.9	22	19	186.5	-5.2
X-2145	CRC	untreated	585.2	22.9	24	192.6	-1.3
X-2145	CRC	untreated	677.6	26	28	238.8	12.1
X-2145	CRC	untreated	763.4	22	32	281.7	-5.2
X-2145	CRC	untreated	805.2	22.1	35	302.6	-4.7
X-2145	CRC	untreated	933.4	25.4	40	366.7	9.5
X-2145	CRC	LFW527 + binimetinib	200.03	23.33	0	0	0
X-2145	CRC	LFW527 + binimetinib	200.65	22.44	3	0.3	-3.8
X-2145	CRC	LFW527 + binimetinib	197.47	22.2	7	-1.3	-4.8
X-2145	CRC	LFW527 + binimetinib	191.33	21.62	10	-4.3	-7.3
X-2145	CRC	LFW527 + binimetinib	187.38	21.45	14	-6.3	-8.1
X-2145	CRC	LFW527 + binimetinib	175.09	21.92	17	-12.5	-6
X-2145	CRC	LFW527 + binimetinib	192.56	22.66	21	-3.7	-2.9
X-2145	CRC	LFW527 + binimetinib	196.55	22.08	24	-1.7	-5.4
X-2145	CRC	LFW527 + binimetinib	200.43	21.74	29	0.2	-6.8
X-2145	CRC	LFW527 + binimetinib	203.77	21.82	32	1.9	-6.5
X-2145	CRC	LFW527 + binimetinib	201.06	21.45	35	0.5	-8.1
X-2145	CRC	LFW527 + binimetinib	204.51	20.91	38	2.2	-10.4
X-2145	CRC	LFW527 + binimetinib	226.02	20.28	42	13	-13.1
X-2145	CRC	LFW527 + binimetinib	278.82	18.55	46	39.4	-20.5
X-2163	CM	BKM120	192.3	23.4	0	0	0
X-2163	CM	BKM120	175	22.8	3	-9	-2.6
X-2163	CM	BKM120	225.2	22.6	6	17.1	-3.4
X-2163	CM	BKM120	243.4	21.9	9	26.6	-6.4
X-2163	CM	BKM120	177.3	23	13	-7.8	-1.7
X-2163	CM	BKM120	219.9	22.6	16	14.3	-3.4
X-2163	CM	BKM120	284.2	23.3	20	47.7	-0.4
X-2163	CM	BKM120	275.1	21.9	23	43	-6.4
X-2163	CM	BKM120	346.5	23.4	27	80.2	0
X-2163	CM	BKM120	252.3	22.9	30	31.2	-2.1
X-2163	CM	BKM120	277.2	23.1	35	44.1	-1.3
X-2163	CM	BKM120	299.7	23.8	38	55.8	1.7
X-2163	CM	BKM120	342.3	23.8	42	77.9	1.7
X-2163	CM	BKM120	355.8	23.6	45	85	0.9
X-2163	CM	BKM120	454.5	24	48	136.3	2.6
X-2163	CM	BKM120	501	23.1	51	160.5	-1.3
X-2163	CM	BKM120	513.6	22.9	55	167	-2.1
X-2163	CM	BKM120 + encorafenib	196	23.4	0	0	0
X-2163	CM	BKM120 + encorafenib	161.5	23.4	3	-17.6	0
X-2163	CM	BKM120 + encorafenib	203.2	23.4	7	3.7	0
X-2163	CM	BKM120 + encorafenib	214.1	23.1	10	9.2	-1.3
X-2163	CM	BKM120 + encorafenib	273.9	22.4	14	39.7	-4.3
X-2163	CM	BKM120 + encorafenib	318.1	22.3	17	62.3	-4.7
X-2163	CM	BKM120 + encorafenib	317.8	22.4	22	62.1	-4.3
X-2163	CM	BKM120 + encorafenib	367.3	22.8	25	87.4	-2.6
X-2163	CM	BKM120 + encorafenib	382.2	21.7	29	95	-7.3
X-2163	CM	BKM120 + encorafenib	382.2	21.7	30	95	-7.3
X-2163	CM	CGM097	191.5	21.7	0	0	0
X-2163	CM	CGM097	297.7	21.4	3	55.4	-1.4
X-2163	CM	CGM097	387.5	21.5	6	102.3	-0.9
X-2163	CM	CGM097	337.5	20.9	9	76.2	-3.7
X-2163	CM	CGM097	335.1	19.9	12	75	-8.3
X-2163	CM	CGM097	408.7	20.4	16	113.4	-6
X-2163	CM	CGM097	439.6	19.9	19	129.5	-8.3
X-2163	CM	CGM097	444.1	18.9	23	131.9	-12.9
X-2163	CM	CGM097	423.1	19.1	26	120.9	-12
X-2163	CM	CGM097	465.7	18.6	27	143.2	-14.3
X-2163	CM	CGM097	513.4	22	30	168.1	1.4
X-2163	CM	CLR457	219.7	27.3	0	0	0
X-2163	CM	CLR457	242.5	28.5	2	10.4	4.4
X-2163	CM	CLR457	219.7	28.4	5	0	4
X-2163	CM	CLR457	224.6	29.5	9	2.2	8.1
X-2163	CM	CLR457	302.3	28.4	12	37.6	4
X-2163	CM	CLR457	359.1	28.7	17	63.5	5.1
X-2163	CM	CLR457	335.4	28.1	20	52.7	2.9
X-2163	CM	CLR457	378.5	28.3	24	72.3	3.7
X-2163	CM	CLR457	432.3	27.5	27	96.8	0.7
X-2163	CM	CLR457	464.2	27.7	30	111.3	1.5
X-2163	CM	CLR457	427.1	27.3	33	94.4	0
X-2163	CM	CLR457	428.8	27.8	37	95.2	1.8
X-2163	CM	dacarbazine	203.7	25.1	0	0	0
X-2163	CM	dacarbazine	176.7	23.9	3	-13.2	-4.8
X-2163	CM	dacarbazine	181	22.1	7	-11.1	-12
X-2163	CM	dacarbazine	188.9	20.9	10	-7.3	-16.7
X-2163	CM	dacarbazine	149.4	20.3	14	-26.6	-19.1
X-2163	CM	LDE225	204.9	22.6	0	0	0
X-2163	CM	LDE225	179.3	21.8	3	-12.5	-3.5
X-2163	CM	LDE225	215.5	20.5	6	5.2	-9.3
X-2163	CM	LDE225	211.9	20.2	10	3.4	-10.6
X-2163	CM	LDE225	248.8	19.2	13	21.4	-15
X-2163	CM	LDE225	254.4	19.9	17	24.2	-11.9
X-2163	CM	LDE225	234.2	18.7	20	14.3	-17.3
X-2163	CM	LDE225	239.4	20.8	21	16.8	-8
X-2163	CM	LDE225	271.1	20.9	24	32.3	-7.5
X-2163	CM	LDE225	282.6	19	27	37.9	-15.9
X-2163	CM	LDE225	333.9	17.5	32	63	-22.6
X-2163	CM	LDK378	212.7	24.7	0	0	0
X-2163	CM	LDK378	191.4	24	2	-10	-2.8
X-2163	CM	LDK378	161.5	23.8	6	-24.1	-3.6
X-2163	CM	LDK378	172.4	22.8	9	-19	-7.7
X-2163	CM	LDK378	190.7	24.3	13	-10.4	-1.6
X-2163	CM	LDK378	185.9	24.1	16	-12.6	-2.4
X-2163	CM	LDK378	260	25.5	20	22.3	3.2
X-2163	CM	LDK378	224.7	25.3	23	5.7	2.4
X-2163	CM	LDK378	202.2	25.1	28	-4.9	1.6
X-2163	CM	LDK378	237.9	24.9	31	11.9	0.8
X-2163	CM	LDK378	160.6	23.7	35	-24.5	-4
X-2163	CM	LDK378	171	23.9	38	-19.6	-3.2
X-2163	CM	LDK378	250.4	23.8	41	17.7	-3.6
X-2163	CM	LDK378	205.3	22.3	44	-3.5	-9.7
X-2163	CM	LDK378	249.6	22.6	48	17.3	-8.5
X-2163	CM	LDK378	292.6	23.6	51	37.6	-4.5
X-2163	CM	LDK378	303.9	24.6	55	42.9	-0.4
X-2163	CM	LDK378	295.1	24.8	58	38.8	0.4
X-2163	CM	LDK378	327.2	23.6	62	53.8	-4.5
X-2163	CM	LEE011	213.6	21.7	0	0	0
X-2163	CM	LEE011	236.8	19.7	3	10.8	-9.2
X-2163	CM	LEE011	211.5	18.2	6	-1	-16.1
X-2163	CM	LEE011	219.2	18	9	2.6	-17.1
X-2163	CM	LEE011 + encorafenib	207	25.8	0	0	0
X-2163	CM	LEE011 + encorafenib	191.2	25.4	3	-7.6	-1.6
X-2163	CM	LEE011 + encorafenib	202.5	25.2	7	-2.2	-2.3
X-2163	CM	LEE011 + encorafenib	188.6	25.2	10	-8.9	-2.3
X-2163	CM	LEE011 + encorafenib	137.9	25.5	14	-33.4	-1.2
X-2163	CM	LEE011 + encorafenib	176.9	25.2	17	-14.6	-2.3
X-2163	CM	LEE011 + encorafenib	196.4	26.6	22	-5.1	3.1
X-2163	CM	LEE011 + encorafenib	256.3	26.7	25	23.8	3.5
X-2163	CM	LEE011 + encorafenib	209.7	25.8	29	1.3	0
X-2163	CM	LEE011 + encorafenib	285.3	26.6	32	37.8	3.1
X-2163	CM	LEE011 + encorafenib	232.4	25.3	35	12.3	-1.9
X-2163	CM	LEE011 + encorafenib	240	26.6	38	15.9	3.1
X-2163	CM	LEE011 + encorafenib	236.1	26.9	42	14.1	4.3
X-2163	CM	LEE011 + encorafenib	309.2	26.8	45	49.3	3.9
X-2163	CM	LEE011 + encorafenib	353.5	27	49	70.8	4.7
X-2163	CM	LEE011 + encorafenib	317.8	26.8	52	53.5	3.9
X-2163	CM	LEE011 + encorafenib	403.8	24.7	56	95	-4.3
X-2163	CM	LEE011 + binimetinib	190.9	24.4	0	0	0
X-2163	CM	LEE011 + binimetinib	178.8	24.1	2	-6.3	-1.2
X-2163	CM	LEE011 + binimetinib	140.9	24.8	5	-26.2	1.6
X-2163	CM	LEE011 + binimetinib	127.7	24.3	9	-33.1	-0.4
X-2163	CM	LEE011 + binimetinib	155	24.2	12	-18.8	-0.8
X-2163	CM	LEE011 + binimetinib	158.4	25.3	17	-17.1	3.7
X-2163	CM	LEE011 + binimetinib	168.5	25.2	20	-11.8	3.3
X-2163	CM	LEE011 + binimetinib	201.4	25.1	24	5.5	2.9
X-2163	CM	LEE011 + binimetinib	159.3	24.8	27	-16.6	1.6
X-2163	CM	LEE011 + binimetinib	158.6	24.7	30	-17	1.2
X-2163	CM	LEE011 + binimetinib	181.5	24.5	33	-4.9	0.4
X-2163	CM	LEE011 + binimetinib	174.4	24.7	37	-8.6	1.2
X-2163	CM	LEE011 + binimetinib	181.7	25.3	40	-4.8	3.7
X-2163	CM	LEE011 + binimetinib	153.2	25.1	44	-19.8	2.9
X-2163	CM	LEE011 + binimetinib	162.8	25.5	47	-14.7	4.5
X-2163	CM	LEE011 + binimetinib	138.4	26.5	51	-27.5	8.6
X-2163	CM	LEE011 + binimetinib	125.8	26.2	54	-34.1	7.4
X-2163	CM	LEE011 + binimetinib	132.6	26.2	58	-30.5	7.4
X-2163	CM	LEE011 + binimetinib	145.5	27.6	61	-23.8	13.1
X-2163	CM	LEE011 + binimetinib	150.9	27.6	65	-21	13.1
X-2163	CM	LEE011 + binimetinib	127.8	26.3	68	-33.1	7.8
X-2163	CM	LEE011 + binimetinib	128.2	27.2	72	-32.9	11.5
X-2163	CM	LEE011 + binimetinib	129.2	27.9	75	-32.3	14.3
X-2163	CM	LEE011 + binimetinib	115.9	27.8	79	-39.3	13.9
X-2163	CM	LEE011 + binimetinib	106.7	27.4	82	-44.1	12.3
X-2163	CM	LEE011 + binimetinib	125.3	27.8	86	-34.4	13.9
X-2163	CM	LEE011 + binimetinib	113.7	27.7	91	-40.4	13.5
X-2163	CM	LEE011 + binimetinib	149.5	26.9	98	-21.7	10.2
X-2163	CM	LEE011 + binimetinib	113.7	26	105	-40.4	6.6
X-2163	CM	LEE011 + binimetinib	103.5	25.5	112	-45.8	4.5
X-2163	CM	LEE011 + binimetinib	75.7	26.6	118	-60.3	9
X-2163	CM	LEE011 + binimetinib	81.1	26.9	125	-57.5	10.2
X-2163	CM	LEE011 + binimetinib	85.7	26.7	131	-55.1	9.4
X-2163	CM	LEE011 + binimetinib	90.9	25.6	137	-52.4	4.9
X-2163	CM	LEE011 + binimetinib	93.3	27.4	144	-51.1	12.3
X-2163	CM	LEE011 + binimetinib	96.8	27.3	151	-49.3	11.9
X-2163	CM	LEE011 + binimetinib	100.7	26.8	161	-47.2	9.8
X-2163	CM	LEE011 + binimetinib	102.6	26.5	167	-46.3	8.6
X-2163	CM	LEE011 + binimetinib	97.5	25.9	174	-48.9	6.1
X-2163	CM	LEE011 + binimetinib	113.4	26	183	-40.6	6.6
X-2163	CM	LEE011 + binimetinib	134	26.8	187	-29.8	9.8
X-2163	CM	LEE011 + binimetinib	115.2	27	194	-39.7	10.7
X-2163	CM	LEE011 + binimetinib	100.4	26.6	201	-47.4	9
X-2163	CM	LEE011 + binimetinib	225	27.6	208	17.8	13.1
X-2163	CM	LEE011 + binimetinib	326.1	26.2	215	70.8	7.4
X-2163	CM	LEE011 + binimetinib	423.8	27.6	221	122	13.1
X-2163	CM	LEE011 + binimetinib	481.6	27.3	228	152.2	11.9
X-2163	CM	LEE011 + binimetinib	539.1	27.6	235	182.3	13.1
X-2163	CM	LEE011 + binimetinib	528.2	26.4	242	176.7	8.2
X-2163	CM	WNT974	196	22.9	0	0	0
X-2163	CM	WNT974	253.2	23.1	4	29.2	0.9
X-2163	CM	WNT974	301.6	22.3	7	53.9	-2.6
X-2163	CM	WNT974	290.7	21.9	11	48.3	-4.4
X-2163	CM	WNT974	281.2	21.6	14	43.5	-5.7
X-2163	CM	WNT974	334.8	21.4	18	70.8	-6.6
X-2163	CM	WNT974	261.4	17.8	21	33.4	-22.3
X-2163	CM	LGW813	216.5	23.4	0	0	0
X-2163	CM	LGW813	303.1	21.8	3	40	-6.8
X-2163	CM	LGW813	311	22.2	6	43.6	-5.1
X-2163	CM	LGW813	540.7	21.9	9	149.8	-6.4
X-2163	CM	LGW813	472.8	23.1	13	118.4	-1.3
X-2163	CM	LGW813	531.3	21.7	16	145.4	-7.3
X-2163	CM	LGW813	518.5	22.7	20	139.5	-3
X-2163	CM	LGW813	516.4	21.3	23	138.5	-9
X-2163	CM	LGW813	741.5	22.7	27	242.5	-3
X-2163	CM	LGW813	589.1	21.2	30	172.1	-9.4
X-2163	CM	LGW813	716.9	21.4	35	231.2	-8.5
X-2163	CM	encorafenib	231	23.4	0	0	0
X-2163	CM	encorafenib	250.6	23.5	3	8.5	0.4
X-2163	CM	encorafenib	305.7	22.7	6	32.3	-3
X-2163	CM	encorafenib	320.8	22.7	9	38.9	-3
X-2163	CM	encorafenib	301.8	21.8	12	30.7	-6.8
X-2163	CM	encorafenib	373.4	22.6	16	61.7	-3.4
X-2163	CM	encorafenib	431.6	21.4	19	86.9	-8.5
X-2163	CM	encorafenib	453.6	23.3	23	96.4	-0.4
X-2163	CM	encorafenib	437.8	22.1	26	89.6	-5.6
X-2163	CM	encorafenib	533.5	22.5	30	131	-3.8
X-2163	CM	encorafenib + binimetinib	208.2	22.3	0	0	0
X-2163	CM	encorafenib + binimetinib	188.1	21.5	3	-9.6	-3.6
X-2163	CM	encorafenib + binimetinib	270.3	22.3	7	29.8	0
X-2163	CM	encorafenib + binimetinib	292.1	21.6	10	40.3	-3.1
X-2163	CM	encorafenib + binimetinib	297.7	22.9	14	43	2.7
X-2163	CM	encorafenib + binimetinib	354.4	22	17	70.2	-1.3
X-2163	CM	encorafenib + binimetinib	417.1	22.1	22	100.3	-0.9
X-2163	CM	encorafenib + binimetinib	511.2	22.5	25	145.5	0.9
X-2163	CM	encorafenib + binimetinib	455.8	22.2	29	118.9	-0.4
X-2163	CM	encorafenib + binimetinib	455.8	22.2	30	118.9	-0.4
X-2163	CM	binimetinib	211.4	25.9	0	0	0
X-2163	CM	binimetinib	155.1	25.6	3	-26.7	-1.2
X-2163	CM	binimetinib	182.6	25.3	6	-13.6	-2.3
X-2163	CM	binimetinib	174.2	25.3	9	-17.6	-2.3
X-2163	CM	binimetinib	187.6	25.3	12	-11.2	-2.3
X-2163	CM	binimetinib	238.4	25	16	12.8	-3.5
X-2163	CM	binimetinib	258	25.1	19	22.1	-3.1
X-2163	CM	binimetinib	266.4	26.1	23	26	0.8
X-2163	CM	binimetinib	244.5	26	26	15.7	0.4
X-2163	CM	binimetinib	273.9	26.3	30	29.5	1.5
X-2163	CM	binimetinib	215.1	25.5	33	1.7	-1.5
X-2163	CM	binimetinib	284	26.2	38	34.3	1.2
X-2163	CM	binimetinib	275.9	26.3	41	30.5	1.5
X-2163	CM	binimetinib	270.6	26.3	45	28	1.5
X-2163	CM	binimetinib	315.4	26.2	48	49.2	1.2
X-2163	CM	binimetinib	294	26.8	51	39	3.5
X-2163	CM	binimetinib	422.6	26.1	54	99.9	0.8
X-2163	CM	binimetinib	473.6	26.6	58	124	2.7
X-2163	CM	TAS266	223.1	23.8	0	0	0
X-2163	CM	TAS266	195.1	23.7	3	-12.5	-0.4
X-2163	CM	TAS266	286.9	23.3	6	28.6	-2.1
X-2163	CM	TAS266	333.2	23.8	9	49.3	0
X-2163	CM	TAS266	292.5	22.8	12	31.1	-4.2
X-2163	CM	TAS266	318.8	23.3	16	42.9	-2.1
X-2163	CM	TAS266	288	22.8	19	29.1	-4.2
X-2163	CM	TAS266	363.2	23.8	23	62.8	0
X-2163	CM	TAS266	378.3	23.8	26	69.5	0
X-2163	CM	TAS266	384	23.6	30	72.1	-0.8
X-2163	CM	untreated	226.1	21.3	0	0	0
X-2163	CM	untreated	403.7	21.3	3	78.5	0
X-2163	CM	untreated	415.6	20.9	6	83.8	-1.9
X-2163	CM	untreated	402.4	19.3	9	78	-9.4
X-2163	CM	untreated	482.6	17.7	12	113.5	-16.9
X-2163	CM	untreated	610.2	18.6	16	169.9	-12.7
X-2163	CM	untreated	541.5	18.3	19	139.5	-14.1
X-2163	CM	untreated	641.5	22.1	23	183.8	3.8
X-2163	CM	untreated	941.1	20.9	26	316.2	-1.9
X-2163	CM	untreated	1235.6	22.3	30	446.5	4.7
X-2182	CRC	5FU	227.4	22.2	0	0	0
X-2182	CRC	5FU	351.1	19.9	3	54.4	-10.4
X-2182	CRC	5FU	351	20.1	7	54.4	-9.5
X-2182	CRC	5FU	390.8	18.2	10	71.9	-18
X-2182	CRC	5FU	502	17.2	15	120.8	-22.5
X-2182	CRC	BKM120	225.4	22.6	0	0	0
X-2182	CRC	BKM120	304.2	21.6	3	35	-4.4
X-2182	CRC	BKM120	375.9	21.6	6	66.8	-4.4
X-2182	CRC	BKM120	969.3	20.1	10	330	-11.1
X-2182	CRC	BKM120	1073.3	19.9	13	376.2	-11.9
X-2182	CRC	BKM120	1639.4	20	16	627.3	-11.5
X-2182	CRC	BKM120 + LJC049	242.6	23.1	0	0	0
X-2182	CRC	BKM120 + LJC049	492	21.9	3	102.8	-5.2
X-2182	CRC	BKM120 + LJC049	739.5	20.4	7	204.8	-11.7
X-2182	CRC	BKM120 + LJC049	1161.8	20.4	10	378.9	-11.7
X-2182	CRC	BKM120 + LJC049	1495.6	20.2	15	516.5	-12.6
X-2182	CRC	BYL719 + cetuximab + encorafenib	242.4	22.2	0	0	0
X-2182	CRC	BYL719 + cetuximab + encorafenib	398.4	22.4	3	64.4	0.9
X-2182	CRC	BYL719 + cetuximab + encorafenib	473.3	24.3	7	95.3	9.5
X-2182	CRC	BYL719 + cetuximab + encorafenib	629.2	23.9	10	159.6	7.7
X-2182	CRC	BYL719 + cetuximab + encorafenib	961.1	24.2	14	296.5	9
X-2182	CRC	BYL719 + cetuximab + encorafenib	1093.9	22.7	16	351.3	2.3
X-2182	CRC	BYL719 + cetuximab + encorafenib	1352.8	22.9	20	458.1	3.2
X-2182	CRC	BYL719 + cetuximab + encorafenib	1565.2	23.3	21	545.7	5
X-2182	CRC	BYL719 + cetuximab	232.3	19	0	0	0
X-2182	CRC	BYL719 + cetuximab	320.9	21.8	4	38.1	14.7
X-2182	CRC	BYL719 + cetuximab	374.1	21.9	7	61	15.3
X-2182	CRC	BYL719 + cetuximab	414.9	20.4	11	78.6	7.4
X-2182	CRC	BYL719 + cetuximab	452.2	21.5	13	94.7	13.2
X-2182	CRC	BYL719 + cetuximab	567.7	20.6	17	144.4	8.4
X-2182	CRC	BYL719 + cetuximab	670	20.2	21	188.4	6.3
X-2182	CRC	BYL719 + cetuximab	772.2	21.4	24	232.4	12.6
X-2182	CRC	BYL719 + cetuximab	889.6	20.9	27	283	10
X-2182	CRC	BYL719 + cetuximab	906.3	20.5	28	290.1	7.9
X-2182	CRC	BYL719	228.7	23.1	0	0	0
X-2182	CRC	BYL719	350.6	22.5	3	53.3	-2.6
X-2182	CRC	BYL719	554.5	21.2	7	142.5	-8.2
X-2182	CRC	BYL719	1073.5	21.4	10	369.4	-7.4
X-2182	CRC	BYL719	1671.5	20.7	15	630.9	-10.4
X-2182	CRC	BYL719 + LJM716	212.8	22	0	0	0
X-2182	CRC	BYL719 + LJM716	299.6	20.1	3	40.8	-8.6
X-2182	CRC	BYL719 + LJM716	371.1	18.9	7	74.4	-14.1
X-2182	CRC	BYL719 + LJM716	532.3	18.5	10	150.1	-15.9
X-2182	CRC	BYL719 + LJM716	928.3	19.1	15	336.2	-13.2
X-2182	CRC	BYL719 + LJM716	1598.4	19	18	651.1	-13.6
X-2182	CRC	BYL719 + binimetinib	218.2	24.5	0	0	0
X-2182	CRC	BYL719 + binimetinib	388.4	23	3	78	-6.1
X-2182	CRC	BYL719 + binimetinib	535	21.7	7	145.2	-11.4
X-2182	CRC	BYL719 + binimetinib	732.6	22.1	10	235.7	-9.8
X-2182	CRC	BYL719 + binimetinib	1035	21	15	374.3	-14.3
X-2182	CRC	BYL719 + binimetinib	1462.9	21	18	570.4	-14.3
X-2182	CRC	BYL719 + encorafenib	219.4	21.4	0	0	0
X-2182	CRC	BYL719 + encorafenib	253.8	20.5	3	15.7	-4.2
X-2182	CRC	BYL719 + encorafenib	351.3	20.1	7	60.1	-6.1
X-2182	CRC	BYL719 + encorafenib	519.5	18.8	10	136.8	-12.1
X-2182	CRC	BYL719 + encorafenib	984.5	19	15	348.7	-11.2
X-2182	CRC	BYL719 + encorafenib	1287.7	19.6	18	486.9	-8.4
X-2182	CRC	BYL719 + encorafenib	1289.2	19.3	22	487.6	-9.8
X-2182	CRC	BYL719 + encorafenib	1487.3	19.1	24	577.9	-10.7
X-2182	CRC	CGM097	230.3	25	0	0	0
X-2182	CRC	CGM097	384.5	23.3	3	67	-6.8
X-2182	CRC	CGM097	619	23.4	6	168.8	-6.4
X-2182	CRC	CGM097	1140.3	22.2	10	395.1	-11.2
X-2182	CRC	CGM097	1738.7	22.1	13	655	-11.6
X-2182	CRC	CKX620	214.7	24.8	0	0	0
X-2182	CRC	CKX620	205.2	23.9	3	-4.4	-3.6
X-2182	CRC	CKX620	233.1	23.9	6	8.6	-3.6
X-2182	CRC	CKX620	330.3	23.8	10	53.8	-4
X-2182	CRC	CKX620	406.3	25.2	13	89.2	1.6
X-2182	CRC	CKX620	401.6	24.9	18	87.1	0.4
X-2182	CRC	CKX620	581.3	25.5	21	170.7	2.8
X-2182	CRC	CKX620	655.9	24.9	25	205.5	0.4
X-2182	CRC	CKX620	779.1	25.6	27	262.9	3.2
X-2182	CRC	CLR457	205.5	21.7	0	0	0
X-2182	CRC	CLR457	243.3	21.7	3	18.4	0
X-2182	CRC	CLR457	344.1	20.3	7	67.4	-6.5
X-2182	CRC	CLR457	432.5	19.5	10	110.5	-10.1
X-2182	CRC	CLR457	506.7	18.3	15	146.6	-15.7
X-2182	CRC	CLR457	582.7	19.1	18	183.6	-12
X-2182	CRC	CLR457	601.1	18.4	22	192.5	-15.2
X-2182	CRC	CLR457	708.8	19	24	244.9	-12.4
X-2182	CRC	HDM201	256.2	24.9	0	0	0
X-2182	CRC	HDM201	461.9	23.6	3	80.3	-5.2
X-2182	CRC	HDM201	763.7	23.3	6	198.1	-6.4
X-2182	CRC	HDM201	811.7	21.6	10	216.8	-13.3
X-2182	CRC	HDM201	1066.1	20.9	13	316.1	-16.1
X-2182	CRC	HDM201	1181.1	20	18	361	-19.7
X-2182	CRC	cetuximab	240.9	21.8	0	0	0
X-2182	CRC	cetuximab	286.5	21.5	3	18.9	-1.4
X-2182	CRC	cetuximab	370.1	20.8	6	53.6	-4.6
X-2182	CRC	cetuximab	537.9	20.2	9	123.3	-7.3
X-2182	CRC	cetuximab	753	21.1	13	212.6	-3.2
X-2182	CRC	cetuximab	993.1	21.3	16	312.2	-2.3
X-2182	CRC	cetuximab	942.3	20.4	20	291.2	-6.4
X-2182	CRC	cetuximab	964.2	24.1	22	300.2	10.6
X-2182	CRC	cetuximab	1159.8	20.9	26	381.4	-4.1
X-2182	CRC	cetuximab	1142.7	20.5	27	374.3	-6
X-2182	CRC	cetuximab + encorafenib	241.7	16.3	0	0	0
X-2182	CRC	cetuximab + encorafenib	367.1	17.8	3	51.9	9.2
X-2182	CRC	cetuximab + encorafenib	468.7	18.6	7	93.9	14.1
X-2182	CRC	cetuximab + encorafenib	548.9	17.7	10	127.1	8.6
X-2182	CRC	cetuximab + encorafenib	771.3	17.3	14	219.1	6.1
X-2182	CRC	cetuximab + encorafenib	828.3	17.9	16	242.7	9.8
X-2182	CRC	cetuximab + encorafenib	1107.4	17.9	20	358.2	9.8
X-2182	CRC	cetuximab + encorafenib	1350	17.9	21	458.5	9.8
X-2182	CRC	LEE011	216	23.5	0	0	0
X-2182	CRC	LEE011	315.8	24.4	3	46.2	3.8
X-2182	CRC	LEE011	569.6	21.8	6	163.7	-7.2
X-2182	CRC	LEE011	748	20.7	10	246.3	-11.9
X-2182	CRC	LEE011	1191.2	20.7	13	451.5	-11.9
X-2182	CRC	LEE011	1412.5	19.2	18	553.9	-18.3
X-2182	CRC	encorafenib	219.8	25	0	0	0
X-2182	CRC	encorafenib	455.4	24.7	3	107.2	-1.2
X-2182	CRC	encorafenib	996.6	24.6	6	353.4	-1.6
X-2182	CRC	encorafenib	1880.4	24.6	10	755.5	-1.6
X-2182	CRC	LJC049	211.3	25.4	0	0	0
X-2182	CRC	LJC049	884.3	25.3	3	318.5	-0.4
X-2182	CRC	LJC049	1990.9	26.3	7	842.2	3.5
X-2182	CRC	LKA136	191.4	26.8	0	0	0
X-2182	CRC	LKA136	268.4	26.4	3	40.2	-1.5
X-2182	CRC	LKA136	505.8	25.4	7	164.3	-5.2
X-2182	CRC	LKA136	654.1	25.2	10	241.7	-6
X-2182	CRC	LKA136	1089.3	24.5	15	469.1	-8.6
X-2182	CRC	LKA136	1768.4	23.9	18	823.9	-10.8
X-2182	CRC	binimetinib	250.8	22.4	0	0	0
X-2182	CRC	binimetinib	467.6	20.4	3	86.4	-8.9
X-2182	CRC	binimetinib	510.8	20	6	103.7	-10.7
X-2182	CRC	binimetinib	1083.2	19.7	10	331.9	-12.1
X-2182	CRC	binimetinib	1104.1	20.2	13	340.2	-9.8
X-2182	CRC	binimetinib	1481.2	20	16	490.6	-10.7
X-2182	CRC	untreated	217.1	23.1	0	0	0
X-2182	CRC	untreated	310.7	22.6	5	43.1	-2.2
X-2182	CRC	untreated	332.6	23	8	53.2	-0.4
X-2182	CRC	untreated	487.2	22.6	12	124.4	-2.2
X-2182	CRC	untreated	591.4	22.6	14	172.4	-2.2
X-2182	CRC	untreated	858.7	22.4	18	295.5	-3
X-2182	CRC	untreated	947.2	22.2	21	336.3	-3.9
X-2182	CRC	LFW527 + binimetinib	268.53	21.83	0	0	0
X-2182	CRC	LFW527 + binimetinib	380.13	20.43	3	41.6	-6.4
X-2182	CRC	LFW527 + binimetinib	566.69	20.56	6	111	-5.8
X-2182	CRC	LFW527 + binimetinib	760.82	19.66	10	183.3	-9.9
X-2182	CRC	LFW527 + binimetinib	881.97	19.75	13	228.4	-9.5
X-2182	CRC	LFW527 + binimetinib	1405.21	25.27	18	423.3	15.8
X-2195	BRCA	BGJ398	211.7	25.9	0	0	0
X-2195	BRCA	BGJ398	244.3	27.8	6	15.4	7.3
X-2195	BRCA	BGJ398	277.5	27.2	9	31.1	5
X-2195	BRCA	BGJ398	289.8	26.8	12	36.9	3.5
X-2195	BRCA	BGJ398	349.5	26.5	16	65.1	2.3
X-2195	BRCA	BGJ398	388.2	25.9	19	83.4	0
X-2195	BRCA	BGJ398	494.5	26.8	34	133.6	3.5
X-2195	BRCA	BGJ398	576.2	27.6	37	172.2	6.6
X-2195	BRCA	BKM120	225.7	25.6	0	0	0
X-2195	BRCA	BKM120	325.3	26.4	6	44.1	3.1
X-2195	BRCA	BKM120	352.2	25.6	9	56	0
X-2195	BRCA	BKM120	338.7	26	12	50.1	1.6
X-2195	BRCA	BKM120	378.4	25.8	16	67.7	0.8
X-2195	BRCA	BKM120	385	24.8	19	70.6	-3.1
X-2195	BRCA	BKM120	469.9	24.4	27	108.2	-4.7
X-2195	BRCA	BKM120	513.6	24.5	34	127.6	-4.3
X-2195	BRCA	BKM120	580.6	23.9	37	157.2	-6.6
X-2195	BRCA	BYL719	214.8	25.2	0	0	0
X-2195	BRCA	BYL719	343.1	25.3	6	59.7	0.4
X-2195	BRCA	BYL719	340.7	24.6	9	58.6	-2.4
X-2195	BRCA	BYL719	387.9	24.5	12	80.6	-2.8
X-2195	BRCA	BYL719	491.5	24.2	16	128.8	-4
X-2195	BRCA	BYL719	457.9	23.4	19	113.2	-7.1
X-2195	BRCA	BYL719	527.2	23.9	27	145.4	-5.2
X-2195	BRCA	BYL719	796.7	24.1	34	270.9	-4.4
X-2195	BRCA	BYL719	827.8	24.2	37	285.4	-4
X-2195	BRCA	BYL719 + LEE011	298.5	23.1	0	0	0
X-2195	BRCA	BYL719 + LEE011	249.8	21	4	-16.3	-9.1
X-2195	BRCA	BYL719 + LEE011	188.4	21.4	11	-36.9	-7.4
X-2195	BRCA	BYL719 + LEE011	202.3	22	14	-32.2	-4.8
X-2195	BRCA	BYL719 + LEE011	180.1	21.3	18	-39.7	-7.8
X-2195	BRCA	BYL719 + LEE011	117.4	18	21	-60.7	-22.1
X-2195	BRCA	BYL719 + LJM716	207.6	25.3	0	0	0
X-2195	BRCA	BYL719 + LJM716	123.9	22.9	3	-40.3	-9.5
X-2195	BRCA	BYL719 + LJM716	157.6	23.4	7	-24.1	-7.5
X-2195	BRCA	BYL719 + LJM716	206.4	24.7	10	-0.6	-2.4
X-2195	BRCA	BYL719 + LJM716	208.1	24.7	14	0.2	-2.4
X-2195	BRCA	BYL719 + LJM716	253.6	25	16	22.2	-1.2
X-2195	BRCA	BYL719 + LJM716	316.7	25.8	20	52.6	2
X-2195	BRCA	BYL719 + LJM716	427.1	26	23	105.7	2.8
X-2195	BRCA	BYL719 + LJM716	396.6	26.3	28	91	4
X-2195	BRCA	BYL719 + LJM716	485.5	25.7	31	133.9	1.6
X-2195	BRCA	BYL719 + LJM716	478.4	25.7	35	130.4	1.6
X-2195	BRCA	CGM097	220.8	24.6	0	0	0
X-2195	BRCA	CGM097	262.8	24.4	6	19	-0.8
X-2195	BRCA	CGM097	278.6	24.9	9	26.2	1.2
X-2195	BRCA	CGM097	263	24.6	12	19.1	0
X-2195	BRCA	CGM097	184.3	25.5	16	-16.5	3.7
X-2195	BRCA	CGM097	286.9	23.3	19	29.9	-5.3
X-2195	BRCA	CGM097	255.5	24.5	27	15.7	-0.4
X-2195	BRCA	CGM097	202	25.9	34	-8.5	5.3
X-2195	BRCA	CGM097	207.3	28.5	37	-6.1	15.9
X-2195	BRCA	CLR457	228.4	25.4	0	0	0
X-2195	BRCA	CLR457	299.4	25.6	6	31.1	0.8
X-2195	BRCA	CLR457	328.7	25	9	43.9	-1.6
X-2195	BRCA	CLR457	364.4	25.1	12	59.5	-1.2
X-2195	BRCA	CLR457	391.8	24.9	16	71.5	-2
X-2195	BRCA	CLR457	411.1	23	19	80	-9.4
X-2195	BRCA	CLR457	528.2	23.8	27	131.3	-6.3
X-2195	BRCA	HDM201	244.3	25.6	0	0	0
X-2195	BRCA	HDM201	286.4	25.8	3	17.2	0.8
X-2195	BRCA	HDM201	280.2	24	6	14.7	-6.2
X-2195	BRCA	HDM201	233.8	25.2	10	-4.3	-1.6
X-2195	BRCA	HDM201	265.3	22.7	13	8.6	-11.3
X-2195	BRCA	HDM201	304.9	23.8	21	24.8	-7
X-2195	BRCA	HDM201	224.7	24.7	28	-8	-3.5
X-2195	BRCA	HDM201	275.8	24	31	12.9	-6.2
X-2195	BRCA	HDM201	332	23	35	35.9	-10.2
X-2195	BRCA	HDM201	291.1	21.3	38	19.2	-16.8
X-2195	BRCA	INC424	198.6	23.2	0	0	0
X-2195	BRCA	INC424	174.2	22.8	2	-12.3	-1.7
X-2195	BRCA	INC424	174.2	22.8	5	-12.3	-1.7
X-2195	BRCA	INC424	172.2	23.2	9	-13.3	0
X-2195	BRCA	INC424	232.7	22.6	12	17.2	-2.6
X-2195	BRCA	INC424	262.6	23.2	20	32.2	0
X-2195	BRCA	INC424	365.3	23.9	27	83.9	3
X-2195	BRCA	INC424	597.9	24.8	30	201.1	6.9
X-2195	BRCA	LEE011	210.5	27.1	0	0	0
X-2195	BRCA	LEE011	258.5	24.2	3	22.8	-10.7
X-2195	BRCA	LEE011	292.4	26.4	11	38.9	-2.6
X-2195	BRCA	LEE011	263.2	25.3	18	25	-6.6
X-2195	BRCA	LEE011	308.9	26.3	21	46.7	-3
X-2195	BRCA	LEE011	332	29.5	24	57.7	8.9
X-2195	BRCA	LEE011 + everolimus	209.7	25.7	0	0	0
X-2195	BRCA	LEE011 + everolimus	274.6	25.9	3	30.9	0.8
X-2195	BRCA	LEE011 + everolimus	288.4	26.2	7	37.5	1.9
X-2195	BRCA	LEE011 + everolimus	255.3	26	10	21.7	1.2
X-2195	BRCA	LEE011 + everolimus	257.9	26.1	14	23	1.6
X-2195	BRCA	LEE011 + everolimus	234.5	27.2	16	11.8	5.8
X-2195	BRCA	LEE011 + everolimus	190.9	29.2	20	-9	13.6
X-2195	BRCA	LEE011 + everolimus	142.9	29.4	23	-31.9	14.4
X-2195	BRCA	LEE011 + everolimus	58.1	25.3	28	-72.3	-1.6
X-2195	BRCA	LEE011 + everolimus	73	26.3	31	-65.2	2.3
X-2195	BRCA	LEE011 + everolimus	0	26.6	35	-100	3.5
X-2195	BRCA	LEE011 + everolimus	0	25.9	38	-100	0.8
X-2195	BRCA	LEE011 + everolimus	0	25.3	41	-100	-1.6
X-2195	BRCA	LEE011 + everolimus	0	26.1	46	-100	1.6
X-2195	BRCA	LEE011 + everolimus	0	25.8	49	-100	0.4
X-2195	BRCA	LEE011 + everolimus	0	25.7	52	-100	0
X-2195	BRCA	LEE011 + everolimus	0	26	55	-100	1.2
X-2195	BRCA	LEE011 + everolimus	0	26.5	59	-100	3.1
X-2195	BRCA	LEE011 + everolimus	0	26.1	62	-100	1.6
X-2195	BRCA	LEE011 + everolimus	0	27.3	69	-100	6.2
X-2195	BRCA	LEE011 + everolimus	0	26.7	73	-100	3.9
X-2195	BRCA	LEE011 + everolimus	0	25.6	76	-100	-0.4
X-2195	BRCA	LEE011 + everolimus	0	26.4	80	-100	2.7
X-2195	BRCA	LFA102	296.1	25.5	0	0	0
X-2195	BRCA	LFA102	306.4	26.8	8	3.5	5.1
X-2195	BRCA	LFA102	324.8	27.1	15	9.7	6.3
X-2195	BRCA	LFA102	420.7	27.8	18	42.1	9
X-2195	BRCA	LFA102	399.2	27.4	21	34.8	7.5
X-2195	BRCA	LJM716	259.1	23.3	0	0	0
X-2195	BRCA	LJM716	378.5	22.5	3	46.1	-3.4
X-2195	BRCA	LJM716	538	23.4	11	107.6	0.4
X-2195	BRCA	LJM716	612.4	23.4	18	136.4	0.4
X-2195	BRCA	LJM716	837.2	23.2	21	223.1	-0.4
X-2195	BRCA	LJM716	1023.2	23.6	24	294.9	1.3
X-2195	BRCA	LJM716 + trastuzumab	216.3	28.1	0	0	0
X-2195	BRCA	LJM716 + trastuzumab	275	27.8	3	27.1	-1.1
X-2195	BRCA	LJM716 + trastuzumab	382.5	27.3	7	76.8	-2.8
X-2195	BRCA	LJM716 + trastuzumab	391.2	27.2	10	80.9	-3.2
X-2195	BRCA	LJM716 + trastuzumab	490.7	27.7	14	126.9	-1.4
X-2195	BRCA	LJM716 + trastuzumab	601.5	27.3	16	178.1	-2.8
X-2195	BRCA	LJM716 + trastuzumab	744.1	28	20	244	-0.4
X-2195	BRCA	LJM716 + trastuzumab	901.7	27.6	23	316.9	-1.8
X-2195	BRCA	LJM716 + trastuzumab	1450.7	28.1	28	570.7	0
X-2195	BRCA	LKA136	202.5	22.5	0	0	0
X-2195	BRCA	LKA136	199.2	22.8	8	-1.6	1.3
X-2195	BRCA	LKA136	217.3	20.5	15	7.3	-8.9
X-2195	BRCA	LKA136	235.9	19.2	18	16.5	-14.7
X-2195	BRCA	LKA136	291.6	22.8	22	44	1.3
X-2195	BRCA	LKA136	314.2	23.8	25	55.2	5.8
X-2195	BRCA	LKA136	340.9	22.1	29	68.3	-1.8
X-2195	BRCA	LKA136	342	22.5	31	68.9	0
X-2195	BRCA	LKA136	377.6	21.9	35	86.5	-2.7
X-2195	BRCA	LKA136	463.5	24.7	38	128.9	9.8
X-2195	BRCA	LKA136	521.2	23.8	43	157.4	5.8
X-2195	BRCA	LKA136	490.1	26.2	46	142	16.4
X-2195	BRCA	LKA136	592.3	21.7	50	192.5	-3.6
X-2195	BRCA	LLM871	261.5	25.2	0	0	0
X-2195	BRCA	LLM871	360.5	25.6	8	37.9	1.6
X-2195	BRCA	LLM871	353.4	23.9	15	35.1	-5.2
X-2195	BRCA	LLM871	187.6	24.7	18	-28.3	-2
X-2195	BRCA	LLM871	202.4	25.1	22	-22.6	-0.4
X-2195	BRCA	LLM871	119.5	26.2	25	-54.3	4
X-2195	BRCA	LLM871	202.5	24.9	29	-22.6	-1.2
X-2195	BRCA	LLM871	203.7	24.3	31	-22.1	-3.6
X-2195	BRCA	LLM871	309.7	25.2	35	18.4	0
X-2195	BRCA	LLM871	356	24.7	38	36.1	-2
X-2195	BRCA	LLM871	472.7	25.3	43	80.8	0.4
X-2195	BRCA	LLM871	453.8	25.3	46	73.5	0.4
X-2195	BRCA	LLM871	733	25.4	50	180.3	0.8
X-2195	BRCA	LLM871	863.8	25.7	53	230.3	2
X-2195	BRCA	LLM871	1036.8	25.2	56	296.5	0
X-2195	BRCA	LLM871	1293	25.6	61	394.5	1.6
X-2195	BRCA	LLM871	1615.5	25.4	64	517.8	0.8
X-2195	BRCA	binimetinib	191.1	25.6	0	0	0
X-2195	BRCA	binimetinib	205.2	24.3	4	7.4	-5.1
X-2195	BRCA	binimetinib	221.6	24.4	7	16	-4.7
X-2195	BRCA	binimetinib	245.8	24.3	11	28.6	-5.1
X-2195	BRCA	binimetinib	237.3	25.1	13	24.2	-2
X-2195	BRCA	binimetinib	275.1	24.5	17	44	-4.3
X-2195	BRCA	binimetinib	324.1	23	20	69.6	-10.2
X-2195	BRCA	binimetinib	309.3	22.8	25	61.9	-10.9
X-2195	BRCA	binimetinib	320.9	23.2	28	67.9	-9.4
X-2195	BRCA	binimetinib	387.2	23.2	32	102.6	-9.4
X-2195	BRCA	paclitaxel	237.8	25.9	0	0	0
X-2195	BRCA	paclitaxel	333.5	25	3	40.2	-3.5
X-2195	BRCA	paclitaxel	344	24.6	7	44.7	-5
X-2195	BRCA	paclitaxel	448.9	25	10	88.8	-3.5
X-2195	BRCA	paclitaxel	524.8	25.5	14	120.7	-1.5
X-2195	BRCA	paclitaxel	578.2	25.7	16	143.1	-0.8
X-2195	BRCA	paclitaxel	648.1	25.7	20	172.5	-0.8
X-2195	BRCA	paclitaxel	793.1	25.9	23	233.5	0
X-2195	BRCA	paclitaxel	921.1	25.2	28	287.3	-2.7
X-2195	BRCA	tamoxifen	198.6	26.4	0	0	0
X-2195	BRCA	tamoxifen	168.9	25.2	4	-15	-4.5
X-2195	BRCA	tamoxifen	147.4	26	11	-25.8	-1.5
X-2195	BRCA	tamoxifen	205.4	27.3	14	3.4	3.4
X-2195	BRCA	tamoxifen	183.7	27.4	18	-7.5	3.8
X-2195	BRCA	tamoxifen	216.1	27.9	21	8.8	5.7
X-2195	BRCA	tamoxifen	219.9	28.3	25	10.7	7.2
X-2195	BRCA	tamoxifen	234.4	28.4	27	18	7.6
X-2195	BRCA	tamoxifen	250.7	28.1	31	26.2	6.4
X-2195	BRCA	trastuzumab	194.5	25.2	0	0	0
X-2195	BRCA	trastuzumab	255.8	26	8	31.5	3.2
X-2195	BRCA	trastuzumab	391.2	26.3	15	101.1	4.4
X-2195	BRCA	trastuzumab	544.6	26.6	18	180	5.6
X-2195	BRCA	trastuzumab	559.2	27.2	21	187.5	7.9
X-2195	BRCA	untreated	214.7	24.8	0	0	0
X-2195	BRCA	untreated	354.7	25.4	6	65.2	2.4
X-2195	BRCA	untreated	489	26	9	127.8	4.8
X-2195	BRCA	untreated	464.4	26.3	12	116.3	6
X-2195	BRCA	untreated	474.8	26.4	16	121.1	6.5
X-2195	BRCA	untreated	689.1	25.7	19	221	3.6
X-2195	BRCA	untreated	836.2	26.1	27	289.5	5.2
X-2195	BRCA	untreated	1284.7	24.8	34	498.4	0
X-2195	BRCA	untreated	1523.3	23.6	37	609.5	-4.8
X-2239	CRC	5FU	214.8	22.9	0	0	0
X-2239	CRC	5FU	217.1	23	6	1.1	0.4
X-2239	CRC	5FU	242.8	20.9	9	13	-8.7
X-2239	CRC	5FU	296.2	20.9	13	37.9	-8.7
X-2239	CRC	5FU	276.1	20.2	16	28.5	-11.8
X-2239	CRC	5FU	292.7	20.4	19	36.3	-10.9
X-2239	CRC	5FU	271	19.1	21	26.2	-16.6
X-2239	CRC	BKM120 + LJC049	217.5	24	0	0	0
X-2239	CRC	BKM120 + LJC049	232.1	24.6	3	6.7	2.5
X-2239	CRC	BKM120 + LJC049	252.6	24.2	7	16.1	0.8
X-2239	CRC	BKM120 + LJC049	277.2	26.5	10	27.4	10.4
X-2239	CRC	BKM120 + LJC049	387.7	24.2	13	78.3	0.8
X-2239	CRC	BKM120 + LJC049	414.3	23.2	18	90.5	-3.3
X-2239	CRC	BKM120 + LJC049	455.7	23	21	109.5	-4.2
X-2239	CRC	BKM120 + LJC049	497.6	23.1	24	128.8	-3.7
X-2239	CRC	BKM120 + LJC049	465.9	23.9	27	114.2	-0.4
X-2239	CRC	BKM120 + LJC049	600.8	23.4	31	176.2	-2.5
X-2239	CRC	BKM120 + LJC049	517.1	25.1	34	137.7	4.6
X-2239	CRC	BKM120 + LJC049	593.8	25.3	38	173	5.4
X-2239	CRC	BKM120 + LJC049	656.6	24.1	41	201.9	0.4
X-2239	CRC	BKM120 + LJC049	711.4	25.3	45	227.1	5.4
X-2239	CRC	BKM120 + LJC049	662.8	25.5	48	204.7	6.2
X-2239	CRC	BYL719	212.2	23.9	0	0	0
X-2239	CRC	BYL719	255.5	22.9	3	20.4	-4.2
X-2239	CRC	BYL719	318.1	22.7	7	49.9	-5
X-2239	CRC	BYL719	303.9	22.4	10	43.2	-6.3
X-2239	CRC	BYL719	361.5	22.4	13	70.4	-6.3
X-2239	CRC	BYL719	367.5	23	18	73.2	-3.8
X-2239	CRC	BYL719	445.2	23.2	21	109.8	-2.9
X-2239	CRC	BYL719	450.1	24.4	24	112.1	2.1
X-2239	CRC	BYL719	481.5	22	27	126.9	-7.9
X-2239	CRC	BYL719	449.9	23	31	112	-3.8
X-2239	CRC	BYL719	505.2	23.8	34	138.1	-0.4
X-2239	CRC	BYL719	598.2	24.5	38	181.9	2.5
X-2239	CRC	BYL719	496.9	24.4	41	134.2	2.1
X-2239	CRC	BYL719	608.6	25.6	45	186.8	7.1
X-2239	CRC	BYL719	639	26	48	201.1	8.8
X-2239	CRC	BYL719	617.7	26.3	52	191.1	10
X-2239	CRC	BYL719	662.9	25.5	55	212.4	6.7
X-2239	CRC	BYL719 + cetuximab + encorafenib	196.3	23.8	0	0	0
X-2239	CRC	BYL719 + cetuximab + encorafenib	190.5	24.4	3	-3	2.5
X-2239	CRC	BYL719 + cetuximab + encorafenib	184.4	25	7	-6.1	5
X-2239	CRC	BYL719 + cetuximab + encorafenib	153.8	23.8	10	-21.7	0
X-2239	CRC	BYL719 + cetuximab + encorafenib	169.5	25	13	-13.7	5
X-2239	CRC	BYL719 + cetuximab + encorafenib	178.3	26.8	18	-9.2	12.6
X-2239	CRC	BYL719 + cetuximab + encorafenib	184.8	26.7	21	-5.9	12.2
X-2239	CRC	BYL719 + cetuximab + encorafenib	199.4	27.4	24	1.6	15.1
X-2239	CRC	BYL719 + cetuximab + encorafenib	195.1	26.9	27	-0.6	13
X-2239	CRC	BYL719 + cetuximab + encorafenib	179.8	26.8	31	-8.4	12.6
X-2239	CRC	BYL719 + cetuximab + encorafenib	175.7	26.4	34	-10.5	10.9
X-2239	CRC	BYL719 + cetuximab + encorafenib	201.2	26	38	2.5	9.2
X-2239	CRC	BYL719 + cetuximab + encorafenib	212.1	26.1	41	8	9.7
X-2239	CRC	BYL719 + binimetinib	193.6	25.9	0	0	0
X-2239	CRC	BYL719 + binimetinib	193	25.1	3	-0.3	-3.1
X-2239	CRC	BYL719 + binimetinib	201.9	25.5	7	4.3	-1.5
X-2239	CRC	BYL719 + binimetinib	195.3	24.2	10	0.9	-6.6
X-2239	CRC	BYL719 + binimetinib	174.9	25.9	13	-9.7	0
X-2239	CRC	BYL719 + binimetinib	165.5	25	18	-14.5	-3.5
X-2239	CRC	BYL719 + binimetinib	172	24.9	21	-11.2	-3.9
X-2239	CRC	BYL719 + binimetinib	182.6	25.2	24	-5.7	-2.7
X-2239	CRC	BYL719 + binimetinib	198.6	24.6	27	2.6	-5
X-2239	CRC	BYL719 + binimetinib	192.5	24.7	31	-0.6	-4.6
X-2239	CRC	BYL719 + binimetinib	203.9	23.6	34	5.3	-8.9
X-2239	CRC	BYL719 + binimetinib	199.6	23.5	38	3.1	-9.3
X-2239	CRC	BYL719 + binimetinib	177.6	21.3	41	-8.3	-17.8
X-2239	CRC	BYL719 + binimetinib	214.3	21.4	43	10.7	-17.4
X-2239	CRC	BYL719 + encorafenib	194.9	26	0	0	0
X-2239	CRC	BYL719 + encorafenib	180.9	25.5	2	-7.2	-1.9
X-2239	CRC	BYL719 + encorafenib	146.9	25.9	5	-24.6	-0.4
X-2239	CRC	BYL719 + encorafenib	162.7	26.6	10	-16.5	2.3
X-2239	CRC	BYL719 + encorafenib	124.7	26.5	13	-36	1.9
X-2239	CRC	BYL719 + encorafenib	137.8	27.8	16	-29.3	6.9
X-2239	CRC	BYL719 + encorafenib	153.6	26.4	19	-21.2	1.5
X-2239	CRC	BYL719 + encorafenib	123.7	27	23	-36.5	3.8
X-2239	CRC	BYL719 + encorafenib	108.8	27.4	26	-44.2	5.4
X-2239	CRC	BYL719 + encorafenib	120.4	27.4	30	-38.2	5.4
X-2239	CRC	BYL719 + encorafenib	102	26.9	33	-47.7	3.5
X-2239	CRC	BYL719 + encorafenib	96	27.5	37	-50.7	5.8
X-2239	CRC	BYL719 + encorafenib	113.9	27.7	40	-41.6	6.5
X-2239	CRC	BYL719 + encorafenib	102.6	26.5	44	-47.4	1.9
X-2239	CRC	BYL719 + encorafenib	155.9	26.4	47	-20	1.5
X-2239	CRC	BYL719 + encorafenib	134.2	25.6	51	-31.1	-1.5
X-2239	CRC	BYL719 + encorafenib	116.2	27	54	-40.4	3.8
X-2239	CRC	BYL719 + encorafenib	121.4	24.8	56	-37.7	-4.6
X-2239	CRC	BYL719 + cetuximab	198.3	27.3	0	0	0
X-2239	CRC	BYL719 + cetuximab	196	27.5	3	-1.2	0.7
X-2239	CRC	BYL719 + cetuximab	202.8	26.8	6	2.3	-1.8
X-2239	CRC	BYL719 + cetuximab	261.7	27.8	9	32	1.8
X-2239	CRC	BYL719 + cetuximab	286.1	27.1	12	44.3	-0.7
X-2239	CRC	BYL719 + cetuximab	372	27.6	16	87.6	1.1
X-2239	CRC	BYL719 + cetuximab	380.8	27.6	19	92	1.1
X-2239	CRC	BYL719 + cetuximab	412.6	28.2	23	108.1	3.3
X-2239	CRC	BYL719 + cetuximab	440.3	27.9	26	122	2.2
X-2239	CRC	BYL719 + cetuximab	608.5	27.4	30	206.9	0.4
X-2239	CRC	BYL719 + cetuximab	685.9	27.4	33	245.9	0.4
X-2239	CRC	BYL719 + cetuximab	719.1	29	37	262.6	6.2
X-2239	CRC	BYL719 + cetuximab	919.4	32.5	40	363.6	19
X-2239	CRC	CLR457	201.6	25.6	0	0	0
X-2239	CRC	CLR457	201.4	25	3	-0.1	-2.3
X-2239	CRC	CLR457	250.1	24.3	7	24.1	-5.1
X-2239	CRC	CLR457	281.6	24.4	10	39.7	-4.7
X-2239	CRC	CLR457	280.3	23.7	13	39	-7.4
X-2239	CRC	CLR457	310.5	25.1	18	54	-2
X-2239	CRC	CLR457	307.4	24.7	21	52.5	-3.5
X-2239	CRC	CLR457	324.8	26.2	24	61.1	2.3
X-2239	CRC	CLR457	330.2	25.3	27	63.8	-1.2
X-2239	CRC	CLR457	374.2	25.3	31	85.6	-1.2
X-2239	CRC	CLR457	466.9	26.3	34	131.6	2.7
X-2239	CRC	CLR457	439.8	26.6	38	118.2	3.9
X-2239	CRC	CLR457	473.3	25.9	41	134.8	1.2
X-2239	CRC	CLR457	512.8	27.6	45	154.4	7.8
X-2239	CRC	CLR457	475.9	28.2	48	136.1	10.2
X-2239	CRC	CLR457	527.9	27.2	52	161.9	6.2
X-2239	CRC	CLR457	586.5	26.5	55	190.9	3.5
X-2239	CRC	cetuximab	247.9	24.9	0	0	0
X-2239	CRC	cetuximab	295.9	24.7	6	19.4	-0.8
X-2239	CRC	cetuximab	338	24.1	9	36.3	-3.2
X-2239	CRC	cetuximab	383	24.2	13	54.5	-2.8
X-2239	CRC	cetuximab	438.6	23.8	16	76.9	-4.4
X-2239	CRC	cetuximab	567.6	25	19	129	0.4
X-2239	CRC	cetuximab	729.4	23.7	24	194.2	-4.8
X-2239	CRC	cetuximab	854.3	23.7	27	244.6	-4.8
X-2239	CRC	cetuximab	916.5	23.6	28	269.7	-5.2
X-2239	CRC	cetuximab + encorafenib	184.6	23.4	0	0	0
X-2239	CRC	cetuximab + encorafenib	178.2	23.3	3	-3.5	-0.4
X-2239	CRC	cetuximab + encorafenib	143	23.1	7	-22.5	-1.3
X-2239	CRC	cetuximab + encorafenib	165.4	22.2	10	-10.4	-5.1
X-2239	CRC	cetuximab + encorafenib	139.1	23.6	13	-24.6	0.9
X-2239	CRC	cetuximab + encorafenib	132	23.1	18	-28.5	-1.3
X-2239	CRC	cetuximab + encorafenib	134.1	23.4	21	-27.4	0
X-2239	CRC	cetuximab + encorafenib	125	23.5	24	-32.3	0.4
X-2239	CRC	cetuximab + encorafenib	121.5	22.7	27	-34.2	-3
X-2239	CRC	cetuximab + encorafenib	127	23.1	31	-31.2	-1.3
X-2239	CRC	cetuximab + encorafenib	112.9	23.5	34	-38.8	0.4
X-2239	CRC	cetuximab + encorafenib	136	24.2	38	-26.3	3.4
X-2239	CRC	cetuximab + encorafenib	141.1	24	41	-23.6	2.6
X-2239	CRC	cetuximab + encorafenib	142.8	24.8	43	-22.6	6
X-2239	CRC	LEE011	214.3	26.6	0	0	0
X-2239	CRC	LEE011	209.9	25.9	6	-2.1	-2.6
X-2239	CRC	LEE011	185.3	26.4	9	-13.5	-0.8
X-2239	CRC	LEE011	161.2	26.8	13	-24.8	0.8
X-2239	CRC	LEE011	189.2	27.5	16	-11.7	3.4
X-2239	CRC	LEE011	168.1	26.8	19	-21.6	0.8
X-2239	CRC	LEE011	154.4	27.4	24	-28	3
X-2239	CRC	LEE011	172.1	27.6	27	-19.7	3.8
X-2239	CRC	LEE011	201.2	29.1	30	-6.1	9.4
X-2239	CRC	LEE011	176.1	27.3	33	-17.8	2.6
X-2239	CRC	LEE011	171.1	27.7	37	-20.2	4.1
X-2239	CRC	LEE011	158.8	28	40	-25.9	5.3
X-2239	CRC	LEE011	156.5	28.7	44	-27	7.9
X-2239	CRC	LEE011	160.4	28.1	47	-25.2	5.6
X-2239	CRC	LEE011	145.4	27.7	51	-32.2	4.1
X-2239	CRC	LEE011	179.9	28.9	54	-16.1	8.6
X-2239	CRC	LEE011	215.2	29.1	58	0.4	9.4
X-2239	CRC	LEE011	231.5	28.5	61	8	7.1
X-2239	CRC	LEE011	205.9	29.4	65	-3.9	10.5
X-2239	CRC	LEE011	176.5	29.3	68	-17.6	10.2
X-2239	CRC	LEE011	220.6	28.8	70	2.9	8.3
X-2239	CRC	encorafenib	193.7	27.1	0	0	0
X-2239	CRC	encorafenib	186.6	26.5	2	-3.7	-2.2
X-2239	CRC	encorafenib	244.8	26	5	26.4	-4.1
X-2239	CRC	encorafenib	306.9	26.8	10	58.4	-1.1
X-2239	CRC	encorafenib	292.4	27.5	13	51	1.5
X-2239	CRC	encorafenib	359.8	27.8	16	85.8	2.6
X-2239	CRC	encorafenib	317.4	26.5	19	63.9	-2.2
X-2239	CRC	encorafenib	354.1	27.4	23	82.8	1.1
X-2239	CRC	encorafenib	350.6	27	26	81	-0.4
X-2239	CRC	encorafenib	384.8	27.7	30	98.7	2.2
X-2239	CRC	encorafenib	404.5	27.4	33	108.8	1.1
X-2239	CRC	encorafenib	426.5	28.9	37	120.2	6.6
X-2239	CRC	encorafenib	449.6	28.5	40	132.1	5.2
X-2239	CRC	encorafenib	511.9	27.8	44	164.3	2.6
X-2239	CRC	encorafenib	466.9	27.7	47	141	2.2
X-2239	CRC	LJC049	198.6	23.4	0	0	0
X-2239	CRC	LJC049	268.4	23.6	6	35.1	0.9
X-2239	CRC	LJC049	285.7	23.7	9	43.9	1.3
X-2239	CRC	LJC049	366.4	24.1	13	84.5	3
X-2239	CRC	LJC049	435.3	25.9	16	119.2	10.7
X-2239	CRC	LJC049	532.9	24.7	19	168.3	5.6
X-2239	CRC	LJC049	670	24	24	237.4	2.6
X-2239	CRC	LJC049	709.7	23.4	27	257.4	0
X-2239	CRC	LJC049	744.7	23.7	30	275	1.3
X-2239	CRC	LJC049	836.9	24.1	33	321.4	3
X-2239	CRC	LJC049	1032.4	23.5	36	419.8	0.4
X-2239	CRC	binimetinib	220.3	27.3	0	0	0
X-2239	CRC	binimetinib	203.6	27.2	3	-7.6	-0.4
X-2239	CRC	binimetinib	195.9	27.5	6	-11.1	0.7
X-2239	CRC	binimetinib	175.2	26.3	9	-20.5	-3.7
X-2239	CRC	binimetinib	190.4	26.7	14	-13.6	-2.2
X-2239	CRC	binimetinib	207.6	26.5	17	-5.8	-2.9
X-2239	CRC	binimetinib	229.8	26.5	21	4.3	-2.9
X-2239	CRC	binimetinib	231.9	26.2	24	5.3	-4
X-2239	CRC	binimetinib	215.7	26.8	27	-2.1	-1.8
X-2239	CRC	binimetinib	205.8	27.6	32	-6.6	1.1
X-2239	CRC	binimetinib	219.3	28	35	-0.5	2.6
X-2239	CRC	binimetinib	203.6	29.2	38	-7.6	7
X-2239	CRC	binimetinib	220.3	28.1	41	0	2.9
X-2239	CRC	binimetinib	236.6	28.1	45	7.4	2.9
X-2239	CRC	binimetinib	301.1	28.2	48	36.7	3.3
X-2239	CRC	binimetinib	291.3	28.4	52	32.2	4
X-2239	CRC	binimetinib	306.7	28.8	55	39.2	5.5
X-2239	CRC	binimetinib	348.5	30.3	59	58.2	11
X-2239	CRC	binimetinib	397.2	29.8	62	80.3	9.2
X-2239	CRC	binimetinib	476.8	29.4	66	116.4	7.7
X-2239	CRC	binimetinib	472	29.1	69	114.3	6.6
X-2239	CRC	binimetinib	395.8	29.5	73	79.7	8.1
X-2239	CRC	binimetinib	503.3	29.3	76	128.5	7.3
X-2239	CRC	binimetinib	552.3	24.3	78	150.7	-11
X-2239	CRC	untreated	212.8	23.1	0	0	0
X-2239	CRC	untreated	249.9	23.2	3	17.4	0.4
X-2239	CRC	untreated	268.5	23.4	7	26.2	1.3
X-2239	CRC	untreated	270.6	23.4	10	27.2	1.3
X-2239	CRC	untreated	377.7	20.1	13	77.5	-13
X-2239	CRC	untreated	373.6	23.6	16	75.6	2.2
X-2239	CRC	untreated	458.5	23.6	21	115.5	2.2
X-2239	CRC	untreated	466.1	22.9	24	119	-0.9
X-2239	CRC	untreated	553.1	23	28	159.9	-0.4
X-2239	CRC	untreated	584.3	22.1	31	174.6	-4.3
X-2239	CRC	untreated	727.9	23.8	34	242.1	3
X-2239	CRC	untreated	783.8	25.2	39	268.3	9.1
X-2239	CRC	untreated	927.6	26	42	335.9	12.6
X-2239	CRC	untreated	1055.3	26.9	43	395.9	16.5
X-2239	CRC	LFW527 + binimetinib	201.89	22.81	0	0	0
X-2239	CRC	LFW527 + binimetinib	211.92	23.25	5	5	1.9
X-2239	CRC	LFW527 + binimetinib	255.44	23.29	9	26.5	2.1
X-2239	CRC	LFW527 + binimetinib	287.04	23.08	12	42.2	1.2
X-2239	CRC	LFW527 + binimetinib	327.91	22.59	15	62.4	-1
X-2239	CRC	LFW527 + binimetinib	322.01	22.97	19	59.5	0.7
X-2239	CRC	LFW527 + binimetinib	370.25	23.04	26	83.4	1
X-2239	CRC	LFW527 + binimetinib	464.92	23.05	29	130.3	1.1
X-2239	CRC	LFW527 + binimetinib	520.05	23	33	157.6	0.8
X-2239	CRC	LFW527 + binimetinib	516.49	23.05	36	155.8	1.1
X-2283	PDAC	abraxane	241.7	25.1	0	0	0
X-2283	PDAC	abraxane	291.6	27.2	3	20.6	8.4
X-2283	PDAC	abraxane	403.6	26.8	7	67	6.8
X-2283	PDAC	abraxane	596.9	26.6	9	147	6
X-2283	PDAC	abraxane	1073.1	26.8	13	344	6.8
X-2283	PDAC	abraxane	1151.2	26.4	16	376.3	5.2
X-2283	PDAC	BKM120	185.5	21.2	0	0	0
X-2283	PDAC	BKM120	218.9	22	3	18	3.8
X-2283	PDAC	BKM120	337.9	22.6	6	82.2	6.6
X-2283	PDAC	BKM120	368.9	24.1	10	98.9	13.7
X-2283	PDAC	BKM120	477.4	23.1	13	157.4	9
X-2283	PDAC	BKM120	692.8	23	17	273.5	8.5
X-2283	PDAC	BYL719	332.9	24.8	0	0	0
X-2283	PDAC	BYL719	496.1	24.4	4	49	-1.6
X-2283	PDAC	BYL719	674.9	24.8	7	102.7	0
X-2283	PDAC	BYL719	835.4	25.1	10	150.9	1.2
X-2283	PDAC	BYL719	891.8	24.8	14	167.9	0
X-2283	PDAC	BYL719	1074.6	23.9	20	222.8	-3.6
X-2283	PDAC	BYL719	1348.2	25.5	25	305	2.8
X-2283	PDAC	BYL719	1421.9	25.3	28	327.1	2
X-2283	PDAC	BYL719	1701.8	25.8	32	411.2	4
X-2283	PDAC	CLR457	256.7	25	0	0	0
X-2283	PDAC	CLR457	391.6	25.7	4	52.6	2.8
X-2283	PDAC	CLR457	514.6	25.6	7	100.5	2.4
X-2283	PDAC	CLR457	620.2	26.5	10	141.6	6
X-2283	PDAC	CLR457	719.5	25.5	14	180.3	2
X-2283	PDAC	CLR457	712.5	25	20	177.6	0
X-2283	PDAC	CLR457	1245.1	23.8	25	385	-4.8
X-2283	PDAC	CLR457	1411.3	24	28	449.8	-4
X-2283	PDAC	CLR457	1562.2	21.8	32	508.6	-12.8
X-2283	PDAC	HDM201	310.6	26.1	0	0	0
X-2283	PDAC	HDM201	585.8	25.5	4	88.6	-2.3
X-2283	PDAC	HDM201	571.2	25.4	7	83.9	-2.7
X-2283	PDAC	HDM201	601.8	25.6	10	93.8	-1.9
X-2283	PDAC	HDM201	1002.7	26	14	222.8	-0.4
X-2283	PDAC	HDM201	602.3	24.9	20	93.9	-4.6
X-2283	PDAC	HDM201	872.7	26.1	25	181	0
X-2283	PDAC	HDM201	758.2	24.5	28	144.1	-6.1
X-2283	PDAC	HDM201	906.2	26.2	32	191.8	0.4
X-2283	PDAC	gemcitabine-50mpk	326.3	23.1	0	0	0
X-2283	PDAC	gemcitabine-50mpk	378.4	22.8	3	16	-1.3
X-2283	PDAC	gemcitabine-50mpk	605	22.1	7	85.4	-4.3
X-2283	PDAC	gemcitabine-50mpk	633.7	NA	11	94.2	-4.3
X-2283	PDAC	gemcitabine-50mpk	846	20.7	14	159.3	-10.4
X-2283	PDAC	gemcitabine-50mpk	946.3	21.6	18	190	-6.5
X-2283	PDAC	gemcitabine-50mpk	961.3	20.9	20	194.6	-9.5
X-2283	PDAC	gemcitabine-50mpk	1102.2	21.6	25	237.8	-6.5
X-2283	PDAC	gemcitabine-50mpk	1434.9	20.2	31	339.7	-12.6
X-2283	PDAC	INC424 + binimetinib	266.3	23.4	0	0	0
X-2283	PDAC	INC424 + binimetinib	443.8	21.1	7	66.7	-9.8
X-2283	PDAC	INC424 + binimetinib	555.9	22.6	14	108.7	-3.4
X-2283	PDAC	INC424 + binimetinib	858.1	20.3	17	222.2	-13.2
X-2283	PDAC	INC424 + binimetinib	1127.2	20.6	21	323.3	-12
X-2283	PDAC	INC424 + binimetinib	1003.2	20.1	24	276.7	-14.1
X-2283	PDAC	INC424 + binimetinib	1653.6	21.5	28	521	-8.1
X-2283	PDAC	INC424	224.1	25.5	0	0	0
X-2283	PDAC	INC424	266.1	25.7	4	18.7	0.8
X-2283	PDAC	INC424	325.7	24	7	45.3	-5.9
X-2283	PDAC	INC424	451	24.3	11	101.2	-4.7
X-2283	PDAC	INC424	520.8	24.9	14	132.4	-2.4
X-2283	PDAC	INC424	601.3	24.4	18	168.3	-4.3
X-2283	PDAC	INC424	713.5	24.7	21	218.4	-3.1
X-2283	PDAC	INC424	660.8	24.4	24	194.9	-4.3
X-2283	PDAC	INC424	764.6	24.3	27	241.2	-4.7
X-2283	PDAC	INC424	773.8	25.2	32	245.3	-1.2
X-2283	PDAC	INC424	881.6	24.3	35	293.4	-4.7
X-2283	PDAC	INC424	898.9	23.5	39	301.1	-7.8
X-2283	PDAC	LEE011	202.9	23.1	0	0	0
X-2283	PDAC	LEE011	215.1	24.1	3	6	4.3
X-2283	PDAC	LEE011	236.9	24.2	7	16.8	4.8
X-2283	PDAC	LEE011	322.5	23.4	9	58.9	1.3
X-2283	PDAC	LEE011	469.7	23.9	13	131.5	3.5
X-2283	PDAC	LEE011	515.7	24	16	154.2	3.9
X-2283	PDAC	LEE011	766.6	25.2	20	277.8	9.1
X-2283	PDAC	LEE011	1208.3	25.3	23	495.5	9.5
X-2283	PDAC	WNT974	271.9	26.7	0	0	0
X-2283	PDAC	WNT974	414.4	24.3	3	52.4	-9
X-2283	PDAC	WNT974	383.9	24.5	5	41.2	-8.2
X-2283	PDAC	WNT974	602	23.8	9	121.4	-10.9
X-2283	PDAC	WNT974	880.9	25.4	13	224	-4.9
X-2283	PDAC	WNT974	1019.8	24.9	16	275.1	-6.7
X-2283	PDAC	LKA136	253.7	28.5	0	0	0
X-2283	PDAC	LKA136	257.2	28.6	3	1.4	0.4
X-2283	PDAC	LKA136	471.4	29	10	85.8	1.8
X-2283	PDAC	LKA136	658.7	28.8	13	159.6	1.1
X-2283	PDAC	LKA136	792.9	28.7	17	212.5	0.7
X-2283	PDAC	LKA136	766.2	29.3	20	202	2.8
X-2283	PDAC	LKA136	1173.2	29.7	25	362.4	4.2
X-2283	PDAC	LKA136	1321.4	30.6	29	420.9	7.4
X-2283	PDAC	binimetinib-3.5mpk	206.1	24.2	0	0	0
X-2283	PDAC	binimetinib-3.5mpk	435.5	22.7	2	111.3	-6.2
X-2283	PDAC	binimetinib-3.5mpk	559.6	23.1	6	171.5	-4.5
X-2283	PDAC	binimetinib-3.5mpk	541.9	23	9	162.9	-5
X-2283	PDAC	binimetinib-3.5mpk	676.9	22.7	13	228.4	-6.2
X-2283	PDAC	binimetinib-3.5mpk	1056	22.6	16	412.4	-6.6
X-2283	PDAC	binimetinib-3.5mpk	1165.1	22.1	20	465.3	-8.7
X-2283	PDAC	binimetinib-3.5mpk	1495.1	21.9	22	625.4	-9.5
X-2283	PDAC	trametinib	190.8	23.3	0	0	0
X-2283	PDAC	trametinib	161.4	24	3	-15.4	3
X-2283	PDAC	trametinib	175.6	24.4	6	-8	4.7
X-2283	PDAC	trametinib	272.9	24.5	10	43	5.2
X-2283	PDAC	trametinib	391.6	24.1	13	105.2	3.4
X-2283	PDAC	trametinib	612	24.6	17	220.8	5.6
X-2283	PDAC	trametinib	785	24.8	25	311.4	6.4
X-2283	PDAC	trametinib	992.8	24.9	28	420.3	6.9
X-2283	PDAC	trametinib	1436.2	24.3	32	652.7	4.3
X-2283	PDAC	trametinib	1513.2	24.5	35	693.1	5.2
X-2283	PDAC	trametinib	1774.3	24.8	39	829.9	6.4
X-2306	CM	BKM120	208.9	22.7	0	0	0
X-2306	CM	BKM120	185.4	23.1	5	-11.3	1.8
X-2306	CM	BKM120	221	23.6	8	5.8	4
X-2306	CM	BKM120	225.8	23.8	12	8.1	4.8
X-2306	CM	BKM120	237.6	24.3	15	13.7	7
X-2306	CM	BKM120	267.9	24.6	19	28.2	8.4
X-2306	CM	BKM120	263.3	22.5	21	26	-0.9
X-2306	CM	BKM120	279.8	24.7	25	33.9	8.8
X-2306	CM	BKM120	386.1	24.3	28	84.8	7
X-2306	CM	BKM120	354.6	24.8	32	69.8	9.3
X-2306	CM	BKM120 + encorafenib	220.3	25.5	0	0	0
X-2306	CM	BKM120 + encorafenib	245.5	25	3	11.4	-2
X-2306	CM	BKM120 + encorafenib	249.2	25	7	13.1	-2
X-2306	CM	BKM120 + encorafenib	309.3	25.6	13	40.4	0.4
X-2306	CM	BKM120 + encorafenib	350.4	25.7	16	59	0.8
X-2306	CM	BKM120 + encorafenib	422.3	25.5	20	91.7	0
X-2306	CM	BKM120 + encorafenib	445.5	26.4	24	102.2	3.5
X-2306	CM	BKM120 + encorafenib	429.3	26.4	27	94.9	3.5
X-2306	CM	CGM097	199.8	23.8	0	0	0
X-2306	CM	CGM097	178.9	23	2	-10.5	-3.4
X-2306	CM	CGM097	123.6	21.8	6	-38.2	-8.4
X-2306	CM	CGM097	147.9	20	9	-26	-16
X-2306	CM	CGM097	128.4	21.2	14	-35.8	-10.9
X-2306	CM	CGM097	105.9	20.3	17	-47	-14.7
X-2306	CM	CGM097	139.4	18.2	22	-30.2	-23.5
X-2306	CM	CLR457	216.3	27.8	0	0	0
X-2306	CM	CLR457	225.3	27	3	4.1	-2.9
X-2306	CM	CLR457	202.6	27.6	7	-6.3	-0.7
X-2306	CM	CLR457	216.6	28.3	13	0.1	1.8
X-2306	CM	CLR457	262.4	29.2	16	21.3	5
X-2306	CM	CLR457	296.2	29.1	21	37	4.7
X-2306	CM	CLR457	348.5	29.3	30	61.1	5.4
X-2306	CM	CLR457	348.5	29.3	31	61.1	5.4
X-2306	CM	dacarbazine	204.3	25.5	0	0	0
X-2306	CM	dacarbazine	153	24.6	4	-25.1	-3.5
X-2306	CM	dacarbazine	204.9	24.2	8	0.3	-5.1
X-2306	CM	dacarbazine	184.5	25.6	13	-9.7	0.4
X-2306	CM	dacarbazine	243.9	25.3	18	19.4	-0.8
X-2306	CM	dacarbazine	287.3	23.6	21	40.7	-7.5
X-2306	CM	dacarbazine	249.1	23.4	25	22	-8.2
X-2306	CM	dacarbazine	272.8	22.7	31	33.6	-11
X-2306	CM	dacarbazine	300.6	23.2	34	47.2	-9
X-2306	CM	dacarbazine	319	22.4	39	56.2	-12.2
X-2306	CM	dacarbazine	319	23.4	41	56.2	-8.2
X-2306	CM	LDE225	199.1	21.5	0	0	0
X-2306	CM	LDE225	213.8	21.6	5	7.3	0.5
X-2306	CM	LDE225	236.3	21.9	8	18.6	1.9
X-2306	CM	LDE225	237.1	21.5	12	19.1	0
X-2306	CM	LDE225	233.9	21.1	15	17.5	-1.9
X-2306	CM	LDE225	292	19.8	19	46.6	-7.9
X-2306	CM	LDE225	293.3	21.1	25	47.3	-1.9
X-2306	CM	LDE225	326.1	18.1	28	63.8	-15.8
X-2306	CM	LDE225	337.6	18.5	32	69.5	-14
X-2306	CM	LDK378	210.4	25.7	0	0	0
X-2306	CM	LDK378	221.4	24.6	2	5.2	-4.3
X-2306	CM	LDK378	258.8	26.2	5	23	1.9
X-2306	CM	LDK378	295.1	26.5	9	40.2	3.1
X-2306	CM	LDK378	308.9	26.6	12	46.8	3.5
X-2306	CM	LDK378	292.5	26	16	39	1.2
X-2306	CM	LDK378	372	27.5	22	76.8	7
X-2306	CM	LDK378	379.9	27.2	25	80.6	5.8
X-2306	CM	LDK378	436.4	27	29	107.4	5.1
X-2306	CM	LEE011	207.8	25.1	0	0	0
X-2306	CM	LEE011	194.4	24.8	3	-6.5	-1.2
X-2306	CM	LEE011	212.5	25.5	8	2.3	1.6
X-2306	CM	LEE011	219.4	25.4	11	5.6	1.2
X-2306	CM	LEE011	259.2	26.3	16	24.7	4.8
X-2306	CM	LEE011	240.1	27.3	19	15.5	8.8
X-2306	CM	LEE011	215.1	28.2	23	3.5	12.4
X-2306	CM	LEE011	246.1	27.7	26	18.4	10.4
X-2306	CM	LEE011	243.4	27.4	30	17.1	9.2
X-2306	CM	LEE011	246.4	27.6	32	18.6	10
X-2306	CM	LEE011	296.2	27.3	36	42.5	8.8
X-2306	CM	LEE011	272	27.8	39	30.9	10.8
X-2306	CM	LEE011	216.3	28.9	43	4.1	15.1
X-2306	CM	LEE011	285.4	29.4	47	37.3	17.1
X-2306	CM	LEE011	272.3	28.8	52	31	14.7
X-2306	CM	LEE011	265.6	28	57	27.8	11.6
X-2306	CM	LEE011	275.6	28.3	60	32.6	12.7
X-2306	CM	LEE011	278.4	27.7	64	34	10.4
X-2306	CM	LEE011	272	28.4	70	30.9	13.1
X-2306	CM	LEE011	292.8	29.6	79	40.9	17.9
X-2306	CM	LEE011	231.2	29.4	84	11.3	17.1
X-2306	CM	LEE011	275.2	30	93	32.4	19.5
X-2306	CM	LEE011	292.5	29.2	99	40.7	16.3
X-2306	CM	LEE011 + encorafenib	198.2	28.2	0	0	0
X-2306	CM	LEE011 + encorafenib	171.2	28.8	3	-13.6	2.1
X-2306	CM	LEE011 + encorafenib	171.1	28.1	7	-13.7	-0.4
X-2306	CM	LEE011 + encorafenib	221.4	29	13	11.7	2.8
X-2306	CM	LEE011 + encorafenib	227.9	28.7	16	15	1.8
X-2306	CM	LEE011 + encorafenib	222	29.2	20	12	3.5
X-2306	CM	LEE011 + encorafenib	223.8	29.8	24	12.9	5.7
X-2306	CM	LEE011 + encorafenib	246.4	29.1	29	24.3	3.2
X-2306	CM	LEE011 + encorafenib	216.6	30.2	34	9.3	7.1
X-2306	CM	LEE011 + encorafenib	210.4	29.7	37	6.2	5.3
X-2306	CM	LEE011 + encorafenib	213.2	30.7	41	7.6	8.9
X-2306	CM	LEE011 + encorafenib	228.9	31.3	47	15.5	11
X-2306	CM	LEE011 + encorafenib	222	31.6	50	12	12.1
X-2306	CM	LEE011 + encorafenib	208.1	30.6	55	5	8.5
X-2306	CM	LEE011 + encorafenib	232.8	31.2	62	17.4	10.6
X-2306	CM	LEE011 + encorafenib	314.9	30.3	68	58.9	7.4
X-2306	CM	LEE011 + binimetinib	194.1	28.8	0	0	0
X-2306	CM	LEE011 + binimetinib	173	29	3	-10.9	0.7
X-2306	CM	LEE011 + binimetinib	192.5	28.4	8	-0.8	-1.4
X-2306	CM	LEE011 + binimetinib	151.4	28.8	17	-22	0
X-2306	CM	LEE011 + binimetinib	168.8	29.2	23	-13	1.4
X-2306	CM	LEE011 + binimetinib	125.4	29.9	31	-35.4	3.8
X-2306	CM	LEE011 + binimetinib	118.1	30.7	43	-39.2	6.6
X-2306	CM	LEE011 + binimetinib	87.1	30.6	50	-55.1	6.2
X-2306	CM	LEE011 + binimetinib	114.5	29	57	-41	0.7
X-2306	CM	LEE011 + binimetinib	115	30.7	67	-40.8	6.6
X-2306	CM	LEE011 + binimetinib	130.5	30.3	75	-32.8	5.2
X-2306	CM	LEE011 + binimetinib	102.1	30.7	81	-47.4	6.6
X-2306	CM	LEE011 + binimetinib	102.9	30.9	89	-47	7.3
X-2306	CM	LEE011 + binimetinib	105.3	31.2	95	-45.7	8.3
X-2306	CM	LEE011 + binimetinib	102.1	30.9	103	-47.4	7.3
X-2306	CM	LEE011 + binimetinib	105.9	30.8	112	-45.5	6.9
X-2306	CM	LEE011 + binimetinib	109.4	30.9	120	-43.7	7.3
X-2306	CM	LEE011 + binimetinib	123.6	30.9	127	-36.3	7.3
X-2306	CM	LEE011 + binimetinib	105.1	30.5	132	-45.9	5.9
X-2306	CM	LEE011 + binimetinib	112.1	30.2	138	-42.3	4.9
X-2306	CM	LEE011 + binimetinib	106	31.7	151	-45.4	10.1
X-2306	CM	LEE011 + binimetinib	100.6	30.6	158	-48.2	6.2
X-2306	CM	LEE011 + binimetinib	107.2	30	165	-44.8	4.2
X-2306	CM	LEE011 + binimetinib	134.5	29.4	172	-30.7	2.1
X-2306	CM	LEE011 + binimetinib	127.8	29.2	179	-34.2	1.4
X-2306	CM	LEE011 + binimetinib	123.6	30	186	-36.3	4.2
X-2306	CM	LEE011 + binimetinib	126	30.2	192	-35.1	4.9
X-2306	CM	LEE011 + binimetinib	138.9	30.3	198	-28.4	5.2
X-2306	CM	LEE011 + binimetinib	136.5	30.4	201	-29.7	5.6
X-2306	CM	WNT974	225	25.7	0	0	0
X-2306	CM	WNT974	294.4	24.6	3	30.8	-4.3
X-2306	CM	WNT974	363.3	24.6	7	61.5	-4.3
X-2306	CM	WNT974	442.2	23.4	10	96.5	-8.9
X-2306	CM	WNT974	465.4	22.8	14	106.8	-11.3
X-2306	CM	WNT974	526.9	22.6	20	134.2	-12.1
X-2306	CM	WNT974	578.3	21.8	23	157	-15.2
X-2306	CM	WNT974	758.9	21.3	27	237.3	-17.1
X-2306	CM	LGW813	194.1	27.4	0	0	0
X-2306	CM	LGW813	191.1	27	5	-1.5	-1.5
X-2306	CM	LGW813	231.2	27.1	8	19.1	-1.1
X-2306	CM	LGW813	236.3	28.2	12	21.7	2.9
X-2306	CM	LGW813	285.8	28.2	15	47.2	2.9
X-2306	CM	LGW813	273.8	27.8	19	41.1	1.5
X-2306	CM	LGW813	275.2	26	21	41.8	-5.1
X-2306	CM	LGW813	340.6	27.6	25	75.5	0.7
X-2306	CM	LGW813	424.1	28	28	118.5	2.2
X-2306	CM	LGW813	469.3	27.5	32	141.8	0.4
X-2306	CM	encorafenib	214.2	21.5	0	0	0
X-2306	CM	encorafenib	244.7	21	4	14.2	-2.3
X-2306	CM	encorafenib	289	21.1	7	34.9	-1.9
X-2306	CM	encorafenib	337.7	21.3	12	57.6	-0.9
X-2306	CM	encorafenib	406.8	22.2	15	89.9	3.3
X-2306	CM	encorafenib	525.8	20.3	20	145.4	-5.6
X-2306	CM	encorafenib	599	19.9	23	179.6	-7.4
X-2306	CM	encorafenib	592.5	21.9	27	176.5	1.9
X-2306	CM	encorafenib	592.5	21.9	28	176.5	1.9
X-2306	CM	encorafenib + binimetinib	202.8	20.7	0	0	0
X-2306	CM	encorafenib + binimetinib	200.4	19.9	3	-1.1	-3.9
X-2306	CM	encorafenib + binimetinib	208.4	20.5	7	2.8	-1
X-2306	CM	encorafenib + binimetinib	184.5	21.9	13	-9	5.8
X-2306	CM	encorafenib + binimetinib	167.4	21	16	-17.4	1.4
X-2306	CM	encorafenib + binimetinib	160.1	21.9	20	-21	5.8
X-2306	CM	encorafenib + binimetinib	158.4	22.2	24	-21.9	7.2
X-2306	CM	encorafenib + binimetinib	196.5	22.8	29	-3.1	10.1
X-2306	CM	encorafenib + binimetinib	190.5	22.1	34	-6	6.8
X-2306	CM	encorafenib + binimetinib	211.3	21.1	37	4.2	1.9
X-2306	CM	encorafenib + binimetinib	215.6	21.6	41	6.3	4.3
X-2306	CM	encorafenib + binimetinib	180	21.9	47	-11.2	5.8
X-2306	CM	encorafenib + binimetinib	215	23	50	6.1	11.1
X-2306	CM	encorafenib + binimetinib	252	22.3	55	24.3	7.7
X-2306	CM	encorafenib + binimetinib	239.6	22.3	62	18.2	7.7
X-2306	CM	encorafenib + binimetinib	300.7	22.5	68	48.3	8.7
X-2306	CM	binimetinib	197.5	24.4	0	0	0
X-2306	CM	binimetinib	148	24	3	-25.1	-1.6
X-2306	CM	binimetinib	176.6	24.1	8	-10.6	-1.2
X-2306	CM	binimetinib	224.3	25	11	13.6	2.5
X-2306	CM	binimetinib	251.4	24.8	16	27.3	1.6
X-2306	CM	binimetinib	184.3	25.8	19	-6.7	5.7
X-2306	CM	binimetinib	262.1	25.8	23	32.7	5.7
X-2306	CM	binimetinib	254	26	26	28.6	6.6
X-2306	CM	binimetinib	351	25.7	30	77.7	5.3
X-2306	CM	binimetinib	345.6	25.5	32	75	4.5
X-2306	CM	TAS266	191.1	22	0	0	0
X-2306	CM	TAS266	206.7	21.7	2	8.2	-1.4
X-2306	CM	TAS266	237.7	22.5	6	24.4	2.3
X-2306	CM	TAS266	244.5	22.2	9	27.9	0.9
X-2306	CM	TAS266	252.1	21.2	14	31.9	-3.6
X-2306	CM	TAS266	314.8	22.1	17	64.7	0.5
X-2306	CM	TAS266	484.4	21.8	22	153.5	-0.9
X-2306	CM	TAS266	538.7	21.9	25	181.9	-0.5
X-2306	CM	TAS266	605.3	22.6	29	216.7	2.7
X-2306	CM	TAS266	605.3	22.6	30	216.7	2.7
X-2306	CM	untreated	211.7	22.2	0	0	0
X-2306	CM	untreated	292	22	3	37.9	-0.9
X-2306	CM	untreated	314	21.4	5	48.3	-3.6
X-2306	CM	untreated	437.7	20.5	9	106.7	-7.7
X-2306	CM	untreated	459.6	20.9	12	117.1	-5.9
X-2306	CM	untreated	562.2	20.6	17	165.5	-7.2
X-2306	CM	untreated	723.2	21	20	241.6	-5.4
X-2306	CM	untreated	968.2	20.1	25	357.3	-9.5
X-2306	CM	untreated	991.9	20.1	27	368.5	-9.5
X-2339	PDAC	abraxane	248.5	27.2	0	0	0
X-2339	PDAC	abraxane	381.1	25.8	5	53.4	-5.1
X-2339	PDAC	abraxane	397.3	27.4	8	59.9	0.7
X-2339	PDAC	abraxane	450.1	27.6	11	81.1	1.5
X-2339	PDAC	abraxane	478.4	26.6	14	92.5	-2.2
X-2339	PDAC	abraxane	636.3	28.3	18	156.1	4
X-2339	PDAC	abraxane	616.3	26.8	21	148	-1.5
X-2339	PDAC	abraxane	750.8	27.5	25	202.1	1.1
X-2339	PDAC	abraxane	823.4	26.8	28	231.3	-1.5
X-2339	PDAC	abraxane	880	28.1	32	254.1	3.3
X-2339	PDAC	BKM120 + binimetinib	236.5	30.1	0	0	0
X-2339	PDAC	BKM120 + binimetinib	213.8	28.5	5	-9.6	-5.3
X-2339	PDAC	BKM120 + binimetinib	204.5	28.7	8	-13.5	-4.7
X-2339	PDAC	BKM120 + binimetinib	132.5	29.2	12	-44	-3
X-2339	PDAC	BKM120 + binimetinib	164.7	28.5	15	-30.4	-5.3
X-2339	PDAC	BKM120 + binimetinib	168.8	29	19	-28.6	-3.7
X-2339	PDAC	BKM120 + binimetinib	171.4	28.5	22	-27.5	-5.3
X-2339	PDAC	BKM120 + binimetinib	143.1	28.7	26	-39.5	-4.7
X-2339	PDAC	BKM120 + binimetinib	146.7	29.4	29	-38	-2.3
X-2339	PDAC	BKM120 + binimetinib	143.8	29.2	33	-39.2	-3
X-2339	PDAC	BKM120 + binimetinib	132.5	29.6	36	-44	-1.7
X-2339	PDAC	BKM120 + binimetinib	102.9	30	40	-56.5	-0.3
X-2339	PDAC	BKM120 + binimetinib	98	29.2	43	-58.6	-3
X-2339	PDAC	BKM120 + binimetinib	133	29	47	-43.8	-3.7
X-2339	PDAC	BKM120 + binimetinib	117.7	29	50	-50.2	-3.7
X-2339	PDAC	BKM120 + binimetinib	123.1	28.2	54	-47.9	-6.3
X-2339	PDAC	BKM120 + binimetinib	112.2	28	61	-52.6	-7
X-2339	PDAC	BKM120 + binimetinib	97.3	29.9	64	-58.9	-0.7
X-2339	PDAC	BKM120 + binimetinib	80.2	29.1	68	-66.1	-3.3
X-2339	PDAC	BKM120 + binimetinib	78.5	29.3	71	-66.8	-2.7
X-2339	PDAC	BKM120 + binimetinib	90.3	27.7	75	-61.8	-8
X-2339	PDAC	BKM120 + binimetinib	106.3	28.5	77	-55.1	-5.3
X-2339	PDAC	BKM120 + binimetinib	114.2	27.7	82	-51.7	-8
X-2339	PDAC	BKM120 + binimetinib	106	29.6	84	-55.2	-1.7
X-2339	PDAC	BKM120 + binimetinib	69.8	27.5	89	-70.5	-8.6
X-2339	PDAC	BKM120 + binimetinib	115.2	27.7	92	-51.3	-8
X-2339	PDAC	BKM120 + binimetinib	115.1	27.5	96	-51.3	-8.6
X-2339	PDAC	BKM120 + binimetinib	98.9	28.3	99	-58.2	-6
X-2339	PDAC	BKM120	155.1	26.8	0	0	0
X-2339	PDAC	BKM120	109	25.6	3	-29.7	-4.5
X-2339	PDAC	BKM120	215.3	26.2	7	38.8	-2.2
X-2339	PDAC	BKM120	219	26.5	10	41.2	-1.1
X-2339	PDAC	BKM120	232.4	27.5	14	49.8	2.6
X-2339	PDAC	BKM120	214.1	27	17	38	0.7
X-2339	PDAC	BKM120	200.1	27.6	22	29	3
X-2339	PDAC	BKM120	330.8	27.3	25	113.3	1.9
X-2339	PDAC	BKM120	287.5	29.1	28	85.4	8.6
X-2339	PDAC	BKM120	253.8	28.2	31	63.6	5.2
X-2339	PDAC	BKM120	245.4	29.1	35	58.2	8.6
X-2339	PDAC	BKM120	250	28.5	38	61.2	6.3
X-2339	PDAC	BKM120	415.1	28.7	42	167.6	7.1
X-2339	PDAC	BKM120	306.6	27.7	46	97.7	3.4
X-2339	PDAC	BKM120	357.6	28.1	50	130.6	4.9
X-2339	PDAC	BKM120	247.6	28.5	53	59.6	6.3
X-2339	PDAC	BKM120	286.3	28.8	56	84.6	7.5
X-2339	PDAC	BKM120	281.5	28.1	59	81.5	4.9
X-2339	PDAC	BKM120	239.6	28.5	64	54.5	6.3
X-2339	PDAC	BKM120	270.4	28.3	70	74.3	5.6
X-2339	PDAC	BKM120	285.1	28.1	74	83.8	4.9
X-2339	PDAC	BKM120	319.3	28.4	77	105.9	6
X-2339	PDAC	BKM120	185.2	28.7	80	19.4	7.1
X-2339	PDAC	BYL719 + LJM716	215.5	23.5	0	0	0
X-2339	PDAC	BYL719 + LJM716	216.5	21.8	4	0.5	-7.2
X-2339	PDAC	BYL719 + LJM716	214.4	19.9	7	-0.5	-15.3
X-2339	PDAC	BYL719 + LJM716	233.5	20	11	8.4	-14.9
X-2339	PDAC	BYL719 + LJM716	245.4	20.7	14	13.9	-11.9
X-2339	PDAC	BYL719 + LJM716	258.1	21.3	18	19.8	-9.4
X-2339	PDAC	BYL719 + LJM716	267.1	20.4	21	23.9	-13.2
X-2339	PDAC	BYL719 + LJM716	273.4	20.8	25	26.9	-11.5
X-2339	PDAC	BYL719 + LJM716	280	21.3	29	29.9	-9.4
X-2339	PDAC	BYL719 + LJM716	289.4	21.7	32	34.3	-7.7
X-2339	PDAC	BYL719 + LJM716	328.3	21.1	35	52.3	-10.2
X-2339	PDAC	BYL719 + LJM716	346.7	21.7	39	60.9	-7.7
X-2339	PDAC	BYL719 + LJM716	351.9	21.6	42	63.3	-8.1
X-2339	PDAC	BYL719 + LJM716	328	21.5	46	52.2	-8.5
X-2339	PDAC	BYL719 + LJM716	364	21.1	49	68.9	-10.2
X-2339	PDAC	BYL719 + LJM716	375	21.2	53	74	-9.8
X-2339	PDAC	BYL719 + LJM716	407.6	20.6	56	89.1	-12.3
X-2339	PDAC	BYL719 + LJM716	413.9	20.1	60	92.1	-14.5
X-2339	PDAC	BYL719 + LJM716	432.9	20.1	63	100.9	-14.5
X-2339	PDAC	BYL719	200.2	26.3	0	0	0
X-2339	PDAC	BYL719	198.5	26.3	4	-0.8	0
X-2339	PDAC	BYL719	194.5	26.4	6	-2.8	0.4
X-2339	PDAC	BYL719	193.1	25.7	10	-3.5	-2.3
X-2339	PDAC	BYL719	183	26.6	13	-8.6	1.1
X-2339	PDAC	BYL719	183.4	26.3	17	-8.4	0
X-2339	PDAC	BYL719	199.8	27.5	20	-0.2	4.6
X-2339	PDAC	BYL719	209.8	27.6	24	4.8	4.9
X-2339	PDAC	BYL719	229.4	27.7	27	14.6	5.3
X-2339	PDAC	BYL719	253.1	27.5	31	26.4	4.6
X-2339	PDAC	BYL719	254.9	26.7	34	27.3	1.5
X-2339	PDAC	BYL719	235.2	27.7	38	17.5	5.3
X-2339	PDAC	BYL719	239.1	27.7	41	19.4	5.3
X-2339	PDAC	BYL719	251.2	27.4	45	25.5	4.2
X-2339	PDAC	BYL719	260.6	27.5	48	30.2	4.6
X-2339	PDAC	BYL719	318.8	27	52	59.2	2.7
X-2339	PDAC	BYL719	322.5	27.7	55	61.1	5.3
X-2339	PDAC	BYL719	313.4	27.3	59	56.5	3.8
X-2339	PDAC	BYL719	325	26.8	62	62.3	1.9
X-2339	PDAC	BYL719	352.4	26.8	66	76	1.9
X-2339	PDAC	BYL719	400.9	26.4	69	100.2	0.4
X-2339	PDAC	CLR457	203.3	27	0	0	0
X-2339	PDAC	CLR457	205.4	27.3	2	1	1.1
X-2339	PDAC	CLR457	132.7	27.5	6	-34.7	1.9
X-2339	PDAC	CLR457	123.4	26.5	9	-39.3	-1.9
X-2339	PDAC	CLR457	114.1	26.9	13	-43.9	-0.4
X-2339	PDAC	CLR457	115.3	26.2	16	-43.3	-3
X-2339	PDAC	CLR457	145	26.5	20	-28.7	-1.9
X-2339	PDAC	CLR457	167.2	26.2	23	-17.8	-3
X-2339	PDAC	CLR457	189.1	26.5	27	-7	-1.9
X-2339	PDAC	CLR457	205.1	26.3	30	0.9	-2.6
X-2339	PDAC	CLR457	223	26.4	34	9.7	-2.2
X-2339	PDAC	CLR457	235.2	26.9	37	15.7	-0.4
X-2339	PDAC	CLR457	242.4	27.3	41	19.2	1.1
X-2339	PDAC	CLR457	257.1	27.5	44	26.5	1.9
X-2339	PDAC	CLR457	263.1	26.9	48	29.4	-0.4
X-2339	PDAC	CLR457	331.7	26.7	51	63.2	-1.1
X-2339	PDAC	HDM201	218.8	23.1	0	0	0
X-2339	PDAC	HDM201	223.9	23.2	4	2.3	0.4
X-2339	PDAC	HDM201	233.2	23.5	6	6.6	1.7
X-2339	PDAC	HDM201	240.4	23.2	10	9.9	0.4
X-2339	PDAC	HDM201	286.3	23.8	13	30.9	3
X-2339	PDAC	HDM201	317.1	23.7	17	44.9	2.6
X-2339	PDAC	HDM201	341	24	20	55.9	3.9
X-2339	PDAC	HDM201	408.2	25.4	24	86.6	10
X-2339	PDAC	HDM201	447	24.7	27	104.3	6.9
X-2339	PDAC	HDM201	498.1	24.3	31	127.7	5.2
X-2339	PDAC	HDM201	528.1	24.1	34	141.4	4.3
X-2339	PDAC	HDM201	565.9	25	38	158.6	8.2
X-2339	PDAC	HDM201	701.5	24.4	41	220.6	5.6
X-2339	PDAC	HDM201	738.2	23.8	45	237.4	3
X-2339	PDAC	HDM201	748.8	23.7	48	242.2	2.6
X-2339	PDAC	HDM201	821.8	23.9	52	275.6	3.5
X-2339	PDAC	HDM201	822.8	24.4	55	276.1	5.6
X-2339	PDAC	figitumumab"	220	25.8	0	0	0
X-2339	PDAC	figitumumab"	240.2	25.2	2	9.2	-2.3
X-2339	PDAC	figitumumab"	340.8	25.9	8	54.9	0.4
X-2339	PDAC	figitumumab"	335.2	27.9	12	52.4	8.1
X-2339	PDAC	figitumumab"	352.9	26.1	15	60.4	1.2
X-2339	PDAC	figitumumab"	393.3	26.5	19	78.8	2.7
X-2339	PDAC	figitumumab"	387.7	26.2	22	76.2	1.6
X-2339	PDAC	figitumumab"	306.6	27.5	26	39.4	6.6
X-2339	PDAC	figitumumab"	393.9	27.3	29	79	5.8
X-2339	PDAC	figitumumab"	319.1	27.8	33	45	7.8
X-2339	PDAC	figitumumab"	340.2	27.6	36	54.6	7
X-2339	PDAC	figitumumab"	354.1	27	40	61	4.7
X-2339	PDAC	figitumumab"	463.2	26.7	43	110.5	3.5
X-2339	PDAC	figitumumab"	398.4	28.3	47	81.1	9.7
X-2339	PDAC	figitumumab"	420.6	27.4	50	91.2	6.2
X-2339	PDAC	figitumumab"	448	27.3	54	103.6	5.8
X-2339	PDAC	figitumumab"	445.2	26.9	57	102.4	4.3
X-2339	PDAC	figitumumab"	472.5	28	61	114.8	8.5
X-2339	PDAC	figitumumab"	485.3	27.8	64	120.6	7.8
X-2339	PDAC	figitumumab"	551.3	28.7	68	150.6	11.2
X-2339	PDAC	figitumumab"	566.6	28.8	71	157.5	11.6
X-2339	PDAC	figitumumab"	620.6	28.2	75	182.1	9.3
X-2339	PDAC	figitumumab"	515.4	27.5	78	134.3	6.6
X-2339	PDAC	figitumumab"	393.9	27.8	82	79	7.8
X-2339	PDAC	figitumumab"	392.7	28.2	85	78.5	9.3
X-2339	PDAC	figitumumab"	502.3	28.7	89	128.3	11.2
X-2339	PDAC	figitumumab"	615.8	29.1	92	179.9	12.8
X-2339	PDAC	figitumumab" + binimetinib	267.3	26.4	0	0	0
X-2339	PDAC	figitumumab" + binimetinib	248.8	25.2	3	-6.9	-4.5
X-2339	PDAC	figitumumab" + binimetinib	277.9	26.4	7	4	0
X-2339	PDAC	figitumumab" + binimetinib	261.5	25.6	11	-2.2	-3
X-2339	PDAC	figitumumab" + binimetinib	236	26.3	15	-11.7	-0.4
X-2339	PDAC	figitumumab" + binimetinib	280.2	26.7	17	4.8	1.1
X-2339	PDAC	figitumumab" + binimetinib	221.9	27.6	21	-17	4.5
X-2339	PDAC	figitumumab" + binimetinib	209.9	25.4	25	-21.5	-3.8
X-2339	PDAC	figitumumab" + binimetinib	202.8	26.5	29	-24.1	0.4
X-2339	PDAC	figitumumab" + binimetinib	203.1	26.3	32	-24	-0.4
X-2339	PDAC	figitumumab" + binimetinib	205.8	25.3	36	-23	-4.2
X-2339	PDAC	figitumumab" + binimetinib	311.4	26.1	39	16.5	-1.1
X-2339	PDAC	figitumumab" + binimetinib	216.3	26.1	43	-19.1	-1.1
X-2339	PDAC	figitumumab" + binimetinib	220.5	26	46	-17.5	-1.5
X-2339	PDAC	figitumumab" + binimetinib	226.4	25.8	51	-15.3	-2.3
X-2339	PDAC	figitumumab" + binimetinib	184	26	56	-31.2	-1.5
X-2339	PDAC	figitumumab" + binimetinib	218.5	25.9	59	-18.3	-1.9
X-2339	PDAC	figitumumab" + binimetinib	281.7	25.9	63	5.4	-1.9
X-2339	PDAC	figitumumab" + binimetinib	182.7	25.8	66	-31.6	-2.3
X-2339	PDAC	figitumumab" + binimetinib	168.6	25.9	70	-36.9	-1.9
X-2339	PDAC	figitumumab" + binimetinib	302.9	26.3	73	13.3	-0.4
X-2339	PDAC	figitumumab" + binimetinib	168.8	25.5	78	-36.8	-3.4
X-2339	PDAC	figitumumab" + binimetinib	270.5	26.7	81	1.2	1.1
X-2339	PDAC	figitumumab" + binimetinib	298.5	25.9	86	11.7	-1.9
X-2339	PDAC	gemcitabine-50mpk	235	31.8	0	0	0
X-2339	PDAC	gemcitabine-50mpk	230.7	31.1	4	-1.8	-2.2
X-2339	PDAC	gemcitabine-50mpk	262.5	31.1	7	11.7	-2.2
X-2339	PDAC	gemcitabine-50mpk	416.3	31.9	12	77.1	0.3
X-2339	PDAC	gemcitabine-50mpk	397.6	31.4	15	69.2	-1.3
X-2339	PDAC	gemcitabine-50mpk	382.5	30.7	18	62.8	-3.5
X-2339	PDAC	gemcitabine-50mpk	384	30.1	21	63.4	-5.3
X-2339	PDAC	gemcitabine-50mpk	367.7	28.3	26	56.5	-11
X-2339	PDAC	gemcitabine-50mpk	391	30.2	29	66.4	-5
X-2339	PDAC	gemcitabine-50mpk	348.8	31.3	32	48.4	-1.6
X-2339	PDAC	gemcitabine-50mpk	543.6	30.9	35	131.3	-2.8
X-2339	PDAC	gemcitabine-50mpk	469.5	31.7	39	99.8	-0.3
X-2339	PDAC	gemcitabine-50mpk	527.1	29.8	43	124.3	-6.3
X-2339	PDAC	gemcitabine-50mpk	508.5	29.4	47	116.4	-7.5
X-2339	PDAC	gemcitabine-50mpk	594.3	NA	50	152.9	-7.5
X-2339	PDAC	gemcitabine-50mpk	565.8	32.1	53	140.8	0.9
X-2339	PDAC	gemcitabine-50mpk	528.9	30.5	56	125.1	-4.1
X-2339	PDAC	gemcitabine-50mpk	526.5	30.7	61	124	-3.5
X-2339	PDAC	gemcitabine-50mpk	597.7	32.4	64	154.3	1.9
X-2339	PDAC	gemcitabine-50mpk	633.2	30.9	68	169.4	-2.8
X-2339	PDAC	gemcitabine-50mpk	808.2	30.1	71	243.9	-5.3
X-2339	PDAC	gemcitabine-50mpk	862.4	31.3	75	267	-1.6
X-2339	PDAC	gemcitabine-50mpk	928	31.5	78	294.9	-0.9
X-2339	PDAC	INC424 + binimetinib	231	29.6	0	0	0
X-2339	PDAC	INC424 + binimetinib	254.3	29.9	2	10.1	1
X-2339	PDAC	INC424 + binimetinib	246.5	29.6	6	6.7	0
X-2339	PDAC	INC424 + binimetinib	229.5	29.7	9	-0.6	0.3
X-2339	PDAC	INC424 + binimetinib	248.9	30.2	13	7.7	2
X-2339	PDAC	INC424 + binimetinib	201.3	30.5	20	-12.9	3
X-2339	PDAC	INC424 + binimetinib	242.6	29.9	23	5	1
X-2339	PDAC	INC424 + binimetinib	175	29.7	27	-24.2	0.3
X-2339	PDAC	INC424 + binimetinib	168.6	29.3	30	-27	-1
X-2339	PDAC	INC424 + binimetinib	214.5	29.5	34	-7.1	-0.3
X-2339	PDAC	INC424 + binimetinib	178	28.8	36	-22.9	-2.7
X-2339	PDAC	INC424 + binimetinib	210.7	28.7	41	-8.8	-3
X-2339	PDAC	INC424 + binimetinib	197.8	29	43	-14.4	-2
X-2339	PDAC	INC424 + binimetinib	173.3	27.5	48	-25	-7.1
X-2339	PDAC	INC424 + binimetinib	159.2	26.4	51	-31.1	-10.8
X-2339	PDAC	INC424 + binimetinib	184.2	27.7	55	-20.3	-6.4
X-2339	PDAC	INC424 + binimetinib	177.8	27.1	58	-23	-8.4
X-2339	PDAC	INC424 + binimetinib	140.8	27.2	62	-39	-8.1
X-2339	PDAC	INC424 + binimetinib	165.4	27.2	65	-28.4	-8.1
X-2339	PDAC	INC424 + binimetinib	141.7	27.4	69	-38.7	-7.4
X-2339	PDAC	INC424 + binimetinib	163.5	26.5	72	-29.2	-10.5
X-2339	PDAC	INC424	211.2	27.4	0	0	0
X-2339	PDAC	INC424	212.1	27.9	4	0.4	1.8
X-2339	PDAC	INC424	216	27.2	7	2.3	-0.7
X-2339	PDAC	INC424	244.2	27.9	11	15.6	1.8
X-2339	PDAC	INC424	257.4	27.6	14	21.9	0.7
X-2339	PDAC	INC424	286.7	28.2	18	35.7	2.9
X-2339	PDAC	INC424	299.6	28.4	21	41.9	3.6
X-2339	PDAC	INC424	313	28.3	25	48.2	3.3
X-2339	PDAC	INC424	311.2	27.1	28	47.3	-1.1
X-2339	PDAC	INC424	300.8	27.4	32	42.4	0
X-2339	PDAC	INC424	326.4	26.5	35	54.5	-3.3
X-2339	PDAC	INC424	318.8	27.6	39	50.9	0.7
X-2339	PDAC	INC424	355.2	27.1	42	68.2	-1.1
X-2339	PDAC	INC424	365	28.2	46	72.8	2.9
X-2339	PDAC	INC424	390.6	28.2	49	84.9	2.9
X-2339	PDAC	INC424	376.3	28.2	53	78.2	2.9
X-2339	PDAC	INC424	365.9	28.1	56	73.2	2.6
X-2339	PDAC	INC424	383.1	27.8	60	81.4	1.5
X-2339	PDAC	INC424	369.7	27.1	63	75	-1.1
X-2339	PDAC	LEE011	236.5	28.8	0	0	0
X-2339	PDAC	LEE011	225.5	29.4	2	-4.7	2.1
X-2339	PDAC	LEE011	212	29.6	5	-10.4	2.8
X-2339	PDAC	LEE011	303.7	29.3	8	28.4	1.7
X-2339	PDAC	LEE011	289.9	31.5	12	22.6	9.4
X-2339	PDAC	LEE011	267.3	30.4	15	13	5.6
X-2339	PDAC	LEE011	275.7	31.1	19	16.6	8
X-2339	PDAC	LEE011	355.2	30.4	22	50.2	5.6
X-2339	PDAC	LEE011	279.2	31	26	18.1	7.6
X-2339	PDAC	LEE011	372.3	31	29	57.4	7.6
X-2339	PDAC	LEE011	267.5	31.8	33	13.1	10.4
X-2339	PDAC	LEE011	268.1	31.6	36	13.4	9.7
X-2339	PDAC	LEE011	268.2	33.1	40	13.4	14.9
X-2339	PDAC	LEE011	293.1	29.2	43	23.9	1.4
X-2339	PDAC	LEE011	273.8	30.8	47	15.8	6.9
X-2339	PDAC	LEE011	276.5	32.7	50	16.9	13.5
X-2339	PDAC	LEE011	288.4	31.3	54	21.9	8.7
X-2339	PDAC	LEE011	284.9	31.8	57	20.5	10.4
X-2339	PDAC	LEE011	252.2	30.4	61	6.6	5.6
X-2339	PDAC	LEE011	244.2	30.2	64	3.3	4.9
X-2339	PDAC	LEE011	296.9	31.2	68	25.5	8.3
X-2339	PDAC	LEE011	371.7	30.4	71	57.2	5.6
X-2339	PDAC	LEE011	421	30.2	75	78	4.9
X-2339	PDAC	LEE011	438.1	30.8	78	85.2	6.9
X-2339	PDAC	LEE011	372.6	32	82	57.5	11.1
X-2339	PDAC	LEE011	342.4	32	85	44.8	11.1
X-2339	PDAC	LEE011	388.6	30.6	89	64.3	6.2
X-2339	PDAC	WNT974	281.4	23.4	0	0	0
X-2339	PDAC	WNT974	263.4	24.1	3	-6.4	3
X-2339	PDAC	WNT974	242.9	22.8	6	-13.7	-2.6
X-2339	PDAC	WNT974	176.7	22.5	10	-37.2	-3.8
X-2339	PDAC	WNT974	207.8	23.4	13	-26.2	0
X-2339	PDAC	WNT974	230.4	22.8	16	-18.1	-2.6
X-2339	PDAC	WNT974	240.8	20	20	-14.4	-14.5
X-2339	PDAC	WNT974	220.9	18.8	21	-21.5	-19.7
X-2339	PDAC	LKA136	219.7	27.9	0	0	0
X-2339	PDAC	LKA136	224.5	26.9	1	2.2	-3.6
X-2339	PDAC	LKA136	280	26.9	6	27.4	-3.6
X-2339	PDAC	LKA136	310	27.2	9	41.1	-2.5
X-2339	PDAC	LKA136	328.5	27	12	49.5	-3.2
X-2339	PDAC	LKA136	377.1	26.5	15	71.6	-5
X-2339	PDAC	LKA136	589.9	27.8	19	168.5	-0.4
X-2339	PDAC	LKA136	558.9	26.1	23	154.4	-6.5
X-2339	PDAC	LKA136	627.4	25.9	27	185.6	-7.2
X-2339	PDAC	LKA136	590.4	26	30	168.7	-6.8
X-2339	PDAC	LKA136	678	27.3	33	208.6	-2.2
X-2339	PDAC	LKA136	765.6	NA	36	248.5	-2.2
X-2339	PDAC	LKA136	840.9	27.5	41	282.7	-1.4
X-2339	PDAC	LKA136	820.4	25.8	44	273.4	-7.5
X-2339	PDAC	LKA136	900.8	27.2	48	310	-2.5
X-2339	PDAC	LKA136	942.9	25.5	51	329.2	-8.6
X-2339	PDAC	LKA136	1122.2	25.5	55	410.8	-8.6
X-2339	PDAC	LKA136	1118.1	25.5	58	408.9	-8.6
X-2339	PDAC	binimetinib	266.5	27.1	0	0	0
X-2339	PDAC	binimetinib	208.2	26.5	5	-21.9	-2.2
X-2339	PDAC	binimetinib	294.6	26.7	8	10.5	-1.5
X-2339	PDAC	binimetinib	308.9	27.5	12	15.9	1.5
X-2339	PDAC	binimetinib	350.4	26.7	15	31.5	-1.5
X-2339	PDAC	binimetinib	319.4	27.7	19	19.8	2.2
X-2339	PDAC	binimetinib	308.3	26.5	22	15.7	-2.2
X-2339	PDAC	binimetinib	230.6	26.9	26	-13.5	-0.7
X-2339	PDAC	binimetinib	253	27.8	29	-5.1	2.6
X-2339	PDAC	binimetinib	281.5	27.3	33	5.6	0.7
X-2339	PDAC	binimetinib	273.5	26.8	36	2.6	-1.1
X-2339	PDAC	binimetinib	312.3	27.1	40	17.2	0
X-2339	PDAC	binimetinib	232	27.7	43	-12.9	2.2
X-2339	PDAC	binimetinib	239.9	27.6	47	-10	1.8
X-2339	PDAC	binimetinib	215.3	27.7	50	-19.2	2.2
X-2339	PDAC	binimetinib	220.7	27.4	54	-17.2	1.1
X-2339	PDAC	binimetinib	225.3	26.2	61	-15.5	-3.3
X-2339	PDAC	binimetinib	199.1	27.4	64	-25.3	1.1
X-2339	PDAC	binimetinib	192.8	26.8	68	-27.7	-1.1
X-2339	PDAC	binimetinib	245	27.1	71	-8.1	0
X-2339	PDAC	binimetinib	192.4	27.1	75	-27.8	0
X-2339	PDAC	binimetinib	204.5	27.3	77	-23.3	0.7
X-2339	PDAC	binimetinib	147.5	27.2	82	-44.7	0.4
X-2339	PDAC	binimetinib	158.9	28.2	84	-40.4	4.1
X-2339	PDAC	binimetinib	162.7	27.3	89	-38.9	0.7
X-2339	PDAC	binimetinib	207.5	27.2	92	-22.1	0.4
X-2339	PDAC	binimetinib	184.9	26.6	96	-30.6	-1.8
X-2339	PDAC	binimetinib	194.8	26.5	99	-26.9	-2.2
X-2339	PDAC	binimetinib-3.5mpk	201.2	25.8	0	0	0
X-2339	PDAC	binimetinib-3.5mpk	136.1	25.5	3	-32.4	-1.2
X-2339	PDAC	binimetinib-3.5mpk	113	25.8	7	-43.8	0
X-2339	PDAC	binimetinib-3.5mpk	229.8	25.4	10	14.2	-1.6
X-2339	PDAC	binimetinib-3.5mpk	182.7	26.1	14	-9.2	1.2
X-2339	PDAC	binimetinib-3.5mpk	164.2	25.6	17	-18.4	-0.8
X-2339	PDAC	binimetinib-3.5mpk	211.5	25.4	22	5.1	-1.6
X-2339	PDAC	binimetinib-3.5mpk	135.8	25.5	25	-32.5	-1.2
X-2339	PDAC	binimetinib-3.5mpk	201.3	25.7	28	0	-0.4
X-2339	PDAC	binimetinib-3.5mpk	179.5	25.8	31	-10.8	0
X-2339	PDAC	binimetinib-3.5mpk	223.8	26.2	35	11.2	1.6
X-2339	PDAC	binimetinib-3.5mpk	210.4	26.5	38	4.6	2.7
X-2339	PDAC	binimetinib-3.5mpk	146.7	26.8	43	-27.1	3.9
X-2339	PDAC	binimetinib-3.5mpk	202.5	26.3	46	0.6	1.9
X-2339	PDAC	binimetinib-3.5mpk	135.4	26.3	50	-32.7	1.9
X-2339	PDAC	binimetinib-3.5mpk	100.8	25.9	53	-49.9	0.4
X-2339	PDAC	binimetinib-3.5mpk	114.7	26.2	56	-43	1.6
X-2339	PDAC	binimetinib-3.5mpk	122.6	25.9	59	-39.1	0.4
X-2339	PDAC	binimetinib-3.5mpk	156.6	26.6	64	-22.2	3.1
X-2339	PDAC	binimetinib-3.5mpk	125.2	26.4	70	-37.8	2.3
X-2339	PDAC	binimetinib-3.5mpk	79.8	26.2	74	-60.3	1.6
X-2339	PDAC	binimetinib-3.5mpk	149.1	25	77	-25.9	-3.1
X-2339	PDAC	binimetinib-3.5mpk	103.2	25.6	80	-48.7	-0.8
X-2339	PDAC	binimetinib-3.5mpk	59.5	26.3	84	-70.4	1.9
X-2339	PDAC	binimetinib-3.5mpk	108.2	25.1	87	-46.2	-2.7
X-2339	PDAC	binimetinib-3.5mpk	68.7	26.2	91	-65.9	1.6
X-2339	PDAC	binimetinib-3.5mpk	61.8	25.3	94	-69.3	-1.9
X-2339	PDAC	binimetinib-3.5mpk	66.5	25.3	98	-66.9	-1.9
X-2339	PDAC	binimetinib-3.5mpk	93.9	25.8	101	-53.3	0
X-2339	PDAC	trametinib	207.2	24.3	0	0	0
X-2339	PDAC	trametinib	193.1	24.4	5	-6.8	0.4
X-2339	PDAC	trametinib	196.4	24.4	8	-5.2	0.4
X-2339	PDAC	trametinib	197.5	25.3	12	-4.7	4.1
X-2339	PDAC	trametinib	184	25.4	15	-11.2	4.5
X-2339	PDAC	trametinib	198	24.7	19	-4.4	1.6
X-2339	PDAC	trametinib	196	25	22	-5.4	2.9
X-2339	PDAC	trametinib	210.4	25.5	27	1.5	4.9
X-2339	PDAC	trametinib	153.4	25.3	29	-26	4.1
X-2339	PDAC	trametinib	162	25.5	33	-21.8	4.9
X-2339	PDAC	trametinib	256.1	24.9	36	23.6	2.5
X-2339	PDAC	trametinib	289	25.4	40	39.5	4.5
X-2339	PDAC	trametinib	289.8	25.5	43	39.9	4.9
X-2339	PDAC	trametinib	278.3	25.1	47	34.3	3.3
X-2339	PDAC	trametinib	274.9	25	50	32.7	2.9
X-2339	PDAC	trametinib	199.8	25.9	55	-3.6	6.6
X-2339	PDAC	trametinib	181	25.5	60	-12.6	4.9
X-2339	PDAC	trametinib	178.1	25.5	63	-14	4.9
X-2339	PDAC	trametinib	167.9	25.8	67	-19	6.2
X-2339	PDAC	trametinib	198.2	25.2	70	-4.3	3.7
X-2339	PDAC	trametinib	211.6	25.5	74	2.1	4.9
X-2339	PDAC	trametinib	174.6	25.6	77	-15.7	5.3
X-2339	PDAC	trametinib	142.5	24.7	81	-31.2	1.6
X-2339	PDAC	trametinib	112.4	25.7	84	-45.8	5.8
X-2339	PDAC	trametinib	118.4	25.3	88	-42.9	4.1
X-2339	PDAC	trametinib	137	25.8	91	-33.9	6.2
X-2339	PDAC	untreated	237.5	27.7	0	0	0
X-2339	PDAC	untreated	266.6	28.3	3	12.3	2.2
X-2339	PDAC	untreated	241.9	29.2	6	1.9	5.4
X-2339	PDAC	untreated	286.8	29.3	10	20.8	5.8
X-2339	PDAC	untreated	298	28.8	13	25.5	4
X-2339	PDAC	untreated	392.3	28.7	18	65.2	3.6
X-2339	PDAC	untreated	320.7	28.4	21	35	2.5
X-2339	PDAC	untreated	381.1	29.3	25	60.5	5.8
X-2339	PDAC	untreated	411.4	28.8	28	73.2	4
X-2339	PDAC	untreated	442	28.5	31	86.1	2.9
X-2339	PDAC	untreated	444	29.7	34	86.9	7.2
X-2339	PDAC	untreated	506.2	29.6	39	113.1	6.9
X-2339	PDAC	untreated	502.6	29.4	42	111.6	6.1
X-2339	PDAC	untreated	580.7	29.6	45	144.5	6.9
X-2339	PDAC	untreated	580.7	30.3	48	144.5	9.4
X-2339	PDAC	untreated	612.3	30	53	157.8	8.3
X-2339	PDAC	untreated	765.4	29.9	56	222.3	7.9
X-2339	PDAC	untreated	707.5	31.3	59	197.9	13
X-2339	PDAC	untreated	690.7	30.4	62	190.8	9.7
X-2339	PDAC	untreated	641.4	30.3	66	170.1	9.4
X-2339	PDAC	untreated	777.4	29.2	74	227.3	5.4
X-2339	PDAC	untreated	801.4	27.2	77	237.4	-1.8
X-2339	PDAC	untreated	816.8	29.9	80	243.9	7.9
X-2339	PDAC	untreated	916	29.7	83	285.7	7.2
X-2339	PDAC	untreated	982.2	30.1	88	313.6	8.7
X-2339	PDAC	untreated	930.6	30.1	91	291.8	8.7
X-2344	BRCA	BGJ398	304.6	28.4	0	0	0
X-2344	BRCA	BGJ398	378.1	28.5	3	24.1	0.4
X-2344	BRCA	BGJ398	429.6	28.5	7	41	0.4
X-2344	BRCA	BGJ398	529.3	28.3	10	73.8	-0.4
X-2344	BRCA	BGJ398	701.3	28.6	18	130.2	0.7
X-2344	BRCA	BGJ398	922.3	27.6	21	202.8	-2.8
X-2344	BRCA	BGJ398	770.6	27.3	24	153	-3.9
X-2344	BRCA	BGJ398	889.2	26.5	28	191.9	-6.7
X-2344	BRCA	BGJ398	1129	28.5	31	270.7	0.4
X-2344	BRCA	BKM120	251.3	28.1	0	0	0
X-2344	BRCA	BKM120	230.9	28.7	4	-8.1	2.1
X-2344	BRCA	BKM120	240.9	27.9	8	-4.1	-0.7
X-2344	BRCA	BKM120	254.9	27.5	11	1.4	-2.1
X-2344	BRCA	BKM120	222.1	28	15	-11.6	-0.4
X-2344	BRCA	BKM120	217.7	27.8	18	-13.4	-1.1
X-2344	BRCA	BKM120	241.7	27.5	22	-3.8	-2.1
X-2344	BRCA	BKM120	228.1	27.7	25	-9.2	-1.4
X-2344	BRCA	BKM120	147.5	27.8	29	-41.3	-1.1
X-2344	BRCA	BKM120	182.9	26.3	32	-27.2	-6.4
X-2344	BRCA	BKM120	169.2	26.8	40	-32.7	-4.6
X-2344	BRCA	BKM120	155.1	23.4	43	-38.3	-16.7
X-2344	BRCA	BYL719 + LEE011	269.7	28.3	0	0	0
X-2344	BRCA	BYL719 + LEE011	200.7	26.7	4	-25.6	-5.7
X-2344	BRCA	BYL719 + LEE011	121.8	24	8	-54.8	-15.2
X-2344	BRCA	BYL719 + LEE011	154.3	26.5	11	-42.8	-6.4
X-2344	BRCA	BYL719 + LEE011	143.4	27.4	15	-46.8	-3.2
X-2344	BRCA	BYL719 + LEE011	186	27.2	18	-31	-3.9
X-2344	BRCA	BYL719 + LEE011	144.8	24.8	25	-46.3	-12.4
X-2344	BRCA	BYL719 + LEE011	188.8	26.1	28	-30	-7.8
X-2344	BRCA	BYL719 + LEE011	164.2	26.7	33	-39.1	-5.7
X-2344	BRCA	BYL719 + LEE011	182.6	27.9	36	-32.3	-1.4
X-2344	BRCA	BYL719 + LEE011	212	24.8	39	-21.4	-12.4
X-2344	BRCA	BYL719 + LEE011	189.1	24	43	-29.9	-15.2
X-2344	BRCA	BYL719 + LEE011	219.7	25.7	46	-18.5	-9.2
X-2344	BRCA	BYL719 + LEE011	389.5	29.1	50	44.4	2.8
X-2344	BRCA	BYL719 + LEE011	348.5	28	53	29.2	-1.1
X-2344	BRCA	BYL719 + LEE011	348.7	27.4	57	29.3	-3.2
X-2344	BRCA	BYL719 + LEE011	292.8	25.7	60	8.6	-9.2
X-2344	BRCA	BYL719 + LEE011	451.8	28.5	64	67.5	0.7
X-2344	BRCA	BYL719 + LEE011	451.5	27.7	67	67.4	-2.1
X-2344	BRCA	BYL719 + LEE011	341.6	26.9	71	26.7	-4.9
X-2344	BRCA	BYL719 + LEE011	359.8	25.4	74	33.4	-10.2
X-2344	BRCA	BYL719 + LEE011	420.8	29.2	78	56	3.2
X-2344	BRCA	BYL719 + LEE011	424.6	28.6	81	57.4	1.1
X-2344	BRCA	BYL719 + LEE011	449.4	26.7	84	66.6	-5.7
X-2344	BRCA	BYL719 + LEE011	267.5	22.2	88	-0.8	-21.6
X-2344	BRCA	BYL719 + LJM716	166.5	24.1	0	0	0
X-2344	BRCA	BYL719 + LJM716	178.8	22.3	4	7.4	-7.5
X-2344	BRCA	BYL719 + LJM716	117	21.5	8	-29.7	-10.8
X-2344	BRCA	BYL719 + LJM716	135.7	22.1	11	-18.5	-8.3
X-2344	BRCA	BYL719 + LJM716	119.1	22.7	15	-28.5	-5.8
X-2344	BRCA	BYL719 + LJM716	195.3	22.8	18	17.3	-5.4
X-2344	BRCA	BYL719 + LJM716	175.7	22	22	5.5	-8.7
X-2344	BRCA	BYL719 + LJM716	219.9	23.2	25	32.1	-3.7
X-2344	BRCA	BYL719 + LJM716	335.1	23.5	29	101.3	-2.5
X-2344	BRCA	BYL719 + LJM716	342.3	23.9	32	105.6	-0.8
X-2344	BRCA	BYL719 + LJM716	544.6	24.5	40	227.1	1.7
X-2344	BRCA	BYL719 + LJM716	681.3	23.4	43	309.2	-2.9
X-2344	BRCA	BYL719 + LJM716	989.4	24.9	46	494.2	3.3
X-2344	BRCA	BYL719	265.5	30	0	0	0
X-2344	BRCA	BYL719	343.4	30	4	29.3	0
X-2344	BRCA	BYL719	416.6	28.8	8	56.9	-4
X-2344	BRCA	BYL719	555.1	29.2	11	109.1	-2.7
X-2344	BRCA	BYL719	634.5	30.4	15	139	1.3
X-2344	BRCA	BYL719	752.5	30.1	18	183.4	0.3
X-2344	BRCA	BYL719	918.2	29.6	22	245.8	-1.3
X-2344	BRCA	BYL719	1140.8	29.8	25	329.7	-0.7
X-2344	BRCA	CGM097	222.9	28.3	0	0	0
X-2344	BRCA	CGM097	395.2	29.4	4	77.3	3.9
X-2344	BRCA	CGM097	624.7	29.1	8	180.3	2.8
X-2344	BRCA	CGM097	828.4	28.9	11	271.6	2.1
X-2344	BRCA	CGM097	1049.5	30.5	15	370.8	7.8
X-2344	BRCA	CGM097	1321	30.5	18	492.6	7.8
X-2344	BRCA	CLR457	235.3	24.1	0	0	0
X-2344	BRCA	CLR457	268.7	23.2	4	14.2	-3.7
X-2344	BRCA	CLR457	296.4	24.1	8	26	0
X-2344	BRCA	CLR457	359.2	23.4	11	52.7	-2.9
X-2344	BRCA	CLR457	418.4	23.6	15	77.8	-2.1
X-2344	BRCA	CLR457	481.1	24.4	18	104.5	1.2
X-2344	BRCA	CLR457	573.3	24.3	22	143.6	0.8
X-2344	BRCA	CLR457	624.9	24.2	25	165.6	0.4
X-2344	BRCA	CLR457	1106.9	25.7	33	370.4	6.6
X-2344	BRCA	HDM201	266.6	29.3	0	0	0
X-2344	BRCA	HDM201	416.1	27.8	4	56.1	-5.1
X-2344	BRCA	HDM201	679.3	26.8	8	154.8	-8.5
X-2344	BRCA	HDM201	637.1	27.1	11	139	-7.5
X-2344	BRCA	HDM201	822.2	27.6	15	208.4	-5.8
X-2344	BRCA	HDM201	912.7	27.4	18	242.3	-6.5
X-2344	BRCA	HDM201	1199.8	26.9	22	350	-8.2
X-2344	BRCA	HDM201	1466.2	26.3	25	450	-10.2
X-2344	BRCA	INC424	215.8	24.7	0	0	0
X-2344	BRCA	INC424	327.6	24.4	4	51.8	-1.2
X-2344	BRCA	INC424	497.5	25.4	8	130.5	2.8
X-2344	BRCA	INC424	652	26.1	11	202.1	5.7
X-2344	BRCA	INC424	802.6	26	15	271.9	5.3
X-2344	BRCA	INC424	964.3	26.5	18	346.8	7.3
X-2344	BRCA	INC424	1269.8	25.8	22	488.4	4.5
X-2344	BRCA	INC424	1429.9	26.7	25	562.6	8.1
X-2344	BRCA	LEE011	389.3	27.3	0	0	0
X-2344	BRCA	LEE011	565.8	26.8	3	45.3	-1.8
X-2344	BRCA	LEE011	594.8	27.2	6	52.8	-0.4
X-2344	BRCA	LEE011	690	27.4	10	77.2	0.4
X-2344	BRCA	LEE011	732.7	27.8	13	88.2	1.8
X-2344	BRCA	LEE011	830.2	27.5	17	113.3	0.7
X-2344	BRCA	LEE011	963.2	28.1	20	147.4	2.9
X-2344	BRCA	LEE011 + everolimus	299.3	26.8	0	0	0
X-2344	BRCA	LEE011 + everolimus	302.9	25.8	3	1.2	-3.7
X-2344	BRCA	LEE011 + everolimus	281.1	26	6	-6.1	-3
X-2344	BRCA	LEE011 + everolimus	209.3	22.8	10	-30.1	-14.9
X-2344	BRCA	LEE011 + everolimus	184.7	23.9	13	-38.3	-10.8
X-2344	BRCA	LEE011 + everolimus	186.3	22.6	17	-37.8	-15.7
X-2344	BRCA	LEE011 + everolimus	200.9	23.5	20	-32.9	-12.3
X-2344	BRCA	LEE011 + everolimus	222.7	22.8	24	-25.6	-14.9
X-2344	BRCA	LFA102	292.2	27	0	0	0
X-2344	BRCA	LFA102	335.3	27.5	3	14.8	1.9
X-2344	BRCA	LFA102	397.9	28.2	7	36.2	4.4
X-2344	BRCA	LFA102	473.7	28.7	10	62.1	6.3
X-2344	BRCA	LFA102	675.9	27.8	14	131.3	3
X-2344	BRCA	LFA102	748	29.4	17	156	8.9
X-2344	BRCA	LFA102	926.5	29	21	217.1	7.4
X-2344	BRCA	LFA102	1096.1	29.2	24	275.1	8.1
X-2344	BRCA	LJM716 + trastuzumab	255.1	26.9	0	0	0
X-2344	BRCA	LJM716 + trastuzumab	221.9	25.1	3	-13	-6.7
X-2344	BRCA	LJM716 + trastuzumab	211.7	25.9	6	-17	-3.7
X-2344	BRCA	LJM716 + trastuzumab	180.2	25.9	10	-29.4	-3.7
X-2344	BRCA	LJM716 + trastuzumab	222.6	25.8	13	-12.7	-4.1
X-2344	BRCA	LJM716 + trastuzumab	218.8	26	17	-14.2	-3.3
X-2344	BRCA	LJM716 + trastuzumab	151	26.5	20	-40.8	-1.5
X-2344	BRCA	LJM716 + trastuzumab	20.1	28	28	-92.1	4.1
X-2344	BRCA	LJM716	354.5	27.6	0	0	0
X-2344	BRCA	LJM716	301.2	27.8	3	-15	0.7
X-2344	BRCA	LJM716	289.7	28.9	6	-18.3	4.7
X-2344	BRCA	LJM716	274.7	30	10	-22.5	8.7
X-2344	BRCA	LJM716	306.3	27.6	13	-13.6	0
X-2344	BRCA	LJM716	316	26.3	17	-10.9	-4.7
X-2344	BRCA	LJM716	346.3	26.9	20	-2.3	-2.5
X-2344	BRCA	LJM716	371.1	24	24	4.7	-13
X-2344	BRCA	LJM716	340.3	22.2	27	-4	-19.6
X-2344	BRCA	LKA136	229.5	24	0	0	0
X-2344	BRCA	LKA136	574.1	24.2	4	150.2	0.8
X-2344	BRCA	LKA136	845.9	25	8	268.6	4.2
X-2344	BRCA	LKA136	1255.7	24.8	11	447.1	3.3
X-2344	BRCA	LKA136	1667.1	25.1	15	626.4	4.6
X-2344	BRCA	LKA136	1851.8	25.3	18	706.9	5.4
X-2344	BRCA	LLM871	211.9	27.9	0	0	0
X-2344	BRCA	LLM871	287.1	26.7	3	35.5	-4.3
X-2344	BRCA	LLM871	377.5	27.6	6	78.2	-1.1
X-2344	BRCA	LLM871	466.4	27.4	10	120.1	-1.8
X-2344	BRCA	LLM871	544.1	27.5	13	156.8	-1.4
X-2344	BRCA	LLM871	784.1	28.8	21	270	3.2
X-2344	BRCA	LLM871	940.2	27.3	24	343.7	-2.2
X-2344	BRCA	LLM871	998.7	28.7	27	371.3	2.9
X-2344	BRCA	LLM871	1273.6	25.7	31	501	-7.9
X-2344	BRCA	LLM871	1433.8	26.5	34	576.6	-5
X-2344	BRCA	binimetinib	247.5	24.5	0	0	0
X-2344	BRCA	binimetinib	515.3	24.5	4	108.2	0
X-2344	BRCA	binimetinib	595.3	25.1	8	140.5	2.4
X-2344	BRCA	binimetinib	737.1	24.8	11	197.8	1.2
X-2344	BRCA	binimetinib	885.4	25.3	15	257.7	3.3
X-2344	BRCA	binimetinib	985.5	25.7	18	298.2	4.9
X-2344	BRCA	paclitaxel	235.1	27.2	0	0	0
X-2344	BRCA	paclitaxel	302.9	27.2	3	28.8	0
X-2344	BRCA	paclitaxel	407.6	28.2	7	73.4	3.7
X-2344	BRCA	paclitaxel	422.1	28.2	10	79.5	3.7
X-2344	BRCA	paclitaxel	624.9	27.7	14	165.8	1.8
X-2344	BRCA	paclitaxel	838.7	27.9	17	256.7	2.6
X-2344	BRCA	paclitaxel	1047.3	28.1	21	345.5	3.3
X-2344	BRCA	paclitaxel	1283.6	28.7	24	446	5.5
X-2344	BRCA	tamoxifen	220.1	26	0	0	0
X-2344	BRCA	tamoxifen	239	25.4	1	8.6	-2.3
X-2344	BRCA	tamoxifen	289.7	25.9	4	31.6	-0.4
X-2344	BRCA	tamoxifen	359.9	26.3	8	63.5	1.2
X-2344	BRCA	tamoxifen	683.7	26.3	11	210.6	1.2
X-2344	BRCA	tamoxifen	921	27.2	15	318.4	4.6
X-2344	BRCA	tamoxifen	1172.9	27.4	18	432.9	5.4
X-2344	BRCA	trastuzumab	241.7	28.5	0	0	0
X-2344	BRCA	trastuzumab	232.6	27.5	3	-3.8	-3.5
X-2344	BRCA	trastuzumab	260.4	26.3	7	7.7	-7.7
X-2344	BRCA	trastuzumab	297.7	27.1	10	23.2	-4.9
X-2344	BRCA	trastuzumab	345.7	26.5	14	43	-7
X-2344	BRCA	trastuzumab	414.6	25.4	17	71.5	-10.9
X-2344	BRCA	trastuzumab	512.2	26.5	21	111.9	-7
X-2344	BRCA	trastuzumab	508.4	25.7	24	110.3	-9.8
X-2344	BRCA	untreated	356.2	25.8	0	0	0
X-2344	BRCA	untreated	517.3	26.3	3	45.2	1.9
X-2344	BRCA	untreated	637.2	26.9	6	78.9	4.3
X-2344	BRCA	untreated	944.9	27	10	165.3	4.7
X-2344	BRCA	untreated	1339.7	27.9	13	276.1	8.1
X-2344	BRCA	LFW527 + everolimus	196.95	25	0	0	0
X-2344	BRCA	LFW527 + everolimus	210.96	23	6	7.1	-8
X-2344	BRCA	LFW527 + everolimus	164.68	22.1	10	-16.4	-11.6
X-2344	BRCA	LFW527 + everolimus	175.79	21.7	14	-10.7	-13.2
X-2344	BRCA	LFW527 + everolimus	171.03	22.6	17	-13.2	-9.6
X-2344	BRCA	LFW527 + everolimus	160.48	21	20	-18.5	-16
X-2344	BRCA	LFW527 + everolimus	177.53	26.2	24	-9.9	4.8
X-2344	BRCA	LFW527 + everolimus	196.04	24.4	27	-0.5	-2.4
X-2344	BRCA	LFW527 + everolimus	237.79	24.7	31	20.7	-1.2
X-2344	BRCA	LFW527 + everolimus	246.49	23.9	34	25.2	-4.4
X-2344	BRCA	LFW527 + everolimus	289.35	23.7	38	46.9	-5.2
X-2344	BRCA	LFW527 + everolimus	289.77	23.2	41	47.1	-7.2
X-2344	BRCA	LFW527 + everolimus	275.06	22.6	44	39.7	-9.6
X-2344	BRCA	LFW527 + everolimus	282.89	22.7	48	43.6	-9.2
X-2344	BRCA	LFW527 + everolimus	316.94	23.6	51	60.9	-5.6
X-2344	BRCA	LFW527 + everolimus	309.97	24.5	55	57.4	-2
X-2344	BRCA	LFW527 + everolimus	312.01	24.3	58	58.4	-2.8
X-2344	BRCA	LFW527 + everolimus	369.53	24	62	87.6	-4
X-2344	BRCA	LFW527 + everolimus	371.24	25.3	65	88.5	1.2
X-2344	BRCA	LFW527 + everolimus	404.77	24.6	69	105.5	-1.6
X-2344	BRCA	LFW527 + everolimus	414.11	21.4	72	110.3	-14.4
X-2344	BRCA	LFW527 + everolimus	373.21	20.8	76	89.5	-16.8
X-2353	BRCA	BGJ398	206.6	25.7	0	0	0
X-2353	BRCA	BGJ398	217.4	25.5	3	5.2	-0.8
X-2353	BRCA	BGJ398	277	26.7	7	34.1	3.9
X-2353	BRCA	BGJ398	285.2	25.7	10	38	0
X-2353	BRCA	BGJ398	397.7	26.3	14	92.5	2.3
X-2353	BRCA	BGJ398	398.4	25.1	17	92.8	-2.3
X-2353	BRCA	BGJ398	411.1	22.4	21	99	-12.8
X-2353	BRCA	BGJ398	481.6	24.6	24	133.1	-4.3
X-2353	BRCA	BGJ398	464.2	24.1	27	124.7	-6.2
X-2353	BRCA	BGJ398	492.3	25.7	36	138.3	0
X-2353	BRCA	BGJ398	542.3	26	38	162.5	1.2
X-2353	BRCA	BGJ398	639.6	26.5	42	209.6	3.1
X-2353	BRCA	BGJ398	681.7	27.5	45	230	7
X-2353	BRCA	BGJ398	731.8	26.8	49	254.2	4.3
X-2353	BRCA	BGJ398	777.3	26.4	52	276.2	2.7
X-2353	BRCA	BGJ398	811.4	26	56	292.7	1.2
X-2353	BRCA	BGJ398	834	26.7	59	303.7	3.9
X-2353	BRCA	BGJ398	842.9	27.1	63	308	5.4
X-2353	BRCA	BGJ398	855.1	27.3	66	313.9	6.2
X-2353	BRCA	BGJ398	865.7	27.4	70	319	6.6
X-2353	BRCA	BGJ398	907	26.6	73	339	3.5
X-2353	BRCA	BGJ398	939	26.5	77	354.5	3.1
X-2353	BRCA	BGJ398	953.5	27.1	80	361.5	5.4
X-2353	BRCA	BGJ398	994.2	27.4	84	381.2	6.6
X-2353	BRCA	BGJ398	1034.5	26.8	87	400.7	4.3
X-2353	BRCA	BGJ398	1120.8	27.4	91	442.5	6.6
X-2353	BRCA	BKM120	226.9	25.8	0	0	0
X-2353	BRCA	BKM120	244.3	26.8	3	7.7	3.9
X-2353	BRCA	BKM120	269.6	27.2	7	18.8	5.4
X-2353	BRCA	BKM120	296.6	27.2	10	30.7	5.4
X-2353	BRCA	BKM120	344.9	28.6	14	52	10.9
X-2353	BRCA	BKM120	388.6	29.1	17	71.3	12.8
X-2353	BRCA	BKM120	436.9	29.1	21	92.6	12.8
X-2353	BRCA	BKM120	450.4	30.3	24	98.5	17.4
X-2353	BRCA	BKM120	500.3	29.7	27	120.5	15.1
X-2353	BRCA	BKM120	586.3	30.7	36	158.4	19
X-2353	BRCA	BKM120	609.1	31.2	38	168.4	20.9
X-2353	BRCA	BKM120	622.4	31	42	174.3	20.2
X-2353	BRCA	BKM120	674	31.3	45	197	21.3
X-2353	BRCA	BKM120	695.6	31.1	49	206.6	20.5
X-2353	BRCA	BKM120	717.7	32.6	52	216.3	26.4
X-2353	BRCA	BKM120	741.3	31.9	56	226.7	23.6
X-2353	BRCA	BKM120	806.6	32.6	59	255.5	26.4
X-2353	BRCA	BKM120	845.2	32.4	63	272.5	25.6
X-2353	BRCA	BKM120	853.1	33.4	66	276	29.5
X-2353	BRCA	BKM120	943	33.1	70	315.6	28.3
X-2353	BRCA	BKM120	977	33.7	73	330.6	30.6
X-2353	BRCA	BKM120	1055.1	32.5	77	365	26
X-2353	BRCA	BKM120	1070.7	33.4	80	371.9	29.5
X-2353	BRCA	BKM120	1235.4	34.1	84	444.5	32.2
X-2353	BRCA	BYL719	240.2	25.8	0	0	0
X-2353	BRCA	BYL719	204.5	26	3	-14.9	0.8
X-2353	BRCA	BYL719	218.1	24.9	7	-9.2	-3.5
X-2353	BRCA	BYL719	223.6	27	10	-6.9	4.7
X-2353	BRCA	BYL719	253.2	25.8	14	5.4	0
X-2353	BRCA	BYL719	266.5	26.8	17	10.9	3.9
X-2353	BRCA	BYL719	290.6	25.9	21	21	0.4
X-2353	BRCA	BYL719	321.2	26.2	24	33.7	1.6
X-2353	BRCA	BYL719	346.5	25.2	27	44.3	-2.3
X-2353	BRCA	BYL719	360.3	24.8	36	50	-3.9
X-2353	BRCA	BYL719	379.8	25.1	38	58.1	-2.7
X-2353	BRCA	BYL719	393.2	25.2	42	63.7	-2.3
X-2353	BRCA	BYL719	423.5	25.8	45	76.3	0
X-2353	BRCA	BYL719	465.6	25.2	49	93.8	-2.3
X-2353	BRCA	BYL719	488.2	26	52	103.2	0.8
X-2353	BRCA	BYL719	535.9	25.4	56	123.1	-1.6
X-2353	BRCA	BYL719	566	25.7	59	135.6	-0.4
X-2353	BRCA	BYL719	584.1	26.4	63	143.2	2.3
X-2353	BRCA	BYL719	595.9	26.3	66	148.1	1.9
X-2353	BRCA	BYL719	667.7	26.3	70	178	1.9
X-2353	BRCA	BYL719	733.8	25.5	73	205.5	-1.2
X-2353	BRCA	BYL719	755.3	26	77	214.4	0.8
X-2353	BRCA	BYL719	871	26.6	80	262.6	3.1
X-2353	BRCA	BYL719	987.1	26.7	84	310.9	3.5
X-2353	BRCA	BYL719	1120.3	26	87	366.4	0.8
X-2353	BRCA	BYL719	1507.8	25.7	91	527.7	-0.4
X-2353	BRCA	BYL719 + LEE011	245.1	25	0	0	0
X-2353	BRCA	BYL719 + LEE011	256.4	24.9	4	4.6	-0.4
X-2353	BRCA	BYL719 + LEE011	253.9	24.4	7	3.6	-2.4
X-2353	BRCA	BYL719 + LEE011	257.1	24.8	11	4.9	-0.8
X-2353	BRCA	BYL719 + LEE011	311.2	25.7	14	27	2.8
X-2353	BRCA	BYL719 + LEE011	294	24.9	17	20	-0.4
X-2353	BRCA	BYL719 + LEE011	292.2	24.7	26	19.2	-1.2
X-2353	BRCA	BYL719 + LEE011	287.8	25.9	28	17.4	3.6
X-2353	BRCA	BYL719 + LEE011	285	24.9	32	16.3	-0.4
X-2353	BRCA	BYL719 + LEE011	283.3	25.6	35	15.6	2.4
X-2353	BRCA	BYL719 + LEE011	296.5	22.7	39	21	-9.2
X-2353	BRCA	BYL719 + LEE011	289.8	25.6	42	18.2	2.4
X-2353	BRCA	BYL719 + LEE011	292.1	24	46	19.2	-4
X-2353	BRCA	BYL719 + LEE011	253.7	25.6	49	3.5	2.4
X-2353	BRCA	BYL719 + LEE011	268.4	24.3	53	9.5	-2.8
X-2353	BRCA	BYL719 + LEE011	267.3	24.8	56	9.1	-0.8
X-2353	BRCA	BYL719 + LEE011	262.6	24.6	60	7.1	-1.6
X-2353	BRCA	BYL719 + LEE011	268.4	26.1	63	9.5	4.4
X-2353	BRCA	BYL719 + LEE011	270	25.2	67	10.2	0.8
X-2353	BRCA	BYL719 + LEE011	280.8	25.3	70	14.6	1.2
X-2353	BRCA	BYL719 + LEE011	282.5	25.7	74	15.3	2.8
X-2353	BRCA	BYL719 + LEE011	284	25.8	77	15.9	3.2
X-2353	BRCA	BYL719 + LEE011	279.9	24.4	81	14.2	-2.4
X-2353	BRCA	BYL719 + LEE011	251.8	25.4	84	2.7	1.6
X-2353	BRCA	BYL719 + LEE011	258.3	25.3	88	5.4	1.2
X-2353	BRCA	BYL719 + LEE011	262.4	25.8	91	7.1	3.2
X-2353	BRCA	BYL719 + LEE011	269.4	20.2	95	9.9	-19.2
X-2353	BRCA	BYL719 + LJM716	226.4	33.3	0	0	0
X-2353	BRCA	BYL719 + LJM716	263.6	28.7	4	16.4	-13.8
X-2353	BRCA	BYL719 + LJM716	328.6	27.4	7	45.1	-17.7
X-2353	BRCA	BYL719 + LJM716	579.4	27.1	11	155.9	-18.6
X-2353	BRCA	BYL719 + LJM716	330.2	22.5	14	45.8	-32.4
X-2353	BRCA	CGM097	269.7	22.7	0	0	0
X-2353	BRCA	CGM097	307.3	23.3	3	13.9	2.6
X-2353	BRCA	CGM097	351.1	24.4	7	30.2	7.5
X-2353	BRCA	CGM097	346.9	25.3	10	28.6	11.5
X-2353	BRCA	CGM097	393.7	25.7	14	46	13.2
X-2353	BRCA	CGM097	427	25.7	17	58.3	13.2
X-2353	BRCA	CGM097	523.9	26.7	21	94.3	17.6
X-2353	BRCA	CGM097	603	26.7	24	123.6	17.6
X-2353	BRCA	CGM097	649.5	26.7	27	140.8	17.6
X-2353	BRCA	CGM097	617.4	27.6	36	128.9	21.6
X-2353	BRCA	CGM097	676.9	27.6	38	151	21.6
X-2353	BRCA	CGM097	706	28.1	42	161.8	23.8
X-2353	BRCA	CGM097	782.3	29.2	45	190.1	28.6
X-2353	BRCA	CGM097	864.1	28.9	49	220.4	27.3
X-2353	BRCA	CGM097	901.2	29.6	52	234.1	30.4
X-2353	BRCA	CGM097	911.1	29.7	56	237.8	30.8
X-2353	BRCA	CGM097	979.1	29.3	59	263	29.1
X-2353	BRCA	CGM097	1006.9	29.1	63	273.3	28.2
X-2353	BRCA	CGM097	1028.4	30	66	281.3	32.2
X-2353	BRCA	CGM097	1118	29.9	70	314.5	31.7
X-2353	BRCA	CLR457	245.7	22	0	0	0
X-2353	BRCA	CLR457	260.7	23.1	4	6.1	5
X-2353	BRCA	CLR457	267.1	22.9	7	8.7	4.1
X-2353	BRCA	CLR457	290.4	22.9	11	18.2	4.1
X-2353	BRCA	CLR457	315.7	23.2	14	28.5	5.5
X-2353	BRCA	CLR457	332.5	23.1	17	35.3	5
X-2353	BRCA	CLR457	365.7	21.3	26	48.8	-3.2
X-2353	BRCA	CLR457	402.6	22.1	28	63.9	0.5
X-2353	BRCA	CLR457	442.7	22.6	32	80.2	2.7
X-2353	BRCA	CLR457	488.6	23.8	35	98.9	8.2
X-2353	BRCA	CLR457	499.5	23.7	39	103.3	7.7
X-2353	BRCA	CLR457	597.9	23.9	42	143.3	8.6
X-2353	BRCA	CLR457	719.4	24.4	46	192.8	10.9
X-2353	BRCA	CLR457	798.8	24.3	49	225.1	10.5
X-2353	BRCA	CLR457	903.1	25.2	53	267.6	14.5
X-2353	BRCA	CLR457	909.5	24.8	56	270.2	12.7
X-2353	BRCA	CLR457	952	25.3	60	287.5	15
X-2353	BRCA	CLR457	974.7	24.9	63	296.7	13.2
X-2353	BRCA	CLR457	1117.8	25.1	67	354.9	14.1
X-2353	BRCA	CLR457	1225.8	25.3	70	398.9	15
X-2353	BRCA	CLR457	1356.7	24.9	74	452.2	13.2
X-2353	BRCA	HDM201	217.7	22.2	0	0	0
X-2353	BRCA	HDM201	235	23.7	3	7.9	6.8
X-2353	BRCA	HDM201	250.2	23.2	7	14.9	4.5
X-2353	BRCA	HDM201	299.7	23.6	10	37.7	6.3
X-2353	BRCA	HDM201	389.1	25.7	14	78.7	15.8
X-2353	BRCA	HDM201	469	25.7	17	115.4	15.8
X-2353	BRCA	HDM201	524.1	25.7	21	140.7	15.8
X-2353	BRCA	HDM201	580.9	25.9	24	166.8	16.7
X-2353	BRCA	HDM201	643.8	25.8	27	195.7	16.2
X-2353	BRCA	HDM201	859.5	26.3	36	294.8	18.5
X-2353	BRCA	HDM201	873.8	27	38	301.4	21.6
X-2353	BRCA	HDM201	926.1	28.5	42	325.4	28.4
X-2353	BRCA	HDM201	969.3	27.4	45	345.2	23.4
X-2353	BRCA	HDM201	1002	27.7	49	360.3	24.8
X-2353	BRCA	HDM201	1094.9	27.6	52	402.9	24.3
X-2353	BRCA	HDM201	1251.7	27.8	56	475	25.2
X-2353	BRCA	INC424	209.8	26	0	0	0
X-2353	BRCA	INC424	240	26.2	4	14.4	0.8
X-2353	BRCA	INC424	264.4	25.9	7	26	-0.4
X-2353	BRCA	INC424	282.6	26.8	11	34.7	3.1
X-2353	BRCA	INC424	301.9	27.1	14	43.9	4.2
X-2353	BRCA	INC424	341.5	27.1	17	62.8	4.2
X-2353	BRCA	INC424	374.4	27.2	26	78.5	4.6
X-2353	BRCA	INC424	392.7	28.1	28	87.2	8.1
X-2353	BRCA	INC424	431.2	28.2	32	105.5	8.5
X-2353	BRCA	INC424	472.3	28.2	35	125.1	8.5
X-2353	BRCA	INC424	486.9	28.3	39	132.1	8.8
X-2353	BRCA	INC424	487.4	28.6	42	132.3	10
X-2353	BRCA	INC424	549.4	28.2	46	161.9	8.5
X-2353	BRCA	INC424	609.5	27.3	49	190.5	5
X-2353	BRCA	INC424	631.9	28.2	53	201.2	8.5
X-2353	BRCA	INC424	647	28.6	56	208.4	10
X-2353	BRCA	INC424	769	27.9	60	266.5	7.3
X-2353	BRCA	INC424	821.6	27.8	63	291.6	6.9
X-2353	BRCA	INC424	890.2	27.9	67	324.3	7.3
X-2353	BRCA	INC424	935.1	27.5	70	345.7	5.8
X-2353	BRCA	INC424	970.6	27.8	74	362.6	6.9
X-2353	BRCA	INC424	1012.6	27.4	77	382.7	5.4
X-2353	BRCA	INC424	1081	28.1	81	415.3	8.1
X-2353	BRCA	INC424	1124.3	28.1	84	435.9	8.1
X-2353	BRCA	INC424	1356.4	28.4	88	546.5	9.2
X-2353	BRCA	LEE011 + everolimus	219.8	25.8	0	0	0
X-2353	BRCA	LEE011 + everolimus	213	24.9	4	-3.1	-3.5
X-2353	BRCA	LEE011 + everolimus	177.6	25.1	7	-19.2	-2.7
X-2353	BRCA	LEE011 + everolimus	178.4	26.1	11	-18.8	1.2
X-2353	BRCA	LEE011 + everolimus	188.2	25.4	14	-14.4	-1.6
X-2353	BRCA	LEE011 + everolimus	192	24.9	17	-12.6	-3.5
X-2353	BRCA	LEE011 + everolimus	196.8	25.9	26	-10.5	0.4
X-2353	BRCA	LEE011 + everolimus	198	25.5	28	-9.9	-1.2
X-2353	BRCA	LEE011 + everolimus	194.3	25.8	32	-11.6	0
X-2353	BRCA	LEE011 + everolimus	219.2	25.1	35	-0.3	-2.7
X-2353	BRCA	LEE011 + everolimus	229.3	22.9	39	4.3	-11.2
X-2353	BRCA	LEE011 + everolimus	236.2	23.4	42	7.5	-9.3
X-2353	BRCA	LEE011 + everolimus	243.5	-0.1	46	10.8	-9.3
X-2353	BRCA	LEE011 + everolimus	237.2	24.3	49	7.9	-5.8
X-2353	BRCA	LEE011 + everolimus	224.7	24.8	53	2.2	-3.9
X-2353	BRCA	LEE011 + everolimus	221.5	25.7	56	0.8	-0.4
X-2353	BRCA	LEE011 + everolimus	221.5	25.9	60	0.8	0.4
X-2353	BRCA	LEE011 + everolimus	226.8	26.1	63	3.2	1.2
X-2353	BRCA	LEE011 + everolimus	218.1	25.5	67	-0.8	-1.2
X-2353	BRCA	LEE011 + everolimus	215.7	25	70	-1.9	-3.1
X-2353	BRCA	LEE011 + everolimus	215.5	24.7	74	-2	-4.3
X-2353	BRCA	LEE011 + everolimus	214	25.1	77	-2.6	-2.7
X-2353	BRCA	LEE011 + everolimus	213.3	25.3	81	-3	-1.9
X-2353	BRCA	LEE011 + everolimus	211.3	24.7	84	-3.9	-4.3
X-2353	BRCA	LEE011 + everolimus	191.9	24	88	-12.7	-7
X-2353	BRCA	LEE011 + everolimus	190.8	25	91	-13.2	-3.1
X-2353	BRCA	LEE011 + everolimus	192	25.1	95	-12.6	-2.7
X-2353	BRCA	LEE011	220.1	26.1	0	0	0
X-2353	BRCA	LEE011	185.8	26.1	4	-15.6	0
X-2353	BRCA	LEE011	189.8	26.5	7	-13.8	1.5
X-2353	BRCA	LEE011	204.3	26.8	11	-7.2	2.7
X-2353	BRCA	LEE011	208.2	27.7	14	-5.4	6.1
X-2353	BRCA	LEE011	229.3	27.2	17	4.2	4.2
X-2353	BRCA	LEE011	233.2	27.7	26	6	6.1
X-2353	BRCA	LEE011	231.5	27.5	28	5.2	5.4
X-2353	BRCA	LEE011	241.2	27.7	32	9.6	6.1
X-2353	BRCA	LEE011	254.5	28.3	35	15.6	8.4
X-2353	BRCA	LEE011	255.1	28.4	39	15.9	8.8
X-2353	BRCA	LEE011	262.2	28.9	42	19.1	10.7
X-2353	BRCA	LEE011	294.3	28.4	46	33.7	8.8
X-2353	BRCA	LEE011	288.5	28.6	49	31.1	9.6
X-2353	BRCA	LEE011	288.3	28.6	53	31	9.6
X-2353	BRCA	LEE011	288.8	29.1	56	31.2	11.5
X-2353	BRCA	LEE011	292.3	29	60	32.8	11.1
X-2353	BRCA	LEE011	292.2	29.2	63	32.8	11.9
X-2353	BRCA	LEE011	288.8	27.1	67	31.2	3.8
X-2353	BRCA	LEE011	280.1	27.1	70	27.3	3.8
X-2353	BRCA	LEE011	269.7	28.3	74	22.5	8.4
X-2353	BRCA	LEE011	276.2	27.7	77	25.5	6.1
X-2353	BRCA	LEE011	292.9	28.2	81	33.1	8
X-2353	BRCA	LEE011	295.4	28.3	84	34.2	8.4
X-2353	BRCA	LEE011	312.2	27.5	88	41.8	5.4
X-2353	BRCA	LEE011	306.1	27.9	91	39.1	6.9
X-2353	BRCA	LEE011	311.1	28.2	95	41.3	8
X-2353	BRCA	LEE011	325.3	27.9	98	47.8	6.9
X-2353	BRCA	LEE011	332.6	28.7	102	51.1	10
X-2353	BRCA	LEE011	349.9	29.4	105	59	12.6
X-2353	BRCA	LEE011	353	28.6	109	60.4	9.6
X-2353	BRCA	LEE011	355.9	29.2	116	61.7	11.9
X-2353	BRCA	LFA102	226.5	26.4	0	0	0
X-2353	BRCA	LFA102	231.9	25.6	3	2.4	-3
X-2353	BRCA	LFA102	298.2	27.5	10	31.7	4.2
X-2353	BRCA	LFA102	332.9	27.4	13	47	3.8
X-2353	BRCA	LFA102	406.9	26.4	22	79.6	0
X-2353	BRCA	LFA102	452.1	26.7	24	99.6	1.1
X-2353	BRCA	LFA102	484.5	24.9	28	113.9	-5.7
X-2353	BRCA	LFA102	492.5	24.2	31	117.4	-8.3
X-2353	BRCA	LFA102	496.5	21.8	35	119.2	-17.4
X-2353	BRCA	LJM716 + trastuzumab	214.6	24.2	0	0	0
X-2353	BRCA	LJM716 + trastuzumab	217.2	23.5	3	1.2	-2.9
X-2353	BRCA	LJM716 + trastuzumab	265.5	24.5	7	23.7	1.2
X-2353	BRCA	LJM716 + trastuzumab	264.9	24.7	10	23.4	2.1
X-2353	BRCA	LJM716 + trastuzumab	257.8	24.6	13	20.1	1.7
X-2353	BRCA	LJM716 + trastuzumab	269.8	25	22	25.7	3.3
X-2353	BRCA	LJM716 + trastuzumab	293.8	25.7	24	36.9	6.2
X-2353	BRCA	LJM716 + trastuzumab	307.6	25.7	28	43.3	6.2
X-2353	BRCA	LJM716 + trastuzumab	360.3	26.4	31	67.9	9.1
X-2353	BRCA	LJM716 + trastuzumab	398.3	25.8	35	85.6	6.6
X-2353	BRCA	LJM716 + trastuzumab	426.4	26.1	38	98.7	7.9
X-2353	BRCA	LJM716 + trastuzumab	462.9	24.9	42	115.7	2.9
X-2353	BRCA	LJM716 + trastuzumab	503.5	25.5	45	134.6	5.4
X-2353	BRCA	LJM716 + trastuzumab	524.6	26.6	49	144.5	9.9
X-2353	BRCA	LJM716 + trastuzumab	555.6	26.3	52	158.9	8.7
X-2353	BRCA	LJM716 + trastuzumab	644	25.8	56	200.1	6.6
X-2353	BRCA	LJM716 + trastuzumab	670.6	25.5	59	212.5	5.4
X-2353	BRCA	LJM716 + trastuzumab	686.6	24.9	63	219.9	2.9
X-2353	BRCA	LJM716 + trastuzumab	709.1	26.1	66	230.4	7.9
X-2353	BRCA	LJM716 + trastuzumab	804.6	26.3	70	274.9	8.7
X-2353	BRCA	LJM716 + trastuzumab	854.5	26	73	298.2	7.4
X-2353	BRCA	LJM716 + trastuzumab	994.6	26.9	77	363.5	11.2
X-2353	BRCA	LJM716 + trastuzumab	1022.6	25.7	80	376.5	6.2
X-2353	BRCA	LJM716 + trastuzumab	1049.3	25.9	84	389	7
X-2353	BRCA	LJM716 + trastuzumab	1152.1	26.3	87	436.9	8.7
X-2353	BRCA	LJM716 + trastuzumab	1324.1	26.9	91	517	11.2
X-2353	BRCA	LJM716	221.2	28.4	0	0	0
X-2353	BRCA	LJM716	184.4	27.3	4	-16.6	-3.9
X-2353	BRCA	LJM716	187.1	28.6	8	-15.4	0.7
X-2353	BRCA	LJM716	195.1	28.5	11	-11.8	0.4
X-2353	BRCA	LJM716	178.8	28.6	14	-19.2	0.7
X-2353	BRCA	LJM716	229.1	27.8	23	3.6	-2.1
X-2353	BRCA	LJM716	266.5	28.7	25	20.5	1.1
X-2353	BRCA	LJM716	278.6	28.3	29	25.9	-0.4
X-2353	BRCA	LJM716	283.1	29.5	36	28	3.9
X-2353	BRCA	LJM716	292.5	28.3	39	32.2	-0.4
X-2353	BRCA	LJM716	305.7	28	43	38.2	-1.4
X-2353	BRCA	LJM716	379.5	28.7	46	71.6	1.1
X-2353	BRCA	LJM716	385	28.6	50	74.1	0.7
X-2353	BRCA	LJM716	378.6	29.1	53	71.2	2.5
X-2353	BRCA	LJM716	387.6	28.5	57	75.2	0.4
X-2353	BRCA	LJM716	403.2	29.3	60	82.3	3.2
X-2353	BRCA	LJM716	409.9	29	64	85.3	2.1
X-2353	BRCA	LJM716	415.8	28.4	67	88	0
X-2353	BRCA	LJM716	443.6	29.4	71	100.5	3.5
X-2353	BRCA	LJM716	475.2	28.4	74	114.8	0
X-2353	BRCA	LJM716	502.7	28.3	78	127.3	-0.4
X-2353	BRCA	LJM716	541.1	29	81	144.6	2.1
X-2353	BRCA	LJM716	598.4	29.1	85	170.5	2.5
X-2353	BRCA	LJM716	621.9	29.2	88	181.1	2.8
X-2353	BRCA	LJM716	651.3	29.3	92	194.4	3.2
X-2353	BRCA	LKA136	265.9	29.4	0	0	0
X-2353	BRCA	LKA136	260	30.9	4	-2.2	5.1
X-2353	BRCA	LKA136	274.4	29.9	7	3.2	1.7
X-2353	BRCA	LKA136	353.9	30.9	11	33.1	5.1
X-2353	BRCA	LKA136	371.3	30.9	14	39.6	5.1
X-2353	BRCA	LKA136	387.6	31.4	17	45.8	6.8
X-2353	BRCA	LKA136	424.7	31.7	26	59.7	7.8
X-2353	BRCA	LKA136	482.8	31.5	28	81.6	7.1
X-2353	BRCA	LKA136	562.2	33.6	32	111.4	14.3
X-2353	BRCA	LKA136	680	34.6	35	155.7	17.7
X-2353	BRCA	LKA136	782	34.4	39	194.1	17
X-2353	BRCA	LKA136	836	34.1	42	214.4	16
X-2353	BRCA	LKA136	857.6	34.4	46	222.5	17
X-2353	BRCA	LKA136	875.5	34.4	49	229.3	17
X-2353	BRCA	LKA136	910.1	34.7	53	242.3	18
X-2353	BRCA	LKA136	929.3	35.2	56	249.5	19.7
X-2353	BRCA	LKA136	957.6	34.9	60	260.1	18.7
X-2353	BRCA	LKA136	1005.1	34.1	63	278	16
X-2353	BRCA	LKA136	1065.7	33.1	67	300.8	12.6
X-2353	BRCA	LKA136	1127	34	70	323.8	15.6
X-2353	BRCA	LKA136	1212.8	33.9	74	356.1	15.3
X-2353	BRCA	LLM871	244.4	23.5	0	0	0
X-2353	BRCA	LLM871	255.2	23.2	8	4.4	-1.3
X-2353	BRCA	LLM871	313.2	23.5	10	28.2	0
X-2353	BRCA	LLM871	372.9	23.1	14	52.6	-1.7
X-2353	BRCA	LLM871	391.3	23.7	17	60.1	0.9
X-2353	BRCA	LLM871	406.9	24.5	21	66.5	4.3
X-2353	BRCA	LLM871	478.8	24.1	24	95.9	2.6
X-2353	BRCA	LLM871	492.8	24.3	28	101.6	3.4
X-2353	BRCA	LLM871	500.6	23.8	31	104.8	1.3
X-2353	BRCA	LLM871	629	24.5	35	157.4	4.3
X-2353	BRCA	LLM871	652.1	25.3	38	166.8	7.7
X-2353	BRCA	LLM871	674.9	27.1	45	176.1	15.3
X-2353	BRCA	LLM871	744.9	26.3	49	204.8	11.9
X-2353	BRCA	LLM871	778.9	27.1	52	218.7	15.3
X-2353	BRCA	LLM871	888.4	27.3	56	263.5	16.2
X-2353	BRCA	LLM871	932.3	28.2	59	281.5	20
X-2353	BRCA	LLM871	1015.8	26.9	63	315.6	14.5
X-2353	BRCA	LLM871	1016	26.5	66	315.7	12.8
X-2353	BRCA	LLM871	1091.3	27	70	346.5	14.9
X-2353	BRCA	LLM871	1147.6	27.8	73	369.6	18.3
X-2353	BRCA	LLM871	1330.9	27.6	77	444.6	17.4
X-2353	BRCA	binimetinib	217.9	26.3	0	0	0
X-2353	BRCA	binimetinib	226.5	27.8	4	3.9	5.7
X-2353	BRCA	binimetinib	251.9	26.4	7	15.6	0.4
X-2353	BRCA	binimetinib	262.6	27.2	11	20.5	3.4
X-2353	BRCA	binimetinib	272.9	27.9	14	25.2	6.1
X-2353	BRCA	binimetinib	275.2	26.7	17	26.3	1.5
X-2353	BRCA	binimetinib	230.5	25.8	26	5.8	-1.9
X-2353	BRCA	binimetinib	247	25.8	28	13.4	-1.9
X-2353	BRCA	binimetinib	250.5	25.7	32	15	-2.3
X-2353	BRCA	binimetinib	238.1	26.1	35	9.3	-0.8
X-2353	BRCA	binimetinib	246.4	25.4	39	13.1	-3.4
X-2353	BRCA	binimetinib	272.5	24.4	42	25.1	-7.2
X-2353	BRCA	binimetinib	275.4	23.8	46	26.4	-9.5
X-2353	BRCA	binimetinib	232.1	22.7	49	6.5	-13.7
X-2353	BRCA	binimetinib	228.8	22.8	53	5	-13.3
X-2353	BRCA	binimetinib	221	21.9	56	1.4	-16.7
X-2353	BRCA	binimetinib	233.3	25.2	60	7.1	-4.2
X-2353	BRCA	binimetinib	259.4	26.7	63	19	1.5
X-2353	BRCA	binimetinib	367.7	28.5	67	68.7	8.4
X-2353	BRCA	binimetinib	385	28.5	70	76.7	8.4
X-2353	BRCA	binimetinib	421.5	29.2	74	93.4	11
X-2353	BRCA	binimetinib	437	29.1	77	100.6	10.6
X-2353	BRCA	binimetinib	464.5	26.7	81	113.2	1.5
X-2353	BRCA	binimetinib	487.7	27.2	84	123.8	3.4
X-2353	BRCA	binimetinib	541.1	28	88	148.3	6.5
X-2353	BRCA	paclitaxel	200.1	23.2	0	0	0
X-2353	BRCA	paclitaxel	219.5	22.7	3	9.7	-2.2
X-2353	BRCA	paclitaxel	233.4	23.1	10	16.6	-0.4
X-2353	BRCA	paclitaxel	256.1	23	13	28	-0.9
X-2353	BRCA	paclitaxel	339.5	23.1	22	69.7	-0.4
X-2353	BRCA	paclitaxel	353.7	23.4	24	76.8	0.9
X-2353	BRCA	paclitaxel	368.5	23	28	84.2	-0.9
X-2353	BRCA	paclitaxel	357.6	23.6	31	78.7	1.7
X-2353	BRCA	paclitaxel	357.4	23.8	35	78.6	2.6
X-2353	BRCA	paclitaxel	367.4	23.2	38	83.6	0
X-2353	BRCA	paclitaxel	364.3	23	42	82.1	-0.9
X-2353	BRCA	paclitaxel	377.7	23	45	88.8	-0.9
X-2353	BRCA	paclitaxel	377.5	23.7	49	88.7	2.2
X-2353	BRCA	paclitaxel	377.7	24	52	88.8	3.4
X-2353	BRCA	paclitaxel	384.6	24.1	56	92.2	3.9
X-2353	BRCA	paclitaxel	387.9	23.2	59	93.9	0
X-2353	BRCA	paclitaxel	379.1	23.4	63	89.5	0.9
X-2353	BRCA	paclitaxel	393.4	23.3	66	96.6	0.4
X-2353	BRCA	paclitaxel	393.3	23.9	70	96.6	3
X-2353	BRCA	paclitaxel	413.4	24.2	73	106.6	4.3
X-2353	BRCA	paclitaxel	435.5	24.4	77	117.6	5.2
X-2353	BRCA	paclitaxel	447.4	23.4	80	123.6	0.9
X-2353	BRCA	paclitaxel	458.8	24.1	84	129.3	3.9
X-2353	BRCA	paclitaxel	472.5	24.2	87	136.1	4.3
X-2353	BRCA	paclitaxel	505.8	24.4	91	152.8	5.2
X-2353	BRCA	tamoxifen	235.3	25.2	0	0	0
X-2353	BRCA	tamoxifen	289.8	26.2	3	23.2	4
X-2353	BRCA	tamoxifen	355.6	26.1	7	51.1	3.6
X-2353	BRCA	tamoxifen	378.5	27.2	10	60.9	7.9
X-2353	BRCA	tamoxifen	475.2	27.1	14	102	7.5
X-2353	BRCA	tamoxifen	497.5	26.9	17	111.4	6.7
X-2353	BRCA	tamoxifen	596.6	27.6	21	153.5	9.5
X-2353	BRCA	tamoxifen	715.7	27.6	24	204.2	9.5
X-2353	BRCA	tamoxifen	736.4	26.5	27	213	5.2
X-2353	BRCA	tamoxifen	823	28.4	36	249.8	12.7
X-2353	BRCA	tamoxifen	851.4	28.2	38	261.8	11.9
X-2353	BRCA	tamoxifen	1118.6	28.6	42	375.4	13.5
X-2353	BRCA	tamoxifen	1153.5	29.1	45	390.2	15.5
X-2353	BRCA	tamoxifen	1223.9	28.3	49	420.1	12.3
X-2353	BRCA	tamoxifen	1231.7	28.5	52	423.5	13.1
X-2353	BRCA	tamoxifen	1331.4	28.6	56	465.8	13.5
X-2353	BRCA	trastuzumab	278.3	24.8	0	0	0
X-2353	BRCA	trastuzumab	345.4	24.5	3	24.1	-1.2
X-2353	BRCA	trastuzumab	457.9	25.9	10	64.5	4.4
X-2353	BRCA	trastuzumab	507.1	26.6	13	82.2	7.3
X-2353	BRCA	trastuzumab	838.2	26.1	22	201.2	5.2
X-2353	BRCA	trastuzumab	916.9	27	24	229.5	8.9
X-2353	BRCA	trastuzumab	974.7	27.1	28	250.2	9.3
X-2353	BRCA	trastuzumab	995.7	27.7	31	257.8	11.7
X-2353	BRCA	trastuzumab	1017.8	27.2	35	265.7	9.7
X-2353	BRCA	trastuzumab	1100.6	27.2	38	295.5	9.7
X-2353	BRCA	trastuzumab	1182.8	27.1	42	325	9.3
X-2353	BRCA	trastuzumab	1275.5	28.1	45	358.3	13.3
X-2353	BRCA	trastuzumab	1509.7	28.1	49	442.5	13.3
X-2353	BRCA	untreated	205	21.6	0	0	0
X-2353	BRCA	untreated	214.7	22.6	3	4.7	4.6
X-2353	BRCA	untreated	240	23.3	7	17.1	7.9
X-2353	BRCA	untreated	319.5	25.9	10	55.9	19.9
X-2353	BRCA	untreated	377.4	23.8	14	84.1	10.2
X-2353	BRCA	untreated	419.2	24.1	17	104.5	11.6
X-2353	BRCA	untreated	473.8	24.7	21	131.1	14.4
X-2353	BRCA	untreated	563.4	25.5	24	174.8	18.1
X-2353	BRCA	untreated	674.1	24.7	27	228.8	14.4
X-2353	BRCA	untreated	758.9	26.3	36	270.2	21.8
X-2353	BRCA	untreated	835.4	25.3	38	307.5	17.1
X-2353	BRCA	untreated	897.4	26.3	42	337.8	21.8
X-2353	BRCA	untreated	931.8	26.5	45	354.5	22.7
X-2353	BRCA	untreated	1032.1	27.2	49	403.5	25.9
X-2353	BRCA	untreated	1084.5	28.8	52	429	33.3
X-2353	BRCA	untreated	1251.5	27.6	56	510.5	27.8
X-2353	BRCA	LFW527 + everolimus	246.8	22.3	0	0	0
X-2353	BRCA	LFW527 + everolimus	198.26	21.5	3	-19.7	-3.6
X-2353	BRCA	LFW527 + everolimus	187.24	20.7	8	-24.1	-7.2
X-2353	BRCA	LFW527 + everolimus	219.64	22	11	-11	-1.3
X-2353	BRCA	LFW527 + everolimus	249.43	19.5	14	1.1	-12.6
X-2353	BRCA	LFW527 + everolimus	215.66	21.7	18	-12.6	-2.7
X-2353	BRCA	LFW527 + everolimus	269.23	24	21	9.1	7.6
X-2353	BRCA	LFW527 + everolimus	290.95	21.7	24	17.9	-2.7
X-2353	BRCA	LFW527 + everolimus	133.42	21.5	28	-45.9	-3.6
X-2353	BRCA	LFW527 + everolimus	139.31	21.7	31	-43.6	-2.7
X-2353	BRCA	LFW527 + everolimus	142.01	23.2	35	-42.5	4
X-2353	BRCA	LFW527 + everolimus	257.51	22.5	38	4.3	0.9
X-2353	BRCA	LFW527 + everolimus	148.08	22.8	41	-40	2.2
X-2353	BRCA	LFW527 + everolimus	311.29	23.4	45	26.1	4.9
X-2353	BRCA	LFW527 + everolimus	378.62	23	49	53.4	3.1
X-2353	BRCA	LFW527 + everolimus	324.13	21.8	52	31.3	-2.2
X-2353	BRCA	LFW527 + everolimus	226.56	22.8	56	-8.2	2.2
X-2353	BRCA	LFW527 + everolimus	319.6	22.6	59	29.5	1.3
X-2353	BRCA	LFW527 + everolimus	312.16	22.2	63	26.5	-0.4
X-2353	BRCA	LFW527 + everolimus	305.24	22.1	66	23.7	-0.9
X-2353	BRCA	LFW527 + everolimus	320.89	23.2	70	30	4
X-2353	BRCA	LFW527 + everolimus	336.27	22.7	74	36.3	1.8
X-2353	BRCA	LFW527 + everolimus	332.01	21.7	77	34.5	-2.7
X-2353	BRCA	LFW527 + everolimus	409.88	23.2	80	66.1	4
X-2353	BRCA	LFW527 + everolimus	340.18	22.5	84	37.8	0.9
X-2353	BRCA	LFW527 + everolimus	328.6	22.5	87	33.1	0.9
X-2353	BRCA	LFW527 + everolimus	353.32	21.6	91	43.2	-3.1
X-2353	BRCA	LFW527 + everolimus	306.75	22.2	94	24.3	-0.4
X-2353	BRCA	LFW527 + everolimus	354.39	23.5	98	43.6	5.4
X-2353	BRCA	LFW527 + everolimus	298.59	23.9	101	21	7.2
X-2353	BRCA	LFW527 + everolimus	349.57	23.2	105	41.6	4
X-2353	BRCA	LFW527 + everolimus	309.35	23.9	108	25.3	7.2
X-2353	BRCA	LFW527 + everolimus	376.11	22.1	112	52.4	-0.9
X-2353	BRCA	LFW527 + everolimus	360.09	22.1	115	45.9	-0.9
X-2353	BRCA	LFW527 + everolimus	351.77	21.7	118	42.5	-2.7
X-2353	BRCA	LFW527 + everolimus	358.51	22	122	45.3	-1.3
X-2353	BRCA	LFW527 + everolimus	444.98	22.2	126	80.3	-0.4
X-2353	BRCA	LFW527 + everolimus	440.82	22.3	129	78.6	0
X-2353	BRCA	LFW527 + everolimus	407.84	21.4	133	65.3	-4
X-2353	BRCA	LFW527 + everolimus	446.09	23.2	136	80.7	4
X-2353	BRCA	LFW527 + everolimus	751.03	21.2	140	204.3	-4.9
X-2353	BRCA	LFW527 + everolimus	720.27	21.9	143	191.8	-1.8
X-2353	BRCA	LFW527 + everolimus	708.71	21.3	147	187.2	-4.5
X-2353	BRCA	LFW527 + everolimus	650.99	20.7	150	163.8	-7.2
X-2353	BRCA	LFW527 + everolimus	560.11	21.9	154	126.9	-1.8
X-2353	BRCA	LFW527 + everolimus	605.96	21.8	157	145.5	-2.2
X-2374	CRC	5FU	212.4	25	0	0	0
X-2374	CRC	5FU	249.7	22.8	3	17.6	-8.8
X-2374	CRC	5FU	243.3	21.9	7	14.5	-12.4
X-2374	CRC	5FU	250.7	24.7	10	18	-1.2
X-2374	CRC	5FU	266.7	24.4	16	25.6	-2.4
X-2374	CRC	5FU	263.4	24.2	23	24	-3.2
X-2374	CRC	5FU	331.1	22.2	28	55.9	-11.2
X-2374	CRC	5FU	342.5	23.8	31	61.3	-4.8
X-2374	CRC	5FU	369.6	25.1	35	74	0.4
X-2374	CRC	5FU	344.7	24.7	38	62.3	-1.2
X-2374	CRC	5FU	335.5	23.8	42	58	-4.8
X-2374	CRC	5FU	395.6	24.4	46	86.3	-2.4
X-2374	CRC	5FU	492.6	25.5	52	131.9	2
X-2374	CRC	5FU	485.4	23.8	56	128.5	-4.8
X-2374	CRC	5FU	414.2	23.2	59	95	-7.2
X-2374	CRC	5FU	426.1	24.1	63	100.6	-3.6
X-2374	CRC	5FU	362.2	24.7	66	70.5	-1.2
X-2374	CRC	5FU	603.7	24	71	184.2	-4
X-2374	CRC	5FU	656.9	24.3	74	209.3	-2.8
X-2374	CRC	5FU	634.8	23.6	77	198.9	-5.6
X-2374	CRC	5FU	613.7	23.1	80	188.9	-7.6
X-2374	CRC	5FU	584.6	22.8	84	175.2	-8.8
X-2374	CRC	5FU	676.4	23.2	87	218.5	-7.2
X-2374	CRC	5FU	674.5	23.4	92	217.6	-6.4
X-2374	CRC	BKM120	206.2	25.2	0	0	0
X-2374	CRC	BKM120	216.4	24.2	3	4.9	-4
X-2374	CRC	BKM120	214.1	24.2	7	3.8	-4
X-2374	CRC	BKM120	203.7	23.9	10	-1.2	-5.2
X-2374	CRC	BKM120	248.7	25.7	16	20.6	2
X-2374	CRC	BKM120	255.3	26.4	23	23.8	4.8
X-2374	CRC	BKM120	403.6	23.7	28	95.7	-6
X-2374	CRC	BKM120	334.4	22.2	31	62.2	-11.9
X-2374	CRC	BKM120	410.6	24.5	35	99.1	-2.8
X-2374	CRC	BKM120	413.3	24.5	38	100.4	-2.8
X-2374	CRC	BKM120	462.5	23.8	42	124.3	-5.6
X-2374	CRC	BKM120	43	NA	43	-79.1	-5.6
X-2374	CRC	BKM120 + LJC049	216.5	22.4	0	0	0
X-2374	CRC	BKM120 + LJC049	241.2	23.9	3	11.4	6.7
X-2374	CRC	BKM120 + LJC049	360.9	22.9	7	66.7	2.2
X-2374	CRC	BKM120 + LJC049	253.9	21.6	10	17.3	-3.6
X-2374	CRC	BKM120 + LJC049	348.7	21.7	14	61.1	-3.1
X-2374	CRC	BKM120 + LJC049	411.7	20.9	18	90.2	-6.7
X-2374	CRC	BKM120 + LJC049	448.9	21.6	24	107.3	-3.6
X-2374	CRC	BKM120 + LJC049	470	18	28	117.1	-19.6
X-2374	CRC	BYL719	198.4	25	0	0	0
X-2374	CRC	BYL719	226.9	24	2	14.4	-4
X-2374	CRC	BYL719	256.8	24.6	9	29.4	-1.6
X-2374	CRC	BYL719	311.5	24.4	14	57	-2.4
X-2374	CRC	BYL719	357	23.1	17	79.9	-7.6
X-2374	CRC	BYL719	470	23.3	21	136.9	-6.8
X-2374	CRC	BYL719	471.9	23.3	24	137.9	-6.8
X-2374	CRC	BYL719	531.2	23	28	167.7	-8
X-2374	CRC	BYL719	537.6	21.5	32	171	-14
X-2374	CRC	BYL719	595.6	21.9	38	200.2	-12.4
X-2374	CRC	BYL719	628.6	21.9	42	216.8	-12.4
X-2374	CRC	BYL719 + LJM716	210	26.5	0	0	0
X-2374	CRC	BYL719 + LJM716	209.4	24.8	2	-0.3	-6.4
X-2374	CRC	BYL719 + LJM716	232.6	26.3	9	10.8	-0.8
X-2374	CRC	BYL719 + LJM716	283	23.3	14	34.8	-12.1
X-2374	CRC	BYL719 + LJM716	304.5	22.3	17	45	-15.8
X-2374	CRC	BYL719 + LJM716	332.9	23.1	21	58.5	-12.8
X-2374	CRC	BYL719 + LJM716	544.2	23.9	24	159.1	-9.8
X-2374	CRC	BYL719 + LJM716	416.7	23.4	28	98.4	-11.7
X-2374	CRC	BYL719 + LJM716	374.1	23.3	32	78.1	-12.1
X-2374	CRC	BYL719 + LJM716	503.9	22.7	38	140	-14.3
X-2374	CRC	BYL719 + LJM716	543.9	24.5	42	159	-7.5
X-2374	CRC	BYL719 + LJM716	510	23.7	45	142.9	-10.6
X-2374	CRC	BYL719 + cetuximab + encorafenib	225.2	26.5	0	0	0
X-2374	CRC	BYL719 + cetuximab + encorafenib	300.9	24.6	5	33.6	-7.2
X-2374	CRC	BYL719 + cetuximab + encorafenib	310.6	24.1	8	37.9	-9.1
X-2374	CRC	BYL719 + cetuximab + encorafenib	323.6	24.5	12	43.7	-7.5
X-2374	CRC	BYL719 + cetuximab + encorafenib	445.8	25.1	15	98	-5.3
X-2374	CRC	BYL719 + cetuximab + encorafenib	431.2	24.3	19	91.5	-8.3
X-2374	CRC	BYL719 + cetuximab + encorafenib	430.3	24.8	23	91.1	-6.4
X-2374	CRC	BYL719 + cetuximab + encorafenib	580.7	23.2	29	157.9	-12.5
X-2374	CRC	BYL719 + cetuximab + encorafenib	837.1	23.7	33	271.7	-10.6
X-2374	CRC	BYL719 + binimetinib	228.6	24.9	0	0	0
X-2374	CRC	BYL719 + binimetinib	321.4	24.6	5	40.6	-1.2
X-2374	CRC	BYL719 + binimetinib	265.5	23	8	16.1	-7.6
X-2374	CRC	BYL719 + binimetinib	257.2	22.9	12	12.5	-8
X-2374	CRC	BYL719 + binimetinib	244.7	24.3	15	7	-2.4
X-2374	CRC	BYL719 + binimetinib	251	24.2	19	9.8	-2.8
X-2374	CRC	BYL719 + binimetinib	245.5	23.5	23	7.4	-5.6
X-2374	CRC	BYL719 + binimetinib	292.3	23.7	29	27.9	-4.8
X-2374	CRC	BYL719 + binimetinib	294.5	24.1	33	28.8	-3.2
X-2374	CRC	BYL719 + binimetinib	225.1	23	36	-1.5	-7.6
X-2374	CRC	BYL719 + binimetinib	219.9	23	40	-3.8	-7.6
X-2374	CRC	BYL719 + binimetinib	217	24.1	43	-5.1	-3.2
X-2374	CRC	BYL719 + binimetinib	215.3	23.9	48	-5.8	-4
X-2374	CRC	BYL719 + binimetinib	245.2	26.1	51	7.3	4.8
X-2374	CRC	BYL719 + binimetinib	276.5	23.5	54	21	-5.6
X-2374	CRC	BYL719 + binimetinib	260.5	23.6	57	14	-5.2
X-2374	CRC	BYL719 + binimetinib	235.8	23.9	61	3.1	-4
X-2374	CRC	BYL719 + binimetinib	234.6	24	64	2.6	-3.6
X-2374	CRC	BYL719 + binimetinib	238.9	24.7	69	4.5	-0.8
X-2374	CRC	BYL719 + binimetinib	225.6	23.8	72	-1.3	-4.4
X-2374	CRC	BYL719 + binimetinib	239.3	24.2	76	4.7	-2.8
X-2374	CRC	BYL719 + binimetinib	251.4	23.8	79	10	-4.4
X-2374	CRC	BYL719 + binimetinib	273.5	24.9	83	19.6	0
X-2374	CRC	BYL719 + binimetinib	305.1	24.4	86	33.5	-2
X-2374	CRC	BYL719 + binimetinib	301.7	24.1	89	32	-3.2
X-2374	CRC	BYL719 + cetuximab	229.5	25.4	0	0	0
X-2374	CRC	BYL719 + cetuximab	333.9	24.5	5	45.5	-3.5
X-2374	CRC	BYL719 + cetuximab	308.3	25	8	34.3	-1.6
X-2374	CRC	BYL719 + cetuximab	297.6	25.1	12	29.7	-1.2
X-2374	CRC	BYL719 + cetuximab	293.5	26	15	27.9	2.4
X-2374	CRC	BYL719 + cetuximab	322.3	25.5	19	40.4	0.4
X-2374	CRC	BYL719 + cetuximab	355	25.2	23	54.7	-0.8
X-2374	CRC	BYL719 + cetuximab	384.4	25.6	29	67.5	0.8
X-2374	CRC	BYL719 + cetuximab	406	25.7	33	76.9	1.2
X-2374	CRC	BYL719 + cetuximab	382.1	24.8	36	66.5	-2.4
X-2374	CRC	BYL719 + cetuximab	400.1	25.2	40	74.3	-0.8
X-2374	CRC	BYL719 + cetuximab	421.1	25.6	43	83.5	0.8
X-2374	CRC	BYL719 + cetuximab	361.4	24.7	48	57.5	-2.8
X-2374	CRC	BYL719 + cetuximab	458.2	25.8	51	99.7	1.6
X-2374	CRC	BYL719 + cetuximab	532.7	24.9	54	132.1	-2
X-2374	CRC	BYL719 + cetuximab	511.1	24.9	57	122.7	-2
X-2374	CRC	BYL719 + cetuximab	548.1	25.5	61	138.8	0.4
X-2374	CRC	BYL719 + cetuximab	573.3	24.5	64	149.8	-3.5
X-2374	CRC	BYL719 + cetuximab	564.1	24.6	69	145.8	-3.1
X-2374	CRC	BYL719 + cetuximab	609.4	24.1	72	165.5	-5.1
X-2374	CRC	BYL719 + cetuximab	652.6	25	76	184.4	-1.6
X-2374	CRC	BYL719 + cetuximab	626	25.1	79	172.8	-1.2
X-2374	CRC	BYL719 + cetuximab	677.1	23	83	195	-9.4
X-2374	CRC	BYL719 + cetuximab	622.6	23.1	86	171.3	-9.1
X-2374	CRC	BYL719 + cetuximab	853.8	23	89	272	-9.4
X-2374	CRC	BYL719 + encorafenib	224.4	24.8	0	0	0
X-2374	CRC	BYL719 + encorafenib	237.3	25.2	3	5.7	1.6
X-2374	CRC	BYL719 + encorafenib	318.3	23.7	7	41.8	-4.4
X-2374	CRC	BYL719 + encorafenib	292.5	24.8	10	30.3	0
X-2374	CRC	BYL719 + encorafenib	278.1	25.1	14	23.9	1.2
X-2374	CRC	BYL719 + encorafenib	329.8	25	18	47	0.8
X-2374	CRC	BYL719 + encorafenib	420.6	25.2	24	87.4	1.6
X-2374	CRC	BYL719 + encorafenib	455.4	24.6	28	102.9	-0.8
X-2374	CRC	BYL719 + encorafenib	417	23.2	31	85.8	-6.5
X-2374	CRC	BYL719 + encorafenib	451.9	23.4	35	101.4	-5.6
X-2374	CRC	BYL719 + encorafenib	499.1	20.4	38	122.4	-17.7
X-2374	CRC	BYL719 + encorafenib	662.5	23.1	43	195.2	-6.9
X-2374	CRC	BYL719 + encorafenib	699.3	24	46	211.6	-3.2
X-2374	CRC	BYL719 + encorafenib	664.4	23.6	49	196.1	-4.8
X-2374	CRC	BYL719 + encorafenib	654	23	52	191.4	-7.3
X-2374	CRC	BYL719 + encorafenib	814.9	23.4	56	263.1	-5.6
X-2374	CRC	BYL719 + encorafenib	997	23.2	59	344.3	-6.5
X-2374	CRC	BYL719 + encorafenib	1119.2	22.9	63	398.8	-7.7
X-2374	CRC	CKX620	218.4	25.1	0	0	0
X-2374	CRC	CKX620	234.8	25.1	1	7.5	0
X-2374	CRC	CKX620	190.5	24	5	-12.8	-4.4
X-2374	CRC	CKX620	184.8	24.9	8	-15.4	-0.8
X-2374	CRC	CKX620	252.8	25	14	15.8	-0.4
X-2374	CRC	CKX620	189.2	24	21	-13.4	-4.4
X-2374	CRC	CKX620	260.2	25.2	26	19.1	0.4
X-2374	CRC	CKX620	222.3	25.5	29	1.8	1.6
X-2374	CRC	CKX620	240.8	27.6	36	10.3	10
X-2374	CRC	CKX620	246.5	27	40	12.9	7.6
X-2374	CRC	CKX620	205.1	26.3	44	-6.1	4.8
X-2374	CRC	CLR457	215	24.5	0	0	0
X-2374	CRC	CLR457	234.6	24.7	6	9.1	0.8
X-2374	CRC	CLR457	232.5	24.2	13	8.1	-1.2
X-2374	CRC	CLR457	347.7	24.6	18	61.7	0.4
X-2374	CRC	CLR457	289.4	24.1	21	34.6	-1.6
X-2374	CRC	CLR457	492.5	22.9	25	129.1	-6.5
X-2374	CRC	HDM201	211.2	25.8	0	0	0
X-2374	CRC	HDM201	208.1	24.9	3	-1.5	-3.5
X-2374	CRC	HDM201	215.6	23.7	7	2.1	-8.1
X-2374	CRC	HDM201	218.1	23.3	10	3.3	-9.7
X-2374	CRC	HDM201	275.9	24.1	16	30.6	-6.6
X-2374	CRC	HDM201	320.6	24.8	23	51.8	-3.9
X-2374	CRC	HDM201	356.7	21.7	28	68.9	-15.9
X-2374	CRC	cetuximab	207.5	22.1	0	0	0
X-2374	CRC	cetuximab	268	22.2	3	29.2	0.5
X-2374	CRC	cetuximab	241.2	23.1	7	16.2	4.5
X-2374	CRC	cetuximab	230.6	23	10	11.1	4.1
X-2374	CRC	cetuximab	236.2	23.2	14	13.8	5
X-2374	CRC	cetuximab	256.7	23.9	17	23.7	8.1
X-2374	CRC	cetuximab	253.6	24.1	23	22.2	9
X-2374	CRC	cetuximab	250.4	23.7	30	20.7	7.2
X-2374	CRC	cetuximab	258.8	23.3	35	24.7	5.4
X-2374	CRC	cetuximab	286.9	24	38	38.3	8.6
X-2374	CRC	cetuximab	308.9	24.3	42	48.9	10
X-2374	CRC	cetuximab	301.5	24.5	45	45.3	10.9
X-2374	CRC	cetuximab	338.8	24.4	49	63.3	10.4
X-2374	CRC	cetuximab	328.8	25	53	58.5	13.1
X-2374	CRC	cetuximab	380.7	24.4	59	83.5	10.4
X-2374	CRC	cetuximab	400.1	24.7	63	92.8	11.8
X-2374	CRC	cetuximab	418.4	23.6	66	101.6	6.8
X-2374	CRC	cetuximab	324	23.6	70	56.1	6.8
X-2374	CRC	cetuximab	304.8	24.1	73	46.9	9
X-2374	CRC	cetuximab	370.6	24.4	78	78.6	10.4
X-2374	CRC	cetuximab	450.5	24.8	81	117.1	12.2
X-2374	CRC	cetuximab	466.1	23.9	84	124.6	8.1
X-2374	CRC	cetuximab	525.3	25.4	87	153.2	14.9
X-2374	CRC	cetuximab	523.6	24.1	91	152.3	9
X-2374	CRC	cetuximab + encorafenib	221.9	26.3	0	0	0
X-2374	CRC	cetuximab + encorafenib	226.8	26	2	2.2	-1.1
X-2374	CRC	cetuximab + encorafenib	290.3	26.6	9	30.8	1.1
X-2374	CRC	cetuximab + encorafenib	346	25.7	14	55.9	-2.3
X-2374	CRC	cetuximab + encorafenib	326.7	26.1	17	47.2	-0.8
X-2374	CRC	cetuximab + encorafenib	341.5	26.4	21	53.9	0.4
X-2374	CRC	cetuximab + encorafenib	329	26.1	24	48.3	-0.8
X-2374	CRC	cetuximab + encorafenib	555.3	26	28	150.2	-1.1
X-2374	CRC	cetuximab + encorafenib	468.5	27.1	32	111.1	3
X-2374	CRC	cetuximab + encorafenib	493.7	27.2	38	122.5	3.4
X-2374	CRC	cetuximab + encorafenib	614.2	30.1	42	176.8	14.4
X-2374	CRC	cetuximab + encorafenib	638	31.3	44	187.5	19
X-2374	CRC	LEE011	212.6	24.8	0	0	0
X-2374	CRC	LEE011	260	23.7	3	22.3	-4.4
X-2374	CRC	LEE011	266.8	23.9	7	25.5	-3.6
X-2374	CRC	LEE011	340.9	23.5	10	60.3	-5.2
X-2374	CRC	LEE011	274.5	24.8	16	29.1	0
X-2374	CRC	LEE011	226.5	24.6	23	6.5	-0.8
X-2374	CRC	LEE011	293	23.3	28	37.8	-6
X-2374	CRC	LEE011	269	23.5	31	26.5	-5.2
X-2374	CRC	LEE011	304.1	23.9	35	43	-3.6
X-2374	CRC	LEE011	309.6	24.6	38	45.6	-0.8
X-2374	CRC	LEE011	248.1	23.6	42	16.7	-4.8
X-2374	CRC	LEE011	285.3	25.3	46	34.2	2
X-2374	CRC	LEE011	346	25.2	52	62.7	1.6
X-2374	CRC	LEE011	366.3	26.4	56	72.3	6.5
X-2374	CRC	LEE011	272.2	25.5	59	28	2.8
X-2374	CRC	LEE011	296.4	25.7	63	39.4	3.6
X-2374	CRC	LEE011	250.3	27.2	66	17.7	9.7
X-2374	CRC	LEE011	291.3	26.1	71	37	5.2
X-2374	CRC	LEE011	341.7	26.6	74	60.7	7.3
X-2374	CRC	LEE011	367.3	26.9	77	72.8	8.5
X-2374	CRC	LEE011	380.8	25.1	80	79.1	1.2
X-2374	CRC	LEE011	384.2	25.6	84	80.7	3.2
X-2374	CRC	LEE011	384.2	24.5	87	80.7	-1.2
X-2374	CRC	LEE011	413.8	26.8	91	94.6	8.1
X-2374	CRC	encorafenib	224.3	26.2	0	0	0
X-2374	CRC	encorafenib	333.1	26.1	3	48.5	-0.4
X-2374	CRC	encorafenib	399.4	25.4	9	78.1	-3.1
X-2374	CRC	encorafenib	645.8	25.2	16	187.9	-3.8
X-2374	CRC	encorafenib	1067.5	24.5	21	375.9	-6.5
X-2374	CRC	LJC049	218.7	23.9	0	0	0
X-2374	CRC	LJC049	243.4	23.9	3	11.3	0
X-2374	CRC	LJC049	278.5	26.1	9	27.3	9.2
X-2374	CRC	LJC049	377.5	24.6	16	72.6	2.9
X-2374	CRC	LJC049	426.3	22.7	21	94.9	-5
X-2374	CRC	LJC049	517.2	23.3	24	136.5	-2.5
X-2374	CRC	LJC049	678.8	21.1	28	210.4	-11.7
X-2374	CRC	LKA136	230	25.3	0	0	0
X-2374	CRC	LKA136	345.9	24.5	3	50.4	-3.2
X-2374	CRC	LKA136	398.2	27.1	9	73.1	7.1
X-2374	CRC	LKA136	512.1	24.6	16	122.7	-2.8
X-2374	CRC	LKA136	616.6	23.4	21	168.1	-7.5
X-2374	CRC	LKA136	733.5	24.4	24	218.9	-3.6
X-2374	CRC	LKA136	1179.7	26.9	28	412.9	6.3
X-2374	CRC	binimetinib	224.1	25.5	0	0	0
X-2374	CRC	binimetinib	242.2	24.8	3	8.1	-2.7
X-2374	CRC	binimetinib	229.5	25.1	7	2.4	-1.6
X-2374	CRC	binimetinib	264.3	25.1	10	17.9	-1.6
X-2374	CRC	binimetinib	240.8	25.8	16	7.5	1.2
X-2374	CRC	binimetinib	239.5	25.5	23	6.9	0
X-2374	CRC	binimetinib	251.8	25	28	12.4	-2
X-2374	CRC	binimetinib	297.2	25.8	31	32.6	1.2
X-2374	CRC	binimetinib	299.2	26.2	35	33.5	2.7
X-2374	CRC	binimetinib	256.6	26	38	14.5	2
X-2374	CRC	binimetinib	320.6	25.6	42	43.1	0.4
X-2374	CRC	binimetinib	261.1	25.4	46	16.5	-0.4
X-2374	CRC	binimetinib	274.6	25.3	52	22.5	-0.8
X-2374	CRC	binimetinib	288.4	25.9	56	28.7	1.6
X-2374	CRC	binimetinib	232.2	25.4	59	3.6	-0.4
X-2374	CRC	binimetinib	216.4	25.4	63	-3.4	-0.4
X-2374	CRC	binimetinib	228.3	26.2	66	1.9	2.7
X-2374	CRC	binimetinib	279.2	25.7	71	24.6	0.8
X-2374	CRC	binimetinib	273.3	26.6	74	22	4.3
X-2374	CRC	binimetinib	276.8	25.8	77	23.5	1.2
X-2374	CRC	binimetinib	298.5	26.5	80	33.2	3.9
X-2374	CRC	binimetinib	326.4	25.5	84	45.6	0
X-2374	CRC	binimetinib	313.1	26.2	87	39.7	2.7
X-2374	CRC	binimetinib	333.8	26.1	91	49	2.4
X-2374	CRC	untreated	218.1	21.9	0	0	0
X-2374	CRC	untreated	224.8	22.1	3	3.1	0.9
X-2374	CRC	untreated	243.7	23	7	11.7	5
X-2374	CRC	untreated	330.8	24.1	10	51.7	10
X-2374	CRC	untreated	357	22.6	14	63.7	3.2
X-2374	CRC	untreated	478.2	22.4	17	119.3	2.3
X-2374	CRC	untreated	506.4	24.1	23	132.2	10
X-2374	CRC	untreated	711.5	22.9	30	226.2	4.6
X-2374	CRC	untreated	1145	21.8	35	425	-0.5
X-2374	CRC	LFW527 + binimetinib	221.76	27.42	0	0	0
X-2374	CRC	LFW527 + binimetinib	248.86	26.22	1	12.2	-4.4
X-2374	CRC	LFW527 + binimetinib	245.04	26.12	5	10.5	-4.7
X-2374	CRC	LFW527 + binimetinib	259.47	24.57	8	17	-10.4
X-2374	CRC	LFW527 + binimetinib	230.36	25.67	12	3.9	-6.4
X-2374	CRC	LFW527 + binimetinib	239.58	28.39	17	8	3.5
X-2374	CRC	LFW527 + binimetinib	257.27	NA	20	16	3.5
X-2374	CRC	LFW527 + binimetinib	260.62	26.06	23	17.5	-5
X-2374	CRC	LFW527 + binimetinib	298.24	26	26	34.5	-5.2
X-2374	CRC	LFW527 + binimetinib	270.83	26.41	27	22.1	-3.7
X-2374	CRC	LFW527 + binimetinib	268.77	26.55	30	21.2	-3.2
X-2374	CRC	LFW527 + binimetinib	277.44	26.47	34	25.1	-3.5
X-2374	CRC	LFW527 + binimetinib	182.65	26.13	41	-17.6	-4.7
X-2374	CRC	LFW527 + binimetinib	171.91	28.09	44	-22.5	2.4
X-2374	CRC	LFW527 + binimetinib	215.05	27.31	48	-3	-0.4
X-2374	CRC	LFW527 + binimetinib	175.02	26.76	51	-21.1	-2.4
X-2374	CRC	LFW527 + binimetinib	200.91	26.53	55	-9.4	-3.2
X-2374	CRC	LFW527 + binimetinib	240.26	27.53	58	8.3	0.4
X-2374	CRC	LFW527 + binimetinib	258.09	26.54	62	16.4	-3.2
X-2374	CRC	LFW527 + binimetinib	250	27.18	65	12.7	-0.9
X-2374	CRC	LFW527 + binimetinib	248.02	26.54	69	11.8	-3.2
X-2374	CRC	LFW527 + binimetinib	256.2	27.38	72	15.5	-0.1
X-2374	CRC	LFW527 + binimetinib	275.39	26.49	75	24.2	-3.4
X-2374	CRC	LFW527 + binimetinib	270.33	26.42	79	21.9	-3.6
X-2374	CRC	LFW527 + binimetinib	269.23	26.35	83	21.4	-3.9
X-2374	CRC	LFW527 + binimetinib	278.78	26.48	86	25.7	-3.4
X-2374	CRC	LFW527 + binimetinib	276.72	26.88	91	24.8	-2
X-2374	CRC	LFW527 + binimetinib	269.01	26.29	97	21.3	-4.1
X-2374	CRC	LFW527 + binimetinib	264.31	24.67	100	19.2	-10
X-2374	CRC	LFW527 + binimetinib	281.74	26.29	104	27	-4.1
X-2374	CRC	LFW527 + binimetinib	290.48	29.66	107	31	8.2
X-2374	CRC	LFW527 + binimetinib	255.74	26.7	111	15.3	-2.6
X-2374	CRC	LFW527 + binimetinib	262.69	26.15	117	18.5	-4.6
X-2374	CRC	LFW527 + binimetinib	266.74	25.8	120	20.3	-5.9
X-2374	CRC	LFW527 + binimetinib	267.31	25.35	124	20.5	-7.5
X-2374	CRC	LFW527 + binimetinib	270.77	25.5	127	22.1	-7
X-2374	CRC	LFW527 + binimetinib	333.07	24.69	131	50.2	-10
X-2374	CRC	LFW527 + binimetinib	295.41	25.84	134	33.2	-5.8
X-2374	CRC	LFW527 + binimetinib	324.86	24.4	139	46.5	-11
X-2374	CRC	LFW527 + binimetinib	358.76	25.72	142	61.8	-6.2
X-2374	CRC	LFW527 + binimetinib	314.38	26.62	146	41.8	-2.9
X-2374	CRC	LFW527 + binimetinib	406.64	26.65	149	83.4	-2.8
X-2374	CRC	LFW527 + binimetinib	396.83	28.5	152	78.9	3.9
X-2374	CRC	LFW527 + binimetinib	403.4	26.59	155	81.9	-3
X-2403	CRC	5FU	235.4	25	0	0	0
X-2403	CRC	5FU	248.5	23.1	3	5.6	-7.6
X-2403	CRC	5FU	267.7	22.9	7	13.7	-8.4
X-2403	CRC	5FU	303.2	22.7	10	28.8	-9.2
X-2403	CRC	5FU	355.9	23.3	14	51.2	-6.8
X-2403	CRC	5FU	270.7	22.3	17	15	-10.8
X-2403	CRC	5FU	309.2	21.9	21	31.4	-12.4
X-2403	CRC	5FU	340.6	20	23	44.7	-20
X-2403	CRC	5FU	298.2	21.2	27	26.7	-15.2
X-2403	CRC	5FU	333.2	21.1	30	41.5	-15.6
X-2403	CRC	5FU	408.1	23.9	34	73.4	-4.4
X-2403	CRC	5FU	443.5	23.5	37	88.4	-6
X-2403	CRC	5FU	452.7	22.4	42	92.3	-10.4
X-2403	CRC	BKM120	215	21.3	0	0	0
X-2403	CRC	BKM120	226.6	19.6	4	5.4	-7.9
X-2403	CRC	BKM120	195.6	19.7	7	-9	-7.3
X-2403	CRC	BKM120	355	18.6	11	65.1	-12.5
X-2403	CRC	BKM120	317.4	18.4	14	47.6	-13.6
X-2403	CRC	BKM120	292.9	19.5	18	36.2	-8.5
X-2403	CRC	BKM120	346.3	18.3	21	61.1	-14.1
X-2403	CRC	BKM120	355.8	19.4	25	65.5	-8.9
X-2403	CRC	BKM120	418.8	20	27	94.8	-6.1
X-2403	CRC	BKM120 + LJC049	243.9	25.1	0	0	0
X-2403	CRC	BKM120 + LJC049	230.3	24.8	3	-5.6	-1.2
X-2403	CRC	BKM120 + LJC049	320.2	23.4	7	31.3	-6.8
X-2403	CRC	BKM120 + LJC049	435.3	22.6	10	78.5	-10
X-2403	CRC	BKM120 + LJC049	575.8	22.1	14	136.1	-12
X-2403	CRC	BKM120 + LJC049	506.6	21.7	17	107.7	-13.5
X-2403	CRC	BKM120 + LJC049	827.8	21.9	21	239.4	-12.7
X-2403	CRC	BKM120 + LJC049	929	23.2	24	280.9	-7.6
X-2403	CRC	BKM120 + LJC049	1025.5	24	28	320.5	-4.4
X-2403	CRC	BYL719 + cetuximab + encorafenib	245	24.8	0	0	0
X-2403	CRC	BYL719 + cetuximab + encorafenib	220.5	25.2	3	-10	1.6
X-2403	CRC	BYL719 + cetuximab + encorafenib	230.1	25.7	7	-6.1	3.6
X-2403	CRC	BYL719 + cetuximab + encorafenib	255.2	23.5	11	4.2	-5.2
X-2403	CRC	BYL719 + cetuximab + encorafenib	15	NA	15	-93.9	-7.3
X-2403	CRC	BYL719 + cetuximab	190	26.8	0	0	0
X-2403	CRC	BYL719 + cetuximab	149.1	27.4	4	-21.5	2.2
X-2403	CRC	BYL719 + cetuximab	140.4	25.3	8	-26.1	-5.6
X-2403	CRC	BYL719 + cetuximab	182.5	24.8	11	-3.9	-7.5
X-2403	CRC	BYL719 + cetuximab	166.8	24.9	13	-12.2	-7.1
X-2403	CRC	BYL719 + cetuximab	161.7	24.2	15	-14.9	-9.7
X-2403	CRC	BYL719 + cetuximab	274.9	26.5	21	44.7	-1.1
X-2403	CRC	BYL719 + cetuximab	340.9	25.1	25	79.4	-6.3
X-2403	CRC	BYL719 + cetuximab	357.9	23.2	34	88.4	-13.4
X-2403	CRC	BYL719 + cetuximab	390.1	23.4	40	105.3	-12.7
X-2403	CRC	BYL719 + cetuximab	443.5	23.1	43	133.4	-13.8
X-2403	CRC	BYL719 + cetuximab	474.4	23.9	46	149.7	-10.8
X-2403	CRC	BYL719 + cetuximab	508.5	24.8	51	167.6	-7.5
X-2403	CRC	BYL719 + cetuximab	529	23.5	54	178.4	-12.3
X-2403	CRC	BYL719 + cetuximab	596.1	25.1	59	213.7	-6.3
X-2403	CRC	BYL719 + cetuximab	709.9	23.5	61	273.6	-12.3
X-2403	CRC	BYL719 + cetuximab	761	24.2	65	300.5	-9.7
X-2403	CRC	BYL719 + cetuximab	779.6	23.6	67	310.3	-11.9
X-2403	CRC	BYL719	212.3	23.4	0	0	0
X-2403	CRC	BYL719	248.5	22.3	3	17.1	-4.7
X-2403	CRC	BYL719	277.6	20.6	7	30.8	-12
X-2403	CRC	BYL719	250.7	20.3	10	18.1	-13.2
X-2403	CRC	BYL719	344.9	20	14	62.5	-14.5
X-2403	CRC	BYL719	348.8	20.1	17	64.3	-14.1
X-2403	CRC	BYL719	380.8	21.1	21	79.4	-9.8
X-2403	CRC	BYL719	497.4	20.1	24	134.3	-14.1
X-2403	CRC	BYL719	416.8	20.1	28	96.3	-14.1
X-2403	CRC	BYL719	413.8	20.5	30	94.9	-12.4
X-2403	CRC	BYL719	374.6	19.3	34	76.4	-17.5
X-2403	CRC	BYL719	487.7	20.1	37	129.7	-14.1
X-2403	CRC	BYL719 + LJM716	258.8	24.1	0	0	0
X-2403	CRC	BYL719 + LJM716	325.4	23.3	4	25.7	-3.3
X-2403	CRC	BYL719 + LJM716	402.2	22.3	7	55.4	-7.5
X-2403	CRC	BYL719 + LJM716	473.3	22.2	11	82.9	-7.9
X-2403	CRC	BYL719 + LJM716	611.1	22.2	14	136.1	-7.9
X-2403	CRC	BYL719 + LJM716	623.6	21.6	18	141	-10.4
X-2403	CRC	BYL719 + LJM716	619.9	22.6	20	139.5	-6.2
X-2403	CRC	BYL719 + LJM716	682.8	22.3	24	163.8	-7.5
X-2403	CRC	BYL719 + LJM716	793.7	21.5	27	206.7	-10.8
X-2403	CRC	BYL719 + binimetinib	231.4	25.7	0	0	0
X-2403	CRC	BYL719 + binimetinib	207.7	25	3	-10.2	-2.7
X-2403	CRC	BYL719 + binimetinib	228.9	24.9	7	-1.1	-3.1
X-2403	CRC	BYL719 + binimetinib	279.1	24.8	10	20.6	-3.5
X-2403	CRC	BYL719 + binimetinib	361.9	24.9	14	56.4	-3.1
X-2403	CRC	BYL719 + binimetinib	484.7	24.7	17	109.5	-3.9
X-2403	CRC	BYL719 + binimetinib	542.9	24.9	21	134.6	-3.1
X-2403	CRC	BYL719 + binimetinib	639	25.6	24	176.1	-0.4
X-2403	CRC	BYL719 + binimetinib	623.1	25.5	28	169.3	-0.8
X-2403	CRC	BYL719 + encorafenib	210.4	23.6	0	0	0
X-2403	CRC	BYL719 + encorafenib	201.8	21.8	3	-4.1	-7.6
X-2403	CRC	BYL719 + encorafenib	239.3	20.7	7	13.7	-12.3
X-2403	CRC	BYL719 + encorafenib	384.6	21.1	10	82.8	-10.6
X-2403	CRC	BYL719 + encorafenib	365.4	21.2	14	73.7	-10.2
X-2403	CRC	BYL719 + encorafenib	502.1	22.1	17	138.6	-6.4
X-2403	CRC	BYL719 + encorafenib	568	21.5	21	170	-8.9
X-2403	CRC	BYL719 + encorafenib	554.2	21	24	163.4	-11
X-2403	CRC	BYL719 + encorafenib	638.2	21.6	28	203.3	-8.5
X-2403	CRC	CGM097	209.2	23.2	0	0	0
X-2403	CRC	CGM097	195.1	21.5	3	-6.7	-7.3
X-2403	CRC	CGM097	227.7	21.6	7	8.8	-6.9
X-2403	CRC	CGM097	235.4	21.8	9	12.5	-6
X-2403	CRC	CGM097	287.7	22.5	13	37.5	-3
X-2403	CRC	CGM097	286.3	20.8	16	36.9	-10.3
X-2403	CRC	CGM097	312.2	19.5	20	49.2	-15.9
X-2403	CRC	CGM097	328.1	21.9	23	56.8	-5.6
X-2403	CRC	CGM097	384.9	19.3	28	84	-16.8
X-2403	CRC	CKX620	212.7	25	0	0	0
X-2403	CRC	CKX620	160.6	23.3	3	-24.5	-6.8
X-2403	CRC	CKX620	168.6	23.9	7	-20.7	-4.4
X-2403	CRC	CKX620	176.1	24	10	-17.2	-4
X-2403	CRC	CKX620	216.9	25.1	14	2	0.4
X-2403	CRC	CKX620	217.6	25.3	16	2.3	1.2
X-2403	CRC	CKX620	275.8	25.9	20	29.7	3.6
X-2403	CRC	CKX620	300.1	23.5	23	41.1	-6
X-2403	CRC	CKX620	261.1	23.9	27	22.8	-4.4
X-2403	CRC	CKX620	253	24.4	30	18.9	-2.4
X-2403	CRC	CKX620	306.5	23.8	35	44.1	-4.8
X-2403	CRC	CKX620	340	24.3	38	59.8	-2.8
X-2403	CRC	CKX620	390.7	26.3	41	83.7	5.2
X-2403	CRC	CLR457	219.7	23.1	0	0	0
X-2403	CRC	CLR457	329.2	25	4	49.8	8.2
X-2403	CRC	CLR457	183.9	21	7	-16.3	-9.1
X-2403	CRC	CLR457	189.2	20.5	11	-13.9	-11.3
X-2403	CRC	CLR457	235.1	20.4	14	7	-11.7
X-2403	CRC	CLR457	305.4	20.5	18	39	-11.3
X-2403	CRC	CLR457	278.9	20.4	21	26.9	-11.7
X-2403	CRC	CLR457	349.7	20.7	25	59.2	-10.4
X-2403	CRC	CLR457	326.6	20.7	28	48.7	-10.4
X-2403	CRC	CLR457	351.1	21.1	32	59.8	-8.7
X-2403	CRC	CLR457	338.7	20.8	34	54.2	-10
X-2403	CRC	CLR457	327.5	20.5	38	49.1	-11.3
X-2403	CRC	CLR457	419.3	19.7	41	90.9	-14.7
X-2403	CRC	HDM201	217	25.4	0	0	0
X-2403	CRC	HDM201	256.8	24.1	3	18.3	-5
X-2403	CRC	HDM201	196.9	22.9	7	-9.3	-9.7
X-2403	CRC	HDM201	220.9	23.2	10	1.8	-8.6
X-2403	CRC	HDM201	232	22.1	14	6.9	-12.9
X-2403	CRC	HDM201	214.3	21.4	16	-1.2	-15.6
X-2403	CRC	HDM201	247.3	21.3	20	14	-16
X-2403	CRC	HDM201	341.2	24.4	23	57.2	-3.8
X-2403	CRC	HDM201	275.1	21.9	27	26.8	-13.7
X-2403	CRC	HDM201	392.4	23.7	30	80.8	-6.6
X-2403	CRC	HDM201	428.3	21.1	35	97.4	-16.8
X-2403	CRC	cetuximab	251.3	28.1	0	0	0
X-2403	CRC	cetuximab	310.3	26.8	8	23.5	-4.6
X-2403	CRC	cetuximab	329.6	27.4	12	31.2	-2.5
X-2403	CRC	cetuximab	354.1	28.1	16	40.9	0
X-2403	CRC	cetuximab	383.3	27.2	19	52.5	-3.2
X-2403	CRC	cetuximab	434.1	27.8	21	72.7	-1.1
X-2403	CRC	cetuximab	486.8	27.7	23	93.7	-1.4
X-2403	CRC	cetuximab	542.4	28.4	29	115.8	1.1
X-2403	CRC	cetuximab	622.1	28.1	33	147.6	0
X-2403	CRC	cetuximab	870	25.7	42	246.2	-8.5
X-2403	CRC	cetuximab	927.5	25.5	48	269.1	-9.3
X-2403	CRC	cetuximab	1126.8	28.8	51	348.4	2.5
X-2403	CRC	cetuximab	1138.2	29.2	54	352.9	3.9
X-2403	CRC	cetuximab + encorafenib	205.5	25.7	0	0	0
X-2403	CRC	cetuximab + encorafenib	289.8	22.7	8	41	-11.7
X-2403	CRC	cetuximab + encorafenib	273.1	21.5	12	32.9	-16.3
X-2403	CRC	LEE011	226.2	27.4	0	0	0
X-2403	CRC	LEE011	220.1	26.8	3	-2.7	-2.2
X-2403	CRC	LEE011	249.3	26.6	7	10.2	-2.9
X-2403	CRC	LEE011	333.3	26.3	10	47.3	-4
X-2403	CRC	LEE011	335.5	25.9	14	48.3	-5.5
X-2403	CRC	LEE011	352.4	24.5	17	55.8	-10.5
X-2403	CRC	LEE011	491.3	25.6	21	117.2	-6.6
X-2403	CRC	LEE011	434.4	25.5	24	92	-6.9
X-2403	CRC	LEE011	563.3	25.8	28	149	-5.8
X-2403	CRC	encorafenib	205.7	25.7	0	0	0
X-2403	CRC	encorafenib	340.3	24.5	3	65.4	-4.7
X-2403	CRC	encorafenib	554.3	24.1	7	169.5	-6.2
X-2403	CRC	encorafenib	446.6	24.4	10	117.1	-5.1
X-2403	CRC	encorafenib	661.3	22.7	14	221.5	-11.7
X-2403	CRC	encorafenib	666	23	17	223.8	-10.5
X-2403	CRC	encorafenib	1178.6	23.1	21	473	-10.1
X-2403	CRC	encorafenib	1577.8	22.5	24	667	-12.5
X-2403	CRC	LJC049	251.1	22.5	0	0	0
X-2403	CRC	LJC049	399.4	22.4	3	59.1	-0.4
X-2403	CRC	LJC049	506.1	21.2	7	101.6	-5.8
X-2403	CRC	LJC049	811.4	21.7	10	223.1	-3.6
X-2403	CRC	LJC049	1018.1	20.8	14	305.5	-7.6
X-2403	CRC	LJC049	1058.4	20.8	17	321.5	-7.6
X-2403	CRC	LJC049	1159.7	20.5	21	361.8	-8.9
X-2403	CRC	LJC049	1442.4	20.6	24	474.4	-8.4
X-2403	CRC	LJC049	2066.9	20.7	28	723.1	-7.9
X-2403	CRC	LKA136	232.7	25.6	0	0	0
X-2403	CRC	LKA136	312.2	25	4	34.2	-2.3
X-2403	CRC	LKA136	389.1	24.8	7	67.2	-3.1
X-2403	CRC	LKA136	452.5	23.3	11	94.5	-9
X-2403	CRC	LKA136	547.2	24	14	135.2	-6.2
X-2403	CRC	LKA136	792.5	24.1	18	240.6	-5.9
X-2403	CRC	LKA136	989.4	23.6	21	325.2	-7.8
X-2403	CRC	LKA136	931.8	24.2	25	300.4	-5.5
X-2403	CRC	LKA136	1042.6	25.1	28	348	-2
X-2403	CRC	binimetinib	231.9	24.6	0	0	0
X-2403	CRC	binimetinib	310.9	24.1	3	34.1	-2
X-2403	CRC	binimetinib	488.8	24.7	7	110.8	0.4
X-2403	CRC	binimetinib	504.4	24.1	10	117.5	-2
X-2403	CRC	binimetinib	575	23.2	14	148	-5.7
X-2403	CRC	binimetinib	723.6	23.8	17	212	-3.3
X-2403	CRC	binimetinib	865.1	23.7	21	273	-3.7
X-2403	CRC	binimetinib	906.2	22.7	24	290.8	-7.7
X-2403	CRC	binimetinib	1112.1	22.3	28	379.6	-9.3
X-2403	CRC	untreated	223.6	23.4	0	0	0
X-2403	CRC	untreated	349.3	22.8	3	56.2	-2.6
X-2403	CRC	untreated	360.9	23	7	61.4	-1.7
X-2403	CRC	untreated	398.1	23.9	10	78	2.1
X-2403	CRC	untreated	486.2	23.2	14	117.4	-0.9
X-2403	CRC	untreated	562.1	23.5	17	151.4	0.4
X-2403	CRC	untreated	709.1	23.1	21	217.1	-1.3
X-2403	CRC	untreated	906.4	24.1	24	305.4	3
X-2403	CRC	untreated	990	23.3	28	342.8	-0.4
X-2428	PDAC	abraxane	218.2	26.1	0	0	0
X-2428	PDAC	abraxane	383.6	24.4	5	75.8	-6.5
X-2428	PDAC	abraxane	405.1	25	8	85.7	-4.2
X-2428	PDAC	abraxane	325.1	25.1	11	49	-3.8
X-2428	PDAC	abraxane	534.4	24.9	14	144.9	-4.6
X-2428	PDAC	abraxane	490.3	25.7	18	124.7	-1.5
X-2428	PDAC	abraxane	442.8	25.7	21	102.9	-1.5
X-2428	PDAC	abraxane	518.3	26.2	25	137.5	0.4
X-2428	PDAC	abraxane	611.7	26	28	180.3	-0.4
X-2428	PDAC	abraxane	625.4	26.3	32	186.6	0.8
X-2428	PDAC	abraxane	723.8	26.9	35	231.7	3.1
X-2428	PDAC	abraxane	899.1	26.9	39	312.1	3.1
X-2428	PDAC	abraxane	1038.3	26.7	42	375.8	2.3
X-2428	PDAC	BKM120 + binimetinib	235.5	23.8	0	0	0
X-2428	PDAC	BKM120 + binimetinib	200.2	24.3	4	-15	2.1
X-2428	PDAC	BKM120 + binimetinib	168.7	24.6	7	-28.4	3.4
X-2428	PDAC	BKM120 + binimetinib	141.4	26	11	-40	9.2
X-2428	PDAC	BKM120 + binimetinib	138.6	26.2	14	-41.1	10.1
X-2428	PDAC	BKM120 + binimetinib	126.5	25.6	18	-46.3	7.6
X-2428	PDAC	BKM120 + binimetinib	166.4	24.6	21	-29.3	3.4
X-2428	PDAC	BKM120 + binimetinib	139.8	26.3	24	-40.6	10.5
X-2428	PDAC	BKM120 + binimetinib	141.4	25.8	27	-40	8.4
X-2428	PDAC	BKM120 + binimetinib	117.1	26.6	32	-50.3	11.8
X-2428	PDAC	BKM120 + binimetinib	121.2	25.9	35	-48.5	8.8
X-2428	PDAC	BKM120 + binimetinib	102.3	26	39	-56.6	9.2
X-2428	PDAC	BKM120 + binimetinib	134.7	26.1	42	-42.8	9.7
X-2428	PDAC	BKM120 + binimetinib	131.9	26.1	45	-44	9.7
X-2428	PDAC	BKM120 + binimetinib	100.2	27.2	49	-57.5	14.3
X-2428	PDAC	BKM120 + binimetinib	128.8	27.2	52	-45.3	14.3
X-2428	PDAC	BKM120 + binimetinib	132.3	26.6	55	-43.8	11.8
X-2428	PDAC	BKM120 + binimetinib	118.1	25.8	59	-49.9	8.4
X-2428	PDAC	BKM120 + binimetinib	140.2	26.8	63	-40.5	12.6
X-2428	PDAC	BKM120 + binimetinib	152.1	27	67	-35.4	13.4
X-2428	PDAC	BKM120 + binimetinib	133.1	26	70	-43.5	9.2
X-2428	PDAC	BKM120 + binimetinib	99.1	26.5	73	-57.9	11.3
X-2428	PDAC	BKM120 + binimetinib	139.1	25.9	77	-40.9	8.8
X-2428	PDAC	BKM120 + binimetinib	143.2	25.1	81	-39.2	5.5
X-2428	PDAC	BKM120 + LDE225	218.1	26.7	0	0	0
X-2428	PDAC	BKM120 + LDE225	207.3	26.3	4	-5	-1.5
X-2428	PDAC	BKM120 + LDE225	159.1	25.3	7	-27.1	-5.2
X-2428	PDAC	BKM120 + LDE225	151.7	26.5	11	-30.4	-0.7
X-2428	PDAC	BKM120 + LDE225	127.5	24.9	14	-41.5	-6.7
X-2428	PDAC	BKM120 + LDE225	128.1	23.5	18	-41.3	-12
X-2428	PDAC	BKM120 + LDE225	130.4	22.8	21	-40.2	-14.6
X-2428	PDAC	BKM120 + LDE225	110.6	23	24	-49.3	-13.9
X-2428	PDAC	BKM120 + LDE225	89.3	24.1	27	-59.1	-9.7
X-2428	PDAC	BKM120 + LDE225	92.8	24.7	32	-57.5	-7.5
X-2428	PDAC	BKM120 + LDE225	122.4	24.5	35	-43.9	-8.2
X-2428	PDAC	BKM120 + LDE225	127.8	26	39	-41.4	-2.6
X-2428	PDAC	BKM120 + LDE225	154.5	25.3	42	-29.2	-5.2
X-2428	PDAC	BKM120 + LDE225	107.4	25.4	45	-50.8	-4.9
X-2428	PDAC	BKM120 + LDE225	80.5	24.3	49	-63.1	-9
X-2428	PDAC	BKM120 + LDE225	140.6	25	52	-35.5	-6.4
X-2428	PDAC	BKM120 + LDE225	114.7	25.3	55	-47.4	-5.2
X-2428	PDAC	BKM120 + LDE225	120	23.9	59	-45	-10.5
X-2428	PDAC	BKM120 + LDE225	117	26.1	63	-46.4	-2.2
X-2428	PDAC	BKM120 + LDE225	132.4	27	67	-39.3	1.1
X-2428	PDAC	BKM120 + LDE225	131.2	25.1	70	-39.8	-6
X-2428	PDAC	BKM120 + LDE225	142.7	25.4	73	-34.6	-4.9
X-2428	PDAC	BKM120 + LDE225	144	26.1	77	-34	-2.2
X-2428	PDAC	BKM120 + LDE225	134.5	24.6	81	-38.3	-7.9
X-2428	PDAC	BKM120	276	27.7	0	0	0
X-2428	PDAC	BKM120	248.4	28.3	5	-10	2.2
X-2428	PDAC	BKM120	197.8	41.8	8	-28.3	2.2
X-2428	PDAC	BKM120	236.8	28.4	12	-14.2	2.5
X-2428	PDAC	BKM120	273.8	28.3	15	-0.8	2.2
X-2428	PDAC	BKM120	302.9	28.2	19	9.7	1.8
X-2428	PDAC	BKM120	272.6	28.7	22	-1.2	3.6
X-2428	PDAC	BKM120	275.2	27.2	27	-0.3	-1.8
X-2428	PDAC	BKM120	255.4	29.9	30	-7.5	7.9
X-2428	PDAC	BKM120	204.4	30.6	35	-25.9	10.5
X-2428	PDAC	BKM120	229.9	30.7	37	-16.7	10.8
X-2428	PDAC	BKM120	261.8	31.3	40	-5.1	13
X-2428	PDAC	BKM120	206.6	29.5	43	-25.1	6.5
X-2428	PDAC	BKM120	226.5	31.4	48	-17.9	13.4
X-2428	PDAC	BKM120	313.9	30.4	51	13.7	9.7
X-2428	PDAC	BKM120	185	30.6	55	-33	10.5
X-2428	PDAC	BKM120	171.3	29.7	58	-37.9	7.2
X-2428	PDAC	BKM120	278.7	30.4	61	1	9.7
X-2428	PDAC	BKM120	210.2	29.7	64	-23.8	7.2
X-2428	PDAC	BKM120	264.5	30.2	68	-4.2	9
X-2428	PDAC	BKM120	305.8	29.7	71	10.8	7.2
X-2428	PDAC	BKM120	485	29.5	75	75.7	6.5
X-2428	PDAC	BKM120	580.1	29.1	78	110.2	5.1
X-2428	PDAC	BYL719	218.5	24.1	0	0	0
X-2428	PDAC	BYL719	214.4	25.4	5	-1.9	5.4
X-2428	PDAC	BYL719	214.5	25.6	10	-1.8	6.2
X-2428	PDAC	BYL719	247.6	24.9	13	13.3	3.3
X-2428	PDAC	BYL719	263.2	25.6	17	20.5	6.2
X-2428	PDAC	BYL719	328.4	24.8	20	50.3	2.9
X-2428	PDAC	BYL719	349.8	25.4	25	60.1	5.4
X-2428	PDAC	BYL719	369.2	26.1	27	69	8.3
X-2428	PDAC	BYL719	427.8	25	31	95.8	3.7
X-2428	PDAC	BYL719	455.6	25.8	34	108.5	7.1
X-2428	PDAC	BYL719	477.6	25.8	38	118.6	7.1
X-2428	PDAC	BYL719	578.6	26.5	41	164.8	10
X-2428	PDAC	BYL719	721.9	26.4	45	230.4	9.5
X-2428	PDAC	BYL719	784.2	26.6	48	258.9	10.4
X-2428	PDAC	BYL719	844.4	26.4	52	286.5	9.5
X-2428	PDAC	BYL719	957.6	26.6	55	338.3	10.4
X-2428	PDAC	BYL719 + LJM716	201.6	27.2	0	0	0
X-2428	PDAC	BYL719 + LJM716	221.6	29	3	9.9	6.6
X-2428	PDAC	BYL719 + LJM716	247	27.7	6	22.5	1.8
X-2428	PDAC	BYL719 + LJM716	267.7	26.6	10	32.8	-2.2
X-2428	PDAC	BYL719 + LJM716	258.6	27.6	13	28.3	1.5
X-2428	PDAC	BYL719 + LJM716	235.2	28.1	17	16.7	3.3
X-2428	PDAC	BYL719 + LJM716	231.9	27.9	20	15	2.6
X-2428	PDAC	BYL719 + LJM716	261.5	28.2	24	29.7	3.7
X-2428	PDAC	BYL719 + LJM716	263.1	27.2	27	30.5	0
X-2428	PDAC	BYL719 + LJM716	259.6	27.8	31	28.8	2.2
X-2428	PDAC	BYL719 + LJM716	267.1	27.1	34	32.5	-0.4
X-2428	PDAC	BYL719 + LJM716	286.2	27.8	38	42	2.2
X-2428	PDAC	BYL719 + LJM716	292.1	28.1	41	44.9	3.3
X-2428	PDAC	BYL719 + LJM716	267.8	25.5	46	32.8	-6.2
X-2428	PDAC	BYL719 + LJM716	269.9	25.3	49	33.9	-7
X-2428	PDAC	BYL719 + LJM716	269.5	26	52	33.7	-4.4
X-2428	PDAC	BYL719 + LJM716	264.2	26.8	55	31.1	-1.5
X-2428	PDAC	BYL719 + LJM716	263.1	26.1	59	30.5	-4
X-2428	PDAC	BYL719 + LJM716	253.3	25.8	62	25.6	-5.1
X-2428	PDAC	BYL719 + LJM716	252	26.8	66	25	-1.5
X-2428	PDAC	BYL719 + LJM716	259	27.3	70	28.5	0.4
X-2428	PDAC	BYL719 + LJM716	278	26	73	37.9	-4.4
X-2428	PDAC	BYL719 + LJM716	305.7	26.5	76	51.6	-2.6
X-2428	PDAC	BYL719 + LJM716	308.6	26.9	80	53.1	-1.1
X-2428	PDAC	BYL719 + LJM716	317.6	27.9	83	57.5	2.6
X-2428	PDAC	BYL719 + LJM716	328.4	26.5	87	62.9	-2.6
X-2428	PDAC	BYL719 + LJM716	339.8	27.3	90	68.6	0.4
X-2428	PDAC	BYL719 + LJM716	342.5	25.8	94	69.9	-5.1
X-2428	PDAC	BYL719 + LJM716	343	27.3	97	70.1	0.4
X-2428	PDAC	CLR457	204.6	27	0	0	0
X-2428	PDAC	CLR457	198.3	26.8	3	-3.1	-0.7
X-2428	PDAC	CLR457	198	27.5	7	-3.2	1.9
X-2428	PDAC	CLR457	205.1	27.2	10	0.2	0.7
X-2428	PDAC	CLR457	194.2	27.3	14	-5.1	1.1
X-2428	PDAC	CLR457	201.1	26.7	17	-1.7	-1.1
X-2428	PDAC	CLR457	214.9	27.1	21	5	0.4
X-2428	PDAC	CLR457	221.6	27.1	24	8.3	0.4
X-2428	PDAC	CLR457	210.4	26.9	29	2.8	-0.4
X-2428	PDAC	CLR457	212.8	27	32	4	0
X-2428	PDAC	CLR457	199.2	26	35	-2.6	-3.7
X-2428	PDAC	CLR457	205.7	26.6	38	0.5	-1.5
X-2428	PDAC	CLR457	205.5	26.2	42	0.4	-3
X-2428	PDAC	CLR457	213.3	26.5	45	4.3	-1.9
X-2428	PDAC	CLR457	224	26.9	49	9.5	-0.4
X-2428	PDAC	CLR457	264.9	26.2	53	29.5	-3
X-2428	PDAC	CLR457	275.5	26.5	56	34.7	-1.9
X-2428	PDAC	CLR457	280.7	26.2	59	37.2	-3
X-2428	PDAC	CLR457	295.1	27	63	44.2	0
X-2428	PDAC	CLR457	296.7	27.8	66	45	3
X-2428	PDAC	CLR457	323.3	26	70	58	-3.7
X-2428	PDAC	CLR457	333.3	26.3	73	62.9	-2.6
X-2428	PDAC	CLR457	344.2	26.8	77	68.2	-0.7
X-2428	PDAC	CLR457	368	26.6	80	79.9	-1.5
X-2428	PDAC	CLR457	383.4	26.3	85	87.4	-2.6
X-2428	PDAC	CLR457	414.6	25.8	88	102.6	-4.4
X-2428	PDAC	CLR457	411.5	26	91	101.1	-3.7
X-2428	PDAC	CLR457	430.1	24	94	110.2	-11.1
X-2428	PDAC	CLR457	438.6	23.6	98	114.4	-12.6
X-2428	PDAC	CLR457	483.3	23.6	101	136.2	-12.6
X-2428	PDAC	CLR457	521.8	24.1	105	155	-10.7
X-2428	PDAC	CLR457	546.2	24.3	108	167	-10
X-2428	PDAC	CLR457	584.1	24.1	113	185.5	-10.7
X-2428	PDAC	CLR457	635	24	116	210.4	-11.1
X-2428	PDAC	CLR457	699.4	24.1	119	241.8	-10.7
X-2428	PDAC	CLR457	788.8	24.3	122	285.5	-10
X-2428	PDAC	HDM201	247.5	26.1	0	0	0
X-2428	PDAC	HDM201	284.4	26.8	3	14.9	2.7
X-2428	PDAC	HDM201	431	27.8	6	74.1	6.5
X-2428	PDAC	HDM201	466.1	28.4	10	88.3	8.8
X-2428	PDAC	HDM201	493.9	27.2	13	99.6	4.2
X-2428	PDAC	HDM201	571.4	27.5	17	130.9	5.4
X-2428	PDAC	HDM201	793.4	28.1	20	220.6	7.7
X-2428	PDAC	HDM201	850.9	27.2	24	243.8	4.2
X-2428	PDAC	figitumumab" + binimetinib	248.7	27.2	0	0	0
X-2428	PDAC	figitumumab" + binimetinib	178.2	27	5	-28.3	-0.7
X-2428	PDAC	figitumumab" + binimetinib	147.5	27.6	8	-40.7	1.5
X-2428	PDAC	figitumumab" + binimetinib	157.5	27	12	-36.7	-0.7
X-2428	PDAC	figitumumab" + binimetinib	116.2	26.9	15	-53.3	-1.1
X-2428	PDAC	figitumumab" + binimetinib	89.9	26.7	19	-63.9	-1.8
X-2428	PDAC	figitumumab" + binimetinib	57.3	27.1	22	-77	-0.4
X-2428	PDAC	figitumumab" + binimetinib	73.3	26.5	27	-70.5	-2.6
X-2428	PDAC	figitumumab" + binimetinib	83.2	27.2	30	-66.5	0
X-2428	PDAC	figitumumab" + binimetinib	51.9	26.5	35	-79.1	-2.6
X-2428	PDAC	figitumumab" + binimetinib	89.8	24.9	37	-63.9	-8.5
X-2428	PDAC	figitumumab" + binimetinib	114.8	26.4	40	-53.8	-2.9
X-2428	PDAC	figitumumab" + binimetinib	73.9	26.7	43	-70.3	-1.8
X-2428	PDAC	figitumumab" + binimetinib	120.6	26	51	-51.5	-4.4
X-2428	PDAC	figitumumab" + binimetinib	62.6	26.5	55	-74.8	-2.6
X-2428	PDAC	figitumumab" + binimetinib	86.4	25.9	58	-65.3	-4.8
X-2428	PDAC	figitumumab" + binimetinib	75	25.7	61	-69.8	-5.5
X-2428	PDAC	figitumumab" + binimetinib	75.3	25.8	64	-69.7	-5.1
X-2428	PDAC	figitumumab" + binimetinib	103.5	26.9	68	-58.4	-1.1
X-2428	PDAC	figitumumab" + binimetinib	128	25.4	71	-48.5	-6.6
X-2428	PDAC	figitumumab" + binimetinib	99.5	26.1	75	-60	-4
X-2428	PDAC	figitumumab" + binimetinib	187	26.3	78	-24.8	-3.3
X-2428	PDAC	figitumumab" + binimetinib	155.5	26.9	82	-37.5	-1.1
X-2428	PDAC	figitumumab" + binimetinib	139.1	26	85	-44.1	-4.4
X-2428	PDAC	figitumumab" + binimetinib	160.9	26.6	90	-35.3	-2.2
X-2428	PDAC	figitumumab"	223.1	25.1	0	0	0
X-2428	PDAC	figitumumab"	298.3	25.6	2	33.7	2
X-2428	PDAC	figitumumab"	315.1	25.6	6	41.2	2
X-2428	PDAC	figitumumab"	314.1	25.4	9	40.8	1.2
X-2428	PDAC	figitumumab"	331.1	26.6	13	48.4	6
X-2428	PDAC	figitumumab"	331.4	26.4	16	48.5	5.2
X-2428	PDAC	figitumumab"	267.4	26.1	20	19.9	4
X-2428	PDAC	figitumumab"	296.3	25.6	22	32.8	2
X-2428	PDAC	figitumumab"	309.4	25.9	26	38.7	3.2
X-2428	PDAC	figitumumab"	379.8	25.7	29	70.2	2.4
X-2428	PDAC	figitumumab"	456.9	26.6	33	104.8	6
X-2428	PDAC	figitumumab"	545.9	26.8	36	144.7	6.8
X-2428	PDAC	figitumumab"	642.6	26.3	41	188	4.8
X-2428	PDAC	figitumumab"	674.2	26.3	43	202.2	4.8
X-2428	PDAC	figitumumab"	728.7	25.7	47	226.6	2.4
X-2428	PDAC	figitumumab"	765.9	26.3	50	243.3	4.8
X-2428	PDAC	figitumumab"	865.7	25.8	54	288	2.8
X-2428	PDAC	figitumumab"	922.4	25.9	57	313.4	3.2
X-2428	PDAC	gemcitabine-50mpk	219.5	23.8	0	0	0
X-2428	PDAC	gemcitabine-50mpk	270.4	24.1	3	23.2	1.3
X-2428	PDAC	gemcitabine-50mpk	273.7	23.7	7	24.7	-0.4
X-2428	PDAC	gemcitabine-50mpk	346.6	24.7	10	57.9	3.8
X-2428	PDAC	gemcitabine-50mpk	434.2	24.9	14	97.8	4.6
X-2428	PDAC	gemcitabine-50mpk	389.3	25.8	17	77.4	8.4
X-2428	PDAC	gemcitabine-50mpk	413.2	26.1	20	88.2	9.7
X-2428	PDAC	gemcitabine-50mpk	392.5	26.7	24	78.8	12.2
X-2428	PDAC	gemcitabine-50mpk	402.2	25.3	28	83.2	6.3
X-2428	PDAC	gemcitabine-50mpk	428.6	25.4	31	95.3	6.7
X-2428	PDAC	gemcitabine-50mpk	476.7	26.7	35	117.2	12.2
X-2428	PDAC	gemcitabine-50mpk	488.2	25.3	38	122.4	6.3
X-2428	PDAC	gemcitabine-50mpk	571.5	27.3	42	160.4	14.7
X-2428	PDAC	gemcitabine-50mpk	459.3	26.1	45	109.2	9.7
X-2428	PDAC	gemcitabine-50mpk	449.7	25.9	48	104.9	8.8
X-2428	PDAC	gemcitabine-50mpk	489.1	25.7	52	122.8	8
X-2428	PDAC	gemcitabine-50mpk	427.6	25	56	94.8	5
X-2428	PDAC	gemcitabine-50mpk	405.1	26.2	59	84.6	10.1
X-2428	PDAC	gemcitabine-50mpk	409.7	27.2	63	86.7	14.3
X-2428	PDAC	gemcitabine-50mpk	506.2	26.8	65	130.6	12.6
X-2428	PDAC	gemcitabine-50mpk	509	27.2	70	131.9	14.3
X-2428	PDAC	gemcitabine-50mpk	484.3	26.9	76	120.6	13
X-2428	PDAC	gemcitabine-50mpk	489.8	26.3	80	123.1	10.5
X-2428	PDAC	gemcitabine-50mpk	460.2	26.7	84	109.7	12.2
X-2428	PDAC	gemcitabine-50mpk	466.1	27	86	112.3	13.4
X-2428	PDAC	gemcitabine-50mpk	569.8	27.5	91	159.6	15.5
X-2428	PDAC	INC424	203.4	22.8	0	0	0
X-2428	PDAC	INC424	219	20.6	5	7.7	-9.6
X-2428	PDAC	INC424	227.7	24.2	10	11.9	6.1
X-2428	PDAC	INC424	239.8	23.9	13	17.9	4.8
X-2428	PDAC	INC424	297.8	24	17	46.4	5.3
X-2428	PDAC	INC424	362.4	23.5	20	78.2	3.1
X-2428	PDAC	INC424	451.9	23.4	25	122.2	2.6
X-2428	PDAC	INC424	456.5	23.4	27	124.4	2.6
X-2428	PDAC	INC424	492.6	23.3	31	142.2	2.2
X-2428	PDAC	INC424	547.6	24	34	169.2	5.3
X-2428	PDAC	INC424	596	23.7	38	193	3.9
X-2428	PDAC	INC424	623.5	23.9	41	206.5	4.8
X-2428	PDAC	INC424	764.7	25	45	276	9.6
X-2428	PDAC	INC424	796.5	23.9	48	291.6	4.8
X-2428	PDAC	INC424	882	24.1	52	333.6	5.7
X-2428	PDAC	INC424	899.4	23.2	55	342.2	1.8
X-2428	PDAC	LEE011	221	25.6	0	0	0
X-2428	PDAC	LEE011	249.8	25.4	2	13	-0.8
X-2428	PDAC	LEE011	252.1	26.1	5	14.1	2
X-2428	PDAC	LEE011	250	25.4	8	13.1	-0.8
X-2428	PDAC	LEE011	268	26.5	12	21.3	3.5
X-2428	PDAC	LEE011	285.3	26.5	15	29.1	3.5
X-2428	PDAC	LEE011	336.9	26.6	19	52.4	3.9
X-2428	PDAC	LEE011	302.4	26.8	22	36.8	4.7
X-2428	PDAC	LEE011	319.5	28.4	26	44.6	10.9
X-2428	PDAC	LEE011	317.3	27.4	29	43.6	7
X-2428	PDAC	LEE011	393.8	28.3	33	78.2	10.5
X-2428	PDAC	LEE011	335.5	27.8	36	51.8	8.6
X-2428	PDAC	LEE011	321.4	28.9	40	45.4	12.9
X-2428	PDAC	LEE011	325.5	27.8	43	47.3	8.6
X-2428	PDAC	LEE011	353	27.7	47	59.7	8.2
X-2428	PDAC	LEE011	312.1	28.9	50	41.2	12.9
X-2428	PDAC	LEE011	322.9	28.3	54	46.1	10.5
X-2428	PDAC	LEE011	351.9	28.5	57	59.2	11.3
X-2428	PDAC	LEE011	364.8	28.6	61	65.1	11.7
X-2428	PDAC	LEE011	345.6	26.9	64	56.4	5.1
X-2428	PDAC	LEE011	356	28	68	61.1	9.4
X-2428	PDAC	LEE011	397.7	27.3	71	80	6.6
X-2428	PDAC	LEE011	349.2	27.2	75	58	6.2
X-2428	PDAC	LEE011	363.4	27.4	78	64.4	7
X-2428	PDAC	LEE011	298.6	28.1	82	35.1	9.8
X-2428	PDAC	LEE011	252.4	28.6	85	14.2	11.7
X-2428	PDAC	LEE011	272.3	27	89	23.2	5.5
X-2428	PDAC	WNT974	229.7	26.2	0	0	0
X-2428	PDAC	WNT974	317.4	53.5	2	38.2	0
X-2428	PDAC	WNT974	317.4	25.6	5	38.2	-2.3
X-2428	PDAC	WNT974	330.5	25.3	8	43.9	-3.4
X-2428	PDAC	WNT974	356.4	22.2	13	55.2	-15.3
X-2428	PDAC	LKA136	213.6	25	0	0	0
X-2428	PDAC	LKA136	311.4	25.9	2	45.8	3.6
X-2428	PDAC	LKA136	317.8	24.7	6	48.8	-1.2
X-2428	PDAC	LKA136	379.1	26.6	9	77.5	6.4
X-2428	PDAC	LKA136	371.7	25.7	13	74	2.8
X-2428	PDAC	LKA136	403.6	25.6	16	89	2.4
X-2428	PDAC	LKA136	393	25.4	19	84	1.6
X-2428	PDAC	LKA136	399.4	24.8	23	87	-0.8
X-2428	PDAC	LKA136	492.2	25	27	130.4	0
X-2428	PDAC	LKA136	584.1	25.9	30	173.5	3.6
X-2428	PDAC	LKA136	858.1	26.6	34	301.7	6.4
X-2428	PDAC	LKA136	938.3	27	37	339.3	8
X-2428	PDAC	binimetinib	222.9	25.8	0	0	0
X-2428	PDAC	binimetinib	254.6	25	4	14.2	-3.1
X-2428	PDAC	binimetinib	249.1	24.9	7	11.8	-3.5
X-2428	PDAC	binimetinib	213.3	24.6	11	-4.3	-4.7
X-2428	PDAC	binimetinib	231.4	24.8	14	3.8	-3.9
X-2428	PDAC	binimetinib	230.1	25	18	3.2	-3.1
X-2428	PDAC	binimetinib	242.5	26	21	8.8	0.8
X-2428	PDAC	binimetinib	199.2	26.2	25	-10.6	1.6
X-2428	PDAC	binimetinib	257.7	25.4	28	15.6	-1.6
X-2428	PDAC	binimetinib	182.5	25.3	32	-18.1	-1.9
X-2428	PDAC	binimetinib	161.7	24.9	35	-27.5	-3.5
X-2428	PDAC	binimetinib	230.6	26.4	39	3.5	2.3
X-2428	PDAC	binimetinib	165.5	24.5	42	-25.8	-5
X-2428	PDAC	binimetinib	175.4	26	46	-21.3	0.8
X-2428	PDAC	binimetinib	150.1	26.1	49	-32.7	1.2
X-2428	PDAC	binimetinib	149.5	26	53	-32.9	0.8
X-2428	PDAC	binimetinib	167.8	24.9	56	-24.7	-3.5
X-2428	PDAC	binimetinib	126	25.4	59	-43.5	-1.6
X-2428	PDAC	binimetinib	171.1	25	62	-23.2	-3.1
X-2428	PDAC	binimetinib	154.2	25.4	67	-30.8	-1.6
X-2428	PDAC	binimetinib	190.5	24.2	70	-14.5	-6.2
X-2428	PDAC	binimetinib	95.4	25.4	74	-57.2	-1.6
X-2428	PDAC	binimetinib	108.8	25.5	77	-51.2	-1.2
X-2428	PDAC	binimetinib-3.5mpk	247.8	27.6	0	0	0
X-2428	PDAC	binimetinib-3.5mpk	186.6	27.5	5	-24.7	-0.4
X-2428	PDAC	binimetinib-3.5mpk	198.1	27.5	8	-20.1	-0.4
X-2428	PDAC	binimetinib-3.5mpk	107.9	27.3	12	-56.5	-1.1
X-2428	PDAC	binimetinib-3.5mpk	153.8	26.7	15	-37.9	-3.3
X-2428	PDAC	binimetinib-3.5mpk	152.4	27.7	19	-38.5	0.4
X-2428	PDAC	binimetinib-3.5mpk	156.1	25.8	22	-37	-6.5
X-2428	PDAC	binimetinib-3.5mpk	132.6	26.7	27	-46.5	-3.3
X-2428	PDAC	binimetinib-3.5mpk	177.5	26.9	30	-28.4	-2.5
X-2428	PDAC	binimetinib-3.5mpk	114	27.6	35	-54	0
X-2428	PDAC	binimetinib-3.5mpk	134.3	26.3	37	-45.8	-4.7
X-2428	PDAC	binimetinib-3.5mpk	137.4	26.3	40	-44.6	-4.7
X-2428	PDAC	binimetinib-3.5mpk	83.3	27.1	43	-66.4	-1.8
X-2428	PDAC	binimetinib-3.5mpk	80.1	26.6	48	-67.7	-3.6
X-2428	PDAC	binimetinib-3.5mpk	116.4	27.6	51	-53	0
X-2428	PDAC	binimetinib-3.5mpk	48.4	26.7	55	-80.5	-3.3
X-2428	PDAC	binimetinib-3.5mpk	61.2	26.5	58	-75.3	-4
X-2428	PDAC	binimetinib-3.5mpk	101	26.3	61	-59.2	-4.7
X-2428	PDAC	binimetinib-3.5mpk	64	26.5	64	-74.2	-4
X-2428	PDAC	binimetinib-3.5mpk	26.8	26.6	68	-89.2	-3.6
X-2428	PDAC	binimetinib-3.5mpk	45.7	26.7	71	-81.6	-3.3
X-2428	PDAC	binimetinib-3.5mpk	47.7	27.5	75	-80.8	-0.4
X-2428	PDAC	binimetinib-3.5mpk	50.4	27.5	78	-79.7	-0.4
X-2428	PDAC	binimetinib-3.5mpk	106.6	26.6	82	-57	-3.6
X-2428	PDAC	trametinib	251.8	24.7	0	0	0
X-2428	PDAC	trametinib	231.2	25.3	4	-8.2	2.4
X-2428	PDAC	trametinib	257.2	25.8	7	2.1	4.5
X-2428	PDAC	trametinib	221.9	25.9	11	-11.9	4.9
X-2428	PDAC	trametinib	244.7	25.2	14	-2.8	2
X-2428	PDAC	trametinib	390.6	25.7	19	55.1	4
X-2428	PDAC	trametinib	420.5	25.6	22	67	3.6
X-2428	PDAC	trametinib	369	26.7	26	46.5	8.1
X-2428	PDAC	trametinib	324.2	25.8	29	28.8	4.5
X-2428	PDAC	trametinib	239.2	24.6	33	-5	-0.4
X-2428	PDAC	trametinib	285.3	23.2	36	13.3	-6.1
X-2428	PDAC	trametinib	407.2	26.3	41	61.7	6.5
X-2428	PDAC	trametinib	397.6	25.1	43	57.9	1.6
X-2428	PDAC	trametinib	361.7	26.3	48	43.6	6.5
X-2428	PDAC	trametinib	356.3	25	50	41.5	1.2
X-2428	PDAC	trametinib	447.4	26	54	77.7	5.3
X-2428	PDAC	trametinib	400.6	25.5	57	59.1	3.2
X-2428	PDAC	trametinib	582.6	26.3	61	131.4	6.5
X-2428	PDAC	untreated	262	28.2	0	0	0
X-2428	PDAC	untreated	144.4	29.5	6	-44.9	4.6
X-2428	PDAC	untreated	160	30.4	9	-38.9	7.8
X-2428	PDAC	untreated	216.7	NA	11	-17.3	7.8
X-2428	PDAC	untreated	212.4	30.1	14	-18.9	6.7
X-2428	PDAC	untreated	199.8	30.8	18	-23.7	9.2
X-2428	PDAC	untreated	237	29.6	21	-9.5	5
X-2428	PDAC	untreated	251.8	29.2	25	-3.9	3.5
X-2428	PDAC	untreated	248	29.7	29	-5.3	5.3
X-2428	PDAC	untreated	180.9	29.2	33	-31	3.5
X-2428	PDAC	untreated	193.3	29	35	-26.2	2.8
X-2428	PDAC	untreated	181.5	30.3	39	-30.7	7.4
X-2428	PDAC	untreated	183.1	28.8	47	-30.1	2.1
X-2428	PDAC	untreated	149.6	28.6	53	-42.9	1.4
X-2428	PDAC	untreated	128.7	28.5	57	-50.9	1.1
X-2428	PDAC	untreated	130.4	30.6	60	-50.2	8.5
X-2428	PDAC	untreated	154.9	30.8	63	-40.9	9.2
X-2428	PDAC	untreated	191.6	30.6	67	-26.9	8.5
X-2428	PDAC	untreated	160.3	29.6	70	-38.8	5
X-2428	PDAC	untreated	163.6	29.7	75	-37.6	5.3
X-2428	PDAC	untreated	109.2	29.8	78	-58.3	5.7
X-2428	PDAC	untreated	119.7	30.4	82	-54.3	7.8
X-2428	PDAC	untreated	132.4	29.2	85	-49.5	3.5
X-2428	PDAC	untreated	151.6	29.6	88	-42.1	5
X-2428	PDAC	untreated	139.2	30.1	91	-46.9	6.7
X-2428	PDAC	untreated	110.3	30.2	96	-57.9	7.1
X-2428	PDAC	untreated	129.4	30.3	99	-50.6	7.4
X-2470	PDAC	abraxane	205.3	26.8	0	0	0
X-2470	PDAC	abraxane	205.9	26.4	4	0.3	-1.5
X-2470	PDAC	abraxane	182.6	26	7	-11.1	-3
X-2470	PDAC	abraxane	222.9	26.5	11	8.6	-1.1
X-2470	PDAC	abraxane	277.2	26.4	14	35	-1.5
X-2470	PDAC	abraxane	385.5	27.9	18	87.8	4.1
X-2470	PDAC	abraxane	437.1	28.6	21	112.9	6.7
X-2470	PDAC	abraxane	453.7	27	25	121	0.7
X-2470	PDAC	abraxane	407.3	27.5	28	98.4	2.6
X-2470	PDAC	abraxane	516	27.3	32	151.3	1.9
X-2470	PDAC	abraxane	592.9	27.8	35	188.8	3.7
X-2470	PDAC	abraxane	713.2	27.8	39	247.4	3.7
X-2470	PDAC	abraxane	735.3	28	42	258.2	4.5
X-2470	PDAC	abraxane	834.5	28.3	46	306.5	5.6
X-2470	PDAC	abraxane	1075.9	27.5	49	424.1	2.6
X-2470	PDAC	BKM120	260.1	28.1	0	0	0
X-2470	PDAC	BKM120	312	27.2	2	20	-3.2
X-2470	PDAC	BKM120	261.2	26.2	6	0.4	-6.8
X-2470	PDAC	BKM120	310.8	26.8	9	19.5	-4.6
X-2470	PDAC	BKM120	324.6	27.2	12	24.8	-3.2
X-2470	PDAC	BKM120	251.8	26.7	15	-3.2	-5
X-2470	PDAC	BKM120	352.4	27.9	20	35.5	-0.7
X-2470	PDAC	BKM120	289	28	26	11.1	-0.4
X-2470	PDAC	BKM120	300	27.4	30	15.3	-2.5
X-2470	PDAC	BKM120	250.9	27.6	33	-3.5	-1.8
X-2470	PDAC	BKM120	313.7	27.2	36	20.6	-3.2
X-2470	PDAC	BKM120	282.7	27.8	40	8.7	-1.1
X-2470	PDAC	BKM120	273.8	27.4	43	5.3	-2.5
X-2470	PDAC	BKM120	459.6	27.9	47	76.7	-0.7
X-2470	PDAC	BKM120	447	27.6	50	71.9	-1.8
X-2470	PDAC	BKM120	306	27.8	54	17.6	-1.1
X-2470	PDAC	BKM120	540.7	28	57	107.9	-0.4
X-2470	PDAC	BYL719	206.9	26.1	0	0	0
X-2470	PDAC	BYL719	211.4	27	3	2.2	3.4
X-2470	PDAC	BYL719	207.6	26.5	7	0.3	1.5
X-2470	PDAC	BYL719	202.1	25.7	10	-2.3	-1.5
X-2470	PDAC	BYL719	235	28	14	13.6	7.3
X-2470	PDAC	BYL719	240.2	27.6	17	16.1	5.7
X-2470	PDAC	BYL719	255	27	21	23.2	3.4
X-2470	PDAC	BYL719	279.4	27.5	24	35	5.4
X-2470	PDAC	BYL719	295.9	27.1	28	43	3.8
X-2470	PDAC	BYL719	333.9	27	31	61.4	3.4
X-2470	PDAC	BYL719	368.2	27.7	35	78	6.1
X-2470	PDAC	BYL719	381	27.3	38	84.1	4.6
X-2470	PDAC	BYL719	426.2	27.8	42	106	6.5
X-2470	PDAC	BYL719	448.7	27.5	45	116.9	5.4
X-2470	PDAC	BYL719	495.5	27.5	49	139.5	5.4
X-2470	PDAC	BYL719	526.7	27.2	52	154.6	4.2
X-2470	PDAC	BYL719	597.5	28.4	56	188.8	8.8
X-2470	PDAC	BYL719	686.8	26.4	58	231.9	1.1
X-2470	PDAC	BYL719	709.9	27.6	63	243.1	5.7
X-2470	PDAC	BYL719	833.1	28	66	302.7	7.3
X-2470	PDAC	BYL719	866.5	28.1	70	318.8	7.7
X-2470	PDAC	CLR457	222.2	24.2	0	0	0
X-2470	PDAC	CLR457	234.4	25.9	3	5.5	7
X-2470	PDAC	CLR457	230	25	7	3.5	3.3
X-2470	PDAC	CLR457	216.6	25.4	10	-2.5	5
X-2470	PDAC	CLR457	221.8	25.9	14	-0.2	7
X-2470	PDAC	CLR457	231.1	25.4	17	4	5
X-2470	PDAC	CLR457	244.4	25.9	21	10	7
X-2470	PDAC	CLR457	228.7	26.5	24	2.9	9.5
X-2470	PDAC	CLR457	226.2	26.7	28	1.8	10.3
X-2470	PDAC	CLR457	203.5	26.5	31	-8.4	9.5
X-2470	PDAC	CLR457	234.5	26.5	35	5.5	9.5
X-2470	PDAC	CLR457	245.5	26.3	38	10.5	8.7
X-2470	PDAC	CLR457	248.7	26.2	42	11.9	8.3
X-2470	PDAC	CLR457	252.9	26.1	45	13.8	7.9
X-2470	PDAC	CLR457	263.6	27	49	18.6	11.6
X-2470	PDAC	CLR457	275.6	26.8	52	24	10.7
X-2470	PDAC	CLR457	287.7	27	56	29.5	11.6
X-2470	PDAC	CLR457	349.9	26.4	59	57.5	9.1
X-2470	PDAC	CLR457	394.2	26.4	62	77.4	9.1
X-2470	PDAC	CLR457	410	26.1	65	84.5	7.9
X-2470	PDAC	CLR457	490.1	27.1	70	120.6	12
X-2470	PDAC	CLR457	481.7	26.6	73	116.8	9.9
X-2470	PDAC	CLR457	494.1	27	77	122.4	11.6
X-2470	PDAC	CLR457	510.2	26.9	80	129.6	11.2
X-2470	PDAC	CLR457	529.6	27.2	83	138.3	12.4
X-2470	PDAC	figitumumab" + binimetinib	209.3	26.5	0	0	0
X-2470	PDAC	figitumumab" + binimetinib	285.4	24.6	2	36.4	-7.2
X-2470	PDAC	figitumumab" + binimetinib	369.5	24.5	6	76.5	-7.5
X-2470	PDAC	figitumumab" + binimetinib	284.8	24.9	9	36.1	-6
X-2470	PDAC	figitumumab" + binimetinib	352.4	25.8	12	68.4	-2.6
X-2470	PDAC	figitumumab" + binimetinib	411	25.2	15	96.4	-4.9
X-2470	PDAC	figitumumab" + binimetinib	471.1	25.3	20	125.1	-4.5
X-2470	PDAC	figitumumab" + binimetinib	444.2	25.3	26	112.2	-4.5
X-2470	PDAC	figitumumab" + binimetinib	414.9	25.4	30	98.2	-4.2
X-2470	PDAC	figitumumab" + binimetinib	465	25.8	33	122.2	-2.6
X-2470	PDAC	figitumumab"	241.8	28.8	0	0	0
X-2470	PDAC	figitumumab"	333	28.8	4	37.7	0
X-2470	PDAC	figitumumab"	530.5	29.5	11	119.4	2.4
X-2470	PDAC	figitumumab"	549.1	29.6	14	127.1	2.8
X-2470	PDAC	figitumumab"	595.3	29.7	18	146.2	3.1
X-2470	PDAC	figitumumab"	640	29.1	21	164.7	1
X-2470	PDAC	figitumumab"	645.5	29.9	25	167	3.8
X-2470	PDAC	figitumumab"	707	30.7	28	192.4	6.6
X-2470	PDAC	figitumumab"	751	30	32	210.6	4.2
X-2470	PDAC	figitumumab"	903.1	30	35	273.5	4.2
X-2470	PDAC	INC424	200.6	29.9	0	0	0
X-2470	PDAC	INC424	206.8	30.1	3	3.1	0.7
X-2470	PDAC	INC424	220.2	30.5	7	9.8	2
X-2470	PDAC	INC424	220.7	29.8	10	10	-0.3
X-2470	PDAC	INC424	221.3	30.9	14	10.3	3.3
X-2470	PDAC	INC424	216.8	32.7	17	8.1	9.4
X-2470	PDAC	INC424	229.4	32.6	21	14.4	9
X-2470	PDAC	INC424	270.7	31.9	24	34.9	6.7
X-2470	PDAC	INC424	295.3	31.8	28	47.2	6.4
X-2470	PDAC	INC424	308.2	31.6	31	53.6	5.7
X-2470	PDAC	INC424	309.5	33.1	35	54.3	10.7
X-2470	PDAC	INC424	310.3	32.3	38	54.7	8
X-2470	PDAC	INC424	351.2	32.1	42	75.1	7.4
X-2470	PDAC	INC424	377.7	32.8	45	88.3	9.7
X-2470	PDAC	INC424	410.2	32.3	49	104.5	8
X-2470	PDAC	INC424	413.7	32.1	52	106.2	7.4
X-2470	PDAC	INC424	463.2	31.8	55	130.9	6.4
X-2470	PDAC	INC424	490.6	32.5	58	144.6	8.7
X-2470	PDAC	INC424	494.8	29.2	63	146.7	-2.3
X-2470	PDAC	INC424	504.5	29.3	66	151.5	-2
X-2470	PDAC	INC424	519.7	31.8	70	159.1	6.4
X-2470	PDAC	INC424	597.5	32.1	73	197.9	7.4
X-2470	PDAC	INC424	619.7	32.8	76	208.9	9.7
X-2470	PDAC	LEE011	234.1	25.5	0	0	0
X-2470	PDAC	LEE011	222.6	26.2	5	-4.9	2.7
X-2470	PDAC	LEE011	246.8	26.9	7	5.4	5.5
X-2470	PDAC	LEE011	243.2	27.6	11	3.9	8.2
X-2470	PDAC	LEE011	304.7	26.5	14	30.2	3.9
X-2470	PDAC	LEE011	314.1	27.2	18	34.2	6.7
X-2470	PDAC	LEE011	377.7	26.8	21	61.3	5.1
X-2470	PDAC	LEE011	392	28.2	25	67.4	10.6
X-2470	PDAC	LEE011	450.6	27	28	92.5	5.9
X-2470	PDAC	LEE011	432.8	27.2	33	84.9	6.7
X-2470	PDAC	LEE011	517.9	28.5	36	121.2	11.8
X-2470	PDAC	LEE011	321	28.5	40	37.1	11.8
X-2470	PDAC	LEE011	842.9	29.5	43	260.1	15.7
X-2470	PDAC	LEE011	893	29.1	47	281.5	14.1
X-2470	PDAC	LEE011	839.8	29.4	50	258.7	15.3
X-2470	PDAC	LEE011	858.2	29.6	54	266.6	16.1
X-2470	PDAC	WNT974	270.4	32.5	0	0	0
X-2470	PDAC	WNT974	271.2	29.9	2	0.3	-8
X-2470	PDAC	WNT974	289.7	29.7	6	7.1	-8.6
X-2470	PDAC	WNT974	283.1	28.8	9	4.7	-11.4
X-2470	PDAC	WNT974	375.6	29.9	12	38.9	-8
X-2470	PDAC	WNT974	493.9	29.7	15	82.7	-8.6
X-2470	PDAC	WNT974	623.5	31.8	20	130.6	-2.2
X-2470	PDAC	WNT974	630.4	30.7	23	133.1	-5.5
X-2470	PDAC	WNT974	774.6	29.8	26	186.5	-8.3
X-2470	PDAC	WNT974	838.6	30.2	29	210.1	-7.1
X-2470	PDAC	LKA136	258.1	27.6	0	0	0
X-2470	PDAC	LKA136	257.2	26.3	2	-0.3	-4.7
X-2470	PDAC	LKA136	347.2	27.4	5	34.5	-0.7
X-2470	PDAC	LKA136	779.5	27.2	8	202	-1.4
X-2470	PDAC	LKA136	991.5	28	13	284.2	1.4
X-2470	PDAC	LKA136	918.6	27.7	16	255.9	0.4
X-2470	PDAC	LKA136	1112.9	28	19	331.2	1.4
X-2470	PDAC	LKA136	1368.2	27.9	22	430.1	1.1
X-2470	PDAC	binimetinib-3.5mpk	232.1	29	0	0	0
X-2470	PDAC	binimetinib-3.5mpk	312.9	29.1	2	34.8	0.3
X-2470	PDAC	binimetinib-3.5mpk	307.8	29.4	6	32.6	1.4
X-2470	PDAC	binimetinib-3.5mpk	310.7	29.1	9	33.9	0.3
X-2470	PDAC	binimetinib-3.5mpk	284.4	29.1	12	22.5	0.3
X-2470	PDAC	binimetinib-3.5mpk	380.5	28.7	15	63.9	-1
X-2470	PDAC	binimetinib-3.5mpk	351.3	30.3	20	51.4	4.5
X-2470	PDAC	binimetinib-3.5mpk	304.8	30.2	26	31.3	4.1
X-2470	PDAC	binimetinib-3.5mpk	348.4	29.9	30	50.1	3.1
X-2470	PDAC	binimetinib-3.5mpk	360.2	31	33	55.2	6.9
X-2470	PDAC	binimetinib-3.5mpk	219.3	29.8	36	-5.5	2.8
X-2470	PDAC	binimetinib-3.5mpk	207.8	29.4	40	-10.5	1.4
X-2470	PDAC	binimetinib-3.5mpk	164.9	28.9	43	-29	-0.3
X-2470	PDAC	binimetinib-3.5mpk	211.8	29.5	47	-8.7	1.7
X-2470	PDAC	binimetinib-3.5mpk	263.2	28.7	50	13.4	-1
X-2470	PDAC	binimetinib-3.5mpk	140.7	28.8	54	-39.4	-0.7
X-2470	PDAC	binimetinib-3.5mpk	132.8	29.5	57	-42.8	1.7
X-2470	PDAC	binimetinib-3.5mpk	238.7	27.8	61	2.8	-4.1
X-2470	PDAC	binimetinib-3.5mpk	218.6	29	64	-5.8	0
X-2470	PDAC	binimetinib-3.5mpk	294.5	29.6	68	26.9	2.1
X-2470	PDAC	binimetinib-3.5mpk	291.9	29.1	72	25.8	0.3
X-2470	PDAC	binimetinib-3.5mpk	292.9	29.1	76	26.2	0.3
X-2470	PDAC	binimetinib-3.5mpk	268.9	29.5	78	15.9	1.7
X-2470	PDAC	binimetinib-3.5mpk	178.8	30.3	82	-23	4.5
X-2470	PDAC	binimetinib-3.5mpk	214.6	30.9	86	-7.5	6.6
X-2470	PDAC	binimetinib-3.5mpk	148.2	30.2	90	-36.1	4.1
X-2470	PDAC	binimetinib-3.5mpk	266.9	29.5	93	15	1.7
X-2470	PDAC	binimetinib-3.5mpk	218.8	29.7	97	-5.7	2.4
X-2470	PDAC	binimetinib-3.5mpk	360.5	28.9	100	55.3	-0.3
X-2470	PDAC	binimetinib-3.5mpk	157.2	29.3	104	-32.3	1
X-2470	PDAC	trametinib	279.3	32.1	0	0	0
X-2470	PDAC	trametinib	225.4	30.8	4	-19.3	-4
X-2470	PDAC	trametinib	244	30.3	7	-12.6	-5.6
X-2470	PDAC	trametinib	203	30.3	11	-27.3	-5.6
X-2470	PDAC	trametinib	258	29.9	14	-7.6	-6.9
X-2470	PDAC	trametinib	215.5	30.9	18	-22.8	-3.7
X-2470	PDAC	trametinib	214	30.3	20	-23.4	-5.6
X-2470	PDAC	trametinib	214.7	29.2	24	-23.1	-9
X-2470	PDAC	trametinib	178.5	30.9	27	-36.1	-3.7
X-2470	PDAC	trametinib	213.5	31.1	31	-23.6	-3.1
X-2470	PDAC	trametinib	226.4	30	34	-18.9	-6.5
X-2470	PDAC	trametinib	185.7	29.5	38	-33.5	-8.1
X-2470	PDAC	trametinib	219.5	30.1	41	-21.4	-6.2
X-2470	PDAC	trametinib	209.7	31.5	45	-24.9	-1.9
X-2470	PDAC	trametinib	205.7	30	48	-26.4	-6.5
X-2470	PDAC	trametinib	200.8	29.9	52	-28.1	-6.9
X-2470	PDAC	trametinib	165.3	30.6	55	-40.8	-4.7
X-2470	PDAC	trametinib	123.7	30.8	59	-55.7	-4
X-2470	PDAC	trametinib	180.8	31.9	62	-35.3	-0.6
X-2470	PDAC	trametinib	172.2	29.7	66	-38.3	-7.5
X-2470	PDAC	trametinib	159	30	68	-43.1	-6.5
X-2470	PDAC	trametinib	270.4	29.2	73	-3.2	-9
X-2470	PDAC	trametinib	272.4	30.7	76	-2.5	-4.4
X-2470	PDAC	trametinib	254.5	27.3	81	-8.9	-15
X-2470	PDAC	untreated	239.8	29.2	0	0	0
X-2470	PDAC	untreated	256.4	28.5	1	6.9	-2.4
X-2470	PDAC	untreated	344.2	27.6	6	43.5	-5.5
X-2470	PDAC	untreated	393.8	53.2	9	64.2	-5.5
X-2470	PDAC	untreated	416.1	27.7	12	73.5	-5.1
X-2470	PDAC	untreated	450.5	28	15	87.9	-4.1
X-2470	PDAC	untreated	561	27.5	20	133.9	-5.8
X-2470	PDAC	untreated	647.5	28.2	23	170	-3.4
X-2470	PDAC	untreated	784.9	28	26	227.3	-4.1
X-2470	PDAC	untreated	761.8	28.1	29	217.7	-3.8
X-2470	PDAC	untreated	970.4	28.7	33	304.7	-1.7
X-2483	CRC	5FU	226.1	26.4	0	0	0
X-2483	CRC	5FU	230.4	24.1	2	1.9	-8.7
X-2483	CRC	5FU	261.6	26.4	6	15.7	0
X-2483	CRC	5FU	274.1	23.7	9	21.2	-10.2
X-2483	CRC	5FU	291.1	25.1	13	28.7	-4.9
X-2483	CRC	5FU	340.3	26.1	19	50.5	-1.1
X-2483	CRC	5FU	349	26	23	54.4	-1.5
X-2483	CRC	5FU	353.3	25.8	27	56.3	-2.3
X-2483	CRC	5FU	364.7	24.8	30	61.3	-6.1
X-2483	CRC	5FU	375.4	27.2	34	66	3
X-2483	CRC	5FU	384.9	23.2	37	70.2	-12.1
X-2483	CRC	5FU	381.6	24.2	40	68.8	-8.3
X-2483	CRC	5FU	384.4	25.3	44	70	-4.2
X-2483	CRC	5FU	398.4	28.2	47	76.2	6.8
X-2483	CRC	5FU	449	30.4	50	98.6	15.2
X-2483	CRC	5FU	490.5	28.3	55	116.9	7.2
X-2483	CRC	5FU	520.9	26.9	58	130.4	1.9
X-2483	CRC	5FU	525.6	27.2	61	132.5	3
X-2483	CRC	5FU	546.7	26.3	64	141.8	-0.4
X-2483	CRC	5FU	560.7	27.5	68	148	4.2
X-2483	CRC	5FU	603	28.3	70	166.7	7.2
X-2483	CRC	BKM120	210.8	21.8	0	0	0
X-2483	CRC	BKM120	213.3	23.1	4	1.2	6
X-2483	CRC	BKM120	204.3	22.4	7	-3.1	2.8
X-2483	CRC	BKM120	227.8	22.4	11	8.1	2.8
X-2483	CRC	BKM120	242.5	22	14	15	0.9
X-2483	CRC	BKM120	255	23	18	21	5.5
X-2483	CRC	BKM120	253.7	23.1	21	20.4	6
X-2483	CRC	BKM120	268.2	24.1	25	27.2	10.6
X-2483	CRC	BKM120	295.1	25.5	31	40	17
X-2483	CRC	BKM120	327.9	26.8	35	55.6	22.9
X-2483	CRC	BKM120	398.4	25.9	39	89	18.8
X-2483	CRC	BKM120	469.8	26.5	42	122.9	21.6
X-2483	CRC	BKM120	454.4	26.9	46	115.6	23.4
X-2483	CRC	BKM120	463.2	25.8	49	119.7	18.3
X-2483	CRC	BKM120	494.5	25.2	52	134.6	15.6
X-2483	CRC	BKM120	527.8	26.6	56	150.4	22
X-2483	CRC	BKM120	572	26.3	59	171.3	20.6
X-2483	CRC	BKM120	589.8	26.8	62	179.8	22.9
X-2483	CRC	BKM120	644	27	67	205.5	23.9
X-2483	CRC	BKM120	656.7	26.4	70	211.5	21.1
X-2483	CRC	BKM120 + LJC049	214.3	24.4	0	0	0
X-2483	CRC	BKM120 + LJC049	233.9	24.1	4	9.1	-1.2
X-2483	CRC	BKM120 + LJC049	237.5	23.1	8	10.8	-5.3
X-2483	CRC	BKM120 + LJC049	254.2	22.4	11	18.6	-8.2
X-2483	CRC	BKM120 + LJC049	275	23.5	15	28.3	-3.7
X-2483	CRC	BKM120 + LJC049	327.3	23.9	18	52.7	-2
X-2483	CRC	BKM120 + LJC049	346.9	24.3	21	61.9	-0.4
X-2483	CRC	BKM120 + LJC049	358.2	23.7	25	67.1	-2.9
X-2483	CRC	BKM120 + LJC049	412.8	22.3	28	92.6	-8.6
X-2483	CRC	BKM120 + LJC049	444.5	22.3	31	107.4	-8.6
X-2483	CRC	BKM120 + LJC049	475.1	19.4	36	121.7	-20.5
X-2483	CRC	BYL719	197.4	25.6	0	0	0
X-2483	CRC	BYL719	221.1	24.8	2	12	-3.1
X-2483	CRC	BYL719	236.7	23.8	6	19.9	-7
X-2483	CRC	BYL719	229.6	24.4	9	16.3	-4.7
X-2483	CRC	BYL719	238.3	24	13	20.7	-6.2
X-2483	CRC	BYL719	263.5	24.4	19	33.5	-4.7
X-2483	CRC	BYL719	282.9	25.7	23	43.3	0.4
X-2483	CRC	BYL719	314.8	25.2	27	59.5	-1.6
X-2483	CRC	BYL719	347.2	24.8	30	75.9	-3.1
X-2483	CRC	BYL719	361.7	24.5	34	83.2	-4.3
X-2483	CRC	BYL719	388.4	23.3	37	96.8	-9
X-2483	CRC	BYL719	392.9	22.4	40	99	-12.5
X-2483	CRC	BYL719	404.3	22.9	44	104.8	-10.5
X-2483	CRC	BYL719	428.6	24.1	47	117.1	-5.9
X-2483	CRC	BYL719	486	24.3	50	146.2	-5.1
X-2483	CRC	BYL719	459.2	23.3	55	132.6	-9
X-2483	CRC	BYL719	578.2	22.4	58	192.9	-12.5
X-2483	CRC	BYL719	649	22.9	61	228.8	-10.5
X-2483	CRC	BYL719	686.3	22.1	64	247.7	-13.7
X-2483	CRC	BYL719	791.7	22.4	68	301.1	-12.5
X-2483	CRC	BYL719	831.2	23.4	70	321.1	-8.6
X-2483	CRC	BYL719 + LJM716	214.6	27.7	0	0	0
X-2483	CRC	BYL719 + LJM716	238.9	25.8	4	11.3	-6.9
X-2483	CRC	BYL719 + LJM716	267.2	26	7	24.5	-6.1
X-2483	CRC	BYL719 + LJM716	276.2	26.4	11	28.7	-4.7
X-2483	CRC	BYL719 + LJM716	295.1	27.2	17	37.5	-1.8
X-2483	CRC	BYL719 + LJM716	284.5	27.9	21	32.6	0.7
X-2483	CRC	BYL719 + LJM716	285.8	28.8	25	33.2	4
X-2483	CRC	BYL719 + LJM716	320.9	26.2	28	49.5	-5.4
X-2483	CRC	BYL719 + LJM716	339.4	26.3	32	58.2	-5.1
X-2483	CRC	BYL719 + LJM716	341.3	27.5	35	59	-0.7
X-2483	CRC	BYL719 + LJM716	354.3	27.4	38	65.1	-1.1
X-2483	CRC	BYL719 + LJM716	354.5	27.6	42	65.2	-0.4
X-2483	CRC	BYL719 + LJM716	364.4	27.1	45	69.8	-2.2
X-2483	CRC	BYL719 + LJM716	401.4	28.4	53	87	2.5
X-2483	CRC	BYL719 + LJM716	417.3	28.4	56	94.5	2.5
X-2483	CRC	BYL719 + LJM716	454.8	28.6	59	111.9	3.2
X-2483	CRC	BYL719 + LJM716	477	28.4	62	122.3	2.5
X-2483	CRC	BYL719 + LJM716	484.5	28.5	66	125.8	2.9
X-2483	CRC	BYL719 + LJM716	513.2	28.3	69	139.1	2.2
X-2483	CRC	BYL719 + cetuximab	230.1	25.3	0	0	0
X-2483	CRC	BYL719 + cetuximab	257.8	24.9	4	12	-1.6
X-2483	CRC	BYL719 + cetuximab	272.7	24.8	7	18.5	-2
X-2483	CRC	BYL719 + cetuximab	308.4	25.5	11	34	0.8
X-2483	CRC	BYL719 + cetuximab	369.5	26.1	17	60.6	3.2
X-2483	CRC	BYL719 + cetuximab	392.4	26.4	21	70.5	4.3
X-2483	CRC	BYL719 + cetuximab	465.3	27.7	25	102.2	9.5
X-2483	CRC	BYL719 + cetuximab	526.7	27	28	128.9	6.7
X-2483	CRC	BYL719 + cetuximab	543	26.8	32	136	5.9
X-2483	CRC	BYL719 + cetuximab	644.9	26.3	35	180.3	4
X-2483	CRC	BYL719 + cetuximab	703.9	25.8	38	205.9	2
X-2483	CRC	BYL719 + cetuximab	766.9	27.1	42	233.3	7.1
X-2483	CRC	BYL719 + cetuximab	861.9	27	45	274.6	6.7
X-2483	CRC	BYL719 + cetuximab	1058.5	27.6	47	360	9.1
X-2483	CRC	BYL719 + binimetinib	217	24.4	0	0	0
X-2483	CRC	BYL719 + binimetinib	233.1	23.8	3	7.4	-2.5
X-2483	CRC	BYL719 + binimetinib	251.7	23.5	7	16	-3.7
X-2483	CRC	BYL719 + binimetinib	260.4	24.7	13	20	1.2
X-2483	CRC	BYL719 + binimetinib	272	24.5	17	25.3	0.4
X-2483	CRC	BYL719 + binimetinib	258.1	24.1	21	18.9	-1.2
X-2483	CRC	BYL719 + binimetinib	247.2	24.6	24	13.9	0.8
X-2483	CRC	BYL719 + binimetinib	236.2	24.6	28	8.8	0.8
X-2483	CRC	BYL719 + binimetinib	237.3	23.7	31	9.4	-2.9
X-2483	CRC	BYL719 + binimetinib	235.1	22.5	34	8.3	-7.8
X-2483	CRC	BYL719 + binimetinib	234.4	24.3	38	8	-0.4
X-2483	CRC	BYL719 + binimetinib	223.3	22.2	41	2.9	-9
X-2483	CRC	BYL719 + binimetinib	223.2	23.9	44	2.9	-2
X-2483	CRC	BYL719 + binimetinib	232.2	23.9	49	7	-2
X-2483	CRC	BYL719 + binimetinib	243.3	23.1	52	12.1	-5.3
X-2483	CRC	BYL719 + binimetinib	256	22.9	55	18	-6.1
X-2483	CRC	BYL719 + binimetinib	258.7	26.7	58	19.2	9.4
X-2483	CRC	BYL719 + binimetinib	264	24.5	62	21.7	0.4
X-2483	CRC	BYL719 + binimetinib	259.1	24	65	19.4	-1.6
X-2483	CRC	BYL719 + binimetinib	267.5	24.4	68	23.3	0
X-2483	CRC	BYL719 + binimetinib	241.5	24.2	71	11.3	-0.8
X-2483	CRC	BYL719 + binimetinib	240	23.8	76	10.6	-2.5
X-2483	CRC	BYL719 + binimetinib	251.9	23.8	79	16.1	-2.5
X-2483	CRC	BYL719 + binimetinib	250.3	21.7	83	15.3	-11.1
X-2483	CRC	BYL719 + binimetinib	248.6	21.9	86	14.6	-10.2
X-2483	CRC	BYL719 + binimetinib	253.5	21.5	89	16.8	-11.9
X-2483	CRC	BYL719 + binimetinib	259.5	21.3	90	19.6	-12.7
X-2483	CRC	BYL719 + encorafenib	203.5	29.7	0	0	0
X-2483	CRC	BYL719 + encorafenib	218.7	29.1	4	7.5	-2
X-2483	CRC	BYL719 + encorafenib	221.7	28.6	8	8.9	-3.7
X-2483	CRC	BYL719 + encorafenib	218.8	28.2	11	7.5	-5.1
X-2483	CRC	BYL719 + encorafenib	228.6	30.7	15	12.3	3.4
X-2483	CRC	BYL719 + encorafenib	232.9	29.5	18	14.4	-0.7
X-2483	CRC	BYL719 + encorafenib	233.9	27.6	21	14.9	-7.1
X-2483	CRC	BYL719 + encorafenib	236.2	28.8	25	16.1	-3
X-2483	CRC	BYL719 + encorafenib	235.5	28.7	28	15.7	-3.4
X-2483	CRC	BYL719 + encorafenib	238.2	29.9	31	17.1	0.7
X-2483	CRC	BYL719 + encorafenib	236.6	28.5	36	16.3	-4
X-2483	CRC	BYL719 + encorafenib	253.1	28.9	39	24.4	-2.7
X-2483	CRC	BYL719 + encorafenib	271.6	27.8	42	33.5	-6.4
X-2483	CRC	BYL719 + encorafenib	267.7	28.3	45	31.5	-4.7
X-2483	CRC	BYL719 + encorafenib	258.2	28.7	49	26.9	-3.4
X-2483	CRC	BYL719 + encorafenib	248	28.2	52	21.9	-5.1
X-2483	CRC	BYL719 + encorafenib	248.4	29.4	55	22.1	-1
X-2483	CRC	BYL719 + encorafenib	259.2	29.1	58	27.4	-2
X-2483	CRC	BYL719 + encorafenib	242.1	28.5	63	19	-4
X-2483	CRC	BYL719 + encorafenib	242.5	28.5	66	19.2	-4
X-2483	CRC	BYL719 + encorafenib	227.1	27.6	70	11.6	-7.1
X-2483	CRC	BYL719 + encorafenib	230.4	28.8	73	13.2	-3
X-2483	CRC	BYL719 + encorafenib	221	29	76	8.6	-2.4
X-2483	CRC	BYL719 + encorafenib	224	28	79	10.1	-5.7
X-2483	CRC	BYL719 + encorafenib	221.3	26.9	83	8.7	-9.4
X-2483	CRC	BYL719 + encorafenib	217.5	27.1	86	6.9	-8.8
X-2483	CRC	BYL719 + encorafenib	214.6	27.4	88	5.5	-7.7
X-2483	CRC	BYL719 + encorafenib	207.5	27.2	92	2	-8.4
X-2483	CRC	BYL719 + encorafenib	227.7	28.1	95	11.9	-5.4
X-2483	CRC	BYL719 + encorafenib	226.3	28.2	99	11.2	-5.1
X-2483	CRC	BYL719 + cetuximab + encorafenib	201.7	24.3	0	0	0
X-2483	CRC	BYL719 + cetuximab + encorafenib	236.1	24.9	4	17.1	2.5
X-2483	CRC	BYL719 + cetuximab + encorafenib	231.7	24.4	7	14.9	0.4
X-2483	CRC	BYL719 + cetuximab + encorafenib	234.2	24.1	10	16.1	-0.8
X-2483	CRC	BYL719 + cetuximab + encorafenib	222.9	24.6	14	10.5	1.2
X-2483	CRC	BYL719 + cetuximab + encorafenib	231.7	25	17	14.9	2.9
X-2483	CRC	BYL719 + cetuximab + encorafenib	247.8	25.1	20	22.9	3.3
X-2483	CRC	BYL719 + cetuximab + encorafenib	247.2	23.8	25	22.6	-2.1
X-2483	CRC	BYL719 + cetuximab + encorafenib	261.8	25.8	28	29.8	6.2
X-2483	CRC	BYL719 + cetuximab + encorafenib	258.9	24.8	31	28.4	2.1
X-2483	CRC	BYL719 + cetuximab + encorafenib	261.2	25.4	34	29.5	4.5
X-2483	CRC	BYL719 + cetuximab + encorafenib	259.1	24.8	38	28.5	2.1
X-2483	CRC	BYL719 + cetuximab + encorafenib	264.5	24.4	41	31.1	0.4
X-2483	CRC	BYL719 + cetuximab + encorafenib	263.6	25.3	44	30.7	4.1
X-2483	CRC	BYL719 + cetuximab + encorafenib	262.1	25.3	47	29.9	4.1
X-2483	CRC	BYL719 + cetuximab + encorafenib	260.6	24.5	52	29.2	0.8
X-2483	CRC	BYL719 + cetuximab + encorafenib	256.8	25.4	55	27.3	4.5
X-2483	CRC	BYL719 + cetuximab + encorafenib	257.6	25.1	59	27.7	3.3
X-2483	CRC	BYL719 + cetuximab + encorafenib	256.6	25.5	62	27.2	4.9
X-2483	CRC	BYL719 + cetuximab + encorafenib	257.3	25.9	65	27.6	6.6
X-2483	CRC	BYL719 + cetuximab + encorafenib	257	25.1	68	27.4	3.3
X-2483	CRC	BYL719 + cetuximab + encorafenib	261.9	24.9	72	29.8	2.5
X-2483	CRC	BYL719 + cetuximab + encorafenib	261.4	24.8	75	29.6	2.1
X-2483	CRC	BYL719 + cetuximab + encorafenib	256.6	25	77	27.2	2.9
X-2483	CRC	BYL719 + cetuximab + encorafenib	256.3	25.3	81	27.1	4.1
X-2483	CRC	BYL719 + cetuximab + encorafenib	260.2	25.1	84	29	3.3
X-2483	CRC	BYL719 + cetuximab + encorafenib	256.6	25.2	88	27.2	3.7
X-2483	CRC	BYL719 + cetuximab + encorafenib	259.1	25.1	91	28.5	3.3
X-2483	CRC	BYL719 + cetuximab + encorafenib	261.7	24.6	94	29.7	1.2
X-2483	CRC	CGM097	211.4	25.9	0	0	0
X-2483	CRC	CGM097	218.5	26.7	4	3.4	3.1
X-2483	CRC	CGM097	244.8	27.6	7	15.8	6.6
X-2483	CRC	CGM097	278.5	27.9	11	31.7	7.7
X-2483	CRC	CGM097	292.7	27.6	14	38.5	6.6
X-2483	CRC	CGM097	356.7	28.7	18	68.7	10.8
X-2483	CRC	CGM097	426.9	28.8	21	101.9	11.2
X-2483	CRC	CGM097	437.4	28.7	25	106.9	10.8
X-2483	CRC	CGM097	508.7	27.8	31	140.6	7.3
X-2483	CRC	CGM097	563.2	28.8	35	166.4	11.2
X-2483	CRC	CGM097	645	28.7	39	205.1	10.8
X-2483	CRC	CGM097	683.3	28.6	42	223.2	10.4
X-2483	CRC	CGM097	730.4	28.6	46	245.5	10.4
X-2483	CRC	CGM097	772.1	26.2	49	265.2	1.2
X-2483	CRC	CGM097	892.4	26.3	52	322.1	1.5
X-2483	CRC	CGM097	888.3	28.6	56	320.2	10.4
X-2483	CRC	CGM097	902.7	28.7	59	327	10.8
X-2483	CRC	CGM097	943.4	28.7	62	346.3	10.8
X-2483	CRC	CGM097	1203.8	29.7	67	469.4	14.7
X-2483	CRC	CGM097	1379.8	29.9	70	552.7	15.4
X-2483	CRC	CKX620	209.7	26	0	0	0
X-2483	CRC	CKX620	225.1	25.5	4	7.3	-1.9
X-2483	CRC	CKX620	212.1	25.6	7	1.1	-1.5
X-2483	CRC	CKX620	223.3	26	11	6.5	0
X-2483	CRC	CKX620	232.1	26.2	14	10.7	0.8
X-2483	CRC	CKX620	242.4	26.6	18	15.6	2.3
X-2483	CRC	CKX620	242.7	26	21	15.7	0
X-2483	CRC	CKX620	235.4	26.8	25	12.3	3.1
X-2483	CRC	CKX620	236.9	26.7	31	13	2.7
X-2483	CRC	CKX620	227.1	26.7	35	8.3	2.7
X-2483	CRC	CKX620	237.6	27.3	39	13.3	5
X-2483	CRC	CKX620	239.2	27.1	42	14.1	4.2
X-2483	CRC	CKX620	247.3	27.4	46	17.9	5.4
X-2483	CRC	CKX620	236.4	26.3	49	12.7	1.2
X-2483	CRC	CKX620	245.1	26.5	52	16.9	1.9
X-2483	CRC	CKX620	260.4	27	56	24.2	3.8
X-2483	CRC	CKX620	259.8	28	59	23.9	7.7
X-2483	CRC	CKX620	281	27.8	62	34	6.9
X-2483	CRC	CKX620	288.5	26.7	67	37.6	2.7
X-2483	CRC	CKX620	300.5	27.4	70	43.3	5.4
X-2483	CRC	CLR457	212.3	27.7	0	0	0
X-2483	CRC	CLR457	217.6	25.2	4	2.5	-9
X-2483	CRC	CLR457	240.2	25.4	7	13.1	-8.3
X-2483	CRC	CLR457	247.9	25.8	11	16.8	-6.9
X-2483	CRC	CLR457	257.9	26.2	14	21.5	-5.4
X-2483	CRC	CLR457	267.9	26.3	18	26.2	-5.1
X-2483	CRC	CLR457	268.2	26.7	24	26.3	-3.6
X-2483	CRC	CLR457	243.3	27.6	28	14.6	-0.4
X-2483	CRC	CLR457	251.8	27.5	32	18.6	-0.7
X-2483	CRC	CLR457	270.4	27.1	35	27.4	-2.2
X-2483	CRC	CLR457	264	27.8	39	24.4	0.4
X-2483	CRC	CLR457	265.3	26.9	42	25	-2.9
X-2483	CRC	CLR457	265.6	26.4	45	25.1	-4.7
X-2483	CRC	CLR457	260	27.5	49	22.5	-0.7
X-2483	CRC	CLR457	251	27.7	52	18.2	0
X-2483	CRC	CLR457	275.6	27.7	55	29.8	0
X-2483	CRC	CLR457	296	28.1	60	39.4	1.4
X-2483	CRC	CLR457	308	28.7	63	45.1	3.6
X-2483	CRC	CLR457	336.4	28.5	66	58.5	2.9
X-2483	CRC	CLR457	363.2	28.2	69	71.1	1.8
X-2483	CRC	HDM201	203.2	24	0	0	0
X-2483	CRC	HDM201	250.5	23.3	4	23.3	-2.9
X-2483	CRC	HDM201	278.1	24.3	7	36.9	1.2
X-2483	CRC	HDM201	304.4	23	11	49.8	-4.2
X-2483	CRC	HDM201	327.5	23.9	14	61.2	-0.4
X-2483	CRC	HDM201	388.5	21.7	18	91.2	-9.6
X-2483	CRC	HDM201	453	21.9	21	122.9	-8.8
X-2483	CRC	HDM201	486.9	22.1	25	139.6	-7.9
X-2483	CRC	HDM201	534.8	21.9	31	163.2	-8.8
X-2483	CRC	HDM201	595.7	20.7	35	193.2	-13.8
X-2483	CRC	HDM201	671.3	20.7	39	230.4	-13.8
X-2483	CRC	cetuximab	213.7	30	0	0	0
X-2483	CRC	cetuximab	242.6	28.9	4	13.5	-3.7
X-2483	CRC	cetuximab	313.1	29	7	46.5	-3.3
X-2483	CRC	cetuximab	348.7	31.4	11	63.2	4.7
X-2483	CRC	cetuximab	393.8	30	17	84.3	0
X-2483	CRC	cetuximab	453.4	30.1	21	112.2	0.3
X-2483	CRC	cetuximab	570.9	29.2	25	167.2	-2.7
X-2483	CRC	cetuximab	692	29.2	28	223.8	-2.7
X-2483	CRC	cetuximab	771.3	29.8	32	260.9	-0.7
X-2483	CRC	cetuximab	912.7	28.7	35	327.1	-4.3
X-2483	CRC	cetuximab	1047.6	29.4	38	390.2	-2
X-2483	CRC	cetuximab	1155.8	29.4	42	440.9	-2
X-2483	CRC	cetuximab	1514.6	30.3	45	608.8	1
X-2483	CRC	cetuximab + encorafenib	226.7	26.2	0	0	0
X-2483	CRC	cetuximab + encorafenib	256.2	26.6	3	13	1.5
X-2483	CRC	cetuximab + encorafenib	266.1	26.1	7	17.4	-0.4
X-2483	CRC	cetuximab + encorafenib	290.7	26.4	13	28.2	0.8
X-2483	CRC	cetuximab + encorafenib	315.2	26.9	17	39	2.7
X-2483	CRC	cetuximab + encorafenib	320.4	26.6	21	41.3	1.5
X-2483	CRC	cetuximab + encorafenib	325.5	26.6	24	43.6	1.5
X-2483	CRC	cetuximab + encorafenib	332.3	27.6	28	46.6	5.3
X-2483	CRC	cetuximab + encorafenib	326.4	27.1	31	44	3.4
X-2483	CRC	cetuximab + encorafenib	339.8	26.9	34	49.9	2.7
X-2483	CRC	cetuximab + encorafenib	364.9	27.6	38	61	5.3
X-2483	CRC	cetuximab + encorafenib	374.5	27.3	41	65.2	4.2
X-2483	CRC	cetuximab + encorafenib	400.4	29.3	44	76.6	11.8
X-2483	CRC	cetuximab + encorafenib	429.4	27.6	49	89.4	5.3
X-2483	CRC	cetuximab + encorafenib	479.6	27.3	52	111.6	4.2
X-2483	CRC	cetuximab + encorafenib	485.6	27.4	55	114.2	4.6
X-2483	CRC	cetuximab + encorafenib	504.4	26.5	58	122.5	1.1
X-2483	CRC	cetuximab + encorafenib	503.8	26.2	62	122.2	0
X-2483	CRC	cetuximab + encorafenib	502.1	26	65	121.5	-0.8
X-2483	CRC	cetuximab + encorafenib	506.8	26.3	68	123.6	0.4
X-2483	CRC	LEE011	195.3	24.5	0	0	0
X-2483	CRC	LEE011	192.9	23.9	4	-1.2	-2.4
X-2483	CRC	LEE011	222.6	23.9	7	14	-2.4
X-2483	CRC	LEE011	231.3	24.5	11	18.4	0
X-2483	CRC	LEE011	232.3	24.4	14	18.9	-0.4
X-2483	CRC	LEE011	236	24.7	18	20.8	0.8
X-2483	CRC	LEE011	242.7	25.5	24	24.3	4.1
X-2483	CRC	LEE011	237.6	26.1	28	21.7	6.5
X-2483	CRC	LEE011	297.5	26.1	32	52.3	6.5
X-2483	CRC	LEE011	318.3	26.3	35	63	7.3
X-2483	CRC	LEE011	320.5	26.2	39	64.1	6.9
X-2483	CRC	LEE011	312	25.7	42	59.8	4.9
X-2483	CRC	LEE011	311.1	26.2	45	59.3	6.9
X-2483	CRC	LEE011	321.7	26.6	49	64.7	8.6
X-2483	CRC	LEE011	352.4	28.7	52	80.4	17.1
X-2483	CRC	LEE011	386.8	27.3	55	98.1	11.4
X-2483	CRC	LEE011	395.6	26.9	60	102.6	9.8
X-2483	CRC	LEE011	427.3	26.8	63	118.8	9.4
X-2483	CRC	LEE011	455.2	26.4	66	133.1	7.8
X-2483	CRC	LEE011	484.4	27.1	69	148	10.6
X-2483	CRC	encorafenib	225	27.6	0	0	0
X-2483	CRC	encorafenib	240.9	28.9	4	7.1	4.7
X-2483	CRC	encorafenib	253.2	27.9	7	12.5	1.1
X-2483	CRC	encorafenib	266.5	27.1	11	18.4	-1.8
X-2483	CRC	encorafenib	292.7	27.3	14	30.1	-1.1
X-2483	CRC	encorafenib	299.9	27.2	18	33.3	-1.4
X-2483	CRC	encorafenib	301.9	27	21	34.2	-2.2
X-2483	CRC	encorafenib	304.4	27.3	25	35.3	-1.1
X-2483	CRC	encorafenib	304.2	27.7	31	35.2	0.4
X-2483	CRC	encorafenib	317.6	28.3	35	41.2	2.5
X-2483	CRC	encorafenib	291.1	27.2	39	29.4	-1.4
X-2483	CRC	encorafenib	290.4	27.8	42	29.1	0.7
X-2483	CRC	encorafenib	287	28.2	46	27.6	2.2
X-2483	CRC	encorafenib	274.2	27.4	49	21.9	-0.7
X-2483	CRC	encorafenib	276.6	27.8	52	22.9	0.7
X-2483	CRC	encorafenib	269.7	27.8	56	19.9	0.7
X-2483	CRC	encorafenib	286.7	27.8	59	27.4	0.7
X-2483	CRC	encorafenib	282.3	28.9	62	25.5	4.7
X-2483	CRC	encorafenib	307.3	28.1	67	36.6	1.8
X-2483	CRC	encorafenib	296.6	27.4	70	31.8	-0.7
X-2483	CRC	encorafenib	307.1	28.1	73	36.5	1.8
X-2483	CRC	encorafenib	294.6	27.9	76	30.9	1.1
X-2483	CRC	encorafenib	300.8	27.3	80	33.7	-1.1
X-2483	CRC	encorafenib	274.2	27.5	83	21.9	-0.4
X-2483	CRC	encorafenib	296.6	28.4	86	31.8	2.9
X-2483	CRC	encorafenib	306	29.4	89	36	6.5
X-2483	CRC	LJC049	198.9	24.3	0	0	0
X-2483	CRC	LJC049	242	26.4	4	21.7	8.6
X-2483	CRC	LJC049	266.9	23.8	7	34.2	-2.1
X-2483	CRC	LJC049	301.1	23.4	11	51.4	-3.7
X-2483	CRC	LJC049	332.3	23.9	14	67.1	-1.6
X-2483	CRC	LJC049	380.7	24.4	18	91.4	0.4
X-2483	CRC	LJC049	447.4	24.5	21	124.9	0.8
X-2483	CRC	LJC049	479	24.9	25	140.8	2.5
X-2483	CRC	LJC049	620.8	24.9	31	212.1	2.5
X-2483	CRC	LJC049	674.9	25.4	35	239.3	4.5
X-2483	CRC	LJC049	834.1	26	39	319.4	7
X-2483	CRC	LJC049	947.8	25.4	42	376.5	4.5
X-2483	CRC	LJC049	1116.2	25.7	46	461.2	5.8
X-2483	CRC	LJC049	1205.5	25.8	49	506.1	6.2
X-2483	CRC	LJC049	1514.7	25.3	52	661.5	4.1
X-2483	CRC	LKA136	212.8	27.9	0	0	0
X-2483	CRC	LKA136	217.6	27.8	4	2.3	-0.4
X-2483	CRC	LKA136	244.9	29.4	7	15.1	5.4
X-2483	CRC	LKA136	282.8	29.3	11	32.9	5
X-2483	CRC	LKA136	308.5	28	14	45	0.4
X-2483	CRC	LKA136	307.3	29.1	18	44.4	4.3
X-2483	CRC	LKA136	325.2	29.5	24	52.8	5.7
X-2483	CRC	LKA136	303.1	30.6	28	42.4	9.7
X-2483	CRC	LKA136	360.8	30.7	32	69.5	10
X-2483	CRC	LKA136	409	31.1	35	92.2	11.5
X-2483	CRC	LKA136	483.5	31.9	39	127.2	14.3
X-2483	CRC	LKA136	496.4	31.1	42	133.3	11.5
X-2483	CRC	LKA136	563.2	30.4	45	164.7	9
X-2483	CRC	LKA136	599.4	30.9	49	181.7	10.8
X-2483	CRC	LKA136	629.3	31	52	195.7	11.1
X-2483	CRC	LKA136	632.1	31	55	197	11.1
X-2483	CRC	LKA136	718	31.2	60	237.4	11.8
X-2483	CRC	LKA136	828	31	63	289.1	11.1
X-2483	CRC	LKA136	853.8	31.4	66	301.2	12.5
X-2483	CRC	LKA136	893.1	30.3	69	319.7	8.6
X-2483	CRC	binimetinib	220.1	23.5	0	0	0
X-2483	CRC	binimetinib	225.8	22.8	4	2.6	-3
X-2483	CRC	binimetinib	221.3	22.5	7	0.5	-4.3
X-2483	CRC	binimetinib	240.6	23.2	11	9.3	-1.3
X-2483	CRC	binimetinib	261.8	23	14	18.9	-2.1
X-2483	CRC	binimetinib	267.6	22.6	18	21.6	-3.8
X-2483	CRC	binimetinib	270.1	22.9	21	22.7	-2.6
X-2483	CRC	binimetinib	280.8	23	25	27.6	-2.1
X-2483	CRC	binimetinib	292.3	23.8	31	32.8	1.3
X-2483	CRC	binimetinib	281.6	23.5	35	27.9	0
X-2483	CRC	binimetinib	263.6	22.9	39	19.8	-2.6
X-2483	CRC	binimetinib	263.1	22.8	42	19.5	-3
X-2483	CRC	binimetinib	263.7	23.3	46	19.8	-0.9
X-2483	CRC	binimetinib	263.1	23.1	49	19.5	-1.7
X-2483	CRC	binimetinib	286	22.9	52	29.9	-2.6
X-2483	CRC	binimetinib	285.3	23.3	56	29.6	-0.9
X-2483	CRC	binimetinib	278.9	24.2	59	26.7	3
X-2483	CRC	binimetinib	281	22.7	62	27.7	-3.4
X-2483	CRC	binimetinib	282.9	23.4	67	28.5	-0.4
X-2483	CRC	binimetinib	297.7	23.9	70	35.3	1.7
X-2483	CRC	binimetinib	304.7	24	73	38.4	2.1
X-2483	CRC	binimetinib	326	24.5	76	48.1	4.3
X-2483	CRC	binimetinib	321.1	24.7	80	45.9	5.1
X-2483	CRC	binimetinib	334.8	24.2	83	52.1	3
X-2483	CRC	binimetinib	344.8	24.4	86	56.7	3.8
X-2483	CRC	binimetinib	357.9	24.3	89	62.6	3.4
X-2483	CRC	untreated	215	26.2	0	0	0
X-2483	CRC	untreated	248.4	26.5	4	15.5	1.1
X-2483	CRC	untreated	263.6	27.2	7	22.6	3.8
X-2483	CRC	untreated	304.2	27.4	11	41.5	4.6
X-2483	CRC	untreated	367.8	26.8	14	71.1	2.3
X-2483	CRC	untreated	376.7	27.2	18	75.2	3.8
X-2483	CRC	untreated	388	27.5	21	80.5	5
X-2483	CRC	untreated	393.7	28.2	25	83.1	7.6
X-2483	CRC	untreated	408.7	28	31	90.1	6.9
X-2483	CRC	untreated	428.2	29.3	35	99.2	11.8
X-2483	CRC	untreated	459.9	29.3	39	113.9	11.8
X-2483	CRC	untreated	473	29.1	42	120	11.1
X-2483	CRC	untreated	541.5	29.3	46	151.9	11.8
X-2483	CRC	untreated	584.8	28.4	49	172	8.4
X-2483	CRC	untreated	609.6	28.7	52	183.5	9.5
X-2483	CRC	untreated	642.7	28.7	56	198.9	9.5
X-2483	CRC	untreated	681.7	30.4	59	217.1	16
X-2483	CRC	untreated	730.8	30	62	239.9	14.5
X-2483	CRC	untreated	776.2	29.2	67	261	11.5
X-2483	CRC	untreated	807.7	28.2	70	275.7	7.6
X-2483	CRC	LFW527 + binimetinib	205.87	29.06	0	0	0
X-2483	CRC	LFW527 + binimetinib	176.92	28.62	5	-14.1	-1.5
X-2483	CRC	LFW527 + binimetinib	157.9	28.03	8	-23.3	-3.5
X-2483	CRC	LFW527 + binimetinib	228.71	28.37	11	11.1	-2.4
X-2483	CRC	LFW527 + binimetinib	254.29	28.02	14	23.5	-3.6
X-2483	CRC	LFW527 + binimetinib	249.6	28.54	18	21.2	-1.8
X-2483	CRC	LFW527 + binimetinib	267.64	28.58	21	30	-1.7
X-2483	CRC	LFW527 + binimetinib	292.72	29.15	25	42.2	0.3
X-2483	CRC	LFW527 + binimetinib	250.32	28.64	29	21.6	-1.4
X-2483	CRC	LFW527 + binimetinib	232.57	28.37	32	13	-2.4
X-2483	CRC	LFW527 + binimetinib	284.01	28.03	35	38	-3.5
X-2483	CRC	LFW527 + binimetinib	203.95	28.26	40	-0.9	-2.8
X-2483	CRC	LFW527 + binimetinib	190.34	28.33	43	-7.5	-2.5
X-2483	CRC	LFW527 + binimetinib	218.85	28.66	47	6.3	-1.4
X-2483	CRC	LFW527 + binimetinib	193.96	28.89	50	-5.8	-0.6
X-2483	CRC	LFW527 + binimetinib	195.57	28.82	53	-5	-0.8
X-2483	CRC	LFW527 + binimetinib	216.81	28.55	56	5.3	-1.8
X-2483	CRC	LFW527 + binimetinib	214.03	28.42	60	4	-2.2
X-2483	CRC	LFW527 + binimetinib	165.99	28.65	63	-19.4	-1.4
X-2483	CRC	LFW527 + binimetinib	165.12	29.36	76	-19.8	1
X-2483	CRC	LFW527 + binimetinib	272.41	28.92	78	32.3	-0.5
X-2483	CRC	LFW527 + binimetinib	226.24	29.23	81	9.9	0.6
X-2483	CRC	LFW527 + binimetinib	211.46	28.93	84	2.7	-0.4
X-2483	CRC	LFW527 + binimetinib	196.01	29.84	90	-4.8	2.7
X-2483	CRC	LFW527 + binimetinib	161.51	28.41	95	-21.5	-2.2
X-2483	CRC	LFW527 + binimetinib	154.3	29.04	98	-25	-0.1
X-2483	CRC	LFW527 + binimetinib	198.78	28.36	102	-3.4	-2.4
X-2483	CRC	LFW527 + binimetinib	199.58	28.12	105	-3.1	-3.2
X-2483	CRC	LFW527 + binimetinib	169.82	27.58	109	-17.5	-5.1
X-2483	CRC	LFW527 + binimetinib	136.47	28.14	112	-33.7	-3.2
X-2483	CRC	LFW527 + binimetinib	183.67	27.54	117	-10.8	-5.2
X-2483	CRC	LFW527 + binimetinib	264.35	27.56	124	28.4	-5.2
X-2483	CRC	LFW527 + binimetinib	256.39	27.69	130	24.5	-4.7
X-2483	CRC	LFW527 + binimetinib	278.64	28.06	133	35.3	-3.4
X-2483	CRC	LFW527 + binimetinib	371.93	28.76	137	80.7	-1
X-2483	CRC	LFW527 + binimetinib	409.99	28.53	140	99.1	-1.8
X-2483	CRC	LFW527 + binimetinib	524.35	28.81	144	154.7	-0.9
X-2483	CRC	LFW527 + binimetinib	624.74	28.34	147	203.5	-2.5
X-2483	CRC	LFW527 + binimetinib	581.52	28.28	151	182.5	-2.7
X-2483	CRC	LFW527 + binimetinib	521.95	28.96	154	153.5	-0.3
X-2483	CRC	LFW527 + binimetinib	712.78	28.51	158	246.2	-1.9
X-2484	CRC	5FU	206.5	22.5	0	0	0
X-2484	CRC	5FU	211.5	23.3	3	2.4	3.6
X-2484	CRC	5FU	217.9	23.6	7	5.5	4.9
X-2484	CRC	5FU	187.1	23.1	9	-9.4	2.7
X-2484	CRC	5FU	222.5	22.8	13	7.7	1.3
X-2484	CRC	5FU	231.2	22	17	12	-2.2
X-2484	CRC	5FU	267.1	21.3	22	29.3	-5.3
X-2484	CRC	5FU	329	21.8	27	59.3	-3.1
X-2484	CRC	5FU	362.3	22.3	30	75.4	-0.9
X-2484	CRC	5FU	414.7	21.2	34	100.8	-5.8
X-2484	CRC	5FU	329.7	21.9	37	59.7	-2.7
X-2484	CRC	5FU	568	21.6	42	175.1	-4
X-2484	CRC	5FU	416.6	20.9	45	101.7	-7.1
X-2484	CRC	5FU	350.4	19.6	48	69.7	-12.9
X-2484	CRC	5FU	433.4	20.7	51	109.9	-8
X-2484	CRC	5FU	486.1	20.4	55	135.4	-9.3
X-2484	CRC	BKM120	196.3	21.6	0	0	0
X-2484	CRC	BKM120	213.9	22.2	3	9	2.8
X-2484	CRC	BKM120	144.6	22.2	7	-26.3	2.8
X-2484	CRC	BKM120	240.5	22.6	9	22.5	4.6
X-2484	CRC	BKM120	227.5	22.4	13	15.9	3.7
X-2484	CRC	BKM120	167.7	22.7	17	-14.6	5.1
X-2484	CRC	BKM120	242.9	22.6	22	23.7	4.6
X-2484	CRC	BKM120	394.7	22.7	27	101.1	5.1
X-2484	CRC	BKM120	289.7	22.2	30	47.6	2.8
X-2484	CRC	BKM120	256.9	21.7	34	30.9	0.5
X-2484	CRC	BKM120	331.6	21.6	37	68.9	0
X-2484	CRC	BKM120	427.2	21.2	42	117.6	-1.9
X-2484	CRC	BKM120 + LJC049	222.3	22.8	0	0	0
X-2484	CRC	BKM120 + LJC049	281.4	23.4	3	26.6	2.6
X-2484	CRC	BKM120 + LJC049	234.7	25.2	6	5.6	10.5
X-2484	CRC	BKM120 + LJC049	279.6	25.7	9	25.8	12.7
X-2484	CRC	BKM120 + LJC049	372	25.5	13	67.3	11.8
X-2484	CRC	BKM120 + LJC049	343.3	25.7	16	54.4	12.7
X-2484	CRC	BKM120 + LJC049	514.7	26.3	21	131.5	15.4
X-2484	CRC	BKM120 + LJC049	564.2	26	23	153.8	14
X-2484	CRC	BKM120 + LJC049	594.4	22.6	27	167.4	-0.9
X-2484	CRC	BKM120 + LJC049	626.8	22.9	30	182	0.4
X-2484	CRC	BYL719	203.5	19.5	0	0	0
X-2484	CRC	BYL719	137.9	18.8	3	-32.2	-3.6
X-2484	CRC	BYL719	165.8	18.3	8	-18.5	-6.2
X-2484	CRC	BYL719	126.3	19.6	13	-37.9	0.5
X-2484	CRC	BYL719	157.8	21	16	-22.5	7.7
X-2484	CRC	BYL719	99.9	21.6	20	-50.9	10.8
X-2484	CRC	BYL719	140.9	21	23	-30.8	7.7
X-2484	CRC	BYL719	102.4	20.8	31	-49.7	6.7
X-2484	CRC	BYL719	191	21.1	34	-6.1	8.2
X-2484	CRC	BYL719	182.9	22.6	37	-10.1	15.9
X-2484	CRC	BYL719	136.3	21.5	41	-33	10.3
X-2484	CRC	BYL719	212.2	21.2	44	4.3	8.7
X-2484	CRC	BYL719	174.3	21.1	49	-14.3	8.2
X-2484	CRC	BYL719	199.5	21.7	51	-2	11.3
X-2484	CRC	BYL719	205.4	22	55	0.9	12.8
X-2484	CRC	BYL719	188.2	22.7	58	-7.5	16.4
X-2484	CRC	BYL719	185.8	22	63	-8.7	12.8
X-2484	CRC	BYL719	174.8	21.3	64	-14.1	9.2
X-2484	CRC	BYL719	169.7	22	66	-16.6	12.8
X-2484	CRC	BYL719	204.6	20.5	70	0.5	5.1
X-2484	CRC	BYL719	215.9	21.7	73	6.1	11.3
X-2484	CRC	BYL719	150.4	21.7	79	-26.1	11.3
X-2484	CRC	BYL719	229.3	21.7	83	12.7	11.3
X-2484	CRC	BYL719	300.1	22.4	87	47.5	14.9
X-2484	CRC	BYL719 + LJM716	221.1	22	0	0	0
X-2484	CRC	BYL719 + LJM716	208.8	20	3	-5.6	-9.1
X-2484	CRC	BYL719 + LJM716	209.6	20.7	8	-5.2	-5.9
X-2484	CRC	BYL719 + LJM716	191.9	21.3	13	-13.2	-3.2
X-2484	CRC	BYL719 + LJM716	175	20.6	16	-20.9	-6.4
X-2484	CRC	BYL719 + LJM716	220.7	20.8	20	-0.2	-5.5
X-2484	CRC	BYL719 + LJM716	262.7	21	23	18.8	-4.5
X-2484	CRC	BYL719 + LJM716	382.3	22.6	31	72.9	2.7
X-2484	CRC	BYL719 + LJM716	285.5	20.8	34	29.1	-5.5
X-2484	CRC	BYL719 + LJM716	352.1	21	37	59.2	-4.5
X-2484	CRC	BYL719 + LJM716	230.5	20.2	41	4.3	-8.2
X-2484	CRC	BYL719 + LJM716	273.7	20.7	44	23.8	-5.9
X-2484	CRC	BYL719 + LJM716	264.9	19.6	49	19.8	-10.9
X-2484	CRC	BYL719 + LJM716	365	20	51	65.1	-9.1
X-2484	CRC	BYL719 + LJM716	252	18.7	55	14	-15
X-2484	CRC	BYL719 + LJM716	159.2	20	58	-28	-9.1
X-2484	CRC	BYL719 + LJM716	134.2	19	63	-39.3	-13.6
X-2484	CRC	BYL719 + LJM716	169.8	19.3	64	-23.2	-12.3
X-2484	CRC	BYL719 + LJM716	96.9	19.1	66	-56.2	-13.2
X-2484	CRC	BYL719 + cetuximab + encorafenib	219.4	20.2	0	0	0
X-2484	CRC	BYL719 + cetuximab + encorafenib	225.3	19.7	6	2.7	-2.5
X-2484	CRC	BYL719 + cetuximab + encorafenib	172.8	20.5	11	-21.2	1.5
X-2484	CRC	BYL719 + cetuximab + encorafenib	241.9	20.5	14	10.3	1.5
X-2484	CRC	BYL719 + cetuximab + encorafenib	241.1	20.8	18	9.9	3
X-2484	CRC	BYL719 + cetuximab + encorafenib	279	21.6	21	27.2	6.9
X-2484	CRC	BYL719 + cetuximab + encorafenib	295.1	19.8	26	34.5	-2
X-2484	CRC	BYL719 + cetuximab + encorafenib	353.4	20.1	29	61.1	-0.5
X-2484	CRC	BYL719 + cetuximab + encorafenib	442.1	19.9	32	101.5	-1.5
X-2484	CRC	BYL719 + cetuximab	209.9	26.5	0	0	0
X-2484	CRC	BYL719 + cetuximab	156.6	25	6	-25.4	-5.7
X-2484	CRC	BYL719 + cetuximab	211.8	26.7	11	0.9	0.8
X-2484	CRC	BYL719 + cetuximab	177.7	27	14	-15.3	1.9
X-2484	CRC	BYL719 + cetuximab	204.5	26.8	18	-2.6	1.1
X-2484	CRC	BYL719 + cetuximab	263.2	27.5	21	25.4	3.8
X-2484	CRC	BYL719 + cetuximab	296.4	25.6	26	41.2	-3.4
X-2484	CRC	BYL719 + cetuximab	329.3	25.4	29	56.9	-4.2
X-2484	CRC	BYL719 + cetuximab	304.8	23.7	32	45.2	-10.6
X-2484	CRC	BYL719 + cetuximab	303	22.7	35	44.4	-14.3
X-2484	CRC	BYL719 + cetuximab	347.9	22.6	39	65.7	-14.7
X-2484	CRC	BYL719 + cetuximab	392.3	22.8	42	86.9	-14
X-2484	CRC	BYL719 + cetuximab	494.2	22.6	47	135.4	-14.7
X-2484	CRC	BYL719 + binimetinib	210.8	24.8	0	0	0
X-2484	CRC	BYL719 + binimetinib	183.3	25.9	5	-13	4.4
X-2484	CRC	BYL719 + binimetinib	206.6	25.2	8	-2	1.6
X-2484	CRC	BYL719 + binimetinib	222.4	25.4	12	5.5	2.4
X-2484	CRC	BYL719 + binimetinib	232.5	25.1	15	10.3	1.2
X-2484	CRC	BYL719 + binimetinib	241.5	24.7	20	14.6	-0.4
X-2484	CRC	BYL719 + binimetinib	245	24.5	23	16.2	-1.2
X-2484	CRC	BYL719 + binimetinib	316.1	25.1	26	50	1.2
X-2484	CRC	BYL719 + binimetinib	340.6	25.1	29	61.6	1.2
X-2484	CRC	BYL719 + binimetinib	288.4	25.4	33	36.8	2.4
X-2484	CRC	BYL719 + binimetinib	305	24.2	36	44.7	-2.4
X-2484	CRC	BYL719 + binimetinib	244.2	24.4	41	15.8	-1.6
X-2484	CRC	BYL719 + binimetinib	325.2	24	43	54.3	-3.2
X-2484	CRC	BYL719 + binimetinib	254.1	25.3	47	20.5	2
X-2484	CRC	BYL719 + binimetinib	272.9	25.1	50	29.5	1.2
X-2484	CRC	BYL719 + binimetinib	304.1	24.9	55	44.3	0.4
X-2484	CRC	BYL719 + binimetinib	209.3	24.7	56	-0.7	-0.4
X-2484	CRC	BYL719 + binimetinib	256.2	24.3	61	21.5	-2
X-2484	CRC	BYL719 + binimetinib	282.6	25.5	65	34.1	2.8
X-2484	CRC	BYL719 + binimetinib	225.4	24.2	71	6.9	-2.4
X-2484	CRC	BYL719 + binimetinib	222.6	24.3	75	5.6	-2
X-2484	CRC	BYL719 + binimetinib	274.3	26.5	79	30.1	6.9
X-2484	CRC	BYL719 + binimetinib	262.3	25.5	83	24.4	2.8
X-2484	CRC	BYL719 + binimetinib	265.1	24	85	25.8	-3.2
X-2484	CRC	BYL719 + binimetinib	331	23.7	89	57	-4.4
X-2484	CRC	BYL719 + encorafenib	213.6	21.5	0	0	0
X-2484	CRC	BYL719 + encorafenib	198.9	20.4	5	-6.9	-5.1
X-2484	CRC	BYL719 + encorafenib	288.1	20.9	8	34.9	-2.8
X-2484	CRC	BYL719 + encorafenib	312.7	21.2	12	46.4	-1.4
X-2484	CRC	BYL719 + encorafenib	293.3	21.3	15	37.3	-0.9
X-2484	CRC	BYL719 + encorafenib	372.1	20.5	20	74.2	-4.7
X-2484	CRC	BYL719 + encorafenib	354.7	20.8	23	66.1	-3.3
X-2484	CRC	BYL719 + encorafenib	399.9	21	26	87.2	-2.3
X-2484	CRC	BYL719 + encorafenib	490.4	20.7	29	129.6	-3.7
X-2484	CRC	BYL719 + encorafenib	399.6	21.1	33	87.1	-1.9
X-2484	CRC	BYL719 + encorafenib	416.3	20.5	36	94.9	-4.7
X-2484	CRC	CGM097	202.2	22.9	0	0	0
X-2484	CRC	CGM097	193.3	21.4	4	-4.4	-6.6
X-2484	CRC	CGM097	202.5	22.1	6	0.1	-3.5
X-2484	CRC	CGM097	239.3	20.1	10	18.3	-12.2
X-2484	CRC	CGM097	189.4	20.1	14	-6.3	-12.2
X-2484	CRC	CGM097	265.5	21	19	31.3	-8.3
X-2484	CRC	CGM097	315.4	20.5	24	56	-10.5
X-2484	CRC	CGM097	342.2	20.7	27	69.2	-9.6
X-2484	CRC	CGM097	364.5	23.5	31	80.3	2.6
X-2484	CRC	CGM097	380.6	22.1	34	88.2	-3.5
X-2484	CRC	CGM097	352.9	23.6	39	74.5	3.1
X-2484	CRC	CGM097	480.9	21.9	42	137.8	-4.4
X-2484	CRC	CGM097	486.3	20.6	45	140.5	-10
X-2484	CRC	CKX620	224	24.1	0	0	0
X-2484	CRC	CKX620	201.7	22.9	4	-10	-5
X-2484	CRC	CKX620	251.6	22.9	6	12.3	-5
X-2484	CRC	CKX620	273.5	23.3	10	22.1	-3.3
X-2484	CRC	CKX620	273.9	23.9	14	22.3	-0.8
X-2484	CRC	CKX620	350.6	24	19	56.5	-0.4
X-2484	CRC	CKX620	344.2	24.4	24	53.7	1.2
X-2484	CRC	CKX620	419.3	24.2	27	87.2	0.4
X-2484	CRC	CKX620	400.4	24.1	31	78.7	0
X-2484	CRC	CKX620	471.8	24.3	34	110.6	0.8
X-2484	CRC	CKX620	593.8	24.4	39	165.1	1.2
X-2484	CRC	CLR457	204.3	24.4	0	0	0
X-2484	CRC	CLR457	212.2	23.1	2	3.9	-5.3
X-2484	CRC	CLR457	188.1	24	6	-7.9	-1.6
X-2484	CRC	CLR457	187.7	23.7	10	-8.1	-2.9
X-2484	CRC	CLR457	218.3	24.7	15	6.9	1.2
X-2484	CRC	CLR457	204.1	25.8	20	-0.1	5.7
X-2484	CRC	CLR457	203.7	25.2	23	-0.3	3.3
X-2484	CRC	CLR457	228.9	25.3	27	12	3.7
X-2484	CRC	CLR457	218.9	25.2	30	7.1	3.3
X-2484	CRC	CLR457	222.3	25.3	38	8.8	3.7
X-2484	CRC	CLR457	233.9	25.6	41	14.5	4.9
X-2484	CRC	CLR457	221.4	25.5	44	8.4	4.5
X-2484	CRC	CLR457	278.6	25.8	48	36.4	5.7
X-2484	CRC	CLR457	278.4	25.6	51	36.3	4.9
X-2484	CRC	CLR457	355.6	25.3	56	74.1	3.7
X-2484	CRC	CLR457	226.8	24.9	58	11	2
X-2484	CRC	CLR457	291.1	24.9	62	42.5	2
X-2484	CRC	CLR457	291.5	25.7	65	42.7	5.3
X-2484	CRC	CLR457	281.1	25.7	70	37.6	5.3
X-2484	CRC	CLR457	272.7	24.5	71	33.5	0.4
X-2484	CRC	CLR457	281.7	24.8	73	37.9	1.6
X-2484	CRC	CLR457	342	24.6	77	67.4	0.8
X-2484	CRC	CLR457	376.7	25.3	80	84.4	3.7
X-2484	CRC	HDM201	217	20.8	0	0	0
X-2484	CRC	HDM201	244.4	20.9	3	12.6	0.5
X-2484	CRC	HDM201	300.5	18.1	7	38.5	-13
X-2484	CRC	HDM201	274.3	18.5	9	26.4	-11.1
X-2484	CRC	HDM201	303.5	17.4	13	39.9	-16.3
X-2484	CRC	HDM201	315.5	16.9	17	45.4	-18.8
X-2484	CRC	HDM201	393	17.1	22	81.1	-17.8
X-2484	CRC	cetuximab	207.9	24.1	0	0	0
X-2484	CRC	cetuximab	177.5	24.9	3	-14.6	3.3
X-2484	CRC	cetuximab	199.3	24.3	7	-4.1	0.8
X-2484	CRC	cetuximab	288.9	24.9	9	39	3.3
X-2484	CRC	cetuximab	290.3	24.9	13	39.6	3.3
X-2484	CRC	cetuximab	320.4	25.8	17	54.1	7.1
X-2484	CRC	cetuximab	381.8	26.2	22	83.6	8.7
X-2484	CRC	cetuximab	435.1	26.7	27	109.3	10.8
X-2484	CRC	cetuximab	453.9	26.4	29	118.3	9.5
X-2484	CRC	cetuximab + encorafenib	206.8	24.7	0	0	0
X-2484	CRC	cetuximab + encorafenib	323.2	24.8	6	56.3	0.4
X-2484	CRC	cetuximab + encorafenib	312	25.7	11	50.9	4
X-2484	CRC	cetuximab + encorafenib	402.9	24.7	14	94.8	0
X-2484	CRC	cetuximab + encorafenib	495.4	24.5	18	139.6	-0.8
X-2484	CRC	cetuximab + encorafenib	601.5	24.8	21	190.9	0.4
X-2484	CRC	cetuximab + encorafenib	669	24.1	26	223.5	-2.4
X-2484	CRC	cetuximab + encorafenib	716.7	24.6	29	246.6	-0.4
X-2484	CRC	cetuximab + encorafenib	936.5	24.5	32	352.9	-0.8
X-2484	CRC	LEE011	211.9	26.2	0	0	0
X-2484	CRC	LEE011	155.4	25.1	3	-26.7	-4.2
X-2484	CRC	LEE011	130.1	25.3	7	-38.6	-3.4
X-2484	CRC	LEE011	114.2	25.9	9	-46.1	-1.1
X-2484	CRC	LEE011	108.4	25.5	13	-48.8	-2.7
X-2484	CRC	LEE011	144.4	27.2	17	-31.9	3.8
X-2484	CRC	LEE011	128	27.8	22	-39.6	6.1
X-2484	CRC	LEE011	182.4	28.3	27	-13.9	8
X-2484	CRC	LEE011	152.2	28.6	30	-28.2	9.2
X-2484	CRC	LEE011	184.9	28	34	-12.7	6.9
X-2484	CRC	LEE011	190.2	28.7	37	-10.2	9.5
X-2484	CRC	LEE011	199.3	28	42	-5.9	6.9
X-2484	CRC	LEE011	223.3	28.6	45	5.4	9.2
X-2484	CRC	LEE011	261.1	27.4	48	23.2	4.6
X-2484	CRC	LEE011	258.3	29.8	51	21.9	13.7
X-2484	CRC	LEE011	312.1	28.4	55	47.3	8.4
X-2484	CRC	LEE011	330.7	27.8	58	56.1	6.1
X-2484	CRC	LEE011	428.3	27.8	63	102.1	6.1
X-2484	CRC	encorafenib	200.2	23.9	0	0	0
X-2484	CRC	encorafenib	209.4	22.8	4	4.6	-4.6
X-2484	CRC	encorafenib	288.3	23.4	6	44	-2.1
X-2484	CRC	encorafenib	262.1	23.1	10	30.9	-3.3
X-2484	CRC	encorafenib	336.4	23.2	14	68	-2.9
X-2484	CRC	encorafenib	504.4	22.8	19	151.9	-4.6
X-2484	CRC	encorafenib	562.4	22.2	24	180.9	-7.1
X-2484	CRC	encorafenib	614.9	22.7	27	207.1	-5
X-2484	CRC	LJC049	217.5	23.3	0	0	0
X-2484	CRC	LJC049	194.8	23.1	4	-10.4	-0.9
X-2484	CRC	LJC049	194.9	23.3	6	-10.4	0
X-2484	CRC	LJC049	270.9	22.4	10	24.6	-3.9
X-2484	CRC	LJC049	291.1	23.1	14	33.8	-0.9
X-2484	CRC	LJC049	474.4	23.4	19	118.1	0.4
X-2484	CRC	LJC049	471.7	22.8	24	116.9	-2.1
X-2484	CRC	LJC049	546.6	22.9	27	151.3	-1.7
X-2484	CRC	LKA136	194.1	23.7	0	0	0
X-2484	CRC	LKA136	208	23	4	7.2	-3
X-2484	CRC	LKA136	235	23.2	6	21.1	-2.1
X-2484	CRC	LKA136	260.7	23.8	10	34.3	0.4
X-2484	CRC	LKA136	315.2	23.9	14	62.4	0.8
X-2484	CRC	LKA136	371	23.3	19	91.1	-1.7
X-2484	CRC	LKA136	438.3	23.7	24	125.8	0
X-2484	CRC	LKA136	638.6	22.1	27	229	-6.8
X-2484	CRC	binimetinib	221.9	24.3	0	0	0
X-2484	CRC	binimetinib	263.8	22.5	3	18.9	-7.4
X-2484	CRC	binimetinib	209	23.5	7	-5.8	-3.3
X-2484	CRC	binimetinib	242.7	24.1	9	9.4	-0.8
X-2484	CRC	binimetinib	229.9	23.6	13	3.6	-2.9
X-2484	CRC	binimetinib	308.5	23.7	17	39	-2.5
X-2484	CRC	binimetinib	333.2	24.9	22	50.2	2.5
X-2484	CRC	binimetinib	421.9	24.6	27	90.1	1.2
X-2484	CRC	binimetinib	463	25	30	108.7	2.9
X-2484	CRC	untreated	213.4	25.9	0	0	0
X-2484	CRC	untreated	211.8	25.1	3	-0.7	-3.1
X-2484	CRC	untreated	280.2	25.4	8	31.3	-1.9
X-2484	CRC	untreated	412.5	26.7	11	93.3	3.1
X-2484	CRC	untreated	413.2	26.1	14	93.6	0.8
X-2484	CRC	untreated	414.2	26.7	17	94.1	3.1
X-2484	CRC	untreated	398.7	25.9	21	86.8	0
X-2484	CRC	untreated	449.3	26.3	24	110.5	1.5
X-2484	CRC	untreated	486.4	25.9	29	127.9	0
X-2484	CRC	untreated	497.9	25.8	31	133.3	-0.4
X-2484	CRC	untreated	487.4	25.2	35	128.4	-2.7
X-2484	CRC	untreated	432.4	25.1	38	102.6	-3.1
X-2484	CRC	untreated	440.5	24.5	43	106.4	-5.4
X-2484	CRC	untreated	560.1	24.4	46	162.5	-5.8
X-2484	CRC	untreated	492.7	24.8	50	130.9	-4.2
X-2484	CRC	untreated	564.6	25.9	53	164.6	0
X-2484	CRC	untreated	567.3	24.7	60	165.8	-4.6
X-2484	CRC	untreated	545.4	24.6	63	155.6	-5
X-2487	BRCA	BGJ398	198.4	24.7	0	0	0
X-2487	BRCA	BGJ398	221.9	24.3	3	11.8	-1.6
X-2487	BRCA	BGJ398	263.7	24.9	6	32.9	0.8
X-2487	BRCA	BGJ398	266.4	24.5	10	34.3	-0.8
X-2487	BRCA	BGJ398	293.8	24.6	13	48.1	-0.4
X-2487	BRCA	BGJ398	361.7	25.5	21	82.3	3.2
X-2487	BRCA	BGJ398	426.2	25.8	24	114.8	4.5
X-2487	BRCA	BGJ398	450	25.1	27	126.8	1.6
X-2487	BRCA	BGJ398	566.6	24.5	31	185.6	-0.8
X-2487	BRCA	BGJ398	691.1	24.6	34	248.3	-0.4
X-2487	BRCA	BGJ398	740.5	24.1	38	273.2	-2.4
X-2487	BRCA	BGJ398	844.7	25.6	41	325.8	3.6
X-2487	BRCA	BGJ398	1056.8	25.3	45	432.7	2.4
X-2487	BRCA	BGJ398	1191.2	26	48	500.4	5.3
X-2487	BRCA	BKM120	225.6	28.2	0	0	0
X-2487	BRCA	BKM120	226.7	28.1	1	0.5	-0.4
X-2487	BRCA	BKM120	304.6	28.8	4	35	2.1
X-2487	BRCA	BKM120	362.1	28.7	8	60.5	1.8
X-2487	BRCA	BKM120	329.7	29.2	11	46.1	3.5
X-2487	BRCA	BKM120	404.9	29	15	79.5	2.8
X-2487	BRCA	BKM120	457.8	28.9	18	102.9	2.5
X-2487	BRCA	BKM120	612.8	27.8	26	171.6	-1.4
X-2487	BRCA	BKM120	736.4	26.5	29	226.4	-6
X-2487	BRCA	BKM120	561.1	26.4	32	148.7	-6.4
X-2487	BRCA	BKM120	644.1	26.8	36	185.5	-5
X-2487	BRCA	BKM120	680.3	28.3	39	201.6	0.4
X-2487	BRCA	BKM120	802.7	26.8	43	255.8	-5
X-2487	BRCA	BKM120	686.4	27.2	46	204.3	-3.5
X-2487	BRCA	BKM120	682.1	26.7	50	202.3	-5.3
X-2487	BRCA	BKM120	751.1	25.6	53	232.9	-9.2
X-2487	BRCA	BYL719 + LJM716	260.5	26.1	0	0	0
X-2487	BRCA	BYL719 + LJM716	234.5	26.4	4	-10	1.1
X-2487	BRCA	BYL719 + LJM716	247.7	26.4	12	-4.9	1.1
X-2487	BRCA	BYL719 + LJM716	234.9	25.9	15	-9.8	-0.8
X-2487	BRCA	BYL719 + LJM716	276.2	26.3	18	6	0.8
X-2487	BRCA	BYL719 + LJM716	303	25.4	22	16.3	-2.7
X-2487	BRCA	BYL719 + LJM716	326.5	26.5	25	25.3	1.5
X-2487	BRCA	BYL719 + LJM716	349.8	26.6	29	34.3	1.9
X-2487	BRCA	BYL719 + LJM716	391.2	27.2	32	50.2	4.2
X-2487	BRCA	BYL719 + LJM716	435.1	26.7	36	67	2.3
X-2487	BRCA	BYL719 + LJM716	459.7	26.9	39	76.5	3.1
X-2487	BRCA	BYL719 + LJM716	534.4	26.2	43	105.1	0.4
X-2487	BRCA	BYL719 + LJM716	537.3	26.5	46	106.3	1.5
X-2487	BRCA	BYL719 + LJM716	608	27.8	53	133.4	6.5
X-2487	BRCA	BYL719 + LJM716	811	26.6	56	211.3	1.9
X-2487	BRCA	BYL719 + LJM716	801.4	26.6	61	207.6	1.9
X-2487	BRCA	BYL719 + LJM716	818.8	26.6	64	214.3	1.9
X-2487	BRCA	BYL719 + LJM716	896	27.5	67	244	5.4
X-2487	BRCA	BYL719 + LEE011	407	25.2	0	0	0
X-2487	BRCA	BYL719 + LEE011	343.8	24.9	3	-15.5	-1.2
X-2487	BRCA	BYL719 + LEE011	323.6	25.2	6	-20.5	0
X-2487	BRCA	BYL719 + LEE011	212.6	20.4	10	-47.8	-19
X-2487	BRCA	BYL719 + LEE011	261.3	23.2	13	-35.8	-7.9
X-2487	BRCA	BYL719 + LEE011	293.1	24.5	17	-28	-2.8
X-2487	BRCA	BYL719 + LEE011	285.2	25.8	20	-29.9	2.4
X-2487	BRCA	BYL719 + LEE011	330.7	25.6	24	-18.7	1.6
X-2487	BRCA	BYL719 + LEE011	297.1	26.3	27	-27	4.4
X-2487	BRCA	BYL719 + LEE011	293.8	26.7	34	-27.8	6
X-2487	BRCA	BYL719 + LEE011	321.3	26.4	37	-21.1	4.8
X-2487	BRCA	BYL719 + LEE011	327.6	26.2	42	-19.5	4
X-2487	BRCA	BYL719 + LEE011	344.9	26.2	45	-15.3	4
X-2487	BRCA	BYL719 + LEE011	389.6	25.1	48	-4.3	-0.4
X-2487	BRCA	BYL719 + LEE011	416.9	27	52	2.4	7.1
X-2487	BRCA	BYL719 + LEE011	425.3	27.3	55	4.5	8.3
X-2487	BRCA	BYL719	201.6	31.7	0	0	0
X-2487	BRCA	BYL719	228.8	31.5	1	13.5	-0.6
X-2487	BRCA	BYL719	214.4	31.4	4	6.3	-0.9
X-2487	BRCA	BYL719	226.8	30.7	8	12.5	-3.2
X-2487	BRCA	BYL719	241	30.7	11	19.5	-3.2
X-2487	BRCA	BYL719	229.6	31	15	13.9	-2.2
X-2487	BRCA	BYL719	293	31	18	45.3	-2.2
X-2487	BRCA	BYL719	366.8	32.3	26	81.9	1.9
X-2487	BRCA	BYL719	388.9	31.8	29	92.9	0.3
X-2487	BRCA	BYL719	440.2	31.3	32	118.4	-1.3
X-2487	BRCA	BYL719	495.7	30.5	36	145.9	-3.8
X-2487	BRCA	BYL719	527.8	32.2	39	161.8	1.6
X-2487	BRCA	BYL719	514.8	30.4	43	155.4	-4.1
X-2487	BRCA	BYL719	584.4	31.5	46	189.9	-0.6
X-2487	BRCA	BYL719	587	31.4	50	191.2	-0.9
X-2487	BRCA	BYL719	643.8	31.7	53	219.3	0
X-2487	BRCA	BYL719	761.8	31.3	57	277.9	-1.3
X-2487	BRCA	BYL719	764.9	31.4	60	279.4	-0.9
X-2487	BRCA	CGM097	203.2	27.9	0	0	0
X-2487	BRCA	CGM097	277.5	28.2	3	36.6	1.1
X-2487	BRCA	CGM097	333.7	28.7	6	64.2	2.9
X-2487	BRCA	CGM097	396.7	29.2	10	95.2	4.7
X-2487	BRCA	CGM097	485.1	29.5	13	138.7	5.7
X-2487	BRCA	CGM097	579	30.1	21	184.9	7.9
X-2487	BRCA	CGM097	843.3	29.3	24	315	5
X-2487	BRCA	CGM097	917.5	29.8	27	351.5	6.8
X-2487	BRCA	CGM097	980.9	29.1	31	382.7	4.3
X-2487	BRCA	CGM097	1286.8	30.1	34	533.3	7.9
X-2487	BRCA	CLR457	214.5	23.1	0	0	0
X-2487	BRCA	CLR457	256.7	22.8	4	19.7	-1.3
X-2487	BRCA	CLR457	247.2	21.9	8	15.2	-5.2
X-2487	BRCA	CLR457	254.3	22.8	11	18.6	-1.3
X-2487	BRCA	CLR457	274.1	23.2	15	27.8	0.4
X-2487	BRCA	CLR457	300.8	22.8	18	40.2	-1.3
X-2487	BRCA	CLR457	371.7	22.6	26	73.3	-2.2
X-2487	BRCA	CLR457	445.6	21.9	29	107.7	-5.2
X-2487	BRCA	CLR457	452.7	23.1	32	111	0
X-2487	BRCA	CLR457	428.1	22.4	36	99.6	-3
X-2487	BRCA	CLR457	573.5	22.9	39	167.4	-0.9
X-2487	BRCA	CLR457	532.3	22.5	43	148.2	-2.6
X-2487	BRCA	CLR457	754.6	24.1	46	251.8	4.3
X-2487	BRCA	CLR457	753.9	23.9	50	251.5	3.5
X-2487	BRCA	CLR457	767.8	24	53	257.9	3.9
X-2487	BRCA	CLR457	729.7	23.8	57	240.2	3
X-2487	BRCA	CLR457	857.3	23.7	60	299.7	2.6
X-2487	BRCA	CLR457	1074.8	24.4	67	401.1	5.6
X-2487	BRCA	HDM201	253.8	27.5	0	0	0
X-2487	BRCA	HDM201	411.4	29.4	8	62.1	6.9
X-2487	BRCA	HDM201	475.6	27.8	11	87.4	1.1
X-2487	BRCA	HDM201	449.1	29.6	14	77	7.6
X-2487	BRCA	HDM201	513.5	28.8	18	102.3	4.7
X-2487	BRCA	HDM201	717.6	27.9	21	182.7	1.5
X-2487	BRCA	HDM201	1003.9	24.3	25	295.5	-11.6
X-2487	BRCA	INC424	209	28.4	0	0	0
X-2487	BRCA	INC424	280	29.3	3	34	3.2
X-2487	BRCA	INC424	349.7	30.3	6	67.3	6.7
X-2487	BRCA	INC424	486	30.1	10	132.5	6
X-2487	BRCA	INC424	598.1	31.2	13	186.2	9.9
X-2487	BRCA	INC424	980.9	32	21	369.3	12.7
X-2487	BRCA	INC424	1180.7	31.7	24	464.9	11.6
X-2487	BRCA	INC424	1367.6	32.2	27	554.4	13.4
X-2487	BRCA	LEE011 + everolimus	542	27.5	0	0	0
X-2487	BRCA	LEE011 + everolimus	471.8	26.5	3	-13	-3.6
X-2487	BRCA	LEE011 + everolimus	460.5	27.5	6	-15	0
X-2487	BRCA	LEE011 + everolimus	585.8	26.6	10	8.1	-3.3
X-2487	BRCA	LEE011 + everolimus	474.3	27.3	13	-12.5	-0.7
X-2487	BRCA	LEE011 + everolimus	522.7	26.4	17	-3.6	-4
X-2487	BRCA	LEE011 + everolimus	474.4	27.7	20	-12.5	0.7
X-2487	BRCA	LEE011 + everolimus	523.4	27.1	24	-3.4	-1.5
X-2487	BRCA	LEE011 + everolimus	486.8	27.1	27	-10.2	-1.5
X-2487	BRCA	LEE011 + everolimus	510.9	27.8	34	-5.7	1.1
X-2487	BRCA	LEE011 + everolimus	572.3	28.3	37	5.6	2.9
X-2487	BRCA	LEE011 + everolimus	491	28.2	42	-9.4	2.5
X-2487	BRCA	LEE011 + everolimus	516.7	28.4	45	-4.7	3.3
X-2487	BRCA	LEE011 + everolimus	543.8	27.3	48	0.3	-0.7
X-2487	BRCA	LEE011 + everolimus	799.8	27.5	52	47.6	0
X-2487	BRCA	LEE011 + everolimus	780.5	27.7	55	44	0.7
X-2487	BRCA	LEE011 + everolimus	701.8	27.8	59	29.5	1.1
X-2487	BRCA	LEE011 + everolimus	849.4	29	62	56.7	5.5
X-2487	BRCA	LEE011 + everolimus	705.8	28.8	66	30.2	4.7
X-2487	BRCA	LEE011 + everolimus	719.4	28.1	69	32.7	2.2
X-2487	BRCA	LEE011 + everolimus	796	27.4	73	46.9	-0.4
X-2487	BRCA	LEE011 + everolimus	986.9	27.4	76	82.1	-0.4
X-2487	BRCA	LEE011 + everolimus	996.1	27.5	80	83.8	0
X-2487	BRCA	LEE011 + everolimus	1083.6	27.6	83	99.9	0.4
X-2487	BRCA	LEE011	388.5	22.2	0	0	0
X-2487	BRCA	LEE011	470	20.2	3	21	-9
X-2487	BRCA	LEE011	614.5	21.1	6	58.2	-5
X-2487	BRCA	LEE011	729.6	22.7	10	87.8	2.3
X-2487	BRCA	LEE011	824.2	22.4	13	112.1	0.9
X-2487	BRCA	LEE011	925.8	22.9	17	138.3	3.2
X-2487	BRCA	LEE011	1014.3	24.1	20	161.1	8.6
X-2487	BRCA	LFA102	189.3	31.4	0	0	0
X-2487	BRCA	LFA102	230.9	32.2	3	22	2.5
X-2487	BRCA	LFA102	258	31.1	6	36.3	-1
X-2487	BRCA	LFA102	301.2	31.2	10	59.1	-0.6
X-2487	BRCA	LFA102	302.6	31	13	59.9	-1.3
X-2487	BRCA	LFA102	490.8	32.1	17	159.3	2.2
X-2487	BRCA	LFA102	520.8	31.9	20	175.1	1.6
X-2487	BRCA	LFA102	691.7	33.7	28	265.4	7.3
X-2487	BRCA	LFA102	864.5	32.4	31	356.7	3.2
X-2487	BRCA	LFA102	922.3	33.6	34	387.2	7
X-2487	BRCA	LJM716 + trastuzumab	240.8	26.7	0	0	0
X-2487	BRCA	LJM716 + trastuzumab	273.5	26.2	3	13.6	-1.9
X-2487	BRCA	LJM716 + trastuzumab	290.1	26.7	6	20.5	0
X-2487	BRCA	LJM716 + trastuzumab	330.6	25.8	10	37.3	-3.4
X-2487	BRCA	LJM716 + trastuzumab	383.6	26.3	13	59.3	-1.5
X-2487	BRCA	LJM716 + trastuzumab	399.9	27	17	66.1	1.1
X-2487	BRCA	LJM716 + trastuzumab	472.4	26.9	20	96.2	0.7
X-2487	BRCA	LJM716 + trastuzumab	740.5	28.4	28	207.5	6.4
X-2487	BRCA	LJM716 + trastuzumab	837.1	27.1	31	247.6	1.5
X-2487	BRCA	LJM716 + trastuzumab	861.9	28	34	257.9	4.9
X-2487	BRCA	LJM716 + trastuzumab	919.1	26.6	38	281.7	-0.4
X-2487	BRCA	LJM716 + trastuzumab	1178.9	28	41	389.6	4.9
X-2487	BRCA	LJM716	236.7	26.9	0	0	0
X-2487	BRCA	LJM716	228.9	27.2	4	-3.3	1.1
X-2487	BRCA	LJM716	270.9	27.3	12	14.4	1.5
X-2487	BRCA	LJM716	258.3	26.9	15	9.1	0
X-2487	BRCA	LJM716	334.3	28.3	18	41.2	5.2
X-2487	BRCA	LJM716	394.8	27.9	22	66.8	3.7
X-2487	BRCA	LJM716	280.5	27.9	25	18.5	3.7
X-2487	BRCA	LJM716	401.5	27.3	29	69.6	1.5
X-2487	BRCA	LJM716	447.5	27.9	32	89.1	3.7
X-2487	BRCA	LJM716	507.2	28.5	36	114.3	5.9
X-2487	BRCA	LJM716	578.9	28.3	39	144.6	5.2
X-2487	BRCA	LJM716	691.2	28.7	43	192	6.7
X-2487	BRCA	LJM716	856	29.2	46	261.6	8.6
X-2487	BRCA	LKA136	206.5	23.7	0	0	0
X-2487	BRCA	LKA136	317.2	24.3	4	53.6	2.5
X-2487	BRCA	LKA136	425.9	24.5	8	106.2	3.4
X-2487	BRCA	LKA136	464.9	24.9	11	125.1	5.1
X-2487	BRCA	LKA136	535.4	24.4	15	159.3	3
X-2487	BRCA	LKA136	999.2	25	18	383.9	5.5
X-2487	BRCA	LLM871	282.4	27.2	0	0	0
X-2487	BRCA	LLM871	359.3	25.3	3	27.2	-7
X-2487	BRCA	LLM871	437.7	24.4	6	55	-10.3
X-2487	BRCA	LLM871	637.7	25.6	10	125.8	-5.9
X-2487	BRCA	LLM871	797.5	25.5	13	182.4	-6.2
X-2487	BRCA	LLM871	987.7	26.7	21	249.8	-1.8
X-2487	BRCA	LLM871	1235.3	26.4	24	337.4	-2.9
X-2487	BRCA	LLM871	1404.9	26.4	27	397.5	-2.9
X-2487	BRCA	binimetinib	289.8	27.9	0	0	0
X-2487	BRCA	binimetinib	367.5	27.6	3	26.8	-1.1
X-2487	BRCA	binimetinib	407	27.6	6	40.4	-1.1
X-2487	BRCA	binimetinib	418.7	27.2	10	44.5	-2.5
X-2487	BRCA	binimetinib	492	27.8	13	69.8	-0.4
X-2487	BRCA	binimetinib	719.5	27.9	21	148.3	0
X-2487	BRCA	binimetinib	851.2	27.9	24	193.7	0
X-2487	BRCA	binimetinib	900.3	27.5	27	210.7	-1.4
X-2487	BRCA	binimetinib	929.3	25.7	31	220.7	-7.9
X-2487	BRCA	binimetinib	962.9	26	34	232.3	-6.8
X-2487	BRCA	paclitaxel	257.3	27.1	0	0	0
X-2487	BRCA	paclitaxel	275.9	26.5	3	7.2	-2.2
X-2487	BRCA	paclitaxel	346.6	26.9	6	34.7	-0.7
X-2487	BRCA	paclitaxel	374.8	27.2	10	45.7	0.4
X-2487	BRCA	paclitaxel	402.1	27.3	13	56.3	0.7
X-2487	BRCA	paclitaxel	452.7	27.1	17	75.9	0
X-2487	BRCA	paclitaxel	456.6	27.6	20	77.5	1.8
X-2487	BRCA	paclitaxel	415.7	28.4	28	61.6	4.8
X-2487	BRCA	paclitaxel	476.1	27.4	31	85	1.1
X-2487	BRCA	paclitaxel	515.7	28	34	100.4	3.3
X-2487	BRCA	paclitaxel	576.5	27.6	38	124.1	1.8
X-2487	BRCA	paclitaxel	606.6	28.3	41	135.8	4.4
X-2487	BRCA	paclitaxel	832	27.8	45	223.4	2.6
X-2487	BRCA	paclitaxel	852	28.6	48	231.1	5.5
X-2487	BRCA	paclitaxel	881.2	28.7	52	242.5	5.9
X-2487	BRCA	paclitaxel	1119.6	29.4	55	335.1	8.5
X-2487	BRCA	tamoxifen	207.2	23.8	0	0	0
X-2487	BRCA	tamoxifen	204.4	23.6	4	-1.4	-0.8
X-2487	BRCA	tamoxifen	214	24	8	3.3	0.8
X-2487	BRCA	tamoxifen	236.6	24.9	11	14.2	4.6
X-2487	BRCA	tamoxifen	254.9	25.4	15	23	6.7
X-2487	BRCA	tamoxifen	270.8	25.9	18	30.7	8.8
X-2487	BRCA	tamoxifen	370.5	26.4	26	78.8	10.9
X-2487	BRCA	tamoxifen	393.8	26.8	29	90.1	12.6
X-2487	BRCA	tamoxifen	469.5	27.2	32	126.6	14.3
X-2487	BRCA	tamoxifen	534	26.8	36	157.7	12.6
X-2487	BRCA	tamoxifen	585.1	27.5	39	182.4	15.5
X-2487	BRCA	tamoxifen	617.3	26.7	43	197.9	12.2
X-2487	BRCA	tamoxifen	734.9	26.7	46	254.7	12.2
X-2487	BRCA	tamoxifen	995.9	26.7	50	380.6	12.2
X-2487	BRCA	tamoxifen	1114.7	27.5	53	438	15.5
X-2487	BRCA	tamoxifen	1405.1	26.5	57	578.1	11.3
X-2487	BRCA	tamoxifen	1575.7	26.8	60	660.5	12.6
X-2487	BRCA	trastuzumab	212.4	28.8	0	0	0
X-2487	BRCA	trastuzumab	252.1	28.3	3	18.7	-1.7
X-2487	BRCA	trastuzumab	284.5	28.1	6	33.9	-2.4
X-2487	BRCA	trastuzumab	435.1	27.7	10	104.8	-3.8
X-2487	BRCA	trastuzumab	482	28.4	13	126.9	-1.4
X-2487	BRCA	trastuzumab	812.8	29.3	21	282.7	1.7
X-2487	BRCA	trastuzumab	1019.1	28.9	24	379.8	0.3
X-2487	BRCA	trastuzumab	1127.1	30.6	27	430.6	6.2
X-2487	BRCA	untreated	211.8	26.7	0	0	0
X-2487	BRCA	untreated	321.1	27.2	4	51.6	1.9
X-2487	BRCA	untreated	521.5	27.5	8	146.2	3
X-2487	BRCA	untreated	613.4	27.7	11	189.6	3.7
X-2487	BRCA	untreated	815.3	28.1	15	284.9	5.2
X-2487	BRCA	untreated	1074.1	28.5	18	407.1	6.7
X-2487	BRCA	LFW527 + everolimus	186.8	26.7	0	0	0
X-2487	BRCA	LFW527 + everolimus	160.93	26.6	4	-13.8	-0.4
X-2487	BRCA	LFW527 + everolimus	197.51	25.8	7	5.7	-3.4
X-2487	BRCA	LFW527 + everolimus	220.48	26.2	10	18	-1.9
X-2487	BRCA	LFW527 + everolimus	194.68	25.6	14	4.2	-4.1
X-2487	BRCA	LFW527 + everolimus	226.05	26.9	17	21	0.7
X-2487	BRCA	LFW527 + everolimus	233.93	27.3	21	25.2	2.2
X-2487	BRCA	LFW527 + everolimus	254.58	27.3	24	36.3	2.2
X-2487	BRCA	LFW527 + everolimus	287.42	27.5	31	53.9	3
X-2487	BRCA	LFW527 + everolimus	253.88	26.7	35	35.9	0
X-2487	BRCA	LFW527 + everolimus	274.46	26.4	39	46.9	-1.1
X-2487	BRCA	LFW527 + everolimus	304.78	26.2	42	63.2	-1.9
X-2487	BRCA	LFW527 + everolimus	312.54	25.1	45	67.3	-6
X-2514	CRC	LFW527 + binimetinib	201.45	25.84	0	0	0
X-2514	CRC	LFW527 + binimetinib	199.56	24.26	2	-0.9	-6.1
X-2514	CRC	LFW527 + binimetinib	225.42	23.49	6	11.9	-9.1
X-2514	CRC	LFW527 + binimetinib	268.09	23.76	9	33.1	-8
X-2514	CRC	LFW527 + binimetinib	415.92	24.29	17	106.5	-6
X-2514	CRC	LFW527 + binimetinib	656.24	24.54	24	225.8	-5
X-2514	CRC	LFW527 + binimetinib	797.92	24.09	27	296.1	-6.8
X-2524	BRCA	BGJ398	314.8	26.5	0	0	0
X-2524	BRCA	BGJ398	426.8	27	3	35.6	1.9
X-2524	BRCA	BGJ398	617.6	28.5	7	96.2	7.5
X-2524	BRCA	BGJ398	965.6	28.9	10	206.7	9.1
X-2524	BRCA	BGJ398	1937.5	29.8	14	515.5	12.5
X-2524	BRCA	BKM120	279.7	24.4	0	0	0
X-2524	BRCA	BKM120	326.8	26.2	3	16.8	7.4
X-2524	BRCA	BKM120	463.7	25.5	7	65.8	4.5
X-2524	BRCA	BKM120	527.1	25.3	10	88.5	3.7
X-2524	BRCA	BKM120	705.4	25.2	14	152.2	3.3
X-2524	BRCA	BKM120	802.5	25.6	17	186.9	4.9
X-2524	BRCA	BKM120	929.1	26.4	21	232.2	8.2
X-2524	BRCA	BKM120	1114.5	26.9	24	298.5	10.2
X-2524	BRCA	BKM120	1383.2	26.7	27	394.5	9.4
X-2524	BRCA	BYL719	348.1	23.1	0	0	0
X-2524	BRCA	BYL719	360.9	24	3	3.7	3.9
X-2524	BRCA	BYL719	457.2	23.6	7	31.3	2.2
X-2524	BRCA	BYL719	512.1	25.1	10	47.1	8.7
X-2524	BRCA	BYL719	591.9	23.7	14	70	2.6
X-2524	BRCA	BYL719	642.2	23.8	17	84.5	3
X-2524	BRCA	BYL719	769	23.8	21	120.9	3
X-2524	BRCA	BYL719	964.9	24.1	24	177.2	4.3
X-2524	BRCA	BYL719	981.6	24.9	27	182	7.8
X-2524	BRCA	BYL719	1541.8	26.1	36	342.9	13
X-2524	BRCA	BYL719 + LEE011	451	26.8	0	0	0
X-2524	BRCA	BYL719 + LEE011	531.2	26.2	4	17.8	-2.2
X-2524	BRCA	BYL719 + LEE011	545.8	23.1	7	21	-13.8
X-2524	BRCA	BYL719 + LEE011	505.6	22.6	11	12.1	-15.7
X-2524	BRCA	BYL719 + LEE011	570.6	21.4	14	26.5	-20.1
X-2524	BRCA	BYL719 + LEE011	612.7	24.1	17	35.9	-10.1
X-2524	BRCA	BYL719 + LEE011	1180	27.3	26	161.6	1.9
X-2524	BRCA	BYL719 + LEE011	1389.4	27.4	28	208.1	2.2
X-2524	BRCA	BYL719 + LEE011	1652.2	25.3	32	266.3	-5.6
X-2524	BRCA	BYL719 + LJM716	268.5	27.8	0	0	0
X-2524	BRCA	BYL719 + LJM716	269.9	26.5	3	0.5	-4.7
X-2524	BRCA	BYL719 + LJM716	287.5	25.4	7	7.1	-8.6
X-2524	BRCA	BYL719 + LJM716	319.1	26.4	10	18.8	-5
X-2524	BRCA	BYL719 + LJM716	338.8	27.6	14	26.2	-0.7
X-2524	BRCA	BYL719 + LJM716	380.8	27.2	17	41.8	-2.2
X-2524	BRCA	BYL719 + LJM716	382.7	27.7	21	42.5	-0.4
X-2524	BRCA	BYL719 + LJM716	445.2	29.1	24	65.8	4.7
X-2524	BRCA	BYL719 + LJM716	467	27.5	28	73.9	-1.1
X-2524	BRCA	BYL719 + LJM716	473.3	28.2	31	76.3	1.4
X-2524	BRCA	BYL719 + LJM716	496.8	27.8	35	85	0
X-2524	BRCA	BYL719 + LJM716	516	27.9	38	92.2	0.4
X-2524	BRCA	BYL719 + LJM716	586.7	28.1	42	118.5	1.1
X-2524	BRCA	BYL719 + LJM716	585.7	28.5	45	118.1	2.5
X-2524	BRCA	BYL719 + LJM716	621.3	27.4	49	131.4	-1.4
X-2524	BRCA	BYL719 + LJM716	709.4	28.3	52	164.2	1.8
X-2524	BRCA	BYL719 + LJM716	739.1	27.7	56	175.3	-0.4
X-2524	BRCA	BYL719 + LJM716	790.1	28.1	59	194.3	1.1
X-2524	BRCA	BYL719 + LJM716	798	28.7	63	197.2	3.2
X-2524	BRCA	BYL719 + LJM716	815.4	27.4	66	203.7	-1.4
X-2524	BRCA	BYL719 + LJM716	926.4	28.8	70	245	3.6
X-2524	BRCA	CGM097	235.8	24	0	0	0
X-2524	BRCA	CGM097	283.2	25.6	3	20.1	6.7
X-2524	BRCA	CGM097	374.8	26.2	7	58.9	9.2
X-2524	BRCA	CGM097	503.3	26.6	10	113.4	10.8
X-2524	BRCA	CGM097	589.7	26.7	14	150.1	11.3
X-2524	BRCA	CGM097	694.2	26.6	17	194.4	10.8
X-2524	BRCA	CGM097	812	27.6	21	244.4	15
X-2524	BRCA	CGM097	1106.9	28.1	24	369.4	17.1
X-2524	BRCA	CGM097	1314.6	27.5	27	457.5	14.6
X-2524	BRCA	CLR457	220.9	25.6	0	0	0
X-2524	BRCA	CLR457	251.1	26.3	3	13.7	2.7
X-2524	BRCA	CLR457	272.8	25.9	7	23.5	1.2
X-2524	BRCA	CLR457	310.6	26.7	10	40.6	4.3
X-2524	BRCA	CLR457	386.2	26.6	14	74.8	3.9
X-2524	BRCA	CLR457	451.3	26.3	17	104.3	2.7
X-2524	BRCA	CLR457	567.8	26.6	21	157	3.9
X-2524	BRCA	CLR457	702.7	26.8	24	218.1	4.7
X-2524	BRCA	CLR457	802.3	26.2	27	263.2	2.3
X-2524	BRCA	CLR457	1161	26.6	36	425.6	3.9
X-2524	BRCA	CLR457	1371.9	26.5	38	521.1	3.5
X-2524	BRCA	CLR457	1434.9	26.6	42	549.6	3.9
X-2524	BRCA	HDM201	263.5	25.7	0	0	0
X-2524	BRCA	HDM201	321.5	26.6	3	22	3.5
X-2524	BRCA	HDM201	362.8	26.6	7	37.7	3.5
X-2524	BRCA	HDM201	463.6	27.1	10	75.9	5.4
X-2524	BRCA	HDM201	569.9	27.9	14	116.3	8.6
X-2524	BRCA	HDM201	814.6	27.3	17	209.1	6.2
X-2524	BRCA	HDM201	904.3	27.5	21	243.2	7
X-2524	BRCA	HDM201	1020.2	27.2	24	287.2	5.8
X-2524	BRCA	HDM201	1281.1	26.7	27	386.2	3.9
X-2524	BRCA	INC424	381.8	26.8	0	0	0
X-2524	BRCA	INC424	504	27.4	3	32	2.2
X-2524	BRCA	INC424	810.9	26.8	7	112.4	0
X-2524	BRCA	INC424	1073.6	27.3	10	181.2	1.9
X-2524	BRCA	INC424	1293.1	28.2	14	238.7	5.2
X-2524	BRCA	INC424	1663.4	28.3	17	335.7	5.6
X-2524	BRCA	LEE011 + everolimus	334.2	25.3	0	0	0
X-2524	BRCA	LEE011 + everolimus	315.6	22.3	4	-5.6	-11.9
X-2524	BRCA	LEE011 + everolimus	351.6	22.1	7	5.2	-12.6
X-2524	BRCA	LEE011 + everolimus	414.9	24.8	11	24.1	-2
X-2524	BRCA	LEE011 + everolimus	459.3	24.7	14	37.4	-2.4
X-2524	BRCA	LEE011 + everolimus	552.9	25.9	17	65.4	2.4
X-2524	BRCA	LEE011 + everolimus	921	28	26	175.6	10.7
X-2524	BRCA	LEE011 + everolimus	956.8	28.6	28	186.3	13
X-2524	BRCA	LEE011 + everolimus	976.9	29.3	32	192.3	15.8
X-2524	BRCA	LEE011 + everolimus	1314.3	28.7	35	293.3	13.4
X-2524	BRCA	LEE011 + everolimus	1335.5	27.1	39	299.6	7.1
X-2524	BRCA	LEE011	237.5	27	0	0	0
X-2524	BRCA	LEE011	309.2	27.8	4	30.2	3
X-2524	BRCA	LEE011	325.8	28.2	7	37.2	4.4
X-2524	BRCA	LEE011	425.5	28.5	11	79.2	5.6
X-2524	BRCA	LEE011	495.7	27.8	14	108.7	3
X-2524	BRCA	LEE011	520.4	28.3	17	119.1	4.8
X-2524	BRCA	LEE011	666.9	29.5	26	180.8	9.3
X-2524	BRCA	LEE011	693.3	30.2	28	191.9	11.9
X-2524	BRCA	LEE011	953.4	30.1	32	301.4	11.5
X-2524	BRCA	LEE011	989.2	30.8	35	316.5	14.1
X-2524	BRCA	LEE011	1121.7	31	39	372.3	14.8
X-2524	BRCA	LEE011	1259.6	31.1	42	430.4	15.2
X-2524	BRCA	LEE011	1544	30.7	46	550.1	13.7
X-2524	BRCA	LFA102	207.7	28.2	0	0	0
X-2524	BRCA	LFA102	260	30.7	8	25.2	8.9
X-2524	BRCA	LFA102	278	30.6	10	33.8	8.5
X-2524	BRCA	LFA102	354.9	30	14	70.9	6.4
X-2524	BRCA	LFA102	448	30.6	17	115.7	8.5
X-2524	BRCA	LFA102	475.4	31.7	21	128.9	12.4
X-2524	BRCA	LFA102	551.8	30.8	24	165.7	9.2
X-2524	BRCA	LFA102	739.1	31.1	28	255.8	10.3
X-2524	BRCA	LFA102	807.5	30.9	31	288.8	9.6
X-2524	BRCA	LFA102	1119.7	31.5	35	439.1	11.7
X-2524	BRCA	LFA102	1463.8	33.1	38	604.8	17.4
X-2524	BRCA	LFA102	1845	34	42	788.3	20.6
X-2524	BRCA	LJM716	205.6	22.6	0	0	0
X-2524	BRCA	LJM716	308	22.6	4	49.8	0
X-2524	BRCA	LJM716	408.4	24.7	8	98.6	9.3
X-2524	BRCA	LJM716	674.6	23.9	11	228.1	5.8
X-2524	BRCA	LJM716	869.1	24.4	14	322.7	8
X-2524	BRCA	LJM716	1571.9	25.6	23	664.5	13.3
X-2524	BRCA	LJM716 + trastuzumab	208.6	27.7	0	0	0
X-2524	BRCA	LJM716 + trastuzumab	200.2	26.2	3	-4	-5.4
X-2524	BRCA	LJM716 + trastuzumab	270.9	27.7	7	29.9	0
X-2524	BRCA	LJM716 + trastuzumab	444.6	28	10	113.1	1.1
X-2524	BRCA	LJM716 + trastuzumab	546.3	27.3	13	161.9	-1.4
X-2524	BRCA	LJM716 + trastuzumab	1174.3	26.7	22	462.9	-3.6
X-2524	BRCA	LJM716 + trastuzumab	1181.8	27.1	24	466.5	-2.2
X-2524	BRCA	LJM716 + trastuzumab	1453.5	27.4	28	596.8	-1.1
X-2524	BRCA	LKA136	182.4	24.5	0	0	0
X-2524	BRCA	LKA136	241.1	24.8	3	32.2	1.2
X-2524	BRCA	LKA136	513.4	24.7	7	181.5	0.8
X-2524	BRCA	LKA136	891.9	25.9	10	389	5.7
X-2524	BRCA	LKA136	1198.6	26.9	14	557.1	9.8
X-2524	BRCA	LKA136	1778.3	26.6	17	874.9	8.6
X-2524	BRCA	LLM871	201.8	25	0	0	0
X-2524	BRCA	LLM871	210.8	23.5	3	4.5	-6
X-2524	BRCA	LLM871	218.6	24.5	7	8.3	-2
X-2524	BRCA	LLM871	233.7	24.9	10	15.8	-0.4
X-2524	BRCA	LLM871	256.3	24.2	14	27	-3.2
X-2524	BRCA	LLM871	301.6	23.4	17	49.5	-6.4
X-2524	BRCA	LLM871	377.8	23.9	21	87.2	-4.4
X-2524	BRCA	LLM871	455.3	25.4	24	125.6	1.6
X-2524	BRCA	LLM871	496.4	24.6	28	146	-1.6
X-2524	BRCA	LLM871	577.1	24.6	31	186	-1.6
X-2524	BRCA	LLM871	607.3	24.2	35	200.9	-3.2
X-2524	BRCA	LLM871	676.2	24.8	38	235.1	-0.8
X-2524	BRCA	LLM871	730.3	25.3	42	261.9	1.2
X-2524	BRCA	LLM871	782.2	25.3	45	287.6	1.2
X-2524	BRCA	LLM871	885.5	25.6	49	338.8	2.4
X-2524	BRCA	LLM871	900	26.2	52	346	4.8
X-2524	BRCA	LLM871	1067.6	26.2	56	429	4.8
X-2524	BRCA	LLM871	1165.7	26.7	59	477.7	6.8
X-2524	BRCA	LLM871	1224	26.7	63	506.5	6.8
X-2524	BRCA	LLM871	1292.6	26.3	70	540.5	5.2
X-2524	BRCA	binimetinib	309.1	25.9	0	0	0
X-2524	BRCA	binimetinib	503.7	26.5	3	63	2.3
X-2524	BRCA	binimetinib	604.1	26.3	7	95.4	1.5
X-2524	BRCA	binimetinib	727.2	27.1	10	135.3	4.6
X-2524	BRCA	binimetinib	1008	28.1	14	226.1	8.5
X-2524	BRCA	binimetinib	1443.8	27.1	17	367.1	4.6
X-2524	BRCA	paclitaxel	229	26	0	0	0
X-2524	BRCA	paclitaxel	270.8	26.4	3	18.3	1.5
X-2524	BRCA	paclitaxel	275.7	26.5	6	20.4	1.9
X-2524	BRCA	paclitaxel	393.1	27.3	15	71.7	5
X-2524	BRCA	paclitaxel	478	27.6	17	108.7	6.2
X-2524	BRCA	paclitaxel	587.3	27.7	21	156.5	6.5
X-2524	BRCA	paclitaxel	660.3	28.9	24	188.3	11.2
X-2524	BRCA	paclitaxel	719.5	28.5	28	214.2	9.6
X-2524	BRCA	paclitaxel	758.5	28.8	31	231.2	10.8
X-2524	BRCA	paclitaxel	844.5	29	35	268.8	11.5
X-2524	BRCA	paclitaxel	1022.9	28.5	38	346.7	9.6
X-2524	BRCA	paclitaxel	1086	30.4	45	374.2	16.9
X-2524	BRCA	paclitaxel	1407.5	29.8	49	514.6	14.6
X-2524	BRCA	tamoxifen	254.6	25.1	0	0	0
X-2524	BRCA	tamoxifen	301	25.9	3	18.2	3.2
X-2524	BRCA	tamoxifen	581.1	25.2	7	128.2	0.4
X-2524	BRCA	tamoxifen	792.4	26.4	10	211.2	5.2
X-2524	BRCA	tamoxifen	983.7	26.5	14	286.4	5.6
X-2524	BRCA	tamoxifen	1176.5	27.1	17	362.1	8
X-2524	BRCA	tamoxifen	2010.1	28.1	21	689.5	12
X-2524	BRCA	trastuzumab	206.9	22.1	0	0	0
X-2524	BRCA	trastuzumab	278.8	21.9	3	34.8	-0.9
X-2524	BRCA	trastuzumab	570	23.5	10	175.5	6.3
X-2524	BRCA	trastuzumab	680	23.5	13	228.7	6.3
X-2524	BRCA	trastuzumab	1577.5	24.2	22	662.4	9.5
X-2524	BRCA	untreated	270.4	27.1	0	0	0
X-2524	BRCA	untreated	499.1	28.2	3	84.6	4.1
X-2524	BRCA	untreated	1011.7	27.8	7	274.1	2.6
X-2524	BRCA	untreated	2015.1	30.9	10	645.2	14
X-2524	BRCA	LFW527 + everolimus	554.74	26.1	16	0	0
X-2524	BRCA	LFW527 + everolimus	562.17	27.3	19	1.3	4.6
X-2524	BRCA	LFW527 + everolimus	646.22	27.2	23	16.5	4.2
X-2524	BRCA	LFW527 + everolimus	637.22	26.8	26	14.9	2.7
X-2538	CRC	5FU	211.9	23.9	0	0	0
X-2538	CRC	5FU	235	24	7	10.9	0.4
X-2538	CRC	5FU	285.9	24.8	11	34.9	3.8
X-2538	CRC	5FU	343.4	25.4	15	62.1	6.3
X-2538	CRC	5FU	428	24.5	18	102	2.5
X-2538	CRC	5FU	494.7	26	22	133.5	8.8
X-2538	CRC	5FU	529.9	25.7	25	150.1	7.5
X-2538	CRC	5FU	566	26.2	29	167.1	9.6
X-2538	CRC	5FU	606.9	26	32	186.4	8.8
X-2538	CRC	BKM120	211.9	24	0	0	0
X-2538	CRC	BKM120	200.4	23.5	2	-5.4	-2.1
X-2538	CRC	BKM120	240.4	25.1	6	13.4	4.6
X-2538	CRC	BKM120	240.7	24.5	9	13.6	2.1
X-2538	CRC	BKM120	267	25	13	26	4.2
X-2538	CRC	BKM120	249.5	26	16	17.7	8.3
X-2538	CRC	BKM120	268	25.6	20	26.5	6.7
X-2538	CRC	BKM120	285.2	25.2	23	34.6	5
X-2538	CRC	BKM120	311.1	25.3	29	46.8	5.4
X-2538	CRC	BKM120	308.6	25.4	35	45.6	5.8
X-2538	CRC	BKM120	298.1	25.9	40	40.7	7.9
X-2538	CRC	BKM120	309.2	25.5	44	45.9	6.2
X-2538	CRC	BKM120	320.5	25.5	48	51.3	6.2
X-2538	CRC	BKM120	307.5	25.5	51	45.1	6.2
X-2538	CRC	BKM120	336.7	26.4	56	58.9	10
X-2538	CRC	BKM120	321	25.8	62	51.5	7.5
X-2538	CRC	BKM120	380.7	25.6	65	79.7	6.7
X-2538	CRC	BKM120	391.8	25.9	68	84.9	7.9
X-2538	CRC	BKM120	395.7	26.3	72	86.7	9.6
X-2538	CRC	BKM120	420.6	25.8	76	98.5	7.5
X-2538	CRC	BKM120	482.3	25.5	79	127.6	6.2
X-2538	CRC	BKM120 + LJC049	193.1	29.5	0	0	0
X-2538	CRC	BKM120 + LJC049	165.2	30.3	7	-14.4	2.7
X-2538	CRC	BKM120 + LJC049	166.4	28.7	10	-13.8	-2.7
X-2538	CRC	BKM120 + LJC049	175.3	29.8	13	-9.2	1
X-2538	CRC	BKM120 + LJC049	205.6	29.2	17	6.5	-1
X-2538	CRC	BKM120 + LJC049	201.4	29	21	4.3	-1.7
X-2538	CRC	BKM120 + LJC049	207.3	29.4	24	7.4	-0.3
X-2538	CRC	BKM120 + LJC049	205.2	28.1	28	6.3	-4.7
X-2538	CRC	BYL719 + cetuximab + encorafenib	217	26	0	0	0
X-2538	CRC	BYL719 + cetuximab + encorafenib	205.3	27.3	3	-5.4	5
X-2538	CRC	BYL719 + cetuximab + encorafenib	242.4	27.6	7	11.7	6.2
X-2538	CRC	BYL719 + cetuximab + encorafenib	274.8	27.8	11	26.6	6.9
X-2538	CRC	BYL719 + cetuximab + encorafenib	453.2	28.1	15	108.8	8.1
X-2538	CRC	BYL719 + cetuximab + encorafenib	489.6	28.6	18	125.6	10
X-2538	CRC	BYL719 + cetuximab + encorafenib	458.3	27.8	22	111.2	6.9
X-2538	CRC	BYL719 + cetuximab + encorafenib	520.5	26.6	25	139.9	2.3
X-2538	CRC	BYL719 + cetuximab + encorafenib	587.6	27	28	170.8	3.8
X-2538	CRC	BYL719 + cetuximab + encorafenib	695.5	26	35	220.5	0
X-2538	CRC	BYL719 + cetuximab + encorafenib	816.6	27.1	39	276.3	4.2
X-2538	CRC	BYL719 + cetuximab	209.8	28.2	0	0	0
X-2538	CRC	BYL719 + cetuximab	226.5	28.2	3	8	0
X-2538	CRC	BYL719 + cetuximab	270.7	28.4	7	29	0.7
X-2538	CRC	BYL719 + cetuximab	260.6	26.4	11	24.2	-6.4
X-2538	CRC	BYL719 + cetuximab	528.6	26.9	15	152	-4.6
X-2538	CRC	BYL719 + cetuximab	492.8	26.8	18	134.9	-5
X-2538	CRC	BYL719 + cetuximab	509.1	26.7	22	142.7	-5.3
X-2538	CRC	BYL719 + cetuximab	485	26.9	25	131.2	-4.6
X-2538	CRC	BYL719 + cetuximab	501.2	28.4	28	138.9	0.7
X-2538	CRC	BYL719 + cetuximab	679.4	26.8	35	223.8	-5
X-2538	CRC	BYL719	194.9	25.1	0	0	0
X-2538	CRC	BYL719	175.8	23.8	3	-9.8	-5.2
X-2538	CRC	BYL719	136.3	23.9	9	-30.1	-4.8
X-2538	CRC	BYL719	130.2	24.2	15	-33.2	-3.6
X-2538	CRC	BYL719	178.4	24.8	20	-8.5	-1.2
X-2538	CRC	BYL719	144.6	24.8	24	-25.8	-1.2
X-2538	CRC	BYL719	163.4	26	28	-16.2	3.6
X-2538	CRC	BYL719	195.9	25.7	31	0.5	2.4
X-2538	CRC	BYL719	192.8	25.4	36	-1.1	1.2
X-2538	CRC	BYL719	216.2	25.3	42	10.9	0.8
X-2538	CRC	BYL719	253.9	24.8	45	30.3	-1.2
X-2538	CRC	BYL719	273	25.2	48	40.1	0.4
X-2538	CRC	BYL719	251.8	25.5	52	29.2	1.6
X-2538	CRC	BYL719	309.9	26.3	56	59	4.8
X-2538	CRC	BYL719	292	26.5	59	49.8	5.6
X-2538	CRC	BYL719	282.8	27	63	45.1	7.6
X-2538	CRC	BYL719	280.9	25.8	69	44.1	2.8
X-2538	CRC	BYL719	284.8	25.6	73	46.1	2
X-2538	CRC	BYL719	311.9	25.9	78	60	3.2
X-2538	CRC	BYL719	353.9	26.6	80	81.6	6
X-2538	CRC	BYL719	388.6	26.4	84	99.4	5.2
X-2538	CRC	BYL719	381	26.7	87	95.5	6.4
X-2538	CRC	BYL719	395	26.2	91	102.7	4.4
X-2538	CRC	BYL719	438.6	26.7	94	125	6.4
X-2538	CRC	BYL719 + LJM716	201	27.5	0	0	0
X-2538	CRC	BYL719 + LJM716	211.5	24.3	3	5.2	-11.6
X-2538	CRC	BYL719 + LJM716	227.2	25	9	13	-9.1
X-2538	CRC	BYL719 + LJM716	291.7	25.4	15	45.1	-7.6
X-2538	CRC	BYL719 + LJM716	267.8	26	20	33.2	-5.5
X-2538	CRC	BYL719 + LJM716	318.8	25.6	24	58.6	-6.9
X-2538	CRC	BYL719 + LJM716	296.9	25.7	28	47.7	-6.5
X-2538	CRC	BYL719 + LJM716	320.6	26.2	31	59.5	-4.7
X-2538	CRC	BYL719 + LJM716	382.3	25.9	36	90.2	-5.8
X-2538	CRC	BYL719 + LJM716	399.3	25.3	42	98.7	-8
X-2538	CRC	BYL719 + LJM716	405	25.4	45	101.5	-7.6
X-2538	CRC	BYL719 + LJM716	412.5	25.8	48	105.2	-6.2
X-2538	CRC	BYL719 + encorafenib	211.8	25.6	0	0	0
X-2538	CRC	BYL719 + encorafenib	254.8	24.9	6	20.3	-2.7
X-2538	CRC	BYL719 + encorafenib	261.9	24.9	9	23.7	-2.7
X-2538	CRC	BYL719 + encorafenib	312.1	25.5	14	47.4	-0.4
X-2538	CRC	BYL719 + encorafenib	327.4	25.6	20	54.6	0
X-2538	CRC	BYL719 + encorafenib	370	24.9	23	74.7	-2.7
X-2538	CRC	BYL719 + encorafenib	392.4	25.5	26	85.3	-0.4
X-2538	CRC	BYL719 + encorafenib	498.9	24.6	30	135.6	-3.9
X-2538	CRC	BYL719 + encorafenib	573.3	25.6	34	170.7	0
X-2538	CRC	BYL719 + encorafenib	791.6	24.8	37	273.7	-3.1
X-2538	CRC	BYL719 + binimetinib	196.2	30.1	0	0	0
X-2538	CRC	BYL719 + binimetinib	217.5	28.5	5	10.9	-5.3
X-2538	CRC	BYL719 + binimetinib	153.9	29.3	8	-21.6	-2.7
X-2538	CRC	BYL719 + binimetinib	176.3	29.6	12	-10.1	-1.7
X-2538	CRC	BYL719 + binimetinib	177	29.8	18	-9.8	-1
X-2538	CRC	BYL719 + binimetinib	184.4	28.8	22	-6	-4.3
X-2538	CRC	BYL719 + binimetinib	219.6	29.5	27	11.9	-2
X-2538	CRC	BYL719 + binimetinib	222	28.3	29	13.1	-6
X-2538	CRC	BYL719 + binimetinib	214.6	29.2	33	9.4	-3
X-2538	CRC	BYL719 + binimetinib	258.7	28.4	36	31.9	-5.6
X-2538	CRC	BYL719 + binimetinib	328.6	29	40	67.5	-3.7
X-2538	CRC	BYL719 + binimetinib	307.2	28.2	44	56.6	-6.3
X-2538	CRC	BYL719 + binimetinib	302.7	30	47	54.3	-0.3
X-2538	CRC	BYL719 + binimetinib	285.1	29.7	50	45.3	-1.3
X-2538	CRC	BYL719 + binimetinib	294.6	28.3	54	50.2	-6
X-2538	CRC	BYL719 + binimetinib	311.9	28.3	60	59	-6
X-2538	CRC	BYL719 + binimetinib	395.4	28.7	66	101.5	-4.7
X-2538	CRC	CGM097	201.5	23.9	0	0	0
X-2538	CRC	CGM097	207	24.5	4	2.7	2.5
X-2538	CRC	CGM097	232.5	24.8	8	15.4	3.8
X-2538	CRC	CGM097	269.4	25.4	11	33.7	6.3
X-2538	CRC	CGM097	288.3	24.4	17	43.1	2.1
X-2538	CRC	CGM097	286.3	25.5	23	42.1	6.7
X-2538	CRC	CGM097	341.4	26.5	28	69.4	10.9
X-2538	CRC	CGM097	352.6	26	32	75	8.8
X-2538	CRC	CGM097	457.8	28.2	36	127.2	18
X-2538	CRC	CGM097	448.3	26	39	122.5	8.8
X-2538	CRC	CGM097	479.8	26.8	44	138.1	12.1
X-2538	CRC	CKX620	211.5	23.1	0	0	0
X-2538	CRC	CKX620	214.1	22.1	2	1.2	-4.3
X-2538	CRC	CKX620	227.9	23.2	6	7.8	0.4
X-2538	CRC	CKX620	175.5	23.8	9	-17	3
X-2538	CRC	CKX620	207.4	23.9	13	-1.9	3.5
X-2538	CRC	CKX620	223.5	24	16	5.7	3.9
X-2538	CRC	CKX620	235.2	23.4	22	11.2	1.3
X-2538	CRC	CKX620	213.6	23.9	28	1	3.5
X-2538	CRC	CKX620	207.2	23.9	33	-2	3.5
X-2538	CRC	CKX620	226.9	24.1	37	7.3	4.3
X-2538	CRC	CKX620	211.2	25.2	44	-0.1	9.1
X-2538	CRC	CKX620	301.2	24.9	49	42.4	7.8
X-2538	CRC	CKX620	292.4	25.2	55	38.3	9.1
X-2538	CRC	CKX620	273.9	24.7	58	29.5	6.9
X-2538	CRC	CKX620	255.8	24.2	61	20.9	4.8
X-2538	CRC	CKX620	272.8	25.3	65	29	9.5
X-2538	CRC	CKX620	265.9	24.8	69	25.7	7.4
X-2538	CRC	CKX620	277.1	24.9	72	31	7.8
X-2538	CRC	CKX620	271.2	25	76	28.2	8.2
X-2538	CRC	CKX620	287.2	24.5	82	35.8	6.1
X-2538	CRC	CKX620	287.6	23.9	86	36	3.5
X-2538	CRC	CKX620	255.3	21.7	90	20.7	-6.1
X-2538	CRC	CLR457	199.3	26.3	0	0	0
X-2538	CRC	CLR457	169.8	25.6	3	-14.8	-2.7
X-2538	CRC	CLR457	134.3	26.9	9	-32.6	2.3
X-2538	CRC	CLR457	140	27.6	15	-29.8	4.9
X-2538	CRC	CLR457	120	28.1	20	-39.8	6.8
X-2538	CRC	CLR457	142.6	28.6	24	-28.4	8.7
X-2538	CRC	CLR457	179.9	29.7	28	-9.7	12.9
X-2538	CRC	CLR457	161.3	28.7	31	-19.1	9.1
X-2538	CRC	CLR457	175.5	29.1	36	-11.9	10.6
X-2538	CRC	CLR457	126.4	27.6	42	-36.6	4.9
X-2538	CRC	CLR457	129.5	28.6	45	-35	8.7
X-2538	CRC	CLR457	105.8	28.2	48	-46.9	7.2
X-2538	CRC	CLR457	142.7	28.3	52	-28.4	7.6
X-2538	CRC	CLR457	132.1	28.7	56	-33.7	9.1
X-2538	CRC	CLR457	156.5	27.9	59	-21.5	6.1
X-2538	CRC	CLR457	141.1	28.6	63	-29.2	8.7
X-2538	CRC	CLR457	137.6	26.6	69	-31	1.1
X-2538	CRC	CLR457	154	27	73	-22.7	2.7
X-2538	CRC	CLR457	116.3	28.2	78	-41.6	7.2
X-2538	CRC	CLR457	134.5	27.5	80	-32.5	4.6
X-2538	CRC	CLR457	189.6	27.7	84	-4.9	5.3
X-2538	CRC	CLR457	160.4	27.9	87	-19.5	6.1
X-2538	CRC	CLR457	157.1	28.1	91	-21.2	6.8
X-2538	CRC	CLR457	140.9	28.2	94	-29.3	7.2
X-2538	CRC	HDM201	208.6	29.4	0	0	0
X-2538	CRC	HDM201	262.8	29.3	2	26	-0.3
X-2538	CRC	HDM201	296.7	28.5	6	42.2	-3.1
X-2538	CRC	HDM201	252.5	27.5	9	21	-6.5
X-2538	CRC	HDM201	288.6	29.9	13	38.4	1.7
X-2538	CRC	HDM201	384.4	30.6	16	84.3	4.1
X-2538	CRC	HDM201	354.4	31.6	22	69.9	7.5
X-2538	CRC	HDM201	398.1	32.7	28	90.8	11.2
X-2538	CRC	HDM201	417.4	31.2	33	100.1	6.1
X-2538	CRC	cetuximab	247.2	26.1	0	0	0
X-2538	CRC	cetuximab	277.8	25.8	5	12.4	-1.1
X-2538	CRC	cetuximab	337.7	26.6	8	36.6	1.9
X-2538	CRC	cetuximab	418.3	26.5	11	69.2	1.5
X-2538	CRC	cetuximab	407.5	26.4	14	64.8	1.1
X-2538	CRC	cetuximab	480	26.9	18	94.2	3.1
X-2538	CRC	cetuximab	521.4	27.2	21	110.9	4.2
X-2538	CRC	cetuximab	565.7	27.7	25	128.8	6.1
X-2538	CRC	cetuximab	721.3	26.9	28	191.8	3.1
X-2538	CRC	cetuximab	691.1	26.9	33	179.6	3.1
X-2538	CRC	cetuximab	980.7	27.9	36	296.7	6.9
X-2538	CRC	cetuximab	1056.2	27.9	39	327.3	6.9
X-2538	CRC	cetuximab + encorafenib	254.7	28	0	0	0
X-2538	CRC	cetuximab + encorafenib	243.1	27.4	2	-4.6	-2.1
X-2538	CRC	cetuximab + encorafenib	309.4	30.6	7	21.5	9.3
X-2538	CRC	cetuximab + encorafenib	411.8	30.4	11	61.7	8.6
X-2538	CRC	cetuximab + encorafenib	454.1	29.4	14	78.3	5
X-2538	CRC	cetuximab + encorafenib	487.2	28.1	21	91.3	0.4
X-2538	CRC	cetuximab + encorafenib	648.6	27.9	24	154.7	-0.4
X-2538	CRC	cetuximab + encorafenib	696.3	28.4	28	173.4	1.4
X-2538	CRC	LEE011	214.2	27.3	0	0	0
X-2538	CRC	LEE011	228.2	27.8	2	6.5	1.8
X-2538	CRC	LEE011	259.9	25.8	6	21.3	-5.5
X-2538	CRC	LEE011	284.7	26.1	9	32.9	-4.4
X-2538	CRC	LEE011	276.3	26.6	13	29	-2.6
X-2538	CRC	LEE011	313.3	26.4	16	46.3	-3.3
X-2538	CRC	LEE011	322.1	26.8	20	50.4	-1.8
X-2538	CRC	LEE011	347.8	28.2	23	62.4	3.3
X-2538	CRC	LEE011	352.3	28.3	29	64.5	3.7
X-2538	CRC	LEE011	364.4	28.8	35	70.1	5.5
X-2538	CRC	LEE011	382.5	28.2	40	78.6	3.3
X-2538	CRC	LEE011	425.1	28.4	44	98.5	4
X-2538	CRC	LEE011	474.9	29.3	48	121.7	7.3
X-2538	CRC	encorafenib	241.1	24.4	0	0	0
X-2538	CRC	encorafenib	293.9	25	4	21.9	2.5
X-2538	CRC	encorafenib	347.2	24.4	8	44	0
X-2538	CRC	encorafenib	353.9	24.1	11	46.8	-1.2
X-2538	CRC	encorafenib	504.4	24.7	17	109.2	1.2
X-2538	CRC	encorafenib	657.6	25.1	23	172.7	2.9
X-2538	CRC	encorafenib	681.9	24.3	28	182.8	-0.4
X-2538	CRC	LJC049	216.3	27.3	0	0	0
X-2538	CRC	LJC049	235.2	27.5	2	8.7	0.7
X-2538	CRC	LJC049	227.8	27.1	6	5.3	-0.7
X-2538	CRC	LJC049	243.8	27.2	9	12.7	-0.4
X-2538	CRC	LJC049	291.8	27.6	15	34.9	1.1
X-2538	CRC	LJC049	451.2	27.6	21	108.6	1.1
X-2538	CRC	LJC049	590.7	27.5	26	173.1	0.7
X-2538	CRC	LJC049	610	27.6	30	182	1.1
X-2538	CRC	LJC049	733.6	28.9	34	239.2	5.9
X-2538	CRC	LKA136	219.5	25	0	0	0
X-2538	CRC	LKA136	248.8	25.7	2	13.3	2.8
X-2538	CRC	LKA136	328.6	26.3	6	49.7	5.2
X-2538	CRC	LKA136	411.4	25.7	9	87.4	2.8
X-2538	CRC	LKA136	440.5	26.7	15	100.7	6.8
X-2538	CRC	LKA136	559.3	26.6	21	154.8	6.4
X-2538	CRC	LKA136	865.4	26.6	26	294.3	6.4
X-2538	CRC	LKA136	813	26.7	30	270.4	6.8
X-2538	CRC	LKA136	1082.3	26.5	34	393.1	6
X-2538	CRC	binimetinib	204.6	22.2	0	0	0
X-2538	CRC	binimetinib	208.3	21.8	4	1.8	-1.8
X-2538	CRC	binimetinib	244.4	23	8	19.5	3.6
X-2538	CRC	binimetinib	270.7	23	11	32.3	3.6
X-2538	CRC	binimetinib	292.5	22.9	15	43	3.2
X-2538	CRC	binimetinib	331.8	23.3	18	62.2	5
X-2538	CRC	binimetinib	321	22.6	22	56.9	1.8
X-2538	CRC	binimetinib	335.4	22.8	25	63.9	2.7
X-2538	CRC	binimetinib	328.5	23.6	31	60.6	6.3
X-2538	CRC	binimetinib	376.3	23.7	37	83.9	6.8
X-2538	CRC	binimetinib	404.8	23.2	42	97.8	4.5
X-2538	CRC	untreated	203.7	20.2	0	0	0
X-2538	CRC	untreated	247.9	20.8	5	21.7	3
X-2538	CRC	untreated	285.5	20.9	8	40.2	3.5
X-2538	CRC	untreated	361.2	21.2	11	77.3	5
X-2538	CRC	untreated	468.6	21.5	14	130	6.4
X-2538	CRC	untreated	548.8	21.7	18	169.4	7.4
X-2538	CRC	untreated	552.1	22.6	21	171	11.9
X-2538	CRC	untreated	605.2	21.8	25	197.1	7.9
X-2538	CRC	untreated	655	21.8	28	221.6	7.9
X-2538	CRC	untreated	871.9	21.8	33	328	7.9
X-2564	PDAC	abraxane	237.5	25.7	0	0	0
X-2564	PDAC	abraxane	388.3	25.6	5	63.5	-0.4
X-2564	PDAC	abraxane	522	26.8	8	119.8	4.3
X-2564	PDAC	abraxane	457.2	27	11	92.5	5.1
X-2564	PDAC	abraxane	652.2	26	14	174.6	1.2
X-2564	PDAC	abraxane	783.4	27.3	18	229.9	6.2
X-2564	PDAC	abraxane	952.3	26	21	301	1.2
X-2564	PDAC	abraxane	1044.4	26.4	25	339.7	2.7
X-2564	PDAC	BKM120 + binimetinib	227.9	27.6	0	0	0
X-2564	PDAC	BKM120 + binimetinib	278	25.9	4	22	-6.2
X-2564	PDAC	BKM120 + binimetinib	258.6	26.2	7	13.5	-5.1
X-2564	PDAC	BKM120 + binimetinib	267.6	27.4	11	17.4	-0.7
X-2564	PDAC	BKM120 + binimetinib	227.2	25.9	14	-0.3	-6.2
X-2564	PDAC	BKM120 + binimetinib	268	26.5	18	17.6	-4
X-2564	PDAC	BKM120 + binimetinib	274.3	26.7	20	20.4	-3.3
X-2564	PDAC	BKM120 + binimetinib	197.9	25.6	25	-13.2	-7.2
X-2564	PDAC	BKM120 + binimetinib	238.2	27.2	27	4.5	-1.4
X-2564	PDAC	BKM120 + binimetinib	215.5	27.3	32	-5.4	-1.1
X-2564	PDAC	BKM120 + binimetinib	196.9	26.6	35	-13.6	-3.6
X-2564	PDAC	BKM120 + binimetinib	268.8	25.2	39	17.9	-8.7
X-2564	PDAC	BKM120 + binimetinib	254.4	26.2	42	11.6	-5.1
X-2564	PDAC	BKM120 + binimetinib	220.3	26.4	46	-3.3	-4.3
X-2564	PDAC	BKM120 + binimetinib	215.8	26.1	49	-5.3	-5.4
X-2564	PDAC	BKM120 + binimetinib	185.3	25.7	53	-18.7	-6.9
X-2564	PDAC	BKM120 + binimetinib	184.2	26.2	56	-19.2	-5.1
X-2564	PDAC	BKM120 + binimetinib	196.1	24.6	60	-14	-10.9
X-2564	PDAC	BKM120 + binimetinib	219.4	25.9	63	-3.7	-6.2
X-2564	PDAC	BKM120 + binimetinib	281.6	26.6	67	23.6	-3.6
X-2564	PDAC	BKM120 + binimetinib	231.4	25.1	70	1.5	-9.1
X-2564	PDAC	BKM120 + binimetinib	251.1	26.2	74	10.2	-5.1
X-2564	PDAC	BKM120 + binimetinib	228.9	26.5	77	0.4	-4
X-2564	PDAC	BKM120 + binimetinib	241.6	26.7	81	6	-3.3
X-2564	PDAC	BKM120 + binimetinib	197.6	27.6	88	-13.3	0
X-2564	PDAC	BKM120 + binimetinib	329.4	27.3	91	44.5	-1.1
X-2564	PDAC	BKM120 + binimetinib	271.1	28.1	95	19	1.8
X-2564	PDAC	BKM120 + binimetinib	219.7	28	98	-3.6	1.4
X-2564	PDAC	BKM120 + binimetinib	268.2	27	102	17.7	-2.2
X-2564	PDAC	BKM120 + LDE225	233.2	24.9	0	0	0
X-2564	PDAC	BKM120 + LDE225	239.6	27.2	3	2.7	9.2
X-2564	PDAC	BKM120 + LDE225	258.6	25.7	6	10.9	3.2
X-2564	PDAC	BKM120 + LDE225	266	24.6	11	14.1	-1.2
X-2564	PDAC	BKM120 + LDE225	243.5	25.5	17	4.4	2.4
X-2564	PDAC	BKM120 + LDE225	309.5	24.7	20	32.7	-0.8
X-2564	PDAC	BKM120 + LDE225	398.1	25.5	25	70.7	2.4
X-2564	PDAC	BKM120 + LDE225	314.7	26	28	34.9	4.4
X-2564	PDAC	BKM120 + LDE225	329.9	25.4	32	41.5	2
X-2564	PDAC	BKM120 + LDE225	245.8	25.7	35	5.4	3.2
X-2564	PDAC	BKM120 + LDE225	316	24.9	39	35.5	0
X-2564	PDAC	BKM120 + LDE225	393.1	22	46	68.6	-11.6
X-2564	PDAC	BKM120 + LDE225	404.7	22.5	53	73.5	-9.6
X-2564	PDAC	BKM120 + LDE225	416.8	22.8	56	78.7	-8.4
X-2564	PDAC	BKM120 + LDE225	613.7	24.9	60	163.2	0
X-2564	PDAC	BKM120 + LDE225	681	25.7	63	192	3.2
X-2564	PDAC	BKM120 + LDE225	734	26.4	67	214.8	6
X-2564	PDAC	BKM120 + LDE225	1012.6	27.7	70	334.2	11.2
X-2564	PDAC	BKM120 + LDE225	915.2	23.8	74	292.5	-4.4
X-2564	PDAC	BKM120 + LDE225	919.8	23.6	77	294.4	-5.2
X-2564	PDAC	BKM120 + LDE225	923	22.2	81	295.8	-10.8
X-2564	PDAC	BKM120 + LDE225	948.9	20.9	84	306.9	-16.1
X-2564	PDAC	BKM120 + LDE225	790.6	19.5	88	239	-21.7
X-2564	PDAC	BKM120 + LDE225	636.5	18.6	91	172.9	-25.3
X-2564	PDAC	BKM120	254.4	28.2	0	0	0
X-2564	PDAC	BKM120	268.4	28.2	5	5.5	0
X-2564	PDAC	BKM120	349.2	28.9	8	37.3	2.5
X-2564	PDAC	BKM120	309.4	29.1	12	21.6	3.2
X-2564	PDAC	BKM120	343.5	28.6	15	35	1.4
X-2564	PDAC	BKM120	304.1	27.9	19	19.5	-1.1
X-2564	PDAC	BKM120	325.9	28.7	22	28.1	1.8
X-2564	PDAC	BKM120	363.9	28.9	27	43	2.5
X-2564	PDAC	BKM120	307.3	28.6	29	20.8	1.4
X-2564	PDAC	BKM120	312.5	29.5	33	22.8	4.6
X-2564	PDAC	BKM120	488.7	29.3	36	92.1	3.9
X-2564	PDAC	BKM120	339.1	28.5	40	33.3	1.1
X-2564	PDAC	BKM120	507.2	29.1	43	99.4	3.2
X-2564	PDAC	BKM120	571.6	29.7	47	124.7	5.3
X-2564	PDAC	BYL719	248.2	29.2	0	0	0
X-2564	PDAC	BYL719	274.1	27.4	3	10.4	-6.2
X-2564	PDAC	BYL719	319.8	26.3	6	28.8	-9.9
X-2564	PDAC	BYL719	365.1	27.9	9	47.1	-4.5
X-2564	PDAC	BYL719	386.1	24.5	12	55.6	-16.1
X-2564	PDAC	BYL719	409.3	27.5	17	64.9	-5.8
X-2564	PDAC	BYL719	429.2	25.8	20	72.9	-11.6
X-2564	PDAC	BYL719	452.1	27.9	23	82.2	-4.5
X-2564	PDAC	BYL719	475.2	25.8	26	91.5	-11.6
X-2564	PDAC	BYL719	529	28.1	30	113.1	-3.8
X-2564	PDAC	BYL719	618	26.3	33	149	-9.9
X-2564	PDAC	BYL719	703.8	29.1	37	183.6	-0.3
X-2564	PDAC	BYL719 + LJM716	220.2	25.7	0	0	0
X-2564	PDAC	BYL719 + LJM716	240.6	25.4	3	9.3	-1.2
X-2564	PDAC	BYL719 + LJM716	241.7	25	7	9.8	-2.7
X-2564	PDAC	BYL719 + LJM716	248.7	24.5	11	12.9	-4.7
X-2564	PDAC	BYL719 + LJM716	248	24	14	12.6	-6.6
X-2564	PDAC	BYL719 + LJM716	318.1	24.5	18	44.5	-4.7
X-2564	PDAC	BYL719 + LJM716	326.1	23.9	21	48.1	-7
X-2564	PDAC	BYL719 + LJM716	348.9	25.2	24	58.4	-1.9
X-2564	PDAC	BYL719 + LJM716	353.5	23.7	29	60.5	-7.8
X-2564	PDAC	BYL719 + LJM716	359.2	24.6	31	63.1	-4.3
X-2564	PDAC	BYL719 + LJM716	332.2	24	35	50.9	-6.6
X-2564	PDAC	BYL719 + LJM716	319.4	24.1	42	45	-6.2
X-2564	PDAC	BYL719 + LJM716	341.8	23.8	45	55.2	-7.4
X-2564	PDAC	BYL719 + LJM716	346.7	23.5	50	57.4	-8.6
X-2564	PDAC	BYL719 + LJM716	376.6	24	53	71	-6.6
X-2564	PDAC	BYL719 + LJM716	371.4	24.6	56	68.7	-4.3
X-2564	PDAC	BYL719 + LJM716	522.5	24.5	60	137.3	-4.7
X-2564	PDAC	BYL719 + LJM716	260.4	24	66	18.3	-6.6
X-2564	PDAC	BYL719 + LJM716	370	22.9	71	68	-10.9
X-2564	PDAC	BYL719 + LJM716	326.5	20.6	74	48.3	-19.8
X-2564	PDAC	BYL719 + LJM716	448.4	23.2	78	103.6	-9.7
X-2564	PDAC	BYL719 + LJM716	425.2	24.4	81	93.1	-5.1
X-2564	PDAC	BYL719 + LJM716	574.8	23.9	85	161	-7
X-2564	PDAC	BYL719 + LJM716	640.8	24.4	88	191	-5.1
X-2564	PDAC	CLR457	228.5	26.4	0	0	0
X-2564	PDAC	CLR457	247.9	26.3	4	8.5	-0.4
X-2564	PDAC	CLR457	238.2	26.9	8	4.2	1.9
X-2564	PDAC	CLR457	221.1	25.7	11	-3.2	-2.7
X-2564	PDAC	CLR457	221	26.1	15	-3.3	-1.1
X-2564	PDAC	CLR457	217.3	26.2	18	-4.9	-0.8
X-2564	PDAC	CLR457	223.7	27.9	22	-2.1	5.7
X-2564	PDAC	CLR457	231.9	27	26	1.5	2.3
X-2564	PDAC	CLR457	241.8	26.1	29	5.8	-1.1
X-2564	PDAC	CLR457	240.2	26.3	33	5.1	-0.4
X-2564	PDAC	CLR457	271.3	27.2	36	18.7	3
X-2564	PDAC	CLR457	289.3	27.9	41	26.6	5.7
X-2564	PDAC	CLR457	299.5	27.3	44	31.1	3.4
X-2564	PDAC	CLR457	308.5	27	48	35	2.3
X-2564	PDAC	CLR457	311.6	26.9	51	36.4	1.9
X-2564	PDAC	CLR457	324.6	27.1	54	42.1	2.7
X-2564	PDAC	CLR457	337.2	27.5	57	47.6	4.2
X-2564	PDAC	CLR457	342.9	27.9	61	50.1	5.7
X-2564	PDAC	CLR457	418.2	28.1	65	83	6.4
X-2564	PDAC	CLR457	430.3	28	69	88.3	6.1
X-2564	PDAC	CLR457	496.6	28.1	73	117.3	6.4
X-2564	PDAC	CLR457	491.6	27.7	76	115.1	4.9
X-2564	PDAC	CLR457	485.1	27.8	78	112.3	5.3
X-2564	PDAC	CLR457	457.9	28	82	100.4	6.1
X-2564	PDAC	CLR457	455.5	27.5	89	99.3	4.2
X-2564	PDAC	CLR457	484.6	28.1	92	112.1	6.4
X-2564	PDAC	CLR457	506.1	28.7	96	121.5	8.7
X-2564	PDAC	CLR457	520.3	28.4	99	127.7	7.6
X-2564	PDAC	CLR457	530.3	28.6	103	132.1	8.3
X-2564	PDAC	CLR457	537.5	27.5	110	135.2	4.2
X-2564	PDAC	CLR457	579.2	28.1	114	153.5	6.4
X-2564	PDAC	CLR457	594.9	27.3	117	160.4	3.4
X-2564	PDAC	CLR457	629.5	27.3	119	175.5	3.4
X-2564	PDAC	CLR457	637.9	26.2	125	179.2	-0.8
X-2564	PDAC	CLR457	643.2	26.2	128	181.5	-0.8
X-2564	PDAC	CLR457	709.8	25.1	131	210.6	-4.9
X-2564	PDAC	HDM201	214.6	25.5	0	0	0
X-2564	PDAC	HDM201	206.2	25.2	3	-3.9	-1.2
X-2564	PDAC	HDM201	225.6	24.6	6	5.1	-3.5
X-2564	PDAC	HDM201	237.2	24.7	10	10.5	-3.1
X-2564	PDAC	HDM201	263.6	24.3	13	22.8	-4.7
X-2564	PDAC	HDM201	278.9	22.9	17	30	-10.2
X-2564	PDAC	HDM201	285.6	24	20	33.1	-5.9
X-2564	PDAC	HDM201	459.1	21	24	113.9	-17.6
X-2564	PDAC	figitumumab" + binimetinib	220.4	30.4	0	0	0
X-2564	PDAC	figitumumab" + binimetinib	241.9	29.6	4	9.8	-2.6
X-2564	PDAC	figitumumab" + binimetinib	268.1	29	7	21.6	-4.6
X-2564	PDAC	figitumumab" + binimetinib	209	28.8	11	-5.2	-5.3
X-2564	PDAC	figitumumab" + binimetinib	273.8	28.8	14	24.2	-5.3
X-2564	PDAC	figitumumab" + binimetinib	245	29.3	18	11.2	-3.6
X-2564	PDAC	figitumumab" + binimetinib	228.9	28.3	21	3.9	-6.9
X-2564	PDAC	figitumumab" + binimetinib	306.5	29.6	25	39.1	-2.6
X-2564	PDAC	figitumumab" + binimetinib	241.2	29.1	29	9.4	-4.3
X-2564	PDAC	figitumumab" + binimetinib	265.6	28.8	33	20.5	-5.3
X-2564	PDAC	figitumumab" + binimetinib	357	29.6	35	62	-2.6
X-2564	PDAC	figitumumab" + binimetinib	271.9	29.9	39	23.4	-1.6
X-2564	PDAC	figitumumab" + binimetinib	375.1	29.3	43	70.2	-3.6
X-2564	PDAC	figitumumab" + binimetinib	379.7	29.5	47	72.3	-3
X-2564	PDAC	figitumumab" + binimetinib	384.7	29.2	50	74.5	-3.9
X-2564	PDAC	figitumumab" + binimetinib	356.8	29.4	54	61.9	-3.3
X-2564	PDAC	figitumumab" + binimetinib	391.7	29.3	57	77.7	-3.6
X-2564	PDAC	figitumumab" + binimetinib	523.3	29.5	61	137.4	-3
X-2564	PDAC	figitumumab" + binimetinib	589.5	29.1	64	167.5	-4.3
X-2564	PDAC	figitumumab" + binimetinib	491.2	29.1	69	122.9	-4.3
X-2564	PDAC	figitumumab" + binimetinib	577.7	29.5	74	162.1	-3
X-2564	PDAC	figitumumab"	222.8	25.9	0	0	0
X-2564	PDAC	figitumumab"	228	26.6	2	2.3	2.7
X-2564	PDAC	figitumumab"	237.9	26	8	6.8	0.4
X-2564	PDAC	figitumumab"	401.3	26.9	12	80.1	3.9
X-2564	PDAC	figitumumab"	440.4	26.1	15	97.7	0.8
X-2564	PDAC	figitumumab"	579.4	25.3	19	160.1	-2.3
X-2564	PDAC	figitumumab"	579.3	25.2	22	160	-2.7
X-2564	PDAC	figitumumab"	625.5	26.8	26	180.7	3.5
X-2564	PDAC	figitumumab"	723.2	26.3	29	224.6	1.5
X-2564	PDAC	gemcitabine-50mpk	266.2	27	0	0	0
X-2564	PDAC	gemcitabine-50mpk	271.9	24.4	4	2.1	-9.6
X-2564	PDAC	gemcitabine-50mpk	318.4	25.8	8	19.6	-4.4
X-2564	PDAC	gemcitabine-50mpk	348.5	NA	11	30.9	-4.4
X-2564	PDAC	gemcitabine-50mpk	385.2	28.3	14	44.7	4.8
X-2564	PDAC	gemcitabine-50mpk	339.8	26.7	17	27.6	-1.1
X-2564	PDAC	gemcitabine-50mpk	364.5	26.8	22	36.9	-0.7
X-2564	PDAC	gemcitabine-50mpk	477.4	26.9	25	79.3	-0.4
X-2564	PDAC	gemcitabine-50mpk	493.7	26.2	29	85.5	-3
X-2564	PDAC	gemcitabine-50mpk	569.9	25.9	32	114.1	-4.1
X-2564	PDAC	gemcitabine-50mpk	557.1	24.3	36	109.3	-10
X-2564	PDAC	gemcitabine-50mpk	645	26.7	39	142.3	-1.1
X-2564	PDAC	gemcitabine-50mpk	706.4	26.5	43	165.4	-1.9
X-2564	PDAC	gemcitabine-50mpk	675.7	26.2	46	153.8	-3
X-2564	PDAC	gemcitabine-50mpk	759.1	25.9	49	185.2	-4.1
X-2564	PDAC	INC424 + binimetinib	230.7	24.2	0	0	0
X-2564	PDAC	INC424 + binimetinib	329.2	24.9	3	42.7	2.9
X-2564	PDAC	INC424 + binimetinib	400.4	24.4	6	73.6	0.8
X-2564	PDAC	INC424 + binimetinib	395.4	23.7	11	71.4	-2.1
X-2564	PDAC	INC424 + binimetinib	334.5	24.8	17	45	2.5
X-2564	PDAC	INC424 + binimetinib	370.3	24.6	20	60.5	1.7
X-2564	PDAC	INC424 + binimetinib	350.7	25.5	25	52	5.4
X-2564	PDAC	INC424 + binimetinib	393.7	25.8	28	70.7	6.6
X-2564	PDAC	INC424 + binimetinib	421.2	25.3	32	82.6	4.5
X-2564	PDAC	INC424 + binimetinib	357.4	25.7	35	54.9	6.2
X-2564	PDAC	INC424 + binimetinib	433.9	24.6	39	88.1	1.7
X-2564	PDAC	INC424 + binimetinib	454.6	25.5	46	97.1	5.4
X-2564	PDAC	INC424 + binimetinib	453.2	25.2	53	96.4	4.1
X-2564	PDAC	INC424 + binimetinib	435.9	24.1	56	88.9	-0.4
X-2564	PDAC	INC424 + binimetinib	549.1	24	60	138	-0.8
X-2564	PDAC	INC424 + binimetinib	504.8	23.8	63	118.8	-1.7
X-2564	PDAC	INC424 + binimetinib	573.5	24.9	67	148.6	2.9
X-2564	PDAC	INC424 + binimetinib	676.9	25.2	70	193.4	4.1
X-2564	PDAC	INC424 + binimetinib	701.8	24.9	74	204.2	2.9
X-2564	PDAC	INC424 + binimetinib	623	25.5	77	170	5.4
X-2564	PDAC	INC424 + binimetinib	879.2	26.2	81	281.1	8.3
X-2564	PDAC	INC424 + binimetinib	900	25.5	84	290.1	5.4
X-2564	PDAC	INC424 + binimetinib	799.2	24.8	88	246.4	2.5
X-2564	PDAC	INC424 + binimetinib	873.1	25.2	91	278.5	4.1
X-2564	PDAC	INC424 + binimetinib	753.8	25.8	95	226.7	6.6
X-2564	PDAC	INC424 + binimetinib	757.6	25.3	98	228.4	4.5
X-2564	PDAC	INC424 + binimetinib	678.5	26.3	102	194.1	8.7
X-2564	PDAC	INC424 + binimetinib	739.1	25.8	105	220.4	6.6
X-2564	PDAC	INC424 + binimetinib	791.1	26.2	109	242.9	8.3
X-2564	PDAC	INC424 + binimetinib	903.7	26.5	112	291.7	9.5
X-2564	PDAC	INC424 + binimetinib	759.6	25.8	115	229.3	6.6
X-2564	PDAC	INC424 + binimetinib	813.5	26.1	118	252.6	7.9
X-2564	PDAC	INC424 + binimetinib	878.5	26.1	123	280.8	7.9
X-2564	PDAC	INC424 + binimetinib	841.7	26	126	264.8	7.4
X-2564	PDAC	INC424	209.6	26	0	0	0
X-2564	PDAC	INC424	209	24	3	-0.3	-7.7
X-2564	PDAC	INC424	222.3	24.8	6	6.1	-4.6
X-2564	PDAC	INC424	251.8	25.5	10	20.1	-1.9
X-2564	PDAC	INC424	279.2	25.7	13	33.2	-1.2
X-2564	PDAC	INC424	308.6	24.8	17	47.2	-4.6
X-2564	PDAC	INC424	325.1	24.7	20	55.1	-5
X-2564	PDAC	INC424	340.5	24.4	24	62.5	-6.2
X-2564	PDAC	INC424	350.7	24.9	27	67.3	-4.2
X-2564	PDAC	INC424	371.1	24.4	32	77.1	-6.2
X-2564	PDAC	INC424	384.7	25	35	83.5	-3.8
X-2564	PDAC	INC424	392.1	25.1	38	87.1	-3.5
X-2564	PDAC	INC424	403.9	25	41	92.7	-3.8
X-2564	PDAC	INC424	463.2	25.9	45	121	-0.4
X-2564	PDAC	INC424	466.5	25.9	48	122.6	-0.4
X-2564	PDAC	INC424	492.7	24.3	52	135.1	-6.5
X-2564	PDAC	INC424	509	24.4	55	142.8	-6.2
X-2564	PDAC	INC424	479.9	24.1	60	129	-7.3
X-2564	PDAC	INC424	476.8	23.4	63	127.5	-10
X-2564	PDAC	INC424	505.2	23.1	66	141	-11.2
X-2564	PDAC	INC424	591.2	24.5	69	182.1	-5.8
X-2564	PDAC	INC424	560.4	24.7	72	167.4	-5
X-2564	PDAC	INC424	612.5	24.8	77	192.2	-4.6
X-2564	PDAC	INC424	606.8	23.4	80	189.5	-10
X-2564	PDAC	INC424	617.6	23.5	83	194.7	-9.6
X-2564	PDAC	INC424	640.8	23.8	86	205.7	-8.5
X-2564	PDAC	INC424	690.7	24.6	90	229.5	-5.4
X-2564	PDAC	INC424	720	24.2	93	243.5	-6.9
X-2564	PDAC	INC424	903.9	27.5	97	331.2	5.8
X-2564	PDAC	LEE011	213.5	26.5	0	0	0
X-2564	PDAC	LEE011	261.6	25.9	4	22.5	-2.3
X-2564	PDAC	LEE011	236.3	25.7	7	10.7	-3
X-2564	PDAC	LEE011	211.7	25.3	11	-0.8	-4.5
X-2564	PDAC	LEE011	266.5	26	14	24.8	-1.9
X-2564	PDAC	LEE011	272.6	26.9	18	27.7	1.5
X-2564	PDAC	LEE011	286.2	26.9	21	34.1	1.5
X-2564	PDAC	LEE011	280.4	28.7	25	31.3	8.3
X-2564	PDAC	LEE011	244	28.6	28	14.3	7.9
X-2564	PDAC	LEE011	279.6	27.8	32	31	4.9
X-2564	PDAC	LEE011	277.3	27.8	35	29.9	4.9
X-2564	PDAC	LEE011	247.2	27.5	39	15.8	3.8
X-2564	PDAC	LEE011	250.2	28	42	17.2	5.7
X-2564	PDAC	LEE011	232.7	28.1	46	9	6
X-2564	PDAC	LEE011	284.2	28.8	49	33.1	8.7
X-2564	PDAC	LEE011	248	28.3	54	16.2	6.8
X-2564	PDAC	LEE011	248.5	28.5	57	16.4	7.5
X-2564	PDAC	LEE011	275.2	28.8	60	28.9	8.7
X-2564	PDAC	LEE011	231.8	28.3	63	8.6	6.8
X-2564	PDAC	LEE011	228.4	28	67	7	5.7
X-2564	PDAC	LEE011	263.6	28.6	70	23.5	7.9
X-2564	PDAC	LEE011	268	28.2	74	25.5	6.4
X-2564	PDAC	LEE011	288.2	28.7	77	35	8.3
X-2564	PDAC	LEE011	257.6	29.1	81	20.7	9.8
X-2564	PDAC	LEE011	262.2	29.3	84	22.8	10.6
X-2564	PDAC	LEE011	319.7	28.7	89	49.7	8.3
X-2564	PDAC	LEE011	365.4	28.9	92	71.1	9.1
X-2564	PDAC	LEE011	368.5	28.6	95	72.6	7.9
X-2564	PDAC	LEE011	318.5	28.3	98	49.2	6.8
X-2564	PDAC	LEE011	438.6	28.9	102	105.4	9.1
X-2564	PDAC	LEE011	430.6	28.5	105	101.7	7.5
X-2564	PDAC	LEE011	464.7	29.2	109	117.7	10.2
X-2564	PDAC	LEE011	413.4	28.6	112	93.6	7.9
X-2564	PDAC	WNT974	245.9	31.5	0	0	0
X-2564	PDAC	WNT974	281.1	30.8	2	14.3	-2.2
X-2564	PDAC	WNT974	269.3	29.7	5	9.5	-5.7
X-2564	PDAC	WNT974	298.2	31	8	21.3	-1.6
X-2564	PDAC	WNT974	376.3	27.6	12	53	-12.4
X-2564	PDAC	LKA136	269.9	29.3	0	0	0
X-2564	PDAC	LKA136	273	29.3	2	1.1	0
X-2564	PDAC	LKA136	313.4	27.8	7	16.1	-5.1
X-2564	PDAC	LKA136	308.7	26.5	10	14.4	-9.6
X-2564	PDAC	LKA136	426.6	25.2	14	58.1	-14
X-2564	PDAC	binimetinib	235	25.4	0	0	0
X-2564	PDAC	binimetinib	355.6	24.8	4	51.3	-2.4
X-2564	PDAC	binimetinib	288.6	25.9	11	22.8	2
X-2564	PDAC	binimetinib	293.5	26.3	14	24.9	3.5
X-2564	PDAC	binimetinib	278.3	25.6	18	18.4	0.8
X-2564	PDAC	binimetinib	221.4	25.8	21	-5.8	1.6
X-2564	PDAC	binimetinib	157.5	26.5	25	-33	4.3
X-2564	PDAC	binimetinib	229.3	25.8	27	-2.4	1.6
X-2564	PDAC	binimetinib	173.1	24.3	32	-26.3	-4.3
X-2564	PDAC	binimetinib	146	25.3	34	-37.9	-0.4
X-2564	PDAC	binimetinib	163.2	24.7	39	-30.6	-2.8
X-2564	PDAC	binimetinib	298.7	24.7	42	27.1	-2.8
X-2564	PDAC	binimetinib	179.4	24.5	46	-23.7	-3.5
X-2564	PDAC	binimetinib	155	24.5	49	-34	-3.5
X-2564	PDAC	binimetinib	164.6	24.1	53	-30	-5.1
X-2564	PDAC	binimetinib	134.2	23.7	56	-42.9	-6.7
X-2564	PDAC	binimetinib	128.1	23.7	60	-45.5	-6.7
X-2564	PDAC	binimetinib	168.9	24.1	63	-28.1	-5.1
X-2564	PDAC	binimetinib-3.5mpk	213.9	25.7	0	0	0
X-2564	PDAC	binimetinib-3.5mpk	382.2	27.2	3	78.7	5.8
X-2564	PDAC	binimetinib-3.5mpk	375.5	26.7	7	75.5	3.9
X-2564	PDAC	binimetinib-3.5mpk	412.3	25.9	11	92.8	0.8
X-2564	PDAC	binimetinib-3.5mpk	286.2	26	15	33.8	1.2
X-2564	PDAC	binimetinib-3.5mpk	321.9	26	17	50.5	1.2
X-2564	PDAC	binimetinib-3.5mpk	356.4	24.9	21	66.6	-3.1
X-2564	PDAC	binimetinib-3.5mpk	353.5	24.7	25	65.3	-3.9
X-2564	PDAC	binimetinib-3.5mpk	322.5	25.7	29	50.8	0
X-2564	PDAC	binimetinib-3.5mpk	286.2	26.1	32	33.8	1.6
X-2564	PDAC	binimetinib-3.5mpk	347.4	26.7	36	62.4	3.9
X-2564	PDAC	binimetinib-3.5mpk	402.6	26	39	88.2	1.2
X-2564	PDAC	binimetinib-3.5mpk	404	26.6	43	88.9	3.5
X-2564	PDAC	binimetinib-3.5mpk	473.4	25.6	46	121.3	-0.4
X-2564	PDAC	binimetinib-3.5mpk	356.9	26.2	51	66.9	1.9
X-2564	PDAC	binimetinib-3.5mpk	476.6	26.3	56	122.8	2.3
X-2564	PDAC	binimetinib-3.5mpk	479.8	26.7	59	124.3	3.9
X-2564	PDAC	binimetinib-3.5mpk	535.9	25.7	63	150.5	0
X-2564	PDAC	binimetinib-3.5mpk	357	25.7	66	66.9	0
X-2564	PDAC	binimetinib-3.5mpk	333.9	25.9	70	56.1	0.8
X-2564	PDAC	binimetinib-3.5mpk	695.7	26.3	73	225.2	2.3
X-2564	PDAC	binimetinib-3.5mpk	503.7	26.3	78	135.5	2.3
X-2564	PDAC	binimetinib-3.5mpk	521.6	26.4	81	143.9	2.7
X-2564	PDAC	binimetinib-3.5mpk	588	26	86	174.9	1.2
X-2564	PDAC	trametinib	206.3	24.9	0	0	0
X-2564	PDAC	trametinib	288.8	26	4	40	4.4
X-2564	PDAC	trametinib	245.8	25.8	7	19.1	3.6
X-2564	PDAC	trametinib	215.4	26.6	11	4.4	6.8
X-2564	PDAC	trametinib	267.5	26	14	29.7	4.4
X-2564	PDAC	trametinib	261.2	25.6	18	26.6	2.8
X-2564	PDAC	trametinib	266.7	25.8	21	29.3	3.6
X-2564	PDAC	trametinib	243.6	25.1	25	18.1	0.8
X-2564	PDAC	trametinib	267.2	25.4	28	29.5	2
X-2564	PDAC	trametinib	170.4	26.1	32	-17.4	4.8
X-2564	PDAC	trametinib	268.6	25.8	35	30.2	3.6
X-2564	PDAC	trametinib	277.1	27	39	34.3	8.4
X-2564	PDAC	trametinib	208.9	26	41	1.3	4.4
X-2564	PDAC	trametinib	293.2	25.9	46	42.1	4
X-2564	PDAC	trametinib	344.2	26	49	66.8	4.4
X-2564	PDAC	trametinib	344.1	26.8	54	66.8	7.6
X-2564	PDAC	trametinib	361.9	26.2	57	75.4	5.2
X-2564	PDAC	trametinib	337.8	26.8	60	63.7	7.6
X-2564	PDAC	trametinib	336.9	24.6	63	63.3	-1.2
X-2564	PDAC	trametinib	455.4	25.5	67	120.7	2.4
X-2564	PDAC	trametinib	380.4	26.5	70	84.4	6.4
X-2564	PDAC	trametinib	535.9	25.7	74	159.8	3.2
X-2564	PDAC	untreated	211.2	26.7	0	0	0
X-2564	PDAC	untreated	226.9	25.2	1	7.4	-5.6
X-2564	PDAC	untreated	197	24.9	6	-6.7	-6.7
X-2564	PDAC	untreated	281.9	25.9	9	33.5	-3
X-2564	PDAC	untreated	307.3	25.3	13	45.5	-5.2
X-2564	PDAC	untreated	385.8	25.4	16	82.7	-4.9
X-2564	PDAC	untreated	485.7	24.6	19	130	-7.9
X-2564	PDAC	untreated	566.6	24.4	21	168.3	-8.6
X-2564	PDAC	untreated	772.9	24.4	27	266	-8.6
X-2564	PDAC	untreated	877.2	23.9	29	315.3	-10.5
X-2564	PDAC	untreated	913	23.2	34	332.3	-13.1
X-2564	PDAC	untreated	1099.9	22.5	37	420.8	-15.7
X-2573	CRC	5FU	229.2	21.9	0	0	0
X-2573	CRC	5FU	241	23.4	4	5.1	6.8
X-2573	CRC	5FU	244.5	22.8	8	6.7	4.1
X-2573	CRC	5FU	252.8	22.6	11	10.3	3.2
X-2573	CRC	5FU	310.8	23.6	15	35.6	7.8
X-2573	CRC	5FU	349.8	20.7	19	52.6	-5.5
X-2573	CRC	5FU	359.6	19.7	22	56.9	-10
X-2573	CRC	5FU	359	19.9	25	56.6	-9.1
X-2573	CRC	5FU	359.9	19.7	28	57	-10
X-2573	CRC	5FU	326.2	19.2	33	42.3	-12.3
X-2573	CRC	BKM120	227.9	25.2	0	0	0
X-2573	CRC	BKM120	236.3	24.4	3	3.7	-3.2
X-2573	CRC	BKM120	320.7	24.8	9	40.7	-1.6
X-2573	CRC	BKM120	430.8	25.2	14	89	0
X-2573	CRC	BKM120	598.6	26.2	18	162.7	4
X-2573	CRC	BKM120	1338.9	26.5	23	487.5	5.2
X-2573	CRC	BKM120 + LJC049	216.4	23.7	0	0	0
X-2573	CRC	BKM120 + LJC049	140.1	24.8	2	-35.3	4.6
X-2573	CRC	BKM120 + LJC049	102.7	24.5	7	-52.5	3.4
X-2573	CRC	BKM120 + LJC049	89.4	24.9	11	-58.7	5.1
X-2573	CRC	BKM120 + LJC049	80.4	23.6	16	-62.8	-0.4
X-2573	CRC	BKM120 + LJC049	107.2	22.4	21	-50.5	-5.5
X-2573	CRC	BKM120 + LJC049	135.5	21.6	25	-37.4	-8.9
X-2573	CRC	BKM120 + LJC049	137.5	19.1	30	-36.5	-19.4
X-2573	CRC	BYL719	287.5	26.6	0	0	0
X-2573	CRC	BYL719	264.6	27.5	2	-8	3.4
X-2573	CRC	BYL719	203	26	7	-29.4	-2.3
X-2573	CRC	BYL719	226	26.2	11	-21.4	-1.5
X-2573	CRC	BYL719	226.9	25.7	16	-21.1	-3.4
X-2573	CRC	BYL719	262.4	25.8	21	-8.7	-3
X-2573	CRC	BYL719	229.2	26.6	25	-20.3	0
X-2573	CRC	BYL719	184.8	27.3	30	-35.7	2.6
X-2573	CRC	BYL719	209.3	27.7	32	-27.2	4.1
X-2573	CRC	BYL719	213.5	29.3	36	-25.7	10.2
X-2573	CRC	BYL719	229	29.3	39	-20.3	10.2
X-2573	CRC	BYL719	243.4	29.9	42	-15.3	12.4
X-2573	CRC	BYL719	247.1	28.1	46	-14.1	5.6
X-2573	CRC	BYL719	251.3	27.5	52	-12.6	3.4
X-2573	CRC	BYL719	265.6	28.3	56	-7.6	6.4
X-2573	CRC	BYL719	265	28	60	-7.8	5.3
X-2573	CRC	BYL719	297	27.4	63	3.3	3
X-2573	CRC	BYL719	288.1	27.6	67	0.2	3.8
X-2573	CRC	BYL719	264	26.8	71	-8.2	0.8
X-2573	CRC	BYL719	237.3	27.2	74	-17.5	2.3
X-2573	CRC	BYL719	206.9	27.9	77	-28	4.9
X-2573	CRC	BYL719	268.9	28.3	80	-6.5	6.4
X-2573	CRC	BYL719	343.2	29.1	85	19.4	9.4
X-2573	CRC	BYL719	351.4	29.5	88	22.2	10.9
X-2573	CRC	BYL719	339.4	29.9	91	18.1	12.4
X-2573	CRC	BYL719 + LJM716	208	22.6	0	0	0
X-2573	CRC	BYL719 + LJM716	56.4	28.2	7	-72.9	24.8
X-2573	CRC	BYL719 + LJM716	73.8	27.8	11	-64.5	23
X-2573	CRC	BYL719 + LJM716	78.2	27.5	16	-62.4	21.7
X-2573	CRC	BYL719 + LJM716	76.2	27.6	21	-63.4	22.1
X-2573	CRC	BYL719 + LJM716	68.7	28.1	25	-67	24.3
X-2573	CRC	BYL719 + LJM716	65.3	26.9	30	-68.6	19
X-2573	CRC	BYL719 + LJM716	91.1	26.1	32	-56.2	15.5
X-2573	CRC	BYL719 + LJM716	110.2	27.9	36	-47	23.5
X-2573	CRC	BYL719 + LJM716	91.6	28.5	39	-56	26.1
X-2573	CRC	BYL719 + LJM716	97.8	28.5	42	-53	26.1
X-2573	CRC	BYL719 + LJM716	102.3	27.5	46	-50.8	21.7
X-2573	CRC	BYL719 + LJM716	75.4	25.5	52	-63.7	12.8
X-2573	CRC	BYL719 + LJM716	86.6	27.8	56	-58.4	23
X-2573	CRC	BYL719 + LJM716	123.1	28.9	58	-40.8	27.9
X-2573	CRC	BYL719 + binimetinib	278.5	24.3	0	0	0
X-2573	CRC	BYL719 + binimetinib	299.2	23.2	2	7.4	-4.5
X-2573	CRC	BYL719 + binimetinib	260.5	24.8	7	-6.5	2.1
X-2573	CRC	BYL719 + binimetinib	246.6	24.9	11	-11.5	2.5
X-2573	CRC	BYL719 + binimetinib	232.7	24.8	16	-16.4	2.1
X-2573	CRC	BYL719 + binimetinib	197.9	24.9	21	-28.9	2.5
X-2573	CRC	BYL719 + binimetinib	215	25.3	25	-22.8	4.1
X-2573	CRC	BYL719 + binimetinib	251.1	25.8	30	-9.8	6.2
X-2573	CRC	BYL719 + binimetinib	328.6	25	32	18	2.9
X-2573	CRC	BYL719 + binimetinib	324.5	25.6	36	16.5	5.3
X-2573	CRC	BYL719 + binimetinib	343.9	25.9	39	23.5	6.6
X-2573	CRC	BYL719 + binimetinib	335.7	24.9	42	20.5	2.5
X-2573	CRC	BYL719 + binimetinib	330.9	25.1	46	18.8	3.3
X-2573	CRC	BYL719 + binimetinib	384.9	24.4	52	38.2	0.4
X-2573	CRC	BYL719 + binimetinib	370	25.6	56	32.9	5.3
X-2573	CRC	BYL719 + binimetinib	371.2	25.1	60	33.3	3.3
X-2573	CRC	BYL719 + binimetinib	355.6	24.3	63	27.7	0
X-2573	CRC	BYL719 + binimetinib	344.3	24.9	67	23.6	2.5
X-2573	CRC	BYL719 + binimetinib	314.8	24.5	71	13	0.8
X-2573	CRC	BYL719 + binimetinib	395.2	26.9	74	41.9	10.7
X-2573	CRC	BYL719 + binimetinib	356.4	25.4	77	28	4.5
X-2573	CRC	BYL719 + binimetinib	321.1	25.2	80	15.3	3.7
X-2573	CRC	BYL719 + binimetinib	323.2	25.3	85	16.1	4.1
X-2573	CRC	BYL719 + binimetinib	311.6	25.5	88	11.9	4.9
X-2573	CRC	BYL719 + binimetinib	302.5	25.9	91	8.6	6.6
X-2573	CRC	BYL719 + encorafenib	197	20.5	0	0	0
X-2573	CRC	BYL719 + encorafenib	302.1	23	7	53.4	12.2
X-2573	CRC	BYL719 + encorafenib	345	22.6	16	75.1	10.2
X-2573	CRC	BYL719 + encorafenib	368.9	20.7	25	87.3	1
X-2573	CRC	BYL719 + encorafenib	293.9	20.3	30	49.2	-1
X-2573	CRC	BYL719 + encorafenib	267.7	19.5	32	35.9	-4.9
X-2573	CRC	BYL719 + encorafenib	277.5	20.2	36	40.9	-1.5
X-2573	CRC	BYL719 + encorafenib	261.4	19.7	39	32.7	-3.9
X-2573	CRC	BYL719 + encorafenib	282.7	19.7	42	43.5	-3.9
X-2573	CRC	BYL719 + encorafenib	281.9	19.6	46	43.1	-4.4
X-2573	CRC	BYL719 + encorafenib	334.5	19.7	52	69.8	-3.9
X-2573	CRC	BYL719 + encorafenib	311.9	19.4	56	58.3	-5.4
X-2573	CRC	BYL719 + encorafenib	326.6	18.3	58	65.8	-10.7
X-2573	CRC	BYL719 + cetuximab + encorafenib	198.4	25.2	0	0	0
X-2573	CRC	BYL719 + cetuximab + encorafenib	203.4	24.9	4	2.5	-1.2
X-2573	CRC	BYL719 + cetuximab + encorafenib	168.3	24.7	9	-15.2	-2
X-2573	CRC	BYL719 + cetuximab + encorafenib	161.8	24	14	-18.4	-4.8
X-2573	CRC	BYL719 + cetuximab + encorafenib	163.1	25.1	18	-17.8	-0.4
X-2573	CRC	BYL719 + cetuximab + encorafenib	181.8	24.4	23	-8.4	-3.2
X-2573	CRC	BYL719 + cetuximab + encorafenib	151.5	24.4	25	-23.6	-3.2
X-2573	CRC	BYL719 + cetuximab + encorafenib	182.4	24	29	-8.1	-4.8
X-2573	CRC	BYL719 + cetuximab + encorafenib	279.6	23.9	32	40.9	-5.2
X-2573	CRC	BYL719 + cetuximab + encorafenib	287.2	24	35	44.8	-4.8
X-2573	CRC	BYL719 + cetuximab + encorafenib	284.5	24	39	43.4	-4.8
X-2573	CRC	BYL719 + cetuximab + encorafenib	294.3	23.2	45	48.3	-7.9
X-2573	CRC	BYL719 + cetuximab + encorafenib	321.3	23.2	49	61.9	-7.9
X-2573	CRC	BYL719 + cetuximab + encorafenib	344.8	23.3	53	73.8	-7.5
X-2573	CRC	BYL719 + cetuximab + encorafenib	397.5	22.8	56	100.4	-9.5
X-2573	CRC	BYL719 + cetuximab + encorafenib	488.6	24.2	60	146.3	-4
X-2573	CRC	BYL719 + cetuximab + encorafenib	496.3	22.9	64	150.2	-9.1
X-2573	CRC	BYL719 + cetuximab + encorafenib	576.5	23.6	67	190.6	-6.3
X-2573	CRC	BYL719 + cetuximab + encorafenib	607.5	23.3	70	206.2	-7.5
X-2573	CRC	BYL719 + cetuximab + encorafenib	523	22.7	73	163.6	-9.9
X-2573	CRC	BYL719 + cetuximab	248	26.6	0	0	0
X-2573	CRC	BYL719 + cetuximab	211	26.9	4	-14.9	1.1
X-2573	CRC	BYL719 + cetuximab	152.5	26.4	9	-38.5	-0.8
X-2573	CRC	BYL719 + cetuximab	191.7	26.8	14	-22.7	0.8
X-2573	CRC	BYL719 + cetuximab	177.1	27.1	18	-28.6	1.9
X-2573	CRC	BYL719 + cetuximab	156.4	27.1	23	-36.9	1.9
X-2573	CRC	BYL719 + cetuximab	174.8	26.7	25	-29.5	0.4
X-2573	CRC	BYL719 + cetuximab	187.4	27.1	29	-24.4	1.9
X-2573	CRC	BYL719 + cetuximab	195.7	27.1	32	-21.1	1.9
X-2573	CRC	BYL719 + cetuximab	199.8	26.5	35	-19.4	-0.4
X-2573	CRC	BYL719 + cetuximab	210.8	27.3	39	-15	2.6
X-2573	CRC	BYL719 + cetuximab	189.1	27.8	45	-23.8	4.5
X-2573	CRC	BYL719 + cetuximab	233.3	27.9	49	-5.9	4.9
X-2573	CRC	BYL719 + cetuximab	238.9	28.7	53	-3.7	7.9
X-2573	CRC	BYL719 + cetuximab	214.6	24.7	56	-13.5	-7.1
X-2573	CRC	BYL719 + cetuximab	233.1	28.3	60	-6	6.4
X-2573	CRC	BYL719 + cetuximab	256.2	27.3	64	3.3	2.6
X-2573	CRC	BYL719 + cetuximab	250.4	24.9	67	1	-6.4
X-2573	CRC	BYL719 + cetuximab	236.5	24	70	-4.6	-9.8
X-2573	CRC	BYL719 + cetuximab	223	23.8	73	-10.1	-10.5
X-2573	CRC	BYL719 + cetuximab	247.3	23.1	77	-0.3	-13.2
X-2573	CRC	CGM097	211	21.4	0	0	0
X-2573	CRC	CGM097	311.6	18.8	3	47.7	-12.1
X-2573	CRC	CGM097	280.6	20.7	9	33	-3.3
X-2573	CRC	CGM097	353.8	22.4	14	67.7	4.7
X-2573	CRC	CGM097	457.8	20.2	18	117	-5.6
X-2573	CRC	CGM097	707.8	19.9	23	235.5	-7
X-2573	CRC	CGM097	743.2	20.3	28	252.2	-5.1
X-2573	CRC	CKX620	237.3	24.1	0	0	0
X-2573	CRC	CKX620	249.6	24.1	3	5.2	0
X-2573	CRC	CKX620	392.8	24.1	9	65.5	0
X-2573	CRC	CKX620	311.8	23.2	14	31.4	-3.7
X-2573	CRC	CKX620	310	22.6	18	30.6	-6.2
X-2573	CRC	CKX620	334.9	21.2	23	41.1	-12
X-2573	CRC	CKX620	402.4	25.5	28	69.6	5.8
X-2573	CRC	CLR457	233.2	25.4	0	0	0
X-2573	CRC	CLR457	171.5	23.2	2	-26.5	-8.7
X-2573	CRC	CLR457	177.8	22.9	7	-23.8	-9.8
X-2573	CRC	CLR457	196.5	22.4	11	-15.7	-11.8
X-2573	CRC	CLR457	166.3	22	16	-28.7	-13.4
X-2573	CRC	CLR457	214.6	23.1	21	-8	-9.1
X-2573	CRC	CLR457	343	22.6	25	47.1	-11
X-2573	CRC	CLR457	331.3	25	30	42.1	-1.6
X-2573	CRC	HDM201	250.7	21.1	0	0	0
X-2573	CRC	HDM201	237	21.3	2	-5.5	0.9
X-2573	CRC	HDM201	356.8	20.2	7	42.3	-4.3
X-2573	CRC	HDM201	422.1	19.7	11	68.4	-6.6
X-2573	CRC	HDM201	491	19.6	16	95.9	-7.1
X-2573	CRC	HDM201	665.4	24.1	21	165.4	14.2
X-2573	CRC	HDM201	863.3	24.1	24	244.4	14.2
X-2573	CRC	cetuximab	254.6	21.2	0	0	0
X-2573	CRC	cetuximab	324.4	21.2	3	27.4	0
X-2573	CRC	cetuximab	370.1	21.1	9	45.4	-0.5
X-2573	CRC	cetuximab	332.4	20.8	14	30.6	-1.9
X-2573	CRC	cetuximab	329.3	20.8	18	29.3	-1.9
X-2573	CRC	cetuximab	365.4	21	23	43.5	-0.9
X-2573	CRC	cetuximab	410.4	21.2	28	61.2	0
X-2573	CRC	cetuximab + encorafenib	130.8	25.3	0	0	0
X-2573	CRC	cetuximab + encorafenib	127.7	25.1	4	-2.4	-0.8
X-2573	CRC	cetuximab + encorafenib	134.8	24	9	3.1	-5.1
X-2573	CRC	cetuximab + encorafenib	167.3	23.1	14	27.9	-8.7
X-2573	CRC	cetuximab + encorafenib	174.6	24.7	18	33.5	-2.4
X-2573	CRC	cetuximab + encorafenib	174.9	23.8	23	33.7	-5.9
X-2573	CRC	cetuximab + encorafenib	204.3	22.8	25	56.2	-9.9
X-2573	CRC	cetuximab + encorafenib	186.7	22.9	29	42.7	-9.5
X-2573	CRC	cetuximab + encorafenib	242.1	22.8	32	85.1	-9.9
X-2573	CRC	cetuximab + encorafenib	254.6	22.5	35	94.6	-11.1
X-2573	CRC	cetuximab + encorafenib	276.5	23.6	39	111.4	-6.7
X-2573	CRC	cetuximab + encorafenib	229.2	24	45	75.2	-5.1
X-2573	CRC	cetuximab + encorafenib	258.2	24.9	49	97.4	-1.6
X-2573	CRC	cetuximab + encorafenib	227.4	25.2	53	73.9	-0.4
X-2573	CRC	LEE011	206.4	21.6	0	0	0
X-2573	CRC	LEE011	177.8	24.5	2	-13.9	13.4
X-2573	CRC	LEE011	322.2	20.7	7	56.1	-4.2
X-2573	CRC	LEE011	350.9	21.4	11	70	-0.9
X-2573	CRC	LEE011	567.5	21.1	16	175	-2.3
X-2573	CRC	LEE011	513.7	22.1	21	148.9	2.3
X-2573	CRC	LEE011	507.1	21.7	24	145.7	0.5
X-2573	CRC	encorafenib	225.9	22.5	0	0	0
X-2573	CRC	encorafenib	254.8	22	3	12.8	-2.2
X-2573	CRC	encorafenib	393.3	21.9	9	74.1	-2.7
X-2573	CRC	encorafenib	399	21.5	14	76.6	-4.4
X-2573	CRC	encorafenib	380.2	21.7	18	68.3	-3.6
X-2573	CRC	encorafenib	428	20.8	23	89.5	-7.6
X-2573	CRC	LJC049	218.2	22.7	0	0	0
X-2573	CRC	LJC049	341.9	23.2	3	56.7	2.2
X-2573	CRC	LJC049	547.5	22.5	9	150.9	-0.9
X-2573	CRC	LJC049	509.5	22.4	14	133.5	-1.3
X-2573	CRC	LJC049	580.4	23.6	18	166	4
X-2573	CRC	LJC049	669.9	23.1	23	207	1.8
X-2573	CRC	LKA136	212.9	20	0	0	0
X-2573	CRC	LKA136	370.6	18.9	3	74.1	-5.5
X-2573	CRC	LKA136	454	18.3	9	113.2	-8.5
X-2573	CRC	LKA136	509.7	20.8	14	139.4	4
X-2573	CRC	LKA136	885.2	20.7	18	315.8	3.5
X-2573	CRC	LKA136	990.6	21.2	23	365.3	6
X-2573	CRC	binimetinib	247.7	21.5	0	0	0
X-2573	CRC	binimetinib	346.9	21.8	9	40	1.4
X-2573	CRC	binimetinib	170.6	20.8	14	-31.1	-3.3
X-2573	CRC	binimetinib	183.6	20.9	18	-25.9	-2.8
X-2573	CRC	binimetinib	183	21	23	-26.1	-2.3
X-2573	CRC	binimetinib	184.2	21	28	-25.6	-2.3
X-2573	CRC	binimetinib	281.3	21.2	32	13.6	-1.4
X-2573	CRC	binimetinib	288	21.8	37	16.3	1.4
X-2573	CRC	binimetinib	269.8	23.4	39	8.9	8.8
X-2573	CRC	binimetinib	295.6	21.1	43	19.3	-1.9
X-2573	CRC	binimetinib	336	21	46	35.6	-2.3
X-2573	CRC	binimetinib	389.8	21.2	49	57.4	-1.4
X-2573	CRC	binimetinib	417.9	21.2	53	68.7	-1.4
X-2573	CRC	binimetinib	363.2	21.4	59	46.6	-0.5
X-2573	CRC	binimetinib	317	21.8	63	28	1.4
X-2573	CRC	binimetinib	423.8	21.8	67	71.1	1.4
X-2573	CRC	binimetinib	423.6	21	70	71	-2.3
X-2573	CRC	binimetinib	471	21.7	74	90.1	0.9
X-2573	CRC	binimetinib	624.4	21.4	78	152.1	-0.5
X-2573	CRC	binimetinib	598.9	21.2	81	141.8	-1.4
X-2573	CRC	binimetinib	613.1	21.6	84	147.5	0.5
X-2573	CRC	binimetinib	584.4	20.7	87	135.9	-3.7
X-2573	CRC	binimetinib	572	21.2	92	130.9	-1.4
X-2573	CRC	untreated	314.6	24.5	0	0	0
X-2573	CRC	untreated	432.3	23.4	3	37.4	-4.5
X-2573	CRC	untreated	687.9	24.1	9	118.7	-1.6
X-2573	CRC	untreated	1167	23.7	14	270.9	-3.3
X-2573	CRC	untreated	1311	26.1	18	316.7	6.5
X-2573	CRC	untreated	1412.3	25.8	23	348.9	5.3
X-2573	CRC	LFW527 + binimetinib	226.7	24.64	0	0	0
X-2573	CRC	LFW527 + binimetinib	238.88	23.17	3	5.4	-6
X-2573	CRC	LFW527 + binimetinib	194.75	23.4	7	-14.1	-5
X-2573	CRC	LFW527 + binimetinib	248.92	24.38	10	9.8	-1.1
X-2573	CRC	LFW527 + binimetinib	225.64	26.84	15	-0.5	8.9
X-2573	CRC	LFW527 + binimetinib	265.02	24.3	18	16.9	-1.4
X-2573	CRC	LFW527 + binimetinib	230.57	23.88	21	1.7	-3.1
X-2573	CRC	LFW527 + binimetinib	213.77	23.82	24	-5.7	-3.3
X-2573	CRC	LFW527 + binimetinib	253.22	24.7	28	11.7	0.2
X-2573	CRC	LFW527 + binimetinib	339.65	24.78	31	49.8	0.6
X-2573	CRC	LFW527 + binimetinib	307.73	24.77	34	35.7	0.5
X-2573	CRC	LFW527 + binimetinib	332.67	24.8	38	46.7	0.6
X-2573	CRC	LFW527 + binimetinib	366.15	25.87	42	61.5	5
X-2573	CRC	LFW527 + binimetinib	306.62	24.67	45	35.3	0.1
X-2573	CRC	LFW527 + binimetinib	288.82	24.98	49	27.4	1.4
X-2573	CRC	LFW527 + binimetinib	293.51	23.82	52	29.5	-3.3
X-2573	CRC	LFW527 + binimetinib	334.6	24.87	56	47.6	0.9
X-2573	CRC	LFW527 + binimetinib	361.18	24.7	59	59.3	0.2
X-2573	CRC	LFW527 + binimetinib	568.63	24.2	63	150.8	-1.8
X-2573	CRC	LFW527 + binimetinib	425.75	23.08	67	87.8	-6.3
X-2573	CRC	LFW527 + binimetinib	388.84	23.75	69	71.5	-3.6
X-2573	CRC	LFW527 + binimetinib	365.27	24.06	74	61.1	-2.4
X-2573	CRC	LFW527 + binimetinib	348.51	23.35	77	53.7	-5.2
X-2573	CRC	LFW527 + binimetinib	371.71	23.85	80	64	-3.2
X-2573	CRC	LFW527 + binimetinib	372.92	23.03	82	64.5	-6.5
X-2573	CRC	LFW527 + binimetinib	436.9	23.56	88	92.7	-4.4
X-2573	CRC	LFW527 + binimetinib	429.29	23.26	91	89.4	-5.6
X-2573	CRC	LFW527 + binimetinib	428.03	23.87	96	88.8	-3.1
X-2573	CRC	LFW527 + binimetinib	424.68	22.81	98	87.3	-7.4
X-2573	CRC	LFW527 + binimetinib	393.93	23.16	102	73.8	-6
X-2573	CRC	LFW527 + binimetinib	387.11	24.4	105	70.8	-1
X-2573	CRC	LFW527 + binimetinib	432.57	22.87	109	90.8	-7.2
X-2573	CRC	LFW527 + binimetinib	474.15	23.37	112	109.2	-5.2
X-2573	CRC	LFW527 + binimetinib	496.55	23.35	116	119	-5.2
X-2573	CRC	LFW527 + binimetinib	551.37	24.44	119	143.2	-0.8
X-2573	CRC	LFW527 + binimetinib	493.62	23.8	123	117.7	-3.4
X-2573	CRC	LFW527 + binimetinib	516.97	23.96	126	128	-2.8
X-2573	CRC	LFW527 + binimetinib	502.86	22.79	130	121.8	-7.5
X-2573	CRC	LFW527 + binimetinib	546.37	23.06	132	141	-6.4
X-2573	CRC	LFW527 + binimetinib	663.8	22.78	136	192.8	-7.5
X-2573	CRC	LFW527 + binimetinib	689.59	23.08	138	204.2	-6.3
X-2573	CRC	LFW527 + binimetinib	648.52	22.26	144	186.1	-9.7
X-2573	CRC	LFW527 + binimetinib	707.84	22.47	147	212.2	-8.8
X-2602	CM	BKM120	185	25.9	0	0	0
X-2602	CM	BKM120	206.7	25.5	3	11.7	-1.5
X-2602	CM	BKM120	227.3	26.7	6	22.9	3.1
X-2602	CM	BKM120	236.3	26.9	9	27.7	3.9
X-2602	CM	BKM120	245.5	27.4	12	32.7	5.8
X-2602	CM	BKM120	257	28.4	15	39	9.7
X-2602	CM	BKM120	260.9	28	19	41	8.1
X-2602	CM	BKM120	287.1	28.4	24	55.2	9.7
X-2602	CM	BKM120	270.7	28.9	27	46.4	11.6
X-2602	CM	BKM120	308.4	29.5	31	66.7	13.9
X-2602	CM	BKM120	316	29.5	34	70.9	13.9
X-2602	CM	BKM120	308.4	29.4	37	66.7	13.5
X-2602	CM	BKM120 + encorafenib	208.3	26	0	0	0
X-2602	CM	BKM120 + encorafenib	187.3	25.6	6	-10.1	-1.5
X-2602	CM	BKM120 + encorafenib	151.2	25.7	9	-27.4	-1.2
X-2602	CM	BKM120 + encorafenib	158.4	26.2	13	-23.9	0.8
X-2602	CM	BKM120 + encorafenib	163.4	26.7	16	-21.6	2.7
X-2602	CM	BKM120 + encorafenib	170.7	26.3	20	-18	1.2
X-2602	CM	BKM120 + encorafenib	172	26.1	24	-17.4	0.4
X-2602	CM	BKM120 + encorafenib	156.3	25.8	28	-25	-0.8
X-2602	CM	BKM120 + encorafenib	208.1	26.7	31	-0.1	2.7
X-2602	CM	BKM120 + encorafenib	174.1	25.6	34	-16.4	-1.5
X-2602	CM	BKM120 + encorafenib	193	26.9	39	-7.3	3.5
X-2602	CM	BKM120 + encorafenib	238.5	26.8	44	14.5	3.1
X-2602	CM	BKM120 + encorafenib	261.6	26.8	50	25.6	3.1
X-2602	CM	BKM120 + encorafenib	258.8	26.5	56	24.2	1.9
X-2602	CM	BKM120 + encorafenib	262.9	27.1	63	26.2	4.2
X-2602	CM	BKM120 + encorafenib	261.1	27	69	25.4	3.8
X-2602	CM	BKM120 + encorafenib	272.8	27	74	31	3.8
X-2602	CM	BKM120 + encorafenib	260.1	26	80	24.9	0
X-2602	CM	BKM120 + encorafenib	245.1	26	86	17.7	0
X-2602	CM	BKM120 + encorafenib	223	27.1	92	7.1	4.2
X-2602	CM	BKM120 + encorafenib	208.1	27.2	99	-0.1	4.6
X-2602	CM	BKM120 + encorafenib	220.5	26.4	103	5.9	1.5
X-2602	CM	BKM120 + encorafenib	233.3	27.1	108	12	4.2
X-2602	CM	BKM120 + encorafenib	243.7	26.8	113	17	3.1
X-2602	CM	BKM120 + encorafenib	283	27.9	120	35.9	7.3
X-2602	CM	BKM120 + encorafenib	298.1	27.4	125	43.2	5.4
X-2602	CM	BKM120 + encorafenib	302.4	27.1	133	45.2	4.2
X-2602	CM	BKM120 + encorafenib	285.9	27.9	141	37.3	7.3
X-2602	CM	BKM120 + encorafenib	304.2	28.1	149	46.1	8.1
X-2602	CM	BKM120 + encorafenib	358.2	28	155	72	7.7
X-2602	CM	BKM120 + encorafenib	312.1	28.8	160	49.8	10.8
X-2602	CM	BKM120 + encorafenib	278.7	29.2	167	33.8	12.3
X-2602	CM	BKM120 + encorafenib	393.6	28.2	176	89	8.5
X-2602	CM	BKM120 + encorafenib	401.2	28.2	180	92.6	8.5
X-2602	CM	CGM097	194.4	22.1	0	0	0
X-2602	CM	CGM097	244.7	21.5	4	25.9	-2.7
X-2602	CM	CGM097	288	21.1	7	48.1	-4.5
X-2602	CM	CGM097	366.9	21.2	10	88.7	-4.1
X-2602	CM	CGM097	353	21	13	81.6	-5
X-2602	CM	CGM097	386.5	21.8	16	98.8	-1.4
X-2602	CM	CGM097	408.7	21.5	19	110.3	-2.7
X-2602	CM	CGM097	414.2	21.4	23	113.1	-3.2
X-2602	CM	CGM097	453.6	21.5	28	133.3	-2.7
X-2602	CM	CGM097	443.6	19.7	31	128.2	-10.9
X-2602	CM	CGM097	467.1	18.4	35	140.3	-16.7
X-2602	CM	dacarbazine	221.8	24.4	0	0	0
X-2602	CM	dacarbazine	310.7	23	3	40.1	-5.7
X-2602	CM	dacarbazine	356.5	22.8	7	60.7	-6.6
X-2602	CM	dacarbazine	380.2	21.4	10	71.4	-12.3
X-2602	CM	dacarbazine	376.7	19.8	13	69.8	-18.9
X-2602	CM	LDE225	208.1	22.2	0	0	0
X-2602	CM	LDE225	249.4	21.7	4	19.9	-2.3
X-2602	CM	LDE225	299.9	22.6	7	44.1	1.8
X-2602	CM	LDE225	278.4	23	10	33.8	3.6
X-2602	CM	LDE225	321.5	22	14	54.5	-0.9
X-2602	CM	LDE225	380.9	21	19	83.1	-5.4
X-2602	CM	LDE225	392.9	20.5	22	88.8	-7.7
X-2602	CM	LDE225	479.9	21.6	26	130.6	-2.7
X-2602	CM	LDE225	478.3	20.9	29	129.9	-5.9
X-2602	CM	LDE225	477.1	20.6	33	129.3	-7.2
X-2602	CM	LDK378	199.8	24.2	0	0	0
X-2602	CM	LDK378	221.2	24	4	10.7	-0.8
X-2602	CM	LDK378	305.1	25	7	52.7	3.3
X-2602	CM	LDK378	316.9	25	10	58.6	3.3
X-2602	CM	LDK378	352	25.2	14	76.1	4.1
X-2602	CM	LDK378	488.5	25.5	19	144.4	5.4
X-2602	CM	LDK378	504.2	26.5	22	152.3	9.5
X-2602	CM	LDK378	560	27.7	26	180.2	14.5
X-2602	CM	LDK378	575	28.2	29	187.7	16.5
X-2602	CM	LDK378	621.9	27.4	33	211.2	13.2
X-2602	CM	LEE011	190.4	27.4	0	0	0
X-2602	CM	LEE011	219	26	3	15	-5.1
X-2602	CM	LEE011	213.2	26.8	6	11.9	-2.2
X-2602	CM	LEE011	171.1	26.3	9	-10.2	-4
X-2602	CM	LEE011	185.7	27.5	12	-2.5	0.4
X-2602	CM	LEE011	175.7	28.4	15	-7.7	3.6
X-2602	CM	LEE011	196	28.6	19	2.9	4.4
X-2602	CM	LEE011	200	28.6	24	5	4.4
X-2602	CM	LEE011	188.5	29	27	-1	5.8
X-2602	CM	LEE011	204.8	29.7	31	7.5	8.4
X-2602	CM	LEE011	178	29.8	34	-6.5	8.8
X-2602	CM	LEE011	185.7	28.7	38	-2.5	4.7
X-2602	CM	LEE011	185	29.5	41	-2.9	7.7
X-2602	CM	LEE011	175.7	29.1	45	-7.7	6.2
X-2602	CM	LEE011	196	29.4	48	2.9	7.3
X-2602	CM	LEE011	195.2	29.6	51	2.5	8
X-2602	CM	LEE011	196.5	30.7	56	3.2	12
X-2602	CM	LEE011	234.5	30.2	61	23.1	10.2
X-2602	CM	LEE011	225.5	31.3	67	18.4	14.2
X-2602	CM	LEE011	231.8	30.4	73	21.7	10.9
X-2602	CM	LEE011	229.2	31.8	80	20.3	16.1
X-2602	CM	LEE011	229.2	32.5	86	20.3	18.6
X-2602	CM	LEE011	212.5	31.1	91	11.6	13.5
X-2602	CM	LEE011	206.7	29	97	8.5	5.8
X-2602	CM	LEE011	207.4	30.2	103	8.9	10.2
X-2602	CM	LEE011	201.6	30	109	5.9	9.5
X-2602	CM	LEE011	176.4	31	116	-7.4	13.1
X-2602	CM	LEE011	189	31.8	120	-0.7	16.1
X-2602	CM	LEE011	219	31.6	125	15	15.3
X-2602	CM	LEE011	230	30.7	131	20.8	12
X-2602	CM	LEE011	257.9	32	138	35.4	16.8
X-2602	CM	LEE011	268.4	31.4	143	40.9	14.6
X-2602	CM	LEE011	278.4	31	151	46.2	13.1
X-2602	CM	LEE011	280.9	32.5	159	47.5	18.6
X-2602	CM	LEE011	273.8	32.8	167	43.8	19.7
X-2602	CM	LEE011	210.7	34.2	173	10.6	24.8
X-2602	CM	LEE011	251.3	33.5	178	31.9	22.3
X-2602	CM	LEE011	208.3	33.4	180	9.4	21.9
X-2602	CM	LEE011 + encorafenib	196	27.6	0	0	0
X-2602	CM	LEE011 + encorafenib	196	27.4	6	0	-0.7
X-2602	CM	LEE011 + encorafenib	217.8	28.4	9	11.1	2.9
X-2602	CM	LEE011 + encorafenib	180.7	29.3	13	-7.8	6.2
X-2602	CM	LEE011 + encorafenib	185.9	30	16	-5.2	8.7
X-2602	CM	LEE011 + encorafenib	163.4	30	20	-16.6	8.7
X-2602	CM	LEE011 + encorafenib	157.6	29.2	24	-19.6	5.8
X-2602	CM	LEE011 + encorafenib	149.9	29	28	-23.5	5.1
X-2602	CM	LEE011 + encorafenib	164.7	29	31	-16	5.1
X-2602	CM	LEE011 + encorafenib	157.6	29.2	34	-19.6	5.8
X-2602	CM	LEE011 + encorafenib	172.1	30.9	39	-12.2	12
X-2602	CM	LEE011 + encorafenib	201.6	29.6	44	2.9	7.2
X-2602	CM	LEE011 + encorafenib	244.7	29.7	50	24.8	7.6
X-2602	CM	LEE011 + encorafenib	264.7	29.9	56	35	8.3
X-2602	CM	LEE011 + encorafenib	255	29.9	62	30.1	8.3
X-2602	CM	LEE011 + encorafenib	235.5	30.8	69	20.1	11.6
X-2602	CM	LEE011 + encorafenib	222.9	30	74	13.7	8.7
X-2602	CM	LEE011 + encorafenib	203.4	29.2	80	3.7	5.8
X-2602	CM	LEE011 + encorafenib	203.4	28.5	86	3.7	3.3
X-2602	CM	LEE011 + encorafenib	196	29.1	92	0	5.4
X-2602	CM	LEE011 + encorafenib	196	29.1	99	0	5.4
X-2602	CM	LEE011 + encorafenib	196	29	103	0	5.1
X-2602	CM	LEE011 + encorafenib	196	29.1	108	0	5.4
X-2602	CM	LEE011 + encorafenib	196	28.7	113	0	4
X-2602	CM	LEE011 + encorafenib	203.4	30.7	120	3.7	11.2
X-2602	CM	LEE011 + encorafenib	200.9	29.1	125	2.5	5.4
X-2602	CM	LEE011 + encorafenib	196	29.7	133	0	7.6
X-2602	CM	LEE011 + encorafenib	204.8	29.9	141	4.5	8.3
X-2602	CM	LEE011 + encorafenib	205.8	29.3	149	5	6.2
X-2602	CM	LEE011 + encorafenib	228.1	30.4	155	16.4	10.1
X-2602	CM	LEE011 + encorafenib	210.7	29.7	160	7.5	7.6
X-2602	CM	LEE011 + encorafenib	210.7	25.1	165	7.5	-9.1
X-2602	CM	WNT974	211.7	23.4	0	0	0
X-2602	CM	WNT974	254.1	24.6	3	20	5.1
X-2602	CM	WNT974	296.5	24.5	7	40	4.7
X-2602	CM	WNT974	293.3	25	12	38.5	6.8
X-2602	CM	WNT974	300.4	26	15	41.9	11.1
X-2602	CM	WNT974	386.5	25	20	82.6	6.8
X-2602	CM	WNT974	388.1	24.5	23	83.3	4.7
X-2602	CM	WNT974	417.9	23.3	27	97.4	-0.4
X-2602	CM	LGW813	182.7	26.9	0	0	0
X-2602	CM	LGW813	210	26.2	3	14.9	-2.6
X-2602	CM	LGW813	215.8	27.3	6	18.2	1.5
X-2602	CM	LGW813	224.5	26.8	9	22.9	-0.4
X-2602	CM	LGW813	272	27.4	12	48.9	1.9
X-2602	CM	LGW813	288	26.6	15	57.7	-1.1
X-2602	CM	LGW813	300.8	27.5	19	64.7	2.2
X-2602	CM	LGW813	299.6	27.2	24	64	1.1
X-2602	CM	LGW813	310.4	27.4	27	69.9	1.9
X-2602	CM	LGW813	369.8	28	31	102.5	4.1
X-2602	CM	LGW813	384.6	27.9	34	110.6	3.7
X-2602	CM	LGW813	402.7	27.2	37	120.5	1.1
X-2602	CM	encorafenib	202.3	23.9	0	0	0
X-2602	CM	encorafenib	211.7	24.4	4	4.6	2.1
X-2602	CM	encorafenib	239.7	24	7	18.5	0.4
X-2602	CM	encorafenib	236.3	24.7	10	16.8	3.3
X-2602	CM	encorafenib	244.7	24	13	20.9	0.4
X-2602	CM	encorafenib	257.9	24.8	16	27.5	3.8
X-2602	CM	encorafenib	255.5	25.5	19	26.3	6.7
X-2602	CM	encorafenib	245.5	25.2	23	21.3	5.4
X-2602	CM	encorafenib	223.8	26	28	10.6	8.8
X-2602	CM	encorafenib	207.4	26.7	31	2.5	11.7
X-2602	CM	encorafenib	213.2	26.3	35	5.3	10
X-2602	CM	encorafenib	212.5	25.9	38	5	8.4
X-2602	CM	encorafenib	200.9	25.7	42	-0.7	7.5
X-2602	CM	encorafenib	175.1	25.7	46	-13.5	7.5
X-2602	CM	encorafenib	200.9	25.2	50	-0.7	5.4
X-2602	CM	encorafenib	279.9	24.8	53	38.3	3.8
X-2602	CM	encorafenib	386.5	24.9	56	91	4.2
X-2602	CM	encorafenib	399.4	26.3	61	97.4	10
X-2602	CM	encorafenib	461.3	26.4	66	128	10.5
X-2602	CM	encorafenib	575	26.6	72	184.2	11.3
X-2602	CM	encorafenib	610	25.6	78	201.5	7.1
X-2602	CM	encorafenib	744.2	26.1	85	267.8	9.2
X-2602	CM	encorafenib	865.2	27	91	327.6	13
X-2602	CM	encorafenib	847	27.4	96	318.6	14.6
X-2602	CM	encorafenib	862.5	27	98	326.2	13
X-2602	CM	encorafenib + binimetinib	205.2	24.5	0	0	0
X-2602	CM	encorafenib + binimetinib	171.1	24.3	6	-16.6	-0.8
X-2602	CM	encorafenib + binimetinib	154.2	24.4	9	-24.8	-0.4
X-2602	CM	encorafenib + binimetinib	136.9	25.4	13	-33.3	3.7
X-2602	CM	encorafenib + binimetinib	129	23.8	16	-37.1	-2.9
X-2602	CM	encorafenib + binimetinib	131	24	20	-36.2	-2
X-2602	CM	encorafenib + binimetinib	111.4	23.6	24	-45.7	-3.7
X-2602	CM	encorafenib + binimetinib	111.6	24	28	-45.6	-2
X-2602	CM	encorafenib + binimetinib	123	24.4	31	-40	-0.4
X-2602	CM	encorafenib + binimetinib	123	24.6	34	-40	0.4
X-2602	CM	encorafenib + binimetinib	117.2	25	39	-42.9	2
X-2602	CM	encorafenib + binimetinib	128.8	24.1	44	-37.2	-1.6
X-2602	CM	encorafenib + binimetinib	147.5	23.8	50	-28.1	-2.9
X-2602	CM	encorafenib + binimetinib	158.4	24.9	56	-22.8	1.6
X-2602	CM	encorafenib + binimetinib	168.3	25.1	62	-18	2.4
X-2602	CM	encorafenib + binimetinib	158.4	24.7	69	-22.8	0.8
X-2602	CM	encorafenib + binimetinib	154.2	25	74	-24.8	2
X-2602	CM	encorafenib + binimetinib	152.1	24.3	80	-25.9	-0.8
X-2602	CM	encorafenib + binimetinib	150	24.7	86	-26.9	0.8
X-2602	CM	encorafenib + binimetinib	147.9	25	92	-27.9	2
X-2602	CM	encorafenib + binimetinib	147.9	24.8	99	-27.9	1.2
X-2602	CM	encorafenib + binimetinib	147.9	24.8	103	-27.9	1.2
X-2602	CM	encorafenib + binimetinib	154.6	25.2	108	-24.6	2.9
X-2602	CM	encorafenib + binimetinib	163.9	25.1	113	-20.1	2.4
X-2602	CM	encorafenib + binimetinib	173.4	25.2	120	-15.5	2.9
X-2602	CM	encorafenib + binimetinib	168.3	25.1	125	-18	2.4
X-2602	CM	encorafenib + binimetinib	168.3	25.2	133	-18	2.9
X-2602	CM	encorafenib + binimetinib	161.2	25.1	141	-21.4	2.4
X-2602	CM	encorafenib + binimetinib	158.4	25.9	149	-22.8	5.7
X-2602	CM	encorafenib + binimetinib	180.3	26.4	155	-12.1	7.8
X-2602	CM	encorafenib + binimetinib	138.6	26.4	160	-32.4	7.8
X-2602	CM	encorafenib + binimetinib	161.2	26.3	167	-21.4	7.3
X-2602	CM	encorafenib + binimetinib	215.8	26.1	176	5.2	6.5
X-2602	CM	encorafenib + binimetinib	196	26.2	180	-4.5	6.9
X-2602	CM	binimetinib	192.8	22	0	0	0
X-2602	CM	binimetinib	211.7	22.1	3	9.8	0.5
X-2602	CM	binimetinib	203.4	23.3	6	5.5	5.9
X-2602	CM	binimetinib	200.9	22.7	9	4.2	3.2
X-2602	CM	binimetinib	203.4	23.4	12	5.5	6.4
X-2602	CM	binimetinib	220.3	24.1	15	14.3	9.5
X-2602	CM	binimetinib	254.1	23.6	19	31.8	7.3
X-2602	CM	binimetinib	289	23.6	24	49.9	7.3
X-2602	CM	binimetinib	281.6	23.5	27	46.1	6.8
X-2602	CM	binimetinib	307.2	23.9	31	59.3	8.6
X-2602	CM	binimetinib	316.4	23.6	34	64.1	7.3
X-2602	CM	binimetinib	345.6	23.8	38	79.2	8.2
X-2602	CM	TAS266	210.7	24.1	0	0	0
X-2602	CM	TAS266	241.1	24.7	3	14.4	2.5
X-2602	CM	TAS266	251.4	24.4	6	19.3	1.2
X-2602	CM	TAS266	303.2	24.4	9	43.9	1.2
X-2602	CM	TAS266	328.5	24.5	12	56	1.7
X-2602	CM	TAS266	313.3	24.4	16	48.7	1.2
X-2602	CM	TAS266	258.5	25	19	22.7	3.7
X-2602	CM	TAS266	247.8	24.7	22	17.6	2.5
X-2602	CM	TAS266	267.2	25.5	25	26.8	5.8
X-2602	CM	TAS266	277.3	25	28	31.6	3.7
X-2602	CM	TAS266	291.7	25.2	32	38.5	4.6
X-2602	CM	TAS266	319.4	26	37	51.6	7.9
X-2602	CM	TAS266	328.5	26.3	40	56	9.1
X-2602	CM	TAS266	342.4	25.6	44	62.5	6.2
X-2602	CM	TAS266	386.5	25.7	47	83.5	6.6
X-2602	CM	TAS266	390.2	25	51	85.2	3.7
X-2602	CM	untreated	243.4	27.6	0	0	0
X-2602	CM	untreated	303.1	27.7	3	24.6	0.4
X-2602	CM	untreated	345.7	28	7	42.1	1.4
X-2602	CM	untreated	400	28.4	11	64.4	2.9
X-2602	CM	untreated	576.2	27.5	15	136.8	-0.4
X-2602	CM	untreated	650	27.6	18	167.1	0
X-2602	CM	untreated	825.7	29.1	21	239.3	5.4
X-2602	CM	untreated	914.8	28.7	26	275.9	4
X-2602	CM	untreated	1009.2	29.1	31	314.7	5.4
X-2602	CM	untreated	1230.1	29.1	37	405.5	5.4
X-2613	CM	BKM120	219	22.9	0	0	0
X-2613	CM	BKM120	248.4	23.7	3	13.4	3.5
X-2613	CM	BKM120	393.8	25.1	8	79.8	9.6
X-2613	CM	BKM120	494.6	24.9	13	125.8	8.7
X-2613	CM	BKM120	503.6	25.2	16	129.9	10
X-2613	CM	BKM120	794.7	25.1	20	262.8	9.6
X-2613	CM	BKM120 + encorafenib	201.8	26.5	0	0	0
X-2613	CM	BKM120 + encorafenib	49.3	26.9	6	-75.6	1.5
X-2613	CM	BKM120 + encorafenib	59.2	28	11	-70.7	5.7
X-2613	CM	BKM120 + encorafenib	79.4	28.7	14	-60.7	8.3
X-2613	CM	BKM120 + encorafenib	103.7	28.3	18	-48.6	6.8
X-2613	CM	BKM120 + encorafenib	64.6	28.2	22	-68	6.4
X-2613	CM	BKM120 + encorafenib	52.7	28.8	28	-73.9	8.7
X-2613	CM	BKM120 + encorafenib	91.1	28.9	33	-54.9	9.1
X-2613	CM	BKM120 + encorafenib	70.6	29	37	-65	9.4
X-2613	CM	BKM120 + encorafenib	63.1	29.5	41	-68.7	11.3
X-2613	CM	BKM120 + encorafenib	65.4	28.8	44	-67.6	8.7
X-2613	CM	BKM120 + encorafenib	63.5	27.2	48	-68.5	2.6
X-2613	CM	BKM120 + encorafenib	103.7	28.4	51	-48.6	7.2
X-2613	CM	BKM120 + encorafenib	70	28	55	-65.3	5.7
X-2613	CM	BKM120 + encorafenib	69.2	27.8	62	-65.7	4.9
X-2613	CM	BKM120 + encorafenib	108.2	27.9	67	-46.4	5.3
X-2613	CM	BKM120 + encorafenib	64.3	28.1	70	-68.1	6
X-2613	CM	BKM120 + encorafenib	67.8	28.6	78	-66.4	7.9
X-2613	CM	BKM120 + encorafenib	110	28.5	82	-45.5	7.5
X-2613	CM	BKM120 + encorafenib	106.9	28.3	85	-47.1	6.8
X-2613	CM	BKM120 + encorafenib	100.7	28.2	89	-50.1	6.4
X-2613	CM	BKM120 + encorafenib	98.7	29.1	95	-51.1	9.8
X-2613	CM	BKM120 + encorafenib	105.8	28.9	98	-47.6	9.1
X-2613	CM	BKM120 + encorafenib	122.1	29.9	102	-39.5	12.8
X-2613	CM	BKM120 + encorafenib	130	29.3	106	-35.6	10.6
X-2613	CM	BKM120 + encorafenib	113.8	29.8	111	-43.6	12.5
X-2613	CM	BKM120 + encorafenib	129.7	29.3	116	-35.8	10.6
X-2613	CM	BKM120 + encorafenib	139.2	28.2	119	-31.1	6.4
X-2613	CM	BKM120 + encorafenib	134.5	29.3	123	-33.4	10.6
X-2613	CM	BKM120 + encorafenib	154.1	29.7	132	-23.6	12.1
X-2613	CM	BKM120 + encorafenib	121.7	30	137	-39.7	13.2
X-2613	CM	BKM120 + encorafenib	119.6	28.8	146	-40.8	8.7
X-2613	CM	BKM120 + encorafenib	222.8	29.4	152	10.4	10.9
X-2613	CM	BKM120 + encorafenib	168.5	29.6	160	-16.5	11.7
X-2613	CM	BKM120 + encorafenib	153.5	29.4	172	-24	10.9
X-2613	CM	BKM120 + encorafenib	143.8	29.5	179	-28.8	11.3
X-2613	CM	BKM120 + encorafenib	157.4	29	186	-22	9.4
X-2613	CM	BKM120 + encorafenib	157.3	29.2	204	-22.1	10.2
X-2613	CM	BKM120 + encorafenib	167.8	30	210	-16.9	13.2
X-2613	CM	BKM120 + encorafenib	186.6	30.2	218	-7.6	14
X-2613	CM	BKM120 + encorafenib	210.2	30	224	4.2	13.2
X-2613	CM	BKM120 + encorafenib	198.5	30.5	232	-1.7	15.1
X-2613	CM	BKM120 + encorafenib	271.6	29.8	241	34.6	12.5
X-2613	CM	BKM120 + encorafenib	230.4	29.7	249	14.1	12.1
X-2613	CM	BKM120 + encorafenib	232.6	30.8	256	15.2	16.2
X-2613	CM	BKM120 + encorafenib	236.2	31.5	261	17	18.9
X-2613	CM	BKM120 + encorafenib	226.2	29.8	267	12.1	12.5
X-2613	CM	BKM120 + encorafenib	285.1	30.3	280	41.2	14.3
X-2613	CM	BKM120 + encorafenib	380.7	30.1	284	88.6	13.6
X-2613	CM	BKM120 + encorafenib	328.6	29.7	287	62.8	12.1
X-2613	CM	BKM120 + encorafenib	324.2	30.8	294	60.6	16.2
X-2613	CM	BKM120 + encorafenib	382.6	29.9	302	89.6	12.8
X-2613	CM	BKM120 + encorafenib	436.6	30.8	308	116.3	16.2
X-2613	CM	BKM120 + encorafenib	434.9	30.9	315	115.5	16.6
X-2613	CM	BKM120 + encorafenib	489	29.9	322	142.3	12.8
X-2613	CM	BKM120 + encorafenib	574.9	28.9	329	184.8	9.1
X-2613	CM	BKM120 + encorafenib	586	28.4	333	190.3	7.2
X-2613	CM	CGM097	192.2	23.5	0	0	0
X-2613	CM	CGM097	242	23.8	3	25.9	1.3
X-2613	CM	CGM097	248.8	22.8	8	29.4	-3
X-2613	CM	CGM097	278.7	22.1	13	45	-6
X-2613	CM	CGM097	182.3	22.2	16	-5.2	-5.5
X-2613	CM	CGM097	157.7	21.9	20	-18	-6.8
X-2613	CM	CGM097	135	23.3	24	-29.8	-0.9
X-2613	CM	CGM097	111.3	24.3	30	-42.1	3.4
X-2613	CM	CGM097	108.8	25.9	35	-43.4	10.2
X-2613	CM	CGM097	82.5	25	39	-57.1	6.4
X-2613	CM	CGM097	81.7	25	43	-57.5	6.4
X-2613	CM	CGM097	61.1	25.7	46	-68.2	9.4
X-2613	CM	CGM097	38.8	25	50	-79.8	6.4
X-2613	CM	CGM097	59.9	25.5	53	-68.8	8.5
X-2613	CM	CGM097	39.2	25.9	57	-79.6	10.2
X-2613	CM	CGM097	58.2	26.3	64	-69.7	11.9
X-2613	CM	CGM097	73	26.1	69	-62	11.1
X-2613	CM	CGM097	68.8	26.8	72	-64.2	14
X-2613	CM	CGM097	49.6	27.4	80	-74.2	16.6
X-2613	CM	CGM097	73	28.1	84	-62	19.6
X-2613	CM	CGM097	120.9	28.5	87	-37.1	21.3
X-2613	CM	CGM097	130.7	27.6	91	-32	17.4
X-2613	CM	CGM097	167.9	26.6	97	-12.6	13.2
X-2613	CM	CGM097	237.1	27.4	100	23.4	16.6
X-2613	CM	CGM097	260.9	27.8	104	35.7	18.3
X-2613	CM	CGM097	339.2	27.8	108	76.4	18.3
X-2613	CM	CGM097	410.5	27.8	111	113.5	18.3
X-2613	CM	CLR457	202.2	22.9	0	0	0
X-2613	CM	CLR457	464.6	23.2	5	129.8	1.3
X-2613	CM	CLR457	490.1	23.5	8	142.4	2.6
X-2613	CM	CLR457	703.9	23.1	12	248.1	0.9
X-2613	CM	CLR457	347.7	22.6	16	72	-1.3
X-2613	CM	CLR457	430.4	24	22	112.9	4.8
X-2613	CM	dacarbazine	222.9	25.2	0	0	0
X-2613	CM	dacarbazine	388.8	26.1	5	74.4	3.6
X-2613	CM	dacarbazine	363.3	25	8	63	-0.8
X-2613	CM	dacarbazine	509	25	12	128.3	-0.8
X-2613	CM	dacarbazine	604.7	24.6	16	171.3	-2.4
X-2613	CM	dacarbazine	874.6	24.2	22	292.4	-4
X-2613	CM	LDE225	206.5	21.9	0	0	0
X-2613	CM	LDE225	313.6	21.2	6	51.9	-3.2
X-2613	CM	LDE225	658.6	20.9	11	219	-4.6
X-2613	CM	LDE225	1036.1	20.9	14	401.8	-4.6
X-2613	CM	LDE225	1436.5	20.8	18	595.7	-5
X-2613	CM	LDE225	2102.8	21	22	918.4	-4.1
X-2613	CM	LDK378	202.6	24.5	0	0	0
X-2613	CM	LDK378	313.6	24.4	6	54.8	-0.4
X-2613	CM	LDK378	516.7	24.6	11	155.1	0.4
X-2613	CM	LDK378	494.2	25.5	14	144	4.1
X-2613	CM	LDK378	578	25.3	18	185.4	3.3
X-2613	CM	LDK378	753.1	25.1	22	271.8	2.4
X-2613	CM	LEE011	215.8	20.9	0	0	0
X-2613	CM	LEE011	234.5	22.4	3	8.6	7.2
X-2613	CM	LEE011	118.6	23.5	8	-45.1	12.4
X-2613	CM	LEE011	188.5	23.7	13	-12.6	13.4
X-2613	CM	LEE011	272.8	23.4	16	26.4	12
X-2613	CM	LEE011	321	23.9	20	48.7	14.4
X-2613	CM	LEE011	367.5	24.4	24	70.3	16.7
X-2613	CM	LEE011	544.6	25.2	30	152.4	20.6
X-2613	CM	LEE011 + encorafenib	194.5	27.6	0	0	0
X-2613	CM	LEE011 + encorafenib	101.9	26.2	5	-47.6	-5.1
X-2613	CM	LEE011 + encorafenib	101.9	26	8	-47.6	-5.8
X-2613	CM	LEE011 + encorafenib	95.5	25.7	12	-50.9	-6.9
X-2613	CM	LEE011 + encorafenib	59.9	26.5	16	-69.2	-4
X-2613	CM	LEE011 + encorafenib	33.8	26.9	22	-82.6	-2.5
X-2613	CM	LEE011 + encorafenib	31.2	26.6	27	-84	-3.6
X-2613	CM	LEE011 + encorafenib	32.7	26.9	31	-83.2	-2.5
X-2613	CM	LEE011 + encorafenib	33.5	27.6	35	-82.8	0
X-2613	CM	LEE011 + encorafenib	14.9	27.1	38	-92.4	-1.8
X-2613	CM	LEE011 + encorafenib	23.1	27.9	42	-88.1	1.1
X-2613	CM	LEE011 + encorafenib	13.9	28.1	45	-92.9	1.8
X-2613	CM	LEE011 + encorafenib	21.6	27.5	49	-88.9	-0.4
X-2613	CM	LEE011 + encorafenib	24.3	27.5	56	-87.5	-0.4
X-2613	CM	LEE011 + encorafenib	34.4	27.8	64	-82.3	0.7
X-2613	CM	LEE011 + encorafenib	21.2	27.6	76	-89.1	0
X-2613	CM	LEE011 + encorafenib	16.8	27.6	79	-91.4	0
X-2613	CM	LEE011 + encorafenib	18	27.3	83	-90.7	-1.1
X-2613	CM	LEE011 + encorafenib	0	27.3	89	-100	-1.1
X-2613	CM	LEE011 + encorafenib	0	27.2	92	-100	-1.4
X-2613	CM	LEE011 + encorafenib	24.5	27.2	96	-87.4	-1.4
X-2613	CM	LEE011 + encorafenib	24.5	27.6	100	-87.4	0
X-2613	CM	LEE011 + encorafenib	36.1	28.2	105	-81.4	2.2
X-2613	CM	LEE011 + encorafenib	34.7	27.3	110	-82.2	-1.1
X-2613	CM	LEE011 + encorafenib	15.3	25.5	113	-92.1	-7.6
X-2613	CM	LEE011 + encorafenib	15.3	26.8	117	-92.1	-2.9
X-2613	CM	LEE011 + encorafenib	23.6	27.4	126	-87.9	-0.7
X-2613	CM	LEE011 + encorafenib	55.5	28	131	-71.5	1.4
X-2613	CM	LEE011 + encorafenib	32.7	27.1	140	-83.2	-1.8
X-2613	CM	LEE011 + encorafenib	32.2	28.5	146	-83.5	3.3
X-2613	CM	LEE011 + encorafenib	20.7	27.1	154	-89.4	-1.8
X-2613	CM	LEE011 + encorafenib	15.9	28.3	166	-91.8	2.5
X-2613	CM	LEE011 + encorafenib	14	28.9	173	-92.8	4.7
X-2613	CM	LEE011 + encorafenib	0	27.3	180	-100	-1.1
X-2613	CM	LEE011 + encorafenib	0	29.4	190	-100	6.5
X-2613	CM	LEE011 + encorafenib	0	27.2	198	-100	-1.4
X-2613	CM	LEE011 + encorafenib	0	29.1	204	-100	5.4
X-2613	CM	LEE011 + encorafenib	0	28.6	212	-100	3.6
X-2613	CM	LEE011 + encorafenib	0	29.1	218	-100	5.4
X-2613	CM	LEE011 + encorafenib	0	29.2	226	-100	5.8
X-2613	CM	LEE011 + encorafenib	0	29.6	235	-100	7.2
X-2613	CM	LEE011 + encorafenib	0	29.7	243	-100	7.6
X-2613	CM	LEE011 + encorafenib	0	29.3	250	-100	6.2
X-2613	CM	LEE011 + encorafenib	0	31.1	255	-100	12.7
X-2613	CM	LEE011 + encorafenib	0	29.1	261	-100	5.4
X-2613	CM	LEE011 + encorafenib	0	31.2	274	-100	13
X-2613	CM	LEE011 + encorafenib	0	31.2	278	-100	13
X-2613	CM	LEE011 + encorafenib	0	28.9	281	-100	4.7
X-2613	CM	LEE011 + encorafenib	0	29.4	288	-100	6.5
X-2613	CM	LEE011 + encorafenib	0	30.9	296	-100	12
X-2613	CM	LEE011 + encorafenib	0	31.4	302	-100	13.8
X-2613	CM	LEE011 + encorafenib	0	30.3	309	-100	9.8
X-2613	CM	LEE011 + encorafenib	0	31.4	316	-100	13.8
X-2613	CM	LEE011 + encorafenib	0	30.5	323	-100	10.5
X-2613	CM	LEE011 + encorafenib	0	30.6	330	-100	10.9
X-2613	CM	LEE011 + encorafenib	0	31.4	337	-100	13.8
X-2613	CM	LEE011 + encorafenib	0	31	344	-100	12.3
X-2613	CM	LEE011 + encorafenib	0	30.6	350	-100	10.9
X-2613	CM	LEE011 + encorafenib	0	31.2	359	-100	13
X-2613	CM	LEE011 + encorafenib	0	30.4	365	-100	10.1
X-2613	CM	LEE011 + encorafenib	0	31.2	372	-100	13
X-2613	CM	LEE011 + encorafenib	0	31.1	379	-100	12.7
X-2613	CM	LEE011 + encorafenib	0	32	386	-100	15.9
X-2613	CM	LEE011 + encorafenib	0	30.5	393	-100	10.5
X-2613	CM	LEE011 + encorafenib	0	32.2	400	-100	16.7
X-2613	CM	LEE011 + encorafenib	0	32.3	404	-100	17
X-2613	CM	LEE011 + binimetinib	193.8	27.1	0	0	0
X-2613	CM	LEE011 + binimetinib	83.8	26.3	4	-56.8	-3
X-2613	CM	LEE011 + binimetinib	44.1	26.6	8	-77.2	-1.8
X-2613	CM	LEE011 + binimetinib	28.8	27.4	14	-85.1	1.1
X-2613	CM	LEE011 + binimetinib	46.6	27.1	19	-76	0
X-2613	CM	LEE011 + binimetinib	26	27	23	-86.6	-0.4
X-2613	CM	LEE011 + binimetinib	32.4	27.3	27	-83.3	0.7
X-2613	CM	LEE011 + binimetinib	33.1	28.4	30	-82.9	4.8
X-2613	CM	LEE011 + binimetinib	48.4	28.8	34	-75	6.3
X-2613	CM	LEE011 + binimetinib	34.2	28.9	37	-82.3	6.6
X-2613	CM	LEE011 + binimetinib	50.6	29.1	41	-73.9	7.4
X-2613	CM	LEE011 + binimetinib	52	29.2	48	-73.2	7.7
X-2613	CM	LEE011 + binimetinib	50.6	28.5	53	-73.9	5.2
X-2613	CM	LEE011 + binimetinib	56.1	29.4	56	-71	8.5
X-2613	CM	LEE011 + binimetinib	61	29.9	68	-68.5	10.3
X-2613	CM	LEE011 + binimetinib	61.8	31	71	-68.1	14.4
X-2613	CM	LEE011 + binimetinib	82.8	28.7	75	-57.3	5.9
X-2613	CM	LEE011 + binimetinib	75.6	29.7	81	-61	9.6
X-2613	CM	LEE011 + binimetinib	78	29	88	-59.7	7
X-2613	CM	LEE011 + binimetinib	80.4	30.4	92	-58.5	12.2
X-2613	CM	LEE011 + binimetinib	98.3	30.9	97	-49.3	14
X-2613	CM	LEE011 + binimetinib	105.3	29.3	102	-45.7	8.1
X-2613	CM	LEE011 + binimetinib	88.8	29.9	105	-54.2	10.3
X-2613	CM	LEE011 + binimetinib	94.1	308	109	-51.5	10.3
X-2613	CM	LEE011 + binimetinib	91.2	30.9	118	-52.9	14
X-2613	CM	LEE011 + binimetinib	126.7	30.2	123	-34.6	11.4
X-2613	CM	LEE011 + binimetinib	94.9	29.8	131	-51	10
X-2613	CM	LEE011 + binimetinib	149.5	30.7	137	-22.9	13.3
X-2613	CM	LEE011 + binimetinib	127	30.7	145	-34.5	13.3
X-2613	CM	LEE011 + binimetinib	127.1	30.5	157	-34.5	12.5
X-2613	CM	LEE011 + binimetinib	139.7	30.3	164	-27.9	11.8
X-2613	CM	LEE011 + binimetinib	157.6	29.7	171	-18.7	9.6
X-2613	CM	LEE011 + binimetinib	141.1	30.2	181	-27.2	11.4
X-2613	CM	LEE011 + binimetinib	312.1	29.9	189	61	10.3
X-2613	CM	LEE011 + binimetinib	339.5	31	195	75.1	14.4
X-2613	CM	LEE011 + binimetinib	349.1	32	203	80.1	18.1
X-2613	CM	LEE011 + binimetinib	189.5	31.8	209	-2.2	17.3
X-2613	CM	LEE011 + binimetinib	174.6	32.1	217	-9.9	18.5
X-2613	CM	LEE011 + binimetinib	196	30.6	226	1.1	12.9
X-2613	CM	LEE011 + binimetinib	242.8	32	234	25.2	18.1
X-2613	CM	LEE011 + binimetinib	264.6	31.5	241	36.5	16.2
X-2613	CM	LEE011 + binimetinib	384	31.9	245	98.1	17.7
X-2613	CM	LEE011 + binimetinib	345.9	32.7	251	78.5	20.7
X-2613	CM	LEE011 + binimetinib	622.1	33.4	264	220.9	23.2
X-2613	CM	LEE011 + binimetinib	766	30.6	268	295.2	12.9
X-2613	CM	LEE011 + binimetinib	799.3	31	271	312.4	14.4
X-2613	CM	WNT974	218.5	22.7	0	0	0
X-2613	CM	WNT974	488.7	23.1	6	123.7	1.8
X-2613	CM	WNT974	1032.3	22.6	11	372.5	-0.4
X-2613	CM	WNT974	1242.2	23	14	468.5	1.3
X-2613	CM	WNT974	1436.5	23.4	18	557.5	3.1
X-2613	CM	WNT974	2376.4	24.8	22	987.6	9.3
X-2613	CM	LGW813	210.5	21.4	0	0	0
X-2613	CM	LGW813	274.6	21.6	3	30.5	0.9
X-2613	CM	LGW813	697.6	22.6	8	231.4	5.6
X-2613	CM	LGW813	992.5	22.4	13	371.5	4.7
X-2613	CM	LGW813	1312.5	22.3	16	523.5	4.2
X-2613	CM	LGW813	1649.4	23	20	683.6	7.5
X-2613	CM	encorafenib	196	22.9	0	0	0
X-2613	CM	encorafenib	82.9	21.7	3	-57.7	-5.2
X-2613	CM	encorafenib	49.7	22.1	8	-74.6	-3.5
X-2613	CM	encorafenib	146.9	22.7	13	-25.1	-0.9
X-2613	CM	encorafenib	160.7	22.8	16	-18	-0.4
X-2613	CM	encorafenib	179.6	23	20	-8.4	0.4
X-2613	CM	encorafenib	146.9	23.4	24	-25.1	2.2
X-2613	CM	encorafenib	124.2	23.4	30	-36.6	2.2
X-2613	CM	encorafenib	181.5	23.5	35	-7.4	2.6
X-2613	CM	encorafenib	173.4	23.3	39	-11.5	1.7
X-2613	CM	encorafenib	154.2	23.5	43	-21.3	2.6
X-2613	CM	encorafenib	191.6	23.4	46	-2.3	2.2
X-2613	CM	encorafenib	240.9	23.4	50	22.9	2.2
X-2613	CM	encorafenib	198.5	23.7	53	1.2	3.5
X-2613	CM	encorafenib	222.4	23.9	57	13.5	4.4
X-2613	CM	encorafenib	238.2	25.1	64	21.5	9.6
X-2613	CM	encorafenib	236.3	25.3	69	20.5	10.5
X-2613	CM	encorafenib	262.1	25.6	72	33.7	11.8
X-2613	CM	encorafenib	260.9	25.4	80	33.1	10.9
X-2613	CM	encorafenib	325.1	25.9	84	65.9	13.1
X-2613	CM	encorafenib	299.6	26.1	87	52.8	14
X-2613	CM	encorafenib	388.8	25.9	91	98.4	13.1
X-2613	CM	encorafenib	392.9	25.9	93	100.4	13.1
X-2613	CM	encorafenib + binimetinib	183.3	23.5	0	0	0
X-2613	CM	encorafenib + binimetinib	67.5	23.7	5	-63.2	0.9
X-2613	CM	encorafenib + binimetinib	29.4	23.5	8	-83.9	0
X-2613	CM	encorafenib + binimetinib	37	23.5	12	-79.8	0
X-2613	CM	encorafenib + binimetinib	10.1	23.4	16	-94.5	-0.4
X-2613	CM	encorafenib + binimetinib	11.4	23.9	22	-93.8	1.7
X-2613	CM	encorafenib + binimetinib	0	23.7	27	-100	0.9
X-2613	CM	encorafenib + binimetinib	0	24	31	-100	2.1
X-2613	CM	encorafenib + binimetinib	0	24	35	-100	2.1
X-2613	CM	encorafenib + binimetinib	0	23.4	38	-100	-0.4
X-2613	CM	encorafenib + binimetinib	0	23.9	42	-100	1.7
X-2613	CM	encorafenib + binimetinib	0	24	45	-100	2.1
X-2613	CM	encorafenib + binimetinib	0	24.1	49	-100	2.6
X-2613	CM	encorafenib + binimetinib	0	23.7	56	-100	0.9
X-2613	CM	encorafenib + binimetinib	0	23.9	61	-100	1.7
X-2613	CM	encorafenib + binimetinib	0	24.3	64	-100	3.4
X-2613	CM	encorafenib + binimetinib	0	24.5	72	-100	4.3
X-2613	CM	encorafenib + binimetinib	0	23.8	76	-100	1.3
X-2613	CM	encorafenib + binimetinib	0	24.2	79	-100	3
X-2613	CM	encorafenib + binimetinib	0	24	83	-100	2.1
X-2613	CM	encorafenib + binimetinib	0	24.2	89	-100	3
X-2613	CM	encorafenib + binimetinib	0	23.9	92	-100	1.7
X-2613	CM	encorafenib + binimetinib	0	24.3	96	-100	3.4
X-2613	CM	encorafenib + binimetinib	0	23.6	100	-100	0.4
X-2613	CM	encorafenib + binimetinib	0	24.2	105	-100	3
X-2613	CM	encorafenib + binimetinib	0	23.5	110	-100	0
X-2613	CM	encorafenib + binimetinib	0	23.2	113	-100	-1.3
X-2613	CM	encorafenib + binimetinib	0	23.9	117	-100	1.7
X-2613	CM	encorafenib + binimetinib	0	24	126	-100	2.1
X-2613	CM	encorafenib + binimetinib	0	23.5	131	-100	0
X-2613	CM	encorafenib + binimetinib	0	22.4	140	-100	-4.7
X-2613	CM	encorafenib + binimetinib	0	24	146	-100	2.1
X-2613	CM	encorafenib + binimetinib	0	23.3	154	-100	-0.9
X-2613	CM	encorafenib + binimetinib	0	23	166	-100	-2.1
X-2613	CM	encorafenib + binimetinib	0	23.8	173	-100	1.3
X-2613	CM	encorafenib + binimetinib	0	22.5	180	-100	-4.3
X-2613	CM	encorafenib + binimetinib	0	23.8	190	-100	1.3
X-2613	CM	encorafenib + binimetinib	23.1	23.6	198	-87.4	0.4
X-2613	CM	encorafenib + binimetinib	43.5	24.2	204	-76.3	3
X-2613	CM	encorafenib + binimetinib	117.6	24.4	212	-35.8	3.8
X-2613	CM	encorafenib + binimetinib	190.1	24.5	218	3.7	4.3
X-2613	CM	encorafenib + binimetinib	12.4	24.1	226	-93.2	2.6
X-2613	CM	encorafenib + binimetinib	0	23.6	235	-100	0.4
X-2613	CM	encorafenib + binimetinib	0	22.8	243	-100	-3
X-2613	CM	encorafenib + binimetinib	0	24	250	-100	2.1
X-2613	CM	encorafenib + binimetinib	0	23.8	255	-100	1.3
X-2613	CM	encorafenib + binimetinib	0	23.1	261	-100	-1.7
X-2613	CM	encorafenib + binimetinib	0	23	274	-100	-2.1
X-2613	CM	encorafenib + binimetinib	0	23.5	278	-100	0
X-2613	CM	encorafenib + binimetinib	0	23.6	281	-100	0.4
X-2613	CM	encorafenib + binimetinib	0	24.5	288	-100	4.3
X-2613	CM	encorafenib + binimetinib	0	23.9	296	-100	1.7
X-2613	CM	encorafenib + binimetinib	0	24.4	302	-100	3.8
X-2613	CM	encorafenib + binimetinib	0	24.3	309	-100	3.4
X-2613	CM	encorafenib + binimetinib	0	24.2	316	-100	3
X-2613	CM	encorafenib + binimetinib	0	24.3	323	-100	3.4
X-2613	CM	encorafenib + binimetinib	0	23.8	330	-100	1.3
X-2613	CM	encorafenib + binimetinib	0	24.5	337	-100	4.3
X-2613	CM	encorafenib + binimetinib	0	24.9	344	-100	6
X-2613	CM	encorafenib + binimetinib	0	23.7	350	-100	0.9
X-2613	CM	encorafenib + binimetinib	0	25.2	359	-100	7.2
X-2613	CM	encorafenib + binimetinib	0	25.5	362	-100	8.5
X-2613	CM	encorafenib + binimetinib	0	26.3	365	-100	11.9
X-2613	CM	encorafenib + binimetinib	25.5	26.8	369	-86.1	14
X-2613	CM	encorafenib + binimetinib	95.4	27.5	376	-48	17
X-2613	CM	encorafenib + binimetinib	155.7	28.6	383	-15.1	21.7
X-2613	CM	encorafenib + binimetinib	291	29.4	390	58.7	25.1
X-2613	CM	encorafenib + binimetinib	584.1	29.7	394	218.6	26.4
X-2613	CM	binimetinib	196	23.1	0	0	0
X-2613	CM	binimetinib	175.7	23.3	3	-10.4	0.9
X-2613	CM	binimetinib	286.7	23	8	46.3	-0.4
X-2613	CM	binimetinib	258.1	22.7	13	31.7	-1.7
X-2613	CM	binimetinib	172.8	24.7	16	-11.8	6.9
X-2613	CM	binimetinib	247.5	24.2	20	26.3	4.8
X-2613	CM	binimetinib	248.4	24.6	24	26.7	6.5
X-2613	CM	binimetinib	320	25.1	30	63.3	8.7
X-2613	CM	binimetinib	397.8	25	35	103	8.2
X-2613	CM	binimetinib	332.4	25.2	39	69.6	9.1
X-2613	CM	binimetinib	346.8	25.9	43	76.9	12.1
X-2613	CM	binimetinib	370.9	25.4	46	89.2	10
X-2613	CM	binimetinib	361.7	26	50	84.5	12.6
X-2613	CM	binimetinib	414.3	25.7	53	111.4	11.3
X-2613	CM	binimetinib	414.3	25.6	56	111.4	10.8
X-2613	CM	TAS266	191.8	22.1	0	0	0
X-2613	CM	TAS266	122.4	21.7	3	-36.2	-1.8
X-2613	CM	TAS266	20.8	22.4	8	-89.2	1.4
X-2613	CM	TAS266	0	23	13	-100	4.1
X-2613	CM	TAS266	0	23	16	-100	4.1
X-2613	CM	TAS266	0	22.7	20	-100	2.7
X-2613	CM	TAS266	0	23.2	24	-100	5
X-2613	CM	TAS266	0	23.8	30	-100	7.7
X-2613	CM	TAS266	0	23.3	35	-100	5.4
X-2613	CM	TAS266	0	23.6	39	-100	6.8
X-2613	CM	TAS266	36.1	23.4	43	-81.2	5.9
X-2613	CM	TAS266	36.8	23.8	46	-80.8	7.7
X-2613	CM	TAS266	93.8	24.1	50	-51.1	9
X-2613	CM	TAS266	126.2	24	53	-34.2	8.6
X-2613	CM	TAS266	291.7	24.6	57	52.1	11.3
X-2613	CM	TAS266	336	24.7	64	75.2	11.8
X-2613	CM	TAS266	625	25	69	225.8	13.1
X-2613	CM	untreated	235.2	22.1	0	0	0
X-2613	CM	untreated	446.2	23	3	89.7	4.1
X-2613	CM	untreated	719.4	24.1	8	205.9	9
X-2613	CM	untreated	1224.5	24.3	13	420.6	10
X-2613	CM	untreated	1528	25.5	16	549.6	15.4
X-2633	PDAC	abraxane	217.4	23	0	0	0
X-2633	PDAC	abraxane	289.2	22.4	4	33	-2.6
X-2633	PDAC	abraxane	341.6	22.8	7	57.1	-0.9
X-2633	PDAC	abraxane	557.5	23.3	11	156.4	1.3
X-2633	PDAC	abraxane	558.2	23.9	14	156.8	3.9
X-2633	PDAC	abraxane	556.4	24	19	155.9	4.3
X-2633	PDAC	abraxane	627	24.2	22	188.4	5.2
X-2633	PDAC	abraxane	751.2	24.6	25	245.5	7
X-2633	PDAC	abraxane	961.8	24.3	28	342.4	5.7
X-2633	PDAC	BKM120 + binimetinib	228.8	23.1	0	0	0
X-2633	PDAC	BKM120 + binimetinib	178.3	25.3	4	-22.1	9.5
X-2633	PDAC	BKM120 + binimetinib	192.3	25.1	6	-16	8.7
X-2633	PDAC	BKM120 + binimetinib	227.7	23.9	11	-0.5	3.5
X-2633	PDAC	BKM120 + binimetinib	220.6	25.2	14	-3.6	9.1
X-2633	PDAC	BKM120 + binimetinib	182.6	25.4	19	-20.2	10
X-2633	PDAC	BKM120 + binimetinib	132.1	24.8	21	-42.3	7.4
X-2633	PDAC	BKM120 + binimetinib	136.8	25.9	26	-40.2	12.1
X-2633	PDAC	BKM120 + binimetinib	113.1	25.7	29	-50.6	11.3
X-2633	PDAC	BKM120 + binimetinib	134.7	26.4	32	-41.1	14.3
X-2633	PDAC	BKM120 + binimetinib	109	25.9	36	-52.4	12.1
X-2633	PDAC	BKM120 + binimetinib	164.4	26.2	41	-28.1	13.4
X-2633	PDAC	BKM120 + binimetinib	108.7	26.7	43	-52.5	15.6
X-2633	PDAC	BKM120 + binimetinib	104.6	25.8	46	-54.3	11.7
X-2633	PDAC	BKM120 + binimetinib	126.5	26.6	48	-44.7	15.2
X-2633	PDAC	BKM120 + binimetinib	115	26.4	50	-49.7	14.3
X-2633	PDAC	BKM120 + binimetinib	115.6	27.3	54	-49.5	18.2
X-2633	PDAC	BKM120 + binimetinib	106.2	26.3	56	-53.6	13.9
X-2633	PDAC	BKM120 + binimetinib	94.7	27.2	61	-58.6	17.7
X-2633	PDAC	BKM120 + binimetinib	99.8	27.1	64	-56.4	17.3
X-2633	PDAC	BKM120 + binimetinib	86.9	26.5	68	-62	14.7
X-2633	PDAC	BKM120 + binimetinib	104.6	25.9	71	-54.3	12.1
X-2633	PDAC	BKM120 + binimetinib	105.7	26.3	75	-53.8	13.9
X-2633	PDAC	BKM120 + binimetinib	86	26.4	78	-62.4	14.3
X-2633	PDAC	BKM120 + binimetinib	97.1	26.7	82	-57.6	15.6
X-2633	PDAC	BKM120 + binimetinib	80	27.1	85	-65	17.3
X-2633	PDAC	BKM120 + binimetinib	80.3	27	89	-64.9	16.9
X-2633	PDAC	BKM120 + binimetinib	99.6	27.2	92	-56.5	17.7
X-2633	PDAC	BKM120 + binimetinib	94.8	27.3	96	-58.6	18.2
X-2633	PDAC	BKM120 + binimetinib	107.7	26.7	99	-52.9	15.6
X-2633	PDAC	BKM120 + binimetinib	83.9	26	103	-63.3	12.6
X-2633	PDAC	BKM120 + binimetinib	92.8	25.8	106	-59.4	11.7
X-2633	PDAC	BKM120 + binimetinib	86.6	25.2	110	-62.2	9.1
X-2633	PDAC	BKM120 + binimetinib	86.9	25.4	117	-62	10
X-2633	PDAC	BKM120 + binimetinib	77.9	25.9	120	-66	12.1
X-2633	PDAC	BKM120 + binimetinib	75.6	25	124	-67	8.2
X-2633	PDAC	BKM120 + binimetinib	69.1	25.6	127	-69.8	10.8
X-2633	PDAC	BKM120 + LDE225	274.6	26	0	0	0
X-2633	PDAC	BKM120 + LDE225	222.6	28.4	3	-18.9	9.2
X-2633	PDAC	BKM120 + LDE225	241.3	29.3	6	-12.1	12.7
X-2633	PDAC	BKM120 + LDE225	365.3	28	9	33	7.7
X-2633	PDAC	BKM120 + LDE225	310.4	29.4	14	13	13.1
X-2633	PDAC	BKM120 + LDE225	338.3	29.1	16	23.2	11.9
X-2633	PDAC	BKM120 + LDE225	249.8	28.8	20	-9	10.8
X-2633	PDAC	BKM120 + LDE225	233.6	28.5	23	-14.9	9.6
X-2633	PDAC	BKM120 + LDE225	248.4	28	28	-9.5	7.7
X-2633	PDAC	BKM120 + LDE225	210.9	28.1	35	-23.2	8.1
X-2633	PDAC	BKM120 + LDE225	322.3	27.9	38	17.4	7.3
X-2633	PDAC	BKM120 + LDE225	288.1	27.9	42	4.9	7.3
X-2633	PDAC	BKM120 + LDE225	344.7	27.5	45	25.5	5.8
X-2633	PDAC	BKM120 + LDE225	300.8	26.7	48	9.5	2.7
X-2633	PDAC	BKM120 + LDE225	315.8	26.9	56	15	3.5
X-2633	PDAC	BKM120 + LDE225	244.1	26.3	58	-11.1	1.2
X-2633	PDAC	BKM120 + LDE225	307	28	63	11.8	7.7
X-2633	PDAC	BKM120 + LDE225	196.4	26.5	66	-28.5	1.9
X-2633	PDAC	BKM120 + LDE225	206.8	26.4	70	-24.7	1.5
X-2633	PDAC	BKM120 + LDE225	304.8	25.9	73	11	-0.4
X-2633	PDAC	BKM120 + LDE225	302.8	26.2	76	10.3	0.8
X-2633	PDAC	BKM120 + LDE225	240.9	25.1	80	-12.3	-3.5
X-2633	PDAC	BKM120 + LDE225	282.2	25.6	84	2.8	-1.5
X-2633	PDAC	BKM120 + LDE225	341.9	26.5	86	24.5	1.9
X-2633	PDAC	BKM120 + LDE225	167.1	26.2	91	-39.1	0.8
X-2633	PDAC	BKM120 + LDE225	116.3	27.1	98	-57.6	4.2
X-2633	PDAC	BKM120 + LDE225	255.9	26.8	105	-6.8	3.1
X-2633	PDAC	BKM120 + LDE225	200.8	26.3	108	-26.9	1.2
X-2633	PDAC	BKM120 + LDE225	189.9	27.2	113	-30.8	4.6
X-2633	PDAC	BKM120 + LDE225	200.8	27.1	115	-26.9	4.2
X-2633	PDAC	BKM120 + LDE225	349.9	26.7	119	27.4	2.7
X-2633	PDAC	BKM120 + LDE225	300.8	27.7	122	9.5	6.5
X-2633	PDAC	BKM120 + LDE225	154.5	27	126	-43.7	3.8
X-2633	PDAC	BKM120 + LDE225	307.2	25.8	129	11.9	-0.8
X-2633	PDAC	BKM120 + LDE225	224.6	26.2	132	-18.2	0.8
X-2633	PDAC	BKM120	224.1	27.3	0	0	0
X-2633	PDAC	BKM120	171.5	27.8	5	-23.5	1.8
X-2633	PDAC	BKM120	203.3	27.6	7	-9.3	1.1
X-2633	PDAC	BKM120	224.4	28.5	10	0.1	4.4
X-2633	PDAC	BKM120	151.9	26.7	13	-32.2	-2.2
X-2633	PDAC	BKM120	234.3	27.5	18	4.6	0.7
X-2633	PDAC	BKM120	192	27.7	21	-14.3	1.5
X-2633	PDAC	BKM120	221.2	28.3	25	-1.3	3.7
X-2633	PDAC	BKM120	194	28.7	28	-13.4	5.1
X-2633	PDAC	BKM120	197.6	29.3	31	-11.8	7.3
X-2633	PDAC	BKM120	218	28.8	34	-2.7	5.5
X-2633	PDAC	BKM120	238	30.1	38	6.2	10.3
X-2633	PDAC	BKM120	353.6	29.3	41	57.8	7.3
X-2633	PDAC	BKM120	303.3	30.8	45	35.3	12.8
X-2633	PDAC	BKM120	240.9	30.5	48	7.5	11.7
X-2633	PDAC	BKM120	346.3	30.6	52	54.5	12.1
X-2633	PDAC	BKM120	365.9	31.3	55	63.3	14.7
X-2633	PDAC	BKM120	227.6	31.6	60	1.6	15.8
X-2633	PDAC	BKM120	416.5	31.2	63	85.9	14.3
X-2633	PDAC	BYL719 + LJM716	237.5	27.3	0	0	0
X-2633	PDAC	BYL719 + LJM716	255.7	27	3	7.7	-1.1
X-2633	PDAC	BYL719 + LJM716	245	26.5	6	3.2	-2.9
X-2633	PDAC	BYL719 + LJM716	222.3	26.7	10	-6.4	-2.2
X-2633	PDAC	BYL719 + LJM716	214.9	27.4	13	-9.5	0.4
X-2633	PDAC	BYL719 + LJM716	206.4	28.3	17	-13.1	3.7
X-2633	PDAC	BYL719 + LJM716	208.3	27.3	20	-12.3	0
X-2633	PDAC	BYL719 + LJM716	215.8	26.2	25	-9.1	-4
X-2633	PDAC	BYL719 + LJM716	215.3	26.1	28	-9.3	-4.4
X-2633	PDAC	BYL719 + LJM716	244.9	26.8	31	3.1	-1.8
X-2633	PDAC	BYL719 + LJM716	227.5	27.8	34	-4.2	1.8
X-2633	PDAC	BYL719 + LJM716	254	25.5	37	6.9	-6.6
X-2633	PDAC	BYL719 + LJM716	264.3	27.6	42	11.3	1.1
X-2633	PDAC	BYL719 + LJM716	262.8	26.5	45	10.7	-2.9
X-2633	PDAC	BYL719 + LJM716	261.8	27.4	48	10.2	0.4
X-2633	PDAC	BYL719 + LJM716	278.6	26.3	51	17.3	-3.7
X-2633	PDAC	BYL719 + LJM716	299.2	27.8	55	26	1.8
X-2633	PDAC	BYL719 + LJM716	320.4	27.1	58	34.9	-0.7
X-2633	PDAC	BYL719 + LJM716	324.4	29.2	62	36.6	7
X-2633	PDAC	BYL719 + LJM716	329.5	26.9	65	38.7	-1.5
X-2633	PDAC	BYL719 + LJM716	334.8	27.8	69	41	1.8
X-2633	PDAC	BYL719 + LJM716	356.2	27.2	73	50	-0.4
X-2633	PDAC	BYL719 + LJM716	361.6	27.4	76	52.3	0.4
X-2633	PDAC	BYL719 + LJM716	340.9	26.3	80	43.5	-3.7
X-2633	PDAC	BYL719 + LJM716	340.4	27.1	83	43.3	-0.7
X-2633	PDAC	BYL719 + LJM716	370.5	27.8	88	56	1.8
X-2633	PDAC	BYL719 + LJM716	422.3	27.1	91	77.8	-0.7
X-2633	PDAC	BYL719 + LJM716	473.2	27.7	95	99.2	1.5
X-2633	PDAC	BYL719 + LJM716	465.6	26.1	98	96	-4.4
X-2633	PDAC	BYL719 + LJM716	483.6	27.1	101	103.6	-0.7
X-2633	PDAC	BYL719 + LJM716	537.1	27.2	104	126.1	-0.4
X-2633	PDAC	BYL719 + LJM716	560.7	28	108	136.1	2.6
X-2633	PDAC	BYL719	210.6	28.3	0	0	0
X-2633	PDAC	BYL719	169.4	27.6	4	-19.6	-2.5
X-2633	PDAC	BYL719	136	29.3	8	-35.4	3.5
X-2633	PDAC	BYL719	121.3	27.5	11	-42.4	-2.8
X-2633	PDAC	BYL719	118.9	29.5	15	-43.5	4.2
X-2633	PDAC	BYL719	131.2	27.5	18	-37.7	-2.8
X-2633	PDAC	BYL719	129	29.8	22	-38.7	5.3
X-2633	PDAC	BYL719	126.2	29	26	-40.1	2.5
X-2633	PDAC	BYL719	140.5	29.6	29	-33.3	4.6
X-2633	PDAC	BYL719	126.4	28.3	33	-40	0
X-2633	PDAC	BYL719	123.7	29.3	36	-41.3	3.5
X-2633	PDAC	BYL719	128.4	30.4	41	-39	7.4
X-2633	PDAC	BYL719	127.4	28.3	44	-39.5	0
X-2633	PDAC	BYL719	127.8	28.9	48	-39.3	2.1
X-2633	PDAC	BYL719	132.4	27.8	51	-37.1	-1.8
X-2633	PDAC	BYL719	141.9	28.8	54	-32.6	1.8
X-2633	PDAC	BYL719	151.1	29.6	57	-28.3	4.6
X-2633	PDAC	BYL719	185.4	29.5	61	-12	4.2
X-2633	PDAC	BYL719	198.6	29	65	-5.7	2.5
X-2633	PDAC	BYL719	272.7	27.7	69	29.5	-2.1
X-2633	PDAC	BYL719	292.8	28.5	73	39	0.7
X-2633	PDAC	BYL719	337.7	28	76	60.4	-1.1
X-2633	PDAC	BYL719	384	28.7	78	82.3	1.4
X-2633	PDAC	BYL719	366.4	29.1	82	74	2.8
X-2633	PDAC	BYL719	370.4	28.8	89	75.9	1.8
X-2633	PDAC	BYL719	326.9	29.8	92	55.2	5.3
X-2633	PDAC	BYL719	312.2	29.6	96	48.2	4.6
X-2633	PDAC	BYL719	271	28.1	99	28.7	-0.7
X-2633	PDAC	BYL719	292	29	103	38.7	2.5
X-2633	PDAC	BYL719	321.2	29.8	107	52.5	5.3
X-2633	PDAC	BYL719	307.9	27.9	110	46.2	-1.4
X-2633	PDAC	BYL719	346.5	29.8	114	64.5	5.3
X-2633	PDAC	BYL719	359.2	28.2	117	70.6	-0.4
X-2633	PDAC	BYL719	370.4	29.1	120	75.9	2.8
X-2633	PDAC	CLR457	227.6	28	0	0	0
X-2633	PDAC	CLR457	234.3	28	4	2.9	0
X-2633	PDAC	CLR457	266.3	27.7	7	17	-1.1
X-2633	PDAC	CLR457	325.6	28.3	11	43.1	1.1
X-2633	PDAC	CLR457	373.8	28.3	14	64.2	1.1
X-2633	PDAC	CLR457	404.7	27.5	19	77.8	-1.8
X-2633	PDAC	CLR457	429.3	26.7	22	88.6	-4.6
X-2633	PDAC	CLR457	439.5	26.6	25	93.1	-5
X-2633	PDAC	CLR457	489.1	27.4	28	114.9	-2.1
X-2633	PDAC	CLR457	529.6	27.3	31	132.7	-2.5
X-2633	PDAC	CLR457	752.3	29.6	36	230.5	5.7
X-2633	PDAC	CLR457	755.7	28.1	39	232	0.4
X-2633	PDAC	CLR457	774	28.5	42	240.1	1.8
X-2633	PDAC	CLR457	758.8	28.6	45	233.4	2.1
X-2633	PDAC	CLR457	810.4	29	49	256.1	3.6
X-2633	PDAC	CLR457	837.1	28.7	52	267.8	2.5
X-2633	PDAC	CLR457	901.4	26.4	56	296	-5.7
X-2633	PDAC	HDM201	222.3	30.6	0	0	0
X-2633	PDAC	HDM201	233.3	28.9	3	4.9	-5.6
X-2633	PDAC	HDM201	252.3	27.9	6	13.5	-8.8
X-2633	PDAC	HDM201	266.7	28.8	10	20	-5.9
X-2633	PDAC	HDM201	279.5	29.1	13	25.7	-4.9
X-2633	PDAC	HDM201	324.9	30.1	17	46.2	-1.6
X-2633	PDAC	HDM201	377.1	30.5	20	69.6	-0.3
X-2633	PDAC	HDM201	390.5	29.3	25	75.7	-4.2
X-2633	PDAC	HDM201	391.1	27.9	28	75.9	-8.8
X-2633	PDAC	HDM201	438.8	28.4	31	97.4	-7.2
X-2633	PDAC	HDM201	437	28.2	34	96.6	-7.8
X-2633	PDAC	HDM201	433.1	26.4	37	94.8	-13.7
X-2633	PDAC	HDM201	422.1	25.4	42	89.9	-17
X-2633	PDAC	figitumumab"	234.2	29	0	0	0
X-2633	PDAC	figitumumab"	233	29.2	5	-0.5	0.7
X-2633	PDAC	figitumumab"	305.5	29.3	12	30.4	1
X-2633	PDAC	figitumumab"	324.4	29.6	15	38.5	2.1
X-2633	PDAC	figitumumab"	333.4	29.2	19	42.4	0.7
X-2633	PDAC	figitumumab"	372	29.1	22	58.8	0.3
X-2633	PDAC	figitumumab"	446.7	29.9	26	90.7	3.1
X-2633	PDAC	figitumumab"	516.1	29.8	29	120.4	2.8
X-2633	PDAC	figitumumab"	651.9	29.7	33	178.4	2.4
X-2633	PDAC	figitumumab"	930.7	29.3	36	297.4	1
X-2633	PDAC	figitumumab" + binimetinib	257.3	25.6	0	0	0
X-2633	PDAC	figitumumab" + binimetinib	255.2	24.8	4	-0.8	-3.1
X-2633	PDAC	figitumumab" + binimetinib	323.4	25.7	6	25.7	0.4
X-2633	PDAC	figitumumab" + binimetinib	231.9	25.5	10	-9.9	-0.4
X-2633	PDAC	figitumumab" + binimetinib	277.4	24.9	14	7.8	-2.7
X-2633	PDAC	figitumumab" + binimetinib	290.7	26.7	18	13	4.3
X-2633	PDAC	figitumumab" + binimetinib	327.7	26.2	21	27.4	2.3
X-2633	PDAC	figitumumab" + binimetinib	232.3	25.4	25	-9.7	-0.8
X-2633	PDAC	figitumumab" + binimetinib	338.6	25.7	28	31.6	0.4
X-2633	PDAC	figitumumab" + binimetinib	324.7	25.5	32	26.2	-0.4
X-2633	PDAC	figitumumab" + binimetinib	328.5	25.2	35	27.7	-1.6
X-2633	PDAC	figitumumab" + binimetinib	303.4	25.5	40	17.9	-0.4
X-2633	PDAC	figitumumab" + binimetinib	367.3	26	45	42.8	1.6
X-2633	PDAC	figitumumab" + binimetinib	378.3	25.7	48	47	0.4
X-2633	PDAC	figitumumab" + binimetinib	401.8	25.4	52	56.2	-0.8
X-2633	PDAC	figitumumab" + binimetinib	337.1	25.7	55	31	0.4
X-2633	PDAC	figitumumab" + binimetinib	264.8	25.9	59	2.9	1.2
X-2633	PDAC	figitumumab" + binimetinib	622	25.6	62	141.7	0
X-2633	PDAC	figitumumab" + binimetinib	460	25.8	70	78.8	0.8
X-2633	PDAC	figitumumab" + binimetinib	464.8	26.3	75	80.6	2.7
X-2633	PDAC	gemcitabine-50mpk	233.8	29.7	0	0	0
X-2633	PDAC	gemcitabine-50mpk	271.1	29.9	3	16	0.7
X-2633	PDAC	gemcitabine-50mpk	256.7	27.3	6	9.8	-8.1
X-2633	PDAC	gemcitabine-50mpk	298.9	27.8	10	27.8	-6.4
X-2633	PDAC	gemcitabine-50mpk	257.9	26.3	14	10.3	-11.4
X-2633	PDAC	gemcitabine-50mpk	259	26	18	10.8	-12.5
X-2633	PDAC	gemcitabine-50mpk	170.3	28.6	21	-27.2	-3.7
X-2633	PDAC	gemcitabine-50mpk	205.8	29.7	24	-12	0
X-2633	PDAC	gemcitabine-50mpk	189.8	29.3	27	-18.8	-1.3
X-2633	PDAC	gemcitabine-50mpk	147.3	29.4	32	-37	-1
X-2633	PDAC	gemcitabine-50mpk	155.3	30	35	-33.6	1
X-2633	PDAC	gemcitabine-50mpk	127.8	28.8	39	-45.3	-3
X-2633	PDAC	gemcitabine-50mpk	123.6	28.4	42	-47.1	-4.4
X-2633	PDAC	gemcitabine-50mpk	102.7	25.5	46	-56.1	-14.1
X-2633	PDAC	gemcitabine-50mpk	111.4	29.7	49	-52.4	0
X-2633	PDAC	gemcitabine-50mpk	106.2	29.2	53	-54.6	-1.7
X-2633	PDAC	gemcitabine-50mpk	96.2	28	56	-58.9	-5.7
X-2633	PDAC	gemcitabine-50mpk	97.5	28.1	59	-58.3	-5.4
X-2633	PDAC	gemcitabine-50mpk	111.3	27.7	62	-52.4	-6.7
X-2633	PDAC	gemcitabine-50mpk	106.1	29.4	67	-54.6	-1
X-2633	PDAC	gemcitabine-50mpk	82	29	70	-64.9	-2.4
X-2633	PDAC	gemcitabine-50mpk	70.4	30	74	-69.9	1
X-2633	PDAC	gemcitabine-50mpk	53.2	29.8	77	-77.2	0.3
X-2633	PDAC	gemcitabine-50mpk	92.1	29.7	80	-60.6	0
X-2633	PDAC	gemcitabine-50mpk	75.4	29.4	82	-67.8	-1
X-2633	PDAC	gemcitabine-50mpk	73.3	30.7	88	-68.6	3.4
X-2633	PDAC	gemcitabine-50mpk	86.1	30.5	90	-63.2	2.7
X-2633	PDAC	gemcitabine-50mpk	113.1	30	95	-51.6	1
X-2633	PDAC	gemcitabine-50mpk	170.9	31	98	-26.9	4.4
X-2633	PDAC	gemcitabine-50mpk	160.9	28.7	101	-31.2	-3.4
X-2633	PDAC	INC424 + binimetinib	202.3	28.4	0	0	0
X-2633	PDAC	INC424 + binimetinib	194.6	27.6	4	-3.8	-2.8
X-2633	PDAC	INC424 + binimetinib	206.3	27.1	6	2	-4.6
X-2633	PDAC	INC424 + binimetinib	316.6	28.6	11	56.5	0.7
X-2633	PDAC	INC424 + binimetinib	331.3	27.9	14	63.8	-1.8
X-2633	PDAC	INC424 + binimetinib	284.5	28.5	19	40.6	0.4
X-2633	PDAC	INC424 + binimetinib	266.6	28.8	21	31.8	1.4
X-2633	PDAC	INC424 + binimetinib	275.9	28.5	26	36.4	0.4
X-2633	PDAC	INC424 + binimetinib	318.5	28	29	57.4	-1.4
X-2633	PDAC	INC424 + binimetinib	351.5	28.3	32	73.8	-0.4
X-2633	PDAC	INC424 + binimetinib	302.1	27.7	36	49.3	-2.5
X-2633	PDAC	INC424 + binimetinib	386.4	28.1	41	91	-1.1
X-2633	PDAC	INC424 + binimetinib	415.3	27.8	43	105.3	-2.1
X-2633	PDAC	INC424 + binimetinib	427.5	28.9	46	111.3	1.8
X-2633	PDAC	INC424 + binimetinib	379.9	29.4	48	87.8	3.5
X-2633	PDAC	INC424 + binimetinib	411.4	29	50	103.4	2.1
X-2633	PDAC	INC424 + binimetinib	444.1	27.5	54	119.5	-3.2
X-2633	PDAC	INC424 + binimetinib	389	28	56	92.3	-1.4
X-2633	PDAC	INC424 + binimetinib	544.1	28.3	64	169	-0.4
X-2633	PDAC	INC424 + binimetinib	785.6	29.1	68	288.3	2.5
X-2633	PDAC	INC424 + binimetinib	953.9	28	71	371.5	-1.4
X-2633	PDAC	INC424 + binimetinib	1057.7	28.2	75	422.8	-0.7
X-2633	PDAC	INC424 + binimetinib	905.7	27.1	78	347.7	-4.6
X-2633	PDAC	INC424 + binimetinib	999.2	27.9	82	393.9	-1.8
X-2633	PDAC	INC424 + binimetinib	1044.6	28.2	85	416.4	-0.7
X-2633	PDAC	INC424 + binimetinib	1081	28.5	89	434.4	0.4
X-2633	PDAC	INC424 + binimetinib	974.1	29.2	92	381.5	2.8
X-2633	PDAC	INC424 + binimetinib	1004	28.2	96	396.3	-0.7
X-2633	PDAC	INC424 + binimetinib	900.7	27.4	99	345.2	-3.5
X-2633	PDAC	INC424 + binimetinib	1033.6	28.2	103	410.9	-0.7
X-2633	PDAC	INC424 + binimetinib	1109.2	28.1	106	448.3	-1.1
X-2633	PDAC	INC424 + binimetinib	1102.8	28.3	110	445.1	-0.4
X-2633	PDAC	INC424 + binimetinib	1106.4	28.2	117	446.9	-0.7
X-2633	PDAC	INC424 + binimetinib	1338.5	29.1	120	561.6	2.5
X-2633	PDAC	INC424 + binimetinib	1201.4	28.4	124	493.9	0
X-2633	PDAC	INC424 + binimetinib	1049.3	27.6	127	418.7	-2.8
X-2633	PDAC	LEE011	243	24.5	0	0	0
X-2633	PDAC	LEE011	317.1	25.3	5	30.5	3.3
X-2633	PDAC	LEE011	348.7	24.1	8	43.5	-1.6
X-2633	PDAC	LEE011	455.2	25	12	87.3	2
X-2633	PDAC	LEE011	512.3	24.8	15	110.8	1.2
X-2633	PDAC	LEE011	500.8	25.5	19	106.1	4.1
X-2633	PDAC	LEE011	443.5	25.5	22	82.5	4.1
X-2633	PDAC	LEE011	473.1	25.7	26	94.7	4.9
X-2633	PDAC	LEE011	545.5	25.4	29	124.5	3.7
X-2633	PDAC	LEE011	587.7	23.9	33	141.9	-2.4
X-2633	PDAC	LEE011	577.7	25.2	36	137.7	2.9
X-2633	PDAC	LEE011	592.5	24.9	40	143.8	1.6
X-2633	PDAC	LEE011	534.8	25.3	43	120.1	3.3
X-2633	PDAC	LEE011	421.6	26.4	47	73.5	7.8
X-2633	PDAC	LEE011	545.1	27	50	124.3	10.2
X-2633	PDAC	LEE011	537.4	25.8	54	121.2	5.3
X-2633	PDAC	LEE011	567.3	26.3	57	133.5	7.3
X-2633	PDAC	LEE011	576	26.8	61	137	9.4
X-2633	PDAC	LEE011	554.8	26.7	64	128.3	9
X-2633	PDAC	LEE011	576.1	27.1	68	137.1	10.6
X-2633	PDAC	LEE011	493.4	28.5	71	103	16.3
X-2633	PDAC	LEE011	545.5	28	76	124.5	14.3
X-2633	PDAC	LEE011	553.2	26.9	79	127.7	9.8
X-2633	PDAC	LEE011	598.3	28.2	82	146.2	15.1
X-2633	PDAC	LEE011	707.6	27.3	85	191.2	11.4
X-2633	PDAC	LEE011	528.7	26.6	89	117.6	8.6
X-2633	PDAC	LEE011	551	28.6	92	126.7	16.7
X-2633	PDAC	LEE011	639.4	27.3	96	163.1	11.4
X-2633	PDAC	LEE011	822.5	28.5	99	238.5	16.3
X-2633	PDAC	WNT974	274.6	26.5	0	0	0
X-2633	PDAC	WNT974	311.4	25.9	2	13.4	-2.3
X-2633	PDAC	WNT974	297.4	26	6	8.3	-1.9
X-2633	PDAC	WNT974	367.2	25.5	9	33.7	-3.8
X-2633	PDAC	WNT974	329.9	25.9	12	20.1	-2.3
X-2633	PDAC	WNT974	367.3	27	15	33.8	1.9
X-2633	PDAC	WNT974	386.8	26.7	20	40.9	0.8
X-2633	PDAC	WNT974	379.5	27.4	23	38.2	3.4
X-2633	PDAC	WNT974	382.3	25.9	26	39.2	-2.3
X-2633	PDAC	WNT974	346.6	26.7	29	26.2	0.8
X-2633	PDAC	WNT974	333.7	26.1	34	21.5	-1.5
X-2633	PDAC	WNT974	358.5	27	37	30.6	1.9
X-2633	PDAC	WNT974	260.2	26.4	40	-5.2	-0.4
X-2633	PDAC	WNT974	370.8	27.2	43	35	2.6
X-2633	PDAC	WNT974	275.3	26.5	47	0.3	0
X-2633	PDAC	WNT974	278.6	25.2	51	1.5	-4.9
X-2633	PDAC	WNT974	303.1	25.7	55	10.4	-3
X-2633	PDAC	WNT974	296.4	26.1	58	7.9	-1.5
X-2633	PDAC	WNT974	266.6	25.5	61	-2.9	-3.8
X-2633	PDAC	WNT974	242.2	26.4	64	-11.8	-0.4
X-2633	PDAC	WNT974	255.7	26.4	69	-6.9	-0.4
X-2633	PDAC	WNT974	299.7	27.3	72	9.1	3
X-2633	PDAC	WNT974	243.6	26.7	76	-11.3	0.8
X-2633	PDAC	WNT974	379.8	25.5	79	38.3	-3.8
X-2633	PDAC	WNT974	260.5	30	84	-5.1	13.2
X-2633	PDAC	WNT974	296.9	26.3	86	8.1	-0.8
X-2633	PDAC	WNT974	361.1	26.2	90	31.5	-1.1
X-2633	PDAC	WNT974	380.7	26.3	93	38.6	-0.8
X-2633	PDAC	WNT974	387.4	25.6	96	41.1	-3.4
X-2633	PDAC	LKA136	276.9	24.9	0	0	0
X-2633	PDAC	LKA136	261.8	23.6	2	-5.5	-5.2
X-2633	PDAC	LKA136	304.3	25.2	5	9.9	1.2
X-2633	PDAC	LKA136	378.2	24.8	8	36.6	-0.4
X-2633	PDAC	LKA136	640.4	25.1	13	131.3	0.8
X-2633	PDAC	LKA136	535.2	25	16	93.3	0.4
X-2633	PDAC	LKA136	643.8	24.7	19	132.5	-0.8
X-2633	PDAC	LKA136	715.4	25.2	22	158.4	1.2
X-2633	PDAC	LKA136	806	24.2	27	191.1	-2.8
X-2633	PDAC	LKA136	883.5	24.3	30	219.1	-2.4
X-2633	PDAC	LKA136	889.9	24.6	33	221.4	-1.2
X-2633	PDAC	binimetinib	238.4	29.9	0	0	0
X-2633	PDAC	binimetinib	264.1	29.4	4	10.8	-1.7
X-2633	PDAC	binimetinib	219.6	29.2	6	-7.9	-2.3
X-2633	PDAC	binimetinib	269.5	29.2	11	13	-2.3
X-2633	PDAC	binimetinib	288.4	29.3	14	21	-2
X-2633	PDAC	binimetinib	247.5	24.7	19	3.8	-17.4
X-2633	PDAC	binimetinib	213.8	24	21	-10.3	-19.7
X-2633	PDAC	binimetinib-3.5mpk	204.9	24	0	0	0
X-2633	PDAC	binimetinib-3.5mpk	154.9	23.7	5	-24.4	-1.3
X-2633	PDAC	binimetinib-3.5mpk	156.7	23.5	7	-23.5	-2.1
X-2633	PDAC	binimetinib-3.5mpk	195	24.4	10	-4.8	1.7
X-2633	PDAC	binimetinib-3.5mpk	129.1	25.3	13	-37	5.4
X-2633	PDAC	binimetinib-3.5mpk	166.8	23.9	18	-18.6	-0.4
X-2633	PDAC	binimetinib-3.5mpk	168.2	23.8	21	-17.9	-0.8
X-2633	PDAC	binimetinib-3.5mpk	147	23.9	25	-28.3	-0.4
X-2633	PDAC	binimetinib-3.5mpk	163.9	23.6	28	-20	-1.7
X-2633	PDAC	binimetinib-3.5mpk	191.7	24.3	31	-6.4	1.2
X-2633	PDAC	binimetinib-3.5mpk	216.4	24.6	34	5.6	2.5
X-2633	PDAC	binimetinib-3.5mpk	250.3	25.1	38	22.2	4.6
X-2633	PDAC	binimetinib-3.5mpk	285.4	24.5	41	39.3	2.1
X-2633	PDAC	binimetinib-3.5mpk	220.3	24.8	45	7.5	3.3
X-2633	PDAC	binimetinib-3.5mpk	241.9	24.8	48	18.1	3.3
X-2633	PDAC	binimetinib-3.5mpk	314.4	25.3	52	53.4	5.4
X-2633	PDAC	binimetinib-3.5mpk	314.2	24.7	55	53.3	2.9
X-2633	PDAC	binimetinib-3.5mpk	342	24.8	60	66.9	3.3
X-2633	PDAC	binimetinib-3.5mpk	335.1	24.6	63	63.5	2.5
X-2633	PDAC	binimetinib-3.5mpk	422.3	24.8	66	106.1	3.3
X-2633	PDAC	binimetinib-3.5mpk	273.3	24.6	69	33.4	2.5
X-2633	PDAC	binimetinib-3.5mpk	393.3	24.6	73	91.9	2.5
X-2633	PDAC	trametinib	271.9	24.2	0	0	0
X-2633	PDAC	trametinib	267.3	23.4	4	-1.7	-3.3
X-2633	PDAC	trametinib	279.7	23.7	7	2.9	-2.1
X-2633	PDAC	trametinib	315.6	25	12	16.1	3.3
X-2633	PDAC	trametinib	282.6	24.1	14	3.9	-0.4
X-2633	PDAC	trametinib	276.1	25.5	18	1.5	5.4
X-2633	PDAC	trametinib	299	24.8	21	10	2.5
X-2633	PDAC	trametinib	382.5	24.7	25	40.7	2.1
X-2633	PDAC	trametinib	246.5	23.8	28	-9.3	-1.7
X-2633	PDAC	trametinib	214.2	25.4	32	-21.2	5
X-2633	PDAC	trametinib	261.1	24.2	35	-4	0
X-2633	PDAC	trametinib	206.5	25.5	40	-24.1	5.4
X-2633	PDAC	trametinib	195.3	24.5	45	-28.2	1.2
X-2633	PDAC	trametinib	120.1	24.3	48	-55.8	0.4
X-2633	PDAC	trametinib	163.3	25.1	52	-39.9	3.7
X-2633	PDAC	trametinib	137.4	24.6	55	-49.5	1.7
X-2633	PDAC	trametinib	122.8	24.8	59	-54.8	2.5
X-2633	PDAC	trametinib	106.2	24.8	62	-60.9	2.5
X-2633	PDAC	trametinib	98.4	23.7	66	-63.8	-2.1
X-2633	PDAC	trametinib	83.2	25	69	-69.4	3.3
X-2633	PDAC	trametinib	108	25.1	73	-60.3	3.7
X-2633	PDAC	trametinib	78.4	24.8	76	-71.2	2.5
X-2633	PDAC	trametinib	75.6	25.1	80	-72.2	3.7
X-2633	PDAC	trametinib	71.8	25.2	84	-73.6	4.1
X-2633	PDAC	trametinib	77.2	24.8	87	-71.6	2.5
X-2633	PDAC	trametinib	39.7	24.9	90	-85.4	2.9
X-2633	PDAC	untreated	264	25.3	0	0	0
X-2633	PDAC	untreated	303.2	25.8	2	14.8	2
X-2633	PDAC	untreated	394.3	26.1	8	49.4	3.2
X-2633	PDAC	untreated	488	26	11	84.8	2.8
X-2633	PDAC	untreated	585	26.4	13	121.6	4.3
X-2633	PDAC	untreated	634	26.3	16	140.2	4
X-2633	PDAC	untreated	616.6	26.6	20	133.6	5.1
X-2633	PDAC	untreated	721.5	26.2	23	173.3	3.6
X-2633	PDAC	untreated	759.1	26.7	27	187.5	5.5
X-2633	PDAC	untreated	894.1	25.8	31	238.7	2
X-2633	PDAC	untreated	1075.8	26.2	35	307.5	3.6
X-2633	PDAC	untreated	1046.6	26.2	37	296.4	3.6
X-2633	PDAC	untreated	1037.8	28.4	41	293.1	12.3
X-2633	PDAC	untreated	1215.9	26.8	44	360.6	5.9
X-2633	PDAC	untreated	1237.2	26.8	49	368.6	5.9
X-2633	PDAC	untreated	1372.8	26.7	55	420	5.5
X-2633	PDAC	untreated	1535.9	NA	59	481.8	5.5
X-2640	BRCA	BGJ398	217.2	28.3	0	0	0
X-2640	BRCA	BGJ398	236.2	28.8	3	8.7	1.8
X-2640	BRCA	BGJ398	258.1	27.7	6	18.8	-2.1
X-2640	BRCA	BGJ398	215.1	27.1	10	-1	-4.2
X-2640	BRCA	BGJ398	232.2	27.5	13	6.9	-2.8
X-2640	BRCA	BGJ398	211.4	27.1	17	-2.7	-4.2
X-2640	BRCA	BGJ398	195.2	27.4	20	-10.1	-3.2
X-2640	BRCA	BGJ398	199.8	26.6	23	-8	-6
X-2640	BRCA	BGJ398	198.1	26.4	27	-8.8	-6.7
X-2640	BRCA	BGJ398	200.6	27.3	30	-7.6	-3.5
X-2640	BRCA	BGJ398	201.5	28.4	34	-7.2	0.4
X-2640	BRCA	BGJ398	202.1	27	37	-7	-4.6
X-2640	BRCA	BGJ398	190.4	26.8	41	-12.3	-5.3
X-2640	BRCA	BGJ398	198.3	27	45	-8.7	-4.6
X-2640	BRCA	BGJ398	172.2	26.5	48	-20.7	-6.4
X-2640	BRCA	BGJ398	204.8	27.6	52	-5.7	-2.5
X-2640	BRCA	BGJ398	192.9	28.1	55	-11.2	-0.7
X-2640	BRCA	BGJ398	180.8	28.2	59	-16.8	-0.4
X-2640	BRCA	BGJ398	169.7	28.1	62	-21.9	-0.7
X-2640	BRCA	BGJ398	161.2	28	66	-25.8	-1.1
X-2640	BRCA	BGJ398	161.3	26.2	69	-25.7	-7.4
X-2640	BRCA	BGJ398	157.3	27.7	73	-27.6	-2.1
X-2640	BRCA	BGJ398	189.3	27.3	76	-12.8	-3.5
X-2640	BRCA	BGJ398	168.2	27.2	80	-22.6	-3.9
X-2640	BRCA	BGJ398	187.5	26.2	83	-13.7	-7.4
X-2640	BRCA	BGJ398	178.4	26.6	87	-17.9	-6
X-2640	BRCA	BGJ398	163.8	27	90	-24.6	-4.6
X-2640	BRCA	BGJ398	170	26.4	94	-21.7	-6.7
X-2640	BRCA	BGJ398	178.3	26.1	97	-17.9	-7.8
X-2640	BRCA	BKM120	215.4	28.7	0	0	0
X-2640	BRCA	BKM120	216.2	29	3	0.4	1
X-2640	BRCA	BKM120	210.7	28	7	-2.2	-2.4
X-2640	BRCA	BKM120	198	29.4	10	-8.1	2.4
X-2640	BRCA	BKM120	195.8	29.9	14	-9.1	4.2
X-2640	BRCA	BKM120	195.7	29.7	17	-9.1	3.5
X-2640	BRCA	BKM120	178.1	29	21	-17.3	1
X-2640	BRCA	BKM120	158.7	30.3	25	-26.3	5.6
X-2640	BRCA	BKM120	155.6	30.8	28	-27.8	7.3
X-2640	BRCA	BKM120	143	30.6	32	-33.6	6.6
X-2640	BRCA	BKM120	139	29.7	35	-35.5	3.5
X-2640	BRCA	BKM120	142.5	31.2	39	-33.8	8.7
X-2640	BRCA	BKM120	132.7	30.9	42	-38.4	7.7
X-2640	BRCA	BKM120	129.2	31.8	46	-40	10.8
X-2640	BRCA	BKM120	131.7	31	49	-38.9	8
X-2640	BRCA	BKM120	119.1	31.1	53	-44.7	8.4
X-2640	BRCA	BKM120	108.9	31.3	56	-49.4	9.1
X-2640	BRCA	BKM120	120	32	60	-44.3	11.5
X-2640	BRCA	BKM120	123.7	32.4	63	-42.6	12.9
X-2640	BRCA	BKM120	121.9	31.8	67	-43.4	10.8
X-2640	BRCA	BKM120	129.7	31.4	70	-39.8	9.4
X-2640	BRCA	BKM120	142.6	32.7	74	-33.8	13.9
X-2640	BRCA	BKM120	121.4	32.3	77	-43.6	12.5
X-2640	BRCA	BKM120	133.1	32.7	81	-38.2	13.9
X-2640	BRCA	BKM120	131.3	31.7	84	-39	10.5
X-2640	BRCA	BKM120	132.4	32.7	88	-38.5	13.9
X-2640	BRCA	BKM120	112.8	32.7	91	-47.6	13.9
X-2640	BRCA	BYL719 + LEE011	237.8	25.5	0	0	0
X-2640	BRCA	BYL719 + LEE011	199.6	24.5	3	-16.1	-3.9
X-2640	BRCA	BYL719 + LEE011	187	23.4	7	-21.4	-8.2
X-2640	BRCA	BYL719 + LEE011	182.5	24.3	10	-23.3	-4.7
X-2640	BRCA	BYL719 + LEE011	173.7	24.4	14	-27	-4.3
X-2640	BRCA	BYL719 + LEE011	151.9	24.7	17	-36.1	-3.1
X-2640	BRCA	BYL719 + LEE011	153.5	23.3	21	-35.4	-8.6
X-2640	BRCA	BYL719 + LEE011	162.9	23.5	24	-31.5	-7.8
X-2640	BRCA	BYL719 + LEE011	147.2	24.9	28	-38.1	-2.4
X-2640	BRCA	BYL719 + LEE011	138.2	25.2	31	-41.9	-1.2
X-2640	BRCA	BYL719 + LEE011	134.2	23.3	35	-43.6	-8.6
X-2640	BRCA	BYL719 + LEE011	137.5	23.6	38	-42.2	-7.5
X-2640	BRCA	BYL719 + LJM716	234.8	28.9	0	0	0
X-2640	BRCA	BYL719 + LJM716	213.6	26.1	3	-9	-9.7
X-2640	BRCA	BYL719 + LJM716	182.1	27.8	7	-22.4	-3.8
X-2640	BRCA	BYL719 + LJM716	196.2	26.7	10	-16.4	-7.6
X-2640	BRCA	BYL719 + LJM716	171	29.1	14	-27.2	0.7
X-2640	BRCA	BYL719 + LJM716	175.2	27.9	17	-25.4	-3.5
X-2640	BRCA	BYL719 + LJM716	184.5	27.9	21	-21.4	-3.5
X-2640	BRCA	BYL719 + LJM716	186	27.4	24	-20.8	-5.2
X-2640	BRCA	BYL719 + LJM716	193.1	28.6	28	-17.8	-1
X-2640	BRCA	BYL719 + LJM716	197.5	28.3	31	-15.9	-2.1
X-2640	BRCA	BYL719	190.6	27.1	0	0	0
X-2640	BRCA	BYL719	156.6	27.1	3	-17.8	0
X-2640	BRCA	BYL719	187.3	26.4	7	-1.7	-2.6
X-2640	BRCA	BYL719	183	26.2	10	-4	-3.3
X-2640	BRCA	BYL719	206.6	27.3	17	8.4	0.7
X-2640	BRCA	BYL719	195.4	27.6	20	2.5	1.8
X-2640	BRCA	BYL719	214	27.7	25	12.3	2.2
X-2640	BRCA	BYL719	190	27.1	28	-0.3	0
X-2640	BRCA	BYL719	231.3	26.8	31	21.4	-1.1
X-2640	BRCA	BYL719	227.3	27.9	35	19.3	3
X-2640	BRCA	BYL719	209.7	27.5	38	10	1.5
X-2640	BRCA	BYL719	226.8	27.9	42	19	3
X-2640	BRCA	BYL719	240.1	27.4	45	26	1.1
X-2640	BRCA	BYL719	249.8	27.8	49	31.1	2.6
X-2640	BRCA	BYL719	268.4	28.7	52	40.8	5.9
X-2640	BRCA	BYL719	340.2	27.3	56	78.5	0.7
X-2640	BRCA	BYL719	344.5	27.7	59	80.7	2.2
X-2640	BRCA	BYL719	373	27.7	63	95.7	2.2
X-2640	BRCA	BYL719	411.9	27.7	66	116.1	2.2
X-2640	BRCA	BYL719	386.6	28.1	70	102.8	3.7
X-2640	BRCA	BYL719	374.8	27.3	73	96.6	0.7
X-2640	BRCA	BYL719	406.1	26.5	76	113.1	-2.2
X-2640	BRCA	BYL719	451.1	27.6	80	136.7	1.8
X-2640	BRCA	BYL719	502.9	28.1	84	163.9	3.7
X-2640	BRCA	BYL719	575.3	27.5	87	201.8	1.5
X-2640	BRCA	CGM097	203.3	23.8	0	0	0
X-2640	BRCA	CGM097	203.3	23.5	3	0	-1.3
X-2640	BRCA	CGM097	197.5	24.6	7	-2.9	3.4
X-2640	BRCA	CGM097	196.5	24.7	10	-3.3	3.8
X-2640	BRCA	CGM097	224.8	26.2	14	10.6	10.1
X-2640	BRCA	CGM097	234.4	25.9	17	15.3	8.8
X-2640	BRCA	CGM097	303.4	25.3	21	49.2	6.3
X-2640	BRCA	CGM097	308	25.1	25	51.5	5.5
X-2640	BRCA	CGM097	352.1	25.5	28	73.2	7.1
X-2640	BRCA	CGM097	389.5	25.1	32	91.6	5.5
X-2640	BRCA	CGM097	409.8	25.1	35	101.6	5.5
X-2640	BRCA	CGM097	455.4	25.6	39	124	7.6
X-2640	BRCA	CGM097	499.2	25.4	42	145.5	6.7
X-2640	BRCA	CGM097	590.5	25.6	46	190.5	7.6
X-2640	BRCA	CGM097	657.9	25.5	49	223.6	7.1
X-2640	BRCA	CGM097	727	25	53	257.6	5
X-2640	BRCA	CGM097	810.8	25.2	56	298.8	5.9
X-2640	BRCA	CGM097	762	25.6	60	274.8	7.6
X-2640	BRCA	CGM097	783.3	25.7	63	285.3	8
X-2640	BRCA	CGM097	877.2	25.8	67	331.5	8.4
X-2640	BRCA	CGM097	1001.6	25.8	70	392.7	8.4
X-2640	BRCA	CLR457	261.6	29.6	0	0	0
X-2640	BRCA	CLR457	257.1	29	3	-1.7	-2
X-2640	BRCA	CLR457	255.1	30.3	6	-2.5	2.4
X-2640	BRCA	CLR457	256.7	30.9	10	-1.9	4.4
X-2640	BRCA	CLR457	267.7	30.8	13	2.3	4.1
X-2640	BRCA	CLR457	266.9	30.3	17	2	2.4
X-2640	BRCA	CLR457	264.6	31.4	20	1.1	6.1
X-2640	BRCA	CLR457	264	30.9	24	0.9	4.4
X-2640	BRCA	CLR457	282.7	31.6	28	8.1	6.8
X-2640	BRCA	CLR457	272.4	32.1	31	4.1	8.4
X-2640	BRCA	CLR457	302.6	31.7	35	15.7	7.1
X-2640	BRCA	CLR457	329.4	32.8	38	25.9	10.8
X-2640	BRCA	CLR457	305.3	31.5	42	16.7	6.4
X-2640	BRCA	CLR457	315.5	31	45	20.6	4.7
X-2640	BRCA	CLR457	397.1	31.8	49	51.8	7.4
X-2640	BRCA	CLR457	369.8	30.9	52	41.4	4.4
X-2640	BRCA	CLR457	420.2	32	56	60.6	8.1
X-2640	BRCA	CLR457	421.5	31.6	59	61.1	6.8
X-2640	BRCA	CLR457	423.6	31.1	63	61.9	5.1
X-2640	BRCA	CLR457	371.1	31.3	66	41.9	5.7
X-2640	BRCA	CLR457	388.7	31.6	70	48.6	6.8
X-2640	BRCA	CLR457	404.4	32	73	54.6	8.1
X-2640	BRCA	CLR457	529.1	32.4	77	102.3	9.5
X-2640	BRCA	CLR457	535.4	32.2	80	104.7	8.8
X-2640	BRCA	CLR457	563.1	33.2	84	115.3	12.2
X-2640	BRCA	CLR457	629.6	32.3	87	140.7	9.1
X-2640	BRCA	HDM201	245.6	25.5	0	0	0
X-2640	BRCA	HDM201	314.2	26.5	3	27.9	3.9
X-2640	BRCA	HDM201	371.7	25.9	7	51.3	1.6
X-2640	BRCA	HDM201	448.9	26.5	10	82.8	3.9
X-2640	BRCA	HDM201	656.6	27.9	17	167.3	9.4
X-2640	BRCA	HDM201	690.5	27.4	20	181.1	7.5
X-2640	BRCA	HDM201	817.2	27.3	25	232.7	7.1
X-2640	BRCA	INC424	230.1	28.2	0	0	0
X-2640	BRCA	INC424	240.2	28.1	3	4.4	-0.4
X-2640	BRCA	INC424	230.7	28.3	6	0.3	0.4
X-2640	BRCA	INC424	315.1	28.7	10	36.9	1.8
X-2640	BRCA	INC424	235.5	28	13	2.3	-0.7
X-2640	BRCA	INC424	328.7	28.6	17	42.9	1.4
X-2640	BRCA	INC424	315.3	28.1	20	37	-0.4
X-2640	BRCA	INC424	314.5	27.7	23	36.7	-1.8
X-2640	BRCA	INC424	329.3	28.9	27	43.1	2.5
X-2640	BRCA	INC424	332.7	28.6	30	44.6	1.4
X-2640	BRCA	INC424	336.6	28.8	34	46.3	2.1
X-2640	BRCA	INC424	357.6	29.5	37	55.4	4.6
X-2640	BRCA	INC424	413.4	28.5	41	79.7	1.1
X-2640	BRCA	INC424	452.2	28.3	45	96.5	0.4
X-2640	BRCA	INC424	444.2	28.3	48	93	0.4
X-2640	BRCA	INC424	449.3	28.5	52	95.3	1.1
X-2640	BRCA	INC424	516.1	28.5	55	124.3	1.1
X-2640	BRCA	INC424	497.7	28.4	59	116.3	0.7
X-2640	BRCA	INC424	578.6	28.2	62	151.5	0
X-2640	BRCA	INC424	640.8	29.6	66	178.5	5
X-2640	BRCA	INC424	648.4	29.1	69	181.8	3.2
X-2640	BRCA	INC424	624.9	28.4	73	171.6	0.7
X-2640	BRCA	INC424	650.6	28.6	76	182.7	1.4
X-2640	BRCA	INC424	704.1	28.4	80	206	0.7
X-2640	BRCA	INC424	676.5	28.6	83	194	1.4
X-2640	BRCA	INC424	724.4	28.9	87	214.8	2.5
X-2640	BRCA	INC424	881.5	29.2	90	283.1	3.5
X-2640	BRCA	LEE011 + everolimus	199.6	23.8	0	0	0
X-2640	BRCA	LEE011 + everolimus	245.9	25.7	4	23.2	8
X-2640	BRCA	LEE011 + everolimus	244.8	24.8	7	22.6	4.2
X-2640	BRCA	LEE011 + everolimus	258.5	25.7	11	29.5	8
X-2640	BRCA	LEE011 + everolimus	250.6	27.4	14	25.6	15.1
X-2640	BRCA	LEE011 + everolimus	269.6	26.5	18	35.1	11.3
X-2640	BRCA	LEE011 + everolimus	308.2	27.7	21	54.4	16.4
X-2640	BRCA	LEE011 + everolimus	345.6	27.4	25	73.1	15.1
X-2640	BRCA	LEE011 + everolimus	340.7	27.8	28	70.7	16.8
X-2640	BRCA	LEE011 + everolimus	345.1	26.4	32	72.9	10.9
X-2640	BRCA	LEE011 + everolimus	377.5	26.8	35	89.1	12.6
X-2640	BRCA	LEE011 + everolimus	369.8	27.4	39	85.3	15.1
X-2640	BRCA	LEE011 + everolimus	378.8	27.8	42	89.8	16.8
X-2640	BRCA	LEE011 + everolimus	360.6	27.7	46	80.7	16.4
X-2640	BRCA	LEE011 + everolimus	397.6	27.8	49	99.2	16.8
X-2640	BRCA	LEE011 + everolimus	456	27	53	128.5	13.4
X-2640	BRCA	LEE011 + everolimus	487.4	28.4	56	144.2	19.3
X-2640	BRCA	LEE011	206.5	25.1	0	0	0
X-2640	BRCA	LEE011	224.2	27.1	4	8.6	8
X-2640	BRCA	LEE011	222.1	27.5	7	7.6	9.6
X-2640	BRCA	LEE011	244.5	27.9	11	18.4	11.2
X-2640	BRCA	LEE011	252	27.8	14	22	10.8
X-2640	BRCA	LEE011	272.6	26.7	18	32	6.4
X-2640	BRCA	LEE011	319.2	27.8	21	54.6	10.8
X-2640	BRCA	LEE011	356.7	27.8	25	72.7	10.8
X-2640	BRCA	LEE011	364.9	27.4	28	76.7	9.2
X-2640	BRCA	LEE011	446.7	26.9	32	116.3	7.2
X-2640	BRCA	LEE011	447.7	27.7	35	116.8	10.4
X-2640	BRCA	LEE011	575.1	27.5	39	178.5	9.6
X-2640	BRCA	LEE011	587.4	28.5	42	184.5	13.5
X-2640	BRCA	LEE011	577.1	26.4	46	179.5	5.2
X-2640	BRCA	LEE011	559.9	27	49	171.1	7.6
X-2640	BRCA	LEE011	610.8	28.2	53	195.8	12.4
X-2640	BRCA	LEE011	673.2	NA	56	226	12.4
X-2640	BRCA	LFA102	193.9	26.7	0	0	0
X-2640	BRCA	LFA102	214.7	26.5	3	10.7	-0.7
X-2640	BRCA	LFA102	242.4	27.2	6	25	1.9
X-2640	BRCA	LFA102	331.3	27.3	10	70.9	2.2
X-2640	BRCA	LFA102	352.4	27.4	13	81.7	2.6
X-2640	BRCA	LFA102	320.5	26.7	17	65.3	0
X-2640	BRCA	LFA102	308.3	27.2	20	59	1.9
X-2640	BRCA	LFA102	336.6	27.5	24	73.6	3
X-2640	BRCA	LFA102	359.6	28.3	27	85.5	6
X-2640	BRCA	LFA102	419.1	27.7	31	116.1	3.7
X-2640	BRCA	LFA102	482.9	29.5	34	149	10.5
X-2640	BRCA	LFA102	457.5	27.8	38	135.9	4.1
X-2640	BRCA	LFA102	490.6	27.2	41	153	1.9
X-2640	BRCA	LFA102	478.4	27.1	45	146.7	1.5
X-2640	BRCA	LFA102	485.1	27.6	48	150.2	3.4
X-2640	BRCA	LFA102	510.5	27.6	52	163.3	3.4
X-2640	BRCA	LFA102	547.3	28.9	56	182.3	8.2
X-2640	BRCA	LFA102	596.8	26.9	59	207.8	0.7
X-2640	BRCA	LFA102	600.6	28.6	62	209.7	7.1
X-2640	BRCA	LFA102	577.5	27.5	66	197.8	3
X-2640	BRCA	LFA102	611.6	28.1	69	215.4	5.2
X-2640	BRCA	LFA102	657.2	28.9	73	238.9	8.2
X-2640	BRCA	LFA102	677.3	28.5	76	249.3	6.7
X-2640	BRCA	LJM716 + trastuzumab	224.1	26.9	0	0	0
X-2640	BRCA	LJM716 + trastuzumab	269.7	26	3	20.3	-3.3
X-2640	BRCA	LJM716 + trastuzumab	268.4	27.8	6	19.8	3.3
X-2640	BRCA	LJM716 + trastuzumab	299.5	28.8	10	33.6	7.1
X-2640	BRCA	LJM716 + trastuzumab	274.5	28	13	22.5	4.1
X-2640	BRCA	LJM716 + trastuzumab	306.3	27.4	17	36.7	1.9
X-2640	BRCA	LJM716 + trastuzumab	314.4	27.6	20	40.3	2.6
X-2640	BRCA	LJM716 + trastuzumab	382.1	27.7	24	70.5	3
X-2640	BRCA	LJM716 + trastuzumab	362.4	28	27	61.7	4.1
X-2640	BRCA	LJM716 + trastuzumab	329.3	26.8	31	46.9	-0.4
X-2640	BRCA	LJM716 + trastuzumab	347.3	26.1	34	55	-3
X-2640	BRCA	LJM716 + trastuzumab	379.6	26.8	38	69.4	-0.4
X-2640	BRCA	LJM716 + trastuzumab	406.1	27.7	41	81.2	3
X-2640	BRCA	LJM716 + trastuzumab	390.7	27.1	45	74.3	0.7
X-2640	BRCA	LJM716 + trastuzumab	397.4	27.4	49	77.3	1.9
X-2640	BRCA	LJM716 + trastuzumab	384.7	26.4	52	71.7	-1.9
X-2640	BRCA	LJM716 + trastuzumab	370.8	27.1	55	65.5	0.7
X-2640	BRCA	LJM716 + trastuzumab	399.3	28	59	78.2	4.1
X-2640	BRCA	LJM716 + trastuzumab	440	27.6	62	96.3	2.6
X-2640	BRCA	LJM716 + trastuzumab	474.7	27.9	66	111.8	3.7
X-2640	BRCA	LJM716 + trastuzumab	474.4	27.5	69	111.7	2.2
X-2640	BRCA	LJM716 + trastuzumab	453.2	27	73	102.2	0.4
X-2640	BRCA	LJM716 + trastuzumab	502.1	28	76	124.1	4.1
X-2640	BRCA	LJM716 + trastuzumab	524.1	27.7	80	133.9	3
X-2640	BRCA	LJM716 + trastuzumab	528.8	27.2	83	136	1.1
X-2640	BRCA	LJM716 + trastuzumab	583.8	25.9	91	160.5	-3.7
X-2640	BRCA	LJM716 + trastuzumab	677.7	27.7	94	202.4	3
X-2640	BRCA	LJM716 + trastuzumab	717.4	27.3	97	220.1	1.5
X-2640	BRCA	LJM716	217.6	27.2	0	0	0
X-2640	BRCA	LJM716	166.9	25.3	4	-23.3	-7
X-2640	BRCA	LJM716	171.5	25.3	7	-21.2	-7
X-2640	BRCA	LJM716	191.9	25.1	11	-11.8	-7.7
X-2640	BRCA	LJM716	194.6	25.5	14	-10.6	-6.2
X-2640	BRCA	LJM716	194.7	25.3	17	-10.5	-7
X-2640	BRCA	LJM716	202.3	25.9	21	-7	-4.8
X-2640	BRCA	LJM716	208.5	26.3	24	-4.2	-3.3
X-2640	BRCA	LJM716	212.6	26	28	-2.3	-4.4
X-2640	BRCA	LJM716	227.8	26.4	31	4.7	-2.9
X-2640	BRCA	LJM716	220.7	24.3	35	1.4	-10.7
X-2640	BRCA	LJM716	212.4	23.2	39	-2.4	-14.7
X-2640	BRCA	LJM716	215.6	23.9	42	-0.9	-12.1
X-2640	BRCA	LJM716	225.3	24.9	46	3.5	-8.5
X-2640	BRCA	LJM716	251.3	24.3	49	15.5	-10.7
X-2640	BRCA	LJM716	214	25	53	-1.7	-8.1
X-2640	BRCA	LJM716	245.3	25.6	56	12.7	-5.9
X-2640	BRCA	LJM716	256.5	26.8	60	17.9	-1.5
X-2640	BRCA	LJM716	247.2	25.7	63	13.6	-5.5
X-2640	BRCA	LJM716	208.7	25.2	67	-4.1	-7.4
X-2640	BRCA	LJM716	258.5	26.1	70	18.8	-4
X-2640	BRCA	LJM716	252.3	26.1	74	15.9	-4
X-2640	BRCA	LJM716	258	26.5	77	18.6	-2.6
X-2640	BRCA	LJM716	244.2	27	81	12.2	-0.7
X-2640	BRCA	LJM716	293.6	26.5	84	34.9	-2.6
X-2640	BRCA	LJM716	277.6	27.6	88	27.6	1.5
X-2640	BRCA	LJM716	270.7	26.4	91	24.4	-2.9
X-2640	BRCA	LJM716	299.4	26.8	95	37.6	-1.5
X-2640	BRCA	LJM716	309.2	26.6	98	42.1	-2.2
X-2640	BRCA	LJM716	300.1	26.4	102	37.9	-2.9
X-2640	BRCA	LJM716	335.4	25.7	105	54.1	-5.5
X-2640	BRCA	LKA136	225.6	27.1	0	0	0
X-2640	BRCA	LKA136	217.7	28	3	-3.5	3.3
X-2640	BRCA	LKA136	224.4	28.1	6	-0.5	3.7
X-2640	BRCA	LKA136	233.1	28.8	9	3.3	6.3
X-2640	BRCA	LKA136	237.7	29.3	13	5.4	8.1
X-2640	BRCA	LKA136	265.3	29.4	16	17.6	8.5
X-2640	BRCA	LKA136	275.4	28.6	20	22.1	5.5
X-2640	BRCA	LKA136	287.3	28.3	23	27.3	4.4
X-2640	BRCA	LKA136	348.9	27.8	27	54.7	2.6
X-2640	BRCA	LKA136	395.1	29	31	75.1	7
X-2640	BRCA	LKA136	366.2	29	34	62.3	7
X-2640	BRCA	LKA136	363.7	28.7	38	61.2	5.9
X-2640	BRCA	LKA136	354.5	28.9	41	57.1	6.6
X-2640	BRCA	LKA136	400.2	28.7	45	77.4	5.9
X-2640	BRCA	LKA136	445.7	28.6	48	97.6	5.5
X-2640	BRCA	LKA136	500.9	28.7	52	122	5.9
X-2640	BRCA	LKA136	522.3	28.7	55	131.5	5.9
X-2640	BRCA	LKA136	566.9	28.4	59	151.3	4.8
X-2640	BRCA	LKA136	569.9	28.2	62	152.6	4.1
X-2640	BRCA	LKA136	552.8	27.5	66	145	1.5
X-2640	BRCA	LKA136	559.3	28.2	69	147.9	4.1
X-2640	BRCA	LKA136	579.7	28.3	73	157	4.4
X-2640	BRCA	LKA136	645.1	30.5	76	185.9	12.5
X-2640	BRCA	LKA136	775.2	29.5	80	243.6	8.9
X-2640	BRCA	LKA136	783.4	29.4	83	247.3	8.5
X-2640	BRCA	LKA136	960.4	29.1	87	325.7	7.4
X-2640	BRCA	LKA136	986.9	29.3	90	337.5	8.1
X-2640	BRCA	LLM871	282.9	24.9	0	0	0
X-2640	BRCA	LLM871	305.8	24.2	3	8.1	-2.8
X-2640	BRCA	LLM871	340.6	24.7	6	20.4	-0.8
X-2640	BRCA	LLM871	279.1	24.8	10	-1.3	-0.4
X-2640	BRCA	LLM871	322.6	24.4	13	14	-2
X-2640	BRCA	LLM871	298.9	24.3	17	5.7	-2.4
X-2640	BRCA	LLM871	298.6	24.7	20	5.5	-0.8
X-2640	BRCA	LLM871	330.6	24.2	24	16.9	-2.8
X-2640	BRCA	LLM871	297.2	24.9	27	5.1	0
X-2640	BRCA	LLM871	280.8	24.3	31	-0.7	-2.4
X-2640	BRCA	LLM871	242.4	24.8	34	-14.3	-0.4
X-2640	BRCA	LLM871	232	24.4	38	-18	-2
X-2640	BRCA	LLM871	195	25.4	41	-31.1	2
X-2640	BRCA	LLM871	141.9	24.7	45	-49.8	-0.8
X-2640	BRCA	LLM871	132.9	25.6	48	-53	2.8
X-2640	BRCA	LLM871	133	25.4	52	-53	2
X-2640	BRCA	LLM871	110.9	26.1	55	-60.8	4.8
X-2640	BRCA	LLM871	58.3	26.5	59	-79.4	6.4
X-2640	BRCA	LLM871	52.6	26.3	63	-81.4	5.6
X-2640	BRCA	LLM871	34.7	24.9	66	-87.7	0
X-2640	BRCA	LLM871	27.7	25.6	69	-90.2	2.8
X-2640	BRCA	LLM871	15.5	24.8	73	-94.5	-0.4
X-2640	BRCA	LLM871	10	26.4	76	-96.5	6
X-2640	BRCA	LLM871	0	27.4	80	-100	10
X-2640	BRCA	LLM871	0	26.5	83	-100	6.4
X-2640	BRCA	LLM871	0	25.8	87	-100	3.6
X-2640	BRCA	LLM871	0	26.4	90	-100	6
X-2640	BRCA	LLM871	0	25.7	94	-100	3.2
X-2640	BRCA	LLM871	0	25.8	97	-100	3.6
X-2640	BRCA	LLM871	0	26.1	105	-100	4.8
X-2640	BRCA	LLM871	0	25.6	108	-100	2.8
X-2640	BRCA	LLM871	0	26.7	111	-100	7.2
X-2640	BRCA	LLM871	0	26.6	119	-100	6.8
X-2640	BRCA	LLM871	0	25.6	122	-100	2.8
X-2640	BRCA	LLM871	0	27.9	125	-100	12
X-2640	BRCA	LLM871	0	27	129	-100	8.4
X-2640	BRCA	LLM871	0	27.5	132	-100	10.4
X-2640	BRCA	LLM871	0	27.5	136	-100	10.4
X-2640	BRCA	LLM871	0	27.6	139	-100	10.8
X-2640	BRCA	binimetinib	265	27.2	0	0	0
X-2640	BRCA	binimetinib	246.2	26.2	3	-7.1	-3.7
X-2640	BRCA	binimetinib	233.2	26.3	7	-12	-3.3
X-2640	BRCA	binimetinib	265.1	25.7	10	0	-5.5
X-2640	BRCA	binimetinib	263.7	26.5	14	-0.5	-2.6
X-2640	BRCA	binimetinib	294.9	25.8	17	11.3	-5.1
X-2640	BRCA	binimetinib	300.5	25.7	21	13.4	-5.5
X-2640	BRCA	binimetinib	272.4	26.1	24	2.8	-4
X-2640	BRCA	binimetinib	282.4	25.8	28	6.6	-5.1
X-2640	BRCA	binimetinib	295.9	25.3	31	11.7	-7
X-2640	BRCA	binimetinib	296	24.5	35	11.7	-9.9
X-2640	BRCA	binimetinib	353.7	24.5	38	33.5	-9.9
X-2640	BRCA	binimetinib	365.2	26.2	42	37.8	-3.7
X-2640	BRCA	binimetinib	352.5	26	45	33	-4.4
X-2640	BRCA	binimetinib	382.7	26.2	49	44.4	-3.7
X-2640	BRCA	binimetinib	397.6	25.8	52	50	-5.1
X-2640	BRCA	binimetinib	389.9	26.3	56	47.1	-3.3
X-2640	BRCA	binimetinib	434.4	26.5	60	63.9	-2.6
X-2640	BRCA	binimetinib	423.7	25.6	63	59.9	-5.9
X-2640	BRCA	binimetinib	434.6	25.4	66	64	-6.6
X-2640	BRCA	binimetinib	441	25.1	70	66.4	-7.7
X-2640	BRCA	binimetinib	402.9	25.1	73	52	-7.7
X-2640	BRCA	binimetinib	429.5	25.7	77	62.1	-5.5
X-2640	BRCA	binimetinib	419.1	25.8	80	58.2	-5.1
X-2640	BRCA	paclitaxel	305.7	27.1	0	0	0
X-2640	BRCA	paclitaxel	244.7	26.3	6	-20	-3
X-2640	BRCA	paclitaxel	292.1	25.9	9	-4.4	-4.4
X-2640	BRCA	paclitaxel	350.2	26.4	14	14.6	-2.6
X-2640	BRCA	paclitaxel	371.2	26.5	17	21.4	-2.2
X-2640	BRCA	paclitaxel	473.3	27	20	54.8	-0.4
X-2640	BRCA	paclitaxel	460.7	26.5	24	50.7	-2.2
X-2640	BRCA	paclitaxel	394.9	26.1	27	29.2	-3.7
X-2640	BRCA	paclitaxel	474.6	27.3	31	55.3	0.7
X-2640	BRCA	paclitaxel	498.2	26.6	34	63	-1.8
X-2640	BRCA	paclitaxel	555.3	26.9	38	81.6	-0.7
X-2640	BRCA	paclitaxel	644.3	27.3	41	110.8	0.7
X-2640	BRCA	paclitaxel	676.3	26.9	45	121.2	-0.7
X-2640	BRCA	paclitaxel	722.7	27.1	48	136.4	0
X-2640	BRCA	paclitaxel	711.8	26.9	52	132.8	-0.7
X-2640	BRCA	paclitaxel	729.8	27.2	55	138.7	0.4
X-2640	BRCA	paclitaxel	858.9	27.1	59	181	0
X-2640	BRCA	paclitaxel	991.5	27.3	62	224.3	0.7
X-2640	BRCA	paclitaxel	959.7	27.5	65	213.9	1.5
X-2640	BRCA	paclitaxel	977.1	27.1	69	219.6	0
X-2640	BRCA	paclitaxel	1158.8	27.7	73	279.1	2.2
X-2640	BRCA	paclitaxel	1198.2	27.7	76	292	2.2
X-2640	BRCA	tamoxifen	265.1	27.9	0	0	0
X-2640	BRCA	tamoxifen	325.6	29.1	3	22.8	4.3
X-2640	BRCA	tamoxifen	375	29	7	41.5	3.9
X-2640	BRCA	tamoxifen	380.3	28.8	10	43.5	3.2
X-2640	BRCA	tamoxifen	552	30.2	17	108.2	8.2
X-2640	BRCA	tamoxifen	571.1	28.5	20	115.4	2.2
X-2640	BRCA	tamoxifen	626.2	30.1	25	136.2	7.9
X-2640	BRCA	tamoxifen	745.8	30.5	28	181.3	9.3
X-2640	BRCA	tamoxifen	861.8	30.2	31	225.1	8.2
X-2640	BRCA	trastuzumab	211.7	26.2	0	0	0
X-2640	BRCA	trastuzumab	247.7	26.7	3	17	1.9
X-2640	BRCA	trastuzumab	307	26.6	6	45	1.5
X-2640	BRCA	trastuzumab	341.8	27.1	10	61.5	3.4
X-2640	BRCA	trastuzumab	304.1	27.5	13	43.6	5
X-2640	BRCA	trastuzumab	363.1	26.7	17	71.5	1.9
X-2640	BRCA	trastuzumab	414.9	27	20	96	3.1
X-2640	BRCA	trastuzumab	465.1	26.8	24	119.7	2.3
X-2640	BRCA	trastuzumab	506.9	27.2	27	139.4	3.8
X-2640	BRCA	trastuzumab	652.1	27.3	31	208	4.2
X-2640	BRCA	trastuzumab	749	29.8	34	253.8	13.7
X-2640	BRCA	trastuzumab	818.9	28.6	38	286.8	9.2
X-2640	BRCA	trastuzumab	852.7	28.2	41	302.8	7.6
X-2640	BRCA	trastuzumab	875.2	29.5	45	313.4	12.6
X-2640	BRCA	trastuzumab	994.6	29.3	48	369.8	11.8
X-2640	BRCA	trastuzumab	1131.4	28.5	52	434.4	8.8
X-2640	BRCA	trastuzumab	1243.7	28.4	56	487.5	8.4
X-2640	BRCA	untreated	199.5	28.7	0	0	0
X-2640	BRCA	untreated	249.7	28	3	25.2	-2.4
X-2640	BRCA	untreated	217.9	28	6	9.2	-2.4
X-2640	BRCA	untreated	241.6	27.2	10	21.1	-5.2
X-2640	BRCA	untreated	334.7	27.6	20	67.8	-3.8
X-2640	BRCA	untreated	323.2	27.3	24	62	-4.9
X-2640	BRCA	untreated	377.8	27.8	27	89.4	-3.1
X-2640	BRCA	untreated	373.1	27.8	31	87	-3.1
X-2640	BRCA	untreated	379.4	27.5	34	90.2	-4.2
X-2640	BRCA	untreated	416.7	27.9	38	108.9	-2.8
X-2640	BRCA	untreated	426.5	27.5	41	113.8	-4.2
X-2640	BRCA	untreated	432.2	28.1	44	116.6	-2.1
X-2640	BRCA	untreated	456.6	28	51	128.9	-2.4
X-2640	BRCA	untreated	471.9	27.9	55	136.5	-2.8
X-2640	BRCA	untreated	464.7	27.9	58	132.9	-2.8
X-2640	BRCA	untreated	443.9	27.5	62	122.5	-4.2
X-2640	BRCA	untreated	422.2	26.8	66	111.6	-6.6
X-2640	BRCA	untreated	472.6	27.1	69	136.9	-5.6
X-2640	BRCA	untreated	451.3	27.7	73	126.2	-3.5
X-2640	BRCA	untreated	491	27.6	76	146.1	-3.8
X-2640	BRCA	untreated	482.7	28	80	142	-2.4
X-2640	BRCA	untreated	487.7	28	83	144.5	-2.4
X-2640	BRCA	untreated	450	28.8	87	125.6	0.3
X-2640	BRCA	untreated	529.5	28.9	90	165.4	0.7
X-2640	BRCA	untreated	513	28.4	94	157.1	-1
X-2640	BRCA	untreated	585.4	27.9	97	193.4	-2.8
X-2640	BRCA	untreated	546.7	28.9	101	174	0.7
X-2640	BRCA	untreated	568.6	28.4	104	185	-1
X-2640	BRCA	untreated	603.6	28.6	108	202.6	-0.3
X-2640	BRCA	untreated	612.6	27.7	111	207.1	-3.5
X-2640	BRCA	untreated	647.9	28.6	115	224.8	-0.3
X-2640	BRCA	untreated	644	29.1	118	222.8	1.4
X-2640	BRCA	untreated	708.7	29	122	255.2	1
X-2640	BRCA	untreated	773.4	28.9	125	287.7	0.7
X-2640	BRCA	LFW527 + everolimus	225.93	28.2	0	0	0
X-2640	BRCA	LFW527 + everolimus	186.22	26.2	2	-17.6	-7.1
X-2640	BRCA	LFW527 + everolimus	125.77	25.9	6	-44.3	-8.2
X-2640	BRCA	LFW527 + everolimus	104.81	26.9	9	-53.6	-4.6
X-2640	BRCA	LFW527 + everolimus	185.81	25.9	13	-17.8	-8.2
X-2640	BRCA	LFW527 + everolimus	138.54	26.7	16	-38.7	-5.3
X-2640	BRCA	LFW527 + everolimus	155.49	26.6	20	-31.2	-5.7
X-2640	BRCA	LFW527 + everolimus	160.41	26.2	23	-29	-7.1
X-2640	BRCA	LFW527 + everolimus	147.67	26.1	27	-34.6	-7.4
X-2640	BRCA	LFW527 + everolimus	261.33	26.5	30	15.7	-6
X-2640	BRCA	LFW527 + everolimus	175.43	27.2	34	-22.4	-3.5
X-2640	BRCA	LFW527 + everolimus	253.28	26.8	37	12.1	-5
X-2640	BRCA	LFW527 + everolimus	160.78	29.6	42	-28.8	5
X-2640	BRCA	LFW527 + everolimus	136.41	28.1	45	-39.6	-0.4
X-2640	BRCA	LFW527 + everolimus	207.85	26.2	48	-8	-7.1
X-2640	BRCA	LFW527 + everolimus	192.07	26.6	51	-15	-5.7
X-2640	BRCA	LFW527 + everolimus	125.51	26.4	55	-44.4	-6.4
X-2640	BRCA	LFW527 + everolimus	229.22	27.6	58	1.5	-2.1
X-2640	BRCA	LFW527 + everolimus	289.36	27.5	62	28.1	-2.5
X-2640	BRCA	LFW527 + everolimus	256.07	26.7	65	13.3	-5.3
X-2640	BRCA	LFW527 + everolimus	233.29	27.5	69	3.3	-2.5
X-2640	BRCA	LFW527 + everolimus	234.35	26.5	72	3.7	-6
X-2640	BRCA	LFW527 + everolimus	183.18	26	76	-18.9	-7.8
X-2640	BRCA	LFW527 + everolimus	169.5	25.8	84	-25	-8.5
X-2640	BRCA	LFW527 + everolimus	169.51	26.4	87	-25	-6.4
X-2640	BRCA	LFW527 + everolimus	140.63	26.4	90	-37.8	-6.4
X-2640	BRCA	LFW527 + everolimus	156.13	26.9	93	-30.9	-4.6
X-2640	BRCA	LFW527 + everolimus	143.58	26.8	97	-36.4	-5
X-2640	BRCA	LFW527 + everolimus	169.5	27.1	100	-25	-3.9
X-2640	BRCA	LFW527 + everolimus	168.79	26.5	104	-25.3	-6
X-2640	BRCA	LFW527 + everolimus	120.24	27.3	107	-46.8	-3.2
X-2640	BRCA	LFW527 + everolimus	150.96	26.4	111	-33.2	-6.4
X-2659	CRC	5FU	200.6	26.4	0	0	0
X-2659	CRC	5FU	242.5	24.5	5	20.9	-7.2
X-2659	CRC	5FU	403.1	23.4	9	100.9	-11.4
X-2659	CRC	5FU	437.9	23	12	118.3	-12.9
X-2659	CRC	5FU	540.9	23	16	169.6	-12.9
X-2659	CRC	5FU	667.7	22.7	19	232.9	-14
X-2659	CRC	5FU	831.8	22.7	20	314.7	-14
X-2659	CRC	BKM120	200	23	0	0	0
X-2659	CRC	BKM120	214.7	23.1	4	7.3	0.4
X-2659	CRC	BKM120	234.8	21.9	8	17.4	-4.8
X-2659	CRC	BKM120	269.3	21	11	34.7	-8.7
X-2659	CRC	BKM120	261.1	20.5	15	30.6	-10.9
X-2659	CRC	BKM120	294.1	21.2	18	47.1	-7.8
X-2659	CRC	BKM120	290.2	20.6	21	45.1	-10.4
X-2659	CRC	BKM120	367	21.5	24	83.5	-6.5
X-2659	CRC	BKM120	381.2	21.1	27	90.6	-8.3
X-2659	CRC	BKM120	379.9	20.7	31	90	-10
X-2659	CRC	BKM120 + LJC049	211.4	20.2	0	0	0
X-2659	CRC	BKM120 + LJC049	240	20.7	3	13.5	2.5
X-2659	CRC	BKM120 + LJC049	252.4	20.8	6	19.4	3
X-2659	CRC	BKM120 + LJC049	262.4	19.3	10	24.1	-4.5
X-2659	CRC	BKM120 + LJC049	280.6	18.8	13	32.7	-6.9
X-2659	CRC	BKM120 + LJC049	297.3	20	16	40.6	-1
X-2659	CRC	BKM120 + LJC049	301.5	20	19	42.6	-1
X-2659	CRC	BKM120 + LJC049	312.5	20.4	22	47.8	1
X-2659	CRC	BKM120 + LJC049	318.1	19.5	26	50.5	-3.5
X-2659	CRC	BKM120 + LJC049	326.9	19	29	54.6	-5.9
X-2659	CRC	BKM120 + LJC049	334.2	16.4	33	58.1	-18.8
X-2659	CRC	BYL719	199	23.7	0	0	0
X-2659	CRC	BYL719	239.2	23.4	3	20.2	-1.3
X-2659	CRC	BYL719	277.5	22.7	7	39.4	-4.2
X-2659	CRC	BYL719	285.1	22.2	10	43.3	-6.3
X-2659	CRC	BYL719	313.9	22.5	14	57.7	-5.1
X-2659	CRC	BYL719	364.3	23.1	17	83.1	-2.5
X-2659	CRC	BYL719	432.3	22.3	20	117.2	-5.9
X-2659	CRC	BYL719	504.9	24	23	153.7	1.3
X-2659	CRC	BYL719 + LJM716	215.3	24.5	0	0	0
X-2659	CRC	BYL719 + LJM716	227	24.3	3	5.4	-0.8
X-2659	CRC	BYL719 + LJM716	241.3	23.1	7	12.1	-5.7
X-2659	CRC	BYL719 + LJM716	271.1	21.9	10	25.9	-10.6
X-2659	CRC	BYL719 + LJM716	289.3	21.5	14	34.4	-12.2
X-2659	CRC	BYL719 + LJM716	331.4	21.4	17	53.9	-12.7
X-2659	CRC	BYL719 + LJM716	348	20.4	20	61.6	-16.7
X-2659	CRC	BYL719 + cetuximab + encorafenib	201.2	24.3	0	0	0
X-2659	CRC	BYL719 + cetuximab + encorafenib	250.4	24.7	4	24.5	1.6
X-2659	CRC	BYL719 + cetuximab + encorafenib	312.7	25.4	7	55.4	4.5
X-2659	CRC	BYL719 + cetuximab + encorafenib	316.2	24.1	11	57.2	-0.8
X-2659	CRC	BYL719 + cetuximab + encorafenib	315.8	24.7	14	57	1.6
X-2659	CRC	BYL719 + cetuximab + encorafenib	316.9	22.7	17	57.5	-6.6
X-2659	CRC	BYL719 + cetuximab + encorafenib	325.5	25.8	20	61.8	6.2
X-2659	CRC	BYL719 + cetuximab + encorafenib	337.5	23.8	23	67.7	-2.1
X-2659	CRC	BYL719 + binimetinib	212.3	22.8	0	0	0
X-2659	CRC	BYL719 + binimetinib	249.7	23.8	4	17.6	4.4
X-2659	CRC	BYL719 + binimetinib	244.3	23.4	7	15.1	2.6
X-2659	CRC	BYL719 + binimetinib	241.5	24.4	11	13.8	7
X-2659	CRC	BYL719 + binimetinib	236.2	22.5	14	11.3	-1.3
X-2659	CRC	BYL719 + binimetinib	198.8	23.1	17	-6.4	1.3
X-2659	CRC	BYL719 + binimetinib	201.5	24.5	20	-5.1	7.5
X-2659	CRC	BYL719 + binimetinib	218.4	23.8	23	2.9	4.4
X-2659	CRC	BYL719 + binimetinib	207.8	21.7	27	-2.1	-4.8
X-2659	CRC	BYL719 + binimetinib	222.1	21.9	30	4.6	-3.9
X-2659	CRC	BYL719 + binimetinib	223.1	22.6	34	5.1	-0.9
X-2659	CRC	BYL719 + binimetinib	228.2	23.4	37	7.5	2.6
X-2659	CRC	BYL719 + binimetinib	245.3	23.5	40	15.5	3.1
X-2659	CRC	BYL719 + binimetinib	257.1	22.8	43	21.1	0
X-2659	CRC	BYL719 + binimetinib	303.3	23.1	47	42.9	1.3
X-2659	CRC	BYL719 + binimetinib	318.8	24.7	50	50.2	8.3
X-2659	CRC	BYL719 + binimetinib	325	24.4	52	53.1	7
X-2659	CRC	BYL719 + binimetinib	327.9	23.2	56	54.5	1.8
X-2659	CRC	BYL719 + binimetinib	324.5	22.7	59	52.8	-0.4
X-2659	CRC	BYL719 + binimetinib	340	22.9	63	60.2	0.4
X-2659	CRC	BYL719 + binimetinib	345.6	23.3	66	62.8	2.2
X-2659	CRC	BYL719 + binimetinib	364.8	23.9	69	71.8	4.8
X-2659	CRC	BYL719 + binimetinib	378.8	22.4	72	78.4	-1.8
X-2659	CRC	BYL719 + binimetinib	416.4	23.5	75	96.1	3.1
X-2659	CRC	BYL719 + binimetinib	480.1	22.7	79	126.1	-0.4
X-2659	CRC	BYL719 + binimetinib	471.5	23.4	83	122.1	2.6
X-2659	CRC	BYL719 + binimetinib	470.5	22.8	87	121.6	0
X-2659	CRC	BYL719 + binimetinib	488.2	23.7	90	130	3.9
X-2659	CRC	BYL719 + cetuximab	219.2	21.8	0	0	0
X-2659	CRC	BYL719 + cetuximab	250	22.3	3	14.1	2.3
X-2659	CRC	BYL719 + cetuximab	259.1	22.7	6	18.2	4.1
X-2659	CRC	BYL719 + cetuximab	257.8	22.7	10	17.6	4.1
X-2659	CRC	BYL719 + cetuximab	288.4	22.8	13	31.6	4.6
X-2659	CRC	BYL719 + cetuximab	299.3	21.2	16	36.5	-2.8
X-2659	CRC	BYL719 + cetuximab	298.6	23.7	19	36.2	8.7
X-2659	CRC	BYL719 + cetuximab	315.5	22.4	22	43.9	2.8
X-2659	CRC	BYL719 + cetuximab	321	20.8	26	46.4	-4.6
X-2659	CRC	BYL719 + cetuximab	351.2	19.2	29	60.2	-11.9
X-2659	CRC	BYL719 + cetuximab	347.2	17.6	33	58.4	-19.3
X-2659	CRC	BYL719 + encorafenib	217.1	24.1	0	0	0
X-2659	CRC	BYL719 + encorafenib	265.2	23.6	3	22.2	-2.1
X-2659	CRC	BYL719 + encorafenib	282.6	23.9	7	30.2	-0.8
X-2659	CRC	BYL719 + encorafenib	314.8	22	10	45	-8.7
X-2659	CRC	BYL719 + encorafenib	320	21	13	47.4	-12.9
X-2659	CRC	BYL719 + encorafenib	341.3	24	16	57.2	-0.4
X-2659	CRC	BYL719 + encorafenib	353.3	24.4	19	62.7	1.2
X-2659	CRC	BYL719 + encorafenib	428.8	22.9	23	97.5	-5
X-2659	CRC	CGM097	211.8	23.8	0	0	0
X-2659	CRC	CGM097	245.4	23.9	3	15.9	0.4
X-2659	CRC	CGM097	305.6	24.1	7	44.3	1.3
X-2659	CRC	CGM097	400.8	25.4	10	89.2	6.7
X-2659	CRC	CGM097	527.1	26.2	14	148.9	10.1
X-2659	CRC	CGM097	741.6	24.1	17	250.1	1.3
X-2659	CRC	CGM097	777.3	23.6	20	267	-0.8
X-2659	CRC	CGM097	812.3	24	23	283.5	0.8
X-2659	CRC	CKX620	195.3	23.3	0	0	0
X-2659	CRC	CKX620	223.5	22.8	4	14.4	-2.1
X-2659	CRC	CKX620	239.2	22.5	8	22.5	-3.4
X-2659	CRC	CKX620	271.7	23.1	11	39.1	-0.9
X-2659	CRC	CKX620	312.1	23	15	59.8	-1.3
X-2659	CRC	CKX620	304.3	24.3	18	55.8	4.3
X-2659	CRC	CKX620	370.6	23.2	21	89.8	-0.4
X-2659	CRC	CKX620	398.1	23.9	24	103.8	2.6
X-2659	CRC	CLR457	205.4	20.6	0	0	0
X-2659	CRC	CLR457	222.9	20.5	3	8.5	-0.5
X-2659	CRC	CLR457	253.3	20.3	7	23.3	-1.5
X-2659	CRC	CLR457	283.5	20.3	10	38	-1.5
X-2659	CRC	CLR457	318.4	19.8	14	55	-3.9
X-2659	CRC	CLR457	365.3	20.5	17	77.8	-0.5
X-2659	CRC	CLR457	405.6	18.9	20	97.5	-8.3
X-2659	CRC	CLR457	429.5	20.7	23	109.1	0.5
X-2659	CRC	HDM201	206.4	22.8	0	0	0
X-2659	CRC	HDM201	294.1	21.2	4	42.5	-7
X-2659	CRC	HDM201	324.6	20.5	8	57.3	-10.1
X-2659	CRC	HDM201	480.7	19.9	11	132.9	-12.7
X-2659	CRC	HDM201	568.4	20.2	15	175.4	-11.4
X-2659	CRC	HDM201	705.4	19.6	18	241.8	-14
X-2659	CRC	HDM201	782.7	20.8	21	279.2	-8.8
X-2659	CRC	cetuximab	234.7	23.8	0	0	0
X-2659	CRC	cetuximab	388	24	5	65.3	0.8
X-2659	CRC	cetuximab	566.8	23.4	9	141.5	-1.7
X-2659	CRC	cetuximab	703.6	23.7	12	199.8	-0.4
X-2659	CRC	cetuximab	910.9	23.4	16	288.1	-1.7
X-2659	CRC	cetuximab	1108.6	23.9	19	372.3	0.4
X-2659	CRC	cetuximab	1312.5	22.6	22	459.2	-5
X-2659	CRC	cetuximab + encorafenib	212.2	25.2	0	0	0
X-2659	CRC	cetuximab + encorafenib	258.7	24.4	4	21.9	-3.2
X-2659	CRC	cetuximab + encorafenib	319.1	24.4	7	50.4	-3.2
X-2659	CRC	cetuximab + encorafenib	454.8	22.9	11	114.3	-9.1
X-2659	CRC	cetuximab + encorafenib	496.5	23	14	134	-8.7
X-2659	CRC	cetuximab + encorafenib	624.8	21.7	17	194.4	-13.9
X-2659	CRC	cetuximab + encorafenib	689	25.6	20	224.7	1.6
X-2659	CRC	cetuximab + encorafenib	834.4	26.4	23	293.2	4.8
X-2659	CRC	LEE011	196.9	23.2	0	0	0
X-2659	CRC	LEE011	255.8	23.3	5	29.9	0.4
X-2659	CRC	LEE011	295.7	24.2	9	50.2	4.3
X-2659	CRC	LEE011	327.7	25.2	12	66.4	8.6
X-2659	CRC	LEE011	386.2	25	16	96.1	7.8
X-2659	CRC	LEE011	424.6	26.4	19	115.6	13.8
X-2659	CRC	LEE011	460	24.7	22	133.6	6.5
X-2659	CRC	encorafenib	211.2	26.2	0	0	0
X-2659	CRC	encorafenib	214.7	25.7	3	1.7	-1.9
X-2659	CRC	encorafenib	293.7	25.3	7	39.1	-3.4
X-2659	CRC	encorafenib	417.1	26.7	10	97.5	1.9
X-2659	CRC	encorafenib	455.8	25.4	14	115.8	-3.1
X-2659	CRC	encorafenib	490.2	25.6	17	132.1	-2.3
X-2659	CRC	encorafenib	529.3	24.2	20	150.6	-7.6
X-2659	CRC	encorafenib	570	27.4	23	169.9	4.6
X-2659	CRC	LJC049	213.9	23.7	0	0	0
X-2659	CRC	LJC049	243.6	24.1	3	13.9	1.7
X-2659	CRC	LJC049	268.2	22.4	7	25.4	-5.5
X-2659	CRC	LJC049	434	23.5	10	102.9	-0.8
X-2659	CRC	LJC049	509.6	23.7	14	138.2	0
X-2659	CRC	LJC049	710.3	22.3	17	232.1	-5.9
X-2659	CRC	LJC049	750.4	21.8	20	250.8	-8
X-2659	CRC	LJC049	837.7	23.4	23	291.6	-1.3
X-2659	CRC	LKA136	209.5	26	0	0	0
X-2659	CRC	LKA136	275.4	27	3	31.5	3.8
X-2659	CRC	LKA136	335.1	27.2	7	60	4.6
X-2659	CRC	LKA136	301.4	27.9	10	43.9	7.3
X-2659	CRC	LKA136	303.5	27.1	14	44.9	4.2
X-2659	CRC	LKA136	269.7	28.3	17	28.7	8.8
X-2659	CRC	LKA136	250.5	27.9	20	19.6	7.3
X-2659	CRC	LKA136	231	28.2	23	10.3	8.5
X-2659	CRC	LKA136	219.5	28.4	30	4.8	9.2
X-2659	CRC	LKA136	222.8	30	33	6.3	15.4
X-2659	CRC	LKA136	222.8	30.2	37	6.3	16.2
X-2659	CRC	LKA136	228.1	29.1	40	8.9	11.9
X-2659	CRC	LKA136	230.4	28.5	43	10	9.6
X-2659	CRC	LKA136	236.1	28.3	46	12.7	8.8
X-2659	CRC	LKA136	249.3	28.9	50	19	11.2
X-2659	CRC	LKA136	254.4	28.3	53	21.4	8.8
X-2659	CRC	LKA136	252	28	55	20.3	7.7
X-2659	CRC	LKA136	279.9	28.2	59	33.6	8.5
X-2659	CRC	LKA136	285.9	28.3	62	36.5	8.8
X-2659	CRC	LKA136	283.1	28.6	66	35.1	10
X-2659	CRC	LKA136	284.6	29.4	69	35.8	13.1
X-2659	CRC	LKA136	283.9	28.7	72	35.5	10.4
X-2659	CRC	LKA136	267.9	29.6	75	27.9	13.8
X-2659	CRC	LKA136	279.2	29.8	78	33.3	14.6
X-2659	CRC	LKA136	296.6	28.4	82	41.6	9.2
X-2659	CRC	LKA136	264.2	28.8	86	26.1	10.8
X-2659	CRC	LKA136	217	28.8	90	3.6	10.8
X-2659	CRC	binimetinib	224.1	22.5	0	0	0
X-2659	CRC	binimetinib	271.6	19.7	5	21.2	-12.4
X-2659	CRC	binimetinib	368.1	20.4	9	64.3	-9.3
X-2659	CRC	binimetinib	418.1	21.3	12	86.6	-5.3
X-2659	CRC	binimetinib	449.5	19.8	16	100.6	-12
X-2659	CRC	binimetinib	480.8	22.4	19	114.5	-0.4
X-2659	CRC	binimetinib	527	20.2	22	135.2	-10.2
X-2659	CRC	untreated	219.6	21.1	0	0	0
X-2659	CRC	untreated	237.5	21.6	3	8.2	2.4
X-2659	CRC	untreated	289.1	20.9	7	31.6	-0.9
X-2659	CRC	untreated	386.9	21.3	10	76.2	0.9
X-2659	CRC	untreated	495.1	20.8	13	125.5	-1.4
X-2659	CRC	untreated	617.1	21.2	16	181	0.5
X-2659	CRC	untreated	671.7	21.1	19	205.9	0
X-2659	CRC	untreated	790.1	20.1	23	259.8	-4.7
X-2659	CRC	LFW527 + binimetinib	218.71	28.9	0	0	0
X-2659	CRC	LFW527 + binimetinib	203.97	27.1	2	-6.7	-6.2
X-2659	CRC	LFW527 + binimetinib	165.06	26.35	6	-24.5	-8.8
X-2659	CRC	LFW527 + binimetinib	165.39	26.69	9	-24.4	-7.6
X-2659	CRC	LFW527 + binimetinib	147.36	27.38	13	-32.6	-5.3
X-2659	CRC	LFW527 + binimetinib	158.19	27	16	-27.7	-6.6
X-2659	CRC	LFW527 + binimetinib	165.86	27.81	20	-24.2	-3.8
X-2659	CRC	LFW527 + binimetinib	188.59	27.53	27	-13.8	-4.7
X-2659	CRC	LFW527 + binimetinib	199.81	27.73	34	-8.6	-4
X-2659	CRC	LFW527 + binimetinib	187.29	27.65	37	-14.4	-4.3
X-2659	CRC	LFW527 + binimetinib	194.55	27.11	41	-11	-6.2
X-2659	CRC	LFW527 + binimetinib	194.44	26.87	44	-11.1	-7
X-2659	CRC	LFW527 + binimetinib	181.58	26.91	47	-17	-6.9
X-2659	CRC	LFW527 + binimetinib	167.54	27.16	50	-23.4	-6
X-2659	CRC	LFW527 + binimetinib	159.11	28.03	55	-27.3	-3
X-2659	CRC	LFW527 + binimetinib	152.81	28.54	61	-30.1	-1.2
X-2659	CRC	LFW527 + binimetinib	105.54	28.56	65	-51.7	-1.2
X-2659	CRC	LFW527 + binimetinib	87.03	27.97	69	-60.2	-3.2
X-2659	CRC	LFW527 + binimetinib	97.82	27.43	72	-55.3	-5.1
X-2659	CRC	LFW527 + binimetinib	91.87	27.97	76	-58	-3.2
X-2659	CRC	LFW527 + binimetinib	65.45	27.87	79	-70.1	-3.6
X-2659	CRC	LFW527 + binimetinib	59.72	28.06	83	-72.7	-2.9
X-2659	CRC	LFW527 + binimetinib	56.71	28.21	86	-74.1	-2.4
X-2659	CRC	LFW527 + binimetinib	52.07	29.13	91	-76.2	0.8
X-2659	CRC	LFW527 + binimetinib	43.57	28.97	93	-80.1	0.2
X-2659	CRC	LFW527 + binimetinib	33.51	30.25	96	-84.7	4.7
X-2659	CRC	LFW527 + binimetinib	30.9	29.43	99	-85.9	1.8
X-2659	CRC	LFW527 + binimetinib	22.45	29.44	104	-89.7	1.9
X-2659	CRC	LFW527 + binimetinib	17.96	29.44	107	-91.8	1.9
X-2659	CRC	LFW527 + binimetinib	17.48	28.9	111	-92	0
X-2659	CRC	LFW527 + binimetinib	16.6	28.73	114	-92.4	-0.6
X-2659	CRC	LFW527 + binimetinib	14.14	28.98	118	-93.5	0.3
X-2659	CRC	LFW527 + binimetinib	0	29.06	121	-100	0.6
X-2659	CRC	LFW527 + binimetinib	0	29.28	125	-100	1.3
X-2659	CRC	LFW527 + binimetinib	0	28.47	127	-100	-1.5
X-2659	CRC	LFW527 + binimetinib	0	28.77	132	-100	-0.4
X-2659	CRC	LFW527 + binimetinib	0	28.68	135	-100	-0.8
X-2659	CRC	LFW527 + binimetinib	0	28.18	139	-100	-2.5
X-2659	CRC	LFW527 + binimetinib	0	28.45	142	-100	-1.6
X-2659	CRC	LFW527 + binimetinib	0	28.81	146	-100	-0.3
X-2659	CRC	LFW527 + binimetinib	0	28.13	149	-100	-2.7
X-2684	PDAC	abraxane	241.8	27.6	0	0	0
X-2684	PDAC	abraxane	274.9	28.5	4	13.7	3.3
X-2684	PDAC	abraxane	276.2	28.3	7	14.2	2.5
X-2684	PDAC	abraxane	357.1	28.4	10	47.7	2.9
X-2684	PDAC	abraxane	426.1	28.8	14	76.2	4.3
X-2684	PDAC	abraxane	486	28.7	17	101	4
X-2684	PDAC	abraxane	648.9	28.5	21	168.4	3.3
X-2684	PDAC	abraxane	792.8	26.8	24	227.9	-2.9
X-2684	PDAC	BKM120 + binimetinib	240.7	24.4	0	0	0
X-2684	PDAC	BKM120 + binimetinib	252.6	22.3	4	4.9	-8.6
X-2684	PDAC	BKM120 + binimetinib	237.6	21.7	6	-1.3	-11.1
X-2684	PDAC	BKM120 + binimetinib	134.7	19.8	11	-44	-18.9
X-2684	PDAC	BKM120 + LDE225	231.1	25.6	0	0	0
X-2684	PDAC	BKM120 + LDE225	230.7	26.4	1	-0.2	3.1
X-2684	PDAC	BKM120 + LDE225	254.7	26.1	6	10.2	2
X-2684	PDAC	BKM120 + LDE225	253.6	25.8	9	9.7	0.8
X-2684	PDAC	BKM120 + LDE225	356.4	25	14	54.2	-2.3
X-2684	PDAC	BKM120 + LDE225	344.9	24.7	16	49.2	-3.5
X-2684	PDAC	BKM120 + LDE225	423.3	23.3	21	83.2	-9
X-2684	PDAC	BKM120 + LDE225	382.3	24.5	24	65.4	-4.3
X-2684	PDAC	BKM120 + LDE225	435.3	24.8	27	88.4	-3.1
X-2684	PDAC	BKM120 + LDE225	343.9	24.9	31	48.8	-2.7
X-2684	PDAC	BKM120 + LDE225	370.4	24	36	60.3	-6.2
X-2684	PDAC	BKM120 + LDE225	351.6	23.5	38	52.1	-8.2
X-2684	PDAC	BKM120 + LDE225	338.7	22.7	41	46.6	-11.3
X-2684	PDAC	BKM120 + LDE225	321.3	22.9	43	39	-10.5
X-2684	PDAC	BKM120 + LDE225	339.3	22	45	46.8	-14.1
X-2684	PDAC	BKM120 + LDE225	377.6	20.7	49	63.4	-19.1
X-2684	PDAC	BKM120	257.1	27	0	0	0
X-2684	PDAC	BKM120	321.1	26.2	3	24.9	-3
X-2684	PDAC	BKM120	352.8	27.8	7	37.2	3
X-2684	PDAC	BKM120	320.7	26.9	10	24.7	-0.4
X-2684	PDAC	BKM120	230.3	27.5	14	-10.4	1.9
X-2684	PDAC	BKM120	244.9	27.5	17	-4.7	1.9
X-2684	PDAC	BKM120	221.4	27.8	21	-13.9	3
X-2684	PDAC	BKM120	305.1	26.8	24	18.7	-0.7
X-2684	PDAC	BKM120	431.6	28.1	28	67.9	4.1
X-2684	PDAC	BKM120	437.1	27.4	30	70	1.5
X-2684	PDAC	BKM120	423.1	27.8	35	64.6	3
X-2684	PDAC	BKM120	421.7	27	38	64	0
X-2684	PDAC	BKM120	321.2	27.6	42	24.9	2.2
X-2684	PDAC	BKM120	271.6	26.4	45	5.6	-2.2
X-2684	PDAC	BKM120	245.2	26.6	49	-4.6	-1.5
X-2684	PDAC	BKM120	388	26.7	52	50.9	-1.1
X-2684	PDAC	BKM120	436.7	26.4	57	69.9	-2.2
X-2684	PDAC	BKM120	363.4	27.3	60	41.3	1.1
X-2684	PDAC	BKM120	298.7	27.5	65	16.2	1.9
X-2684	PDAC	BKM120	327.9	27	67	27.5	0
X-2684	PDAC	BKM120	322.4	27.3	70	25.4	1.1
X-2684	PDAC	BKM120	339.6	26.6	73	32.1	-1.5
X-2684	PDAC	BKM120	453.5	26.8	78	76.4	-0.7
X-2684	PDAC	BKM120	500.8	25.2	81	94.8	-6.7
X-2684	PDAC	BKM120	500.8	26.6	85	94.8	-1.5
X-2684	PDAC	BKM120	627.8	26.5	88	144.2	-1.9
X-2684	PDAC	BKM120	566.4	27	91	120.3	0
X-2684	PDAC	BYL719 + LJM716	202.2	26.6	0	0	0
X-2684	PDAC	BYL719 + LJM716	224.6	26.6	4	11.1	0
X-2684	PDAC	BYL719 + LJM716	248.1	26.8	7	22.7	0.8
X-2684	PDAC	BYL719 + LJM716	259.5	26	11	28.3	-2.3
X-2684	PDAC	BYL719 + LJM716	275.7	26.5	14	36.4	-0.4
X-2684	PDAC	BYL719 + LJM716	280.5	26.5	18	38.7	-0.4
X-2684	PDAC	BYL719 + LJM716	286.2	26.8	21	41.5	0.8
X-2684	PDAC	BYL719 + LJM716	281.3	25.6	25	39.1	-3.8
X-2684	PDAC	BYL719 + LJM716	308.8	26	32	52.7	-2.3
X-2684	PDAC	BYL719 + LJM716	306.1	25.7	35	51.4	-3.4
X-2684	PDAC	BYL719 + LJM716	322.1	27	39	59.3	1.5
X-2684	PDAC	BYL719 + LJM716	343.6	25.3	42	69.9	-4.9
X-2684	PDAC	BYL719 + LJM716	372.9	26.8	46	84.4	0.8
X-2684	PDAC	BYL719 + LJM716	389	26.1	49	92.4	-1.9
X-2684	PDAC	BYL719 + LJM716	409.6	25.9	53	102.6	-2.6
X-2684	PDAC	BYL719 + LJM716	493.6	25.8	56	144.1	-3
X-2684	PDAC	BYL719 + LJM716	448	27.1	62	121.6	1.9
X-2684	PDAC	BYL719 + LJM716	462	27	67	128.5	1.5
X-2684	PDAC	BYL719 + LJM716	470	26.8	70	132.4	0.8
X-2684	PDAC	BYL719 + LJM716	478	26.6	74	136.4	0
X-2684	PDAC	BYL719 + LJM716	495.2	26.6	77	144.9	0
X-2684	PDAC	BYL719 + LJM716	514.5	26.1	82	154.5	-1.9
X-2684	PDAC	BYL719 + LJM716	521	26.5	84	157.7	-0.4
X-2684	PDAC	BYL719 + LJM716	522.6	25.4	88	158.5	-4.5
X-2684	PDAC	BYL719 + LJM716	532.8	25.2	91	163.5	-5.3
X-2684	PDAC	BYL719 + LJM716	548.2	26.7	95	171.1	0.4
X-2684	PDAC	BYL719	209.9	28.6	0	0	0
X-2684	PDAC	BYL719	203.5	29.2	3	-3	2.1
X-2684	PDAC	BYL719	188.1	29.1	6	-10.4	1.7
X-2684	PDAC	BYL719	205.1	28.6	10	-2.3	0
X-2684	PDAC	BYL719	303.5	28.7	17	44.6	0.3
X-2684	PDAC	BYL719	341.1	30.4	20	62.5	6.3
X-2684	PDAC	BYL719	462.9	29.4	24	120.5	2.8
X-2684	PDAC	BYL719	504.5	29.2	27	140.4	2.1
X-2684	PDAC	BYL719	532.7	28.1	31	153.8	-1.7
X-2684	PDAC	BYL719	547.1	28.3	34	160.6	-1
X-2684	PDAC	BYL719	636	28.7	38	203	0.3
X-2684	PDAC	BYL719	728.4	28.5	41	247	-0.3
X-2684	PDAC	CLR457	230.5	24.2	0	0	0
X-2684	PDAC	CLR457	286.5	24	3	24.3	-0.8
X-2684	PDAC	CLR457	313.4	23.4	10	36	-3.3
X-2684	PDAC	CLR457	375.9	22.2	13	63.1	-8.3
X-2684	PDAC	CLR457	503.2	21	17	118.3	-13.2
X-2684	PDAC	CLR457	581.6	20.9	20	152.3	-13.6
X-2684	PDAC	CLR457	586.3	21.3	24	154.4	-12
X-2684	PDAC	CLR457	613.9	20.7	27	166.3	-14.5
X-2684	PDAC	CLR457	648.4	19.8	31	181.3	-18.2
X-2684	PDAC	HDM201	219.3	24.4	0	0	0
X-2684	PDAC	HDM201	259.5	24.8	3	18.3	1.6
X-2684	PDAC	HDM201	486.8	26.5	7	122	8.6
X-2684	PDAC	HDM201	598.2	25.1	10	172.8	2.9
X-2684	PDAC	HDM201	708.3	26	14	223	6.6
X-2684	PDAC	HDM201	899	26	16	309.9	6.6
X-2684	PDAC	HDM201	1076.4	25.1	21	390.8	2.9
X-2684	PDAC	HDM201	1164.9	25.1	24	431.2	2.9
X-2684	PDAC	HDM201	1387.4	21.4	28	532.6	-12.3
X-2684	PDAC	figitumumab"	210.1	29.1	0	0	0
X-2684	PDAC	figitumumab"	188.9	30.2	3	-10.1	3.8
X-2684	PDAC	figitumumab"	161.4	30.1	10	-23.2	3.4
X-2684	PDAC	figitumumab"	164.2	29.8	13	-21.8	2.4
X-2684	PDAC	figitumumab"	202.3	29.6	17	-3.7	1.7
X-2684	PDAC	figitumumab"	166.5	29.9	20	-20.8	2.7
X-2684	PDAC	figitumumab"	163.4	29.2	24	-22.2	0.3
X-2684	PDAC	figitumumab"	211.3	29.2	27	0.6	0.3
X-2684	PDAC	figitumumab"	164.2	30.3	31	-21.8	4.1
X-2684	PDAC	figitumumab"	186.6	30.1	35	-11.2	3.4
X-2684	PDAC	figitumumab"	238.6	29.9	38	13.6	2.7
X-2684	PDAC	figitumumab"	184.2	29.5	41	-12.3	1.4
X-2684	PDAC	figitumumab"	225.7	29.7	45	7.4	2.1
X-2684	PDAC	figitumumab"	234.1	29.3	48	11.4	0.7
X-2684	PDAC	figitumumab"	52.2	28.7	53	-75.2	-1.4
X-2684	PDAC	figitumumab"	77.2	29.9	55	-63.3	2.7
X-2684	PDAC	figitumumab"	82.3	29.8	59	-60.8	2.4
X-2684	PDAC	figitumumab"	92.2	28.6	62	-56.1	-1.7
X-2684	PDAC	figitumumab"	101.2	29.7	66	-51.8	2.1
X-2684	PDAC	figitumumab"	131.2	29.6	69	-37.6	1.7
X-2684	PDAC	figitumumab"	81.2	29.5	73	-61.4	1.4
X-2684	PDAC	figitumumab"	85.9	29.2	76	-59.1	0.3
X-2684	PDAC	figitumumab"	111.1	30.8	80	-47.1	5.8
X-2684	PDAC	figitumumab"	108.7	28.6	83	-48.3	-1.7
X-2684	PDAC	figitumumab"	118.7	29.1	87	-43.5	0
X-2684	PDAC	figitumumab"	183.6	29.3	90	-12.6	0.7
X-2684	PDAC	figitumumab"	221.6	29.8	94	5.5	2.4
X-2684	PDAC	figitumumab"	225.4	28.9	98	7.3	-0.7
X-2684	PDAC	figitumumab"	191.8	28.2	101	-8.7	-3.1
X-2684	PDAC	figitumumab"	233	29.1	104	10.9	0
X-2684	PDAC	figitumumab" + binimetinib	255.6	26	0	0	0
X-2684	PDAC	figitumumab" + binimetinib	425.2	26.4	3	66.4	1.5
X-2684	PDAC	figitumumab" + binimetinib	456.9	26.6	7	78.8	2.3
X-2684	PDAC	figitumumab" + binimetinib	634.8	26	10	148.4	0
X-2684	PDAC	figitumumab" + binimetinib	672.1	26.9	14	162.9	3.5
X-2684	PDAC	figitumumab" + binimetinib	481.2	25.9	17	88.3	-0.4
X-2684	PDAC	figitumumab" + binimetinib	323.3	25.8	21	26.5	-0.8
X-2684	PDAC	figitumumab" + binimetinib	354.7	25.5	24	38.8	-1.9
X-2684	PDAC	figitumumab" + binimetinib	339.6	26.6	28	32.9	2.3
X-2684	PDAC	figitumumab" + binimetinib	306.7	27.8	30	20	6.9
X-2684	PDAC	figitumumab" + binimetinib	196.5	27.9	35	-23.1	7.3
X-2684	PDAC	figitumumab" + binimetinib	124.2	28	38	-51.4	7.7
X-2684	PDAC	figitumumab" + binimetinib	118.7	27.4	42	-53.6	5.4
X-2684	PDAC	figitumumab" + binimetinib	63.8	27.1	45	-75	4.2
X-2684	PDAC	figitumumab" + binimetinib	107.8	27.1	49	-57.8	4.2
X-2684	PDAC	figitumumab" + binimetinib	132.5	27.3	52	-48.2	5
X-2684	PDAC	figitumumab" + binimetinib	198.7	27.2	57	-22.3	4.6
X-2684	PDAC	figitumumab" + binimetinib	152.9	28.1	60	-40.2	8.1
X-2684	PDAC	figitumumab" + binimetinib	92	27.2	65	-64	4.6
X-2684	PDAC	figitumumab" + binimetinib	102.9	25.8	67	-59.7	-0.8
X-2684	PDAC	figitumumab" + binimetinib	114.9	27.8	70	-55	6.9
X-2684	PDAC	figitumumab" + binimetinib	77.4	26.3	73	-69.7	1.2
X-2684	PDAC	figitumumab" + binimetinib	79.6	26.2	78	-68.9	0.8
X-2684	PDAC	figitumumab" + binimetinib	79.6	26.5	81	-68.9	1.9
X-2684	PDAC	figitumumab" + binimetinib	87.8	27.4	85	-65.6	5.4
X-2684	PDAC	figitumumab" + binimetinib	102.7	26.8	88	-59.8	3.1
X-2684	PDAC	figitumumab" + binimetinib	70.4	27.7	91	-72.5	6.5
X-2684	PDAC	figitumumab" + binimetinib	70.8	27.3	94	-72.3	5
X-2684	PDAC	figitumumab" + binimetinib	116.3	27.3	98	-54.5	5
X-2684	PDAC	figitumumab" + binimetinib	79.5	26.4	101	-68.9	1.5
X-2684	PDAC	INC424 + binimetinib	202.9	25.9	0	0	0
X-2684	PDAC	INC424 + binimetinib	291.5	25.6	1	43.7	-1.2
X-2684	PDAC	INC424 + binimetinib	355.5	26.7	6	75.2	3.1
X-2684	PDAC	INC424 + binimetinib	376.5	26.1	9	85.6	0.8
X-2684	PDAC	INC424 + binimetinib	451.3	26.6	14	122.4	2.7
X-2684	PDAC	INC424 + binimetinib	485.3	26.8	16	139.2	3.5
X-2684	PDAC	INC424 + binimetinib	469	26.7	21	131.1	3.1
X-2684	PDAC	INC424 + binimetinib	525.7	26.1	24	159.1	0.8
X-2684	PDAC	INC424 + binimetinib	614.2	26.7	27	202.7	3.1
X-2684	PDAC	INC424 + binimetinib	537.1	27	31	164.7	4.2
X-2684	PDAC	INC424	233.1	24.8	0	0	0
X-2684	PDAC	INC424	248.4	25.4	3	6.6	2.4
X-2684	PDAC	INC424	276.4	22.9	6	18.6	-7.7
X-2684	PDAC	INC424	327.8	22.3	10	40.6	-10.1
X-2684	PDAC	INC424	339.5	25.4	17	45.6	2.4
X-2684	PDAC	INC424	345.4	24.6	20	48.2	-0.8
X-2684	PDAC	INC424	409.3	25.4	24	75.6	2.4
X-2684	PDAC	INC424	438.1	22.4	27	87.9	-9.7
X-2684	PDAC	INC424	500.9	24.9	31	114.9	0.4
X-2684	PDAC	INC424	531.2	24.6	34	127.9	-0.8
X-2684	PDAC	INC424	639.6	24.2	38	174.4	-2.4
X-2684	PDAC	INC424	646.1	24.7	41	177.2	-0.4
X-2684	PDAC	LEE011	217.4	27.3	0	0	0
X-2684	PDAC	LEE011	195.7	28.9	2	-10	5.9
X-2684	PDAC	LEE011	174.4	29.2	5	-19.8	7
X-2684	PDAC	LEE011	181.1	28.4	8	-16.7	4
X-2684	PDAC	LEE011	239.3	29.5	12	10.1	8.1
X-2684	PDAC	LEE011	328.1	28.5	15	50.9	4.4
X-2684	PDAC	LEE011	346.7	28.7	19	59.5	5.1
X-2684	PDAC	LEE011	319.8	28.9	22	47.1	5.9
X-2684	PDAC	LEE011	443.1	29.8	26	103.8	9.2
X-2684	PDAC	LEE011	476.7	30.3	30	119.3	11
X-2684	PDAC	LEE011	529.9	29.9	33	143.7	9.5
X-2684	PDAC	LEE011	554.8	29.6	36	155.2	8.4
X-2684	PDAC	LEE011	538.1	29.7	40	147.5	8.8
X-2684	PDAC	LEE011	605.6	29.4	42	178.6	7.7
X-2684	PDAC	WNT974	263.6	29.1	0	0	0
X-2684	PDAC	WNT974	404.2	29.2	3	53.3	0.3
X-2684	PDAC	WNT974	460.1	26.6	7	74.5	-8.6
X-2684	PDAC	WNT974	788.4	26.7	10	199.1	-8.2
X-2684	PDAC	WNT974	1056.7	24.7	14	300.9	-15.1
X-2684	PDAC	WNT974	920.1	23.1	15	249.1	-20.6
X-2684	PDAC	LKA136	261.5	24.2	0	0	0
X-2684	PDAC	LKA136	434.9	23.5	3	66.3	-2.9
X-2684	PDAC	LKA136	521	23.3	6	99.2	-3.7
X-2684	PDAC	LKA136	565.1	22.5	10	116.1	-7
X-2684	PDAC	LKA136	641.7	23	13	145.4	-5
X-2684	PDAC	LKA136	821.7	22.2	17	214.2	-8.3
X-2684	PDAC	LKA136	1125.7	20.9	20	330.5	-13.6
X-2684	PDAC	LKA136	1144.7	21.3	24	337.7	-12
X-2684	PDAC	binimetinib	226.6	25.5	0	0	0
X-2684	PDAC	binimetinib	177.2	26.9	4	-21.8	5.5
X-2684	PDAC	binimetinib	196.4	26.8	6	-13.3	5.1
X-2684	PDAC	binimetinib	258.2	25.8	11	13.9	1.2
X-2684	PDAC	binimetinib	280.3	25.9	14	23.7	1.6
X-2684	PDAC	binimetinib	226.3	23.6	19	-0.1	-7.5
X-2684	PDAC	binimetinib	202.9	22.6	21	-10.5	-11.4
X-2684	PDAC	binimetinib	335.7	21.9	26	48.1	-14.1
X-2684	PDAC	binimetinib	188	20.6	29	-17	-19.2
X-2684	PDAC	binimetinib-3.5mpk	273.2	28.3	0	0	0
X-2684	PDAC	binimetinib-3.5mpk	446.1	27.8	3	63.3	-1.8
X-2684	PDAC	binimetinib-3.5mpk	505.6	27.7	7	85.1	-2.1
X-2684	PDAC	binimetinib-3.5mpk	529.6	28.6	10	93.9	1.1
X-2684	PDAC	binimetinib-3.5mpk	754.7	28	14	176.2	-1.1
X-2684	PDAC	binimetinib-3.5mpk	770.6	28.5	17	182.1	0.7
X-2684	PDAC	binimetinib-3.5mpk	649	28	21	137.6	-1.1
X-2684	PDAC	binimetinib-3.5mpk	723.5	27.4	24	164.8	-3.2
X-2684	PDAC	binimetinib-3.5mpk	755.5	26.6	28	176.5	-6
X-2684	PDAC	trametinib	234	26.6	0	0	0
X-2684	PDAC	trametinib	287.1	25.3	2	22.7	-4.9
X-2684	PDAC	trametinib	242.4	24.6	6	3.6	-7.5
X-2684	PDAC	trametinib	282.6	24.7	9	20.8	-7.1
X-2684	PDAC	trametinib	240.6	26	12	2.8	-2.3
X-2684	PDAC	trametinib	278.2	25	15	18.9	-6
X-2684	PDAC	trametinib	324.4	25.9	19	38.6	-2.6
X-2684	PDAC	trametinib	486.2	25.6	22	107.8	-3.8
X-2684	PDAC	trametinib	479.8	25.4	26	105	-4.5
X-2684	PDAC	trametinib	548.8	25.3	29	134.5	-4.9
X-2684	PDAC	trametinib	577.5	25.1	33	146.8	-5.6
X-2684	PDAC	untreated	260.5	27.3	0	0	0
X-2684	PDAC	untreated	311.6	27.3	2	19.6	0
X-2684	PDAC	untreated	387	26.1	6	48.6	-4.4
X-2684	PDAC	untreated	622.2	26	9	138.8	-4.8
X-2684	PDAC	untreated	629.7	26.8	13	141.7	-1.8
X-2684	PDAC	untreated	561.9	27.1	16	115.7	-0.7
X-2684	PDAC	untreated	865.3	26.7	20	232.2	-2.2
X-2684	PDAC	untreated	840.6	27.9	23	222.7	2.2
X-2684	PDAC	untreated	1181.3	27.8	27	353.5	1.8
X-2684	PDAC	untreated	878.1	27.6	29	237.1	1.1
X-2684	PDAC	untreated	1192.6	28.1	34	357.8	2.9
X-2700	CM	BKM120	198.5	24	0	0	0
X-2700	CM	BKM120	211.7	23.9	2	6.7	-0.4
X-2700	CM	BKM120	223.8	24.5	5	12.8	2.1
X-2700	CM	BKM120	236.3	24.8	9	19	3.3
X-2700	CM	BKM120	302.6	25.4	12	52.5	5.8
X-2700	CM	BKM120	305.9	25.3	15	54.2	5.4
X-2700	CM	BKM120	345.7	26.4	19	74.2	10
X-2700	CM	BKM120	409.1	26	23	106.1	8.3
X-2700	CM	BKM120	449.8	26.9	27	126.6	12.1
X-2700	CM	BKM120 + encorafenib	193	23.7	0	0	0
X-2700	CM	BKM120 + encorafenib	224.3	23.9	5	16.2	0.8
X-2700	CM	BKM120 + encorafenib	238.5	25.1	9	23.5	5.9
X-2700	CM	BKM120 + encorafenib	273.8	25.2	12	41.8	6.3
X-2700	CM	BKM120 + encorafenib	251.4	25.1	15	30.2	5.9
X-2700	CM	BKM120 + encorafenib	320	26.3	19	65.8	11
X-2700	CM	BKM120 + encorafenib	336.2	26.3	23	74.2	11
X-2700	CM	BKM120 + encorafenib	414.2	27	27	114.6	13.9
X-2700	CM	BKM120 + encorafenib	406.8	26.8	30	110.7	13.1
X-2700	CM	BKM120 + encorafenib	490.9	27.5	33	154.3	16
X-2700	CM	CGM097	190.8	24.4	0	0	0
X-2700	CM	CGM097	296.5	24.9	3	55.4	2
X-2700	CM	CGM097	288.8	24.3	7	51.4	-0.4
X-2700	CM	CGM097	306.1	23.8	10	60.5	-2.5
X-2700	CM	CGM097	343.3	23.9	14	79.9	-2
X-2700	CM	CGM097	404.6	24.6	17	112.1	0.8
X-2700	CM	CGM097	415.4	25.7	20	117.8	5.3
X-2700	CM	CGM097	486	23.4	24	154.7	-4.1
X-2700	CM	CGM097	494.1	24.7	27	159	1.2
X-2700	CM	CLR457	216.3	24.8	0	0	0
X-2700	CM	CLR457	294.4	25.7	4	36.1	3.6
X-2700	CM	CLR457	368.5	25.8	8	70.4	4
X-2700	CM	CLR457	564.5	26.9	12	161	8.5
X-2700	CM	CLR457	600.3	26.1	15	177.5	5.2
X-2700	CM	CLR457	683.6	26.9	18	216	8.5
X-2700	CM	CLR457	758.4	26.1	23	250.6	5.2
X-2700	CM	CLR457	738.7	26.9	26	241.5	8.5
X-2700	CM	dacarbazine	198.5	25	0	0	0
X-2700	CM	dacarbazine	200.9	23.8	1	1.2	-4.8
X-2700	CM	dacarbazine	226.5	23.2	4	14.1	-7.2
X-2700	CM	dacarbazine	322.8	23.8	8	62.6	-4.8
X-2700	CM	dacarbazine	399.4	23	12	101.2	-8
X-2700	CM	dacarbazine	499.4	25.2	16	151.6	0.8
X-2700	CM	dacarbazine	576	23	19	190.2	-8
X-2700	CM	dacarbazine	577.6	25.1	22	191.1	0.4
X-2700	CM	dacarbazine	675	24.7	27	240.1	-1.2
X-2700	CM	LDE225	205.8	24.8	0	0	0
X-2700	CM	LDE225	231.8	24.1	5	12.6	-2.8
X-2700	CM	LDE225	300.8	23.8	8	46.2	-4
X-2700	CM	LDE225	307.2	23.3	11	49.3	-6
X-2700	CM	LDE225	388.3	23	15	88.7	-7.3
X-2700	CM	LDE225	397.4	22.9	19	93.1	-7.7
X-2700	CM	LDE225	433.9	23.2	23	110.9	-6.5
X-2700	CM	LDE225	437.5	22.6	25	112.6	-8.9
X-2700	CM	LDE225	451.6	22.9	28	119.4	-7.7
X-2700	CM	LDK378	196	25.6	0	0	0
X-2700	CM	LDK378	268.4	25.3	5	36.9	-1.2
X-2700	CM	LDK378	310.4	26.2	8	58.4	2.3
X-2700	CM	LDK378	351.3	26	11	79.3	1.6
X-2700	CM	LDK378	416.3	25.8	15	112.4	0.8
X-2700	CM	LDK378	381	25.7	19	94.4	0.4
X-2700	CM	LDK378	390.2	26.3	23	99.1	2.7
X-2700	CM	LDK378	495.1	26.6	25	152.6	3.9
X-2700	CM	LDK378	459.6	26.6	28	134.5	3.9
X-2700	CM	LEE011	224.5	23.9	0	0	0
X-2700	CM	LEE011	271.5	23.8	4	20.9	-0.4
X-2700	CM	LEE011	339.6	23.1	7	51.2	-3.3
X-2700	CM	LEE011	320	23.4	11	42.5	-2.1
X-2700	CM	LEE011	321.5	24	14	43.2	0.4
X-2700	CM	LEE011	310.4	24.8	17	38.3	3.8
X-2700	CM	LEE011	359.9	25.6	21	60.3	7.1
X-2700	CM	LEE011	374	26.1	25	66.6	9.2
X-2700	CM	LEE011	414.3	27	27	84.5	13
X-2700	CM	LEE011 + encorafenib	204.8	25.1	0	0	0
X-2700	CM	LEE011 + encorafenib	199.1	26.5	4	-2.8	5.6
X-2700	CM	LEE011 + encorafenib	197.6	26.5	8	-3.5	5.6
X-2700	CM	LEE011 + encorafenib	196.6	26	11	-4	3.6
X-2700	CM	LEE011 + encorafenib	168.3	25.7	14	-17.8	2.4
X-2700	CM	LEE011 + encorafenib	210.8	26.5	18	3	5.6
X-2700	CM	LEE011 + encorafenib	216.6	26.8	22	5.8	6.8
X-2700	CM	LEE011 + encorafenib	196	27.5	26	-4.3	9.6
X-2700	CM	LEE011 + encorafenib	207.8	26.4	29	1.5	5.2
X-2700	CM	LEE011 + encorafenib	219	26.6	32	7	6
X-2700	CM	LEE011 + encorafenib	210.5	26.1	37	2.8	4
X-2700	CM	LEE011 + encorafenib	210.8	26.3	40	3	4.8
X-2700	CM	LEE011 + encorafenib	202.5	27.3	44	-1.1	8.8
X-2700	CM	LEE011 + encorafenib	224.5	28	47	9.6	11.6
X-2700	CM	LEE011 + encorafenib	240.1	28.5	56	17.3	13.5
X-2700	CM	LEE011 + encorafenib	237.2	27.8	62	15.8	10.8
X-2700	CM	LEE011 + encorafenib	231	29.8	66	12.8	18.7
X-2700	CM	LEE011 + encorafenib	203.4	28.2	69	-0.7	12.4
X-2700	CM	LEE011 + encorafenib	222.4	28.7	80	8.6	14.3
X-2700	CM	LEE011 + encorafenib	210.9	29	85	3	15.5
X-2700	CM	LEE011 + encorafenib	156.8	28.1	92	-23.4	12
X-2700	CM	LEE011 + encorafenib	202.5	28.7	98	-1.1	14.3
X-2700	CM	LEE011 + encorafenib	184.1	29.3	106	-10.1	16.7
X-2700	CM	LEE011 + encorafenib	130.2	28.6	118	-36.4	13.9
X-2700	CM	LEE011 + encorafenib	147.9	27.6	125	-27.8	10
X-2700	CM	LEE011 + encorafenib	204.2	28.2	132	-0.3	12.4
X-2700	CM	LEE011 + encorafenib	197.2	28.1	142	-3.7	12
X-2700	CM	LEE011 + encorafenib	171.1	28.3	150	-16.4	12.7
X-2700	CM	LEE011 + encorafenib	224.5	29.8	156	9.6	18.7
X-2700	CM	LEE011 + encorafenib	212.5	26.5	164	3.8	5.6
X-2700	CM	LEE011 + encorafenib	196	27.8	170	-4.3	10.8
X-2700	CM	LEE011 + encorafenib	213.2	29	178	4.1	15.5
X-2700	CM	LEE011 + encorafenib	251.3	28.4	187	22.7	13.1
X-2700	CM	LEE011 + encorafenib	196	27.8	195	-4.3	10.8
X-2700	CM	LEE011 + encorafenib	169	29.5	202	-17.5	17.5
X-2700	CM	LEE011 + encorafenib	178	29	207	-13.1	15.5
X-2700	CM	LEE011 + encorafenib	171.1	29.7	213	-16.4	18.3
X-2700	CM	LEE011 + encorafenib	216.3	29.9	226	5.6	19.1
X-2700	CM	LEE011 + encorafenib	258.6	28.7	233	26.3	14.3
X-2700	CM	LEE011 + encorafenib	271.5	29.5	240	32.6	17.5
X-2700	CM	LEE011 + encorafenib	451.3	30.9	247	120.4	23.1
X-2700	CM	LEE011 + encorafenib	482.8	30.8	254	135.8	22.7
X-2700	CM	LEE011 + binimetinib	204.2	25.7	0	0	0
X-2700	CM	LEE011 + binimetinib	188.1	25.3	3	-7.9	-1.6
X-2700	CM	LEE011 + binimetinib	172.1	27	7	-15.7	5.1
X-2700	CM	LEE011 + binimetinib	196	26.9	11	-4	4.7
X-2700	CM	LEE011 + binimetinib	154.2	26.3	14	-24.5	2.3
X-2700	CM	LEE011 + binimetinib	163.4	26.7	17	-20	3.9
X-2700	CM	LEE011 + binimetinib	155.7	26.4	22	-23.8	2.7
X-2700	CM	LEE011 + binimetinib	149.5	27	25	-26.8	5.1
X-2700	CM	LEE011 + binimetinib	153.8	26.5	29	-24.7	3.1
X-2700	CM	LEE011 + binimetinib	160.6	27	32	-21.4	5.1
X-2700	CM	LEE011 + binimetinib	168.3	26.9	40	-17.5	4.7
X-2700	CM	LEE011 + binimetinib	140.3	26.2	46	-31.3	1.9
X-2700	CM	LEE011 + binimetinib	120.6	27.8	50	-40.9	8.2
X-2700	CM	LEE011 + binimetinib	166.6	27.1	54	-18.4	5.4
X-2700	CM	LEE011 + binimetinib	101.9	28.3	65	-50.1	10.1
X-2700	CM	LEE011 + binimetinib	116.1	28	70	-43.2	8.9
X-2700	CM	LEE011 + binimetinib	132.9	27.9	77	-34.9	8.6
X-2700	CM	LEE011 + binimetinib	78	29	83	-61.8	12.8
X-2700	CM	LEE011 + binimetinib	99.1	27.9	91	-51.4	8.6
X-2700	CM	LEE011 + binimetinib	92.3	28.9	110	-54.8	12.5
X-2700	CM	LEE011 + binimetinib	123	28	117	-39.7	8.9
X-2700	CM	LEE011 + binimetinib	75.7	27.6	127	-62.9	7.4
X-2700	CM	LEE011 + binimetinib	81.7	28.6	135	-60	11.3
X-2700	CM	LEE011 + binimetinib	87.7	28.8	141	-57	12.1
X-2700	CM	LEE011 + binimetinib	96.8	28.9	149	-52.6	12.5
X-2700	CM	LEE011 + binimetinib	102.3	28	155	-49.9	8.9
X-2700	CM	LEE011 + binimetinib	89.2	28.7	163	-56.3	11.7
X-2700	CM	LEE011 + binimetinib	139.4	26.9	172	-31.7	4.7
X-2700	CM	LEE011 + binimetinib	90.6	27.3	180	-55.6	6.2
X-2700	CM	LEE011 + binimetinib	61.8	27.3	187	-69.7	6.2
X-2700	CM	LEE011 + binimetinib	109.8	25.6	192	-46.2	-0.4
X-2700	CM	LEE011 + binimetinib	94.2	28.6	198	-53.8	11.3
X-2700	CM	LEE011 + binimetinib	86	28.5	211	-57.9	10.9
X-2700	CM	LEE011 + binimetinib	100.9	27.2	228	-50.6	5.8
X-2700	CM	LEE011 + binimetinib	115.2	27.6	235	-43.6	7.4
X-2700	CM	WNT974	210.5	28.7	0	0	0
X-2700	CM	WNT974	215.1	28.9	1	2.2	0.7
X-2700	CM	WNT974	224.5	29.8	4	6.7	3.8
X-2700	CM	WNT974	255.9	29.2	7	21.6	1.7
X-2700	CM	WNT974	255.5	27	11	21.4	-5.9
X-2700	CM	WNT974	292.5	28.6	15	39	-0.3
X-2700	CM	WNT974	309.3	28	19	46.9	-2.4
X-2700	CM	WNT974	310.5	27.7	22	47.5	-3.5
X-2700	CM	WNT974	242.6	28.1	25	15.2	-2.1
X-2700	CM	WNT974	364	28.2	29	72.9	-1.7
X-2700	CM	WNT974	437.4	27.5	33	107.8	-4.2
X-2700	CM	WNT974	530	28	37	151.8	-2.4
X-2700	CM	WNT974	572.2	26.7	40	171.8	-7
X-2700	CM	WNT974	584.1	28.2	43	177.5	-1.7
X-2700	CM	LGW813	196.5	24.5	0	0	0
X-2700	CM	LGW813	273.8	24.5	5	39.3	0
X-2700	CM	LGW813	327.7	24.2	8	66.7	-1.2
X-2700	CM	LGW813	359.7	25.5	11	83.1	4.1
X-2700	CM	LGW813	432.7	24	15	120.2	-2
X-2700	CM	LGW813	454.1	25.6	19	131.1	4.5
X-2700	CM	LGW813	596.8	23.7	23	203.7	-3.3
X-2700	CM	LGW813	1007.2	25.8	26	412.5	5.3
X-2700	CM	LGW813	1031.5	26	27	424.9	6.1
X-2700	CM	encorafenib	203.4	23.4	0	0	0
X-2700	CM	encorafenib	257.9	24.1	2	26.8	3
X-2700	CM	encorafenib	366.1	24.7	6	80	5.6
X-2700	CM	encorafenib	383.3	24.4	9	88.5	4.3
X-2700	CM	encorafenib	450.6	24.1	13	121.6	3
X-2700	CM	encorafenib	471.4	24.5	16	131.8	4.7
X-2700	CM	encorafenib	611.1	24.9	19	200.5	6.4
X-2700	CM	encorafenib	641.8	25.4	23	215.6	8.5
X-2700	CM	encorafenib	676	25	27	232.4	6.8
X-2700	CM	encorafenib + binimetinib	207.4	28.8	0	0	0
X-2700	CM	encorafenib + binimetinib	223.8	28.5	4	7.9	-1
X-2700	CM	encorafenib + binimetinib	230.6	28.4	7	11.2	-1.4
X-2700	CM	encorafenib + binimetinib	242.6	28.3	10	17	-1.7
X-2700	CM	encorafenib + binimetinib	351.3	28.1	14	69.4	-2.4
X-2700	CM	encorafenib + binimetinib	362.4	27.7	18	74.8	-3.8
X-2700	CM	encorafenib + binimetinib	359.5	27.7	22	73.4	-3.8
X-2700	CM	encorafenib + binimetinib	418.2	27.3	25	101.7	-5.2
X-2700	CM	encorafenib + binimetinib	404	28.1	28	94.8	-2.4
X-2700	CM	binimetinib	205.8	28.7	0	0	0
X-2700	CM	binimetinib	254.1	28.9	3	23.5	0.7
X-2700	CM	binimetinib	226.5	27.2	6	10	-5.2
X-2700	CM	binimetinib	215.1	27.6	10	4.5	-3.8
X-2700	CM	binimetinib	240.9	28	13	17.1	-2.4
X-2700	CM	binimetinib	217.7	28.2	16	5.8	-1.7
X-2700	CM	binimetinib	177.5	28	20	-13.8	-2.4
X-2700	CM	binimetinib	171.1	29.1	24	-16.9	1.4
X-2700	CM	binimetinib	150.8	28.8	28	-26.7	0.3
X-2700	CM	binimetinib	153.6	29.4	31	-25.4	2.4
X-2700	CM	binimetinib	178	28.6	34	-13.5	-0.3
X-2700	CM	binimetinib	158.4	28.9	38	-23	0.7
X-2700	CM	binimetinib	144.2	28.7	42	-30	0
X-2700	CM	binimetinib	169	30	46	-17.9	4.5
X-2700	CM	binimetinib	165.5	29.2	49	-19.6	1.7
X-2700	CM	binimetinib	154.8	30.5	52	-24.8	6.3
X-2700	CM	binimetinib	205.8	29.7	57	0	3.5
X-2700	CM	binimetinib	197.6	29.7	60	-4	3.5
X-2700	CM	binimetinib	210.7	30	64	2.4	4.5
X-2700	CM	binimetinib	246.4	30	67	19.7	4.5
X-2700	CM	binimetinib	286	28.4	75	38.9	-1
X-2700	CM	binimetinib	345.6	30	81	67.9	4.5
X-2700	CM	binimetinib	354.3	30.3	85	72.2	5.6
X-2700	CM	TAS266	210.5	21.3	0	0	0
X-2700	CM	TAS266	240.1	21.2	3	14.1	-0.5
X-2700	CM	TAS266	367.8	22	6	74.7	3.3
X-2700	CM	TAS266	480.2	27.4	10	128.1	28.6
X-2700	CM	TAS266	582.6	22.7	13	176.8	6.6
X-2700	CM	TAS266	831.7	22.8	17	295.1	7
X-2700	CM	TAS266	863.3	23	20	310.1	8
X-2700	CM	TAS266	1187.6	24	23	464.2	12.7
X-2700	CM	TAS266	1466.4	24.1	27	596.6	13.1
X-2700	CM	untreated	193	26.7	0	0	0
X-2700	CM	untreated	230.3	26.3	4	19.3	-1.5
X-2700	CM	untreated	303.8	26.5	7	57.4	-0.7
X-2700	CM	untreated	406.4	27.6	10	110.5	3.4
X-2700	CM	untreated	518.4	27.4	14	168.6	2.6
X-2700	CM	untreated	645.3	27.8	17	234.3	4.1
X-2700	CM	untreated	854.4	27.9	21	342.6	4.5
X-2700	CM	untreated	860	28.4	24	345.5	6.4
X-2700	CM	untreated	931.6	28	27	382.6	4.9
X-2723	CM	BKM120	221.8	27.4	0	0	0
X-2723	CM	BKM120	223.8	27.1	4	0.9	-1.1
X-2723	CM	BKM120	368	27.3	8	65.9	-0.4
X-2723	CM	BKM120	400.2	28.9	11	80.4	5.5
X-2723	CM	BKM120	530.7	28.4	15	139.3	3.6
X-2723	CM	BKM120	640.6	29.1	18	188.8	6.2
X-2723	CM	BKM120	677.1	30.1	22	205.3	9.9
X-2723	CM	BKM120	622.7	30	23	180.7	9.5
X-2723	CM	BKM120 + encorafenib	190.4	24.5	0	0	0
X-2723	CM	BKM120 + encorafenib	120.1	24.8	3	-36.9	1.2
X-2723	CM	BKM120 + encorafenib	37.6	24.6	7	-80.3	0.4
X-2723	CM	BKM120 + encorafenib	32.5	25	11	-82.9	2
X-2723	CM	BKM120 + encorafenib	28.8	25.1	14	-84.9	2.4
X-2723	CM	BKM120 + encorafenib	78	25.2	19	-59	2.9
X-2723	CM	BKM120 + encorafenib	37	25.5	23	-80.6	4.1
X-2723	CM	BKM120 + encorafenib	78	25.2	27	-59	2.9
X-2723	CM	BKM120 + encorafenib	80	26.2	30	-58	6.9
X-2723	CM	BKM120 + encorafenib	74.4	26.7	34	-61	9
X-2723	CM	BKM120 + encorafenib	117	26.5	37	-38.6	8.2
X-2723	CM	BKM120 + encorafenib	117	26	41	-38.6	6.1
X-2723	CM	BKM120 + encorafenib	104.4	25.5	47	-45.2	4.1
X-2723	CM	BKM120 + encorafenib	99.8	25.1	50	-47.6	2.4
X-2723	CM	BKM120 + encorafenib	141.5	25.5	54	-25.7	4.1
X-2723	CM	BKM120 + encorafenib	168.3	26	58	-11.6	6.1
X-2723	CM	BKM120 + encorafenib	166.5	26.3	63	-12.6	7.3
X-2723	CM	BKM120 + encorafenib	180.3	25.9	68	-5.3	5.7
X-2723	CM	BKM120 + encorafenib	199.8	25.7	71	4.9	4.9
X-2723	CM	BKM120 + encorafenib	194.4	26.1	75	2.1	6.5
X-2723	CM	BKM120 + encorafenib	222.4	26.7	84	16.8	9
X-2723	CM	BKM120 + encorafenib	161.8	26.6	89	-15	8.6
X-2723	CM	BKM120 + encorafenib	158.4	26.8	98	-16.8	9.4
X-2723	CM	BKM120 + encorafenib	180.8	26.5	104	-5.1	8.2
X-2723	CM	BKM120 + encorafenib	261.6	26.7	112	37.4	9
X-2723	CM	BKM120 + encorafenib	243.7	26.1	124	27.9	6.5
X-2723	CM	BKM120 + encorafenib	331.3	26.3	131	74	7.3
X-2723	CM	BKM120 + encorafenib	387.2	26.4	138	103.3	7.8
X-2723	CM	BKM120 + encorafenib	437.4	26	140	129.7	6.1
X-2723	CM	CGM097	230.9	27.7	0	0	0
X-2723	CM	CGM097	293	28.2	4	26.9	1.8
X-2723	CM	CGM097	327.7	26.8	8	41.9	-3.2
X-2723	CM	CGM097	345.6	27.6	11	49.7	-0.4
X-2723	CM	CGM097	352	27	15	52.4	-2.5
X-2723	CM	CGM097	398.7	27.7	18	72.6	0
X-2723	CM	CGM097	522.5	28.8	22	126.3	4
X-2723	CM	CGM097	506.6	28.8	23	119.4	4
X-2723	CM	CLR457	195.2	24.2	0	0	0
X-2723	CM	CLR457	172.1	24.1	3	-11.9	-0.4
X-2723	CM	CLR457	240.3	24.8	8	23.1	2.5
X-2723	CM	CLR457	194.1	24.6	12	-0.6	1.7
X-2723	CM	CLR457	275.6	24.9	16	41.2	2.9
X-2723	CM	CLR457	255.9	25.7	19	31.1	6.2
X-2723	CM	CLR457	273.8	25.8	23	40.3	6.6
X-2723	CM	CLR457	305.9	26.6	26	56.7	9.9
X-2723	CM	CLR457	282.3	26.1	30	44.6	7.9
X-2723	CM	CLR457	502.2	26.4	36	157.3	9.1
X-2723	CM	CLR457	454.9	26.4	38	133	9.1
X-2723	CM	dacarbazine	213.2	27.3	0	0	0
X-2723	CM	dacarbazine	455.6	27.5	5	113.7	0.7
X-2723	CM	dacarbazine	462.1	26.6	9	116.7	-2.6
X-2723	CM	dacarbazine	522.1	26.6	13	144.9	-2.6
X-2723	CM	dacarbazine	661.7	26.8	16	210.3	-1.8
X-2723	CM	dacarbazine	857.4	27.6	20	302.1	1.1
X-2723	CM	dacarbazine	893.9	27.5	23	319.2	0.7
X-2723	CM	LDE225	190.1	23.7	0	0	0
X-2723	CM	LDE225	314.8	23.4	4	65.6	-1.3
X-2723	CM	LDE225	390	23.2	7	105.1	-2.1
X-2723	CM	LDE225	455.2	22.7	11	139.4	-4.2
X-2723	CM	LDE225	495.6	22.4	14	160.7	-5.5
X-2723	CM	LDE225	596.7	22.7	18	213.8	-4.2
X-2723	CM	LDE225	637.6	22.8	22	235.4	-3.8
X-2723	CM	LDE225	683.3	23	25	259.4	-3
X-2723	CM	LDK378	197.2	25	0	0	0
X-2723	CM	LDK378	204.2	25.4	4	3.5	1.6
X-2723	CM	LDK378	249.6	26	7	26.6	4
X-2723	CM	LDK378	233.4	26.1	11	18.4	4.4
X-2723	CM	LDK378	306.9	26.5	14	55.7	6
X-2723	CM	LDK378	310.5	26.3	18	57.5	5.2
X-2723	CM	LDK378	419	26.3	22	112.5	5.2
X-2723	CM	LDK378	475.2	26.2	25	141	4.8
X-2723	CM	LEE011	219.6	23	0	0	0
X-2723	CM	LEE011	339.2	23.1	4	54.4	0.4
X-2723	CM	LEE011	444.3	23.2	8	102.3	0.9
X-2723	CM	LEE011	503.3	24.8	11	129.2	7.8
X-2723	CM	LEE011	622.7	24.2	15	183.5	5.2
X-2723	CM	LEE011	658.9	24.4	18	200	6.1
X-2723	CM	LEE011	785.5	25.2	22	257.6	9.6
X-2723	CM	LEE011	785.5	25.2	23	257.6	9.6
X-2723	CM	LEE011 + encorafenib	218.3	23.3	0	0	0
X-2723	CM	LEE011 + encorafenib	130.1	23.3	3	-40.4	0
X-2723	CM	LEE011 + encorafenib	86.2	23.2	7	-60.5	-0.4
X-2723	CM	LEE011 + encorafenib	101.6	23	11	-53.5	-1.3
X-2723	CM	LEE011 + encorafenib	115	22.9	14	-47.3	-1.7
X-2723	CM	LEE011 + encorafenib	217.1	23.7	19	-0.6	1.7
X-2723	CM	LEE011 + encorafenib	141.4	23.8	23	-35.2	2.1
X-2723	CM	LEE011 + encorafenib	88.8	23.7	27	-59.3	1.7
X-2723	CM	LEE011 + encorafenib	110.5	24.3	30	-49.4	4.3
X-2723	CM	LEE011 + encorafenib	95	23	34	-56.5	-1.3
X-2723	CM	LEE011 + encorafenib	77	23.7	37	-64.8	1.7
X-2723	CM	LEE011 + encorafenib	97.5	23.3	41	-55.3	0
X-2723	CM	LEE011 + encorafenib	86.4	24.2	47	-60.4	3.9
X-2723	CM	LEE011 + encorafenib	41.2	23.8	50	-81.1	2.1
X-2723	CM	LEE011 + encorafenib	84.2	23.6	54	-61.4	1.3
X-2723	CM	LEE011 + encorafenib	41.9	23.6	58	-80.8	1.3
X-2723	CM	LEE011 + encorafenib	59.2	24.3	63	-72.9	4.3
X-2723	CM	LEE011 + encorafenib	32.5	23.7	68	-85.1	1.7
X-2723	CM	LEE011 + encorafenib	36.8	23.9	71	-83.1	2.6
X-2723	CM	LEE011 + encorafenib	28.5	24	75	-86.9	3
X-2723	CM	LEE011 + encorafenib	0	24.4	84	-100	4.7
X-2723	CM	LEE011 + encorafenib	0	25.2	89	-100	8.2
X-2723	CM	LEE011 + encorafenib	0	25.3	98	-100	8.6
X-2723	CM	LEE011 + encorafenib	0	25.1	104	-100	7.7
X-2723	CM	LEE011 + encorafenib	0	24.4	112	-100	4.7
X-2723	CM	LEE011 + encorafenib	0	24.6	124	-100	5.6
X-2723	CM	LEE011 + encorafenib	0	24.2	131	-100	3.9
X-2723	CM	LEE011 + encorafenib	0	23.6	138	-100	1.3
X-2723	CM	LEE011 + encorafenib	0	24.5	148	-100	5.2
X-2723	CM	LEE011 + encorafenib	0	24.5	156	-100	5.2
X-2723	CM	LEE011 + encorafenib	0	25.2	162	-100	8.2
X-2723	CM	LEE011 + encorafenib	0	25.3	170	-100	8.6
X-2723	CM	LEE011 + encorafenib	0	25.2	176	-100	8.2
X-2723	CM	LEE011 + encorafenib	0	25.6	184	-100	9.9
X-2723	CM	LEE011 + encorafenib	0	25.4	193	-100	9
X-2723	CM	LEE011 + encorafenib	0	27	201	-100	15.9
X-2723	CM	LEE011 + encorafenib	0	27	208	-100	15.9
X-2723	CM	LEE011 + encorafenib	0	27	212	-100	15.9
X-2723	CM	LEE011 + encorafenib	0	27	218	-100	15.9
X-2723	CM	LEE011 + encorafenib	0	26.9	231	-100	15.5
X-2723	CM	LEE011 + encorafenib	0	26.3	238	-100	12.9
X-2723	CM	LEE011 + encorafenib	0	25.2	245	-100	8.2
X-2723	CM	LEE011 + binimetinib	197	25.8	0	0	0
X-2723	CM	LEE011 + binimetinib	100.9	25.5	3	-48.8	-1.2
X-2723	CM	LEE011 + binimetinib	117.2	24.8	8	-40.5	-3.9
X-2723	CM	LEE011 + binimetinib	57.1	24.8	12	-71	-3.9
X-2723	CM	LEE011 + binimetinib	66.3	24.7	16	-66.4	-4.3
X-2723	CM	LEE011 + binimetinib	50.8	25	19	-74.2	-3.1
X-2723	CM	LEE011 + binimetinib	70.2	25.2	23	-64.3	-2.3
X-2723	CM	LEE011 + binimetinib	62.5	25.8	26	-68.3	0
X-2723	CM	LEE011 + binimetinib	86.2	24.3	30	-56.2	-5.8
X-2723	CM	LEE011 + binimetinib	66.3	25.6	36	-66.4	-0.8
X-2723	CM	LEE011 + binimetinib	77.1	25.3	39	-60.9	-1.9
X-2723	CM	LEE011 + binimetinib	52.9	25.1	43	-73.1	-2.7
X-2723	CM	LEE011 + binimetinib	33.2	24.8	47	-83.1	-3.9
X-2723	CM	LEE011 + binimetinib	27.4	25.3	52	-86.1	-1.9
X-2723	CM	LEE011 + binimetinib	24	24.5	57	-87.8	-5
X-2723	CM	LEE011 + binimetinib	37.8	24.8	60	-80.8	-3.9
X-2723	CM	LEE011 + binimetinib	19.5	25.1	64	-90.1	-2.7
X-2723	CM	LEE011 + binimetinib	24.5	25.3	73	-87.6	-1.9
X-2723	CM	LEE011 + binimetinib	21.4	25.4	78	-89.1	-1.6
X-2723	CM	LEE011 + binimetinib	0	25	87	-100	-3.1
X-2723	CM	LEE011 + binimetinib	12.6	25.2	93	-93.6	-2.3
X-2723	CM	LEE011 + binimetinib	10.6	25.2	101	-94.6	-2.3
X-2723	CM	LEE011 + binimetinib	6.9	25.2	113	-96.5	-2.3
X-2723	CM	LEE011 + binimetinib	0	26.1	120	-100	1.2
X-2723	CM	LEE011 + binimetinib	6.6	24.9	127	-96.6	-3.5
X-2723	CM	LEE011 + binimetinib	10.1	24.5	137	-94.9	-5
X-2723	CM	LEE011 + binimetinib	9.4	24.9	145	-95.2	-3.5
X-2723	CM	LEE011 + binimetinib	12.2	25.2	151	-93.8	-2.3
X-2723	CM	LEE011 + binimetinib	12.6	25.8	159	-93.6	0
X-2723	CM	LEE011 + binimetinib	15.3	26.2	165	-92.2	1.6
X-2723	CM	LEE011 + binimetinib	20.2	25.8	173	-89.8	0
X-2723	CM	LEE011 + binimetinib	20.2	24.4	182	-89.8	-5.4
X-2723	CM	LEE011 + binimetinib	46.5	26.2	190	-76.4	1.6
X-2723	CM	LEE011 + binimetinib	18	26.5	197	-90.9	2.7
X-2723	CM	LEE011 + binimetinib	0	26.3	202	-100	1.9
X-2723	CM	LEE011 + binimetinib	0	25.7	208	-100	-0.4
X-2723	CM	LEE011 + binimetinib	0	26	221	-100	0.8
X-2723	CM	LEE011 + binimetinib	0	25	228	-100	-3.1
X-2723	CM	LEE011 + binimetinib	0	25.2	235	-100	-2.3
X-2723	CM	WNT974	210	23.9	0	0	0
X-2723	CM	WNT974	269.8	23.3	3	28.5	-2.5
X-2723	CM	WNT974	285.4	22.7	7	35.9	-5
X-2723	CM	WNT974	273.8	22.6	10	30.4	-5.4
X-2723	CM	WNT974	440.7	22.9	14	109.9	-4.2
X-2723	CM	WNT974	451.6	22.6	18	115.1	-5.4
X-2723	CM	WNT974	631.3	23.5	21	200.7	-1.7
X-2723	CM	LGW813	194.2	25.3	0	0	0
X-2723	CM	LGW813	105.6	27.3	4	-45.6	7.9
X-2723	CM	LGW813	61.9	26.5	7	-68.1	4.7
X-2723	CM	LGW813	81.5	25.5	11	-58.1	0.8
X-2723	CM	LGW813	44.6	26.7	14	-77.1	5.5
X-2723	CM	LGW813	62.2	27	18	-68	6.7
X-2723	CM	LGW813	63.8	28.4	22	-67.2	12.3
X-2723	CM	LGW813	145.1	27.5	25	-25.3	8.7
X-2723	CM	LGW813	213.2	26.9	30	9.8	6.3
X-2723	CM	LGW813	238.1	26.3	34	22.6	4
X-2723	CM	LGW813	269.7	27	38	38.9	6.7
X-2723	CM	LGW813	290.4	27.8	41	49.5	9.9
X-2723	CM	LGW813	377.2	28	45	94.2	10.7
X-2723	CM	LGW813	377.2	28	46	94.2	10.7
X-2723	CM	encorafenib	210.9	24.2	0	0	0
X-2723	CM	encorafenib	328.6	25	4	55.8	3.3
X-2723	CM	encorafenib	416	25.1	8	97.2	3.7
X-2723	CM	encorafenib	438.4	25.4	11	107.8	5
X-2723	CM	encorafenib	385.4	24.7	15	82.7	2.1
X-2723	CM	encorafenib	424.4	25.3	18	101.2	4.5
X-2723	CM	encorafenib	575.1	25.2	22	172.6	4.1
X-2723	CM	encorafenib	660.2	25.2	23	213	4.1
X-2723	CM	encorafenib + binimetinib	189	26.3	0	0	0
X-2723	CM	encorafenib + binimetinib	50.6	26.1	4	-73.2	-0.8
X-2723	CM	encorafenib + binimetinib	37.9	25.1	8	-79.9	-4.6
X-2723	CM	encorafenib + binimetinib	58.5	25.9	11	-69	-1.5
X-2723	CM	encorafenib + binimetinib	117.7	25.2	16	-37.7	-4.2
X-2723	CM	encorafenib + binimetinib	105	25.2	20	-44.5	-4.2
X-2723	CM	encorafenib + binimetinib	111.6	25.1	24	-41	-4.6
X-2723	CM	encorafenib + binimetinib	120.6	26.1	27	-36.2	-0.8
X-2723	CM	encorafenib + binimetinib	140.3	26.5	31	-25.8	0.8
X-2723	CM	encorafenib + binimetinib	178	26.1	34	-5.8	-0.8
X-2723	CM	encorafenib + binimetinib	208.1	25.3	37	10.1	-3.8
X-2723	CM	encorafenib + binimetinib	131	25.9	43	-30.7	-1.5
X-2723	CM	encorafenib + binimetinib	140.9	25.4	47	-25.5	-3.4
X-2723	CM	encorafenib + binimetinib	176.4	24.7	51	-6.7	-6.1
X-2723	CM	encorafenib + binimetinib	150.3	25.2	55	-20.5	-4.2
X-2723	CM	encorafenib + binimetinib	168.8	25.7	60	-10.7	-2.3
X-2723	CM	encorafenib + binimetinib	140.9	25.6	65	-25.5	-2.7
X-2723	CM	encorafenib + binimetinib	165.5	25.4	68	-12.4	-3.4
X-2723	CM	encorafenib + binimetinib	103.5	26	72	-45.3	-1.1
X-2723	CM	encorafenib + binimetinib	121.1	26.1	81	-35.9	-0.8
X-2723	CM	encorafenib + binimetinib	121.1	26.3	86	-35.9	0
X-2723	CM	encorafenib + binimetinib	139.6	26.8	95	-26.2	1.9
X-2723	CM	encorafenib + binimetinib	191.1	26.7	101	1.1	1.5
X-2723	CM	encorafenib + binimetinib	139.4	26.7	109	-26.2	1.5
X-2723	CM	encorafenib + binimetinib	81.7	26	121	-56.8	-1.1
X-2723	CM	encorafenib + binimetinib	94.1	25.8	128	-50.2	-1.9
X-2723	CM	encorafenib + binimetinib	136.8	25.4	135	-27.6	-3.4
X-2723	CM	encorafenib + binimetinib	240.1	26.6	145	27	1.1
X-2723	CM	encorafenib + binimetinib	276.8	25.8	153	46.4	-1.9
X-2723	CM	encorafenib + binimetinib	232.7	26.6	159	23.1	1.1
X-2723	CM	encorafenib + binimetinib	328.1	25.2	167	73.5	-4.2
X-2723	CM	encorafenib + binimetinib	401	26.1	173	112.1	-0.8
X-2723	CM	encorafenib + binimetinib	399.6	26.3	181	111.4	0
X-2723	CM	encorafenib + binimetinib	416.3	27.1	190	120.2	3
X-2723	CM	encorafenib + binimetinib	538.7	26.6	198	184.9	1.1
X-2723	CM	encorafenib + binimetinib	534.6	26.3	205	182.8	0
X-2723	CM	encorafenib + binimetinib	728.3	26.5	210	285.3	0.8
X-2723	CM	encorafenib + binimetinib	790.6	27	216	318.2	2.7
X-2723	CM	encorafenib + binimetinib	955.9	28.6	229	405.7	8.7
X-2723	CM	binimetinib	198.5	23.2	0	0	0
X-2723	CM	binimetinib	161.2	24	4	-18.8	3.4
X-2723	CM	binimetinib	213.6	24	8	7.6	3.4
X-2723	CM	binimetinib	292	24.1	11	47.2	3.9
X-2723	CM	binimetinib	249	24.3	15	25.5	4.7
X-2723	CM	binimetinib	222	24.5	18	11.8	5.6
X-2723	CM	binimetinib	210.4	25.1	22	6	8.2
X-2723	CM	binimetinib	190.1	24.7	26	-4.2	6.5
X-2723	CM	binimetinib	181.7	24.7	29	-8.5	6.5
X-2723	CM	binimetinib	351	25.6	34	76.9	10.3
X-2723	CM	binimetinib	493	25.1	38	148.4	8.2
X-2723	CM	binimetinib	446.2	24.6	42	124.9	6
X-2723	CM	binimetinib	493	24.8	44	148.4	6.9
X-2723	CM	TAS266	235.7	24.7	0	0	0
X-2723	CM	TAS266	347.7	24.6	4	47.5	-0.4
X-2723	CM	TAS266	415.4	24.5	8	76.3	-0.8
X-2723	CM	TAS266	476.9	25.2	11	102.3	2
X-2723	CM	TAS266	516.7	25.4	15	119.2	2.8
X-2723	CM	TAS266	557.6	25.5	18	136.6	3.2
X-2723	CM	TAS266	713.5	25.9	22	202.8	4.9
X-2723	CM	TAS266	698.3	25.9	23	196.3	4.9
X-2723	CM	untreated	209.2	23.5	0	0	0
X-2723	CM	untreated	243.7	24.8	4	16.5	5.5
X-2723	CM	untreated	257.9	24.9	8	23.3	6
X-2723	CM	untreated	311.7	25.6	11	49	8.9
X-2723	CM	untreated	431.4	25.1	15	106.2	6.8
X-2723	CM	untreated	677.4	25.7	18	223.8	9.4
X-2723	CM	untreated	957.2	25.8	22	357.5	9.8
X-2723	CM	untreated	976	25.8	23	366.6	9.8
X-2753	CM	BKM120	210	24.4	0	0	0
X-2753	CM	BKM120	185.8	24.9	4	-11.5	2
X-2753	CM	BKM120	239.8	24.6	7	14.2	0.8
X-2753	CM	BKM120	235.2	25.5	11	12	4.5
X-2753	CM	BKM120	285.4	24.8	14	35.9	1.6
X-2753	CM	BKM120	421.7	25.2	19	100.9	3.3
X-2753	CM	BKM120	637.2	24.7	22	203.5	1.2
X-2753	CM	BKM120	724.4	24.8	25	245	1.6
X-2753	CM	BKM120 + encorafenib	219.6	26.8	0	0	0
X-2753	CM	BKM120 + encorafenib	356.8	27.3	5	62.5	1.9
X-2753	CM	BKM120 + encorafenib	483.8	26.3	8	120.3	-1.9
X-2753	CM	BKM120 + encorafenib	655.9	27.7	13	198.7	3.4
X-2753	CM	BKM120 + encorafenib	703.5	27.9	16	220.4	4.1
X-2753	CM	BKM120 + encorafenib	928.3	26.7	19	322.7	-0.4
X-2753	CM	BKM120 + encorafenib	1145.5	25.8	22	421.6	-3.7
X-2753	CM	CGM097	209.9	25.2	0	0	0
X-2753	CM	CGM097	334.1	23.8	4	59.2	-5.6
X-2753	CM	CGM097	275.8	22.7	7	31.4	-9.9
X-2753	CM	CGM097	188.4	21.6	11	-10.2	-14.3
X-2753	CM	CGM097	140.7	20.5	14	-33	-18.7
X-2753	CM	CGM097	144.7	20.6	15	-31.1	-18.3
X-2753	CM	CLR457	199	22.7	0	0	0
X-2753	CM	CLR457	235.9	24.1	4	18.5	6.2
X-2753	CM	CLR457	203.4	23.7	7	2.2	4.4
X-2753	CM	CLR457	269.5	24.1	10	35.4	6.2
X-2753	CM	CLR457	239.4	24.4	13	20.3	7.5
X-2753	CM	CLR457	250.3	24.5	17	25.7	7.9
X-2753	CM	CLR457	316.3	24.6	20	58.9	8.4
X-2753	CM	CLR457	320.4	24.7	24	61	8.8
X-2753	CM	dacarbazine	204.5	26.7	0	0	0
X-2753	CM	dacarbazine	241.8	25.9	5	18.2	-3
X-2753	CM	dacarbazine	251.9	23.7	8	23.2	-11.2
X-2753	CM	dacarbazine	470.7	24.6	13	130.2	-7.9
X-2753	CM	dacarbazine	516	24.7	16	152.3	-7.5
X-2753	CM	dacarbazine	758	26.2	19	270.7	-1.9
X-2753	CM	dacarbazine	1290.3	25.6	22	531	-4.1
X-2753	CM	LDE225	214.5	26.2	0	0	0
X-2753	CM	LDE225	275.9	26.2	4	28.6	0
X-2753	CM	LDE225	301.9	25.6	7	40.8	-2.3
X-2753	CM	LDE225	606	24.4	11	182.6	-6.9
X-2753	CM	LDE225	580.2	23.2	14	170.5	-11.5
X-2753	CM	LDE225	578.2	22.3	19	169.6	-14.9
X-2753	CM	LDE225	679.9	20.3	22	217	-22.5
X-2753	CM	LDK378	199.3	23.9	0	0	0
X-2753	CM	LDK378	225.5	23.9	4	13.1	0
X-2753	CM	LDK378	293.1	23.8	7	47.1	-0.4
X-2753	CM	LDK378	406.2	24.9	11	103.9	4.2
X-2753	CM	LDK378	569.1	23.9	14	185.6	0
X-2753	CM	LDK378	661.8	24.5	19	232.1	2.5
X-2753	CM	LDK378	883	24.6	22	343.1	2.9
X-2753	CM	LDK378	1055.8	24.9	25	429.9	4.2
X-2753	CM	LEE011	230.7	23.1	0	0	0
X-2753	CM	LEE011	392.2	23.1	4	70	0
X-2753	CM	LEE011	447.3	22.6	7	93.9	-2.2
X-2753	CM	LEE011	529.1	21.2	11	129.3	-8.2
X-2753	CM	LEE011	572.1	20.5	14	147.9	-11.3
X-2753	CM	LEE011	651.9	20.4	19	182.5	-11.7
X-2753	CM	LEE011	819.1	19.1	22	255	-17.3
X-2753	CM	LEE011 + encorafenib	216.1	21.9	0	0	0
X-2753	CM	LEE011 + encorafenib	240.2	21.5	5	11.2	-1.8
X-2753	CM	LEE011 + encorafenib	185.2	20.5	8	-14.3	-6.4
X-2753	CM	LEE011 + encorafenib	192.2	21.5	13	-11.1	-1.8
X-2753	CM	LEE011 + encorafenib	196	20.1	16	-9.3	-8.2
X-2753	CM	LEE011 + encorafenib	211.9	20.3	19	-1.9	-7.3
X-2753	CM	LEE011 + encorafenib	236.3	20.3	22	9.4	-7.3
X-2753	CM	LEE011 + encorafenib	211.1	16.5	26	-2.3	-24.7
X-2753	CM	LEE011 + binimetinib	201.7	26.5	0	0	0
X-2753	CM	LEE011 + binimetinib	202.5	27.4	4	0.4	3.4
X-2753	CM	LEE011 + binimetinib	228.2	27.2	7	13.1	2.6
X-2753	CM	LEE011 + binimetinib	200.6	27.5	10	-0.5	3.8
X-2753	CM	LEE011 + binimetinib	255	28.7	13	26.4	8.3
X-2753	CM	LEE011 + binimetinib	294.1	28.8	17	45.8	8.7
X-2753	CM	LEE011 + binimetinib	398.1	27.9	20	97.3	5.3
X-2753	CM	LEE011 + binimetinib	497.7	29.1	24	146.7	9.8
X-2753	CM	WNT974	198.6	24.7	0	0	0
X-2753	CM	WNT974	266.1	26.1	4	34	5.7
X-2753	CM	WNT974	351.3	26.2	7	76.9	6.1
X-2753	CM	WNT974	560.2	26.7	11	182.1	8.1
X-2753	CM	WNT974	752.3	26.1	14	278.9	5.7
X-2753	CM	WNT974	1571.1	25.4	19	691.2	2.8
X-2753	CM	LGW813	194.8	24.7	0	0	0
X-2753	CM	LGW813	237.8	25.1	4	22	1.6
X-2753	CM	LGW813	246.4	24.1	7	26.5	-2.4
X-2753	CM	LGW813	221	25.2	11	13.5	2
X-2753	CM	LGW813	169.6	24	14	-12.9	-2.8
X-2753	CM	LGW813	204.2	25	19	4.8	1.2
X-2753	CM	LGW813	205	25.2	22	5.2	2
X-2753	CM	LGW813	157	25.3	25	-19.4	2.4
X-2753	CM	LGW813	185.6	25.5	28	-4.7	3.2
X-2753	CM	LGW813	113	25.5	32	-42	3.2
X-2753	CM	LGW813	92.4	25.2	35	-52.6	2
X-2753	CM	LGW813	115.8	26.3	39	-40.6	6.5
X-2753	CM	LGW813	111	25.5	42	-43	3.2
X-2753	CM	LGW813	113.6	27	46	-41.7	9.3
X-2753	CM	LGW813	99.6	25.9	49	-48.9	4.9
X-2753	CM	LGW813	93	26.4	53	-52.3	6.9
X-2753	CM	LGW813	85.6	26.4	56	-56	6.9
X-2753	CM	LGW813	103.8	26.7	60	-46.7	8.1
X-2753	CM	LGW813	91.6	25.7	63	-53	4
X-2753	CM	LGW813	205.3	26.5	68	5.4	7.3
X-2753	CM	LGW813	235.6	26.7	71	20.9	8.1
X-2753	CM	LGW813	258.4	26.6	75	32.6	7.7
X-2753	CM	LGW813	294.7	27.1	78	51.3	9.7
X-2753	CM	LGW813	306.2	27.3	81	57.2	10.5
X-2753	CM	LGW813	245.4	27	84	26	9.3
X-2753	CM	LGW813	175.9	28.6	88	-9.7	15.8
X-2753	CM	LGW813	207.6	27.2	91	6.6	10.1
X-2753	CM	LGW813	217.6	27.5	95	11.7	11.3
X-2753	CM	LGW813	211.1	27.5	98	8.3	11.3
X-2753	CM	LGW813	233	27.5	102	19.6	11.3
X-2753	CM	LGW813	314.8	27.5	105	61.6	11.3
X-2753	CM	LGW813	366.4	27.3	109	88.1	10.5
X-2753	CM	encorafenib	233.7	24.5	0	0	0
X-2753	CM	encorafenib	290.4	25.1	4	24.3	2.4
X-2753	CM	encorafenib	345.4	24	7	47.8	-2
X-2753	CM	encorafenib	539.3	24.9	11	130.8	1.6
X-2753	CM	encorafenib	647.9	24	14	177.2	-2
X-2753	CM	encorafenib	830	24.4	19	255.2	-0.4
X-2753	CM	encorafenib	1046.6	23.9	22	347.9	-2.4
X-2753	CM	encorafenib	1243.4	23.9	25	432.1	-2.4
X-2753	CM	encorafenib + binimetinib	226.2	22.5	0	0	0
X-2753	CM	encorafenib + binimetinib	320.8	22.9	5	41.9	1.8
X-2753	CM	encorafenib + binimetinib	364.9	22.8	8	61.3	1.3
X-2753	CM	encorafenib + binimetinib	639.6	23.5	13	182.8	4.4
X-2753	CM	encorafenib + binimetinib	606.1	23.3	16	168	3.6
X-2753	CM	encorafenib + binimetinib	649.9	23.3	19	187.4	3.6
X-2753	CM	encorafenib + binimetinib	800.3	22.9	22	253.8	1.8
X-2753	CM	binimetinib	227.4	24.8	0	0	0
X-2753	CM	binimetinib	292	24.8	4	28.4	0
X-2753	CM	binimetinib	364.5	24.9	7	60.3	0.4
X-2753	CM	binimetinib	550.8	26.5	11	142.2	6.9
X-2753	CM	binimetinib	610.8	26	14	168.5	4.8
X-2753	CM	binimetinib	893	24.3	19	292.6	-2
X-2753	CM	binimetinib	1261.5	24.4	22	454.7	-1.6
X-2753	CM	binimetinib	1406.3	24.5	25	518.3	-1.2
X-2753	CM	TAS266	225.8	24.5	0	0	0
X-2753	CM	TAS266	257.2	24.9	4	13.9	1.6
X-2753	CM	TAS266	291.4	24.3	7	29.1	-0.8
X-2753	CM	TAS266	389.6	24.9	11	72.6	1.6
X-2753	CM	TAS266	398.2	24.5	14	76.4	0
X-2753	CM	TAS266	594.7	25.2	19	163.4	2.9
X-2753	CM	TAS266	702	25	22	210.9	2
X-2753	CM	TAS266	807.9	25.2	25	257.9	2.9
X-2753	CM	untreated	190.1	26.3	0	0	0
X-2753	CM	untreated	301.3	24.9	5	58.4	-5.3
X-2753	CM	untreated	515.8	24.6	9	171.3	-6.5
X-2753	CM	untreated	463.4	24.6	12	143.7	-6.5
X-2753	CM	untreated	508.5	25.2	16	167.5	-4.2
X-2753	CM	untreated	704.6	24.2	19	270.6	-8
X-2753	CM	untreated	854.1	25.3	24	349.2	-3.8
X-2761	CRC	LFW527 + binimetinib	199.53	23.63	0	0	0
X-2761	CRC	LFW527 + binimetinib	188.96	22.73	3	-5.3	-3.8
X-2761	CRC	LFW527 + binimetinib	174.85	23.4	6	-12.4	-1
X-2761	CRC	LFW527 + binimetinib	192.13	23.91	10	-3.7	1.2
X-2761	CRC	LFW527 + binimetinib	199.51	22.97	13	0	-2.8
X-2761	CRC	LFW527 + binimetinib	216.96	22.88	17	8.7	-3.2
X-2761	CRC	LFW527 + binimetinib	225.11	22.97	20	12.8	-2.8
X-2761	CRC	LFW527 + binimetinib	276.39	23.12	24	38.5	-2.2
X-2761	CRC	LFW527 + binimetinib	300.44	24.08	27	50.6	1.9
X-2761	CRC	LFW527 + binimetinib	364.16	23.53	31	82.5	-0.4
X-2761	CRC	LFW527 + binimetinib	381.8	22.33	34	91.3	-5.5
X-2761	CRC	LFW527 + binimetinib	408.69	22.09	38	104.8	-6.5
X-2761	CRC	LFW527 + binimetinib	413.99	22.76	41	107.5	-3.7
X-2761	CRC	LFW527 + binimetinib	427.43	22.51	45	114.2	-4.7
X-2761	CRC	LFW527 + binimetinib	432	22.42	48	116.5	-5.1
X-2761	CRC	LFW527 + binimetinib	455.84	23.14	52	128.5	-2.1
X-2761	CRC	LFW527 + binimetinib	478	22.56	54	139.6	-4.5
X-2761	CRC	LFW527 + binimetinib	523.76	23.8	59	162.5	0.7
X-2761	CRC	LFW527 + binimetinib	488.45	22.21	62	144.8	-6
X-2761	CRC	LFW527 + binimetinib	512.15	22.68	66	156.7	-4
X-2761	CRC	LFW527 + binimetinib	521.33	22.13	69	161.3	-6.3
X-2761	CRC	LFW527 + binimetinib	564.44	22.56	73	182.9	-4.5
X-2761	CRC	LFW527 + binimetinib	570.53	21.76	76	185.9	-7.9
X-2761	CRC	LFW527 + binimetinib	629.42	22.2	80	215.5	-6.1
X-2761	CRC	LFW527 + binimetinib	618.63	22.23	83	210	-5.9
X-2780	BRCA	BGJ398	279.4	28.2	0	0	0
X-2780	BRCA	BGJ398	239.3	28.4	3	-14.4	0.7
X-2780	BRCA	BGJ398	265.7	26.8	6	-4.9	-5
X-2780	BRCA	BGJ398	547.7	27.4	14	96	-2.8
X-2780	BRCA	BGJ398	573.8	26.8	17	105.4	-5
X-2780	BRCA	BGJ398	759	27.6	20	171.7	-2.1
X-2780	BRCA	BGJ398	792.5	28.1	24	183.6	-0.4
X-2780	BRCA	BGJ398	1065.4	28.9	28	281.3	2.5
X-2780	BRCA	BGJ398	1033	28.5	31	269.7	1.1
X-2780	BRCA	BGJ398	1110.2	27.7	34	297.4	-1.8
X-2780	BRCA	BKM120	228	24.2	0	0	0
X-2780	BRCA	BKM120	224.1	25.6	4	-1.7	5.8
X-2780	BRCA	BKM120	244.2	25.9	8	7.1	7
X-2780	BRCA	BKM120	196.2	26.4	11	-13.9	9.1
X-2780	BRCA	BKM120	174.2	25.7	15	-23.6	6.2
X-2780	BRCA	BKM120	203.2	26	18	-10.9	7.4
X-2780	BRCA	BKM120	189.2	25.8	22	-17	6.6
X-2780	BRCA	BKM120	216.2	24.5	25	-5.2	1.2
X-2780	BRCA	BKM120	214.3	24.7	29	-6	2.1
X-2780	BRCA	BKM120	268.9	25.3	32	17.9	4.5
X-2780	BRCA	BKM120	257.6	24.2	40	13	0
X-2780	BRCA	BKM120	276.9	23.8	43	21.4	-1.7
X-2780	BRCA	BKM120	254.4	22.2	46	11.6	-8.3
X-2780	BRCA	BKM120	165.2	21.4	50	-27.5	-11.6
X-2780	BRCA	BKM120	199	18.8	54	-12.7	-22.3
X-2780	BRCA	BYL719	241	28.8	0	0	0
X-2780	BRCA	BYL719	234	29.6	4	-2.9	2.8
X-2780	BRCA	BYL719	221.9	29.3	8	-7.9	1.7
X-2780	BRCA	BYL719	248.1	29.9	11	2.9	3.8
X-2780	BRCA	BYL719	183	29.4	15	-24.1	2.1
X-2780	BRCA	BYL719	208.2	29	18	-13.6	0.7
X-2780	BRCA	BYL719	263.5	29	22	9.3	0.7
X-2780	BRCA	BYL719	226.1	27.2	25	-6.2	-5.6
X-2780	BRCA	BYL719	274.3	27.9	29	13.8	-3.1
X-2780	BRCA	BYL719	354.8	28.5	32	47.2	-1
X-2780	BRCA	BYL719	515.6	24.8	40	113.9	-13.9
X-2780	BRCA	BYL719	618.4	19.9	43	156.6	-30.9
X-2780	BRCA	BYL719 + LEE011	380.5	28.6	0	0	0
X-2780	BRCA	BYL719 + LEE011	458.6	29	1	20.5	1.4
X-2780	BRCA	BYL719 + LEE011	244	24.6	5	-35.9	-14
X-2780	BRCA	BYL719 + LJM716	198.2	24	0	0	0
X-2780	BRCA	BYL719 + LJM716	258.5	25.5	4	30.4	6.2
X-2780	BRCA	BYL719 + LJM716	203.2	21.4	8	2.5	-10.8
X-2780	BRCA	BYL719 + LJM716	235.8	25.1	11	19	4.6
X-2780	BRCA	BYL719 + LJM716	302	24.7	15	52.4	2.9
X-2780	BRCA	BYL719 + LJM716	258.7	24.8	18	30.5	3.3
X-2780	BRCA	BYL719 + LJM716	391	25.8	22	97.3	7.5
X-2780	BRCA	BYL719 + LJM716	415.1	23.8	25	109.4	-0.8
X-2780	BRCA	BYL719 + LJM716	385.5	24.7	29	94.5	2.9
X-2780	BRCA	BYL719 + LJM716	443.6	25	32	123.8	4.2
X-2780	BRCA	CGM097	299.4	31.2	0	0	0
X-2780	BRCA	CGM097	298.6	31.9	3	-0.3	2.2
X-2780	BRCA	CGM097	273.1	32.4	6	-8.8	3.8
X-2780	BRCA	CGM097	479.7	33.3	10	60.2	6.7
X-2780	BRCA	CGM097	515.4	33.2	13	72.1	6.4
X-2780	BRCA	CGM097	425.6	30	17	42.2	-3.8
X-2780	BRCA	CGM097	471.1	30.5	20	57.3	-2.2
X-2780	BRCA	CGM097	599.2	32.4	24	100.1	3.8
X-2780	BRCA	CGM097	825	32.1	27	175.6	2.9
X-2780	BRCA	CLR457	234.2	30.2	0	0	0
X-2780	BRCA	CLR457	258.1	29.2	1	10.2	-3.3
X-2780	BRCA	CLR457	285.5	28.6	4	21.9	-5.3
X-2780	BRCA	CLR457	293.4	28.4	8	25.3	-6
X-2780	BRCA	CLR457	348.6	27.6	11	48.8	-8.6
X-2780	BRCA	CLR457	281	27.9	15	20	-7.6
X-2780	BRCA	CLR457	296.5	28.4	18	26.6	-6
X-2780	BRCA	CLR457	353.3	31.3	26	50.9	3.6
X-2780	BRCA	CLR457	472.6	31	29	101.8	2.6
X-2780	BRCA	CLR457	524.1	30.5	32	123.8	1
X-2780	BRCA	CLR457	520.6	31.3	36	122.3	3.6
X-2780	BRCA	CLR457	545.9	31.5	40	133.1	4.3
X-2780	BRCA	CLR457	533.2	30.1	43	127.7	-0.3
X-2780	BRCA	CLR457	594.9	30.2	46	154	0
X-2780	BRCA	HDM201	216.2	22.2	0	0	0
X-2780	BRCA	HDM201	246	23.2	4	13.8	4.5
X-2780	BRCA	HDM201	302.2	22.2	8	39.8	0
X-2780	BRCA	HDM201	218.6	22.5	11	1.1	1.4
X-2780	BRCA	HDM201	215	23	15	-0.6	3.6
X-2780	BRCA	HDM201	290.6	22.2	18	34.4	0
X-2780	BRCA	HDM201	285	21.8	22	31.8	-1.8
X-2780	BRCA	HDM201	305.8	20.7	25	41.4	-6.8
X-2780	BRCA	HDM201	473.3	19.8	29	118.9	-10.8
X-2780	BRCA	HDM201	640.4	20.5	32	196.2	-7.7
X-2780	BRCA	INC424	197.4	25.2	0	0	0
X-2780	BRCA	INC424	300.8	26	3	52.4	3.2
X-2780	BRCA	INC424	414	26.7	6	109.7	6
X-2780	BRCA	INC424	536.7	26.7	10	171.9	6
X-2780	BRCA	INC424	607.8	26.6	13	207.9	5.6
X-2780	BRCA	INC424	714.1	25.9	17	261.8	2.8
X-2780	BRCA	INC424	1031.6	26.3	20	422.6	4.4
X-2780	BRCA	INC424	1407	26.3	28	612.8	4.4
X-2780	BRCA	LEE011	199.1	30.4	0	0	0
X-2780	BRCA	LEE011	334	31.3	3	67.8	3
X-2780	BRCA	LEE011	269	30.4	7	35.1	0
X-2780	BRCA	LEE011	399.4	29.9	10	100.6	-1.6
X-2780	BRCA	LEE011	400.7	29.7	13	101.3	-2.3
X-2780	BRCA	LEE011	356.4	29.8	17	79	-2
X-2780	BRCA	LEE011	449.1	32	21	125.6	5.3
X-2780	BRCA	LEE011	440.1	31.6	24	121	3.9
X-2780	BRCA	LEE011	460.7	31.6	27	131.4	3.9
X-2780	BRCA	LEE011 + everolimus	385	27.9	0	0	0
X-2780	BRCA	LEE011 + everolimus	361.3	31	1	-6.2	11.1
X-2780	BRCA	LEE011 + everolimus	357.6	26.4	5	-7.1	-5.4
X-2780	BRCA	LEE011 + everolimus	332.7	27.3	8	-13.6	-2.2
X-2780	BRCA	LEE011 + everolimus	374.2	27.9	11	-2.8	0
X-2780	BRCA	LEE011 + everolimus	246.8	27.6	15	-35.9	-1.1
X-2780	BRCA	LEE011 + everolimus	217.2	28.2	19	-43.6	1.1
X-2780	BRCA	LEE011 + everolimus	156.6	28.5	22	-59.3	2.2
X-2780	BRCA	LEE011 + everolimus	235.7	29.5	25	-38.8	5.7
X-2780	BRCA	LEE011 + everolimus	221.9	29.3	32	-42.4	5
X-2780	BRCA	LEE011 + everolimus	214.3	29	36	-44.3	3.9
X-2780	BRCA	LEE011 + everolimus	260.2	29	40	-32.4	3.9
X-2780	BRCA	LEE011 + everolimus	299.3	29	43	-22.3	3.9
X-2780	BRCA	LEE011 + everolimus	248.9	29.4	47	-35.4	5.4
X-2780	BRCA	LEE011 + everolimus	277.7	27.7	50	-27.9	-0.7
X-2780	BRCA	LEE011 + everolimus	247.4	29.1	53	-35.7	4.3
X-2780	BRCA	LEE011 + everolimus	277.3	27.5	57	-28	-1.4
X-2780	BRCA	LEE011 + everolimus	209.1	28.2	61	-45.7	1.1
X-2780	BRCA	LEE011 + everolimus	240.6	30.9	64	-37.5	10.8
X-2780	BRCA	LEE011 + everolimus	250.6	28.8	68	-34.9	3.2
X-2780	BRCA	LEE011 + everolimus	279.6	29	71	-27.4	3.9
X-2780	BRCA	LEE011 + everolimus	327.7	28.4	74	-14.9	1.8
X-2780	BRCA	LEE011 + everolimus	278.5	28.4	78	-27.7	1.8
X-2780	BRCA	LEE011 + everolimus	307	27.9	81	-20.3	0
X-2780	BRCA	LEE011 + everolimus	282.7	29.7	85	-26.6	6.5
X-2780	BRCA	LEE011 + everolimus	264.2	27.5	88	-31.4	-1.4
X-2780	BRCA	LFA102	199.7	25.4	0	0	0
X-2780	BRCA	LFA102	251.7	25.4	3	26	0
X-2780	BRCA	LFA102	304.7	25.9	6	52.6	2
X-2780	BRCA	LFA102	457.6	26.5	10	129.1	4.3
X-2780	BRCA	LFA102	616	26.1	13	208.5	2.8
X-2780	BRCA	LFA102	896.1	25.5	17	348.7	0.4
X-2780	BRCA	LFA102	1057.1	27.5	20	429.3	8.3
X-2780	BRCA	LFA102	2607.1	28.1	28	1205.5	10.6
X-2780	BRCA	LJM716	248.7	32.4	0	0	0
X-2780	BRCA	LJM716	277.1	31.6	3	11.4	-2.5
X-2780	BRCA	LJM716	267.5	31	6	7.6	-4.3
X-2780	BRCA	LJM716	277.3	31.4	10	11.5	-3.1
X-2780	BRCA	LJM716	622.5	30.7	13	150.3	-5.2
X-2780	BRCA	LJM716	804.5	31.8	17	223.5	-1.9
X-2780	BRCA	LJM716	1005.6	32.2	20	304.3	-0.6
X-2780	BRCA	LJM716 + trastuzumab	226.6	23.6	0	0	0
X-2780	BRCA	LJM716 + trastuzumab	194.9	22.9	3	-14	-3
X-2780	BRCA	LJM716 + trastuzumab	285.6	22.8	6	26	-3.4
X-2780	BRCA	LJM716 + trastuzumab	364.8	22.6	10	61	-4.2
X-2780	BRCA	LJM716 + trastuzumab	399.5	21.5	13	76.3	-8.9
X-2780	BRCA	LJM716 + trastuzumab	527.3	21.3	17	132.7	-9.7
X-2780	BRCA	LJM716 + trastuzumab	595.6	22.2	20	162.8	-5.9
X-2780	BRCA	LJM716 + trastuzumab	1019.1	22.3	28	349.7	-5.5
X-2780	BRCA	LJM716 + trastuzumab	1302.3	22.8	31	474.7	-3.4
X-2780	BRCA	LJM716 + trastuzumab	1769.5	24	34	680.9	1.7
X-2780	BRCA	LKA136	238.5	27.5	0	0	0
X-2780	BRCA	LKA136	333.6	26.8	3	39.9	-2.5
X-2780	BRCA	LKA136	465.9	27.2	6	95.3	-1.1
X-2780	BRCA	LKA136	504.7	27.4	10	111.6	-0.4
X-2780	BRCA	LKA136	556	27.9	13	133.1	1.5
X-2780	BRCA	LKA136	855.2	28.3	21	258.6	2.9
X-2780	BRCA	LKA136	814.3	28.8	24	241.4	4.7
X-2780	BRCA	LKA136	855.1	28.2	27	258.5	2.5
X-2780	BRCA	LKA136	826.2	28.9	31	246.4	5.1
X-2780	BRCA	LKA136	783.6	29.6	35	228.6	7.6
X-2780	BRCA	LKA136	713.2	29.3	38	199	6.5
X-2780	BRCA	LKA136	1034.8	29.3	41	333.9	6.5
X-2780	BRCA	LLM871	192.7	27.3	0	0	0
X-2780	BRCA	LLM871	183.9	26.6	3	-4.6	-2.6
X-2780	BRCA	LLM871	223.2	27.8	6	15.8	1.8
X-2780	BRCA	LLM871	277.9	28.2	10	44.2	3.3
X-2780	BRCA	LLM871	274.2	27.8	13	42.3	1.8
X-2780	BRCA	LLM871	168.8	27	17	-12.4	-1.1
X-2780	BRCA	LLM871	99.1	26.9	20	-48.6	-1.5
X-2780	BRCA	LLM871	54.4	27	24	-71.8	-1.1
X-2780	BRCA	LLM871	87.9	30	27	-54.4	9.9
X-2780	BRCA	LLM871	37.3	28.2	35	-80.6	3.3
X-2780	BRCA	LLM871	28.1	29	38	-85.4	6.2
X-2780	BRCA	LLM871	35.1	27.2	41	-81.8	-0.4
X-2780	BRCA	LLM871	0	27.6	45	-100	1.1
X-2780	BRCA	LLM871	0	27.8	49	-100	1.8
X-2780	BRCA	LLM871	0	26.2	52	-100	-4
X-2780	BRCA	LLM871	0	26.9	55	-100	-1.5
X-2780	BRCA	LLM871	0	27.1	59	-100	-0.7
X-2780	BRCA	LLM871	0	25.3	63	-100	-7.3
X-2780	BRCA	binimetinib	223	25.2	0	0	0
X-2780	BRCA	binimetinib	242.4	24.3	3	8.7	-3.6
X-2780	BRCA	binimetinib	264.6	25.4	6	18.7	0.8
X-2780	BRCA	binimetinib	264.6	23.7	10	18.7	-6
X-2780	BRCA	binimetinib	284.5	24.1	13	27.6	-4.4
X-2780	BRCA	binimetinib	321.8	22.7	17	44.3	-9.9
X-2780	BRCA	binimetinib	261.4	20.1	20	17.2	-20.2
X-2780	BRCA	binimetinib	245.3	20.4	21	10	-19
X-2780	BRCA	binimetinib	380.6	22.6	28	70.7	-10.3
X-2780	BRCA	binimetinib	444.5	22.1	31	99.3	-12.3
X-2780	BRCA	binimetinib	833.2	25	38	273.6	-0.8
X-2780	BRCA	binimetinib	1384.9	24.6	42	521	-2.4
X-2780	BRCA	paclitaxel	194.7	27.9	0	0	0
X-2780	BRCA	paclitaxel	224.1	28.6	3	15.1	2.5
X-2780	BRCA	paclitaxel	180.5	28.5	6	-7.3	2.2
X-2780	BRCA	paclitaxel	254.2	29.1	10	30.6	4.3
X-2780	BRCA	paclitaxel	301.5	29.1	13	54.9	4.3
X-2780	BRCA	paclitaxel	439.8	29.3	17	125.9	5
X-2780	BRCA	paclitaxel	497.6	28.3	20	155.6	1.4
X-2780	BRCA	paclitaxel	550.6	27.9	24	182.8	0
X-2780	BRCA	paclitaxel	674.7	28.3	27	246.5	1.4
X-2780	BRCA	paclitaxel	999.6	26.7	35	413.4	-4.3
X-2780	BRCA	tamoxifen	209.3	29.3	0	0	0
X-2780	BRCA	tamoxifen	158.5	29.7	4	-24.3	1.4
X-2780	BRCA	tamoxifen	181.6	30.1	8	-13.2	2.7
X-2780	BRCA	tamoxifen	210.2	29.9	11	0.4	2
X-2780	BRCA	tamoxifen	210.4	29.7	15	0.5	1.4
X-2780	BRCA	tamoxifen	271.1	29.6	18	29.5	1
X-2780	BRCA	tamoxifen	292.9	30.7	22	39.9	4.8
X-2780	BRCA	tamoxifen	295.2	30.9	25	41	5.5
X-2780	BRCA	tamoxifen	410	29.9	33	95.9	2
X-2780	BRCA	tamoxifen	421.5	30.7	36	101.4	4.8
X-2780	BRCA	tamoxifen	479.3	31.2	39	129	6.5
X-2780	BRCA	tamoxifen	531.4	30.8	41	153.9	5.1
X-2780	BRCA	trastuzumab	203.4	26.9	0	0	0
X-2780	BRCA	trastuzumab	292.7	27	3	43.9	0.4
X-2780	BRCA	trastuzumab	218.2	27.4	6	7.3	1.9
X-2780	BRCA	trastuzumab	169.8	27.6	10	-16.5	2.6
X-2780	BRCA	trastuzumab	198.7	27.9	13	-2.3	3.7
X-2780	BRCA	trastuzumab	203.1	27.6	17	-0.1	2.6
X-2780	BRCA	trastuzumab	222.7	27.5	20	9.5	2.2
X-2780	BRCA	trastuzumab	173.7	26.7	24	-14.6	-0.7
X-2780	BRCA	trastuzumab	226.5	28	27	11.4	4.1
X-2780	BRCA	trastuzumab	386.1	26.7	35	89.8	-0.7
X-2780	BRCA	trastuzumab	356	27.9	38	75	3.7
X-2780	BRCA	trastuzumab	365.6	28.3	41	79.7	5.2
X-2780	BRCA	trastuzumab	251	27.6	45	23.4	2.6
X-2780	BRCA	trastuzumab	373.8	28.3	49	83.8	5.2
X-2780	BRCA	trastuzumab	321.5	24.9	52	58.1	-7.4
X-2780	BRCA	trastuzumab	343.9	27.7	55	69.1	3
X-2780	BRCA	trastuzumab	346.2	28.5	59	70.2	5.9
X-2780	BRCA	trastuzumab	366.2	23.2	63	80	-13.8
X-2780	BRCA	trastuzumab	392.8	23.8	66	93.1	-11.5
X-2780	BRCA	trastuzumab	431.7	26.1	69	112.2	-3
X-2780	BRCA	untreated	342	25.5	0	0	0
X-2780	BRCA	untreated	447.9	25.2	3	31	-1.2
X-2780	BRCA	untreated	567.9	24.7	6	66.1	-3.1
X-2780	BRCA	untreated	815.8	25.5	10	138.5	0
X-2780	BRCA	untreated	1001.4	26.4	13	192.8	3.5
X-2780	BRCA	untreated	2090	27.3	21	511.1	7.1
X-2780	BRCA	LFW527 + everolimus	185.37	26.4	0	0	0
X-2780	BRCA	LFW527 + everolimus	174.03	27.7	3	-6.1	4.9
X-2780	BRCA	LFW527 + everolimus	165.08	26.7	6	-10.9	1.1
X-2780	BRCA	LFW527 + everolimus	199.66	26.8	10	7.7	1.5
X-2780	BRCA	LFW527 + everolimus	199.89	26.3	13	7.8	-0.4
X-2780	BRCA	LFW527 + everolimus	151.39	26.7	17	-18.3	1.1
X-2780	BRCA	LFW527 + everolimus	224.87	27.2	20	21.3	3
X-2780	BRCA	LFW527 + everolimus	205.33	28.3	24	10.8	7.2
X-2780	BRCA	LFW527 + everolimus	193.39	26.4	27	4.3	0
X-2780	BRCA	LFW527 + everolimus	182.7	26.5	31	-1.4	0.4
X-2780	BRCA	LFW527 + everolimus	187.74	25.8	34	1.3	-2.3
X-2780	BRCA	LFW527 + everolimus	236.83	24.8	38	27.8	-6.1
X-2780	BRCA	LFW527 + everolimus	142.92	25.1	42	-22.9	-4.9
X-2780	BRCA	LFW527 + everolimus	191.76	25.3	45	3.4	-4.2
X-2780	BRCA	LFW527 + everolimus	174.93	25.9	49	-5.6	-1.9
X-2780	BRCA	LFW527 + everolimus	249.6	26.1	52	34.6	-1.1
X-2780	BRCA	LFW527 + everolimus	304.96	26.9	55	64.5	1.9
X-2780	BRCA	LFW527 + everolimus	358.83	23.4	59	93.6	-11.4
X-2780	BRCA	LFW527 + everolimus	263.78	25.7	62	42.3	-2.7
X-2780	BRCA	LFW527 + everolimus	412.75	26.5	66	122.7	0.4
X-2780	BRCA	LFW527 + everolimus	418.69	25.9	69	125.9	-1.9
X-2780	BRCA	LFW527 + everolimus	457.94	25.3	73	147	-4.2
X-2780	BRCA	LFW527 + everolimus	435.66	25.2	76	135	-4.5
X-2780	BRCA	LFW527 + everolimus	525.74	26.3	80	183.6	-0.4
X-2780	BRCA	LFW527 + everolimus	516.31	24.9	84	178.5	-5.7
X-2780	BRCA	LFW527 + everolimus	619.55	24.7	87	234.2	-6.4
X-2780	BRCA	LFW527 + everolimus	658.85	24.6	90	255.4	-6.8
X-2780	BRCA	LFW527 + everolimus	691.1	24.7	94	272.8	-6.4
X-2780	BRCA	LFW527 + everolimus	715.81	24.4	98	286.2	-7.6
X-2780	BRCA	LFW527 + everolimus	683.91	25.3	101	268.9	-4.2
X-2780	BRCA	LFW527 + everolimus	840.08	24.4	105	353.2	-7.6
X-2780	BRCA	LFW527 + everolimus	859.89	25.2	108	363.9	-4.5
X-2822	CRC	5FU	211.5	26.4	0	0	0
X-2822	CRC	5FU	211.5	26.6	3	0	0.8
X-2822	CRC	5FU	210.4	27.5	8	-0.5	4.2
X-2822	CRC	5FU	218	26.5	11	3.1	0.4
X-2822	CRC	5FU	238.8	26.9	14	12.9	1.9
X-2822	CRC	5FU	242.5	27.1	17	14.7	2.7
X-2822	CRC	5FU	245.6	27.7	21	16.1	4.9
X-2822	CRC	5FU	284.2	28.3	24	34.4	7.2
X-2822	CRC	5FU	303.9	27.7	28	43.7	4.9
X-2822	CRC	5FU	301.6	25.7	31	42.6	-2.7
X-2822	CRC	5FU	342.9	26	35	62.1	-1.5
X-2822	CRC	5FU	371.7	26.1	38	75.7	-1.1
X-2822	CRC	5FU	451.6	28.2	42	113.5	6.8
X-2822	CRC	5FU	498.8	27.5	45	135.8	4.2
X-2822	CRC	5FU	566.9	27.5	49	168	4.2
X-2822	CRC	5FU	562.4	27.1	52	165.9	2.7
X-2822	CRC	5FU	530.6	27.4	56	150.9	3.8
X-2822	CRC	5FU	527.5	27.8	59	149.4	5.3
X-2822	CRC	5FU	543.9	27.1	63	157.2	2.7
X-2822	CRC	5FU	565.3	27.1	67	167.3	2.7
X-2822	CRC	5FU	581.9	27.3	70	175.1	3.4
X-2822	CRC	5FU	581.5	29.2	73	174.9	10.6
X-2822	CRC	5FU	583.5	27.8	77	175.9	5.3
X-2822	CRC	5FU	599.4	25.7	80	183.4	-2.7
X-2822	CRC	5FU	638.4	26.8	84	201.8	1.5
X-2822	CRC	5FU	676.9	27.9	91	220	5.7
X-2822	CRC	BKM120	201.1	22.8	0	0	0
X-2822	CRC	BKM120	200.1	22.6	2	-0.5	-0.9
X-2822	CRC	BKM120	204.9	22	6	1.9	-3.5
X-2822	CRC	BKM120	220.1	21	9	9.4	-7.9
X-2822	CRC	BKM120	231.5	23.5	13	15.1	3.1
X-2822	CRC	BKM120	260.1	21	18	29.3	-7.9
X-2822	CRC	BKM120	323	19	21	60.6	-16.7
X-2822	CRC	BKM120 + LJC049	211.5	24.4	0	0	0
X-2822	CRC	BKM120 + LJC049	211.9	24.4	3	0.2	0
X-2822	CRC	BKM120 + LJC049	215.9	24.3	7	2.1	-0.4
X-2822	CRC	BKM120 + LJC049	217.2	25.3	10	2.7	3.7
X-2822	CRC	BKM120 + LJC049	239.4	25.8	13	13.2	5.7
X-2822	CRC	BKM120 + LJC049	276.2	27.3	18	30.6	11.9
X-2822	CRC	BKM120 + LJC049	325.5	26.8	21	53.9	9.8
X-2822	CRC	BKM120 + LJC049	345.5	26	24	63.4	6.6
X-2822	CRC	BKM120 + LJC049	391.6	25.4	27	85.2	4.1
X-2822	CRC	BKM120 + LJC049	471.8	25	31	123.1	2.5
X-2822	CRC	BKM120 + LJC049	469.9	25.3	34	122.2	3.7
X-2822	CRC	BKM120 + LJC049	462.8	25.2	38	118.8	3.3
X-2822	CRC	BKM120 + LJC049	512.4	24	41	142.3	-1.6
X-2822	CRC	BKM120 + LJC049	578.9	25	45	173.7	2.5
X-2822	CRC	BKM120 + LJC049	653.6	25.6	48	209	4.9
X-2822	CRC	BKM120 + LJC049	874.4	26.2	52	313.4	7.4
X-2822	CRC	BYL719	203.5	21.5	0	0	0
X-2822	CRC	BYL719	205.2	21.9	3	0.8	1.9
X-2822	CRC	BYL719	223.8	21.3	7	10	-0.9
X-2822	CRC	BYL719	250.2	20.6	12	22.9	-4.2
X-2822	CRC	BYL719	288.9	20.6	15	42	-4.2
X-2822	CRC	BYL719	301	19.8	18	47.9	-7.9
X-2822	CRC	BYL719	305.6	18.9	21	50.2	-12.1
X-2822	CRC	BYL719	369.8	19	25	81.7	-11.6
X-2822	CRC	BYL719	397.8	20.6	28	95.5	-4.2
X-2822	CRC	BYL719	410.5	18.6	31	101.7	-13.5
X-2822	CRC	BYL719	422.4	19.8	36	107.6	-7.9
X-2822	CRC	BYL719 + LJM716	199.9	24.6	0	0	0
X-2822	CRC	BYL719 + LJM716	198.2	22.8	3	-0.9	-7.3
X-2822	CRC	BYL719 + LJM716	198.3	24.8	7	-0.8	0.8
X-2822	CRC	BYL719 + LJM716	196.5	24.7	12	-1.7	0.4
X-2822	CRC	BYL719 + LJM716	197.9	24.5	15	-1	-0.4
X-2822	CRC	BYL719 + LJM716	199.6	24.9	18	-0.2	1.2
X-2822	CRC	BYL719 + LJM716	201.9	24.1	21	1	-2
X-2822	CRC	BYL719 + LJM716	205.8	25.2	25	3	2.4
X-2822	CRC	BYL719 + LJM716	215.5	26	28	7.8	5.7
X-2822	CRC	BYL719 + LJM716	207.8	26.4	31	4	7.3
X-2822	CRC	BYL719 + LJM716	215.5	24.3	36	7.8	-1.2
X-2822	CRC	BYL719 + LJM716	229	25.7	39	14.6	4.5
X-2822	CRC	BYL719 + LJM716	224.9	27.1	42	12.5	10.2
X-2822	CRC	BYL719 + LJM716	222.6	26.5	45	11.4	7.7
X-2822	CRC	BYL719 + LJM716	245.4	27	49	22.8	9.8
X-2822	CRC	BYL719 + LJM716	268	26.4	52	34.1	7.3
X-2822	CRC	BYL719 + LJM716	286.9	26.6	56	43.5	8.1
X-2822	CRC	BYL719 + LJM716	321.4	26.2	59	60.8	6.5
X-2822	CRC	BYL719 + LJM716	377.9	25.5	63	89	3.7
X-2822	CRC	BYL719 + LJM716	432.1	24.3	66	116.2	-1.2
X-2822	CRC	BYL719 + LJM716	478.9	26	70	139.6	5.7
X-2822	CRC	BYL719 + LJM716	546.9	25.9	73	173.6	5.3
X-2822	CRC	BYL719 + LJM716	564.6	26.2	77	182.4	6.5
X-2822	CRC	BYL719 + LJM716	549.6	27.4	80	174.9	11.4
X-2822	CRC	BYL719 + LJM716	539.9	26.1	84	170.1	6.1
X-2822	CRC	BYL719 + cetuximab + encorafenib	206.8	23.4	0	0	0
X-2822	CRC	BYL719 + cetuximab + encorafenib	215.6	23.8	5	4.3	1.7
X-2822	CRC	BYL719 + cetuximab + encorafenib	218.2	22.7	8	5.5	-3
X-2822	CRC	BYL719 + cetuximab + encorafenib	242.4	21.1	11	17.2	-9.8
X-2822	CRC	BYL719 + cetuximab + encorafenib	261.9	22	14	26.6	-6
X-2822	CRC	BYL719 + cetuximab + encorafenib	340.6	22.6	18	64.7	-3.4
X-2822	CRC	BYL719 + cetuximab + encorafenib	341.6	23.2	21	65.2	-0.9
X-2822	CRC	BYL719 + cetuximab + encorafenib	435.4	23.4	24	110.5	0
X-2822	CRC	BYL719 + cetuximab + encorafenib	441.5	23.5	29	113.5	0.4
X-2822	CRC	BYL719 + cetuximab + encorafenib	561.3	22.7	32	171.4	-3
X-2822	CRC	BYL719 + cetuximab + encorafenib	571.1	21.7	35	176.2	-7.3
X-2822	CRC	BYL719 + cetuximab + encorafenib	685.2	21	38	231.3	-10.3
X-2822	CRC	BYL719 + cetuximab + encorafenib	833.1	22.7	42	302.9	-3
X-2822	CRC	BYL719 + binimetinib	208	28.7	0	0	0
X-2822	CRC	BYL719 + binimetinib	207.3	27.6	3	-0.3	-3.8
X-2822	CRC	BYL719 + binimetinib	213.8	28.2	7	2.8	-1.7
X-2822	CRC	BYL719 + binimetinib	213.4	29	10	2.6	1
X-2822	CRC	BYL719 + binimetinib	212.5	28.6	13	2.2	-0.3
X-2822	CRC	BYL719 + binimetinib	211	29	18	1.4	1
X-2822	CRC	BYL719 + binimetinib	201.8	29.2	21	-3	1.7
X-2822	CRC	BYL719 + binimetinib	194.7	28.6	24	-6.4	-0.3
X-2822	CRC	BYL719 + binimetinib	189.1	30.1	27	-9.1	4.9
X-2822	CRC	BYL719 + binimetinib	210.5	29.8	31	1.2	3.8
X-2822	CRC	BYL719 + binimetinib	203.4	28.6	34	-2.2	-0.3
X-2822	CRC	BYL719 + binimetinib	213.4	29.3	38	2.6	2.1
X-2822	CRC	BYL719 + binimetinib	219.6	29.4	41	5.6	2.4
X-2822	CRC	BYL719 + binimetinib	228.7	28.4	45	10	-1
X-2822	CRC	BYL719 + binimetinib	259.9	29.4	48	25	2.4
X-2822	CRC	BYL719 + binimetinib	249.7	29.1	52	20	1.4
X-2822	CRC	BYL719 + binimetinib	261.1	28	55	25.5	-2.4
X-2822	CRC	BYL719 + binimetinib	323.3	29.8	59	55.4	3.8
X-2822	CRC	BYL719 + binimetinib	323.7	29.1	62	55.6	1.4
X-2822	CRC	BYL719 + binimetinib	378.2	29.6	66	81.8	3.1
X-2822	CRC	BYL719 + binimetinib	362.2	29.5	69	74.1	2.8
X-2822	CRC	BYL719 + binimetinib	358.4	29.5	73	72.3	2.8
X-2822	CRC	BYL719 + binimetinib	360.5	30.1	77	73.3	4.9
X-2822	CRC	BYL719 + binimetinib	322.3	28.9	80	55	0.7
X-2822	CRC	BYL719 + binimetinib	327.7	27.8	83	57.5	-3.1
X-2822	CRC	BYL719 + binimetinib	330.4	29	87	58.8	1
X-2822	CRC	BYL719 + cetuximab	206.1	24.7	0	0	0
X-2822	CRC	BYL719 + cetuximab	205.8	25	3	-0.1	1.2
X-2822	CRC	BYL719 + cetuximab	216.8	25.6	7	5.2	3.6
X-2822	CRC	BYL719 + cetuximab	212.6	26.1	10	3.2	5.7
X-2822	CRC	BYL719 + cetuximab	215.4	25.8	13	4.5	4.5
X-2822	CRC	BYL719 + cetuximab	229	26.1	18	11.1	5.7
X-2822	CRC	BYL719 + cetuximab	240.2	25.7	21	16.5	4
X-2822	CRC	BYL719 + cetuximab	257.8	25.7	24	25.1	4
X-2822	CRC	BYL719 + cetuximab	248.7	25.5	27	20.7	3.2
X-2822	CRC	BYL719 + cetuximab	254.4	25.6	31	23.4	3.6
X-2822	CRC	BYL719 + cetuximab	241.7	25.7	34	17.3	4
X-2822	CRC	BYL719 + cetuximab	241.9	26.6	38	17.4	7.7
X-2822	CRC	BYL719 + cetuximab	234.7	25.9	41	13.9	4.9
X-2822	CRC	BYL719 + cetuximab	274.5	25.6	45	33.2	3.6
X-2822	CRC	BYL719 + cetuximab	322.9	25.6	48	56.7	3.6
X-2822	CRC	BYL719 + cetuximab	368.1	25.8	52	78.6	4.5
X-2822	CRC	BYL719 + cetuximab	390.6	25.7	55	89.5	4
X-2822	CRC	BYL719 + cetuximab	390.3	26.1	59	89.4	5.7
X-2822	CRC	BYL719 + cetuximab	341	26.6	62	65.5	7.7
X-2822	CRC	BYL719 + cetuximab	325.3	26.3	66	57.8	6.5
X-2822	CRC	BYL719 + cetuximab	322.7	25.9	69	56.6	4.9
X-2822	CRC	BYL719 + cetuximab	307.8	26.4	73	49.3	6.9
X-2822	CRC	BYL719 + cetuximab	291.5	27.1	77	41.4	9.7
X-2822	CRC	BYL719 + cetuximab	282.7	26.3	80	37.2	6.5
X-2822	CRC	BYL719 + cetuximab	288	26.6	83	39.7	7.7
X-2822	CRC	BYL719 + cetuximab	288.3	26.2	87	39.9	6.1
X-2822	CRC	BYL719 + encorafenib	208.3	29.1	0	0	0
X-2822	CRC	BYL719 + encorafenib	211	29.2	3	1.3	0.3
X-2822	CRC	BYL719 + encorafenib	229.1	29.9	7	10	2.7
X-2822	CRC	BYL719 + encorafenib	247.4	30.3	10	18.8	4.1
X-2822	CRC	BYL719 + encorafenib	294.8	30.1	13	41.5	3.4
X-2822	CRC	BYL719 + encorafenib	304.6	30.3	18	46.2	4.1
X-2822	CRC	BYL719 + encorafenib	315.8	30.7	21	51.6	5.5
X-2822	CRC	BYL719 + encorafenib	311.4	30.6	24	49.5	5.2
X-2822	CRC	BYL719 + encorafenib	372.4	29.9	27	78.8	2.7
X-2822	CRC	BYL719 + encorafenib	476.3	30.3	31	128.7	4.1
X-2822	CRC	BYL719 + encorafenib	483.8	30	34	132.3	3.1
X-2822	CRC	BYL719 + encorafenib	530.2	30.3	38	154.5	4.1
X-2822	CRC	BYL719 + encorafenib	571.2	29.9	41	174.2	2.7
X-2822	CRC	BYL719 + encorafenib	861.1	29.6	45	313.4	1.7
X-2822	CRC	BYL719 + encorafenib	985.7	29.3	48	373.2	0.7
X-2822	CRC	BYL719 + encorafenib	1311.3	29.7	52	529.5	2.1
X-2822	CRC	CGM097	201.7	27.5	0	0	0
X-2822	CRC	CGM097	200.7	27.2	4	-0.5	-1.1
X-2822	CRC	CGM097	268.2	27.5	7	33	0
X-2822	CRC	CGM097	271.9	28.3	11	34.8	2.9
X-2822	CRC	CGM097	306.3	28.9	16	51.9	5.1
X-2822	CRC	CGM097	357.3	28.9	19	77.1	5.1
X-2822	CRC	CGM097	419.7	28.8	22	108.1	4.7
X-2822	CRC	CGM097	491.7	29.6	25	143.8	7.6
X-2822	CRC	CGM097	542.8	28.6	29	169.1	4
X-2822	CRC	CGM097	636.6	29	32	215.6	5.5
X-2822	CRC	CGM097	785.4	31.8	35	289.4	15.6
X-2822	CRC	CGM097	858.8	29.4	40	325.8	6.9
X-2822	CRC	CGM097	974.6	28.3	43	383.2	2.9
X-2822	CRC	CGM097	980.8	28.5	46	386.3	3.6
X-2822	CRC	CGM097	1153.5	28.5	49	471.9	3.6
X-2822	CRC	CKX620	208.2	26.9	0	0	0
X-2822	CRC	CKX620	204.5	26.8	2	-1.8	-0.4
X-2822	CRC	CKX620	226.6	28.5	6	8.8	5.9
X-2822	CRC	CKX620	227.8	27.8	9	9.4	3.3
X-2822	CRC	CKX620	229.7	28.4	13	10.3	5.6
X-2822	CRC	CKX620	259.5	26.7	18	24.6	-0.7
X-2822	CRC	CKX620	279.4	26.9	21	34.2	0
X-2822	CRC	CKX620	287.8	28.3	24	38.2	5.2
X-2822	CRC	CKX620	300.5	29.3	27	44.3	8.9
X-2822	CRC	CKX620	352	27	31	69.1	0.4
X-2822	CRC	CKX620	369.4	28.6	34	77.4	6.3
X-2822	CRC	CKX620	378.3	29.2	37	81.7	8.6
X-2822	CRC	CKX620	511.2	29.4	42	145.5	9.3
X-2822	CRC	CKX620	529.9	27.6	45	154.5	2.6
X-2822	CRC	CKX620	561.5	28.3	48	169.7	5.2
X-2822	CRC	CKX620	588.5	28.1	51	182.7	4.5
X-2822	CRC	CKX620	675.5	28.8	55	224.4	7.1
X-2822	CRC	CKX620	662.8	28.2	58	218.3	4.8
X-2822	CRC	CKX620	823.7	29.5	62	295.6	9.7
X-2822	CRC	CLR457	199.2	23.4	0	0	0
X-2822	CRC	CLR457	200.1	23.2	3	0.5	-0.9
X-2822	CRC	CLR457	200.6	23.8	7	0.7	1.7
X-2822	CRC	CLR457	200.6	23.6	12	0.7	0.9
X-2822	CRC	CLR457	200	23.1	15	0.4	-1.3
X-2822	CRC	CLR457	204.1	23.7	18	2.5	1.3
X-2822	CRC	CLR457	206.7	23.2	21	3.8	-0.9
X-2822	CRC	CLR457	205.9	24.3	25	3.4	3.8
X-2822	CRC	CLR457	206.1	24.3	28	3.5	3.8
X-2822	CRC	CLR457	217.7	23.9	31	9.3	2.1
X-2822	CRC	CLR457	226.4	23.9	36	13.7	2.1
X-2822	CRC	CLR457	221	23.9	39	10.9	2.1
X-2822	CRC	CLR457	203.1	24	42	2	2.6
X-2822	CRC	CLR457	205	24	45	2.9	2.6
X-2822	CRC	CLR457	228.6	24	49	14.8	2.6
X-2822	CRC	CLR457	246.7	23.9	52	23.8	2.1
X-2822	CRC	CLR457	246.9	24.3	56	23.9	3.8
X-2822	CRC	CLR457	255.8	24.4	59	28.4	4.3
X-2822	CRC	CLR457	290	23.4	63	45.6	0
X-2822	CRC	CLR457	322.9	23.6	66	62.1	0.9
X-2822	CRC	CLR457	414.9	24.7	70	108.3	5.6
X-2822	CRC	CLR457	407.6	23.8	73	104.6	1.7
X-2822	CRC	CLR457	440.5	23.4	77	121.1	0
X-2822	CRC	CLR457	436.9	23.8	80	119.3	1.7
X-2822	CRC	CLR457	428.1	24.1	84	114.9	3
X-2822	CRC	HDM201	203.9	24.7	0	0	0
X-2822	CRC	HDM201	200.6	23.1	2	-1.6	-6.5
X-2822	CRC	HDM201	206.3	22.5	6	1.2	-8.9
X-2822	CRC	HDM201	218.3	23.9	9	7.1	-3.2
X-2822	CRC	HDM201	242.1	21.2	13	18.7	-14.2
X-2822	CRC	HDM201	277.9	21	18	36.3	-15
X-2822	CRC	HDM201	347.3	21	21	70.3	-15
X-2822	CRC	HDM201	356	20.2	24	74.6	-18.2
X-2822	CRC	cetuximab	211	23.9	0	0	0
X-2822	CRC	cetuximab	290.8	24.7	4	37.8	3.3
X-2822	CRC	cetuximab	301.5	23.6	7	42.9	-1.3
X-2822	CRC	cetuximab	312.2	23.8	11	48	-0.4
X-2822	CRC	cetuximab	337.5	25.1	14	60	5
X-2822	CRC	cetuximab	353.6	24.8	18	67.6	3.8
X-2822	CRC	cetuximab	373.4	23.8	23	77	-0.4
X-2822	CRC	cetuximab	395.2	24.2	26	87.3	1.3
X-2822	CRC	cetuximab	403	24.3	29	91	1.7
X-2822	CRC	cetuximab	440.4	22.8	32	108.7	-4.6
X-2822	CRC	cetuximab	465.5	22.3	36	120.6	-6.7
X-2822	CRC	cetuximab	539.6	23.1	39	155.7	-3.3
X-2822	CRC	cetuximab	544.2	22.3	42	157.9	-6.7
X-2822	CRC	cetuximab	587.9	23	47	178.6	-3.8
X-2822	CRC	cetuximab	614.7	22.7	50	191.3	-5
X-2822	CRC	cetuximab	604.6	23	53	186.5	-3.8
X-2822	CRC	cetuximab	616.9	22.8	56	192.4	-4.6
X-2822	CRC	cetuximab	708.8	22.5	60	235.9	-5.9
X-2822	CRC	cetuximab	925.8	22.9	63	338.8	-4.2
X-2822	CRC	cetuximab + encorafenib	198.3	23.8	0	0	0
X-2822	CRC	cetuximab + encorafenib	201.8	24.7	5	1.8	3.8
X-2822	CRC	cetuximab + encorafenib	224.4	24.5	8	13.2	2.9
X-2822	CRC	cetuximab + encorafenib	241.1	24.7	11	21.6	3.8
X-2822	CRC	cetuximab + encorafenib	256.1	24	14	29.1	0.8
X-2822	CRC	cetuximab + encorafenib	286.7	24.3	18	44.6	2.1
X-2822	CRC	cetuximab + encorafenib	316.3	24.1	21	59.5	1.3
X-2822	CRC	cetuximab + encorafenib	351.3	24.4	24	77.2	2.5
X-2822	CRC	cetuximab + encorafenib	407.1	24.7	29	105.3	3.8
X-2822	CRC	cetuximab + encorafenib	459.7	25.6	32	131.8	7.6
X-2822	CRC	cetuximab + encorafenib	496.2	25	35	150.2	5
X-2822	CRC	cetuximab + encorafenib	503.5	25.6	38	153.9	7.6
X-2822	CRC	cetuximab + encorafenib	521.9	25.5	42	163.2	7.1
X-2822	CRC	cetuximab + encorafenib	536.2	25.5	45	170.4	7.1
X-2822	CRC	cetuximab + encorafenib	553.8	26.2	49	179.3	10.1
X-2822	CRC	cetuximab + encorafenib	601.3	26.3	52	203.2	10.5
X-2822	CRC	cetuximab + encorafenib	754.2	25.7	56	280.3	8
X-2822	CRC	cetuximab + encorafenib	918.5	26.1	59	363.2	9.7
X-2822	CRC	cetuximab + encorafenib	1039.8	26.5	63	424.4	11.3
X-2822	CRC	LEE011	201.3	22.6	0	0	0
X-2822	CRC	LEE011	204.4	23.1	3	1.5	2.2
X-2822	CRC	LEE011	205.8	22.8	7	2.2	0.9
X-2822	CRC	LEE011	213	22.8	12	5.8	0.9
X-2822	CRC	LEE011	214.7	23.2	15	6.7	2.7
X-2822	CRC	LEE011	217.1	22.1	18	7.8	-2.2
X-2822	CRC	LEE011	217.4	21.1	21	8	-6.6
X-2822	CRC	LEE011	230.6	23.4	25	14.6	3.5
X-2822	CRC	LEE011	236.2	23.8	28	17.3	5.3
X-2822	CRC	LEE011	235.9	24.6	31	17.2	8.8
X-2822	CRC	LEE011	228.9	25.1	36	13.7	11.1
X-2822	CRC	LEE011	311.8	24.5	39	54.9	8.4
X-2822	CRC	LEE011	243.4	24.1	42	20.9	6.6
X-2822	CRC	LEE011	242.1	24.5	45	20.3	8.4
X-2822	CRC	LEE011	235.5	24	49	17	6.2
X-2822	CRC	LEE011	232.1	24.2	52	15.3	7.1
X-2822	CRC	LEE011	246.3	25.6	56	22.4	13.3
X-2822	CRC	LEE011	280.7	24.5	59	39.4	8.4
X-2822	CRC	LEE011	306.1	24.1	63	52.1	6.6
X-2822	CRC	LEE011	316.2	24.8	66	57.1	9.7
X-2822	CRC	LEE011	389.1	24.2	70	93.3	7.1
X-2822	CRC	LEE011	413.2	24	73	105.3	6.2
X-2822	CRC	LEE011	440.1	24.5	77	118.6	8.4
X-2822	CRC	LEE011	414.3	21.1	80	105.8	-6.6
X-2822	CRC	LEE011	401.7	21.1	84	99.6	-6.6
X-2822	CRC	encorafenib	200.9	20.8	0	0	0
X-2822	CRC	encorafenib	256.5	22.4	4	27.7	7.7
X-2822	CRC	encorafenib	290.8	21.1	7	44.7	1.4
X-2822	CRC	encorafenib	299.8	20.7	11	49.2	-0.5
X-2822	CRC	encorafenib	390.3	20.6	16	94.3	-1
X-2822	CRC	encorafenib	472.2	20.6	19	135	-1
X-2822	CRC	encorafenib	516.5	20	22	157.1	-3.8
X-2822	CRC	encorafenib	587.9	19.2	25	192.6	-7.7
X-2822	CRC	encorafenib	736.4	19.7	29	266.6	-5.3
X-2822	CRC	encorafenib	934.3	19.6	32	365.1	-5.8
X-2822	CRC	encorafenib	1083.7	21.7	35	439.4	4.3
X-2822	CRC	encorafenib	1512	21.4	40	652.6	2.9
X-2822	CRC	LJC049	199.8	26.1	0	0	0
X-2822	CRC	LJC049	197.7	27.3	3	-1.1	4.6
X-2822	CRC	LJC049	197.8	25.7	7	-1	-1.5
X-2822	CRC	LJC049	199.8	26.2	12	0	0.4
X-2822	CRC	LJC049	203.4	26.7	15	1.8	2.3
X-2822	CRC	LJC049	219.1	26.1	18	9.7	0
X-2822	CRC	LJC049	203.8	26.3	21	2	0.8
X-2822	CRC	LJC049	221.5	26.1	25	10.9	0
X-2822	CRC	LJC049	220.9	26.5	28	10.6	1.5
X-2822	CRC	LJC049	225.9	26.8	31	13.1	2.7
X-2822	CRC	LJC049	232	28.2	36	16.1	8
X-2822	CRC	LJC049	242.7	27.4	39	21.5	5
X-2822	CRC	LJC049	246.2	27.2	42	23.2	4.2
X-2822	CRC	LJC049	249.6	27.9	45	24.9	6.9
X-2822	CRC	LJC049	271.2	27.6	49	35.7	5.7
X-2822	CRC	LJC049	283.6	25.3	52	41.9	-3.1
X-2822	CRC	LJC049	312.7	24.3	56	56.5	-6.9
X-2822	CRC	LJC049	306.5	23.6	59	53.4	-9.6
X-2822	CRC	LJC049	338.3	23.6	63	69.3	-9.6
X-2822	CRC	LJC049	393	23	66	96.7	-11.9
X-2822	CRC	LJC049	481.7	24.9	70	141.1	-4.6
X-2822	CRC	LJC049	506.4	25.8	73	153.5	-1.1
X-2822	CRC	LJC049	554.5	26.4	77	177.5	1.1
X-2822	CRC	LJC049	552.2	26.3	80	176.4	0.8
X-2822	CRC	LJC049	542.8	26.3	84	171.7	0.8
X-2822	CRC	LKA136	199.6	25.6	0	0	0
X-2822	CRC	LKA136	201.3	25.5	3	0.9	-0.4
X-2822	CRC	LKA136	201	26.2	7	0.7	2.3
X-2822	CRC	LKA136	203.5	26.7	12	2	4.3
X-2822	CRC	LKA136	213.7	26.1	15	7.1	2
X-2822	CRC	LKA136	230.6	26.3	18	15.5	2.7
X-2822	CRC	LKA136	234.9	26.2	21	17.7	2.3
X-2822	CRC	LKA136	255	27	25	27.8	5.5
X-2822	CRC	LKA136	249.1	27.1	28	24.8	5.9
X-2822	CRC	LKA136	266.7	26.6	31	33.6	3.9
X-2822	CRC	LKA136	272.2	27.3	36	36.4	6.6
X-2822	CRC	LKA136	313	27.2	39	56.8	6.2
X-2822	CRC	LKA136	310.1	27.1	42	55.4	5.9
X-2822	CRC	LKA136	298.5	27	45	49.5	5.5
X-2822	CRC	LKA136	334	27.3	49	67.3	6.6
X-2822	CRC	LKA136	344.9	27	52	72.8	5.5
X-2822	CRC	LKA136	374.5	28.2	56	87.6	10.2
X-2822	CRC	LKA136	414.7	26.7	59	107.8	4.3
X-2822	CRC	LKA136	456.6	26	63	128.8	1.6
X-2822	CRC	LKA136	564.1	26.4	66	182.6	3.1
X-2822	CRC	LKA136	546.3	26.9	70	173.7	5.1
X-2822	CRC	LKA136	607.3	26.8	73	204.3	4.7
X-2822	CRC	LKA136	641.2	26.6	77	221.2	3.9
X-2822	CRC	LKA136	641	27.9	80	221.1	9
X-2822	CRC	LKA136	639.8	26.5	84	220.5	3.5
X-2822	CRC	binimetinib	198.9	21.9	0	0	0
X-2822	CRC	binimetinib	205	22.8	4	3.1	4.1
X-2822	CRC	binimetinib	209.3	22.1	7	5.2	0.9
X-2822	CRC	binimetinib	216.3	22.6	11	8.7	3.2
X-2822	CRC	binimetinib	221.9	22.7	14	11.6	3.7
X-2822	CRC	binimetinib	223.8	22.9	18	12.5	4.6
X-2822	CRC	binimetinib	227.1	23	23	14.2	5
X-2822	CRC	binimetinib	253.7	23.3	26	27.6	6.4
X-2822	CRC	binimetinib	261.5	23.6	29	31.5	7.8
X-2822	CRC	binimetinib	263	23.2	32	32.2	5.9
X-2822	CRC	binimetinib	279.9	23.3	36	40.7	6.4
X-2822	CRC	binimetinib	281.2	23.8	39	41.4	8.7
X-2822	CRC	binimetinib	281.1	23.6	42	41.3	7.8
X-2822	CRC	binimetinib	261.1	24.2	47	31.3	10.5
X-2822	CRC	binimetinib	290.5	24.2	50	46.1	10.5
X-2822	CRC	binimetinib	297.2	24.8	53	49.4	13.2
X-2822	CRC	binimetinib	328.2	23.5	56	65	7.3
X-2822	CRC	binimetinib	344.2	24.8	60	73.1	13.2
X-2822	CRC	binimetinib	346.6	24.1	63	74.3	10
X-2822	CRC	binimetinib	350.2	25.7	67	76.1	17.4
X-2822	CRC	binimetinib	404.4	24.3	70	103.3	11
X-2822	CRC	binimetinib	470.9	23.1	74	136.8	5.5
X-2822	CRC	binimetinib	474.3	25.4	77	138.5	16
X-2822	CRC	binimetinib	480.5	23	81	141.6	5
X-2822	CRC	binimetinib	579.7	23.5	84	191.5	7.3
X-2822	CRC	binimetinib	594.4	23.8	88	198.8	8.7
X-2822	CRC	binimetinib	586.1	24	91	194.7	9.6
X-2822	CRC	untreated	238.9	25.7	0	0	0
X-2822	CRC	untreated	315	28	4	31.9	8.9
X-2822	CRC	untreated	335.6	25	7	40.5	-2.7
X-2822	CRC	untreated	414.8	25.5	11	73.6	-0.8
X-2822	CRC	untreated	461.3	25.5	14	93.1	-0.8
X-2822	CRC	untreated	563.8	25.4	18	136	-1.2
X-2822	CRC	untreated	611.2	25.7	23	155.8	0
X-2822	CRC	untreated	865.2	25	26	262.2	-2.7
X-2822	CRC	untreated	1034.8	25.3	29	333.2	-1.6
X-2822	CRC	untreated	1067.1	29.4	32	346.7	14.4
X-2822	CRC	untreated	1168.9	27.8	36	389.3	8.2
X-2822	CRC	untreated	1296.4	25.3	39	442.7	-1.6
X-2822	CRC	untreated	1332.5	29.9	42	457.8	16.3
X-2822	CRC	untreated	1569.4	26.5	47	556.9	3.1
X-2838	CM	BKM120	201.7	22.9	0	0	0
X-2838	CM	BKM120	262.3	23.7	3	30	3.5
X-2838	CM	BKM120	253.6	23.4	7	25.7	2.2
X-2838	CM	BKM120	189.7	24.9	10	-5.9	8.7
X-2838	CM	BKM120	244.7	24.9	14	21.3	8.7
X-2838	CM	BKM120	256.6	24.6	17	27.2	7.4
X-2838	CM	BKM120	416.3	25.9	21	106.4	13.1
X-2838	CM	BKM120	328.8	25.9	24	63	13.1
X-2838	CM	BKM120	424.3	25.8	28	110.4	12.7
X-2838	CM	BKM120	289.9	26.5	31	43.7	15.7
X-2838	CM	BKM120	417.9	25	36	107.2	9.2
X-2838	CM	BKM120	417.9	25	37	107.2	9.2
X-2838	CM	BKM120 + encorafenib	202.6	23.4	0	0	0
X-2838	CM	BKM120 + encorafenib	160	24.1	4	-21	3
X-2838	CM	BKM120 + encorafenib	182.7	23.7	7	-9.8	1.3
X-2838	CM	BKM120 + encorafenib	174.5	24.2	11	-13.9	3.4
X-2838	CM	BKM120 + encorafenib	126.3	24.1	14	-37.6	3
X-2838	CM	BKM120 + encorafenib	188.5	24.3	18	-7	3.8
X-2838	CM	BKM120 + encorafenib	147.9	24.6	21	-27	5.1
X-2838	CM	BKM120 + encorafenib	188.7	23.9	26	-6.9	2.1
X-2838	CM	BKM120 + encorafenib	199.6	23.9	29	-1.5	2.1
X-2838	CM	BKM120 + encorafenib	233.4	23.6	33	15.2	0.9
X-2838	CM	BKM120 + encorafenib	268.8	24.8	36	32.7	6
X-2838	CM	BKM120 + encorafenib	220.6	24.6	41	8.9	5.1
X-2838	CM	BKM120 + encorafenib	254.2	23.7	46	25.5	1.3
X-2838	CM	BKM120 + encorafenib	203.3	24.5	50	0.3	4.7
X-2838	CM	BKM120 + encorafenib	217.2	24.5	53	7.2	4.7
X-2838	CM	BKM120 + encorafenib	247.9	24.6	56	22.3	5.1
X-2838	CM	BKM120 + encorafenib	334.7	24.9	60	65.2	6.4
X-2838	CM	BKM120 + encorafenib	264.1	25.4	66	30.4	8.5
X-2838	CM	BKM120 + encorafenib	251	24.9	74	23.9	6.4
X-2838	CM	BKM120 + encorafenib	420.9	25.2	83	107.8	7.7
X-2838	CM	CGM097	209.6	22.2	0	0	0
X-2838	CM	CGM097	173	23.4	3	-17.5	5.4
X-2838	CM	CGM097	214.1	23.2	7	2.1	4.5
X-2838	CM	CGM097	225.5	24	10	7.6	8.1
X-2838	CM	CGM097	240.5	23.5	14	14.7	5.9
X-2838	CM	CGM097	240.1	25.1	17	14.6	13.1
X-2838	CM	CGM097	263	24.2	21	25.5	9
X-2838	CM	CGM097	293.4	24.5	24	40	10.4
X-2838	CM	CGM097	325.1	25.4	28	55.1	14.4
X-2838	CM	CLR457	214.1	25.6	0	0	0
X-2838	CM	CLR457	172.8	26.2	3	-19.3	2.3
X-2838	CM	CLR457	207.4	25.1	8	-3.2	-2
X-2838	CM	CLR457	199.6	25.1	11	-6.8	-2
X-2838	CM	CLR457	212.5	25.5	15	-0.7	-0.4
X-2838	CM	CLR457	233.4	25.7	18	9	0.4
X-2838	CM	CLR457	230.8	26	23	7.8	1.6
X-2838	CM	CLR457	220	25.6	28	2.8	0
X-2838	CM	CLR457	221.3	25.8	32	3.3	0.8
X-2838	CM	CLR457	214	26.2	35	-0.1	2.3
X-2838	CM	CLR457	226.1	25.9	38	5.6	1.2
X-2838	CM	CLR457	251.3	25.6	42	17.4	0
X-2838	CM	CLR457	233.5	25.6	48	9.1	0
X-2838	CM	CLR457	265.4	25.8	56	23.9	0.8
X-2838	CM	CLR457	336.3	26.3	65	57.1	2.7
X-2838	CM	CLR457	306.2	26.2	70	43	2.3
X-2838	CM	CLR457	337.4	25.9	77	57.6	1.2
X-2838	CM	CLR457	280.1	25.4	84	30.8	-0.8
X-2838	CM	CLR457	280.8	25.3	91	31.2	-1.2
X-2838	CM	CLR457	323	25.3	98	50.8	-1.2
X-2838	CM	CLR457	304.8	25.6	105	42.4	0
X-2838	CM	CLR457	277.4	26.1	112	29.5	2
X-2838	CM	CLR457	356.7	26.5	119	66.6	3.5
X-2838	CM	CLR457	378.1	26.2	126	76.6	2.3
X-2838	CM	CLR457	448.5	26.7	133	109.5	4.3
X-2838	CM	CLR457	485.2	25.9	140	126.6	1.2
X-2838	CM	CLR457	534.8	26.3	147	149.8	2.7
X-2838	CM	CLR457	556.7	26.2	155	160	2.3
X-2838	CM	CLR457	616.5	25.9	161	187.9	1.2
X-2838	CM	CLR457	633	26.6	165	195.7	3.9
X-2838	CM	dacarbazine	212.1	26.9	0	0	0
X-2838	CM	dacarbazine	201.5	27.2	4	-5	1.1
X-2838	CM	dacarbazine	200.1	26.4	7	-5.7	-1.9
X-2838	CM	dacarbazine	135.1	25.9	11	-36.3	-3.7
X-2838	CM	dacarbazine	125.5	25.7	14	-40.9	-4.5
X-2838	CM	dacarbazine	144.5	25.9	19	-31.9	-3.7
X-2838	CM	dacarbazine	147.6	25.6	22	-30.4	-4.8
X-2838	CM	dacarbazine	178.2	26.1	26	-16	-3
X-2838	CM	dacarbazine	235.2	25.6	29	10.9	-4.8
X-2838	CM	dacarbazine	373.9	25.8	34	76.3	-4.1
X-2838	CM	dacarbazine	592.7	26.9	39	179.4	0
X-2838	CM	LDE225	196.5	25.1	0	0	0
X-2838	CM	LDE225	158.5	25.1	3	-19.4	0
X-2838	CM	LDE225	207	25.4	7	5.3	1.2
X-2838	CM	LDE225	230	24.9	10	17	-0.8
X-2838	CM	LDE225	313.2	25.1	14	59.4	0
X-2838	CM	LDE225	294.4	24.7	17	49.8	-1.6
X-2838	CM	LDE225	319.4	25.2	21	62.5	0.4
X-2838	CM	LDE225	276.6	24.9	24	40.8	-0.8
X-2838	CM	LDE225	335.2	24.5	29	70.5	-2.4
X-2838	CM	LDE225	335.2	24.5	30	70.5	-2.4
X-2838	CM	LDK378	211.7	22.8	0	0	0
X-2838	CM	LDK378	171.2	23.2	4	-19.1	1.8
X-2838	CM	LDK378	174.7	22.3	7	-17.5	-2.2
X-2838	CM	LDK378	201.7	22.4	11	-4.7	-1.8
X-2838	CM	LDK378	194.3	22.7	14	-8.2	-0.4
X-2838	CM	LDK378	176.1	23.2	18	-16.8	1.8
X-2838	CM	LDK378	156	22.5	21	-26.3	-1.3
X-2838	CM	LDK378	184.1	23	26	-13	0.9
X-2838	CM	LDK378	174.2	23.1	29	-17.7	1.3
X-2838	CM	LDK378	223.8	23.8	33	5.8	4.4
X-2838	CM	LDK378	259.9	23.3	36	22.8	2.2
X-2838	CM	LDK378	316.6	24.3	41	49.6	6.6
X-2838	CM	LDK378	395.2	24.1	46	86.7	5.7
X-2838	CM	LDK378	352.7	23.8	50	66.7	4.4
X-2838	CM	LDK378	352.2	23.8	53	66.4	4.4
X-2838	CM	LDK378	358.5	24.1	56	69.4	5.7
X-2838	CM	LDK378	438.7	24.5	60	107.3	7.5
X-2838	CM	LEE011	207.1	23.6	0	0	0
X-2838	CM	LEE011	237.3	24.7	3	14.6	4.7
X-2838	CM	LEE011	259.1	24.2	7	25.1	2.5
X-2838	CM	LEE011	270.4	25.3	10	30.6	7.2
X-2838	CM	LEE011	273.3	25.2	14	32	6.8
X-2838	CM	LEE011	276.4	25.6	17	33.5	8.5
X-2838	CM	LEE011	340.9	26.2	21	64.6	11
X-2838	CM	LEE011	312.1	26.1	24	50.7	10.6
X-2838	CM	LEE011	335.3	26.6	28	61.9	12.7
X-2838	CM	LEE011	394.7	26.3	31	90.6	11.4
X-2838	CM	LEE011 + encorafenib	195.6	26.1	0	0	0
X-2838	CM	LEE011 + encorafenib	186.5	27.4	4	-4.7	5
X-2838	CM	LEE011 + encorafenib	143.5	26.8	7	-26.6	2.7
X-2838	CM	LEE011 + encorafenib	143.2	28.4	11	-26.8	8.8
X-2838	CM	LEE011 + encorafenib	129.9	29.7	14	-33.6	13.8
X-2838	CM	LEE011 + encorafenib	159.5	28	19	-18.5	7.3
X-2838	CM	LEE011 + encorafenib	156.8	29.4	22	-19.9	12.6
X-2838	CM	LEE011 + encorafenib	138.4	28.7	26	-29.3	10
X-2838	CM	LEE011 + encorafenib	151.6	29.3	29	-22.5	12.3
X-2838	CM	LEE011 + encorafenib	179.9	29.3	34	-8	12.3
X-2838	CM	LEE011 + encorafenib	152.2	28.1	39	-22.2	7.7
X-2838	CM	LEE011 + encorafenib	121.4	28.2	43	-38	8
X-2838	CM	LEE011 + encorafenib	124.7	29.2	47	-36.3	11.9
X-2838	CM	LEE011 + encorafenib	122.1	29	50	-37.6	11.1
X-2838	CM	LEE011 + encorafenib	97.2	29	54	-50.3	11.1
X-2838	CM	LEE011 + encorafenib	96.7	27.6	60	-50.5	5.7
X-2838	CM	LEE011 + encorafenib	89.1	27.8	68	-54.4	6.5
X-2838	CM	LEE011 + encorafenib	89.7	27.7	77	-54.1	6.1
X-2838	CM	LEE011 + encorafenib	93.3	27.4	82	-52.3	5
X-2838	CM	LEE011 + encorafenib	91.8	28.5	89	-53.1	9.2
X-2838	CM	LEE011 + encorafenib	108.3	28.4	96	-44.6	8.8
X-2838	CM	LEE011 + encorafenib	111.9	29.1	103	-42.8	11.5
X-2838	CM	LEE011 + encorafenib	117.2	28.9	110	-40.1	10.7
X-2838	CM	LEE011 + encorafenib	135.7	28.4	117	-30.6	8.8
X-2838	CM	LEE011 + encorafenib	110.7	28.9	124	-43.4	10.7
X-2838	CM	LEE011 + encorafenib	95.8	29.1	131	-51.1	11.5
X-2838	CM	LEE011 + encorafenib	77.2	30.1	138	-60.5	15.3
X-2838	CM	LEE011 + encorafenib	71	30.7	145	-63.7	17.6
X-2838	CM	LEE011 + encorafenib	73	30.1	152	-62.7	15.3
X-2838	CM	LEE011 + encorafenib	88.3	29.3	159	-54.9	12.3
X-2838	CM	LEE011 + encorafenib	135.2	29.2	167	-30.9	11.9
X-2838	CM	LEE011 + encorafenib	149.2	30.5	173	-23.7	16.9
X-2838	CM	LEE011 + encorafenib	188.1	29.8	180	-3.8	14.2
X-2838	CM	LEE011 + encorafenib	217.1	30.4	187	11	16.5
X-2838	CM	LEE011 + encorafenib	195.5	28.7	194	-0.1	10
X-2838	CM	LEE011 + encorafenib	193.6	28.9	201	-1.1	10.7
X-2838	CM	LEE011 + encorafenib	189.3	30.8	208	-3.3	18
X-2838	CM	LEE011 + encorafenib	181.4	28.6	215	-7.3	9.6
X-2838	CM	LEE011 + encorafenib	178.7	30.3	221	-8.7	16.1
X-2838	CM	LEE011 + encorafenib	170.7	28.8	230	-12.8	10.3
X-2838	CM	LEE011 + encorafenib	185.9	28.7	236	-5	10
X-2838	CM	LEE011 + binimetinib	224	25.7	0	0	0
X-2838	CM	LEE011 + binimetinib	199.3	26.2	5	-11	1.9
X-2838	CM	LEE011 + binimetinib	171.2	24.8	9	-23.6	-3.5
X-2838	CM	LEE011 + binimetinib	177.8	24.8	12	-20.6	-3.5
X-2838	CM	LEE011 + binimetinib	137.4	25.3	15	-38.7	-1.6
X-2838	CM	LEE011 + binimetinib	109.5	26.2	19	-51.1	1.9
X-2838	CM	LEE011 + binimetinib	126.4	27.4	25	-43.6	6.6
X-2838	CM	LEE011 + binimetinib	126	27.3	33	-43.7	6.2
X-2838	CM	LEE011 + binimetinib	174.5	26.8	42	-22.1	4.3
X-2838	CM	LEE011 + binimetinib	130.2	25.3	47	-41.9	-1.6
X-2838	CM	LEE011 + binimetinib	153.9	26.4	54	-31.3	2.7
X-2838	CM	LEE011 + binimetinib	199.1	26.9	61	-11.1	4.7
X-2838	CM	LEE011 + binimetinib	150.5	26.6	68	-32.8	3.5
X-2838	CM	LEE011 + binimetinib	157	26.9	75	-29.9	4.7
X-2838	CM	LEE011 + binimetinib	186.8	27.1	82	-16.6	5.4
X-2838	CM	LEE011 + binimetinib	190.4	26.2	89	-15	1.9
X-2838	CM	LEE011 + binimetinib	187.6	27.2	96	-16.2	5.8
X-2838	CM	LEE011 + binimetinib	196	25.8	103	-12.5	0.4
X-2838	CM	LEE011 + binimetinib	220	26.3	110	-1.8	2.3
X-2838	CM	LEE011 + binimetinib	219.2	26.1	117	-2.1	1.6
X-2838	CM	LEE011 + binimetinib	241.8	26.2	124	7.9	1.9
X-2838	CM	LEE011 + binimetinib	328	25.9	132	46.5	0.8
X-2838	CM	LEE011 + binimetinib	268.4	24.3	138	19.8	-5.4
X-2838	CM	LEE011 + binimetinib	268.4	25.2	139	19.8	-1.9
X-2838	CM	WNT974	193.2	25.8	0	0	0
X-2838	CM	WNT974	172.6	25.6	4	-10.7	-0.8
X-2838	CM	WNT974	188.9	25.2	7	-2.2	-2.3
X-2838	CM	WNT974	226.5	26.2	11	17.2	1.6
X-2838	CM	WNT974	212.7	26.9	14	10.1	4.3
X-2838	CM	WNT974	315.8	26.1	18	63.5	1.2
X-2838	CM	WNT974	308.5	26.2	21	59.7	1.6
X-2838	CM	WNT974	438.4	25.3	26	127	-1.9
X-2838	CM	WNT974	438.4	25.3	27	127	-1.9
X-2838	CM	LGW813	224.9	22.5	0	0	0
X-2838	CM	LGW813	242.7	21.8	3	7.9	-3.1
X-2838	CM	LGW813	235.6	22.6	7	4.8	0.4
X-2838	CM	LGW813	278.7	22.5	10	23.9	0
X-2838	CM	LGW813	237	23.2	14	5.4	3.1
X-2838	CM	LGW813	269.3	22.9	17	19.8	1.8
X-2838	CM	LGW813	343.9	23.7	21	52.9	5.3
X-2838	CM	LGW813	405.5	23.9	24	80.3	6.2
X-2838	CM	encorafenib	187.5	22.1	0	0	0
X-2838	CM	encorafenib	189.6	22	3	1.1	-0.5
X-2838	CM	encorafenib	217.6	21.4	7	16	-3.2
X-2838	CM	encorafenib	221.8	22.4	10	18.3	1.4
X-2838	CM	encorafenib	192.6	22.6	14	2.7	2.3
X-2838	CM	encorafenib	216.9	22.4	17	15.6	1.4
X-2838	CM	encorafenib	211.4	22.4	21	12.8	1.4
X-2838	CM	encorafenib	160.3	22.6	24	-14.5	2.3
X-2838	CM	encorafenib	211.9	22.9	28	13	3.6
X-2838	CM	encorafenib	244.5	22.5	31	30.4	1.8
X-2838	CM	encorafenib	232.8	22.3	36	24.1	0.9
X-2838	CM	encorafenib	232.8	22.7	39	24.1	2.7
X-2838	CM	encorafenib	278.4	23.2	44	48.5	5
X-2838	CM	encorafenib	344.5	23	47	83.7	4.1
X-2838	CM	encorafenib	557.6	23.5	52	197.3	6.3
X-2838	CM	encorafenib	672.7	24.3	57	258.7	10
X-2838	CM	encorafenib + binimetinib	213.9	28.1	0	0	0
X-2838	CM	encorafenib + binimetinib	323.4	29.7	4	51.2	5.7
X-2838	CM	encorafenib + binimetinib	301.6	29.7	7	41	5.7
X-2838	CM	encorafenib + binimetinib	306.2	29.9	11	43.2	6.4
X-2838	CM	encorafenib + binimetinib	339.7	27.8	14	58.8	-1.1
X-2838	CM	encorafenib + binimetinib	332.4	29	19	55.4	3.2
X-2838	CM	encorafenib + binimetinib	335.2	29.6	22	56.7	5.3
X-2838	CM	encorafenib + binimetinib	369.8	29.5	26	72.9	5
X-2838	CM	encorafenib + binimetinib	369.8	29.5	27	72.9	5
X-2838	CM	binimetinib	212.8	24.3	0	0	0
X-2838	CM	binimetinib	281.8	24.1	3	32.4	-0.8
X-2838	CM	binimetinib	269.1	23.7	7	26.4	-2.5
X-2838	CM	binimetinib	304.3	24.9	10	42.9	2.5
X-2838	CM	binimetinib	328.2	24.7	14	54.2	1.6
X-2838	CM	binimetinib	423.3	24.5	17	98.9	0.8
X-2838	CM	binimetinib	601.8	25	21	182.8	2.9
X-2838	CM	binimetinib	594.3	25.6	24	179.2	5.3
X-2838	CM	TAS266	194.5	24.3	0	0	0
X-2838	CM	TAS266	162.6	26.1	3	-16.4	7.4
X-2838	CM	TAS266	254.4	26	7	30.8	7
X-2838	CM	TAS266	230.9	25.6	10	18.7	5.3
X-2838	CM	TAS266	236.7	25.2	14	21.7	3.7
X-2838	CM	TAS266	247.1	25.8	17	27.1	6.2
X-2838	CM	TAS266	306.6	26.1	21	57.6	7.4
X-2838	CM	TAS266	290.7	25.7	24	49.4	5.8
X-2838	CM	TAS266	510.8	26.6	28	162.6	9.5
X-2838	CM	untreated	198.2	20.7	0	0	0
X-2838	CM	untreated	233.7	21.1	4	17.9	1.9
X-2838	CM	untreated	297.9	22.1	7	50.3	6.8
X-2838	CM	untreated	369.4	21.6	11	86.4	4.3
X-2838	CM	untreated	391.5	22.3	14	97.5	7.7
X-2838	CM	untreated	586.6	21.9	18	196	5.8
X-2838	CM	untreated	803.4	22.5	21	305.3	8.7
X-2838	CM	untreated	819.7	22.5	25	313.6	8.7
X-2846	CRC	5FU	259.3	25.6	0	0	0
X-2846	CRC	5FU	347.5	23.4	2	34	-8.6
X-2846	CRC	5FU	338.8	22.4	5	30.7	-12.5
X-2846	CRC	5FU	360.1	23.8	8	38.9	-7
X-2846	CRC	5FU	479.5	23.2	13	84.9	-9.4
X-2846	CRC	5FU	499.9	25.6	19	92.8	0
X-2846	CRC	5FU	397	23.5	23	53.1	-8.2
X-2846	CRC	5FU	608.7	22.6	26	134.7	-11.7
X-2846	CRC	5FU	669.9	22	30	158.3	-14.1
X-2846	CRC	5FU	701.9	25.7	35	170.7	0.4
X-2846	CRC	5FU	734.8	24.8	40	183.4	-3.1
X-2846	CRC	5FU	767.8	25.3	47	196.1	-1.2
X-2846	CRC	5FU	921.1	25.6	50	255.2	0
X-2846	CRC	5FU	1059.4	24.9	55	308.6	-2.7
X-2846	CRC	5FU	1094.4	26.2	58	322.1	2.3
X-2846	CRC	5FU	1179.4	25.6	62	354.8	0
X-2846	CRC	BKM120	196.7	20.8	0	0	0
X-2846	CRC	BKM120	183.6	19.7	4	-6.7	-5.3
X-2846	CRC	BKM120	183.4	20.2	11	-6.8	-2.9
X-2846	CRC	BKM120	176.1	20.3	14	-10.5	-2.4
X-2846	CRC	BKM120	201.3	21.3	19	2.3	2.4
X-2846	CRC	BKM120	214.5	21.4	25	9	2.9
X-2846	CRC	BKM120	211.2	20.2	29	7.4	-2.9
X-2846	CRC	BKM120	208.5	19.4	32	6	-6.7
X-2846	CRC	BKM120	202.2	19.1	36	2.8	-8.2
X-2846	CRC	BKM120	201.9	19.3	41	2.6	-7.2
X-2846	CRC	BKM120	181.2	19.1	46	-7.9	-8.2
X-2846	CRC	BKM120	233.3	21.9	53	18.6	5.3
X-2846	CRC	BKM120	243.5	18.4	56	23.8	-11.5
X-2846	CRC	BKM120	319.4	20.2	64	62.4	-2.9
X-2846	CRC	BKM120	356.4	20.3	68	81.2	-2.4
X-2846	CRC	BKM120 + LJC049	227.9	27.4	0	0	0
X-2846	CRC	BKM120 + LJC049	248.9	29.7	3	9.2	8.4
X-2846	CRC	BKM120 + LJC049	296.3	29.8	10	30	8.8
X-2846	CRC	BKM120 + LJC049	296.8	28.5	13	30.2	4
X-2846	CRC	BKM120 + LJC049	327.1	26.9	18	43.5	-1.8
X-2846	CRC	BKM120 + LJC049	374.1	28.2	21	64.2	2.9
X-2846	CRC	BKM120 + LJC049	383.9	26.6	25	68.5	-2.9
X-2846	CRC	BYL719 + LJM716	281.9	27	0	0	0
X-2846	CRC	BYL719 + LJM716	199	27.4	6	-29.4	1.5
X-2846	CRC	BYL719 + LJM716	112.3	28.8	12	-60.2	6.7
X-2846	CRC	BYL719 + LJM716	163.1	27.8	28	-42.1	3
X-2846	CRC	BYL719 + LJM716	109.5	28.1	33	-61.2	4.1
X-2846	CRC	BYL719 + LJM716	140.3	28.6	40	-50.2	5.9
X-2846	CRC	BYL719 + LJM716	242.4	27.1	43	-14	0.4
X-2846	CRC	BYL719 + LJM716	320.3	27.1	51	13.6	0.4
X-2846	CRC	BYL719 + LJM716	751.4	27.1	55	166.5	0.4
X-2846	CRC	BYL719	254.2	24.9	0	0	0
X-2846	CRC	BYL719	287.6	25.8	6	13.1	3.6
X-2846	CRC	BYL719	328.5	26.5	12	29.2	6.4
X-2846	CRC	BYL719	374	25.8	16	47.1	3.6
X-2846	CRC	BYL719	381.3	24.6	23	50	-1.2
X-2846	CRC	BYL719	404.2	25.6	28	59	2.8
X-2846	CRC	BYL719	414.4	26.2	33	63	5.2
X-2846	CRC	BYL719 + binimetinib	231.9	23.7	0	0	0
X-2846	CRC	BYL719 + binimetinib	212.9	23.4	6	-8.2	-1.3
X-2846	CRC	BYL719 + binimetinib	188	24.1	12	-18.9	1.7
X-2846	CRC	BYL719 + binimetinib	181.6	22.9	16	-21.7	-3.4
X-2846	CRC	BYL719 + binimetinib	130.8	22.5	19	-43.6	-5.1
X-2846	CRC	BYL719 + binimetinib	132.5	23	23	-42.9	-3
X-2846	CRC	BYL719 + binimetinib	175.5	25.9	28	-24.3	9.3
X-2846	CRC	BYL719 + binimetinib	160.2	24.5	33	-30.9	3.4
X-2846	CRC	BYL719 + binimetinib	184.9	24.8	40	-20.3	4.6
X-2846	CRC	BYL719 + binimetinib	165.5	23.3	43	-28.6	-1.7
X-2846	CRC	BYL719 + binimetinib	156.8	23.7	48	-32.4	0
X-2846	CRC	BYL719 + binimetinib	69.3	25.5	51	-70.1	7.6
X-2846	CRC	BYL719 + binimetinib	71.3	22.6	55	-69.3	-4.6
X-2846	CRC	BYL719 + binimetinib	70.8	22.7	58	-69.5	-4.2
X-2846	CRC	BYL719 + binimetinib	112.7	23.6	66	-51.4	-0.4
X-2846	CRC	BYL719 + binimetinib	123.9	23.9	69	-46.6	0.8
X-2846	CRC	BYL719 + binimetinib	87.4	23.3	71	-62.3	-1.7
X-2846	CRC	BYL719 + binimetinib	85.1	24.9	75	-63.3	5.1
X-2846	CRC	BYL719 + binimetinib	118.4	25.7	78	-48.9	8.4
X-2846	CRC	BYL719 + binimetinib	103	25.2	83	-55.6	6.3
X-2846	CRC	BYL719 + binimetinib	88.5	25	88	-61.8	5.5
X-2846	CRC	BYL719 + binimetinib	87.6	24.5	92	-62.2	3.4
X-2846	CRC	BYL719 + encorafenib	242.9	23.8	0	0	0
X-2846	CRC	BYL719 + encorafenib	255.4	23.5	7	5.1	-1.3
X-2846	CRC	BYL719 + encorafenib	250.8	22.9	11	3.3	-3.8
X-2846	CRC	BYL719 + encorafenib	223.9	23.5	14	-7.8	-1.3
X-2846	CRC	BYL719 + encorafenib	177.8	23.1	18	-26.8	-2.9
X-2846	CRC	BYL719 + encorafenib	228.3	23.9	23	-6	0.4
X-2846	CRC	BYL719 + encorafenib	249.5	23.3	28	2.7	-2.1
X-2846	CRC	BYL719 + encorafenib	249.5	24	35	2.7	0.8
X-2846	CRC	BYL719 + encorafenib	262.4	24.3	38	8	2.1
X-2846	CRC	BYL719 + encorafenib	304.9	24.9	43	25.5	4.6
X-2846	CRC	BYL719 + encorafenib	291	25.7	46	19.8	8
X-2846	CRC	BYL719 + encorafenib	333.6	24	50	37.3	0.8
X-2846	CRC	BYL719 + cetuximab + encorafenib	195.7	23.4	0	0	0
X-2846	CRC	BYL719 + cetuximab + encorafenib	128.6	22.1	3	-34.3	-5.6
X-2846	CRC	BYL719 + cetuximab + encorafenib	82	23.8	10	-58.1	1.7
X-2846	CRC	BYL719 + cetuximab + encorafenib	75.6	23.4	13	-61.4	0
X-2846	CRC	BYL719 + cetuximab + encorafenib	64	23.8	18	-67.3	1.7
X-2846	CRC	BYL719 + cetuximab + encorafenib	84.5	22.9	25	-56.8	-2.1
X-2846	CRC	BYL719 + cetuximab + encorafenib	83.9	22.8	28	-57.1	-2.6
X-2846	CRC	BYL719 + cetuximab + encorafenib	31.1	23.6	33	-84.1	0.9
X-2846	CRC	BYL719 + cetuximab + encorafenib	60.9	22.9	36	-68.9	-2.1
X-2846	CRC	BYL719 + cetuximab + encorafenib	47.9	22.3	39	-75.5	-4.7
X-2846	CRC	BYL719 + cetuximab + encorafenib	50.1	22.2	41	-74.4	-5.1
X-2846	CRC	BYL719 + cetuximab + encorafenib	47.6	23.5	45	-75.7	0.4
X-2846	CRC	BYL719 + cetuximab + encorafenib	41.5	22.3	48	-78.8	-4.7
X-2846	CRC	BYL719 + cetuximab + encorafenib	49.6	23.4	53	-74.7	0
X-2846	CRC	BYL719 + cetuximab + encorafenib	41.9	23.4	58	-78.6	0
X-2846	CRC	BYL719 + cetuximab + encorafenib	35.7	23.3	62	-81.8	-0.4
X-2846	CRC	BYL719 + cetuximab + encorafenib	44.1	21.6	67	-77.5	-7.7
X-2846	CRC	BYL719 + cetuximab + encorafenib	44.5	21.6	70	-77.3	-7.7
X-2846	CRC	BYL719 + cetuximab + encorafenib	50	21.5	73	-74.5	-8.1
X-2846	CRC	BYL719 + cetuximab + encorafenib	32.9	22.1	77	-83.2	-5.6
X-2846	CRC	BYL719 + cetuximab + encorafenib	34.7	22.3	80	-82.3	-4.7
X-2846	CRC	BYL719 + cetuximab + encorafenib	23.8	22.6	84	-87.8	-3.4
X-2846	CRC	BYL719 + cetuximab + encorafenib	32.3	23.5	88	-83.5	0.4
X-2846	CRC	BYL719 + cetuximab + encorafenib	25.6	24.3	97	-86.9	3.8
X-2846	CRC	BYL719 + cetuximab	190.1	25.4	0	0	0
X-2846	CRC	BYL719 + cetuximab	130.8	24.2	3	-31.2	-4.7
X-2846	CRC	BYL719 + cetuximab	86	25.3	10	-54.8	-0.4
X-2846	CRC	BYL719 + cetuximab	62.3	24.5	13	-67.2	-3.5
X-2846	CRC	BYL719 + cetuximab	51	23.4	18	-73.2	-7.9
X-2846	CRC	BYL719 + cetuximab	61.3	24.5	21	-67.8	-3.5
X-2846	CRC	BYL719 + cetuximab	38.3	25.7	25	-79.9	1.2
X-2846	CRC	BYL719 + cetuximab	29.9	25.6	28	-84.3	0.8
X-2846	CRC	BYL719 + cetuximab	29	27.3	33	-84.7	7.5
X-2846	CRC	BYL719 + cetuximab	26.7	27.4	36	-86	7.9
X-2846	CRC	BYL719 + cetuximab	18	26.7	39	-90.5	5.1
X-2846	CRC	BYL719 + cetuximab	27.8	26.4	41	-85.4	3.9
X-2846	CRC	BYL719 + cetuximab	24.6	26.9	45	-87.1	5.9
X-2846	CRC	BYL719 + cetuximab	0	27.8	48	-100	9.4
X-2846	CRC	BYL719 + cetuximab	0	27.9	53	-100	9.8
X-2846	CRC	BYL719 + cetuximab	0	27	58	-100	6.3
X-2846	CRC	BYL719 + cetuximab	0	27.7	62	-100	9.1
X-2846	CRC	BYL719 + cetuximab	0	27.5	67	-100	8.3
X-2846	CRC	BYL719 + cetuximab	0	23.2	70	-100	-8.7
X-2846	CRC	BYL719 + cetuximab	0	25.8	73	-100	1.6
X-2846	CRC	CGM097	242.7	23.5	0	0	0
X-2846	CRC	CGM097	350.5	25.4	4	44.4	8.1
X-2846	CRC	CGM097	665.1	26.4	8	174	12.3
X-2846	CRC	CGM097	682	25.1	11	181	6.8
X-2846	CRC	CGM097	793.5	24.7	14	226.9	5.1
X-2846	CRC	CGM097	864	23.9	19	256	1.7
X-2846	CRC	CGM097	924.6	21.6	29	281	-8.1
X-2846	CRC	CGM097	894.4	20.9	32	268.5	-11.1
X-2846	CRC	CGM097	1054.2	19.6	36	334.4	-16.6
X-2846	CRC	CGM097	1269.3	21.6	41	423	-8.1
X-2846	CRC	CGM097	1305.5	21.5	46	437.9	-8.5
X-2846	CRC	CKX620	229.5	26.6	0	0	0
X-2846	CRC	CKX620	196.7	27.1	4	-14.3	1.9
X-2846	CRC	CKX620	204.2	28.4	8	-11	6.8
X-2846	CRC	CKX620	185.3	28	11	-19.3	5.3
X-2846	CRC	CKX620	164.5	29.1	14	-28.3	9.4
X-2846	CRC	CKX620	172.7	30.6	19	-24.7	15
X-2846	CRC	CKX620	111.3	28.5	25	-51.5	7.1
X-2846	CRC	CKX620	93.2	27.9	29	-59.4	4.9
X-2846	CRC	CKX620	65.8	28.9	32	-71.3	8.6
X-2846	CRC	CKX620	48.9	29.1	36	-78.7	9.4
X-2846	CRC	CKX620	33.5	30.1	41	-85.4	13.2
X-2846	CRC	CKX620	33.5	29.4	46	-85.4	10.5
X-2846	CRC	CKX620	35.7	30.2	53	-84.4	13.5
X-2846	CRC	CKX620	32.3	29.4	56	-85.9	10.5
X-2846	CRC	CKX620	29.1	29.4	64	-87.3	10.5
X-2846	CRC	CKX620	30	29.2	68	-86.9	9.8
X-2846	CRC	CKX620	0	29	71	-100	9
X-2846	CRC	CKX620	0	28.9	76	-100	8.6
X-2846	CRC	CKX620	0	29.6	79	-100	11.3
X-2846	CRC	CKX620	0	29.1	84	-100	9.4
X-2846	CRC	CKX620	0	30.2	88	-100	13.5
X-2846	CRC	CKX620	0	29.2	91	-100	9.8
X-2846	CRC	CKX620	0	29.5	96	-100	10.9
X-2846	CRC	CKX620	0	31.1	101	-100	16.9
X-2846	CRC	CKX620	0	29.8	105	-100	12
X-2846	CRC	CLR457	230.4	26.2	0	0	0
X-2846	CRC	CLR457	110.7	25.4	4	-52	-3.1
X-2846	CRC	CLR457	114.1	26.4	8	-50.5	0.8
X-2846	CRC	CLR457	107	25.2	11	-53.6	-3.8
X-2846	CRC	CLR457	124.7	26.3	14	-45.9	0.4
X-2846	CRC	CLR457	148.2	26.7	19	-35.7	1.9
X-2846	CRC	CLR457	192.8	26.1	25	-16.3	-0.4
X-2846	CRC	CLR457	173.7	25.9	29	-24.6	-1.1
X-2846	CRC	CLR457	195	26.9	32	-15.4	2.7
X-2846	CRC	CLR457	189.3	26.8	36	-17.8	2.3
X-2846	CRC	CLR457	195.6	27.3	41	-15.1	4.2
X-2846	CRC	CLR457	238.8	26.1	46	3.6	-0.4
X-2846	CRC	CLR457	235.4	26.5	53	2.2	1.1
X-2846	CRC	CLR457	217.7	25.8	56	-5.5	-1.5
X-2846	CRC	CLR457	169	26.2	64	-26.6	0
X-2846	CRC	CLR457	190.6	25.9	68	-17.3	-1.1
X-2846	CRC	CLR457	180.8	25.4	76	-21.5	-3.1
X-2846	CRC	CLR457	112.7	26.3	79	-51.1	0.4
X-2846	CRC	CLR457	128	25.7	82	-44.4	-1.9
X-2846	CRC	CLR457	158.5	25.3	84	-31.2	-3.4
X-2846	CRC	CLR457	141.2	25.6	88	-38.7	-2.3
X-2846	CRC	CLR457	129.6	25.6	91	-43.8	-2.3
X-2846	CRC	CLR457	127.9	26.2	96	-44.5	0
X-2846	CRC	CLR457	85	26	105	-63.1	-0.8
X-2846	CRC	HDM201	297.6	28.1	0	0	0
X-2846	CRC	HDM201	614.2	28.4	4	106.4	1.1
X-2846	CRC	HDM201	735.6	27.6	8	147.2	-1.8
X-2846	CRC	HDM201	807.9	29.3	11	171.5	4.3
X-2846	CRC	HDM201	1045.5	30.9	19	251.3	10
X-2846	CRC	HDM201	1367.9	30.3	25	359.6	7.8
X-2846	CRC	cetuximab	196.9	26.2	0	0	0
X-2846	CRC	cetuximab	167.8	27.9	4	-14.8	6.5
X-2846	CRC	cetuximab	157.3	26.8	8	-20.1	2.3
X-2846	CRC	cetuximab	136.5	27.2	11	-30.7	3.8
X-2846	CRC	cetuximab	154.7	27.1	14	-21.4	3.4
X-2846	CRC	cetuximab	143.1	29.5	19	-27.3	12.6
X-2846	CRC	cetuximab	142	27.9	25	-27.9	6.5
X-2846	CRC	cetuximab	165.4	26.3	32	-16	0.4
X-2846	CRC	cetuximab	146.4	26.7	36	-25.6	1.9
X-2846	CRC	cetuximab	128.7	27.3	41	-34.6	4.2
X-2846	CRC	cetuximab	156.1	27.7	46	-20.7	5.7
X-2846	CRC	cetuximab	162.2	27.9	53	-17.6	6.5
X-2846	CRC	cetuximab	139.4	27.9	56	-29.2	6.5
X-2846	CRC	cetuximab	146.2	27.9	69	-25.7	6.5
X-2846	CRC	cetuximab	110	27.9	71	-44.1	6.5
X-2846	CRC	cetuximab	123.2	28	76	-37.4	6.9
X-2846	CRC	cetuximab	108.3	27.5	79	-45	5
X-2846	CRC	cetuximab	133.9	27.3	82	-32	4.2
X-2846	CRC	cetuximab	135.4	27.7	84	-31.2	5.7
X-2846	CRC	cetuximab	132.7	28.2	88	-32.6	7.6
X-2846	CRC	cetuximab	151.3	28.5	91	-23.2	8.8
X-2846	CRC	cetuximab	132.3	28.1	101	-32.8	7.3
X-2846	CRC	cetuximab	163.4	27.5	105	-17	5
X-2846	CRC	cetuximab + encorafenib	187.5	26.4	0	0	0
X-2846	CRC	cetuximab + encorafenib	161.7	25.8	3	-13.8	-2.3
X-2846	CRC	cetuximab + encorafenib	125.9	28.4	10	-32.9	7.6
X-2846	CRC	cetuximab + encorafenib	130	27.6	13	-30.7	4.5
X-2846	CRC	cetuximab + encorafenib	140.1	23.6	18	-25.3	-10.6
X-2846	CRC	cetuximab + encorafenib	134	28	25	-28.5	6.1
X-2846	CRC	cetuximab + encorafenib	114.2	29	28	-39.1	9.8
X-2846	CRC	cetuximab + encorafenib	69	29	33	-63.2	9.8
X-2846	CRC	cetuximab + encorafenib	115.8	28	36	-38.2	6.1
X-2846	CRC	cetuximab + encorafenib	130.2	28.5	39	-30.6	8
X-2846	CRC	cetuximab + encorafenib	95.8	28.6	41	-48.9	8.3
X-2846	CRC	cetuximab + encorafenib	65.3	29.1	45	-65.2	10.2
X-2846	CRC	cetuximab + encorafenib	70.9	28.9	53	-62.2	9.5
X-2846	CRC	cetuximab + encorafenib	68.4	28.6	58	-63.5	8.3
X-2846	CRC	cetuximab + encorafenib	80.9	29	62	-56.9	9.8
X-2846	CRC	cetuximab + encorafenib	74.2	29	67	-60.4	9.8
X-2846	CRC	cetuximab + encorafenib	75.6	29.3	70	-59.7	11
X-2846	CRC	cetuximab + encorafenib	66.8	28.7	73	-64.4	8.7
X-2846	CRC	cetuximab + encorafenib	68.1	29.7	77	-63.7	12.5
X-2846	CRC	cetuximab + encorafenib	61.4	29.4	80	-67.3	11.4
X-2846	CRC	cetuximab + encorafenib	47.6	30.1	84	-74.6	14
X-2846	CRC	cetuximab + encorafenib	73.1	28.9	88	-61	9.5
X-2846	CRC	LEE011	245	27.7	0	0	0
X-2846	CRC	LEE011	231.8	28.6	4	-5.4	3.2
X-2846	CRC	LEE011	259.5	27.6	8	5.9	-0.4
X-2846	CRC	LEE011	255.3	27.6	11	4.2	-0.4
X-2846	CRC	LEE011	299.3	29.3	14	22.2	5.8
X-2846	CRC	LEE011	288	28.9	19	17.6	4.3
X-2846	CRC	LEE011	364.4	29.1	25	48.7	5.1
X-2846	CRC	LEE011	345.5	29.3	29	41	5.8
X-2846	CRC	LEE011	405	29.7	32	65.3	7.2
X-2846	CRC	LEE011	423.3	30	36	72.8	8.3
X-2846	CRC	LEE011	356.5	29.7	41	45.5	7.2
X-2846	CRC	LEE011	439.4	28.9	46	79.3	4.3
X-2846	CRC	encorafenib	220	28.1	0	0	0
X-2846	CRC	encorafenib	183.8	28.1	4	-16.5	0
X-2846	CRC	encorafenib	165.7	31	8	-24.7	10.3
X-2846	CRC	encorafenib	202	30.9	11	-8.2	10
X-2846	CRC	encorafenib	228	30.4	14	3.6	8.2
X-2846	CRC	encorafenib	302.4	31	19	37.5	10.3
X-2846	CRC	encorafenib	358.9	29.9	29	63.1	6.4
X-2846	CRC	encorafenib	419.4	29.3	32	90.6	4.3
X-2846	CRC	encorafenib	452.8	28.8	36	105.8	2.5
X-2846	CRC	encorafenib	481.5	30.9	41	118.9	10
X-2846	CRC	encorafenib	341	28.9	46	55	2.8
X-2846	CRC	LJC049	199.7	24.7	0	0	0
X-2846	CRC	LJC049	215.7	24.8	4	8	0.4
X-2846	CRC	LJC049	240.9	23.5	8	20.6	-4.9
X-2846	CRC	LJC049	375.1	24.8	11	87.8	0.4
X-2846	CRC	LJC049	528.7	24.2	14	164.7	-2
X-2846	CRC	LJC049	567.2	23.9	19	184	-3.2
X-2846	CRC	LJC049	609.9	24.4	25	205.4	-1.2
X-2846	CRC	LJC049	550.3	23.1	29	175.6	-6.5
X-2846	CRC	LJC049	561.5	23.2	32	181.2	-6.1
X-2846	CRC	LJC049	562	21.9	36	181.4	-11.3
X-2846	CRC	LJC049	734.1	21.6	41	267.6	-12.6
X-2846	CRC	LJC049	1955.6	24.9	46	879.3	0.8
X-2846	CRC	LKA136	210	25.5	0	0	0
X-2846	CRC	LKA136	218.8	26.3	4	4.2	3.1
X-2846	CRC	LKA136	254.6	26.1	8	21.2	2.4
X-2846	CRC	LKA136	307.9	25.3	11	46.6	-0.8
X-2846	CRC	LKA136	313.9	25.6	14	49.5	0.4
X-2846	CRC	LKA136	296.3	26.3	19	41.1	3.1
X-2846	CRC	LKA136	325.6	26.7	25	55	4.7
X-2846	CRC	LKA136	394	26.9	29	87.6	5.5
X-2846	CRC	LKA136	367.1	25.7	32	74.8	0.8
X-2846	CRC	LKA136	383.3	25.6	36	82.5	0.4
X-2846	CRC	LKA136	437.7	25.3	41	108.4	-0.8
X-2846	CRC	LKA136	515.1	28.5	46	145.3	11.8
X-2846	CRC	binimetinib	253.2	23.6	0	0	0
X-2846	CRC	binimetinib	200.3	24.8	4	-20.9	5.1
X-2846	CRC	binimetinib	227.3	22.5	8	-10.2	-4.7
X-2846	CRC	binimetinib	276.5	22.2	11	9.2	-5.9
X-2846	CRC	binimetinib	296.5	23.2	14	17.1	-1.7
X-2846	CRC	binimetinib	317.4	22.9	19	25.4	-3
X-2846	CRC	binimetinib	468	23.3	25	84.8	-1.3
X-2846	CRC	binimetinib	418.9	22.8	29	65.4	-3.4
X-2846	CRC	binimetinib	358.4	23.1	36	41.5	-2.1
X-2846	CRC	binimetinib	383.7	22.7	41	51.5	-3.8
X-2846	CRC	binimetinib	438.4	22.4	46	73.1	-5.1
X-2846	CRC	untreated	266	23.1	0	0	0
X-2846	CRC	untreated	557.5	25.3	4	109.6	9.5
X-2846	CRC	untreated	728.5	23	8	173.9	-0.4
X-2846	CRC	untreated	872.6	22.1	11	228	-4.3
X-2846	CRC	untreated	892.9	22	14	235.7	-4.8
X-2846	CRC	untreated	1040.7	21.3	19	291.2	-7.8
X-2846	CRC	untreated	1091.7	21	25	310.4	-9.1
X-2861	CRC	5FU	247.5	23.4	0	0	0
X-2861	CRC	5FU	353.3	23	5	42.7	-1.7
X-2861	CRC	5FU	404.5	22.3	8	63.4	-4.7
X-2861	CRC	5FU	318.2	20.7	11	28.6	-11.5
X-2861	CRC	5FU	358.1	21.3	14	44.7	-9
X-2861	CRC	5FU	413.4	20.9	21	67	-10.7
X-2861	CRC	5FU	419.6	21.3	27	69.5	-9
X-2861	CRC	5FU	457.2	21.7	30	84.7	-7.3
X-2861	CRC	5FU	455.1	20.7	33	83.9	-11.5
X-2861	CRC	BKM120	229.2	21.1	0	0	0
X-2861	CRC	BKM120	295.8	19.2	6	29.1	-9
X-2861	CRC	BKM120	369.5	22.1	11	61.2	4.7
X-2861	CRC	BKM120	374.6	20.6	14	63.4	-2.4
X-2861	CRC	BKM120	403.9	18.4	17	76.2	-12.8
X-2861	CRC	BKM120	506.8	20.1	20	121.1	-4.7
X-2861	CRC	BKM120	564.7	18.2	27	146.4	-13.7
X-2861	CRC	BKM120 + LJC049	206.7	22.4	0	0	0
X-2861	CRC	BKM120 + LJC049	243.2	21.5	5	17.7	-4
X-2861	CRC	BKM120 + LJC049	358.1	21.5	8	73.2	-4
X-2861	CRC	BKM120 + LJC049	382.8	20.2	11	85.2	-9.8
X-2861	CRC	BKM120 + LJC049	457.3	19.6	14	121.2	-12.5
X-2861	CRC	BYL719 + LJM716	219.2	26.4	0	0	0
X-2861	CRC	BYL719 + LJM716	202.2	23.9	6	-7.8	-9.5
X-2861	CRC	BYL719 + LJM716	262.7	22.9	11	19.8	-13.3
X-2861	CRC	BYL719 + LJM716	390	22.5	14	77.9	-14.8
X-2861	CRC	BYL719 + LJM716	439.6	23.5	17	100.5	-11
X-2861	CRC	BYL719 + LJM716	600.9	23	20	174.1	-12.9
X-2861	CRC	BYL719 + LJM716	660.7	23.3	27	201.4	-11.7
X-2861	CRC	BYL719	210.8	23.4	0	0	0
X-2861	CRC	BYL719	243.2	21.2	6	15.4	-9.4
X-2861	CRC	BYL719	313.3	21.5	11	48.6	-8.1
X-2861	CRC	BYL719	322.5	20.5	14	53	-12.4
X-2861	CRC	BYL719	486.1	19	17	130.6	-18.8
X-2861	CRC	BYL719	513	19.3	20	143.4	-17.5
X-2861	CRC	BYL719 + cetuximab + encorafenib	211.3	23.4	0	0	0
X-2861	CRC	BYL719 + cetuximab + encorafenib	262.1	23	6	24	-1.7
X-2861	CRC	BYL719 + cetuximab + encorafenib	354.1	21.7	11	67.6	-7.3
X-2861	CRC	BYL719 + cetuximab + encorafenib	610.8	21.6	14	189.1	-7.7
X-2861	CRC	BYL719 + cetuximab + encorafenib	645.9	20.7	17	205.7	-11.5
X-2861	CRC	BYL719 + cetuximab + encorafenib	777.4	21.6	20	267.9	-7.7
X-2861	CRC	BYL719 + cetuximab + encorafenib	1326.5	22.8	27	527.8	-2.6
X-2861	CRC	BYL719 + cetuximab	178.5	18.4	0	0	0
X-2861	CRC	BYL719 + cetuximab	252.8	19.4	6	41.6	5.4
X-2861	CRC	BYL719 + cetuximab	375.4	19.3	11	110.3	4.9
X-2861	CRC	BYL719 + cetuximab	459.4	18.8	14	157.4	2.2
X-2861	CRC	BYL719 + cetuximab	921.4	19.6	17	416.2	6.5
X-2861	CRC	BYL719 + cetuximab	965.3	19.6	20	440.8	6.5
X-2861	CRC	BYL719 + cetuximab	909.4	19.9	27	409.5	8.2
X-2861	CRC	BYL719 + binimetinib	218.7	22.3	0	0	0
X-2861	CRC	BYL719 + binimetinib	152.8	22.8	5	-30.1	2.2
X-2861	CRC	BYL719 + binimetinib	117.1	22.3	8	-46.5	0
X-2861	CRC	BYL719 + binimetinib	146	21.2	11	-33.2	-4.9
X-2861	CRC	BYL719 + binimetinib	151.3	22	14	-30.8	-1.3
X-2861	CRC	BYL719 + binimetinib	149.9	22.3	21	-31.5	0
X-2861	CRC	BYL719 + binimetinib	139.8	22.3	27	-36.1	0
X-2861	CRC	BYL719 + binimetinib	174.7	22.6	30	-20.1	1.3
X-2861	CRC	BYL719 + binimetinib	173.6	17.9	32	-20.6	-19.7
X-2861	CRC	BYL719 + encorafenib	223.5	24.1	0	0	0
X-2861	CRC	BYL719 + encorafenib	400	24.6	5	79	2.1
X-2861	CRC	BYL719 + encorafenib	435.4	25.5	8	94.8	5.8
X-2861	CRC	BYL719 + encorafenib	472	23.1	11	111.2	-4.1
X-2861	CRC	BYL719 + encorafenib	570.7	22.3	14	155.3	-7.5
X-2861	CRC	BYL719 + encorafenib	875.7	22.8	21	291.8	-5.4
X-2861	CRC	BYL719 + encorafenib	1171.9	26.4	27	424.3	9.5
X-2861	CRC	BYL719 + encorafenib	1147.7	25.6	30	413.5	6.2
X-2861	CRC	BYL719 + encorafenib	1190	26.1	33	432.4	8.3
X-2861	CRC	CGM097	232.2	24.4	0	0	0
X-2861	CRC	CGM097	329.5	25.7	5	41.9	5.3
X-2861	CRC	CGM097	466.9	25	8	101.1	2.5
X-2861	CRC	CGM097	503.2	22.6	11	116.7	-7.4
X-2861	CRC	CGM097	564.4	23.5	14	143.1	-3.7
X-2861	CRC	CGM097	768.5	25	21	231	2.5
X-2861	CRC	CGM097	901.3	23.9	27	288.2	-2
X-2861	CRC	CGM097	1074.2	26.6	30	362.6	9
X-2861	CRC	CGM097	1135.5	24.4	33	389	0
X-2861	CRC	CKX620	224.8	25	0	0	0
X-2861	CRC	CKX620	136.8	21.9	6	-39.1	-12.4
X-2861	CRC	CKX620	184.7	23.3	11	-17.8	-6.8
X-2861	CRC	CKX620	215.8	22.4	14	-4	-10.4
X-2861	CRC	CKX620	228.1	22.4	17	1.5	-10.4
X-2861	CRC	CKX620	223.8	22.1	20	-0.4	-11.6
X-2861	CRC	CKX620	227.3	25.4	27	1.1	1.6
X-2861	CRC	CKX620	239.9	25.6	33	6.7	2.4
X-2861	CRC	CKX620	251.7	24.7	36	12	-1.2
X-2861	CRC	CKX620	298.5	25.5	39	32.8	2
X-2861	CRC	CKX620	345.5	26.1	42	53.7	4.4
X-2861	CRC	CKX620	326.3	25.8	47	45.2	3.2
X-2861	CRC	CKX620	372.4	26.2	50	65.7	4.8
X-2861	CRC	CKX620	415.5	26.1	53	84.8	4.4
X-2861	CRC	CLR457	219.4	22.7	0	0	0
X-2861	CRC	CLR457	243.6	20.9	5	11	-7.9
X-2861	CRC	CLR457	259.6	23	8	18.3	1.3
X-2861	CRC	CLR457	290.1	23	11	32.2	1.3
X-2861	CRC	CLR457	339.1	24.7	14	54.6	8.8
X-2861	CRC	CLR457	501.9	24.3	21	128.8	7
X-2861	CRC	CLR457	479.6	23.1	27	118.6	1.8
X-2861	CRC	CLR457	504.5	23.2	30	129.9	2.2
X-2861	CRC	CLR457	533.2	23.2	33	143	2.2
X-2861	CRC	HDM201	252.6	24	0	0	0
X-2861	CRC	HDM201	315.7	21.6	6	25	-10
X-2861	CRC	HDM201	644.9	22.5	11	155.3	-6.2
X-2861	CRC	HDM201	662.8	18.8	14	162.4	-21.7
X-2861	CRC	cetuximab	280.8	26.3	0	0	0
X-2861	CRC	cetuximab	505	25.9	6	79.8	-1.5
X-2861	CRC	cetuximab	1088.5	25.3	11	287.6	-3.8
X-2861	CRC	cetuximab	1109.7	24.5	14	295.2	-6.8
X-2861	CRC	cetuximab	1296.2	23.5	17	361.6	-10.6
X-2861	CRC	cetuximab	1748.1	24.3	20	522.5	-7.6
X-2861	CRC	cetuximab + encorafenib	236	21.2	0	0	0
X-2861	CRC	cetuximab + encorafenib	551.7	21.3	6	133.8	0.5
X-2861	CRC	cetuximab + encorafenib	1240.9	21.3	11	425.8	0.5
X-2861	CRC	cetuximab + encorafenib	1513.4	20.7	14	541.3	-2.4
X-2861	CRC	LEE011	221.5	24.7	0	0	0
X-2861	CRC	LEE011	227.7	24.2	4	2.8	-2
X-2861	CRC	LEE011	240.5	22.2	9	8.6	-10.1
X-2861	CRC	LEE011	400.8	24.3	14	80.9	-1.6
X-2861	CRC	LEE011	444.6	22.1	17	100.7	-10.5
X-2861	CRC	LEE011	465.1	21.6	20	110	-12.6
X-2861	CRC	LEE011	506.7	22.7	23	128.8	-8.1
X-2861	CRC	LEE011	800	24.4	30	261.2	-1.2
X-2861	CRC	encorafenib	231.9	20.2	0	0	0
X-2861	CRC	encorafenib	432.5	21.8	3	86.5	7.9
X-2861	CRC	encorafenib	458.8	21.1	6	97.8	4.5
X-2861	CRC	encorafenib	510.8	21.7	13	120.3	7.4
X-2861	CRC	encorafenib	765.4	20.8	19	230.1	3
X-2861	CRC	encorafenib	789.8	19.4	22	240.6	-4
X-2861	CRC	encorafenib	910.7	22.3	25	292.7	10.4
X-2861	CRC	encorafenib	1134	23.3	28	389	15.3
X-2861	CRC	encorafenib	1394.5	23	36	501.3	13.9
X-2861	CRC	encorafenib	1843.8	21.7	39	695.1	7.4
X-2861	CRC	LJC049	231.1	25.3	0	0	0
X-2861	CRC	LJC049	533.3	24.1	6	130.8	-4.7
X-2861	CRC	LJC049	950.9	23.5	11	311.5	-7.1
X-2861	CRC	LJC049	1153.1	22.6	14	399	-10.7
X-2861	CRC	LJC049	1321.7	23.5	17	471.9	-7.1
X-2861	CRC	LJC049	1587.4	20	20	586.9	-20.9
X-2861	CRC	LKA136	193.6	22.6	0	0	0
X-2861	CRC	LKA136	191.1	24.1	5	-1.3	6.6
X-2861	CRC	LKA136	210.5	23.7	8	8.7	4.9
X-2861	CRC	LKA136	303	23.6	11	56.5	4.4
X-2861	CRC	LKA136	348.6	23.9	14	80.1	5.8
X-2861	CRC	LKA136	408.8	23.7	21	111.2	4.9
X-2861	CRC	LKA136	559.1	23.9	27	188.8	5.8
X-2861	CRC	LKA136	560.9	23.8	30	189.7	5.3
X-2861	CRC	LKA136	1113.4	23.9	33	475.1	5.8
X-2861	CRC	binimetinib	254.5	20.9	0	0	0
X-2861	CRC	binimetinib	319.8	18.6	4	25.7	-11
X-2861	CRC	binimetinib	516.3	21.1	9	102.9	1
X-2861	CRC	binimetinib	697.8	20.4	14	174.2	-2.4
X-2861	CRC	binimetinib	852.8	19.5	17	235.1	-6.7
X-2861	CRC	binimetinib	968.3	20.5	20	280.5	-1.9
X-2861	CRC	binimetinib	1240.6	21.4	23	387.5	2.4
X-2861	CRC	untreated	226.8	22.7	0	0	0
X-2861	CRC	untreated	355.2	23	5	56.6	1.3
X-2861	CRC	untreated	374.9	22.6	11	65.3	-0.4
X-2861	CRC	untreated	425.8	22.7	14	87.7	0
X-2861	CRC	untreated	515.5	22.6	21	127.3	-0.4
X-2861	CRC	untreated	682.1	23.2	27	200.7	2.2
X-2861	CRC	untreated	755.4	22.8	30	233.1	0.4
X-2861	CRC	untreated	801	22.5	33	253.2	-0.9
X-2861	CRC	untreated	934.6	22.6	36	312.1	-0.4
X-2861	CRC	untreated	1003.1	21.3	41	342.3	-6.2
X-2861	CRC	untreated	1019	21.3	44	349.3	-6.2
X-2861	CRC	untreated	1232.4	22	47	443.4	-3.1
X-2861	CRC	LFW527 + binimetinib	212.93	23.39	0	0	0
X-2861	CRC	LFW527 + binimetinib	221.06	22.35	3	3.8	-4.4
X-2861	CRC	LFW527 + binimetinib	270.21	21.96	6	26.9	-6.1
X-2861	CRC	LFW527 + binimetinib	251.48	22.23	10	18.1	-5
X-2861	CRC	LFW527 + binimetinib	356.62	22.32	13	67.5	-4.6
X-2861	CRC	LFW527 + binimetinib	329.57	24.24	18	54.8	3.6
X-2861	CRC	LFW527 + binimetinib	255.78	22.69	21	20.1	-3
X-2861	CRC	LFW527 + binimetinib	260.98	23.01	24	22.6	-1.6
X-2861	CRC	LFW527 + binimetinib	271.97	22.6	27	27.7	-3.4
X-2861	CRC	LFW527 + binimetinib	303.14	23.34	31	42.4	-0.2
X-2861	CRC	LFW527 + binimetinib	388.92	23.03	34	82.7	-1.5
X-2861	CRC	LFW527 + binimetinib	366.22	22.43	37	72	-4.1
X-2861	CRC	LFW527 + binimetinib	512.78	22.27	41	140.8	-4.8
X-2861	CRC	LFW527 + binimetinib	397.27	23.43	45	86.6	0.2
X-2861	CRC	LFW527 + binimetinib	359.66	22.58	48	68.9	-3.5
X-2861	CRC	LFW527 + binimetinib	561.57	22.79	52	163.7	-2.6
X-2861	CRC	LFW527 + binimetinib	466.71	22.49	55	119.2	-3.8
X-2861	CRC	LFW527 + binimetinib	683.06	22.86	59	220.8	-2.3
X-2861	CRC	LFW527 + binimetinib	586.15	22.35	62	175.3	-4.4
X-2861	CRC	LFW527 + binimetinib	622.19	22.44	66	192.2	-4.1
X-2861	CRC	LFW527 + binimetinib	616.83	21.61	70	189.7	-7.6
X-2861	CRC	LFW527 + binimetinib	627.53	22.8	73	194.7	-2.5
X-2861	CRC	LFW527 + binimetinib	665.04	21.9	77	212.3	-6.4
X-2861	CRC	LFW527 + binimetinib	672.64	21.67	80	215.9	-7.4
X-2861	CRC	LFW527 + binimetinib	682.89	22.25	83	220.7	-4.9
X-2861	CRC	LFW527 + binimetinib	706.65	21.65	87	231.9	-7.4
X-2861	CRC	LFW527 + binimetinib	702.49	21.91	92	229.9	-6.3
X-2861	CRC	LFW527 + binimetinib	697.93	21.57	98	227.8	-7.8
X-2861	CRC	LFW527 + binimetinib	721.18	21.78	101	238.7	-6.9
X-2861	CRC	LFW527 + binimetinib	756.57	21.56	106	255.3	-7.8
X-2921	CM	BKM120	230	22	0	0	0
X-2921	CM	BKM120	256	22.5	2	11.3	2.3
X-2921	CM	BKM120	344.4	22.4	6	49.7	1.8
X-2921	CM	BKM120	550.9	22.5	11	139.5	2.3
X-2921	CM	BKM120	635.4	21.2	16	176.3	-3.6
X-2921	CM	BKM120	664.9	20.1	19	189.1	-8.6
X-2921	CM	BKM120	1119.3	21.2	23	386.7	-3.6
X-2921	CM	BKM120 + encorafenib	207.4	20.8	0	0	0
X-2921	CM	BKM120 + encorafenib	211.7	20.9	5	2.1	0.5
X-2921	CM	BKM120 + encorafenib	141.4	21.1	8	-31.8	1.4
X-2921	CM	BKM120 + encorafenib	84.3	21.8	12	-59.4	4.8
X-2921	CM	BKM120 + encorafenib	56.3	21.6	16	-72.8	3.8
X-2921	CM	BKM120 + encorafenib	0	22	22	-100	5.8
X-2921	CM	BKM120 + encorafenib	0	21.7	27	-100	4.3
X-2921	CM	BKM120 + encorafenib	0	22	31	-100	5.8
X-2921	CM	BKM120 + encorafenib	0	22	35	-100	5.8
X-2921	CM	BKM120 + encorafenib	0	22.1	38	-100	6.2
X-2921	CM	BKM120 + encorafenib	0	22	42	-100	5.8
X-2921	CM	BKM120 + encorafenib	0	22.2	45	-100	6.7
X-2921	CM	BKM120 + encorafenib	0	23	49	-100	10.6
X-2921	CM	BKM120 + encorafenib	0	22.6	56	-100	8.7
X-2921	CM	BKM120 + encorafenib	0	22.6	61	-100	8.7
X-2921	CM	BKM120 + encorafenib	0	23.3	64	-100	12
X-2921	CM	BKM120 + encorafenib	0	22.9	69	-100	10.1
X-2921	CM	BKM120 + encorafenib	0	21.2	72	-100	1.9
X-2921	CM	BKM120 + encorafenib	0	23	76	-100	10.6
X-2921	CM	BKM120 + encorafenib	0	23.7	79	-100	13.9
X-2921	CM	BKM120 + encorafenib	0	22.9	83	-100	10.1
X-2921	CM	BKM120 + encorafenib	0	22.8	89	-100	9.6
X-2921	CM	BKM120 + encorafenib	0	22.7	92	-100	9.1
X-2921	CM	BKM120 + encorafenib	0	23.5	96	-100	13
X-2921	CM	BKM120 + encorafenib	0	23.7	100	-100	13.9
X-2921	CM	BKM120 + encorafenib	0	24.4	105	-100	17.3
X-2921	CM	BKM120 + encorafenib	0	24.8	110	-100	19.2
X-2921	CM	BKM120 + encorafenib	0	23.9	113	-100	14.9
X-2921	CM	BKM120 + encorafenib	0	23.6	117	-100	13.5
X-2921	CM	BKM120 + encorafenib	0	25.1	126	-100	20.7
X-2921	CM	BKM120 + encorafenib	0	24.7	131	-100	18.8
X-2921	CM	BKM120 + encorafenib	0	24.2	140	-100	16.3
X-2921	CM	BKM120 + encorafenib	0	23.7	146	-100	13.9
X-2921	CM	BKM120 + encorafenib	0	22.7	166	-100	9.1
X-2921	CM	BKM120 + encorafenib	0	24	173	-100	15.4
X-2921	CM	BKM120 + encorafenib	0	24.3	180	-100	16.8
X-2921	CM	BKM120 + encorafenib	0	24.1	190	-100	15.9
X-2921	CM	BKM120 + encorafenib	0	24.7	198	-100	18.8
X-2921	CM	BKM120 + encorafenib	0	25.6	204	-100	23.1
X-2921	CM	BKM120 + encorafenib	0	24.7	212	-100	18.8
X-2921	CM	BKM120 + encorafenib	0	24.9	218	-100	19.7
X-2921	CM	BKM120 + encorafenib	0	24.6	226	-100	18.3
X-2921	CM	BKM120 + encorafenib	0	24.5	235	-100	17.8
X-2921	CM	BKM120 + encorafenib	0	24.6	243	-100	18.3
X-2921	CM	BKM120 + encorafenib	0	24.5	250	-100	17.8
X-2921	CM	BKM120 + encorafenib	0	25.6	255	-100	23.1
X-2921	CM	BKM120 + encorafenib	0	24.6	261	-100	18.3
X-2921	CM	BKM120 + encorafenib	0	24.3	272	-100	16.8
X-2921	CM	CGM097	205.2	21.6	0	0	0
X-2921	CM	CGM097	428.1	21.3	5	108.7	-1.4
X-2921	CM	CGM097	849.7	21.8	9	314.1	0.9
X-2921	CM	CGM097	1550.7	22.2	14	655.8	2.8
X-2921	CM	CLR457	229.2	25.6	0	0	0
X-2921	CM	CLR457	241.1	25.3	7	5.2	-1.2
X-2921	CM	CLR457	520.3	24.6	12	127	-3.9
X-2921	CM	CLR457	405.8	25.1	15	77.1	-2
X-2921	CM	CLR457	489.3	24.7	20	113.5	-3.5
X-2921	CM	CLR457	491.9	24.9	22	114.6	-2.7
X-2921	CM	dacarbazine	215.6	23.7	0	0	0
X-2921	CM	dacarbazine	78.4	23	6	-63.6	-3
X-2921	CM	dacarbazine	55.3	23.7	11	-74.4	0
X-2921	CM	dacarbazine	62.4	22.5	15	-71	-5.1
X-2921	CM	dacarbazine	40.7	23.3	19	-81.1	-1.7
X-2921	CM	dacarbazine	67.5	22.2	22	-68.7	-6.3
X-2921	CM	dacarbazine	63.8	22.8	26	-70.4	-3.8
X-2921	CM	dacarbazine	77.1	22.5	29	-64.3	-5.1
X-2921	CM	dacarbazine	106	23.2	33	-50.8	-2.1
X-2921	CM	dacarbazine	135.2	22.2	40	-37.3	-6.3
X-2921	CM	dacarbazine	242.6	21.5	45	12.5	-9.3
X-2921	CM	dacarbazine	294.4	21.5	48	36.5	-9.3
X-2921	CM	dacarbazine	388.8	22	53	80.3	-7.2
X-2921	CM	dacarbazine	480.2	21.9	55	122.7	-7.6
X-2921	CM	LDE225	217.7	22.8	0	0	0
X-2921	CM	LDE225	224.5	23	2	3.1	0.9
X-2921	CM	LDE225	358.7	22.6	6	64.7	-0.9
X-2921	CM	LDE225	501.6	22	11	130.4	-3.5
X-2921	CM	LDE225	625.7	22	16	187.4	-3.5
X-2921	CM	LDE225	585.8	21.8	19	169.1	-4.4
X-2921	CM	LDE225	638.7	21	23	193.3	-7.9
X-2921	CM	LDK378	208.1	23	0	0	0
X-2921	CM	LDK378	415.4	22.7	4	99.7	-1.3
X-2921	CM	LDK378	624.3	23.3	9	200	1.3
X-2921	CM	LDK378	980.1	21.4	14	371	-7
X-2921	CM	LDK378	1281	22.5	17	515.6	-2.2
X-2921	CM	LDK378	1690	21.6	21	712.2	-6.1
X-2921	CM	LEE011	198.5	21.6	0	0	0
X-2921	CM	LEE011	271.5	20.5	5	36.8	-5.1
X-2921	CM	LEE011	429.9	19.4	9	116.6	-10.2
X-2921	CM	LEE011	774.5	19.4	14	290.3	-10.2
X-2921	CM	LEE011	1039.6	18.1	19	423.9	-16.2
X-2921	CM	LEE011	951.8	19.5	22	379.6	-9.7
X-2921	CM	LEE011 + encorafenib	196	24.1	0	0	0
X-2921	CM	LEE011 + encorafenib	172.1	24.2	3	-12.2	0.4
X-2921	CM	LEE011 + encorafenib	222.9	22.6	7	13.7	-6.2
X-2921	CM	LEE011 + encorafenib	221.8	22.8	11	13.2	-5.4
X-2921	CM	LEE011 + encorafenib	241.1	23.3	17	23	-3.3
X-2921	CM	LEE011 + encorafenib	223	23.4	22	13.7	-2.9
X-2921	CM	LEE011 + encorafenib	213.2	23.1	26	8.8	-4.1
X-2921	CM	LEE011 + encorafenib	197.5	22.6	30	0.8	-6.2
X-2921	CM	LEE011 + encorafenib	174.1	23.2	33	-11.2	-3.7
X-2921	CM	LEE011 + encorafenib	172.8	25.6	37	-11.8	6.2
X-2921	CM	LEE011 + encorafenib	188.7	25.6	40	-3.7	6.2
X-2921	CM	LEE011 + encorafenib	202.2	26.3	44	3.2	9.1
X-2921	CM	LEE011 + encorafenib	255.9	25.7	51	30.6	6.6
X-2921	CM	LEE011 + encorafenib	311.7	25.9	56	59	7.5
X-2921	CM	LEE011 + encorafenib	330.7	25.3	59	68.7	5
X-2921	CM	LEE011 + encorafenib	426.5	24.1	64	117.6	0
X-2921	CM	LEE011 + encorafenib	555	24	66	183.2	-0.4
X-2921	CM	LEE011 + binimetinib	293.5	24.4	0	0	0
X-2921	CM	LEE011 + binimetinib	514.4	25.4	7	75.3	4.1
X-2921	CM	LEE011 + binimetinib	578.8	24.1	12	97.2	-1.2
X-2921	CM	LEE011 + binimetinib	510.3	24	15	73.9	-1.6
X-2921	CM	LEE011 + binimetinib	683.5	23.8	20	132.9	-2.5
X-2921	CM	LEE011 + binimetinib	672.4	24	22	129.1	-1.6
X-2921	CM	WNT974	219.3	24.8	0	0	0
X-2921	CM	WNT974	267.2	25	2	21.8	0.8
X-2921	CM	WNT974	279.8	24.6	7	27.6	-0.8
X-2921	CM	WNT974	374.5	23.9	12	70.8	-3.6
X-2921	CM	WNT974	390.4	24.1	15	78	-2.8
X-2921	CM	WNT974	416	24.1	19	89.7	-2.8
X-2921	CM	WNT974	558.4	24.8	23	154.7	0
X-2921	CM	LGW813	209.2	20.7	0	0	0
X-2921	CM	LGW813	240.1	20.8	2	14.8	0.5
X-2921	CM	LGW813	349.8	21.1	6	67.2	1.9
X-2921	CM	LGW813	592.5	21.8	11	183.2	5.3
X-2921	CM	LGW813	623.4	20.6	16	198	-0.5
X-2921	CM	LGW813	652.1	20.5	19	211.7	-1
X-2921	CM	LGW813	846.8	20.1	23	304.8	-2.9
X-2921	CM	encorafenib	201.6	26.2	0	0	0
X-2921	CM	encorafenib	477	25.8	5	136.6	-1.5
X-2921	CM	encorafenib	739.6	25.1	9	266.8	-4.2
X-2921	CM	encorafenib	1427.4	24.4	14	607.9	-6.9
X-2921	CM	encorafenib	1286.8	24.4	19	538.2	-6.9
X-2921	CM	encorafenib	1690	24.7	22	738.1	-5.7
X-2921	CM	encorafenib + binimetinib	201.6	23.5	0	0	0
X-2921	CM	encorafenib + binimetinib	289.1	23	4	43.4	-2.1
X-2921	CM	encorafenib + binimetinib	506.9	24.2	10	151.4	3
X-2921	CM	encorafenib + binimetinib	701.1	24.6	15	247.7	4.7
X-2921	CM	encorafenib + binimetinib	1028.5	24.6	19	410.1	4.7
X-2921	CM	binimetinib	220.5	23.3	0	0	0
X-2921	CM	binimetinib	335	23.5	2	51.9	0.9
X-2921	CM	binimetinib	671.5	23.6	6	204.6	1.3
X-2921	CM	binimetinib	795.9	24.1	11	261	3.4
X-2921	CM	binimetinib	1347	23.9	16	510.9	2.6
X-2921	CM	binimetinib	1468.4	23.8	19	565.9	2.1
X-2921	CM	TAS266	223.8	22.3	0	0	0
X-2921	CM	TAS266	576	23.2	5	157.3	4
X-2921	CM	TAS266	605.3	23.5	9	170.4	5.4
X-2921	CM	TAS266	978.4	23.4	14	337.2	4.9
X-2921	CM	TAS266	1152	22.4	19	414.7	0.4
X-2921	CM	TAS266	1327.1	21.8	22	492.9	-2.2
X-2921	CM	untreated	265.6	24.2	0	0	0
X-2921	CM	untreated	1481.4	24	5	457.8	-0.8
X-2921	CM	untreated	2788.9	24.2	9	950.1	0
X-2997	PDAC	abraxane	218.9	24.9	0	0	0
X-2997	PDAC	abraxane	268.1	24.8	2	22.5	-0.4
X-2997	PDAC	abraxane	323.2	24.5	5	47.6	-1.6
X-2997	PDAC	abraxane	442.2	24.9	8	102	0
X-2997	PDAC	abraxane	686.1	25	12	213.4	0.4
X-2997	PDAC	abraxane	773.8	25.4	15	253.5	2
X-2997	PDAC	abraxane	841.9	26.2	19	284.6	5.2
X-2997	PDAC	abraxane	1127.2	26.1	22	414.9	4.8
X-2997	PDAC	abraxane	1276.6	26.1	26	483.2	4.8
X-2997	PDAC	BKM120 + binimetinib	228.9	21.5	0	0	0
X-2997	PDAC	BKM120 + binimetinib	233.1	21.6	5	1.8	0.5
X-2997	PDAC	BKM120 + binimetinib	285.5	21.4	7	24.7	-0.5
X-2997	PDAC	BKM120 + binimetinib	256.5	21.5	10	12.1	0
X-2997	PDAC	BKM120 + binimetinib	220.2	22.6	12	-3.8	5.1
X-2997	PDAC	BKM120 + binimetinib	251.7	22.1	14	10	2.8
X-2997	PDAC	BKM120 + binimetinib	224.5	23	18	-1.9	7
X-2997	PDAC	BKM120 + binimetinib	267.7	21.8	20	17	1.4
X-2997	PDAC	BKM120 + binimetinib	195.9	22.4	25	-14.4	4.2
X-2997	PDAC	BKM120 + binimetinib	273.7	21.9	28	19.6	1.9
X-2997	PDAC	BKM120 + binimetinib	209.3	23.6	32	-8.6	9.8
X-2997	PDAC	BKM120 + binimetinib	292.1	22	35	27.6	2.3
X-2997	PDAC	BKM120 + binimetinib	381.1	22.5	39	66.5	4.7
X-2997	PDAC	BKM120 + binimetinib	416.9	22.1	42	82.1	2.8
X-2997	PDAC	BKM120 + binimetinib	351	22.6	46	53.3	5.1
X-2997	PDAC	BKM120 + binimetinib	252.1	23.3	49	10.1	8.4
X-2997	PDAC	BKM120 + binimetinib	223	22.4	53	-2.6	4.2
X-2997	PDAC	BKM120 + binimetinib	220.2	23.4	56	-3.8	8.8
X-2997	PDAC	BKM120 + binimetinib	297.8	24.3	60	30.1	13
X-2997	PDAC	BKM120 + binimetinib	606.7	24.1	63	165.1	12.1
X-2997	PDAC	BKM120 + binimetinib	474.8	23.2	67	107.4	7.9
X-2997	PDAC	BKM120 + binimetinib	446.3	23.6	70	95	9.8
X-2997	PDAC	BKM120 + binimetinib	684.5	22.9	74	199	6.5
X-2997	PDAC	BKM120 + binimetinib	646.2	22.9	81	182.3	6.5
X-2997	PDAC	BKM120 + binimetinib	578.7	23.9	84	152.8	11.2
X-2997	PDAC	BKM120 + binimetinib	1083.8	23.7	88	373.5	10.2
X-2997	PDAC	BKM120 + binimetinib	750.5	23.8	91	227.9	10.7
X-2997	PDAC	BKM120 + LDE225	214.7	23.9	0	0	0
X-2997	PDAC	BKM120 + LDE225	281.8	24.9	2	31.3	4.2
X-2997	PDAC	BKM120 + LDE225	243.8	24.6	5	13.6	2.9
X-2997	PDAC	BKM120 + LDE225	195.8	26	7	-8.8	8.8
X-2997	PDAC	BKM120 + LDE225	235.9	24.7	9	9.9	3.3
X-2997	PDAC	BKM120 + LDE225	335.5	24.6	13	56.3	2.9
X-2997	PDAC	BKM120 + LDE225	362.4	23.5	15	68.8	-1.7
X-2997	PDAC	BKM120 + LDE225	273.6	24	20	27.4	0.4
X-2997	PDAC	BKM120 + LDE225	359	22.6	23	67.2	-5.4
X-2997	PDAC	BKM120 + LDE225	318.6	23.3	27	48.4	-2.5
X-2997	PDAC	BKM120 + LDE225	429.2	22.2	30	99.9	-7.1
X-2997	PDAC	BKM120 + LDE225	352.5	20.9	34	64.2	-12.6
X-2997	PDAC	BKM120 + LDE225	319.8	22.5	35	49	-5.9
X-2997	PDAC	BKM120 + LDE225	322.1	20.8	37	50	-13
X-2997	PDAC	BKM120 + LDE225	401.5	20.4	41	87	-14.6
X-2997	PDAC	BKM120 + LDE225	274.8	22.1	44	28	-7.5
X-2997	PDAC	BKM120 + LDE225	357.5	21.9	48	66.5	-8.4
X-2997	PDAC	BKM120 + LDE225	362.8	22	51	69	-7.9
X-2997	PDAC	BKM120 + LDE225	324.3	22.4	55	51	-6.3
X-2997	PDAC	BKM120 + LDE225	316.6	22.2	58	47.5	-7.1
X-2997	PDAC	BKM120 + LDE225	365.6	22.9	62	70.3	-4.2
X-2997	PDAC	BKM120 + LDE225	320.9	22.9	65	49.5	-4.2
X-2997	PDAC	BKM120 + LDE225	339	23.5	69	57.9	-1.7
X-2997	PDAC	BKM120	207.5	25.9	0	0	0
X-2997	PDAC	BKM120	221.9	26.4	2	6.9	1.9
X-2997	PDAC	BKM120	196	26.2	6	-5.5	1.2
X-2997	PDAC	BKM120	231.9	25.4	9	11.8	-1.9
X-2997	PDAC	BKM120	333.6	28.4	13	60.8	9.7
X-2997	PDAC	BKM120	321.6	26.8	15	55	3.5
X-2997	PDAC	BKM120	288.7	27.5	20	39.1	6.2
X-2997	PDAC	BKM120	283.5	27.1	23	36.6	4.6
X-2997	PDAC	BKM120	356.7	27.6	27	71.9	6.6
X-2997	PDAC	BKM120	341.1	24.6	30	64.4	-5
X-2997	PDAC	BKM120	354.9	27.2	34	71	5
X-2997	PDAC	BKM120	314.3	26.3	37	51.5	1.5
X-2997	PDAC	BKM120	441.3	26.4	42	112.7	1.9
X-2997	PDAC	BKM120	420.3	26.6	45	102.6	2.7
X-2997	PDAC	BKM120	529.4	27.3	50	155.1	5.4
X-2997	PDAC	BKM120	506	26.5	52	143.9	2.3
X-2997	PDAC	BKM120	726.4	26.8	55	250.1	3.5
X-2997	PDAC	BKM120	760.9	26.8	58	266.7	3.5
X-2997	PDAC	BYL719	247.9	30.5	0	0	0
X-2997	PDAC	BYL719	302.2	30.6	2	21.9	0.3
X-2997	PDAC	BYL719	326.5	28.7	6	31.7	-5.9
X-2997	PDAC	BYL719	395.2	28.7	13	59.4	-5.9
X-2997	PDAC	BYL719	442.8	30.2	16	78.6	-1
X-2997	PDAC	BYL719	543.9	29.5	20	119.4	-3.3
X-2997	PDAC	BYL719	589.5	29.5	23	137.8	-3.3
X-2997	PDAC	BYL719	620.7	29.9	27	150.4	-2
X-2997	PDAC	BYL719	661.9	30.2	30	167	-1
X-2997	PDAC	BYL719	712.4	30.4	34	187.4	-0.3
X-2997	PDAC	BYL719	831.4	30.4	37	235.4	-0.3
X-2997	PDAC	BYL719 + LJM716	246.5	23.1	0	0	0
X-2997	PDAC	BYL719 + LJM716	350	21.6	6	42	-6.5
X-2997	PDAC	BYL719 + LJM716	366.4	21.5	9	48.6	-6.9
X-2997	PDAC	BYL719 + LJM716	374.4	22.6	13	51.9	-2.2
X-2997	PDAC	BYL719 + LJM716	365.8	22.1	16	48.4	-4.3
X-2997	PDAC	BYL719 + LJM716	362.7	21.3	20	47.1	-7.8
X-2997	PDAC	BYL719 + LJM716	367.6	22.5	23	49.1	-2.6
X-2997	PDAC	BYL719 + LJM716	439.5	20.4	27	78.3	-11.7
X-2997	PDAC	BYL719 + LJM716	454.9	18.8	30	84.5	-18.6
X-2997	PDAC	CLR457	249.9	26.7	0	0	0
X-2997	PDAC	CLR457	367.4	26.7	3	47	0
X-2997	PDAC	CLR457	406.5	26.6	10	62.7	-0.4
X-2997	PDAC	CLR457	490.3	26.1	13	96.2	-2.2
X-2997	PDAC	CLR457	559.5	26.8	17	123.9	0.4
X-2997	PDAC	CLR457	666.5	27.1	20	166.7	1.5
X-2997	PDAC	CLR457	685.9	26.6	24	174.5	-0.4
X-2997	PDAC	CLR457	700.5	26.8	27	180.3	0.4
X-2997	PDAC	CLR457	777.7	27.3	31	211.2	2.2
X-2997	PDAC	HDM201	246.9	23.9	0	0	0
X-2997	PDAC	HDM201	360.2	22.9	4	45.9	-4.2
X-2997	PDAC	HDM201	595.2	24.4	6	141.1	2.1
X-2997	PDAC	HDM201	766.1	24.6	11	210.3	2.9
X-2997	PDAC	HDM201	957.3	24	14	287.7	0.4
X-2997	PDAC	HDM201	1221.1	23.2	18	394.6	-2.9
X-2997	PDAC	HDM201	1504.4	23.4	21	509.3	-2.1
X-2997	PDAC	figitumumab" + binimetinib	256.4	25.6	0	0	0
X-2997	PDAC	figitumumab" + binimetinib	325	24.7	4	26.8	-3.5
X-2997	PDAC	figitumumab" + binimetinib	414.3	25	7	61.6	-2.3
X-2997	PDAC	figitumumab" + binimetinib	625.6	24.7	11	144	-3.5
X-2997	PDAC	figitumumab" + binimetinib	732.4	24.7	13	185.6	-3.5
X-2997	PDAC	figitumumab" + binimetinib	862.2	25.8	18	236.3	0.8
X-2997	PDAC	figitumumab" + binimetinib	880.1	25.2	21	243.3	-1.6
X-2997	PDAC	figitumumab" + binimetinib	1117	25.3	25	335.6	-1.2
X-2997	PDAC	figitumumab" + binimetinib	1192.3	24.8	28	365	-3.1
X-2997	PDAC	figitumumab" + binimetinib	1013.6	24.5	32	295.3	-4.3
X-2997	PDAC	figitumumab"	242.1	24.8	0	0	0
X-2997	PDAC	figitumumab"	334.6	25	3	38.2	0.8
X-2997	PDAC	figitumumab"	599	25.3	10	147.4	2
X-2997	PDAC	figitumumab"	641.3	25.9	13	164.9	4.4
X-2997	PDAC	figitumumab"	673.6	25.6	17	178.2	3.2
X-2997	PDAC	figitumumab"	907.9	25	20	275	0.8
X-2997	PDAC	figitumumab"	966	25.3	25	299	2
X-2997	PDAC	figitumumab"	1322.4	25.2	27	446.2	1.6
X-2997	PDAC	INC424 + binimetinib	229.7	25	0	0	0
X-2997	PDAC	INC424 + binimetinib	246.9	26	2	7.5	4
X-2997	PDAC	INC424 + binimetinib	276.8	26.6	5	20.5	6.4
X-2997	PDAC	INC424 + binimetinib	221.3	26.9	7	-3.7	7.6
X-2997	PDAC	INC424 + binimetinib	267	26.7	9	16.2	6.8
X-2997	PDAC	INC424 + binimetinib	319.9	25.8	13	39.3	3.2
X-2997	PDAC	INC424 + binimetinib	329	26.9	15	43.2	7.6
X-2997	PDAC	INC424 + binimetinib	460	26.7	23	100.3	6.8
X-2997	PDAC	INC424 + binimetinib	445	27.1	27	93.7	8.4
X-2997	PDAC	INC424 + binimetinib	492.7	26.8	30	114.5	7.2
X-2997	PDAC	INC424 + binimetinib	392.8	27.3	34	71	9.2
X-2997	PDAC	INC424 + binimetinib	449	27	37	95.5	8
X-2997	PDAC	INC424 + binimetinib	518.6	27.4	41	125.8	9.6
X-2997	PDAC	INC424 + binimetinib	573	27.3	44	149.5	9.2
X-2997	PDAC	INC424 + binimetinib	618.5	27.5	48	169.3	10
X-2997	PDAC	INC424 + binimetinib	564.6	27.4	51	145.8	9.6
X-2997	PDAC	INC424 + binimetinib	483.1	27.6	55	110.3	10.4
X-2997	PDAC	INC424 + binimetinib	718	27.3	58	212.6	9.2
X-2997	PDAC	INC424 + binimetinib	718.7	27	62	212.9	8
X-2997	PDAC	INC424 + binimetinib	805.3	31.6	65	250.6	26.4
X-2997	PDAC	INC424 + binimetinib	767.3	27.5	69	234	10
X-2997	PDAC	INC424 + binimetinib	898.8	27.1	76	291.3	8.4
X-2997	PDAC	INC424 + binimetinib	961.6	27.5	79	318.6	10
X-2997	PDAC	INC424 + binimetinib	983	27.5	83	327.9	10
X-2997	PDAC	INC424 + binimetinib	999.2	27.6	86	335	10.4
X-2997	PDAC	INC424 + binimetinib	1112.3	25.9	90	384.2	3.6
X-2997	PDAC	INC424 + binimetinib	1269.3	26.7	92	452.6	6.8
X-2997	PDAC	INC424 + binimetinib	1509	28.3	97	556.9	13.2
X-2997	PDAC	INC424 + binimetinib	1586.5	29.6	99	590.7	18.4
X-2997	PDAC	INC424	248.5	24	0	0	0
X-2997	PDAC	INC424	357.3	22.3	2	43.8	-7.1
X-2997	PDAC	INC424	484.3	23.1	6	94.9	-3.7
X-2997	PDAC	INC424	805.2	24	13	224	0
X-2997	PDAC	INC424	932.8	23.1	16	275.4	-3.7
X-2997	PDAC	INC424	1053.1	23.7	20	323.8	-1.3
X-2997	PDAC	INC424	1261.8	22.9	23	407.8	-4.6
X-2997	PDAC	INC424	1484.6	23.6	27	497.4	-1.7
X-2997	PDAC	LEE011	213.8	21.9	0	0	0
X-2997	PDAC	LEE011	385.5	22.7	4	80.3	3.7
X-2997	PDAC	LEE011	428.4	23.1	8	100.4	5.5
X-2997	PDAC	LEE011	400.6	23.1	11	87.4	5.5
X-2997	PDAC	LEE011	448.8	23.5	14	109.9	7.3
X-2997	PDAC	LEE011	616.6	24.1	18	188.4	10
X-2997	PDAC	LEE011	624.1	23.5	21	191.9	7.3
X-2997	PDAC	LEE011	607.9	23.8	25	184.3	8.7
X-2997	PDAC	LEE011	903.2	23.3	27	322.5	6.4
X-2997	PDAC	LKA136	282.8	24.4	0	0	0
X-2997	PDAC	LKA136	398.5	24.3	3	40.9	-0.4
X-2997	PDAC	LKA136	534.7	23.6	6	89.1	-3.3
X-2997	PDAC	LKA136	689.6	24.2	10	143.8	-0.8
X-2997	PDAC	LKA136	858.4	24.1	13	203.5	-1.2
X-2997	PDAC	LKA136	1000.7	23.2	17	253.9	-4.9
X-2997	PDAC	LKA136	1084	23.4	19	283.3	-4.1
X-2997	PDAC	LKA136	1369.8	23.6	24	384.4	-3.3
X-2997	PDAC	binimetinib	212.4	24.5	0	0	0
X-2997	PDAC	binimetinib	257.1	24.2	5	21	-1.2
X-2997	PDAC	binimetinib	276.3	23.1	7	30.1	-5.7
X-2997	PDAC	binimetinib	302.7	25.1	10	42.5	2.4
X-2997	PDAC	binimetinib	309.5	25	12	45.7	2
X-2997	PDAC	binimetinib	348	25.5	14	63.8	4.1
X-2997	PDAC	binimetinib	367.6	25.2	18	73.1	2.9
X-2997	PDAC	binimetinib	475.7	24.9	20	124	1.6
X-2997	PDAC	binimetinib	465.6	24.7	25	119.2	0.8
X-2997	PDAC	binimetinib	588.2	25.1	28	176.9	2.4
X-2997	PDAC	binimetinib	519.2	25.7	32	144.4	4.9
X-2997	PDAC	binimetinib	635	24.9	35	199	1.6
X-2997	PDAC	binimetinib	743	25	39	249.8	2
X-2997	PDAC	binimetinib	766.5	25.7	42	260.9	4.9
X-2997	PDAC	binimetinib	775.6	26.2	46	265.2	6.9
X-2997	PDAC	binimetinib	850.7	26.3	49	300.5	7.3
X-2997	PDAC	binimetinib	914.9	26.8	53	330.7	9.4
X-2997	PDAC	binimetinib	943.1	27	56	344	10.2
X-2997	PDAC	binimetinib	1084	26.1	60	410.4	6.5
X-2997	PDAC	binimetinib	1555.8	27	63	632.5	10.2
X-2997	PDAC	binimetinib-3.5mpk	264.1	25.4	0	0	0
X-2997	PDAC	binimetinib-3.5mpk	451.9	25.7	4	71.1	1.2
X-2997	PDAC	binimetinib-3.5mpk	592.4	25.5	7	124.3	0.4
X-2997	PDAC	binimetinib-3.5mpk	830.7	25.8	11	214.5	1.6
X-2997	PDAC	binimetinib-3.5mpk	773.3	25.6	13	192.8	0.8
X-2997	PDAC	binimetinib-3.5mpk	952.6	26.3	18	260.7	3.5
X-2997	PDAC	binimetinib-3.5mpk	1374.2	25.6	21	420.3	0.8
X-2997	PDAC	binimetinib-3.5mpk	1447	25.9	25	447.9	2
X-2997	PDAC	trametinib	275.1	23.1	0	0	0
X-2997	PDAC	trametinib	400	23.4	2	45.4	1.3
X-2997	PDAC	trametinib	381.4	23.4	6	38.6	1.3
X-2997	PDAC	trametinib	388.3	23.5	9	41.1	1.7
X-2997	PDAC	trametinib	394.2	23.7	12	43.3	2.6
X-2997	PDAC	trametinib	525.3	23.2	15	90.9	0.4
X-2997	PDAC	trametinib	543.8	23.6	19	97.7	2.2
X-2997	PDAC	trametinib	691.7	23.3	22	151.4	0.9
X-2997	PDAC	trametinib	642.3	23.2	26	133.5	0.4
X-2997	PDAC	trametinib	772.4	23.3	29	180.8	0.9
X-2997	PDAC	trametinib	1079	23.8	33	292.2	3
X-2997	PDAC	untreated	262.1	25.7	0	0	0
X-2997	PDAC	untreated	234.7	26.5	1	-10.5	3.1
X-2997	PDAC	untreated	397.7	26.9	5	51.7	4.7
X-2997	PDAC	untreated	420.3	25.1	8	60.4	-2.3
X-2997	PDAC	untreated	518.9	25.9	12	98	0.8
X-2997	PDAC	untreated	621.5	27.7	15	137.1	7.8
X-2997	PDAC	untreated	842.2	27.3	19	221.3	6.2
X-2997	PDAC	untreated	1084.1	27	22	313.6	5.1
X-2997	PDAC	untreated	1464.7	27.3	26	458.8	6.2
X-2997	PDAC	untreated	1452.2	27.8	28	454.1	8.2
X-3028	PDAC	abraxane	201.8	26.1	0	0	0
X-3028	PDAC	abraxane	169.2	25.8	3	-16.2	-1.1
X-3028	PDAC	abraxane	231.1	26.2	6	14.5	0.4
X-3028	PDAC	abraxane	291.5	27.3	10	44.4	4.6
X-3028	PDAC	abraxane	357	26.2	14	76.9	0.4
X-3028	PDAC	abraxane	356.2	27.3	17	76.5	4.6
X-3028	PDAC	abraxane	461.9	27.3	20	128.9	4.6
X-3028	PDAC	abraxane	609.4	27.3	24	202	4.6
X-3028	PDAC	BKM120 + binimetinib	249.2	30.8	0	0	0
X-3028	PDAC	BKM120 + binimetinib	320.4	30.3	1	28.6	-1.6
X-3028	PDAC	BKM120 + binimetinib	248	28.1	5	-0.5	-8.8
X-3028	PDAC	BKM120 + binimetinib	258	26.4	8	3.5	-14.3
X-3028	PDAC	BKM120 + binimetinib	236.3	27.7	12	-5.2	-10.1
X-3028	PDAC	BKM120 + binimetinib	191.7	28.7	14	-23.1	-6.8
X-3028	PDAC	BKM120 + binimetinib	275.4	28.1	19	10.5	-8.8
X-3028	PDAC	BKM120 + binimetinib	348.9	29	22	40	-5.8
X-3028	PDAC	BKM120 + binimetinib	299.5	28.5	27	20.2	-7.5
X-3028	PDAC	BKM120 + binimetinib	234.7	28.8	29	-5.8	-6.5
X-3028	PDAC	BKM120 + binimetinib	225.6	29	34	-9.5	-5.8
X-3028	PDAC	BKM120 + binimetinib	271.3	29.2	37	8.9	-5.2
X-3028	PDAC	BKM120 + binimetinib	255.6	29.1	40	2.6	-5.5
X-3028	PDAC	BKM120 + binimetinib	245.3	30	44	-1.6	-2.6
X-3028	PDAC	BKM120 + binimetinib	275.6	28.6	49	10.6	-7.1
X-3028	PDAC	BKM120 + binimetinib	323	28.3	51	29.6	-8.1
X-3028	PDAC	BKM120 + binimetinib	224.5	27.8	54	-9.9	-9.7
X-3028	PDAC	BKM120 + binimetinib	231	29.3	56	-7.3	-4.9
X-3028	PDAC	BKM120 + binimetinib	273.9	29.9	58	9.9	-2.9
X-3028	PDAC	BKM120 + binimetinib	304.6	29.1	62	22.2	-5.5
X-3028	PDAC	BKM120 + binimetinib	305	28	64	22.4	-9.1
X-3028	PDAC	BKM120 + binimetinib	280	29	69	12.4	-5.8
X-3028	PDAC	BKM120 + binimetinib	327.8	28	72	31.5	-9.1
X-3028	PDAC	BKM120 + binimetinib	265	28.9	76	6.3	-6.2
X-3028	PDAC	BKM120 + binimetinib	339.2	27.4	79	36.1	-11
X-3028	PDAC	BKM120 + binimetinib	300	28.4	83	20.4	-7.8
X-3028	PDAC	BKM120 + binimetinib	294.4	28.3	86	18.1	-8.1
X-3028	PDAC	BKM120 + binimetinib	271.1	28.5	90	8.8	-7.5
X-3028	PDAC	BKM120 + binimetinib	231	29.2	93	-7.3	-5.2
X-3028	PDAC	BKM120 + binimetinib	243.7	28.9	97	-2.2	-6.2
X-3028	PDAC	BKM120 + binimetinib	266.7	29.3	100	7	-4.9
X-3028	PDAC	BKM120 + binimetinib	273.5	29.6	104	9.8	-3.9
X-3028	PDAC	BKM120 + binimetinib	252.6	29	107	1.4	-5.8
X-3028	PDAC	BKM120 + binimetinib	327.2	29.9	111	31.3	-2.9
X-3028	PDAC	BKM120 + binimetinib	282.5	29.6	114	13.4	-3.9
X-3028	PDAC	BKM120 + binimetinib	314.4	27.8	118	26.2	-9.7
X-3028	PDAC	BKM120 + binimetinib	333	27.5	125	33.6	-10.7
X-3028	PDAC	BKM120 + binimetinib	323.2	28.6	128	29.7	-7.1
X-3028	PDAC	BKM120 + binimetinib	307.7	27.8	132	23.5	-9.7
X-3028	PDAC	BKM120 + binimetinib	256.6	27.9	135	3	-9.4
X-3028	PDAC	BKM120 + LDE225	220	26	0	0	0
X-3028	PDAC	BKM120 + LDE225	178.5	25.1	5	-18.9	-3.5
X-3028	PDAC	BKM120 + LDE225	166.3	25.2	7	-24.4	-3.1
X-3028	PDAC	BKM120 + LDE225	177.9	25.2	10	-19.1	-3.1
X-3028	PDAC	BKM120 + LDE225	167.7	24.9	14	-23.8	-4.2
X-3028	PDAC	BKM120 + LDE225	177	24.6	18	-19.5	-5.4
X-3028	PDAC	BKM120 + LDE225	178.9	23.2	20	-18.7	-10.8
X-3028	PDAC	BKM120 + LDE225	135.9	19.6	25	-38.2	-24.6
X-3028	PDAC	BKM120	242.4	24.4	0	0	0
X-3028	PDAC	BKM120	208.7	24	2	-13.9	-1.6
X-3028	PDAC	BKM120	233.4	23.9	6	-3.7	-2
X-3028	PDAC	BKM120	239.3	23.1	9	-1.3	-5.3
X-3028	PDAC	BKM120	313.5	23.9	13	29.3	-2
X-3028	PDAC	BKM120	326.7	24.5	16	34.8	0.4
X-3028	PDAC	BKM120	249.8	24.3	20	3.1	-0.4
X-3028	PDAC	BKM120	287.2	24.4	23	18.5	0
X-3028	PDAC	BKM120	291.5	24.5	27	20.3	0.4
X-3028	PDAC	BKM120	344.2	23.9	30	42	-2
X-3028	PDAC	BKM120	383.1	24.3	34	58	-0.4
X-3028	PDAC	BKM120	329	24.5	36	35.7	0.4
X-3028	PDAC	BKM120	375.3	25.2	41	54.8	3.3
X-3028	PDAC	BKM120	265.2	24.9	44	9.4	2
X-3028	PDAC	BKM120	307.9	24.6	48	27	0.8
X-3028	PDAC	BKM120	305.5	24.4	51	26	0
X-3028	PDAC	BKM120	308.1	24.8	55	27.1	1.6
X-3028	PDAC	BKM120	367.9	23.9	58	51.8	-2
X-3028	PDAC	BKM120	336.3	24.5	63	38.7	0.4
X-3028	PDAC	BKM120	284.7	25.1	66	17.5	2.9
X-3028	PDAC	BKM120	275.1	25.1	71	13.5	2.9
X-3028	PDAC	BKM120	304.8	24.6	73	25.7	0.8
X-3028	PDAC	BKM120	338.5	24.8	76	39.6	1.6
X-3028	PDAC	BKM120	235.9	24	79	-2.7	-1.6
X-3028	PDAC	BKM120	403.9	24.1	84	66.6	-1.2
X-3028	PDAC	BKM120	446.7	23.7	87	84.3	-2.9
X-3028	PDAC	BKM120	414.3	24	91	70.9	-1.6
X-3028	PDAC	BKM120	511.4	23.8	94	111	-2.5
X-3028	PDAC	BKM120	483.5	24.7	97	99.5	1.2
X-3028	PDAC	BYL719 + LJM716	237.7	25.5	0	0	0
X-3028	PDAC	BYL719 + LJM716	248	25.6	3	4.3	0.4
X-3028	PDAC	BYL719 + LJM716	313.1	25.4	6	31.7	-0.4
X-3028	PDAC	BYL719 + LJM716	381.5	24.8	10	60.5	-2.7
X-3028	PDAC	BYL719 + LJM716	413.8	25.3	17	74.1	-0.8
X-3028	PDAC	BYL719 + LJM716	451.5	25.1	20	89.9	-1.6
X-3028	PDAC	BYL719 + LJM716	542.5	26.7	24	128.2	4.7
X-3028	PDAC	BYL719 + LJM716	596.3	26.5	27	150.9	3.9
X-3028	PDAC	BYL719 + LJM716	616.8	25.5	31	159.5	0
X-3028	PDAC	BYL719 + LJM716	718.6	25	34	202.3	-2
X-3028	PDAC	BYL719 + LJM716	752.5	25.3	38	216.6	-0.8
X-3028	PDAC	BYL719	244.2	28.2	0	0	0
X-3028	PDAC	BYL719	302.8	28.5	3	24	1.1
X-3028	PDAC	BYL719	324.4	27.9	7	32.8	-1.1
X-3028	PDAC	BYL719	372.1	29.2	10	52.4	3.5
X-3028	PDAC	BYL719	383.2	28.5	14	56.9	1.1
X-3028	PDAC	BYL719	387.2	28.4	17	58.6	0.7
X-3028	PDAC	BYL719	391.6	28.4	21	60.4	0.7
X-3028	PDAC	BYL719	400.4	28.4	24	64	0.7
X-3028	PDAC	BYL719	403	28.3	30	65	0.4
X-3028	PDAC	BYL719	403.5	28.3	35	65.2	0.4
X-3028	PDAC	BYL719	409.1	28.6	38	67.5	1.4
X-3028	PDAC	BYL719	426.9	28.3	42	74.8	0.4
X-3028	PDAC	BYL719	443.1	27.8	45	81.4	-1.4
X-3028	PDAC	BYL719	449.7	28.1	50	84.2	-0.4
X-3028	PDAC	BYL719	455	28.2	52	86.3	0
X-3028	PDAC	BYL719	447.9	27.2	56	83.4	-3.5
X-3028	PDAC	BYL719	382.7	27.9	59	56.7	-1.1
X-3028	PDAC	BYL719	353.9	28.3	63	44.9	0.4
X-3028	PDAC	BYL719	377	28.2	66	54.4	0
X-3028	PDAC	BYL719	389.7	28.5	70	59.6	1.1
X-3028	PDAC	BYL719	398.8	28.7	73	63.3	1.8
X-3028	PDAC	BYL719	351.4	28	77	43.9	-0.7
X-3028	PDAC	BYL719	299.8	27.8	80	22.8	-1.4
X-3028	PDAC	BYL719	269.2	28.1	84	10.2	-0.4
X-3028	PDAC	BYL719	271.8	28.7	87	11.3	1.8
X-3028	PDAC	BYL719	276.1	29.4	91	13.1	4.3
X-3028	PDAC	CLR457	224.2	26.2	0	0	0
X-3028	PDAC	CLR457	223.5	26.5	3	-0.3	1.1
X-3028	PDAC	CLR457	228.1	26.5	6	1.7	1.1
X-3028	PDAC	CLR457	232.4	25.1	10	3.7	-4.2
X-3028	PDAC	CLR457	240.8	27	17	7.4	3.1
X-3028	PDAC	CLR457	247.5	27.6	20	10.4	5.3
X-3028	PDAC	CLR457	264.2	28.4	24	17.8	8.4
X-3028	PDAC	CLR457	280.2	27.6	27	25	5.3
X-3028	PDAC	CLR457	284.9	26.8	31	27.1	2.3
X-3028	PDAC	CLR457	319.1	26.8	34	42.3	2.3
X-3028	PDAC	CLR457	330.7	26.7	38	47.5	1.9
X-3028	PDAC	CLR457	369.2	26.6	41	64.7	1.5
X-3028	PDAC	CLR457	388.6	27.9	47	73.3	6.5
X-3028	PDAC	CLR457	401.1	27.2	52	78.9	3.8
X-3028	PDAC	CLR457	412.2	27	55	83.9	3.1
X-3028	PDAC	CLR457	408.9	27.5	59	82.4	5
X-3028	PDAC	CLR457	421.6	27.7	62	88	5.7
X-3028	PDAC	CLR457	460	27.9	67	105.2	6.5
X-3028	PDAC	CLR457	464.3	27.7	69	107.1	5.7
X-3028	PDAC	CLR457	473.1	26.9	73	111	2.7
X-3028	PDAC	CLR457	484.6	27.1	76	116.1	3.4
X-3028	PDAC	CLR457	491.9	27.2	80	119.4	3.8
X-3028	PDAC	CLR457	521.9	27.5	83	132.8	5
X-3028	PDAC	CLR457	539.4	27.9	87	140.6	6.5
X-3028	PDAC	CLR457	553.7	27.1	90	147	3.4
X-3028	PDAC	HDM201	206.8	26.8	0	0	0
X-3028	PDAC	HDM201	203.9	26.3	3	-1.4	-1.9
X-3028	PDAC	HDM201	203.2	23.5	6	-1.7	-12.3
X-3028	PDAC	HDM201	221	24.7	10	6.9	-7.8
X-3028	PDAC	HDM201	229.6	25.8	12	11	-3.7
X-3028	PDAC	HDM201	246.4	24.5	17	19.1	-8.6
X-3028	PDAC	HDM201	282.6	24.8	20	36.7	-7.5
X-3028	PDAC	HDM201	356.4	23.5	24	72.3	-12.3
X-3028	PDAC	HDM201	357.2	23.6	27	72.7	-11.9
X-3028	PDAC	HDM201	331.7	20.8	31	60.4	-22.4
X-3028	PDAC	figitumumab"	206.3	24.1	0	0	0
X-3028	PDAC	figitumumab"	272.3	24	2	32	-0.4
X-3028	PDAC	figitumumab"	198.7	24.1	8	-3.7	0
X-3028	PDAC	figitumumab"	341.2	24	12	65.4	-0.4
X-3028	PDAC	figitumumab"	393.7	23.9	15	90.8	-0.8
X-3028	PDAC	figitumumab"	390.1	23.8	19	89.1	-1.2
X-3028	PDAC	figitumumab"	547.9	24.3	21	165.6	0.8
X-3028	PDAC	figitumumab"	499.6	24.3	22	142.2	0.8
X-3028	PDAC	figitumumab"	483.9	25.2	26	134.6	4.6
X-3028	PDAC	figitumumab"	654.7	24.8	30	217.4	2.9
X-3028	PDAC	figitumumab"	693.8	24.8	33	236.3	2.9
X-3028	PDAC	figitumumab"	669.2	24.6	36	224.4	2.1
X-3028	PDAC	figitumumab"	850.1	24.8	40	312.1	2.9
X-3028	PDAC	figitumumab"	939.9	24.7	42	355.6	2.5
X-3028	PDAC	figitumumab" + binimetinib	212.5	26.3	0	0	0
X-3028	PDAC	figitumumab" + binimetinib	379.4	26.5	3	78.5	0.8
X-3028	PDAC	figitumumab" + binimetinib	264.8	25.3	7	24.6	-3.8
X-3028	PDAC	figitumumab" + binimetinib	440	26.6	10	107.1	1.1
X-3028	PDAC	figitumumab" + binimetinib	447.8	26.5	14	110.7	0.8
X-3028	PDAC	figitumumab" + binimetinib	362.9	26.6	17	70.8	1.1
X-3028	PDAC	figitumumab" + binimetinib	359.4	26	21	69.1	-1.1
X-3028	PDAC	figitumumab" + binimetinib	302.9	25.7	24	42.5	-2.3
X-3028	PDAC	figitumumab" + binimetinib	497.6	25.6	28	134.2	-2.7
X-3028	PDAC	figitumumab" + binimetinib	405.4	26.2	30	90.8	-0.4
X-3028	PDAC	figitumumab" + binimetinib	447.1	26.7	35	110.4	1.5
X-3028	PDAC	figitumumab" + binimetinib	484.1	26.9	38	127.8	2.3
X-3028	PDAC	figitumumab" + binimetinib	545.2	27.5	42	156.6	4.6
X-3028	PDAC	figitumumab" + binimetinib	364.1	25.4	45	71.3	-3.4
X-3028	PDAC	figitumumab" + binimetinib	575.7	27	49	170.9	2.7
X-3028	PDAC	figitumumab" + binimetinib	404.9	26.3	52	90.5	0
X-3028	PDAC	figitumumab" + binimetinib	659.3	26.2	57	210.3	-0.4
X-3028	PDAC	INC424 + binimetinib	292	24.6	0	0	0
X-3028	PDAC	INC424 + binimetinib	328.7	23.1	4	12.6	-6.1
X-3028	PDAC	INC424 + binimetinib	351.1	24.2	7	20.2	-1.6
X-3028	PDAC	INC424 + binimetinib	445.7	23.9	11	52.6	-2.8
X-3028	PDAC	INC424 + binimetinib	371.9	24.3	13	27.4	-1.2
X-3028	PDAC	INC424 + binimetinib	476.3	24.7	18	63.1	0.4
X-3028	PDAC	INC424 + binimetinib	479.7	25.6	21	64.3	4.1
X-3028	PDAC	INC424 + binimetinib	442.9	24.9	26	51.7	1.2
X-3028	PDAC	INC424 + binimetinib	547.1	25.1	28	87.4	2
X-3028	PDAC	INC424 + binimetinib	537	26	33	83.9	5.7
X-3028	PDAC	INC424 + binimetinib	506.2	25.5	36	73.4	3.7
X-3028	PDAC	INC424 + binimetinib	557.9	25.7	39	91.1	4.5
X-3028	PDAC	INC424 + binimetinib	498.3	25.9	43	70.7	5.3
X-3028	PDAC	INC424 + binimetinib	600.6	25.3	48	105.7	2.8
X-3028	PDAC	INC424 + binimetinib	628.6	25.2	50	115.3	2.4
X-3028	PDAC	INC424 + binimetinib	676.5	25.1	53	131.7	2
X-3028	PDAC	INC424 + binimetinib	671.8	25.4	55	130.1	3.3
X-3028	PDAC	INC424 + binimetinib	800.2	25.2	57	174	2.4
X-3028	PDAC	INC424	205.2	25.1	0	0	0
X-3028	PDAC	INC424	225.3	25.2	3	9.8	0.4
X-3028	PDAC	INC424	228.7	27.2	10	11.5	8.4
X-3028	PDAC	INC424	228.3	27.5	13	11.3	9.6
X-3028	PDAC	INC424	224.6	27.7	17	9.5	10.4
X-3028	PDAC	INC424	240.1	27.1	20	17	8
X-3028	PDAC	INC424	243.8	27	24	18.8	7.6
X-3028	PDAC	INC424	275.4	27.1	27	34.2	8
X-3028	PDAC	INC424	300.2	27.1	31	46.3	8
X-3028	PDAC	INC424	291.6	26.4	34	42.1	5.2
X-3028	PDAC	INC424	295.1	27.2	40	43.8	8.4
X-3028	PDAC	INC424	305.5	27.1	45	48.9	8
X-3028	PDAC	INC424	308.3	26.5	48	50.2	5.6
X-3028	PDAC	INC424	344	24	52	67.6	-4.4
X-3028	PDAC	INC424	355.4	24.4	55	73.2	-2.8
X-3028	PDAC	INC424	394.2	24.7	60	92.1	-1.6
X-3028	PDAC	INC424	452.6	24.9	62	120.6	-0.8
X-3028	PDAC	INC424	466	26	66	127.1	3.6
X-3028	PDAC	INC424	499.9	25.3	69	143.6	0.8
X-3028	PDAC	INC424	515.1	25.7	73	151	2.4
X-3028	PDAC	INC424	589.3	25.7	76	187.2	2.4
X-3028	PDAC	INC424	603.2	26.8	80	194	6.8
X-3028	PDAC	INC424	622.8	25.3	83	203.5	0.8
X-3028	PDAC	INC424	642.7	24.9	87	213.2	-0.8
X-3028	PDAC	INC424	671.7	25	90	227.3	-0.4
X-3028	PDAC	LEE011	216.9	26.1	0	0	0
X-3028	PDAC	LEE011	171.6	27.1	2	-20.9	3.8
X-3028	PDAC	LEE011	129.8	27.4	5	-40.2	5
X-3028	PDAC	LEE011	136.2	27.3	8	-37.2	4.6
X-3028	PDAC	LEE011	145.4	28.3	12	-33	8.4
X-3028	PDAC	LEE011	174	28.8	15	-19.8	10.3
X-3028	PDAC	LEE011	135.3	28.9	19	-37.6	10.7
X-3028	PDAC	LEE011	142.7	28.7	22	-34.2	10
X-3028	PDAC	LEE011	217.3	29.5	26	0.2	13
X-3028	PDAC	LEE011	223.7	29.7	30	3.1	13.8
X-3028	PDAC	LEE011	239.3	29.1	33	10.3	11.5
X-3028	PDAC	LEE011	189	29	36	-12.9	11.1
X-3028	PDAC	LEE011	193.2	29.6	40	-10.9	13.4
X-3028	PDAC	LEE011	226.6	29.9	43	4.5	14.6
X-3028	PDAC	LEE011	207.6	29	47	-4.3	11.1
X-3028	PDAC	LEE011	242.1	28.8	50	11.6	10.3
X-3028	PDAC	LEE011	244	30.6	54	12.5	17.2
X-3028	PDAC	LEE011	247.5	29.3	57	14.1	12.3
X-3028	PDAC	LEE011	199.6	30	61	-8	14.9
X-3028	PDAC	LEE011	265.3	28.7	64	22.3	10
X-3028	PDAC	LEE011	226.3	29.9	68	4.3	14.6
X-3028	PDAC	LEE011	223.7	28.4	71	3.1	8.8
X-3028	PDAC	LEE011	173.6	30	75	-20	14.9
X-3028	PDAC	LEE011	194.8	29.4	78	-10.2	12.6
X-3028	PDAC	LEE011	267.7	29.7	82	23.4	13.8
X-3028	PDAC	LEE011	295.6	30.5	85	36.3	16.9
X-3028	PDAC	LEE011	302.5	30.8	89	39.5	18
X-3028	PDAC	LEE011	350.9	29.2	93	61.8	11.9
X-3028	PDAC	LEE011	426.3	29.5	96	96.5	13
X-3028	PDAC	LEE011	408.1	29.8	99	88.2	14.2
X-3028	PDAC	WNT974	250.2	26.1	0	0	0
X-3028	PDAC	WNT974	299.1	25.9	4	19.5	-0.8
X-3028	PDAC	WNT974	256.1	24.9	7	2.4	-4.6
X-3028	PDAC	WNT974	337.9	23.9	11	35.1	-8.4
X-3028	PDAC	WNT974	338.2	24.5	14	35.2	-6.1
X-3028	PDAC	WNT974	295.4	20.9	18	18.1	-19.9
X-3028	PDAC	LKA136	250.5	25.2	0	0	0
X-3028	PDAC	LKA136	240.1	25.1	1	-4.2	-0.4
X-3028	PDAC	LKA136	268.6	24.9	5	7.2	-1.2
X-3028	PDAC	LKA136	359.6	25.9	8	43.6	2.8
X-3028	PDAC	LKA136	276	25.5	12	10.2	1.2
X-3028	PDAC	LKA136	346.5	26.1	15	38.3	3.6
X-3028	PDAC	LKA136	300	25.6	19	19.8	1.6
X-3028	PDAC	LKA136	291	26.8	22	16.2	6.3
X-3028	PDAC	LKA136	272.3	26.6	26	8.7	5.6
X-3028	PDAC	LKA136	345.9	26.9	29	38.1	6.7
X-3028	PDAC	LKA136	354.7	26.6	33	41.6	5.6
X-3028	PDAC	LKA136	344.8	27.2	35	37.6	7.9
X-3028	PDAC	LKA136	314.4	26.2	40	25.5	4
X-3028	PDAC	LKA136	294.7	27	44	17.6	7.1
X-3028	PDAC	LKA136	312.1	25.5	47	24.6	1.2
X-3028	PDAC	LKA136	267.2	NA	49	6.7	1.2
X-3028	PDAC	LKA136	291	26.7	51	16.2	6
X-3028	PDAC	LKA136	309.2	27.6	55	23.4	9.5
X-3028	PDAC	LKA136	310.6	26.4	58	24	4.8
X-3028	PDAC	LKA136	321.8	26.2	61	28.5	4
X-3028	PDAC	LKA136	323.5	25.8	64	29.1	2.4
X-3028	PDAC	LKA136	312.3	26.4	70	24.7	4.8
X-3028	PDAC	LKA136	326.8	27.1	73	30.5	7.5
X-3028	PDAC	LKA136	328.6	27.2	75	31.2	7.9
X-3028	PDAC	LKA136	295.1	27.2	78	17.8	7.9
X-3028	PDAC	LKA136	397.4	26.8	82	58.6	6.3
X-3028	PDAC	LKA136	418.4	26.3	85	67	4.4
X-3028	PDAC	LKA136	412.2	27.5	89	64.6	9.1
X-3028	PDAC	LKA136	362.8	27.6	93	44.8	9.5
X-3028	PDAC	LKA136	403	28	96	60.9	11.1
X-3028	PDAC	binimetinib	210.7	24.4	0	0	0
X-3028	PDAC	binimetinib	265.4	27	4	26	10.7
X-3028	PDAC	binimetinib	240.4	25.4	6	14.1	4.1
X-3028	PDAC	binimetinib	373.6	25.1	11	77.3	2.9
X-3028	PDAC	binimetinib	345.4	25.2	14	63.9	3.3
X-3028	PDAC	binimetinib	281.5	25.2	19	33.6	3.3
X-3028	PDAC	binimetinib	284.7	25.4	21	35.1	4.1
X-3028	PDAC	binimetinib	381	25.5	26	80.8	4.5
X-3028	PDAC	binimetinib	303	25.4	29	43.8	4.1
X-3028	PDAC	binimetinib	366.6	25	32	74	2.5
X-3028	PDAC	binimetinib	369	25.6	36	75.1	4.9
X-3028	PDAC	binimetinib	427	25.1	41	102.7	2.9
X-3028	PDAC	binimetinib	357.1	25	43	69.5	2.5
X-3028	PDAC	binimetinib	379.2	25.5	46	80	4.5
X-3028	PDAC	binimetinib	323	25.7	48	53.3	5.3
X-3028	PDAC	binimetinib	496	26.5	50	135.4	8.6
X-3028	PDAC	binimetinib	347	26.3	54	64.7	7.8
X-3028	PDAC	binimetinib	420.6	25.8	56	99.6	5.7
X-3028	PDAC	binimetinib	359.7	25.9	61	70.7	6.1
X-3028	PDAC	binimetinib	371.4	25.9	64	76.3	6.1
X-3028	PDAC	binimetinib	777.9	26.3	68	269.2	7.8
X-3028	PDAC	binimetinib	613.7	26.1	71	191.3	7
X-3028	PDAC	binimetinib	579.5	26.5	75	175	8.6
X-3028	PDAC	binimetinib	622.1	26.2	78	195.3	7.4
X-3028	PDAC	binimetinib	705	26.2	82	234.6	7.4
X-3028	PDAC	binimetinib	588.6	27.1	85	179.4	11.1
X-3028	PDAC	binimetinib	614.2	26.5	89	191.5	8.6
X-3028	PDAC	binimetinib	705.7	26.9	92	234.9	10.2
X-3028	PDAC	binimetinib	1118.6	27.3	96	430.9	11.9
X-3028	PDAC	binimetinib	999.6	27.6	99	374.4	13.1
X-3028	PDAC	binimetinib	907.7	27.3	103	330.8	11.9
X-3028	PDAC	binimetinib	1051.6	27.2	106	399.1	11.5
X-3028	PDAC	binimetinib	1083.9	27.7	110	414.4	13.5
X-3028	PDAC	binimetinib	945.5	26.9	117	348.7	10.2
X-3028	PDAC	binimetinib	1042.7	27.2	120	394.9	11.5
X-3028	PDAC	binimetinib	1222.5	27.2	124	480.2	11.5
X-3028	PDAC	binimetinib	1104.8	27.2	127	424.3	11.5
X-3028	PDAC	binimetinib-3.5mpk	226.3	28.3	0	0	0
X-3028	PDAC	binimetinib-3.5mpk	423.8	28.3	2	87.3	0
X-3028	PDAC	binimetinib-3.5mpk	381.3	27.3	6	68.5	-3.5
X-3028	PDAC	binimetinib-3.5mpk	525.5	27.1	9	132.2	-4.2
X-3028	PDAC	binimetinib-3.5mpk	590.6	28.8	13	161	1.8
X-3028	PDAC	binimetinib-3.5mpk	712.3	28.8	15	214.8	1.8
X-3028	PDAC	binimetinib-3.5mpk	539	28.6	20	138.2	1.1
X-3028	PDAC	binimetinib-3.5mpk	720.6	28.1	23	218.4	-0.7
X-3028	PDAC	binimetinib-3.5mpk	614.2	28.5	27	171.4	0.7
X-3028	PDAC	trametinib	200.4	25.4	0	0	0
X-3028	PDAC	trametinib	227.3	25.7	2	13.4	1.2
X-3028	PDAC	trametinib	251.1	25.5	6	25.3	0.4
X-3028	PDAC	trametinib	241.2	25.3	9	20.4	-0.4
X-3028	PDAC	trametinib	214.3	26.4	12	6.9	3.9
X-3028	PDAC	trametinib	266.3	26.1	15	32.9	2.8
X-3028	PDAC	trametinib	306.1	26.8	19	52.7	5.5
X-3028	PDAC	trametinib	268.1	26.2	22	33.8	3.1
X-3028	PDAC	trametinib	376.1	26	26	87.7	2.4
X-3028	PDAC	trametinib	305.3	25.9	29	52.3	2
X-3028	PDAC	trametinib	439.5	26	33	119.3	2.4
X-3028	PDAC	untreated	225.6	23.2	0	0	0
X-3028	PDAC	untreated	260.9	NA	2	15.6	0
X-3028	PDAC	untreated	325.8	24.4	6	44.4	5.2
X-3028	PDAC	untreated	407.3	24.8	8	80.5	6.9
X-3028	PDAC	untreated	597.3	24.4	13	164.8	5.2
X-3028	PDAC	untreated	668.7	24.5	17	196.4	5.6
X-3028	PDAC	untreated	796.9	25.2	20	253.2	8.6
X-3028	PDAC	untreated	817.1	NA	22	262.2	8.6
X-3028	PDAC	untreated	794.9	25.1	24	252.3	8.2
X-3028	PDAC	untreated	1170.9	24.8	28	419	6.9
X-3028	PDAC	untreated	1144.7	24.9	29	407.4	7.3
X-3029	NSCLC	BGJ398	184.5	23.9	0	0	0
X-3029	NSCLC	BGJ398	189.8	22.4	3	2.9	-6.3
X-3029	NSCLC	BGJ398	161.7	23.3	7	-12.4	-2.5
X-3029	NSCLC	BGJ398	191.1	23.6	10	3.6	-1.3
X-3029	NSCLC	BGJ398	189.1	24.5	14	2.5	2.5
X-3029	NSCLC	BGJ398	219.5	24.3	17	19	1.7
X-3029	NSCLC	BGJ398	216.5	24.8	21	17.3	3.8
X-3029	NSCLC	BGJ398	223.7	25	23	21.2	4.6
X-3029	NSCLC	BGJ398	258.5	25	28	40.1	4.6
X-3029	NSCLC	BGJ398	296.1	25	31	60.5	4.6
X-3029	NSCLC	BGJ398	259.8	24.5	35	40.8	2.5
X-3029	NSCLC	BGJ398	312.6	25.9	38	69.4	8.4
X-3029	NSCLC	BGJ398	335	25.7	42	81.6	7.5
X-3029	NSCLC	BGJ398	395.3	25.8	45	114.3	7.9
X-3029	NSCLC	BGJ398	377.2	25.6	49	104.4	7.1
X-3029	NSCLC	BKM120 + binimetinib	194.3	25.2	0	0	0
X-3029	NSCLC	BKM120 + binimetinib	202	26.7	3	4	6
X-3029	NSCLC	BKM120 + binimetinib	135.3	25.9	7	-30.4	2.8
X-3029	NSCLC	BKM120 + binimetinib	146.9	26	10	-24.4	3.2
X-3029	NSCLC	BKM120 + binimetinib	190.6	26.2	14	-1.9	4
X-3029	NSCLC	BKM120 + binimetinib	150.3	25.6	17	-22.6	1.6
X-3029	NSCLC	BKM120 + binimetinib	150.8	26.2	21	-22.4	4
X-3029	NSCLC	BKM120 + binimetinib	94.5	25.9	23	-51.4	2.8
X-3029	NSCLC	BKM120 + binimetinib	119.3	26.2	28	-38.6	4
X-3029	NSCLC	BKM120 + binimetinib	94.4	26.3	31	-51.4	4.4
X-3029	NSCLC	BKM120 + binimetinib	66.8	26.6	35	-65.6	5.6
X-3029	NSCLC	BKM120 + binimetinib	68.1	26.2	38	-65	4
X-3029	NSCLC	BKM120 + binimetinib	100.2	26.6	42	-48.4	5.6
X-3029	NSCLC	BKM120 + binimetinib	112.9	26.4	45	-41.9	4.8
X-3029	NSCLC	BKM120 + binimetinib	73	26.2	49	-62.4	4
X-3029	NSCLC	BKM120 + binimetinib	91.9	25.3	52	-52.7	0.4
X-3029	NSCLC	BKM120 + binimetinib	101	25.1	56	-48	-0.4
X-3029	NSCLC	BKM120 + binimetinib	67.4	26.1	59	-65.3	3.6
X-3029	NSCLC	BKM120 + binimetinib	92.6	26.8	63	-52.3	6.3
X-3029	NSCLC	BKM120 + binimetinib	69	26.4	66	-64.5	4.8
X-3029	NSCLC	BKM120 + binimetinib	66.5	27	70	-65.8	7.1
X-3029	NSCLC	BKM120 + binimetinib	87.2	26.2	73	-55.1	4
X-3029	NSCLC	BKM120 + binimetinib	60.3	26.3	77	-69	4.4
X-3029	NSCLC	BKM120 + binimetinib	66.3	26.2	80	-65.9	4
X-3029	NSCLC	BKM120 + binimetinib	52.6	26.5	84	-72.9	5.2
X-3029	NSCLC	BKM120 + binimetinib	101.1	26.3	86	-48	4.4
X-3029	NSCLC	BKM120 + binimetinib	66.1	27	88	-66	7.1
X-3029	NSCLC	BKM120	203.5	23.6	0	0	0
X-3029	NSCLC	BKM120	141.8	23.7	3	-30.3	0.4
X-3029	NSCLC	BKM120	152.6	24.1	7	-25	2.1
X-3029	NSCLC	BKM120	86.2	23.9	10	-57.6	1.3
X-3029	NSCLC	BKM120	90.2	24	14	-55.7	1.7
X-3029	NSCLC	BKM120	55.5	24.4	17	-72.7	3.4
X-3029	NSCLC	BKM120	87.8	24.8	21	-56.9	5.1
X-3029	NSCLC	BKM120	83.9	24.7	24	-58.8	4.7
X-3029	NSCLC	BKM120	64.8	25.3	28	-68.2	7.2
X-3029	NSCLC	BKM120	59.6	25.1	30	-70.7	6.4
X-3029	NSCLC	BKM120	77	25.6	35	-62.2	8.5
X-3029	NSCLC	BKM120	51.1	26.1	38	-74.9	10.6
X-3029	NSCLC	BKM120	67.8	26.1	42	-66.7	10.6
X-3029	NSCLC	BKM120	67	26.4	45	-67.1	11.9
X-3029	NSCLC	BKM120	60.5	26.4	49	-70.3	11.9
X-3029	NSCLC	BKM120	101.4	25.8	52	-50.2	9.3
X-3029	NSCLC	BKM120	62.7	26.4	56	-69.2	11.9
X-3029	NSCLC	BKM120	87.1	26.6	59	-57.2	12.7
X-3029	NSCLC	BKM120	98.8	27.2	63	-51.4	15.3
X-3029	NSCLC	BKM120	91.4	28	66	-55.1	18.6
X-3029	NSCLC	BKM120	81.1	27.4	70	-60.1	16.1
X-3029	NSCLC	BKM120	58.8	27.6	73	-71.1	16.9
X-3029	NSCLC	BKM120	89.5	27.3	77	-56	15.7
X-3029	NSCLC	BKM120	91.2	27.7	80	-55.2	17.4
X-3029	NSCLC	BKM120	75.7	27.1	84	-62.8	14.8
X-3029	NSCLC	BKM120	84	27.5	87	-58.7	16.5
X-3029	NSCLC	BKM120	47.4	27.5	91	-76.7	16.5
X-3029	NSCLC	BYL719 + LJM716	202.3	31.2	0	0	0
X-3029	NSCLC	BYL719 + LJM716	193	29.5	4	-4.6	-5.4
X-3029	NSCLC	BYL719 + LJM716	134.3	28.5	6	-33.6	-8.7
X-3029	NSCLC	BYL719 + LJM716	85.2	27.8	11	-57.9	-10.9
X-3029	NSCLC	BYL719 + LJM716	63.6	28	14	-68.6	-10.3
X-3029	NSCLC	BYL719 + LJM716	56.5	28	18	-72.1	-10.3
X-3029	NSCLC	BYL719 + LJM716	62.9	28.5	21	-68.9	-8.7
X-3029	NSCLC	BYL719 + LJM716	39	28.4	25	-80.7	-9
X-3029	NSCLC	BYL719 + LJM716	44	25.9	28	-78.3	-17
X-3029	NSCLC	BYL719 + LJM716	46.1	26.1	32	-77.2	-16.3
X-3029	NSCLC	BYL719 + LJM716	45.2	26.8	35	-77.7	-14.1
X-3029	NSCLC	BYL719 + LJM716	43.1	25.8	39	-78.7	-17.3
X-3029	NSCLC	BYL719	192.7	27.8	0	0	0
X-3029	NSCLC	BYL719	202.9	26.5	3	5.3	-4.7
X-3029	NSCLC	BYL719	194.1	26	7	0.7	-6.5
X-3029	NSCLC	BYL719	84.6	26.2	10	-56.1	-5.8
X-3029	NSCLC	BYL719	107.1	26.1	14	-44.4	-6.1
X-3029	NSCLC	BYL719	98.4	26.3	16	-48.9	-5.4
X-3029	NSCLC	BYL719	79.6	27.1	21	-58.7	-2.5
X-3029	NSCLC	BYL719	79.6	26.5	24	-58.7	-4.7
X-3029	NSCLC	BYL719	83.1	26.6	28	-56.9	-4.3
X-3029	NSCLC	BYL719	101.6	27	31	-47.3	-2.9
X-3029	NSCLC	BYL719	84.3	27.1	35	-56.3	-2.5
X-3029	NSCLC	BYL719	69	27.2	38	-64.2	-2.2
X-3029	NSCLC	BYL719	70	27.3	42	-63.7	-1.8
X-3029	NSCLC	BYL719	91.2	27	45	-52.7	-2.9
X-3029	NSCLC	BYL719	113.4	28.3	49	-41.2	1.8
X-3029	NSCLC	BYL719	144.4	28	52	-25.1	0.7
X-3029	NSCLC	BYL719	91.5	28.6	56	-52.5	2.9
X-3029	NSCLC	BYL719	42.2	28.1	59	-78.1	1.1
X-3029	NSCLC	BYL719	58.6	27.1	63	-69.6	-2.5
X-3029	NSCLC	BYL719	74.5	27.5	66	-61.3	-1.1
X-3029	NSCLC	BYL719	52.2	28.3	70	-72.9	1.8
X-3029	NSCLC	BYL719	72.1	30.1	73	-62.6	8.3
X-3029	NSCLC	BYL719	65.8	27.9	77	-65.9	0.4
X-3029	NSCLC	BYL719	84.8	27.2	79	-56	-2.2
X-3029	NSCLC	BYL719	58.3	25.9	84	-69.7	-6.8
X-3029	NSCLC	BYL719 + LGH447	199.4	28	0	0	0
X-3029	NSCLC	BYL719 + LGH447	224.9	25.9	3	12.8	-7.5
X-3029	NSCLC	BYL719 + LGH447	93.6	25.7	7	-53.1	-8.2
X-3029	NSCLC	BYL719 + LGH447	107.5	25.8	10	-46.1	-7.9
X-3029	NSCLC	BYL719 + LGH447	84.9	26.1	14	-57.4	-6.8
X-3029	NSCLC	BYL719 + LGH447	86.1	25.7	16	-56.8	-8.2
X-3029	NSCLC	BYL719 + LGH447	81.5	25.9	21	-59.1	-7.5
X-3029	NSCLC	BYL719 + LGH447	90.1	25.1	24	-54.8	-10.4
X-3029	NSCLC	BYL719 + LGH447	56.5	25.1	28	-71.7	-10.4
X-3029	NSCLC	BYL719 + LGH447	49.6	24.3	31	-75.1	-13.2
X-3029	NSCLC	BYL719 + LGH447	46.4	23.7	35	-76.7	-15.4
X-3029	NSCLC	BYL719 + LGH447	38.2	24.7	38	-80.8	-11.8
X-3029	NSCLC	CGM097	205.4	25.7	0	0	0
X-3029	NSCLC	CGM097	184.3	25.9	4	-10.3	0.8
X-3029	NSCLC	CGM097	113.1	26.5	7	-44.9	3.1
X-3029	NSCLC	CGM097	137.5	27.5	11	-33.1	7
X-3029	NSCLC	CGM097	139.2	28.5	14	-32.2	10.9
X-3029	NSCLC	CGM097	137	28.1	18	-33.3	9.3
X-3029	NSCLC	CGM097	89.5	27.6	21	-56.4	7.4
X-3029	NSCLC	CGM097	70.7	27.4	25	-65.6	6.6
X-3029	NSCLC	CGM097	97	27.3	28	-52.8	6.2
X-3029	NSCLC	CGM097	58.9	27.6	32	-71.3	7.4
X-3029	NSCLC	CGM097	82	27.4	34	-60.1	6.6
X-3029	NSCLC	CGM097	49.6	27.8	39	-75.9	8.2
X-3029	NSCLC	CGM097	38.2	28.3	42	-81.4	10.1
X-3029	NSCLC	CGM097	64.2	28.2	61	-68.7	9.7
X-3029	NSCLC	CGM097	68.6	28	64	-66.6	8.9
X-3029	NSCLC	CGM097	39.3	27.5	67	-80.9	7
X-3029	NSCLC	CGM097	63.5	26.8	70	-69.1	4.3
X-3029	NSCLC	CGM097	53.9	26.6	74	-73.8	3.5
X-3029	NSCLC	CGM097	47.1	26.9	77	-77.1	4.7
X-3029	NSCLC	CGM097	80.2	27.7	85	-61	7.8
X-3029	NSCLC	CGM097	59.7	26.6	88	-70.9	3.5
X-3029	NSCLC	CGM097	54.1	27.1	90	-73.7	5.4
X-3029	NSCLC	CKX620	218.3	28.9	0	0	0
X-3029	NSCLC	CKX620	196.1	27.1	3	-10.2	-6.2
X-3029	NSCLC	CKX620	117	26.4	7	-46.4	-8.7
X-3029	NSCLC	CKX620	114	23.5	10	-47.8	-18.7
X-3029	NSCLC	CKX620	163.2	23.1	14	-25.2	-20.1
X-3029	NSCLC	CKX620	59.5	24.8	16	-72.7	-14.2
X-3029	NSCLC	CKX620	95	27.8	21	-56.5	-3.8
X-3029	NSCLC	CKX620	89.4	27.5	24	-59	-4.8
X-3029	NSCLC	CKX620	96.9	27.7	28	-55.6	-4.2
X-3029	NSCLC	CKX620	118.8	27.5	31	-45.6	-4.8
X-3029	NSCLC	CKX620	102.2	26.6	35	-53.2	-8
X-3029	NSCLC	CKX620	70.1	26.3	38	-67.9	-9
X-3029	NSCLC	CKX620	92.7	27.4	42	-57.5	-5.2
X-3029	NSCLC	CLR457	220.9	24.8	0	0	0
X-3029	NSCLC	CLR457	120	22.6	5	-45.7	-8.9
X-3029	NSCLC	CLR457	76.1	23.2	8	-65.6	-6.5
X-3029	NSCLC	CLR457	81.5	22.8	12	-63.1	-8.1
X-3029	NSCLC	CLR457	81.1	23.6	15	-63.3	-4.8
X-3029	NSCLC	CLR457	104.8	23.6	19	-52.6	-4.8
X-3029	NSCLC	CLR457	120.2	23.7	22	-45.6	-4.4
X-3029	NSCLC	CLR457	120.6	23.7	26	-45.4	-4.4
X-3029	NSCLC	CLR457	117.3	23.8	29	-46.9	-4
X-3029	NSCLC	CLR457	132	24.2	33	-40.2	-2.4
X-3029	NSCLC	CLR457	137.7	23.9	35	-37.7	-3.6
X-3029	NSCLC	CLR457	130.7	24.6	40	-40.8	-0.8
X-3029	NSCLC	CLR457	147.2	24.7	43	-33.4	-0.4
X-3029	NSCLC	CLR457	162.4	25.4	47	-26.5	2.4
X-3029	NSCLC	CLR457	170	25.1	50	-23	1.2
X-3029	NSCLC	CLR457	159.6	24.7	54	-27.8	-0.4
X-3029	NSCLC	CLR457	184.8	25.1	57	-16.3	1.2
X-3029	NSCLC	CLR457	192.5	24.9	61	-12.9	0.4
X-3029	NSCLC	CLR457	177.6	25.2	64	-19.6	1.6
X-3029	NSCLC	CLR457	165	25.9	68	-25.3	4.4
X-3029	NSCLC	CLR457	208.2	26.1	71	-5.7	5.2
X-3029	NSCLC	CLR457	210.1	25.9	75	-4.9	4.4
X-3029	NSCLC	CLR457	156.9	25.2	78	-29	1.6
X-3029	NSCLC	CLR457	190.6	25.3	82	-13.7	2
X-3029	NSCLC	CLR457	156.3	25.3	85	-29.2	2
X-3029	NSCLC	CLR457	186	25.9	89	-15.8	4.4
X-3029	NSCLC	CLR457	173.2	25.8	92	-21.6	4
X-3029	NSCLC	CLR457	185.4	26.3	96	-16.1	6
X-3029	NSCLC	HDM201	210.5	23.1	0	0	0
X-3029	NSCLC	HDM201	185	22.6	3	-12.1	-2.2
X-3029	NSCLC	HDM201	95.5	22.6	7	-54.6	-2.2
X-3029	NSCLC	HDM201	141.8	23.5	10	-32.6	1.7
X-3029	NSCLC	HDM201	148.3	23.4	14	-29.5	1.3
X-3029	NSCLC	HDM201	156.2	23.1	17	-25.8	0
X-3029	NSCLC	HDM201	182.1	24.7	21	-13.5	6.9
X-3029	NSCLC	HDM201	194.2	24.5	24	-7.7	6.1
X-3029	NSCLC	HDM201	269.3	23.5	28	27.9	1.7
X-3029	NSCLC	HDM201	195	23.2	30	-7.4	0.4
X-3029	NSCLC	HDM201	245	23.1	35	16.4	0
X-3029	NSCLC	HDM201	224.4	22	38	6.6	-4.8
X-3029	NSCLC	HDM201	251.5	18.4	42	19.5	-20.3
X-3029	NSCLC	cetuximab	197.1	33.8	0	0	0
X-3029	NSCLC	cetuximab	141.6	33.3	4	-28.2	-1.5
X-3029	NSCLC	cetuximab	126.7	33.5	7	-35.7	-0.9
X-3029	NSCLC	cetuximab	96.1	33.6	11	-51.2	-0.6
X-3029	NSCLC	cetuximab	125.4	33.7	14	-36.4	-0.3
X-3029	NSCLC	cetuximab	75.6	33.7	18	-61.6	-0.3
X-3029	NSCLC	cetuximab	48.5	33	21	-75.4	-2.4
X-3029	NSCLC	cetuximab	75.3	33	25	-61.8	-2.4
X-3029	NSCLC	cetuximab	143.8	32.8	28	-27	-3
X-3029	NSCLC	cetuximab	53.1	32.6	32	-73.1	-3.6
X-3029	NSCLC	cetuximab	78	32.6	34	-60.4	-3.6
X-3029	NSCLC	cetuximab	45.5	32	39	-76.9	-5.3
X-3029	NSCLC	cetuximab	54.7	32.6	42	-72.2	-3.6
X-3029	NSCLC	cetuximab	13.6	32.4	61	-93.1	-4.1
X-3029	NSCLC	cetuximab	35.7	30	64	-81.9	-11.2
X-3029	NSCLC	cetuximab	43.9	29	67	-77.7	-14.2
X-3029	NSCLC	erlotinib	209.5	26.6	0	0	0
X-3029	NSCLC	erlotinib	218.3	23.8	4	4.2	-10.5
X-3029	NSCLC	erlotinib	115.3	21.5	6	-45	-19.2
X-3029	NSCLC	erlotinib	89.3	25.9	11	-57.4	-2.6
X-3029	NSCLC	erlotinib	114.2	25.5	14	-45.5	-4.1
X-3029	NSCLC	erlotinib	105.2	25.7	18	-49.8	-3.4
X-3029	NSCLC	erlotinib	105.9	25.6	21	-49.5	-3.8
X-3029	NSCLC	erlotinib	97.9	26.1	25	-53.3	-1.9
X-3029	NSCLC	erlotinib	71.9	24.1	28	-65.7	-9.4
X-3029	NSCLC	erlotinib	80.2	25.8	32	-61.7	-3
X-3029	NSCLC	erlotinib	104.2	27.2	35	-50.3	2.3
X-3029	NSCLC	erlotinib	79.8	27	39	-61.9	1.5
X-3029	NSCLC	erlotinib	90.2	25.7	42	-56.9	-3.4
X-3029	NSCLC	erlotinib	139.8	26.7	46	-33.3	0.4
X-3029	NSCLC	erlotinib	87.9	27.2	49	-58	2.3
X-3029	NSCLC	erlotinib	89.4	26.2	53	-57.3	-1.5
X-3029	NSCLC	erlotinib	114.8	27.1	56	-45.2	1.9
X-3029	NSCLC	erlotinib	70.5	25.7	60	-66.3	-3.4
X-3029	NSCLC	erlotinib	75.8	26.1	63	-63.8	-1.9
X-3029	NSCLC	erlotinib	97.2	27	67	-53.6	1.5
X-3029	NSCLC	erlotinib	80.8	26	69	-61.4	-2.3
X-3029	NSCLC	erlotinib	60.2	26.2	74	-71.3	-1.5
X-3029	NSCLC	erlotinib	73.6	26.1	77	-64.9	-1.9
X-3029	NSCLC	erlotinib	56.9	23.9	96	-72.8	-10.2
X-3029	NSCLC	HSP990	197.9	31	0	0	0
X-3029	NSCLC	HSP990	187.4	28.3	4	-5.3	-8.7
X-3029	NSCLC	HSP990	120.6	28.3	7	-39.1	-8.7
X-3029	NSCLC	HSP990	86.5	28.5	11	-56.3	-8.1
X-3029	NSCLC	HSP990	114.5	27.1	14	-42.1	-12.6
X-3029	NSCLC	HSP990	87.2	25.6	18	-55.9	-17.4
X-3029	NSCLC	INC280	213.9	22	0	0	0
X-3029	NSCLC	INC280	133.4	22.6	5	-37.6	2.7
X-3029	NSCLC	INC280	103.2	23.4	8	-51.8	6.4
X-3029	NSCLC	INC280	114.8	23	12	-46.3	4.5
X-3029	NSCLC	INC280	94.9	23.4	15	-55.6	6.4
X-3029	NSCLC	INC280	164.5	24.2	19	-23.1	10
X-3029	NSCLC	INC280	132.6	24.3	22	-38	10.5
X-3029	NSCLC	INC280	158.2	24.6	26	-26	11.8
X-3029	NSCLC	INC280	161.2	23.8	29	-24.6	8.2
X-3029	NSCLC	INC280	292.5	24	33	36.7	9.1
X-3029	NSCLC	INC280	217.2	24.7	35	1.5	12.3
X-3029	NSCLC	INC280	217.6	23.9	40	1.7	8.6
X-3029	NSCLC	INC280	218.2	23.6	43	2	7.3
X-3029	NSCLC	INC280	248.5	23.5	47	16.2	6.8
X-3029	NSCLC	INC280	234.4	24.2	50	9.6	10
X-3029	NSCLC	INC280	286	23.7	54	33.7	7.7
X-3029	NSCLC	INC280	337.5	23.6	57	57.8	7.3
X-3029	NSCLC	INC280	349.8	23.3	61	63.5	5.9
X-3029	NSCLC	INC280	316	23.7	64	47.7	7.7
X-3029	NSCLC	INC280	285.2	25	68	33.3	13.6
X-3029	NSCLC	INC280	349.1	25.3	71	63.2	15
X-3029	NSCLC	INC280	408.4	24.9	75	90.9	13.2
X-3029	NSCLC	INC280	394.2	24	78	84.3	9.1
X-3029	NSCLC	INC280	418.7	24	82	95.7	9.1
X-3029	NSCLC	INC280	423.5	24	85	98	9.1
X-3029	NSCLC	INC280	481.8	24.1	89	125.2	9.5
X-3029	NSCLC	INC280	537.8	24.5	92	151.4	11.4
X-3029	NSCLC	INC280	620.1	25.5	96	189.9	15.9
X-3029	NSCLC	LCL161 + paclitaxel	211.3	25.1	0	0	0
X-3029	NSCLC	LCL161 + paclitaxel	194.1	23.8	4	-8.1	-5.2
X-3029	NSCLC	LCL161 + paclitaxel	114.9	24.4	7	-45.6	-2.8
X-3029	NSCLC	LCL161 + paclitaxel	178.8	25.3	11	-15.4	0.8
X-3029	NSCLC	LCL161 + paclitaxel	76	26.5	14	-64	5.6
X-3029	NSCLC	LCL161 + paclitaxel	96.7	25	18	-54.2	-0.4
X-3029	NSCLC	LCL161 + paclitaxel	84.8	25.4	20	-59.9	1.2
X-3029	NSCLC	LCL161 + paclitaxel	108.7	25.4	25	-48.6	1.2
X-3029	NSCLC	LCL161 + paclitaxel	86.5	26.6	28	-59.1	6
X-3029	NSCLC	LCL161 + paclitaxel	101.2	26.2	32	-52.1	4.4
X-3029	NSCLC	LCL161 + paclitaxel	118.8	26.2	35	-43.8	4.4
X-3029	NSCLC	LCL161 + paclitaxel	111.4	25.5	39	-47.3	1.6
X-3029	NSCLC	LCL161 + paclitaxel	106	25.6	42	-49.8	2
X-3029	NSCLC	LCL161 + paclitaxel	131.5	25.7	46	-37.8	2.4
X-3029	NSCLC	LCL161 + paclitaxel	151.9	26.5	49	-28.1	5.6
X-3029	NSCLC	LCL161 + paclitaxel	98.4	23.5	53	-53.4	-6.4
X-3029	NSCLC	LCL161 + paclitaxel	134.7	25.6	56	-36.3	2
X-3029	NSCLC	LCL161 + paclitaxel	82.4	23.2	60	-61	-7.6
X-3029	NSCLC	LCL161 + paclitaxel	85.6	25.2	63	-59.5	0.4
X-3029	NSCLC	LCL161 + paclitaxel	74.5	20	67	-64.7	-20.3
X-3029	NSCLC	LCL161 + paclitaxel	80.4	22.8	70	-61.9	-9.2
X-3029	NSCLC	LCL161 + paclitaxel	60.5	16.4	74	-71.4	-34.7
X-3029	NSCLC	LEE011	181.3	24.5	0	0	0
X-3029	NSCLC	LEE011	192.2	24.8	3	6	1.2
X-3029	NSCLC	LEE011	65.1	23.4	7	-64.1	-4.5
X-3029	NSCLC	LEE011	108.6	24	10	-40.1	-2
X-3029	NSCLC	LEE011	65.4	24.6	14	-63.9	0.4
X-3029	NSCLC	LEE011	71.9	25.4	17	-60.3	3.7
X-3029	NSCLC	LEE011	80.2	25.7	21	-55.8	4.9
X-3029	NSCLC	LEE011	94.3	25.8	24	-48	5.3
X-3029	NSCLC	LEE011	92.4	26.6	28	-49	8.6
X-3029	NSCLC	LEE011	53.7	26	30	-70.4	6.1
X-3029	NSCLC	LEE011	77.6	25.9	35	-57.2	5.7
X-3029	NSCLC	LEE011	87.6	26.3	38	-51.7	7.3
X-3029	NSCLC	LEE011	96.3	26.8	42	-46.9	9.4
X-3029	NSCLC	LEE011	111.6	26.7	45	-38.4	9
X-3029	NSCLC	LEE011	115	26.1	49	-36.6	6.5
X-3029	NSCLC	LEE011	111.9	26.1	52	-38.3	6.5
X-3029	NSCLC	LEE011	158.7	27.3	56	-12.5	11.4
X-3029	NSCLC	LEE011	150.5	26.7	59	-17	9
X-3029	NSCLC	LEE011	148.9	26.1	63	-17.9	6.5
X-3029	NSCLC	LEE011	225.2	27.6	66	24.2	12.7
X-3029	NSCLC	LEE011	176	26.8	70	-2.9	9.4
X-3029	NSCLC	LEE011	251.2	27.6	73	38.6	12.7
X-3029	NSCLC	LEE011	268.6	26.8	77	48.2	9.4
X-3029	NSCLC	LEE011	297.1	27.2	80	63.9	11
X-3029	NSCLC	LEE011	238.4	27.7	84	31.5	13.1
X-3029	NSCLC	LEE011	350.1	26.9	87	93.1	9.8
X-3029	NSCLC	LEE011	316.1	27.3	91	74.4	11.4
X-3029	NSCLC	LGH447	201.2	28.3	0	0	0
X-3029	NSCLC	LGH447	206.2	27.5	3	2.5	-2.8
X-3029	NSCLC	LGH447	65.1	26.6	7	-67.6	-6
X-3029	NSCLC	LGH447	65.1	25.9	10	-67.6	-8.5
X-3029	NSCLC	LGH447	82	26.1	14	-59.2	-7.8
X-3029	NSCLC	LGH447	52.7	26.7	17	-73.8	-5.7
X-3029	NSCLC	LGH447	62.7	26.5	21	-68.8	-6.4
X-3029	NSCLC	LGH447	85.4	26.3	24	-57.6	-7.1
X-3029	NSCLC	LGH447	76.6	27	28	-61.9	-4.6
X-3029	NSCLC	LGH447	69.2	26.8	30	-65.6	-5.3
X-3029	NSCLC	LGH447	55.9	27.1	35	-72.2	-4.2
X-3029	NSCLC	LGH447	75	27.4	38	-62.7	-3.2
X-3029	NSCLC	LGH447	95.5	27.5	42	-52.5	-2.8
X-3029	NSCLC	LGH447	92.4	27.8	45	-54.1	-1.8
X-3029	NSCLC	LGH447	86.2	27.3	49	-57.2	-3.5
X-3029	NSCLC	LGH447	73.6	27.6	52	-63.4	-2.5
X-3029	NSCLC	LGH447	84.1	28.6	56	-58.2	1.1
X-3029	NSCLC	LGH447	120.8	28.3	59	-40	0
X-3029	NSCLC	LGH447	115.2	29.7	63	-42.7	4.9
X-3029	NSCLC	LGH447	117.4	30.2	66	-41.7	6.7
X-3029	NSCLC	LGH447	106.5	29.6	70	-47.1	4.6
X-3029	NSCLC	LGH447	111.5	29.8	73	-44.6	5.3
X-3029	NSCLC	LGH447	104.6	29.8	77	-48	5.3
X-3029	NSCLC	LGH447	140.6	30.3	80	-30.1	7.1
X-3029	NSCLC	LGH447	123.6	30.9	84	-38.6	9.2
X-3029	NSCLC	LGH447	123.2	30.6	87	-38.8	8.1
X-3029	NSCLC	LGH447	156.9	30.1	91	-22	6.4
X-3029	NSCLC	LLM871	196.2	28.2	0	0	0
X-3029	NSCLC	LLM871	200.4	26.9	3	2.1	-4.6
X-3029	NSCLC	LLM871	195.4	26.9	7	-0.4	-4.6
X-3029	NSCLC	LLM871	198.2	27.2	10	1	-3.5
X-3029	NSCLC	LLM871	122.4	27	14	-37.6	-4.3
X-3029	NSCLC	LLM871	199.5	26.2	17	1.7	-7.1
X-3029	NSCLC	LLM871	132.2	27.2	21	-32.6	-3.5
X-3029	NSCLC	LLM871	91.9	27.9	24	-53.2	-1.1
X-3029	NSCLC	LLM871	109.4	28	28	-44.2	-0.7
X-3029	NSCLC	LLM871	108.6	27.6	31	-44.6	-2.1
X-3029	NSCLC	LLM871	117.1	29.3	35	-40.3	3.9
X-3029	NSCLC	LLM871	110.9	28.4	38	-43.5	0.7
X-3029	NSCLC	LLM871	133.5	28.5	42	-32	1.1
X-3029	NSCLC	LLM871	60.3	28	45	-69.3	-0.7
X-3029	NSCLC	LLM871	102	28.5	49	-48	1.1
X-3029	NSCLC	LLM871	127.8	28.3	52	-34.9	0.4
X-3029	NSCLC	LLM871	126.8	29.1	56	-35.4	3.2
X-3029	NSCLC	LLM871	125.6	28.6	58	-36	1.4
X-3029	NSCLC	LLM871	91.6	28.8	63	-53.3	2.1
X-3029	NSCLC	LLM871	89.1	29.1	66	-54.6	3.2
X-3029	NSCLC	LLM871	146.7	28.9	85	-25.2	2.5
X-3029	NSCLC	LLM871	110.9	28.2	88	-43.5	0
X-3029	NSCLC	LLM871	90.8	28.7	91	-53.7	1.8
X-3029	NSCLC	LLM871	177.9	28.7	94	-9.3	1.8
X-3029	NSCLC	LLM871	178.7	29.5	98	-8.9	4.6
X-3029	NSCLC	LLM871	200.4	29	112	2.1	2.8
X-3029	NSCLC	LLM871	171.2	28.7	114	-12.7	1.8
X-3029	NSCLC	binimetinib	213.9	23.6	0	0	0
X-3029	NSCLC	binimetinib	96.7	23.2	5	-54.8	-1.7
X-3029	NSCLC	binimetinib	83.8	23.7	8	-60.8	0.4
X-3029	NSCLC	binimetinib	88.5	23.7	12	-58.6	0.4
X-3029	NSCLC	binimetinib	70.7	23.9	15	-66.9	1.3
X-3029	NSCLC	binimetinib	43.7	24.9	19	-79.6	5.5
X-3029	NSCLC	binimetinib	43.1	24.9	22	-79.9	5.5
X-3029	NSCLC	binimetinib	62.1	24.4	26	-71	3.4
X-3029	NSCLC	binimetinib	67.8	24.8	29	-68.3	5.1
X-3029	NSCLC	binimetinib	33.3	24.9	33	-84.4	5.5
X-3029	NSCLC	binimetinib	37.4	25.2	35	-82.5	6.8
X-3029	NSCLC	binimetinib	0	24.5	40	-100	3.8
X-3029	NSCLC	binimetinib	0	23.6	43	-100	0
X-3029	NSCLC	binimetinib	0	22.2	47	-100	-5.9
X-3029	NSCLC	binimetinib	0	23.7	50	-100	0.4
X-3029	NSCLC	binimetinib	0	23.1	54	-100	-2.1
X-3029	NSCLC	binimetinib	0	22.2	57	-100	-5.9
X-3029	NSCLC	binimetinib	0	22.9	61	-100	-3
X-3029	NSCLC	binimetinib	0	22.9	64	-100	-3
X-3029	NSCLC	paclitaxel	209.6	24.1	0	0	0
X-3029	NSCLC	paclitaxel	226.2	24	4	7.9	-0.4
X-3029	NSCLC	paclitaxel	152.6	23.5	7	-27.2	-2.5
X-3029	NSCLC	paclitaxel	123.4	24.1	11	-41.1	0
X-3029	NSCLC	paclitaxel	106.5	24.2	14	-49.2	0.4
X-3029	NSCLC	paclitaxel	94.3	24.8	18	-55	2.9
X-3029	NSCLC	paclitaxel	116.3	24.7	20	-44.5	2.5
X-3029	NSCLC	paclitaxel	122.3	24.6	25	-41.7	2.1
X-3029	NSCLC	paclitaxel	145.3	24.3	28	-30.7	0.8
X-3029	NSCLC	paclitaxel	131.9	25	32	-37.1	3.7
X-3029	NSCLC	paclitaxel	135.1	25	35	-35.5	3.7
X-3029	NSCLC	paclitaxel	186	24.8	39	-11.3	2.9
X-3029	NSCLC	paclitaxel	183.9	24.6	42	-12.3	2.1
X-3029	NSCLC	paclitaxel	243.4	24.5	46	16.1	1.7
X-3029	NSCLC	paclitaxel	222.4	25.3	49	6.1	5
X-3029	NSCLC	paclitaxel	280	25.2	53	33.6	4.6
X-3029	NSCLC	paclitaxel	280.5	24.9	56	33.8	3.3
X-3029	NSCLC	paclitaxel	278.6	25.3	60	32.9	5
X-3029	NSCLC	paclitaxel	330.5	24.7	63	57.7	2.5
X-3029	NSCLC	paclitaxel	313.2	24.8	67	49.4	2.9
X-3029	NSCLC	paclitaxel	317	24.8	70	51.2	2.9
X-3029	NSCLC	paclitaxel	325.2	24.6	74	55.2	2.1
X-3029	NSCLC	paclitaxel	331.1	24.9	77	58	3.3
X-3029	NSCLC	paclitaxel	317.8	25.8	81	51.6	7.1
X-3029	NSCLC	paclitaxel	429.2	25.5	83	104.8	5.8
X-3029	NSCLC	paclitaxel	350.1	24.8	88	67	2.9
X-3029	NSCLC	untreated	208.8	22.8	0	0	0
X-3029	NSCLC	untreated	207.9	23.8	3	-0.4	4.4
X-3029	NSCLC	untreated	206.2	24.1	7	-1.2	5.7
X-3029	NSCLC	untreated	262.1	24.2	10	25.5	6.1
X-3029	NSCLC	untreated	227.1	25.6	14	8.8	12.3
X-3029	NSCLC	untreated	233.4	25.4	17	11.8	11.4
X-3029	NSCLC	untreated	202.7	24.9	21	-2.9	9.2
X-3029	NSCLC	untreated	254.9	25.3	24	22.1	11
X-3029	NSCLC	untreated	269.9	26.1	28	29.3	14.5
X-3029	NSCLC	untreated	280.5	25.2	30	34.3	10.5
X-3029	NSCLC	untreated	306.1	26	35	46.6	14
X-3029	NSCLC	untreated	371.4	25.9	38	77.9	13.6
X-3029	NSCLC	untreated	306.1	25.4	42	46.6	11.4
X-3029	NSCLC	untreated	407.2	26.4	45	95	15.8
X-3029	NSCLC	untreated	499.7	26.2	49	139.3	14.9
X-3029	NSCLC	untreated	445.8	26.4	52	113.5	15.8
X-3029	NSCLC	untreated	476.4	26.9	56	128.2	18
X-3029	NSCLC	untreated	495.8	27.6	59	137.5	21.1
X-3029	NSCLC	untreated	551.8	27.7	63	164.3	21.5
X-3029	NSCLC	untreated	557.1	28	66	166.8	22.8
X-3029	NSCLC	untreated	636.2	27	70	204.7	18.4
X-3029	NSCLC	untreated	700	27.1	73	235.2	18.9
X-3029	NSCLC	untreated	663.7	26.9	77	217.9	18
X-3029	NSCLC	untreated	803.2	27.5	80	284.7	20.6
X-3029	NSCLC	untreated	923.1	26.9	84	342.1	18
X-3038	PDAC	abraxane	201.9	27.1	0	0	0
X-3038	PDAC	abraxane	283.4	27.2	2	40.4	0.4
X-3038	PDAC	abraxane	283.9	27.8	6	40.6	2.6
X-3038	PDAC	abraxane	335.3	27.3	9	66.1	0.7
X-3038	PDAC	abraxane	386.9	27.2	13	91.6	0.4
X-3038	PDAC	abraxane	381.3	26.3	17	88.9	-3
X-3038	PDAC	abraxane	426.7	27.9	20	111.3	3
X-3038	PDAC	abraxane	346.1	27.4	23	71.4	1.1
X-3038	PDAC	abraxane	499.2	27.2	27	147.3	0.4
X-3038	PDAC	abraxane	536.9	28.1	30	165.9	3.7
X-3038	PDAC	abraxane	560.4	28	34	177.6	3.3
X-3038	PDAC	abraxane	623.1	26.8	37	208.6	-1.1
X-3038	PDAC	abraxane	638.7	27.7	41	216.3	2.2
X-3038	PDAC	abraxane	648.7	26.8	44	221.3	-1.1
X-3038	PDAC	abraxane	670.4	27.6	48	232	1.8
X-3038	PDAC	abraxane	857.4	27.1	51	324.7	0
X-3038	PDAC	BKM120 + binimetinib	221.2	28.1	0	0	0
X-3038	PDAC	BKM120 + binimetinib	283.1	27.5	2	28	-2.1
X-3038	PDAC	BKM120 + binimetinib	172.6	27.3	6	-22	-2.8
X-3038	PDAC	BKM120 + binimetinib	223.4	26.8	9	1	-4.6
X-3038	PDAC	BKM120 + binimetinib	194.4	27.8	13	-12.1	-1.1
X-3038	PDAC	BKM120 + binimetinib	225.4	27.9	16	1.9	-0.7
X-3038	PDAC	BKM120 + binimetinib	179.6	27.3	20	-18.8	-2.8
X-3038	PDAC	BKM120 + binimetinib	205.1	28.8	23	-7.3	2.5
X-3038	PDAC	BKM120 + binimetinib	190	28.8	27	-14.1	2.5
X-3038	PDAC	BKM120 + binimetinib	172.2	29	30	-22.2	3.2
X-3038	PDAC	BKM120 + binimetinib	237.3	28.8	34	7.3	2.5
X-3038	PDAC	BKM120 + binimetinib	201	28.4	37	-9.1	1.1
X-3038	PDAC	BKM120 + binimetinib	171	28.9	41	-22.7	2.8
X-3038	PDAC	BKM120 + binimetinib	230.7	28.4	44	4.3	1.1
X-3038	PDAC	BKM120 + binimetinib	179.6	26.7	48	-18.8	-5
X-3038	PDAC	BKM120 + binimetinib	142.5	21.6	54	-35.6	-23.1
X-3038	PDAC	BKM120 + LDE225	281.1	29	0	0	0
X-3038	PDAC	BKM120 + LDE225	286.3	29.9	4	1.8	3.1
X-3038	PDAC	BKM120 + LDE225	458.7	29.6	7	63.2	2.1
X-3038	PDAC	BKM120 + LDE225	353.5	31.5	11	25.8	8.6
X-3038	PDAC	BKM120 + LDE225	460.3	31.7	14	63.7	9.3
X-3038	PDAC	BKM120 + LDE225	369.9	31.3	18	31.6	7.9
X-3038	PDAC	BKM120 + LDE225	410.1	31.4	25	45.9	8.3
X-3038	PDAC	BKM120 + LDE225	350.6	30.5	28	24.7	5.2
X-3038	PDAC	BKM120 + LDE225	426.3	30.5	32	51.7	5.2
X-3038	PDAC	BKM120 + LDE225	389.1	31	35	38.4	6.9
X-3038	PDAC	BKM120 + LDE225	309.4	29.6	39	10.1	2.1
X-3038	PDAC	BKM120 + LDE225	355.9	30.7	42	26.6	5.9
X-3038	PDAC	BKM120 + LDE225	375.2	30	46	33.5	3.4
X-3038	PDAC	BKM120 + LDE225	400.7	29.5	48	42.5	1.7
X-3038	PDAC	BKM120 + LDE225	379.1	30.1	54	34.9	3.8
X-3038	PDAC	BKM120 + LDE225	477.5	29.7	60	69.9	2.4
X-3038	PDAC	BKM120 + LDE225	388.2	30.3	63	38.1	4.5
X-3038	PDAC	BKM120 + LDE225	610.4	30.3	66	117.1	4.5
X-3038	PDAC	BKM120 + LDE225	665.3	29.9	69	136.7	3.1
X-3038	PDAC	BKM120 + LDE225	745.6	32.4	74	165.2	11.7
X-3038	PDAC	BKM120 + LDE225	679.4	31.8	76	141.7	9.7
X-3038	PDAC	BKM120 + LDE225	659.9	31.3	80	134.8	7.9
X-3038	PDAC	BKM120 + LDE225	839.5	31.2	83	198.6	7.6
X-3038	PDAC	BKM120 + LDE225	915.5	30.7	88	225.7	5.9
X-3038	PDAC	BKM120 + LDE225	865	29.3	95	207.7	1
X-3038	PDAC	BKM120	198.4	26.9	0	0	0
X-3038	PDAC	BKM120	177.9	26.4	3	-10.3	-1.9
X-3038	PDAC	BKM120	189	26.1	6	-4.7	-3
X-3038	PDAC	BKM120	184	26.1	10	-7.3	-3
X-3038	PDAC	BKM120	241.2	24.2	13	21.6	-10
X-3038	PDAC	BKM120	270.4	26.6	18	36.3	-1.1
X-3038	PDAC	BKM120	247.6	27	21	24.8	0.4
X-3038	PDAC	BKM120	223.8	27.5	26	12.8	2.2
X-3038	PDAC	BKM120	254	26.7	28	28	-0.7
X-3038	PDAC	BKM120	217.9	26.9	31	9.8	0
X-3038	PDAC	BKM120	232.9	26.4	34	17.4	-1.9
X-3038	PDAC	BKM120	279.8	27	39	41	0.4
X-3038	PDAC	BKM120	353.2	25.7	42	78	-4.5
X-3038	PDAC	BKM120	349.5	26.7	46	76.2	-0.7
X-3038	PDAC	BKM120	366.8	26.6	49	84.9	-1.1
X-3038	PDAC	BKM120	274.3	27.3	52	38.3	1.5
X-3038	PDAC	BKM120	390.9	27.4	55	97	1.9
X-3038	PDAC	BKM120	314.5	27.7	59	58.5	3
X-3038	PDAC	BKM120	494.7	26.3	62	149.3	-2.2
X-3038	PDAC	BYL719 + LJM716	237.3	26	0	0	0
X-3038	PDAC	BYL719 + LJM716	244.4	26.7	4	3	2.7
X-3038	PDAC	BYL719 + LJM716	249.9	27.6	6	5.3	6.2
X-3038	PDAC	BYL719 + LJM716	252.1	27.9	10	6.2	7.3
X-3038	PDAC	BYL719 + LJM716	245.1	27.9	13	3.3	7.3
X-3038	PDAC	BYL719 + LJM716	207.8	29.4	17	-12.4	13.1
X-3038	PDAC	BYL719 + LJM716	212.8	29.5	20	-10.3	13.5
X-3038	PDAC	BYL719 + LJM716	220.9	29.8	24	-6.9	14.6
X-3038	PDAC	BYL719 + LJM716	208.7	29.5	27	-12.1	13.5
X-3038	PDAC	BYL719 + LJM716	195.8	29.7	31	-17.5	14.2
X-3038	PDAC	BYL719 + LJM716	200.3	29.3	35	-15.6	12.7
X-3038	PDAC	BYL719 + LJM716	203.7	29.5	38	-14.2	13.5
X-3038	PDAC	BYL719 + LJM716	204.8	29.2	41	-13.7	12.3
X-3038	PDAC	BYL719 + LJM716	200.6	29.1	45	-15.5	11.9
X-3038	PDAC	BYL719 + LJM716	202.6	29.1	48	-14.6	11.9
X-3038	PDAC	BYL719 + LJM716	203.5	28.7	52	-14.2	10.4
X-3038	PDAC	BYL719 + LJM716	203.7	29	55	-14.2	11.5
X-3038	PDAC	BYL719 + LJM716	223.8	28.7	59	-5.7	10.4
X-3038	PDAC	BYL719 + LJM716	242.2	28.3	62	2.1	8.8
X-3038	PDAC	BYL719 + LJM716	233.4	29.3	66	-1.6	12.7
X-3038	PDAC	BYL719 + LJM716	223.1	28.4	69	-6	9.2
X-3038	PDAC	BYL719 + LJM716	203.3	28.9	73	-14.3	11.2
X-3038	PDAC	BYL719 + LJM716	205.5	29.1	76	-13.4	11.9
X-3038	PDAC	BYL719 + LJM716	206.5	27.3	81	-13	5
X-3038	PDAC	BYL719 + LJM716	203.3	26.7	84	-14.3	2.7
X-3038	PDAC	BYL719 + LJM716	194.5	27.1	87	-18	4.2
X-3038	PDAC	BYL719 + LJM716	196.1	28.7	90	-17.4	10.4
X-3038	PDAC	BYL719 + LJM716	197.6	27.6	94	-16.7	6.2
X-3038	PDAC	BYL719 + LJM716	189.7	27.8	97	-20.1	6.9
X-3038	PDAC	BYL719 + LJM716	190.2	28.7	101	-19.8	10.4
X-3038	PDAC	BYL719	230.3	24.1	0	0	0
X-3038	PDAC	BYL719	237.3	25	2	3	3.7
X-3038	PDAC	BYL719	240.4	25.8	6	4.4	7.1
X-3038	PDAC	BYL719	230.3	25.9	9	0	7.5
X-3038	PDAC	BYL719	225.2	22.9	15	-2.2	-5
X-3038	PDAC	BYL719	222.3	25.5	20	-3.5	5.8
X-3038	PDAC	BYL719	236.9	25.6	23	2.9	6.2
X-3038	PDAC	BYL719	263.2	25.4	27	14.3	5.4
X-3038	PDAC	BYL719	292.6	25.1	30	27.1	4.1
X-3038	PDAC	BYL719	306.5	25.2	35	33.1	4.6
X-3038	PDAC	BYL719	299.7	25.2	37	30.1	4.6
X-3038	PDAC	BYL719	274.2	24.6	41	19.1	2.1
X-3038	PDAC	BYL719	272.6	25.6	44	18.4	6.2
X-3038	PDAC	BYL719	308.8	25.9	48	34.1	7.5
X-3038	PDAC	BYL719	309	25.7	51	34.2	6.6
X-3038	PDAC	BYL719	330.9	26.4	55	43.7	9.5
X-3038	PDAC	BYL719	342.6	26.7	58	48.8	10.8
X-3038	PDAC	BYL719	409.4	26	62	77.8	7.9
X-3038	PDAC	BYL719	405.8	25.9	65	76.2	7.5
X-3038	PDAC	BYL719	435.8	26.5	69	89.2	10
X-3038	PDAC	BYL719	441	26.8	72	91.5	11.2
X-3038	PDAC	BYL719	441	26.7	76	91.5	10.8
X-3038	PDAC	BYL719	448.4	26.5	79	94.7	10
X-3038	PDAC	BYL719	460.3	26.8	83	99.9	11.2
X-3038	PDAC	BYL719	463.6	27.3	86	101.3	13.3
X-3038	PDAC	BYL719	471.1	27.5	90	104.6	14.1
X-3038	PDAC	BYL719	578.3	27	93	151.1	12
X-3038	PDAC	BYL719	568.5	26.8	97	146.9	11.2
X-3038	PDAC	BYL719	580.2	27	100	151.9	12
X-3038	PDAC	CLR457	206.8	22.5	0	0	0
X-3038	PDAC	CLR457	221.5	22.9	5	7.1	1.8
X-3038	PDAC	CLR457	245.1	23	10	18.5	2.2
X-3038	PDAC	CLR457	270	23.5	13	30.6	4.4
X-3038	PDAC	CLR457	291.1	24	17	40.8	6.7
X-3038	PDAC	CLR457	310.3	24	20	50	6.7
X-3038	PDAC	CLR457	336.8	24.1	25	62.9	7.1
X-3038	PDAC	CLR457	340.4	24.2	27	64.6	7.6
X-3038	PDAC	CLR457	344.9	23.5	31	66.8	4.4
X-3038	PDAC	CLR457	370.9	23.3	34	79.4	3.6
X-3038	PDAC	CLR457	431.5	24.4	38	108.7	8.4
X-3038	PDAC	CLR457	491	24.7	41	137.4	9.8
X-3038	PDAC	CLR457	524.1	25.1	45	153.4	11.6
X-3038	PDAC	CLR457	580.6	25	48	180.8	11.1
X-3038	PDAC	CLR457	632.6	25.4	52	205.9	12.9
X-3038	PDAC	CLR457	667.6	26.8	55	222.8	19.1
X-3038	PDAC	HDM201	201.2	26.5	0	0	0
X-3038	PDAC	HDM201	206.6	28	3	2.7	5.7
X-3038	PDAC	HDM201	216.7	27.5	7	7.7	3.8
X-3038	PDAC	HDM201	243.1	28.1	10	20.8	6
X-3038	PDAC	HDM201	278.2	27.6	14	38.3	4.2
X-3038	PDAC	HDM201	290.8	28.1	17	44.5	6
X-3038	PDAC	HDM201	300.9	27.7	23	49.6	4.5
X-3038	PDAC	HDM201	301.1	26.6	28	49.7	0.4
X-3038	PDAC	HDM201	324.4	27.9	31	61.2	5.3
X-3038	PDAC	HDM201	333.1	25.8	35	65.6	-2.6
X-3038	PDAC	HDM201	319.5	24.1	38	58.8	-9.1
X-3038	PDAC	HDM201	289.2	22.2	43	43.7	-16.2
X-3038	PDAC	HDM201	254	23.2	45	26.2	-12.5
X-3038	PDAC	figitumumab"	219.7	23.4	0	0	0
X-3038	PDAC	figitumumab"	240.3	23.8	2	9.4	1.7
X-3038	PDAC	figitumumab"	267.9	23.7	9	21.9	1.3
X-3038	PDAC	figitumumab"	335.4	23.2	14	52.7	-0.9
X-3038	PDAC	figitumumab"	343.9	23.7	16	56.5	1.3
X-3038	PDAC	figitumumab"	368	24.4	20	67.5	4.3
X-3038	PDAC	figitumumab"	393.8	23.9	23	79.2	2.1
X-3038	PDAC	figitumumab"	483.5	24	27	120.1	2.6
X-3038	PDAC	figitumumab"	436	23.7	30	98.5	1.3
X-3038	PDAC	figitumumab"	446.3	24.6	34	103.1	5.1
X-3038	PDAC	figitumumab"	450.2	23.3	37	104.9	-0.4
X-3038	PDAC	figitumumab"	381.5	24.5	41	73.6	4.7
X-3038	PDAC	figitumumab"	374.1	24.1	44	70.3	3
X-3038	PDAC	figitumumab"	413.9	23.8	48	88.4	1.7
X-3038	PDAC	figitumumab"	409	24.9	51	86.2	6.4
X-3038	PDAC	figitumumab"	433	24.9	59	97.1	6.4
X-3038	PDAC	figitumumab"	469.3	24.7	62	113.6	5.6
X-3038	PDAC	figitumumab"	477.6	25.2	65	117.4	7.7
X-3038	PDAC	figitumumab"	499.1	24.5	70	127.2	4.7
X-3038	PDAC	figitumumab"	390.6	25	73	77.8	6.8
X-3038	PDAC	figitumumab"	328.5	25	76	49.5	6.8
X-3038	PDAC	figitumumab"	304.9	25	79	38.8	6.8
X-3038	PDAC	figitumumab"	181.1	25.5	83	-17.6	9
X-3038	PDAC	figitumumab"	164.9	25.1	86	-24.9	7.3
X-3038	PDAC	figitumumab"	139.4	25.5	90	-36.5	9
X-3038	PDAC	figitumumab"	136.3	25.1	93	-38	7.3
X-3038	PDAC	figitumumab"	113.5	25.7	97	-48.3	9.8
X-3038	PDAC	figitumumab" + binimetinib	224.5	29.4	0	0	0
X-3038	PDAC	figitumumab" + binimetinib	236	30.5	3	5.1	3.7
X-3038	PDAC	figitumumab" + binimetinib	286.6	29.5	6	27.7	0.3
X-3038	PDAC	figitumumab" + binimetinib	278.9	29.7	10	24.2	1
X-3038	PDAC	figitumumab" + binimetinib	323.3	30.2	13	44	2.7
X-3038	PDAC	figitumumab" + binimetinib	346.6	29.8	17	54.4	1.4
X-3038	PDAC	figitumumab" + binimetinib	307.7	29.7	20	37.1	1
X-3038	PDAC	figitumumab" + binimetinib	476.8	29.9	25	112.4	1.7
X-3038	PDAC	figitumumab" + binimetinib	428.3	29.7	28	90.8	1
X-3038	PDAC	figitumumab" + binimetinib	498.6	29.2	31	122.1	-0.7
X-3038	PDAC	figitumumab" + binimetinib	421	28.8	34	87.5	-2
X-3038	PDAC	figitumumab" + binimetinib	655.6	28.9	38	192	-1.7
X-3038	PDAC	INC424 + binimetinib	237.6	28.7	0	0	0
X-3038	PDAC	INC424 + binimetinib	194.6	29.8	4	-18.1	3.8
X-3038	PDAC	INC424 + binimetinib	202	30.7	7	-15	7
X-3038	PDAC	INC424 + binimetinib	134.8	31	11	-43.3	8
X-3038	PDAC	INC424 + binimetinib	215.5	31.8	14	-9.3	10.8
X-3038	PDAC	INC424 + binimetinib	190.7	30.8	18	-19.7	7.3
X-3038	PDAC	INC424 + binimetinib	202.1	30.6	21	-14.9	6.6
X-3038	PDAC	INC424 + binimetinib	136.1	31.1	25	-42.7	8.4
X-3038	PDAC	INC424 + binimetinib	183.7	30.9	28	-22.7	7.7
X-3038	PDAC	INC424 + binimetinib	169.6	31.5	32	-28.6	9.8
X-3038	PDAC	INC424 + binimetinib	174.9	30.8	39	-26.4	7.3
X-3038	PDAC	INC424 + binimetinib	284.7	30.6	46	19.8	6.6
X-3038	PDAC	INC424 + binimetinib	173.5	31.9	49	-27	11.1
X-3038	PDAC	INC424 + binimetinib	208.4	31.7	53	-12.3	10.5
X-3038	PDAC	INC424 + binimetinib	174.2	31.3	56	-26.7	9.1
X-3038	PDAC	INC424 + binimetinib	207.7	30.4	60	-12.6	5.9
X-3038	PDAC	INC424 + binimetinib	275.4	30.3	62	15.9	5.6
X-3038	PDAC	INC424 + binimetinib	277.4	28.7	67	16.8	0
X-3038	PDAC	INC424 + binimetinib	301.7	30.1	69	27	4.9
X-3038	PDAC	INC424 + binimetinib	210.8	29.1	74	-11.3	1.4
X-3038	PDAC	INC424 + binimetinib	356.5	28.6	77	50	-0.3
X-3038	PDAC	INC424 + binimetinib	300.2	28.4	81	26.3	-1
X-3038	PDAC	INC424 + binimetinib	325.8	28.1	84	37.1	-2.1
X-3038	PDAC	INC424 + binimetinib	354.6	29.4	88	49.2	2.4
X-3038	PDAC	INC424	221.8	30.3	0	0	0
X-3038	PDAC	INC424	270.2	29	4	21.8	-4.3
X-3038	PDAC	INC424	274.2	29.1	6	23.6	-4
X-3038	PDAC	INC424	284.1	30.3	10	28.1	0
X-3038	PDAC	INC424	295.3	28.6	13	33.1	-5.6
X-3038	PDAC	INC424	307	28.6	17	38.4	-5.6
X-3038	PDAC	INC424	336.1	28.9	20	51.5	-4.6
X-3038	PDAC	INC424	369.1	30.3	24	66.4	0
X-3038	PDAC	INC424	387.5	27.9	27	74.7	-7.9
X-3038	PDAC	INC424	406.1	28.1	31	83.1	-7.3
X-3038	PDAC	INC424	403.1	27.9	34	81.7	-7.9
X-3038	PDAC	INC424	353.9	27.7	38	59.6	-8.6
X-3038	PDAC	INC424	355.7	26.9	41	60.4	-11.2
X-3038	PDAC	INC424	368.2	28	45	66	-7.6
X-3038	PDAC	INC424	357.7	28	48	61.3	-7.6
X-3038	PDAC	INC424	374.7	28.2	52	68.9	-6.9
X-3038	PDAC	INC424	366.1	29.2	55	65.1	-3.6
X-3038	PDAC	INC424	379.8	28.8	59	71.2	-5
X-3038	PDAC	INC424	387.4	28.3	62	74.7	-6.6
X-3038	PDAC	INC424	388.1	27.8	66	75	-8.3
X-3038	PDAC	INC424	404.9	27.3	69	82.6	-9.9
X-3038	PDAC	LEE011	205.9	31.3	0	0	0
X-3038	PDAC	LEE011	208.8	30.2	4	1.4	-3.5
X-3038	PDAC	LEE011	201.4	28.8	7	-2.2	-8
X-3038	PDAC	LEE011	195.3	30	11	-5.1	-4.2
X-3038	PDAC	LEE011	239.3	29.9	15	16.2	-4.5
X-3038	PDAC	LEE011	255.5	29.4	18	24.1	-6.1
X-3038	PDAC	LEE011	188.6	29.9	21	-8.4	-4.5
X-3038	PDAC	LEE011	209.5	30	25	1.7	-4.2
X-3038	PDAC	LEE011	287.9	29.3	28	39.8	-6.4
X-3038	PDAC	LEE011	279.2	29.7	32	35.6	-5.1
X-3038	PDAC	LEE011	328	29.1	35	59.3	-7
X-3038	PDAC	LEE011	292.3	30.9	39	42	-1.3
X-3038	PDAC	LEE011	299.7	30.1	42	45.6	-3.8
X-3038	PDAC	LEE011	297.2	31.5	46	44.3	0.6
X-3038	PDAC	LEE011	305.6	30.3	49	48.4	-3.2
X-3038	PDAC	LEE011	297.9	31.4	53	44.7	0.3
X-3038	PDAC	LEE011	298.7	30.4	56	45.1	-2.9
X-3038	PDAC	LEE011	197.1	30.4	60	-4.3	-2.9
X-3038	PDAC	LEE011	202.9	31.4	63	-1.5	0.3
X-3038	PDAC	LEE011	228.8	32	67	11.1	2.2
X-3038	PDAC	LEE011	208.6	31	70	1.3	-1
X-3038	PDAC	LEE011	246.6	30.7	74	19.8	-1.9
X-3038	PDAC	LEE011	200.9	30.5	78	-2.4	-2.6
X-3038	PDAC	LEE011	294.3	30.9	81	42.9	-1.3
X-3038	PDAC	LEE011	280.3	31.1	84	36.1	-0.6
X-3038	PDAC	LEE011	277.2	30.8	89	34.6	-1.6
X-3038	PDAC	LEE011	217	30.4	92	5.4	-2.9
X-3038	PDAC	LEE011	238.4	31.1	95	15.8	-0.6
X-3038	PDAC	LEE011	239.9	30.1	98	16.5	-3.8
X-3038	PDAC	LEE011	196.6	31.1	102	-4.5	-0.6
X-3038	PDAC	LEE011	188.3	30.3	105	-8.5	-3.2
X-3038	PDAC	LEE011	212.9	30.6	109	3.4	-2.2
X-3038	PDAC	WNT974	213.7	23.7	0	0	0
X-3038	PDAC	WNT974	242.4	23.6	1	13.4	-0.4
X-3038	PDAC	WNT974	241.9	23.5	5	13.2	-0.8
X-3038	PDAC	WNT974	269.7	23.9	9	26.2	0.8
X-3038	PDAC	WNT974	272.8	23.5	12	27.7	-0.8
X-3038	PDAC	WNT974	290.3	24.7	15	35.8	4.2
X-3038	PDAC	WNT974	347.3	24.3	19	62.5	2.5
X-3038	PDAC	WNT974	507.4	24.1	22	137.4	1.7
X-3038	PDAC	WNT974	720.6	25	27	237.2	5.5
X-3038	PDAC	WNT974	878.8	24.7	30	311.2	4.2
X-3038	PDAC	LKA136	216.1	29.7	0	0	0
X-3038	PDAC	LKA136	288	28.8	3	33.3	-3
X-3038	PDAC	LKA136	385	28.6	6	78.2	-3.7
X-3038	PDAC	LKA136	368.4	54.1	10	70.5	-3.7
X-3038	PDAC	LKA136	503.8	29.5	13	133.1	-0.7
X-3038	PDAC	LKA136	511.9	29.3	17	136.9	-1.3
X-3038	PDAC	LKA136	558.7	29.2	20	158.5	-1.7
X-3038	PDAC	LKA136	732.4	29.2	24	238.9	-1.7
X-3038	PDAC	binimetinib	258.4	25.3	0	0	0
X-3038	PDAC	binimetinib	332	25.6	5	28.5	1.2
X-3038	PDAC	binimetinib	314.6	25	8	21.7	-1.2
X-3038	PDAC	binimetinib	312.8	26.2	12	21.1	3.6
X-3038	PDAC	binimetinib	357.1	25.1	15	38.2	-0.8
X-3038	PDAC	binimetinib	429.1	25	19	66.1	-1.2
X-3038	PDAC	binimetinib	369.1	24.4	22	42.8	-3.6
X-3038	PDAC	binimetinib	326.8	22.6	26	26.5	-10.7
X-3038	PDAC	binimetinib	322.7	23.3	29	24.9	-7.9
X-3038	PDAC	binimetinib	303.7	23	33	17.5	-9.1
X-3038	PDAC	binimetinib	318.9	22.7	36	23.4	-10.3
X-3038	PDAC	binimetinib	276.3	22.2	40	6.9	-12.3
X-3038	PDAC	binimetinib	262.5	21.3	43	1.6	-15.8
X-3038	PDAC	binimetinib-3.5mpk	233.8	23.1	0	0	0
X-3038	PDAC	binimetinib-3.5mpk	284	22.8	3	21.5	-1.3
X-3038	PDAC	binimetinib-3.5mpk	264.9	21.5	6	13.3	-6.9
X-3038	PDAC	binimetinib-3.5mpk	291.8	22.8	10	24.8	-1.3
X-3038	PDAC	binimetinib-3.5mpk	412.2	22.4	13	76.3	-3
X-3038	PDAC	binimetinib-3.5mpk	549.7	22.7	18	135.1	-1.7
X-3038	PDAC	binimetinib-3.5mpk	605.8	24.1	21	159.1	4.3
X-3038	PDAC	binimetinib-3.5mpk	563.9	23.4	26	141.2	1.3
X-3038	PDAC	binimetinib-3.5mpk	569.4	23.6	28	143.5	2.2
X-3038	PDAC	binimetinib-3.5mpk	538.2	23.4	31	130.2	1.3
X-3038	PDAC	binimetinib-3.5mpk	481.1	23.4	34	105.8	1.3
X-3038	PDAC	binimetinib-3.5mpk	640.2	23.3	39	173.8	0.9
X-3038	PDAC	trametinib	262.5	28.6	0	0	0
X-3038	PDAC	trametinib	224.6	28.8	5	-14.4	0.7
X-3038	PDAC	trametinib	222.1	28.2	8	-15.4	-1.4
X-3038	PDAC	trametinib	232.7	28.3	11	-11.4	-1
X-3038	PDAC	trametinib	267.5	28.1	14	1.9	-1.7
X-3038	PDAC	trametinib	271.1	27.8	18	3.3	-2.8
X-3038	PDAC	trametinib	205.8	26.4	21	-21.6	-7.7
X-3038	PDAC	trametinib	131.8	25.4	26	-49.8	-11.2
X-3038	PDAC	trametinib	152	23.9	29	-42.1	-16.4
X-3038	PDAC	untreated	275.2	25.3	0	0	0
X-3038	PDAC	untreated	473.7	24.1	3	72.1	-4.7
X-3038	PDAC	untreated	541.2	24.4	6	96.7	-3.6
X-3038	PDAC	untreated	482.6	25.3	10	75.4	0
X-3038	PDAC	untreated	628	26.3	13	128.2	4
X-3038	PDAC	untreated	784.5	25.6	17	185.1	1.2
X-3038	PDAC	untreated	730.6	25.9	20	165.5	2.4
X-3038	PDAC	untreated	872.7	26.8	24	217.1	5.9
X-3038	PDAC	untreated	935.3	26.9	26	239.9	6.3
X-3038	PDAC	untreated	946.4	26.7	31	243.9	5.5
X-3052	PDAC	abraxane	215.4	24.7	0	0	0
X-3052	PDAC	abraxane	243.7	26.2	4	13.1	6.1
X-3052	PDAC	abraxane	272.7	26.1	7	26.6	5.7
X-3052	PDAC	abraxane	361	24.6	11	67.6	-0.4
X-3052	PDAC	abraxane	378.4	24.8	14	75.7	0.4
X-3052	PDAC	abraxane	449	25	18	108.4	1.2
X-3052	PDAC	abraxane	507.5	24.9	21	135.6	0.8
X-3052	PDAC	abraxane	591.7	25.9	25	174.7	4.9
X-3052	PDAC	abraxane	632.9	26	28	193.8	5.3
X-3052	PDAC	abraxane	672.9	25.9	33	212.4	4.9
X-3052	PDAC	abraxane	753.4	26	36	249.8	5.3
X-3052	PDAC	BKM120 + binimetinib	254.1	32.1	0	0	0
X-3052	PDAC	BKM120 + binimetinib	302.5	31.5	3	19	-1.9
X-3052	PDAC	BKM120 + binimetinib	232.6	32	8	-8.5	-0.3
X-3052	PDAC	BKM120 + binimetinib	241.3	31.9	10	-5	-0.6
X-3052	PDAC	BKM120 + binimetinib	204.7	31	14	-19.4	-3.4
X-3052	PDAC	BKM120 + binimetinib	281	32.4	17	10.6	0.9
X-3052	PDAC	BKM120 + binimetinib	217.5	28.3	21	-14.4	-11.8
X-3052	PDAC	BKM120 + binimetinib	219.1	30.3	24	-13.8	-5.6
X-3052	PDAC	BKM120 + binimetinib	187	32.9	27	-26.4	2.5
X-3052	PDAC	BKM120 + binimetinib	254.3	33	30	0.1	2.8
X-3052	PDAC	BKM120 + binimetinib	265.2	32	35	4.4	-0.3
X-3052	PDAC	BKM120 + binimetinib	296.8	32.7	41	16.8	1.9
X-3052	PDAC	BKM120 + binimetinib	335.7	32.5	44	32.1	1.2
X-3052	PDAC	BKM120 + binimetinib	477.7	33.5	49	88	4.4
X-3052	PDAC	BKM120 + binimetinib	301.4	34	52	18.6	5.9
X-3052	PDAC	BKM120 + binimetinib	482.9	34.1	56	90	6.2
X-3052	PDAC	BKM120 + binimetinib	497.8	33.6	59	95.9	4.7
X-3052	PDAC	BKM120 + binimetinib	389.6	32.6	63	53.3	1.6
X-3052	PDAC	BKM120 + binimetinib	219.3	31.6	65	-13.7	-1.6
X-3052	PDAC	BKM120 + binimetinib	712.7	32.5	70	180.5	1.2
X-3052	PDAC	BKM120 + binimetinib	443.5	32.3	77	74.5	0.6
X-3052	PDAC	BKM120 + binimetinib	700.8	31.4	80	175.8	-2.2
X-3052	PDAC	BKM120 + binimetinib	767.6	31.1	84	202.1	-3.1
X-3052	PDAC	BKM120 + binimetinib	745.3	30.9	87	193.3	-3.7
X-3052	PDAC	BKM120 + binimetinib	782.6	31.1	91	208	-3.1
X-3052	PDAC	BKM120 + LDE225	262.7	23	0	0	0
X-3052	PDAC	BKM120 + LDE225	169.2	22.8	2	-35.6	-0.9
X-3052	PDAC	BKM120 + LDE225	270.6	23.6	7	3	2.6
X-3052	PDAC	BKM120 + LDE225	294.6	24.3	14	12.1	5.7
X-3052	PDAC	BKM120 + LDE225	335.7	24.3	17	27.8	5.7
X-3052	PDAC	BKM120 + LDE225	337.9	25.1	21	28.6	9.1
X-3052	PDAC	BKM120 + LDE225	387	26.1	24	47.3	13.5
X-3052	PDAC	BKM120 + LDE225	465.9	25.5	28	77.4	10.9
X-3052	PDAC	BKM120 + LDE225	610.4	25.6	31	132.4	11.3
X-3052	PDAC	BKM120 + LDE225	461.1	24.6	35	75.5	7
X-3052	PDAC	BKM120 + LDE225	527.2	25.6	38	100.7	11.3
X-3052	PDAC	BKM120 + LDE225	615.7	25.8	42	134.4	12.2
X-3052	PDAC	BKM120 + LDE225	548.5	24.6	45	108.8	7
X-3052	PDAC	BKM120 + LDE225	497.7	23.9	49	89.5	3.9
X-3052	PDAC	BKM120 + LDE225	604.3	24.1	52	130	4.8
X-3052	PDAC	BKM120 + LDE225	532.5	24.6	56	102.7	7
X-3052	PDAC	BKM120 + LDE225	512.8	22.4	59	95.2	-2.6
X-3052	PDAC	BKM120 + LDE225	485.9	23.5	63	85	2.2
X-3052	PDAC	BKM120 + LDE225	591.3	21.9	66	125.1	-4.8
X-3052	PDAC	BKM120 + LDE225	497.6	21.4	70	89.4	-7
X-3052	PDAC	BKM120 + LDE225	584	21.1	73	122.3	-8.3
X-3052	PDAC	BKM120 + LDE225	507.4	20.6	76	93.1	-10.4
X-3052	PDAC	BKM120 + LDE225	630.3	21.2	79	139.9	-7.8
X-3052	PDAC	BKM120 + LDE225	587.7	19.7	84	123.7	-14.3
X-3052	PDAC	BKM120 + LDE225	616.3	20.8	87	134.6	-9.6
X-3052	PDAC	BKM120 + LDE225	680	22.6	91	158.9	-1.7
X-3052	PDAC	BKM120 + LDE225	776.4	23	94	195.5	0
X-3052	PDAC	BKM120 + LDE225	839.9	22.4	97	219.7	-2.6
X-3052	PDAC	BKM120 + LDE225	829	21.7	101	215.6	-5.7
X-3052	PDAC	BKM120 + LDE225	1440.9	20.5	104	448.5	-10.9
X-3052	PDAC	BKM120 + LDE225	1076.3	21.2	107	309.7	-7.8
X-3052	PDAC	BKM120	255.3	28.7	0	0	0
X-3052	PDAC	BKM120	263.2	27.7	2	3.1	-3.5
X-3052	PDAC	BKM120	213.3	28.3	6	-16.5	-1.4
X-3052	PDAC	BKM120	277.6	28.9	9	8.7	0.7
X-3052	PDAC	BKM120	268.3	29	12	5.1	1
X-3052	PDAC	BKM120	302.1	28.4	15	18.3	-1
X-3052	PDAC	BKM120	324.3	29	20	27	1
X-3052	PDAC	BKM120	374.4	28.7	26	46.7	0
X-3052	PDAC	BKM120	497.3	28.6	30	94.8	-0.3
X-3052	PDAC	BKM120	541.4	28.5	33	112.1	-0.7
X-3052	PDAC	BKM120	549	27.8	36	115	-3.1
X-3052	PDAC	BYL719	218.3	26.5	0	0	0
X-3052	PDAC	BYL719	233.8	26.5	2	7.1	0
X-3052	PDAC	BYL719	257.3	28.1	6	17.9	6
X-3052	PDAC	BYL719	251.3	27.5	9	15.1	3.8
X-3052	PDAC	BYL719	251.2	27.8	13	15.1	4.9
X-3052	PDAC	BYL719	263.5	27.1	16	20.7	2.3
X-3052	PDAC	BYL719	312.2	27.8	20	43	4.9
X-3052	PDAC	BYL719	366.4	28.1	23	67.8	6
X-3052	PDAC	BYL719	400.3	28.1	27	83.4	6
X-3052	PDAC	BYL719	451.4	26.8	30	106.8	1.1
X-3052	PDAC	BYL719	562.8	27.9	34	157.8	5.3
X-3052	PDAC	BYL719	665.1	28.6	37	204.7	7.9
X-3052	PDAC	BYL719 + LJM716	219.3	24.2	0	0	0
X-3052	PDAC	BYL719 + LJM716	205.5	23.6	3	-6.3	-2.5
X-3052	PDAC	BYL719 + LJM716	204	21.2	6	-7	-12.4
X-3052	PDAC	BYL719 + LJM716	173.5	23.7	10	-20.9	-2.1
X-3052	PDAC	BYL719 + LJM716	151.8	23.8	13	-30.8	-1.7
X-3052	PDAC	BYL719 + LJM716	141.5	24.2	17	-35.5	0
X-3052	PDAC	BYL719 + LJM716	145.6	24.3	21	-33.6	0.4
X-3052	PDAC	BYL719 + LJM716	152	23.7	24	-30.7	-2.1
X-3052	PDAC	BYL719 + LJM716	157	24.8	27	-28.4	2.5
X-3052	PDAC	BYL719 + LJM716	167.6	25.4	31	-23.6	5
X-3052	PDAC	BYL719 + LJM716	169.6	25.8	34	-22.7	6.6
X-3052	PDAC	BYL719 + LJM716	173.3	23.9	38	-21	-1.2
X-3052	PDAC	BYL719 + LJM716	181.6	24.7	41	-17.2	2.1
X-3052	PDAC	BYL719 + LJM716	217.9	24.3	45	-0.6	0.4
X-3052	PDAC	BYL719 + LJM716	220.4	26	48	0.5	7.4
X-3052	PDAC	BYL719 + LJM716	308.9	25.5	53	40.9	5.4
X-3052	PDAC	BYL719 + LJM716	344	26.1	56	56.9	7.9
X-3052	PDAC	BYL719 + LJM716	452.3	26.5	59	106.2	9.5
X-3052	PDAC	BYL719 + LJM716	503.1	26.2	62	129.4	8.3
X-3052	PDAC	BYL719 + LJM716	546	26	66	149	7.4
X-3052	PDAC	BYL719 + LJM716	675	26.9	69	207.8	11.2
X-3052	PDAC	BYL719 + LJM716	729.2	26.8	73	232.5	10.7
X-3052	PDAC	BYL719 + LJM716	801.1	25.7	75	265.3	6.2
X-3052	PDAC	CLR457	224.5	23.6	0	0	0
X-3052	PDAC	CLR457	223.5	23.4	4	-0.4	-0.8
X-3052	PDAC	CLR457	259.3	23.4	7	15.5	-0.8
X-3052	PDAC	CLR457	305.6	22.9	11	36.1	-3
X-3052	PDAC	CLR457	349.5	23.3	14	55.7	-1.3
X-3052	PDAC	CLR457	379.2	24.4	18	68.9	3.4
X-3052	PDAC	CLR457	387.3	24.2	21	72.5	2.5
X-3052	PDAC	CLR457	434.4	23.7	25	93.5	0.4
X-3052	PDAC	CLR457	481.4	23.7	28	114.4	0.4
X-3052	PDAC	CLR457	494.4	24	32	120.2	1.7
X-3052	PDAC	CLR457	533.5	23.5	35	137.6	-0.4
X-3052	PDAC	CLR457	574.3	24.2	39	155.8	2.5
X-3052	PDAC	CLR457	606.7	24.2	42	170.2	2.5
X-3052	PDAC	CLR457	653.6	24.4	46	191.1	3.4
X-3052	PDAC	CLR457	755.3	24.5	49	236.4	3.8
X-3052	PDAC	HDM201	221.6	24	0	0	0
X-3052	PDAC	HDM201	247.3	23.6	4	11.6	-1.7
X-3052	PDAC	HDM201	260.2	23.6	6	17.4	-1.7
X-3052	PDAC	HDM201	280.5	24.2	10	26.6	0.8
X-3052	PDAC	HDM201	307.9	23.9	13	38.9	-0.4
X-3052	PDAC	HDM201	327.2	22.2	17	47.7	-7.5
X-3052	PDAC	HDM201	346.1	21.1	20	56.2	-12.1
X-3052	PDAC	figitumumab" + binimetinib	238.3	27	0	0	0
X-3052	PDAC	figitumumab" + binimetinib	220.5	26.9	2	-7.5	-0.4
X-3052	PDAC	figitumumab" + binimetinib	161.1	26.9	6	-32.4	-0.4
X-3052	PDAC	figitumumab" + binimetinib	332	27.2	9	39.3	0.7
X-3052	PDAC	figitumumab" + binimetinib	183.5	27.5	14	-23	1.9
X-3052	PDAC	figitumumab" + binimetinib	326.8	27.9	17	37.1	3.3
X-3052	PDAC	figitumumab" + binimetinib	368.4	27.5	22	54.6	1.9
X-3052	PDAC	figitumumab" + binimetinib	273.7	27.9	24	14.9	3.3
X-3052	PDAC	figitumumab" + binimetinib	389.1	27.2	28	63.3	0.7
X-3052	PDAC	figitumumab" + binimetinib	293.5	28.1	31	23.2	4.1
X-3052	PDAC	figitumumab" + binimetinib	286.9	28.1	35	20.4	4.1
X-3052	PDAC	figitumumab" + binimetinib	253.2	27.6	37	6.3	2.2
X-3052	PDAC	figitumumab" + binimetinib	244.4	28.8	42	2.6	6.7
X-3052	PDAC	figitumumab" + binimetinib	250.1	28.6	45	5	5.9
X-3052	PDAC	figitumumab" + binimetinib	223.1	28.2	49	-6.4	4.4
X-3052	PDAC	figitumumab" + binimetinib	292.9	29.1	52	22.9	7.8
X-3052	PDAC	figitumumab" + binimetinib	317.9	28.5	56	33.4	5.6
X-3052	PDAC	figitumumab" + binimetinib	339.4	28.6	59	42.4	5.9
X-3052	PDAC	figitumumab" + binimetinib	254.1	29.1	63	6.6	7.8
X-3052	PDAC	figitumumab"	238.1	28.3	0	0	0
X-3052	PDAC	figitumumab"	400.8	28.5	4	68.3	0.7
X-3052	PDAC	figitumumab"	505.9	28.6	11	112.5	1.1
X-3052	PDAC	figitumumab"	608.6	28.1	14	155.6	-0.7
X-3052	PDAC	figitumumab"	852.7	28.4	18	258.1	0.4
X-3052	PDAC	figitumumab"	942	28.1	21	295.6	-0.7
X-3052	PDAC	gemcitabine-50mpk	266.3	25	0	0	0
X-3052	PDAC	gemcitabine-50mpk	281.2	25.8	3	5.6	3.2
X-3052	PDAC	gemcitabine-50mpk	476.4	24.1	6	78.9	-3.6
X-3052	PDAC	gemcitabine-50mpk	616.4	25.9	10	131.5	3.6
X-3052	PDAC	gemcitabine-50mpk	572.4	25.2	14	114.9	0.8
X-3052	PDAC	gemcitabine-50mpk	648.3	25.3	18	143.4	1.2
X-3052	PDAC	gemcitabine-50mpk	901.4	26.1	21	238.5	4.4
X-3052	PDAC	gemcitabine-50mpk	1214	27	24	355.9	8
X-3052	PDAC	gemcitabine-50mpk	1207.9	26.5	27	353.6	6
X-3052	PDAC	gemcitabine-50mpk	1589.1	25.5	32	496.7	2
X-3052	PDAC	gemcitabine-50mpk	1719.4	26.5	35	545.7	6
X-3052	PDAC	INC424 + binimetinib	233.5	21.8	0	0	0
X-3052	PDAC	INC424 + binimetinib	267.1	22.3	3	14.4	2.3
X-3052	PDAC	INC424 + binimetinib	244.5	22.4	8	4.7	2.8
X-3052	PDAC	INC424 + binimetinib	232.1	22.9	10	-0.6	5
X-3052	PDAC	INC424 + binimetinib	266.5	22.3	14	14.1	2.3
X-3052	PDAC	INC424 + binimetinib	431.1	22.9	17	84.6	5
X-3052	PDAC	INC424 + binimetinib	408.9	22.6	21	75.1	3.7
X-3052	PDAC	INC424 + binimetinib	385.9	22	24	65.3	0.9
X-3052	PDAC	INC424 + binimetinib	263.2	22.9	27	12.7	5
X-3052	PDAC	INC424 + binimetinib	451	22.4	30	93.1	2.8
X-3052	PDAC	INC424 + binimetinib	534.6	22.2	35	129	1.8
X-3052	PDAC	INC424 + binimetinib	496.2	22.9	41	112.5	5
X-3052	PDAC	INC424 + binimetinib	550.6	22.5	44	135.8	3.2
X-3052	PDAC	INC424 + binimetinib	618.3	23.5	49	164.8	7.8
X-3052	PDAC	INC424 + binimetinib	669.5	23.5	52	186.7	7.8
X-3052	PDAC	INC424 + binimetinib	657.7	23.7	56	181.7	8.7
X-3052	PDAC	INC424 + binimetinib	738.6	23.6	59	216.3	8.3
X-3052	PDAC	INC424 + binimetinib	758.3	21.3	63	224.8	-2.3
X-3052	PDAC	INC424 + binimetinib	444.1	21.9	65	90.2	0.5
X-3052	PDAC	INC424 + binimetinib	981.3	23.2	70	320.3	6.4
X-3052	PDAC	INC424 + binimetinib	1304.5	23.1	77	458.7	6
X-3052	PDAC	INC424 + binimetinib	1119.2	22.8	80	379.3	4.6
X-3052	PDAC	INC424 + binimetinib	1070.7	22.7	84	358.5	4.1
X-3052	PDAC	INC424 + binimetinib	1529.2	23.2	87	554.9	6.4
X-3052	PDAC	INC424 + binimetinib	1993.7	23.5	91	753.8	7.8
X-3052	PDAC	INC424	241.8	22.8	0	0	0
X-3052	PDAC	INC424	296.1	22.2	3	22.5	-2.6
X-3052	PDAC	INC424	353	22.8	7	46	0
X-3052	PDAC	INC424	387.5	22.8	10	60.3	0
X-3052	PDAC	INC424	422	22.5	13	74.5	-1.3
X-3052	PDAC	INC424	438.3	22.4	17	81.3	-1.8
X-3052	PDAC	INC424	457.3	22.5	20	89.1	-1.3
X-3052	PDAC	INC424	584	23.1	24	141.5	1.3
X-3052	PDAC	INC424	661.5	22.1	27	173.6	-3.1
X-3052	PDAC	INC424	789.7	22.5	31	226.6	-1.3
X-3052	PDAC	INC424	864	23.3	34	257.3	2.2
X-3052	PDAC	INC424	1043.2	23	39	331.4	0.9
X-3052	PDAC	INC424	1073.9	22.1	42	344.1	-3.1
X-3052	PDAC	INC424	1134.6	23.5	45	369.2	3.1
X-3052	PDAC	LEE011	226.4	26	0	0	0
X-3052	PDAC	LEE011	266.6	25.8	4	17.8	-0.8
X-3052	PDAC	LEE011	393.5	26.6	7	73.8	2.3
X-3052	PDAC	LEE011	438.9	27.3	11	93.9	5
X-3052	PDAC	LEE011	461.7	26.5	14	103.9	1.9
X-3052	PDAC	LEE011	479.6	27	18	111.8	3.8
X-3052	PDAC	LEE011	482.5	26.4	21	113.1	1.5
X-3052	PDAC	LEE011	457.1	26.5	25	101.9	1.9
X-3052	PDAC	LEE011	376.1	27.1	28	66.1	4.2
X-3052	PDAC	LEE011	364.9	26.6	32	61.2	2.3
X-3052	PDAC	LEE011	373.1	26.1	35	64.8	0.4
X-3052	PDAC	LEE011	306.8	27.1	39	35.5	4.2
X-3052	PDAC	LEE011	285.9	27.8	42	26.3	6.9
X-3052	PDAC	LEE011	242.6	26.6	46	7.2	2.3
X-3052	PDAC	LEE011	155.7	26.6	49	-31.2	2.3
X-3052	PDAC	LEE011	154.1	26.3	53	-31.9	1.2
X-3052	PDAC	LEE011	103.2	26.9	56	-54.4	3.5
X-3052	PDAC	LEE011	117.8	26.6	60	-48	2.3
X-3052	PDAC	LEE011	78.5	27.9	63	-65.3	7.3
X-3052	PDAC	LEE011	83.2	27.2	68	-63.3	4.6
X-3052	PDAC	LEE011	83.6	27.6	71	-63.1	6.2
X-3052	PDAC	LEE011	27.5	28.3	74	-87.9	8.8
X-3052	PDAC	LEE011	40.9	26.7	77	-81.9	2.7
X-3052	PDAC	LEE011	26.5	27.6	81	-88.3	6.2
X-3052	PDAC	LEE011	31.8	26.8	84	-86	3.1
X-3052	PDAC	LEE011	38.9	26.9	88	-82.8	3.5
X-3052	PDAC	LEE011	36.2	27.6	91	-84	6.2
X-3052	PDAC	LEE011	45.1	27.7	95	-80.1	6.5
X-3052	PDAC	LEE011	9.7	27.9	98	-95.7	7.3
X-3052	PDAC	WNT974	267.4	28.3	0	0	0
X-3052	PDAC	WNT974	256.7	27.6	1	-4	-2.5
X-3052	PDAC	WNT974	455.4	28.6	5	70.3	1.1
X-3052	PDAC	WNT974	552.1	27.8	8	106.5	-1.8
X-3052	PDAC	WNT974	767	27.1	13	186.8	-4.2
X-3052	PDAC	WNT974	1018.2	51.4	16	280.8	-4.2
X-3052	PDAC	WNT974	1239	26.9	19	363.4	-4.9
X-3052	PDAC	WNT974	1272.6	27.3	23	375.9	-3.5
X-3052	PDAC	WNT974	1573.7	27.9	26	488.5	-1.4
X-3052	PDAC	WNT974	1678	26.5	29	527.5	-6.4
X-3052	PDAC	LKA136	265.6	26.9	0	0	0
X-3052	PDAC	LKA136	259	27.1	1	-2.5	0.7
X-3052	PDAC	LKA136	398.5	27.4	6	50	1.9
X-3052	PDAC	LKA136	411.8	27.1	9	55	0.7
X-3052	PDAC	LKA136	505.6	27.2	12	90.4	1.1
X-3052	PDAC	LKA136	597.5	27.1	15	125	0.7
X-3052	PDAC	LKA136	788.4	24.3	20	196.8	-9.7
X-3052	PDAC	LKA136	1017.6	28.1	23	283.1	4.5
X-3052	PDAC	LKA136	1171.5	25.6	26	341.1	-4.8
X-3052	PDAC	LKA136	1241	28.9	29	367.2	7.4
X-3052	PDAC	LKA136	1473	29.3	33	454.6	8.9
X-3052	PDAC	binimetinib	365.4	23.7	0	0	0
X-3052	PDAC	binimetinib	231.9	23.2	2	-36.5	-2.1
X-3052	PDAC	binimetinib	454.4	25.2	7	24.4	6.3
X-3052	PDAC	binimetinib	397.6	25.2	14	8.8	6.3
X-3052	PDAC	binimetinib	510.1	24.6	17	39.6	3.8
X-3052	PDAC	binimetinib	457.1	24.7	21	25.1	4.2
X-3052	PDAC	binimetinib	463.8	25.1	24	26.9	5.9
X-3052	PDAC	binimetinib	411.2	24.9	28	12.5	5.1
X-3052	PDAC	binimetinib	443.7	24.8	31	21.4	4.6
X-3052	PDAC	binimetinib	487.8	25	35	33.5	5.5
X-3052	PDAC	binimetinib	422.9	26.3	38	15.7	11
X-3052	PDAC	binimetinib	606.4	26	42	66	9.7
X-3052	PDAC	binimetinib	592.4	26.3	45	62.1	11
X-3052	PDAC	binimetinib	669.8	26.1	49	83.3	10.1
X-3052	PDAC	binimetinib	671.8	26.4	52	83.9	11.4
X-3052	PDAC	binimetinib	471.5	27.3	56	29	15.2
X-3052	PDAC	binimetinib	668.6	26.8	59	83	13.1
X-3052	PDAC	binimetinib	709.6	27.6	63	94.2	16.5
X-3052	PDAC	binimetinib	607.8	26.7	66	66.3	12.7
X-3052	PDAC	binimetinib	651.3	27.4	70	78.2	15.6
X-3052	PDAC	binimetinib	610.2	26.4	73	67	11.4
X-3052	PDAC	binimetinib	540.6	26.8	76	47.9	13.1
X-3052	PDAC	binimetinib	846.2	26	79	131.6	9.7
X-3052	PDAC	binimetinib	668.6	26.3	84	83	11
X-3052	PDAC	binimetinib	708.8	26.6	87	94	12.2
X-3052	PDAC	binimetinib	585.6	26.5	91	60.3	11.8
X-3052	PDAC	binimetinib	705.2	26.1	94	93	10.1
X-3052	PDAC	binimetinib-3.5mpk	205.8	27.2	0	0	0
X-3052	PDAC	binimetinib-3.5mpk	283.2	27.6	2	37.6	1.5
X-3052	PDAC	binimetinib-3.5mpk	223.1	28.4	6	8.4	4.4
X-3052	PDAC	binimetinib-3.5mpk	314.4	28.7	9	52.8	5.5
X-3052	PDAC	binimetinib-3.5mpk	269.4	28.1	14	30.9	3.3
X-3052	PDAC	binimetinib-3.5mpk	478	29.6	17	132.3	8.8
X-3052	PDAC	binimetinib-3.5mpk	630	28.6	22	206.1	5.1
X-3052	PDAC	trametinib	253.7	24.6	0	0	0
X-3052	PDAC	trametinib	335.1	24.4	4	32.1	-0.8
X-3052	PDAC	trametinib	411.6	24.3	6	62.2	-1.2
X-3052	PDAC	trametinib	433.1	24	10	70.7	-2.4
X-3052	PDAC	trametinib	490.6	25.4	13	93.4	3.3
X-3052	PDAC	trametinib	785.8	25.6	17	209.7	4.1
X-3052	PDAC	trametinib	725.4	25.1	20	185.9	2
X-3052	PDAC	trametinib	942.5	24.7	24	271.5	0.4
X-3052	PDAC	trametinib	1223.7	25.3	27	382.3	2.8
X-3052	PDAC	untreated	284.4	25.5	0	0	0
X-3052	PDAC	untreated	312.9	24.6	1	10	-3.5
X-3052	PDAC	untreated	290	25.1	6	2	-1.6
X-3052	PDAC	untreated	488.7	25.6	9	71.8	0.4
X-3052	PDAC	untreated	489.6	25.3	12	72.2	-0.8
X-3052	PDAC	untreated	624.3	25.1	15	119.5	-1.6
X-3052	PDAC	untreated	811.3	24.8	20	185.3	-2.7
X-3052	PDAC	untreated	991.5	25.6	23	248.6	0.4
X-3052	PDAC	untreated	996.4	26	26	250.4	2
X-3052	PDAC	untreated	1180.3	26.3	29	315	3.1
X-3052	PDAC	untreated	1360.5	26.1	33	378.4	2.4
X-3077	BRCA	BGJ398	211.3	31.7	0	0	0
X-3077	BRCA	BGJ398	217.7	31.6	1	3	-0.3
X-3077	BRCA	BGJ398	217.9	30.4	4	3.1	-4.1
X-3077	BRCA	BGJ398	158.8	30.4	8	-24.8	-4.1
X-3077	BRCA	BGJ398	185.1	32.2	11	-12.4	1.6
X-3077	BRCA	BGJ398	159.4	29.7	19	-24.6	-6.3
X-3077	BRCA	BGJ398	132.2	28.7	22	-37.4	-9.5
X-3077	BRCA	BGJ398	167.8	29.2	25	-20.6	-7.9
X-3077	BRCA	BGJ398	110.8	26.2	29	-47.6	-17.4
X-3077	BRCA	BKM120	205.1	27.7	0	0	0
X-3077	BRCA	BKM120	141	29.1	4	-31.3	5.1
X-3077	BRCA	BKM120	103.4	29	8	-49.6	4.7
X-3077	BRCA	BKM120	82.5	29.5	11	-59.8	6.5
X-3077	BRCA	BKM120	101.2	28.8	15	-50.7	4
X-3077	BRCA	BKM120	110.5	27.5	18	-46.1	-0.7
X-3077	BRCA	BKM120	111.5	25.8	22	-45.6	-6.9
X-3077	BRCA	BKM120	87.1	25	25	-57.5	-9.7
X-3077	BRCA	BKM120	112.9	25.2	29	-45	-9
X-3077	BRCA	BKM120	137.8	24.8	32	-32.8	-10.5
X-3077	BRCA	BYL719 + LEE011	272.2	28.3	0	0	0
X-3077	BRCA	BYL719 + LEE011	221.6	29.1	1	-18.6	2.8
X-3077	BRCA	BYL719 + LEE011	163.4	28	5	-40	-1.1
X-3077	BRCA	BYL719 + LEE011	138.7	26.8	8	-49	-5.3
X-3077	BRCA	BYL719 + LEE011	156.7	26.5	11	-42.4	-6.4
X-3077	BRCA	BYL719 + LEE011	94.8	24	15	-65.2	-15.2
X-3077	BRCA	BYL719 + LEE011	114.3	26.3	19	-58	-7.1
X-3077	BRCA	BYL719 + LEE011	103.9	26.6	22	-61.8	-6
X-3077	BRCA	BYL719 + LEE011	107.1	26.8	25	-60.7	-5.3
X-3077	BRCA	BYL719 + LEE011	45.9	NA	32	-83.1	-5.3
X-3077	BRCA	BYL719 + LEE011	58.4	27.1	36	-78.5	-4.2
X-3077	BRCA	BYL719 + LEE011	67.9	26	40	-75.1	-8.1
X-3077	BRCA	BYL719 + LEE011	74.8	26.4	43	-72.5	-6.7
X-3077	BRCA	BYL719 + LEE011	63.8	26	47	-76.6	-8.1
X-3077	BRCA	BYL719 + LEE011	88.7	25.9	50	-67.4	-8.5
X-3077	BRCA	BYL719 + LEE011	68.4	23.3	53	-74.9	-17.7
X-3077	BRCA	BYL719 + LEE011	98.5	26.9	57	-63.8	-4.9
X-3077	BRCA	BYL719 + LEE011	78.9	26.7	61	-71	-5.7
X-3077	BRCA	BYL719 + LEE011	66.6	25.7	64	-75.5	-9.2
X-3077	BRCA	BYL719 + LEE011	60.5	24.9	68	-77.8	-12
X-3077	BRCA	BYL719 + LEE011	66.1	25.5	71	-75.7	-9.9
X-3077	BRCA	BYL719 + LEE011	87.9	22.2	74	-67.7	-21.6
X-3077	BRCA	BYL719	202.1	23	0	0	0
X-3077	BRCA	BYL719	139.6	23.8	4	-30.9	3.5
X-3077	BRCA	BYL719	146	22.9	8	-27.8	-0.4
X-3077	BRCA	BYL719	132.2	24.1	11	-34.6	4.8
X-3077	BRCA	BYL719	111.7	24.1	15	-44.7	4.8
X-3077	BRCA	BYL719	108.1	24.2	18	-46.5	5.2
X-3077	BRCA	BYL719	112.3	24.3	22	-44.4	5.7
X-3077	BRCA	BYL719	88.6	21.1	25	-56.2	-8.3
X-3077	BRCA	BYL719	100.5	19.9	29	-50.3	-13.5
X-3077	BRCA	BYL719	69	21.9	32	-65.9	-4.8
X-3077	BRCA	BYL719	75.8	19.4	40	-62.5	-15.7
X-3077	BRCA	BYL719	79.6	18.8	43	-60.6	-18.3
X-3077	BRCA	BYL719 + LJM716	248.2	28.3	0	0	0
X-3077	BRCA	BYL719 + LJM716	163.1	26.5	1	-34.3	-6.4
X-3077	BRCA	BYL719 + LJM716	110.4	26.6	4	-55.5	-6
X-3077	BRCA	BYL719 + LJM716	43.6	24.4	12	-82.4	-13.8
X-3077	BRCA	BYL719 + LJM716	57.8	25	15	-76.7	-11.7
X-3077	BRCA	BYL719 + LJM716	48.7	26.4	18	-80.4	-6.7
X-3077	BRCA	BYL719 + LJM716	0	27.7	22	-100	-2.1
X-3077	BRCA	BYL719 + LJM716	0	25.7	26	-100	-9.2
X-3077	BRCA	BYL719 + LJM716	0	25.9	29	-100	-8.5
X-3077	BRCA	BYL719 + LJM716	0	24.6	32	-100	-13.1
X-3077	BRCA	BYL719 + LJM716	0	22	36	-100	-22.3
X-3077	BRCA	CGM097	267	30.3	0	0	0
X-3077	BRCA	CGM097	263.8	32.8	4	-1.2	8.3
X-3077	BRCA	CGM097	271.6	32.4	8	1.7	6.9
X-3077	BRCA	CGM097	279.4	32.8	11	4.6	8.3
X-3077	BRCA	CGM097	336.1	32.6	15	25.9	7.6
X-3077	BRCA	CGM097	408.3	28.6	18	52.9	-5.6
X-3077	BRCA	CGM097	435.3	30.3	22	63	0
X-3077	BRCA	CGM097	539.2	29	25	101.9	-4.3
X-3077	BRCA	CGM097	605.2	30.6	29	126.7	1
X-3077	BRCA	CGM097	942.3	31.4	32	252.9	3.6
X-3077	BRCA	CLR457	251.1	27.5	0	0	0
X-3077	BRCA	CLR457	156.4	27.4	4	-37.7	-0.4
X-3077	BRCA	CLR457	184.7	27.3	8	-26.4	-0.7
X-3077	BRCA	CLR457	169.3	26.9	11	-32.6	-2.2
X-3077	BRCA	CLR457	118.9	27	15	-52.6	-1.8
X-3077	BRCA	CLR457	99.2	25.9	18	-60.5	-5.8
X-3077	BRCA	CLR457	87.7	25.8	22	-65.1	-6.2
X-3077	BRCA	CLR457	113.3	26.6	25	-54.9	-3.3
X-3077	BRCA	CLR457	133.6	26	33	-46.8	-5.5
X-3077	BRCA	CLR457	55.5	25.7	36	-77.9	-6.5
X-3077	BRCA	CLR457	52.3	25.8	39	-79.2	-6.2
X-3077	BRCA	CLR457	43.9	26.2	43	-82.5	-4.7
X-3077	BRCA	CLR457	62.8	26.8	47	-75	-2.5
X-3077	BRCA	CLR457	86.1	25	50	-65.7	-9.1
X-3077	BRCA	CLR457	64.5	25.3	53	-74.3	-8
X-3077	BRCA	CLR457	170	24.9	57	-32.3	-9.5
X-3077	BRCA	CLR457	111.6	25.2	61	-55.6	-8.4
X-3077	BRCA	CLR457	131.2	24.2	64	-47.7	-12
X-3077	BRCA	CLR457	165.6	23.8	67	-34.1	-13.5
X-3077	BRCA	CLR457	220	26.7	74	-12.4	-2.9
X-3077	BRCA	CLR457	227.1	25.6	78	-9.6	-6.9
X-3077	BRCA	CLR457	195.2	24.4	82	-22.3	-11.3
X-3077	BRCA	CLR457	187	24	85	-25.5	-12.7
X-3077	BRCA	CLR457	253	25.1	89	0.8	-8.7
X-3077	BRCA	HDM201	185	27.7	0	0	0
X-3077	BRCA	HDM201	182.9	27.3	4	-1.1	-1.4
X-3077	BRCA	HDM201	221.6	27.3	8	19.8	-1.4
X-3077	BRCA	HDM201	196.8	27.8	11	6.4	0.4
X-3077	BRCA	HDM201	265.4	27.4	15	43.5	-1.1
X-3077	BRCA	HDM201	300.9	27.4	18	62.6	-1.1
X-3077	BRCA	HDM201	389.6	27.3	22	110.6	-1.4
X-3077	BRCA	HDM201	476	26.2	25	157.3	-5.4
X-3077	BRCA	HDM201	356.3	25.4	29	92.6	-8.3
X-3077	BRCA	HDM201	449.2	22.5	32	142.8	-18.8
X-3077	BRCA	INC424	193.8	26.6	0	0	0
X-3077	BRCA	INC424	268.5	25.2	1	38.5	-5.3
X-3077	BRCA	INC424	192.6	25	4	-0.6	-6
X-3077	BRCA	INC424	244.7	24.1	12	26.3	-9.4
X-3077	BRCA	INC424	305.1	24.5	15	57.4	-7.9
X-3077	BRCA	INC424	300	24.1	18	54.8	-9.4
X-3077	BRCA	INC424	275.5	26.1	22	42.2	-1.9
X-3077	BRCA	INC424	350.4	24.8	26	80.8	-6.8
X-3077	BRCA	INC424	362.7	24.2	29	87.2	-9
X-3077	BRCA	INC424	464.9	24.6	32	139.9	-7.5
X-3077	BRCA	INC424	528	24.6	36	172.4	-7.5
X-3077	BRCA	INC424	569.3	24.8	40	193.8	-6.8
X-3077	BRCA	INC424	509.2	24.3	43	162.7	-8.6
X-3077	BRCA	INC424	718.7	25	46	270.8	-6
X-3077	BRCA	LEE011 + everolimus	277.5	25.3	0	0	0
X-3077	BRCA	LEE011 + everolimus	239.9	27	1	-13.5	6.7
X-3077	BRCA	LEE011 + everolimus	151.4	24.7	5	-45.4	-2.4
X-3077	BRCA	LEE011 + everolimus	166.6	24.9	8	-40	-1.6
X-3077	BRCA	LEE011 + everolimus	209.2	26.1	11	-24.6	3.2
X-3077	BRCA	LEE011 + everolimus	152.8	25.2	15	-44.9	-0.4
X-3077	BRCA	LEE011 + everolimus	137.4	25	22	-50.5	-1.2
X-3077	BRCA	LEE011 + everolimus	227	25.1	25	-18.2	-0.8
X-3077	BRCA	LEE011 + everolimus	113.8	25.8	32	-59	2
X-3077	BRCA	LEE011 + everolimus	120.3	26.4	36	-56.6	4.3
X-3077	BRCA	LEE011 + everolimus	220.3	25.3	40	-20.6	0
X-3077	BRCA	LEE011 + everolimus	159.9	25.8	43	-42.4	2
X-3077	BRCA	LEE011 + everolimus	141.9	24.5	47	-48.9	-3.2
X-3077	BRCA	LEE011 + everolimus	161.9	24.6	50	-41.7	-2.8
X-3077	BRCA	LEE011 + everolimus	189.8	24.1	53	-31.6	-4.7
X-3077	BRCA	LEE011 + everolimus	177.7	24.8	57	-36	-2
X-3077	BRCA	LEE011 + everolimus	165.9	25.8	61	-40.2	2
X-3077	BRCA	LEE011 + everolimus	190.6	25.1	64	-31.3	-0.8
X-3077	BRCA	LEE011 + everolimus	202.2	24.6	68	-27.1	-2.8
X-3077	BRCA	LEE011 + everolimus	209.2	24.4	71	-24.6	-3.6
X-3077	BRCA	LEE011 + everolimus	264.2	24.7	74	-4.8	-2.4
X-3077	BRCA	LEE011 + everolimus	362.9	24.9	78	30.8	-1.6
X-3077	BRCA	LEE011 + everolimus	241.2	24.1	81	-13.1	-4.7
X-3077	BRCA	LEE011 + everolimus	261.4	24.1	85	-5.8	-4.7
X-3077	BRCA	LEE011 + everolimus	256.8	25.4	88	-7.5	0.4
X-3077	BRCA	LEE011 + everolimus	296.6	23.6	96	6.9	-6.7
X-3077	BRCA	LEE011	208.9	25.8	0	0	0
X-3077	BRCA	LEE011	256.1	29.8	3	22.6	15.5
X-3077	BRCA	LEE011	236.9	28.6	7	13.4	10.9
X-3077	BRCA	LEE011	293.7	28.8	10	40.6	11.6
X-3077	BRCA	LEE011	227.7	30.4	13	9	17.8
X-3077	BRCA	LEE011	260.3	30.8	17	24.6	19.4
X-3077	BRCA	LEE011	295.6	32.3	21	41.5	25.2
X-3077	BRCA	LEE011	295.7	31.7	24	41.6	22.9
X-3077	BRCA	LEE011	359.2	32.1	27	71.9	24.4
X-3077	BRCA	LEE011	530.9	33.1	34	154.1	28.3
X-3077	BRCA	LFA102	194.2	25.2	0	0	0
X-3077	BRCA	LFA102	179.1	25	3	-7.8	-0.8
X-3077	BRCA	LFA102	197.2	24.5	6	1.5	-2.8
X-3077	BRCA	LFA102	288.3	24.8	10	48.5	-1.6
X-3077	BRCA	LFA102	369.2	26.2	13	90.1	4
X-3077	BRCA	LFA102	504	25.2	21	159.5	0
X-3077	BRCA	LFA102	624.6	25.4	24	221.6	0.8
X-3077	BRCA	LFA102	716.7	25.4	27	269.1	0.8
X-3077	BRCA	LFA102	802.5	24.3	31	313.2	-3.6
X-3077	BRCA	LFA102	945	25.8	35	386.6	2.4
X-3077	BRCA	LJM716	200.2	23.5	0	0	0
X-3077	BRCA	LJM716	215.5	23.8	4	7.6	1.3
X-3077	BRCA	LJM716	208.5	23.6	8	4.1	0.4
X-3077	BRCA	LJM716	166.1	24.4	11	-17	3.8
X-3077	BRCA	LJM716	190.3	24.4	15	-4.9	3.8
X-3077	BRCA	LJM716	185.5	24	18	-7.3	2.1
X-3077	BRCA	LJM716	235.6	24.8	22	17.7	5.5
X-3077	BRCA	LJM716	269.7	23.2	25	34.7	-1.3
X-3077	BRCA	LJM716	294.2	23.9	29	47	1.7
X-3077	BRCA	LJM716	313.5	24	32	56.6	2.1
X-3077	BRCA	LJM716	383.1	23.5	40	91.4	0
X-3077	BRCA	LJM716	376.6	24.4	43	88.1	3.8
X-3077	BRCA	LJM716	748.1	23.3	46	273.7	-0.9
X-3077	BRCA	LJM716	619.5	23.9	48	209.4	1.7
X-3077	BRCA	LJM716 + trastuzumab	206	27.1	0	0	0
X-3077	BRCA	LJM716 + trastuzumab	157.8	25.8	3	-23.4	-4.8
X-3077	BRCA	LJM716 + trastuzumab	120	27.3	6	-41.7	0.7
X-3077	BRCA	LJM716 + trastuzumab	111.8	26.3	14	-45.7	-3
X-3077	BRCA	LJM716 + trastuzumab	84.4	26.9	17	-59	-0.7
X-3077	BRCA	LJM716 + trastuzumab	79.2	27.3	20	-61.6	0.7
X-3077	BRCA	LJM716 + trastuzumab	59.5	29.2	24	-71.1	7.7
X-3077	BRCA	LJM716 + trastuzumab	86	27.4	28	-58.3	1.1
X-3077	BRCA	LJM716 + trastuzumab	151.3	27.2	31	-26.6	0.4
X-3077	BRCA	LJM716 + trastuzumab	111	26.8	34	-46.1	-1.1
X-3077	BRCA	LJM716 + trastuzumab	176	26.8	38	-14.6	-1.1
X-3077	BRCA	LJM716 + trastuzumab	171.7	28.8	42	-16.7	6.3
X-3077	BRCA	LJM716 + trastuzumab	245.2	26.8	45	19	-1.1
X-3077	BRCA	LJM716 + trastuzumab	247	27.1	48	19.9	0
X-3077	BRCA	LJM716 + trastuzumab	406	27.6	55	97.1	1.8
X-3077	BRCA	LJM716 + trastuzumab	482.2	28.1	59	134.1	3.7
X-3077	BRCA	LJM716 + trastuzumab	537.7	27.5	63	161	1.5
X-3077	BRCA	LKA136	227.5	27.7	0	0	0
X-3077	BRCA	LKA136	217.6	26.7	4	-4.4	-3.6
X-3077	BRCA	LKA136	186.5	26.4	8	-18	-4.7
X-3077	BRCA	LKA136	410.9	26.7	11	80.6	-3.6
X-3077	BRCA	LKA136	414.3	26.5	15	82.1	-4.3
X-3077	BRCA	LKA136	643.2	25.5	18	182.7	-7.9
X-3077	BRCA	LKA136	627.6	26	22	175.9	-6.1
X-3077	BRCA	LKA136	767.2	27.1	25	237.2	-2.2
X-3077	BRCA	LLM871	217.9	26.5	0	0	0
X-3077	BRCA	LLM871	267.6	25.5	3	22.8	-3.8
X-3077	BRCA	LLM871	244.6	26.8	6	12.3	1.1
X-3077	BRCA	LLM871	190.5	26.5	10	-12.6	0
X-3077	BRCA	LLM871	308.1	26.6	13	41.4	0.4
X-3077	BRCA	LLM871	305.4	26.1	17	40.2	-1.5
X-3077	BRCA	LLM871	313.6	25.6	20	43.9	-3.4
X-3077	BRCA	LLM871	273.7	25.3	24	25.6	-4.5
X-3077	BRCA	LLM871	296.1	27.1	27	35.9	2.3
X-3077	BRCA	LLM871	287	26.1	35	31.7	-1.5
X-3077	BRCA	LLM871	636.3	26.5	38	192	0
X-3077	BRCA	LLM871	690.7	25.9	41	217	-2.3
X-3077	BRCA	binimetinib	189.5	23.3	0	0	0
X-3077	BRCA	binimetinib	219.3	23.5	3	15.7	0.9
X-3077	BRCA	binimetinib	262.5	27.5	4	38.5	18
X-3077	BRCA	binimetinib	218.2	22.9	6	15.1	-1.7
X-3077	BRCA	binimetinib	335.7	27.8	8	77.2	19.3
X-3077	BRCA	binimetinib	337.8	25.3	11	78.3	8.6
X-3077	BRCA	binimetinib	230.2	21.9	14	21.5	-6
X-3077	BRCA	binimetinib	276.8	18.4	15	46.1	-21
X-3077	BRCA	binimetinib	226.4	22.1	17	19.5	-5.2
X-3077	BRCA	binimetinib	182.7	17.9	20	-3.6	-23.2
X-3077	BRCA	paclitaxel	233.2	25.3	0	0	0
X-3077	BRCA	paclitaxel	214	25	3	-8.2	-1.2
X-3077	BRCA	paclitaxel	289.1	25	6	24	-1.2
X-3077	BRCA	paclitaxel	255.9	24.3	10	9.7	-4
X-3077	BRCA	paclitaxel	249.1	25.2	13	6.8	-0.4
X-3077	BRCA	paclitaxel	450	24	21	93	-5.1
X-3077	BRCA	paclitaxel	471.6	23.6	24	102.2	-6.7
X-3077	BRCA	paclitaxel	561.7	24.6	27	140.9	-2.8
X-3077	BRCA	paclitaxel	597.7	24.6	31	156.3	-2.8
X-3077	BRCA	paclitaxel	744.9	21.8	38	219.4	-13.8
X-3077	BRCA	paclitaxel	791.7	24.5	41	239.5	-3.2
X-3077	BRCA	tamoxifen	282.4	26	0	0	0
X-3077	BRCA	tamoxifen	252.5	26.9	1	-10.6	3.5
X-3077	BRCA	tamoxifen	204.3	27.2	4	-27.7	4.6
X-3077	BRCA	tamoxifen	309.5	25.9	8	9.6	-0.4
X-3077	BRCA	tamoxifen	297.3	25.6	11	5.3	-1.5
X-3077	BRCA	tamoxifen	368.4	26.3	15	30.5	1.2
X-3077	BRCA	tamoxifen	310.6	26.6	18	10	2.3
X-3077	BRCA	tamoxifen	411.5	26.3	26	45.7	1.2
X-3077	BRCA	tamoxifen	423.9	27.1	29	50.1	4.2
X-3077	BRCA	tamoxifen	547.8	26.8	32	94	3.1
X-3077	BRCA	tamoxifen	540.4	27.9	36	91.4	7.3
X-3077	BRCA	tamoxifen	644.9	26.7	40	128.4	2.7
X-3077	BRCA	tamoxifen	885.1	25.9	43	213.4	-0.4
X-3077	BRCA	tamoxifen	843.9	25.3	46	198.8	-2.7
X-3077	BRCA	trastuzumab	233.5	30.3	0	0	0
X-3077	BRCA	trastuzumab	276.2	29.9	3	18.3	-1.3
X-3077	BRCA	trastuzumab	369.9	29.9	6	58.4	-1.3
X-3077	BRCA	trastuzumab	405.2	29.7	10	73.5	-2
X-3077	BRCA	trastuzumab	431.4	30.5	13	84.8	0.7
X-3077	BRCA	trastuzumab	557.2	30.5	21	138.6	0.7
X-3077	BRCA	trastuzumab	796.5	30.8	24	241.1	1.7
X-3077	BRCA	trastuzumab	777.6	30.3	27	233	0
X-3077	BRCA	trastuzumab	838.6	30.8	31	259.1	1.7
X-3077	BRCA	trastuzumab	1058.9	31.6	35	353.5	4.3
X-3077	BRCA	trastuzumab	1200.9	27.2	38	414.3	-10.2
X-3077	BRCA	trastuzumab	1205.9	30.5	41	416.4	0.7
X-3077	BRCA	untreated	185.5	28.6	0	0	0
X-3077	BRCA	untreated	204.6	28.9	1	10.3	1
X-3077	BRCA	untreated	224.4	29.7	4	21	3.8
X-3077	BRCA	untreated	224.7	29	8	21.1	1.4
X-3077	BRCA	untreated	238.6	29	11	28.6	1.4
X-3077	BRCA	untreated	384.6	28.9	15	107.3	1
X-3077	BRCA	untreated	495.2	29.7	18	167	3.8
X-3077	BRCA	untreated	553.8	28.2	26	198.5	-1.4
X-3077	BRCA	untreated	536.4	27.6	29	189.2	-3.5
X-3077	BRCA	untreated	507.2	26.6	32	173.4	-7
X-3077	BRCA	untreated	526.8	27.2	36	184	-4.9
X-3077	BRCA	untreated	602.2	28.5	40	224.6	-0.3
X-3077	BRCA	untreated	733.5	24.4	43	295.4	-14.7
X-3077	BRCA	untreated	751.4	24.2	46	305.1	-15.4
X-3077	BRCA	LFW527 + everolimus	238.7	28.9	0	0	0
X-3077	BRCA	LFW527 + everolimus	228.94	27.1	3	-4.1	-6.2
X-3077	BRCA	LFW527 + everolimus	210.87	26.6	6	-11.7	-8
X-3077	BRCA	LFW527 + everolimus	236.74	25	10	-0.8	-13.5
X-3077	BRCA	LFW527 + everolimus	210.82	25.7	13	-11.7	-11.1
X-3077	BRCA	LFW527 + everolimus	248.97	24.6	17	4.3	-14.9
X-3077	BRCA	LFW527 + everolimus	228.48	25.5	20	-4.3	-11.8
X-3077	BRCA	LFW527 + everolimus	211.73	22.3	27	-11.3	-22.8
X-3078	BRCA	BGJ398	293.9	26.3	0	0	0
X-3078	BRCA	BGJ398	375.2	27	4	27.7	2.7
X-3078	BRCA	BGJ398	465.1	25.6	8	58.3	-2.7
X-3078	BRCA	BGJ398	560.3	25.3	11	90.6	-3.8
X-3078	BRCA	BGJ398	576.6	24.9	15	96.2	-5.3
X-3078	BRCA	BGJ398	597.2	25.3	18	103.2	-3.8
X-3078	BRCA	BGJ398	727	25.8	22	147.4	-1.9
X-3078	BRCA	BGJ398	782.4	26.3	25	166.2	0
X-3078	BRCA	BGJ398	933.1	25.1	29	217.5	-4.6
X-3078	BRCA	BGJ398	1074.6	25.6	32	265.6	-2.7
X-3078	BRCA	BKM120	338.5	27.5	0	0	0
X-3078	BRCA	BKM120	343.9	28.2	4	1.6	2.5
X-3078	BRCA	BKM120	369.1	27.6	8	9	0.4
X-3078	BRCA	BKM120	409.6	27.1	11	21	-1.5
X-3078	BRCA	BKM120	465.4	26.2	15	37.5	-4.7
X-3078	BRCA	BKM120	460.3	25.3	18	36	-8
X-3078	BRCA	BKM120	475	21.9	25	40.3	-20.4
X-3078	BRCA	BYL719 + LEE011	289.9	29	0	0	0
X-3078	BRCA	BYL719 + LEE011	180.4	29	4	-37.8	0
X-3078	BRCA	BYL719 + LEE011	152.8	27.7	8	-47.3	-4.5
X-3078	BRCA	BYL719 + LEE011	171.5	29.2	11	-40.8	0.7
X-3078	BRCA	BYL719 + LEE011	170.7	27.9	15	-41.1	-3.8
X-3078	BRCA	BYL719 + LEE011	192.8	27.3	18	-33.5	-5.9
X-3078	BRCA	BYL719 + LEE011	152.1	22.7	25	-47.5	-21.7
X-3078	BRCA	BYL719 + LEE011	196	22.8	28	-32.4	-21.4
X-3078	BRCA	BYL719 + LEE011	208.3	24.8	33	-28.1	-14.5
X-3078	BRCA	BYL719 + LEE011	227.4	25.7	36	-21.6	-11.4
X-3078	BRCA	BYL719 + LEE011	281.7	23.7	39	-2.8	-18.3
X-3078	BRCA	BYL719 + LJM716	192.3	27.3	0	0	0
X-3078	BRCA	BYL719 + LJM716	170.8	25.6	3	-11.2	-6.2
X-3078	BRCA	BYL719 + LJM716	178.2	25.2	6	-7.3	-7.7
X-3078	BRCA	BYL719 + LJM716	153.6	24.7	10	-20.1	-9.5
X-3078	BRCA	BYL719 + LJM716	138.9	25.3	13	-27.8	-7.3
X-3078	BRCA	BYL719 + LJM716	134.7	25	17	-30	-8.4
X-3078	BRCA	BYL719 + LJM716	180.4	25	20	-6.2	-8.4
X-3078	BRCA	BYL719 + LJM716	225.6	25.3	28	17.3	-7.3
X-3078	BRCA	BYL719 + LJM716	203.6	24.6	31	5.9	-9.9
X-3078	BRCA	BYL719 + LJM716	205.5	24.8	34	6.9	-9.2
X-3078	BRCA	BYL719 + LJM716	180.5	22.7	38	-6.1	-16.8
X-3078	BRCA	BYL719 + LJM716	225.6	23.8	41	17.3	-12.8
X-3078	BRCA	BYL719 + LJM716	235.3	23.8	45	22.4	-12.8
X-3078	BRCA	BYL719 + LJM716	319.7	24.4	48	66.3	-10.6
X-3078	BRCA	BYL719 + LJM716	333	23.4	52	73.2	-14.3
X-3078	BRCA	BYL719 + LJM716	362.1	24.7	55	88.3	-9.5
X-3078	BRCA	BYL719 + LJM716	411.6	25.8	59	114	-5.5
X-3078	BRCA	BYL719 + LJM716	460.6	25.8	62	139.5	-5.5
X-3078	BRCA	BYL719 + LJM716	513.6	25.5	69	167.1	-6.6
X-3078	BRCA	BYL719 + LJM716	584.7	25.2	72	204.1	-7.7
X-3078	BRCA	BYL719	252.3	27.5	0	0	0
X-3078	BRCA	BYL719	210.9	25.8	3	-16.4	-6.2
X-3078	BRCA	BYL719	229.2	26.5	7	-9.2	-3.6
X-3078	BRCA	BYL719	236.5	26.2	10	-6.3	-4.7
X-3078	BRCA	BYL719	266.6	26.3	14	5.7	-4.4
X-3078	BRCA	BYL719	302.2	26.4	17	19.8	-4
X-3078	BRCA	BYL719	301.6	25	21	19.5	-9.1
X-3078	BRCA	BYL719	268	24.6	24	6.2	-10.5
X-3078	BRCA	BYL719	263.3	23.7	32	4.4	-13.8
X-3078	BRCA	CGM097	241.9	26.2	0	0	0
X-3078	BRCA	CGM097	297.1	27.5	3	22.8	5
X-3078	BRCA	CGM097	328.4	28.2	6	35.8	7.6
X-3078	BRCA	CGM097	374.8	26.7	10	54.9	1.9
X-3078	BRCA	CGM097	411.9	27.3	13	70.3	4.2
X-3078	BRCA	CGM097	510.7	28.3	17	111.1	8
X-3078	BRCA	CGM097	457.7	29	20	89.2	10.7
X-3078	BRCA	CGM097	721.7	29.8	28	198.3	13.7
X-3078	BRCA	CGM097	699.5	28.8	31	189.2	9.9
X-3078	BRCA	CGM097	742.7	28.7	34	207	9.5
X-3078	BRCA	CGM097	534.3	24.6	38	120.9	-6.1
X-3078	BRCA	CGM097	398.2	23.9	39	64.6	-8.8
X-3078	BRCA	CLR457	220	24.5	0	0	0
X-3078	BRCA	CLR457	230.9	23.3	4	5	-4.9
X-3078	BRCA	CLR457	241.6	24.6	8	9.8	0.4
X-3078	BRCA	CLR457	259.3	24.2	11	17.9	-1.2
X-3078	BRCA	CLR457	311	24.1	15	41.4	-1.6
X-3078	BRCA	CLR457	284.7	23.6	18	29.4	-3.7
X-3078	BRCA	CLR457	257.4	23.1	22	17	-5.7
X-3078	BRCA	CLR457	311.5	22.8	25	41.6	-6.9
X-3078	BRCA	CLR457	327.9	17.5	31	49	-28.6
X-3078	BRCA	HDM201	500.9	29.2	0	0	0
X-3078	BRCA	HDM201	265.7	31.8	3	-47	8.9
X-3078	BRCA	HDM201	262.5	31	6	-47.6	6.2
X-3078	BRCA	HDM201	392.6	30.3	10	-21.6	3.8
X-3078	BRCA	HDM201	391.5	29.8	13	-21.8	2.1
X-3078	BRCA	HDM201	480.7	30.1	17	-4	3.1
X-3078	BRCA	HDM201	500.9	29.2	20	0	0
X-3078	BRCA	HDM201	459.3	27.2	28	-8.3	-6.8
X-3078	BRCA	HDM201	421.6	23.8	31	-15.8	-18.5
X-3078	BRCA	HDM201	415.3	21	34	-17.1	-28.1
X-3078	BRCA	INC424	200.3	27.8	0	0	0
X-3078	BRCA	INC424	252.3	27.8	3	26	0
X-3078	BRCA	INC424	297.1	27.8	6	48.3	0
X-3078	BRCA	INC424	337.1	27.4	10	68.3	-1.4
X-3078	BRCA	INC424	367.7	28.8	13	83.6	3.6
X-3078	BRCA	INC424	427.1	28.5	17	113.2	2.5
X-3078	BRCA	INC424	484.4	28.6	20	141.8	2.9
X-3078	BRCA	INC424	721.6	28.9	28	260.3	4
X-3078	BRCA	INC424	824.3	27.8	31	311.5	0
X-3078	BRCA	INC424	874.3	28.2	34	336.5	1.4
X-3078	BRCA	INC424	1061	27.4	38	429.7	-1.4
X-3078	BRCA	INC424	1091	28.2	41	444.7	1.4
X-3078	BRCA	LEE011 + everolimus	235	28.8	0	0	0
X-3078	BRCA	LEE011 + everolimus	219.1	27.6	6	-6.8	-4.2
X-3078	BRCA	LEE011 + everolimus	221.9	27.5	9	-5.6	-4.5
X-3078	BRCA	LEE011 + everolimus	190	26.5	14	-19.1	-8
X-3078	BRCA	LEE011 + everolimus	198.1	27.4	17	-15.7	-4.9
X-3078	BRCA	LEE011 + everolimus	233.1	27.2	20	-0.8	-5.6
X-3078	BRCA	LEE011 + everolimus	246.3	27	24	4.8	-6.2
X-3078	BRCA	LEE011 + everolimus	231	25.6	27	-1.7	-11.1
X-3078	BRCA	LEE011 + everolimus	193.4	24.5	31	-17.7	-14.9
X-3078	BRCA	LEE011 + everolimus	207.9	22.9	34	-11.5	-20.5
X-3078	BRCA	LEE011 + everolimus	168.6	21.9	38	-28.3	-24
X-3078	BRCA	LEE011 + everolimus	196.2	21.4	41	-16.5	-25.7
X-3078	BRCA	LEE011	209.3	29.3	0	0	0
X-3078	BRCA	LEE011	253	29.8	3	20.9	1.7
X-3078	BRCA	LEE011	276.9	29.9	10	32.3	2
X-3078	BRCA	LEE011	317.5	29.5	13	51.7	0.7
X-3078	BRCA	LEE011	336.8	29.1	18	60.9	-0.7
X-3078	BRCA	LEE011	388.3	30.2	21	85.5	3.1
X-3078	BRCA	LEE011	444.2	28.7	24	112.2	-2
X-3078	BRCA	LEE011	480.2	29.4	28	129.4	0.3
X-3078	BRCA	LEE011	566.7	29.9	31	170.8	2
X-3078	BRCA	LEE011	642.9	30.4	35	207.2	3.8
X-3078	BRCA	LEE011	716.2	30.7	38	242.2	4.8
X-3078	BRCA	LEE011	851.3	31.3	42	306.7	6.8
X-3078	BRCA	LEE011	978.3	32.1	45	367.4	9.6
X-3078	BRCA	LFA102	353.5	26.2	0	0	0
X-3078	BRCA	LFA102	314.3	25.3	3	-11.1	-3.4
X-3078	BRCA	LFA102	343.5	25.8	7	-2.8	-1.5
X-3078	BRCA	LFA102	370.9	24.5	10	4.9	-6.5
X-3078	BRCA	LFA102	459.6	22.3	14	30	-14.9
X-3078	BRCA	LFA102	555	22.2	17	57	-15.3
X-3078	BRCA	LFA102	671.6	24.6	21	90	-6.1
X-3078	BRCA	LFA102	748.3	23.5	24	111.7	-10.3
X-3078	BRCA	LFA102	1316	27	32	272.3	3.1
X-3078	BRCA	LJM716 + trastuzumab	260.4	22.6	0	0	0
X-3078	BRCA	LJM716 + trastuzumab	295.3	22.9	3	13.4	1.3
X-3078	BRCA	LJM716 + trastuzumab	302.8	22.8	6	16.3	0.9
X-3078	BRCA	LJM716 + trastuzumab	300.3	22.7	10	15.3	0.4
X-3078	BRCA	LJM716 + trastuzumab	335.6	22.7	13	28.9	0.4
X-3078	BRCA	LJM716 + trastuzumab	361.5	22.1	17	38.8	-2.2
X-3078	BRCA	LJM716 + trastuzumab	465.6	22.7	20	78.8	0.4
X-3078	BRCA	LJM716 + trastuzumab	539	23.5	28	107	4
X-3078	BRCA	LJM716 + trastuzumab	641.5	21.5	31	146.4	-4.9
X-3078	BRCA	LJM716 + trastuzumab	809.5	21.8	34	210.9	-3.5
X-3078	BRCA	LJM716	273.5	24.5	0	0	0
X-3078	BRCA	LJM716	318.9	23.9	3	16.6	-2.4
X-3078	BRCA	LJM716	361.7	23.6	6	32.2	-3.7
X-3078	BRCA	LJM716	393.9	22.3	10	44	-9
X-3078	BRCA	LJM716	523.6	23.4	13	91.4	-4.5
X-3078	BRCA	LJM716	709.9	23.8	17	159.6	-2.9
X-3078	BRCA	LJM716	777	23.7	20	184.1	-3.3
X-3078	BRCA	LJM716	1055.8	23.1	28	286	-5.7
X-3078	BRCA	LKA136	193.6	27.2	0	0	0
X-3078	BRCA	LKA136	247.8	27.5	4	28	1.1
X-3078	BRCA	LKA136	272.7	28.2	8	40.9	3.7
X-3078	BRCA	LKA136	409.5	28.3	11	111.5	4
X-3078	BRCA	LKA136	396.4	27.8	15	104.8	2.2
X-3078	BRCA	LKA136	511.2	28.1	18	164	3.3
X-3078	BRCA	LKA136	473	27.7	22	144.3	1.8
X-3078	BRCA	LKA136	689.8	27.9	25	256.3	2.6
X-3078	BRCA	LKA136	835.6	28.3	33	331.6	4
X-3078	BRCA	LKA136	976.4	28.6	36	404.3	5.1
X-3078	BRCA	LKA136	1065.8	29	39	450.5	6.6
X-3078	BRCA	LLM871	225.4	26.3	0	0	0
X-3078	BRCA	LLM871	238.1	24.4	3	5.6	-7.2
X-3078	BRCA	LLM871	332.7	25.1	6	47.6	-4.6
X-3078	BRCA	LLM871	314.5	25	10	39.5	-4.9
X-3078	BRCA	LLM871	348.8	25.1	13	54.7	-4.6
X-3078	BRCA	LLM871	409.1	26.3	21	81.5	0
X-3078	BRCA	LLM871	491.2	25.7	24	117.9	-2.3
X-3078	BRCA	LLM871	503.3	25.7	27	123.3	-2.3
X-3078	BRCA	binimetinib	189.3	29.8	0	0	0
X-3078	BRCA	binimetinib	255.4	28.7	4	34.9	-3.7
X-3078	BRCA	binimetinib	370.1	29.6	8	95.5	-0.7
X-3078	BRCA	binimetinib	449.3	29.5	11	137.3	-1
X-3078	BRCA	binimetinib	566.9	27.9	15	199.5	-6.4
X-3078	BRCA	binimetinib	512.2	25.4	18	170.6	-14.8
X-3078	BRCA	binimetinib	682.9	27.5	22	260.8	-7.7
X-3078	BRCA	binimetinib	720.6	27.3	25	280.7	-8.4
X-3078	BRCA	binimetinib	942.2	22.7	33	397.7	-23.8
X-3078	BRCA	paclitaxel	227.3	25.9	0	0	0
X-3078	BRCA	paclitaxel	204	26.1	3	-10.3	0.8
X-3078	BRCA	paclitaxel	140.1	26.4	7	-38.4	1.9
X-3078	BRCA	paclitaxel	103.3	25.9	10	-54.6	0
X-3078	BRCA	paclitaxel	105.8	26	14	-53.5	0.4
X-3078	BRCA	paclitaxel	96	26.1	17	-57.8	0.8
X-3078	BRCA	paclitaxel	77.3	26.2	21	-66	1.2
X-3078	BRCA	paclitaxel	62.1	26.1	24	-72.7	0.8
X-3078	BRCA	paclitaxel	63.1	26.7	32	-72.2	3.1
X-3078	BRCA	paclitaxel	74.9	25.8	35	-67	-0.4
X-3078	BRCA	paclitaxel	55.2	26.8	38	-75.7	3.5
X-3078	BRCA	paclitaxel	58.9	25.8	42	-74.1	-0.4
X-3078	BRCA	paclitaxel	80.5	27	45	-64.6	4.2
X-3078	BRCA	paclitaxel	106.6	26	49	-53.1	0.4
X-3078	BRCA	paclitaxel	119.2	26.7	52	-47.6	3.1
X-3078	BRCA	paclitaxel	137.9	26.3	56	-39.3	1.5
X-3078	BRCA	paclitaxel	129.1	26.9	59	-43.2	3.9
X-3078	BRCA	paclitaxel	142.7	25.9	63	-37.2	0
X-3078	BRCA	paclitaxel	132.5	26.8	66	-41.7	3.5
X-3078	BRCA	paclitaxel	189.2	27.5	73	-16.8	6.2
X-3078	BRCA	paclitaxel	206.4	26.7	76	-9.2	3.1
X-3078	BRCA	paclitaxel	167.4	27	81	-26.4	4.2
X-3078	BRCA	paclitaxel	185.3	26.9	84	-18.5	3.9
X-3078	BRCA	paclitaxel	228.7	27.2	87	0.6	5
X-3078	BRCA	paclitaxel	274.4	24.5	91	20.7	-5.4
X-3078	BRCA	paclitaxel	234.1	27.5	94	3	6.2
X-3078	BRCA	tamoxifen	203.7	29.3	0	0	0
X-3078	BRCA	tamoxifen	219.9	29.1	4	8	-0.7
X-3078	BRCA	tamoxifen	255.9	28.9	8	25.6	-1.4
X-3078	BRCA	tamoxifen	293	29.8	11	43.8	1.7
X-3078	BRCA	tamoxifen	320.8	29.5	15	57.5	0.7
X-3078	BRCA	tamoxifen	330.9	30	18	62.4	2.4
X-3078	BRCA	tamoxifen	448.5	30.7	26	120.2	4.8
X-3078	BRCA	tamoxifen	591.4	30.2	29	190.3	3.1
X-3078	BRCA	tamoxifen	606.7	30.6	32	197.8	4.4
X-3078	BRCA	tamoxifen	736.6	30.1	36	261.6	2.7
X-3078	BRCA	tamoxifen	789.4	29.9	39	287.5	2
X-3078	BRCA	tamoxifen	865.4	30	43	324.8	2.4
X-3078	BRCA	tamoxifen	928.5	29.7	46	355.8	1.4
X-3078	BRCA	trastuzumab	253.6	26.4	0	0	0
X-3078	BRCA	trastuzumab	264	26	3	4.1	-1.5
X-3078	BRCA	trastuzumab	325.3	26.8	7	28.3	1.5
X-3078	BRCA	trastuzumab	409.9	26.6	10	61.6	0.8
X-3078	BRCA	trastuzumab	480.6	26.9	14	89.5	1.9
X-3078	BRCA	trastuzumab	503.1	27.6	17	98.4	4.5
X-3078	BRCA	trastuzumab	602.2	27	21	137.5	2.3
X-3078	BRCA	trastuzumab	662.9	27.2	24	161.4	3
X-3078	BRCA	trastuzumab	842.5	29.2	32	232.2	10.6
X-3078	BRCA	trastuzumab	1041.5	27.6	35	310.7	4.5
X-3078	BRCA	trastuzumab	1057.5	28.5	38	317	8
X-3078	BRCA	untreated	306.6	25.5	0	0	0
X-3078	BRCA	untreated	405.7	26.3	4	32.3	3.1
X-3078	BRCA	untreated	515.2	26.3	7	68	3.1
X-3078	BRCA	untreated	559.3	27.1	15	82.4	6.3
X-3078	BRCA	untreated	633.2	25.8	18	106.5	1.2
X-3078	BRCA	untreated	736.4	26.3	21	140.2	3.1
X-3078	BRCA	untreated	839.2	26	25	173.7	2
X-3078	BRCA	untreated	835.5	26.4	28	172.5	3.5
X-3078	BRCA	untreated	1062.1	25.9	32	246.4	1.6
X-3078	BRCA	untreated	1022	26.7	35	233.3	4.7
X-3078	BRCA	LFW527 + everolimus	232.84	25.5	0	0	0
X-3078	BRCA	LFW527 + everolimus	248.44	24.5	3	6.7	-3.9
X-3078	BRCA	LFW527 + everolimus	253.21	24.1	7	8.7	-5.5
X-3078	BRCA	LFW527 + everolimus	235.26	22.3	9	1	-12.5
X-3078	BRCA	LFW527 + everolimus	178.75	21.4	13	-23.2	-16.1
X-3078	BRCA	LFW527 + everolimus	214.85	23.9	16	-7.7	-6.3
X-3078	BRCA	LFW527 + everolimus	215.87	19.3	21	-7.3	-24.3
X-3093	CRC	5FU	292.3	19.4	0	0	0
X-3093	CRC	5FU	493.9	18.5	2	69	-4.6
X-3093	CRC	5FU	639.6	17.6	7	118.8	-9.3
X-3093	CRC	5FU	647.5	18.7	10	121.5	-3.6
X-3093	CRC	5FU	875.5	18.2	13	199.5	-6.2
X-3093	CRC	5FU	1060.1	19	16	262.7	-2.1
X-3093	CRC	5FU	822.9	17.6	20	181.5	-9.3
X-3093	CRC	5FU	1221.3	17.4	23	317.8	-10.3
X-3093	CRC	5FU	1678.8	16.8	27	474.3	-13.4
X-3093	CRC	BKM120	220.8	22.8	0	0	0
X-3093	CRC	BKM120	247.6	22.2	5	12.1	-2.6
X-3093	CRC	BKM120	234.6	22.5	8	6.2	-1.3
X-3093	CRC	BKM120	252.1	21	11	14.2	-7.9
X-3093	CRC	BKM120	356.1	24	14	61.3	5.3
X-3093	CRC	BKM120	299.9	21.5	18	35.8	-5.7
X-3093	CRC	BKM120	295.6	21.8	21	33.9	-4.4
X-3093	CRC	BKM120	373.1	NA	25	69	-4.4
X-3093	CRC	BKM120	490.6	22.4	29	122.2	-1.8
X-3093	CRC	BKM120	420.4	19.3	32	90.4	-15.4
X-3093	CRC	BKM120	529.7	19.1	35	139.9	-16.2
X-3093	CRC	BKM120 + LJC049	225.3	28.1	0	0	0
X-3093	CRC	BKM120 + LJC049	264.1	26.7	3	17.2	-5
X-3093	CRC	BKM120 + LJC049	200	26.1	6	-11.2	-7.1
X-3093	CRC	BKM120 + LJC049	241.7	26.7	9	7.3	-5
X-3093	CRC	BKM120 + LJC049	304.9	25.3	13	35.3	-10
X-3093	CRC	BKM120 + LJC049	365.7	24.7	16	62.3	-12.1
X-3093	CRC	BKM120 + LJC049	396.3	24.6	20	75.9	-12.5
X-3093	CRC	BKM120 + LJC049	497.6	25.9	24	120.9	-7.8
X-3093	CRC	BKM120 + LJC049	620.2	22.9	27	175.3	-18.5
X-3093	CRC	BKM120 + LJC049	708.6	24.7	30	214.5	-12.1
X-3093	CRC	BYL719 + cetuximab	299.2	26.6	0	0	0
X-3093	CRC	BYL719 + cetuximab	272.5	26.9	2	-8.9	1.1
X-3093	CRC	BYL719 + cetuximab	294.8	27.5	5	-1.5	3.4
X-3093	CRC	BYL719 + cetuximab	357.7	25.4	9	19.6	-4.5
X-3093	CRC	BYL719 + cetuximab	313.1	25.7	12	4.6	-3.4
X-3093	CRC	BYL719 + cetuximab	318.1	26.5	16	6.3	-0.4
X-3093	CRC	BYL719 + cetuximab	356	26.3	19	19	-1.1
X-3093	CRC	BYL719 + cetuximab	446.4	26.3	23	49.2	-1.1
X-3093	CRC	BYL719 + cetuximab	402.8	26.2	26	34.6	-1.5
X-3093	CRC	BYL719 + cetuximab	412.6	26.1	33	37.9	-1.9
X-3093	CRC	BYL719 + cetuximab	567.5	25.8	44	89.7	-3
X-3093	CRC	BYL719 + cetuximab	623.8	25.6	48	108.5	-3.8
X-3093	CRC	BYL719 + cetuximab	639.7	25.4	56	113.8	-4.5
X-3093	CRC	BYL719 + cetuximab	743.3	25.3	64	148.4	-4.9
X-3093	CRC	BYL719 + binimetinib	210.9	23.2	0	0	0
X-3093	CRC	BYL719 + binimetinib	232.8	20.6	3	10.4	-11.2
X-3093	CRC	BYL719 + binimetinib	245.5	20.1	6	16.4	-13.4
X-3093	CRC	BYL719 + LJM716	239.5	23	0	0	0
X-3093	CRC	BYL719 + LJM716	237	21.4	3	-1	-7
X-3093	CRC	BYL719 + LJM716	220.4	19.7	6	-8	-14.3
X-3093	CRC	BYL719 + LJM716	253	20.2	9	5.6	-12.2
X-3093	CRC	BYL719 + LJM716	342.4	19.7	13	43	-14.3
X-3093	CRC	BYL719	213.7	28.3	0	0	0
X-3093	CRC	BYL719	205.5	27.8	3	-3.8	-1.8
X-3093	CRC	BYL719	204	26.6	6	-4.5	-6
X-3093	CRC	BYL719	264.7	27.8	9	23.9	-1.8
X-3093	CRC	BYL719	283.7	26.3	13	32.8	-7.1
X-3093	CRC	BYL719	341.8	26.7	16	59.9	-5.7
X-3093	CRC	BYL719	353.3	27	20	65.3	-4.6
X-3093	CRC	BYL719	372.8	27.7	24	74.5	-2.1
X-3093	CRC	BYL719	385.3	24.9	27	80.3	-12
X-3093	CRC	BYL719	572.4	24.4	30	167.9	-13.8
X-3093	CRC	BYL719 + encorafenib	285.2	25.8	0	0	0
X-3093	CRC	BYL719 + encorafenib	403.1	23.3	3	41.3	-9.7
X-3093	CRC	BYL719 + encorafenib	837.6	25.4	6	193.7	-1.6
X-3093	CRC	BYL719 + encorafenib	1159.4	23.2	10	306.5	-10.1
X-3093	CRC	BYL719 + encorafenib	1720.4	22.1	13	503.2	-14.3
X-3093	CRC	BYL719 + cetuximab + encorafenib	191.8	23.6	0	0	0
X-3093	CRC	BYL719 + cetuximab + encorafenib	317.3	23	5	65.4	-2.5
X-3093	CRC	BYL719 + cetuximab + encorafenib	320.7	22.7	8	67.2	-3.8
X-3093	CRC	BYL719 + cetuximab + encorafenib	475.1	22.7	11	147.7	-3.8
X-3093	CRC	BYL719 + cetuximab + encorafenib	416.9	22.4	14	117.4	-5.1
X-3093	CRC	BYL719 + cetuximab + encorafenib	760	21.5	18	296.2	-8.9
X-3093	CRC	BYL719 + cetuximab + encorafenib	770.9	20.6	21	301.9	-12.7
X-3093	CRC	BYL719 + cetuximab + encorafenib	1110.9	21.9	25	479.2	-7.2
X-3093	CRC	BYL719 + cetuximab + encorafenib	895.5	23	29	366.9	-2.5
X-3093	CRC	BYL719 + cetuximab + encorafenib	1323.4	20.5	32	590	-13.1
X-3093	CRC	CGM097	208.2	25.2	0	0	0
X-3093	CRC	CGM097	305.4	23.8	3	46.7	-5.6
X-3093	CRC	CGM097	284.7	22.5	6	36.7	-10.7
X-3093	CRC	CGM097	309.9	22.6	9	48.8	-10.3
X-3093	CRC	CGM097	342.8	22.5	13	64.6	-10.7
X-3093	CRC	CGM097	508.8	24	16	144.4	-4.8
X-3093	CRC	CGM097	583.6	23.8	20	180.3	-5.6
X-3093	CRC	CGM097	657	23.4	24	215.6	-7.1
X-3093	CRC	CGM097	601.1	20.5	27	188.7	-18.7
X-3093	CRC	CKX620	264	28.2	0	0	0
X-3093	CRC	CKX620	312.8	25.6	5	18.5	-9.2
X-3093	CRC	CKX620	296.8	25.3	8	12.4	-10.3
X-3093	CRC	CKX620	298.5	24.8	11	13.1	-12.1
X-3093	CRC	CKX620	320.4	25.1	14	21.4	-11
X-3093	CRC	CLR457	203.1	25	0	0	0
X-3093	CRC	CLR457	296	25.5	3	45.7	2
X-3093	CRC	CLR457	275.8	24.5	6	35.8	-2
X-3093	CRC	CLR457	233.9	26.3	9	15.2	5.2
X-3093	CRC	CLR457	345.8	23.8	13	70.3	-4.8
X-3093	CRC	CLR457	385.8	22.5	16	90	-10
X-3093	CRC	CLR457	378.7	22.9	20	86.5	-8.4
X-3093	CRC	CLR457	452.5	25.5	24	122.8	2
X-3093	CRC	CLR457	723.9	23.1	27	256.4	-7.6
X-3093	CRC	CLR457	800	23.3	30	293.9	-6.8
X-3093	CRC	HDM201	231.8	25	0	0	0
X-3093	CRC	HDM201	310.7	24.6	3	34	-1.6
X-3093	CRC	HDM201	268.7	23.5	6	15.9	-6
X-3093	CRC	HDM201	260.6	24.7	9	12.4	-1.2
X-3093	CRC	HDM201	286.3	27.3	13	23.5	9.2
X-3093	CRC	HDM201	392.4	23.8	16	69.3	-4.8
X-3093	CRC	HDM201	422	22.7	20	82.1	-9.2
X-3093	CRC	HDM201	523.7	23.6	24	125.9	-5.6
X-3093	CRC	HDM201	544.3	21.5	27	134.8	-14
X-3093	CRC	HDM201	585.7	22.9	30	152.7	-8.4
X-3093	CRC	cetuximab + encorafenib	174.5	22.6	0	0	0
X-3093	CRC	cetuximab + encorafenib	348.2	21.6	5	99.5	-4.4
X-3093	CRC	cetuximab + encorafenib	534.6	20.9	8	206.4	-7.5
X-3093	CRC	cetuximab + encorafenib	588.5	20.3	11	237.2	-10.2
X-3093	CRC	cetuximab + encorafenib	891.5	20.7	14	410.9	-8.4
X-3093	CRC	cetuximab + encorafenib	1442	20.9	18	726.4	-7.5
X-3093	CRC	cetuximab + encorafenib	1556	20	21	791.7	-11.5
X-3093	CRC	cetuximab	210.4	22.9	0	0	0
X-3093	CRC	cetuximab	278.1	22.9	5	32.2	0
X-3093	CRC	cetuximab	326.8	23.5	8	55.3	2.6
X-3093	CRC	cetuximab	356.4	22.7	11	69.4	-0.9
X-3093	CRC	cetuximab	424.3	22.9	14	101.7	0
X-3093	CRC	cetuximab	602.9	23	18	186.5	0.4
X-3093	CRC	cetuximab	858.9	21.8	21	308.2	-4.8
X-3093	CRC	cetuximab	1059	22.4	25	403.3	-2.2
X-3093	CRC	cetuximab	1382.2	21.8	29	556.9	-4.8
X-3093	CRC	cetuximab	1734.6	21.7	32	724.4	-5.2
X-3093	CRC	LEE011	215.9	24.2	0	0	0
X-3093	CRC	LEE011	211	24.8	5	-2.3	2.5
X-3093	CRC	LEE011	306.5	23.4	8	42	-3.3
X-3093	CRC	LEE011	313	24.9	11	45	2.9
X-3093	CRC	LEE011	408.3	25.3	14	89.1	4.5
X-3093	CRC	LEE011	391.9	27	18	81.5	11.6
X-3093	CRC	LEE011	407.3	25.9	21	88.7	7
X-3093	CRC	LEE011	360.7	24.4	25	67.1	0.8
X-3093	CRC	LEE011	406.8	26.3	29	88.4	8.7
X-3093	CRC	LEE011	407.2	26.9	32	88.6	11.2
X-3093	CRC	LEE011	465.1	28.5	35	115.4	17.8
X-3093	CRC	encorafenib	242.7	27.2	0	0	0
X-3093	CRC	encorafenib	276.7	25.7	3	14	-5.5
X-3093	CRC	encorafenib	394.5	24.3	6	62.5	-10.7
X-3093	CRC	encorafenib	464	24.3	9	91.2	-10.7
X-3093	CRC	encorafenib	685.4	25	13	182.4	-8.1
X-3093	CRC	encorafenib	1139.9	23.3	16	369.7	-14.3
X-3093	CRC	encorafenib	1526.3	22.7	20	528.9	-16.5
X-3093	CRC	LJC049	254.7	26	0	0	0
X-3093	CRC	LJC049	310.8	25.6	3	22	-1.5
X-3093	CRC	LJC049	384.6	24.5	6	51	-5.8
X-3093	CRC	LJC049	453	23.9	9	77.9	-8.1
X-3093	CRC	LJC049	604	21.9	13	137.1	-15.8
X-3093	CRC	LKA136	233	24.7	0	0	0
X-3093	CRC	LKA136	363.2	24.7	3	55.9	0
X-3093	CRC	LKA136	338	23.3	6	45.1	-5.7
X-3093	CRC	LKA136	447.6	23.9	9	92.1	-3.2
X-3093	CRC	LKA136	489.3	23.1	13	110	-6.5
X-3093	CRC	LKA136	622.5	23.2	16	167.2	-6.1
X-3093	CRC	LKA136	698	22.9	20	199.6	-7.3
X-3093	CRC	LKA136	925.5	25.1	24	297.2	1.6
X-3093	CRC	LKA136	1289.7	22.7	27	453.5	-8.1
X-3093	CRC	LKA136	1305	22.9	30	460.1	-7.3
X-3093	CRC	binimetinib	223.6	26	0	0	0
X-3093	CRC	binimetinib	204.9	23.8	2	-8.4	-8.5
X-3093	CRC	binimetinib	201.5	22.7	7	-9.9	-12.7
X-3093	CRC	untreated	239.8	18.3	0	0	0
X-3093	CRC	untreated	328.2	21.4	7	36.9	16.9
X-3093	CRC	untreated	388	18.8	11	61.8	2.7
X-3093	CRC	untreated	528.5	21	15	120.4	14.8
X-3093	CRC	untreated	454.9	18.8	18	89.7	2.7
X-3093	CRC	untreated	519.6	20.2	21	116.7	10.4
X-3093	CRC	untreated	578.8	20.2	24	141.4	10.4
X-3093	CRC	untreated	699.5	20.5	29	191.7	12
X-3127	CM	BKM120	204.8	26.5	0	0	0
X-3127	CM	BKM120	227.3	25.7	2	11	-3
X-3127	CM	BKM120	232.7	26.5	6	13.7	0
X-3127	CM	BKM120	248.4	26.6	9	21.3	0.4
X-3127	CM	BKM120	221.2	27.3	13	8	3
X-3127	CM	BKM120	294.4	26.5	16	43.8	0
X-3127	CM	BKM120	300.8	28.1	20	46.9	6
X-3127	CM	BKM120	319.4	27.4	23	56	3.4
X-3127	CM	BKM120	328.1	27.4	27	60.2	3.4
X-3127	CM	BKM120	429.3	27.6	32	109.6	4.2
X-3127	CM	BKM120	402.7	27.5	36	96.7	3.8
X-3127	CM	BKM120	463.9	27.6	39	126.5	4.2
X-3127	CM	BKM120	548.9	27.1	42	168	2.3
X-3127	CM	BKM120	563.6	27	43	175.2	1.9
X-3127	CM	BKM120 + encorafenib	195.2	23	0	0	0
X-3127	CM	BKM120 + encorafenib	222.9	23.4	3	14.2	1.7
X-3127	CM	BKM120 + encorafenib	232.7	23.6	7	19.2	2.6
X-3127	CM	BKM120 + encorafenib	231.9	23	10	18.8	0
X-3127	CM	BKM120 + encorafenib	266.5	22.6	14	36.5	-1.7
X-3127	CM	BKM120 + encorafenib	274.4	22.7	17	40.6	-1.3
X-3127	CM	BKM120 + encorafenib	208.3	22.9	21	6.7	-0.4
X-3127	CM	BKM120 + encorafenib	199.6	24	26	2.2	4.3
X-3127	CM	BKM120 + encorafenib	208.1	23.9	30	6.6	3.9
X-3127	CM	BKM120 + encorafenib	224.5	24.2	33	15	5.2
X-3127	CM	BKM120 + encorafenib	237.2	23.5	36	21.5	2.2
X-3127	CM	BKM120 + encorafenib	306.6	23.6	40	57	2.6
X-3127	CM	BKM120 + encorafenib	310.4	24.1	44	59	4.8
X-3127	CM	BKM120 + encorafenib	313.6	24	48	60.7	4.3
X-3127	CM	BKM120 + encorafenib	323.2	21.4	51	65.6	-7
X-3127	CM	BKM120 + encorafenib	320	20.4	55	63.9	-11.3
X-3127	CM	BKM120 + encorafenib	309.3	19.7	58	58.5	-14.3
X-3127	CM	BKM120 + encorafenib	305.9	19.6	61	56.7	-14.8
X-3127	CM	CGM097	205.4	24.8	0	0	0
X-3127	CM	CGM097	227.3	25	3	10.7	0.8
X-3127	CM	CGM097	252	26.1	7	22.7	5.2
X-3127	CM	CGM097	278.4	26	10	35.6	4.8
X-3127	CM	CGM097	275.2	25.4	14	34	2.4
X-3127	CM	CGM097	306.6	24.9	17	49.3	0.4
X-3127	CM	CGM097	314	24.7	21	52.9	-0.4
X-3127	CM	CGM097	355.7	23.5	24	73.2	-5.2
X-3127	CM	CGM097	336.5	23.4	28	63.9	-5.6
X-3127	CM	CGM097	310	23.3	33	51	-6
X-3127	CM	CGM097	288.7	23.5	37	40.6	-5.2
X-3127	CM	CGM097	259.2	23.2	40	26.2	-6.5
X-3127	CM	CGM097	275.2	23.3	43	34	-6
X-3127	CM	CGM097	255.5	21.9	47	24.4	-11.7
X-3127	CM	CGM097	233.9	21.8	51	13.9	-12.1
X-3127	CM	CGM097	227.8	22.2	55	10.9	-10.5
X-3127	CM	CGM097	213.2	22.5	58	3.8	-9.3
X-3127	CM	CGM097	236.3	22.3	62	15	-10.1
X-3127	CM	CGM097	262.4	24.3	65	27.8	-2
X-3127	CM	CGM097	231	23.2	68	12.5	-6.5
X-3127	CM	CGM097	264.7	23	72	28.9	-7.3
X-3127	CM	CGM097	261.6	23.7	76	27.4	-4.4
X-3127	CM	CGM097	233.4	24.4	80	13.7	-1.6
X-3127	CM	CGM097	225	24.2	83	9.6	-2.4
X-3127	CM	CGM097	231	23.8	87	12.5	-4
X-3127	CM	CGM097	184	24.6	91	-10.4	-0.8
X-3127	CM	CGM097	230	24.2	94	12	-2.4
X-3127	CM	CGM097	252.8	25.3	98	23.1	2
X-3127	CM	CGM097	258.6	25.2	101	25.9	1.6
X-3127	CM	CGM097	244.7	25.4	105	19.2	2.4
X-3127	CM	CGM097	255.5	24	109	24.4	-3.2
X-3127	CM	CGM097	300.8	26.1	116	46.5	5.2
X-3127	CM	CGM097	357.6	26.4	124	74.2	6.5
X-3127	CM	CGM097	445.4	27.1	128	116.9	9.3
X-3127	CM	CGM097	509.7	25.8	131	148.2	4
X-3127	CM	CLR457	210.5	25	0	0	0
X-3127	CM	CLR457	215.8	23.8	3	2.5	-4.8
X-3127	CM	CLR457	216.8	25.6	7	3	2.4
X-3127	CM	CLR457	236.3	24.2	10	12.2	-3.2
X-3127	CM	CLR457	260.9	24.1	14	23.9	-3.6
X-3127	CM	CLR457	314.3	24.6	19	49.3	-1.6
X-3127	CM	CLR457	310.7	24.9	23	47.6	-0.4
X-3127	CM	CLR457	336.8	24.7	26	60	-1.2
X-3127	CM	CLR457	364	24.3	29	72.9	-2.8
X-3127	CM	CLR457	364.4	24.9	33	73.1	-0.4
X-3127	CM	CLR457	405	25.4	37	92.4	1.6
X-3127	CM	CLR457	472.7	24.8	41	124.6	-0.8
X-3127	CM	CLR457	524.4	24.6	43	149.1	-1.6
X-3127	CM	dacarbazine	204.2	27.9	0	0	0
X-3127	CM	dacarbazine	203.4	26.3	3	-0.4	-5.7
X-3127	CM	dacarbazine	212.5	26.3	7	4.1	-5.7
X-3127	CM	dacarbazine	190.4	25.6	10	-6.7	-8.2
X-3127	CM	dacarbazine	78.4	25.7	14	-61.6	-7.9
X-3127	CM	dacarbazine	58.1	27.8	19	-71.6	-0.4
X-3127	CM	dacarbazine	36.8	27	23	-82	-3.2
X-3127	CM	dacarbazine	40	27.5	26	-80.4	-1.4
X-3127	CM	dacarbazine	42.5	26.4	29	-79.2	-5.4
X-3127	CM	dacarbazine	36	27	33	-82.4	-3.2
X-3127	CM	dacarbazine	33.2	26.9	37	-83.7	-3.6
X-3127	CM	dacarbazine	24.5	28	41	-88	0.4
X-3127	CM	dacarbazine	18	26.9	44	-91.2	-3.6
X-3127	CM	dacarbazine	18	27.3	48	-91.2	-2.2
X-3127	CM	dacarbazine	24.5	27	51	-88	-3.2
X-3127	CM	dacarbazine	20.2	25	54	-90.1	-10.4
X-3127	CM	dacarbazine	21.4	24	58	-89.5	-14
X-3127	CM	dacarbazine	15.8	25.6	62	-92.3	-8.2
X-3127	CM	dacarbazine	15.8	25.4	66	-92.3	-9
X-3127	CM	dacarbazine	13.5	27.8	69	-93.4	-0.4
X-3127	CM	dacarbazine	13.5	28.6	73	-93.4	2.5
X-3127	CM	dacarbazine	13.5	25.4	77	-93.4	-9
X-3127	CM	dacarbazine	13.5	24.7	80	-93.4	-11.5
X-3127	CM	dacarbazine	13.5	25.1	82	-93.4	-10
X-3127	CM	dacarbazine	6	24.6	85	-97.1	-11.8
X-3127	CM	dacarbazine	4	25.6	89	-98	-8.2
X-3127	CM	dacarbazine	4	25.2	93	-98	-9.7
X-3127	CM	dacarbazine	4	24.7	100	-98	-11.5
X-3127	CM	dacarbazine	4	24	108	-98	-14
X-3127	CM	dacarbazine	4	24	112	-98	-14
X-3127	CM	dacarbazine	4	24	115	-98	-14
X-3127	CM	dacarbazine	4	23.9	121	-98	-14.3
X-3127	CM	dacarbazine	7.3	22.2	131	-96.4	-20.4
X-3127	CM	dacarbazine	0	22.7	136	-100	-18.6
X-3127	CM	LDE225	201.6	30.4	0	0	0
X-3127	CM	LDE225	239.1	29.8	4	18.6	-2
X-3127	CM	LDE225	257.9	29.4	8	27.9	-3.3
X-3127	CM	LDE225	293.3	28.5	11	45.5	-6.2
X-3127	CM	LDE225	311.7	28.4	15	54.6	-6.6
X-3127	CM	LDE225	362.4	26.9	18	79.7	-11.5
X-3127	CM	LDE225	367.1	27.1	22	82.1	-10.9
X-3127	CM	LDE225	463.9	26.9	27	130.1	-11.5
X-3127	CM	LDE225	535	26.2	31	165.3	-13.8
X-3127	CM	LDE225	558.7	25.4	34	177.1	-16.4
X-3127	CM	LDE225	558.7	27	35	177.1	-11.2
X-3127	CM	LDE225	611.1	25.8	36	203.1	-15.1
X-3127	CM	LDE225	622.9	25.5	37	208.9	-16.1
X-3127	CM	LDK378	198.5	24.1	0	0	0
X-3127	CM	LDK378	238.2	25.2	4	20	4.6
X-3127	CM	LDK378	241.9	25	8	21.9	3.7
X-3127	CM	LDK378	281.6	23.6	11	41.9	-2.1
X-3127	CM	LDK378	289	24.9	15	45.6	3.3
X-3127	CM	LDK378	392	23.3	18	97.5	-3.3
X-3127	CM	LDK378	379.3	24	22	91.1	-0.4
X-3127	CM	LDK378	438.9	24	27	121.2	-0.4
X-3127	CM	LDK378	483.8	23.4	31	143.8	-2.9
X-3127	CM	LDK378	575	24.8	34	189.7	2.9
X-3127	CM	LDK378	700.1	24.2	37	252.8	0.4
X-3127	CM	LDK378	798.1	24.4	41	302.1	1.2
X-3127	CM	LDK378	815.4	24.5	43	310.9	1.7
X-3127	CM	LEE011	203.4	27.1	0	0	0
X-3127	CM	LEE011	226.5	26.3	3	11.4	-3
X-3127	CM	LEE011	243.7	25.9	7	19.8	-4.4
X-3127	CM	LEE011	239.8	26.1	10	17.9	-3.7
X-3127	CM	LEE011	261.6	26.6	14	28.6	-1.8
X-3127	CM	LEE011	257.4	26	17	26.6	-4.1
X-3127	CM	LEE011	260.1	26.2	21	27.9	-3.3
X-3127	CM	LEE011	296.5	26.9	24	45.8	-0.7
X-3127	CM	LEE011	320	26.9	28	57.4	-0.7
X-3127	CM	LEE011	316.4	26.7	33	55.6	-1.5
X-3127	CM	LEE011	304.2	25.7	37	49.6	-5.2
X-3127	CM	LEE011	281.3	27.1	40	38.3	0
X-3127	CM	LEE011	353	27.3	43	73.6	0.7
X-3127	CM	LEE011 + encorafenib	216.3	26.3	0	0	0
X-3127	CM	LEE011 + encorafenib	216.6	25.6	3	0.1	-2.7
X-3127	CM	LEE011 + encorafenib	227.8	27.1	7	5.3	3
X-3127	CM	LEE011 + encorafenib	232.7	26	10	7.6	-1.1
X-3127	CM	LEE011 + encorafenib	161.2	26.3	14	-25.5	0
X-3127	CM	LEE011 + encorafenib	131	26.2	17	-39.4	-0.4
X-3127	CM	LEE011 + encorafenib	161.6	26.4	21	-25.3	0.4
X-3127	CM	LEE011 + encorafenib	152.1	27	26	-29.7	2.7
X-3127	CM	LEE011 + encorafenib	126	27.3	30	-41.7	3.8
X-3127	CM	LEE011 + encorafenib	120.6	27.4	33	-44.2	4.2
X-3127	CM	LEE011 + encorafenib	143.7	26.6	36	-33.6	1.1
X-3127	CM	LEE011 + encorafenib	135.8	27	40	-37.2	2.7
X-3127	CM	LEE011 + encorafenib	158.4	27.9	44	-26.7	6.1
X-3127	CM	LEE011 + encorafenib	139.4	28.2	48	-35.5	7.2
X-3127	CM	LEE011 + encorafenib	126	27.2	51	-41.7	3.4
X-3127	CM	LEE011 + encorafenib	152.1	27.8	55	-29.7	5.7
X-3127	CM	LEE011 + encorafenib	147.9	28.2	58	-31.6	7.2
X-3127	CM	LEE011 + encorafenib	151.6	27.6	61	-29.9	4.9
X-3127	CM	LEE011 + encorafenib	168.8	27.8	65	-22	5.7
X-3127	CM	LEE011 + encorafenib	168.3	28.5	69	-22.2	8.4
X-3127	CM	LEE011 + encorafenib	150	28.7	73	-30.7	9.1
X-3127	CM	LEE011 + encorafenib	178.9	31.2	76	-17.3	18.6
X-3127	CM	LEE011 + encorafenib	127.8	31.6	80	-40.9	20.2
X-3127	CM	LEE011 + encorafenib	168.3	28.9	84	-22.2	9.9
X-3127	CM	LEE011 + encorafenib	137.2	27.6	87	-36.6	4.9
X-3127	CM	LEE011 + encorafenib	164.2	29	91	-24.1	10.3
X-3127	CM	LEE011 + encorafenib	156.8	27.3	94	-27.5	3.8
X-3127	CM	LEE011 + encorafenib	147.5	27.3	98	-31.8	3.8
X-3127	CM	LEE011 + encorafenib	164.2	26.4	102	-24.1	0.4
X-3127	CM	LEE011 + encorafenib	141.5	27.5	109	-34.6	4.6
X-3127	CM	LEE011 + encorafenib	171.4	28.9	117	-20.8	9.9
X-3127	CM	LEE011 + encorafenib	150	29	121	-30.7	10.3
X-3127	CM	LEE011 + encorafenib	143.7	27.8	124	-33.6	5.7
X-3127	CM	LEE011 + encorafenib	143.7	26.8	129	-33.6	1.9
X-3127	CM	LEE011 + encorafenib	157.1	27.7	132	-27.4	5.3
X-3127	CM	LEE011 + encorafenib	109.8	28.4	142	-49.2	8
X-3127	CM	LEE011 + encorafenib	139.3	28.9	147	-35.6	9.9
X-3127	CM	LEE011 + encorafenib	135	29.1	154	-37.6	10.6
X-3127	CM	LEE011 + encorafenib	159.5	28.1	160	-26.2	6.8
X-3127	CM	LEE011 + encorafenib	108	28.1	165	-50.1	6.8
X-3127	CM	LEE011 + encorafenib	129	28.6	172	-40.4	8.7
X-3127	CM	LEE011 + encorafenib	152.5	28.8	179	-29.5	9.5
X-3127	CM	LEE011 + encorafenib	176.2	27.4	186	-18.6	4.2
X-3127	CM	LEE011 + encorafenib	210.8	28.7	192	-2.5	9.1
X-3127	CM	LEE011 + encorafenib	231.2	28	199	6.9	6.5
X-3127	CM	LEE011 + encorafenib	231	26.5	204	6.8	0.8
X-3127	CM	LEE011 + binimetinib	210.5	25.5	0	0	0
X-3127	CM	LEE011 + binimetinib	196	24.7	5	-6.9	-3.1
X-3127	CM	LEE011 + binimetinib	205.2	23.6	9	-2.5	-7.5
X-3127	CM	LEE011 + binimetinib	180.3	23.8	12	-14.3	-6.7
X-3127	CM	LEE011 + binimetinib	172.8	24.6	15	-17.9	-3.5
X-3127	CM	LEE011 + binimetinib	204.2	25.3	19	-3	-0.8
X-3127	CM	LEE011 + binimetinib	171.1	25.7	23	-18.7	0.8
X-3127	CM	LEE011 + binimetinib	152.1	27.3	27	-27.7	7.1
X-3127	CM	LEE011 + binimetinib	137.7	27.2	30	-34.6	6.7
X-3127	CM	LEE011 + binimetinib	98.3	27	34	-53.3	5.9
X-3127	CM	LEE011 + binimetinib	104	27	37	-50.6	5.9
X-3127	CM	LEE011 + binimetinib	107.2	25.9	40	-49.1	1.6
X-3127	CM	LEE011 + binimetinib	87.1	26.8	44	-58.6	5.1
X-3127	CM	LEE011 + binimetinib	85.7	26.4	48	-59.3	3.5
X-3127	CM	LEE011 + binimetinib	64.5	26.7	52	-69.4	4.7
X-3127	CM	LEE011 + binimetinib	71.3	28.4	55	-66.2	11.4
X-3127	CM	LEE011 + binimetinib	71.3	25.9	60	-66.2	1.6
X-3127	CM	LEE011 + binimetinib	67.5	27.2	63	-67.9	6.7
X-3127	CM	LEE011 + binimetinib	58.2	26.4	66	-72.4	3.5
X-3127	CM	LEE011 + binimetinib	68.8	27	70	-67.3	5.9
X-3127	CM	LEE011 + binimetinib	81.5	25.8	73	-61.3	1.2
X-3127	CM	LEE011 + binimetinib	59.6	26.3	77	-71.7	3.1
X-3127	CM	LEE011 + binimetinib	52.9	26.5	81	-74.9	3.9
X-3127	CM	LEE011 + binimetinib	52.9	26.2	88	-74.9	2.7
X-3127	CM	LEE011 + binimetinib	37.6	27	96	-82.1	5.9
X-3127	CM	LEE011 + binimetinib	40	27.3	100	-81	7.1
X-3127	CM	LEE011 + binimetinib	34.2	27.7	103	-83.7	8.6
X-3127	CM	LEE011 + binimetinib	37.6	26.7	108	-82.1	4.7
X-3127	CM	LEE011 + binimetinib	27.6	26.2	111	-86.9	2.7
X-3127	CM	LEE011 + binimetinib	34.9	27.8	121	-83.4	9
X-3127	CM	LEE011 + binimetinib	29.6	27	126	-85.9	5.9
X-3127	CM	LEE011 + binimetinib	28.9	26.2	133	-86.3	2.7
X-3127	CM	LEE011 + binimetinib	28.9	27	139	-86.3	5.9
X-3127	CM	LEE011 + binimetinib	18	27.1	144	-91.4	6.3
X-3127	CM	LEE011 + binimetinib	21.8	26.6	151	-89.7	4.3
X-3127	CM	LEE011 + binimetinib	28.9	25.7	158	-86.3	0.8
X-3127	CM	LEE011 + binimetinib	33.6	25.6	165	-84	0.4
X-3127	CM	LEE011 + binimetinib	27.6	26	172	-86.9	2
X-3127	CM	LEE011 + binimetinib	30.8	26.2	179	-85.4	2.7
X-3127	CM	LEE011 + binimetinib	30.4	27	185	-85.5	5.9
X-3127	CM	LEE011 + binimetinib	32.7	26.5	191	-84.5	3.9
X-3127	CM	LEE011 + binimetinib	50.8	27.8	198	-75.9	9
X-3127	CM	LEE011 + binimetinib	55	27.9	205	-73.9	9.4
X-3127	CM	LEE011 + binimetinib	68.8	27.3	215	-67.3	7.1
X-3127	CM	LEE011 + binimetinib	97.5	27.5	221	-53.7	7.8
X-3127	CM	LEE011 + binimetinib	111.6	27.5	227	-47	7.8
X-3127	CM	WNT974	204.2	28.2	0	0	0
X-3127	CM	WNT974	222.9	27.1	4	9.2	-3.9
X-3127	CM	WNT974	226.5	27.4	8	10.9	-2.8
X-3127	CM	WNT974	226.5	26.8	11	10.9	-5
X-3127	CM	WNT974	205.8	27.1	15	0.8	-3.9
X-3127	CM	WNT974	251.9	26	18	23.4	-7.8
X-3127	CM	WNT974	250.5	26.9	22	22.7	-4.6
X-3127	CM	WNT974	344.5	26.9	27	68.7	-4.6
X-3127	CM	WNT974	326.4	26	31	59.9	-7.8
X-3127	CM	WNT974	336	24.8	34	64.6	-12.1
X-3127	CM	WNT974	346.3	24.2	37	69.6	-14.2
X-3127	CM	WNT974	329.6	23.5	41	61.4	-16.7
X-3127	CM	WNT974	332.8	23.8	43	63	-15.6
X-3127	CM	LGW813	200.9	23.7	0	0	0
X-3127	CM	LGW813	220.3	23.7	4	9.7	0
X-3127	CM	LGW813	157.7	23.7	7	-21.5	0
X-3127	CM	LGW813	114.5	24.2	11	-43	2.1
X-3127	CM	LGW813	87.9	24	14	-56.3	1.3
X-3127	CM	LGW813	114.5	25.1	18	-43	5.9
X-3127	CM	LGW813	112.9	24.3	21	-43.8	2.5
X-3127	CM	LGW813	133.2	24.7	25	-33.7	4.2
X-3127	CM	LGW813	126.2	24.9	30	-37.2	5.1
X-3127	CM	LGW813	126	24.1	34	-37.3	1.7
X-3127	CM	LGW813	127.1	24.4	37	-36.8	3
X-3127	CM	LGW813	117	23.7	40	-41.8	0
X-3127	CM	LGW813	144	23.8	44	-28.3	0.4
X-3127	CM	LGW813	172	23.8	48	-14.4	0.4
X-3127	CM	LGW813	203.4	24.6	52	1.2	3.8
X-3127	CM	LGW813	165.9	24.4	55	-17.4	3
X-3127	CM	LGW813	179.6	24.3	59	-10.6	2.5
X-3127	CM	LGW813	190.4	24.5	62	-5.2	3.4
X-3127	CM	LGW813	203.4	24.2	65	1.2	2.1
X-3127	CM	LGW813	253.1	24.4	69	26	3
X-3127	CM	LGW813	281.6	24.4	73	40.2	3
X-3127	CM	LGW813	264.4	24.6	77	31.6	3.8
X-3127	CM	LGW813	307.2	25	80	52.9	5.5
X-3127	CM	LGW813	302.7	24.5	84	50.7	3.4
X-3127	CM	LGW813	364.9	25.3	88	81.6	6.8
X-3127	CM	LGW813	349.3	25.5	91	73.9	7.6
X-3127	CM	LGW813	415.9	26.5	95	107	11.8
X-3127	CM	LGW813	384.6	25.6	98	91.4	8
X-3127	CM	LGW813	486	25.5	102	141.9	7.6
X-3127	CM	LGW813	448.6	25.7	106	123.3	8.4
X-3127	CM	encorafenib	202.5	25	0	0	0
X-3127	CM	encorafenib	224.5	25.6	3	10.9	2.4
X-3127	CM	encorafenib	236.8	25.7	7	16.9	2.8
X-3127	CM	encorafenib	225	25.7	10	11.1	2.8
X-3127	CM	encorafenib	239.1	26.3	14	18.1	5.2
X-3127	CM	encorafenib	246.1	25.6	17	21.5	2.4
X-3127	CM	encorafenib	303.4	26	21	49.8	4
X-3127	CM	encorafenib	323.8	25.6	24	59.9	2.4
X-3127	CM	encorafenib	327.2	25.2	28	61.6	0.8
X-3127	CM	encorafenib	375.6	25.8	33	85.5	3.2
X-3127	CM	encorafenib	377.2	25.3	37	86.3	1.2
X-3127	CM	encorafenib	394.9	25	40	95	0
X-3127	CM	encorafenib	392	25.5	43	93.6	2
X-3127	CM	encorafenib + binimetinib	207.8	22.9	0	0	0
X-3127	CM	encorafenib + binimetinib	236.3	22.5	4	13.7	-1.7
X-3127	CM	encorafenib + binimetinib	239.1	22.1	7	15	-3.5
X-3127	CM	encorafenib + binimetinib	237.1	21.4	11	14.1	-6.6
X-3127	CM	encorafenib + binimetinib	289	21.7	14	39.1	-5.2
X-3127	CM	encorafenib + binimetinib	297.6	22.3	18	43.2	-2.6
X-3127	CM	encorafenib + binimetinib	342.2	22	23	64.7	-3.9
X-3127	CM	encorafenib + binimetinib	342.2	21.6	27	64.7	-5.7
X-3127	CM	encorafenib + binimetinib	332.8	21.5	30	60.2	-6.1
X-3127	CM	encorafenib + binimetinib	363.4	21.5	33	74.8	-6.1
X-3127	CM	encorafenib + binimetinib	377.2	21.6	37	81.5	-5.7
X-3127	CM	encorafenib + binimetinib	377.2	21.2	41	81.5	-7.4
X-3127	CM	encorafenib + binimetinib	388.3	21.7	45	86.8	-5.2
X-3127	CM	encorafenib + binimetinib	348.8	20.9	48	67.8	-8.7
X-3127	CM	encorafenib + binimetinib	382.9	20.8	52	84.3	-9.2
X-3127	CM	encorafenib + binimetinib	399.4	20.6	55	92.2	-10
X-3127	CM	encorafenib + binimetinib	386.5	20.9	58	86	-8.7
X-3127	CM	encorafenib + binimetinib	382.9	20.3	62	84.3	-11.4
X-3127	CM	encorafenib + binimetinib	416.3	21	66	100.3	-8.3
X-3127	CM	encorafenib + binimetinib	401	20.7	70	92.9	-9.6
X-3127	CM	encorafenib + binimetinib	408.2	23.6	73	96.4	3.1
X-3127	CM	encorafenib + binimetinib	413.3	22.7	77	98.9	-0.9
X-3127	CM	encorafenib + binimetinib	415.4	20.5	81	99.9	-10.5
X-3127	CM	encorafenib + binimetinib	406.8	20.3	84	95.7	-11.4
X-3127	CM	encorafenib + binimetinib	441.4	21.2	88	112.4	-7.4
X-3127	CM	encorafenib + binimetinib	414.2	20.9	91	99.3	-8.7
X-3127	CM	encorafenib + binimetinib	406.8	20.8	95	95.7	-9.2
X-3127	CM	encorafenib + binimetinib	391.6	21.1	99	88.4	-7.9
X-3127	CM	encorafenib + binimetinib	414.2	20.7	106	99.3	-9.6
X-3127	CM	encorafenib + binimetinib	406.8	20.7	114	95.7	-9.6
X-3127	CM	encorafenib + binimetinib	437.5	21.8	118	110.5	-4.8
X-3127	CM	encorafenib + binimetinib	447.5	21	121	115.3	-8.3
X-3127	CM	binimetinib	198.5	26.2	0	0	0
X-3127	CM	binimetinib	218.5	24.6	2	10.1	-6.1
X-3127	CM	binimetinib	204.2	24.6	6	2.9	-6.1
X-3127	CM	binimetinib	223.8	23.8	9	12.8	-9.2
X-3127	CM	binimetinib	238.2	24.8	13	20	-5.3
X-3127	CM	binimetinib	301.8	24.7	16	52.1	-5.7
X-3127	CM	binimetinib	250.3	24.5	20	26.1	-6.5
X-3127	CM	binimetinib	296.5	23.3	23	49.4	-11.1
X-3127	CM	binimetinib	321.5	23.5	27	62	-10.3
X-3127	CM	binimetinib	300.8	24	32	51.6	-8.4
X-3127	CM	binimetinib	297.6	23.8	36	50	-9.2
X-3127	CM	binimetinib	327.2	23.5	39	64.9	-10.3
X-3127	CM	binimetinib	386	23.7	42	94.5	-9.5
X-3127	CM	binimetinib	380.9	24.1	43	91.9	-8
X-3127	CM	TAS266	203.4	27	0	0	0
X-3127	CM	TAS266	211.7	27.6	3	4.1	2.2
X-3127	CM	TAS266	210.7	27.6	7	3.6	2.2
X-3127	CM	TAS266	140.9	27.5	10	-30.7	1.9
X-3127	CM	TAS266	145.4	28.5	14	-28.5	5.6
X-3127	CM	TAS266	88.9	27.5	17	-56.3	1.9
X-3127	CM	TAS266	56.1	27.8	21	-72.4	3
X-3127	CM	TAS266	57.1	27	24	-71.9	0
X-3127	CM	TAS266	44.4	27.1	28	-78.2	0.4
X-3127	CM	TAS266	63.4	27.9	33	-68.8	3.3
X-3127	CM	TAS266	55.2	28.2	37	-72.8	4.4
X-3127	CM	TAS266	55.2	28.1	40	-72.8	4.1
X-3127	CM	TAS266	44.4	27.5	43	-78.2	1.9
X-3127	CM	TAS266	44.1	27.3	47	-78.3	1.1
X-3127	CM	TAS266	57.6	28.1	51	-71.7	4.1
X-3127	CM	TAS266	55.7	27.9	55	-72.6	3.3
X-3127	CM	TAS266	39.5	28.6	58	-80.6	5.9
X-3127	CM	TAS266	51.8	28.4	62	-74.5	5.2
X-3127	CM	TAS266	49.6	29.3	65	-75.6	8.5
X-3127	CM	TAS266	50.6	28.9	68	-75.1	7
X-3127	CM	TAS266	55.2	28.7	72	-72.9	6.3
X-3127	CM	TAS266	88.5	28.9	76	-56.5	7
X-3127	CM	TAS266	53.7	28.4	80	-73.6	5.2
X-3127	CM	TAS266	75	28.9	83	-63.1	7
X-3127	CM	TAS266	70	29.1	87	-65.6	7.8
X-3127	CM	TAS266	89.9	29.8	91	-55.8	10.4
X-3127	CM	TAS266	85.2	28.9	94	-58.1	7
X-3127	CM	TAS266	119.4	29.7	98	-41.3	10
X-3127	CM	TAS266	117	28.7	101	-42.5	6.3
X-3127	CM	TAS266	106.6	29.6	105	-47.6	9.6
X-3127	CM	TAS266	86.5	28.8	109	-57.4	6.7
X-3127	CM	TAS266	95.5	29.1	116	-53	7.8
X-3127	CM	TAS266	105.9	29.1	124	-47.9	7.8
X-3127	CM	TAS266	128.8	29	128	-36.7	7.4
X-3127	CM	TAS266	124.9	29.3	131	-38.6	8.5
X-3127	CM	TAS266	141.5	29.7	136	-30.4	10
X-3127	CM	TAS266	157.1	29.3	139	-22.7	8.5
X-3127	CM	TAS266	122.4	30.3	149	-39.8	12.2
X-3127	CM	TAS266	155.7	29.9	154	-23.4	10.7
X-3127	CM	TAS266	62.6	30.1	161	-69.2	11.5
X-3127	CM	TAS266	109.8	30.6	167	-46	13.3
X-3127	CM	TAS266	84.3	30	172	-58.6	11.1
X-3127	CM	TAS266	50.6	30	179	-75.1	11.1
X-3127	CM	TAS266	78.4	30.6	186	-61.4	13.3
X-3127	CM	TAS266	70.8	30.9	193	-65.2	14.4
X-3127	CM	TAS266	57.6	30.5	199	-71.7	13
X-3127	CM	TAS266	60	30.6	206	-70.5	13.3
X-3127	CM	TAS266	80.2	31	212	-60.6	14.8
X-3127	CM	TAS266	81.1	30.6	218	-60.1	13.3
X-3127	CM	TAS266	113.7	31.7	225	-44.1	17.4
X-3127	CM	TAS266	109.8	31.9	232	-46	18.1
X-3127	CM	TAS266	108.9	31	242	-46.4	14.8
X-3127	CM	TAS266	122.3	31.3	250	-39.9	15.9
X-3127	CM	TAS266	130.5	31.5	256	-35.8	16.7
X-3127	CM	untreated	201.6	22.8	0	0	0
X-3127	CM	untreated	215.8	23.7	3	7	3.9
X-3127	CM	untreated	263.8	24.1	7	30.8	5.7
X-3127	CM	untreated	284	23.3	10	40.8	2.2
X-3127	CM	untreated	361.3	24.2	14	79.2	6.1
X-3127	CM	untreated	389.8	23.8	17	93.3	4.4
X-3127	CM	untreated	437.4	23.5	21	116.9	3.1
X-3127	CM	untreated	414.1	24	24	105.3	5.3
X-3127	CM	untreated	561.8	24.3	28	178.6	6.6
X-3127	CM	untreated	661.5	24.5	33	228.1	7.5
X-3127	CM	untreated	667	24.1	37	230.8	5.7
X-3127	CM	untreated	776.2	24.2	40	285	6.1
X-3127	CM	untreated	870.7	24.7	43	331.8	8.3
X-3201	BRCA	BGJ398	244.6	28	0	0	0
X-3201	BRCA	BGJ398	286.1	27	3	17	-3.6
X-3201	BRCA	BGJ398	335.1	29.1	6	37	3.9
X-3201	BRCA	BGJ398	430.9	27.7	10	76.2	-1.1
X-3201	BRCA	BGJ398	488.8	27.6	13	99.8	-1.4
X-3201	BRCA	BGJ398	578.3	27.8	17	136.4	-0.7
X-3201	BRCA	BGJ398	603.2	27.7	20	146.6	-1.1
X-3201	BRCA	BGJ398	669.1	27.8	24	173.5	-0.7
X-3201	BRCA	BGJ398	664.8	28.7	27	171.8	2.5
X-3201	BRCA	BKM120	254.6	24.5	0	0	0
X-3201	BRCA	BKM120	343.2	24.5	3	34.8	0
X-3201	BRCA	BKM120	462.9	25.4	6	81.8	3.7
X-3201	BRCA	BKM120	513.6	25.8	10	101.7	5.3
X-3201	BRCA	BKM120	520.6	25.4	13	104.5	3.7
X-3201	BRCA	BKM120	685	26.7	17	169	9
X-3201	BRCA	BKM120	768.4	25.3	20	201.8	3.3
X-3201	BRCA	BKM120	858.4	26.6	24	237.2	8.6
X-3201	BRCA	BKM120	889.5	25.9	27	249.4	5.7
X-3201	BRCA	BYL719 + LJM716	228.4	30	0	0	0
X-3201	BRCA	BYL719 + LJM716	182.3	27.1	6	-20.2	-9.7
X-3201	BRCA	BYL719 + LJM716	247.5	25.7	12	8.4	-14.3
X-3201	BRCA	BYL719 + LJM716	319.1	28.6	17	39.7	-4.7
X-3201	BRCA	BYL719 + LJM716	353.6	27.6	21	54.8	-8
X-3201	BRCA	BYL719 + LJM716	403.6	28.5	24	76.7	-5
X-3201	BRCA	BYL719 + LJM716	411	29.1	28	79.9	-3
X-3201	BRCA	BYL719 + LJM716	496.8	25.9	31	117.5	-13.7
X-3201	BRCA	BYL719 + LJM716	594.5	27.5	35	160.3	-8.3
X-3201	BRCA	BYL719 + LJM716	570.2	27.9	38	149.6	-7
X-3201	BRCA	BYL719 + LJM716	665.8	29.2	42	191.5	-2.7
X-3201	BRCA	BYL719 + LJM716	760.5	27.4	45	233	-8.7
X-3201	BRCA	BYL719	222.9	28.9	0	0	0
X-3201	BRCA	BYL719	276.8	28.5	4	24.2	-1.4
X-3201	BRCA	BYL719	245.1	28.7	7	10	-0.7
X-3201	BRCA	BYL719	323.6	28.1	11	45.2	-2.8
X-3201	BRCA	BYL719	377	27.9	17	69.1	-3.5
X-3201	BRCA	BYL719	391.3	24.6	23	75.5	-14.9
X-3201	BRCA	BYL719	475.3	27.9	28	113.2	-3.5
X-3201	BRCA	BYL719	591.4	28.9	32	165.3	0
X-3201	BRCA	BYL719	609.5	28.5	35	173.4	-1.4
X-3201	BRCA	BYL719	756.5	28.6	39	239.4	-1
X-3201	BRCA	BYL719	779.8	27.6	42	249.8	-4.5
X-3201	BRCA	BYL719	813.2	28.3	46	264.8	-2.1
X-3201	BRCA	BYL719	871.6	27.2	49	291	-5.9
X-3201	BRCA	BYL719	726.7	21.3	53	226	-26.3
X-3201	BRCA	BYL719 + LEE011	229.4	27	0	0	0
X-3201	BRCA	BYL719 + LEE011	221.2	24.6	3	-3.6	-8.9
X-3201	BRCA	BYL719 + LEE011	206	22.8	7	-10.2	-15.6
X-3201	BRCA	BYL719 + LEE011	222.7	24	10	-2.9	-11.1
X-3201	BRCA	BYL719 + LEE011	253	25.6	14	10.3	-5.2
X-3201	BRCA	BYL719 + LEE011	276.7	26.8	17	20.6	-0.7
X-3201	BRCA	BYL719 + LEE011	266.1	24.9	21	16	-7.8
X-3201	BRCA	BYL719 + LEE011	257.3	24.8	24	12.2	-8.1
X-3201	BRCA	BYL719 + LEE011	281.9	21.7	32	22.9	-19.6
X-3201	BRCA	BYL719 + LEE011	273.8	22.3	35	19.4	-17.4
X-3201	BRCA	BYL719 + LEE011	356.4	26	38	55.4	-3.7
X-3201	BRCA	BYL719 + LEE011	349.1	23.6	46	52.2	-12.6
X-3201	BRCA	BYL719 + LEE011	376.3	27.4	49	64	1.5
X-3201	BRCA	BYL719 + LEE011	393.9	27.7	52	71.7	2.6
X-3201	BRCA	BYL719 + LEE011	359.5	23.6	56	56.7	-12.6
X-3201	BRCA	BYL719 + LEE011	403.7	27.8	59	76	3
X-3201	BRCA	BYL719 + LEE011	373.5	25.2	63	62.8	-6.7
X-3201	BRCA	CGM097	236.2	29.6	0	0	0
X-3201	BRCA	CGM097	284.1	31.7	3	20.3	7.1
X-3201	BRCA	CGM097	361.5	31.7	7	53	7.1
X-3201	BRCA	CGM097	507.6	31.4	13	114.9	6.1
X-3201	BRCA	CGM097	456.7	31.7	19	93.4	7.1
X-3201	BRCA	CGM097	688.3	32.7	24	191.4	10.5
X-3201	BRCA	CGM097	827.5	31.9	28	250.3	7.8
X-3201	BRCA	CGM097	834.4	31	31	253.3	4.7
X-3201	BRCA	CGM097	1062.1	31.4	35	349.7	6.1
X-3201	BRCA	CGM097	1219.2	31.5	38	416.2	6.4
X-3201	BRCA	CLR457	341.8	30.5	0	0	0
X-3201	BRCA	CLR457	421.2	29.5	4	23.2	-3.3
X-3201	BRCA	CLR457	489.3	30.5	8	43.2	0
X-3201	BRCA	CLR457	509.1	30.1	11	48.9	-1.3
X-3201	BRCA	CLR457	508	30.1	15	48.6	-1.3
X-3201	BRCA	CLR457	481.4	30.5	18	40.8	0
X-3201	BRCA	CLR457	585.8	30.3	22	71.4	-0.7
X-3201	BRCA	CLR457	768.9	27.8	28	125	-8.9
X-3201	BRCA	CLR457	795.8	30.2	34	132.8	-1
X-3201	BRCA	CLR457	1054.3	29.7	39	208.5	-2.6
X-3201	BRCA	HDM201	210	29	0	0	0
X-3201	BRCA	HDM201	252.6	29.1	4	20.3	0.3
X-3201	BRCA	HDM201	372	28.5	10	77.1	-1.7
X-3201	BRCA	HDM201	439.3	28.4	16	109.2	-2.1
X-3201	BRCA	HDM201	469.6	28.2	21	123.6	-2.8
X-3201	BRCA	HDM201	545.4	29	25	159.7	0
X-3201	BRCA	HDM201	553.3	27.3	28	163.5	-5.9
X-3201	BRCA	HDM201	593.3	27.5	32	182.5	-5.2
X-3201	BRCA	HDM201	614	26.2	35	192.4	-9.7
X-3201	BRCA	HDM201	684.8	26.7	39	226.1	-7.9
X-3201	BRCA	HDM201	645.5	24.3	42	207.4	-16.2
X-3201	BRCA	HDM201	719.3	25.3	46	242.5	-12.8
X-3201	BRCA	HDM201	879.1	27.4	49	318.6	-5.5
X-3201	BRCA	INC424	304.8	28.6	0	0	0
X-3201	BRCA	INC424	380	30.8	3	24.7	7.7
X-3201	BRCA	INC424	444.8	29.8	6	45.9	4.2
X-3201	BRCA	INC424	661.2	29.1	10	116.9	1.7
X-3201	BRCA	INC424	765.2	30.4	13	151	6.3
X-3201	BRCA	LEE011 + everolimus	402.8	29.6	0	0	0
X-3201	BRCA	LEE011 + everolimus	436.7	28.5	3	8.4	-3.7
X-3201	BRCA	LEE011 + everolimus	488.8	27.6	7	21.4	-6.8
X-3201	BRCA	LEE011 + everolimus	480.2	28.6	10	19.2	-3.4
X-3201	BRCA	LEE011 + everolimus	492	29.4	14	22.1	-0.7
X-3201	BRCA	LEE011 + everolimus	483.5	28.9	17	20	-2.4
X-3201	BRCA	LEE011 + everolimus	441.4	28.7	25	9.6	-3
X-3201	BRCA	LEE011 + everolimus	508	29.3	28	26.1	-1
X-3201	BRCA	LEE011 + everolimus	544.2	28.9	31	35.1	-2.4
X-3201	BRCA	LEE011 + everolimus	501.7	29.4	39	24.6	-0.7
X-3201	BRCA	LEE011 + everolimus	501.8	29	42	24.6	-2
X-3201	BRCA	LEE011 + everolimus	509.4	30.1	45	26.5	1.7
X-3201	BRCA	LEE011 + everolimus	524.4	28.6	49	30.2	-3.4
X-3201	BRCA	LEE011 + everolimus	530.9	28.3	52	31.8	-4.4
X-3201	BRCA	LEE011 + everolimus	599.2	27.9	56	48.8	-5.7
X-3201	BRCA	LEE011 + everolimus	554.4	28	59	37.6	-5.4
X-3201	BRCA	LEE011	245	24.3	0	0	0
X-3201	BRCA	LEE011	350.9	25.4	4	43.2	4.5
X-3201	BRCA	LEE011	423.2	26.2	8	72.7	7.8
X-3201	BRCA	LEE011	429.3	25.2	11	75.2	3.7
X-3201	BRCA	LEE011	557.5	26.4	14	127.6	8.6
X-3201	BRCA	LEE011	572.3	26.9	18	133.6	10.7
X-3201	BRCA	LEE011	570.5	26.6	21	132.9	9.5
X-3201	BRCA	LEE011	630.8	27.6	25	157.5	13.6
X-3201	BRCA	LEE011	641.2	27.1	28	161.7	11.5
X-3201	BRCA	LEE011	665.7	27.3	32	171.7	12.3
X-3201	BRCA	LEE011	705.2	28.8	35	187.8	18.5
X-3201	BRCA	LFA102	231.3	34.3	0	0	0
X-3201	BRCA	LFA102	269.3	33.5	3	16.4	-2.3
X-3201	BRCA	LFA102	226.6	34.2	6	-2	-0.3
X-3201	BRCA	LFA102	225.5	32.9	10	-2.5	-4.1
X-3201	BRCA	LFA102	287.8	34.9	16	24.4	1.7
X-3201	BRCA	LFA102	329.1	32.9	22	42.3	-4.1
X-3201	BRCA	LFA102	379	34.6	27	63.9	0.9
X-3201	BRCA	LFA102	435	33.8	31	88.1	-1.5
X-3201	BRCA	LFA102	500.6	34.3	34	116.4	0
X-3201	BRCA	LFA102	543.8	34	38	135.1	-0.9
X-3201	BRCA	LFA102	556.2	34.3	41	140.5	0
X-3201	BRCA	LFA102	671.7	35.2	45	190.4	2.6
X-3201	BRCA	LFA102	654.6	35.4	48	183	3.2
X-3201	BRCA	LFA102	742.2	34	52	220.9	-0.9
X-3201	BRCA	LFA102	786.2	34.8	55	239.9	1.5
X-3201	BRCA	LFA102	972	34.1	59	320.2	-0.6
X-3201	BRCA	LFA102	1062	34.5	62	359.1	0.6
X-3201	BRCA	LFA102	1268	34.4	66	448.2	0.3
X-3201	BRCA	LFA102	1317.1	34.6	69	469.4	0.9
X-3201	BRCA	LJM716 + trastuzumab	244.5	26.9	0	0	0
X-3201	BRCA	LJM716 + trastuzumab	280.8	22.9	6	14.8	-14.9
X-3201	BRCA	LJM716 + trastuzumab	398.6	25.3	10	63	-5.9
X-3201	BRCA	LJM716 + trastuzumab	533.7	25.5	13	118.3	-5.2
X-3201	BRCA	LJM716 + trastuzumab	548.4	26	17	124.3	-3.3
X-3201	BRCA	LJM716 + trastuzumab	588.2	25.1	20	140.6	-6.7
X-3201	BRCA	LJM716 + trastuzumab	715.4	24.1	24	192.6	-10.4
X-3201	BRCA	LJM716 + trastuzumab	775.9	24.7	27	217.3	-8.2
X-3201	BRCA	LJM716 + trastuzumab	886.1	23.7	31	262.4	-11.9
X-3201	BRCA	LJM716 + trastuzumab	988.7	23.5	34	304.4	-12.6
X-3201	BRCA	LJM716	248.6	27	0	0	0
X-3201	BRCA	LJM716	241.2	24.3	3	-3	-10
X-3201	BRCA	LJM716	313.8	25.9	7	26.2	-4.1
X-3201	BRCA	LJM716	354.3	26.9	10	42.5	-0.4
X-3201	BRCA	LJM716	434.1	26.6	14	74.6	-1.5
X-3201	BRCA	LJM716	656.5	28.9	17	164.1	7
X-3201	BRCA	LJM716	803.3	27.9	21	223.1	3.3
X-3201	BRCA	LJM716	1007.2	27.2	24	305.1	0.7
X-3201	BRCA	LKA136	220	25.1	0	0	0
X-3201	BRCA	LKA136	357.8	24.9	3	62.6	-0.8
X-3201	BRCA	LKA136	461.8	25.3	6	109.9	0.8
X-3201	BRCA	LKA136	698.1	24.6	10	217.3	-2
X-3201	BRCA	LKA136	846.1	25.8	13	284.6	2.8
X-3201	BRCA	LLM871	182.7	25.1	0	0	0
X-3201	BRCA	LLM871	214.7	24.6	3	17.5	-2
X-3201	BRCA	LLM871	224.8	25.5	6	23	1.6
X-3201	BRCA	LLM871	257	25.5	10	40.7	1.6
X-3201	BRCA	LLM871	314.3	25.1	16	72	0
X-3201	BRCA	LLM871	359.2	25	22	96.6	-0.4
X-3201	BRCA	LLM871	416.2	25	27	127.8	-0.4
X-3201	BRCA	LLM871	474.1	24.8	31	159.5	-1.2
X-3201	BRCA	LLM871	500.7	26.4	34	174.1	5.2
X-3201	BRCA	LLM871	548.4	25.7	38	200.2	2.4
X-3201	BRCA	LLM871	647	25.5	41	254.1	1.6
X-3201	BRCA	LLM871	672.1	26.2	45	267.9	4.4
X-3201	BRCA	LLM871	736	25.3	48	302.8	0.8
X-3201	BRCA	LLM871	826.5	26.6	52	352.4	6
X-3201	BRCA	LLM871	901.6	26	55	393.5	3.6
X-3201	BRCA	binimetinib	300.1	30.1	0	0	0
X-3201	BRCA	binimetinib	358	29.2	4	19.3	-3
X-3201	BRCA	binimetinib	438	29.2	8	46	-3
X-3201	BRCA	binimetinib	503	29.8	11	67.6	-1
X-3201	BRCA	binimetinib	577.3	29.4	15	92.4	-2.3
X-3201	BRCA	binimetinib	551.3	29.5	18	83.7	-2
X-3201	BRCA	binimetinib	538.1	28.9	22	79.3	-4
X-3201	BRCA	binimetinib	465.7	28.7	28	55.2	-4.7
X-3201	BRCA	binimetinib	583.4	27.9	34	94.4	-7.3
X-3201	BRCA	binimetinib	568.1	29	39	89.3	-3.7
X-3201	BRCA	binimetinib	608.6	28.5	43	102.8	-5.3
X-3201	BRCA	binimetinib	698.7	28	46	132.8	-7
X-3201	BRCA	binimetinib	542.2	28.2	50	80.7	-6.3
X-3201	BRCA	binimetinib	568.9	27.9	53	89.6	-7.3
X-3201	BRCA	binimetinib	633.2	27.8	57	111	-7.6
X-3201	BRCA	binimetinib	692	27.6	60	130.6	-8.3
X-3201	BRCA	binimetinib	679.1	27.5	64	126.3	-8.6
X-3201	BRCA	binimetinib	683.1	27.3	67	127.6	-9.3
X-3201	BRCA	binimetinib	683.5	26.6	71	127.8	-11.6
X-3201	BRCA	binimetinib	668.6	27	74	122.8	-10.3
X-3201	BRCA	binimetinib	647.3	26.3	78	115.7	-12.6
X-3201	BRCA	binimetinib	692.3	27.1	81	130.7	-10
X-3201	BRCA	binimetinib	619.2	28.6	85	106.3	-5
X-3201	BRCA	binimetinib	716	27.6	88	138.6	-8.3
X-3201	BRCA	binimetinib	608.7	27.4	92	102.8	-9
X-3201	BRCA	binimetinib	645.6	26.8	95	115.1	-11
X-3201	BRCA	paclitaxel	226.5	32.2	0	0	0
X-3201	BRCA	paclitaxel	227.5	30.8	3	0.4	-4.3
X-3201	BRCA	paclitaxel	197	31.2	6	-13	-3.1
X-3201	BRCA	paclitaxel	208.5	29.1	10	-7.9	-9.6
X-3201	BRCA	paclitaxel	224.4	32.7	13	-0.9	1.6
X-3201	BRCA	paclitaxel	232.6	33.5	17	2.7	4
X-3201	BRCA	paclitaxel	180.2	34.6	20	-20.4	7.5
X-3201	BRCA	paclitaxel	183.4	34.2	24	-19	6.2
X-3201	BRCA	paclitaxel	183.1	36.2	27	-19.2	12.4
X-3201	BRCA	paclitaxel	183.1	36	31	-19.2	11.8
X-3201	BRCA	paclitaxel	155.2	35.3	34	-31.5	9.6
X-3201	BRCA	paclitaxel	199.7	34.2	38	-11.8	6.2
X-3201	BRCA	paclitaxel	171.4	34.4	41	-24.3	6.8
X-3201	BRCA	paclitaxel	155.4	34.1	45	-31.4	5.9
X-3201	BRCA	paclitaxel	186.5	34.8	49	-17.7	8.1
X-3201	BRCA	paclitaxel	196.6	33.3	52	-13.2	3.4
X-3201	BRCA	paclitaxel	226.8	34.7	55	0.1	7.8
X-3201	BRCA	paclitaxel	271	34.2	59	19.6	6.2
X-3201	BRCA	paclitaxel	316.2	35.1	62	39.6	9
X-3201	BRCA	paclitaxel	288.7	34	66	27.5	5.6
X-3201	BRCA	paclitaxel	318.7	35.3	69	40.7	9.6
X-3201	BRCA	paclitaxel	321.1	34.4	73	41.8	6.8
X-3201	BRCA	paclitaxel	367.4	34.6	76	62.2	7.5
X-3201	BRCA	paclitaxel	414	30.9	80	82.8	-4
X-3201	BRCA	paclitaxel	405.5	31.7	83	79	-1.6
X-3201	BRCA	paclitaxel	474.5	36.8	91	109.5	14.3
X-3201	BRCA	paclitaxel	521.7	38	94	130.3	18
X-3201	BRCA	paclitaxel	644.9	37.2	97	184.7	15.5
X-3201	BRCA	paclitaxel	730.8	38.2	105	222.6	18.6
X-3201	BRCA	tamoxifen	263.3	28	0	0	0
X-3201	BRCA	tamoxifen	297	28.1	4	12.8	0.4
X-3201	BRCA	tamoxifen	478.6	28.7	10	81.8	2.5
X-3201	BRCA	tamoxifen	707.8	29.7	16	168.8	6.1
X-3201	BRCA	tamoxifen	970.8	30.2	21	268.7	7.9
X-3201	BRCA	trastuzumab	236.4	29.7	0	0	0
X-3201	BRCA	trastuzumab	238	29.5	3	0.7	-0.7
X-3201	BRCA	trastuzumab	275	30.1	6	16.3	1.3
X-3201	BRCA	trastuzumab	353.9	29.3	10	49.7	-1.3
X-3201	BRCA	trastuzumab	501	29	16	111.9	-2.4
X-3201	BRCA	trastuzumab	660.3	30.7	22	179.3	3.4
X-3201	BRCA	trastuzumab	668.2	30.1	27	182.7	1.3
X-3201	BRCA	trastuzumab	732.1	30	31	209.7	1
X-3201	BRCA	trastuzumab	829.6	31	34	250.9	4.4
X-3201	BRCA	trastuzumab	838.9	31.3	38	254.9	5.4
X-3201	BRCA	trastuzumab	1082.3	31.1	41	357.8	4.7
X-3201	BRCA	untreated	306.2	31.6	0	0	0
X-3201	BRCA	untreated	428.5	30.8	4	39.9	-2.5
X-3201	BRCA	untreated	637.2	31.5	8	108.1	-0.3
X-3201	BRCA	untreated	843.4	31.8	11	175.4	0.6
X-3201	BRCA	untreated	1053.5	31.1	15	244.1	-1.6
X-3201	BRCA	untreated	1184.5	33	18	286.8	4.4
X-3201	BRCA	LFW527 + everolimus	220.65	30.7	0	0	0
X-3201	BRCA	LFW527 + everolimus	217.06	29.8	2	-1.6	-2.9
X-3201	BRCA	LFW527 + everolimus	322.43	27.8	6	46.1	-9.4
X-3201	BRCA	LFW527 + everolimus	381.58	28.5	10	72.9	-7.2
X-3201	BRCA	LFW527 + everolimus	311.79	28	14	41.3	-8.8
X-3201	BRCA	LFW527 + everolimus	306.39	27.2	17	38.9	-11.4
X-3201	BRCA	LFW527 + everolimus	288.94	27.4	21	30.9	-10.7
X-3201	BRCA	LFW527 + everolimus	326.36	26.6	24	47.9	-13.4
X-3201	BRCA	LFW527 + everolimus	322.15	26.7	28	46	-13
X-3201	BRCA	LFW527 + everolimus	338.79	26	30	53.5	-15.3
X-3201	BRCA	LFW527 + everolimus	331.08	26	34	50	-15.3
X-3201	BRCA	LFW527 + everolimus	369.3	27.9	37	67.4	-9.1
X-3201	BRCA	LFW527 + everolimus	365.72	26	42	65.7	-15.3
X-3201	BRCA	LFW527 + everolimus	386.35	29	45	75.1	-5.5
X-3201	BRCA	LFW527 + everolimus	336.82	27	55	52.6	-12.1
X-3201	BRCA	LFW527 + everolimus	369.77	28.8	59	67.6	-6.2
X-3201	BRCA	LFW527 + everolimus	292.17	26.3	63	32.4	-14.3
X-3201	BRCA	LFW527 + everolimus	333.28	23.5	66	51	-23.5
X-3201	BRCA	LFW527 + everolimus	234.34	21.3	68	6.2	-30.6
X-3205	CRC	5FU	200.5	22.2	0	0	0
X-3205	CRC	5FU	200.7	21.3	3	0.1	-4.1
X-3205	CRC	5FU	314.6	21.1	6	56.9	-5
X-3205	CRC	5FU	383	21.5	9	91	-3.2
X-3205	CRC	5FU	317.5	24.6	14	58.4	10.8
X-3205	CRC	5FU	379.2	24.5	17	89.1	10.4
X-3205	CRC	5FU	406.9	21.6	22	102.9	-2.7
X-3205	CRC	BKM120	200.3	20.2	0	0	0
X-3205	CRC	BKM120	176.7	19.9	5	-11.8	-1.5
X-3205	CRC	BKM120	221.3	20.9	8	10.5	3.5
X-3205	CRC	BKM120	196.6	20.3	13	-1.8	0.5
X-3205	CRC	BKM120	258.7	20.9	19	29.2	3.5
X-3205	CRC	BKM120	248.6	20	22	24.1	-1
X-3205	CRC	BKM120	297.9	21	27	48.7	4
X-3205	CRC	BKM120	324.4	20.6	29	62	2
X-3205	CRC	BKM120	358.6	20.6	32	79	2
X-3205	CRC	BKM120	361.2	21	36	80.3	4
X-3205	CRC	BKM120 + LJC049	231.7	30.3	0	0	0
X-3205	CRC	BKM120 + LJC049	229.3	28.3	3	-1	-6.6
X-3205	CRC	BKM120 + LJC049	203.6	27.9	8	-12.1	-7.9
X-3205	CRC	BKM120 + LJC049	266.8	29	10	15.1	-4.3
X-3205	CRC	BKM120 + LJC049	272	29.7	13	17.4	-2
X-3205	CRC	BKM120 + LJC049	282.2	29.2	17	21.8	-3.6
X-3205	CRC	BKM120 + LJC049	271.8	29	22	17.3	-4.3
X-3205	CRC	BKM120 + LJC049	285.5	28.8	25	23.2	-5
X-3205	CRC	BKM120 + LJC049	286.5	28.9	28	23.7	-4.6
X-3205	CRC	BKM120 + LJC049	279.9	28.8	30	20.8	-5
X-3205	CRC	BKM120 + LJC049	394.8	29.9	34	70.4	-1.3
X-3205	CRC	BKM120 + LJC049	682.3	28.6	37	194.5	-5.6
X-3205	CRC	BKM120 + LJC049	679.9	29.4	42	193.4	-3
X-3205	CRC	BYL719 + LJM716	238.4	28	0	0	0
X-3205	CRC	BYL719 + LJM716	502.2	27.1	5	110.7	-3.2
X-3205	CRC	BYL719 + LJM716	631.8	25.7	8	165	-8.2
X-3205	CRC	BYL719 + LJM716	668.1	25.3	13	180.2	-9.6
X-3205	CRC	BYL719 + LJM716	686.9	26.7	19	188.1	-4.6
X-3205	CRC	BYL719 + encorafenib	240.6	26.2	0	0	0
X-3205	CRC	BYL719 + encorafenib	263	24.6	3	9.3	-6.1
X-3205	CRC	BYL719 + encorafenib	272.7	25.9	8	13.3	-1.1
X-3205	CRC	BYL719 + encorafenib	377.9	25.9	10	57.1	-1.1
X-3205	CRC	BYL719 + encorafenib	405.8	26.1	13	68.7	-0.4
X-3205	CRC	BYL719 + encorafenib	393.7	27.7	17	63.6	5.7
X-3205	CRC	BYL719 + encorafenib	437.4	26.5	22	81.8	1.1
X-3205	CRC	BYL719 + encorafenib	425	26.9	25	76.6	2.7
X-3205	CRC	BYL719 + encorafenib	438.6	27.4	28	82.3	4.6
X-3205	CRC	BYL719	261.2	25.5	0	0	0
X-3205	CRC	BYL719	288	24.2	3	10.3	-5.1
X-3205	CRC	BYL719	316.8	25.7	8	21.3	0.8
X-3205	CRC	BYL719	328.1	25.9	10	25.6	1.6
X-3205	CRC	BYL719	341.7	26.4	13	30.8	3.5
X-3205	CRC	BYL719	363.9	26.5	17	39.3	3.9
X-3205	CRC	BYL719	354.4	26	22	35.7	2
X-3205	CRC	BYL719 + binimetinib	237	22.9	0	0	0
X-3205	CRC	BYL719 + binimetinib	262.4	21.6	3	10.7	-5.7
X-3205	CRC	BYL719 + binimetinib	239.2	22.5	8	0.9	-1.7
X-3205	CRC	BYL719 + binimetinib	316.5	23	10	33.5	0.4
X-3205	CRC	BYL719 + binimetinib	298.5	22.3	13	25.9	-2.6
X-3205	CRC	BYL719 + binimetinib	280.2	22.2	17	18.2	-3.1
X-3205	CRC	BYL719 + binimetinib	259.8	22	22	9.6	-3.9
X-3205	CRC	BYL719 + binimetinib	255	21.9	25	7.6	-4.4
X-3205	CRC	BYL719 + binimetinib	272.9	22.1	28	15.1	-3.5
X-3205	CRC	BYL719 + binimetinib	236.2	21.3	30	-0.3	-7
X-3205	CRC	BYL719 + binimetinib	243.7	22.3	34	2.8	-2.6
X-3205	CRC	BYL719 + binimetinib	258.7	22.1	37	9.2	-3.5
X-3205	CRC	BYL719 + binimetinib	240.1	22.7	42	1.3	-0.9
X-3205	CRC	BYL719 + binimetinib	234.1	NA	48	-1.2	-0.9
X-3205	CRC	BYL719 + binimetinib	275	22.7	52	16	-0.9
X-3205	CRC	BYL719 + binimetinib	251	21.4	56	5.9	-6.6
X-3205	CRC	BYL719 + binimetinib	322.3	21.4	62	36	-6.6
X-3205	CRC	BYL719 + binimetinib	294.7	21.4	65	24.3	-6.6
X-3205	CRC	BYL719 + binimetinib	280.8	21.9	69	18.5	-4.4
X-3205	CRC	BYL719 + binimetinib	260.2	22.6	73	9.8	-1.3
X-3205	CRC	BYL719 + binimetinib	213.6	20.2	77	-9.9	-11.8
X-3205	CRC	BYL719 + cetuximab + encorafenib	209.8	25.1	0	0	0
X-3205	CRC	BYL719 + cetuximab + encorafenib	312.8	22.9	3	49.1	-8.8
X-3205	CRC	BYL719 + cetuximab + encorafenib	440.1	24.7	8	109.8	-1.6
X-3205	CRC	BYL719 + cetuximab + encorafenib	453.3	23.8	10	116.1	-5.2
X-3205	CRC	BYL719 + cetuximab + encorafenib	454.5	24.8	13	116.6	-1.2
X-3205	CRC	BYL719 + cetuximab + encorafenib	634.4	22.9	17	202.4	-8.8
X-3205	CRC	BYL719 + cetuximab + encorafenib	652.7	24.6	22	211.1	-2
X-3205	CRC	BYL719 + cetuximab + encorafenib	600.6	22.6	25	186.3	-10
X-3205	CRC	BYL719 + cetuximab + encorafenib	739.6	23.8	28	252.5	-5.2
X-3205	CRC	BYL719 + cetuximab	269.4	27.6	0	0	0
X-3205	CRC	BYL719 + cetuximab	394.4	24.6	3	46.4	-10.9
X-3205	CRC	BYL719 + cetuximab	623.2	27.8	8	131.3	0.7
X-3205	CRC	BYL719 + cetuximab	808	28.1	10	199.9	1.8
X-3205	CRC	BYL719 + cetuximab	905.9	26.9	13	236.3	-2.5
X-3205	CRC	BYL719 + cetuximab	1107.7	23.5	17	311.2	-14.9
X-3205	CRC	BYL719 + cetuximab	1322.5	23	22	390.9	-16.7
X-3205	CRC	CGM097	280.6	24.1	0	0	0
X-3205	CRC	CGM097	337	23.5	3	20.1	-2.5
X-3205	CRC	CGM097	357.9	23.1	8	27.5	-4.1
X-3205	CRC	CGM097	423.4	23.4	10	50.9	-2.9
X-3205	CRC	CGM097	415.7	23.5	13	48.1	-2.5
X-3205	CRC	CGM097	431.2	23.3	17	53.7	-3.3
X-3205	CRC	CGM097	490.3	23	22	74.7	-4.6
X-3205	CRC	CGM097	520.2	23.6	25	85.4	-2.1
X-3205	CRC	CGM097	593.9	23.1	28	111.7	-4.1
X-3205	CRC	CKX620	226.4	28.8	0	0	0
X-3205	CRC	CKX620	264.7	27.2	5	16.9	-5.6
X-3205	CRC	CKX620	265.7	27.6	8	17.4	-4.2
X-3205	CRC	CKX620	276.1	28	13	22	-2.8
X-3205	CRC	CKX620	279.3	28.9	19	23.4	0.3
X-3205	CRC	CKX620	278.3	29.3	22	22.9	1.7
X-3205	CRC	CKX620	286.4	29	27	26.5	0.7
X-3205	CRC	CKX620	270.1	28.8	29	19.3	0
X-3205	CRC	CKX620	278	30.5	32	22.8	5.9
X-3205	CRC	CKX620	246.7	29.7	36	9	3.1
X-3205	CRC	CKX620	258.3	29.9	41	14.1	3.8
X-3205	CRC	CKX620	250.2	29.2	44	10.5	1.4
X-3205	CRC	CKX620	251.8	29.2	47	11.2	1.4
X-3205	CRC	CKX620	227.9	29.2	49	0.7	1.4
X-3205	CRC	CKX620	266	29.9	53	17.5	3.8
X-3205	CRC	CKX620	241.6	30.7	56	6.7	6.6
X-3205	CRC	CKX620	187.6	30	61	-17.1	4.2
X-3205	CRC	CKX620	139.4	NA	67	-38.4	4.2
X-3205	CRC	CKX620	153.6	30.5	71	-32.2	5.9
X-3205	CRC	CKX620	166.7	29.9	75	-26.4	3.8
X-3205	CRC	CKX620	142.3	30.4	81	-37.1	5.6
X-3205	CRC	CKX620	170.1	32.2	84	-24.9	11.8
X-3205	CRC	CKX620	143.5	29.6	88	-36.6	2.8
X-3205	CRC	CKX620	122.3	30.1	92	-46	4.5
X-3205	CRC	CKX620	174	31.8	96	-23.1	10.4
X-3205	CRC	CKX620	157.4	32.4	106	-30.5	12.5
X-3205	CRC	CLR457	195.3	21.8	0	0	0
X-3205	CRC	CLR457	204.2	24.4	5	4.6	11.9
X-3205	CRC	CLR457	191.4	22.4	8	-2	2.8
X-3205	CRC	CLR457	200.7	21.2	13	2.8	-2.8
X-3205	CRC	CLR457	221.6	21.7	19	13.5	-0.5
X-3205	CRC	CLR457	255.7	21.2	22	30.9	-2.8
X-3205	CRC	CLR457	264.1	22	27	35.2	0.9
X-3205	CRC	CLR457	278.4	21.5	29	42.5	-1.4
X-3205	CRC	CLR457	319.7	22.2	32	63.7	1.8
X-3205	CRC	CLR457	413.5	25	36	111.7	14.7
X-3205	CRC	CLR457	376.7	20.6	41	92.9	-5.5
X-3205	CRC	CLR457	408	22.2	44	108.9	1.8
X-3205	CRC	CLR457	454.5	20	47	132.7	-8.3
X-3205	CRC	HDM201	228.6	24.3	0	0	0
X-3205	CRC	HDM201	232.9	24.2	5	1.9	-0.4
X-3205	CRC	HDM201	281.6	24.1	8	23.2	-0.8
X-3205	CRC	HDM201	396.6	24	13	73.5	-1.2
X-3205	CRC	HDM201	476	23.9	19	108.2	-1.6
X-3205	CRC	HDM201	478	24.9	22	109.1	2.5
X-3205	CRC	HDM201	497.1	23.1	27	117.5	-4.9
X-3205	CRC	cetuximab	238.4	26.6	0	0	0
X-3205	CRC	cetuximab	501	23.8	3	110.2	-10.5
X-3205	CRC	cetuximab	428.1	27.8	6	79.6	4.5
X-3205	CRC	cetuximab	629.9	24.6	9	164.2	-7.5
X-3205	CRC	cetuximab	846	23.4	14	254.9	-12
X-3205	CRC	cetuximab	1168	26.5	17	389.9	-0.4
X-3205	CRC	cetuximab	1319.2	26.1	22	453.4	-1.9
X-3205	CRC	cetuximab + encorafenib	209.6	24	0	0	0
X-3205	CRC	cetuximab + encorafenib	422.4	23.3	5	101.5	-2.9
X-3205	CRC	cetuximab + encorafenib	452.3	23.2	8	115.8	-3.3
X-3205	CRC	cetuximab + encorafenib	488.9	23.2	13	133.3	-3.3
X-3205	CRC	cetuximab + encorafenib	468.6	24.6	19	123.6	2.5
X-3205	CRC	cetuximab + encorafenib	464.6	23.4	22	121.7	-2.5
X-3205	CRC	cetuximab + encorafenib	511.7	24.6	27	144.1	2.5
X-3205	CRC	LEE011	235.5	21.7	0	0	0
X-3205	CRC	LEE011	217.1	20.8	3	-7.8	-4.1
X-3205	CRC	LEE011	201.6	24.4	6	-14.4	12.4
X-3205	CRC	LEE011	210.9	20.1	9	-10.4	-7.4
X-3205	CRC	LEE011	318.7	20.2	14	35.3	-6.9
X-3205	CRC	LEE011	300.2	21.7	17	27.5	0
X-3205	CRC	LEE011	403.6	18	22	71.4	-17.1
X-3205	CRC	encorafenib	235	24.2	0	0	0
X-3205	CRC	encorafenib	448.2	23.6	3	90.7	-2.5
X-3205	CRC	encorafenib	790.2	23.7	8	236.3	-2.1
X-3205	CRC	encorafenib	839.3	22.8	10	257.1	-5.8
X-3205	CRC	encorafenib	896.8	22.9	13	281.6	-5.4
X-3205	CRC	encorafenib	1292.2	24.7	17	449.9	2.1
X-3205	CRC	encorafenib	1650.6	26.2	22	602.4	8.3
X-3205	CRC	LJC049	242.3	21.4	0	0	0
X-3205	CRC	LJC049	351.9	20.1	5	45.2	-6.1
X-3205	CRC	LJC049	372.2	19.7	8	53.6	-7.9
X-3205	CRC	LJC049	567.1	20.6	13	134	-3.7
X-3205	CRC	LJC049	591	19.5	19	143.9	-8.9
X-3205	CRC	LJC049	769.4	20	22	217.5	-6.5
X-3205	CRC	LJC049	886.9	20	27	266	-6.5
X-3205	CRC	LKA136	249.8	28.2	0	0	0
X-3205	CRC	LKA136	424.9	26.7	5	70.1	-5.3
X-3205	CRC	LKA136	452.2	27	8	81	-4.3
X-3205	CRC	LKA136	612.3	27.1	13	145.1	-3.9
X-3205	CRC	LKA136	682.1	27.1	19	173.1	-3.9
X-3205	CRC	LKA136	680	26.8	22	172.2	-5
X-3205	CRC	LKA136	887.2	26.1	27	255.2	-7.4
X-3205	CRC	binimetinib	245.2	23.6	0	0	0
X-3205	CRC	binimetinib	271.8	22.9	3	10.8	-3
X-3205	CRC	binimetinib	263.9	22.5	6	7.6	-4.7
X-3205	CRC	binimetinib	339	22.4	9	38.3	-5.1
X-3205	CRC	binimetinib	311.2	22.2	14	26.9	-5.9
X-3205	CRC	binimetinib	516.2	25.9	17	110.5	9.7
X-3205	CRC	binimetinib	562.1	26.7	22	129.2	13.1
X-3205	CRC	untreated	270	21.6	0	0	0
X-3205	CRC	untreated	470.4	20.5	3	74.2	-5.1
X-3205	CRC	untreated	657.6	20.2	6	143.6	-6.5
X-3205	CRC	untreated	748.1	19.3	9	177.1	-10.6
X-3205	CRC	untreated	1047.4	23.1	14	287.9	6.9
X-3205	CRC	untreated	1412.3	21.6	17	423.1	0
X-3205	CRC	untreated	1612.8	22.7	22	497.3	5.1
X-3205	CRC	LFW527 + binimetinib	203.51	22.85	0	0	0
X-3205	CRC	LFW527 + binimetinib	278.51	20.2	5	36.9	-11.6
X-3205	CRC	LFW527 + binimetinib	284.77	20.81	8	39.9	-8.9
X-3205	CRC	LFW527 + binimetinib	362.56	20.58	12	78.2	-9.9
X-3205	CRC	LFW527 + binimetinib	380.03	20.78	15	86.7	-9.1
X-3205	CRC	LFW527 + binimetinib	420.17	20.34	19	106.5	-11
X-3205	CRC	LFW527 + binimetinib	529.58	21.82	22	160.2	-4.5
X-3205	CRC	LFW527 + binimetinib	654.43	21.45	26	221.6	-6.1
X-3205	CRC	LFW527 + binimetinib	638	20.99	29	213.5	-8.1
X-3205	CRC	LFW527 + binimetinib	644.68	22.74	33	216.8	-0.5
X-3205	CRC	LFW527 + binimetinib	720.87	20.39	35	254.2	-10.8
X-3205	CRC	LFW527 + binimetinib	778.11	21	39	282.3	-8.1
X-3205	CRC	LFW527 + binimetinib	831.33	21.04	41	308.5	-7.9
X-3211	CM	BKM120	209.9	22.5	0	0	0
X-3211	CM	BKM120	190.9	21.2	6	-9.1	-5.8
X-3211	CM	BKM120	171.1	20.7	9	-18.5	-8
X-3211	CM	BKM120	180.4	20.6	12	-14.1	-8.4
X-3211	CM	BKM120	168	20	15	-20	-11.1
X-3211	CM	BKM120	248.5	20.1	19	18.4	-10.7
X-3211	CM	BKM120	268.1	21.2	22	27.7	-5.8
X-3211	CM	BKM120	258.9	20.8	26	23.3	-7.6
X-3211	CM	BKM120	261.8	21.4	29	24.7	-4.9
X-3211	CM	BKM120	247.1	21.4	33	17.7	-4.9
X-3211	CM	BKM120	269.9	21.6	36	28.6	-4
X-3211	CM	BKM120	256.3	21.1	40	22.1	-6.2
X-3211	CM	BKM120	322.2	21.6	43	53.5	-4
X-3211	CM	BKM120	330.5	21.4	47	57.4	-4.9
X-3211	CM	BKM120	349.2	20.2	50	66.3	-10.2
X-3211	CM	BKM120	351.6	20.7	54	67.5	-8
X-3211	CM	BKM120	379.4	20.4	57	80.7	-9.3
X-3211	CM	BKM120	475.3	20.7	61	126.4	-8
X-3211	CM	BKM120	525.6	22.1	64	150.3	-1.8
X-3211	CM	BKM120 + encorafenib	190.9	25.4	0	0	0
X-3211	CM	BKM120 + encorafenib	127.4	26.1	3	-33.3	2.8
X-3211	CM	BKM120 + encorafenib	103.3	25.8	7	-45.9	1.6
X-3211	CM	BKM120 + encorafenib	78.1	26.4	10	-59.1	3.9
X-3211	CM	BKM120 + encorafenib	78.3	26.9	14	-59	5.9
X-3211	CM	BKM120 + encorafenib	66.8	27.8	17	-65	9.4
X-3211	CM	BKM120 + encorafenib	63.6	28.1	21	-66.7	10.6
X-3211	CM	BKM120 + encorafenib	44.2	27.4	24	-76.8	7.9
X-3211	CM	BKM120 + encorafenib	57.9	28.1	28	-69.7	10.6
X-3211	CM	BKM120 + encorafenib	41.7	28.1	31	-78.2	10.6
X-3211	CM	BKM120 + encorafenib	34	28.3	35	-82.2	11.4
X-3211	CM	BKM120 + encorafenib	40.8	28.5	38	-78.6	12.2
X-3211	CM	BKM120 + encorafenib	32	28.4	43	-83.2	11.8
X-3211	CM	BKM120 + encorafenib	13.5	27.8	46	-92.9	9.4
X-3211	CM	BKM120 + encorafenib	13.5	27.9	50	-92.9	9.8
X-3211	CM	BKM120 + encorafenib	6	28.3	53	-96.9	11.4
X-3211	CM	BKM120 + encorafenib	24.4	28.9	58	-87.2	13.8
X-3211	CM	BKM120 + encorafenib	26.7	29.1	63	-86	14.6
X-3211	CM	BKM120 + encorafenib	17	28.9	67	-91.1	13.8
X-3211	CM	BKM120 + encorafenib	23.2	28.9	70	-87.8	13.8
X-3211	CM	BKM120 + encorafenib	24.2	28.8	73	-87.3	13.4
X-3211	CM	BKM120 + encorafenib	22.2	28.9	77	-88.3	13.8
X-3211	CM	BKM120 + encorafenib	23.9	28.5	83	-87.5	12.2
X-3211	CM	BKM120 + encorafenib	27.8	28.2	91	-85.4	11
X-3211	CM	BKM120 + encorafenib	26.9	28.4	100	-85.9	11.8
X-3211	CM	BKM120 + encorafenib	22.3	28.7	105	-88.3	13
X-3211	CM	BKM120 + encorafenib	24.3	28.3	112	-87.2	11.4
X-3211	CM	BKM120 + encorafenib	24.4	28.3	119	-87.2	11.4
X-3211	CM	BKM120 + encorafenib	17	28.3	126	-91.1	11.4
X-3211	CM	BKM120 + encorafenib	17.5	28.1	133	-90.8	10.6
X-3211	CM	BKM120 + encorafenib	23.3	28.4	140	-87.8	11.8
X-3211	CM	BKM120 + encorafenib	21.1	29.1	147	-88.9	14.6
X-3211	CM	BKM120 + encorafenib	16.9	28.6	154	-91.2	12.6
X-3211	CM	BKM120 + encorafenib	25.1	29.3	161	-86.8	15.4
X-3211	CM	BKM120 + encorafenib	25.1	29.4	168	-86.8	15.7
X-3211	CM	BKM120 + encorafenib	23.4	29.5	175	-87.8	16.1
X-3211	CM	BKM120 + encorafenib	16	29.1	182	-91.6	14.6
X-3211	CM	BKM120 + encorafenib	19.2	28.9	190	-89.9	13.8
X-3211	CM	BKM120 + encorafenib	21.9	28.8	196	-88.5	13.4
X-3211	CM	BKM120 + encorafenib	20.9	29.9	203	-89.1	17.7
X-3211	CM	BKM120 + encorafenib	16.5	29.8	210	-91.3	17.3
X-3211	CM	BKM120 + encorafenib	16.9	29.9	217	-91.1	17.7
X-3211	CM	BKM120 + encorafenib	18.4	30.9	224	-90.3	21.7
X-3211	CM	BKM120 + encorafenib	19.6	30.2	228	-89.7	18.9
X-3211	CM	CGM097	205	23.8	0	0	0
X-3211	CM	CGM097	180.2	23.9	2	-12.1	0.4
X-3211	CM	CGM097	197	22.3	5	-3.9	-6.3
X-3211	CM	CGM097	254.6	21.9	11	24.2	-8
X-3211	CM	CGM097	228.3	19.9	17	11.4	-16.4
X-3211	CM	CGM097	228.3	19.8	18	11.4	-16.8
X-3211	CM	CLR457	194.8	23.9	0	0	0
X-3211	CM	CLR457	163	23.3	4	-16.3	-2.5
X-3211	CM	CLR457	191.7	23.8	7	-1.6	-0.4
X-3211	CM	CLR457	166.3	24.4	11	-14.7	2.1
X-3211	CM	CLR457	182.1	23.9	14	-6.5	0
X-3211	CM	CLR457	153.6	23.3	19	-21.2	-2.5
X-3211	CM	CLR457	126.5	23.1	22	-35.1	-3.3
X-3211	CM	CLR457	135.8	23.4	26	-30.3	-2.1
X-3211	CM	CLR457	158.4	22.6	29	-18.7	-5.4
X-3211	CM	CLR457	134.7	22.8	34	-30.9	-4.6
X-3211	CM	CLR457	116.4	23.4	39	-40.2	-2.1
X-3211	CM	CLR457	114.9	22.2	43	-41	-7.1
X-3211	CM	CLR457	106.9	21.6	47	-45.1	-9.6
X-3211	CM	CLR457	145.2	22.6	50	-25.5	-5.4
X-3211	CM	CLR457	173.9	22.6	54	-10.7	-5.4
X-3211	CM	CLR457	202	22.6	60	3.7	-5.4
X-3211	CM	CLR457	142.1	22.1	68	-27.1	-7.5
X-3211	CM	CLR457	116.4	22.3	77	-40.3	-6.7
X-3211	CM	dacarbazine	208.4	24.3	0	0	0
X-3211	CM	dacarbazine	227.5	24.1	4	9.1	-0.8
X-3211	CM	dacarbazine	191.7	22.8	7	-8.1	-6.2
X-3211	CM	dacarbazine	252.7	22.5	11	21.2	-7.4
X-3211	CM	dacarbazine	240.4	21.9	14	15.3	-9.9
X-3211	CM	dacarbazine	217.7	21.2	19	4.5	-12.8
X-3211	CM	dacarbazine	200.9	21.6	22	-3.6	-11.1
X-3211	CM	dacarbazine	232.7	21.3	26	11.7	-12.3
X-3211	CM	dacarbazine	269.8	21	29	29.4	-13.6
X-3211	CM	dacarbazine	268.9	20.5	34	29	-15.6
X-3211	CM	LDE225	204.2	23	0	0	0
X-3211	CM	LDE225	208.1	21.8	4	1.9	-5.2
X-3211	CM	LDE225	179.2	20.5	7	-12.2	-10.9
X-3211	CM	LDE225	197.1	19.3	10	-3.4	-16.1
X-3211	CM	LDE225	187.5	18.6	12	-8.1	-19.1
X-3211	CM	LDK378	239.9	20	0	0	0
X-3211	CM	LDK378	260.8	19	4	8.7	-5
X-3211	CM	LDK378	264.5	18.4	7	10.2	-8
X-3211	CM	LDK378	319.8	18.9	11	33.3	-5.5
X-3211	CM	LDK378	292.5	18.7	14	21.9	-6.5
X-3211	CM	LDK378	325.3	18.7	18	35.6	-6.5
X-3211	CM	LDK378	345.6	19.1	21	44	-4.5
X-3211	CM	LDK378	365.2	18.4	25	52.2	-8
X-3211	CM	LDK378	404.7	20.1	28	68.7	0.5
X-3211	CM	LDK378	340.8	19.7	32	42	-1.5
X-3211	CM	LDK378	410.4	19	35	71	-5
X-3211	CM	LDK378	511.2	20	39	113	0
X-3211	CM	LDK378	445.1	19.6	42	85.5	-2
X-3211	CM	LEE011	201.3	25.2	0	0	0
X-3211	CM	LEE011	189.2	23.7	2	-6	-6
X-3211	CM	LEE011	245	22.5	5	21.7	-10.7
X-3211	CM	LEE011	258	22.9	11	28.2	-9.1
X-3211	CM	LEE011	249.5	21.3	17	24	-15.5
X-3211	CM	LEE011	249.5	21.5	18	24	-14.7
X-3211	CM	LEE011 + encorafenib	197.9	28.6	0	0	0
X-3211	CM	LEE011 + encorafenib	131.1	29.1	3	-33.8	1.7
X-3211	CM	LEE011 + encorafenib	135.7	28.2	7	-31.4	-1.4
X-3211	CM	LEE011 + encorafenib	94.3	27.6	10	-52.4	-3.5
X-3211	CM	LEE011 + encorafenib	103.3	28.5	14	-47.8	-0.3
X-3211	CM	LEE011 + encorafenib	95.7	28.6	17	-51.7	0
X-3211	CM	LEE011 + encorafenib	100.9	28.9	21	-49	1
X-3211	CM	LEE011 + encorafenib	92.1	28.7	24	-53.5	0.3
X-3211	CM	LEE011 + encorafenib	58.2	28.4	29	-70.6	-0.7
X-3211	CM	LEE011 + encorafenib	41.5	29	32	-79.1	1.4
X-3211	CM	LEE011 + encorafenib	72.9	28.3	36	-63.2	-1
X-3211	CM	LEE011 + encorafenib	75	28.6	39	-62.1	0
X-3211	CM	LEE011 + encorafenib	89.6	28.9	44	-54.7	1
X-3211	CM	LEE011 + encorafenib	89.7	29.4	49	-54.7	2.8
X-3211	CM	LEE011 + encorafenib	88.2	29.3	53	-55.4	2.4
X-3211	CM	LEE011 + encorafenib	90.1	29.2	56	-54.5	2.1
X-3211	CM	LEE011 + encorafenib	63.5	29.3	59	-67.9	2.4
X-3211	CM	LEE011 + encorafenib	69.8	29.3	63	-64.7	2.4
X-3211	CM	LEE011 + encorafenib	67.6	28.8	69	-65.8	0.7
X-3211	CM	LEE011 + encorafenib	76.9	28.5	77	-61.2	-0.3
X-3211	CM	LEE011 + encorafenib	57.6	28.7	86	-70.9	0.3
X-3211	CM	LEE011 + encorafenib	70.5	29.2	91	-64.4	2.1
X-3211	CM	LEE011 + encorafenib	64.8	29	98	-67.3	1.4
X-3211	CM	LEE011 + encorafenib	69.9	28.6	105	-64.7	0
X-3211	CM	LEE011 + encorafenib	62.7	28.9	112	-68.3	1
X-3211	CM	LEE011 + encorafenib	53.3	29.1	119	-73	1.7
X-3211	CM	LEE011 + encorafenib	66.4	29.6	126	-66.4	3.5
X-3211	CM	LEE011 + encorafenib	79.4	30.2	133	-59.9	5.6
X-3211	CM	LEE011 + encorafenib	73.8	30.3	140	-62.7	5.9
X-3211	CM	LEE011 + encorafenib	73.6	29.2	147	-62.8	2.1
X-3211	CM	LEE011 + encorafenib	82.1	30.2	154	-58.5	5.6
X-3211	CM	LEE011 + encorafenib	76.5	29.4	161	-61.3	2.8
X-3211	CM	LEE011 + encorafenib	74.7	29.8	168	-62.3	4.2
X-3211	CM	LEE011 + encorafenib	100.8	29.9	176	-49.1	4.5
X-3211	CM	LEE011 + encorafenib	96.2	29.8	182	-51.4	4.2
X-3211	CM	LEE011 + encorafenib	117.1	29.9	189	-40.8	4.5
X-3211	CM	LEE011 + encorafenib	169.2	29.8	196	-14.5	4.2
X-3211	CM	LEE011 + encorafenib	233.5	28.9	203	18	1
X-3211	CM	LEE011 + encorafenib	372.9	28.9	210	88.5	1
X-3211	CM	LEE011 + encorafenib	401.4	28.7	214	102.8	0.3
X-3211	CM	LEE011 + binimetinib	213.8	24.6	0	0	0
X-3211	CM	LEE011 + binimetinib	171.3	23.8	3	-19.9	-3.3
X-3211	CM	LEE011 + binimetinib	213.3	22.9	7	-0.2	-6.9
X-3211	CM	LEE011 + binimetinib	203.4	24.1	10	-4.8	-2
X-3211	CM	LEE011 + binimetinib	158.4	24.1	15	-25.9	-2
X-3211	CM	LEE011 + binimetinib	126.9	24.2	18	-40.7	-1.6
X-3211	CM	LEE011 + binimetinib	109.7	25	22	-48.7	1.6
X-3211	CM	LEE011 + binimetinib	74.1	24.9	25	-65.3	1.2
X-3211	CM	LEE011 + binimetinib	83.3	26.2	30	-61	6.5
X-3211	CM	LEE011 + binimetinib	62.2	28.1	35	-70.9	14.2
X-3211	CM	LEE011 + binimetinib	67.2	26.7	39	-68.6	8.5
X-3211	CM	LEE011 + binimetinib	64.2	26.5	42	-70	7.7
X-3211	CM	LEE011 + binimetinib	81.4	26.3	45	-61.9	6.9
X-3211	CM	LEE011 + binimetinib	53	26.4	49	-75.2	7.3
X-3211	CM	LEE011 + binimetinib	53.2	26.2	55	-75.1	6.5
X-3211	CM	LEE011 + binimetinib	46.2	27.1	63	-78.4	10.2
X-3211	CM	LEE011 + binimetinib	45	26.6	72	-78.9	8.1
X-3211	CM	LEE011 + binimetinib	41.3	27.5	77	-80.7	11.8
X-3211	CM	LEE011 + binimetinib	41.7	27.5	84	-80.5	11.8
X-3211	CM	LEE011 + binimetinib	46.8	28.4	91	-78.1	15.4
X-3211	CM	LEE011 + binimetinib	45.9	28.7	98	-78.5	16.7
X-3211	CM	LEE011 + binimetinib	45.9	28.6	105	-78.5	16.3
X-3211	CM	LEE011 + binimetinib	42.2	28.5	112	-80.3	15.9
X-3211	CM	LEE011 + binimetinib	23.5	28.4	119	-89	15.4
X-3211	CM	LEE011 + binimetinib	35.9	28.1	126	-83.2	14.2
X-3211	CM	LEE011 + binimetinib	35	28.4	133	-83.6	15.4
X-3211	CM	LEE011 + binimetinib	38.5	28.6	140	-82	16.3
X-3211	CM	LEE011 + binimetinib	30.9	28.9	147	-85.5	17.5
X-3211	CM	LEE011 + binimetinib	25.8	24.7	154	-87.9	0.4
X-3211	CM	LEE011 + binimetinib	27	27.2	162	-87.4	10.6
X-3211	CM	LEE011 + binimetinib	24.6	27.1	168	-88.5	10.2
X-3211	CM	LEE011 + binimetinib	27.3	26.7	175	-87.2	8.5
X-3211	CM	LEE011 + binimetinib	27.3	27.7	176	-87.2	12.6
X-3211	CM	WNT974	200.9	23.7	0	0	0
X-3211	CM	WNT974	186	23.5	2	-7.4	-0.8
X-3211	CM	WNT974	174.6	22.7	5	-13.1	-4.2
X-3211	CM	WNT974	161.8	22.3	9	-19.5	-5.9
X-3211	CM	WNT974	169.2	21.9	12	-15.8	-7.6
X-3211	CM	WNT974	159.9	21.2	16	-20.4	-10.5
X-3211	CM	WNT974	190.4	21.7	19	-5.2	-8.4
X-3211	CM	WNT974	179.1	21	23	-10.8	-11.4
X-3211	CM	WNT974	183.2	22.3	26	-8.8	-5.9
X-3211	CM	WNT974	179.4	21.7	30	-10.7	-8.4
X-3211	CM	WNT974	186.8	21.5	33	-7	-9.3
X-3211	CM	WNT974	258	21.8	37	28.4	-8
X-3211	CM	WNT974	330.3	21	40	64.4	-11.4
X-3211	CM	LGW813	218.6	22.8	0	0	0
X-3211	CM	LGW813	157.4	22	4	-28	-3.5
X-3211	CM	LGW813	164.6	22.9	7	-24.7	0.4
X-3211	CM	LGW813	192.2	22.8	10	-12.1	0
X-3211	CM	LGW813	207.1	22.3	13	-5.3	-2.2
X-3211	CM	LGW813	154.1	22.9	17	-29.5	0.4
X-3211	CM	LGW813	149.3	22.8	20	-31.7	0
X-3211	CM	LGW813	211.7	22.9	24	-3.1	0.4
X-3211	CM	LGW813	175.2	23.2	27	-19.9	1.8
X-3211	CM	LGW813	156.3	22.3	31	-28.5	-2.2
X-3211	CM	LGW813	193	23.4	34	-11.7	2.6
X-3211	CM	LGW813	192	23.7	38	-12.2	3.9
X-3211	CM	LGW813	162.5	24.1	41	-25.7	5.7
X-3211	CM	LGW813	135	22.9	45	-38.3	0.4
X-3211	CM	LGW813	137.6	23.4	48	-37.1	2.6
X-3211	CM	LGW813	176.3	23.6	52	-19.3	3.5
X-3211	CM	LGW813	163.6	22.8	55	-25.2	0
X-3211	CM	LGW813	108.6	22.5	61	-50.3	-1.3
X-3211	CM	LGW813	168.2	20.6	64	-23.1	-9.6
X-3211	CM	LGW813	142.2	20.9	69	-34.9	-8.3
X-3211	CM	LGW813	118.6	21	72	-45.7	-7.9
X-3211	CM	LGW813	116	20.6	76	-46.9	-9.6
X-3211	CM	LGW813	117.6	19.7	77	-46.2	-13.6
X-3211	CM	encorafenib	223.2	25.9	0	0	0
X-3211	CM	encorafenib	172.7	26.2	2	-22.6	1.2
X-3211	CM	encorafenib	155.8	26.8	5	-30.2	3.5
X-3211	CM	encorafenib	182.7	28.3	11	-18.2	9.3
X-3211	CM	encorafenib	122.9	28.3	17	-44.9	9.3
X-3211	CM	encorafenib	110.7	28.6	20	-50.4	10.4
X-3211	CM	encorafenib	106.9	27.9	23	-52.1	7.7
X-3211	CM	encorafenib	111.1	30.1	26	-50.3	16.2
X-3211	CM	encorafenib	171.5	28.1	30	-23.2	8.5
X-3211	CM	encorafenib	132.3	27.7	33	-40.7	6.9
X-3211	CM	encorafenib	170	28.2	37	-23.8	8.9
X-3211	CM	encorafenib	167.5	28.1	40	-25	8.5
X-3211	CM	encorafenib	162.5	27.3	44	-27.2	5.4
X-3211	CM	encorafenib	149.2	26.9	47	-33.2	3.9
X-3211	CM	encorafenib	128.5	26.6	51	-42.4	2.7
X-3211	CM	encorafenib	172.3	28.9	54	-22.8	11.6
X-3211	CM	encorafenib	167.1	26.6	58	-25.2	2.7
X-3211	CM	encorafenib	153.5	26.1	61	-31.2	0.8
X-3211	CM	encorafenib	182.4	26.2	65	-18.3	1.2
X-3211	CM	encorafenib	168.2	26.1	68	-24.7	0.8
X-3211	CM	encorafenib	173.1	26.1	72	-22.5	0.8
X-3211	CM	encorafenib	193.3	27.3	75	-13.4	5.4
X-3211	CM	encorafenib	190.8	25.7	80	-14.5	-0.8
X-3211	CM	encorafenib	195.3	26.4	83	-12.5	1.9
X-3211	CM	encorafenib	204.7	25.3	87	-8.3	-2.3
X-3211	CM	encorafenib	246.4	25.1	90	10.4	-3.1
X-3211	CM	encorafenib	239.1	25.3	95	7.1	-2.3
X-3211	CM	encorafenib	228	25.6	100	2.1	-1.2
X-3211	CM	encorafenib	259.1	24.8	104	16	-4.2
X-3211	CM	encorafenib	343.3	24.6	107	53.8	-5
X-3211	CM	encorafenib	267.2	25.6	110	19.7	-1.2
X-3211	CM	encorafenib	275	26.3	114	23.2	1.5
X-3211	CM	encorafenib	332.8	25.8	120	49.1	-0.4
X-3211	CM	encorafenib	358.2	25.3	128	60.5	-2.3
X-3211	CM	encorafenib	379.5	25.4	137	70	-1.9
X-3211	CM	encorafenib	405	25.5	142	81.4	-1.5
X-3211	CM	encorafenib + binimetinib	218	22.9	0	0	0
X-3211	CM	encorafenib + binimetinib	111.7	22.9	4	-48.8	0
X-3211	CM	encorafenib + binimetinib	76.2	22.1	7	-65	-3.5
X-3211	CM	encorafenib + binimetinib	70.3	23.3	11	-67.7	1.7
X-3211	CM	encorafenib + binimetinib	63.4	23.3	14	-70.9	1.7
X-3211	CM	encorafenib + binimetinib	61.1	23.7	18	-72	3.5
X-3211	CM	encorafenib + binimetinib	78.5	23.4	21	-64	2.2
X-3211	CM	encorafenib + binimetinib	62.5	22.5	26	-71.3	-1.7
X-3211	CM	encorafenib + binimetinib	13.5	23.4	29	-93.8	2.2
X-3211	CM	encorafenib + binimetinib	6	23.2	33	-97.2	1.3
X-3211	CM	encorafenib + binimetinib	6	23.9	36	-97.2	4.4
X-3211	CM	encorafenib + binimetinib	48.5	23	41	-77.8	0.4
X-3211	CM	encorafenib + binimetinib	49.4	23.7	46	-77.3	3.5
X-3211	CM	encorafenib + binimetinib	49.2	23.8	50	-77.4	3.9
X-3211	CM	encorafenib + binimetinib	47.8	24	53	-78.1	4.8
X-3211	CM	encorafenib + binimetinib	29.3	23.5	56	-86.5	2.6
X-3211	CM	encorafenib + binimetinib	30	23.1	60	-86.3	0.9
X-3211	CM	encorafenib + binimetinib	47.6	23.2	66	-78.2	1.3
X-3211	CM	encorafenib + binimetinib	36.6	23.8	74	-83.2	3.9
X-3211	CM	encorafenib + binimetinib	30	24.1	83	-86.2	5.2
X-3211	CM	encorafenib + binimetinib	28.7	23.8	88	-86.8	3.9
X-3211	CM	encorafenib + binimetinib	26	24.1	95	-88.1	5.2
X-3211	CM	encorafenib + binimetinib	27.2	23.9	102	-87.5	4.4
X-3211	CM	encorafenib + binimetinib	37.5	23.7	109	-82.8	3.5
X-3211	CM	encorafenib + binimetinib	32	23.9	116	-85.3	4.4
X-3211	CM	encorafenib + binimetinib	23.5	23.9	123	-89.2	4.4
X-3211	CM	encorafenib + binimetinib	22	24.1	130	-89.9	5.2
X-3211	CM	encorafenib + binimetinib	25.5	24.3	137	-88.3	6.1
X-3211	CM	encorafenib + binimetinib	16.3	24.5	144	-92.5	7
X-3211	CM	encorafenib + binimetinib	24	24.2	151	-89	5.7
X-3211	CM	encorafenib + binimetinib	15.2	24.5	158	-93	7
X-3211	CM	encorafenib + binimetinib	9.4	24.2	165	-95.7	5.7
X-3211	CM	encorafenib + binimetinib	8.9	23.5	173	-95.9	2.6
X-3211	CM	encorafenib + binimetinib	9.6	23.2	179	-95.6	1.3
X-3211	CM	encorafenib + binimetinib	27.6	24.6	186	-87.3	7.4
X-3211	CM	encorafenib + binimetinib	25.4	24.6	193	-88.4	7.4
X-3211	CM	encorafenib + binimetinib	38	24.6	200	-82.6	7.4
X-3211	CM	encorafenib + binimetinib	68.5	24.7	207	-68.6	7.9
X-3211	CM	encorafenib + binimetinib	82.5	24.7	211	-62.1	7.9
X-3211	CM	binimetinib	219.5	22	0	0	0
X-3211	CM	binimetinib	207.5	22.9	2	-5.4	4.1
X-3211	CM	binimetinib	148.5	22.2	5	-32.3	0.9
X-3211	CM	binimetinib	113.9	23.9	11	-48.1	8.6
X-3211	CM	binimetinib	80.3	24.1	17	-63.4	9.5
X-3211	CM	binimetinib	109.6	24.6	20	-50.1	11.8
X-3211	CM	binimetinib	93.2	25.2	23	-57.5	14.5
X-3211	CM	binimetinib	98.5	25	26	-55.1	13.6
X-3211	CM	binimetinib	116.3	25.2	30	-47	14.5
X-3211	CM	binimetinib	79	25.2	33	-64	14.5
X-3211	CM	binimetinib	81.6	25.4	37	-62.8	15.5
X-3211	CM	binimetinib	115.8	26.2	40	-47.3	19.1
X-3211	CM	binimetinib	94.6	25.9	44	-56.9	17.7
X-3211	CM	binimetinib	97.9	26.2	47	-55.4	19.1
X-3211	CM	binimetinib	87	24.9	51	-60.4	13.2
X-3211	CM	binimetinib	75.2	26.3	54	-65.7	19.5
X-3211	CM	binimetinib	76.9	26.4	58	-64.9	20
X-3211	CM	binimetinib	64.9	25.6	61	-70.4	16.4
X-3211	CM	binimetinib	106.3	26.7	65	-51.6	21.4
X-3211	CM	binimetinib	80.5	26.5	68	-63.3	20.5
X-3211	CM	binimetinib	71.9	26.3	72	-67.3	19.5
X-3211	CM	binimetinib	71.8	27.3	75	-67.3	24.1
X-3211	CM	binimetinib	62.5	25.6	80	-71.5	16.4
X-3211	CM	binimetinib	62.5	25.6	83	-71.5	16.4
X-3211	CM	binimetinib	68.8	25.5	87	-68.7	15.9
X-3211	CM	binimetinib	75	25	90	-65.8	13.6
X-3211	CM	binimetinib	80.5	25.2	95	-63.3	14.5
X-3211	CM	binimetinib	74.2	25.7	100	-66.2	16.8
X-3211	CM	binimetinib	67.6	25.3	104	-69.2	15
X-3211	CM	binimetinib	86.4	25.5	107	-60.7	15.9
X-3211	CM	binimetinib	93.5	26.5	110	-57.4	20.5
X-3211	CM	binimetinib	116.4	25.8	114	-46.9	17.3
X-3211	CM	binimetinib	100.7	25.7	120	-54.1	16.8
X-3211	CM	binimetinib	117.6	26.1	128	-46.4	18.6
X-3211	CM	binimetinib	112.4	26.5	137	-48.8	20.5
X-3211	CM	binimetinib	110.4	25.8	142	-49.7	17.3
X-3211	CM	binimetinib	118	25.7	149	-46.3	16.8
X-3211	CM	binimetinib	156.8	26.7	156	-28.6	21.4
X-3211	CM	binimetinib	121.4	27.2	163	-44.7	23.6
X-3211	CM	binimetinib	145.6	27.1	170	-33.7	23.2
X-3211	CM	binimetinib	138.3	26.3	177	-37	19.5
X-3211	CM	binimetinib	194.4	25.3	184	-11.4	15
X-3211	CM	binimetinib	164.9	25.2	191	-24.9	14.5
X-3211	CM	binimetinib	222.2	24.8	198	1.2	12.7
X-3211	CM	binimetinib	240	25.5	205	9.4	15.9
X-3211	CM	binimetinib	281.3	25.5	208	28.2	15.9
X-3211	CM	TAS266	218	23.6	0	0	0
X-3211	CM	TAS266	186.6	23.7	4	-14.4	0.4
X-3211	CM	TAS266	214.8	22.4	7	-1.5	-5.1
X-3211	CM	TAS266	296	22.2	13	35.8	-5.9
X-3211	CM	TAS266	433.5	21.7	18	98.9	-8.1
X-3211	CM	TAS266	585.1	21.7	21	168.4	-8.1
X-3211	CM	TAS266	531.9	21.3	24	144	-9.7
X-3211	CM	TAS266	660.5	21.6	27	203	-8.5
X-3211	CM	TAS266	650.8	20	31	198.5	-15.3
X-3211	CM	TAS266	727.8	19.9	34	233.9	-15.7
X-3211	CM	TAS266	746.3	20	38	242.3	-15.3
X-3211	CM	untreated	197.1	23.6	0	0	0
X-3211	CM	untreated	200.4	23.9	3	1.7	1.3
X-3211	CM	untreated	179.5	26	7	-8.9	10.2
X-3211	CM	untreated	229	25.4	10	16.2	7.6
X-3211	CM	untreated	256.9	25.7	16	30.4	8.9
X-3211	CM	untreated	270.8	23.4	22	37.4	-0.8
X-3211	CM	untreated	329.4	24.2	25	67.1	2.5
X-3211	CM	untreated	328	24.2	28	66.4	2.5
X-3211	CM	untreated	348	27	31	76.5	14.4
X-3211	CM	untreated	458.5	23.4	35	132.7	-0.8
X-3211	CM	untreated	407.9	22.2	38	107	-5.9
X-3211	CM	untreated	482.1	22.4	42	144.6	-5.1
X-3211	CM	untreated	555.9	23.3	45	182.1	-1.3
X-3211	CM	untreated	560.5	22.8	49	184.4	-3.4
X-3211	CM	untreated	583.9	23	52	196.2	-2.5
X-3211	CM	untreated	632.3	22.8	56	220.8	-3.4
X-3211	CM	untreated	727	24.1	59	268.9	2.1
X-3211	CM	untreated	755	23.3	63	283.1	-1.3
X-3211	CM	untreated	930.4	23.3	66	372.1	-1.3
X-3211	CM	untreated	931.5	23.7	67	372.6	0.4
X-3224	CRC	5FU	201.9	25.4	0	0	0
X-3224	CRC	5FU	201.2	25.1	4	-0.3	-1.2
X-3224	CRC	5FU	231.3	26.7	7	14.6	5.1
X-3224	CRC	5FU	251.1	25.5	12	24.4	0.4
X-3224	CRC	5FU	269.8	26	15	33.6	2.4
X-3224	CRC	5FU	263.9	26.7	20	30.7	5.1
X-3224	CRC	5FU	371.6	23.9	24	84.1	-5.9
X-3224	CRC	BKM120 + LJC049	238.3	23.4	0	0	0
X-3224	CRC	BKM120 + LJC049	736.7	24.5	7	209.1	4.7
X-3224	CRC	BKM120 + LJC049	1076.3	24.8	10	351.7	6
X-3224	CRC	BKM120 + LJC049	1122.1	25.3	14	370.9	8.1
X-3224	CRC	BKM120 + LJC049	1104.1	24.9	18	363.3	6.4
X-3224	CRC	BKM120 + LJC049	1033.2	25.9	21	333.6	10.7
X-3224	CRC	BKM120	279	28	0	0	0
X-3224	CRC	BKM120	279.3	27.4	3	0.1	-2.1
X-3224	CRC	BKM120	225.6	28.2	7	-19.1	0.7
X-3224	CRC	BKM120	200.7	29	10	-28.1	3.6
X-3224	CRC	BKM120	223.4	30.3	14	-19.9	8.2
X-3224	CRC	BKM120	232.3	30.1	18	-16.7	7.5
X-3224	CRC	BKM120	268.6	29.6	21	-3.7	5.7
X-3224	CRC	BKM120	238.2	30.4	26	-14.6	8.6
X-3224	CRC	BKM120	254.7	29.3	34	-8.7	4.6
X-3224	CRC	BKM120	322.4	29.7	38	15.6	6.1
X-3224	CRC	BKM120	420.3	29.2	43	50.6	4.3
X-3224	CRC	BKM120	537.4	29.8	49	92.6	6.4
X-3224	CRC	BYL719 + binimetinib	352.1	24.9	0	0	0
X-3224	CRC	BYL719 + binimetinib	545.2	25	3	54.8	0.4
X-3224	CRC	BYL719 + binimetinib	504.2	24.4	7	43.2	-2
X-3224	CRC	BYL719 + binimetinib	534.7	24.6	10	51.9	-1.2
X-3224	CRC	BYL719 + binimetinib	515.3	24.4	14	46.4	-2
X-3224	CRC	BYL719 + binimetinib	539.3	24.1	18	53.2	-3.2
X-3224	CRC	BYL719 + binimetinib	499.7	25.7	21	41.9	3.2
X-3224	CRC	BYL719 + binimetinib	378.9	24.1	26	7.6	-3.2
X-3224	CRC	BYL719 + binimetinib	402.3	23.9	29	14.3	-4
X-3224	CRC	BYL719 + binimetinib	383.6	23.5	34	8.9	-5.6
X-3224	CRC	BYL719 + binimetinib	431.8	20.7	38	22.6	-16.9
X-3224	CRC	BYL719 + LJM716	191.4	25	0	0	0
X-3224	CRC	BYL719 + LJM716	162.4	23.7	3	-15.2	-5.2
X-3224	CRC	BYL719 + LJM716	164.5	23.5	7	-14.1	-6
X-3224	CRC	BYL719 + LJM716	163.9	23.7	10	-14.4	-5.2
X-3224	CRC	BYL719 + LJM716	156.8	24.2	14	-18.1	-3.2
X-3224	CRC	BYL719 + LJM716	168.9	24.1	18	-11.8	-3.6
X-3224	CRC	BYL719 + LJM716	154.1	23.9	21	-19.5	-4.4
X-3224	CRC	BYL719 + LJM716	134.5	24.2	26	-29.7	-3.2
X-3224	CRC	BYL719 + LJM716	136.3	24.8	29	-28.8	-0.8
X-3224	CRC	BYL719 + LJM716	124.2	24.1	34	-35.1	-3.6
X-3224	CRC	BYL719 + LJM716	135.5	24.2	38	-29.2	-3.2
X-3224	CRC	BYL719 + LJM716	112.8	29.2	43	-41.1	16.8
X-3224	CRC	BYL719 + LJM716	132.8	23.7	49	-30.6	-5.2
X-3224	CRC	BYL719 + LJM716	129.9	23.9	52	-32.1	-4.4
X-3224	CRC	BYL719 + LJM716	113.8	24.1	55	-40.5	-3.6
X-3224	CRC	BYL719 + LJM716	116.3	24.5	62	-39.2	-2
X-3224	CRC	BYL719 + LJM716	96.3	24.9	67	-49.7	-0.4
X-3224	CRC	BYL719 + LJM716	83.5	24.7	71	-56.4	-1.2
X-3224	CRC	BYL719 + LJM716	89.8	25.5	76	-53.1	2
X-3224	CRC	BYL719 + LJM716	88.6	24.6	80	-53.7	-1.6
X-3224	CRC	BYL719 + LJM716	77.6	23.8	85	-59.5	-4.8
X-3224	CRC	BYL719 + LJM716	109.2	24.5	90	-42.9	-2
X-3224	CRC	BYL719 + cetuximab + encorafenib	219.7	25.4	0	0	0
X-3224	CRC	BYL719 + cetuximab + encorafenib	257	24.5	3	17	-3.5
X-3224	CRC	BYL719 + cetuximab + encorafenib	364.1	26.4	7	65.7	3.9
X-3224	CRC	BYL719 + cetuximab + encorafenib	381.7	26.1	10	73.7	2.8
X-3224	CRC	BYL719 + cetuximab + encorafenib	397.9	26.9	14	81.1	5.9
X-3224	CRC	BYL719 + cetuximab + encorafenib	418.2	27.1	18	90.4	6.7
X-3224	CRC	BYL719 + cetuximab + encorafenib	434.6	26.7	21	97.8	5.1
X-3224	CRC	BYL719 + cetuximab + encorafenib	562.9	26.1	38	156.2	2.8
X-3224	CRC	BYL719	239.7	25.6	0	0	0
X-3224	CRC	BYL719	190.9	22.8	1	-20.4	-10.9
X-3224	CRC	BYL719	215.8	22.8	6	-10	-10.9
X-3224	CRC	BYL719	203.4	25.1	12	-15.1	-2
X-3224	CRC	BYL719	220.4	24.9	15	-8.1	-2.7
X-3224	CRC	BYL719	228.9	25.7	18	-4.5	0.4
X-3224	CRC	BYL719	236.1	25.3	25	-1.5	-1.2
X-3224	CRC	BYL719	239.7	25.9	30	0	1.2
X-3224	CRC	BYL719	267.2	29	34	11.5	13.3
X-3224	CRC	BYL719	256.5	25.9	39	7	1.2
X-3224	CRC	BYL719	313.1	26	43	30.6	1.6
X-3224	CRC	BYL719	347.2	25.4	48	44.8	-0.8
X-3224	CRC	BYL719	345.9	25.4	57	44.3	-0.8
X-3224	CRC	BYL719	313.5	26.1	61	30.8	2
X-3224	CRC	BYL719	336.7	25.7	64	40.5	0.4
X-3224	CRC	BYL719	326.9	26.9	68	36.4	5.1
X-3224	CRC	BYL719	288.7	25.9	71	20.4	1.2
X-3224	CRC	BYL719	312.2	25.9	74	30.2	1.2
X-3224	CRC	BYL719	313.6	26.1	78	30.8	2
X-3224	CRC	BYL719	288.7	25.4	84	20.4	-0.8
X-3224	CRC	BYL719	260.4	25.9	88	8.6	1.2
X-3224	CRC	BYL719	300.8	25.7	92	25.5	0.4
X-3224	CRC	BYL719	346.2	25.9	95	44.4	1.2
X-3224	CRC	BYL719	385.6	25.6	99	60.9	0
X-3224	CRC	BYL719	391.8	25.4	103	63.5	-0.8
X-3224	CRC	BYL719	414.1	25.7	106	72.8	0.4
X-3224	CRC	BYL719	419.4	26	109	75	1.6
X-3224	CRC	BYL719	443.7	24.8	110	85.1	-3.1
X-3224	CRC	BYL719 + cetuximab	204.4	27.1	0	0	0
X-3224	CRC	BYL719 + cetuximab	262.8	26.8	1	28.6	-1.1
X-3224	CRC	BYL719 + cetuximab	198.2	25.9	6	-3	-4.4
X-3224	CRC	BYL719 + cetuximab	228.2	26.3	12	11.6	-3
X-3224	CRC	BYL719 + cetuximab	229.3	26.5	15	12.2	-2.2
X-3224	CRC	BYL719 + cetuximab	282.1	25.9	18	38	-4.4
X-3224	CRC	BYL719 + cetuximab	186.9	26	25	-8.6	-4.1
X-3224	CRC	BYL719 + cetuximab	180.2	24.3	30	-11.8	-10.3
X-3224	CRC	BYL719 + cetuximab	171.4	24.8	34	-16.1	-8.5
X-3224	CRC	BYL719 + encorafenib	214.4	28.7	0	0	0
X-3224	CRC	BYL719 + encorafenib	264.5	27	6	23.4	-5.9
X-3224	CRC	BYL719 + encorafenib	333.1	26.3	12	55.4	-8.4
X-3224	CRC	BYL719 + encorafenib	354.7	26.5	15	65.4	-7.7
X-3224	CRC	BYL719 + encorafenib	366.8	27.9	18	71.1	-2.8
X-3224	CRC	BYL719 + encorafenib	415.3	27.5	25	93.7	-4.2
X-3224	CRC	BYL719 + encorafenib	444.7	27.9	30	107.4	-2.8
X-3224	CRC	BYL719 + encorafenib	489.2	28	34	128.2	-2.4
X-3224	CRC	CGM097	247.6	23.9	0	0	0
X-3224	CRC	CGM097	265.7	24.6	4	7.3	2.9
X-3224	CRC	CGM097	343.5	25.7	7	38.7	7.5
X-3224	CRC	CGM097	614	26.1	12	148	9.2
X-3224	CRC	CGM097	637.7	24.7	15	157.6	3.3
X-3224	CRC	CGM097	691.4	25.3	20	179.2	5.9
X-3224	CRC	CGM097	468.5	25.1	24	89.2	5
X-3224	CRC	CKX620	201.2	30.5	0	0	0
X-3224	CRC	CKX620	545	29.8	3	170.9	-2.3
X-3224	CRC	CKX620	543	28.9	7	169.9	-5.2
X-3224	CRC	CKX620	545.1	29	10	170.9	-4.9
X-3224	CRC	CLR457	235.5	25.3	0	0	0
X-3224	CRC	CLR457	240.2	24.9	3	2	-1.6
X-3224	CRC	CLR457	285	25.4	7	21	0.4
X-3224	CRC	CLR457	274.8	25.2	10	16.7	-0.4
X-3224	CRC	CLR457	272.8	25.8	14	15.8	2
X-3224	CRC	CLR457	298.3	29.1	18	26.7	15
X-3224	CRC	CLR457	297.5	28.7	21	26.3	13.4
X-3224	CRC	CLR457	373	27.5	26	58.4	8.7
X-3224	CRC	CLR457	478.6	26.9	29	103.2	6.3
X-3224	CRC	CLR457	610.9	27.9	34	159.4	10.3
X-3224	CRC	CLR457	577.5	25.9	38	145.2	2.4
X-3224	CRC	CLR457	420.3	29.2	43	78.5	15.4
X-3224	CRC	CLR457	538.5	26.3	49	128.7	4
X-3224	CRC	CLR457	538.5	26.3	52	128.7	4
X-3224	CRC	CLR457	622.1	26.9	55	164.2	6.3
X-3224	CRC	CLR457	877.2	26.9	62	272.5	6.3
X-3224	CRC	CLR457	1302	27.8	67	452.9	9.9
X-3224	CRC	HDM201	261.8	24.6	0	0	0
X-3224	CRC	HDM201	801.6	24.3	3	206.2	-1.2
X-3224	CRC	HDM201	762.7	24	7	191.3	-2.4
X-3224	CRC	HDM201	782.6	24.2	10	198.9	-1.6
X-3224	CRC	HDM201	784.2	24	14	199.5	-2.4
X-3224	CRC	HDM201	840.7	24.9	18	221.1	1.2
X-3224	CRC	HDM201	803.8	25.1	21	207	2
X-3224	CRC	HDM201	1212.2	25.8	26	363	4.9
X-3224	CRC	HDM201	1245.9	25	34	375.9	1.6
X-3224	CRC	HDM201	1392.3	25.6	38	431.8	4.1
X-3224	CRC	cetuximab + encorafenib	208.3	27.3	0	0	0
X-3224	CRC	cetuximab + encorafenib	203.5	27.7	7	-2.3	1.5
X-3224	CRC	cetuximab + encorafenib	272.3	27.1	10	30.7	-0.7
X-3224	CRC	cetuximab + encorafenib	270.5	28.1	14	29.9	2.9
X-3224	CRC	cetuximab + encorafenib	268.2	28.7	18	28.8	5.1
X-3224	CRC	cetuximab + encorafenib	286.5	29.7	21	37.5	8.8
X-3224	CRC	cetuximab + encorafenib	341.8	29.5	26	64.1	8.1
X-3224	CRC	cetuximab	274.1	28.5	0	0	0
X-3224	CRC	cetuximab	311.8	29.1	4	13.8	2.1
X-3224	CRC	cetuximab	338	28.7	7	23.3	0.7
X-3224	CRC	cetuximab	426.3	29.4	12	55.5	3.2
X-3224	CRC	cetuximab	477.5	28.9	15	74.2	1.4
X-3224	CRC	cetuximab	502.7	29.1	20	83.4	2.1
X-3224	CRC	cetuximab	628.1	28.7	24	129.1	0.7
X-3224	CRC	LEE011	324.5	23.4	0	0	0
X-3224	CRC	LEE011	655.6	23.9	3	102	2.1
X-3224	CRC	LEE011	740	24.4	7	128	4.3
X-3224	CRC	LEE011	752.6	24.1	10	131.9	3
X-3224	CRC	LEE011	861.7	25.4	14	165.5	8.5
X-3224	CRC	LEE011	758	25.1	18	133.6	7.3
X-3224	CRC	LEE011	875.2	25.8	21	169.7	10.3
X-3224	CRC	encorafenib	294.9	24.3	0	0	0
X-3224	CRC	encorafenib	321.2	24.7	4	8.9	1.6
X-3224	CRC	encorafenib	335.5	25.1	7	13.8	3.3
X-3224	CRC	encorafenib	463.6	24.6	12	57.2	1.2
X-3224	CRC	encorafenib	471.5	24.1	20	59.9	-0.8
X-3224	CRC	encorafenib	616.8	22.7	24	109.2	-6.6
X-3224	CRC	LJC049	222.2	28.4	0	0	0
X-3224	CRC	LJC049	209.6	27.5	1	-5.7	-3.2
X-3224	CRC	LJC049	198	29.2	6	-10.9	2.8
X-3224	CRC	LJC049	193.2	27.7	12	-13.1	-2.5
X-3224	CRC	LJC049	263	26.3	15	18.4	-7.4
X-3224	CRC	LJC049	265.6	27.1	18	19.5	-4.6
X-3224	CRC	LJC049	482.7	28.8	25	117.2	1.4
X-3224	CRC	LJC049	693.4	29.3	30	212.1	3.2
X-3224	CRC	LKA136	199.9	26.7	0	0	0
X-3224	CRC	LKA136	359.5	26.2	3	79.8	-1.9
X-3224	CRC	LKA136	398.8	25.9	7	99.5	-3
X-3224	CRC	LKA136	476.2	25.7	10	138.2	-3.7
X-3224	CRC	LKA136	671.9	26.8	14	236.1	0.4
X-3224	CRC	LKA136	779.7	29.1	18	290	9
X-3224	CRC	LKA136	843.4	28.7	21	321.9	7.5
X-3224	CRC	binimetinib	305.5	26.1	0	0	0
X-3224	CRC	binimetinib	393.2	26.8	3	28.7	2.7
X-3224	CRC	binimetinib	853.4	26.5	7	179.3	1.5
X-3224	CRC	binimetinib	988.4	25.8	10	223.5	-1.1
X-3224	CRC	binimetinib	1208.9	26.8	14	295.7	2.7
X-3224	CRC	binimetinib	1343.3	27.1	18	339.7	3.8
X-3224	CRC	binimetinib	1470.3	28.7	21	381.3	10
X-3224	CRC	untreated	198.1	26.1	0	0	0
X-3224	CRC	untreated	161.8	26.6	1	-18.3	1.9
X-3224	CRC	untreated	181.7	26.9	12	-8.3	3.1
X-3224	CRC	untreated	156.6	27.5	15	-20.9	5.4
X-3224	CRC	untreated	144.2	26.9	18	-27.2	3.1
X-3224	CRC	untreated	190.5	27.5	25	-3.8	5.4
X-3224	CRC	untreated	225.8	28	30	14	7.3
X-3224	CRC	untreated	293.2	28.2	34	48	8
X-3224	CRC	untreated	254	28.6	39	28.2	9.6
X-3224	CRC	untreated	248.9	28.9	43	25.6	10.7
X-3224	CRC	untreated	246.9	28.4	48	24.6	8.8
X-3224	CRC	untreated	258.5	27.6	53	30.5	5.7
X-3224	CRC	untreated	245.7	28	57	24	7.3
X-3224	CRC	untreated	263.6	27.5	61	33.1	5.4
X-3224	CRC	untreated	268.2	27.9	64	35.4	6.9
X-3224	CRC	untreated	248.3	28	68	25.3	7.3
X-3224	CRC	untreated	277.5	28.1	71	40.1	7.7
X-3224	CRC	untreated	312.7	26.3	74	57.8	0.8
X-3224	CRC	untreated	331	28.5	78	67.1	9.2
X-3224	CRC	untreated	357.2	28.1	84	80.3	7.7
X-3224	CRC	untreated	344.7	29.9	88	74	14.6
X-3224	CRC	untreated	377	29.1	92	90.3	11.5
X-3224	CRC	untreated	379.2	28.4	95	91.4	8.8
X-3224	CRC	untreated	417.1	29.1	99	110.6	11.5
X-3224	CRC	untreated	463.4	27.7	103	133.9	6.1
X-3224	CRC	untreated	487.3	28.1	106	146	7.7
X-3224	CRC	untreated	502.4	28.7	109	153.6	10
X-3224	CRC	untreated	552.8	29.4	110	179.1	12.6
X-3237	NSCLC	BGJ398	216.8	22.2	0	0	0
X-3237	NSCLC	BGJ398	192.6	21.7	3	-11.2	-2.3
X-3237	NSCLC	BGJ398	202.9	22.6	6	-6.4	1.8
X-3237	NSCLC	BGJ398	390.8	22.4	10	80.3	0.9
X-3237	NSCLC	BGJ398	416.3	21.7	13	92	-2.3
X-3237	NSCLC	BGJ398	567.5	20.8	17	161.8	-6.3
X-3237	NSCLC	BGJ398	575.9	20.3	20	165.6	-8.6
X-3237	NSCLC	BGJ398	1018.7	20	24	369.9	-9.9
X-3237	NSCLC	BGJ398	980.3	18	27	352.2	-18.9
X-3237	NSCLC	BKM120	256.4	24.2	0	0	0
X-3237	NSCLC	BKM120	160	23.5	3	-37.6	-2.9
X-3237	NSCLC	BKM120	273.8	23.8	7	6.8	-1.7
X-3237	NSCLC	BKM120	304.7	23.6	10	18.8	-2.5
X-3237	NSCLC	BKM120	348.2	24.2	14	35.8	0
X-3237	NSCLC	BKM120	420.3	24	17	63.9	-0.8
X-3237	NSCLC	BKM120	517.3	23.5	21	101.8	-2.9
X-3237	NSCLC	BKM120	713.9	22.8	24	178.4	-5.8
X-3237	NSCLC	BKM120 + binimetinib	215.6	21.5	0	0	0
X-3237	NSCLC	BKM120 + binimetinib	119.9	21.4	3	-44.4	-0.5
X-3237	NSCLC	BKM120 + binimetinib	129	21.6	7	-40.2	0.5
X-3237	NSCLC	BKM120 + binimetinib	178.2	21.4	10	-17.3	-0.5
X-3237	NSCLC	BKM120 + binimetinib	194.1	21.8	14	-10	1.4
X-3237	NSCLC	BKM120 + binimetinib	197.6	21.8	17	-8.3	1.4
X-3237	NSCLC	BKM120 + binimetinib	183.2	22	21	-15	2.3
X-3237	NSCLC	BKM120 + binimetinib	173.7	22.2	24	-19.4	3.3
X-3237	NSCLC	BKM120 + binimetinib	301.3	21.9	28	39.7	1.9
X-3237	NSCLC	BKM120 + binimetinib	209.5	22.3	31	-2.8	3.7
X-3237	NSCLC	BKM120 + binimetinib	334.5	22.1	35	55.1	2.8
X-3237	NSCLC	BKM120 + binimetinib	251.3	22	38	16.6	2.3
X-3237	NSCLC	BKM120 + binimetinib	350.9	22.1	42	62.8	2.8
X-3237	NSCLC	BKM120 + binimetinib	346.2	22.4	45	60.6	4.2
X-3237	NSCLC	BKM120 + binimetinib	282.7	22.3	49	31.1	3.7
X-3237	NSCLC	BKM120 + binimetinib	303.9	22.7	52	41	5.6
X-3237	NSCLC	BKM120 + binimetinib	599.2	22.5	56	177.9	4.7
X-3237	NSCLC	BKM120 + binimetinib	589.1	22.9	60	173.2	6.5
X-3237	NSCLC	BKM120 + binimetinib	540.7	23.6	63	150.8	9.8
X-3237	NSCLC	BKM120 + binimetinib	833	23.6	67	286.4	9.8
X-3237	NSCLC	BKM120 + binimetinib	518.3	24.2	70	140.4	12.6
X-3237	NSCLC	BKM120 + binimetinib	534.7	24.3	73	148	13
X-3237	NSCLC	BKM120 + binimetinib	739.4	24.7	78	242.9	14.9
X-3237	NSCLC	BYL719	212.1	23.1	0	0	0
X-3237	NSCLC	BYL719	171.7	23.5	3	-19	1.7
X-3237	NSCLC	BYL719	141.1	23.2	6	-33.5	0.4
X-3237	NSCLC	BYL719	182.7	23.2	10	-13.9	0.4
X-3237	NSCLC	BYL719	174.4	23.2	13	-17.8	0.4
X-3237	NSCLC	BYL719	162.8	23.8	17	-23.2	3
X-3237	NSCLC	BYL719	195.9	24.3	20	-7.6	5.2
X-3237	NSCLC	BYL719	276.2	24.5	24	30.2	6.1
X-3237	NSCLC	BYL719	284.3	24.3	27	34	5.2
X-3237	NSCLC	BYL719	249.1	24	31	17.4	3.9
X-3237	NSCLC	BYL719	322.7	24.2	34	52.1	4.8
X-3237	NSCLC	BYL719	273.5	23.5	38	28.9	1.7
X-3237	NSCLC	BYL719	388.2	23.4	41	83	1.3
X-3237	NSCLC	BYL719	363.2	23.2	45	71.2	0.4
X-3237	NSCLC	BYL719	562	24.1	48	165	4.3
X-3237	NSCLC	BYL719	809.5	23.7	52	281.7	2.6
X-3237	NSCLC	BYL719 + LJM716	218.2	28.1	0	0	0
X-3237	NSCLC	BYL719 + LJM716	230.6	27.1	3	5.7	-3.6
X-3237	NSCLC	BYL719 + LJM716	262	25.8	7	20.1	-8.2
X-3237	NSCLC	BYL719 + LJM716	343.5	25.9	10	57.4	-7.8
X-3237	NSCLC	BYL719 + LJM716	432.4	25.9	14	98.2	-7.8
X-3237	NSCLC	BYL719 + LJM716	451.6	25.1	17	107	-10.7
X-3237	NSCLC	BYL719 + LJM716	602.9	26.2	21	176.3	-6.8
X-3237	NSCLC	BYL719 + LJM716	883.3	25.2	24	304.8	-10.3
X-3237	NSCLC	BYL719 + LGH447	219.6	23.2	0	0	0
X-3237	NSCLC	BYL719 + LGH447	189.6	22.9	1	-13.7	-1.3
X-3237	NSCLC	BYL719 + LGH447	190.5	23.2	5	-13.3	0
X-3237	NSCLC	BYL719 + LGH447	146.5	22.5	8	-33.3	-3
X-3237	NSCLC	BYL719 + LGH447	201.3	22.9	12	-8.3	-1.3
X-3237	NSCLC	BYL719 + LGH447	173.7	21.5	15	-20.9	-7.3
X-3237	NSCLC	BYL719 + LGH447	270.4	22.1	19	23.1	-4.7
X-3237	NSCLC	BYL719 + LGH447	243.4	22.6	22	10.8	-2.6
X-3237	NSCLC	BYL719 + LGH447	321	22.6	26	46.2	-2.6
X-3237	NSCLC	BYL719 + LGH447	279.6	22.6	29	27.3	-2.6
X-3237	NSCLC	BYL719 + LGH447	317.2	22.7	33	44.4	-2.2
X-3237	NSCLC	BYL719 + LGH447	407	23.3	36	85.3	0.4
X-3237	NSCLC	BYL719 + LGH447	435.8	20.4	40	98.5	-12.1
X-3237	NSCLC	BYL719 + LGH447	379.6	23.2	43	72.9	0
X-3237	NSCLC	BYL719 + LGH447	679.3	21.1	47	209.3	-9.1
X-3237	NSCLC	CGM097	205.6	23.2	0	0	0
X-3237	NSCLC	CGM097	293.2	24.2	5	42.6	4.3
X-3237	NSCLC	CGM097	483	26	8	134.9	12.1
X-3237	NSCLC	CGM097	607.9	27	12	195.7	16.4
X-3237	NSCLC	CGM097	939	27.3	14	356.7	17.7
X-3237	NSCLC	CKX620	273.3	25.5	0	0	0
X-3237	NSCLC	CKX620	159.7	24.9	5	-41.6	-2.4
X-3237	NSCLC	CKX620	208.2	25	8	-23.8	-2
X-3237	NSCLC	CKX620	224	26	12	-18	2
X-3237	NSCLC	CKX620	231.8	26	15	-15.2	2
X-3237	NSCLC	CKX620	295.2	26.5	19	8	3.9
X-3237	NSCLC	CKX620	256.7	26.6	22	-6.1	4.3
X-3237	NSCLC	CKX620	329.7	26.1	26	20.6	2.4
X-3237	NSCLC	CKX620	354.2	27	29	29.6	5.9
X-3237	NSCLC	CKX620	408.9	27	33	49.6	5.9
X-3237	NSCLC	CKX620	343.8	27.4	36	25.8	7.5
X-3237	NSCLC	CKX620	383.6	27.5	40	40.4	7.8
X-3237	NSCLC	CKX620	551.2	27.4	43	101.7	7.5
X-3237	NSCLC	CKX620	385	27.8	47	40.9	9
X-3237	NSCLC	CKX620	570.7	28.9	50	108.8	13.3
X-3237	NSCLC	CKX620	632.5	29.2	54	131.4	14.5
X-3237	NSCLC	CKX620	694.5	29.8	58	154.1	16.9
X-3237	NSCLC	CKX620	798.8	29.5	61	192.3	15.7
X-3237	NSCLC	CLR457	247.2	23.5	0	0	0
X-3237	NSCLC	CLR457	244.7	22.9	3	-1	-2.6
X-3237	NSCLC	CLR457	234.5	23.2	7	-5.1	-1.3
X-3237	NSCLC	CLR457	306.6	23.3	10	24	-0.9
X-3237	NSCLC	CLR457	377.1	23.5	14	52.5	0
X-3237	NSCLC	CLR457	391.4	23	17	58.3	-2.1
X-3237	NSCLC	CLR457	360.3	23	21	45.8	-2.1
X-3237	NSCLC	CLR457	337.2	22.9	24	36.4	-2.6
X-3237	NSCLC	CLR457	679.3	22.4	28	174.8	-4.7
X-3237	NSCLC	CLR457	1341.5	21.1	31	442.7	-10.2
X-3237	NSCLC	HDM201	217.7	24.8	0	0	0
X-3237	NSCLC	HDM201	211.4	24.3	3	-2.9	-2
X-3237	NSCLC	HDM201	227.4	24	7	4.5	-3.2
X-3237	NSCLC	HDM201	332.8	25	10	52.9	0.8
X-3237	NSCLC	HDM201	328.3	24.8	14	50.8	0
X-3237	NSCLC	HDM201	451.5	24.1	17	107.4	-2.8
X-3237	NSCLC	HDM201	606	24.5	21	178.4	-1.2
X-3237	NSCLC	HDM201	389.1	23.7	24	78.7	-4.4
X-3237	NSCLC	HDM201	757.6	21.9	28	248	-11.7
X-3237	NSCLC	HDM201	571.1	21.8	31	162.3	-12.1
X-3237	NSCLC	cetuximab	172	23.4	0	0	0
X-3237	NSCLC	cetuximab	186.2	24.9	3	8.3	6.4
X-3237	NSCLC	cetuximab	171.3	25.2	7	-0.4	7.7
X-3237	NSCLC	cetuximab	298.1	25.4	10	73.3	8.5
X-3237	NSCLC	cetuximab	263.1	25.8	14	53	10.3
X-3237	NSCLC	cetuximab	299.7	26	17	74.2	11.1
X-3237	NSCLC	cetuximab	435.3	25.6	21	153.1	9.4
X-3237	NSCLC	cetuximab	502.3	26	24	192	11.1
X-3237	NSCLC	cetuximab	584.6	26	28	239.9	11.1
X-3237	NSCLC	cetuximab	815.7	26.7	30	374.2	14.1
X-3237	NSCLC	erlotinib	205.1	27	0	0	0
X-3237	NSCLC	erlotinib	174.4	24.6	5	-15	-8.9
X-3237	NSCLC	erlotinib	256.6	26.1	8	25.1	-3.3
X-3237	NSCLC	erlotinib	250.7	22.9	12	22.2	-15.2
X-3237	NSCLC	erlotinib	313.7	24.6	13	52.9	-8.9
X-3237	NSCLC	erlotinib	310.4	23.3	15	51.3	-13.7
X-3237	NSCLC	erlotinib	302.6	24.1	19	47.5	-10.7
X-3237	NSCLC	erlotinib	347.7	26.4	22	69.5	-2.2
X-3237	NSCLC	erlotinib	415.5	27.6	26	102.6	2.2
X-3237	NSCLC	erlotinib	394.3	26.4	29	92.2	-2.2
X-3237	NSCLC	erlotinib	398.6	26.4	33	94.3	-2.2
X-3237	NSCLC	erlotinib	409.3	27.1	36	99.6	0.4
X-3237	NSCLC	erlotinib	429.2	26.4	40	109.3	-2.2
X-3237	NSCLC	erlotinib	542.9	26.5	43	164.7	-1.9
X-3237	NSCLC	erlotinib	689.7	25.7	47	236.3	-4.8
X-3237	NSCLC	erlotinib	830.3	26	50	304.8	-3.7
X-3237	NSCLC	erlotinib	1005.5	27.1	54	390.2	0.4
X-3237	NSCLC	HSP990	221.3	24.5	0	0	0
X-3237	NSCLC	HSP990	161.6	22.6	5	-27	-7.8
X-3237	NSCLC	HSP990	141.8	21.4	8	-35.9	-12.7
X-3237	NSCLC	HSP990	191.4	24.8	12	-13.5	1.2
X-3237	NSCLC	HSP990	317.1	25.2	15	43.3	2.9
X-3237	NSCLC	HSP990	391.5	24.7	19	76.9	0.8
X-3237	NSCLC	HSP990	375.8	25.3	22	69.8	3.3
X-3237	NSCLC	HSP990	396.4	21	26	79.1	-14.3
X-3237	NSCLC	INC280	195.3	22.6	0	0	0
X-3237	NSCLC	INC280	315.9	22.4	3	61.8	-0.9
X-3237	NSCLC	INC280	313.4	21.6	7	60.5	-4.4
X-3237	NSCLC	INC280	386.4	22.6	10	97.8	0
X-3237	NSCLC	INC280	628.6	23	14	221.9	1.8
X-3237	NSCLC	INC280	746.8	22.5	16	282.4	-0.4
X-3237	NSCLC	LCL161 + paclitaxel	208.2	23.6	0	0	0
X-3237	NSCLC	LCL161 + paclitaxel	206.5	23.9	4	-0.8	1.3
X-3237	NSCLC	LCL161 + paclitaxel	235.8	24.1	7	13.3	2.1
X-3237	NSCLC	LCL161 + paclitaxel	178.4	24.2	11	-14.3	2.5
X-3237	NSCLC	LCL161 + paclitaxel	170.9	25.1	14	-17.9	6.4
X-3237	NSCLC	LCL161 + paclitaxel	226.5	25	18	8.8	5.9
X-3237	NSCLC	LCL161 + paclitaxel	255.1	25.3	21	22.5	7.2
X-3237	NSCLC	LCL161 + paclitaxel	169.1	26	25	-18.8	10.2
X-3237	NSCLC	LCL161 + paclitaxel	243.1	26	28	16.8	10.2
X-3237	NSCLC	LCL161 + paclitaxel	304.8	26.9	32	46.4	14
X-3237	NSCLC	LCL161 + paclitaxel	337.2	27.2	35	62	15.3
X-3237	NSCLC	LCL161 + paclitaxel	322.5	27	39	54.9	14.4
X-3237	NSCLC	LCL161 + paclitaxel	274.6	27.1	42	31.9	14.8
X-3237	NSCLC	LCL161 + paclitaxel	589.6	27.2	46	183.2	15.3
X-3237	NSCLC	LCL161 + paclitaxel	717.5	27.8	50	244.6	17.8
X-3237	NSCLC	LCL161 + paclitaxel	985.5	28.5	53	373.3	20.8
X-3237	NSCLC	LEE011	239.6	25.1	0	0	0
X-3237	NSCLC	LEE011	226.3	23.7	3	-5.6	-5.6
X-3237	NSCLC	LEE011	230.3	24.2	7	-3.9	-3.6
X-3237	NSCLC	LEE011	310.4	24.6	10	29.5	-2
X-3237	NSCLC	LEE011	277.1	25.5	14	15.7	1.6
X-3237	NSCLC	LEE011	392.9	25.3	17	64	0.8
X-3237	NSCLC	LEE011	474.8	26.7	21	98.2	6.4
X-3237	NSCLC	LEE011	505.6	26.3	24	111	4.8
X-3237	NSCLC	LEE011	556.4	25.1	28	132.2	0
X-3237	NSCLC	LEE011	516.3	26.2	31	115.5	4.4
X-3237	NSCLC	LEE011	770	25.6	35	221.4	2
X-3237	NSCLC	LEE011	870.8	24.6	37	263.4	-2
X-3237	NSCLC	LGH447	217.2	24.4	0	0	0
X-3237	NSCLC	LGH447	142.6	23.7	3	-34.3	-2.9
X-3237	NSCLC	LGH447	235.8	23.2	7	8.6	-4.9
X-3237	NSCLC	LGH447	353.4	24.3	10	62.7	-0.4
X-3237	NSCLC	LGH447	417.1	23.7	14	92	-2.9
X-3237	NSCLC	LGH447	468	23.8	17	115.5	-2.5
X-3237	NSCLC	LGH447	831.9	22.8	21	283	-6.6
X-3237	NSCLC	LGH447	1042.8	23.1	24	380.1	-5.3
X-3237	NSCLC	LLM871	171.6	26.8	0	0	0
X-3237	NSCLC	LLM871	121.4	26	3	-29.3	-3
X-3237	NSCLC	LLM871	149	27.1	6	-13.2	1.1
X-3237	NSCLC	LLM871	233.8	27.7	10	36.2	3.4
X-3237	NSCLC	LLM871	228.4	27.8	13	33.1	3.7
X-3237	NSCLC	LLM871	265.4	27.5	17	54.7	2.6
X-3237	NSCLC	LLM871	345.1	28	20	101.1	4.5
X-3237	NSCLC	LLM871	412.4	29.7	24	140.3	10.8
X-3237	NSCLC	LLM871	496.8	29	27	189.5	8.2
X-3237	NSCLC	LLM871	556.4	28.1	31	224.2	4.9
X-3237	NSCLC	LLM871	750.8	29.2	33	337.5	9
X-3237	NSCLC	binimetinib	232.6	22.3	0	0	0
X-3237	NSCLC	binimetinib	161.1	21.4	3	-30.7	-4
X-3237	NSCLC	binimetinib	156.6	21.7	7	-32.7	-2.7
X-3237	NSCLC	binimetinib	115.5	22.3	10	-50.3	0
X-3237	NSCLC	binimetinib	94.7	22.4	14	-59.3	0.4
X-3237	NSCLC	binimetinib	123.8	22	17	-46.8	-1.3
X-3237	NSCLC	binimetinib	211.1	21.7	21	-9.2	-2.7
X-3237	NSCLC	binimetinib	217.7	22.2	24	-6.4	-0.4
X-3237	NSCLC	binimetinib	205.1	21.7	28	-11.8	-2.7
X-3237	NSCLC	binimetinib	340.1	21.7	31	46.2	-2.7
X-3237	NSCLC	binimetinib	356.6	21.8	35	53.3	-2.2
X-3237	NSCLC	binimetinib	358.5	20.9	38	54.1	-6.3
X-3237	NSCLC	binimetinib	414.8	20	42	78.3	-10.3
X-3237	NSCLC	binimetinib	394.9	18.4	45	69.8	-17.5
X-3237	NSCLC	binimetinib	277.6	18.7	46	19.3	-16.1
X-3237	NSCLC	binimetinib	398.1	18.1	49	71.2	-18.8
X-3237	NSCLC	paclitaxel	203.7	26.5	0	0	0
X-3237	NSCLC	paclitaxel	232.3	25.3	4	14	-4.5
X-3237	NSCLC	paclitaxel	277.1	26.1	7	36	-1.5
X-3237	NSCLC	paclitaxel	329	25.9	11	61.5	-2.3
X-3237	NSCLC	paclitaxel	461.6	26.5	14	126.6	0
X-3237	NSCLC	paclitaxel	479.6	25.9	18	135.4	-2.3
X-3237	NSCLC	paclitaxel	610.2	26.3	21	199.6	-0.8
X-3237	NSCLC	paclitaxel	730.9	27.1	25	258.8	2.3
X-3237	NSCLC	paclitaxel	731	27.4	27	258.9	3.4
X-3237	NSCLC	untreated	249.8	22.1	0	0	0
X-3237	NSCLC	untreated	308.3	22.7	3	23.4	2.7
X-3237	NSCLC	untreated	643.8	23.4	7	157.7	5.9
X-3237	NSCLC	untreated	852.3	23.7	9	241.2	7.2
X-3237	NSCLC	LFW527 + binimetinib	248.47	24.4	0	0	0
X-3237	NSCLC	LFW527 + binimetinib	164.13	25	3	-33.9	2.5
X-3237	NSCLC	LFW527 + binimetinib	81.34	24.6	7	-67.3	0.8
X-3237	NSCLC	LFW527 + binimetinib	135.66	24.9	10	-45.4	2
X-3237	NSCLC	LFW527 + binimetinib	182.65	25	13	-26.5	2.5
X-3237	NSCLC	LFW527 + binimetinib	194.69	24.8	17	-21.6	1.6
X-3237	NSCLC	LFW527 + binimetinib	226.23	24.7	20	-9	1.2
X-3237	NSCLC	LFW527 + binimetinib	286.85	24.8	24	15.4	1.6
X-3237	NSCLC	LFW527 + binimetinib	303.73	24.7	27	22.2	1.2
X-3237	NSCLC	LFW527 + binimetinib	311.45	24.6	31	25.3	0.8
X-3237	NSCLC	LFW527 + binimetinib	396.55	25.4	34	59.6	4.1
X-3237	NSCLC	LFW527 + binimetinib	426.37	24.9	38	71.6	2
X-3237	NSCLC	LFW527 + binimetinib	475.62	25.7	41	91.4	5.3
X-3237	NSCLC	LFW527 + binimetinib	437.86	25.2	45	76.2	3.3
X-3237	NSCLC	LFW527 + binimetinib	468.21	25.1	48	88.4	2.9
X-3237	NSCLC	LFW527 + binimetinib	641.34	26.4	52	158.1	8.2
X-3237	NSCLC	LFW527 + binimetinib	375.52	26.5	55	51.1	8.6
X-3237	NSCLC	LFW527 + binimetinib	883.77	25.6	59	255.7	4.9
X-3237	NSCLC	LFW527 + binimetinib	894.3	25.1	61	259.9	2.9
X-3267	CRC	5FU	208.5	23.5	0	0	0
X-3267	CRC	5FU	208.6	22.4	2	0	-4.7
X-3267	CRC	5FU	219.9	22.3	5	5.5	-5.1
X-3267	CRC	5FU	211.9	22.8	8	1.6	-3
X-3267	CRC	5FU	205.5	23	12	-1.4	-2.1
X-3267	CRC	5FU	201.1	23.2	15	-3.5	-1.3
X-3267	CRC	5FU	220.7	24.4	19	5.9	3.8
X-3267	CRC	5FU	222.6	24.4	22	6.8	3.8
X-3267	CRC	5FU	209.7	24.8	26	0.6	5.5
X-3267	CRC	5FU	199.8	23.7	29	-4.2	0.9
X-3267	CRC	5FU	170.7	23.5	33	-18.1	0
X-3267	CRC	5FU	177.7	24.1	36	-14.8	2.6
X-3267	CRC	5FU	180.6	24.2	40	-13.4	3
X-3267	CRC	5FU	168.1	23.9	43	-19.4	1.7
X-3267	CRC	5FU	145.7	23.9	47	-30.1	1.7
X-3267	CRC	5FU	174.8	24.2	50	-16.2	3
X-3267	CRC	5FU	144	24.1	54	-30.9	2.6
X-3267	CRC	5FU	202.4	23.2	57	-2.9	-1.3
X-3267	CRC	5FU	134.1	23.6	61	-35.7	0.4
X-3267	CRC	5FU	197	23.5	64	-5.5	0
X-3267	CRC	5FU	149.3	24.7	68	-28.4	5.1
X-3267	CRC	5FU	147.1	23.4	71	-29.4	-0.4
X-3267	CRC	5FU	170.7	22.7	78	-18.1	-3.4
X-3267	CRC	5FU	131.2	23.2	82	-37.1	-1.3
X-3267	CRC	5FU	156.5	23.1	86	-24.9	-1.7
X-3267	CRC	5FU	144.9	24.5	89	-30.5	4.3
X-3267	CRC	BKM120	228.1	24.4	0	0	0
X-3267	CRC	BKM120	211.3	24.9	2	-7.4	2
X-3267	CRC	BKM120	210.6	24.5	5	-7.7	0.4
X-3267	CRC	BKM120	229.9	24.7	8	0.8	1.2
X-3267	CRC	BKM120	253.2	25.3	12	11	3.7
X-3267	CRC	BKM120	252.7	24.1	15	10.8	-1.2
X-3267	CRC	BKM120	275.5	25.2	19	20.8	3.3
X-3267	CRC	BKM120	280.1	26	22	22.8	6.6
X-3267	CRC	BKM120	243.4	25.7	26	6.7	5.3
X-3267	CRC	BKM120	282.8	25.7	29	24	5.3
X-3267	CRC	BKM120	277.5	25.8	33	21.7	5.7
X-3267	CRC	BKM120	301	26.7	36	32	9.4
X-3267	CRC	BKM120	297	26.2	40	30.2	7.4
X-3267	CRC	BKM120	320	26.6	43	40.3	9
X-3267	CRC	BKM120	352.8	26.5	47	54.7	8.6
X-3267	CRC	BKM120	343.8	27.5	50	50.7	12.7
X-3267	CRC	BKM120	322.1	26.4	54	41.2	8.2
X-3267	CRC	BKM120	366.7	26.2	57	60.8	7.4
X-3267	CRC	BKM120	381.5	27.1	61	67.3	11.1
X-3267	CRC	BKM120	389.1	26	64	70.6	6.6
X-3267	CRC	BKM120	387.3	26.8	68	69.8	9.8
X-3267	CRC	BKM120	376.1	25.8	71	64.9	5.7
X-3267	CRC	BKM120	452	26.1	78	98.2	7
X-3267	CRC	BKM120	415	27.9	82	81.9	14.3
X-3267	CRC	BKM120	525.1	26.1	86	130.2	7
X-3267	CRC	BKM120	437.7	27	89	91.9	10.7
X-3267	CRC	BKM120 + LJC049	216.9	24	0	0	0
X-3267	CRC	BKM120 + LJC049	218.2	26.4	3	0.6	10
X-3267	CRC	BKM120 + LJC049	207	25.2	6	-4.6	5
X-3267	CRC	BKM120 + LJC049	205.7	23.6	10	-5.2	-1.7
X-3267	CRC	BKM120 + LJC049	205.4	24.4	13	-5.3	1.7
X-3267	CRC	BKM120 + LJC049	201.3	24.6	17	-7.2	2.5
X-3267	CRC	BKM120 + LJC049	224.7	24.3	20	3.6	1.2
X-3267	CRC	BKM120 + LJC049	273.7	24.3	24	26.2	1.2
X-3267	CRC	BKM120 + LJC049	287	24.8	27	32.3	3.3
X-3267	CRC	BKM120 + LJC049	319.3	24.7	31	47.2	2.9
X-3267	CRC	BKM120 + LJC049	309.8	23.5	34	42.8	-2.1
X-3267	CRC	BKM120 + LJC049	352.3	25.2	38	62.4	5
X-3267	CRC	BYL719	204	25.8	0	0	0
X-3267	CRC	BYL719	213.5	25.5	3	4.7	-1.2
X-3267	CRC	BYL719	200.9	24.6	7	-1.5	-4.7
X-3267	CRC	BYL719	218.1	24.7	10	6.9	-4.3
X-3267	CRC	BYL719	216	25.1	14	5.9	-2.7
X-3267	CRC	BYL719	241	26.1	17	18.1	1.2
X-3267	CRC	BYL719	235.5	26.2	21	15.4	1.6
X-3267	CRC	BYL719	218.4	26.2	24	7.1	1.6
X-3267	CRC	BYL719	216	25.7	28	5.9	-0.4
X-3267	CRC	BYL719	240.3	26.9	31	17.8	4.3
X-3267	CRC	BYL719	219.2	25.8	35	7.5	0
X-3267	CRC	BYL719	210.9	24.6	38	3.4	-4.7
X-3267	CRC	BYL719	218.5	24.4	42	7.1	-5.4
X-3267	CRC	BYL719	221.2	24.6	45	8.4	-4.7
X-3267	CRC	BYL719	227.8	25.6	49	11.7	-0.8
X-3267	CRC	BYL719	239.5	24.1	52	17.4	-6.6
X-3267	CRC	BYL719	304.2	25.2	59	49.1	-2.3
X-3267	CRC	BYL719	317.8	27	63	55.8	4.7
X-3267	CRC	BYL719	293.5	26.3	66	43.9	1.9
X-3267	CRC	BYL719	392.1	25.1	73	92.2	-2.7
X-3267	CRC	BYL719	321.7	25.4	77	57.7	-1.6
X-3267	CRC	BYL719	430.5	25.9	81	111	0.4
X-3267	CRC	BYL719	417.3	26.3	84	104.6	1.9
X-3267	CRC	BYL719	464.8	26.8	87	127.8	3.9
X-3267	CRC	BYL719 + LJM716	214.9	21.9	0	0	0
X-3267	CRC	BYL719 + LJM716	208.2	21.3	3	-3.1	-2.7
X-3267	CRC	BYL719 + LJM716	212.6	20.7	7	-1.1	-5.5
X-3267	CRC	BYL719 + LJM716	230.3	21.4	10	7.2	-2.3
X-3267	CRC	BYL719 + LJM716	210.6	20.7	14	-2	-5.5
X-3267	CRC	BYL719 + LJM716	240.2	21.4	17	11.8	-2.3
X-3267	CRC	BYL719 + LJM716	227.1	20.5	21	5.7	-6.4
X-3267	CRC	BYL719 + LJM716	239.4	21.2	24	11.4	-3.2
X-3267	CRC	BYL719 + LJM716	245.9	20.5	28	14.4	-6.4
X-3267	CRC	BYL719 + LJM716	215.6	20.7	31	0.3	-5.5
X-3267	CRC	BYL719 + LJM716	234.2	19.8	35	9	-9.6
X-3267	CRC	BYL719 + LJM716	253.6	20.4	38	18	-6.8
X-3267	CRC	BYL719 + LJM716	261.5	20.7	42	21.7	-5.5
X-3267	CRC	BYL719 + LJM716	199.9	20.2	45	-7	-7.8
X-3267	CRC	BYL719 + LJM716	278	20.1	49	29.4	-8.2
X-3267	CRC	BYL719 + LJM716	303.5	19.4	52	41.2	-11.4
X-3267	CRC	BYL719 + LJM716	320	19.7	56	48.9	-10
X-3267	CRC	BYL719 + LJM716	312.3	19.8	59	45.3	-9.6
X-3267	CRC	BYL719 + LJM716	217.5	20.4	63	1.2	-6.8
X-3267	CRC	BYL719 + LJM716	262.9	20.2	66	22.3	-7.8
X-3267	CRC	BYL719 + LJM716	325.1	21.3	73	51.3	-2.7
X-3267	CRC	BYL719 + LJM716	302.5	21.2	77	40.8	-3.2
X-3267	CRC	BYL719 + LJM716	287.8	21.4	81	33.9	-2.3
X-3267	CRC	BYL719 + LJM716	261.9	20.1	84	21.9	-8.2
X-3267	CRC	BYL719 + LJM716	216	19.7	87	0.5	-10
X-3267	CRC	BYL719 + encorafenib	225.6	23.1	0	0	0
X-3267	CRC	BYL719 + encorafenib	229.3	23	3	1.6	-0.4
X-3267	CRC	BYL719 + encorafenib	243.7	23.4	6	8	1.3
X-3267	CRC	BYL719 + encorafenib	246.6	23.3	10	9.3	0.9
X-3267	CRC	BYL719 + encorafenib	250.2	23.1	13	10.9	0
X-3267	CRC	BYL719 + encorafenib	313.2	23.8	17	38.8	3
X-3267	CRC	BYL719 + encorafenib	325	23.9	20	44.1	3.5
X-3267	CRC	BYL719 + encorafenib	341.2	24.6	24	51.2	6.5
X-3267	CRC	BYL719 + encorafenib	398.6	25.2	27	76.7	9.1
X-3267	CRC	BYL719 + encorafenib	352.3	24.6	31	56.2	6.5
X-3267	CRC	BYL719 + encorafenib	388.4	24	34	72.2	3.9
X-3267	CRC	BYL719 + encorafenib	377.4	24.1	38	67.3	4.3
X-3267	CRC	BYL719 + encorafenib	412.7	25.3	41	82.9	9.5
X-3267	CRC	BYL719 + encorafenib	473.4	24.7	45	109.8	6.9
X-3267	CRC	BYL719 + encorafenib	443.7	26.1	48	96.7	13
X-3267	CRC	BYL719 + encorafenib	477.8	25.5	52	111.8	10.4
X-3267	CRC	BYL719 + encorafenib	501.5	24.8	55	122.3	7.4
X-3267	CRC	BYL719 + encorafenib	517.6	25.7	59	129.4	11.3
X-3267	CRC	BYL719 + encorafenib	504	25.2	62	123.4	9.1
X-3267	CRC	BYL719 + encorafenib	503.8	25.1	69	123.3	8.7
X-3267	CRC	BYL719 + encorafenib	583.7	25.2	73	158.7	9.1
X-3267	CRC	BYL719 + encorafenib	647.3	25	77	186.9	8.2
X-3267	CRC	BYL719 + encorafenib	752.9	24.6	80	233.7	6.5
X-3267	CRC	BYL719 + encorafenib	761.5	25.4	83	237.5	10
X-3267	CRC	BYL719 + cetuximab	223.5	23.4	0	0	0
X-3267	CRC	BYL719 + cetuximab	212.2	23.2	3	-5.1	-0.9
X-3267	CRC	BYL719 + cetuximab	199.1	23.8	6	-10.9	1.7
X-3267	CRC	BYL719 + cetuximab	234.9	24.4	10	5.1	4.3
X-3267	CRC	BYL719 + cetuximab	227.4	23.6	13	1.7	0.9
X-3267	CRC	BYL719 + cetuximab	225.1	24.3	17	0.7	3.8
X-3267	CRC	BYL719 + cetuximab	226.6	24.6	20	1.4	5.1
X-3267	CRC	BYL719 + cetuximab	264.4	24.2	24	18.3	3.4
X-3267	CRC	BYL719 + cetuximab	244	25.3	27	9.2	8.1
X-3267	CRC	BYL719 + cetuximab	205.9	25.2	31	-7.9	7.7
X-3267	CRC	BYL719 + cetuximab	245.9	25	34	10	6.8
X-3267	CRC	BYL719 + cetuximab	241	25.3	38	7.8	8.1
X-3267	CRC	BYL719 + cetuximab	251.8	24.8	41	12.7	6
X-3267	CRC	BYL719 + cetuximab	252.8	25	45	13.1	6.8
X-3267	CRC	BYL719 + cetuximab	291	25.6	48	30.2	9.4
X-3267	CRC	BYL719 + cetuximab	242.6	26.4	52	8.5	12.8
X-3267	CRC	BYL719 + cetuximab	257.7	25.5	55	15.3	9
X-3267	CRC	BYL719 + cetuximab	234.9	26.2	59	5.1	12
X-3267	CRC	BYL719 + cetuximab	261.2	26.5	62	16.9	13.2
X-3267	CRC	BYL719 + cetuximab	277	25.9	69	23.9	10.7
X-3267	CRC	BYL719 + cetuximab	244.3	25.7	73	9.3	9.8
X-3267	CRC	BYL719 + cetuximab	298.5	26	77	33.6	11.1
X-3267	CRC	BYL719 + cetuximab	276.9	26.7	80	23.9	14.1
X-3267	CRC	BYL719 + cetuximab	285.8	26.9	83	27.9	15
X-3267	CRC	BYL719 + cetuximab + encorafenib	212.6	24.2	0	0	0
X-3267	CRC	BYL719 + cetuximab + encorafenib	196.7	24.5	3	-7.5	1.2
X-3267	CRC	BYL719 + cetuximab + encorafenib	193.2	24.6	7	-9.1	1.7
X-3267	CRC	BYL719 + cetuximab + encorafenib	204.4	25.3	10	-3.9	4.5
X-3267	CRC	BYL719 + cetuximab + encorafenib	199.3	25.9	14	-6.3	7
X-3267	CRC	BYL719 + cetuximab + encorafenib	204.2	25.8	17	-4	6.6
X-3267	CRC	BYL719 + cetuximab + encorafenib	204.3	24.7	21	-3.9	2.1
X-3267	CRC	BYL719 + cetuximab + encorafenib	257.7	24.9	24	21.2	2.9
X-3267	CRC	BYL719 + cetuximab + encorafenib	228.8	25	28	7.6	3.3
X-3267	CRC	BYL719 + cetuximab + encorafenib	228.9	25.5	31	7.7	5.4
X-3267	CRC	BYL719 + cetuximab + encorafenib	244.5	25.4	35	15	5
X-3267	CRC	BYL719 + cetuximab + encorafenib	240	25.7	38	12.9	6.2
X-3267	CRC	BYL719 + cetuximab + encorafenib	340.9	25.9	42	60.3	7
X-3267	CRC	BYL719 + cetuximab + encorafenib	355.8	25.5	45	67.4	5.4
X-3267	CRC	BYL719 + cetuximab + encorafenib	411.6	26.4	49	93.6	9.1
X-3267	CRC	BYL719 + cetuximab + encorafenib	448	26.1	52	110.7	7.9
X-3267	CRC	BYL719 + cetuximab + encorafenib	419.8	26.2	56	97.5	8.3
X-3267	CRC	BYL719 + cetuximab + encorafenib	472	25.9	59	122	7
X-3267	CRC	BYL719 + cetuximab + encorafenib	627.5	24.7	66	195.2	2.1
X-3267	CRC	BYL719 + cetuximab + encorafenib	681.1	25.3	70	220.4	4.5
X-3267	CRC	BYL719 + cetuximab + encorafenib	726.1	25.6	74	241.5	5.8
X-3267	CRC	BYL719 + cetuximab + encorafenib	945.9	25.5	77	344.9	5.4
X-3267	CRC	BYL719 + binimetinib	211.2	24	0	0	0
X-3267	CRC	BYL719 + binimetinib	232.8	22.4	5	10.2	-6.7
X-3267	CRC	BYL719 + binimetinib	213.8	23.6	8	1.2	-1.7
X-3267	CRC	BYL719 + binimetinib	192.8	23.3	12	-8.7	-2.9
X-3267	CRC	BYL719 + binimetinib	175	22.4	15	-17.1	-6.7
X-3267	CRC	BYL719 + binimetinib	178.1	23.5	19	-15.7	-2.1
X-3267	CRC	BYL719 + binimetinib	142.2	24.2	22	-32.7	0.8
X-3267	CRC	BYL719 + binimetinib	151.1	24.6	26	-28.5	2.5
X-3267	CRC	BYL719 + binimetinib	130.4	23.9	29	-38.3	-0.4
X-3267	CRC	BYL719 + binimetinib	139.1	24.2	33	-34.1	0.8
X-3267	CRC	BYL719 + binimetinib	155.7	23.3	36	-26.3	-2.9
X-3267	CRC	BYL719 + binimetinib	158.6	22.2	40	-24.9	-7.5
X-3267	CRC	BYL719 + binimetinib	200.2	23.6	43	-5.2	-1.7
X-3267	CRC	BYL719 + binimetinib	122.7	22.9	47	-41.9	-4.6
X-3267	CRC	BYL719 + binimetinib	120.8	22.9	50	-42.8	-4.6
X-3267	CRC	BYL719 + binimetinib	100.3	23	54	-52.5	-4.2
X-3267	CRC	BYL719 + binimetinib	119.5	23.4	57	-43.4	-2.5
X-3267	CRC	BYL719 + binimetinib	103.5	23.9	64	-51	-0.4
X-3267	CRC	BYL719 + binimetinib	119.4	23.3	68	-43.5	-2.9
X-3267	CRC	BYL719 + binimetinib	173.4	24	72	-17.9	0
X-3267	CRC	BYL719 + binimetinib	114.1	23.3	75	-46	-2.9
X-3267	CRC	BYL719 + binimetinib	122.9	24.3	78	-41.8	1.2
X-3267	CRC	BYL719 + binimetinib	126.7	22.9	82	-40	-4.6
X-3267	CRC	BYL719 + binimetinib	152.9	23.8	85	-27.6	-0.8
X-3267	CRC	BYL719 + binimetinib	135.5	24.3	90	-35.8	1.2
X-3267	CRC	CGM097	218.1	24.2	0	0	0
X-3267	CRC	CGM097	245.6	22	3	12.6	-9.1
X-3267	CRC	CGM097	231	24.5	6	5.9	1.2
X-3267	CRC	CGM097	243.2	25	10	11.5	3.3
X-3267	CRC	CGM097	305.7	25.2	13	40.2	4.1
X-3267	CRC	CGM097	340	25.7	17	55.9	6.2
X-3267	CRC	CGM097	377.6	26.1	20	73.1	7.9
X-3267	CRC	CGM097	360.9	26	24	65.5	7.4
X-3267	CRC	CGM097	438.3	26.5	27	101	9.5
X-3267	CRC	CKX620	230.8	25.4	0	0	0
X-3267	CRC	CKX620	221.7	24.8	3	-3.9	-2.4
X-3267	CRC	CKX620	228.5	25.7	6	-1	1.2
X-3267	CRC	CKX620	223.2	25.3	10	-3.3	-0.4
X-3267	CRC	CKX620	231.6	25.8	13	0.3	1.6
X-3267	CRC	CKX620	223.6	25.9	17	-3.1	2
X-3267	CRC	CKX620	234	26.8	20	1.4	5.5
X-3267	CRC	CKX620	232.7	25.7	24	0.8	1.2
X-3267	CRC	CKX620	242.5	25.3	27	5.1	-0.4
X-3267	CRC	CKX620	216.5	26.6	31	-6.2	4.7
X-3267	CRC	CKX620	241.3	26.7	34	4.5	5.1
X-3267	CRC	CKX620	259.5	25.9	38	12.4	2
X-3267	CRC	CKX620	221.7	26.7	41	-3.9	5.1
X-3267	CRC	CKX620	231.3	26	45	0.2	2.4
X-3267	CRC	CKX620	243	26	48	5.3	2.4
X-3267	CRC	CKX620	231.9	26.2	52	0.5	3.1
X-3267	CRC	CKX620	215.8	19.7	55	-6.5	-22.4
X-3267	CRC	CKX620	204.9	23.8	59	-11.2	-6.3
X-3267	CRC	CLR457	206.5	24.2	0	0	0
X-3267	CRC	CLR457	209.3	23.5	3	1.4	-2.9
X-3267	CRC	CLR457	214.9	22.9	7	4.1	-5.4
X-3267	CRC	CLR457	219.6	23.6	10	6.3	-2.5
X-3267	CRC	CLR457	213	23.6	14	3.1	-2.5
X-3267	CRC	CLR457	217.6	23.9	17	5.4	-1.2
X-3267	CRC	CLR457	214.3	23.9	21	3.8	-1.2
X-3267	CRC	CLR457	248.8	23.7	24	20.5	-2.1
X-3267	CRC	CLR457	209.9	24.2	28	1.6	0
X-3267	CRC	CLR457	254.6	24.6	31	23.3	1.7
X-3267	CRC	CLR457	233.4	24.5	35	13	1.2
X-3267	CRC	CLR457	255.2	23.8	38	23.6	-1.7
X-3267	CRC	CLR457	276.5	24	42	33.9	-0.8
X-3267	CRC	CLR457	300.1	24	45	45.3	-0.8
X-3267	CRC	CLR457	287.8	24	49	39.4	-0.8
X-3267	CRC	CLR457	269.1	23.4	52	30.3	-3.3
X-3267	CRC	CLR457	340.8	24.1	56	65	-0.4
X-3267	CRC	CLR457	308.3	23.5	59	49.3	-2.9
X-3267	CRC	CLR457	308.3	24.6	63	49.3	1.7
X-3267	CRC	CLR457	310.4	24.5	66	50.3	1.2
X-3267	CRC	CLR457	406.3	23.5	73	96.8	-2.9
X-3267	CRC	CLR457	408.1	24	77	97.6	-0.8
X-3267	CRC	CLR457	420.3	24.1	81	103.5	-0.4
X-3267	CRC	CLR457	522.9	24.3	84	153.2	0.4
X-3267	CRC	CLR457	533.9	24.7	87	158.5	2.1
X-3267	CRC	HDM201	224	27.9	0	0	0
X-3267	CRC	HDM201	229.8	25.5	3	2.6	-8.6
X-3267	CRC	HDM201	255.9	26.5	10	14.2	-5
X-3267	CRC	HDM201	265	26.8	13	18.3	-3.9
X-3267	CRC	HDM201	295.5	27.1	17	31.9	-2.9
X-3267	CRC	HDM201	285.7	27.5	20	27.5	-1.4
X-3267	CRC	HDM201	303.9	26.8	24	35.7	-3.9
X-3267	CRC	HDM201	309.6	25.9	27	38.2	-7.2
X-3267	CRC	HDM201	323.1	25.5	31	44.2	-8.6
X-3267	CRC	HDM201	334.1	24.7	34	49.2	-11.5
X-3267	CRC	HDM201	328.6	24.9	38	46.7	-10.8
X-3267	CRC	HDM201	340.7	22.3	41	52.1	-20.1
X-3267	CRC	cetuximab	233.4	30.1	0	0	0
X-3267	CRC	cetuximab	236.8	28.8	2	1.5	-4.3
X-3267	CRC	cetuximab	249.3	29.3	5	6.8	-2.7
X-3267	CRC	cetuximab	246.4	31.8	8	5.6	5.6
X-3267	CRC	cetuximab	250.1	32.3	12	7.2	7.3
X-3267	CRC	cetuximab	267.5	28.4	15	14.6	-5.6
X-3267	CRC	cetuximab	270.7	33	19	16	9.6
X-3267	CRC	cetuximab	317.4	33.3	22	36	10.6
X-3267	CRC	cetuximab	290.5	32.5	26	24.5	8
X-3267	CRC	cetuximab	294.1	31.8	29	26	5.6
X-3267	CRC	cetuximab	257.7	33.1	33	10.4	10
X-3267	CRC	cetuximab	313.7	32.5	36	34.4	8
X-3267	CRC	cetuximab	299.1	32.6	40	28.1	8.3
X-3267	CRC	cetuximab	297.8	32.8	43	27.6	9
X-3267	CRC	cetuximab	301.3	31.8	47	29.1	5.6
X-3267	CRC	cetuximab	303.4	32	50	30	6.3
X-3267	CRC	cetuximab	307.8	32.9	54	31.9	9.3
X-3267	CRC	cetuximab	363.5	31.1	57	55.7	3.3
X-3267	CRC	cetuximab	326.3	32.5	61	39.8	8
X-3267	CRC	cetuximab	370.8	33	64	58.9	9.6
X-3267	CRC	cetuximab	317.5	32.6	68	36	8.3
X-3267	CRC	cetuximab	326.6	32.6	71	39.9	8.3
X-3267	CRC	cetuximab	387.2	33.1	78	65.9	10
X-3267	CRC	cetuximab	332.2	31.5	82	42.3	4.7
X-3267	CRC	cetuximab	404	33.2	86	73.1	10.3
X-3267	CRC	cetuximab	394.3	32.3	89	68.9	7.3
X-3267	CRC	cetuximab + encorafenib	204.7	25.1	0	0	0
X-3267	CRC	cetuximab + encorafenib	210.7	25.2	3	2.9	0.4
X-3267	CRC	cetuximab + encorafenib	204.5	25.5	6	-0.1	1.6
X-3267	CRC	cetuximab + encorafenib	245.4	26	10	19.9	3.6
X-3267	CRC	cetuximab + encorafenib	235.4	25.5	13	15	1.6
X-3267	CRC	cetuximab + encorafenib	233.7	25.7	17	14.2	2.4
X-3267	CRC	cetuximab + encorafenib	307.9	26.2	20	50.4	4.4
X-3267	CRC	cetuximab + encorafenib	277.1	26.4	24	35.4	5.2
X-3267	CRC	cetuximab + encorafenib	311.4	26.5	27	52.1	5.6
X-3267	CRC	cetuximab + encorafenib	332.3	26.5	31	62.3	5.6
X-3267	CRC	cetuximab + encorafenib	318.4	27.5	34	55.5	9.6
X-3267	CRC	cetuximab + encorafenib	348.3	26	38	70.2	3.6
X-3267	CRC	cetuximab + encorafenib	358.5	28.1	41	75.1	12
X-3267	CRC	cetuximab + encorafenib	425.1	27.9	45	107.7	11.2
X-3267	CRC	cetuximab + encorafenib	487.1	27.2	48	138	8.4
X-3267	CRC	cetuximab + encorafenib	545.6	27.7	52	166.5	10.4
X-3267	CRC	cetuximab + encorafenib	502.4	27.2	55	145.4	8.4
X-3267	CRC	cetuximab + encorafenib	581.9	27.5	59	184.3	9.6
X-3267	CRC	cetuximab + encorafenib	496.1	28.1	62	142.4	12
X-3267	CRC	cetuximab + encorafenib	583.6	27	69	185.1	7.6
X-3267	CRC	cetuximab + encorafenib	655.2	27.7	73	220.1	10.4
X-3267	CRC	cetuximab + encorafenib	753.6	27.5	77	268.1	9.6
X-3267	CRC	cetuximab + encorafenib	935.4	27.5	80	357	9.6
X-3267	CRC	LEE011	237.3	23.8	0	0	0
X-3267	CRC	LEE011	234.5	23.3	2	-1.2	-2.1
X-3267	CRC	LEE011	251.3	22.7	5	5.9	-4.6
X-3267	CRC	LEE011	242	23.5	8	2	-1.3
X-3267	CRC	LEE011	270.9	25	12	14.2	5
X-3267	CRC	LEE011	274.5	23.2	15	15.7	-2.5
X-3267	CRC	LEE011	276	23.6	19	16.3	-0.8
X-3267	CRC	LEE011	279.4	24.1	22	17.7	1.3
X-3267	CRC	LEE011	297.8	23.4	26	25.5	-1.7
X-3267	CRC	LEE011	391.5	23.1	29	65	-2.9
X-3267	CRC	LEE011	358.5	23.2	33	51.1	-2.5
X-3267	CRC	LEE011	410.2	24	36	72.9	0.8
X-3267	CRC	LEE011	448.9	24	40	89.2	0.8
X-3267	CRC	LEE011	429	24.2	43	80.8	1.7
X-3267	CRC	LEE011	531.7	24.4	47	124.1	2.5
X-3267	CRC	LEE011	540.9	24.5	50	127.9	2.9
X-3267	CRC	LEE011	489.5	24.5	54	106.3	2.9
X-3267	CRC	LEE011	684.3	25	57	188.4	5
X-3267	CRC	LEE011	657.8	25.5	61	177.2	7.1
X-3267	CRC	LEE011	660.2	24.1	64	178.2	1.3
X-3267	CRC	LEE011	831.8	25	68	250.5	5
X-3267	CRC	LEE011	907.9	24.8	71	282.6	4.2
X-3267	CRC	encorafenib	233.6	27.4	0	0	0
X-3267	CRC	encorafenib	236.6	26.9	3	1.3	-1.8
X-3267	CRC	encorafenib	233.8	27.5	6	0.1	0.4
X-3267	CRC	encorafenib	227.5	27.6	10	-2.6	0.7
X-3267	CRC	encorafenib	291.2	27.4	13	24.7	0
X-3267	CRC	encorafenib	280.6	28.3	17	20.1	3.3
X-3267	CRC	encorafenib	354.3	29.7	20	51.7	8.4
X-3267	CRC	encorafenib	422.1	28.6	24	80.7	4.4
X-3267	CRC	encorafenib	431	28	27	84.5	2.2
X-3267	CRC	encorafenib	466.6	28.7	31	99.7	4.7
X-3267	CRC	encorafenib	456.9	28.2	34	95.6	2.9
X-3267	CRC	encorafenib	687.4	27.6	38	194.3	0.7
X-3267	CRC	LJC049	218.3	24.4	0	0	0
X-3267	CRC	LJC049	205.3	24.4	3	-6	0
X-3267	CRC	LJC049	213.2	25.2	7	-2.3	3.3
X-3267	CRC	LJC049	227.7	24.9	10	4.3	2
X-3267	CRC	LJC049	283.5	25.7	14	29.9	5.3
X-3267	CRC	LJC049	307.9	25.4	17	41	4.1
X-3267	CRC	LJC049	363	24.3	21	66.3	-0.4
X-3267	CRC	LJC049	453	25.7	24	107.5	5.3
X-3267	CRC	LKA136	208.3	24.6	0	0	0
X-3267	CRC	LKA136	212.6	24.5	3	2.1	-0.4
X-3267	CRC	LKA136	273.6	24.3	7	31.3	-1.2
X-3267	CRC	LKA136	268.9	24.7	10	29.1	0.4
X-3267	CRC	LKA136	252	25.3	14	21	2.8
X-3267	CRC	LKA136	252.7	25.2	17	21.3	2.4
X-3267	CRC	LKA136	320.2	25.2	21	53.7	2.4
X-3267	CRC	LKA136	361.4	24.6	24	73.5	0
X-3267	CRC	LKA136	402.9	25.6	28	93.4	4.1
X-3267	CRC	LKA136	397	25.7	31	90.6	4.5
X-3267	CRC	LKA136	476.2	26.1	35	128.6	6.1
X-3267	CRC	binimetinib	219.6	25.8	0	0	0
X-3267	CRC	binimetinib	219.1	25.6	2	-0.2	-0.8
X-3267	CRC	binimetinib	224.4	24.9	5	2.2	-3.5
X-3267	CRC	binimetinib	214.5	25.3	8	-2.3	-1.9
X-3267	CRC	binimetinib	233.8	25.8	12	6.5	0
X-3267	CRC	binimetinib	242.3	25.1	15	10.3	-2.7
X-3267	CRC	binimetinib	252.8	25.5	19	15.1	-1.2
X-3267	CRC	binimetinib	237.5	24.6	22	8.2	-4.7
X-3267	CRC	binimetinib	200	25.3	26	-8.9	-1.9
X-3267	CRC	binimetinib	183.6	24.6	29	-16.4	-4.7
X-3267	CRC	binimetinib	172	24.4	33	-21.7	-5.4
X-3267	CRC	binimetinib	182.2	24.9	36	-17	-3.5
X-3267	CRC	binimetinib	228.2	25.2	40	3.9	-2.3
X-3267	CRC	binimetinib	211.7	25.2	43	-3.6	-2.3
X-3267	CRC	binimetinib	202.5	24.7	47	-7.8	-4.3
X-3267	CRC	binimetinib	180.1	25.3	50	-18	-1.9
X-3267	CRC	binimetinib	167.5	24.3	54	-23.7	-5.8
X-3267	CRC	binimetinib	163.5	24.5	57	-25.5	-5
X-3267	CRC	binimetinib	173.9	25.1	61	-20.8	-2.7
X-3267	CRC	binimetinib	184.2	26.8	64	-16.1	3.9
X-3267	CRC	binimetinib	189	25.3	68	-13.9	-1.9
X-3267	CRC	binimetinib	153.5	25.3	71	-30.1	-1.9
X-3267	CRC	binimetinib	163	25	78	-25.8	-3.1
X-3267	CRC	binimetinib	186.8	25.1	82	-14.9	-2.7
X-3267	CRC	binimetinib	182.4	24.9	86	-16.9	-3.5
X-3267	CRC	binimetinib	165	25.1	89	-24.9	-2.7
X-3267	CRC	untreated	270.6	22	0	0	0
X-3267	CRC	untreated	287.7	23.6	4	6.3	7.3
X-3267	CRC	untreated	268.8	24.1	7	-0.7	9.5
X-3267	CRC	untreated	298.7	23.9	11	10.4	8.6
X-3267	CRC	untreated	318.9	25.1	14	17.8	14.1
X-3267	CRC	untreated	310.5	24.8	18	14.7	12.7
X-3267	CRC	untreated	371.8	23.9	21	37.4	8.6
X-3267	CRC	untreated	354.9	24.4	25	31.2	10.9
X-3267	CRC	untreated	359.8	23.6	28	33	7.3
X-3267	CRC	untreated	370	25	32	36.7	13.6
X-3267	CRC	untreated	367.2	24.7	35	35.7	12.3
X-3267	CRC	untreated	454.1	23.7	42	67.8	7.7
X-3267	CRC	untreated	428.7	23.6	46	58.4	7.3
X-3267	CRC	untreated	393.5	25.4	50	45.4	15.5
X-3267	CRC	untreated	440.1	25.9	53	62.6	17.7
X-3267	CRC	untreated	498.5	25.2	56	84.2	14.5
X-3267	CRC	untreated	526.3	25.4	60	94.5	15.5
X-3267	CRC	untreated	479.3	25.2	63	77.1	14.5
X-3267	CRC	untreated	509.6	25.5	68	88.3	15.9
X-3267	CRC	untreated	485.2	26.2	74	79.3	19.1
X-3267	CRC	untreated	567.4	25.9	77	109.7	17.7
X-3267	CRC	untreated	641.2	25.4	81	137	15.5
X-3267	CRC	untreated	724.6	26.1	84	167.8	18.6
X-3267	CRC	untreated	734.3	26.1	88	171.4	18.6
X-3268	PDAC	abraxane	207.3	26.6	0	0	0
X-3268	PDAC	abraxane	280.3	26.2	4	35.2	-1.5
X-3268	PDAC	abraxane	314.4	26.7	7	51.7	0.4
X-3268	PDAC	abraxane	351.3	26.6	11	69.5	0
X-3268	PDAC	abraxane	428.6	25.1	14	106.8	-5.6
X-3268	PDAC	abraxane	458.4	26.7	18	121.1	0.4
X-3268	PDAC	abraxane	492.2	25.9	21	137.4	-2.6
X-3268	PDAC	abraxane	697	26.9	25	236.2	1.1
X-3268	PDAC	abraxane	897	26.3	28	332.7	-1.1
X-3268	PDAC	BKM120 + binimetinib	222	29.7	0	0	0
X-3268	PDAC	BKM120 + binimetinib	246.6	30.1	2	11.1	1.3
X-3268	PDAC	BKM120 + binimetinib	215.9	29.3	6	-2.7	-1.3
X-3268	PDAC	BKM120 + binimetinib	259.5	29.4	8	16.9	-1
X-3268	PDAC	BKM120 + binimetinib	231	30.5	14	4.1	2.7
X-3268	PDAC	BKM120 + binimetinib	249.4	31.7	20	12.3	6.7
X-3268	PDAC	BKM120 + binimetinib	220.6	31.1	23	-0.6	4.7
X-3268	PDAC	BKM120 + binimetinib	298.9	31.4	26	34.6	5.7
X-3268	PDAC	BKM120 + binimetinib	312.5	30.5	29	40.8	2.7
X-3268	PDAC	BKM120 + binimetinib	219.5	30.8	34	-1.1	3.7
X-3268	PDAC	BKM120 + binimetinib	400.6	31.7	36	80.5	6.7
X-3268	PDAC	BKM120 + binimetinib	248.7	31.3	40	12	5.4
X-3268	PDAC	BKM120 + binimetinib	329.7	31.8	43	48.5	7.1
X-3268	PDAC	BKM120 + binimetinib	301.1	30.7	48	35.6	3.4
X-3268	PDAC	BKM120 + binimetinib	240.7	30.1	55	8.4	1.3
X-3268	PDAC	BKM120 + binimetinib	280.5	32.4	58	26.4	9.1
X-3268	PDAC	BKM120 + binimetinib	301.6	30.9	62	35.9	4
X-3268	PDAC	BKM120 + binimetinib	256.8	31.1	65	15.7	4.7
X-3268	PDAC	BKM120 + binimetinib	334	32	68	50.5	7.7
X-3268	PDAC	BKM120 + binimetinib	243.7	30.3	76	9.8	2
X-3268	PDAC	BKM120 + binimetinib	293	30.1	78	32	1.3
X-3268	PDAC	BKM120 + binimetinib	264.5	32.1	83	19.1	8.1
X-3268	PDAC	BKM120 + binimetinib	319.6	31.4	86	44	5.7
X-3268	PDAC	BKM120 + binimetinib	300.1	30.4	90	35.2	2.4
X-3268	PDAC	BKM120 + binimetinib	394	30.8	93	77.5	3.7
X-3268	PDAC	BKM120 + binimetinib	390.2	30.9	96	75.8	4
X-3268	PDAC	BKM120 + LDE225	265.3	23.8	0	0	0
X-3268	PDAC	BKM120 + LDE225	379.1	25.2	4	42.9	5.9
X-3268	PDAC	BKM120 + LDE225	419	23.9	6	57.9	0.4
X-3268	PDAC	BKM120 + LDE225	426.2	23	11	60.6	-3.4
X-3268	PDAC	BKM120 + LDE225	421.1	24.7	18	58.7	3.8
X-3268	PDAC	BKM120 + LDE225	577.3	24.5	25	117.6	2.9
X-3268	PDAC	BKM120 + LDE225	760.6	24	28	186.7	0.8
X-3268	PDAC	BKM120 + LDE225	476	25.3	33	79.4	6.3
X-3268	PDAC	BKM120 + LDE225	483.8	24.6	35	82.4	3.4
X-3268	PDAC	BKM120 + LDE225	525.3	23.2	39	98	-2.5
X-3268	PDAC	BKM120 + LDE225	384.2	24.7	42	44.8	3.8
X-3268	PDAC	BKM120 + LDE225	400.7	23.5	46	51	-1.3
X-3268	PDAC	BKM120 + LDE225	508.5	22.5	49	91.7	-5.5
X-3268	PDAC	BKM120 + LDE225	552.2	23.8	52	108.1	0
X-3268	PDAC	BKM120 + LDE225	607.3	22.6	55	128.9	-5
X-3268	PDAC	BKM120 + LDE225	646.9	21.6	60	143.8	-9.2
X-3268	PDAC	BKM120 + LDE225	541.9	21.6	66	104.3	-9.2
X-3268	PDAC	BKM120 + LDE225	587.6	21.5	69	121.5	-9.7
X-3268	PDAC	BKM120 + LDE225	565.9	22.6	74	113.3	-5
X-3268	PDAC	BKM120 + LDE225	566.7	22.6	77	113.6	-5
X-3268	PDAC	BKM120 + LDE225	697.6	22.7	81	162.9	-4.6
X-3268	PDAC	BKM120 + LDE225	895.9	22.9	84	237.7	-3.8
X-3268	PDAC	BKM120	216.1	26.1	0	0	0
X-3268	PDAC	BKM120	251.7	25.9	1	16.5	-0.8
X-3268	PDAC	BKM120	245	24.8	4	13.4	-5
X-3268	PDAC	BKM120	166.6	26.5	7	-22.9	1.5
X-3268	PDAC	BKM120	157.5	26.1	10	-27.1	0
X-3268	PDAC	BKM120	195.3	26.6	14	-9.6	1.9
X-3268	PDAC	BKM120	177.2	25.1	17	-18	-3.8
X-3268	PDAC	BKM120	233.8	26.1	24	8.2	0
X-3268	PDAC	BKM120	162.1	26.3	28	-25	0.8
X-3268	PDAC	BKM120	219.9	26.3	31	1.8	0.8
X-3268	PDAC	BKM120	187.6	26.1	36	-13.2	0
X-3268	PDAC	BKM120	193.9	25.8	39	-10.3	-1.1
X-3268	PDAC	BKM120	360.3	26.6	42	66.7	1.9
X-3268	PDAC	BKM120	226.9	26.4	45	5	1.1
X-3268	PDAC	BKM120	202.7	26.7	49	-6.2	2.3
X-3268	PDAC	BKM120	226.4	27	52	4.8	3.4
X-3268	PDAC	BKM120	194.5	26.6	56	-10	1.9
X-3268	PDAC	BKM120	233.7	26.1	60	8.1	0
X-3268	PDAC	BKM120	194.7	25.9	64	-9.9	-0.8
X-3268	PDAC	BKM120	187.8	25.9	67	-13.1	-0.8
X-3268	PDAC	BKM120	187	26.5	70	-13.5	1.5
X-3268	PDAC	BKM120	220.5	25.7	73	2	-1.5
X-3268	PDAC	BKM120	179.6	25.5	78	-16.9	-2.3
X-3268	PDAC	BKM120	175.7	26.1	84	-18.7	0
X-3268	PDAC	BKM120	217.4	25.5	88	0.6	-2.3
X-3268	PDAC	BKM120	251.2	26.6	91	16.2	1.9
X-3268	PDAC	BKM120	222.8	25.6	94	3.1	-1.9
X-3268	PDAC	BKM120	251.5	26.4	98	16.4	1.1
X-3268	PDAC	BKM120	160.8	25.9	101	-25.6	-0.8
X-3268	PDAC	BKM120	190.9	26.7	105	-11.7	2.3
X-3268	PDAC	BKM120	229.7	26.2	108	6.3	0.4
X-3268	PDAC	BKM120	182	24.4	112	-15.8	-6.5
X-3268	PDAC	BKM120	176.8	25.6	115	-18.2	-1.9
X-3268	PDAC	BYL719 + LJM716	246.4	28.6	0	0	0
X-3268	PDAC	BYL719 + LJM716	229.3	26.8	6	-6.9	-6.3
X-3268	PDAC	BYL719 + LJM716	211.4	25.9	9	-14.2	-9.4
X-3268	PDAC	BYL719 + LJM716	211.3	26.8	12	-14.2	-6.3
X-3268	PDAC	BYL719 + LJM716	237.1	27.7	15	-3.8	-3.1
X-3268	PDAC	BYL719 + LJM716	241.6	26.4	18	-1.9	-7.7
X-3268	PDAC	BYL719 + LJM716	242.1	28.5	23	-1.7	-0.3
X-3268	PDAC	BYL719 + LJM716	286.6	27.1	26	16.3	-5.2
X-3268	PDAC	BYL719 + LJM716	287.1	28.2	29	16.5	-1.4
X-3268	PDAC	BYL719 + LJM716	276.7	26.8	32	12.3	-6.3
X-3268	PDAC	BYL719 + LJM716	274.1	29.2	36	11.2	2.1
X-3268	PDAC	BYL719 + LJM716	218.6	28.2	39	-11.3	-1.4
X-3268	PDAC	BYL719 + LJM716	247.2	29.5	43	0.3	3.1
X-3268	PDAC	BYL719 + LJM716	267.5	28.9	46	8.6	1
X-3268	PDAC	BYL719 + LJM716	279.9	29.4	50	13.6	2.8
X-3268	PDAC	BYL719 + LJM716	282.9	28	54	14.8	-2.1
X-3268	PDAC	BYL719 + LJM716	262.5	28.4	57	6.5	-0.7
X-3268	PDAC	BYL719 + LJM716	260	27.7	61	5.5	-3.1
X-3268	PDAC	BYL719 + LJM716	255.6	28.4	64	3.7	-0.7
X-3268	PDAC	BYL719 + LJM716	253	28.8	69	2.7	0.7
X-3268	PDAC	BYL719 + LJM716	259.2	27.9	72	5.2	-2.4
X-3268	PDAC	BYL719 + LJM716	259.6	29	76	5.4	1.4
X-3268	PDAC	BYL719 + LJM716	294.8	27.4	79	19.6	-4.2
X-3268	PDAC	BYL719 + LJM716	283.2	28.3	82	14.9	-1
X-3268	PDAC	BYL719 + LJM716	288.3	28.9	85	17	1
X-3268	PDAC	BYL719 + LJM716	309.8	29.5	89	25.7	3.1
X-3268	PDAC	BYL719 + LJM716	309.9	27.5	93	25.8	-3.8
X-3268	PDAC	BYL719 + LJM716	301.4	26.4	97	22.3	-7.7
X-3268	PDAC	BYL719 + LJM716	310.9	28.1	101	26.2	-1.7
X-3268	PDAC	BYL719 + LJM716	320.3	26.7	104	30	-6.6
X-3268	PDAC	BYL719 + LJM716	362.5	27.2	106	47.1	-4.9
X-3268	PDAC	BYL719 + LJM716	372.2	26.2	110	51.1	-8.4
X-3268	PDAC	BYL719 + LJM716	382.4	26.3	117	55.2	-8
X-3268	PDAC	BYL719 + LJM716	390.3	26.9	120	58.4	-5.9
X-3268	PDAC	BYL719 + LJM716	257.6	28.7	124	4.5	0.3
X-3268	PDAC	BYL719 + LJM716	271.9	27.1	127	10.3	-5.2
X-3268	PDAC	BYL719 + LJM716	295.5	27.6	131	19.9	-3.5
X-3268	PDAC	BYL719 + LJM716	318.5	27.3	135	29.3	-4.5
X-3268	PDAC	BYL719 + LJM716	277.5	26.2	138	12.6	-8.4
X-3268	PDAC	BYL719 + LJM716	253.4	27.9	142	2.8	-2.4
X-3268	PDAC	BYL719 + LJM716	250.9	24.3	145	1.8	-15
X-3268	PDAC	BYL719 + LJM716	253.3	28.1	148	2.8	-1.7
X-3268	PDAC	BYL719	215.5	29.2	0	0	0
X-3268	PDAC	BYL719	221.4	29.7	4	2.7	1.7
X-3268	PDAC	BYL719	222.2	30	7	3.1	2.7
X-3268	PDAC	BYL719	216.6	31.1	11	0.5	6.5
X-3268	PDAC	BYL719	200.9	30.2	14	-6.8	3.4
X-3268	PDAC	BYL719	196.1	29.6	19	-9	1.4
X-3268	PDAC	BYL719	198.2	28.9	22	-8	-1
X-3268	PDAC	BYL719	199.5	29.9	25	-7.4	2.4
X-3268	PDAC	BYL719	214.1	31.6	28	-0.6	8.2
X-3268	PDAC	BYL719	215.7	30.3	32	0.1	3.8
X-3268	PDAC	BYL719	229.8	29.7	35	6.6	1.7
X-3268	PDAC	BYL719	228.6	31.6	39	6.1	8.2
X-3268	PDAC	BYL719	241.8	30.6	43	12.2	4.8
X-3268	PDAC	BYL719	245.6	30.8	46	14	5.5
X-3268	PDAC	BYL719	333.2	31.4	49	54.6	7.5
X-3268	PDAC	BYL719	337.6	30.6	53	56.7	4.8
X-3268	PDAC	BYL719	353.2	31.5	56	63.9	7.9
X-3268	PDAC	BYL719	362.4	29.6	60	68.2	1.4
X-3268	PDAC	BYL719	373.7	30.5	63	73.4	4.5
X-3268	PDAC	BYL719	286.5	29.7	67	32.9	1.7
X-3268	PDAC	BYL719	303.2	31	70	40.7	6.2
X-3268	PDAC	BYL719	340.5	30.2	75	58	3.4
X-3268	PDAC	BYL719	312.4	31.3	78	45	7.2
X-3268	PDAC	BYL719	319.9	31.1	81	48.4	6.5
X-3268	PDAC	BYL719	352	31.4	84	63.3	7.5
X-3268	PDAC	BYL719	367.7	32	88	70.6	9.6
X-3268	PDAC	BYL719	353.1	32.1	91	63.9	9.9
X-3268	PDAC	BYL719	367.7	32.3	95	70.6	10.6
X-3268	PDAC	BYL719	388.1	31.6	98	80.1	8.2
X-3268	PDAC	BYL719	376	30.3	103	74.5	3.8
X-3268	PDAC	BYL719	293.7	30.5	106	36.3	4.5
X-3268	PDAC	BYL719	287	29.4	109	33.2	0.7
X-3268	PDAC	BYL719	352	28.9	112	63.3	-1
X-3268	PDAC	BYL719	351	27.7	115	62.9	-5.1
X-3268	PDAC	BYL719	373.1	28.9	120	73.1	-1
X-3268	PDAC	CLR457	224.8	26.4	0	0	0
X-3268	PDAC	CLR457	245.1	27	4	9	2.3
X-3268	PDAC	CLR457	255.8	27.3	7	13.8	3.4
X-3268	PDAC	CLR457	303.9	28	11	35.2	6.1
X-3268	PDAC	CLR457	365.1	28.1	14	62.4	6.4
X-3268	PDAC	CLR457	391.5	27.8	19	74.2	5.3
X-3268	PDAC	CLR457	393.1	27.7	22	74.9	4.9
X-3268	PDAC	CLR457	392.7	27.2	25	74.7	3
X-3268	PDAC	CLR457	395.8	27.1	28	76.1	2.7
X-3268	PDAC	CLR457	399.2	27.8	32	77.6	5.3
X-3268	PDAC	CLR457	409.5	27.5	35	82.2	4.2
X-3268	PDAC	CLR457	412.2	28	39	83.4	6.1
X-3268	PDAC	CLR457	491.9	27.7	43	118.8	4.9
X-3268	PDAC	CLR457	506	28.3	46	125.1	7.2
X-3268	PDAC	CLR457	514.9	28.2	49	129	6.8
X-3268	PDAC	CLR457	527	28.6	53	134.4	8.3
X-3268	PDAC	CLR457	536.1	28.3	56	138.5	7.2
X-3268	PDAC	CLR457	551.4	27.2	60	145.3	3
X-3268	PDAC	CLR457	584.1	25.8	63	159.8	-2.3
X-3268	PDAC	CLR457	586.3	26.8	67	160.8	1.5
X-3268	PDAC	CLR457	516.5	27.4	70	129.8	3.8
X-3268	PDAC	CLR457	494.2	28.1	75	119.8	6.4
X-3268	PDAC	CLR457	485.4	27.9	78	115.9	5.7
X-3268	PDAC	CLR457	423.9	29.4	81	88.6	11.4
X-3268	PDAC	CLR457	470.7	28.9	84	109.4	9.5
X-3268	PDAC	CLR457	512.4	29.3	88	127.9	11
X-3268	PDAC	CLR457	526.8	28.9	91	134.3	9.5
X-3268	PDAC	CLR457	560.7	28.4	95	149.4	7.6
X-3268	PDAC	CLR457	600.5	28.5	98	167.1	8
X-3268	PDAC	CLR457	610.1	28.5	103	171.4	8
X-3268	PDAC	CLR457	616.9	28.4	106	174.4	7.6
X-3268	PDAC	CLR457	689.3	28.4	109	206.6	7.6
X-3268	PDAC	CLR457	719.9	28.5	112	220.2	8
X-3268	PDAC	HDM201	243	26.7	0	0	0
X-3268	PDAC	HDM201	290.4	27.1	2	19.5	1.5
X-3268	PDAC	HDM201	316.8	27.8	5	30.4	4.1
X-3268	PDAC	HDM201	392.2	29.5	8	61.4	10.5
X-3268	PDAC	HDM201	463.8	29.2	12	90.9	9.4
X-3268	PDAC	HDM201	527.7	30.8	15	117.2	15.4
X-3268	PDAC	HDM201	579.4	30.3	20	138.4	13.5
X-3268	PDAC	HDM201	674.6	28.7	23	177.6	7.5
X-3268	PDAC	HDM201	755.1	28.9	26	210.7	8.2
X-3268	PDAC	HDM201	788.6	30.5	29	224.5	14.2
X-3268	PDAC	HDM201	899.5	27.6	33	270.2	3.4
X-3268	PDAC	HDM201	942	28	36	287.7	4.9
X-3268	PDAC	HDM201	974.4	28.4	40	301	6.4
X-3268	PDAC	HDM201	1097.4	28.9	44	351.6	8.2
X-3268	PDAC	HDM201	1189.2	28.4	47	389.4	6.4
X-3268	PDAC	HDM201	1356.3	29	50	458.1	8.6
X-3268	PDAC	figitumumab"	208.9	29.1	0	0	0
X-3268	PDAC	figitumumab"	266.3	29.4	4	27.5	1
X-3268	PDAC	figitumumab"	476.7	28.6	12	128.2	-1.7
X-3268	PDAC	figitumumab"	549.1	29.4	14	162.9	1
X-3268	PDAC	figitumumab"	702.3	29	18	236.2	-0.3
X-3268	PDAC	figitumumab" + binimetinib	230.8	27.6	0	0	0
X-3268	PDAC	figitumumab" + binimetinib	197.5	28.2	1	-14.4	2.2
X-3268	PDAC	figitumumab" + binimetinib	305.8	27.7	4	32.5	0.4
X-3268	PDAC	figitumumab" + binimetinib	224.6	27.6	7	-2.7	0
X-3268	PDAC	figitumumab" + binimetinib	217.3	27.3	10	-5.8	-1.1
X-3268	PDAC	figitumumab" + binimetinib	248.1	27.4	14	7.5	-0.7
X-3268	PDAC	figitumumab" + binimetinib	278	26.8	17	20.5	-2.9
X-3268	PDAC	figitumumab" + binimetinib	334.2	27.9	21	44.8	1.1
X-3268	PDAC	figitumumab" + binimetinib	452.8	27.8	24	96.2	0.7
X-3268	PDAC	figitumumab" + binimetinib	584	27.6	28	153	0
X-3268	PDAC	figitumumab" + binimetinib	667	NA	31	189	0
X-3268	PDAC	figitumumab" + binimetinib	513	27.9	36	122.3	1.1
X-3268	PDAC	gemcitabine-50mpk	266.2	27.9	0	0	0
X-3268	PDAC	gemcitabine-50mpk	304.5	26.9	4	14.4	-3.6
X-3268	PDAC	gemcitabine-50mpk	346.8	28	7	30.3	0.4
X-3268	PDAC	gemcitabine-50mpk	376.4	26.7	10	41.4	-4.3
X-3268	PDAC	gemcitabine-50mpk	481.7	28	14	81	0.4
X-3268	PDAC	gemcitabine-50mpk	471.9	27	18	77.3	-3.2
X-3268	PDAC	gemcitabine-50mpk	497.2	28	21	86.8	0.4
X-3268	PDAC	gemcitabine-50mpk	352.9	20.2	26	32.6	-27.6
X-3268	PDAC	INC424 + binimetinib	242.4	28.5	0	0	0
X-3268	PDAC	INC424 + binimetinib	223.6	26.1	5	-7.8	-8.4
X-3268	PDAC	INC424 + binimetinib	265	25.3	8	9.3	-11.2
X-3268	PDAC	INC424 + binimetinib	374.9	26.5	12	54.7	-7
X-3268	PDAC	INC424 + binimetinib	277.9	26.5	15	14.6	-7
X-3268	PDAC	INC424 + binimetinib	343.4	26.6	19	41.7	-6.7
X-3268	PDAC	INC424 + binimetinib	275.1	26.6	22	13.5	-6.7
X-3268	PDAC	INC424 + binimetinib	242.6	26.4	26	0.1	-7.4
X-3268	PDAC	INC424 + binimetinib	260.8	25.9	29	7.6	-9.1
X-3268	PDAC	INC424 + binimetinib	316.9	26.1	33	30.7	-8.4
X-3268	PDAC	INC424 + binimetinib	234.9	26.2	36	-3.1	-8.1
X-3268	PDAC	INC424 + binimetinib	278.4	26.1	40	14.9	-8.4
X-3268	PDAC	INC424 + binimetinib	237	26.2	43	-2.2	-8.1
X-3268	PDAC	INC424 + binimetinib	318.2	26.8	47	31.3	-6
X-3268	PDAC	INC424 + binimetinib	289.3	26.1	50	19.3	-8.4
X-3268	PDAC	INC424 + binimetinib	283	26.7	54	16.7	-6.3
X-3268	PDAC	INC424 + binimetinib	333.6	27.8	61	37.6	-2.5
X-3268	PDAC	INC424 + binimetinib	388.1	26.6	64	60.1	-6.7
X-3268	PDAC	INC424 + binimetinib	530.2	26.8	68	118.7	-6
X-3268	PDAC	INC424 + binimetinib	380.8	26.9	71	57.1	-5.6
X-3268	PDAC	INC424 + binimetinib	413.3	25.7	75	70.5	-9.8
X-3268	PDAC	INC424 + binimetinib	367.8	26.7	78	51.7	-6.3
X-3268	PDAC	INC424 + binimetinib	340.5	25.5	82	40.5	-10.5
X-3268	PDAC	INC424 + binimetinib	365.8	26.4	84	50.9	-7.4
X-3268	PDAC	INC424 + binimetinib	342.9	26.2	90	41.5	-8.1
X-3268	PDAC	INC424 + binimetinib	467.4	26.2	96	92.8	-8.1
X-3268	PDAC	INC424 + binimetinib	367.4	26.5	99	51.6	-7
X-3268	PDAC	INC424 + binimetinib	442.2	27.6	102	82.4	-3.2
X-3268	PDAC	INC424 + binimetinib	450.5	26.5	105	85.8	-7
X-3268	PDAC	INC424 + binimetinib	441.9	26.4	110	82.3	-7.4
X-3268	PDAC	INC424 + binimetinib	501.3	26.3	112	106.8	-7.7
X-3268	PDAC	INC424 + binimetinib	425	26.8	116	75.3	-6
X-3268	PDAC	INC424 + binimetinib	341	26.2	119	40.7	-8.1
X-3268	PDAC	INC424 + binimetinib	524.2	26.6	124	116.3	-6.7
X-3268	PDAC	INC424 + binimetinib	672.5	26.1	131	177.4	-8.4
X-3268	PDAC	INC424	225.5	27.3	0	0	0
X-3268	PDAC	INC424	230.7	26.4	4	2.3	-3.3
X-3268	PDAC	INC424	259.4	26.1	7	15	-4.4
X-3268	PDAC	INC424	341.9	27	11	51.6	-1.1
X-3268	PDAC	INC424	399.3	27	14	77.1	-1.1
X-3268	PDAC	INC424	464	27.3	19	105.8	0
X-3268	PDAC	INC424	548	27.6	22	143	1.1
X-3268	PDAC	INC424	624.8	27.6	25	177.1	1.1
X-3268	PDAC	INC424	626.1	27.7	28	177.6	1.5
X-3268	PDAC	INC424	760.4	26.6	32	237.2	-2.6
X-3268	PDAC	INC424	791.1	26.4	35	250.8	-3.3
X-3268	PDAC	INC424	882.9	26.4	39	291.5	-3.3
X-3268	PDAC	LEE011	204.2	26.2	0	0	0
X-3268	PDAC	LEE011	255.2	26	3	25	-0.8
X-3268	PDAC	LEE011	244.2	25.7	6	19.6	-1.9
X-3268	PDAC	LEE011	249.6	25.4	9	22.2	-3.1
X-3268	PDAC	LEE011	193.1	26.6	13	-5.4	1.5
X-3268	PDAC	LEE011	223.5	26.7	16	9.5	1.9
X-3268	PDAC	LEE011	275.8	27.2	20	35.1	3.8
X-3268	PDAC	LEE011	235.6	26.5	23	15.4	1.1
X-3268	PDAC	LEE011	283.1	27.9	27	38.6	6.5
X-3268	PDAC	LEE011	321.8	28	30	57.6	6.9
X-3268	PDAC	LEE011	389.7	28.2	34	90.8	7.6
X-3268	PDAC	LEE011	456.5	27.5	37	123.6	5
X-3268	PDAC	LEE011	328.7	28.2	41	61	7.6
X-3268	PDAC	LEE011	338.2	27.6	44	65.6	5.3
X-3268	PDAC	LEE011	301.1	29.3	48	47.5	11.8
X-3268	PDAC	LEE011	333.7	28.3	51	63.4	8
X-3268	PDAC	LEE011	305	28.7	55	49.4	9.5
X-3268	PDAC	LEE011	363.2	29.1	58	77.9	11.1
X-3268	PDAC	LEE011	314.3	31	62	53.9	18.3
X-3268	PDAC	LEE011	445.1	29.2	66	118	11.5
X-3268	PDAC	LEE011	439.8	29	69	115.4	10.7
X-3268	PDAC	LEE011	391.9	29.5	72	91.9	12.6
X-3268	PDAC	LEE011	263.9	28.7	77	29.2	9.5
X-3268	PDAC	LEE011	282.3	28.8	80	38.2	9.9
X-3268	PDAC	LEE011	278.9	28.8	83	36.6	9.9
X-3268	PDAC	LEE011	296.2	28.4	86	45.1	8.4
X-3268	PDAC	LEE011	304.1	30.3	90	48.9	15.6
X-3268	PDAC	LEE011	324.6	29.4	93	59	12.2
X-3268	PDAC	LEE011	399.7	29.8	97	95.7	13.7
X-3268	PDAC	LEE011	306.4	29	100	50	10.7
X-3268	PDAC	LEE011	291.1	30.6	104	42.6	16.8
X-3268	PDAC	WNT974	218.4	24	0	0	0
X-3268	PDAC	WNT974	215	23.3	1	-1.6	-2.9
X-3268	PDAC	WNT974	173.5	23.2	6	-20.6	-3.3
X-3268	PDAC	WNT974	185	23.2	9	-15.3	-3.3
X-3268	PDAC	WNT974	275.6	23.5	13	26.2	-2.1
X-3268	PDAC	WNT974	292.8	24.8	16	34.1	3.3
X-3268	PDAC	WNT974	299.7	24.5	19	37.2	2.1
X-3268	PDAC	WNT974	527.4	26.7	21	141.5	11.3
X-3268	PDAC	WNT974	416.2	25.6	27	90.6	6.7
X-3268	PDAC	WNT974	422.7	25.1	29	93.5	4.6
X-3268	PDAC	WNT974	469.4	24.8	34	114.9	3.3
X-3268	PDAC	WNT974	383.2	26	37	75.5	8.3
X-3268	PDAC	WNT974	514.4	24.4	40	135.5	1.7
X-3268	PDAC	WNT974	558.6	25.5	44	155.8	6.2
X-3268	PDAC	WNT974	601	27.3	48	175.2	13.7
X-3268	PDAC	WNT974	610.1	25.1	51	179.3	4.6
X-3268	PDAC	WNT974	755.6	26.1	56	246	8.8
X-3268	PDAC	WNT974	841.2	26.8	58	285.2	11.7
X-3268	PDAC	WNT974	798.8	26.3	62	265.8	9.6
X-3268	PDAC	WNT974	820.9	27.7	65	275.9	15.4
X-3268	PDAC	LKA136	275	28.3	0	0	0
X-3268	PDAC	LKA136	258.1	29.6	3	-6.1	4.6
X-3268	PDAC	LKA136	331.1	29.1	7	20.4	2.8
X-3268	PDAC	LKA136	315.4	29.1	11	14.7	2.8
X-3268	PDAC	LKA136	346.6	28.7	14	26	1.4
X-3268	PDAC	LKA136	353.3	31.3	17	28.5	10.6
X-3268	PDAC	LKA136	370.9	29.7	20	34.9	4.9
X-3268	PDAC	LKA136	463.3	29.6	25	68.5	4.6
X-3268	PDAC	LKA136	416.1	30.5	28	51.3	7.8
X-3268	PDAC	LKA136	520.2	30.1	32	89.2	6.4
X-3268	PDAC	LKA136	536	30.3	35	94.9	7.1
X-3268	PDAC	LKA136	544.1	29.5	39	97.9	4.2
X-3268	PDAC	LKA136	655	30.7	42	138.2	8.5
X-3268	PDAC	LKA136	542.5	31.3	46	97.3	10.6
X-3268	PDAC	LKA136	621.4	30.8	49	126	8.8
X-3268	PDAC	LKA136	677.2	30.1	52	146.3	6.4
X-3268	PDAC	binimetinib	207.7	26.4	0	0	0
X-3268	PDAC	binimetinib	245.3	26.5	1	18.1	0.4
X-3268	PDAC	binimetinib	182.5	25.9	5	-12.1	-1.9
X-3268	PDAC	binimetinib	136.3	25.7	7	-34.4	-2.7
X-3268	PDAC	binimetinib	144	24.3	12	-30.7	-8
X-3268	PDAC	binimetinib	210.8	26.5	14	1.5	0.4
X-3268	PDAC	binimetinib	146.3	25.1	19	-29.6	-4.9
X-3268	PDAC	binimetinib	134	24.3	22	-35.5	-8
X-3268	PDAC	binimetinib	187.6	25.1	26	-9.7	-4.9
X-3268	PDAC	binimetinib	197.4	24.4	29	-5	-7.6
X-3268	PDAC	binimetinib	128.4	24.3	33	-38.2	-8
X-3268	PDAC	binimetinib	178.9	23.9	36	-13.9	-9.5
X-3268	PDAC	binimetinib	93.8	22.9	40	-54.8	-13.3
X-3268	PDAC	binimetinib	154.3	24	43	-25.7	-9.1
X-3268	PDAC	binimetinib	135.8	24.1	47	-34.6	-8.7
X-3268	PDAC	binimetinib	164.9	26.4	50	-20.6	0
X-3268	PDAC	binimetinib	146.5	25	54	-29.5	-5.3
X-3268	PDAC	binimetinib	211.5	26.2	61	1.8	-0.8
X-3268	PDAC	binimetinib	105.3	26	64	-49.3	-1.5
X-3268	PDAC	binimetinib	135.3	26.2	68	-34.9	-0.8
X-3268	PDAC	binimetinib	145	26.5	75	-30.2	0.4
X-3268	PDAC	binimetinib	189.5	26.3	78	-8.8	-0.4
X-3268	PDAC	binimetinib	154.1	25.7	82	-25.8	-2.7
X-3268	PDAC	binimetinib	163.9	26	85	-21.1	-1.5
X-3268	PDAC	binimetinib	96.2	22.3	89	-53.7	-15.5
X-3268	PDAC	binimetinib-3.5mpk	231	30.3	0	0	0
X-3268	PDAC	binimetinib-3.5mpk	195.1	30.9	3	-15.5	2
X-3268	PDAC	binimetinib-3.5mpk	215.1	30.4	6	-6.9	0.3
X-3268	PDAC	binimetinib-3.5mpk	262.1	31.4	11	13.5	3.6
X-3268	PDAC	binimetinib-3.5mpk	200.3	30.5	14	-13.3	0.7
X-3268	PDAC	binimetinib-3.5mpk	287.6	31.1	17	24.5	2.6
X-3268	PDAC	binimetinib-3.5mpk	266.6	31.4	20	15.4	3.6
X-3268	PDAC	binimetinib-3.5mpk	246.2	31	24	6.6	2.3
X-3268	PDAC	binimetinib-3.5mpk	223.8	30.9	27	-3.1	2
X-3268	PDAC	binimetinib-3.5mpk	184.6	31.7	32	-20.1	4.6
X-3268	PDAC	binimetinib-3.5mpk	244.6	31	35	5.9	2.3
X-3268	PDAC	binimetinib-3.5mpk	344.1	30.5	39	49	0.7
X-3268	PDAC	binimetinib-3.5mpk	231.1	31.4	42	0	3.6
X-3268	PDAC	binimetinib-3.5mpk	224.8	30.5	45	-2.7	0.7
X-3268	PDAC	binimetinib-3.5mpk	259	31.2	48	12.1	3
X-3268	PDAC	binimetinib-3.5mpk	224.5	31.3	53	-2.8	3.3
X-3268	PDAC	binimetinib-3.5mpk	201.8	31.4	59	-12.6	3.6
X-3268	PDAC	binimetinib-3.5mpk	202.7	30.3	63	-12.3	0
X-3268	PDAC	binimetinib-3.5mpk	247.5	34.7	66	7.1	14.5
X-3268	PDAC	binimetinib-3.5mpk	212.3	30.4	69	-8.1	0.3
X-3268	PDAC	binimetinib-3.5mpk	204.5	29.9	73	-11.5	-1.3
X-3268	PDAC	binimetinib-3.5mpk	199.3	29.7	76	-13.7	-2
X-3268	PDAC	binimetinib-3.5mpk	231.3	30.4	80	0.1	0.3
X-3268	PDAC	binimetinib-3.5mpk	219.6	29.6	83	-4.9	-2.3
X-3268	PDAC	binimetinib-3.5mpk	173.6	30.6	87	-24.8	1
X-3268	PDAC	binimetinib-3.5mpk	199.1	30.4	90	-13.8	0.3
X-3268	PDAC	trametinib	179	25.1	0	0	0
X-3268	PDAC	trametinib	152.7	25.4	3	-14.7	1.2
X-3268	PDAC	trametinib	157	24.9	6	-12.3	-0.8
X-3268	PDAC	trametinib	153.5	25.4	10	-14.2	1.2
X-3268	PDAC	trametinib	205.7	25.6	13	14.9	2
X-3268	PDAC	trametinib	196.4	25.6	17	9.7	2
X-3268	PDAC	trametinib	174.5	25.5	20	-2.5	1.6
X-3268	PDAC	trametinib	246.5	24.9	24	37.7	-0.8
X-3268	PDAC	trametinib	193.1	24.4	27	7.9	-2.8
X-3268	PDAC	trametinib	249.9	26.1	32	39.6	4
X-3268	PDAC	trametinib	241.7	24.9	35	35	-0.8
X-3268	PDAC	trametinib	324.4	25.5	38	81.2	1.6
X-3268	PDAC	trametinib	293.2	25.5	41	63.8	1.6
X-3268	PDAC	trametinib	231	25.1	45	29.1	0
X-3268	PDAC	trametinib	204	24.2	48	14	-3.6
X-3268	PDAC	trametinib	231.8	24.6	53	29.5	-2
X-3268	PDAC	trametinib	277.6	24	56	55.1	-4.4
X-3268	PDAC	trametinib	241.7	22.1	60	35	-12
X-3268	PDAC	trametinib	207	22.2	63	15.6	-11.6
X-3268	PDAC	trametinib	205.1	23.2	66	14.6	-7.6
X-3268	PDAC	trametinib	234.8	25.4	69	31.2	1.2
X-3268	PDAC	trametinib	251.1	26.3	74	40.3	4.8
X-3268	PDAC	trametinib	279.1	25.8	80	55.9	2.8
X-3268	PDAC	trametinib	206.8	25.3	84	15.5	0.8
X-3268	PDAC	trametinib	265.8	26	87	48.5	3.6
X-3268	PDAC	trametinib	239.3	24.8	90	33.7	-1.2
X-3268	PDAC	trametinib	230.7	26	94	28.9	3.6
X-3268	PDAC	trametinib	257.5	26.5	97	43.9	5.6
X-3268	PDAC	trametinib	268.9	25.6	101	50.2	2
X-3268	PDAC	trametinib	287.5	25.8	104	60.6	2.8
X-3268	PDAC	trametinib	248.6	25.6	108	38.9	2
X-3268	PDAC	trametinib	343.7	25.4	111	92	1.2
X-3268	PDAC	untreated	208.3	NA	0	0	0
X-3268	PDAC	untreated	234.7	30.9	4	12.7	0
X-3268	PDAC	untreated	339.8	31.8	7	63.1	2.9
X-3268	PDAC	untreated	398.1	31.9	12	91.1	3.2
X-3268	PDAC	untreated	470.3	31.9	14	125.8	3.2
X-3268	PDAC	untreated	458.9	32	18	120.3	3.6
X-3268	PDAC	untreated	470.9	30.8	21	126.1	-0.3
X-3268	PDAC	untreated	580.9	35.2	24	178.9	13.9
X-3268	PDAC	untreated	613.9	31.4	27	194.7	1.6
X-3268	PDAC	untreated	701.3	33.6	32	236.7	8.7
X-3268	PDAC	untreated	710.4	32	35	241	3.6
X-3268	PDAC	untreated	826.4	31.5	39	296.7	1.9
X-3268	PDAC	untreated	1034.4	32.1	42	396.6	3.9
X-3268	PDAC	untreated	1067.1	32.5	46	412.3	5.2
X-3268	PDAC	untreated	1170.8	31.3	48	462.1	1.3
X-3298	BRCA	BGJ398	328	26.7	0	0	0
X-3298	BRCA	BGJ398	373	29	4	13.7	8.6
X-3298	BRCA	BGJ398	492.2	26.9	8	50.1	0.7
X-3298	BRCA	BGJ398	545.6	27.7	11	66.3	3.7
X-3298	BRCA	BGJ398	573.2	26.9	15	74.8	0.7
X-3298	BRCA	BGJ398	730.4	27.9	18	122.7	4.5
X-3298	BRCA	BGJ398	778.1	26.8	22	137.2	0.4
X-3298	BRCA	BGJ398	918.9	27.7	25	180.2	3.7
X-3298	BRCA	BGJ398	1012.5	28.4	32	208.7	6.4
X-3298	BRCA	BKM120	277.8	29	0	0	0
X-3298	BRCA	BKM120	314.1	30.7	4	13.1	5.9
X-3298	BRCA	BKM120	319.8	28.3	8	15.1	-2.4
X-3298	BRCA	BKM120	416.6	30.5	11	50	5.2
X-3298	BRCA	BKM120	358.7	30.2	15	29.1	4.1
X-3298	BRCA	BKM120	406.6	31.9	18	46.4	10
X-3298	BRCA	BKM120	436.7	31.6	22	57.2	9
X-3298	BRCA	BKM120	526.7	31.5	25	89.6	8.6
X-3298	BRCA	BKM120	640.8	31.8	32	130.7	9.7
X-3298	BRCA	BKM120	749	31.6	35	169.6	9
X-3298	BRCA	BKM120	774.4	30.7	40	178.8	5.9
X-3298	BRCA	BKM120	882.7	31.5	43	217.7	8.6
X-3298	BRCA	BKM120	867.9	32.1	46	212.4	10.7
X-3298	BRCA	BKM120	883.9	34.7	50	218.2	19.7
X-3298	BRCA	BKM120	888.5	33.6	53	219.8	15.9
X-3298	BRCA	BKM120	857.4	34	57	208.6	17.2
X-3298	BRCA	BKM120	889.3	33	60	220.1	13.8
X-3298	BRCA	BKM120	925.1	33.4	64	233	15.2
X-3298	BRCA	BKM120	933.7	33.1	67	236.1	14.1
X-3298	BRCA	BKM120	1069.5	33.6	71	285	15.9
X-3298	BRCA	BKM120	1204.8	33.3	74	333.7	14.8
X-3298	BRCA	BYL719	281.3	27.2	0	0	0
X-3298	BRCA	BYL719	283	26.2	1	0.6	-3.7
X-3298	BRCA	BYL719	301.5	27.3	4	7.2	0.4
X-3298	BRCA	BYL719	374.2	27.1	8	33	-0.4
X-3298	BRCA	BYL719	381	27.6	11	35.4	1.5
X-3298	BRCA	BYL719	434	27	15	54.3	-0.7
X-3298	BRCA	BYL719	473.6	26.4	18	68.4	-2.9
X-3298	BRCA	BYL719	628.8	28	25	123.5	2.9
X-3298	BRCA	BYL719	740.2	26.9	28	163.1	-1.1
X-3298	BRCA	BYL719	1067.8	27.7	33	279.6	1.8
X-3298	BRCA	BYL719 + LJM716	276.5	29	0	0	0
X-3298	BRCA	BYL719 + LJM716	308.9	29.5	4	11.7	1.7
X-3298	BRCA	BYL719 + LJM716	314.3	29.2	8	13.7	0.7
X-3298	BRCA	BYL719 + LJM716	326.7	28.8	11	18.2	-0.7
X-3298	BRCA	BYL719 + LJM716	289.4	28.5	15	4.7	-1.7
X-3298	BRCA	BYL719 + LJM716	393.8	28.9	18	42.4	-0.3
X-3298	BRCA	BYL719 + LJM716	386	29.9	25	39.6	3.1
X-3298	BRCA	BYL719 + LJM716	452.5	30.1	28	63.7	3.8
X-3298	BRCA	BYL719 + LJM716	468.6	29.9	33	69.5	3.1
X-3298	BRCA	BYL719 + LJM716	483.2	29.6	36	74.8	2.1
X-3298	BRCA	BYL719 + LJM716	517.3	31.3	39	87.1	7.9
X-3298	BRCA	BYL719 + LJM716	715.3	31.7	43	158.7	9.3
X-3298	BRCA	BYL719 + LJM716	679.9	32	46	145.9	10.3
X-3298	BRCA	BYL719 + LJM716	737.2	32	50	166.6	10.3
X-3298	BRCA	BYL719 + LJM716	787.6	30.9	53	184.8	6.6
X-3298	BRCA	BYL719 + LJM716	832.3	30.8	57	201	6.2
X-3298	BRCA	BYL719 + LJM716	1004.6	33.7	60	263.3	16.2
X-3298	BRCA	BYL719 + LEE011	286.4	29.7	0	0	0
X-3298	BRCA	BYL719 + LEE011	255.9	29.1	4	-10.6	-2
X-3298	BRCA	BYL719 + LEE011	255.5	27.3	7	-10.8	-8.1
X-3298	BRCA	BYL719 + LEE011	267.9	26.7	11	-6.5	-10.1
X-3298	BRCA	BYL719 + LEE011	301.9	28.9	14	5.4	-2.7
X-3298	BRCA	BYL719 + LEE011	419.5	30.5	18	46.5	2.7
X-3298	BRCA	BYL719 + LEE011	432.6	28.9	21	51	-2.7
X-3298	BRCA	BYL719 + LEE011	447.3	29.4	25	56.2	-1
X-3298	BRCA	BYL719 + LEE011	401.5	28.5	28	40.2	-4
X-3298	BRCA	BYL719 + LEE011	434.2	29.3	32	51.6	-1.3
X-3298	BRCA	BYL719 + LEE011	450.9	28.8	35	57.4	-3
X-3298	BRCA	BYL719 + LEE011	424.9	28.1	38	48.4	-5.4
X-3298	BRCA	BYL719 + LEE011	495.3	28.7	42	72.9	-3.4
X-3298	BRCA	BYL719 + LEE011	602.7	29.2	46	110.4	-1.7
X-3298	BRCA	BYL719 + LEE011	502.6	30.2	49	75.5	1.7
X-3298	BRCA	BYL719 + LEE011	577	29.4	53	101.5	-1
X-3298	BRCA	BYL719 + LEE011	694.5	29.9	63	142.5	0.7
X-3298	BRCA	BYL719 + LEE011	719.8	29.9	67	151.3	0.7
X-3298	BRCA	BYL719 + LEE011	792.5	29.9	70	176.7	0.7
X-3298	BRCA	BYL719 + LEE011	961.4	30.7	74	235.7	3.4
X-3298	BRCA	BYL719 + LEE011	933.3	30.9	77	225.9	4
X-3298	BRCA	CGM097	316.7	27.8	0	0	0
X-3298	BRCA	CGM097	419.3	28	4	32.4	0.7
X-3298	BRCA	CGM097	482.5	28.9	8	52.4	4
X-3298	BRCA	CGM097	581	29.6	11	83.5	6.5
X-3298	BRCA	CGM097	741.7	29.3	15	134.2	5.4
X-3298	BRCA	CGM097	880.1	29.3	18	177.9	5.4
X-3298	BRCA	CLR457	204.7	26.4	0	0	0
X-3298	BRCA	CLR457	236.9	27.3	4	15.7	3.4
X-3298	BRCA	CLR457	275.5	26.6	8	34.6	0.8
X-3298	BRCA	CLR457	312	26.8	11	52.4	1.5
X-3298	BRCA	CLR457	326.1	27	15	59.3	2.3
X-3298	BRCA	CLR457	355.3	27.2	18	73.6	3
X-3298	BRCA	CLR457	460.2	28.2	25	124.8	6.8
X-3298	BRCA	CLR457	422.2	26.8	28	106.3	1.5
X-3298	BRCA	CLR457	448.6	26.7	33	119.1	1.1
X-3298	BRCA	CLR457	486.8	27.1	36	137.8	2.7
X-3298	BRCA	CLR457	519.7	27.6	39	153.9	4.5
X-3298	BRCA	CLR457	597.6	28.2	43	191.9	6.8
X-3298	BRCA	CLR457	671.7	28.9	46	228.1	9.5
X-3298	BRCA	HDM201	348.4	27.9	0	0	0
X-3298	BRCA	HDM201	471.8	27.4	4	35.4	-1.8
X-3298	BRCA	HDM201	533.4	26.2	8	53.1	-6.1
X-3298	BRCA	HDM201	583.3	27.3	11	67.4	-2.2
X-3298	BRCA	HDM201	674.6	27.8	15	93.6	-0.4
X-3298	BRCA	HDM201	750.9	28.3	18	115.5	1.4
X-3298	BRCA	HDM201	905.9	27.7	22	160	-0.7
X-3298	BRCA	HDM201	962.8	28.2	25	176.3	1.1
X-3298	BRCA	INC424	209.8	25.7	0	0	0
X-3298	BRCA	INC424	296.1	26.5	5	41.1	3.1
X-3298	BRCA	INC424	365.1	26.8	8	74	4.3
X-3298	BRCA	INC424	409.3	27	11	95.1	5.1
X-3298	BRCA	INC424	482.7	26.8	15	130.1	4.3
X-3298	BRCA	INC424	465.8	27.4	18	122	6.6
X-3298	BRCA	INC424	553.4	27.8	22	163.8	8.2
X-3298	BRCA	INC424	535.9	27.5	25	155.4	7
X-3298	BRCA	INC424	648.4	28.1	29	209.1	9.3
X-3298	BRCA	INC424	724.7	27.5	32	245.4	7
X-3298	BRCA	INC424	827.5	27.8	36	294.4	8.2
X-3298	BRCA	INC424	918.7	28.2	39	337.9	9.7
X-3298	BRCA	INC424	1092.3	27.9	43	420.6	8.6
X-3298	BRCA	INC424	1119.8	27.7	46	433.7	7.8
X-3298	BRCA	LEE011	186.7	27.1	0	0	0
X-3298	BRCA	LEE011	245.7	28	5	31.6	3.3
X-3298	BRCA	LEE011	254.4	27.8	8	36.3	2.6
X-3298	BRCA	LEE011	298.4	27.2	11	59.8	0.4
X-3298	BRCA	LEE011	280.6	28.5	15	50.3	5.2
X-3298	BRCA	LEE011	270.3	28.7	18	44.8	5.9
X-3298	BRCA	LEE011	318.2	29.4	22	70.4	8.5
X-3298	BRCA	LEE011	346.6	29.6	25	85.6	9.2
X-3298	BRCA	LEE011	372	30.1	29	99.3	11.1
X-3298	BRCA	LEE011	388.9	29.5	32	108.3	8.9
X-3298	BRCA	LEE011	417.6	28.5	36	123.7	5.2
X-3298	BRCA	LEE011	416.7	29.4	39	123.2	8.5
X-3298	BRCA	LEE011	400	29.5	43	114.2	8.9
X-3298	BRCA	LEE011	418.6	29.8	46	124.2	10
X-3298	BRCA	LEE011	479.9	29.6	50	157	9.2
X-3298	BRCA	LEE011	557.6	29.9	53	198.7	10.3
X-3298	BRCA	LEE011	551.6	29.5	56	195.4	8.9
X-3298	BRCA	LEE011	618	29.6	60	231	9.2
X-3298	BRCA	LEE011	624.6	29.6	64	234.5	9.2
X-3298	BRCA	LEE011	684.6	30	67	266.7	10.7
X-3298	BRCA	LEE011	727.6	29.5	71	289.7	8.9
X-3298	BRCA	LEE011	842.9	29.9	81	351.5	10.3
X-3298	BRCA	LEE011 + everolimus	236.6	29	0	0	0
X-3298	BRCA	LEE011 + everolimus	210.9	27.8	4	-10.9	-4.1
X-3298	BRCA	LEE011 + everolimus	234.5	28.6	8	-0.9	-1.4
X-3298	BRCA	LEE011 + everolimus	261	28.7	11	10.3	-1
X-3298	BRCA	LEE011 + everolimus	230.8	29.9	15	-2.5	3.1
X-3298	BRCA	LEE011 + everolimus	246	29.7	18	4	2.4
X-3298	BRCA	LEE011 + everolimus	273.3	30.6	22	15.5	5.5
X-3298	BRCA	LEE011 + everolimus	331	31.5	25	39.9	8.6
X-3298	BRCA	LEE011 + everolimus	295.1	30.6	28	24.7	5.5
X-3298	BRCA	LEE011 + everolimus	285.9	32.2	32	20.8	11
X-3298	BRCA	LEE011 + everolimus	369.9	32.4	36	56.3	11.7
X-3298	BRCA	LEE011 + everolimus	374.4	32.7	39	58.2	12.8
X-3298	BRCA	LEE011 + everolimus	366.7	32.2	43	55	11
X-3298	BRCA	LEE011 + everolimus	414.8	32	53	75.3	10.3
X-3298	BRCA	LEE011 + everolimus	465.5	30.1	57	96.7	3.8
X-3298	BRCA	LEE011 + everolimus	434.9	31.2	60	83.8	7.6
X-3298	BRCA	LEE011 + everolimus	551.3	30.4	64	133	4.8
X-3298	BRCA	LEE011 + everolimus	559.4	31.5	67	136.4	8.6
X-3298	BRCA	LEE011 + everolimus	603.7	31	71	155.2	6.9
X-3298	BRCA	LEE011 + everolimus	576.5	31	74	143.7	6.9
X-3298	BRCA	LEE011 + everolimus	583	32.3	77	146.4	11.4
X-3298	BRCA	LEE011 + everolimus	598.7	31	81	153	6.9
X-3298	BRCA	LEE011 + everolimus	640	30.4	84	170.5	4.8
X-3298	BRCA	LEE011 + everolimus	694.8	31.2	88	193.7	7.6
X-3298	BRCA	LEE011 + everolimus	711	31.1	91	200.5	7.2
X-3298	BRCA	LEE011 + everolimus	902.7	31.7	95	281.5	9.3
X-3298	BRCA	LFA102	220.2	26.3	0	0	0
X-3298	BRCA	LFA102	324.1	25.6	6	47.2	-2.7
X-3298	BRCA	LFA102	299.9	24.8	9	36.2	-5.7
X-3298	BRCA	LFA102	297	25.4	14	34.9	-3.4
X-3298	BRCA	LFA102	324.6	25.4	17	47.4	-3.4
X-3298	BRCA	LFA102	340.2	25.9	20	54.5	-1.5
X-3298	BRCA	LFA102	308.1	25.6	24	39.9	-2.7
X-3298	BRCA	LFA102	359	26.1	27	63	-0.8
X-3298	BRCA	LFA102	389	26.7	31	76.7	1.5
X-3298	BRCA	LFA102	329.8	26.1	34	49.8	-0.8
X-3298	BRCA	LFA102	363.4	26.6	38	65	1.1
X-3298	BRCA	LFA102	412.1	26.8	41	87.1	1.9
X-3298	BRCA	LFA102	375.8	26.3	45	70.7	0
X-3298	BRCA	LFA102	430.9	26.3	48	95.7	0
X-3298	BRCA	LFA102	409.7	26.2	52	86.1	-0.4
X-3298	BRCA	LFA102	496.5	25.9	55	125.5	-1.5
X-3298	BRCA	LFA102	458.5	26.3	59	108.2	0
X-3298	BRCA	LFA102	461.1	26.5	62	109.4	0.8
X-3298	BRCA	LFA102	491.5	26.9	65	123.2	2.3
X-3298	BRCA	LFA102	492.2	27	69	123.5	2.7
X-3298	BRCA	LFA102	551.8	26.9	73	150.6	2.3
X-3298	BRCA	LFA102	507.7	27	76	130.6	2.7
X-3298	BRCA	LFA102	593	27.1	80	169.3	3
X-3298	BRCA	LFA102	635.4	27.6	90	188.6	4.9
X-3298	BRCA	LJM716	250.6	25.8	0	0	0
X-3298	BRCA	LJM716	246.7	25.7	4	-1.6	-0.4
X-3298	BRCA	LJM716	297.9	25.4	8	18.9	-1.6
X-3298	BRCA	LJM716	298.4	25.7	11	19.1	-0.4
X-3298	BRCA	LJM716	317.2	26.2	15	26.6	1.6
X-3298	BRCA	LJM716	385.6	26.1	18	53.9	1.2
X-3298	BRCA	LJM716	416.7	26.1	25	66.3	1.2
X-3298	BRCA	LJM716	511.4	27.4	28	104.1	6.2
X-3298	BRCA	LJM716	472.5	26.6	33	88.5	3.1
X-3298	BRCA	LJM716	613.8	27.1	36	144.9	5
X-3298	BRCA	LJM716	763.3	27.2	39	204.6	5.4
X-3298	BRCA	LJM716	925.2	27.8	43	269.2	7.8
X-3298	BRCA	LJM716	1351.7	27.7	46	439.4	7.4
X-3298	BRCA	LJM716 + trastuzumab	223.2	28.4	0	0	0
X-3298	BRCA	LJM716 + trastuzumab	232.7	27.8	2	4.3	-2.1
X-3298	BRCA	LJM716 + trastuzumab	274.1	27.8	7	22.8	-2.1
X-3298	BRCA	LJM716 + trastuzumab	338.3	27.6	10	51.6	-2.8
X-3298	BRCA	LJM716 + trastuzumab	333.4	29.7	13	49.4	4.6
X-3298	BRCA	LJM716 + trastuzumab	313.2	28.6	17	40.3	0.7
X-3298	BRCA	LJM716 + trastuzumab	367.1	28.3	20	64.5	-0.4
X-3298	BRCA	LJM716 + trastuzumab	345.9	27.9	24	55	-1.8
X-3298	BRCA	LJM716 + trastuzumab	422.1	27.2	27	89.1	-4.2
X-3298	BRCA	LJM716 + trastuzumab	441.6	27.7	31	97.8	-2.5
X-3298	BRCA	LJM716 + trastuzumab	431.6	28.1	34	93.4	-1.1
X-3298	BRCA	LJM716 + trastuzumab	505.7	27.4	38	126.6	-3.5
X-3298	BRCA	LJM716 + trastuzumab	513.8	27	41	130.2	-4.9
X-3298	BRCA	LJM716 + trastuzumab	598.9	28.3	45	168.3	-0.4
X-3298	BRCA	LJM716 + trastuzumab	533	27.4	48	138.8	-3.5
X-3298	BRCA	LJM716 + trastuzumab	605.4	28.3	52	171.2	-0.4
X-3298	BRCA	LJM716 + trastuzumab	612.4	27.8	55	174.4	-2.1
X-3298	BRCA	LJM716 + trastuzumab	695.4	27.4	58	211.6	-3.5
X-3298	BRCA	LJM716 + trastuzumab	786.2	27.6	62	252.2	-2.8
X-3298	BRCA	LJM716 + trastuzumab	833.1	27.3	66	273.3	-3.9
X-3298	BRCA	LJM716 + trastuzumab	848.6	28	69	280.2	-1.4
X-3298	BRCA	LJM716 + trastuzumab	849.9	28.6	73	280.8	0.7
X-3298	BRCA	LJM716 + trastuzumab	1156.9	28.5	83	418.3	0.4
X-3298	BRCA	LKA136	237.5	24.1	0	0	0
X-3298	BRCA	LKA136	237.4	25.3	4	0	5
X-3298	BRCA	LKA136	311.1	26.6	8	31	10.4
X-3298	BRCA	LKA136	320.2	27.3	11	34.8	13.3
X-3298	BRCA	LKA136	376.7	25.5	15	58.6	5.8
X-3298	BRCA	LKA136	463.4	26.1	18	95.1	8.3
X-3298	BRCA	LKA136	484.7	26.7	22	104.1	10.8
X-3298	BRCA	LKA136	474.6	25.7	25	99.8	6.6
X-3298	BRCA	LKA136	556.9	25	29	134.5	3.7
X-3298	BRCA	LKA136	494.6	24.3	32	108.3	0.8
X-3298	BRCA	LKA136	484.5	24.7	36	104	2.5
X-3298	BRCA	LKA136	533.2	24.4	39	124.5	1.2
X-3298	BRCA	LKA136	540.9	24.4	42	127.7	1.2
X-3298	BRCA	LKA136	644.2	24.4	46	171.2	1.2
X-3298	BRCA	LKA136	660.5	24	50	178.1	-0.4
X-3298	BRCA	LKA136	634.8	24.9	53	167.3	3.3
X-3298	BRCA	LKA136	634	24.7	57	166.9	2.5
X-3298	BRCA	LKA136	796	25.3	67	235.2	5
X-3298	BRCA	LKA136	708	24.8	71	198.1	2.9
X-3298	BRCA	LKA136	823.3	24.7	74	246.7	2.5
X-3298	BRCA	LKA136	883.9	24.5	78	272.2	1.7
X-3298	BRCA	LKA136	937.3	25	81	294.7	3.7
X-3298	BRCA	LLM871	200.5	25.5	0	0	0
X-3298	BRCA	LLM871	185.7	22.8	6	-7.4	-10.6
X-3298	BRCA	LLM871	180.7	23.3	9	-9.9	-8.6
X-3298	BRCA	LLM871	181.6	22.8	14	-9.4	-10.6
X-3298	BRCA	LLM871	227.8	22.8	17	13.6	-10.6
X-3298	BRCA	LLM871	237.1	25.8	20	18.3	1.2
X-3298	BRCA	LLM871	217.1	22.9	24	8.3	-10.2
X-3298	BRCA	LLM871	198.9	23.6	27	-0.8	-7.5
X-3298	BRCA	LLM871	238.7	23.1	31	19.1	-9.4
X-3298	BRCA	LLM871	252.3	23.9	34	25.8	-6.3
X-3298	BRCA	LLM871	245.4	24.2	38	22.4	-5.1
X-3298	BRCA	LLM871	249.4	26.4	41	24.4	3.5
X-3298	BRCA	LLM871	256.3	23.8	45	27.8	-6.7
X-3298	BRCA	LLM871	246.1	24.8	48	22.7	-2.7
X-3298	BRCA	LLM871	315.8	24.2	52	57.5	-5.1
X-3298	BRCA	LLM871	318.6	26.4	55	58.9	3.5
X-3298	BRCA	LLM871	340.9	24.2	59	70	-5.1
X-3298	BRCA	LLM871	363.3	25.9	62	81.2	1.6
X-3298	BRCA	LLM871	383	24.2	65	91	-5.1
X-3298	BRCA	LLM871	377.4	24.9	69	88.2	-2.4
X-3298	BRCA	LLM871	410	24.6	73	104.5	-3.5
X-3298	BRCA	LLM871	375.7	25.1	76	87.4	-1.6
X-3298	BRCA	LLM871	419.4	25.2	80	109.2	-1.2
X-3298	BRCA	LLM871	442.7	25.6	90	120.8	0.4
X-3298	BRCA	LLM871	503.5	25.5	94	151.1	0
X-3298	BRCA	LLM871	506.3	25.1	97	152.5	-1.6
X-3298	BRCA	LLM871	538	24.2	101	168.3	-5.1
X-3298	BRCA	LLM871	536.8	26.6	104	167.7	4.3
X-3298	BRCA	LLM871	595.3	24.9	108	196.9	-2.4
X-3298	BRCA	LLM871	621.2	25.1	111	209.8	-1.6
X-3298	BRCA	binimetinib	229	23.5	0	0	0
X-3298	BRCA	binimetinib	227.1	26.8	4	-0.8	14
X-3298	BRCA	binimetinib	346.9	26.9	7	51.5	14.5
X-3298	BRCA	binimetinib	369.9	26.4	11	61.5	12.3
X-3298	BRCA	binimetinib	372.7	25.9	14	62.8	10.2
X-3298	BRCA	binimetinib	458.9	25.3	18	100.4	7.7
X-3298	BRCA	binimetinib	486.1	25.6	21	112.3	8.9
X-3298	BRCA	binimetinib	513.5	25.8	25	124.2	9.8
X-3298	BRCA	binimetinib	702.1	26	28	206.6	10.6
X-3298	BRCA	binimetinib	601.9	25.6	32	162.8	8.9
X-3298	BRCA	binimetinib	962.1	26.5	35	320.1	12.8
X-3298	BRCA	binimetinib	1142.5	25.9	38	398.9	10.2
X-3298	BRCA	binimetinib	1485.1	26.4	42	548.5	12.3
X-3298	BRCA	paclitaxel	324.6	27.1	0	0	0
X-3298	BRCA	paclitaxel	273.8	27.9	3	-15.7	3
X-3298	BRCA	paclitaxel	229.6	28.5	6	-29.3	5.2
X-3298	BRCA	paclitaxel	138	27.2	10	-57.5	0.4
X-3298	BRCA	paclitaxel	121.7	28.1	13	-62.5	3.7
X-3298	BRCA	paclitaxel	68.8	28.9	20	-78.8	6.6
X-3298	BRCA	paclitaxel	85.4	29.1	23	-73.7	7.4
X-3298	BRCA	paclitaxel	58.2	28.6	28	-82.1	5.5
X-3298	BRCA	paclitaxel	37.4	28.4	31	-88.5	4.8
X-3298	BRCA	paclitaxel	45.5	28.6	34	-86	5.5
X-3298	BRCA	paclitaxel	37.6	28.8	38	-88.4	6.3
X-3298	BRCA	paclitaxel	41.1	29.1	41	-87.3	7.4
X-3298	BRCA	paclitaxel	35.3	28.7	45	-89.1	5.9
X-3298	BRCA	paclitaxel	16	29.1	48	-95.1	7.4
X-3298	BRCA	paclitaxel	24.8	28.9	52	-92.4	6.6
X-3298	BRCA	paclitaxel	32.4	29.5	55	-90	8.9
X-3298	BRCA	paclitaxel	37.9	29.1	59	-88.3	7.4
X-3298	BRCA	paclitaxel	37.2	29.1	62	-88.5	7.4
X-3298	BRCA	paclitaxel	26.3	28.9	66	-91.9	6.6
X-3298	BRCA	paclitaxel	24.7	30.6	69	-92.4	12.9
X-3298	BRCA	paclitaxel	20.9	29.1	73	-93.6	7.4
X-3298	BRCA	paclitaxel	17.6	29.1	76	-94.6	7.4
X-3298	BRCA	paclitaxel	23.9	28.9	79	-92.6	6.6
X-3298	BRCA	paclitaxel	17.4	28.5	83	-94.6	5.2
X-3298	BRCA	paclitaxel	25.2	29	87	-92.2	7
X-3298	BRCA	paclitaxel	15.5	28.6	90	-95.2	5.5
X-3298	BRCA	tamoxifen	328.2	22.3	0	0	0
X-3298	BRCA	tamoxifen	459.9	21.6	4	40.1	-3.1
X-3298	BRCA	tamoxifen	514.5	23	8	56.8	3.1
X-3298	BRCA	tamoxifen	566.3	22.7	11	72.5	1.8
X-3298	BRCA	tamoxifen	656.1	23	15	99.9	3.1
X-3298	BRCA	tamoxifen	836.9	24	18	155	7.6
X-3298	BRCA	tamoxifen	1097.6	24	22	234.4	7.6
X-3298	BRCA	tamoxifen	1207.8	24.1	25	268	8.1
X-3298	BRCA	trastuzumab	266.3	26.8	0	0	0
X-3298	BRCA	trastuzumab	226.7	26.3	3	-14.9	-1.9
X-3298	BRCA	trastuzumab	310.6	26.1	6	16.6	-2.6
X-3298	BRCA	trastuzumab	277.5	26.4	10	4.2	-1.5
X-3298	BRCA	trastuzumab	323.4	26.1	13	21.4	-2.6
X-3298	BRCA	trastuzumab	384	26.7	17	44.2	-0.4
X-3298	BRCA	trastuzumab	407.6	28	20	53.1	4.5
X-3298	BRCA	trastuzumab	450.8	27.1	24	69.3	1.1
X-3298	BRCA	trastuzumab	427.9	26.7	27	60.7	-0.4
X-3298	BRCA	trastuzumab	530	27.2	31	99	1.5
X-3298	BRCA	trastuzumab	552.3	26.7	34	107.4	-0.4
X-3298	BRCA	trastuzumab	606.1	27.3	38	127.6	1.9
X-3298	BRCA	trastuzumab	661.3	27.2	41	148.3	1.5
X-3298	BRCA	trastuzumab	742.5	26.7	44	178.8	-0.4
X-3298	BRCA	trastuzumab	882.3	26.9	48	231.3	0.4
X-3298	BRCA	trastuzumab	931.6	27.4	52	249.8	2.2
X-3298	BRCA	trastuzumab	900.6	27.7	55	238.2	3.4
X-3298	BRCA	trastuzumab	978.2	27.9	59	267.3	4.1
X-3298	BRCA	trastuzumab	1101.6	28.3	69	313.7	5.6
X-3298	BRCA	untreated	226.8	33.8	0	0	0
X-3298	BRCA	untreated	363.4	33	3	60.2	-2.4
X-3298	BRCA	untreated	435.9	33.7	10	92.2	-0.3
X-3298	BRCA	untreated	415.1	33.9	13	83	0.3
X-3298	BRCA	untreated	521	34.1	18	129.7	0.9
X-3298	BRCA	untreated	555.2	34	21	144.8	0.6
X-3298	BRCA	untreated	536.7	34.4	24	136.6	1.8
X-3298	BRCA	untreated	632.5	34.1	28	178.9	0.9
X-3298	BRCA	untreated	679.3	34.4	31	199.5	1.8
X-3298	BRCA	untreated	722.4	34.6	35	218.5	2.4
X-3298	BRCA	untreated	800.4	35.8	38	252.9	5.9
X-3298	BRCA	untreated	890.1	35.1	42	292.5	3.8
X-3298	BRCA	untreated	867	35.8	45	282.3	5.9
X-3298	BRCA	untreated	1029.2	35	49	353.8	3.6
X-3298	BRCA	untreated	1145.7	36.1	52	405.2	6.8
X-3450	BRCA	BGJ398	213.7	28.5	0	0	0
X-3450	BRCA	BGJ398	219.6	27.4	3	2.8	-3.9
X-3450	BRCA	BGJ398	219.1	28.2	7	2.5	-1.1
X-3450	BRCA	BGJ398	236.9	28.5	10	10.9	0
X-3450	BRCA	BGJ398	257.5	28.5	13	20.5	0
X-3450	BRCA	BGJ398	286.6	28.6	17	34.1	0.4
X-3450	BRCA	BGJ398	302.6	27.6	22	41.6	-3.2
X-3450	BRCA	BGJ398	310.3	27	24	45.2	-5.3
X-3450	BRCA	BGJ398	340.5	26.8	28	59.3	-6
X-3450	BRCA	BGJ398	383.7	26.8	31	79.6	-6
X-3450	BRCA	BGJ398	429	26.4	35	100.7	-7.4
X-3450	BRCA	BGJ398	457.1	27.4	38	113.9	-3.9
X-3450	BRCA	BGJ398	474.5	27.3	42	122	-4.2
X-3450	BRCA	BGJ398	496.2	27.7	45	132.2	-2.8
X-3450	BRCA	BGJ398	538.5	27.1	49	152	-4.9
X-3450	BRCA	BGJ398	727.4	26.1	52	240.4	-8.4
X-3450	BRCA	BGJ398	764.7	26.7	56	257.8	-6.3
X-3450	BRCA	BKM120	221.8	27	0	0	0
X-3450	BRCA	BKM120	226.8	24.7	4	2.3	-8.5
X-3450	BRCA	BKM120	168.3	25.9	7	-24.1	-4.1
X-3450	BRCA	BKM120	169.6	26.8	11	-23.5	-0.7
X-3450	BRCA	BKM120	157	26.6	14	-29.2	-1.5
X-3450	BRCA	BKM120	140.8	26.3	18	-36.5	-2.6
X-3450	BRCA	BKM120	133.9	23	21	-39.6	-14.8
X-3450	BRCA	BKM120	125.8	20	25	-43.3	-25.9
X-3450	BRCA	BKM120	114	19.5	28	-48.6	-27.8
X-3450	BRCA	BKM120	103.6	23.2	33	-53.3	-14.1
X-3450	BRCA	BKM120	95.1	23.9	35	-57.1	-11.5
X-3450	BRCA	BKM120	99.4	26.2	39	-55.2	-3
X-3450	BRCA	BKM120	118.3	27.1	42	-46.7	0.4
X-3450	BRCA	BKM120	169.7	27.4	45	-23.5	1.5
X-3450	BRCA	BKM120	174.8	27	49	-21.2	0
X-3450	BRCA	BKM120	172.7	26.5	53	-22.1	-1.9
X-3450	BRCA	BKM120	167.2	26.4	56	-24.6	-2.2
X-3450	BRCA	BKM120	172	23.8	59	-22.5	-11.9
X-3450	BRCA	BYL719 + LJM716	223.6	28.2	0	0	0
X-3450	BRCA	BYL719 + LJM716	187.4	25.5	5	-16.2	-9.6
X-3450	BRCA	BYL719 + LJM716	166.4	25.3	7	-25.6	-10.3
X-3450	BRCA	BYL719 + LJM716	107.7	25.2	11	-51.8	-10.6
X-3450	BRCA	BYL719 + LJM716	85.5	25.1	14	-61.8	-11
X-3450	BRCA	BYL719 + LJM716	57.1	24.7	18	-74.5	-12.4
X-3450	BRCA	BYL719 + LJM716	46.1	24.6	21	-79.4	-12.8
X-3450	BRCA	BYL719 + LJM716	22.9	24.9	25	-89.8	-11.7
X-3450	BRCA	BYL719 + LJM716	24.2	26.7	28	-89.2	-5.3
X-3450	BRCA	BYL719 + LJM716	21.5	26	32	-90.4	-7.8
X-3450	BRCA	BYL719 + LJM716	20.8	26.3	35	-90.7	-6.7
X-3450	BRCA	BYL719 + LJM716	17.5	26.1	39	-92.2	-7.4
X-3450	BRCA	BYL719 + LJM716	15.6	25.9	42	-93	-8.2
X-3450	BRCA	BYL719 + LJM716	11	26.8	46	-95.1	-5
X-3450	BRCA	BYL719 + LJM716	11.7	26.2	49	-94.8	-7.1
X-3450	BRCA	BYL719 + LJM716	9.7	25.1	54	-95.7	-11
X-3450	BRCA	BYL719 + LJM716	8.4	24.9	56	-96.2	-11.7
X-3450	BRCA	BYL719 + LJM716	8.3	24.9	60	-96.3	-11.7
X-3450	BRCA	BYL719 + LJM716	7.9	24.9	63	-96.5	-11.7
X-3450	BRCA	BYL719 + LJM716	7.2	24.4	66	-96.8	-13.5
X-3450	BRCA	BYL719	228.3	25.6	0	0	0
X-3450	BRCA	BYL719	206.7	25.9	3	-9.5	1.2
X-3450	BRCA	BYL719	215.6	24.9	7	-5.6	-2.7
X-3450	BRCA	BYL719	221.9	25.7	10	-2.8	0.4
X-3450	BRCA	BYL719	216.2	25.1	13	-5.3	-2
X-3450	BRCA	BYL719	211.5	25.7	17	-7.4	0.4
X-3450	BRCA	BYL719	193.6	26.8	22	-15.2	4.7
X-3450	BRCA	BYL719	191.5	26.5	24	-16.1	3.5
X-3450	BRCA	BYL719	196.4	25.8	28	-14	0.8
X-3450	BRCA	BYL719	184.7	26.5	31	-19.1	3.5
X-3450	BRCA	BYL719	179.6	25.7	35	-21.3	0.4
X-3450	BRCA	BYL719	161.5	25.8	38	-29.3	0.8
X-3450	BRCA	BYL719	156.5	26.3	42	-31.4	2.7
X-3450	BRCA	BYL719	160.8	27.3	45	-29.6	6.6
X-3450	BRCA	BYL719	170.8	27.4	49	-25.2	7
X-3450	BRCA	BYL719	170	26.4	52	-25.5	3.1
X-3450	BRCA	BYL719	182	26.3	56	-20.3	2.7
X-3450	BRCA	BYL719	218.4	26.8	59	-4.3	4.7
X-3450	BRCA	BYL719	241.1	26.3	63	5.6	2.7
X-3450	BRCA	BYL719	251.8	26.8	66	10.3	4.7
X-3450	BRCA	BYL719	271	25.2	71	18.7	-1.6
X-3450	BRCA	BYL719	278.2	26.3	73	21.9	2.7
X-3450	BRCA	BYL719	306	26.2	77	34	2.3
X-3450	BRCA	BYL719	336.9	27.1	80	47.6	5.9
X-3450	BRCA	BYL719	386	27.1	83	69.1	5.9
X-3450	BRCA	BYL719	389.1	27.5	87	70.4	7.4
X-3450	BRCA	BYL719	457	27.7	91	100.2	8.2
X-3450	BRCA	BYL719 + LEE011	203.5	27.1	0	0	0
X-3450	BRCA	BYL719 + LEE011	195.6	26	5	-3.9	-4.1
X-3450	BRCA	BYL719 + LEE011	162.7	23.6	7	-20	-12.9
X-3450	BRCA	BYL719 + LEE011	166.5	26.7	11	-18.2	-1.5
X-3450	BRCA	BYL719 + LEE011	167.8	27.2	14	-17.5	0.4
X-3450	BRCA	BYL719 + LEE011	172.9	28	17	-15	3.3
X-3450	BRCA	BYL719 + LEE011	173.6	26.3	21	-14.7	-3
X-3450	BRCA	BYL719 + LEE011	161.4	23.1	25	-20.7	-14.8
X-3450	BRCA	BYL719 + LEE011	160.8	19.7	28	-21	-27.3
X-3450	BRCA	BYL719 + LEE011	153.7	23.7	31	-24.5	-12.5
X-3450	BRCA	BYL719 + LEE011	162.4	25.9	35	-20.2	-4.4
X-3450	BRCA	BYL719 + LEE011	166.1	28.1	39	-18.4	3.7
X-3450	BRCA	BYL719 + LEE011	167.2	26.7	42	-17.8	-1.5
X-3450	BRCA	BYL719 + LEE011	155.3	21.4	46	-23.7	-21
X-3450	BRCA	BYL719 + LEE011	153.8	24.4	48	-24.4	-10
X-3450	BRCA	BYL719 + LEE011	154.7	26.8	52	-24	-1.1
X-3450	BRCA	BYL719 + LEE011	182.2	28.4	56	-10.5	4.8
X-3450	BRCA	BYL719 + LEE011	149.4	20.9	60	-26.6	-22.9
X-3450	BRCA	CGM097	244	29.8	0	0	0
X-3450	BRCA	CGM097	258.7	30.6	3	6	2.7
X-3450	BRCA	CGM097	270.3	30.7	7	10.8	3
X-3450	BRCA	CGM097	311.8	30.7	10	27.8	3
X-3450	BRCA	CGM097	393.6	32.3	13	61.3	8.4
X-3450	BRCA	CGM097	428.7	31.9	17	75.7	7
X-3450	BRCA	CGM097	445	32	22	82.4	7.4
X-3450	BRCA	CGM097	470	32.3	24	92.6	8.4
X-3450	BRCA	CGM097	507.4	31.4	28	108	5.4
X-3450	BRCA	CGM097	508.4	31.5	31	108.4	5.7
X-3450	BRCA	CGM097	515.1	32.6	35	111.1	9.4
X-3450	BRCA	CGM097	531.2	32.1	38	117.7	7.7
X-3450	BRCA	CGM097	535.5	31.8	42	119.5	6.7
X-3450	BRCA	CGM097	543.6	32.1	45	122.8	7.7
X-3450	BRCA	CGM097	529.5	33.3	49	117	11.7
X-3450	BRCA	CGM097	554.7	32.2	52	127.3	8.1
X-3450	BRCA	CGM097	566	32	56	132	7.4
X-3450	BRCA	CGM097	577.4	32	59	136.6	7.4
X-3450	BRCA	CGM097	613.4	31.8	63	151.4	6.7
X-3450	BRCA	CGM097	630.5	32.3	66	158.4	8.4
X-3450	BRCA	CGM097	650.3	32.9	71	166.5	10.4
X-3450	BRCA	CGM097	671.1	33.5	73	175	12.4
X-3450	BRCA	CGM097	678.6	33.5	77	178.1	12.4
X-3450	BRCA	CGM097	737.1	32.2	80	202.1	8.1
X-3450	BRCA	CGM097	760.5	30.8	83	211.7	3.4
X-3450	BRCA	CGM097	792	30.9	87	224.6	3.7
X-3450	BRCA	CGM097	827.5	32.4	91	239.1	8.7
X-3450	BRCA	CLR457	211.2	27	0	0	0
X-3450	BRCA	CLR457	213.5	28.1	3	1.1	4.1
X-3450	BRCA	CLR457	217.5	27	6	3	0
X-3450	BRCA	CLR457	227.3	26.5	10	7.6	-1.9
X-3450	BRCA	CLR457	222.3	25.9	15	5.3	-4.1
X-3450	BRCA	CLR457	204.8	25	17	-3	-7.4
X-3450	BRCA	CLR457	186.8	25.1	21	-11.6	-7
X-3450	BRCA	CLR457	164	26.3	24	-22.3	-2.6
X-3450	BRCA	CLR457	147.8	25.1	28	-30	-7
X-3450	BRCA	CLR457	114.1	25.2	31	-46	-6.7
X-3450	BRCA	CLR457	84.3	23.3	35	-60.1	-13.7
X-3450	BRCA	CLR457	82.4	24.6	38	-61	-8.9
X-3450	BRCA	CLR457	82	25.2	42	-61.2	-6.7
X-3450	BRCA	CLR457	97.7	25.7	45	-53.7	-4.8
X-3450	BRCA	CLR457	94.3	26.2	49	-55.4	-3
X-3450	BRCA	CLR457	90.1	22.8	52	-57.3	-15.6
X-3450	BRCA	CLR457	78	23.8	56	-63.1	-11.9
X-3450	BRCA	CLR457	69.6	23.4	59	-67	-13.3
X-3450	BRCA	HDM201	205.7	30.4	0	0	0
X-3450	BRCA	HDM201	221.3	30.2	3	7.6	-0.7
X-3450	BRCA	HDM201	289.6	30.3	7	40.8	-0.3
X-3450	BRCA	HDM201	309.3	31.1	10	50.4	2.3
X-3450	BRCA	HDM201	339.6	31.2	13	65.1	2.6
X-3450	BRCA	HDM201	354.1	31.4	17	72.1	3.3
X-3450	BRCA	HDM201	380.7	31.3	22	85.1	3
X-3450	BRCA	HDM201	391.3	31.1	24	90.2	2.3
X-3450	BRCA	HDM201	401.3	30.4	28	95.1	0
X-3450	BRCA	HDM201	431.6	28.7	31	109.8	-5.6
X-3450	BRCA	HDM201	442.9	26	35	115.3	-14.5
X-3450	BRCA	HDM201	439.3	25.3	38	113.6	-16.8
X-3450	BRCA	HDM201	441.8	26.5	42	114.8	-12.8
X-3450	BRCA	HDM201	462	28.1	45	124.6	-7.6
X-3450	BRCA	HDM201	499.5	28.9	49	142.8	-4.9
X-3450	BRCA	HDM201	579.4	28.5	52	181.7	-6.2
X-3450	BRCA	HDM201	789.6	27.7	56	283.9	-8.9
X-3450	BRCA	INC424	226.9	29.1	0	0	0
X-3450	BRCA	INC424	230.3	29.7	1	1.5	2.1
X-3450	BRCA	INC424	257.5	29.3	5	13.5	0.7
X-3450	BRCA	INC424	268.7	29.5	8	18.4	1.4
X-3450	BRCA	INC424	283.8	28.9	12	25.1	-0.7
X-3450	BRCA	INC424	324.5	29.6	15	43	1.7
X-3450	BRCA	INC424	336	30.5	19	48.1	4.8
X-3450	BRCA	INC424	378.1	30.8	22	66.6	5.8
X-3450	BRCA	INC424	378.3	30.6	26	66.7	5.2
X-3450	BRCA	INC424	389.7	29.8	29	71.7	2.4
X-3450	BRCA	INC424	397.7	30.2	33	75.3	3.8
X-3450	BRCA	INC424	405	29.9	36	78.5	2.7
X-3450	BRCA	INC424	432.4	29.5	40	90.6	1.4
X-3450	BRCA	INC424	456.2	29	43	101.1	-0.3
X-3450	BRCA	INC424	483.2	29.4	48	113	1
X-3450	BRCA	INC424	513.8	29.5	50	126.4	1.4
X-3450	BRCA	INC424	524.7	30.4	54	131.2	4.5
X-3450	BRCA	INC424	595.6	29.8	57	162.5	2.4
X-3450	BRCA	INC424	615.6	30.2	60	171.3	3.8
X-3450	BRCA	INC424	653.6	30.2	64	188.1	3.8
X-3450	BRCA	INC424	660.6	30.6	68	191.1	5.2
X-3450	BRCA	LEE011	259.4	30.3	0	0	0
X-3450	BRCA	LEE011	261.9	30.8	3	1	1.7
X-3450	BRCA	LEE011	259.8	30.7	7	0.2	1.3
X-3450	BRCA	LEE011	273.6	30.8	10	5.5	1.7
X-3450	BRCA	LEE011	271.8	30.4	14	4.8	0.3
X-3450	BRCA	LEE011	286.9	30.4	17	10.6	0.3
X-3450	BRCA	LEE011	297.3	30.1	21	14.6	-0.7
X-3450	BRCA	LEE011	315.1	29.9	24	21.5	-1.3
X-3450	BRCA	LEE011	316.6	31	29	22.1	2.3
X-3450	BRCA	LEE011	328.7	31.2	31	26.7	3
X-3450	BRCA	LEE011	325.7	30.4	35	25.6	0.3
X-3450	BRCA	LEE011	319.3	31.5	41	23.1	4
X-3450	BRCA	LEE011	320.7	31	45	23.6	2.3
X-3450	BRCA	LEE011	295.7	31.3	49	14	3.3
X-3450	BRCA	LEE011	291.2	31.2	52	12.3	3
X-3450	BRCA	LEE011	285.6	29.7	55	10.1	-2
X-3450	BRCA	LEE011	288.1	31.8	59	11.1	5
X-3450	BRCA	LEE011	281.3	30.3	63	8.4	0
X-3450	BRCA	LEE011	284.9	28	66	9.8	-7.6
X-3450	BRCA	LEE011	288.7	32.4	70	11.3	6.9
X-3450	BRCA	LEE011	286.7	30.9	72	10.5	2
X-3450	BRCA	LEE011	270.6	28.1	76	4.3	-7.3
X-3450	BRCA	LEE011 + everolimus	215.5	27.9	0	0	0
X-3450	BRCA	LEE011 + everolimus	210.3	27.9	5	-2.4	0
X-3450	BRCA	LEE011 + everolimus	196.3	27.3	7	-8.9	-2.2
X-3450	BRCA	LEE011 + everolimus	184.5	27.6	11	-14.4	-1.1
X-3450	BRCA	LEE011 + everolimus	171.6	26.4	14	-20.4	-5.4
X-3450	BRCA	LEE011 + everolimus	161.9	26.8	17	-24.9	-3.9
X-3450	BRCA	LEE011 + everolimus	148.9	26.4	21	-30.9	-5.4
X-3450	BRCA	LEE011 + everolimus	144.2	26.3	25	-33.1	-5.7
X-3450	BRCA	LEE011 + everolimus	139.4	27.7	28	-35.3	-0.7
X-3450	BRCA	LEE011 + everolimus	136.6	27	31	-36.6	-3.2
X-3450	BRCA	LEE011 + everolimus	121.8	27.4	35	-43.5	-1.8
X-3450	BRCA	LEE011 + everolimus	106.8	27.6	39	-50.4	-1.1
X-3450	BRCA	LEE011 + everolimus	109.9	26.9	42	-49	-3.6
X-3450	BRCA	LEE011 + everolimus	103.5	26.2	46	-52	-6.1
X-3450	BRCA	LEE011 + everolimus	97.1	27.6	48	-54.9	-1.1
X-3450	BRCA	LEE011 + everolimus	97.3	26.8	52	-54.8	-3.9
X-3450	BRCA	LEE011 + everolimus	100.3	26.5	56	-53.5	-5
X-3450	BRCA	LEE011 + everolimus	101.6	25.9	60	-52.9	-7.2
X-3450	BRCA	LEE011 + everolimus	92.1	26.3	63	-57.3	-5.7
X-3450	BRCA	LEE011 + everolimus	93.8	23.3	67	-56.5	-16.5
X-3450	BRCA	LFA102	271.1	30.4	0	0	0
X-3450	BRCA	LFA102	281.5	31.1	3	3.8	2.3
X-3450	BRCA	LFA102	333.1	31.8	7	22.9	4.6
X-3450	BRCA	LFA102	344.7	30.8	10	27.1	1.3
X-3450	BRCA	LFA102	381.6	31.9	14	40.8	4.9
X-3450	BRCA	LFA102	400.5	31.3	17	47.7	3
X-3450	BRCA	LFA102	377.2	25.5	21	39.1	-16.1
X-3450	BRCA	LJM716	224.7	30.3	0	0	0
X-3450	BRCA	LJM716	226.5	30.5	2	0.8	0.7
X-3450	BRCA	LJM716	181.1	29.8	6	-19.4	-1.7
X-3450	BRCA	LJM716	143.7	29	9	-36	-4.3
X-3450	BRCA	LJM716	109.7	26.6	13	-51.2	-12.2
X-3450	BRCA	LJM716	92.6	27.9	16	-58.8	-7.9
X-3450	BRCA	LJM716	96.6	29.9	20	-57	-1.3
X-3450	BRCA	LJM716	86.6	29.8	23	-61.5	-1.7
X-3450	BRCA	LJM716	76.8	29.4	27	-65.8	-3
X-3450	BRCA	LJM716	79.9	27.9	30	-64.4	-7.9
X-3450	BRCA	LJM716	74.8	26.6	34	-66.7	-12.2
X-3450	BRCA	LJM716	69.5	26.8	37	-69.1	-11.6
X-3450	BRCA	LJM716	59.7	26.5	41	-73.4	-12.5
X-3450	BRCA	LJM716	59.4	26.8	44	-73.6	-11.6
X-3450	BRCA	LJM716	40.5	27.2	49	-82	-10.2
X-3450	BRCA	LJM716	40.5	26.9	51	-82	-11.2
X-3450	BRCA	LJM716	39.7	26.8	55	-82.3	-11.6
X-3450	BRCA	LJM716	35.9	26.6	58	-84	-12.2
X-3450	BRCA	LJM716	26.2	23.1	61	-88.3	-23.8
X-3450	BRCA	LJM716 + trastuzumab	213.4	27	0	0	0
X-3450	BRCA	LJM716 + trastuzumab	224.3	26.6	3	5.1	-1.5
X-3450	BRCA	LJM716 + trastuzumab	218.2	25.9	7	2.2	-4.1
X-3450	BRCA	LJM716 + trastuzumab	213.7	26	10	0.1	-3.7
X-3450	BRCA	LJM716 + trastuzumab	172.8	23.2	14	-19	-14.1
X-3450	BRCA	LJM716 + trastuzumab	170.2	23	17	-20.2	-14.8
X-3450	BRCA	LJM716 + trastuzumab	152.7	21.6	21	-28.4	-20
X-3450	BRCA	LJM716 + trastuzumab	126.8	21.1	24	-40.6	-21.9
X-3450	BRCA	LJM716 + trastuzumab	111.6	22.6	28	-47.7	-16.3
X-3450	BRCA	LJM716 + trastuzumab	111.3	23.1	31	-47.8	-14.4
X-3450	BRCA	LJM716 + trastuzumab	92.5	20.8	36	-56.7	-23
X-3450	BRCA	LJM716 + trastuzumab	90.8	19.9	38	-57.5	-26.3
X-3450	BRCA	LKA136	206.7	27	0	0	0
X-3450	BRCA	LKA136	215.2	28.1	3	4.1	4.1
X-3450	BRCA	LKA136	226.2	28.2	7	9.4	4.4
X-3450	BRCA	LKA136	238	28.1	10	15.1	4.1
X-3450	BRCA	LKA136	238.1	28.2	14	15.2	4.4
X-3450	BRCA	LKA136	253.9	28.9	17	22.8	7
X-3450	BRCA	LKA136	270.8	29.4	21	31	8.9
X-3450	BRCA	LKA136	312.6	28.5	24	51.2	5.6
X-3450	BRCA	LKA136	344.6	28.5	28	66.7	5.6
X-3450	BRCA	LKA136	364.4	28.4	31	76.3	5.2
X-3450	BRCA	LLM871	255.9	28.4	0	0	0
X-3450	BRCA	LLM871	268.1	27.9	3	4.8	-1.8
X-3450	BRCA	LLM871	289.6	28.5	7	13.2	0.4
X-3450	BRCA	LLM871	313.1	28.9	10	22.4	1.8
X-3450	BRCA	LLM871	359.2	28.4	14	40.4	0
X-3450	BRCA	LLM871	374.5	28.7	17	46.3	1.1
X-3450	BRCA	LLM871	385.4	28.9	21	50.6	1.8
X-3450	BRCA	LLM871	427.2	28.9	24	66.9	1.8
X-3450	BRCA	LLM871	495.9	29.3	31	93.8	3.2
X-3450	BRCA	LLM871	520.8	28.9	35	103.5	1.8
X-3450	BRCA	LLM871	541.2	29.3	38	111.5	3.2
X-3450	BRCA	LLM871	554.9	29.6	43	116.8	4.2
X-3450	BRCA	LLM871	574.1	29.4	45	124.3	3.5
X-3450	BRCA	LLM871	612.9	29.5	49	139.5	3.9
X-3450	BRCA	LLM871	639.5	29.6	52	149.9	4.2
X-3450	BRCA	LLM871	683.6	30.3	55	167.1	6.7
X-3450	BRCA	binimetinib	213.4	28.4	0	0	0
X-3450	BRCA	binimetinib	228.4	27.5	3	7	-3.2
X-3450	BRCA	binimetinib	236.3	28.1	7	10.7	-1.1
X-3450	BRCA	binimetinib	243.9	27.1	10	14.3	-4.6
X-3450	BRCA	binimetinib	249.1	27.5	14	16.7	-3.2
X-3450	BRCA	binimetinib	249	27	17	16.7	-4.9
X-3450	BRCA	binimetinib	245.8	26.3	21	15.2	-7.4
X-3450	BRCA	binimetinib	233	25.9	24	9.2	-8.8
X-3450	BRCA	binimetinib	236.2	26.7	28	10.7	-6
X-3450	BRCA	binimetinib	230	26.2	31	7.8	-7.7
X-3450	BRCA	binimetinib	226.6	26.7	36	6.2	-6
X-3450	BRCA	binimetinib	208.2	26.5	38	-2.4	-6.7
X-3450	BRCA	binimetinib	207.1	26.1	42	-3	-8.1
X-3450	BRCA	binimetinib	214	25.8	45	0.3	-9.2
X-3450	BRCA	binimetinib	208.8	25.7	48	-2.2	-9.5
X-3450	BRCA	binimetinib	214.5	25.4	52	0.5	-10.6
X-3450	BRCA	binimetinib	225.2	25.6	56	5.5	-9.9
X-3450	BRCA	binimetinib	215.6	25.4	59	1	-10.6
X-3450	BRCA	binimetinib	226.1	25	62	6	-12
X-3450	BRCA	binimetinib	227.3	25.2	66	6.5	-11.3
X-3450	BRCA	binimetinib	234.1	23.6	70	9.7	-16.9
X-3450	BRCA	binimetinib	240.6	24.9	73	12.7	-12.3
X-3450	BRCA	binimetinib	250.7	24.2	77	17.5	-14.8
X-3450	BRCA	binimetinib	258.8	26.8	79	21.3	-5.6
X-3450	BRCA	binimetinib	293.3	27.5	83	37.4	-3.2
X-3450	BRCA	binimetinib	343.7	27.7	87	61.1	-2.5
X-3450	BRCA	binimetinib	467.3	24.6	91	119	-13.4
X-3450	BRCA	paclitaxel	247.4	26.2	0	0	0
X-3450	BRCA	paclitaxel	262.9	-0.1	3	6.3	0
X-3450	BRCA	paclitaxel	304.4	27.3	7	23	4.2
X-3450	BRCA	paclitaxel	376.8	27	10	52.3	3.1
X-3450	BRCA	paclitaxel	420.6	27.2	14	70	3.8
X-3450	BRCA	paclitaxel	424.5	27.6	17	71.6	5.3
X-3450	BRCA	paclitaxel	440.8	27.4	21	78.2	4.6
X-3450	BRCA	paclitaxel	453.8	26	24	83.4	-0.8
X-3450	BRCA	paclitaxel	477.2	27.4	28	92.9	4.6
X-3450	BRCA	paclitaxel	512.9	27	31	107.3	3.1
X-3450	BRCA	paclitaxel	519.1	27.9	35	109.8	6.5
X-3450	BRCA	paclitaxel	534.7	27.1	38	116.1	3.4
X-3450	BRCA	paclitaxel	517.2	28.6	43	109.1	9.2
X-3450	BRCA	paclitaxel	506	27.8	45	104.5	6.1
X-3450	BRCA	paclitaxel	511.7	29.4	49	106.8	12.2
X-3450	BRCA	paclitaxel	538.5	27.5	52	117.7	5
X-3450	BRCA	paclitaxel	553.9	28	55	123.9	6.9
X-3450	BRCA	paclitaxel	576.8	27.7	59	133.1	5.7
X-3450	BRCA	paclitaxel	605.3	28.4	63	144.7	8.4
X-3450	BRCA	tamoxifen	223.4	23	0	0	0
X-3450	BRCA	tamoxifen	235	24.3	5	5.2	5.7
X-3450	BRCA	tamoxifen	252	24.8	7	12.8	7.8
X-3450	BRCA	tamoxifen	260.1	25	11	16.4	8.7
X-3450	BRCA	tamoxifen	294.9	25.3	14	32	10
X-3450	BRCA	tamoxifen	311	26.8	18	39.2	16.5
X-3450	BRCA	tamoxifen	303.9	26.9	21	36	17
X-3450	BRCA	tamoxifen	307.7	26.7	25	37.7	16.1
X-3450	BRCA	tamoxifen	357.6	27	28	60.1	17.4
X-3450	BRCA	tamoxifen	364.9	26.3	32	63.3	14.3
X-3450	BRCA	tamoxifen	385.6	26.2	35	72.6	13.9
X-3450	BRCA	tamoxifen	377.4	26.3	39	68.9	14.3
X-3450	BRCA	tamoxifen	409	26.1	42	83.1	13.5
X-3450	BRCA	tamoxifen	424.7	26.2	46	90.1	13.9
X-3450	BRCA	tamoxifen	428.7	26	49	91.9	13
X-3450	BRCA	tamoxifen	434	26.6	54	94.3	15.7
X-3450	BRCA	tamoxifen	478.3	26.7	56	114.1	16.1
X-3450	BRCA	tamoxifen	491.7	27.1	60	120.1	17.8
X-3450	BRCA	tamoxifen	510.1	27.6	63	128.3	20
X-3450	BRCA	tamoxifen	562.7	27.8	66	151.9	20.9
X-3450	BRCA	tamoxifen	604	27.6	70	170.4	20
X-3450	BRCA	tamoxifen	681.9	27	74	205.2	17.4
X-3450	BRCA	trastuzumab	252.6	30	0	0	0
X-3450	BRCA	trastuzumab	275	31.9	3	8.9	6.3
X-3450	BRCA	trastuzumab	326.4	31.8	7	29.2	6
X-3450	BRCA	trastuzumab	365	29.9	10	44.5	-0.3
X-3450	BRCA	trastuzumab	424.7	30.4	14	68.1	1.3
X-3450	BRCA	trastuzumab	445	30.2	17	76.2	0.7
X-3450	BRCA	trastuzumab	473.8	30.1	22	87.6	0.3
X-3450	BRCA	trastuzumab	499.1	27.5	24	97.6	-8.3
X-3450	BRCA	untreated	218.3	29.3	0	0	0
X-3450	BRCA	untreated	227.5	30.2	5	4.2	3.1
X-3450	BRCA	untreated	231	30.5	7	5.8	4.1
X-3450	BRCA	untreated	235.9	30.5	11	8.1	4.1
X-3450	BRCA	untreated	243.6	31.2	14	11.6	6.5
X-3450	BRCA	untreated	254.3	30.6	18	16.5	4.4
X-3450	BRCA	untreated	264.9	31.8	21	21.3	8.5
X-3450	BRCA	untreated	268.9	32.8	25	23.2	11.9
X-3450	BRCA	untreated	278.6	32.5	28	27.6	10.9
X-3450	BRCA	untreated	295.7	32.6	32	35.5	11.3
X-3450	BRCA	untreated	326.3	32.6	35	49.5	11.3
X-3450	BRCA	untreated	342.6	32.4	39	56.9	10.6
X-3450	BRCA	untreated	368.1	32.2	42	68.6	9.9
X-3450	BRCA	untreated	404.4	31.7	46	85.2	8.2
X-3450	BRCA	untreated	431.6	32.1	49	97.7	9.6
X-3450	BRCA	untreated	512.8	32.3	54	134.9	10.2
X-3450	BRCA	untreated	569.8	32.6	56	161	11.3
X-3450	BRCA	untreated	627.4	33.2	60	187.4	13.3
X-3450	BRCA	untreated	697.5	33.3	63	219.5	13.7
X-3450	BRCA	untreated	734.4	32.2	66	236.4	9.9
X-3450	BRCA	untreated	778.6	33.6	70	256.7	14.7
X-3450	BRCA	untreated	829	33.2	74	279.8	13.3
X-3450	BRCA	LFW527 + everolimus	265.31	23.4	0	0	0
X-3450	BRCA	LFW527 + everolimus	205.35	23.1	3	-22.6	-1.3
X-3450	BRCA	LFW527 + everolimus	208	22.3	6	-21.6	-4.7
X-3450	BRCA	LFW527 + everolimus	219.13	21.5	10	-17.4	-8.1
X-3450	BRCA	LFW527 + everolimus	185.94	18	13	-29.9	-23.1
X-3453	BRCA	LFW527 + everolimus	231.8	29.2	0	0	0
X-3453	BRCA	LFW527 + everolimus	233.11	28.5	3	0.6	-2.4
X-3453	BRCA	LFW527 + everolimus	221.15	27.7	6	-4.6	-5.1
X-3453	BRCA	LFW527 + everolimus	200.87	28.1	10	-13.3	-3.8
X-3453	BRCA	LFW527 + everolimus	186.57	29	14	-19.5	-0.7
X-3453	BRCA	LFW527 + everolimus	201.85	28.7	17	-12.9	-1.7
X-3453	BRCA	LFW527 + everolimus	172.44	28.4	20	-25.6	-2.7
X-3453	BRCA	LFW527 + everolimus	137.33	28.3	24	-40.8	-3.1
X-3453	BRCA	LFW527 + everolimus	127.76	27.7	27	-44.9	-5.1
X-3453	BRCA	LFW527 + everolimus	133.22	28.4	31	-42.5	-2.7
X-3453	BRCA	LFW527 + everolimus	134.47	27.4	34	-42	-6.2
X-3453	BRCA	LFW527 + everolimus	122.9	26.8	38	-47	-8.2
X-3453	BRCA	LFW527 + everolimus	132.94	27.1	41	-42.6	-7.2
X-3453	BRCA	LFW527 + everolimus	103.04	27	45	-55.5	-7.5
X-3453	BRCA	LFW527 + everolimus	108.85	27.4	48	-53	-6.2
X-3453	BRCA	LFW527 + everolimus	90.33	26.7	52	-61	-8.6
X-3453	BRCA	LFW527 + everolimus	100.41	26.9	55	-56.7	-7.9
X-3453	BRCA	LFW527 + everolimus	98.75	27.9	59	-57.4	-4.5
X-3453	BRCA	LFW527 + everolimus	103.76	26.4	62	-55.2	-9.6
X-3453	BRCA	LFW527 + everolimus	99.07	25.2	66	-57.3	-13.7
X-3453	BRCA	LFW527 + everolimus	91.46	25.8	70	-60.5	-11.6
X-3453	BRCA	LFW527 + everolimus	117.95	24.8	74	-49.1	-15.1
X-3453	BRCA	LFW527 + everolimus	116.9	26	77	-49.6	-11
X-3453	BRCA	LFW527 + everolimus	122.15	27.5	80	-47.3	-5.8
X-3453	BRCA	LFW527 + everolimus	149.51	28.3	83	-35.5	-3.1
X-3453	BRCA	LFW527 + everolimus	91.82	28.8	87	-60.4	-1.4
X-3453	BRCA	LFW527 + everolimus	108.35	29.6	90	-53.3	1.4
X-3453	BRCA	LFW527 + everolimus	124.19	27.2	94	-46.4	-6.8
X-3453	BRCA	LFW527 + everolimus	119.69	27.3	97	-48.4	-6.5
X-3453	BRCA	LFW527 + everolimus	93.96	24.6	101	-59.5	-15.8
X-3453	BRCA	LFW527 + everolimus	135.79	26.9	104	-41.4	-7.9
X-3453	BRCA	LFW527 + everolimus	132.24	26.9	108	-43	-7.9
X-3453	BRCA	LFW527 + everolimus	127.33	27.2	111	-45.1	-6.8
X-3453	BRCA	LFW527 + everolimus	129.98	29	115	-43.9	-0.7
X-3453	BRCA	LFW527 + everolimus	130.57	28.7	118	-43.7	-1.7
X-3453	BRCA	LFW527 + everolimus	106.25	22.1	123	-54.2	-24.3
X-3468	BRCA	BGJ398	241.8	33.1	0	0	0
X-3468	BRCA	BGJ398	273.8	32	4	13.2	-3.3
X-3468	BRCA	BGJ398	354	32.8	7	46.4	-0.9
X-3468	BRCA	BGJ398	427.6	32.6	11	76.8	-1.5
X-3468	BRCA	BGJ398	623.3	33.1	14	157.8	0
X-3468	BRCA	BGJ398	645.4	32.4	18	166.9	-2.1
X-3468	BRCA	BGJ398	704.6	32.1	21	191.4	-3
X-3468	BRCA	BGJ398	777.8	32.6	25	221.7	-1.5
X-3468	BRCA	BGJ398	879.9	30.8	28	263.9	-6.9
X-3468	BRCA	BGJ398	964.1	30.6	32	298.7	-7.6
X-3468	BRCA	BGJ398	988.1	30	35	308.6	-9.4
X-3468	BRCA	BGJ398	1026.4	28.7	39	324.5	-13.3
X-3468	BRCA	BGJ398	1041.3	28.2	46	330.6	-14.8
X-3468	BRCA	BGJ398	1081.6	28.2	49	347.3	-14.8
X-3468	BRCA	BGJ398	1129.3	29.2	53	367	-11.8
X-3468	BRCA	BKM120	233.2	26.9	0	0	0
X-3468	BRCA	BKM120	234.8	28.5	4	0.7	5.9
X-3468	BRCA	BKM120	232.4	27.9	7	-0.3	3.7
X-3468	BRCA	BKM120	245	27.4	11	5.1	1.9
X-3468	BRCA	BKM120	240.1	27.1	14	3	0.7
X-3468	BRCA	BKM120	242.7	27.4	18	4.1	1.9
X-3468	BRCA	BKM120	244.3	28.5	21	4.8	5.9
X-3468	BRCA	BKM120	195.2	27.7	25	-16.3	3
X-3468	BRCA	BKM120	209.8	28.3	28	-10	5.2
X-3468	BRCA	BKM120	216	28.9	32	-7.4	7.4
X-3468	BRCA	BKM120	236.5	28.3	35	1.4	5.2
X-3468	BRCA	BKM120	241.5	29.4	39	3.6	9.3
X-3468	BRCA	BKM120	236.6	29.7	46	1.5	10.4
X-3468	BRCA	BKM120	240.3	29	49	3	7.8
X-3468	BRCA	BKM120	228.7	28.7	53	-1.9	6.7
X-3468	BRCA	BKM120	239	27.8	56	2.5	3.3
X-3468	BRCA	BKM120	240.3	28.5	60	3	5.9
X-3468	BRCA	BKM120	239.6	29	63	2.7	7.8
X-3468	BRCA	BKM120	241.1	29.4	67	3.4	9.3
X-3468	BRCA	BKM120	250.8	29.6	70	7.5	10
X-3468	BRCA	BKM120	202.9	29.9	74	-13	11.2
X-3468	BRCA	BKM120	197.4	30.6	77	-15.4	13.8
X-3468	BRCA	BKM120	205.7	29.3	80	-11.8	8.9
X-3468	BRCA	BKM120	211.8	30.7	84	-9.2	14.1
X-3468	BRCA	BKM120	209.6	30.8	87	-10.1	14.5
X-3468	BRCA	BKM120	204.4	30.7	90	-12.3	14.1
X-3468	BRCA	BKM120	202.4	29.4	94	-13.2	9.3
X-3468	BRCA	BYL719 + LEE011	201	34	0	0	0
X-3468	BRCA	BYL719 + LEE011	200.5	31.5	3	-0.2	-7.4
X-3468	BRCA	BYL719 + LEE011	179.5	30.5	6	-10.7	-10.3
X-3468	BRCA	BYL719 + LEE011	163.8	30.4	10	-18.5	-10.6
X-3468	BRCA	BYL719 + LEE011	137.9	24.8	14	-31.4	-27.1
X-3468	BRCA	BYL719 + LEE011	125.8	27.8	17	-37.4	-18.2
X-3468	BRCA	BYL719 + LEE011	121.9	29.7	21	-39.4	-12.6
X-3468	BRCA	BYL719 + LEE011	116.2	30.4	24	-42.2	-10.6
X-3468	BRCA	BYL719 + LEE011	116.8	33.4	28	-41.9	-1.8
X-3468	BRCA	BYL719 + LEE011	99.9	32.5	31	-50.3	-4.4
X-3468	BRCA	BYL719 + LEE011	96.4	31.7	35	-52	-6.8
X-3468	BRCA	BYL719 + LEE011	70.3	25.9	38	-65	-23.8
X-3468	BRCA	BYL719 + LJM716	214.2	26.5	0	0	0
X-3468	BRCA	BYL719 + LJM716	205.9	24.8	3	-3.9	-6.4
X-3468	BRCA	BYL719 + LJM716	159.3	26	7	-25.6	-1.9
X-3468	BRCA	BYL719 + LJM716	127.2	25	10	-40.6	-5.7
X-3468	BRCA	BYL719 + LJM716	125.9	26	14	-41.2	-1.9
X-3468	BRCA	BYL719 + LJM716	107.7	26.5	21	-49.7	0
X-3468	BRCA	BYL719 + LJM716	106.1	27.2	24	-50.5	2.6
X-3468	BRCA	BYL719 + LJM716	112.3	26.9	28	-47.6	1.5
X-3468	BRCA	BYL719 + LJM716	109.7	25.6	31	-48.8	-3.4
X-3468	BRCA	BYL719 + LJM716	108.5	26.1	35	-49.3	-1.5
X-3468	BRCA	BYL719 + LJM716	107.9	27.2	38	-49.6	2.6
X-3468	BRCA	BYL719 + LJM716	109.2	26.7	42	-49	0.8
X-3468	BRCA	BYL719 + LJM716	107.4	27	45	-49.9	1.9
X-3468	BRCA	BYL719 + LJM716	111.5	27.7	49	-47.9	4.5
X-3468	BRCA	BYL719 + LJM716	119.3	27.6	52	-44.3	4.2
X-3468	BRCA	BYL719 + LJM716	174.4	26.3	55	-18.6	-0.8
X-3468	BRCA	BYL719 + LJM716	175	26.8	59	-18.3	1.1
X-3468	BRCA	BYL719 + LJM716	186	26.9	62	-13.2	1.5
X-3468	BRCA	BYL719 + LJM716	194.3	27.3	65	-9.3	3
X-3468	BRCA	BYL719 + LJM716	167.7	26.8	69	-21.7	1.1
X-3468	BRCA	BYL719 + LJM716	192.7	27.6	72	-10	4.2
X-3468	BRCA	BYL719 + LJM716	194.2	28.1	77	-9.3	6
X-3468	BRCA	BYL719 + LJM716	197.1	27.4	80	-8	3.4
X-3468	BRCA	BYL719 + LJM716	203.2	27.4	84	-5.1	3.4
X-3468	BRCA	BYL719 + LJM716	204.8	28.3	87	-4.4	6.8
X-3468	BRCA	BYL719 + LJM716	212.3	28	91	-0.9	5.7
X-3468	BRCA	BYL719 + LJM716	206.7	27.6	94	-3.5	4.2
X-3468	BRCA	BYL719 + LJM716	217.9	27	98	1.7	1.9
X-3468	BRCA	BYL719 + LJM716	214.2	27.7	101	0	4.5
X-3468	BRCA	BYL719 + LJM716	187.8	27.9	105	-12.3	5.3
X-3468	BRCA	BYL719 + LJM716	213.7	27.7	108	-0.2	4.5
X-3468	BRCA	BYL719 + LJM716	244.4	28	112	14.1	5.7
X-3468	BRCA	BYL719 + LJM716	288.8	28.6	115	34.8	7.9
X-3468	BRCA	BYL719 + LJM716	302.9	27.8	118	41.4	4.9
X-3468	BRCA	BYL719 + LJM716	325.3	28.4	122	51.9	7.2
X-3468	BRCA	BYL719 + LJM716	327.7	28.2	126	53	6.4
X-3468	BRCA	BYL719 + LJM716	344.8	28.6	129	61	7.9
X-3468	BRCA	BYL719 + LJM716	347.8	28.4	133	62.4	7.2
X-3468	BRCA	BYL719 + LJM716	357.6	28.6	136	66.9	7.9
X-3468	BRCA	BYL719 + LJM716	356.4	27.7	140	66.4	4.5
X-3468	BRCA	BYL719 + LJM716	341.6	27.8	143	59.5	4.9
X-3468	BRCA	BYL719 + LJM716	363.4	27.9	147	69.7	5.3
X-3468	BRCA	BYL719	198.6	25.5	0	0	0
X-3468	BRCA	BYL719	194.5	25.3	4	-2.1	-0.8
X-3468	BRCA	BYL719	197.1	25	7	-0.8	-2
X-3468	BRCA	BYL719	193.7	25.5	11	-2.5	0
X-3468	BRCA	BYL719	196.7	25.3	14	-1	-0.8
X-3468	BRCA	BYL719	194	25.7	18	-2.3	0.8
X-3468	BRCA	BYL719	198.7	25.7	21	0.1	0.8
X-3468	BRCA	BYL719	199.2	25.3	25	0.3	-0.8
X-3468	BRCA	BYL719	198	24.8	28	-0.3	-2.7
X-3468	BRCA	BYL719	182.5	25.2	32	-8.1	-1.2
X-3468	BRCA	BYL719	182.5	25.5	39	-8.1	0
X-3468	BRCA	BYL719	190.9	25.6	42	-3.9	0.4
X-3468	BRCA	BYL719	200.5	25.6	46	1	0.4
X-3468	BRCA	BYL719	215.3	25.7	49	8.4	0.8
X-3468	BRCA	BYL719	230.4	25.3	53	16	-0.8
X-3468	BRCA	BYL719	238.7	25.7	56	20.2	0.8
X-3468	BRCA	BYL719	279.5	25.2	60	40.7	-1.2
X-3468	BRCA	BYL719	285.4	25.7	63	43.7	0.8
X-3468	BRCA	BYL719	298.7	26.1	67	50.4	2.4
X-3468	BRCA	BYL719	337.2	26.3	70	69.8	3.1
X-3468	BRCA	BYL719	441.9	25.1	73	122.5	-1.6
X-3468	BRCA	BYL719	452.1	25.5	77	127.6	0
X-3468	BRCA	BYL719	497.7	26	80	150.6	2
X-3468	BRCA	BYL719	507	26.2	83	155.3	2.7
X-3468	BRCA	BYL719	472.8	25.9	87	138.1	1.6
X-3468	BRCA	BYL719	482.8	25.4	90	143.1	-0.4
X-3468	BRCA	BYL719	501.2	26.2	95	152.4	2.7
X-3468	BRCA	BYL719	502.6	25.5	98	153.1	0
X-3468	BRCA	BYL719	510.3	23.4	102	156.9	-8.2
X-3468	BRCA	BYL719	520.9	24.3	105	162.3	-4.7
X-3468	BRCA	BYL719	506.8	24.8	109	155.2	-2.7
X-3468	BRCA	BYL719	508.3	26	112	155.9	2
X-3468	BRCA	BYL719	532.7	27.3	116	168.2	7.1
X-3468	BRCA	BYL719	552.3	26.6	119	178.1	4.3
X-3468	BRCA	BYL719	596.5	26.1	123	200.4	2.4
X-3468	BRCA	BYL719	639.2	26.7	126	221.9	4.7
X-3468	BRCA	BYL719	710.8	25.9	130	257.9	1.6
X-3468	BRCA	CGM097	210.2	24.4	0	0	0
X-3468	BRCA	CGM097	226.2	25.8	4	7.6	5.7
X-3468	BRCA	CGM097	242.2	26.3	7	15.2	7.8
X-3468	BRCA	CGM097	289.9	27.1	11	37.9	11.1
X-3468	BRCA	CGM097	346.6	28.1	14	64.9	15.2
X-3468	BRCA	CGM097	394	27.8	18	87.4	13.9
X-3468	BRCA	CGM097	479.6	27.6	21	128.2	13.1
X-3468	BRCA	CGM097	514.8	27.9	25	144.9	14.3
X-3468	BRCA	CGM097	551.7	28.4	28	162.5	16.4
X-3468	BRCA	CGM097	606	28.3	32	188.3	16
X-3468	BRCA	CGM097	845.4	28.3	39	302.2	16
X-3468	BRCA	CGM097	902.4	28.3	42	329.3	16
X-3468	BRCA	CGM097	1089.7	28.8	46	418.4	18
X-3468	BRCA	CLR457	211.1	25.8	0	0	0
X-3468	BRCA	CLR457	216.7	26.3	4	2.7	1.9
X-3468	BRCA	CLR457	173.4	26.2	7	-17.9	1.6
X-3468	BRCA	CLR457	156.4	26.9	11	-25.9	4.3
X-3468	BRCA	CLR457	153	26.6	14	-27.5	3.1
X-3468	BRCA	CLR457	140.7	27.9	18	-33.3	8.1
X-3468	BRCA	CLR457	118.4	27.4	21	-43.9	6.2
X-3468	BRCA	CLR457	119	26.7	25	-43.6	3.5
X-3468	BRCA	CLR457	117.6	26.9	28	-44.3	4.3
X-3468	BRCA	CLR457	110.6	26.9	32	-47.6	4.3
X-3468	BRCA	CLR457	119.9	27	39	-43.2	4.7
X-3468	BRCA	CLR457	126.6	27.4	42	-40	6.2
X-3468	BRCA	CLR457	129.1	27.5	46	-38.8	6.6
X-3468	BRCA	CLR457	142.1	27.4	49	-32.7	6.2
X-3468	BRCA	CLR457	168.6	26.8	53	-20.1	3.9
X-3468	BRCA	CLR457	175.4	27.3	56	-16.9	5.8
X-3468	BRCA	CLR457	188.4	27.7	60	-10.8	7.4
X-3468	BRCA	CLR457	196	28	63	-7.2	8.5
X-3468	BRCA	CLR457	209.9	28.6	67	-0.6	10.9
X-3468	BRCA	CLR457	238.1	27.4	70	12.8	6.2
X-3468	BRCA	CLR457	264.7	26.1	73	25.4	1.2
X-3468	BRCA	CLR457	316.3	27	77	49.8	4.7
X-3468	BRCA	CLR457	311	27	80	47.3	4.7
X-3468	BRCA	CLR457	321	26.9	83	52.1	4.3
X-3468	BRCA	CLR457	352.6	26.3	87	67	1.9
X-3468	BRCA	CLR457	355.8	26.6	90	68.5	3.1
X-3468	BRCA	CLR457	360	26.2	95	70.5	1.6
X-3468	BRCA	CLR457	367.7	25.9	98	74.2	0.4
X-3468	BRCA	CLR457	371	26.9	102	75.7	4.3
X-3468	BRCA	CLR457	374.8	26.3	105	77.5	1.9
X-3468	BRCA	CLR457	373.7	26.7	109	77	3.5
X-3468	BRCA	CLR457	380.4	25.6	112	80.2	-0.8
X-3468	BRCA	CLR457	390.3	25.9	116	84.9	0.4
X-3468	BRCA	HDM201	214.8	26.4	0	0	0
X-3468	BRCA	HDM201	218.7	26.3	4	1.8	-0.4
X-3468	BRCA	HDM201	217.8	26.4	7	1.4	0
X-3468	BRCA	HDM201	218.5	27.3	11	1.7	3.4
X-3468	BRCA	HDM201	214.2	27.5	14	-0.3	4.2
X-3468	BRCA	HDM201	223.2	28.1	18	3.9	6.4
X-3468	BRCA	HDM201	243.1	28.6	21	13.2	8.3
X-3468	BRCA	HDM201	251.3	27.2	25	17	3
X-3468	BRCA	HDM201	262.2	27.9	28	22.1	5.7
X-3468	BRCA	HDM201	274.6	28.3	32	27.8	7.2
X-3468	BRCA	HDM201	294.9	28.7	35	37.3	8.7
X-3468	BRCA	HDM201	299.2	28.1	39	39.3	6.4
X-3468	BRCA	HDM201	368.8	27.9	46	71.7	5.7
X-3468	BRCA	HDM201	423.2	27.8	49	97	5.3
X-3468	BRCA	HDM201	501.6	27.8	53	133.5	5.3
X-3468	BRCA	HDM201	624.1	28	56	190.5	6.1
X-3468	BRCA	HDM201	688.5	29.2	60	220.5	10.6
X-3468	BRCA	HDM201	704.7	28.4	63	228.1	7.6
X-3468	BRCA	HDM201	771.3	30.8	67	259.1	16.7
X-3468	BRCA	HDM201	903.2	30.5	70	320.5	15.5
X-3468	BRCA	HDM201	973.4	31.1	74	353.2	17.8
X-3468	BRCA	INC424	213.9	23	0	0	0
X-3468	BRCA	INC424	224.2	24	4	4.8	4.3
X-3468	BRCA	INC424	235.8	23.6	7	10.2	2.6
X-3468	BRCA	INC424	237.5	23.2	11	11	0.9
X-3468	BRCA	INC424	265.2	23.3	14	24	1.3
X-3468	BRCA	INC424	280.9	23.4	18	31.3	1.7
X-3468	BRCA	INC424	304.8	23.7	21	42.5	3
X-3468	BRCA	INC424	316.1	23.7	25	47.8	3
X-3468	BRCA	INC424	335.8	23.6	28	57	2.6
X-3468	BRCA	INC424	352	23.6	32	64.6	2.6
X-3468	BRCA	INC424	357	22.9	39	66.9	-0.4
X-3468	BRCA	INC424	365	23.2	42	70.6	0.9
X-3468	BRCA	INC424	372.9	22.3	46	74.3	-3
X-3468	BRCA	INC424	396.5	23.1	49	85.4	0.4
X-3468	BRCA	INC424	422.6	23.4	53	97.6	1.7
X-3468	BRCA	INC424	436.8	23.9	56	104.2	3.9
X-3468	BRCA	INC424	454.1	22.5	60	112.3	-2.2
X-3468	BRCA	INC424	464.6	22.6	63	117.2	-1.7
X-3468	BRCA	INC424	488.2	23	67	128.2	0
X-3468	BRCA	INC424	499.1	23.1	70	133.3	0.4
X-3468	BRCA	INC424	587.2	23.4	73	174.5	1.7
X-3468	BRCA	INC424	610.2	23.6	77	185.3	2.6
X-3468	BRCA	INC424	595.5	23.6	80	178.4	2.6
X-3468	BRCA	INC424	612.8	23.7	83	186.5	3
X-3468	BRCA	INC424	635.6	23	87	197.1	0
X-3468	BRCA	INC424	622	23	90	190.8	0
X-3468	BRCA	INC424	628.3	23.2	95	193.7	0.9
X-3468	BRCA	INC424	667.6	23.3	98	212.1	1.3
X-3468	BRCA	INC424	761.9	23.6	102	256.2	2.6
X-3468	BRCA	INC424	799	23.3	105	273.5	1.3
X-3468	BRCA	INC424	864.8	23.8	109	304.3	3.5
X-3468	BRCA	INC424	876.9	24.6	112	310	7
X-3468	BRCA	INC424	931	23.6	116	335.3	2.6
X-3468	BRCA	LEE011 + everolimus	149.4	27.5	0	0	0
X-3468	BRCA	LEE011 + everolimus	206.9	24.3	4	38.5	-11.6
X-3468	BRCA	LEE011 + everolimus	193.9	22.8	7	29.8	-17.1
X-3468	BRCA	LEE011 + everolimus	197.4	23.7	11	32.1	-13.8
X-3468	BRCA	LEE011 + everolimus	187.4	23.5	14	25.4	-14.5
X-3468	BRCA	LEE011 + everolimus	189.4	24.4	18	26.8	-11.3
X-3468	BRCA	LEE011 + everolimus	187.2	25.6	21	25.3	-6.9
X-3468	BRCA	LEE011 + everolimus	184.9	25.6	25	23.8	-6.9
X-3468	BRCA	LEE011 + everolimus	171.2	25.9	32	14.6	-5.8
X-3468	BRCA	LEE011 + everolimus	175.3	26	35	17.3	-5.5
X-3468	BRCA	LEE011 + everolimus	172.9	26	39	15.7	-5.5
X-3468	BRCA	LEE011 + everolimus	157	26	42	5.1	-5.5
X-3468	BRCA	LEE011 + everolimus	154.9	27.7	46	3.7	0.7
X-3468	BRCA	LEE011 + everolimus	155.7	26.6	49	4.2	-3.3
X-3468	BRCA	LEE011 + everolimus	155.6	27.6	53	4.1	0.4
X-3468	BRCA	LEE011 + everolimus	152.1	28	56	1.8	1.8
X-3468	BRCA	LEE011 + everolimus	154.3	28.2	60	3.3	2.5
X-3468	BRCA	LEE011 + everolimus	154.6	27.5	63	3.5	0
X-3468	BRCA	LEE011 + everolimus	145.4	27.7	66	-2.7	0.7
X-3468	BRCA	LEE011 + everolimus	149.4	27.5	70	0	0
X-3468	BRCA	LEE011 + everolimus	152.5	27.1	73	2.1	-1.5
X-3468	BRCA	LEE011 + everolimus	138.7	26.4	76	-7.2	-4
X-3468	BRCA	LEE011 + everolimus	130.7	27.4	80	-12.5	-0.4
X-3468	BRCA	LEE011 + everolimus	129.7	26.3	83	-13.2	-4.4
X-3468	BRCA	LEE011 + everolimus	131	25.3	88	-12.3	-8
X-3468	BRCA	LEE011 + everolimus	133.6	25.1	91	-10.6	-8.7
X-3468	BRCA	LEE011 + everolimus	125.7	27.2	95	-15.9	-1.1
X-3468	BRCA	LEE011 + everolimus	120.8	27	98	-19.1	-1.8
X-3468	BRCA	LEE011 + everolimus	121.5	27.2	102	-18.7	-1.1
X-3468	BRCA	LEE011 + everolimus	122.3	25.6	105	-18.1	-6.9
X-3468	BRCA	LEE011 + everolimus	119.8	26	109	-19.8	-5.5
X-3468	BRCA	LEE011 + everolimus	119.2	25.3	112	-20.2	-8
X-3468	BRCA	LEE011 + everolimus	119.5	26.2	116	-20	-4.7
X-3468	BRCA	LEE011 + everolimus	117.5	26.8	119	-21.4	-2.5
X-3468	BRCA	LEE011 + everolimus	117.6	26.7	123	-21.3	-2.9
X-3468	BRCA	LEE011 + everolimus	108.2	25.6	126	-27.6	-6.9
X-3468	BRCA	LEE011 + everolimus	104.6	24.1	129	-30	-12.4
X-3468	BRCA	LEE011 + everolimus	102.6	24	133	-31.3	-12.7
X-3468	BRCA	LEE011 + everolimus	106.3	23.8	137	-28.8	-13.5
X-3468	BRCA	LEE011	201	27	0	0	0
X-3468	BRCA	LEE011	207.7	27.9	4	3.3	3.3
X-3468	BRCA	LEE011	215.5	27.7	7	7.2	2.6
X-3468	BRCA	LEE011	223.6	26.9	11	11.2	-0.4
X-3468	BRCA	LEE011	229.3	28.1	14	14.1	4.1
X-3468	BRCA	LEE011	240.3	29	18	19.6	7.4
X-3468	BRCA	LEE011	267	29	21	32.8	7.4
X-3468	BRCA	LEE011	309.4	28.4	25	53.9	5.2
X-3468	BRCA	LEE011	348	28.9	32	73.1	7
X-3468	BRCA	LEE011	369.6	28.5	35	83.9	5.6
X-3468	BRCA	LEE011	412.9	28.8	39	105.4	6.7
X-3468	BRCA	LEE011	463.7	29	42	130.7	7.4
X-3468	BRCA	LEE011	531.2	30	46	164.3	11.1
X-3468	BRCA	LEE011	600.5	27.7	49	198.8	2.6
X-3468	BRCA	LEE011	646.1	30.7	53	221.4	13.7
X-3468	BRCA	LEE011	664.2	28.2	56	230.4	4.4
X-3468	BRCA	LEE011	670.6	29.6	60	233.6	9.6
X-3468	BRCA	LEE011	767.8	29.1	63	282	7.8
X-3468	BRCA	LEE011	992.3	30.1	66	393.7	11.5
X-3468	BRCA	LEE011	997.6	30.1	70	396.3	11.5
X-3468	BRCA	LEE011	1027.1	29.3	73	411	8.5
X-3468	BRCA	LFA102	207.4	28.4	0	0	0
X-3468	BRCA	LFA102	215.3	28.1	3	3.8	-1.1
X-3468	BRCA	LFA102	223.4	28.2	7	7.7	-0.7
X-3468	BRCA	LFA102	249.7	29.3	10	20.4	3.2
X-3468	BRCA	LFA102	280.3	29.5	14	35.1	3.9
X-3468	BRCA	LFA102	328.8	29	17	58.5	2.1
X-3468	BRCA	LFA102	391.4	29.3	21	88.7	3.2
X-3468	BRCA	LFA102	449.6	29.3	28	116.8	3.2
X-3468	BRCA	LFA102	543	29.9	31	161.8	5.3
X-3468	BRCA	LFA102	604.1	30.2	35	191.3	6.3
X-3468	BRCA	LFA102	747.5	30.5	38	260.4	7.4
X-3468	BRCA	LFA102	812.2	30.5	42	291.6	7.4
X-3468	BRCA	LFA102	841.5	30	45	305.7	5.6
X-3468	BRCA	LFA102	979.5	31.3	49	372.3	10.2
X-3468	BRCA	LFA102	1101.4	31.7	52	431.1	11.6
X-3468	BRCA	LFA102	1155.7	31.8	56	457.2	12
X-3468	BRCA	LJM716 + trastuzumab	229.9	25.4	0	0	0
X-3468	BRCA	LJM716 + trastuzumab	241.9	26	3	5.2	2.4
X-3468	BRCA	LJM716 + trastuzumab	247.8	26	7	7.8	2.4
X-3468	BRCA	LJM716 + trastuzumab	244.5	26.6	10	6.4	4.7
X-3468	BRCA	LJM716 + trastuzumab	218.3	26.6	21	-5	4.7
X-3468	BRCA	LJM716 + trastuzumab	222.3	26.8	24	-3.3	5.5
X-3468	BRCA	LJM716 + trastuzumab	234.5	26.7	28	2	5.1
X-3468	BRCA	LJM716 + trastuzumab	249.3	27.2	31	8.4	7.1
X-3468	BRCA	LJM716 + trastuzumab	294.6	26.4	35	28.1	3.9
X-3468	BRCA	LJM716 + trastuzumab	319.5	25.8	38	39	1.6
X-3468	BRCA	LJM716 + trastuzumab	326.7	26.4	42	42.1	3.9
X-3468	BRCA	LJM716 + trastuzumab	340.8	26.8	45	48.2	5.5
X-3468	BRCA	LJM716 + trastuzumab	338.6	27	49	47.3	6.3
X-3468	BRCA	LJM716 + trastuzumab	349.9	26.9	52	52.2	5.9
X-3468	BRCA	LJM716 + trastuzumab	411.1	26.2	55	78.8	3.1
X-3468	BRCA	LJM716 + trastuzumab	444.1	26.2	59	93.2	3.1
X-3468	BRCA	LJM716 + trastuzumab	542.1	26.5	62	135.8	4.3
X-3468	BRCA	LJM716 + trastuzumab	588.8	26.9	65	156.1	5.9
X-3468	BRCA	LJM716 + trastuzumab	546.4	26.9	69	137.7	5.9
X-3468	BRCA	LJM716 + trastuzumab	562.8	27.3	72	144.8	7.5
X-3468	BRCA	LJM716 + trastuzumab	628	28.8	77	173.2	13.4
X-3468	BRCA	LJM716 + trastuzumab	636.3	27.3	80	176.8	7.5
X-3468	BRCA	LJM716 + trastuzumab	740	27.2	84	221.9	7.1
X-3468	BRCA	LJM716 + trastuzumab	753.2	27	87	227.6	6.3
X-3468	BRCA	LJM716 + trastuzumab	907	28.6	91	294.5	12.6
X-3468	BRCA	LJM716	232.5	29.9	0	0	0
X-3468	BRCA	LJM716	237.2	28.5	3	2	-4.7
X-3468	BRCA	LJM716	227.6	27.6	7	-2.1	-7.7
X-3468	BRCA	LJM716	229.9	28.1	10	-1.1	-6
X-3468	BRCA	LJM716	232.3	27.5	14	-0.1	-8
X-3468	BRCA	LJM716	248.1	28	17	6.7	-6.4
X-3468	BRCA	LJM716	257.1	28.1	21	10.6	-6
X-3468	BRCA	LJM716	295.8	27.5	24	27.2	-8
X-3468	BRCA	LJM716	363.1	26.7	27	56.2	-10.7
X-3468	BRCA	LJM716	362.6	27.6	31	56	-7.7
X-3468	BRCA	LJM716	423.9	27.1	34	82.3	-9.4
X-3468	BRCA	LJM716	486.8	27.2	37	109.4	-9
X-3468	BRCA	LJM716	516.6	28.2	41	122.2	-5.7
X-3468	BRCA	LJM716	599.7	28.6	44	157.9	-4.3
X-3468	BRCA	LJM716	636.8	29	49	173.9	-3
X-3468	BRCA	LJM716	685.2	28.9	52	194.7	-3.3
X-3468	BRCA	LJM716	730.5	27.9	56	214.2	-6.7
X-3468	BRCA	LJM716	778.4	29.7	59	234.8	-0.7
X-3468	BRCA	LJM716	813.3	29.8	63	249.8	-0.3
X-3468	BRCA	LJM716	871.9	29.1	66	275	-2.7
X-3468	BRCA	LJM716	933.4	28.1	70	301.5	-6
X-3468	BRCA	LKA136	227.4	28.8	0	0	0
X-3468	BRCA	LKA136	230.4	29.2	4	1.3	1.4
X-3468	BRCA	LKA136	237.7	29.2	7	4.5	1.4
X-3468	BRCA	LKA136	242.5	29.8	11	6.6	3.5
X-3468	BRCA	LKA136	255.6	29.8	14	12.4	3.5
X-3468	BRCA	LKA136	278.3	29.4	18	22.4	2.1
X-3468	BRCA	LKA136	338.9	29.1	21	49	1
X-3468	BRCA	LKA136	381.7	29.2	25	67.9	1.4
X-3468	BRCA	LKA136	453.8	29.8	32	99.6	3.5
X-3468	BRCA	LKA136	488.3	30.1	35	114.7	4.5
X-3468	BRCA	LKA136	500.3	30	39	120	4.2
X-3468	BRCA	LKA136	578.3	30.4	42	154.3	5.6
X-3468	BRCA	LKA136	618.8	31	46	172.1	7.6
X-3468	BRCA	LKA136	681.6	30.6	49	199.7	6.2
X-3468	BRCA	LKA136	751.1	30.7	53	230.3	6.6
X-3468	BRCA	LKA136	833.8	31.1	56	266.7	8
X-3468	BRCA	LKA136	865.6	31.2	60	280.7	8.3
X-3468	BRCA	LKA136	941	31.4	63	313.8	9
X-3468	BRCA	LKA136	1249.9	30.2	66	449.6	4.9
X-3468	BRCA	LLM871	207.8	27.8	0	0	0
X-3468	BRCA	LLM871	216.6	27.3	3	4.2	-1.8
X-3468	BRCA	LLM871	216.7	27.4	7	4.3	-1.4
X-3468	BRCA	LLM871	234.3	27	10	12.8	-2.9
X-3468	BRCA	LLM871	243.1	26.6	14	17	-4.3
X-3468	BRCA	LLM871	247.7	27	17	19.2	-2.9
X-3468	BRCA	LLM871	264.8	26.8	21	27.4	-3.6
X-3468	BRCA	LLM871	329.4	27.1	31	58.5	-2.5
X-3468	BRCA	LLM871	358.8	27.4	35	72.7	-1.4
X-3468	BRCA	LLM871	395.3	27	38	90.2	-2.9
X-3468	BRCA	LLM871	399.2	27.5	42	92.1	-1.1
X-3468	BRCA	LLM871	404.6	27.4	45	94.7	-1.4
X-3468	BRCA	LLM871	421.9	28.1	49	103	1.1
X-3468	BRCA	LLM871	449.3	27.9	52	116.2	0.4
X-3468	BRCA	LLM871	466.8	27.8	56	124.6	0
X-3468	BRCA	LLM871	482.2	27.3	59	132.1	-1.8
X-3468	BRCA	LLM871	544.3	26.7	62	161.9	-4
X-3468	BRCA	LLM871	544.2	27.2	66	161.9	-2.2
X-3468	BRCA	LLM871	605.9	28.5	69	191.6	2.5
X-3468	BRCA	LLM871	635.7	27.5	72	205.9	-1.1
X-3468	BRCA	LLM871	652.7	27.9	76	214.1	0.4
X-3468	BRCA	LLM871	654.9	28.4	79	215.2	2.2
X-3468	BRCA	LLM871	678.2	29.2	84	226.4	5
X-3468	BRCA	LLM871	711	29.2	87	242.2	5
X-3468	BRCA	LLM871	762.5	29.2	91	266.9	5
X-3468	BRCA	LLM871	799	28.9	94	284.5	4
X-3468	BRCA	LLM871	831	29.2	98	299.9	5
X-3468	BRCA	LLM871	919.8	28.9	101	342.6	4
X-3468	BRCA	LLM871	1047.9	29	105	404.3	4.3
X-3468	BRCA	LLM871	1147.8	29.5	108	452.4	6.1
X-3468	BRCA	LLM871	1256.8	29	112	504.8	4.3
X-3468	BRCA	binimetinib	220.3	28.3	0	0	0
X-3468	BRCA	binimetinib	241.6	28.4	4	9.7	0.4
X-3468	BRCA	binimetinib	274.1	28.2	7	24.4	-0.4
X-3468	BRCA	binimetinib	282.1	28.9	11	28.1	2.1
X-3468	BRCA	binimetinib	300.7	29.4	14	36.5	3.9
X-3468	BRCA	binimetinib	336.4	28.5	18	52.7	0.7
X-3468	BRCA	binimetinib	351.4	29.2	21	59.5	3.2
X-3468	BRCA	binimetinib	373.5	27.4	25	69.5	-3.2
X-3468	BRCA	binimetinib	380.6	25.2	32	72.8	-11
X-3468	BRCA	binimetinib	391	25	35	77.5	-11.7
X-3468	BRCA	binimetinib	414.3	25.1	39	88.1	-11.3
X-3468	BRCA	binimetinib	438.6	26.1	42	99.1	-7.8
X-3468	BRCA	binimetinib	448.9	25	46	103.8	-11.7
X-3468	BRCA	binimetinib	459.9	25.3	49	108.8	-10.6
X-3468	BRCA	binimetinib	471.9	25.3	53	114.2	-10.6
X-3468	BRCA	binimetinib	481.8	23.6	56	118.7	-16.6
X-3468	BRCA	binimetinib	486.7	27.3	60	120.9	-3.5
X-3468	BRCA	binimetinib	539.9	28.1	63	145.1	-0.7
X-3468	BRCA	binimetinib	655.1	27.8	66	197.4	-1.8
X-3468	BRCA	binimetinib	733.6	28.3	70	233	0
X-3468	BRCA	binimetinib	764.2	28.4	73	246.9	0.4
X-3468	BRCA	binimetinib	776.7	28.1	76	252.6	-0.7
X-3468	BRCA	binimetinib	782	28.4	80	255	0.4
X-3468	BRCA	binimetinib	754.7	28.4	83	242.6	0.4
X-3468	BRCA	binimetinib	735.3	26.7	88	233.8	-5.7
X-3468	BRCA	binimetinib	639.9	26.2	91	190.5	-7.4
X-3468	BRCA	binimetinib	647.8	25.4	95	194.1	-10.2
X-3468	BRCA	paclitaxel	223.2	26.6	0	0	0
X-3468	BRCA	paclitaxel	230.8	26.7	3	3.4	0.4
X-3468	BRCA	paclitaxel	233.4	27.5	7	4.6	3.4
X-3468	BRCA	paclitaxel	236.9	26.9	10	6.1	1.1
X-3468	BRCA	paclitaxel	236.8	27.5	14	6.1	3.4
X-3468	BRCA	paclitaxel	243.5	27.9	17	9.1	4.9
X-3468	BRCA	paclitaxel	250.5	28.5	21	12.2	7.1
X-3468	BRCA	paclitaxel	218.1	27.7	28	-2.3	4.1
X-3468	BRCA	paclitaxel	222.3	27.4	31	-0.4	3
X-3468	BRCA	paclitaxel	209.5	28.6	35	-6.1	7.5
X-3468	BRCA	paclitaxel	221	28.1	38	-1	5.6
X-3468	BRCA	paclitaxel	215.9	29.2	42	-3.3	9.8
X-3468	BRCA	paclitaxel	218.8	28	45	-2	5.3
X-3468	BRCA	paclitaxel	218.4	29	49	-2.2	9
X-3468	BRCA	paclitaxel	218.6	29.5	52	-2.1	10.9
X-3468	BRCA	paclitaxel	215.6	29.6	59	-3.4	11.3
X-3468	BRCA	paclitaxel	192.3	29.2	62	-13.8	9.8
X-3468	BRCA	paclitaxel	166.2	28.1	66	-25.5	5.6
X-3468	BRCA	paclitaxel	178.7	28.4	69	-19.9	6.8
X-3468	BRCA	paclitaxel	150.6	28.3	72	-32.5	6.4
X-3468	BRCA	paclitaxel	145.2	29	76	-34.9	9
X-3468	BRCA	paclitaxel	151.9	28.7	79	-31.9	7.9
X-3468	BRCA	paclitaxel	156.4	29.8	84	-29.9	12
X-3468	BRCA	paclitaxel	156.3	29.7	87	-30	11.7
X-3468	BRCA	paclitaxel	174.9	29.8	91	-21.6	12
X-3468	BRCA	paclitaxel	175.1	29.3	94	-21.6	10.2
X-3468	BRCA	paclitaxel	186.6	29.2	98	-16.4	9.8
X-3468	BRCA	paclitaxel	167.7	28.3	101	-24.9	6.4
X-3468	BRCA	paclitaxel	181.9	29	105	-18.5	9
X-3468	BRCA	paclitaxel	229.4	29.5	108	2.8	10.9
X-3468	BRCA	paclitaxel	255.9	29.8	112	14.7	12
X-3468	BRCA	paclitaxel	293.9	29.3	115	31.7	10.2
X-3468	BRCA	paclitaxel	315.8	28.3	119	41.5	6.4
X-3468	BRCA	paclitaxel	350.4	28.1	122	57	5.6
X-3468	BRCA	paclitaxel	385.7	29.2	125	72.8	9.8
X-3468	BRCA	paclitaxel	424.6	29	129	90.2	9
X-3468	BRCA	paclitaxel	485.5	30.6	133	117.5	15
X-3468	BRCA	paclitaxel	570.9	30	136	155.8	12.8
X-3468	BRCA	paclitaxel	611.6	28.7	140	174	7.9
X-3468	BRCA	paclitaxel	619.2	29.3	143	177.4	10.2
X-3468	BRCA	paclitaxel	658.7	30	147	195.1	12.8
X-3468	BRCA	paclitaxel	703.4	29.7	150	215.1	11.7
X-3468	BRCA	paclitaxel	697.6	29.5	154	212.5	10.9
X-3468	BRCA	tamoxifen	201.9	28.3	0	0	0
X-3468	BRCA	tamoxifen	198.6	28	4	-1.6	-1.1
X-3468	BRCA	tamoxifen	204.8	27.4	7	1.4	-3.2
X-3468	BRCA	tamoxifen	204.8	28.1	11	1.4	-0.7
X-3468	BRCA	tamoxifen	222.8	28.2	14	10.4	-0.4
X-3468	BRCA	tamoxifen	247.9	29.9	18	22.8	5.7
X-3468	BRCA	tamoxifen	308.5	29.9	21	52.8	5.7
X-3468	BRCA	tamoxifen	348.3	29.8	25	72.5	5.3
X-3468	BRCA	tamoxifen	385.2	29	28	90.8	2.5
X-3468	BRCA	tamoxifen	432.1	29.3	32	114	3.5
X-3468	BRCA	tamoxifen	519.6	30.1	35	157.4	6.4
X-3468	BRCA	tamoxifen	593.2	29.9	39	193.8	5.7
X-3468	BRCA	tamoxifen	777	31	46	284.8	9.5
X-3468	BRCA	tamoxifen	1021.7	31.1	49	406	9.9
X-3468	BRCA	tamoxifen	1362.9	31.6	53	575	11.7
X-3468	BRCA	trastuzumab	222.5	27.9	0	0	0
X-3468	BRCA	trastuzumab	229.6	27.5	3	3.2	-1.4
X-3468	BRCA	trastuzumab	251.3	27.9	7	12.9	0
X-3468	BRCA	trastuzumab	311	27.7	10	39.8	-0.7
X-3468	BRCA	trastuzumab	352.7	28.1	14	58.5	0.7
X-3468	BRCA	trastuzumab	395.6	28.3	17	77.8	1.4
X-3468	BRCA	trastuzumab	450.2	27.7	21	102.3	-0.7
X-3468	BRCA	trastuzumab	509.3	28.6	28	128.9	2.5
X-3468	BRCA	trastuzumab	637.6	29.1	31	186.6	4.3
X-3468	BRCA	trastuzumab	728.3	29.6	35	227.3	6.1
X-3468	BRCA	trastuzumab	812.9	29.3	38	265.3	5
X-3468	BRCA	trastuzumab	915.9	29.6	42	311.6	6.1
X-3468	BRCA	trastuzumab	989.6	29.4	45	344.8	5.4
X-3468	BRCA	trastuzumab	1118	30.3	49	402.5	8.6
X-3468	BRCA	trastuzumab	1221	30.5	52	448.8	9.3
X-3468	BRCA	trastuzumab	1406.1	30.9	56	532	10.8
X-3468	BRCA	untreated	243	23.5	0	0	0
X-3468	BRCA	untreated	289.2	24.6	4	19	4.7
X-3468	BRCA	untreated	341.8	24.7	7	40.7	5.1
X-3468	BRCA	untreated	462.8	24.1	11	90.5	2.6
X-3468	BRCA	untreated	530.1	25	14	118.1	6.4
X-3468	BRCA	untreated	692.6	25.3	18	185	7.7
X-3468	BRCA	untreated	767.7	25.6	21	215.9	8.9
X-3468	BRCA	untreated	934.8	26.2	25	284.7	11.5
X-3468	BRCA	untreated	987.4	26.2	28	306.3	11.5
X-3468	BRCA	untreated	1061.3	26	32	336.7	10.6
X-3468	BRCA	untreated	1201.5	25.9	35	394.4	10.2
X-3468	BRCA	untreated	1414.7	26.2	39	482.2	11.5
X-3468	BRCA	LFW527 + everolimus	298.98	29	0	0	0
X-3468	BRCA	LFW527 + everolimus	297.97	27.7	4	-0.3	-4.5
X-3468	BRCA	LFW527 + everolimus	258.14	28	7	-13.7	-3.4
X-3468	BRCA	LFW527 + everolimus	234.3	26.9	11	-21.6	-7.2
X-3468	BRCA	LFW527 + everolimus	210.47	28.8	14	-29.6	-0.7
X-3468	BRCA	LFW527 + everolimus	186.73	28.1	17	-37.5	-3.1
X-3468	BRCA	LFW527 + everolimus	201.5	28.4	21	-32.6	-2.1
X-3468	BRCA	LFW527 + everolimus	199.31	27.8	25	-33.3	-4.1
X-3468	BRCA	LFW527 + everolimus	155.39	29.7	28	-48	2.4
X-3468	BRCA	LFW527 + everolimus	182.63	28.8	31	-38.9	-0.7
X-3468	BRCA	LFW527 + everolimus	196.71	28.1	36	-34.2	-3.1
X-3468	BRCA	LFW527 + everolimus	213.68	27.1	39	-28.5	-6.6
X-3468	BRCA	LFW527 + everolimus	198.68	29.4	42	-33.5	1.4
X-3468	BRCA	LFW527 + everolimus	187.76	27	45	-37.2	-6.9
X-3468	BRCA	LFW527 + everolimus	180.17	27.6	49	-39.7	-4.8
X-3468	BRCA	LFW527 + everolimus	153.18	26.8	52	-48.8	-7.6
X-3468	BRCA	LFW527 + everolimus	131.65	28	56	-56	-3.4
X-3468	BRCA	LFW527 + everolimus	137.28	27.3	59	-54.1	-5.9
X-3468	BRCA	LFW527 + everolimus	139.29	28.9	63	-53.4	-0.3
X-3468	BRCA	LFW527 + everolimus	133.64	27.4	66	-55.3	-5.5
X-3468	BRCA	LFW527 + everolimus	119.54	26.4	70	-60	-9
X-3468	BRCA	LFW527 + everolimus	134.92	27	73	-54.9	-6.9
X-3468	BRCA	LFW527 + everolimus	126.56	26.2	77	-57.7	-9.7
X-3468	BRCA	LFW527 + everolimus	98.14	26.5	81	-67.2	-8.6
X-3468	BRCA	LFW527 + everolimus	75.74	27	84	-74.7	-6.9
X-3468	BRCA	LFW527 + everolimus	82.85	27.1	88	-72.3	-6.6
X-3468	BRCA	LFW527 + everolimus	95.95	28	91	-67.9	-3.4
X-3468	BRCA	LFW527 + everolimus	98.65	28.1	94	-67	-3.1
X-3468	BRCA	LFW527 + everolimus	84.6	25.4	98	-71.7	-12.4
X-3468	BRCA	LFW527 + everolimus	76.54	27.7	101	-74.4	-4.5
X-3468	BRCA	LFW527 + everolimus	115.36	28.4	105	-61.4	-2.1
X-3468	BRCA	LFW527 + everolimus	127.7	27.6	108	-57.3	-4.8
X-3468	BRCA	LFW527 + everolimus	87	27.7	112	-70.9	-4.5
X-3468	BRCA	LFW527 + everolimus	119.89	26.2	115	-59.9	-9.7
X-3468	BRCA	LFW527 + everolimus	117.15	27.4	119	-60.8	-5.5
X-3468	BRCA	LFW527 + everolimus	120.04	25.7	123	-59.9	-11.4
X-3468	BRCA	LFW527 + everolimus	136.49	25.4	126	-54.3	-12.4
X-3483	CM	BKM120	221.2	24.6	0	0	0
X-3483	CM	BKM120	161.8	23.9	3	-26.8	-2.8
X-3483	CM	BKM120	207	23.8	6	-6.4	-3.3
X-3483	CM	BKM120	163.6	24.4	10	-26	-0.8
X-3483	CM	BKM120	174.6	24	13	-21	-2.4
X-3483	CM	BKM120	217.1	24	17	-1.8	-2.4
X-3483	CM	BKM120	217.8	25	20	-1.5	1.6
X-3483	CM	BKM120	254.8	24.6	24	15.2	0
X-3483	CM	BKM120	300.7	25.5	27	36	3.7
X-3483	CM	BKM120	266.6	25.3	32	20.6	2.8
X-3483	CM	BKM120	494.1	24.8	35	123.4	0.8
X-3483	CM	BKM120	583.2	24.4	38	163.7	-0.8
X-3483	CM	BKM120	586.6	23.7	41	165.3	-3.7
X-3483	CM	BKM120	730.3	23.1	45	230.2	-6.1
X-3483	CM	BKM120	640	NA	46	189.4	-6.1
X-3483	CM	BKM120 + encorafenib	192.5	21.8	0	0	0
X-3483	CM	BKM120 + encorafenib	62.9	21.4	3	-67.3	-1.8
X-3483	CM	BKM120 + encorafenib	14.7	21.8	7	-92.4	0
X-3483	CM	BKM120 + encorafenib	12.9	21.8	10	-93.3	0
X-3483	CM	BKM120 + encorafenib	9.5	22	14	-95.1	0.9
X-3483	CM	BKM120 + encorafenib	11.8	22.3	17	-93.9	2.3
X-3483	CM	BKM120 + encorafenib	13.5	22.4	21	-93	2.8
X-3483	CM	BKM120 + encorafenib	0	22.6	24	-100	3.7
X-3483	CM	BKM120 + encorafenib	0	23.3	29	-100	6.9
X-3483	CM	BKM120 + encorafenib	0	23.6	32	-100	8.3
X-3483	CM	BKM120 + encorafenib	0	23.8	35	-100	9.2
X-3483	CM	BKM120 + encorafenib	0	23.6	38	-100	8.3
X-3483	CM	BKM120 + encorafenib	0	23.7	42	-100	8.7
X-3483	CM	BKM120 + encorafenib	0	23.9	46	-100	9.6
X-3483	CM	BKM120 + encorafenib	0	24	51	-100	10.1
X-3483	CM	BKM120 + encorafenib	0	23.8	57	-100	9.2
X-3483	CM	BKM120 + encorafenib	0	24.2	63	-100	11
X-3483	CM	BKM120 + encorafenib	0	23	66	-100	5.5
X-3483	CM	BKM120 + encorafenib	0	22.5	71	-100	3.2
X-3483	CM	BKM120 + encorafenib	0	22.9	74	-100	5
X-3483	CM	BKM120 + encorafenib	0	22.3	78	-100	2.3
X-3483	CM	BKM120 + encorafenib	0	22.9	81	-100	5
X-3483	CM	BKM120 + encorafenib	0	23.4	86	-100	7.3
X-3483	CM	BKM120 + encorafenib	0	23.2	91	-100	6.4
X-3483	CM	BKM120 + encorafenib	0	22.7	94	-100	4.1
X-3483	CM	BKM120 + encorafenib	0	22.7	99	-100	4.1
X-3483	CM	BKM120 + encorafenib	0	23.7	106	-100	8.7
X-3483	CM	BKM120 + encorafenib	0	23	113	-100	5.5
X-3483	CM	BKM120 + encorafenib	0	24	120	-100	10.1
X-3483	CM	BKM120 + encorafenib	0	24.1	123	-100	10.6
X-3483	CM	BKM120 + encorafenib	0	23.4	127	-100	7.3
X-3483	CM	BKM120 + encorafenib	0	24	131	-100	10.1
X-3483	CM	BKM120 + encorafenib	0	24.4	137	-100	11.9
X-3483	CM	BKM120 + encorafenib	0	25.1	142	-100	15.1
X-3483	CM	BKM120 + encorafenib	0	25	151	-100	14.7
X-3483	CM	BKM120 + encorafenib	0	25.2	156	-100	15.6
X-3483	CM	BKM120 + encorafenib	0	24.8	163	-100	13.8
X-3483	CM	BKM120 + encorafenib	0	24.1	172	-100	10.6
X-3483	CM	BKM120 + encorafenib	0	24.7	179	-100	13.3
X-3483	CM	BKM120 + encorafenib	0	24.6	185	-100	12.8
X-3483	CM	BKM120 + encorafenib	0	24.5	193	-100	12.4
X-3483	CM	BKM120 + encorafenib	0	24.7	204	-100	13.3
X-3483	CM	BKM120 + encorafenib	0	25	214	-100	14.7
X-3483	CM	BKM120 + encorafenib	0	25.2	225	-100	15.6
X-3483	CM	BKM120 + encorafenib	0	25.4	232	-100	16.5
X-3483	CM	BKM120 + encorafenib	0	25.8	243	-100	18.3
X-3483	CM	BKM120 + encorafenib	0	27.2	251	-100	24.8
X-3483	CM	BKM120 + encorafenib	0	27	258	-100	23.9
X-3483	CM	BKM120 + encorafenib	0	26.5	266	-100	21.6
X-3483	CM	BKM120 + encorafenib	0	25.4	272	-100	16.5
X-3483	CM	CGM097	260.9	24.5	0	0	0
X-3483	CM	CGM097	300.8	25	3	15.3	2
X-3483	CM	CGM097	348.9	24.7	6	33.8	0.8
X-3483	CM	CGM097	292	24.5	9	11.9	0
X-3483	CM	CGM097	303.4	26	13	16.3	6.1
X-3483	CM	CGM097	169.9	25	16	-34.9	2
X-3483	CM	CGM097	135	25.4	20	-48.3	3.7
X-3483	CM	CGM097	106	26.8	23	-59.4	9.4
X-3483	CM	CGM097	90.8	26	27	-65.2	6.1
X-3483	CM	CGM097	43.5	27.2	30	-83.3	11
X-3483	CM	CGM097	50.6	27.2	35	-80.6	11
X-3483	CM	CGM097	34.4	26.7	38	-86.8	9
X-3483	CM	CGM097	24	26.5	41	-90.8	8.2
X-3483	CM	CGM097	35.2	26.6	44	-86.5	8.6
X-3483	CM	CGM097	36	27.4	48	-86.2	11.8
X-3483	CM	CGM097	0	27.9	52	-100	13.9
X-3483	CM	CGM097	0	28.7	57	-100	17.1
X-3483	CM	CGM097	0	28	63	-100	14.3
X-3483	CM	CGM097	0	29	69	-100	18.4
X-3483	CM	CGM097	0	28.9	72	-100	18
X-3483	CM	CGM097	0	29.7	77	-100	21.2
X-3483	CM	CGM097	0	29.6	80	-100	20.8
X-3483	CM	CGM097	0	29.7	84	-100	21.2
X-3483	CM	CGM097	0	29.7	87	-100	21.2
X-3483	CM	CGM097	0	29.5	92	-100	20.4
X-3483	CM	CGM097	0	29.5	97	-100	20.4
X-3483	CM	CGM097	0	29.8	105	-100	21.6
X-3483	CM	CGM097	0	29.6	112	-100	20.8
X-3483	CM	CGM097	0	30.1	119	-100	22.9
X-3483	CM	CGM097	0	31.1	126	-100	26.9
X-3483	CM	CGM097	0	30.7	129	-100	25.3
X-3483	CM	CGM097	0	29.6	133	-100	20.8
X-3483	CM	CGM097	0	30	137	-100	22.4
X-3483	CM	CGM097	0	30	143	-100	22.4
X-3483	CM	CGM097	0	30.4	148	-100	24.1
X-3483	CM	CGM097	0	30	150	-100	22.4
X-3483	CM	CGM097	0	31.2	157	-100	27.3
X-3483	CM	CGM097	0	29.9	162	-100	22
X-3483	CM	CGM097	0	31.2	169	-100	27.3
X-3483	CM	CGM097	0	25.3	178	-100	3.3
X-3483	CM	CGM097	0	26.7	181	-100	9
X-3483	CM	dacarbazine	206.7	23	0	0	0
X-3483	CM	dacarbazine	205.8	21.1	3	-0.4	-8.3
X-3483	CM	dacarbazine	159.5	23	7	-22.8	0
X-3483	CM	dacarbazine	124.2	20.6	10	-39.9	-10.4
X-3483	CM	dacarbazine	76.3	21.5	14	-63.1	-6.5
X-3483	CM	dacarbazine	42.5	21.1	17	-79.4	-8.3
X-3483	CM	dacarbazine	52.9	22.7	21	-74.4	-1.3
X-3483	CM	dacarbazine	50.6	21.8	24	-75.5	-5.2
X-3483	CM	dacarbazine	30	23.8	29	-85.5	3.5
X-3483	CM	dacarbazine	12.4	21.5	32	-94	-6.5
X-3483	CM	dacarbazine	18	23.5	35	-91.3	2.2
X-3483	CM	dacarbazine	25.4	21.8	38	-87.7	-5.2
X-3483	CM	dacarbazine	19.4	22.5	42	-90.6	-2.2
X-3483	CM	dacarbazine	18.9	22.4	46	-90.8	-2.6
X-3483	CM	dacarbazine	0	23.3	51	-100	1.3
X-3483	CM	dacarbazine	0	23.2	57	-100	0.9
X-3483	CM	dacarbazine	0	23.3	63	-100	1.3
X-3483	CM	dacarbazine	0	22.1	66	-100	-3.9
X-3483	CM	dacarbazine	0	21.9	71	-100	-4.8
X-3483	CM	dacarbazine	0	21.9	74	-100	-4.8
X-3483	CM	dacarbazine	0	21.3	78	-100	-7.4
X-3483	CM	dacarbazine	0	21	81	-100	-8.7
X-3483	CM	dacarbazine	0	20.5	86	-100	-10.9
X-3483	CM	dacarbazine	0	20.6	91	-100	-10.4
X-3483	CM	dacarbazine	0	19.8	94	-100	-13.9
X-3483	CM	dacarbazine	0	19.9	99	-100	-13.5
X-3483	CM	dacarbazine	0	19.7	106	-100	-14.3
X-3483	CM	dacarbazine	0	20.1	113	-100	-12.6
X-3483	CM	dacarbazine	0	18.7	116	-100	-18.7
X-3483	CM	dacarbazine	0	18.8	117	-100	-18.3
X-3483	CM	dacarbazine	0	19	119	-100	-17.4
X-3483	CM	LDE225	254	27	0	0	0
X-3483	CM	LDE225	427.4	26	3	68.3	-3.7
X-3483	CM	LDE225	423.7	24.5	6	66.8	-9.3
X-3483	CM	LDE225	738	21.8	10	190.6	-19.3
X-3483	CM	LDK378	213.8	22.5	0	0	0
X-3483	CM	LDK378	302.6	21.9	3	41.6	-2.7
X-3483	CM	LDK378	440.1	21.6	6	105.9	-4
X-3483	CM	LDK378	770.1	21.7	10	260.3	-3.6
X-3483	CM	LDK378	998.5	20.3	13	367.1	-9.8
X-3483	CM	LEE011	213.2	28.3	0	0	0
X-3483	CM	LEE011	240.3	27.2	3	12.7	-3.9
X-3483	CM	LEE011	230.9	27.9	6	8.3	-1.4
X-3483	CM	LEE011	261.6	27.9	10	22.7	-1.4
X-3483	CM	LEE011	179.6	27.8	13	-15.8	-1.8
X-3483	CM	LEE011	221.8	27.5	17	4.1	-2.8
X-3483	CM	LEE011	166.7	27.8	20	-21.8	-1.8
X-3483	CM	LEE011	154.2	28	24	-27.7	-1.1
X-3483	CM	LEE011	77.3	27.7	27	-63.8	-2.1
X-3483	CM	LEE011	90.9	28.9	32	-57.3	2.1
X-3483	CM	LEE011	68.9	28.9	35	-67.7	2.1
X-3483	CM	LEE011	72	28.7	38	-66.2	1.4
X-3483	CM	LEE011	77.1	29.1	41	-63.8	2.8
X-3483	CM	LEE011	64.8	28.8	45	-69.6	1.8
X-3483	CM	LEE011	43.6	28.6	49	-79.6	1.1
X-3483	CM	LEE011	31.5	29.5	54	-85.2	4.2
X-3483	CM	LEE011	26	28.8	60	-87.8	1.8
X-3483	CM	LEE011	20.7	29.3	66	-90.3	3.5
X-3483	CM	LEE011	31.8	28.4	69	-85.1	0.4
X-3483	CM	LEE011	0	30	74	-100	6
X-3483	CM	LEE011	0	29.5	77	-100	4.2
X-3483	CM	LEE011	0	28.7	81	-100	1.4
X-3483	CM	LEE011	0	30.2	84	-100	6.7
X-3483	CM	LEE011	0	29.6	89	-100	4.6
X-3483	CM	LEE011	0	30.4	94	-100	7.4
X-3483	CM	LEE011	0	30	97	-100	6
X-3483	CM	LEE011	0	29.9	102	-100	5.7
X-3483	CM	LEE011	0	28.7	109	-100	1.4
X-3483	CM	LEE011	0	29.7	116	-100	4.9
X-3483	CM	LEE011	0	29.4	123	-100	3.9
X-3483	CM	LEE011	0	29.6	126	-100	4.6
X-3483	CM	LEE011	0	29.4	130	-100	3.9
X-3483	CM	LEE011	0	29.3	134	-100	3.5
X-3483	CM	LEE011	0	30.4	140	-100	7.4
X-3483	CM	LEE011	0	29.5	145	-100	4.2
X-3483	CM	LEE011	0	30.3	154	-100	7.1
X-3483	CM	LEE011	0	30.2	159	-100	6.7
X-3483	CM	LEE011	0	30.4	166	-100	7.4
X-3483	CM	LEE011	0	29.9	175	-100	5.7
X-3483	CM	LEE011	0	30.7	182	-100	8.5
X-3483	CM	LEE011 + encorafenib	191.8	22.2	0	0	0
X-3483	CM	LEE011 + encorafenib	87.5	21.7	3	-54.4	-2.3
X-3483	CM	LEE011 + encorafenib	18	22	7	-90.6	-0.9
X-3483	CM	LEE011 + encorafenib	6.9	21.2	10	-96.4	-4.5
X-3483	CM	LEE011 + encorafenib	4	21.4	14	-97.9	-3.6
X-3483	CM	LEE011 + encorafenib	4	21.7	17	-97.9	-2.3
X-3483	CM	LEE011 + encorafenib	0	21.3	21	-100	-4.1
X-3483	CM	LEE011 + encorafenib	0	21.9	24	-100	-1.4
X-3483	CM	LEE011 + encorafenib	0	22.9	29	-100	3.2
X-3483	CM	LEE011 + encorafenib	0	22.3	32	-100	0.5
X-3483	CM	LEE011 + encorafenib	0	22.8	35	-100	2.7
X-3483	CM	LEE011 + encorafenib	0	22.2	38	-100	0
X-3483	CM	LEE011 + encorafenib	0	23.1	42	-100	4.1
X-3483	CM	LEE011 + encorafenib	0	21.5	46	-100	-3.2
X-3483	CM	LEE011 + encorafenib	0	23.2	51	-100	4.5
X-3483	CM	LEE011 + encorafenib	0	22.6	57	-100	1.8
X-3483	CM	LEE011 + encorafenib	0	23.2	63	-100	4.5
X-3483	CM	LEE011 + encorafenib	0	22.4	66	-100	0.9
X-3483	CM	LEE011 + encorafenib	0	23.1	71	-100	4.1
X-3483	CM	LEE011 + encorafenib	0	22.7	74	-100	2.3
X-3483	CM	LEE011 + encorafenib	0	23.3	78	-100	5
X-3483	CM	LEE011 + encorafenib	0	22.3	81	-100	0.5
X-3483	CM	LEE011 + encorafenib	0	23.1	86	-100	4.1
X-3483	CM	LEE011 + encorafenib	0	23.3	91	-100	5
X-3483	CM	LEE011 + encorafenib	0	23.1	94	-100	4.1
X-3483	CM	LEE011 + encorafenib	0	23.7	99	-100	6.8
X-3483	CM	LEE011 + encorafenib	0	23.6	106	-100	6.3
X-3483	CM	LEE011 + encorafenib	0	23.6	113	-100	6.3
X-3483	CM	LEE011 + encorafenib	0	23.3	120	-100	5
X-3483	CM	LEE011 + encorafenib	0	23.6	123	-100	6.3
X-3483	CM	LEE011 + encorafenib	0	22.9	127	-100	3.2
X-3483	CM	LEE011 + encorafenib	0	23.3	131	-100	5
X-3483	CM	LEE011 + encorafenib	0	23.5	137	-100	5.9
X-3483	CM	LEE011 + encorafenib	0	23.7	142	-100	6.8
X-3483	CM	LEE011 + encorafenib	0	24.3	151	-100	9.5
X-3483	CM	LEE011 + encorafenib	0	24.4	156	-100	9.9
X-3483	CM	LEE011 + encorafenib	0	24.6	163	-100	10.8
X-3483	CM	LEE011 + encorafenib	0	24.5	172	-100	10.4
X-3483	CM	LEE011 + encorafenib	0	25.1	179	-100	13.1
X-3483	CM	LEE011 + encorafenib	0	25	185	-100	12.6
X-3483	CM	LEE011 + encorafenib	0	24.7	193	-100	11.3
X-3483	CM	LEE011 + encorafenib	0	24.3	204	-100	9.5
X-3483	CM	LEE011 + encorafenib	0	23.8	214	-100	7.2
X-3483	CM	LEE011 + encorafenib	0	24	225	-100	8.1
X-3483	CM	LEE011 + encorafenib	0	23.8	232	-100	7.2
X-3483	CM	LEE011 + encorafenib	0	23.8	243	-100	7.2
X-3483	CM	LEE011 + encorafenib	0	25.6	251	-100	15.3
X-3483	CM	LEE011 + encorafenib	0	25.7	258	-100	15.8
X-3483	CM	LEE011 + encorafenib	0	24.5	266	-100	10.4
X-3483	CM	LEE011 + encorafenib	0	25	272	-100	12.6
X-3483	CM	WNT974	197.2	22	0	0	0
X-3483	CM	WNT974	255.5	22.4	3	29.6	1.8
X-3483	CM	WNT974	347.9	22.7	6	76.4	3.2
X-3483	CM	WNT974	611.1	22.8	10	209.9	3.6
X-3483	CM	WNT974	960.7	21.6	13	387.2	-1.8
X-3483	CM	LGW813	198.7	22.7	0	0	0
X-3483	CM	LGW813	384.2	22	6	93.4	-3.1
X-3483	CM	LGW813	525.4	22.1	10	164.5	-2.6
X-3483	CM	LGW813	649	22.4	13	226.7	-1.3
X-3483	CM	encorafenib	254.8	22.7	0	0	0
X-3483	CM	encorafenib	137.7	23.2	3	-46	2.2
X-3483	CM	encorafenib	61.2	23.3	6	-76	2.6
X-3483	CM	encorafenib	33.7	22.8	9	-86.8	0.4
X-3483	CM	encorafenib	30.3	23.6	13	-88.1	4
X-3483	CM	encorafenib	12.1	23.4	16	-95.3	3.1
X-3483	CM	encorafenib	15.3	23.1	20	-94	1.8
X-3483	CM	encorafenib	10.8	23	23	-95.8	1.3
X-3483	CM	encorafenib	0	22.8	27	-100	0.4
X-3483	CM	encorafenib	0	23.1	30	-100	1.8
X-3483	CM	encorafenib	0	24	35	-100	5.7
X-3483	CM	encorafenib	0	24.3	38	-100	7
X-3483	CM	encorafenib	0	24.2	41	-100	6.6
X-3483	CM	encorafenib	0	24	44	-100	5.7
X-3483	CM	encorafenib	0	24.7	48	-100	8.8
X-3483	CM	encorafenib	0	24.6	52	-100	8.4
X-3483	CM	encorafenib	0	25.1	57	-100	10.6
X-3483	CM	encorafenib	0	24.6	63	-100	8.4
X-3483	CM	encorafenib	0	24.6	69	-100	8.4
X-3483	CM	encorafenib	0	24.1	72	-100	6.2
X-3483	CM	encorafenib	0	24.3	77	-100	7
X-3483	CM	encorafenib	0	24.1	80	-100	6.2
X-3483	CM	encorafenib	0	23.6	84	-100	4
X-3483	CM	encorafenib	0	23.6	87	-100	4
X-3483	CM	encorafenib	0	22.9	92	-100	0.9
X-3483	CM	encorafenib	0	23.5	97	-100	3.5
X-3483	CM	encorafenib	0	23.9	105	-100	5.3
X-3483	CM	encorafenib	0	23.9	112	-100	5.3
X-3483	CM	encorafenib	0	24.5	119	-100	7.9
X-3483	CM	encorafenib	24	25.3	126	-90.6	11.5
X-3483	CM	encorafenib	35.4	25.3	129	-86.1	11.5
X-3483	CM	encorafenib	77.1	24.7	133	-69.8	8.8
X-3483	CM	encorafenib	154.2	25.2	137	-39.5	11
X-3483	CM	encorafenib	355	23.3	143	39.3	2.6
X-3483	CM	encorafenib	412.5	21.1	148	61.9	-7
X-3483	CM	encorafenib	634.8	19.4	150	149.1	-14.5
X-3483	CM	encorafenib + binimetinib	197.6	21.7	0	0	0
X-3483	CM	encorafenib + binimetinib	73.2	22.3	3	-62.9	2.8
X-3483	CM	encorafenib + binimetinib	23.3	22	7	-88.2	1.4
X-3483	CM	encorafenib + binimetinib	16.3	21	10	-91.7	-3.2
X-3483	CM	encorafenib + binimetinib	19.5	20.7	14	-90.2	-4.6
X-3483	CM	encorafenib + binimetinib	10	21	17	-94.9	-3.2
X-3483	CM	encorafenib + binimetinib	9.5	21.4	21	-95.2	-1.4
X-3483	CM	encorafenib + binimetinib	7.8	21.9	24	-96.1	0.9
X-3483	CM	encorafenib + binimetinib	0	22.5	29	-100	3.7
X-3483	CM	encorafenib + binimetinib	0	21.8	32	-100	0.5
X-3483	CM	encorafenib + binimetinib	0	21.1	35	-100	-2.8
X-3483	CM	encorafenib + binimetinib	0	20.6	38	-100	-5.1
X-3483	CM	encorafenib + binimetinib	0	20.9	42	-100	-3.7
X-3483	CM	encorafenib + binimetinib	0	21.5	46	-100	-0.9
X-3483	CM	encorafenib + binimetinib	0	22.2	51	-100	2.3
X-3483	CM	encorafenib + binimetinib	0	22.7	57	-100	4.6
X-3483	CM	encorafenib + binimetinib	0	22.8	63	-100	5.1
X-3483	CM	encorafenib + binimetinib	0	22.1	66	-100	1.8
X-3483	CM	encorafenib + binimetinib	0	22.6	71	-100	4.1
X-3483	CM	encorafenib + binimetinib	0	22.3	74	-100	2.8
X-3483	CM	encorafenib + binimetinib	0	22	78	-100	1.4
X-3483	CM	encorafenib + binimetinib	0	21.9	81	-100	0.9
X-3483	CM	encorafenib + binimetinib	0	22.1	86	-100	1.8
X-3483	CM	encorafenib + binimetinib	0	22.5	91	-100	3.7
X-3483	CM	encorafenib + binimetinib	0	22.6	94	-100	4.1
X-3483	CM	encorafenib + binimetinib	0	21.8	99	-100	0.5
X-3483	CM	encorafenib + binimetinib	0	21.6	106	-100	-0.5
X-3483	CM	encorafenib + binimetinib	0	22.3	113	-100	2.8
X-3483	CM	encorafenib + binimetinib	0	23.3	120	-100	7.4
X-3483	CM	encorafenib + binimetinib	0	22.2	123	-100	2.3
X-3483	CM	encorafenib + binimetinib	0	21.8	127	-100	0.5
X-3483	CM	encorafenib + binimetinib	0	22.5	131	-100	3.7
X-3483	CM	encorafenib + binimetinib	0	21.7	137	-100	0
X-3483	CM	encorafenib + binimetinib	0	22.3	142	-100	2.8
X-3483	CM	encorafenib + binimetinib	0	23.3	151	-100	7.4
X-3483	CM	encorafenib + binimetinib	0	23.2	156	-100	6.9
X-3483	CM	encorafenib + binimetinib	0	22.4	163	-100	3.2
X-3483	CM	encorafenib + binimetinib	0	22.2	172	-100	2.3
X-3483	CM	encorafenib + binimetinib	0	21.9	179	-100	0.9
X-3483	CM	encorafenib + binimetinib	0	22	185	-100	1.4
X-3483	CM	encorafenib + binimetinib	0	22.1	193	-100	1.8
X-3483	CM	encorafenib + binimetinib	0	21.6	204	-100	-0.5
X-3483	CM	encorafenib + binimetinib	0	21.3	214	-100	-1.8
X-3483	CM	encorafenib + binimetinib	0	22	225	-100	1.4
X-3483	CM	encorafenib + binimetinib	0	22.4	232	-100	3.2
X-3483	CM	encorafenib + binimetinib	0	21.6	243	-100	-0.5
X-3483	CM	encorafenib + binimetinib	0	22.3	251	-100	2.8
X-3483	CM	encorafenib + binimetinib	0	22.1	258	-100	1.8
X-3483	CM	encorafenib + binimetinib	0	21	266	-100	-3.2
X-3483	CM	encorafenib + binimetinib	0	20.6	272	-100	-5.1
X-3483	CM	binimetinib	232.8	24.7	0	0	0
X-3483	CM	binimetinib	213.2	24.1	3	-8.4	-2.4
X-3483	CM	binimetinib	213.2	23.6	6	-8.4	-4.5
X-3483	CM	binimetinib	249	24.4	10	7	-1.2
X-3483	CM	binimetinib	213.6	23.5	13	-8.2	-4.9
X-3483	CM	binimetinib	262.1	23.7	17	12.6	-4
X-3483	CM	binimetinib	224.3	24	20	-3.6	-2.8
X-3483	CM	binimetinib	224.5	23	24	-3.5	-6.9
X-3483	CM	binimetinib	212.5	24.1	27	-8.7	-2.4
X-3483	CM	binimetinib	202.6	24.5	32	-12.9	-0.8
X-3483	CM	binimetinib	194.4	24.3	35	-16.5	-1.6
X-3483	CM	binimetinib	173.4	24.6	38	-25.5	-0.4
X-3483	CM	binimetinib	220.5	24.4	41	-5.3	-1.2
X-3483	CM	binimetinib	165.5	24.4	45	-28.9	-1.2
X-3483	CM	binimetinib	186.2	24.4	49	-20	-1.2
X-3483	CM	binimetinib	195.3	25.1	54	-16.1	1.6
X-3483	CM	binimetinib	207.4	24.8	60	-10.9	0.4
X-3483	CM	binimetinib	241.1	24.7	66	3.6	0
X-3483	CM	binimetinib	198.8	24.5	69	-14.6	-0.8
X-3483	CM	binimetinib	137.5	25.1	74	-40.9	1.6
X-3483	CM	binimetinib	174.2	25.2	77	-25.1	2
X-3483	CM	binimetinib	189.6	24.7	81	-18.5	0
X-3483	CM	binimetinib	160.7	24.9	84	-30.9	0.8
X-3483	CM	binimetinib	185.1	24.9	89	-20.5	0.8
X-3483	CM	binimetinib	178.6	25.4	94	-23.3	2.8
X-3483	CM	binimetinib	208.3	25.4	97	-10.5	2.8
X-3483	CM	binimetinib	235.5	25	102	1.2	1.2
X-3483	CM	binimetinib	241.9	24.7	109	3.9	0
X-3483	CM	binimetinib	272	25.7	116	16.9	4
X-3483	CM	binimetinib	265.2	25.3	123	14	2.4
X-3483	CM	binimetinib	292	25.2	126	25.4	2
X-3483	CM	binimetinib	306.9	23.9	130	31.9	-3.2
X-3483	CM	binimetinib	340.2	26.2	134	46.2	6.1
X-3483	CM	binimetinib	343.9	26.4	140	47.8	6.9
X-3483	CM	binimetinib	352	25.8	145	51.2	4.5
X-3483	CM	binimetinib	352	25	154	51.2	1.2
X-3483	CM	binimetinib	313.6	26.8	159	34.7	8.5
X-3483	CM	binimetinib	419.5	26.2	166	80.2	6.1
X-3483	CM	binimetinib	451.3	25.6	175	93.9	3.6
X-3483	CM	binimetinib	450.6	25.8	182	93.6	4.5
X-3483	CM	TAS266	213.2	22.6	0	0	0
X-3483	CM	TAS266	21.4	22.9	3	-90	1.3
X-3483	CM	TAS266	0	23.4	6	-100	3.5
X-3483	CM	TAS266	0	22.3	9	-100	-1.3
X-3483	CM	TAS266	0	23.3	13	-100	3.1
X-3483	CM	TAS266	0	22.7	16	-100	0.4
X-3483	CM	TAS266	0	22.7	20	-100	0.4
X-3483	CM	TAS266	0	23	23	-100	1.8
X-3483	CM	TAS266	0	23	27	-100	1.8
X-3483	CM	TAS266	0	22.9	30	-100	1.3
X-3483	CM	TAS266	0	23.7	35	-100	4.9
X-3483	CM	TAS266	0	24.1	38	-100	6.6
X-3483	CM	TAS266	0	24.4	41	-100	8
X-3483	CM	TAS266	0	23.6	44	-100	4.4
X-3483	CM	TAS266	0	24.7	48	-100	9.3
X-3483	CM	TAS266	0	24.6	52	-100	8.8
X-3483	CM	TAS266	0	25.2	57	-100	11.5
X-3483	CM	TAS266	0	24.5	63	-100	8.4
X-3483	CM	TAS266	0	25.7	69	-100	13.7
X-3483	CM	TAS266	0	25.3	72	-100	11.9
X-3483	CM	TAS266	0	25.1	77	-100	11.1
X-3483	CM	TAS266	0	25.9	80	-100	14.6
X-3483	CM	TAS266	0	24.7	84	-100	9.3
X-3483	CM	TAS266	0	25.6	87	-100	13.3
X-3483	CM	TAS266	0	26.4	92	-100	16.8
X-3483	CM	TAS266	0	26.7	97	-100	18.1
X-3483	CM	TAS266	0	26.2	105	-100	15.9
X-3483	CM	TAS266	0	25.5	112	-100	12.8
X-3483	CM	TAS266	0	25.6	119	-100	13.3
X-3483	CM	TAS266	0	25.9	126	-100	14.6
X-3483	CM	TAS266	0	26.1	129	-100	15.5
X-3483	CM	TAS266	0	25.4	133	-100	12.3
X-3483	CM	TAS266	0	26	137	-100	15
X-3483	CM	TAS266	0	26.4	143	-100	16.8
X-3483	CM	TAS266	0	26.8	148	-100	18.6
X-3483	CM	TAS266	0	26.7	150	-100	18.1
X-3483	CM	TAS266	0	26.4	157	-100	16.8
X-3483	CM	TAS266	0	26.6	162	-100	17.7
X-3483	CM	TAS266	0	27.8	169	-100	23
X-3483	CM	TAS266	0	27.2	178	-100	20.4
X-3483	CM	TAS266	0	27.2	181	-100	20.4
X-3483	CM	untreated	230	21.5	0	0	0
X-3483	CM	untreated	354	21.6	3	53.9	0.6
X-3483	CM	untreated	479.9	20.8	6	108.6	-3.2
X-3483	CM	untreated	600.3	20	9	161	-6.9
X-3483	CM	untreated	921.6	18.7	13	300.7	-12.9
X-3483	CM	untreated	1617	18	16	603.1	-16.2
X-3486	CM	BKM120	208.3	22.7	0	0	0
X-3486	CM	BKM120	240.1	21.3	3	15.3	-6.2
X-3486	CM	BKM120	264.6	20.5	6	27.1	-9.7
X-3486	CM	BKM120	279.9	20.3	8	34.4	-10.6
X-3486	CM	BKM120	309.1	19	12	48.4	-16.3
X-3486	CM	BKM120 + encorafenib	207.4	23.2	0	0	0
X-3486	CM	BKM120 + encorafenib	248.8	23	3	20	-0.9
X-3486	CM	BKM120 + encorafenib	374	22.8	5	80.3	-1.7
X-3486	CM	BKM120 + encorafenib	401.2	21.9	9	93.5	-5.6
X-3486	CM	BKM120 + encorafenib	481.6	21.9	12	132.2	-5.6
X-3486	CM	BKM120 + encorafenib	541	20.3	16	160.9	-12.5
X-3486	CM	BKM120 + encorafenib	545	19.5	20	162.8	-15.9
X-3486	CM	BKM120 + encorafenib	535	19.7	23	158	-15.1
X-3486	CM	CGM097	186.3	20.3	0	0	0
X-3486	CM	CGM097	320	19.3	4	71.8	-4.9
X-3486	CM	CGM097	339.2	18.3	7	82.1	-9.9
X-3486	CM	CGM097	465.8	18.8	10	150	-7.4
X-3486	CM	CGM097	522.5	17	12	180.4	-16.3
X-3486	CM	dacarbazine	193.6	24.4	0	0	0
X-3486	CM	dacarbazine	220.3	23	4	13.8	-5.7
X-3486	CM	dacarbazine	262.8	21.2	7	35.8	-13.1
X-3486	CM	dacarbazine	372	20.5	11	92.2	-16
X-3486	CM	dacarbazine	352	19.3	15	81.9	-20.9
X-3486	CM	LDE225	213.6	21.5	0	0	0
X-3486	CM	LDE225	246.4	20.1	3	15.4	-6.5
X-3486	CM	LDE225	366.5	19.2	6	71.6	-10.7
X-3486	CM	LDE225	415.4	19.2	8	94.5	-10.7
X-3486	CM	LDE225	567.1	17.9	11	165.5	-16.7
X-3486	CM	LDE225	588.1	17.5	12	175.4	-18.6
X-3486	CM	LDK378	214.2	20.9	0	0	0
X-3486	CM	LDK378	238.5	20	3	11.3	-4.3
X-3486	CM	LDK378	400	19.8	6	86.7	-5.3
X-3486	CM	LDK378	460.8	19.6	8	115.1	-6.2
X-3486	CM	LDK378	557.7	20	11	160.3	-4.3
X-3486	CM	LDK378	601.8	20.1	12	180.9	-3.8
X-3486	CM	LDK378	640.7	19.8	15	199	-5.3
X-3486	CM	LDK378	757.8	19.4	19	253.7	-7.2
X-3486	CM	LDK378	931.5	19	21	334.8	-9.1
X-3486	CM	LEE011	195.2	24.8	0	0	0
X-3486	CM	LEE011	226.2	23.6	4	15.9	-4.8
X-3486	CM	LEE011	244.5	22.2	7	25.3	-10.5
X-3486	CM	LEE011	258.5	22.6	9	32.4	-8.9
X-3486	CM	LEE011	248.8	22.8	13	27.5	-8.1
X-3486	CM	LEE011	277.3	24.4	16	42.1	-1.6
X-3486	CM	LEE011	245	24	20	25.5	-3.2
X-3486	CM	LEE011	245	25.8	24	25.5	4
X-3486	CM	LEE011	226.2	26.6	27	15.9	7.3
X-3486	CM	LEE011	223.8	26.3	32	14.6	6
X-3486	CM	LEE011	212.7	26.9	34	9	8.5
X-3486	CM	LEE011	208.1	26.4	38	6.6	6.5
X-3486	CM	LEE011	214.3	26.4	43	9.8	6.5
X-3486	CM	LEE011	254	26.5	45	30.1	6.9
X-3486	CM	LEE011	252.1	26.2	49	29.1	5.6
X-3486	CM	LEE011	245	25.7	54	25.5	3.6
X-3486	CM	LEE011	273.8	26.5	58	40.3	6.9
X-3486	CM	LEE011	304.2	26.6	64	55.8	7.3
X-3486	CM	LEE011	356.4	26.5	68	82.6	6.9
X-3486	CM	LEE011 + encorafenib	213.2	20.6	0	0	0
X-3486	CM	LEE011 + encorafenib	350.4	20.5	3	64.4	-0.5
X-3486	CM	LEE011 + encorafenib	371.7	20	5	74.4	-2.9
X-3486	CM	LEE011 + encorafenib	414.3	20.2	9	94.4	-1.9
X-3486	CM	LEE011 + encorafenib	330.7	20.4	12	55.1	-1
X-3486	CM	LEE011 + encorafenib	310	20.5	16	45.4	-0.5
X-3486	CM	LEE011 + encorafenib	304	19.6	20	42.6	-4.9
X-3486	CM	LEE011 + encorafenib	271.5	20.3	23	27.4	-1.5
X-3486	CM	LEE011 + encorafenib	264.4	19.2	28	24	-6.8
X-3486	CM	LEE011 + encorafenib	261.6	20.7	30	22.7	0.5
X-3486	CM	LEE011 + encorafenib	258.8	20.6	34	21.4	0
X-3486	CM	LEE011 + encorafenib	289	20.6	39	35.6	0
X-3486	CM	LEE011 + encorafenib	322.8	20.6	41	51.4	0
X-3486	CM	LEE011 + encorafenib	361.3	20.9	45	69.5	1.5
X-3486	CM	LEE011 + encorafenib	352.8	21.8	50	65.5	5.8
X-3486	CM	LEE011 + encorafenib	369.8	20.4	55	73.5	-1
X-3486	CM	LEE011 + encorafenib	398.8	21	61	87.1	1.9
X-3486	CM	LEE011 + encorafenib	407.9	20.2	70	91.4	-1.9
X-3486	CM	LEE011 + encorafenib	433.4	20.4	75	103.3	-1
X-3486	CM	LEE011 + encorafenib	443	21.8	81	107.8	5.8
X-3486	CM	LEE011 + encorafenib	447.2	22.2	86	109.8	7.8
X-3486	CM	WNT974	213.6	20.4	0	0	0
X-3486	CM	WNT974	302.7	20	3	41.7	-2
X-3486	CM	WNT974	425.3	19.5	6	99.1	-4.4
X-3486	CM	WNT974	501	19.2	8	134.6	-5.9
X-3486	CM	WNT974	640.8	17.5	11	200	-14.2
X-3486	CM	WNT974	658.9	17	12	208.6	-16.7
X-3486	CM	LGW813	195.3	22.5	0	0	0
X-3486	CM	LGW813	224.5	22.3	3	14.9	-0.9
X-3486	CM	LGW813	334.7	21.9	6	71.4	-2.7
X-3486	CM	LGW813	345.9	21.4	8	77.2	-4.9
X-3486	CM	LGW813	385.3	21.2	12	97.3	-5.8
X-3486	CM	LGW813	516.7	21.5	15	164.6	-4.4
X-3486	CM	LGW813	568.3	20.6	19	191.1	-8.4
X-3486	CM	LGW813	568.3	20	21	191.1	-11.1
X-3486	CM	encorafenib	219	23.9	0	0	0
X-3486	CM	encorafenib	508.1	22.5	4	132	-5.9
X-3486	CM	encorafenib	740.7	23	7	238.1	-3.8
X-3486	CM	encorafenib	957.6	22.5	9	337.2	-5.9
X-3486	CM	encorafenib	1650.5	21.5	13	653.5	-10
X-3486	CM	encorafenib	1833.8	21.6	16	737.2	-9.6
X-3486	CM	encorafenib + binimetinib	213.6	23.6	0	0	0
X-3486	CM	encorafenib + binimetinib	249.4	23.5	3	16.8	-0.4
X-3486	CM	encorafenib + binimetinib	230.6	23.3	5	8	-1.3
X-3486	CM	encorafenib + binimetinib	275.2	22.2	9	28.9	-5.9
X-3486	CM	encorafenib + binimetinib	302.7	21.6	12	41.7	-8.5
X-3486	CM	encorafenib + binimetinib	334.1	20.3	16	56.5	-14
X-3486	CM	encorafenib + binimetinib	414.2	20.6	20	93.9	-12.7
X-3486	CM	encorafenib + binimetinib	406.8	19.8	23	90.5	-16.1
X-3486	CM	binimetinib	220.3	24.2	0	0	0
X-3486	CM	binimetinib	246.4	22.6	3	11.8	-6.6
X-3486	CM	binimetinib	268.6	22.7	6	21.9	-6.2
X-3486	CM	binimetinib	231.8	23.4	8	5.2	-3.3
X-3486	CM	binimetinib	220.5	24.2	12	0.1	0
X-3486	CM	binimetinib	237.7	23.8	15	7.9	-1.7
X-3486	CM	binimetinib	220.5	24.3	19	0.1	0.4
X-3486	CM	binimetinib	226.6	23.9	23	2.8	-1.2
X-3486	CM	binimetinib	228.9	23.9	26	3.9	-1.2
X-3486	CM	binimetinib	217.8	24	31	-1.1	-0.8
X-3486	CM	binimetinib	211.3	24.9	33	-4.1	2.9
X-3486	CM	binimetinib	237.9	24.3	37	8	0.4
X-3486	CM	binimetinib	262.2	24.8	42	19	2.5
X-3486	CM	binimetinib	287.3	23.4	44	30.4	-3.3
X-3486	CM	binimetinib	326.3	23.7	48	48.1	-2.1
X-3486	CM	binimetinib	337.5	24.6	53	53.2	1.7
X-3486	CM	binimetinib	383.6	18.8	55	74.1	-22.3
X-3486	CM	TAS266	215.1	21.4	0	0	0
X-3486	CM	TAS266	327.7	21.2	5	52.3	-0.9
X-3486	CM	TAS266	470.7	20.8	8	118.8	-2.8
X-3486	CM	TAS266	480.8	21.8	11	123.5	1.9
X-3486	CM	TAS266	605.5	21	13	181.5	-1.9
X-3486	CM	TAS266	804.1	20	17	273.7	-6.5
X-3486	CM	TAS266	888.7	19.8	20	313.1	-7.5
X-3486	CM	untreated	207.8	23.4	0	0	0
X-3486	CM	untreated	272	23.6	3	30.9	0.9
X-3486	CM	untreated	473.8	24.6	7	128	5.1
X-3486	CM	untreated	649	23	10	212.3	-1.7
X-3486	CM	untreated	818.6	24	13	293.9	2.6
X-3486	CM	untreated	949.9	23.3	15	357	-0.4
X-3486	CM	untreated	1224	21.8	19	488.9	-6.8
X-3486	CM	untreated	1467.7	21.7	22	606.2	-7.3
X-3503	CM	BKM120	190.8	23.1	0	0	0
X-3503	CM	BKM120	207.1	24	1	8.6	3.9
X-3503	CM	BKM120	232.8	23	5	22	-0.4
X-3503	CM	BKM120	257.1	23.1	9	34.8	0
X-3503	CM	BKM120	248.8	22.3	12	30.4	-3.5
X-3503	CM	BKM120	389.8	23.3	16	104.3	0.9
X-3503	CM	BKM120	250.5	22.5	18	31.3	-2.6
X-3503	CM	BKM120	270	23	23	41.5	-0.4
X-3503	CM	BKM120	270	22.2	26	41.5	-3.9
X-3503	CM	BKM120	300.9	23.2	28	57.7	0.4
X-3503	CM	BKM120 + encorafenib	185	23	0	0	0
X-3503	CM	BKM120 + encorafenib	200	23.6	2	8.1	2.6
X-3503	CM	BKM120 + encorafenib	214.2	23.5	6	15.8	2.2
X-3503	CM	BKM120 + encorafenib	196	23.9	9	6	3.9
X-3503	CM	BKM120 + encorafenib	196	24.5	13	6	6.5
X-3503	CM	BKM120 + encorafenib	191.9	24	15	3.8	4.3
X-3503	CM	BKM120 + encorafenib	129.6	24.5	20	-29.9	6.5
X-3503	CM	BKM120 + encorafenib	187.3	24.3	23	1.2	5.7
X-3503	CM	BKM120 + encorafenib	179.6	24.5	25	-2.9	6.5
X-3503	CM	BKM120 + encorafenib	165.5	24.6	29	-10.5	7
X-3503	CM	BKM120 + encorafenib	151.6	24.6	32	-18.1	7
X-3503	CM	BKM120 + encorafenib	183.3	24.8	36	-0.9	7.8
X-3503	CM	BKM120 + encorafenib	203.4	25.1	40	9.9	9.1
X-3503	CM	BKM120 + encorafenib	215.1	24.4	43	16.3	6.1
X-3503	CM	BKM120 + encorafenib	222.9	24.7	50	20.5	7.4
X-3503	CM	BKM120 + encorafenib	288	25.3	56	55.7	10
X-3503	CM	BKM120 + encorafenib	288	25.7	60	55.7	11.7
X-3503	CM	BKM120 + encorafenib	332.4	25.7	70	79.7	11.7
X-3503	CM	BKM120 + encorafenib	364.4	25.5	76	97	10.9
X-3503	CM	BKM120 + encorafenib	393.3	25.8	83	112.6	12.2
X-3503	CM	BKM120 + encorafenib	514.6	26	90	178.2	13
X-3503	CM	BKM120 + encorafenib	504.8	25.5	96	172.9	10.9
X-3503	CM	CGM097	196	24.6	0	0	0
X-3503	CM	CGM097	200.9	25.2	2	2.5	2.4
X-3503	CM	CGM097	204.2	25.1	5	4.2	2
X-3503	CM	CGM097	219.3	26.7	9	11.9	8.5
X-3503	CM	CGM097	244.7	26.9	13	24.8	9.3
X-3503	CM	CGM097	346.8	26.9	16	76.9	9.3
X-3503	CM	CGM097	335.2	28	20	71	13.8
X-3503	CM	CGM097	351.3	27	22	79.2	9.8
X-3503	CM	dacarbazine	190.4	27.4	0	0	0
X-3503	CM	dacarbazine	204.7	26.1	3	7.5	-4.7
X-3503	CM	dacarbazine	229.2	26.5	7	20.3	-3.3
X-3503	CM	dacarbazine	309.3	26.1	9	62.4	-4.7
X-3503	CM	dacarbazine	288	27	14	51.2	-1.5
X-3503	CM	dacarbazine	254.6	25.8	17	33.7	-5.8
X-3503	CM	dacarbazine	296.5	27.6	19	55.7	0.7
X-3503	CM	dacarbazine	342.9	26.1	23	80.1	-4.7
X-3503	CM	dacarbazine	385.8	27.1	26	102.6	-1.1
X-3503	CM	dacarbazine	416.3	27.1	30	118.6	-1.1
X-3503	CM	LDE225	200.9	22.3	0	0	0
X-3503	CM	LDE225	230.6	23.1	4	14.8	3.6
X-3503	CM	LDE225	271.5	22.8	7	35.1	2.2
X-3503	CM	LDE225	266.8	21.8	10	32.8	-2.2
X-3503	CM	LDE225	285.9	22	14	42.3	-1.3
X-3503	CM	LDE225	322.8	21.2	16	60.7	-4.9
X-3503	CM	LDE225	301.2	21.2	21	49.9	-4.9
X-3503	CM	LDE225	293.5	20.8	24	46.1	-6.7
X-3503	CM	LDE225	361.7	21.5	26	80	-3.6
X-3503	CM	LDK378	204.8	23.4	0	0	0
X-3503	CM	LDK378	207.4	22.4	2	1.3	-4.3
X-3503	CM	LDK378	277.7	23	6	35.6	-1.7
X-3503	CM	LDK378	326.1	22.8	9	59.3	-2.6
X-3503	CM	LDK378	350.4	23.6	13	71.1	0.9
X-3503	CM	LDK378	393.6	23.2	15	92.2	-0.9
X-3503	CM	LDK378	469.3	23.4	20	129.2	0
X-3503	CM	LDK378	530.7	23.1	23	159.2	-1.3
X-3503	CM	LDK378	686.1	24	25	235	2.6
X-3503	CM	LEE011	191.9	25.5	0	0	0
X-3503	CM	LEE011	232.7	25.3	2	21.3	-0.8
X-3503	CM	LEE011	234.5	25.8	5	22.2	1.2
X-3503	CM	LEE011	264.4	27.4	9	37.8	7.5
X-3503	CM	LEE011	278.7	27	13	45.2	5.9
X-3503	CM	LEE011	274.4	26	16	43	2
X-3503	CM	LEE011	283	26.6	20	47.5	4.3
X-3503	CM	LEE011	313.6	26.8	22	63.4	5.1
X-3503	CM	LEE011	275.6	26.3	27	43.6	3.1
X-3503	CM	LEE011	286.9	25.7	30	49.5	0.8
X-3503	CM	LEE011	309	26.8	32	61	5.1
X-3503	CM	LEE011 + encorafenib	190.4	25.2	0	0	0
X-3503	CM	LEE011 + encorafenib	192.8	25.5	3	1.2	1.2
X-3503	CM	LEE011 + encorafenib	196	26.2	7	2.9	4
X-3503	CM	LEE011 + encorafenib	239.1	26	9	25.5	3.2
X-3503	CM	LEE011 + encorafenib	195.2	26.4	14	2.5	4.8
X-3503	CM	LEE011 + encorafenib	204.7	25.9	17	7.5	2.8
X-3503	CM	LEE011 + encorafenib	226.5	27	19	18.9	7.1
X-3503	CM	LEE011 + encorafenib	217.7	27.5	23	14.3	9.1
X-3503	CM	LEE011 + encorafenib	238.2	27.1	26	25.1	7.5
X-3503	CM	LEE011 + encorafenib	275.7	27.1	30	44.8	7.5
X-3503	CM	LEE011 + encorafenib	347.9	28	34	82.7	11.1
X-3503	CM	LEE011 + encorafenib	344.5	28.6	37	80.9	13.5
X-3503	CM	LEE011 + encorafenib	365.1	29	44	91.7	15.1
X-3503	CM	LEE011 + encorafenib	437.4	29.2	50	129.7	15.9
X-3503	CM	LEE011 + encorafenib	465.8	29.3	53	144.6	16.3
X-3503	CM	WNT974	190.8	23.5	0	0	0
X-3503	CM	WNT974	205.8	22.8	2	7.9	-3
X-3503	CM	WNT974	239.1	23.5	6	25.3	0
X-3503	CM	WNT974	254.1	22.8	9	33.2	-3
X-3503	CM	WNT974	309.3	23.2	13	62.1	-1.3
X-3503	CM	WNT974	320.3	22.8	15	67.9	-3
X-3503	CM	WNT974	362.4	23.1	20	90	-1.7
X-3503	CM	WNT974	382.9	22.5	23	100.7	-4.3
X-3503	CM	WNT974	414.2	23.6	25	117.1	0.4
X-3503	CM	LGW813	196.6	23.2	0	0	0
X-3503	CM	LGW813	239.7	23.8	3	21.9	2.6
X-3503	CM	LGW813	303.1	23.3	7	54.2	0.4
X-3503	CM	LGW813	347.6	22.9	10	76.8	-1.3
X-3503	CM	LGW813	426.5	24	14	116.9	3.4
X-3503	CM	LGW813	455.8	23.5	16	131.8	1.3
X-3503	CM	LGW813	516.1	25	21	162.5	7.8
X-3503	CM	encorafenib	196	25.2	0	0	0
X-3503	CM	encorafenib	203.4	24.5	2	3.7	-2.8
X-3503	CM	encorafenib	208.3	24.7	5	6.2	-2
X-3503	CM	encorafenib	245.1	25	9	25.1	-0.8
X-3503	CM	encorafenib	344.5	25.1	13	75.7	-0.4
X-3503	CM	encorafenib	393.7	25.6	16	100.8	1.6
X-3503	CM	encorafenib	423.4	25.8	20	116	2.4
X-3503	CM	encorafenib	443.8	26.2	22	126.4	4
X-3503	CM	encorafenib + binimetinib	197	21.2	0	0	0
X-3503	CM	encorafenib + binimetinib	208.1	21.7	3	5.6	2.4
X-3503	CM	encorafenib + binimetinib	199.8	22.3	7	1.4	5.2
X-3503	CM	encorafenib + binimetinib	243.4	22	9	23.5	3.8
X-3503	CM	encorafenib + binimetinib	200.9	22.2	14	2	4.7
X-3503	CM	encorafenib + binimetinib	226.5	22	17	15	3.8
X-3503	CM	encorafenib + binimetinib	291.2	22.3	19	47.8	5.2
X-3503	CM	encorafenib + binimetinib	300.8	22.2	23	52.7	4.7
X-3503	CM	encorafenib + binimetinib	307.2	22.6	26	55.9	6.6
X-3503	CM	encorafenib + binimetinib	314.9	22.3	30	59.9	5.2
X-3503	CM	encorafenib + binimetinib	352	22.5	34	78.7	6.1
X-3503	CM	encorafenib + binimetinib	368	23.2	37	86.8	9.4
X-3503	CM	encorafenib + binimetinib	422.7	22.5	44	114.6	6.1
X-3503	CM	encorafenib + binimetinib	518.4	22.8	50	163.2	7.5
X-3503	CM	encorafenib + binimetinib	613.7	23.5	53	211.5	10.8
X-3503	CM	binimetinib	204.8	22.9	0	0	0
X-3503	CM	binimetinib	231.8	22.1	3	13.2	-3.5
X-3503	CM	binimetinib	270	22.2	7	31.9	-3.1
X-3503	CM	binimetinib	334.6	22.5	11	63.4	-1.7
X-3503	CM	binimetinib	342.9	22.5	14	67.5	-1.7
X-3503	CM	binimetinib	346.3	22.5	18	69.1	-1.7
X-3503	CM	binimetinib	363.4	22.2	20	77.5	-3.1
X-3503	CM	binimetinib	410.5	22.5	25	100.5	-1.7
X-3503	CM	TAS266	210.8	23.6	0	0	0
X-3503	CM	TAS266	239.7	23.6	2	13.7	0
X-3503	CM	TAS266	259	23.7	5	22.8	0.4
X-3503	CM	TAS266	258.6	24.3	9	22.6	3
X-3503	CM	TAS266	372.6	24.7	13	76.7	4.7
X-3503	CM	TAS266	431.7	24.2	16	104.7	2.5
X-3503	CM	TAS266	523.5	25.3	20	148.3	7.2
X-3503	CM	TAS266	551.4	24.8	22	161.5	5.1
X-3503	CM	untreated	199.1	22	0	0	0
X-3503	CM	untreated	246.4	23.1	4	23.8	5
X-3503	CM	untreated	375.5	23	7	88.6	4.5
X-3503	CM	untreated	461.7	23.9	10	131.9	8.6
X-3503	CM	untreated	561.1	24.9	14	181.8	13.2
X-3503	CM	untreated	847	25.2	18	325.4	14.5
X-3503	CM	untreated	1130.4	24.6	21	467.7	11.8
X-3503	CM	untreated	1436.5	25.5	25	621.4	15.9
X-3671	CRC	5FU	203.3	26.2	0	0	0
X-3671	CRC	5FU	226.3	25.2	4	11.3	-3.8
X-3671	CRC	5FU	278.4	26.9	7	36.9	2.7
X-3671	CRC	5FU	430.1	25.9	10	111.6	-1.1
X-3671	CRC	5FU	552	26.2	14	171.5	0
X-3671	CRC	5FU	555.6	26.3	17	173.3	0.4
X-3671	CRC	5FU	670.8	26.2	21	230	0
X-3671	CRC	5FU	922.8	25.4	24	353.9	-3.1
X-3671	CRC	5FU	1282.8	25.8	28	531	-1.5
X-3671	CRC	5FU	1358.4	24.5	33	568.2	-6.5
X-3671	CRC	5FU	1592.9	25.2	36	683.5	-3.8
X-3671	CRC	cetuximab	197.7	27	0	0	0
X-3671	CRC	cetuximab	194.1	28	4	-1.8	3.7
X-3671	CRC	cetuximab	190.7	29.2	7	-3.5	8.1
X-3671	CRC	cetuximab	101.1	28.4	10	-48.9	5.2
X-3671	CRC	cetuximab	48.7	29.7	14	-75.4	10
X-3671	CRC	cetuximab	33.7	28.3	17	-83	4.8
X-3671	CRC	cetuximab	34.3	29.1	21	-82.7	7.8
X-3671	CRC	cetuximab	28.3	29.3	24	-85.7	8.5
X-3671	CRC	cetuximab	17.2	29.3	28	-91.3	8.5
X-3671	CRC	cetuximab	12.2	28.9	33	-93.8	7
X-3671	CRC	cetuximab	8.3	28.3	36	-95.8	4.8
X-3671	CRC	cetuximab	1.9	28.5	39	-99	5.6
X-3671	CRC	cetuximab	1.3	28.8	42	-99.3	6.7
X-3671	CRC	cetuximab	1.2	27.5	46	-99.4	1.9
X-3671	CRC	cetuximab	0.4	27.5	49	-99.8	1.9
X-3671	CRC	cetuximab	2.6	28.2	52	-98.7	4.4
X-3671	CRC	cetuximab	0.9	28.5	57	-99.5	5.6
X-3671	CRC	cetuximab	0.5	28.6	60	-99.7	5.9
X-3671	CRC	cetuximab	0	28.6	63	-100	5.9
X-3671	CRC	cetuximab	0	28	66	-100	3.7
X-3671	CRC	cetuximab	0	28.3	70	-100	4.8
X-3671	CRC	cetuximab	0.5	27.8	73	-99.7	3
X-3671	CRC	cetuximab	0.4	28.9	77	-99.8	7
X-3671	CRC	cetuximab	0	29	80	-100	7.4
X-3671	CRC	cetuximab	0	28.8	84	-100	6.7
X-3671	CRC	cetuximab	0	28.5	87	-100	5.6
X-3671	CRC	cetuximab	0	28.7	91	-100	6.3
X-3671	CRC	cetuximab	0	28.7	94	-100	6.3
X-3671	CRC	cetuximab	0	28.5	98	-100	5.6
X-3671	CRC	cetuximab	0	28.8	101	-100	6.7
X-3671	CRC	cetuximab	0	29.2	105	-100	8.1
X-3671	CRC	cetuximab	0	28.8	108	-100	6.7
X-3671	CRC	binimetinib	271.6	24.2	0	0	0
X-3671	CRC	binimetinib	271.6	22.3	3	0	-7.9
X-3671	CRC	binimetinib	271.1	24.7	6	-0.2	2.1
X-3671	CRC	binimetinib	278.2	21.9	9	2.4	-9.5
X-3671	CRC	binimetinib	275.4	25.5	13	1.4	5.4
X-3671	CRC	binimetinib	280.6	22.8	16	3.3	-5.8
X-3671	CRC	binimetinib	283.7	26.6	20	4.5	9.9
X-3671	CRC	binimetinib	285.6	24	23	5.2	-0.8
X-3671	CRC	binimetinib	344.2	22.6	27	26.7	-6.6
X-3671	CRC	binimetinib	496.1	25.3	30	82.7	4.5
X-3671	CRC	binimetinib	586	22.8	34	115.8	-5.8
X-3671	CRC	binimetinib	532.3	22.7	37	96	-6.2
X-3671	CRC	binimetinib	571.1	23.9	41	110.3	-1.2
X-3671	CRC	binimetinib	659.7	23.6	44	142.9	-2.5
X-3671	CRC	binimetinib	646.7	23.4	48	138.1	-3.3
X-3671	CRC	binimetinib	654.8	24.8	51	141.1	2.5
X-3671	CRC	binimetinib	647.7	25.3	55	138.5	4.5
X-3671	CRC	binimetinib	657.6	24.2	59	142.1	0
X-3671	CRC	binimetinib	636	23.1	62	134.2	-4.5
X-3671	CRC	binimetinib	656.1	23.5	65	141.6	-2.9
X-3671	CRC	binimetinib	638.9	24	69	135.2	-0.8
X-3671	CRC	untreated	202.4	26	0	0	0
X-3671	CRC	untreated	261.1	26.1	4	29	0.4
X-3671	CRC	untreated	345.3	24.3	7	70.6	-6.5
X-3671	CRC	untreated	559.4	28.9	10	176.4	11.2
X-3671	CRC	untreated	845.9	27.4	14	317.9	5.4
X-3671	CRC	untreated	964.8	25.5	17	376.7	-1.9
X-3671	CRC	untreated	1200.3	25	21	493	-3.8
X-3671	CRC	untreated	1545.3	25.4	24	663.5	-2.3
X-3676	CM	BKM120	228.2	22.1	0	0	0
X-3676	CM	BKM120	255	22.3	2	11.7	0.9
X-3676	CM	BKM120	311.7	22.3	6	36.6	0.9
X-3676	CM	BKM120	506.9	22.7	9	122.2	2.7
X-3676	CM	BKM120	643.6	21.9	12	182.1	-0.9
X-3676	CM	BKM120	1027	21.2	16	350.1	-4.1
X-3676	CM	BKM120 + encorafenib	225	23	0	0	0
X-3676	CM	BKM120 + encorafenib	161.8	23.8	4	-28.1	3.5
X-3676	CM	BKM120 + encorafenib	152.6	23.5	7	-32.2	2.2
X-3676	CM	BKM120 + encorafenib	147.9	23.7	11	-34.3	3
X-3676	CM	BKM120 + encorafenib	147.9	24.5	16	-34.3	6.5
X-3676	CM	BKM120 + encorafenib	193.6	24.5	19	-14	6.5
X-3676	CM	BKM120 + encorafenib	226.5	24.7	22	0.7	7.4
X-3676	CM	BKM120 + encorafenib	251.3	24.8	24	11.7	7.8
X-3676	CM	BKM120 + encorafenib	241.9	25.2	28	7.5	9.6
X-3676	CM	BKM120 + encorafenib	219	25.1	31	-2.6	9.1
X-3676	CM	BKM120 + encorafenib	232.7	25	35	3.4	8.7
X-3676	CM	BKM120 + encorafenib	302.6	24.3	39	34.5	5.7
X-3676	CM	BKM120 + encorafenib	335.2	24	49	49	4.3
X-3676	CM	BKM120 + encorafenib	369.8	23.9	51	64.4	3.9
X-3676	CM	BKM120 + encorafenib	362.4	23	53	61.1	0
X-3676	CM	BKM120 + encorafenib	362.4	22	56	61.1	-4.3
X-3676	CM	BKM120 + encorafenib	497.7	21.4	60	121.2	-7
X-3676	CM	CGM097	230	22.7	0	0	0
X-3676	CM	CGM097	351.3	23.2	2	52.8	2.2
X-3676	CM	CGM097	804.7	23	6	249.9	1.3
X-3676	CM	CGM097	1595.4	23.7	9	593.7	4.4
X-3676	CM	dacarbazine	195.3	24.9	0	0	0
X-3676	CM	dacarbazine	426.3	22.5	4	118.3	-9.6
X-3676	CM	dacarbazine	605.2	21.5	7	209.9	-13.7
X-3676	CM	dacarbazine	898.1	20	11	359.9	-19.7
X-3676	CM	LDE225	207.4	21.5	0	0	0
X-3676	CM	LDE225	252.5	21.9	2	21.8	1.9
X-3676	CM	LDE225	535	21.2	6	158	-1.4
X-3676	CM	LDE225	747.3	20.8	9	260.4	-3.3
X-3676	CM	LDE225	1022.5	19.6	12	393.1	-8.8
X-3676	CM	LDK378	227.3	21.6	0	0	0
X-3676	CM	LDK378	305.1	21.3	2	34.3	-1.4
X-3676	CM	LDK378	736	20.8	6	223.9	-3.7
X-3676	CM	LDK378	1026.7	20.9	9	351.8	-3.2
X-3676	CM	LEE011	247.5	24.2	0	0	0
X-3676	CM	LEE011	434.8	23.7	2	75.7	-2.1
X-3676	CM	LEE011	712.7	23	6	187.9	-5
X-3676	CM	LEE011	1176.6	24	9	375.4	-0.8
X-3676	CM	LEE011 + encorafenib	236.3	23.1	0	0	0
X-3676	CM	LEE011 + encorafenib	282.9	24.2	4	19.8	4.8
X-3676	CM	LEE011 + encorafenib	299.2	23.8	7	26.7	3
X-3676	CM	LEE011 + encorafenib	306.6	24.4	11	29.8	5.6
X-3676	CM	LEE011 + encorafenib	330.7	25	16	40	8.2
X-3676	CM	LEE011 + encorafenib	304	24.7	19	28.7	6.9
X-3676	CM	LEE011 + encorafenib	427.4	25	22	80.9	8.2
X-3676	CM	LEE011 + encorafenib	440.1	25.5	24	86.3	10.4
X-3676	CM	LEE011 + encorafenib	463.9	25.8	28	96.4	11.7
X-3676	CM	LEE011 + encorafenib	582.6	25.8	31	146.6	11.7
X-3676	CM	LEE011 + encorafenib	724.7	26.7	35	206.8	15.6
X-3676	CM	LEE011 + encorafenib	766.1	25.8	37	224.3	11.7
X-3676	CM	WNT974	216.3	22.8	0	0	0
X-3676	CM	WNT974	457.7	22.1	4	111.6	-3.1
X-3676	CM	WNT974	691.9	21.8	7	219.9	-4.4
X-3676	CM	WNT974	1095.1	22.7	10	406.3	-0.4
X-3676	CM	LGW813	222.2	20.8	0	0	0
X-3676	CM	LGW813	234.2	20.6	2	5.4	-1
X-3676	CM	LGW813	490.1	20.6	6	120.6	-1
X-3676	CM	LGW813	605.7	20.9	9	172.6	0.5
X-3676	CM	LGW813	1211.7	20.4	12	445.3	-1.9
X-3676	CM	encorafenib	202.3	23.5	0	0	0
X-3676	CM	encorafenib	235.5	23.7	2	16.4	0.9
X-3676	CM	encorafenib	279.9	23.5	6	38.3	0
X-3676	CM	encorafenib	377.3	24	9	86.4	2.1
X-3676	CM	encorafenib	396.1	24.5	12	95.8	4.3
X-3676	CM	encorafenib	667.5	24.5	16	229.9	4.3
X-3676	CM	encorafenib	871.2	24.8	21	330.6	5.5
X-3676	CM	encorafenib + binimetinib	219	24.4	0	0	0
X-3676	CM	encorafenib + binimetinib	137.7	24.4	4	-37.1	0
X-3676	CM	encorafenib + binimetinib	156.3	24	7	-28.6	-1.6
X-3676	CM	encorafenib + binimetinib	157.7	23.6	11	-28	-3.3
X-3676	CM	encorafenib + binimetinib	120.6	25	16	-44.9	2.5
X-3676	CM	encorafenib + binimetinib	174.2	24.8	19	-20.5	1.6
X-3676	CM	encorafenib + binimetinib	215.1	24.9	22	-1.8	2
X-3676	CM	encorafenib + binimetinib	226.5	24.9	24	3.4	2
X-3676	CM	encorafenib + binimetinib	203.4	25.2	28	-7.2	3.3
X-3676	CM	encorafenib + binimetinib	251.9	25.4	31	15	4.1
X-3676	CM	encorafenib + binimetinib	261.6	25.1	35	19.4	2.9
X-3676	CM	encorafenib + binimetinib	272.7	24.3	39	24.5	-0.4
X-3676	CM	encorafenib + binimetinib	369.8	24.5	49	68.8	0.4
X-3676	CM	encorafenib + binimetinib	390.2	24.2	51	78.1	-0.8
X-3676	CM	encorafenib + binimetinib	397.4	24.3	53	81.4	-0.4
X-3676	CM	encorafenib + binimetinib	419.1	24.8	56	91.3	1.6
X-3676	CM	encorafenib + binimetinib	516.9	23.7	60	136	-2.9
X-3676	CM	binimetinib	217.7	25	0	0	0
X-3676	CM	binimetinib	247.5	24.2	2	13.7	-3.2
X-3676	CM	binimetinib	178.6	23.7	6	-18	-5.2
X-3676	CM	binimetinib	254	24.1	9	16.7	-3.6
X-3676	CM	binimetinib	337.9	24.1	12	55.2	-3.6
X-3676	CM	binimetinib	397.4	24.4	16	82.5	-2.4
X-3676	CM	binimetinib	522.5	24.8	21	140	-0.8
X-3676	CM	binimetinib	538.3	24.7	24	147.2	-1.2
X-3676	CM	binimetinib	609.2	24.6	27	179.8	-1.6
X-3676	CM	binimetinib	654.3	24.8	29	200.5	-0.8
X-3676	CM	TAS266	227.8	23.6	0	0	0
X-3676	CM	TAS266	288.8	24.2	2	26.8	2.5
X-3676	CM	TAS266	712.7	23.3	6	212.8	-1.3
X-3676	CM	TAS266	1113.9	22.8	9	389	-3.4
X-3676	CM	untreated	343.2	25.2	0	0	0
X-3676	CM	untreated	463.7	24.9	2	35.1	-1.2
X-3676	CM	untreated	972.2	24.8	6	183.3	-1.6
X-3676	CM	untreated	1518.8	25.2	9	342.6	0
X-3684	CRC	LFW527 + binimetinib	200.49	23.7	0	0	0
X-3684	CRC	LFW527 + binimetinib	217	22.59	3	8.2	-4.7
X-3684	CRC	LFW527 + binimetinib	460.71	23.25	8	129.8	-1.9
X-3684	CRC	LFW527 + binimetinib	1330.32	24.76	11	563.5	4.5
X-3697	BRCA	BGJ398	208.7	22.5	0	0	0
X-3697	BRCA	BGJ398	193.1	23.5	3	-7.5	4.4
X-3697	BRCA	BGJ398	207.7	22.6	6	-0.5	0.4
X-3697	BRCA	BGJ398	213.6	22	13	2.3	-2.2
X-3697	BRCA	BGJ398	227.8	23.3	17	9.2	3.6
X-3697	BRCA	BGJ398	226.2	22.5	20	8.4	0
X-3697	BRCA	BGJ398	225.3	23.1	24	8	2.7
X-3697	BRCA	BGJ398	244.9	23.8	27	17.3	5.8
X-3697	BRCA	BGJ398	348.9	22.8	31	67.2	1.3
X-3697	BRCA	BGJ398	370.5	23.3	34	77.5	3.6
X-3697	BRCA	BGJ398	464.6	22.5	41	122.6	0
X-3697	BRCA	BGJ398	510.2	21.7	45	144.5	-3.6
X-3697	BRCA	BGJ398	623.7	21.9	48	198.9	-2.7
X-3697	BRCA	BKM120	282.8	26.2	0	0	0
X-3697	BRCA	BKM120	273.9	28.3	5	-3.1	8
X-3697	BRCA	BKM120	262.5	26.4	8	-7.2	0.8
X-3697	BRCA	BKM120	284.7	27.6	11	0.7	5.3
X-3697	BRCA	BKM120	295.7	26	15	4.6	-0.8
X-3697	BRCA	BKM120	302.5	25.6	18	7	-2.3
X-3697	BRCA	BKM120	305.2	25.5	22	7.9	-2.7
X-3697	BRCA	BKM120	319.5	26.3	25	13	0.4
X-3697	BRCA	BKM120	327	25.3	29	15.6	-3.4
X-3697	BRCA	BKM120	329.1	25.9	33	16.4	-1.1
X-3697	BRCA	BKM120	236.4	25.6	36	-16.4	-2.3
X-3697	BRCA	BKM120	203.6	23	39	-28	-12.2
X-3697	BRCA	BKM120	256.1	23	43	-9.4	-12.2
X-3697	BRCA	BKM120	281.3	28.6	47	-0.5	9.2
X-3697	BRCA	BKM120	229.2	26	51	-19	-0.8
X-3697	BRCA	BKM120	250.2	25.3	54	-11.5	-3.4
X-3697	BRCA	BKM120	260	25.7	58	-8.1	-1.9
X-3697	BRCA	BKM120	284.6	26.5	62	0.6	1.1
X-3697	BRCA	BKM120	273.3	26.4	66	-3.4	0.8
X-3697	BRCA	BKM120	247.3	23.3	68	-12.6	-11.1
X-3697	BRCA	BKM120	282.5	21.9	71	-0.1	-16.4
X-3697	BRCA	BYL719 + LJM716	195.5	25.3	0	0	0
X-3697	BRCA	BYL719 + LJM716	188.4	26.5	3	-3.6	4.7
X-3697	BRCA	BYL719 + LJM716	115.9	25.7	6	-40.7	1.6
X-3697	BRCA	BYL719 + LJM716	150.4	23.3	13	-23.1	-7.9
X-3697	BRCA	BYL719 + LJM716	109	21.5	17	-44.2	-15
X-3697	BRCA	BYL719 + LJM716	137.2	22.3	20	-29.8	-11.9
X-3697	BRCA	BYL719 + LJM716	192.5	22.6	24	-1.5	-10.7
X-3697	BRCA	BYL719 + LJM716	208.1	20.4	27	6.4	-19.4
X-3697	BRCA	BYL719 + LJM716	243.2	21.6	31	24.4	-14.6
X-3697	BRCA	BYL719 + LJM716	274.1	21	34	40.2	-17
X-3697	BRCA	BYL719 + LJM716	308.7	21	38	57.9	-17
X-3697	BRCA	BYL719 + LJM716	354.1	21.6	41	81.1	-14.6
X-3697	BRCA	BYL719 + LJM716	441.4	21.9	42	125.8	-13.4
X-3697	BRCA	BYL719	201.9	27	0	0	0
X-3697	BRCA	BYL719	122	25.9	4	-39.6	-4.1
X-3697	BRCA	BYL719	139.2	25.1	11	-31.1	-7
X-3697	BRCA	BYL719	128.9	26.7	15	-36.2	-1.1
X-3697	BRCA	BYL719	151.4	25.7	18	-25	-4.8
X-3697	BRCA	BYL719	121.8	25.3	22	-39.7	-6.3
X-3697	BRCA	BYL719	115.7	23.6	25	-42.7	-12.6
X-3697	BRCA	BYL719	134	23.1	29	-33.6	-14.4
X-3697	BRCA	BYL719	122.5	22.3	32	-39.3	-17.4
X-3697	BRCA	BYL719	203.1	23	36	0.6	-14.8
X-3697	BRCA	BYL719	235.7	23	39	16.7	-14.8
X-3697	BRCA	BYL719 + LEE011	191.3	25	0	0	0
X-3697	BRCA	BYL719 + LEE011	145.3	23.7	3	-24	-5.2
X-3697	BRCA	BYL719 + LEE011	119.9	22.2	6	-37.3	-11.2
X-3697	BRCA	BYL719 + LEE011	141.9	24.5	10	-25.8	-2
X-3697	BRCA	BYL719 + LEE011	180.8	24.6	13	-5.5	-1.6
X-3697	BRCA	BYL719 + LEE011	127.2	22.7	17	-33.5	-9.2
X-3697	BRCA	BYL719 + LEE011	116.4	23.2	20	-39.2	-7.2
X-3697	BRCA	BYL719 + LEE011	200.3	25.3	24	4.7	1.2
X-3697	BRCA	BYL719 + LEE011	165.8	23.5	27	-13.3	-6
X-3697	BRCA	BYL719 + LEE011	63.7	22.1	31	-66.7	-11.6
X-3697	BRCA	BYL719 + LEE011	95.2	23	34	-50.2	-8
X-3697	BRCA	CGM097	196.2	26.5	0	0	0
X-3697	BRCA	CGM097	195.6	26.8	1	-0.3	1.1
X-3697	BRCA	CGM097	215.7	26.7	4	9.9	0.8
X-3697	BRCA	CGM097	213.1	26.6	8	8.6	0.4
X-3697	BRCA	CGM097	236.8	27.7	11	20.7	4.5
X-3697	BRCA	CGM097	271.4	27	18	38.3	1.9
X-3697	BRCA	CGM097	321.8	27.5	22	64	3.8
X-3697	BRCA	CGM097	411.9	26.3	25	109.9	-0.8
X-3697	BRCA	CGM097	401.7	26.8	29	104.7	1.1
X-3697	BRCA	CGM097	463	25.7	32	136	-3
X-3697	BRCA	CGM097	570.8	24.7	36	190.9	-6.8
X-3697	BRCA	CGM097	721.9	25	39	267.9	-5.7
X-3697	BRCA	CGM097	842.9	25.9	41	329.6	-2.3
X-3697	BRCA	CLR457	211.6	27.1	0	0	0
X-3697	BRCA	CLR457	118.6	25.2	6	-44	-7
X-3697	BRCA	CLR457	117.5	25	10	-44.5	-7.7
X-3697	BRCA	CLR457	117.9	24.8	13	-44.3	-8.5
X-3697	BRCA	CLR457	99.4	24.1	17	-53	-11.1
X-3697	BRCA	CLR457	101.8	23.4	20	-51.9	-13.7
X-3697	BRCA	CLR457	86.3	22.5	24	-59.2	-17
X-3697	BRCA	CLR457	119.4	22.3	27	-43.6	-17.7
X-3697	BRCA	CLR457	122.5	23.2	31	-42.1	-14.4
X-3697	BRCA	CLR457	137.3	21.9	34	-35.1	-19.2
X-3697	BRCA	HDM201	232.5	24.2	0	0	0
X-3697	BRCA	HDM201	305.6	23.4	4	31.4	-3.3
X-3697	BRCA	HDM201	356.8	22.5	7	53.5	-7
X-3697	BRCA	HDM201	408.4	22.8	10	75.7	-5.8
X-3697	BRCA	HDM201	437.7	22.6	14	88.3	-6.6
X-3697	BRCA	HDM201	471.5	21.5	17	102.8	-11.2
X-3697	BRCA	HDM201	523.7	20.1	21	125.2	-16.9
X-3697	BRCA	HDM201	540.5	19.1	24	132.5	-21.1
X-3697	BRCA	HDM201	547.7	19	28	135.6	-21.5
X-3697	BRCA	HDM201	605.3	17.7	32	160.3	-26.9
X-3697	BRCA	INC424	217.5	23.2	0	0	0
X-3697	BRCA	INC424	217.4	23.4	4	0	0.9
X-3697	BRCA	INC424	244.2	22.3	11	12.3	-3.9
X-3697	BRCA	INC424	252.9	23.6	15	16.3	1.7
X-3697	BRCA	INC424	278.6	23.3	18	28.1	0.4
X-3697	BRCA	INC424	333.8	22.4	22	53.5	-3.4
X-3697	BRCA	INC424	342.4	22.5	25	57.4	-3
X-3697	BRCA	INC424	372.3	22.2	29	71.2	-4.3
X-3697	BRCA	INC424	350.5	22.6	32	61.1	-2.6
X-3697	BRCA	INC424	451.4	23	36	107.5	-0.9
X-3697	BRCA	INC424	528.5	23.2	39	143	0
X-3697	BRCA	INC424	637.9	21.3	43	193.3	-8.2
X-3697	BRCA	INC424	619	21.7	46	184.6	-6.5
X-3697	BRCA	INC424	644.9	21.2	50	196.5	-8.6
X-3697	BRCA	INC424	660.8	21.9	53	203.8	-5.6
X-3697	BRCA	LEE011 + everolimus	294.5	23.3	0	0	0
X-3697	BRCA	LEE011 + everolimus	261.9	24.4	4	-11.1	4.7
X-3697	BRCA	LEE011 + everolimus	265.2	22.2	7	-9.9	-4.7
X-3697	BRCA	LEE011 + everolimus	270.5	21.4	10	-8.1	-8.2
X-3697	BRCA	LEE011 + everolimus	293.1	21.8	14	-0.5	-6.4
X-3697	BRCA	LEE011 + everolimus	292.6	21.5	17	-0.6	-7.7
X-3697	BRCA	LEE011 + everolimus	261.8	20.8	21	-11.1	-10.7
X-3697	BRCA	LEE011 + everolimus	275.3	21.4	24	-6.5	-8.2
X-3697	BRCA	LEE011 + everolimus	288.9	22.1	28	-1.9	-5.2
X-3697	BRCA	LEE011 + everolimus	313.2	22.7	32	6.3	-2.6
X-3697	BRCA	LEE011 + everolimus	333.1	23.1	35	13.1	-0.9
X-3697	BRCA	LEE011 + everolimus	284.1	23	38	-3.5	-1.3
X-3697	BRCA	LEE011 + everolimus	234.8	21.3	42	-20.3	-8.6
X-3697	BRCA	LEE011 + everolimus	240.8	24.3	46	-18.2	4.3
X-3697	BRCA	LEE011 + everolimus	252.6	23.9	50	-14.2	2.6
X-3697	BRCA	LEE011 + everolimus	265.4	23.1	53	-9.9	-0.9
X-3697	BRCA	LEE011 + everolimus	259.4	22.4	57	-11.9	-3.9
X-3697	BRCA	LEE011 + everolimus	245.7	20.8	61	-16.6	-10.7
X-3697	BRCA	LEE011	270.2	26.5	0	0	0
X-3697	BRCA	LEE011	345	26.1	3	27.7	-1.5
X-3697	BRCA	LEE011	400.2	26.3	7	48.1	-0.8
X-3697	BRCA	LEE011	444.9	26.2	10	64.7	-1.1
X-3697	BRCA	LEE011	406.9	26.5	14	50.6	0
X-3697	BRCA	LEE011	366.3	28.2	17	35.6	6.4
X-3697	BRCA	LEE011	384.3	27.8	20	42.2	4.9
X-3697	BRCA	LEE011	396.2	28.1	24	46.6	6
X-3697	BRCA	LEE011	407	29.4	27	50.6	10.9
X-3697	BRCA	LEE011	405.3	29.7	31	50	12.1
X-3697	BRCA	LEE011	410.9	29.5	34	52.1	11.3
X-3697	BRCA	LEE011	426.5	27.9	38	57.8	5.3
X-3697	BRCA	LEE011	413.1	29.4	42	52.9	10.9
X-3697	BRCA	LEE011	369.6	30.3	45	36.8	14.3
X-3697	BRCA	LEE011	352.8	30.2	48	30.6	14
X-3697	BRCA	LEE011	272.3	29.3	52	0.8	10.6
X-3697	BRCA	LEE011	291	29.3	56	7.7	10.6
X-3697	BRCA	LEE011	305.1	30.8	60	12.9	16.2
X-3697	BRCA	LEE011	367.8	29.7	63	36.1	12.1
X-3697	BRCA	LEE011	400.1	29.4	67	48.1	10.9
X-3697	BRCA	LEE011	406.7	27.3	71	50.5	3
X-3697	BRCA	LEE011	392.5	28.8	75	45.3	8.7
X-3697	BRCA	LEE011	446.6	28.4	77	65.3	7.2
X-3697	BRCA	LEE011	480.5	28.4	80	77.8	7.2
X-3697	BRCA	LEE011	558.8	29.5	84	106.8	11.3
X-3697	BRCA	LEE011	599.6	29.7	87	121.9	12.1
X-3697	BRCA	LEE011	638.5	29.5	94	136.3	11.3
X-3697	BRCA	LEE011	677	28.9	97	150.6	9.1
X-3697	BRCA	LEE011	687.9	29.3	101	154.6	10.6
X-3697	BRCA	LEE011	729.4	29.9	105	169.9	12.8
X-3697	BRCA	LEE011	859.4	30.9	112	218.1	16.6
X-3697	BRCA	LEE011	891.7	30.8	117	230	16.2
X-3697	BRCA	LEE011	992.5	30.6	124	267.3	15.5
X-3697	BRCA	LEE011	1159.1	30.8	130	329	16.2
X-3697	BRCA	LFA102	212.1	24	0	0	0
X-3697	BRCA	LFA102	212.2	26.3	3	0	9.6
X-3697	BRCA	LFA102	233.2	25.1	6	9.9	4.6
X-3697	BRCA	LFA102	274.8	24.5	13	29.6	2.1
X-3697	BRCA	LFA102	338.2	23.7	17	59.5	-1.3
X-3697	BRCA	LFA102	404.1	23.1	20	90.5	-3.7
X-3697	BRCA	LFA102	443.4	22.4	24	109.1	-6.7
X-3697	BRCA	LFA102	452.6	22.7	27	113.4	-5.4
X-3697	BRCA	LFA102	469.8	24.2	31	121.5	0.8
X-3697	BRCA	LFA102	556	23.2	34	162.1	-3.3
X-3697	BRCA	LJM716 + trastuzumab	197.8	29.7	0	0	0
X-3697	BRCA	LJM716 + trastuzumab	145.8	30.4	3	-26.3	2.4
X-3697	BRCA	LJM716 + trastuzumab	134.2	29.9	6	-32.2	0.7
X-3697	BRCA	LJM716 + trastuzumab	202.5	28.5	10	2.4	-4
X-3697	BRCA	LJM716 + trastuzumab	235.4	28.3	13	19	-4.7
X-3697	BRCA	LJM716 + trastuzumab	311.6	27.4	17	57.5	-7.7
X-3697	BRCA	LJM716 + trastuzumab	329.5	27.8	20	66.6	-6.4
X-3697	BRCA	LJM716 + trastuzumab	308.8	29.1	24	56.1	-2
X-3697	BRCA	LJM716 + trastuzumab	327.3	29.5	27	65.5	-0.7
X-3697	BRCA	LJM716 + trastuzumab	449.4	29.3	31	127.2	-1.3
X-3697	BRCA	LJM716 + trastuzumab	609.8	29.3	34	208.3	-1.3
X-3697	BRCA	LJM716 + trastuzumab	678.9	29.3	38	243.2	-1.3
X-3697	BRCA	LJM716 + trastuzumab	785.2	28.4	41	297	-4.4
X-3697	BRCA	LJM716	241.5	27	0	0	0
X-3697	BRCA	LJM716	242	26.9	3	0.2	-0.4
X-3697	BRCA	LJM716	223.7	26.2	6	-7.4	-3
X-3697	BRCA	LJM716	301.9	24.9	13	25	-7.8
X-3697	BRCA	LJM716	375.9	25	17	55.7	-7.4
X-3697	BRCA	LJM716	485.9	24.7	20	101.2	-8.5
X-3697	BRCA	LJM716	544.3	25.2	24	125.4	-6.7
X-3697	BRCA	LJM716	567.7	23.3	27	135.1	-13.7
X-3697	BRCA	LJM716	626.7	23.5	31	159.5	-13
X-3697	BRCA	LJM716	818.4	23.2	34	238.9	-14.1
X-3697	BRCA	LJM716	1033.2	23.4	36	327.8	-13.3
X-3697	BRCA	LKA136	194.6	26.5	0	0	0
X-3697	BRCA	LKA136	217.5	25.9	4	11.8	-2.3
X-3697	BRCA	LKA136	258.2	26	11	32.7	-1.9
X-3697	BRCA	LKA136	237.6	25.8	15	22.1	-2.6
X-3697	BRCA	LKA136	268.4	25.6	18	37.9	-3.4
X-3697	BRCA	LKA136	344.2	25.4	22	76.9	-4.2
X-3697	BRCA	LKA136	353.6	26	25	81.7	-1.9
X-3697	BRCA	LKA136	469.2	25.4	29	141.1	-4.2
X-3697	BRCA	LKA136	625.4	25.6	32	221.4	-3.4
X-3697	BRCA	LKA136	719.7	26.3	34	269.8	-0.8
X-3697	BRCA	LLM871	201.9	26.4	0	0	0
X-3697	BRCA	LLM871	157.3	23.3	6	-22.1	-11.7
X-3697	BRCA	LLM871	151.5	23.8	10	-25	-9.8
X-3697	BRCA	LLM871	177.9	23.2	13	-11.9	-12.1
X-3697	BRCA	LLM871	183.2	21.8	17	-9.3	-17.4
X-3697	BRCA	LLM871	252.5	17.2	20	25.1	-34.8
X-3697	BRCA	binimetinib	224.8	28	0	0	0
X-3697	BRCA	binimetinib	212.5	27.8	5	-5.5	-0.7
X-3697	BRCA	binimetinib	235.1	27.4	8	4.6	-2.1
X-3697	BRCA	binimetinib	246.7	28	11	9.7	0
X-3697	BRCA	binimetinib	265.5	29.9	15	18.1	6.8
X-3697	BRCA	binimetinib	274.8	27.6	18	22.2	-1.4
X-3697	BRCA	binimetinib	286	25.8	22	27.2	-7.9
X-3697	BRCA	binimetinib	289.6	25.5	25	28.8	-8.9
X-3697	BRCA	binimetinib	294.7	24.3	33	31.1	-13.2
X-3697	BRCA	binimetinib	331.8	25.1	36	47.6	-10.4
X-3697	BRCA	binimetinib	357.2	27.4	39	58.9	-2.1
X-3697	BRCA	binimetinib	385.9	27.9	43	71.7	-0.4
X-3697	BRCA	binimetinib	376.4	28.3	47	67.4	1.1
X-3697	BRCA	binimetinib	370.5	27.2	54	64.8	-2.9
X-3697	BRCA	binimetinib	452	27.3	58	101.1	-2.5
X-3697	BRCA	binimetinib	475.6	26.2	62	111.6	-6.4
X-3697	BRCA	binimetinib	466	27.5	66	107.3	-1.8
X-3697	BRCA	binimetinib	506.1	29.1	68	125.1	3.9
X-3697	BRCA	binimetinib	542.2	27.5	71	141.2	-1.8
X-3697	BRCA	paclitaxel	223.1	28.9	0	0	0
X-3697	BRCA	paclitaxel	226.1	28	3	1.3	-3.1
X-3697	BRCA	paclitaxel	228.8	27.6	6	2.6	-4.5
X-3697	BRCA	paclitaxel	258.6	28.4	10	15.9	-1.7
X-3697	BRCA	paclitaxel	234.8	27.9	13	5.2	-3.5
X-3697	BRCA	paclitaxel	232.9	28.2	17	4.4	-2.4
X-3697	BRCA	paclitaxel	229.6	28.1	20	2.9	-2.8
X-3697	BRCA	paclitaxel	241.9	28.2	23	8.4	-2.4
X-3697	BRCA	paclitaxel	266.7	28.4	27	19.5	-1.7
X-3697	BRCA	paclitaxel	271.6	26.6	30	21.7	-8
X-3697	BRCA	paclitaxel	277.6	26.3	34	24.4	-9
X-3697	BRCA	paclitaxel	281.5	25.3	37	26.2	-12.5
X-3697	BRCA	paclitaxel	293.5	24.5	41	31.6	-15.2
X-3697	BRCA	paclitaxel	313.4	23.9	45	40.5	-17.3
X-3697	BRCA	paclitaxel	317.1	24.6	51	42.1	-14.9
X-3697	BRCA	tamoxifen	227.7	25.2	0	0	0
X-3697	BRCA	tamoxifen	224.4	24.8	1	-1.4	-1.6
X-3697	BRCA	tamoxifen	180.3	24.6	4	-20.8	-2.4
X-3697	BRCA	tamoxifen	183.7	23.4	8	-19.3	-7.1
X-3697	BRCA	tamoxifen	196.5	23	11	-13.7	-8.7
X-3697	BRCA	tamoxifen	311	24.3	18	36.6	-3.6
X-3697	BRCA	tamoxifen	331.8	24.1	22	45.7	-4.4
X-3697	BRCA	tamoxifen	359	24.5	25	57.7	-2.8
X-3697	BRCA	tamoxifen	350.8	25.3	29	54.1	0.4
X-3697	BRCA	tamoxifen	429.8	24.1	32	88.8	-4.4
X-3697	BRCA	tamoxifen	469.8	23.6	36	106.3	-6.3
X-3697	BRCA	tamoxifen	583	23.7	39	156	-6
X-3697	BRCA	tamoxifen	752.4	25.2	41	230.4	0
X-3697	BRCA	trastuzumab	225.8	26	0	0	0
X-3697	BRCA	trastuzumab	225.5	26.1	3	-0.1	0.4
X-3697	BRCA	trastuzumab	209	25.5	6	-7.4	-1.9
X-3697	BRCA	trastuzumab	263.1	24.3	13	16.5	-6.5
X-3697	BRCA	trastuzumab	276.5	24.4	17	22.5	-6.2
X-3697	BRCA	trastuzumab	364.9	26.7	20	61.6	2.7
X-3697	BRCA	trastuzumab	447.8	26	24	98.3	0
X-3697	BRCA	trastuzumab	509	25	27	125.4	-3.8
X-3697	BRCA	trastuzumab	542.9	23.5	31	140.4	-9.6
X-3697	BRCA	trastuzumab	829.7	22.8	34	267.4	-12.3
X-3697	BRCA	untreated	247.7	31.6	0	0	0
X-3697	BRCA	untreated	314.4	31.7	3	26.9	0.3
X-3697	BRCA	untreated	329.6	32.6	6	33.1	3.2
X-3697	BRCA	untreated	331.2	32.7	10	33.7	3.5
X-3697	BRCA	untreated	379.6	33	13	53.2	4.4
X-3697	BRCA	untreated	382.4	32.6	17	54.4	3.2
X-3697	BRCA	untreated	394.3	32.4	20	59.2	2.5
X-3697	BRCA	untreated	421.7	31	24	70.2	-1.9
X-3697	BRCA	untreated	519.9	31.6	28	109.9	0
X-3697	BRCA	untreated	557.8	32	31	125.2	1.3
X-3697	BRCA	untreated	579.4	32.3	34	133.9	2.2
X-3697	BRCA	untreated	645.8	31.2	38	160.7	-1.3
X-3697	BRCA	untreated	685.3	32.4	42	176.7	2.5
X-3697	BRCA	untreated	713.4	32	46	188	1.3
X-3697	BRCA	untreated	777.6	31.4	49	213.9	-0.6
X-3697	BRCA	untreated	835.6	31.7	53	237.3	0.3
X-3697	BRCA	untreated	856.3	31.6	57	245.7	0
X-3697	BRCA	untreated	874.7	31.9	61	253.1	0.9
X-3697	BRCA	untreated	951.4	31.5	63	284.1	-0.3
X-3697	BRCA	untreated	1109.8	31.4	66	348	-0.6
X-3746	CM	BKM120	194.4	25.4	0	0	0
X-3746	CM	BKM120	166.1	26.2	5	-14.6	3.1
X-3746	CM	BKM120	202.5	26.9	11	4.2	5.9
X-3746	CM	BKM120	351.3	27.7	17	80.7	9.1
X-3746	CM	BKM120	387.2	28.1	20	99.2	10.6
X-3746	CM	BKM120	427.4	28.8	25	119.9	13.4
X-3746	CM	BKM120 + encorafenib	255.8	22.5	0	0	0
X-3746	CM	BKM120 + encorafenib	154.9	23.1	7	-39.5	2.7
X-3746	CM	BKM120 + encorafenib	0	23.8	13	-100	5.8
X-3746	CM	BKM120 + encorafenib	0	23	16	-100	2.2
X-3746	CM	BKM120 + encorafenib	0	24.2	21	-100	7.6
X-3746	CM	BKM120 + encorafenib	0	24.1	24	-100	7.1
X-3746	CM	BKM120 + encorafenib	0	24.4	28	-100	8.4
X-3746	CM	BKM120 + encorafenib	0	24.4	31	-100	8.4
X-3746	CM	BKM120 + encorafenib	0	25.6	36	-100	13.8
X-3746	CM	BKM120 + encorafenib	0	25.7	41	-100	14.2
X-3746	CM	BKM120 + encorafenib	0	26.1	44	-100	16
X-3746	CM	BKM120 + encorafenib	0	25.3	49	-100	12.4
X-3746	CM	BKM120 + encorafenib	0	24.6	56	-100	9.3
X-3746	CM	BKM120 + encorafenib	0	26.1	59	-100	16
X-3746	CM	BKM120 + encorafenib	0	26.6	63	-100	18.2
X-3746	CM	BKM120 + encorafenib	0	27	66	-100	20
X-3746	CM	BKM120 + encorafenib	0	26.8	70	-100	19.1
X-3746	CM	BKM120 + encorafenib	0	27	73	-100	20
X-3746	CM	BKM120 + encorafenib	0	26.1	77	-100	16
X-3746	CM	BKM120 + encorafenib	0	26	81	-100	15.6
X-3746	CM	BKM120 + encorafenib	0	26.4	88	-100	17.3
X-3746	CM	BKM120 + encorafenib	0	27	92	-100	20
X-3746	CM	BKM120 + encorafenib	0	26	101	-100	15.6
X-3746	CM	BKM120 + encorafenib	0	24.5	106	-100	8.9
X-3746	CM	BKM120 + encorafenib	0	23.8	113	-100	5.8
X-3746	CM	BKM120 + encorafenib	0	24.6	122	-100	9.3
X-3746	CM	BKM120 + encorafenib	0	24	129	-100	6.7
X-3746	CM	BKM120 + encorafenib	0	24	135	-100	6.7
X-3746	CM	BKM120 + encorafenib	0	23.9	141	-100	6.2
X-3746	CM	BKM120 + encorafenib	0	24.7	147	-100	9.8
X-3746	CM	BKM120 + encorafenib	0	23.3	154	-100	3.6
X-3746	CM	BKM120 + encorafenib	0	22.3	160	-100	-0.9
X-3746	CM	BKM120 + encorafenib	15.8	23	168	-93.8	2.2
X-3746	CM	BKM120 + encorafenib	24.5	23.2	175	-90.4	3.1
X-3746	CM	BKM120 + encorafenib	65.7	22.7	179	-74.3	0.9
X-3746	CM	BKM120 + encorafenib	72	22.8	184	-71.8	1.3
X-3746	CM	BKM120 + encorafenib	91.3	23.3	190	-64.3	3.6
X-3746	CM	BKM120 + encorafenib	125.3	22.2	193	-51	-1.3
X-3746	CM	BKM120 + encorafenib	121.1	22.8	201	-52.7	1.3
X-3746	CM	BKM120 + encorafenib	153	22.7	208	-40.2	0.9
X-3746	CM	BKM120 + encorafenib	154.8	23.5	216	-39.5	4.4
X-3746	CM	BKM120 + encorafenib	194.2	23.1	220	-24.1	2.7
X-3746	CM	BKM120 + encorafenib	195.3	23	226	-23.7	2.2
X-3746	CM	BKM120 + encorafenib	213.2	22.7	230	-16.7	0.9
X-3746	CM	BKM120 + encorafenib	141.3	22.7	241	-44.7	0.9
X-3746	CM	BKM120 + encorafenib	197.5	22.9	246	-22.8	1.8
X-3746	CM	BKM120 + encorafenib	193.8	22.2	253	-24.2	-1.3
X-3746	CM	CGM097	207.8	24.2	0	0	0
X-3746	CM	CGM097	213.2	24.3	2	2.6	0.4
X-3746	CM	CGM097	288	25	7	38.6	3.3
X-3746	CM	CGM097	470	25.2	13	126.2	4.1
X-3746	CM	CGM097	643.6	26.2	19	209.7	8.3
X-3746	CM	CGM097	675.5	25.7	22	225	6.2
X-3746	CM	dacarbazine	202.2	27.5	0	0	0
X-3746	CM	dacarbazine	197	26.7	3	-2.6	-2.9
X-3746	CM	dacarbazine	230.6	28.4	9	14.1	3.3
X-3746	CM	dacarbazine	310	26.6	12	53.3	-3.3
X-3746	CM	dacarbazine	392.9	28	17	94.3	1.8
X-3746	CM	dacarbazine	415.2	26.9	20	105.3	-2.2
X-3746	CM	dacarbazine	446.2	26.9	23	120.7	-2.2
X-3746	CM	LDE225	189	21.5	0	0	0
X-3746	CM	LDE225	443.6	20.8	7	134.6	-3.3
X-3746	CM	LDE225	720.4	21.2	13	281.1	-1.4
X-3746	CM	LDE225	962.3	20.8	14	409	-3.3
X-3746	CM	LDE225	986.2	20.4	19	421.7	-5.1
X-3746	CM	LDE225	1160.3	19.9	22	513.8	-7.4
X-3746	CM	LDK378	202.5	23.3	0	0	0
X-3746	CM	LDK378	288.7	23.6	7	42.6	1.3
X-3746	CM	LDK378	606.4	24.2	13	199.4	3.9
X-3746	CM	LDK378	758.9	24.1	14	274.8	3.4
X-3746	CM	LDK378	851.2	24.8	19	320.4	6.4
X-3746	CM	LDK378	1064.2	25.1	22	425.5	7.7
X-3746	CM	LEE011	195.3	26	0	0	0
X-3746	CM	LEE011	275.2	26.4	5	40.9	1.5
X-3746	CM	LEE011	348.2	26.5	11	78.3	1.9
X-3746	CM	LEE011	541	26	17	177.1	0
X-3746	CM	LEE011	485	26.8	20	148.4	3.1
X-3746	CM	LEE011	540	26.1	25	176.5	0.4
X-3746	CM	LEE011 + encorafenib	191.9	20.2	0	0	0
X-3746	CM	LEE011 + encorafenib	73.7	20.5	7	-61.6	1.5
X-3746	CM	LEE011 + encorafenib	0	21.4	13	-100	5.9
X-3746	CM	LEE011 + encorafenib	0	21.5	16	-100	6.4
X-3746	CM	LEE011 + encorafenib	0	22.1	21	-100	9.4
X-3746	CM	LEE011 + encorafenib	0	22.4	24	-100	10.9
X-3746	CM	LEE011 + encorafenib	0	22.5	28	-100	11.4
X-3746	CM	LEE011 + encorafenib	0	22.5	31	-100	11.4
X-3746	CM	LEE011 + encorafenib	0	22.8	36	-100	12.9
X-3746	CM	LEE011 + encorafenib	0	23.4	41	-100	15.8
X-3746	CM	LEE011 + encorafenib	0	23.3	44	-100	15.3
X-3746	CM	LEE011 + encorafenib	0	23.7	49	-100	17.3
X-3746	CM	LEE011 + encorafenib	0	23.1	56	-100	14.4
X-3746	CM	LEE011 + encorafenib	0	23.7	59	-100	17.3
X-3746	CM	LEE011 + encorafenib	0	23.8	63	-100	17.8
X-3746	CM	LEE011 + encorafenib	0	22.8	66	-100	12.9
X-3746	CM	LEE011 + encorafenib	0	23.7	70	-100	17.3
X-3746	CM	LEE011 + encorafenib	0	23.5	73	-100	16.3
X-3746	CM	LEE011 + encorafenib	0	22.6	77	-100	11.9
X-3746	CM	LEE011 + encorafenib	0	23	81	-100	13.9
X-3746	CM	LEE011 + encorafenib	0	24.1	88	-100	19.3
X-3746	CM	LEE011 + encorafenib	0	24.3	92	-100	20.3
X-3746	CM	LEE011 + encorafenib	0	24.6	101	-100	21.8
X-3746	CM	LEE011 + encorafenib	0	23.4	106	-100	15.8
X-3746	CM	LEE011 + encorafenib	0	25.4	113	-100	25.7
X-3746	CM	LEE011 + encorafenib	0	24.4	122	-100	20.8
X-3746	CM	LEE011 + encorafenib	0	24.8	129	-100	22.8
X-3746	CM	LEE011 + encorafenib	0	22.6	135	-100	11.9
X-3746	CM	LEE011 + encorafenib	0	24	141	-100	18.8
X-3746	CM	LEE011 + encorafenib	0	25	147	-100	23.8
X-3746	CM	LEE011 + encorafenib	0	24	154	-100	18.8
X-3746	CM	LEE011 + encorafenib	0	24.2	160	-100	19.8
X-3746	CM	LEE011 + encorafenib	0	24	168	-100	18.8
X-3746	CM	LEE011 + encorafenib	0	24.1	175	-100	19.3
X-3746	CM	LEE011 + encorafenib	0	24.6	179	-100	21.8
X-3746	CM	LEE011 + encorafenib	0	NA	184	-100	21.8
X-3746	CM	LEE011 + encorafenib	0	24.6	190	-100	21.8
X-3746	CM	LEE011 + encorafenib	0	23.6	193	-100	16.8
X-3746	CM	LEE011 + encorafenib	0	23.8	201	-100	17.8
X-3746	CM	LEE011 + encorafenib	62.5	23.2	208	-67.4	14.9
X-3746	CM	LEE011 + encorafenib	146.1	22.8	216	-23.9	12.9
X-3746	CM	LEE011 + encorafenib	203.4	23.6	220	6	16.8
X-3746	CM	LEE011 + encorafenib	219.3	23.5	226	14.3	16.3
X-3746	CM	LEE011 + encorafenib	329.5	23.8	230	71.7	17.8
X-3746	CM	LEE011 + encorafenib	151.8	24.7	241	-20.9	22.3
X-3746	CM	LEE011 + encorafenib	181.8	25.3	246	-5.3	25.2
X-3746	CM	LEE011 + encorafenib	126	25.4	253	-34.3	25.7
X-3746	CM	WNT974	193.6	26	0	0	0
X-3746	CM	WNT974	230	25.8	7	18.8	-0.8
X-3746	CM	WNT974	487.4	26.2	13	151.8	0.8
X-3746	CM	WNT974	555	26.1	14	186.8	0.4
X-3746	CM	WNT974	683.5	27	19	253.1	3.8
X-3746	CM	WNT974	884.4	26.5	22	356.9	1.9
X-3746	CM	LGW813	215	21.9	0	0	0
X-3746	CM	LGW813	539.1	22.6	7	150.7	3.2
X-3746	CM	LGW813	1114.8	24.5	13	418.5	11.9
X-3746	CM	LGW813	1173.6	23.6	14	445.8	7.8
X-3746	CM	LGW813	1544.2	24.6	19	618.2	12.3
X-3746	CM	LGW813	1580.2	24	22	634.9	9.6
X-3746	CM	encorafenib	191.1	23	0	0	0
X-3746	CM	encorafenib	204.2	22.8	5	6.8	-0.9
X-3746	CM	encorafenib	170.6	22.7	11	-10.7	-1.3
X-3746	CM	encorafenib	202.2	23.1	17	5.8	0.4
X-3746	CM	encorafenib	113.4	23.5	20	-40.7	2.2
X-3746	CM	encorafenib	36.3	21.9	25	-81	-4.8
X-3746	CM	encorafenib	58.5	22.9	28	-69.4	-0.4
X-3746	CM	encorafenib	36.5	22.8	32	-80.9	-0.9
X-3746	CM	encorafenib	31.2	23.4	35	-83.7	1.7
X-3746	CM	encorafenib	0	24.4	40	-100	6.1
X-3746	CM	encorafenib	0	23.6	45	-100	2.6
X-3746	CM	encorafenib	0	21.3	48	-100	-7.4
X-3746	CM	encorafenib	0	23	53	-100	0
X-3746	CM	encorafenib	0	23.8	60	-100	3.5
X-3746	CM	encorafenib	0	24.3	63	-100	5.7
X-3746	CM	encorafenib	0	24.4	67	-100	6.1
X-3746	CM	encorafenib	0	24.4	70	-100	6.1
X-3746	CM	encorafenib	65	23.6	74	-66	2.6
X-3746	CM	encorafenib	94.2	24.7	77	-50.7	7.4
X-3746	CM	encorafenib	136.8	23.6	81	-28.4	2.6
X-3746	CM	encorafenib	208.3	24	85	9	4.3
X-3746	CM	encorafenib	388.1	23.9	92	103.1	3.9
X-3746	CM	encorafenib	505.4	25	96	164.5	8.7
X-3746	CM	encorafenib	610	24.7	98	219.2	7.4
X-3746	CM	encorafenib + binimetinib	194.4	24.6	0	0	0
X-3746	CM	encorafenib + binimetinib	116.3	26	7	-40.2	5.7
X-3746	CM	encorafenib + binimetinib	62.9	27	13	-67.7	9.8
X-3746	CM	encorafenib + binimetinib	39	26.5	16	-79.9	7.7
X-3746	CM	encorafenib + binimetinib	41.8	26.8	21	-78.5	8.9
X-3746	CM	encorafenib + binimetinib	23.4	26.9	24	-88	9.3
X-3746	CM	encorafenib + binimetinib	0	27.5	28	-100	11.8
X-3746	CM	encorafenib + binimetinib	0	27.4	31	-100	11.4
X-3746	CM	encorafenib + binimetinib	0	27	36	-100	9.8
X-3746	CM	encorafenib + binimetinib	0	27	41	-100	9.8
X-3746	CM	encorafenib + binimetinib	0	27	44	-100	9.8
X-3746	CM	encorafenib + binimetinib	0	26.8	49	-100	8.9
X-3746	CM	encorafenib + binimetinib	0	26	56	-100	5.7
X-3746	CM	encorafenib + binimetinib	0	27.6	59	-100	12.2
X-3746	CM	encorafenib + binimetinib	0	27	63	-100	9.8
X-3746	CM	encorafenib + binimetinib	0	27.2	66	-100	10.6
X-3746	CM	encorafenib + binimetinib	0	27.2	70	-100	10.6
X-3746	CM	encorafenib + binimetinib	0	27.1	73	-100	10.2
X-3746	CM	encorafenib + binimetinib	0	27.4	77	-100	11.4
X-3746	CM	encorafenib + binimetinib	0	27	81	-100	9.8
X-3746	CM	encorafenib + binimetinib	0	27	88	-100	9.8
X-3746	CM	encorafenib + binimetinib	0	27.5	92	-100	11.8
X-3746	CM	encorafenib + binimetinib	0	28.3	101	-100	15
X-3746	CM	encorafenib + binimetinib	0	28.6	106	-100	16.3
X-3746	CM	encorafenib + binimetinib	0	28.5	113	-100	15.9
X-3746	CM	encorafenib + binimetinib	0	28.7	122	-100	16.7
X-3746	CM	encorafenib + binimetinib	0	29	129	-100	17.9
X-3746	CM	encorafenib + binimetinib	0	29	135	-100	17.9
X-3746	CM	encorafenib + binimetinib	0	28	141	-100	13.8
X-3746	CM	encorafenib + binimetinib	0	30	147	-100	22
X-3746	CM	encorafenib + binimetinib	0	29.5	154	-100	19.9
X-3746	CM	encorafenib + binimetinib	0	29	160	-100	17.9
X-3746	CM	encorafenib + binimetinib	0	30.1	168	-100	22.4
X-3746	CM	encorafenib + binimetinib	0	29.2	175	-100	18.7
X-3746	CM	encorafenib + binimetinib	0	30	179	-100	22
X-3746	CM	encorafenib + binimetinib	0	NA	184	-100	22
X-3746	CM	encorafenib + binimetinib	0	30.3	190	-100	23.2
X-3746	CM	encorafenib + binimetinib	0	30.7	193	-100	24.8
X-3746	CM	encorafenib + binimetinib	0	31.1	201	-100	26.4
X-3746	CM	encorafenib + binimetinib	0	30.5	208	-100	24
X-3746	CM	encorafenib + binimetinib	0	31.2	216	-100	26.8
X-3746	CM	encorafenib + binimetinib	0	30	220	-100	22
X-3746	CM	encorafenib + binimetinib	0	31.8	226	-100	29.3
X-3746	CM	encorafenib + binimetinib	0	31.8	230	-100	29.3
X-3746	CM	encorafenib + binimetinib	0	31.4	241	-100	27.6
X-3746	CM	encorafenib + binimetinib	0	31.8	246	-100	29.3
X-3746	CM	encorafenib + binimetinib	0	30.6	253	-100	24.4
X-3746	CM	binimetinib	226.5	26.3	0	0	0
X-3746	CM	binimetinib	213.4	25.8	5	-5.8	-1.9
X-3746	CM	binimetinib	178.6	26	11	-21.1	-1.1
X-3746	CM	binimetinib	167.5	26.3	17	-26.1	0
X-3746	CM	binimetinib	163.7	26.7	20	-27.7	1.5
X-3746	CM	binimetinib	143	25.9	25	-36.9	-1.5
X-3746	CM	binimetinib	122.5	25.6	28	-45.9	-2.7
X-3746	CM	binimetinib	138.1	25.6	32	-39	-2.7
X-3746	CM	binimetinib	122.5	25.9	35	-45.9	-1.5
X-3746	CM	binimetinib	124.4	26.7	40	-45.1	1.5
X-3746	CM	binimetinib	100.2	26.9	45	-55.8	2.3
X-3746	CM	binimetinib	111.3	26.7	48	-50.9	1.5
X-3746	CM	binimetinib	127.8	26.2	53	-43.6	-0.4
X-3746	CM	binimetinib	145.8	26.3	60	-35.6	0
X-3746	CM	binimetinib	126.4	26.4	63	-44.2	0.4
X-3746	CM	binimetinib	160.2	26.5	67	-29.3	0.8
X-3746	CM	binimetinib	172.8	26.3	70	-23.7	0
X-3746	CM	binimetinib	162.5	26	74	-28.3	-1.1
X-3746	CM	binimetinib	174.6	26.4	77	-22.9	0.4
X-3746	CM	binimetinib	312.2	26.2	81	37.8	-0.4
X-3746	CM	binimetinib	364.8	26.5	85	61.1	0.8
X-3746	CM	binimetinib	482	26.7	92	112.8	1.5
X-3746	CM	binimetinib	491.1	27	96	116.8	2.7
X-3746	CM	binimetinib	509.3	26.5	98	124.8	0.8
X-3746	CM	TAS266	199.8	22.1	0	0	0
X-3746	CM	TAS266	194.4	22.2	2	-2.7	0.5
X-3746	CM	TAS266	201.6	21.7	7	0.9	-1.8
X-3746	CM	TAS266	388.8	22.1	13	94.6	0
X-3746	CM	TAS266	457.7	22.7	19	129	2.7
X-3746	CM	TAS266	606.4	23	22	203.4	4.1
X-3746	CM	untreated	213.6	23.4	0	0	0
X-3746	CM	untreated	248.4	24.5	2	16.3	4.7
X-3746	CM	untreated	447.2	23.7	7	109.4	1.3
X-3746	CM	untreated	984.4	24.4	13	360.9	4.3
X-3746	CM	untreated	1642.8	25.2	19	669.2	7.7
X-3746	CM	untreated	1679.6	25	22	686.5	6.8
X-3773	CM	BKM120	196	24.8	0	0	0
X-3773	CM	BKM120	244.5	25.4	3	24.7	2.4
X-3773	CM	BKM120	204.7	25.1	7	4.4	1.2
X-3773	CM	BKM120	246.2	25.8	10	25.6	4
X-3773	CM	BKM120	295.1	25.4	14	50.5	2.4
X-3773	CM	BKM120	404.9	25.2	17	106.6	1.6
X-3773	CM	BKM120	441.5	24.9	20	125.2	0.4
X-3773	CM	BKM120	480.3	24.8	23	145	0
X-3773	CM	BKM120	486.7	24.8	27	148.3	0
X-3773	CM	BKM120	516.9	23.9	30	163.7	-3.6
X-3773	CM	BKM120	497.3	24	33	153.7	-3.2
X-3773	CM	BKM120	495.1	24.1	36	152.6	-2.8
X-3773	CM	BKM120	503.6	24.2	39	156.9	-2.4
X-3773	CM	BKM120	555	25.2	43	183.2	1.6
X-3773	CM	BKM120 + encorafenib	202.2	25.9	0	0	0
X-3773	CM	BKM120 + encorafenib	204.8	26.5	2	1.3	2.3
X-3773	CM	BKM120 + encorafenib	239.1	26.4	5	18.2	1.9
X-3773	CM	BKM120 + encorafenib	235.5	25.7	9	16.5	-0.8
X-3773	CM	BKM120 + encorafenib	230	25.8	12	13.8	-0.4
X-3773	CM	BKM120 + encorafenib	235.5	25.9	15	16.5	0
X-3773	CM	BKM120 + encorafenib	290.2	26.1	18	43.5	0.8
X-3773	CM	BKM120 + encorafenib	297.6	25.4	21	47.2	-1.9
X-3773	CM	BKM120 + encorafenib	301.8	26	25	49.3	0.4
X-3773	CM	BKM120 + encorafenib	328.1	25.4	28	62.3	-1.9
X-3773	CM	BKM120 + encorafenib	382.2	25.1	32	89.1	-3.1
X-3773	CM	BKM120 + encorafenib	401.2	25.6	35	98.4	-1.2
X-3773	CM	BKM120 + encorafenib	440.1	26.2	39	117.7	1.2
X-3773	CM	BKM120 + encorafenib	436.4	25.5	41	115.8	-1.5
X-3773	CM	BKM120 + encorafenib	450.4	26.1	44	122.8	0.8
X-3773	CM	CGM097	192.6	25.5	0	0	0
X-3773	CM	CGM097	108.2	25.3	5	-43.8	-0.8
X-3773	CM	CGM097	127.5	26.3	9	-33.8	3.1
X-3773	CM	CGM097	139.3	26.5	13	-27.7	3.9
X-3773	CM	CGM097	220.3	27	16	14.4	5.9
X-3773	CM	CGM097	214.2	26.8	20	11.2	5.1
X-3773	CM	CGM097	261	26.8	23	35.5	5.1
X-3773	CM	CGM097	163.9	26.7	27	-14.9	4.7
X-3773	CM	CGM097	244.8	27.2	30	27.1	6.7
X-3773	CM	CGM097	225.8	26.1	34	17.2	2.4
X-3773	CM	CGM097	297.9	26.6	37	54.7	4.3
X-3773	CM	CGM097	378.4	27	40	96.4	5.9
X-3773	CM	CGM097	474.3	27	43	146.3	5.9
X-3773	CM	CLR457	202.2	29.8	0	0	0
X-3773	CM	CLR457	207.4	30	3	2.6	0.7
X-3773	CM	CLR457	225	28	7	11.3	-6
X-3773	CM	CLR457	227.8	28.4	9	12.7	-4.7
X-3773	CM	CLR457	219	29.1	12	8.3	-2.3
X-3773	CM	CLR457	219	29.6	16	8.3	-0.7
X-3773	CM	CLR457	261.6	29.1	19	29.4	-2.3
X-3773	CM	CLR457	245.5	28.9	23	21.4	-3
X-3773	CM	CLR457	216.3	27.6	26	7	-7.4
X-3773	CM	CLR457	250.3	28.7	30	23.8	-3.7
X-3773	CM	CLR457	235.5	29.1	34	16.5	-2.3
X-3773	CM	CLR457	248.4	28.8	37	22.8	-3.4
X-3773	CM	CLR457	264.4	27	41	30.8	-9.4
X-3773	CM	CLR457	275.7	29.5	44	36.4	-1
X-3773	CM	CLR457	253.1	29.7	48	25.2	-0.3
X-3773	CM	CLR457	271.5	29.5	56	34.3	-1
X-3773	CM	CLR457	240.9	30	64	19.2	0.7
X-3773	CM	CLR457	250.3	29.9	72	23.8	0.3
X-3773	CM	CLR457	291.2	30.2	79	44	1.3
X-3773	CM	CLR457	291.2	29.9	87	44	0.3
X-3773	CM	CLR457	290.2	29.5	94	43.5	-1
X-3773	CM	CLR457	238.5	28.6	102	17.9	-4
X-3773	CM	CLR457	294.4	28.7	109	45.6	-3.7
X-3773	CM	CLR457	288	28.3	115	42.4	-5
X-3773	CM	CLR457	300.8	28.6	118	48.8	-4
X-3773	CM	CLR457	181.5	29.4	128	-10.2	-1.3
X-3773	CM	CLR457	231	29.4	133	14.3	-1.3
X-3773	CM	CLR457	249.6	29.1	140	23.5	-2.3
X-3773	CM	CLR457	252.5	29.1	146	24.9	-2.3
X-3773	CM	CLR457	265.6	29	154	31.4	-2.7
X-3773	CM	CLR457	239.1	29.2	166	18.2	-2
X-3773	CM	CLR457	288	29	173	42.4	-2.7
X-3773	CM	CLR457	317.5	28.8	180	57	-3.4
X-3773	CM	dacarbazine	198.5	26	0	0	0
X-3773	CM	dacarbazine	205.8	26.5	3	3.7	1.9
X-3773	CM	dacarbazine	214.2	27.3	7	8	5
X-3773	CM	dacarbazine	216.8	26.5	10	9.2	1.9
X-3773	CM	dacarbazine	220.3	27.3	14	11	5
X-3773	CM	dacarbazine	216.8	27.9	16	9.2	7.3
X-3773	CM	dacarbazine	233.3	28.6	19	17.6	10
X-3773	CM	dacarbazine	239.8	26.9	23	20.8	3.5
X-3773	CM	dacarbazine	242.5	27.8	26	22.2	6.9
X-3773	CM	dacarbazine	247.8	26.9	33	24.9	3.5
X-3773	CM	dacarbazine	267.2	26.7	37	34.6	2.7
X-3773	CM	dacarbazine	267.2	27.7	41	34.6	6.5
X-3773	CM	dacarbazine	265.6	26.7	44	33.8	2.7
X-3773	CM	dacarbazine	264.4	27	48	33.2	3.8
X-3773	CM	dacarbazine	267.2	26.3	51	34.6	1.2
X-3773	CM	dacarbazine	280.1	26.6	55	41.2	2.3
X-3773	CM	dacarbazine	278.4	26.1	63	40.3	0.4
X-3773	CM	dacarbazine	271.1	26.6	71	36.6	2.3
X-3773	CM	dacarbazine	281.3	26	79	41.7	0
X-3773	CM	dacarbazine	286.9	25.3	86	44.6	-2.7
X-3773	CM	dacarbazine	299.4	28	94	50.9	7.7
X-3773	CM	dacarbazine	300.4	29.5	101	51.3	13.5
X-3773	CM	dacarbazine	297.5	25.4	109	49.9	-2.3
X-3773	CM	dacarbazine	303.2	25.6	115	52.8	-1.5
X-3773	CM	dacarbazine	303.2	22.9	121	52.8	-11.9
X-3773	CM	dacarbazine	287.5	24.5	124	44.9	-5.8
X-3773	CM	dacarbazine	287.5	22.9	130	44.9	-11.9
X-3773	CM	LDE225	214.2	27.2	0	0	0
X-3773	CM	LDE225	221	27.2	3	3.2	0
X-3773	CM	LDE225	276.5	26.6	7	29.1	-2.2
X-3773	CM	LDE225	330.8	27.1	10	54.4	-0.4
X-3773	CM	LDE225	340.3	26.9	13	58.9	-1.1
X-3773	CM	LDE225	388.4	26.3	16	81.3	-3.3
X-3773	CM	LDE225	408.8	26.6	20	90.8	-2.2
X-3773	CM	LDE225	458.6	26	23	114.1	-4.4
X-3773	CM	LDE225	440.1	25.2	26	105.4	-7.4
X-3773	CM	LDE225	477	26	29	122.7	-4.4
X-3773	CM	LDE225	517.7	24.5	32	141.7	-9.9
X-3773	CM	LDE225	660.2	21.8	36	208.2	-19.9
X-3773	CM	LDK378	225.4	23	0	0	0
X-3773	CM	LDK378	258.8	21.2	3	14.8	-7.8
X-3773	CM	LDK378	261.6	19.7	4	16	-14.3
X-3773	CM	LDK378	262.9	20.6	6	16.6	-10.4
X-3773	CM	LDK378	307.2	20.8	9	36.3	-9.6
X-3773	CM	LDK378	258.5	18.6	13	14.7	-19.1
X-3773	CM	LEE011	202.6	27.7	0	0	0
X-3773	CM	LEE011	209.1	29.1	3	3.3	5.1
X-3773	CM	LEE011	226.7	29	7	11.9	4.7
X-3773	CM	LEE011	180.2	29.9	10	-11	7.9
X-3773	CM	LEE011	282.3	29.5	14	39.4	6.5
X-3773	CM	LEE011	301.2	31	17	48.7	11.9
X-3773	CM	LEE011	340.1	30.4	21	67.9	9.7
X-3773	CM	LEE011	433.5	30	24	114	8.3
X-3773	CM	LEE011	486	30.2	27	139.9	9
X-3773	CM	LEE011	507.8	30.1	30	150.7	8.7
X-3773	CM	LEE011	520.5	30.8	34	157	11.2
X-3773	CM	LEE011	553	30.6	37	173	10.5
X-3773	CM	LEE011	585.8	28.9	40	189.2	4.3
X-3773	CM	LEE011	705.6	31.1	43	248.4	12.3
X-3773	CM	LEE011 + encorafenib	204.2	28	0	0	0
X-3773	CM	LEE011 + encorafenib	211.7	28.3	2	3.7	1.1
X-3773	CM	LEE011 + encorafenib	261.6	28.7	5	28.1	2.5
X-3773	CM	LEE011 + encorafenib	257	28.6	9	25.9	2.1
X-3773	CM	LEE011 + encorafenib	239.1	30.1	12	17.1	7.5
X-3773	CM	LEE011 + encorafenib	312.1	27.7	15	52.8	-1.1
X-3773	CM	LEE011 + encorafenib	330.7	28.9	18	62	3.2
X-3773	CM	LEE011 + encorafenib	330.7	28.3	21	62	1.1
X-3773	CM	LEE011 + encorafenib	404	29.5	25	97.9	5.4
X-3773	CM	LEE011 + encorafenib	402.7	28.3	28	97.2	1.1
X-3773	CM	LEE011 + encorafenib	391.1	30	32	91.6	7.1
X-3773	CM	LEE011 + encorafenib	374.7	27.6	35	83.5	-1.4
X-3773	CM	LEE011 + encorafenib	437.4	29.4	39	114.2	5
X-3773	CM	LEE011 + encorafenib	461.3	29.9	41	125.9	6.8
X-3773	CM	LEE011 + encorafenib	487.4	29.5	44	138.7	5.4
X-3773	CM	LEE011 + binimetinib	204.8	29.4	0	0	0
X-3773	CM	LEE011 + binimetinib	230	29.3	4	12.3	-0.3
X-3773	CM	LEE011 + binimetinib	232.7	28.6	7	13.7	-2.7
X-3773	CM	LEE011 + binimetinib	257.9	28.6	11	26	-2.7
X-3773	CM	LEE011 + binimetinib	259.9	27.6	14	26.9	-6.1
X-3773	CM	LEE011 + binimetinib	368.5	27	18	80	-8.2
X-3773	CM	LEE011 + binimetinib	289.1	28.6	22	41.2	-2.7
X-3773	CM	LEE011 + binimetinib	295.9	28	25	44.5	-4.8
X-3773	CM	LEE011 + binimetinib	275.7	28.4	29	34.6	-3.4
X-3773	CM	LEE011 + binimetinib	292	29.3	32	42.6	-0.3
X-3773	CM	LEE011 + binimetinib	289	29.1	36	41.1	-1
X-3773	CM	LEE011 + binimetinib	323.8	28.4	44	58.1	-3.4
X-3773	CM	LEE011 + binimetinib	295.3	29.2	52	44.2	-0.7
X-3773	CM	LEE011 + binimetinib	301.8	29.1	60	47.4	-1
X-3773	CM	LEE011 + binimetinib	320.3	30	67	56.4	2
X-3773	CM	LEE011 + binimetinib	316.9	28.5	75	54.8	-3.1
X-3773	CM	LEE011 + binimetinib	309.3	27.9	82	51	-5.1
X-3773	CM	LEE011 + binimetinib	312.7	28.6	90	52.7	-2.7
X-3773	CM	LEE011 + binimetinib	305.1	29.1	96	49	-1
X-3773	CM	LEE011 + binimetinib	307.2	28.9	102	50	-1.7
X-3773	CM	LEE011 + binimetinib	342.2	27.8	105	67.1	-5.4
X-3773	CM	LEE011 + binimetinib	235.2	28.4	115	14.9	-3.4
X-3773	CM	LEE011 + binimetinib	260.1	29.1	120	27	-1
X-3773	CM	LEE011 + binimetinib	262.9	28.9	127	28.4	-1.7
X-3773	CM	LEE011 + binimetinib	255.8	28.9	133	24.9	-1.7
X-3773	CM	LEE011 + binimetinib	257.4	28.7	141	25.7	-2.4
X-3773	CM	LEE011 + binimetinib	215.6	29.3	153	5.3	-0.3
X-3773	CM	LEE011 + binimetinib	247	28.8	160	20.6	-2
X-3773	CM	LEE011 + binimetinib	298.1	28.8	167	45.6	-2
X-3773	CM	WNT974	211.7	25.7	0	0	0
X-3773	CM	WNT974	253.1	25.8	3	19.6	0.4
X-3773	CM	WNT974	310.4	24.1	6	46.6	-6.2
X-3773	CM	WNT974	358.2	24.4	10	69.2	-5.1
X-3773	CM	WNT974	330.8	22.9	13	56.2	-10.9
X-3773	CM	WNT974	398.7	23.1	16	88.3	-10.1
X-3773	CM	WNT974	443.8	23.6	19	109.6	-8.2
X-3773	CM	WNT974	454.1	23.6	22	114.5	-8.2
X-3773	CM	WNT974	534.1	23.5	26	152.3	-8.6
X-3773	CM	WNT974	564.1	22.7	29	166.4	-11.7
X-3773	CM	WNT974	709	23.3	33	234.9	-9.3
X-3773	CM	WNT974	676.3	21.8	36	219.4	-15.2
X-3773	CM	WNT974	732	22.1	40	245.7	-14
X-3773	CM	WNT974	835.8	22.9	42	294.8	-10.9
X-3773	CM	LGW813	197.5	23.4	0	0	0
X-3773	CM	LGW813	189.5	23	3	-4.1	-1.7
X-3773	CM	LGW813	187.3	23.3	7	-5.2	-0.4
X-3773	CM	LGW813	194.4	23.8	10	-1.6	1.7
X-3773	CM	LGW813	224.5	22.3	14	13.6	-4.7
X-3773	CM	LGW813	281.3	21.2	17	42.4	-9.4
X-3773	CM	LGW813	329.6	22.8	20	66.9	-2.6
X-3773	CM	LGW813	351	22.9	23	77.7	-2.1
X-3773	CM	LGW813	393.6	23.8	27	99.3	1.7
X-3773	CM	LGW813	465.8	22.9	30	135.8	-2.1
X-3773	CM	LGW813	583.2	22.4	33	195.3	-4.3
X-3773	CM	LGW813	599	23.4	36	203.3	0
X-3773	CM	LGW813	594.4	23	39	200.9	-1.7
X-3773	CM	LGW813	552.3	22.8	43	179.6	-2.6
X-3773	CM	encorafenib	192.6	26.6	0	0	0
X-3773	CM	encorafenib	196.2	25.8	5	1.9	-3
X-3773	CM	encorafenib	244.7	26.4	9	27	-0.8
X-3773	CM	encorafenib	150.2	26.2	13	-22	-1.5
X-3773	CM	encorafenib	210.2	27.3	16	9.2	2.6
X-3773	CM	encorafenib	236.2	26.5	20	22.6	-0.4
X-3773	CM	encorafenib	242.9	26.6	23	26.1	0
X-3773	CM	encorafenib	368.4	26.2	27	91.3	-1.5
X-3773	CM	encorafenib	393.8	26.8	30	104.4	0.8
X-3773	CM	encorafenib	558.4	25.6	34	189.9	-3.8
X-3773	CM	encorafenib	657.3	25.5	37	241.3	-4.1
X-3773	CM	encorafenib	676	25.9	40	251	-2.6
X-3773	CM	encorafenib	768.3	24.8	43	298.9	-6.8
X-3773	CM	encorafenib + binimetinib	210	26.7	0	0	0
X-3773	CM	encorafenib + binimetinib	215.1	27.2	3	2.5	1.9
X-3773	CM	encorafenib + binimetinib	222.9	27.4	6	6.2	2.6
X-3773	CM	encorafenib + binimetinib	248.4	26.9	9	18.3	0.7
X-3773	CM	encorafenib + binimetinib	224.5	27.5	13	6.9	3
X-3773	CM	encorafenib + binimetinib	249	27.9	16	18.6	4.5
X-3773	CM	encorafenib + binimetinib	321.7	28.3	20	53.2	6
X-3773	CM	encorafenib + binimetinib	317.9	27.5	23	51.4	3
X-3773	CM	encorafenib + binimetinib	337.6	27.9	27	60.8	4.5
X-3773	CM	encorafenib + binimetinib	344.5	27.4	29	64.1	2.6
X-3773	CM	encorafenib + binimetinib	355	28.1	32	69.1	5.2
X-3773	CM	encorafenib + binimetinib	393.6	28.1	36	87.5	5.2
X-3773	CM	encorafenib + binimetinib	473.9	27.5	39	125.7	3
X-3773	CM	binimetinib	190.1	27.4	0	0	0
X-3773	CM	binimetinib	192.2	27.7	3	1.1	1.1
X-3773	CM	binimetinib	200.4	26	7	5.4	-5.1
X-3773	CM	binimetinib	148	28.3	10	-22.1	3.3
X-3773	CM	binimetinib	146.2	27.9	14	-23.1	1.8
X-3773	CM	binimetinib	171.2	28.3	17	-10	3.3
X-3773	CM	binimetinib	307.2	28.4	21	61.6	3.6
X-3773	CM	binimetinib	414.2	28.2	24	117.8	2.9
X-3773	CM	binimetinib	414.2	29.2	27	117.8	6.6
X-3773	CM	binimetinib	427.7	29	30	124.9	5.8
X-3773	CM	binimetinib	431.7	29.7	34	127	8.4
X-3773	CM	binimetinib	451.5	28.4	37	137.5	3.6
X-3773	CM	binimetinib	500.9	28.8	40	163.4	5.1
X-3773	CM	binimetinib	581	29.5	43	205.6	7.7
X-3773	CM	TAS266	191.1	24.2	0	0	0
X-3773	CM	TAS266	138.6	24.7	5	-27.5	2.1
X-3773	CM	TAS266	167.7	24.6	9	-12.2	1.7
X-3773	CM	TAS266	137.2	24.6	13	-28.2	1.7
X-3773	CM	TAS266	170	25.1	16	-11.1	3.7
X-3773	CM	TAS266	235.9	24.5	20	23.4	1.2
X-3773	CM	TAS266	284	24.3	23	48.6	0.4
X-3773	CM	TAS266	494.8	25.1	27	158.9	3.7
X-3773	CM	TAS266	383.3	25	30	100.6	3.3
X-3773	CM	TAS266	353	25.4	34	84.7	5
X-3773	CM	TAS266	403.1	25.8	37	110.9	6.6
X-3773	CM	TAS266	494.8	25.6	40	158.9	5.8
X-3773	CM	TAS266	709.8	25.3	43	271.4	4.5
X-3773	CM	untreated	190.1	24.1	0	0	0
X-3773	CM	untreated	217.6	24.2	5	14.5	0.4
X-3773	CM	untreated	237.6	24.3	7	25	0.8
X-3773	CM	untreated	253.8	23.9	12	33.5	-0.8
X-3773	CM	untreated	356.1	24.1	16	87.3	0
X-3773	CM	untreated	366.6	24.5	20	92.9	1.7
X-3773	CM	untreated	399.2	24.6	23	110	2.1
X-3773	CM	untreated	410.3	24.1	27	115.9	0
X-3773	CM	untreated	459.2	24.1	30	141.6	0
X-3773	CM	untreated	487.4	24	34	156.4	-0.4
X-3773	CM	untreated	560.3	24.3	37	194.8	0.8
X-3773	CM	untreated	706	24	41	271.5	-0.4
X-3773	CM	untreated	813.6	23.8	43	328	-1.2
X-3782		abraxane	203.6	24	0	0	0
X-3782		abraxane	211.9	24.9	5	4.1	3.7
X-3782		abraxane	262.4	25	8	28.9	4.2
X-3782		abraxane	253.8	24.9	13	24.7	3.7
X-3782		abraxane	354.4	25.6	16	74.1	6.7
X-3782		abraxane	188	26	20	-7.7	8.3
X-3782		abraxane	364.1	25.1	23	78.8	4.6
X-3782		abraxane	497.8	26.3	27	144.5	9.6
X-3782		abraxane	535	25.8	30	162.8	7.5
X-3782		abraxane	601.8	25.2	34	195.6	5
X-3782		abraxane	612.4	26.3	37	200.8	9.6
X-3782		abraxane	667.2	25.7	41	227.7	7.1
X-3782		abraxane	671.7	26.3	43	229.9	9.6
X-3782		abraxane	775.2	25.8	47	280.7	7.5
X-3782		abraxane	990.4	25.7	50	386.4	7.1
X-3782		BKM120 + binimetinib	358	30.2	0	0	0
X-3782		BKM120 + binimetinib	292.2	29.6	1	-18.4	-2
X-3782		BKM120 + binimetinib	258.9	29.2	4	-27.7	-3.3
X-3782		BKM120 + binimetinib	260.5	29.3	8	-27.2	-3
X-3782		BKM120 + binimetinib	261.1	30.3	11	-27.1	0.3
X-3782		BKM120 + binimetinib	201.4	29.1	14	-43.7	-3.6
X-3782		BKM120 + binimetinib	265.4	29	18	-25.9	-4
X-3782		BKM120 + binimetinib	266.5	30.9	22	-25.6	2.3
X-3782		BKM120 + binimetinib	290.6	31	26	-18.8	2.6
X-3782		BKM120 + binimetinib	343.4	29.6	29	-4.1	-2
X-3782		BKM120 + binimetinib	322.2	30.4	32	-10	0.7
X-3782		BKM120 + binimetinib	314.2	30.7	36	-12.2	1.7
X-3782		BKM120 + binimetinib	287.1	29.7	40	-19.8	-1.7
X-3782		BKM120 + binimetinib	226.2	29.8	43	-36.8	-1.3
X-3782		BKM120 + binimetinib	264.3	30.5	47	-26.2	1
X-3782		BKM120 + binimetinib	304	30.6	53	-15.1	1.3
X-3782		BKM120 + binimetinib	375.6	29.5	64	4.9	-2.3
X-3782		BKM120 + binimetinib	411.1	28.9	67	14.8	-4.3
X-3782		BKM120 + binimetinib	374.6	29.4	70	4.6	-2.6
X-3782		BKM120 + binimetinib	427.4	28.5	74	19.4	-5.6
X-3782		BKM120 + binimetinib	425.1	30.5	77	18.7	1
X-3782	PDAC	BKM120 + binimetinib	428.3	29.7	82	19.6	-1.7
X-3782	PDAC	BKM120 + binimetinib	473.2	30.3	85	32.2	0.3
X-3782	PDAC	BKM120 + binimetinib	374.5	29.7	88	4.6	-1.7
X-3782	PDAC	BKM120 + binimetinib	323.6	30.4	91	-9.6	0.7
X-3782	PDAC	BKM120 + binimetinib	247.7	29.3	95	-30.8	-3
X-3782	PDAC	BKM120 + binimetinib	261.4	30.5	98	-27	1
X-3782	PDAC	BKM120 + binimetinib	135.6	30.3	102	-62.1	0.3
X-3782	PDAC	BKM120 + binimetinib	143.1	28.7	105	-60	-5
X-3782	PDAC	BKM120 + binimetinib	123.7	29.2	109	-65.4	-3.3
X-3782	PDAC	BKM120 + binimetinib	102.3	29.2	113	-71.4	-3.3
X-3782	PDAC	BKM120 + binimetinib	103.7	29.4	116	-71	-2.6
X-3782	PDAC	CLR457	265.8	23.3	0	0	0
X-3782	PDAC	CLR457	239.4	23.8	4	-9.9	2.1
X-3782	PDAC	CLR457	261.8	23.3	7	-1.5	0
X-3782	PDAC	CLR457	264.1	22.9	10	-0.6	-1.7
X-3782	PDAC	CLR457	274.2	23.3	13	3.2	0
X-3782	PDAC	CLR457	286.5	24.1	18	7.8	3.4
X-3782	PDAC	CLR457	292.8	23.9	21	10.2	2.6
X-3782	PDAC	CLR457	335.9	24.2	25	26.4	3.9
X-3782	PDAC	CLR457	342.2	25.9	28	28.7	11.2
X-3782	PDAC	CLR457	392	25.3	31	47.5	8.6
X-3782	PDAC	figitumumab"	235.8	27.9	0	0	0
X-3782	PDAC	figitumumab"	308.1	28	5	30.7	0.4
X-3782	PDAC	figitumumab"	375.4	27.9	8	59.2	0
X-3782	PDAC	figitumumab"	430.3	27.8	13	82.5	-0.4
X-3782	PDAC	figitumumab"	550.7	28.7	16	133.5	2.9
X-3782	PDAC	figitumumab"	478.5	28.7	20	102.9	2.9
X-3782	PDAC	figitumumab"	818.3	28.5	23	247	2.2
X-3782	PDAC	figitumumab"	716.3	30	27	203.8	7.5
X-3782	PDAC	figitumumab"	1037.3	30.5	30	339.9	9.3
X-3782	PDAC	figitumumab"	1267.4	29.7	34	437.5	6.5
X-3782	PDAC	figitumumab" + binimetinib	225.4	24	0	0	0
X-3782	PDAC	figitumumab" + binimetinib	242.4	24.1	4	7.5	0.4
X-3782	PDAC	figitumumab" + binimetinib	262.6	23.9	8	16.5	-0.4
X-3782	PDAC	figitumumab" + binimetinib	294.4	23.1	11	30.6	-3.7
X-3782	PDAC	figitumumab" + binimetinib	306.7	23.4	15	36.1	-2.5
X-3782	PDAC	figitumumab" + binimetinib	347.5	24.2	18	54.2	0.8
X-3782	PDAC	figitumumab" + binimetinib	349.4	23.7	22	55	-1.3
X-3782	PDAC	figitumumab" + binimetinib	346.5	24	25	53.7	0
X-3782	PDAC	figitumumab" + binimetinib	409.6	24.4	30	81.7	1.7
X-3782	PDAC	figitumumab" + binimetinib	469.8	24.5	32	108.4	2.1
X-3782	PDAC	figitumumab" + binimetinib	419.8	23.7	36	86.2	-1.3
X-3782	PDAC	figitumumab" + binimetinib	520.7	24.6	39	131	2.5
X-3782	PDAC	figitumumab" + binimetinib	622.3	24.2	43	176.1	0.8
X-3782	PDAC	figitumumab" + binimetinib	744.3	24.6	46	230.2	2.5
X-3782	PDAC	gemcitabine-50mpk	278.9	21.7	0	0	0
X-3782	PDAC	gemcitabine-50mpk	308.9	22.4	3	10.8	3.2
X-3782	PDAC	gemcitabine-50mpk	415.6	22.6	7	49	4.1
X-3782	PDAC	gemcitabine-50mpk	469.4	23.5	10	68.3	8.3
X-3782	PDAC	gemcitabine-50mpk	417.1	22.7	14	49.6	4.6
X-3782	PDAC	gemcitabine-50mpk	543.8	23.1	17	95	6.5
X-3782	PDAC	gemcitabine-50mpk	661.8	23.4	20	137.3	7.8
X-3782	PDAC	gemcitabine-50mpk	646.4	23.4	24	131.8	7.8
X-3782	PDAC	gemcitabine-50mpk	744.8	22.7	28	167	4.6
X-3782	PDAC	gemcitabine-50mpk	1078	24.5	35	286.5	12.9
X-3782	PDAC	INC424	222.6	29	0	0	0
X-3782	PDAC	INC424	290.5	29.3	4	30.5	1
X-3782	PDAC	INC424	309.2	28.7	7	38.9	-1
X-3782	PDAC	INC424	343.4	29.1	10	54.3	0.3
X-3782	PDAC	INC424	568.5	27.9	18	155.4	-3.8
X-3782	PDAC	INC424	627.2	27.8	21	181.8	-4.1
X-3782	PDAC	INC424	653.7	28.9	25	193.7	-0.3
X-3782	PDAC	INC424	725.6	29.2	28	226	0.7
X-3782	PDAC	INC424	807.2	30.2	31	262.6	4.1
X-3782	PDAC	LEE011	200.1	21.1	0	0	0
X-3782	PDAC	LEE011	195	22.4	5	-2.5	6.2
X-3782	PDAC	LEE011	220.6	21.6	8	10.2	2.4
X-3782	PDAC	LEE011	274.6	21.8	13	37.2	3.3
X-3782	PDAC	LEE011	288.1	23.2	16	44	10
X-3782	PDAC	LEE011	190.1	23.9	20	-5	13.3
X-3782	PDAC	LEE011	414.1	23.7	23	106.9	12.3
X-3782	PDAC	LEE011	487.7	23.8	27	143.7	12.8
X-3782	PDAC	LEE011	403.4	24.1	30	101.6	14.2
X-3782	PDAC	LEE011	425.6	23.9	34	112.7	13.3
X-3782	PDAC	LEE011	383.2	24.4	37	91.5	15.6
X-3782	PDAC	LEE011	403.4	23.6	41	101.6	11.8
X-3782	PDAC	LEE011	436.7	24.3	43	118.2	15.2
X-3782	PDAC	LEE011	435.2	23.5	47	117.5	11.4
X-3782	PDAC	LEE011	515.1	23.5	50	157.4	11.4
X-3782	PDAC	LEE011	513.1	23.9	54	156.4	13.3
X-3782	PDAC	LEE011	499.2	23.9	57	149.5	13.3
X-3782	PDAC	LEE011	491.6	24.6	62	145.7	16.6
X-3782	PDAC	LEE011	480.9	24	64	140.3	13.7
X-3782	PDAC	LEE011	551.4	23.7	68	175.6	12.3
X-3782	PDAC	LEE011	568.5	24	71	184.1	13.7
X-3782	PDAC	LEE011	477.4	24.1	75	138.6	14.2
X-3782	PDAC	LEE011	537	24	78	168.4	13.7
X-3782	PDAC	WNT974	225	23.9	0	0	0
X-3782	PDAC	WNT974	234.1	23.3	2	4	-2.5
X-3782	PDAC	WNT974	357.6	24.1	6	58.9	0.8
X-3782	PDAC	WNT974	618.1	22.3	9	174.7	-6.7
X-3782	PDAC	WNT974	580.6	21.2	13	158	-11.3
X-3782	PDAC	WNT974	602.8	18.3	16	167.9	-23.4
X-3782	PDAC	binimetinib	252.6	21.5	0	0	0
X-3782	PDAC	binimetinib	266	21.5	4	5.3	0
X-3782	PDAC	binimetinib	297.2	21	7	17.7	-2.3
X-3782	PDAC	binimetinib	197.6	21.8	11	-21.8	1.4
X-3782	PDAC	binimetinib	335.2	20.8	14	32.7	-3.3
X-3782	PDAC	binimetinib	326.9	21.1	17	29.4	-1.9
X-3782	PDAC	binimetinib	260.4	21.5	20	3.1	0
X-3782	PDAC	binimetinib	224.7	21.1	25	-11	-1.9
X-3782	PDAC	binimetinib	142.3	20.7	28	-43.7	-3.7
X-3782	PDAC	binimetinib	134.1	20.9	32	-46.9	-2.8
X-3782	PDAC	binimetinib	36.3	21	35	-85.6	-2.3
X-3782	PDAC	binimetinib-3.5mpk	244.3	26.1	0	0	0
X-3782	PDAC	binimetinib-3.5mpk	383.6	26.4	4	57	1.1
X-3782	PDAC	binimetinib-3.5mpk	439.7	27.5	8	80	5.4
X-3782	PDAC	binimetinib-3.5mpk	385.3	27.2	11	57.7	4.2
X-3782	PDAC	binimetinib-3.5mpk	225.4	27.8	15	-7.7	6.5
X-3782	PDAC	binimetinib-3.5mpk	186.3	27.3	18	-23.7	4.6
X-3782	PDAC	binimetinib-3.5mpk	246.9	26.4	22	1.1	1.1
X-3782	PDAC	binimetinib-3.5mpk	150.2	26.8	25	-38.5	2.7
X-3782	PDAC	binimetinib-3.5mpk	114.4	27.5	30	-53.2	5.4
X-3782	PDAC	binimetinib-3.5mpk	111.8	27	32	-54.2	3.4
X-3782	PDAC	binimetinib-3.5mpk	147.8	26.9	36	-39.5	3.1
X-3782	PDAC	binimetinib-3.5mpk	71.1	26.4	39	-70.9	1.1
X-3782	PDAC	binimetinib-3.5mpk	42.3	27.2	43	-82.7	4.2
X-3782	PDAC	binimetinib-3.5mpk	59.6	27.1	46	-75.6	3.8
X-3782	PDAC	binimetinib-3.5mpk	110.1	26.4	50	-54.9	1.1
X-3782	PDAC	binimetinib-3.5mpk	38.3	26.1	52	-84.3	0
X-3782	PDAC	binimetinib-3.5mpk	61.1	27.4	56	-75	5
X-3782	PDAC	binimetinib-3.5mpk	7	26.6	59	-97.1	1.9
X-3782	PDAC	binimetinib-3.5mpk	14.3	27	64	-94.1	3.4
X-3782	PDAC	binimetinib-3.5mpk	11.1	27.5	67	-95.5	5.4
X-3782	PDAC	binimetinib-3.5mpk	34.1	27.4	71	-86	5
X-3782	PDAC	binimetinib-3.5mpk	0	27.9	77	-100	6.9
X-3782	PDAC	binimetinib-3.5mpk	0	27.6	80	-100	5.7
X-3782	PDAC	binimetinib-3.5mpk	0	27.3	85	-100	4.6
X-3782	PDAC	binimetinib-3.5mpk	0	27.3	87	-100	4.6
X-3782	PDAC	binimetinib-3.5mpk	0	26.9	91	-100	3.1
X-3782	PDAC	binimetinib-3.5mpk	0	25.8	98	-100	-1.1
X-3782	PDAC	trametinib	200.1	25.5	0	0	0
X-3782	PDAC	trametinib	197.3	27.8	3	-1.4	9
X-3782	PDAC	trametinib	166.3	26.8	7	-16.9	5.1
X-3782	PDAC	trametinib	129.3	26.9	10	-35.4	5.5
X-3782	PDAC	trametinib	132.4	27.6	15	-33.8	8.2
X-3782	PDAC	trametinib	136.3	26.5	17	-31.9	3.9
X-3782	PDAC	trametinib	121.8	27.1	21	-39.1	6.3
X-3782	PDAC	trametinib	129.1	27.2	24	-35.5	6.7
X-3782	PDAC	trametinib	149.5	27.2	28	-25.3	6.7
X-3782	PDAC	trametinib	128.3	27.2	31	-35.9	6.7
X-3782	PDAC	trametinib	123.3	27.1	35	-38.4	6.3
X-3782	PDAC	trametinib	163.8	26.7	38	-18.1	4.7
X-3782	PDAC	trametinib	142.2	26.5	42	-28.9	3.9
X-3782	PDAC	trametinib	147.4	26.4	45	-26.3	3.5
X-3782	PDAC	trametinib	120.6	26.9	51	-39.7	5.5
X-3782	PDAC	untreated	322.9	24.5	0	0	0
X-3782	PDAC	untreated	264.9	24.6	3	-18	0.4
X-3782	PDAC	untreated	417.8	25.5	7	29.4	4.1
X-3782	PDAC	untreated	496.7	24.8	10	53.8	1.2
X-3782	PDAC	untreated	553.5	25.4	14	71.4	3.7
X-3782	PDAC	untreated	648.6	25.4	17	100.9	3.7
X-3782	PDAC	untreated	809.3	25.7	20	150.6	4.9
X-3782	PDAC	untreated	873.3	26.2	24	170.5	6.9
X-3782	PDAC	untreated	938	26.5	28	190.5	8.2
X-3782	PDAC	untreated	1156.9	25.7	31	258.3	4.9
X-3782	PDAC	untreated	1486.4	26.7	35	360.3	9
X-3782	PDAC	untreated	1466.6	25.7	37	354.2	4.9
X-3792	CRC	5FU	220.4	25.3	0	0	0
X-3792	CRC	5FU	256	23.6	3	16.2	-6.7
X-3792	CRC	5FU	339.3	24.3	7	54	-4
X-3792	CRC	5FU	355.6	23.5	10	61.4	-7.1
X-3792	CRC	5FU	383.7	23.9	14	74.1	-5.5
X-3792	CRC	5FU	378.4	22.6	17	71.7	-10.7
X-3792	CRC	5FU	384.1	23.6	21	74.3	-6.7
X-3792	CRC	5FU	406.6	23.1	23	84.5	-8.7
X-3792	CRC	5FU	414.2	23.1	27	88	-8.7
X-3792	CRC	BKM120	224.2	24.8	0	0	0
X-3792	CRC	BKM120	216.2	24.2	4	-3.6	-2.4
X-3792	CRC	BKM120	279.2	24.7	7	24.5	-0.4
X-3792	CRC	BKM120	321.6	24	11	43.4	-3.2
X-3792	CRC	BKM120	448.7	24.5	14	100.1	-1.2
X-3792	CRC	BKM120	415.7	24.5	18	85.4	-1.2
X-3792	CRC	BKM120	494.2	23.9	21	120.4	-3.6
X-3792	CRC	BKM120	376.2	25.2	25	67.8	1.6
X-3792	CRC	BKM120	557.4	25.5	27	148.6	2.8
X-3792	CRC	BKM120 + LJC049	241.5	26.5	0	0	0
X-3792	CRC	BKM120 + LJC049	308.5	26.5	3	27.8	0
X-3792	CRC	BKM120 + LJC049	385.5	25.8	7	59.6	-2.6
X-3792	CRC	BKM120 + LJC049	406.7	25.1	9	68.4	-5.3
X-3792	CRC	BKM120 + LJC049	380.8	23.5	13	57.7	-11.3
X-3792	CRC	BKM120 + LJC049	533.7	23.4	16	121	-11.7
X-3792	CRC	BYL719 + cetuximab + encorafenib	207.2	22.3	0	0	0
X-3792	CRC	BYL719 + cetuximab + encorafenib	235.4	27.3	3	13.6	22.4
X-3792	CRC	BYL719 + cetuximab + encorafenib	221	26	5	6.7	16.6
X-3792	CRC	BYL719 + cetuximab + encorafenib	269.6	27.6	10	30.1	23.8
X-3792	CRC	BYL719 + cetuximab + encorafenib	364.4	27	14	75.9	21.1
X-3792	CRC	BYL719 + cetuximab + encorafenib	386.3	29.1	17	86.4	30.5
X-3792	CRC	BYL719 + cetuximab + encorafenib	494.9	28.8	24	138.9	29.1
X-3792	CRC	BYL719 + cetuximab + encorafenib	565.2	29.2	27	172.8	30.9
X-3792	CRC	BYL719 + cetuximab + encorafenib	711.6	29.3	31	243.4	31.4
X-3792	CRC	BYL719 + cetuximab	235.2	24.1	0	0	0
X-3792	CRC	BYL719 + cetuximab	317.6	24.9	3	35	3.3
X-3792	CRC	BYL719 + cetuximab	305.9	24	5	30.1	-0.4
X-3792	CRC	BYL719 + cetuximab	327.6	23.3	10	39.3	-3.3
X-3792	CRC	BYL719 + cetuximab	444.8	21.9	14	89.1	-9.1
X-3792	CRC	BYL719 + cetuximab	466.4	22.6	17	98.3	-6.2
X-3792	CRC	BYL719 + cetuximab	494.7	21.7	24	110.3	-10
X-3792	CRC	BYL719 + cetuximab	555.9	23.5	27	136.4	-2.5
X-3792	CRC	BYL719 + cetuximab	614.3	23.3	31	161.2	-3.3
X-3792	CRC	BYL719	224	26.2	0	0	0
X-3792	CRC	BYL719	268.5	27.2	4	19.8	3.8
X-3792	CRC	BYL719	232.4	26.7	7	3.7	1.9
X-3792	CRC	BYL719	190.9	26.7	11	-14.8	1.9
X-3792	CRC	BYL719	241.6	26.8	13	7.8	2.3
X-3792	CRC	BYL719	232.8	26.8	17	3.9	2.3
X-3792	CRC	BYL719	248	26.8	20	10.7	2.3
X-3792	CRC	BYL719	308.8	27.3	24	37.9	4.2
X-3792	CRC	BYL719	339	27.3	27	51.3	4.2
X-3792	CRC	BYL719	410.6	26.7	32	83.3	1.9
X-3792	CRC	BYL719 + LJM716	229.2	24.6	0	0	0
X-3792	CRC	BYL719 + LJM716	157.8	23	4	-31.2	-6.5
X-3792	CRC	BYL719 + LJM716	189.3	21.7	7	-17.4	-11.8
X-3792	CRC	BYL719 + LJM716	163.9	21.5	11	-28.5	-12.6
X-3792	CRC	BYL719 + LJM716	188.3	21.8	13	-17.9	-11.4
X-3792	CRC	BYL719 + LJM716	236	22.2	17	3	-9.8
X-3792	CRC	BYL719 + LJM716	257.7	22.9	20	12.4	-6.9
X-3792	CRC	BYL719 + LJM716	270.8	22.7	24	18.1	-7.7
X-3792	CRC	BYL719 + LJM716	279.7	22.6	27	22	-8.1
X-3792	CRC	BYL719 + LJM716	320.9	22.4	32	40	-8.9
X-3792	CRC	BYL719 + LJM716	354.8	21.9	35	54.8	-11
X-3792	CRC	BYL719 + LJM716	350.5	21.6	38	52.9	-12.2
X-3792	CRC	BYL719 + LJM716	403.6	22.4	41	76.1	-9.1
X-3792	CRC	BYL719 + binimetinib	210.9	23.4	0	0	0
X-3792	CRC	BYL719 + binimetinib	258	21.2	3	22.4	-9.4
X-3792	CRC	BYL719 + binimetinib	208.5	21.2	7	-1.1	-9.4
X-3792	CRC	BYL719 + binimetinib	191.4	20.8	9	-9.2	-11.1
X-3792	CRC	BYL719 + binimetinib	274	20.9	13	29.9	-10.7
X-3792	CRC	BYL719 + binimetinib	348.9	20.5	16	65.5	-12.4
X-3792	CRC	BYL719 + binimetinib	496.3	21.7	20	135.4	-7.3
X-3792	CRC	BYL719 + binimetinib	447.7	22.8	23	112.3	-2.6
X-3792	CRC	BYL719 + binimetinib	412.8	23	28	95.8	-1.7
X-3792	CRC	BYL719 + encorafenib	224.6	25.9	0	0	0
X-3792	CRC	BYL719 + encorafenib	199	28.2	2	-11.4	8.9
X-3792	CRC	BYL719 + encorafenib	239.7	27.4	6	6.7	5.8
X-3792	CRC	BYL719 + encorafenib	206.9	27	9	-7.9	4.2
X-3792	CRC	BYL719 + encorafenib	335.3	28.5	13	49.3	10
X-3792	CRC	BYL719 + encorafenib	398.9	28.2	16	77.6	8.9
X-3792	CRC	CGM097	209.9	25.7	0	0	0
X-3792	CRC	CGM097	193.9	24.9	4	-7.6	-3.1
X-3792	CRC	CGM097	186.5	24.9	7	-11.2	-3.1
X-3792	CRC	CGM097	203.7	24.6	11	-2.9	-4.3
X-3792	CRC	CGM097	229.5	25.6	14	9.3	-0.4
X-3792	CRC	CGM097	288.3	25.1	18	37.3	-2.3
X-3792	CRC	CGM097	265.4	25.7	21	26.4	0
X-3792	CRC	CGM097	334.4	25.8	25	59.3	0.4
X-3792	CRC	CGM097	387.5	26.2	28	84.6	1.9
X-3792	CRC	CGM097	397.9	27.2	32	89.5	5.8
X-3792	CRC	CGM097	369.7	26.5	34	76.1	3.1
X-3792	CRC	CGM097	398.7	26.5	38	89.9	3.1
X-3792	CRC	CGM097	429.9	26.5	41	104.8	3.1
X-3792	CRC	CKX620	231.5	26.6	0	0	0
X-3792	CRC	CKX620	249.8	24.7	3	7.9	-7.1
X-3792	CRC	CKX620	233.2	26.1	7	0.7	-1.8
X-3792	CRC	CKX620	229.4	26.8	10	-0.9	0.8
X-3792	CRC	CKX620	291.9	27.1	14	26.1	1.9
X-3792	CRC	CKX620	312.2	26.8	16	34.8	0.8
X-3792	CRC	CKX620	373.7	27.2	20	61.4	2.3
X-3792	CRC	CKX620	388.7	25.5	23	67.9	-4.1
X-3792	CRC	CKX620	436.1	25.6	27	88.4	-3.8
X-3792	CRC	CLR457	223.4	23.1	0	0	0
X-3792	CRC	CLR457	239.9	21.6	3	7.4	-6.5
X-3792	CRC	CLR457	271.2	21.2	7	21.4	-8.2
X-3792	CRC	CLR457	261.2	22.2	10	16.9	-3.9
X-3792	CRC	CLR457	375.7	22.7	14	68.2	-1.7
X-3792	CRC	CLR457	273.9	22.5	16	22.6	-2.6
X-3792	CRC	CLR457	332.6	22.6	20	48.9	-2.2
X-3792	CRC	CLR457	317.4	22.3	23	42.1	-3.5
X-3792	CRC	CLR457	381.7	22.6	27	70.9	-2.2
X-3792	CRC	CLR457	352.7	22.6	30	57.9	-2.2
X-3792	CRC	CLR457	428.1	22.4	35	91.7	-3
X-3792	CRC	HDM201	231.9	27.2	0	0	0
X-3792	CRC	HDM201	332.5	26.5	3	43.4	-2.6
X-3792	CRC	HDM201	445.3	25	7	92	-8.1
X-3792	CRC	HDM201	422	24.9	10	82	-8.5
X-3792	CRC	HDM201	357.7	23.7	14	54.2	-12.9
X-3792	CRC	HDM201	416	23.1	16	79.4	-15.1
X-3792	CRC	HDM201	400.4	22.3	20	72.6	-18
X-3792	CRC	HDM201	534.2	24.9	23	130.3	-8.5
X-3792	CRC	HDM201	635.1	22.9	27	173.8	-15.8
X-3792	CRC	cetuximab	228.5	24.9	0	0	0
X-3792	CRC	cetuximab	232.9	24	3	1.9	-3.6
X-3792	CRC	cetuximab	324.3	22.5	8	41.9	-9.6
X-3792	CRC	cetuximab	411.7	22.7	11	80.2	-8.8
X-3792	CRC	cetuximab	474.3	20.1	14	107.6	-19.3
X-3792	CRC	cetuximab + encorafenib	201.2	24.7	0	0	0
X-3792	CRC	cetuximab + encorafenib	266.2	24.8	5	32.3	0.4
X-3792	CRC	cetuximab + encorafenib	254.7	24.5	8	26.6	-0.8
X-3792	CRC	cetuximab + encorafenib	274.2	24.3	11	36.3	-1.6
X-3792	CRC	cetuximab + encorafenib	258.9	24.5	13	28.7	-0.8
X-3792	CRC	cetuximab + encorafenib	327	27.2	18	62.5	10.1
X-3792	CRC	cetuximab + encorafenib	335	24.9	22	66.5	0.8
X-3792	CRC	cetuximab + encorafenib	356	25.5	25	76.9	3.2
X-3792	CRC	cetuximab + encorafenib	394.9	24.9	32	96.3	0.8
X-3792	CRC	cetuximab + encorafenib	430.6	24.6	35	114	-0.4
X-3792	CRC	cetuximab + encorafenib	457.6	24.9	39	127.4	0.8
X-3792	CRC	LEE011	246.9	23.9	0	0	0
X-3792	CRC	LEE011	229.4	24.4	4	-7.1	2.1
X-3792	CRC	LEE011	366.1	24.7	7	48.3	3.3
X-3792	CRC	LEE011	340.8	24.2	11	38	1.3
X-3792	CRC	LEE011	308.1	24.7	14	24.8	3.3
X-3792	CRC	LEE011	347.2	25.5	18	40.7	6.7
X-3792	CRC	LEE011	458.8	25.3	21	85.8	5.9
X-3792	CRC	LEE011	430.5	25.6	25	74.4	7.1
X-3792	CRC	LEE011	455.1	25.3	28	84.4	5.9
X-3792	CRC	encorafenib	220.5	24	0	0	0
X-3792	CRC	encorafenib	556.6	23.7	4	152.4	-1.3
X-3792	CRC	encorafenib	726.4	24.4	7	229.4	1.7
X-3792	CRC	encorafenib	1044.5	23.6	11	373.6	-1.7
X-3792	CRC	encorafenib	1111.8	24.5	14	404.2	2.1
X-3792	CRC	encorafenib	1550.9	24.5	18	603.3	2.1
X-3792	CRC	encorafenib	1824	24.5	21	727.1	2.1
X-3792	CRC	LJC049	201.7	27	0	0	0
X-3792	CRC	LJC049	211.3	26.9	3	4.8	-0.4
X-3792	CRC	LJC049	278.4	26.1	7	38	-3.3
X-3792	CRC	LJC049	339.1	25.5	10	68.1	-5.6
X-3792	CRC	LJC049	320.4	26.4	14	58.8	-2.2
X-3792	CRC	LJC049	415.7	27	17	106.1	0
X-3792	CRC	LJC049	600.7	26.5	21	197.8	-1.9
X-3792	CRC	LJC049	625.4	26.5	23	210	-1.9
X-3792	CRC	LJC049	722.6	26.3	24	258.2	-2.6
X-3792	CRC	LJC049	912.6	26.3	27	352.5	-2.6
X-3792	CRC	LKA136	246.8	23.1	0	0	0
X-3792	CRC	LKA136	297.5	23.3	3	20.5	0.9
X-3792	CRC	LKA136	273.9	22.3	7	11	-3.5
X-3792	CRC	LKA136	317.7	22.4	10	28.7	-3
X-3792	CRC	LKA136	308.3	22.3	14	24.9	-3.5
X-3792	CRC	LKA136	426.2	23	17	72.7	-0.4
X-3792	CRC	LKA136	425	22.8	21	72.2	-1.3
X-3792	CRC	LKA136	547.5	22.4	23	121.8	-3
X-3792	CRC	LKA136	549.9	22.6	27	122.8	-2.2
X-3792	CRC	binimetinib	213.5	24.3	0	0	0
X-3792	CRC	binimetinib	283.2	24.1	4	32.6	-0.8
X-3792	CRC	binimetinib	343.1	24.5	7	60.7	0.8
X-3792	CRC	binimetinib	468.1	23.9	11	119.2	-1.6
X-3792	CRC	binimetinib	376.8	24.4	14	76.5	0.4
X-3792	CRC	binimetinib	565.7	25.2	18	165	3.7
X-3792	CRC	binimetinib	729.7	24.3	21	241.8	0
X-3792	CRC	binimetinib	631.1	24.8	25	195.6	2.1
X-3792	CRC	binimetinib	676.2	24.8	28	216.7	2.1
X-3792	CRC	untreated	229.4	24.5	0	0	0
X-3792	CRC	untreated	406.6	24.1	3	77.2	-1.6
X-3792	CRC	untreated	433.9	24	7	89.1	-2
X-3792	CRC	untreated	698.8	25	10	204.6	2
X-3792	CRC	untreated	775.6	23.3	14	238.1	-4.9
X-3792	CRC	untreated	951.2	23.8	17	314.6	-2.9
X-3792	CRC	untreated	1440.1	23.8	21	527.7	-2.9
X-3792	CRC	untreated	1459.7	24.1	24	536.3	-1.6
X-3792	CRC	untreated	1650.6	23.7	28	619.4	-3.4
X-3792	CRC	LFW527 + binimetinib	200.87	25.39	0	0	0
X-3792	CRC	LFW527 + binimetinib	201.33	24.22	2	0.2	-4.6
X-3792	CRC	LFW527 + binimetinib	203.73	24.42	6	1.4	-3.8
X-3792	CRC	LFW527 + binimetinib	210.36	24.34	8	4.7	-4.1
X-3792	CRC	LFW527 + binimetinib	256.38	25.39	13	27.6	0
X-3792	CRC	LFW527 + binimetinib	283.38	24.28	16	41.1	-4.4
X-3792	CRC	LFW527 + binimetinib	306.45	24.36	20	52.6	-4.1
X-3792	CRC	LFW527 + binimetinib	316.38	24.52	23	57.5	-3.4
X-3792	CRC	LFW527 + binimetinib	409.36	25.47	27	103.8	0.3
X-3792	CRC	LFW527 + binimetinib	402.61	24.71	30	100.4	-2.7
X-3792	CRC	LFW527 + binimetinib	481.98	24.77	34	139.9	-2.4
X-3792	CRC	LFW527 + binimetinib	618.24	24.79	37	207.8	-2.4
X-3800	PDAC	abraxane	225.6	29.5	0	0	0
X-3800	PDAC	abraxane	358.5	29	5	58.9	-1.7
X-3800	PDAC	abraxane	429.6	29.5	8	90.4	0
X-3800	PDAC	abraxane	404.9	30.1	11	79.5	2
X-3800	PDAC	abraxane	492	29.4	14	118.1	-0.3
X-3800	PDAC	abraxane	698.1	29	18	209.4	-1.7
X-3800	PDAC	abraxane	790.9	29.9	21	250.6	1.4
X-3800	PDAC	BKM120 + binimetinib	209.3	26.7	0	0	0
X-3800	PDAC	BKM120 + binimetinib	180.1	27.3	5	-14	2.2
X-3800	PDAC	BKM120 + binimetinib	91.3	26.9	8	-56.4	0.7
X-3800	PDAC	BKM120 + binimetinib	158.7	27	11	-24.2	1.1
X-3800	PDAC	BKM120 + binimetinib	122.3	26.7	15	-41.6	0
X-3800	PDAC	BKM120 + binimetinib	151	27	20	-27.9	1.1
X-3800	PDAC	BKM120 + binimetinib	86.4	26.4	22	-58.7	-1.1
X-3800	PDAC	BKM120 + binimetinib	63.7	25.8	25	-69.6	-3.4
X-3800	PDAC	BKM120 + binimetinib	48.6	26.7	27	-76.8	0
X-3800	PDAC	BKM120 + binimetinib	61.8	26.9	29	-70.5	0.7
X-3800	PDAC	BKM120 + binimetinib	99.6	27.1	33	-52.4	1.5
X-3800	PDAC	BKM120 + binimetinib	109.3	25.8	35	-47.8	-3.4
X-3800	PDAC	BKM120 + binimetinib	64.5	26.8	40	-69.2	0.4
X-3800	PDAC	BKM120 + binimetinib	49.9	26.3	43	-76.2	-1.5
X-3800	PDAC	BKM120 + binimetinib	63.5	27	47	-69.7	1.1
X-3800	PDAC	BKM120 + binimetinib	57.3	26	50	-72.6	-2.6
X-3800	PDAC	BKM120 + binimetinib	33.1	26.6	54	-84.2	-0.4
X-3800	PDAC	BKM120 + binimetinib	38.8	26.1	57	-81.5	-2.2
X-3800	PDAC	BKM120 + binimetinib	26.5	26.2	61	-87.3	-1.9
X-3800	PDAC	BKM120 + binimetinib	35.7	27.4	64	-82.9	2.6
X-3800	PDAC	BKM120 + binimetinib	20	27.3	68	-90.4	2.2
X-3800	PDAC	BKM120 + binimetinib	19.9	27.7	71	-90.5	3.7
X-3800	PDAC	BKM120 + binimetinib	23.4	27.6	75	-88.8	3.4
X-3800	PDAC	BKM120 + binimetinib	26.4	26.6	78	-87.4	-0.4
X-3800	PDAC	BKM120 + binimetinib	26.5	26.7	82	-87.3	0
X-3800	PDAC	BKM120 + binimetinib	27.6	26.8	85	-86.8	0.4
X-3800	PDAC	BKM120 + binimetinib	18.9	25.9	89	-91	-3
X-3800	PDAC	BKM120 + binimetinib	25.6	25.8	96	-87.8	-3.4
X-3800	PDAC	BKM120 + binimetinib	21	26.7	103	-90	0
X-3800	PDAC	BKM120 + binimetinib	0	26.9	106	-100	0.7
X-3800	PDAC	BKM120 + LDE225	262.1	25.5	0	0	0
X-3800	PDAC	BKM120 + LDE225	243.5	23.6	5	-7.1	-7.5
X-3800	PDAC	BKM120 + LDE225	195.5	23.9	8	-25.4	-6.3
X-3800	PDAC	BKM120 + LDE225	180.1	24.4	11	-31.3	-4.3
X-3800	PDAC	BKM120 + LDE225	115.6	24.6	15	-55.9	-3.5
X-3800	PDAC	BKM120 + LDE225	96.7	23.8	20	-63.1	-6.7
X-3800	PDAC	BKM120 + LDE225	95.9	23.7	22	-63.4	-7.1
X-3800	PDAC	BKM120 + LDE225	54.8	23.7	25	-79.1	-7.1
X-3800	PDAC	BKM120 + LDE225	80.8	23.5	27	-69.2	-7.8
X-3800	PDAC	BKM120 + LDE225	101.8	22.5	29	-61.2	-11.8
X-3800	PDAC	BKM120 + LDE225	112.3	20.7	33	-57.2	-18.8
X-3800	PDAC	BKM120	243.7	27.8	0	0	0
X-3800	PDAC	BKM120	202.8	28.9	4	-16.8	4
X-3800	PDAC	BKM120	324.2	28	7	33	0.7
X-3800	PDAC	BKM120	377.1	28.6	12	54.7	2.9
X-3800	PDAC	BKM120	364.6	29.2	15	49.6	5
X-3800	PDAC	BKM120	394.6	29.6	19	61.9	6.5
X-3800	PDAC	BKM120	415.3	29.7	22	70.4	6.8
X-3800	PDAC	BKM120	386.2	29.5	26	58.5	6.1
X-3800	PDAC	BKM120	237.8	28.7	29	-2.4	3.2
X-3800	PDAC	BKM120	398	29.1	34	63.3	4.7
X-3800	PDAC	BKM120	401.1	28.4	36	64.6	2.2
X-3800	PDAC	BKM120	435.4	29.5	40	78.7	6.1
X-3800	PDAC	BKM120	428.8	29.6	43	76	6.5
X-3800	PDAC	BKM120	344.3	29.1	47	41.3	4.7
X-3800	PDAC	BKM120	558.4	28.9	50	129.1	4
X-3800	PDAC	BKM120	882.3	29.3	54	262	5.4
X-3800	PDAC	BYL719	218	24.8	0	0	0
X-3800	PDAC	BYL719	206.4	25	4	-5.3	0.8
X-3800	PDAC	BYL719	229.7	25.4	7	5.4	2.4
X-3800	PDAC	BYL719	248	25.2	11	13.8	1.6
X-3800	PDAC	BYL719	245.5	25.7	14	12.6	3.6
X-3800	PDAC	BYL719	216.8	24.8	19	-0.6	0
X-3800	PDAC	BYL719	221.5	24.7	22	1.6	-0.4
X-3800	PDAC	BYL719	191.1	24.7	25	-12.3	-0.4
X-3800	PDAC	BYL719	191.4	25.9	28	-12.2	4.4
X-3800	PDAC	BYL719	206.5	23.9	31	-5.3	-3.6
X-3800	PDAC	BYL719	238.2	25.9	36	9.3	4.4
X-3800	PDAC	BYL719	255.9	24.7	39	17.4	-0.4
X-3800	PDAC	BYL719	273.9	25.8	42	25.6	4
X-3800	PDAC	BYL719	311.1	24.3	45	42.7	-2
X-3800	PDAC	BYL719	331.1	26.1	49	51.9	5.2
X-3800	PDAC	BYL719	329.8	25.1	52	51.3	1.2
X-3800	PDAC	BYL719	360.2	26	56	65.2	4.8
X-3800	PDAC	BYL719	414.1	24.2	59	90	-2.4
X-3800	PDAC	BYL719	440.4	25.8	63	102	4
X-3800	PDAC	BYL719	441.1	25.8	67	102.3	4
X-3800	PDAC	BYL719	597.4	26.1	70	174	5.2
X-3800	PDAC	BYL719	651.9	24.7	74	199	-0.4
X-3800	PDAC	BYL719	665.5	26.1	77	205.3	5.2
X-3800	PDAC	BYL719	729.3	25.7	82	234.5	3.6
X-3800	PDAC	BYL719	780.2	24.5	85	257.9	-1.2
X-3800	PDAC	BYL719	853.8	23.5	89	291.7	-5.2
X-3800	PDAC	BYL719	897.7	24.1	92	311.8	-2.8
X-3800	PDAC	BYL719	954.3	24.5	95	337.8	-1.2
X-3800	PDAC	BYL719 + LJM716	224.2	26.6	0	0	0
X-3800	PDAC	BYL719 + LJM716	250.7	26.2	3	11.8	-1.5
X-3800	PDAC	BYL719 + LJM716	239.5	26.1	6	6.8	-1.9
X-3800	PDAC	BYL719 + LJM716	235.3	25.7	11	5	-3.4
X-3800	PDAC	BYL719 + LJM716	235.6	25.7	14	5.1	-3.4
X-3800	PDAC	BYL719 + LJM716	244.2	25.5	17	8.9	-4.1
X-3800	PDAC	BYL719 + LJM716	252.8	26.6	20	12.8	0
X-3800	PDAC	BYL719 + LJM716	273.5	25.1	23	22	-5.6
X-3800	PDAC	BYL719 + LJM716	285.1	26.3	28	27.2	-1.1
X-3800	PDAC	BYL719 + LJM716	310.6	25.1	31	38.5	-5.6
X-3800	PDAC	BYL719 + LJM716	361	26.5	34	61	-0.4
X-3800	PDAC	BYL719 + LJM716	369.5	25.1	37	64.8	-5.6
X-3800	PDAC	BYL719 + LJM716	363.9	25.8	41	62.3	-3
X-3800	PDAC	BYL719 + LJM716	482.2	25.6	44	115.1	-3.8
X-3800	PDAC	BYL719 + LJM716	506.4	26.7	48	125.9	0.4
X-3800	PDAC	BYL719 + LJM716	546.9	24.9	51	143.9	-6.4
X-3800	PDAC	BYL719 + LJM716	641.1	25.5	55	186	-4.1
X-3800	PDAC	CLR457	200	25.8	0	0	0
X-3800	PDAC	CLR457	182	25.5	3	-9	-1.2
X-3800	PDAC	CLR457	165	26.2	6	-17.5	1.6
X-3800	PDAC	CLR457	154.1	26.4	9	-23	2.3
X-3800	PDAC	CLR457	121.6	26.3	12	-39.2	1.9
X-3800	PDAC	CLR457	108.9	28.3	17	-45.6	9.7
X-3800	PDAC	CLR457	131.3	25.7	20	-34.3	-0.4
X-3800	PDAC	CLR457	139.5	26.7	23	-30.2	3.5
X-3800	PDAC	CLR457	140.6	26.6	26	-29.7	3.1
X-3800	PDAC	CLR457	135.4	27.1	30	-32.3	5
X-3800	PDAC	CLR457	124.4	26.6	33	-37.8	3.1
X-3800	PDAC	CLR457	137.1	26.3	37	-31.4	1.9
X-3800	PDAC	CLR457	148.6	26.5	40	-25.7	2.7
X-3800	PDAC	CLR457	149.9	27.2	44	-25	5.4
X-3800	PDAC	CLR457	139.2	27.2	48	-30.4	5.4
X-3800	PDAC	CLR457	133.2	27.1	51	-33.4	5
X-3800	PDAC	CLR457	142.7	27.2	55	-28.7	5.4
X-3800	PDAC	CLR457	137.6	27.1	58	-31.2	5
X-3800	PDAC	CLR457	143.5	28	63	-28.2	8.5
X-3800	PDAC	CLR457	174.6	27.6	66	-12.7	7
X-3800	PDAC	CLR457	182.9	27.1	70	-8.6	5
X-3800	PDAC	CLR457	210.9	27.3	73	5.4	5.8
X-3800	PDAC	CLR457	211.6	27.8	76	5.8	7.8
X-3800	PDAC	CLR457	204.9	27.5	79	2.4	6.6
X-3800	PDAC	CLR457	192.6	28.1	83	-3.7	8.9
X-3800	PDAC	CLR457	170.5	28.2	87	-14.7	9.3
X-3800	PDAC	CLR457	161.8	27.1	91	-19.1	5
X-3800	PDAC	CLR457	168.3	27.5	95	-15.8	6.6
X-3800	PDAC	CLR457	175	27.4	98	-12.5	6.2
X-3800	PDAC	CLR457	175.8	27.1	100	-12.1	5
X-3800	PDAC	CLR457	174.2	28.2	104	-12.9	9.3
X-3800	PDAC	CLR457	165.8	27.6	111	-17.1	7
X-3800	PDAC	CLR457	150.1	28	114	-25	8.5
X-3800	PDAC	CLR457	157.5	28.9	118	-21.3	12
X-3800	PDAC	CLR457	160	28.7	121	-20	11.2
X-3800	PDAC	CLR457	143	28.6	125	-28.5	10.9
X-3800	PDAC	CLR457	127.8	28.3	132	-36.1	9.7
X-3800	PDAC	CLR457	124.3	28.4	136	-37.9	10.1
X-3800	PDAC	HDM201	201.5	31.7	0	0	0
X-3800	PDAC	HDM201	199.9	31.7	3	-0.8	0
X-3800	PDAC	HDM201	176.8	31.5	7	-12.3	-0.6
X-3800	PDAC	HDM201	154.9	31.8	10	-23.1	0.3
X-3800	PDAC	HDM201	129.9	32.1	14	-35.5	1.3
X-3800	PDAC	HDM201	125	33.1	17	-38	4.4
X-3800	PDAC	HDM201	125.3	31.6	22	-37.8	-0.3
X-3800	PDAC	HDM201	123.4	30.6	25	-38.8	-3.5
X-3800	PDAC	HDM201	160.9	29.6	28	-20.1	-6.6
X-3800	PDAC	HDM201	161.8	31	31	-19.7	-2.2
X-3800	PDAC	HDM201	131.3	29.8	34	-34.8	-6
X-3800	PDAC	HDM201	124.7	31.6	39	-38.1	-0.3
X-3800	PDAC	HDM201	106.7	29.4	42	-47	-7.3
X-3800	PDAC	HDM201	115.2	31.4	45	-42.8	-0.9
X-3800	PDAC	HDM201	118.8	30.5	48	-41	-3.8
X-3800	PDAC	HDM201	145.7	32	52	-27.7	0.9
X-3800	PDAC	HDM201	150.4	30.9	55	-25.4	-2.5
X-3800	PDAC	HDM201	184.4	34.2	59	-8.5	7.9
X-3800	PDAC	HDM201	200.4	30.1	62	-0.5	-5
X-3800	PDAC	HDM201	191.1	33	66	-5.2	4.1
X-3800	PDAC	HDM201	207.6	33.1	70	3	4.4
X-3800	PDAC	HDM201	253	33.2	73	25.6	4.7
X-3800	PDAC	HDM201	240.1	31.1	77	19.2	-1.9
X-3800	PDAC	HDM201	235.1	32.4	80	16.7	2.2
X-3800	PDAC	HDM201	251	32.5	85	24.6	2.5
X-3800	PDAC	HDM201	267.7	31	88	32.9	-2.2
X-3800	PDAC	HDM201	263.3	32.6	92	30.7	2.8
X-3800	PDAC	HDM201	317.2	31.1	95	57.4	-1.9
X-3800	PDAC	HDM201	344.3	31.3	98	70.9	-1.3
X-3800	PDAC	HDM201	349.6	32.7	101	73.5	3.2
X-3800	PDAC	HDM201	359.9	33	105	78.6	4.1
X-3800	PDAC	HDM201	388	32.8	109	92.6	3.5
X-3800	PDAC	HDM201	408.9	31.3	113	102.9	-1.3
X-3800	PDAC	HDM201	414.6	32.1	117	105.8	1.3
X-3800	PDAC	HDM201	432.3	31.1	120	114.5	-1.9
X-3800	PDAC	HDM201	448.1	31.3	122	122.4	-1.3
X-3800	PDAC	HDM201	462.3	30.6	126	129.4	-3.5
X-3800	PDAC	HDM201	487.1	29	133	141.7	-8.5
X-3800	PDAC	HDM201	494	27.1	136	145.2	-14.5
X-3800	PDAC	HDM201	468.3	28.3	140	132.4	-10.7
X-3800	PDAC	figitumumab" + binimetinib	229.6	26.7	0	0	0
X-3800	PDAC	figitumumab" + binimetinib	451.1	26.7	2	96.5	0
X-3800	PDAC	figitumumab" + binimetinib	277.8	27.2	6	21	1.9
X-3800	PDAC	figitumumab" + binimetinib	543.5	27.6	9	136.7	3.4
X-3800	PDAC	figitumumab" + binimetinib	340.6	27	14	48.3	1.1
X-3800	PDAC	figitumumab" + binimetinib	509.2	28	17	121.8	4.9
X-3800	PDAC	figitumumab" + binimetinib	422.5	27.5	22	84	3
X-3800	PDAC	figitumumab" + binimetinib	360.8	27.5	24	57.1	3
X-3800	PDAC	figitumumab" + binimetinib	537.8	27.4	28	134.2	2.6
X-3800	PDAC	figitumumab" + binimetinib	481	27.7	31	109.5	3.7
X-3800	PDAC	figitumumab" + binimetinib	504.1	28.1	35	119.6	5.2
X-3800	PDAC	figitumumab" + binimetinib	642.2	27.7	37	179.7	3.7
X-3800	PDAC	figitumumab" + binimetinib	550.1	27.6	42	139.6	3.4
X-3800	PDAC	figitumumab" + binimetinib	505.9	27.5	45	120.3	3
X-3800	PDAC	figitumumab" + binimetinib	564.5	27.6	49	145.9	3.4
X-3800	PDAC	figitumumab"	204.9	26.7	0	0	0
X-3800	PDAC	figitumumab"	221.2	25.9	5	8	-3
X-3800	PDAC	figitumumab"	287.4	26.1	11	40.3	-2.2
X-3800	PDAC	figitumumab"	403.2	26.1	14	96.8	-2.2
X-3800	PDAC	figitumumab"	419.7	27.3	18	104.8	2.2
X-3800	PDAC	figitumumab"	511	26.8	21	149.4	0.4
X-3800	PDAC	figitumumab"	620.4	26.4	25	202.8	-1.1
X-3800	PDAC	figitumumab"	675.8	25.6	28	229.8	-4.1
X-3800	PDAC	figitumumab"	883.1	27.3	32	331	2.2
X-3800	PDAC	figitumumab"	919.9	26.9	35	349	0.7
X-3800	PDAC	gemcitabine-50mpk	263.1	33.9	0	0	0
X-3800	PDAC	gemcitabine-50mpk	352.7	33.9	3	34.1	0
X-3800	PDAC	gemcitabine-50mpk	315.4	31.9	7	19.9	-5.9
X-3800	PDAC	gemcitabine-50mpk	326.1	31.3	10	23.9	-7.7
X-3800	PDAC	gemcitabine-50mpk	329.5	28.5	14	25.2	-15.9
X-3800	PDAC	gemcitabine-50mpk	275.2	31.6	17	4.6	-6.8
X-3800	PDAC	gemcitabine-50mpk	341.1	32.7	21	29.6	-3.5
X-3800	PDAC	gemcitabine-50mpk	342.3	31.9	24	30.1	-5.9
X-3800	PDAC	gemcitabine-50mpk	308.7	31.9	27	17.3	-5.9
X-3800	PDAC	gemcitabine-50mpk	271.1	32.4	30	3	-4.4
X-3800	PDAC	gemcitabine-50mpk	209	33.3	35	-20.6	-1.8
X-3800	PDAC	gemcitabine-50mpk	211.9	33.2	38	-19.5	-2.1
X-3800	PDAC	gemcitabine-50mpk	248.1	33.4	42	-5.7	-1.5
X-3800	PDAC	gemcitabine-50mpk	204.8	34.3	45	-22.2	1.2
X-3800	PDAC	gemcitabine-50mpk	274.2	34.1	48	4.2	0.6
X-3800	PDAC	gemcitabine-50mpk	233.9	35.2	50	-11.1	3.8
X-3800	PDAC	gemcitabine-50mpk	238.8	35.4	56	-9.2	4.4
X-3800	PDAC	gemcitabine-50mpk	294.8	36.5	58	12	7.7
X-3800	PDAC	gemcitabine-50mpk	235.2	33.8	63	-10.6	-0.3
X-3800	PDAC	gemcitabine-50mpk	280.7	36	66	6.7	6.2
X-3800	PDAC	gemcitabine-50mpk	272.3	35.6	69	3.5	5
X-3800	PDAC	gemcitabine-50mpk	259.9	36.2	73	-1.2	6.8
X-3800	PDAC	gemcitabine-50mpk	276.9	35.5	77	5.2	4.7
X-3800	PDAC	gemcitabine-50mpk	233.5	36.9	80	-11.3	8.8
X-3800	PDAC	gemcitabine-50mpk	177.9	36.2	85	-32.4	6.8
X-3800	PDAC	gemcitabine-50mpk	191.4	36.6	87	-27.3	8
X-3800	PDAC	gemcitabine-50mpk	144.9	36.4	91	-44.9	7.4
X-3800	PDAC	gemcitabine-50mpk	198.2	35.7	94	-24.7	5.3
X-3800	PDAC	INC424 + binimetinib	256.7	24.2	0	0	0
X-3800	PDAC	INC424 + binimetinib	215.7	24.1	4	-16	-0.4
X-3800	PDAC	INC424 + binimetinib	228.2	25.2	7	-11.1	4.1
X-3800	PDAC	INC424 + binimetinib	278.1	25.7	11	8.3	6.2
X-3800	PDAC	INC424 + binimetinib	202.8	25.4	14	-21	5
X-3800	PDAC	INC424 + binimetinib	162.4	24.8	18	-36.7	2.5
X-3800	PDAC	INC424 + binimetinib	193.5	24.8	20	-24.6	2.5
X-3800	PDAC	INC424 + binimetinib	247.6	25.1	25	-3.5	3.7
X-3800	PDAC	INC424 + binimetinib	189.7	25.3	27	-26.1	4.5
X-3800	PDAC	INC424 + binimetinib	170.3	25.5	32	-33.7	5.4
X-3800	PDAC	INC424 + binimetinib	225.8	24.7	35	-12	2.1
X-3800	PDAC	INC424 + binimetinib	194.3	25.3	39	-24.3	4.5
X-3800	PDAC	INC424 + binimetinib	193.7	25.1	42	-24.5	3.7
X-3800	PDAC	INC424 + binimetinib	141.3	24.9	46	-45	2.9
X-3800	PDAC	INC424 + binimetinib	177.8	25.1	49	-30.7	3.7
X-3800	PDAC	INC424 + binimetinib	97.8	24.5	53	-61.9	1.2
X-3800	PDAC	INC424 + binimetinib	131.2	24.1	56	-48.9	-0.4
X-3800	PDAC	INC424 + binimetinib	171.7	24.6	60	-33.1	1.7
X-3800	PDAC	INC424 + binimetinib	124.9	24.6	63	-51.3	1.7
X-3800	PDAC	INC424 + binimetinib	174.1	24.5	67	-32.2	1.2
X-3800	PDAC	INC424 + binimetinib	138.5	24.1	70	-46	-0.4
X-3800	PDAC	INC424 + binimetinib	165	24.9	74	-35.7	2.9
X-3800	PDAC	INC424 + binimetinib	115.7	24.9	77	-54.9	2.9
X-3800	PDAC	INC424 + binimetinib	127.1	25	81	-50.5	3.3
X-3800	PDAC	INC424 + binimetinib	121.5	25.7	88	-52.7	6.2
X-3800	PDAC	INC424 + binimetinib	170	24.5	91	-33.8	1.2
X-3800	PDAC	INC424 + binimetinib	161.2	24.6	95	-37.2	1.7
X-3800	PDAC	INC424 + binimetinib	72.1	24.5	98	-71.9	1.2
X-3800	PDAC	INC424 + binimetinib	139.1	24.5	102	-45.8	1.2
X-3800	PDAC	INC424	215.5	26.5	0	0	0
X-3800	PDAC	INC424	208.4	27.7	3	-3.3	4.5
X-3800	PDAC	INC424	240.8	27.6	7	11.7	4.2
X-3800	PDAC	INC424	285.6	28	10	32.5	5.7
X-3800	PDAC	INC424	314.5	28.1	14	45.9	6
X-3800	PDAC	INC424	325.8	26.7	17	51.2	0.8
X-3800	PDAC	INC424	360.9	27.7	22	67.5	4.5
X-3800	PDAC	INC424	417.8	27	25	93.9	1.9
X-3800	PDAC	INC424	398.1	26.9	28	84.7	1.5
X-3800	PDAC	INC424	396.3	28.1	31	83.9	6
X-3800	PDAC	INC424	476.5	28.1	34	121.1	6
X-3800	PDAC	INC424	497.7	28.9	39	131	9.1
X-3800	PDAC	INC424	563.3	28.4	42	161.4	7.2
X-3800	PDAC	INC424	571.7	27.3	45	165.3	3
X-3800	PDAC	INC424	578.8	26.8	48	168.6	1.1
X-3800	PDAC	INC424	641.3	28	52	197.6	5.7
X-3800	PDAC	INC424	684.5	26.8	55	217.6	1.1
X-3800	PDAC	INC424	838.8	28.3	59	289.2	6.8
X-3800	PDAC	INC424	842.1	27.8	62	290.8	4.9
X-3800	PDAC	INC424	900.4	28.1	66	317.8	6
X-3800	PDAC	LEE011	201.2	28	0	0	0
X-3800	PDAC	LEE011	169.7	25.6	5	-15.7	-8.6
X-3800	PDAC	LEE011	215.9	26.4	8	7.3	-5.7
X-3800	PDAC	LEE011	205.6	27.3	11	2.2	-2.5
X-3800	PDAC	LEE011	162.6	26.6	14	-19.2	-5
X-3800	PDAC	LEE011	161.1	27.1	18	-19.9	-3.2
X-3800	PDAC	LEE011	155.1	26.8	21	-22.9	-4.3
X-3800	PDAC	LEE011	178.6	27.4	25	-11.2	-2.1
X-3800	PDAC	LEE011	155.8	27.9	32	-22.6	-0.4
X-3800	PDAC	LEE011	172	27.6	35	-14.5	-1.4
X-3800	PDAC	LEE011	159.3	28.9	39	-20.8	3.2
X-3800	PDAC	LEE011	159.7	29.7	42	-20.6	6.1
X-3800	PDAC	LEE011	135.5	29.1	46	-32.7	3.9
X-3800	PDAC	LEE011	153.9	28.1	49	-23.5	0.4
X-3800	PDAC	LEE011	151.7	29.4	53	-24.6	5
X-3800	PDAC	LEE011	159.9	29.7	56	-20.5	6.1
X-3800	PDAC	LEE011	149.2	28.8	60	-25.8	2.9
X-3800	PDAC	LEE011	136	28.1	63	-32.4	0.4
X-3800	PDAC	LEE011	130.3	28.7	67	-35.2	2.5
X-3800	PDAC	LEE011	65.1	27.5	70	-67.6	-1.8
X-3800	PDAC	LEE011	78	28.9	74	-61.2	3.2
X-3800	PDAC	LEE011	84.6	28.9	77	-58	3.2
X-3800	PDAC	LEE011	79.2	29	81	-60.6	3.6
X-3800	PDAC	LEE011	96.6	28.4	84	-52	1.4
X-3800	PDAC	LEE011	104.3	29.3	88	-48.2	4.6
X-3800	PDAC	LEE011	98.5	29.6	91	-51	5.7
X-3800	PDAC	LEE011	108.2	28.4	95	-46.2	1.4
X-3800	PDAC	WNT974	253.8	27	0	0	0
X-3800	PDAC	WNT974	271.6	27.3	2	7	1.1
X-3800	PDAC	WNT974	267.4	27.6	6	5.4	2.2
X-3800	PDAC	WNT974	206	27.3	9	-18.8	1.1
X-3800	PDAC	WNT974	226.6	26.8	12	-10.7	-0.7
X-3800	PDAC	WNT974	249.7	26.5	15	-1.6	-1.9
X-3800	PDAC	WNT974	280.7	22.8	20	10.6	-15.6
X-3800	PDAC	WNT974	233.4	25.6	23	-8	-5.2
X-3800	PDAC	WNT974	306.9	26.3	27	20.9	-2.6
X-3800	PDAC	WNT974	295.6	26.1	30	16.5	-3.3
X-3800	PDAC	WNT974	306.5	25.9	33	20.8	-4.1
X-3800	PDAC	WNT974	302.5	25.5	35	19.2	-5.6
X-3800	PDAC	WNT974	363	26.7	43	43	-1.1
X-3800	PDAC	WNT974	498.5	25	48	96.4	-7.4
X-3800	PDAC	WNT974	422.8	22.7	50	66.6	-15.9
X-3800	PDAC	WNT974	480.5	25	51	89.3	-7.4
X-3800	PDAC	WNT974	464.7	23.9	54	83.1	-11.5
X-3800	PDAC	WNT974	389	24.4	58	53.3	-9.6
X-3800	PDAC	WNT974	387.4	22.3	62	52.6	-17.4
X-3800	PDAC	WNT974	414.4	25.9	65	63.3	-4.1
X-3800	PDAC	LKA136	276.9	26.7	0	0	0
X-3800	PDAC	LKA136	290.6	27.1	1	4.9	1.5
X-3800	PDAC	LKA136	305.1	27.3	5	10.2	2.2
X-3800	PDAC	LKA136	440.4	26.8	8	59	0.4
X-3800	PDAC	LKA136	514.8	26.7	11	85.9	0
X-3800	PDAC	LKA136	603.8	26.9	15	118.1	0.7
X-3800	PDAC	LKA136	697.2	27.3	19	151.8	2.2
X-3800	PDAC	LKA136	713.7	27.1	22	157.7	1.5
X-3800	PDAC	LKA136	971.9	27.3	26	251	2.2
X-3800	PDAC	LKA136	1015	27.3	29	266.6	2.2
X-3800	PDAC	LKA136	1393.1	26.5	32	403.1	-0.7
X-3800	PDAC	binimetinib	237.5	29.8	0	0	0
X-3800	PDAC	binimetinib	216	29.6	4	-9.1	-0.7
X-3800	PDAC	binimetinib	201.9	28.6	11	-15	-4
X-3800	PDAC	binimetinib	158.4	29	14	-33.3	-2.7
X-3800	PDAC	binimetinib	181.5	29.1	18	-23.6	-2.3
X-3800	PDAC	binimetinib	148	29	21	-37.7	-2.7
X-3800	PDAC	binimetinib	176.3	27.3	25	-25.8	-8.4
X-3800	PDAC	binimetinib	167.9	27.5	27	-29.3	-7.7
X-3800	PDAC	binimetinib	137.7	25.8	32	-42	-13.4
X-3800	PDAC	binimetinib	130.9	26.4	34	-44.9	-11.4
X-3800	PDAC	binimetinib	105	24.5	39	-55.8	-17.8
X-3800	PDAC	binimetinib	80.8	23.2	42	-66	-22.1
X-3800	PDAC	trametinib	269.4	24.5	0	0	0
X-3800	PDAC	trametinib	281.2	25.7	5	4.4	4.9
X-3800	PDAC	trametinib	262.2	25.4	8	-2.7	3.7
X-3800	PDAC	trametinib	277.6	25.4	12	3	3.7
X-3800	PDAC	trametinib	237.8	24.6	15	-11.7	0.4
X-3800	PDAC	trametinib	183.5	24	19	-31.9	-2
X-3800	PDAC	trametinib	205.2	23.3	22	-23.8	-4.9
X-3800	PDAC	trametinib	193.9	24.5	27	-28	0
X-3800	PDAC	trametinib	203.8	25.1	29	-24.4	2.4
X-3800	PDAC	trametinib	211.5	25.4	33	-21.5	3.7
X-3800	PDAC	trametinib	209.2	25.3	36	-22.3	3.3
X-3800	PDAC	trametinib	201.6	25.5	40	-25.2	4.1
X-3800	PDAC	trametinib	184.2	25.2	43	-31.6	2.9
X-3800	PDAC	trametinib	198.1	25.6	47	-26.5	4.5
X-3800	PDAC	trametinib	182.7	25.1	50	-32.2	2.4
X-3800	PDAC	trametinib	145.6	25.9	55	-46	5.7
X-3800	PDAC	trametinib	228	25.4	60	-15.4	3.7
X-3800	PDAC	trametinib	186.7	25.2	63	-30.7	2.9
X-3800	PDAC	trametinib	192.4	25.9	67	-28.6	5.7
X-3800	PDAC	trametinib	172.2	25	70	-36.1	2
X-3800	PDAC	trametinib	141.3	24.9	74	-47.6	1.6
X-3800	PDAC	trametinib	153.9	25	77	-42.9	2
X-3800	PDAC	trametinib	185	24.7	81	-31.3	0.8
X-3800	PDAC	trametinib	172	25.3	84	-36.2	3.3
X-3800	PDAC	trametinib	189.9	25.4	88	-29.5	3.7
X-3800	PDAC	trametinib	184.4	25.4	91	-31.6	3.7
X-3800	PDAC	untreated	281.2	28.4	0	0	0
X-3800	PDAC	untreated	285.5	26.8	2	1.5	-5.6
X-3800	PDAC	untreated	308.8	26.3	7	9.8	-7.4
X-3800	PDAC	untreated	381.3	26.9	10	35.6	-5.3
X-3800	PDAC	untreated	583.8	26.4	14	107.6	-7
X-3800	PDAC	untreated	630.9	59.6	17	124.4	-7
X-3800	PDAC	untreated	601.8	26	21	114	-8.5
X-3800	PDAC	untreated	687.2	26.2	24	144.4	-7.7
X-3800	PDAC	untreated	744.1	25.8	31	164.6	-9.2
X-3800	PDAC	untreated	995.3	26.1	34	253.9	-8.1
X-3800	PDAC	untreated	1032.4	25.3	37	267.1	-10.9
X-3800	PDAC	untreated	1161.5	25.1	42	313.1	-11.6
X-3800	PDAC	untreated	1308.1	25.6	45	365.2	-9.9
X-3800	PDAC	untreated	1275.6	25.3	49	353.6	-10.9
X-3800	PDAC	untreated	1318.2	25.7	52	368.8	-9.5
X-3816	PDAC	abraxane	226.2	30	0	0	0
X-3816	PDAC	abraxane	199.4	30.5	3	-11.8	1.7
X-3816	PDAC	abraxane	247.5	30.4	6	9.4	1.3
X-3816	PDAC	abraxane	298	29.2	11	31.7	-2.7
X-3816	PDAC	abraxane	304.6	29.5	13	34.7	-1.7
X-3816	PDAC	abraxane	323.7	30.1	17	43.1	0.3
X-3816	PDAC	abraxane	375.4	29.7	20	66	-1
X-3816	PDAC	abraxane	414.2	29.1	24	83.1	-3
X-3816	PDAC	abraxane	516.5	29.4	27	128.3	-2
X-3816	PDAC	abraxane	610.5	29.5	31	169.9	-1.7
X-3816	PDAC	abraxane	618.9	29.6	34	173.6	-1.3
X-3816	PDAC	abraxane	626.4	30	39	176.9	0
X-3816	PDAC	abraxane	682.2	30.3	42	201.6	1
X-3816	PDAC	abraxane	420.6	30.3	46	85.9	1
X-3816	PDAC	abraxane	606.5	29.1	49	168.1	-3
X-3816	PDAC	abraxane	821.2	31.3	53	263	4.3
X-3816	PDAC	abraxane	642.7	30.4	56	184.1	1.3
X-3816	PDAC	abraxane	1131.2	29.9	60	400.1	-0.3
X-3816	PDAC	BKM120 + binimetinib	204.6	25.6	0	0	0
X-3816	PDAC	BKM120 + binimetinib	247.7	26.5	4	21.1	3.5
X-3816	PDAC	BKM120 + binimetinib	360	26.8	6	76	4.7
X-3816	PDAC	BKM120 + binimetinib	329	26.9	11	60.8	5.1
X-3816	PDAC	BKM120 + binimetinib	301	26.7	18	47.1	4.3
X-3816	PDAC	BKM120 + binimetinib	357.7	26.9	25	74.8	5.1
X-3816	PDAC	BKM120 + binimetinib	359.5	26.4	28	75.7	3.1
X-3816	PDAC	BKM120 + binimetinib	381.1	26.2	33	86.3	2.3
X-3816	PDAC	BKM120 + binimetinib	277.6	27	35	35.7	5.5
X-3816	PDAC	BKM120 + binimetinib	284.3	26.2	39	39	2.3
X-3816	PDAC	BKM120 + binimetinib	332	26.7	42	62.3	4.3
X-3816	PDAC	BKM120 + binimetinib	272.7	24.4	46	33.3	-4.7
X-3816	PDAC	BKM120 + binimetinib	276.7	26	49	35.2	1.6
X-3816	PDAC	BKM120 + binimetinib	349.2	27.7	52	70.7	8.2
X-3816	PDAC	BKM120 + binimetinib	285.2	27.4	55	39.4	7
X-3816	PDAC	BKM120 + binimetinib	356.4	25.9	60	74.2	1.2
X-3816	PDAC	BKM120 + binimetinib	286.2	26.2	66	39.9	2.3
X-3816	PDAC	BKM120 + binimetinib	395.9	26	69	93.5	1.6
X-3816	PDAC	BKM120 + binimetinib	299.2	27.2	74	46.2	6.2
X-3816	PDAC	BKM120 + binimetinib	314.9	27.6	77	53.9	7.8
X-3816	PDAC	BKM120 + binimetinib	386.9	27.3	81	89.1	6.6
X-3816	PDAC	BKM120 + binimetinib	342.9	27.3	84	67.6	6.6
X-3816	PDAC	BKM120	241.9	25.7	0	0	0
X-3816	PDAC	BKM120	243.9	25.9	3	0.8	0.8
X-3816	PDAC	BKM120	246.9	25.1	6	2.1	-2.3
X-3816	PDAC	BKM120	303.5	25.3	10	25.5	-1.6
X-3816	PDAC	BKM120	354.7	25.6	13	46.6	-0.4
X-3816	PDAC	BKM120	326	25.3	18	34.8	-1.6
X-3816	PDAC	BKM120	521.8	25.3	21	115.7	-1.6
X-3816	PDAC	BKM120	544.4	25.8	24	125.1	0.4
X-3816	PDAC	BKM120	686.2	25.4	27	183.7	-1.2
X-3816	PDAC	BKM120	683.7	26	31	182.6	1.2
X-3816	PDAC	BYL719 + LJM716	224.4	20.7	0	0	0
X-3816	PDAC	BYL719 + LJM716	215.3	20.6	3	-4.1	-0.5
X-3816	PDAC	BYL719 + LJM716	208.4	19.4	6	-7.1	-6.3
X-3816	PDAC	BYL719 + LJM716	188.4	20	9	-16	-3.4
X-3816	PDAC	BYL719 + LJM716	194.1	19.6	13	-13.5	-5.3
X-3816	PDAC	BYL719 + LJM716	218.4	20.1	16	-2.7	-2.9
X-3816	PDAC	BYL719 + LJM716	255.5	19.3	20	13.9	-6.8
X-3816	PDAC	BYL719 + LJM716	264.3	20.2	23	17.8	-2.4
X-3816	PDAC	BYL719 + LJM716	406.6	19.5	27	81.2	-5.8
X-3816	PDAC	BYL719 + LJM716	648.3	21	30	188.9	1.4
X-3816	PDAC	BYL719 + LJM716	733.7	19.9	35	227	-3.9
X-3816	PDAC	BYL719 + LJM716	781.3	20.6	38	248.2	-0.5
X-3816	PDAC	BYL719 + LJM716	883.7	21.1	41	293.8	1.9
X-3816	PDAC	BYL719 + LJM716	987.4	21.1	44	340	1.9
X-3816	PDAC	BYL719 + LJM716	1056.4	20.1	48	370.8	-2.9
X-3816	PDAC	BYL719	211	23.9	0	0	0
X-3816	PDAC	BYL719	211	24.1	3	0	0.8
X-3816	PDAC	BYL719	206.5	23.4	6	-2.1	-2.1
X-3816	PDAC	BYL719	223.5	24	9	5.9	0.4
X-3816	PDAC	BYL719	239.1	24	13	13.3	0.4
X-3816	PDAC	BYL719	247	25	16	17.1	4.6
X-3816	PDAC	BYL719	301.9	23.3	20	43.1	-2.5
X-3816	PDAC	BYL719	339.5	23.9	23	60.9	0
X-3816	PDAC	BYL719	407.6	23.5	27	93.2	-1.7
X-3816	PDAC	BYL719	459.9	25.7	30	118	7.5
X-3816	PDAC	BYL719	465.9	24.6	35	120.8	2.9
X-3816	PDAC	BYL719	546.2	25.9	38	158.9	8.4
X-3816	PDAC	BYL719	656.8	25.7	41	211.3	7.5
X-3816	PDAC	BYL719	683.1	26.1	44	223.7	9.2
X-3816	PDAC	BYL719	738.6	25.9	48	250	8.4
X-3816	PDAC	BYL719	866.3	26.3	51	310.6	10
X-3816	PDAC	CLR457	205	25.9	0	0	0
X-3816	PDAC	CLR457	212.3	27.2	3	3.6	5
X-3816	PDAC	CLR457	208.8	27.3	6	1.9	5.4
X-3816	PDAC	CLR457	197.8	27.2	9	-3.5	5
X-3816	PDAC	CLR457	205.8	27.1	13	0.4	4.6
X-3816	PDAC	CLR457	229	27.1	16	11.7	4.6
X-3816	PDAC	CLR457	310.1	26.3	20	51.3	1.5
X-3816	PDAC	CLR457	341.6	26.4	23	66.6	1.9
X-3816	PDAC	CLR457	440.5	27.1	27	114.9	4.6
X-3816	PDAC	CLR457	463.7	27.5	30	126.2	6.2
X-3816	PDAC	CLR457	538.3	26.7	35	162.6	3.1
X-3816	PDAC	CLR457	596	27.2	38	190.7	5
X-3816	PDAC	CLR457	737.9	28.6	41	260	10.4
X-3816	PDAC	CLR457	827.3	27.7	44	303.6	6.9
X-3816	PDAC	CLR457	1029.7	28.4	48	402.3	9.7
X-3816	PDAC	HDM201	226.5	25.3	0	0	0
X-3816	PDAC	HDM201	235.8	25.8	3	4.1	2
X-3816	PDAC	HDM201	283.2	25.3	6	25	0
X-3816	PDAC	HDM201	402.8	25.3	9	77.8	0
X-3816	PDAC	HDM201	418.7	25.9	13	84.9	2.4
X-3816	PDAC	HDM201	497.2	25.6	16	119.5	1.2
X-3816	PDAC	HDM201	641.7	25.5	20	183.3	0.8
X-3816	PDAC	HDM201	716.6	25.5	23	216.4	0.8
X-3816	PDAC	HDM201	852.6	24.6	27	276.4	-2.8
X-3816	PDAC	HDM201	864.2	25.4	30	281.5	0.4
X-3816	PDAC	figitumumab"	202.7	24.3	0	0	0
X-3816	PDAC	figitumumab"	215	24.1	1	6.1	-0.8
X-3816	PDAC	figitumumab"	435.8	24.6	8	115	1.2
X-3816	PDAC	figitumumab"	578.8	25	12	185.5	2.9
X-3816	PDAC	figitumumab"	604	24.7	15	198	1.6
X-3816	PDAC	figitumumab"	807	25.5	19	298.1	4.9
X-3816	PDAC	figitumumab"	1087.8	25.7	22	436.7	5.8
X-3816	PDAC	figitumumab"	1262.3	25.5	26	522.7	4.9
X-3816	PDAC	figitumumab"	1525.5	26.9	29	652.6	10.7
X-3816	PDAC	figitumumab" + binimetinib	178	24.7	0	0	0
X-3816	PDAC	figitumumab" + binimetinib	157.8	24.5	3	-11.3	-0.8
X-3816	PDAC	figitumumab" + binimetinib	164.3	25.3	6	-7.7	2.4
X-3816	PDAC	figitumumab" + binimetinib	199.8	25.4	10	12.2	2.8
X-3816	PDAC	figitumumab" + binimetinib	216.2	25	13	21.5	1.2
X-3816	PDAC	figitumumab" + binimetinib	259.1	25.6	18	45.6	3.6
X-3816	PDAC	figitumumab" + binimetinib	287.3	25.3	21	61.4	2.4
X-3816	PDAC	figitumumab" + binimetinib	288.6	25.3	24	62.1	2.4
X-3816	PDAC	figitumumab" + binimetinib	290.5	24.8	27	63.2	0.4
X-3816	PDAC	figitumumab" + binimetinib	348.3	25.2	31	95.7	2
X-3816	PDAC	gemcitabine-50mpk	260.3	24.2	0	0	0
X-3816	PDAC	gemcitabine-50mpk	270.5	24.6	4	3.9	1.7
X-3816	PDAC	gemcitabine-50mpk	319	24.2	7	22.6	0
X-3816	PDAC	gemcitabine-50mpk	373.6	24.8	10	43.5	2.5
X-3816	PDAC	gemcitabine-50mpk	319	25.2	14	22.6	4.1
X-3816	PDAC	gemcitabine-50mpk	346.4	25	18	33.1	3.3
X-3816	PDAC	gemcitabine-50mpk	393.2	24.1	21	51.1	-0.4
X-3816	PDAC	gemcitabine-50mpk	383.7	25.4	25	47.4	5
X-3816	PDAC	gemcitabine-50mpk	417.8	24.6	28	60.5	1.7
X-3816	PDAC	gemcitabine-50mpk	449.9	26.6	32	72.8	9.9
X-3816	PDAC	gemcitabine-50mpk	428.4	26.1	35	64.6	7.9
X-3816	PDAC	gemcitabine-50mpk	401.7	24.6	38	54.3	1.7
X-3816	PDAC	gemcitabine-50mpk	486.4	25.5	42	86.9	5.4
X-3816	PDAC	gemcitabine-50mpk	420.6	25.2	46	61.6	4.1
X-3816	PDAC	gemcitabine-50mpk	448.7	25.6	49	72.4	5.8
X-3816	PDAC	gemcitabine-50mpk	403.4	27.2	53	55	12.4
X-3816	PDAC	gemcitabine-50mpk	573	26.2	55	120.1	8.3
X-3816	PDAC	gemcitabine-50mpk	468.5	26.1	60	80	7.9
X-3816	PDAC	gemcitabine-50mpk	448	26.9	66	72.1	11.2
X-3816	PDAC	gemcitabine-50mpk	533.6	26.3	70	105	8.7
X-3816	PDAC	gemcitabine-50mpk	478.6	26.8	74	83.9	10.7
X-3816	PDAC	gemcitabine-50mpk	448	26.9	76	72.1	11.2
X-3816	PDAC	gemcitabine-50mpk	536.6	26.3	81	106.1	8.7
X-3816	PDAC	INC424 + binimetinib	247.6	30.1	0	0	0
X-3816	PDAC	INC424 + binimetinib	233.1	28.6	2	-5.9	-5
X-3816	PDAC	INC424 + binimetinib	218.5	28.3	6	-11.8	-6
X-3816	PDAC	INC424 + binimetinib	258.9	28.2	9	4.6	-6.3
X-3816	PDAC	INC424 + binimetinib	310.5	28.7	12	25.4	-4.7
X-3816	PDAC	INC424 + binimetinib	256.2	28	16	3.5	-7
X-3816	PDAC	INC424 + binimetinib	285.8	28.4	20	15.4	-5.6
X-3816	PDAC	INC424 + binimetinib	355.1	28.5	22	43.4	-5.3
X-3816	PDAC	INC424 + binimetinib	391.1	29.1	27	58	-3.3
X-3816	PDAC	INC424 + binimetinib	319.2	29.3	34	28.9	-2.7
X-3816	PDAC	INC424 + binimetinib	277.1	29.5	41	11.9	-2
X-3816	PDAC	INC424 + binimetinib	399.3	29.7	44	61.3	-1.3
X-3816	PDAC	INC424 + binimetinib	403.7	28.9	49	63	-4
X-3816	PDAC	INC424 + binimetinib	364.4	29	51	47.2	-3.7
X-3816	PDAC	INC424 + binimetinib	350.4	30.3	55	41.5	0.7
X-3816	PDAC	INC424 + binimetinib	435.3	30.1	58	75.8	0
X-3816	PDAC	INC424 + binimetinib	373.5	32.1	62	50.8	6.6
X-3816	PDAC	INC424 + binimetinib	483.7	29	65	95.4	-3.7
X-3816	PDAC	INC424 + binimetinib	411.1	29.5	68	66	-2
X-3816	PDAC	INC424 + binimetinib	312.7	30.4	71	26.3	1
X-3816	PDAC	INC424 + binimetinib	430.5	29	76	73.9	-3.7
X-3816	PDAC	INC424 + binimetinib	480	30	82	93.9	-0.3
X-3816	PDAC	INC424 + binimetinib	589.3	29.4	85	138	-2.3
X-3816	PDAC	INC424 + binimetinib	665	29.5	90	168.6	-2
X-3816	PDAC	INC424 + binimetinib	580.8	29.8	93	134.6	-1
X-3816	PDAC	INC424 + binimetinib	717	30.1	97	189.6	0
X-3816	PDAC	INC424 + binimetinib	770	30.2	100	211	0.3
X-3816	PDAC	INC424	200.9	30	0	0	0
X-3816	PDAC	INC424	217.1	29	5	8.1	-3.3
X-3816	PDAC	INC424	260.6	31.1	7	29.7	3.7
X-3816	PDAC	INC424	264.4	32.6	11	31.6	8.7
X-3816	PDAC	INC424	326.8	31.6	18	62.7	5.3
X-3816	PDAC	INC424	414	32.3	21	106.1	7.7
X-3816	PDAC	INC424	426.9	31.5	26	112.5	5
X-3816	PDAC	INC424	464.7	31.3	29	131.3	4.3
X-3816	PDAC	INC424	451.1	31.7	32	124.5	5.7
X-3816	PDAC	INC424	424.6	30.2	36	111.3	0.7
X-3816	PDAC	INC424	581.4	30.8	42	189.4	2.7
X-3816	PDAC	INC424	608.5	32	47	202.9	6.7
X-3816	PDAC	INC424	554.6	30.8	50	176.1	2.7
X-3816	PDAC	INC424	688.9	29.9	54	242.9	-0.3
X-3816	PDAC	INC424	798.5	31.6	57	297.5	5.3
X-3816	PDAC	INC424	889.9	31	61	343	3.3
X-3816	PDAC	INC424	1082.5	31.3	64	438.8	4.3
X-3816	PDAC	LEE011	205.9	22.7	0	0	0
X-3816	PDAC	LEE011	246.9	23.1	1	19.9	1.8
X-3816	PDAC	LEE011	292	24.1	5	41.8	6.2
X-3816	PDAC	LEE011	395.2	24.3	8	91.9	7
X-3816	PDAC	LEE011	481	24.3	12	133.6	7
X-3816	PDAC	LEE011	579.3	24.5	15	181.4	7.9
X-3816	PDAC	LEE011	726.5	25.5	19	252.8	12.3
X-3816	PDAC	LEE011	701.7	26.3	22	240.8	15.9
X-3816	PDAC	LEE011	790.7	26	26	284	14.5
X-3816	PDAC	LEE011	749.1	25.7	29	263.8	13.2
X-3816	PDAC	LEE011	711.9	25.6	33	245.8	12.8
X-3816	PDAC	LEE011	955.1	25.8	37	363.9	13.7
X-3816	PDAC	LEE011	1101.9	25.9	40	435.2	14.1
X-3816	PDAC	LEE011	1143	26.7	43	455.1	17.6
X-3816	PDAC	WNT974	243.6	24.2	0	0	0
X-3816	PDAC	WNT974	263.2	23.9	1	8	-1.2
X-3816	PDAC	WNT974	519.1	23.5	5	113.1	-2.9
X-3816	PDAC	WNT974	570.6	24.1	9	134.2	-0.4
X-3816	PDAC	WNT974	852.9	23.9	12	250.1	-1.2
X-3816	PDAC	WNT974	828.2	24.5	15	240	1.2
X-3816	PDAC	WNT974	1282.2	24.4	19	426.4	0.8
X-3816	PDAC	WNT974	1437.8	24	22	490.2	-0.8
X-3816	PDAC	WNT974	1386.2	24.7	27	469	2.1
X-3816	PDAC	WNT974	1598.6	25	30	556.2	3.3
X-3816	PDAC	LKA136	223.3	28.2	0	0	0
X-3816	PDAC	LKA136	263.5	27.3	2	18	-3.2
X-3816	PDAC	LKA136	313.6	28.4	6	40.4	0.7
X-3816	PDAC	LKA136	358.4	29	10	60.5	2.8
X-3816	PDAC	LKA136	463.8	30	13	107.7	6.4
X-3816	PDAC	LKA136	469.4	29.2	16	110.2	3.5
X-3816	PDAC	LKA136	435.1	28.3	20	94.8	0.4
X-3816	PDAC	LKA136	549.2	28.6	23	145.9	1.4
X-3816	PDAC	LKA136	980.3	29.7	28	339	5.3
X-3816	PDAC	LKA136	982.7	29.1	31	340.1	3.2
X-3816	PDAC	LKA136	975.5	29.3	34	336.9	3.9
X-3816	PDAC	LKA136	1179.7	29.4	38	428.3	4.3
X-3816	PDAC	LKA136	1163.3	30.9	41	421	9.6
X-3816	PDAC	LKA136	1152.7	30.5	44	416.2	8.2
X-3816	PDAC	binimetinib	212.9	29.8	0	0	0
X-3816	PDAC	binimetinib	229.4	30.2	4	7.8	1.3
X-3816	PDAC	binimetinib	293.4	30.2	6	37.8	1.3
X-3816	PDAC	binimetinib	257.2	28.3	11	20.8	-5
X-3816	PDAC	binimetinib	280.5	29.5	18	31.8	-1
X-3816	PDAC	binimetinib	256.2	27.6	25	20.3	-7.4
X-3816	PDAC	binimetinib	279.6	27.5	28	31.3	-7.7
X-3816	PDAC	binimetinib-3.5mpk	181.6	24.8	0	0	0
X-3816	PDAC	binimetinib-3.5mpk	144.9	24.9	5	-20.2	0.4
X-3816	PDAC	binimetinib-3.5mpk	129.5	23.9	8	-28.7	-3.6
X-3816	PDAC	binimetinib-3.5mpk	220.1	25.8	11	21.2	4
X-3816	PDAC	binimetinib-3.5mpk	221.5	25.4	14	22	2.4
X-3816	PDAC	binimetinib-3.5mpk	247.7	24.9	18	36.4	0.4
X-3816	PDAC	binimetinib-3.5mpk	223.4	23.8	21	23	-4
X-3816	PDAC	binimetinib-3.5mpk	238.6	24.5	26	31.4	-1.2
X-3816	PDAC	binimetinib-3.5mpk	285.4	25	29	57.2	0.8
X-3816	PDAC	binimetinib-3.5mpk	356.3	24.6	33	96.2	-0.8
X-3816	PDAC	binimetinib-3.5mpk	291.8	24.9	36	60.7	0.4
X-3816	PDAC	binimetinib-3.5mpk	345.6	24.9	39	90.3	0.4
X-3816	PDAC	binimetinib-3.5mpk	423.7	24.9	42	133.3	0.4
X-3816	PDAC	binimetinib-3.5mpk	442.3	24.7	47	143.6	-0.4
X-3816	PDAC	binimetinib-3.5mpk	503.6	25.2	53	177.3	1.6
X-3816	PDAC	binimetinib-3.5mpk	546	24.8	57	200.7	0
X-3816	PDAC	binimetinib-3.5mpk	542.4	25.3	60	198.7	2
X-3816	PDAC	binimetinib-3.5mpk	691.6	26	63	280.8	4.8
X-3816	PDAC	trametinib	265.7	24.8	0	0	0
X-3816	PDAC	trametinib	549.1	23.7	5	106.7	-4.4
X-3816	PDAC	trametinib	391	23.4	8	47.2	-5.6
X-3816	PDAC	trametinib	491.2	23.5	11	84.9	-5.2
X-3816	PDAC	trametinib	488.2	24.1	14	83.7	-2.8
X-3816	PDAC	trametinib	345.4	24.5	18	30	-1.2
X-3816	PDAC	trametinib	311.8	24.1	21	17.4	-2.8
X-3816	PDAC	trametinib	240.9	25.3	26	-9.3	2
X-3816	PDAC	trametinib	277.8	25.2	29	4.6	1.6
X-3816	PDAC	trametinib	326.5	24.6	33	22.9	-0.8
X-3816	PDAC	trametinib	279.3	23.8	36	5.1	-4
X-3816	PDAC	trametinib	320	23.9	39	20.4	-3.6
X-3816	PDAC	trametinib	261.4	23.1	42	-1.6	-6.9
X-3816	PDAC	trametinib	251.9	23.1	47	-5.2	-6.9
X-3816	PDAC	untreated	252.7	32.1	0	0	0
X-3816	PDAC	untreated	270	32.6	3	6.8	1.6
X-3816	PDAC	untreated	367.7	33.2	11	45.5	3.4
X-3816	PDAC	untreated	350.7	32.8	14	38.8	2.2
X-3816	PDAC	untreated	431.2	33	17	70.6	2.8
X-3816	PDAC	untreated	561.6	33.5	20	122.2	4.4
X-3816	PDAC	untreated	653.5	33.5	25	158.6	4.4
X-3816	PDAC	untreated	690.1	33.7	28	173.1	5
X-3816	PDAC	untreated	855.2	34	32	238.4	5.9
X-3816	PDAC	untreated	1159.6	34	35	358.9	5.9
X-3843	NSCLC	BGJ398	299.8	26.9	0	0	0
X-3843	NSCLC	BGJ398	436.1	26.9	6	45.5	0
X-3843	NSCLC	BGJ398	424.6	27.3	16	41.6	1.5
X-3843	NSCLC	BGJ398	436.9	28.8	21	45.7	7.1
X-3843	NSCLC	BGJ398	736.7	28.6	27	145.7	6.3
X-3843	NSCLC	BKM120 + binimetinib	239.3	23.6	0	0	0
X-3843	NSCLC	BKM120 + binimetinib	317.1	22.6	6	32.5	-4.2
X-3843	NSCLC	BKM120 + binimetinib	337.9	24.2	10	41.2	2.5
X-3843	NSCLC	BKM120 + binimetinib	347.4	23.5	13	45.2	-0.4
X-3843	NSCLC	BKM120 + binimetinib	348.2	24.1	17	45.5	2.1
X-3843	NSCLC	BKM120 + binimetinib	414.8	23.8	20	73.3	0.8
X-3843	NSCLC	BKM120 + binimetinib	606.4	23.5	29	153.4	-0.4
X-3843	NSCLC	BKM120 + binimetinib	743.9	25	35	210.9	5.9
X-3843	NSCLC	BKM120 + binimetinib	807.6	22.7	45	237.5	-3.8
X-3843	NSCLC	BKM120 + binimetinib	1337.8	23.8	50	459	0.8
X-3843	NSCLC	BKM120	267.1	22.1	0	0	0
X-3843	NSCLC	BKM120	385.9	22	6	44.5	-0.5
X-3843	NSCLC	BKM120	355.1	22.8	10	32.9	3.2
X-3843	NSCLC	BKM120	562.5	22.9	13	110.6	3.6
X-3843	NSCLC	BKM120	568.7	23.1	17	112.9	4.5
X-3843	NSCLC	BKM120	585.6	23.2	20	119.2	5
X-3843	NSCLC	BKM120	687.6	22.2	29	157.4	0.5
X-3843	NSCLC	BKM120	693.7	24	35	159.7	8.6
X-3843	NSCLC	BKM120	778.3	23.8	45	191.4	7.7
X-3843	NSCLC	BKM120	682.8	24.1	50	155.6	9
X-3843	NSCLC	BKM120	795.3	24.4	56	197.8	10.4
X-3843	NSCLC	BYL719 + LGH447	227.5	25.8	0	0	0
X-3843	NSCLC	BYL719 + LGH447	352.9	24.3	9	55.1	-5.8
X-3843	NSCLC	BYL719 + LGH447	184.4	24.3	15	-18.9	-5.8
X-3843	NSCLC	BYL719 + LGH447	259.6	24.3	25	14.1	-5.8
X-3843	NSCLC	BYL719 + LGH447	273.3	25.4	30	20.1	-1.6
X-3843	NSCLC	BYL719 + LGH447	303.9	23.9	36	33.6	-7.4
X-3843	NSCLC	BYL719 + LGH447	303.4	24.5	43	33.4	-5
X-3843	NSCLC	BYL719 + LGH447	349	25.4	51	53.4	-1.6
X-3843	NSCLC	BYL719 + LGH447	363.2	24.5	60	59.6	-5
X-3843	NSCLC	BYL719 + LGH447	382.8	25.8	63	68.3	0
X-3843	NSCLC	BYL719 + LGH447	289.6	25.8	67	27.3	0
X-3843	NSCLC	BYL719 + LGH447	295.5	24.7	70	29.9	-4.3
X-3843	NSCLC	BYL719 + LGH447	376.3	25.2	74	65.4	-2.3
X-3843	NSCLC	BYL719 + LGH447	362.1	24.6	77	59.2	-4.7
X-3843	NSCLC	BYL719 + LGH447	376.7	26.1	84	65.6	1.2
X-3843	NSCLC	BYL719 + LGH447	387.9	25.3	91	70.5	-1.9
X-3843	NSCLC	BYL719 + LJM716	222.7	24.1	0	0	0
X-3843	NSCLC	BYL719 + LJM716	285.5	23.8	6	28.2	-1.2
X-3843	NSCLC	BYL719 + LJM716	279.8	24.4	16	25.6	1.2
X-3843	NSCLC	BYL719 + LJM716	283.2	24.4	21	27.2	1.2
X-3843	NSCLC	BYL719 + LJM716	284.3	24.4	27	27.7	1.2
X-3843	NSCLC	BYL719 + LJM716	280.8	24.4	34	26.1	1.2
X-3843	NSCLC	BYL719 + LJM716	223.8	24.3	42	0.5	0.8
X-3843	NSCLC	BYL719 + LJM716	217.2	24.5	51	-2.5	1.7
X-3843	NSCLC	BYL719 + LJM716	223.6	24.1	54	0.4	0
X-3843	NSCLC	BYL719	204.1	27.2	0	0	0
X-3843	NSCLC	BYL719	200.6	27.6	4	-1.7	1.5
X-3843	NSCLC	BYL719	178.6	27.9	7	-12.5	2.6
X-3843	NSCLC	BYL719	229.7	27	16	12.5	-0.7
X-3843	NSCLC	BYL719	260.1	23.7	22	27.4	-12.9
X-3843	NSCLC	BYL719	297.2	26	32	45.6	-4.4
X-3843	NSCLC	BYL719	352.4	27.9	37	72.7	2.6
X-3843	NSCLC	BYL719	396.5	28.6	43	94.3	5.1
X-3843	NSCLC	BYL719	436.7	28	50	114	2.9
X-3843	NSCLC	BYL719	462.2	29.1	58	126.5	7
X-3843	NSCLC	BYL719	569.3	27.8	67	178.9	2.2
X-3843	NSCLC	BYL719	845.4	30.3	70	314.2	11.4
X-3843	NSCLC	CGM097	198.4	28.9	0	0	0
X-3843	NSCLC	CGM097	270.8	30	4	36.5	3.8
X-3843	NSCLC	CGM097	314.7	29.8	7	58.6	3.1
X-3843	NSCLC	CGM097	329.2	30	11	65.9	3.8
X-3843	NSCLC	CGM097	423.2	30.8	14	113.3	6.6
X-3843	NSCLC	CGM097	682.5	30.3	23	244	4.8
X-3843	NSCLC	CGM097	874	30.3	29	340.5	4.8
X-3843	NSCLC	CKX620	244.7	27.8	0	0	0
X-3843	NSCLC	CKX620	511.6	27.6	6	109.1	-0.7
X-3843	NSCLC	CKX620	563.7	29.7	10	130.4	6.8
X-3843	NSCLC	CKX620	719.3	30.3	13	194	9
X-3843	NSCLC	CLR457	188.6	23.1	0	0	0
X-3843	NSCLC	CLR457	252.8	21.8	6	34	-5.6
X-3843	NSCLC	CLR457	228.7	23.2	10	21.3	0.4
X-3843	NSCLC	CLR457	224.7	22.8	13	19.1	-1.3
X-3843	NSCLC	CLR457	305.9	23	17	62.2	-0.4
X-3843	NSCLC	CLR457	279.7	23	20	48.3	-0.4
X-3843	NSCLC	CLR457	204.7	22	29	8.5	-4.8
X-3843	NSCLC	CLR457	259.1	23.4	35	37.4	1.3
X-3843	NSCLC	CLR457	311.3	23.3	45	65.1	0.9
X-3843	NSCLC	CLR457	269	23.3	50	42.6	0.9
X-3843	NSCLC	CLR457	271.5	23.1	56	44	0
X-3843	NSCLC	CLR457	268.9	21.8	63	42.6	-5.6
X-3843	NSCLC	CLR457	263.7	23.4	71	39.8	1.3
X-3843	NSCLC	CLR457	277.1	23.1	80	46.9	0
X-3843	NSCLC	CLR457	398.9	23.4	83	111.5	1.3
X-3843	NSCLC	CLR457	447.9	22.6	87	137.5	-2.2
X-3843	NSCLC	CLR457	501.6	22.5	90	166	-2.6
X-3843	NSCLC	CLR457	547.4	23.1	94	190.2	0
X-3843	NSCLC	CLR457	449.8	22.5	97	138.5	-2.6
X-3843	NSCLC	CLR457	510.8	22.5	104	170.8	-2.6
X-3843	NSCLC	HDM201	212.2	24.5	0	0	0
X-3843	NSCLC	HDM201	347.7	24	6	63.9	-2
X-3843	NSCLC	HDM201	394.9	24.6	10	86.1	0.4
X-3843	NSCLC	HDM201	397.7	25	13	87.4	2
X-3843	NSCLC	HDM201	464.8	24.4	17	119	-0.4
X-3843	NSCLC	HDM201	530.1	24.8	20	149.8	1.2
X-3843	NSCLC	cetuximab	180.2	24.5	0	0	0
X-3843	NSCLC	cetuximab	340.2	24.4	6	88.8	-0.4
X-3843	NSCLC	cetuximab	443.8	24.2	10	146.3	-1.2
X-3843	NSCLC	cetuximab	530.1	24.9	13	194.2	1.6
X-3843	NSCLC	cetuximab	686	25	17	280.7	2
X-3843	NSCLC	cetuximab	939	25.4	20	421.1	3.7
X-3843	NSCLC	erlotinib	243.9	24.6	0	0	0
X-3843	NSCLC	erlotinib	438.1	22.1	4	79.6	-10.2
X-3843	NSCLC	erlotinib	468.6	23.4	7	92.1	-4.9
X-3843	NSCLC	erlotinib	605.4	23.4	11	148.2	-4.9
X-3843	NSCLC	erlotinib	818.2	25.2	14	235.5	2.4
X-3843	NSCLC	erlotinib	1029.3	23.8	23	322	-3.3
X-3843	NSCLC	erlotinib	1276.2	24.6	29	423.2	0
X-3843	NSCLC	HSP990	184.5	28.9	0	0	0
X-3843	NSCLC	HSP990	105.5	27.8	1	-42.8	-3.8
X-3843	NSCLC	HSP990	171	30	4	-7.3	3.8
X-3843	NSCLC	HSP990	196.5	28.9	8	6.5	0
X-3843	NSCLC	HSP990	218.2	30.5	11	18.3	5.5
X-3843	NSCLC	HSP990	331	29.9	20	79.4	3.5
X-3843	NSCLC	HSP990	466.2	29	26	152.7	0.3
X-3843	NSCLC	HSP990	421.7	28.8	36	128.6	-0.3
X-3843	NSCLC	HSP990	410.7	28.2	41	122.6	-2.4
X-3843	NSCLC	HSP990	466	30.2	47	152.6	4.5
X-3843	NSCLC	HSP990	617.4	30.4	54	234.6	5.2
X-3843	NSCLC	HSP990	733	31.2	62	297.3	8
X-3843	NSCLC	HSP990	843.3	30.9	71	357.1	6.9
X-3843	NSCLC	HSP990	981	32.2	74	431.7	11.4
X-3843	NSCLC	INC280	259.8	23.2	0	0	0
X-3843	NSCLC	INC280	386	22.3	6	48.6	-3.9
X-3843	NSCLC	INC280	499.8	24.2	10	92.4	4.3
X-3843	NSCLC	INC280	577.3	24	13	122.2	3.4
X-3843	NSCLC	INC280	648.4	24.2	17	149.6	4.3
X-3843	NSCLC	INC280	794.3	23.9	20	205.7	3
X-3843	NSCLC	LCL161 + paclitaxel	146.7	25.8	0	0	0
X-3843	NSCLC	LCL161 + paclitaxel	108	24.5	3	-26.4	-5
X-3843	NSCLC	LCL161 + paclitaxel	84.6	25.6	8	-42.3	-0.8
X-3843	NSCLC	LCL161 + paclitaxel	83.8	26.3	14	-42.9	1.9
X-3843	NSCLC	LCL161 + paclitaxel	113.8	27.5	21	-22.4	6.6
X-3843	NSCLC	LCL161 + paclitaxel	150	27.5	29	2.2	6.6
X-3843	NSCLC	LCL161 + paclitaxel	916.3	27.9	38	524.6	8.1
X-3843	NSCLC	LCL161 + paclitaxel	1318.9	29.1	41	799	12.8
X-3843	NSCLC	LEE011	223.1	25	0	0	0
X-3843	NSCLC	LEE011	224.6	25	15	0.7	0
X-3843	NSCLC	LEE011	218.8	25.8	25	-1.9	3.2
X-3843	NSCLC	LEE011	201.4	25.7	30	-9.7	2.8
X-3843	NSCLC	LEE011	213.9	25.5	36	-4.1	2
X-3843	NSCLC	LEE011	327.9	26.3	43	47	5.2
X-3843	NSCLC	LEE011	387.9	26.4	51	73.9	5.6
X-3843	NSCLC	LEE011	472.8	26.8	60	111.9	7.2
X-3843	NSCLC	LEE011	446	27.7	63	99.9	10.8
X-3843	NSCLC	LEE011	567.7	28.2	67	154.5	12.8
X-3843	NSCLC	LEE011	551.3	27.6	70	147.1	10.4
X-3843	NSCLC	LEE011	604.1	26.9	74	170.8	7.6
X-3843	NSCLC	LEE011	597.6	27	77	167.9	8
X-3843	NSCLC	LEE011	618.6	27.4	84	177.3	9.6
X-3843	NSCLC	LEE011	669.7	28.2	91	200.2	12.8
X-3843	NSCLC	LGH447	241.3	24	0	0	0
X-3843	NSCLC	LGH447	303.8	24	6	25.9	0
X-3843	NSCLC	LGH447	530.3	23.4	10	119.8	-2.5
X-3843	NSCLC	LGH447	576.3	24.3	13	138.8	1.2
X-3843	NSCLC	LGH447	747.1	24.4	17	209.6	1.7
X-3843	NSCLC	LGH447	829.8	24.3	20	243.9	1.2
X-3843	NSCLC	LLM871	266.2	24.7	0	0	0
X-3843	NSCLC	LLM871	215.9	23.9	1	-18.9	-3.2
X-3843	NSCLC	LLM871	199.9	24.7	4	-24.9	0
X-3843	NSCLC	LLM871	278.9	24.6	8	4.8	-0.4
X-3843	NSCLC	LLM871	337.2	24.1	11	26.7	-2.4
X-3843	NSCLC	LLM871	487.3	24.5	20	83.1	-0.8
X-3843	NSCLC	LLM871	578.7	26.2	26	117.4	6.1
X-3843	NSCLC	LLM871	713.8	25.6	36	168.1	3.6
X-3843	NSCLC	binimetinib	235	22.3	0	0	0
X-3843	NSCLC	binimetinib	307.7	21.8	6	30.9	-2.2
X-3843	NSCLC	binimetinib	309.4	22.8	10	31.7	2.2
X-3843	NSCLC	binimetinib	309.1	22.4	13	31.5	0.4
X-3843	NSCLC	binimetinib	369.1	22.4	17	57.1	0.4
X-3843	NSCLC	binimetinib	456.9	23.3	20	94.4	4.5
X-3843	NSCLC	binimetinib	475.2	21.6	29	102.2	-3.1
X-3843	NSCLC	binimetinib	1151.6	23.7	45	390	6.3
X-3843	NSCLC	binimetinib	1429.1	23.3	50	508.1	4.5
X-3843	NSCLC	paclitaxel	184.5	27.3	0	0	0
X-3843	NSCLC	paclitaxel	161.3	27.5	4	-12.6	0.7
X-3843	NSCLC	paclitaxel	187.1	28	8	1.4	2.6
X-3843	NSCLC	paclitaxel	259.8	28.6	11	40.8	4.8
X-3843	NSCLC	paclitaxel	368.5	28.5	15	99.7	4.4
X-3843	NSCLC	paclitaxel	357.1	29	18	93.6	6.2
X-3843	NSCLC	paclitaxel	350.3	29.4	27	89.9	7.7
X-3843	NSCLC	paclitaxel	481.5	30.7	33	161	12.5
X-3843	NSCLC	paclitaxel	632.7	29	43	242.9	6.2
X-3843	NSCLC	paclitaxel	671.2	28.1	48	263.8	2.9
X-3843	NSCLC	paclitaxel	746.4	30	54	304.6	9.9
X-3843	NSCLC	untreated	273.6	24.8	0	0	0
X-3843	NSCLC	untreated	470.3	24.8	5	71.9	0
X-3843	NSCLC	untreated	709.6	26.5	11	159.4	6.9
X-3843	NSCLC	untreated	972.9	27	15	255.6	8.9
X-3843	NSCLC	untreated	1355.8	26.5	18	395.5	6.9
X-3843	NSCLC	LFW527 + binimetinib	178.1	24.4	0	0	0
X-3843	NSCLC	LFW527 + binimetinib	137.61	24.4	1	-22.7	0
X-3843	NSCLC	LFW527 + binimetinib	211.82	NA	6	18.9	0
X-3843	NSCLC	LFW527 + binimetinib	240.24	24.8	10	34.9	1.6
X-3843	NSCLC	LFW527 + binimetinib	268.88	25.2	15	51	3.3
X-3843	NSCLC	LFW527 + binimetinib	385.02	25.5	21	116.2	4.5
X-3843	NSCLC	LFW527 + binimetinib	428.53	26	24	140.6	6.6
X-3843	NSCLC	LFW527 + binimetinib	591.78	25.3	29	232.3	3.7
X-3843	NSCLC	LFW527 + binimetinib	707.25	25.7	36	297.1	5.3
X-3846	PDAC	abraxane	219.8	27.1	0	0	0
X-3846	PDAC	abraxane	201.4	27.8	2	-8.4	2.6
X-3846	PDAC	abraxane	224.4	27.4	6	2.1	1.1
X-3846	PDAC	abraxane	255.8	28.2	9	16.4	4.1
X-3846	PDAC	abraxane	433.9	28.4	13	97.4	4.8
X-3846	PDAC	abraxane	495.8	28.8	16	125.6	6.3
X-3846	PDAC	abraxane	662	28.4	21	201.2	4.8
X-3846	PDAC	abraxane	1123	28	24	410.9	3.3
X-3846	PDAC	BKM120 + binimetinib	237.3	21.1	0	0	0
X-3846	PDAC	BKM120 + binimetinib	233.1	19.5	4	-1.8	-7.6
X-3846	PDAC	BKM120 + binimetinib	184.5	19.6	7	-22.3	-7.1
X-3846	PDAC	BKM120 + binimetinib	161.4	20	11	-32	-5.2
X-3846	PDAC	BKM120 + binimetinib	304.5	20.1	14	28.3	-4.7
X-3846	PDAC	BKM120 + binimetinib	177.1	20.5	18	-25.4	-2.8
X-3846	PDAC	BKM120 + binimetinib	178.7	21.4	21	-24.7	1.4
X-3846	PDAC	BKM120 + binimetinib	195.7	21.9	25	-17.5	3.8
X-3846	PDAC	BKM120 + binimetinib	252.6	21.4	28	6.4	1.4
X-3846	PDAC	BKM120 + binimetinib	240.1	20.3	32	1.2	-3.8
X-3846	PDAC	BKM120 + binimetinib	175.4	20.2	35	-26.1	-4.3
X-3846	PDAC	BKM120 + binimetinib	200.8	21.1	39	-15.4	0
X-3846	PDAC	BKM120 + binimetinib	180.4	19.8	42	-24	-6.2
X-3846	PDAC	BKM120 + binimetinib	212.4	20	46	-10.5	-5.2
X-3846	PDAC	BKM120 + binimetinib	192.4	20.2	49	-18.9	-4.3
X-3846	PDAC	BKM120 + binimetinib	131.1	16.1	53	-44.8	-23.7
X-3846	PDAC	BKM120 + LDE225	247.8	25.3	0	0	0
X-3846	PDAC	BKM120 + LDE225	193.7	26.4	3	-21.8	4.3
X-3846	PDAC	BKM120 + LDE225	276.5	28.1	6	11.6	11.1
X-3846	PDAC	BKM120 + LDE225	274.7	26.4	9	10.9	4.3
X-3846	PDAC	BKM120 + LDE225	283.3	27.5	14	14.3	8.7
X-3846	PDAC	BKM120 + LDE225	272.5	26.9	16	10	6.3
X-3846	PDAC	BKM120 + LDE225	283.2	27.4	20	14.3	8.3
X-3846	PDAC	BKM120 + LDE225	249.9	27.4	23	0.8	8.3
X-3846	PDAC	BKM120 + LDE225	256.8	26.3	28	3.6	4
X-3846	PDAC	BKM120 + LDE225	261.2	25.8	35	5.4	2
X-3846	PDAC	BKM120 + LDE225	243.3	27.1	38	-1.8	7.1
X-3846	PDAC	BKM120 + LDE225	204.2	27.2	42	-17.6	7.5
X-3846	PDAC	BKM120 + LDE225	299.1	28.8	45	20.7	13.8
X-3846	PDAC	BKM120 + LDE225	186	25.1	48	-24.9	-0.8
X-3846	PDAC	BKM120 + LDE225	238.9	25.6	56	-3.6	1.2
X-3846	PDAC	BKM120 + LDE225	173.5	24.8	58	-30	-2
X-3846	PDAC	BKM120 + LDE225	186.5	27.4	63	-24.7	8.3
X-3846	PDAC	BKM120 + LDE225	271.5	25.2	66	9.6	-0.4
X-3846	PDAC	BKM120 + LDE225	241	25.6	70	-2.7	1.2
X-3846	PDAC	BKM120 + LDE225	298.8	25	73	20.6	-1.2
X-3846	PDAC	BKM120 + LDE225	232.7	26.3	76	-6.1	4
X-3846	PDAC	BKM120 + LDE225	253.9	24.5	80	2.5	-3.2
X-3846	PDAC	BKM120 + LDE225	303.4	25.8	84	22.4	2
X-3846	PDAC	BKM120 + LDE225	231.6	26	86	-6.5	2.8
X-3846	PDAC	BKM120 + LDE225	364.2	25.9	91	47	2.4
X-3846	PDAC	BKM120 + LDE225	248.4	27.3	98	0.2	7.9
X-3846	PDAC	BKM120 + LDE225	420	26.1	105	69.5	3.2
X-3846	PDAC	BKM120 + LDE225	216.9	25.5	108	-12.5	0.8
X-3846	PDAC	BKM120 + LDE225	256.4	26.3	113	3.5	4
X-3846	PDAC	BKM120 + LDE225	406.4	26.6	115	64	5.1
X-3846	PDAC	BKM120 + LDE225	303.3	24.4	119	22.4	-3.6
X-3846	PDAC	BKM120 + LDE225	180.2	25.7	122	-27.3	1.6
X-3846	PDAC	BKM120 + LDE225	128.5	24.7	126	-48.1	-2.4
X-3846	PDAC	BKM120 + LDE225	175.5	24.2	129	-29.2	-4.3
X-3846	PDAC	BKM120 + LDE225	209.6	24.7	132	-15.4	-2.4
X-3846	PDAC	BKM120	211.3	22.5	0	0	0
X-3846	PDAC	BKM120	188.9	23.1	4	-10.6	2.7
X-3846	PDAC	BKM120	181.9	22.4	7	-13.9	-0.4
X-3846	PDAC	BKM120	146.7	22.6	11	-30.6	0.4
X-3846	PDAC	BKM120	132.1	22.3	14	-37.5	-0.9
X-3846	PDAC	BKM120	167.4	22.4	18	-20.8	-0.4
X-3846	PDAC	BKM120	202.6	22.3	21	-4.1	-0.9
X-3846	PDAC	BKM120	160.7	21.6	25	-23.9	-4
X-3846	PDAC	BKM120	228.2	21.7	28	8	-3.6
X-3846	PDAC	BKM120	268.6	22.7	32	27.1	0.9
X-3846	PDAC	BKM120	300.5	20.9	34	42.2	-7.1
X-3846	PDAC	BKM120	369	22.4	39	74.6	-0.4
X-3846	PDAC	BKM120	740.2	21.9	42	250.3	-2.7
X-3846	PDAC	BKM120	526.8	21.9	47	149.3	-2.7
X-3846	PDAC	BKM120	736.5	21	50	248.6	-6.7
X-3846	PDAC	BYL719	281.9	22.8	0	0	0
X-3846	PDAC	BYL719	288.6	24.6	3	2.4	7.9
X-3846	PDAC	BYL719	287.4	22.1	7	2	-3.1
X-3846	PDAC	BYL719	303.4	22.1	10	7.6	-3.1
X-3846	PDAC	BYL719	316.1	21	14	12.1	-7.9
X-3846	PDAC	BYL719	319	20.6	17	13.2	-9.6
X-3846	PDAC	BYL719	300.4	21.8	21	6.6	-4.4
X-3846	PDAC	BYL719	307.6	21.3	24	9.1	-6.6
X-3846	PDAC	BYL719	354.5	21.1	28	25.8	-7.5
X-3846	PDAC	BYL719	389.5	21.7	31	38.2	-4.8
X-3846	PDAC	BYL719	439.9	21.6	35	56	-5.3
X-3846	PDAC	BYL719	607.6	21.1	38	115.5	-7.5
X-3846	PDAC	BYL719	665.1	21.6	42	135.9	-5.3
X-3846	PDAC	BYL719	685.2	22.1	45	143.1	-3.1
X-3846	PDAC	BYL719	711.9	21.9	49	152.5	-3.9
X-3846	PDAC	BYL719	709.2	21.3	52	151.6	-6.6
X-3846	PDAC	BYL719	825.3	21.6	56	192.8	-5.3
X-3846	PDAC	BYL719	811.3	20.9	59	187.8	-8.3
X-3846	PDAC	BYL719	820.6	22.3	63	191.1	-2.2
X-3846	PDAC	BYL719	880.9	21	65	212.5	-7.9
X-3846	PDAC	BYL719	1199	22.2	70	325.3	-2.6
X-3846	PDAC	BYL719	1213.9	22.3	73	330.6	-2.2
X-3846	PDAC	BYL719	1252.2	22	77	344.2	-3.5
X-3846	PDAC	CLR457	274.7	22.5	0	0	0
X-3846	PDAC	CLR457	288.2	22.1	2	4.9	-1.8
X-3846	PDAC	CLR457	294.9	23.6	5	7.4	4.9
X-3846	PDAC	CLR457	300.7	22.9	12	9.5	1.8
X-3846	PDAC	CLR457	297.1	23.1	15	8.2	2.7
X-3846	PDAC	CLR457	296.1	23.5	20	7.8	4.4
X-3846	PDAC	CLR457	344.2	23.8	23	25.3	5.8
X-3846	PDAC	CLR457	314.3	24	26	14.4	6.7
X-3846	PDAC	CLR457	306.6	24.1	30	11.6	7.1
X-3846	PDAC	CLR457	500.6	24.2	41	82.2	7.6
X-3846	PDAC	CLR457	313.3	23.8	44	14.1	5.8
X-3846	PDAC	CLR457	404.7	23.4	48	47.3	4
X-3846	PDAC	CLR457	420.3	23.5	51	53	4.4
X-3846	PDAC	CLR457	482.7	22.5	55	75.7	0
X-3846	PDAC	CLR457	509.4	22.5	58	85.4	0
X-3846	PDAC	CLR457	530.5	23.1	62	93.1	2.7
X-3846	PDAC	CLR457	534.5	23.2	65	94.6	3.1
X-3846	PDAC	CLR457	580.1	22.6	69	111.2	0.4
X-3846	PDAC	CLR457	631.5	22.8	72	129.9	1.3
X-3846	PDAC	CLR457	656.5	21.8	76	139	-3.1
X-3846	PDAC	CLR457	664.5	22.1	79	141.9	-1.8
X-3846	PDAC	CLR457	671	21.1	83	144.3	-6.2
X-3846	PDAC	CLR457	676.6	20.7	86	146.3	-8
X-3846	PDAC	CLR457	713.3	20.1	90	159.7	-10.7
X-3846	PDAC	CLR457	731.5	20.1	93	166.3	-10.7
X-3846	PDAC	CLR457	747.1	19.6	97	172	-12.9
X-3846	PDAC	HDM201	261.9	27.1	0	0	0
X-3846	PDAC	HDM201	271.4	26.7	3	3.6	-1.5
X-3846	PDAC	HDM201	288.2	25.5	7	10	-5.9
X-3846	PDAC	HDM201	445.1	26.1	10	70	-3.7
X-3846	PDAC	HDM201	536.8	26.6	14	105	-1.8
X-3846	PDAC	HDM201	767.7	26.3	17	193.1	-3
X-3846	PDAC	HDM201	823.1	27.3	21	214.3	0.7
X-3846	PDAC	HDM201	1065.9	26.8	24	307	-1.1
X-3846	PDAC	HDM201	1225.3	26.3	28	367.9	-3
X-3846	PDAC	HDM201	1274.1	26.8	31	386.5	-1.1
X-3846	PDAC	figitumumab"	211.3	23.1	0	0	0
X-3846	PDAC	figitumumab"	363	23.6	2	71.8	2.2
X-3846	PDAC	figitumumab"	421.1	24.2	9	99.3	4.8
X-3846	PDAC	figitumumab"	341	24	14	61.4	3.9
X-3846	PDAC	figitumumab"	760.1	24.4	20	259.7	5.6
X-3846	PDAC	figitumumab"	1588	22.9	24	651.5	-0.9
X-3846	PDAC	figitumumab"	1657.5	24.6	27	684.4	6.5
X-3846	PDAC	figitumumab" + binimetinib	283.5	25.1	0	0	0
X-3846	PDAC	figitumumab" + binimetinib	362.2	24.8	4	27.8	-1.2
X-3846	PDAC	figitumumab" + binimetinib	446.2	23.8	7	57.4	-5.2
X-3846	PDAC	figitumumab" + binimetinib	490.8	25	11	73.1	-0.4
X-3846	PDAC	figitumumab" + binimetinib	568.6	23.6	13	100.6	-6
X-3846	PDAC	figitumumab" + binimetinib	434.3	24	18	53.2	-4.4
X-3846	PDAC	figitumumab" + binimetinib	431	23.8	21	52	-5.2
X-3846	PDAC	figitumumab" + binimetinib	575	24.6	25	102.8	-2
X-3846	PDAC	figitumumab" + binimetinib	496	22.8	28	75	-9.2
X-3846	PDAC	figitumumab" + binimetinib	579	23.8	31	104.2	-5.2
X-3846	PDAC	figitumumab" + binimetinib	670.5	24	34	136.5	-4.4
X-3846	PDAC	figitumumab" + binimetinib	793.7	23.5	39	180	-6.4
X-3846	PDAC	gemcitabine-50mpk	282.3	24.5	0	0	0
X-3846	PDAC	gemcitabine-50mpk	361.5	22.6	7	28.1	-7.8
X-3846	PDAC	gemcitabine-50mpk	315.9	23.7	10	11.9	-3.3
X-3846	PDAC	gemcitabine-50mpk	486.3	23.7	14	72.3	-3.3
X-3846	PDAC	gemcitabine-50mpk	415.1	24.3	17	47	-0.8
X-3846	PDAC	gemcitabine-50mpk	394.1	23.8	21	39.6	-2.9
X-3846	PDAC	gemcitabine-50mpk	511.6	24.1	24	81.2	-1.6
X-3846	PDAC	gemcitabine-50mpk	558.4	25.1	28	97.8	2.4
X-3846	PDAC	gemcitabine-50mpk	415.7	24.3	31	47.3	-0.8
X-3846	PDAC	gemcitabine-50mpk	602.5	23.4	34	113.4	-4.5
X-3846	PDAC	gemcitabine-50mpk	584.4	23.6	39	107	-3.7
X-3846	PDAC	gemcitabine-50mpk	597.7	24.3	41	111.7	-0.8
X-3846	PDAC	gemcitabine-50mpk	658.4	23.5	45	133.2	-4.1
X-3846	PDAC	gemcitabine-50mpk	632.3	23.9	47	124	-2.4
X-3846	PDAC	gemcitabine-50mpk	773.8	23.8	53	174.1	-2.9
X-3846	PDAC	INC424 + binimetinib	251.7	26.1	0	0	0
X-3846	PDAC	INC424 + binimetinib	377.6	25.7	4	50	-1.5
X-3846	PDAC	INC424 + binimetinib	288.5	25.1	7	14.6	-3.8
X-3846	PDAC	INC424 + binimetinib	371.5	26.1	11	47.6	0
X-3846	PDAC	INC424 + binimetinib	354.8	25	14	41	-4.2
X-3846	PDAC	INC424 + binimetinib	681.3	25.2	18	170.7	-3.4
X-3846	PDAC	INC424 + binimetinib	1116.5	25.9	21	343.6	-0.8
X-3846	PDAC	INC424 + binimetinib	1059.5	25.8	25	320.9	-1.1
X-3846	PDAC	INC424 + binimetinib	1155.1	25.4	28	358.9	-2.7
X-3846	PDAC	INC424 + binimetinib	1228.9	24.1	32	388.2	-7.7
X-3846	PDAC	INC424 + binimetinib	1336.1	24.1	35	430.8	-7.7
X-3846	PDAC	INC424 + binimetinib	1359.5	24.5	39	440.1	-6.1
X-3846	PDAC	INC424 + binimetinib	1394.6	24.2	42	454.1	-7.3
X-3846	PDAC	INC424 + binimetinib	1240.2	25.1	46	392.7	-3.8
X-3846	PDAC	INC424 + binimetinib	1137	24.6	49	351.7	-5.7
X-3846	PDAC	INC424 + binimetinib	1141.9	25.5	53	353.7	-2.3
X-3846	PDAC	INC424 + binimetinib	919	24.8	56	265.1	-5
X-3846	PDAC	INC424 + binimetinib	1211.4	25.3	59	381.3	-3.1
X-3846	PDAC	INC424 + binimetinib	898.8	23.3	62	257.1	-10.7
X-3846	PDAC	INC424 + binimetinib	1119.6	24	67	344.8	-8
X-3846	PDAC	INC424 + binimetinib	1069.2	23.4	70	324.8	-10.3
X-3846	PDAC	INC424 + binimetinib	1250.2	23.6	74	396.7	-9.6
X-3846	PDAC	INC424 + binimetinib	1737.3	23.5	77	590.2	-10
X-3846	PDAC	INC424 + binimetinib	1626.1	23	80	546	-11.9
X-3846	PDAC	INC424	243.8	26.8	0	0	0
X-3846	PDAC	INC424	284.4	26.5	3	16.7	-1.1
X-3846	PDAC	INC424	311.1	26.8	6	27.6	0
X-3846	PDAC	INC424	395.1	28.2	11	62.1	5.2
X-3846	PDAC	INC424	473.6	27.6	14	94.3	3
X-3846	PDAC	INC424	486.3	27.2	18	99.5	1.5
X-3846	PDAC	INC424	548.1	26	21	124.8	-3
X-3846	PDAC	INC424	592	27.6	24	142.8	3
X-3846	PDAC	INC424	718.8	28	27	194.8	4.5
X-3846	PDAC	INC424	819.2	28.1	31	236	4.9
X-3846	PDAC	WNT974	250.4	22.4	0	0	0
X-3846	PDAC	WNT974	217.7	23.3	2	-13.1	4
X-3846	PDAC	WNT974	252.6	23.6	6	0.9	5.4
X-3846	PDAC	WNT974	295.8	23.1	9	18.1	3.1
X-3846	PDAC	WNT974	375.3	22.8	12	49.9	1.8
X-3846	PDAC	WNT974	410.8	22.9	15	64.1	2.2
X-3846	PDAC	WNT974	408.8	23.1	20	63.3	3.1
X-3846	PDAC	WNT974	457.5	22.9	23	82.7	2.2
X-3846	PDAC	WNT974	424.7	22.8	27	69.6	1.8
X-3846	PDAC	WNT974	348.7	24	30	39.3	7.1
X-3846	PDAC	WNT974	532	23.5	33	112.5	4.9
X-3846	PDAC	WNT974	608.2	22.7	35	142.9	1.3
X-3846	PDAC	WNT974	702.6	23.6	41	180.6	5.4
X-3846	PDAC	WNT974	639.1	24.2	43	155.2	8
X-3846	PDAC	WNT974	617.5	22.6	48	146.6	0.9
X-3846	PDAC	WNT974	702.9	23	51	180.7	2.7
X-3846	PDAC	WNT974	850.4	21.7	54	239.6	-3.1
X-3846	PDAC	WNT974	497	19	57	98.5	-15.2
X-3846	PDAC	LKA136	264.3	25.4	0	0	0
X-3846	PDAC	LKA136	295.7	25	3	11.9	-1.6
X-3846	PDAC	LKA136	300.6	25.7	7	13.7	1.2
X-3846	PDAC	LKA136	331	26.2	10	25.2	3.1
X-3846	PDAC	LKA136	344.5	25.1	14	30.3	-1.2
X-3846	PDAC	LKA136	375.3	24.6	17	42	-3.1
X-3846	PDAC	LKA136	427.2	25.1	21	61.6	-1.2
X-3846	PDAC	LKA136	605.5	25.2	27	129.1	-0.8
X-3846	PDAC	LKA136	709.8	25.1	32	168.6	-1.2
X-3846	PDAC	binimetinib	252.3	26.7	0	0	0
X-3846	PDAC	binimetinib	215	25.5	2	-14.8	-4.5
X-3846	PDAC	binimetinib	166.1	24.4	6	-34.2	-8.6
X-3846	PDAC	binimetinib	158.9	24.4	8	-37	-8.6
X-3846	PDAC	binimetinib	108.4	25.4	14	-57	-4.9
X-3846	PDAC	binimetinib	154.1	26.2	20	-38.9	-1.9
X-3846	PDAC	binimetinib	170.8	25.3	23	-32.3	-5.2
X-3846	PDAC	binimetinib	143.9	24.9	26	-43	-6.7
X-3846	PDAC	binimetinib	195	25.3	29	-22.7	-5.2
X-3846	PDAC	binimetinib	170.5	25.6	34	-32.4	-4.1
X-3846	PDAC	binimetinib	162.4	26.1	36	-35.6	-2.2
X-3846	PDAC	binimetinib	263.7	25.9	40	4.5	-3
X-3846	PDAC	binimetinib	157.2	25.5	43	-37.7	-4.5
X-3846	PDAC	binimetinib	252.5	25.2	48	0.1	-5.6
X-3846	PDAC	binimetinib	231.6	24.9	55	-8.2	-6.7
X-3846	PDAC	binimetinib	193.8	25.7	58	-23.2	-3.7
X-3846	PDAC	binimetinib	219.1	25.5	62	-13.2	-4.5
X-3846	PDAC	binimetinib	160	25.6	65	-36.6	-4.1
X-3846	PDAC	binimetinib	255.8	25.8	68	1.4	-3.4
X-3846	PDAC	binimetinib	289.7	27	76	14.8	1.1
X-3846	PDAC	binimetinib	355.4	26.2	78	40.9	-1.9
X-3846	PDAC	binimetinib	366.2	26.3	83	45.1	-1.5
X-3846	PDAC	binimetinib	247	25.7	86	-2.1	-3.7
X-3846	PDAC	binimetinib	454.1	26.1	90	80	-2.2
X-3846	PDAC	binimetinib	484	24.9	93	91.8	-6.7
X-3846	PDAC	binimetinib	609.9	25.7	96	141.7	-3.7
X-3846	PDAC	binimetinib-3.5mpk	217.1	20.6	0	0	0
X-3846	PDAC	binimetinib-3.5mpk	182.8	18.9	3	-15.8	-8.3
X-3846	PDAC	binimetinib-3.5mpk	235.9	19.7	7	8.7	-4.4
X-3846	PDAC	binimetinib-3.5mpk	214.9	18.9	11	-1	-8.3
X-3846	PDAC	binimetinib-3.5mpk	421.6	19.1	15	94.2	-7.3
X-3846	PDAC	binimetinib-3.5mpk	470.5	18.7	18	116.7	-9.2
X-3846	PDAC	binimetinib-3.5mpk	323.2	19.1	22	48.9	-7.3
X-3846	PDAC	binimetinib-3.5mpk	362.1	18.6	24	66.8	-9.7
X-3846	PDAC	binimetinib-3.5mpk	343.9	19.2	29	58.4	-6.8
X-3846	PDAC	binimetinib-3.5mpk	444.5	18.5	32	104.7	-10.2
X-3846	PDAC	binimetinib-3.5mpk	651.4	18.9	36	200	-8.3
X-3846	PDAC	binimetinib-3.5mpk	458.3	17.8	39	111.1	-13.6
X-3846	PDAC	binimetinib-3.5mpk	538.7	18.3	42	148.1	-11.2
X-3846	PDAC	binimetinib-3.5mpk	559	17.4	45	157.5	-15.5
X-3846	PDAC	binimetinib-3.5mpk	840.3	17.4	50	287.1	-15.5
X-3846	PDAC	trametinib	226.4	24.2	0	0	0
X-3846	PDAC	trametinib	146.4	23.3	4	-35.3	-3.7
X-3846	PDAC	trametinib	125.3	23.5	7	-44.7	-2.9
X-3846	PDAC	trametinib	100.4	25.4	11	-55.7	5
X-3846	PDAC	trametinib	145.1	25.1	14	-35.9	3.7
X-3846	PDAC	trametinib	118.6	24.9	18	-47.6	2.9
X-3846	PDAC	trametinib	189.7	25.1	21	-16.2	3.7
X-3846	PDAC	trametinib	151.1	25.1	25	-33.3	3.7
X-3846	PDAC	trametinib	199.8	26.1	28	-11.7	7.9
X-3846	PDAC	trametinib	246.6	25.3	32	8.9	4.5
X-3846	PDAC	trametinib	228.4	24.8	34	0.9	2.5
X-3846	PDAC	trametinib	434.3	25.1	39	91.8	3.7
X-3846	PDAC	trametinib	527.6	25	42	133	3.3
X-3846	PDAC	trametinib	654	21.7	47	188.9	-10.3
X-3846	PDAC	untreated	276.8	23.2	0	0	0
X-3846	PDAC	untreated	283	23.1	1	2.2	-0.4
X-3846	PDAC	untreated	391.7	22.6	6	41.5	-2.6
X-3846	PDAC	untreated	469.6	22.7	9	69.7	-2.2
X-3846	PDAC	untreated	581.9	22.7	13	110.2	-2.2
X-3846	PDAC	untreated	608	22.9	16	119.7	-1.3
X-3846	PDAC	untreated	712.9	23.1	19	157.6	-0.4
X-3846	PDAC	untreated	899.3	22.5	21	224.9	-3
X-3846	PDAC	untreated	1285.1	23.2	27	364.3	0
X-3846	PDAC	untreated	1329.8	22.4	29	380.4	-3.4
X-3846	PDAC	untreated	1556.9	21.6	34	462.5	-6.9
X-3846	PDAC	untreated	1626.6	22	37	487.6	-5.2
X-3851	CM	BKM120	181.8	20.2	0	0	0
X-3851	CM	BKM120	209.5	19.7	3	15.2	-2.5
X-3851	CM	BKM120	216.6	19.5	6	19.1	-3.5
X-3851	CM	BKM120	231.1	20.6	10	27.1	2
X-3851	CM	BKM120	211.2	20.4	13	16.2	1
X-3851	CM	BKM120	256.6	20.7	17	41.1	2.5
X-3851	CM	BKM120	316.1	21.1	20	73.9	4.5
X-3851	CM	BKM120	410.8	20.7	25	126	2.5
X-3851	CM	BKM120 + encorafenib	192.1	24.9	0	0	0
X-3851	CM	BKM120 + encorafenib	189.3	25.9	3	-1.5	4
X-3851	CM	BKM120 + encorafenib	193.2	24.9	6	0.5	0
X-3851	CM	BKM120 + encorafenib	176.4	26.3	11	-8.2	5.6
X-3851	CM	BKM120 + encorafenib	260.1	26.8	17	35.4	7.6
X-3851	CM	BKM120 + encorafenib	606	26.6	24	215.4	6.8
X-3851	CM	BKM120 + encorafenib	676.9	26	31	252.3	4.4
X-3851	CM	CGM097	211.3	20.9	0	0	0
X-3851	CM	CGM097	270.6	21.3	3	28.1	1.9
X-3851	CM	CGM097	349.1	22.8	6	65.2	9.1
X-3851	CM	CGM097	315	22.6	9	49.1	8.1
X-3851	CM	CGM097	322.9	22.5	12	52.8	7.7
X-3851	CM	CGM097	388.1	23.8	16	83.7	13.9
X-3851	CM	CGM097	523.8	23.1	19	147.9	10.5
X-3851	CM	CGM097	781.1	22.5	23	269.7	7.7
X-3851	CM	CGM097	870.3	23.1	26	311.9	10.5
X-3851	CM	CLR457	196	25.6	0	0	0
X-3851	CM	CLR457	184.1	25.5	3	-6.1	-0.4
X-3851	CM	CLR457	226.5	27	9	15.6	5.5
X-3851	CM	CLR457	171.1	27.6	16	-12.7	7.8
X-3851	CM	CLR457	299.2	28.8	23	52.7	12.5
X-3851	CM	CLR457	340.6	30.2	27	73.8	18
X-3851	CM	CLR457	485	30	38	147.4	17.2
X-3851	CM	dacarbazine	196.5	23.2	0	0	0
X-3851	CM	dacarbazine	280.9	23.5	6	42.9	1.3
X-3851	CM	dacarbazine	228.1	22.8	13	16.1	-1.7
X-3851	CM	dacarbazine	200	22.9	20	1.8	-1.3
X-3851	CM	dacarbazine	136.8	23.3	24	-30.4	0.4
X-3851	CM	dacarbazine	92.3	23.3	35	-53.1	0.4
X-3851	CM	dacarbazine	62.4	23	48	-68.2	-0.9
X-3851	CM	dacarbazine	37.9	24.3	55	-80.7	4.7
X-3851	CM	dacarbazine	43.6	23.1	64	-77.8	-0.4
X-3851	CM	dacarbazine	30.4	22.6	72	-84.5	-2.6
X-3851	CM	dacarbazine	30.4	22.4	77	-84.5	-3.4
X-3851	CM	dacarbazine	17.9	23.2	80	-90.9	0
X-3851	CM	dacarbazine	32	22.2	87	-83.7	-4.3
X-3851	CM	dacarbazine	31.8	22.2	91	-83.8	-4.3
X-3851	CM	dacarbazine	27.9	22.7	97	-85.8	-2.2
X-3851	CM	dacarbazine	25.3	21.7	100	-87.1	-6.5
X-3851	CM	dacarbazine	33.5	22.2	104	-83	-4.3
X-3851	CM	dacarbazine	113.4	22	113	-42.3	-5.2
X-3851	CM	dacarbazine	117.2	21.7	118	-40.4	-6.5
X-3851	CM	dacarbazine	219.4	21.2	125	11.6	-8.6
X-3851	CM	dacarbazine	290.5	20.7	134	47.8	-10.8
X-3851	CM	dacarbazine	396.1	19.7	141	101.5	-15.1
X-3851	CM	LDE225	241.1	27.3	0	0	0
X-3851	CM	LDE225	281.2	25.1	3	16.6	-8.1
X-3851	CM	LDE225	288.1	24.4	7	19.5	-10.6
X-3851	CM	LDE225	356.4	24.2	10	47.8	-11.4
X-3851	CM	LDE225	445.4	24.1	15	84.7	-11.7
X-3851	CM	LDE225	618	24.6	21	156.3	-9.9
X-3851	CM	LDE225	1169.3	24.8	28	385	-9.2
X-3851	CM	LDK378	183.3	25.9	0	0	0
X-3851	CM	LDK378	207.9	25.1	3	13.4	-3.1
X-3851	CM	LDK378	254.2	26.1	7	38.7	0.8
X-3851	CM	LDK378	268.1	25.8	10	46.3	-0.4
X-3851	CM	LDK378	313.6	26.4	15	71.1	1.9
X-3851	CM	LDK378	300.4	27.4	21	63.9	5.8
X-3851	CM	LDK378	370.7	26.4	28	102.2	1.9
X-3851	CM	LEE011	215.5	20.8	0	0	0
X-3851	CM	LEE011	252	21.6	3	16.9	3.8
X-3851	CM	LEE011	331.1	22.7	6	53.6	9.1
X-3851	CM	LEE011	268.9	23.1	9	24.8	11.1
X-3851	CM	LEE011	260.1	22.8	12	20.7	9.6
X-3851	CM	LEE011	296.2	23.1	16	37.4	11.1
X-3851	CM	LEE011	279.9	23.4	19	29.9	12.5
X-3851	CM	LEE011	315.3	23.5	23	46.3	13
X-3851	CM	LEE011	430.3	23.4	26	99.6	12.5
X-3851	CM	LEE011 + encorafenib	215.5	23.3	0	0	0
X-3851	CM	LEE011 + encorafenib	205.8	22.6	3	-4.5	-3
X-3851	CM	LEE011 + encorafenib	196.5	25.1	8	-8.8	7.7
X-3851	CM	LEE011 + encorafenib	162	23.9	14	-24.8	2.6
X-3851	CM	LEE011 + encorafenib	169.3	24	21	-21.4	3
X-3851	CM	LEE011 + encorafenib	187.3	24.4	28	-13.1	4.7
X-3851	CM	LEE011 + encorafenib	184.5	25.4	32	-14.4	9
X-3851	CM	LEE011 + encorafenib	160	24.8	43	-25.7	6.4
X-3851	CM	LEE011 + encorafenib	156.6	25.4	56	-27.3	9
X-3851	CM	LEE011 + encorafenib	122.2	27.8	63	-43.3	19.3
X-3851	CM	LEE011 + encorafenib	93.8	26.5	72	-56.5	13.7
X-3851	CM	LEE011 + encorafenib	75.1	26.2	80	-65.1	12.4
X-3851	CM	LEE011 + encorafenib	84	26.2	85	-61	12.4
X-3851	CM	LEE011 + encorafenib	79.2	26.7	88	-63.2	14.6
X-3851	CM	LEE011 + encorafenib	89.7	27.4	95	-58.4	17.6
X-3851	CM	LEE011 + encorafenib	93.8	27.5	99	-56.5	18
X-3851	CM	LEE011 + encorafenib	73.7	26	105	-65.8	11.6
X-3851	CM	LEE011 + encorafenib	83.2	28.5	108	-61.4	22.3
X-3851	CM	LEE011 + encorafenib	147	28.5	112	-31.8	22.3
X-3851	CM	LEE011 + encorafenib	202.6	26.6	121	-6	14.2
X-3851	CM	LEE011 + encorafenib	252.1	27.1	126	17	16.3
X-3851	CM	LEE011 + encorafenib	397.4	27.1	133	84.4	16.3
X-3851	CM	LEE011 + encorafenib	443.8	28.2	142	105.9	21
X-3851	CM	LEE011 + binimetinib	226.9	24	0	0	0
X-3851	CM	LEE011 + binimetinib	303.4	25.1	4	33.7	4.6
X-3851	CM	LEE011 + binimetinib	227.9	25.3	15	0.4	5.4
X-3851	CM	LEE011 + binimetinib	284.6	25.6	28	25.5	6.7
X-3851	CM	LEE011 + binimetinib	379.5	26.8	35	67.3	11.7
X-3851	CM	LEE011 + binimetinib	333	26.9	44	46.8	12.1
X-3851	CM	LEE011 + binimetinib	255	26.9	52	12.4	12.1
X-3851	CM	LEE011 + binimetinib	272.3	26.7	57	20	11.3
X-3851	CM	LEE011 + binimetinib	299.9	27.4	60	32.2	14.2
X-3851	CM	LEE011 + binimetinib	232.7	27.6	67	2.6	15
X-3851	CM	LEE011 + binimetinib	221.2	26.9	71	-2.5	12.1
X-3851	CM	LEE011 + binimetinib	262.1	27	77	15.5	12.5
X-3851	CM	LEE011 + binimetinib	236.3	27.3	80	4.1	13.7
X-3851	CM	LEE011 + binimetinib	194.1	27.2	84	-14.4	13.3
X-3851	CM	LEE011 + binimetinib	172.1	27	93	-24.2	12.5
X-3851	CM	LEE011 + binimetinib	207.8	27.3	98	-8.4	13.7
X-3851	CM	LEE011 + binimetinib	222.4	28	105	-2	16.7
X-3851	CM	LEE011 + binimetinib	216.6	27.5	114	-4.5	14.6
X-3851	CM	LEE011 + binimetinib	221.2	27.7	121	-2.5	15.4
X-3851	CM	LEE011 + binimetinib	252.5	26.7	128	11.3	11.3
X-3851	CM	LEE011 + binimetinib	272	26.6	134	19.9	10.8
X-3851	CM	LEE011 + binimetinib	321.5	26.7	139	41.7	11.3
X-3851	CM	LEE011 + binimetinib	329.1	26	142	45.1	8.3
X-3851	CM	WNT974	182.2	22.8	0	0	0
X-3851	CM	WNT974	150.3	21.7	3	-17.5	-4.8
X-3851	CM	WNT974	227.2	21.7	7	24.7	-4.8
X-3851	CM	WNT974	274	21.7	10	50.3	-4.8
X-3851	CM	WNT974	313.3	21.9	15	71.9	-3.9
X-3851	CM	WNT974	401	22.1	21	120	-3.1
X-3851	CM	WNT974	564.5	22	28	209.8	-3.5
X-3851	CM	LGW813	225.4	26.7	0	0	0
X-3851	CM	LGW813	237.2	25.5	2	5.2	-4.5
X-3851	CM	LGW813	430	26.8	6	90.7	0.4
X-3851	CM	LGW813	633	26.2	9	180.8	-1.9
X-3851	CM	LGW813	763	27.4	13	238.5	2.6
X-3851	CM	LGW813	823.4	27.2	16	265.3	1.9
X-3851	CM	LGW813	1301.8	28	21	477.4	4.9
X-3851	CM	LGW813	2082.8	29.3	27	823.9	9.7
X-3851	CM	encorafenib	197.4	21.8	0	0	0
X-3851	CM	encorafenib	220	22.3	3	11.5	2.3
X-3851	CM	encorafenib	292.7	22.9	6	48.3	5
X-3851	CM	encorafenib	331.9	22.7	9	68.1	4.1
X-3851	CM	encorafenib	435.8	22.1	12	120.8	1.4
X-3851	CM	encorafenib	457.4	23.1	16	131.7	6
X-3851	CM	encorafenib	486.3	22.2	19	146.4	1.8
X-3851	CM	encorafenib	624.5	22.4	23	216.4	2.8
X-3851	CM	encorafenib	624	22.4	26	216.1	2.8
X-3851	CM	encorafenib + binimetinib	224.6	22.5	0	0	0
X-3851	CM	encorafenib + binimetinib	230	22.4	5	2.4	-0.4
X-3851	CM	encorafenib + binimetinib	493.1	22.6	11	119.6	0.4
X-3851	CM	encorafenib + binimetinib	561.1	22.3	18	149.8	-0.9
X-3851	CM	encorafenib + binimetinib	796	22.9	25	254.5	1.8
X-3851	CM	binimetinib	200.2	26.3	0	0	0
X-3851	CM	binimetinib	203.2	26.6	3	1.5	1.1
X-3851	CM	binimetinib	202.7	26.1	6	1.3	-0.8
X-3851	CM	binimetinib	161.9	26.2	9	-19.1	-0.4
X-3851	CM	binimetinib	238	26.6	13	18.9	1.1
X-3851	CM	binimetinib	238.3	26.6	16	19	1.1
X-3851	CM	binimetinib	355.2	26.9	20	77.4	2.3
X-3851	CM	binimetinib	511.2	26.8	23	155.4	1.9
X-3851	CM	binimetinib	513.8	26	28	156.7	-1.1
X-3851	CM	TAS266	197.2	20.9	0	0	0
X-3851	CM	TAS266	202	21.6	3	2.4	3.3
X-3851	CM	TAS266	250.9	22.4	6	27.2	7.2
X-3851	CM	TAS266	352.7	22.1	9	78.8	5.7
X-3851	CM	TAS266	454.5	21.7	12	130.4	3.8
X-3851	CM	TAS266	453.4	22.6	16	129.9	8.1
X-3851	CM	TAS266	507	21.9	19	157.1	4.8
X-3851	CM	TAS266	553.4	22.3	23	180.6	6.7
X-3851	CM	TAS266	511.2	22.3	26	159.2	6.7
X-3851	CM	untreated	220.6	21.2	0	0	0
X-3851	CM	untreated	223.4	20.8	3	1.2	-1.9
X-3851	CM	untreated	227.7	22.3	6	3.2	5.2
X-3851	CM	untreated	315.3	21.9	9	42.9	3.3
X-3851	CM	untreated	368	21.2	12	66.8	0
X-3851	CM	untreated	447.5	22.2	16	102.8	4.7
X-3851	CM	untreated	574.4	22.1	19	160.3	4.2
X-3851	CM	untreated	688.9	22.3	23	212.2	5.2
X-3851	CM	untreated	927.1	22.6	26	320.2	6.6
X-3873	BRCA	BGJ398	288.5	28.7	0	0	0
X-3873	BRCA	BGJ398	383.9	27.7	3	33.1	-3.5
X-3873	BRCA	BGJ398	436.9	27.1	7	51.4	-5.6
X-3873	BRCA	BGJ398	454.9	26.7	10	57.7	-7
X-3873	BRCA	BGJ398	525.8	27.2	14	82.3	-5.2
X-3873	BRCA	BGJ398	588.8	27.6	17	104.1	-3.8
X-3873	BRCA	BGJ398	734.5	28.3	21	154.6	-1.4
X-3873	BRCA	BGJ398	785.7	28.9	24	172.3	0.7
X-3873	BRCA	BGJ398	745.6	28.5	27	158.4	-0.7
X-3873	BRCA	BGJ398	1199.3	28.6	36	315.7	-0.3
X-3873	BRCA	BGJ398	1192.1	28.3	38	313.2	-1.4
X-3873	BRCA	BGJ398	1461.2	29.1	42	406.5	1.4
X-3873	BRCA	BKM120	253.5	25.5	0	0	0
X-3873	BRCA	BKM120	202.4	26.2	4	-20.2	2.7
X-3873	BRCA	BKM120	152.4	25.8	7	-39.9	1.2
X-3873	BRCA	BKM120	137.6	26.1	11	-45.7	2.4
X-3873	BRCA	BKM120	140.1	25.1	14	-44.7	-1.6
X-3873	BRCA	BYL719	434.2	29.2	0	0	0
X-3873	BRCA	BYL719	371.5	28.9	3	-14.4	-1
X-3873	BRCA	BYL719	420.6	26.7	7	-3.1	-8.6
X-3873	BRCA	BYL719	438.5	27.6	10	1	-5.5
X-3873	BRCA	BYL719	473.5	25.9	14	9.1	-11.3
X-3873	BRCA	BYL719	615.9	25.8	17	41.8	-11.6
X-3873	BRCA	BYL719	723.5	25.6	21	66.6	-12.3
X-3873	BRCA	BYL719	748.8	26.5	24	72.5	-9.2
X-3873	BRCA	BYL719	790.4	26.5	27	82	-9.2
X-3873	BRCA	BYL719	1047.6	27.4	36	141.3	-6.2
X-3873	BRCA	BYL719	1080.5	26.8	38	148.8	-8.2
X-3873	BRCA	BYL719	1165.4	26.4	42	168.4	-9.6
X-3873	BRCA	BYL719	1271.7	27	45	192.9	-7.5
X-3873	BRCA	BYL719	1320.4	25.6	49	204.1	-12.3
X-3873	BRCA	BYL719 + LJM716	207.6	25.4	0	0	0
X-3873	BRCA	BYL719 + LJM716	194	24.9	4	-6.6	-2
X-3873	BRCA	BYL719 + LJM716	195.5	26.3	8	-5.8	3.5
X-3873	BRCA	BYL719 + LJM716	193.8	25.8	11	-6.6	1.6
X-3873	BRCA	BYL719 + LJM716	162.1	25	14	-21.9	-1.6
X-3873	BRCA	BYL719 + LJM716	129.2	22.7	23	-37.8	-10.6
X-3873	BRCA	BYL719 + LJM716	133.2	24.5	25	-35.8	-3.5
X-3873	BRCA	BYL719 + LJM716	126.1	23.8	29	-39.3	-6.3
X-3873	BRCA	BYL719 + LJM716	94.2	24	36	-54.6	-5.5
X-3873	BRCA	BYL719 + LJM716	85.5	24.9	39	-58.8	-2
X-3873	BRCA	BYL719 + LJM716	81.4	25.2	43	-60.8	-0.8
X-3873	BRCA	BYL719 + LJM716	75.6	25.2	46	-63.6	-0.8
X-3873	BRCA	BYL719 + LJM716	73.2	25	50	-64.7	-1.6
X-3873	BRCA	BYL719 + LEE011	241	27.5	0	0	0
X-3873	BRCA	BYL719 + LEE011	150.2	24.8	8	-37.7	-9.8
X-3873	BRCA	BYL719 + LEE011	117.8	22.1	10	-51.1	-19.6
X-3873	BRCA	CGM097	209.6	30.5	0	0	0
X-3873	BRCA	CGM097	198	31.4	4	-5.5	3
X-3873	BRCA	CGM097	219.5	34.1	7	4.7	11.8
X-3873	BRCA	CGM097	229.2	39.6	11	9.4	29.8
X-3873	BRCA	CGM097	271.1	38.5	14	29.3	26.2
X-3873	BRCA	CLR457	176.1	26.9	0	0	0
X-3873	BRCA	CLR457	174.4	27.5	4	-1	2.2
X-3873	BRCA	CLR457	165.3	25.8	7	-6.1	-4.1
X-3873	BRCA	CLR457	152.9	25.8	11	-13.2	-4.1
X-3873	BRCA	CLR457	139.5	25.8	14	-20.8	-4.1
X-3873	BRCA	CLR457	120.9	23.7	17	-31.3	-11.9
X-3873	BRCA	CLR457	75.9	25	26	-56.9	-7.1
X-3873	BRCA	CLR457	49.9	23.9	28	-71.7	-11.2
X-3873	BRCA	CLR457	26.9	24.1	32	-84.7	-10.4
X-3873	BRCA	CLR457	26.2	25.6	35	-85.1	-4.8
X-3873	BRCA	CLR457	21.4	25.2	39	-87.8	-6.3
X-3873	BRCA	CLR457	17.8	25.6	42	-89.9	-4.8
X-3873	BRCA	CLR457	16.2	25.2	46	-90.8	-6.3
X-3873	BRCA	CLR457	14.1	26.4	49	-92	-1.9
X-3873	BRCA	CLR457	12.9	25.3	53	-92.7	-5.9
X-3873	BRCA	CLR457	11.1	25	56	-93.7	-7.1
X-3873	BRCA	CLR457	11.6	23.5	60	-93.4	-12.6
X-3873	BRCA	CLR457	11.2	22.8	63	-93.6	-15.2
X-3873	BRCA	CLR457	12.8	24.9	67	-92.7	-7.4
X-3873	BRCA	CLR457	13	26.1	70	-92.6	-3
X-3873	BRCA	CLR457	12.7	27.8	74	-92.8	3.3
X-3873	BRCA	CLR457	13.8	28.2	77	-92.2	4.8
X-3873	BRCA	CLR457	15.1	27.6	81	-91.4	2.6
X-3873	BRCA	CLR457	15.3	27.2	84	-91.3	1.1
X-3873	BRCA	CLR457	14.5	26.2	88	-91.8	-2.6
X-3873	BRCA	HDM201	356.6	28.4	0	0	0
X-3873	BRCA	HDM201	454.7	27.6	4	27.5	-2.8
X-3873	BRCA	HDM201	505.1	25.6	7	41.6	-9.9
X-3873	BRCA	HDM201	582.6	25.9	11	63.4	-8.8
X-3873	BRCA	HDM201	600.3	23.8	14	68.3	-16.2
X-3873	BRCA	HDM201	647.2	23.4	17	81.5	-17.6
X-3873	BRCA	HDM201	849.6	24.4	26	138.3	-14.1
X-3873	BRCA	HDM201	910.7	24.9	28	155.4	-12.3
X-3873	BRCA	HDM201	1099.4	27	32	208.3	-4.9
X-3873	BRCA	HDM201	1611.6	29	35	351.9	2.1
X-3873	BRCA	HDM201	1839.3	28.2	39	415.8	-0.7
X-3873	BRCA	INC424	200.2	30.3	0	0	0
X-3873	BRCA	INC424	206.7	27.6	3	3.2	-8.9
X-3873	BRCA	INC424	185.2	25.6	6	-7.5	-15.5
X-3873	BRCA	INC424	200.6	28.6	15	0.2	-5.6
X-3873	BRCA	INC424	209.2	29.3	17	4.5	-3.3
X-3873	BRCA	INC424	216.9	30.4	21	8.3	0.3
X-3873	BRCA	INC424	228.6	31.3	24	14.2	3.3
X-3873	BRCA	INC424	229.7	30.1	28	14.7	-0.7
X-3873	BRCA	INC424	222.2	29.7	31	11	-2
X-3873	BRCA	INC424	227.3	28.8	35	13.5	-5
X-3873	BRCA	LEE011	218.6	29.5	0	0	0
X-3873	BRCA	LEE011	227	30.7	3	3.8	4.1
X-3873	BRCA	LEE011	230	29.4	6	5.2	-0.3
X-3873	BRCA	LEE011	254.3	29.6	15	16.3	0.3
X-3873	BRCA	LEE011	258	26.4	17	18	-10.5
X-3873	BRCA	LEE011	275.5	27.2	21	26	-7.8
X-3873	BRCA	LEE011	268.6	30	24	22.9	1.7
X-3873	BRCA	LEE011	263.3	23.7	28	20.4	-19.7
X-3873	BRCA	LEE011 + everolimus	249.3	28.5	0	0	0
X-3873	BRCA	LEE011 + everolimus	246.3	26.8	8	-1.2	-6
X-3873	BRCA	LEE011 + everolimus	252.2	26.6	10	1.2	-6.7
X-3873	BRCA	LEE011 + everolimus	188.7	26.5	14	-24.3	-7
X-3873	BRCA	LEE011 + everolimus	178.4	26.7	17	-28.4	-6.3
X-3873	BRCA	LEE011 + everolimus	145.8	26.3	21	-41.5	-7.7
X-3873	BRCA	LEE011 + everolimus	131.6	26.8	24	-47.2	-6
X-3873	BRCA	LEE011 + everolimus	108.8	27	28	-56.4	-5.3
X-3873	BRCA	LEE011 + everolimus	95.4	26.4	31	-61.7	-7.4
X-3873	BRCA	LEE011 + everolimus	89.3	26.6	35	-64.2	-6.7
X-3873	BRCA	LEE011 + everolimus	82	26.7	38	-67.1	-6.3
X-3873	BRCA	LEE011 + everolimus	68.5	26.7	42	-72.5	-6.3
X-3873	BRCA	LEE011 + everolimus	70.5	26.8	45	-71.7	-6
X-3873	BRCA	LEE011 + everolimus	66.2	26.1	49	-73.4	-8.4
X-3873	BRCA	LEE011 + everolimus	59.9	25.1	52	-76	-11.9
X-3873	BRCA	LEE011 + everolimus	55.2	24.8	56	-77.9	-13
X-3873	BRCA	LEE011 + everolimus	54	25.5	59	-78.3	-10.5
X-3873	BRCA	LEE011 + everolimus	52.8	24	63	-78.8	-15.8
X-3873	BRCA	LEE011 + everolimus	49.5	24.4	66	-80.1	-14.4
X-3873	BRCA	LEE011 + everolimus	47.8	23.7	70	-80.8	-16.8
X-3873	BRCA	LEE011 + everolimus	39.9	23.9	73	-84	-16.1
X-3873	BRCA	LEE011 + everolimus	39.1	25.8	77	-84.3	-9.5
X-3873	BRCA	LEE011 + everolimus	36.2	26	80	-85.5	-8.8
X-3873	BRCA	LEE011 + everolimus	38.7	24.6	84	-84.5	-13.7
X-3873	BRCA	LEE011 + everolimus	37.1	25.6	87	-85.1	-10.2
X-3873	BRCA	LEE011 + everolimus	38	26.7	91	-84.8	-6.3
X-3873	BRCA	LFA102	342	30.5	0	0	0
X-3873	BRCA	LFA102	717.4	30.7	7	109.8	0.7
X-3873	BRCA	LFA102	1439.6	32.4	14	320.9	6.2
X-3873	BRCA	LJM716	251.2	28	0	0	0
X-3873	BRCA	LJM716	252.6	26.8	3	0.6	-4.3
X-3873	BRCA	LJM716	237.5	26.8	7	-5.5	-4.3
X-3873	BRCA	LJM716	227.9	27.3	10	-9.3	-2.5
X-3873	BRCA	LJM716	239.8	27	14	-4.5	-3.6
X-3873	BRCA	LJM716	245.3	27.7	17	-2.3	-1.1
X-3873	BRCA	LJM716	259.2	26.7	21	3.2	-4.6
X-3873	BRCA	LJM716	273.8	27.8	24	9	-0.7
X-3873	BRCA	LJM716	395.2	27.8	28	57.3	-0.7
X-3873	BRCA	LJM716	455.5	27.4	31	81.3	-2.1
X-3873	BRCA	LJM716	518.4	28.3	35	106.4	1.1
X-3873	BRCA	LJM716	674.4	27.6	38	168.5	-1.4
X-3873	BRCA	LJM716	734.8	27.5	42	192.5	-1.8
X-3873	BRCA	LJM716	895	27.4	49	256.3	-2.1
X-3873	BRCA	LJM716	975	28	52	288.1	0
X-3873	BRCA	LJM716	1054.3	28.8	56	319.7	2.9
X-3873	BRCA	LJM716	1112.3	28.1	63	342.8	0.4
X-3873	BRCA	LJM716	1172.6	28.9	66	366.8	3.2
X-3873	BRCA	LJM716	1185.7	28.9	70	372	3.2
X-3873	BRCA	LJM716 + trastuzumab	212.6	29.8	0	0	0
X-3873	BRCA	LJM716 + trastuzumab	204.5	27.7	3	-3.8	-7
X-3873	BRCA	LJM716 + trastuzumab	192.1	28.9	7	-9.6	-3
X-3873	BRCA	LJM716 + trastuzumab	209.4	28.8	10	-1.5	-3.4
X-3873	BRCA	LJM716 + trastuzumab	214.7	29.4	13	1	-1.3
X-3873	BRCA	LJM716 + trastuzumab	198.4	29.3	22	-6.7	-1.7
X-3873	BRCA	LJM716 + trastuzumab	198.3	29.2	24	-6.7	-2
X-3873	BRCA	LJM716 + trastuzumab	250.9	27.1	28	18	-9.1
X-3873	BRCA	LJM716 + trastuzumab	249.1	24.6	31	17.2	-17.4
X-3873	BRCA	LKA136	201.9	29.8	0	0	0
X-3873	BRCA	LKA136	203	31.1	2	0.5	4.4
X-3873	BRCA	LKA136	223.6	30.9	6	10.7	3.7
X-3873	BRCA	LKA136	256.5	32	9	27	7.4
X-3873	BRCA	LKA136	312.7	31.2	13	54.9	4.7
X-3873	BRCA	LKA136	371.9	31.2	16	84.2	4.7
X-3873	BRCA	LKA136	478.3	32	20	136.9	7.4
X-3873	BRCA	LKA136	649.3	33.1	23	221.6	11.1
X-3873	BRCA	LKA136	924	33.6	27	357.7	12.8
X-3873	BRCA	LKA136	1046.1	34	30	418.1	14.1
X-3873	BRCA	LKA136	1378	33.8	34	582.5	13.4
X-3873	BRCA	LLM871	365.4	29.8	0	0	0
X-3873	BRCA	LLM871	348.3	27.9	3	-4.7	-6.4
X-3873	BRCA	LLM871	342.1	27.2	7	-6.4	-8.7
X-3873	BRCA	LLM871	462.9	26.1	17	26.7	-12.4
X-3873	BRCA	LLM871	514.5	27.1	21	40.8	-9.1
X-3873	BRCA	LLM871	540.1	27.2	24	47.8	-8.7
X-3873	BRCA	LLM871	618.5	27.3	27	69.3	-8.4
X-3873	BRCA	LLM871	696.6	27.3	36	90.6	-8.4
X-3873	BRCA	LLM871	806	28.1	38	120.6	-5.7
X-3873	BRCA	LLM871	847.1	27.6	42	131.8	-7.4
X-3873	BRCA	LLM871	958	28.9	45	162.2	-3
X-3873	BRCA	LLM871	955.7	28.9	49	161.5	-3
X-3873	BRCA	LLM871	1133	27.2	52	210.1	-8.7
X-3873	BRCA	LLM871	1217.7	27.2	56	233.3	-8.7
X-3873	BRCA	LLM871	1245.4	27.7	59	240.8	-7
X-3873	BRCA	LLM871	1272.9	27.9	63	248.4	-6.4
X-3873	BRCA	LLM871	1355.9	28.3	66	271.1	-5
X-3873	BRCA	LLM871	1434.8	30.1	70	292.7	1
X-3873	BRCA	binimetinib	222.2	28.9	0	0	0
X-3873	BRCA	binimetinib	254.8	26.3	3	14.7	-9
X-3873	BRCA	binimetinib	263.7	25.6	6	18.7	-11.4
X-3873	BRCA	binimetinib	251.7	25.1	15	13.3	-13.1
X-3873	BRCA	binimetinib	235.6	26.1	17	6	-9.7
X-3873	BRCA	binimetinib	217.5	25.9	21	-2.1	-10.4
X-3873	BRCA	binimetinib	187.3	25.5	24	-15.7	-11.8
X-3873	BRCA	binimetinib	194.8	24.3	28	-12.3	-15.9
X-3873	BRCA	binimetinib	191	27.5	31	-14	-4.8
X-3873	BRCA	binimetinib	196.2	27.5	35	-11.7	-4.8
X-3873	BRCA	binimetinib	208.8	26.9	38	-6	-6.9
X-3873	BRCA	binimetinib	216.2	26.8	42	-2.7	-7.3
X-3873	BRCA	binimetinib	224.6	26.9	45	1.1	-6.9
X-3873	BRCA	binimetinib	270.2	24.9	49	21.6	-13.8
X-3873	BRCA	binimetinib	298.5	23.4	52	34.3	-19
X-3873	BRCA	binimetinib	312.5	27.6	56	40.6	-4.5
X-3873	BRCA	binimetinib	355.3	29.2	59	59.9	1
X-3873	BRCA	binimetinib	578.1	28.7	63	160.2	-0.7
X-3873	BRCA	binimetinib	641.8	25.2	66	188.8	-12.8
X-3873	BRCA	binimetinib	684.3	22.1	70	208	-23.5
X-3873	BRCA	paclitaxel	401.7	26.3	0	0	0
X-3873	BRCA	paclitaxel	408.9	26.1	3	1.8	-0.8
X-3873	BRCA	paclitaxel	423.1	25.5	7	5.3	-3
X-3873	BRCA	paclitaxel	429.8	25.2	10	7	-4.2
X-3873	BRCA	paclitaxel	392.7	25.3	14	-2.2	-3.8
X-3873	BRCA	paclitaxel	343	24	17	-14.6	-8.7
X-3873	BRCA	paclitaxel	308.3	25.4	24	-23.3	-3.4
X-3873	BRCA	paclitaxel	222.1	25.5	27	-44.7	-3
X-3873	BRCA	paclitaxel	171.1	25.6	36	-57.4	-2.7
X-3873	BRCA	paclitaxel	169.6	26.9	38	-57.8	2.3
X-3873	BRCA	paclitaxel	167.6	27.3	42	-58.3	3.8
X-3873	BRCA	paclitaxel	158	27.9	45	-60.7	6.1
X-3873	BRCA	paclitaxel	151.2	28.8	49	-62.4	9.5
X-3873	BRCA	paclitaxel	155.8	28.8	52	-61.2	9.5
X-3873	BRCA	paclitaxel	172.2	27.9	56	-57.1	6.1
X-3873	BRCA	paclitaxel	186	29.1	59	-53.7	10.6
X-3873	BRCA	paclitaxel	250.6	29.7	63	-37.6	12.9
X-3873	BRCA	paclitaxel	272.4	30.6	66	-32.2	16.3
X-3873	BRCA	paclitaxel	272.9	31.1	70	-32.1	18.3
X-3873	BRCA	tamoxifen	258.5	27.8	0	0	0
X-3873	BRCA	tamoxifen	348.2	27.3	8	34.7	-1.8
X-3873	BRCA	tamoxifen	365.2	27.6	10	41.3	-0.7
X-3873	BRCA	tamoxifen	427	28.5	14	65.2	2.5
X-3873	BRCA	tamoxifen	455.9	28.9	17	76.4	4
X-3873	BRCA	tamoxifen	524.2	29.1	21	102.8	4.7
X-3873	BRCA	tamoxifen	646.1	29.7	24	149.9	6.8
X-3873	BRCA	tamoxifen	743.5	29.8	28	187.6	7.2
X-3873	BRCA	tamoxifen	771	30.5	31	198.3	9.7
X-3873	BRCA	tamoxifen	821.2	30.2	35	217.7	8.6
X-3873	BRCA	tamoxifen	916.9	30	38	254.7	7.9
X-3873	BRCA	tamoxifen	956.1	29.5	42	269.9	6.1
X-3873	BRCA	tamoxifen	1044.2	30.1	45	303.9	8.3
X-3873	BRCA	tamoxifen	1449.9	29.4	49	460.9	5.8
X-3873	BRCA	trastuzumab	203	31.6	0	0	0
X-3873	BRCA	trastuzumab	215.4	31.7	3	6.1	0.3
X-3873	BRCA	trastuzumab	463.1	32.7	10	128.1	3.5
X-3873	BRCA	trastuzumab	671.1	32.6	13	230.6	3.2
X-3873	BRCA	trastuzumab	1326.3	34.2	22	553.3	8.2
X-3873	BRCA	untreated	208.6	28.6	0	0	0
X-3873	BRCA	untreated	213.1	28.9	3	2.2	1
X-3873	BRCA	untreated	226.9	28	7	8.8	-2.1
X-3873	BRCA	untreated	229	28.5	10	9.8	-0.3
X-3873	BRCA	untreated	232.9	27.1	14	11.6	-5.2
X-3873	BRCA	untreated	241.7	25.6	17	15.9	-10.5
X-3873	BRCA	untreated	245.7	24.3	21	17.8	-15
X-3873	BRCA	untreated	251.4	22.8	24	20.5	-20.3
X-3873	BRCA	untreated	249.4	23.6	28	19.6	-17.5
X-3873	BRCA	untreated	246.5	24.4	31	18.2	-14.7
X-3873	BRCA	untreated	254.8	26.2	35	22.1	-8.4
X-3873	BRCA	untreated	263.9	27.5	38	26.5	-3.8
X-3873	BRCA	untreated	271.2	26.7	42	30	-6.6
X-3873	BRCA	untreated	278.7	26.9	45	33.6	-5.9
X-3873	BRCA	untreated	283.7	26.9	49	36	-5.9
X-3873	BRCA	untreated	286.6	26.3	52	37.4	-8
X-3873	BRCA	untreated	280.9	27.8	56	34.7	-2.8
X-3873	BRCA	untreated	281	28.5	59	34.7	-0.3
X-3873	BRCA	untreated	289.7	27.3	63	38.9	-4.5
X-3873	BRCA	untreated	288.9	26.5	66	38.5	-7.3
X-3873	BRCA	untreated	299.9	26.5	70	43.8	-7.3
X-3873	BRCA	untreated	301.1	27.8	77	44.3	-2.8
X-3873	BRCA	untreated	315.2	28.2	84	51.1	-1.4
X-3873	BRCA	untreated	314.6	28.5	87	50.8	-0.3
X-3873	BRCA	untreated	317.5	29.7	91	52.2	3.8
X-3873	BRCA	untreated	321.5	30.1	94	54.1	5.2
X-3873	BRCA	untreated	313.2	27.3	98	50.1	-4.5
X-3873	BRCA	untreated	317.6	27.9	101	52.3	-2.4
X-3873	BRCA	untreated	319.4	29.5	105	53.1	3.1
X-3873	BRCA	untreated	315.7	28.8	108	51.3	0.7
X-3873	BRCA	untreated	281.5	27.8	111	34.9	-2.8
X-3873	BRCA	untreated	264.9	28.5	115	27	-0.3
X-3873	BRCA	untreated	282.6	28.8	118	35.5	0.7
X-3873	BRCA	untreated	247.5	29.1	121	18.6	1.7
X-3873	BRCA	untreated	243	28.7	125	16.5	0.3
X-3873	BRCA	untreated	262.2	30.1	128	25.7	5.2
X-3873	BRCA	untreated	280.4	30.8	133	34.4	7.7
X-3873	BRCA	untreated	277.7	29.6	136	33.1	3.5
X-3873	BRCA	LFW527 + everolimus	252.14	25.9	0	0	0
X-3873	BRCA	LFW527 + everolimus	264.21	24.5	3	4.8	-5.4
X-3873	BRCA	LFW527 + everolimus	331.38	24.6	7	31.4	-5
X-3873	BRCA	LFW527 + everolimus	296.62	25.1	10	17.6	-3.1
X-3873	BRCA	LFW527 + everolimus	329.46	25.2	14	30.7	-2.7
X-3873	BRCA	LFW527 + everolimus	341.04	26.4	17	35.3	1.9
X-3873	BRCA	LFW527 + everolimus	338.46	25.1	20	34.2	-3.1
X-3873	BRCA	LFW527 + everolimus	348.8	24.3	24	38.3	-6.2
X-3873	BRCA	LFW527 + everolimus	305.46	25.8	27	21.1	-0.4
X-3873	BRCA	LFW527 + everolimus	355.9	25.1	31	41.2	-3.1
X-3873	BRCA	LFW527 + everolimus	383.71	25.3	34	52.2	-2.3
X-3873	BRCA	LFW527 + everolimus	352.41	24.8	38	39.8	-4.2
X-3873	BRCA	LFW527 + everolimus	301.38	25.8	41	19.5	-0.4
X-3873	BRCA	LFW527 + everolimus	286.93	25.4	45	13.8	-1.9
X-3873	BRCA	LFW527 + everolimus	323.65	25.2	48	28.4	-2.7
X-3873	BRCA	LFW527 + everolimus	294.7	25.6	55	16.9	-1.2
X-3873	BRCA	LFW527 + everolimus	347.26	24.4	59	37.7	-5.8
X-3873	BRCA	LFW527 + everolimus	237.75	22.3	63	-5.7	-13.9
X-3873	BRCA	LFW527 + everolimus	198.14	25.5	66	-21.4	-1.5
X-3873	BRCA	LFW527 + everolimus	196.67	25.2	69	-22	-2.7
X-3873	BRCA	LFW527 + everolimus	229.14	26.2	73	-9.1	1.2
X-3873	BRCA	LFW527 + everolimus	237.48	24.3	76	-5.8	-6.2
X-3873	BRCA	LFW527 + everolimus	188.3	22.5	80	-25.3	-13.1
X-3873	BRCA	LFW527 + everolimus	249.48	21.9	83	-1.1	-15.4
X-3873	BRCA	LFW527 + everolimus	222.43	25	87	-11.8	-3.5
X-3873	BRCA	LFW527 + everolimus	352.83	21.4	91	39.9	-17.4
X-3873	BRCA	LFW527 + everolimus	390.66	21.9	94	54.9	-15.4
X-3873	BRCA	LFW527 + everolimus	504.35	21.4	98	100	-17.4
X-3880	CM	BKM120	183.5	24.9	0	0	0
X-3880	CM	BKM120	213.7	23.6	5	16.4	-5.2
X-3880	CM	BKM120	234.6	22.6	10	27.9	-9.2
X-3880	CM	BKM120	232.4	23	13	26.7	-7.6
X-3880	CM	BKM120	213.6	22.7	17	16.4	-8.8
X-3880	CM	BKM120	240.7	22.5	20	31.2	-9.6
X-3880	CM	BKM120	290.4	22.7	24	58.2	-8.8
X-3880	CM	BKM120	319.5	23.1	27	74.1	-7.2
X-3880	CM	BKM120	287.7	23.1	31	56.8	-7.2
X-3880	CM	BKM120	241.1	22.9	34	31.4	-8
X-3880	CM	BKM120	237.3	23.2	38	29.3	-6.8
X-3880	CM	BKM120	191	22.4	41	4.1	-10
X-3880	CM	BKM120	364.4	22	46	98.6	-11.6
X-3880	CM	BKM120 + encorafenib	184.8	25.6	0	0	0
X-3880	CM	BKM120 + encorafenib	207.4	24.2	2	12.2	-5.5
X-3880	CM	BKM120 + encorafenib	216.4	23.2	7	17.1	-9.4
X-3880	CM	BKM120 + encorafenib	206.2	22.3	10	11.5	-12.9
X-3880	CM	BKM120 + encorafenib	196.7	23.4	14	6.4	-8.6
X-3880	CM	BKM120 + encorafenib	174.1	23.8	17	-5.8	-7
X-3880	CM	BKM120 + encorafenib	216	24.4	21	16.8	-4.7
X-3880	CM	BKM120 + encorafenib	231.6	24.7	24	25.3	-3.5
X-3880	CM	BKM120 + encorafenib	246.6	24.8	28	33.4	-3.1
X-3880	CM	BKM120 + encorafenib	253.4	24.1	31	37.1	-5.9
X-3880	CM	BKM120 + encorafenib	301.8	24.1	35	63.3	-5.9
X-3880	CM	BKM120 + encorafenib	236.4	22.7	37	27.9	-11.3
X-3880	CM	BKM120 + encorafenib	244.1	22.9	38	32.1	-10.5
X-3880	CM	BKM120 + encorafenib	275.7	24.7	43	49.2	-3.5
X-3880	CM	CGM097	238.5	26.1	0	0	0
X-3880	CM	CGM097	418	25.2	5	75.3	-3.4
X-3880	CM	CGM097	471.2	25.1	10	97.6	-3.8
X-3880	CM	CGM097	506.5	25	13	112.4	-4.2
X-3880	CM	CGM097	571.3	25.5	17	139.5	-2.3
X-3880	CM	CGM097	544.5	25.6	20	128.3	-1.9
X-3880	CM	CGM097	583.2	26.7	24	144.5	2.3
X-3880	CM	dacarbazine	235.4	22.7	0	0	0
X-3880	CM	dacarbazine	461.2	21.3	5	95.9	-6.2
X-3880	CM	dacarbazine	439.6	20.8	8	86.7	-8.4
X-3880	CM	dacarbazine	539.9	22.3	12	129.3	-1.8
X-3880	CM	dacarbazine	561.6	21.1	15	138.6	-7
X-3880	CM	dacarbazine	587.5	21.2	19	149.6	-6.6
X-3880	CM	dacarbazine	596.6	21.7	22	153.4	-4.4
X-3880	CM	LDE225	228.1	23.8	0	0	0
X-3880	CM	LDE225	213.5	21.9	2	-6.4	-8
X-3880	CM	LDE225	293.4	19.5	7	28.6	-18.1
X-3880	CM	LDK378	183.4	22.3	0	0	0
X-3880	CM	LDK378	256.1	20.1	2	39.6	-9.9
X-3880	CM	LDK378	339.1	20.3	7	84.9	-9
X-3880	CM	LDK378	452.3	20.6	10	146.6	-7.6
X-3880	CM	LDK378	510.3	21.6	14	178.3	-3.1
X-3880	CM	LDK378	627.8	19.8	17	242.4	-11.2
X-3880	CM	LDK378	573.1	20.2	21	212.6	-9.4
X-3880	CM	LEE011	209	26.7	0	0	0
X-3880	CM	LEE011	298.8	24.3	5	43	-9
X-3880	CM	LEE011	239.3	24.7	10	14.5	-7.5
X-3880	CM	LEE011	285.2	28	13	36.5	4.9
X-3880	CM	LEE011	327.2	28.6	17	56.6	7.1
X-3880	CM	LEE011	302.5	28.4	20	44.8	6.4
X-3880	CM	LEE011	355.2	30.7	24	70	15
X-3880	CM	LEE011 + encorafenib	223.3	21.7	0	0	0
X-3880	CM	LEE011 + encorafenib	247.6	19.9	2	10.9	-8.3
X-3880	CM	LEE011 + encorafenib	308.3	20.3	7	38.1	-6.5
X-3880	CM	LEE011 + encorafenib	300.8	21.3	10	34.7	-1.8
X-3880	CM	LEE011 + encorafenib	318.7	22	14	42.7	1.4
X-3880	CM	LEE011 + encorafenib	278.4	22.2	17	24.7	2.3
X-3880	CM	LEE011 + encorafenib	363.2	22.7	21	62.7	4.6
X-3880	CM	WNT974	186	25.6	0	0	0
X-3880	CM	WNT974	171.1	23.9	2	-8	-6.6
X-3880	CM	WNT974	223.1	24.1	7	19.9	-5.9
X-3880	CM	WNT974	252.2	23.6	10	35.6	-7.8
X-3880	CM	WNT974	332.4	23.7	14	78.7	-7.4
X-3880	CM	WNT974	308.3	23.1	17	65.7	-9.8
X-3880	CM	WNT974	356.7	23.4	21	91.8	-8.6
X-3880	CM	LGW813	219.1	26.3	0	0	0
X-3880	CM	LGW813	197.1	25.6	5	-10	-2.7
X-3880	CM	LGW813	255.8	25.5	10	16.7	-3
X-3880	CM	LGW813	319.6	25.6	13	45.9	-2.7
X-3880	CM	LGW813	429.8	25.9	17	96.2	-1.5
X-3880	CM	LGW813	379.4	24.2	20	73.2	-8
X-3880	CM	LGW813	458.9	24.7	24	109.5	-6.1
X-3880	CM	encorafenib	180.4	22.4	0	0	0
X-3880	CM	encorafenib	275.7	21.6	5	52.8	-3.6
X-3880	CM	encorafenib	277.4	21.4	10	53.8	-4.5
X-3880	CM	encorafenib	252.1	22.9	13	39.8	2.2
X-3880	CM	encorafenib	256.8	23.4	17	42.4	4.5
X-3880	CM	encorafenib	294.9	23.2	20	63.5	3.6
X-3880	CM	encorafenib	333.7	23.4	24	85	4.5
X-3880	CM	encorafenib + binimetinib	189.5	24.5	0	0	0
X-3880	CM	encorafenib + binimetinib	155.2	24.9	2	-18.1	1.6
X-3880	CM	encorafenib + binimetinib	178.3	24.8	7	-6	1.2
X-3880	CM	encorafenib + binimetinib	165.8	25.3	10	-12.5	3.3
X-3880	CM	encorafenib + binimetinib	178.5	27.1	14	-5.8	10.6
X-3880	CM	encorafenib + binimetinib	189.5	25.3	17	0	3.3
X-3880	CM	encorafenib + binimetinib	215.5	26.2	21	13.7	6.9
X-3880	CM	encorafenib + binimetinib	160.5	26.1	24	-15.3	6.5
X-3880	CM	encorafenib + binimetinib	155.7	25.3	28	-17.8	3.3
X-3880	CM	encorafenib + binimetinib	175.8	23.1	31	-7.3	-5.7
X-3880	CM	encorafenib + binimetinib	173.7	24.7	35	-8.3	0.8
X-3880	CM	encorafenib + binimetinib	203.1	25.4	38	7.1	3.7
X-3880	CM	encorafenib + binimetinib	214.9	26.1	43	13.4	6.5
X-3880	CM	encorafenib + binimetinib	230.4	25.8	46	21.5	5.3
X-3880	CM	encorafenib + binimetinib	262.9	25.9	49	38.7	5.7
X-3880	CM	encorafenib + binimetinib	324.8	25.3	52	71.4	3.3
X-3880	CM	encorafenib + binimetinib	307.8	26.5	56	62.4	8.2
X-3880	CM	encorafenib + binimetinib	324.3	25.4	59	71.1	3.7
X-3880	CM	encorafenib + binimetinib	314.7	26.4	63	66	7.8
X-3880	CM	encorafenib + binimetinib	359.8	25.2	66	89.8	2.9
X-3880	CM	encorafenib + binimetinib	351.3	26.1	71	85.4	6.5
X-3880	CM	encorafenib + binimetinib	375.7	25.5	77	98.2	4.1
X-3880	CM	encorafenib + binimetinib	368.5	24.9	87	94.4	1.6
X-3880	CM	binimetinib	180.9	22.5	0	0	0
X-3880	CM	binimetinib	104.7	22.6	5	-42.1	0.4
X-3880	CM	binimetinib	116.9	22.3	10	-35.4	-0.9
X-3880	CM	binimetinib	105.4	22.7	13	-41.7	0.9
X-3880	CM	binimetinib	106.7	23.4	17	-41	4
X-3880	CM	binimetinib	125.6	23.1	20	-30.6	2.7
X-3880	CM	binimetinib	108.5	23.5	24	-40	4.4
X-3880	CM	binimetinib	81.4	24.1	27	-55	7.1
X-3880	CM	binimetinib	95.6	24.4	31	-47.2	8.4
X-3880	CM	binimetinib	95.2	23.5	34	-47.4	4.4
X-3880	CM	binimetinib	85.7	24.1	38	-52.6	7.1
X-3880	CM	binimetinib	88.2	23.5	41	-51.3	4.4
X-3880	CM	binimetinib	80.3	24.2	46	-55.6	7.6
X-3880	CM	binimetinib	70.1	24.6	49	-61.3	9.3
X-3880	CM	binimetinib	74.5	24.3	52	-58.8	8
X-3880	CM	binimetinib	44.4	24	55	-75.4	6.7
X-3880	CM	binimetinib	44.6	24.5	59	-75.3	8.9
X-3880	CM	binimetinib	58	23.4	62	-67.9	4
X-3880	CM	binimetinib	69.3	23.9	66	-61.7	6.2
X-3880	CM	binimetinib	63.7	24.1	69	-64.8	7.1
X-3880	CM	binimetinib	44.4	24.8	74	-75.5	10.2
X-3880	CM	binimetinib	27.4	24.2	80	-84.9	7.6
X-3880	CM	binimetinib	31.1	24.7	94	-82.8	9.8
X-3880	CM	binimetinib	37	24.9	98	-79.6	10.7
X-3880	CM	binimetinib	30.3	24.9	109	-83.2	10.7
X-3880	CM	binimetinib	45.9	25.3	122	-74.7	12.4
X-3880	CM	binimetinib	49	25.7	126	-72.9	14.2
X-3880	CM	binimetinib	51.8	25.1	130	-71.3	11.6
X-3880	CM	binimetinib	31.9	25.6	137	-82.3	13.8
X-3880	CM	binimetinib	70.2	25.7	142	-61.2	14.2
X-3880	CM	binimetinib	42.9	27.2	145	-76.3	20.9
X-3880	CM	binimetinib	40.3	25.7	150	-77.7	14.2
X-3880	CM	binimetinib	28.9	26.8	157	-84	19.1
X-3880	CM	binimetinib	56.1	26.1	164	-69	16
X-3880	CM	binimetinib	79.5	26.1	170	-56.1	16
X-3880	CM	binimetinib	66.7	25.7	173	-63.2	14.2
X-3880	CM	binimetinib	102.1	26.2	177	-43.6	16.4
X-3880	CM	binimetinib	73.7	25.8	181	-59.2	14.7
X-3880	CM	binimetinib	119.4	26.6	186	-34	18.2
X-3880	CM	binimetinib	175.3	26.6	191	-3.1	18.2
X-3880	CM	binimetinib	185.9	25.8	195	2.8	14.7
X-3880	CM	binimetinib	182.6	25.8	199	0.9	14.7
X-3880	CM	binimetinib	263.8	26.6	208	45.8	18.2
X-3880	CM	binimetinib	169	26.7	213	-6.6	18.7
X-3880	CM	binimetinib	202.6	25.8	222	12	14.7
X-3880	CM	binimetinib	243.1	25.8	228	34.4	14.7
X-3880	CM	binimetinib	267.7	26	236	48	15.6
X-3880	CM	binimetinib	331.6	25.5	248	83.3	13.3
X-3880	CM	binimetinib	350.4	25.5	255	93.7	13.3
X-3880	CM	binimetinib	469.3	26.3	262	159.4	16.9
X-3880	CM	TAS266	207	23.6	0	0	0
X-3880	CM	TAS266	362	23.1	3	74.9	-2.1
X-3880	CM	TAS266	533	22.5	8	157.4	-4.7
X-3880	CM	TAS266	753	21.6	13	263.7	-8.5
X-3880	CM	TAS266	737.6	22.1	16	256.3	-6.4
X-3880	CM	TAS266	681.1	21.9	20	229	-7.2
X-3880	CM	TAS266	903.9	22.1	23	336.6	-6.4
X-3880	CM	TAS266	819	22	27	295.6	-6.8
X-3880	CM	untreated	181.7	22.9	0	0	0
X-3880	CM	untreated	268.1	22.9	3	47.6	0
X-3880	CM	untreated	389.3	22.7	6	114.3	-0.9
X-3880	CM	untreated	468.5	22.9	8	157.9	0
X-3880	CM	untreated	770.1	22.1	13	323.9	-3.5
X-3880	CM	untreated	1014.2	21.7	18	458.2	-5.2
X-3880	CM	untreated	1193.3	22.3	21	556.8	-2.6
X-3898	PDAC	abraxane	208.4	28.3	0	0	0
X-3898	PDAC	abraxane	201.3	28.9	5	-3.4	2.1
X-3898	PDAC	abraxane	273.6	28.9	8	31.3	2.1
X-3898	PDAC	abraxane	321.9	29	12	54.5	2.5
X-3898	PDAC	abraxane	451.6	29.8	15	116.7	5.3
X-3898	PDAC	abraxane	513.1	29	20	146.2	2.5
X-3898	PDAC	abraxane	610.8	30	22	193.1	6
X-3898	PDAC	abraxane	630.1	29.8	26	202.4	5.3
X-3898	PDAC	abraxane	768.1	30.4	30	268.6	7.4
X-3898	PDAC	abraxane	918.9	29.6	34	340.9	4.6
X-3898	PDAC	abraxane	1182.1	30.7	37	467.2	8.5
X-3898	PDAC	abraxane	1242.1	32.2	40	496	13.8
X-3898	PDAC	BKM120 + binimetinib	258.1	25	0	0	0
X-3898	PDAC	BKM120 + binimetinib	369.3	26.6	2	43.1	6.4
X-3898	PDAC	BKM120 + binimetinib	436.6	26.2	6	69.2	4.8
X-3898	PDAC	BKM120 + binimetinib	460.5	25.8	9	78.4	3.2
X-3898	PDAC	BKM120 + binimetinib	438.8	25.1	13	70	0.4
X-3898	PDAC	BKM120 + binimetinib	466.9	26.1	16	80.9	4.4
X-3898	PDAC	BKM120 + binimetinib	534.4	27.5	20	107.1	10
X-3898	PDAC	BKM120 + binimetinib	499.6	26	23	93.6	4
X-3898	PDAC	BKM120 + binimetinib	512.6	26.4	27	98.6	5.6
X-3898	PDAC	BKM120 + binimetinib	522.4	26.5	30	102.4	6
X-3898	PDAC	BKM120 + binimetinib	424.3	26.9	34	64.4	7.6
X-3898	PDAC	BKM120 + binimetinib	465.4	25.7	37	80.3	2.8
X-3898	PDAC	BKM120 + binimetinib	452.7	25.9	40	75.4	3.6
X-3898	PDAC	BKM120 + binimetinib	500.1	25.7	43	93.8	2.8
X-3898	PDAC	BKM120 + binimetinib	514.2	26.1	48	99.2	4.4
X-3898	PDAC	BKM120 + binimetinib	449.3	25.9	51	74.1	3.6
X-3898	PDAC	BKM120 + binimetinib	558.9	25.6	55	116.5	2.4
X-3898	PDAC	BKM120 + binimetinib	447.1	25.8	58	73.2	3.2
X-3898	PDAC	BKM120 + binimetinib	471.8	25.8	61	82.8	3.2
X-3898	PDAC	BKM120 + binimetinib	488.3	26.2	65	89.2	4.8
X-3898	PDAC	BKM120 + binimetinib	744	26.3	68	188.3	5.2
X-3898	PDAC	BKM120 + binimetinib	442.2	25.8	71	71.3	3.2
X-3898	PDAC	BKM120 + binimetinib	426.6	24.6	75	65.3	-1.6
X-3898	PDAC	BKM120 + binimetinib	476.7	26.3	79	84.7	5.2
X-3898	PDAC	BKM120 + binimetinib	552.8	27.2	83	114.2	8.8
X-3898	PDAC	BKM120 + binimetinib	605.4	26.2	86	134.6	4.8
X-3898	PDAC	BKM120 + binimetinib	464.1	26.3	89	79.8	5.2
X-3898	PDAC	BKM120 + binimetinib	565.4	26.8	93	119.1	7.2
X-3898	PDAC	BKM120 + LDE225	327.5	26.6	0	0	0
X-3898	PDAC	BKM120 + LDE225	342.6	26.2	1	4.6	-1.5
X-3898	PDAC	BKM120 + LDE225	258.1	25.6	4	-21.2	-3.8
X-3898	PDAC	BKM120 + LDE225	308.9	25.8	8	-5.7	-3
X-3898	PDAC	BKM120 + LDE225	385.7	26.6	11	17.8	0
X-3898	PDAC	BKM120 + LDE225	313	25	14	-4.4	-6
X-3898	PDAC	BKM120 + LDE225	260.5	25.6	18	-20.5	-3.8
X-3898	PDAC	BKM120 + LDE225	286.1	26.7	22	-12.6	0.4
X-3898	PDAC	BKM120 + LDE225	313.2	25.8	26	-4.4	-3
X-3898	PDAC	BKM120 + LDE225	305.9	25	29	-6.6	-6
X-3898	PDAC	BKM120 + LDE225	294.9	25.5	32	-10	-4.1
X-3898	PDAC	BKM120 + LDE225	297.4	25.4	36	-9.2	-4.5
X-3898	PDAC	BKM120 + LDE225	312.2	25	40	-4.7	-6
X-3898	PDAC	BKM120 + LDE225	314.9	25.3	43	-3.8	-4.9
X-3898	PDAC	BKM120 + LDE225	292.8	25.4	47	-10.6	-4.5
X-3898	PDAC	BKM120 + LDE225	341.7	25.5	53	4.3	-4.1
X-3898	PDAC	BKM120 + LDE225	273.5	25.6	64	-16.5	-3.8
X-3898	PDAC	BKM120 + LDE225	220.3	23.4	67	-32.7	-12
X-3898	PDAC	BKM120 + LDE225	207.6	24.4	70	-36.6	-8.3
X-3898	PDAC	BKM120 + LDE225	196.9	23.2	74	-39.9	-12.8
X-3898	PDAC	BKM120 + LDE225	202.8	24.9	77	-38.1	-6.4
X-3898	PDAC	BKM120 + LDE225	197.7	24.9	82	-39.6	-6.4
X-3898	PDAC	BKM120 + LDE225	171.1	23.8	85	-47.8	-10.5
X-3898	PDAC	BKM120 + LDE225	176.3	25.5	88	-46.2	-4.1
X-3898	PDAC	BKM120 + LDE225	192.4	26	91	-41.3	-2.3
X-3898	PDAC	BKM120 + LDE225	180.2	23.5	95	-45	-11.7
X-3898	PDAC	BKM120 + LDE225	163.6	26.6	98	-50	0
X-3898	PDAC	BKM120 + LDE225	158.7	25	102	-51.5	-6
X-3898	PDAC	BKM120 + LDE225	156.9	24.8	105	-52.1	-6.8
X-3898	PDAC	BKM120 + LDE225	123.3	22.9	109	-62.4	-13.9
X-3898	PDAC	BKM120 + LDE225	115	23.8	113	-64.9	-10.5
X-3898	PDAC	BKM120	219.7	23.5	0	0	0
X-3898	PDAC	BKM120	244.7	23.7	4	11.4	0.9
X-3898	PDAC	BKM120	259.1	23.6	7	17.9	0.4
X-3898	PDAC	BKM120	249.4	23.6	11	13.5	0.4
X-3898	PDAC	BKM120	295.8	24.6	14	34.6	4.7
X-3898	PDAC	BKM120	217.5	24.8	18	-1	5.5
X-3898	PDAC	BKM120	313.7	24.3	21	42.8	3.4
X-3898	PDAC	BKM120	318.1	24.7	25	44.8	5.1
X-3898	PDAC	BKM120	289.6	25.3	28	31.8	7.7
X-3898	PDAC	BKM120	352	25.5	32	60.2	8.5
X-3898	PDAC	BKM120	298.7	25.9	35	36	10.2
X-3898	PDAC	BKM120	287.1	25.6	39	30.7	8.9
X-3898	PDAC	BKM120	434.8	25.9	42	97.9	10.2
X-3898	PDAC	BKM120	394.3	25.8	46	79.5	9.8
X-3898	PDAC	BKM120	546.2	25.3	48	148.6	7.7
X-3898	PDAC	BYL719	241.8	24.6	0	0	0
X-3898	PDAC	BYL719	252.1	24.8	5	4.3	0.8
X-3898	PDAC	BYL719	262	25.2	8	8.4	2.4
X-3898	PDAC	BYL719	257.8	25.3	12	6.6	2.8
X-3898	PDAC	BYL719	264.6	25.1	15	9.4	2
X-3898	PDAC	BYL719	267.2	26.4	18	10.5	7.3
X-3898	PDAC	BYL719 + LJM716	309.2	24.9	0	0	0
X-3898	PDAC	BYL719 + LJM716	316.3	25.2	3	2.3	1.2
X-3898	PDAC	BYL719 + LJM716	320.6	24.7	7	3.7	-0.8
X-3898	PDAC	BYL719 + LJM716	337.8	24	10	9.2	-3.6
X-3898	PDAC	BYL719 + LJM716	334.9	24.5	14	8.3	-1.6
X-3898	PDAC	BYL719 + LJM716	444	25	17	43.6	0.4
X-3898	PDAC	BYL719 + LJM716	467.5	25.4	21	51.2	2
X-3898	PDAC	BYL719 + LJM716	488.2	24	23	57.9	-3.6
X-3898	PDAC	BYL719 + LJM716	493.7	25.1	28	59.7	0.8
X-3898	PDAC	BYL719 + LJM716	533	25.3	31	72.4	1.6
X-3898	PDAC	BYL719 + LJM716	541.5	25.2	35	75.1	1.2
X-3898	PDAC	BYL719 + LJM716	595.5	25.4	38	92.6	2
X-3898	PDAC	BYL719 + LJM716	616.6	26.7	41	99.4	7.2
X-3898	PDAC	HDM201	241.5	27.8	0	0	0
X-3898	PDAC	HDM201	239.8	27.7	2	-0.7	-0.4
X-3898	PDAC	HDM201	323.4	27.3	5	33.9	-1.8
X-3898	PDAC	HDM201	379.8	26.6	8	57.3	-4.3
X-3898	PDAC	HDM201	672.9	26.8	13	178.6	-3.6
X-3898	PDAC	HDM201	725.1	27.1	15	200.2	-2.5
X-3898	PDAC	HDM201	750.1	27.3	19	210.6	-1.8
X-3898	PDAC	HDM201	944.5	27.4	26	291.1	-1.4
X-3898	PDAC	figitumumab"	204.1	23.9	0	0	0
X-3898	PDAC	figitumumab"	197.5	25	5	-3.2	4.6
X-3898	PDAC	figitumumab"	236.6	25.1	8	15.9	5
X-3898	PDAC	figitumumab"	246.3	24.9	12	20.7	4.2
X-3898	PDAC	figitumumab"	243.8	25.1	15	19.5	5
X-3898	PDAC	figitumumab"	385.3	24.6	20	88.8	2.9
X-3898	PDAC	figitumumab"	400.2	24.8	22	96.1	3.8
X-3898	PDAC	figitumumab"	337.3	25.1	26	65.3	5
X-3898	PDAC	figitumumab"	385.7	24.9	30	89	4.2
X-3898	PDAC	figitumumab"	511.9	24.9	34	150.8	4.2
X-3898	PDAC	figitumumab"	559.5	24.7	37	174.1	3.3
X-3898	PDAC	figitumumab"	577	26	40	182.7	8.8
X-3898	PDAC	figitumumab"	554.8	25.9	44	171.8	8.4
X-3898	PDAC	figitumumab"	372.5	25.7	48	82.5	7.5
X-3898	PDAC	figitumumab"	435.9	25.3	51	113.6	5.9
X-3898	PDAC	figitumumab"	754.5	25.6	55	269.7	7.1
X-3898	PDAC	figitumumab" + binimetinib	289	24.6	0	0	0
X-3898	PDAC	figitumumab" + binimetinib	367.9	24.9	2	27.3	1.2
X-3898	PDAC	figitumumab" + binimetinib	340.2	24.3	6	17.7	-1.2
X-3898	PDAC	figitumumab" + binimetinib	537.7	25.5	9	86.1	3.7
X-3898	PDAC	figitumumab" + binimetinib	600.4	25.6	13	107.8	4.1
X-3898	PDAC	figitumumab" + binimetinib	590.8	25.1	16	104.4	2
X-3898	PDAC	figitumumab" + binimetinib	826.5	24.6	20	186	0
X-3898	PDAC	figitumumab" + binimetinib	888.7	24.1	22	207.5	-2
X-3898	PDAC	figitumumab" + binimetinib	775.2	25.4	26	168.2	3.3
X-3898	PDAC	figitumumab" + binimetinib	714.9	23.4	29	147.4	-4.9
X-3898	PDAC	gemcitabine-50mpk	254.7	24.8	0	0	0
X-3898	PDAC	gemcitabine-50mpk	270.8	26.2	3	6.3	5.6
X-3898	PDAC	gemcitabine-50mpk	286.4	25.5	7	12.4	2.8
X-3898	PDAC	gemcitabine-50mpk	317	24.4	10	24.5	-1.6
X-3898	PDAC	gemcitabine-50mpk	329.7	26.3	14	29.4	6
X-3898	PDAC	gemcitabine-50mpk	314.9	26.9	17	23.6	8.5
X-3898	PDAC	gemcitabine-50mpk	355.3	25.3	20	39.5	2
X-3898	PDAC	gemcitabine-50mpk	360.2	24.9	25	41.4	0.4
X-3898	PDAC	gemcitabine-50mpk	343.9	26.1	27	35	5.2
X-3898	PDAC	gemcitabine-50mpk	335.2	25.3	31	31.6	2
X-3898	PDAC	gemcitabine-50mpk	410.8	26.5	33	61.3	6.9
X-3898	PDAC	gemcitabine-50mpk	413.2	25.6	39	62.2	3.2
X-3898	PDAC	gemcitabine-50mpk	381.8	25.4	43	49.9	2.4
X-3898	PDAC	gemcitabine-50mpk	322.1	25.3	45	26.5	2
X-3898	PDAC	gemcitabine-50mpk	340.6	25	49	33.7	0.8
X-3898	PDAC	gemcitabine-50mpk	478.8	25.9	53	88	4.4
X-3898	PDAC	gemcitabine-50mpk	413.3	26	56	62.3	4.8
X-3898	PDAC	gemcitabine-50mpk	642.8	27.1	63	152.4	9.3
X-3898	PDAC	gemcitabine-50mpk	407.3	25.1	66	59.9	1.2
X-3898	PDAC	gemcitabine-50mpk	529.1	25.5	71	107.7	2.8
X-3898	PDAC	gemcitabine-50mpk	494.8	27	75	94.3	8.9
X-3898	PDAC	gemcitabine-50mpk	519.5	27.1	77	104	9.3
X-3898	PDAC	gemcitabine-50mpk	740.1	25.7	81	190.6	3.6
X-3898	PDAC	gemcitabine-50mpk	545	26.2	84	114	5.6
X-3898	PDAC	gemcitabine-50mpk	816.1	25.3	88	220.4	2
X-3898	PDAC	gemcitabine-50mpk	818.6	26.2	91	221.4	5.6
X-3898	PDAC	gemcitabine-50mpk	905.1	26.8	94	255.4	8.1
X-3898	PDAC	gemcitabine-50mpk	1065.7	26.6	98	318.4	7.3
X-3898	PDAC	gemcitabine-50mpk	1182.4	25.7	102	364.2	3.6
X-3898	PDAC	gemcitabine-50mpk	1246.3	25.9	105	389.3	4.4
X-3898	PDAC	gemcitabine-50mpk	1396.3	26.8	109	448.2	8.1
X-3898	PDAC	INC424 + binimetinib	242.9	26.7	0	0	0
X-3898	PDAC	INC424 + binimetinib	234.2	25.6	4	-3.6	-4.1
X-3898	PDAC	INC424 + binimetinib	240.6	26.2	7	-0.9	-1.9
X-3898	PDAC	INC424 + binimetinib	215.2	26.5	11	-11.4	-0.7
X-3898	PDAC	INC424 + binimetinib	205.6	26.1	14	-15.4	-2.2
X-3898	PDAC	INC424 + binimetinib	218.1	26.3	18	-10.2	-1.5
X-3898	PDAC	INC424 + binimetinib	255.1	26.4	21	5	-1.1
X-3898	PDAC	INC424 + binimetinib	218.6	26.7	25	-10	0
X-3898	PDAC	INC424 + binimetinib	278.3	26.9	28	14.6	0.7
X-3898	PDAC	INC424 + binimetinib	282.6	27.1	31	16.3	1.5
X-3898	PDAC	INC424 + binimetinib	263	27	34	8.3	1.1
X-3898	PDAC	INC424 + binimetinib	250.6	26.9	39	3.2	0.7
X-3898	PDAC	INC424 + binimetinib	285.4	26.8	42	17.5	0.4
X-3898	PDAC	INC424 + binimetinib	235.4	26.3	46	-3.1	-1.5
X-3898	PDAC	INC424 + binimetinib	280.2	26.6	49	15.4	-0.4
X-3898	PDAC	INC424 + binimetinib	253.9	27.2	52	4.5	1.9
X-3898	PDAC	INC424 + binimetinib	299.7	26.6	56	23.4	-0.4
X-3898	PDAC	INC424 + binimetinib	346.4	27.3	59	42.6	2.2
X-3898	PDAC	INC424 + binimetinib	287.3	27.7	62	18.3	3.7
X-3898	PDAC	INC424 + binimetinib	306.4	28	66	26.1	4.9
X-3898	PDAC	INC424 + binimetinib	288.9	28.1	70	18.9	5.2
X-3898	PDAC	INC424 + binimetinib	291.7	27.8	74	20.1	4.1
X-3898	PDAC	INC424 + binimetinib	280.5	27.6	77	15.5	3.4
X-3898	PDAC	INC424 + binimetinib	289.4	27.8	80	19.1	4.1
X-3898	PDAC	INC424 + binimetinib	310.8	27.9	84	28	4.5
X-3898	PDAC	INC424	217.1	23.5	0	0	0
X-3898	PDAC	INC424	253.9	23.1	3	17	-1.7
X-3898	PDAC	INC424	296.5	23.1	6	36.6	-1.7
X-3898	PDAC	INC424	385.8	25.5	10	77.7	8.5
X-3898	PDAC	INC424	407.1	25.4	13	87.5	8.1
X-3898	PDAC	INC424	472.1	25.7	17	117.5	9.4
X-3898	PDAC	INC424	616.6	24.4	24	184	3.8
X-3898	PDAC	INC424	649.2	25.2	28	199	7.2
X-3898	PDAC	INC424	713.9	25	31	228.8	6.4
X-3898	PDAC	INC424	724.4	26.2	34	233.7	11.5
X-3898	PDAC	INC424	828.5	24.4	39	281.6	3.8
X-3898	PDAC	INC424	906.1	23.9	41	317.4	1.7
X-3898	PDAC	INC424	962.1	26.2	45	343.2	11.5
X-3898	PDAC	LEE011	220.7	27.3	0	0	0
X-3898	PDAC	LEE011	298	27.8	3	35	1.8
X-3898	PDAC	LEE011	378.3	27.4	6	71.4	0.4
X-3898	PDAC	LEE011	505.7	26.9	10	129.1	-1.5
X-3898	PDAC	LEE011	620.4	26.8	13	181.1	-1.8
X-3898	PDAC	LEE011	487.8	27.2	17	121	-0.4
X-3898	PDAC	LEE011	489	28.3	20	121.6	3.7
X-3898	PDAC	LEE011	536.1	27.1	25	142.9	-0.7
X-3898	PDAC	LEE011	501.2	27.8	27	127.1	1.8
X-3898	PDAC	LEE011	421.4	28.4	31	90.9	4
X-3898	PDAC	LEE011	265.4	28.2	35	20.3	3.3
X-3898	PDAC	LEE011	285.8	28	39	29.5	2.6
X-3898	PDAC	LEE011	290.7	28.2	42	31.7	3.3
X-3898	PDAC	LEE011	245.4	28.4	45	11.2	4
X-3898	PDAC	LEE011	257.9	29.5	49	16.9	8.1
X-3898	PDAC	LEE011	182.3	30.2	53	-17.4	10.6
X-3898	PDAC	LEE011	208.3	29.4	56	-5.6	7.7
X-3898	PDAC	LEE011	243.6	29.3	60	10.4	7.3
X-3898	PDAC	LEE011	239.7	30.1	63	8.6	10.3
X-3898	PDAC	LEE011	268.4	30.6	66	21.6	12.1
X-3898	PDAC	LEE011	330.4	29.5	69	49.7	8.1
X-3898	PDAC	LEE011	304	28.6	74	37.7	4.8
X-3898	PDAC	LEE011	299.4	30.4	76	35.7	11.4
X-3898	PDAC	LEE011	330.4	29.4	80	49.7	7.7
X-3898	PDAC	LEE011	409.5	28.5	83	85.5	4.4
X-3898	PDAC	LEE011	457.9	28.6	87	107.5	4.8
X-3898	PDAC	LEE011	507.9	29.5	90	130.1	8.1
X-3898	PDAC	LEE011	481.4	29.9	94	118.1	9.5
X-3898	PDAC	LEE011	494.4	30.5	97	124	11.7
X-3898	PDAC	WNT974	284.2	26.7	0	0	0
X-3898	PDAC	WNT974	338.7	25.3	2	19.2	-5.2
X-3898	PDAC	WNT974	389.3	24.1	7	37	-9.7
X-3898	PDAC	WNT974	400.2	25.1	9	40.8	-6
X-3898	PDAC	WNT974	467.2	24.2	13	64.4	-9.4
X-3898	PDAC	WNT974	495.4	24	16	74.3	-10.1
X-3898	PDAC	WNT974	513.4	25.6	19	80.6	-4.1
X-3898	PDAC	WNT974	922.3	25.5	22	224.5	-4.5
X-3898	PDAC	WNT974	944.2	26.1	27	232.2	-2.2
X-3898	PDAC	LKA136	227.9	31.8	0	0	0
X-3898	PDAC	LKA136	211.2	31	3	-7.3	-2.5
X-3898	PDAC	LKA136	289.9	31.5	7	27.2	-0.9
X-3898	PDAC	LKA136	278.3	31.7	10	22.1	-0.3
X-3898	PDAC	LKA136	322.5	31.4	14	41.5	-1.3
X-3898	PDAC	LKA136	403	30.5	17	76.8	-4.1
X-3898	PDAC	LKA136	422.3	31.4	21	85.3	-1.3
X-3898	PDAC	LKA136	597.1	32.2	27	162	1.3
X-3898	PDAC	LKA136	747.8	32.3	32	228.1	1.6
X-3898	PDAC	LKA136	871.5	31.9	34	282.4	0.3
X-3898	PDAC	LKA136	874.8	32.6	38	283.9	2.5
X-3898	PDAC	binimetinib	220.1	27.4	0	0	0
X-3898	PDAC	binimetinib	408	26.6	2	85.4	-2.9
X-3898	PDAC	binimetinib	408.9	27	6	85.8	-1.5
X-3898	PDAC	binimetinib	471.1	26.3	9	114	-4
X-3898	PDAC	binimetinib	588.1	27.1	13	167.2	-1.1
X-3898	PDAC	binimetinib	565	27.6	16	156.7	0.7
X-3898	PDAC	binimetinib	719.3	28.5	20	226.8	4
X-3898	PDAC	binimetinib	628.3	29	23	185.5	5.8
X-3898	PDAC	binimetinib	707.9	28.8	27	221.6	5.1
X-3898	PDAC	binimetinib	754.8	27.9	30	242.9	1.8
X-3898	PDAC	binimetinib	753.5	29.5	34	242.3	7.7
X-3898	PDAC	binimetinib	980.8	28.7	37	345.6	4.7
X-3898	PDAC	binimetinib	855.3	29.3	40	288.6	6.9
X-3898	PDAC	binimetinib	921.5	29.7	43	318.7	8.4
X-3898	PDAC	binimetinib	927.5	29.7	48	321.4	8.4
X-3898	PDAC	binimetinib	658.5	27.5	51	199.2	0.4
X-3898	PDAC	binimetinib	794.1	29.1	55	260.8	6.2
X-3898	PDAC	binimetinib	542.1	29.1	58	146.3	6.2
X-3898	PDAC	binimetinib-3.5mpk	226.6	25.9	0	0	0
X-3898	PDAC	binimetinib-3.5mpk	344.3	25.9	2	51.9	0
X-3898	PDAC	binimetinib-3.5mpk	558.1	25.5	6	146.3	-1.5
X-3898	PDAC	binimetinib-3.5mpk	536.7	26.7	9	136.8	3.1
X-3898	PDAC	binimetinib-3.5mpk	769.2	27.4	12	239.5	5.8
X-3898	PDAC	binimetinib-3.5mpk	731.8	26.3	14	222.9	1.5
X-3898	PDAC	binimetinib-3.5mpk	924.5	26.7	19	308	3.1
X-3898	PDAC	binimetinib-3.5mpk	995.8	27.8	26	339.5	7.3
X-3898	PDAC	binimetinib-3.5mpk	894.1	27.3	29	294.6	5.4
X-3898	PDAC	binimetinib-3.5mpk	1021.1	29.3	33	350.6	13.1
X-3898	PDAC	trametinib	224	26.1	0	0	0
X-3898	PDAC	trametinib	232.8	26	4	3.9	-0.4
X-3898	PDAC	trametinib	241.6	27	7	7.9	3.4
X-3898	PDAC	trametinib	263.9	26.5	11	17.8	1.5
X-3898	PDAC	trametinib	241.4	25.7	14	7.8	-1.5
X-3898	PDAC	trametinib	255.4	25.4	21	14	-2.7
X-3898	PDAC	trametinib	236.9	27.6	25	5.8	5.7
X-3898	PDAC	trametinib	333.1	26.1	28	48.7	0
X-3898	PDAC	trametinib	374.8	27.1	32	67.3	3.8
X-3898	PDAC	trametinib	337.6	27	35	50.7	3.4
X-3898	PDAC	trametinib	211.2	26.6	39	-5.7	1.9
X-3898	PDAC	trametinib	274.1	26.6	42	22.4	1.9
X-3898	PDAC	trametinib	247.8	27.3	46	10.6	4.6
X-3898	PDAC	trametinib	310.8	27	48	38.7	3.4
X-3898	PDAC	trametinib	390.2	27.5	53	74.2	5.4
X-3898	PDAC	trametinib	465.1	27	56	107.6	3.4
X-3898	PDAC	trametinib	524.5	24.2	61	134.2	-7.3
X-3898	PDAC	untreated	283.2	27.3	0	0	0
X-3898	PDAC	untreated	358.7	27.5	2	26.7	0.7
X-3898	PDAC	untreated	434.8	26	7	53.5	-4.8
X-3898	PDAC	untreated	577.8	27.7	9	104	1.5
X-3898	PDAC	untreated	634.5	27.8	13	124	1.8
X-3898	PDAC	untreated	779.7	27.8	16	175.3	1.8
X-3898	PDAC	untreated	900	29	19	217.8	6.2
X-3898	PDAC	untreated	1006.6	27.9	22	255.4	2.2
X-3898	PDAC	untreated	1091.4	31	27	285.4	13.6
X-3947	PDAC	abraxane	218	26.8	0	0	0
X-3947	PDAC	abraxane	189.3	27.8	3	-13.2	3.7
X-3947	PDAC	abraxane	162.7	27.5	7	-25.4	2.6
X-3947	PDAC	abraxane	89.9	27.2	10	-58.8	1.5
X-3947	PDAC	abraxane	130.1	27.6	13	-40.3	3
X-3947	PDAC	abraxane	196.7	27.9	17	-9.8	4.1
X-3947	PDAC	abraxane	230.5	27.7	20	5.7	3.4
X-3947	PDAC	abraxane	224.4	28.1	24	2.9	4.9
X-3947	PDAC	abraxane	274.8	27.5	27	26.1	2.6
X-3947	PDAC	abraxane	349.2	27.5	31	60.2	2.6
X-3947	PDAC	abraxane	470.9	26.5	35	116	-1.1
X-3947	PDAC	abraxane	661	28.6	38	203.2	6.7
X-3947	PDAC	abraxane	668.2	27.7	41	206.5	3.4
X-3947	PDAC	abraxane	948.1	28.2	45	334.9	5.2
X-3947	PDAC	BKM120 + binimetinib	328.7	20.2	0	0	0
X-3947	PDAC	BKM120 + binimetinib	300.3	19.4	4	-8.6	-4
X-3947	PDAC	BKM120 + binimetinib	198.8	20.1	7	-39.5	-0.5
X-3947	PDAC	BKM120 + binimetinib	268.8	20.6	11	-18.2	2
X-3947	PDAC	BKM120 + binimetinib	237.2	19.6	14	-27.8	-3
X-3947	PDAC	BKM120 + binimetinib	217.5	19.7	18	-33.8	-2.5
X-3947	PDAC	BKM120 + binimetinib	212.8	20.4	21	-35.3	1
X-3947	PDAC	BKM120 + binimetinib	228.2	19.3	25	-30.6	-4.5
X-3947	PDAC	BKM120 + binimetinib	231.4	19.1	28	-29.6	-5.4
X-3947	PDAC	BKM120 + binimetinib	223.1	19.8	31	-32.1	-2
X-3947	PDAC	BKM120 + binimetinib	214.2	18.1	34	-34.8	-10.4
X-3947	PDAC	BKM120 + binimetinib	222.3	17.7	39	-32.4	-12.4
X-3947	PDAC	BKM120 + binimetinib	186.5	14.7	42	-43.3	-27.2
X-3947	PDAC	BKM120 + LDE225	330.7	22.9	0	0	0
X-3947	PDAC	BKM120 + LDE225	387.3	23.5	4	17.1	2.6
X-3947	PDAC	BKM120 + LDE225	434.2	23.8	7	31.3	3.9
X-3947	PDAC	BKM120 + LDE225	580.1	23.5	11	75.4	2.6
X-3947	PDAC	BKM120 + LDE225	577.8	23.2	14	74.7	1.3
X-3947	PDAC	BKM120 + LDE225	691.5	24	18	109.1	4.8
X-3947	PDAC	BKM120 + LDE225	868.9	22.9	21	162.7	0
X-3947	PDAC	BKM120 + LDE225	1113.1	24.8	25	236.6	8.3
X-3947	PDAC	BKM120 + LDE225	1456.3	23.4	28	340.4	2.2
X-3947	PDAC	BKM120 + LDE225	2037.3	24.1	31	516.1	5.2
X-3947	PDAC	BKM120 + LDE225	1501.3	24.5	34	354	7
X-3947	PDAC	BKM120 + LDE225	2173.5	23.2	39	557.2	1.3
X-3947	PDAC	BKM120 + LDE225	2705	24.4	42	718	6.6
X-3947	PDAC	BKM120	222.6	25.8	0	0	0
X-3947	PDAC	BKM120	315.6	26.2	1	41.8	1.6
X-3947	PDAC	BKM120	418.4	26.1	5	88	1.2
X-3947	PDAC	BKM120	749.4	25.7	8	236.7	-0.4
X-3947	PDAC	BKM120	754.8	25.6	12	239.1	-0.8
X-3947	PDAC	BKM120	857.6	26.6	15	285.3	3.1
X-3947	PDAC	BKM120	1012.4	26.4	19	354.8	2.3
X-3947	PDAC	BKM120	1090.6	25.1	22	389.9	-2.7
X-3947	PDAC	BKM120	1369.8	25.2	26	515.4	-2.3
X-3947	PDAC	BYL719 + LJM716	252.5	25.3	0	0	0
X-3947	PDAC	BYL719 + LJM716	346.3	24.8	3	37.1	-2
X-3947	PDAC	BYL719 + LJM716	472.9	24	6	87.3	-5.1
X-3947	PDAC	BYL719 + LJM716	749.5	24.4	10	196.8	-3.6
X-3947	PDAC	BYL719 + LJM716	832.7	24.1	13	229.8	-4.7
X-3947	PDAC	BYL719 + LJM716	959.7	23.8	16	280.1	-5.9
X-3947	PDAC	BYL719 + LJM716	1340.5	23.9	20	430.9	-5.5
X-3947	PDAC	BYL719 + LJM716	1790.9	23.7	22	609.3	-6.3
X-3947	PDAC	BYL719	248.7	NA	0	0	0
X-3947	PDAC	BYL719	256.9	24.3	3	3.3	0
X-3947	PDAC	BYL719	478.2	22.6	6	92.3	-7
X-3947	PDAC	BYL719	578.9	23.7	10	132.8	-2.5
X-3947	PDAC	BYL719	824.9	23	13	231.7	-5.3
X-3947	PDAC	BYL719	1014.2	22.8	16	307.8	-6.2
X-3947	PDAC	BYL719	1652.7	23	20	564.5	-5.3
X-3947	PDAC	CLR457	218.2	26.6	0	0	0
X-3947	PDAC	CLR457	288.4	28.4	3	32.2	6.8
X-3947	PDAC	CLR457	302.4	27.9	6	38.6	4.9
X-3947	PDAC	CLR457	359.7	27.7	9	64.8	4.1
X-3947	PDAC	CLR457	528.5	28.6	13	142.2	7.5
X-3947	PDAC	CLR457	717	28.4	17	228.6	6.8
X-3947	PDAC	CLR457	870.9	27.5	20	299.1	3.4
X-3947	PDAC	CLR457	971.3	29.5	24	345.1	10.9
X-3947	PDAC	CLR457	1145.9	29.6	27	425.2	11.3
X-3947	PDAC	CLR457	1212.4	30.3	30	455.6	13.9
X-3947	PDAC	CLR457	1391.1	29.4	34	537.5	10.5
X-3947	PDAC	CLR457	1521.2	29.6	37	597.2	11.3
X-3947	PDAC	HDM201	243.8	26.2	0	0	0
X-3947	PDAC	HDM201	265.5	26.5	3	8.9	1.1
X-3947	PDAC	HDM201	323.8	25.3	6	32.8	-3.4
X-3947	PDAC	HDM201	415.8	25.6	9	70.5	-2.3
X-3947	PDAC	HDM201	603.5	26	13	147.5	-0.8
X-3947	PDAC	HDM201	787.6	24.6	16	223.1	-6.1
X-3947	PDAC	HDM201	1216.5	20.2	20	399	-22.9
X-3947	PDAC	figitumumab"	212.5	25.8	0	0	0
X-3947	PDAC	figitumumab"	364.6	26.8	4	71.6	3.9
X-3947	PDAC	figitumumab"	532	27	10	150.4	4.7
X-3947	PDAC	figitumumab"	880	28.3	14	314.1	9.7
X-3947	PDAC	figitumumab"	1172.5	28.9	17	451.8	12
X-3947	PDAC	figitumumab"	1332.7	29.4	19	527.2	14
X-3947	PDAC	figitumumab" + binimetinib	269.1	24.1	0	0	0
X-3947	PDAC	figitumumab" + binimetinib	397	23.9	3	47.5	-0.8
X-3947	PDAC	figitumumab" + binimetinib	608.2	23.7	7	126	-1.7
X-3947	PDAC	figitumumab" + binimetinib	902.3	23	10	235.3	-4.6
X-3947	PDAC	figitumumab" + binimetinib	991.8	22.9	14	268.6	-5
X-3947	PDAC	figitumumab" + binimetinib	980.2	23.6	17	264.3	-2.1
X-3947	PDAC	figitumumab" + binimetinib	1040.4	24.3	21	286.6	0.8
X-3947	PDAC	figitumumab" + binimetinib	1374.7	25	24	410.9	3.7
X-3947	PDAC	figitumumab" + binimetinib	1629	25.2	28	505.4	4.6
X-3947	PDAC	gemcitabine-50mpk	314.8	24.9	0	0	0
X-3947	PDAC	gemcitabine-50mpk	389.6	22.3	3	23.8	-10.4
X-3947	PDAC	gemcitabine-50mpk	496.7	22.7	6	57.8	-8.8
X-3947	PDAC	gemcitabine-50mpk	494.5	24.5	9	57.1	-1.6
X-3947	PDAC	gemcitabine-50mpk	518.9	23.7	13	64.8	-4.8
X-3947	PDAC	gemcitabine-50mpk	445.7	23	17	41.6	-7.6
X-3947	PDAC	gemcitabine-50mpk	450.2	24	20	43	-3.6
X-3947	PDAC	gemcitabine-50mpk	430.1	25.1	24	36.6	0.8
X-3947	PDAC	gemcitabine-50mpk	334.2	25.2	27	6.2	1.2
X-3947	PDAC	gemcitabine-50mpk	261.2	26.5	31	-17	6.4
X-3947	PDAC	gemcitabine-50mpk	257.2	25.6	34	-18.3	2.8
X-3947	PDAC	gemcitabine-50mpk	177.5	25	37	-43.6	0.4
X-3947	PDAC	gemcitabine-50mpk	182.5	25.7	41	-42	3.2
X-3947	PDAC	gemcitabine-50mpk	188.6	25.2	45	-40.1	1.2
X-3947	PDAC	gemcitabine-50mpk	178.6	24.7	48	-43.3	-0.8
X-3947	PDAC	gemcitabine-50mpk	252.7	26.3	52	-19.7	5.6
X-3947	PDAC	gemcitabine-50mpk	220	26	54	-30.1	4.4
X-3947	PDAC	gemcitabine-50mpk	190.5	25.4	59	-39.5	2
X-3947	PDAC	gemcitabine-50mpk	183.9	25	65	-41.6	0.4
X-3947	PDAC	gemcitabine-50mpk	127.5	26.3	69	-59.5	5.6
X-3947	PDAC	gemcitabine-50mpk	172.4	26	73	-45.2	4.4
X-3947	PDAC	gemcitabine-50mpk	188.2	26.2	75	-40.2	5.2
X-3947	PDAC	gemcitabine-50mpk	209.6	26.8	80	-33.4	7.6
X-3947	PDAC	gemcitabine-50mpk	163.7	26.5	82	-48	6.4
X-3947	PDAC	INC424 + binimetinib	325.6	24.8	0	0	0
X-3947	PDAC	INC424 + binimetinib	290.1	24.5	4	-10.9	-1.2
X-3947	PDAC	INC424 + binimetinib	360.8	25.5	7	10.8	2.8
X-3947	PDAC	INC424 + binimetinib	362.5	26.2	11	11.3	5.6
X-3947	PDAC	INC424 + binimetinib	348.7	26.5	14	7.1	6.9
X-3947	PDAC	INC424 + binimetinib	338.8	26.6	18	4.1	7.3
X-3947	PDAC	INC424 + binimetinib	395.3	26.2	21	21.4	5.6
X-3947	PDAC	INC424 + binimetinib	401.4	25.9	25	23.3	4.4
X-3947	PDAC	INC424 + binimetinib	449.5	27.5	28	38.1	10.9
X-3947	PDAC	INC424 + binimetinib	397.9	26.4	31	22.2	6.5
X-3947	PDAC	INC424 + binimetinib	411.4	27.2	34	26.4	9.7
X-3947	PDAC	INC424 + binimetinib	395.5	27	39	21.5	8.9
X-3947	PDAC	INC424 + binimetinib	483.3	26.5	42	48.4	6.9
X-3947	PDAC	INC424 + binimetinib	476.7	26.2	46	46.4	5.6
X-3947	PDAC	INC424 + binimetinib	424.1	26.2	49	30.3	5.6
X-3947	PDAC	INC424 + binimetinib	445.3	26.5	52	36.8	6.9
X-3947	PDAC	INC424 + binimetinib	433.7	27.5	56	33.2	10.9
X-3947	PDAC	INC424 + binimetinib	574	27.6	59	76.3	11.3
X-3947	PDAC	INC424 + binimetinib	472.3	26.9	62	45.1	8.5
X-3947	PDAC	INC424 + binimetinib	428.1	27.3	66	31.5	10.1
X-3947	PDAC	INC424 + binimetinib	515.2	28.3	70	58.2	14.1
X-3947	PDAC	INC424 + binimetinib	517.8	28.1	74	59	13.3
X-3947	PDAC	INC424 + binimetinib	414.2	27.9	77	27.2	12.5
X-3947	PDAC	INC424 + binimetinib	428.5	27.7	80	31.6	11.7
X-3947	PDAC	INC424 + binimetinib	588	28.3	84	80.6	14.1
X-3947	PDAC	INC424	238.8	24.7	0	0	0
X-3947	PDAC	INC424	244.8	26.5	4	2.5	7.3
X-3947	PDAC	INC424	259.4	26.5	7	8.6	7.3
X-3947	PDAC	INC424	295	26.6	11	23.5	7.7
X-3947	PDAC	INC424	347.6	26.3	14	45.6	6.5
X-3947	PDAC	INC424	418.2	25.8	18	75.1	4.5
X-3947	PDAC	INC424	471.4	26.2	21	97.4	6.1
X-3947	PDAC	INC424	521	25.9	24	118.2	4.9
X-3947	PDAC	INC424	569.1	26	27	138.3	5.3
X-3947	PDAC	INC424	700.5	26.3	32	193.3	6.5
X-3947	PDAC	INC424	790.4	25.7	35	231	4
X-3947	PDAC	INC424	951.4	25.5	39	298.4	3.2
X-3947	PDAC	LEE011	236.1	25.2	0	0	0
X-3947	PDAC	LEE011	329.3	26.1	3	39.5	3.6
X-3947	PDAC	LEE011	374.1	NA	6	58.4	3.6
X-3947	PDAC	LEE011	533.2	26.1	10	125.8	3.6
X-3947	PDAC	LEE011	754.2	26.6	12	219.4	5.6
X-3947	PDAC	WNT974	262.9	24.5	0	0	0
X-3947	PDAC	WNT974	446.8	22.4	3	70	-8.6
X-3947	PDAC	WNT974	806.9	21.9	7	206.9	-10.6
X-3947	PDAC	LKA136	217	25.2	0	0	0
X-3947	PDAC	LKA136	218.8	26.6	3	0.8	5.6
X-3947	PDAC	LKA136	311.4	28	6	43.5	11.1
X-3947	PDAC	LKA136	407.1	26.9	10	87.6	6.7
X-3947	PDAC	LKA136	486	28	13	124	11.1
X-3947	PDAC	LKA136	681.9	27.6	17	214.2	9.5
X-3947	PDAC	LKA136	886.9	28.5	20	308.7	13.1
X-3947	PDAC	LKA136	1234.5	28.4	24	468.9	12.7
X-3947	PDAC	LKA136	1278.2	29.1	25	489	15.5
X-3947	PDAC	binimetinib	201.9	26.5	0	0	0
X-3947	PDAC	binimetinib	243.8	26.4	6	20.8	-0.4
X-3947	PDAC	binimetinib	309	26.1	9	53	-1.5
X-3947	PDAC	binimetinib	310.9	26	13	54	-1.9
X-3947	PDAC	binimetinib	337.8	26.8	16	67.3	1.1
X-3947	PDAC	binimetinib	293	26.8	20	45.1	1.1
X-3947	PDAC	binimetinib	288.8	26.2	23	43	-1.1
X-3947	PDAC	binimetinib	259.3	26.4	26	28.4	-0.4
X-3947	PDAC	binimetinib	405.7	27.4	29	100.9	3.4
X-3947	PDAC	binimetinib	373.4	26.1	33	84.9	-1.5
X-3947	PDAC	binimetinib	386	26.5	36	91.2	0
X-3947	PDAC	binimetinib	321.5	28.2	40	59.2	6.4
X-3947	PDAC	binimetinib	395.7	27.7	42	96	4.5
X-3947	PDAC	binimetinib	443.8	27	47	119.8	1.9
X-3947	PDAC	binimetinib	478	27.2	50	136.8	2.6
X-3947	PDAC	binimetinib	332.7	26.8	55	64.8	1.1
X-3947	PDAC	binimetinib	427.9	26.6	57	111.9	0.4
X-3947	PDAC	binimetinib	492.8	26.5	62	144.1	0
X-3947	PDAC	binimetinib	550.2	26.4	65	172.5	-0.4
X-3947	PDAC	binimetinib	376.2	26.6	68	86.3	0.4
X-3947	PDAC	binimetinib	421.6	26.5	72	108.8	0
X-3947	PDAC	binimetinib	373	26.4	77	84.7	-0.4
X-3947	PDAC	binimetinib	407.7	26.8	79	101.9	1.1
X-3947	PDAC	binimetinib	444.2	26.2	82	120	-1.1
X-3947	PDAC	binimetinib	461.6	27.5	84	128.6	3.8
X-3947	PDAC	binimetinib	420.2	27	86	108.1	1.9
X-3947	PDAC	binimetinib	332.6	26.9	90	64.7	1.5
X-3947	PDAC	binimetinib	360.3	27.6	92	78.5	4.2
X-3947	PDAC	binimetinib	406.4	27.7	97	101.3	4.5
X-3947	PDAC	binimetinib	419.3	27.5	100	107.7	3.8
X-3947	PDAC	binimetinib	548.8	28	104	171.8	5.7
X-3947	PDAC	binimetinib	534.6	27.5	107	164.8	3.8
X-3947	PDAC	binimetinib	510.6	28.1	111	152.9	6
X-3947	PDAC	binimetinib	530.3	28.2	114	162.7	6.4
X-3947	PDAC	binimetinib	512.9	28	118	154	5.7
X-3947	PDAC	binimetinib	453.5	27.8	121	124.6	4.9
X-3947	PDAC	binimetinib	637	27.6	125	215.5	4.2
X-3947	PDAC	binimetinib	481.8	27.8	128	138.6	4.9
X-3947	PDAC	binimetinib	660.1	27.7	132	226.9	4.5
X-3947	PDAC	binimetinib	746.4	28.8	135	269.7	8.7
X-3947	PDAC	binimetinib	545.2	28.4	139	170	7.2
X-3947	PDAC	binimetinib	733.4	28.1	142	263.2	6
X-3947	PDAC	binimetinib	782.7	27.8	146	287.7	4.9
X-3947	PDAC	binimetinib	819.2	28.6	153	305.7	7.9
X-3947	PDAC	binimetinib	614.7	29.1	156	204.5	9.8
X-3947	PDAC	binimetinib	922.5	29.2	160	356.9	10.2
X-3947	PDAC	binimetinib	717.4	29.3	163	255.3	10.6
X-3947	PDAC	binimetinib-3.5mpk	257.2	29.2	0	0	0
X-3947	PDAC	binimetinib-3.5mpk	451.2	28.5	2	75.4	-2.4
X-3947	PDAC	binimetinib-3.5mpk	572.1	27.8	6	122.4	-4.8
X-3947	PDAC	binimetinib-3.5mpk	651.8	28.2	9	153.4	-3.4
X-3947	PDAC	binimetinib-3.5mpk	901.1	29.3	13	250.3	0.3
X-3947	PDAC	binimetinib-3.5mpk	1663.2	29.8	16	546.7	2.1
X-3947	PDAC	trametinib	195.1	26.7	0	0	0
X-3947	PDAC	trametinib	239	28.1	5	22.5	5.2
X-3947	PDAC	trametinib	321.5	26.9	7	64.8	0.7
X-3947	PDAC	trametinib	317.2	28.9	11	62.6	8.2
X-3947	PDAC	trametinib	310.6	28.9	14	59.2	8.2
X-3947	PDAC	trametinib	356.6	28.9	18	82.8	8.2
X-3947	PDAC	trametinib	356.8	28.7	21	82.9	7.5
X-3947	PDAC	trametinib	403.5	28.2	25	106.8	5.6
X-3947	PDAC	trametinib	383.3	27.3	28	96.5	2.2
X-3947	PDAC	trametinib	356.1	28.3	32	82.5	6
X-3947	PDAC	trametinib	452.5	27.8	35	131.9	4.1
X-3947	PDAC	trametinib	372.4	NA	41	90.9	4.1
X-3947	PDAC	untreated	270.8	24.5	0	0	0
X-3947	PDAC	untreated	340	23.9	3	25.6	-2.4
X-3947	PDAC	untreated	551.7	24.3	6	103.7	-0.8
X-3947	PDAC	untreated	563.5	37.4	10	108.1	-0.8
X-3947	PDAC	untreated	628.8	24.9	13	132.2	1.6
X-3947	PDAC	untreated	816.4	25.1	17	201.5	2.4
X-3947	PDAC	untreated	1235.5	26.1	20	356.2	6.5
X-3947	PDAC	untreated	1235.3	NA	21	356.2	6.5
X-3990	PDAC	abraxane	213.9	26.7	0	0	0
X-3990	PDAC	abraxane	310.4	28.1	4	45.1	5.2
X-3990	PDAC	abraxane	393.3	28.3	7	83.9	6
X-3990	PDAC	abraxane	429	29	11	100.6	8.6
X-3990	PDAC	abraxane	535.7	29.3	14	150.4	9.7
X-3990	PDAC	abraxane	677.1	29.4	18	216.5	10.1
X-3990	PDAC	abraxane	953.9	29.1	21	346	9
X-3990	PDAC	BKM120 + binimetinib	268.4	26.3	0	0	0
X-3990	PDAC	BKM120 + binimetinib	337.6	24.4	4	25.8	-7.2
X-3990	PDAC	BKM120 + binimetinib	231.3	25.3	7	-13.8	-3.8
X-3990	PDAC	BKM120 + binimetinib	282.4	24.6	11	5.2	-6.5
X-3990	PDAC	BKM120 + binimetinib	221.7	24.7	14	-17.4	-6.1
X-3990	PDAC	BKM120 + binimetinib	298	25.2	18	11	-4.2
X-3990	PDAC	BKM120 + binimetinib	196.6	26	21	-26.8	-1.1
X-3990	PDAC	BKM120 + binimetinib	253.8	26.3	25	-5.4	0
X-3990	PDAC	BKM120 + binimetinib	206.4	25.9	28	-23.1	-1.5
X-3990	PDAC	BKM120 + binimetinib	226.2	25.3	32	-15.7	-3.8
X-3990	PDAC	BKM120 + binimetinib	227.4	25.9	35	-15.3	-1.5
X-3990	PDAC	BKM120 + binimetinib	246.8	26	39	-8	-1.1
X-3990	PDAC	BKM120 + binimetinib	218.6	24.7	42	-18.6	-6.1
X-3990	PDAC	BKM120 + binimetinib	143.6	25.6	46	-46.5	-2.7
X-3990	PDAC	BKM120 + binimetinib	214.8	23.6	49	-20	-10.3
X-3990	PDAC	BKM120 + binimetinib	166.8	26.4	53	-37.9	0.4
X-3990	PDAC	BKM120 + binimetinib	143.3	25.2	56	-46.6	-4.2
X-3990	PDAC	BKM120 + binimetinib	199.9	25.3	59	-25.5	-3.8
X-3990	PDAC	BKM120 + binimetinib	149	25.3	62	-44.5	-3.8
X-3990	PDAC	BKM120 + binimetinib	142	26.1	67	-47.1	-0.8
X-3990	PDAC	BKM120 + binimetinib	133.1	25.3	70	-50.4	-3.8
X-3990	PDAC	BKM120 + binimetinib	130.3	26	74	-51.5	-1.1
X-3990	PDAC	BKM120 + binimetinib	137	26.2	77	-49	-0.4
X-3990	PDAC	BKM120 + binimetinib	132.4	25.4	80	-50.7	-3.4
X-3990	PDAC	BKM120 + binimetinib	157.9	25.6	84	-41.2	-2.7
X-3990	PDAC	BKM120 + binimetinib	119.3	26.3	87	-55.6	0
X-3990	PDAC	BKM120 + binimetinib	132.6	25.1	90	-50.6	-4.6
X-3990	PDAC	BKM120 + binimetinib	118.6	24.6	94	-55.8	-6.5
X-3990	PDAC	BKM120 + LDE225	224	24.5	0	0	0
X-3990	PDAC	BKM120 + LDE225	205.7	25.5	4	-8.2	4.1
X-3990	PDAC	BKM120 + LDE225	241.6	25.3	7	7.9	3.3
X-3990	PDAC	BKM120 + LDE225	236.4	26.2	11	5.5	6.9
X-3990	PDAC	BKM120 + LDE225	282.7	26.9	14	26.2	9.8
X-3990	PDAC	BKM120 + LDE225	193.4	24.4	18	-13.7	-0.4
X-3990	PDAC	BKM120 + LDE225	184.1	25.1	21	-17.8	2.4
X-3990	PDAC	BKM120 + LDE225	232.9	24.7	25	4	0.8
X-3990	PDAC	BKM120 + LDE225	169.7	23.8	28	-24.2	-2.9
X-3990	PDAC	BKM120 + LDE225	193	23.3	32	-13.8	-4.9
X-3990	PDAC	BKM120 + LDE225	184.1	23.7	35	-17.8	-3.3
X-3990	PDAC	BKM120 + LDE225	257.8	22.3	39	15.1	-9
X-3990	PDAC	BKM120 + LDE225	180.7	22.1	42	-19.3	-9.8
X-3990	PDAC	BKM120 + LDE225	161.7	21.5	46	-27.8	-12.2
X-3990	PDAC	BKM120 + LDE225	157.2	16.8	49	-29.8	-31.4
X-3990	PDAC	BKM120	224.2	24.9	0	0	0
X-3990	PDAC	BKM120	400.9	24.8	4	78.8	-0.4
X-3990	PDAC	BKM120	438.3	26.7	6	95.5	7.2
X-3990	PDAC	BKM120	519.9	28	11	131.9	12.4
X-3990	PDAC	BKM120	548.6	27.7	14	144.7	11.2
X-3990	PDAC	BKM120	933.3	28	18	316.3	12.4
X-3990	PDAC	BKM120	794	26.3	21	254.1	5.6
X-3990	PDAC	BKM120	831	28.6	25	270.7	14.9
X-3990	PDAC	BKM120	1445.7	27.8	28	544.8	11.6
X-3990	PDAC	BYL719	229.2	28.8	0	0	0
X-3990	PDAC	BYL719	223.5	30.3	3	-2.5	5.2
X-3990	PDAC	BYL719	216.6	30.8	6	-5.5	6.9
X-3990	PDAC	BYL719	211.8	29.4	11	-7.6	2.1
X-3990	PDAC	BYL719	203.1	29.6	14	-11.4	2.8
X-3990	PDAC	BYL719	198.5	29.4	17	-13.4	2.1
X-3990	PDAC	BYL719	234.5	30.5	20	2.3	5.9
X-3990	PDAC	BYL719	239.4	30.1	24	4.5	4.5
X-3990	PDAC	BYL719	261.5	31.7	27	14.1	10.1
X-3990	PDAC	BYL719	325.5	31.6	31	42	9.7
X-3990	PDAC	BYL719	335.4	30.5	35	46.3	5.9
X-3990	PDAC	BYL719	345.7	29.7	38	50.8	3.1
X-3990	PDAC	BYL719	432.8	30.4	41	88.8	5.6
X-3990	PDAC	BYL719	484.4	30.2	45	111.3	4.9
X-3990	PDAC	BYL719	540.4	30.3	48	135.8	5.2
X-3990	PDAC	BYL719	630.9	28.3	52	175.3	-1.7
X-3990	PDAC	BYL719	687.7	29.3	55	200	1.7
X-3990	PDAC	BYL719	731.4	28.8	59	219.1	0
X-3990	PDAC	BYL719	797.5	30.3	62	247.9	5.2
X-3990	PDAC	BYL719 + LJM716	245.3	24.5	0	0	0
X-3990	PDAC	BYL719 + LJM716	305.2	24.3	4	24.4	-0.8
X-3990	PDAC	BYL719 + LJM716	329.1	22.6	7	34.2	-7.8
X-3990	PDAC	BYL719 + LJM716	410.4	23.9	11	67.3	-2.4
X-3990	PDAC	BYL719 + LJM716	481.5	23.5	14	96.3	-4.1
X-3990	PDAC	BYL719 + LJM716	530.5	24	17	116.3	-2
X-3990	PDAC	BYL719 + LJM716	565.3	23.1	22	130.5	-5.7
X-3990	PDAC	BYL719 + LJM716	606	23.4	24	147	-4.5
X-3990	PDAC	BYL719 + LJM716	638.5	22.6	28	160.3	-7.8
X-3990	PDAC	BYL719 + LJM716	642.5	19.1	35	161.9	-22
X-3990	PDAC	CLR457	213.8	30.8	0	0	0
X-3990	PDAC	CLR457	228.8	32.3	4	7	4.9
X-3990	PDAC	CLR457	252.3	30.7	7	18	-0.3
X-3990	PDAC	CLR457	255.9	30.8	11	19.7	0
X-3990	PDAC	CLR457	259	31.7	14	21.1	2.9
X-3990	PDAC	CLR457	264.6	33.1	19	23.8	7.5
X-3990	PDAC	CLR457	281.1	32.2	22	31.5	4.5
X-3990	PDAC	CLR457	306.6	31	26	43.4	0.6
X-3990	PDAC	CLR457	312.5	31.6	29	46.2	2.6
X-3990	PDAC	CLR457	327.4	31.8	32	53.1	3.2
X-3990	PDAC	CLR457	339	32.6	35	58.6	5.8
X-3990	PDAC	CLR457	348.7	31.8	39	63.1	3.2
X-3990	PDAC	CLR457	380.4	32	43	77.9	3.9
X-3990	PDAC	CLR457	387.4	32.2	47	81.2	4.5
X-3990	PDAC	CLR457	383	32.9	51	79.1	6.8
X-3990	PDAC	CLR457	355.7	31.5	54	66.4	2.3
X-3990	PDAC	CLR457	377.7	29.5	56	76.7	-4.2
X-3990	PDAC	CLR457	418.7	31.5	60	95.8	2.3
X-3990	PDAC	CLR457	407.3	28.8	67	90.5	-6.5
X-3990	PDAC	CLR457	453.8	31.4	70	112.3	1.9
X-3990	PDAC	CLR457	433.7	33.3	74	102.9	8.1
X-3990	PDAC	CLR457	465.4	32.8	77	117.7	6.5
X-3990	PDAC	CLR457	480.6	33.7	81	124.8	9.4
X-3990	PDAC	CLR457	495.4	31.2	88	131.7	1.3
X-3990	PDAC	CLR457	618.8	28.4	92	189.4	-7.8
X-3990	PDAC	CLR457	645.1	27.2	95	201.7	-11.7
X-3990	PDAC	CLR457	673.5	27.5	97	215	-10.7
X-3990	PDAC	HDM201	233.2	25.7	0	0	0
X-3990	PDAC	HDM201	279.3	25.1	3	19.8	-2.3
X-3990	PDAC	HDM201	297.5	24.1	7	27.6	-6.2
X-3990	PDAC	HDM201	391	24.2	11	67.7	-5.8
X-3990	PDAC	HDM201	548.6	24.1	14	135.2	-6.2
X-3990	PDAC	HDM201	575.4	24.9	18	146.7	-3.1
X-3990	PDAC	HDM201	713.4	24.8	21	205.9	-3.5
X-3990	PDAC	HDM201	852.5	24.5	24	265.6	-4.7
X-3990	PDAC	HDM201	878.6	22.8	29	276.8	-11.3
X-3990	PDAC	HDM201	925.9	22.4	31	297	-12.8
X-3990	PDAC	HDM201	1167.2	21.8	35	400.5	-15.2
X-3990	PDAC	figitumumab"	235.3	24.1	0	0	0
X-3990	PDAC	figitumumab"	382.1	23.8	1	62.4	-1.2
X-3990	PDAC	figitumumab"	577.2	24.6	8	145.3	2.1
X-3990	PDAC	figitumumab"	901.2	25.5	12	283	5.8
X-3990	PDAC	figitumumab"	959	24.6	15	307.6	2.1
X-3990	PDAC	figitumumab" + binimetinib	206.6	22.6	0	0	0
X-3990	PDAC	figitumumab" + binimetinib	350.7	22.4	4	69.7	-0.9
X-3990	PDAC	figitumumab" + binimetinib	594.6	22.5	6	187.8	-0.4
X-3990	PDAC	figitumumab" + binimetinib	681.5	22.9	11	229.9	1.3
X-3990	PDAC	figitumumab" + binimetinib	829.6	23.1	14	301.5	2.2
X-3990	PDAC	figitumumab" + binimetinib	845.1	23.4	18	309.1	3.5
X-3990	PDAC	figitumumab" + binimetinib	716.8	23.6	21	247	4.4
X-3990	PDAC	figitumumab" + binimetinib	1433	23.8	25	593.6	5.3
X-3990	PDAC	gemcitabine-50mpk	255.7	28.2	0	0	0
X-3990	PDAC	gemcitabine-50mpk	295.1	28.6	4	15.4	1.4
X-3990	PDAC	gemcitabine-50mpk	538.1	27.3	7	110.4	-3.2
X-3990	PDAC	gemcitabine-50mpk	567.5	29.1	12	121.9	3.2
X-3990	PDAC	gemcitabine-50mpk	411.1	28.5	15	60.8	1.1
X-3990	PDAC	gemcitabine-50mpk	217.3	28	18	-15	-0.7
X-3990	PDAC	gemcitabine-50mpk	172.4	28.6	21	-32.6	1.4
X-3990	PDAC	gemcitabine-50mpk	101.8	27.6	26	-60.2	-2.1
X-3990	PDAC	gemcitabine-50mpk	84.1	28.4	29	-67.1	0.7
X-3990	PDAC	gemcitabine-50mpk	80.7	27.2	32	-68.4	-3.5
X-3990	PDAC	gemcitabine-50mpk	72.4	28.9	35	-71.7	2.5
X-3990	PDAC	gemcitabine-50mpk	66.2	28.2	39	-74.1	0
X-3990	PDAC	gemcitabine-50mpk	63.1	28.8	43	-75.3	2.1
X-3990	PDAC	gemcitabine-50mpk	68.2	27.5	47	-73.3	-2.5
X-3990	PDAC	gemcitabine-50mpk	0	28.3	50	-100	0.4
X-3990	PDAC	gemcitabine-50mpk	0	29.2	53	-100	3.5
X-3990	PDAC	gemcitabine-50mpk	0	29.4	56	-100	4.3
X-3990	PDAC	gemcitabine-50mpk	0	28.6	61	-100	1.4
X-3990	PDAC	gemcitabine-50mpk	0	29.5	64	-100	4.6
X-3990	PDAC	gemcitabine-50mpk	0	28.6	68	-100	1.4
X-3990	PDAC	gemcitabine-50mpk	0	26.6	71	-100	-5.7
X-3990	PDAC	gemcitabine-50mpk	0	28.5	75	-100	1.1
X-3990	PDAC	gemcitabine-50mpk	0	29	78	-100	2.8
X-3990	PDAC	gemcitabine-50mpk	0	29.8	82	-100	5.7
X-3990	PDAC	gemcitabine-50mpk	0	30	85	-100	6.4
X-3990	PDAC	gemcitabine-50mpk	0	28.9	88	-100	2.5
X-3990	PDAC	INC424 + binimetinib	241.4	25.5	0	0	0
X-3990	PDAC	INC424 + binimetinib	475	25.5	3	96.8	0
X-3990	PDAC	INC424 + binimetinib	331.9	25	8	37.5	-2
X-3990	PDAC	INC424 + binimetinib	439.5	25.8	10	82.1	1.2
X-3990	PDAC	INC424 + binimetinib	387.5	25.4	14	60.5	-0.4
X-3990	PDAC	INC424 + binimetinib	316.1	27.3	17	30.9	7.1
X-3990	PDAC	INC424 + binimetinib	411.5	26	21	70.5	2
X-3990	PDAC	INC424 + binimetinib	336.3	24.7	24	39.3	-3.1
X-3990	PDAC	INC424 + binimetinib	366.5	25.7	27	51.8	0.8
X-3990	PDAC	INC424 + binimetinib	581.8	24.4	30	141	-4.3
X-3990	PDAC	INC424 + binimetinib	660.1	25	35	173.4	-2
X-3990	PDAC	INC424 + binimetinib	782.7	25.5	41	224.2	0
X-3990	PDAC	INC424 + binimetinib	626.7	24.7	44	159.6	-3.1
X-3990	PDAC	INC424 + binimetinib	563.7	25.9	49	133.5	1.6
X-3990	PDAC	INC424 + binimetinib	826.3	25.4	52	242.3	-0.4
X-3990	PDAC	INC424 + binimetinib	729.1	25.1	56	202	-1.6
X-3990	PDAC	INC424 + binimetinib	833.3	25.4	59	245.2	-0.4
X-3990	PDAC	INC424 + binimetinib	805	25	63	233.5	-2
X-3990	PDAC	INC424 + binimetinib	487	24.6	65	101.7	-3.5
X-3990	PDAC	INC424 + binimetinib	1644	25.3	70	581	-0.8
X-3990	PDAC	INC424 + binimetinib	1268.4	25.5	77	425.4	0
X-3990	PDAC	INC424 + binimetinib	1146.7	24.1	80	375	-5.5
X-3990	PDAC	INC424 + binimetinib	1643.9	23.8	84	581	-6.7
X-3990	PDAC	INC424 + binimetinib	1609.1	23.6	87	566.6	-7.5
X-3990	PDAC	INC424 + binimetinib	2381.7	24.8	91	886.6	-2.7
X-3990	PDAC	INC424	249.5	27	0	0	0
X-3990	PDAC	INC424	307.9	27.5	3	23.4	1.9
X-3990	PDAC	INC424	330.8	27.6	6	32.6	2.2
X-3990	PDAC	INC424	349.9	27.7	11	40.2	2.6
X-3990	PDAC	INC424	385.6	28.4	14	54.5	5.2
X-3990	PDAC	INC424	442.1	27.5	17	77.2	1.9
X-3990	PDAC	INC424	415.9	27.7	20	66.7	2.6
X-3990	PDAC	INC424	466.8	27.1	24	87.1	0.4
X-3990	PDAC	INC424	488.7	27.2	27	95.9	0.7
X-3990	PDAC	INC424	535.4	27.1	31	114.6	0.4
X-3990	PDAC	INC424	560.1	26.8	35	124.5	-0.7
X-3990	PDAC	INC424	614.2	26.5	38	146.2	-1.9
X-3990	PDAC	INC424	638.7	27.4	41	156	1.5
X-3990	PDAC	INC424	891.1	28	45	257.2	3.7
X-3990	PDAC	LEE011	248.6	24.8	0	0	0
X-3990	PDAC	LEE011	531.7	26.5	5	113.9	6.9
X-3990	PDAC	LEE011	464.9	25.5	8	87	2.8
X-3990	PDAC	LEE011	757.9	26.5	12	204.9	6.9
X-3990	PDAC	LEE011	658.3	26.4	15	164.8	6.5
X-3990	PDAC	LEE011	704.4	26.8	19	183.3	8.1
X-3990	PDAC	LEE011	768.3	26.3	22	209.1	6
X-3990	PDAC	LEE011	803.5	26.6	26	223.2	7.3
X-3990	PDAC	LEE011	893.8	25.8	29	259.5	4
X-3990	PDAC	LEE011	861.5	27.9	33	246.5	12.5
X-3990	PDAC	LEE011	1268.4	27.9	36	410.2	12.5
X-3990	PDAC	WNT974	262.3	25.2	0	0	0
X-3990	PDAC	WNT974	271.8	24.9	1	3.6	-1.2
X-3990	PDAC	WNT974	279.8	25.5	5	6.7	1.2
X-3990	PDAC	WNT974	330.8	25.7	8	26.1	2
X-3990	PDAC	WNT974	571.1	25.8	13	117.7	2.4
X-3990	PDAC	WNT974	837.3	26.2	16	219.2	4
X-3990	PDAC	WNT974	814.4	25.6	19	210.5	1.6
X-3990	PDAC	WNT974	1108.7	25.8	23	322.7	2.4
X-3990	PDAC	WNT974	1253.2	27.3	26	377.8	8.3
X-3990	PDAC	WNT974	1736.6	27.4	29	562.1	8.7
X-3990	PDAC	LKA136	242.6	23	0	0	0
X-3990	PDAC	LKA136	273.9	23.4	3	12.9	1.7
X-3990	PDAC	LKA136	348.1	23.7	5	43.5	3
X-3990	PDAC	LKA136	551	24.1	10	127.1	4.8
X-3990	PDAC	LKA136	572.3	24.3	14	135.9	5.7
X-3990	PDAC	LKA136	845.3	24.1	17	248.4	4.8
X-3990	PDAC	LKA136	879	NA	19	262.3	4.8
X-3990	PDAC	LKA136	953.6	24	21	293.1	4.3
X-3990	PDAC	LKA136	1188.7	24.9	25	390	8.3
X-3990	PDAC	LKA136	1163.8	24.1	26	379.7	4.8
X-3990	PDAC	binimetinib	266.2	24.1	0	0	0
X-3990	PDAC	binimetinib	276.9	20.7	3	4	-14.1
X-3990	PDAC	binimetinib-3.5mpk	280.1	25.1	0	0	0
X-3990	PDAC	binimetinib-3.5mpk	786.9	23.5	4	180.9	-6.4
X-3990	PDAC	binimetinib-3.5mpk	744.7	23.7	6	165.9	-5.6
X-3990	PDAC	binimetinib-3.5mpk	491.6	24.3	11	75.5	-3.2
X-3990	PDAC	binimetinib-3.5mpk	485.4	23.1	14	73.3	-8
X-3990	PDAC	binimetinib-3.5mpk	721.5	24	18	157.6	-4.4
X-3990	PDAC	binimetinib-3.5mpk	733.5	23.9	21	161.9	-4.8
X-3990	PDAC	binimetinib-3.5mpk	834	24.7	25	197.8	-1.6
X-3990	PDAC	binimetinib-3.5mpk	1160	23.4	28	314.1	-6.8
X-3990	PDAC	trametinib	281	27.2	0	0	0
X-3990	PDAC	trametinib	293.2	25.6	4	4.3	-5.9
X-3990	PDAC	trametinib	271.8	25.2	7	-3.3	-7.4
X-3990	PDAC	trametinib	240.2	26.9	11	-14.5	-1.1
X-3990	PDAC	trametinib	245.6	27.4	14	-12.6	0.7
X-3990	PDAC	trametinib	263.5	26.7	18	-6.2	-1.8
X-3990	PDAC	trametinib	268.8	27.2	21	-4.3	0
X-3990	PDAC	trametinib	208.9	27.8	25	-25.7	2.2
X-3990	PDAC	trametinib	272.4	26.9	28	-3.1	-1.1
X-3990	PDAC	trametinib	262.8	26.6	32	-6.5	-2.2
X-3990	PDAC	trametinib	246	26.3	34	-12.5	-3.3
X-3990	PDAC	trametinib	343.4	27.6	39	22.2	1.5
X-3990	PDAC	trametinib	373.9	28.4	42	33.1	4.4
X-3990	PDAC	trametinib	369	28.6	47	31.3	5.1
X-3990	PDAC	trametinib	345.8	28.4	50	23.1	4.4
X-3990	PDAC	trametinib	357	27.6	53	27	1.5
X-3990	PDAC	trametinib	357.6	27.5	56	27.3	1.1
X-3990	PDAC	trametinib	373.6	28.2	60	33	3.7
X-3990	PDAC	trametinib	385.9	28.1	63	37.3	3.3
X-3990	PDAC	trametinib	364.1	27.5	67	29.6	1.1
X-3990	PDAC	trametinib	332.9	28.9	75	18.5	6.2
X-3990	PDAC	trametinib	291.9	28.4	78	3.9	4.4
X-3990	PDAC	trametinib	369.5	28.7	82	31.5	5.5
X-3990	PDAC	trametinib	397	27.9	85	41.3	2.6
X-3990	PDAC	trametinib	394.8	27.9	89	40.5	2.6
X-3990	PDAC	trametinib	488.2	28.3	92	73.7	4
X-3990	PDAC	untreated	259.5	25.5	0	0	0
X-3990	PDAC	untreated	280.3	25.8	6	8	1.2
X-3990	PDAC	untreated	301.2	27.1	9	16.1	6.3
X-3990	PDAC	untreated	561.3	27.6	11	116.3	8.2
X-3990	PDAC	untreated	529.8	NA	14	104.2	8.2
X-3990	PDAC	untreated	719.1	27.1	18	177.1	6.3
X-3990	PDAC	untreated	846.8	27.1	21	226.3	6.3
X-3990	PDAC	untreated	1080.4	25.3	25	316.3	-0.8
X-3990	PDAC	untreated	1393.2	25.4	29	436.9	-0.4
X-3990	PDAC	untreated	1419.2	27.2	33	446.9	6.7
X-3990	PDAC	untreated	1380.7	26.9	35	432.1	5.5
X-3990	PDAC	untreated	1537.1	30.1	39	492.3	18
X-3990	PDAC	untreated	1772	29.3	42	582.9	14.9
X-4015	PDAC	abraxane	225.3	25.1	0	0	0
X-4015	PDAC	abraxane	355.1	25.2	5	57.6	0.4
X-4015	PDAC	abraxane	427.8	25.7	8	89.9	2.4
X-4015	PDAC	abraxane	760.8	25.8	12	237.7	2.8
X-4015	PDAC	abraxane	897.7	25.3	15	298.4	0.8
X-4015	PDAC	BKM120 + binimetinib	232.5	26.7	0	0	0
X-4015	PDAC	BKM120 + binimetinib	346.2	28.5	2	48.9	6.7
X-4015	PDAC	BKM120 + binimetinib	270.6	28.4	6	16.4	6.4
X-4015	PDAC	BKM120 + binimetinib	286.4	28.3	9	23.2	6
X-4015	PDAC	BKM120 + binimetinib	424.8	27.7	13	82.7	3.7
X-4015	PDAC	BKM120 + binimetinib	369.2	28.6	16	58.8	7.1
X-4015	PDAC	BKM120 + binimetinib	464.9	29.6	20	100	10.9
X-4015	PDAC	BKM120 + binimetinib	436.5	28.4	23	87.7	6.4
X-4015	PDAC	BKM120 + binimetinib	416.4	28.7	27	79.1	7.5
X-4015	PDAC	BKM120 + binimetinib	518.1	28.3	30	122.8	6
X-4015	PDAC	BKM120 + binimetinib	432.7	29.1	34	86.1	9
X-4015	PDAC	BKM120 + binimetinib	550	28.9	37	136.6	8.2
X-4015	PDAC	BKM120 + binimetinib	520.3	28.9	40	123.8	8.2
X-4015	PDAC	BKM120 + binimetinib	772.7	28.7	43	232.3	7.5
X-4015	PDAC	BKM120 + binimetinib	706.3	29.4	48	203.8	10.1
X-4015	PDAC	BKM120 + binimetinib	1153.5	29	51	396.1	8.6
X-4015	PDAC	BKM120 + binimetinib	833.1	28.5	55	258.3	6.7
X-4015	PDAC	BKM120 + binimetinib	1271.7	28.4	58	447	6.4
X-4015	PDAC	BKM120 + binimetinib	1001.2	28.2	61	330.6	5.6
X-4015	PDAC	BKM120 + binimetinib	1360.3	28.1	65	485.1	5.2
X-4015	PDAC	BKM120 + binimetinib	1934.6	29	68	732.1	8.6
X-4015	PDAC	BKM120 + binimetinib	1628.7	27.5	71	600.5	3
X-4015	PDAC	BKM120 + LDE225	296.2	25.6	0	0	0
X-4015	PDAC	BKM120 + LDE225	333.2	28.5	2	12.5	11.3
X-4015	PDAC	BKM120 + LDE225	470.5	27	6	58.8	5.5
X-4015	PDAC	BKM120 + LDE225	460.9	26.4	9	55.6	3.1
X-4015	PDAC	BKM120 + LDE225	405.9	25.5	13	37	-0.4
X-4015	PDAC	BKM120 + LDE225	496.5	25.8	16	67.6	0.8
X-4015	PDAC	BKM120 + LDE225	513.3	25.1	20	73.3	-2
X-4015	PDAC	BKM120 + LDE225	549.1	25.3	23	85.4	-1.2
X-4015	PDAC	BKM120 + LDE225	528.5	25.2	27	78.4	-1.6
X-4015	PDAC	BKM120 + LDE225	596.7	24.5	30	101.5	-4.3
X-4015	PDAC	BKM120 + LDE225	677.3	24.9	34	128.7	-2.7
X-4015	PDAC	BKM120 + LDE225	546.4	23.5	37	84.5	-8.2
X-4015	PDAC	BKM120 + LDE225	755.9	23.9	40	155.2	-6.6
X-4015	PDAC	BKM120 + LDE225	542.4	24.3	43	83.1	-5.1
X-4015	PDAC	BKM120 + LDE225	536.2	21.3	48	81	-16.8
X-4015	PDAC	BKM120 + LDE225	1431.3	22.9	51	383.2	-10.5
X-4015	PDAC	BKM120 + LDE225	1542.9	24.6	55	420.9	-3.9
X-4015	PDAC	BKM120 + LDE225	1528.9	24.9	58	416.2	-2.7
X-4015	PDAC	BKM120 + LDE225	1288.8	23.8	61	335.1	-7
X-4015	PDAC	BKM120 + LDE225	1247.9	23.6	65	321.3	-7.8
X-4015	PDAC	BKM120 + LDE225	2059.9	23.8	68	595.4	-7
X-4015	PDAC	BKM120 + LDE225	2013.1	22.1	71	579.6	-13.7
X-4015	PDAC	BYL719 + LJM716	233	22	0	0	0
X-4015	PDAC	BYL719 + LJM716	258.9	21.3	6	11.1	-3.2
X-4015	PDAC	BYL719 + LJM716	278.9	22.5	9	19.7	2.3
X-4015	PDAC	BYL719 + LJM716	289.5	22.6	13	24.2	2.7
X-4015	PDAC	BYL719 + LJM716	320.6	22.6	16	37.6	2.7
X-4015	PDAC	BYL719 + LJM716	315.7	22.4	20	35.5	1.8
X-4015	PDAC	BYL719 + LJM716	308.9	22.4	23	32.6	1.8
X-4015	PDAC	BYL719 + LJM716	318.8	22.7	27	36.8	3.2
X-4015	PDAC	BYL719 + LJM716	310.9	22.2	30	33.4	0.9
X-4015	PDAC	BYL719 + LJM716	288.8	23.1	36	23.9	5
X-4015	PDAC	BYL719 + LJM716	287.2	22.3	41	23.3	1.4
X-4015	PDAC	BYL719 + LJM716	301.3	22.6	44	29.3	2.7
X-4015	PDAC	BYL719 + LJM716	327.9	22.8	48	40.7	3.6
X-4015	PDAC	BYL719 + LJM716	328.4	22.2	51	40.9	0.9
X-4015	PDAC	BYL719 + LJM716	311.6	21.6	56	33.7	-1.8
X-4015	PDAC	BYL719 + LJM716	295	22.3	58	26.6	1.4
X-4015	PDAC	BYL719 + LJM716	250.7	21.8	62	7.6	-0.9
X-4015	PDAC	BYL719 + LJM716	224.1	21.1	65	-3.8	-4.1
X-4015	PDAC	BYL719 + LJM716	208.9	22.4	69	-10.3	1.8
X-4015	PDAC	BYL719 + LJM716	207.4	22.5	72	-11	2.3
X-4015	PDAC	BYL719 + LJM716	212.8	22.5	76	-8.7	2.3
X-4015	PDAC	BYL719 + LJM716	218.7	22.3	79	-6.1	1.4
X-4015	PDAC	BYL719 + LJM716	215.1	22	83	-7.7	0
X-4015	PDAC	BYL719 + LJM716	238.1	22.4	87	2.2	1.8
X-4015	PDAC	BYL719 + LJM716	244.6	22.5	90	5	2.3
X-4015	PDAC	BYL719 + LJM716	239.8	22.3	93	2.9	1.4
X-4015	PDAC	BYL719 + LJM716	224.7	22	97	-3.6	0
X-4015	PDAC	BYL719	238.2	23.8	0	0	0
X-4015	PDAC	BYL719	239.2	25	3	0.4	5
X-4015	PDAC	BYL719	237.1	23.6	7	-0.5	-0.8
X-4015	PDAC	BYL719	267	23.9	10	12.1	0.4
X-4015	PDAC	BYL719	270.6	23.4	14	13.6	-1.7
X-4015	PDAC	BYL719	299.6	23.2	17	25.8	-2.5
X-4015	PDAC	BYL719	344	24.7	21	44.4	3.8
X-4015	PDAC	BYL719	383.7	24.9	24	61.1	4.6
X-4015	PDAC	BYL719	429.6	24.6	28	80.4	3.4
X-4015	PDAC	BYL719	462	24.2	31	94	1.7
X-4015	PDAC	BYL719	582.4	24	35	144.5	0.8
X-4015	PDAC	BYL719	644	24.3	38	170.4	2.1
X-4015	PDAC	BYL719	682.6	24.9	42	186.6	4.6
X-4015	PDAC	BYL719	721.7	22.5	44	203	-5.5
X-4015	PDAC	BYL719	797.8	24.4	49	234.9	2.5
X-4015	PDAC	BYL719	816.5	23.1	52	242.8	-2.9
X-4015	PDAC	BYL719	840.7	21.3	56	252.9	-10.5
X-4015	PDAC	BYL719	863.7	20.6	59	262.6	-13.4
X-4015	PDAC	BYL719	988.6	23	62	315	-3.4
X-4015	PDAC	CLR457	242.8	27.7	0	0	0
X-4015	PDAC	CLR457	287.1	26.7	3	18.2	-3.6
X-4015	PDAC	CLR457	334.7	26.7	7	37.9	-3.6
X-4015	PDAC	CLR457	471.4	26.7	10	94.2	-3.6
X-4015	PDAC	CLR457	477.3	26.8	14	96.6	-3.2
X-4015	PDAC	CLR457	499.1	27.2	17	105.6	-1.8
X-4015	PDAC	CLR457	514.5	27.4	21	111.9	-1.1
X-4015	PDAC	CLR457	539.9	25.2	24	122.4	-9
X-4015	PDAC	CLR457	543.5	26.4	30	123.8	-4.7
X-4015	PDAC	CLR457	637.2	28.2	35	162.4	1.8
X-4015	PDAC	CLR457	677.1	28.3	38	178.9	2.2
X-4015	PDAC	CLR457	698.2	28.5	42	187.6	2.9
X-4015	PDAC	CLR457	740.8	28.1	45	205.1	1.4
X-4015	PDAC	CLR457	914.9	28	50	276.8	1.1
X-4015	PDAC	CLR457	923.1	27.8	52	280.2	0.4
X-4015	PDAC	HDM201	203.6	26.9	0	0	0
X-4015	PDAC	HDM201	197	28	3	-3.2	4.1
X-4015	PDAC	HDM201	187.5	27	7	-7.9	0.4
X-4015	PDAC	HDM201	181.2	28.5	10	-11	5.9
X-4015	PDAC	HDM201	201.1	28.4	14	-1.2	5.6
X-4015	PDAC	HDM201	235.8	29.1	17	15.8	8.2
X-4015	PDAC	HDM201	251.4	29.2	21	23.5	8.6
X-4015	PDAC	HDM201	256.9	28.7	24	26.2	6.7
X-4015	PDAC	HDM201	261.1	27.2	30	28.2	1.1
X-4015	PDAC	HDM201	272	26.3	35	33.6	-2.2
X-4015	PDAC	HDM201	285	26.3	38	40	-2.2
X-4015	PDAC	HDM201	288.7	23	42	41.8	-14.5
X-4015	PDAC	figitumumab" + binimetinib	260.9	26.3	0	0	0
X-4015	PDAC	figitumumab" + binimetinib	468	25	2	79.4	-4.9
X-4015	PDAC	figitumumab" + binimetinib	511.4	24.7	6	96	-6.1
X-4015	PDAC	figitumumab" + binimetinib	359.4	24.6	9	37.8	-6.5
X-4015	PDAC	figitumumab" + binimetinib	312.3	25.3	12	19.7	-3.8
X-4015	PDAC	figitumumab" + binimetinib	401.7	25.2	15	54	-4.2
X-4015	PDAC	figitumumab" + binimetinib	509.5	25.1	20	95.3	-4.6
X-4015	PDAC	figitumumab" + binimetinib	637.1	24.7	26	144.2	-6.1
X-4015	PDAC	figitumumab" + binimetinib	630.1	25.4	30	141.5	-3.4
X-4015	PDAC	figitumumab" + binimetinib	757	25.3	33	190.1	-3.8
X-4015	PDAC	figitumumab"	216	2.8	0	0	0
X-4015	PDAC	figitumumab"	410.2	22.9	5	89.9	0
X-4015	PDAC	figitumumab"	585.5	21.8	12	171.1	-4.8
X-4015	PDAC	figitumumab"	765	21.8	15	254.2	-4.8
X-4015	PDAC	figitumumab"	869.1	22.8	19	302.4	-0.4
X-4015	PDAC	figitumumab"	1327.6	22.9	22	514.6	0
X-4015	PDAC	gemcitabine-50mpk	238.6	23.8	0	0	0
X-4015	PDAC	gemcitabine-50mpk	217.9	23	3	-8.7	-3.4
X-4015	PDAC	gemcitabine-50mpk	218.8	24.4	7	-8.3	2.5
X-4015	PDAC	gemcitabine-50mpk	215.5	24.6	10	-9.7	3.4
X-4015	PDAC	gemcitabine-50mpk	253.1	26.3	14	6.1	10.5
X-4015	PDAC	gemcitabine-50mpk	218	24.4	17	-8.6	2.5
X-4015	PDAC	gemcitabine-50mpk	147.5	24.5	20	-38.2	2.9
X-4015	PDAC	gemcitabine-50mpk	240.4	25.4	24	0.8	6.7
X-4015	PDAC	gemcitabine-50mpk	163.9	24.9	28	-31.3	4.6
X-4015	PDAC	gemcitabine-50mpk	185.5	24.1	31	-22.3	1.3
X-4015	PDAC	gemcitabine-50mpk	186.8	25.5	35	-21.7	7.1
X-4015	PDAC	gemcitabine-50mpk	187.2	24.7	37	-21.5	3.8
X-4015	PDAC	gemcitabine-50mpk	196	24.9	42	-17.9	4.6
X-4015	PDAC	gemcitabine-50mpk	204.6	25	48	-14.2	5
X-4015	PDAC	gemcitabine-50mpk	129.4	25.3	52	-45.8	6.3
X-4015	PDAC	gemcitabine-50mpk	128.4	25.2	56	-46.2	5.9
X-4015	PDAC	gemcitabine-50mpk	101	24.3	58	-57.7	2.1
X-4015	PDAC	gemcitabine-50mpk	127	25.1	63	-46.8	5.5
X-4015	PDAC	gemcitabine-50mpk	156	24.6	65	-34.6	3.4
X-4015	PDAC	gemcitabine-50mpk	170.3	24.4	70	-28.6	2.5
X-4015	PDAC	gemcitabine-50mpk	192.1	25.1	73	-19.5	5.5
X-4015	PDAC	gemcitabine-50mpk	116.1	24.9	77	-51.3	4.6
X-4015	PDAC	gemcitabine-50mpk	152.5	24.8	80	-36.1	4.2
X-4015	PDAC	gemcitabine-50mpk	140.9	24.8	84	-40.9	4.2
X-4015	PDAC	gemcitabine-50mpk	155.8	24.7	87	-34.7	3.8
X-4015	PDAC	gemcitabine-50mpk	136.5	24.7	90	-42.8	3.8
X-4015	PDAC	INC424 + binimetinib	310.3	29	0	0	0
X-4015	PDAC	INC424 + binimetinib	285.1	27.6	3	-8.1	-4.8
X-4015	PDAC	INC424 + binimetinib	337.2	27.9	7	8.7	-3.8
X-4015	PDAC	INC424 + binimetinib	289.7	28	10	-6.6	-3.4
X-4015	PDAC	INC424 + binimetinib	264.5	28.5	14	-14.8	-1.7
X-4015	PDAC	INC424 + binimetinib	358.8	28.6	17	15.6	-1.4
X-4015	PDAC	INC424 + binimetinib	347.4	28.7	21	12	-1
X-4015	PDAC	INC424 + binimetinib	391.9	27.6	24	26.3	-4.8
X-4015	PDAC	INC424 + binimetinib	392.9	28.4	28	26.6	-2.1
X-4015	PDAC	INC424 + binimetinib	463.5	28.4	31	49.4	-2.1
X-4015	PDAC	INC424 + binimetinib	576.7	28.6	35	85.9	-1.4
X-4015	PDAC	INC424 + binimetinib	610	28.3	38	96.6	-2.4
X-4015	PDAC	INC424 + binimetinib	516.8	29.5	42	66.5	1.7
X-4015	PDAC	INC424 + binimetinib	780.5	29.1	45	151.5	0.3
X-4015	PDAC	INC424 + binimetinib	755.2	29.5	49	143.4	1.7
X-4015	PDAC	INC424 + binimetinib	769.2	29.9	56	147.9	3.1
X-4015	PDAC	INC424 + binimetinib	866.1	28.7	59	179.1	-1
X-4015	PDAC	INC424 + binimetinib	966.3	29	63	211.4	0
X-4015	PDAC	INC424 + binimetinib	1091	28.7	66	251.6	-1
X-4015	PDAC	INC424 + binimetinib	1300.7	29.2	70	319.2	0.7
X-4015	PDAC	INC424	220.7	28.9	0	0	0
X-4015	PDAC	INC424	298.3	28.4	3	35.2	-1.7
X-4015	PDAC	INC424	356.3	27.9	7	61.4	-3.5
X-4015	PDAC	INC424	463.2	28.3	10	109.9	-2.1
X-4015	PDAC	INC424	555.1	28.1	14	151.5	-2.8
X-4015	PDAC	INC424	598.5	28.2	17	171.2	-2.4
X-4015	PDAC	INC424	796.6	28.1	21	260.9	-2.8
X-4015	PDAC	INC424	895.4	27.7	24	305.7	-4.2
X-4015	PDAC	INC424	985	27.6	28	346.3	-4.5
X-4015	PDAC	INC424	1158.1	27.3	31	424.7	-5.5
X-4015	PDAC	INC424	1439.5	26.9	35	552.2	-6.9
X-4015	PDAC	WNT974	271.8	28.2	0	0	0
X-4015	PDAC	WNT974	440.2	26.5	5	62	-6
X-4015	PDAC	WNT974	605.5	26.5	9	122.8	-6
X-4015	PDAC	WNT974	805.6	26	12	196.4	-7.8
X-4015	PDAC	WNT974	774.7	27.1	16	185	-3.9
X-4015	PDAC	WNT974	1013.1	27.4	20	272.7	-2.8
X-4015	PDAC	WNT974	1021.3	27.3	23	275.8	-3.2
X-4015	PDAC	WNT974	1467.8	27	26	440	-4.3
X-4015	PDAC	WNT974	1321.9	28.3	28	386.4	0.4
X-4015	PDAC	LKA136	207.8	25.7	0	0	0
X-4015	PDAC	LKA136	329.9	28.4	7	58.8	10.5
X-4015	PDAC	LKA136	420.8	29.3	11	102.5	14
X-4015	PDAC	LKA136	541.1	27.7	14	160.4	7.8
X-4015	PDAC	LKA136	611.7	NA	16	194.4	7.8
X-4015	PDAC	LKA136	733.2	28.6	18	252.8	11.3
X-4015	PDAC	LKA136	862.2	28.3	22	314.9	10.1
X-4015	PDAC	LKA136	876.6	28.9	25	321.8	12.5
X-4015	PDAC	binimetinib	241.8	26.8	0	0	0
X-4015	PDAC	binimetinib	219.5	27	1	-9.2	0.7
X-4015	PDAC	binimetinib	278.9	26.9	5	15.3	0.4
X-4015	PDAC	binimetinib	224.4	26.5	7	-7.2	-1.1
X-4015	PDAC	binimetinib	234.1	26.9	12	-3.2	0.4
X-4015	PDAC	binimetinib	189.1	28.3	14	-21.8	5.6
X-4015	PDAC	binimetinib	222.2	26.3	19	-8.1	-1.9
X-4015	PDAC	binimetinib	219.8	26	22	-9.1	-3
X-4015	PDAC	binimetinib	234.1	27	26	-3.2	0.7
X-4015	PDAC	binimetinib	244.3	26.3	29	1	-1.9
X-4015	PDAC	binimetinib	243.7	26.6	33	0.8	-0.7
X-4015	PDAC	binimetinib	223.4	27.2	36	-7.6	1.5
X-4015	PDAC	binimetinib	228.6	25.8	40	-5.5	-3.7
X-4015	PDAC	binimetinib	190.8	27.3	43	-21.1	1.9
X-4015	PDAC	binimetinib	265.1	27.2	47	9.6	1.5
X-4015	PDAC	binimetinib	288.4	28.8	50	19.3	7.5
X-4015	PDAC	binimetinib	234.2	27.4	54	-3.1	2.2
X-4015	PDAC	binimetinib	247.7	27.9	61	2.4	4.1
X-4015	PDAC	binimetinib	214.3	27.5	64	-11.4	2.6
X-4015	PDAC	binimetinib	224.4	27.8	68	-7.2	3.7
X-4015	PDAC	binimetinib	288.3	28	75	19.2	4.5
X-4015	PDAC	binimetinib	325	27.1	78	34.4	1.1
X-4015	PDAC	binimetinib	342.7	27.1	82	41.7	1.1
X-4015	PDAC	binimetinib	261.3	27.8	85	8.1	3.7
X-4015	PDAC	binimetinib	161.5	24.5	89	-33.2	-8.6
X-4015	PDAC	untreated	229.9	25.3	0	0	0
X-4015	PDAC	untreated	253.5	26.3	2	10.3	4
X-4015	PDAC	untreated	295.8	26.2	7	28.7	3.6
X-4015	PDAC	untreated	453.6	26.2	11	97.3	3.6
X-4015	PDAC	untreated	523.9	27.2	14	127.9	7.5
X-4015	PDAC	untreated	745.3	NA	16	224.2	7.5
X-4015	PDAC	untreated	762.2	25.6	18	231.5	1.2
X-4015	PDAC	untreated	805.1	26.3	22	250.2	4
X-4015	PDAC	untreated	1080	26.1	24	369.8	3.2
X-4018	PDAC	abraxane	218.8	22.9	0	0	0
X-4018	PDAC	abraxane	190.9	23.2	4	-12.8	1.3
X-4018	PDAC	abraxane	235.6	24.8	7	7.7	8.3
X-4018	PDAC	abraxane	317.9	25.1	11	45.3	9.6
X-4018	PDAC	abraxane	396.3	24.8	13	81.1	8.3
X-4018	PDAC	abraxane	491	24.7	17	124.4	7.9
X-4018	PDAC	abraxane	573.2	23.6	20	162	3.1
X-4018	PDAC	abraxane	656	24.9	24	199.8	8.7
X-4018	PDAC	abraxane	679.3	24.6	27	210.5	7.4
X-4018	PDAC	abraxane	775.1	24.5	32	254.3	7
X-4018	PDAC	abraxane	844.8	24.5	34	286.1	7
X-4018	PDAC	BKM120 + binimetinib	250.3	22.5	0	0	0
X-4018	PDAC	BKM120 + binimetinib	285.5	22.6	2	14.1	0.4
X-4018	PDAC	BKM120 + binimetinib	265.4	22.7	6	6	0.9
X-4018	PDAC	BKM120 + binimetinib	295	22.5	9	17.9	0
X-4018	PDAC	BKM120 + binimetinib	236.2	22.1	13	-5.6	-1.8
X-4018	PDAC	BKM120 + binimetinib	267.5	22.6	16	6.9	0.4
X-4018	PDAC	BKM120 + binimetinib	231.1	24.6	20	-7.7	9.3
X-4018	PDAC	BKM120 + binimetinib	229	23.3	23	-8.5	3.6
X-4018	PDAC	BKM120 + binimetinib	198.7	23.6	27	-20.6	4.9
X-4018	PDAC	BKM120 + binimetinib	190.6	23.9	30	-23.9	6.2
X-4018	PDAC	BKM120 + binimetinib	192.5	23.3	34	-23.1	3.6
X-4018	PDAC	BKM120 + binimetinib	155	23.1	37	-38.1	2.7
X-4018	PDAC	BKM120 + binimetinib	143.5	23	40	-42.7	2.2
X-4018	PDAC	BKM120 + binimetinib	180.8	23.2	43	-27.8	3.1
X-4018	PDAC	BKM120 + binimetinib	160.7	23.2	48	-35.8	3.1
X-4018	PDAC	BKM120 + binimetinib	136.3	23.1	51	-45.5	2.7
X-4018	PDAC	BKM120 + binimetinib	183	23.2	55	-26.9	3.1
X-4018	PDAC	BKM120 + binimetinib	210.1	23.8	58	-16.1	5.8
X-4018	PDAC	BKM120 + binimetinib	176.6	24	61	-29.4	6.7
X-4018	PDAC	BKM120 + binimetinib	200.4	24.2	65	-19.9	7.6
X-4018	PDAC	BKM120 + binimetinib	288.7	24.5	68	15.3	8.9
X-4018	PDAC	BKM120 + binimetinib	258.7	23.8	71	3.4	5.8
X-4018	PDAC	BKM120 + binimetinib	288.5	23.5	75	15.3	4.4
X-4018	PDAC	BKM120 + binimetinib	378.8	24.6	79	51.3	9.3
X-4018	PDAC	BKM120 + binimetinib	418.6	23.8	83	67.2	5.8
X-4018	PDAC	BKM120 + binimetinib	367.1	23.6	86	46.7	4.9
X-4018	PDAC	BKM120 + binimetinib	422.2	23.9	89	68.7	6.2
X-4018	PDAC	BKM120 + binimetinib	498.7	24.3	93	99.2	8
X-4018	PDAC	BKM120 + LDE225	267.7	23.9	0	0	0
X-4018	PDAC	BKM120 + LDE225	293.3	25.6	4	9.6	7.1
X-4018	PDAC	BKM120 + LDE225	236.7	22.9	6	-11.6	-4.2
X-4018	PDAC	BKM120 + LDE225	416.7	22.8	11	55.7	-4.6
X-4018	PDAC	BKM120 + LDE225	432.6	24	18	61.6	0.4
X-4018	PDAC	BKM120 + LDE225	495.3	23.4	21	85	-2.1
X-4018	PDAC	BKM120 + LDE225	740	25.1	25	176.4	5
X-4018	PDAC	BKM120 + LDE225	797.9	26.1	28	198.1	9.2
X-4018	PDAC	BKM120 + LDE225	1083.5	26	32	304.7	8.8
X-4018	PDAC	BKM120 + LDE225	1265.3	26.3	35	372.7	10
X-4018	PDAC	BKM120 + LDE225	1151	23.5	39	330	-1.7
X-4018	PDAC	BKM120 + LDE225	1201.9	23.8	42	349	-0.4
X-4018	PDAC	BKM120 + LDE225	1487.5	23.2	46	455.7	-2.9
X-4018	PDAC	BKM120 + LDE225	1352.9	21.9	49	405.4	-8.4
X-4018	PDAC	BKM120 + LDE225	1421.3	21.2	53	430.9	-11.3
X-4018	PDAC	BKM120 + LDE225	1315	21.2	56	391.2	-11.3
X-4018	PDAC	BKM120 + LDE225	1196.9	21.3	60	347.1	-10.9
X-4018	PDAC	BKM120 + LDE225	1067.8	21	63	298.9	-12.1
X-4018	PDAC	BKM120 + LDE225	831.3	18.7	67	210.5	-21.8
X-4018	PDAC	BKM120	194.9	23	0	0	0
X-4018	PDAC	BKM120	304.9	23.6	4	56.4	2.6
X-4018	PDAC	BKM120	353.4	22.9	7	81.3	-0.4
X-4018	PDAC	BKM120	322.1	23.1	11	65.3	0.4
X-4018	PDAC	BKM120	325.4	23.7	14	67	3
X-4018	PDAC	BKM120	303.4	25.6	19	55.7	11.3
X-4018	PDAC	BKM120	307.7	23.9	21	57.9	3.9
X-4018	PDAC	BKM120	304.4	24	25	56.2	4.3
X-4018	PDAC	BKM120	349.5	24.7	28	79.3	7.4
X-4018	PDAC	BKM120	527.8	24.6	32	170.8	7
X-4018	PDAC	BKM120	511.4	24.5	35	162.4	6.5
X-4018	PDAC	BKM120	432.7	25.4	39	122	10.4
X-4018	PDAC	BKM120	592.8	24.4	42	204.2	6.1
X-4018	PDAC	BKM120	545	24.6	46	179.6	7
X-4018	PDAC	BKM120	495.3	24.6	49	154.1	7
X-4018	PDAC	BKM120	628.7	24.2	55	222.6	5.2
X-4018	PDAC	BYL719	253.1	29.4	0	0	0
X-4018	PDAC	BYL719	390.2	29.4	5	54.2	0
X-4018	PDAC	BYL719	397.2	28.9	8	56.9	-1.7
X-4018	PDAC	BYL719	433	29.7	12	71.1	1
X-4018	PDAC	BYL719	440.4	29.6	15	74	0.7
X-4018	PDAC	BYL719	437.7	31.9	18	72.9	8.5
X-4018	PDAC	CLR457	222.9	26.2	0	0	0
X-4018	PDAC	CLR457	237.9	26.2	5	6.7	0
X-4018	PDAC	CLR457	254.6	25.6	8	14.2	-2.3
X-4018	PDAC	CLR457	258.7	25.4	12	16.1	-3.1
X-4018	PDAC	CLR457	276.1	25.3	15	23.9	-3.4
X-4018	PDAC	CLR457	285.5	26.1	18	28.1	-0.4
X-4018	PDAC	HDM201	251.6	27.5	0	0	0
X-4018	PDAC	HDM201	273.2	26.1	4	8.6	-5.1
X-4018	PDAC	HDM201	359.3	25.9	7	42.8	-5.8
X-4018	PDAC	HDM201	371.7	27.8	11	47.7	1.1
X-4018	PDAC	HDM201	394.7	27.8	13	56.9	1.1
X-4018	PDAC	HDM201	442.4	28.1	18	75.8	2.2
X-4018	PDAC	HDM201	450.3	29.3	21	79	6.5
X-4018	PDAC	HDM201	552	29.5	25	119.4	7.3
X-4018	PDAC	HDM201	566.1	28.8	28	125	4.7
X-4018	PDAC	HDM201	697.7	28.7	31	177.3	4.4
X-4018	PDAC	figitumumab"	226.7	23.4	0	0	0
X-4018	PDAC	figitumumab"	236.8	24.3	3	4.5	3.8
X-4018	PDAC	figitumumab"	348.7	23.6	7	53.8	0.9
X-4018	PDAC	figitumumab"	326.4	23.7	9	44	1.3
X-4018	PDAC	figitumumab"	243.7	24.2	13	7.5	3.4
X-4018	PDAC	figitumumab"	290.7	23.8	16	28.2	1.7
X-4018	PDAC	figitumumab"	333.7	23.9	20	47.2	2.1
X-4018	PDAC	figitumumab"	244.7	24.2	23	7.9	3.4
X-4018	PDAC	figitumumab"	285.4	25.1	28	25.9	7.3
X-4018	PDAC	figitumumab"	233.3	23.9	30	2.9	2.1
X-4018	PDAC	figitumumab"	177.6	23.4	34	-21.7	0
X-4018	PDAC	figitumumab"	190.3	24.1	37	-16.1	3
X-4018	PDAC	figitumumab"	239.6	24.2	41	5.7	3.4
X-4018	PDAC	figitumumab"	240.5	23.9	44	6.1	2.1
X-4018	PDAC	figitumumab" + binimetinib	123.1	26.5	7	-59.3	1.5
X-4018	PDAC	figitumumab" + binimetinib	275	25.2	12	-9.2	-3.4
X-4018	PDAC	figitumumab" + binimetinib	342.6	26.5	15	13.1	1.5
X-4018	PDAC	figitumumab" + binimetinib	403.4	26.3	19	33.2	0.8
X-4018	PDAC	figitumumab" + binimetinib	368.7	26	25	21.8	-0.4
X-4018	PDAC	gemcitabine-50mpk	268.7	24.5	0	0	0
X-4018	PDAC	gemcitabine-50mpk	298.6	24.6	2	11.1	0.4
X-4018	PDAC	gemcitabine-50mpk	354.1	24	4	31.8	-2
X-4018	PDAC	gemcitabine-50mpk	299.6	23.9	8	11.5	-2.4
X-4018	PDAC	gemcitabine-50mpk	371	23.7	12	38.1	-3.3
X-4018	PDAC	gemcitabine-50mpk	387	23.5	15	44	-4.1
X-4018	PDAC	gemcitabine-50mpk	478.6	24.7	22	78.1	0.8
X-4018	PDAC	gemcitabine-50mpk	406.7	25.3	25	51.4	3.3
X-4018	PDAC	gemcitabine-50mpk	380.9	23.9	30	41.8	-2.4
X-4018	PDAC	gemcitabine-50mpk	322.3	24.9	34	19.9	1.6
X-4018	PDAC	gemcitabine-50mpk	467.6	25.2	36	74	2.9
X-4018	PDAC	gemcitabine-50mpk	418.3	24.3	40	55.7	-0.8
X-4018	PDAC	gemcitabine-50mpk	554.5	25	43	106.4	2
X-4018	PDAC	gemcitabine-50mpk	578.1	24.3	47	115.1	-0.8
X-4018	PDAC	gemcitabine-50mpk	677.3	24.9	50	152.1	1.6
X-4018	PDAC	gemcitabine-50mpk	513.1	25.5	53	91	4.1
X-4018	PDAC	gemcitabine-50mpk	567.2	25.6	57	111.1	4.5
X-4018	PDAC	gemcitabine-50mpk	638.8	25.5	61	137.7	4.1
X-4018	PDAC	gemcitabine-50mpk	788	26	64	193.3	6.1
X-4018	PDAC	gemcitabine-50mpk	841.2	26	68	213.1	6.1
X-4018	PDAC	INC424 + binimetinib	331.4	27.9	0	0	0
X-4018	PDAC	INC424 + binimetinib	253.8	28.2	4	-23.4	1.1
X-4018	PDAC	INC424 + binimetinib	273.8	27.7	7	-17.4	-0.7
X-4018	PDAC	INC424 + binimetinib	300.4	28.9	10	-9.4	3.6
X-4018	PDAC	INC424 + binimetinib	267.8	28.2	14	-19.2	1.1
X-4018	PDAC	INC424 + binimetinib	322.4	29.1	18	-2.7	4.3
X-4018	PDAC	INC424 + binimetinib	352.4	28.7	20	6.3	2.9
X-4018	PDAC	INC424 + binimetinib	306.8	29.2	25	-7.4	4.7
X-4018	PDAC	INC424 + binimetinib	441.9	29.2	32	33.3	4.7
X-4018	PDAC	INC424 + binimetinib	535.5	29.2	39	61.6	4.7
X-4018	PDAC	INC424 + binimetinib	432.3	28.4	42	30.4	1.8
X-4018	PDAC	INC424 + binimetinib	578.3	28.4	47	74.5	1.8
X-4018	PDAC	INC424 + binimetinib	603.5	28	49	82.1	0.4
X-4018	PDAC	INC424 + binimetinib	604	27	53	82.3	-3.2
X-4018	PDAC	INC424 + binimetinib	505.9	26.7	56	52.7	-4.3
X-4018	PDAC	INC424 + binimetinib	539.5	28.5	60	62.8	2.2
X-4018	PDAC	INC424 + binimetinib	688.2	26.1	63	107.7	-6.5
X-4018	PDAC	INC424 + binimetinib	718.7	26.1	66	116.9	-6.5
X-4018	PDAC	INC424 + binimetinib	889.7	27.1	69	168.5	-2.9
X-4018	PDAC	INC424 + binimetinib	1133.2	25.6	74	241.9	-8.2
X-4018	PDAC	INC424 + binimetinib	1245.8	25.8	80	275.9	-7.5
X-4018	PDAC	INC424 + binimetinib	1887.8	25.2	83	469.6	-9.7
X-4018	PDAC	INC424 + binimetinib	1430.6	26.1	88	331.7	-6.5
X-4018	PDAC	INC424 + binimetinib	1268.7	26.1	91	282.8	-6.5
X-4018	PDAC	INC424 + binimetinib	1692.9	27.3	95	410.8	-2.2
X-4018	PDAC	INC424 + binimetinib	2086.4	26.8	98	529.6	-3.9
X-4018	PDAC	LEE011	248.5	24.3	0	0	0
X-4018	PDAC	LEE011	289.4	24.8	2	16.5	2.1
X-4018	PDAC	LEE011	332.5	24.3	5	33.8	0
X-4018	PDAC	LEE011	437.2	24.6	9	75.9	1.2
X-4018	PDAC	LEE011	277.5	24.2	13	11.7	-0.4
X-4018	PDAC	LEE011	330.9	23.3	16	33.2	-4.1
X-4018	PDAC	LEE011	687	23.5	20	176.5	-3.3
X-4018	PDAC	WNT974	234.7	25.8	0	0	0
X-4018	PDAC	WNT974	248.4	25.3	1	5.8	-1.9
X-4018	PDAC	WNT974	354.4	22.4	5	51	-13.2
X-4018	PDAC	WNT974	397.2	24.2	7	69.2	-6.2
X-4018	PDAC	WNT974	492.1	23.1	13	109.7	-10.5
X-4018	PDAC	WNT974	572.6	22.1	17	144	-14.3
X-4018	PDAC	WNT974	581.3	23.4	19	147.7	-9.3
X-4018	PDAC	WNT974	911.3	22.6	23	288.3	-12.4
X-4018	PDAC	WNT974	924.7	23.4	27	294	-9.3
X-4018	PDAC	WNT974	1047.8	22.5	30	346.4	-12.8
X-4018	PDAC	LKA136	254.8	23.4	0	0	0
X-4018	PDAC	LKA136	289.6	23.3	1	13.7	-0.4
X-4018	PDAC	LKA136	357.3	23.5	5	40.2	0.4
X-4018	PDAC	LKA136	356.5	23.1	7	39.9	-1.3
X-4018	PDAC	LKA136	488.6	22.8	13	91.8	-2.6
X-4018	PDAC	LKA136	750.2	24.3	19	194.4	3.8
X-4018	PDAC	LKA136	851.7	22.1	23	234.3	-5.6
X-4018	PDAC	LKA136	1029.3	24.4	27	304	4.3
X-4018	PDAC	LKA136	1185.7	NA	30	365.3	4.3
X-4018	PDAC	binimetinib	253.9	23.7	0	0	0
X-4018	PDAC	binimetinib	298.8	22.9	2	17.7	-3.4
X-4018	PDAC	binimetinib	281.4	23.3	6	10.8	-1.7
X-4018	PDAC	binimetinib	311.6	22.1	9	22.7	-6.8
X-4018	PDAC	binimetinib	312.6	25.2	12	23.1	6.3
X-4018	PDAC	binimetinib	246.4	23.6	16	-3	-0.4
X-4018	PDAC	binimetinib	325.4	24.5	20	28.2	3.4
X-4018	PDAC	binimetinib	271.2	24.4	22	6.8	3
X-4018	PDAC	binimetinib	354.1	24.6	27	39.5	3.8
X-4018	PDAC	binimetinib	312.8	23	34	23.2	-3
X-4018	PDAC	binimetinib	260.4	22.4	41	2.6	-5.5
X-4018	PDAC	binimetinib	253.9	21.5	44	0	-9.3
X-4018	PDAC	binimetinib-3.5mpk	162.3	26.7	0	0	0
X-4018	PDAC	binimetinib-3.5mpk	140.5	26.2	4	-13.4	-1.9
X-4018	PDAC	binimetinib-3.5mpk	100.3	25.7	8	-38.2	-3.7
X-4018	PDAC	binimetinib-3.5mpk	179.9	26.2	11	10.8	-1.9
X-4018	PDAC	binimetinib-3.5mpk	133.2	26.8	15	-17.9	0.4
X-4018	PDAC	binimetinib-3.5mpk	132.3	25.8	18	-18.5	-3.4
X-4018	PDAC	binimetinib-3.5mpk	151.6	24.4	22	-6.6	-8.6
X-4018	PDAC	binimetinib-3.5mpk	173.5	26.8	30	6.9	0.4
X-4018	PDAC	binimetinib-3.5mpk	99.9	26.6	32	-38.4	-0.4
X-4018	PDAC	binimetinib-3.5mpk	93.3	26.1	36	-42.5	-2.2
X-4018	PDAC	binimetinib-3.5mpk	124.1	26.2	39	-23.5	-1.9
X-4018	PDAC	binimetinib-3.5mpk	81.1	27.1	46	-50	1.5
X-4018	PDAC	binimetinib-3.5mpk	84.8	26.3	50	-47.8	-1.5
X-4018	PDAC	binimetinib-3.5mpk	32	26.2	52	-80.3	-1.9
X-4018	PDAC	binimetinib-3.5mpk	33.2	27	56	-79.5	1.1
X-4018	PDAC	binimetinib-3.5mpk	10.9	26.9	59	-93.3	0.7
X-4018	PDAC	binimetinib-3.5mpk	10.4	24.7	64	-93.6	-7.5
X-4018	PDAC	binimetinib-3.5mpk	26.8	26.3	67	-83.5	-1.5
X-4018	PDAC	binimetinib-3.5mpk	53.5	26.5	77	-67	-0.7
X-4018	PDAC	binimetinib-3.5mpk	7.8	26	80	-95.2	-2.6
X-4018	PDAC	binimetinib-3.5mpk	0	26.3	85	-100	-1.5
X-4018	PDAC	binimetinib-3.5mpk	0	26.8	87	-100	0.4
X-4018	PDAC	binimetinib-3.5mpk	0	26.6	91	-100	-0.4
X-4018	PDAC	binimetinib-3.5mpk	0	26.3	98	-100	-1.5
X-4018	PDAC	trametinib	177.6	25.9	0	0	0
X-4018	PDAC	trametinib	217.1	25.6	3	22.2	-1.2
X-4018	PDAC	trametinib	212.9	25.4	7	19.9	-1.9
X-4018	PDAC	trametinib	229.1	25.8	10	29	-0.4
X-4018	PDAC	trametinib	200.9	26.5	15	13.1	2.3
X-4018	PDAC	trametinib	207.6	26.1	17	16.9	0.8
X-4018	PDAC	trametinib	234.3	27.4	21	31.9	5.8
X-4018	PDAC	trametinib	248.8	26.6	24	40.1	2.7
X-4018	PDAC	trametinib	289.9	26.1	28	63.2	0.8
X-4018	PDAC	trametinib	331.4	27.4	31	86.6	5.8
X-4018	PDAC	trametinib	341.2	26.5	35	92.1	2.3
X-4018	PDAC	trametinib	331.1	26.3	38	86.4	1.5
X-4018	PDAC	trametinib	319.3	26.6	42	79.8	2.7
X-4018	PDAC	trametinib	336.4	25.7	45	89.4	-0.8
X-4018	PDAC	trametinib	371.7	27.7	51	109.3	6.9
X-4018	PDAC	untreated	274.6	28.1	0	0	0
X-4018	PDAC	untreated	387.1	28.2	4	41	0.4
X-4018	PDAC	untreated	373.3	27.6	6	35.9	-1.8
X-4018	PDAC	untreated	439.9	27	11	60.2	-3.9
X-4018	PDAC	untreated	411.6	27.9	14	49.9	-0.7
X-4018	PDAC	untreated	544.3	27.3	18	98.2	-2.8
X-4018	PDAC	untreated	647.2	26.8	21	135.7	-4.6
X-4018	PDAC	untreated	642.3	28.6	24	133.9	1.8
X-4018	PDAC	untreated	744.9	27.5	28	171.3	-2.1
X-4018	PDAC	untreated	898.1	27.7	31	227.1	-1.4
X-4018	PDAC	untreated	883.5	28	35	221.7	-0.4
X-4018	PDAC	untreated	976.5	28.2	38	255.6	0.4
X-4018	PDAC	untreated	916	28.4	42	233.6	1.1
X-4018	PDAC	untreated	1388.6	28.8	48	405.7	2.5
X-4087	CRC	5FU	558.1	22.5	0	0	0
X-4087	CRC	5FU	587.3	22.9	3	5.2	1.8
X-4087	CRC	5FU	611.1	20.3	6	9.5	-9.8
X-4087	CRC	5FU	560.3	20.8	11	0.4	-7.6
X-4087	CRC	5FU	637.8	21.8	14	14.3	-3.1
X-4087	CRC	5FU	879	21.3	17	57.5	-5.3
X-4087	CRC	5FU	1029.3	22.8	20	84.4	1.3
X-4087	CRC	BKM120	614.4	20.9	0	0	0
X-4087	CRC	BKM120	799.8	22.1	3	30.2	5.7
X-4087	CRC	BKM120	734	20	6	19.5	-4.3
X-4087	CRC	BKM120	845.3	19.6	11	37.6	-6.2
X-4087	CRC	BKM120	1076.6	19.6	14	75.2	-6.2
X-4087	CRC	BKM120	1135.2	19.3	17	84.8	-7.7
X-4087	CRC	BKM120	1229.7	20.8	20	100.1	-0.5
X-4087	CRC	BKM120 + LJC049	213.2	28.5	0	0	0
X-4087	CRC	BKM120 + LJC049	351.3	27.5	3	64.8	-3.5
X-4087	CRC	BKM120 + LJC049	409.1	27.1	6	91.9	-4.9
X-4087	CRC	BKM120 + LJC049	591.7	28	9	177.6	-1.8
X-4087	CRC	BKM120 + LJC049	704.1	26.5	11	230.3	-7
X-4087	CRC	BKM120 + LJC049	744.2	26.4	14	249.1	-7.4
X-4087	CRC	BKM120 + LJC049	927.5	26.2	18	335.1	-8.1
X-4087	CRC	BKM120 + LJC049	867.9	27.2	24	307.2	-4.6
X-4087	CRC	BKM120 + LJC049	882.9	24.1	27	314.2	-15.4
X-4087	CRC	BKM120 + LJC049	1088.7	24.3	30	410.7	-14.7
X-4087	CRC	BYL719 + cetuximab + encorafenib	249.6	25.1	0	0	0
X-4087	CRC	BYL719 + cetuximab + encorafenib	295.9	23.8	6	18.5	-5.2
X-4087	CRC	BYL719 + cetuximab + encorafenib	380.7	23.1	9	52.5	-8
X-4087	CRC	BYL719 + cetuximab + encorafenib	382	23.4	12	53	-6.8
X-4087	CRC	BYL719 + cetuximab + encorafenib	506.1	21.5	17	102.8	-14.3
X-4087	CRC	BYL719 + cetuximab + encorafenib	618.5	21.2	20	147.8	-15.5
X-4087	CRC	BYL719 + cetuximab + encorafenib	824.8	21.1	25	230.4	-15.9
X-4087	CRC	BYL719 + cetuximab + encorafenib	888.9	21	27	256.1	-16.3
X-4087	CRC	BYL719 + LJM716	312.5	21.6	0	0	0
X-4087	CRC	BYL719 + LJM716	399.6	23.4	3	27.9	8.3
X-4087	CRC	BYL719 + LJM716	417.1	22	6	33.5	1.9
X-4087	CRC	BYL719 + LJM716	422.2	21.2	11	35.1	-1.9
X-4087	CRC	BYL719 + LJM716	431.2	21.7	14	38	0.5
X-4087	CRC	BYL719 + LJM716	448.9	21.6	17	43.6	0
X-4087	CRC	BYL719 + LJM716	493.6	23.7	20	58	9.7
X-4087	CRC	BYL719	504	18	0	0	0
X-4087	CRC	BYL719	619.4	17.9	3	22.9	-0.6
X-4087	CRC	BYL719 + binimetinib	354.5	25.2	0	0	0
X-4087	CRC	BYL719 + binimetinib	463.7	27.1	3	30.8	7.5
X-4087	CRC	BYL719 + binimetinib	475	26.6	6	34	5.6
X-4087	CRC	BYL719 + binimetinib	527.3	26.6	11	48.7	5.6
X-4087	CRC	BYL719 + binimetinib	666.4	26.6	14	88	5.6
X-4087	CRC	BYL719 + binimetinib	830.5	27.9	17	134.3	10.7
X-4087	CRC	BYL719 + binimetinib	845	28	20	138.4	11.1
X-4087	CRC	BYL719 + cetuximab	361	25.8	12	0	0
X-4087	CRC	BYL719 + cetuximab	396.9	25.6	15	9.9	-0.8
X-4087	CRC	BYL719 + cetuximab	424.3	25.1	23	17.5	-2.7
X-4087	CRC	BYL719 + cetuximab	539.1	25.1	26	49.3	-2.7
X-4087	CRC	BYL719 + cetuximab	440.1	24.8	29	21.9	-3.9
X-4087	CRC	BYL719 + cetuximab	580.6	24.6	31	60.8	-4.7
X-4087	CRC	BYL719 + encorafenib	204.9	25.4	0	0	0
X-4087	CRC	BYL719 + encorafenib	226.1	24.6	3	10.3	-3.1
X-4087	CRC	BYL719 + encorafenib	295.7	24.9	7	44.3	-2
X-4087	CRC	BYL719 + encorafenib	363.8	22.8	10	77.5	-10.2
X-4087	CRC	BYL719 + encorafenib	360.3	22.8	15	75.8	-10.2
X-4087	CRC	BYL719 + encorafenib	370.3	22	18	80.7	-13.4
X-4087	CRC	BYL719 + encorafenib	368.8	21.1	21	80	-16.9
X-4087	CRC	BYL719 + encorafenib	369.1	21.7	24	80.1	-14.6
X-4087	CRC	CGM097	1079.1	28.9	0	0	0
X-4087	CRC	CGM097	1364	30.8	3	26.4	6.6
X-4087	CRC	CGM097	1750.8	28.9	6	62.2	0
X-4087	CRC	CKX620	676.7	25.2	0	0	0
X-4087	CRC	CKX620	703.2	26.4	3	3.9	4.8
X-4087	CRC	CKX620	681.3	25.4	6	0.7	0.8
X-4087	CRC	CKX620	718.1	25.7	11	6.1	2
X-4087	CRC	CKX620	837.5	26.4	14	23.8	4.8
X-4087	CRC	CKX620	809.7	26.1	17	19.7	3.6
X-4087	CRC	CKX620	1131	26.5	20	67.1	5.2
X-4087	CRC	CLR457	751.8	20.2	0	0	0
X-4087	CRC	CLR457	795	20	3	5.7	-1
X-4087	CRC	CLR457	896.3	19.1	6	19.2	-5.4
X-4087	CRC	CLR457	1028.3	18.3	11	36.8	-9.4
X-4087	CRC	CLR457	1201.2	19.5	14	59.8	-3.5
X-4087	CRC	CLR457	1171.6	19	17	55.8	-5.9
X-4087	CRC	CLR457	1574.5	20.8	20	109.4	3
X-4087	CRC	HDM201	460	23.1	0	0	0
X-4087	CRC	HDM201	441.2	24.6	3	-4.1	6.5
X-4087	CRC	HDM201	541.1	22.3	6	17.6	-3.5
X-4087	CRC	HDM201	625.6	22.8	11	36	-1.3
X-4087	CRC	HDM201	764.6	21.7	14	66.2	-6.1
X-4087	CRC	HDM201	875.1	21.1	17	90.2	-8.7
X-4087	CRC	HDM201	839.5	22.5	20	82.5	-2.6
X-4087	CRC	cetuximab	215.4	25.7	0	0	0
X-4087	CRC	cetuximab	460.7	24.7	9	113.9	-3.9
X-4087	CRC	cetuximab	646.2	24	15	200	-6.6
X-4087	CRC	cetuximab	898.3	26.2	18	317	1.9
X-4087	CRC	cetuximab	988.4	24.8	21	358.9	-3.5
X-4087	CRC	cetuximab + encorafenib	231.5	22.3	0	0	0
X-4087	CRC	cetuximab + encorafenib	544.4	21.3	9	135.2	-4.5
X-4087	CRC	cetuximab + encorafenib	981.5	22.2	15	324	-0.4
X-4087	CRC	cetuximab + encorafenib	1607	22.1	18	594.2	-0.9
X-4087	CRC	cetuximab + encorafenib	1922.1	22.5	21	730.3	0.9
X-4087	CRC	LEE011	446.6	25.8	0	0	0
X-4087	CRC	LEE011	411.6	26	3	-7.8	0.8
X-4087	CRC	LEE011	433	26	6	-3	0.8
X-4087	CRC	LEE011	528.9	27.7	11	18.4	7.4
X-4087	CRC	LEE011	543.9	29.1	14	21.8	12.8
X-4087	CRC	LEE011	707.8	28.2	17	58.5	9.3
X-4087	CRC	LEE011	520.8	28.3	20	16.6	9.7
X-4087	CRC	encorafenib	1180.1	20.5	0	0	0
X-4087	CRC	encorafenib	1415.1	21	3	19.9	2.4
X-4087	CRC	encorafenib	1576.9	20.4	6	33.6	-0.5
X-4087	CRC	LJC049	830.3	23.6	0	0	0
X-4087	CRC	LJC049	945.1	24.2	3	13.8	2.5
X-4087	CRC	LJC049	1173.2	22.8	6	41.3	-3.4
X-4087	CRC	LJC049	972.7	22.4	11	17.2	-5.1
X-4087	CRC	LJC049	1519.9	23.2	14	83.1	-1.7
X-4087	CRC	LKA136	847.8	27.1	0	0	0
X-4087	CRC	LKA136	1178	29.3	3	38.9	8.1
X-4087	CRC	LKA136	1507.6	26.3	6	77.8	-3
X-4087	CRC	binimetinib	202.3	26.3	0	0	0
X-4087	CRC	binimetinib	202.5	26.2	3	0.1	-0.4
X-4087	CRC	binimetinib	161.6	27	6	-20.1	2.7
X-4087	CRC	binimetinib	229.1	26.7	10	13.2	1.5
X-4087	CRC	binimetinib	199.1	26.9	13	-1.6	2.3
X-4087	CRC	binimetinib	136.8	27.5	17	-32.4	4.6
X-4087	CRC	binimetinib	142.9	29.2	21	-29.4	11
X-4087	CRC	binimetinib	211.7	26.5	24	4.6	0.8
X-4087	CRC	binimetinib	208.1	26.9	27	2.8	2.3
X-4087	CRC	untreated	226.6	24.9	0	0	0
X-4087	CRC	untreated	283.4	24.3	9	25.1	-2.4
X-4087	CRC	untreated	292.3	25.5	15	29	2.4
X-4087	CRC	untreated	348.7	26.3	18	53.9	5.6
X-4087	CRC	untreated	359.7	27.2	21	58.7	9.2
X-4087	CRC	untreated	421.4	25.6	26	86	2.8
X-4087	CRC	untreated	490.8	26.2	29	116.6	5.2
X-4087	CRC	untreated	550	27.2	34	142.7	9.2
X-4087	CRC	untreated	684.2	26.3	36	201.9	5.6
X-4087	CRC	untreated	824.7	26.7	40	263.9	7.2
X-4087	CRC	untreated	900.9	26.8	42	297.6	7.6
X-4087	CRC	LFW527 + binimetinib	211.73	24.82	0	0	0
X-4087	CRC	LFW527 + binimetinib	280.23	24.23	2	32.4	-2.4
X-4087	CRC	LFW527 + binimetinib	184.65	23.35	5	-12.8	-5.9
X-4087	CRC	LFW527 + binimetinib	212.53	24.71	9	0.4	-0.4
X-4087	CRC	LFW527 + binimetinib	286.09	23.57	11	35.1	-5
X-4087	CRC	LFW527 + binimetinib	162.47	24.31	15	-23.3	-2.1
X-4087	CRC	LFW527 + binimetinib	255.92	23.64	18	20.9	-4.8
X-4087	CRC	LFW527 + binimetinib	377.75	24.34	22	78.4	-1.9
X-4087	CRC	LFW527 + binimetinib	360.05	24.7	24	70.1	-0.5
X-4087	CRC	LFW527 + binimetinib	412.92	24.53	29	95	-1.2
X-4087	CRC	LFW527 + binimetinib	542.88	24.36	32	156.4	-1.9
X-4087	CRC	LFW527 + binimetinib	520.57	25.65	38	145.9	3.3
X-4145	CRC	abraxane	253.6	25.7	0	0	0
X-4145	CRC	abraxane	302.6	26.1	2	19.3	1.6
X-4145	CRC	abraxane	395.5	26.9	6	56	4.7
X-4145	CRC	abraxane	513.9	26.7	10	102.6	3.9
X-4145	CRC	abraxane	737.3	26.9	13	190.7	4.7
X-4145	CRC	abraxane	748.7	27.2	16	195.2	5.8
X-4145	CRC	abraxane	1021.2	28.1	20	302.7	9.3
X-4145	CRC	BKM120 + binimetinib	223.8	23.9	0	0	0
X-4145	CRC	BKM120 + binimetinib	309.4	23.8	5	38.2	-0.4
X-4145	CRC	BKM120 + binimetinib	299.9	24.6	8	34	2.9
X-4145	CRC	BKM120 + binimetinib	279.8	24.9	12	25	4.2
X-4145	CRC	BKM120 + binimetinib	254.7	25	15	13.8	4.6
X-4145	CRC	BKM120 + binimetinib	274.2	24.2	19	22.5	1.3
X-4145	CRC	BKM120 + binimetinib	253.9	24.1	22	13.4	0.8
X-4145	CRC	BKM120 + binimetinib	302.1	24	25	35	0.4
X-4145	CRC	BKM120 + binimetinib	394.3	25.3	27	76.2	5.9
X-4145	CRC	BKM120 + binimetinib	529	26.2	28	136.4	9.6
X-4145	CRC	BKM120 + binimetinib	462.8	24.4	32	106.8	2.1
X-4145	CRC	BKM120 + binimetinib	320.6	25.3	35	43.3	5.9
X-4145	CRC	BKM120 + binimetinib	393.6	25.6	39	75.9	7.1
X-4145	CRC	BKM120 + binimetinib	351.4	26.4	41	57	10.5
X-4145	CRC	BKM120 + binimetinib	667	26.3	46	198	10
X-4145	CRC	BKM120 + binimetinib	718.5	27	49	221	13
X-4145	CRC	BKM120 + binimetinib	531.4	25.9	54	137.4	8.4
X-4145	CRC	BKM120 + binimetinib	517.6	26.8	56	131.3	12.1
X-4145	CRC	BKM120 + binimetinib	418.4	26.8	61	87	12.1
X-4145	CRC	BKM120 + binimetinib	391.3	26.5	64	74.8	10.9
X-4145	CRC	BKM120 + binimetinib	563.3	26.8	67	151.7	12.1
X-4145	CRC	BKM120 + binimetinib	563	26.6	71	151.6	11.3
X-4145	CRC	BKM120 + LDE225	277.8	24.1	0	0	0
X-4145	CRC	BKM120 + LDE225	312.5	24.9	2	12.5	3.3
X-4145	CRC	BKM120 + LDE225	380	24.5	6	36.8	1.7
X-4145	CRC	BKM120 + LDE225	418.7	23.3	9	50.7	-3.3
X-4145	CRC	BKM120 + LDE225	314.9	22.8	13	13.4	-5.4
X-4145	CRC	BKM120 + LDE225	395.7	24	16	42.4	-0.4
X-4145	CRC	BKM120 + LDE225	422.3	24.1	20	52	0
X-4145	CRC	BKM120 + LDE225	419.2	22.4	23	50.9	-7.1
X-4145	CRC	BKM120 + LDE225	493.3	23.8	27	77.6	-1.2
X-4145	CRC	BKM120 + LDE225	488.8	21	30	76	-12.9
X-4145	CRC	BKM120 + LDE225	660.6	21	34	137.8	-12.9
X-4145	CRC	BKM120 + LDE225	524.5	21.2	37	88.8	-12
X-4145	CRC	BKM120 + LDE225	622.9	22.2	40	124.2	-7.9
X-4145	CRC	BKM120 + LDE225	499.9	21.2	43	79.9	-12
X-4145	CRC	BKM120 + LDE225	616.1	21.1	48	121.8	-12.4
X-4145	CRC	BKM120 + LDE225	1139.8	22.2	51	310.3	-7.9
X-4145	CRC	BKM120 + LDE225	958.8	23.3	55	245.1	-3.3
X-4145	CRC	BKM120 + LDE225	951.3	24.3	58	242.4	0.8
X-4145	CRC	BKM120 + LDE225	942.3	24.5	61	239.2	1.7
X-4145	CRC	BKM120 + LDE225	939.3	24.7	65	238.1	2.5
X-4145	CRC	BKM120 + LDE225	1316.5	24.8	68	373.9	2.9
X-4145	CRC	BKM120 + LDE225	1041.7	23.4	71	275	-2.9
X-4145	CRC	BKM120	256.8	25.5	0	0	0
X-4145	CRC	BKM120	368.1	26.1	2	43.3	2.4
X-4145	CRC	BKM120	414.1	26.9	6	61.3	5.5
X-4145	CRC	BKM120	447.8	26	9	74.4	2
X-4145	CRC	BKM120	629.1	27.4	13	145	7.5
X-4145	CRC	BKM120	848.6	27.6	16	230.5	8.2
X-4145	CRC	BKM120	1009.5	27.8	20	293.1	9
X-4145	CRC	BKM120	1007.7	26.4	23	292.4	3.5
X-4145	CRC	BKM120	1139.5	27.5	27	343.7	7.8
X-4145	CRC	BYL719	207.7	27.3	0	0	0
X-4145	CRC	BYL719	200.8	29.3	3	-3.3	7.3
X-4145	CRC	BYL719	215.9	28.3	6	3.9	3.7
X-4145	CRC	BYL719	240.7	28.8	10	15.9	5.5
X-4145	CRC	BYL719	331.1	28.5	13	59.4	4.4
X-4145	CRC	BYL719	382.5	28.3	17	84.2	3.7
X-4145	CRC	BYL719	418.6	28.2	20	101.5	3.3
X-4145	CRC	BYL719	520.4	29.1	24	150.6	6.6
X-4145	CRC	BYL719	670.3	28.4	31	222.7	4
X-4145	CRC	BYL719	779.1	28.1	33	275.1	2.9
X-4145	CRC	BYL719 + LJM716	251.3	28.6	0	0	0
X-4145	CRC	BYL719 + LJM716	314	27.2	2	25	-4.9
X-4145	CRC	BYL719 + LJM716	360.9	27.3	6	43.6	-4.5
X-4145	CRC	BYL719 + LJM716	376.2	28.1	9	49.7	-1.7
X-4145	CRC	BYL719 + LJM716	397.6	28.4	13	58.2	-0.7
X-4145	CRC	BYL719 + LJM716	401.1	27.7	16	59.6	-3.1
X-4145	CRC	BYL719 + LJM716	401.2	28.1	20	59.6	-1.7
X-4145	CRC	BYL719 + LJM716	405.9	28.5	24	61.5	-0.3
X-4145	CRC	BYL719 + LJM716	412.6	29.2	27	64.2	2.1
X-4145	CRC	BYL719 + LJM716	436.3	28.2	30	73.6	-1.4
X-4145	CRC	BYL719 + LJM716	442.8	28.1	34	76.2	-1.7
X-4145	CRC	BYL719 + LJM716	434.7	27.8	37	73	-2.8
X-4145	CRC	BYL719 + LJM716	413.7	27.7	41	64.6	-3.1
X-4145	CRC	BYL719 + LJM716	425.2	27.9	44	69.2	-2.4
X-4145	CRC	BYL719 + LJM716	427	28	48	69.9	-2.1
X-4145	CRC	BYL719 + LJM716	447.3	27.8	51	78	-2.8
X-4145	CRC	BYL719 + LJM716	455.5	28	55	81.3	-2.1
X-4145	CRC	BYL719 + LJM716	493	27.4	58	96.2	-4.2
X-4145	CRC	CLR457	242.3	25.8	0	0	0
X-4145	CRC	CLR457	260.5	26.4	2	7.5	2.3
X-4145	CRC	CLR457	311.3	25.6	5	28.5	-0.8
X-4145	CRC	CLR457	392.1	24.6	8	61.8	-4.7
X-4145	CRC	CLR457	443.4	26.5	12	83	2.7
X-4145	CRC	CLR457	471.4	26.8	15	94.6	3.9
X-4145	CRC	CLR457	475.6	26.8	19	96.3	3.9
X-4145	CRC	CLR457	477.7	26.8	22	97.2	3.9
X-4145	CRC	CLR457	499.8	25.6	26	106.3	-0.8
X-4145	CRC	CLR457	659	25.9	33	172	0.4
X-4145	CRC	CLR457	704.3	25.7	35	190.7	-0.4
X-4145	CRC	HDM201	206.9	23.4	0	0	0
X-4145	CRC	HDM201	229.9	28.7	3	11.1	22.6
X-4145	CRC	HDM201	329.1	24.5	6	59.1	4.7
X-4145	CRC	HDM201	392.5	25.4	10	89.7	8.5
X-4145	CRC	HDM201	460.1	26.6	13	122.4	13.7
X-4145	CRC	HDM201	566.9	29.1	16	174	24.4
X-4145	CRC	HDM201	795	28.3	20	284.2	20.9
X-4145	CRC	HDM201	1021.3	26.2	23	393.6	12
X-4145	CRC	HDM201	1149.9	27.3	27	455.8	16.7
X-4145	CRC	HDM201	1240.9	26.9	30	499.8	15
X-4145	CRC	HDM201	1339	27.2	34	547.2	16.2
X-4145	CRC	HDM201	1557.5	26.3	37	652.8	12.4
X-4145	CRC	figitumumab" + binimetinib	223.5	29.3	0	0	0
X-4145	CRC	figitumumab" + binimetinib	272.7	28.1	4	22	-4.1
X-4145	CRC	figitumumab" + binimetinib	235.6	28.8	7	5.4	-1.7
X-4145	CRC	figitumumab" + binimetinib	226.4	28.7	11	1.3	-2
X-4145	CRC	figitumumab" + binimetinib	271.5	28.3	14	21.5	-3.4
X-4145	CRC	figitumumab" + binimetinib	354.9	27.8	18	58.8	-5.1
X-4145	CRC	figitumumab" + binimetinib	351.9	28	21	57.4	-4.4
X-4145	CRC	figitumumab" + binimetinib	444.5	26.9	25	98.9	-8.2
X-4145	CRC	figitumumab" + binimetinib	407.1	28.4	27	82.1	-3.1
X-4145	CRC	figitumumab" + binimetinib	328	29	32	46.8	-1
X-4145	CRC	figitumumab" + binimetinib	364.3	28.6	35	63	-2.4
X-4145	CRC	figitumumab" + binimetinib	368.1	28.8	39	64.7	-1.7
X-4145	CRC	figitumumab" + binimetinib	328.5	28.4	42	47	-3.1
X-4145	CRC	figitumumab" + binimetinib	353.3	28.1	46	58.1	-4.1
X-4145	CRC	figitumumab" + binimetinib	377.8	28.5	49	69	-2.7
X-4145	CRC	figitumumab" + binimetinib	457.5	28.4	54	104.7	-3.1
X-4145	CRC	figitumumab" + binimetinib	344.4	29.1	57	54.1	-0.7
X-4145	CRC	figitumumab" + binimetinib	488.9	28	62	118.7	-4.4
X-4145	CRC	figitumumab" + binimetinib	400.7	28.3	64	79.3	-3.4
X-4145	CRC	figitumumab" + binimetinib	417.3	28.6	67	86.7	-2.4
X-4145	CRC	figitumumab" + binimetinib	388.3	28.6	70	73.7	-2.4
X-4145	CRC	figitumumab" + binimetinib	409.3	28.7	75	83.1	-2
X-4145	CRC	figitumumab" + binimetinib	485.9	28	78	117.4	-4.4
X-4145	CRC	figitumumab"	227.3	24.2	0	0	0
X-4145	CRC	figitumumab"	241.3	25.2	2	6.2	4.1
X-4145	CRC	figitumumab"	279.6	26.6	10	23	9.9
X-4145	CRC	figitumumab"	482.9	NA	13	112.5	9.9
X-4145	CRC	figitumumab"	549.3	26	16	141.7	7.4
X-4145	CRC	figitumumab"	650.4	27	20	186.1	11.6
X-4145	CRC	figitumumab"	703.1	26.2	23	209.3	8.3
X-4145	CRC	figitumumab"	959.5	25.6	28	322.1	5.8
X-4145	CRC	figitumumab"	953.2	26.4	30	319.4	9.1
X-4145	CRC	figitumumab"	1188.4	26.7	34	422.8	10.3
X-4145	CRC	gemcitabine-50mpk	262.6	24.3	0	0	0
X-4145	CRC	gemcitabine-50mpk	276.5	24.6	4	5.3	1.2
X-4145	CRC	gemcitabine-50mpk	309.2	24.8	7	17.7	2.1
X-4145	CRC	gemcitabine-50mpk	339.5	25.2	11	29.3	3.7
X-4145	CRC	gemcitabine-50mpk	413.2	25.3	14	57.3	4.1
X-4145	CRC	gemcitabine-50mpk	329.5	26.1	18	25.5	7.4
X-4145	CRC	gemcitabine-50mpk	303.3	26.1	21	15.5	7.4
X-4145	CRC	gemcitabine-50mpk	227.5	26.6	24	-13.4	9.5
X-4145	CRC	gemcitabine-50mpk	209.2	26.5	28	-20.3	9.1
X-4145	CRC	gemcitabine-50mpk	215	25.6	32	-18.1	5.3
X-4145	CRC	gemcitabine-50mpk	174.1	26.4	35	-33.7	8.6
X-4145	CRC	gemcitabine-50mpk	220	27.1	39	-16.2	11.5
X-4145	CRC	gemcitabine-50mpk	173.4	27.4	41	-34	12.8
X-4145	CRC	gemcitabine-50mpk	185.7	27.1	46	-29.3	11.5
X-4145	CRC	gemcitabine-50mpk	100.3	27.9	52	-61.8	14.8
X-4145	CRC	gemcitabine-50mpk	125.2	27.2	56	-52.3	11.9
X-4145	CRC	gemcitabine-50mpk	116	27.4	60	-55.8	12.8
X-4145	CRC	gemcitabine-50mpk	119.4	27.1	62	-54.5	11.5
X-4145	CRC	gemcitabine-50mpk	166.1	27.5	67	-36.7	13.2
X-4145	CRC	gemcitabine-50mpk	119	27.4	69	-54.7	12.8
X-4145	CRC	gemcitabine-50mpk	122	27	74	-53.5	11.1
X-4145	CRC	gemcitabine-50mpk	75.4	27.9	77	-71.3	14.8
X-4145	CRC	gemcitabine-50mpk	84.5	27.6	81	-67.8	13.6
X-4145	CRC	gemcitabine-50mpk	103.4	27.5	84	-60.6	13.2
X-4145	CRC	gemcitabine-50mpk	87.6	26.5	88	-66.6	9.1
X-4145	CRC	gemcitabine-50mpk	81.8	28.5	91	-68.8	17.3
X-4145	CRC	INC424 + binimetinib	268.5	22.9	0	0	0
X-4145	CRC	INC424 + binimetinib	320.2	22.9	2	19.3	0
X-4145	CRC	INC424 + binimetinib	390.8	23.4	5	45.5	2.2
X-4145	CRC	INC424 + binimetinib	409.5	24.2	7	52.5	5.7
X-4145	CRC	INC424 + binimetinib	519.3	24.1	9	93.4	5.2
X-4145	CRC	INC424 + binimetinib	608	22	13	126.4	-3.9
X-4145	CRC	INC424 + binimetinib	592.9	22.6	15	120.8	-1.3
X-4145	CRC	INC424 + binimetinib	567.5	23.2	20	111.4	1.3
X-4145	CRC	INC424 + binimetinib	642.6	23.7	23	139.3	3.5
X-4145	CRC	INC424 + binimetinib	569.8	24	27	112.2	4.8
X-4145	CRC	INC424 + binimetinib	700.3	23.1	30	160.8	0.9
X-4145	CRC	INC424 + binimetinib	855.2	22.9	34	218.5	0
X-4145	CRC	INC424 + binimetinib	784.4	23.1	37	192.1	0.9
X-4145	CRC	INC424 + binimetinib	855.2	23.5	41	218.5	2.6
X-4145	CRC	INC424 + binimetinib	796.1	23.5	44	196.5	2.6
X-4145	CRC	INC424 + binimetinib	924.6	24	48	244.4	4.8
X-4145	CRC	INC424 + binimetinib	1030.4	24	51	283.8	4.8
X-4145	CRC	INC424 + binimetinib	906.7	23.7	55	237.7	3.5
X-4145	CRC	INC424 + binimetinib	931.2	23.7	58	246.8	3.5
X-4145	CRC	INC424 + binimetinib	1204.6	24	62	348.6	4.8
X-4145	CRC	INC424 + binimetinib	1192.3	24	65	344.1	4.8
X-4145	CRC	INC424 + binimetinib	1499.5	24.8	69	458.5	8.3
X-4145	CRC	INC424 + binimetinib	1833.3	25.5	76	582.8	11.4
X-4145	CRC	INC424 + binimetinib	1884.4	25	79	601.8	9.2
X-4145	CRC	INC424 + binimetinib	2090.5	25.1	83	678.6	9.6
X-4145	CRC	INC424 + binimetinib	1986.3	25.3	86	639.8	10.5
X-4145	CRC	INC424	257.3	23.1	0	0	0
X-4145	CRC	INC424	297.5	23.1	3	15.6	0
X-4145	CRC	INC424	394.1	23.1	7	53.2	0
X-4145	CRC	INC424	442.4	22.9	10	71.9	-0.9
X-4145	CRC	INC424	471	23.2	14	83.1	0.4
X-4145	CRC	INC424	516.2	23.8	17	100.6	3
X-4145	CRC	INC424	585.6	23.6	20	127.6	2.2
X-4145	CRC	INC424	587.2	28.8	23	128.2	24.7
X-4145	CRC	INC424	694.2	24.4	28	169.8	5.6
X-4145	CRC	INC424	810.9	24.5	31	215.2	6.1
X-4145	CRC	INC424	823	24.2	35	219.9	4.8
X-4145	CRC	INC424	859	24.3	38	233.9	5.2
X-4145	CRC	INC424	911.8	26.1	41	254.4	13
X-4145	CRC	LEE011	247.1	26.4	0	0	0
X-4145	CRC	LEE011	251.9	26.5	2	1.9	0.4
X-4145	CRC	LEE011	315.5	28.5	6	27.7	8
X-4145	CRC	LEE011	592.6	28.2	10	139.8	6.8
X-4145	CRC	LEE011	601.3	28.4	13	143.3	7.6
X-4145	CRC	LEE011	638.4	28.9	16	158.4	9.5
X-4145	CRC	LEE011	810.4	29	20	228	9.8
X-4145	CRC	LEE011	827.3	28.8	23	234.8	9.1
X-4145	CRC	LEE011	834	28.9	27	237.5	9.5
X-4145	CRC	LEE011	878.5	29.4	30	255.5	11.4
X-4145	CRC	LEE011	946.6	29.7	34	283.1	12.5
X-4145	CRC	WNT974	282.4	31.4	0	0	0
X-4145	CRC	WNT974	225.5	29.5	4	-20.1	-6.1
X-4145	CRC	WNT974	290.8	31.5	7	3	0.3
X-4145	CRC	WNT974	367.8	28.9	11	30.2	-8
X-4145	CRC	WNT974	366.5	28.1	14	29.8	-10.5
X-4145	CRC	WNT974	333.4	21.6	18	18.1	-31.2
X-4145	CRC	LKA136	202.7	24.5	0	0	0
X-4145	CRC	LKA136	254.1	23.1	3	25.4	-5.7
X-4145	CRC	LKA136	343.9	25	6	69.7	2
X-4145	CRC	LKA136	402.9	24.4	9	98.8	-0.4
X-4145	CRC	LKA136	494.9	25.4	13	144.2	3.7
X-4145	CRC	LKA136	599.3	25.9	16	195.7	5.7
X-4145	CRC	LKA136	656.8	24.3	20	224	-0.8
X-4145	CRC	LKA136	856.9	25.4	23	322.7	3.7
X-4145	CRC	LKA136	988	26.4	27	387.4	7.8
X-4145	CRC	LKA136	923	26.6	28	355.4	8.6
X-4145	CRC	binimetinib	231.8	23.8	0	0	0
X-4145	CRC	binimetinib	178.8	24.5	1	-22.9	2.9
X-4145	CRC	binimetinib	213.4	24.4	7	-7.9	2.5
X-4145	CRC	binimetinib	198	25.1	10	-14.6	5.5
X-4145	CRC	binimetinib	148.4	25	14	-36	5
X-4145	CRC	binimetinib	149.6	25.9	17	-35.5	8.8
X-4145	CRC	binimetinib	129.8	25.7	21	-44	8
X-4145	CRC	binimetinib	152.9	24.5	24	-34	2.9
X-4145	CRC	binimetinib	176.2	24.1	27	-24	1.3
X-4145	CRC	binimetinib	195.8	24.6	30	-15.5	3.4
X-4145	CRC	binimetinib	149.1	24.2	34	-35.7	1.7
X-4145	CRC	binimetinib	224.2	23.8	37	-3.3	0
X-4145	CRC	binimetinib	145.3	24.6	41	-37.3	3.4
X-4145	CRC	binimetinib	169.7	22.5	43	-26.8	-5.5
X-4145	CRC	binimetinib	188.7	22	48	-18.6	-7.6
X-4145	CRC	binimetinib	212.2	21.1	51	-8.5	-11.3
X-4145	CRC	binimetinib-3.5mpk	266.7	28.3	0	0	0
X-4145	CRC	binimetinib-3.5mpk	626.8	27.7	4	135	-2.1
X-4145	CRC	binimetinib-3.5mpk	518.4	28.2	7	94.4	-0.4
X-4145	CRC	binimetinib-3.5mpk	543.8	28	11	103.9	-1.1
X-4145	CRC	binimetinib-3.5mpk	499.9	28	14	87.4	-1.1
X-4145	CRC	binimetinib-3.5mpk	637.2	28.3	18	138.9	0
X-4145	CRC	binimetinib-3.5mpk	710.6	27.6	21	166.4	-2.5
X-4145	CRC	binimetinib-3.5mpk	664.7	28	25	149.2	-1.1
X-4145	CRC	binimetinib-3.5mpk	811.4	27.7	27	204.2	-2.1
X-4145	CRC	trametinib	219.3	29.3	0	0	0
X-4145	CRC	trametinib	452.7	29	4	106.4	-1
X-4145	CRC	trametinib	580.5	27.3	7	164.7	-6.8
X-4145	CRC	trametinib	492.2	28.4	12	124.4	-3.1
X-4145	CRC	trametinib	650.6	27.6	15	196.7	-5.8
X-4145	CRC	trametinib	638.7	27.3	19	191.2	-6.8
X-4145	CRC	trametinib	638.3	28.2	22	191.1	-3.8
X-4145	CRC	trametinib	745	27.8	25	239.7	-5.1
X-4145	CRC	trametinib	768.3	28	28	250.3	-4.4
X-4145	CRC	trametinib	809.2	26.1	33	269	-10.9
X-4145	CRC	trametinib	971.5	27.2	39	343	-7.2
X-4145	CRC	untreated	256.8	30	0	0	0
X-4145	CRC	untreated	375.7	29.6	3	46.3	-1.3
X-4145	CRC	untreated	562	31.3	7	118.8	4.3
X-4145	CRC	untreated	698	31.7	10	171.8	5.7
X-4145	CRC	untreated	757.9	31.9	14	195.1	6.3
X-4145	CRC	untreated	1056.5	31.9	17	311.4	6.3
X-4145	CRC	untreated	1140.3	31.6	21	344	5.3
X-4145	CRC	untreated	1391.1	32.5	24	441.7	8.3
X-4145	CRC	untreated	1463.7	NA	25	470	8.3
X-4157	CM	BKM120	204.8	21.5	0	0	0
X-4157	CM	BKM120	207.4	22.1	3	1.3	2.8
X-4157	CM	BKM120	219	22.1	6	7	2.8
X-4157	CM	BKM120	265.6	22	11	29.7	2.3
X-4157	CM	BKM120	295.9	21.4	14	44.5	-0.5
X-4157	CM	BKM120	336.5	21.1	17	64.3	-1.9
X-4157	CM	BKM120	328.7	20.7	20	60.5	-3.7
X-4157	CM	BKM120	332.8	21.2	25	62.5	-1.4
X-4157	CM	BKM120	340.2	21.6	28	66.1	0.5
X-4157	CM	BKM120 + encorafenib	198.5	26.4	0	0	0
X-4157	CM	BKM120 + encorafenib	206.7	25.4	3	4.1	-3.8
X-4157	CM	BKM120 + encorafenib	221.2	26.1	6	11.4	-1.1
X-4157	CM	BKM120 + encorafenib	223.8	26.1	9	12.8	-1.1
X-4157	CM	BKM120 + encorafenib	239.1	26.5	14	20.5	0.4
X-4157	CM	BKM120 + encorafenib	223.8	27.3	18	12.8	3.4
X-4157	CM	BKM120 + encorafenib	241.9	26.9	21	21.9	1.9
X-4157	CM	BKM120 + encorafenib	342.2	27	25	72.4	2.3
X-4157	CM	BKM120 + encorafenib	359.9	26.9	28	81.3	1.9
X-4157	CM	CGM097	210	20.8	0	0	0
X-4157	CM	CGM097	258.6	20.8	3	23.2	0
X-4157	CM	CGM097	288	21	6	37.2	1
X-4157	CM	CGM097	305.1	20.4	9	45.3	-1.9
X-4157	CM	CGM097	364.9	20.1	14	73.8	-3.4
X-4157	CM	CGM097	388.3	19.8	17	84.9	-4.8
X-4157	CM	CGM097	399.4	21.7	20	90.2	4.3
X-4157	CM	CGM097	532.5	19	23	153.6	-8.7
X-4157	CM	CGM097	550.5	19	28	162.2	-8.7
X-4157	CM	CLR457	190.8	24.7	0	0	0
X-4157	CM	CLR457	203.5	24.1	3	6.6	-2.4
X-4157	CM	CLR457	242.5	24.9	5	27.1	0.8
X-4157	CM	CLR457	308.3	24.1	8	61.6	-2.4
X-4157	CM	CLR457	345.6	24	11	81.2	-2.8
X-4157	CM	CLR457	399.6	24.2	14	109.4	-2
X-4157	CM	CLR457	397.4	23.6	17	108.3	-4.5
X-4157	CM	CLR457	404.6	23.8	20	112.1	-3.6
X-4157	CM	CLR457	477.9	23.1	24	150.5	-6.5
X-4157	CM	CLR457	461.7	23.8	28	142	-3.6
X-4157	CM	dacarbazine	210	26.8	0	0	0
X-4157	CM	dacarbazine	236.3	25.5	3	12.5	-4.9
X-4157	CM	dacarbazine	230	25.5	7	9.5	-4.9
X-4157	CM	dacarbazine	239.1	25.4	10	13.9	-5.2
X-4157	CM	dacarbazine	302.6	26	14	44.1	-3
X-4157	CM	dacarbazine	305.9	25.4	17	45.7	-5.2
X-4157	CM	dacarbazine	331.6	24.8	20	58	-7.5
X-4157	CM	dacarbazine	335.2	25.6	23	59.6	-4.5
X-4157	CM	dacarbazine	331.6	24.7	26	58	-7.8
X-4157	CM	dacarbazine	334.1	25	29	59.1	-6.7
X-4157	CM	LDE225	196	24	0	0	0
X-4157	CM	LDE225	196	22.5	4	0	-6.2
X-4157	CM	LDE225	215.6	20.6	9	10	-14.2
X-4157	CM	LDE225	243.7	20	12	24.3	-16.7
X-4157	CM	LDE225	257.4	20	13	31.3	-16.7
X-4157	CM	LDK378	188.5	23	0	0	0
X-4157	CM	LDK378	207.1	22.5	4	9.8	-2.2
X-4157	CM	LDK378	255.8	23.1	9	35.7	0.4
X-4157	CM	LDK378	269.1	22.6	12	42.7	-1.7
X-4157	CM	LDK378	279.8	22.4	15	48.4	-2.6
X-4157	CM	LDK378	314.2	22.6	18	66.7	-1.7
X-4157	CM	LDK378	320.2	23.2	23	69.8	0.9
X-4157	CM	LDK378	311.9	24	25	65.4	4.3
X-4157	CM	LDK378	334	23.3	28	77.2	1.3
X-4157	CM	LEE011	190.8	18.7	0	0	0
X-4157	CM	LEE011	202.3	18.2	2	6.1	-2.7
X-4157	CM	LEE011	220.5	18.9	5	15.6	1.1
X-4157	CM	LEE011	226.9	18.8	8	18.9	0.5
X-4157	CM	LEE011	246.4	19.3	13	29.2	3.2
X-4157	CM	LEE011	279.8	19.5	16	46.6	4.3
X-4157	CM	LEE011	309	20	19	62	7
X-4157	CM	LEE011	327.7	19.6	22	71.7	4.8
X-4157	CM	LEE011	389.2	20	27	104	7
X-4157	CM	LEE011	411.8	20.5	28	115.9	9.6
X-4157	CM	LEE011 + encorafenib	200.9	20.6	0	0	0
X-4157	CM	LEE011 + encorafenib	232.7	20.6	3	15.8	0
X-4157	CM	LEE011 + encorafenib	221.2	19.5	6	10.1	-5.3
X-4157	CM	LEE011 + encorafenib	295.9	20.9	11	47.3	1.5
X-4157	CM	LEE011 + encorafenib	280.9	19.8	15	39.8	-3.9
X-4157	CM	LEE011 + encorafenib	272.8	20	18	35.8	-2.9
X-4157	CM	LEE011 + encorafenib	335.2	20.2	22	66.8	-1.9
X-4157	CM	LEE011 + encorafenib	364.9	20.3	25	81.6	-1.5
X-4157	CM	LEE011 + encorafenib	509.9	19.8	28	153.8	-3.9
X-4157	CM	WNT974	198.5	20.2	0	0	0
X-4157	CM	WNT974	210.7	19.8	3	6.2	-2
X-4157	CM	WNT974	242.5	19.8	6	22.2	-2
X-4157	CM	WNT974	255.8	19	9	28.9	-5.9
X-4157	CM	WNT974	284.1	19	14	43.1	-5.9
X-4157	CM	WNT974	365.1	18.6	18	84	-7.9
X-4157	CM	WNT974	459.4	18.7	21	131.5	-7.4
X-4157	CM	WNT974	496.9	19.1	25	150.4	-5.4
X-4157	CM	WNT974	630	18.4	28	217.5	-8.9
X-4157	CM	LGW813	193	26.3	0	0	0
X-4157	CM	LGW813	172	25.5	3	-10.9	-3
X-4157	CM	LGW813	144	25.7	5	-25.4	-2.3
X-4157	CM	LGW813	144.7	24.6	8	-25.1	-6.5
X-4157	CM	LGW813	147.6	25.2	11	-23.5	-4.2
X-4157	CM	LGW813	162.7	26.6	14	-15.7	1.1
X-4157	CM	LGW813	221.8	25.5	17	14.9	-3
X-4157	CM	LGW813	226.9	26	20	17.5	-1.1
X-4157	CM	LGW813	221.4	25.8	24	14.7	-1.9
X-4157	CM	LGW813	236.9	26.4	28	22.7	0.4
X-4157	CM	LGW813	237.7	26.1	31	23.1	-0.8
X-4157	CM	LGW813	265.6	27.3	37	37.6	3.8
X-4157	CM	LGW813	299.4	27.2	44	55.1	3.4
X-4157	CM	LGW813	295.7	27.2	48	53.2	3.4
X-4157	CM	LGW813	322.5	27.8	52	67	5.7
X-4157	CM	LGW813	347.7	26.9	58	80.1	2.3
X-4157	CM	LGW813	328.5	26.7	62	70.2	1.5
X-4157	CM	LGW813	356.4	27.5	65	84.6	4.6
X-4157	CM	LGW813	404.6	27.5	69	109.6	4.6
X-4157	CM	LGW813	425.3	28.1	72	120.3	6.8
X-4157	CM	LGW813	499.4	28.6	75	158.7	8.7
X-4157	CM	LGW813	506	28	79	162.1	6.5
X-4157	CM	LGW813	521.3	27.4	83	170.1	4.2
X-4157	CM	LGW813	521.3	27.2	87	170.1	3.4
X-4157	CM	LGW813	532.5	28.5	94	175.9	8.4
X-4157	CM	LGW813	620.6	28.1	98	221.5	6.8
X-4157	CM	LGW813	627.3	27.5	102	225	4.6
X-4157	CM	LGW813	645	27.8	105	234.1	5.7
X-4157	CM	encorafenib	190.8	20.9	0	0	0
X-4157	CM	encorafenib	201.1	21	2	5.4	0.5
X-4157	CM	encorafenib	227.9	20.9	5	19.4	0
X-4157	CM	encorafenib	237.7	20.5	8	24.6	-1.9
X-4157	CM	encorafenib	272.2	21	13	42.7	0.5
X-4157	CM	encorafenib	320.2	20.1	17	67.8	-3.8
X-4157	CM	encorafenib	393.4	20.6	20	106.2	-1.4
X-4157	CM	encorafenib	466	20.1	23	144.2	-3.8
X-4157	CM	encorafenib	567.1	20	28	197.2	-4.3
X-4157	CM	encorafenib + binimetinib	202.2	22.9	0	0	0
X-4157	CM	encorafenib + binimetinib	207.8	23.1	5	2.8	0.9
X-4157	CM	encorafenib + binimetinib	210.5	24.3	9	4.1	6.1
X-4157	CM	encorafenib + binimetinib	175.1	23.6	12	-13.4	3.1
X-4157	CM	encorafenib + binimetinib	134.5	24.4	16	-33.5	6.6
X-4157	CM	encorafenib + binimetinib	196	23.6	19	-3.1	3.1
X-4157	CM	encorafenib + binimetinib	185.7	23.3	22	-8.2	1.7
X-4157	CM	encorafenib + binimetinib	175.7	24.3	25	-13.1	6.1
X-4157	CM	encorafenib + binimetinib	201.6	23.7	28	-0.3	3.5
X-4157	CM	encorafenib + binimetinib	212.5	23.7	31	5.1	3.5
X-4157	CM	encorafenib + binimetinib	200	24.2	35	-1.1	5.7
X-4157	CM	encorafenib + binimetinib	179.6	24.5	40	-11.2	7
X-4157	CM	encorafenib + binimetinib	204.7	23.7	43	1.3	3.5
X-4157	CM	encorafenib + binimetinib	300.8	24.3	49	48.8	6.1
X-4157	CM	encorafenib + binimetinib	297.6	25.4	56	47.2	10.9
X-4157	CM	encorafenib + binimetinib	344.4	25.1	60	70.3	9.6
X-4157	CM	encorafenib + binimetinib	370.9	24.5	64	83.4	7
X-4157	CM	encorafenib + binimetinib	448.6	25	70	121.9	9.2
X-4157	CM	encorafenib + binimetinib	410.4	25.9	74	103	13.1
X-4157	CM	encorafenib + binimetinib	435.7	25.6	81	115.5	11.8
X-4157	CM	encorafenib + binimetinib	590	26.2	84	191.8	14.4
X-4157	CM	encorafenib + binimetinib	585	25.7	87	189.3	12.2
X-4157	CM	binimetinib	187.3	24.8	0	0	0
X-4157	CM	binimetinib	198.8	23.8	2	6.2	-4
X-4157	CM	binimetinib	231.8	25	5	23.8	0.8
X-4157	CM	binimetinib	205.8	24.8	8	9.9	0
X-4157	CM	binimetinib	239.8	25.3	13	28	2
X-4157	CM	binimetinib	246.4	25.9	16	31.6	4.4
X-4157	CM	binimetinib	237.1	25.8	19	26.6	4
X-4157	CM	binimetinib	222.9	25.6	22	19	3.2
X-4157	CM	binimetinib	214.2	26.5	27	14.4	6.9
X-4157	CM	binimetinib	209.2	26.7	30	11.7	7.7
X-4157	CM	binimetinib	266.8	26.3	33	42.4	6
X-4157	CM	binimetinib	269.8	26.8	37	44	8.1
X-4157	CM	binimetinib	291.2	26.7	40	55.5	7.7
X-4157	CM	binimetinib	280.9	26.8	43	49.9	8.1
X-4157	CM	binimetinib	284	27	46	51.6	8.9
X-4157	CM	binimetinib	244.7	27	49	30.6	8.9
X-4157	CM	binimetinib	219	26.8	52	16.9	8.1
X-4157	CM	binimetinib	195.2	26.7	56	4.2	7.7
X-4157	CM	binimetinib	159.7	26.8	60	-14.7	8.1
X-4157	CM	binimetinib	203.4	26.2	63	8.6	5.6
X-4157	CM	binimetinib	241.9	26.4	69	29.1	6.5
X-4157	CM	binimetinib	240.9	25.6	77	28.6	3.2
X-4157	CM	binimetinib	277.3	26.2	81	48	5.6
X-4157	CM	binimetinib	307.2	26.5	85	64	6.9
X-4157	CM	binimetinib	413.1	27.4	91	120.5	10.5
X-4157	CM	binimetinib	410.4	26.8	95	119.1	8.1
X-4157	CM	binimetinib	419.8	27.1	98	124.1	9.3
X-4157	CM	binimetinib	427.7	26.6	102	128.4	7.3
X-4157	CM	binimetinib	457.7	27	105	144.3	8.9
X-4157	CM	binimetinib	461.7	27.7	108	146.5	11.7
X-4157	CM	TAS266	204.2	22.4	0	0	0
X-4157	CM	TAS266	206.7	22.6	3	1.2	0.9
X-4157	CM	TAS266	232.7	23	6	14	2.7
X-4157	CM	TAS266	250.3	23.1	9	22.6	3.1
X-4157	CM	TAS266	379.3	23.6	14	85.8	5.4
X-4157	CM	TAS266	414.3	23.5	17	102.9	4.9
X-4157	CM	TAS266	496.9	23.9	20	143.4	6.7
X-4157	CM	TAS266	581	23.4	23	184.6	4.5
X-4157	CM	TAS266	751.7	24	28	268.2	7.1
X-4157	CM	untreated	201.6	23.4	0	0	0
X-4157	CM	untreated	238.5	23	3	18.3	-1.7
X-4157	CM	untreated	276.5	23.5	6	37.1	0.4
X-4157	CM	untreated	337.9	23.1	9	67.6	-1.3
X-4157	CM	untreated	486.7	23	14	141.4	-1.7
X-4157	CM	untreated	627.4	21.9	17	211.1	-6.4
X-4157	CM	untreated	685	23.6	20	239.7	0.9
X-4157	CM	untreated	729.4	20.7	23	261.7	-11.5
X-4157	CM	untreated	931.7	20.4	28	362.1	-12.8
X-4226	PDAC	abraxane	240.3	26.9	0	0	0
X-4226	PDAC	abraxane	256.3	26	2	6.7	-3.3
X-4226	PDAC	abraxane	464.2	26.5	6	93.2	-1.5
X-4226	PDAC	abraxane	550.1	28.3	9	128.9	5.2
X-4226	PDAC	abraxane	594.6	29	14	147.4	7.8
X-4226	PDAC	abraxane	908.7	28.7	20	278.2	6.7
X-4226	PDAC	abraxane	1098.9	28.3	24	357.3	5.2
X-4226	PDAC	abraxane	1417.4	28.2	27	489.8	4.8
X-4226	PDAC	BKM120 + binimetinib	217.7	25.9	0	0	0
X-4226	PDAC	BKM120 + binimetinib	266	27.7	4	22.2	6.9
X-4226	PDAC	BKM120 + binimetinib	198.3	27.3	11	-8.9	5.4
X-4226	PDAC	BKM120 + binimetinib	207.6	27.6	14	-4.6	6.6
X-4226	PDAC	BKM120 + binimetinib	223.7	27.7	18	2.8	6.9
X-4226	PDAC	BKM120 + binimetinib	217.3	27.9	21	-0.2	7.7
X-4226	PDAC	BKM120 + binimetinib	214.3	26.5	25	-1.6	2.3
X-4226	PDAC	BKM120 + binimetinib	251.6	27.9	28	15.6	7.7
X-4226	PDAC	BKM120 + binimetinib	188	26.3	32	-13.6	1.5
X-4226	PDAC	BKM120 + binimetinib	179.7	26.6	34	-17.5	2.7
X-4226	PDAC	BKM120 + binimetinib	183.5	27.3	40	-15.7	5.4
X-4226	PDAC	BKM120 + binimetinib	259	28.3	46	19	9.3
X-4226	PDAC	BKM120 + binimetinib	181.8	28.4	49	-16.5	9.7
X-4226	PDAC	BKM120 + binimetinib	209.3	28.6	52	-3.9	10.4
X-4226	PDAC	BKM120 + binimetinib	266.8	27.6	55	22.6	6.6
X-4226	PDAC	BKM120 + binimetinib	301.7	27.9	60	38.6	7.7
X-4226	PDAC	BKM120 + binimetinib	247.5	28	62	13.7	8.1
X-4226	PDAC	BKM120 + binimetinib	330.3	28.2	66	51.7	8.9
X-4226	PDAC	BKM120 + binimetinib	334.3	28.3	69	53.6	9.3
X-4226	PDAC	BKM120 + binimetinib	550.7	28	74	153	8.1
X-4226	PDAC	BKM120 + binimetinib	549.5	27.8	81	152.4	7.3
X-4226	PDAC	BKM120 + binimetinib	445.4	28.1	84	104.6	8.5
X-4226	PDAC	BKM120 + binimetinib	535.1	27.1	88	145.8	4.6
X-4226	PDAC	BKM120 + binimetinib	376.9	27	91	73.1	4.2
X-4226	PDAC	BKM120 + binimetinib	458.6	27.3	94	110.7	5.4
X-4226	PDAC	BKM120 + binimetinib	522.6	25.6	102	140.1	-1.2
X-4226	PDAC	BKM120 + binimetinib	640.5	25.9	104	194.2	0
X-4226	PDAC	BKM120 + binimetinib	1009.6	27.4	109	363.8	5.8
X-4226	PDAC	BKM120 + binimetinib	720	26.5	112	230.7	2.3
X-4226	PDAC	BKM120 + binimetinib	494.8	26.4	116	127.3	1.9
X-4226	PDAC	BKM120 + binimetinib	713.9	26.4	119	227.9	1.9
X-4226	PDAC	BKM120 + binimetinib	868.5	27.3	122	298.9	5.4
X-4226	PDAC	BKM120 + LDE225	234.4	24.4	0	0	0
X-4226	PDAC	BKM120 + LDE225	190	24.1	3	-18.9	-1.2
X-4226	PDAC	BKM120 + LDE225	199.2	23.3	11	-15	-4.5
X-4226	PDAC	BKM120 + LDE225	162.5	22.7	13	-30.7	-7
X-4226	PDAC	BKM120 + LDE225	179	24.9	18	-23.6	2
X-4226	PDAC	BKM120 + LDE225	248.6	23.8	21	6.1	-2.5
X-4226	PDAC	BKM120 + LDE225	245.8	23.4	25	4.9	-4.1
X-4226	PDAC	BKM120 + LDE225	252.6	22.7	28	7.8	-7
X-4226	PDAC	BKM120 + LDE225	267.3	24.2	31	14	-0.8
X-4226	PDAC	BKM120 + LDE225	290.8	22.6	35	24.1	-7.4
X-4226	PDAC	BKM120 + LDE225	384.7	23.3	39	64.1	-4.5
X-4226	PDAC	BKM120 + LDE225	353.1	23.8	41	50.6	-2.5
X-4226	PDAC	BKM120 + LDE225	256.6	23.6	46	9.5	-3.3
X-4226	PDAC	BKM120 + LDE225	195.4	23.8	53	-16.6	-2.5
X-4226	PDAC	BKM120 + LDE225	255	23.1	60	8.8	-5.3
X-4226	PDAC	BKM120 + LDE225	314.2	23.1	63	34	-5.3
X-4226	PDAC	BKM120 + LDE225	355.2	23.1	68	51.5	-5.3
X-4226	PDAC	BKM120 + LDE225	383	22.7	70	63.4	-7
X-4226	PDAC	BKM120 + LDE225	309.1	20.3	74	31.9	-16.8
X-4226	PDAC	BKM120 + LDE225	252.3	20.1	77	7.6	-17.6
X-4226	PDAC	BKM120 + LDE225	227.9	16.9	81	-2.8	-30.7
X-4226	PDAC	BKM120	265.5	27.6	0	0	0
X-4226	PDAC	BKM120	289.3	28.3	3	9	2.5
X-4226	PDAC	BKM120	354.1	28.5	8	33.4	3.3
X-4226	PDAC	BKM120	313.2	27.9	10	18	1.1
X-4226	PDAC	BKM120	326.8	28.2	13	23.1	2.2
X-4226	PDAC	BKM120	208.1	28.2	16	-21.6	2.2
X-4226	PDAC	BKM120	356.7	27.9	21	34.4	1.1
X-4226	PDAC	BKM120	337.2	27.8	24	27	0.7
X-4226	PDAC	BKM120	520.5	28.4	28	96	2.9
X-4226	PDAC	BKM120	467.1	28.1	31	75.9	1.8
X-4226	PDAC	BKM120	470.1	28.7	34	77.1	4
X-4226	PDAC	BKM120	550.4	28.2	37	107.3	2.2
X-4226	PDAC	BKM120	463	29.1	41	74.4	5.4
X-4226	PDAC	BKM120	639.6	27.5	44	140.9	-0.4
X-4226	PDAC	BYL719 + LJM716	247.6	26.1	0	0	0
X-4226	PDAC	BYL719 + LJM716	257.7	27.8	3	4.1	6.5
X-4226	PDAC	BYL719 + LJM716	289.6	27.5	7	17	5.4
X-4226	PDAC	BYL719 + LJM716	318.3	27.1	10	28.6	3.8
X-4226	PDAC	BYL719 + LJM716	310	28.2	14	25.2	8
X-4226	PDAC	BYL719 + LJM716	333.1	27.5	17	34.5	5.4
X-4226	PDAC	BYL719 + LJM716	367.9	27.5	21	48.6	5.4
X-4226	PDAC	BYL719 + LJM716	386.8	28	24	56.2	7.3
X-4226	PDAC	BYL719 + LJM716	355.8	26.3	29	43.7	0.8
X-4226	PDAC	BYL719 + LJM716	400.7	26	32	61.8	-0.4
X-4226	PDAC	BYL719 + LJM716	399.1	26.6	35	61.2	1.9
X-4226	PDAC	BYL719 + LJM716	416.4	27.2	38	68.2	4.2
X-4226	PDAC	BYL719 + LJM716	428.2	26	42	72.9	-0.4
X-4226	PDAC	BYL719 + LJM716	558.5	25.8	45	125.6	-1.1
X-4226	PDAC	BYL719 + LJM716	687.3	27.1	49	177.6	3.8
X-4226	PDAC	BYL719 + LJM716	870	26.5	53	251.4	1.5
X-4226	PDAC	BYL719 + LJM716	918.6	26.1	56	271	0
X-4226	PDAC	BYL719 + LJM716	987	26.5	59	298.6	1.5
X-4226	PDAC	BYL719 + LJM716	1055.9	27.1	63	326.5	3.8
X-4226	PDAC	BYL719	200.9	27.4	0	0	0
X-4226	PDAC	BYL719	197.2	27.1	3	-1.8	-1.1
X-4226	PDAC	BYL719	194.5	27.2	7	-3.2	-0.7
X-4226	PDAC	BYL719	202.2	26.9	10	0.6	-1.8
X-4226	PDAC	BYL719	198.8	26.3	14	-1	-4
X-4226	PDAC	BYL719	211.1	26.8	17	5.1	-2.2
X-4226	PDAC	BYL719	230.3	27.6	21	14.6	0.7
X-4226	PDAC	BYL719	266.2	26.7	24	32.5	-2.6
X-4226	PDAC	BYL719	280.8	25.3	29	39.8	-7.7
X-4226	PDAC	BYL719	272.7	24.4	32	35.7	-10.9
X-4226	PDAC	BYL719	257	25.1	35	27.9	-8.4
X-4226	PDAC	BYL719	261.6	26.9	38	30.2	-1.8
X-4226	PDAC	BYL719	287.7	26.2	42	43.2	-4.4
X-4226	PDAC	BYL719	354.5	27.2	45	76.5	-0.7
X-4226	PDAC	BYL719	369.1	27.4	49	83.7	0
X-4226	PDAC	BYL719	426.4	27.5	53	112.2	0.4
X-4226	PDAC	BYL719	452.8	27.5	56	125.4	0.4
X-4226	PDAC	BYL719	486.6	28	59	142.2	2.2
X-4226	PDAC	BYL719	487.6	27.6	63	142.7	0.7
X-4226	PDAC	BYL719	492.6	28.4	66	145.2	3.6
X-4226	PDAC	BYL719	511.6	26.5	70	154.7	-3.3
X-4226	PDAC	BYL719	571.1	27.3	73	184.3	-0.4
X-4226	PDAC	BYL719	575.1	25.9	77	186.3	-5.5
X-4226	PDAC	BYL719	664.5	27.9	80	230.8	1.8
X-4226	PDAC	BYL719	728.5	27.1	85	262.6	-1.1
X-4226	PDAC	BYL719	765.9	27.9	88	281.2	1.8
X-4226	PDAC	BYL719	797.4	28.7	91	296.9	4.7
X-4226	PDAC	CLR457	223.2	25.3	0	0	0
X-4226	PDAC	CLR457	226.2	26.4	3	1.3	4.3
X-4226	PDAC	CLR457	237.2	26.6	7	6.3	5.1
X-4226	PDAC	CLR457	274.8	26.1	10	23.1	3.2
X-4226	PDAC	CLR457	300.5	26.1	14	34.6	3.2
X-4226	PDAC	CLR457	343.8	25.6	17	54	1.2
X-4226	PDAC	CLR457	368.2	25.7	22	65	1.6
X-4226	PDAC	CLR457	381.3	25.7	25	70.8	1.6
X-4226	PDAC	CLR457	417.7	24.6	28	87.1	-2.8
X-4226	PDAC	CLR457	443.9	25	31	98.9	-1.2
X-4226	PDAC	CLR457	457.9	24.2	35	105.2	-4.3
X-4226	PDAC	CLR457	477.3	24.6	38	113.8	-2.8
X-4226	PDAC	CLR457	535.1	24.7	42	139.7	-2.4
X-4226	PDAC	CLR457	544.6	24.8	46	144	-2
X-4226	PDAC	CLR457	643.2	25	49	188.2	-1.2
X-4226	PDAC	CLR457	669.6	25.5	52	200	0.8
X-4226	PDAC	CLR457	682.9	25.2	56	206	-0.4
X-4226	PDAC	CLR457	767.1	25.6	59	243.7	1.2
X-4226	PDAC	CLR457	812.6	24	63	264.1	-5.1
X-4226	PDAC	CLR457	839	25.6	66	275.9	1.2
X-4226	PDAC	CLR457	905.7	25.9	70	305.8	2.4
X-4226	PDAC	CLR457	956.5	25.5	73	328.5	0.8
X-4226	PDAC	HDM201	249.6	27.6	0	0	0
X-4226	PDAC	HDM201	311.3	27.4	2	24.7	-0.7
X-4226	PDAC	HDM201	373.5	28.8	5	49.6	4.3
X-4226	PDAC	HDM201	513.1	28.5	8	105.6	3.3
X-4226	PDAC	HDM201	552.6	28.5	12	121.4	3.3
X-4226	PDAC	HDM201	805.2	28.4	15	222.6	2.9
X-4226	PDAC	HDM201	899.7	28.5	20	260.5	3.3
X-4226	PDAC	HDM201	1072.7	27.9	23	329.8	1.1
X-4226	PDAC	HDM201	1133	28	26	353.9	1.4
X-4226	PDAC	HDM201	1269.4	28.1	29	408.6	1.8
X-4226	PDAC	HDM201	1404.8	27	33	462.8	-2.2
X-4226	PDAC	figitumumab" + binimetinib	241.8	27	0	0	0
X-4226	PDAC	figitumumab" + binimetinib	442	26.6	4	82.8	-1.5
X-4226	PDAC	figitumumab" + binimetinib	512.3	27.5	7	111.9	1.9
X-4226	PDAC	figitumumab" + binimetinib	620.6	25.9	11	156.7	-4.1
X-4226	PDAC	figitumumab" + binimetinib	616.6	26.1	14	155	-3.3
X-4226	PDAC	figitumumab" + binimetinib	583.1	26.2	18	141.1	-3
X-4226	PDAC	figitumumab" + binimetinib	583.1	26.5	21	141.1	-1.9
X-4226	PDAC	figitumumab" + binimetinib	671.1	26	25	177.5	-3.7
X-4226	PDAC	figitumumab" + binimetinib	834.7	25.9	28	245.2	-4.1
X-4226	PDAC	figitumumab"	209.2	26.5	0	0	0
X-4226	PDAC	figitumumab"	186.6	29.4	6	-10.8	10.9
X-4226	PDAC	figitumumab"	219.2	28.1	12	4.8	6
X-4226	PDAC	figitumumab"	278.3	28.3	15	33	6.8
X-4226	PDAC	figitumumab"	423	28.6	19	102.2	7.9
X-4226	PDAC	figitumumab"	389	27.3	22	85.9	3
X-4226	PDAC	figitumumab"	332	28.8	26	58.7	8.7
X-4226	PDAC	figitumumab"	465.2	28.6	29	122.4	7.9
X-4226	PDAC	figitumumab"	528.6	28.4	33	152.7	7.2
X-4226	PDAC	figitumumab"	763.6	29.1	36	265	9.8
X-4226	PDAC	gemcitabine-50mpk	252.6	23.9	0	0	0
X-4226	PDAC	gemcitabine-50mpk	291.7	23.3	2	15.5	-2.5
X-4226	PDAC	gemcitabine-50mpk	374.2	23	7	48.1	-3.8
X-4226	PDAC	gemcitabine-50mpk	367.3	22.1	10	45.4	-7.5
X-4226	PDAC	gemcitabine-50mpk	365.9	20.9	14	44.9	-12.6
X-4226	PDAC	gemcitabine-50mpk	364.9	20.8	17	44.5	-13
X-4226	PDAC	INC424 + binimetinib	275	25.9	0	0	0
X-4226	PDAC	INC424 + binimetinib	312.6	25.6	2	13.7	-1.2
X-4226	PDAC	INC424 + binimetinib	349.1	26.2	5	26.9	1.2
X-4226	PDAC	INC424 + binimetinib	282.8	27.4	7	2.8	5.8
X-4226	PDAC	INC424 + binimetinib	282.8	27.2	9	2.8	5
X-4226	PDAC	INC424 + binimetinib	291.2	25.5	13	5.9	-1.5
X-4226	PDAC	INC424 + binimetinib	236.2	25.4	15	-14.1	-1.9
X-4226	PDAC	INC424 + binimetinib	226.5	26	20	-17.6	0.4
X-4226	PDAC	INC424 + binimetinib	320.2	26.2	23	16.4	1.2
X-4226	PDAC	INC424 + binimetinib	259	27.4	27	-5.8	5.8
X-4226	PDAC	INC424 + binimetinib	289.8	25.7	30	5.4	-0.8
X-4226	PDAC	INC424 + binimetinib	320.7	25.8	34	16.6	-0.4
X-4226	PDAC	INC424 + binimetinib	288.7	25.2	37	5	-2.7
X-4226	PDAC	INC424 + binimetinib	255.7	25.5	41	-7	-1.5
X-4226	PDAC	INC424 + binimetinib	276.9	26.1	44	0.7	0.8
X-4226	PDAC	INC424 + binimetinib	310.6	26.5	48	12.9	2.3
X-4226	PDAC	INC424 + binimetinib	283.5	25.9	51	3.1	0
X-4226	PDAC	INC424 + binimetinib	274.7	26	55	-0.1	0.4
X-4226	PDAC	INC424 + binimetinib	318.9	25.5	58	16	-1.5
X-4226	PDAC	INC424 + binimetinib	389.2	25.9	62	41.5	0
X-4226	PDAC	INC424 + binimetinib	667.3	25.1	65	142.7	-3.1
X-4226	PDAC	INC424 + binimetinib	661	25.8	69	140.4	-0.4
X-4226	PDAC	INC424 + binimetinib	695.5	25	79	152.9	-3.5
X-4226	PDAC	INC424 + binimetinib	778.3	25.1	83	183	-3.1
X-4226	PDAC	INC424 + binimetinib	404.1	25.4	86	46.9	-1.9
X-4226	PDAC	INC424 + binimetinib	395.9	25.2	90	44	-2.7
X-4226	PDAC	INC424 + binimetinib	403.8	24.4	92	46.8	-5.8
X-4226	PDAC	INC424 + binimetinib	484.2	25.4	97	76.1	-1.9
X-4226	PDAC	INC424 + binimetinib	452.2	26	99	64.4	0.4
X-4226	PDAC	INC424	235.7	28.2	0	0	0
X-4226	PDAC	INC424	240.8	26.8	5	2.2	-5
X-4226	PDAC	INC424	275.3	27.9	8	16.8	-1.1
X-4226	PDAC	INC424	375.7	29.1	12	59.4	3.2
X-4226	PDAC	INC424	414.6	27.7	15	75.9	-1.8
X-4226	PDAC	INC424	432	28.7	20	83.3	1.8
X-4226	PDAC	INC424	453.6	29.4	23	92.4	4.3
X-4226	PDAC	INC424	471.6	29.1	26	100.1	3.2
X-4226	PDAC	INC424	485.1	29.7	29	105.8	5.3
X-4226	PDAC	INC424	488.7	28.5	33	107.3	1.1
X-4226	PDAC	INC424	503	27.8	36	113.4	-1.4
X-4226	PDAC	INC424	554.9	28.5	40	135.4	1.1
X-4226	PDAC	INC424	584.3	26.4	44	147.9	-6.4
X-4226	PDAC	INC424	692.3	27.4	47	193.7	-2.8
X-4226	PDAC	INC424	701.8	28.4	50	197.8	0.7
X-4226	PDAC	INC424	779.9	28.3	54	230.9	0.4
X-4226	PDAC	INC424	789.2	29.4	57	234.8	4.3
X-4226	PDAC	INC424	786.6	28.4	61	233.7	0.7
X-4226	PDAC	INC424	848.8	27.7	64	260.1	-1.8
X-4226	PDAC	INC424	987.2	27.5	68	318.8	-2.5
X-4226	PDAC	INC424	1055.4	27.7	71	347.8	-1.8
X-4226	PDAC	LEE011	243	29.6	0	0	0
X-4226	PDAC	LEE011	402.1	29.5	6	65.5	-0.3
X-4226	PDAC	LEE011	463.6	29.3	9	90.8	-1
X-4226	PDAC	LEE011	462.9	30.4	12	90.5	2.7
X-4226	PDAC	LEE011	628.1	30.1	15	158.5	1.7
X-4226	PDAC	LEE011	614	30.2	19	152.7	2
X-4226	PDAC	LEE011	672.1	29.9	22	176.6	1
X-4226	PDAC	LEE011	736.9	30.8	26	203.3	4.1
X-4226	PDAC	LEE011	953.1	31.5	29	292.2	6.4
X-4226	PDAC	WNT974	280.2	27.2	0	0	0
X-4226	PDAC	WNT974	381.8	26.6	2	36.3	-2.2
X-4226	PDAC	WNT974	372.6	25.9	5	33	-4.8
X-4226	PDAC	WNT974	500.2	25	9	78.5	-8.1
X-4226	PDAC	WNT974	637.7	25.4	13	127.6	-6.6
X-4226	PDAC	WNT974	750.7	24.6	16	167.9	-9.6
X-4226	PDAC	WNT974	912.4	25	19	225.6	-8.1
X-4226	PDAC	WNT974	1046	25.8	21	273.3	-5.1
X-4226	PDAC	WNT974	1049.3	24.6	22	274.5	-9.6
X-4226	PDAC	LKA136	229.8	26.4	0	0	0
X-4226	PDAC	LKA136	265.9	26.7	2	15.7	1.1
X-4226	PDAC	LKA136	299.6	25.9	6	30.4	-1.9
X-4226	PDAC	LKA136	328.9	24.4	10	43.1	-7.6
X-4226	PDAC	LKA136	378.8	23	13	64.8	-12.9
X-4226	PDAC	LKA136	354.7	25.2	16	54.4	-4.5
X-4226	PDAC	LKA136	366.4	25.2	20	59.4	-4.5
X-4226	PDAC	LKA136	371.4	24.3	23	61.6	-8
X-4226	PDAC	LKA136	568.9	25	28	147.6	-5.3
X-4226	PDAC	LKA136	599.5	24.1	31	160.9	-8.7
X-4226	PDAC	LKA136	559.7	22.6	34	143.6	-14.4
X-4226	PDAC	LKA136	605.2	22.8	36	163.4	-13.6
X-4226	PDAC	binimetinib	204.5	23.6	0	0	0
X-4226	PDAC	binimetinib	242.7	22.8	5	18.7	-3.4
X-4226	PDAC	binimetinib	208.7	22.4	7	2.1	-5.1
X-4226	PDAC	binimetinib	269.7	22	10	31.9	-6.8
X-4226	PDAC	binimetinib	154.1	23.3	12	-24.6	-1.3
X-4226	PDAC	binimetinib	206.3	23.2	14	0.9	-1.7
X-4226	PDAC	binimetinib	203	22	18	-0.7	-6.8
X-4226	PDAC	binimetinib	143.6	21.2	20	-29.8	-10.2
X-4226	PDAC	binimetinib	172	21.4	25	-15.9	-9.3
X-4226	PDAC	binimetinib	142.5	21.8	28	-30.3	-7.6
X-4226	PDAC	binimetinib	184.6	20.6	32	-9.7	-12.7
X-4226	PDAC	binimetinib	177.4	19.6	35	-13.3	-16.9
X-4226	PDAC	binimetinib-3.5mpk	252.6	27	0	0	0
X-4226	PDAC	binimetinib-3.5mpk	340.4	26.9	3	34.8	-0.4
X-4226	PDAC	binimetinib-3.5mpk	440	27.6	8	74.2	2.2
X-4226	PDAC	binimetinib-3.5mpk	335.9	27.5	10	33	1.9
X-4226	PDAC	binimetinib-3.5mpk	364.4	27.8	13	44.3	3
X-4226	PDAC	binimetinib-3.5mpk	363.2	28.3	16	43.8	4.8
X-4226	PDAC	binimetinib-3.5mpk	384	27.1	21	52	0.4
X-4226	PDAC	binimetinib-3.5mpk	416.9	26.6	24	65	-1.5
X-4226	PDAC	binimetinib-3.5mpk	512.3	27	28	102.8	0
X-4226	PDAC	binimetinib-3.5mpk	527	26.3	31	108.6	-2.6
X-4226	PDAC	binimetinib-3.5mpk	731.2	27.8	34	189.5	3
X-4226	PDAC	trametinib	263.2	28.3	0	0	0
X-4226	PDAC	trametinib	207	29.1	4	-21.4	2.8
X-4226	PDAC	trametinib	299.8	28.7	7	13.9	1.4
X-4226	PDAC	trametinib	243.6	30.3	11	-7.4	7.1
X-4226	PDAC	trametinib	318.7	29.1	14	21.1	2.8
X-4226	PDAC	trametinib	263.2	28.9	18	0	2.1
X-4226	PDAC	trametinib	297.1	29.2	21	12.9	3.2
X-4226	PDAC	trametinib	330.7	29.5	25	25.6	4.2
X-4226	PDAC	trametinib	477.8	29.1	27	81.5	2.8
X-4226	PDAC	trametinib	548.1	28.8	31	108.2	1.8
X-4226	PDAC	trametinib	529.3	28.4	34	101.1	0.4
X-4226	PDAC	trametinib	684.8	29.6	38	160.2	4.6
X-4226	PDAC	trametinib	712.9	29.4	41	170.9	3.9
X-4226	PDAC	trametinib	775.1	29.1	45	194.5	2.8
X-4226	PDAC	trametinib	828.9	28.5	48	214.9	0.7
X-4226	PDAC	untreated	278.1	22.2	0	0	0
X-4226	PDAC	untreated	316.5	22.3	3	13.8	0.5
X-4226	PDAC	untreated	322.5	22.8	6	16	2.7
X-4226	PDAC	untreated	420.6	22.3	10	51.2	0.5
X-4226	PDAC	untreated	448.8	22	13	61.4	-0.9
X-4226	PDAC	untreated	487.8	22.7	17	75.4	2.3
X-4226	PDAC	untreated	557	23	19	100.3	3.6
X-4226	PDAC	untreated	511	23.2	24	83.7	4.5
X-4226	PDAC	untreated	598	22.5	28	115	1.4
X-4226	PDAC	untreated	690.9	24	31	148.4	8.1
X-4226	PDAC	untreated	624.1	NA	33	124.4	8.1
X-4226	PDAC	untreated	765	22.9	35	175.1	3.2
X-4226	PDAC	untreated	717	23.7	39	157.8	6.8
X-4226	PDAC	untreated	980.1	22.7	40	252.4	2.3
X-4316	PDAC	abraxane	227.3	24.8	0	0	0
X-4316	PDAC	abraxane	308.3	25.7	5	35.6	3.6
X-4316	PDAC	abraxane	360	25.6	8	58.4	3.2
X-4316	PDAC	abraxane	332.2	26.5	12	46.2	6.9
X-4316	PDAC	abraxane	423.2	26.4	15	86.2	6.5
X-4316	PDAC	abraxane	503.6	26.2	19	121.6	5.6
X-4316	PDAC	abraxane	505.1	25.5	22	122.2	2.8
X-4316	PDAC	abraxane	545.2	26	26	139.9	4.8
X-4316	PDAC	abraxane	576.2	26.1	29	153.5	5.2
X-4316	PDAC	abraxane	737.2	26.8	33	224.3	8.1
X-4316	PDAC	abraxane	671.4	25.4	36	195.4	2.4
X-4316	PDAC	abraxane	719.5	27	40	216.5	8.9
X-4316	PDAC	abraxane	779.6	25.3	43	243	2
X-4316	PDAC	abraxane	784.3	25.9	47	245.1	4.4
X-4316	PDAC	abraxane	866	27	50	281	8.9
X-4316	PDAC	abraxane	936.5	26.4	54	312	6.5
X-4316	PDAC	BKM120 + LDE225	224.4	26.9	0	0	0
X-4316	PDAC	BKM120 + LDE225	236.7	26.7	1	5.5	-0.7
X-4316	PDAC	BKM120 + LDE225	164	25.8	4	-26.9	-4.1
X-4316	PDAC	BKM120 + LDE225	184.7	26.3	8	-17.7	-2.2
X-4316	PDAC	BKM120 + LDE225	223.8	26.9	11	-0.3	0
X-4316	PDAC	BKM120 + LDE225	179	25.6	14	-20.2	-4.8
X-4316	PDAC	BKM120 + LDE225	209.3	24.9	18	-6.7	-7.4
X-4316	PDAC	BKM120 + LDE225	226.2	26.5	22	0.8	-1.5
X-4316	PDAC	BKM120 + LDE225	248.7	26.8	26	10.8	-0.4
X-4316	PDAC	BKM120 + LDE225	278.3	25.7	29	24	-4.5
X-4316	PDAC	BKM120 + LDE225	290.9	25.9	32	29.6	-3.7
X-4316	PDAC	BKM120 + LDE225	317.3	25.7	36	41.4	-4.5
X-4316	PDAC	BKM120 + LDE225	317.3	24.5	40	41.4	-8.9
X-4316	PDAC	BKM120 + LDE225	314.7	24.8	43	40.2	-7.8
X-4316	PDAC	BKM120 + LDE225	349.9	24.9	47	55.9	-7.4
X-4316	PDAC	BKM120 + LDE225	414.7	23.4	53	84.8	-13
X-4316	PDAC	BKM120	270	23	0	0	0
X-4316	PDAC	BKM120	260.2	22.3	3	-3.6	-3
X-4316	PDAC	BKM120	308.8	21.3	6	14.4	-7.4
X-4316	PDAC	BKM120	357.3	20.9	10	32.3	-9.1
X-4316	PDAC	BKM120	423.4	21.5	13	56.8	-6.5
X-4316	PDAC	BKM120	589.9	20.8	18	118.5	-9.6
X-4316	PDAC	BKM120	522.1	21.2	21	93.4	-7.8
X-4316	PDAC	BKM120	638.8	21.2	26	136.6	-7.8
X-4316	PDAC	BKM120	755	21	28	179.6	-8.7
X-4316	PDAC	BYL719 + LJM716	225.6	28.6	0	0	0
X-4316	PDAC	BYL719 + LJM716	219.5	28.1	2	-2.7	-1.7
X-4316	PDAC	BYL719 + LJM716	225.4	29.3	6	-0.1	2.4
X-4316	PDAC	BYL719 + LJM716	232.3	29.2	9	3	2.1
X-4316	PDAC	BYL719 + LJM716	228.2	30.6	13	1.2	7
X-4316	PDAC	BYL719 + LJM716	242.7	31	17	7.6	8.4
X-4316	PDAC	BYL719 + LJM716	255.9	31.2	20	13.4	9.1
X-4316	PDAC	BYL719 + LJM716	317.6	30.8	23	40.8	7.7
X-4316	PDAC	BYL719 + LJM716	333.5	29.6	27	47.8	3.5
X-4316	PDAC	BYL719 + LJM716	381.1	29.6	30	68.9	3.5
X-4316	PDAC	BYL719 + LJM716	418.5	30.1	34	85.5	5.2
X-4316	PDAC	BYL719 + LJM716	418.3	30.1	37	85.4	5.2
X-4316	PDAC	BYL719 + LJM716	446	30.3	41	97.7	5.9
X-4316	PDAC	BYL719 + LJM716	516.6	30.1	44	129	5.2
X-4316	PDAC	BYL719 + LJM716	551.1	30.3	48	144.3	5.9
X-4316	PDAC	BYL719 + LJM716	592.7	30.1	51	162.7	5.2
X-4316	PDAC	BYL719	203.3	24.7	0	0	0
X-4316	PDAC	BYL719	205.7	22.8	3	1.2	-7.7
X-4316	PDAC	BYL719	204.5	24.6	7	0.6	-0.4
X-4316	PDAC	BYL719	202.1	24.2	10	-0.6	-2
X-4316	PDAC	BYL719	265.6	24.3	14	30.6	-1.6
X-4316	PDAC	BYL719	311	25	17	53	1.2
X-4316	PDAC	BYL719	350.7	23.5	22	72.5	-4.9
X-4316	PDAC	BYL719	375.5	23.2	25	84.7	-6.1
X-4316	PDAC	BYL719	377.2	23.5	28	85.5	-4.9
X-4316	PDAC	BYL719	430.1	25.8	31	111.6	4.5
X-4316	PDAC	BYL719	430.2	24	35	111.6	-2.8
X-4316	PDAC	BYL719	442.7	23.9	38	117.8	-3.2
X-4316	PDAC	BYL719	493.3	24.9	42	142.6	0.8
X-4316	PDAC	BYL719	541.1	24.8	46	166.2	0.4
X-4316	PDAC	BYL719	546.5	24.6	49	168.8	-0.4
X-4316	PDAC	BYL719	579.8	25.6	52	185.2	3.6
X-4316	PDAC	BYL719	596.6	25.7	56	193.5	4
X-4316	PDAC	BYL719	601.7	25.8	59	196	4.5
X-4316	PDAC	BYL719	575.5	23.5	63	183.1	-4.9
X-4316	PDAC	BYL719	511.3	24.2	66	151.5	-2
X-4316	PDAC	BYL719	494.4	23.9	70	143.2	-3.2
X-4316	PDAC	BYL719	471.2	25.6	73	131.8	3.6
X-4316	PDAC	BYL719	512.8	24.3	78	152.2	-1.6
X-4316	PDAC	BYL719	546.5	25.9	81	168.8	4.9
X-4316	PDAC	BYL719	567.7	26.6	84	179.2	7.7
X-4316	PDAC	BYL719	578	26.7	87	184.3	8.1
X-4316	PDAC	BYL719	577.1	26.2	91	183.9	6.1
X-4316	PDAC	BYL719	582.7	26.7	94	186.6	8.1
X-4316	PDAC	BYL719	623.8	26.3	98	206.8	6.5
X-4316	PDAC	BYL719	649	26.2	101	219.2	6.1
X-4316	PDAC	BYL719	693.6	25.5	106	241.2	3.2
X-4316	PDAC	BYL719	712.4	25.4	109	250.4	2.8
X-4316	PDAC	BYL719	715.7	24.8	112	252	0.4
X-4316	PDAC	BYL719	727.9	26.7	115	258	8.1
X-4316	PDAC	CLR457	209.9	24.9	0	0	0
X-4316	PDAC	CLR457	209.8	25.4	2	0	2
X-4316	PDAC	CLR457	204.2	24.6	6	-2.7	-1.2
X-4316	PDAC	CLR457	234.2	24.5	9	11.6	-1.6
X-4316	PDAC	CLR457	241.5	24	13	15.1	-3.6
X-4316	PDAC	CLR457	268.3	24.2	16	27.8	-2.8
X-4316	PDAC	CLR457	337.3	23.9	20	60.7	-4
X-4316	PDAC	CLR457	515.8	24.5	23	145.7	-1.6
X-4316	PDAC	CLR457	589.4	24.6	27	180.8	-1.2
X-4316	PDAC	CLR457	620.3	23.7	30	195.5	-4.8
X-4316	PDAC	CLR457	658.9	24.1	34	213.9	-3.2
X-4316	PDAC	CLR457	782.8	24.2	37	272.9	-2.8
X-4316	PDAC	HDM201	202.6	24.9	0	0	0
X-4316	PDAC	HDM201	210.9	24.4	2	4.1	-2
X-4316	PDAC	HDM201	241.7	24.6	6	19.3	-1.2
X-4316	PDAC	HDM201	308.7	23.8	9	52.4	-4.4
X-4316	PDAC	HDM201	346.5	23.7	13	71	-4.8
X-4316	PDAC	HDM201	403	23.1	16	98.9	-7.2
X-4316	PDAC	HDM201	471.2	24.8	20	132.6	-0.4
X-4316	PDAC	HDM201	471.3	23.7	23	132.6	-4.8
X-4316	PDAC	HDM201	535.5	22.8	27	164.3	-8.4
X-4316	PDAC	HDM201	545.1	21.8	30	169.1	-12.4
X-4316	PDAC	figitumumab"	209	23.6	0	0	0
X-4316	PDAC	figitumumab"	224.6	22.9	1	7.5	-3
X-4316	PDAC	figitumumab"	392.5	23.3	8	87.8	-1.3
X-4316	PDAC	figitumumab"	325.7	23.7	12	55.8	0.4
X-4316	PDAC	figitumumab"	331.1	22.7	15	58.4	-3.8
X-4316	PDAC	figitumumab"	204.6	23.7	19	-2.1	0.4
X-4316	PDAC	figitumumab"	312.5	24	22	49.5	1.7
X-4316	PDAC	figitumumab"	337.1	25	26	61.3	5.9
X-4316	PDAC	figitumumab"	393.8	24.7	29	88.4	4.7
X-4316	PDAC	figitumumab"	548.6	25.4	33	162.5	7.6
X-4316	PDAC	figitumumab"	520.9	24.6	37	149.2	4.2
X-4316	PDAC	figitumumab"	523.9	24.2	40	150.7	2.5
X-4316	PDAC	figitumumab"	528.7	25.2	43	153	6.8
X-4316	PDAC	figitumumab"	613.7	24.4	48	193.6	3.4
X-4316	PDAC	figitumumab"	653.1	25.2	51	212.5	6.8
X-4316	PDAC	figitumumab"	694.2	25.4	54	232.2	7.6
X-4316	PDAC	figitumumab"	616	25.2	57	194.7	6.8
X-4316	PDAC	figitumumab"	692.8	25.7	61	231.5	8.9
X-4316	PDAC	figitumumab"	767.5	24.7	64	267.2	4.7
X-4316	PDAC	figitumumab"	891.3	25.3	68	326.5	7.2
X-4316	PDAC	figitumumab" + binimetinib	215.3	24.9	0	0	0
X-4316	PDAC	figitumumab" + binimetinib	307.8	24.8	2	43	-0.4
X-4316	PDAC	figitumumab" + binimetinib	729.3	23.7	6	238.7	-4.8
X-4316	PDAC	figitumumab" + binimetinib	587.6	23.9	9	172.9	-4
X-4316	PDAC	figitumumab" + binimetinib	673.7	24.6	12	212.9	-1.2
X-4316	PDAC	figitumumab" + binimetinib	837.6	24.3	15	289	-2.4
X-4316	PDAC	figitumumab" + binimetinib	809.6	24.7	20	276	-0.8
X-4316	PDAC	figitumumab" + binimetinib	943.4	26.4	26	338.2	6
X-4316	PDAC	figitumumab" + binimetinib	1011.7	25.2	30	369.9	1.2
X-4316	PDAC	figitumumab" + binimetinib	1068.3	26.3	33	396.2	5.6
X-4316	PDAC	gemcitabine-50mpk	328	24.2	0	0	0
X-4316	PDAC	gemcitabine-50mpk	368.9	23.5	3	12.5	-2.9
X-4316	PDAC	gemcitabine-50mpk	417.8	25	7	27.4	3.3
X-4316	PDAC	gemcitabine-50mpk	320	24.4	9	-2.4	0.8
X-4316	PDAC	gemcitabine-50mpk	324.6	25.1	14	-1	3.7
X-4316	PDAC	gemcitabine-50mpk	249.6	24.9	20	-23.9	2.9
X-4316	PDAC	gemcitabine-50mpk	207.6	24.3	24	-36.7	0.4
X-4316	PDAC	gemcitabine-50mpk	202.8	24.1	28	-38.2	-0.4
X-4316	PDAC	gemcitabine-50mpk	152.6	24.5	30	-53.5	1.2
X-4316	PDAC	gemcitabine-50mpk	183.8	25.3	35	-44	4.5
X-4316	PDAC	gemcitabine-50mpk	204.2	24.7	37	-37.7	2.1
X-4316	PDAC	gemcitabine-50mpk	212.9	24.6	42	-35.1	1.7
X-4316	PDAC	gemcitabine-50mpk	161.9	25.2	45	-50.6	4.1
X-4316	PDAC	gemcitabine-50mpk	95.6	25.1	49	-70.9	3.7
X-4316	PDAC	gemcitabine-50mpk	91.8	25	52	-72	3.3
X-4316	PDAC	gemcitabine-50mpk	125.1	24.3	56	-61.9	0.4
X-4316	PDAC	gemcitabine-50mpk	115	25.2	59	-64.9	4.1
X-4316	PDAC	gemcitabine-50mpk	120.1	25.5	62	-63.4	5.4
X-4316	PDAC	gemcitabine-50mpk	92.8	24.5	66	-71.7	1.2
X-4316	PDAC	gemcitabine-50mpk	101.7	24.8	70	-69	2.5
X-4316	PDAC	gemcitabine-50mpk	109.2	24.7	73	-66.7	2.1
X-4316	PDAC	gemcitabine-50mpk	65.5	24.6	77	-80	1.7
X-4316	PDAC	INC424	214.2	28.7	0	0	0
X-4316	PDAC	INC424	204.5	28.9	3	-4.5	0.7
X-4316	PDAC	INC424	219.1	24.8	7	2.3	-13.6
X-4316	PDAC	INC424	240.3	24.4	10	12.2	-15
X-4316	PDAC	INC424	281.8	26.5	14	31.6	-7.7
X-4316	PDAC	INC424	293.4	26.8	17	37	-6.6
X-4316	PDAC	INC424	309.2	27.4	22	44.4	-4.5
X-4316	PDAC	INC424	314.8	28.7	25	47	0
X-4316	PDAC	INC424	320.2	28.9	28	49.5	0.7
X-4316	PDAC	INC424	324.3	26.6	31	51.4	-7.3
X-4316	PDAC	INC424	339.7	26.7	35	58.6	-7
X-4316	PDAC	INC424	356	24.4	38	66.2	-15
X-4316	PDAC	INC424	358.8	25.8	42	67.5	-10.1
X-4316	PDAC	INC424	372.3	24.7	46	73.8	-13.9
X-4316	PDAC	INC424	384.4	26.9	49	79.5	-6.3
X-4316	PDAC	INC424	400.9	27.4	52	87.2	-4.5
X-4316	PDAC	INC424	414.7	28.4	56	93.6	-1
X-4316	PDAC	INC424	444	27.9	59	107.3	-2.8
X-4316	PDAC	INC424	498.4	28.6	63	132.7	-0.3
X-4316	PDAC	INC424	509.2	28.2	66	137.7	-1.7
X-4316	PDAC	INC424	537.1	28	70	150.7	-2.4
X-4316	PDAC	INC424	587.3	28.2	73	174.2	-1.7
X-4316	PDAC	INC424	597	29	78	178.7	1
X-4316	PDAC	INC424	628.8	27.6	81	193.6	-3.8
X-4316	PDAC	INC424	660.1	28.7	84	208.2	0
X-4316	PDAC	INC424	694.7	29.4	87	224.3	2.4
X-4316	PDAC	INC424	762.4	29.3	91	255.9	2.1
X-4316	PDAC	INC424	755.1	27	94	252.5	-5.9
X-4316	PDAC	INC424	778.9	28.4	98	263.6	-1
X-4316	PDAC	INC424	795.2	26.4	101	271.2	-8
X-4316	PDAC	INC424	852.3	27.2	106	297.9	-5.2
X-4316	PDAC	INC424	1007.3	27.4	109	370.3	-4.5
X-4316	PDAC	INC424	1031.8	27	112	381.7	-5.9
X-4316	PDAC	INC424	1072.8	27.4	115	400.8	-4.5
X-4316	PDAC	LEE011	206.6	24.6	0	0	0
X-4316	PDAC	LEE011	173	25.1	4	-16.3	2
X-4316	PDAC	LEE011	216.3	25.1	7	4.7	2
X-4316	PDAC	LEE011	246.4	24.1	11	19.3	-2
X-4316	PDAC	LEE011	225.3	23.2	14	9.1	-5.7
X-4316	PDAC	LEE011	231.9	22.5	18	12.2	-8.5
X-4316	PDAC	LEE011	212.7	22.8	21	3	-7.3
X-4316	PDAC	LEE011	244.3	23.4	25	18.2	-4.9
X-4316	PDAC	LEE011	276.4	23.8	28	33.8	-3.3
X-4316	PDAC	LEE011	290.8	22.8	32	40.8	-7.3
X-4316	PDAC	LEE011	305.6	24	35	47.9	-2.4
X-4316	PDAC	LEE011	328.6	26.3	39	59.1	6.9
X-4316	PDAC	LEE011	271.5	25.3	42	31.4	2.8
X-4316	PDAC	LEE011	279.4	24.6	46	35.2	0
X-4316	PDAC	LEE011	302.1	25	49	46.2	1.6
X-4316	PDAC	LEE011	294.9	25.7	53	42.7	4.5
X-4316	PDAC	LEE011	311.3	24.9	56	50.7	1.2
X-4316	PDAC	LEE011	338.8	25.1	60	64	2
X-4316	PDAC	LEE011	422.4	26.3	63	104.5	6.9
X-4316	PDAC	LEE011	468.5	24.9	68	126.8	1.2
X-4316	PDAC	LEE011	499.8	24.1	71	141.9	-2
X-4316	PDAC	LEE011	477.3	24.8	74	131	0.8
X-4316	PDAC	LEE011	466.5	24.8	77	125.8	0.8
X-4316	PDAC	WNT974	202	24.6	0	0	0
X-4316	PDAC	WNT974	217	25.4	1	7.4	3.3
X-4316	PDAC	WNT974	226.3	25.2	5	12	2.4
X-4316	PDAC	WNT974	287.3	23.7	8	42.2	-3.7
X-4316	PDAC	WNT974	277.7	24.9	13	37.5	1.2
X-4316	PDAC	WNT974	256.1	24.9	16	26.8	1.2
X-4316	PDAC	WNT974	259.3	25.7	19	28.4	4.5
X-4316	PDAC	WNT974	360.1	25.1	23	78.3	2
X-4316	PDAC	WNT974	338.7	25.8	26	67.7	4.9
X-4316	PDAC	WNT974	458.8	25.4	29	127.1	3.3
X-4316	PDAC	WNT974	540.9	24.5	33	167.8	-0.4
X-4316	PDAC	WNT974	590	23.9	36	192.1	-2.8
X-4316	PDAC	WNT974	793.2	24.2	41	292.7	-1.6
X-4316	PDAC	WNT974	825.6	24.3	44	308.7	-1.2
X-4316	PDAC	WNT974	865.4	26.2	48	328.4	6.5
X-4316	PDAC	WNT974	1004	25	51	397	1.6
X-4316	PDAC	LKA136	232.1	26.5	0	0	0
X-4316	PDAC	LKA136	253.3	26	3	9.1	-1.9
X-4316	PDAC	LKA136	275.3	26.2	7	18.6	-1.1
X-4316	PDAC	LKA136	238.5	25.8	10	2.8	-2.6
X-4316	PDAC	LKA136	272.3	25.8	15	17.3	-2.6
X-4316	PDAC	LKA136	362.6	26	18	56.2	-1.9
X-4316	PDAC	LKA136	369.4	26	22	59.2	-1.9
X-4316	PDAC	LKA136	461.2	25.8	25	98.7	-2.6
X-4316	PDAC	LKA136	463.6	26	28	99.7	-1.9
X-4316	PDAC	LKA136	460.9	26.7	31	98.6	0.8
X-4316	PDAC	LKA136	638.8	27	36	175.2	1.9
X-4316	PDAC	LKA136	540.1	27.1	39	132.7	2.3
X-4316	PDAC	LKA136	714	26.1	42	207.6	-1.5
X-4316	PDAC	LKA136	729.9	27.3	45	214.5	3
X-4316	PDAC	binimetinib	224	26.2	0	0	0
X-4316	PDAC	binimetinib	188.7	26.7	4	-15.8	1.9
X-4316	PDAC	binimetinib	206.7	27.9	14	-7.7	6.5
X-4316	PDAC	binimetinib	201.5	27.6	18	-10	5.3
X-4316	PDAC	binimetinib	161.8	28	21	-27.8	6.9
X-4316	PDAC	binimetinib	185.9	27.7	25	-17	5.7
X-4316	PDAC	binimetinib	157.1	27.1	28	-29.9	3.4
X-4316	PDAC	binimetinib	160.6	26.9	32	-28.3	2.7
X-4316	PDAC	binimetinib	140.2	26.4	34	-37.4	0.8
X-4316	PDAC	binimetinib	137	28.3	40	-38.8	8
X-4316	PDAC	binimetinib	127.4	26.6	46	-43.1	1.5
X-4316	PDAC	binimetinib	153.4	26.7	49	-31.5	1.9
X-4316	PDAC	binimetinib	147.9	27.7	52	-34	5.7
X-4316	PDAC	binimetinib	196.7	26.3	55	-12.2	0.4
X-4316	PDAC	binimetinib	173.7	24.2	60	-22.5	-7.6
X-4316	PDAC	binimetinib	137.5	26.8	62	-38.6	2.3
X-4316	PDAC	binimetinib	155.5	27.8	66	-30.6	6.1
X-4316	PDAC	binimetinib	175.4	27.3	69	-21.7	4.2
X-4316	PDAC	binimetinib	167.7	26.4	74	-25.1	0.8
X-4316	PDAC	binimetinib	159.4	26.8	81	-28.8	2.3
X-4316	PDAC	binimetinib	196.7	27.9	84	-12.2	6.5
X-4316	PDAC	binimetinib	154.3	27.4	88	-31.1	4.6
X-4316	PDAC	binimetinib	126	27.9	91	-43.8	6.5
X-4316	PDAC	binimetinib	132.5	29.1	94	-40.8	11.1
X-4316	PDAC	binimetinib	177.5	27.8	102	-20.8	6.1
X-4316	PDAC	binimetinib	153.4	26.8	104	-31.5	2.3
X-4316	PDAC	binimetinib	122.8	28.6	109	-45.2	9.2
X-4316	PDAC	binimetinib	233.8	27.2	112	4.4	3.8
X-4316	PDAC	binimetinib	144.3	28.4	116	-35.6	8.4
X-4316	PDAC	binimetinib	182.3	27.5	119	-18.6	5
X-4316	PDAC	binimetinib	144.7	29.7	122	-35.4	13.4
X-4316	PDAC	binimetinib-3.5mpk	223.3	25.1	0	0	0
X-4316	PDAC	binimetinib-3.5mpk	255	25.2	3	14.2	0.4
X-4316	PDAC	binimetinib-3.5mpk	204.5	24.5	6	-8.4	-2.4
X-4316	PDAC	binimetinib-3.5mpk	238.2	25.6	10	6.7	2
X-4316	PDAC	binimetinib-3.5mpk	308.5	24.3	13	38.2	-3.2
X-4316	PDAC	binimetinib-3.5mpk	288.5	24.8	18	29.2	-1.2
X-4316	PDAC	binimetinib-3.5mpk	462.6	26	21	107.2	3.6
X-4316	PDAC	binimetinib-3.5mpk	378.5	25	26	69.5	-0.4
X-4316	PDAC	binimetinib-3.5mpk	413.7	25.1	28	85.3	0
X-4316	PDAC	binimetinib-3.5mpk	470.9	25.8	31	110.9	2.8
X-4316	PDAC	binimetinib-3.5mpk	472	25.1	34	111.4	0
X-4316	PDAC	binimetinib-3.5mpk	543.3	25.2	39	143.3	0.4
X-4316	PDAC	trametinib	235	28.4	0	0	0
X-4316	PDAC	trametinib	235.2	28.3	5	0.1	-0.4
X-4316	PDAC	trametinib	227.5	28.4	8	-3.2	0
X-4316	PDAC	trametinib	220.5	28.2	12	-6.2	-0.7
X-4316	PDAC	trametinib	177.7	28.3	15	-24.4	-0.4
X-4316	PDAC	trametinib	159.6	27.7	19	-32.1	-2.5
X-4316	PDAC	trametinib	203.4	27.8	22	-13.4	-2.1
X-4316	PDAC	trametinib	207.6	28.1	27	-11.7	-1.1
X-4316	PDAC	trametinib	191.6	27.7	29	-18.5	-2.5
X-4316	PDAC	trametinib	226.1	28.2	33	-3.8	-0.7
X-4316	PDAC	trametinib	208.8	28.4	36	-11.1	0
X-4316	PDAC	trametinib	175.1	28.5	40	-25.5	0.4
X-4316	PDAC	trametinib	293.1	28.9	43	24.7	1.8
X-4316	PDAC	trametinib	314.8	28	47	34	-1.4
X-4316	PDAC	trametinib	282.8	28	50	20.3	-1.4
X-4316	PDAC	trametinib	259.2	29.7	55	10.3	4.6
X-4316	PDAC	trametinib	328.1	29.2	60	39.6	2.8
X-4316	PDAC	trametinib	286.6	29.7	63	22	4.6
X-4316	PDAC	trametinib	333.9	30	67	42.1	5.6
X-4316	PDAC	trametinib	332	28.9	70	41.3	1.8
X-4316	PDAC	trametinib	403.7	28.4	74	71.8	0
X-4316	PDAC	trametinib	355.2	28.6	77	51.1	0.7
X-4316	PDAC	trametinib	291.7	27.8	81	24.1	-2.1
X-4316	PDAC	trametinib	272.1	28.7	84	15.8	1.1
X-4316	PDAC	trametinib	269.4	28.4	88	14.6	0
X-4316	PDAC	trametinib	280.9	28.7	91	19.5	1.1
X-4316	PDAC	untreated	271.4	25.3	0	0	0
X-4316	PDAC	untreated	321.3	26	2	18.4	2.8
X-4316	PDAC	untreated	256.1	26	8	-5.6	2.8
X-4316	PDAC	untreated	375	26.4	11	38.2	4.3
X-4316	PDAC	untreated	355.2	26.6	13	30.9	5.1
X-4316	PDAC	untreated	613.1	26.4	16	125.9	4.3
X-4316	PDAC	untreated	631.7	26.6	20	132.8	5.1
X-4316	PDAC	untreated	720.8	25.8	23	165.6	2
X-4316	PDAC	untreated	889.7	25.3	27	227.8	0
X-4316	PDAC	untreated	1102.9	25.1	31	306.4	-0.8
X-4316	PDAC	untreated	1129.9	25.7	35	316.3	1.6
X-4316	PDAC	untreated	1140.8	25.7	37	320.3	1.6
X-4316	PDAC	untreated	1114.3	27.3	41	310.6	7.9
X-4316	PDAC	untreated	1334.9	26	44	391.9	2.8
X-4339	CM	BKM120	197.6	22.9	0	0	0
X-4339	CM	BKM120	206.7	23.2	1	4.6	1.3
X-4339	CM	BKM120	178.5	20.2	5	-9.6	-11.8
X-4339	CM	BKM120	147.9	20	8	-25.2	-12.7
X-4339	CM	BKM120	199.1	20	12	0.8	-12.7
X-4339	CM	BKM120	145.4	20.7	16	-26.4	-9.6
X-4339	CM	BKM120	166.1	20.1	19	-15.9	-12.2
X-4339	CM	BKM120	190.4	20.8	23	-3.6	-9.2
X-4339	CM	BKM120	186.2	19.7	27	-5.8	-14
X-4339	CM	BKM120	198.5	19.6	30	0.4	-14.4
X-4339	CM	BKM120	239.1	20.5	34	21	-10.5
X-4339	CM	BKM120	235.9	19.6	37	19.4	-14.4
X-4339	CM	BKM120	238.2	19.4	42	20.6	-15.3
X-4339	CM	BKM120	226.5	19	44	14.6	-17
X-4339	CM	BKM120 + encorafenib	194.2	23.1	0	0	0
X-4339	CM	BKM120 + encorafenib	205.8	21.4	3	6	-7.4
X-4339	CM	BKM120 + encorafenib	205.8	20.9	7	6	-9.5
X-4339	CM	BKM120 + encorafenib	204.2	20.1	11	5.1	-13
X-4339	CM	BKM120 + encorafenib	193.6	20.1	14	-0.3	-13
X-4339	CM	BKM120 + encorafenib	220.3	20.5	18	13.4	-11.3
X-4339	CM	BKM120 + encorafenib	205.8	22	21	6	-4.8
X-4339	CM	BKM120 + encorafenib	210.7	20	26	8.5	-13.4
X-4339	CM	BKM120 + encorafenib	211.7	20	30	9	-13.4
X-4339	CM	BKM120 + encorafenib	225.5	19.7	33	16.1	-14.7
X-4339	CM	BKM120 + encorafenib	214.2	19.7	36	10.3	-14.7
X-4339	CM	BKM120 + encorafenib	213.2	19.5	40	9.8	-15.6
X-4339	CM	CGM097	203.4	21.3	0	0	0
X-4339	CM	CGM097	203.4	21.3	1	0	0
X-4339	CM	CGM097	211.7	21.3	4	4.1	0
X-4339	CM	CGM097	238.5	20.5	7	17.3	-3.8
X-4339	CM	CGM097	276.8	20.9	11	36.1	-1.9
X-4339	CM	CGM097	298.1	21.6	15	46.6	1.4
X-4339	CM	CGM097	286	20.8	18	40.6	-2.3
X-4339	CM	CGM097	305.1	20.1	22	50	-5.6
X-4339	CM	CGM097	311.7	20.5	25	53.3	-3.8
X-4339	CM	CGM097	357.6	19.8	29	75.9	-7
X-4339	CM	CGM097	350.4	21.1	33	72.3	-0.9
X-4339	CM	CGM097	335.2	20	36	64.8	-6.1
X-4339	CM	CGM097	364.9	20.7	40	79.4	-2.8
X-4339	CM	CGM097	356.3	21.5	44	75.2	0.9
X-4339	CM	CGM097	352.8	22.8	47	73.5	7
X-4339	CM	CGM097	364.9	22.1	51	79.4	3.8
X-4339	CM	CGM097	369.8	21.5	54	81.9	0.9
X-4339	CM	CGM097	369.8	22.2	59	81.9	4.2
X-4339	CM	CGM097	377.2	21.8	63	85.5	2.3
X-4339	CM	CGM097	425.3	21.4	66	109.1	0.5
X-4339	CM	CLR457	196	26.5	0	0	0
X-4339	CM	CLR457	203.4	26	2	3.7	-1.9
X-4339	CM	CLR457	220.3	26	5	12.4	-1.9
X-4339	CM	CLR457	214.2	25.1	8	9.3	-5.3
X-4339	CM	CLR457	220.3	25.7	12	12.4	-3
X-4339	CM	CLR457	288.9	25.5	15	47.4	-3.8
X-4339	CM	CLR457	237.6	25.3	19	21.2	-4.5
X-4339	CM	CLR457	214.9	25.3	22	9.6	-4.5
X-4339	CM	CLR457	221.3	26.1	26	12.9	-1.5
X-4339	CM	CLR457	286	26.9	29	45.9	1.5
X-4339	CM	CLR457	268.8	26.5	35	37.1	0
X-4339	CM	CLR457	258.6	27.4	41	31.9	3.4
X-4339	CM	CLR457	236.3	26.9	44	20.5	1.5
X-4339	CM	CLR457	241.9	27.5	48	23.4	3.8
X-4339	CM	CLR457	243.7	27.1	53	24.3	2.3
X-4339	CM	CLR457	257.9	26.2	60	31.6	-1.1
X-4339	CM	CLR457	300.8	26.7	67	53.5	0.8
X-4339	CM	CLR457	316.8	26.9	73	61.6	1.5
X-4339	CM	CLR457	361.3	26.2	80	84.3	-1.1
X-4339	CM	CLR457	389.8	25.9	85	98.9	-2.3
X-4339	CM	dacarbazine	200.9	23.7	0	0	0
X-4339	CM	dacarbazine	250.5	20.4	5	24.7	-13.9
X-4339	CM	dacarbazine	235.5	20.2	9	17.2	-14.8
X-4339	CM	dacarbazine	229.2	20.1	12	14.1	-15.2
X-4339	CM	dacarbazine	220.3	19	15	9.7	-19.8
X-4339	CM	LDE225	203.4	24.5	0	0	0
X-4339	CM	LDE225	230	22.5	4	13.1	-8.2
X-4339	CM	LDE225	248.4	23	8	22.1	-6.1
X-4339	CM	LDE225	247.5	21.4	11	21.7	-12.7
X-4339	CM	LDE225	234.5	20.9	15	15.3	-14.7
X-4339	CM	LDE225	230.7	20.9	19	13.4	-14.7
X-4339	CM	LDE225	230.7	21.7	20	13.4	-11.4
X-4339	CM	LDE225	238.2	20.1	22	17.1	-18
X-4339	CM	LDK378	213.6	25.7	0	0	0
X-4339	CM	LDK378	227.3	23.6	4	6.4	-8.2
X-4339	CM	LDK378	230	23.9	8	7.7	-7
X-4339	CM	LDK378	253.1	22.7	11	18.5	-11.7
X-4339	CM	LDK378	260.9	24.5	15	22.2	-4.7
X-4339	CM	LDK378	248.4	22.7	19	16.3	-11.7
X-4339	CM	LDK378	301.8	23.8	22	41.3	-7.4
X-4339	CM	LDK378	314.9	25.8	26	47.5	0.4
X-4339	CM	LDK378	300.8	25	29	40.9	-2.7
X-4339	CM	LDK378	302.7	23.8	34	41.7	-7.4
X-4339	CM	LDK378	299.6	25.8	38	40.3	0.4
X-4339	CM	LDK378	356.3	24.1	41	66.9	-6.2
X-4339	CM	LDK378	380.9	26.3	44	78.4	2.3
X-4339	CM	LEE011	200	26.4	0	0	0
X-4339	CM	LEE011	230.3	26.6	4	15.2	0.8
X-4339	CM	LEE011	232.8	27.8	7	16.4	5.3
X-4339	CM	LEE011	227.9	24.2	11	13.9	-8.3
X-4339	CM	LEE011	236.9	24.9	14	18.5	-5.7
X-4339	CM	LEE011	218.1	24.8	18	9	-6.1
X-4339	CM	LEE011	183.8	26.5	22	-8.1	0.4
X-4339	CM	LEE011	200	25.2	25	0	-4.5
X-4339	CM	LEE011	175.3	25.8	29	-12.3	-2.3
X-4339	CM	LEE011	160.6	26.6	33	-19.7	0.8
X-4339	CM	LEE011	138.9	27.7	36	-30.5	4.9
X-4339	CM	LEE011	153.6	28.1	40	-23.2	6.4
X-4339	CM	LEE011	132.3	27.9	43	-33.8	5.7
X-4339	CM	LEE011	140.4	28.1	48	-29.8	6.4
X-4339	CM	LEE011	148	29.4	52	-26	11.4
X-4339	CM	LEE011	127.1	28.8	55	-36.5	9.1
X-4339	CM	LEE011	120.6	30	58	-39.7	13.6
X-4339	CM	LEE011	135.8	29.5	62	-32.1	11.7
X-4339	CM	LEE011	148.7	30.6	65	-25.6	15.9
X-4339	CM	LEE011	137.5	29.9	69	-31.2	13.3
X-4339	CM	LEE011	123.7	29.2	72	-38.1	10.6
X-4339	CM	LEE011	137.3	29.9	76	-31.3	13.3
X-4339	CM	LEE011	125.3	30.3	79	-37.3	14.8
X-4339	CM	LEE011	117.6	29.3	85	-41.2	11
X-4339	CM	LEE011	109.8	30.7	91	-45.1	16.3
X-4339	CM	LEE011	80	30.7	94	-60	16.3
X-4339	CM	LEE011	98.3	30.3	98	-50.8	14.8
X-4339	CM	LEE011	87.5	29.6	103	-56.3	12.1
X-4339	CM	LEE011	71.3	31	110	-64.4	17.4
X-4339	CM	LEE011	66.8	30.4	117	-66.6	15.2
X-4339	CM	LEE011	60	31	123	-70	17.4
X-4339	CM	LEE011	63.6	31.6	130	-68.2	19.7
X-4339	CM	LEE011	55.2	32	136	-72.4	21.2
X-4339	CM	LEE011	60	32	142	-70	21.2
X-4339	CM	LEE011	54.7	32	149	-72.7	21.2
X-4339	CM	LEE011	61.4	32.4	156	-69.3	22.7
X-4339	CM	LEE011	72	31.9	166	-64	20.8
X-4339	CM	LEE011	75	32.2	172	-62.5	22
X-4339	CM	LEE011	73.8	33.1	179	-63.1	25.4
X-4339	CM	LEE011	74.4	31.6	188	-62.8	19.7
X-4339	CM	LEE011	78.8	33	192	-60.6	25
X-4339	CM	LEE011	102.1	33	199	-49	25
X-4339	CM	LEE011	112.9	32.1	206	-43.5	21.6
X-4339	CM	LEE011	115	32.7	213	-42.5	23.9
X-4339	CM	LEE011	122.3	32.2	220	-38.8	22
X-4339	CM	LEE011	125.1	31.1	226	-37.4	17.8
X-4339	CM	LEE011	127.1	30.5	233	-36.5	15.5
X-4339	CM	LEE011	129.6	31.6	240	-35.2	19.7
X-4339	CM	LEE011 + encorafenib	212.5	28.1	0	0	0
X-4339	CM	LEE011 + encorafenib	202.2	26.6	3	-4.9	-5.3
X-4339	CM	LEE011 + encorafenib	222.2	26.5	7	4.5	-5.7
X-4339	CM	LEE011 + encorafenib	224.5	27	11	5.6	-3.9
X-4339	CM	LEE011 + encorafenib	213.2	25.3	14	0.3	-10
X-4339	CM	LEE011 + encorafenib	202.5	26.9	18	-4.7	-4.3
X-4339	CM	LEE011 + encorafenib	201.6	29	21	-5.1	3.2
X-4339	CM	LEE011 + encorafenib	230.6	25.2	26	8.5	-10.3
X-4339	CM	LEE011 + encorafenib	230.6	24.6	30	8.5	-12.5
X-4339	CM	LEE011 + encorafenib	227.8	27.1	33	7.2	-3.6
X-4339	CM	LEE011 + encorafenib	219	27.8	36	3.1	-1.1
X-4339	CM	LEE011 + encorafenib	225	27.3	40	5.9	-2.8
X-4339	CM	LEE011 + encorafenib	200.1	29.2	43	-5.8	3.9
X-4339	CM	LEE011 + encorafenib	174.9	28.7	47	-17.7	2.1
X-4339	CM	LEE011 + encorafenib	203.1	29.4	50	-4.4	4.6
X-4339	CM	LEE011 + encorafenib	213.5	29.8	54	0.5	6
X-4339	CM	LEE011 + encorafenib	228.4	29.8	57	7.5	6
X-4339	CM	LEE011 + encorafenib	201.6	28.1	63	-5.1	0
X-4339	CM	LEE011 + encorafenib	180.3	28.8	69	-15.2	2.5
X-4339	CM	LEE011 + encorafenib	161.2	29.6	72	-24.2	5.3
X-4339	CM	LEE011 + encorafenib	166.1	29	76	-21.9	3.2
X-4339	CM	LEE011 + encorafenib	178.5	27.5	81	-16	-2.1
X-4339	CM	LEE011 + encorafenib	136.9	28.6	88	-35.6	1.8
X-4339	CM	LEE011 + encorafenib	178.9	28.3	95	-15.9	0.7
X-4339	CM	LEE011 + encorafenib	126.9	28.1	101	-40.3	0
X-4339	CM	LEE011 + encorafenib	171.4	28.9	108	-19.4	2.8
X-4339	CM	LEE011 + encorafenib	139.3	30	114	-34.5	6.8
X-4339	CM	LEE011 + encorafenib	109.8	29.6	120	-48.3	5.3
X-4339	CM	LEE011 + encorafenib	137.2	29.8	127	-35.4	6
X-4339	CM	LEE011 + encorafenib	113.4	31	134	-46.6	10.3
X-4339	CM	LEE011 + encorafenib	113.1	31	144	-46.8	10.3
X-4339	CM	LEE011 + encorafenib	129.6	29.1	150	-39	3.6
X-4339	CM	LEE011 + encorafenib	153.6	28.9	157	-27.7	2.8
X-4339	CM	LEE011 + encorafenib	149.5	27.5	166	-29.7	-2.1
X-4339	CM	LEE011 + encorafenib	158.4	28	170	-25.5	-0.4
X-4339	CM	LEE011 + binimetinib	204.2	24.2	0	0	0
X-4339	CM	LEE011 + binimetinib	161	22.6	3	-21.1	-6.6
X-4339	CM	LEE011 + binimetinib	162.4	25.2	7	-20.4	4.1
X-4339	CM	LEE011 + binimetinib	166.6	25.3	10	-18.4	4.5
X-4339	CM	LEE011 + binimetinib	150.7	26.3	14	-26.2	8.7
X-4339	CM	LEE011 + binimetinib	89.6	26.6	17	-56.1	9.9
X-4339	CM	LEE011 + binimetinib	76.3	26.1	23	-62.7	7.9
X-4339	CM	LEE011 + binimetinib	109.8	26	29	-46.2	7.4
X-4339	CM	LEE011 + binimetinib	112.1	26.1	32	-45.1	7.9
X-4339	CM	LEE011 + binimetinib	71.3	26.5	36	-65.1	9.5
X-4339	CM	LEE011 + binimetinib	66	26.4	41	-67.7	9.1
X-4339	CM	LEE011 + binimetinib	62.2	26.7	48	-69.5	10.3
X-4339	CM	LEE011 + binimetinib	54	25.6	55	-73.6	5.8
X-4339	CM	LEE011 + binimetinib	55	25.5	61	-73.1	5.4
X-4339	CM	LEE011 + binimetinib	49.9	26.8	68	-75.5	10.7
X-4339	CM	LEE011 + binimetinib	42	27.2	73	-79.4	12.4
X-4339	CM	LEE011 + binimetinib	40	26.2	79	-80.4	8.3
X-4339	CM	LEE011 + binimetinib	32.5	27.5	86	-84.1	13.6
X-4339	CM	LEE011 + binimetinib	35.2	27.3	93	-82.8	12.8
X-4339	CM	LEE011 + binimetinib	27	27.9	103	-86.8	15.3
X-4339	CM	LEE011 + binimetinib	28.8	25.9	109	-85.9	7
X-4339	CM	LEE011 + binimetinib	28.2	26.3	116	-86.2	8.7
X-4339	CM	LEE011 + binimetinib	33.2	26.5	125	-83.7	9.5
X-4339	CM	LEE011 + binimetinib	32.5	27	129	-84.1	11.6
X-4339	CM	LEE011 + binimetinib	34.2	27.1	136	-83.2	12
X-4339	CM	LEE011 + binimetinib	32	26.7	143	-84.3	10.3
X-4339	CM	LEE011 + binimetinib	32	26.8	150	-84.3	10.7
X-4339	CM	LEE011 + binimetinib	39.7	26.2	157	-80.6	8.3
X-4339	CM	LEE011 + binimetinib	35.4	26.6	163	-82.7	9.9
X-4339	CM	LEE011 + binimetinib	36.8	26	170	-82	7.4
X-4339	CM	LEE011 + binimetinib	35.7	26.4	177	-82.5	9.1
X-4339	CM	WNT974	198.5	23.5	0	0	0
X-4339	CM	WNT974	215.1	22.2	4	8.4	-5.5
X-4339	CM	WNT974	222.9	22.6	8	12.3	-3.8
X-4339	CM	WNT974	230	21.5	11	15.9	-8.5
X-4339	CM	WNT974	239.1	21.3	15	20.5	-9.4
X-4339	CM	WNT974	232.7	21	19	17.3	-10.6
X-4339	CM	WNT974	242.6	21	22	22.2	-10.6
X-4339	CM	WNT974	276.8	19.5	26	39.5	-17
X-4339	CM	LGW813	200	28.3	0	0	0
X-4339	CM	LGW813	227.3	28.6	4	13.6	1.1
X-4339	CM	LGW813	225	26.9	7	12.5	-4.9
X-4339	CM	LGW813	226.5	27.4	11	13.3	-3.2
X-4339	CM	LGW813	243.7	28.4	15	21.9	0.4
X-4339	CM	LGW813	239.1	27.1	18	19.6	-4.2
X-4339	CM	LGW813	292.5	28.7	22	46.3	1.4
X-4339	CM	LGW813	306.6	27.6	26	53.3	-2.5
X-4339	CM	LGW813	306.6	28.4	29	53.3	0.4
X-4339	CM	LGW813	303.1	29.4	33	51.6	3.9
X-4339	CM	LGW813	324.6	29.1	36	62.3	2.8
X-4339	CM	LGW813	361.3	28.1	44	80.7	-0.7
X-4339	CM	LGW813	361.3	28.4	48	80.7	0.4
X-4339	CM	LGW813	423.2	27.8	51	111.6	-1.8
X-4339	CM	encorafenib	206.7	24.1	0	0	0
X-4339	CM	encorafenib	247.5	22.5	6	19.8	-6.6
X-4339	CM	encorafenib	276.8	23.4	10	33.9	-2.9
X-4339	CM	encorafenib	347.9	22.2	14	68.3	-7.9
X-4339	CM	encorafenib	425.9	22	17	106.1	-8.7
X-4339	CM	encorafenib	416.3	22.1	21	101.4	-8.3
X-4339	CM	encorafenib	392	22.1	24	89.7	-8.3
X-4339	CM	encorafenib	496.4	22	28	140.2	-8.7
X-4339	CM	encorafenib	458.4	23.2	32	121.8	-3.7
X-4339	CM	encorafenib	467.1	21.8	35	126	-9.5
X-4339	CM	encorafenib	568.5	21.9	39	175	-9.1
X-4339	CM	encorafenib	601.9	21.8	43	191.2	-9.5
X-4339	CM	encorafenib	707.5	22.6	46	242.3	-6.2
X-4339	CM	encorafenib + binimetinib	209.2	26.1	0	0	0
X-4339	CM	encorafenib + binimetinib	227.3	24.6	4	8.6	-5.7
X-4339	CM	encorafenib + binimetinib	255	23.6	7	21.9	-9.6
X-4339	CM	encorafenib + binimetinib	288	24.4	11	37.7	-6.5
X-4339	CM	encorafenib + binimetinib	327.2	25	14	56.4	-4.2
X-4339	CM	encorafenib + binimetinib	384.6	22.7	19	83.8	-13
X-4339	CM	encorafenib + binimetinib	382.9	25.1	23	83	-3.8
X-4339	CM	encorafenib + binimetinib	379.3	24.4	26	81.3	-6.5
X-4339	CM	encorafenib + binimetinib	386.5	24.6	29	84.8	-5.7
X-4339	CM	encorafenib + binimetinib	433.5	24.4	33	107.2	-6.5
X-4339	CM	encorafenib + binimetinib	653.1	24.3	36	212.2	-6.9
X-4339	CM	encorafenib + binimetinib	622.6	25.1	40	197.6	-3.8
X-4339	CM	encorafenib + binimetinib	695.1	24.2	43	232.3	-7.3
X-4339	CM	encorafenib + binimetinib	758.8	25	47	262.7	-4.2
X-4339	CM	binimetinib	199.1	20.6	0	0	0
X-4339	CM	binimetinib	198.5	22.2	4	-0.3	7.8
X-4339	CM	binimetinib	216.3	22	7	8.6	6.8
X-4339	CM	binimetinib	194.4	22.7	11	-2.4	10.2
X-4339	CM	binimetinib	188.7	20.6	14	-5.3	0
X-4339	CM	binimetinib	218.5	21	18	9.7	1.9
X-4339	CM	binimetinib	205.4	21.9	22	3.1	6.3
X-4339	CM	binimetinib	221.8	21.2	25	11.4	2.9
X-4339	CM	binimetinib	236.8	22.2	29	18.9	7.8
X-4339	CM	binimetinib	212.5	21.1	33	6.7	2.4
X-4339	CM	binimetinib	226.5	22.3	36	13.7	8.3
X-4339	CM	binimetinib	237.1	23.1	40	19.1	12.1
X-4339	CM	binimetinib	239.8	21	43	20.4	1.9
X-4339	CM	binimetinib	267.2	21	48	34.2	1.9
X-4339	CM	binimetinib	298.1	21.1	52	49.7	2.4
X-4339	CM	binimetinib	298.1	20.7	55	49.7	0.5
X-4339	CM	binimetinib	313.6	21.5	58	57.5	4.4
X-4339	CM	binimetinib	313.3	21.5	62	57.4	4.4
X-4339	CM	binimetinib	277.4	21.7	65	39.3	5.3
X-4339	CM	binimetinib	274.3	21.6	69	37.8	4.9
X-4339	CM	binimetinib	345.2	20.7	72	73.4	0.5
X-4339	CM	binimetinib	374.3	20.9	76	88	1.5
X-4339	CM	binimetinib	410.6	21.2	79	106.2	2.9
X-4339	CM	binimetinib	431.4	21.6	85	116.7	4.9
X-4339	CM	TAS266	196	20	0	0	0
X-4339	CM	TAS266	235.5	19.7	4	20.1	-1.5
X-4339	CM	TAS266	214.2	19.4	7	9.3	-3
X-4339	CM	TAS266	223.8	19.4	13	14.2	-3
X-4339	CM	TAS266	225	20.2	17	14.8	1
X-4339	CM	TAS266	243.4	20	21	24.2	0
X-4339	CM	TAS266	239.7	20.4	24	22.3	2
X-4339	CM	TAS266	261.6	19.4	28	33.5	-3
X-4339	CM	TAS266	284.8	19.7	31	45.3	-1.5
X-4339	CM	TAS266	335.2	19	35	71	-5
X-4339	CM	TAS266	410.4	21.1	39	109.4	5.5
X-4339	CM	TAS266	393.6	19	42	100.8	-5
X-4339	CM	TAS266	444.4	20.1	46	126.7	0.5
X-4339	CM	TAS266	444.4	20.2	47	126.7	1
X-4339	CM	untreated	198.5	20.5	0	0	0
X-4339	CM	untreated	255	20.2	3	28.5	-1.5
X-4339	CM	untreated	264.7	20.2	7	33.4	-1.5
X-4339	CM	untreated	294.4	20	10	48.3	-2.4
X-4339	CM	untreated	371.7	20.5	16	87.3	0
X-4339	CM	untreated	375.6	19.4	20	89.3	-5.4
X-4339	CM	untreated	484.6	19	24	144.2	-7.3
X-4339	CM	untreated	530.5	19.3	27	167.3	-5.9
X-4339	CM	untreated	556.6	19	31	180.5	-7.3
X-4339	CM	untreated	629.2	19.6	34	217.1	-4.4
X-4339	CM	untreated	807.7	19.5	38	307	-4.9
X-4339	CM	untreated	766.8	22.3	42	286.4	8.8
X-4339	CM	untreated	856.3	20	45	331.5	-2.4
X-4347	BRCA	BGJ398	210.9	23.8	0	0	0
X-4347	BRCA	BGJ398	232.9	23.8	3	10.4	0
X-4347	BRCA	BGJ398	193.2	24	7	-8.4	0.8
X-4347	BRCA	BGJ398	223.8	23.5	10	6.1	-1.3
X-4347	BRCA	BGJ398	267.9	24.8	14	27	4.2
X-4347	BRCA	BGJ398	313	24.6	17	48.4	3.4
X-4347	BRCA	BGJ398	328.7	23.9	21	55.9	0.4
X-4347	BRCA	BGJ398	393.6	23.8	24	86.6	0
X-4347	BRCA	BGJ398	350.1	23.7	28	66	-0.4
X-4347	BRCA	BGJ398	420.2	23.7	31	99.2	-0.4
X-4347	BRCA	BGJ398	506	23.7	35	139.9	-0.4
X-4347	BRCA	BGJ398	544.8	24.6	38	158.3	3.4
X-4347	BRCA	BGJ398	573.9	24.3	42	172.1	2.1
X-4347	BRCA	BGJ398	583.7	24.4	45	176.8	2.5
X-4347	BRCA	BGJ398	654.5	24.3	49	210.3	2.1
X-4347	BRCA	BGJ398	698.7	25.9	52	231.3	8.8
X-4347	BRCA	BGJ398	824.9	23.8	56	291.1	0
X-4347	BRCA	BGJ398	937.7	24.9	60	344.6	4.6
X-4347	BRCA	BKM120	221.8	29.9	0	0	0
X-4347	BRCA	BKM120	216.6	29.2	4	-2.3	-2.3
X-4347	BRCA	BKM120	196.7	30.3	8	-11.3	1.3
X-4347	BRCA	BKM120	172.9	27.4	11	-22	-8.4
X-4347	BRCA	BKM120	192.5	29.3	15	-13.2	-2
X-4347	BRCA	BKM120	180.7	29.1	18	-18.5	-2.7
X-4347	BRCA	BKM120	202	29.7	22	-8.9	-0.7
X-4347	BRCA	BKM120	198.9	28	28	-10.3	-6.4
X-4347	BRCA	BKM120	180	29.3	34	-18.8	-2
X-4347	BRCA	BKM120	210.8	30.7	39	-5	2.7
X-4347	BRCA	BKM120	227.1	30.4	43	2.4	1.7
X-4347	BRCA	BKM120	226.4	31	46	2.1	3.7
X-4347	BRCA	BKM120	239.1	30.8	50	7.8	3
X-4347	BRCA	BKM120	246.9	29.5	53	11.3	-1.3
X-4347	BRCA	BKM120	232.9	30.4	57	5	1.7
X-4347	BRCA	BKM120	243.3	30.5	60	9.7	2
X-4347	BRCA	BKM120	236.6	31	64	6.7	3.7
X-4347	BRCA	BKM120	263.5	26.1	67	18.8	-12.7
X-4347	BRCA	BYL719	256.6	30.9	0	0	0
X-4347	BRCA	BYL719	240.4	30.8	3	-6.3	-0.3
X-4347	BRCA	BYL719	291.8	30.4	6	13.7	-1.6
X-4347	BRCA	BYL719	310.5	30.6	10	21	-1
X-4347	BRCA	BYL719	298.1	31.1	13	16.2	0.6
X-4347	BRCA	BYL719	451.9	30.7	17	76.1	-0.6
X-4347	BRCA	BYL719	485.1	29.9	23	89	-3.2
X-4347	BRCA	BYL719	442.8	29.9	29	72.6	-3.2
X-4347	BRCA	BYL719	418.6	32.8	34	63.1	6.1
X-4347	BRCA	BYL719	497.3	33.3	38	93.8	7.8
X-4347	BRCA	BYL719	438.3	32.2	41	70.8	4.2
X-4347	BRCA	BYL719	487	32.6	45	89.8	5.5
X-4347	BRCA	BYL719	566.9	32	48	120.9	3.6
X-4347	BRCA	BYL719	526.1	29.5	52	105	-4.5
X-4347	BRCA	BYL719	495.6	28.3	55	93.1	-8.4
X-4347	BRCA	BYL719	504.1	30.5	59	96.5	-1.3
X-4347	BRCA	BYL719	609.7	31.2	62	137.6	1
X-4347	BRCA	BYL719	579.1	31.9	66	125.7	3.2
X-4347	BRCA	BYL719	659.9	31.3	69	157.2	1.3
X-4347	BRCA	BYL719	641.2	32	73	149.9	3.6
X-4347	BRCA	BYL719	679	32	76	164.6	3.6
X-4347	BRCA	BYL719	716	32.2	80	179	4.2
X-4347	BRCA	BYL719	743.3	31.5	83	189.7	1.9
X-4347	BRCA	BYL719	797.5	31.2	87	210.8	1
X-4347	BRCA	BYL719	795.8	30.6	90	210.1	-1
X-4347	BRCA	BYL719	802.1	31.7	94	212.6	2.6
X-4347	BRCA	BYL719	794.3	31	98	209.5	0.3
X-4347	BRCA	BYL719 + LJM716	245.9	35.5	0	0	0
X-4347	BRCA	BYL719 + LJM716	202.1	33	4	-17.8	-7
X-4347	BRCA	BYL719 + LJM716	208.7	34.4	8	-15.1	-3.1
X-4347	BRCA	BYL719 + LJM716	209.9	33.6	11	-14.6	-5.4
X-4347	BRCA	BYL719 + LJM716	245.8	35	15	0	-1.4
X-4347	BRCA	BYL719 + LJM716	255.5	34.9	18	3.9	-1.7
X-4347	BRCA	BYL719 + LJM716	273.5	33.8	22	11.2	-4.8
X-4347	BRCA	BYL719 + LJM716	284.1	33.6	28	15.5	-5.4
X-4347	BRCA	BYL719 + LJM716	357.6	33	34	45.4	-7
X-4347	BRCA	BYL719 + LJM716	349	35.2	39	41.9	-0.8
X-4347	BRCA	BYL719 + LJM716	403.1	35.5	43	63.9	0
X-4347	BRCA	BYL719 + LJM716	421.5	35.3	46	71.4	-0.6
X-4347	BRCA	BYL719 + LJM716	427	35.5	50	73.6	0
X-4347	BRCA	BYL719 + LJM716	409.7	33.7	53	66.6	-5.1
X-4347	BRCA	BYL719 + LJM716	454.3	33.9	57	84.7	-4.5
X-4347	BRCA	BYL719 + LJM716	420.8	33.4	60	71.1	-5.9
X-4347	BRCA	BYL719 + LJM716	513.6	34.9	64	108.9	-1.7
X-4347	BRCA	BYL719 + LJM716	499.2	34.6	67	103	-2.5
X-4347	BRCA	BYL719 + LJM716	549.6	35.9	71	123.5	1.1
X-4347	BRCA	BYL719 + LJM716	597.2	35.8	74	142.9	0.8
X-4347	BRCA	BYL719 + LJM716	601.7	35.5	78	144.7	0
X-4347	BRCA	BYL719 + LJM716	607	35.2	81	146.8	-0.8
X-4347	BRCA	BYL719 + LJM716	565.7	29.2	85	130.1	-17.7
X-4347	BRCA	BYL719 + LJM716	560.1	21.5	88	127.8	-39.4
X-4347	BRCA	BYL719 + LEE011	202	28.8	0	0	0
X-4347	BRCA	BYL719 + LEE011	226.2	28	3	12	-2.8
X-4347	BRCA	BYL719 + LEE011	122	26.6	6	-39.6	-7.6
X-4347	BRCA	BYL719 + LEE011	103.8	24.1	10	-48.6	-16.3
X-4347	BRCA	BYL719 + LEE011	136.8	26.2	13	-32.3	-9
X-4347	BRCA	BYL719 + LEE011	129.1	27.2	17	-36.1	-5.6
X-4347	BRCA	BYL719 + LEE011	178.5	27.9	20	-11.6	-3.1
X-4347	BRCA	BYL719 + LEE011	126.4	27.6	24	-37.4	-4.2
X-4347	BRCA	BYL719 + LEE011	93.9	27	28	-53.5	-6.2
X-4347	BRCA	BYL719 + LEE011	84.7	23.5	31	-58.1	-18.4
X-4347	BRCA	BYL719 + LEE011	77.6	27.7	34	-61.6	-3.8
X-4347	BRCA	BYL719 + LEE011	68	26.3	38	-66.3	-8.7
X-4347	BRCA	BYL719 + LEE011	69.4	26.2	41	-65.6	-9
X-4347	BRCA	BYL719 + LEE011	53.9	26.9	45	-73.3	-6.6
X-4347	BRCA	BYL719 + LEE011	66	24.8	48	-67.3	-13.9
X-4347	BRCA	CGM097	219	32.9	0	0	0
X-4347	BRCA	CGM097	218.1	31.8	4	-0.4	-3.3
X-4347	BRCA	CGM097	221.4	32.5	8	1.1	-1.2
X-4347	BRCA	CGM097	236.9	32.7	11	8.2	-0.6
X-4347	BRCA	CGM097	306.7	32.9	15	40	0
X-4347	BRCA	CGM097	321.5	33.3	18	46.8	1.2
X-4347	BRCA	CGM097	392.6	33.1	22	79.3	0.6
X-4347	BRCA	CGM097	467.5	30.8	28	113.5	-6.4
X-4347	BRCA	CGM097	433.5	31.6	34	97.9	-4
X-4347	BRCA	CGM097	491.7	34.3	39	124.5	4.3
X-4347	BRCA	CGM097	646.6	33.6	43	195.3	2.1
X-4347	BRCA	CGM097	632.3	32.9	46	188.7	0
X-4347	BRCA	CGM097	647.3	32.7	50	195.6	-0.6
X-4347	BRCA	CGM097	657.3	32.6	53	200.1	-0.9
X-4347	BRCA	CGM097	844.4	32.6	57	285.6	-0.9
X-4347	BRCA	CGM097	856.5	32.1	60	291.1	-2.4
X-4347	BRCA	CGM097	895.8	33.5	64	309	1.8
X-4347	BRCA	CGM097	1070.7	33.2	67	388.9	0.9
X-4347	BRCA	CLR457	292.7	29.7	0	0	0
X-4347	BRCA	CLR457	275.8	29.1	4	-5.8	-2
X-4347	BRCA	CLR457	251	28.8	7	-14.2	-3
X-4347	BRCA	CLR457	328.9	29.7	11	12.4	0
X-4347	BRCA	CLR457	341.8	30.3	14	16.8	2
X-4347	BRCA	CLR457	355	30.5	18	21.3	2.7
X-4347	BRCA	CLR457	411.8	30.5	21	40.7	2.7
X-4347	BRCA	CLR457	437.3	30.5	25	49.4	2.7
X-4347	BRCA	CLR457	424	30.8	28	44.9	3.7
X-4347	BRCA	CLR457	461.8	29.9	32	57.8	0.7
X-4347	BRCA	CLR457	447.5	28	38	52.9	-5.7
X-4347	BRCA	CLR457	515.1	29.7	44	76	0
X-4347	BRCA	CLR457	474.6	29.6	49	62.1	-0.3
X-4347	BRCA	CLR457	524.5	29.3	53	79.2	-1.3
X-4347	BRCA	CLR457	523.8	29.2	56	79	-1.7
X-4347	BRCA	CLR457	487.4	28	60	66.5	-5.7
X-4347	BRCA	CLR457	516.5	25.9	63	76.5	-12.8
X-4347	BRCA	CLR457	459.7	28.2	67	57.1	-5.1
X-4347	BRCA	CLR457	466.4	24.7	70	59.3	-16.8
X-4347	BRCA	CLR457	533.3	26.1	74	82.2	-12.1
X-4347	BRCA	CLR457	571.6	28.1	77	95.3	-5.4
X-4347	BRCA	CLR457	695.5	30.3	81	137.6	2
X-4347	BRCA	CLR457	709.2	31.1	84	142.3	4.7
X-4347	BRCA	CLR457	794.2	30.3	88	171.3	2
X-4347	BRCA	CLR457	830	31.9	91	183.6	7.4
X-4347	BRCA	HDM201	240.2	29.4	0	0	0
X-4347	BRCA	HDM201	247.8	28.7	4	3.2	-2.4
X-4347	BRCA	HDM201	239.6	29.9	7	-0.2	1.7
X-4347	BRCA	HDM201	239.6	28.8	11	-0.2	-2
X-4347	BRCA	HDM201	369.1	28.8	17	53.7	-2
X-4347	BRCA	HDM201	324.8	28.8	23	35.2	-2
X-4347	BRCA	HDM201	352.3	29.7	28	46.7	1
X-4347	BRCA	HDM201	378.5	30	32	57.6	2
X-4347	BRCA	HDM201	373.7	28	35	55.6	-4.8
X-4347	BRCA	HDM201	321.1	28.7	39	33.7	-2.4
X-4347	BRCA	HDM201	430.5	28.3	42	79.2	-3.7
X-4347	BRCA	HDM201	397.4	26.6	46	65.4	-9.5
X-4347	BRCA	HDM201	426.1	25.2	49	77.4	-14.3
X-4347	BRCA	HDM201	455.1	25	53	89.5	-15
X-4347	BRCA	HDM201	461.7	24.1	56	92.2	-18
X-4347	BRCA	INC424	245	30.9	0	0	0
X-4347	BRCA	INC424	258.1	30.3	4	5.3	-1.9
X-4347	BRCA	INC424	335.7	29.9	7	37	-3.2
X-4347	BRCA	INC424	367.8	30	11	50.1	-2.9
X-4347	BRCA	INC424	412.2	30.2	14	68.2	-2.3
X-4347	BRCA	INC424	430.6	30.5	18	75.8	-1.3
X-4347	BRCA	INC424	494	30.4	21	101.6	-1.6
X-4347	BRCA	INC424	578.7	31	25	136.2	0.3
X-4347	BRCA	INC424	623	30.7	28	154.3	-0.6
X-4347	BRCA	LEE011	200.1	30.5	0	0	0
X-4347	BRCA	LEE011	267.3	31.9	3	33.6	4.6
X-4347	BRCA	LEE011	262.5	31	7	31.2	1.6
X-4347	BRCA	LEE011	253.6	31	10	26.7	1.6
X-4347	BRCA	LEE011	266.9	31.3	14	33.4	2.6
X-4347	BRCA	LEE011	242.3	31.1	17	21.1	2
X-4347	BRCA	LEE011	258.1	30.8	21	29	1
X-4347	BRCA	LEE011	236.4	31.6	24	18.1	3.6
X-4347	BRCA	LEE011	249	30.8	28	24.4	1
X-4347	BRCA	LEE011	238.9	31.5	34	19.4	3.3
X-4347	BRCA	LEE011	214.9	31.9	40	7.4	4.6
X-4347	BRCA	LEE011	201	31.8	45	0.4	4.3
X-4347	BRCA	LEE011	192.6	31.4	49	-3.7	3
X-4347	BRCA	LEE011	184.2	32.5	52	-7.9	6.6
X-4347	BRCA	LEE011	184.4	33	56	-7.8	8.2
X-4347	BRCA	LEE011	197.8	32.2	59	-1.1	5.6
X-4347	BRCA	LEE011	194.8	32.5	63	-2.6	6.6
X-4347	BRCA	LEE011	218	32.1	66	8.9	5.2
X-4347	BRCA	LEE011	210.1	32.6	70	5	6.9
X-4347	BRCA	LEE011	236.2	33	73	18	8.2
X-4347	BRCA	LEE011	209.5	33.3	77	4.7	9.2
X-4347	BRCA	LEE011	211.6	32.6	80	5.7	6.9
X-4347	BRCA	LEE011	216.8	31.4	84	8.3	3
X-4347	BRCA	LEE011	200.8	32	87	0.3	4.9
X-4347	BRCA	LEE011	213.6	32.2	91	6.7	5.6
X-4347	BRCA	LEE011	238.3	34.2	94	19.1	12.1
X-4347	BRCA	LEE011	253.2	33	98	26.5	8.2
X-4347	BRCA	LEE011	279.9	33	101	39.9	8.2
X-4347	BRCA	LEE011	286.9	33.2	105	43.4	8.9
X-4347	BRCA	LEE011	301.5	33.1	109	50.7	8.5
X-4347	BRCA	LEE011	306.8	32.2	112	53.3	5.6
X-4347	BRCA	LEE011	316.6	31.8	115	58.2	4.3
X-4347	BRCA	LEE011	323.3	31.9	119	61.6	4.6
X-4347	BRCA	LEE011	380.4	32.8	122	90.1	7.5
X-4347	BRCA	LEE011	353.7	33	126	76.8	8.2
X-4347	BRCA	LEE011	388.3	33	129	94.1	8.2
X-4347	BRCA	LEE011	383	33.2	133	91.4	8.9
X-4347	BRCA	LEE011	431.5	33.1	136	115.6	8.5
X-4347	BRCA	LEE011	466.1	32.7	140	132.9	7.2
X-4347	BRCA	LEE011	436.7	32.5	143	118.2	6.6
X-4347	BRCA	LEE011 + everolimus	208.3	28.3	0	0	0
X-4347	BRCA	LEE011 + everolimus	213.9	29.4	3	2.7	3.9
X-4347	BRCA	LEE011 + everolimus	175.3	27.5	7	-15.8	-2.8
X-4347	BRCA	LEE011 + everolimus	159.3	28	10	-23.5	-1.1
X-4347	BRCA	LEE011 + everolimus	171.3	28	14	-17.8	-1.1
X-4347	BRCA	LEE011 + everolimus	137.4	27	17	-34	-4.6
X-4347	BRCA	LEE011 + everolimus	131.7	27.5	21	-36.8	-2.8
X-4347	BRCA	LEE011 + everolimus	111.6	28.3	24	-46.4	0
X-4347	BRCA	LEE011 + everolimus	112.1	28.5	28	-46.2	0.7
X-4347	BRCA	LEE011 + everolimus	104.7	28.2	31	-49.7	-0.4
X-4347	BRCA	LEE011 + everolimus	115	28.1	35	-44.8	-0.7
X-4347	BRCA	LEE011 + everolimus	102.9	27.9	38	-50.6	-1.4
X-4347	BRCA	LEE011 + everolimus	78.9	27.9	42	-62.1	-1.4
X-4347	BRCA	LEE011 + everolimus	108.6	29	45	-47.9	2.5
X-4347	BRCA	LEE011 + everolimus	99.1	28.9	49	-52.4	2.1
X-4347	BRCA	LEE011 + everolimus	82.4	29.3	52	-60.4	3.5
X-4347	BRCA	LEE011 + everolimus	80.7	29	56	-61.3	2.5
X-4347	BRCA	LEE011 + everolimus	72	28.7	60	-65.4	1.4
X-4347	BRCA	LEE011 + everolimus	70.4	27.7	63	-66.2	-2.1
X-4347	BRCA	LEE011 + everolimus	77	29	66	-63	2.5
X-4347	BRCA	LEE011 + everolimus	57.7	27.7	70	-72.3	-2.1
X-4347	BRCA	LEE011 + everolimus	46.3	27.2	73	-77.8	-3.9
X-4347	BRCA	LEE011 + everolimus	53.8	28.6	77	-74.2	1.1
X-4347	BRCA	LEE011 + everolimus	50	28.6	80	-76	1.1
X-4347	BRCA	LEE011 + everolimus	47.8	27.8	84	-77.1	-1.8
X-4347	BRCA	LEE011 + everolimus	34.1	25.4	87	-83.6	-10.2
X-4347	BRCA	LFA102	213.9	27.2	0	0	0
X-4347	BRCA	LFA102	263.1	27.8	6	23	2.2
X-4347	BRCA	LFA102	277.9	28	10	29.9	2.9
X-4347	BRCA	LFA102	358.4	28.5	13	67.6	4.8
X-4347	BRCA	LFA102	420.2	28.7	17	96.4	5.5
X-4347	BRCA	LFA102	561.7	28.9	20	162.6	6.2
X-4347	BRCA	LFA102	754.9	28.7	24	252.9	5.5
X-4347	BRCA	LFA102	650.1	28.8	27	203.9	5.9
X-4347	BRCA	LFA102	825	28.7	31	285.7	5.5
X-4347	BRCA	LFA102	810.6	29.4	34	279	8.1
X-4347	BRCA	LFA102	1073.3	29.5	38	401.8	8.5
X-4347	BRCA	LFA102	1094.8	29.4	41	411.8	8.1
X-4347	BRCA	LFA102	1202	29.5	45	461.9	8.5
X-4347	BRCA	LFA102	1265.9	30.4	48	491.8	11.8
X-4347	BRCA	LJM716 + trastuzumab	237.2	26.8	0	0	0
X-4347	BRCA	LJM716 + trastuzumab	262.8	23.4	6	10.8	-12.7
X-4347	BRCA	LJM716 + trastuzumab	282.3	23.7	10	19	-11.6
X-4347	BRCA	LJM716 + trastuzumab	339.6	25.2	13	43.2	-6
X-4347	BRCA	LJM716 + trastuzumab	359	25.6	17	51.3	-4.5
X-4347	BRCA	LJM716 + trastuzumab	532.7	24.7	20	124.6	-7.8
X-4347	BRCA	LJM716 + trastuzumab	545.1	25.2	24	129.8	-6
X-4347	BRCA	LJM716 + trastuzumab	690.7	25.9	27	191.2	-3.4
X-4347	BRCA	LJM716 + trastuzumab	801.9	26.2	31	238.1	-2.2
X-4347	BRCA	LJM716 + trastuzumab	884.1	25.6	34	272.7	-4.5
X-4347	BRCA	LJM716 + trastuzumab	978.8	25.6	38	312.6	-4.5
X-4347	BRCA	LJM716 + trastuzumab	1006.1	25.9	41	324.2	-3.4
X-4347	BRCA	LJM716 + trastuzumab	1395.5	26	45	488.3	-3
X-4347	BRCA	LJM716 + trastuzumab	1373.4	26	48	479	-3
X-4347	BRCA	LJM716	226.6	29.1	0	0	0
X-4347	BRCA	LJM716	293.5	28.8	4	29.5	-1
X-4347	BRCA	LJM716	373.2	29.2	10	64.7	0.3
X-4347	BRCA	LJM716	407.5	28.6	16	79.8	-1.7
X-4347	BRCA	LJM716	498.4	29.8	21	119.9	2.4
X-4347	BRCA	LJM716	552.2	29.4	25	143.7	1
X-4347	BRCA	LJM716	597.3	30.3	28	163.6	4.1
X-4347	BRCA	LJM716	507.9	31.4	32	124.1	7.9
X-4347	BRCA	LJM716	662.8	31.7	35	192.5	8.9
X-4347	BRCA	LJM716	755.2	30.6	39	233.3	5.2
X-4347	BRCA	LJM716	787.5	31	42	247.5	6.5
X-4347	BRCA	LJM716	852.5	31.4	46	276.2	7.9
X-4347	BRCA	LJM716	881.2	31.1	49	288.9	6.9
X-4347	BRCA	LKA136	261	29.2	0	0	0
X-4347	BRCA	LKA136	365.9	31.2	4	40.2	6.8
X-4347	BRCA	LKA136	354.9	30.2	7	36	3.4
X-4347	BRCA	LKA136	353.5	30.8	11	35.4	5.5
X-4347	BRCA	LKA136	451.7	31.1	14	73.1	6.5
X-4347	BRCA	LKA136	584.7	31.4	18	124	7.5
X-4347	BRCA	LKA136	592.7	31.3	21	127.1	7.2
X-4347	BRCA	LKA136	723.1	30.8	25	177	5.5
X-4347	BRCA	LKA136	783.3	31.9	28	200.1	9.2
X-4347	BRCA	LLM871	277.2	27.1	0	0	0
X-4347	BRCA	LLM871	358.9	25.8	3	29.5	-4.8
X-4347	BRCA	LLM871	359.8	26.7	6	29.8	-1.5
X-4347	BRCA	LLM871	333.4	26.6	10	20.3	-1.8
X-4347	BRCA	LLM871	408.2	26.5	13	47.3	-2.2
X-4347	BRCA	LLM871	475	26.1	17	71.4	-3.7
X-4347	BRCA	LLM871	481.3	27.1	20	73.6	0
X-4347	BRCA	LLM871	477	26.4	24	72.1	-2.6
X-4347	BRCA	LLM871	606.5	27.5	27	118.8	1.5
X-4347	BRCA	LLM871	736.6	26.6	31	165.7	-1.8
X-4347	BRCA	LLM871	709.2	27.9	34	155.8	3
X-4347	BRCA	LLM871	883	27.6	38	218.5	1.8
X-4347	BRCA	LLM871	1092.7	28.1	41	294.2	3.7
X-4347	BRCA	binimetinib	257.1	32.5	0	0	0
X-4347	BRCA	binimetinib	239.7	32.5	4	-6.8	0
X-4347	BRCA	binimetinib	239.8	33	8	-6.7	1.5
X-4347	BRCA	binimetinib	210.6	31.9	11	-18.1	-1.8
X-4347	BRCA	binimetinib	165.3	32.2	14	-35.7	-0.9
X-4347	BRCA	binimetinib	206.1	31.6	18	-19.8	-2.8
X-4347	BRCA	binimetinib	189	32	21	-26.5	-1.5
X-4347	BRCA	binimetinib	177.7	32.2	25	-30.9	-0.9
X-4347	BRCA	binimetinib	162.7	31.6	28	-36.7	-2.8
X-4347	BRCA	binimetinib	126.8	32	32	-50.7	-1.5
X-4347	BRCA	binimetinib	175.8	31.7	35	-31.6	-2.5
X-4347	BRCA	binimetinib	177.3	30.7	39	-31	-5.5
X-4347	BRCA	binimetinib	155.3	30.9	42	-39.6	-4.9
X-4347	BRCA	binimetinib	107.2	29.5	50	-58.3	-9.2
X-4347	BRCA	binimetinib	112.9	26.8	53	-56.1	-17.5
X-4347	BRCA	binimetinib	105.9	27	56	-58.8	-16.9
X-4347	BRCA	paclitaxel	210.8	26.5	0	0	0
X-4347	BRCA	paclitaxel	276.1	29.2	6	31	10.2
X-4347	BRCA	paclitaxel	278.8	28.4	10	32.3	7.2
X-4347	BRCA	paclitaxel	343	28	13	62.7	5.7
X-4347	BRCA	paclitaxel	344.4	27.2	17	63.4	2.6
X-4347	BRCA	paclitaxel	387.5	27.8	20	83.8	4.9
X-4347	BRCA	paclitaxel	376.2	28.2	24	78.5	6.4
X-4347	BRCA	paclitaxel	387.1	29.1	27	83.6	9.8
X-4347	BRCA	paclitaxel	393.6	28.6	31	86.7	7.9
X-4347	BRCA	paclitaxel	532.3	28.6	37	152.5	7.9
X-4347	BRCA	paclitaxel	501.3	29.6	48	137.8	11.7
X-4347	BRCA	paclitaxel	749.5	29.4	52	255.6	10.9
X-4347	BRCA	paclitaxel	724.7	30.4	55	243.8	14.7
X-4347	BRCA	paclitaxel	768	30.2	59	264.3	14
X-4347	BRCA	paclitaxel	892.2	29.8	62	323.2	12.5
X-4347	BRCA	tamoxifen	223.3	30.9	0	0	0
X-4347	BRCA	tamoxifen	288.9	31.7	4	29.4	2.6
X-4347	BRCA	tamoxifen	330.9	32.2	10	48.2	4.2
X-4347	BRCA	tamoxifen	406.4	32.9	16	82	6.5
X-4347	BRCA	tamoxifen	441.3	33.2	21	97.6	7.4
X-4347	BRCA	tamoxifen	451.5	32.2	25	102.2	4.2
X-4347	BRCA	tamoxifen	435.3	32.1	28	94.9	3.9
X-4347	BRCA	tamoxifen	432.9	32.5	32	93.9	5.2
X-4347	BRCA	tamoxifen	539.2	32.3	35	141.5	4.5
X-4347	BRCA	tamoxifen	627.3	32.8	39	180.9	6.1
X-4347	BRCA	tamoxifen	785.8	32.7	42	251.9	5.8
X-4347	BRCA	tamoxifen	821.1	32.5	46	267.7	5.2
X-4347	BRCA	tamoxifen	863.2	33.2	49	286.6	7.4
X-4347	BRCA	trastuzumab	222.2	26.4	0	0	0
X-4347	BRCA	trastuzumab	310.6	27	6	39.8	2.3
X-4347	BRCA	trastuzumab	364.1	27.9	10	63.9	5.7
X-4347	BRCA	trastuzumab	397.9	28.4	13	79.1	7.6
X-4347	BRCA	trastuzumab	355.3	28.3	17	59.9	7.2
X-4347	BRCA	trastuzumab	508	28.2	20	128.6	6.8
X-4347	BRCA	trastuzumab	526	28.3	24	136.7	7.2
X-4347	BRCA	trastuzumab	525.6	28.7	27	136.5	8.7
X-4347	BRCA	trastuzumab	602.8	28.4	31	171.3	7.6
X-4347	BRCA	trastuzumab	697.3	29	34	213.8	9.8
X-4347	BRCA	trastuzumab	709.2	29.2	38	219.2	10.6
X-4347	BRCA	trastuzumab	725.6	29.8	41	226.6	12.9
X-4347	BRCA	trastuzumab	775.1	28.5	45	248.8	8
X-4347	BRCA	trastuzumab	774.2	29.2	48	248.4	10.6
X-4347	BRCA	trastuzumab	868.6	29.4	52	290.9	11.4
X-4347	BRCA	trastuzumab	979.3	29.1	55	340.7	10.2
X-4347	BRCA	trastuzumab	984.1	29.9	59	342.9	13.3
X-4347	BRCA	trastuzumab	1187	30.3	62	434.2	14.8
X-4347	BRCA	untreated	369.4	31.5	0	0	0
X-4347	BRCA	untreated	404.4	31	3	9.5	-1.6
X-4347	BRCA	untreated	575.3	31.4	6	55.7	-0.3
X-4347	BRCA	untreated	698.2	30.8	10	89	-2.2
X-4347	BRCA	untreated	804.7	32.3	13	117.8	2.5
X-4347	BRCA	untreated	981.8	32	17	165.8	1.6
X-4347	BRCA	LFW527 + everolimus	187.85	26.9	0	0	0
X-4347	BRCA	LFW527 + everolimus	176.99	25.4	4	-5.8	-5.6
X-4347	BRCA	LFW527 + everolimus	199.49	24.8	8	6.2	-7.8
X-4347	BRCA	LFW527 + everolimus	202.54	24.8	11	7.8	-7.8
X-4347	BRCA	LFW527 + everolimus	179.82	23.6	14	-4.3	-12.3
X-4347	BRCA	LFW527 + everolimus	196.76	23.5	18	4.7	-12.6
X-4347	BRCA	LFW527 + everolimus	174.45	23.4	21	-7.1	-13
X-4347	BRCA	LFW527 + everolimus	228.94	23.5	25	21.9	-12.6
X-4347	BRCA	LFW527 + everolimus	228.86	23.5	28	21.8	-12.6
X-4347	BRCA	LFW527 + everolimus	231.1	24.2	32	23	-10
X-4347	BRCA	LFW527 + everolimus	210.89	24.5	35	12.3	-8.9
X-4347	BRCA	LFW527 + everolimus	221.12	24.1	38	17.7	-10.4
X-4347	BRCA	LFW527 + everolimus	242.15	23.5	42	28.9	-12.6
X-4347	BRCA	LFW527 + everolimus	242.14	22.6	45	28.9	-16
X-4347	BRCA	LFW527 + everolimus	263.8	25.7	49	40.4	-4.5
X-4347	BRCA	LFW527 + everolimus	307	24.1	52	63.4	-10.4
X-4347	BRCA	LFW527 + everolimus	287.75	24.1	56	53.2	-10.4
X-4347	BRCA	LFW527 + everolimus	353.94	24.5	59	88.4	-8.9
X-4347	BRCA	LFW527 + everolimus	326.49	24.4	63	73.8	-9.3
X-4347	BRCA	LFW527 + everolimus	357.25	23.8	66	90.2	-11.5
X-4347	BRCA	LFW527 + everolimus	331.07	23.8	70	76.2	-11.5
X-4347	BRCA	LFW527 + everolimus	360.86	23.8	73	92.1	-11.5
X-4347	BRCA	LFW527 + everolimus	369.97	23.9	77	96.9	-11.2
X-4347	BRCA	LFW527 + everolimus	384.8	24.1	81	104.8	-10.4
X-4347	BRCA	LFW527 + everolimus	315.36	22.7	84	67.9	-15.6
X-4347	BRCA	LFW527 + everolimus	364.9	24.7	87	94.3	-8.2
X-4347	BRCA	LFW527 + everolimus	390.25	24.8	91	107.7	-7.8
X-4347	BRCA	LFW527 + everolimus	360.48	24.2	94	91.9	-10
X-4347	BRCA	LFW527 + everolimus	372.71	23	98	98.4	-14.5
X-4377	PDAC	abraxane	245.5	23.8	0	0	0
X-4377	PDAC	abraxane	408	24.1	2	66.2	1.3
X-4377	PDAC	abraxane	574.5	23.8	6	134	0
X-4377	PDAC	abraxane	878.3	24.6	9	257.8	3.4
X-4377	PDAC	BKM120 + binimetinib	217.2	24.9	0	0	0
X-4377	PDAC	BKM120 + binimetinib	245.2	24.7	4	12.9	-0.8
X-4377	PDAC	BKM120 + binimetinib	243.4	24.9	7	12.1	0
X-4377	PDAC	BKM120 + binimetinib	202.2	23.5	11	-6.9	-5.6
X-4377	PDAC	BKM120 + binimetinib	250.7	22.4	14	15.4	-10
X-4377	PDAC	BKM120 + binimetinib	187.6	22.8	17	-13.6	-8.4
X-4377	PDAC	BKM120 + binimetinib	234.2	23.3	20	7.8	-6.4
X-4377	PDAC	BKM120 + binimetinib	265.6	24.1	25	22.3	-3.2
X-4377	PDAC	BKM120 + binimetinib	236.3	23.6	28	8.8	-5.2
X-4377	PDAC	BKM120 + binimetinib	204.1	24.6	32	-6	-1.2
X-4377	PDAC	BKM120 + binimetinib	437.8	25.8	35	101.6	3.6
X-4377	PDAC	BKM120 + binimetinib	270.2	25.1	38	24.4	0.8
X-4377	PDAC	BKM120 + binimetinib	353.2	24.9	42	62.6	0
X-4377	PDAC	BKM120 + binimetinib	311.7	25.8	45	43.5	3.6
X-4377	PDAC	BKM120 + binimetinib	289.4	25.4	48	33.2	2
X-4377	PDAC	BKM120 + binimetinib	322	24.7	52	48.3	-0.8
X-4377	PDAC	BKM120 + binimetinib	356.1	26.1	56	64	4.8
X-4377	PDAC	BKM120 + binimetinib	519	25.9	60	139	4
X-4377	PDAC	BKM120 + binimetinib	582.9	24.8	63	168.4	-0.4
X-4377	PDAC	BKM120 + binimetinib	496.1	24.6	66	128.4	-1.2
X-4377	PDAC	BKM120 + binimetinib	580.8	25.6	70	167.4	2.8
X-4377	PDAC	BKM120 + binimetinib	720.4	24.7	74	231.7	-0.8
X-4377	PDAC	BKM120 + LDE225	393.1	26.1	0	0	0
X-4377	PDAC	BKM120 + LDE225	489.3	26.5	1	24.5	1.5
X-4377	PDAC	BKM120 + LDE225	341.4	25.5	4	-13.2	-2.3
X-4377	PDAC	BKM120 + LDE225	334.2	25	8	-15	-4.2
X-4377	PDAC	BKM120 + LDE225	306.9	25.5	11	-21.9	-2.3
X-4377	PDAC	BKM120 + LDE225	274.7	25.1	14	-30.1	-3.8
X-4377	PDAC	BKM120 + LDE225	253.5	24.7	18	-35.5	-5.4
X-4377	PDAC	BKM120 + LDE225	233	25.8	22	-40.7	-1.1
X-4377	PDAC	BKM120 + LDE225	249.1	24.4	26	-36.6	-6.5
X-4377	PDAC	BKM120 + LDE225	211.2	20.6	29	-46.3	-21.1
X-4377	PDAC	BKM120	200.1	26.4	0	0	0
X-4377	PDAC	BKM120	167.3	26	1	-16.4	-1.5
X-4377	PDAC	BKM120	280.8	27.8	6	40.3	5.3
X-4377	PDAC	BKM120	269.8	27.7	8	34.8	4.9
X-4377	PDAC	BKM120	288.5	28.4	12	44.2	7.6
X-4377	PDAC	BKM120	383	27.4	15	91.4	3.8
X-4377	PDAC	BKM120	432.8	28.2	19	116.3	6.8
X-4377	PDAC	BKM120	687.2	27.1	22	243.4	2.7
X-4377	PDAC	BKM120	587.1	28	26	193.4	6.1
X-4377	PDAC	BKM120	619.1	27	29	209.4	2.3
X-4377	PDAC	BYL719	276.5	22.9	0	0	0
X-4377	PDAC	BYL719	368.5	23.5	4	33.3	2.6
X-4377	PDAC	BYL719	381.4	21.3	7	37.9	-7
X-4377	PDAC	BYL719	528.5	22.7	11	91.1	-0.9
X-4377	PDAC	BYL719	594.5	22.2	14	115	-3.1
X-4377	PDAC	BYL719	646	21	17	133.6	-8.3
X-4377	PDAC	BYL719	716	21.2	22	159	-7.4
X-4377	PDAC	BYL719	781.6	20.9	24	182.7	-8.7
X-4377	PDAC	BYL719	811.3	19.5	28	193.4	-14.8
X-4377	PDAC	CLR457	260.4	28.8	0	0	0
X-4377	PDAC	CLR457	270.5	29	3	3.9	0.7
X-4377	PDAC	CLR457	336	28.3	7	29	-1.7
X-4377	PDAC	CLR457	351.3	29.3	10	34.9	1.7
X-4377	PDAC	CLR457	373.1	29.2	14	43.3	1.4
X-4377	PDAC	CLR457	412.6	29.3	17	58.4	1.7
X-4377	PDAC	CLR457	431.1	29.3	20	65.6	1.7
X-4377	PDAC	CLR457	503	28.5	23	93.2	-1
X-4377	PDAC	CLR457	551.9	30.3	28	111.9	5.2
X-4377	PDAC	CLR457	605.1	29.5	31	132.4	2.4
X-4377	PDAC	CLR457	671.6	27.5	35	157.9	-4.5
X-4377	PDAC	CLR457	685.3	29.9	38	163.2	3.8
X-4377	PDAC	CLR457	741.1	29.5	41	184.6	2.4
X-4377	PDAC	HDM201	230.1	25.2	0	0	0
X-4377	PDAC	HDM201	289.2	25.2	3	25.7	0
X-4377	PDAC	HDM201	462.5	25.1	6	101	-0.4
X-4377	PDAC	HDM201	514.1	25	9	123.4	-0.8
X-4377	PDAC	HDM201	680.1	24.1	14	195.6	-4.4
X-4377	PDAC	HDM201	758.8	24.2	16	229.8	-4
X-4377	PDAC	HDM201	830.5	24.2	20	260.9	-4
X-4377	PDAC	HDM201	1048.9	24.7	27	355.8	-2
X-4377	PDAC	figitumumab" + binimetinib	273.8	28.1	0	0	0
X-4377	PDAC	figitumumab" + binimetinib	407.1	27.1	2	48.7	-3.6
X-4377	PDAC	figitumumab" + binimetinib	799.7	27.6	7	192.1	-1.8
X-4377	PDAC	figitumumab" + binimetinib	1046.5	26.9	10	282.2	-4.3
X-4377	PDAC	figitumumab" + binimetinib	1229.8	26.8	14	349.2	-4.6
X-4377	PDAC	figitumumab" + binimetinib	1004.5	26.9	17	266.9	-4.3
X-4377	PDAC	figitumumab" + binimetinib	1609.4	27	21	487.8	-3.9
X-4377	PDAC	figitumumab"	224.7	32.4	0	0	0
X-4377	PDAC	figitumumab"	229.7	32.9	2	2.2	1.5
X-4377	PDAC	figitumumab"	536.3	31	9	138.7	-4.3
X-4377	PDAC	figitumumab"	733.8	32.8	13	226.6	1.2
X-4377	PDAC	figitumumab"	947.5	34	16	321.7	4.9
X-4377	PDAC	gemcitabine-50mpk	251.3	25.1	0	0	0
X-4377	PDAC	gemcitabine-50mpk	263.1	24.9	3	4.7	-0.8
X-4377	PDAC	gemcitabine-50mpk	301.6	25.5	7	20	1.6
X-4377	PDAC	gemcitabine-50mpk	330.1	25.6	11	31.4	2
X-4377	PDAC	gemcitabine-50mpk	371.7	26.1	14	47.9	4
X-4377	PDAC	gemcitabine-50mpk	387.6	26.2	18	54.2	4.4
X-4377	PDAC	gemcitabine-50mpk	359.2	26.4	20	42.9	5.2
X-4377	PDAC	gemcitabine-50mpk	311.8	26.4	25	24.1	5.2
X-4377	PDAC	gemcitabine-50mpk	283.7	26.6	31	12.9	6
X-4377	PDAC	gemcitabine-50mpk	252.9	26	35	0.6	3.6
X-4377	PDAC	gemcitabine-50mpk	227.2	26.5	39	-9.6	5.6
X-4377	PDAC	gemcitabine-50mpk	197.9	26.1	41	-21.2	4
X-4377	PDAC	gemcitabine-50mpk	216.3	26.8	46	-13.9	6.8
X-4377	PDAC	gemcitabine-50mpk	215.3	25.8	48	-14.3	2.8
X-4377	PDAC	gemcitabine-50mpk	274.8	25.5	53	9.4	1.6
X-4377	PDAC	gemcitabine-50mpk	283.4	26.1	56	12.8	4
X-4377	PDAC	gemcitabine-50mpk	257.4	26.5	60	2.4	5.6
X-4377	PDAC	gemcitabine-50mpk	235.9	25.8	63	-6.1	2.8
X-4377	PDAC	gemcitabine-50mpk	317	25.4	67	26.1	1.2
X-4377	PDAC	gemcitabine-50mpk	371.1	26.3	70	47.7	4.8
X-4377	PDAC	gemcitabine-50mpk	512.8	25.6	73	104.1	2
X-4377	PDAC	INC424 + binimetinib	303.9	34.2	0	0	0
X-4377	PDAC	INC424 + binimetinib	351.9	33.7	1	15.8	-1.5
X-4377	PDAC	INC424 + binimetinib	347	31.1	4	14.2	-9.1
X-4377	PDAC	INC424 + binimetinib	366.3	31.5	8	20.5	-7.9
X-4377	PDAC	INC424 + binimetinib	597.9	32	11	96.7	-6.4
X-4377	PDAC	INC424 + binimetinib	440.4	32.5	14	44.9	-5
X-4377	PDAC	INC424 + binimetinib	679.9	31.6	18	123.7	-7.6
X-4377	PDAC	INC424 + binimetinib	800.9	32.4	22	163.5	-5.3
X-4377	PDAC	INC424 + binimetinib	946.3	32	26	211.4	-6.4
X-4377	PDAC	INC424 + binimetinib	978	31.4	29	221.8	-8.2
X-4377	PDAC	INC424 + binimetinib	1007.4	31.2	32	231.5	-8.8
X-4377	PDAC	INC424 + binimetinib	1614.5	31.2	36	431.3	-8.8
X-4377	PDAC	INC424	231.5	25.6	0	0	0
X-4377	PDAC	INC424	306.1	25.6	3	32.2	0
X-4377	PDAC	INC424	457.6	24.9	6	97.7	-2.7
X-4377	PDAC	INC424	559.7	25.4	9	141.8	-0.8
X-4377	PDAC	INC424	699.7	24.7	14	202.2	-3.5
X-4377	PDAC	INC424	816.1	25	16	252.5	-2.3
X-4377	PDAC	INC424	905.1	24.6	20	291	-3.9
X-4377	PDAC	LEE011	214.7	23.7	0	0	0
X-4377	PDAC	LEE011	266.6	24.9	4	24.2	5.1
X-4377	PDAC	LEE011	263.6	24.1	7	22.8	1.7
X-4377	PDAC	LEE011	289.3	24.4	11	34.7	3
X-4377	PDAC	LEE011	320.2	25.9	14	49.1	9.3
X-4377	PDAC	LEE011	461.6	25.7	18	115	8.4
X-4377	PDAC	LEE011	492	26.6	21	129.2	12.2
X-4377	PDAC	LEE011	565	27.2	25	163.2	14.8
X-4377	PDAC	LEE011	631.8	27.6	28	194.3	16.5
X-4377	PDAC	LEE011	731	27.3	33	240.5	15.2
X-4377	PDAC	LEE011	811.3	27.8	36	277.9	17.3
X-4377	PDAC	LEE011	948.6	27.5	39	341.8	16
X-4377	PDAC	LEE011	1055.5	28.1	42	391.6	18.6
X-4377	PDAC	WNT974	216.8	25.8	0	0	0
X-4377	PDAC	WNT974	278.7	26.9	2	28.6	4.3
X-4377	PDAC	WNT974	281.7	25.3	5	29.9	-1.9
X-4377	PDAC	WNT974	288.3	25.5	8	33	-1.2
X-4377	PDAC	WNT974	305	25.5	13	40.7	-1.2
X-4377	PDAC	WNT974	231.8	25.7	16	6.9	-0.4
X-4377	PDAC	WNT974	350.4	25.7	20	61.6	-0.4
X-4377	PDAC	WNT974	384.3	26.7	23	77.3	3.5
X-4377	PDAC	WNT974	547.9	26.8	26	152.7	3.9
X-4377	PDAC	WNT974	752.1	26.8	34	246.9	3.9
X-4377	PDAC	WNT974	874.7	27	36	303.5	4.7
X-4377	PDAC	WNT974	756.2	26.6	41	248.8	3.1
X-4377	PDAC	WNT974	1162.6	27.5	44	436.3	6.6
X-4377	PDAC	WNT974	992.8	26.8	47	357.9	3.9
X-4377	PDAC	WNT974	1047.4	NA	51	383.1	3.9
X-4377	PDAC	WNT974	1103.2	26.8	55	408.9	3.9
X-4377	PDAC	WNT974	1209.6	28.1	58	457.9	8.9
X-4377	PDAC	WNT974	1244.7	27.1	63	474.1	5
X-4377	PDAC	LKA136	202.5	26.7	0	0	0
X-4377	PDAC	LKA136	217.4	26.7	1	7.4	0
X-4377	PDAC	LKA136	182.3	26	5	-10	-2.6
X-4377	PDAC	LKA136	84.9	25.7	8	-58.1	-3.7
X-4377	PDAC	LKA136	72.1	24.5	11	-64.4	-8.2
X-4377	PDAC	LKA136	15.6	25.5	15	-92.3	-4.5
X-4377	PDAC	LKA136	0	25.2	19	-100	-5.6
X-4377	PDAC	LKA136	0	25.4	22	-100	-4.9
X-4377	PDAC	LKA136	0	26.3	26	-100	-1.5
X-4377	PDAC	LKA136	0	26.2	29	-100	-1.9
X-4377	PDAC	LKA136	0	25.8	32	-100	-3.4
X-4377	PDAC	LKA136	0	26.3	34	-100	-1.5
X-4377	PDAC	LKA136	0	26.5	40	-100	-0.7
X-4377	PDAC	LKA136	0	26.6	42	-100	-0.4
X-4377	PDAC	LKA136	0	26.2	47	-100	-1.9
X-4377	PDAC	LKA136	0	26.1	53	-100	-2.2
X-4377	PDAC	LKA136	0	26.8	57	-100	0.4
X-4377	PDAC	LKA136	0	27.1	61	-100	1.5
X-4377	PDAC	LKA136	0.1	27.1	64	-100	1.5
X-4377	PDAC	LKA136	0	25.9	69	-100	-3
X-4377	PDAC	LKA136	0	27.1	71	-100	1.5
X-4377	PDAC	LKA136	0	27	75	-100	1.1
X-4377	PDAC	LKA136	0	26.6	78	-100	-0.4
X-4377	PDAC	LKA136	0	27.2	81	-100	1.9
X-4377	PDAC	LKA136	0	27.1	84	-100	1.5
X-4377	PDAC	LKA136	0	25.3	89	-100	-5.2
X-4377	PDAC	binimetinib	290.2	25.9	0	0	0
X-4377	PDAC	binimetinib	291	25.7	4	0.3	-0.8
X-4377	PDAC	binimetinib	268.8	25.4	7	-7.4	-1.9
X-4377	PDAC	binimetinib	274	26.2	11	-5.6	1.2
X-4377	PDAC	binimetinib	400	26.3	14	37.8	1.5
X-4377	PDAC	binimetinib	288.8	25.6	17	-0.5	-1.2
X-4377	PDAC	binimetinib	308.1	26.3	20	6.2	1.5
X-4377	PDAC	binimetinib	331.2	26	25	14.1	0.4
X-4377	PDAC	binimetinib	337.7	25.9	28	16.4	0
X-4377	PDAC	binimetinib	250.1	25.6	32	-13.8	-1.2
X-4377	PDAC	binimetinib	204.1	24.9	35	-29.7	-3.9
X-4377	PDAC	binimetinib-3.5mpk	251.2	29.1	0	0	0
X-4377	PDAC	binimetinib-3.5mpk	289.5	29	2	15.2	-0.3
X-4377	PDAC	binimetinib-3.5mpk	455.8	30.2	6	81.4	3.8
X-4377	PDAC	binimetinib-3.5mpk	413.7	29	9	64.7	-0.3
X-4377	PDAC	binimetinib-3.5mpk	773.2	28.4	13	207.8	-2.4
X-4377	PDAC	binimetinib-3.5mpk	769.7	29.4	16	206.4	1
X-4377	PDAC	binimetinib-3.5mpk	1005.5	29.6	20	300.3	1.7
X-4377	PDAC	binimetinib-3.5mpk	1226.3	29.9	23	388.2	2.7
X-4377	PDAC	binimetinib-3.5mpk	1339.2	30.3	26	433.1	4.1
X-4377	PDAC	binimetinib-3.5mpk	1619.3	30	28	544.6	3.1
X-4377	PDAC	trametinib	285	24.9	0	0	0
X-4377	PDAC	trametinib	176.3	24.7	4	-38.1	-0.8
X-4377	PDAC	trametinib	201.7	25.1	7	-29.2	0.8
X-4377	PDAC	trametinib	305.9	26	12	7.3	4.4
X-4377	PDAC	trametinib	321	25.7	14	12.6	3.2
X-4377	PDAC	trametinib	292.9	25.9	18	2.8	4
X-4377	PDAC	trametinib	286.9	25.6	21	0.7	2.8
X-4377	PDAC	trametinib	248.5	25.2	25	-12.8	1.2
X-4377	PDAC	trametinib	331.4	25.2	28	16.3	1.2
X-4377	PDAC	trametinib	322.6	26.2	32	13.2	5.2
X-4377	PDAC	trametinib	364.9	24.9	35	28	0
X-4377	PDAC	trametinib	497.8	25.5	40	74.7	2.4
X-4377	PDAC	trametinib	497.9	24.8	45	74.7	-0.4
X-4377	PDAC	trametinib	663.7	25.2	48	132.9	1.2
X-4377	PDAC	trametinib	817.6	26.4	52	186.9	6
X-4378	PDAC	abraxane	222	24.6	0	0	0
X-4378	PDAC	abraxane	230.8	25	2	4	1.6
X-4378	PDAC	abraxane	314.2	24.8	6	41.5	0.8
X-4378	PDAC	abraxane	389.5	25.8	9	75.5	4.9
X-4378	PDAC	abraxane	443.5	26.3	13	99.8	6.9
X-4378	PDAC	abraxane	478.8	26.7	16	115.7	8.5
X-4378	PDAC	abraxane	621.8	27.1	21	180.1	10.2
X-4378	PDAC	abraxane	785.7	27.2	24	253.9	10.6
X-4378	PDAC	BKM120 + binimetinib	269	36.7	0	0	0
X-4378	PDAC	BKM120 + binimetinib	251.4	31	4	-6.5	-15.5
X-4378	PDAC	BKM120 + binimetinib	248.5	32.6	7	-7.6	-11.2
X-4378	PDAC	BKM120 + binimetinib	270	33.2	11	0.4	-9.5
X-4378	PDAC	BKM120 + binimetinib	260	33	14	-3.3	-10.1
X-4378	PDAC	BKM120 + binimetinib	240.2	34.2	18	-10.7	-6.8
X-4378	PDAC	BKM120 + binimetinib	237.7	33.9	21	-11.6	-7.6
X-4378	PDAC	BKM120 + binimetinib	299.6	34.3	25	11.4	-6.5
X-4378	PDAC	BKM120 + binimetinib	306.8	33.4	28	14.1	-9
X-4378	PDAC	BKM120 + binimetinib	244.6	33.9	31	-9.1	-7.6
X-4378	PDAC	BKM120 + binimetinib	232.8	33.4	34	-13.5	-9
X-4378	PDAC	BKM120 + binimetinib	227.1	34.1	39	-15.6	-7.1
X-4378	PDAC	BKM120 + binimetinib	311.1	33	42	15.7	-10.1
X-4378	PDAC	BKM120 + binimetinib	259.1	32.8	46	-3.7	-10.6
X-4378	PDAC	BKM120 + binimetinib	305.7	32.9	49	13.6	-10.4
X-4378	PDAC	BKM120 + binimetinib	239.6	33.1	52	-10.9	-9.8
X-4378	PDAC	BKM120 + binimetinib	295	33.8	56	9.7	-7.9
X-4378	PDAC	BKM120 + binimetinib	498.5	34.5	59	85.3	-6
X-4378	PDAC	BKM120 + binimetinib	336.8	33.7	62	25.2	-8.2
X-4378	PDAC	BKM120 + binimetinib	338.3	33.4	66	25.8	-9
X-4378	PDAC	BKM120 + binimetinib	451.6	34.3	70	67.9	-6.5
X-4378	PDAC	BKM120 + binimetinib	532.3	35	74	97.9	-4.6
X-4378	PDAC	BKM120 + binimetinib	454.3	34.3	77	68.9	-6.5
X-4378	PDAC	BKM120 + binimetinib	479.9	34.3	80	78.4	-6.5
X-4378	PDAC	BKM120 + binimetinib	542	34.3	84	101.5	-6.5
X-4378	PDAC	BKM120 + LDE225	349	24.9	0	0	0
X-4378	PDAC	BKM120 + LDE225	249.8	23.9	4	-28.4	-4
X-4378	PDAC	BKM120 + LDE225	300.6	24.7	7	-13.9	-0.8
X-4378	PDAC	BKM120 + LDE225	212.2	24	11	-39.2	-3.6
X-4378	PDAC	BKM120 + LDE225	191.8	22.9	14	-45	-8
X-4378	PDAC	BKM120 + LDE225	273.5	23.7	18	-21.6	-4.8
X-4378	PDAC	BKM120 + LDE225	138.8	22.8	21	-60.2	-8.4
X-4378	PDAC	BKM120 + LDE225	144	23.3	25	-58.7	-6.4
X-4378	PDAC	BKM120 + LDE225	124.8	21.7	28	-64.2	-12.9
X-4378	PDAC	BKM120 + LDE225	136.2	22	31	-61	-11.6
X-4378	PDAC	BKM120 + LDE225	129.3	21.7	34	-63	-12.9
X-4378	PDAC	BKM120 + LDE225	117.5	20	39	-66.3	-19.7
X-4378	PDAC	BKM120 + LDE225	140.6	22.3	42	-59.7	-10.4
X-4378	PDAC	BKM120 + LDE225	129.2	23.8	46	-63	-4.4
X-4378	PDAC	BKM120 + LDE225	143.1	24.9	49	-59	0
X-4378	PDAC	BKM120 + LDE225	194.4	24.8	52	-44.3	-0.4
X-4378	PDAC	BKM120 + LDE225	186.1	26.1	56	-46.7	4.8
X-4378	PDAC	BKM120 + LDE225	286.9	27.2	59	-17.8	9.2
X-4378	PDAC	BKM120 + LDE225	187.5	26.1	62	-46.3	4.8
X-4378	PDAC	BKM120 + LDE225	216.6	25.6	66	-37.9	2.8
X-4378	PDAC	BKM120 + LDE225	233.9	26.6	70	-33	6.8
X-4378	PDAC	BKM120 + LDE225	258.8	25.9	74	-25.8	4
X-4378	PDAC	BKM120 + LDE225	166.7	25.1	77	-52.2	0.8
X-4378	PDAC	BKM120 + LDE225	177.3	25.6	80	-49.2	2.8
X-4378	PDAC	BKM120 + LDE225	195.8	25.5	84	-43.9	2.4
X-4378	PDAC	BKM120	206.7	27.3	0	0	0
X-4378	PDAC	BKM120	238.3	28.3	5	15.3	3.7
X-4378	PDAC	BKM120	320	27	7	54.8	-1.1
X-4378	PDAC	BKM120	237.7	27.1	11	15	-0.7
X-4378	PDAC	BKM120	326.2	27.6	14	57.8	1.1
X-4378	PDAC	BKM120	500.6	27.9	18	142.2	2.2
X-4378	PDAC	BKM120	503.4	26.9	21	143.5	-1.5
X-4378	PDAC	BKM120	571	27.2	25	176.2	-0.4
X-4378	PDAC	BKM120	418.1	28.2	28	102.3	3.3
X-4378	PDAC	BKM120	531.5	28.2	32	157.1	3.3
X-4378	PDAC	BKM120	468.4	28.9	35	126.6	5.9
X-4378	PDAC	BKM120	477.3	28.4	41	130.9	4
X-4378	PDAC	BYL719 + LJM716	325	31.5	0	0	0
X-4378	PDAC	BYL719 + LJM716	326.3	32.8	4	0.4	4.1
X-4378	PDAC	BYL719 + LJM716	362.3	31.5	7	11.5	0
X-4378	PDAC	BYL719 + LJM716	434.4	30.5	11	33.7	-3.2
X-4378	PDAC	BYL719 + LJM716	437.5	30.9	14	34.6	-1.9
X-4378	PDAC	BYL719 + LJM716	446.1	30.6	18	37.3	-2.9
X-4378	PDAC	BYL719 + LJM716	531.7	30.6	21	63.6	-2.9
X-4378	PDAC	BYL719 + LJM716	553.8	31.8	25	70.4	1
X-4378	PDAC	BYL719 + LJM716	585.1	30.4	27	80	-3.5
X-4378	PDAC	BYL719 + LJM716	525.6	31.2	32	61.7	-1
X-4378	PDAC	BYL719 + LJM716	535.9	31.3	35	64.9	-0.6
X-4378	PDAC	BYL719 + LJM716	566.1	30.7	39	74.2	-2.5
X-4378	PDAC	BYL719 + LJM716	577.9	31.4	42	77.8	-0.3
X-4378	PDAC	BYL719 + LJM716	587.6	31.3	45	80.8	-0.6
X-4378	PDAC	BYL719	203.4	26.3	0	0	0
X-4378	PDAC	BYL719	193.7	25.2	3	-4.8	-4.2
X-4378	PDAC	BYL719	169.6	25.9	8	-16.6	-1.5
X-4378	PDAC	BYL719	156.2	26	11	-23.2	-1.1
X-4378	PDAC	BYL719	152.3	27	14	-25.1	2.7
X-4378	PDAC	BYL719	181.2	26.2	18	-10.9	-0.4
X-4378	PDAC	BYL719	117.6	25.1	29	-42.2	-4.6
X-4378	PDAC	BYL719	111.4	24.3	32	-45.2	-7.6
X-4378	PDAC	BYL719	173	25.2	36	-14.9	-4.2
X-4378	PDAC	BYL719	168.5	25.9	39	-17.2	-1.5
X-4378	PDAC	BYL719	140.5	24.7	43	-30.9	-6.1
X-4378	PDAC	BYL719	136	25.5	46	-33.1	-3
X-4378	PDAC	BYL719	139.7	25.3	50	-31.3	-3.8
X-4378	PDAC	BYL719	140.3	24.4	53	-31	-7.2
X-4378	PDAC	BYL719	147.9	25.4	57	-27.3	-3.4
X-4378	PDAC	BYL719	149.8	25.9	60	-26.4	-1.5
X-4378	PDAC	BYL719	148.9	25.9	64	-26.8	-1.5
X-4378	PDAC	BYL719	159.3	26	67	-21.7	-1.1
X-4378	PDAC	BYL719	157.1	25	71	-22.8	-4.9
X-4378	PDAC	BYL719	158.4	25.3	74	-22.1	-3.8
X-4378	PDAC	BYL719	164.2	26.2	78	-19.3	-0.4
X-4378	PDAC	BYL719	162.7	26.1	81	-20	-0.8
X-4378	PDAC	BYL719	168.1	26.1	85	-17.4	-0.8
X-4378	PDAC	BYL719	148.4	26.5	88	-27	0.8
X-4378	PDAC	BYL719	155.1	26.8	92	-23.7	1.9
X-4378	PDAC	BYL719	153.8	26.2	95	-24.4	-0.4
X-4378	PDAC	BYL719	157	25.4	99	-22.8	-3.4
X-4378	PDAC	BYL719	154.2	24.4	101	-24.2	-7.2
X-4378	PDAC	BYL719	163.1	25.8	106	-19.8	-1.9
X-4378	PDAC	BYL719	183.2	27.4	109	-9.9	4.2
X-4378	PDAC	BYL719	188.4	26.1	113	-7.4	-0.8
X-4378	PDAC	BYL719	190.2	25.8	116	-6.5	-1.9
X-4378	PDAC	BYL719	190.5	27.3	119	-6.3	3.8
X-4378	PDAC	CLR457	201.4	27.9	0	0	0
X-4378	PDAC	CLR457	202	28.5	3	0.3	2.2
X-4378	PDAC	CLR457	206.2	28.4	10	2.4	1.8
X-4378	PDAC	CLR457	226	28	13	12.2	0.4
X-4378	PDAC	CLR457	249.4	29	18	23.8	3.9
X-4378	PDAC	CLR457	250.4	29.2	21	24.3	4.7
X-4378	PDAC	CLR457	236.1	29.8	24	17.2	6.8
X-4378	PDAC	CLR457	278.9	28.7	28	38.5	2.9
X-4378	PDAC	CLR457	172.6	29	34	-14.3	3.9
X-4378	PDAC	CLR457	299.3	29.6	42	48.6	6.1
X-4378	PDAC	CLR457	469.1	29.8	46	132.9	6.8
X-4378	PDAC	CLR457	480	30.1	49	138.3	7.9
X-4378	PDAC	CLR457	502.4	29.4	53	149.5	5.4
X-4378	PDAC	CLR457	649.6	30.1	56	222.5	7.9
X-4378	PDAC	CLR457	763.8	28.6	60	279.2	2.5
X-4378	PDAC	CLR457	848.2	27.4	63	321.2	-1.8
X-4378	PDAC	CLR457	987	29.9	67	390.1	7.2
X-4378	PDAC	CLR457	1078.3	30	70	435.4	7.5
X-4378	PDAC	CLR457	1268.5	30.3	74	529.8	8.6
X-4378	PDAC	CLR457	1317.3	29.6	77	554.1	6.1
X-4378	PDAC	HDM201	266.8	25.6	0	0	0
X-4378	PDAC	HDM201	274.2	27.5	3	2.8	7.4
X-4378	PDAC	HDM201	301.3	25.9	7	12.9	1.2
X-4378	PDAC	HDM201	333.4	26.1	10	25	2
X-4378	PDAC	HDM201	374.8	27.1	14	40.5	5.9
X-4378	PDAC	HDM201	414.9	26.4	17	55.5	3.1
X-4378	PDAC	HDM201	459.2	27.1	21	72.1	5.9
X-4378	PDAC	HDM201	453.6	27.1	24	70	5.9
X-4378	PDAC	HDM201	501.4	27.2	28	87.9	6.2
X-4378	PDAC	HDM201	493.9	26.2	31	85.1	2.3
X-4378	PDAC	HDM201	483.9	24.9	35	81.4	-2.7
X-4378	PDAC	figitumumab"	213.6	25.4	0	0	0
X-4378	PDAC	figitumumab"	256.9	25.8	6	20.3	1.6
X-4378	PDAC	figitumumab"	343.4	27	14	60.8	6.3
X-4378	PDAC	figitumumab"	404	26.8	17	89.1	5.5
X-4378	PDAC	figitumumab"	488.9	26.2	20	128.9	3.1
X-4378	PDAC	figitumumab"	618.4	26	24	189.5	2.4
X-4378	PDAC	figitumumab"	997.4	28	27	366.9	10.2
X-4378	PDAC	figitumumab" + binimetinib	252.7	30	0	0	0
X-4378	PDAC	figitumumab" + binimetinib	274.8	30.1	2	8.7	0.3
X-4378	PDAC	figitumumab" + binimetinib	264.7	29	6	4.7	-3.3
X-4378	PDAC	figitumumab" + binimetinib	420.5	29.7	9	66.4	-1
X-4378	PDAC	figitumumab" + binimetinib	363.3	30	13	43.8	0
X-4378	PDAC	figitumumab" + binimetinib	369.6	30.3	16	46.3	1
X-4378	PDAC	figitumumab" + binimetinib	414.6	29.7	20	64.1	-1
X-4378	PDAC	figitumumab" + binimetinib	416.1	29.3	22	64.7	-2.3
X-4378	PDAC	figitumumab" + binimetinib	316.6	29.6	26	25.3	-1.3
X-4378	PDAC	figitumumab" + binimetinib	279.5	29.7	29	10.6	-1
X-4378	PDAC	gemcitabine-50mpk	256.2	24.7	0	0	0
X-4378	PDAC	gemcitabine-50mpk	261.1	24.4	2	1.9	-1.2
X-4378	PDAC	gemcitabine-50mpk	199.7	23.7	7	-22.1	-4
X-4378	PDAC	gemcitabine-50mpk	236.5	23.8	10	-7.7	-3.6
X-4378	PDAC	gemcitabine-50mpk	377.2	23.4	14	47.2	-5.3
X-4378	PDAC	gemcitabine-50mpk	264.6	25.4	17	3.3	2.8
X-4378	PDAC	gemcitabine-50mpk	207.6	25.3	20	-19	2.4
X-4378	PDAC	gemcitabine-50mpk	214.5	25	24	-16.3	1.2
X-4378	PDAC	gemcitabine-50mpk	246.4	26.4	27	-3.8	6.9
X-4378	PDAC	gemcitabine-50mpk	254	25.1	31	-0.9	1.6
X-4378	PDAC	gemcitabine-50mpk	229.5	24.2	34	-10.4	-2
X-4378	PDAC	gemcitabine-50mpk	229.1	25.9	38	-10.6	4.9
X-4378	PDAC	gemcitabine-50mpk	226.9	25.9	41	-11.4	4.9
X-4378	PDAC	gemcitabine-50mpk	222.1	24.9	44	-13.3	0.8
X-4378	PDAC	gemcitabine-50mpk	206.3	24.6	49	-19.5	-0.4
X-4378	PDAC	gemcitabine-50mpk	182.9	24.9	51	-28.6	0.8
X-4378	PDAC	gemcitabine-50mpk	209.9	25	55	-18.1	1.2
X-4378	PDAC	gemcitabine-50mpk	230.3	25.4	57	-10.1	2.8
X-4378	PDAC	gemcitabine-50mpk	224.2	24.7	63	-12.5	0
X-4378	PDAC	gemcitabine-50mpk	214.3	24.8	67	-16.4	0.4
X-4378	PDAC	gemcitabine-50mpk	185.6	25.2	69	-27.6	2
X-4378	PDAC	gemcitabine-50mpk	182.7	24	73	-28.7	-2.8
X-4378	PDAC	gemcitabine-50mpk	268.4	26	77	4.8	5.3
X-4378	PDAC	gemcitabine-50mpk	199	25	80	-22.3	1.2
X-4378	PDAC	gemcitabine-50mpk	202	25.2	83	-21.2	2
X-4378	PDAC	gemcitabine-50mpk	212.9	25.8	87	-16.9	4.5
X-4378	PDAC	gemcitabine-50mpk	224	26.1	90	-12.6	5.7
X-4378	PDAC	gemcitabine-50mpk	228.8	25	95	-10.7	1.2
X-4378	PDAC	gemcitabine-50mpk	210.4	25.9	99	-17.9	4.9
X-4378	PDAC	gemcitabine-50mpk	231.3	25.8	101	-9.7	4.5
X-4378	PDAC	gemcitabine-50mpk	224.1	25.4	105	-12.5	2.8
X-4378	PDAC	gemcitabine-50mpk	265.4	25.7	108	3.6	4
X-4378	PDAC	gemcitabine-50mpk	237.9	26.1	112	-7.1	5.7
X-4378	PDAC	INC424 + binimetinib	240.6	28	0	0	0
X-4378	PDAC	INC424 + binimetinib	241	27.7	4	0.2	-1.1
X-4378	PDAC	INC424 + binimetinib	212.5	27.5	7	-11.7	-1.8
X-4378	PDAC	INC424 + binimetinib	289.4	29.3	11	20.3	4.6
X-4378	PDAC	INC424 + binimetinib	298.5	28.6	14	24.1	2.1
X-4378	PDAC	INC424 + binimetinib	311	28.9	18	29.3	3.2
X-4378	PDAC	INC424 + binimetinib	293.8	28.3	21	22.1	1.1
X-4378	PDAC	INC424 + binimetinib	296	29.4	25	23	5
X-4378	PDAC	INC424 + binimetinib	375.9	29.1	28	56.2	3.9
X-4378	PDAC	INC424 + binimetinib	411.6	29.1	31	71.1	3.9
X-4378	PDAC	INC424 + binimetinib	426.4	28.9	34	77.2	3.2
X-4378	PDAC	INC424 + binimetinib	374.5	29	39	55.7	3.6
X-4378	PDAC	INC424 + binimetinib	413.6	29	42	71.9	3.6
X-4378	PDAC	INC424 + binimetinib	349.2	28.6	46	45.1	2.1
X-4378	PDAC	INC424 + binimetinib	375	27.6	49	55.9	-1.4
X-4378	PDAC	INC424 + binimetinib	402	28.1	52	67.1	0.4
X-4378	PDAC	INC424 + binimetinib	389.2	27.7	56	61.8	-1.1
X-4378	PDAC	INC424 + binimetinib	419.9	28.4	59	74.5	1.4
X-4378	PDAC	INC424 + binimetinib	384.8	NA	62	59.9	1.4
X-4378	PDAC	INC424 + binimetinib	440.5	27.9	66	83.1	-0.4
X-4378	PDAC	INC424 + binimetinib	456	28.2	70	89.5	0.7
X-4378	PDAC	INC424 + binimetinib	460.3	28.9	74	91.3	3.2
X-4378	PDAC	INC424 + binimetinib	644.6	28.6	77	167.9	2.1
X-4378	PDAC	INC424 + binimetinib	562.6	28.5	80	133.8	1.8
X-4378	PDAC	INC424 + binimetinib	570.3	28.8	84	137	2.9
X-4378	PDAC	INC424	323.2	29.4	0	0	0
X-4378	PDAC	INC424	430.9	29.5	5	33.3	0.3
X-4378	PDAC	INC424	538.4	29.1	8	66.6	-1
X-4378	PDAC	INC424	575.4	29.1	12	78	-1
X-4378	PDAC	INC424	681.2	29	15	110.8	-1.4
X-4378	PDAC	INC424	694.8	29.9	18	115	1.7
X-4378	PDAC	LEE011	239.6	29	0	0	0
X-4378	PDAC	LEE011	291	28.6	2	21.5	-1.4
X-4378	PDAC	LEE011	364.6	29.9	6	52.2	3.1
X-4378	PDAC	LEE011	445.7	29.3	9	86	1
X-4378	PDAC	LEE011	469.5	30	13	96	3.4
X-4378	PDAC	LEE011	515	29.9	16	114.9	3.1
X-4378	PDAC	LEE011	494.8	30.4	21	106.5	4.8
X-4378	PDAC	LEE011	547.4	30.8	24	128.5	6.2
X-4378	PDAC	LEE011	580.6	30.6	27	142.3	5.5
X-4378	PDAC	LEE011	663.6	30.9	30	177	6.6
X-4378	PDAC	LEE011	669.7	31.1	34	179.5	7.2
X-4378	PDAC	LEE011	728	30.5	37	203.8	5.2
X-4378	PDAC	LEE011	856.4	30.8	41	257.4	6.2
X-4378	PDAC	LEE011	888.6	30.5	44	270.9	5.2
X-4378	PDAC	WNT974	214.3	28.3	0	0	0
X-4378	PDAC	WNT974	264	25.9	2	23.2	-8.5
X-4378	PDAC	WNT974	348.7	26.2	6	62.7	-7.4
X-4378	PDAC	WNT974	424.4	25.6	9	98	-9.5
X-4378	PDAC	WNT974	449.1	25.9	12	109.6	-8.5
X-4378	PDAC	WNT974	465	25.9	16	117	-8.5
X-4378	PDAC	WNT974	503.2	26.2	19	134.8	-7.4
X-4378	PDAC	WNT974	589.7	25.6	24	175.2	-9.5
X-4378	PDAC	WNT974	539.8	26.3	28	151.9	-7.1
X-4378	PDAC	WNT974	595.5	25.3	30	177.9	-10.6
X-4378	PDAC	WNT974	639.3	25.2	34	198.3	-11
X-4378	PDAC	WNT974	763	25.3	41	256	-10.6
X-4378	PDAC	LKA136	225.9	29.1	0	0	0
X-4378	PDAC	LKA136	254.3	29	2	12.6	-0.3
X-4378	PDAC	LKA136	425	28.2	8	88.1	-3.1
X-4378	PDAC	LKA136	581.4	28.9	13	157.4	-0.7
X-4378	PDAC	LKA136	587.7	28.6	15	160.2	-1.7
X-4378	PDAC	LKA136	592.1	29.4	19	162.1	1
X-4378	PDAC	LKA136	695.3	28.5	21	207.8	-2.1
X-4378	PDAC	LKA136	799	27.8	27	253.7	-4.5
X-4378	PDAC	binimetinib	301.4	27.3	0	0	0
X-4378	PDAC	binimetinib	258.4	26.4	4	-14.3	-3.3
X-4378	PDAC	binimetinib	238.7	27.1	7	-20.8	-0.7
X-4378	PDAC	binimetinib	252.8	28.9	11	-16.1	5.9
X-4378	PDAC	binimetinib	286.8	26.9	14	-4.8	-1.5
X-4378	PDAC	binimetinib	284.3	27	18	-5.7	-1.1
X-4378	PDAC	binimetinib	285.7	26.9	21	-5.2	-1.5
X-4378	PDAC	binimetinib	298.2	27.7	25	-1.1	1.5
X-4378	PDAC	binimetinib	234	26.9	28	-22.4	-1.5
X-4378	PDAC	binimetinib	246.7	26.6	31	-18.1	-2.6
X-4378	PDAC	binimetinib	268.9	27	34	-10.8	-1.1
X-4378	PDAC	binimetinib	239.9	27.8	39	-20.4	1.8
X-4378	PDAC	binimetinib	367.3	26.5	42	21.9	-2.9
X-4378	PDAC	binimetinib	277.2	27.1	46	-8	-0.7
X-4378	PDAC	binimetinib	239.2	26.6	49	-20.6	-2.6
X-4378	PDAC	binimetinib-3.5mpk	244.9	25.4	0	0	0
X-4378	PDAC	binimetinib-3.5mpk	274.3	25.1	2	12	-1.2
X-4378	PDAC	binimetinib-3.5mpk	442.9	24.9	6	80.8	-2
X-4378	PDAC	binimetinib-3.5mpk	410.4	24	9	67.6	-5.5
X-4378	PDAC	binimetinib-3.5mpk	430.5	24.9	12	75.8	-2
X-4378	PDAC	binimetinib-3.5mpk	588.8	24.7	15	140.4	-2.8
X-4378	PDAC	binimetinib-3.5mpk	696.8	23.8	20	184.5	-6.3
X-4378	PDAC	binimetinib-3.5mpk	719.8	24	23	193.9	-5.5
X-4378	PDAC	trametinib	208.2	28.6	0	0	0
X-4378	PDAC	trametinib	285.1	29	5	36.9	1.4
X-4378	PDAC	trametinib	305.3	26.8	7	46.6	-6.3
X-4378	PDAC	trametinib	352.6	27.1	11	69.4	-5.2
X-4378	PDAC	trametinib	286.8	27.1	14	37.8	-5.2
X-4378	PDAC	trametinib	315.5	28.2	18	51.5	-1.4
X-4378	PDAC	trametinib	345.8	27.8	21	66.1	-2.8
X-4378	PDAC	trametinib	474.4	27.5	25	127.9	-3.8
X-4378	PDAC	trametinib	441.8	26.7	28	112.2	-6.6
X-4378	PDAC	trametinib	471	27.4	32	126.2	-4.2
X-4378	PDAC	trametinib	440	27.4	35	111.3	-4.2
X-4378	PDAC	trametinib	430.7	27.2	41	106.9	-4.9
X-4378	PDAC	untreated	271	28.2	0	0	0
X-4378	PDAC	untreated	338.9	26.9	5	25.1	-4.6
X-4378	PDAC	untreated	327.1	26.7	8	20.7	-5.3
X-4378	PDAC	untreated	421.3	27.7	12	55.5	-1.8
X-4378	PDAC	untreated	451.2	27.2	14	66.5	-3.5
X-4378	PDAC	untreated	465.6	28.3	19	71.8	0.4
X-4378	PDAC	untreated	507.6	27.2	21	87.3	-3.5
X-4378	PDAC	untreated	531.2	28.8	26	96	2.1
X-4378	PDAC	untreated	619.2	30.8	29	128.5	9.2
X-4378	PDAC	untreated	531.1	28.2	33	96	0
X-4378	PDAC	untreated	617.3	29.4	36	127.8	4.3
X-4378	PDAC	untreated	621.8	29.9	39	129.4	6
X-4378	PDAC	untreated	636.3	29.5	43	134.8	4.6
X-4378	PDAC	untreated	721.1	29.9	46	166.1	6
X-4378	PDAC	untreated	633.3	29.9	50	133.7	6
X-4378	PDAC	untreated	806	29.9	53	197.4	6
X-4378	PDAC	untreated	773.7	29.7	57	185.5	5.3
X-4378	PDAC	untreated	992.2	30.4	63	266.1	7.8
X-4426	CM	BKM120	229.5	22.7	0	0	0
X-4426	CM	BKM120	284.8	21.7	4	24.1	-4.4
X-4426	CM	BKM120	392.1	21.2	7	70.8	-6.6
X-4426	CM	BKM120	445.4	21	11	94.1	-7.5
X-4426	CM	BKM120	469.3	21	14	104.5	-7.5
X-4426	CM	BKM120	502.3	19.6	17	118.9	-13.7
X-4426	CM	BKM120	477.1	19	20	107.9	-16.3
X-4426	CM	BKM120	477.1	18.5	22	107.9	-18.5
X-4426	CM	BKM120 + encorafenib	233.4	23.5	0	0	0
X-4426	CM	BKM120 + encorafenib	328.1	24.4	3	40.6	3.8
X-4426	CM	BKM120 + encorafenib	366.1	23.4	6	56.8	-0.4
X-4426	CM	BKM120 + encorafenib	379.3	23.2	9	62.5	-1.3
X-4426	CM	BKM120 + encorafenib	467.1	23.3	12	100.1	-0.9
X-4426	CM	BKM120 + encorafenib	491.9	22.7	16	110.7	-3.4
X-4426	CM	BKM120 + encorafenib	448.6	21.7	21	92.2	-7.7
X-4426	CM	BKM120 + encorafenib	425.3	21	24	82.2	-10.6
X-4426	CM	BKM120 + encorafenib	345.7	21	27	48.1	-10.6
X-4426	CM	BKM120 + encorafenib	350.4	20.6	30	50.1	-12.3
X-4426	CM	BKM120 + encorafenib	257.4	19.2	34	10.3	-18.3
X-4426	CM	CGM097	203.4	24.8	0	0	0
X-4426	CM	CGM097	255.5	25.8	3	25.6	4
X-4426	CM	CGM097	321.7	27	7	58.2	8.9
X-4426	CM	CGM097	340.2	26	10	67.2	4.8
X-4426	CM	CGM097	469.8	27	13	130.9	8.9
X-4426	CM	CGM097	612.1	27	17	200.9	8.9
X-4426	CM	CGM097	674.2	27.4	20	231.4	10.5
X-4426	CM	dacarbazine	219.4	24.3	0	0	0
X-4426	CM	dacarbazine	295.3	24.5	3	34.6	0.8
X-4426	CM	dacarbazine	357.6	24.7	6	63	1.6
X-4426	CM	dacarbazine	454.1	25.4	10	107	4.5
X-4426	CM	dacarbazine	561.8	25	15	156.1	2.9
X-4426	CM	dacarbazine	892.1	24.7	21	306.7	1.6
X-4426	CM	LDE225	205.4	25.9	0	0	0
X-4426	CM	LDE225	278.8	25.3	5	35.8	-2.3
X-4426	CM	LDE225	383.3	25.3	8	86.7	-2.3
X-4426	CM	LDE225	467.1	23.5	11	127.4	-9.3
X-4426	CM	LDE225	518.9	23.5	14	152.7	-9.3
X-4426	CM	LDE225	673.3	22.6	17	227.9	-12.7
X-4426	CM	LDE225	825.7	22	20	302.1	-15.1
X-4426	CM	LDK378	202.5	25.1	0	0	0
X-4426	CM	LDK378	222.2	24.5	5	9.7	-2.4
X-4426	CM	LDK378	268.6	24.3	8	32.6	-3.2
X-4426	CM	LDK378	347.7	23.7	11	71.7	-5.6
X-4426	CM	LDK378	395.1	24	14	95.1	-4.4
X-4426	CM	LDK378	559.6	24.7	17	176.3	-1.6
X-4426	CM	LDK378	653.1	25.5	20	222.5	1.6
X-4426	CM	LEE011 + encorafenib	213.6	23.2	0	0	0
X-4426	CM	LEE011 + encorafenib	282.4	23	3	32.2	-0.9
X-4426	CM	LEE011 + encorafenib	317.5	23.8	6	48.7	2.6
X-4426	CM	LEE011 + encorafenib	317.5	24.3	9	48.7	4.7
X-4426	CM	LEE011 + encorafenib	324.6	23.1	13	52	-0.4
X-4426	CM	LEE011 + encorafenib	242.6	23.3	18	13.6	0.4
X-4426	CM	LEE011 + encorafenib	245.5	23.1	21	14.9	-0.4
X-4426	CM	LEE011 + encorafenib	197	24	24	-7.8	3.4
X-4426	CM	LEE011 + encorafenib	183.8	23.8	27	-14	2.6
X-4426	CM	LEE011 + encorafenib	194.4	23.1	31	-9	-0.4
X-4426	CM	LEE011 + encorafenib	150	23.5	36	-29.8	1.3
X-4426	CM	LEE011 + encorafenib	105.6	24.8	40	-50.6	6.9
X-4426	CM	LEE011 + encorafenib	105.6	24.5	43	-50.6	5.6
X-4426	CM	LEE011 + encorafenib	120.9	24.5	46	-43.4	5.6
X-4426	CM	LEE011 + encorafenib	115.2	25.3	51	-46.1	9.1
X-4426	CM	LEE011 + encorafenib	157.1	25.2	56	-26.4	8.6
X-4426	CM	LEE011 + encorafenib	210.5	25.4	62	-1.4	9.5
X-4426	CM	LEE011 + encorafenib	344.4	25.3	68	61.3	9.1
X-4426	CM	LEE011 + encorafenib	504.8	26.1	75	136.4	12.5
X-4426	CM	LEE011 + encorafenib	727.6	25.3	81	240.7	9.1
X-4426	CM	LEE011 + encorafenib	893.1	25.5	86	318.2	9.9
X-4426	CM	LEE011 + encorafenib	943.2	24.6	88	341.7	6
X-4426	CM	LEE011	219.4	27	0	0	0
X-4426	CM	LEE011	321.7	28	5	46.7	3.7
X-4426	CM	LEE011	376.3	27	10	71.5	0
X-4426	CM	LEE011	367.1	27	13	67.3	0
X-4426	CM	LEE011	339.6	27.9	16	54.8	3.3
X-4426	CM	LEE011	328.1	25.5	19	49.6	-5.6
X-4426	CM	LEE011	288	22.2	23	31.3	-17.8
X-4426	CM	WNT974	207.8	25.9	0	0	0
X-4426	CM	WNT974	247.5	25	5	19.1	-3.5
X-4426	CM	WNT974	404	24.1	8	94.4	-6.9
X-4426	CM	WNT974	676	23.5	11	225.3	-9.3
X-4426	CM	WNT974	844.7	22.9	14	306.5	-11.6
X-4426	CM	WNT974	909.7	22.3	17	337.7	-13.9
X-4426	CM	WNT974	965.1	21	20	364.4	-18.9
X-4426	CM	LGW813	202.3	28.5	0	0	0
X-4426	CM	LGW813	286	27	4	41.3	-5.3
X-4426	CM	LGW813	324.5	27.9	7	60.4	-2.1
X-4426	CM	LGW813	429.9	27.8	11	112.5	-2.5
X-4426	CM	LGW813	553.5	28.7	14	173.6	0.7
X-4426	CM	LGW813	635.1	28.7	17	213.9	0.7
X-4426	CM	LGW813	666.5	27.5	20	229.4	-3.5
X-4426	CM	LGW813	777.3	26.5	23	284.1	-7
X-4426	CM	LGW813	898.1	27.9	26	343.9	-2.1
X-4426	CM	encorafenib	249.8	24.2	0	0	0
X-4426	CM	encorafenib	375.6	23.8	3	50.4	-1.7
X-4426	CM	encorafenib	473.8	23.8	7	89.7	-1.7
X-4426	CM	encorafenib	633.9	22.5	10	153.8	-7
X-4426	CM	encorafenib	866.2	22.1	13	246.8	-8.7
X-4426	CM	encorafenib	1135.1	22	17	354.5	-9.1
X-4426	CM	encorafenib	1171.5	22	20	369.1	-9.1
X-4426	CM	encorafenib + binimetinib	205.2	23.8	0	0	0
X-4426	CM	encorafenib + binimetinib	258.6	23.2	3	26	-2.5
X-4426	CM	encorafenib + binimetinib	419.5	23.6	6	104.5	-0.8
X-4426	CM	encorafenib + binimetinib	508.1	24.1	9	147.6	1.3
X-4426	CM	encorafenib + binimetinib	892.7	24.5	13	335.1	2.9
X-4426	CM	encorafenib + binimetinib	1044	24	18	408.8	0.8
X-4426	CM	encorafenib + binimetinib	1466.4	23	19	614.7	-3.4
X-4426	CM	binimetinib	210.5	20.7	0	0	0
X-4426	CM	binimetinib	289.3	21.6	4	37.5	4.3
X-4426	CM	binimetinib	310.7	21.2	7	47.6	2.4
X-4426	CM	binimetinib	325.4	22.7	10	54.6	9.7
X-4426	CM	binimetinib	388.8	22.5	14	84.7	8.7
X-4426	CM	binimetinib	355	22.9	17	68.7	10.6
X-4426	CM	binimetinib	436.8	22.6	20	107.5	9.2
X-4426	CM	binimetinib	450.6	22	23	114.1	6.3
X-4426	CM	binimetinib	484.6	21.5	26	130.2	3.9
X-4426	CM	binimetinib	545	22.5	29	158.9	8.7
X-4426	CM	TAS266	219	24.6	0	0	0
X-4426	CM	TAS266	156.3	25.4	5	-28.6	3.3
X-4426	CM	TAS266	102.6	25.5	10	-53.2	3.7
X-4426	CM	TAS266	119.1	25.2	13	-45.6	2.4
X-4426	CM	TAS266	145.9	25.6	16	-33.4	4.1
X-4426	CM	TAS266	150	25	19	-31.5	1.6
X-4426	CM	TAS266	205.2	24.8	22	-6.3	0.8
X-4426	CM	TAS266	259.9	25.5	26	18.7	3.7
X-4426	CM	TAS266	313.3	24.5	30	43	-0.4
X-4426	CM	TAS266	473.9	24.2	33	116.3	-1.6
X-4426	CM	TAS266	576.2	24.9	36	163.1	1.2
X-4426	CM	TAS266	877.3	24	41	300.5	-2.4
X-4426	CM	untreated	210	26.5	0	0	0
X-4426	CM	untreated	356.2	26	3	69.7	-1.9
X-4426	CM	untreated	715	26.9	7	240.6	1.5
X-4426	CM	untreated	1095.4	26.2	12	421.7	-1.1
X-4426	CM	untreated	1319.8	25.7	15	528.6	-3
X-4426	CM	untreated	1801.2	25.1	18	757.9	-5.3
X-4455	CM	BKM120	215.4	23.5	0	0	0
X-4455	CM	BKM120	207.5	22.8	3	-3.6	-3
X-4455	CM	BKM120	455.7	22.2	9	111.6	-5.5
X-4455	CM	BKM120	1119.6	21.1	12	419.9	-10.2
X-4455	CM	BKM120 + encorafenib	186.2	22.7	0	0	0
X-4455	CM	BKM120 + encorafenib	212.6	22.3	3	14.1	-1.8
X-4455	CM	BKM120 + encorafenib	279.4	22.8	6	50	0.4
X-4455	CM	BKM120 + encorafenib	409.8	22.9	9	120.1	0.9
X-4455	CM	BKM120 + encorafenib	583.1	21.2	12	213.1	-6.6
X-4455	CM	BKM120 + encorafenib	669.2	21.6	16	259.3	-4.8
X-4455	CM	BKM120 + encorafenib	957.5	21.6	19	414.1	-4.8
X-4455	CM	BKM120 + encorafenib	1090.3	20.7	21	485.4	-8.8
X-4455	CM	CGM097	211.2	23.1	0	0	0
X-4455	CM	CGM097	272.7	22.6	3	29.1	-2.2
X-4455	CM	CGM097	220.7	22.3	9	4.5	-3.5
X-4455	CM	CGM097	428	21.2	12	102.6	-8.2
X-4455	CM	CGM097	508.4	21.8	17	140.7	-5.6
X-4455	CM	CGM097	558.9	21.5	20	164.6	-6.9
X-4455	CM	CGM097	670.6	21.6	23	217.5	-6.5
X-4455	CM	CLR457	181.8	23.5	0	0	0
X-4455	CM	CLR457	155.7	23.9	3	-14.4	1.7
X-4455	CM	CLR457	180.9	24.2	7	-0.5	3
X-4455	CM	CLR457	298.3	23.6	10	64.1	0.4
X-4455	CM	CLR457	427.4	24.1	15	135.1	2.6
X-4455	CM	CLR457	490.1	23.8	21	169.6	1.3
X-4455	CM	dacarbazine	185.5	23.5	0	0	0
X-4455	CM	dacarbazine	250.4	22.9	3	35	-2.6
X-4455	CM	dacarbazine	250.2	21.1	6	34.9	-10.2
X-4455	CM	dacarbazine	292.3	22.2	10	57.6	-5.5
X-4455	CM	dacarbazine	307.4	22.7	13	65.7	-3.4
X-4455	CM	dacarbazine	366	21.3	17	97.3	-9.4
X-4455	CM	dacarbazine	465.3	20.3	20	150.8	-13.6
X-4455	CM	dacarbazine	558.6	20.1	21	201.2	-14.5
X-4455	CM	LDE225	206.5	21.6	0	0	0
X-4455	CM	LDE225	227.1	22.6	4	10	4.6
X-4455	CM	LDE225	182.6	20.5	7	-11.6	-5.1
X-4455	CM	LDE225	237.5	20.3	12	15	-6
X-4455	CM	LDE225	382.2	19.8	15	85.1	-8.3
X-4455	CM	LDE225	421.1	19.1	18	103.9	-11.6
X-4455	CM	LDE225	418.8	18	21	102.8	-16.7
X-4455	CM	LDK378	190.3	23.3	0	0	0
X-4455	CM	LDK378	277.1	23.3	4	45.6	0
X-4455	CM	LDK378	407	22.1	7	113.9	-5.2
X-4455	CM	LDK378	678.9	22.6	12	256.8	-3
X-4455	CM	LDK378	992.4	22.8	15	421.5	-2.1
X-4455	CM	LDK378	1042.1	23.4	18	447.6	0.4
X-4455	CM	LEE011	206.2	21.1	0	0	0
X-4455	CM	LEE011	231.9	20.7	3	12.5	-1.9
X-4455	CM	LEE011	261.6	20.1	9	26.9	-4.7
X-4455	CM	LEE011	302.2	20.7	12	46.6	-1.9
X-4455	CM	LEE011	202.4	21.4	17	-1.8	1.4
X-4455	CM	LEE011	346.7	22.4	20	68.2	6.2
X-4455	CM	LEE011	380.5	23.1	23	84.6	9.5
X-4455	CM	LEE011 + encorafenib	189	23.1	0	0	0
X-4455	CM	LEE011 + encorafenib	161.4	23.1	3	-14.6	0
X-4455	CM	LEE011 + encorafenib	183.1	23.1	6	-3.1	0
X-4455	CM	LEE011 + encorafenib	179.7	22.8	9	-4.9	-1.3
X-4455	CM	LEE011 + encorafenib	181.3	21.4	12	-4.1	-7.4
X-4455	CM	LEE011 + encorafenib	186	23.3	16	-1.6	0.9
X-4455	CM	LEE011 + encorafenib	207.4	23.1	19	9.7	0
X-4455	CM	LEE011 + encorafenib	253.1	23.9	23	33.9	3.5
X-4455	CM	LEE011 + encorafenib	298.4	23.5	26	57.9	1.7
X-4455	CM	LEE011 + encorafenib	218.5	23.2	30	15.6	0.4
X-4455	CM	LEE011 + encorafenib	222.4	24.4	36	17.6	5.6
X-4455	CM	LEE011 + encorafenib	205.4	25.1	50	8.6	8.7
X-4455	CM	LEE011 + encorafenib	291.2	26	54	54.1	12.6
X-4455	CM	LEE011 + encorafenib	262.4	25.8	65	38.8	11.7
X-4455	CM	LEE011 + encorafenib	294.4	25.5	78	55.8	10.4
X-4455	CM	LEE011 + encorafenib	390.2	23.1	85	106.4	0
X-4455	CM	LEE011 + encorafenib	413.1	23.7	88	118.5	2.6
X-4455	CM	WNT974	188.3	22.1	0	0	0
X-4455	CM	WNT974	219.5	23.2	4	16.6	5
X-4455	CM	WNT974	293.8	22.3	7	56.1	0.9
X-4455	CM	WNT974	426.4	22.9	12	126.5	3.6
X-4455	CM	WNT974	588.1	23.4	15	212.4	5.9
X-4455	CM	WNT974	551.4	22.2	18	192.9	0.5
X-4455	CM	WNT974	806.9	22.1	21	328.6	0
X-4455	CM	LGW813	187.5	22.3	0	0	0
X-4455	CM	LGW813	231.2	22.6	4	23.3	1.3
X-4455	CM	LGW813	253.2	21.5	7	35	-3.6
X-4455	CM	LGW813	401.4	22	12	114	-1.3
X-4455	CM	LGW813	539.5	21.6	15	187.7	-3.1
X-4455	CM	LGW813	722.4	20.9	18	285.2	-6.3
X-4455	CM	LGW813	818.5	20.8	21	336.4	-6.7
X-4455	CM	encorafenib	184.2	24.4	0	0	0
X-4455	CM	encorafenib	188.6	24.3	3	2.4	-0.4
X-4455	CM	encorafenib	253.3	22.7	9	37.5	-7
X-4455	CM	encorafenib	490.1	22.3	12	166.1	-8.6
X-4455	CM	encorafenib	665.3	22.1	17	261.1	-9.4
X-4455	CM	encorafenib	663	21.4	20	259.9	-12.3
X-4455	CM	encorafenib	718	20.8	23	289.8	-14.8
X-4455	CM	encorafenib + binimetinib	218.7	24.8	0	0	0
X-4455	CM	encorafenib + binimetinib	246.6	23.6	3	12.8	-4.8
X-4455	CM	encorafenib + binimetinib	384.7	22.7	6	75.9	-8.5
X-4455	CM	encorafenib + binimetinib	526.3	24.5	10	140.6	-1.2
X-4455	CM	encorafenib + binimetinib	679.6	24.1	13	210.7	-2.8
X-4455	CM	encorafenib + binimetinib	891.5	24.1	17	307.7	-2.8
X-4455	CM	encorafenib + binimetinib	1267.3	23.5	20	479.5	-5.2
X-4455	CM	encorafenib + binimetinib	1437.2	23.1	21	557.2	-6.9
X-4455	CM	binimetinib	240	23.9	0	0	0
X-4455	CM	binimetinib	282.9	24.2	3	17.9	1.3
X-4455	CM	binimetinib	516.8	24.3	9	115.4	1.7
X-4455	CM	binimetinib	549.2	24.3	12	128.9	1.7
X-4455	CM	binimetinib	655.1	24.3	17	173	1.7
X-4455	CM	binimetinib	770.6	25.2	20	221.1	5.4
X-4455	CM	binimetinib	990	25.4	23	312.5	6.3
X-4455	CM	TAS266	189.3	23.4	0	0	0
X-4455	CM	TAS266	219.5	22.8	3	15.9	-2.6
X-4455	CM	TAS266	414.5	22.1	9	118.9	-5.6
X-4455	CM	TAS266	272.4	22	12	43.9	-6
X-4455	CM	TAS266	303.1	21.9	17	60.1	-6.4
X-4455	CM	TAS266	376.3	21.9	20	98.7	-6.4
X-4455	CM	TAS266	520.2	21.8	23	174.8	-6.8
X-4455	CM	untreated	241.6	22.1	0	0	0
X-4455	CM	untreated	462.7	21.7	5	91.5	-1.8
X-4455	CM	untreated	755.7	19.5	11	212.8	-11.8
X-4455	CM	untreated	780.5	19.3	14	223	-12.7
X-4455	CM	untreated	1522.3	20.5	19	530	-7.2
X-4455	CM	untreated	2030.6	19.5	21	740.4	-11.8
X-4530	CM	BKM120	200.9	26.4	0	0	0
X-4530	CM	BKM120	201.1	26.8	3	0.1	1.5
X-4530	CM	BKM120	173	26.4	7	-13.9	0
X-4530	CM	BKM120	297.5	27.3	11	48.1	3.4
X-4530	CM	BKM120	433.7	28.2	16	115.9	6.8
X-4530	CM	BKM120	617.5	27.9	22	207.4	5.7
X-4530	CM	BKM120 + encorafenib	224.5	24.8	0	0	0
X-4530	CM	BKM120 + encorafenib	169.3	26.1	7	-24.6	5.2
X-4530	CM	BKM120 + encorafenib	180.7	26.7	13	-19.5	7.7
X-4530	CM	BKM120 + encorafenib	240.4	26.8	16	7.1	8.1
X-4530	CM	BKM120 + encorafenib	213.3	27.2	21	-5	9.7
X-4530	CM	BKM120 + encorafenib	232.4	27.3	24	3.5	10.1
X-4530	CM	BKM120 + encorafenib	230.6	27	28	2.7	8.9
X-4530	CM	BKM120 + encorafenib	204.4	27	31	-9	8.9
X-4530	CM	BKM120 + encorafenib	203.7	27.5	36	-9.3	10.9
X-4530	CM	BKM120 + encorafenib	201.6	28.3	41	-10.2	14.1
X-4530	CM	BKM120 + encorafenib	267.2	28.7	44	19	15.7
X-4530	CM	BKM120 + encorafenib	311.3	27.8	49	38.6	12.1
X-4530	CM	BKM120 + encorafenib	387.2	28.5	52	72.5	14.9
X-4530	CM	BKM120 + encorafenib	423.7	27.4	59	88.7	10.5
X-4530	CM	BKM120 + encorafenib	571.1	27.9	62	154.3	12.5
X-4530	CM	BKM120 + encorafenib	758.7	28	66	237.9	12.9
X-4530	CM	BKM120 + encorafenib	827.5	28.6	69	268.6	15.3
X-4530	CM	BKM120 + encorafenib	973.4	28.3	72	333.5	14.1
X-4530	CM	CGM097	210.5	28.4	0	0	0
X-4530	CM	CGM097	280.9	29.6	5	33.4	4.2
X-4530	CM	CGM097	277.7	29.7	8	31.9	4.6
X-4530	CM	CGM097	330.8	30	11	57.1	5.6
X-4530	CM	CGM097	393.7	30.7	14	87	8.1
X-4530	CM	CGM097	635.9	30.1	18	202.1	6
X-4530	CM	CGM097	842.7	30.4	22	300.3	7
X-4530	CM	LDE225	188.1	24.4	0	0	0
X-4530	CM	LDE225	198.8	25	4	5.7	2.5
X-4530	CM	LDE225	159	25.3	9	-15.5	3.7
X-4530	CM	LDE225	275.2	25	15	46.3	2.5
X-4530	CM	LDE225	348.5	24.3	21	85.3	-0.4
X-4530	CM	LDE225	401	24.1	24	113.2	-1.2
X-4530	CM	LDE225	458.4	23.1	29	143.8	-5.3
X-4530	CM	LDK378	191.7	24.1	0	0	0
X-4530	CM	LDK378	219.6	23.6	4	14.6	-2.1
X-4530	CM	LDK378	245.1	24.4	9	27.9	1.2
X-4530	CM	LDK378	451.2	24.3	15	135.4	0.8
X-4530	CM	LDK378	649.2	24.6	21	238.7	2.1
X-4530	CM	LEE011	193	21.4	0	0	0
X-4530	CM	LEE011	202	21.7	3	4.7	1.4
X-4530	CM	LEE011	290.2	22.2	6	50.4	3.7
X-4530	CM	LEE011	289.7	22.4	9	50.1	4.7
X-4530	CM	LEE011	404.6	22.6	12	109.6	5.6
X-4530	CM	LEE011	512.5	23.5	16	165.5	9.8
X-4530	CM	LEE011	715.6	23.9	20	270.7	11.7
X-4530	CM	LEE011 + encorafenib	190.1	28.5	0	0	0
X-4530	CM	LEE011 + encorafenib	83.8	28.3	7	-56	-0.7
X-4530	CM	LEE011 + encorafenib	66.6	29.6	13	-65	3.9
X-4530	CM	LEE011 + encorafenib	76.2	29	16	-59.9	1.8
X-4530	CM	LEE011 + encorafenib	28.9	30.1	21	-84.8	5.6
X-4530	CM	LEE011 + encorafenib	28.7	29.7	24	-84.9	4.2
X-4530	CM	LEE011 + encorafenib	25.1	29.2	28	-86.8	2.5
X-4530	CM	LEE011 + encorafenib	26.7	30	31	-86	5.3
X-4530	CM	LEE011 + encorafenib	0	31.3	36	-100	9.8
X-4530	CM	LEE011 + encorafenib	0	32.4	41	-100	13.7
X-4530	CM	LEE011 + encorafenib	0	30	44	-100	5.3
X-4530	CM	LEE011 + encorafenib	9.5	29.7	49	-95	4.2
X-4530	CM	LEE011 + encorafenib	16.4	29.3	52	-91.4	2.8
X-4530	CM	LEE011 + encorafenib	15.1	29.6	59	-92	3.9
X-4530	CM	LEE011 + encorafenib	14.7	30.7	62	-92.3	7.7
X-4530	CM	LEE011 + encorafenib	17.1	31.4	66	-91	10.2
X-4530	CM	LEE011 + encorafenib	20	31.4	69	-89.5	10.2
X-4530	CM	LEE011 + encorafenib	32.8	31.5	73	-82.7	10.5
X-4530	CM	LEE011 + encorafenib	74.5	31.7	76	-60.8	11.2
X-4530	CM	LEE011 + encorafenib	82.8	31	81	-56.4	8.8
X-4530	CM	LEE011 + encorafenib	116	32	84	-39	12.3
X-4530	CM	LEE011 + encorafenib	254.1	32.9	91	33.7	15.4
X-4530	CM	LEE011 + encorafenib	375.7	32.8	99	97.6	15.1
X-4530	CM	LEE011 + encorafenib	475.3	31.4	105	150	10.2
X-4530	CM	LEE011 + encorafenib	480.1	32.4	110	152.5	13.7
X-4530	CM	LEE011 + encorafenib	562.9	31.4	113	196	10.2
X-4530	CM	LEE011 + encorafenib	571.3	32.9	117	200.5	15.4
X-4530	CM	LEE011 + encorafenib	579.8	32.9	119	204.9	15.4
X-4530	CM	WNT974	191.1	24.8	0	0	0
X-4530	CM	WNT974	205.8	25.6	4	7.7	3.2
X-4530	CM	WNT974	555.1	25.9	9	190.5	4.4
X-4530	CM	WNT974	1238.3	25.5	15	548	2.8
X-4530	CM	WNT974	1960	25.1	21	925.6	1.2
X-4530	CM	LGW813	232.4	26.3	0	0	0
X-4530	CM	LGW813	253.5	25.5	3	9.1	-3
X-4530	CM	LGW813	445.9	26.5	7	91.9	0.8
X-4530	CM	LGW813	631.4	26.7	11	171.7	1.5
X-4530	CM	LGW813	799.1	27.8	16	243.9	5.7
X-4530	CM	encorafenib	286	21.2	0	0	0
X-4530	CM	encorafenib	404	22.1	5	41.3	4.2
X-4530	CM	encorafenib	465.5	23.1	8	62.8	9
X-4530	CM	encorafenib	549.2	23.6	11	92.1	11.3
X-4530	CM	encorafenib	589.8	23.9	14	106.3	12.7
X-4530	CM	encorafenib	658.6	24.1	18	130.3	13.7
X-4530	CM	encorafenib	855.5	24.5	22	199.2	15.6
X-4530	CM	encorafenib + binimetinib	190.8	27.2	0	0	0
X-4530	CM	encorafenib + binimetinib	101.4	27.4	6	-46.8	0.7
X-4530	CM	encorafenib + binimetinib	91.1	27.6	9	-52.2	1.5
X-4530	CM	encorafenib + binimetinib	70.7	27.8	21	-62.9	2.2
X-4530	CM	encorafenib + binimetinib	34.2	27.9	24	-82.1	2.6
X-4530	CM	encorafenib + binimetinib	74.1	28.6	29	-61.1	5.1
X-4530	CM	encorafenib + binimetinib	68.4	29	34	-64.1	6.6
X-4530	CM	encorafenib + binimetinib	98.3	28.6	37	-48.5	5.1
X-4530	CM	encorafenib + binimetinib	235.5	28.5	42	23.4	4.8
X-4530	CM	encorafenib + binimetinib	270.7	28.6	45	41.9	5.1
X-4530	CM	encorafenib + binimetinib	494.1	27.9	52	159	2.6
X-4530	CM	encorafenib + binimetinib	486	28.5	55	154.7	4.8
X-4530	CM	encorafenib + binimetinib	599	29	59	214	6.6
X-4530	CM	encorafenib + binimetinib	627.3	29.3	62	228.8	7.7
X-4530	CM	encorafenib + binimetinib	744.2	29.3	65	290.1	7.7
X-4530	CM	binimetinib	190.4	24.7	0	0	0
X-4530	CM	binimetinib	192.8	24.6	1	1.2	-0.4
X-4530	CM	binimetinib	187.3	24.4	4	-1.6	-1.2
X-4530	CM	binimetinib	184.3	25.4	7	-3.2	2.8
X-4530	CM	binimetinib	163.8	25	11	-14	1.2
X-4530	CM	binimetinib	128.6	24.8	15	-32.5	0.4
X-4530	CM	binimetinib	156.7	25.7	20	-17.7	4
X-4530	CM	binimetinib	258.5	26	26	35.7	5.3
X-4530	CM	binimetinib	257.1	25.4	32	35	2.8
X-4530	CM	binimetinib	279.8	25.3	35	46.9	2.4
X-4530	CM	binimetinib	350.5	25.5	40	84	3.2
X-4530	CM	TAS266	201.6	23.5	0	0	0
X-4530	CM	TAS266	290.2	24.4	5	43.9	3.8
X-4530	CM	TAS266	450.5	24.2	8	123.4	3
X-4530	CM	TAS266	618.5	24.8	11	206.7	5.5
X-4530	CM	TAS266	870.8	25	14	331.9	6.4
X-4530	CM	TAS266	1207.9	25.4	18	499	8.1
X-4530	CM	untreated	205.8	21.9	0	0	0
X-4530	CM	untreated	256.6	23	5	24.7	5
X-4530	CM	untreated	342.4	23.4	8	66.4	6.8
X-4530	CM	untreated	358.4	23.6	11	74.1	7.8
X-4530	CM	untreated	473.1	24.3	14	129.9	11
X-4530	CM	untreated	517.6	24.4	18	151.5	11.4
X-4530	CM	untreated	686.7	24.2	22	233.7	10.5
X-4530	CM	untreated	936.4	24.5	27	355	11.9
X-4530	CM	untreated	1567.2	26.1	33	661.5	19.2
X-4538	CM	BKM120	207.6	23.7	0	0	0
X-4538	CM	BKM120	200.7	23.6	4	-3.3	-0.4
X-4538	CM	BKM120	202.6	24.7	7	-2.4	4.2
X-4538	CM	BKM120	235.8	24.7	11	13.6	4.2
X-4538	CM	BKM120	257.3	24.9	14	23.9	5.1
X-4538	CM	BKM120	233.3	26.3	19	12.4	11
X-4538	CM	BKM120	334	25.4	22	60.9	7.2
X-4538	CM	BKM120	316.2	26	25	52.3	9.7
X-4538	CM	BKM120	366.9	26.2	28	76.7	10.5
X-4538	CM	BKM120	323.4	26.3	32	55.8	11
X-4538	CM	BKM120	410.6	26.3	36	97.8	11
X-4538	CM	BKM120	486.4	26.2	41	134.3	10.5
X-4538	CM	BKM120	628.7	26.2	47	202.8	10.5
X-4538	CM	BKM120 + encorafenib	269	25.1	0	0	0
X-4538	CM	BKM120 + encorafenib	237.2	25.8	3	-11.8	2.8
X-4538	CM	BKM120 + encorafenib	188.1	25.4	7	-30.1	1.2
X-4538	CM	BKM120 + encorafenib	176.4	26	10	-34.4	3.6
X-4538	CM	BKM120 + encorafenib	104.3	26.6	15	-61.2	6
X-4538	CM	BKM120 + encorafenib	154.9	26.1	18	-42.4	4
X-4538	CM	BKM120 + encorafenib	121.1	26.8	21	-55	6.8
X-4538	CM	BKM120 + encorafenib	131.1	26.8	24	-51.3	6.8
X-4538	CM	BKM120 + encorafenib	127	27.4	28	-52.8	9.2
X-4538	CM	BKM120 + encorafenib	136.9	27	32	-49.1	7.6
X-4538	CM	BKM120 + encorafenib	117	27.1	37	-56.5	8
X-4538	CM	BKM120 + encorafenib	136.9	28.1	43	-49.1	12
X-4538	CM	BKM120 + encorafenib	139.4	28.3	49	-48.2	12.7
X-4538	CM	BKM120 + encorafenib	114.9	28.2	52	-57.3	12.4
X-4538	CM	BKM120 + encorafenib	136.5	28	57	-49.3	11.6
X-4538	CM	BKM120 + encorafenib	109.7	27.4	60	-59.2	9.2
X-4538	CM	BKM120 + encorafenib	104	26.9	64	-61.3	7.2
X-4538	CM	BKM120 + encorafenib	109.7	27	67	-59.2	7.6
X-4538	CM	BKM120 + encorafenib	94.2	27.3	72	-65	8.8
X-4538	CM	BKM120 + encorafenib	120.9	28.1	77	-55	12
X-4538	CM	BKM120 + encorafenib	104.3	28.2	80	-61.2	12.4
X-4538	CM	BKM120 + encorafenib	99.2	27.8	85	-63.1	10.8
X-4538	CM	BKM120 + encorafenib	143.4	27.2	92	-46.7	8.4
X-4538	CM	BKM120 + encorafenib	126.9	27.8	95	-52.8	10.8
X-4538	CM	BKM120 + encorafenib	130.7	27.1	99	-51.4	8
X-4538	CM	BKM120 + encorafenib	118.8	28	102	-55.8	11.6
X-4538	CM	BKM120 + encorafenib	141.5	27.9	106	-47.4	11.2
X-4538	CM	BKM120 + encorafenib	133.1	27.6	109	-50.5	10
X-4538	CM	BKM120 + encorafenib	159.5	26.4	113	-40.7	5.2
X-4538	CM	BKM120 + encorafenib	205.4	27.5	119	-23.7	9.6
X-4538	CM	BKM120 + encorafenib	237.2	28.1	124	-11.8	12
X-4538	CM	BKM120 + encorafenib	310.5	28.7	131	15.4	14.3
X-4538	CM	BKM120 + encorafenib	314.3	28.8	137	16.8	14.7
X-4538	CM	BKM120 + encorafenib	274.6	28.9	142	2.1	15.1
X-4538	CM	BKM120 + encorafenib	347.6	28.2	149	29.2	12.4
X-4538	CM	BKM120 + encorafenib	494	27.9	158	83.6	11.2
X-4538	CM	BKM120 + encorafenib	662.9	28.3	161	146.4	12.7
X-4538	CM	BKM120 + encorafenib	641.1	28.5	165	138.3	13.5
X-4538	CM	BKM120 + encorafenib	441.8	27.7	171	64.2	10.4
X-4538	CM	BKM120 + encorafenib	380.7	27.9	177	41.5	11.2
X-4538	CM	BKM120 + encorafenib	380.7	28.9	182	41.5	15.1
X-4538	CM	CGM097	197	21.3	0	0	0
X-4538	CM	CGM097	255.5	22.1	3	29.7	3.8
X-4538	CM	CGM097	251.3	22.1	6	27.5	3.8
X-4538	CM	CGM097	352.4	22	10	78.9	3.3
X-4538	CM	CGM097	319.4	22.6	13	62.1	6.1
X-4538	CM	CGM097	344.5	21.9	17	74.9	2.8
X-4538	CM	CGM097	351.3	21.6	20	78.4	1.4
X-4538	CM	CGM097	316.9	22.2	25	60.9	4.2
X-4538	CM	CGM097	405	22.5	28	105.6	5.6
X-4538	CM	CGM097	472.7	22.1	31	140	3.8
X-4538	CM	CGM097	566.2	21.4	34	187.4	0.5
X-4538	CM	CGM097	665.5	21.9	38	237.8	2.8
X-4538	CM	dacarbazine	193	22.2	0	0	0
X-4538	CM	dacarbazine	165.3	22.6	3	-14.4	1.8
X-4538	CM	dacarbazine	167.2	22.3	7	-13.4	0.5
X-4538	CM	dacarbazine	178.6	21.9	10	-7.5	-1.4
X-4538	CM	dacarbazine	168.7	23.3	15	-12.6	5
X-4538	CM	dacarbazine	204.7	22.3	18	6.1	0.5
X-4538	CM	dacarbazine	226.6	22.8	21	17.4	2.7
X-4538	CM	dacarbazine	274.8	23.1	24	42.3	4.1
X-4538	CM	dacarbazine	325.5	23	28	68.6	3.6
X-4538	CM	dacarbazine	374.4	22.3	32	94	0.5
X-4538	CM	dacarbazine	462.4	23.6	37	139.5	6.3
X-4538	CM	dacarbazine	579.8	22	43	200.4	-0.9
X-4538	CM	LDE225	191.8	25.3	0	0	0
X-4538	CM	LDE225	186.2	26.2	3	-2.9	3.6
X-4538	CM	LDE225	200.9	25.2	7	4.7	-0.4
X-4538	CM	LDE225	238.2	25.5	10	24.2	0.8
X-4538	CM	LDE225	414.7	25.8	15	116.2	2
X-4538	CM	LDE225	635.1	25.2	18	231.1	-0.4
X-4538	CM	LDE225	716.1	26	21	273.3	2.8
X-4538	CM	LDK378	203.4	25	0	0	0
X-4538	CM	LDK378	246.4	25	3	21.2	0
X-4538	CM	LDK378	356.5	24.6	7	75.3	-1.6
X-4538	CM	LDK378	361.3	25.3	10	77.6	1.2
X-4538	CM	LDK378	627.3	26.3	15	208.5	5.2
X-4538	CM	LDK378	796.5	25.9	18	291.7	3.6
X-4538	CM	LDK378	919.4	26.3	21	352.1	5.2
X-4538	CM	LEE011	246.2	26.2	0	0	0
X-4538	CM	LEE011	261.6	24.6	3	6.2	-6.1
X-4538	CM	LEE011	378.9	24.9	7	53.9	-5
X-4538	CM	LEE011	484.3	25.6	10	96.7	-2.3
X-4538	CM	LEE011	443	24.6	14	79.9	-6.1
X-4538	CM	LEE011	510.3	23.7	17	107.2	-9.5
X-4538	CM	LEE011	486	24.7	23	97.4	-5.7
X-4538	CM	LEE011	486.7	25.4	25	97.6	-3.1
X-4538	CM	LEE011	534.5	25.9	28	117.1	-1.1
X-4538	CM	LEE011	550.4	24.8	31	123.5	-5.3
X-4538	CM	LEE011	465.5	26.1	35	89.1	-0.4
X-4538	CM	LEE011 + encorafenib	208.3	22.9	0	0	0
X-4538	CM	LEE011 + encorafenib	223.8	24.1	3	7.5	5.2
X-4538	CM	LEE011 + encorafenib	130	24	7	-37.6	4.8
X-4538	CM	LEE011 + encorafenib	102.5	23.4	10	-50.8	2.2
X-4538	CM	LEE011 + encorafenib	110.8	23.9	15	-46.8	4.4
X-4538	CM	LEE011 + encorafenib	101.4	24.2	18	-51.3	5.7
X-4538	CM	LEE011 + encorafenib	97.3	24.8	21	-53.3	8.3
X-4538	CM	LEE011 + encorafenib	110.8	25	24	-46.8	9.2
X-4538	CM	LEE011 + encorafenib	82.5	25.2	28	-60.4	10
X-4538	CM	LEE011 + encorafenib	88.7	24.9	32	-57.4	8.7
X-4538	CM	LEE011 + encorafenib	82.5	25.7	37	-60.4	12.2
X-4538	CM	LEE011 + encorafenib	118.8	26.1	43	-43	14
X-4538	CM	LEE011 + encorafenib	90.6	26	49	-56.5	13.5
X-4538	CM	LEE011 + encorafenib	120.6	25.7	52	-42.1	12.2
X-4538	CM	LEE011 + encorafenib	90.6	25.6	57	-56.5	11.8
X-4538	CM	LEE011 + encorafenib	99.1	26	60	-52.4	13.5
X-4538	CM	LEE011 + encorafenib	81.9	25.6	64	-60.7	11.8
X-4538	CM	LEE011 + encorafenib	89.2	25.9	67	-57.1	13.1
X-4538	CM	LEE011 + encorafenib	66.3	25.7	72	-68.2	12.2
X-4538	CM	LEE011 + encorafenib	94.1	26.6	77	-54.8	16.2
X-4538	CM	LEE011 + encorafenib	73.8	27	80	-64.6	17.9
X-4538	CM	LEE011 + encorafenib	90.4	26.7	85	-56.6	16.6
X-4538	CM	LEE011 + encorafenib	73.2	25.8	92	-64.8	12.7
X-4538	CM	LEE011 + encorafenib	83.8	27	95	-59.8	17.9
X-4538	CM	LEE011 + encorafenib	66.8	26	99	-67.9	13.5
X-4538	CM	LEE011 + encorafenib	85.2	26.2	102	-59.1	14.4
X-4538	CM	LEE011 + encorafenib	99.2	26.6	106	-52.3	16.2
X-4538	CM	LEE011 + encorafenib	74.9	26.5	109	-64	15.7
X-4538	CM	LEE011 + encorafenib	74.4	26.6	113	-64.3	16.2
X-4538	CM	LEE011 + encorafenib	87.8	26.5	119	-57.8	15.7
X-4538	CM	LEE011 + encorafenib	113.4	26.3	124	-45.5	14.8
X-4538	CM	LEE011 + encorafenib	143.4	26.5	131	-31.2	15.7
X-4538	CM	LEE011 + encorafenib	148.8	26.9	137	-28.5	17.5
X-4538	CM	LEE011 + encorafenib	130.2	27.1	142	-37.5	18.3
X-4538	CM	LEE011 + encorafenib	126	25.6	149	-39.5	11.8
X-4538	CM	LEE011 + encorafenib	169.9	26.9	158	-18.4	17.5
X-4538	CM	LEE011 + encorafenib	140.3	27.2	161	-32.6	18.8
X-4538	CM	LEE011 + encorafenib	126	27.8	165	-39.5	21.4
X-4538	CM	LEE011 + encorafenib	120.6	27.2	171	-42.1	18.8
X-4538	CM	LEE011 + encorafenib	217.6	27.8	177	4.5	21.4
X-4538	CM	LEE011 + encorafenib	217.6	28.8	182	4.5	25.8
X-4538	CM	WNT974	240.1	24.6	0	0	0
X-4538	CM	WNT974	363.3	25	3	51.3	1.6
X-4538	CM	WNT974	393.6	25.2	7	63.9	2.4
X-4538	CM	WNT974	478.2	24	10	99.2	-2.4
X-4538	CM	WNT974	659.8	24	15	174.8	-2.4
X-4538	CM	WNT974	890.2	24.4	18	270.7	-0.8
X-4538	CM	WNT974	1003.5	24.7	21	317.9	0.4
X-4538	CM	LGW813	204.8	22	0	0	0
X-4538	CM	LGW813	269.5	25	4	31.6	13.6
X-4538	CM	LGW813	338.4	23.5	7	65.2	6.8
X-4538	CM	LGW813	480	23.6	11	134.4	7.3
X-4538	CM	LGW813	603.3	23.8	14	194.6	8.2
X-4538	CM	LGW813	696.6	24.5	19	240.1	11.4
X-4538	CM	LGW813	891.9	24.5	22	335.5	11.4
X-4538	CM	LGW813	1040.4	25.3	25	408	15
X-4538	CM	encorafenib	194.1	25.7	0	0	0
X-4538	CM	encorafenib	156.8	24.6	3	-19.2	-4.3
X-4538	CM	encorafenib	183.8	25.2	7	-5.3	-1.9
X-4538	CM	encorafenib	174	26.2	10	-10.4	1.9
X-4538	CM	encorafenib	186.5	25	14	-3.9	-2.7
X-4538	CM	encorafenib	230	25.4	17	18.5	-1.2
X-4538	CM	encorafenib	230.6	25.9	22	18.8	0.8
X-4538	CM	encorafenib	215.1	26.2	25	10.9	1.9
X-4538	CM	encorafenib	258.8	26.4	28	33.3	2.7
X-4538	CM	encorafenib	294.4	25.6	31	51.7	-0.4
X-4538	CM	encorafenib	322.8	25	35	66.3	-2.7
X-4538	CM	encorafenib	323.8	21.6	39	66.8	-16
X-4538	CM	encorafenib + binimetinib	230.3	23.4	0	0	0
X-4538	CM	encorafenib + binimetinib	101.3	23.2	3	-56	-0.9
X-4538	CM	encorafenib + binimetinib	109.8	22.6	7	-52.3	-3.4
X-4538	CM	encorafenib + binimetinib	67.8	23	10	-70.5	-1.7
X-4538	CM	encorafenib + binimetinib	80.6	23.3	15	-65	-0.4
X-4538	CM	encorafenib + binimetinib	61	23.2	18	-73.5	-0.9
X-4538	CM	encorafenib + binimetinib	76	23.1	21	-67	-1.3
X-4538	CM	encorafenib + binimetinib	87.5	23.2	24	-62	-0.9
X-4538	CM	encorafenib + binimetinib	71.9	23.3	28	-68.8	-0.4
X-4538	CM	encorafenib + binimetinib	68.9	23.1	32	-70.1	-1.3
X-4538	CM	encorafenib + binimetinib	49.4	23.8	37	-78.6	1.7
X-4538	CM	encorafenib + binimetinib	65.7	23.3	43	-71.5	-0.4
X-4538	CM	encorafenib + binimetinib	75	23.7	49	-67.4	1.3
X-4538	CM	encorafenib + binimetinib	55.7	23.3	52	-75.8	-0.4
X-4538	CM	encorafenib + binimetinib	68.8	23.9	57	-70.1	2.1
X-4538	CM	encorafenib + binimetinib	54.1	23.5	60	-76.5	0.4
X-4538	CM	encorafenib + binimetinib	33.5	23.6	64	-85.5	0.9
X-4538	CM	encorafenib + binimetinib	44.4	23.9	67	-80.7	2.1
X-4538	CM	encorafenib + binimetinib	39.6	24.3	72	-82.8	3.8
X-4538	CM	encorafenib + binimetinib	23.7	24	77	-89.7	2.6
X-4538	CM	encorafenib + binimetinib	28.8	24.2	80	-87.5	3.4
X-4538	CM	encorafenib + binimetinib	41.5	23.8	85	-82	1.7
X-4538	CM	encorafenib + binimetinib	51.8	23.7	92	-77.5	1.3
X-4538	CM	encorafenib + binimetinib	60.8	23.8	95	-73.6	1.7
X-4538	CM	encorafenib + binimetinib	32	23.9	99	-86.1	2.1
X-4538	CM	encorafenib + binimetinib	37.6	24.4	102	-83.7	4.3
X-4538	CM	encorafenib + binimetinib	52.9	24.5	106	-77	4.7
X-4538	CM	encorafenib + binimetinib	36.8	23.9	109	-84	2.1
X-4538	CM	encorafenib + binimetinib	48.7	24.2	113	-78.9	3.4
X-4538	CM	encorafenib + binimetinib	62.5	24.5	119	-72.9	4.7
X-4538	CM	encorafenib + binimetinib	75	23.9	124	-67.4	2.1
X-4538	CM	encorafenib + binimetinib	117	24.7	131	-49.2	5.6
X-4538	CM	encorafenib + binimetinib	129	25.7	137	-44	9.8
X-4538	CM	encorafenib + binimetinib	117.2	25.1	142	-49.1	7.3
X-4538	CM	encorafenib + binimetinib	130.2	24.4	149	-43.4	4.3
X-4538	CM	encorafenib + binimetinib	199.6	24.5	158	-13.3	4.7
X-4538	CM	encorafenib + binimetinib	188.7	24.8	161	-18.1	6
X-4538	CM	encorafenib + binimetinib	245.5	24.7	165	6.6	5.6
X-4538	CM	encorafenib + binimetinib	243.4	24.7	171	5.7	5.6
X-4538	CM	encorafenib + binimetinib	302.6	26	177	31.4	11.1
X-4538	CM	encorafenib + binimetinib	302.6	27	182	31.4	15.4
X-4538	CM	binimetinib	191.9	22.7	0	0	0
X-4538	CM	binimetinib	300.4	22.8	4	56.5	0.4
X-4538	CM	binimetinib	311.3	23.2	7	62.2	2.2
X-4538	CM	binimetinib	260.9	23.7	11	35.9	4.4
X-4538	CM	binimetinib	355.2	23.9	14	85.1	5.3
X-4538	CM	binimetinib	302.7	24.6	19	57.7	8.4
X-4538	CM	binimetinib	384	24.3	22	100.1	7
X-4538	CM	binimetinib	443.8	24.5	25	131.2	7.9
X-4538	CM	binimetinib	512.1	24.5	28	166.8	7.9
X-4538	CM	binimetinib	574.3	24.3	32	199.3	7
X-4538	CM	TAS266	342.4	20.9	0	0	0
X-4538	CM	TAS266	406.8	23	3	18.8	10
X-4538	CM	TAS266	501	22.4	6	46.3	7.2
X-4538	CM	TAS266	843.4	22.7	10	146.3	8.6
X-4538	CM	TAS266	1072.2	23.3	13	213.1	11.5
X-4538	CM	TAS266	1470.3	23.2	17	329.4	11
X-4538	CM	TAS266	1780.6	24	20	420	14.8
X-4538	CM	untreated	191.6	22.5	0	0	0
X-4538	CM	untreated	249.6	23.4	3	30.3	4
X-4538	CM	untreated	377.2	23.5	6	96.9	4.4
X-4538	CM	untreated	516.3	23.7	10	169.5	5.3
X-4538	CM	untreated	686.7	24.2	13	258.5	7.6
X-4538	CM	untreated	1005.1	24.7	17	424.7	9.8
X-4538	CM	untreated	1394.2	24.8	20	627.8	10.2
X-4538	CM	untreated	1793.4	25.7	25	836.2	14.2
X-4567	BRCA	BGJ398	274.9	28.2	0	0	0
X-4567	BRCA	BGJ398	320.1	28.3	4	16.4	0.4
X-4567	BRCA	BGJ398	308.2	28.7	7	12.1	1.8
X-4567	BRCA	BGJ398	389.7	28.1	11	41.8	-0.4
X-4567	BRCA	BGJ398	491.8	28.1	14	78.9	-0.4
X-4567	BRCA	BGJ398	506.8	27.9	18	84.4	-1.1
X-4567	BRCA	BGJ398	537.4	27.5	21	95.5	-2.5
X-4567	BRCA	BGJ398	502.7	26.8	25	82.9	-5
X-4567	BRCA	BGJ398	603.5	27.3	28	119.5	-3.2
X-4567	BRCA	BGJ398	674.8	28.7	32	145.5	1.8
X-4567	BRCA	BGJ398	720.6	28.2	35	162.1	0
X-4567	BRCA	BGJ398	850	28.1	39	209.2	-0.4
X-4567	BRCA	BGJ398	969.9	28.7	42	252.8	1.8
X-4567	BRCA	BKM120	262.2	28	0	0	0
X-4567	BRCA	BKM120	121.9	27.9	4	-53.5	-0.4
X-4567	BRCA	BKM120	128.4	27.8	7	-51	-0.7
X-4567	BRCA	BKM120	103.2	29	11	-60.6	3.6
X-4567	BRCA	BKM120	62.5	28.5	14	-76.2	1.8
X-4567	BRCA	BKM120	46.2	29.3	18	-82.4	4.6
X-4567	BRCA	BKM120	67.5	29.1	21	-74.3	3.9
X-4567	BRCA	BKM120	48	28.8	25	-81.7	2.9
X-4567	BRCA	BKM120	31.4	29	28	-88	3.6
X-4567	BRCA	BKM120	22.8	29.3	32	-91.3	4.6
X-4567	BRCA	BKM120	20	28.8	35	-92.4	2.9
X-4567	BRCA	BKM120	0	28.8	39	-100	2.9
X-4567	BRCA	BKM120	0	29.7	42	-100	6.1
X-4567	BRCA	BKM120	0	28.3	45	-100	1.1
X-4567	BRCA	BKM120	0	29.3	49	-100	4.6
X-4567	BRCA	BKM120	0	30.2	53	-100	7.9
X-4567	BRCA	BKM120	0	31.1	56	-100	11.1
X-4567	BRCA	BKM120	0	29.9	60	-100	6.8
X-4567	BRCA	BKM120	0	30.8	70	-100	10
X-4567	BRCA	BKM120	0	30	74	-100	7.1
X-4567	BRCA	BKM120	0	29.4	77	-100	5
X-4567	BRCA	BKM120	0	30.7	81	-100	9.6
X-4567	BRCA	BKM120	0	30.9	84	-100	10.4
X-4567	BRCA	BYL719	281	25.5	0	0	0
X-4567	BRCA	BYL719	171.8	24.5	5	-38.9	-3.9
X-4567	BRCA	BYL719	118.3	24.4	8	-57.9	-4.3
X-4567	BRCA	BYL719	92.8	24.4	11	-67	-4.3
X-4567	BRCA	BYL719	67.1	25.4	15	-76.1	-0.4
X-4567	BRCA	BYL719	65.1	25.6	18	-76.8	0.4
X-4567	BRCA	BYL719	56.5	25.9	22	-79.9	1.6
X-4567	BRCA	BYL719	51	25.6	25	-81.9	0.4
X-4567	BRCA	BYL719	41.3	25.4	29	-85.3	-0.4
X-4567	BRCA	BYL719	40.1	26.2	32	-85.7	2.7
X-4567	BRCA	BYL719	24.2	25.5	36	-91.4	0
X-4567	BRCA	BYL719	16.3	25.9	39	-94.2	1.6
X-4567	BRCA	BYL719	23	26.3	43	-91.8	3.1
X-4567	BRCA	BYL719	10.8	26.4	46	-96.2	3.5
X-4567	BRCA	BYL719	12.4	26.4	50	-95.6	3.5
X-4567	BRCA	BYL719	12.4	26	53	-95.6	2
X-4567	BRCA	BYL719	0	26.1	56	-100	2.4
X-4567	BRCA	BYL719	0	26.4	60	-100	3.5
X-4567	BRCA	BYL719	0	27.1	64	-100	6.3
X-4567	BRCA	BYL719	0	26.1	67	-100	2.4
X-4567	BRCA	BYL719	0	27.2	71	-100	6.7
X-4567	BRCA	BYL719	0	26.6	81	-100	4.3
X-4567	BRCA	BYL719	0	26.8	85	-100	5.1
X-4567	BRCA	BYL719	0	26.3	88	-100	3.1
X-4567	BRCA	BYL719	0	27.2	92	-100	6.7
X-4567	BRCA	BYL719	0	27.4	95	-100	7.5
X-4567	BRCA	BYL719 + LJM716	229.3	25.9	0	0	0
X-4567	BRCA	BYL719 + LJM716	91.7	25.8	5	-60	-0.4
X-4567	BRCA	BYL719 + LJM716	59.6	24	8	-74	-7.3
X-4567	BRCA	BYL719 + LJM716	66.4	25.1	11	-71	-3.1
X-4567	BRCA	BYL719 + LJM716	44.5	25.6	15	-80.6	-1.2
X-4567	BRCA	BYL719 + LJM716	43.5	25	18	-81	-3.5
X-4567	BRCA	BYL719 + LJM716	35	25.7	22	-84.7	-0.8
X-4567	BRCA	BYL719 + LJM716	31	24.4	25	-86.5	-5.8
X-4567	BRCA	BYL719 + LJM716	34	24.7	29	-85.2	-4.6
X-4567	BRCA	BYL719 + LJM716	23.3	25.6	32	-89.8	-1.2
X-4567	BRCA	BYL719 + LJM716	21.6	25.6	36	-90.6	-1.2
X-4567	BRCA	BYL719 + LJM716	21.2	23.6	39	-90.8	-8.9
X-4567	BRCA	BYL719 + LJM716	18.4	24.7	43	-92	-4.6
X-4567	BRCA	BYL719 + LJM716	17.3	25.3	46	-92.5	-2.3
X-4567	BRCA	BYL719 + LJM716	16.4	25.6	50	-92.8	-1.2
X-4567	BRCA	BYL719 + LJM716	13.2	23.5	53	-94.2	-9.3
X-4567	BRCA	BYL719 + LJM716	18.7	23.5	56	-91.8	-9.3
X-4567	BRCA	BYL719 + LJM716	14.9	24.8	60	-93.5	-4.2
X-4567	BRCA	BYL719 + LJM716	13.5	24.8	64	-94.1	-4.2
X-4567	BRCA	BYL719 + LJM716	10.7	24.9	67	-95.3	-3.9
X-4567	BRCA	BYL719 + LJM716	9.3	23.4	71	-95.9	-9.7
X-4567	BRCA	BYL719 + LJM716	8	24.6	81	-96.5	-5
X-4567	BRCA	BYL719 + LJM716	6.4	25.6	85	-97.2	-1.2
X-4567	BRCA	BYL719 + LJM716	8	25.9	88	-96.5	0
X-4567	BRCA	BYL719 + LJM716	7.8	25.8	92	-96.6	-0.4
X-4567	BRCA	BYL719 + LJM716	8.7	25.6	95	-96.2	-1.2
X-4567	BRCA	BYL719 + LEE011	284.6	28.5	0	0	0
X-4567	BRCA	BYL719 + LEE011	211.1	28.7	4	-25.8	0.7
X-4567	BRCA	BYL719 + LEE011	136.8	27.7	7	-51.9	-2.8
X-4567	BRCA	BYL719 + LEE011	123	27.6	11	-56.8	-3.2
X-4567	BRCA	BYL719 + LEE011	90.1	27.7	15	-68.3	-2.8
X-4567	BRCA	BYL719 + LEE011	40.6	27.4	18	-85.7	-3.9
X-4567	BRCA	BYL719 + LEE011	33.1	27	22	-88.4	-5.3
X-4567	BRCA	BYL719 + LEE011	18.7	28.2	32	-93.4	-1.1
X-4567	BRCA	BYL719 + LEE011	9.3	27.6	36	-96.7	-3.2
X-4567	BRCA	BYL719 + LEE011	7.6	28.8	39	-97.3	1.1
X-4567	BRCA	BYL719 + LEE011	19.3	29.3	43	-93.2	2.8
X-4567	BRCA	BYL719 + LEE011	14.8	29.3	46	-94.8	2.8
X-4567	BRCA	BYL719 + LEE011	7.6	28.7	50	-97.3	0.7
X-4567	BRCA	BYL719 + LEE011	7.2	27.9	53	-97.5	-2.1
X-4567	BRCA	BYL719 + LEE011	6.2	28.4	56	-97.8	-0.4
X-4567	BRCA	BYL719 + LEE011	5.6	28.1	60	-98	-1.4
X-4567	BRCA	BYL719 + LEE011	5.1	28	63	-98.2	-1.8
X-4567	BRCA	BYL719 + LEE011	3.9	28.1	67	-98.6	-1.4
X-4567	BRCA	BYL719 + LEE011	1.1	28.2	70	-99.6	-1.1
X-4567	BRCA	BYL719 + LEE011	0	28.1	74	-100	-1.4
X-4567	BRCA	BYL719 + LEE011	2.8	27.8	78	-99	-2.5
X-4567	BRCA	BYL719 + LEE011	2.8	28	81	-99	-1.8
X-4567	BRCA	BYL719 + LEE011	3.8	28	85	-98.7	-1.8
X-4567	BRCA	BYL719 + LEE011	3.8	26.6	88	-98.7	-6.7
X-4567	BRCA	CGM097	213.1	25.4	0	0	0
X-4567	BRCA	CGM097	168.5	27.2	3	-20.9	7.1
X-4567	BRCA	CGM097	183.6	27.7	6	-13.8	9.1
X-4567	BRCA	CGM097	249.2	27.8	11	16.9	9.4
X-4567	BRCA	CGM097	300.2	29	14	40.9	14.2
X-4567	BRCA	CGM097	433.9	29.1	17	103.6	14.6
X-4567	BRCA	CGM097	389.2	29	21	82.6	14.2
X-4567	BRCA	CGM097	345.8	28.8	24	62.3	13.4
X-4567	BRCA	CGM097	388.6	29.3	28	82.4	15.4
X-4567	BRCA	CGM097	411.7	27.9	31	93.2	9.8
X-4567	BRCA	CGM097	529	28.9	35	148.2	13.8
X-4567	BRCA	CGM097	508.6	28.3	38	138.7	11.4
X-4567	BRCA	CGM097	606.1	27.7	42	184.4	9.1
X-4567	BRCA	CGM097	584.7	28.5	45	174.4	12.2
X-4567	BRCA	CGM097	640.2	28.7	49	200.4	13
X-4567	BRCA	CGM097	846.3	28.8	52	297.1	13.4
X-4567	BRCA	CGM097	811.7	27.9	56	280.9	9.8
X-4567	BRCA	CGM097	870	28.2	59	308.3	11
X-4567	BRCA	CLR457	223.5	23.5	0	0	0
X-4567	BRCA	CLR457	209.5	24	3	-6.3	2.1
X-4567	BRCA	CLR457	197.5	23.4	7	-11.6	-0.4
X-4567	BRCA	CLR457	151.3	24.4	10	-32.3	3.8
X-4567	BRCA	CLR457	111.2	24.2	14	-50.2	3
X-4567	BRCA	CLR457	80.4	25.4	17	-64	8.1
X-4567	BRCA	CLR457	52.7	25.3	21	-76.4	7.7
X-4567	BRCA	CLR457	28.9	25.9	24	-87.1	10.2
X-4567	BRCA	CLR457	41.3	24.5	27	-81.5	4.3
X-4567	BRCA	CLR457	14.4	24.5	31	-93.6	4.3
X-4567	BRCA	CLR457	10.7	23.9	35	-95.2	1.7
X-4567	BRCA	CLR457	5.2	25.3	38	-97.7	7.7
X-4567	BRCA	CLR457	5.7	25.4	42	-97.4	8.1
X-4567	BRCA	CLR457	8.8	24.9	52	-96.1	6
X-4567	BRCA	CLR457	4	26.1	56	-98.2	11.1
X-4567	BRCA	CLR457	3.9	26.3	59	-98.3	11.9
X-4567	BRCA	CLR457	7.1	25.3	63	-96.8	7.7
X-4567	BRCA	CLR457	5.4	26.9	66	-97.6	14.5
X-4567	BRCA	CLR457	7.4	27	70	-96.7	14.9
X-4567	BRCA	CLR457	6.6	25.8	73	-97	9.8
X-4567	BRCA	CLR457	6.4	26.1	76	-97.1	11.1
X-4567	BRCA	CLR457	5.7	25.8	80	-97.4	9.8
X-4567	BRCA	CLR457	4.8	25	83	-97.9	6.4
X-4567	BRCA	CLR457	5.2	26.4	87	-97.7	12.3
X-4567	BRCA	CLR457	0.8	26.9	90	-99.6	14.5
X-4567	BRCA	CLR457	5.1	26	94	-97.7	10.6
X-4567	BRCA	HDM201	259.9	26.7	0	0	0
X-4567	BRCA	HDM201	245.3	26.2	4	-5.6	-1.9
X-4567	BRCA	HDM201	213.5	25.4	7	-17.9	-4.9
X-4567	BRCA	HDM201	247.7	24.5	11	-4.7	-8.2
X-4567	BRCA	HDM201	267	24.7	14	2.7	-7.5
X-4567	BRCA	HDM201	294.1	24.4	18	13.2	-8.6
X-4567	BRCA	HDM201	306.6	25	21	18	-6.4
X-4567	BRCA	HDM201	312.8	24.1	25	20.4	-9.7
X-4567	BRCA	HDM201	295.5	23.1	28	13.7	-13.5
X-4567	BRCA	HDM201	321.2	23.6	31	23.6	-11.6
X-4567	BRCA	HDM201	363.9	26.4	35	40	-1.1
X-4567	BRCA	HDM201	421.5	25.1	39	62.2	-6
X-4567	BRCA	HDM201	462.9	24.6	42	78.1	-7.9
X-4567	BRCA	HDM201	436.2	23.6	46	67.8	-11.6
X-4567	BRCA	HDM201	626.1	25.5	56	140.9	-4.5
X-4567	BRCA	HDM201	635.7	27.4	60	144.6	2.6
X-4567	BRCA	HDM201	602.2	25.7	63	131.7	-3.7
X-4567	BRCA	HDM201	587.3	24.2	67	126	-9.4
X-4567	BRCA	HDM201	575.8	25	70	121.5	-6.4
X-4567	BRCA	HDM201	519.5	24.1	74	99.9	-9.7
X-4567	BRCA	HDM201	466	23.4	77	79.3	-12.4
X-4567	BRCA	HDM201	427.1	19.4	80	64.3	-27.3
X-4567	BRCA	INC424	264.5	26.6	0	0	0
X-4567	BRCA	INC424	353.5	26.9	4	33.6	1.1
X-4567	BRCA	INC424	355.1	27.3	7	34.3	2.6
X-4567	BRCA	INC424	255.5	27.4	11	-3.4	3
X-4567	BRCA	INC424	222.3	27.6	14	-16	3.8
X-4567	BRCA	INC424	215.9	26.6	18	-18.4	0
X-4567	BRCA	INC424	218.3	26.9	21	-17.5	1.1
X-4567	BRCA	INC424	182.4	27	25	-31	1.5
X-4567	BRCA	INC424	228.2	28.1	28	-13.7	5.6
X-4567	BRCA	INC424	256.1	27.9	31	-3.2	4.9
X-4567	BRCA	INC424	289.6	27.1	35	9.5	1.9
X-4567	BRCA	INC424	204.6	27.3	39	-22.6	2.6
X-4567	BRCA	INC424	201.2	27.5	42	-23.9	3.4
X-4567	BRCA	INC424	307.4	27	46	16.2	1.5
X-4567	BRCA	INC424	386.6	27.7	56	46.2	4.1
X-4567	BRCA	INC424	435.6	27.1	60	64.7	1.9
X-4567	BRCA	INC424	480.6	27.7	63	81.7	4.1
X-4567	BRCA	INC424	603.4	27.3	67	128.1	2.6
X-4567	BRCA	INC424	640.3	27.3	70	142.1	2.6
X-4567	BRCA	INC424	698.7	27.9	74	164.2	4.9
X-4567	BRCA	INC424	559.5	28.2	77	111.5	6
X-4567	BRCA	INC424	566.6	27.6	80	114.2	3.8
X-4567	BRCA	INC424	570.8	28.9	84	115.8	8.6
X-4567	BRCA	INC424	583.6	29	87	120.6	9
X-4567	BRCA	INC424	675.7	28.4	91	155.5	6.8
X-4567	BRCA	LEE011	294.6	30.7	0	0	0
X-4567	BRCA	LEE011	395.9	32.5	4	34.4	5.9
X-4567	BRCA	LEE011	464.5	31.8	7	57.7	3.6
X-4567	BRCA	LEE011	459.5	31.9	11	56	3.9
X-4567	BRCA	LEE011	493.6	31.7	15	67.5	3.3
X-4567	BRCA	LEE011	417.6	31.4	18	41.8	2.3
X-4567	BRCA	LEE011	400	32	22	35.8	4.2
X-4567	BRCA	LEE011	504	32.7	32	71.1	6.5
X-4567	BRCA	LEE011	511.6	32	36	73.7	4.2
X-4567	BRCA	LEE011	569.7	32.6	39	93.4	6.2
X-4567	BRCA	LEE011	680.3	32.5	43	130.9	5.9
X-4567	BRCA	LEE011	640.9	33.4	46	117.5	8.8
X-4567	BRCA	LEE011	649.2	32.8	50	120.4	6.8
X-4567	BRCA	LEE011	670.3	32.1	53	127.5	4.6
X-4567	BRCA	LEE011	700.2	32.7	56	137.7	6.5
X-4567	BRCA	LEE011	707.4	32.9	60	140.1	7.2
X-4567	BRCA	LEE011	752.2	33.8	63	155.3	10.1
X-4567	BRCA	LEE011	627	31.5	67	112.8	2.6
X-4567	BRCA	LEE011	476.8	31.7	70	61.8	3.3
X-4567	BRCA	LEE011	334.5	32.6	74	13.5	6.2
X-4567	BRCA	LEE011	376.9	32	78	27.9	4.2
X-4567	BRCA	LEE011	412.2	32	81	39.9	4.2
X-4567	BRCA	LEE011	477.6	33	85	62.1	7.5
X-4567	BRCA	LEE011	496.4	32.1	88	68.5	4.6
X-4567	BRCA	LEE011	510.8	32.5	92	73.4	5.9
X-4567	BRCA	LEE011	507	33.2	95	72.1	8.1
X-4567	BRCA	LEE011	521.5	32.6	99	77	6.2
X-4567	BRCA	LEE011	545.5	33.3	102	85.2	8.5
X-4567	BRCA	LEE011	634.5	32.1	106	115.4	4.6
X-4567	BRCA	LEE011	634	32.2	109	115.2	4.9
X-4567	BRCA	LEE011 + everolimus	243.7	25.9	0	0	0
X-4567	BRCA	LEE011 + everolimus	276.6	26	2	13.5	0.4
X-4567	BRCA	LEE011 + everolimus	199.4	26.2	6	-18.2	1.2
X-4567	BRCA	LEE011 + everolimus	140.5	27.1	10	-42.3	4.6
X-4567	BRCA	LEE011 + everolimus	129.3	27.6	13	-46.9	6.6
X-4567	BRCA	LEE011 + everolimus	99.6	26.9	17	-59.1	3.9
X-4567	BRCA	LEE011 + everolimus	52.3	26.4	27	-78.5	1.9
X-4567	BRCA	LEE011 + everolimus	65.1	27.5	31	-73.3	6.2
X-4567	BRCA	LEE011 + everolimus	41.8	27.4	34	-82.8	5.8
X-4567	BRCA	LEE011 + everolimus	69	26.9	38	-71.7	3.9
X-4567	BRCA	LEE011 + everolimus	50.7	27.2	41	-79.2	5
X-4567	BRCA	LEE011 + everolimus	53.7	26.9	45	-78	3.9
X-4567	BRCA	LEE011 + everolimus	54.1	26.3	48	-77.8	1.5
X-4567	BRCA	LEE011 + everolimus	52.4	27	51	-78.5	4.2
X-4567	BRCA	LEE011 + everolimus	48.9	27.2	55	-79.9	5
X-4567	BRCA	LEE011 + everolimus	51.5	27.4	58	-78.9	5.8
X-4567	BRCA	LEE011 + everolimus	51.7	27	62	-78.8	4.2
X-4567	BRCA	LEE011 + everolimus	48.5	26.6	65	-80.1	2.7
X-4567	BRCA	LEE011 + everolimus	22	25.9	69	-91	0
X-4567	BRCA	LEE011 + everolimus	27.3	25.7	73	-88.8	-0.8
X-4567	BRCA	LEE011 + everolimus	12.5	26.3	76	-94.9	1.5
X-4567	BRCA	LEE011 + everolimus	16.5	25.9	80	-93.2	0
X-4567	BRCA	LEE011 + everolimus	8.9	25.6	83	-96.3	-1.2
X-4567	BRCA	LEE011 + everolimus	16.5	25.8	87	-93.2	-0.4
X-4567	BRCA	LEE011 + everolimus	13.1	25.6	90	-94.6	-1.2
X-4567	BRCA	LEE011 + everolimus	7.1	27.9	94	-97.1	7.7
X-4567	BRCA	LEE011 + everolimus	12.1	27.2	97	-95	5
X-4567	BRCA	LEE011 + everolimus	10.7	26.1	101	-95.6	0.8
X-4567	BRCA	LEE011 + everolimus	8.5	26.5	104	-96.5	2.3
X-4567	BRCA	LFA102	256.3	28.7	0	0	0
X-4567	BRCA	LFA102	238.3	29.5	3	-7	2.8
X-4567	BRCA	LFA102	278.7	30.1	6	8.7	4.9
X-4567	BRCA	LFA102	320.5	29.8	10	25	3.8
X-4567	BRCA	LFA102	349.6	30.4	13	36.4	5.9
X-4567	BRCA	LFA102	397.4	30.4	17	55.1	5.9
X-4567	BRCA	LFA102	458.9	31	20	79	8
X-4567	BRCA	LFA102	506.1	31.8	24	97.5	10.8
X-4567	BRCA	LFA102	524.9	30.9	27	104.8	7.7
X-4567	BRCA	LFA102	607.4	30.7	30	137	7
X-4567	BRCA	LFA102	801.1	31.6	34	212.6	10.1
X-4567	BRCA	LFA102	1095.6	31	38	327.5	8
X-4567	BRCA	LFA102	1261.3	30.7	41	392.1	7
X-4567	BRCA	LJM716	240.9	28.5	0	0	0
X-4567	BRCA	LJM716	202.1	26.7	2	-16.1	-6.3
X-4567	BRCA	LJM716	165.1	26.5	7	-31.5	-7
X-4567	BRCA	LJM716	211	26.2	10	-12.4	-8.1
X-4567	BRCA	LJM716	202.2	27.8	13	-16.1	-2.5
X-4567	BRCA	LJM716	218.6	27	17	-9.3	-5.3
X-4567	BRCA	LJM716	251.7	27.2	20	4.5	-4.6
X-4567	BRCA	LJM716	278.6	26.5	24	15.6	-7
X-4567	BRCA	LJM716	257.4	26.3	27	6.8	-7.7
X-4567	BRCA	LJM716	269.5	26.8	31	11.9	-6
X-4567	BRCA	LJM716	213.7	28.6	34	-11.3	0.4
X-4567	BRCA	LJM716	275.3	27	38	14.3	-5.3
X-4567	BRCA	LJM716	251.9	28.4	41	4.6	-0.4
X-4567	BRCA	LJM716	253.9	27.4	45	5.4	-3.9
X-4567	BRCA	LJM716	243.9	27.3	48	1.2	-4.2
X-4567	BRCA	LJM716	223.3	28.3	52	-7.3	-0.7
X-4567	BRCA	LJM716	225.4	27.7	55	-6.4	-2.8
X-4567	BRCA	LJM716	206.2	27.7	58	-14.4	-2.8
X-4567	BRCA	LJM716	200.2	26.7	62	-16.9	-6.3
X-4567	BRCA	LJM716	241.6	27.2	66	0.3	-4.6
X-4567	BRCA	LJM716	189.5	27.6	69	-21.3	-3.2
X-4567	BRCA	LJM716	224.8	27.2	73	-6.7	-4.6
X-4567	BRCA	LJM716	198.8	27.9	83	-17.5	-2.1
X-4567	BRCA	LJM716	212.1	28.1	87	-12	-1.4
X-4567	BRCA	LJM716	234.4	26.7	90	-2.7	-6.3
X-4567	BRCA	LJM716	301.4	26.6	94	25.1	-6.7
X-4567	BRCA	LJM716	290.4	27.5	97	20.5	-3.5
X-4567	BRCA	LJM716	420.8	27.6	101	74.7	-3.2
X-4567	BRCA	LJM716	437.9	27.9	104	81.8	-2.1
X-4567	BRCA	LJM716 + trastuzumab	202	24.1	0	0	0
X-4567	BRCA	LJM716 + trastuzumab	165.9	23.4	2	-17.9	-2.9
X-4567	BRCA	LJM716 + trastuzumab	48.6	24.4	7	-75.9	1.2
X-4567	BRCA	LJM716 + trastuzumab	0	24	10	-100	-0.4
X-4567	BRCA	LJM716 + trastuzumab	0	25.9	13	-100	7.5
X-4567	BRCA	LJM716 + trastuzumab	0	24.5	17	-100	1.7
X-4567	BRCA	LJM716 + trastuzumab	0	23.8	20	-100	-1.2
X-4567	BRCA	LJM716 + trastuzumab	0	24.1	24	-100	0
X-4567	BRCA	LJM716 + trastuzumab	0	24.4	27	-100	1.2
X-4567	BRCA	LJM716 + trastuzumab	0	24.4	31	-100	1.2
X-4567	BRCA	LJM716 + trastuzumab	0	24.4	34	-100	1.2
X-4567	BRCA	LJM716 + trastuzumab	0	24.3	38	-100	0.8
X-4567	BRCA	LJM716 + trastuzumab	0	23.7	41	-100	-1.7
X-4567	BRCA	LJM716 + trastuzumab	0	24.4	45	-100	1.2
X-4567	BRCA	LJM716 + trastuzumab	0	24.2	48	-100	0.4
X-4567	BRCA	LJM716 + trastuzumab	0	24.3	52	-100	0.8
X-4567	BRCA	LJM716 + trastuzumab	0	23.8	55	-100	-1.2
X-4567	BRCA	LJM716 + trastuzumab	0	23.5	58	-100	-2.5
X-4567	BRCA	LJM716 + trastuzumab	0	24.6	62	-100	2.1
X-4567	BRCA	LJM716 + trastuzumab	0	24.4	66	-100	1.2
X-4567	BRCA	LJM716 + trastuzumab	0	24.7	69	-100	2.5
X-4567	BRCA	LJM716 + trastuzumab	0	24.5	73	-100	1.7
X-4567	BRCA	LJM716 + trastuzumab	0	24.6	83	-100	2.1
X-4567	BRCA	LJM716 + trastuzumab	0	24.4	87	-100	1.2
X-4567	BRCA	LJM716 + trastuzumab	0	24.8	90	-100	2.9
X-4567	BRCA	LKA136	249	24.1	0	0	0
X-4567	BRCA	LKA136	265.3	23.5	3	6.5	-2.5
X-4567	BRCA	LKA136	227.1	23.5	6	-8.8	-2.5
X-4567	BRCA	LKA136	302.1	24.8	10	21.3	2.9
X-4567	BRCA	LKA136	445.3	25.4	13	78.8	5.4
X-4567	BRCA	LKA136	429.3	25.2	16	72.4	4.6
X-4567	BRCA	LKA136	469.3	25.1	20	88.5	4.1
X-4567	BRCA	LKA136	551.6	24.7	24	121.5	2.5
X-4567	BRCA	LKA136	606.7	24.7	27	143.7	2.5
X-4567	BRCA	LKA136	630.7	24.8	31	153.3	2.9
X-4567	BRCA	LKA136	1044.8	25.8	41	319.6	7.1
X-4567	BRCA	LLM871	303.2	32.3	0	0	0
X-4567	BRCA	LLM871	289.9	30.1	2	-4.4	-6.8
X-4567	BRCA	LLM871	188.4	28.1	6	-37.9	-13
X-4567	BRCA	LLM871	151.6	27.9	10	-50	-13.6
X-4567	BRCA	LLM871	79.3	30	13	-73.8	-7.1
X-4567	BRCA	LLM871	58.6	29.7	17	-80.7	-8
X-4567	BRCA	LLM871	37.1	27.1	24	-87.8	-16.1
X-4567	BRCA	LLM871	28.7	28.7	27	-90.5	-11.1
X-4567	BRCA	LLM871	12.4	28.7	31	-95.9	-11.1
X-4567	BRCA	LLM871	9.1	29.7	34	-97	-8
X-4567	BRCA	LLM871	0	29.4	38	-100	-9
X-4567	BRCA	LLM871	0	29.5	41	-100	-8.7
X-4567	BRCA	LLM871	0	29	45	-100	-10.2
X-4567	BRCA	LLM871	0	30.1	48	-100	-6.8
X-4567	BRCA	LLM871	0	30.6	52	-100	-5.3
X-4567	BRCA	LLM871	0	30	55	-100	-7.1
X-4567	BRCA	LLM871	0	29.3	59	-100	-9.3
X-4567	BRCA	LLM871	0	29.4	62	-100	-9
X-4567	BRCA	LLM871	0	29.3	66	-100	-9.3
X-4567	BRCA	LLM871	0	30.4	69	-100	-5.9
X-4567	BRCA	binimetinib	210.4	35.1	0	0	0
X-4567	BRCA	binimetinib	204.2	33	3	-2.9	-6
X-4567	BRCA	binimetinib	257.6	34	6	22.4	-3.1
X-4567	BRCA	binimetinib	238.4	33.4	10	13.3	-4.8
X-4567	BRCA	binimetinib	269.4	33.9	13	28	-3.4
X-4567	BRCA	binimetinib	258.4	33.4	16	22.8	-4.8
X-4567	BRCA	binimetinib	190.9	32.7	20	-9.3	-6.8
X-4567	BRCA	binimetinib	127.2	33.7	24	-39.5	-4
X-4567	BRCA	binimetinib	123.8	33.8	27	-41.2	-3.7
X-4567	BRCA	binimetinib	117.3	33.2	31	-44.2	-5.4
X-4567	BRCA	binimetinib	82.4	32.5	41	-60.8	-7.4
X-4567	BRCA	binimetinib	62.9	35.3	45	-70.1	0.6
X-4567	BRCA	binimetinib	53.5	35.4	48	-74.6	0.9
X-4567	BRCA	binimetinib	69.2	32.7	52	-67.1	-6.8
X-4567	BRCA	binimetinib	74.2	35.9	55	-64.7	2.3
X-4567	BRCA	binimetinib	77.8	33.9	59	-63	-3.4
X-4567	BRCA	binimetinib	77.7	33	62	-63.1	-6
X-4567	BRCA	binimetinib	78.6	33.1	65	-62.6	-5.7
X-4567	BRCA	binimetinib	78.7	34	69	-62.6	-3.1
X-4567	BRCA	binimetinib	75.8	35.5	72	-64	1.1
X-4567	BRCA	binimetinib	79	34	76	-62.5	-3.1
X-4567	BRCA	binimetinib	80.5	34.2	79	-61.7	-2.6
X-4567	BRCA	binimetinib	82.1	35.2	83	-61	0.3
X-4567	BRCA	binimetinib	63.2	37.1	87	-70	5.7
X-4567	BRCA	binimetinib	72.9	37.8	90	-65.4	7.7
X-4567	BRCA	binimetinib	64	37.8	94	-69.6	7.7
X-4567	BRCA	binimetinib	41.4	39.2	97	-80.3	11.7
X-4567	BRCA	paclitaxel	300.9	26.8	0	0	0
X-4567	BRCA	paclitaxel	333.8	25.7	3	10.9	-4.1
X-4567	BRCA	paclitaxel	290.4	25.9	6	-3.5	-3.4
X-4567	BRCA	paclitaxel	273.8	24.9	10	-9	-7.1
X-4567	BRCA	paclitaxel	201.9	25.2	13	-32.9	-6
X-4567	BRCA	paclitaxel	149	25.2	17	-50.5	-6
X-4567	BRCA	paclitaxel	122.8	25.4	20	-59.2	-5.2
X-4567	BRCA	paclitaxel	72.3	26.5	24	-76	-1.1
X-4567	BRCA	paclitaxel	54.7	26.2	27	-81.8	-2.2
X-4567	BRCA	paclitaxel	33.3	26.7	30	-88.9	-0.4
X-4567	BRCA	paclitaxel	42.5	26.4	34	-85.9	-1.5
X-4567	BRCA	paclitaxel	39.8	25.1	38	-86.8	-6.3
X-4567	BRCA	paclitaxel	26.8	26.9	41	-91.1	0.4
X-4567	BRCA	paclitaxel	31.8	26.3	45	-89.4	-1.9
X-4567	BRCA	paclitaxel	0	26.5	55	-100	-1.1
X-4567	BRCA	paclitaxel	0	26	59	-100	-3
X-4567	BRCA	paclitaxel	0	26.3	62	-100	-1.9
X-4567	BRCA	paclitaxel	0	27	66	-100	0.7
X-4567	BRCA	paclitaxel	0	27.5	69	-100	2.6
X-4567	BRCA	paclitaxel	0	26.6	73	-100	-0.7
X-4567	BRCA	paclitaxel	0	27.9	76	-100	4.1
X-4567	BRCA	paclitaxel	0	26.8	79	-100	0
X-4567	BRCA	paclitaxel	0	26.5	83	-100	-1.1
X-4567	BRCA	paclitaxel	0	26.4	86	-100	-1.5
X-4567	BRCA	paclitaxel	0	26.5	90	-100	-1.1
X-4567	BRCA	paclitaxel	0	27.9	93	-100	4.1
X-4567	BRCA	paclitaxel	0	27.5	97	-100	2.6
X-4567	BRCA	tamoxifen	278.5	27.1	0	0	0
X-4567	BRCA	tamoxifen	340	29	5	22.1	7
X-4567	BRCA	tamoxifen	417.5	29.4	8	49.9	8.5
X-4567	BRCA	tamoxifen	611.2	29.7	11	119.5	9.6
X-4567	BRCA	tamoxifen	638.4	NA	15	129.2	9.6
X-4567	BRCA	tamoxifen	771.7	30.4	18	177.1	12.2
X-4567	BRCA	tamoxifen	786.3	30.7	22	182.3	13.3
X-4567	BRCA	tamoxifen	783.2	31	25	181.2	14.4
X-4567	BRCA	tamoxifen	946	31.4	29	239.7	15.9
X-4567	BRCA	tamoxifen	1085.8	31.7	32	289.9	17
X-4567	BRCA	trastuzumab	256.6	25.6	0	0	0
X-4567	BRCA	trastuzumab	299.3	25.8	6	16.6	0.8
X-4567	BRCA	trastuzumab	383.3	25.2	9	49.4	-1.6
X-4567	BRCA	trastuzumab	378.8	25.1	14	47.6	-2
X-4567	BRCA	trastuzumab	395.5	25.8	17	54.1	0.8
X-4567	BRCA	trastuzumab	445.2	26.5	20	73.5	3.5
X-4567	BRCA	trastuzumab	405.1	25.9	24	57.9	1.2
X-4567	BRCA	trastuzumab	475.6	25.7	27	85.3	0.4
X-4567	BRCA	trastuzumab	506.9	25.9	31	97.5	1.2
X-4567	BRCA	trastuzumab	529.4	26.7	34	106.3	4.3
X-4567	BRCA	trastuzumab	544.1	26.2	38	112	2.3
X-4567	BRCA	trastuzumab	514.9	26.4	41	100.7	3.1
X-4567	BRCA	trastuzumab	506.4	26.8	45	97.3	4.7
X-4567	BRCA	trastuzumab	583.7	26.5	48	127.5	3.5
X-4567	BRCA	trastuzumab	639.3	26.8	52	149.1	4.7
X-4567	BRCA	trastuzumab	703.6	26.9	55	174.2	5.1
X-4567	BRCA	trastuzumab	660.6	27.4	59	157.4	7
X-4567	BRCA	trastuzumab	779.3	27.7	62	203.7	8.2
X-4567	BRCA	trastuzumab	773.1	26.2	65	201.3	2.3
X-4567	BRCA	trastuzumab	798.9	26.5	69	211.3	3.5
X-4567	BRCA	trastuzumab	896.6	26.8	73	249.4	4.7
X-4567	BRCA	trastuzumab	1019.8	26.9	76	297.4	5.1
X-4567	BRCA	untreated	186.7	23.8	0	0	0
X-4567	BRCA	untreated	295.8	24.6	6	58.4	3.4
X-4567	BRCA	untreated	421.8	25.7	9	125.9	8
X-4567	BRCA	untreated	548.8	25.4	14	193.9	6.7
X-4567	BRCA	untreated	638.5	25.4	17	242	6.7
X-4567	BRCA	untreated	794.6	25.1	20	325.6	5.5
X-4567	BRCA	untreated	1189.9	25.6	24	537.3	7.6
X-4567	BRCA	untreated	1544.5	25.7	27	727.3	8
X-4567	BRCA	LFW527 + everolimus	338.57	26.5	0	0	0
X-4567	BRCA	LFW527 + everolimus	401.59	25.3	4	18.6	-4.5
X-4567	BRCA	LFW527 + everolimus	273	24.6	7	-19.4	-7.2
X-4567	BRCA	LFW527 + everolimus	182.73	25.4	11	-46	-4.2
X-4567	BRCA	LFW527 + everolimus	182.63	23.1	14	-46.1	-12.8
X-4567	BRCA	LFW527 + everolimus	262.32	25.2	18	-22.5	-4.9
X-4567	BRCA	LFW527 + everolimus	165.11	24.4	21	-51.2	-7.9
X-4567	BRCA	LFW527 + everolimus	158.56	20.5	25	-53.2	-22.6
X-4567	BRCA	LFW527 + everolimus	135.7	22.7	28	-59.9	-14.3
X-4567	BRCA	LFW527 + everolimus	160.66	24.2	31	-52.5	-8.7
X-4567	BRCA	LFW527 + everolimus	137.55	23.3	35	-59.4	-12.1
X-4567	BRCA	LFW527 + everolimus	158.29	23.6	39	-53.2	-10.9
X-4567	BRCA	LFW527 + everolimus	140.04	24.6	42	-58.6	-7.2
X-4567	BRCA	LFW527 + everolimus	107.85	23.4	46	-68.1	-11.7
X-4567	BRCA	LFW527 + everolimus	120.7	24.4	49	-64.4	-7.9
X-4567	BRCA	LFW527 + everolimus	124.13	20.8	53	-63.3	-21.5
X-4567	BRCA	LFW527 + everolimus	121.37	20.9	56	-64.2	-21.1
X-4644	CM	BKM120	190.8	22	0	0	0
X-4644	CM	BKM120	180.3	22	3	-5.5	0
X-4644	CM	BKM120	243.4	22.7	7	27.6	3.2
X-4644	CM	BKM120	245.5	22.5	11	28.7	2.3
X-4644	CM	BKM120	292	23.2	14	53	5.5
X-4644	CM	BKM120	275.7	23.2	17	44.5	5.5
X-4644	CM	BKM120	433	23.3	20	126.9	5.9
X-4644	CM	BKM120	530.5	22.8	24	178	3.6
X-4644	CM	BKM120 + encorafenib	205.2	26.3	0	0	0
X-4644	CM	BKM120 + encorafenib	147.5	26.5	3	-28.1	0.8
X-4644	CM	BKM120 + encorafenib	61.2	27	7	-70.2	2.7
X-4644	CM	BKM120 + encorafenib	32	26.7	10	-84.4	1.5
X-4644	CM	BKM120 + encorafenib	14	26.6	14	-93.2	1.1
X-4644	CM	BKM120 + encorafenib	9.8	26.7	17	-95.2	1.5
X-4644	CM	BKM120 + encorafenib	0	26.7	21	-100	1.5
X-4644	CM	BKM120 + encorafenib	0	26.9	24	-100	2.3
X-4644	CM	BKM120 + encorafenib	0	27.3	27	-100	3.8
X-4644	CM	BKM120 + encorafenib	0	27	30	-100	2.7
X-4644	CM	BKM120 + encorafenib	0	27.3	34	-100	3.8
X-4644	CM	BKM120 + encorafenib	0	26.7	37	-100	1.5
X-4644	CM	BKM120 + encorafenib	0	27.2	40	-100	3.4
X-4644	CM	BKM120 + encorafenib	0	27.8	43	-100	5.7
X-4644	CM	BKM120 + encorafenib	0	26.4	46	-100	0.4
X-4644	CM	BKM120 + encorafenib	0	26.6	50	-100	1.1
X-4644	CM	BKM120 + encorafenib	0	26.9	53	-100	2.3
X-4644	CM	BKM120 + encorafenib	0	27.8	57	-100	5.7
X-4644	CM	BKM120 + encorafenib	0	27.9	60	-100	6.1
X-4644	CM	BKM120 + encorafenib	0	28.1	66	-100	6.8
X-4644	CM	BKM120 + encorafenib	0	28.1	73	-100	6.8
X-4644	CM	BKM120 + encorafenib	0	28.3	77	-100	7.6
X-4644	CM	BKM120 + encorafenib	0	28.8	81	-100	9.5
X-4644	CM	BKM120 + encorafenib	0	28.6	85	-100	8.7
X-4644	CM	BKM120 + encorafenib	0	28.2	91	-100	7.2
X-4644	CM	BKM120 + encorafenib	0	28.6	98	-100	8.7
X-4644	CM	BKM120 + encorafenib	0	28	108	-100	6.5
X-4644	CM	BKM120 + encorafenib	0	28.7	116	-100	9.1
X-4644	CM	BKM120 + encorafenib	0	29.5	123	-100	12.2
X-4644	CM	BKM120 + encorafenib	0	28.4	127	-100	8
X-4644	CM	BKM120 + encorafenib	0	28.3	137	-100	7.6
X-4644	CM	BKM120 + encorafenib	0	28.7	145	-100	9.1
X-4644	CM	BKM120 + encorafenib	0	28.9	152	-100	9.9
X-4644	CM	BKM120 + encorafenib	0	30	160	-100	14.1
X-4644	CM	BKM120 + encorafenib	0	30	172	-100	14.1
X-4644	CM	BKM120 + encorafenib	0	30.6	175	-100	16.3
X-4644	CM	BKM120 + encorafenib	0	30.8	185	-100	17.1
X-4644	CM	BKM120 + encorafenib	0	30.6	190	-100	16.3
X-4644	CM	BKM120 + encorafenib	0	31.9	197	-100	21.3
X-4644	CM	BKM120 + encorafenib	0	30.1	203	-100	14.4
X-4644	CM	BKM120 + encorafenib	0	31.2	211	-100	18.6
X-4644	CM	BKM120 + encorafenib	0	31.4	223	-100	19.4
X-4644	CM	BKM120 + encorafenib	36	31.4	230	-82.5	19.4
X-4644	CM	BKM120 + encorafenib	90.8	31.4	237	-55.8	19.4
X-4644	CM	BKM120 + encorafenib	225.4	32.7	247	9.9	24.3
X-4644	CM	CGM097	190.8	25.7	0	0	0
X-4644	CM	CGM097	357.6	26.1	5	87.4	1.6
X-4644	CM	CGM097	492.7	26.3	9	158.3	2.3
X-4644	CM	CGM097	654.3	27.1	13	243	5.4
X-4644	CM	CGM097	821.9	26.9	16	330.8	4.7
X-4644	CM	CGM097	1069.2	26.6	20	460.4	3.5
X-4644	CM	CLR457	214.2	26.2	0	0	0
X-4644	CM	CLR457	274.4	27.7	5	28.1	5.7
X-4644	CM	CLR457	311.9	25.3	8	45.6	-3.4
X-4644	CM	CLR457	412.8	26.5	11	92.7	1.1
X-4644	CM	CLR457	542.6	25.9	14	153.3	-1.1
X-4644	CM	CLR457	510.9	25.6	17	138.5	-2.3
X-4644	CM	CLR457	682.2	25.4	21	218.4	-3.1
X-4644	CM	dacarbazine	204.7	24.8	0	0	0
X-4644	CM	dacarbazine	255.9	24.3	1	25	-2
X-4644	CM	dacarbazine	271.6	23.6	4	32.7	-4.8
X-4644	CM	dacarbazine	382.5	23.4	8	86.8	-5.6
X-4644	CM	dacarbazine	490.9	22.6	11	139.8	-8.9
X-4644	CM	dacarbazine	558.4	23.5	14	172.7	-5.2
X-4644	CM	dacarbazine	648	22.4	17	216.5	-9.7
X-4644	CM	dacarbazine	691.9	25.2	21	238	1.6
X-4644	CM	LDE225	207.1	25.7	0	0	0
X-4644	CM	LDE225	257.9	25.5	2	24.5	-0.8
X-4644	CM	LDE225	300.8	25.1	6	45.2	-2.3
X-4644	CM	LDE225	484.6	26	9	134	1.2
X-4644	CM	LDE225	635.7	25.8	13	206.9	0.4
X-4644	CM	LDE225	733.2	26	16	254	1.2
X-4644	CM	LDE225	738.7	25.4	20	256.7	-1.2
X-4644	CM	LDK378	194.1	23	0	0	0
X-4644	CM	LDK378	249.2	22.9	2	28.4	-0.4
X-4644	CM	LDK378	317.5	23.7	6	63.6	3
X-4644	CM	LDK378	427.7	24.9	9	120.4	8.3
X-4644	CM	LDK378	643.6	25.1	13	231.6	9.1
X-4644	CM	LDK378	736	24.7	16	279.2	7.4
X-4644	CM	LDK378	1119.5	24.7	20	476.8	7.4
X-4644	CM	LEE011	191.1	27	0	0	0
X-4644	CM	LEE011	274.6	25.4	5	43.7	-5.9
X-4644	CM	LEE011	396.1	26.1	9	107.2	-3.3
X-4644	CM	LEE011	493	25.6	13	158	-5.2
X-4644	CM	LEE011	610	26.8	16	219.2	-0.7
X-4644	CM	LEE011	837.8	26.9	20	338.4	-0.4
X-4644	CM	LEE011 + encorafenib	210.7	26.7	0	0	0
X-4644	CM	LEE011 + encorafenib	82.5	26.2	4	-60.8	-1.9
X-4644	CM	LEE011 + encorafenib	41.5	24.4	7	-80.3	-8.6
X-4644	CM	LEE011 + encorafenib	25.1	25.9	11	-88.1	-3
X-4644	CM	LEE011 + encorafenib	16.3	26.6	14	-92.2	-0.4
X-4644	CM	LEE011 + encorafenib	0	26.2	18	-100	-1.9
X-4644	CM	LEE011 + encorafenib	0	25.8	21	-100	-3.4
X-4644	CM	LEE011 + encorafenib	0	26.3	24	-100	-1.5
X-4644	CM	LEE011 + encorafenib	0	27.4	27	-100	2.6
X-4644	CM	LEE011 + encorafenib	0	27.3	31	-100	2.2
X-4644	CM	LEE011 + encorafenib	0	26.6	34	-100	-0.4
X-4644	CM	LEE011 + encorafenib	0	26.8	37	-100	0.4
X-4644	CM	LEE011 + encorafenib	0	26.6	40	-100	-0.4
X-4644	CM	LEE011 + encorafenib	0	26.7	43	-100	0
X-4644	CM	LEE011 + encorafenib	0	27.5	47	-100	3
X-4644	CM	LEE011 + encorafenib	0	26.8	50	-100	0.4
X-4644	CM	LEE011 + encorafenib	0	28.6	54	-100	7.1
X-4644	CM	LEE011 + encorafenib	0	26.4	57	-100	-1.1
X-4644	CM	LEE011 + encorafenib	0	28.2	63	-100	5.6
X-4644	CM	LEE011 + encorafenib	0	28.8	70	-100	7.9
X-4644	CM	LEE011 + encorafenib	0	29.1	74	-100	9
X-4644	CM	LEE011 + encorafenib	0	28.7	78	-100	7.5
X-4644	CM	LEE011 + encorafenib	0	28.5	82	-100	6.7
X-4644	CM	LEE011 + encorafenib	0	28	88	-100	4.9
X-4644	CM	LEE011 + encorafenib	0	25.6	95	-100	-4.1
X-4644	CM	LEE011 + encorafenib	0	28.2	105	-100	5.6
X-4644	CM	LEE011 + encorafenib	0	27.6	113	-100	3.4
X-4644	CM	LEE011 + encorafenib	0	27.3	120	-100	2.2
X-4644	CM	LEE011 + encorafenib	0	27	124	-100	1.1
X-4644	CM	LEE011 + encorafenib	0	26.7	134	-100	0
X-4644	CM	LEE011 + encorafenib	0	26.9	142	-100	0.7
X-4644	CM	LEE011 + encorafenib	0	27	149	-100	1.1
X-4644	CM	LEE011 + encorafenib	0	27.1	157	-100	1.5
X-4644	CM	LEE011 + encorafenib	0	28.4	169	-100	6.4
X-4644	CM	LEE011 + encorafenib	0	28.6	172	-100	7.1
X-4644	CM	LEE011 + encorafenib	0	27.6	182	-100	3.4
X-4644	CM	LEE011 + encorafenib	14	28.4	187	-93.4	6.4
X-4644	CM	LEE011 + encorafenib	35.3	28.4	194	-83.2	6.4
X-4644	CM	LEE011 + encorafenib	67.4	28.7	200	-68	7.5
X-4644	CM	LEE011 + encorafenib	111.6	28.5	208	-47	6.7
X-4644	CM	LEE011 + encorafenib	310	28.8	220	47.1	7.9
X-4644	CM	LEE011 + encorafenib	336.5	27.3	227	59.7	2.2
X-4644	CM	LEE011 + encorafenib	405.8	27.3	234	92.6	2.2
X-4644	CM	LEE011 + encorafenib	511.5	27.8	244	142.8	4.1
X-4644	CM	WNT974	234	23.7	0	0	0
X-4644	CM	WNT974	294.1	24	3	25.7	1.3
X-4644	CM	WNT974	376.1	24	7	60.7	1.3
X-4644	CM	WNT974	418.4	23.9	10	78.8	0.8
X-4644	CM	WNT974	804.4	24.3	14	243.7	2.5
X-4644	CM	WNT974	1055.6	23.9	17	351.1	0.8
X-4644	CM	WNT974	1711.7	24.2	21	631.5	2.1
X-4644	CM	LGW813	191.1	21.6	0	0	0
X-4644	CM	LGW813	266.8	22.6	4	39.6	4.6
X-4644	CM	LGW813	413.1	23.1	7	116.2	6.9
X-4644	CM	LGW813	584.1	23	10	205.6	6.5
X-4644	CM	LGW813	726.9	22.8	14	280.4	5.6
X-4644	CM	LGW813	991.8	22.1	17	419	2.3
X-4644	CM	LGW813	1409.3	21.9	21	637.5	1.4
X-4644	CM	encorafenib	202.6	27.4	0	0	0
X-4644	CM	encorafenib	144.9	26	5	-28.5	-5.1
X-4644	CM	encorafenib	71.7	26.6	9	-64.6	-2.9
X-4644	CM	encorafenib	73	27.3	13	-64	-0.4
X-4644	CM	encorafenib	73	28.2	16	-64	2.9
X-4644	CM	encorafenib	64.8	28.2	20	-68	2.9
X-4644	CM	encorafenib	65	28	23	-67.9	2.2
X-4644	CM	encorafenib	73	26.8	27	-64	-2.2
X-4644	CM	encorafenib	95.7	26.7	30	-52.8	-2.6
X-4644	CM	encorafenib	102.7	27.4	34	-49.3	0
X-4644	CM	encorafenib	104.4	27.1	37	-48.5	-1.1
X-4644	CM	encorafenib	118.8	26.6	40	-41.4	-2.9
X-4644	CM	encorafenib	133.2	26.8	43	-34.3	-2.2
X-4644	CM	encorafenib	144.2	26.9	47	-28.9	-1.8
X-4644	CM	encorafenib	126	26.1	50	-37.8	-4.7
X-4644	CM	encorafenib	152.1	26.6	53	-24.9	-2.9
X-4644	CM	encorafenib	230.6	27.3	56	13.8	-0.4
X-4644	CM	encorafenib	219	27.2	59	8.1	-0.7
X-4644	CM	encorafenib	207.4	28.4	63	2.3	3.6
X-4644	CM	encorafenib	180.3	27.2	66	-11	-0.7
X-4644	CM	encorafenib	163.4	27.8	70	-19.4	1.5
X-4644	CM	encorafenib	193.6	27	73	-4.5	-1.5
X-4644	CM	encorafenib	388.1	28.4	79	91.6	3.6
X-4644	CM	encorafenib	411.9	29.1	86	103.3	6.2
X-4644	CM	encorafenib	494	28.8	90	143.8	5.1
X-4644	CM	encorafenib	567	27.7	94	179.9	1.1
X-4644	CM	encorafenib	664	28.1	98	227.7	2.6
X-4644	CM	encorafenib + binimetinib	189	23.9	0	0	0
X-4644	CM	encorafenib + binimetinib	61.4	23.8	4	-67.5	-0.4
X-4644	CM	encorafenib + binimetinib	39.7	23.5	7	-79	-1.7
X-4644	CM	encorafenib + binimetinib	31.2	23.1	11	-83.5	-3.3
X-4644	CM	encorafenib + binimetinib	18	23	14	-90.5	-3.8
X-4644	CM	encorafenib + binimetinib	13.5	24	17	-92.9	0.4
X-4644	CM	encorafenib + binimetinib	0	23.3	20	-100	-2.5
X-4644	CM	encorafenib + binimetinib	0	23.9	24	-100	0
X-4644	CM	encorafenib + binimetinib	0	22.8	27	-100	-4.6
X-4644	CM	encorafenib + binimetinib	0	22.8	30	-100	-4.6
X-4644	CM	encorafenib + binimetinib	0	23.5	33	-100	-1.7
X-4644	CM	encorafenib + binimetinib	0	23	36	-100	-3.8
X-4644	CM	encorafenib + binimetinib	0	23.8	40	-100	-0.4
X-4644	CM	encorafenib + binimetinib	0	22.3	43	-100	-6.7
X-4644	CM	encorafenib + binimetinib	0	23.3	47	-100	-2.5
X-4644	CM	encorafenib + binimetinib	0	23	50	-100	-3.8
X-4644	CM	encorafenib + binimetinib	0	23.5	56	-100	-1.7
X-4644	CM	encorafenib + binimetinib	0	23.5	63	-100	-1.7
X-4644	CM	encorafenib + binimetinib	0	23.7	67	-100	-0.8
X-4644	CM	encorafenib + binimetinib	0	24	71	-100	0.4
X-4644	CM	encorafenib + binimetinib	0	24.2	75	-100	1.3
X-4644	CM	encorafenib + binimetinib	0	24.1	81	-100	0.8
X-4644	CM	encorafenib + binimetinib	0	23.3	88	-100	-2.5
X-4644	CM	encorafenib + binimetinib	0	23.6	98	-100	-1.3
X-4644	CM	encorafenib + binimetinib	0	21.7	106	-100	-9.2
X-4644	CM	encorafenib + binimetinib	0	23	113	-100	-3.8
X-4644	CM	encorafenib + binimetinib	0	24.4	117	-100	2.1
X-4644	CM	encorafenib + binimetinib	0	24	127	-100	0.4
X-4644	CM	encorafenib + binimetinib	0	24.2	135	-100	1.3
X-4644	CM	encorafenib + binimetinib	0	24	143	-100	0.4
X-4644	CM	encorafenib + binimetinib	0	23.8	150	-100	-0.4
X-4644	CM	encorafenib + binimetinib	0	24.1	162	-100	0.8
X-4644	CM	encorafenib + binimetinib	0	24.1	165	-100	0.8
X-4644	CM	encorafenib + binimetinib	0	24.5	175	-100	2.5
X-4644	CM	encorafenib + binimetinib	0	23.8	180	-100	-0.4
X-4644	CM	encorafenib + binimetinib	0	25	187	-100	4.6
X-4644	CM	encorafenib + binimetinib	0	24.9	193	-100	4.2
X-4644	CM	encorafenib + binimetinib	0	24.7	201	-100	3.3
X-4644	CM	encorafenib + binimetinib	0	25.5	213	-100	6.7
X-4644	CM	encorafenib + binimetinib	0	24.8	220	-100	3.8
X-4644	CM	encorafenib + binimetinib	0	24.8	227	-100	3.8
X-4644	CM	encorafenib + binimetinib	8.9	24.7	237	-95.3	3.3
X-4644	CM	binimetinib	211.9	25.6	0	0	0
X-4644	CM	binimetinib	163.4	25.3	3	-22.9	-1.2
X-4644	CM	binimetinib	138.6	25.1	7	-34.6	-2
X-4644	CM	binimetinib	148.8	25	11	-29.7	-2.3
X-4644	CM	binimetinib	154.9	25.5	14	-26.9	-0.4
X-4644	CM	binimetinib	148.8	25.4	17	-29.7	-0.8
X-4644	CM	binimetinib	140.9	25.4	20	-33.5	-0.8
X-4644	CM	binimetinib	114.4	25.1	24	-46	-2
X-4644	CM	binimetinib	118.6	24.9	27	-44	-2.7
X-4644	CM	binimetinib	158.4	25.3	31	-25.2	-1.2
X-4644	CM	binimetinib	175.1	25.7	34	-17.4	0.4
X-4644	CM	binimetinib	196	25.9	37	-7.5	1.2
X-4644	CM	binimetinib	199.6	25.5	40	-5.8	-0.4
X-4644	CM	binimetinib	188.7	25.6	44	-11	0
X-4644	CM	binimetinib	230	24.8	47	8.6	-3.1
X-4644	CM	binimetinib	255.9	25.7	50	20.8	0.4
X-4644	CM	binimetinib	246.4	26.6	53	16.3	3.9
X-4644	CM	binimetinib	257.9	27.2	56	21.7	6.2
X-4644	CM	binimetinib	243.7	26.2	60	15	2.3
X-4644	CM	binimetinib	245.1	25.2	63	15.7	-1.6
X-4644	CM	binimetinib	284.8	25.8	67	34.4	0.8
X-4644	CM	binimetinib	304	25.8	70	43.5	0.8
X-4644	CM	binimetinib	369.8	25.9	73	74.5	1.2
X-4644	CM	binimetinib	389.8	25.9	76	84	1.2
X-4644	CM	binimetinib	472.7	26.1	77	123.1	2
X-4644	CM	binimetinib	561.8	25.7	81	165.2	0.4
X-4644	CM	binimetinib	512.5	25.3	85	141.9	-1.2
X-4644	CM	TAS266	191.6	24.7	0	0	0
X-4644	CM	TAS266	285.4	24.4	5	49	-1.2
X-4644	CM	TAS266	413.1	24.6	9	115.7	-0.4
X-4644	CM	TAS266	636.5	25.3	13	232.3	2.4
X-4644	CM	TAS266	966.3	25.6	16	404.4	3.6
X-4644	CM	TAS266	1285.5	25.1	20	571.1	1.6
X-4644	CM	untreated	197	27.1	0	0	0
X-4644	CM	untreated	390	28	5	98	3.3
X-4644	CM	untreated	659	28.1	9	234.5	3.7
X-4644	CM	untreated	856.3	27.8	13	334.7	2.6
X-4644	CM	untreated	1191.5	27.9	16	504.9	3
X-4644	CM	untreated	1410.4	27.2	20	616	0.4
X-4649	PDAC	abraxane	257.3	25.7	0	0	0
X-4649	PDAC	abraxane	340.5	26.6	4	32.3	3.5
X-4649	PDAC	abraxane	386.6	26.1	7	50.3	1.6
X-4649	PDAC	abraxane	385.5	27.8	11	49.8	8.2
X-4649	PDAC	abraxane	437.1	26.7	13	69.9	3.9
X-4649	PDAC	abraxane	556	27	17	116.1	5.1
X-4649	PDAC	abraxane	593.3	26.4	20	130.6	2.7
X-4649	PDAC	abraxane	632.2	26.5	24	145.7	3.1
X-4649	PDAC	abraxane	656.1	26.8	27	155	4.3
X-4649	PDAC	abraxane	668.4	27	32	159.8	5.1
X-4649	PDAC	abraxane	772.3	26.4	34	200.2	2.7
X-4649	PDAC	abraxane	773.1	27	38	200.5	5.1
X-4649	PDAC	abraxane	942.2	27.6	41	266.2	7.4
X-4649	PDAC	BKM120 + binimetinib	218.2	27	0	0	0
X-4649	PDAC	BKM120 + binimetinib	215.5	25.9	4	-1.2	-4.1
X-4649	PDAC	BKM120 + binimetinib	246.2	26.5	7	12.8	-1.9
X-4649	PDAC	BKM120 + binimetinib	239.2	26.6	11	9.6	-1.5
X-4649	PDAC	BKM120 + binimetinib	179.2	26.4	14	-17.9	-2.2
X-4649	PDAC	BKM120 + binimetinib	188.1	26.8	18	-13.8	-0.7
X-4649	PDAC	BKM120 + binimetinib	207.6	28	21	-4.9	3.7
X-4649	PDAC	BKM120 + binimetinib	169	27.9	25	-22.5	3.3
X-4649	PDAC	BKM120 + binimetinib	198	27.6	28	-9.3	2.2
X-4649	PDAC	BKM120 + binimetinib	201.5	26.8	32	-7.7	-0.7
X-4649	PDAC	BKM120 + binimetinib	191.6	27.4	35	-12.2	1.5
X-4649	PDAC	BKM120 + binimetinib	237.2	28.1	39	8.7	4.1
X-4649	PDAC	BKM120 + binimetinib	217.9	26.7	42	-0.1	-1.1
X-4649	PDAC	BKM120 + binimetinib	161.6	26.8	46	-25.9	-0.7
X-4649	PDAC	BKM120 + binimetinib	181.8	28.4	49	-16.7	5.2
X-4649	PDAC	BKM120 + binimetinib	192.5	27	53	-11.8	0
X-4649	PDAC	BKM120 + binimetinib	193.4	26.2	56	-11.4	-3
X-4649	PDAC	BKM120 + binimetinib	185.4	26.6	59	-15	-1.5
X-4649	PDAC	BKM120 + binimetinib	184.8	26.3	62	-15.3	-2.6
X-4649	PDAC	BKM120 + binimetinib	172.8	27.2	67	-20.8	0.7
X-4649	PDAC	BKM120 + binimetinib	199.5	26.3	70	-8.6	-2.6
X-4649	PDAC	BKM120 + binimetinib	170	26.4	74	-22.1	-2.2
X-4649	PDAC	BKM120 + binimetinib	160	27.1	77	-26.7	0.4
X-4649	PDAC	BKM120 + binimetinib	171.7	26.4	80	-21.3	-2.2
X-4649	PDAC	BKM120 + binimetinib	213	26.7	84	-2.4	-1.1
X-4649	PDAC	BKM120 + binimetinib	256	27.1	87	17.3	0.4
X-4649	PDAC	BKM120 + binimetinib	240.7	26.4	90	10.3	-2.2
X-4649	PDAC	BKM120 + binimetinib	261	25.6	94	19.6	-5.2
X-4649	PDAC	BKM120 + LDE225	257.2	30.1	0	0	0
X-4649	PDAC	BKM120 + LDE225	298.6	31.9	4	16.1	6
X-4649	PDAC	BKM120 + LDE225	406.8	31.8	7	58.2	5.6
X-4649	PDAC	BKM120 + LDE225	392.7	33.7	11	52.7	12
X-4649	PDAC	BKM120 + LDE225	556.8	32.8	14	116.5	9
X-4649	PDAC	BKM120 + LDE225	370.7	29	18	44.1	-3.7
X-4649	PDAC	BKM120 + LDE225	463.8	30.1	21	80.3	0
X-4649	PDAC	BKM120 + LDE225	388.5	30.2	25	51	0.3
X-4649	PDAC	BKM120 + LDE225	345.6	29.5	28	34.4	-2
X-4649	PDAC	BKM120 + LDE225	332.2	28.9	32	29.2	-4
X-4649	PDAC	BKM120 + LDE225	414.3	29	35	61.1	-3.7
X-4649	PDAC	BKM120 + LDE225	396.3	29.7	39	54.1	-1.3
X-4649	PDAC	BKM120 + LDE225	408.5	29.2	42	58.8	-3
X-4649	PDAC	BKM120 + LDE225	247.3	28.7	46	-3.8	-4.7
X-4649	PDAC	BKM120 + LDE225	339	28.7	49	31.8	-4.7
X-4649	PDAC	BKM120 + LDE225	299.4	29.6	53	16.4	-1.7
X-4649	PDAC	BKM120 + LDE225	295.4	28	56	14.9	-7
X-4649	PDAC	BKM120 + LDE225	251.3	28.2	59	-2.3	-6.3
X-4649	PDAC	BKM120 + LDE225	342.5	28	62	33.2	-7
X-4649	PDAC	BKM120 + LDE225	241.7	27.8	67	-6	-7.6
X-4649	PDAC	BKM120 + LDE225	353.2	27.9	70	37.3	-7.3
X-4649	PDAC	BKM120 + LDE225	456.3	28.5	74	77.4	-5.3
X-4649	PDAC	BKM120 + LDE225	410.2	28.8	77	59.5	-4.3
X-4649	PDAC	BKM120 + LDE225	359.4	28.3	80	39.7	-6
X-4649	PDAC	BKM120 + LDE225	407.8	28.6	84	58.6	-5
X-4649	PDAC	BKM120 + LDE225	508.8	29.2	87	97.8	-3
X-4649	PDAC	BKM120 + LDE225	367.9	27.9	90	43	-7.3
X-4649	PDAC	BKM120 + LDE225	273.9	27.7	94	6.5	-8
X-4649	PDAC	BKM120	178.4	29.8	0	0	0
X-4649	PDAC	BKM120	205.6	29	2	15.2	-2.7
X-4649	PDAC	BKM120	182.6	28.1	6	2.4	-5.7
X-4649	PDAC	BKM120	230.4	27.7	9	29.1	-7
X-4649	PDAC	BKM120	266.8	28.1	13	49.6	-5.7
X-4649	PDAC	BKM120	230.2	29.7	16	29	-0.3
X-4649	PDAC	BKM120	241.5	30.5	21	35.4	2.3
X-4649	PDAC	BKM120	251.2	28.6	23	40.8	-4
X-4649	PDAC	BKM120	234	28.8	27	31.2	-3.4
X-4649	PDAC	BKM120	245	29.4	30	37.3	-1.3
X-4649	PDAC	BKM120	251.3	28.6	34	40.9	-4
X-4649	PDAC	BKM120	279.9	27.9	37	56.9	-6.4
X-4649	PDAC	BKM120	313.4	29.6	41	75.7	-0.7
X-4649	PDAC	BKM120	354.6	28.4	44	98.8	-4.7
X-4649	PDAC	BKM120	334.6	28.8	48	87.6	-3.4
X-4649	PDAC	BKM120	321.8	29.3	51	80.4	-1.7
X-4649	PDAC	BKM120	328.8	28.8	57	84.3	-3.4
X-4649	PDAC	BYL719	201.3	26.8	0	0	0
X-4649	PDAC	BYL719	208.8	29.3	5	3.7	9.3
X-4649	PDAC	BYL719	221.9	28.5	8	10.2	6.3
X-4649	PDAC	BYL719	227	27.9	12	12.8	4.1
X-4649	PDAC	BYL719	217.6	27.9	15	8.1	4.1
X-4649	PDAC	BYL719	217	28	19	7.8	4.5
X-4649	PDAC	BYL719	202	28	22	0.3	4.5
X-4649	PDAC	BYL719	204.8	29.6	26	1.7	10.4
X-4649	PDAC	BYL719	205.5	27	28	2.1	0.7
X-4649	PDAC	BYL719	209.5	28.2	33	4.1	5.2
X-4649	PDAC	BYL719	210.2	28.6	36	4.4	6.7
X-4649	PDAC	BYL719	222.5	28.3	40	10.5	5.6
X-4649	PDAC	BYL719	232.7	28.8	43	15.6	7.5
X-4649	PDAC	BYL719	239.9	30	46	19.2	11.9
X-4649	PDAC	BYL719 + LJM716	205.4	32.4	0	0	0
X-4649	PDAC	BYL719 + LJM716	198	32.9	3	-3.6	1.5
X-4649	PDAC	BYL719 + LJM716	179.2	31.9	7	-12.8	-1.5
X-4649	PDAC	BYL719 + LJM716	175.7	32.4	10	-14.5	0
X-4649	PDAC	BYL719 + LJM716	164.3	31.7	14	-20	-2.2
X-4649	PDAC	BYL719 + LJM716	171.6	32.2	17	-16.5	-0.6
X-4649	PDAC	BYL719 + LJM716	177.6	32.2	21	-13.5	-0.6
X-4649	PDAC	BYL719 + LJM716	196.3	32.9	24	-4.4	1.5
X-4649	PDAC	BYL719 + LJM716	241.6	34.1	28	17.6	5.2
X-4649	PDAC	BYL719 + LJM716	237.5	34.2	31	15.6	5.6
X-4649	PDAC	BYL719 + LJM716	244.3	34.4	35	18.9	6.2
X-4649	PDAC	BYL719 + LJM716	251.6	33.6	38	22.5	3.7
X-4649	PDAC	BYL719 + LJM716	246.5	34.5	42	20	6.5
X-4649	PDAC	BYL719 + LJM716	244.3	32.5	44	18.9	0.3
X-4649	PDAC	BYL719 + LJM716	243.6	33.7	49	18.6	4
X-4649	PDAC	BYL719 + LJM716	254.8	33.9	52	24.1	4.6
X-4649	PDAC	BYL719 + LJM716	344.7	34.5	56	67.8	6.5
X-4649	PDAC	BYL719 + LJM716	354.6	34.6	59	72.6	6.8
X-4649	PDAC	BYL719 + LJM716	349.8	34.3	62	70.3	5.9
X-4649	PDAC	CLR457	309.1	25	0	0	0
X-4649	PDAC	CLR457	318.4	24.5	3	3	-2
X-4649	PDAC	CLR457	342.6	24.7	7	10.8	-1.2
X-4649	PDAC	CLR457	365.1	24	10	18.1	-4
X-4649	PDAC	CLR457	345.8	24.5	14	11.9	-2
X-4649	PDAC	CLR457	357	26	17	15.5	4
X-4649	PDAC	CLR457	356.7	25.8	20	15.4	3.2
X-4649	PDAC	CLR457	378.5	25.3	23	22.5	1.2
X-4649	PDAC	CLR457	371.4	27.2	28	20.2	8.8
X-4649	PDAC	CLR457	349.1	26.2	31	12.9	4.8
X-4649	PDAC	CLR457	285.3	26	35	-7.7	4
X-4649	PDAC	CLR457	319.7	26.6	38	3.4	6.4
X-4649	PDAC	CLR457	349.8	26.8	41	13.2	7.2
X-4649	PDAC	HDM201	201.8	31.6	0	0	0
X-4649	PDAC	HDM201	202.3	30	3	0.2	-5.1
X-4649	PDAC	HDM201	214.9	29.4	7	6.5	-7
X-4649	PDAC	HDM201	222.8	28.9	10	10.4	-8.5
X-4649	PDAC	HDM201	235.2	28.4	14	16.6	-10.1
X-4649	PDAC	HDM201	246.7	28.8	17	22.2	-8.9
X-4649	PDAC	HDM201	266.3	28	21	32	-11.4
X-4649	PDAC	HDM201	275.7	27.8	24	36.6	-12
X-4649	PDAC	HDM201	302.1	27.7	28	49.7	-12.3
X-4649	PDAC	HDM201	310.6	28	31	53.9	-11.4
X-4649	PDAC	HDM201	316.5	28.2	35	56.8	-10.8
X-4649	PDAC	HDM201	359.4	28.1	38	78.1	-11.1
X-4649	PDAC	HDM201	365.8	27.8	42	81.3	-12
X-4649	PDAC	HDM201	396.1	27.3	44	96.3	-13.6
X-4649	PDAC	HDM201	373.8	27.7	49	85.2	-12.3
X-4649	PDAC	HDM201	375.3	27.9	52	86	-11.7
X-4649	PDAC	HDM201	384	28.3	56	90.3	-10.4
X-4649	PDAC	HDM201	399.5	27.5	59	98	-13
X-4649	PDAC	HDM201	426.4	27.3	62	111.3	-13.6
X-4649	PDAC	figitumumab" + binimetinib	228.8	28.8	0	0	0
X-4649	PDAC	figitumumab" + binimetinib	265.4	24.5	4	16	-14.9
X-4649	PDAC	figitumumab" + binimetinib	341.8	28.5	7	49.4	-1
X-4649	PDAC	figitumumab" + binimetinib	298.9	28	11	30.6	-2.8
X-4649	PDAC	figitumumab" + binimetinib	275	29.1	17	20.2	1
X-4649	PDAC	figitumumab"	206.2	28.7	0	0	0
X-4649	PDAC	figitumumab"	233.9	29.1	3	13.4	1.4
X-4649	PDAC	figitumumab"	264	28.3	7	28	-1.4
X-4649	PDAC	figitumumab"	263.8	27.4	9	27.9	-4.5
X-4649	PDAC	figitumumab"	370.8	28.4	13	79.8	-1
X-4649	PDAC	figitumumab"	470.7	28.2	16	128.3	-1.7
X-4649	PDAC	figitumumab"	547.6	28.2	20	165.6	-1.7
X-4649	PDAC	figitumumab"	562	29	23	172.6	1
X-4649	PDAC	figitumumab"	716	28.5	28	247.2	-0.7
X-4649	PDAC	figitumumab"	787.5	27.8	30	281.9	-3.1
X-4649	PDAC	figitumumab"	905.6	28.7	34	339.2	0
X-4649	PDAC	gemcitabine-50mpk	274.2	28	0	0	0
X-4649	PDAC	gemcitabine-50mpk	336.5	NA	1	22.7	0
X-4649	PDAC	gemcitabine-50mpk	255.2	27	3	-6.9	-3.6
X-4649	PDAC	gemcitabine-50mpk	274.8	25.6	7	0.2	-8.6
X-4649	PDAC	gemcitabine-50mpk	228.9	26	9	-16.5	-7.1
X-4649	PDAC	gemcitabine-50mpk	181.9	21.3	15	-33.7	-23.9
X-4649	PDAC	INC424 + binimetinib	267.3	24.6	0	0	0
X-4649	PDAC	INC424 + binimetinib	258.5	24.9	2	-3.3	1.2
X-4649	PDAC	INC424 + binimetinib	394.2	22.6	6	47.5	-8.1
X-4649	PDAC	INC424 + binimetinib	294.1	22.8	8	10	-7.3
X-4649	PDAC	INC424 + binimetinib	659.6	25.6	13	146.8	4.1
X-4649	PDAC	INC424 + binimetinib	511.3	26	20	91.3	5.7
X-4649	PDAC	INC424 + binimetinib	491.3	24.7	23	83.8	0.4
X-4649	PDAC	INC424 + binimetinib	572.9	25.1	27	114.3	2
X-4649	PDAC	INC424 + binimetinib	545.3	25.5	30	104	3.7
X-4649	PDAC	INC424 + binimetinib	675.7	25.7	34	152.8	4.5
X-4649	PDAC	INC424 + binimetinib	688.8	25.8	37	157.7	4.9
X-4649	PDAC	INC424 + binimetinib	792.8	25.9	41	196.6	5.3
X-4649	PDAC	INC424 + binimetinib	1084.9	27.3	44	305.9	11
X-4649	PDAC	INC424 + binimetinib	1770.6	27.2	48	562.4	10.6
X-4649	PDAC	INC424 + binimetinib	1314.5	26.4	51	391.8	7.3
X-4649	PDAC	INC424 + binimetinib	1026.3	26.4	55	284	7.3
X-4649	PDAC	INC424 + binimetinib	1087.7	26.3	58	306.9	6.9
X-4649	PDAC	INC424 + binimetinib	1325.6	26.8	62	395.9	8.9
X-4649	PDAC	INC424 + binimetinib	1248.8	26.6	65	367.2	8.1
X-4649	PDAC	INC424 + binimetinib	1489.6	27.1	69	457.3	10.2
X-4649	PDAC	INC424 + binimetinib	1575.4	26.8	72	489.4	8.9
X-4649	PDAC	INC424 + binimetinib	1324.4	27.9	76	395.5	13.4
X-4649	PDAC	INC424 + binimetinib	1526.4	27.5	79	471	11.8
X-4649	PDAC	INC424 + binimetinib	1638.9	26.5	82	513.1	7.7
X-4649	PDAC	INC424 + binimetinib	1600.8	26.9	85	498.9	9.3
X-4649	PDAC	INC424 + binimetinib	1637.9	25.8	90	512.8	4.9
X-4649	PDAC	INC424 + binimetinib	1642.8	25.7	93	514.6	4.5
X-4649	PDAC	INC424	293.5	29.3	0	0	0
X-4649	PDAC	INC424	393.8	28.5	3	34.2	-2.7
X-4649	PDAC	INC424	423.4	27.6	7	44.3	-5.8
X-4649	PDAC	INC424	492.1	27.9	10	67.7	-4.8
X-4649	PDAC	INC424	550.8	28.4	14	87.7	-3.1
X-4649	PDAC	INC424	633	28.1	17	115.7	-4.1
X-4649	PDAC	INC424	687	30	21	134.1	2.4
X-4649	PDAC	INC424	731.5	29.4	24	149.2	0.3
X-4649	PDAC	INC424	790.4	28.9	28	169.3	-1.4
X-4649	PDAC	INC424	847.8	28.8	31	188.9	-1.7
X-4649	PDAC	INC424	979.5	29	35	233.7	-1
X-4649	PDAC	INC424	1047.3	28.3	38	256.8	-3.4
X-4649	PDAC	INC424	1094.2	29.6	41	272.8	1
X-4649	PDAC	INC424	1079.3	29.1	44	267.7	-0.7
X-4649	PDAC	INC424	1164.9	29.3	49	296.9	0
X-4649	PDAC	INC424	1194.3	28.9	52	306.9	-1.4
X-4649	PDAC	INC424	1297.7	28.7	56	342.1	-2
X-4649	PDAC	LEE011	260.6	23.8	0	0	0
X-4649	PDAC	LEE011	305	24	3	17	0.8
X-4649	PDAC	LEE011	380	23.6	7	45.8	-0.8
X-4649	PDAC	LEE011	467.5	22.2	9	79.4	-6.7
X-4649	PDAC	LEE011	573.3	20.2	13	120	-15.1
X-4649	PDAC	WNT974	208.8	31.1	0	0	0
X-4649	PDAC	WNT974	261.2	30.3	2	25.1	-2.6
X-4649	PDAC	WNT974	334.8	30.9	6	60.3	-0.6
X-4649	PDAC	WNT974	416.3	30.2	9	99.4	-2.9
X-4649	PDAC	WNT974	506.4	29.3	12	142.5	-5.8
X-4649	PDAC	WNT974	675.3	30.4	16	223.4	-2.3
X-4649	PDAC	WNT974	865.2	30.4	19	314.4	-2.3
X-4649	PDAC	WNT974	905.9	30	24	333.9	-3.5
X-4649	PDAC	WNT974	979.3	31	28	369	-0.3
X-4649	PDAC	LKA136	228.4	24.2	0	0	0
X-4649	PDAC	LKA136	265.1	24.5	1	16.1	1.2
X-4649	PDAC	LKA136	215.5	24.6	3	-5.6	1.7
X-4649	PDAC	LKA136	240	24.3	7	5.1	0.4
X-4649	PDAC	LKA136	434.9	25.1	11	90.4	3.7
X-4649	PDAC	LKA136	241.5	NA	14	5.7	3.7
X-4649	PDAC	LKA136	299.8	25.3	17	31.3	4.5
X-4649	PDAC	LKA136	320.9	25.2	21	40.5	4.1
X-4649	PDAC	LKA136	338.5	25.5	24	48.2	5.4
X-4649	PDAC	LKA136	407.4	25.5	29	78.4	5.4
X-4649	PDAC	LKA136	538.8	25.2	33	135.9	4.1
X-4649	PDAC	LKA136	643.5	24.7	39	181.7	2.1
X-4649	PDAC	LKA136	676.6	24.4	42	196.2	0.8
X-4649	PDAC	LKA136	746.5	23.7	46	226.8	-2.1
X-4649	PDAC	binimetinib	286.9	29.1	0	0	0
X-4649	PDAC	binimetinib	306.7	27	4	6.9	-7.2
X-4649	PDAC	binimetinib	388	27.6	7	35.2	-5.2
X-4649	PDAC	binimetinib	321.8	28.1	11	12.2	-3.4
X-4649	PDAC	binimetinib	370	27.8	14	29	-4.5
X-4649	PDAC	binimetinib	373.6	27.6	18	30.2	-5.2
X-4649	PDAC	binimetinib	354.7	28.5	21	23.6	-2.1
X-4649	PDAC	binimetinib	465	28.2	25	62.1	-3.1
X-4649	PDAC	binimetinib	437.6	28.2	28	52.5	-3.1
X-4649	PDAC	binimetinib	348.9	28.1	32	21.6	-3.4
X-4649	PDAC	binimetinib	312.8	28.1	35	9	-3.4
X-4649	PDAC	binimetinib	398.6	30.2	39	38.9	3.8
X-4649	PDAC	binimetinib	359.4	28.9	42	25.3	-0.7
X-4649	PDAC	binimetinib	375.3	28.5	46	30.8	-2.1
X-4649	PDAC	binimetinib	416.6	28.7	49	45.2	-1.4
X-4649	PDAC	binimetinib	469.6	27.6	53	63.7	-5.2
X-4649	PDAC	binimetinib	450.1	28.2	56	56.9	-3.1
X-4649	PDAC	binimetinib	364.5	28.5	59	27	-2.1
X-4649	PDAC	binimetinib	411	28.2	62	43.3	-3.1
X-4649	PDAC	binimetinib	469.5	28	67	63.6	-3.8
X-4649	PDAC	binimetinib	485.3	28.6	70	69.2	-1.7
X-4649	PDAC	binimetinib	339.3	26.8	74	18.3	-7.9
X-4649	PDAC	binimetinib	489.4	26	77	70.6	-10.7
X-4649	PDAC	binimetinib-3.5mpk	211.4	21.1	0	0	0
X-4649	PDAC	binimetinib-3.5mpk	264.6	21.1	2	25.2	0
X-4649	PDAC	binimetinib-3.5mpk	417.7	20.6	6	97.6	-2.4
X-4649	PDAC	binimetinib-3.5mpk	400.7	20.6	9	89.5	-2.4
X-4649	PDAC	binimetinib-3.5mpk	487.4	17.9	12	130.6	-15.2
X-4649	PDAC	binimetinib-3.5mpk	539.2	20.8	15	155.1	-1.4
X-4649	PDAC	binimetinib-3.5mpk	549.7	20.4	20	160	-3.3
X-4649	PDAC	binimetinib-3.5mpk	612.8	20.4	23	189.9	-3.3
X-4649	PDAC	trametinib	188.2	27.7	0	0	0
X-4649	PDAC	trametinib	249	27.9	2	32.3	0.7
X-4649	PDAC	trametinib	153.1	26.8	6	-18.7	-3.2
X-4649	PDAC	trametinib	167.9	28	9	-10.8	1.1
X-4649	PDAC	trametinib	190.6	28.2	13	1.3	1.8
X-4649	PDAC	trametinib	142	27.9	16	-24.5	0.7
X-4649	PDAC	trametinib	152.2	27.3	21	-19.1	-1.4
X-4649	PDAC	trametinib	173.9	26.8	23	-7.6	-3.2
X-4649	PDAC	trametinib	142.6	27.1	27	-24.2	-2.2
X-4649	PDAC	trametinib	192.8	27.5	30	2.4	-0.7
X-4649	PDAC	trametinib	194.5	28	34	3.3	1.1
X-4649	PDAC	trametinib	245.7	28.9	37	30.6	4.3
X-4649	PDAC	trametinib	242.7	28.5	41	29	2.9
X-4649	PDAC	trametinib	211.2	27.9	44	12.2	0.7
X-4649	PDAC	trametinib	200.4	28.2	48	6.5	1.8
X-4649	PDAC	trametinib	185.7	27.5	51	-1.3	-0.7
X-4649	PDAC	trametinib	224.5	28.6	57	19.3	3.2
X-4649	PDAC	untreated	318.1	24.3	0	0	0
X-4649	PDAC	untreated	368.1	25.3	4	15.7	4.1
X-4649	PDAC	untreated	451.7	24.5	8	42	0.8
X-4649	PDAC	untreated	432.6	25.2	11	36	3.7
X-4649	PDAC	untreated	524.9	25.7	15	65	5.8
X-4649	PDAC	untreated	615.7	25.3	18	93.6	4.1
X-4649	PDAC	untreated	555.6	26.5	22	74.7	9.1
X-4649	PDAC	untreated	654.7	25.8	25	105.8	6.2
X-4649	PDAC	untreated	809.8	26	28	154.6	7
X-4649	PDAC	untreated	843.5	27	32	165.2	11.1
X-4649	PDAC	untreated	873.5	26.2	36	174.6	7.8
X-4649	PDAC	untreated	920.4	25.7	39	189.3	5.8
X-4649	PDAC	untreated	994.7	25.8	43	212.7	6.2
X-4649	PDAC	untreated	1028.6	26.7	45	223.4	9.9
X-4649	PDAC	untreated	1102.7	26.2	53	246.7	7.8
X-4649	PDAC	untreated	1303.5	27.1	56	309.8	11.5
X-4649	PDAC	untreated	1390.6	27.1	60	337.2	11.5
X-4668	CM	BKM120	210.7	24.6	0	0	0
X-4668	CM	BKM120	255.8	24.5	3	21.4	-0.4
X-4668	CM	BKM120	272.8	23.4	7	29.5	-4.9
X-4668	CM	BKM120	345.6	22.9	10	64	-6.9
X-4668	CM	BKM120	421.6	22.2	14	100.1	-9.8
X-4668	CM	BKM120	497.3	22.5	17	136	-8.5
X-4668	CM	BKM120	689.6	22.6	20	227.3	-8.1
X-4668	CM	BKM120 + encorafenib	204.2	23.2	0	0	0
X-4668	CM	BKM120 + encorafenib	163.9	22.4	4	-19.7	-3.4
X-4668	CM	BKM120 + encorafenib	143.7	22.2	8	-29.6	-4.3
X-4668	CM	BKM120 + encorafenib	154.2	23.1	11	-24.5	-0.4
X-4668	CM	BKM120 + encorafenib	150	23.3	14	-26.5	0.4
X-4668	CM	BKM120 + encorafenib	219	22.8	18	7.3	-1.7
X-4668	CM	BKM120 + encorafenib	233.4	23.4	23	14.3	0.9
X-4668	CM	BKM120 + encorafenib	241.9	23.7	26	18.5	2.2
X-4668	CM	BKM120 + encorafenib	241.9	22.9	29	18.5	-1.3
X-4668	CM	BKM120 + encorafenib	255	23.1	31	24.9	-0.4
X-4668	CM	BKM120 + encorafenib	275.2	22.5	35	34.8	-3
X-4668	CM	BKM120 + encorafenib	297.6	21.7	38	45.8	-6.5
X-4668	CM	BKM120 + encorafenib	374.7	21.6	42	83.5	-6.9
X-4668	CM	BKM120 + encorafenib	387.2	22	44	89.7	-5.2
X-4668	CM	CGM097	205.2	25.4	0	0	0
X-4668	CM	CGM097	268.4	25.1	3	30.8	-1.2
X-4668	CM	CGM097	356.2	25.2	7	73.6	-0.8
X-4668	CM	CGM097	423.2	25.1	10	106.3	-1.2
X-4668	CM	CGM097	413.1	24.8	14	101.3	-2.4
X-4668	CM	CGM097	574	25.2	17	179.7	-0.8
X-4668	CM	CGM097	660.7	24.8	20	222	-2.4
X-4668	CM	dacarbazine	219.4	22.6	0	0	0
X-4668	CM	dacarbazine	321.5	22.1	4	46.6	-2.2
X-4668	CM	dacarbazine	352.4	21.9	7	60.6	-3.1
X-4668	CM	dacarbazine	572.9	21.6	11	161.1	-4.4
X-4668	CM	dacarbazine	587.8	22.3	16	168	-1.3
X-4668	CM	dacarbazine	664	21.8	19	202.7	-3.5
X-4668	CM	dacarbazine	695.8	21.6	22	217.1	-4.4
X-4668	CM	dacarbazine	738.1	21.9	24	236.4	-3.1
X-4668	CM	dacarbazine	744.2	21.1	28	239.2	-6.6
X-4668	CM	LDE225	216.6	23.5	0	0	0
X-4668	CM	LDE225	367.8	21.5	5	69.9	-8.5
X-4668	CM	LDE225	540	20.5	8	149.4	-12.8
X-4668	CM	LDE225	674.2	19	11	211.3	-19.1
X-4668	CM	LDK378	194.4	26	0	0	0
X-4668	CM	LDK378	340.6	27.3	5	75.2	5
X-4668	CM	LDK378	414.1	27.4	8	113	5.4
X-4668	CM	LDK378	582.6	26.7	12	199.7	2.7
X-4668	CM	LDK378	780.5	27.3	15	301.5	5
X-4668	CM	LDK378	1195.2	26.5	18	514.8	1.9
X-4668	CM	LEE011	188.4	24.1	0	0	0
X-4668	CM	LEE011	211.3	23	3	12.1	-4.6
X-4668	CM	LEE011	206.9	21.5	7	9.8	-10.8
X-4668	CM	LEE011	198.5	21.6	10	5.3	-10.4
X-4668	CM	LEE011	254.8	20.3	14	35.2	-15.8
X-4668	CM	LEE011 + encorafenib	207.8	22.8	0	0	0
X-4668	CM	LEE011 + encorafenib	126	23.4	4	-39.4	2.6
X-4668	CM	LEE011 + encorafenib	128.8	24.4	7	-38	7
X-4668	CM	LEE011 + encorafenib	129.6	24.2	10	-37.6	6.1
X-4668	CM	LEE011 + encorafenib	130.7	24.3	14	-37.1	6.6
X-4668	CM	LEE011 + encorafenib	138.9	25.2	19	-33.2	10.5
X-4668	CM	LEE011 + encorafenib	126	25.3	22	-39.4	11
X-4668	CM	LEE011 + encorafenib	138.9	25.1	25	-33.2	10.1
X-4668	CM	LEE011 + encorafenib	143.4	26.3	27	-31	15.4
X-4668	CM	LEE011 + encorafenib	147.5	25.6	31	-29	12.3
X-4668	CM	LEE011 + encorafenib	147.5	26.1	34	-29	14.5
X-4668	CM	LEE011 + encorafenib	147.5	24.6	38	-29	7.9
X-4668	CM	LEE011 + encorafenib	148.8	24.7	42	-28.4	8.3
X-4668	CM	LEE011 + encorafenib	155.7	25	52	-25.1	9.6
X-4668	CM	LEE011 + encorafenib	153.6	26	56	-26.1	14
X-4668	CM	LEE011 + encorafenib	178	26	63	-14.3	14
X-4668	CM	LEE011 + encorafenib	190.8	26.4	67	-8.2	15.8
X-4668	CM	LEE011 + encorafenib	239.8	26.6	70	15.4	16.7
X-4668	CM	LEE011 + encorafenib	253.1	25.2	77	21.8	10.5
X-4668	CM	LEE011 + encorafenib	288	25.5	83	38.6	11.8
X-4668	CM	LEE011 + encorafenib	328.7	25.4	89	58.2	11.4
X-4668	CM	LEE011 + encorafenib	366.1	25.4	92	76.2	11.4
X-4668	CM	LEE011 + encorafenib	422.3	26	97	103.2	14
X-4668	CM	LEE011 + encorafenib	516.1	27	103	148.3	18.4
X-4668	CM	LEE011 + encorafenib	639.5	27.3	108	207.7	19.7
X-4668	CM	WNT974	198.5	25.6	0	0	0
X-4668	CM	WNT974	268.4	23.6	4	35.2	-7.8
X-4668	CM	WNT974	339.6	23.3	8	71.1	-9
X-4668	CM	WNT974	461.3	23.2	11	132.4	-9.4
X-4668	CM	WNT974	638.1	22	14	221.6	-14.1
X-4668	CM	LGW813	170.6	23.6	0	0	0
X-4668	CM	LGW813	202.3	22.5	3	18.6	-4.7
X-4668	CM	LGW813	272.8	21.5	7	59.9	-8.9
X-4668	CM	LGW813	384.6	20.9	10	125.4	-11.4
X-4668	CM	LGW813	521.7	20.2	14	205.8	-14.4
X-4668	CM	LGW813	592.5	21	17	247.3	-11
X-4668	CM	LGW813	839.8	20.5	20	392.3	-13.1
X-4668	CM	encorafenib	197.6	24.5	0	0	0
X-4668	CM	encorafenib	191.9	23.9	3	-2.9	-2.4
X-4668	CM	encorafenib	170	24.7	7	-14	0.8
X-4668	CM	encorafenib	160.7	24.7	10	-18.6	0.8
X-4668	CM	encorafenib	189.5	24.5	14	-4.1	0
X-4668	CM	encorafenib	258.5	25.2	17	30.8	2.9
X-4668	CM	encorafenib	312.1	25.3	20	57.9	3.3
X-4668	CM	encorafenib	392.7	25.4	24	98.7	3.7
X-4668	CM	encorafenib	396.1	25.6	29	100.5	4.5
X-4668	CM	encorafenib	465.8	24.5	32	135.7	0
X-4668	CM	encorafenib	512.5	23.3	35	159.4	-4.9
X-4668	CM	encorafenib	564.1	23.4	37	185.5	-4.5
X-4668	CM	encorafenib + binimetinib	207.4	27.5	0	0	0
X-4668	CM	encorafenib + binimetinib	191.8	26.7	4	-7.5	-2.9
X-4668	CM	encorafenib + binimetinib	171.1	25.8	7	-17.5	-6.2
X-4668	CM	encorafenib + binimetinib	166.1	26.3	11	-19.9	-4.4
X-4668	CM	encorafenib + binimetinib	143.7	26.4	16	-30.7	-4
X-4668	CM	encorafenib + binimetinib	166.1	26.2	19	-19.9	-4.7
X-4668	CM	encorafenib + binimetinib	149.5	26.3	22	-27.9	-4.4
X-4668	CM	encorafenib + binimetinib	159	26.7	24	-23.3	-2.9
X-4668	CM	encorafenib + binimetinib	154.2	25.7	28	-25.6	-6.5
X-4668	CM	encorafenib + binimetinib	163.9	26.3	31	-21	-4.4
X-4668	CM	encorafenib + binimetinib	166.5	26	35	-19.7	-5.5
X-4668	CM	encorafenib + binimetinib	188.7	26.1	39	-9	-5.1
X-4668	CM	encorafenib + binimetinib	186.2	26	49	-10.2	-5.5
X-4668	CM	encorafenib + binimetinib	196	26.6	53	-5.5	-3.3
X-4668	CM	encorafenib + binimetinib	268.6	26.8	60	29.5	-2.5
X-4668	CM	encorafenib + binimetinib	298.1	26.3	63	43.8	-4.4
X-4668	CM	encorafenib + binimetinib	328.1	26	67	58.2	-5.5
X-4668	CM	encorafenib + binimetinib	332.8	26.2	74	60.5	-4.7
X-4668	CM	encorafenib + binimetinib	352.8	27.1	80	70.1	-1.5
X-4668	CM	encorafenib + binimetinib	352.8	27.4	86	70.1	-0.4
X-4668	CM	encorafenib + binimetinib	361.3	26.8	89	74.2	-2.5
X-4668	CM	encorafenib + binimetinib	380.9	26.8	94	83.7	-2.5
X-4668	CM	encorafenib + binimetinib	399.4	27.2	100	92.6	-1.1
X-4668	CM	encorafenib + binimetinib	465.8	27	105	124.6	-1.8
X-4668	CM	binimetinib	198.8	26.9	0	0	0
X-4668	CM	binimetinib	226.2	26.6	3	13.7	-1.1
X-4668	CM	binimetinib	231.2	26.8	7	16.3	-0.4
X-4668	CM	binimetinib	240.5	27.4	10	20.9	1.9
X-4668	CM	binimetinib	291.6	25.6	14	46.6	-4.8
X-4668	CM	binimetinib	339.5	27	17	70.8	0.4
X-4668	CM	binimetinib	369.6	27.1	20	85.9	0.7
X-4668	CM	binimetinib	471.9	27.6	24	137.3	2.6
X-4668	CM	binimetinib	460.6	28.2	29	131.7	4.8
X-4668	CM	binimetinib	599.4	26.4	32	201.5	-1.9
X-4668	CM	binimetinib	663.3	26.1	35	233.6	-3
X-4668	CM	binimetinib	728.1	27.5	37	266.2	2.2
X-4668	CM	TAS266	190.8	21	0	0	0
X-4668	CM	TAS266	188.5	21.6	3	-1.2	2.9
X-4668	CM	TAS266	117.7	21.6	7	-38.3	2.9
X-4668	CM	TAS266	80.1	21.5	10	-58	2.4
X-4668	CM	TAS266	50.6	21.2	14	-73.5	1
X-4668	CM	TAS266	35.3	21.9	17	-81.5	4.3
X-4668	CM	TAS266	20.2	21.4	20	-89.4	1.9
X-4668	CM	TAS266	23.3	21.3	24	-87.8	1.4
X-4668	CM	TAS266	23.9	22.3	29	-87.5	6.2
X-4668	CM	TAS266	21.4	22.4	32	-88.8	6.7
X-4668	CM	TAS266	13.5	22.8	35	-92.9	8.6
X-4668	CM	TAS266	18	22.7	37	-90.6	8.1
X-4668	CM	TAS266	18	21.6	41	-90.6	2.9
X-4668	CM	TAS266	18	23.1	44	-90.6	10
X-4668	CM	TAS266	0	22.5	48	-100	7.1
X-4668	CM	TAS266	0	23	52	-100	9.5
X-4668	CM	TAS266	0	23.4	62	-100	11.4
X-4668	CM	TAS266	0	23	66	-100	9.5
X-4668	CM	TAS266	0	23.2	70	-100	10.5
X-4668	CM	TAS266	0	23.3	77	-100	11
X-4668	CM	TAS266	0	23.6	81	-100	12.4
X-4668	CM	TAS266	0	24	87	-100	14.3
X-4668	CM	TAS266	0	24	93	-100	14.3
X-4668	CM	TAS266	0	23.9	99	-100	13.8
X-4668	CM	TAS266	0	24	102	-100	14.3
X-4668	CM	TAS266	0	23.8	107	-100	13.3
X-4668	CM	TAS266	0	24.3	113	-100	15.7
X-4668	CM	TAS266	0	24.7	118	-100	17.6
X-4668	CM	TAS266	0	25	135	-100	19
X-4668	CM	TAS266	0	24.5	142	-100	16.7
X-4668	CM	TAS266	0	24.8	151	-100	18.1
X-4668	CM	TAS266	0	25	158	-100	19
X-4668	CM	TAS266	0	24.7	164	-100	17.6
X-4668	CM	TAS266	0	24	170	-100	14.3
X-4668	CM	TAS266	0	24.5	176	-100	16.7
X-4668	CM	TAS266	0	23	183	-100	9.5
X-4668	CM	TAS266	0	24.4	193	-100	16.2
X-4668	CM	TAS266	0	24.8	201	-100	18.1
X-4668	CM	TAS266	0	24.7	208	-100	17.6
X-4668	CM	TAS266	0	25.2	219	-100	20
X-4668	CM	TAS266	0	24.9	230	-100	18.6
X-4668	CM	TAS266	0	24.8	237	-100	18.1
X-4668	CM	TAS266	0	24.6	245	-100	17.1
X-4668	CM	TAS266	0	25	251	-100	19
X-4668	CM	untreated	205.8	26.8	0	0	0
X-4668	CM	untreated	253.1	26.9	3	23	0.4
X-4668	CM	untreated	397.4	27.3	7	93.1	1.9
X-4668	CM	untreated	554.4	26.3	10	169.4	-1.9
X-4668	CM	untreated	978.4	26.7	14	375.4	-0.4
X-4668	CM	untreated	1104.3	27.7	17	436.6	3.4
X-4668	CM	untreated	1263.3	26.5	20	513.8	-1.1
X-4676	PDAC	abraxane	250	21.3	0	0	0
X-4676	PDAC	abraxane	353.7	22.9	6	41.5	7.5
X-4676	PDAC	abraxane	610.9	23	9	144.4	8
X-4676	PDAC	abraxane	848.3	24.1	12	239.3	13.1
X-4676	PDAC	abraxane	1097.2	23.7	15	338.9	11.3
X-4676	PDAC	BKM120 + binimetinib	273.9	29.7	0	0	0
X-4676	PDAC	BKM120 + binimetinib	313.6	29.8	2	14.5	0.3
X-4676	PDAC	BKM120 + binimetinib	358.2	28.6	6	30.8	-3.7
X-4676	PDAC	BKM120 + binimetinib	334.8	28.1	8	22.2	-5.4
X-4676	PDAC	BKM120 + binimetinib	391.4	29.7	14	42.9	0
X-4676	PDAC	BKM120 + binimetinib	242.2	29.9	20	-11.6	0.7
X-4676	PDAC	BKM120 + binimetinib	375.5	29.9	23	37.1	0.7
X-4676	PDAC	BKM120 + binimetinib	297	30	26	8.4	1
X-4676	PDAC	BKM120 + binimetinib	189.3	28.9	29	-30.9	-2.7
X-4676	PDAC	BKM120 + binimetinib	143.6	28.7	34	-47.6	-3.4
X-4676	PDAC	BKM120 + binimetinib	156	29.3	36	-43	-1.3
X-4676	PDAC	BKM120 + binimetinib	138.7	28.9	40	-49.4	-2.7
X-4676	PDAC	BKM120 + binimetinib	153.1	29.3	43	-44.1	-1.3
X-4676	PDAC	BKM120 + binimetinib	137.5	28.5	48	-49.8	-4
X-4676	PDAC	BKM120 + binimetinib	81.6	28.2	55	-70.2	-5.1
X-4676	PDAC	BKM120 + binimetinib	55.3	29.5	58	-79.8	-0.7
X-4676	PDAC	BKM120 + binimetinib	57.1	28.8	62	-79.2	-3
X-4676	PDAC	BKM120 + binimetinib	25.3	28.8	65	-90.8	-3
X-4676	PDAC	BKM120 + binimetinib	15.6	29.5	68	-94.3	-0.7
X-4676	PDAC	BKM120 + binimetinib	13.4	28.5	76	-95.1	-4
X-4676	PDAC	BKM120 + binimetinib	16	28.4	78	-94.2	-4.4
X-4676	PDAC	BKM120 + binimetinib	15.8	29.2	83	-94.2	-1.7
X-4676	PDAC	BKM120 + binimetinib	12.7	28.8	86	-95.4	-3
X-4676	PDAC	BKM120 + binimetinib	17.4	28.4	90	-93.6	-4.4
X-4676	PDAC	BKM120 + binimetinib	0	27.6	93	-100	-7.1
X-4676	PDAC	BKM120 + binimetinib	0	27.5	96	-100	-7.4
X-4676	PDAC	BKM120 + LDE225	218.6	25	0	0	0
X-4676	PDAC	BKM120 + LDE225	162.8	25.9	2	-25.5	3.6
X-4676	PDAC	BKM120 + LDE225	125.4	25.9	6	-42.6	3.6
X-4676	PDAC	BKM120 + LDE225	134.4	25	9	-38.5	0
X-4676	PDAC	BKM120 + LDE225	138.4	23.6	13	-36.7	-5.6
X-4676	PDAC	BKM120 + LDE225	142.6	24.1	16	-34.8	-3.6
X-4676	PDAC	BKM120 + LDE225	124.6	25.9	20	-43	3.6
X-4676	PDAC	BKM120 + LDE225	114	24.4	23	-47.8	-2.4
X-4676	PDAC	BKM120 + LDE225	110.4	26.2	27	-49.5	4.8
X-4676	PDAC	BKM120 + LDE225	142.8	25.7	30	-34.7	2.8
X-4676	PDAC	BKM120 + LDE225	119.1	26.6	34	-45.5	6.4
X-4676	PDAC	BKM120 + LDE225	117.3	25.6	37	-46.3	2.4
X-4676	PDAC	BKM120 + LDE225	143.4	26.5	40	-34.4	6
X-4676	PDAC	BKM120 + LDE225	108.4	26.5	43	-50.4	6
X-4676	PDAC	BKM120 + LDE225	106.1	26	48	-51.5	4
X-4676	PDAC	BKM120 + LDE225	139.3	25.2	51	-36.3	0.8
X-4676	PDAC	BKM120 + LDE225	165.9	25.3	55	-24.1	1.2
X-4676	PDAC	BKM120 + LDE225	240.7	26.2	58	10.1	4.8
X-4676	PDAC	BKM120 + LDE225	175.2	25.9	61	-19.9	3.6
X-4676	PDAC	BKM120 + LDE225	200.6	26	65	-8.2	4
X-4676	PDAC	BKM120 + LDE225	274.7	27.1	68	25.7	8.4
X-4676	PDAC	BKM120 + LDE225	218.1	25.5	71	-0.2	2
X-4676	PDAC	BKM120 + LDE225	240	26.1	75	9.8	4.4
X-4676	PDAC	BKM120 + LDE225	269.3	27.1	79	23.2	8.4
X-4676	PDAC	BKM120 + LDE225	341.5	27.4	83	56.2	9.6
X-4676	PDAC	BKM120 + LDE225	270.4	25.8	86	23.7	3.2
X-4676	PDAC	BKM120 + LDE225	340.6	26.8	89	55.8	7.2
X-4676	PDAC	BKM120 + LDE225	324.1	26.6	93	48.3	6.4
X-4676	PDAC	BKM120	184.6	22.5	0	0	0
X-4676	PDAC	BKM120	188.9	24.9	5	2.3	10.7
X-4676	PDAC	BKM120	227.1	22.7	7	23	0.9
X-4676	PDAC	BKM120	191.7	22.6	11	3.8	0.4
X-4676	PDAC	BKM120	266.8	23.3	14	44.5	3.6
X-4676	PDAC	BKM120	283.1	23.2	18	53.4	3.1
X-4676	PDAC	BKM120	297.3	23.5	25	61.1	4.4
X-4676	PDAC	BKM120	315.2	23.8	28	70.7	5.8
X-4676	PDAC	BKM120	264.4	23.9	32	43.2	6.2
X-4676	PDAC	BKM120	242	24.3	35	31.1	8
X-4676	PDAC	BKM120	214.4	23.5	41	16.1	4.4
X-4676	PDAC	BYL719	246.3	24.2	0	0	0
X-4676	PDAC	BYL719	392.3	23.8	5	59.3	-1.7
X-4676	PDAC	BYL719	483.5	25.1	8	96.3	3.7
X-4676	PDAC	BYL719	622.8	25.2	11	152.9	4.1
X-4676	PDAC	BYL719	733.4	24.7	14	197.8	2.1
X-4676	PDAC	BYL719	815.1	25.2	18	230.9	4.1
X-4676	PDAC	BYL719	830.7	25.9	21	237.3	7
X-4676	PDAC	BYL719	981.9	25.5	25	298.7	5.4
X-4676	PDAC	BYL719	998.4	26.1	28	305.4	7.9
X-4676	PDAC	BYL719	1450	24.4	33	488.7	0.8
X-4676	PDAC	BYL719	1664.5	23.9	36	575.8	-1.2
X-4676	PDAC	BYL719 + LJM716	291.9	25.3	0	0	0
X-4676	PDAC	BYL719 + LJM716	308.1	24.6	4	5.5	-2.8
X-4676	PDAC	BYL719 + LJM716	333.9	24.1	7	14.4	-4.7
X-4676	PDAC	BYL719 + LJM716	434.8	25	11	49	-1.2
X-4676	PDAC	BYL719 + LJM716	497.1	24	14	70.3	-5.1
X-4676	PDAC	BYL719 + LJM716	510.9	25.2	18	75	-0.4
X-4676	PDAC	BYL719 + LJM716	523.4	23.5	20	79.3	-7.1
X-4676	PDAC	BYL719 + LJM716	580.8	24.8	25	99	-2
X-4676	PDAC	BYL719 + LJM716	540.2	23.5	28	85.1	-7.1
X-4676	PDAC	BYL719 + LJM716	537.5	24.4	32	84.1	-3.6
X-4676	PDAC	BYL719 + LJM716	531.9	24.2	35	82.2	-4.3
X-4676	PDAC	BYL719 + LJM716	565.9	25	38	93.9	-1.2
X-4676	PDAC	CLR457	246.8	26.3	0	0	0
X-4676	PDAC	CLR457	285.4	25.1	5	15.6	-4.6
X-4676	PDAC	CLR457	291.7	25.7	8	18.2	-2.3
X-4676	PDAC	CLR457	286.9	25.8	11	16.2	-1.9
X-4676	PDAC	CLR457	353.3	26.3	14	43.2	0
X-4676	PDAC	CLR457	400.7	27.1	18	62.4	3
X-4676	PDAC	CLR457	458	26.8	21	85.6	1.9
X-4676	PDAC	CLR457	680.5	26.5	25	175.7	0.8
X-4676	PDAC	CLR457	833.5	26.2	28	237.7	-0.4
X-4676	PDAC	CLR457	924.6	25	33	274.6	-4.9
X-4676	PDAC	CLR457	1160.4	24.6	36	370.2	-6.5
X-4676	PDAC	CLR457	1443.7	25.7	39	485	-2.3
X-4676	PDAC	CLR457	1514.7	25.7	42	513.7	-2.3
X-4676	PDAC	HDM201	245.7	22.3	0	0	0
X-4676	PDAC	HDM201	236.4	22.8	5	-3.8	2.2
X-4676	PDAC	HDM201	240	22.8	8	-2.3	2.2
X-4676	PDAC	HDM201	278.3	23.4	11	13.3	4.9
X-4676	PDAC	HDM201	425.4	23.8	14	73.1	6.7
X-4676	PDAC	HDM201	491.3	24.8	18	100	11.2
X-4676	PDAC	HDM201	505.5	23.7	21	105.7	6.3
X-4676	PDAC	HDM201	631.5	22.8	25	157	2.2
X-4676	PDAC	HDM201	1028.1	22.9	28	318.4	2.7
X-4676	PDAC	figitumumab"	204.6	23.5	0	0	0
X-4676	PDAC	figitumumab"	211.1	25	6	3.2	6.4
X-4676	PDAC	figitumumab"	318.9	26	12	55.9	10.6
X-4676	PDAC	figitumumab"	336.5	25.4	15	64.5	8.1
X-4676	PDAC	figitumumab"	390.1	25.6	19	90.7	8.9
X-4676	PDAC	figitumumab"	465.9	27	22	127.7	14.9
X-4676	PDAC	figitumumab"	621.7	26.5	26	203.9	12.8
X-4676	PDAC	figitumumab"	714	27.2	29	249	15.7
X-4676	PDAC	figitumumab"	758.9	27.8	33	270.9	18.3
X-4676	PDAC	figitumumab"	903.6	27.8	36	341.6	18.3
X-4676	PDAC	figitumumab" + binimetinib	232.7	25.1	0	0	0
X-4676	PDAC	figitumumab" + binimetinib	323.5	26.4	4	39	5.2
X-4676	PDAC	figitumumab" + binimetinib	465.2	26.7	7	99.9	6.4
X-4676	PDAC	figitumumab" + binimetinib	442.1	26.1	11	90	4
X-4676	PDAC	figitumumab" + binimetinib	485.4	26	17	108.6	3.6
X-4676	PDAC	gemcitabine-50mpk	210.2	24.6	0	0	0
X-4676	PDAC	gemcitabine-50mpk	268.7	25	2	27.8	1.6
X-4676	PDAC	gemcitabine-50mpk	280.7	24.5	7	33.5	-0.4
X-4676	PDAC	gemcitabine-50mpk	238.9	25.1	10	13.7	2
X-4676	PDAC	gemcitabine-50mpk	222.2	24.4	14	5.7	-0.8
X-4676	PDAC	gemcitabine-50mpk	281.4	25.2	17	33.9	2.4
X-4676	PDAC	gemcitabine-50mpk	184.6	25.4	20	-12.2	3.3
X-4676	PDAC	gemcitabine-50mpk	260.3	24.9	23	23.8	1.2
X-4676	PDAC	gemcitabine-50mpk	217.7	24.7	28	3.6	0.4
X-4676	PDAC	gemcitabine-50mpk	192.3	25	31	-8.5	1.6
X-4676	PDAC	gemcitabine-50mpk	166.4	26.1	35	-20.8	6.1
X-4676	PDAC	gemcitabine-50mpk	133.2	25.8	37	-36.6	4.9
X-4676	PDAC	gemcitabine-50mpk	146.6	26.2	42	-30.3	6.5
X-4676	PDAC	gemcitabine-50mpk	91.9	24.5	44	-56.3	-0.4
X-4676	PDAC	gemcitabine-50mpk	61	26	49	-71	5.7
X-4676	PDAC	gemcitabine-50mpk	89.6	25.7	52	-57.4	4.5
X-4676	PDAC	gemcitabine-50mpk	44.4	25.8	56	-78.9	4.9
X-4676	PDAC	gemcitabine-50mpk	77.1	26.9	59	-63.3	9.3
X-4676	PDAC	gemcitabine-50mpk	62.8	26.7	62	-70.1	8.5
X-4676	PDAC	gemcitabine-50mpk	63.5	26.7	66	-69.8	8.5
X-4676	PDAC	gemcitabine-50mpk	95.8	28	69	-54.4	13.8
X-4676	PDAC	gemcitabine-50mpk	69.2	25.3	73	-67.1	2.8
X-4676	PDAC	gemcitabine-50mpk	51.3	25.4	76	-75.6	3.3
X-4676	PDAC	gemcitabine-50mpk	69.2	27.3	80	-67.1	11
X-4676	PDAC	gemcitabine-50mpk	54.6	27.7	83	-74	12.6
X-4676	PDAC	gemcitabine-50mpk	56.4	NA	86	-73.2	12.6
X-4676	PDAC	gemcitabine-50mpk	64.3	25.5	91	-69.4	3.7
X-4676	PDAC	gemcitabine-50mpk	43.1	26.6	93	-79.5	8.1
X-4676	PDAC	gemcitabine-50mpk	42.7	25.6	97	-79.7	4.1
X-4676	PDAC	INC424 + binimetinib	268.7	22.7	0	0	0
X-4676	PDAC	INC424 + binimetinib	246.7	22.2	4	-8.2	-2.2
X-4676	PDAC	INC424 + binimetinib	282.6	23.6	7	5.2	4
X-4676	PDAC	INC424 + binimetinib	259.3	23.5	11	-3.5	3.5
X-4676	PDAC	INC424 + binimetinib	330.4	23.4	14	23	3.1
X-4676	PDAC	INC424 + binimetinib	259.1	23.6	18	-3.6	4
X-4676	PDAC	INC424 + binimetinib	278.9	23.7	21	3.8	4.4
X-4676	PDAC	INC424 + binimetinib	192.7	23.6	25	-28.3	4
X-4676	PDAC	INC424 + binimetinib	239.7	23.5	28	-10.8	3.5
X-4676	PDAC	INC424 + binimetinib	219.6	23.6	31	-18.3	4
X-4676	PDAC	INC424 + binimetinib	197.5	24.3	34	-26.5	7
X-4676	PDAC	INC424 + binimetinib	225.8	23.5	39	-16	3.5
X-4676	PDAC	INC424 + binimetinib	211.2	23.9	42	-21.4	5.3
X-4676	PDAC	INC424 + binimetinib	198.3	23.7	46	-26.2	4.4
X-4676	PDAC	INC424 + binimetinib	298	24.4	49	10.9	7.5
X-4676	PDAC	INC424 + binimetinib	198.6	24.6	52	-26.1	8.4
X-4676	PDAC	INC424 + binimetinib	206	24.5	56	-23.3	7.9
X-4676	PDAC	INC424 + binimetinib	218.4	24.4	59	-18.7	7.5
X-4676	PDAC	INC424 + binimetinib	245.5	24.7	62	-8.6	8.8
X-4676	PDAC	INC424 + binimetinib	306.2	24.6	66	14	8.4
X-4676	PDAC	INC424 + binimetinib	294.4	24	70	9.6	5.7
X-4676	PDAC	INC424 + binimetinib	296	23.7	74	10.2	4.4
X-4676	PDAC	INC424 + binimetinib	213.5	23.4	77	-20.5	3.1
X-4676	PDAC	INC424 + binimetinib	235.4	23.6	80	-12.4	4
X-4676	PDAC	INC424 + binimetinib	258.5	24.1	84	-3.8	6.2
X-4676	PDAC	INC424	237.3	23.8	0	0	0
X-4676	PDAC	INC424	369	25	5	55.5	5
X-4676	PDAC	INC424	449.8	26	8	89.5	9.2
X-4676	PDAC	INC424	489.4	27	11	106.2	13.4
X-4676	PDAC	INC424	639.9	27.2	14	169.7	14.3
X-4676	PDAC	INC424	801.1	26	18	237.6	9.2
X-4676	PDAC	INC424	868	27.6	21	265.8	16
X-4676	PDAC	LEE011	228.6	22.3	0	0	0
X-4676	PDAC	LEE011	413.7	23.5	6	81	5.4
X-4676	PDAC	LEE011	550.5	24.2	9	140.8	8.5
X-4676	PDAC	LEE011	595.2	25.2	12	160.4	13
X-4676	PDAC	LEE011	924.4	25.1	15	304.4	12.6
X-4676	PDAC	WNT974	296.2	20.5	0	0	0
X-4676	PDAC	WNT974	337	20.7	2	13.8	1
X-4676	PDAC	WNT974	509.8	20.4	6	72.1	-0.5
X-4676	PDAC	WNT974	661.6	19.9	9	123.4	-2.9
X-4676	PDAC	WNT974	711.9	21.2	13	140.3	3.4
X-4676	PDAC	WNT974	781.1	20.4	16	163.7	-0.5
X-4676	PDAC	WNT974	791.6	21.5	20	167.3	4.9
X-4676	PDAC	WNT974	934.1	21.7	23	215.4	5.9
X-4676	PDAC	WNT974	1218.1	20.7	26	311.2	1
X-4676	PDAC	LKA136	205.3	29.7	0	0	0
X-4676	PDAC	LKA136	208.6	30.3	1	1.6	2
X-4676	PDAC	LKA136	237.7	29.5	6	15.8	-0.7
X-4676	PDAC	LKA136	273.3	29.4	12	33.1	-1
X-4676	PDAC	LKA136	367	29.8	16	78.8	0.3
X-4676	PDAC	LKA136	433.1	30.3	20	111	2
X-4676	PDAC	LKA136	524.3	31.1	23	155.4	4.7
X-4676	PDAC	LKA136	653.1	30.4	28	218.1	2.4
X-4676	PDAC	LKA136	710	31.2	30	245.8	5.1
X-4676	PDAC	LKA136	898	27.9	34	337.4	-6.1
X-4676	PDAC	binimetinib	249.6	26.2	0	0	0
X-4676	PDAC	binimetinib	286.6	25.8	2	14.8	-1.5
X-4676	PDAC	binimetinib	262.4	25.6	6	5.1	-2.3
X-4676	PDAC	binimetinib	300.7	25.8	8	20.5	-1.5
X-4676	PDAC	binimetinib	395.4	26.7	14	58.4	1.9
X-4676	PDAC	binimetinib	300.1	25.2	20	20.2	-3.8
X-4676	PDAC	binimetinib	277.6	24.9	23	11.2	-5
X-4676	PDAC	binimetinib	228.8	25.9	26	-8.3	-1.1
X-4676	PDAC	binimetinib	278.5	25.6	29	11.6	-2.3
X-4676	PDAC	binimetinib	178.6	26	34	-28.4	-0.8
X-4676	PDAC	binimetinib	151.9	25.9	36	-39.1	-1.1
X-4676	PDAC	binimetinib	189.5	25.6	40	-24.1	-2.3
X-4676	PDAC	binimetinib	179.3	25.3	43	-28.2	-3.4
X-4676	PDAC	binimetinib	164.3	23.9	48	-34.2	-8.8
X-4676	PDAC	binimetinib	128.7	23.7	55	-48.4	-9.5
X-4676	PDAC	binimetinib	115.1	24.4	58	-53.9	-6.9
X-4676	PDAC	binimetinib	79.1	24.8	62	-68.3	-5.3
X-4676	PDAC	binimetinib	45.6	24.3	65	-81.7	-7.3
X-4676	PDAC	binimetinib	29.4	23.1	68	-88.2	-11.8
X-4676	PDAC	binimetinib	13.6	25.4	76	-94.6	-3.1
X-4676	PDAC	binimetinib	0	26.1	83	-100	-0.4
X-4676	PDAC	binimetinib	0	24.7	86	-100	-5.7
X-4676	PDAC	binimetinib	0	27.2	90	-100	3.8
X-4676	PDAC	binimetinib	0	24.9	93	-100	-5
X-4676	PDAC	binimetinib	0	26.2	96	-100	0
X-4676	PDAC	binimetinib-3.5mpk	185.4	24.5	0	0	0
X-4676	PDAC	binimetinib-3.5mpk	239.2	23.6	1	29	-3.7
X-4676	PDAC	binimetinib-3.5mpk	308.2	23	5	66.2	-6.1
X-4676	PDAC	binimetinib-3.5mpk	296.1	22.5	7	59.7	-8.2
X-4676	PDAC	binimetinib-3.5mpk	429.7	22	12	131.8	-10.2
X-4676	PDAC	binimetinib-3.5mpk	518.8	22.3	15	179.8	-9
X-4676	PDAC	binimetinib-3.5mpk	592.1	22.8	19	219.4	-6.9
X-4676	PDAC	trametinib	261.5	26.3	0	0	0
X-4676	PDAC	trametinib	307.9	26.2	3	17.7	-0.4
X-4676	PDAC	trametinib	259.8	26.7	7	-0.7	1.5
X-4676	PDAC	trametinib	195.8	25.7	10	-25.1	-2.3
X-4676	PDAC	trametinib	196.2	27.1	14	-25	3
X-4676	PDAC	trametinib	218.5	26.3	17	-16.4	0
X-4676	PDAC	trametinib	239	28.1	22	-8.6	6.8
X-4676	PDAC	trametinib	194.4	27.7	27	-25.7	5.3
X-4676	PDAC	trametinib	269.1	27.5	30	2.9	4.6
X-4676	PDAC	trametinib	282.4	27.5	34	8	4.6
X-4676	PDAC	trametinib	285.4	27.3	37	9.1	3.8
X-4676	PDAC	trametinib	231.9	27.4	41	-11.3	4.2
X-4676	PDAC	trametinib	258.1	26.9	44	-1.3	2.3
X-4676	PDAC	trametinib	247.4	26.6	48	-5.4	1.1
X-4676	PDAC	trametinib	238.7	27.9	51	-8.7	6.1
X-4676	PDAC	trametinib	296.5	27.5	55	13.4	4.6
X-4676	PDAC	trametinib	214.1	27.1	58	-18.1	3
X-4676	PDAC	trametinib	229.5	27.1	62	-12.2	3
X-4676	PDAC	trametinib	223.1	27.3	66	-14.7	3.8
X-4676	PDAC	trametinib	279.5	26.5	69	6.9	0.8
X-4676	PDAC	trametinib	180	26.8	72	-31.2	1.9
X-4676	PDAC	trametinib	218.9	27.4	76	-16.3	4.2
X-4676	PDAC	trametinib	256.8	27.8	79	-1.8	5.7
X-4676	PDAC	trametinib	257.5	28.1	84	-1.5	6.8
X-4676	PDAC	trametinib	239	27.4	87	-8.6	4.2
X-4676	PDAC	trametinib	298.6	27.7	91	14.2	5.3
X-4676	PDAC	untreated	272.1	26.4	0	0	0
X-4676	PDAC	untreated	311.9	23.8	2	14.6	-9.8
X-4676	PDAC	untreated	410.6	28.3	5	50.9	7.2
X-4676	PDAC	untreated	616.2	26	8	126.5	-1.5
X-4676	PDAC	untreated	712.7	27.6	13	161.9	4.5
X-4676	PDAC	untreated	793.4	26.1	16	191.6	-1.1
X-4676	PDAC	untreated	998.6	28.2	20	267	6.8
X-4676	PDAC	untreated	1308.6	27.7	23	380.9	4.9
X-4676	PDAC	untreated	1336.4	27.3	27	391.1	3.4
X-4676	PDAC	untreated	1398.4	27.5	29	413.9	4.2
X-4819	NSCLC	BGJ398	285	22.6	0	0	0
X-4819	NSCLC	BGJ398	665.4	21.7	3	133.5	-4
X-4819	NSCLC	BGJ398	877.1	18.2	5	207.8	-19.5
X-4819	NSCLC	BKM120	228.8	24.8	0	0	0
X-4819	NSCLC	BKM120	233.1	25	3	1.9	0.8
X-4819	NSCLC	BKM120	620.3	25.2	6	171.1	1.6
X-4819	NSCLC	BKM120	1088.9	25.2	10	375.9	1.6
X-4819	NSCLC	BKM120	1316.1	24.1	11	475.2	-2.8
X-4819	NSCLC	BKM120 + binimetinib	324	25.1	0	0	0
X-4819	NSCLC	BKM120 + binimetinib	794.8	25.6	3	145.3	2
X-4819	NSCLC	BKM120 + binimetinib	1154.8	25.4	5	256.4	1.2
X-4819	NSCLC	BYL719	248.1	24	0	0	0
X-4819	NSCLC	BYL719	414.9	24.1	3	67.2	0.4
X-4819	NSCLC	BYL719	644.9	23.4	6	159.9	-2.5
X-4819	NSCLC	BYL719	842.1	23.9	10	239.4	-0.4
X-4819	NSCLC	BYL719	1237.2	24	11	398.7	0
X-4819	NSCLC	BYL719 + LGH447	315.6	22.1	0	0	0
X-4819	NSCLC	BYL719 + LGH447	849.5	21.3	3	169.2	-3.6
X-4819	NSCLC	BYL719 + LGH447	1024	19.7	5	224.5	-10.9
X-4819	NSCLC	BYL719 + LJM716	254.2	23.6	0	0	0
X-4819	NSCLC	BYL719 + LJM716	928.3	23.2	3	265.2	-1.7
X-4819	NSCLC	BYL719 + LJM716	1360.9	21	5	435.4	-11
X-4819	NSCLC	CGM097	326.9	24	0	0	0
X-4819	NSCLC	CGM097	972.4	24.3	3	197.5	1.2
X-4819	NSCLC	CGM097	1277	23.4	5	290.6	-2.5
X-4819	NSCLC	CKX620	196.7	24.1	0	0	0
X-4819	NSCLC	CKX620	234.1	24.2	3	19	0.4
X-4819	NSCLC	CKX620	245.5	24.8	6	24.8	2.9
X-4819	NSCLC	CKX620	117.3	25	10	-40.4	3.7
X-4819	NSCLC	CKX620	134.6	24.6	13	-31.6	2.1
X-4819	NSCLC	CKX620	82.4	25.1	17	-58.1	4.1
X-4819	NSCLC	CKX620	236.5	25.3	20	20.2	5
X-4819	NSCLC	CKX620	290.8	25.3	24	47.8	5
X-4819	NSCLC	CKX620	250.8	25.9	27	27.5	7.5
X-4819	NSCLC	CKX620	480.3	25.9	31	144.2	7.5
X-4819	NSCLC	CKX620	497.7	26.6	34	153	10.4
X-4819	NSCLC	CKX620	528.3	25.8	38	168.6	7.1
X-4819	NSCLC	CKX620	741.2	26.1	41	276.8	8.3
X-4819	NSCLC	CKX620	892	25.6	45	353.5	6.2
X-4819	NSCLC	CKX620	873.6	26.3	46	344.1	9.1
X-4819	NSCLC	CLR457	211.9	24.1	0	0	0
X-4819	NSCLC	CLR457	357.3	23.7	3	68.6	-1.7
X-4819	NSCLC	CLR457	427	24.2	6	101.5	0.4
X-4819	NSCLC	CLR457	244	23.7	10	15.1	-1.7
X-4819	NSCLC	CLR457	773.7	23.4	13	265.1	-2.9
X-4819	NSCLC	CLR457	1060.7	23.5	17	400.6	-2.5
X-4819	NSCLC	CLR457	1150.1	23.5	20	442.8	-2.5
X-4819	NSCLC	HDM201	279	24.3	0	0	0
X-4819	NSCLC	HDM201	777	23.5	3	178.5	-3.3
X-4819	NSCLC	HDM201	1363.7	21.3	5	388.8	-12.3
X-4819	NSCLC	cetuximab	365.3	23.1	0	0	0
X-4819	NSCLC	cetuximab	824.5	24	3	125.7	3.9
X-4819	NSCLC	cetuximab	1067.3	24.3	5	192.2	5.2
X-4819	NSCLC	erlotinib	274.2	23.9	0	0	0
X-4819	NSCLC	erlotinib	1200.5	24.3	3	337.8	1.7
X-4819	NSCLC	erlotinib	1793.1	23.9	5	553.9	0
X-4819	NSCLC	HSP990	271.5	22.8	0	0	0
X-4819	NSCLC	HSP990	650	20.5	3	139.4	-10.1
X-4819	NSCLC	HSP990	960.5	20.3	5	253.8	-11
X-4819	NSCLC	INC280	220.7	24	0	0	0
X-4819	NSCLC	INC280	384.5	23.5	3	74.2	-2.1
X-4819	NSCLC	INC280	563.2	23.3	6	155.2	-2.9
X-4819	NSCLC	INC280	892.6	24.9	10	304.4	3.7
X-4819	NSCLC	INC280	1547.2	24.3	11	601	1.2
X-4819	NSCLC	LCL161 + paclitaxel	222.1	22.4	0	0	0
X-4819	NSCLC	LCL161 + paclitaxel	184.9	21.9	3	-16.7	-2.2
X-4819	NSCLC	LCL161 + paclitaxel	367.3	22.5	6	65.4	0.4
X-4819	NSCLC	LCL161 + paclitaxel	810.3	24.2	10	264.8	8
X-4819	NSCLC	LCL161 + paclitaxel	1315.3	23.6	11	492.2	5.4
X-4819	NSCLC	LEE011	348.5	26.5	0	0	0
X-4819	NSCLC	LEE011	1211.4	25	3	247.6	-5.7
X-4819	NSCLC	LEE011	1449.9	21.2	5	316	-20
X-4819	NSCLC	LGH447	261.2	25.2	0	0	0
X-4819	NSCLC	LGH447	485.4	26.3	3	85.8	4.4
X-4819	NSCLC	LGH447	781.2	23.8	6	199.1	-5.6
X-4819	NSCLC	LGH447	1137.1	23.1	10	335.3	-8.3
X-4819	NSCLC	LGH447	1213	23	11	364.4	-8.7
X-4819	NSCLC	LLM871	208	20.2	0	0	0
X-4819	NSCLC	LLM871	465.5	20.6	3	123.8	2
X-4819	NSCLC	LLM871	748.8	21.2	6	260	5
X-4819	NSCLC	LLM871	924	21.2	10	344.2	5
X-4819	NSCLC	binimetinib	231.7	21	0	0	0
X-4819	NSCLC	binimetinib	383.2	20.7	3	65.4	-1.4
X-4819	NSCLC	binimetinib	285.8	21	6	23.3	0
X-4819	NSCLC	binimetinib	253.9	21.3	10	9.6	1.4
X-4819	NSCLC	binimetinib	211.2	21.2	13	-8.8	1
X-4819	NSCLC	binimetinib	287.1	21.5	17	23.9	2.4
X-4819	NSCLC	binimetinib	339.8	22	20	46.7	4.8
X-4819	NSCLC	binimetinib	913.2	21.1	24	294.1	0.5
X-4819	NSCLC	binimetinib	1456.5	20.5	27	528.6	-2.4
X-4819	NSCLC	paclitaxel	160.4	24	0	0	0
X-4819	NSCLC	paclitaxel	354.8	24.8	3	121.2	3.3
X-4819	NSCLC	paclitaxel	917	25.7	6	471.7	7.1
X-4819	NSCLC	paclitaxel	1093.9	25.9	10	582	7.9
X-4819	NSCLC	paclitaxel	1321.7	25.6	11	724	6.7
X-4819	NSCLC	untreated	409.4	21.4	0	0	0
X-4819	NSCLC	untreated	892	21.5	3	117.9	0.5
X-4819	NSCLC	untreated	1446.7	20.7	5	253.4	-3.3
X-4819	NSCLC	LFW527 + binimetinib	322.57	21.6	0	0	0
X-4819	NSCLC	LFW527 + binimetinib	340.33	22.9	2	5.5	6
X-4819	NSCLC	LFW527 + binimetinib	685.63	23.3	6	112.6	7.9
X-4819	NSCLC	LFW527 + binimetinib	848.06	22.4	9	162.9	3.7
X-4819	NSCLC	LFW527 + binimetinib	1036.97	23	13	221.5	6.5
X-4819	NSCLC	LFW527 + binimetinib	1391.75	23.5	16	331.5	8.8
X-4819	NSCLC	LFW527 + binimetinib	2118.1	23.7	20	556.6	9.7
X-4819	NSCLC	LFW527 + binimetinib	2702.19	23	21	737.7	6.5
X-4824	BRCA	BGJ398	209.3	25.3	0	0	0
X-4824	BRCA	BGJ398	234.6	24.8	4	12.1	-2
X-4824	BRCA	BGJ398	269.3	25.5	7	28.7	0.8
X-4824	BRCA	BGJ398	356.5	25	11	70.3	-1.2
X-4824	BRCA	BGJ398	430.9	25.6	14	105.9	1.2
X-4824	BRCA	BGJ398	485.6	26.1	18	132	3.2
X-4824	BRCA	BGJ398	555.4	25.4	22	165.4	0.4
X-4824	BRCA	BGJ398	638.5	25.7	25	205.1	1.6
X-4824	BRCA	BGJ398	756.8	25.7	29	261.6	1.6
X-4824	BRCA	BGJ398	885.4	25.3	32	323	0
X-4824	BRCA	BGJ398	953.3	25	34	355.5	-1.2
X-4824	BRCA	BKM120	210.8	27.9	0	0	0
X-4824	BRCA	BKM120	213.8	27.6	4	1.4	-1.1
X-4824	BRCA	BKM120	218.5	27.6	7	3.7	-1.1
X-4824	BRCA	BKM120	215.4	27.5	11	2.2	-1.4
X-4824	BRCA	BKM120	223.4	28.4	14	6	1.8
X-4824	BRCA	BKM120	230.3	27.4	18	9.3	-1.8
X-4824	BRCA	BKM120	238	28.8	22	12.9	3.2
X-4824	BRCA	BKM120	214	28.4	25	1.5	1.8
X-4824	BRCA	BKM120	246	27.6	29	16.7	-1.1
X-4824	BRCA	BKM120	245.1	27.8	32	16.3	-0.4
X-4824	BRCA	BKM120	207	28.4	36	-1.8	1.8
X-4824	BRCA	BKM120	201.7	28.1	39	-4.3	0.7
X-4824	BRCA	BKM120	190.9	29.4	43	-9.4	5.4
X-4824	BRCA	BKM120	190	29.8	46	-9.9	6.8
X-4824	BRCA	BKM120	188.8	28.5	49	-10.4	2.2
X-4824	BRCA	BKM120	185.5	29.3	54	-12	5
X-4824	BRCA	BKM120	172.2	29.4	57	-18.3	5.4
X-4824	BRCA	BKM120	183.5	29.2	60	-13	4.7
X-4824	BRCA	BKM120	186.3	27.5	64	-11.6	-1.4
X-4824	BRCA	BKM120	153.9	28	68	-27	0.4
X-4824	BRCA	BKM120	173.3	28.5	71	-17.8	2.2
X-4824	BRCA	BKM120	156.6	28.5	77	-25.7	2.2
X-4824	BRCA	BKM120	171.6	29.5	83	-18.6	5.7
X-4824	BRCA	BKM120	167.1	28	88	-20.7	0.4
X-4824	BRCA	BYL719	211.7	27	0	0	0
X-4824	BRCA	BYL719	212.4	26.9	4	0.3	-0.4
X-4824	BRCA	BYL719	210.7	26	7	-0.5	-3.7
X-4824	BRCA	BYL719	223.9	26	11	5.8	-3.7
X-4824	BRCA	BYL719	248.4	26.3	14	17.3	-2.6
X-4824	BRCA	BYL719	254.6	26.9	18	20.3	-0.4
X-4824	BRCA	BYL719	250.6	26.5	22	18.4	-1.9
X-4824	BRCA	BYL719	308.5	26.4	25	45.7	-2.2
X-4824	BRCA	BYL719	332.9	25.9	29	57.3	-4.1
X-4824	BRCA	BYL719	340.2	25.3	32	60.7	-6.3
X-4824	BRCA	BYL719	365.4	25	36	72.6	-7.4
X-4824	BRCA	BYL719	379.9	25.1	39	79.5	-7
X-4824	BRCA	BYL719 + LEE011	209.9	26.1	0	0	0
X-4824	BRCA	BYL719 + LEE011	212.5	25.5	4	1.2	-2.3
X-4824	BRCA	BYL719 + LEE011	218.3	25.7	8	4	-1.5
X-4824	BRCA	BYL719 + LEE011	223.4	25.7	11	6.4	-1.5
X-4824	BRCA	BYL719 + LEE011	229.8	26.3	15	9.5	0.8
X-4824	BRCA	BYL719 + LEE011	244	24.8	18	16.2	-5
X-4824	BRCA	BYL719 + LEE011	231.6	24.1	22	10.3	-7.7
X-4824	BRCA	BYL719 + LEE011	184.2	22.6	25	-12.2	-13.4
X-4824	BRCA	BYL719 + LEE011	182.6	24.7	29	-13	-5.4
X-4824	BRCA	BYL719 + LEE011	181.6	26.4	32	-13.5	1.1
X-4824	BRCA	BYL719 + LEE011	144.1	22.3	35	-31.3	-14.6
X-4824	BRCA	BYL719 + LEE011	148.9	23.3	40	-29.1	-10.7
X-4824	BRCA	BYL719 + LEE011	140	23.6	43	-33.3	-9.6
X-4824	BRCA	BYL719 + LEE011	119.6	23.7	46	-43	-9.2
X-4824	BRCA	BYL719 + LEE011	77.1	19.8	50	-63.3	-24.1
X-4824	BRCA	BYL719 + LJM716	207.5	25.9	0	0	0
X-4824	BRCA	BYL719 + LJM716	238.1	25.8	4	14.7	-0.4
X-4824	BRCA	BYL719 + LJM716	232.7	25.1	8	12.1	-3.1
X-4824	BRCA	BYL719 + LJM716	236.1	24.8	11	13.8	-4.2
X-4824	BRCA	BYL719 + LJM716	230.2	24.2	15	10.9	-6.6
X-4824	BRCA	BYL719 + LJM716	246.5	24.2	18	18.8	-6.6
X-4824	BRCA	BYL719 + LJM716	247.8	24.7	22	19.4	-4.6
X-4824	BRCA	BYL719 + LJM716	252.3	24.8	25	21.6	-4.2
X-4824	BRCA	BYL719 + LJM716	252.9	25	29	21.9	-3.5
X-4824	BRCA	BYL719 + LJM716	260	24.6	32	25.3	-5
X-4824	BRCA	BYL719 + LJM716	282.5	23.6	35	36.1	-8.9
X-4824	BRCA	BYL719 + LJM716	323.5	23.8	40	55.9	-8.1
X-4824	BRCA	BYL719 + LJM716	341.2	23.9	43	64.4	-7.7
X-4824	BRCA	CGM097	210	28.2	0	0	0
X-4824	BRCA	CGM097	237.3	28	4	13	-0.7
X-4824	BRCA	CGM097	287.2	26.8	7	36.8	-5
X-4824	BRCA	CGM097	322.7	27.7	11	53.7	-1.8
X-4824	BRCA	CGM097	411.9	28.4	14	96.1	0.7
X-4824	BRCA	CGM097	471.5	28.9	18	124.5	2.5
X-4824	BRCA	CGM097	510.6	28.1	22	143.1	-0.4
X-4824	BRCA	CGM097	600.2	28.2	25	185.8	0
X-4824	BRCA	CGM097	711.2	28.8	29	238.7	2.1
X-4824	BRCA	CGM097	765.1	27.2	32	264.3	-3.5
X-4824	BRCA	CGM097	922.9	28.1	34	339.5	-0.4
X-4824	BRCA	CLR457	212.9	26.2	0	0	0
X-4824	BRCA	CLR457	207.9	24.6	5	-2.3	-6.1
X-4824	BRCA	CLR457	200.5	24.7	8	-5.8	-5.7
X-4824	BRCA	CLR457	192.3	25.5	12	-9.7	-2.7
X-4824	BRCA	CLR457	162.2	24.7	16	-23.8	-5.7
X-4824	BRCA	CLR457	150	24.4	19	-29.5	-6.9
X-4824	BRCA	CLR457	138.3	23	23	-35	-12.2
X-4824	BRCA	CLR457	123.8	22.3	26	-41.9	-14.9
X-4824	BRCA	CLR457	117.7	22.7	30	-44.7	-13.4
X-4824	BRCA	CLR457	113.4	22.4	33	-46.7	-14.5
X-4824	BRCA	CLR457	112.4	22.5	37	-47.2	-14.1
X-4824	BRCA	CLR457	97.1	22.7	40	-54.4	-13.4
X-4824	BRCA	CLR457	98.7	21.5	43	-53.6	-17.9
X-4824	BRCA	HDM201	233.6	25.7	0	0	0
X-4824	BRCA	HDM201	230.6	24.1	3	-1.3	-6.2
X-4824	BRCA	HDM201	275.4	24.9	6	17.9	-3.1
X-4824	BRCA	HDM201	312.4	25.3	10	33.7	-1.6
X-4824	BRCA	HDM201	370.8	24.5	13	58.7	-4.7
X-4824	BRCA	HDM201	427.2	26.2	17	82.9	1.9
X-4824	BRCA	HDM201	556	26.4	20	138	2.7
X-4824	BRCA	HDM201	610.6	25	24	161.4	-2.7
X-4824	BRCA	HDM201	697.9	24.6	28	198.8	-4.3
X-4824	BRCA	HDM201	803.3	24.7	31	243.9	-3.9
X-4824	BRCA	HDM201	884.4	23.9	35	278.6	-7
X-4824	BRCA	HDM201	1113.5	24.1	38	376.7	-6.2
X-4824	BRCA	HDM201	1120.9	24.4	40	379.8	-5.1
X-4824	BRCA	INC424	220.3	27	0	0	0
X-4824	BRCA	INC424	322.5	25.9	5	46.4	-4.1
X-4824	BRCA	INC424	350.2	26.4	8	59	-2.2
X-4824	BRCA	INC424	353.7	27.7	12	60.6	2.6
X-4824	BRCA	INC424	374.8	26.9	16	70.1	-0.4
X-4824	BRCA	INC424	381	27.3	19	72.9	1.1
X-4824	BRCA	INC424	387.1	26.9	23	75.7	-0.4
X-4824	BRCA	INC424	404.6	26.4	26	83.7	-2.2
X-4824	BRCA	INC424	423.6	27.4	30	92.3	1.5
X-4824	BRCA	INC424	437.9	27.2	33	98.8	0.7
X-4824	BRCA	LEE011 + everolimus	214.9	22.2	0	0	0
X-4824	BRCA	LEE011 + everolimus	220.3	20.6	3	2.5	-7.2
X-4824	BRCA	LEE011 + everolimus	218.4	20.5	6	1.6	-7.7
X-4824	BRCA	LEE011 + everolimus	204.6	21.4	10	-4.8	-3.6
X-4824	BRCA	LEE011 + everolimus	170.4	22	13	-20.7	-0.9
X-4824	BRCA	LEE011 + everolimus	142.7	22.3	17	-33.6	0.5
X-4824	BRCA	LEE011 + everolimus	131.7	23.9	24	-38.7	7.7
X-4824	BRCA	LEE011 + everolimus	126.4	23.6	28	-41.2	6.3
X-4824	BRCA	LEE011 + everolimus	116.8	22.8	31	-45.6	2.7
X-4824	BRCA	LEE011 + everolimus	121.4	23.6	35	-43.5	6.3
X-4824	BRCA	LEE011 + everolimus	130.6	22.7	38	-39.2	2.3
X-4824	BRCA	LEE011 + everolimus	114.2	23.4	42	-46.9	5.4
X-4824	BRCA	LEE011 + everolimus	94.5	23.2	45	-56	4.5
X-4824	BRCA	LEE011 + everolimus	86.4	24.3	49	-59.8	9.5
X-4824	BRCA	LEE011 + everolimus	102.4	24.7	52	-52.3	11.3
X-4824	BRCA	LEE011 + everolimus	98.8	23.4	55	-54	5.4
X-4824	BRCA	LEE011 + everolimus	93.4	22.1	60	-56.5	-0.5
X-4824	BRCA	LEE011 + everolimus	87.1	22.6	63	-59.5	1.8
X-4824	BRCA	LEE011 + everolimus	73.7	21.7	66	-65.7	-2.3
X-4824	BRCA	LEE011 + everolimus	75.3	22.8	70	-65	2.7
X-4824	BRCA	LEE011 + everolimus	61.3	24.4	74	-71.5	9.9
X-4824	BRCA	LEE011 + everolimus	57.6	24.9	77	-73.2	12.2
X-4824	BRCA	LEE011 + everolimus	60.4	23.3	83	-71.9	5
X-4824	BRCA	LEE011 + everolimus	36.5	23.7	89	-83	6.8
X-4824	BRCA	LEE011 + everolimus	34.3	24.3	94	-84	9.5
X-4824	BRCA	LEE011	209.3	25.4	0	0	0
X-4824	BRCA	LEE011	238.4	23.9	4	13.9	-5.9
X-4824	BRCA	LEE011	256	23.6	7	22.3	-7.1
X-4824	BRCA	LEE011	279.5	24.2	11	33.5	-4.7
X-4824	BRCA	LEE011	284.4	24.2	15	35.9	-4.7
X-4824	BRCA	LEE011	340.6	24.1	18	62.7	-5.1
X-4824	BRCA	LEE011	387.3	24	22	85	-5.5
X-4824	BRCA	LEE011	388.8	22.8	25	85.8	-10.2
X-4824	BRCA	LEE011	405	22.9	29	93.5	-9.8
X-4824	BRCA	LEE011	407.2	23.5	32	94.6	-7.5
X-4824	BRCA	LEE011	425.2	22.8	34	103.2	-10.2
X-4824	BRCA	LFA102	212.5	25.4	0	0	0
X-4824	BRCA	LFA102	228.7	26.2	4	7.6	3.1
X-4824	BRCA	LFA102	262.5	25.6	7	23.5	0.8
X-4824	BRCA	LFA102	306.3	22.3	11	44.1	-12.2
X-4824	BRCA	LFA102	316.5	27.1	14	48.9	6.7
X-4824	BRCA	LFA102	326.5	25.6	18	53.6	0.8
X-4824	BRCA	LFA102	361.1	25.9	21	69.9	2
X-4824	BRCA	LFA102	380.2	27	24	78.9	6.3
X-4824	BRCA	LFA102	426.2	25.8	29	100.6	1.6
X-4824	BRCA	LFA102	447.6	26.4	32	110.6	3.9
X-4824	BRCA	LFA102	483.1	26.9	35	127.3	5.9
X-4824	BRCA	LJM716	212.9	24.1	0	0	0
X-4824	BRCA	LJM716	226.8	23.9	2	6.5	-0.8
X-4824	BRCA	LJM716	233.8	24	5	9.8	-0.4
X-4824	BRCA	LJM716	251	23.5	9	17.9	-2.5
X-4824	BRCA	LJM716	254.3	22.1	12	19.4	-8.3
X-4824	BRCA	LJM716	269.6	23.4	16	26.6	-2.9
X-4824	BRCA	LJM716	293.7	23.1	19	38	-4.1
X-4824	BRCA	LJM716	320.8	23.5	23	50.7	-2.5
X-4824	BRCA	LJM716	333.2	23.5	29	56.5	-2.5
X-4824	BRCA	LJM716	412.1	23	34	93.6	-4.6
X-4824	BRCA	LJM716	442	22.9	37	107.6	-5
X-4824	BRCA	LJM716 + trastuzumab	210.8	27.5	0	0	0
X-4824	BRCA	LJM716 + trastuzumab	207.7	26.8	4	-1.5	-2.5
X-4824	BRCA	LJM716 + trastuzumab	197.3	26.5	7	-6.4	-3.6
X-4824	BRCA	LJM716 + trastuzumab	196.1	27.9	11	-7	1.5
X-4824	BRCA	LJM716 + trastuzumab	195	27.6	14	-7.5	0.4
X-4824	BRCA	LJM716 + trastuzumab	190.9	28.4	18	-9.4	3.3
X-4824	BRCA	LJM716 + trastuzumab	187.1	28.6	21	-11.2	4
X-4824	BRCA	LJM716 + trastuzumab	185.1	28	24	-12.2	1.8
X-4824	BRCA	LJM716 + trastuzumab	190.4	27.5	29	-9.7	0
X-4824	BRCA	LJM716 + trastuzumab	168.2	29	32	-20.2	5.5
X-4824	BRCA	LJM716 + trastuzumab	197.7	28	35	-6.2	1.8
X-4824	BRCA	LJM716 + trastuzumab	202	27.4	39	-4.2	-0.4
X-4824	BRCA	LJM716 + trastuzumab	183.5	28.2	43	-13	2.5
X-4824	BRCA	LJM716 + trastuzumab	185.2	26.7	46	-12.1	-2.9
X-4824	BRCA	LJM716 + trastuzumab	184.4	26.8	52	-12.5	-2.5
X-4824	BRCA	LJM716 + trastuzumab	184.9	27.1	58	-12.3	-1.5
X-4824	BRCA	LJM716 + trastuzumab	151.8	27.1	63	-28	-1.5
X-4824	BRCA	LJM716 + trastuzumab	154	27.3	71	-26.9	-0.7
X-4824	BRCA	LJM716 + trastuzumab	150	27	75	-28.8	-1.8
X-4824	BRCA	LJM716 + trastuzumab	157.5	27	81	-25.3	-1.8
X-4824	BRCA	LJM716 + trastuzumab	158.9	27.1	92	-24.6	-1.5
X-4824	BRCA	LKA136	206.7	26.6	0	0	0
X-4824	BRCA	LKA136	257.3	26.6	5	24.5	0
X-4824	BRCA	LKA136	304.7	27.8	8	47.4	4.5
X-4824	BRCA	LKA136	317.5	27.2	12	53.6	2.3
X-4824	BRCA	LKA136	360.1	26.5	16	74.2	-0.4
X-4824	BRCA	LKA136	433.8	26.6	19	109.9	0
X-4824	BRCA	LKA136	520.8	26.9	23	152	1.1
X-4824	BRCA	LKA136	561.8	26.8	26	171.8	0.8
X-4824	BRCA	LKA136	613.3	27.5	30	196.7	3.4
X-4824	BRCA	LKA136	734.9	27.5	33	255.5	3.4
X-4824	BRCA	LLM871	215.5	28.2	0	0	0
X-4824	BRCA	LLM871	284.4	27	3	32	-4.3
X-4824	BRCA	LLM871	290.9	27.5	7	35	-2.5
X-4824	BRCA	LLM871	311.7	27.2	11	44.6	-3.5
X-4824	BRCA	LLM871	348.6	27	14	61.8	-4.3
X-4824	BRCA	LLM871	351.6	26.2	18	63.2	-7.1
X-4824	BRCA	LLM871	344.7	26.7	21	60	-5.3
X-4824	BRCA	LLM871	380.3	27.5	25	76.5	-2.5
X-4824	BRCA	LLM871	377.5	27.8	28	75.2	-1.4
X-4824	BRCA	LLM871	385.1	27.4	32	78.7	-2.8
X-4824	BRCA	LLM871	396.7	28.3	35	84.1	0.4
X-4824	BRCA	binimetinib	212.3	26.9	0	0	0
X-4824	BRCA	binimetinib	219.2	26.1	3	3.3	-3
X-4824	BRCA	binimetinib	228.2	26	6	7.5	-3.3
X-4824	BRCA	binimetinib	242.7	26.5	10	14.3	-1.5
X-4824	BRCA	binimetinib	264.8	26.5	13	24.7	-1.5
X-4824	BRCA	binimetinib	245.3	26.9	17	15.5	0
X-4824	BRCA	binimetinib	260	27.1	20	22.5	0.7
X-4824	BRCA	binimetinib	247.2	27.1	24	16.4	0.7
X-4824	BRCA	binimetinib	251	26.7	28	18.2	-0.7
X-4824	BRCA	binimetinib	263.1	25.7	31	23.9	-4.5
X-4824	BRCA	binimetinib	223.6	25.6	35	5.3	-4.8
X-4824	BRCA	binimetinib	216.3	24.6	38	1.9	-8.6
X-4824	BRCA	binimetinib	237.4	23.6	42	11.8	-12.3
X-4824	BRCA	binimetinib	233.6	24.7	45	10	-8.2
X-4824	BRCA	paclitaxel	212.3	28.9	0	0	0
X-4824	BRCA	paclitaxel	249.3	29.4	3	17.4	1.7
X-4824	BRCA	paclitaxel	326.6	30.4	7	53.8	5.2
X-4824	BRCA	paclitaxel	365.7	29.8	11	72.3	3.1
X-4824	BRCA	paclitaxel	402.6	29.7	14	89.6	2.8
X-4824	BRCA	paclitaxel	424.3	28.9	18	99.9	0
X-4824	BRCA	paclitaxel	476.1	29.1	21	124.3	0.7
X-4824	BRCA	paclitaxel	496.6	30.6	25	133.9	5.9
X-4824	BRCA	paclitaxel	523.9	29.3	28	146.8	1.4
X-4824	BRCA	paclitaxel	621.2	28.3	32	192.6	-2.1
X-4824	BRCA	paclitaxel	646.2	31.2	35	204.4	8
X-4824	BRCA	tamoxifen	205.9	24	0	0	0
X-4824	BRCA	tamoxifen	213.9	24.7	2	3.9	2.9
X-4824	BRCA	tamoxifen	249.8	25.5	6	21.3	6.2
X-4824	BRCA	tamoxifen	294.4	25.4	10	43	5.8
X-4824	BRCA	tamoxifen	472.4	24.9	17	129.4	3.7
X-4824	BRCA	tamoxifen	559.5	24.2	20	171.7	0.8
X-4824	BRCA	tamoxifen	697.1	27.1	24	238.6	12.9
X-4824	BRCA	tamoxifen	754.4	24.3	27	266.4	1.2
X-4824	BRCA	tamoxifen	782.6	23.4	31	280.1	-2.5
X-4824	BRCA	tamoxifen	823.5	23.6	34	300	-1.7
X-4824	BRCA	trastuzumab	226.7	26.9	0	0	0
X-4824	BRCA	trastuzumab	279.4	26.5	4	23.2	-1.5
X-4824	BRCA	trastuzumab	308.4	26.7	7	36	-0.7
X-4824	BRCA	trastuzumab	353.2	27.1	11	55.8	0.7
X-4824	BRCA	trastuzumab	371.8	26.3	14	64	-2.2
X-4824	BRCA	trastuzumab	485.9	25.9	18	114.3	-3.7
X-4824	BRCA	trastuzumab	537.4	25.4	21	137.1	-5.6
X-4824	BRCA	untreated	220.8	26.2	0	0	0
X-4824	BRCA	untreated	261.7	26.5	4	18.5	1.1
X-4824	BRCA	untreated	352.3	27	8	59.6	3.1
X-4824	BRCA	untreated	395.4	26.4	11	79.1	0.8
X-4824	BRCA	untreated	468.9	27	14	112.4	3.1
X-4824	BRCA	untreated	532.7	27	18	141.3	3.1
X-4824	BRCA	untreated	660.1	26.6	21	199	1.5
X-4824	BRCA	untreated	830.1	24.4	25	276	-6.9
X-4824	BRCA	untreated	1098.9	27.7	28	397.7	5.7
X-4824	BRCA	untreated	1146.6	27.1	32	419.3	3.4
X-4824	BRCA	untreated	1312.8	26.9	34	494.6	2.7
X-4832	CM	BKM120	191.1	24.2	0	0	0
X-4832	CM	BKM120	384.6	23.5	6	101.3	-2.9
X-4832	CM	BKM120	316.4	22.2	9	65.6	-8.3
X-4832	CM	BKM120	800.9	22.8	14	319.1	-5.8
X-4832	CM	BKM120 + encorafenib	207.1	22.8	0	0	0
X-4832	CM	BKM120 + encorafenib	301.2	21.7	3	45.4	-4.8
X-4832	CM	BKM120 + encorafenib	359.7	21.2	8	73.7	-7
X-4832	CM	BKM120 + encorafenib	484.4	19.3	11	133.9	-15.4
X-4832	CM	BKM120 + encorafenib	437.1	19.2	14	111.1	-15.8
X-4832	CM	CGM097	211.3	22.9	0	0	0
X-4832	CM	CGM097	262.2	20	6	24.1	-12.7
X-4832	CM	CGM097	223.4	20.4	9	5.8	-10.9
X-4832	CM	CGM097	167.9	18.9	14	-20.5	-17.5
X-4832	CM	dacarbazine	231.8	20.2	0	0	0
X-4832	CM	dacarbazine	230.7	17.5	3	-0.5	-13.4
X-4832	CM	dacarbazine	230.7	16.6	4	-0.5	-17.8
X-4832	CM	LDE225	214.3	23	0	0	0
X-4832	CM	LDE225	451.2	21.4	4	110.6	-7
X-4832	CM	LDE225	834	19	7	289.3	-17.4
X-4832	CM	LDK378	191.1	22.8	0	0	0
X-4832	CM	LDK378	289.1	22.1	3	51.3	-3.1
X-4832	CM	LDK378	436.8	19.7	6	128.6	-13.6
X-4832	CM	LEE011	203.4	23.1	0	0	0
X-4832	CM	LEE011	477.4	21.2	6	134.7	-8.2
X-4832	CM	LEE011	537.9	19	9	164.5	-17.7
X-4832	CM	LEE011 + encorafenib	213.2	26	0	0	0
X-4832	CM	LEE011 + encorafenib	327.2	24.2	3	53.5	-6.9
X-4832	CM	LEE011 + encorafenib	351	21.8	8	64.7	-16.2
X-4832	CM	LEE011 + encorafenib	389.2	23	11	82.6	-11.5
X-4832	CM	LEE011 + encorafenib	344.5	23.4	15	61.6	-10
X-4832	CM	LEE011 + encorafenib	318.3	24	18	49.3	-7.7
X-4832	CM	LEE011 + encorafenib	321.5	24	22	50.8	-7.7
X-4832	CM	WNT974	224.3	21.4	0	0	0
X-4832	CM	WNT974	298.1	19.4	3	32.9	-9.3
X-4832	CM	WNT974	515	19	8	129.6	-11.2
X-4832	CM	WNT974	681.9	19.1	11	204.1	-10.7
X-4832	CM	WNT974	725	17.8	13	223.3	-16.8
X-4832	CM	WNT974	725	17.3	14	223.3	-19.2
X-4832	CM	LGW813	294	20	0	0	0
X-4832	CM	LGW813	415.9	19.3	4	41.5	-3.5
X-4832	CM	LGW813	462.4	17.8	7	57.3	-11
X-4832	CM	LGW813	931	19.2	12	216.7	-4
X-4832	CM	LGW813	926.8	18.3	15	215.2	-8.5
X-4832	CM	LGW813	885.6	17	19	201.2	-15
X-4832	CM	encorafenib	229.4	21	0	0	0
X-4832	CM	encorafenib	795.7	19.6	6	246.9	-6.7
X-4832	CM	encorafenib	1159.2	20.2	9	405.4	-3.8
X-4832	CM	encorafenib	1705.2	19.4	14	643.4	-7.6
X-4832	CM	encorafenib + binimetinib	238.1	22.6	0	0	0
X-4832	CM	encorafenib + binimetinib	321.2	21	3	34.9	-7.1
X-4832	CM	encorafenib + binimetinib	383.8	22.8	8	61.2	0.9
X-4832	CM	encorafenib + binimetinib	574.3	21	11	141.3	-7.1
X-4832	CM	encorafenib + binimetinib	579.7	21.2	15	143.5	-6.2
X-4832	CM	encorafenib + binimetinib	645	21.9	18	171	-3.1
X-4832	CM	encorafenib + binimetinib	743.9	22	22	212.5	-2.7
X-4832	CM	binimetinib	235.5	23.7	0	0	0
X-4832	CM	binimetinib	361.6	23.4	6	53.6	-1.3
X-4832	CM	binimetinib	386.6	22.1	9	64.2	-6.8
X-4832	CM	binimetinib	612.6	22.8	14	160.1	-3.8
X-4832	CM	binimetinib	744.2	22.3	17	216	-5.9
X-4832	CM	binimetinib	915.1	23.9	21	288.6	0.8
X-4832	CM	TAS266	206.7	23	0	0	0
X-4832	CM	TAS266	249.2	22.4	6	20.6	-2.6
X-4832	CM	TAS266	328.5	22.1	9	59	-3.9
X-4832	CM	TAS266	718.8	21.4	14	247.8	-7
X-4832	CM	TAS266	758.2	20.1	17	266.8	-12.6
X-4832	CM	TAS266	1216.8	21.1	21	488.7	-8.3
X-4832	CM	untreated	252.5	21.4	0	0	0
X-4832	CM	untreated	928.3	20	6	267.6	-6.5
X-4832	CM	untreated	1241.9	20.4	9	391.9	-4.7
X-4832	CM	untreated	1510.9	19.4	14	498.4	-9.3
X-4849	CM	BKM120	228.3	24.7	0	0	0
X-4849	CM	BKM120	299.8	24.2	3	31.3	-2
X-4849	CM	BKM120	396.9	23.4	6	73.8	-5.3
X-4849	CM	BKM120	492.6	22.1	9	115.7	-10.5
X-4849	CM	BKM120	490.5	21.1	13	114.8	-14.6
X-4849	CM	BKM120	541.3	21.5	16	137.1	-13
X-4849	CM	BKM120	612.6	20.5	20	168.3	-17
X-4849	CM	BKM120 + encorafenib	214.2	22.9	0	0	0
X-4849	CM	BKM120 + encorafenib	253.7	23.6	3	18.4	3.1
X-4849	CM	BKM120 + encorafenib	245.5	23.1	7	14.6	0.9
X-4849	CM	BKM120 + encorafenib	196.6	22.6	10	-8.2	-1.3
X-4849	CM	BKM120 + encorafenib	195.7	23.2	14	-8.6	1.3
X-4849	CM	BKM120 + encorafenib	164.9	22.7	17	-23	-0.9
X-4849	CM	BKM120 + encorafenib	187.3	22.5	21	-12.6	-1.7
X-4849	CM	BKM120 + encorafenib	139.1	23.4	24	-35.1	2.2
X-4849	CM	BKM120 + encorafenib	141.1	23.4	28	-34.2	2.2
X-4849	CM	BKM120 + encorafenib	146.5	23.1	31	-31.6	0.9
X-4849	CM	BKM120 + encorafenib	147.3	24.3	35	-31.2	6.1
X-4849	CM	BKM120 + encorafenib	117.6	23.3	38	-45.1	1.7
X-4849	CM	BKM120 + encorafenib	136.6	24	43	-36.2	4.8
X-4849	CM	BKM120 + encorafenib	137.3	24.2	46	-35.9	5.7
X-4849	CM	BKM120 + encorafenib	170.1	24.4	50	-20.6	6.6
X-4849	CM	BKM120 + encorafenib	149.8	24.6	53	-30.1	7.4
X-4849	CM	BKM120 + encorafenib	173.9	23.8	56	-18.8	3.9
X-4849	CM	BKM120 + encorafenib	144	24.6	59	-32.8	7.4
X-4849	CM	BKM120 + encorafenib	119.7	23	63	-44.1	0.4
X-4849	CM	BKM120 + encorafenib	123.6	23.2	66	-42.3	1.3
X-4849	CM	BKM120 + encorafenib	160.9	23.5	70	-24.9	2.6
X-4849	CM	BKM120 + encorafenib	111.9	24.4	73	-47.8	6.6
X-4849	CM	BKM120 + encorafenib	102.9	24.4	77	-52	6.6
X-4849	CM	BKM120 + encorafenib	109.4	24.5	80	-48.9	7
X-4849	CM	BKM120 + encorafenib	94.2	24.1	84	-56	5.2
X-4849	CM	BKM120 + encorafenib	83.2	24.4	87	-61.1	6.6
X-4849	CM	BKM120 + encorafenib	105.9	24.9	91	-50.6	8.7
X-4849	CM	BKM120 + encorafenib	90.5	24.3	94	-57.7	6.1
X-4849	CM	BKM120 + encorafenib	121.7	24.5	98	-43.2	7
X-4849	CM	BKM120 + encorafenib	96.5	24.4	101	-54.9	6.6
X-4849	CM	BKM120 + encorafenib	86	23.8	105	-59.9	3.9
X-4849	CM	BKM120 + encorafenib	93.9	24.3	108	-56.2	6.1
X-4849	CM	BKM120 + encorafenib	84.3	23.4	112	-60.7	2.2
X-4849	CM	BKM120 + encorafenib	68.8	24.6	117	-67.9	7.4
X-4849	CM	BKM120 + encorafenib	78.4	23.4	124	-63.4	2.2
X-4849	CM	BKM120 + encorafenib	80.1	24.6	131	-62.6	7.4
X-4849	CM	BKM120 + encorafenib	64.8	23	138	-69.7	0.4
X-4849	CM	BKM120 + encorafenib	57.1	22.9	144	-73.3	0
X-4849	CM	BKM120 + encorafenib	73.8	22.6	151	-65.6	-1.3
X-4849	CM	BKM120 + encorafenib	60.8	24	157	-71.6	4.8
X-4849	CM	BKM120 + encorafenib	67.5	23.6	163	-68.5	3.1
X-4849	CM	BKM120 + encorafenib	55.2	25.5	170	-74.2	11.4
X-4849	CM	BKM120 + encorafenib	68.8	25.8	177	-67.9	12.7
X-4849	CM	BKM120 + encorafenib	59.9	25.8	187	-72	12.7
X-4849	CM	BKM120 + encorafenib	63.4	26.5	193	-70.4	15.7
X-4849	CM	BKM120 + encorafenib	68.8	25.6	200	-67.9	11.8
X-4849	CM	BKM120 + encorafenib	57.6	25.6	203	-73.1	11.8
X-4849	CM	BKM120 + encorafenib	54.1	25.6	209	-74.7	11.8
X-4849	CM	BKM120 + encorafenib	55.2	26	210	-74.2	13.5
X-4849	CM	BKM120 + encorafenib	46.2	25	217	-78.4	9.2
X-4849	CM	BKM120 + encorafenib	46.2	26.1	224	-78.4	14
X-4849	CM	BKM120 + encorafenib	57.4	26.5	231	-73.2	15.7
X-4849	CM	BKM120 + encorafenib	51.3	24.9	237	-76.1	8.7
X-4849	CM	CGM097	221.8	24.8	0	0	0
X-4849	CM	CGM097	235.9	23.9	7	6.3	-3.6
X-4849	CM	CGM097	263.1	23.2	11	18.6	-6.5
X-4849	CM	CGM097	283.9	21.2	15	28	-14.5
X-4849	CM	CGM097	310.1	21.2	18	39.8	-14.5
X-4849	CM	CGM097	320	21.2	21	44.3	-14.5
X-4849	CM	CGM097	390.8	20.6	24	76.2	-16.9
X-4849	CM	CLR457	193.3	25.5	0	0	0
X-4849	CM	CLR457	221.3	24.5	4	14.5	-3.9
X-4849	CM	CLR457	225	23.4	7	16.4	-8.2
X-4849	CM	CLR457	352.1	22.8	12	82.1	-10.6
X-4849	CM	CLR457	554.9	24.6	15	187	-3.5
X-4849	CM	CLR457	485.8	21.8	19	151.2	-14.5
X-4849	CM	CLR457	496.4	23.1	20	156.7	-9.4
X-4849	CM	CLR457	746.8	22.4	22	286.3	-12.2
X-4849	CM	CLR457	710.5	21.9	25	267.5	-14.1
X-4849	CM	CLR457	760.5	21.1	27	293.3	-17.3
X-4849	CM	dacarbazine	192.9	24.5	0	0	0
X-4849	CM	dacarbazine	218.6	23.6	4	13.3	-3.7
X-4849	CM	dacarbazine	292.7	21.8	7	51.8	-11
X-4849	CM	dacarbazine	389.2	21.8	11	101.8	-11
X-4849	CM	dacarbazine	495.4	20.9	14	156.9	-14.7
X-4849	CM	dacarbazine	523.8	22.9	18	171.6	-6.5
X-4849	CM	dacarbazine	622.7	22.7	21	222.9	-7.3
X-4849	CM	dacarbazine	709	22.6	25	267.6	-7.8
X-4849	CM	LDE225	207.2	27.3	0	0	0
X-4849	CM	LDE225	222.1	24.7	3	7.2	-9.5
X-4849	CM	LDE225	264.3	22.9	6	27.6	-16.1
X-4849	CM	LDE225	274.3	20.8	9	32.4	-23.8
X-4849	CM	LDK378	204	29.8	0	0	0
X-4849	CM	LDK378	235.1	28.4	3	15.3	-4.7
X-4849	CM	LDK378	427.2	29.3	7	109.4	-1.7
X-4849	CM	LDK378	413	28.9	10	102.5	-3
X-4849	CM	LDK378	596.7	28	14	192.5	-6
X-4849	CM	LDK378	647.9	27.2	17	217.6	-8.7
X-4849	CM	LDK378	913	26.5	21	347.6	-11.1
X-4849	CM	LDK378	1014.7	26.1	24	397.5	-12.4
X-4849	CM	LEE011	245.6	24.4	0	0	0
X-4849	CM	LEE011	301.9	23.8	4	22.9	-2.5
X-4849	CM	LEE011	391.9	23.1	7	59.6	-5.3
X-4849	CM	LEE011	348.1	23.5	10	41.8	-3.7
X-4849	CM	LEE011	410.9	22.9	13	67.3	-6.1
X-4849	CM	LEE011	382.4	23.3	17	55.7	-4.5
X-4849	CM	LEE011	433.9	24.1	20	76.7	-1.2
X-4849	CM	LEE011	424.2	24	24	72.7	-1.6
X-4849	CM	LEE011 + encorafenib	222.5	23.8	0	0	0
X-4849	CM	LEE011 + encorafenib	172.7	23.2	4	-22.4	-2.5
X-4849	CM	LEE011 + encorafenib	177.1	22.4	7	-20.4	-5.9
X-4849	CM	LEE011 + encorafenib	158	23.6	11	-29	-0.8
X-4849	CM	LEE011 + encorafenib	223.5	23.3	14	0.4	-2.1
X-4849	CM	LEE011 + encorafenib	178.8	24.7	18	-19.6	3.8
X-4849	CM	LEE011 + encorafenib	215.2	24.3	21	-3.3	2.1
X-4849	CM	LEE011 + encorafenib	216.9	23.9	25	-2.5	0.4
X-4849	CM	LEE011 + encorafenib	208.1	24.6	28	-6.5	3.4
X-4849	CM	LEE011 + encorafenib	164.7	25.7	32	-26	8
X-4849	CM	LEE011 + encorafenib	171.4	24.1	35	-23	1.3
X-4849	CM	LEE011 + encorafenib	169.1	24.8	40	-24	4.2
X-4849	CM	LEE011 + encorafenib	252	25.2	43	13.2	5.9
X-4849	CM	LEE011 + encorafenib	202.3	24.8	47	-9.1	4.2
X-4849	CM	LEE011 + encorafenib	262	25.6	50	17.7	7.6
X-4849	CM	LEE011 + encorafenib	217.8	24.1	53	-2.1	1.3
X-4849	CM	LEE011 + encorafenib	247.9	26	56	11.4	9.2
X-4849	CM	LEE011 + encorafenib	230.6	23.8	60	3.6	0
X-4849	CM	LEE011 + encorafenib	254.4	24.3	63	14.3	2.1
X-4849	CM	LEE011 + encorafenib	277.5	24	67	24.7	0.8
X-4849	CM	LEE011 + encorafenib	262.3	24.3	70	17.9	2.1
X-4849	CM	LEE011 + encorafenib	348	23.8	74	56.4	0
X-4849	CM	LEE011 + encorafenib	332.6	24.4	77	49.5	2.5
X-4849	CM	LEE011 + binimetinib	200.2	23	0	0	0
X-4849	CM	LEE011 + binimetinib	149.9	23	3	-25.1	0
X-4849	CM	LEE011 + binimetinib	144.6	22	7	-27.8	-4.3
X-4849	CM	LEE011 + binimetinib	128	21.6	10	-36.1	-6.1
X-4849	CM	LEE011 + binimetinib	117.4	22.3	13	-41.3	-3
X-4849	CM	LEE011 + binimetinib	129.3	24	16	-35.4	4.3
X-4849	CM	LEE011 + binimetinib	143.8	23.3	20	-28.2	1.3
X-4849	CM	LEE011 + binimetinib	168.3	23.3	23	-15.9	1.3
X-4849	CM	LEE011 + binimetinib	204.9	23.2	27	2.4	0.9
X-4849	CM	LEE011 + binimetinib	157.9	23.4	30	-21.1	1.7
X-4849	CM	LEE011 + binimetinib	122.1	23.4	34	-39	1.7
X-4849	CM	LEE011 + binimetinib	158.9	23.4	37	-20.6	1.7
X-4849	CM	LEE011 + binimetinib	168.9	22.9	41	-15.6	-0.4
X-4849	CM	LEE011 + binimetinib	175	24.1	44	-12.6	4.8
X-4849	CM	LEE011 + binimetinib	215.7	23.8	48	7.8	3.5
X-4849	CM	LEE011 + binimetinib	229.3	23.5	51	14.6	2.2
X-4849	CM	LEE011 + binimetinib	394.4	23.6	55	97	2.6
X-4849	CM	LEE011 + binimetinib	337.4	23.9	58	68.6	3.9
X-4849	CM	LEE011 + binimetinib	353.7	26.3	62	76.7	14.3
X-4849	CM	LEE011 + binimetinib	427.1	21.9	65	113.4	-4.8
X-4849	CM	WNT974	213.9	24.9	0	0	0
X-4849	CM	WNT974	233.6	23.1	3	9.2	-7.2
X-4849	CM	WNT974	510.2	22.7	7	138.5	-8.8
X-4849	CM	WNT974	803.5	22.5	10	275.6	-9.6
X-4849	CM	WNT974	900	20.9	14	320.7	-16.1
X-4849	CM	WNT974	1135.2	19.9	15	430.7	-20.1
X-4849	CM	LGW813	218.3	22.7	0	0	0
X-4849	CM	LGW813	337.4	21	3	54.6	-7.5
X-4849	CM	LGW813	404.9	20.1	6	85.5	-11.5
X-4849	CM	LGW813	412.6	19.3	9	89	-15
X-4849	CM	LGW813	640.7	18.9	13	193.5	-16.7
X-4849	CM	encorafenib	206.8	26.5	0	0	0
X-4849	CM	encorafenib	253.4	27.2	3	22.5	2.6
X-4849	CM	encorafenib	312	25.6	7	50.8	-3.4
X-4849	CM	encorafenib	416.7	25.8	11	101.5	-2.6
X-4849	CM	encorafenib	531.5	26.4	14	157	-0.4
X-4849	CM	encorafenib	727.4	25.9	17	251.7	-2.3
X-4849	CM	encorafenib	761.4	24.9	20	268.1	-6
X-4849	CM	encorafenib	830.3	24.9	24	301.5	-6
X-4849	CM	encorafenib + binimetinib	209.3	22.3	0	0	0
X-4849	CM	encorafenib + binimetinib	247.8	22.4	4	18.4	0.4
X-4849	CM	encorafenib + binimetinib	218.3	22.4	7	4.3	0.4
X-4849	CM	encorafenib + binimetinib	243	22.9	11	16.1	2.7
X-4849	CM	encorafenib + binimetinib	252.5	22.9	14	20.7	2.7
X-4849	CM	encorafenib + binimetinib	245.5	23.2	18	17.3	4
X-4849	CM	encorafenib + binimetinib	197.8	22.5	21	-5.5	0.9
X-4849	CM	encorafenib + binimetinib	217.8	22.4	25	4.1	0.4
X-4849	CM	encorafenib + binimetinib	191.6	22.4	28	-8.4	0.4
X-4849	CM	encorafenib + binimetinib	205.5	23.6	32	-1.8	5.8
X-4849	CM	encorafenib + binimetinib	193.4	22.9	35	-7.6	2.7
X-4849	CM	encorafenib + binimetinib	219.1	23.5	40	4.7	5.4
X-4849	CM	encorafenib + binimetinib	215.5	23.3	43	3	4.5
X-4849	CM	encorafenib + binimetinib	214.7	23.2	47	2.6	4
X-4849	CM	encorafenib + binimetinib	234.1	24.2	50	11.9	8.5
X-4849	CM	encorafenib + binimetinib	264.4	23.2	53	26.4	4
X-4849	CM	encorafenib + binimetinib	259.5	24.1	56	24	8.1
X-4849	CM	encorafenib + binimetinib	230	23.2	60	9.9	4
X-4849	CM	encorafenib + binimetinib	269	23.1	63	28.6	3.6
X-4849	CM	encorafenib + binimetinib	308.8	22.9	67	47.6	2.7
X-4849	CM	encorafenib + binimetinib	356.2	23.8	70	70.2	6.7
X-4849	CM	encorafenib + binimetinib	318.5	23	74	52.2	3.1
X-4849	CM	encorafenib + binimetinib	315.1	23.7	77	50.6	6.3
X-4849	CM	binimetinib	234.8	21.1	0	0	0
X-4849	CM	binimetinib	288.5	20.8	4	22.9	-1.4
X-4849	CM	binimetinib	289.1	21.2	7	23.2	0.5
X-4849	CM	binimetinib	383.8	21.1	10	63.5	0
X-4849	CM	binimetinib	322.8	20.6	13	37.5	-2.4
X-4849	CM	binimetinib	376.2	21.1	17	60.2	0
X-4849	CM	binimetinib	360.3	21.6	20	53.5	2.4
X-4849	CM	binimetinib	446.2	21.8	24	90.1	3.3
X-4849	CM	TAS266	246	22.9	0	0	0
X-4849	CM	TAS266	455.3	21.4	3	85.1	-6.6
X-4849	CM	TAS266	657.8	22.1	7	167.4	-3.5
X-4849	CM	TAS266	953.5	21.8	11	287.6	-4.8
X-4849	CM	TAS266	1182.4	21.4	15	380.7	-6.6
X-4849	CM	TAS266	1432.5	21.7	18	482.3	-5.2
X-4849	CM	TAS266	1463.2	21.3	21	494.8	-7
X-4849	CM	TAS266	1833.5	22.1	24	645.4	-3.5
X-4849	CM	untreated	236.5	17.8	0	0	0
X-4849	CM	untreated	479.9	16.6	3	102.9	-6.7
X-4849	CM	untreated	812.5	16.4	7	243.5	-7.9
X-4849	CM	untreated	685.9	15.7	11	190	-11.8
X-4849	CM	untreated	947.9	15.6	15	300.8	-12.4
X-4849	CM	untreated	957.5	15.9	18	304.8	-10.7
X-4849	CM	untreated	1087.2	15.8	21	359.7	-11.2
X-4849	CM	untreated	1162.3	15.8	24	391.5	-11.2
X-4888	BRCA	BGJ398	241.9	21.7	0	0	0
X-4888	BRCA	BGJ398	229.5	22.9	4	-5.1	5.5
X-4888	BRCA	BGJ398	207.8	22.9	7	-14.1	5.5
X-4888	BRCA	BGJ398	204.7	23.3	11	-15.4	7.4
X-4888	BRCA	BGJ398	218.9	23.2	14	-9.5	6.9
X-4888	BRCA	BGJ398	228.5	23	18	-5.5	6
X-4888	BRCA	BGJ398	231.5	22.4	21	-4.3	3.2
X-4888	BRCA	BGJ398	279.2	22.4	25	15.4	3.2
X-4888	BRCA	BGJ398	258.2	22.3	28	6.7	2.8
X-4888	BRCA	BGJ398	251.6	23	32	4	6
X-4888	BRCA	BGJ398	212.2	23.1	35	-12.3	6.5
X-4888	BRCA	BGJ398	233.8	23.3	39	-3.3	7.4
X-4888	BRCA	BGJ398	237.8	22.5	42	-1.7	3.7
X-4888	BRCA	BGJ398	268.6	21.8	45	11	0.5
X-4888	BRCA	BGJ398	268.7	22.9	49	11.1	5.5
X-4888	BRCA	BGJ398	272.4	23.1	53	12.6	6.5
X-4888	BRCA	BGJ398	277.3	23.6	56	14.6	8.8
X-4888	BRCA	BGJ398	307.3	23.4	60	27	7.8
X-4888	BRCA	BGJ398	349.4	22.9	70	44.4	5.5
X-4888	BRCA	BGJ398	338.7	23.1	74	40	6.5
X-4888	BRCA	BGJ398	364.7	21.9	77	50.8	0.9
X-4888	BRCA	BGJ398	415.9	19.6	81	71.9	-9.7
X-4888	BRCA	BGJ398	464.2	22.8	84	91.9	5.1
X-4888	BRCA	BKM120	312.9	24.4	0	0	0
X-4888	BRCA	BKM120	359.9	27	4	15	10.7
X-4888	BRCA	BKM120	436.4	27.3	7	39.5	11.9
X-4888	BRCA	BKM120	448.3	28.2	11	43.3	15.6
X-4888	BRCA	BKM120	503.4	28.2	14	60.9	15.6
X-4888	BRCA	BKM120	525.4	28.2	18	67.9	15.6
X-4888	BRCA	BKM120	519.1	28.3	21	65.9	16
X-4888	BRCA	BKM120	548.1	27.9	25	75.2	14.3
X-4888	BRCA	BKM120	500.9	28.6	28	60.1	17.2
X-4888	BRCA	BKM120	558.2	28.8	32	78.4	18
X-4888	BRCA	BKM120	522.7	29.2	35	67.1	19.7
X-4888	BRCA	BKM120	548.3	30.1	39	75.2	23.4
X-4888	BRCA	BKM120	627.1	30.2	42	100.4	23.8
X-4888	BRCA	BKM120	614.4	29	45	96.4	18.9
X-4888	BRCA	BKM120	663.5	29.6	49	112	21.3
X-4888	BRCA	BKM120	705.1	30.7	53	125.3	25.8
X-4888	BRCA	BKM120	685.2	30.5	56	119	25
X-4888	BRCA	BKM120	705.5	30.5	60	125.5	25
X-4888	BRCA	BKM120	948.4	30.3	70	203.1	24.2
X-4888	BRCA	BKM120	974.8	30.4	74	211.5	24.6
X-4888	BRCA	BKM120	1004.8	31	77	221.1	27
X-4888	BRCA	BYL719	235.2	24.2	0	0	0
X-4888	BRCA	BYL719	256.8	24.9	4	9.2	2.9
X-4888	BRCA	BYL719	282.9	25.4	7	20.3	5
X-4888	BRCA	BYL719	287.7	25.6	11	22.3	5.8
X-4888	BRCA	BYL719	312	24.5	14	32.7	1.2
X-4888	BRCA	BYL719	298	24.5	18	26.7	1.2
X-4888	BRCA	BYL719	307.2	26	21	30.6	7.4
X-4888	BRCA	BYL719	256.9	24.2	25	9.2	0
X-4888	BRCA	BYL719	240.6	25	28	2.3	3.3
X-4888	BRCA	BYL719	209	25.3	32	-11.1	4.5
X-4888	BRCA	BYL719	209.6	25.6	35	-10.9	5.8
X-4888	BRCA	BYL719	228.1	25.6	39	-3	5.8
X-4888	BRCA	BYL719	264	26.4	42	12.2	9.1
X-4888	BRCA	BYL719	247.3	25.5	45	5.1	5.4
X-4888	BRCA	BYL719	253.9	25.7	49	8	6.2
X-4888	BRCA	BYL719	263.7	25.8	53	12.1	6.6
X-4888	BRCA	BYL719	213.3	25.6	56	-9.3	5.8
X-4888	BRCA	BYL719	220.1	26	60	-6.4	7.4
X-4888	BRCA	BYL719	270.4	26.4	70	15	9.1
X-4888	BRCA	BYL719	290.7	26.3	74	23.6	8.7
X-4888	BRCA	BYL719	319.5	26.3	77	35.8	8.7
X-4888	BRCA	BYL719	340.4	27.2	81	44.7	12.4
X-4888	BRCA	BYL719	321.7	27.1	84	36.8	12
X-4888	BRCA	BYL719 + LJM716	216.1	26.8	0	0	0
X-4888	BRCA	BYL719 + LJM716	239.7	24.1	3	10.9	-10.1
X-4888	BRCA	BYL719 + LJM716	254.7	26	7	17.9	-3
X-4888	BRCA	BYL719 + LJM716	277.9	26.3	10	28.6	-1.9
X-4888	BRCA	BYL719 + LJM716	259.9	25	14	20.3	-6.7
X-4888	BRCA	BYL719 + LJM716	229.4	26.2	17	6.2	-2.2
X-4888	BRCA	BYL719 + LJM716	253.9	26.7	20	17.5	-0.4
X-4888	BRCA	BYL719 + LJM716	282.8	28	24	30.9	4.5
X-4888	BRCA	BYL719 + LJM716	338.5	26.9	28	56.6	0.4
X-4888	BRCA	BYL719 + LJM716	308.2	27.8	31	42.6	3.7
X-4888	BRCA	BYL719 + LJM716	378.7	26.3	35	75.2	-1.9
X-4888	BRCA	BYL719 + LJM716	434	27.8	45	100.8	3.7
X-4888	BRCA	BYL719 + LJM716	481.4	27.6	49	122.8	3
X-4888	BRCA	BYL719 + LJM716	490.9	28.5	52	127.2	6.3
X-4888	BRCA	BYL719 + LJM716	551.4	26.9	56	155.2	0.4
X-4888	BRCA	BYL719 + LJM716	574.7	27	59	165.9	0.7
X-4888	BRCA	BYL719 + LJM716	604.1	27	63	179.5	0.7
X-4888	BRCA	BYL719 + LJM716	613.7	27.8	66	184	3.7
X-4888	BRCA	BYL719 + LJM716	632.9	27.6	69	192.9	3
X-4888	BRCA	BYL719 + LJM716	740	27.4	73	242.4	2.2
X-4888	BRCA	BYL719 + LJM716	870.9	27.9	76	303	4.1
X-4888	BRCA	BYL719 + LJM716	1095.7	28.7	80	407	7.1
X-4888	BRCA	BYL719 + LEE011	246	25.2	0	0	0
X-4888	BRCA	BYL719 + LEE011	234.3	25.5	4	-4.8	1.2
X-4888	BRCA	BYL719 + LEE011	234.8	25	7	-4.6	-0.8
X-4888	BRCA	BYL719 + LEE011	212.2	24.9	11	-13.7	-1.2
X-4888	BRCA	BYL719 + LEE011	194.6	24.4	15	-20.9	-3.2
X-4888	BRCA	BYL719 + LEE011	153.2	23	18	-37.7	-8.7
X-4888	BRCA	BYL719 + LEE011	173.8	22.2	22	-29.3	-11.9
X-4888	BRCA	BYL719 + LEE011	240.3	27.7	32	-2.3	9.9
X-4888	BRCA	BYL719 + LEE011	208	26.1	36	-15.4	3.6
X-4888	BRCA	BYL719 + LEE011	226.2	24.8	39	-8	-1.6
X-4888	BRCA	BYL719 + LEE011	227.7	24.4	43	-7.4	-3.2
X-4888	BRCA	BYL719 + LEE011	243.6	25.3	46	-1	0.4
X-4888	BRCA	BYL719 + LEE011	195.5	24.9	50	-20.5	-1.2
X-4888	BRCA	BYL719 + LEE011	194	25.4	53	-21.1	0.8
X-4888	BRCA	BYL719 + LEE011	193.2	25.3	56	-21.5	0.4
X-4888	BRCA	BYL719 + LEE011	190.8	25.2	60	-22.4	0
X-4888	BRCA	BYL719 + LEE011	202.4	25.9	63	-17.7	2.8
X-4888	BRCA	BYL719 + LEE011	204	25	67	-17.1	-0.8
X-4888	BRCA	BYL719 + LEE011	201.4	24.5	70	-18.1	-2.8
X-4888	BRCA	BYL719 + LEE011	175.9	24.3	74	-28.5	-3.6
X-4888	BRCA	BYL719 + LEE011	159.8	24.9	78	-35	-1.2
X-4888	BRCA	BYL719 + LEE011	161.4	24.8	81	-34.4	-1.6
X-4888	BRCA	BYL719 + LEE011	132.9	25.5	85	-46	1.2
X-4888	BRCA	BYL719 + LEE011	133.4	24.3	88	-45.8	-3.6
X-4888	BRCA	BYL719 + LEE011	124.1	21.9	92	-49.6	-13.1
X-4888	BRCA	BYL719 + LEE011	112.5	22.7	95	-54.3	-9.9
X-4888	BRCA	BYL719 + LEE011	119.7	24.6	99	-51.3	-2.4
X-4888	BRCA	BYL719 + LEE011	113.9	22.7	102	-53.7	-9.9
X-4888	BRCA	CGM097	243.9	26.6	0	0	0
X-4888	BRCA	CGM097	310.2	26.9	4	27.2	1.1
X-4888	BRCA	CGM097	345.7	26.8	7	41.7	0.8
X-4888	BRCA	CGM097	432.2	28.2	11	77.2	6
X-4888	BRCA	CGM097	382.4	27.8	14	56.8	4.5
X-4888	BRCA	CGM097	477	28.7	18	95.6	7.9
X-4888	BRCA	CGM097	459.7	28.3	21	88.5	6.4
X-4888	BRCA	CGM097	651.4	28	25	167.1	5.3
X-4888	BRCA	CGM097	705.2	29.1	28	189.1	9.4
X-4888	BRCA	CGM097	773	29.5	32	216.9	10.9
X-4888	BRCA	CGM097	783.4	28.7	35	221.2	7.9
X-4888	BRCA	CGM097	743.5	29.2	39	204.8	9.8
X-4888	BRCA	CGM097	749.7	29.3	42	207.4	10.2
X-4888	BRCA	CGM097	757.6	28.9	45	210.6	8.6
X-4888	BRCA	CGM097	807.4	30	49	231	12.8
X-4888	BRCA	CGM097	838.2	31	53	243.7	16.5
X-4888	BRCA	CGM097	884.4	30.6	56	262.6	15
X-4888	BRCA	CGM097	998.3	30.1	60	309.3	13.2
X-4888	BRCA	CGM097	1219	31.8	70	399.8	19.5
X-4888	BRCA	CLR457	294.6	27.9	0	0	0
X-4888	BRCA	CLR457	255.4	28.1	4	-13.3	0.7
X-4888	BRCA	CLR457	287.4	29	7	-2.4	3.9
X-4888	BRCA	CLR457	281	28.2	11	-4.6	1.1
X-4888	BRCA	CLR457	344	29.6	21	16.8	6.1
X-4888	BRCA	CLR457	316.8	31.4	25	7.5	12.5
X-4888	BRCA	CLR457	349.6	29.9	28	18.7	7.2
X-4888	BRCA	CLR457	353.5	29.8	32	20	6.8
X-4888	BRCA	CLR457	365.4	31.4	35	24	12.5
X-4888	BRCA	CLR457	383.4	30.3	39	30.1	8.6
X-4888	BRCA	CLR457	387.7	30.7	42	31.6	10
X-4888	BRCA	CLR457	400.2	31.2	45	35.8	11.8
X-4888	BRCA	CLR457	412.5	30.4	49	40	9
X-4888	BRCA	CLR457	409.8	30.2	52	39.1	8.2
X-4888	BRCA	CLR457	427.5	30.9	56	45.1	10.8
X-4888	BRCA	CLR457	439	31.2	59	49	11.8
X-4888	BRCA	CLR457	533.6	30	63	81.1	7.5
X-4888	BRCA	CLR457	509.7	31.2	67	73	11.8
X-4888	BRCA	CLR457	536.1	32.4	70	82	16.1
X-4888	BRCA	CLR457	557.2	31.3	74	89.1	12.2
X-4888	BRCA	CLR457	555.6	31.1	77	88.6	11.5
X-4888	BRCA	CLR457	574.2	29.8	81	94.9	6.8
X-4888	BRCA	CLR457	563.1	29.6	84	91.1	6.1
X-4888	BRCA	CLR457	644.6	29.9	88	118.8	7.2
X-4888	BRCA	CLR457	644.4	29.3	91	118.7	5
X-4888	BRCA	CLR457	716.7	30	95	143.3	7.5
X-4888	BRCA	CLR457	763.1	29.6	98	159	6.1
X-4888	BRCA	CLR457	738.6	29.6	102	150.7	6.1
X-4888	BRCA	CLR457	797.2	29.5	105	170.6	5.7
X-4888	BRCA	CLR457	741.3	29.2	109	151.6	4.7
X-4888	BRCA	CLR457	818.2	26.5	112	177.7	-5
X-4888	BRCA	HDM201	206.5	20.7	0	0	0
X-4888	BRCA	HDM201	227.8	21.8	4	10.3	5.3
X-4888	BRCA	HDM201	273.6	21.4	7	32.5	3.4
X-4888	BRCA	HDM201	258.5	22.2	11	25.2	7.2
X-4888	BRCA	HDM201	282.2	21.7	14	36.7	4.8
X-4888	BRCA	HDM201	283.5	22.1	18	37.3	6.8
X-4888	BRCA	HDM201	289.6	22.5	21	40.2	8.7
X-4888	BRCA	HDM201	315.6	22.5	25	52.8	8.7
X-4888	BRCA	HDM201	319.3	22.7	28	54.6	9.7
X-4888	BRCA	HDM201	328.2	23.1	32	58.9	11.6
X-4888	BRCA	HDM201	320.5	23.6	35	55.2	14
X-4888	BRCA	HDM201	338.4	23.4	39	63.9	13
X-4888	BRCA	HDM201	370	23.1	42	79.2	11.6
X-4888	BRCA	HDM201	411.5	22.7	45	99.3	9.7
X-4888	BRCA	HDM201	451.1	23.6	49	118.5	14
X-4888	BRCA	HDM201	520.2	23	53	151.9	11.1
X-4888	BRCA	HDM201	494	23.1	56	139.2	11.6
X-4888	BRCA	HDM201	504.8	23	60	144.5	11.1
X-4888	BRCA	HDM201	621.3	23.1	70	200.9	11.6
X-4888	BRCA	HDM201	733.5	23.1	74	255.2	11.6
X-4888	BRCA	HDM201	934	23.4	77	352.3	13
X-4888	BRCA	HDM201	1096.5	23	81	431	11.1
X-4888	BRCA	HDM201	1171.4	24.1	84	467.3	16.4
X-4888	BRCA	INC424	270	25.8	0	0	0
X-4888	BRCA	INC424	301.2	26.7	3	11.6	3.5
X-4888	BRCA	INC424	321.3	26.9	7	19	4.3
X-4888	BRCA	INC424	330.9	26.4	10	22.6	2.3
X-4888	BRCA	INC424	385.5	NA	14	42.8	2.3
X-4888	BRCA	INC424	390.5	26.9	17	44.6	4.3
X-4888	BRCA	INC424	451.8	27	21	67.3	4.7
X-4888	BRCA	INC424	479.3	28	24	77.5	8.5
X-4888	BRCA	INC424	553.4	27.6	28	105	7
X-4888	BRCA	INC424	584.8	28.1	31	116.6	8.9
X-4888	BRCA	INC424	630.3	27.5	34	133.4	6.6
X-4888	BRCA	INC424	664.3	27.6	38	146	7
X-4888	BRCA	INC424	641.7	27.6	42	137.7	7
X-4888	BRCA	INC424	634.3	28	45	134.9	8.5
X-4888	BRCA	INC424	748.1	28.8	49	177.1	11.6
X-4888	BRCA	INC424	1380.7	28.7	59	411.4	11.2
X-4888	BRCA	LEE011 + everolimus	223.3	28	0	0	0
X-4888	BRCA	LEE011 + everolimus	251	26.7	10	12.4	-4.6
X-4888	BRCA	LEE011 + everolimus	245.6	27	14	10	-3.6
X-4888	BRCA	LEE011 + everolimus	203.6	27.6	17	-8.8	-1.4
X-4888	BRCA	LEE011 + everolimus	220.2	27.6	21	-1.4	-1.4
X-4888	BRCA	LEE011 + everolimus	238.9	28.6	24	7	2.1
X-4888	BRCA	LEE011 + everolimus	249.4	29	28	11.7	3.6
X-4888	BRCA	LEE011 + everolimus	244.7	29.3	31	9.6	4.6
X-4888	BRCA	LEE011 + everolimus	240.8	29.7	34	7.8	6.1
X-4888	BRCA	LEE011 + everolimus	235.7	30.2	38	5.6	7.9
X-4888	BRCA	LEE011 + everolimus	226.2	29.3	41	1.3	4.6
X-4888	BRCA	LEE011 + everolimus	220.1	29.5	45	-1.4	5.4
X-4888	BRCA	LEE011 + everolimus	205.5	29.4	48	-8	5
X-4888	BRCA	LEE011 + everolimus	225.2	28.9	52	0.9	3.2
X-4888	BRCA	LEE011 + everolimus	207	28.3	56	-7.3	1.1
X-4888	BRCA	LEE011 + everolimus	204.3	28.9	59	-8.5	3.2
X-4888	BRCA	LEE011 + everolimus	189.2	28.6	63	-15.3	2.1
X-4888	BRCA	LEE011 + everolimus	190.1	28.3	66	-14.9	1.1
X-4888	BRCA	LEE011 + everolimus	188.4	28.4	70	-15.6	1.4
X-4888	BRCA	LEE011 + everolimus	177.2	28.6	73	-20.6	2.1
X-4888	BRCA	LEE011 + everolimus	174.5	28.8	77	-21.9	2.9
X-4888	BRCA	LEE011 + everolimus	193.3	29.5	80	-13.4	5.4
X-4888	BRCA	LEE011 + everolimus	192.1	27.5	84	-14	-1.8
X-4888	BRCA	LEE011 + everolimus	156.2	29.1	87	-30	3.9
X-4888	BRCA	LEE011 + everolimus	182.6	29.4	91	-18.2	5
X-4888	BRCA	LEE011 + everolimus	173.5	29.3	94	-22.3	4.6
X-4888	BRCA	LEE011 + everolimus	216	28.3	98	-3.3	1.1
X-4888	BRCA	LEE011 + everolimus	179.2	27.3	101	-19.7	-2.5
X-4888	BRCA	LEE011 + everolimus	183.9	27.8	105	-17.6	-0.7
X-4888	BRCA	LEE011 + everolimus	173.9	29.5	108	-22.1	5.4
X-4888	BRCA	LEE011 + everolimus	164.3	29.4	112	-26.4	5
X-4888	BRCA	LEE011 + everolimus	182.3	29.9	115	-18.4	6.8
X-4888	BRCA	LEE011	245	24.5	0	0	0
X-4888	BRCA	LEE011	249.4	25.6	3	1.8	4.5
X-4888	BRCA	LEE011	305.5	26.1	7	24.7	6.5
X-4888	BRCA	LEE011	329.1	26.4	10	34.3	7.8
X-4888	BRCA	LEE011	342	26.2	14	39.6	6.9
X-4888	BRCA	LEE011	306.9	26.1	17	25.3	6.5
X-4888	BRCA	LEE011	336.3	25.8	20	37.3	5.3
X-4888	BRCA	LEE011	275.5	26.3	24	12.4	7.3
X-4888	BRCA	LEE011	300.6	27.1	28	22.7	10.6
X-4888	BRCA	LEE011	285.6	26.6	31	16.6	8.6
X-4888	BRCA	LEE011	312.7	26.9	35	27.6	9.8
X-4888	BRCA	LEE011	261	27	45	6.5	10.2
X-4888	BRCA	LEE011	278.6	27.8	49	13.7	13.5
X-4888	BRCA	LEE011	241.7	28.1	52	-1.3	14.7
X-4888	BRCA	LEE011	356.4	27.8	56	45.5	13.5
X-4888	BRCA	LEE011	330.5	28.2	59	34.9	15.1
X-4888	BRCA	LEE011	373.8	27.5	63	52.6	12.2
X-4888	BRCA	LEE011	338.9	27.5	66	38.3	12.2
X-4888	BRCA	LEE011	341.1	27.9	69	39.2	13.9
X-4888	BRCA	LEE011	340.8	28.3	73	39.1	15.5
X-4888	BRCA	LEE011	357.9	28.5	76	46.1	16.3
X-4888	BRCA	LEE011	376.4	29	80	53.6	18.4
X-4888	BRCA	LEE011	374.4	28.2	83	52.8	15.1
X-4888	BRCA	LEE011	382.7	29.5	87	56.2	20.4
X-4888	BRCA	LEE011	380.5	27.4	91	55.3	11.8
X-4888	BRCA	LEE011	367.6	27.7	94	50	13.1
X-4888	BRCA	LFA102	218.1	27.1	0	0	0
X-4888	BRCA	LFA102	204.8	25.9	3	-6.1	-4.4
X-4888	BRCA	LFA102	201.6	26	6	-7.6	-4.1
X-4888	BRCA	LFA102	194.1	26	10	-11	-4.1
X-4888	BRCA	LFA102	208.2	26.7	13	-4.5	-1.5
X-4888	BRCA	LFA102	230.7	26.7	16	5.8	-1.5
X-4888	BRCA	LFA102	284.2	26.4	20	30.3	-2.6
X-4888	BRCA	LFA102	359.2	26.9	24	64.7	-0.7
X-4888	BRCA	LFA102	349.8	26.8	27	60.4	-1.1
X-4888	BRCA	LFA102	429.3	28.8	31	96.8	6.3
X-4888	BRCA	LFA102	652.1	27	41	199	-0.4
X-4888	BRCA	LFA102	796	27.4	45	265	1.1
X-4888	BRCA	LFA102	939.3	27.2	48	330.7	0.4
X-4888	BRCA	LJM716 + trastuzumab	203.9	24.9	0	0	0
X-4888	BRCA	LJM716 + trastuzumab	235.1	25.4	3	15.3	2
X-4888	BRCA	LJM716 + trastuzumab	218.8	25	6	7.3	0.4
X-4888	BRCA	LJM716 + trastuzumab	289.9	25.2	10	42.2	1.2
X-4888	BRCA	LJM716 + trastuzumab	266.6	25	13	30.8	0.4
X-4888	BRCA	LJM716 + trastuzumab	366.1	25.7	17	79.5	3.2
X-4888	BRCA	LJM716 + trastuzumab	422.8	25.7	20	107.4	3.2
X-4888	BRCA	LJM716 + trastuzumab	473.9	25.8	24	132.4	3.6
X-4888	BRCA	LJM716 + trastuzumab	478.6	26.5	27	134.7	6.4
X-4888	BRCA	LJM716 + trastuzumab	575.9	26.3	30	182.4	5.6
X-4888	BRCA	LJM716 + trastuzumab	635.6	25.7	34	211.7	3.2
X-4888	BRCA	LJM716 + trastuzumab	788	26.2	38	286.5	5.2
X-4888	BRCA	LJM716 + trastuzumab	832.3	27.6	41	308.2	10.8
X-4888	BRCA	LJM716 + trastuzumab	856.5	27.4	45	320.1	10
X-4888	BRCA	LJM716 + trastuzumab	608	26.8	55	198.2	7.6
X-4888	BRCA	LJM716 + trastuzumab	536	27	59	162.9	8.4
X-4888	BRCA	LJM716 + trastuzumab	594.8	27.1	62	191.7	8.8
X-4888	BRCA	LJM716 + trastuzumab	676	27	66	231.5	8.4
X-4888	BRCA	LJM716 + trastuzumab	692.9	27.3	69	239.8	9.6
X-4888	BRCA	LJM716 + trastuzumab	673.2	27	73	230.2	8.4
X-4888	BRCA	LJM716 + trastuzumab	681.7	27.4	76	234.3	10
X-4888	BRCA	LJM716 + trastuzumab	687.9	27.1	79	237.4	8.8
X-4888	BRCA	LJM716 + trastuzumab	737.8	27.6	83	261.8	10.8
X-4888	BRCA	LJM716 + trastuzumab	776.6	27.4	86	280.9	10
X-4888	BRCA	LJM716 + trastuzumab	940.4	27.1	90	361.2	8.8
X-4888	BRCA	LJM716	257.9	28.4	0	0	0
X-4888	BRCA	LJM716	350.1	28.6	4	35.8	0.7
X-4888	BRCA	LJM716	446.8	29	7	73.2	2.1
X-4888	BRCA	LJM716	520.1	28.3	11	101.7	-0.4
X-4888	BRCA	LJM716	555.3	28.3	14	115.3	-0.4
X-4888	BRCA	LJM716	571.8	28.5	17	121.7	0.4
X-4888	BRCA	LJM716	610.7	28.9	21	136.8	1.8
X-4888	BRCA	LJM716	624.8	29.1	24	142.3	2.5
X-4888	BRCA	LJM716	694.7	30.4	28	169.4	7
X-4888	BRCA	LJM716	873.2	31.3	31	238.6	10.2
X-4888	BRCA	LJM716	1322.4	29.5	35	412.8	3.9
X-4888	BRCA	LKA136	199.5	23.5	0	0	0
X-4888	BRCA	LKA136	297.9	23.4	4	49.3	-0.4
X-4888	BRCA	LKA136	332.3	24.6	8	66.6	4.7
X-4888	BRCA	LKA136	365.4	24.6	11	83.2	4.7
X-4888	BRCA	LKA136	389.3	24.3	15	95.1	3.4
X-4888	BRCA	LKA136	408.4	24.8	18	104.7	5.5
X-4888	BRCA	LKA136	461.8	24.5	22	131.5	4.3
X-4888	BRCA	LKA136	443.7	24.4	25	122.4	3.8
X-4888	BRCA	LKA136	485.1	24.9	29	143.2	6
X-4888	BRCA	LKA136	494.5	25.4	32	147.9	8.1
X-4888	BRCA	LKA136	588.4	24.9	36	194.9	6
X-4888	BRCA	LKA136	710.9	25.1	39	256.3	6.8
X-4888	BRCA	LKA136	728.3	25.9	42	265.1	10.2
X-4888	BRCA	LKA136	823.2	25.1	46	312.6	6.8
X-4888	BRCA	LKA136	920	25.4	50	361.2	8.1
X-4888	BRCA	LKA136	987	26	53	394.7	10.6
X-4888	BRCA	LLM871	236.7	25.9	0	0	0
X-4888	BRCA	LLM871	289.3	26	3	22.2	0.4
X-4888	BRCA	LLM871	292.3	26.4	6	23.5	1.9
X-4888	BRCA	LLM871	315.5	26.2	10	33.3	1.2
X-4888	BRCA	LLM871	303	26.1	13	28	0.8
X-4888	BRCA	LLM871	306.3	25.5	17	29.4	-1.5
X-4888	BRCA	LLM871	288.8	25.3	20	22	-2.3
X-4888	BRCA	LLM871	296.9	26.1	24	25.4	0.8
X-4888	BRCA	LLM871	346.4	26	27	46.3	0.4
X-4888	BRCA	LLM871	368.3	26.7	31	55.6	3.1
X-4888	BRCA	LLM871	411.8	27.6	34	74	6.6
X-4888	BRCA	LLM871	455.6	27.1	37	92.5	4.6
X-4888	BRCA	LLM871	518.8	27.6	41	119.2	6.6
X-4888	BRCA	LLM871	654.8	27.5	45	176.6	6.2
X-4888	BRCA	LLM871	640.9	28	48	170.8	8.1
X-4888	BRCA	LLM871	724.8	28.2	52	206.2	8.9
X-4888	BRCA	LLM871	821.1	28.6	62	246.9	10.4
X-4888	BRCA	LLM871	1111.1	24.6	66	369.4	-5
X-4888	BRCA	LLM871	1001.9	28.6	69	323.3	10.4
X-4888	BRCA	binimetinib	244.5	26.5	0	0	0
X-4888	BRCA	binimetinib	261.8	26	4	7.1	-1.9
X-4888	BRCA	binimetinib	273.4	26.3	7	11.8	-0.8
X-4888	BRCA	binimetinib	326.8	26.3	11	33.7	-0.8
X-4888	BRCA	binimetinib	321.7	26.6	14	31.6	0.4
X-4888	BRCA	binimetinib	397.4	26.2	18	62.5	-1.1
X-4888	BRCA	binimetinib	334.8	26.1	21	36.9	-1.5
X-4888	BRCA	binimetinib	398	25.9	25	62.8	-2.3
X-4888	BRCA	binimetinib	449.8	27.4	28	84	3.4
X-4888	BRCA	binimetinib	457.7	27.1	32	87.2	2.3
X-4888	BRCA	binimetinib	445.3	27.2	35	82.1	2.6
X-4888	BRCA	binimetinib	452.1	26.3	38	84.9	-0.8
X-4888	BRCA	binimetinib	540.6	27	42	121.1	1.9
X-4888	BRCA	binimetinib	538.4	26.6	46	120.2	0.4
X-4888	BRCA	binimetinib	508.6	26.2	49	108	-1.1
X-4888	BRCA	binimetinib	573.1	27.1	53	134.4	2.3
X-4888	BRCA	binimetinib	624.9	27.3	63	155.6	3
X-4888	BRCA	binimetinib	628.6	29.5	67	157.1	11.3
X-4888	BRCA	binimetinib	632.1	28.3	70	158.5	6.8
X-4888	BRCA	binimetinib	704.1	26.7	74	188	0.8
X-4888	BRCA	binimetinib	674.3	26.3	77	175.8	-0.8
X-4888	BRCA	binimetinib	653	25.7	81	167.1	-3
X-4888	BRCA	binimetinib	663	26.9	84	171.2	1.5
X-4888	BRCA	binimetinib	663.9	26.9	87	171.5	1.5
X-4888	BRCA	binimetinib	676.7	26.8	91	176.8	1.1
X-4888	BRCA	binimetinib	680.9	26.8	94	178.5	1.1
X-4888	BRCA	binimetinib	713.5	25.9	98	191.8	-2.3
X-4888	BRCA	paclitaxel	203.5	25.5	0	0	0
X-4888	BRCA	paclitaxel	225.9	24.8	3	11	-2.7
X-4888	BRCA	paclitaxel	226.2	24.7	6	11.2	-3.1
X-4888	BRCA	paclitaxel	210.1	24.4	10	3.2	-4.3
X-4888	BRCA	paclitaxel	192.9	25.4	13	-5.2	-0.4
X-4888	BRCA	paclitaxel	174.1	25.3	17	-14.4	-0.8
X-4888	BRCA	paclitaxel	175.7	25.5	20	-13.7	0
X-4888	BRCA	paclitaxel	154.8	24.8	23	-23.9	-2.7
X-4888	BRCA	paclitaxel	159.1	24.7	27	-21.8	-3.1
X-4888	BRCA	paclitaxel	176.8	25.6	31	-13.1	0.4
X-4888	BRCA	paclitaxel	142.5	25.3	34	-30	-0.8
X-4888	BRCA	paclitaxel	113.6	26	38	-44.2	2
X-4888	BRCA	paclitaxel	111.1	26.1	48	-45.4	2.4
X-4888	BRCA	paclitaxel	113.6	26.1	52	-44.2	2.4
X-4888	BRCA	paclitaxel	132.3	26	55	-35	2
X-4888	BRCA	paclitaxel	182.1	25.9	59	-10.5	1.6
X-4888	BRCA	paclitaxel	205.1	26.2	62	0.8	2.7
X-4888	BRCA	paclitaxel	176.7	25.9	66	-13.2	1.6
X-4888	BRCA	paclitaxel	190.8	26.5	69	-6.2	3.9
X-4888	BRCA	paclitaxel	196.9	25.8	72	-3.2	1.2
X-4888	BRCA	paclitaxel	192.9	25.4	76	-5.2	-0.4
X-4888	BRCA	paclitaxel	196.2	26.2	79	-3.6	2.7
X-4888	BRCA	paclitaxel	216.7	26.1	83	6.5	2.4
X-4888	BRCA	paclitaxel	210.2	26.1	86	3.3	2.4
X-4888	BRCA	paclitaxel	202.6	25.7	90	-0.4	0.8
X-4888	BRCA	paclitaxel	175.9	26.2	94	-13.6	2.7
X-4888	BRCA	paclitaxel	115.7	26	97	-43.1	2
X-4888	BRCA	paclitaxel	83	25.7	101	-59.2	0.8
X-4888	BRCA	paclitaxel	155.8	25.6	104	-23.4	0.4
X-4888	BRCA	tamoxifen	277.7	24.9	0	0	0
X-4888	BRCA	tamoxifen	361.7	27.7	4	30.2	11.2
X-4888	BRCA	tamoxifen	481.1	28.6	7	73.2	14.9
X-4888	BRCA	tamoxifen	565.3	29.7	11	103.6	19.3
X-4888	BRCA	tamoxifen	666.2	NA	14	139.9	19.3
X-4888	BRCA	tamoxifen	695.2	29.9	18	150.3	20.1
X-4888	BRCA	tamoxifen	758.1	30.4	21	173	22.1
X-4888	BRCA	tamoxifen	839.7	30	25	202.4	20.5
X-4888	BRCA	tamoxifen	874.4	31	28	214.9	24.5
X-4888	BRCA	tamoxifen	1007.4	31	32	262.8	24.5
X-4888	BRCA	tamoxifen	990.5	31.2	35	256.7	25.3
X-4888	BRCA	tamoxifen	1044.3	31.1	39	276.1	24.9
X-4888	BRCA	tamoxifen	1079.4	31.3	42	288.7	25.7
X-4888	BRCA	trastuzumab	203.4	28.4	0	0	0
X-4888	BRCA	trastuzumab	259.2	28.4	3	27.4	0
X-4888	BRCA	trastuzumab	300.7	28	6	47.8	-1.4
X-4888	BRCA	trastuzumab	380.3	28	10	87	-1.4
X-4888	BRCA	trastuzumab	385	28	13	89.3	-1.4
X-4888	BRCA	trastuzumab	401.7	28.6	17	97.5	0.7
X-4888	BRCA	trastuzumab	518.1	29.6	20	154.7	4.2
X-4888	BRCA	trastuzumab	577.2	28.1	23	183.8	-1.1
X-4888	BRCA	trastuzumab	697.6	28.9	27	243	1.8
X-4888	BRCA	trastuzumab	866.5	28.9	31	326	1.8
X-4888	BRCA	trastuzumab	907.5	29.2	34	346.2	2.8
X-4888	BRCA	trastuzumab	928.2	28.7	38	356.3	1.1
X-4888	BRCA	trastuzumab	1541.5	30.2	48	657.9	6.3
X-4888	BRCA	untreated	248.9	21.3	0	0	0
X-4888	BRCA	untreated	326	22.4	4	31	5.2
X-4888	BRCA	untreated	358	22	7	43.8	3.3
X-4888	BRCA	untreated	374.3	23.4	11	50.4	9.9
X-4888	BRCA	untreated	391.5	23.6	14	57.3	10.8
X-4888	BRCA	untreated	470.9	24	18	89.2	12.7
X-4888	BRCA	untreated	481.3	23.2	21	93.4	8.9
X-4888	BRCA	untreated	546	23.3	25	119.4	9.4
X-4888	BRCA	untreated	537.1	23.5	28	115.8	10.3
X-4888	BRCA	untreated	610.1	23.9	32	145.1	12.2
X-4888	BRCA	untreated	615.9	23.8	35	147.4	11.7
X-4888	BRCA	untreated	643	24.1	39	158.3	13.1
X-4888	BRCA	untreated	812.1	24.2	42	226.3	13.6
X-4888	BRCA	untreated	842.9	24.2	45	238.7	13.6
X-4888	BRCA	untreated	931.1	24.7	49	274.1	16
X-4888	BRCA	untreated	1475.1	25	53	492.6	17.4
X-4888	BRCA	untreated	1275.3	25.6	56	412.4	20.2
X-4888	BRCA	LFW527 + everolimus	219.17	24.7	0	0	0
X-4888	BRCA	LFW527 + everolimus	210.71	24.6	4	-3.9	-0.4
X-4888	BRCA	LFW527 + everolimus	187.81	24.9	7	-14.3	0.8
X-4888	BRCA	LFW527 + everolimus	187.07	25	10	-14.6	1.2
X-4888	BRCA	LFW527 + everolimus	234.11	25.5	14	6.8	3.2
X-4888	BRCA	LFW527 + everolimus	247.8	25.1	17	13.1	1.6
X-4888	BRCA	LFW527 + everolimus	252.96	26	21	15.4	5.3
X-4888	BRCA	LFW527 + everolimus	283.41	26.5	24	29.3	7.3
X-4888	BRCA	LFW527 + everolimus	268.39	25.8	28	22.5	4.5
X-4888	BRCA	LFW527 + everolimus	281	26.5	31	28.2	7.3
X-4888	BRCA	LFW527 + everolimus	274.16	26.2	35	25.1	6.1
X-4888	BRCA	LFW527 + everolimus	279.93	25.8	38	27.7	4.5
X-4888	BRCA	LFW527 + everolimus	315.1	26.3	42	43.8	6.5
X-4888	BRCA	LFW527 + everolimus	311.4	26.4	45	42.1	6.9
X-4888	BRCA	LFW527 + everolimus	324.16	25.6	49	47.9	3.6
X-4888	BRCA	LFW527 + everolimus	445.03	25.9	53	103.1	4.9
X-4888	BRCA	LFW527 + everolimus	454.48	25.3	56	107.4	2.4
X-4888	BRCA	LFW527 + everolimus	511.76	24.5	59	133.5	-0.8
X-4888	BRCA	LFW527 + everolimus	617.08	24.6	63	181.6	-0.4
X-4888	BRCA	LFW527 + everolimus	484.1	19.8	66	120.9	-19.8
X-4927	PDAC	abraxane	257.5	27.6	0	0	0
X-4927	PDAC	abraxane	427.7	27.8	3	66.1	0.7
X-4927	PDAC	abraxane	547.5	28	6	112.6	1.4
X-4927	PDAC	abraxane	739	28.5	11	187	3.3
X-4927	PDAC	abraxane	818.8	29.1	13	218	5.4
X-4927	PDAC	abraxane	1252.1	29.2	17	386.3	5.8
X-4927	PDAC	BKM120 + binimetinib	243.5	23.6	0	0	0
X-4927	PDAC	BKM120 + binimetinib	305.3	23.8	4	25.4	0.8
X-4927	PDAC	BKM120 + binimetinib	293.1	23.6	7	20.4	0
X-4927	PDAC	BKM120 + binimetinib	303.6	24	11	24.7	1.7
X-4927	PDAC	BKM120 + binimetinib	277.1	23.9	14	13.8	1.3
X-4927	PDAC	BKM120 + binimetinib	225.5	23	18	-7.4	-2.5
X-4927	PDAC	BKM120 + binimetinib	201.8	23.2	21	-17.1	-1.7
X-4927	PDAC	BKM120 + binimetinib	204.6	23.6	24	-16	0
X-4927	PDAC	BKM120 + binimetinib	239.5	23.5	27	-1.6	-0.4
X-4927	PDAC	BKM120 + binimetinib	163.1	24	32	-33	1.7
X-4927	PDAC	BKM120 + binimetinib	167.6	23.2	35	-31.2	-1.7
X-4927	PDAC	BKM120 + binimetinib	115.1	23.2	39	-52.7	-1.7
X-4927	PDAC	BKM120 + binimetinib	131.3	23.2	42	-46.1	-1.7
X-4927	PDAC	BKM120 + binimetinib	107.8	23.4	45	-55.7	-0.8
X-4927	PDAC	BKM120 + binimetinib	77.7	23.9	49	-68.1	1.3
X-4927	PDAC	BKM120 + binimetinib	162.3	24	52	-33.3	1.7
X-4927	PDAC	BKM120 + binimetinib	125.2	23.4	55	-48.6	-0.8
X-4927	PDAC	BKM120 + binimetinib	90.2	23.6	59	-63	0
X-4927	PDAC	BKM120 + binimetinib	114.1	24.4	63	-53.1	3.4
X-4927	PDAC	BKM120 + binimetinib	112.3	24	67	-53.9	1.7
X-4927	PDAC	BKM120 + binimetinib	87.4	23.5	70	-64.1	-0.4
X-4927	PDAC	BKM120 + binimetinib	92.7	23.6	73	-61.9	0
X-4927	PDAC	BKM120 + binimetinib	109.5	24	77	-55	1.7
X-4927	PDAC	BKM120 + binimetinib	104.8	22.8	81	-57	-3.4
X-4927	PDAC	BKM120 + LDE225	301.6	24.3	0	0	0
X-4927	PDAC	BKM120 + LDE225	291.6	24.4	4	-3.3	0.4
X-4927	PDAC	BKM120 + LDE225	334.9	23.8	7	11	-2.1
X-4927	PDAC	BKM120 + LDE225	440.7	25	11	46.1	2.9
X-4927	PDAC	BKM120 + LDE225	378.6	23.7	14	25.5	-2.5
X-4927	PDAC	BKM120 + LDE225	361	23.1	18	19.7	-4.9
X-4927	PDAC	BKM120 + LDE225	371.4	23.6	21	23.1	-2.9
X-4927	PDAC	BKM120 + LDE225	386.3	24.5	24	28.1	0.8
X-4927	PDAC	BKM120 + LDE225	415.9	25.6	27	37.9	5.3
X-4927	PDAC	BKM120 + LDE225	535.2	24.1	32	77.5	-0.8
X-4927	PDAC	BKM120 + LDE225	574.7	23.7	35	90.6	-2.5
X-4927	PDAC	BKM120 + LDE225	751.2	24.4	39	149.1	0.4
X-4927	PDAC	BKM120 + LDE225	1000	24.1	42	231.6	-0.8
X-4927	PDAC	BKM120 + LDE225	886.9	26	45	194.1	7
X-4927	PDAC	BKM120 + LDE225	989.7	26	49	228.1	7
X-4927	PDAC	BKM120 + LDE225	2074.4	26.1	52	587.8	7.4
X-4927	PDAC	BKM120 + LDE225	1831.4	24.8	55	507.2	2.1
X-4927	PDAC	BKM120	195.7	24	0	0	0
X-4927	PDAC	BKM120	297.6	24.9	3	52.1	3.7
X-4927	PDAC	BKM120	384.9	23.5	5	96.7	-2.1
X-4927	PDAC	BKM120	651.8	25	10	233.1	4.2
X-4927	PDAC	BKM120	1024.6	24.8	13	423.6	3.3
X-4927	PDAC	BKM120	1147.4	25.5	18	486.3	6.2
X-4927	PDAC	BKM120	1402.6	25.7	21	616.7	7.1
X-4927	PDAC	BYL719 + LJM716	201.8	24.3	0	0	0
X-4927	PDAC	BYL719 + LJM716	245	24.6	3	21.4	1.2
X-4927	PDAC	BYL719 + LJM716	117.4	23.3	9	-41.8	-4.1
X-4927	PDAC	BYL719 + LJM716	135.3	24.4	14	-33	0.4
X-4927	PDAC	BYL719 + LJM716	191.2	24.2	17	-5.3	-0.4
X-4927	PDAC	BYL719 + LJM716	307	25.7	21	52.1	5.8
X-4927	PDAC	BYL719 + LJM716	347.4	26	24	72.2	7
X-4927	PDAC	BYL719 + LJM716	508.1	24.4	28	151.8	0.4
X-4927	PDAC	BYL719 + LJM716	594.9	25.2	31	194.8	3.7
X-4927	PDAC	BYL719 + LJM716	617.4	24.9	35	205.9	2.5
X-4927	PDAC	BYL719 + LJM716	673.6	23.1	38	233.8	-4.9
X-4927	PDAC	BYL719 + LJM716	787.1	24.5	42	290	0.8
X-4927	PDAC	BYL719 + LJM716	847.2	25.2	45	319.8	3.7
X-4927	PDAC	BYL719 + LJM716	870	25.4	49	331.1	4.5
X-4927	PDAC	BYL719 + LJM716	926.7	25.5	52	359.2	4.9
X-4927	PDAC	BYL719	286.8	30	0	0	0
X-4927	PDAC	BYL719	485.9	28.1	5	69.4	-6.3
X-4927	PDAC	BYL719	613.7	29.5	7	114	-1.7
X-4927	PDAC	BYL719	743.6	28.8	11	159.3	-4
X-4927	PDAC	BYL719	1202.8	29.4	18	319.4	-2
X-4927	PDAC	HDM201	249.3	27.5	0	0	0
X-4927	PDAC	HDM201	318.2	26.9	4	27.6	-2.2
X-4927	PDAC	HDM201	427.9	27.5	7	71.6	0
X-4927	PDAC	HDM201	502.2	26.8	10	101.4	-2.5
X-4927	PDAC	HDM201	970	26.7	14	289.1	-2.9
X-4927	PDAC	HDM201	696.7	26.5	20	179.5	-3.6
X-4927	PDAC	HDM201	1494	27.9	25	499.3	1.5
X-4927	PDAC	HDM201	1077.3	27.4	28	332.1	-0.4
X-4927	PDAC	HDM201	1554.5	28.7	32	523.5	4.4
X-4927	PDAC	figitumumab"	269.2	25.8	0	0	0
X-4927	PDAC	figitumumab"	309.1	25.6	3	14.8	-0.8
X-4927	PDAC	figitumumab"	507.8	25.6	6	88.6	-0.8
X-4927	PDAC	figitumumab"	656.5	25.7	11	143.9	-0.4
X-4927	PDAC	figitumumab"	650	26	13	141.5	0.8
X-4927	PDAC	figitumumab"	831.7	26.1	17	209	1.2
X-4927	PDAC	figitumumab" + binimetinib	197.7	25.3	0	0	0
X-4927	PDAC	figitumumab" + binimetinib	204.9	25.2	2	3.6	-0.4
X-4927	PDAC	figitumumab" + binimetinib	533.1	25.5	12	169.7	0.8
X-4927	PDAC	figitumumab" + binimetinib	681.8	25.4	15	244.9	0.4
X-4927	PDAC	figitumumab" + binimetinib	1584.4	25.6	20	701.4	1.2
X-4927	PDAC	gemcitabine-50mpk	202.8	25.6	0	0	0
X-4927	PDAC	gemcitabine-50mpk	198.3	25.9	1	-2.2	1.2
X-4927	PDAC	gemcitabine-50mpk	170.1	24.6	3	-16.1	-3.9
X-4927	PDAC	gemcitabine-50mpk	106.7	23.3	7	-47.4	-9
X-4927	PDAC	gemcitabine-50mpk	93.3	24.5	9	-54	-4.3
X-4927	PDAC	gemcitabine-50mpk	103.1	23.8	15	-49.2	-7
X-4927	PDAC	gemcitabine-50mpk	59.9	22.6	19	-70.5	-11.7
X-4927	PDAC	gemcitabine-50mpk	85	24.3	21	-58.1	-5.1
X-4927	PDAC	gemcitabine-50mpk	91.8	24	25	-54.7	-6.2
X-4927	PDAC	gemcitabine-50mpk	150.7	25.1	29	-25.7	-2
X-4927	PDAC	gemcitabine-50mpk	142.5	24.4	32	-29.7	-4.7
X-4927	PDAC	gemcitabine-50mpk	199.1	25.4	35	-1.8	-0.8
X-4927	PDAC	gemcitabine-50mpk	286.5	25.4	39	41.3	-0.8
X-4927	PDAC	gemcitabine-50mpk	438.7	24.5	42	116.3	-4.3
X-4927	PDAC	gemcitabine-50mpk	672.3	25	47	231.5	-2.3
X-4927	PDAC	gemcitabine-50mpk	719.6	25.4	51	254.8	-0.8
X-4927	PDAC	gemcitabine-50mpk	788.1	24.8	53	288.6	-3.1
X-4927	PDAC	gemcitabine-50mpk	1124.1	24.3	57	454.3	-5.1
X-4927	PDAC	gemcitabine-50mpk	1198.1	25.4	60	490.8	-0.8
X-4927	PDAC	INC424 + binimetinib	273.5	26.1	0	0	0
X-4927	PDAC	INC424 + binimetinib	295.6	26.2	4	8.1	0.4
X-4927	PDAC	INC424 + binimetinib	312.3	26.5	7	14.2	1.5
X-4927	PDAC	INC424 + binimetinib	394.6	26.2	11	44.3	0.4
X-4927	PDAC	INC424 + binimetinib	435.3	26	14	59.2	-0.4
X-4927	PDAC	INC424 + binimetinib	535.6	25.9	18	95.8	-0.8
X-4927	PDAC	INC424 + binimetinib	785.4	25.9	21	187.2	-0.8
X-4927	PDAC	INC424 + binimetinib	881.4	26.6	25	222.3	1.9
X-4927	PDAC	INC424 + binimetinib	910	26.2	28	232.7	0.4
X-4927	PDAC	INC424 + binimetinib	909.2	25.3	31	232.4	-3.1
X-4927	PDAC	INC424 + binimetinib	942.8	23.5	34	244.7	-10
X-4927	PDAC	INC424 + binimetinib	867.5	25.4	39	217.2	-2.7
X-4927	PDAC	INC424 + binimetinib	1064	24.8	42	289	-5
X-4927	PDAC	INC424 + binimetinib	1028.2	24.2	46	275.9	-7.3
X-4927	PDAC	INC424 + binimetinib	1180.5	24.6	49	331.6	-5.7
X-4927	PDAC	INC424 + binimetinib	1007	24.1	52	268.2	-7.7
X-4927	PDAC	INC424 + binimetinib	1159.6	24.5	56	324	-6.1
X-4927	PDAC	INC424 + binimetinib	1899	24.2	59	594.3	-7.3
X-4927	PDAC	INC424 + binimetinib	1341.8	24.2	62	390.6	-7.3
X-4927	PDAC	INC424	238.3	25.3	0	0	0
X-4927	PDAC	INC424	263	26.1	3	10.4	3.2
X-4927	PDAC	INC424	286	26	6	20	2.8
X-4927	PDAC	INC424	399.2	26	10	67.5	2.8
X-4927	PDAC	INC424	583.1	24.3	16	144.7	-4
X-4927	PDAC	INC424	786.4	27	21	230	6.7
X-4927	PDAC	INC424	706.2	25.9	24	196.3	2.4
X-4927	PDAC	INC424	1231.7	25.1	28	416.9	-0.8
X-4927	PDAC	LEE011	250.1	24.5	0	0	0
X-4927	PDAC	LEE011	280.4	24.9	2	12.1	1.6
X-4927	PDAC	LEE011	352.6	25.8	5	41	5.3
X-4927	PDAC	LEE011	443.4	25.8	9	77.3	5.3
X-4927	PDAC	LEE011	348.9	24.5	13	39.5	0
X-4927	PDAC	LEE011	338	25.2	16	35.1	2.9
X-4927	PDAC	LEE011	480.7	25.4	20	92.2	3.7
X-4927	PDAC	LEE011	480.3	25.3	23	92	3.3
X-4927	PDAC	LEE011	538.4	26.5	26	115.3	8.2
X-4927	PDAC	LEE011	470.6	25.2	29	88.2	2.9
X-4927	PDAC	LEE011	412.8	26.2	34	65.1	6.9
X-4927	PDAC	LEE011	375.5	23.4	36	50.1	-4.5
X-4927	PDAC	LEE011	459.5	26.4	40	83.7	7.8
X-4927	PDAC	LEE011	570.8	26.8	43	128.2	9.4
X-4927	PDAC	LEE011	786.8	26.9	47	214.6	9.8
X-4927	PDAC	LEE011	1106.5	27.4	50	342.4	11.8
X-4927	PDAC	WNT974	206.8	26.2	0	0	0
X-4927	PDAC	WNT974	283.3	24.7	3	37	-5.7
X-4927	PDAC	WNT974	296.3	25.3	5	43.3	-3.4
X-4927	PDAC	WNT974	546.8	24.6	9	164.4	-6.1
X-4927	PDAC	WNT974	720.3	25.8	13	248.3	-1.5
X-4927	PDAC	WNT974	798.5	25.1	16	286.1	-4.2
X-4927	PDAC	LKA136	210.6	27.5	0	0	0
X-4927	PDAC	LKA136	282.7	26.1	5	34.2	-5.1
X-4927	PDAC	LKA136	366.4	25.8	7	74	-6.2
X-4927	PDAC	LKA136	486.9	27.1	11	131.2	-1.5
X-4927	PDAC	LKA136	536.4	27.2	13	154.7	-1.1
X-4927	PDAC	LKA136	939.4	26.9	19	346.1	-2.2
X-4927	PDAC	binimetinib	271.7	26.2	0	0	0
X-4927	PDAC	binimetinib	185.3	26.6	7	-31.8	1.5
X-4927	PDAC	binimetinib	222.9	27.1	14	-18	3.4
X-4927	PDAC	binimetinib	219.8	26	17	-19.1	-0.8
X-4927	PDAC	binimetinib	225.6	26.1	21	-17	-0.4
X-4927	PDAC	binimetinib	220.9	26.2	24	-18.7	0
X-4927	PDAC	binimetinib	149	26.6	28	-45.2	1.5
X-4927	PDAC	binimetinib	158.6	26.4	31	-41.6	0.8
X-4927	PDAC	binimetinib	210.6	26.6	35	-22.5	1.5
X-4927	PDAC	binimetinib	252.1	27.6	38	-7.2	5.3
X-4927	PDAC	binimetinib	147.4	27.9	42	-45.7	6.5
X-4927	PDAC	binimetinib	266.1	28	45	-2.1	6.9
X-4927	PDAC	binimetinib	174.9	26.9	49	-35.6	2.7
X-4927	PDAC	binimetinib	189.9	26.9	52	-30.1	2.7
X-4927	PDAC	binimetinib	202.1	27.8	56	-25.6	6.1
X-4927	PDAC	binimetinib	228.9	27.9	59	-15.8	6.5
X-4927	PDAC	binimetinib	263.8	28	63	-2.9	6.9
X-4927	PDAC	binimetinib	201.4	27.3	66	-25.9	4.2
X-4927	PDAC	binimetinib	206.5	27.9	70	-24	6.5
X-4927	PDAC	binimetinib	180.2	27.5	73	-33.7	5
X-4927	PDAC	binimetinib	184.3	27.4	76	-32.2	4.6
X-4927	PDAC	binimetinib	228.7	27.6	79	-15.8	5.3
X-4927	PDAC	binimetinib	139.9	27.5	84	-48.5	5
X-4927	PDAC	binimetinib	174.9	27	87	-35.6	3.1
X-4927	PDAC	binimetinib	179	26.8	91	-34.1	2.3
X-4927	PDAC	binimetinib	143.9	27.1	94	-47	3.4
X-4927	PDAC	binimetinib-3.5mpk	183.6	24.1	0	0	0
X-4927	PDAC	binimetinib-3.5mpk	291.5	23.2	2	58.8	-3.7
X-4927	PDAC	binimetinib-3.5mpk	346.3	23.2	6	88.6	-3.7
X-4927	PDAC	binimetinib-3.5mpk	536.7	21.6	9	192.3	-10.4
X-4927	PDAC	binimetinib-3.5mpk	669.2	23.3	12	264.5	-3.3
X-4927	PDAC	binimetinib-3.5mpk	769.5	23.8	15	319.1	-1.2
X-4927	PDAC	binimetinib-3.5mpk	1060.1	23.1	20	477.4	-4.1
X-4927	PDAC	binimetinib-3.5mpk	1478	23.8	23	705	-1.2
X-4927	PDAC	trametinib	196.3	24.6	0	0	0
X-4927	PDAC	trametinib	362.8	23.2	3	84.8	-5.7
X-4927	PDAC	trametinib	382.3	23	5	94.8	-6.5
X-4927	PDAC	trametinib	1095.4	23.8	10	458	-3.3
X-4927	PDAC	trametinib	862.2	24.4	13	339.2	-0.8
X-4927	PDAC	trametinib	846.9	21.2	18	331.4	-13.8
X-4927	PDAC	untreated	279.4	25.5	0	0	0
X-4927	PDAC	untreated	532.2	24.6	5	90.5	-3.5
X-4927	PDAC	untreated	711.6	25	7	154.7	-2
X-4927	PDAC	untreated	1029.4	25	11	268.4	-2
X-4927	PDAC	untreated	1189.6	27	13	325.8	5.9
X-4927	PDAC	untreated	1681.5	27.1	19	501.8	6.3
X-4949	BRCA	BGJ398	221.6	23.3	0	0	0
X-4949	BRCA	BGJ398	244.4	24	7	10.3	3
X-4949	BRCA	BGJ398	400.9	24.1	10	80.9	3.4
X-4949	BRCA	BGJ398	366.8	24.1	13	65.5	3.4
X-4949	BRCA	BGJ398	369.4	24.4	17	66.7	4.7
X-4949	BRCA	BGJ398	349.9	24.2	21	57.9	3.9
X-4949	BRCA	BGJ398	444.7	23.8	24	100.7	2.1
X-4949	BRCA	BGJ398	660.7	23.9	27	198.1	2.6
X-4949	BRCA	BGJ398	589.8	22	31	166.2	-5.6
X-4949	BRCA	BGJ398	481.6	22.9	35	117.3	-1.7
X-4949	BRCA	BGJ398	539.6	22.2	38	143.5	-4.7
X-4949	BRCA	BGJ398	427	22.5	41	92.7	-3.4
X-4949	BRCA	BKM120	209.5	27.2	0	0	0
X-4949	BRCA	BKM120	217.4	26.2	1	3.8	-3.7
X-4949	BRCA	BKM120	151.9	25.1	4	-27.5	-7.7
X-4949	BRCA	BKM120	169.5	27.6	8	-19.1	1.5
X-4949	BRCA	BKM120	172.8	26.6	12	-17.5	-2.2
X-4949	BRCA	BKM120	155.2	24.4	15	-25.9	-10.3
X-4949	BRCA	BKM120	111	24.5	18	-47	-9.9
X-4949	BRCA	BKM120	148.1	23.8	22	-29.3	-12.5
X-4949	BRCA	BKM120	150.8	23.1	26	-28	-15.1
X-4949	BRCA	BYL719 + LEE011	192.1	28.8	0	0	0
X-4949	BRCA	BYL719 + LEE011	204.5	28.8	1	6.5	0
X-4949	BRCA	BYL719 + LEE011	127	23.3	5	-33.9	-19.1
X-4949	BRCA	BYL719 + LEE011	142	25.9	8	-26.1	-10.1
X-4949	BRCA	BYL719 + LEE011	135.3	24.5	11	-29.6	-14.9
X-4949	BRCA	BYL719 + LEE011	168.3	25.6	15	-12.4	-11.1
X-4949	BRCA	BYL719 + LEE011	233.9	27.5	19	21.8	-4.5
X-4949	BRCA	BYL719 + LEE011	236.3	27.8	22	23	-3.5
X-4949	BRCA	BYL719 + LEE011	400.2	27.4	25	108.3	-4.9
X-4949	BRCA	BYL719 + LEE011	392.2	22.5	32	104.2	-21.9
X-4949	BRCA	BYL719 + LJM716	181.8	28.3	0	0	0
X-4949	BRCA	BYL719 + LJM716	142.5	26.8	1	-21.6	-5.3
X-4949	BRCA	BYL719 + LJM716	182.1	28	4	0.2	-1.1
X-4949	BRCA	BYL719 + LJM716	147.9	25.5	12	-18.6	-9.9
X-4949	BRCA	BYL719 + LJM716	175.9	25.9	15	-3.2	-8.5
X-4949	BRCA	BYL719 + LJM716	271.9	26.1	18	49.6	-7.8
X-4949	BRCA	BYL719 + LJM716	290.1	27.5	22	59.6	-2.8
X-4949	BRCA	BYL719 + LJM716	330.3	26.3	26	81.7	-7.1
X-4949	BRCA	BYL719 + LJM716	307.1	26.3	29	68.9	-7.1
X-4949	BRCA	BYL719 + LJM716	300.3	25.5	32	65.2	-9.9
X-4949	BRCA	BYL719 + LJM716	298.7	26	36	64.3	-8.1
X-4949	BRCA	BYL719 + LJM716	379	26.4	40	108.5	-6.7
X-4949	BRCA	BYL719 + LJM716	433.5	25.7	43	138.4	-9.2
X-4949	BRCA	BYL719 + LJM716	643.7	27.3	46	254.1	-3.5
X-4949	BRCA	BYL719	217.7	25.8	0	0	0
X-4949	BRCA	BYL719	185	25	7	-15	-3.1
X-4949	BRCA	BYL719	192.6	25.4	10	-11.5	-1.6
X-4949	BRCA	BYL719	214.5	25.2	13	-1.5	-2.3
X-4949	BRCA	BYL719	227.3	27.2	17	4.4	5.4
X-4949	BRCA	BYL719	255.9	26.9	21	17.5	4.3
X-4949	BRCA	BYL719	300.5	25.4	24	38	-1.6
X-4949	BRCA	BYL719	335.2	24.5	27	54	-5
X-4949	BRCA	BYL719	306	24.9	31	40.6	-3.5
X-4949	BRCA	BYL719	369.2	25.7	35	69.6	-0.4
X-4949	BRCA	BYL719	421.7	24.8	38	93.7	-3.9
X-4949	BRCA	BYL719	513.5	26.9	41	135.9	4.3
X-4949	BRCA	CGM097	285.5	31.3	0	0	0
X-4949	BRCA	CGM097	486.5	32.9	7	70.4	5.1
X-4949	BRCA	CGM097	636.1	32.3	10	122.8	3.2
X-4949	BRCA	CGM097	601.2	32.9	13	110.6	5.1
X-4949	BRCA	CGM097	754.6	33.9	17	164.3	8.3
X-4949	BRCA	CGM097	924.3	33.2	21	223.7	6.1
X-4949	BRCA	CGM097	970.6	32.1	24	240	2.6
X-4949	BRCA	CGM097	1423	31.9	27	398.4	1.9
X-4949	BRCA	CLR457	209.5	29.7	0	0	0
X-4949	BRCA	CLR457	370.3	30.6	7	76.8	3
X-4949	BRCA	CLR457	327.2	31.4	10	56.2	5.7
X-4949	BRCA	CLR457	462	30.2	13	120.5	1.7
X-4949	BRCA	CLR457	502.3	31.3	17	139.8	5.4
X-4949	BRCA	CLR457	621.1	31.6	21	196.5	6.4
X-4949	BRCA	CLR457	693.8	29.6	24	231.2	-0.3
X-4949	BRCA	CLR457	639.5	31.2	27	205.3	5.1
X-4949	BRCA	CLR457	889.5	30.5	31	324.6	2.7
X-4949	BRCA	CLR457	1087.1	30	35	418.9	1
X-4949	BRCA	CLR457	1432.5	28.8	38	583.8	-3
X-4949	BRCA	CLR457	1359.8	29.2	41	549.1	-1.7
X-4949	BRCA	HDM201	221.8	26.2	0	0	0
X-4949	BRCA	HDM201	376.2	26.7	7	69.6	1.9
X-4949	BRCA	HDM201	584.5	26.3	10	163.5	0.4
X-4949	BRCA	HDM201	598.7	25.1	13	169.9	-4.2
X-4949	BRCA	HDM201	681.1	27.8	17	207.1	6.1
X-4949	BRCA	HDM201	494	26.5	21	122.7	1.1
X-4949	BRCA	HDM201	961.6	25.5	24	333.5	-2.7
X-4949	BRCA	HDM201	1030.7	27.5	27	364.7	5
X-4949	BRCA	INC424	239.4	30	0	0	0
X-4949	BRCA	INC424	204.5	29.8	1	-14.6	-0.7
X-4949	BRCA	INC424	323.7	28.6	4	35.2	-4.7
X-4949	BRCA	INC424	406.6	30.2	8	69.8	0.7
X-4949	BRCA	INC424	452.8	30.7	12	89.1	2.3
X-4949	BRCA	INC424	618.3	29.8	15	158.3	-0.7
X-4949	BRCA	INC424	783	31.2	18	227.1	4
X-4949	BRCA	INC424	1011.6	30.6	22	322.6	2
X-4949	BRCA	INC424	1225.8	30.9	26	412	3
X-4949	BRCA	INC424	1280.4	29.4	29	434.8	-2
X-4949	BRCA	INC424	1565.1	30.7	32	553.8	2.3
X-4949	BRCA	LEE011	241.4	28.1	0	0	0
X-4949	BRCA	LEE011	282.4	25.5	3	17	-9.3
X-4949	BRCA	LEE011	223.1	25	6	-7.6	-11
X-4949	BRCA	LEE011	268.7	27	10	11.3	-3.9
X-4949	BRCA	LEE011	388.3	29.1	14	60.9	3.6
X-4949	BRCA	LEE011	462.6	29.9	17	91.6	6.4
X-4949	BRCA	LEE011	487	30	20	101.7	6.8
X-4949	BRCA	LEE011	740.8	29.9	27	206.9	6.4
X-4949	BRCA	LEE011 + everolimus	238.6	27.5	0	0	0
X-4949	BRCA	LEE011 + everolimus	259.6	29.1	1	8.8	5.8
X-4949	BRCA	LEE011 + everolimus	180.6	26.5	5	-24.3	-3.6
X-4949	BRCA	LEE011 + everolimus	327.7	26.3	8	37.3	-4.4
X-4949	BRCA	LEE011 + everolimus	261	26	11	9.4	-5.5
X-4949	BRCA	LEE011 + everolimus	255.7	25.5	15	7.2	-7.3
X-4949	BRCA	LEE011 + everolimus	265.1	27.4	19	11.1	-0.4
X-4949	BRCA	LEE011 + everolimus	327.1	26.3	22	37.1	-4.4
X-4949	BRCA	LEE011 + everolimus	428.7	27.4	25	79.7	-0.4
X-4949	BRCA	LEE011 + everolimus	604	28	32	153.1	1.8
X-4949	BRCA	LFA102	195.2	26.1	0	0	0
X-4949	BRCA	LFA102	321.5	28.8	7	64.7	10.3
X-4949	BRCA	LFA102	366.3	28.8	10	87.7	10.3
X-4949	BRCA	LFA102	543	29.4	13	178.2	12.6
X-4949	BRCA	LFA102	665.3	29.5	17	240.8	13
X-4949	BRCA	LFA102	638.6	29	21	227.2	11.1
X-4949	BRCA	LFA102	826.3	26.3	24	323.3	0.8
X-4949	BRCA	LFA102	1012.6	29.6	27	418.8	13.4
X-4949	BRCA	LJM716 + trastuzumab	223.3	25.6	0	0	0
X-4949	BRCA	LJM716 + trastuzumab	262.9	24.1	3	17.7	-5.9
X-4949	BRCA	LJM716 + trastuzumab	209.3	24.9	6	-6.3	-2.7
X-4949	BRCA	LJM716 + trastuzumab	230.5	26.3	10	3.2	2.7
X-4949	BRCA	LJM716 + trastuzumab	384.7	24.9	14	72.3	-2.7
X-4949	BRCA	LJM716 + trastuzumab	344.4	24.5	17	54.2	-4.3
X-4949	BRCA	LJM716 + trastuzumab	533.6	24.6	20	139	-3.9
X-4949	BRCA	LJM716 + trastuzumab	826.5	24.4	24	270.1	-4.7
X-4949	BRCA	LJM716 + trastuzumab	908.5	26.7	28	306.9	4.3
X-4949	BRCA	LJM716 + trastuzumab	973.1	24.8	31	335.8	-3.1
X-4949	BRCA	LJM716 + trastuzumab	1430.1	25.3	34	540.4	-1.2
X-4949	BRCA	LJM716	196.7	27.1	0	0	0
X-4949	BRCA	LJM716	213.3	23.6	3	8.4	-12.9
X-4949	BRCA	LJM716	280.2	23	6	42.5	-15.1
X-4949	BRCA	LJM716	291.3	24.3	10	48.1	-10.3
X-4949	BRCA	LJM716	262.2	23.5	14	33.3	-13.3
X-4949	BRCA	LJM716	359.7	23.8	17	82.9	-12.2
X-4949	BRCA	LJM716	460.5	23.7	20	134.1	-12.5
X-4949	BRCA	LJM716	504.3	27.5	24	156.4	1.5
X-4949	BRCA	LJM716	505.7	22.8	28	157.1	-15.9
X-4949	BRCA	LJM716	589.6	23.4	31	199.7	-13.7
X-4949	BRCA	LJM716	479.7	20.7	34	143.9	-23.6
X-4949	BRCA	LKA136	248.1	28.4	0	0	0
X-4949	BRCA	LKA136	255.2	28.5	1	2.9	0.4
X-4949	BRCA	LKA136	350	27.9	4	41.1	-1.8
X-4949	BRCA	LKA136	921.9	28.8	12	271.6	1.4
X-4949	BRCA	LKA136	882.3	29.1	15	255.6	2.5
X-4949	BRCA	LKA136	1197.1	28.7	18	382.5	1.1
X-4949	BRCA	LKA136	1381.1	29.6	22	456.7	4.2
X-4949	BRCA	LKA136	1568	30	26	532	5.6
X-4949	BRCA	LLM871	233.2	29.7	0	0	0
X-4949	BRCA	LLM871	203.4	28.2	3	-12.8	-5.1
X-4949	BRCA	LLM871	198.4	27.9	7	-14.9	-6.1
X-4949	BRCA	LLM871	411.6	26.5	10	76.5	-10.8
X-4949	BRCA	LLM871	346.4	27.8	13	48.5	-6.4
X-4949	BRCA	LLM871	596.2	27.9	17	155.7	-6.1
X-4949	BRCA	LLM871	589	29.4	21	152.6	-1
X-4949	BRCA	LLM871	774.3	29.5	24	232	-0.7
X-4949	BRCA	LLM871	955.2	29.8	27	309.6	0.3
X-4949	BRCA	binimetinib	229.2	24	0	0	0
X-4949	BRCA	binimetinib	258.5	23.3	1	12.8	-2.9
X-4949	BRCA	binimetinib	286.8	23	4	25.1	-4.2
X-4949	BRCA	binimetinib	418.5	23.5	12	82.6	-2.1
X-4949	BRCA	binimetinib	506	23.9	15	120.8	-0.4
X-4949	BRCA	binimetinib	515.6	23.2	18	125	-3.3
X-4949	BRCA	binimetinib	625.1	24.6	22	172.7	2.5
X-4949	BRCA	binimetinib	657.2	24.5	26	186.7	2.1
X-4949	BRCA	binimetinib	674.9	22.7	29	194.5	-5.4
X-4949	BRCA	binimetinib	854.4	24.6	32	272.8	2.5
X-4949	BRCA	binimetinib	693.8	24.3	36	202.7	1.2
X-4949	BRCA	binimetinib	1274.5	24.3	40	456.1	1.2
X-4949	BRCA	binimetinib	1111.7	23.7	43	385	-1.3
X-4949	BRCA	binimetinib	1360.5	24.1	46	493.6	0.4
X-4949	BRCA	paclitaxel	206.1	26.8	0	0	0
X-4949	BRCA	paclitaxel	271.2	26.2	7	31.6	-2.2
X-4949	BRCA	paclitaxel	323.4	25.7	10	56.9	-4.1
X-4949	BRCA	paclitaxel	388.7	26.9	13	88.6	0.4
X-4949	BRCA	paclitaxel	363.2	26.6	17	76.2	-0.7
X-4949	BRCA	paclitaxel	481.6	27.6	21	133.7	3
X-4949	BRCA	paclitaxel	496.4	23.2	24	140.9	-13.4
X-4949	BRCA	paclitaxel	542.9	26.8	27	163.4	0
X-4949	BRCA	paclitaxel	581.5	26.4	31	182.1	-1.5
X-4949	BRCA	paclitaxel	735.2	27.5	35	256.7	2.6
X-4949	BRCA	paclitaxel	957.9	27.3	38	364.8	1.9
X-4949	BRCA	paclitaxel	1147.5	27.5	41	456.8	2.6
X-4949	BRCA	tamoxifen	260.3	27	0	0	0
X-4949	BRCA	tamoxifen	317.8	27.8	3	22.1	3
X-4949	BRCA	tamoxifen	505.9	27.5	6	94.4	1.9
X-4949	BRCA	tamoxifen	1109.1	27.7	14	326.1	2.6
X-4949	BRCA	tamoxifen	1447	27.9	17	455.9	3.3
X-4949	BRCA	tamoxifen	1403	28.2	20	439	4.4
X-4949	BRCA	tamoxifen	1602.5	29.6	22	515.6	9.6
X-4949	BRCA	trastuzumab	280.5	28.3	0	0	0
X-4949	BRCA	trastuzumab	351.5	28.1	3	25.3	-0.7
X-4949	BRCA	trastuzumab	448.3	27.9	6	59.8	-1.4
X-4949	BRCA	trastuzumab	384.4	26.9	10	37	-4.9
X-4949	BRCA	trastuzumab	444.1	28.1	14	58.3	-0.7
X-4949	BRCA	trastuzumab	533.7	27.5	17	90.3	-2.8
X-4949	BRCA	trastuzumab	597.2	27.7	20	112.9	-2.1
X-4949	BRCA	trastuzumab	547	28.3	24	95	0
X-4949	BRCA	trastuzumab	722.9	28.3	28	157.7	0
X-4949	BRCA	trastuzumab	792.7	27.7	31	182.6	-2.1
X-4949	BRCA	trastuzumab	882.4	28.3	34	214.6	0
X-4949	BRCA	untreated	229.7	29.5	0	0	0
X-4949	BRCA	untreated	434.9	28.1	3	89.3	-4.7
X-4949	BRCA	untreated	482.4	27.5	6	110	-6.8
X-4949	BRCA	untreated	781	28.4	10	240	-3.7
X-4949	BRCA	untreated	998.9	29.4	14	334.9	-0.3
X-4949	BRCA	untreated	1194.6	29.2	17	420.1	-1
X-4949	BRCA	untreated	1643.6	29.8	20	615.5	1
X-5189	CM	BKM120	223	20.5	0	0	0
X-5189	CM	BKM120	227.9	18.2	4	2.2	-11.2
X-5189	CM	BKM120	215	16.9	8	-3.6	-17.6
X-5189	CM	BKM120	224.3	17.8	13	0.6	-13.2
X-5189	CM	BKM120	224.3	16.3	18	0.6	-20.5
X-5189	CM	BKM120 + encorafenib	196	26.8	0	0	0
X-5189	CM	BKM120 + encorafenib	213.2	24.6	4	8.8	-8.2
X-5189	CM	BKM120 + encorafenib	236.8	24.6	9	20.8	-8.2
X-5189	CM	BKM120 + encorafenib	237.1	23.2	14	21	-13.4
X-5189	CM	BKM120 + encorafenib	278.7	22.5	17	42.2	-16
X-5189	CM	BKM120 + encorafenib	342.2	21.8	21	74.6	-18.7
X-5189	CM	CGM097	188.7	21	0	0	0
X-5189	CM	CGM097	191.1	22.2	3	1.3	5.7
X-5189	CM	CGM097	199.8	20.5	7	5.9	-2.4
X-5189	CM	CGM097	253.1	20.8	11	34.2	-1
X-5189	CM	CGM097	318.2	20.1	16	68.7	-4.3
X-5189	CM	CGM097	330.7	19.7	21	75.3	-6.2
X-5189	CM	CGM097	359.5	19.5	24	90.6	-7.1
X-5189	CM	CGM097	572.2	19.2	28	203.3	-8.6
X-5189	CM	CGM097	510	19	34	170.3	-9.5
X-5189	CM	CGM097	510	19	35	170.3	-9.5
X-5189	CM	CLR457	191.6	21.6	0	0	0
X-5189	CM	CLR457	202.6	20.9	5	5.7	-3.2
X-5189	CM	CLR457	270.7	19.8	10	41.3	-8.3
X-5189	CM	CLR457	340.2	18.8	13	77.6	-13
X-5189	CM	CLR457	305.1	18.7	17	59.3	-13.4
X-5189	CM	CLR457	334.1	18.8	23	74.4	-13
X-5189	CM	CLR457	334.1	18.8	24	74.4	-13
X-5189	CM	dacarbazine	198.8	21.4	0	0	0
X-5189	CM	dacarbazine	207.1	21.3	5	4.2	-0.5
X-5189	CM	dacarbazine	237.2	18.2	10	19.3	-15
X-5189	CM	dacarbazine	284.1	17.5	13	42.9	-18.2
X-5189	CM	LDE225	210.7	24	0	0	0
X-5189	CM	LDE225	243.7	22.2	4	15.6	-7.5
X-5189	CM	LDE225	252.1	21.5	8	19.6	-10.4
X-5189	CM	LDE225	222	20.4	13	5.3	-15
X-5189	CM	LDE225	238.2	18.6	18	13.1	-22.5
X-5189	CM	LDK378	210.4	19.6	0	0	0
X-5189	CM	LDK378	190.8	20	4	-9.3	2
X-5189	CM	LDK378	322.5	20.8	8	53.3	6.1
X-5189	CM	LDK378	316.8	19.9	13	50.6	1.5
X-5189	CM	LDK378	488.7	18.8	18	132.3	-4.1
X-5189	CM	LDK378	539	18.8	21	156.2	-4.1
X-5189	CM	LEE011	210.7	21.3	0	0	0
X-5189	CM	LEE011	227.8	23.2	3	8.1	8.9
X-5189	CM	LEE011	186.4	18.8	7	-11.5	-11.7
X-5189	CM	LEE011	241.1	19.2	11	14.4	-9.9
X-5189	CM	LEE011	245.1	20.6	16	16.3	-3.3
X-5189	CM	LEE011	267	20	21	26.7	-6.1
X-5189	CM	LEE011	269.6	20.1	24	27.9	-5.6
X-5189	CM	LEE011	273.8	20.5	28	29.9	-3.8
X-5189	CM	LEE011	343.9	18.8	34	63.2	-11.7
X-5189	CM	LEE011	343.9	18.8	35	63.2	-11.7
X-5189	CM	LEE011 + encorafenib	208.3	23.4	0	0	0
X-5189	CM	LEE011 + encorafenib	244.5	21.9	4	17.4	-6.4
X-5189	CM	LEE011 + encorafenib	348.8	21.7	9	67.5	-7.3
X-5189	CM	LEE011 + encorafenib	487.4	21.7	14	134	-7.3
X-5189	CM	LEE011 + encorafenib	539.1	21	17	158.9	-10.3
X-5189	CM	LEE011 + encorafenib	503.7	20	21	141.8	-14.5
X-5189	CM	LEE011 + binimetinib	217.7	21.5	0	0	0
X-5189	CM	LEE011 + binimetinib	128.8	20.4	5	-40.9	-5.1
X-5189	CM	LEE011 + binimetinib	94.2	20.8	8	-56.7	-3.3
X-5189	CM	LEE011 + binimetinib	57.6	22.2	12	-73.5	3.3
X-5189	CM	LEE011 + binimetinib	52.9	24.2	18	-75.7	12.6
X-5189	CM	LEE011 + binimetinib	62.5	25.7	21	-71.3	19.5
X-5189	CM	LEE011 + binimetinib	58.5	26.4	26	-73.1	22.8
X-5189	CM	LEE011 + binimetinib	20.2	23.2	35	-90.7	7.9
X-5189	CM	LEE011 + binimetinib	29.6	21	41	-86.4	-2.3
X-5189	CM	WNT974	231	22.6	0	0	0
X-5189	CM	WNT974	489.3	21.9	4	111.8	-3.1
X-5189	CM	WNT974	817.2	21.7	8	253.7	-4
X-5189	CM	WNT974	1266.6	21.7	13	448.2	-4
X-5189	CM	WNT974	1838	21.4	18	695.5	-5.3
X-5189	CM	LGW813	211.9	21.1	0	0	0
X-5189	CM	LGW813	182.3	20.1	4	-14	-4.7
X-5189	CM	LGW813	190.1	19.4	8	-10.3	-8.1
X-5189	CM	LGW813	274.4	19.9	13	29.5	-5.7
X-5189	CM	LGW813	259.2	19.3	18	22.3	-8.5
X-5189	CM	LGW813	340.7	18.5	21	60.8	-12.3
X-5189	CM	LGW813	396.1	18.2	25	87	-13.7
X-5189	CM	LGW813	306.4	18.6	31	44.6	-11.8
X-5189	CM	LGW813	306.4	18.6	32	44.6	-11.8
X-5189	CM	encorafenib	233.3	21.9	0	0	0
X-5189	CM	encorafenib	518.9	22	3	122.5	0.5
X-5189	CM	encorafenib	744.2	20.3	7	219	-7.3
X-5189	CM	encorafenib	948.7	20.4	11	306.7	-6.8
X-5189	CM	encorafenib	1163.6	20.5	16	398.8	-6.4
X-5189	CM	encorafenib	1368.5	20.4	21	486.6	-6.8
X-5189	CM	encorafenib + binimetinib	222.2	22.4	0	0	0
X-5189	CM	encorafenib + binimetinib	166.5	20.8	4	-25.1	-7.1
X-5189	CM	encorafenib + binimetinib	154.9	21.8	9	-30.3	-2.7
X-5189	CM	encorafenib + binimetinib	148.1	21.2	14	-33.3	-5.4
X-5189	CM	encorafenib + binimetinib	112.1	21.2	17	-49.6	-5.4
X-5189	CM	encorafenib + binimetinib	96	21.4	21	-56.8	-4.5
X-5189	CM	encorafenib + binimetinib	118.8	22	27	-46.5	-1.8
X-5189	CM	encorafenib + binimetinib	175.1	22.9	30	-21.2	2.2
X-5189	CM	encorafenib + binimetinib	126	22.5	35	-43.3	0.4
X-5189	CM	encorafenib + binimetinib	195.3	21	44	-12.1	-6.2
X-5189	CM	encorafenib + binimetinib	172	20.3	50	-22.6	-9.4
X-5189	CM	encorafenib + binimetinib	281.6	20.6	58	26.8	-8
X-5189	CM	binimetinib	221.8	21	0	0	0
X-5189	CM	binimetinib	201.6	21.5	3	-9.1	2.4
X-5189	CM	binimetinib	129	19.6	7	-41.8	-6.7
X-5189	CM	binimetinib	135.2	20.8	11	-39.1	-1
X-5189	CM	binimetinib	65.3	21.4	16	-70.6	1.9
X-5189	CM	binimetinib	134.9	22.4	21	-39.2	6.7
X-5189	CM	binimetinib	144.2	23.2	24	-35	10.5
X-5189	CM	binimetinib	130	22	28	-41.4	4.8
X-5189	CM	binimetinib	164.7	21.7	34	-25.7	3.3
X-5189	CM	binimetinib	240.1	21.4	37	8.3	1.9
X-5189	CM	binimetinib	220.5	21.2	42	-0.6	1
X-5189	CM	binimetinib	261.8	20.2	51	18	-3.8
X-5189	CM	binimetinib	269.3	20.6	56	21.4	-1.9
X-5189	CM	binimetinib	274.4	20.6	64	23.7	-1.9
X-5189	CM	TAS266	189	20.7	0	0	0
X-5189	CM	TAS266	68.8	23.2	3	-63.6	12.1
X-5189	CM	TAS266	24	23.8	7	-87.3	15
X-5189	CM	TAS266	25.4	24.2	11	-86.5	16.9
X-5189	CM	TAS266	31.1	25.4	16	-83.6	22.7
X-5189	CM	TAS266	36.1	24.8	21	-80.9	19.8
X-5189	CM	TAS266	34.4	23.8	24	-81.8	15
X-5189	CM	TAS266	33.6	23.4	28	-82.2	13
X-5189	CM	TAS266	33.5	24.7	34	-82.3	19.3
X-5189	CM	TAS266	48.1	25.8	37	-74.6	24.6
X-5189	CM	TAS266	50.3	25.1	42	-73.4	21.3
X-5189	CM	TAS266	99.1	24.1	51	-47.6	16.4
X-5189	CM	TAS266	130.2	24.5	56	-31.1	18.4
X-5189	CM	TAS266	133.2	24.6	64	-29.5	18.8
X-5189	CM	TAS266	154.8	23.8	76	-18.1	15
X-5189	CM	TAS266	228.1	23.7	83	20.7	14.5
X-5189	CM	TAS266	275.6	22.3	90	45.8	7.7
X-5189	CM	TAS266	339.6	22	92	79.6	6.3
X-5189	CM	untreated	228.1	20.9	0	0	0
X-5189	CM	untreated	404	22.3	3	77.1	6.7
X-5189	CM	untreated	620.6	20.2	7	172.1	-3.3
X-5189	CM	untreated	867.9	21.6	11	280.5	3.3
X-5189	CM	untreated	921.7	21.2	16	304.1	1.4
X-5189	CM	untreated	1359.1	21.3	21	495.8	1.9
X-5205	PDAC	BKM120 + binimetinib	211.9	30	0	0	0
X-5205	PDAC	BKM120 + binimetinib	215.8	30.9	4	1.8	3
X-5205	PDAC	BKM120 + binimetinib	206.9	31.4	6	-2.4	4.7
X-5205	PDAC	BKM120 + binimetinib	170.2	31.8	11	-19.7	6
X-5205	PDAC	BKM120 + binimetinib	141	32	18	-33.5	6.7
X-5205	PDAC	BKM120 + binimetinib	124.8	32.1	25	-41.1	7
X-5205	PDAC	BKM120 + binimetinib	156.6	31.9	28	-26.1	6.3
X-5205	PDAC	BKM120 + binimetinib	139.6	32.5	33	-34.1	8.3
X-5205	PDAC	BKM120 + binimetinib	119.5	32.9	35	-43.6	9.7
X-5205	PDAC	BKM120 + binimetinib	149	32.6	39	-29.7	8.7
X-5205	PDAC	BKM120 + binimetinib	139.3	34	42	-34.3	13.3
X-5205	PDAC	BKM120 + binimetinib	136.4	30.9	46	-35.6	3
X-5205	PDAC	BKM120 + binimetinib	141.9	33	49	-33	10
X-5205	PDAC	BKM120 + binimetinib	166	34.1	52	-21.7	13.7
X-5205	PDAC	BKM120 + binimetinib	196.2	33.7	55	-7.4	12.3
X-5205	PDAC	BKM120 + binimetinib	172.7	32.8	60	-18.5	9.3
X-5205	PDAC	BKM120 + binimetinib	130.6	32.7	66	-38.4	9
X-5205	PDAC	BKM120 + binimetinib	232	32.1	69	9.5	7
X-5205	PDAC	BKM120 + binimetinib	220.4	32.9	74	4	9.7
X-5205	PDAC	BKM120 + binimetinib	234.4	33.3	77	10.6	11
X-5205	PDAC	BKM120 + binimetinib	293.3	33.4	81	38.4	11.3
X-5205	PDAC	BKM120 + binimetinib	181.7	32.6	84	-14.3	8.7
X-5205	PDAC	BKM120 + LDE225	249.8	25.7	0	0	0
X-5205	PDAC	BKM120 + LDE225	186.7	25.8	1	-25.3	0.4
X-5205	PDAC	BKM120 + LDE225	207.9	24.4	6	-16.8	-5.1
X-5205	PDAC	BKM120 + LDE225	176.3	24.7	12	-29.4	-3.9
X-5205	PDAC	BKM120 + LDE225	141.9	24.2	15	-43.2	-5.8
X-5205	PDAC	BKM120 + LDE225	160.4	23.9	20	-35.8	-7
X-5205	PDAC	BKM120 + LDE225	138.1	24.2	23	-44.7	-5.8
X-5205	PDAC	BKM120 + LDE225	132.5	23.9	27	-47	-7
X-5205	PDAC	BKM120 + LDE225	101	24.2	30	-59.6	-5.8
X-5205	PDAC	BKM120 + LDE225	70.9	23.6	34	-71.6	-8.2
X-5205	PDAC	BKM120 + LDE225	56.7	22.6	36	-77.3	-12.1
X-5205	PDAC	BKM120 + LDE225	130	22.5	41	-48	-12.5
X-5205	PDAC	BKM120 + LDE225	113.4	22.3	48	-54.6	-13.2
X-5205	PDAC	BKM120 + LDE225	114	22.8	51	-54.4	-11.3
X-5205	PDAC	BKM120 + LDE225	128.1	23	55	-48.7	-10.5
X-5205	PDAC	BKM120 + LDE225	154	24.5	58	-38.4	-4.7
X-5205	PDAC	BKM120 + LDE225	233.9	26.6	62	-6.4	3.5
X-5205	PDAC	BKM120 + LDE225	276.8	26.6	65	10.8	3.5
X-5205	PDAC	BKM120 + LDE225	309.7	24.4	69	24	-5.1
X-5205	PDAC	BKM120 + LDE225	359.2	23.9	72	43.8	-7
X-5205	PDAC	BKM120 + LDE225	399.4	23.9	76	59.9	-7
X-5205	PDAC	BKM120 + LDE225	271.5	22.6	79	8.7	-12.1
X-5205	PDAC	BKM120 + LDE225	272.8	21.6	83	9.2	-16
X-5205	PDAC	BKM120 + LDE225	257.7	21.1	86	3.2	-17.9
X-5205	PDAC	BKM120	253.1	24.4	0	0	0
X-5205	PDAC	BKM120	283.8	24.4	4	12.1	0
X-5205	PDAC	BKM120	369.2	24.1	7	45.9	-1.2
X-5205	PDAC	BKM120	369.4	23.9	11	46	-2
X-5205	PDAC	BKM120	467.8	24.1	14	84.8	-1.2
X-5205	PDAC	BKM120	564.7	25	18	123.1	2.5
X-5205	PDAC	BKM120	765.7	25.7	21	202.5	5.3
X-5205	PDAC	BKM120	553.9	25.7	25	118.8	5.3
X-5205	PDAC	BKM120	692.9	26	28	173.8	6.6
X-5205	PDAC	BKM120	787.9	26.8	32	211.3	9.8
X-5205	PDAC	BKM120	943.4	25.6	34	272.7	4.9
X-5205	PDAC	BYL719 + LJM716	223.5	28.7	0	0	0
X-5205	PDAC	BYL719 + LJM716	242.2	27.8	4	8.4	-3.1
X-5205	PDAC	BYL719 + LJM716	247.5	26.8	7	10.7	-6.6
X-5205	PDAC	BYL719 + LJM716	250.4	27.6	11	12	-3.8
X-5205	PDAC	BYL719 + LJM716	267.7	26.5	14	19.8	-7.7
X-5205	PDAC	BYL719 + LJM716	300.7	27.4	18	34.5	-4.5
X-5205	PDAC	BYL719 + LJM716	332.8	27.1	21	48.9	-5.6
X-5205	PDAC	BYL719 + LJM716	350.8	27.6	25	57	-3.8
X-5205	PDAC	BYL719 + LJM716	408.2	25.7	27	82.6	-10.5
X-5205	PDAC	BYL719 + LJM716	441	26.7	32	97.3	-7
X-5205	PDAC	BYL719 + LJM716	488.9	26.8	35	118.7	-6.6
X-5205	PDAC	BYL719 + LJM716	494.9	26.7	39	121.4	-7
X-5205	PDAC	BYL719 + LJM716	518.9	27.3	42	132.2	-4.9
X-5205	PDAC	BYL719 + LJM716	516.7	27.7	45	131.2	-3.5
X-5205	PDAC	BYL719	257.1	33.8	0	0	0
X-5205	PDAC	BYL719	251.4	33.2	4	-2.2	-1.8
X-5205	PDAC	BYL719	234.3	33.1	7	-8.9	-2.1
X-5205	PDAC	BYL719	255.7	31.8	11	-0.5	-5.9
X-5205	PDAC	BYL719	262.7	32.4	14	2.2	-4.1
X-5205	PDAC	BYL719	268.7	33.3	18	4.5	-1.5
X-5205	PDAC	BYL719	296.4	32.8	21	15.3	-3
X-5205	PDAC	BYL719	334.1	33.6	25	29.9	-0.6
X-5205	PDAC	BYL719	345.7	32	27	34.5	-5.3
X-5205	PDAC	BYL719	463.7	33	32	80.4	-2.4
X-5205	PDAC	BYL719	463.1	33.7	35	80.1	-0.3
X-5205	PDAC	BYL719	468.4	32.9	39	82.2	-2.7
X-5205	PDAC	BYL719	448.9	32.2	42	74.6	-4.7
X-5205	PDAC	BYL719	449.7	33.1	45	74.9	-2.1
X-5205	PDAC	CLR457	292.3	25.2	0	0	0
X-5205	PDAC	CLR457	361.4	24.9	4	23.6	-1.2
X-5205	PDAC	CLR457	368.5	24.8	7	26.1	-1.6
X-5205	PDAC	CLR457	382.6	24	11	30.9	-4.8
X-5205	PDAC	CLR457	398.8	23.8	14	36.4	-5.6
X-5205	PDAC	CLR457	456.8	24.5	18	56.3	-2.8
X-5205	PDAC	CLR457	426.4	24.4	21	45.9	-3.2
X-5205	PDAC	CLR457	421.1	23.7	24	44.1	-6
X-5205	PDAC	CLR457	454.3	24.1	27	55.4	-4.4
X-5205	PDAC	CLR457	502.1	25.7	32	71.8	2
X-5205	PDAC	CLR457	576.7	24.9	35	97.3	-1.2
X-5205	PDAC	CLR457	631.1	24.9	39	115.9	-1.2
X-5205	PDAC	CLR457	651.3	24.4	42	122.8	-3.2
X-5205	PDAC	CLR457	694.8	24.4	45	137.7	-3.2
X-5205	PDAC	HDM201	212.2	26.4	0	0	0
X-5205	PDAC	HDM201	158.5	24.5	4	-25.3	-7.2
X-5205	PDAC	HDM201	82.4	25.6	6	-61.2	-3
X-5205	PDAC	HDM201	28.2	26.8	11	-86.7	1.5
X-5205	PDAC	HDM201	27.1	27.8	14	-87.2	5.3
X-5205	PDAC	HDM201	11.3	28.4	18	-94.7	7.6
X-5205	PDAC	HDM201	10.5	27	21	-95.1	2.3
X-5205	PDAC	HDM201	9.4	26.8	24	-95.6	1.5
X-5205	PDAC	figitumumab"	221.7	24.5	0	0	0
X-5205	PDAC	figitumumab"	181.2	23.6	6	-18.3	-3.7
X-5205	PDAC	figitumumab"	226.8	23.8	8	2.3	-2.9
X-5205	PDAC	figitumumab"	218.9	24.2	12	-1.3	-1.2
X-5205	PDAC	figitumumab"	297.6	24.8	16	34.2	1.2
X-5205	PDAC	figitumumab"	344.8	25.5	20	55.5	4.1
X-5205	PDAC	figitumumab"	417.2	24.7	23	88.2	0.8
X-5205	PDAC	figitumumab"	422.4	24.5	26	90.5	0
X-5205	PDAC	figitumumab"	430.6	24.9	30	94.2	1.6
X-5205	PDAC	figitumumab"	385.1	25.7	34	73.7	4.9
X-5205	PDAC	figitumumab"	306.5	26.3	37	38.2	7.3
X-5205	PDAC	figitumumab"	450.8	24.3	41	103.3	-0.8
X-5205	PDAC	figitumumab"	547.8	25.1	44	147.1	2.4
X-5205	PDAC	figitumumab"	595.6	25.6	47	168.7	4.5
X-5205	PDAC	figitumumab"	628.3	25	50	183.4	2
X-5205	PDAC	figitumumab"	580.7	26	55	161.9	6.1
X-5205	PDAC	figitumumab"	691.7	27.1	57	212	10.6
X-5205	PDAC	figitumumab"	674.7	25.2	61	204.3	2.9
X-5205	PDAC	figitumumab"	633.8	24.8	64	185.9	1.2
X-5205	PDAC	figitumumab"	699.6	24.7	68	215.6	0.8
X-5205	PDAC	figitumumab"	826.2	25.3	71	272.7	3.3
X-5205	PDAC	figitumumab"	842.4	25.5	75	280	4.1
X-5205	PDAC	figitumumab"	835.4	25.6	78	276.8	4.5
X-5205	PDAC	figitumumab"	865.4	26	83	290.3	6.1
X-5205	PDAC	gemcitabine-50mpk	280.2	27	0	0	0
X-5205	PDAC	gemcitabine-50mpk	285.9	24.8	2	2	-8.1
X-5205	PDAC	gemcitabine-50mpk	216	23.2	7	-22.9	-14.1
X-5205	PDAC	gemcitabine-50mpk	177	25.8	10	-36.8	-4.4
X-5205	PDAC	gemcitabine-50mpk	143.1	26.1	14	-48.9	-3.3
X-5205	PDAC	gemcitabine-50mpk	126.6	26.3	17	-54.8	-2.6
X-5205	PDAC	gemcitabine-50mpk	72	27.4	20	-74.3	1.5
X-5205	PDAC	gemcitabine-50mpk	81.4	26.7	24	-70.9	-1.1
X-5205	PDAC	gemcitabine-50mpk	75.1	27.6	27	-73.2	2.2
X-5205	PDAC	gemcitabine-50mpk	71	26.4	31	-74.7	-2.2
X-5205	PDAC	gemcitabine-50mpk	73.2	25.2	34	-73.9	-6.7
X-5205	PDAC	gemcitabine-50mpk	50.3	27.8	38	-82	3
X-5205	PDAC	gemcitabine-50mpk	35.4	26.9	41	-87.4	-0.4
X-5205	PDAC	gemcitabine-50mpk	65.5	26	44	-76.6	-3.7
X-5205	PDAC	gemcitabine-50mpk	31.2	25.2	49	-88.9	-6.7
X-5205	PDAC	gemcitabine-50mpk	39.3	26.8	51	-86	-0.7
X-5205	PDAC	gemcitabine-50mpk	42.2	26.7	55	-84.9	-1.1
X-5205	PDAC	gemcitabine-50mpk	33	27.6	57	-88.2	2.2
X-5205	PDAC	gemcitabine-50mpk	31.8	26.3	63	-88.7	-2.6
X-5205	PDAC	gemcitabine-50mpk	28.2	26.4	67	-89.9	-2.2
X-5205	PDAC	gemcitabine-50mpk	17.2	26.6	69	-93.9	-1.5
X-5205	PDAC	gemcitabine-50mpk	27.8	25.9	73	-90.1	-4.1
X-5205	PDAC	gemcitabine-50mpk	18.7	26.7	80	-93.3	-1.1
X-5205	PDAC	gemcitabine-50mpk	0	27.4	83	-100	1.5
X-5205	PDAC	gemcitabine-50mpk	0	27.4	90	-100	1.5
X-5205	PDAC	gemcitabine-50mpk	0	26.3	95	-100	-2.6
X-5205	PDAC	gemcitabine-50mpk	2.9	26.8	99	-99	-0.7
X-5205	PDAC	gemcitabine-50mpk	0	27.5	101	-100	1.9
X-5205	PDAC	gemcitabine-50mpk	0	26.9	105	-100	-0.4
X-5205	PDAC	gemcitabine-50mpk	0	27.3	108	-100	1.1
X-5205	PDAC	gemcitabine-50mpk	0	27.9	112	-100	3.3
X-5205	PDAC	INC424 + binimetinib	225	29.1	0	0	0
X-5205	PDAC	INC424 + binimetinib	282	28.4	4	25.3	-2.4
X-5205	PDAC	INC424 + binimetinib	258.8	29.4	7	15	1
X-5205	PDAC	INC424 + binimetinib	249.2	29.5	11	10.8	1.4
X-5205	PDAC	INC424 + binimetinib	330	29.7	14	46.7	2.1
X-5205	PDAC	INC424 + binimetinib	410.7	30	18	82.5	3.1
X-5205	PDAC	INC424 + binimetinib	417.5	29.9	21	85.6	2.7
X-5205	PDAC	INC424 + binimetinib	359.1	30	25	59.6	3.1
X-5205	PDAC	INC424 + binimetinib	435.4	29.5	28	93.5	1.4
X-5205	PDAC	INC424 + binimetinib	400.2	30.1	31	77.9	3.4
X-5205	PDAC	INC424 + binimetinib	482.5	29.4	34	114.4	1
X-5205	PDAC	INC424 + binimetinib	579.1	30.3	39	157.4	4.1
X-5205	PDAC	INC424 + binimetinib	608.4	29.7	42	170.4	2.1
X-5205	PDAC	INC424 + binimetinib	641.4	30	46	185.1	3.1
X-5205	PDAC	INC424 + binimetinib	680.7	30.4	49	202.5	4.5
X-5205	PDAC	INC424 + binimetinib	674.9	30.2	52	200	3.8
X-5205	PDAC	INC424 + binimetinib	763.1	29.8	56	239.2	2.4
X-5205	PDAC	INC424 + binimetinib	1252.8	30.1	59	456.8	3.4
X-5205	PDAC	INC424 + binimetinib	1066.1	30.2	62	373.8	3.8
X-5205	PDAC	WNT974	251.1	26	0	0	0
X-5205	PDAC	WNT974	276.1	25.9	1	10	-0.4
X-5205	PDAC	WNT974	313.4	24.5	5	24.8	-5.8
X-5205	PDAC	WNT974	296.4	26.6	7	18	2.3
X-5205	PDAC	WNT974	287.3	25.4	13	14.4	-2.3
X-5205	PDAC	WNT974	378.6	24.9	17	50.8	-4.2
X-5205	PDAC	WNT974	368.6	25.4	19	46.8	-2.3
X-5205	PDAC	WNT974	472.1	25.1	23	88	-3.5
X-5205	PDAC	WNT974	403.8	26.3	27	60.8	1.2
X-5205	PDAC	WNT974	483.3	26.3	30	92.5	1.2
X-5205	PDAC	WNT974	431.4	26.3	33	71.8	1.2
X-5205	PDAC	WNT974	635	25.5	37	152.9	-1.9
X-5205	PDAC	WNT974	653.7	26.4	40	160.3	1.5
X-5205	PDAC	WNT974	657.5	25.7	45	161.8	-1.2
X-5205	PDAC	WNT974	646.9	26.3	49	157.6	1.2
X-5205	PDAC	WNT974	732.7	25.7	51	191.8	-1.2
X-5205	PDAC	WNT974	708.5	25.9	55	182.2	-0.4
X-5205	PDAC	WNT974	848.7	25.5	58	238	-1.9
X-5205	PDAC	WNT974	888.7	26.2	62	253.9	0.8
X-5205	PDAC	LKA136	278.1	28	0	0	0
X-5205	PDAC	LKA136	224.8	28	3	-19.2	0
X-5205	PDAC	LKA136	260.8	27.6	7	-6.2	-1.4
X-5205	PDAC	LKA136	311.9	28.3	10	12.2	1.1
X-5205	PDAC	LKA136	357.7	26.6	14	28.6	-5
X-5205	PDAC	LKA136	341.5	26.8	17	22.8	-4.3
X-5205	PDAC	LKA136	322.1	28	21	15.8	0
X-5205	PDAC	LKA136	492.1	28.2	27	77	0.7
X-5205	PDAC	LKA136	546.7	28.4	32	96.6	1.4
X-5205	PDAC	LKA136	516.8	27.7	34	85.8	-1.1
X-5205	PDAC	LKA136	609.3	28	38	119.1	0
X-5205	PDAC	binimetinib	272.9	27.6	0	0	0
X-5205	PDAC	binimetinib	316.8	27.5	2	16.1	-0.4
X-5205	PDAC	binimetinib	302	26.8	6	10.7	-2.9
X-5205	PDAC	binimetinib	247.7	26	9	-9.2	-5.8
X-5205	PDAC	binimetinib	310.6	29.4	12	13.8	6.5
X-5205	PDAC	binimetinib	248.2	27.2	16	-9.1	-1.4
X-5205	PDAC	binimetinib	310.7	27.3	20	13.9	-1.1
X-5205	PDAC	binimetinib	394.8	26.9	22	44.7	-2.5
X-5205	PDAC	binimetinib	275.2	26.3	27	0.8	-4.7
X-5205	PDAC	binimetinib	300.5	25.1	34	10.1	-9.1
X-5205	PDAC	binimetinib-3.5mpk	293.9	31.6	0	0	0
X-5205	PDAC	binimetinib-3.5mpk	368	30.8	4	25.2	-2.5
X-5205	PDAC	binimetinib-3.5mpk	296.3	30.2	7	0.8	-4.4
X-5205	PDAC	binimetinib-3.5mpk	344.2	31.4	12	17.1	-0.6
X-5205	PDAC	binimetinib-3.5mpk	280.5	31.1	15	-4.6	-1.6
X-5205	PDAC	binimetinib-3.5mpk	140.6	31.3	19	-52.2	-0.9
X-5205	PDAC	binimetinib-3.5mpk	49.1	31	25	-83.3	-1.9
X-5205	PDAC	binimetinib-3.5mpk	54.5	31.4	28	-81.5	-0.6
X-5205	PDAC	binimetinib-3.5mpk	0	30.2	33	-100	-4.4
X-5205	PDAC	binimetinib-3.5mpk	0	30.9	35	-100	-2.2
X-5205	PDAC	binimetinib-3.5mpk	0	30	39	-100	-5.1
X-5205	PDAC	binimetinib-3.5mpk	0	29.7	46	-100	-6
X-5205	PDAC	trametinib	210.7	28.6	0	0	0
X-5205	PDAC	trametinib	299.2	27.6	5	42	-3.5
X-5205	PDAC	trametinib	349.4	25.4	7	65.8	-11.2
X-5205	PDAC	trametinib	366.6	26.6	11	74	-7
X-5205	PDAC	trametinib	561.9	25	14	166.7	-12.6
X-5205	PDAC	untreated	288.5	27.9	0	0	0
X-5205	PDAC	untreated	406.4	30.3	3	40.9	8.6
X-5205	PDAC	untreated	538.9	31	6	86.8	11.1
X-5205	PDAC	untreated	643.7	30.7	10	123.1	10
X-5205	PDAC	untreated	656.7	30.7	13	127.6	10
X-5205	PDAC	untreated	900.6	31	17	212.2	11.1
X-5205	PDAC	untreated	1063.3	30.8	20	268.6	10.4
X-5205	PDAC	untreated	1180.6	31.4	24	309.2	12.5
X-5205	PDAC	untreated	1315.5	31.5	30	356	12.9
X-5238	CRC	LFW527 + binimetinib	201.11	23.38	0	0	0
X-5238	CRC	LFW527 + binimetinib	215.02	22.52	3	6.9	-3.7
X-5238	CRC	LFW527 + binimetinib	259.78	22.83	7	29.2	-2.4
X-5238	CRC	LFW527 + binimetinib	295.93	22.24	10	47.1	-4.9
X-5238	CRC	LFW527 + binimetinib	308.33	23.01	14	53.3	-1.6
X-5238	CRC	LFW527 + binimetinib	337.48	22.65	17	67.8	-3.1
X-5238	CRC	LFW527 + binimetinib	381.56	23.94	22	89.7	2.4
X-5238	CRC	LFW527 + binimetinib	383.74	23.29	25	90.8	-0.4
X-5238	CRC	LFW527 + binimetinib	391.04	23.66	28	94.4	1.2
X-5238	CRC	LFW527 + binimetinib	405.76	24.1	31	101.8	3.1
X-5238	CRC	LFW527 + binimetinib	390.2	24	35	94	2.7
X-5238	CRC	LFW527 + binimetinib	404.52	24.64	38	101.1	5.4
X-5238	CRC	LFW527 + binimetinib	408.6	24.55	42	103.2	5
X-5238	CRC	LFW527 + binimetinib	473.94	25.05	45	135.7	7.1
X-5249	BRCA	BGJ398	194.6	25.9	0	0	0
X-5249	BRCA	BGJ398	125.7	27.6	3	-35.4	6.6
X-5249	BRCA	BGJ398	113.7	28.4	6	-41.6	9.7
X-5249	BRCA	BGJ398	45.3	27.9	14	-76.7	7.7
X-5249	BRCA	BGJ398	37.9	27.8	17	-80.5	7.3
X-5249	BRCA	BGJ398	31.5	27.5	20	-83.8	6.2
X-5249	BRCA	BGJ398	33.3	29	24	-82.9	12
X-5249	BRCA	BGJ398	28.7	28.1	28	-85.3	8.5
X-5249	BRCA	BGJ398	20.8	26.5	31	-89.3	2.3
X-5249	BRCA	BGJ398	18.8	26.7	34	-90.3	3.1
X-5249	BRCA	BGJ398	19.3	26.7	38	-90.1	3.1
X-5249	BRCA	BGJ398	14.5	27.2	42	-92.5	5
X-5249	BRCA	BGJ398	14.6	25.7	45	-92.5	-0.8
X-5249	BRCA	BGJ398	15.5	27	48	-92	4.2
X-5249	BRCA	BGJ398	18.2	27.7	55	-90.6	6.9
X-5249	BRCA	BGJ398	14	27.5	59	-92.8	6.2
X-5249	BRCA	BGJ398	0	26.9	63	-100	3.9
X-5249	BRCA	BGJ398	0	27.2	66	-100	5
X-5249	BRCA	BGJ398	0	26.7	70	-100	3.1
X-5249	BRCA	BGJ398	0	26.2	73	-100	1.2
X-5249	BRCA	BGJ398	0	26.6	76	-100	2.7
X-5249	BRCA	BGJ398	0	25.3	80	-100	-2.3
X-5249	BRCA	BGJ398	0	24.6	84	-100	-5
X-5249	BRCA	BGJ398	0	24.6	87	-100	-5
X-5249	BRCA	BGJ398	0	23.6	91	-100	-8.9
X-5249	BRCA	BKM120	211.5	24.1	0	0	0
X-5249	BRCA	BKM120	224.5	26	1	6.1	7.9
X-5249	BRCA	BKM120	174.6	25.1	5	-17.4	4.1
X-5249	BRCA	BKM120	115.3	23.9	8	-45.5	-0.8
X-5249	BRCA	BKM120	139.3	23.9	11	-34.1	-0.8
X-5249	BRCA	BKM120	195.8	23.3	15	-7.4	-3.3
X-5249	BRCA	BKM120	270.8	24.3	19	28	0.8
X-5249	BRCA	BKM120	297.4	23	22	40.6	-4.6
X-5249	BRCA	BKM120	366.4	24.1	25	73.2	0
X-5249	BRCA	BKM120	360.8	24.8	32	70.6	2.9
X-5249	BRCA	BKM120	373.4	24.7	36	76.5	2.5
X-5249	BRCA	BKM120	421.7	24.6	40	99.4	2.1
X-5249	BRCA	BYL719 + LEE011	214.5	26	0	0	0
X-5249	BRCA	BYL719 + LEE011	179.3	25.4	3	-16.4	-2.3
X-5249	BRCA	BYL719 + LEE011	242.6	24.4	6	13.1	-6.2
X-5249	BRCA	BYL719 + LEE011	211.2	24.2	10	-1.5	-6.9
X-5249	BRCA	BYL719 + LEE011	210.8	25.2	14	-1.7	-3.1
X-5249	BRCA	BYL719 + LEE011	166.7	24.2	17	-22.3	-6.9
X-5249	BRCA	BYL719 + LEE011	162.3	24.4	20	-24.3	-6.2
X-5249	BRCA	BYL719 + LEE011	133.6	21.4	27	-37.7	-17.7
X-5249	BRCA	BYL719 + LEE011	144.7	23.7	31	-32.5	-8.8
X-5249	BRCA	BYL719	257.7	23.7	0	0	0
X-5249	BRCA	BYL719	242.2	23.6	3	-6	-0.4
X-5249	BRCA	BYL719	296.3	25.7	6	15	8.4
X-5249	BRCA	BYL719	1032.6	25.2	14	300.7	6.3
X-5249	BRCA	BYL719	1089.6	25.5	17	322.8	7.6
X-5249	BRCA	BYL719	1022.8	25	20	296.9	5.5
X-5249	BRCA	BYL719	1193.1	26	24	363	9.7
X-5249	BRCA	BYL719	1342.8	25.8	28	421.1	8.9
X-5249	BRCA	BYL719 + LJM716	197.4	25.6	0	0	0
X-5249	BRCA	BYL719 + LJM716	241.1	25.4	1	22.1	-0.8
X-5249	BRCA	BYL719 + LJM716	347.1	25.9	4	75.8	1.2
X-5249	BRCA	BYL719 + LJM716	416.2	24	12	110.8	-6.2
X-5249	BRCA	BYL719 + LJM716	460.7	24.2	15	133.4	-5.5
X-5249	BRCA	BYL719 + LJM716	434.1	24.8	18	119.9	-3.1
X-5249	BRCA	BYL719 + LJM716	497.8	26.8	22	152.2	4.7
X-5249	BRCA	BYL719 + LJM716	596.9	25.8	26	202.4	0.8
X-5249	BRCA	BYL719 + LJM716	695.6	25.6	29	252.4	0
X-5249	BRCA	BYL719 + LJM716	641	24.9	32	224.7	-2.7
X-5249	BRCA	CGM097	299.7	24.7	0	0	0
X-5249	BRCA	CGM097	501.5	25.8	7	67.3	4.5
X-5249	BRCA	CGM097	708.7	25.8	10	136.5	4.5
X-5249	BRCA	CGM097	685.4	26.6	13	128.7	7.7
X-5249	BRCA	CGM097	833.9	26.4	17	178.2	6.9
X-5249	BRCA	CGM097	832.4	24	21	177.7	-2.8
X-5249	BRCA	CGM097	1006.9	24.6	24	236	-0.4
X-5249	BRCA	CGM097	1444.9	24.7	27	382.1	0
X-5249	BRCA	CLR457	248.5	26.1	0	0	0
X-5249	BRCA	CLR457	249.4	25.5	1	0.4	-2.3
X-5249	BRCA	CLR457	341.1	26	5	37.3	-0.4
X-5249	BRCA	CLR457	370.3	24	8	49	-8
X-5249	BRCA	CLR457	446.3	25	11	79.6	-4.2
X-5249	BRCA	CLR457	276.1	24.2	15	11.1	-7.3
X-5249	BRCA	CLR457	433.5	25	19	74.4	-4.2
X-5249	BRCA	CLR457	461.5	25.2	22	85.7	-3.4
X-5249	BRCA	CLR457	443.4	25.4	25	78.4	-2.7
X-5249	BRCA	CLR457	577.8	26.8	32	132.5	2.7
X-5249	BRCA	HDM201	295.8	26.6	0	0	0
X-5249	BRCA	HDM201	296	27.3	3	0.1	2.6
X-5249	BRCA	HDM201	384.8	27.2	6	30.1	2.3
X-5249	BRCA	HDM201	654.5	27.2	14	121.3	2.3
X-5249	BRCA	HDM201	711.6	27.2	17	140.6	2.3
X-5249	BRCA	HDM201	885.5	27.8	20	199.4	4.5
X-5249	BRCA	HDM201	1003.4	28.3	24	239.2	6.4
X-5249	BRCA	HDM201	1361.6	28.3	28	360.3	6.4
X-5249	BRCA	INC424	204.1	29.8	0	0	0
X-5249	BRCA	INC424	301.5	29.6	1	47.7	-0.7
X-5249	BRCA	INC424	395	29.5	4	93.5	-1
X-5249	BRCA	INC424	548.4	31.4	8	168.7	5.4
X-5249	BRCA	INC424	484.8	30.8	12	137.5	3.4
X-5249	BRCA	INC424	577.1	29.5	15	182.8	-1
X-5249	BRCA	INC424	683.2	30	18	234.7	0.7
X-5249	BRCA	INC424	992.5	29.4	22	386.3	-1.3
X-5249	BRCA	INC424	979.8	30.4	26	380.1	2
X-5249	BRCA	INC424	1233.8	29.9	29	504.5	0.3
X-5249	BRCA	INC424	1545.7	31	32	657.3	4
X-5249	BRCA	LEE011	254.7	28	0	0	0
X-5249	BRCA	LEE011	242.5	29.1	3	-4.8	3.9
X-5249	BRCA	LEE011	195.1	29.2	6	-23.4	4.3
X-5249	BRCA	LEE011	140.8	28.9	10	-44.7	3.2
X-5249	BRCA	LEE011	133.7	30.1	14	-47.5	7.5
X-5249	BRCA	LEE011	69.5	30.4	17	-72.7	8.6
X-5249	BRCA	LEE011	94.8	29.8	20	-62.8	6.4
X-5249	BRCA	LEE011	124.6	30.4	27	-51.1	8.6
X-5249	BRCA	LEE011	195.5	30.8	31	-23.2	10
X-5249	BRCA	LEE011	279.5	30.1	35	9.7	7.5
X-5249	BRCA	LEE011	286.8	30.1	38	12.6	7.5
X-5249	BRCA	LEE011	279.6	30.1	42	9.8	7.5
X-5249	BRCA	LEE011	408.3	29.2	45	60.3	4.3
X-5249	BRCA	LEE011	451.5	30.9	48	77.3	10.4
X-5249	BRCA	LEE011	520.3	30.1	52	104.3	7.5
X-5249	BRCA	LEE011	646.2	30.9	56	153.7	10.4
X-5249	BRCA	LEE011 + everolimus	225.4	26.5	0	0	0
X-5249	BRCA	LEE011 + everolimus	217.6	25.2	3	-3.5	-4.9
X-5249	BRCA	LEE011 + everolimus	252.4	25.5	6	12	-3.8
X-5249	BRCA	LEE011 + everolimus	249.9	24.4	10	10.9	-7.9
X-5249	BRCA	LEE011 + everolimus	229.1	26.1	14	1.6	-1.5
X-5249	BRCA	LEE011 + everolimus	241.9	25.6	17	7.3	-3.4
X-5249	BRCA	LEE011 + everolimus	239.7	25.7	20	6.3	-3
X-5249	BRCA	LEE011 + everolimus	228.9	27.3	27	1.6	3
X-5249	BRCA	LEE011 + everolimus	175.3	22.7	31	-22.2	-14.3
X-5249	BRCA	LEE011 + everolimus	199.2	24.3	35	-11.6	-8.3
X-5249	BRCA	LEE011 + everolimus	248.4	24.9	38	10.2	-6
X-5249	BRCA	LEE011 + everolimus	280.9	24.2	42	24.6	-8.7
X-5249	BRCA	LEE011 + everolimus	389.4	25.2	45	72.8	-4.9
X-5249	BRCA	LEE011 + everolimus	366.7	25	48	62.7	-5.7
X-5249	BRCA	LEE011 + everolimus	337.9	25.4	52	49.9	-4.2
X-5249	BRCA	LEE011 + everolimus	332.2	25.7	56	47.4	-3
X-5249	BRCA	LEE011 + everolimus	336.4	26.2	59	49.2	-1.1
X-5249	BRCA	LEE011 + everolimus	385.7	25.9	63	71.1	-2.3
X-5249	BRCA	LFA102	292.1	27	0	0	0
X-5249	BRCA	LFA102	450.9	27.6	3	54.4	2.2
X-5249	BRCA	LFA102	523.9	28.9	6	79.4	7
X-5249	BRCA	LFA102	847.3	29.1	14	190.1	7.8
X-5249	BRCA	LFA102	1070.1	28.4	17	266.3	5.2
X-5249	BRCA	LFA102	1126.7	29.3	20	285.7	8.5
X-5249	BRCA	LFA102	1008.3	30.4	24	245.2	12.6
X-5249	BRCA	LFA102	940.1	29.8	28	221.8	10.4
X-5249	BRCA	LFA102	999.1	28	31	242	3.7
X-5249	BRCA	LFA102	1130.1	30.5	34	286.9	13
X-5249	BRCA	LJM716 + trastuzumab	217.8	25.6	0	0	0
X-5249	BRCA	LJM716 + trastuzumab	450.1	24.6	3	106.7	-3.9
X-5249	BRCA	LJM716 + trastuzumab	323.7	25.8	6	48.6	0.8
X-5249	BRCA	LJM716 + trastuzumab	696.7	25.8	14	219.9	0.8
X-5249	BRCA	LJM716 + trastuzumab	838.3	25.7	17	284.9	0.4
X-5249	BRCA	LJM716 + trastuzumab	965.6	26.4	20	343.3	3.1
X-5249	BRCA	LJM716	332.5	23.8	0	0	0
X-5249	BRCA	LJM716	348.4	25.4	3	4.8	6.7
X-5249	BRCA	LJM716	437.7	25.2	6	31.6	5.9
X-5249	BRCA	LJM716	681.1	25.8	14	104.8	8.4
X-5249	BRCA	LJM716	614	26.4	17	84.7	10.9
X-5249	BRCA	LJM716	778	25.6	20	134	7.6
X-5249	BRCA	LJM716	510.4	27.4	24	53.5	15.1
X-5249	BRCA	LJM716	456.9	26.3	28	37.4	10.5
X-5249	BRCA	LJM716	467.9	26.3	31	40.7	10.5
X-5249	BRCA	LJM716	567.1	25.7	34	70.6	8
X-5249	BRCA	LJM716	466.6	25.7	38	40.3	8
X-5249	BRCA	LJM716	354.6	26.5	42	6.6	11.3
X-5249	BRCA	LJM716	337.5	24.9	45	1.5	4.6
X-5249	BRCA	LJM716	292.3	25.9	48	-12.1	8.8
X-5249	BRCA	LJM716	207.9	25.8	55	-37.5	8.4
X-5249	BRCA	LJM716	127.1	26.6	59	-61.8	11.8
X-5249	BRCA	LJM716	84.2	26.3	63	-74.7	10.5
X-5249	BRCA	LJM716	67.1	26.3	66	-79.8	10.5
X-5249	BRCA	LJM716	64.6	26.4	70	-80.6	10.9
X-5249	BRCA	LJM716	65.6	26	73	-80.3	9.2
X-5249	BRCA	LJM716	79.1	26.6	76	-76.2	11.8
X-5249	BRCA	LJM716	77.2	26.1	80	-76.8	9.7
X-5249	BRCA	LJM716	84	26.4	84	-74.7	10.9
X-5249	BRCA	LJM716	69	25.8	87	-79.2	8.4
X-5249	BRCA	LJM716	62.6	27.5	91	-81.2	15.5
X-5249	BRCA	LKA136	221.2	24.2	0	0	0
X-5249	BRCA	LKA136	281.6	24.1	1	27.3	-0.4
X-5249	BRCA	LKA136	341.5	23.5	4	54.4	-2.9
X-5249	BRCA	LKA136	385.6	24.4	8	74.3	0.8
X-5249	BRCA	LKA136	395.4	25.2	12	78.8	4.1
X-5249	BRCA	LKA136	592.2	23.9	15	167.7	-1.2
X-5249	BRCA	LKA136	611.4	25	18	176.4	3.3
X-5249	BRCA	LKA136	523.4	25	22	136.6	3.3
X-5249	BRCA	LKA136	579.1	25.2	26	161.8	4.1
X-5249	BRCA	LKA136	663.6	24.9	29	200	2.9
X-5249	BRCA	LKA136	710	26.2	32	221	8.3
X-5249	BRCA	LLM871	252.3	25	0	0	0
X-5249	BRCA	LLM871	274.5	23.9	3	8.8	-4.4
X-5249	BRCA	LLM871	280.7	24.9	7	11.3	-0.4
X-5249	BRCA	LLM871	372.5	22.9	10	47.6	-8.4
X-5249	BRCA	LLM871	621.8	23.9	13	146.5	-4.4
X-5249	BRCA	LLM871	989.6	23.5	17	292.2	-6
X-5249	BRCA	LLM871	868.3	24.5	21	244.2	-2
X-5249	BRCA	LLM871	1294.5	24.5	24	413.1	-2
X-5249	BRCA	LLM871	1333.6	24.7	27	428.6	-1.2
X-5249	BRCA	binimetinib	250.3	27.4	0	0	0
X-5249	BRCA	binimetinib	285.9	28	1	14.2	2.2
X-5249	BRCA	binimetinib	290.5	26.4	4	16.1	-3.6
X-5249	BRCA	binimetinib	327.4	27.5	8	30.8	0.4
X-5249	BRCA	binimetinib	241.2	27.3	12	-3.6	-0.4
X-5249	BRCA	binimetinib	355.9	25.6	15	42.2	-6.6
X-5249	BRCA	binimetinib	327.4	27.3	18	30.8	-0.4
X-5249	BRCA	binimetinib	311.2	27.1	22	24.3	-1.1
X-5249	BRCA	binimetinib	342.9	28	26	37	2.2
X-5249	BRCA	binimetinib	397.4	27.3	29	58.8	-0.4
X-5249	BRCA	binimetinib	442.2	27.6	32	76.7	0.7
X-5249	BRCA	binimetinib	613.4	28	39	145.1	2.2
X-5249	BRCA	paclitaxel	251.7	25.7	0	0	0
X-5249	BRCA	paclitaxel	215.3	26.3	7	-14.5	2.3
X-5249	BRCA	paclitaxel	254.3	24.5	10	1	-4.7
X-5249	BRCA	paclitaxel	313.1	25.2	13	24.4	-1.9
X-5249	BRCA	paclitaxel	329.5	25	17	30.9	-2.7
X-5249	BRCA	paclitaxel	324.2	24.8	21	28.8	-3.5
X-5249	BRCA	paclitaxel	334.8	21.6	24	33	-16
X-5249	BRCA	paclitaxel	294.8	24.4	27	17.1	-5.1
X-5249	BRCA	paclitaxel	304.4	24.3	31	20.9	-5.4
X-5249	BRCA	paclitaxel	352.1	24.5	35	39.9	-4.7
X-5249	BRCA	paclitaxel	379.2	23.9	38	50.7	-7
X-5249	BRCA	paclitaxel	439.3	24.3	41	74.5	-5.4
X-5249	BRCA	paclitaxel	440.3	24.8	48	74.9	-3.5
X-5249	BRCA	tamoxifen	285.5	26.5	0	0	0
X-5249	BRCA	tamoxifen	379.3	28.6	3	32.9	7.9
X-5249	BRCA	tamoxifen	373.8	28.4	6	30.9	7.2
X-5249	BRCA	tamoxifen	589.4	27.9	14	106.4	5.3
X-5249	BRCA	tamoxifen	733.7	28.5	17	157	7.5
X-5249	BRCA	tamoxifen	767.2	28.9	20	168.7	9.1
X-5249	BRCA	tamoxifen	894.7	31	24	213.4	17
X-5249	BRCA	tamoxifen	1104.8	30.4	28	287	14.7
X-5249	BRCA	tamoxifen	1268.6	29.7	31	344.3	12.1
X-5249	BRCA	tamoxifen	1263.1	29.3	34	342.4	10.6
X-5249	BRCA	trastuzumab	245.4	25.7	0	0	0
X-5249	BRCA	trastuzumab	318.1	26.5	3	29.6	3.1
X-5249	BRCA	trastuzumab	306.2	27.4	6	24.8	6.6
X-5249	BRCA	trastuzumab	561.7	26.5	14	128.9	3.1
X-5249	BRCA	trastuzumab	700	27.1	17	185.2	5.4
X-5249	BRCA	trastuzumab	645.1	27.5	20	162.9	7
X-5249	BRCA	trastuzumab	651.7	28.6	24	165.6	11.3
X-5249	BRCA	trastuzumab	795.8	29.3	28	224.3	14
X-5249	BRCA	trastuzumab	1170.5	28.2	31	377	9.7
X-5249	BRCA	trastuzumab	1394.6	28.5	34	468.3	10.9
X-5249	BRCA	untreated	198.4	24.7	0	0	0
X-5249	BRCA	untreated	214.8	23.4	3	8.3	-5.3
X-5249	BRCA	untreated	365.7	24.4	6	84.3	-1.2
X-5249	BRCA	untreated	403	24.3	10	103.1	-1.6
X-5249	BRCA	untreated	410	25.2	14	106.7	2
X-5249	BRCA	untreated	411.7	24.5	17	107.5	-0.8
X-5249	BRCA	untreated	430.2	24.3	20	116.8	-1.6
X-5249	BRCA	untreated	460.5	25.6	27	132.1	3.6
X-5249	BRCA	untreated	494.9	25.7	31	149.4	4
X-5249	BRCA	untreated	664.7	26.2	35	235	6.1
X-5249	BRCA	untreated	720.6	26.3	38	263.2	6.5
X-5249	BRCA	untreated	765.1	26.3	42	285.6	6.5
X-5249	BRCA	untreated	813	26.2	45	309.8	6.1
X-5249	BRCA	untreated	840.9	26.2	48	323.8	6.1
X-5249	BRCA	untreated	940.5	25.9	52	374	4.9
X-5249	BRCA	untreated	1087.6	27.2	56	448.2	10.1
X-5249	BRCA	untreated	1168.1	27.2	59	488.8	10.1
X-5249	BRCA	untreated	1261	27.6	63	535.6	11.7
X-5249	BRCA	LFW527 + everolimus	245.96	26.8	0	0	0
X-5249	BRCA	LFW527 + everolimus	218.24	25.4	3	-11.3	-5.2
X-5249	BRCA	LFW527 + everolimus	244.99	24.7	7	-0.4	-7.8
X-5249	BRCA	LFW527 + everolimus	217.55	25.1	10	-11.6	-6.3
X-5249	BRCA	LFW527 + everolimus	252.87	25.3	14	2.8	-5.6
X-5249	BRCA	LFW527 + everolimus	266.41	25.5	18	8.3	-4.9
X-5249	BRCA	LFW527 + everolimus	284.7	25.3	21	15.8	-5.6
X-5249	BRCA	LFW527 + everolimus	271.03	26.8	24	10.2	0
X-5249	BRCA	LFW527 + everolimus	303.7	26.1	28	23.5	-2.6
X-5249	BRCA	LFW527 + everolimus	330.99	26.7	31	34.6	-0.4
X-5249	BRCA	LFW527 + everolimus	312.16	25.1	35	26.9	-6.3
X-5249	BRCA	LFW527 + everolimus	449.67	25.9	38	82.8	-3.4
X-5249	BRCA	LFW527 + everolimus	351.05	26.8	42	42.7	0
X-5249	BRCA	LFW527 + everolimus	359.23	26.5	45	46.1	-1.1
X-5249	BRCA	LFW527 + everolimus	548.84	26.5	49	123.1	-1.1
X-5249	BRCA	LFW527 + everolimus	391.52	27.1	52	59.2	1.1
X-5249	BRCA	LFW527 + everolimus	436.62	25.4	56	77.5	-5.2
X-5249	BRCA	LFW527 + everolimus	615.56	25	59	150.3	-6.7
X-5249	BRCA	LFW527 + everolimus	553.27	25.4	62	124.9	-5.2
X-5249	BRCA	LFW527 + everolimus	591.97	25.4	66	140.7	-5.2
X-5249	BRCA	LFW527 + everolimus	732.13	26.3	70	197.7	-1.9
X-5249	BRCA	LFW527 + everolimus	770.63	26.1	73	213.3	-2.6
X-5254	CRC	5FU	207.5	23.3	0	0	0
X-5254	CRC	5FU	187.1	21.8	3	-9.8	-6.4
X-5254	CRC	5FU	107.6	22.9	6	-48.1	-1.7
X-5254	CRC	5FU	154.7	24	9	-25.4	3
X-5254	CRC	5FU	181.2	23.7	14	-12.7	1.7
X-5254	CRC	5FU	212.4	22.8	17	2.4	-2.1
X-5254	CRC	5FU	271.2	26	21	30.7	11.6
X-5254	CRC	5FU	260	26.6	23	25.3	14.2
X-5254	CRC	5FU	285	26.1	27	37.3	12
X-5254	CRC	5FU	339.5	24.9	30	63.6	6.9
X-5254	CRC	5FU	330.2	26.9	35	59.1	15.5
X-5254	CRC	BKM120	196.7	22.3	0	0	0
X-5254	CRC	BKM120	162.5	21.8	3	-17.4	-2.2
X-5254	CRC	BKM120	217.8	21.3	6	10.7	-4.5
X-5254	CRC	BKM120	186.9	22	9	-5	-1.3
X-5254	CRC	BKM120	262	23.1	14	33.2	3.6
X-5254	CRC	BKM120	300.4	22.9	17	52.7	2.7
X-5254	CRC	BKM120	353.7	21.7	21	79.8	-2.7
X-5254	CRC	BKM120	396.6	22.6	23	101.6	1.3
X-5254	CRC	BKM120 + LJC049	266.2	22.7	0	0	0
X-5254	CRC	BKM120 + LJC049	289.4	22.2	4	8.7	-2.2
X-5254	CRC	BKM120 + LJC049	473.9	23.6	7	78	4
X-5254	CRC	BKM120 + LJC049	486.6	21.7	12	82.8	-4.4
X-5254	CRC	BKM120 + LJC049	713.7	21.5	15	168.1	-5.3
X-5254	CRC	BKM120 + LJC049	627.3	20.1	19	135.6	-11.5
X-5254	CRC	BKM120 + LJC049	666.8	20.2	22	150.5	-11
X-5254	CRC	BKM120 + LJC049	818.3	19.5	25	207.4	-14.1
X-5254	CRC	BYL719 + cetuximab + encorafenib	233.4	25.2	0	0	0
X-5254	CRC	BYL719 + cetuximab + encorafenib	232.3	24.7	4	-0.5	-2
X-5254	CRC	BYL719 + cetuximab + encorafenib	243.7	25.8	7	4.4	2.4
X-5254	CRC	BYL719 + cetuximab + encorafenib	286.2	25.3	10	22.6	0.4
X-5254	CRC	BYL719 + cetuximab + encorafenib	336.9	24.5	15	44.3	-2.8
X-5254	CRC	BYL719 + cetuximab + encorafenib	341.2	24.9	18	46.2	-1.2
X-5254	CRC	BYL719 + cetuximab + encorafenib	395.1	25.1	21	69.3	-0.4
X-5254	CRC	BYL719 + cetuximab + encorafenib	473.2	24.8	24	102.7	-1.6
X-5254	CRC	BYL719 + cetuximab + encorafenib	630.3	25.7	28	170.1	2
X-5254	CRC	BYL719 + cetuximab	247.2	24.1	0	0	0
X-5254	CRC	BYL719 + cetuximab	288	25.5	4	16.5	5.8
X-5254	CRC	BYL719 + cetuximab	383.8	26.4	7	55.3	9.5
X-5254	CRC	BYL719 + cetuximab	388.5	27	10	57.2	12
X-5254	CRC	BYL719 + cetuximab	467.9	24.9	15	89.3	3.3
X-5254	CRC	BYL719 + cetuximab	447.3	25.2	18	80.9	4.6
X-5254	CRC	BYL719 + cetuximab	506.3	24.6	21	104.8	2.1
X-5254	CRC	BYL719 + cetuximab	550.1	24.7	24	122.5	2.5
X-5254	CRC	BYL719 + cetuximab	684	25.9	28	176.7	7.5
X-5254	CRC	BYL719	256.6	22.7	0	0	0
X-5254	CRC	BYL719	200.5	23.6	5	-21.9	4
X-5254	CRC	BYL719	325.5	NA	8	26.9	4
X-5254	CRC	BYL719	323.4	22	14	26	-3.1
X-5254	CRC	BYL719	386.7	21.5	18	50.7	-5.3
X-5254	CRC	BYL719	386.9	21.6	21	50.8	-4.8
X-5254	CRC	BYL719	391.3	21.8	26	52.5	-4
X-5254	CRC	BYL719 + binimetinib	209.1	24.8	0	0	0
X-5254	CRC	BYL719 + binimetinib	314.2	24.4	5	50.3	-1.6
X-5254	CRC	BYL719 + binimetinib	276.4	24.2	8	32.2	-2.4
X-5254	CRC	BYL719 + binimetinib	312.7	23.8	12	49.5	-4
X-5254	CRC	BYL719 + binimetinib	317.9	23.9	14	52	-3.6
X-5254	CRC	BYL719 + binimetinib	298.9	24.6	18	42.9	-0.8
X-5254	CRC	BYL719 + binimetinib	358.8	24.5	21	71.6	-1.2
X-5254	CRC	BYL719 + binimetinib	425.5	23.6	27	103.5	-4.8
X-5254	CRC	BYL719 + LJM716	299.1	21.5	0	0	0
X-5254	CRC	BYL719 + LJM716	189.5	21.5	5	-36.6	0
X-5254	CRC	BYL719 + LJM716	185.5	21	8	-38	-2.3
X-5254	CRC	BYL719 + LJM716	235	21.7	12	-21.4	0.9
X-5254	CRC	BYL719 + LJM716	214.6	22.4	14	-28.3	4.2
X-5254	CRC	BYL719 + LJM716	223.8	22.5	18	-25.2	4.7
X-5254	CRC	BYL719 + LJM716	214.7	22	21	-28.2	2.3
X-5254	CRC	BYL719 + LJM716	289.3	20.3	26	-3.3	-5.6
X-5254	CRC	BYL719 + LJM716	358.9	19.6	29	20	-8.8
X-5254	CRC	BYL719 + LJM716	378.9	18.4	36	26.7	-14.4
X-5254	CRC	BYL719 + LJM716	420.7	19.6	39	40.7	-8.8
X-5254	CRC	BYL719 + LJM716	537.6	18.9	47	79.7	-12.1
X-5254	CRC	BYL719 + encorafenib	206.1	26.2	0	0	0
X-5254	CRC	BYL719 + encorafenib	204.8	26.4	3	-0.6	0.8
X-5254	CRC	BYL719 + encorafenib	289.9	24.5	7	40.7	-6.5
X-5254	CRC	BYL719 + encorafenib	452.2	24.6	13	119.4	-6.1
X-5254	CRC	BYL719 + encorafenib	507.6	25.6	16	146.3	-2.3
X-5254	CRC	BYL719 + encorafenib	523.8	23	21	154.1	-12.2
X-5254	CRC	CGM097	251.8	21.2	0	0	0
X-5254	CRC	CGM097	373.7	21.6	3	48.4	1.9
X-5254	CRC	CGM097	415.1	22.3	6	64.9	5.2
X-5254	CRC	CGM097	531.3	23.8	11	111	12.3
X-5254	CRC	CGM097	748.4	24.1	14	197.2	13.7
X-5254	CRC	CGM097	945.5	23.9	18	275.5	12.7
X-5254	CRC	CGM097	1255.6	23.8	20	398.6	12.3
X-5254	CRC	CKX620	198.4	21.2	0	0	0
X-5254	CRC	CKX620	213.8	23.7	3	7.8	11.8
X-5254	CRC	CKX620	263.1	23.9	6	32.6	12.7
X-5254	CRC	CKX620	284.4	24.1	11	43.3	13.7
X-5254	CRC	CKX620	322.2	24.7	14	62.4	16.5
X-5254	CRC	CKX620	382.5	25.2	18	92.8	18.9
X-5254	CRC	CKX620	270.1	24.7	20	36.1	16.5
X-5254	CRC	CKX620	297.8	24.9	24	50.1	17.5
X-5254	CRC	CKX620	362.9	26.9	27	82.9	26.9
X-5254	CRC	CLR457	209.2	22.6	0	0	0
X-5254	CRC	CLR457	142.1	21.9	3	-32.1	-3.1
X-5254	CRC	CLR457	127	22.6	11	-39.3	0
X-5254	CRC	CLR457	164.1	23.1	14	-21.6	2.2
X-5254	CRC	CLR457	186	22.8	18	-11.1	0.9
X-5254	CRC	CLR457	175.4	22.6	20	-16.2	0
X-5254	CRC	CLR457	182.6	23	24	-12.7	1.8
X-5254	CRC	CLR457	194.8	22.9	27	-6.9	1.3
X-5254	CRC	CLR457	232.1	23.4	32	10.9	3.5
X-5254	CRC	CLR457	235.4	21.2	35	12.5	-6.2
X-5254	CRC	HDM201	216.5	23.8	0	0	0
X-5254	CRC	HDM201	179.5	23.2	3	-17.1	-2.5
X-5254	CRC	HDM201	226.5	23.4	6	4.6	-1.7
X-5254	CRC	HDM201	318	22.7	9	46.9	-4.6
X-5254	CRC	HDM201	293.9	23.4	14	35.8	-1.7
X-5254	CRC	HDM201	441.6	23.5	17	104	-1.3
X-5254	CRC	HDM201	442.9	23.6	21	104.6	-0.8
X-5254	CRC	HDM201	503.5	23.4	23	132.6	-1.7
X-5254	CRC	cetuximab	207.6	25.7	0	0	0
X-5254	CRC	cetuximab	190	24.1	3	-8.5	-6.2
X-5254	CRC	cetuximab	181.2	25.4	7	-12.7	-1.2
X-5254	CRC	cetuximab	222.4	26.6	9	7.1	3.5
X-5254	CRC	cetuximab	268.4	26.5	13	29.3	3.1
X-5254	CRC	cetuximab	402.3	25.4	17	93.8	-1.2
X-5254	CRC	cetuximab	512.1	26.9	20	146.7	4.7
X-5254	CRC	cetuximab	570.8	25.7	23	175	0
X-5254	CRC	cetuximab	695.5	26.5	28	235	3.1
X-5254	CRC	cetuximab	830.9	27.3	31	300.2	6.2
X-5254	CRC	cetuximab + encorafenib	225.8	23.4	0	0	0
X-5254	CRC	cetuximab + encorafenib	273.7	25.1	2	21.2	7.3
X-5254	CRC	cetuximab + encorafenib	321.3	24.5	6	42.3	4.7
X-5254	CRC	cetuximab + encorafenib	356.4	23.4	10	57.8	0
X-5254	CRC	cetuximab + encorafenib	410.9	24.3	13	82	3.8
X-5254	CRC	cetuximab + encorafenib	391.1	24	16	73.2	2.6
X-5254	CRC	cetuximab + encorafenib	415.3	23.3	21	83.9	-0.4
X-5254	CRC	cetuximab + encorafenib	446	24.1	24	97.5	3
X-5254	CRC	cetuximab + encorafenib	460.6	24.7	27	104	5.6
X-5254	CRC	cetuximab + encorafenib	451.2	25	30	99.8	6.8
X-5254	CRC	cetuximab + encorafenib	502.7	25	34	122.6	6.8
X-5254	CRC	cetuximab + encorafenib	508.4	24.8	37	125.2	6
X-5254	CRC	cetuximab + encorafenib	484.5	25.2	41	114.6	7.7
X-5254	CRC	cetuximab + encorafenib	475.3	25.6	44	110.5	9.4
X-5254	CRC	cetuximab + encorafenib	557.3	25.1	49	146.8	7.3
X-5254	CRC	cetuximab + encorafenib	563.1	25	52	149.4	6.8
X-5254	CRC	cetuximab + encorafenib	665.2	24.9	55	194.6	6.4
X-5254	CRC	LEE011	263	23.6	0	0	0
X-5254	CRC	LEE011	269.6	23.3	3	2.5	-1.3
X-5254	CRC	LEE011	300.1	22.7	6	14.1	-3.8
X-5254	CRC	LEE011	364.9	22.3	9	38.7	-5.5
X-5254	CRC	LEE011	400.6	24	14	52.3	1.7
X-5254	CRC	LEE011	552.2	23.9	17	110	1.3
X-5254	CRC	LEE011	630.6	24.1	21	139.8	2.1
X-5254	CRC	LEE011	642.5	24.8	23	144.3	5.1
X-5254	CRC	encorafenib	236.8	23.3	0	0	0
X-5254	CRC	encorafenib	275.9	23.7	5	16.5	1.7
X-5254	CRC	encorafenib	440.4	22.1	8	86	-5.2
X-5254	CRC	encorafenib	725.7	23.6	12	206.5	1.3
X-5254	CRC	encorafenib	1010.5	23.2	18	326.7	-0.4
X-5254	CRC	encorafenib	1426.5	25.1	21	502.4	7.7
X-5254	CRC	LJC049	271.5	22.8	0	0	0
X-5254	CRC	LJC049	251.5	24.1	3	-7.4	5.7
X-5254	CRC	LJC049	434.5	23.9	6	60	4.8
X-5254	CRC	LJC049	533.6	23	11	96.5	0.9
X-5254	CRC	LJC049	839.7	21.5	14	209.3	-5.7
X-5254	CRC	LJC049	867.2	22.6	18	219.4	-0.9
X-5254	CRC	LJC049	1077	20.6	20	296.7	-9.6
X-5254	CRC	LKA136	203.3	22.8	0	0	0
X-5254	CRC	LKA136	184.2	24.5	5	-9.4	7.5
X-5254	CRC	LKA136	214.8	24.6	8	5.7	7.9
X-5254	CRC	LKA136	455	25.7	12	123.8	12.7
X-5254	CRC	LKA136	445.6	24.8	14	119.2	8.8
X-5254	CRC	LKA136	454.8	24.5	18	123.7	7.5
X-5254	CRC	LKA136	472.2	24.9	21	132.3	9.2
X-5254	CRC	LKA136	623.6	24.9	26	206.7	9.2
X-5254	CRC	binimetinib	191.2	24.4	0	0	0
X-5254	CRC	binimetinib	268.2	23.4	4	40.3	-4.1
X-5254	CRC	binimetinib	257.5	22.4	7	34.7	-8.2
X-5254	CRC	binimetinib	235.9	23	10	23.4	-5.7
X-5254	CRC	binimetinib	249.1	23.7	13	30.3	-2.9
X-5254	CRC	binimetinib	289.9	24	18	51.6	-1.6
X-5254	CRC	binimetinib	324.7	24.2	21	69.8	-0.8
X-5254	CRC	binimetinib	491.8	24	25	157.2	-1.6
X-5254	CRC	binimetinib	414.9	23.4	27	117	-4.1
X-5254	CRC	binimetinib	421.8	24.4	31	120.6	0
X-5254	CRC	binimetinib	441.7	24.9	34	131	2
X-5254	CRC	untreated	253.2	21.9	0	0	0
X-5254	CRC	untreated	312	25.3	4	23.2	15.5
X-5254	CRC	untreated	380.2	23.5	7	50.2	7.3
X-5254	CRC	untreated	480	22.3	11	89.6	1.8
X-5254	CRC	untreated	528.4	23.5	13	108.7	7.3
X-5254	CRC	untreated	719.6	24.8	17	184.2	13.2
X-5254	CRC	untreated	880.9	22.7	21	247.9	3.7
X-5254	CRC	untreated	1030.1	23.8	24	306.8	8.7
X-5254	CRC	untreated	1211.3	23.5	27	378.4	7.3
X-5254	CRC	untreated	1268.1	24	28	400.8	9.6
X-5254	CRC	LFW527 + binimetinib	216.45	24.43	0	0	0
X-5254	CRC	LFW527 + binimetinib	253.14	25.06	2	17	2.6
X-5254	CRC	LFW527 + binimetinib	280.8	25.46	8	29.7	4.2
X-5254	CRC	LFW527 + binimetinib	327.14	24.14	12	51.1	-1.2
X-5254	CRC	LFW527 + binimetinib	325.51	23.86	16	50.4	-2.3
X-5254	CRC	LFW527 + binimetinib	424.8	23.76	19	96.3	-2.7
X-5254	CRC	LFW527 + binimetinib	422.75	23.48	22	95.3	-3.9
X-5254	CRC	LFW527 + binimetinib	512.88	23.62	29	137	-3.3
X-5254	CRC	LFW527 + binimetinib	587.91	26.23	34	171.6	7.4
X-5254	CRC	LFW527 + binimetinib	551.13	25.68	37	154.6	5.1
X-5254	CRC	LFW527 + binimetinib	679.75	23.92	40	214	-2.1
X-5254	CRC	LFW527 + binimetinib	488.3	24.46	43	125.6	0.1
X-5254	CRC	LFW527 + binimetinib	841.12	23.69	49	288.6	-3
X-5254	CRC	LFW527 + binimetinib	850.98	24.35	54	293.2	-0.3
X-5254	CRC	LFW527 + binimetinib	1050.21	24.7	57	385.2	1.1
X-5254	CRC	LFW527 + binimetinib	1237.18	24.56	61	471.6	0.5
X-5355	BRCA	BGJ398	314.6	22.2	0	0	0
X-5355	BRCA	BGJ398	440.1	23.4	4	39.9	5.4
X-5355	BRCA	BGJ398	558.3	23.1	7	77.5	4.1
X-5355	BRCA	BGJ398	769.2	23.3	11	144.5	5
X-5355	BRCA	BGJ398	885.7	23.8	14	181.5	7.2
X-5355	BRCA	BGJ398	1054.2	23.9	17	235.1	7.7
X-5355	BRCA	BGJ398	1192.4	23.6	21	279	6.3
X-5355	BRCA	BKM120	314.7	23.4	0	0	0
X-5355	BRCA	BKM120	260.8	23.7	3	-17.1	1.3
X-5355	BRCA	BKM120	228.5	22.7	8	-27.4	-3
X-5355	BRCA	BKM120	202.8	23.1	11	-35.6	-1.3
X-5355	BRCA	BKM120	198.1	23.8	14	-37.1	1.7
X-5355	BRCA	BKM120	185.3	26.3	18	-41.1	12.4
X-5355	BRCA	BKM120	198.9	26.8	21	-36.8	14.5
X-5355	BRCA	BKM120	181.8	27.6	25	-42.2	17.9
X-5355	BRCA	BKM120	145.8	27.1	28	-53.7	15.8
X-5355	BRCA	BKM120	137.5	27.9	32	-56.3	19.2
X-5355	BRCA	BKM120	136.4	27.7	35	-56.7	18.4
X-5355	BRCA	BKM120	148	27.5	39	-53	17.5
X-5355	BRCA	BKM120	131.6	27.8	42	-58.2	18.8
X-5355	BRCA	BKM120	136	29.7	46	-56.8	26.9
X-5355	BRCA	BKM120	138.1	27.6	49	-56.1	17.9
X-5355	BRCA	BKM120	121.2	28.4	53	-61.5	21.4
X-5355	BRCA	BKM120	118.9	27.8	56	-62.2	18.8
X-5355	BRCA	BKM120	121.8	26.2	59	-61.3	12
X-5355	BRCA	BKM120	110.4	28.3	63	-64.9	20.9
X-5355	BRCA	BKM120	126.5	29.2	67	-59.8	24.8
X-5355	BRCA	BKM120	130.5	28.5	70	-58.5	21.8
X-5355	BRCA	BKM120	143.8	26.9	74	-54.3	15
X-5355	BRCA	BKM120	153.3	28.2	84	-51.3	20.5
X-5355	BRCA	BKM120	121.4	28.3	88	-61.4	20.9
X-5355	BRCA	BKM120	188.6	27.7	91	-40.1	18.4
X-5355	BRCA	BYL719	338	25.2	0	0	0
X-5355	BRCA	BYL719	343.1	26	3	1.5	3.2
X-5355	BRCA	BYL719	400.6	26.6	8	18.5	5.6
X-5355	BRCA	BYL719	391.5	26.8	11	15.8	6.3
X-5355	BRCA	BYL719	409.9	26.8	14	21.3	6.3
X-5355	BRCA	BYL719	395.5	28.3	18	17	12.3
X-5355	BRCA	BYL719	366.6	28.5	21	8.5	13.1
X-5355	BRCA	BYL719	437.3	27.9	25	29.4	10.7
X-5355	BRCA	BYL719	510.9	28.5	28	51.2	13.1
X-5355	BRCA	BYL719	537.6	28.6	32	59.1	13.5
X-5355	BRCA	BYL719	568.3	29.5	35	68.1	17.1
X-5355	BRCA	BYL719	571.5	28.8	39	69.1	14.3
X-5355	BRCA	BYL719	426.7	29.1	42	26.2	15.5
X-5355	BRCA	BYL719	414.8	30.3	46	22.7	20.2
X-5355	BRCA	BYL719	445.7	30.8	49	31.9	22.2
X-5355	BRCA	BYL719	521	30.8	53	54.1	22.2
X-5355	BRCA	BYL719	557.2	29.5	56	64.9	17.1
X-5355	BRCA	BYL719	692.6	29.5	59	104.9	17.1
X-5355	BRCA	BYL719	727.7	30.1	63	115.3	19.4
X-5355	BRCA	BYL719	848.1	31.1	67	150.9	23.4
X-5355	BRCA	BYL719	1048	30.8	70	210.1	22.2
X-5355	BRCA	BYL719 + LJM716	310.3	29.9	0	0	0
X-5355	BRCA	BYL719 + LJM716	286.5	26.3	3	-7.7	-12
X-5355	BRCA	BYL719 + LJM716	268.8	27	7	-13.4	-9.7
X-5355	BRCA	BYL719 + LJM716	245.1	27.5	10	-21	-8
X-5355	BRCA	BYL719 + LJM716	248.2	27.8	13	-20	-7
X-5355	BRCA	BYL719 + LJM716	255.5	26.4	17	-17.7	-11.7
X-5355	BRCA	BYL719 + LJM716	259.9	28.8	20	-16.2	-3.7
X-5355	BRCA	BYL719 + LJM716	257.8	29.4	24	-16.9	-1.7
X-5355	BRCA	BYL719 + LJM716	272.7	29.9	27	-12.1	0
X-5355	BRCA	BYL719 + LJM716	319.4	29.5	31	2.9	-1.3
X-5355	BRCA	BYL719 + LJM716	369.4	27.2	35	19	-9
X-5355	BRCA	BYL719 + LJM716	399.3	28.7	38	28.7	-4
X-5355	BRCA	BYL719 + LJM716	420.2	29.1	42	35.4	-2.7
X-5355	BRCA	BYL719 + LJM716	473.5	28.3	45	52.6	-5.4
X-5355	BRCA	BYL719 + LJM716	439.7	27.2	49	41.7	-9
X-5355	BRCA	BYL719 + LJM716	396.4	26	52	27.7	-13
X-5355	BRCA	BYL719 + LJM716	382.2	26	56	23.2	-13
X-5355	BRCA	BYL719 + LJM716	413.5	24	59	33.3	-19.7
X-5355	BRCA	BYL719 + LEE011	196.3	25	0	0	0
X-5355	BRCA	BYL719 + LEE011	186.7	24.2	3	-4.9	-3.2
X-5355	BRCA	BYL719 + LEE011	204.1	23.2	7	4	-7.2
X-5355	BRCA	BYL719 + LEE011	135.9	22.9	10	-30.8	-8.4
X-5355	BRCA	BYL719 + LEE011	102.1	22.5	14	-48	-10
X-5355	BRCA	BYL719 + LEE011	111.9	26.1	24	-43	4.4
X-5355	BRCA	BYL719 + LEE011	97.4	25.7	28	-50.4	2.8
X-5355	BRCA	BYL719 + LEE011	104.5	25	31	-46.8	0
X-5355	BRCA	BYL719 + LEE011	139.9	25.6	35	-28.7	2.4
X-5355	BRCA	BYL719 + LEE011	122.2	25.5	38	-37.7	2
X-5355	BRCA	BYL719 + LEE011	121.1	24.9	42	-38.3	-0.4
X-5355	BRCA	BYL719 + LEE011	119.2	23.9	45	-39.3	-4.4
X-5355	BRCA	BYL719 + LEE011	113.8	23	48	-42	-8
X-5355	BRCA	BYL719 + LEE011	102.7	20.8	52	-47.7	-16.8
X-5355	BRCA	CGM097	360.5	24.4	0	0	0
X-5355	BRCA	CGM097	636.8	26.9	3	76.6	10.2
X-5355	BRCA	CGM097	718.2	28.2	8	99.2	15.6
X-5355	BRCA	CGM097	867.6	29.4	11	140.7	20.5
X-5355	BRCA	CGM097	903.2	30.3	14	150.5	24.2
X-5355	BRCA	CGM097	1183.1	30.9	18	228.2	26.6
X-5355	BRCA	CGM097	1583.4	30.9	21	339.2	26.6
X-5355	BRCA	CLR457	272.2	25.7	0	0	0
X-5355	BRCA	CLR457	214.1	25.3	5	-21.3	-1.6
X-5355	BRCA	CLR457	229.8	25.4	8	-15.6	-1.2
X-5355	BRCA	CLR457	223.5	26.3	11	-17.9	2.3
X-5355	BRCA	CLR457	253.2	27	15	-7	5.1
X-5355	BRCA	CLR457	249.8	27	18	-8.2	5.1
X-5355	BRCA	CLR457	273.4	28.4	22	0.4	10.5
X-5355	BRCA	CLR457	275.2	27.7	25	1.1	7.8
X-5355	BRCA	CLR457	312	27.5	29	14.6	7
X-5355	BRCA	CLR457	296.7	28.1	32	9	9.3
X-5355	BRCA	CLR457	288.8	27.4	36	6.1	6.6
X-5355	BRCA	CLR457	288.5	27.2	39	6	5.8
X-5355	BRCA	CLR457	308.3	26.8	43	13.3	4.3
X-5355	BRCA	CLR457	262.4	27.1	46	-3.6	5.4
X-5355	BRCA	CLR457	251.6	28.2	50	-7.6	9.7
X-5355	BRCA	CLR457	270.8	28	53	-0.5	8.9
X-5355	BRCA	CLR457	284.9	28.1	56	4.7	9.3
X-5355	BRCA	CLR457	370.9	24.7	60	36.3	-3.9
X-5355	BRCA	CLR457	261.4	24.5	64	-4	-4.7
X-5355	BRCA	CLR457	286	25.4	67	5.1	-1.2
X-5355	BRCA	CLR457	322.7	25.8	71	18.6	0.4
X-5355	BRCA	CLR457	386.9	27	81	42.1	5.1
X-5355	BRCA	CLR457	341.3	27.4	85	25.4	6.6
X-5355	BRCA	CLR457	356.2	28.1	88	30.9	9.3
X-5355	BRCA	CLR457	396.7	27.5	92	45.7	7
X-5355	BRCA	CLR457	431.1	28.9	95	58.4	12.5
X-5355	BRCA	HDM201	224.8	26.8	0	0	0
X-5355	BRCA	HDM201	309.7	25.2	4	37.8	-6
X-5355	BRCA	HDM201	413	26.4	7	83.7	-1.5
X-5355	BRCA	HDM201	545.7	26	11	142.7	-3
X-5355	BRCA	HDM201	607.4	26.5	14	170.2	-1.1
X-5355	BRCA	HDM201	786.1	26.7	17	249.7	-0.4
X-5355	BRCA	HDM201	806.8	29.3	21	258.9	9.3
X-5355	BRCA	HDM201	922.2	28.3	25	310.2	5.6
X-5355	BRCA	HDM201	992.1	27.8	28	341.3	3.7
X-5355	BRCA	INC424	320.5	20.9	0	0	0
X-5355	BRCA	INC424	346.1	21.7	2	8	3.8
X-5355	BRCA	INC424	407.8	23	7	27.2	10
X-5355	BRCA	INC424	436.2	23.4	10	36.1	12
X-5355	BRCA	INC424	497.6	23.2	13	55.3	11
X-5355	BRCA	INC424	503.4	23.4	17	57.1	12
X-5355	BRCA	INC424	481.9	23.5	20	50.4	12.4
X-5355	BRCA	INC424	477.4	23.2	24	49	11
X-5355	BRCA	INC424	494.3	24.3	27	54.2	16.3
X-5355	BRCA	INC424	542.6	24.4	31	69.3	16.7
X-5355	BRCA	INC424	562.9	24.4	34	75.6	16.7
X-5355	BRCA	INC424	595.3	24.5	38	85.7	17.2
X-5355	BRCA	INC424	554.5	24.6	41	73	17.7
X-5355	BRCA	INC424	561.8	24.4	45	75.3	16.7
X-5355	BRCA	INC424	544.3	24.9	48	69.8	19.1
X-5355	BRCA	INC424	526.9	25	52	64.4	19.6
X-5355	BRCA	INC424	573.7	26.1	55	79	24.9
X-5355	BRCA	INC424	578	25.4	58	80.3	21.5
X-5355	BRCA	INC424	561.8	25.6	62	75.3	22.5
X-5355	BRCA	INC424	553.8	25.7	66	72.8	23
X-5355	BRCA	INC424	547.6	25.9	69	70.9	23.9
X-5355	BRCA	INC424	573.9	25.7	73	79.1	23
X-5355	BRCA	INC424	709.8	24.5	83	121.5	17.2
X-5355	BRCA	INC424	681	25.1	87	112.5	20.1
X-5355	BRCA	INC424	664.3	25.6	90	107.3	22.5
X-5355	BRCA	LEE011	225	23.1	0	0	0
X-5355	BRCA	LEE011	231.2	24.8	3	2.8	7.4
X-5355	BRCA	LEE011	273	25.2	6	21.3	9.1
X-5355	BRCA	LEE011	214.7	25.6	10	-4.6	10.8
X-5355	BRCA	LEE011	230	25.7	13	2.2	11.3
X-5355	BRCA	LEE011	286.2	26	17	27.2	12.6
X-5355	BRCA	LEE011	304.7	27.2	20	35.4	17.7
X-5355	BRCA	LEE011	364.9	27.3	24	62.2	18.2
X-5355	BRCA	LEE011	372.3	27.2	27	65.5	17.7
X-5355	BRCA	LEE011	405.1	25.7	31	80	11.3
X-5355	BRCA	LEE011	402.1	26.3	34	78.7	13.9
X-5355	BRCA	LEE011	394.8	26.9	38	75.5	16.5
X-5355	BRCA	LEE011	438	28.1	41	94.7	21.6
X-5355	BRCA	LEE011	464.4	27.8	45	106.4	20.3
X-5355	BRCA	LEE011	498.7	27.7	48	121.6	19.9
X-5355	BRCA	LEE011	643.5	27.5	51	186	19
X-5355	BRCA	LEE011	628.6	27.9	55	179.4	20.8
X-5355	BRCA	LEE011	640.1	28	59	184.5	21.2
X-5355	BRCA	LEE011	631.8	28	62	180.8	21.2
X-5355	BRCA	LEE011	654.1	28.5	66	190.7	23.4
X-5355	BRCA	LEE011	650.6	28.1	76	189.2	21.6
X-5355	BRCA	LEE011	571.5	28.2	80	154	22.1
X-5355	BRCA	LEE011	532.3	28.5	83	136.6	23.4
X-5355	BRCA	LEE011	514.7	28.4	87	128.8	22.9
X-5355	BRCA	LEE011	549.6	28.7	90	144.3	24.2
X-5355	BRCA	LEE011	528.7	28	94	135	21.2
X-5355	BRCA	LEE011	537.7	28.7	97	139	24.2
X-5355	BRCA	LEE011 + everolimus	265.7	31.1	0	0	0
X-5355	BRCA	LEE011 + everolimus	270.8	29.2	2	1.9	-6.1
X-5355	BRCA	LEE011 + everolimus	191.5	29.2	6	-27.9	-6.1
X-5355	BRCA	LEE011 + everolimus	178.4	29	10	-32.9	-6.8
X-5355	BRCA	LEE011 + everolimus	158.1	28.5	13	-40.5	-8.4
X-5355	BRCA	LEE011 + everolimus	127.4	NA	17	-52.1	-8.4
X-5355	BRCA	LEE011 + everolimus	103.7	28.5	27	-61	-8.4
X-5355	BRCA	LEE011 + everolimus	91.6	29.6	31	-65.5	-4.8
X-5355	BRCA	LEE011 + everolimus	88.7	28.8	34	-66.6	-7.4
X-5355	BRCA	LEE011 + everolimus	77.3	28.6	38	-70.9	-8
X-5355	BRCA	LEE011 + everolimus	90.3	29	41	-66	-6.8
X-5355	BRCA	LEE011 + everolimus	107.5	29.1	45	-59.5	-6.4
X-5355	BRCA	LEE011 + everolimus	106.6	29	48	-59.9	-6.8
X-5355	BRCA	LEE011 + everolimus	102.6	30.1	51	-61.4	-3.2
X-5355	BRCA	LEE011 + everolimus	102.2	30.1	55	-61.5	-3.2
X-5355	BRCA	LEE011 + everolimus	104.3	29.9	58	-60.7	-3.9
X-5355	BRCA	LEE011 + everolimus	97.5	29.5	62	-63.3	-5.1
X-5355	BRCA	LEE011 + everolimus	97.3	29.6	65	-63.4	-4.8
X-5355	BRCA	LEE011 + everolimus	94	28.5	69	-64.6	-8.4
X-5355	BRCA	LEE011 + everolimus	94.1	28.2	73	-64.6	-9.3
X-5355	BRCA	LEE011 + everolimus	95.6	28.9	76	-64	-7.1
X-5355	BRCA	LEE011 + everolimus	83.8	28.3	80	-68.5	-9
X-5355	BRCA	LEE011 + everolimus	78.6	28.6	83	-70.4	-8
X-5355	BRCA	LEE011 + everolimus	90.2	28.3	87	-66.1	-9
X-5355	BRCA	LEE011 + everolimus	97.3	29.2	90	-63.4	-6.1
X-5355	BRCA	LEE011 + everolimus	98.3	30.3	94	-63	-2.6
X-5355	BRCA	LEE011 + everolimus	108.1	30.4	97	-59.3	-2.3
X-5355	BRCA	LEE011 + everolimus	74.1	28.9	101	-72.1	-7.1
X-5355	BRCA	LEE011 + everolimus	89.3	28.4	104	-66.4	-8.7
X-5355	BRCA	LFA102	238.4	22.4	0	0	0
X-5355	BRCA	LFA102	279.8	21.5	2	17.4	-4
X-5355	BRCA	LFA102	378	22.6	7	58.6	0.9
X-5355	BRCA	LFA102	423.8	22.3	10	77.8	-0.4
X-5355	BRCA	LFA102	556.4	22.7	13	133.4	1.3
X-5355	BRCA	LFA102	640.4	23.7	17	168.6	5.8
X-5355	BRCA	LFA102	711.2	24.4	20	198.3	8.9
X-5355	BRCA	LFA102	835.9	24.8	24	250.6	10.7
X-5355	BRCA	LFA102	933.9	23.7	27	291.7	5.8
X-5355	BRCA	LFA102	1182.6	24.4	31	396.1	8.9
X-5355	BRCA	LFA102	1245.7	24.8	34	422.5	10.7
X-5355	BRCA	LJM716 + trastuzumab	267.1	24.5	0	0	0
X-5355	BRCA	LJM716 + trastuzumab	351.6	24.2	2	31.6	-1.2
X-5355	BRCA	LJM716 + trastuzumab	499.4	24.5	7	87	0
X-5355	BRCA	LJM716 + trastuzumab	693.5	24.4	10	159.6	-0.4
X-5355	BRCA	LJM716 + trastuzumab	796.6	25.2	13	198.2	2.9
X-5355	BRCA	LJM716 + trastuzumab	919.1	25.7	17	244.1	4.9
X-5355	BRCA	LJM716 + trastuzumab	1008.1	26.4	20	277.4	7.8
X-5355	BRCA	LJM716	224.4	21.7	0	0	0
X-5355	BRCA	LJM716	264.8	21.7	5	18	0
X-5355	BRCA	LJM716	281.9	21	8	25.6	-3.2
X-5355	BRCA	LJM716	302.4	22.7	11	34.8	4.6
X-5355	BRCA	LJM716	393.3	22.7	15	75.3	4.6
X-5355	BRCA	LJM716	403.9	22.5	18	80	3.7
X-5355	BRCA	LJM716	592.6	22.6	22	164.1	4.1
X-5355	BRCA	LJM716	622.5	22	25	177.4	1.4
X-5355	BRCA	LJM716	694	21.9	29	209.3	0.9
X-5355	BRCA	LJM716	726.1	22.4	32	223.6	3.2
X-5355	BRCA	LJM716	944.3	22.9	36	320.8	5.5
X-5355	BRCA	LJM716	1005.7	22.4	39	348.2	3.2
X-5355	BRCA	LKA136	224	24.1	0	0	0
X-5355	BRCA	LKA136	290.1	24.5	4	29.5	1.7
X-5355	BRCA	LKA136	325.6	24.5	7	45.4	1.7
X-5355	BRCA	LKA136	323.8	25.1	10	44.6	4.1
X-5355	BRCA	LKA136	346.5	24.9	14	54.7	3.3
X-5355	BRCA	LKA136	388.2	24.6	18	73.3	2.1
X-5355	BRCA	LKA136	431.9	25.4	21	92.8	5.4
X-5355	BRCA	LKA136	610.4	25.8	25	172.5	7.1
X-5355	BRCA	LKA136	759.4	26.4	35	239	9.5
X-5355	BRCA	LKA136	707.7	25.5	39	215.9	5.8
X-5355	BRCA	LKA136	790.2	26.3	42	252.8	9.1
X-5355	BRCA	LKA136	980.6	25.9	46	337.8	7.5
X-5355	BRCA	LKA136	910	26.9	49	306.2	11.6
X-5355	BRCA	LLM871	236.4	28	0	0	0
X-5355	BRCA	LLM871	303.5	27.4	3	28.4	-2.1
X-5355	BRCA	LLM871	310.1	27.2	6	31.2	-2.9
X-5355	BRCA	LLM871	336	27.1	10	42.1	-3.2
X-5355	BRCA	LLM871	320.6	27.5	13	35.6	-1.8
X-5355	BRCA	LLM871	318	27.2	17	34.5	-2.9
X-5355	BRCA	LLM871	282.7	27.3	20	19.6	-2.5
X-5355	BRCA	LLM871	382.9	28.1	24	62	0.4
X-5355	BRCA	LLM871	503	28.4	27	112.8	1.4
X-5355	BRCA	LLM871	562.6	28	31	138	0
X-5355	BRCA	LLM871	632.4	28.9	34	167.5	3.2
X-5355	BRCA	LLM871	817.7	28.5	37	245.9	1.8
X-5355	BRCA	LLM871	1082.4	29.8	41	357.9	6.4
X-5355	BRCA	binimetinib	299.7	27.8	0	0	0
X-5355	BRCA	binimetinib	181.6	27.4	4	-39.4	-1.4
X-5355	BRCA	binimetinib	147.6	28.2	7	-50.8	1.4
X-5355	BRCA	binimetinib	150.2	28	10	-49.9	0.7
X-5355	BRCA	binimetinib	131.1	28.2	14	-56.3	1.4
X-5355	BRCA	binimetinib	110.7	28.1	18	-63.1	1.1
X-5355	BRCA	binimetinib	129.4	28.2	21	-56.8	1.4
X-5355	BRCA	binimetinib	148.6	28.5	25	-50.4	2.5
X-5355	BRCA	binimetinib	199.5	30	35	-33.4	7.9
X-5355	BRCA	binimetinib	169.2	32.5	39	-43.5	16.9
X-5355	BRCA	binimetinib	170	31.7	42	-43.3	14
X-5355	BRCA	binimetinib	206.7	30	46	-31	7.9
X-5355	BRCA	binimetinib	251.7	29.6	49	-16	6.5
X-5355	BRCA	binimetinib	256.2	28.8	53	-14.5	3.6
X-5355	BRCA	binimetinib	212.2	29	56	-29.2	4.3
X-5355	BRCA	binimetinib	200.5	28.6	59	-33.1	2.9
X-5355	BRCA	binimetinib	168.6	27.7	63	-43.7	-0.4
X-5355	BRCA	binimetinib	166.4	27.9	66	-44.5	0.4
X-5355	BRCA	binimetinib	179.4	30.2	70	-40.1	8.6
X-5355	BRCA	binimetinib	191.6	30.5	73	-36.1	9.7
X-5355	BRCA	binimetinib	236.8	30.2	77	-21	8.6
X-5355	BRCA	binimetinib	264.3	30	81	-11.8	7.9
X-5355	BRCA	binimetinib	267.9	28.6	84	-10.6	2.9
X-5355	BRCA	binimetinib	281.8	29.5	88	-6	6.1
X-5355	BRCA	binimetinib	284.9	29.3	91	-4.9	5.4
X-5355	BRCA	binimetinib	338.4	29.5	95	12.9	6.1
X-5355	BRCA	binimetinib	415.1	29.5	98	38.5	6.1
X-5355	BRCA	binimetinib	479.4	29.1	102	60	4.7
X-5355	BRCA	binimetinib	514.2	28.6	105	71.6	2.9
X-5355	BRCA	binimetinib	518.9	28.7	109	73.1	3.2
X-5355	BRCA	binimetinib	520.5	29.9	112	73.7	7.6
X-5355	BRCA	binimetinib	541.4	28.9	116	80.6	4
X-5355	BRCA	binimetinib	544.9	29.2	119	81.8	5
X-5355	BRCA	binimetinib	629.4	28.6	123	110	2.9
X-5355	BRCA	binimetinib	622.9	28.2	126	107.8	1.4
X-5355	BRCA	binimetinib	737.6	27.4	130	146.1	-1.4
X-5355	BRCA	binimetinib	700.1	27.2	133	133.6	-2.2
X-5355	BRCA	binimetinib	736.4	28.2	137	145.7	1.4
X-5355	BRCA	binimetinib	714	28.4	140	138.2	2.2
X-5355	BRCA	paclitaxel	290.3	23.9	0	0	0
X-5355	BRCA	paclitaxel	304.2	23.2	2	4.8	-2.9
X-5355	BRCA	paclitaxel	306.5	24.2	7	5.6	1.3
X-5355	BRCA	paclitaxel	250.8	24.7	10	-13.6	3.3
X-5355	BRCA	paclitaxel	228.7	25	13	-21.2	4.6
X-5355	BRCA	paclitaxel	146.4	25.1	17	-49.6	5
X-5355	BRCA	paclitaxel	118.9	24.9	20	-59	4.2
X-5355	BRCA	paclitaxel	103.5	25.6	24	-64.3	7.1
X-5355	BRCA	paclitaxel	90.4	25.6	27	-68.9	7.1
X-5355	BRCA	paclitaxel	116.3	25.8	31	-59.9	7.9
X-5355	BRCA	paclitaxel	83.2	26.6	34	-71.3	11.3
X-5355	BRCA	paclitaxel	144.1	25.8	38	-50.4	7.9
X-5355	BRCA	paclitaxel	109.2	25.8	41	-62.4	7.9
X-5355	BRCA	paclitaxel	82.1	26.6	45	-71.7	11.3
X-5355	BRCA	paclitaxel	97.9	27.3	48	-66.3	14.2
X-5355	BRCA	paclitaxel	103.4	26.4	52	-64.4	10.5
X-5355	BRCA	paclitaxel	119.1	27.2	55	-59	13.8
X-5355	BRCA	paclitaxel	147	25.6	58	-49.4	7.1
X-5355	BRCA	paclitaxel	154.7	26	62	-46.7	8.8
X-5355	BRCA	paclitaxel	237.6	25.9	66	-18.2	8.4
X-5355	BRCA	paclitaxel	250.2	26.3	69	-13.8	10
X-5355	BRCA	paclitaxel	351.2	26.5	73	21	10.9
X-5355	BRCA	paclitaxel	508.1	26.7	83	75	11.7
X-5355	BRCA	paclitaxel	645.8	27.3	87	122.5	14.2
X-5355	BRCA	paclitaxel	729.9	27	90	151.4	13
X-5355	BRCA	paclitaxel	826.8	26.8	94	184.8	12.1
X-5355	BRCA	paclitaxel	1013	27.3	97	248.9	14.2
X-5355	BRCA	tamoxifen	330.8	25.6	0	0	0
X-5355	BRCA	tamoxifen	415.1	26.4	3	25.5	3.1
X-5355	BRCA	tamoxifen	534.4	26.1	8	61.5	2
X-5355	BRCA	tamoxifen	686.5	27.3	11	107.5	6.6
X-5355	BRCA	tamoxifen	782	27.2	14	136.4	6.2
X-5355	BRCA	tamoxifen	972.7	27.9	18	194	9
X-5355	BRCA	tamoxifen	1233.9	27.6	21	273	7.8
X-5355	BRCA	trastuzumab	262.2	25.8	0	0	0
X-5355	BRCA	trastuzumab	326.4	25.5	2	24.5	-1.2
X-5355	BRCA	trastuzumab	443.7	25.7	7	69.2	-0.4
X-5355	BRCA	trastuzumab	551.3	26.5	10	110.3	2.7
X-5355	BRCA	trastuzumab	516.1	27	13	96.8	4.7
X-5355	BRCA	trastuzumab	590	27	17	125	4.7
X-5355	BRCA	trastuzumab	793	27.1	20	202.4	5
X-5355	BRCA	trastuzumab	929.3	28.7	24	254.4	11.2
X-5355	BRCA	trastuzumab	1197.9	28.5	27	356.9	10.5
X-5355	BRCA	untreated	226.3	25.3	0	0	0
X-5355	BRCA	untreated	328.5	25.8	4	45.2	2
X-5355	BRCA	untreated	290.3	25.3	7	28.3	0
X-5355	BRCA	untreated	352.9	26.1	11	55.9	3.2
X-5355	BRCA	untreated	428.6	26.5	14	89.4	4.7
X-5355	BRCA	untreated	532.8	26.4	17	135.4	4.3
X-5355	BRCA	untreated	493.9	27.2	21	118.3	7.5
X-5355	BRCA	untreated	679.7	27.2	25	200.4	7.5
X-5355	BRCA	untreated	663	27.5	28	193	8.7
X-5355	BRCA	untreated	754.4	27.6	32	233.4	9.1
X-5355	BRCA	untreated	945.4	28.2	42	317.8	11.5
X-5355	BRCA	untreated	1120.4	27.7	46	395.1	9.5
X-5355	BRCA	untreated	1138.9	27.6	49	403.3	9.1
X-5355	BRCA	untreated	1334	28.1	53	489.5	11.1
X-5355	BRCA	untreated	1373.5	28.2	56	506.9	11.5
X-5355	BRCA	LFW527 + everolimus	214.61	29.4	0	0	0
X-5355	BRCA	LFW527 + everolimus	185.53	27.9	2	-13.6	-5.1
X-5355	BRCA	LFW527 + everolimus	181.87	25.6	6	-15.3	-12.9
X-5355	BRCA	LFW527 + everolimus	135.48	25.8	9	-36.9	-12.2
X-5355	BRCA	LFW527 + everolimus	147.54	26.7	13	-31.3	-9.2
X-5355	BRCA	LFW527 + everolimus	121.52	26.4	16	-43.4	-10.2
X-5355	BRCA	LFW527 + everolimus	123.96	26	20	-42.2	-11.6
X-5355	BRCA	LFW527 + everolimus	103.75	26.7	23	-51.7	-9.2
X-5355	BRCA	LFW527 + everolimus	96.74	23.7	27	-54.9	-19.4
X-5355	BRCA	LFW527 + everolimus	118.81	27.2	30	-44.6	-7.5
X-5355	BRCA	LFW527 + everolimus	82.74	26.5	34	-61.4	-9.9
X-5355	BRCA	LFW527 + everolimus	88.73	25	37	-58.7	-15
X-5355	BRCA	LFW527 + everolimus	86.75	27.4	41	-59.6	-6.8
X-5355	BRCA	LFW527 + everolimus	97.06	26.1	44	-54.8	-11.2
X-5355	BRCA	LFW527 + everolimus	86.74	25.3	48	-59.6	-13.9
X-5355	BRCA	LFW527 + everolimus	91.26	26.7	52	-57.5	-9.2
X-5355	BRCA	LFW527 + everolimus	111.19	25.3	56	-48.2	-13.9
X-5355	BRCA	LFW527 + everolimus	108.92	24.8	59	-49.2	-15.6
X-5355	BRCA	LFW527 + everolimus	105.16	27.6	62	-51	-6.1
X-5355	BRCA	LFW527 + everolimus	129.22	29.5	65	-39.8	0.3
X-5355	BRCA	LFW527 + everolimus	90.14	25.8	69	-58	-12.2
X-5355	BRCA	LFW527 + everolimus	81.62	26.4	72	-62	-10.2
X-5355	BRCA	LFW527 + everolimus	99.68	25.7	76	-53.6	-12.6
X-5355	BRCA	LFW527 + everolimus	107.15	25.6	79	-50.1	-12.9
X-5355	BRCA	LFW527 + everolimus	219.01	26.2	83	2.1	-10.9
X-5355	BRCA	LFW527 + everolimus	139.63	26.1	86	-34.9	-11.2
X-5355	BRCA	LFW527 + everolimus	131.27	26.5	90	-38.8	-9.9
X-5355	BRCA	LFW527 + everolimus	126.99	26.2	93	-40.8	-10.9
X-5355	BRCA	LFW527 + everolimus	109.37	27.3	97	-49	-7.1
X-5355	BRCA	LFW527 + everolimus	114.65	27.5	100	-46.6	-6.5
X-5355	BRCA	LFW527 + everolimus	127.09	28.2	107	-40.8	-4.1
X-5355	BRCA	LFW527 + everolimus	110.82	27.4	114	-48.4	-6.8
X-5355	BRCA	LFW527 + everolimus	101.77	26.8	119	-52.6	-8.8
X-5355	BRCA	LFW527 + everolimus	127.83	26.4	122	-40.4	-10.2
X-5355	BRCA	LFW527 + everolimus	101.73	26.7	125	-52.6	-9.2
X-5355	BRCA	LFW527 + everolimus	106.68	27.7	128	-50.3	-5.8
X-5355	BRCA	LFW527 + everolimus	96.54	26.7	132	-55	-9.2
X-5355	BRCA	LFW527 + everolimus	102.38	26.8	135	-52.3	-8.8
X-5355	BRCA	LFW527 + everolimus	86.07	26.4	139	-59.9	-10.2
X-5355	BRCA	LFW527 + everolimus	98.84	27.3	142	-53.9	-7.1
X-5355	BRCA	LFW527 + everolimus	107.55	27.6	146	-49.9	-6.1
X-5355	BRCA	LFW527 + everolimus	92.41	27.1	149	-56.9	-7.8
X-5405	CRC	5FU	204.7	22.1	0	0	0
X-5405	CRC	5FU	197.1	22.5	2	-3.7	1.8
X-5405	CRC	5FU	202	23	6	-1.3	4.1
X-5405	CRC	5FU	216.5	23	9	5.8	4.1
X-5405	CRC	5FU	276.2	23.2	13	34.9	5
X-5405	CRC	5FU	336.4	22.5	16	64.3	1.8
X-5405	CRC	5FU	380.7	21.6	20	86	-2.3
X-5405	CRC	5FU	417	21.5	23	103.7	-2.7
X-5405	CRC	5FU	471.6	20.4	27	130.4	-7.7
X-5405	CRC	5FU	485	20.1	30	136.9	-9
X-5405	CRC	5FU	524.6	20.4	34	156.3	-7.7
X-5405	CRC	BKM120	215	24.1	0	0	0
X-5405	CRC	BKM120	208.1	23.7	4	-3.2	-1.7
X-5405	CRC	BKM120	209.6	22.8	7	-2.5	-5.4
X-5405	CRC	BKM120	224.5	21.8	11	4.4	-9.5
X-5405	CRC	BKM120	243.9	23.7	14	13.4	-1.7
X-5405	CRC	BKM120	325.7	23.3	18	51.5	-3.3
X-5405	CRC	BKM120	334	22.9	21	55.3	-5
X-5405	CRC	BKM120	370.9	22.8	25	72.5	-5.4
X-5405	CRC	BKM120	487.1	23.6	28	126.6	-2.1
X-5405	CRC	BKM120	568.2	22.4	32	164.3	-7.1
X-5405	CRC	BKM120	634.6	22.1	35	195.2	-8.3
X-5405	CRC	BKM120	619.1	23.2	39	188	-3.7
X-5405	CRC	BKM120	741.1	21.8	42	244.7	-9.5
X-5405	CRC	BKM120	883.3	22.7	46	310.8	-5.8
X-5405	CRC	BKM120	850.5	22.5	49	295.6	-6.6
X-5405	CRC	BKM120 + LJC049	211.1	25.3	0	0	0
X-5405	CRC	BKM120 + LJC049	210	26.1	3	-0.5	3.2
X-5405	CRC	BKM120 + LJC049	220.6	26.4	7	4.5	4.3
X-5405	CRC	BKM120 + LJC049	229	23.7	10	8.5	-6.3
X-5405	CRC	BKM120 + LJC049	243.8	22.8	14	15.5	-9.9
X-5405	CRC	BKM120 + LJC049	283.2	19.5	17	34.2	-22.9
X-5405	CRC	BYL719 + cetuximab + encorafenib	236.7	24.6	0	0	0
X-5405	CRC	BYL719 + cetuximab + encorafenib	315.1	25	3	33.1	1.6
X-5405	CRC	BYL719 + cetuximab + encorafenib	371.9	24.3	6	57.1	-1.2
X-5405	CRC	BYL719 + cetuximab + encorafenib	401.3	24.2	9	69.5	-1.6
X-5405	CRC	BYL719 + cetuximab + encorafenib	587.4	24.5	13	148.2	-0.4
X-5405	CRC	BYL719 + cetuximab + encorafenib	680.7	22.9	16	187.6	-6.9
X-5405	CRC	BYL719 + cetuximab + encorafenib	769.8	24.3	20	225.2	-1.2
X-5405	CRC	BYL719 + cetuximab + encorafenib	1013	23.9	23	328	-2.8
X-5405	CRC	BYL719 + cetuximab + encorafenib	1275.9	21.9	28	439	-11
X-5405	CRC	BYL719 + cetuximab	214.6	24.9	0	0	0
X-5405	CRC	BYL719 + cetuximab	211.5	24.9	4	-1.4	0
X-5405	CRC	BYL719 + cetuximab	212.8	24.3	7	-0.8	-2.4
X-5405	CRC	BYL719 + cetuximab	205.3	24.1	11	-4.3	-3.2
X-5405	CRC	BYL719 + cetuximab	258.7	24.4	14	20.5	-2
X-5405	CRC	BYL719 + cetuximab	267.5	24.4	19	24.7	-2
X-5405	CRC	BYL719 + cetuximab	340.7	24.7	22	58.8	-0.8
X-5405	CRC	BYL719 + cetuximab	328.8	24.8	25	53.2	-0.4
X-5405	CRC	BYL719 + cetuximab	350.8	24.5	27	63.5	-1.6
X-5405	CRC	BYL719 + cetuximab	356.5	24.8	32	66.1	-0.4
X-5405	CRC	BYL719 + cetuximab	394.4	23.4	36	83.8	-6
X-5405	CRC	BYL719 + cetuximab	426.5	23.9	39	98.7	-4
X-5405	CRC	BYL719 + cetuximab	506.5	23.8	46	136	-4.4
X-5405	CRC	BYL719 + cetuximab	535.2	24.5	49	149.4	-1.6
X-5405	CRC	BYL719 + cetuximab	614.2	24	53	186.2	-3.6
X-5405	CRC	BYL719	223.2	22.8	0	0	0
X-5405	CRC	BYL719	266.4	22.3	5	19.4	-2.2
X-5405	CRC	BYL719	325.3	21.7	8	45.7	-4.8
X-5405	CRC	BYL719	552.1	20.5	12	147.4	-10.1
X-5405	CRC	BYL719	656.4	20.3	15	194.1	-11
X-5405	CRC	BYL719	825.2	19.6	19	269.7	-14
X-5405	CRC	BYL719	877.2	21.3	22	293	-6.6
X-5405	CRC	BYL719	1392.3	19.9	26	523.8	-12.7
X-5405	CRC	BYL719 + LJM716	241.2	27.7	0	0	0
X-5405	CRC	BYL719 + LJM716	192.9	25.1	5	-20	-9.4
X-5405	CRC	BYL719 + LJM716	198.6	24.3	8	-17.7	-12.3
X-5405	CRC	BYL719 + LJM716	201.7	24.4	12	-16.4	-11.9
X-5405	CRC	BYL719 + LJM716	220.6	25	15	-8.5	-9.7
X-5405	CRC	BYL719 + LJM716	232.6	25.3	19	-3.6	-8.7
X-5405	CRC	BYL719 + LJM716	224.4	23.8	22	-7	-14.1
X-5405	CRC	BYL719 + LJM716	189.4	24.9	26	-21.5	-10.1
X-5405	CRC	BYL719 + LJM716	229.4	24.5	29	-4.9	-11.6
X-5405	CRC	BYL719 + LJM716	268.1	25	33	11.2	-9.7
X-5405	CRC	BYL719 + LJM716	226.2	25.2	36	-6.2	-9
X-5405	CRC	BYL719 + LJM716	239.2	24.6	40	-0.8	-11.2
X-5405	CRC	BYL719 + LJM716	284.8	24.4	43	18.1	-11.9
X-5405	CRC	BYL719 + LJM716	306.5	24.8	50	27.1	-10.5
X-5405	CRC	BYL719 + LJM716	305.5	24.3	54	26.7	-12.3
X-5405	CRC	BYL719 + LJM716	305.2	24.2	58	26.5	-12.6
X-5405	CRC	BYL719 + LJM716	309.7	24.9	61	28.4	-10.1
X-5405	CRC	BYL719 + LJM716	310.4	24.9	64	28.7	-10.1
X-5405	CRC	BYL719 + LJM716	379.4	25	68	57.3	-9.7
X-5405	CRC	BYL719 + LJM716	331.9	24.5	71	37.6	-11.6
X-5405	CRC	BYL719 + LJM716	320.8	25.3	76	33	-8.7
X-5405	CRC	BYL719 + LJM716	324	24	82	34.3	-13.4
X-5405	CRC	BYL719 + LJM716	338.6	24	85	40.4	-13.4
X-5405	CRC	BYL719 + LJM716	372.2	26.1	89	54.3	-5.8
X-5405	CRC	BYL719 + binimetinib	236.8	25.1	0	0	0
X-5405	CRC	BYL719 + binimetinib	212.5	23.8	5	-10.3	-5.2
X-5405	CRC	BYL719 + binimetinib	179.5	22.1	8	-24.2	-12
X-5405	CRC	BYL719 + binimetinib	174	24.4	12	-26.5	-2.8
X-5405	CRC	BYL719 + binimetinib	174.5	22.7	15	-26.3	-9.6
X-5405	CRC	BYL719 + binimetinib	222.9	22.9	19	-5.9	-8.8
X-5405	CRC	BYL719 + binimetinib	255.9	21.2	22	8.1	-15.5
X-5405	CRC	BYL719 + binimetinib	192.3	22.9	26	-18.8	-8.8
X-5405	CRC	BYL719 + binimetinib	290.9	22.5	29	22.8	-10.4
X-5405	CRC	BYL719 + binimetinib	183.2	22.1	33	-22.6	-12
X-5405	CRC	BYL719 + binimetinib	188.2	23.2	36	-20.5	-7.6
X-5405	CRC	BYL719 + binimetinib	224	22	40	-5.4	-12.4
X-5405	CRC	BYL719 + binimetinib	140.7	22.1	43	-40.6	-12
X-5405	CRC	BYL719 + binimetinib	124.7	20	50	-47.3	-20.3
X-5405	CRC	BYL719 + encorafenib	201.7	23.7	0	0	0
X-5405	CRC	BYL719 + encorafenib	231.5	23.6	5	14.8	-0.4
X-5405	CRC	BYL719 + encorafenib	261.5	23.3	8	29.6	-1.7
X-5405	CRC	BYL719 + encorafenib	350.9	22.6	12	74	-4.6
X-5405	CRC	BYL719 + encorafenib	454	22.7	15	125.1	-4.2
X-5405	CRC	BYL719 + encorafenib	530.2	22.3	19	162.9	-5.9
X-5405	CRC	BYL719 + encorafenib	665.6	24.5	22	230	3.4
X-5405	CRC	BYL719 + encorafenib	650.9	22.2	26	222.7	-6.3
X-5405	CRC	BYL719 + encorafenib	812.2	23.9	29	302.7	0.8
X-5405	CRC	BYL719 + encorafenib	1139.6	22.4	33	465	-5.5
X-5405	CRC	BYL719 + encorafenib	1443.5	22.1	36	615.7	-6.8
X-5405	CRC	CGM097	214.8	24.6	0	0	0
X-5405	CRC	CGM097	282.2	21.4	3	31.4	-13
X-5405	CRC	CGM097	289.2	21.3	7	34.6	-13.4
X-5405	CRC	CGM097	268.5	21.7	10	25	-11.8
X-5405	CRC	CGM097	324.3	23.5	14	51	-4.5
X-5405	CRC	CGM097	327.1	23.2	17	52.3	-5.7
X-5405	CRC	CGM097	404.1	21.5	21	88.1	-12.6
X-5405	CRC	CGM097	456.4	20.8	24	112.5	-15.4
X-5405	CRC	CKX620	213.8	23.9	0	0	0
X-5405	CRC	CKX620	225.3	22.6	3	5.4	-5.4
X-5405	CRC	CKX620	278.7	23.8	7	30.4	-0.4
X-5405	CRC	CKX620	291.5	24.6	10	36.3	2.9
X-5405	CRC	CKX620	308.5	23.6	14	44.3	-1.3
X-5405	CRC	CKX620	313.5	23.9	17	46.6	0
X-5405	CRC	CKX620	378.6	23.4	21	77.1	-2.1
X-5405	CRC	CKX620	350.8	23.5	24	64.1	-1.7
X-5405	CRC	CKX620	368.9	23	28	72.5	-3.8
X-5405	CRC	CKX620	346	19.1	31	61.8	-20.1
X-5405	CRC	CLR457	217.8	24.3	0	0	0
X-5405	CRC	CLR457	222.4	24.4	3	2.1	0.4
X-5405	CRC	CLR457	222.8	23.8	7	2.3	-2.1
X-5405	CRC	CLR457	260	23.8	10	19.4	-2.1
X-5405	CRC	CLR457	321.2	24.1	14	47.5	-0.8
X-5405	CRC	CLR457	374.1	23.7	17	71.8	-2.5
X-5405	CRC	CLR457	420.6	24.7	21	93.1	1.6
X-5405	CRC	CLR457	418.3	23.1	24	92.1	-4.9
X-5405	CRC	CLR457	430.3	24.1	28	97.6	-0.8
X-5405	CRC	CLR457	520.7	24.8	31	139.1	2.1
X-5405	CRC	CLR457	531.9	23.2	38	144.2	-4.5
X-5405	CRC	CLR457	549.4	23.7	42	152.2	-2.5
X-5405	CRC	CLR457	592.1	23.6	46	171.9	-2.9
X-5405	CRC	CLR457	591.9	23.5	49	171.8	-3.3
X-5405	CRC	CLR457	636.9	23.6	52	192.4	-2.9
X-5405	CRC	CLR457	576.7	22.6	56	164.8	-7
X-5405	CRC	CLR457	788.6	22.1	59	262.1	-9.1
X-5405	CRC	CLR457	854.6	21.9	64	292.4	-9.9
X-5405	CRC	CLR457	1009.2	23.2	70	363.4	-4.5
X-5405	CRC	CLR457	1301.7	22.8	73	497.7	-6.2
X-5405	CRC	HDM201	202.2	23.8	0	0	0
X-5405	CRC	HDM201	207.2	21.9	4	2.5	-8
X-5405	CRC	HDM201	218.6	21.3	7	8.1	-10.5
X-5405	CRC	HDM201	192.2	21.7	11	-4.9	-8.8
X-5405	CRC	HDM201	218.8	20.4	14	8.2	-14.3
X-5405	CRC	HDM201	328.9	23.6	18	62.7	-0.8
X-5405	CRC	HDM201	352.8	21.5	21	74.5	-9.7
X-5405	CRC	HDM201	304.4	23	25	50.5	-3.4
X-5405	CRC	HDM201	350.5	21.7	28	73.3	-8.8
X-5405	CRC	HDM201	358.1	23.2	32	77.1	-2.5
X-5405	CRC	HDM201	359.5	19.4	35	77.8	-18.5
X-5405	CRC	cetuximab	212.7	23.5	0	0	0
X-5405	CRC	cetuximab	278.2	23.4	4	30.8	-0.4
X-5405	CRC	cetuximab	306.8	22.8	8	44.2	-3
X-5405	CRC	cetuximab	330.5	24.6	11	55.4	4.7
X-5405	CRC	cetuximab	386	22.9	14	81.5	-2.6
X-5405	CRC	cetuximab	430.2	22.5	19	102.3	-4.3
X-5405	CRC	cetuximab	401.3	21.4	22	88.7	-8.9
X-5405	CRC	cetuximab	484.5	21.2	25	127.8	-9.8
X-5405	CRC	cetuximab	546	21.2	28	156.7	-9.8
X-5405	CRC	cetuximab + encorafenib	234.4	24.9	0	0	0
X-5405	CRC	cetuximab + encorafenib	297.6	23.8	3	27	-4.4
X-5405	CRC	cetuximab + encorafenib	475.8	22.9	8	103	-8
X-5405	CRC	cetuximab + encorafenib	707	23.1	11	201.6	-7.2
X-5405	CRC	cetuximab + encorafenib	830.4	23.6	14	254.3	-5.2
X-5405	CRC	cetuximab + encorafenib	1106.4	23.1	17	372	-7.2
X-5405	CRC	cetuximab + encorafenib	1493.9	24.2	21	537.3	-2.8
X-5405	CRC	LEE011	197.6	22	0	0	0
X-5405	CRC	LEE011	196	22.8	2	-0.8	3.6
X-5405	CRC	LEE011	171.4	21.7	6	-13.3	-1.4
X-5405	CRC	LEE011	195.9	22	9	-0.9	0
X-5405	CRC	LEE011	204	23.5	13	3.2	6.8
X-5405	CRC	LEE011	196.3	21.4	16	-0.7	-2.7
X-5405	CRC	LEE011	211.9	21.7	20	7.2	-1.4
X-5405	CRC	LEE011	237.4	23.3	23	20.1	5.9
X-5405	CRC	LEE011	252.4	19.7	27	27.7	-10.5
X-5405	CRC	LEE011	273.5	20.3	30	38.4	-7.7
X-5405	CRC	LEE011	332.4	21.6	34	68.2	-1.8
X-5405	CRC	LEE011	429.2	20.2	37	117.2	-8.2
X-5405	CRC	LEE011	400.6	22.8	41	102.7	3.6
X-5405	CRC	LEE011	515.3	22.5	44	160.8	2.3
X-5405	CRC	LEE011	659.4	20.9	48	233.7	-5
X-5405	CRC	LEE011	580.2	21.9	51	193.6	-0.5
X-5405	CRC	LEE011	773	22.5	58	291.2	2.3
X-5405	CRC	LEE011	747.7	22.6	62	278.4	2.7
X-5405	CRC	LEE011	1047.3	19.5	66	430	-11.4
X-5405	CRC	LEE011	1059.5	20.3	69	436.2	-7.7
X-5405	CRC	encorafenib	209.3	26.7	0	0	0
X-5405	CRC	encorafenib	238.5	26.1	5	14	-2.2
X-5405	CRC	encorafenib	247.1	25.9	8	18.1	-3
X-5405	CRC	encorafenib	285.6	25.7	12	36.5	-3.7
X-5405	CRC	encorafenib	364.9	27.7	15	74.3	3.7
X-5405	CRC	encorafenib	551.1	26.5	19	163.3	-0.7
X-5405	CRC	encorafenib	749.3	26.6	22	258	-0.4
X-5405	CRC	encorafenib	815.8	24.6	26	289.8	-7.9
X-5405	CRC	encorafenib	1061.2	22.5	29	407	-15.7
X-5405	CRC	LJC049	208.5	24	0	0	0
X-5405	CRC	LJC049	355.2	23.8	5	70.4	-0.8
X-5405	CRC	LJC049	465.2	24.2	8	123.1	0.8
X-5405	CRC	LJC049	604.7	23.3	12	190	-2.9
X-5405	CRC	LJC049	743.2	25.4	15	256.5	5.8
X-5405	CRC	LJC049	924.9	22.7	19	343.6	-5.4
X-5405	CRC	LJC049	1313.9	22.7	22	530.2	-5.4
X-5405	CRC	LKA136	239.4	26.5	0	0	0
X-5405	CRC	LKA136	244.5	26.9	5	2.1	1.5
X-5405	CRC	LKA136	234.5	26.1	8	-2	-1.5
X-5405	CRC	LKA136	289.9	25.7	12	21.1	-3
X-5405	CRC	LKA136	355.5	25.4	15	48.5	-4.2
X-5405	CRC	LKA136	423.1	25.4	19	76.7	-4.2
X-5405	CRC	LKA136	394.2	25.8	22	64.7	-2.6
X-5405	CRC	LKA136	459.4	25.8	26	91.9	-2.6
X-5405	CRC	LKA136	544.6	26	29	127.5	-1.9
X-5405	CRC	LKA136	576.2	26.6	33	140.7	0.4
X-5405	CRC	LKA136	743.2	27.3	36	210.4	3
X-5405	CRC	LKA136	870.6	26.6	40	263.7	0.4
X-5405	CRC	LKA136	792.1	26.5	43	230.9	0
X-5405	CRC	binimetinib	192.9	23	0	0	0
X-5405	CRC	binimetinib	174	22.6	2	-9.8	-1.7
X-5405	CRC	binimetinib	134.4	22	6	-30.3	-4.3
X-5405	CRC	binimetinib	148.7	21.6	9	-22.9	-6.1
X-5405	CRC	binimetinib	117.8	21.3	13	-38.9	-7.4
X-5405	CRC	binimetinib	165.7	22.1	16	-14.1	-3.9
X-5405	CRC	binimetinib	193.5	22.1	20	0.3	-3.9
X-5405	CRC	binimetinib	192.1	22.2	23	-0.4	-3.5
X-5405	CRC	binimetinib	206.3	22	27	6.9	-4.3
X-5405	CRC	binimetinib	200.6	21.9	30	4	-4.8
X-5405	CRC	binimetinib	179.9	22	34	-6.7	-4.3
X-5405	CRC	binimetinib	240.7	21.1	37	24.8	-8.3
X-5405	CRC	binimetinib	214.4	21.4	41	11.1	-7
X-5405	CRC	binimetinib	246.9	23.8	44	28	3.5
X-5405	CRC	binimetinib	202.1	19.2	48	4.8	-16.5
X-5405	CRC	untreated	221.8	27.2	0	0	0
X-5405	CRC	untreated	279.1	27.2	3	25.8	0
X-5405	CRC	untreated	429.2	27.6	8	93.5	1.5
X-5405	CRC	untreated	517.2	27	14	133.2	-0.7
X-5405	CRC	untreated	528.6	27.1	17	138.3	-0.4
X-5405	CRC	untreated	843.3	26.8	21	280.2	-1.5
X-5405	CRC	untreated	1226	26.6	24	452.8	-2.2
X-5405	CRC	untreated	1521.3	26	28	585.9	-4.4
X-5421	CRC	LFW527 + binimetinib	209.94	13	0	0	0
X-5421	CRC	LFW527 + binimetinib	329.19	20.57	1	56.8	58.2
X-5421	CRC	LFW527 + binimetinib	424.28	20.03	4	102.1	54.1
X-5421	CRC	LFW527 + binimetinib	464.96	20.54	7	121.5	58
X-5421	CRC	LFW527 + binimetinib	687.02	21.01	11	227.2	61.6
X-5421	CRC	LFW527 + binimetinib	688.34	21.1	14	227.9	62.3
X-5421	CRC	LFW527 + binimetinib	760.78	20.9	18	262.4	60.8
X-5438	CRC	5FU	231.3	26.3	0	0	0
X-5438	CRC	5FU	309.4	27.1	2	33.8	3
X-5438	CRC	5FU	285	26.5	7	23.2	0.8
X-5438	CRC	5FU	399	28.8	10	72.5	9.5
X-5438	CRC	5FU	414.6	27.9	15	79.2	6.1
X-5438	CRC	5FU	516.1	30.9	20	123.1	17.5
X-5438	CRC	5FU	504.7	27.2	23	118.2	3.4
X-5438	CRC	5FU	485.3	27.6	27	109.8	4.9
X-5438	CRC	5FU	530	26	31	129.1	-1.1
X-5438	CRC	5FU	622.9	26.1	34	169.3	-0.8
X-5438	CRC	5FU	663.4	25.2	37	186.8	-4.2
X-5438	CRC	5FU	630.8	27	42	172.7	2.7
X-5438	CRC	5FU	623.6	27.1	45	169.6	3
X-5438	CRC	5FU	583.5	21.7	50	152.3	-17.5
X-5438	CRC	BKM120	198	27.4	0	0	0
X-5438	CRC	BKM120	199.3	27.3	4	0.7	-0.4
X-5438	CRC	BKM120	172.8	28.6	10	-12.7	4.4
X-5438	CRC	BKM120	181.2	29.6	15	-8.5	8
X-5438	CRC	BKM120	193.6	28.8	18	-2.2	5.1
X-5438	CRC	BKM120	196	28.3	23	-1	3.3
X-5438	CRC	BKM120	198.7	31.2	28	0.4	13.9
X-5438	CRC	BKM120	192.3	29.4	31	-2.9	7.3
X-5438	CRC	BKM120	250.5	29	35	26.5	5.8
X-5438	CRC	BKM120	240.4	28.3	39	21.4	3.3
X-5438	CRC	BKM120	290.5	28.3	42	46.7	3.3
X-5438	CRC	BKM120	287.3	28.4	45	45.1	3.6
X-5438	CRC	BKM120	328.6	28.1	50	66	2.6
X-5438	CRC	BKM120	326.6	30	53	64.9	9.5
X-5438	CRC	BKM120	306.6	29.8	58	54.8	8.8
X-5438	CRC	BKM120	295.8	29.3	64	49.4	6.9
X-5438	CRC	BKM120	381.4	28.6	67	92.6	4.4
X-5438	CRC	BKM120	414.8	29.8	72	109.5	8.8
X-5438	CRC	BKM120	397.1	28.9	74	100.6	5.5
X-5438	CRC	BKM120	382.1	29	77	93	5.8
X-5438	CRC	BKM120	428.5	30	81	116.4	9.5
X-5438	CRC	BKM120 + LJC049	201	26.8	0	0	0
X-5438	CRC	BKM120 + LJC049	349.8	26.5	5	74	-1.1
X-5438	CRC	BKM120 + LJC049	361.6	25.8	8	79.9	-3.7
X-5438	CRC	BKM120 + LJC049	317.9	25.2	13	58.2	-6
X-5438	CRC	BKM120 + LJC049	407.5	26.6	15	102.7	-0.7
X-5438	CRC	BKM120 + LJC049	597.7	25.8	18	197.4	-3.7
X-5438	CRC	BKM120 + LJC049	628	24.6	22	212.4	-8.2
X-5438	CRC	BKM120 + LJC049	585	24.7	27	191	-7.8
X-5438	CRC	BKM120 + LJC049	619.6	25.3	30	208.3	-5.6
X-5438	CRC	BKM120 + LJC049	749.2	25.6	33	272.7	-4.5
X-5438	CRC	BKM120 + LJC049	799.1	27.3	35	297.6	1.9
X-5438	CRC	BKM120 + LJC049	835.2	26.8	39	315.5	0
X-5438	CRC	BKM120 + LJC049	905.6	26.1	42	350.5	-2.6
X-5438	CRC	BKM120 + LJC049	884.9	26	47	340.2	-3
X-5438	CRC	BYL719	191.8	25.1	0	0	0
X-5438	CRC	BYL719	140	25.2	4	-27	0.4
X-5438	CRC	BYL719	159.3	24.7	7	-16.9	-1.6
X-5438	CRC	BYL719	192.9	25.2	10	0.6	0.4
X-5438	CRC	BYL719	196	24.9	15	2.2	-0.8
X-5438	CRC	BYL719	245.7	25.5	18	28.1	1.6
X-5438	CRC	BYL719	299	24.3	23	55.9	-3.2
X-5438	CRC	BYL719	284.7	25.1	29	48.4	0
X-5438	CRC	BYL719	384	25.3	32	100.2	0.8
X-5438	CRC	BYL719	400.7	24	37	108.9	-4.4
X-5438	CRC	BYL719	518	24.4	39	170.1	-2.8
X-5438	CRC	BYL719	599.6	24.4	42	212.6	-2.8
X-5438	CRC	BYL719	681.1	22.9	46	255.1	-8.8
X-5438	CRC	BYL719	836	22.9	51	335.9	-8.8
X-5438	CRC	BYL719	1133.6	23.2	54	491	-7.6
X-5438	CRC	BYL719	1803	23.4	57	840	-6.8
X-5438	CRC	BYL719 + LJM716	233.4	29.5	0	0	0
X-5438	CRC	BYL719 + LJM716	333	27.5	4	42.7	-6.8
X-5438	CRC	BYL719 + LJM716	312.9	24.9	7	34.1	-15.6
X-5438	CRC	BYL719 + LJM716	356.2	26	12	52.6	-11.9
X-5438	CRC	BYL719 + LJM716	350.7	27	18	50.3	-8.5
X-5438	CRC	BYL719 + LJM716	353.7	27	21	51.5	-8.5
X-5438	CRC	BYL719 + LJM716	359	28.2	26	53.8	-4.4
X-5438	CRC	BYL719 + LJM716	341.1	27.1	28	46.1	-8.1
X-5438	CRC	BYL719 + LJM716	350.8	25.5	31	50.3	-13.6
X-5438	CRC	BYL719 + LJM716	338.2	27.2	35	44.9	-7.8
X-5438	CRC	BYL719 + LJM716	338.1	26.4	40	44.9	-10.5
X-5438	CRC	BYL719 + LJM716	395.4	26.9	43	69.4	-8.8
X-5438	CRC	BYL719 + LJM716	388.2	26.8	46	66.3	-9.2
X-5438	CRC	BYL719 + LJM716	371.1	27.4	48	59	-7.1
X-5438	CRC	BYL719 + LJM716	391.2	26.8	52	67.6	-9.2
X-5438	CRC	BYL719 + LJM716	367.8	27.2	55	57.6	-7.8
X-5438	CRC	BYL719 + LJM716	364.7	28.3	60	56.3	-4.1
X-5438	CRC	BYL719 + LJM716	446.6	NA	66	91.3	-4.1
X-5438	CRC	BYL719 + LJM716	395.6	26.2	70	69.5	-11.2
X-5438	CRC	BYL719 + LJM716	326.7	26.1	74	40	-11.5
X-5438	CRC	BYL719 + cetuximab + encorafenib	206.1	28.3	0	0	0
X-5438	CRC	BYL719 + cetuximab + encorafenib	247.8	27	4	20.2	-4.6
X-5438	CRC	BYL719 + cetuximab + encorafenib	257	27.3	7	24.7	-3.5
X-5438	CRC	BYL719 + cetuximab + encorafenib	279.3	26.4	12	35.5	-6.7
X-5438	CRC	BYL719 + cetuximab + encorafenib	263	28.4	18	27.6	0.4
X-5438	CRC	BYL719 + cetuximab + encorafenib	265.6	28.1	21	28.9	-0.7
X-5438	CRC	BYL719 + cetuximab + encorafenib	255.7	28	26	24.1	-1.1
X-5438	CRC	BYL719 + cetuximab + encorafenib	308.9	27.6	28	49.9	-2.5
X-5438	CRC	BYL719 + cetuximab + encorafenib	304.5	27.7	31	47.7	-2.1
X-5438	CRC	BYL719 + cetuximab + encorafenib	326.8	28	35	58.6	-1.1
X-5438	CRC	BYL719 + cetuximab + encorafenib	323.5	28.5	40	57	0.7
X-5438	CRC	BYL719 + cetuximab + encorafenib	284.1	27.8	43	37.8	-1.8
X-5438	CRC	BYL719 + cetuximab + encorafenib	289.6	27.8	46	40.5	-1.8
X-5438	CRC	BYL719 + cetuximab + encorafenib	312.8	26.9	48	51.8	-4.9
X-5438	CRC	BYL719 + cetuximab + encorafenib	328	28.5	52	59.1	0.7
X-5438	CRC	BYL719 + cetuximab + encorafenib	318.4	27.7	55	54.5	-2.1
X-5438	CRC	BYL719 + cetuximab + encorafenib	328.3	28.2	60	59.3	-0.4
X-5438	CRC	BYL719 + cetuximab + encorafenib	253.5	NA	66	23	-0.4
X-5438	CRC	BYL719 + cetuximab + encorafenib	271.3	27.6	70	31.6	-2.5
X-5438	CRC	BYL719 + cetuximab + encorafenib	289.6	27.8	74	40.5	-1.8
X-5438	CRC	BYL719 + binimetinib	196.2	27	0	0	0
X-5438	CRC	BYL719 + binimetinib	191.6	24.3	4	-2.3	-10
X-5438	CRC	BYL719 + binimetinib	158.8	24.6	7	-19.1	-8.9
X-5438	CRC	BYL719 + binimetinib	164	24.6	12	-16.4	-8.9
X-5438	CRC	BYL719 + binimetinib	201	25.4	18	2.4	-5.9
X-5438	CRC	BYL719 + binimetinib	187.2	24.8	21	-4.6	-8.1
X-5438	CRC	BYL719 + binimetinib	153.2	24.2	26	-21.9	-10.4
X-5438	CRC	BYL719 + binimetinib	174.5	25.1	28	-11.1	-7
X-5438	CRC	BYL719 + binimetinib	171.3	25	31	-12.7	-7.4
X-5438	CRC	BYL719 + binimetinib	181.6	24.7	35	-7.4	-8.5
X-5438	CRC	BYL719 + binimetinib	193.9	24.1	40	-1.2	-10.7
X-5438	CRC	BYL719 + binimetinib	201.4	24.4	43	2.7	-9.6
X-5438	CRC	BYL719 + binimetinib	184	24	46	-6.2	-11.1
X-5438	CRC	BYL719 + binimetinib	204.6	23.8	48	4.3	-11.9
X-5438	CRC	BYL719 + binimetinib	206.3	24.9	52	5.1	-7.8
X-5438	CRC	BYL719 + binimetinib	248.8	25	60	26.8	-7.4
X-5438	CRC	BYL719 + binimetinib	205	NA	66	4.5	-7.4
X-5438	CRC	BYL719 + binimetinib	223.2	23.9	70	13.8	-11.5
X-5438	CRC	BYL719 + binimetinib	258	24.5	74	31.5	-9.3
X-5438	CRC	BYL719 + binimetinib	230.9	23.6	80	17.7	-12.6
X-5438	CRC	BYL719 + binimetinib	230.6	23.8	83	17.5	-11.9
X-5438	CRC	BYL719 + binimetinib	215	24	87	9.6	-11.1
X-5438	CRC	BYL719 + binimetinib	190	24.9	91	-3.2	-7.8
X-5438	CRC	BYL719 + binimetinib	225.3	24.3	95	14.8	-10
X-5438	CRC	BYL719 + binimetinib	306.4	23.6	105	56.2	-12.6
X-5438	CRC	BYL719 + cetuximab	193.1	28.1	0	0	0
X-5438	CRC	BYL719 + cetuximab	208.9	28.3	5	8.2	0.7
X-5438	CRC	BYL719 + cetuximab	202.9	27.5	8	5.1	-2.1
X-5438	CRC	BYL719 + cetuximab	186.6	28	13	-3.4	-0.4
X-5438	CRC	BYL719 + cetuximab	251.8	28	15	30.4	-0.4
X-5438	CRC	BYL719 + cetuximab	239.7	27.7	18	24.1	-1.4
X-5438	CRC	BYL719 + cetuximab	264.8	27.9	22	37.1	-0.7
X-5438	CRC	BYL719 + cetuximab	280.6	28.5	27	45.3	1.4
X-5438	CRC	BYL719 + cetuximab	306.8	28.5	30	58.9	1.4
X-5438	CRC	BYL719 + cetuximab	316.6	28.4	33	64	1.1
X-5438	CRC	BYL719 + cetuximab	342.2	28.4	35	77.2	1.1
X-5438	CRC	BYL719 + cetuximab	295	28.8	42	52.8	2.5
X-5438	CRC	BYL719 + cetuximab	340.2	29.5	47	76.2	5
X-5438	CRC	BYL719 + cetuximab	336.9	NA	53	74.5	5
X-5438	CRC	BYL719 + cetuximab	417	30.1	57	116	7.1
X-5438	CRC	BYL719 + cetuximab	388.3	29.1	61	101.1	3.6
X-5438	CRC	BYL719 + cetuximab	379.9	29.5	67	96.7	5
X-5438	CRC	BYL719 + cetuximab	371.1	29.9	70	92.2	6.4
X-5438	CRC	BYL719 + cetuximab	408.4	29.2	74	111.5	3.9
X-5438	CRC	BYL719 + cetuximab	297.7	29.4	78	54.2	4.6
X-5438	CRC	BYL719 + cetuximab	397.4	28.1	82	105.8	0
X-5438	CRC	BYL719 + cetuximab	480.1	29.3	92	148.6	4.3
X-5438	CRC	BYL719 + encorafenib	223.5	26.2	0	0	0
X-5438	CRC	BYL719 + encorafenib	195.3	26.5	5	-12.6	1.1
X-5438	CRC	BYL719 + encorafenib	159.5	27.2	8	-28.6	3.8
X-5438	CRC	BYL719 + encorafenib	168.1	27.4	13	-24.8	4.6
X-5438	CRC	BYL719 + encorafenib	175.2	27.1	15	-21.6	3.4
X-5438	CRC	BYL719 + encorafenib	180.3	25.9	18	-19.3	-1.1
X-5438	CRC	BYL719 + encorafenib	192.8	22.6	22	-13.7	-13.7
X-5438	CRC	BYL719 + encorafenib	188.6	24.9	27	-15.6	-5
X-5438	CRC	BYL719 + encorafenib	134.8	24.1	30	-39.7	-8
X-5438	CRC	BYL719 + encorafenib	150.3	23.5	33	-32.8	-10.3
X-5438	CRC	BYL719 + encorafenib	136.5	25.9	35	-38.9	-1.1
X-5438	CRC	BYL719 + encorafenib	166.7	26.4	39	-25.4	0.8
X-5438	CRC	BYL719 + encorafenib	155.9	26.3	42	-30.2	0.4
X-5438	CRC	BYL719 + encorafenib	198.4	26	47	-11.2	-0.8
X-5438	CRC	BYL719 + encorafenib	193.8	NA	53	-13.3	-0.8
X-5438	CRC	BYL719 + encorafenib	221.3	26.6	57	-1	1.5
X-5438	CRC	BYL719 + encorafenib	173.9	25.9	61	-22.2	-1.1
X-5438	CRC	BYL719 + encorafenib	175.6	23.7	67	-21.4	-9.5
X-5438	CRC	BYL719 + encorafenib	156.9	22.8	70	-29.8	-13
X-5438	CRC	BYL719 + encorafenib	132.5	22.9	74	-40.7	-12.6
X-5438	CRC	BYL719 + encorafenib	139.6	23.8	78	-37.5	-9.2
X-5438	CRC	BYL719 + encorafenib	198.3	25.5	82	-11.3	-2.7
X-5438	CRC	BYL719 + encorafenib	215.7	25.2	92	-3.5	-3.8
X-5438	CRC	CGM097	203	27.9	0	0	0
X-5438	CRC	CGM097	194.5	26.6	3	-4.2	-4.7
X-5438	CRC	CGM097	187.1	26.7	8	-7.8	-4.3
X-5438	CRC	CGM097	184.2	27.6	13	-9.3	-1.1
X-5438	CRC	CGM097	217.1	27.8	16	6.9	-0.4
X-5438	CRC	CGM097	222	28.1	20	9.4	0.7
X-5438	CRC	CGM097	190.1	28.9	24	-6.4	3.6
X-5438	CRC	CGM097	233.9	29.6	27	15.2	6.1
X-5438	CRC	CGM097	221.9	28.8	30	9.3	3.2
X-5438	CRC	CGM097	232.8	28.4	35	14.7	1.8
X-5438	CRC	CGM097	205.3	29.7	38	1.1	6.5
X-5438	CRC	CGM097	185.6	28.7	43	-8.6	2.9
X-5438	CRC	CGM097	190.5	28.3	49	-6.2	1.4
X-5438	CRC	CGM097	210.5	28.1	52	3.7	0.7
X-5438	CRC	CGM097	233.2	28.5	57	14.9	2.2
X-5438	CRC	CGM097	257.1	28.6	59	26.7	2.5
X-5438	CRC	CGM097	257.2	29.3	62	26.7	5
X-5438	CRC	CGM097	241.9	29	66	19.2	3.9
X-5438	CRC	CGM097	239.5	28.6	71	18	2.5
X-5438	CRC	CGM097	247.8	30	74	22.1	7.5
X-5438	CRC	CGM097	256.3	29.4	77	26.3	5.4
X-5438	CRC	CGM097	230.2	29	79	13.4	3.9
X-5438	CRC	CGM097	250.7	28.8	83	23.5	3.2
X-5438	CRC	CGM097	304.7	27.4	86	50.1	-1.8
X-5438	CRC	CGM097	258.4	27.9	91	27.3	0
X-5438	CRC	CGM097	301.4	NA	97	48.5	0
X-5438	CRC	CGM097	262.6	29	101	29.4	3.9
X-5438	CRC	CGM097	284.5	29.6	105	40.1	6.1
X-5438	CRC	CKX620	203.1	25.3	0	0	0
X-5438	CRC	CKX620	178.6	24.9	3	-12.1	-1.6
X-5438	CRC	CKX620	190.3	24.6	8	-6.3	-2.8
X-5438	CRC	CKX620	220.9	25.4	13	8.8	0.4
X-5438	CRC	CKX620	201.7	26.1	16	-0.7	3.2
X-5438	CRC	CKX620	219.7	25.3	20	8.2	0
X-5438	CRC	CKX620	255.7	25.4	24	25.9	0.4
X-5438	CRC	CKX620	251.1	25.8	27	23.6	2
X-5438	CRC	CKX620	282	26.1	30	38.8	3.2
X-5438	CRC	CKX620	279.4	25.2	35	37.6	-0.4
X-5438	CRC	CKX620	301.9	26.1	38	48.6	3.2
X-5438	CRC	CKX620	312.4	26	43	53.8	2.8
X-5438	CRC	CKX620	309.6	25.4	49	52.4	0.4
X-5438	CRC	CKX620	327	25.4	52	61	0.4
X-5438	CRC	CKX620	361	25.8	57	77.7	2
X-5438	CRC	CKX620	352.3	25.3	59	73.5	0
X-5438	CRC	CKX620	370.2	26.8	62	82.3	5.9
X-5438	CRC	CKX620	440.4	26.4	66	116.8	4.3
X-5438	CRC	CKX620	435.9	25.2	71	114.6	-0.4
X-5438	CRC	CKX620	480.8	24.6	74	136.7	-2.8
X-5438	CRC	CKX620	499.9	25.1	77	146.1	-0.8
X-5438	CRC	CLR457	201.8	24.9	0	0	0
X-5438	CRC	CLR457	227.1	24.3	4	12.5	-2.4
X-5438	CRC	CLR457	233.7	24.4	7	15.8	-2
X-5438	CRC	CLR457	200.9	25.1	10	-0.4	0.8
X-5438	CRC	CLR457	218.7	25.6	15	8.4	2.8
X-5438	CRC	CLR457	233.4	25.8	18	15.7	3.6
X-5438	CRC	CLR457	271.9	24.8	23	34.7	-0.4
X-5438	CRC	CLR457	253.7	24.5	29	25.7	-1.6
X-5438	CRC	CLR457	291.3	23.8	32	44.4	-4.4
X-5438	CRC	CLR457	288	24.2	37	42.7	-2.8
X-5438	CRC	CLR457	342.5	23.2	39	69.7	-6.8
X-5438	CRC	CLR457	323.3	23.6	42	60.2	-5.2
X-5438	CRC	CLR457	347.8	25.9	46	72.3	4
X-5438	CRC	CLR457	391.8	24.5	51	94.2	-1.6
X-5438	CRC	CLR457	404.2	26.1	54	100.3	4.8
X-5438	CRC	CLR457	466	26.4	57	130.9	6
X-5438	CRC	CLR457	414.9	25.9	59	105.6	4
X-5438	CRC	HDM201	206.1	26.3	0	0	0
X-5438	CRC	HDM201	206.3	27.5	2	0.1	4.6
X-5438	CRC	HDM201	277.1	25.6	7	34.4	-2.7
X-5438	CRC	HDM201	309.1	26	10	50	-1.1
X-5438	CRC	HDM201	336.1	28	15	63.1	6.5
X-5438	CRC	HDM201	366.8	27.8	20	78	5.7
X-5438	CRC	HDM201	402.3	26	23	95.2	-1.1
X-5438	CRC	HDM201	430.9	25.8	27	109.1	-1.9
X-5438	CRC	HDM201	523.7	24.8	31	154.1	-5.7
X-5438	CRC	HDM201	482.6	24.9	34	134.2	-5.3
X-5438	CRC	HDM201	547.6	25.6	37	165.7	-2.7
X-5438	CRC	HDM201	533.7	26	42	159	-1.1
X-5438	CRC	HDM201	509	25.1	45	147	-4.6
X-5438	CRC	HDM201	620.2	25.4	50	200.9	-3.4
X-5438	CRC	HDM201	738.6	24.2	56	258.4	-8
X-5438	CRC	HDM201	809.4	23.8	59	292.7	-9.5
X-5438	CRC	HDM201	790.1	23.3	64	283.4	-11.4
X-5438	CRC	HDM201	835.7	27	66	305.5	2.7
X-5438	CRC	HDM201	961.9	26.7	69	366.7	1.5
X-5438	CRC	HDM201	993.7	27.8	73	382.1	5.7
X-5438	CRC	HDM201	1074	26.4	78	421.1	0.4
X-5438	CRC	HDM201	1069.9	23.4	81	419.1	-11
X-5438	CRC	HDM201	1159.7	22.5	84	462.7	-14.4
X-5438	CRC	cetuximab	199.9	21.1	0	0	0
X-5438	CRC	cetuximab	182.5	21.1	2	-8.7	0
X-5438	CRC	cetuximab	143.4	21.5	8	-28.3	1.9
X-5438	CRC	cetuximab	167.7	21.8	12	-16.1	3.3
X-5438	CRC	cetuximab	230.5	22.1	15	15.3	4.7
X-5438	CRC	cetuximab	221.2	22.4	20	10.7	6.2
X-5438	CRC	cetuximab	204.8	22.3	23	2.5	5.7
X-5438	CRC	cetuximab	192.1	21.8	26	-3.9	3.3
X-5438	CRC	cetuximab	236.6	22.6	30	18.4	7.1
X-5438	CRC	cetuximab	253.9	23.1	34	27	9.5
X-5438	CRC	cetuximab	300.3	21.7	40	50.2	2.8
X-5438	CRC	cetuximab	313.1	22	44	56.6	4.3
X-5438	CRC	cetuximab	306	22	50	53.1	4.3
X-5438	CRC	cetuximab	338.6	22.5	55	69.4	6.6
X-5438	CRC	cetuximab	325.7	22.4	58	62.9	6.2
X-5438	CRC	cetuximab	459.4	22.7	63	129.8	7.6
X-5438	CRC	cetuximab	550.5	23.3	68	175.4	10.4
X-5438	CRC	cetuximab	508.5	24.4	71	154.4	15.6
X-5438	CRC	cetuximab	464.8	23.6	75	132.5	11.8
X-5438	CRC	cetuximab + encorafenib	192.4	27	0	0	0
X-5438	CRC	cetuximab + encorafenib	220.9	28.1	5	14.8	4.1
X-5438	CRC	cetuximab + encorafenib	156.6	27.3	8	-18.6	1.1
X-5438	CRC	cetuximab + encorafenib	163.3	28.5	13	-15.1	5.6
X-5438	CRC	cetuximab + encorafenib	141.5	27.7	15	-26.5	2.6
X-5438	CRC	cetuximab + encorafenib	144.6	28.3	18	-24.8	4.8
X-5438	CRC	cetuximab + encorafenib	199.4	27.8	22	3.6	3
X-5438	CRC	cetuximab + encorafenib	205.1	28.4	27	6.6	5.2
X-5438	CRC	cetuximab + encorafenib	257.6	27.8	30	33.9	3
X-5438	CRC	cetuximab + encorafenib	294.2	27.7	33	52.9	2.6
X-5438	CRC	cetuximab + encorafenib	236.5	28.2	35	22.9	4.4
X-5438	CRC	cetuximab + encorafenib	242.1	28.2	39	25.8	4.4
X-5438	CRC	cetuximab + encorafenib	233.1	27.3	42	21.2	1.1
X-5438	CRC	cetuximab + encorafenib	228.4	26.9	47	18.7	-0.4
X-5438	CRC	cetuximab + encorafenib	236.2	NA	53	22.8	-0.4
X-5438	CRC	cetuximab + encorafenib	214.8	27.5	57	11.6	1.9
X-5438	CRC	cetuximab + encorafenib	276.1	26.8	61	43.5	-0.7
X-5438	CRC	cetuximab + encorafenib	259.6	27.6	67	34.9	2.2
X-5438	CRC	cetuximab + encorafenib	288.8	27.4	70	50.1	1.5
X-5438	CRC	cetuximab + encorafenib	281.4	26.6	82	46.3	-1.5
X-5438	CRC	cetuximab + encorafenib	341.3	26.6	92	77.4	-1.5
X-5438	CRC	LEE011	240.4	26	0	0	0
X-5438	CRC	LEE011	237.3	27.8	4	-1.3	6.9
X-5438	CRC	LEE011	277	26.6	10	15.2	2.3
X-5438	CRC	LEE011	281	27.6	15	16.9	6.2
X-5438	CRC	LEE011	287.6	27.5	18	19.6	5.8
X-5438	CRC	LEE011	335.1	28.3	23	39.4	8.8
X-5438	CRC	LEE011	356.1	27.3	28	48.1	5
X-5438	CRC	LEE011	350.7	26.8	31	45.9	3.1
X-5438	CRC	LEE011	385.1	27.8	35	60.2	6.9
X-5438	CRC	LEE011	401.5	28.1	39	67	8.1
X-5438	CRC	LEE011	428.1	30.1	42	78.1	15.8
X-5438	CRC	LEE011	459.5	27.2	45	91.1	4.6
X-5438	CRC	LEE011	472.2	27.2	50	96.4	4.6
X-5438	CRC	LEE011	500.9	28	53	108.4	7.7
X-5438	CRC	LEE011	516.9	31.6	58	115	21.5
X-5438	CRC	LEE011	598	28.3	64	148.8	8.8
X-5438	CRC	LEE011	634.4	27.4	67	163.9	5.4
X-5438	CRC	LEE011	604.4	28.7	72	151.4	10.4
X-5438	CRC	LEE011	579.8	28.1	74	141.2	8.1
X-5438	CRC	LEE011	659.8	30.3	77	174.5	16.5
X-5438	CRC	LEE011	676	28.2	81	181.2	8.5
X-5438	CRC	encorafenib	222.8	25.4	0	0	0
X-5438	CRC	encorafenib	291.6	25.8	5	30.9	1.6
X-5438	CRC	encorafenib	334.1	26.7	8	50	5.1
X-5438	CRC	encorafenib	497.1	26	12	123.1	2.4
X-5438	CRC	encorafenib	541.4	25.4	16	143	0
X-5438	CRC	encorafenib	567.7	25.2	19	154.8	-0.8
X-5438	CRC	encorafenib	634.5	25.5	22	184.8	0.4
X-5438	CRC	encorafenib	900.3	28.4	27	304.1	11.8
X-5438	CRC	encorafenib	971	27.3	30	335.8	7.5
X-5438	CRC	encorafenib	1091.6	25.5	35	389.9	0.4
X-5438	CRC	encorafenib	1112.7	25.9	41	399.4	2
X-5438	CRC	encorafenib	1203.3	25.4	44	440.1	0
X-5438	CRC	encorafenib	1340.6	25.7	49	501.7	1.2
X-5438	CRC	encorafenib	1434.3	24.8	51	543.8	-2.4
X-5438	CRC	encorafenib	1441.4	25.4	54	546.9	0
X-5438	CRC	encorafenib	1513.3	26.7	58	579.2	5.1
X-5438	CRC	LJC049	224.8	27.3	0	0	0
X-5438	CRC	LJC049	308.4	27	3	37.2	-1.1
X-5438	CRC	LJC049	458.9	26.1	7	104.1	-4.4
X-5438	CRC	LJC049	397.4	25.8	11	76.8	-5.5
X-5438	CRC	LJC049	462	26.1	14	105.5	-4.4
X-5438	CRC	LJC049	844.3	25.3	17	275.6	-7.3
X-5438	CRC	LJC049	640.4	24.9	22	184.9	-8.8
X-5438	CRC	LJC049	958	26	25	326.2	-4.8
X-5438	CRC	LJC049	1078.3	25.2	30	379.7	-7.7
X-5438	CRC	LJC049	1409.4	24.8	36	527	-9.2
X-5438	CRC	LJC049	1305	25.7	39	480.5	-5.9
X-5438	CRC	LJC049	1531.1	25.3	44	581.1	-7.3
X-5438	CRC	LKA136	207.3	27.3	0	0	0
X-5438	CRC	LKA136	235.3	27.2	4	13.5	-0.4
X-5438	CRC	LKA136	223.1	26.9	7	7.6	-1.5
X-5438	CRC	LKA136	192	27.9	10	-7.4	2.2
X-5438	CRC	LKA136	198.7	27.2	15	-4.1	-0.4
X-5438	CRC	LKA136	241.5	28.2	18	16.5	3.3
X-5438	CRC	LKA136	266.3	27.3	23	28.5	0
X-5438	CRC	LKA136	231.2	28	29	11.5	2.6
X-5438	CRC	LKA136	267.1	27.9	32	28.8	2.2
X-5438	CRC	LKA136	305.1	27.6	37	47.2	1.1
X-5438	CRC	LKA136	312.8	29.3	39	50.9	7.3
X-5438	CRC	LKA136	419	29.8	42	102.1	9.2
X-5438	CRC	LKA136	473.6	28.5	46	128.5	4.4
X-5438	CRC	LKA136	521	28.1	51	151.3	2.9
X-5438	CRC	LKA136	642.4	27.5	54	209.9	0.7
X-5438	CRC	LKA136	568.4	27.3	57	174.2	0
X-5438	CRC	LKA136	589.5	27	59	184.4	-1.1
X-5438	CRC	LKA136	612	27.6	63	195.2	1.1
X-5438	CRC	LKA136	608.8	27	66	193.7	-1.1
X-5438	CRC	LKA136	650.9	27.3	71	214	0
X-5438	CRC	LKA136	710.2	NA	77	242.6	0
X-5438	CRC	LKA136	1019.7	27.9	81	391.9	2.2
X-5438	CRC	LKA136	961.6	27.4	85	363.9	0.4
X-5438	CRC	binimetinib	195.2	27.4	0	0	0
X-5438	CRC	binimetinib	203.9	25.5	4	4.5	-6.9
X-5438	CRC	binimetinib	204.3	25.7	8	4.7	-6.2
X-5438	CRC	binimetinib	185	25.3	14	-5.2	-7.7
X-5438	CRC	binimetinib	162.9	25	18	-16.5	-8.8
X-5438	CRC	binimetinib	205.4	25.7	24	5.2	-6.2
X-5438	CRC	binimetinib	169.8	24.6	29	-13	-10.2
X-5438	CRC	binimetinib	181.9	25.3	32	-6.8	-7.7
X-5438	CRC	binimetinib	172.3	25.7	37	-11.7	-6.2
X-5438	CRC	binimetinib	212.1	26.3	42	8.7	-4
X-5438	CRC	binimetinib	216.8	25.8	45	11.1	-5.8
X-5438	CRC	binimetinib	255.4	26.1	49	30.8	-4.7
X-5438	CRC	binimetinib	258.9	26	53	32.6	-5.1
X-5438	CRC	binimetinib	274.8	26.2	56	40.8	-4.4
X-5438	CRC	binimetinib	253.7	26	59	30	-5.1
X-5438	CRC	binimetinib	235.7	25.5	64	20.7	-6.9
X-5438	CRC	binimetinib	303.2	27.2	67	55.3	-0.7
X-5438	CRC	binimetinib	302.2	30.6	72	54.8	11.7
X-5438	CRC	binimetinib	284.2	26.4	78	45.6	-3.6
X-5438	CRC	binimetinib	265.2	26.3	81	35.9	-4
X-5438	CRC	binimetinib	237.8	26.6	86	21.8	-2.9
X-5438	CRC	binimetinib	255.4	26.7	88	30.8	-2.6
X-5438	CRC	binimetinib	230.2	26.5	91	17.9	-3.3
X-5438	CRC	binimetinib	246.6	26.8	100	26.3	-2.2
X-5438	CRC	binimetinib	194.5	27.1	103	-0.4	-1.1
X-5438	CRC	binimetinib	205.2	26.2	106	5.1	-4.4
X-5438	CRC	untreated	208.5	26.2	0	0	0
X-5438	CRC	untreated	196.9	26.4	5	-5.6	0.8
X-5438	CRC	untreated	194.9	25.8	8	-6.5	-1.5
X-5438	CRC	untreated	220	26	13	5.5	-0.8
X-5438	CRC	untreated	212.1	26.4	15	1.7	0.8
X-5438	CRC	untreated	229.5	26.3	18	10.1	0.4
X-5438	CRC	untreated	268.2	27	22	28.6	3.1
X-5438	CRC	untreated	266.6	28.4	27	27.9	8.4
X-5438	CRC	untreated	276.8	26.4	30	32.8	0.8
X-5438	CRC	untreated	261.2	26.1	33	25.3	-0.4
X-5438	CRC	untreated	249.1	25.6	35	19.5	-2.3
X-5438	CRC	untreated	247.6	26.2	39	18.8	0
X-5438	CRC	untreated	262.6	26.6	42	25.9	1.5
X-5438	CRC	untreated	302.7	26	47	45.2	-0.8
X-5438	CRC	untreated	271.8	NA	53	30.4	-0.8
X-5438	CRC	untreated	302.9	26.4	57	45.3	0.8
X-5438	CRC	untreated	303.7	26.2	61	45.7	0
X-5438	CRC	untreated	300.2	26.2	67	44	0
X-5438	CRC	untreated	342.4	26.3	70	64.2	0.4
X-5438	CRC	untreated	313.5	25.8	74	50.4	-1.5
X-5438	CRC	untreated	286.5	26.1	78	37.4	-0.4
X-5438	CRC	untreated	312.6	26.6	82	49.9	1.5
X-5438	CRC	untreated	324.6	26.4	92	55.7	0.8
X-5438	CRC	LFW527 + binimetinib	238.28	27.33	0	0	0
X-5438	CRC	LFW527 + binimetinib	158.07	26.59	4	-33.7	-2.7
X-5438	CRC	LFW527 + binimetinib	155.81	27.72	7	-34.6	1.4
X-5438	CRC	LFW527 + binimetinib	510.56	26.45	12	114.3	-3.2
X-5438	CRC	LFW527 + binimetinib	409.24	25.91	15	71.7	-5.2
X-5438	CRC	LFW527 + binimetinib	523.29	25.54	19	119.6	-6.5
X-5438	CRC	LFW527 + binimetinib	524.38	25.33	22	120.1	-7.3
X-5438	CRC	LFW527 + binimetinib	507.3	25.67	25	112.9	-6.1
X-5438	CRC	LFW527 + binimetinib	479.27	25.66	28	101.1	-6.1
X-5438	CRC	LFW527 + binimetinib	477.76	24.57	32	100.5	-10.1
X-5446	CRC	5FU	214.1	25	0	0	0
X-5446	CRC	5FU	227.9	22.2	4	6.4	-11.2
X-5446	CRC	5FU	228.9	24.2	7	6.9	-3.2
X-5446	CRC	5FU	223.8	22.9	10	4.5	-8.4
X-5446	CRC	5FU	208.9	22.8	14	-2.4	-8.8
X-5446	CRC	5FU	255.4	22.3	17	19.3	-10.8
X-5446	CRC	5FU	287.4	23.7	21	34.2	-5.2
X-5446	CRC	5FU	472.4	25.8	24	120.6	3.2
X-5446	CRC	5FU	425.5	24	30	98.7	-4
X-5446	CRC	5FU	461.4	25.1	34	115.5	0.4
X-5446	CRC	5FU	480.5	24.4	37	124.4	-2.4
X-5446	CRC	5FU	507.7	23.3	42	137.1	-6.8
X-5446	CRC	BKM120	248.5	25.7	0	0	0
X-5446	CRC	BKM120	326.5	24.4	4	31.4	-5.1
X-5446	CRC	BKM120	388.9	23.7	8	56.5	-7.8
X-5446	CRC	BKM120	427.3	24.2	11	72	-5.8
X-5446	CRC	BKM120	548.4	23.3	14	120.7	-9.3
X-5446	CRC	BKM120	560.5	24.6	18	125.6	-4.3
X-5446	CRC	BKM120	647.5	22.9	21	160.6	-10.9
X-5446	CRC	BKM120	649.6	24.3	25	161.4	-5.4
X-5446	CRC	BKM120 + LJC049	203.8	23.7	0	0	0
X-5446	CRC	BKM120 + LJC049	252.3	24.1	4	23.8	1.7
X-5446	CRC	BKM120 + LJC049	261.8	21.4	7	28.5	-9.7
X-5446	CRC	BKM120 + LJC049	350.7	23.3	13	72.1	-1.7
X-5446	CRC	BKM120 + LJC049	392.5	22.4	17	92.6	-5.5
X-5446	CRC	BKM120 + LJC049	447.9	23	20	119.8	-3
X-5446	CRC	BKM120 + LJC049	463.3	24.5	25	127.3	3.4
X-5446	CRC	BKM120 + LJC049	470.2	25	28	130.7	5.5
X-5446	CRC	BKM120 + LJC049	460.9	24.7	31	126.2	4.2
X-5446	CRC	BYL719	195	26.2	0	0	0
X-5446	CRC	BYL719	233	26	4	19.5	-0.8
X-5446	CRC	BYL719	280.7	24.9	8	43.9	-5
X-5446	CRC	BYL719	209.7	24.8	11	7.5	-5.3
X-5446	CRC	BYL719	264.9	24.7	14	35.8	-5.7
X-5446	CRC	BYL719	294.2	24.3	18	50.9	-7.3
X-5446	CRC	BYL719	293.3	24.7	21	50.4	-5.7
X-5446	CRC	BYL719	314.8	23.6	25	61.4	-9.9
X-5446	CRC	BYL719	373.3	25.1	28	91.4	-4.2
X-5446	CRC	BYL719	408.3	25.4	34	109.4	-3.1
X-5446	CRC	BYL719	421.2	25.3	38	116	-3.4
X-5446	CRC	BYL719	427.1	22.8	41	119	-13
X-5446	CRC	BYL719	548.2	27.1	46	181.1	3.4
X-5446	CRC	BYL719 + LJM716	205.8	27	0	0	0
X-5446	CRC	BYL719 + LJM716	367.1	23.4	3	78.4	-13.3
X-5446	CRC	BYL719 + LJM716	384.9	24.6	7	87	-8.9
X-5446	CRC	BYL719 + LJM716	421.5	23.5	10	104.8	-13
X-5446	CRC	BYL719 + LJM716	418.7	25.2	14	103.4	-6.7
X-5446	CRC	BYL719 + LJM716	413.7	25.8	17	101	-4.4
X-5446	CRC	BYL719 + LJM716	540.5	26.5	23	162.6	-1.9
X-5446	CRC	BYL719 + LJM716	529	25.5	27	157	-5.6
X-5446	CRC	BYL719 + LJM716	523	24.6	30	154.1	-8.9
X-5446	CRC	BYL719 + LJM716	634.1	26.9	35	208.1	-0.4
X-5446	CRC	BYL719 + cetuximab + encorafenib	201.5	25.6	0	0	0
X-5446	CRC	BYL719 + cetuximab + encorafenib	268.8	24.4	3	33.4	-4.7
X-5446	CRC	BYL719 + cetuximab + encorafenib	333.3	24.6	7	65.4	-3.9
X-5446	CRC	BYL719 + cetuximab + encorafenib	336.6	23.6	10	67	-7.8
X-5446	CRC	BYL719 + cetuximab + encorafenib	420.6	22.6	14	108.7	-11.7
X-5446	CRC	BYL719 + cetuximab + encorafenib	427.9	23.1	17	112.4	-9.8
X-5446	CRC	BYL719 + cetuximab + encorafenib	658.8	23.6	23	226.9	-7.8
X-5446	CRC	BYL719 + cetuximab + encorafenib	651.3	23.6	27	223.2	-7.8
X-5446	CRC	BYL719 + cetuximab + encorafenib	737.9	22.6	30	266.2	-11.7
X-5446	CRC	BYL719 + cetuximab + encorafenib	950.1	22.6	35	371.5	-11.7
X-5446	CRC	BYL719 + binimetinib	213	25.7	0	0	0
X-5446	CRC	BYL719 + binimetinib	218.3	24.4	4	2.5	-5.1
X-5446	CRC	BYL719 + binimetinib	185.3	24.2	8	-13	-5.8
X-5446	CRC	BYL719 + binimetinib	130.5	24.4	11	-38.7	-5.1
X-5446	CRC	BYL719 + binimetinib	166.3	24.9	17	-21.9	-3.1
X-5446	CRC	BYL719 + binimetinib	194.1	25.4	21	-8.9	-1.2
X-5446	CRC	BYL719 + binimetinib	168.6	24.3	24	-20.8	-5.4
X-5446	CRC	BYL719 + binimetinib	248.5	24.7	29	16.7	-3.9
X-5446	CRC	BYL719 + binimetinib	225.4	24.6	32	5.8	-4.3
X-5446	CRC	BYL719 + binimetinib	283.1	24.7	35	32.9	-3.9
X-5446	CRC	BYL719 + binimetinib	298.8	25.2	39	40.3	-1.9
X-5446	CRC	BYL719 + binimetinib	293.9	24.6	43	38	-4.3
X-5446	CRC	BYL719 + binimetinib	285.4	26.9	49	34	4.7
X-5446	CRC	BYL719 + binimetinib	257.8	26.1	53	21	1.6
X-5446	CRC	BYL719 + binimetinib	291.4	25.9	59	36.8	0.8
X-5446	CRC	BYL719 + binimetinib	272.9	25.3	64	28.1	-1.6
X-5446	CRC	BYL719 + binimetinib	298.6	24.9	67	40.2	-3.1
X-5446	CRC	BYL719 + binimetinib	286.7	24.6	72	34.6	-4.3
X-5446	CRC	BYL719 + binimetinib	315.9	26	77	48.3	1.2
X-5446	CRC	BYL719 + binimetinib	358.7	26.2	80	68.4	1.9
X-5446	CRC	BYL719 + binimetinib	381.8	26.9	84	79.2	4.7
X-5446	CRC	BYL719 + cetuximab	205.4	24.3	0	0	0
X-5446	CRC	BYL719 + cetuximab	236.1	24.7	4	14.9	1.6
X-5446	CRC	BYL719 + cetuximab	249.5	24	8	21.5	-1.2
X-5446	CRC	BYL719 + cetuximab	229.6	26.1	11	11.8	7.4
X-5446	CRC	BYL719 + cetuximab	252.5	27	17	22.9	11.1
X-5446	CRC	BYL719 + cetuximab	282.6	24.6	21	37.6	1.2
X-5446	CRC	BYL719 + cetuximab	232.7	23.3	24	13.3	-4.1
X-5446	CRC	BYL719 + cetuximab	262.1	25.2	29	27.6	3.7
X-5446	CRC	BYL719 + cetuximab	304.4	25.4	32	48.2	4.5
X-5446	CRC	BYL719 + cetuximab	277.2	25.4	35	35	4.5
X-5446	CRC	BYL719 + cetuximab	318	26.5	39	54.8	9.1
X-5446	CRC	BYL719 + cetuximab	366.4	25.5	43	78.4	4.9
X-5446	CRC	BYL719 + cetuximab	332.1	24.5	49	61.7	0.8
X-5446	CRC	BYL719 + cetuximab	313.3	24.4	53	52.5	0.4
X-5446	CRC	BYL719 + cetuximab	375	23.8	59	82.6	-2.1
X-5446	CRC	BYL719 + cetuximab	375.2	24	64	82.7	-1.2
X-5446	CRC	BYL719 + cetuximab	377.8	24.9	67	83.9	2.5
X-5446	CRC	BYL719 + cetuximab	478.7	25.4	72	133.1	4.5
X-5446	CRC	BYL719 + cetuximab	505.5	25.9	77	146.1	6.6
X-5446	CRC	BYL719 + cetuximab	592.1	26.7	80	188.3	9.9
X-5446	CRC	BYL719 + cetuximab	593.6	26.5	84	189	9.1
X-5446	CRC	BYL719 + encorafenib	200.4	27.4	0	0	0
X-5446	CRC	BYL719 + encorafenib	196.2	26.1	4	-2.1	-4.7
X-5446	CRC	BYL719 + encorafenib	235.4	25.7	7	17.5	-6.2
X-5446	CRC	BYL719 + encorafenib	269.1	26	13	34.3	-5.1
X-5446	CRC	BYL719 + encorafenib	385	27	17	92.1	-1.5
X-5446	CRC	BYL719 + encorafenib	412.1	25.8	20	105.6	-5.8
X-5446	CRC	BYL719 + encorafenib	392.4	29	25	95.8	5.8
X-5446	CRC	BYL719 + encorafenib	439.8	28.8	28	119.5	5.1
X-5446	CRC	BYL719 + encorafenib	430	28.2	31	114.6	2.9
X-5446	CRC	CGM097	206.5	23.6	0	0	0
X-5446	CRC	CGM097	460.3	23.9	8	122.9	1.3
X-5446	CRC	CGM097	519.2	24.2	11	151.4	2.5
X-5446	CRC	CGM097	773.6	23.4	14	274.6	-0.8
X-5446	CRC	CGM097	781.7	23.1	18	278.5	-2.1
X-5446	CRC	CGM097	981.4	23	21	375.3	-2.5
X-5446	CRC	CGM097	1124.9	22.9	25	444.7	-3
X-5446	CRC	CKX620	218.7	22.6	0	0	0
X-5446	CRC	CKX620	255.9	22.3	4	17	-1.3
X-5446	CRC	CKX620	282.4	22.2	8	29.1	-1.8
X-5446	CRC	CKX620	328	22.1	11	50	-2.2
X-5446	CRC	CKX620	307.6	21.6	14	40.6	-4.4
X-5446	CRC	CKX620	329.9	21.9	18	50.8	-3.1
X-5446	CRC	CKX620	395.9	22.2	21	81	-1.8
X-5446	CRC	CKX620	385.3	21.9	25	76.2	-3.1
X-5446	CRC	CKX620	416.1	22.2	28	90.3	-1.8
X-5446	CRC	CKX620	571.5	21.9	34	161.3	-3.1
X-5446	CRC	CKX620	507	22.8	38	131.8	0.9
X-5446	CRC	CKX620	592.9	21.7	41	171.1	-4
X-5446	CRC	CKX620	701.2	21.6	49	220.6	-4.4
X-5446	CRC	CKX620	825.4	21.4	52	277.4	-5.3
X-5446	CRC	CLR457	213.9	26.5	0	0	0
X-5446	CRC	CLR457	237.8	26.4	4	11.2	-0.4
X-5446	CRC	CLR457	278.2	26.6	8	30.1	0.4
X-5446	CRC	CLR457	268	26.7	11	25.3	0.8
X-5446	CRC	CLR457	285.7	26.5	17	33.6	0
X-5446	CRC	CLR457	301	26.7	21	40.7	0.8
X-5446	CRC	CLR457	319.5	26.9	24	49.4	1.5
X-5446	CRC	CLR457	382.2	27.9	29	78.7	5.3
X-5446	CRC	CLR457	371.9	28	32	73.9	5.7
X-5446	CRC	CLR457	401.4	27.7	35	87.7	4.5
X-5446	CRC	HDM201	197.2	24.8	0	0	0
X-5446	CRC	HDM201	203.3	23.9	4	3.1	-3.6
X-5446	CRC	HDM201	240.8	24.2	8	22.1	-2.4
X-5446	CRC	HDM201	263.2	25.5	11	33.5	2.8
X-5446	CRC	HDM201	368.1	25.3	14	86.7	2
X-5446	CRC	HDM201	373	25.4	18	89.1	2.4
X-5446	CRC	HDM201	345.3	25.7	21	75.1	3.6
X-5446	CRC	HDM201	321.3	24.6	25	62.9	-0.8
X-5446	CRC	HDM201	375.9	23.6	28	90.6	-4.8
X-5446	CRC	HDM201	434.9	23.7	34	120.5	-4.4
X-5446	CRC	HDM201	414.9	24.1	38	110.4	-2.8
X-5446	CRC	HDM201	446.3	24.5	41	126.3	-1.2
X-5446	CRC	HDM201	500.8	28	46	154	12.9
X-5446	CRC	cetuximab	201.3	25.2	0	0	0
X-5446	CRC	cetuximab	268.3	25.6	4	33.3	1.6
X-5446	CRC	cetuximab	261	26	7	29.7	3.2
X-5446	CRC	cetuximab	341	25.5	10	69.4	1.2
X-5446	CRC	cetuximab	373.2	26.2	14	85.4	4
X-5446	CRC	cetuximab	474.1	25.8	17	135.5	2.4
X-5446	CRC	cetuximab	502.4	26.2	21	149.6	4
X-5446	CRC	cetuximab	636.3	26.3	24	216.1	4.4
X-5446	CRC	cetuximab	691.2	26.1	30	243.4	3.6
X-5446	CRC	cetuximab	750.2	27.5	34	272.7	9.1
X-5446	CRC	cetuximab	893.9	26.6	37	344.1	5.6
X-5446	CRC	cetuximab	1098	26.6	42	445.5	5.6
X-5446	CRC	cetuximab + encorafenib	231.7	24.5	0	0	0
X-5446	CRC	cetuximab + encorafenib	359.6	23.5	3	55.2	-4.1
X-5446	CRC	cetuximab + encorafenib	442	23.8	7	90.8	-2.9
X-5446	CRC	cetuximab + encorafenib	591.1	23.9	10	155.1	-2.4
X-5446	CRC	cetuximab + encorafenib	598.8	23.8	14	158.4	-2.9
X-5446	CRC	cetuximab + encorafenib	546.3	23.4	17	135.8	-4.5
X-5446	CRC	cetuximab + encorafenib	597.1	26.9	23	157.7	9.8
X-5446	CRC	cetuximab + encorafenib	695.6	25.7	27	200.2	4.9
X-5446	CRC	cetuximab + encorafenib	756.4	25	30	226.5	2
X-5446	CRC	cetuximab + encorafenib	819	25	35	253.5	2
X-5446	CRC	LEE011	221.4	23.2	0	0	0
X-5446	CRC	LEE011	251.4	23	2	13.6	-0.9
X-5446	CRC	LEE011	311.6	22.9	6	40.7	-1.3
X-5446	CRC	LEE011	321.8	23.9	10	45.3	3
X-5446	CRC	LEE011	325.8	24.5	13	47.2	5.6
X-5446	CRC	LEE011	474.9	24.7	16	114.5	6.5
X-5446	CRC	LEE011	385.8	25	20	74.3	7.8
X-5446	CRC	LEE011	479.4	24.4	23	116.5	5.2
X-5446	CRC	LEE011	554.6	24.4	27	150.5	5.2
X-5446	CRC	encorafenib	235.4	22.8	0	0	0
X-5446	CRC	encorafenib	337.4	21.9	4	43.3	-3.9
X-5446	CRC	encorafenib	518.9	21.7	8	120.4	-4.8
X-5446	CRC	encorafenib	652.2	21.3	11	177.1	-6.6
X-5446	CRC	encorafenib	691.1	20.4	14	193.6	-10.5
X-5446	CRC	encorafenib	870.7	23.3	18	269.9	2.2
X-5446	CRC	encorafenib	1110.6	22.4	21	371.8	-1.8
X-5446	CRC	encorafenib	1009.4	20.1	25	328.8	-11.8
X-5446	CRC	LJC049	211.9	26	0	0	0
X-5446	CRC	LJC049	305.7	24.7	4	44.3	-5
X-5446	CRC	LJC049	359.3	24.8	8	69.6	-4.6
X-5446	CRC	LJC049	469.8	24.8	11	121.7	-4.6
X-5446	CRC	LJC049	613.1	24.6	14	189.3	-5.4
X-5446	CRC	LJC049	668.4	24.5	18	215.4	-5.8
X-5446	CRC	LJC049	814.2	27.7	21	284.2	6.5
X-5446	CRC	LJC049	978.5	26.9	25	361.8	3.5
X-5446	CRC	LKA136	210.4	23.6	0	0	0
X-5446	CRC	LKA136	268.6	23	4	27.7	-2.5
X-5446	CRC	LKA136	484.4	23.3	8	130.2	-1.3
X-5446	CRC	LKA136	601.2	24	11	185.7	1.7
X-5446	CRC	LKA136	716.6	23.4	14	240.6	-0.8
X-5446	CRC	LKA136	753.4	24	18	258.1	1.7
X-5446	CRC	LKA136	1016.2	24.2	21	383	2.5
X-5446	CRC	LKA136	1108.1	23.5	25	426.7	-0.4
X-5446	CRC	binimetinib	255.3	24.3	0	0	0
X-5446	CRC	binimetinib	299.6	23.1	2	17.4	-4.9
X-5446	CRC	binimetinib	484.3	21.6	6	89.7	-11.1
X-5446	CRC	binimetinib	611.9	22.8	10	139.7	-6.2
X-5446	CRC	binimetinib	630.9	23.3	13	147.1	-4.1
X-5446	CRC	binimetinib	802.2	22.5	16	214.2	-7.4
X-5446	CRC	binimetinib	1057.1	22.9	20	314.1	-5.8
X-5446	CRC	binimetinib	1202.3	25.2	23	370.9	3.7
X-5446	CRC	binimetinib	1223	25.6	27	379	5.3
X-5446	CRC	untreated	205.3	22.8	0	0	0
X-5446	CRC	untreated	263.4	22	4	28.3	-3.5
X-5446	CRC	untreated	299.5	22.7	7	45.9	-0.4
X-5446	CRC	untreated	423.3	23.4	13	106.2	2.6
X-5446	CRC	untreated	471.9	23.6	17	129.9	3.5
X-5446	CRC	untreated	540.1	23.3	20	163.1	2.2
X-5446	CRC	untreated	660.4	23.2	25	221.7	1.8
X-5446	CRC	untreated	647.4	23.1	28	215.3	1.3
X-5446	CRC	untreated	763.6	22.9	31	271.9	0.4
X-5446	CRC	untreated	813.4	22.3	35	296.2	-2.2
X-5446	CRC	untreated	894.7	22.5	39	335.8	-1.3
X-5446	CRC	untreated	1012.8	23.2	45	393.3	1.8
X-5446	CRC	untreated	1058.7	23	49	415.7	0.9
X-5446	CRC	untreated	1253.3	23.7	55	510.5	3.9
X-5446	CRC	untreated	1528.6	23.7	60	644.6	3.9
X-5446	CRC	untreated	1605.1	24	63	681.8	5.3
X-5446	CRC	LFW527 + binimetinib	207.69	21.22	0	0	0
X-5446	CRC	LFW527 + binimetinib	177.98	20.16	3	-14.3	-5
X-5446	CRC	LFW527 + binimetinib	189.61	20.58	7	-8.7	-3
X-5446	CRC	LFW527 + binimetinib	216.59	20.24	10	4.3	-4.6
X-5446	CRC	LFW527 + binimetinib	262.19	21.08	15	26.2	-0.7
X-5446	CRC	LFW527 + binimetinib	246.54	20.98	22	18.7	-1.1
X-5446	CRC	LFW527 + binimetinib	365.1	21.37	24	75.8	0.7
X-5446	CRC	LFW527 + binimetinib	453.77	20.77	28	118.5	-2.1
X-5446	CRC	LFW527 + binimetinib	496.56	20.36	30	139.1	-4.1
X-5446	CRC	LFW527 + binimetinib	503.44	20.64	32	142.4	-2.7
X-5446	CRC	LFW527 + binimetinib	519.67	20.61	35	150.2	-2.9
X-5446	CRC	LFW527 + binimetinib	510.77	21.05	39	145.9	-0.8
X-5446	CRC	LFW527 + binimetinib	536.84	20.6	42	158.5	-2.9
X-5446	CRC	LFW527 + binimetinib	546.58	21.48	49	163.2	1.2
X-5446	CRC	LFW527 + binimetinib	587.22	19.2	53	182.7	-9.5
X-5446	CRC	LFW527 + binimetinib	633.99	19.99	56	205.3	-5.8
X-5494	CRC	5FU	243.3	28.9	0	0	0
X-5494	CRC	5FU	265.9	27.7	2	9.3	-4.2
X-5494	CRC	5FU	249.4	28.5	6	2.5	-1.4
X-5494	CRC	5FU	271	29.5	9	11.4	2.1
X-5494	CRC	5FU	293.6	29.9	13	20.7	3.5
X-5494	CRC	5FU	292.8	28	16	20.3	-3.1
X-5494	CRC	5FU	300.1	28.8	19	23.3	-0.3
X-5494	CRC	5FU	292.1	29	23	20.1	0.3
X-5494	CRC	5FU	359.8	29.5	29	47.9	2.1
X-5494	CRC	5FU	401.6	29.1	33	65.1	0.7
X-5494	CRC	5FU	383.1	27.4	37	57.5	-5.2
X-5494	CRC	5FU	414.4	27.4	40	70.3	-5.2
X-5494	CRC	5FU	440	30.5	44	80.8	5.5
X-5494	CRC	5FU	470.4	29.2	48	93.3	1
X-5494	CRC	5FU	479.9	27.3	51	97.2	-5.5
X-5494	CRC	5FU	517.1	28.7	54	112.5	-0.7
X-5494	CRC	5FU	557.6	28.5	55	129.2	-1.4
X-5494	CRC	BKM120	213.1	26.5	0	0	0
X-5494	CRC	BKM120	234.1	26.4	5	9.9	-0.4
X-5494	CRC	BKM120	249.6	26	11	17.1	-1.9
X-5494	CRC	BKM120	159.6	26.1	15	-25.1	-1.5
X-5494	CRC	BKM120	211.1	26.6	20	-0.9	0.4
X-5494	CRC	BKM120	112.5	27.4	24	-47.2	3.4
X-5494	CRC	BKM120	254.2	26	29	19.3	-1.9
X-5494	CRC	BKM120	145.4	26	32	-31.8	-1.9
X-5494	CRC	BKM120	207.8	26.5	36	-2.5	0
X-5494	CRC	BKM120	199.3	25.2	40	-6.5	-4.9
X-5494	CRC	BKM120	239	24.5	44	12.2	-7.5
X-5494	CRC	BKM120	225.6	25.6	49	5.9	-3.4
X-5494	CRC	BKM120	183.1	26.5	54	-14.1	0
X-5494	CRC	BKM120	148.8	26.1	57	-30.2	-1.5
X-5494	CRC	BKM120	145.1	26.4	61	-31.9	-0.4
X-5494	CRC	BKM120	194.9	25.9	64	-8.5	-2.3
X-5494	CRC	BKM120	202.2	25.9	68	-5.1	-2.3
X-5494	CRC	BKM120	187	25.1	71	-12.2	-5.3
X-5494	CRC	BKM120	166.5	26.2	75	-21.9	-1.1
X-5494	CRC	BKM120	135.5	25.9	78	-36.4	-2.3
X-5494	CRC	BKM120	185.8	25.3	84	-12.8	-4.5
X-5494	CRC	BKM120	159.8	26.1	89	-25	-1.5
X-5494	CRC	BKM120 + LJC049	227.4	25.1	0	0	0
X-5494	CRC	BKM120 + LJC049	216	24.5	5	-5	-2.4
X-5494	CRC	BKM120 + LJC049	202.2	24.9	9	-11.1	-0.8
X-5494	CRC	BKM120 + LJC049	128.2	25.1	14	-43.6	0
X-5494	CRC	BKM120 + LJC049	128.5	24.9	22	-43.5	-0.8
X-5494	CRC	BKM120 + LJC049	183.4	24.1	26	-19.3	-4
X-5494	CRC	BKM120 + LJC049	195.7	23.9	29	-13.9	-4.8
X-5494	CRC	BKM120 + LJC049	174.8	22.7	33	-23.1	-9.6
X-5494	CRC	BKM120 + LJC049	177.3	26.1	36	-22	4
X-5494	CRC	BKM120 + LJC049	192.6	25.9	40	-15.3	3.2
X-5494	CRC	BKM120 + LJC049	196.5	25.3	43	-13.6	0.8
X-5494	CRC	BKM120 + LJC049	186.2	25.7	49	-18.1	2.4
X-5494	CRC	BKM120 + LJC049	197.4	23.8	54	-13.2	-5.2
X-5494	CRC	BKM120 + LJC049	191	23.9	58	-16	-4.8
X-5494	CRC	BKM120 + LJC049	181	24.1	61	-20.4	-4
X-5494	CRC	BKM120 + LJC049	183.4	23.8	66	-19.3	-5.2
X-5494	CRC	BKM120 + LJC049	172.6	24.3	68	-24.1	-3.2
X-5494	CRC	BKM120 + LJC049	152.8	24.2	71	-32.8	-3.6
X-5494	CRC	BKM120 + LJC049	125.4	24.1	74	-44.9	-4
X-5494	CRC	BKM120 + LJC049	148.1	24.3	81	-34.9	-3.2
X-5494	CRC	BKM120 + LJC049	168.9	23.4	86	-25.7	-6.8
X-5494	CRC	BYL719	183	25	0	0	0
X-5494	CRC	BYL719	206.2	23.2	4	12.7	-7.2
X-5494	CRC	BYL719	272.7	25.1	9	49	0.4
X-5494	CRC	BYL719	326	25.6	13	78.1	2.4
X-5494	CRC	BYL719	325.3	23	18	77.8	-8
X-5494	CRC	BYL719	384.4	23.1	21	110.1	-7.6
X-5494	CRC	BYL719	403.2	22.9	25	120.3	-8.4
X-5494	CRC	BYL719 + LJM716	217	26.8	0	0	0
X-5494	CRC	BYL719 + LJM716	110.8	30.6	5	-48.9	14.2
X-5494	CRC	BYL719 + LJM716	90.8	28.3	9	-58.2	5.6
X-5494	CRC	BYL719 + LJM716	65.6	28.2	14	-69.8	5.2
X-5494	CRC	BYL719 + LJM716	48.3	28	17	-77.7	4.5
X-5494	CRC	BYL719 + LJM716	86.1	29.5	21	-60.3	10.1
X-5494	CRC	BYL719 + LJM716	65	28.1	25	-70	4.9
X-5494	CRC	BYL719 + LJM716	57.3	30.2	29	-73.6	12.7
X-5494	CRC	BYL719 + LJM716	41.9	31	34	-80.7	15.7
X-5494	CRC	BYL719 + LJM716	48.9	31.5	42	-77.5	17.5
X-5494	CRC	BYL719 + LJM716	70.4	29.9	46	-67.6	11.6
X-5494	CRC	BYL719 + LJM716	65.9	29	49	-69.6	8.2
X-5494	CRC	BYL719 + LJM716	85.8	30.8	53	-60.5	14.9
X-5494	CRC	BYL719 + binimetinib	199.6	26.9	0	0	0
X-5494	CRC	BYL719 + binimetinib	127	25.6	9	-36.4	-4.8
X-5494	CRC	BYL719 + binimetinib	104	26.3	14	-47.9	-2.2
X-5494	CRC	BYL719 + binimetinib	92.7	25.6	17	-53.6	-4.8
X-5494	CRC	BYL719 + binimetinib	102	24.1	21	-48.9	-10.4
X-5494	CRC	BYL719 + binimetinib	79.8	24.9	25	-60	-7.4
X-5494	CRC	BYL719 + binimetinib	81.8	26.2	29	-59	-2.6
X-5494	CRC	BYL719 + binimetinib	59.2	27.5	34	-70.3	2.2
X-5494	CRC	BYL719 + binimetinib	46	27.3	42	-77	1.5
X-5494	CRC	BYL719 + binimetinib	69.6	25.9	46	-65.1	-3.7
X-5494	CRC	BYL719 + binimetinib	82.8	25.8	49	-58.5	-4.1
X-5494	CRC	BYL719 + binimetinib	74.6	25.9	53	-62.6	-3.7
X-5494	CRC	BYL719 + binimetinib	50	26.1	56	-74.9	-3
X-5494	CRC	BYL719 + binimetinib	59.4	25.9	60	-70.2	-3.7
X-5494	CRC	BYL719 + binimetinib	55.6	25.3	63	-72.1	-5.9
X-5494	CRC	BYL719 + binimetinib	57.9	25.7	69	-71	-4.5
X-5494	CRC	BYL719 + binimetinib	54.4	26.1	74	-72.7	-3
X-5494	CRC	BYL719 + binimetinib	70.7	25.4	81	-64.6	-5.6
X-5494	CRC	BYL719 + encorafenib	245.3	29.5	0	0	0
X-5494	CRC	BYL719 + encorafenib	201.5	30.2	5	-17.9	2.4
X-5494	CRC	BYL719 + encorafenib	186.2	29.9	9	-24.1	1.4
X-5494	CRC	BYL719 + encorafenib	200.2	28.5	14	-18.4	-3.4
X-5494	CRC	BYL719 + encorafenib	202.2	28.2	22	-17.6	-4.4
X-5494	CRC	BYL719 + encorafenib	206.2	28.1	26	-15.9	-4.7
X-5494	CRC	BYL719 + encorafenib	298.8	28	29	21.8	-5.1
X-5494	CRC	BYL719 + encorafenib	275.9	28.5	33	12.5	-3.4
X-5494	CRC	BYL719 + encorafenib	300.7	26.1	36	22.6	-11.5
X-5494	CRC	BYL719 + encorafenib	422.4	25.9	40	72.2	-12.2
X-5494	CRC	BYL719 + encorafenib	472.2	25.3	43	92.5	-14.2
X-5494	CRC	BYL719 + encorafenib	461.4	25.7	49	88.1	-12.9
X-5494	CRC	BYL719 + encorafenib	520.7	27.1	54	112.3	-8.1
X-5494	CRC	BYL719 + cetuximab + encorafenib	254.9	24.2	0	0	0
X-5494	CRC	BYL719 + cetuximab + encorafenib	221.5	25.2	5	-13.1	4.1
X-5494	CRC	BYL719 + cetuximab + encorafenib	205.7	24.2	8	-19.3	0
X-5494	CRC	BYL719 + cetuximab + encorafenib	150.7	25.8	12	-40.9	6.6
X-5494	CRC	BYL719 + cetuximab + encorafenib	96.4	26.7	18	-62.2	10.3
X-5494	CRC	BYL719 + cetuximab + encorafenib	59.7	26.6	25	-76.6	9.9
X-5494	CRC	BYL719 + cetuximab + encorafenib	57.2	26.8	30	-77.6	10.7
X-5494	CRC	BYL719 + cetuximab + encorafenib	69.2	26.9	33	-72.9	11.2
X-5494	CRC	BYL719 + cetuximab + encorafenib	51.6	27.1	36	-79.8	12
X-5494	CRC	BYL719 + cetuximab + encorafenib	48.3	27	39	-81.1	11.6
X-5494	CRC	BYL719 + cetuximab + encorafenib	46.4	26.3	43	-81.8	8.7
X-5494	CRC	BYL719 + cetuximab + encorafenib	37.1	25.6	48	-85.4	5.8
X-5494	CRC	BYL719 + cetuximab + encorafenib	43.3	26	53	-83	7.4
X-5494	CRC	BYL719 + cetuximab + encorafenib	56.9	26.7	57	-77.7	10.3
X-5494	CRC	BYL719 + cetuximab + encorafenib	56.9	26.3	61	-77.7	8.7
X-5494	CRC	BYL719 + cetuximab + encorafenib	38	25.6	64	-85.1	5.8
X-5494	CRC	BYL719 + cetuximab + encorafenib	41.6	25.7	68	-83.7	6.2
X-5494	CRC	BYL719 + cetuximab + encorafenib	51.7	25.7	71	-79.7	6.2
X-5494	CRC	BYL719 + cetuximab + encorafenib	54.2	25.9	74	-78.7	7
X-5494	CRC	BYL719 + cetuximab + encorafenib	55.9	25.8	78	-78.1	6.6
X-5494	CRC	BYL719 + cetuximab + encorafenib	22.1	25.9	84	-91.3	7
X-5494	CRC	BYL719 + cetuximab + encorafenib	29	25.8	88	-88.6	6.6
X-5494	CRC	CGM097	201.1	24.1	0	0	0
X-5494	CRC	CGM097	311.1	24.8	5	54.7	2.9
X-5494	CRC	CGM097	422.2	25.1	11	109.9	4.1
X-5494	CRC	CGM097	505.9	25.3	20	151.6	5
X-5494	CRC	CGM097	476.1	24	24	136.7	-0.4
X-5494	CRC	CGM097	694.6	24	29	245.4	-0.4
X-5494	CRC	CGM097	745.6	24.2	32	270.8	0.4
X-5494	CRC	CGM097	743.1	24.2	36	269.5	0.4
X-5494	CRC	CKX620	259.9	24.2	0	0	0
X-5494	CRC	CKX620	489.7	24.4	5	88.4	0.8
X-5494	CRC	CKX620	645.9	24.2	11	148.5	0
X-5494	CRC	CKX620	667.6	24.3	15	156.9	0.4
X-5494	CRC	CKX620	677	24.2	20	160.5	0
X-5494	CRC	CKX620	644.3	23.7	24	147.9	-2.1
X-5494	CRC	CKX620	467.6	24.2	32	79.9	0
X-5494	CRC	CKX620	550.7	24.5	36	111.9	1.2
X-5494	CRC	CLR457	205	27.2	0	0	0
X-5494	CRC	CLR457	79	26.8	4	-61.5	-1.5
X-5494	CRC	CLR457	147.2	26.9	9	-28.2	-1.1
X-5494	CRC	CLR457	135.5	26	13	-33.9	-4.4
X-5494	CRC	CLR457	319.9	26.4	18	56	-2.9
X-5494	CRC	CLR457	274.4	27.5	21	33.9	1.1
X-5494	CRC	CLR457	316.9	28	25	54.6	2.9
X-5494	CRC	HDM201	211.9	28.8	0	0	0
X-5494	CRC	HDM201	372.6	28.4	5	75.8	-1.4
X-5494	CRC	HDM201	488.4	29.1	11	130.5	1
X-5494	CRC	HDM201	529.2	29.6	15	149.7	2.8
X-5494	CRC	HDM201	467.9	31.3	20	120.8	8.7
X-5494	CRC	HDM201	671.6	29.7	24	216.9	3.1
X-5494	CRC	HDM201	651.4	29.4	29	207.4	2.1
X-5494	CRC	HDM201	464.1	27.4	32	119	-4.9
X-5494	CRC	HDM201	489	28.2	36	130.8	-2.1
X-5494	CRC	cetuximab + encorafenib	220.4	26.5	0	0	0
X-5494	CRC	cetuximab + encorafenib	255.5	27.4	5	15.9	3.4
X-5494	CRC	cetuximab + encorafenib	109.3	27.3	9	-50.4	3
X-5494	CRC	cetuximab + encorafenib	122.3	27	14	-44.5	1.9
X-5494	CRC	cetuximab + encorafenib	65.4	27	17	-70.3	1.9
X-5494	CRC	cetuximab + encorafenib	57.3	26.9	21	-74	1.5
X-5494	CRC	cetuximab + encorafenib	67.2	28.2	25	-69.5	6.4
X-5494	CRC	cetuximab + encorafenib	64.3	27.8	29	-70.8	4.9
X-5494	CRC	cetuximab + encorafenib	44.6	28.5	34	-79.8	7.5
X-5494	CRC	cetuximab + encorafenib	58.6	27.7	39	-73.4	4.5
X-5494	CRC	cetuximab + encorafenib	41.4	27	42	-81.2	1.9
X-5494	CRC	cetuximab + encorafenib	49.4	28.5	46	-77.6	7.5
X-5494	CRC	cetuximab + encorafenib	73.1	27.5	49	-66.8	3.8
X-5494	CRC	cetuximab + encorafenib	0	28.3	53	-100	6.8
X-5494	CRC	cetuximab + encorafenib	0	25.1	56	-100	-5.3
X-5494	CRC	cetuximab + encorafenib	0	26.2	60	-100	-1.1
X-5494	CRC	cetuximab + encorafenib	0	25.9	63	-100	-2.3
X-5494	CRC	cetuximab + encorafenib	0	25.3	69	-100	-4.5
X-5494	CRC	cetuximab + encorafenib	0.7	26.3	74	-99.7	-0.8
X-5494	CRC	cetuximab + encorafenib	1.8	27.1	78	-99.2	2.3
X-5494	CRC	cetuximab + encorafenib	7.8	26.5	81	-96.5	0
X-5494	CRC	cetuximab + encorafenib	0	26.5	86	-100	0
X-5494	CRC	cetuximab + encorafenib	0	26.5	90	-100	0
X-5494	CRC	LEE011	224.9	28.1	0	0	0
X-5494	CRC	LEE011	253.9	28.4	5	12.9	1.1
X-5494	CRC	LEE011	356.7	28.9	11	58.6	2.8
X-5494	CRC	LEE011	271.9	26.6	15	20.9	-5.3
X-5494	CRC	LEE011	337.6	27.1	20	50.1	-3.6
X-5494	CRC	LEE011	415.5	28.2	24	84.7	0.4
X-5494	CRC	LEE011	324.5	29.7	29	44.3	5.7
X-5494	CRC	LEE011	308	28.5	32	36.9	1.4
X-5494	CRC	LEE011	318.5	28.7	36	41.6	2.1
X-5494	CRC	encorafenib	228.7	27.3	0	0	0
X-5494	CRC	encorafenib	263.5	27.4	5	15.2	0.4
X-5494	CRC	encorafenib	382.3	27.6	11	67.2	1.1
X-5494	CRC	encorafenib	337.6	28.9	15	47.6	5.9
X-5494	CRC	encorafenib	395.7	28.6	24	73	4.8
X-5494	CRC	encorafenib	353.1	24.4	29	54.4	-10.6
X-5494	CRC	encorafenib	519.6	28.7	32	127.2	5.1
X-5494	CRC	encorafenib	594.6	29.1	36	160	6.6
X-5494	CRC	LJC049	193	27.6	0	0	0
X-5494	CRC	LJC049	93.7	28.1	4	-51.5	1.8
X-5494	CRC	LJC049	87.4	27	9	-54.7	-2.2
X-5494	CRC	LJC049	56.6	27.5	13	-70.7	-0.4
X-5494	CRC	LJC049	46.2	29.7	18	-76.1	7.6
X-5494	CRC	LJC049	33.1	29.1	21	-82.8	5.4
X-5494	CRC	LJC049	27.9	30.2	25	-85.5	9.4
X-5494	CRC	LJC049	58.2	29.5	29	-69.8	6.9
X-5494	CRC	LJC049	90.1	28.5	33	-53.3	3.3
X-5494	CRC	LJC049	161.1	29.6	38	-16.5	7.2
X-5494	CRC	LJC049	159.2	30.3	43	-17.5	9.8
X-5494	CRC	LJC049	257.1	28.4	46	33.2	2.9
X-5494	CRC	LJC049	361.8	29.3	50	87.5	6.2
X-5494	CRC	LJC049	339	29.1	53	75.6	5.4
X-5494	CRC	LJC049	512	30	57	165.3	8.7
X-5494	CRC	LKA136	162.2	24.3	0	0	0
X-5494	CRC	LKA136	206	25	4	27	2.9
X-5494	CRC	LKA136	190.9	24.7	9	17.7	1.6
X-5494	CRC	LKA136	194.1	24.5	13	19.7	0.8
X-5494	CRC	LKA136	255.8	25.1	18	57.7	3.3
X-5494	CRC	LKA136	362.7	24.4	21	123.6	0.4
X-5494	CRC	LKA136	414	26	25	155.2	7
X-5494	CRC	binimetinib	216	23.7	0	0	0
X-5494	CRC	binimetinib	188.6	24.4	5	-12.7	3
X-5494	CRC	binimetinib	155.7	24.9	11	-27.9	5.1
X-5494	CRC	binimetinib	128.7	23.9	15	-40.4	0.8
X-5494	CRC	binimetinib	199.5	24	20	-7.6	1.3
X-5494	CRC	binimetinib	140.6	23.7	24	-34.9	0
X-5494	CRC	binimetinib	166.6	23.9	29	-22.9	0.8
X-5494	CRC	binimetinib	188.9	24.5	32	-12.5	3.4
X-5494	CRC	binimetinib	189.4	25.5	36	-12.3	7.6
X-5494	CRC	binimetinib	186	25.1	40	-13.9	5.9
X-5494	CRC	binimetinib	225.3	24.9	44	4.3	5.1
X-5494	CRC	binimetinib	277.4	24.2	49	28.4	2.1
X-5494	CRC	binimetinib	307.4	23.9	54	42.3	0.8
X-5494	CRC	binimetinib	351.8	23.3	57	62.9	-1.7
X-5494	CRC	untreated	254.5	25.4	0	0	0
X-5494	CRC	untreated	340.1	26.4	5	33.6	3.9
X-5494	CRC	untreated	515.9	26.1	11	102.7	2.8
X-5494	CRC	untreated	562.4	24.1	15	121	-5.1
X-5494	CRC	untreated	552	25	20	116.9	-1.6
X-5494	CRC	untreated	552.2	24.4	24	117	-3.9
X-5494	CRC	untreated	636	26.4	29	149.9	3.9
X-5494	CRC	untreated	771.3	25.2	32	203.1	-0.8
X-5494	CRC	untreated	872.1	26.7	36	242.7	5.1
X-5495	CRC	5FU	200.3	25.4	0	0	0
X-5495	CRC	5FU	211.9	24.2	5	5.8	-4.7
X-5495	CRC	5FU	228.9	24.5	8	14.3	-3.5
X-5495	CRC	5FU	280.2	23	12	39.9	-9.4
X-5495	CRC	5FU	288.7	22.4	15	44.1	-11.8
X-5495	CRC	5FU	284.3	24.3	20	41.9	-4.3
X-5495	CRC	5FU	334.5	23	23	67	-9.4
X-5495	CRC	5FU	371.9	23	26	85.7	-9.4
X-5495	CRC	5FU	354.1	23.5	29	76.8	-7.5
X-5495	CRC	5FU	349.6	22.8	33	74.5	-10.2
X-5495	CRC	5FU	384.2	21.7	36	91.8	-14.6
X-5495	CRC	5FU	316.4	21.8	41	58	-14.2
X-5495	CRC	5FU	327.5	21.3	43	63.5	-16.1
X-5495	CRC	5FU	387.6	24.9	47	93.5	-2
X-5495	CRC	5FU	407.3	25.5	50	103.3	0.4
X-5495	CRC	5FU	455.4	25.7	55	127.4	1.2
X-5495	CRC	BKM120	220.4	22.2	0	0	0
X-5495	CRC	BKM120	255.6	23.2	3	16	4.5
X-5495	CRC	BKM120	216.5	20.7	7	-1.8	-6.8
X-5495	CRC	BKM120	242.5	19.5	10	10	-12.2
X-5495	CRC	BKM120	218.4	19.3	15	-0.9	-13.1
X-5495	CRC	BKM120	228.2	20.5	18	3.5	-7.7
X-5495	CRC	BKM120	210.4	19	21	-4.5	-14.4
X-5495	CRC	BKM120	247	20.9	24	12.1	-5.9
X-5495	CRC	BKM120	274.4	20.8	28	24.5	-6.3
X-5495	CRC	BKM120	309.7	20.8	31	40.5	-6.3
X-5495	CRC	BKM120	371.9	21.2	36	68.7	-4.5
X-5495	CRC	BKM120	317.2	21.6	38	43.9	-2.7
X-5495	CRC	BKM120	304.4	22.1	42	38.1	-0.5
X-5495	CRC	BKM120	257.4	21.9	45	16.8	-1.4
X-5495	CRC	BKM120	273	22.2	50	23.9	0
X-5495	CRC	BKM120	271.4	22.5	51	23.1	1.4
X-5495	CRC	BKM120	273	22.9	53	23.9	3.2
X-5495	CRC	BKM120	212.6	21.7	57	-3.5	-2.3
X-5495	CRC	BKM120	222	22.1	60	0.7	-0.5
X-5495	CRC	BKM120	219.3	22.2	67	-0.5	0
X-5495	CRC	BKM120	225.3	21.9	80	2.2	-1.4
X-5495	CRC	BKM120	228.1	21.7	84	3.5	-2.3
X-5495	CRC	BKM120	228.5	21.5	88	3.7	-3.2
X-5495	CRC	BKM120 + LJC049	204.2	25	0	0	0
X-5495	CRC	BKM120 + LJC049	301.9	23.6	3	47.8	-5.6
X-5495	CRC	BKM120 + LJC049	227.9	22.6	6	11.6	-9.6
X-5495	CRC	BKM120 + LJC049	235.7	22.6	9	15.4	-9.6
X-5495	CRC	BKM120 + LJC049	194.2	20.3	13	-4.9	-18.8
X-5495	CRC	BKM120 + LJC049	220.1	20.7	16	7.8	-17.2
X-5495	CRC	BYL719 + cetuximab + encorafenib	296.8	22.9	0	0	0
X-5495	CRC	BYL719 + cetuximab + encorafenib	395.3	22.9	4	33.2	0
X-5495	CRC	BYL719 + cetuximab + encorafenib	388.6	20.9	7	30.9	-8.7
X-5495	CRC	BYL719 + cetuximab + encorafenib	595.8	22	10	100.7	-3.9
X-5495	CRC	BYL719 + cetuximab + encorafenib	1067.1	20.8	17	259.5	-9.2
X-5495	CRC	BYL719 + cetuximab	214.2	23.7	0	0	0
X-5495	CRC	BYL719 + cetuximab	291.7	22.9	4	36.2	-3.4
X-5495	CRC	BYL719 + cetuximab	266.5	21.7	7	24.4	-8.4
X-5495	CRC	BYL719 + cetuximab	269.2	24.4	10	25.7	3
X-5495	CRC	BYL719 + cetuximab	290.5	22.4	17	35.6	-5.5
X-5495	CRC	BYL719 + cetuximab	339.2	26	21	58.4	9.7
X-5495	CRC	BYL719 + cetuximab	342.8	25.4	25	60	7.2
X-5495	CRC	BYL719 + cetuximab	303.8	26.4	28	41.8	11.4
X-5495	CRC	BYL719 + cetuximab	313.5	26.4	31	46.4	11.4
X-5495	CRC	BYL719 + cetuximab	330.8	25.5	34	54.4	7.6
X-5495	CRC	BYL719 + cetuximab	298.7	25.3	39	39.4	6.8
X-5495	CRC	BYL719 + cetuximab	303.8	26	42	41.8	9.7
X-5495	CRC	BYL719 + cetuximab	302.1	26	46	41	9.7
X-5495	CRC	BYL719 + cetuximab	270.2	25.5	49	26.1	7.6
X-5495	CRC	BYL719 + cetuximab	305.7	26.6	54	42.7	12.2
X-5495	CRC	BYL719 + cetuximab	350.6	26.1	56	63.7	10.1
X-5495	CRC	BYL719 + cetuximab	351	25.8	61	63.9	8.9
X-5495	CRC	BYL719 + cetuximab	325.4	26.5	63	51.9	11.8
X-5495	CRC	BYL719 + cetuximab	377.3	27.3	66	76.1	15.2
X-5495	CRC	BYL719 + cetuximab	377.8	26.1	70	76.4	10.1
X-5495	CRC	BYL719 + cetuximab	361.1	25.7	73	68.6	8.4
X-5495	CRC	BYL719 + cetuximab	424.4	26	77	98.1	9.7
X-5495	CRC	BYL719 + cetuximab	412.8	26.1	80	92.7	10.1
X-5495	CRC	BYL719 + cetuximab	431.4	26.5	84	101.4	11.8
X-5495	CRC	BYL719 + cetuximab	393.2	27.4	87	83.6	15.6
X-5495	CRC	BYL719 + cetuximab	447.9	26	94	109.1	9.7
X-5495	CRC	BYL719 + cetuximab	668.2	26	105	212	9.7
X-5495	CRC	BYL719 + cetuximab	699.7	25.7	109	226.7	8.4
X-5495	CRC	BYL719 + cetuximab	794.9	25.9	117	271.1	9.3
X-5495	CRC	BYL719 + cetuximab	827.5	25.5	125	286.3	7.6
X-5495	CRC	BYL719	195.7	22.6	0	0	0
X-5495	CRC	BYL719	183.5	24.4	3	-6.2	8
X-5495	CRC	BYL719	230.5	22.3	6	17.8	-1.3
X-5495	CRC	BYL719	195.5	21.8	11	-0.1	-3.5
X-5495	CRC	BYL719	228.6	20.6	14	16.8	-8.8
X-5495	CRC	BYL719	259.9	20	17	32.8	-11.5
X-5495	CRC	BYL719	283.7	20.4	20	45	-9.7
X-5495	CRC	BYL719	278.8	19.3	24	42.5	-14.6
X-5495	CRC	BYL719	251.2	19.5	27	28.4	-13.7
X-5495	CRC	BYL719	312.2	18.8	32	59.5	-16.8
X-5495	CRC	BYL719	304.1	18.3	34	55.4	-19
X-5495	CRC	BYL719	312.1	19.2	38	59.5	-15
X-5495	CRC	BYL719	316.9	19.7	41	61.9	-12.8
X-5495	CRC	BYL719	380.7	18.3	46	94.5	-19
X-5495	CRC	BYL719 + LJM716	216.4	21.6	0	0	0
X-5495	CRC	BYL719 + LJM716	157.5	19.4	3	-27.2	-10.2
X-5495	CRC	BYL719 + LJM716	187	19	8	-13.6	-12
X-5495	CRC	BYL719 + LJM716	212.5	20.6	11	-1.8	-4.6
X-5495	CRC	BYL719 + LJM716	182	18.9	14	-15.9	-12.5
X-5495	CRC	BYL719 + LJM716	186.4	20.1	17	-13.9	-6.9
X-5495	CRC	BYL719 + LJM716	262	18.6	21	21.1	-13.9
X-5495	CRC	BYL719 + LJM716	236.2	18.2	24	9.1	-15.7
X-5495	CRC	BYL719 + LJM716	286	18.4	29	32.2	-14.8
X-5495	CRC	BYL719 + LJM716	297.1	17.3	31	37.3	-19.9
X-5495	CRC	BYL719 + encorafenib	216.9	25.6	0	0	0
X-5495	CRC	BYL719 + encorafenib	286.4	24.9	3	32	-2.7
X-5495	CRC	BYL719 + encorafenib	296.8	24	6	36.8	-6.2
X-5495	CRC	BYL719 + encorafenib	368.4	24.3	9	69.8	-5.1
X-5495	CRC	BYL719 + encorafenib	409.5	23.5	13	88.8	-8.2
X-5495	CRC	BYL719 + encorafenib	437	22.7	16	101.5	-11.3
X-5495	CRC	BYL719 + encorafenib	663.7	23.2	21	206	-9.4
X-5495	CRC	BYL719 + encorafenib	601.9	22.2	23	177.5	-13.3
X-5495	CRC	BYL719 + encorafenib	729.5	22.9	27	236.3	-10.5
X-5495	CRC	BYL719 + encorafenib	637.9	22.9	30	194.1	-10.5
X-5495	CRC	BYL719 + encorafenib	405.9	22	35	87.1	-14.1
X-5495	CRC	BYL719 + encorafenib	618.4	24	36	185.1	-6.2
X-5495	CRC	BYL719 + encorafenib	691.8	21	42	218.9	-18
X-5495	CRC	BYL719 + encorafenib	901.2	22.1	45	315.5	-13.7
X-5495	CRC	BYL719 + binimetinib	204.2	19.6	0	0	0
X-5495	CRC	BYL719 + binimetinib	157.5	21.4	3	-22.9	9.2
X-5495	CRC	BYL719 + binimetinib	162.7	19.6	7	-20.3	0
X-5495	CRC	BYL719 + binimetinib	151.4	21.6	10	-25.9	10.2
X-5495	CRC	BYL719 + binimetinib	136.3	22.6	15	-33.3	15.3
X-5495	CRC	BYL719 + binimetinib	122	22.1	17	-40.3	12.8
X-5495	CRC	BYL719 + binimetinib	117.6	18.9	21	-42.4	-3.6
X-5495	CRC	BYL719 + binimetinib	114.1	19.1	24	-44.1	-2.6
X-5495	CRC	BYL719 + binimetinib	33.6	19.2	29	-83.5	-2
X-5495	CRC	BYL719 + binimetinib	74.3	19.1	30	-63.6	-2.6
X-5495	CRC	BYL719 + binimetinib	73.5	18.7	32	-64	-4.6
X-5495	CRC	BYL719 + binimetinib	56.7	17.5	36	-72.2	-10.7
X-5495	CRC	BYL719 + binimetinib	48.9	16.7	39	-76.1	-14.8
X-5495	CRC	CGM097	208.5	23.1	0	0	0
X-5495	CRC	CGM097	283.2	22.4	3	35.8	-3
X-5495	CRC	CGM097	298.9	21.3	6	43.4	-7.8
X-5495	CRC	CGM097	294.1	24.4	11	41.1	5.6
X-5495	CRC	CGM097	261.9	21.1	14	25.6	-8.7
X-5495	CRC	CGM097	281.7	19.7	17	35.1	-14.7
X-5495	CRC	CGM097	323.4	19.8	20	55.1	-14.3
X-5495	CRC	CGM097	330.2	19.4	24	58.4	-16
X-5495	CRC	CGM097	357.5	19.8	27	71.5	-14.3
X-5495	CRC	CGM097	498.2	22	32	138.9	-4.8
X-5495	CRC	CKX620	206.5	18.9	0	0	0
X-5495	CRC	CKX620	244.3	20.6	3	18.3	9
X-5495	CRC	CKX620	169.1	17.3	7	-18.1	-8.5
X-5495	CRC	CKX620	163.7	16.7	10	-20.7	-11.6
X-5495	CRC	CLR457	226.2	22.1	0	0	0
X-5495	CRC	CLR457	189.3	21.9	3	-16.3	-0.9
X-5495	CRC	CLR457	185.3	22	6	-18.1	-0.5
X-5495	CRC	CLR457	174	22.2	11	-23.1	0.5
X-5495	CRC	CLR457	183.5	23.3	14	-18.9	5.4
X-5495	CRC	CLR457	184.8	23.2	17	-18.3	5
X-5495	CRC	CLR457	193.5	23.3	20	-14.5	5.4
X-5495	CRC	CLR457	183.7	23.9	24	-18.8	8.1
X-5495	CRC	CLR457	180.1	23.3	27	-20.4	5.4
X-5495	CRC	CLR457	178.2	23.6	32	-21.2	6.8
X-5495	CRC	CLR457	187	24.2	34	-17.3	9.5
X-5495	CRC	CLR457	157.1	23.6	38	-30.5	6.8
X-5495	CRC	CLR457	176.8	24.4	41	-21.8	10.4
X-5495	CRC	CLR457	161.6	23.9	49	-28.6	8.1
X-5495	CRC	CLR457	167.3	24.1	53	-26	9
X-5495	CRC	CLR457	170.7	23.9	56	-24.5	8.1
X-5495	CRC	CLR457	178.6	23.5	63	-21	6.3
X-5495	CRC	CLR457	185.2	24.1	66	-18.1	9
X-5495	CRC	CLR457	174.7	23.3	70	-22.8	5.4
X-5495	CRC	CLR457	239.4	23.2	76	5.8	5
X-5495	CRC	CLR457	255.3	22.7	80	12.9	2.7
X-5495	CRC	CLR457	285.8	23.1	84	26.3	4.5
X-5495	CRC	CLR457	314.3	22.5	88	38.9	1.8
X-5495	CRC	CLR457	360	23	90	59.2	4.1
X-5495	CRC	HDM201	205.7	23.5	0	0	0
X-5495	CRC	HDM201	238.1	23.3	3	15.8	-0.9
X-5495	CRC	HDM201	236.6	21.2	7	15	-9.8
X-5495	CRC	HDM201	386.9	20.5	10	88.1	-12.8
X-5495	CRC	HDM201	302.9	20.3	15	47.3	-13.6
X-5495	CRC	HDM201	320.9	20.9	18	56	-11.1
X-5495	CRC	HDM201	405.9	21.2	21	97.3	-9.8
X-5495	CRC	HDM201	460.3	21.2	24	123.8	-9.8
X-5495	CRC	HDM201	443.3	19	28	115.5	-19.1
X-5495	CRC	cetuximab	206	20.6	0	0	0
X-5495	CRC	cetuximab	262	19.6	4	27.2	-4.9
X-5495	CRC	cetuximab	335.7	20.8	8	63	1
X-5495	CRC	cetuximab	389.5	20.6	11	89.1	0
X-5495	CRC	cetuximab	287.7	19.9	15	39.7	-3.4
X-5495	CRC	cetuximab	257.2	20.6	18	24.9	0
X-5495	CRC	cetuximab	236.4	20.7	21	14.8	0.5
X-5495	CRC	cetuximab	273.6	21	28	32.8	1.9
X-5495	CRC	cetuximab	274.9	21.4	32	33.4	3.9
X-5495	CRC	cetuximab + encorafenib	223.6	24.2	0	0	0
X-5495	CRC	cetuximab + encorafenib	330.6	23.7	4	47.9	-2.1
X-5495	CRC	cetuximab + encorafenib	389.6	22.2	7	74.2	-8.3
X-5495	CRC	cetuximab + encorafenib	515	24	10	130.3	-0.8
X-5495	CRC	cetuximab + encorafenib	730.4	22.3	17	226.7	-7.9
X-5495	CRC	LEE011	218.7	24.9	0	0	0
X-5495	CRC	LEE011	304.5	23.3	5	39.2	-6.4
X-5495	CRC	LEE011	311.2	24	8	42.3	-3.6
X-5495	CRC	LEE011	366.2	21.9	12	67.4	-12
X-5495	CRC	LEE011	528.2	21.3	15	141.5	-14.5
X-5495	CRC	LEE011	466.4	21.7	20	113.3	-12.9
X-5495	CRC	LEE011	594.4	22.2	23	171.8	-10.8
X-5495	CRC	LEE011	645.8	23.1	26	195.3	-7.2
X-5495	CRC	LEE011	857.5	24.4	29	292.1	-2
X-5495	CRC	LEE011	1111.8	21.8	33	408.4	-12.4
X-5495	CRC	encorafenib	209.7	21.6	0	0	0
X-5495	CRC	encorafenib	210.5	21.7	3	0.4	0.5
X-5495	CRC	encorafenib	236.6	20.7	6	12.8	-4.2
X-5495	CRC	encorafenib	279.1	19.6	11	33.1	-9.3
X-5495	CRC	encorafenib	368.5	19.7	14	75.7	-8.8
X-5495	CRC	encorafenib	424.1	20.4	17	102.2	-5.6
X-5495	CRC	encorafenib	486.4	22.1	20	132	2.3
X-5495	CRC	encorafenib	574.6	20.3	24	174	-6
X-5495	CRC	encorafenib	629.4	20.3	27	200.1	-6
X-5495	CRC	encorafenib	752.1	19.7	32	258.7	-8.8
X-5495	CRC	LJC049	200.9	21.2	0	0	0
X-5495	CRC	LJC049	160.8	21.8	3	-20	2.8
X-5495	CRC	LJC049	311.9	20.3	6	55.3	-4.2
X-5495	CRC	LJC049	528.6	22.5	11	163.1	6.1
X-5495	CRC	LJC049	718.9	21.2	14	257.8	0
X-5495	CRC	LJC049	912.6	21.8	17	354.3	2.8
X-5495	CRC	LJC049	1204.1	21	20	499.4	-0.9
X-5495	CRC	LJC049	1527.3	20.4	24	660.2	-3.8
X-5495	CRC	LKA136	201.9	20.1	0	0	0
X-5495	CRC	LKA136	194.2	19.6	3	-3.8	-2.5
X-5495	CRC	LKA136	225.2	19.2	6	11.5	-4.5
X-5495	CRC	LKA136	271.6	20.3	11	34.5	1
X-5495	CRC	LKA136	306.7	20	14	51.9	-0.5
X-5495	CRC	LKA136	464.3	20	17	130	-0.5
X-5495	CRC	LKA136	486.4	19.9	20	140.9	-1
X-5495	CRC	LKA136	444	19.8	24	119.9	-1.5
X-5495	CRC	LKA136	530.7	19.5	27	162.9	-3
X-5495	CRC	LKA136	612.7	19.1	32	203.5	-5
X-5495	CRC	binimetinib	202.5	25.6	0	0	0
X-5495	CRC	binimetinib	181.4	23.7	5	-10.4	-7.4
X-5495	CRC	binimetinib	155.2	23.8	8	-23.4	-7
X-5495	CRC	binimetinib	160.7	23.2	12	-20.6	-9.4
X-5495	CRC	binimetinib	127.7	23.4	15	-36.9	-8.6
X-5495	CRC	binimetinib	196.8	26.8	20	-2.8	4.7
X-5495	CRC	binimetinib	207.4	25.9	23	2.4	1.2
X-5495	CRC	binimetinib	230.6	24	26	13.9	-6.2
X-5495	CRC	binimetinib	309.1	24	29	52.6	-6.2
X-5495	CRC	binimetinib	235.4	24.3	33	16.2	-5.1
X-5495	CRC	binimetinib	304.6	24.6	36	50.4	-3.9
X-5495	CRC	binimetinib	332.1	24.8	41	64	-3.1
X-5495	CRC	binimetinib	324.6	24.5	43	60.3	-4.3
X-5495	CRC	binimetinib	437.2	25.2	47	115.9	-1.6
X-5495	CRC	binimetinib	484.7	22.1	50	139.4	-13.7
X-5495	CRC	untreated	222.2	27.1	0	0	0
X-5495	CRC	untreated	373	26.1	3	67.9	-3.7
X-5495	CRC	untreated	406.3	25.5	8	82.9	-5.9
X-5495	CRC	untreated	534.4	24	11	140.5	-11.4
X-5495	CRC	untreated	491.3	23.4	15	121.1	-13.7
X-5495	CRC	untreated	663.2	24.9	18	198.5	-8.1
X-5495	CRC	untreated	654.5	23.8	23	194.6	-12.2
X-5495	CRC	untreated	782.8	23.3	26	252.3	-14
X-5495	CRC	untreated	936.4	25.2	29	321.4	-7
X-5495	CRC	LFW527 + binimetinib	203.52	26.04	0	0	0
X-5495	CRC	LFW527 + binimetinib	177.96	25.8	3	-12.6	-0.9
X-5495	CRC	LFW527 + binimetinib	159.7	23.75	6	-21.5	-8.8
X-5495	CRC	LFW527 + binimetinib	153.08	24.89	10	-24.8	-4.4
X-5495	CRC	LFW527 + binimetinib	125.75	24.3	13	-38.2	-6.7
X-5495	CRC	LFW527 + binimetinib	160.22	25.7	16	-21.3	-1.3
X-5495	CRC	LFW527 + binimetinib	167.95	25.67	20	-17.5	-1.4
X-5495	CRC	LFW527 + binimetinib	152.95	25.1	23	-24.8	-3.6
X-5495	CRC	LFW527 + binimetinib	186.08	25.05	27	-8.6	-3.8
X-5495	CRC	LFW527 + binimetinib	146.05	24.41	30	-28.2	-6.3
X-5495	CRC	LFW527 + binimetinib	159.69	23.87	34	-21.5	-8.3
X-5502	BRCA	BGJ398	241.3	28.4	0	0	0
X-5502	BRCA	BGJ398	289	28.3	4	19.8	-0.4
X-5502	BRCA	BGJ398	306.4	27.6	7	27	-2.8
X-5502	BRCA	BGJ398	393.1	27.7	10	62.9	-2.5
X-5502	BRCA	BGJ398	430.5	27.6	14	78.4	-2.8
X-5502	BRCA	BGJ398	466	27	18	93.1	-4.9
X-5502	BRCA	BGJ398	471.6	25.1	21	95.4	-11.6
X-5502	BRCA	BGJ398	471.5	24	24	95.4	-15.5
X-5502	BRCA	BKM120	235.6	28.1	0	0	0
X-5502	BRCA	BKM120	264.7	29.7	3	12.4	5.7
X-5502	BRCA	BKM120	272	30.3	7	15.4	7.8
X-5502	BRCA	BKM120	280.9	29.4	10	19.2	4.6
X-5502	BRCA	BKM120	309	30	14	31.2	6.8
X-5502	BRCA	BKM120	314.4	30	17	33.4	6.8
X-5502	BRCA	BKM120	316.4	30.8	21	34.3	9.6
X-5502	BRCA	BKM120	305	31.7	24	29.5	12.8
X-5502	BRCA	BKM120	285	32.9	29	21	17.1
X-5502	BRCA	BKM120	286.9	32.6	31	21.8	16
X-5502	BRCA	BKM120	265.7	33.1	35	12.8	17.8
X-5502	BRCA	BKM120	247.8	33.7	38	5.2	19.9
X-5502	BRCA	BKM120	239.8	33.8	41	1.8	20.3
X-5502	BRCA	BKM120	228.2	32.9	45	-3.1	17.1
X-5502	BRCA	BKM120	218.4	32	49	-7.3	13.9
X-5502	BRCA	BKM120	222.1	31.7	52	-5.7	12.8
X-5502	BRCA	BKM120	212.7	30.7	55	-9.7	9.3
X-5502	BRCA	BKM120	203.8	31.9	59	-13.5	13.5
X-5502	BRCA	BKM120	201.1	32.3	63	-14.6	14.9
X-5502	BRCA	BKM120	206.1	32.4	66	-12.5	15.3
X-5502	BRCA	BKM120	215	32.2	70	-8.7	14.6
X-5502	BRCA	BKM120	216.6	31.6	72	-8.1	12.5
X-5502	BRCA	BKM120	265	29.9	76	12.5	6.4
X-5502	BRCA	BKM120	256	31.7	80	8.7	12.8
X-5502	BRCA	BKM120	260.4	31.2	84	10.5	11
X-5502	BRCA	BKM120	255.7	30.6	87	8.5	8.9
X-5502	BRCA	BKM120	250	30.2	91	6.1	7.5
X-5502	BRCA	BKM120	250	29.7	94	6.1	5.7
X-5502	BRCA	BKM120	251.8	31.2	98	6.9	11
X-5502	BRCA	BKM120	241.8	28.4	100	2.6	1.1
X-5502	BRCA	BKM120	244.4	29.5	104	3.7	5
X-5502	BRCA	BKM120	244.3	29.3	107	3.7	4.3
X-5502	BRCA	BKM120	320.7	30.7	112	36.1	9.3
X-5502	BRCA	BKM120	326.7	30.9	115	38.7	10
X-5502	BRCA	BKM120	329.2	30.6	125	39.7	8.9
X-5502	BRCA	BKM120	329.4	31	129	39.8	10.3
X-5502	BRCA	BKM120	362.6	31.9	133	53.9	13.5
X-5502	BRCA	BKM120	501.1	31.1	136	112.7	10.7
X-5502	BRCA	BKM120	528.1	32.3	140	124.2	14.9
X-5502	BRCA	BKM120	551.2	31.6	143	134	12.5
X-5502	BRCA	BKM120	696	31.7	147	195.4	12.8
X-5502	BRCA	BKM120	781.6	33.3	150	231.7	18.5
X-5502	BRCA	BKM120	902.4	32.3	153	283	14.9
X-5502	BRCA	BYL719 + LEE011	203.1	27.7	0	0	0
X-5502	BRCA	BYL719 + LEE011	201.2	25.6	1	-0.9	-7.6
X-5502	BRCA	BYL719 + LEE011	201.1	28	9	-1	1.1
X-5502	BRCA	BYL719 + LEE011	170.1	26.1	13	-16.2	-5.8
X-5502	BRCA	BYL719 + LEE011	154.2	26.4	16	-24.1	-4.7
X-5502	BRCA	BYL719 + LEE011	132.4	26.2	20	-34.8	-5.4
X-5502	BRCA	BYL719 + LEE011	109.6	26.8	23	-46	-3.2
X-5502	BRCA	BYL719 + LEE011	112.6	28.2	27	-44.6	1.8
X-5502	BRCA	BYL719	258.6	31.2	0	0	0
X-5502	BRCA	BYL719	265.1	31	3	2.5	-0.6
X-5502	BRCA	BYL719	266.2	29	7	2.9	-7.1
X-5502	BRCA	BYL719	267.1	29.6	10	3.3	-5.1
X-5502	BRCA	BYL719	277.7	30.6	14	7.4	-1.9
X-5502	BRCA	BYL719	274.5	30.5	17	6.1	-2.2
X-5502	BRCA	BYL719	281	31.2	21	8.7	0
X-5502	BRCA	BYL719	279.9	31.2	24	8.2	0
X-5502	BRCA	BYL719	281	31	29	8.7	-0.6
X-5502	BRCA	BYL719	285.1	31.4	31	10.2	0.6
X-5502	BRCA	BYL719	281	31.1	35	8.7	-0.3
X-5502	BRCA	BYL719	268.3	30.6	38	3.8	-1.9
X-5502	BRCA	BYL719	265.8	31.4	41	2.8	0.6
X-5502	BRCA	BYL719	246.9	32.2	45	-4.5	3.2
X-5502	BRCA	BYL719	234.9	32.1	49	-9.2	2.9
X-5502	BRCA	BYL719	238.3	32.1	52	-7.8	2.9
X-5502	BRCA	BYL719	246.1	31	55	-4.8	-0.6
X-5502	BRCA	BYL719	242.6	31.9	59	-6.2	2.2
X-5502	BRCA	BYL719	239.7	29.5	63	-7.3	-5.4
X-5502	BRCA	BYL719	242.4	30.1	66	-6.3	-3.5
X-5502	BRCA	BYL719	245.2	28.3	70	-5.2	-9.3
X-5502	BRCA	BYL719	237.9	29.9	72	-8	-4.2
X-5502	BRCA	BYL719	242	29.2	76	-6.4	-6.4
X-5502	BRCA	BYL719	240.9	29.8	80	-6.8	-4.5
X-5502	BRCA	BYL719	245	31	84	-5.3	-0.6
X-5502	BRCA	BYL719	246	30.2	87	-4.9	-3.2
X-5502	BRCA	BYL719	258.7	29.6	91	0	-5.1
X-5502	BRCA	BYL719	237.3	30	94	-8.2	-3.8
X-5502	BRCA	BYL719	269.1	30.9	98	4.1	-1
X-5502	BRCA	BYL719	272.7	30.4	100	5.5	-2.6
X-5502	BRCA	BYL719	269.8	32.3	104	4.3	3.5
X-5502	BRCA	BYL719	267.7	31.6	107	3.5	1.3
X-5502	BRCA	BYL719	275.4	31.6	112	6.5	1.3
X-5502	BRCA	BYL719	276.5	30.8	115	6.9	-1.3
X-5502	BRCA	BYL719	279.4	30.3	125	8	-2.9
X-5502	BRCA	BYL719	286	30.1	129	10.6	-3.5
X-5502	BRCA	BYL719	292.1	31.2	133	13	0
X-5502	BRCA	BYL719	306.5	30.9	136	18.5	-1
X-5502	BRCA	BYL719	324.7	31.4	140	25.6	0.6
X-5502	BRCA	BYL719	341.3	31	143	32	-0.6
X-5502	BRCA	BYL719	394.5	31	147	52.6	-0.6
X-5502	BRCA	BYL719	393.3	27.7	150	52.1	-11.2
X-5502	BRCA	BYL719 + LJM716	225.2	26	0	0	0
X-5502	BRCA	BYL719 + LJM716	220.9	25.2	4	-1.9	-3.1
X-5502	BRCA	BYL719 + LJM716	213.8	26	7	-5.1	0
X-5502	BRCA	BYL719 + LJM716	204	25.3	12	-9.4	-2.7
X-5502	BRCA	BYL719 + LJM716	210.7	26.9	14	-6.4	3.5
X-5502	BRCA	BYL719 + LJM716	230.5	24.9	18	2.4	-4.2
X-5502	BRCA	BYL719 + LJM716	251.5	26.1	21	11.7	0.4
X-5502	BRCA	BYL719 + LJM716	268.7	26.7	28	19.3	2.7
X-5502	BRCA	BYL719 + LJM716	272.3	25.6	32	20.9	-1.5
X-5502	BRCA	BYL719 + LJM716	313.5	26.6	35	39.2	2.3
X-5502	BRCA	BYL719 + LJM716	335.6	25.3	38	49	-2.7
X-5502	BRCA	BYL719 + LJM716	414.7	25.7	42	84.1	-1.2
X-5502	BRCA	BYL719 + LJM716	472.7	26.9	46	109.9	3.5
X-5502	BRCA	BYL719 + LJM716	658.6	26.9	49	192.5	3.5
X-5502	BRCA	BYL719 + LJM716	678.8	26.4	53	201.4	1.5
X-5502	BRCA	BYL719 + LJM716	738.2	27.3	55	227.8	5
X-5502	BRCA	BYL719 + LJM716	1115.8	23.8	59	395.5	-8.5
X-5502	BRCA	BYL719 + LJM716	1187.5	25.8	63	427.3	-0.8
X-5502	BRCA	BYL719 + LJM716	1480.1	26.7	67	557.2	2.7
X-5502	BRCA	CGM097	203.8	28.5	0	0	0
X-5502	BRCA	CGM097	221.1	30.2	3	8.5	6
X-5502	BRCA	CGM097	234	32.4	7	14.8	13.7
X-5502	BRCA	CGM097	254.2	31.2	10	24.7	9.5
X-5502	BRCA	CGM097	301.1	31.5	14	47.7	10.5
X-5502	BRCA	CGM097	411.7	30.1	17	102	5.6
X-5502	BRCA	CGM097	483.1	28.9	21	137	1.4
X-5502	BRCA	CGM097	500.9	27	24	145.8	-5.3
X-5502	BRCA	CGM097	500.7	24.2	28	145.7	-15.1
X-5502	BRCA	CLR457	223.1	29.5	0	0	0
X-5502	BRCA	CLR457	224.8	29.9	3	0.8	1.4
X-5502	BRCA	CLR457	225.2	29.7	7	0.9	0.7
X-5502	BRCA	CLR457	208.5	30.4	10	-6.5	3.1
X-5502	BRCA	CLR457	215	30.6	14	-3.6	3.7
X-5502	BRCA	CLR457	225.9	30.3	17	1.3	2.7
X-5502	BRCA	CLR457	230.8	30.7	21	3.5	4.1
X-5502	BRCA	CLR457	244.3	31.7	24	9.5	7.5
X-5502	BRCA	CLR457	255.5	31.2	29	14.5	5.8
X-5502	BRCA	CLR457	259.7	30.9	31	16.4	4.7
X-5502	BRCA	CLR457	266.6	31.4	35	19.5	6.4
X-5502	BRCA	CLR457	272.6	30.4	38	22.2	3.1
X-5502	BRCA	CLR457	287.9	30.5	41	29	3.4
X-5502	BRCA	CLR457	289.7	30.6	45	29.9	3.7
X-5502	BRCA	CLR457	276.1	30.9	49	23.8	4.7
X-5502	BRCA	CLR457	278.3	30.5	52	24.7	3.4
X-5502	BRCA	CLR457	315.5	29.1	55	41.4	-1.4
X-5502	BRCA	CLR457	303.5	30.8	59	36	4.4
X-5502	BRCA	CLR457	310.9	30.3	63	39.4	2.7
X-5502	BRCA	CLR457	312.7	30.5	66	40.2	3.4
X-5502	BRCA	CLR457	292.5	28.8	70	31.1	-2.4
X-5502	BRCA	CLR457	283.3	30.3	72	27	2.7
X-5502	BRCA	CLR457	338.9	29.1	76	51.9	-1.4
X-5502	BRCA	CLR457	332.2	30	80	48.9	1.7
X-5502	BRCA	CLR457	332.6	30.5	84	49.1	3.4
X-5502	BRCA	CLR457	275.1	30.4	87	23.3	3.1
X-5502	BRCA	CLR457	320	29.7	91	43.4	0.7
X-5502	BRCA	CLR457	300.4	29.1	94	34.6	-1.4
X-5502	BRCA	CLR457	329.9	30.2	98	47.9	2.4
X-5502	BRCA	CLR457	338.8	29.7	100	51.9	0.7
X-5502	BRCA	CLR457	354.8	30.4	104	59	3.1
X-5502	BRCA	CLR457	367	30.1	107	64.5	2
X-5502	BRCA	CLR457	365	30.7	112	63.6	4.1
X-5502	BRCA	CLR457	371.9	30.7	115	66.7	4.1
X-5502	BRCA	CLR457	409.5	30.3	125	83.5	2.7
X-5502	BRCA	CLR457	452.4	30.1	129	102.8	2
X-5502	BRCA	CLR457	460.7	30.8	133	106.5	4.4
X-5502	BRCA	CLR457	465.6	30.7	136	108.7	4.1
X-5502	BRCA	CLR457	475.8	31	140	113.3	5.1
X-5502	BRCA	CLR457	501.4	30.4	143	124.7	3.1
X-5502	BRCA	CLR457	526	30.5	147	135.8	3.4
X-5502	BRCA	CLR457	527	31.1	150	136.2	5.4
X-5502	BRCA	CLR457	556.3	30.8	153	149.4	4.4
X-5502	BRCA	HDM201	214.5	29.7	0	0	0
X-5502	BRCA	HDM201	237.2	29	3	10.6	-2.4
X-5502	BRCA	HDM201	268.8	28.8	6	25.3	-3
X-5502	BRCA	HDM201	279.4	30.3	10	30.3	2
X-5502	BRCA	HDM201	302.2	30.2	14	40.9	1.7
X-5502	BRCA	HDM201	312.3	30.6	17	45.6	3
X-5502	BRCA	HDM201	382.9	30.4	20	78.5	2.4
X-5502	BRCA	HDM201	398.1	31.7	24	85.6	6.7
X-5502	BRCA	HDM201	461.3	30.9	28	115.1	4
X-5502	BRCA	HDM201	462.8	32	31	115.8	7.7
X-5502	BRCA	HDM201	490	31.2	35	128.4	5.1
X-5502	BRCA	HDM201	530.3	31.8	37	147.2	7.1
X-5502	BRCA	HDM201	594.3	30.7	41	177.1	3.4
X-5502	BRCA	HDM201	635.7	31.7	45	196.4	6.7
X-5502	BRCA	HDM201	889	30.6	49	314.5	3
X-5502	BRCA	INC424	216.2	29.6	0	0	0
X-5502	BRCA	INC424	225.6	28.4	3	4.3	-4.1
X-5502	BRCA	INC424	230.5	28.1	7	6.6	-5.1
X-5502	BRCA	INC424	238.3	28.3	10	10.2	-4.4
X-5502	BRCA	INC424	246.6	29	14	14.1	-2
X-5502	BRCA	INC424	251.2	28.3	17	16.2	-4.4
X-5502	BRCA	INC424	282.8	29	21	30.8	-2
X-5502	BRCA	INC424	301.6	28.8	24	39.5	-2.7
X-5502	BRCA	INC424	313.6	28.3	28	45.1	-4.4
X-5502	BRCA	INC424	339.5	28.5	31	57	-3.7
X-5502	BRCA	INC424	374.3	28.7	36	73.1	-3
X-5502	BRCA	INC424	378.2	29	38	74.9	-2
X-5502	BRCA	INC424	390.2	30	42	80.5	1.4
X-5502	BRCA	INC424	426.4	30.2	45	97.2	2
X-5502	BRCA	INC424	480	29.5	48	122	-0.3
X-5502	BRCA	INC424	526	29.8	52	143.3	0.7
X-5502	BRCA	INC424	579.9	29.7	56	168.2	0.3
X-5502	BRCA	LEE011	215.7	30.3	0	0	0
X-5502	BRCA	LEE011	224.4	28.9	4	4	-4.6
X-5502	BRCA	LEE011	245.7	28.4	7	13.9	-6.3
X-5502	BRCA	LEE011	261.9	28.5	11	21.4	-5.9
X-5502	BRCA	LEE011	262.4	29.4	14	21.7	-3
X-5502	BRCA	LEE011	247.9	29.8	19	14.9	-1.7
X-5502	BRCA	LEE011	243.7	29.6	21	13	-2.3
X-5502	BRCA	LEE011	251.6	29.9	25	16.6	-1.3
X-5502	BRCA	LEE011	275.4	30.3	31	27.7	0
X-5502	BRCA	LEE011	306.7	30.3	35	42.2	0
X-5502	BRCA	LEE011	333.2	30.6	39	54.5	1
X-5502	BRCA	LEE011	340.6	29.8	42	57.9	-1.7
X-5502	BRCA	LEE011	353	29.7	45	63.7	-2
X-5502	BRCA	LEE011	377.4	31.4	49	75	3.6
X-5502	BRCA	LEE011	394.6	32.1	53	82.9	5.9
X-5502	BRCA	LEE011	435.8	30.9	56	102	2
X-5502	BRCA	LEE011	510.4	31.8	60	136.6	5
X-5502	BRCA	LEE011	521.3	31.6	62	141.7	4.3
X-5502	BRCA	LEE011	574.3	31.6	66	166.2	4.3
X-5502	BRCA	LEE011	613.5	32.1	70	184.4	5.9
X-5502	BRCA	LEE011	676.8	31.5	74	213.8	4
X-5502	BRCA	LEE011 + everolimus	237.1	28.1	0	0	0
X-5502	BRCA	LEE011 + everolimus	236.3	28.6	3	-0.3	1.8
X-5502	BRCA	LEE011 + everolimus	219.7	28	6	-7.3	-0.4
X-5502	BRCA	LEE011 + everolimus	214.4	29.1	10	-9.6	3.6
X-5502	BRCA	LEE011 + everolimus	191.6	27.6	14	-19.2	-1.8
X-5502	BRCA	LEE011 + everolimus	157.9	28.3	17	-33.4	0.7
X-5502	BRCA	LEE011 + everolimus	157.8	27.3	21	-33.4	-2.8
X-5502	BRCA	LEE011 + everolimus	152.6	28.7	23	-35.6	2.1
X-5502	BRCA	LEE011 + everolimus	146.9	28.4	27	-38	1.1
X-5502	BRCA	LEE011 + everolimus	150	28.1	31	-36.7	0
X-5502	BRCA	LEE011 + everolimus	152.1	28.5	35	-35.8	1.4
X-5502	BRCA	LEE011 + everolimus	149.2	28.5	38	-37.1	1.4
X-5502	BRCA	LEE011 + everolimus	144.7	27.3	42	-39	-2.8
X-5502	BRCA	LEE011 + everolimus	85.5	24.6	45	-63.9	-12.5
X-5502	BRCA	LFA102	207.7	29.7	0	0	0
X-5502	BRCA	LFA102	211	30.2	3	1.6	1.7
X-5502	BRCA	LFA102	245.7	29.6	8	18.3	-0.3
X-5502	BRCA	LFA102	264.5	29.7	10	27.3	0
X-5502	BRCA	LFA102	312	30.3	14	50.2	2
X-5502	BRCA	LFA102	333.8	30.4	17	60.7	2.4
X-5502	BRCA	LFA102	377.5	30.1	20	81.8	1.3
X-5502	BRCA	LFA102	430.4	30.2	24	107.2	1.7
X-5502	BRCA	LFA102	569.4	31	28	174.1	4.4
X-5502	BRCA	LFA102	697.8	31.3	31	236	5.4
X-5502	BRCA	LFA102	826.6	31.6	34	298	6.4
X-5502	BRCA	LFA102	921.4	31.1	38	343.6	4.7
X-5502	BRCA	LFA102	1303.2	32	42	527.4	7.7
X-5502	BRCA	LJM716 + trastuzumab	213.1	28.1	0	0	0
X-5502	BRCA	LJM716 + trastuzumab	222.6	26.9	3	4.5	-4.3
X-5502	BRCA	LJM716 + trastuzumab	228.1	27.2	6	7	-3.2
X-5502	BRCA	LJM716 + trastuzumab	285.1	27.8	10	33.8	-1.1
X-5502	BRCA	LJM716 + trastuzumab	326.3	28.5	14	53.1	1.4
X-5502	BRCA	LJM716 + trastuzumab	347.3	28.5	17	63	1.4
X-5502	BRCA	LJM716 + trastuzumab	376	27.6	20	76.4	-1.8
X-5502	BRCA	LJM716 + trastuzumab	419.3	27.7	24	96.8	-1.4
X-5502	BRCA	LJM716 + trastuzumab	440.2	27.8	28	106.6	-1.1
X-5502	BRCA	LJM716 + trastuzumab	466.6	28.3	31	119	0.7
X-5502	BRCA	LJM716 + trastuzumab	600	28.3	35	181.6	0.7
X-5502	BRCA	LJM716 + trastuzumab	687.2	28.6	37	222.5	1.8
X-5502	BRCA	LJM716 + trastuzumab	935.3	28.8	45	338.9	2.5
X-5502	BRCA	LJM716 + trastuzumab	1156.8	28.7	49	442.8	2.1
X-5502	BRCA	LJM716	207.4	26.4	0	0	0
X-5502	BRCA	LJM716	210.8	25.3	4	1.6	-4.2
X-5502	BRCA	LJM716	211.5	24.4	7	2	-7.6
X-5502	BRCA	LJM716	235.7	25.1	11	13.6	-4.9
X-5502	BRCA	LJM716	261.9	25.1	14	26.3	-4.9
X-5502	BRCA	LJM716	319.1	25.3	19	53.9	-4.2
X-5502	BRCA	LJM716	354.7	25.1	21	71	-4.9
X-5502	BRCA	LJM716	374	25.7	25	80.3	-2.7
X-5502	BRCA	LJM716	418.6	26.4	28	101.8	0
X-5502	BRCA	LJM716	542.4	26.6	31	161.5	0.8
X-5502	BRCA	LJM716	590	26.8	35	184.5	1.5
X-5502	BRCA	LJM716	811.8	26.7	39	291.4	1.1
X-5502	BRCA	LKA136	214	29.9	0	0	0
X-5502	BRCA	LKA136	217.9	30.3	3	1.8	1.3
X-5502	BRCA	LKA136	222.9	29.7	7	4.2	-0.7
X-5502	BRCA	LKA136	233.5	29.7	10	9.1	-0.7
X-5502	BRCA	LKA136	249.2	30.5	14	16.4	2
X-5502	BRCA	LKA136	283.2	30.2	17	32.3	1
X-5502	BRCA	LKA136	338.8	30.2	21	58.3	1
X-5502	BRCA	LKA136	392.2	29.5	24	83.3	-1.3
X-5502	BRCA	LKA136	434.3	29.9	28	102.9	0
X-5502	BRCA	LKA136	461.8	30	31	115.8	0.3
X-5502	BRCA	LKA136	468.6	30.1	36	119	0.7
X-5502	BRCA	LKA136	503.4	29.6	38	135.2	-1
X-5502	BRCA	LKA136	538.8	29.6	42	151.8	-1
X-5502	BRCA	LKA136	580.6	30.2	45	171.3	1
X-5502	BRCA	LKA136	649	30.2	48	203.3	1
X-5502	BRCA	LLM871	215.1	27.4	0	0	0
X-5502	BRCA	LLM871	226.9	26.1	3	5.5	-4.7
X-5502	BRCA	LLM871	240.6	26.4	7	11.9	-3.6
X-5502	BRCA	LLM871	271.1	26.4	10	26	-3.6
X-5502	BRCA	LLM871	306.8	26	14	42.6	-5.1
X-5502	BRCA	LLM871	307.1	25.9	17	42.8	-5.5
X-5502	BRCA	LLM871	333.7	26.4	21	55.1	-3.6
X-5502	BRCA	LLM871	344.8	26.8	24	60.3	-2.2
X-5502	BRCA	LLM871	410.8	27.5	31	91	0.4
X-5502	BRCA	LLM871	447.4	27	35	108	-1.5
X-5502	BRCA	LLM871	517.5	27.8	38	140.6	1.5
X-5502	BRCA	LLM871	554.7	28.2	43	157.9	2.9
X-5502	BRCA	LLM871	602	27.9	45	179.9	1.8
X-5502	BRCA	LLM871	648.6	27.5	49	201.5	0.4
X-5502	BRCA	LLM871	715.2	27	52	232.5	-1.5
X-5502	BRCA	LLM871	759.1	27.7	55	252.9	1.1
X-5502	BRCA	binimetinib	231.5	28.2	0	0	0
X-5502	BRCA	binimetinib	228.7	28.1	4	-1.2	-0.4
X-5502	BRCA	binimetinib	218.7	28	7	-5.5	-0.7
X-5502	BRCA	binimetinib	222.9	28.3	12	-3.7	0.4
X-5502	BRCA	binimetinib	227	28.3	14	-1.9	0.4
X-5502	BRCA	binimetinib	247.2	28	18	6.8	-0.7
X-5502	BRCA	binimetinib	262.3	27.8	21	13.3	-1.4
X-5502	BRCA	binimetinib	273.8	28.4	24	18.3	0.7
X-5502	BRCA	binimetinib	279.3	28.1	28	20.6	-0.4
X-5502	BRCA	binimetinib	365.4	26.8	32	57.8	-5
X-5502	BRCA	binimetinib	366.6	26.7	35	58.4	-5.3
X-5502	BRCA	binimetinib	366.5	26.8	38	58.3	-5
X-5502	BRCA	binimetinib	317.1	26.8	42	37	-5
X-5502	BRCA	binimetinib	318.8	25.7	46	37.7	-8.9
X-5502	BRCA	binimetinib	319.4	24.5	49	38	-13.1
X-5502	BRCA	binimetinib	315.3	23.7	53	36.2	-16
X-5502	BRCA	binimetinib	310	24.8	55	33.9	-12.1
X-5502	BRCA	binimetinib	333.7	27.7	59	44.1	-1.8
X-5502	BRCA	binimetinib	363.3	28.4	63	56.9	0.7
X-5502	BRCA	binimetinib	433.7	27.1	67	87.3	-3.9
X-5502	BRCA	paclitaxel	216.1	28.5	0	0	0
X-5502	BRCA	paclitaxel	234.8	28	3	8.7	-1.8
X-5502	BRCA	paclitaxel	235.8	28	6	9.1	-1.8
X-5502	BRCA	paclitaxel	250.3	27.7	10	15.8	-2.8
X-5502	BRCA	paclitaxel	264.7	27.4	14	22.5	-3.9
X-5502	BRCA	paclitaxel	250.4	26.5	17	15.9	-7
X-5502	BRCA	paclitaxel	252.6	26.1	20	16.9	-8.4
X-5502	BRCA	paclitaxel	251	24.7	24	16.1	-13.3
X-5502	BRCA	paclitaxel	257.1	26.3	28	19	-7.7
X-5502	BRCA	paclitaxel	242.8	23	31	12.4	-19.3
X-5502	BRCA	paclitaxel	183.2	23	35	-15.2	-19.3
X-5502	BRCA	paclitaxel	165	22.9	37	-23.6	-19.6
X-5502	BRCA	paclitaxel	155.3	22.6	41	-28.1	-20.7
X-5502	BRCA	tamoxifen	205.1	28.7	0	0	0
X-5502	BRCA	tamoxifen	232.1	30.2	4	13.2	5.2
X-5502	BRCA	tamoxifen	235.7	30.1	7	14.9	4.9
X-5502	BRCA	tamoxifen	266.7	30.9	12	30	7.7
X-5502	BRCA	tamoxifen	282.1	31.3	14	37.5	9.1
X-5502	BRCA	tamoxifen	338.4	31.2	18	65	8.7
X-5502	BRCA	tamoxifen	404.5	31.3	21	97.2	9.1
X-5502	BRCA	tamoxifen	451.5	32	24	120.1	11.5
X-5502	BRCA	tamoxifen	538.4	31.1	28	162.5	8.4
X-5502	BRCA	tamoxifen	616.5	31.6	32	200.6	10.1
X-5502	BRCA	tamoxifen	694	31.6	35	238.4	10.1
X-5502	BRCA	tamoxifen	766.8	31.4	38	273.9	9.4
X-5502	BRCA	tamoxifen	813.2	32.2	42	296.5	12.2
X-5502	BRCA	tamoxifen	841.3	31.7	46	310.2	10.5
X-5502	BRCA	tamoxifen	882.2	31.9	49	330.1	11.1
X-5502	BRCA	tamoxifen	928.6	31.8	53	352.8	10.8
X-5502	BRCA	tamoxifen	944.1	32	55	360.3	11.5
X-5502	BRCA	tamoxifen	979.3	31.3	59	377.5	9.1
X-5502	BRCA	tamoxifen	1060.5	31.9	63	417.1	11.1
X-5502	BRCA	tamoxifen	1078	31.1	67	425.6	8.4
X-5502	BRCA	trastuzumab	213.5	26.1	0	0	0
X-5502	BRCA	trastuzumab	215.6	24.5	3	1	-6.1
X-5502	BRCA	trastuzumab	228.7	25.3	7	7.1	-3.1
X-5502	BRCA	trastuzumab	267.9	25.3	10	25.5	-3.1
X-5502	BRCA	trastuzumab	302.2	26.4	14	41.5	1.1
X-5502	BRCA	trastuzumab	320.4	26.9	17	50.1	3.1
X-5502	BRCA	trastuzumab	349.4	26.8	21	63.7	2.7
X-5502	BRCA	trastuzumab	396.6	26.1	24	85.8	0
X-5502	BRCA	trastuzumab	490.8	25.9	28	129.9	-0.8
X-5502	BRCA	trastuzumab	515.4	26.7	31	141.4	2.3
X-5502	BRCA	trastuzumab	574.5	25.9	36	169.1	-0.8
X-5502	BRCA	trastuzumab	619.9	25.7	38	190.4	-1.5
X-5502	BRCA	trastuzumab	655.4	25.8	42	207	-1.1
X-5502	BRCA	trastuzumab	762.3	25.9	45	257	-0.8
X-5502	BRCA	trastuzumab	790.1	26.1	48	270.1	0
X-5502	BRCA	trastuzumab	866.6	26.1	52	305.9	0
X-5502	BRCA	trastuzumab	930.5	26.2	56	335.8	0.4
X-5502	BRCA	untreated	215.2	25.9	0	0	0
X-5502	BRCA	untreated	218.5	26.5	4	1.5	2.3
X-5502	BRCA	untreated	223.2	27.1	7	3.7	4.6
X-5502	BRCA	untreated	225.2	27.1	11	4.6	4.6
X-5502	BRCA	untreated	249.3	27.3	14	15.8	5.4
X-5502	BRCA	untreated	271	27.4	18	25.9	5.8
X-5502	BRCA	untreated	274.9	27.2	21	27.7	5
X-5502	BRCA	untreated	261.6	27	25	21.6	4.2
X-5502	BRCA	untreated	269.8	27.2	28	25.4	5
X-5502	BRCA	untreated	283.2	27.9	33	31.6	7.7
X-5502	BRCA	untreated	297.4	27.5	35	38.2	6.2
X-5502	BRCA	untreated	343.1	27.8	39	59.4	7.3
X-5502	BRCA	untreated	361.9	27.5	42	68.2	6.2
X-5502	BRCA	untreated	378.4	27.5	45	75.8	6.2
X-5502	BRCA	untreated	434.8	28.8	49	102	11.2
X-5502	BRCA	untreated	451.7	29	53	109.9	12
X-5502	BRCA	untreated	490.2	27	56	127.8	4.2
X-5502	BRCA	untreated	524	27.8	59	143.5	7.3
X-5502	BRCA	untreated	555.1	28	63	157.9	8.1
X-5502	BRCA	untreated	560.5	28.1	67	160.5	8.5
X-5502	BRCA	untreated	660.1	27.6	70	206.7	6.6
X-5502	BRCA	untreated	669.2	28.1	74	211	8.5
X-5502	BRCA	untreated	725.1	27.5	76	236.9	6.2
X-5502	BRCA	untreated	784.2	28.1	80	264.4	8.5
X-5502	BRCA	untreated	821.8	28.5	84	281.9	10
X-5502	BRCA	untreated	870.9	28.3	88	304.7	9.3
X-5502	BRCA	LFW527 + everolimus	201.68	32.4	0	0	0
X-5502	BRCA	LFW527 + everolimus	187.57	31	2	-7	-4.3
X-5502	BRCA	LFW527 + everolimus	171.3	30.1	6	-15.1	-7.1
X-5502	BRCA	LFW527 + everolimus	183.99	30.8	9	-8.8	-4.9
X-5502	BRCA	LFW527 + everolimus	166.7	29.9	13	-17.3	-7.7
X-5502	BRCA	LFW527 + everolimus	184.74	29.9	16	-8.4	-7.7
X-5502	BRCA	LFW527 + everolimus	283.43	28.1	20	40.5	-13.3
X-5502	BRCA	LFW527 + everolimus	293.64	27.9	23	45.6	-13.9
X-5502	BRCA	LFW527 + everolimus	256.73	29.3	28	27.3	-9.6
X-5502	BRCA	LFW527 + everolimus	225.77	31.4	35	11.9	-3.1
X-5502	BRCA	LFW527 + everolimus	245.28	30.5	41	21.6	-5.9
X-5502	BRCA	LFW527 + everolimus	279.61	29.5	44	38.6	-9
X-5502	BRCA	LFW527 + everolimus	300.83	31.3	48	49.2	-3.4
X-5502	BRCA	LFW527 + everolimus	284.99	31.3	51	41.3	-3.4
X-5502	BRCA	LFW527 + everolimus	260.83	31.2	55	29.3	-3.7
X-5502	BRCA	LFW527 + everolimus	254.22	31.3	58	26.1	-3.4
X-5502	BRCA	LFW527 + everolimus	306.38	29.2	62	51.9	-9.9
X-5502	BRCA	LFW527 + everolimus	274.45	29.2	65	36.1	-9.9
X-5502	BRCA	LFW527 + everolimus	305.99	27.7	69	51.7	-14.5
X-5502	BRCA	LFW527 + everolimus	394.57	31.1	72	95.6	-4
X-5502	BRCA	LFW527 + everolimus	262.9	26	76	30.4	-19.8
X-5502	BRCA	LFW527 + everolimus	323.64	29.1	79	60.5	-10.2
X-5502	BRCA	LFW527 + everolimus	510.62	32.1	83	153.2	-0.9
X-5502	BRCA	LFW527 + everolimus	347.12	28	86	72.1	-13.6
X-5502	BRCA	LFW527 + everolimus	490.17	31	91	143	-4.3
X-5502	BRCA	LFW527 + everolimus	516.43	28.5	94	156.1	-12
X-5502	BRCA	LFW527 + everolimus	734.36	28.6	97	264.1	-11.7
X-5541	BRCA	LFW527 + everolimus	308.36	24.8	0	0	0
X-5541	BRCA	LFW527 + everolimus	290.47	23.6	3	-5.8	-4.8
X-5541	BRCA	LFW527 + everolimus	251.95	22.7	6	-18.3	-8.5
X-5541	BRCA	LFW527 + everolimus	186.54	23.1	10	-39.5	-6.9
X-5541	BRCA	LFW527 + everolimus	156.14	23.1	13	-49.4	-6.9
X-5541	BRCA	LFW527 + everolimus	177.51	23.8	17	-42.4	-4
X-5541	BRCA	LFW527 + everolimus	153.28	23	20	-50.3	-7.3
X-5541	BRCA	LFW527 + everolimus	170.82	23.4	24	-44.6	-5.6
X-5541	BRCA	LFW527 + everolimus	140.15	21.4	27	-54.5	-13.7
X-5541	BRCA	LFW527 + everolimus	157.06	22.2	30	-49.1	-10.5
X-5541	BRCA	LFW527 + everolimus	191.41	23.8	34	-37.9	-4
X-5541	BRCA	LFW527 + everolimus	181.73	23.2	38	-41.1	-6.5
X-5541	BRCA	LFW527 + everolimus	162.42	22.7	41	-47.3	-8.5
X-5541	BRCA	LFW527 + everolimus	176.4	21.2	45	-42.8	-14.5
X-5541	BRCA	LFW527 + everolimus	149.95	22.6	48	-51.4	-8.9
X-5541	BRCA	LFW527 + everolimus	313.73	21.1	52	1.7	-14.9
X-5541	BRCA	LFW527 + everolimus	332.4	22.7	55	7.8	-8.5
X-5541	BRCA	LFW527 + everolimus	346.84	22.6	59	12.5	-8.9
X-5541	BRCA	LFW527 + everolimus	461.86	23.5	62	49.8	-5.2
X-5541	BRCA	LFW527 + everolimus	553.77	23.8	66	79.6	-4
X-5541	BRCA	LFW527 + everolimus	503.02	19.5	69	63.1	-21.4
X-5578	CRC	5FU	231.2	28.9	0	0	0
X-5578	CRC	5FU	239	28.3	7	3.4	-2.1
X-5578	CRC	5FU	525.4	30.5	15	127.2	5.5
X-5578	CRC	5FU	808.1	28.9	20	249.5	0
X-5578	CRC	5FU	862.7	29	24	273.1	0.3
X-5578	CRC	5FU	1023.3	29.2	29	342.6	1
X-5578	CRC	5FU	985.1	28.9	33	326.1	0
X-5578	CRC	BKM120	224	25.3	0	0	0
X-5578	CRC	BKM120	199	23.2	10	-11.2	-8.3
X-5578	CRC	BKM120	255.7	24.1	14	14.2	-4.7
X-5578	CRC	BKM120	294.4	23.8	17	31.4	-5.9
X-5578	CRC	BKM120	252.8	24.3	21	12.9	-4
X-5578	CRC	BKM120	314.8	24	29	40.5	-5.1
X-5578	CRC	BKM120	350.7	25.2	36	56.6	-0.4
X-5578	CRC	BKM120	474.3	25.3	43	111.7	0
X-5578	CRC	BKM120 + LJC049	186.5	26.2	0	0	0
X-5578	CRC	BKM120 + LJC049	135.1	25.4	4	-27.6	-3.1
X-5578	CRC	BKM120 + LJC049	238.9	25.3	9	28.1	-3.4
X-5578	CRC	BKM120 + LJC049	221.9	27.2	13	19	3.8
X-5578	CRC	BKM120 + LJC049	98.1	21.9	28	-47.4	-16.4
X-5578	CRC	BYL719	206.7	25.7	0	0	0
X-5578	CRC	BYL719	185.4	28.1	4	-10.3	9.3
X-5578	CRC	BYL719	275.8	26.4	7	33.4	2.7
X-5578	CRC	BYL719	289.6	26.4	11	40.1	2.7
X-5578	CRC	BYL719	354.4	24.7	19	71.5	-3.9
X-5578	CRC	BYL719	497.5	25.6	26	140.7	-0.4
X-5578	CRC	BYL719	524.8	25.9	33	153.9	0.8
X-5578	CRC	BYL719	528.3	26.8	34	155.6	4.3
X-5578	CRC	BYL719	650.1	26.9	39	214.5	4.7
X-5578	CRC	BYL719	907.8	25.1	43	339.2	-2.3
X-5578	CRC	BYL719	662.2	24.6	48	220.4	-4.3
X-5578	CRC	BYL719	802	28.7	52	288	11.7
X-5578	CRC	BYL719	808.1	24.5	57	291	-4.7
X-5578	CRC	BYL719	764	21.7	67	269.6	-15.6
X-5578	CRC	BYL719	953.7	23.7	72	361.4	-7.8
X-5578	CRC	BYL719	795.5	22.7	80	284.9	-11.7
X-5578	CRC	BYL719 + LJM716	225.7	22.6	0	0	0
X-5578	CRC	BYL719 + LJM716	209.9	20.8	4	-7	-8
X-5578	CRC	BYL719 + LJM716	221.4	21.1	7	-1.9	-6.6
X-5578	CRC	BYL719 + LJM716	202.9	21.7	11	-10.1	-4
X-5578	CRC	BYL719 + LJM716	210.7	20.9	19	-6.6	-7.5
X-5578	CRC	BYL719 + LJM716	215.7	22	26	-4.4	-2.7
X-5578	CRC	BYL719 + LJM716	181.7	22	34	-19.5	-2.7
X-5578	CRC	BYL719 + LJM716	251.1	23	39	11.3	1.8
X-5578	CRC	BYL719 + LJM716	293	22.2	43	29.8	-1.8
X-5578	CRC	BYL719 + LJM716	262.8	22.5	48	16.4	-0.4
X-5578	CRC	BYL719 + LJM716	175.5	23.2	52	-22.2	2.7
X-5578	CRC	BYL719 + LJM716	159.4	22.3	57	-29.4	-1.3
X-5578	CRC	BYL719 + LJM716	131.4	18.8	67	-41.8	-16.8
X-5578	CRC	BYL719 + LJM716	138.9	21.1	72	-38.5	-6.6
X-5578	CRC	BYL719 + LJM716	260.6	21.5	80	15.5	-4.9
X-5578	CRC	BYL719 + LJM716	267.8	21	86	18.7	-7.1
X-5578	CRC	BYL719 + LJM716	235.5	23	91	4.3	1.8
X-5578	CRC	BYL719 + LJM716	296.1	21.5	96	31.2	-4.9
X-5578	CRC	BYL719 + LJM716	445.9	22.1	100	97.6	-2.2
X-5578	CRC	BYL719 + LJM716	599.6	23.3	105	165.7	3.1
X-5578	CRC	BYL719 + cetuximab + encorafenib	190.2	22.9	0	0	0
X-5578	CRC	BYL719 + cetuximab + encorafenib	255.7	23.8	7	34.4	3.9
X-5578	CRC	BYL719 + cetuximab + encorafenib	458.1	26.8	15	140.9	17
X-5578	CRC	BYL719 + cetuximab + encorafenib	579.8	26.6	20	204.8	16.2
X-5578	CRC	BYL719 + cetuximab + encorafenib	471.1	26.1	24	147.7	14
X-5578	CRC	BYL719 + cetuximab + encorafenib	488.2	25.7	29	156.7	12.2
X-5578	CRC	BYL719 + cetuximab + encorafenib	471	25.8	33	147.6	12.7
X-5578	CRC	BYL719 + cetuximab + encorafenib	571.7	26.1	38	200.6	14
X-5578	CRC	BYL719 + cetuximab + encorafenib	693.7	24.5	48	264.7	7
X-5578	CRC	BYL719 + cetuximab + encorafenib	565.2	25.9	61	197.2	13.1
X-5578	CRC	BYL719 + cetuximab + encorafenib	801.7	25.7	67	321.5	12.2
X-5578	CRC	BYL719 + cetuximab + encorafenib	874.8	24.8	72	359.9	8.3
X-5578	CRC	BYL719 + cetuximab + encorafenib	1216	25.4	77	539.3	10.9
X-5578	CRC	BYL719 + cetuximab + encorafenib	1361.9	25.3	81	616	10.5
X-5578	CRC	BYL719 + binimetinib	202.9	30	0	0	0
X-5578	CRC	BYL719 + binimetinib	144.1	28.9	9	-29	-3.7
X-5578	CRC	BYL719 + binimetinib	177.5	28.8	14	-12.5	-4
X-5578	CRC	BYL719 + binimetinib	234.2	29.3	18	15.4	-2.3
X-5578	CRC	BYL719 + binimetinib	243	27.7	23	19.8	-7.7
X-5578	CRC	BYL719 + binimetinib	232.2	28	27	14.4	-6.7
X-5578	CRC	BYL719 + binimetinib	233.9	28.8	32	15.3	-4
X-5578	CRC	BYL719 + binimetinib	297.1	28.3	42	46.4	-5.7
X-5578	CRC	BYL719 + binimetinib	384.8	29.6	47	89.7	-1.3
X-5578	CRC	BYL719 + binimetinib	348.8	30.9	55	71.9	3
X-5578	CRC	BYL719 + binimetinib	356.3	27.7	62	75.6	-7.7
X-5578	CRC	BYL719 + binimetinib	302.5	27.6	66	49.1	-8
X-5578	CRC	BYL719 + binimetinib	340.2	26.9	71	67.7	-10.3
X-5578	CRC	BYL719 + binimetinib	348.2	27.7	75	71.6	-7.7
X-5578	CRC	BYL719 + binimetinib	382.9	29.4	80	88.7	-2
X-5578	CRC	BYL719 + cetuximab	218.7	26.4	0	0	0
X-5578	CRC	BYL719 + cetuximab	359.7	28.5	5	64.5	8
X-5578	CRC	BYL719 + cetuximab	460.4	25.8	9	110.5	-2.3
X-5578	CRC	BYL719 + cetuximab	520.7	25.6	14	138.1	-3
X-5578	CRC	BYL719 + cetuximab	425.5	26.5	18	94.6	0.4
X-5578	CRC	BYL719 + cetuximab	235.5	26.7	23	7.7	1.1
X-5578	CRC	BYL719 + cetuximab	163.4	25.6	33	-25.3	-3
X-5578	CRC	BYL719 + cetuximab	247.3	24.8	38	13.1	-6.1
X-5578	CRC	BYL719 + cetuximab	262.3	24.9	46	19.9	-5.7
X-5578	CRC	BYL719 + cetuximab	259.9	25.8	52	18.8	-2.3
X-5578	CRC	BYL719 + cetuximab	283.1	24.8	57	29.4	-6.1
X-5578	CRC	BYL719 + cetuximab	203.1	25.9	62	-7.1	-1.9
X-5578	CRC	BYL719 + cetuximab	455.2	25.3	66	108.1	-4.2
X-5578	CRC	BYL719 + cetuximab	348.6	26.4	71	59.4	0
X-5578	CRC	BYL719 + encorafenib	208	24.9	0	0	0
X-5578	CRC	BYL719 + encorafenib	174.5	27.4	8	-16.1	10
X-5578	CRC	BYL719 + encorafenib	135.4	26.5	14	-34.9	6.4
X-5578	CRC	BYL719 + encorafenib	116.3	25.5	19	-44.1	2.4
X-5578	CRC	BYL719 + encorafenib	133.3	25.4	24	-35.9	2
X-5578	CRC	BYL719 + encorafenib	135.4	26.2	28	-34.9	5.2
X-5578	CRC	BYL719 + encorafenib	171.4	25.9	33	-17.6	4
X-5578	CRC	BYL719 + encorafenib	170.2	25.9	37	-18.2	4
X-5578	CRC	BYL719 + encorafenib	167.8	25.9	40	-19.3	4
X-5578	CRC	BYL719 + encorafenib	187.6	25.9	44	-9.8	4
X-5578	CRC	BYL719 + encorafenib	203.1	25.9	48	-2.4	4
X-5578	CRC	BYL719 + encorafenib	229.8	25.9	53	10.5	4
X-5578	CRC	BYL719 + encorafenib	228.8	25.5	58	10	2.4
X-5578	CRC	CGM097	195.6	24.4	0	0	0
X-5578	CRC	CGM097	323.2	23.4	10	65.2	-4.1
X-5578	CRC	CGM097	427.7	24.7	14	118.7	1.2
X-5578	CRC	CGM097	440.4	23.3	17	125.2	-4.5
X-5578	CRC	CGM097	619.1	24	21	216.5	-1.6
X-5578	CRC	CGM097	650.7	23.7	29	232.7	-2.9
X-5578	CRC	CGM097	646.3	23.7	36	230.4	-2.9
X-5578	CRC	CGM097	731.5	25.6	43	274	4.9
X-5578	CRC	CKX620	186.1	23.1	0	0	0
X-5578	CRC	CKX620	289.8	24.5	10	55.7	6.1
X-5578	CRC	CKX620	243.1	24.6	14	30.6	6.5
X-5578	CRC	CKX620	307.9	24.4	17	65.4	5.6
X-5578	CRC	CKX620	316.3	24.2	21	70	4.8
X-5578	CRC	CKX620	353.1	24.5	29	89.7	6.1
X-5578	CRC	CKX620	466	24.7	36	150.4	6.9
X-5578	CRC	CKX620	518.8	24.5	43	178.8	6.1
X-5578	CRC	CLR457	252.3	27.1	0	0	0
X-5578	CRC	CLR457	225.3	26	4	-10.7	-4.1
X-5578	CRC	CLR457	290.6	25.9	7	15.2	-4.4
X-5578	CRC	CLR457	262.3	25.7	11	4	-5.2
X-5578	CRC	CLR457	285	27	19	13	-0.4
X-5578	CRC	CLR457	252.8	27	26	0.2	-0.4
X-5578	CRC	CLR457	287.8	28.4	34	14.1	4.8
X-5578	CRC	CLR457	292.8	29.4	39	16.1	8.5
X-5578	CRC	CLR457	379.8	27.6	43	50.5	1.8
X-5578	CRC	CLR457	418.7	27.3	48	66	0.7
X-5578	CRC	CLR457	400.1	27.6	52	58.6	1.8
X-5578	CRC	CLR457	310	27.9	57	22.9	3
X-5578	CRC	CLR457	354.4	26.9	67	40.5	-0.7
X-5578	CRC	CLR457	447.6	26.8	72	77.4	-1.1
X-5578	CRC	CLR457	406.2	28.1	80	61	3.7
X-5578	CRC	HDM201	226.6	24.4	0	0	0
X-5578	CRC	HDM201	417.6	25.2	10	84.3	3.3
X-5578	CRC	HDM201	544	25.2	14	140.1	3.3
X-5578	CRC	HDM201	551.1	24.6	17	143.2	0.8
X-5578	CRC	HDM201	671.7	23.8	21	196.4	-2.5
X-5578	CRC	HDM201	829.8	23.2	29	266.2	-4.9
X-5578	CRC	HDM201	881.3	22.6	36	288.9	-7.4
X-5578	CRC	HDM201	1114.8	22	43	392	-9.8
X-5578	CRC	cetuximab	222.4	24.4	0	0	0
X-5578	CRC	cetuximab	231.8	24	4	4.2	-1.6
X-5578	CRC	cetuximab	336.1	24.3	14	51.1	-0.4
X-5578	CRC	cetuximab	335.2	25	18	50.7	2.5
X-5578	CRC	cetuximab	340.1	25.1	21	52.9	2.9
X-5578	CRC	cetuximab	497	24.4	25	123.5	0
X-5578	CRC	cetuximab	596.4	25	33	168.2	2.5
X-5578	CRC	cetuximab + encorafenib	289.3	25.6	0	0	0
X-5578	CRC	cetuximab + encorafenib	236.5	26.5	1	-18.3	3.5
X-5578	CRC	cetuximab + encorafenib	380.7	25.6	9	31.6	0
X-5578	CRC	cetuximab + encorafenib	309.7	23.6	14	7.1	-7.8
X-5578	CRC	cetuximab + encorafenib	249.4	25.5	18	-13.8	-0.4
X-5578	CRC	cetuximab + encorafenib	255.4	26.2	23	-11.7	2.3
X-5578	CRC	cetuximab + encorafenib	255.9	28.4	27	-11.5	10.9
X-5578	CRC	cetuximab + encorafenib	256.2	30.6	32	-11.4	19.5
X-5578	CRC	cetuximab + encorafenib	324.8	29.3	42	12.3	14.5
X-5578	CRC	cetuximab + encorafenib	347.8	29	47	20.2	13.3
X-5578	CRC	cetuximab + encorafenib	387.4	27.7	55	33.9	8.2
X-5578	CRC	LEE011	196	24.5	0	0	0
X-5578	CRC	LEE011	210.1	22.4	10	7.2	-8.6
X-5578	CRC	LEE011	246	23.7	14	25.5	-3.3
X-5578	CRC	LEE011	293	23.3	17	49.5	-4.9
X-5578	CRC	LEE011	356.7	23.5	21	82	-4.1
X-5578	CRC	LEE011	384.3	25.8	29	96.1	5.3
X-5578	CRC	LEE011	390.7	26.2	36	99.3	6.9
X-5578	CRC	LEE011	830.7	24.7	43	323.8	0.8
X-5578	CRC	encorafenib	188.3	24.1	0	0	0
X-5578	CRC	encorafenib	184.7	23.6	1	-1.9	-2.1
X-5578	CRC	encorafenib	268.6	22.5	5	42.6	-6.6
X-5578	CRC	encorafenib	219.7	23.5	13	16.7	-2.5
X-5578	CRC	encorafenib	252.3	26.2	20	34	8.7
X-5578	CRC	encorafenib	465.4	25.1	28	147.2	4.1
X-5578	CRC	encorafenib	497.3	23.1	33	164.1	-4.1
X-5578	CRC	encorafenib	669.6	22.7	37	255.6	-5.8
X-5578	CRC	encorafenib	612.3	23.2	42	225.2	-3.7
X-5578	CRC	LJC049	181.4	22.4	0	0	0
X-5578	CRC	LJC049	185.7	22.9	4	2.4	2.2
X-5578	CRC	LJC049	281.1	22.7	7	55	1.3
X-5578	CRC	LJC049	365.2	22.2	11	101.3	-0.9
X-5578	CRC	LJC049	510.8	23.1	19	181.6	3.1
X-5578	CRC	LJC049	476.8	23.7	26	162.8	5.8
X-5578	CRC	LJC049	728.7	23.9	34	301.7	6.7
X-5578	CRC	LJC049	823.8	22.2	39	354.1	-0.9
X-5578	CRC	LJC049	939.9	22.7	43	418.1	1.3
X-5578	CRC	LJC049	1088.5	22.7	48	500.1	1.3
X-5578	CRC	LKA136	259.9	22.2	0	0	0
X-5578	CRC	LKA136	267.6	22	4	3	-0.9
X-5578	CRC	LKA136	299.9	22.5	7	15.4	1.4
X-5578	CRC	LKA136	435.2	23.3	11	67.4	5
X-5578	CRC	LKA136	513.6	22.8	19	97.6	2.7
X-5578	CRC	LKA136	647.6	22.9	26	149.2	3.2
X-5578	CRC	LKA136	928	24.6	34	257.1	10.8
X-5578	CRC	LKA136	1083	25.2	39	316.7	13.5
X-5578	CRC	LKA136	1406.7	21.9	43	441.2	-1.4
X-5578	CRC	LKA136	1453.8	21.9	48	459.4	-1.4
X-5578	CRC	binimetinib	209.7	26.7	0	0	0
X-5578	CRC	binimetinib	333.6	26	4	59.1	-2.6
X-5578	CRC	binimetinib	447.9	24.3	14	113.6	-9
X-5578	CRC	binimetinib	413	25.6	18	96.9	-4.1
X-5578	CRC	binimetinib	590.6	25.7	21	181.6	-3.7
X-5578	CRC	binimetinib	847.6	25.7	25	304.2	-3.7
X-5578	CRC	binimetinib	656.4	25.9	33	213	-3
X-5578	CRC	untreated	186.7	22.6	0	0	0
X-5578	CRC	untreated	208.6	22.4	4	11.7	-0.9
X-5578	CRC	untreated	485.8	22.5	14	160.2	-0.4
X-5578	CRC	untreated	591.7	22.8	18	216.9	0.9
X-5578	CRC	untreated	715.8	22.4	21	283.4	-0.9
X-5578	CRC	untreated	788.3	21.9	25	322.2	-3.1
X-5578	CRC	untreated	858.8	21.9	28	360	-3.1
X-5578	CRC	untreated	993	21.7	33	431.9	-4
X-5975	BRCA	BGJ398	211.6	26	0	0	0
X-5975	BRCA	BGJ398	203	27.5	5	-4.1	5.8
X-5975	BRCA	BGJ398	260.1	27.1	8	22.9	4.2
X-5975	BRCA	BGJ398	326.8	27	13	54.4	3.8
X-5975	BRCA	BGJ398	325.3	27.3	15	53.7	5
X-5975	BRCA	BGJ398	440.6	27.5	20	108.2	5.8
X-5975	BRCA	BGJ398	458.8	27.4	22	116.8	5.4
X-5975	BRCA	BGJ398	560.9	27.2	26	165.1	4.6
X-5975	BRCA	BGJ398	605.5	27.7	29	186.2	6.5
X-5975	BRCA	BGJ398	706.9	27.9	32	234.1	7.3
X-5975	BRCA	BGJ398	785.1	28.2	36	271	8.5
X-5975	BRCA	BGJ398	970.1	28.6	39	358.5	10
X-5975	BRCA	BKM120	242.6	27	0	0	0
X-5975	BRCA	BKM120	288.9	26.9	3	19.1	-0.4
X-5975	BRCA	BKM120	344.4	27.8	6	42	3
X-5975	BRCA	BKM120	312.4	27.9	11	28.8	3.3
X-5975	BRCA	BKM120	349	27.8	13	43.9	3
X-5975	BRCA	BKM120	359.8	28	18	48.3	3.7
X-5975	BRCA	BKM120	410	27.8	20	69	3
X-5975	BRCA	BKM120	444.5	27.7	24	83.2	2.6
X-5975	BRCA	BKM120	576.6	27.3	27	137.7	1.1
X-5975	BRCA	BKM120	633.9	28.7	30	161.3	6.3
X-5975	BRCA	BKM120	696.2	28	34	187	3.7
X-5975	BRCA	BKM120	763.6	28.4	37	214.8	5.2
X-5975	BRCA	BYL719	220.3	26.8	0	0	0
X-5975	BRCA	BYL719	251.3	28.3	3	14.1	5.6
X-5975	BRCA	BYL719	231.6	29.6	6	5.1	10.4
X-5975	BRCA	BYL719	209.3	28.9	11	-5	7.8
X-5975	BRCA	BYL719	329.9	29.2	13	49.8	9
X-5975	BRCA	BYL719	340.4	30.4	18	54.5	13.4
X-5975	BRCA	BYL719	362.9	29.2	20	64.7	9
X-5975	BRCA	BYL719	457.2	28.5	24	107.5	6.3
X-5975	BRCA	BYL719	504	30.1	27	128.8	12.3
X-5975	BRCA	BYL719	569	29.9	30	158.3	11.6
X-5975	BRCA	BYL719	693.7	28.9	34	214.9	7.8
X-5975	BRCA	BYL719	790.9	28.5	37	259	6.3
X-5975	BRCA	BYL719 + LEE011	217	24.7	0	0	0
X-5975	BRCA	BYL719 + LEE011	204.2	24.6	2	-5.9	-0.4
X-5975	BRCA	BYL719 + LEE011	192.7	23.1	6	-11.2	-6.5
X-5975	BRCA	BYL719 + LEE011	200.9	23.7	9	-7.4	-4
X-5975	BRCA	BYL719 + LEE011	201.4	24.5	12	-7.2	-0.8
X-5975	BRCA	BYL719 + LEE011	156.9	24.5	16	-27.7	-0.8
X-5975	BRCA	BYL719 + LEE011	161.1	25.2	19	-25.8	2
X-5975	BRCA	BYL719 + LEE011	156.8	26.4	23	-27.7	6.9
X-5975	BRCA	BYL719 + LEE011	154.8	25.4	26	-28.7	2.8
X-5975	BRCA	BYL719 + LEE011	108.1	23.7	30	-50.2	-4
X-5975	BRCA	BYL719 + LEE011	84.3	23.6	33	-61.2	-4.5
X-5975	BRCA	BYL719 + LEE011	66.5	25.5	37	-69.4	3.2
X-5975	BRCA	BYL719 + LEE011	62.1	25.5	40	-71.4	3.2
X-5975	BRCA	BYL719 + LEE011	72.2	23	43	-66.7	-6.9
X-5975	BRCA	BYL719 + LEE011	68.9	24.4	48	-68.2	-1.2
X-5975	BRCA	BYL719 + LEE011	31.3	23.8	51	-85.6	-3.6
X-5975	BRCA	BYL719 + LEE011	14.6	27.1	54	-93.3	9.7
X-5975	BRCA	BYL719 + LEE011	29.6	24.2	58	-86.4	-2
X-5975	BRCA	BYL719 + LJM716	203.5	26.9	0	0	0
X-5975	BRCA	BYL719 + LJM716	221.5	25.9	4	8.8	-3.7
X-5975	BRCA	BYL719 + LJM716	240.1	26.1	7	18	-3
X-5975	BRCA	BYL719 + LJM716	256.4	24.4	11	26	-9.3
X-5975	BRCA	BYL719 + LJM716	264.7	24.9	14	30.1	-7.4
X-5975	BRCA	BYL719 + LJM716	303.4	25.7	18	49.1	-4.5
X-5975	BRCA	BYL719 + LJM716	333.5	25.9	21	63.9	-3.7
X-5975	BRCA	BYL719 + LJM716	377.3	26.3	25	85.4	-2.2
X-5975	BRCA	BYL719 + LJM716	443.4	26	28	117.9	-3.3
X-5975	BRCA	BYL719 + LJM716	474.4	24.8	31	133.1	-7.8
X-5975	BRCA	BYL719 + LJM716	540.8	25.4	36	165.7	-5.6
X-5975	BRCA	BYL719 + LJM716	588.1	24	39	189	-10.8
X-5975	BRCA	CGM097	238.2	28.8	0	0	0
X-5975	BRCA	CGM097	320.7	28.8	3	34.6	0
X-5975	BRCA	CGM097	292.2	30.3	6	22.7	5.2
X-5975	BRCA	CGM097	476.1	32	11	99.9	11.1
X-5975	BRCA	CGM097	585	32.8	13	145.6	13.9
X-5975	BRCA	CGM097	740.6	32.7	18	210.9	13.5
X-5975	BRCA	CGM097	883.7	32.7	19	271	13.5
X-5975	BRCA	CLR457	223.2	26.7	0	0	0
X-5975	BRCA	CLR457	276.4	26.1	2	23.8	-2.2
X-5975	BRCA	CLR457	343	26.5	7	53.7	-0.7
X-5975	BRCA	CLR457	351.7	26.3	9	57.6	-1.5
X-5975	BRCA	CLR457	339.8	26.1	13	52.2	-2.2
X-5975	BRCA	CLR457	397.4	26.5	16	78	-0.7
X-5975	BRCA	CLR457	467.7	26.2	19	109.5	-1.9
X-5975	BRCA	CLR457	474.8	25.9	23	112.7	-3
X-5975	BRCA	CLR457	527.8	25.5	26	136.5	-4.5
X-5975	BRCA	CLR457	562.6	25.6	30	152.1	-4.1
X-5975	BRCA	CLR457	628.5	24.9	33	181.6	-6.7
X-5975	BRCA	CLR457	629.8	26.1	35	182.2	-2.2
X-5975	BRCA	HDM201	205.6	26.5	0	0	0
X-5975	BRCA	HDM201	195.8	26.1	2	-4.8	-1.5
X-5975	BRCA	HDM201	218	25.9	7	6	-2.3
X-5975	BRCA	HDM201	235.4	25.9	9	14.5	-2.3
X-5975	BRCA	HDM201	241.5	25.4	13	17.5	-4.2
X-5975	BRCA	HDM201	267.4	26.1	16	30.1	-1.5
X-5975	BRCA	HDM201	314.1	25.7	19	52.8	-3
X-5975	BRCA	HDM201	342.1	26.5	23	66.4	0
X-5975	BRCA	HDM201	374.4	26.6	26	82.1	0.4
X-5975	BRCA	HDM201	379.7	26.1	30	84.7	-1.5
X-5975	BRCA	HDM201	405.5	25.6	33	97.2	-3.4
X-5975	BRCA	HDM201	446.2	24.9	35	117	-6
X-5975	BRCA	INC424	234.5	26.7	0	0	0
X-5975	BRCA	INC424	229.8	27.4	2	-2	2.6
X-5975	BRCA	INC424	227.3	26.2	6	-3.1	-1.9
X-5975	BRCA	INC424	252.1	26.9	9	7.5	0.7
X-5975	BRCA	INC424	327.1	27.5	12	39.5	3
X-5975	BRCA	INC424	398.4	27.3	16	69.9	2.2
X-5975	BRCA	INC424	459.5	27.7	19	95.9	3.7
X-5975	BRCA	INC424	500.1	27	23	113.3	1.1
X-5975	BRCA	INC424	537.7	26.5	26	129.3	-0.7
X-5975	BRCA	INC424	585.8	27.3	28	149.8	2.2
X-5975	BRCA	LEE011	210.6	26.8	0	0	0
X-5975	BRCA	LEE011	287.5	26.6	2	36.5	-0.7
X-5975	BRCA	LEE011	329.1	26.8	6	56.3	0
X-5975	BRCA	LEE011	370.3	27.6	9	75.8	3
X-5975	BRCA	LEE011	410.2	27.5	12	94.8	2.6
X-5975	BRCA	LEE011	400.9	26.2	16	90.4	-2.2
X-5975	BRCA	LEE011	433.2	27	19	105.7	0.7
X-5975	BRCA	LEE011	358.8	27	23	70.4	0.7
X-5975	BRCA	LEE011	244.5	27.3	26	16.1	1.9
X-5975	BRCA	LEE011	205	27	30	-2.7	0.7
X-5975	BRCA	LEE011	190	25.7	33	-9.8	-4.1
X-5975	BRCA	LEE011	98.4	28.3	37	-53.3	5.6
X-5975	BRCA	LEE011	108.5	28.4	40	-48.5	6
X-5975	BRCA	LEE011	86.5	28.3	43	-58.9	5.6
X-5975	BRCA	LEE011	75	25.7	48	-64.4	-4.1
X-5975	BRCA	LEE011	54.8	26.9	51	-74	0.4
X-5975	BRCA	LEE011	36.8	29.6	54	-82.5	10.4
X-5975	BRCA	LEE011	35.9	27.3	58	-83	1.9
X-5975	BRCA	LEE011	35	28	62	-83.4	4.5
X-5975	BRCA	LEE011	30.7	28	65	-85.4	4.5
X-5975	BRCA	LEE011	26.5	27.5	71	-87.4	2.6
X-5975	BRCA	LEE011	20.1	27.7	77	-90.5	3.4
X-5975	BRCA	LEE011	14.1	27.9	82	-93.3	4.1
X-5975	BRCA	LEE011	0	28.1	90	-100	4.9
X-5975	BRCA	LEE011	0	27.5	94	-100	2.6
X-5975	BRCA	LEE011 + everolimus	205.6	29.5	0	0	0
X-5975	BRCA	LEE011 + everolimus	256.1	27	4	24.6	-8.5
X-5975	BRCA	LEE011 + everolimus	262.9	27.7	7	27.9	-6.1
X-5975	BRCA	LEE011 + everolimus	245.1	28.1	11	19.2	-4.7
X-5975	BRCA	LEE011 + everolimus	246.2	27.9	14	19.7	-5.4
X-5975	BRCA	LEE011 + everolimus	215.9	27.5	18	5	-6.8
X-5975	BRCA	LEE011 + everolimus	214.8	27.3	21	4.5	-7.5
X-5975	BRCA	LEE011 + everolimus	160.9	28	25	-21.7	-5.1
X-5975	BRCA	LEE011 + everolimus	142.6	28.5	28	-30.6	-3.4
X-5975	BRCA	LEE011 + everolimus	79.3	27	31	-61.4	-8.5
X-5975	BRCA	LEE011 + everolimus	55.7	26.7	36	-72.9	-9.5
X-5975	BRCA	LEE011 + everolimus	30.2	28.1	39	-85.3	-4.7
X-5975	BRCA	LEE011 + everolimus	36.1	29.6	42	-82.4	0.3
X-5975	BRCA	LEE011 + everolimus	32.5	28.2	46	-84.2	-4.4
X-5975	BRCA	LEE011 + everolimus	36.3	29.3	50	-82.3	-0.7
X-5975	BRCA	LEE011 + everolimus	30	30.4	53	-85.4	3.1
X-5975	BRCA	LEE011 + everolimus	20.4	28.4	59	-90.1	-3.7
X-5975	BRCA	LEE011 + everolimus	22.8	27.6	65	-88.9	-6.4
X-5975	BRCA	LEE011 + everolimus	14.1	28.9	70	-93.1	-2
X-5975	BRCA	LEE011 + everolimus	0	28.3	78	-100	-4.1
X-5975	BRCA	LEE011 + everolimus	0	28.2	82	-100	-4.4
X-5975	BRCA	LEE011 + everolimus	0	27.5	88	-100	-6.8
X-5975	BRCA	LEE011 + everolimus	0	26.6	91	-100	-9.8
X-5975	BRCA	LFA102	207.1	25	0	0	0
X-5975	BRCA	LFA102	216.8	24.9	4	4.7	-0.4
X-5975	BRCA	LFA102	244.1	24.6	7	17.9	-1.6
X-5975	BRCA	LFA102	258.9	25	10	25	0
X-5975	BRCA	LFA102	276.5	24.9	15	33.5	-0.4
X-5975	BRCA	LFA102	294	24.8	18	42	-0.8
X-5975	BRCA	LFA102	284.8	25.3	21	37.5	1.2
X-5975	BRCA	LFA102	292	24	25	41	-4
X-5975	BRCA	LFA102	310.7	25.1	29	50	0.4
X-5975	BRCA	LFA102	307.6	25	32	48.5	0
X-5975	BRCA	LFA102	317	26.2	38	53.1	4.8
X-5975	BRCA	LFA102	352.6	25.8	44	70.3	3.2
X-5975	BRCA	LFA102	305.8	26.3	49	47.7	5.2
X-5975	BRCA	LFA102	315.3	26.5	57	52.2	6
X-5975	BRCA	LFA102	319.4	25.5	61	54.2	2
X-5975	BRCA	LFA102	311.8	25.3	67	50.6	1.2
X-5975	BRCA	LFA102	301.8	25.3	70	45.7	1.2
X-5975	BRCA	LFA102	286.4	25.8	78	38.3	3.2
X-5975	BRCA	LFA102	268.3	26	84	29.6	4
X-5975	BRCA	LFA102	267.3	26	101	29.1	4
X-5975	BRCA	LFA102	224.4	26.1	105	8.4	4.4
X-5975	BRCA	LJM716	207.3	27.5	0	0	0
X-5975	BRCA	LJM716	212.1	26.1	4	2.3	-5.1
X-5975	BRCA	LJM716	254.6	26.8	7	22.8	-2.5
X-5975	BRCA	LJM716	256.2	26.9	10	23.6	-2.2
X-5975	BRCA	LJM716	310.7	26.4	15	49.9	-4
X-5975	BRCA	LJM716	401.1	27.9	18	93.5	1.5
X-5975	BRCA	LJM716	487.8	27	21	135.3	-1.8
X-5975	BRCA	LKA136	201.5	25.7	0	0	0
X-5975	BRCA	LKA136	204.2	25.4	2	1.3	-1.2
X-5975	BRCA	LKA136	231.3	24.8	6	14.8	-3.5
X-5975	BRCA	LKA136	285.9	24.8	9	41.9	-3.5
X-5975	BRCA	LKA136	352.9	25.5	12	75.1	-0.8
X-5975	BRCA	LKA136	401	25.5	16	99	-0.8
X-5975	BRCA	LKA136	463	25.4	19	129.8	-1.2
X-5975	BRCA	LKA136	603.8	25.3	23	199.7	-1.6
X-5975	BRCA	LKA136	669.6	25.4	26	232.3	-1.2
X-5975	BRCA	LKA136	720.7	26	28	257.7	1.2
X-5975	BRCA	LLM871	220.3	25.9	0	0	0
X-5975	BRCA	LLM871	193.9	25.8	1	-12	-0.4
X-5975	BRCA	LLM871	232.5	24.8	4	5.5	-4.2
X-5975	BRCA	LLM871	242	25.9	7	9.9	0
X-5975	BRCA	LLM871	215.5	24.7	11	-2.2	-4.6
X-5975	BRCA	LLM871	215.7	25.4	14	-2.1	-1.9
X-5975	BRCA	LLM871	204.2	26.2	18	-7.3	1.2
X-5975	BRCA	LLM871	207.8	24.7	21	-5.7	-4.6
X-5975	BRCA	LLM871	162.2	25.6	25	-26.4	-1.2
X-5975	BRCA	LLM871	125.5	25.6	28	-43	-1.2
X-5975	BRCA	LLM871	122.2	25.1	32	-44.5	-3.1
X-5975	BRCA	LLM871	122.7	27.3	35	-44.3	5.4
X-5975	BRCA	LLM871	112.6	26.4	38	-48.9	1.9
X-5975	BRCA	LLM871	95.6	22.8	43	-56.6	-12
X-5975	BRCA	LLM871	25.9	24.4	46	-88.2	-5.8
X-5975	BRCA	LLM871	24.8	24.8	49	-88.7	-4.2
X-5975	BRCA	LLM871	25	26.6	53	-88.7	2.7
X-5975	BRCA	LLM871	18.9	24.7	57	-91.4	-4.6
X-5975	BRCA	LLM871	32.3	24.8	60	-85.3	-4.2
X-5975	BRCA	LLM871	11.1	25.2	66	-95	-2.7
X-5975	BRCA	binimetinib	202.2	26.6	0	0	0
X-5975	BRCA	binimetinib	205.2	26.3	2	1.5	-1.1
X-5975	BRCA	binimetinib	230.4	26.1	6	13.9	-1.9
X-5975	BRCA	binimetinib	253.3	27.1	9	25.3	1.9
X-5975	BRCA	binimetinib	263.9	27.1	12	30.5	1.9
X-5975	BRCA	binimetinib	251.2	27	16	24.2	1.5
X-5975	BRCA	binimetinib	231	26.9	19	14.2	1.1
X-5975	BRCA	binimetinib	207.3	26.3	23	2.5	-1.1
X-5975	BRCA	binimetinib	232.9	25.8	26	15.2	-3
X-5975	BRCA	binimetinib	224.4	24.6	30	11	-7.5
X-5975	BRCA	binimetinib	218.4	23.7	33	8	-10.9
X-5975	BRCA	paclitaxel	206.7	27.5	0	0	0
X-5975	BRCA	paclitaxel	170	26.6	1	-17.8	-3.3
X-5975	BRCA	paclitaxel	179.2	27.2	4	-13.3	-1.1
X-5975	BRCA	paclitaxel	179.7	27	7	-13.1	-1.8
X-5975	BRCA	paclitaxel	154.3	26.6	11	-25.4	-3.3
X-5975	BRCA	paclitaxel	170.5	27.2	14	-17.5	-1.1
X-5975	BRCA	paclitaxel	195.2	26.9	18	-5.6	-2.2
X-5975	BRCA	paclitaxel	199.4	27.1	21	-3.5	-1.5
X-5975	BRCA	paclitaxel	144.9	27.7	25	-29.9	0.7
X-5975	BRCA	paclitaxel	115.4	26.7	28	-44.2	-2.9
X-5975	BRCA	paclitaxel	106.1	26.4	32	-48.7	-4
X-5975	BRCA	paclitaxel	99.4	27	35	-51.9	-1.8
X-5975	BRCA	paclitaxel	89.2	27.2	38	-56.8	-1.1
X-5975	BRCA	paclitaxel	88.9	26	43	-57	-5.5
X-5975	BRCA	paclitaxel	72.5	28.1	46	-64.9	2.2
X-5975	BRCA	paclitaxel	61.6	27.2	49	-70.2	-1.1
X-5975	BRCA	paclitaxel	53	27	53	-74.4	-1.8
X-5975	BRCA	paclitaxel	35.4	26.9	57	-82.9	-2.2
X-5975	BRCA	paclitaxel	31.6	26.8	60	-84.7	-2.5
X-5975	BRCA	paclitaxel	27.1	27.4	66	-86.9	-0.4
X-5975	BRCA	paclitaxel	25.8	27.7	72	-87.5	0.7
X-5975	BRCA	paclitaxel	14.1	28.1	77	-93.2	2.2
X-5975	BRCA	paclitaxel	13.9	27.3	85	-93.3	-0.7
X-5975	BRCA	paclitaxel	0	27.6	89	-100	0.4
X-5975	BRCA	tamoxifen	212.9	28	0	0	0
X-5975	BRCA	tamoxifen	244.8	28	2	15	0
X-5975	BRCA	tamoxifen	257.8	27.6	6	21.1	-1.4
X-5975	BRCA	tamoxifen	299.9	28.8	9	40.9	2.9
X-5975	BRCA	tamoxifen	359.6	29.7	12	68.9	6.1
X-5975	BRCA	tamoxifen	406.9	29.2	16	91.1	4.3
X-5975	BRCA	tamoxifen	529.6	25.9	23	148.8	-7.5
X-5975	BRCA	tamoxifen	617.6	28.1	26	190.1	0.4
X-5975	BRCA	tamoxifen	614.3	29.8	30	188.5	6.4
X-5975	BRCA	tamoxifen	618.4	28.1	33	190.5	0.4
X-5975	BRCA	untreated	196.4	26.8	0	0	0
X-5975	BRCA	untreated	410.7	27.6	5	109.1	3
X-5975	BRCA	untreated	389.1	28.3	8	98.1	5.6
X-5975	BRCA	untreated	568.4	28.7	13	189.4	7.1
X-5975	BRCA	untreated	605.7	29.2	15	208.4	9
X-5975	BRCA	untreated	716.4	29.8	20	264.8	11.2
X-5975	BRCA	untreated	1016.9	29.8	22	417.8	11.2
X-5975	BRCA	untreated	1435.4	28.6	26	630.9	6.7
X-5975	BRCA	untreated	1692.1	28.1	27	761.6	4.9
X-6047	BRCA	BGJ398	200.8	24	0	0	0
X-6047	BRCA	BGJ398	207.5	25.3	2	3.3	5.4
X-6047	BRCA	BGJ398	229.5	24.5	6	14.3	2.1
X-6047	BRCA	BGJ398	272.8	25.8	9	35.9	7.5
X-6047	BRCA	BGJ398	281.3	25.3	14	40.1	5.4
X-6047	BRCA	BGJ398	269.3	25.1	16	34.1	4.6
X-6047	BRCA	BGJ398	411.1	25.5	21	104.7	6.2
X-6047	BRCA	BGJ398	411.3	25.6	23	104.8	6.7
X-6047	BRCA	BGJ398	450.8	25.5	27	124.5	6.2
X-6047	BRCA	BGJ398	483.7	26.6	30	140.9	10.8
X-6047	BRCA	BGJ398	450.9	26.2	33	124.6	9.2
X-6047	BRCA	BGJ398	567.4	26	37	182.6	8.3
X-6047	BRCA	BGJ398	484	25.9	40	141	7.9
X-6047	BRCA	BGJ398	557.7	25.6	44	177.7	6.7
X-6047	BRCA	BGJ398	554.3	25.7	47	176	7.1
X-6047	BRCA	BGJ398	576.9	25.7	49	187.3	7.1
X-6047	BRCA	BKM120	239.3	25.8	0	0	0
X-6047	BRCA	BKM120	236.3	25.1	4	-1.3	-2.7
X-6047	BRCA	BKM120	244	26.1	7	2	1.2
X-6047	BRCA	BKM120	384.1	26.5	11	60.5	2.7
X-6047	BRCA	BKM120	460.7	27.8	14	92.5	7.8
X-6047	BRCA	BKM120	570.1	27.1	19	138.2	5
X-6047	BRCA	BKM120	655.1	27.9	21	173.8	8.1
X-6047	BRCA	BKM120	900.5	27.4	26	276.3	6.2
X-6047	BRCA	BKM120	1017.8	27.8	28	325.3	7.8
X-6047	BRCA	BYL719	239.2	24.4	0	0	0
X-6047	BRCA	BYL719	422.6	23.3	4	76.7	-4.5
X-6047	BRCA	BYL719	520.7	24.4	7	117.7	0
X-6047	BRCA	BYL719	666.4	24.1	11	178.6	-1.2
X-6047	BRCA	BYL719	787.7	25.1	14	229.3	2.9
X-6047	BRCA	BYL719	984.5	25.4	19	311.6	4.1
X-6047	BRCA	BYL719 + LEE011	210	25.9	0	0	0
X-6047	BRCA	BYL719 + LEE011	263.4	25.1	4	25.4	-3.1
X-6047	BRCA	BYL719 + LEE011	323.4	25.1	7	54	-3.1
X-6047	BRCA	BYL719 + LEE011	279.4	25.8	11	33	-0.4
X-6047	BRCA	BYL719 + LEE011	340.3	27	14	62	4.2
X-6047	BRCA	BYL719 + LEE011	369.1	26.7	19	75.8	3.1
X-6047	BRCA	BYL719 + LEE011	400.2	26.2	21	90.6	1.2
X-6047	BRCA	BYL719 + LEE011	770.3	28.1	26	266.8	8.5
X-6047	BRCA	BYL719 + LEE011	1106.8	28.1	28	427	8.5
X-6047	BRCA	BYL719 + LJM716	211.4	26.7	0	0	0
X-6047	BRCA	BYL719 + LJM716	191.8	26	4	-9.3	-2.6
X-6047	BRCA	BYL719 + LJM716	203.1	27.4	7	-3.9	2.6
X-6047	BRCA	BYL719 + LJM716	226.1	26.7	12	7	0
X-6047	BRCA	BYL719 + LJM716	228.4	27.6	14	8	3.4
X-6047	BRCA	BYL719 + LJM716	330.5	27.7	19	56.3	3.7
X-6047	BRCA	BYL719 + LJM716	372.2	27.1	21	76.1	1.5
X-6047	BRCA	BYL719 + LJM716	574.3	26.7	25	171.7	0
X-6047	BRCA	BYL719 + LJM716	812.8	28	28	284.5	4.9
X-6047	BRCA	BYL719 + LJM716	875.1	28.1	31	314	5.2
X-6047	BRCA	CGM097	244.5	24.3	0	0	0
X-6047	BRCA	CGM097	493.2	25.7	4	101.7	5.8
X-6047	BRCA	CGM097	667.9	27.1	7	173.2	11.5
X-6047	BRCA	CGM097	994.4	26.8	11	306.7	10.3
X-6047	BRCA	CGM097	1354.2	28.9	14	453.9	18.9
X-6047	BRCA	CLR457	240.3	26.7	0	0	0
X-6047	BRCA	CLR457	264.8	24.5	4	10.2	-8.2
X-6047	BRCA	CLR457	324	25.8	7	34.8	-3.4
X-6047	BRCA	CLR457	365.9	26.3	11	52.3	-1.5
X-6047	BRCA	CLR457	425.8	27	14	77.2	1.1
X-6047	BRCA	CLR457	499.5	27.6	19	107.9	3.4
X-6047	BRCA	CLR457	517.2	28	21	115.2	4.9
X-6047	BRCA	CLR457	570.8	27.3	26	137.5	2.2
X-6047	BRCA	CLR457	592.9	27	28	146.7	1.1
X-6047	BRCA	CLR457	789	26.3	32	228.3	-1.5
X-6047	BRCA	CLR457	913.1	27.4	35	280	2.6
X-6047	BRCA	CLR457	859	26.3	38	257.5	-1.5
X-6047	BRCA	HDM201	229.8	28	0	0	0
X-6047	BRCA	HDM201	477.1	26.8	4	107.6	-4.3
X-6047	BRCA	HDM201	603.6	28.4	7	162.7	1.4
X-6047	BRCA	HDM201	811.3	28.4	11	253	1.4
X-6047	BRCA	HDM201	928.6	29.6	14	304.1	5.7
X-6047	BRCA	INC424	201.2	24.3	0	0	0
X-6047	BRCA	INC424	185.1	24.2	2	-8	-0.4
X-6047	BRCA	INC424	204	24	6	1.4	-1.2
X-6047	BRCA	INC424	232.4	24.5	9	15.5	0.8
X-6047	BRCA	INC424	298.3	24.9	14	48.3	2.5
X-6047	BRCA	INC424	309.2	25.1	16	53.7	3.3
X-6047	BRCA	INC424	350.5	25.7	21	74.2	5.8
X-6047	BRCA	INC424	384.4	24.8	23	91.1	2.1
X-6047	BRCA	INC424	565.1	25	27	180.9	2.9
X-6047	BRCA	INC424	629.3	25.4	30	212.8	4.5
X-6047	BRCA	INC424	855.4	25.3	33	325.1	4.1
X-6047	BRCA	LEE011	226.7	25.1	0	0	0
X-6047	BRCA	LEE011	388.8	25.7	4	71.5	2.4
X-6047	BRCA	LEE011	445.4	26.8	7	96.5	6.8
X-6047	BRCA	LEE011	681	26.2	11	200.4	4.4
X-6047	BRCA	LEE011	794.9	28.3	14	250.6	12.7
X-6047	BRCA	LEE011	1013.3	29.1	19	347	15.9
X-6047	BRCA	LEE011 + everolimus	227.9	21.6	0	0	0
X-6047	BRCA	LEE011 + everolimus	231.4	20.8	4	1.5	-3.7
X-6047	BRCA	LEE011 + everolimus	230.5	21.9	7	1.1	1.4
X-6047	BRCA	LEE011 + everolimus	283.4	21.7	11	24.4	0.5
X-6047	BRCA	LEE011 + everolimus	268.3	22.6	14	17.7	4.6
X-6047	BRCA	LEE011 + everolimus	257.3	22.6	19	12.9	4.6
X-6047	BRCA	LEE011 + everolimus	309.9	23.1	21	36	6.9
X-6047	BRCA	LEE011 + everolimus	504.8	23.4	26	121.5	8.3
X-6047	BRCA	LEE011 + everolimus	549.7	23.9	28	141.2	10.6
X-6047	BRCA	LEE011 + everolimus	689.1	24	32	202.4	11.1
X-6047	BRCA	LEE011 + everolimus	771.7	24.2	35	238.6	12
X-6047	BRCA	LEE011 + everolimus	810.9	24.5	38	255.8	13.4
X-6047	BRCA	LFA102	217.7	25	0	0	0
X-6047	BRCA	LFA102	281.7	24.2	1	29.4	-3.2
X-6047	BRCA	LFA102	396.3	24.2	4	82	-3.2
X-6047	BRCA	LFA102	625.6	23.9	8	187.4	-4.4
X-6047	BRCA	LFA102	820.6	25.8	11	276.9	3.2
X-6047	BRCA	LFA102	1149.7	25.9	16	428.1	3.6
X-6047	BRCA	LFA102	1442.4	25.5	17	562.6	2
X-6047	BRCA	LJM716	234.1	25.1	0	0	0
X-6047	BRCA	LJM716	381.7	25.8	4	63	2.8
X-6047	BRCA	LJM716	473.7	27	7	102.3	7.6
X-6047	BRCA	LJM716	648.4	26.2	11	177	4.4
X-6047	BRCA	LJM716	799.4	28.3	14	241.5	12.7
X-6047	BRCA	LJM716	858	27.7	19	266.5	10.4
X-6047	BRCA	LJM716	1131.7	27.7	21	383.4	10.4
X-6047	BRCA	LJM716 + trastuzumab	230.3	25.8	0	0	0
X-6047	BRCA	LJM716 + trastuzumab	334.8	25.7	4	45.4	-0.4
X-6047	BRCA	LJM716 + trastuzumab	455.6	26	7	97.8	0.8
X-6047	BRCA	LJM716 + trastuzumab	698.2	26.2	11	203.2	1.6
X-6047	BRCA	LJM716 + trastuzumab	1011.2	27.8	14	339.1	7.8
X-6047	BRCA	LKA136	200.1	28.2	0	0	0
X-6047	BRCA	LKA136	204.5	28.7	2	2.2	1.8
X-6047	BRCA	LKA136	229.3	28.9	6	14.6	2.5
X-6047	BRCA	LKA136	292.8	29.7	9	46.3	5.3
X-6047	BRCA	LKA136	433.7	29.6	14	116.7	5
X-6047	BRCA	LKA136	476.7	29.9	16	138.2	6
X-6047	BRCA	LKA136	699.3	30.4	21	249.5	7.8
X-6047	BRCA	LKA136	884.5	30.1	23	342	6.7
X-6047	BRCA	LKA136	1325.3	30.6	27	562.3	8.5
X-6047	BRCA	LKA136	1352.9	30.5	28	576.1	8.2
X-6047	BRCA	LLM871	221.7	27.3	0	0	0
X-6047	BRCA	LLM871	198	26.8	2	-10.7	-1.8
X-6047	BRCA	LLM871	200.7	27.5	7	-9.5	0.7
X-6047	BRCA	LLM871	234.2	27.7	9	5.6	1.5
X-6047	BRCA	LLM871	296.6	24.6	13	33.8	-9.9
X-6047	BRCA	LLM871	303.6	26.4	16	36.9	-3.3
X-6047	BRCA	LLM871	339.5	26.4	19	53.1	-3.3
X-6047	BRCA	LLM871	403.8	25.3	23	82.1	-7.3
X-6047	BRCA	LLM871	457.1	26.1	26	106.2	-4.4
X-6047	BRCA	LLM871	502	26	30	126.4	-4.8
X-6047	BRCA	LLM871	614.1	25.8	33	177	-5.5
X-6047	BRCA	LLM871	736.8	26.3	35	232.3	-3.7
X-6047	BRCA	binimetinib	257.8	27.1	0	0	0
X-6047	BRCA	binimetinib	634.8	26.3	4	146.2	-3
X-6047	BRCA	binimetinib	805.1	27	7	212.3	-0.4
X-6047	BRCA	binimetinib	1247.1	27.8	11	383.7	2.6
X-6047	BRCA	binimetinib	1627.2	28.7	14	531.2	5.9
X-6047	BRCA	paclitaxel	212.4	25.7	0	0	0
X-6047	BRCA	paclitaxel	197.8	26.1	4	-6.9	1.6
X-6047	BRCA	paclitaxel	208.5	27.8	7	-1.8	8.2
X-6047	BRCA	paclitaxel	281.4	27.3	12	32.5	6.2
X-6047	BRCA	paclitaxel	360.9	28.4	14	69.9	10.5
X-6047	BRCA	paclitaxel	436	28.4	19	105.3	10.5
X-6047	BRCA	paclitaxel	478.1	28.5	21	125.1	10.9
X-6047	BRCA	paclitaxel	688.5	27.3	25	224.2	6.2
X-6047	BRCA	paclitaxel	791.4	28.4	28	272.6	10.5
X-6047	BRCA	paclitaxel	1000.7	28.5	31	371.1	10.9
X-6047	BRCA	tamoxifen	207.4	24.7	0	0	0
X-6047	BRCA	tamoxifen	262.9	26.9	4	26.8	8.9
X-6047	BRCA	tamoxifen	289.5	28.6	7	39.6	15.8
X-6047	BRCA	tamoxifen	332.5	29.1	12	60.3	17.8
X-6047	BRCA	tamoxifen	377	29.7	14	81.8	20.2
X-6047	BRCA	tamoxifen	517.1	30.2	19	149.3	22.3
X-6047	BRCA	tamoxifen	536.6	30.3	21	158.7	22.7
X-6047	BRCA	tamoxifen	910	29.2	25	338.8	18.2
X-6047	BRCA	tamoxifen	936.8	30.3	28	351.7	22.7
X-6047	BRCA	tamoxifen	1299.3	30.1	31	526.5	21.9
X-6047	BRCA	trastuzumab	213.5	21.8	0	0	0
X-6047	BRCA	trastuzumab	247	22.3	4	15.7	2.3
X-6047	BRCA	trastuzumab	364.3	24.4	7	70.6	11.9
X-6047	BRCA	trastuzumab	505.5	23.6	11	136.8	8.3
X-6047	BRCA	trastuzumab	563.8	24.9	14	164.1	14.2
X-6047	BRCA	trastuzumab	872.2	24.8	19	308.5	13.8
X-6047	BRCA	trastuzumab	1072.3	25.4	21	402.2	16.5
X-6047	BRCA	untreated	226	25.7	0	0	0
X-6047	BRCA	untreated	421	26.5	4	86.3	3.1
X-6047	BRCA	untreated	546.1	27.3	7	141.6	6.2
X-6047	BRCA	untreated	852.4	27.4	11	277.2	6.6
X-6047	BRCA	untreated	1142.2	27.5	14	405.4	7
